PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Bernhardt, J; Langhorne, P; Lindley, RI; Thrift, AG; Ellery, F; Collier, J; Churilov, L; Moodie, M; Dewey, H; Donnan, G				Bernhardt, Julie; Langhorne, Peter; Lindley, Richard I.; Thrift, Amanda G.; Ellery, Fiona; Collier, Janice; Churilov, Leonid; Moodie, Marjory; Dewey, Helen; Donnan, Geoffrey		AVERT Trial Collaboration Grp	Efficacy and safety of very early mobilisation within 24 h of stroke onset (AVERT): a randomised controlled trial	LANCET			English	Article							EARLY REHABILITATION TRIAL; PHASE-II; ASSUMPTION-FREE; UNIT; COMPLICATIONS; METAANALYSIS; RECOVERY; EXERCISE; WALKING; CARE	Background Early mobilisation after stroke is thought to contribute to the effects of stroke-unit care; however, the intervention is poorly defined and not underpinned by strong evidence. We aimed to compare the effectiveness of frequent, higher dose, very early mobilisation with usual care after stroke. Methods We did this parallel-group, single-blind, randomised controlled trial at 56 acute stroke units in five countries. Patients (aged >= 18 years) with ischaemic or haemorrhagic stroke, first or recurrent, who met physiological criteria were randomly assigned (1: 1), via a web-based computer generated block randomisation procedure (block size of six), to receive usual stroke-unit care alone or very early mobilisation in addition to usual care. Treatment with recombinant tissue plasminogen activator was allowed. Randomisation was stratified by study site and stroke severity. Patients, outcome assessors, and investigators involved in trial and data management were masked to treatment allocation. The primary outcome was a favourable outcome 3 months after stroke, defined as a modified Rankin Scale score of 0-2. We did analysis on an intention-to-treat basis. The trial is registered with the Australian New Zealand Clinical Trials Registry, number ACTRN12606000185561. Findings Between July 18, 2006, and Oct 16, 2014, we randomly assigned 2104 patients to receive either very early mobilisation (n=1054) or usual care (n=1050); 2083 (99%) patients were included in the 3 month follow-up assessment. 965 (92%) patients were mobilised within 24 h in the very early mobilisation group compared with 623 (59%) patients in the usual care group. Fewer patients in the very early mobilisation group had a favourable outcome than those in the usual care group (n=480 [46%] vs n=525 [50%]; adjusted odds ratio [OR] 0.73, 95% CI 0.59-0.90; p=0.004). 88 (8%) patients died in the very early mobilisation group compared with 72 (7%) patients in the usual care group (OR 1.34, 95% CI 0.93-1.93, p=0.113). 201 (19%) patients in the very early mobilisation group and 208 (20%) of those in the usual care group had a non-fatal serious adverse event, with no reduction in immobility-related complications with very early mobilisation. Interpretation First mobilisation took place within 24 h for most patients in this trial. The higher dose, very early mobilisation protocol was associated with a reduction in the odds of a favourable outcome at 3 months. Early mobilisation after stroke is recommended in many clinical practice guidelines worldwide, and our findings should affect clinical practice by refining present guidelines; however, clinical recommendations should be informed by future analyses of dose-response associations.	[Bernhardt, Julie; Ellery, Fiona; Collier, Janice; Churilov, Leonid; Dewey, Helen; Donnan, Geoffrey] Univ Melbourne, Florey Inst Neurosci & Mental Hlth, Melbourne, Vic, Australia; [Bernhardt, Julie] La Trobe Univ, Dept Rehabil Nutr & Sport, Bundoora, Vic, Australia; [Langhorne, Peter] Univ Glasgow, Coll Med Vet & Life Sci, Inst Cardiovasc & Med Sci, Glasgow, Lanark, Scotland; [Lindley, Richard I.] Univ Sydney, George Inst Global Hlth, Sydney, NSW 2006, Australia; [Lindley, Richard I.] Univ Sydney, Westmead Hosp, Sch Clin, Sydney Med Sch, Sydney, NSW 2006, Australia; [Thrift, Amanda G.] Monash Univ, Monash Hlth, Sch Clin Sci, Stroke & Ageing Res Grp,Dept Med, Clayton, Vic 3800, Australia; [Moodie, Marjory] Deakin Univ, Fac Hlth, Deakin Hlth Econ, Melbourne, Vic, Australia; [Dewey, Helen] Monash Univ, Fac Med Nursing & Hlth Sci, Australia & Eastern Clin Sch, Melbourne, Vic 3004, Australia	Florey Institute of Neuroscience & Mental Health; University of Melbourne; La Trobe University; University of Glasgow; George Institute for Global Health; University of Sydney; University of Sydney; Monash University; Deakin University; Monash University	Bernhardt, J (corresponding author), Florey Inst Neurosci & Mental Hlth, Austin Campus, Heidelberg, Vic 3084, Australia.	julie.bernhardt@florey.edu.au	Thrift, Amanda/I-6251-2012; Lindley, Richard/B-8148-2013; Hankey, Graeme J/H-4968-2014; FRACP, Tissa Wijeratne MD PhD/I-2086-2019; Collier, Janice/S-6179-2019; Macleod, Malcolm Robert/B-2052-2010; Collier, Janice M/K-4563-2015; Bernhardt, Julie/F-9538-2015	Thrift, Amanda/0000-0001-8533-4170; Lindley, Richard/0000-0002-0104-5679; Hankey, Graeme J/0000-0002-6044-7328; FRACP, Tissa Wijeratne MD PhD/0000-0002-1701-7111; Macleod, Malcolm Robert/0000-0001-9187-9839; Collier, Janice M/0000-0003-2950-4870; Kramer, Sharon/0000-0003-2795-6259; Lennon, Sheila/0000-0001-5434-0893; Ellery, Fiona/0000-0002-7302-1895; Bernhardt, Julie/0000-0002-2787-8484; Nicol, Marcus/0000-0002-5706-4684; Kwan, Joseph/0000-0003-4635-3322	National Health and Medical Research Council; Singapore Health; Chest Heart and Stroke Scotland; Northern Ireland Chest Heart and Stroke; UK Stroke Association; National Institute of Health Research; National Institute for Health Research [12/01/16] Funding Source: researchfish; Stroke Association [TSA2009/09] Funding Source: researchfish; Chest Heart and Stroke Scotland [Res08/A114] Funding Source: researchfish	National Health and Medical Research Council(National Health and Medical Research Council (NHMRC) of Australia); Singapore Health; Chest Heart and Stroke Scotland; Northern Ireland Chest Heart and Stroke; UK Stroke Association; National Institute of Health Research(National Institute for Health Research (NIHR)); National Institute for Health Research(National Institute for Health Research (NIHR)); Stroke Association; Chest Heart and Stroke Scotland	National Health and Medical Research Council, Singapore Health, Chest Heart and Stroke Scotland, Northern Ireland Chest Heart and Stroke, UK Stroke Association, National Institute of Health Research.	Allen C, 1999, LANCET, V354, P1229, DOI 10.1016/S0140-6736(98)10063-6; Austin MW, 2014, NEUROSCI RES, V87, P8, DOI 10.1016/j.neures.2014.06.007; Bernhardt J, 2004, STROKE, V35, P1005, DOI 10.1161/01.STR.0000120727.40792.40; Bernhardt J, 2008, STROKE, V39, P390, DOI 10.1161/STROKEAHA.107.492363; Bernhardt J, 2015, STROKE, V46, P1141, DOI 10.1161/STROKEAHA.114.007434; Bernhardt J, 2015, INT J STROKE, V10, P23, DOI 10.1111/ijs.12423; Bernhardt J, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006187.pub2; Briggs DE, 2001, STROKE, V32, P871, DOI 10.1161/01.STR.32.4.871; Churilov L, 2014, INT J STROKE, V9, P999, DOI 10.1111/ijs.12364; Craig LE, 2010, STROKE, V41, P2632, DOI 10.1161/STROKEAHA.110.588244; Cumming TB, 2011, STROKE, V42, P153, DOI 10.1161/STROKEAHA.110.594598; Egan KJ, 2014, NEUROREHAB NEURAL RE, V28, P800, DOI 10.1177/1545968314521694; Govan L, 2007, STROKE, V38, P2536, DOI 10.1161/STROKEAHA.106.478842; Howard G, 2012, STROKE, V43, P664, DOI 10.1161/STROKEAHA.111.632935; Indredavik B, 1999, STROKE, V30, P917, DOI 10.1161/01.STR.30.5.917; Krakauer JW, 2012, NEUROREHAB NEURAL RE, V26, P923, DOI 10.1177/1545968312440745; Langhorne P, 2000, STROKE, V31, P1223, DOI 10.1161/01.STR.31.6.1223; Murphy TH, 2009, NAT REV NEUROSCI, V10, P861, DOI 10.1038/nrn2735; Olavarria VV, 2014, CEREBROVASC DIS, V37, P401, DOI 10.1159/000362533; Saver JL, 2014, JAMA-J AM MED ASSOC, V311, P469, DOI 10.1001/jama.2013.282544; Skarin M, 2011, INT J STROKE, V6, P10, DOI 10.1111/j.1747-4949.2010.00534.x; Sundseth A, 2012, STROKE, V43, P2389, DOI 10.1161/STROKEAHA.111.646687; Tay-Teo K, 2008, CEREBROVASC DIS, V26, P475, DOI 10.1159/000155984; VANSWIETEN JC, 1988, STROKE, V19, P604, DOI 10.1161/01.STR.19.5.604; White IR, 2011, BMJ-BRIT MED J, V342, DOI 10.1136/bmj.d40	25	394	405	2	84	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 4	2015	386	9988					46	55		10.1016/S0140-6736(15)60690-0	http://dx.doi.org/10.1016/S0140-6736(15)60690-0			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CM2OA	25892679	hybrid, Green Accepted, Green Submitted			2023-01-03	WOS:000357519400027
J	Choueiri, MB; Shen, JP; Gross, AM; Huang, JK; Ideker, T; Fanta, P				Choueiri, Michel B.; Shen, John Paul; Gross, Andrew M.; Huang, Justin K.; Ideker, Trey; Fanta, Paul			ERCC1 and TS Expression as Prognostic and Predictive Biomarkers in Metastatic Colon Cancer	PLOS ONE			English	Article							ADVANCED COLORECTAL-CANCER; THYMIDYLATE SYNTHASE EXPRESSION; MESSENGER-RNA LEVELS; RECTAL-CANCER; MICROSATELLITE INSTABILITY; FLUOROURACIL CHEMOTHERAPY; GASTRIC-CANCER; SURVIVAL; GENE; KRAS	In patients with metastatic colon cancer, response to first line chemotherapy is a strong predictor of overall survival (OS). Currently, oncologists lack diagnostic tests to determine which chemotherapy regimen offers the greatest chance for response in an individual patient. Here we present the results of gene expression analysis for two genes, ERCC1 and TS, measured with the commercially available ResponseDX: Colon assay (Response Genetics, Los Angeles, CA) in 41 patients with de novo metastatic colon cancer diagnosed between July 2008 and August 2013 at the University of California, San Diego. In addition ERCC1 and TS expression levels as determined by RNAseq and survival data for patients in TCGA were downloaded from the TCGA data portal. We found that patients with low expression of ERCC1 (n = 33) had significantly longer median OS (36.0 vs. 10.1 mo, HR 0.29, 95% CI.095 to .84, log-rank p = 9.0x10(-6)) and median time to treatment to failure (TTF) following first line chemotherapy (14.1 vs. 2.4 mo, HR 0.17, 95% CI 0.048 to 0.58, log-rank p = 5.3x10(-4)) relative to those with high expression (n = 4). After accounting for the covariates age, sex, tumor grade and ECOG performance status in a Cox proportional hazard model the association of low ERCC1 with longer OS (HR 0.18, 95% CI 0.14 to 0.26, p = 0.0448) and TTF (HR 0.16, 95% CI 0.14 to 0.21, p = 0.0053) remained significant. Patients with low TS expression (n = 29) had significantly longer median OS (36.0 vs. 14.8 mo, HR 0.25, 95% CI 0.074 to 0.82, log-rank p = 0.022) relative to those with high expression (n = 12). The combined low expression of ERCC1/TS was predictive of response in patients treated with FOLFOX (40% vs. 91%, RR 2.3, Fisher's exact test p = 0.03, n = 27), but not with FOLFIRI (71% vs. 71%, RR 1.0, Fisher's exact test p = 1, n = 14). Overall, these findings suggest that measurement of ERCC1 and TS expression has potential clinical utility in managing patients with metastatic colorectal cancer.	[Choueiri, Michel B.; Shen, John Paul; Ideker, Trey; Fanta, Paul] Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; [Gross, Andrew M.; Huang, Justin K.; Ideker, Trey] Univ Calif San Diego, Bioinformat & Syst Biol Program, La Jolla, CA 92093 USA; [Choueiri, Michel B.; Shen, John Paul; Ideker, Trey; Fanta, Paul] Univ Calif San Diego, Moores Canc Ctr, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego	Fanta, P (corresponding author), Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA.	pfanta@ucsd.edu		Shen, John Paul/0000-0003-4588-2775; Ideker, Trey/0000-0002-1708-8454	American Society of Clinical Oncology; Marsha Rivkin Center for Ovarian Cancer Research; United States National Institutes of Health [R01 ES014811, U24 CA184427]; NATIONAL CANCER INSTITUTE [U24CA184427] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES014811] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008806] Funding Source: NIH RePORTER	American Society of Clinical Oncology; Marsha Rivkin Center for Ovarian Cancer Research; United States National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	American Society of Clinical Oncology: www.asco.org, Young Investigator Award to J.P.S., Marsha Rivkin Center for Ovarian Cancer Research: www.marsharivkin.org, Scientific Scholar Award to J.P.S., United States National Institutes of Health: www.nih.gov, R01 ES014811 to T.I., U24 CA184427 to T.I. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Amado RG, 2008, J CLIN ONCOL, V26, P1626, DOI 10.1200/JCO.2007.14.7116; Bardelli A, 2013, CANCER DISCOV, V3, P658, DOI 10.1158/2159-8290.CD-12-0558; Basso M, 2013, BRIT J CANCER, V108, P115, DOI 10.1038/bjc.2012.526; Bertagnolli MM, 2011, J CLIN ONCOL, V29, P3153, DOI 10.1200/JCO.2010.33.0092; Buyse M, 2000, LANCET, V356, P373, DOI 10.1016/S0140-6736(00)02528-9; Colucci G, 2005, J CLIN ONCOL, V23, P4866, DOI 10.1200/JCO.2005.07.113; Di Nicolantonio F, 2008, J CLIN ONCOL, V26, P5705, DOI 10.1200/JCO.2008.18.0786; Etienne MC, 2002, J CLIN ONCOL, V20, P2832, DOI 10.1200/JCO.2002.09.091; Giralt J, 2005, RADIOTHER ONCOL, V74, P101, DOI 10.1016/j.radonc.2004.12.021; Grimminger PP, 2012, PHARMACOGENOMICS J, V12, P404, DOI 10.1038/tpj.2011.29; Iacopetta B, 2001, BRIT J CANCER, V85, P827, DOI 10.1054/bjoc.2001.2007; JOHNSTON PG, 1995, CANCER RES, V55, P1407; Joshi MBM, 2005, CLIN CANCER RES, V11, P2215; Kohonen-Corish MRJ, 2005, J CLIN ONCOL, V23, P2318, DOI 10.1200/JCO.2005.00.109; Kwon HC, 2007, ANN ONCOL, V18, P504, DOI 10.1093/annonc/mdl430; Leichman CG, 1997, J CLIN ONCOL, V15, P3223, DOI 10.1200/JCO.1997.15.10.3223; Lenz HJ, 1998, CLIN CANCER RES, V4, P1227; Li P, 2013, BRIT J CANCER, V108, P1238, DOI 10.1038/bjc.2013.83; Lievre A, 2008, J CLIN ONCOL, V26, P374, DOI 10.1200/JCO.2007.12.5906; MCILWRATH AJ, 1994, CANCER RES, V54, P3718; Metzger R, 1998, J CLIN ONCOL, V16, P309, DOI 10.1200/JCO.1998.16.1.309; Moroni M, 2005, LANCET ONCOL, V6, P279, DOI 10.1016/S1470-2045(05)70102-9; Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252; Rees M, 2008, ANN SURG, V247, P125, DOI 10.1097/SLA.0b013e31815aa2c2; Richman SD, 2009, J CLIN ONCOL, V27, P5931, DOI 10.1200/JCO.2009.22.4295; Saw RPM, 2003, DIS COLON RECTUM, V46, P192, DOI 10.1007/s10350-004-6524-2; Shirota Y, 2001, J CLIN ONCOL, V19, P4298, DOI 10.1200/JCO.2001.19.23.4298; Sotelo MJ, 2014, WORLD J GASTROENTERO, V20, P4208, DOI 10.3748/wjg.v20.i15.4208; Stoehlmacher J, 2008, CANCER LETT, V272, P221, DOI 10.1016/j.canlet.2008.07.008; Valtorta E, 2013, INT J CANCER, V133, P1259, DOI 10.1002/ijc.28106; Van Cutsem E, 2014, ANN ONCOL, V25, P1, DOI 10.1093/annonc/mdu260	31	27	28	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 17	2015	10	6							e0126898	10.1371/journal.pone.0126898	http://dx.doi.org/10.1371/journal.pone.0126898			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CK9NS	26083491	Green Published, Green Submitted, gold			2023-01-03	WOS:000356567400007
J	Cox, TM; Drelichman, G; Cravo, R; Balwani, M; Burrow, TA; Martins, AM; Lukina, E; Rosenbloom, B; Ross, L; Angell, J; Puga, AC				Cox, Timothy M.; Drelichman, Guillermo; Cravo, Renata; Balwani, Manisha; Burrow, Thomas Andrew; Martins, Ana Maria; Lukina, Elena; Rosenbloom, Barry; Ross, Leorah; Angell, Jennifer; Puga, Ana Cristina			Eliglustat compared with imiglucerase in patients with Gaucher's disease type 1 stabilised on enzyme replacement therapy: a phase 3, randomised, open-label, non-inferiority trial	LANCET			English	Article							MAINTENANCE THERAPY; TALIGLUCERASE ALPHA; MIGLUSTAT; RECOMMENDATIONS; MANIFESTATIONS; PROPORTIONS; DIAGNOSIS	Background The mainstay of treatment for Gaucher's disease type 1 is alternate-week infusion of enzyme replacement therapy (ERT). We investigated whether patients stable on such treatment would remain so after switching to oral eliglustat, a selective inhibitor of glucosylceramide synthase. Methods In this phase 3, randomised, multinational, open-label, non-inferiority trial, we enrolled adults (aged >= 18 years) who had received ERT for 3 years or more for Gaucher's disease. Patients were randomly allocated 2:1 at 39 clinics (stratified by ERT dose; block sizes of four; computer-generated centrally) to receive either oral eliglustat or imiglucerase infusions for 12 months. Participants and investigators were aware of treatment assignment, but the central reader who assessed organ volumes was masked. The composite primary efficacy endpoint was percentage of patients whose haematological variables and organ volumes remained stable for 12 months (ie, haemoglobin decrease not more than 15 g/L, platelet count decrease not more than 25%, spleen volume increase not more than 25%, and liver volume increase not more than 20%, in multiples of normal from baseline). The non-inferiority margin was 25% for eliglustat relative to imiglucerase, assessed in all patients who completed 12 months of treatment. This trial is registered with ClinicalTrials.gov, number NCT00943111, and EudraCT, number 2008-005223-28. Findings Between Sept 15, 2009, and Nov 9, 2011, we randomly allocated 106 (66%) patients to eliglustat and 54 (34%) to imiglucerase. In the per-protocol population, 84 (85%) of 99 patients who completed eliglustat treatment and 44 (94%) of 47 patients who completed imiglucerase treatment met the composite primary endpoint (between-group difference -8.8%; 95% CI -17.6 to 4.2). The lower bound of the 95% CI of -17.6% was within the prespecified threshold for non-inferiority. Dropouts occurred due to palpitations (one patient on eliglustat), myocardial infarction (one patient on eliglustat), and psychotic disorder (one patient on imiglucerase). No deaths occurred. 97 (92%) of 106 patients in the eliglustat group had treatment-emergent adverse events, as did 42 (79%) of 53 in the imiglucerase group (mostly mild or moderate in severity). Interpretation Oral eliglustat maintained haematological and organ volume stability in adults with Gaucher's disease type 1 already controlled by intravenous ERT and could be a useful therapeutic option.	[Cox, Timothy M.] Univ Cambridge, Addenbrookes Hosp, Dept Med, Cambridge CB2 0QQ, England; [Drelichman, Guillermo] Hosp Ninos Dr Ricardo Gutierrez, Buenos Aires, DF, Argentina; [Cravo, Renata] State Inst Haematol Arthur de Siqueira Cavalcanti, Rio De Janeiro, Brazil; [Balwani, Manisha] Mt Sinai Hosp, New York, NY 10029 USA; [Burrow, Thomas Andrew] Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH 45229 USA; [Martins, Ana Maria] Univ Fed Sao Paulo, Sao Paulo, SP, Brazil; [Lukina, Elena] Minist Publ Hlth Russia, Hematol Res Ctr, Moscow, Russia; [Rosenbloom, Barry] Cedars Sinai Oncol, Beverly Hills, CA USA; [Rosenbloom, Barry] Tower Hematol Oncol, Beverly Hills, CA USA; [Ross, Leorah; Angell, Jennifer; Puga, Ana Cristina] Genzyme, Cambridge, MA USA	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; Hospital de Ninos Doctor Ricardo Gutierrez; University of Buenos Aires; Icahn School of Medicine at Mount Sinai; Cincinnati Children's Hospital Medical Center; Universidade Federal de Sao Paulo (UNIFESP); Russian Academy of Medical Sciences; National Medical Research Center for Hematology; Sanofi-Aventis; Genzyme Corporation	Cox, TM (corresponding author), Univ Cambridge, Addenbrookes Hosp, Dept Med, Cambridge CB2 0QQ, England.	tmc12@medschl.cam.ac.uk	Lukina, Elena/N-4536-2014	Lukina, Elena/0000-0002-8774-850X	Genzyme, a Sanofi company; UK Medical Research Council [MR/K015338/1]; National Center for Advancing Translational Sciences, National Institutes of Health [UL1TR000067]; Medical Research Council [MR/K025570/1, MR/K015338/1] Funding Source: researchfish; Sparks Charity [14CAM03] Funding Source: researchfish; MRC [MR/K025570/1, MR/K015338/1] Funding Source: UKRI	Genzyme, a Sanofi company(Sanofi-AventisGenzyme Corporation); UK Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); National Center for Advancing Translational Sciences, National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); Sparks Charity; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	Genzyme, a Sanofi company.; This work was funded by Genzyme, a Sanofi company. The authors thank the patients and health-care professionals (appendix) who participated; Laurie LaRusso for medical writing support funded by Genzyme, a Sanofi company; Raymond Mankoski and Lisa Underhill, Genzyme Global Medical Affairs, and M Judith Peterschmitt and Gerald F Cox, Genzyme Clinical Development, for critical review. Work at the University of Cambridge was supported by grant MR/K015338/1 from the UK Medical Research Council and at Mount Sinai Hospital by grant UL1TR000067 from the National Center for Advancing Translational Sciences, National Institutes of Health.	Agresti A, 2000, AM STAT, V54, P280, DOI 10.2307/2685779; [Anonymous], 2009, CEREZYME SUMMARY PRO; [Anonymous], 2013, ZAVESCA SUMMARY PROD; BARTON NW, 1991, NEW ENGL J MED, V324, P1464, DOI 10.1056/NEJM199105233242104; Chen M, 2008, ARCH PATHOL LAB MED, V132, P851, DOI 10.1043/1543-2165(2008)132[851:GDROTL]2.0.CO;2; Cox T, 2000, LANCET, V355, P1481, DOI 10.1016/S0140-6736(00)02161-9; Cox TM, 2012, ORPHANET J RARE DIS, V7, DOI 10.1186/1750-1172-7-102; Dann RS, 2008, PHARM STAT, V7, P130, DOI 10.1002/pst.287; Deegan PB, 2011, MEDICINE, V90, P52, DOI 10.1097/MD.0b013e3182057be4; Elstein D, 2007, BLOOD, V110, P2296, DOI 10.1182/blood-2007-02-075960; Giraldo P, 2006, HAEMATOLOGICA, V91, P703; Giraldo P, 2009, HAEMATOL-HEMATOL J, V94, P1771, DOI 10.3324/haematol.2009.008078; Grabowski G.A., 2006, ONLINE METABOLIC MOL; Grabowski GA, 2008, LANCET, V372, P1263, DOI 10.1016/S0140-6736(08)61522-6; Haddley K, 2012, DRUG TODAY, V48, P525, DOI [10.1358/dot.2012.48.8.1844608, 10.1358/dot.2012.48.8.1844808]; Hollak CEM, 2012, CORE EVID, V7, P15, DOI 10.2147/CE.S20201; Kamath RS, 2014, SKELETAL RADIOL, V43, P1353, DOI 10.1007/s00256-014-1891-9; Kaplan P, 2013, EUR J PEDIATR, V172, P447, DOI 10.1007/s00431-012-1771-z; Kishnani PS, 2009, MOL GENET METAB, V96, P164, DOI 10.1016/j.ymgme.2008.12.015; Kuter DJ, 2013, BLOOD CELL MOL DIS, V51, P116, DOI 10.1016/j.bcmd.2013.04.005; Lukina E, 2014, BLOOD CELL MOL DIS, V53, P274, DOI 10.1016/j.bcmd.2014.04.002; Lukina E, 2010, BLOOD, V116, P893, DOI 10.1182/blood-2010-03-273151; Maas M, 2008, SKELETAL RADIOL, V37, P185, DOI 10.1007/s00256-007-0425-0; McEachern KA, 2007, MOL GENET METAB, V91, P259, DOI 10.1016/j.ymgme.2007.04.001; Mistry PK, 1996, LANCET, V348, P1555, DOI 10.1016/S0140-6736(96)04451-0; Mistry PK, 2015, JAMA-J AM MED ASSOC, V313, P695, DOI 10.1001/jama.2015.459; Mistry PK, 2009, BRIT J HAEMATOL, V147, P561, DOI 10.1111/j.1365-2141.2009.07872.x; Pastores GM, 2004, SEMIN HEMATOL, V41, P4, DOI 10.1053/j.seminhematol.2004.07.009; Robertson PL, 2007, AM J ROENTGENOL, V188, P1521, DOI 10.2214/AJR.06.1410; Ross DJ, 1997, NEW ENGL J MED, V336, P379, DOI 10.1056/NEJM199701303360516; Taddei TH, 2010, J INHERIT METAB DIS, V33, P291, DOI 10.1007/s10545-010-9070-1; Weinreb Neal J., 2013, Critical Reviews in Oncogenesis, V18, P177	32	94	97	0	12	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 13	2015	385	9985					2355	2362		10.1016/S0140-6736(14)61841-9	http://dx.doi.org/10.1016/S0140-6736(14)61841-9			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CK1XV	25819691				2023-01-03	WOS:000356003700028
J	Tor, YS; Yazan, LS; Foo, JB; Wibowo, A; Ismail, N; Cheah, YK; Abdullah, R; Ismail, M; Ismail, IS; Yeap, SK				Tor, Yin Sim; Yazan, Latifah Saiful; Foo, Jhi Biau; Wibowo, Agustono; Ismail, Norsharina; Cheah, Yoke Kqueen; Abdullah, Rasedee; Ismail, Maznah; Ismail, Intan Safinar; Yeap, Swee Keong			Induction of Apoptosis in MCF-7 Cells via Oxidative Stress Generation, Mitochondria-Dependent and Caspase-Independent Pathway by Ethyl Acetate Extract of Dillenia suffruticosa and Its Chemical Profile	PLOS ONE			English	Article							ANTIOXIDANT ACTIVITY; MEDIATED APOPTOSIS; ALPHA-TOCOPHEROL; REACTIVE OXYGEN; DOWN-REGULATION; CANCER CELLS; DEATH; FLAVONOIDS; ACID; ERK	Dillenia suffruticosa, which is locally known as Simpoh air, has been traditionally used to treat cancerous growth. The ethyl acetate extract of D. suffruticosa (EADs) has been shown to induce apoptosis in MCF-7 breast cancer cells in our previous study. The present study aimed to elucidate the molecular mechanisms involved in EADs-induced apoptosis and to identify the major compounds in the extract. EADs was found to promote oxidative stress in MCF-7 cells that led to cell death because the pre-treatment with antioxidants a-tocopherol and ascorbic acid significantly reduced the cytotoxicity of the extract (P<0.05). DCFH-DA assay revealed that treatment with EADs attenuated the generation of intracellular ROS. Apoptosis induced by EADs was not inhibited by the use of caspase-inhibitor Z-VAD-FMK, suggesting that the cell death is caspase-independent. The use of JC-1 dye reflected that EADs caused disruption in the mitochondrial membrane potential. The related molecular pathways involved in EADs-induced apoptosis were determined by GeXP multiplex system and Western blot analysis. EADs is postulated to induce cell cycle arrest that is p53- and p21-dependent based on the upregulated expression of p53- and p21 (P<0.05). The expression of Bax was upregulated with downregulation of Bcl-2 following treatment with EADs. The elevated Bax/Bcl-2 ratio and the depolarization of mitochondrial membrane potential suggest that EADs-induced apoptosis is mitochondria-dependent. The expression of oxidative stress-related AKT, p-AKT, ERK, and p-ERK was downregulated with upregulation of JNK and p-JNK. The data indicate that induction of oxidative-stress related apoptosis by EADs was mediated by inhibition of AKT and ERK, and activation of JNK. The isolation of compounds in EADs was carried out using column chromatography and elucidated using the nuclear resonance magnetic analysis producing a total of six compounds including 3-epimaslinic acid, kaempferol, kaempferide, protocatechuic acid, gallic acid and beta-sitosterol-3-O-a-D-glucopyranoside. The cytotoxicity of the isolated compounds was determined using MTT assay. Gallic acid was found to be most cytotoxic against MCF-7 cell line compared to others, with IC50 of 36 +/- 1.7 mu g/mL (P<0.05). In summary, EADs generated oxidative stress, induced cell cycle arrest and apoptosis in MCF-7 cells by regulating numerous genes and proteins that are involved in the apoptotic signal transduction pathway. Therefore, EADs has the potential to be developed as an anti-cancer agent against breast cancer.	[Tor, Yin Sim; Yazan, Latifah Saiful; Foo, Jhi Biau; Wibowo, Agustono; Ismail, Norsharina; Ismail, Maznah] Univ Putra Malaysia, Lab Mol Biomed, Inst Biosci, Serdang 43400, Selangor, Malaysia; [Yazan, Latifah Saiful; Cheah, Yoke Kqueen] Univ Putra Malaysia, Fac Med & Hlth Sci, Dept Biomed Sci, Serdang 43400, Selangor, Malaysia; [Abdullah, Rasedee] Univ Putra Malaysia, Fac Vet Med, Dept Vet Pathol & Microbiol, Serdang 43400, Selangor, Malaysia; [Ismail, Intan Safinar] Univ Putra Malaysia, Fac Sci, Dept Chem, Serdang 43400, Selangor, Malaysia; [Yeap, Swee Keong] Univ Putra Malaysia, Inst Biosci, Lab Vaccines & Immunotherapeut, Serdang 43400, Selangor, Malaysia	Universiti Putra Malaysia; Universiti Putra Malaysia; Universiti Putra Malaysia; Universiti Putra Malaysia; Universiti Putra Malaysia	Yazan, LS (corresponding author), Univ Putra Malaysia, Lab Mol Biomed, Inst Biosci, Serdang 43400, Selangor, Malaysia.	latifahsy@upm.edu.my	Wibowo, Agustono/U-8679-2019; sim, tor yin/M-6258-2017; Rasedee, Abdullah/E-9119-2013; Yeap, Swee Keong/H-9285-2013; Ismail, Intan Safinar/AAO-5386-2020; Foo, Jhi Biau/J-2844-2019	Wibowo, Agustono/0000-0001-6588-9507; sim, tor yin/0000-0002-4354-1486; Rasedee, Abdullah/0000-0001-6625-508X; Yeap, Swee Keong/0000-0002-4736-0674; Ismail, Intan Safinar/0000-0003-3960-0022; Foo, Jhi Biau/0000-0002-5880-2220; Cheah, Yoke Kqueen/0000-0001-9258-3749; ISMAIL, MAZNAH/0000-0002-2378-0519	Ministry of Higher Education (MOHE), Malaysia [04-04-10-884FR]	Ministry of Higher Education (MOHE), Malaysia	The work was supported by Fundamental Research Grant Scheme (04-04-10-884FR) from Ministry of Higher Education (MOHE), Malaysia. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ahmad R, 2013, ANTIOXIDANT PRINCIPL; Armania N, 2013, J ETHNOPHARMACOL, V146, P525, DOI 10.1016/j.jep.2013.01.017; Bai L, 2006, J CANC MOL, V2, P141; Balasundram N, 2006, FOOD CHEM, V99, P191, DOI 10.1016/j.foodchem.2005.07.042; Batra P, 2013, 3 BIOTECH, V3, P439, DOI 10.1007/s13205-013-0117-5; Bayoumi SAL, 2010, PHYTOCHEMISTRY, V71, P598, DOI 10.1016/j.phytochem.2009.10.012; Bhatt AN, 2010, INDIAN J MED RES, V132, P129; Blagosklonny MV, 2000, LEUKEMIA, V14, P1502, DOI 10.1038/sj.leu.2401864; Blokhina O, 2003, ANN BOT-LONDON, V91, P179, DOI 10.1093/aob/mcf118; Boulares AH, 1999, J BIOL CHEM, V274, P22932, DOI 10.1074/jbc.274.33.22932; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Broker LE, 2005, CLIN CANCER RES, V11, P3155, DOI 10.1158/1078-0432.CCR-04-2223; BUETTNER GR, 1993, ARCH BIOCHEM BIOPHYS, V300, P535, DOI 10.1006/abbi.1993.1074; Burlacu A, 2003, J CELL MOL MED, V7, P249, DOI 10.1111/j.1582-4934.2003.tb00225.x; BUTTKE TM, 1994, IMMUNOL TODAY, V15, P7, DOI 10.1016/0167-5699(94)90018-3; Cagnol S, 2010, FEBS J, V277, P2, DOI 10.1111/j.1742-4658.2009.07366.x; Calderon-Montano JM, 2011, MINI-REV MED CHEM, V11, P298, DOI 10.2174/138955711795305335; Chen YR, 1996, J BIOL CHEM, V271, P631, DOI 10.1074/jbc.271.2.631; Constantinou C, 2009, CURR CANCER DRUG TAR, V9, P717, DOI 10.2174/156800909789271512; Nguyen DMC, 2013, MICROB PATHOGENESIS, V59-60, P52, DOI 10.1016/j.micpath.2013.04.005; Dhanasekaran DN, 2008, ONCOGENE, V27, P6245, DOI 10.1038/onc.2008.301; Eldahshan O. A., 2011, Current Research Journal of Biological Sciences, V3, P52; Elmore S, 2007, TOXICOL PATHOL, V35, P495, DOI 10.1080/01926230701320337; Foo JB, 2014, BMC COMPLEM ALTERN M, V14, DOI 10.1186/1472-6882-14-197; Fridman JS, 2003, ONCOGENE, V22, P9030, DOI 10.1038/sj.onc.1207116; Gartel AL, 2002, MOL CANCER THER, V1, P639; Gomes CA, 2003, J MED CHEM, V46, P5395, DOI 10.1021/jm030956v; Halestrap AP, 2002, BIOCHIMIE, V84, P153, DOI 10.1016/S0300-9084(02)01375-5; Halliwell B, 2004, BRIT J PHARMACOL, V142, P231, DOI 10.1038/sj.bjp.0705776; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hsu JD, 2011, J AGR FOOD CHEM, V59, P1996, DOI 10.1021/jf103656v; Hung H, 2004, J CELL PHYSIOL, V198, P197, DOI 10.1002/jcp.10398; Janicke RU, 2009, BREAST CANCER RES TR, V117, P219, DOI 10.1007/s10549-008-0217-9; Jiang GX, 2013, FOOD CHEM, V136, P563, DOI 10.1016/j.foodchem.2012.08.089; Kalyanaraman B, 2012, FREE RADICAL BIO MED, V52, P1, DOI 10.1016/j.freeradbiomed.2011.09.030; KamalEldin A, 1996, LIPIDS, V31, P671, DOI 10.1007/BF02522884; Kang GY, 2009, EUR J PHARMACOL, V611, P17, DOI 10.1016/j.ejphar.2009.03.068; Kasibhatla S, 2003, MOL CANCER THER, V2, P573; Kim AH, 2001, MOL CELL BIOL, V21, P893, DOI 10.1128/MCB.21.3.893-901.2001; Karamac Magdalena, 2006, Polish Journal of Food and Nutrition Sciences, V15, P55; Lee E, 2008, B KOREAN CHEM SOC, V29, P507; Lee HJ, 2010, J KOREAN SOC APPL BI, V53, P826, DOI 10.3839/jksabc.2010.125; Leist M, 2003, CASPASE INDEPENDENT; Li XC, 2011, FUNCT FOODS HEALTH D, V1, P232; Liu J, 2005, CELL RES, V15, P36, DOI 10.1038/sj.cr.7290262; Lu ZM, 2006, IUBMB LIFE, V58, P621, DOI 10.1080/15216540600957438; Luo HT, 2010, CANCER CELL INT, V10, DOI 10.1186/1475-2867-10-16; Ly JD, 2003, APOPTOSIS, V8, P115, DOI 10.1023/A:1022945107762; Ma XH, 2009, DRUG DISCOV TODAY, V14, P579, DOI 10.1016/j.drudis.2009.03.012; Manning BD, 2007, CELL, V129, P1261, DOI 10.1016/j.cell.2007.06.009; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Mundhe K. S., 2011, Journal of Chemical and Pharmaceutical Research, V3, P764; Nylandsted J, 2000, P NATL ACAD SCI USA, V97, P7871, DOI 10.1073/pnas.97.14.7871; Ohashi T, 2002, FEBS LETT, V511, P21, DOI 10.1016/S0014-5793(01)03262-8; Ostrakhovitch EA, 2005, J CELL BIOCHEM, V95, P1120, DOI 10.1002/jcb.20484; Otake Y, 2002, DRUG METAB DISPOS, V30, P103, DOI 10.1124/dmd.30.2.103; Patra RC, 2001, TOXICOLOGY, V162, P81, DOI 10.1016/S0300-483X(01)00345-6; PETIT PX, 1995, J CELL BIOL, V130, P157, DOI 10.1083/jcb.130.1.157; Petrelli A, 2008, CURR MED CHEM, V15, P422; Piccolo MT., 2012, J CAN RES UPDATES, V1, P189, DOI DOI 10.6000/1929-2279.2012.01.02.5; Ravishankar D, 2013, INT J BIOCHEM CELL B, V45, P2821, DOI 10.1016/j.biocel.2013.10.004; RiceEvans CA, 1996, FREE RADICAL BIO MED, V20, P933, DOI 10.1016/0891-5849(95)02227-9; Roberts PJ, 2007, ONCOGENE, V26, P3291, DOI 10.1038/sj.onc.1210422; Roy Sanjit K, 2010, J Mol Signal, V5, P10, DOI 10.1186/1750-2187-5-10; Seo S Y T, 1981, JOURNAL OF THE AMERI, V101, P2075; Shim HY, 2007, MOL CELLS, V24, P95; SIES H, 1991, KLIN WOCHENSCHR, V69, P965, DOI 10.1007/BF01645140; SOULE HD, 1990, CANCER RES, V50, P6075; Tanaka T., 2011, Journal of Experimental and Clinical Medicine, V3, P27, DOI 10.1016/j.jecm.2010.12.005; TOR YS, 2014, BMC COMPLEM ALTERN M, V14, DOI DOI 10.1186/1472-6882-; vanAcker SABE, 1996, FREE RADICAL BIO MED, V20, P331, DOI 10.1016/0891-5849(95)02047-0; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Wagner H, 2009, PHYTOMEDICINE, V16, P97, DOI 10.1016/j.phymed.2008.12.018; WALDMAN T, 1995, CANCER RES, V55, P5187; Wang K, 2014, J BIOCHEM MOL TOXIC, V28, P387, DOI 10.1002/jbt.21575; Wardman P, 2002, J FLUORESC, V12, P65, DOI 10.1023/A:1015363220266; Wen J, 2002, J BIOL CHEM, V277, P38954, DOI 10.1074/jbc.M203842200; Williamson EM, 2001, PHYTOMEDICINE, V8, P401, DOI 10.1078/0944-7113-00060	78	61	63	0	19	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 5	2015	10	6							e0127441	10.1371/journal.pone.0127441	http://dx.doi.org/10.1371/journal.pone.0127441			25	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CJ7CR	26047480	Green Published, gold, Green Submitted			2023-01-03	WOS:000355652200021
J	Bennett, SD; Otieno, R; Ayers, TL; Odhiambo, A; Faith, SH; Quick, R				Bennett, Sarah D.; Otieno, Ronald; Ayers, Tracy L.; Odhiambo, Aloyce; Faith, Sitnah H.; Quick, Robert			Acceptability and Use of Portable Drinking Water and Hand Washing Stations in Health Care Facilities and Their Impact on Patient Hygiene Practices, Western Kenya	PLOS ONE			English	Article							ANTENATAL SERVICES; INTEGRATION; PROMOTION; SCALE	Many health care facilities (HCF) in developing countries lack access to reliable hand washing stations and safe drinking water. To address this problem, we installed portable, low-cost hand washing stations (HWS) and drinking water stations (DWS), and trained healthcare workers (HCW) on hand hygiene, safe drinking water, and patient education techniques at 200 rural HCFs lacking a reliable water supply in western Kenya. We performed a survey at baseline and a follow-up evaluation at 15 months to assess the impact of the intervention at a random sample of 40 HCFs and 391 households nearest to these HCFs. From baseline to follow-up, there was a statistically significant increase in the percentage of dispensaries with access to HWSs with soap (42% vs. 77%, p<0.01) and access to safe drinking water (6% vs. 55%, p<0.01). Female heads of household in the HCF catchment area exhibited statistically significant increases from baseline to follow-up in the ability to state target times for hand washing (10% vs. 35%, p<0.01), perform all four hand washing steps correctly (32% vs. 43%, p = 0.01), and report treatment of stored drinking water using any method (73% vs. 92%, p<0.01); the percentage of households with detectable free residual chlorine in stored drinking water did not change (6%, vs. 8%, p = 0.14). The installation of low-cost, low-maintenance, locally-available, portable hand washing and drinking water stations in rural HCFs without access to 24-hour piped water helped assure that health workers had a place to wash their hands and provide safe drinking water. This HCF intervention may have also contributed to the improvement of hand hygiene and reported safe drinking water behaviors among households nearest to HCFs.	[Bennett, Sarah D.; Ayers, Tracy L.; Quick, Robert] Ctr Dis Control & Prevent, Div Foodborne Waterborne & Environm Dis, Atlanta, GA 30329 USA; [Bennett, Sarah D.] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA USA; [Otieno, Ronald; Odhiambo, Aloyce; Faith, Sitnah H.] Safe Water & AIDS Project, Kisumu, Nyanza Province, Kenya	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA	Quick, R (corresponding author), Ctr Dis Control & Prevent, Div Foodborne Waterborne & Environm Dis, Atlanta, GA 30329 USA.	rxq1@cdc.gov		Ayers, Tracy/0000-0003-4140-3263	UNICEF Kenya	UNICEF Kenya	Funding was provided by UNICEF Kenya. Recipients were Christian Health Association of Kenya and Safe Water and AIDS Project. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Albert J, 2010, ENVIRON SCI TECHNOL, V44, P4426, DOI 10.1021/es1000566; Brown J, 2009, J WATER HEALTH, V7, P404, DOI 10.2166/wh.2009.085; Daniels NA, 1999, AM J TROP MED HYG, V60, P1051, DOI 10.4269/ajtmh.1999.60.1051; Date K, 2013, J INFECT DIS, V208, pS62, DOI 10.1093/infdis/jit198; Engelhart S, 2001, J INFECTION, V43, P57, DOI 10.1053/jinf.2001.0851; Forrester JD, 2014, MMWR-MORBID MORTAL W, V63, P891; Loharikar A, 2013, AM J TROP MED HYG, V88, P267, DOI 10.4269/ajtmh.2012.11-0375; Luby SP, 2008, AM J TROP MED HYG, V78, P382, DOI 10.4269/ajtmh.2008.78.382; Organization WH, 2009, WHO GUID HAND HYG HL; Organization WH, 2007, IMPR HAND HYG PREV H; Parker AA, 2006, EPIDEMIOL INFECT, V134, P1029, DOI 10.1017/S0950268806005954; Pittet D, 2008, J HOSP INFECT, V68, P285, DOI 10.1016/j.jhin.2007.12.013; Russo ET, 2012, AM J TROP MED HYG, V86, P860, DOI 10.4269/ajtmh.2012.11-0259; Sheth AN, 2010, AM J TROP MED HYG, V83, P1315, DOI 10.4269/ajtmh.2010.10-0211; Sreenivasan N, 2015, EPIDEMIOL INFECT, V143, P873, DOI 10.1017/S095026881400082X; Ulmer BC, 2000, ASS PREOPERATIVE REG, V71, P1126; World Health Organization, 2015, WATER SANITATION HYG; World Health Organization UNICEF Joint Monitoring Programme, 2014, WASH POST 2015 PROP; WYKLICKY H, 1983, Infection Control (Thorofare), V4, P367	19	11	11	1	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 11	2015	10	5							e0126916	10.1371/journal.pone.0126916	http://dx.doi.org/10.1371/journal.pone.0126916			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CI1YY	25961293	Green Published, gold			2023-01-03	WOS:000354542500157
J	Li, P; Chen, YP; Liu, JP; Hong, J; Deng, YY; Yang, F; Jin, XP; Gao, J; Li, J; Fang, H; Liu, GL; Shi, LP; Du, JH; Li, Y; Yan, MH; Wen, YM; Yang, WY				Li, Ping; Chen, Yiping; Liu, Jianping; Hong, Jing; Deng, Yueyi; Yang, Fang; Jin, Xiuping; Gao, Jing; Li, Jing; Fang, Hui; Liu, Geling; Shi, Liping; Du, Jinhang; Li, Yang; Yan, Meihua; Wen, Yumin; Yang, Wenying			Efficacy and Safety of Tangshen Formula on Patients with Type 2 Diabetic Kidney Disease: A Multicenter Double-Blinded Randomized Placebo-Controlled Trial	PLOS ONE			English	Article							TRADITIONAL CHINESE MEDICINE; NEPHROPATHY; PREVALENCE; MICROALBUMINURIA; PROGRESSION; PREVENTION; ALISKIREN; LOSARTAN; THERAPY; RISK	Background Persons with diabetes are at high risk of developing diabetic kidney disease (DKD), which is associated with high morbidity and mortality. Current drug therapies for DKD, such as angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs), are not entirely satisfactory. This study aimed to evaluate the additional benefit and safety of the Chinese herbal granule Tangshen Formula (TSF) in treating DKD. Methods The study was designed as a six-center randomized, double-blind, placebo-controlled trial. From April 2007 through December 2009, 180 patients with DKD were enrolled. In addition to conventional treatment with ACEIs or ARBs, 122 participants were randomly assigned to receive TSF and 58 participants to receive placebo for 24 weeks. Primary outcome was urinary protein level, measured by urinary albumin excretion rate (UAER) for participants with microalbuminuria, 24-hour urinary protein (24h UP) for participants with macroalbuminuria. Secondary outcomes included renal function, serum lipids, quality of life, symptoms, and adverse events. Findings After 24 weeks of treatment, no statistically significant difference in UAER (TSF -19.53 mu g/min compared with placebo -7.01 mu g/min, with a mean difference of -12.52 mu g/min; 95% CI, -68.67 to 43.63, P = 0.696) was found between TSF and placebo groups. However, TSF displayed a statistically significant decrease in 24h UP (TSF-0.21 g compared with placebo 0.36 g, with a mean difference of -0.57g; 95% CI, -1.05 to -0.09, P = 0.024). Estimated glomerular filtration rate (eGFR) was improved in both patients with microalbuminuria and macroalbuminuria, with a mean difference of 15.51 ml/min/1.73m(2) (95% CI, 3.71 to 27.31), 9.01ml/min/1.73 m(2) (95% CI, -0.10 to 18.13), respectively. Other secondary outcomes showed no statistically significant difference between groups or in the incidence of adverse events. Conclusions Based on conventional treatments, TSF appears to provide additional benefits compared with placebo in decreasing proteinuria and improving eGFR in DKD patients with macroalbuminuria. Nevertheless, further study is needed to evaluate TSF treating patients with microalbuminuria.	[Li, Ping; Yan, Meihua; Wen, Yumin] China Japan Friendship Hosp, Inst Clin Med Sci, Beijing, Peoples R China; [Chen, Yiping; Deng, Yueyi] Shanghai Univ TCM, Longhua Hosp, Dept Nephrol, Shanghai, Peoples R China; [Liu, Jianping] Beijing Univ Chinese Med, Ctr Evidence Based Chinese Med, Beijing, Peoples R China; [Hong, Jing; Yang, Wenying] China Japan Friendship Hosp, Dept Endocrinol, Beijing, Peoples R China; [Yang, Fang] Hebei United Univ, Res Ctr Expt Med, Tangshan, Peoples R China; [Jin, Xiuping] Hebei United Univ Affiliated Hosp, Dept Endocrinol, Tangshan, Peoples R China; [Gao, Jing; Li, Jing] Beijing Univ Chinese Med, Dongzhimen Hosp, Dept Nephrol, Beijing, Peoples R China; [Fang, Hui; Liu, Geling] Tangshan Gongren Hosp, Dept Endocrinol, Tangshan, Peoples R China; [Shi, Liping] Kailuan Gen Hosp, Dept Endocrinol, Tangshan, Peoples R China; [Du, Jinhang] China Japan Friendship Hosp, Dept Nephrol, Beijing, Peoples R China; [Li, Yang] Renmin Univ China, Sch Stat, Beijing, Peoples R China	China-Japan Friendship Hospital; Shanghai University of Traditional Chinese Medicine; Beijing University of Chinese Medicine; China-Japan Friendship Hospital; North China University of Science & Technology; Beijing University of Chinese Medicine; China-Japan Friendship Hospital; Renmin University of China	Li, P (corresponding author), China Japan Friendship Hosp, Inst Clin Med Sci, Beijing, Peoples R China.	lp8675@163.com	Chen, Yi/HIR-2608-2022	Liu, Jianping/0000-0002-0320-061X	Major State Basic Research Development Program of China (973 Program) [2005CB523503]; China International Science and Technology Cooperation [2006DFB31480, 2011DFA31860]; Key Program of National Natural Science Foundation of China [81130066]	Major State Basic Research Development Program of China (973 Program)(National Basic Research Program of China); China International Science and Technology Cooperation; Key Program of National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work was supported by a grant from the Major State Basic Research Development Program of China (973 Program) (No. 2005CB523503), the China International Science and Technology Cooperation (No. 2006DFB31480), the China International Science and Technology Cooperation (No. 2011DFA31860) and the Key Program of National Natural Science Foundation of China (No. 81130066). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alkhalaf A, 2010, DIABETES CARE, V33, P1598, DOI 10.2337/dc09-2241; Altemtam N, 2012, NEPHROL DIAL TRANSPL, V27, P1847, DOI 10.1093/ndt/gfr561; Am Diabetes Assoc, 2006, DIABETES CARE, V29, pS4; Amer Diabet Assoc, 2013, DIABETES CARE, V36, pS11, DOI 10.2337/dc13-S011; Baek GH, 2012, INFLAMMATION, V35, P1232, DOI 10.1007/s10753-012-9433-x; Barnett AH, 2004, NEW ENGL J MED, V351, P1952, DOI 10.1056/NEJMoa042274; Brenner BM, 2001, NEW ENGL J MED, V345, P861, DOI 10.1056/NEJMoa011161; Chang B, 2012, AM J CHINESE MED, V40, P1177, DOI 10.1142/S0192415X12500875; Chen YP, 2013, AM J KIDNEY DIS, V62, P1068, DOI 10.1053/j.ajkd.2013.05.005; Chinese Pharmacopoeia Commission, 2005, CHINESE PHARMACOPOEI; Colmers IN, 2012, CAN MED ASSOC J, V184, pE675, DOI 10.1503/cmaj.112102; de Boer IH, 2011, JAMA-J AM MED ASSOC, V305, P2532, DOI 10.1001/jama.2011.861; Dong Z, 2013, PHYTOMEDICINE, V20, P1023, DOI 10.1016/j.phymed.2013.04.007; Fang JQ., 2001, QUALITY LIFE MEASURE; Feng J, 2000, CHINESE J INTEGRATIV, V20, P212; Gao Q, 2010, PLANTA MED, V76, P27, DOI 10.1055/s-0029-1185948; Haller H, 2011, NEW ENGL J MED, V364, P907, DOI 10.1056/NEJMoa1007994; Harper A, 1998, PSYCHOL MED, V28, P551, DOI 10.1017/S0033291798006667; Hemmelgarn BR, 2006, KIDNEY INT, V69, P2155, DOI 10.1038/sj.ki.5000270; House AA, 2010, JAMA-J AM MED ASSOC, V303, P1603, DOI 10.1001/jama.2010.490; Komajda M, 2010, EUR HEART J, V31, P824, DOI 10.1093/eurheartj/ehp604; Levin A, 2007, AM J KIDNEY DIS, V49, pS10, DOI 10.1053/j.ajkd.2006.12.004; Lewis EJ, 2012, J AM SOC NEPHROL, V23, P131, DOI 10.1681/ASN.2011030272; Li MX, 2011, J ETHNOPHARMACOL, V133, P412, DOI 10.1016/j.jep.2010.10.012; [刘明平 LIU Ming-ping], 2009, [西安交通大学学报. 医学版, Journal of Xi'an Jiaotong University. Medical Sciences], V30, P377; Mamtani R, 2012, JNCI-J NATL CANCER I, V104, P1411, DOI 10.1093/jnci/djs328; Mann JFE, 2010, J AM SOC NEPHROL, V21, P527, DOI 10.1681/ASN.2009060593; Nie YN, 2014, BMC COMPLEM ALTERN M, V14, DOI 10.1186/1472-6882-14-148; Packham DK, 2012, J AM SOC NEPHROL, V23, P123, DOI 10.1681/ASN.2011040378; Parving HH, 2006, KIDNEY INT, V69, P2057, DOI 10.1038/sj.ki.5000377; Parving HH, 2012, J RENIN-ANGIO-ALDO S, V13, P387, DOI 10.1177/1470320311434818; Persson F, 2010, DIABETES CARE, V33, P2304, DOI 10.2337/dc10-0833; Pistrosch F, 2012, HORM METAB RES, V44, P914, DOI 10.1055/s-0032-1314836; Ruggenenti P, 2004, NEW ENGL J MED, V351, P1941, DOI 10.1056/NEJMoa042167; Sarafidis PA, 2010, AM J KIDNEY DIS, V55, P835, DOI 10.1053/j.ajkd.2009.11.013; Shaw JE, 2010, DIABETES RES CLIN PR, V87, P4, DOI 10.1016/j.diabres.2009.10.007; Srinivasan S, 2012, CHEM-BIOL INTERACT, V195, P43, DOI 10.1016/j.cbi.2011.10.003; Sun T, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/929025; Uzayisenga R, 2014, PHYTOTHER RES, V28, P510, DOI 10.1002/ptr.5026; Wang H, 2012, COCHRANE DB SYST REV, V7; Wang YJ, 2012, J ETHNOPHARMACOL, V139, P757, DOI 10.1016/j.jep.2011.12.009; Xiao Y, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/937549; Xu HQ, 2004, BIOL PHARM BULL, V27, P1014, DOI 10.1248/bpb.27.1014; Xu Y, 2013, JAMA-J AM MED ASSOC, V310, P948, DOI 10.1001/jama.2013.168118; Yang WY, 2010, NEW ENGL J MED, V362, P1090, DOI 10.1056/NEJMoa0908292; Zhang H, 2009, J BEIJING U TRADITIO, V32, P244; Zhang H, 2009, CHIN J INTEGR TRADIT, V10, P290; Zhang HT, 2011, EURASIP J WIREL COMM, P1, DOI 10.1186/1687-1499-2011-69; Zhang JQ, 2009, J ETHNOPHARMACOL, V126, P189, DOI 10.1016/j.jep.2009.08.046; Zheng XY, 2002, CLIN RES GUID NEW IN	50	48	55	5	29	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 4	2015	10	5							e0126027	10.1371/journal.pone.0126027	http://dx.doi.org/10.1371/journal.pone.0126027			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CH3PP	25938778	Green Submitted, Green Published, gold			2023-01-03	WOS:000353943000131
J	Sondermann, W; Griewank, KG; Schilling, B; Livingstone, E; Leyh, JC; Rompoti, N; Cosgarea, I; Schimming, T; Schadendorf, D; Zimmer, L; Hillen, U				Sondermann, Wiebke; Griewank, Klaus G.; Schilling, Bastian; Livingstone, Elisabeth; Leyh, Julia C.; Rompoti, Natalia; Cosgarea, Ioana; Schimming, Tobias; Schadendorf, Dirk; Zimmer, Lisa; Hillen, Uwe			Corticosteroids Augment BRAF Inhibitor Vemurafenib Induced Lymphopenia and Risk of Infection	PLOS ONE			English	Article							LYMPHOCYTE SUBPOPULATIONS; METASTATIC MELANOMA; IPILIMUMAB; SURVIVAL; DABRAFENIB; SAFETY; ANTI-PD-1; THERAPY	We have previously demonstrated an impact of the BRAF inhibitor vemurafenib on patient lymphocyte counts. In the current study, the extent to which concomitant use of corticosteroids in BRAF inhibitor treated patients affects lymphocyte counts and predisposes to infection was investigated. A cohort of 102 patients receiving either the selective BRAF inhibitor vemurafenib or dabrafenib was analyzed. The amount of patients receiving either medication with or without systemic corticosteroids (dexamethasone) was determined and lymphocyte counts before and under therapy assessed. Additionally, the number and severity of infections occurring in these groups was analyzed. Vemurafenib treatment led to a considerable decrease in lymphocyte cell counts, with 62.3% of patients having lymphopenia. Dabrafenib treated patients only rarely demonstrated lymphopenia (12.5%). Dexamethasone co-administration further diminished lymphocyte counts. Lymphopenias were observed in 84.6% of patients receiving vemurafenib and dexamethasone. In our cohort, infections were noted in 9 patients, 4 of these were severe and 2 eventually fatal. All 9 cases with infections demonstrated lymphopenia, 8 of these had received dexamethasone and 7 of these a therapy with vemurafenib. Our findings demonstrate a significant lymphopenia in patients treated with the BRAF inhibitor vemurafenib, which is further augmented by dexamethasone and predisposes to infection. If validated in other studies, risk of infection should be considered when applying corticosteroids in combination with BRAF inhibitors, in particular vemurafenib.	[Griewank, Klaus G.] Univ Duisburg Essen, Univ Hosp Essen, West German Canc Ctr, Dept Dermatol, Essen, Germany; German Canc Consortium DKTK, Essen, Germany	University of Duisburg Essen; Helmholtz Association; German Cancer Research Center (DKFZ)	Griewank, KG (corresponding author), Univ Duisburg Essen, Univ Hosp Essen, West German Canc Ctr, Dept Dermatol, Essen, Germany.	klaus.griewank@uk-essen.de; uwe.hillen@uk-essen.de	Livingstone, Elisabeth/AHE-9171-2022; Griewank, Klaus G/A-9097-2017; Schilling, Bastian/AAY-8646-2020; Zimmer, Lisa/AAP-8495-2021; Schadendorf, Dirk/AAE-8206-2019	Griewank, Klaus G/0000-0003-3899-9449; Schilling, Bastian/0000-0001-8859-4103; Zimmer, Lisa/0000-0002-3680-3521; 	Bristol-Myers Squibb	Bristol-Myers Squibb(Bristol-Myers Squibb)	Wiebke Sondermann has received honoraria from Roche and travel support from Bristol-Myers Squibb. Bastian Schilling has received honoraria from Roche and travel support as well research funding from Bristol-Myers Squibb. Elisabeth Livingstone has received honoraria from Roche, Bristol-Myers Squibb, Amgen, Boehringer Ingelheim, Merck Sharp & Dohme, and Merck, and travel support from Bristol-Myers Squibb. Lisa Zimmer has received honoraria from Roche, Bristol-Myers Squibb, Boehringer Ingelheim and Amgen, and travel support from Merck Sharp & Dohme and Bristol-Myers Squibb. Uwe Hillen has received honoraria from Roche. Dirk Schadendorf is on the advisory board or has received honoraria from Roche, Genentech, Novartis, Amgen, GlaxoSmithKline, Bristol-Myers Squibb, Boehringer Ingelheim, and Merck Sharp & Dohme. The remaining authors have declared no conflicts of interest. This does not alter the authors' adherence to PLOS ONE policies on sharing data and materials.	Boni A, 2010, CANCER RES, V70, P5213, DOI 10.1158/0008-5472.CAN-10-0118; Chapman PB, 2011, NEW ENGL J MED, V364, P2507, DOI 10.1056/NEJMoa1103782; Danielli R, 2012, CANCER IMMUNOL IMMUN, V61, P41, DOI 10.1007/s00262-011-1089-0; Deichmann M, 2000, J EXP CLIN CANC RES, V19, P301; FAUCI AS, 1975, IMMUNOLOGY, V28, P669; Flaherty KT, 2010, NEW ENGL J MED, V363, P809, DOI 10.1056/NEJMoa1002011; Hamid O, 2013, NEW ENGL J MED, V369, P134, DOI 10.1056/NEJMoa1305133; Hauschild A, 2012, LANCET, V380, P358, DOI 10.1016/S0140-6736(12)60868-X; Hodi FS, 2010, NEW ENGL J MED, V363, P711, DOI 10.1056/NEJMoa1003466; Lipson EJ, 2013, CLIN CANCER RES, V19, P462, DOI 10.1158/1078-0432.CCR-12-2625; Long GV, 2014, NEW ENGL J MED, V371, P1877, DOI 10.1056/NEJMoa1406037; Lozano R, 2012, LANCET, V380, P2095, DOI 10.1016/S0140-6736(12)61728-0; Ribas A, 2013, NEW ENGL J MED, V368, P1365, DOI 10.1056/NEJMc1302338; Robert C, 2015, NEW ENGL J MED, V372, P30, DOI 10.1056/NEJMoa1412690; Robert C, 2011, NEW ENGL J MED, V364, P2517, DOI 10.1056/NEJMoa1104621; Schilling B, 2014, ANN ONCOL, V25, P747, DOI 10.1093/annonc/mdt587; Siegel R, 2014, CA-CANCER J CLIN, V64, P9, DOI 10.3322/caac.21208; Siroy AE, 2014, J INVESTIGATIVE DERM; Topalian SL, 2014, J CLIN ONCOL, V32, P1020, DOI 10.1200/JCO.2013.53.0105; Wolchok JD, 2013, ANN ONCOL, V24, P2174, DOI 10.1093/annonc/mdt161; Wolchok JD, 2013, NEW ENGL J MED, V369, P122, DOI 10.1056/NEJMoa1302369; Yamane H, 2014, J CLIN ONCOL, V32, P607, DOI 10.1200/JCO.2013.53.2226; YU DTY, 1974, J CLIN INVEST, V53, P565, DOI 10.1172/JCI107591	23	5	5	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 21	2015	10	4							e0124590	10.1371/journal.pone.0124590	http://dx.doi.org/10.1371/journal.pone.0124590			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CG3XJ	25897843	Green Published, gold, Green Submitted			2023-01-03	WOS:000353212600075
J	Watt, C; Abuya, T; Warren, CE; Obare, F; Kanya, L; Bellows, B				Watt, Claire; Abuya, Timothy; Warren, Charlotte E.; Obare, Francis; Kanya, Lucy; Bellows, Ben			Can Reproductive Health Voucher Programs Improve Quality of Postnatal Care? A Quasi-Experimental Evaluation of Kenya's Safe Motherhood Voucher Scheme	PLOS ONE			English	Article							OF-CARE; INTERVENTION; NEWBORN	This study tests the group-level causal relationship between the expansion of Kenya's Safe Motherhood voucher program and changes in quality of postnatal care (PNC) provided at voucher-contracted facilities. We compare facilities accredited since program inception in 2006 (phase I) and facilities accredited since 2010-2011 (phase II) relative to comparable non-voucher facilities. PNC quality is assessed using observed clinical content processes, as well as client-reported outcome measures. Two-tailed unpaired t-tests are used to identify differences in mean process quality scores and client-reported outcome measures, comparing changes between intervention and comparison groups at the 2010 and 2012 data collection periods. Difference-in-differences analysis is used to estimate the reproductive health (RH) voucher program's causal effect on quality of care by exploiting group-level differences between voucher-accredited and non-accredited facilities in 2010 and 2012. Participation in the voucher scheme since 2006 significantly improves overall quality of postnatal care by 39% (p=0.02), where quality is defined as the observable processes or components of service provision that occur during a PNC consultation. Program participation since phase I is estimated to improve the quality of observed maternal postnatal care by 86% (p=0.02), with the largest quality improvements in counseling on family planning methods (IRR 5.0; p=0.01) and return to fertility (IRR 2.6; p=0.01). Despite improvements in maternal aspects of PNC, we find a high proportion of mothers who seek PNC are not being checked by any provider after delivery. Additional strategies will be necessary to standardize provision of packaged postnatal interventions to both mother and newborn. This study addresses an important gap in the existing RH literature by using a strong evaluation design to assess RH voucher program effectiveness on quality improvement.	[Watt, Claire] Jacaranda Hlth, Nairobi, Kenya; [Abuya, Timothy; Obare, Francis; Kanya, Lucy; Bellows, Ben] Populat Council, Nairobi, Kenya; [Warren, Charlotte E.] Populat Council, Washington, DC USA	Population Council	Watt, C (corresponding author), Jacaranda Hlth, Nairobi, Kenya.	cew690@mail.harvard.edu	Abuya, Timothy/AAH-5479-2020	Rothschild, Claire/0000-0002-2419-9881; Bellows, Ben/0000-0001-9205-6623	Bill & Melinda Gates Foundation [51761]	Bill & Melinda Gates Foundation(Bill & Melinda Gates Foundation)	Funding for the Reproductive Health Voucher Program Evaluation was provided by the Bill & Melinda Gates Foundation (http://www.gatesfoundation.org/). Project Title: Evaluation of voucher and accreditation interventions for improving business models applied to reproductive health service delivery systems (Grant Number 51761). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abuya T, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-540; Ahmed S, 2011, HEALTH POLICY PLANN, V26, P25, DOI 10.1093/heapol/czq015; Anderson ML, 2008, J AM STAT ASSOC, V103, P1481, DOI 10.1198/016214508000000841; Bellows B, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-667; Bellows N., 2012, VOUCHERS REPROD HLTH; Bellows NM, 2011, TROP MED INT HEALTH, V16, P84, DOI 10.1111/j.1365-3156.2010.02667.x; Benjamini Y, 2006, BIOMETRIKA, V93, P491, DOI 10.1093/biomet/93.3.491; Bhatia M. R., 2007, Journal of International Development, V19, P975, DOI 10.1002/jid.1361; Bhutta ZA, 2011, SYSTEMATIC REV HUMAN; Bhutta ZA, 2010, LANCET, V375, P2032, DOI 10.1016/S0140-6736(10)60678-2; BRUCE J, 1990, STUD FAMILY PLANN, V21, P61, DOI 10.2307/1966669; DONABEDIAN A, 1988, JAMA-J AM MED ASSOC, V260, P1743, DOI 10.1001/jama.260.12.1743; Friberg IK, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000295; Gabrysch S, 2012, TROP MED INT HEALTH, V17, P2, DOI 10.1111/j.1365-3156.2011.02851.x; Hatt L., 2010, EC EVALUATION DEMAND; Hodgins S, 2014, GLOB HEALTH-SCI PRAC, V2, P173, DOI 10.9745/GHSP-D-13-00176; Hogan MC, 2010, LANCET, V375, P1609, DOI 10.1016/S0140-6736(10)60518-1; Kanya L, 2014, HEALTH POLICY PLANN, V29, pI4, DOI 10.1093/heapol/czt079; Kerber KJ, 2007, LANCET, V370, P1358, DOI 10.1016/S0140-6736(07)61578-5; Kinney MV, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000294; Lawn J, 2009, STATE WORLDS CHILDRE; Lozano R, 2011, LANCET, V378, P1139, DOI 10.1016/S0140-6736(11)61337-8; Meuwissen LE, 2006, INT J QUAL HEALTH C, V18, P35, DOI 10.1093/intqhc/mzi073; Meuwissen LE, 2006, BMC PUBLIC HEALTH, V6, DOI 10.1186/1471-2458-6-204; Meuwissen LE, 2006, TROP MED INT HEALTH, V11, P889, DOI 10.1111/j.1365-3156.2006.01632.x; Morgan L., 2011, MORE CHOICES WOMEN V; Obare F, 2013, LANCET, V2013, P381, DOI [10.1016/S0140-6736(13)61354-9, DOI 10.1016/S0140-6736(13)61354-9]; Obare F, 2013, HEALTH POLICY PLANN, V28, P165, DOI 10.1093/heapol/czs033; Rogo KO, 2006, DISEASE AND MORTALITY IN SUB-SAHARAN AFRICA, 2ND EDITION, P223; Ross JA, 2001, INT FAM PLAN PERSPEC, V27, P20, DOI 10.2307/2673801; Sandiford P, 2005, GUIDE COMPETITIVE VO; Warren C, 2006, POSTNATAL CARE OPPOR, P79; Warren C, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-177; World Health Organization, 2014, WHO REC POSTN CAR MO; Zwane AP, 2011, P NATL ACAD SCI USA, V108, P1821, DOI 10.1073/pnas.1000776108	35	20	20	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 2	2015	10	4							e0122828	10.1371/journal.pone.0122828	http://dx.doi.org/10.1371/journal.pone.0122828			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	CE9BS	25835713	Green Published, gold, Green Submitted, Green Accepted			2023-01-03	WOS:000352139000114
J	Grau, A; Tabib, A; Grau, I; Reiner, I; Mevorach, D				Grau, Amir; Tabib, Adi; Grau, Inna; Reiner, Inna; Mevorach, Dror			Apoptotic Cells Induce NF-kappa B and Inflammasome Negative Signaling	PLOS ONE			English	Article							NALP3 INFLAMMASOME; REACTIVE OXYGEN; EXPERIMENTAL COLITIS; NLRP3 INFLAMMASOME; IMMUNE-RESPONSE; DENDRITIC CELLS; MACROPHAGES; RECOGNITION; ACTIVATION; CLEARANCE	As they undergo phagocytosis, most early apoptotic cells negatively regulate proinflammatory signaling and were suggested as a major mechanism in the resolution of inflammation. The dextran sulfate sodium model is generally viewed as an epithelial damage model suited to investigate innate immune responses. Macrophages primed with LPS and subsequently exposed to DSS secrete high levels of IL-1 beta in an NLRP3-, ASC-, and caspase-1-dependent manner. The aim of this research was to test the therapeutic effect of a single dose of apoptotic cells in a DSS-colitis model and to explore possible mechanisms. Primary peritoneal macrophages, the DSS mice model, and Nlrp3-deficient mice, were used to assess the effect apoptotic cells on colitis. Immunohistochemistry, flow-cytometer, and western blots helped to explore the effect and mechanisms. Using a variety of NLRP3 triggering mechanisms, we show that apoptotic cells negatively regulate NF-kappa B and NLRP3 activation in primary peritoneal macrophages, at pre- and post-transcription levels, via inhibition of reactive oxygen species, lysosomal stabilization, and blocking K+ efflux. This property of apoptotic cells is demonstrated in a dramatic clinical, histological, and immunological amelioration of DSS colitis in Balb/c and B6 mice following a single administration of apoptotic cells.	[Grau, Amir; Tabib, Adi; Grau, Inna; Reiner, Inna; Mevorach, Dror] Hadassah Hebrew Univ Med Ctr, Lab Cellular & Mol Immunol, Rheumatol Res Ctr, Dept Med, Jerusalem, Israel	Hebrew University of Jerusalem	Mevorach, D (corresponding author), Hadassah Hebrew Univ Med Ctr, Lab Cellular & Mol Immunol, Rheumatol Res Ctr, Dept Med, Jerusalem, Israel.	mevorachd@hadassah.org.il			Hadassah-Hebrew University Medical Center	Hadassah-Hebrew University Medical Center	This research was partially supported by a grant from the Hadassah-Hebrew University Medical Center. No additional external funding received for this study. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Allen IC, 2010, J EXP MED, V207, P1045, DOI 10.1084/jem.20100050; Allen IC, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00169; Amarilyo G, 2010, EUR J IMMUNOL, V40, P699, DOI 10.1002/eji.200838951; Ariel A, 2006, NAT IMMUNOL, V7, P1209, DOI 10.1038/ni1392; Bauer C, 2012, DIGEST DIS, V30, P82, DOI 10.1159/000341681; Bauer C, 2010, GUT, V59, P1192, DOI 10.1136/gut.2009.197822; Cadwell K, 2010, CELL, V141, P1135, DOI 10.1016/j.cell.2010.05.009; Cruz CM, 2007, J BIOL CHEM, V282, P2871, DOI 10.1074/jbc.M608083200; Cvetanovic M, 2004, J IMMUNOL, V172, P880, DOI 10.4049/jimmunol.172.2.880; Cvetanovic M, 2006, J BIOL CHEM, V281, P20055, DOI 10.1074/jbc.M603920200; Dostert C, 2008, SCIENCE, V320, P674, DOI 10.1126/science.1156995; Dupaul-Chicoine J, 2010, IMMUNITY, V32, P367, DOI 10.1016/j.immuni.2010.02.012; Elinav E, 2011, CELL, V145, P745, DOI 10.1016/j.cell.2011.04.022; Elliott MR, 2010, J CELL BIOL, V189, P1059, DOI 10.1083/jcb.201004096; Erwig LP, 2006, P NATL ACAD SCI USA, V103, P12825, DOI 10.1073/pnas.0605331103; FADOK VA, 1992, J IMMUNOL, V148, P2207; Fadok VA, 1998, J CLIN INVEST, V101, P890, DOI 10.1172/JCI1112; Fubini B, 2003, FREE RADICAL BIO MED, V34, P1507, DOI 10.1016/S0891-5849(03)00149-7; Hartmann G, 2000, J PHARMACOL EXP THER, V292, P22; HISCOTT J, 1993, MOL CELL BIOL, V13, P6231, DOI 10.1128/MCB.13.10.6231; Hornung V, 2008, NAT IMMUNOL, V9, P847, DOI 10.1038/ni.1631; Hwang YS, 2004, ONCOGENE, V23, P6603, DOI 10.1038/sj.onc.1207867; Johann AM, 2006, CELL DEATH DIFFER, V13, P1533, DOI 10.1038/sj.cdd.4401832; Kanneganti TD, 2007, IMMUNITY, V26, P433, DOI 10.1016/j.immuni.2007.03.008; Krispin A, 2006, BLOOD, V108, P3580, DOI 10.1182/blood-2006-03-013334; Kwon KH, 2005, BIOCHEM BIOPH RES CO, V337, P647, DOI 10.1016/j.bbrc.2005.09.107; Kwon KH, 2007, LIFE SCI, V81, P362, DOI 10.1016/j.lfs.2007.05.022; Lucas M, 2006, J IMMUNOL, V177, P4047, DOI 10.4049/jimmunol.177.6.4047; Mariathasan S, 2006, NATURE, V440, P228, DOI 10.1038/nature04515; Martinez FO, 2009, ANNU REV IMMUNOL, V27, P451, DOI 10.1146/annurev.immunol.021908.132532; Martinon F, 2006, NATURE, V440, P237, DOI 10.1038/nature04516; Martinon F, 2002, MOL CELL, V10, P417, DOI 10.1016/S1097-2765(02)00599-3; Petrilli V, 2007, CELL DEATH DIFFER, V14, P1583, DOI 10.1038/sj.cdd.4402195; Podolsky DK, 2002, NEW ENGL J MED, P347; Rothlin CV, 2007, CELL, V131, P1124, DOI 10.1016/j.cell.2007.10.034; Saas P, 2010, ANN NY ACAD SCI, V1209, P118, DOI 10.1111/j.1749-6632.2010.05741.x; Saitoh T, 2008, NATURE, V456, P264, DOI 10.1038/nature07383; SAVILL J, 1995, SEMIN CELL BIOL, V6, P385, DOI 10.1016/S1043-4682(05)80009-1; Schroder K, 2010, CELL, V140, P821, DOI 10.1016/j.cell.2010.01.040; Serinkan BF, 2005, CELL DEATH DIFFER, V12, P1141, DOI 10.1038/sj.cdd.4401619; Verbovetski I, 2002, J EXP MED, V196, P1553, DOI 10.1084/jem.20020263; Zaki MH, 2010, IMMUNITY, V32, P379, DOI 10.1016/j.immuni.2010.03.003	42	19	22	2	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 30	2015	10	3							e0122440	10.1371/journal.pone.0122440	http://dx.doi.org/10.1371/journal.pone.0122440			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CE9AD	25822487	gold, Green Published, Green Submitted			2023-01-03	WOS:000352134700175
J	Binder, E; Natarajan, D; Cooper, J; Kronfli, R; Cananzi, M; Delalande, JM; McCann, C; Burns, AJ; Thapar, N				Binder, Ellen; Natarajan, Dipa; Cooper, Julie; Kronfli, Rania; Cananzi, Mara; Delalande, Jean-Marie; McCann, Conor; Burns, Alan J.; Thapar, Nikhil			Enteric Neurospheres Are Not Specific to Neural Crest Cultures: Implications for Neural Stem Cell Therapies	PLOS ONE			English	Article							SYSTEM PROGENITOR CELLS; TYROSINE KINASE RET; NERVOUS-SYSTEM; HIRSCHSPRUNGS-DISEASE; FOLLOW-UP; RECEPTOR; COLON; AGANGLIONOSIS; NEUROPATHIES; NEURONS	Objectives Enteric neural stem cells provide hope of curative treatment for enteric neuropathies. Current protocols for their harvesting from humans focus on the generation of 'neurospheres' from cultures of dissociated gut tissue. The study aims to better understand the derivation, generation and composition of enteric neurospheres. Design Gut tissue was obtained from Wnt1-Cre; Rosa26(Yfp/Yfp) transgenic mice (constitutively labeled neural crest cells) and paediatric patients. Gut cells were cultured either unsorted (mixed neural crest/non-neural crest), or following FACS selection into neural crest (murine-YFP+ve/human-p75+ve) or non-neural crest (YFP-ve/p75-ve) populations. Cultures and resultant neurospheres were characterized using immunolabelling in vitro and following transplantation in vivo. Results Cultures of (i) unsorted, (ii) neural crest, and (iii) non-neural crest cell populations generated neurospheres similar in numbers, size and morphology. Unsorted neurospheres were highly heterogeneous for neural crest content. Neural crest-derived (YFP+ve/p75+ve) neurospheres contained only neural derivatives (neurons and glia) and were devoid of non-neural cells (i.e. negative for SMA, c-Kit), with the converse true for non-neural crest-derived (YFP-ve/p75-ve) 'neurospheres'. Under differentiation conditions only YFP+ve cells gave rise to neural derivatives. Both YFP+ve and YFP-ve cells displayed proliferation and spread upon transplantation in vivo, but YFP-ve cells did not locate or integrate within the host ENS. Conclusions Spherical accumulations of cells, so-called 'neurospheres' forming in cultures of dissociated gut contain variable proportions of neural crest-derived cells. If they are to be used for ENS cell replacement therapy then improved protocols for their generation, including cell selection, should be sought in order to avoid inadvertent transplantation of non-therapeutic, nonENS cells.	[Binder, Ellen; Natarajan, Dipa; Cooper, Julie; Kronfli, Rania; Cananzi, Mara; Delalande, Jean-Marie; McCann, Conor; Burns, Alan J.; Thapar, Nikhil] UCL Inst Child Hlth, Stem Cells & Regenerat Med, London, England; [Burns, Alan J.] Erasmus MC, Dept Clin Genet, Rotterdam, Netherlands; [Thapar, Nikhil] Great Ormond St Hosp Sick Children, Dept Gastroenterol, London WC1N 3JH, England	University of London; University College London; Erasmus University Rotterdam; Erasmus MC; University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust	Burns, AJ (corresponding author), UCL Inst Child Hlth, Stem Cells & Regenerat Med, London, England.	alan.burns@ucl.ac.uk; n.thapar@ucl.ac.uk	Burns, Alan/AAC-1266-2022; cananzi, mara/AAS-8540-2020; Burns, Alan J/C-4988-2008	Cananzi, Mara/0000-0002-7177-2847; Burns, Alan/0000-0002-1725-1071; McCann, Conor/0000-0002-9324-5984	Great Ormond Street Hospital Children's Charity [W1018C, V1222]; Medical Research Council [G0800973]; MRC [G0800973] Funding Source: UKRI	Great Ormond Street Hospital Children's Charity; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	This work was supported by Great Ormond Street Hospital Children's Charity, W1018C (NT and AJB); Great Ormond Street Hospital Children's Charity, V1222 (NT); and Medical Research Council, G0800973 (NT and AJB). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Almond S, 2007, GUT, V56, P489, DOI 10.1136/gut.2006.094565; Amiel J, 2008, J MED GENET, V45, P1, DOI 10.1136/jmg.2007.053959; Barlow A, 2003, NEURON, V40, P905, DOI 10.1016/S0896-6273(03)00730-X; BAYNASH AG, 1994, CELL, V79, P1277, DOI 10.1016/0092-8674(94)90018-3; Becker L, 2012, AM J PHYSIOL-GASTR L, V302, pG958, DOI 10.1152/ajpgi.00511.2011; Bixby S, 2002, NEURON, V35, P643, DOI 10.1016/S0896-6273(02)00825-5; Boeckxstaens GE, 2014, LANCET, V383, P83, DOI 10.1016/S0140-6736(13)60651-0; Bondurand N, 2003, DEVELOPMENT, V130, P6387, DOI 10.1242/dev.00857; Burns AJ, 2004, NEUROGASTROENT MOTIL, V16, P3, DOI 10.1111/j.1743-3150.2004.00466.x; Burns AJ, 2014, NAT REV GASTRO HEPAT, V11, P317, DOI 10.1038/nrgastro.2013.226; Caldwell C, 2007, J PEDIATR GASTR NUTR, V44, P15; Catto-Smith AG, 2007, J GASTROEN HEPATOL, V22, P2273, DOI 10.1111/j.1440-1746.2006.04750.x; Conway SJ, 2007, J PEDIATR SURG, V42, P1429, DOI 10.1016/j.jpedsurg.2007.03.046; Danielian PS, 1998, CURR BIOL, V8, P1323, DOI 10.1016/S0960-9822(07)00562-3; Druckenbrod NR, 2005, DEV BIOL, V287, P125, DOI 10.1016/j.ydbio.2005.08.040; Gershon MD, 2007, GUT, V56, P459, DOI 10.1136/gut.2006.107748; Hanani M, 2003, J COMP NEUROL, V462, P315, DOI 10.1002/cne.10721; Heanue TA, 2007, NAT REV NEUROSCI, V8, P466, DOI 10.1038/nrn2137; Hetz S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093605; Hotta R, 2013, J CLIN INVEST, V123, P1182, DOI 10.1172/JCI65963; Hotta Ryo, 2011, J Pediatr Gastroenterol Nutr, V53 Suppl 2, pS43; Howe Steven J, 2012, Methods Mol Biol, V891, P85, DOI 10.1007/978-1-61779-873-3_5; Jiang XB, 2000, DEVELOPMENT, V127, P1607; Kalcheim C, 1999, NEURAL CREST; Knowles CH, 2013, NAT REV GASTRO HEPAT, V10, P206, DOI 10.1038/nrgastro.2013.18; Laranjeira C, 2011, J CLIN INVEST, V121, P3412, DOI 10.1172/JCI58200; Lindley RM, 2008, GASTROENTEROLOGY, V135, P205, DOI 10.1053/j.gastro.2008.03.035; Liu MT, 2009, J NEUROSCI, V29, P9683, DOI 10.1523/JNEUROSCI.1145-09.2009; Ludman L, 2002, ARCH DIS CHILD, V86, P348, DOI 10.1136/adc.86.5.348; Matsuda Y, 2013, WORLD J GASTROENTERO, V19, P42, DOI 10.3748/wjg.v19.i1.42; McKeown SJ, 2013, WIRES DEV BIOL, V2, P113, DOI 10.1002/wdev.57; Metzger M, 2009, GASTROENTEROLOGY, V136, P2214, DOI 10.1053/j.gastro.2009.02.048; Mifflin RC, 2011, AM J PHYSIOL-GASTR L, V300, pG684, DOI 10.1152/ajpgi.00474.2010; Nagoshi N, 2008, CELL STEM CELL, V2, P392, DOI 10.1016/j.stem.2008.03.005; Natarajan D, 2002, DEVELOPMENT, V129, P5151; Nunes MC, 2003, NAT MED, V9, P439, DOI 10.1038/nm837; Pallari HM, 2011, MOL BIOL CELL, V22, P1539, DOI 10.1091/mbc.E10-07-0568; Panza E, 2012, PROG NEUROBIOL, V96, P176, DOI 10.1016/j.pneurobio.2012.01.001; Prato AP, 2008, PEDIATR SURG INT, V24, P175, DOI 10.1007/s00383-007-2089-1; Rauch U, 2006, INT J COLORECTAL DIS, V21, P554, DOI 10.1007/s00384-005-0051-z; Rodrigues DM, 2011, NEUROGASTROENT MOTIL, V23, pe44, DOI 10.1111/j.1365-2982.2010.01626.x; Rothman TP, 1996, DEV BIOL, V178, P498, DOI 10.1006/dbio.1996.0234; Sanchez MP, 1996, NATURE, V382, P70, DOI 10.1038/382070a0; Sasselli V, 2012, DEV BIOL, V366, P64, DOI 10.1016/j.ydbio.2012.01.012; Srinivas S, 2001, BMC Dev Biol, V1, P4, DOI 10.1186/1471-213X-1-4; Thapar N, 2007, J PEDIATR GASTR NUTR, V45, pS110, DOI 10.1097/MPG.0b013e31812e667c; Theocharatos S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054809; Tsai YH, 2011, NEUROGASTROENT MOTIL, V23, P362, DOI 10.1111/j.1365-2982.2010.01656.x; Tsuji H, 1999, J PEDIATR SURG, V34, P158, DOI 10.1016/S0022-3468(99)90248-8; Wallace AS, 2005, CELL TISSUE RES, V319, P367, DOI 10.1007/s00441-004-1023-2; Zani A, 2014, GUT, V63, P300, DOI 10.1136/gutjnl-2012-303735; Zufferey R, 1999, J VIROL, V73, P2886, DOI 10.1128/JVI.73.4.2886-2892.1999	52	35	37	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 23	2015	10	3							e0119467	10.1371/journal.pone.0119467	http://dx.doi.org/10.1371/journal.pone.0119467			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CE6ZS	25799576	Green Published, Green Submitted, gold			2023-01-03	WOS:000351987300052
J	Hasselqvist-Ax, I; Riva, G; Herlitz, J; Rosenqvist, M; Hollenberg, J; Nordberg, P; Ringh, M; Jonsson, M; Axelsson, C; Lindqvist, J; Karlsson, T; Svensson, L				Hasselqvist-Ax, Ingela; Riva, Gabriel; Herlitz, Johan; Rosenqvist, Marten; Hollenberg, Jacob; Nordberg, Per; Ringh, Mattias; Jonsson, Martin; Axelsson, Christer; Lindqvist, Jonny; Karlsson, Thomas; Svensson, Leif			Early Cardiopulmonary Resuscitation in Out-of-Hospital Cardiac Arrest	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							AMERICAN-HEART-ASSOCIATION; BASIC LIFE-SUPPORT; COUNCIL GUIDELINES; SURVIVAL; POPULATION; RATES	BACKGROUND Three million people in Sweden are trained in cardiopulmonary resuscitation (CPR). Whether this training increases the frequency of bystander CPR or the survival rate among persons who have out-of-hospital cardiac arrests has been questioned. METHODS We analyzed a total of 30,381 out-of-hospital cardiac arrests witnessed in Sweden from January 1, 1990, through December 31, 2011, to determine whether CPR was performed before the arrival of emergency medical services (EMS) and whether early CPR was correlated with survival. RESULTS CPR was performed before the arrival of EMS in 15,512 cases (51.1%) and was not performed before the arrival of EMS in 14,869 cases (48.9%). The 30-day survival rate was 10.5% when CPR was performed before EMS arrival versus 4.0% when CPR was not performed before EMS arrival (P< 0.001). When adjustment was made for a propensity score (which included the variables of age, sex, location of cardiac arrest, cause of cardiac arrest, initial cardiac rhythm, EMS response time, time from collapse to call for EMS, and year of event), CPR before the arrival of EMS was associated with an increased 30-day survival rate (odds ratio, 2.15; 95% confidence interval, 1.88 to 2.45). When the time to defibrillation in patients who were found to be in ventricular fibrillation was included in the propensity score, the results were similar. The positive correlation between early CPR and survival rate remained stable over the course of the study period. An association was also observed between the time from collapse to the start of CPR and the 30-day survival rate. CONCLUSIONS CPR performed before EMS arrival was associated with a 30-day survival rate after an out-of-hospital cardiac arrest that was more than twice as high as that associated with no CPR before EMS arrival.	[Hasselqvist-Ax, Ingela; Riva, Gabriel; Hollenberg, Jacob; Nordberg, Per; Ringh, Mattias; Jonsson, Martin; Svensson, Leif] Ctr Resuscitat Sci, Solna, Sweden; [Rosenqvist, Marten] Danderyd Hosp, Dept Clin Sci, Cardiol Sect, S-18288 Danderyd, Sweden; [Herlitz, Johan] Karolinska Inst, Stockholm, Sweden; [Herlitz, Johan] Univ Boras, Ctr Prehosp Res Western Sweden, Boras, Sweden; [Axelsson, Christer] Univ Boras, Sch Hlth Sci, Boras, Sweden; [Herlitz, Johan] Sahlgrens Univ Hosp, Gothenburg, Sweden; [Lindqvist, Jonny] Sahlgrens Univ Hosp, Dept Metab & Cardiovasc Res, Inst Internal Med, Gothenburg, Sweden; [Karlsson, Thomas] Univ Gothenburg, Sahlgrenska Acad, Ctr Appl Biostat, Gothenburg, Sweden	Danderyds Hospital; Karolinska Institutet; University of Boras; University of Boras; Sahlgrenska University Hospital; Sahlgrenska University Hospital; University of Gothenburg	Herlitz, J (corresponding author), Univ Boras, Ctr Prehosp Res, SE-50190 Boras, Sweden.	johan.herlitz@hb.se	Jonsson, Martin/AEF-9167-2022	Riva, Gabriel/0000-0003-3038-0027; Jonsson, Martin/0000-0002-3539-8317	Laerdal Foundation for Acute Medicine	Laerdal Foundation for Acute Medicine	Funded by the Laerdal Foundation for Acute Medicine and others.	American Heart Association, 2012, CPR SUDD CARD ARR DE; [Anonymous], 2012, CENTR GOV ACT AMB SE; Atwood C, 2005, RESUSCITATION, V67, P75, DOI 10.1016/j.resuscitation.2005.03.021; Bardy GH, 2011, NEW ENGL J MED, V364, P374, DOI 10.1056/NEJMe1012554; Berdowski J, 2010, RESUSCITATION, V81, P1479, DOI 10.1016/j.resuscitation.2010.08.006; Caffrey SL, 2002, NEW ENGL J MED, V347, P1242, DOI 10.1056/NEJMoa020932; Christenson J, 2009, CIRCULATION, V120, P1241, DOI 10.1161/CIRCULATIONAHA.109.852202; CUMMINS RO, 1985, AM J EMERG MED, V3, P114, DOI 10.1016/0735-6757(85)90032-4; Field JM, 2010, CIRCULATION, V122, pS640, DOI 10.1161/CIRCULATIONAHA.110.970889; Go AS, 2014, CIRCULATION, V129, pE28, DOI 10.1161/01.cir.0000441139.02102.80; Handley AJ, 2005, RESUSCITATION, V67, pS7, DOI 10.1016/j.resuscitation.2005.10.007; Hollenberg J, 2005, J INTERN MED, V257, P247, DOI 10.1111/j.1365-2796.2004.01447.x; Holmberg M, 2001, EUR HEART J, V22, P511, DOI 10.1053/euhj.2000.2421; Jacobs I, 2004, CIRCULATION, V110, P3385, DOI 10.1161/01.CIR.0000147236.85306.15; Kim C, 2001, CIRCULATION, V104, P2699, DOI 10.1161/hc4701.099784; Kitamura T, 2014, RESUSCITATION, V85, P1432, DOI 10.1016/j.resuscitation.2014.07.017; Kitamura T, 2012, CIRCULATION, V126, P2834, DOI 10.1161/CIRCULATIONAHA.112.109496; Nolan JP, 2010, RESUSCITATION, V81, P1219, DOI 10.1016/j.resuscitation.2010.08.021; Nordberg P, 2009, RESUSCITATION, V80, P329, DOI 10.1016/j.resuscitation.2008.11.013; Ringh M, 2015, NEW ENGL J MED, V372, P2316, DOI 10.1056/NEJMoa1406038; Statistics Sweden, 2014, POP STAT JAN JUN 201; Stromsoe A, 2013, RESUSCITATION, V84, P952, DOI 10.1016/j.resuscitation.2012.12.026; Swedish Society of Medicine, 1997, SWED IND EM MED ASS; Vaillancourt C, 2013, RESUSCITATION, V84, P1747, DOI 10.1016/j.resuscitation.2013.08.001; Valenzuela TD, 2000, NEW ENGL J MED, V343, P1206, DOI 10.1056/NEJM200010263431701; Waalewijn RA, 2002, RESUSCITATION, V54, P31, DOI 10.1016/S0300-9572(02)00047-3; WEAVER WD, 1986, J AM COLL CARDIOL, V7, P752, DOI 10.1016/S0735-1097(86)80332-1; Wissenberg M, 2013, JAMA-J AM MED ASSOC, V310, P1377, DOI 10.1001/jama.2013.278483	28	507	528	3	37	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 11	2015	372	24					2307	2315		10.1056/NEJMoa1405796	http://dx.doi.org/10.1056/NEJMoa1405796			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CK2DB	26061835				2023-01-03	WOS:000356019200006
J	Galappaththige, S; Roth, BJ				Galappaththige, Suran; Roth, Bradley J.			Electrical Pacing of Cardiac Tissue Including Potassium Inward Rectification	PLOS ONE			English	Article							DIASTOLIC FIELD STIMULATION; UNIPOLAR STIMULATION; VIRTUAL ELECTRODES; ACTIVATION; PROPAGATION; SIMULATIONS	In this study cardiac tissue is stimulated electrically through a small unipolar electrode. Numerical simulations predict that around an electrode are adjacent regions of depolarization and hyperpolarization. Experiments have shown that during pacing of resting cardiac tissue the hyperpolarization is often inhibited. Our goal is to determine if the inward rectifying potassium current (I-K1) causes the inhibition of hyperpolarization. Numerical simulations were carried out using the bidomain model with potassium dynamics specified to be inward rectifying. In the simulations, adjacent regions of depolarization and hyperpolarization were observed surrounding the electrode. For cathodal currents the virtual anode produces a hyperpolarization that decreases over time. For long duration pulses the current-voltage curve is non-linear, with very small hyperpolarization compared to depolarization. For short pulses, the hyperpolarization is more prominent. Without the inward potassium rectification, the current voltage curve is linear and the hyperpolarization is evident for both long and short pulses. In conclusion, the inward rectification of the potassium current explains the inhibition of hyperpolarization for long duration stimulus pulses, but not for short duration pulses.	[Galappaththige, Suran; Roth, Bradley J.] Oakland Univ, Dept Phys, Rochester, MI 48309 USA	Oakland University	Roth, BJ (corresponding author), Oakland Univ, Dept Phys, Rochester, MI 48309 USA.	roth@oakland.edu	Roth, Bradley J/A-4920-2008; Galappaththige, Suran/AAE-1623-2021	Roth, Bradley J/0000-0003-4321-9806; Galappaththige, Suran/0000-0001-5268-1838	National Institutes of Health [R01HL118392]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL118392] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	National Institutes of Health R01HL118392. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Anumonwo JMB, 2014, CARDIAC ELECTROPHYSI, P33; Efimov IR, 2003, J CARDIOVASC ELECTR, V14, P1223, DOI 10.1046/j.1540-8167.2003.03442.x; Henriquez CS, 1992, CRIT REV BIOMED ENG, V21, P1; KNISLEY SB, 1995, CIRC RES, V77, P1229, DOI 10.1161/01.RES.77.6.1229; LUO CH, 1994, CIRC RES, V74, P1071, DOI 10.1161/01.RES.74.6.1071; Maleckar MM, 2008, AM J PHYSIOL-HEART C, V295, pH1626, DOI 10.1152/ajpheart.00706.2008; NEUNLIST M, 1995, BIOPHYS J, V68, P2310, DOI 10.1016/S0006-3495(95)80413-3; Press W.H., 1992, NUMERICAL RECIPES C; Puwal S, 2006, J BIOL SYST, V14, P101, DOI 10.1142/S0218339006001684; Roth BJ, 1998, J ELECTROCARDIOL, V31, P6, DOI 10.1016/S1053-0770(98)90272-5; ROTH BJ, 1991, CIRC RES, V68, P162, DOI 10.1161/01.RES.68.1.162; Roth BJ, 1993, ENG MED BIOL SOC 199, P857; Sambelashvili AT, 2003, AM J PHYSIOL-HEART C, V284, pH2368, DOI 10.1152/ajpheart.00988.2002; SEPULVEDA NG, 1989, BIOPHYS J, V55, P987, DOI 10.1016/S0006-3495(89)82897-8; Sharifov OF, 2003, J CARDIOVASC ELECTR, V14, P1215, DOI 10.1046/j.1540-8167.2003.03188.x; Wikswo JP, 1995, BIOPHYS J, V69, P2195, DOI 10.1016/S0006-3495(95)80115-3; Woods MC, 2013, BIOPHYS J, V105, P523, DOI 10.1016/j.bpj.2013.06.009	17	2	2	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 9	2015	10	6							e0127837	10.1371/journal.pone.0127837	http://dx.doi.org/10.1371/journal.pone.0127837			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CK6PC	26057242	Green Submitted, Green Published, gold			2023-01-03	WOS:000356349000012
J	Bosch, FH; Fleming, DA				Bosch, Frank H.; Fleming, David A.			Moving to High-Value Care: More Thoughtful Use of Cardiopulmonary Resuscitation	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							HOSPITAL CARDIAC-ARREST; SURVIVAL; TRENDS		[Bosch, Frank H.] Rijnstate Hosp, Dept Internal Med, NL-6800 TA Arnhem, Netherlands; Univ Missouri, Sch Med, Columbia, MO USA	Rijnstate Hospital; University of Missouri System; University of Missouri Columbia	Bosch, FH (corresponding author), Rijnstate Hosp, Dept Internal Med, POB 9555, NL-6800 TA Arnhem, Netherlands.	fhbosch@gmail.com	Bosch, Frank/AAW-6704-2020					Alahmar AE, 2014, HEART, V100, P1125, DOI 10.1136/heartjnl-2014-305696; Chan PS, 2014, CIRCULATION, V130, P1876, DOI 10.1161/CIRCULATIONAHA.114.009711; Girotra S, 2012, NEW ENGL J MED, V367, P1912, DOI 10.1056/NEJMoa1109148; Green Michael J, 2015, Ann Intern Med, V162, pW74, DOI 10.7326/G14-0009; Kellehear, 2014, INNER LIFE DYING PER; KOUWENHOVEN WB, 1960, JAMA-J AM MED ASSOC, V173, P1064, DOI 10.1001/jama.1960.03020280004002; Pizzo PA, 2015, ANN INTERN MED, V162, P228, DOI 10.7326/M14-2399; SAFAR P, 1958, NEW ENGL J MED, V258, P671, DOI 10.1056/NEJM195804032581401; Smith CD, 2012, ANN INTERN MED, V157, P284, DOI 10.7326/0003-4819-157-4-201208210-00496; Stapleton RD, 2014, CHEST, V146, P1214, DOI 10.1378/chest.13-2110	10	0	0	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 2	2015	162	11					790	791		10.7326/M15-0492	http://dx.doi.org/10.7326/M15-0492			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CJ5ZH	25844884				2023-01-03	WOS:000355572300008
J	Asrih, M; Altirriba, J; Rohner-Jeanrenaud, F; Jornayvaz, FR				Asrih, Mohamed; Altirriba, Jordi; Rohner-Jeanrenaud, Francoise; Jornayvaz, Francois R.			Ketogenic Diet Impairs FGF21 Signaling and Promotes Differential Inflammatory Responses in the Liver and White Adipose Tissue	PLOS ONE			English	Article							GROWTH-FACTOR 21; INSULIN-RESISTANCE; LOW-CARBOHYDRATE; HIGH-FAT; GLUCOSE-TOLERANCE; ENERGY-EXPENDITURE; KETONE-BODIES; BETA-KLOTHO; LONG-TERM; MICE	Background/Hypothesis Beside its beneficial effects on weight loss, ketogenic diet (KD) causes dyslipidemia, a proinflammatory state involved in the development of hepatic steatosis, glucose intolerance and insulin resistance, although the latter is still being debated. Additionally, KD is known to increase fibroblast growth factor 21 (FGF21) plasma levels. However, FGF21 cannot initiate its beneficial actions on metabolism in these conditions. We therefore hypothesized and tested in the present study that KD may impair FGF21 signaling. Methods/Results Using indirect calorimetry, we found that KD-fed mice exhibited higher energy expenditure than regular chow (RC)-fed mice associated with increased Ucp1 levels in white adipose tissue (WAT), along with increased plasma FGF21 levels. We then assessed the effect of KD on FGF21 signaling in both the liver and WAT. We found that Fgfr4 and Klb (beta-klotho) were downregulated in the liver, while Fgfr1 was downregulated in WAT of KD-fed mice. Because inflammation could be one of the mechanisms linking KD to impaired FGF21 signaling, we measured the expression levels of inflammatory markers and macrophage accumulation in WAT and liver and found an increased inflammation and macrophage accumulation in the liver, but surprisingly, a reduction of inflammation in WAT. We also showed that KD enhances lipid accumulation in the liver, which may explain hepatic inflammation and impaired Fgfr4 and Klb expression. In contrast, import of lipids from the circulation was significantly reduced in WAT of KD-fed mice, as suggested by a downregulation of Lpl and Cd36. This was further associated with reduced inflammation in WAT. Conclusion Altogether, these results indicate that KD could be beneficial for a given tissue but deleterious for another.	[Asrih, Mohamed; Altirriba, Jordi; Rohner-Jeanrenaud, Francoise; Jornayvaz, Francois R.] Univ Hosp Geneva, Div Endocrinol Diabet Hypertens & Nutr, CH-1211 Geneva 14, Switzerland	University of Geneva	Jornayvaz, FR (corresponding author), Univ Hosp Geneva, Div Endocrinol Diabet Hypertens & Nutr, Rue Gabrielle Perret Gentil 4, CH-1211 Geneva 14, Switzerland.	Francois.Jornayvaz@chuv.ch	Jornayvaz, François/AAL-2134-2020	Jornayvaz, Francois/0000-0001-9425-3137	Olga Mayenfisch Foundation; Hjelt Diabetes Foundation; Fondation de Reuter; Fondation Schmidheiny; Helmut Horten Foundation; SwissLife	Olga Mayenfisch Foundation; Hjelt Diabetes Foundation; Fondation de Reuter; Fondation Schmidheiny; Helmut Horten Foundation; SwissLife	This work was supported by the Olga Mayenfisch Foundation, the Hjelt Diabetes Foundation, the Fondation de Reuter, the Fondation Schmidheiny, the Helmut Horten Foundation and SwissLife. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adams AC, 2013, MOL METAB, V2, P31, DOI 10.1016/j.molmet.2012.08.007; Asrih M, 2013, J ENDOCRINOL, V218, pR25, DOI 10.1530/JOE-13-0201; Badman MK, 2007, CELL METAB, V5, P426, DOI 10.1016/j.cmet.2007.05.002; Badman MK, 2009, ENDOCRINOLOGY, V150, P4931, DOI 10.1210/en.2009-0532; Badman MK, 2009, AM J PHYSIOL-ENDOC M, V297, pE1197, DOI 10.1152/ajpendo.00357.2009; Bergqvist AGC, 2012, EPILEPSY RES, V100, P261, DOI 10.1016/j.eplepsyres.2011.05.020; Bielohuby M, 2013, AM J PHYSIOL-ENDOC M, V305, pE1059, DOI 10.1152/ajpendo.00208.2013; Bisschop PH, 2001, AM J CLIN NUTR, V73, P554; Camporez JPG, 2013, ENDOCRINOLOGY, V154, P1021, DOI 10.1210/en.2012-1989; Chavez AO, 2009, DIABETES CARE, V32, P1542, DOI 10.2337/dc09-0684; Chen W, 2011, J BIOL CHEM, V286, P34559, DOI 10.1074/jbc.M111.285965; Diaz-Delfin J, 2012, ENDOCRINOLOGY, V153, P4238, DOI 10.1210/en.2012-1193; Ding XS, 2012, CELL METAB, V16, P387, DOI 10.1016/j.cmet.2012.08.002; Dushay J, 2010, GASTROENTEROLOGY, V139, P456, DOI 10.1053/j.gastro.2010.04.054; Emanuelli B, 2014, J CLIN INVEST, V124, P515, DOI 10.1172/JCI67353; Fedorenko A, 2012, CELL, V151, P400, DOI 10.1016/j.cell.2012.09.010; Fisher FM, 2012, GENE DEV, V26, P271, DOI 10.1101/gad.177857.111; Fisher FM, 2011, ENDOCRINOLOGY, V152, P2996, DOI 10.1210/en.2011-0281; Fisher FM, 2010, DIABETES, V59, P2781, DOI 10.2337/db10-0193; Foster GD, 2003, NEW ENGL J MED, V348, P2082, DOI 10.1056/NEJMoa022207; Garbow JR, 2011, AM J PHYSIOL-GASTR L, V300, pG956, DOI 10.1152/ajpgi.00539.2010; Gariani K, 2013, DIABETES METAB, V39, P16, DOI 10.1016/j.diabet.2012.11.002; Holland WL, 2013, CELL METAB, V17, P790, DOI 10.1016/j.cmet.2013.03.019; Hotta Y, 2009, ENDOCRINOLOGY, V150, P4625, DOI 10.1210/en.2009-0119; Jornayvaz FR, 2011, AM J CLIN NUTR, V94, P955, DOI 10.3945/ajcn.111.019646; Jornayvaz FR, 2010, AM J PHYSIOL-ENDOC M, V299, pE808, DOI 10.1152/ajpendo.00361.2010; Jornayvaz FR, 2010, ANNU REV NUTR, V30, P273, DOI 10.1146/annurev.nutr.012809.104726; Kennedy AR, 2007, AM J PHYSIOL-ENDOC M, V292, pE1724, DOI 10.1152/ajpendo.00717.2006; Kim DY, 2007, J NEUROCHEM, V101, P1316, DOI 10.1111/j.1471-4159.2007.04483.x; Kim JK, 2001, P NATL ACAD SCI USA, V98, P7522, DOI 10.1073/pnas.121164498; Kossoff Eric H, 2013, Biomed J, V36, P2, DOI 10.4103/2319-4170.107152; Lin ZF, 2013, CELL METAB, V17, P779, DOI 10.1016/j.cmet.2013.04.005; Murata Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069330; Partsalaki I, 2012, J PEDIATR ENDOCR MET, V25, P697, DOI 10.1515/jpem-2012-0131; Peyrou M, 2015, J HEPATOL, V62, P421, DOI 10.1016/j.jhep.2014.09.012; Portincasa P, 2005, CLIN BIOCHEM, V38, P203, DOI 10.1016/j.clinbiochem.2004.10.014; Saisho Y, 2013, DIABETES CARE, V36, P111, DOI 10.2337/dc12-0421; Samaha FF, 2003, NEW ENGL J MED, V348, P2074, DOI 10.1056/NEJMoa022637; Samuel VT, 2010, LANCET, V375, P2267, DOI 10.1016/S0140-6736(10)60408-4; Veech RL, 2004, PROSTAG LEUKOTR ESS, V70, P309, DOI 10.1016/j.plefa.2003.09.007; Veniant MM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040164	41	40	43	0	36	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 14	2015	10	5							e0126364	10.1371/journal.pone.0126364	http://dx.doi.org/10.1371/journal.pone.0126364			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CI2AC	25973847	Green Published, Green Submitted, gold			2023-01-03	WOS:000354545600048
J	Lee, CC; Chang, TS; Wu, CJ; Yang, CC; Chen, PC				Lee, Ching-Chih; Chang, Ting-Shou; Wu, Cheng-Jung; Yang, Ching-Chieh; Chen, Po-Chun			Determinants of End-of-Life Expenditures in Patients with Oral Cancer in Taiwan: A Population-Based Study	PLOS ONE			English	Article							COMORBIDITY; NECK; HEAD; CARE; VOLUME; AGGRESSIVENESS; QUALITY; IMPACT	Background To investigate the association of basic demographic data, socioeconomic status, medical services, and hospital characteristics with end-of-life expenditure in patients with oral cancer in Taiwan who died between 2009 to 2011. Methods This nationwide population-based, retrospective cohort study identified 5,386 patients who died from oral cancer. We evaluated medical cost in the last month of life by universal health insurance. The impact of each variable on the end-of-life expenditure was examined by hierarchical generalized linear model (HGLM) using a hospital-level random-intercept model. Results The mean medical cost in the last six months of life was $2,611 +/- 3,329 (U.S. dollars). In HGLM using a random-intercept model, we found that patients younger than 65 years had an additional cost of $819 over those aged >= 65 years. Patients who had a high Charlson Comorbidity Index Score (CCIS) had an additional $616 cost over those with a low CCIS. Those who survived post-diagnosis less than 6 months had an additional $659 in expenses over those who survived more than 24 months. Medical cost was $249 more for patients who had medium to high individual SES, and $319 more for those who were treated by nononcologists. Conclusion This study provides useful information for decision makers in understanding end-of-life expenditure in oral cancer. We found significantly increased end-of-life expenditure in patients if they were younger than 65 years or treated by non-oncologists, or had high CCIS, medium to high individual SES, and survival of less than 6 months after diagnosis.	[Lee, Ching-Chih] Buddhist Tzu Chi Med Fdn, Dalin Tzu Chi Hosp, Dept Otolaryngol, Chiayi, Taiwan; [Lee, Ching-Chih] Tzu Chi Univ, Sch Med, Hualien, Taiwan; [Chang, Ting-Shou] Kaohsiung Vet Gen Hosp, Dept Otolaryngol, Kaohsiung, Taiwan; [Wu, Cheng-Jung] Taipei Med Univ, Shung Ho Hosp, Dept Otolaryngol, Taipei, Taiwan; [Yang, Ching-Chieh] Chi Mei Med Ctr, Dept Radiat Oncol, Tainan, Taiwan; [Chen, Po-Chun] Pingtung Christian Hosp, Dept Radiat Oncol, Pingtung, Taiwan	Buddhist Tzu Chi General Hospital; Dalin Tzu Chi Hospital; Tzu Chi University; Kaohsiung Veterans General Hospital; Taipei Medical University; Chi Mei Hospital	Chen, PC (corresponding author), Pingtung Christian Hosp, Dept Radiat Oncol, Pingtung, Taiwan.	salmon901@hotmail.com						Al-Refaie WB, 2012, J AM COLL SURGEONS, V214, P81, DOI 10.1016/j.jamcollsurg.2011.10.003; Amonkar Mayur M, 2011, J Med Econ, V14, P421, DOI 10.3111/13696998.2011.584096; Boje CR, 2013, ACTA ONCOL, V52, P285, DOI 10.3109/0284186X.2012.742964; Chang TS, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073889; Chen LF, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065077; Chiang TL, 1997, HEALTH POLICY, V39, P225, DOI 10.1016/S0168-8510(96)00877-9; DEYO RA, 1992, J CLIN EPIDEMIOL, V45, P613, DOI 10.1016/0895-4356(92)90133-8; Diez-Roux AV, 1998, AM J PUBLIC HEALTH, V88, P216, DOI 10.2105/AJPH.88.2.216; Diez-Roux AV, 2000, ANNU REV PUBL HEALTH, V21, P171, DOI 10.1146/annurev.publhealth.21.1.171; Earle CC, 2008, J CLIN ONCOL, V26, P3860, DOI 10.1200/JCO.2007.15.8253; Fiorentino A, 2013, CLIN TRANSL ONCOL, V15, P665, DOI 10.1007/s12094-012-0986-9; Ho TH, 2011, J CLIN ONCOL, V29, P1587, DOI 10.1200/JCO.2010.31.9897; Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI [10.3322/caac.20115, 10.3322/caac.20107]; Kim K, 2011, HEAD NECK ONCOL, V3, DOI 10.1186/1758-3284-3-47; Kong AL, 2011, ANN SURG ONCOL, V18, P3220, DOI 10.1245/s10434-011-2001-z; Lang K, 2004, ARCH OTOLARYNGOL, V130, P1269, DOI 10.1001/archotol.130.11.1269; Lee Y, 1996, J ROY STAT SOC B MET, V58, P619; Lin CC, 2008, SURGERY, V143, P343, DOI 10.1016/j.surg.2007.09.033; Nao EEM, 2011, EUR ANN OTORHINOLARY, V128, P47, DOI 10.1016/j.anorl.2010.12.001; Piccirillo JF, 2004, JAMA-J AM MED ASSOC, V291, P2441, DOI 10.1001/jama.291.20.2441; Rietjens JAC, 2012, SOC SCI MED, V74, P1282, DOI 10.1016/j.socscimed.2011.12.046; Setoguchi S, 2008, J CLIN ONCOL, V26, P5671, DOI 10.1200/JCO.2008.16.3956; Singh B, 1998, HEAD NECK-J SCI SPEC, V20, P1; Stryhn H, 2014, PREV VET MED, V113, P304, DOI 10.1016/j.prevetmed.2013.10.001; Tang ST, 2009, J CLIN ONCOL, V27, P4613, DOI 10.1200/JCO.2008.20.5096	25	6	7	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 6	2015	10	5							e0126482	10.1371/journal.pone.0126482	http://dx.doi.org/10.1371/journal.pone.0126482			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	CH5BQ	25946011	Green Published, Green Submitted, gold			2023-01-03	WOS:000354049700134
J	Gerding, DN; Meyer, T; Lee, C; Cohen, SH; Murthy, UK; Poirier, A; Van Schooneveld, TC; Pardi, DS; Ramos, A; Barron, MA; Chen, HZ; Villano, S				Gerding, Dale N.; Meyer, Thomas; Lee, Christine; Cohen, Stuart H.; Murthy, Uma K.; Poirier, Andre; Van Schooneveld, Trevor C.; Pardi, Darrell S.; Ramos, Antonio; Barron, Michelle A.; Chen, Hongzi; Villano, Stephen			Administration of Spores of Nontoxigenic Clostridium difficile Strain M3 for Prevention of Recurrent C difficile Infection A Randomized Clinical Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DIARRHEA; DISEASE; METRONIDAZOLE; COLONIZATION; VANCOMYCIN; HAMSTERS	IMPORTANCE Clostridium difficile is the most common cause of health care-associated infection in US hospitals. Recurrence occurs in 25% to 30% of patients. OBJECTIVE To determine the safety, fecal colonization, recurrence rate, and optimal dosing schedule of nontoxigenic C difficile strain M3 (VP20621; NTCD-M3) for prevention of recurrent C difficile infection (CDI). DESIGN, SETTING, AND PARTICIPANTS Phase 2, randomized, double-blind, placebo-controlled, dose-ranging study conducted from June 2011 to June 2013 among 173 patients aged 18 years or older who were diagnosed as having CDI (first episode or first recurrence) and had successfully completed treatment with metronidazole, oral vancomycin, or both at 44 study centers in the United States, Canada, and Europe. INTERVENTIONS Patients were randomly assigned to receive 1 of 4 treatments: oral liquid formulation of NTCD-M3, 104 spores/d for 7 days (n = 43), 107 spores/d for 7 days (n = 44), or 107 spores/d for 14 days (n = 42), or placebo for 14 days (n = 44). MAIN OUTCOMES AND MEASURES The primary outcomewas safety and tolerability of NTCD-M3 within 7 days of treatment. Exploratory secondary outcomes included fecal colonization with NTCD-M3 from end of study drug through week 6 and CDI recurrence from day 1 through week 6. RESULTS Among 168 patients who started treatment, 157 completed treatment. One or more treatment-emergent adverse events were reported in 78% of patients receiving NTCD-M3 and 86% of patients receiving placebo. Diarrhea and abdominal pain were reported in 46% and 17% of patients receiving NTCD-M3 and 60% and 33% of placebo patients, respectively. Serious treatment-emergent adverse events were reported in 7% of patients receiving placebo and 3% of all patients who received NTCD-M3. Headache was reported in 10% of patients receiving NTCD-M3 and 2% of placebo patients. Fecal colonization occurred in 69% of NTCD-M3 patients: 71% with 10(7) spores/d and 63% with 10(4) spores/d. Recurrence of CDI occurred in 13 (30%) of 43 placebo patients and 14 (11%) of 125 NTCD-M3 patients (odds ratio [OR], 0.28; 95% CI, 0.11-0.69; P = .006); the lowest recurrence was in 2 (5%) of 43 patients receiving 10(7) spores/d for 7 days (OR, 0.1; 95% CI, 0.0-0.6; P = .01 vs placebo]). Recurrence occurred in 2 (2%) of 86 patients who were colonized vs 12 (31%) of 39 patients who received NTCD-M3 and were not colonized (OR, 0.01; 95% CI, 0.00-0.05; P < .001). CONCLUSIONS AND RELEVANCE Among patients with CDI who clinically recovered following treatment with metronidazole or vancomycin, oral administration of spores of NTCD-M3 was well tolerated and appeared to be safe. Nontoxigenic C difficile strain M3 colonized the gastrointestinal tract and significantly reduced CDI recurrence. Copyright 2015 American Medical Association. All rights reserved.	[Gerding, Dale N.] US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Hines, IL 60141 USA; [Gerding, Dale N.] Loyola Univ Chicago, Stritch Sch Med, Maywood, IL USA; [Meyer, Thomas] Indiana Univ, Hlth Arnett Hosp, Lafayette, IN USA; [Lee, Christine] McMaster Univ, St Josephs Healthcare Hamilton, Hamilton, ON, Canada; [Cohen, Stuart H.] Univ Calif Davis, Med Ctr, Div Infect Dis, Sacramento, CA 95817 USA; [Murthy, Uma K.] VA Med Ctr, Syracuse, NY USA; [Murthy, Uma K.] SUNY Upstate Med Univ, Syracuse, NY 13210 USA; [Poirier, Andre] Ctr Sante & Serv Sociaux Trois Rivieres, Trois Rivieres, PQ, Canada; [Van Schooneveld, Trevor C.] Univ Nebraska Med Ctr, Div Infect Dis, Omaha, NE USA; [Pardi, Darrell S.] Mayo Clin, Div Gastroenterol & Hepatol, Rochester, MN USA; [Ramos, Antonio] Hosp Univ Puerta Hierro, Madrid, Spain; [Barron, Michelle A.] Univ Colorado Denver, Internal Med & Infect Dis, Aurora, CO USA; [Chen, Hongzi; Villano, Stephen] Shire, Wayne, PA USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Edward Hines Jr. VA Hospital; Loyola University Chicago; Indiana University System; McMaster University; University of California System; University of California Davis; State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center; University of Nebraska System; University of Nebraska Medical Center; Mayo Clinic; Hospital Puerta de Hierro-Majadahonda; Children's Hospital Colorado; University of Colorado System; University of Colorado Anschutz Medical Campus; Shire Pharmaceuticals Limited	Gerding, DN (corresponding author), US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Res & Dev, Fifth Ave & Roosevelt Rd,Bldg 1,Room B347, Hines, IL 60141 USA.	dale.gerding2@va.gov	Ramos-Martinez, Antonio/A-7456-2018	Ramos-Martinez, Antonio/0000-0002-4840-9425; Van Schooneveld, Trevor/0000-0002-9928-4546	ViroPharma Incorporated, which is now part of the Shire group of companies	ViroPharma Incorporated, which is now part of the Shire group of companies	This study was sponsored by ViroPharma Incorporated, which is now part of the Shire group of companies.	Al-Nassir WN, 2008, CLIN INFECT DIS, V47, P56, DOI 10.1086/588293; BORRIELLO SP, 1985, J MED MICROBIOL, V19, P339, DOI 10.1099/00222615-19-3-339; Brouwer MSM, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3601; Chang JY, 2008, J INFECT DIS, V197, P435, DOI 10.1086/525047; CLABOTS CR, 1993, J CLIN MICROBIOL, V31, P1870, DOI 10.1128/JCM.31.7.1870-1875.1993; Foglia G, 2012, VACCINE, V30, P4307, DOI 10.1016/j.vaccine.2012.01.056; Gerding DN, 2012, DISCOV MED, V13, P75; JOHNSON S, 1992, ANN INTERN MED, V117, P297, DOI 10.7326/0003-4819-117-4-297; Johnson S, 2014, CLIN INFECT DIS, V59, P345, DOI 10.1093/cid/ciu313; Lessa FC, 2015, NEW ENGL J MED, V372, P2369, DOI [10.1056/NEJMc1505190, 10.1056/NEJMoa1408913]; Lowy I, 2010, NEW ENGL J MED, V362, P197, DOI 10.1056/NEJMoa0907635; Magill SS, 2014, NEW ENGL J MED, V370, P1198, DOI 10.1056/NEJMoa1306801; Merrigan MM, 2003, J INFECT DIS, V188, P1922, DOI 10.1086/379836; Sambol SP, 2002, J INFECT DIS, V186, P1781, DOI 10.1086/345676; SEAL D, 1987, EUR J CLIN MICROBIOL, V6, P51, DOI 10.1007/BF02097191; Shim JK, 1998, LANCET, V351, P633, DOI 10.1016/S0140-6736(97)08062-8; van Nood E, 2013, NEW ENGL J MED, V368, P407, DOI 10.1056/NEJMoa1205037; Villano SA, 2012, ANTIMICROB AGENTS CH, V56, P5224, DOI 10.1128/AAC.00913-12; WILSON KH, 1983, J INFECT DIS, V147, P733, DOI 10.1093/infdis/147.4.733; Zar FA, 2007, CLIN INFECT DIS, V45, P302, DOI 10.1086/519265	20	198	207	2	21	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 5	2015	313	17					1719	1727		10.1001/jama.2015.3725	http://dx.doi.org/10.1001/jama.2015.3725			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CH3HQ	25942722	Bronze			2023-01-03	WOS:000353921000017
J	Todd, DA; Gulledge, TV; Britton, ER; Oberhofer, M; Leyte-Lugo, M; Moody, AN; Shymanovich, T; Grubbs, LF; Juzumaite, M; Graf, TN; Oberlies, NH; Faeth, SH; Laster, SM; Cech, NB				Todd, Daniel A.; Gulledge, Travis V.; Britton, Emily R.; Oberhofer, Martina; Leyte-Lugo, Martha; Moody, Ashley N.; Shymanovich, Tatsiana; Grubbs, Laura F.; Juzumaite, Monika; Graf, Tyler N.; Oberlies, Nicholas H.; Faeth, Stanley H.; Laster, Scott M.; Cech, Nadja B.			Ethanolic Echinacea purpurea Extracts Contain a Mixture of Cytokine-Suppressive and Cytokine-Inducing Compounds, Including Some That Originate from Endophytic Bacteria	PLOS ONE			English	Article							VITRO MACROPHAGE ACTIVATION; CAFFEIC ACID-DERIVATIVES; INFLAMMATORY CYTOKINES; CELL-CULTURES; PATHOGENESIS; ALKAMIDES; LIPOPOLYSACCHARIDES; LIPOPROTEINS; ALKYLAMIDES; INFECTIONS	Echinacea preparations, which are used for the prevention and treatment of upper respiratory infections, account for 10% of the dietary supplement market in the U.S., with sales totaling more than $ 100 million annually. In an attempt to shed light on Echinacea's mechanism of action, we evaluated the effects of a 75% ethanolic root extract of Echinacea purpurea, prepared in accord with industry methods, on cytokine and chemokine production from RAW 264.7 macrophage-like cells. We found that the extract displayed dual activities; the extract could itself stimulate production of the cytokine TNF-alpha, and also suppress production of TNF-alpha in response to stimulation with exogenous LPS. Liquid: liquid partitioning followed by normal-phase flash chromatography resulted in separation of the stimulatory and inhibitory activities into different fractions, confirming the complex nature of this extract. We also studied the role of alkylamides in the suppressive activity of this E. purpurea extract. Our fractionation method concentrated the alkylamides into a single fraction, which suppressed production of TNF-alpha, CCL3, and CCL5; however fractions that did not contain detectable alkylamides also displayed similar suppressive effects. Alkylamides, therefore, likely contribute to the suppressive activity of the extract but are not solely responsible for that activity. From the fractions without detectable alkylamides, we purified xanthienopyran, a compound not previously known to be a constituent of the Echinacea genus. Xanthienopyran suppressed production of TNF-alpha suggesting that it may contribute to the suppressive activity of the crude ethanolic extract. Finally, we show that ethanolic extracts prepared from E. purpurea plants grown under sterile conditions and from sterilized seeds, do not contain LPS and do not stimulate macrophage production of TNF-alpha, supporting the hypothesis that the macrophage-stimulating activity in E. purpurea extracts can originate from endophytic bacteria. Together, our findings indicate that ethanolic E. purpurea extracts contain multiple constituents that differentially regulate cytokine production by macrophages.	[Todd, Daniel A.; Britton, Emily R.; Leyte-Lugo, Martha; Moody, Ashley N.; Graf, Tyler N.; Oberlies, Nicholas H.; Cech, Nadja B.] Univ N Carolina, Dept Chem & Biochem, Greensboro, NC 27412 USA; [Gulledge, Travis V.; Juzumaite, Monika; Laster, Scott M.] N Carolina State Univ, Dept Biol Sci, Raleigh, NC 27695 USA; [Oberhofer, Martina; Shymanovich, Tatsiana; Grubbs, Laura F.; Faeth, Stanley H.] Univ N Carolina, Dept Biol, Greensboro, NC 27412 USA	University of North Carolina; University of North Carolina Greensboro; University of North Carolina; North Carolina State University; University of North Carolina; University of North Carolina Greensboro	Cech, NB (corresponding author), Univ N Carolina, Dept Chem & Biochem, Greensboro, NC 27412 USA.	nadja_cech@uncg.edu	Shymanovich, Tatsiana/R-4958-2019; Leyte-Lugo, Martha/O-6682-2019; Oberlies, Nicholas/D-8162-2011	Oberlies, Nicholas/0000-0002-0354-8464; Todd, Daniel/0000-0003-2199-1029; Britton, Emily/0000-0002-5331-7963; Graf, Tyler/0000-0003-4145-2815; Leyte-Lugo, Martha/0000-0003-4940-6194	National Center for Complementary and Alternative Medicine (NCCAM) [1R15AT007259]; National Institutes of Health; NATIONAL CENTER FOR COMPLEMENTARY & ALTERNATIVE MEDICINE [R15AT007259] Funding Source: NIH RePORTER	National Center for Complementary and Alternative Medicine (NCCAM)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CENTER FOR COMPLEMENTARY & ALTERNATIVE MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine)	This project was supported by grant # 1R15AT007259 from the National Center for Complementary and Alternative Medicine (NCCAM), a component of the National Institutes of Health.	Barrett B, 2010, ANN INTERN MED, V153, P769, DOI 10.7326/0003-4819-153-12-201012210-00003; BAUER R, 1991, PLANTA MED, V57, P447, DOI 10.1055/s-2006-960147; BAUER R, 1989, PLANTA MED, P367, DOI 10.1055/s-2006-962030; Cech NB, 2010, INT IMMUNOPHARMACOL, V10, P1268, DOI 10.1016/j.intimp.2010.07.009; Cech NB, 2006, J CHROMATOGR A, V1103, P219, DOI 10.1016/j.chroma.2005.11.008; Coimbra S, 2012, INT J DERMATOL, V51, P389, DOI 10.1111/j.1365-4632.2011.05154.x; Duque GA, 2014, FRONT IMMUNOL, V5, P1, DOI 10.3389/fimmu.2014.00491; Eads D, 2009, J INFLAMM-LOND, V6, DOI 10.1186/1476-9255-6-2; EMMENDORFFER AC, 1999, IMMUNOMODULATORY AGE, P89; Fonseca FN, 2014, INT IMMUNOPHARMACOL, V19, P94, DOI 10.1016/j.intimp.2013.12.019; Fukuyama S, 2011, CURR OPIN IMMUNOL, V23, P481, DOI 10.1016/j.coi.2011.07.016; Jawad M, 2012, EVID-BASED COMPL ALT, V2012, P7; Karsch-Volk M, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000530.pub3; Kennedy JL, 2012, CURR OPIN VIROL, V2, P287, DOI 10.1016/j.coviro.2012.03.008; Lalone CA, 2007, J AGR FOOD CHEM, V55, P7314, DOI 10.1021/jf063711a; LaLone CA, 2009, J AGR FOOD CHEM, V57, P8820, DOI 10.1021/jf901202y; Lee CL, 2008, PLANTA MED, V74, P1276, DOI 10.1055/s-2008-1081295; LEUCHTMANN A, 1988, MYCOLOGIA, V80, P192, DOI 10.2307/3807793; LUETTIG B, 1989, J NATL CANCER I, V81, P669, DOI 10.1093/jnci/81.9.669; MAHMOUD AA, 1995, TETRAHEDRON LETT, V36, P8985, DOI 10.1016/0040-4039(95)01966-L; Maurer M, 2004, INT J BIOCHEM CELL B, V36, P1882, DOI 10.1016/j.biocel.2003.10.019; McInnes IB, 2007, NAT REV IMMUNOL, V7, P429, DOI 10.1038/nri2094; Mueller M, 2004, J BIOL CHEM, V279, P26307, DOI 10.1074/jbc.M401231200; MURASHIGE T, 1962, PHYSIOL PLANTARUM, V15, P473, DOI 10.1111/j.1399-3054.1962.tb08052.x; Neurath MF, 2014, NAT REV IMMUNOL, V14, P329, DOI 10.1038/nri3661; Pugh ND, 2008, INT IMMUNOPHARMACOL, V8, P1023, DOI 10.1016/j.intimp.2008.03.007; Pugh ND, 2013, PLANTA MED, V79, P9, DOI 10.1055/s-0032-1328023; Raduner S, 2006, J BIOL CHEM, V281, P14192, DOI 10.1074/jbc.M601074200; Sasagawa M, 2006, INT IMMUNOPHARMACOL, V6, P1214, DOI 10.1016/j.intimp.2006.02.003; Sharma M, 2009, ANTIVIR RES, V83, P165, DOI 10.1016/j.antiviral.2009.04.009; Spelman K, 2009, INT IMMUNOPHARMACOL, V9, P1260, DOI 10.1016/j.intimp.2009.08.009; Tamta H, 2008, J AGR FOOD CHEM, V56, P10552, DOI 10.1021/jf8023722; Taylor JA, 2003, JAMA-J AM MED ASSOC, V290, P2824, DOI 10.1001/jama.290.21.2824; U.S. Nutrition Industry Overview, 2009, NUTRITION BUSINESS J, V14, P1; Vohra S, 2009, CAN J PHYSIOL PHARM, V87, P371, DOI [10.1139/Y09-021, 10.1139/y09-021]; WAGNER H, 1988, PHYTOCHEMISTRY, V27, P119, DOI 10.1016/0031-9422(88)80601-0	36	38	41	0	19	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 1	2015	10	5							e0124276	10.1371/journal.pone.0124276	http://dx.doi.org/10.1371/journal.pone.0124276			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CH2XA	25933416	Green Published, gold, Green Submitted			2023-01-03	WOS:000353887100035
J	Attenello, FJ; Wen, T; Cen, SY; Ng, A; Kim-Tenser, M; Sanossian, N; Amar, AP; Mack, WJ				Attenello, Frank J.; Wen, Timothy; Cen, Steven Y.; Ng, Alvin; Kim-Tenser, May; Sanossian, Nerses; Amar, Arun P.; Mack, William J.			Incidence of "never events" among weekend admissions versus weekday admissions to US hospitals: national analysis	BMJ-BRITISH MEDICAL JOURNAL			English	Article							LENGTH-OF-STAY; INPATIENT SAMPLE DATABASE; PATIENT SAFETY; MORTALITY; CARE; IMPACT; COMPLICATIONS; PERFORMANCE; SERVICES; MEDICARE	OBJECTIVE To evaluate the association between weekend admission to hospital and 14 hospital acquired conditions recently considered by the Centers for Medicare and Medicaid as "never events," serious, costly, and preventable medical errors, for which resulting healthcare costs are not reimbursed. DESIGN National analysis. SETTING US Nationwide Inpatient Sample discharge database. PARTICIPANTS 351 million patients discharged from US hospitals, 2002-10. MAIN OUTCOME MEASURES Univariate rates and multivariable likelihood of hospital acquired conditions among patients admitted on weekdays versus weekends, as well as the impacts of these events on prolonged length of stay and total inpatient charges. RESULTS From 2002 to 2010, 351 170 803 patients were admitted to hospital, with 19% admitted on a weekend. Hospital acquired conditions occurred at an overall frequency of 4.1% (5.7% among weekend admissions versus 3.7% among weekday admissions). Adjusting for patient and hospital cofactors the probability of having one or more hospital acquired conditions was more than 20% higher in weekend admissions compared with weekday admissions (odds ratio 1.25, 95% confidence interval 1.24 to 1.26, P < 0.01). Hospital acquired conditions have a negative impact on both hospital charges and length of stay. At least one hospital acquired condition was associated with an 83% (1.83, 1.77 to 1.90, P < 0.01) likelihood of increased charges and 38% likelihood of prolonged length of stay (1.38, 1.36 to 1.41, P < 0.01). CONCLUSION Weekend admission to hospital is associated with an increased likelihood of hospital acquired condition, cost, and length of stay. Future protocols and staffing regulations must be tailored to the requirements of this high risk subgroup.	[Attenello, Frank J.; Amar, Arun P.; Mack, William J.] Univ So Calif, Keck Sch Med, Dept Neurosurg, Los Angeles, CA 90033 USA; [Wen, Timothy] Univ So Calif, Keck Sch Med, Los Angeles, CA 90089 USA; [Cen, Steven Y.; Kim-Tenser, May; Sanossian, Nerses] Univ So Calif, Keck Sch Med, Dept Neurol, Los Angeles, CA 90089 USA; [Cen, Steven Y.] Univ So Calif, Keck Sch Med, Dept Radiol, Los Angeles, CA 90089 USA; [Ng, Alvin] Univ So Calif, Keck Sch Med, Dept Prevent Med, Los Angeles, CA 90089 USA	University of Southern California; University of Southern California; University of Southern California; University of Southern California; University of Southern California	Wen, T (corresponding author), Univ So Calif, Keck Sch Med, Los Angeles, CA 90089 USA.	wentimot@usc.edu						Agency for Healthcare Research and Quality, 2014, HEALTHC COST UT PROJ; Allareddy V, 2013, OR SURG OR MED OR PA, V115, P710, DOI 10.1016/j.oooo.2012.09.004; Angus DC, 2006, CRIT CARE MED, V34, P1016, DOI 10.1097/01.CCM.0000206105.05626.15; Attenello FJ, 2014, WORLD NEUROSURG, V82, DOI 10.1016/j.wneu.2014.08.053; Aujesky D, 2009, CIRCULATION, V119, P962, DOI 10.1161/CIRCULATIONAHA.108.824292; Barba R, 2006, EUR J INTERN MED, V17, P322, DOI 10.1016/j.ejim.2006.01.003; Bejanyan N, 2010, CANCER-AM CANCER SOC, V116, P3614, DOI 10.1002/cncr.25086; Bell CM, 2001, NEW ENGL J MED, V345, P663, DOI 10.1056/NEJMsa003376; Blegen MA, 1998, NURS ECON, V16, P196; Brown Sarah B, 2008, Hosp Health Netw, V82, P72; Burns EM, 2012, J PUBLIC HEALTH-UK, V34, P138, DOI 10.1093/pubmed/fdr054; Champaneria MC, 2013, ANN PLASTIC SURG; CMS, 2014, HOSP ACQ COND HAC AC; CMS, 2014, EFF IMPR PAT SAF RES; Cram P, 2004, AM J MED, V117, P151, DOI 10.1016/j.amjmed.2004.02.035; Crowley RW, 2009, STROKE, V40, P2387, DOI 10.1161/STROKEAHA.108.546572; Czaplinski C, 1998, MED CARE, V36, P1626, DOI 10.1097/00005650-199812000-00002; Dasenbrock HH, 2012, NEUROSURGERY, V70, P586, DOI 10.1227/NEU.0b013e318232d1ee; Fakih MG, 2013, INFECT CONT HOSP EP, V34, P1048, DOI 10.1086/673149; Fargen KM, 2013, J NEUROSURG, V119, P966, DOI 10.3171/2013.5.JNS122378; Gosbee J, 2002, QUAL SAF HEALTH CARE, V11, P352, DOI 10.1136/qhc.11.4.352; Hanks N, 2014, WEST J EMERG MED, V15, P499, DOI 10.5811/westjem.2014.2.20388; Harbarth S, 2003, J HOSP INFECT, V54, P258, DOI 10.1016/S0195-6701(03)00150-6; Hennessey P, 2012, LARYNGOSCOPE, V122, P2199, DOI 10.1002/lary.23459; Hoh BL, 2010, STROKE, V41, P2323, DOI 10.1161/STROKEAHA.110.591081; Horst MA, 2012, AM J MED QUAL, V27, P16, DOI 10.1177/1062860611409199; Houchens R, 2001, 20032 HCUP; Joice GA, 2013, UROLOGY, V81, P527, DOI 10.1016/j.urology.2012.09.050; Kaiman J., 2014, GUARDIAN; Karsh BT, 2006, QUAL SAF HEALTH CARE, V15, pI59, DOI 10.1136/qshc.2005.015974; Kostis WJ, 2007, NEW ENGL J MED, V356, P1099, DOI 10.1056/NEJMoa063355; Lee MK, 2013, OR SURG OR MED OR PA, V116, P147, DOI 10.1016/j.oooo.2013.02.006; Mehtsun WT, 2013, SURGERY, V153, P465, DOI 10.1016/j.surg.2012.10.005; Milstein A, 2009, NEW ENGL J MED, V360, P2388, DOI 10.1056/NEJMp0809125; Morse BC, 2010, AM SURGEON, V76, P841; Naessens JM, 2012, AM J MED QUAL, V27, P48, DOI 10.1177/1062860611413456; Palmer WL, 2012, ARCH NEUROL-CHICAGO, V69, P1296, DOI 10.1001/archneurol.2012.1030; Panaich SS, 2014, AM J CARDIOL, V114, P1390, DOI 10.1016/j.amjcard.2014.07.075; Pronovost PJ, 2008, JAMA-J AM MED ASSOC, V299, P2197, DOI 10.1001/jama.299.18.2197; Rahman M, 2010, STROKE, V41, P916, DOI 10.1161/STROKEAHA.109.574244; Rosenthal MB, 2007, NEW ENGL J MED, V357, P1573, DOI 10.1056/NEJMp078184; Saposnik G, 2007, STROKE, V38, P1211, DOI 10.1161/01.STR.0000259622.78616.ea; SAS, 2010, SAS GLOB FOR P; Shaheen AAM, 2009, CLIN GASTROENTEROL H, V7, P303, DOI 10.1016/j.cgh.2008.08.033; Sharp AL, 2013, AM J EMERG MED, V31, P835, DOI 10.1016/j.ajem.2013.01.006; Teufack SG, 2010, J NEUROSURG, V112, P249, DOI 10.3171/2009.7.JNS09753; Turin TC, 2009, EUR J EPIDEMIOL, V24, P93, DOI 10.1007/s10654-008-9308-5; Wen T, 2014, J NEUROSURG, V121, P580, DOI 10.3171/2014.4.JNS131253; Wen T, 2014, NEUROSURGERY, V75, P43, DOI 10.1227/NEU.0000000000000352; Wen T, 2014, J ENDOUROL, V28, P660, DOI 10.1089/end.2013.0623; Zhan CL, 2003, JAMA-J AM MED ASSOC, V290, P1868, DOI 10.1001/jama.290.14.1868	51	60	61	0	9	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	APR 15	2015	350								h1460	10.1136/bmj.h1460	http://dx.doi.org/10.1136/bmj.h1460			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CG5JP	25876878	hybrid, Green Published			2023-01-03	WOS:000353328000001
J	Forsblom, E; Ruotsalainen, E; Jarvinen, A				Forsblom, Erik; Ruotsalainen, Eeva; Jarvinen, Asko			Improved Outcome with Early Rifampicin Combination Treatment in Methicillin-Sensitive Staphylococcus aureus Bacteraemia with a Deep Infection Focus - A Retrospective Cohort Study	PLOS ONE			English	Article							PROSTHETIC JOINT INFECTIONS; RANDOMIZED CLINICAL-TRIAL; ANTIBIOTIC-TREATMENT; DRUG-USERS; ENDOCARDITIS; RESISTANT; THERAPY; VANCOMYCIN; MORTALITY; OSTEOMYELITIS	Introduction Rifampicin has been used as adjunctive therapy in Staphylococcus aureus bacteraemia (SAB) with a deep infection focus. However, data for prognostic impact of rifampicin therapy is unestablished including the optimal initiation time point. We studied the impact of rifampicin therapy and the optimal initiation time for rifampicin treatment on prognosis in methicillin-sensitive S. aureus bacteraemia with a deep infection. Methods Retrospective, multicentre study in Finland including 357 SAB patients with a deep infection focus. Patients with alcoholism, liver disease or patients who died within 3 days were excluded. Patients were categorised according to duration of rifampicin therapy and according to whether rifampicin was initiated early (within 7 days) or late (7 days after) after the positive blood cultures. Primary end point was 90 days mortality. Results Twenty-seven percent of patients received no rifampicin therapy, 14% received rifampicin for 1-13 days whereas 59% received rifampicin >= 14 days. The 90 day mortality was; 26% for patients treated without rifampicin, 16% for rifampicin therapy of any length and 10% for early onset rifampicin therapy >= 14 days. Lack of rifampicin therapy increased (OR 1.89, p=0.026), rifampicin of any duration decreased (OR 0.53, p=0.026) and rifampicin therapy >= 14 days with early onset lowered the risk for a fatal outcome (OR 0.33, p<0.01) during 90 days follow-up. Conclusion Rifampicin adjunctive therapy for at least 14 days and initiated within 7 days of positive blood culture associated with improved outcome among SAB patients with a deep infection.	[Forsblom, Erik; Ruotsalainen, Eeva; Jarvinen, Asko] Univ Helsinki, Cent Hosp, Dept Med, Div Infect Dis, Helsinki, Finland	University of Helsinki; Helsinki University Central Hospital	Forsblom, E (corresponding author), Univ Helsinki, Cent Hosp, Dept Med, Div Infect Dis, Helsinki, Finland.	erik.forsblom@helsinki.fi			Medical Society of Finland; Medicinska Understodsforeningen Liv och Halsa; SSAC-foundation; Maud Kuistila Memorial Foundation; Suomen Infektiolaakarit r.y. foundation; Swedish Cultural Foundation in Finland	Medical Society of Finland; Medicinska Understodsforeningen Liv och Halsa; SSAC-foundation; Maud Kuistila Memorial Foundation; Suomen Infektiolaakarit r.y. foundation; Swedish Cultural Foundation in Finland	This study was financially supported by grants from: The Medical Society of Finland, The Medicinska Understodsforeningen Liv och Halsa, The SSAC-foundation, The Maud Kuistila Memorial Foundation, The Suomen Infektiolaakarit r.y. foundation and The Swedish Cultural Foundation in Finland. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alexander EH, 2001, APPL MICROBIOL BIOT, V56, P361, DOI 10.1007/s002530100703; Berdal JE, 2005, CLIN MICROBIOL INFEC, V11, P843, DOI 10.1111/j.1469-0691.2005.01230.x; Calfee DP, 2005, PRINCIPLES PRACTICE, V1, P374; Cosgrove SE, 2003, CLIN INFECT DIS, V36, P53, DOI 10.1086/345476; Craig WA, 2004, INFECT DIS, P277; DWORKIN RJ, 1989, LANCET, V2, P1071; Finnish National Institute for Health and Welfare, 172011 FINN NAT I HL, P28; Forsblom E, 2013, CLIN INFECT DIS, V56, P527, DOI 10.1093/cid/cis889; Forsblom E, 2011, J HOSP INFECT, V78, P102, DOI 10.1016/j.jhin.2011.03.010; Fowler VG, 2003, ARCH INTERN MED, V163, P2066, DOI 10.1001/archinte.163.17.2066; Garzoni C, 2009, TRENDS MICROBIOL, V17, P59, DOI 10.1016/j.tim.2008.11.005; Heldman AW, 1996, AM J MED, V101, P68, DOI 10.1016/S0002-9343(96)00070-8; Jensen AG, 2002, ARCH INTERN MED, V162, P25, DOI 10.1001/archinte.162.1.25; Lai CC, 2010, J AM GERIATR SOC, V58, P1001, DOI 10.1111/j.1532-5415.2010.02842.x; LEVINE DP, 1991, ANN INTERN MED, V115, P674, DOI 10.7326/0003-4819-115-9-674; Levy MM, 2003, CRIT CARE MED, V31, P1250, DOI 10.1097/01.CCM.0000050454.01978.3B; Li JS, 2000, CLIN INFECT DIS, V30, P633, DOI 10.1086/313753; Liu C, 2011, CLIN INFECT DIS, V52, P285, DOI 10.1093/cid/cir034; Lodise TP, 2003, CLIN INFECT DIS, V36, P1418, DOI 10.1086/375057; Lowy FD, 2000, TRENDS MICROBIOL, V8, P341, DOI 10.1016/S0966-842X(00)01803-5; Maor Y, 2009, J INFECT DIS, V199, P619, DOI 10.1086/596629; MCCABE WR, 1962, ARCH INTERN MED, V110, P847, DOI 10.1001/archinte.1962.03620240029006; Mylotte JM, 2000, CLIN INFECT DIS, V31, P1170, DOI 10.1086/317421; NORDEN CW, 1986, SOUTHERN MED J, V79, P947, DOI 10.1097/00007611-198608000-00008; NORDEN CW, 1983, REV INFECT DIS, V5, pS495; Riedel DJ, 2008, ANTIMICROB AGENTS CH, V52, P2463, DOI 10.1128/AAC.00300-08; Rieg S, 2009, J INFECTION, V59, P232, DOI 10.1016/j.jinf.2009.07.015; Ringberg H, 2000, INFECTION, V28, P132, DOI 10.1007/s150100050065; Ruotsalainen E, 2006, J INTERN MED, V259, P179, DOI 10.1111/j.1365-2796.2005.01598.x; Saukkonen JJ, 2006, AM J RESP CRIT CARE, V174, P935, DOI 10.1164/rccm.200510-1666ST; Schrenzel J, 2004, CLIN INFECT DIS, V39, P1285, DOI 10.1086/424506; Sendi P, 2009, TRENDS MICROBIOL, V17, P54, DOI 10.1016/j.tim.2008.11.004; Senneville E, 2011, CLIN INFECT DIS, V53, P334, DOI 10.1093/cid/cir402; Siegman-Igra Y, 2005, SCAND J INFECT DIS, V37, P572, DOI 10.1080/00365540510038488; SPRATT BG, 1994, SCIENCE, V264, P388, DOI 10.1126/science.8153626; Thwaites G, 2012, TRIALS, V13, DOI 10.1186/1745-6215-13-241; Thwaites GE, 2011, LANCET INFECT DIS, V11, P208, DOI 10.1016/S1473-3099(10)70285-1; Thwaites GE, 2011, NAT REV MICROBIOL, V9, P215, DOI 10.1038/nrmicro2508; Tice AD, 2003, J ANTIMICROB CHEMOTH, V51, P1261, DOI 10.1093/jac/dkg186; VANDERAUWERA P, 1985, ANTIMICROB AGENTS CH, V28, P467, DOI 10.1128/AAC.28.4.467; VANDERAUWERA P, 1983, REV INFECT DIS, V5, pS515; Zimmerli W, 1998, JAMA-J AM MED ASSOC, V279, P1537, DOI 10.1001/jama.279.19.1537; ZIMMERLI W, 1994, J ANTIMICROB CHEMOTH, V33, P959	43	19	19	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 13	2015	10	4							e0122824	10.1371/journal.pone.0122824	http://dx.doi.org/10.1371/journal.pone.0122824			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CF8XK	25874546	Green Published, Green Submitted, gold			2023-01-03	WOS:000352845100106
J	Patila, T; Miyagawa, S; Imanishi, Y; Fukushima, S; Siltanen, A; Mervaala, E; Kankuri, E; Harjula, A; Sawa, Y				Patila, Tommi; Miyagawa, Shigeru; Imanishi, Yukiko; Fukushima, Satsuki; Siltanen, Antti; Mervaala, Eero; Kankuri, Esko; Harjula, Ari; Sawa, Yoshiki			Comparison of Arrhythmogenicity and Proinflammatory Activity Induced by Intramyocardial or Epicardial Myoblast Sheet Delivery in a Rat Model of Ischemic Heart Failure	PLOS ONE			English	Article							MYOCARDIAL-INFARCTION; CELL THERAPY; TRANSPLANTATION; INTERLEUKIN-1-BETA; PHASE; INFLAMMATION; EXPRESSION; INJURY; REPAIR	Although cell therapy of the failing heart by intramyocardial injections of myoblasts to results in regenerative benefit, it has also been associated with undesired and prospectively fatal arrhythmias. We hypothesized that intramyocardial injections of myoblasts could enhance inflammatory reactivity and facilitate electrical cardiac abnormalities that can be reduced by epicardial myoblast sheet delivery. In a rat model of ischemic heart failure, myoblast therapy either by intramyocardial injections or epicardial cell sheets was given 2 weeks after occlusion of the coronary artery. Ventricular premature contractions (VPCs) were assessed, using an implanted three-lead electrocardiograph at 1, 7, and 14 days after therapy, and 16-point epicardial electropotential mapping (EEPM) was used to evaluate ventricular arrhythmogenicity under isoproterenol stress. Cardiac functioning was assessed by echocardiography. Both transplantation groups showed therapeutic benefit over sham therapy. However, VPCs were more frequent in the Injection group on day 1 and day 14 after therapy than in animals receiving epicardial or sham therapy (p < 0.05 and p < 0.01, respectively). EEPM under isoproterenol stress showed macroreentry at the infarct border area, leading to ventricular tachycardias in the Injection group, but not in the myoblast sheet- or sham-treated groups (p = 0.045). Both transplantation types modified the myocardial cytokine expression profile. In animals receiving epicardial myoblast therapy, selective reductions in the expressions of interferon gamma, interleukin (IL)-1 beta and IL12 were observed, accompanied by reduced infiltration of inflammatory CD11b- and CD68-positive leukocytes, compared with animals receiving myoblasts as intramyocardial injections. Intramyocardial myoblast delivery was associated with enhanced inflammatory and immunomodulatory reactivity and increased frequency of VPCs. In comparison to intramyocardial injection, the epicardial route may serve as the preferred method of skeletal myoblast transplantation to treat heart failure.	[Patila, Tommi; Miyagawa, Shigeru; Imanishi, Yukiko; Fukushima, Satsuki; Sawa, Yoshiki] Osaka Univ, Grad Sch Med, Dept Cardiothorac Surg, Osaka, Japan; [Harjula, Ari] Univ Helsinki, Dept Cardiothorac Surg, Helsinki, Finland; [Harjula, Ari] Helsinki Univ Hosp, Helsinki, Finland; [Siltanen, Antti; Mervaala, Eero; Kankuri, Esko] Univ Helsinki, Pharmacol, Helsinki, Finland; [Patila, Tommi] Univ Helsinki, Dept Pediat Cardiac Surg, Hosp Children & Adolescents, Helsinki, Finland	Osaka University; University of Helsinki; University of Helsinki; Helsinki University Central Hospital; University of Helsinki; University of Helsinki	Patila, T (corresponding author), Osaka Univ, Grad Sch Med, Dept Cardiothorac Surg, Osaka, Japan.	tommi.patila@hus.fi	Fukushima, Satsuki/ABE-6582-2020	Fukushima, Satsuki/0000-0002-9481-8860; Imanishi, Yukiko/0000-0001-6241-0644; harjula, ari/0000-0001-6691-3636; Miyagawa, Shigeru/0000-0003-0015-6569; Kankuri, Esko/0000-0002-2193-8773	Japan Society for the Promotion of Science; Japan Science and Technology Agency (eSEED project); Finnish Academy [130919, 275882]; Finnish Funding Agency for Technology and Innovation TEKES [2703/31/2010]; Finnish Government Subsidiary Funds (HUCH-EVO); Sigrid Juselius Foundation; Finnish Foundation for Cardiovascular Research	Japan Society for the Promotion of Science(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); Japan Science and Technology Agency (eSEED project); Finnish Academy(Academy of Finland); Finnish Funding Agency for Technology and Innovation TEKES(Finnish Funding Agency for Technology & Innovation (TEKES)); Finnish Government Subsidiary Funds (HUCH-EVO); Sigrid Juselius Foundation(Sigrid Juselius Foundation); Finnish Foundation for Cardiovascular Research	This study has been supported by Japan Society for the Promotion of Science (http://www.jsps.go.jp); the Japan Science and Technology Agency (eSEED project to YS); Finnish Academy (http://www.aka.fi, Decision no: 130919 to AH and no: 275882 to EM); Finnish Funding Agency for Technology and Innovation TEKES (eSEED project: 2703/31/2010 to EK); Finnish Government Subsidiary Funds (HUCH-EVO to AH), Sigrid Juselius Foundation (EM and EK), and the Finnish Foundation for Cardiovascular Research(AS). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abbate A, 2013, EXP PHYSIOL, V98, P385, DOI 10.1113/expphysiol.2012.069021; Bujak M, 2008, AM J PATHOL, V173, P57, DOI 10.2353/ajpath.2008.070974; Combes A, 2002, PFLUG ARCH EUR J PHY, V445, P246, DOI 10.1007/s00424-002-0921-y; Coppen SR, 2008, CIRCULATION, V118, pS138, DOI 10.1161/CIRCULATIONAHA.107.779629; Deten A, 2002, CARDIOVASC RES, V55, P329, DOI 10.1016/S0008-6363(02)00413-3; Fernandes S, 2006, CARDIOVASC RES, V69, P348, DOI 10.1016/j.cardiores.2005.10.003; Fukushima S, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003071; Hagege AA, 2006, CIRCULATION, V114, pI108, DOI 10.1161/CIRCULATIONAHA.105.000521; Hata H, 2006, J THORAC CARDIOV SUR, V132, P918, DOI 10.1016/j.jtcvs.2006.01.024; Henkel DM, 2006, AM HEART J, V151, P806, DOI 10.1016/j.ahj.2005.05.015; Kitabayashi K, 2010, CELL TRANSPLANT, V19, P573, DOI 10.3727/096368909X486048; Kondoh H, 2006, CARDIOVASC RES, V69, P466, DOI 10.1016/j.cardiores.2005.11.005; Lambert JM, 2008, INT J CARDIOL, V130, P147, DOI 10.1016/j.ijcard.2008.04.059; Li QH, 2011, BASIC RES CARDIOL, V106, P849, DOI 10.1007/s00395-011-0180-1; Long C S, 2001, Heart Fail Rev, V6, P81; McTiernan CF, 1997, CIRC RES, V81, P493, DOI 10.1161/01.RES.81.4.493; Memon IA, 2005, J THORAC CARDIOV SUR, V130, P1333, DOI 10.1016/j.jtcvs.2005.07.023; Menasche P, 2001, LANCET, V357, P279, DOI 10.1016/S0140-6736(00)03617-5; Menasche P, 2011, J MOL CELL CARDIOL, V50, P258, DOI 10.1016/j.yjmcc.2010.06.010; Menasche P, 2008, J AM COLL CARDIOL, V52, P1881, DOI 10.1016/j.jacc.2008.07.066; Menasche P, 2009, CIRCULATION, V119, P2735, DOI 10.1161/CIRCULATIONAHA.108.812693; Miyagawa S, 2011, ANN THORAC SURG, V91, P320, DOI 10.1016/j.athoracsur.2010.09.080; Morimoto H, 2008, CARDIOVASC RES, V78, P554, DOI 10.1093/cvr/cvn035; Morimoto H, 2006, CIRC RES, V99, P891, DOI 10.1161/01.RES.0000246113.82111.2d; Murray PJ, 2011, NAT REV IMMUNOL, V11, P723, DOI 10.1038/nri3073; Nahrendorf M, 2010, CIRCULATION, V121, P2437, DOI 10.1161/CIRCULATIONAHA.109.916346; Narita T, 2013, INT J CARDIOL, V168, P261, DOI 10.1016/j.ijcard.2012.09.081; Okura Y, 1998, CIRC RES, V82, P1035, DOI 10.1161/01.RES.82.10.1035; Reinecke H, 2002, J MOL CELL CARDIOL, V34, P241, DOI 10.1006/jmcc.2001.1507; Shimizu T, 2003, BIOMATERIALS, V24, P2309, DOI 10.1016/S0142-9612(03)00110-8; Siltanen A, 2011, TISSUE ENG PT A, V17, P115, DOI 10.1089/ten.TEA.2010.0205; Siminiak T, 2004, AM HEART J, V148, P531, DOI 10.1016/j.ahj.2004.03.043; Smits PC, 2003, J AM COLL CARDIOL, V42, P2063, DOI 10.1016/j.jacc.2003.06.017; Suzuki K, 2004, FASEB J, V18, P1153, DOI 10.1096/fj.03-1308fje; Suzuki K, 2004, CIRCULATION, V110, pII219, DOI 10.1161/01.CIR.0000138388.55416.06; Trinchieri G, 2003, NAT REV IMMUNOL, V3, P133, DOI 10.1038/nri1001; Wang S, 2012, CLIN EXP IMMUNOL, V169, P320, DOI 10.1111/j.1365-2249.2012.04612.x; Zitta K, 2010, BIOCHEM BIOPH RES CO, V399, P542, DOI 10.1016/j.bbrc.2010.07.106	38	11	11	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 10	2015	10	4							e0123963	10.1371/journal.pone.0123963	http://dx.doi.org/10.1371/journal.pone.0123963			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CF5II	25860790	Green Submitted, Green Published, gold			2023-01-03	WOS:000352590300125
J	Mahapatra, T; Mahapatra, S; Banerjee, B; Mahapatra, U; Samanta, S; Pal, D; Chakraborty, ND; Manna, B; Sur, D; Kanungo, S				Mahapatra, Tanmay; Mahapatra, Sanchita; Banerjee, Barnali; Mahapatra, Umakanta; Samanta, Sandip; Pal, Debottam; Chakraborty, Nandini Datta; Manna, Byomkesh; Sur, Dipika; Kanungo, Suman			Predictors of Rational Management of Diarrhea in an Endemic Setting: Observation from India	PLOS ONE			English	Article							HEALTH-SEEKING BEHAVIOR; ANTIBIOTIC USE; PRESCRIBING PRACTICES; CHILDHOOD DIARRHEA; RURAL BANGLADESH; CARE PROVIDERS; URBAN SLUMS; KNOWLEDGE; RESISTANCE; CHILDREN	Background Decades after the establishment of clear guidelines for management, mostly due to irrational approach, diarrhea is still a major concern in the developing world, including India. The scenario is even worse in urban slums owing to poor health-seeking and socio-environmental vulnerability. Determining the distribution of rational diarrhea management by practitioners and identification of its important predictors seemed urgent to minimize the potential for antibiotic resistance, diarrhea-related mortality and morbidity in these areas. Methods Between May 2011 and January 2012, 264 consenting, randomly selected qualified and non-qualified practitioners (including pharmacists) were interviewed in the slums of Kolkata, a populous city in eastern India, regarding their characteristics, diarrhea-related knowledge (overall and in six separate domains: signs/symptoms, occurrence/spread, management, prevention/control, cholera and ORS), prescribed antibiotics, intravenous fluid (IVF) and laboratory investigations. Rationality was established based on standard textbooks. Results Among participants, 53.03% had no medical qualifications, 6.06% were attached to Governmental hospitals, 19.32% had best knowledge regarding diarrhea. While treating diarrhea, 7.20%, 17.80% and 20.08% respectively advised antibiotics, IVF and laboratory tests rationally. Logistic regression revealed that qualified and Governmental-sector practitioners managed diarrhea more rationally. Having best diarrhea-related knowledge regarding signs/symptoms (OR=5.49, p value=0.020), occurrence/spread (OR=3.26, p value=0.035) and overall (OR=6.82, p value=0.006) were associated with rational antibiotic prescription. Rational IVF administration was associated with best knowledge regarding diarrheal signs/symptoms (OR=3.00, p value=0.017), occurrence/spread (OR=3.57, p value=0.004), prevention/control (OR=4.89, p value=0.037), ORS (OR=2.55, p value=0.029) and overall (OR=4.57, p value<0.001). Best overall (OR=2.68, p value=0.020) and cholera-related knowledge (OR=2.34, p value=0.019) were associated with rational laboratory testing strategy. Conclusion Diarrheal management practices were unsatisfactory in urban slums where practitioners' knowledge was a strong predictor for rational management. Interventions targeting non-qualified, independent practitioners to improve their diarrhea-related knowledge seemed to be required urgently to ensure efficient management of diarrhea in these endemic settings.	[Mahapatra, Tanmay; Mahapatra, Sanchita; Pal, Debottam; Chakraborty, Nandini Datta; Sur, Dipika; Kanungo, Suman] Natl Inst Cholera & Enter Dis, Dept Epidemiol, Scheme XM, Kolkata 700010, W Bengal, India; [Banerjee, Barnali; Manna, Byomkesh] Natl Inst Cholera & Enter Dis, Dept Data Management, Scheme XM, Kolkata 700010, W Bengal, India; [Mahapatra, Umakanta] Midnapore Med Coll & Hosp, Dept Gen Med, Medinipur 721101, W Bengal, India; [Samanta, Sandip] Dr BC Roy Mem Hosp Children, Dept Pediat, Kolkata 700005, W Bengal, India; [Sur, Dipika] PATH India Off, New Delhi 110067, India	Indian Council of Medical Research (ICMR); ICMR - National Institute of Cholera & Enteric Diseases (NICED); Indian Council of Medical Research (ICMR); ICMR - National Institute of Cholera & Enteric Diseases (NICED); Midnapore Medical College	Kanungo, S (corresponding author), Natl Inst Cholera & Enter Dis, Dept Epidemiol, Scheme XM, P-33,CIT Rd, Kolkata 700010, W Bengal, India.	sumankanungo@gmail.com	Kanungo, Sloka/HHM-7508-2022	Kanungo, Suman/0000-0003-4441-4443	Institutional Intramural Funding of National Institute of Cholera and Enteric Diseases, Kolkata, Government of India [IM/SK/09-10/40]	Institutional Intramural Funding of National Institute of Cholera and Enteric Diseases, Kolkata, Government of India	This work was supported by the Institutional Intramural Funding (IM/SK/09-10/40) of National Institute of Cholera and Enteric Diseases, Kolkata, Government of India (http://www.niced.org.in/). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ahmed SM, 2007, HEALTH POLICY, V84, P332, DOI 10.1016/j.healthpol.2007.05.011; [Anonymous], 2004, MED RATIONAL USE MED; BAPNA JS, 1992, EUR J CLIN PHARMACOL, V43, P413, DOI 10.1007/BF02220618; Basu S, 2008, NIGER J CLIN PRACT, V11, P52; Behrman RE, 2004, NELSONS TXB PEDIAT; Bharathiraja R., 2005, Indian Journal of Pediatrics, V72, P877, DOI 10.1007/BF02731121; BOJALIL R, 1994, J CLIN EPIDEMIOL, V47, P147, DOI 10.1016/0895-4356(94)90019-1; Chakraborti S, 2011, INDIAN PEDIATR, V48, P811, DOI 10.1007/s13312-011-0125-7; Das B. P., 2005, Southeast Asian Journal of Tropical Medicine and Public Health, V36, P1562; Das SK, 2013, AM J TROP MED HYG, V89, P62, DOI 10.4269/ajtmh.13-0107; DEAN AG, 2000, DATABASE STAT PROGRA; Dekate P, 2013, INDIAN J PEDIATR, V80, P235, DOI 10.1007/s12098-012-0909-3; Ecker Lucie, 2013, Rev. perú. med. exp. salud publica, V30, P181; Gaash B., 2008, INDIAN J PRACTISING, V5; Ganguly NK, 2011, INDIAN J MED RES, V134, P281; GREENHALGH T, 1987, SOC SCI MED, V25, P307, DOI 10.1016/0277-9536(87)90233-4; GUTIERREZ G, 1994, MED CARE, V32, P436, DOI 10.1097/00005650-199405000-00003; Hardman J. G., 2001, GOODMAN GILMANS PHAR; Hennessy TW, 2004, CLIN INFECT DIS, V38, pS203, DOI 10.1086/381588; Hussain S, 2011, AFR J PHARM PHARMACO, V5, P1484, DOI 10.5897/AJPP11.242; Kanungo S, 2014, EPIDEMIOL INFECT, V142, P314, DOI 10.1017/S0950268813001076; Karras DJ, 2003, ANN EMERG MED, V42, P835, DOI 10.1016/S0196-0644(03)00602-4; Kiang KM, 2005, EMERG INFECT DIS, V11, P904, DOI 10.3201/eid1106.05144; Kristiansson C, 2008, TROP MED INT HEALTH, V13, P434, DOI 10.1111/j.1365-3156.2008.02019.x; Laxminarayan R, 2014, SCIENCE, V345, P1299, DOI 10.1126/science.1254163; Longo DL, 2012, HARRISONS PRINCIPLES; Mahajan V, 2012, INDIAN PEDIATR, V49, P963, DOI 10.1007/s13312-012-0251-x; Manna B, 2013, AM J TROP MED HYG, V89, P56, DOI 10.4269/ajtmh.12-0756; Mansourian A. R., 2007, Journal of Medical Sciences (Pakistan), V7, P427; McNulty CAM, 2012, BMC FAM PRACT, V13, DOI 10.1186/1471-2296-13-77; Mebratie AD, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2013-004020; Mittal SK, 2001, J PEDIATR GASTR NUTR, V33, pS26, DOI 10.1097/00005176-200110002-00005; Mukherjee P, 2014, ANTIMICROB AGENTS CH, V58, P4248, DOI 10.1128/AAC.02931-14; Nair GB, 2010, GUT PATHOG, V2, DOI 10.1186/1757-4749-2-4; Okeke TA, 1996, J DIARRHOEAL DIS RES, V14, P33; Ouyang-Latimer J, 2011, ANTIMICROB AGENTS CH, V55, P874, DOI 10.1128/AAC.00739-10; Paredes P, 1996, SOC SCI MED, V42, P1141, DOI 10.1016/0277-9536(95)00387-8; Patel V, 2005, J Postgrad Med, V51, P9; Raghunath D, 2008, J BIOSCIENCES, V33, P593, DOI 10.1007/s12038-008-0077-9; Reardon S, 2014, NATURE, V509, P141, DOI 10.1038/509141a; Riaz H, 2011, AFR J PHARM PHARMACO, V5, P596, DOI 10.5897/AJPP11.051; Riddle MS, 2005, MIL MED, V170, P492, DOI 10.7205/MILMED.170.6.492; Rosner B, 2010, FUNDAMENTALS BIOSTAT, V7th; Salazar-Lindo E, 1991, J DIARRHOEAL DIS RES, P227; SCHORLING JB, 1991, INT J EPIDEMIOL, V20, P293, DOI 10.1093/ije/20.1.293; Seyal T, 2009, ANNALS, V1, P38; Siddiqi S, 2002, INT J HEALTH PLAN M, V17, P23, DOI 10.1002/hpm.650; Smorenberg A, 2013, PERIOPER MED, V2, DOI 10.1186/2047-0525-2-17; Sosa A, 2002, PHYS ANTIBIOTIC PRES; Supcharassaeng Surachai, 2011, Journal of the Medical Association of Thailand, V94, P545; Sur D, 2001, J Indian Med Assoc, V99, P587; Sur Dipika, 2006, J Indian Med Assoc, V104, P220; Van Boeckel TP, 2014, LANCET INFECT DIS, V14, P742, DOI 10.1016/S1473-3099(14)70780-7; Wattal Chand, 2010, J Assoc Physicians India, V58 Suppl, P32; Webair HH, 2013, PATIENT PREFER ADHER, V7, P1129, DOI 10.2147/PPA.S51124; WHO, 2004, WORLD MED SIT; World Health Organization, 2014, ANTIMICROBIAL RESIST; Zaidi S Shujaat H, 2006, J Coll Physicians Surg Pak, V16, P245	58	6	6	1	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 7	2015	10	4							e0123479	10.1371/journal.pone.0123479	http://dx.doi.org/10.1371/journal.pone.0123479			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CF3VU	25849617	Green Published, Green Submitted, gold			2023-01-03	WOS:000352477800235
J	Lam, LCW; Chan, WC; Leung, T; Fung, AWT; Leung, EMF				Lam, Linda Chiu-wa; Chan, Wai Chi; Leung, Tony; Fung, Ada Wai-tung; Leung, Edward Man-fuk			Would Older Adults with Mild Cognitive Impairment Adhere to and Benefit from a Structured Lifestyle Activity Intervention to Enhance Cognition?: A Cluster Randomized Controlled Trial	PLOS ONE			English	Article							PHYSICAL-ACTIVITY; ALZHEIMERS-DISEASE; DEMENTIA; EXERCISE; VALIDATION; MEMORY; PREVALENCE; HEALTH; RISK	Background Epidemiologic evidence suggests that cognitive and physical activities are associated with better cognition in late life. The present study was conducted to examine the possible benefits of four structured lifestyle activity interventions and compare their effectiveness in optimizing cognition for older adults with mild cognitive impairment (MCI). Method and Findings This was a 12-month cluster randomized controlled trial. 555 community-dwelling Chinese older adults with MCI (295 with multiple-domain deficits (mdMCI), 260 with single-domain deficit (sdMCI)) were recruited. Participants were randomized into physical exercise (P), cognitive activity (C), integrated cognitive and physical exercise (CP), and social activity (S, active control) groups. Interventions comprised of one-hour structured activities three times per week. Primary outcome was Clinical Dementia Rating sum of boxes (CDR-SOB) scores. Secondary outcomes included Chinese versions of Alzheimer's Disease Assessment Scale Cognitive subscale (ADAS-Cog), delayed recall, Mini-Mental State Examination, Category Verbal Fluency Test (CVFT) and Disability Assessment for Dementia - Instrumental Activities of Daily Living (DAD-IADL). Percentage adherence to programs and factors affecting adherence were also examined. At 12th month, 423 (76.2%) completed final assessment. There was no change in CDR-SOB and DAD-IADL scores across time and intervention groups. Multilevel normal model and linear link function showed improvement in ADAS-Cog, delayed recall and CVFT with time (p<0.05). Post-hoc subgroup analyses showed that the CP group, compared with other intervention groups, had more significant improvements of ADAS-Cog, delayed recall and CVFT performance with sdMCI participants (p<0.05). Overall adherence rate was 73.3%. Improvements in ADAS-Cog and delayed recall scores were associated with adherence after controlling for age, education, and intervention groups (univariate analyses). Conclusions Structured lifestyle activity interventions were not associated with changes in everyday functioning, albeit with some improvements in cognitive scores across time. Higher adherence was associated with greater improvement in cognitive scores. Factors to enhance adherence should be specially considered in the design of psychosocial interventions for older adults with cognitive decline.	[Lam, Linda Chiu-wa; Leung, Tony; Fung, Ada Wai-tung] Chinese Univ Hong Kong, Dept Psychiat, Hong Kong, Hong Kong, Peoples R China; [Chan, Wai Chi] Univ Hong Kong, Dept Psychiat, Hong Kong, Hong Kong, Peoples R China; [Leung, Edward Man-fuk] United Christian Hosp, Dept Med & Geriatr, Hong Kong, Hong Kong, Peoples R China	Chinese University of Hong Kong; University of Hong Kong; United Christian Hospital	Lam, LCW (corresponding author), Chinese Univ Hong Kong, Dept Psychiat, Hong Kong, Hong Kong, Peoples R China.	cwlam@cuhk.edu.hk	Chan, Wai Chi/J-6947-2012; FUNG, Ada Wai-Tung/K-7383-2019	FUNG, Ada Wai-Tung/0000-0001-7439-3503	Simon KY Lee Fund for the Elderly in Hong Kong	Simon KY Lee Fund for the Elderly in Hong Kong	This project was funded by a donation from the Simon KY Lee Fund for the Elderly in Hong Kong. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Barnes DE, 2013, JAMA INTERN MED, V173, P797, DOI 10.1001/jamainternmed.2013.189; Chiu HFK, 1998, NEUROLOGY, V50, P1002, DOI 10.1212/WNL.50.4.1002; Chu L. W., 2000, Annals Academy of Medicine Singapore, V29, P474; Coley N, 2008, EPIDEMIOL REV, V30, P35, DOI 10.1093/epirev/mxn010; Cooper C, 2013, BRIT J PSYCHIAT, V203, P255, DOI 10.1192/bjp.bp.113.127811; Etgen T, 2011, DTSCH ARZTEBL INT, V108, P743, DOI 10.3238/arztebl.2011.0743; Hall CB, 2009, NEUROLOGY, V73, P356, DOI 10.1212/WNL.0b013e3181b04ae3; Heo M, 2009, STAT MED, V28, P1017, DOI 10.1002/sim.3527; Lam CK, 2004, INT J GERIATR PSYCH, V19, P422, DOI 10.1002/gps.1098; Lam LC, 2001, ALZ DIS ASSOC DIS, V24, P343; Lam LCW, 2012, J AM MED DIR ASSOC, V13, DOI 10.1016/j.jamda.2012.03.008; Lam LCW, 2006, DEMENT GERIATR COGN, V22, P159, DOI 10.1159/000094543; Lautenschlager NT, 2008, JAMA-J AM MED ASSOC, V300, P1027, DOI 10.1001/jama.300.9.1027; Legault C, 2011, BMC GERIATR, V11, DOI 10.1186/1471-2318-11-27; Leung Grace Tak Yu, 2011, East Asian Arch Psychiatry, V21, P123; Lui VWC, 2006, INT J GERIATR PSYCH, V21, P917, DOI 10.1002/gps.1580; Mok CCM, 2005, DEMENT GERIATR COGN, V20, P112, DOI 10.1159/000086612; Morris JC, 1997, ALZ DIS ASSOC DIS, V11, P1, DOI 10.1097/00002093-199706001-00001; Murray DM, 2007, STAT MED, V26, P2297, DOI 10.1002/sim.2714; Nagamatsu Lindsay S, 2013, J Aging Res, V2013, P861893, DOI 10.1155/2013/861893; Pitkala KH, 2013, JAMA INTERN MED, V173, P894, DOI 10.1001/jamainternmed.2013.359; Prince M, 2013, ALZHEIMERS DEMENT, V9, P63, DOI 10.1016/j.jalz.2012.11.007; Raschetti R, 2007, PLOS MED, V4, P1818, DOI 10.1371/journal.pmed.0040338; Smith GE, 2009, J AM GERIATR SOC, V57, P594, DOI 10.1111/j.1532-5415.2008.02167.x; Smith PJ, 2010, PSYCHOSOM MED, V72, P239, DOI 10.1097/PSY.0b013e3181d14633; Suzuki T, 2012, BMC NEUROL, V12, DOI 10.1186/1471-2377-12-128; Valenzuela MJ, 2012, BIOL PSYCHIAT, V71, P783, DOI 10.1016/j.biopsych.2011.07.036; van Nimwegen M, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f576; Wilson RS, 2012, NEUROLOGY, V78, P1116, DOI 10.1212/WNL.0b013e31824f7ff2; Winblad B, 2004, J INTERN MED, V256, P240, DOI 10.1111/j.1365-2796.2004.01380.x	30	84	87	1	40	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 31	2015	10	3							e0118173	10.1371/journal.pone.0118173	http://dx.doi.org/10.1371/journal.pone.0118173			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	CE8IF	25826620	gold, Green Published, Green Submitted			2023-01-03	WOS:000352084800002
J	Yune, HY; Chung, SP; Park, YS; Chung, HS; Lee, HS; Lee, JW; Park, JW; You, JS; Park, I; Lee, HS				Yune, Ho Young; Chung, Sung Phil; Park, Yoo Seok; Chung, Hyun Soo; Lee, Hye Sun; Lee, Jong Wook; Park, Jong Woo; You, Je Sung; Park, Incheol; Lee, Hahn Shick			Delta Neutrophil Index as a Promising Prognostic Marker in Out of Hospital Cardiac Arrest	PLOS ONE			English	Article							MORTALITY; CARDIOPULMONARY; RESUSCITATION; DIAGNOSIS	Background The post-resuscitation phase after out-of-hospital cardiac arrest (OHCA) is characterised by a systemic inflammatory response (e.g., severe sepsis), for which the immature granulocyte count is a diagnostic marker. In this study we evaluated the prognostic significance of the delta neutrophil index (DNI), which is the difference in leukocyte subfractions as assessed by an automated blood cell analyser, for early mortality after OHCA. Materials and Methods OHCA records from the emergency department cardiac arrest registry were retrospectively analysed. Patients who survived at least 24 h after return of spontaneous circulation were included in the analysis. We evaluated mortality and cerebral performance category scores at 30 days. Results A total of 83 patients with OHCA were included in the study. Our results showed that DNI >8.4% on day 1 (hazard ratio [HR], 3.227; 95% CI, 1.485-6.967; p = 0.001) and DNI >10.5% on day 2 (HR, 3.292; 95% CI, 1.662-6.519; p<0.001) were associated with increased 30-day mortality in patients with OHCA. Additionally, DNI >8.4% on day 1 (HR, 2.718; 95% CI, 1.508-4.899; p<0.001) and DNI >10.5% on day 2 (HR, 1.709; 95% CI, 1.051-2.778; p = 0.02) were associated with worse neurologic outcomes 30 days after OHCA. Conclusion A higher DNI is a promising prognostic marker for 30-day mortality and neurologic outcomes after OHCA. Our findings indicate that patients with elevated DNI values after OHCA might be closely monitored so that appropriate treatment strategies can be implemented.	[Yune, Ho Young; Chung, Sung Phil; Park, Yoo Seok; Chung, Hyun Soo; You, Je Sung; Park, Incheol; Lee, Hahn Shick] Yonsei Univ, Coll Med, Dept Emergency Med, Seoul, South Korea; [Lee, Hye Sun] Yonsei Univ, Coll Med, Dept Res Affairs, Biostat Collaborat Unit, Seoul, South Korea; [Lee, Jong Wook] Jincheon Sungmo Hosp, Dept Lab Med, Jincheon, South Korea; [Park, Jong Woo] Changwon Fatima Hosp, Dept Emergency Med, Chang Won, South Korea; [You, Je Sung] Kangwon Natl Univ, Grad Sch Med, Dept Emergency Med, Chunchon, South Korea	Yonsei University; Yonsei University Health System; Yonsei University; Yonsei University Health System; Kangwon National University	You, JS (corresponding author), Yonsei Univ, Coll Med, Dept Emergency Med, Seoul, South Korea.	youjsmd@yuhs.ac	; Lee, Hye Sun/J-2154-2015; Chung, Sung Phil/F-8344-2016	You, Je Sung/0000-0002-2074-6745; Park, Incheol/0000-0001-7033-766X; Lee, Hye Sun/0000-0001-6328-6948; Chung, Sung Phil/0000-0002-3074-011X; Park, Yoo Seok/0000-0003-1543-4664	Basic Science Research Program through the National Research Foundation of Korea (NRF) - Ministry of Education [NRF-2013R1A1A2009391]	Basic Science Research Program through the National Research Foundation of Korea (NRF) - Ministry of Education	This research was supported by Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education (NRF-2013R1A1A2009391). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adrie C, 2002, CIRCULATION, V106, P562, DOI 10.1161/01.CIR.0000023891.80661.AD; Adrie Christophe, 2004, Curr Opin Crit Care, V10, P208, DOI 10.1097/01.ccx.0000126090.06275.fe; Alves JC, 2010, SHOCK, V34, P15, DOI 10.1097/SHK.0b013e3181e7e61b; Andersson U, 2011, ANNU REV IMMUNOL, V29, P139, DOI 10.1146/annurev-immunol-030409-101323; Engel H, 2013, RESUSCITATION, V84, P776, DOI 10.1016/j.resuscitation.2013.01.029; Go AS, 2014, CIRCULATION, V129, pE28, DOI 10.1161/01.cir.0000441139.02102.80; Grigoriu BD, 2007, CLIN CANCER RES, V13, P2928, DOI 10.1158/1078-0432.CCR-06-2144; Ha SO, 2015, SCAND J CLIN LAB INV, V75, P36, DOI 10.3109/00365513.2014.965736; HyunNahm C, 2008, ANN CLIN LAB SCI, V38, P241; Kim HW, 2012, SCAND J INFECT DIS, V44, P475, DOI 10.3109/00365548.2012.657232; Kim J, 2013, RESUSCITATION, V84, P48, DOI 10.1016/j.resuscitation.2012.09.003; Kim J, 2012, RESUSCITATION, V83, P1248, DOI 10.1016/j.resuscitation.2012.01.038; Lim TS, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0086884; Nolan JP, 2008, RESUSCITATION, V79, P350, DOI 10.1016/j.resuscitation.2008.09.017; Park BH, 2011, BMC INFECT DIS, V11, DOI 10.1186/1471-2334-11-299; Pyo JY, 2013, LUPUS, V22, P1102, DOI 10.1177/0961203313499957; Roger VL, 2011, CIRCULATION, V123, pE18, DOI 10.1161/CIR.0b013e3182009701; Seok Y, 2012, SHOCK, V37, P242, DOI 10.1097/SHK.0b013e3182454acf; Vincent JL, 2014, CLIN EXP EMERG MED, V1, P3, DOI 10.15441/ceem.14.005	19	34	34	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 23	2015	10	3							e0120677	10.1371/journal.pone.0120677	http://dx.doi.org/10.1371/journal.pone.0120677			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CE6ZS	25798609	Green Published, Green Submitted, gold			2023-01-03	WOS:000351987300163
J	Contreras-Ruiz, L; Masli, S				Contreras-Ruiz, Laura; Masli, Sharmila			Immunomodulatory Cross-Talk between Conjunctival Goblet Cells and Dendritic Cells	PLOS ONE			English	Article							TGF-BETA; EPITHELIAL-CELLS; CROHNS-DISEASE; MURINE MODEL; T-CELLS; THROMBOSPONDIN-1; EXPRESSION; PEPTIDE; TEAR; INFLAMMATION	Goblet cells are secretory epithelial cells of mucosal tissues that confer protection from environmental agents or pathogens via expression and secretion of soluble mucins. Loss of these cells is associated with several chronic inflammatory disorders of the mucosa. Although demonstrated to transfer antigens from the luminal surface to stromal cells in the intestinal mucosa, it is not known if goblet cells contribute to the regulation of an immune response. In this study we report that similar to intestinal and respiratory mucosal epithelia, mouse ocular surface epithelia predominantly express the TGF-beta 2 isoform. Specifically, we demonstrate the ability of goblet cells to express TGF-beta 2 and increase it in response to Toll-Like Receptor 4 mediated stimulus in cultures. Goblet cells not only express TGF-beta 2, but are also able to activate it in a thrombospondin-1 (TSP-1) dependent manner via their cell surface receptor CD36. Furthermore, goblet cell derived soluble factors that possibly include TGF-beta 2, alter dendritic cell (DC) phenotype to a tolerogenic type by downregulating DC expression of MHC class II and co-stimulatory molecules CD80, CD86 and CD40. Thus our study demonstrates goblet cells as a cellular source of active TGF-beta 2 in ocular mucosa and implicates their immunomodulatory function in maintaining mucosal immune homeostasis.	[Contreras-Ruiz, Laura; Masli, Sharmila] Boston Univ, Sch Med, Dept Ophthalmol, Boston, MA 02118 USA	Boston University	Masli, S (corresponding author), Boston Univ, Sch Med, Dept Ophthalmol, Boston, MA 02118 USA.	smasli@bu.edu			National Eye Institute Grant [EY015472]; NATIONAL EYE INSTITUTE [R01EY015472] Funding Source: NIH RePORTER	National Eye Institute Grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))	Funding was provided by National Eye Institute Grant EY015472 (https://www.nei.nih.gov/). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Annes JP, 2003, J CELL SCI, V116, P217, DOI 10.1242/jcs.00229; Balzar S, 2005, J ALLERGY CLIN IMMUN, V115, P110, DOI 10.1016/j.jaci.2004.09.034; Chu HW, 2004, AM J PATHOL, V165, P1097, DOI 10.1016/S0002-9440(10)63371-8; Contreras-Ruiz L, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/636812; Contreras-Ruiz L, 2014, OPHTHALMOLOGY, V121, P1389, DOI 10.1016/j.ophtha.2014.01.033; Contreras-Ruiz L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075937; Coombes JL, 2007, J EXP MED, V204, P1757, DOI 10.1084/jem.20070590; Egan RM, 2000, J IMMUNOL, V164, P4543, DOI 10.4049/jimmunol.164.9.4543; Ezzie ME, 2011, AM J RESP CELL MOL, V44, P556, DOI 10.1165/rcmb.2009-0019OC; Fukata M, 2005, AM J PHYSIOL-GASTR L, V288, pG1055, DOI 10.1152/ajpgi.00328.2004; Gandhi NB, 2013, J LEUKOCYTE BIOL, V94, P1293, DOI 10.1189/jlb.1012524; Gersemann M, 2009, DIFFERENTIATION, V77, P84, DOI 10.1016/j.diff.2008.09.008; GILBARD JP, 1990, OPHTHALMOLOGY, V97, P308; Gipson IK, 1998, ADV EXP MED BIOL, V438, P221; Benito MJ, 2013, EXP EYE RES, V107, P88, DOI 10.1016/j.exer.2012.11.017; Kasper M, 2002, CLIN EXP ALLERGY, V32, P1251, DOI 10.1046/j.1365-2745.2002.01423.x; Khandelwal P, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064193; Knop N, 2000, INVEST OPHTH VIS SCI, V41, P1270; Laffont S, 2010, EUR J IMMUNOL, V40, P1877, DOI 10.1002/eji.200939957; Leonardi A, 2011, CLIN EXP ALLERGY, V41, P52, DOI 10.1111/j.1365-2222.2010.03626.x; Leonardi A, 2006, GRAEF ARCH CLIN EXP, V244, P1240, DOI 10.1007/s00417-006-0285-7; Maheshwari A, 2011, GASTROENTEROLOGY, V140, P242, DOI 10.1053/j.gastro.2010.09.043; Mantelli F, 2008, CURR OPIN ALLERGY CL, V8, P477, DOI 10.1097/ACI.0b013e32830e6b04; Nakamura T, 2001, INVEST OPHTH VIS SCI, V42, P549; Pflugfelder SC, 2008, CORNEA, V27, P64, DOI 10.1097/ICO.0b013e318158f6dc; Punekar S, 2008, PATHOBIOLOGY, V75, P9, DOI 10.1159/000113790; Rakoff-Nahoum S, 2004, CELL, V118, P229, DOI 10.1016/j.cell.2004.07.002; Ramalingam R, 2012, J IMMUNOL, V189, P3878, DOI 10.4049/jimmunol.1201029; Reinoso R, 2012, MUCOSAL IMMUNOL, V5, P455, DOI 10.1038/mi.2012.27; Ribeiro SMF, 1999, J BIOL CHEM, V274, P13586, DOI 10.1074/jbc.274.19.13586; Schaumburg CS, 2014, INVEST OPHTHALMOL VI, V55; Siebelmann S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082355; Tesseur I, 2006, BMC CELL BIOL, V7, DOI 10.1186/1471-2121-7-15; Thompson HGR, 2006, AM J PHYSIOL-LUNG C, V291, pL1277, DOI 10.1152/ajplung.00057.2006; TSENG SCG, 1984, OPHTHALMOLOGY, V91, P545; Turpie B, 2009, AM J PATHOL, V175, P1136, DOI 10.2353/ajpath.2009.081058; Wen FQ, 2002, AM J RESP CELL MOL, V26, P484, DOI 10.1165/ajrcmb.26.4.4784; Wu F, 2007, INFLAMM BOWEL DIS, V13, P807, DOI 10.1002/ibd.20110; Yamaguchi Y, 1997, STEM CELLS, V15, P144, DOI 10.1002/stem.150144; Yehualaeshet T, 1999, AM J PATHOL, V155, P841, DOI 10.1016/S0002-9440(10)65183-8	40	57	60	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 20	2015	10	3							e0120284	10.1371/journal.pone.0120284	http://dx.doi.org/10.1371/journal.pone.0120284			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CE8HY	25793763	gold, Green Submitted, Green Published			2023-01-03	WOS:000352083900008
J	Yancy, WS; Mayer, SB; Coffman, CJ; Smith, VA; Kolotkin, RL; Geiselman, PJ; McVay, MA; Oddone, EZ; Voils, CI				Yancy, William S., Jr.; Mayer, Stephanie B.; Coffman, Cynthia J.; Smith, Valerie A.; Kolotkin, Ronette L.; Geiselman, Paula J.; McVay, Megan A.; Oddone, Eugene Z.; Voils, Corrine I.			Effect of Allowing Choice of Diet on Weight Loss A Randomized Trial	ANNALS OF INTERNAL MEDICINE			English	Article							LOW-CARBOHYDRATE DIET; LOW-FAT DIET; OBESE ADULTS; RISK-FACTORS; OVERWEIGHT; QUESTIONNAIRE; PREFERENCE; IMPACT; RELIABILITY; MANAGEMENT	Background: Choosing a diet rather than being prescribed one could improve weight loss. Objective: To examine whether offering choice of diet improves weight loss. Design: Double-randomized preference trial of choice between 2 diets (choice) versus random assignment to a diet (comparator) over 48 weeks. (ClinicalTrials.gov: NCT01152359) Setting: Outpatient clinic at a Veterans Affairs medical center. Patients: Outpatients with a body mass index of at least 30 kg/m(2). Intervention: Choice participants received information about their food preferences and 2 diet options (low-carbohydrate diet [LCD] or low-fat diet [LFD]) before choosing and were allowed to switch diets at 12 weeks. Comparator participants were randomly assigned to 1 diet for 48 weeks. Both groups received group and telephone counseling for 48 weeks. Measurements: The primary outcome was weight at 48 weeks. Results: Of 105 choice participants, 61 (58%) chose the LCD and 44 (42%) chose the LFD; 5 (3 on the LCD and 2 on the LFD) switched diets at 12 weeks, and 87 (83%) completed measurements at 48 weeks. Of 102 comparator participants, 53 (52%) were randomly assigned to the LCD and 49 (48%) were assigned to the LFD; 88 (86%) completed measurements. At 48 weeks, estimated mean weight loss was 5.7 kg (95% CI, 4.3 to 7.0 kg) in the choice group and 6.7 kg (CI, 5.4 to 8.0 kg) in the comparator group (mean difference, -1.1 kg [CI, -2.9 to 0.8 kg]; P = 0.26). Secondary outcomes of dietary adherence, physical activity, and weight-related quality of life were similar between groups at 48 weeks. Limitations: Only 2 diet options were provided. Results from this sample of older veterans might not be generalizable to other populations. Conclusion: Contrary to expectations, the opportunity to choose a diet did not improve weight loss.	Vet Adm Med Ctr, Ctr Hlth Serv Res Primary Care, Durham, NC 27705 USA; Duke Univ, Med Ctr, Durham, NC USA; Virginia Commonwealth Univ, Richmond, VA USA; Sogn Og Fjordane Univ Coll, Forde, Norway; Forde Cent Hosp, Forde, Norway; Vestfold Hosp Trust, Tonsberg, Norway; Louisiana State Univ, Pennington Biomed Res Ctr, Baton Rouge, LA 70808 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Duke University; Virginia Commonwealth University; Western Norway University of Applied Sciences; Louisiana State University System; Louisiana State University; Pennington Biomedical Research Center	Yancy, WS (corresponding author), Durham VA Med Ctr, 152,508 Fulton St, Durham, NC 27705 USA.	yancy006@mc.duke.edu		Smith, Valerie/0000-0001-5170-9819; Kolotkin, Ronette/0000-0002-1300-2131; Mayer, Stephanie B./0000-0003-2437-347X	Department of Veterans Affairs [IIR 09-381]; Veterans Affairs [I01HX000263] Funding Source: NIH RePORTER	Department of Veterans Affairs(US Department of Veterans Affairs); Veterans Affairs(US Department of Veterans Affairs)	Grant Support: By the Department of Veterans Affairs (IIR 09-381).	American Heart Association, 2011, NO FAD DIET; [Anonymous], 1999, STAT MED, V18, P1905; [Anonymous], NEW ATKINS NEW YOU; Bazzano LA, 2014, ANN INTERN MED, V161, P309, DOI 10.7326/M14-0180; Bodenheimer T, 2002, JAMA-J AM MED ASSOC, V288, P2469, DOI 10.1001/jama.288.19.2469; Borradaile KE, 2012, OBESITY, V20, P1218, DOI 10.1038/oby.2011.216; Borushek A, 2007, CALORIE KING CALORIE; Burke LE, 2008, INT J OBESITY, V32, P166, DOI 10.1038/sj.ijo.0803706; Cohen J., 2013, STAT POWER ANAL BEHA; Craig CL, 2003, MED SCI SPORT EXER, V35, P1381, DOI 10.1249/01.MSS.0000078924.61453.FB; Dansinger ML, 2005, JAMA-J AM MED ASSOC, V293, P43, DOI 10.1001/jama.293.1.43; DREWNOWSKI A, 1992, DIETARY FATS, P59; Foster GD, 2010, ANN INTERN MED, V153, P147, DOI 10.7326/0003-4819-153-3-201008030-00005; Foster GD, 2003, NEW ENGL J MED, V348, P2082, DOI 10.1056/NEJMoa022207; Gardner CD, 2007, JAMA-J AM MED ASSOC, V297, P969, DOI 10.1001/jama.297.9.969; Geiselman PJ, 1998, PHYSIOL BEHAV, V63, P919, DOI 10.1016/S0031-9384(97)00542-8; GEISELMAN PJ, 1988, APPETITE, V11, P26, DOI 10.1016/S0195-6663(88)80043-6; Goldstein H, 2003, MULTILEVEL STAT MODE; Hartman AM, 1996, NUTR CANCER, V25, P305, DOI 10.1080/01635589609514454; Harvey JR, 2014, PREV MED, V68, P71, DOI 10.1016/j.ypmed.2014.05.015; Haskell WL, 2007, MED SCI SPORT EXER, V39, P1423, DOI [10.1249/mss.0b013e3180616b27, 10.1161/CIRCULATIONAHA.107.185649]; Institute of Medicine Food and Nutrition Board, 2002, DIET REF INT EN CARB; Jensen MD, 2014, CIRCULATION, V129, pS102, DOI 10.1161/01.cir.0000437739.71477.ee; Johnston BC, 2014, JAMA-J AM MED ASSOC, V312, P923, DOI 10.1001/jama.2014.10397; Klar N, 2000, DESIGN ANAL CLUSTER, DOI [10.17843/rpmesp.2016.333.2293, DOI 10.17843/RPMESP.2016.333.2293]; Kolotkin RL, 2002, QUAL LIFE RES, V11, P157, DOI 10.1023/A:1015081805439; Kolotkin RL, 2001, OBES RES, V9, P102, DOI 10.1038/oby.2001.13; Marcus SM, 2012, PSYCHOL METHODS, V17, P244, DOI 10.1037/a0028031; McVay MA, 2014, APPETITE, V83, P117, DOI 10.1016/j.appet.2014.08.023; National Institutes of Health, 2000, PRACT GUID ID EV TRE; Nordmann AJ, 2006, ARCH INTERN MED, V166, P285, DOI 10.1001/archinte.166.3.285; Pagoto SL, 2013, JAMA-J AM MED ASSOC, V310, P687, DOI 10.1001/jama.2013.8601; Pagoto SL, 2012, OBESITY, V20, P1234, DOI 10.1038/oby.2011.140; Rollnick S, 2009, BEHAV COGN PSYCHOTH, V23, P325, DOI [DOI 10.1017/S135246580001643X, 10.1017/S135246580001643X]; Sacks FM, 2009, NEW ENGL J MED, V360, P859, DOI 10.1056/NEJMoa0804748; Shai I, 2008, NEW ENGL J MED, V359, P229, DOI 10.1056/NEJMoa0708681; SPITZER L, 1981, APPETITE, V2, P293, DOI 10.1016/S0195-6663(81)80018-9; Stern L, 2004, ANN INTERN MED, V140, P778, DOI 10.7326/0003-4819-140-10-200405180-00007; WYANT KW, 1984, J AM DIET ASSOC, V84, P169; Yancy WS, 2013, CONTEMP CLIN TRIALS, V35, P106, DOI 10.1016/j.cct.2013.03.002; Yancy WS, 2010, ARCH INTERN MED, V170, P136, DOI 10.1001/archinternmed.2009.492; Yancy WS, 2004, ANN INTERN MED, V140, P769, DOI 10.7326/0003-4819-140-10-200405180-00006	42	30	30	0	15	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 16	2015	162	12					805	+		10.7326/M14-2358	http://dx.doi.org/10.7326/M14-2358			15	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CK8VC	26075751	Green Accepted			2023-01-03	WOS:000356516300015
J	Leshem, E; Tate, JE; Steiner, CA; Curns, AT; Lopman, BA; Parashar, UD				Leshem, Eyal; Tate, Jacqueline E.; Steiner, Claudia A.; Curns, Aaron T.; Lopman, Ben A.; Parashar, Umesh D.			Acute Gastroenteritis Hospitalizations Among US Children Following Implementation of the Rotavirus Vaccine	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter							HEALTH-CARE UTILIZATION; UNITED-STATES; DIARRHEA		[Leshem, Eyal; Tate, Jacqueline E.; Curns, Aaron T.; Lopman, Ben A.; Parashar, Umesh D.] US Ctr Dis Control & Prevent, Div Viral Dis, Atlanta, GA 30333 USA; [Steiner, Claudia A.] Agcy Healthcare Res & Qual, Healthcare Cost & Utilizat Project, Rockville, MD USA	Centers for Disease Control & Prevention - USA; Agency for Healthcare Research & Quality	Leshem, E (corresponding author), US Ctr Dis Control & Prevent, Div Viral Dis, 1600 Clifton Rd NE,Mail Stop A-34, Atlanta, GA 30333 USA.	eleshem@cdc.gov		Leshem, Eyal/0000-0003-1267-6131				Cortes JE, 2011, NEW ENGL J MED, V365, P1108, DOI 10.1056/NEJMoa1000446; Cortese Margaret M., 2009, Morbidity and Mortality Weekly Report, V58, P1; Curns AT, 2010, J INFECT DIS, V201, P1617, DOI 10.1086/652403; Elam-Evans LD, 2014, MMWR-MORBID MORTAL W, V63, P741; Leshem E, 2014, PEDIATRICS, V134, P15, DOI 10.1542/peds.2013-3849; US Centers for Disease Control and Prevention, BRIDG RAC POP EST DA	6	49	50	0	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 9	2015	313	22					2282	2284		10.1001/jama.2015.5571	http://dx.doi.org/10.1001/jama.2015.5571			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CK1VH	26057291	Bronze			2023-01-03	WOS:000355995300024
J	Sheng, J; Yang, YP; Ma, YX; Yang, BJ; Zhang, YX; Kang, SY; Zhou, T; Hong, SD; Qin, T; Hu, ZH; Fang, WF; Huang, Y; Zhang, L				Sheng, Jin; Yang, Yunpeng; Ma, Yuxiang; Yang, Bijun; Zhang, Yaxiong; Kang, Shiyang; Zhou, Ting; Hong, Shaodong; Qin, Tao; Hu, Zhihuang; Fang, Wenfeng; Huang, Yan; Zhang, Li			The Efficacy of Combining Antiangiogenic Agents with Chemotherapy for Patients with Advanced Non-Small Cell Lung Cancer Who Failed First-Line Chemotherapy: A Systematic Review and Meta-Analysis	PLOS ONE			English	Article							PHASE-III TRIAL; ENDOTHELIAL PROGENITOR CELLS; PLATINUM-BASED CHEMOTHERAPY; VANDETANIB PLUS DOCETAXEL; DOUBLE-BLIND; 2ND-LINE TREATMENT; BEVACIZUMAB; ERLOTINIB; PLACEBO; CARBOPLATIN	Background The clinical outcomes of patients with NSCLC who progressed after first-line treatments remain poor. The purpose of this study was to assess the advantage of antiangiogenic therapy plus standard treatment versus standard treatment alone for this population of patients. Methods We conducted a rigorous search using electronic databases for eligible studies reporting antiangiogenic therapy combined with standard second-line chemotherapy versus standard second-line treatment for patient who progressed after front-line treatment. Pooled risk ratio and 95% confidence intervals were calculated using proper statistical method. Predefined subgroup analyses were conducted to identify the potential proper patients. Results Thirteen phase II/III RCTs which involved a total of 8358 participants were included. Overall, there was significant improvement in OS (HR 0.94, 95% CI: 0.89-0.99, p = 0.03), PFS (HR 0.80, 95% CI: 0.76-0.84, p < 0.00001), ORR (RR 1.75, 95% CI: 1.55-1.98, p < 0.00001) and DCR (RR 1.23, 95% CI: 1.18-1.28, p < 0.00001) in the group with antiangiogenic therapy plus standard treatment versus the group with standard treatment alone. Subgroup analysis showed that OS benefit was presented only in patients treated with docetaxel plus antiangiogenic agents (HR 0.92, 95% CI: 0.86-0.99, p = 0.02) and patients with non-squamous NSCLC (HR for OS 0.92, 95% CI: 0.86-0.99, p = 0.02). Conclusions This study revealed that the addition of antiangiogenic agents to the standard treatments could provide clinical benefit to NSCLC patients who failed their first-line therapy. Furthermore, proper selection of the combined standard cytotoxic agent, as well as the patient population by tumor histology, is warranted for future studies and clinical application of antiangiogenic therapy.	[Sheng, Jin; Yang, Yunpeng; Ma, Yuxiang; Zhou, Ting; Hong, Shaodong; Qin, Tao; Hu, Zhihuang; Fang, Wenfeng; Huang, Yan; Zhang, Li] Sun Yat Sen Univ, Ctr Canc, Dept Med Oncol, Guangzhou 510275, Guangdong, Peoples R China; [Sheng, Jin; Yang, Yunpeng; Ma, Yuxiang; Zhou, Ting; Hong, Shaodong; Qin, Tao; Hu, Zhihuang; Fang, Wenfeng; Huang, Yan; Zhang, Li] State Key Lab Oncol South China, Guangzhou, Guangdong, Peoples R China; [Sheng, Jin; Yang, Yunpeng; Ma, Yuxiang; Zhou, Ting; Hong, Shaodong; Qin, Tao; Hu, Zhihuang; Fang, Wenfeng; Huang, Yan; Zhang, Li] Collaborat Innovat Ctr Canc Med, Guangzhou, Guangdong, Peoples R China; [Yang, Bijun; Zhang, Yaxiong; Kang, Shiyang] Sun Yat Sen Univ, Zhongshan Sch Med, Guangzhou 510275, Guangdong, Peoples R China	Sun Yat Sen University; State Key Lab Oncology South China; Sun Yat Sen University	Zhang, L (corresponding author), Sun Yat Sen Univ, Ctr Canc, Dept Med Oncol, Guangzhou 510275, Guangdong, Peoples R China.	zhangli6@mail.sysu.edu.cn			National High Technology Research and Development Program of China [2012AA02A502]; Innovative drug RD center [2013ZX09401003-002]; National Natural Science Funds of China [81372502]; Wu Jieping Medical Foundation Project [320.6750.131]	National High Technology Research and Development Program of China(National High Technology Research and Development Program of China); Innovative drug RD center; National Natural Science Funds of China(National Natural Science Foundation of China (NSFC)); Wu Jieping Medical Foundation Project	1. National High Technology Research and Development Program of China (Grant No. 2012AA02A502). 2. Innovative drug R&D center based on real-time high-throughput cell-based screening platform and large capacity compound library (Grant No. 2013ZX09401003-002). 3. National Natural Science Funds of China (Grant No. 81372502). 4. Wu Jieping Medical Foundation Project (Grant No. 320.6750.131). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bass MB, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108048; Bertolini F, 2003, CANCER RES, V63, P4342; Brauer MJ, 2013, CLIN CANCER RES, V19, P3681, DOI 10.1158/1078-0432.CCR-12-3635; Lima ABC, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022681; de Boer RH, 2011, J CLIN ONCOL, V29, P1067, DOI 10.1200/JCO.2010.29.5717; Ettinger DS, 2012, J NATL COMPR CANC NE, V10, P1236, DOI 10.6004/jnccn.2012.0130; Garon EB, 2014, LANCET, V384, P665, DOI 10.1016/S0140-6736(14)60845-X; Groen HJM, 2013, ANN ONCOL, V24, P2382, DOI 10.1093/annonc/mdt212; Hanna NH, 2013, J CLIN ONCOL, V31; Heist RS, 2014, J THORAC ONCOL, V9, P214, DOI 10.1097/JTO.0000000000000071; Herbst RS, 2007, J CLIN ONCOL, V25, P4743, DOI 10.1200/JCO.2007.12.3026; Herbst RS, 2011, LANCET, V377, P1846, DOI 10.1016/S0140-6736(11)60545-X; Herbst RS, 2010, LANCET ONCOL, V11, P619, DOI 10.1016/S1470-2045(10)70132-7; Heymach JV, 2007, J CLIN ONCOL, V25, P4270, DOI 10.1200/JCO.2006.10.5122; Hotta K, 2007, J THORAC ONCOL, V2, P402, DOI 10.1097/01.JTO.0000268673.95119.c7; Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4; Leighl NB, 2012, CURR ONCOL, V19, pS52, DOI 10.3747/co.19.1114; Li TH, 2013, J CLIN ONCOL, V31, P1039, DOI 10.1200/JCO.2012.45.3753; Mok T, 2014, J THORAC ONCOL, V9, P848, DOI 10.1097/JTO.0000000000000160; Mok TS, 2009, NEW ENGL J MED, V361, P947, DOI 10.1056/NEJMoa0810699; National Comprehensive Cancer Network, 2015, NCCN CLIN PRACT GUID; Ramlau R, 2012, J CLIN ONCOL, V30, P3640, DOI 10.1200/JCO.2012.42.6932; Reck M, 2014, ANN ONCOL, V25, P27, DOI 10.1093/annonc/mdu199; Reck M, 2010, ANN ONCOL, V21, P1804, DOI 10.1093/annonc/mdq020; Reck M, 2014, LANCET ONCOL, V15, P143, DOI 10.1016/S1470-2045(13)70586-2; Sandler A, 2006, NEW ENGL J MED, V355, P2542, DOI 10.1056/NEJMoa061884; Scagliotti GV, 2012, J CLIN ONCOL, V30, P2070, DOI 10.1200/JCO.2011.39.2993; Scagliotti GV, 2009, J THORAC ONCOL, V4, P1568, DOI 10.1097/JTO.0b013e3181c06980; Shaked Y, 2008, CANCER CELL, V14, P263, DOI 10.1016/j.ccr.2008.08.001; Shaked Y, 2006, SCIENCE, V313, P1785, DOI 10.1126/science.1127592; Shepherd FA, 2005, NEW ENGL J MED, V353, P123, DOI 10.1056/NEJMoa050753; Shepherd FA, 2000, J CLIN ONCOL, V18, P2095, DOI 10.1200/JCO.2000.18.10.2095; Soria JC, 2013, ANN ONCOL, V24, P20, DOI 10.1093/annonc/mds590; Spigel DR, 2011, J CLIN ONCOL, V29, P2582, DOI 10.1200/JCO.2010.30.7678	34	12	15	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 2	2015	10	6							e0127306	10.1371/journal.pone.0127306	http://dx.doi.org/10.1371/journal.pone.0127306			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CJ7SJ	26034985	Green Published, Green Submitted, gold			2023-01-03	WOS:000355699100011
J	Ghate, NB; Chaudhuri, D; Das, A; Panja, S; Mandal, N				Ghate, Nikhil Baban; Chaudhuri, Dipankar; Das, Abhishek; Panja, Sourav; Mandal, Nripendranath			An Antioxidant Extract of the Insectivorous Plant Drosera burmannii Vahl. Alleviates Iron-Induced Oxidative Stress and Hepatic Injury in Mice	PLOS ONE			English	Article							THALASSEMIA MAJOR; LONG-TERM; LIVER; OVERLOAD; ACID; HEMOCHROMATOSIS; SUPEROXIDE; MECHANISMS; RESERPINE	Free iron typically leads to the formation of excess free radicals, and additional iron deposition in the liver contributes to the oxidative pathologic processes of liver disease. Many pharmacological properties of the insectivorous plant Drosera burmannii Vahl. have been reported in previous studies; however, there is no evidence of its antioxidant or hepatoprotective potential against iron overload. The antioxidant activity of 70% methanolic extract of D. burmannii (DBME) was evaluated. DBME showed excellent DPPH, hydroxyl, hypochlorous, superoxide, singlet oxygen, nitric oxide, peroxynitrite radical and hydrogen peroxide scavenging activity. A substantial iron chelation (IC50 = 40.90 +/- 0.31 mu g/ml) and supercoiled DNA protection ([P](50) = 50.41 +/- 0.55 mu g) were observed. DBME also displayed excellent in vivo hepatoprotective activity in iron-overloaded Swiss albino mice compared to the standard desirox treatment. Administration of DBME significantly normalized serum enzyme levels and restored liver antioxidant enzymes levels. DBME lowered the raised levels of liver damage parameters, also reflected from the morphological analysis of the liver sections. DBME also reduced liver iron content by 115.90% which is also seen by Perls' staining. A phytochemical analysis of DBME confirms the presence of various phytoconstituents, including phenols, flavonoids, carbohydrates, tannins, alkaloids and ascorbic acid. Alkaloids, phenols and flavonoids were abundantly found in DBME. An HPLC analysis of DBME revealed the presence of purpurin, catechin, tannic acid, reserpine, methyl gallate and rutin. Purpurin, tannic acid, methyl gallate and rutin displayed excellent iron chelation but exhibited cytotoxicity toward normal (WI-38) cells; while DBME found to be non-toxic to the normal cells. These findings suggest that the constituents present in DBME contributed to its iron chelation activity. Additional studies are needed to determine if DBME can be used as a treatment for iron overload diseases.	[Ghate, Nikhil Baban; Chaudhuri, Dipankar; Das, Abhishek; Panja, Sourav; Mandal, Nripendranath] Bose Inst, Div Mol Med, Kolkata, W Bengal, India	Department of Science & Technology (India); Bose Institute	Mandal, N (corresponding author), Bose Inst, Div Mol Med, P 1-12,Scheme VIIM, Kolkata, W Bengal, India.	mandaln@rediffmail.com	PANJA, SOURAV/AAA-7163-2022; Mandal, Nripendranath/ABC-3918-2020; Panja, Sourav/AFO-5798-2022; Chudhuri, Dipankar/AAU-6215-2021; Ghate, Nikhil/T-4153-2017	Mandal, Nripendranath/0000-0002-8733-3566; Panja, Sourav/0000-0001-8540-5266; Ghate, Nikhil/0000-0002-4447-3737; Chaudhuri, Dipankar/0000-0001-7991-0469	Department of Biotechnology (DBT), Govt. of India	Department of Biotechnology (DBT), Govt. of India(Department of Biotechnology (DBT) India)	Dr. Abhishek Das is grateful to the Department of Biotechnology (DBT), Govt. of India for the support of Research Associateship.	ALREFAIE FN, 1992, BLOOD, V80, P593; [Anonymous], 1998, WEALTH INDIA, V3; Arezzini B, 2003, INT J BIOCHEM CELL B, V35, P486, DOI 10.1016/S1357-2725(02)00298-4; Arthur MJP, 1996, J GASTROEN HEPATOL, V11, P1124, DOI 10.1111/j.1440-1746.1996.tb01840.x; ARUOMA OI, 1989, FREE RADICAL BIO MED, V6, P593, DOI 10.1016/0891-5849(89)90066-X; BARRY M, 1971, LANCET, V1, P100; Beckman KB, 1998, PHYSIOL REV, V78, P547, DOI 10.1152/physrev.1998.78.2.547; Begum S, 2012, NAT PROD RES, V26, P2084, DOI 10.1080/14786419.2011.625502; Bibhabasu Hazra, 2012, American Journal of Pharmacology and Toxicology, V7, P109; BONAVENTURA J, 1972, ARCH BIOCHEM BIOPHYS, V150, P606, DOI 10.1016/0003-9861(72)90080-X; BONKOWSKY HL, 1981, BIOCHEM J, V196, P57, DOI 10.1042/bj1960057; Buege J A, 1978, Methods Enzymol, V52, P302; Christophe W, 2006, ETHNOPHARMACOLOGY ME, P37; Das A., 2012, ASIAN J PHARM CLIN R, V5, P74; DAWSON TM, 1992, ANN NEUROL, V32, P297, DOI 10.1002/ana.410320302; DEUGNIER YM, 1992, GASTROENTEROLOGY, V102, P2050, DOI 10.1016/0016-5085(92)90331-R; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; Gardi C, 2002, BIOCHEM PHARMACOL, V64, P1139, DOI 10.1016/S0006-2952(02)01257-1; Ghate NB, 2014, CYTOTECHNOLOGY, V66, P209, DOI 10.1007/s10616-013-9553-7; Ghate NB, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082293; GOLDIN A, 1957, SCIENCE, V125, P156, DOI 10.1126/science.125.3239.156-a; HABIG WH, 1974, J BIOL CHEM, V249, P7130; HALLIWELL B, 1991, AM J MED, V91, pS14, DOI 10.1016/0002-9343(91)90279-7; Harborne J.B., 1995, PHYTOCHEMICAL DICT H; Haro-Vicente JF, 2006, FOOD CHEM, V98, P639, DOI 10.1016/j.foodchem.2005.06.040; Hazra B, 2008, BMC COMPLEM ALTERN M, V8, DOI 10.1186/1472-6882-8-63; Hema B., 2009, INT J APPL RES NAT P, V2, P1; Hermes-Lima M, 1998, FREE RADICAL BIO MED, V25, P875, DOI 10.1016/S0891-5849(98)00117-8; Hynes MJ, 2002, J INORG BIOCHEM, V90, P18, DOI 10.1016/S0162-0134(02)00383-5; KAKKAR P, 1984, INDIAN J BIOCHEM BIO, V21, P130; Kochevar IE, 2000, METHOD ENZYMOL, V319, P20; Kokate C, 2017, PHARMACOGNOSY, V53rd, pA22; Kumar M., 2012, ASIAN PAC J TROP DIS, V2S, pS692, DOI [DOI 10.1016/S2222-1808(12)60245-X, 10.1016/S2222-1808(12)60245-X]; Lushchak VI, 2011, COMP BIOCHEM PHYS C, V153, P175, DOI 10.1016/j.cbpc.2010.10.004; Madhavan V, 2009, PHARM BIOL, V47, P128, DOI 10.1080/13880200802437149; MAXWELL SRJ, 1995, DRUGS, V49, P345, DOI 10.2165/00003495-199549030-00003; Nabavi S. M, 2008, PHARMACOLOGYONLINE, P560, DOI DOI 10.1007/BF01091994; NIEDERAU C, 1985, NEW ENGL J MED, V313, P1256, DOI 10.1056/NEJM198511143132004; OBRIEN RT, 1974, ANN NY ACAD SCI, V232, P221, DOI 10.1111/j.1749-6632.1974.tb20588.x; OLYNYK J, 1995, J HEPATOL, V22, P671, DOI 10.1016/0168-8278(95)80222-3; Perron NR, 2009, CELL BIOCHEM BIOPHYS, V53, P75, DOI 10.1007/s12013-009-9043-x; Raju A., 2012, Journal of Pharmacy Research, V5, P1418; Ramm GA, 2005, SEMIN LIVER DIS, V25, P433, DOI 10.1055/s-2005-923315; Reddy ACP, 1996, TOXICOLOGY, V107, P39, DOI 10.1016/0300-483X(95)03199-P; Richardson, 1999, Expert Opin Investig Drugs, V8, P2141, DOI 10.1517/13543784.8.12.2141; Sarkar R, 2013, INDIAN J EXP BIOL, V51, P165; Sarkar R, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/896341; Sayre Lawrence M, 2005, Ann Ist Super Sanita, V41, P143; de Jesus NZT, 2012, INT J MOL SCI, V13, P3203, DOI 10.3390/ijms13033203; VINKENBORG J, 1969, Pharmaceutisch Weekblad, V104, P45; Visioli F, 1998, BIOCHEM BIOPH RES CO, V247, P60, DOI 10.1006/bbrc.1998.8735; Wagner H., 1984, PLANT DRUG ANAL; Wang Q, 1998, Zhong Yao Cai, V21, P401; Ward FM, 1999, CLIN PHARMACOL THER, V5thed, P195; Wolf P L, 1999, Indian J Clin Biochem, V14, P59, DOI 10.1007/BF02869152; Yao LH, 2004, PLANT FOOD HUM NUTR, V59, P113, DOI 10.1007/s11130-004-0049-7	56	20	20	0	22	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 26	2015	10	5							e0128221	10.1371/journal.pone.0128221	http://dx.doi.org/10.1371/journal.pone.0128221			21	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CJ0QZ	26010614	Green Published, gold, Green Submitted			2023-01-03	WOS:000355183900209
J	Rroji, O; van Kuyck, K; Nuttin, B; Wenderoth, N				Rroji, Orjon; van Kuyck, Kris; Nuttin, Bart; Wenderoth, Nicole			Anodal tDCS over the Primary Motor Cortex Facilitates Long-Term Memory Formation Reflecting Use-Dependent Plasticity	PLOS ONE			English	Article							DIRECT-CURRENT STIMULATION; EARLY CONSOLIDATION; PREMOTOR CORTEX; EXCITABILITY; MODULATION; IMPLICIT; POLARIZATION; MECHANISMS	Previous research suggests that anodal transcranial direct current stimulation (tDCS) over the primary motor cortex (M1) modulates NMDA receptor dependent processes that mediate synaptic plasticity. Here we test this proposal by applying anodal versus sham tDCS while subjects practiced to flex the thumb as fast as possible (ballistic movements). Repetitive practice of this task has been shown to result in performance improvements that reflect use-dependent plasticity resulting from NMDA receptor mediated, long-term potentiation (LTP)-like processes. Using a double-blind within-subject cross-over design, subjects (n=14) participated either in an anodal or a sham tDCS session which were at least 3 months apart. Sham or anodal tDCS (1 mA) was applied for 20 min during motor practice and retention was tested 30 min, 24 hours and one week later. All subjects improved performance during each of the two sessions (p < 0.001) and learning gains were similar. Our main result is that long term retention performance (i.e. 1 week after practice) was significantly better when practice was performed with anodal tDCS than with sham tDCS (p < 0.001). This effect was large (Cohen's d=1.01) and all but one subject followed the group trend. Our data strongly suggest that anodal tDCS facilitates long-term memory formation reflecting use-dependent plasticity. Our results support the notion that anodal tDCS facilitates synaptic plasticity mediated by an LTP-like mechanism, which is in accordance with previous research.	[Rroji, Orjon; Wenderoth, Nicole] Katholieke Univ Leuven, Res Ctr Movement Control & Neuroplast, Dept Kinesiol, Leuven, Belgium; [van Kuyck, Kris; Nuttin, Bart] Katholieke Univ Leuven, Dept Neurosci, Res Grp Expt Neurosurg & Neuroanat, Leuven, Belgium; [Wenderoth, Nicole] ETH, Dept Hlth Sci & Technol, Neural Control Movement Lab, Zurich, Switzerland	KU Leuven; KU Leuven; Swiss Federal Institutes of Technology Domain; ETH Zurich	Wenderoth, N (corresponding author), Katholieke Univ Leuven, Res Ctr Movement Control & Neuroplast, Dept Kinesiol, Leuven, Belgium.	nicole.wenderoth@hest.ethz.ch	Wenderoth, Nicole/D-7262-2015	Wenderoth, Nicole/0000-0002-3246-9386	Flanders Fund for Scientific Research [G.0401.12]; KU Leuven	Flanders Fund for Scientific Research(FWO); KU Leuven(KU Leuven)	Support for this study was provided through grant G.0401.12 from the Flanders Fund for Scientific Research (http://www.fwo.be). OR was supported by a DBOF PhD fellowship from KU Leuven (http://www.kuleuven.be). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alaerts K, 2009, CORTEX, V45, P1148, DOI 10.1016/j.cortex.2008.10.005; Alonzo A, 2012, BRAIN STIMUL, V5, P208, DOI 10.1016/j.brs.2011.04.006; Antal A, 2004, EUR J NEUROSCI, V19, P2888, DOI 10.1111/j.1460-9568.2004.03367.x; Bisio A, 2015, CLIN NEUROPHYSIOL, V126, P1212, DOI 10.1016/j.clinph.2014.08.024; Boggio PS, 2006, NEUROSCI LETT, V404, P232, DOI 10.1016/j.neulet.2006.05.051; Bortoletto M, 2015, BRAIN STIMUL, V8, P269, DOI 10.1016/j.brs.2014.11.006; Brasil-Neto Joaquim P, 2012, Front Psychiatry, V3, P80, DOI 10.3389/fpsyt.2012.00080; Butefisch CM, 2000, P NATL ACAD SCI USA, V97, P3661, DOI 10.1073/pnas.050350297; Classen J, 1998, J NEUROPHYSIOL, V79, P1117, DOI 10.1152/jn.1998.79.2.1117; Convento S, 2014, CORTEX, V57, P51, DOI 10.1016/j.cortex.2014.03.006; de Xivry JJO, 2014, EXP BRAIN RES, V232, P3379, DOI 10.1007/s00221-014-4087-6; de Xivry JJO, 2011, J NEUROSCI, V31, P7102, DOI 10.1523/JNEUROSCI.0273-11.2011; Floyer-Lea A, 2006, J NEUROPHYSIOL, V95, P1639, DOI 10.1152/jn.00346.2005; Fritsch B, 2010, NEURON, V66, P198, DOI 10.1016/j.neuron.2010.03.035; Furuya S, 2014, J NEUROSCI, V34, P13834, DOI 10.1523/JNEUROSCI.1170-14.2014; Galea JM, 2011, CEREB CORTEX, V21, P1761, DOI 10.1093/cercor/bhq246; Galea JM, 2009, J NEUROPHYSIOL, V102, P294, DOI 10.1152/jn.00184.2009; Hummel FC, 2010, NEUROBIOL AGING, V31, P2160, DOI 10.1016/j.neurobiolaging.2008.12.008; Javadi AH, 2013, BRAIN STIMUL, V6, P668, DOI 10.1016/j.brs.2012.10.007; Kantak SS, 2012, EUR J NEUROSCI, V36, P2710, DOI 10.1111/j.1460-9568.2012.08175.x; Karok S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0085693; Marquez CMS, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00333; Meinzer M, 2014, CORTEX, V50, P137, DOI 10.1016/j.cortex.2013.07.013; Missitzi J, 2013, PHYSIOL REP, V1, DOI 10.1002/phy2.188; Monte-Silva K, 2013, BRAIN STIMUL, V6, P424, DOI 10.1016/j.brs.2012.04.011; Muellbacher W, 2002, NATURE, V415, P640, DOI 10.1038/nature712; Muller-Dahlhaus F, 2015, NEUROSCIENTIST, V21, P185, DOI 10.1177/1073858414526645; Nitsche MA, 2004, NEUROPSYCHOPHARMACOL, V29, P1573, DOI 10.1038/sj.npp.1300517; Nitsche MA, 2003, J COGNITIVE NEUROSCI, V15, P619, DOI 10.1162/089892903321662994; Nitsche MA, 2000, J PHYSIOL-LONDON, V527, P633, DOI 10.1111/j.1469-7793.2000.t01-1-00633.x; Nitsche MA, 2005, J PHYSIOL-LONDON, V568, P291, DOI 10.1113/jphysiol.2005.092429; Nitsche MA, 2008, BRAIN STIMUL, V1, P206, DOI 10.1016/j.brs.2008.06.004; OLDFIELD RC, 1971, NEUROPSYCHOLOGIA, V9, P97, DOI 10.1016/0028-3932(71)90067-4; Parikh PJ, 2014, PHYSIOL REP, V2, DOI 10.1002/phy2.255; PASCUALLEONE A, 1994, SCIENCE, V263, P1287, DOI 10.1126/science.8122113; Paulus W, 2003, SUPPL CLIN NEUROPHYS, V56, P249; Pavlova E, 2014, BRAIN RES, V1576, P52, DOI 10.1016/j.brainres.2014.06.023; Peters MAK, 2013, NEUROPSYCHOLOGIA, V51, P1234, DOI 10.1016/j.neuropsychologia.2013.03.013; Reis Janine, 2015, Cereb Cortex, V25, P109, DOI 10.1093/cercor/bht208; Reis J, 2009, P NATL ACAD SCI USA, V106, P1590, DOI 10.1073/pnas.0805413106; RICKHAM PP, 1964, BRIT MED J, V2, P173; Rosenkranz K, 2007, J NEUROSCI, V27, P12058, DOI 10.1523/JNEUROSCI.2663-07.2007; Rosenkranz K, 2007, J NEUROSCI, V27, P5200, DOI 10.1523/JNEUROSCI.0836-07.2007; Schambra HM, 2011, J NEUROPHYSIOL, V106, P652, DOI 10.1152/jn.00210.2011; Schwartz AB, 2007, J PHYSIOL-LONDON, V579, P581, DOI 10.1113/jphysiol.2006.126698; Soekadar SR, 2015, CEREB CORTEX, V25, P2409, DOI 10.1093/cercor/bhu043; Stagg CJ, 2011, CURR BIOL, V21, P480, DOI 10.1016/j.cub.2011.01.069; Stagg CJ, 2009, J NEUROSCI, V29, P5202, DOI 10.1523/JNEUROSCI.4432-08.2009; Tanaka S, 2009, EXP BRAIN RES, V196, P459, DOI 10.1007/s00221-009-1863-9; Tecchio F, 2010, J NEUROPHYSIOL, V104, P1134, DOI 10.1152/jn.00661.2009; Vines BW, 2008, EUR J NEUROSCI, V28, P1667, DOI 10.1111/j.1460-9568.2008.06459.x; Wiestler T, 2013, ELIFE, V2, DOI 10.7554/eLife.00801; Zhang X, 2011, J NEUROSCI, V31, P11515, DOI 10.1523/JNEUROSCI.6759-10.2011; Ziemann U, 1998, J NEUROSCI, V18, P7000	54	40	40	0	19	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 21	2015	10	5							e0127270	10.1371/journal.pone.0127270	http://dx.doi.org/10.1371/journal.pone.0127270			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CK7VW	25996937	gold, Green Published, Green Submitted			2023-01-03	WOS:000356444000052
J	Champ, CE; Smith, RP				Champ, Colin E.; Smith, Ryan P.			Radiation Recall and Woody Fibrosis	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Champ, Colin E.; Smith, Ryan P.] Univ Pittsburgh, Med Ctr, Pittsburgh, PA 15260 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Champ, CE (corresponding author), Univ Pittsburgh, Med Ctr, Pittsburgh, PA 15260 USA.	champce@upmc.edu	Champ, Colin/AAA-6842-2019	Champ, Colin/0000-0002-1879-7463					0	0	0	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 14	2015	372	20							e26	10.1056/NEJMicm1409470	http://dx.doi.org/10.1056/NEJMicm1409470			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CI1HB	25970071				2023-01-03	WOS:000354493300011
J	Malhotra, A; Maughan, D; Ansell, J; Lehman, R; Henderson, A; Gray, M; Stephenson, T; Bailey, S				Malhotra, A.; Maughan, D.; Ansell, J.; Lehman, R.; Henderson, A.; Gray, M.; Stephenson, T.; Bailey, S.			Choosing Wisely in the UK: the Academy of Medical Royal Colleges' initiative to reduce the harms of too much medicine	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							SHARED DECISION-MAKING; CARE; INTERVENTIONS; BENEFITS		[Malhotra, A.; Henderson, A.; Stephenson, T.; Bailey, S.] Acad Med Royal Coll, London, England; [Maughan, D.] Ctr Sustainable Healthcare, Oxford, England; [Ansell, J.] Cardiff Medictr, Welsh Inst Minimal Access Therapy, Cardiff, S Glam, Wales; [Lehman, R.] Univ Oxford, Dept Primary Hlth Care, Oxford, England; [Gray, M.] Better Value Healthcare, Oxford, England; [Stephenson, T.] Inst Child Hlth, London, England	Cardiff University; University of Oxford; University of London; University College London	Malhotra, A (corresponding author), Acad Med Royal Coll, London, England.	Aseem_malhotra@hotmail.com		Stephenson, Terence/0000-0001-8871-7847				Academy of Royal Medical Colleges, 2014, PROTECTING RESOURCES; [Anonymous], 2014, UNNECESSARY TESTS AN; [Anonymous], 2010, NHS ATLAS OF VARIATI; Clement F, 2015, JAMA INT MED; Djulbegovic B, 2011, JAMA-J AM MED ASSOC, V305, P2005, DOI 10.1001/jama.2011.650; Durand MA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094670; Fontana M, 2014, CIRCULATION, V129, P2539, DOI 10.1161/CIRCULATIONAHA.113.007595; Garner S, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d4519; Gigerenzer G, 2011, ENVISIONING HEALTHCA; Gigerenzer G, 2009, B WORLD HEALTH ORGAN, V87, P567, DOI 10.2471/BLT.09.069872; Glover J A, 1938, Proc R Soc Med, V31, P1219; Hoffman A, 2009, HEALTH AFFAIR, V28, pW710, DOI 10.1377/hlthaff.28.4.w710; Hurley R, 2014, BMJ-BRIT MED J, V349, DOI 10.1136/bmj.g4289; Kontopantelis E, 2015, BMJ-BRIT MED J, V350, DOI 10.1136/bmj.h904; Levinson W, 2015, BMJ QUAL SAF, V24, P167, DOI 10.1136/bmjqs-2014-003821; Macdonald H, 2015, BMJ-BRIT MED J, V350, DOI 10.1136/bmj.h1163; Malhotra A, 2014, JAMA INTERN MED, V174, P1367, DOI 10.1001/jamainternmed.2013.9190; Morden NE, 2014, NEW ENGL J MED, V370, P589, DOI 10.1056/NEJMp1314965; Morgan DJ, 2015, JAMA INTERN MED, V175, P120, DOI 10.1001/jamainternmed.2014.5444; Rothberg MB, 2014, JAMA INTERN MED, V174, P1623, DOI 10.1001/jamainternmed.2014.3331; Stacey D, 2014, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD001431.pub4, 10.1002/14651858.CD001431.pub2, 10.1002/14651858.CD001431.pub3]; Walsh T, 2014, BMJ-BRIT MED J, V348, DOI 10.1136/bmj.g188; Welch H., 2012, OVERDIAGNOSED MAKING; WENNBERG J, 1973, SCIENCE, V182, P1102, DOI 10.1126/science.182.4117.1102	24	98	99	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 12	2015	350								h2308	10.1136/bmj.h2308	http://dx.doi.org/10.1136/bmj.h2308			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CI5BX	25985331	Green Published, hybrid			2023-01-03	WOS:000354769000004
J	Catanzaro, D; Rancan, S; Orso, G; Dall'Acqua, S; Brun, P; Giron, MC; Carrara, M; Castagliuolo, I; Ragazzi, E; Caparrotta, L; Montopoli, M				Catanzaro, Daniela; Rancan, Serena; Orso, Genny; Dall'Acqua, Stefano; Brun, Paola; Giron, Maria Cecilia; Carrara, Maria; Castagliuolo, Ignazio; Ragazzi, Eugenio; Caparrotta, Laura; Montopoli, Monica			Boswellia serrata Preserves Intestinal Epithelial Barrier from Oxidative and Inflammatory Damage	PLOS ONE			English	Article							NF-KAPPA-B; BOWEL-DISEASE; IN-VITRO; IFN-GAMMA; PERMEABILITY; MECHANISMS; EXPRESSION; INDUCTION; MODELS	Aminosalicylates, corticosteroids and immunosuppressants are currently the therapeutic choices in inflammatory bowel diseases (IBD), however, with limited remission and often serious side effects. Meanwhile complementary and alternative medicine (CAM) use is increasing, particularly herbal medicine. Boswellia serrata is a traditional Ayurvedic remedy with anti-inflammatory properties, of interest for its usefulness in IBDs. The mechanism of this pharmacological potential of Boswellia serrata was investigated in colonic epithelial cell monolayers exposed to H2O2 or INF-gamma+TNF-alpha, chosen as in vitro experimental model of intestinal inflammation. The barrier function was evaluated by the transepithelial electrical resistance (TEER) and paracellular permeability assay, and by the tight junction proteins (zonula occludens-1, ZO-1 and occludin) immunofluorescence. The expression of phosphorylated NF-kappa B and reactive oxygen species (ROS) generation were determined by immunoblot and cytofluorimetric assay, respectively. Boswellia serrata oleo-gum extract (BSE) and its pure derivative acetyl-11-keto-beta-boswellic acid (AKBA), were tested at 0.1-10 mu g/ml and 0.027 mu g/ml, respectively. BSE and AKBA safety was demonstrated by no alteration of intestinal cell viability and barrier function and integrity biomarkers. H2O2 or INF-gamma+TNF-alpha treatment of Caco-2 cell monolayers significantly reduced TEER, increased paracellular permeability and caused the disassembly of tight junction proteins occludin and ZO-1. BSE and AKBA pretreatment significantly prevented functional and morphological alterations and also the NF-kappa B phosphorylation induced by the inflammatory stimuli. At the same concentrations BSE and AKBA counteracted the increase of ROS caused by H2O2 exposure. Data showed the positive correlation of the antioxidant activity with the mechanism involved in the physiologic maintenance of the integrity and function of the intestinal epithelium. This study elucidates the pharmacological mechanisms mediated by BSE, in protecting intestinal epithelial barrier from inflammatory damage and supports its use as safe adjuvant in patients affected by IBD.	[Catanzaro, Daniela; Rancan, Serena; Dall'Acqua, Stefano; Giron, Maria Cecilia; Carrara, Maria; Ragazzi, Eugenio; Caparrotta, Laura; Montopoli, Monica] Univ Padua, Dept Pharmaceut & Pharmacol Sci, I-35131 Padua, Italy; [Orso, Genny] IRCCS E Medea, Conegliano, Italy; [Brun, Paola; Castagliuolo, Ignazio] Univ Padua, Dept Mol Med, I-35121 Padua, Italy	University of Padua; IRCCS Eugenio Medea; University of Padua	Caparrotta, L (corresponding author), Univ Padua, Dept Pharmaceut & Pharmacol Sci, Largo E Meneghetti 2, I-35131 Padua, Italy.	laura.caparrotta@unipd.it; monica.montopoli@unipd.it	Catanzaro, Daniela/AAB-8715-2019; Montopoli, Monica/W-9666-2019; castagliuolo, ignazio/K-9963-2016; Giron, Maria Cecilia/K-7557-2019; Ragazzi, Eugenio/ACX-1875-2022; Giron, Maria Cecilia/AAL-4438-2021; Orso, Genny/C-6492-2016; Dall'Acqua, Stefano/C-1353-2013	Catanzaro, Daniela/0000-0003-0765-3058; castagliuolo, ignazio/0000-0001-9888-7030; Giron, Maria Cecilia/0000-0002-0825-7965; Ragazzi, Eugenio/0000-0002-0390-6823; Giron, Maria Cecilia/0000-0002-0825-7965; Orso, Genny/0000-0002-2959-8806; MONTOPOLI, MONICA/0000-0001-6182-4132	University of Padova [CPDA124517/12, CPDR134012]; University of Padova (UNIPD) [n. 60A04-0443, n.60A04-9128/14]	University of Padova; University of Padova (UNIPD)	This work was supported by grants from the University of Padova (CPDA124517/12 to MM; UNIPDex60% n. 60A04-0443 to ER, LC and MM, UNIPDex60% n.60A04-9128/14 to MCG and MM). DC fellowship was supported by the grant n. CPDR134012 from the University of Padova. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abdel-Tawab M, 2011, CLIN PHARMACOKINET, V50, P349, DOI 10.2165/11586800-000000000-00000; Abraham C, 2009, NEW ENGL J MED, V361, P2066, DOI 10.1056/NEJMra0804647; Ammon HPT, 2010, PHYTOMEDICINE, V17, P862, DOI 10.1016/j.phymed.2010.03.003; Anthoni C, 2006, AM J PHYSIOL-GASTR L, V290, pG1131, DOI 10.1152/ajpgi.00562.2005; Atreya I, 2008, J INTERN MED, V263, P591, DOI 10.1111/j.1365-2796.2008.01953.x; Balimane PV, 2005, DRUG DISCOV TODAY, V10, P335, DOI 10.1016/S1359-6446(04)03354-9; Bernstein CN, 2001, CANCER-AM CANCER SOC, V91, P854, DOI 10.1002/1097-0142(20010215)91:4<854::AID-CNCR1073>3.0.CO;2-Z; Blau S, 1999, MOL CELL BIOCHEM, V194, P185, DOI 10.1023/A:1006994800272; Cao M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061944; Fleet JC, 2003, PHYSIOL GENOMICS, V13, P57, DOI 10.1152/physiolgenomics.00152.2002; Florean C, 2012, BIOCHEM PHARMACOL, V84, P1223, DOI 10.1016/j.bcp.2012.07.001; Frank A, 2006, J CHROMATOGR A, V1112, P255, DOI 10.1016/j.chroma.2005.11.116; Guidi L, 2011, CLIN EXP GASTROENTER, V4, P163, DOI 10.2147/CEG.S14558; Gupta I, 2001, PLANTA MED, V67, P391, DOI 10.1055/s-2001-15802; Harhaj NS, 2004, INT J BIOCHEM CELL B, V36, P1206, DOI 10.1016/j.biocel.2003.08.007; Hartmann RM, 2014, PHYTOTHER RES, V28, P1392, DOI 10.1002/ptr.5142; Hering NA, 2012, J PHYSIOL-LONDON, V590, P1035, DOI 10.1113/jphysiol.2011.224568; Huang MT, 2000, BIOFACTORS, V13, P225, DOI 10.1002/biof.5520130135; John LJ, 2011, ANTIOXID REDOX SIGN, V15, P1255, DOI 10.1089/ars.2011.3892; Ke F, 2012, SAUDI J GASTROENTERO, V18, P3, DOI 10.4103/1319-3767.91726; Kiela PR, 2005, AM J PHYSIOL-GASTR L, V288, pG798, DOI 10.1152/ajpgi.00433.2004; Konishi Y, 2002, BIOSCI BIOTECH BIOCH, V66, P2449, DOI 10.1271/bbb.66.2449; Li QR, 2008, CLIN IMMUNOL, V126, P67, DOI 10.1016/j.clim.2007.08.017; Liu H, 2012, CELL PHYSIOL BIOCHEM, V29, P799, DOI 10.1159/000188076; Ma TY, 2004, AM J PHYSIOL-GASTR L, V286, pG367, DOI 10.1152/ajpgi.00173.2003; Madisch A, 2007, INT J COLORECTAL DIS, V22, P1445, DOI 10.1007/s00384-007-0364-1; Mariadason JM, 2002, CANCER RES, V62, P4791; Montopoli M, 2009, CELL PROLIFERAT, V42, P195, DOI 10.1111/j.1365-2184.2009.00585.x; Moussaieff A, 2009, J PHARM PHARMACOL, V61, P1281, DOI [10.1211/jpp.61.10.0003, 10.1211/jpp/61.10.0003]; Mudter J, 2011, WORLD J GASTROENTERO, V17, P3177, DOI 10.3748/wjg.v17.i27.3177; Ng SC, 2013, ALIMENT PHARM THER, V38, P854, DOI 10.1111/apt.12464; Pastorelli L, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00280; Pavlick KP, 2002, FREE RADICAL BIO MED, V33, P311, DOI 10.1016/S0891-5849(02)00853-5; Peloquin JM, 2013, ANAEROBE, V24, P102, DOI 10.1016/j.anaerobe.2013.04.006; Perli E, 2012, HUM MOL GENET, V21, P85, DOI 10.1093/hmg/ddr440; PETERSON MD, 1993, J CELL SCI, V105, P445; Poeckel D, 2006, CURR MED CHEM, V13, P3359, DOI 10.2174/092986706779010333; Pravda J, 2005, WORLD J GASTROENTERO, V11, P2371, DOI 10.3748/wjg.v11.i16.2371; Rahimi R, 2013, WORLD J GASTROENTERO, V19, P5738, DOI 10.3748/wjg.v19.i34.5738; Rotoli BM, 2000, CELL PHYSIOL BIOCHEM, V10, P13, DOI 10.1159/000016331; Salim SY, 2011, INFLAMM BOWEL DIS, V17, P362, DOI 10.1002/ibd.21403; Shin K, 2006, ANNU REV CELL DEV BI, V22, P207, DOI 10.1146/annurev.cellbio.22.010305.104219; Siddiqui MZ, 2011, INDIAN J PHARM SCI, V73, P255, DOI 10.4103/0250-474X.93507; Suzuki T, 2013, CELL MOL LIFE SCI, V70, P631, DOI 10.1007/s00018-012-1070-x; Turner JR, 2009, NAT REV IMMUNOL, V9, P799, DOI 10.1038/nri2653; Wan P, 2014, WORLD J GASTROENTERO, V20, P14099, DOI 10.3748/wjg.v20.i39.14099; Wang FJ, 2006, GASTROENTEROLOGY, V131, P1153, DOI 10.1053/j.gastro.2006.08.022; Xavier RJ, 2007, NATURE, V448, P427, DOI 10.1038/nature06005; Yapali S, 2007, ANN GASTROENTEROL, V20, P48; Youmba SB, 2012, J PEDIATR GASTR NUTR, V54, P463, DOI 10.1097/MPG.0b013e318247240d; Zhu H, 2012, EXP BIOL MED, V237, P474, DOI 10.1258/ebm.2011.011358	51	57	61	1	31	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 8	2015	10	5							e0125375	10.1371/journal.pone.0125375	http://dx.doi.org/10.1371/journal.pone.0125375			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CL2IX	25955295	gold, Green Submitted, Green Published			2023-01-03	WOS:000356768100051
J	Lou, YT; Chen, CW; Fan, YC; Chang, WC; Lu, CY; Wu, IC; Hsu, WH; Huang, CW; Wang, JY				Lou, Yun-Ting; Chen, Chao-Wen; Fan, Yun-Ching; Chang, Wei-Chiao; Lu, Chien-Yu; Wu, I-Chen; Hsu, Wen-Hung; Huang, Ching-Wen; Wang, Jaw-Yuan			LINE-1 Methylation Status Correlates Significantly to Post-Therapeutic Recurrence in Stage III Colon Cancer Patients Receiving FOLFOX-4 Adjuvant Chemotherapy	PLOS ONE			English	Article							COLORECTAL-CANCER; DNA METHYLATION; VASCULAR INVASION; HYPOMETHYLATION; SURVEILLANCE; PHENOTYPE; PROGNOSIS; EVENTS; BLOOD; AGE	Background Methylation levels of long interspersed nucleotide elements (LINE-1) are representative of genome-wide methylation status and crucial in maintaining genomic stability and expression. Their prognostic impact on colon cancer patients receiving adjuvant chemotherapy has not been well established. We evaluated the association between LINE-1 methylation status and clinicopathologic features and postoperative oncological outcomes in stage III colon cancer patients. Materials and Methods 129 UICC stage III colon cancer patients who had received radical resection and FOLFOX adjuvant chemotherapy were enrolled. Global methylation was estimated by analyzing tumor LINE-1 methylation status using bisulfite-polymerase chain reaction (PCR) and pyrosequencing assay. Demographics, clinicopathological data, and postoperative outcomes were recorded by trained abstractors. Outcome measurements included postoperative recurrence and disease-free survival. Univariate, multivariate, and survival analyses were conducted to identify prognostic factors of oncological outcomes. Results The LINE-1 methylation of all 129 patients was measured on a 0-100 scale (mean 63.3; median 63.7, standard deviation 7.1), LINE-1 hypomethylation was more common in patients aged 65 years and above (61.7%+/- 7.6% vs. 64.6 +/- 6.4, p=0.019) and those with post-therapeutic recurrence (61.7 +/- 7.4 vs 64.3 +/- 6.7, p=0.041). Considering risk adjustment, LINE-1 hypomethylation was found to be an independent risk factor of post-therapeutic recurrence (Adjusted OR=14.1, p=0.012). Kaplan-Meier analysis indicated that patients in the low methylation group had shorter period of disease free survival (p=0.01). In a stratified analysis that included 48 patients with post-therapeutic recurrence, it was found that those who experienced shorter period of disease free survival (<= 6 months) appeared to have lower LINE-1 methylation levels than patients who reported of recurrence after 6 months (56.68 +/- 15.75 vs. 63.55 +/- 7.57, p=0.041) Conclusion There was a significantly greater risk of early postoperative recurrence and a shorter period of disease-free survival in Stage III colon cancer patients exhibiting LINE-1 hypomethylation status after being treated with radical resection and FOLFOX chemotherapy.	[Lou, Yun-Ting; Fan, Yun-Ching; Chang, Wei-Chiao; Wang, Jaw-Yuan] Kaohsiung Med Univ, Coll Med, Grad Inst Genom Med, Kaohsiung, Taiwan; [Lou, Yun-Ting] I Shou Univ, E DA Hosp, Dept Ophthalmol, Kaohsiung, Taiwan; [Chen, Chao-Wen; Wang, Jaw-Yuan] Kaohsiung Med Univ, Kaohsiung Med Univ Hosp, Dept Surg, Kaohsiung, Taiwan; [Chen, Chao-Wen] Kaohsiung Med Univ, Coll Med, Fac Med, Dept Surg, Kaohsiung, Taiwan; [Chen, Chao-Wen] Kaohsiung Med Univ, Coll Med, Fac Med, Dept Emergency Med, Kaohsiung, Taiwan; [Chang, Wei-Chiao] Taipei Med Univ, Sch Pharm, Dept Clin Pharm, Taipei, Taiwan; [Chang, Wei-Chiao; Wang, Jaw-Yuan] Taipei Med Univ, Wanfang Hosp, Dept Pharm, Taipei, Taiwan; [Chang, Wei-Chiao] Kaohsiung Med Univ, Kaohsiung Med Univ Hosp, Ctr Canc, Kaohsiung, Taiwan; [Chang, Wei-Chiao] Taipei Med Univ, Sch Pharm, Master Program Clin Pharmacogen & Pharmacoprote, Taipei, Taiwan; [Lu, Chien-Yu; Wu, I-Chen; Hsu, Wen-Hung] Kaohsiung Med Univ, Coll Med, Fac Med, Dept Internal Med, Kaohsiung, Taiwan; [Lu, Chien-Yu; Wu, I-Chen; Hsu, Wen-Hung; Wang, Jaw-Yuan] Kaohsiung Med Univ, Div Gastroenterol, Kaohsiung Med Univ Hosp, Dept Internal Med, Kaohsiung, Taiwan; [Huang, Ching-Wen; Wang, Jaw-Yuan] Kaohsiung Med Univ, Dept Surg, Kaohsiung Med Univ Hosp, Div Gastrointestinal & Gen Surg, Kaohsiung, Taiwan; [Huang, Ching-Wen; Wang, Jaw-Yuan] Kaohsiung Med Univ, Coll Med, Grad Inst Med, Kaohsiung, Taiwan; [Wang, Jaw-Yuan] Kaohsiung Med Univ, Coll Med, Grad Inst Clin Med, Kaohsiung, Taiwan; [Wang, Jaw-Yuan] Kaohsiung Med Univ, Ctr Biomarkers & Biotech Drugs, Kaohsiung, Taiwan	Kaohsiung Medical University; E-Da Hospital; I Shou University; Kaohsiung Medical University; Kaohsiung Medical University Hospital; Kaohsiung Medical University; Kaohsiung Medical University; Taipei Medical University; Taipei Medical University; Taipei Municipal WanFang Hospital; Kaohsiung Medical University; Kaohsiung Medical University Hospital; Taipei Medical University; Kaohsiung Medical University; Kaohsiung Medical University; Kaohsiung Medical University Hospital; Kaohsiung Medical University; Kaohsiung Medical University Hospital; Kaohsiung Medical University; Kaohsiung Medical University; Kaohsiung Medical University	Wang, JY (corresponding author), Kaohsiung Med Univ, Coll Med, Grad Inst Genom Med, Kaohsiung, Taiwan.	cy614112@ms14.hinet.net	Jaw-Yuan, Wang/AFS-8845-2022	Jaw-Yuan, Wang/0000-0002-7705-2621; Chen, Chao Wen/0000-0002-8405-342X; Chang, Wei-Chiao/0000-0002-8573-5924	Kaohsiung Medical University Research Foundation [KMU-1M-30]; Center for Biomarkers and Biotech Drugs, Kaohsiung Medical University [KMU-TP103C03, KMU-TP103H11]; Biosignature in Colorectal Cancers, Academia Sinica, Taiwan	Kaohsiung Medical University Research Foundation; Center for Biomarkers and Biotech Drugs, Kaohsiung Medical University; Biosignature in Colorectal Cancers, Academia Sinica, Taiwan	Funding: This study was supported by Kaohsiung Medical University Research Foundation (KMU-1M-30), Center for Biomarkers and Biotech Drugs, Kaohsiung Medical University (KMU-TP103C03, KMU-TP103H11), and the Grant of Biosignature in Colorectal Cancers, Academia Sinica, Taiwan. CWC and JYW received the funding. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ahn JB, 2011, CANCER-AM CANCER SOC, V117, P1847, DOI 10.1002/cncr.25737; Antelo M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045357; Baba Y, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-125; Baca B, 2011, DIS COLON RECTUM, V54, P1036, DOI 10.1007/DCR.0b013e31820db364; Banaz-Yasar F, 2012, DNA CELL BIOL, V31, P1458, DOI 10.1089/dna.2012.1676; Betge J, 2011, ACTA GASTRO-ENT BELG, V74, P516; Boland CR, 2010, GASTROENTEROLOGY, V138, P2073, DOI [10.1053/j.gastro.2009.12.064, 10.1053/j.gastro.2010.04.024]; Bosch LJW, 2011, CLIN COLORECTAL CANC, V10, P8, DOI 10.3816/CCC.2011.n.002; Brennan K, 2012, CANCER PREV RES, V5, P1345, DOI 10.1158/1940-6207.CAPR-12-0316; Das PM, 2004, J CLIN ONCOL, V22, P4632, DOI 10.1200/JCO.2004.07.151; Desch CE, 2005, J CLIN ONCOL, V23, P8512, DOI 10.1200/JCO.2005.04.0063; Edge S., 2010, AJCC CANC STAGING MA; Goel A, 2010, GASTROENTEROLOGY, V138, P1854, DOI 10.1053/j.gastro.2010.01.035; Hahn MA, 2010, MUTAT RES-FUND MOL M, V693, P77, DOI 10.1016/j.mrfmmm.2009.10.005; Heyn H, 2013, EXPERT REV MOL DIAGN, V13, P473, DOI [10.1586/ERM.13.36, 10.1586/erm.13.36]; Horii J, 2008, CLIN BIOCHEM, V41, P1440, DOI 10.1016/j.clinbiochem.2008.08.089; Hur K, 2014, GUT, V63, P635, DOI 10.1136/gutjnl-2012-304219; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI [10.3322/caac.20115, 10.3322/caac.20107]; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029; Kawakami K, 2011, CANCER SCI, V102, P166, DOI 10.1111/j.1349-7006.2010.01776.x; Khare Sharad, 2012, Methods Mol Biol, V863, P177, DOI 10.1007/978-1-61779-612-8_10; Kim MS, 2010, CANCER METAST REV, V29, P181, DOI 10.1007/s10555-010-9207-6; Kozak KR, 2008, J SURG ONCOL, V98, P161, DOI 10.1002/jso.21107; Lara E, 2011, EPIGENETIC ASPECTS OF CHRONIC DISEASES, P21, DOI 10.1007/978-1-84882-644-1_2; Markowitz SD, 2009, NEW ENGL J MED, V361, P2449, DOI 10.1056/NEJMra0804588; Nelson RL, 1997, CANCER-AM CANCER SOC, V80, P193, DOI 10.1002/(SICI)1097-0142(19970715)80:2<193::AID-CNCR4>3.0.CO;2-V; Ogino S, 2008, J NATL CANCER I, V100, P1734, DOI 10.1093/jnci/djn359; Piyathilake CJ, 2011, NUTRITION, V27, P513, DOI 10.1016/j.nut.2010.08.018; Rodic N, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003402; Rosati G, 2010, WORLD J GASTROENTERO, V16, P1427, DOI 10.3748/wjg.v16.i12.1427; Saito K, 2010, CLIN CANCER RES, V16, P2418, DOI 10.1158/1078-0432.CCR-09-2819; Samowitz WS, 2005, GASTROENTEROLOGY, V129, P837, DOI 10.1053/j.gastro.2005.06.020; Schweiger MR, 2013, BRIEF FUNCT GENOMICS, V12, P411, DOI 10.1093/bfgp/elt024; Sunami E, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018884; Tournier B, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-12; Tsai HL, 2008, J SURG ONCOL, V97, P383, DOI 10.1002/jso.20942; Tsai HL, 2013, INT J COLORECTAL DIS, V28, P415, DOI 10.1007/s00384-012-1570-z; van Ijzendoorn MH, 2010, BIOL PSYCHIAT, V68, P405, DOI 10.1016/j.biopsych.2010.05.008; Wangsri S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045292; Yamauchi M, 2012, GUT, V61, P847, DOI 10.1136/gutjnl-2011-300865; Yang AS, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh032; Zeilinger S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063812; Zhang FF, 2011, EPIGENETICS-US, V6, P293, DOI 10.4161/epi.6.3.14378	45	17	17	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 28	2015	10	4							e0123973	10.1371/journal.pone.0123973	http://dx.doi.org/10.1371/journal.pone.0123973			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CG9SE	25919688	Green Published, gold, Green Submitted			2023-01-03	WOS:000353659400040
J	Zhuang, CL; Wang, SL; Huang, DD; Pang, WY; Lou, N; Chen, BC; Chen, XL; Yu, Z; Shen, X				Zhuang, Cheng-Le; Wang, Su-Lin; Huang, Dong-Dong; Pang, Wen-Yang; Lou, Neng; Chen, Bi-Cheng; Chen, Xiao-Lei; Yu, Zhen; Shen, Xian			Risk Factors for Hospital Readmission after Radical Gastrectomy for Gastric Cancer: A Prospective Study	PLOS ONE			English	Article							AMERICAN-COLLEGE; MORTALITY; SURGERY; QUALITY; COMPLICATIONS; MANAGEMENT; MORBIDITY; PATIENT	Background Hospital readmission is gathering increasing attention as a measure of health care quality and a potential cost-saving target. The purpose of this prospective study was to determine risk factors for readmission within 30 days of discharge after gastrectomy for patients with gastric cancer. Methods We conducted a prospective study of patients undergoing radical gastrectomy for gastric cancer from October 2013 to November 2014 in our institution. The incidence, cause and risk factors for 30-day readmission were determined. Results A total of 376 patients were included in our analysis without loss in follow-up. The 30-day readmission rate after radical gastrectomy for gastric cancer was 7.2% (27of 376). The most common cause for readmission included gastrointestinal complications and postoperative infections. On the basis of multivariate logistic regression analysis, preoperative nutritional risk screening 2002 score >= 3 was an independent risk factor for 30-day readmission. Factors not associated with a higher readmission rate included a history of a major postoperative complication during the index hospitalization, prolonged primary length of hospital stay after surgery, a history of previous abdominal surgery, advanced age, body mass index, pre-existing cardiopulmonary comorbidities, American Society of Anesthesiology grade, type of resection, extent of node dissection and discharge disposition. Conclusions Readmission within 30 days of discharge after radical gastrectomy for gastric cancer is common. Patients with nutritional risk preoperatively are at high risk for 30-day readmission. Preoperative optimization of nutritional status of patients at nutritional risk may effectively decrease readmission rates.	[Zhuang, Cheng-Le; Wang, Su-Lin; Huang, Dong-Dong; Pang, Wen-Yang; Lou, Neng; Chen, Xiao-Lei; Yu, Zhen; Shen, Xian] Wenzhou Med Univ, Affiliated Hosp 1, Dept Gastrointestinal Surg, Wenzhou, Peoples R China; [Chen, Bi-Cheng] Wenzhou Med Univ, Affiliated Hosp 1, Wenzhou Key Lab Surg, Wenzhou, Peoples R China; [Yu, Zhen] Tongji Univ, Shanghai Peoples Hosp 10, Dept Gastrointestinal Surg, Shanghai 200092, Peoples R China	Wenzhou Medical University; Wenzhou Medical University; Tongji University	Yu, Z (corresponding author), Wenzhou Med Univ, Affiliated Hosp 1, Dept Gastrointestinal Surg, Wenzhou, Peoples R China.	yuzhen0577@gmail.com; shenxian5166@126.com			National Natural Science Foundation of China [81171857]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work was supported by the National Natural Science Foundation of China (No. 81171857). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ahmad R, 2014, J AM COLL SURGEONS, V218, P1215, DOI 10.1016/j.jamcollsurg.2014.02.015; Ahmad SA, 2012, ANN SURG, V256, P529, DOI 10.1097/SLA.0b013e318265ef0b; Bartlett EK, 2014, SURGERY, V156, P298, DOI 10.1016/j.surg.2014.03.022; Braga M, 2009, CLIN NUTR, V28, P378, DOI 10.1016/j.clnu.2009.04.002; Coburn N, 2014, ANN SURG, V259, P102, DOI 10.1097/SLA.0b013e318288dd2b; Dindo D, 2004, ANN SURG, V240, P205, DOI 10.1097/01.sla.0000133083.54934.ae; Gavazzi C, 2011, BRIT J NUTR, V106, P1773, DOI 10.1017/S0007114511002509; Japanese Gastric Canc Assoc, 2011, GASTRIC CANCER, V14, P113, DOI 10.1007/s10120-011-0042-4; Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI [10.3322/caac.20115, 10.3322/caac.20107]; Jencks SF, 2009, NEW ENGL J MED, V360, P1418, DOI 10.1056/NEJMsa0803563; Jie B, 2012, NUTRITION, V28, P1022, DOI 10.1016/j.nut.2012.01.017; Kassin MT, 2012, J AM COLL SURGEONS, V215, P322, DOI 10.1016/j.jamcollsurg.2012.05.024; Kerwel TG, 2014, DIS COLON RECTUM, V57, P98, DOI 10.1097/DCR.0000000000000007; Kim MC, 2012, ANN SURG ONCOL, V19, P2459, DOI 10.1245/s10434-012-2271-0; Kimbrough CW, 2014, SURGERY, V156, P1039, DOI 10.1016/j.surg.2014.06.057; Kondrup J, 2003, CLIN NUTR, V22, P321, DOI 10.1016/S0261-5614(02)00214-5; Kulaylat AN, 2015, J SURG RES, V193, P528, DOI 10.1016/j.jss.2014.09.029; Kwaan MR, 2013, DIS COLON RECTUM, V56, P1087, DOI 10.1097/DCR.0b013e31829aa758; Mariette C, 2012, ANN SURG ONCOL, V19, P2128, DOI 10.1245/s10434-012-2225-6; Papenfuss WA, 2014, ANN SURG ONCOL, V21, P3008, DOI 10.1245/s10434-014-3664-z; Ryu SW, 2010, WORLD J GASTROENTERO, V16, P3310, DOI 10.3748/wjg.v16.i26.3310; Schneider EB, 2012, J AM COLL SURGEONS, V215, P607, DOI 10.1016/j.jamcollsurg.2012.07.007; Sellers MM, 2013, J AM COLL SURGEONS, V216, P420, DOI 10.1016/j.jamcollsurg.2012.11.013; Sutton JM, 2014, DIS COLON RECTUM, V57, P1371, DOI 10.1097/DCR.0000000000000227; Thrumurthy SG, 2013, BMJ-BRIT MED J, V347, DOI 10.1136/bmj.f6367; Tsai TC, 2013, NEW ENGL J MED, V369, P1134, DOI 10.1056/NEJMsa1303118; Worhunsky DJ, 2015, J NATL COMPR CANC NE, V13, P319, DOI 10.6004/jnccn.2015.0044; Yamamoto M, 2015, J GASTROINTEST ONCOL, V6, P79, DOI 10.3978/j.issn.2078-6891.2014.097; Zhou W, 2013, SURG ENDOSC, V27, P2569, DOI 10.1007/s00464-013-2790-1	29	26	28	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 27	2015	10	4							e0125572	10.1371/journal.pone.0125572	http://dx.doi.org/10.1371/journal.pone.0125572			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CG9SB	25915547	Green Submitted, gold, Green Published			2023-01-03	WOS:000353659100135
J	Luta, X; Maessen, M; Egger, M; Stuck, AE; Goodman, D; Clough-Gorr, KM				Luta, Xhyljeta; Maessen, Maud; Egger, Matthias; Stuck, Andreas E.; Goodman, David; Clough-Gorr, Kerri M.			Measuring Intensity of End of Life Care: A Systematic Review	PLOS ONE			English	Review							LAST 6 MONTHS; OBSTRUCTIVE PULMONARY-DISEASE; INPATIENT TREATMENT INTENSITY; LUNG-CANCER PATIENTS; QUALITY-OF-CARE; MEDICARE BENEFICIARIES; PALLIATIVE CARE; REGIONAL-VARIATIONS; CHEMOTHERAPY USE; UNITED-STATES	Background Many studies have measured the intensity of end of life care. However, no summary of the measures used in the field is currently available. Objectives To summarise features, characteristics of use and reported validity of measures used for evaluating intensity of end of life care. Methods This was a systematic review according to PRISMA guidelines. We performed a comprehensive literature search in Ovid Medline, Embase, The Cochrane Library of Systematic Reviews and reference lists published between 1990-2014. Two reviewers independently screened titles, abstracts, full texts and extracted data. Studies were eligible if they used a measure of end of life care intensity, defined as all quantifiable measures describing the type and intensity of medical care administered during the last year of life. Results A total of 58 of 1590 potentially eligible studies met our inclusion criteria and were included. The most commonly reported measures were hospitalizations (n = 44), intensive care unit admissions (n = 39) and chemotherapy use (n = 27). Studies measured intensity of care in different timeframes ranging from 48 hours to 12 months. The majority of studies were conducted in cancer patients (n = 31). Only 4 studies included information on validation of the measures used. None evaluated construct validity, while 3 studies considered criterion and 1 study reported both content and criterion validity. Conclusions This review provides a synthesis to aid in choosing intensity of end of life care measures based on their previous use but simultaneously highlights the crucial need for more validation studies and consensus in the field.	[Luta, Xhyljeta; Maessen, Maud; Egger, Matthias; Stuck, Andreas E.; Clough-Gorr, Kerri M.] Univ Bern, Inst Social & Prevent Med, Bern, Switzerland; [Stuck, Andreas E.] Univ Dept Geriatr, Inselspital Bern, Bern, Switzerland; [Goodman, David] Dartmouth Inst Hlth Policy & Clin Practice, Lebanon, NH USA; [Clough-Gorr, Kerri M.] Boston Univ, Med Ctr, Sect Geriatr, Boston, MA USA	University of Bern; Dartmouth College; Boston University	Clough-Gorr, KM (corresponding author), Univ Bern, Inst Social & Prevent Med, Bern, Switzerland.	kclough@ispm.unibe.ch	Goodman, David/AAG-7497-2020	Egger, Matthias/0000-0001-7462-5132; Maessen, Maud/0000-0002-5439-9948	Swiss National Science Foundation [16-803]	Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission)	This study was supported by the Swiss National Science Foundation (grant number 16-803) (www.snf.ch). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abel J, 2009, PALLIATIVE MED, V23, P616, DOI 10.1177/0269216309106460; Alonso-Babarro A, 2013, PALLIATIVE MED, V27, P68, DOI 10.1177/0269216312442973; Alturki A, 2014, J NEURO-ONCOL, V117, P103, DOI 10.1007/s11060-014-1360-2; Angus DC, 2004, CRIT CARE MED, V32, P638, DOI 10.1097/01.CCM.0000114816.62331.08; Au DH, 2006, ARCH INTERN MED, V166, P326, DOI 10.1001/archinte.166.3.326; Axelsson B, 1997, EUR J SURG ONCOL, V23, P145, DOI 10.1016/S0748-7983(97)80009-1; Bach PB, 2004, JAMA-J AM MED ASSOC, V292, P2765, DOI 10.1001/jama.292.22.2765; Barbera L, 2006, J PALLIATIVE CARE, V22, P12, DOI 10.1177/082585970602200103; Barbera L, 2008, J PAIN SYMPTOM MANAG, V35, P267, DOI 10.1016/j.jpainsymman.2007.04.019; Barnato AE, 2004, HEALTH SERV RES, V39, P363, DOI 10.1111/j.1475-6773.2004.00232.x; Barnato AE, 2007, MED CARE, V45, P386, DOI 10.1097/01.mlr.0000255248.79308.41; Barnato AE, 2007, J GEN INTERN MED, V22, P338, DOI 10.1007/s11606-006-0088-x; Barnato AE, 2006, HEALTH SERV RES, V41, P2219, DOI 10.1111/j.1475-6773.2006.00598.x; Barnato AE, 2010, MED CARE, V48, P125, DOI 10.1097/MLR.0b013e3181c161e4; Barnato AE, 2009, MED CARE, V47, P1098, DOI 10.1097/MLR.0b013e3181993191; Barnet CS, 2013, ANESTHESIOLOGY, V119, P796, DOI 10.1097/ALN.0b013e31829c2db0; Bergman J, 2011, ARCH INTERN MED, V171, P204, DOI 10.1001/archinternmed.2010.394; Bergman J, 2010, CANCER-AM CANCER SOC, V116, P2126, DOI [10.1002/cncr25039, 10.1002/cncr.25039]; Braga S, 2007, PSYCHO-ONCOL, V16, P863, DOI 10.1002/pon.1140; Bukki J, 2013, SUPPORT CARE CANCER, V21, P1743, DOI 10.1007/s00520-013-1721-y; Chan KW, 2012, J ASIAN PUBLIC POLIC, V5, P71, DOI 10.1080/17516234.2012.662358; Cintron Alexie, 2003, J Palliat Med, V6, P757, DOI 10.1089/109662103322515266; Cooper Z, 2012, J HEALTH CARE POOR U, V23, P857, DOI 10.1353/hpu.2012.0064; Cowall DE, 2012, J ONCOL PRACT, V8, pE40, DOI 10.1200/JOP.2011.000451; Curtis JR, 2012, AM J RESP CRIT CARE, V186, P587, DOI 10.1164/rccm.201206-1020CP; Da Silva Roxane Borges, 2011, Healthc Policy, V6, pe106; Earle CC, 2006, J CLIN ONCOL, V24, P838, DOI 10.1200/JCO.2005.03.9388; Earle CC, 2005, INT J QUAL HEALTH C, V17, P505, DOI 10.1093/intqhc/mzi061; Earle CC, 2004, J CLIN ONCOL, V22, P315, DOI 10.1200/JCO.2004.08.136; Earle CC, 2008, J CLIN ONCOL, V26, P3860, DOI 10.1200/JCO.2007.15.8253; Emanuel EJ, 2003, ANN INTERN MED, V138, P639, DOI 10.7326/0003-4819-138-8-200304150-00011; Fisher ES, 2003, ANN INTERN MED, V138, P273, DOI 10.7326/0003-4819-138-4-200302180-00006; Fisher ES, 2003, ANN INTERN MED, V138, P136; Forero R, 2012, LIT REV CARE END OF; Gagnon B, 2006, J CLIN ONCOL, V24, P856, DOI 10.1200/JCO.2005.02.1790; George Linda K, 2002, Gerontologist, V42 Spec No 3, P86; Gielen B, 2010, HEALTH POLICY, V97, P53, DOI 10.1016/j.healthpol.2010.03.002; Giovanis P, 2010, TUMORI J, V96, P443, DOI 10.1177/030089161009600311; Glare PA, 2008, J PALLIAT MED, V11, P84, DOI 10.1089/jpm.2008.9992; Gonsalves WI, 2011, J PALLIAT MED, V14, P1231, DOI 10.1089/jpm.2011.0131; Goodman D, 2010, DARTMOUTH ATLAS OF H; Goodman D, 2011, DARTMOUTH ATLAS OF H; Goodridge D, 2010, RURAL REMOTE HEALTH, V10; Goodridge D, 2008, RESP MED, V102, P885, DOI 10.1016/j.rmed.2008.01.007; Greer JA, 2012, J CLIN ONCOL, V30, P394, DOI 10.1200/JCO.2011.35.7996; Hearn J, 1997, J PUBLIC HEALTH MED, V19, P193, DOI 10.1093/oxfordjournals.pubmed.a024608; Hearn J, 1999, QUAL HEALTH CARE, V8, P219, DOI 10.1136/qshc.8.4.219; HENDERSON J, 1990, BRIT MED J, V301, P17, DOI 10.1136/bmj.301.6742.17; HENDERSON J, 1992, J PUBLIC HEALTH MED, V14, P39; Ho TH, 2011, J CLIN ONCOL, V29, P1587, DOI 10.1200/JCO.2010.31.9897; Izumi S, 2012, NURS ETHICS, V19, P608, DOI 10.1177/0969733011436205; Keam B, 2008, JPN J CLIN ONCOL, V38, P381, DOI 10.1093/jjco/hyn031; Keating NL, 2010, CANCER-AM CANCER SOC, V116, P3732, DOI 10.1002/cncr.25077; Kelley AS, 2011, LANCET, V378, P1364, DOI 10.1016/S0140-6736(11)61420-7; Kwok AC, 2011, LANCET, V378, P1408, DOI 10.1016/S0140-6736(11)61268-3; Langton JM, 2014, PALLIATIVE MED, V28, P1167, DOI 10.1177/0269216314533813; Le Conte P, 2004, INTENS CARE MED, V30, P2216, DOI 10.1007/s00134-004-2475-2; Liberati A, 2009, PLOS MED, V6, DOI [10.1371/journal.pmed.1000100, 10.1136/bmj.b2700, 10.7326/0003-4819-151-4-200908180-00136]; Lin CY, 2009, MED CARE, V47, P524, DOI 10.1097/MLR.0b013e31819261bd; Lunney JR, 2003, JAMA-J AM MED ASSOC, V289, P2387, DOI 10.1001/jama.289.18.2387; Mack JW, 2012, J CLIN ONCOL, V30, P4387, DOI 10.1200/JCO.2012.43.6055; Miesfeldt S, 2012, J PALLIAT MED, V15, P548, DOI 10.1089/jpm.2011.0310; Morden NE, 2012, HEALTH AFFAIR, V31, P786, DOI 10.1377/hlthaff.2011.0650; Mularski RA, 2007, HEALTH SERV RES, V42, P1848, DOI 10.1111/j.1475-6773.2007.00721.x; O'Hare AM, 2010, JAMA-J AM MED ASSOC, V304, P180, DOI 10.1001/jama.2010.924; Ohta B, 2011, J PALLIAT MED, V14, P722, DOI 10.1089/jpm.2010.0360; Raijmakers NJH, 2011, ANN ONCOL, V22, P1478, DOI 10.1093/annonc/mdq620; Ramroth H, 2006, BMC HEALTH SERV RES, V6, DOI 10.1186/1472-6963-6-70; Reed SD, 2012, AM J CARDIOL, V110, P1150, DOI 10.1016/j.amjcard.2012.05.059; Richardson SS, 2007, HEALTH SERV RES, V42, P183, DOI 10.1111/j.1475-6773.2006.00608.x; Rosenwax LK, 2011, MED J AUSTRALIA, V194, P570, DOI 10.5694/j.1326-5377.2011.tb03106.x; Sampson EL, 2006, AGE AGEING, V35, P187, DOI 10.1093/ageing/afj025; Sato K, 2008, SUPPORT CARE CANCER, V16, P113, DOI 10.1007/s00520-007-0332-x; Seow H, 2010, MED CARE, V48, P118, DOI 10.1097/MLR.0b013e3181c162ef; Sepulveda C, 2002, J PAIN SYMPTOM MANAG, V24, P91, DOI 10.1016/S0885-3924(02)00440-2; Sheffield KM, 2011, CANCER-AM CANCER SOC, V117, P5003, DOI 10.1002/cncr.26115; Smith AK, 2009, J AM GERIATR SOC, V57, P153, DOI 10.1111/j.1532-5415.2008.02081.x; Tang ST, 2009, J CLIN ONCOL, V27, P4613, DOI 10.1200/JCO.2008.20.5096; Temel JS, 2008, CANCER-AM CANCER SOC, V113, P826, DOI 10.1002/cncr.23620; Teno JM, 1999, J PAIN SYMPTOM MANAG, V17, P109, DOI 10.1016/S0885-3924(98)00132-8; Teno Joan M, 2005, J Palliat Med, V8 Suppl 1, pS42; Teno JM, 2013, JAMA-J AM MED ASSOC, V309, P470, DOI 10.1001/jama.2012.207624; Toole M, 2012, J AM COLL RADIOL, V9, P199, DOI 10.1016/j.jacr.2011.11.006; Unroe KT, 2011, ARCH INTERN MED, V171, P196, DOI 10.1001/archinternmed.2010.371; van der Steen JT, 2008, PALLIATIVE MED, V22, P750, DOI 10.1177/0269216308094102; van Walraven C, 2001, JAMA-J AM MED ASSOC, V285, P1602, DOI 10.1001/jama.285.12.1602; Warren JL, 2011, J NATL CANCER I, V103, P853, DOI 10.1093/jnci/djr145; Wennberg JE, 2004, BMJ-BRIT MED J, V328, P607, DOI 10.1136/bmj.328.7440.607; Wentlandt K, 2012, AGGRESSIVE TREATMENT; Wong SPY, 2012, ARCH INTERN MED, V172, P661, DOI 10.1001/archinternmed.2012.268; Yabroff KR, 2007, NAT CLIN PRACT ONCOL, V4, P643, DOI 10.1038/ncponc0978	91	48	48	1	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 14	2015	10	4							e0123764	10.1371/journal.pone.0123764	http://dx.doi.org/10.1371/journal.pone.0123764			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	CG1EB	25875471	Green Published, gold, Green Submitted			2023-01-03	WOS:000353014700041
J	Topalian, SL				Topalian, Suzanne L.			On Breakthroughs and Evolution	CELL			English	News Item									Johns Hopkins Kimmel Canc Ctr, Baltimore, MD USA	Johns Hopkins University; Johns Hopkins Medicine	Topalian, SL (corresponding author), Johns Hopkins Kimmel Canc Ctr, Baltimore, MD USA.				NATIONAL CANCER INSTITUTE [ZIABC010984, P30CA008748] Funding Source: NIH RePORTER; Intramural NIH HHS [Z01 BC010984-01] Funding Source: Medline; NCI NIH HHS [P30 CA008748] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))			0	71	80	0	7	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 9	2015	161	2					185	185						1	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	CF7AL	26042237				2023-01-03	WOS:000352708300001
J	Weise, D; Adamidis, M; Pizzolato, F; Rumpf, JJ; Fricke, C; Classen, J				Weise, David; Adamidis, Melanie; Pizzolato, Fabio; Rumpf, Jost-Julian; Fricke, Christopher; Classen, Joseph			Assessment of Brainstem Function with Auricular Branch of Vagus Nerve Stimulation in Parkinson's Disease	PLOS ONE			English	Article							CARDIAC SYMPATHETIC DENERVATION; HEART-RATE-VARIABILITY; FAR-FIELD POTENTIALS; EVOKED-POTENTIALS; PATHOLOGY; PROJECTIONS; IMPAIRMENT; DIAGNOSIS; GANGLIA	Background The efferent dorsal motor nucleus of the vagal nuclei complex may degenerate early in the course of Parkinson's disease (PD), while efferent nucleus ambiguous, the principal source of parasympathetic vagal neurons innervating the heart, and afferent somatosensory nuclei remain intact. Objective To obtain neurophysiological evidence related to this pattern, we tested processing of afferent sensory information transmitted via the auricular branch of the vagus nerve (ABVN) which is known to be connected to autonomic regulation of cardiac rhythm. Methods In this cross-sectional observational study, we recorded (i) somatosensory evoked potentials (ABVN-SEP) and (ii) cutaneo-cardioautonomic response elicited by stimulation of the ABVN (modulation of heart-rate variability (HRV index; low frequency power, ln(LF), high frequency power, ln(HF); ln(LF/HF) ratio)) in 50 PD patients and 50 age and sex matched healthy controls. Additionally, auditory evoked potentials and trigeminal nerve SEP were assessed. Results Neither ABVN-SEP nor any of the other functional brainstem parameters differed between patients and controls. Although HRV index was decreased in PD patients, modulation of ln (LF/HF) by ABVN-stimulation, likely indicating cardiac parasympathetic activation, did not differ between both groups. Conclusions Findings do not point to prominent dysfunction of processing afferent information from ABVN and its connected parasympathetic cardiac pathway in PD. They are consistent with the known pattern of degeneration of the vagal nuclei complex of the brainstem.	[Weise, David; Adamidis, Melanie; Pizzolato, Fabio; Rumpf, Jost-Julian; Fricke, Christopher; Classen, Joseph] Univ Leipzig, Dept Neurol, D-04109 Leipzig, Germany; [Pizzolato, Fabio] Univ Verona, Dept Neurol Neuropsychol Morphol & Movement Sci, I-37100 Verona, Italy	Leipzig University; University of Verona	Weise, D (corresponding author), Univ Leipzig, Dept Neurol, D-04109 Leipzig, Germany.	david.weise@medizin.uni-leipzig.de		Classen, Joseph/0000-0001-7182-6967	Medical Faculty, University of Leipzig	Medical Faculty, University of Leipzig	The study was supported by a junior research grant by the Medical Faculty, University of Leipzig (DW). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	BLOUSTINE S, 1976, ANN OTO RHINOL LARYN, V85, P406, DOI 10.1177/000348947608500315; Braak H, 2003, NEUROBIOL AGING, V24, P197, DOI 10.1016/S0197-4580(02)00065-9; Braak H, 2011, J NEURAL TRANSM, V118, P809, DOI 10.1007/s00702-010-0508-2; Camm AJ, 1996, CIRCULATION, V93, P1043; Cersosimo MG, 2012, J NEUROL SCI, V313, P57, DOI 10.1016/j.jns.2011.09.030; Cheng ZJ, 2004, AM J PHYSIOL-REG I, V286, pR625, DOI 10.1152/ajpregu.00143.2003; Cheng ZX, 1999, J COMP NEUROL, V410, P320; Clancy JA, 2014, BRAIN STIMUL, V7, P871, DOI 10.1016/j.brs.2014.07.031; Curran-Everett D, 2000, AM J PHYSIOL-REG I, V279, pR1, DOI 10.1152/ajpregu.2000.279.1.R1; Dalrymple-Alford JC, 2010, NEUROLOGY, V75, P1717, DOI 10.1212/WNL.0b013e3181fc29c9; Del Tredici K, 2002, J NEUROPATH EXP NEUR, V61, P413, DOI 10.1093/jnen/61.5.413; Dietrich S, 2008, BIOMED TECH, V53, P104, DOI 10.1515/BMT.2008.022; Eckberg DL, 1997, CIRCULATION, V96, P3224, DOI 10.1161/01.CIR.96.9.3224; Fallgatter AJ, 2005, INT J PSYCHOPHYSIOL, V56, P37, DOI 10.1016/j.ijpsycho.2004.09.007; Fallgatter AJ, 2003, J NEURAL TRANSM, V110, P1437, DOI 10.1007/s00702-003-0087-6; GAWEL MJ, 1981, J NEUROL NEUROSUR PS, V44, P227, DOI 10.1136/jnnp.44.3.227; Goldstein DS, 2003, LANCET NEUROL, V2, P669, DOI 10.1016/S1474-4422(03)00555-6; GUPTA D, 1986, SURG RADIOL ANAT, V8, P217, DOI 10.1007/BF02425070; Haapaniemi TH, 2001, J NEUROL NEUROSUR PS, V70, P305, DOI 10.1136/jnnp.70.3.305; Haensch CA, 2009, PARKINSONISM RELAT D, V15, P134, DOI 10.1016/j.parkreldis.2008.04.031; Heimer L., 1995, HUMAN BRAIN SPINAL C; HUGHES AJ, 1992, J NEUROL NEUROSUR PS, V55, P181, DOI 10.1136/jnnp.55.3.181; Jain S, 2011, PARKINSONISM RELAT D, V17, P119, DOI 10.1016/j.parkreldis.2010.11.005; Jellinger KA, 2008, ACTA NEUROPATHOL, V116, P1, DOI 10.1007/s00401-008-0406-y; Kalaitzakis ME, 2008, ACTA NEUROPATHOL, V116, P125, DOI 10.1007/s00401-008-0381-3; KALIA M, 1982, J COMP NEUROL, V211, P248, DOI 10.1002/cne.902110304; Kraus T, 2013, BRAIN STIMUL, V6, P798, DOI 10.1016/j.brs.2013.01.011; Krzywinski M, 2014, NAT METHODS, V11, P119, DOI 10.1038/nmeth.2813; LEANDRI M, 1985, ELECTROEN CLIN NEURO, V62, P99, DOI 10.1016/0168-5597(85)90021-8; Leutzow B, 2013, BRAIN STIMUL, V6, P812, DOI 10.1016/j.brs.2013.03.005; Metzgera FG, 2012, DEMENT GERIATR COGN, V33, P289, DOI 10.1159/000339359; NOMURA S, 1984, BRAIN RES, V292, P199, DOI 10.1016/0006-8993(84)90756-X; Parvizi J, 2001, ANN NEUROL, V49, P53, DOI 10.1002/1531-8249(200101)49:1<53::AID-ANA30>3.0.CO;2-Q; Poewe W, 2008, EUR J NEUROL, V15, P14, DOI 10.1111/j.1468-1331.2008.02056.x; Polak T, 2007, J NEURAL TRANSM, V114, P613, DOI 10.1007/s00702-007-0625-8; Polak T, 2011, J NEUROL, V258, P2276, DOI 10.1007/s00415-011-6084-z; Polak T, 2009, J NEURAL TRANSM, V116, P473, DOI 10.1007/s00702-009-0202-4; Seidel K, 2014, BRAIN PATHOLOGY ZURI; Shibata M, 2009, J NEUROL SCI, V276, P79, DOI 10.1016/j.jns.2008.09.005; Takatsu H, 2000, J NUCL MED, V41, P71; Tomlinson CL, 2010, MOVEMENT DISORD, V25, P2649, DOI 10.1002/mds.23429; Vitale C, 2012, MOVEMENT DISORD, V27, P1530, DOI 10.1002/mds.25149; Yu LL, 2013, HEART RHYTHM, V10, P428, DOI 10.1016/j.hrthm.2012.11.019; Zamotrinsky AV, 2001, AUTON NEUROSCI-BASIC, V88, P109, DOI 10.1016/S1566-0702(01)00227-2; Zhang YH, 2009, CIRC-HEART FAIL, V2, P692, DOI 10.1161/CIRCHEARTFAILURE.109.873968; Zhao M, 2012, CLIN EXP PHARMACOL P, V39, P701, DOI 10.1111/j.1440-1681.2011.05644.x	46	24	25	2	21	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 7	2015	10	4							e0120786	10.1371/journal.pone.0120786	http://dx.doi.org/10.1371/journal.pone.0120786			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CF3VU	25849807	Green Published, Green Submitted, gold			2023-01-03	WOS:000352477800032
J	Ullenhag, GJ; Rossmann, E; Liljefors, M				Ullenhag, Gustav J.; Rossmann, Eva; Liljefors, Maria			A Phase I Dose-Escalation Study of Lenalidomide in Combination with Gemcitabine in Patients with Advanced Pancreatic Cancer	PLOS ONE			English	Article							THALIDOMIDE ANALOG; CLINICAL-TRIAL; III TRIAL; T-CELLS; CARCINOMA; SURVIVAL; CC-5013; THROMBOPROPHYLAXIS; ADENOCARCINOMA; THROMBOSIS	Purpose Lenalidomide have both immunomodulatory and anti-angiogenic properties which could confer anti-cancer effects. The aim of this study was to assess the feasibility of combining lenalidomide with the standard treatment gemcitabine in pancreatic cancer patients with advanced disease. Patients and Methods Eligible patients had locally advanced or metastatic adenocarcinoma of the pancreas. Patients received lenalidomide days 1-21 orally and gemcitabine 1000 mg/m(2) intravenously (days 1, 8 and 15), each 28 day cycle. Three cohorts of lenalidomide were examined (Cohort I = 15 mg, Cohort II = 20 mg and Cohort III = 25 mg daily). The maximum tolerated dose (MTD) of lenalidomide given in combination with gemcitabine was defined as the highest dose level at which no more than one out of four (25%) subjects experiences a dose-limiting toxicity (DLT). Patients should also be able to receive daily low molecular weight heparin (LMWH) (e.g. dalteparin 5000 IU s.c. daily) as a prophylactic anticoagulant for venous thromboembolic events (VTEs). Twelve patients (n = 4, n = 3 and n = 5 in cohort I, II and III, respectively) were enrolled in this study. Results Median duration of treatment was 11 weeks (range 1-66), and median number of treatment cycles were three (range 1-14). The only DLT was a cardiac failure grade 3 in cohort III. Frequent treatment-related adverse events (AEs) (all grades) included neutropenia, leucopenia and fatigue (83% each, but there was no febrile neutropenia); thrombocytopenia (75%); dermatological toxicity (75%); diarrhea and nausea (42% each); and neuropathy (42%). Discussion This phase I study demonstrates the feasibility of the combination of lenalidomide and gemcitabine as first-line treatment in patients with advanced pancreatic cancer. The tolerability profile demonstrated in the dose escalation schedule of lenalidomide suggests the dosing of lenalidomide to be 25 mg daily on days 1-21 with standard dosing of gemcitabine and merits further evaluation in a phase II trial.	[Ullenhag, Gustav J.] Uppsala Univ, Dept Radiol Oncol & Radiat Sci, Sect Oncol, Uppsala, Sweden; [Ullenhag, Gustav J.] Univ Uppsala Hosp, Dept Oncol, S-75185 Uppsala, Sweden; [Rossmann, Eva; Liljefors, Maria] Karolinska Univ Hosp Solna, Karolinska Inst, Canc Ctr Karolinska, Dept Oncol & Pathol Radiumhemmet, Stockholm, Sweden	Uppsala University; Uppsala University; Uppsala University Hospital; Karolinska Institutet; Karolinska University Hospital	Liljefors, M (corresponding author), Karolinska Univ Hosp Solna, Karolinska Inst, Canc Ctr Karolinska, Dept Oncol & Pathol Radiumhemmet, Stockholm, Sweden.	maria.gustafsson-liljefors@karolinska.se		Gustafsson Liljefors, Maria/0000-0002-7914-2372	Swedish Cancer Society; Karolinska Institute Foundation; Stockholm County Council; Research Foundation Stiftelsen Onkologiska Klinikens i Uppsala Forskningsfond; Lion's Cancer Fund; Celgene Corporation, Summit, NJ	Swedish Cancer Society(Swedish Cancer Society); Karolinska Institute Foundation(Karolinska Institutet); Stockholm County Council(Stockholm County Council); Research Foundation Stiftelsen Onkologiska Klinikens i Uppsala Forskningsfond; Lion's Cancer Fund; Celgene Corporation, Summit, NJ(Bristol-Myers SquibbCelgene Corporation)	This study was supported by the Swedish Cancer Society, The Karolinska Institute Foundation and the Stockholm County Council, the Research Foundation Stiftelsen Onkologiska Klinikens i Uppsala Forskningsfond, Lion's Cancer Fund and in part by a grant from Celgene Corporation, Summit, NJ. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abu-Hejleh T, 2012, CURR ONCOL REP, V14, P277, DOI 10.1007/s11912-012-0238-8; Alexakis N, 2004, BRIT J SURG, V91, P1410, DOI 10.1002/bjs.4794; Amato RJ, 2008, AM J CLIN ONCOL-CANC, V31, P244, DOI [10.1097/COC.0b013e31815e45H, 10.1097/COC.0b013e31815e451f]; Andhavarapu S, 2013, EXPERT REV HEMATOL, V6, P69, DOI [10.1586/EHM.12.62, 10.1586/ehm.12.62]; Arkenau H, 2011, J CLIN ONCOL, V29, DOI 10.1200/jco.2011.29.15_suppl.e14640; Bartlett JB, 2004, BRIT J CANCER, V90, P955, DOI 10.1038/sj.bjc.6601579; Bergmann-Leitner ES, 2001, CANCER IMMUNOL IMMUN, V50, P445, DOI 10.1007/s002620100229; Blom JW, 2006, EUR J CANCER, V42, P410, DOI 10.1016/j.ejca.2005.09.013; Bringhen S, 2012, EXPERT OPIN DRUG MET, V8, P1209, DOI 10.1517/17425255.2012.712685; Burris HA, 1997, J CLIN ONCOL, V15, P2403, DOI 10.1200/JCO.1997.15.6.2403; Conroy T, 2011, NEW ENGL J MED, V364, P1817, DOI 10.1056/NEJMoa1011923; Corral LG, 1999, J IMMUNOL, V163, P380; Correale P, 2005, J CLIN ONCOL, V23, P8950, DOI 10.1200/JCO.2005.12.147; Crane E, 2005, CANCER INVEST, V23, P625, DOI 10.1080/07357900500283101; Cunningham D, 2009, J CLIN ONCOL, V27, P5513, DOI 10.1200/JCO.2009.24.2446; Dimopoulos MA, 2012, BLOOD, V119, P2764, DOI 10.1182/blood-2011-08-373514; Dredge K, 2005, MICROVASC RES, V69, P56, DOI 10.1016/j.mvr.2005.01.002; Freelove R, 2006, AM FAM PHYSICIAN, V73, P485; Howe HL, 2006, CANCER-AM CANCER SOC, V107, P1711, DOI 10.1002/cncr.22193; Infante JR, 2013, CANCER BIOL THER, V14, P340, DOI 10.4161/cbt.23625; Infante JR, 2011, EUR J CANCER, V47, P199, DOI 10.1016/j.ejca.2010.09.002; Khorana AA, 2004, LANCET ONCOL, V5, P655, DOI 10.1016/S1470-2045(04)01606-7; Kindler HL, 2011, LANCET ONCOL, V12, P256, DOI 10.1016/S1470-2045(11)70004-3; Kindler HL, 2010, J CLIN ONCOL, V28, P3617, DOI 10.1200/JCO.2010.28.1386; Le Tourneau C, 2009, J CLIN ONCOL, V27, P5965, DOI 10.1200/JCO.2009.22.3685; LeBlanc R, 2004, BLOOD, V103, P1787, DOI 10.1182/blood-2003-02-0361; Mandala M, 2011, EXPERT REV ANTICANC, V11, P579, DOI [10.1586/era.10.184, 10.1586/ERA.10.184]; Maples WJ, 2004, J CLIN ONCOL, V22, P4082; Maraveyas A, 2012, EUR J CANCER, V48, P1283, DOI 10.1016/j.ejca.2011.10.017; McCarthy PL, 2012, NEW ENGL J MED, V366, P1770, DOI 10.1056/NEJMoa1114083; Miller AA, 2007, J THORAC ONCOL, V2, P445, DOI 10.1097/01.JTO.0000268679.33238.67; Moore MJ, 2007, J CLIN ONCOL, V25, P1960, DOI 10.1200/JCO.2006.07.9525; Nowak AK, 2003, J IMMUNOL, V170, P4905, DOI 10.4049/jimmunol.170.10.4905; Palumbo A, 2008, LEUKEMIA, V22, P414, DOI 10.1038/sj.leu.2405062; Plate JMD, 2005, CANCER IMMUNOL IMMUN, V54, P915, DOI 10.1007/s00262-004-0638-1; Richardson PG, 2002, BLOOD, V100, P3063, DOI 10.1182/blood-2002-03-0996; Sanborn SL, 2009, INVEST NEW DRUG, V27, P453, DOI 10.1007/s10637-008-9200-x; Sharma RA, 2006, EUR J CANCER, V42, P2318, DOI 10.1016/j.ejca.2006.05.018; Shevchenko I, 2013, INT J CANCER, V133, P98, DOI 10.1002/ijc.27990; Soeda A, 2009, JPN J CLIN ONCOL, V39, P797, DOI 10.1093/jjco/hyp112; Sohn TA, 2000, J GASTROINTEST SURG, V4, P567, DOI 10.1016/S1091-255X(00)80105-5; Storer BE, 2001, STAT MED, V20, P2399, DOI 10.1002/sim.903.abs; Tabernero J, 2009, J CLIN ONCOL, V27, P5487, DOI 10.1200/JCO.2009.23.3098; Teo SK, 2005, AAPS J, V7, pE14, DOI 10.1208/aapsj070103; Vizio B, 2012, EXP THER MED, V4, P70, DOI 10.3892/etm.2012.553; Von Hoff DD, 2013, NEW ENGL J MED, V369, P1691, DOI 10.1056/NEJMoa1304369; Wu L, 2011, CANCER IMMUNOL IMMUN, V60, P61, DOI 10.1007/s00262-010-0919-9	47	8	8	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 2	2015	10	4							e0121197	10.1371/journal.pone.0121197	http://dx.doi.org/10.1371/journal.pone.0121197			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CE9BS	25837499	Green Submitted, Green Published, gold			2023-01-03	WOS:000352139000041
J	Sun, QJ; Wu, M; Bu, XH; Xiong, L				Sun, Qingjie; Wu, Min; Bu, Xianghui; Xiong, Liu			Effect of the Amount and Particle Size of Wheat Fiber on the Physicochemical Properties and Gel Morphology of Starches	PLOS ONE			English	Article							GUM; MICROSTRUCTURE	Effects of added wheat fiber, with different levels and particle sizes, on the physicochemical properties and gel morphology of wheat starch and mung bean starch were investigated, using rapid visco analyzer (RVA), texture analyzer (TPA) and scanning electron microscopy (SEM). Each starch was added with wheat fiber at 10, 20, 30 and 40% (weight basis, g/100g), and different sizes of 60, 100 and 180 mesh, respectively. The peak viscosity (PV) of starches with wheat fiber were higher than the control. Starches had the highest PV with 40%, 60 mesh wheat fiber. The starches with wheat fiber showed higher hardness when compared to the control. Wheat starch and mung bean starch, with 40%, 60 mesh wheat fiber, had the highest hardnesses of 147.78 and 1032.11g, respectively. SEM showed that the dense honeycomb structure of starch gel was diminished with increasing wheat fiber. Additionally, the number of internal pores was reduced, and a large lamellar structure was formed.	[Sun, Qingjie; Wu, Min; Bu, Xianghui; Xiong, Liu] Qingdao Agr Univ, Coll Food Sci & Engn, Qingdao, Peoples R China	Qingdao Agricultural University	Sun, QJ (corresponding author), Qingdao Agr Univ, Coll Food Sci & Engn, Qingdao, Peoples R China.	phdsun@163.com			Qingdao Municipal Science and Technology Plan Project [14-2-3-48-nsh]	Qingdao Municipal Science and Technology Plan Project	Financial support from the Qingdao Municipal Science and Technology Plan Project (grant number: 14-2-3-48-nsh) is gratefully acknowledged. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alamri MS, 2013, FOOD HYDROCOLLOID, V30, P541, DOI 10.1016/j.foodhyd.2012.07.003; Alvarez V, 2006, J COMPOS MATER, V40, P21, DOI 10.1177/0021998305053508; [Anonymous], 2001, CEREAL FOOD WORLD, V46, P112; Appelqvist IAM, 1997, FOOD REV INT, V13, P163, DOI 10.1080/87559129709541105; BeMiller JN, 2011, CARBOHYD POLYM, V86, P386, DOI 10.1016/j.carbpol.2011.05.064; Clodualdo CM, 2010, CEREAL CHEM, V87, P305; Debiagi F, 2010, CIENC AGROTEC, V34, P1522, DOI 10.1590/S1413-70542010000600024; Fabunmi OO, 2011, J POLYM ENVIRON, V19, P841, DOI 10.1007/s10924-011-0374-5; Fahrizio E, 2005, ANTIOXIDANT ACTIVITY; Feng T, 2012, CARBOHYD POLYM, V90, P667, DOI 10.1016/j.carbpol.2012.05.094; Gregory MG, 2008, STARCH, V60, P476; Huang CC, 2009, INT J FOOD SCI TECH, V44, P50, DOI 10.1111/j.1365-2621.2007.01634.x; Hung PV, 2006, TRENDS FOOD SCI TECH, V17, P448, DOI 10.1016/j.tifs.2005.12.006; Kaur L, 2008, FOOD CHEM, V111, P1, DOI 10.1016/j.foodchem.2008.03.027; Kim MJ, 2008, CARBOHYD POLYM, V74, P787, DOI 10.1016/j.carbpol.2008.04.043; Lai P, 2011, FOOD CHEM, V127, P153, DOI 10.1016/j.foodchem.2010.12.116; Li WH, 2011, INT J FOOD SCI TECH, V46, P1621, DOI 10.1111/j.1365-2621.2011.02663.x; Ramirez MGL, 2011, CARBOHYD POLYM, V86, P1712, DOI 10.1016/j.carbpol.2011.07.002; Mann JI, 2009, NUTR METAB CARDIOVAS, V19, P226, DOI 10.1016/j.numecd.2009.02.002; Pons M, 1996, J TEXTURE STUD, V27, P597, DOI 10.1111/j.1745-4603.1996.tb00996.x; Prachayawarakorn J, 2012, J POLYM ENVIRON, V20, P88, DOI 10.1007/s10924-011-0371-8; Rosa MF, 2009, BIORESOURCE TECHNOL, V100, P5196, DOI 10.1016/j.biortech.2009.03.085; Sharma P, 2011, J CEREAL SCI, V53, P25, DOI 10.1016/j.jcs.2010.08.005; Sharma R, 2009, J FOOD PROCESS PRES, V33, P401, DOI 10.1111/j.1745-4549.2008.00283.x; Singh H, 2009, INT J FOOD PROP, V12, P713, DOI 10.1080/10942910801995614; Symons LJ, 2004, J FOOD SCI, V69, pC257, DOI 10.1111/j.1365-2621.2004.tb06325.x; Tan HZ, 2009, FOOD RES INT, V42, P551, DOI 10.1016/j.foodres.2009.02.015; Zhang YC, 2011, CARBOHYD POLYM, V86, P700, DOI 10.1016/j.carbpol.2011.05.009; Zhu KX, 2010, FOOD RES INT, V43, P943, DOI 10.1016/j.foodres.2010.01.005	29	12	12	2	30	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 8	2015	10	6							e0128665	10.1371/journal.pone.0128665	http://dx.doi.org/10.1371/journal.pone.0128665			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CK1GM	26053534	Green Submitted, Green Published, gold			2023-01-03	WOS:000355955300051
J	Kadivar, A; Kamalidehghan, B; Javar, HA; Davoudi, ET; Zaharuddin, ND; Sabeti, B; Chung, LY; Noordin, MI				Kadivar, Ali; Kamalidehghan, Behnam; Javar, Hamid Akbari; Davoudi, Ehsan Taghizadeh; Zaharuddin, Nurul Dhania; Sabeti, Bahareh; Chung, Lip Yong; Noordin, Mohamed Ibrahim			Formulation and In Vitro, In Vivo Evaluation of Effervescent Floating Sustained-Release Imatinib Mesylate Tablet	PLOS ONE			English	Article							DRUG-DELIVERY SYSTEMS; GASTROINTESTINAL STROMAL TUMORS; CHRONIC MYELOID-LEUKEMIA; MATRIX TABLETS; HEALTHY-VOLUNTEERS; GASTRIC RETENTION; HYDROCHLORIDE; COMBINATION; PERFORMANCE; STABILITY	Introduction Imatinib mesylate is an antineoplastic agent which has high absorption in the upper part of the gastrointestinal tract (GIT). Conventional imatinib mesylate (Gleevec) tablets produce rapid and relatively high peak blood levels and requires frequent administration to keep the plasma drug level at an effective range. This might cause side effects, reduced effectiveness and poor therapeutic management. Therefore, floating sustained-release Imatinib tablets were developed to allow the tablets to be released in the upper part of the GIT and overcome the inadequacy of conventional tablets. Methodology Floating sustained-release Imatinib mesylate tablets were prepared using the wet granulation method. Tablets were formulated using Hydroxypropyl Methylcellulose (HPMC K4M), with Sodium alginate (SA) and Carbomer 934P (CP) as release-retarding polymers, sodium bicarbonate (NaHCO3) as the effervescent agent and lactose as a filler. Floating behavior, in vitro drug release, and swelling index studies were conducted. Initial and total drug release duration was compared with a commercial tablet (Gleevec) in 0.1 N HCl (pH 1.2) at 37 +/- 0.5 degrees C for 24 hours. Tablets were then evaluated for various physical parameters, including weight variation, thickness, hardness, friability, and drug content. Consequently, 6 months of physical stability studies and in vitro gastro-retentive studies were conducted. Results and Discussion Statistical data analysis revealed that tablets containing a composition of 14.67% w/w HPMC K4M, 10.67%, w/w Na alginate, 1.33%, w/w Carbomer 934P and 9.33%, w/w NaHCO3 produced the most favorable formulation to develop 24-hour sustained-release tablets with optimum floating behavior and satisfactory physicochemical characteristics. Furthermore, in vitro release study revealed that the formulated SR tablet had significantly lower C-max and higher T-max compared to the conventional tablet (Gleevec). Thus, formulated SR tablets preserved persistent concentration of plasma up to 24 hours. Conclusion In conclusion, in order to suggest a better drug delivery system with constant favorable release, resulting in optimized absorption and less side effects, formulated CP-HPMC-SA based imatinib mesylate floating sustained-release tablets can be a promising candidate for cancer chemotherapy.	[Kadivar, Ali; Kamalidehghan, Behnam; Davoudi, Ehsan Taghizadeh; Zaharuddin, Nurul Dhania; Sabeti, Bahareh; Chung, Lip Yong; Noordin, Mohamed Ibrahim] Univ Malaya, Fac Med, Dept Pharm, Kuala Lumpur, Malaysia; [Javar, Hamid Akbari] Univ Tehran Med Sci, Fac Pharm, Dept Pharmaceut, Tehran, Iran	Universiti Malaya; Tehran University of Medical Sciences	Noordin, MI (corresponding author), Univ Malaya, Fac Med, Dept Pharm, Kuala Lumpur, Malaysia.	ibrahimn@um.edu.my	Noordin, Mohamed/AAK-4152-2021; CHUNG, LIP YONG/B-7764-2010; javar, hamid akbari/B-1928-2018; Kamalidehghan, Behnam/B-5401-2013	CHUNG, LIP YONG/0000-0002-3596-768X; javar, hamid akbari/0000-0003-4137-6939; Kamalidehghan, Behnam/0000-0001-8530-8124; akbari javar, hamid/0000-0001-6036-1084; Noordin, Mohamed Ibrahim/0000-0002-9424-8925	University of Malaya through IPPP research Grant [PV047/2011A]; Malaysian Ministry of Higher Education's MOHE-HIR [UM.C/625/1/MOHE/MED/17, UM.C/625/1/MOHE/MED/33]	University of Malaya through IPPP research Grant; Malaysian Ministry of Higher Education's MOHE-HIR	The authors would like to express their utmost gratitude and appreciation to University of Malaya through IPPP research Grant (Grant no. PV047/2011A), and Malaysian Ministry of Higher Education's MOHE-HIR Grants (UM.C/625/1/MOHE/MED/17 and UM.C/625/1/MOHE/MED/33) for providing financial supports to conduct this study. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Anjali Devi N., 2013, INT J PHARM PHARM SC, V5, P271; Asnaashari S, 2011, PHARM DEV TECHNOL, V16, P400, DOI 10.3109/10837451003774393; Berry MR, 2007, J PHARMACEUT BIOMED, V45, P194, DOI 10.1016/j.jpba.2007.05.021; Boyapally H, 2010, COLLOID SURFACE B, V77, P227, DOI 10.1016/j.colsurfb.2010.01.031; Center for Drug Evaluation and Research of the U. S. Department of Health and Human Services Food and Drug Administration Guidance for Industry, 2001, GUID IND BIOAN METH; Chavanpatil MD, 2006, INT J PHARMACEUT, V316, P86, DOI 10.1016/j.ijpharm.2006.02.038; Chen RN, 2010, EUR J PHARM SCI, V39, P82, DOI 10.1016/j.ejps.2009.10.015; Chen YC, 2013, INT J PHARMACEUT, V441, P162, DOI 10.1016/j.ijpharm.2012.12.002; Cohen MH, 2002, ONCOLOGIST, V7, P393, DOI 10.1634/theoncologist.7-5-393; Dash S, 2010, ACTA POL PHARM, V67, P217; Davoudi ET, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/495319; De Kogel CE, 2007, ONCOLOGIST, V12, P1390, DOI 10.1634/theoncologist.12-12-1390; de Lemos ML, 2015, J ONCOL PHARM PRACT, V21, P76, DOI 10.1177/1078155214522143; de Wit D, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-575; Deininger MWN, 2003, PHARMACOL REV, V55, P401, DOI 10.1124/pr.55.3.4; Deshpande AA, 1997, PHARMACEUT RES, V14, P815, DOI 10.1023/A:1012171010492; Dorozynski P, 2004, DRUG DEV IND PHARM, V30, P947, DOI 10.1081/DDC-200037179; Druker BJ, 2003, SEMIN HEMATOL, V40, P50, DOI 10.1053/shem.2003.50000; Gambhire MN, 2007, AAPS PHARMSCITECH, V8, DOI 10.1208/pt0803073; Gande S, 2011, DARU, V19, P202; Genc L, 1999, Pharm Acta Helv, V74, P43, DOI 10.1016/S0031-6865(99)00017-5; Guguloth Mohan, 2011, PDA J Pharm Sci Technol, V65, P198, DOI 10.5731/pdajpst.2011.00685; HODSDON AC, 1995, J CONTROL RELEASE, V33, P143, DOI 10.1016/0168-3659(94)00076-7; Hwang SJ, 1998, CRIT REV THER DRUG, V15, P243; Jagdale SC, 2009, AAPS PHARMSCITECH, V10, P1071, DOI 10.1208/s12249-009-9300-8; Khan GM, 1998, J CONTROL RELEASE, V54, P185, DOI 10.1016/S0168-3659(97)00225-3; Kose-Ozkan C, 2010, COMB CHEM HIGH T SCR, V13, P683, DOI 10.2174/138620710791920347; Kuu WY, 1998, INT J PHARM, V166, P167, DOI 10.1016/S0378-5173(98)00049-0; Macdonald JB, 2015, J AM ACAD DERMATOL, V72, P203, DOI 10.1016/j.jaad.2014.07.032; Matthews BR, 1999, DRUG DEV IND PHARM, V25, P831, DOI 10.1081/DDC-100102245; Meco D, 2005, CANCER LETT, V228, P211, DOI 10.1016/j.canlet.2005.02.054; Moen MD, 2007, DRUGS, V67, P299, DOI 10.2165/00003495-200767020-00010; Mortazavi SA, 2014, IRAN J PHARM RES, V13, P19; Newell DR, 2005, EUR J CANCER, V41, P676, DOI 10.1016/j.ejca.2004.12.024; Novartis FDA, 2003, GLEEV IM MES; Nunthanid J, 2004, J CONTROL RELEASE, V99, P15, DOI 10.1016/j.jconrel.2004.06.008; Parise RA, 2003, J CHROMATOGR B, V791, P39, DOI 10.1016/S1570-0232(03)00206-X; Pather SI, 1998, INT J PHARM, V164, P1, DOI 10.1016/S0378-5173(97)00348-7; Pharmacopoeia TB, 2007, BRIT PHARMACOPOEIA; RAO KVR, 1988, INT J PHARM, V48, P1; Rehman AU, 2013, TROP J PHARM RES, V12, P169, DOI 10.4314/tjpr.v12i2.6; Sauzet C, 2009, INT J PHARMACEUT, V378, P23, DOI 10.1016/j.ijpharm.2009.05.027; SHAW JE, 1980, ANNU REP MED CHEM, V15, P302; Singh BN, 2000, J CONTROL RELEASE, V63, P235, DOI 10.1016/S0168-3659(99)00204-7; Srinatha A, 2008, DRUG DELIV, V15, P471, DOI [10.1080/10717540802329282, 10.1080/10717540802329282 ]; Tadros MI, 2010, EUR J PHARM BIOPHARM, V74, P332, DOI 10.1016/j.ejpb.2009.11.010; Teng JFT, 2012, THER DRUG MONIT, V34, P85, DOI 10.1097/FTD.0b013e31823cdec9; Titier K, 2005, THER DRUG MONIT, V27, P634, DOI 10.1097/01.ftd.0000175973.71140.91; USP, 2004, US PHARM, VXXVII; Varshosaz J, 2006, DRUG DELIV, V13, P277, DOI 10.1080/10717540500395106; Vilches AP, 2002, INT J PHARM, V246, P17, DOI 10.1016/S0378-5173(02)00333-2; Wadher KJ, 2011, INDIAN J PHARM SCI, V73, P208; Weigel MT, 2009, CANCER LETT, V273, P70, DOI 10.1016/j.canlet.2008.07.040; Wong DWY, 2008, CLIN ONCOL-UK, V20, P517, DOI 10.1016/j.clon.2008.04.008; Xu XQ, 2006, INT J PHARMACEUT, V310, P139, DOI 10.1016/j.ijpharm.2005.12.003; Yin LF, 2013, INT J PHARMACEUT, V452, P241, DOI 10.1016/j.ijpharm.2013.05.011; Zahaby EI- SA, SAUDI PHARM J; Zaharuddin ND, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/735891; Zhang CG, 2012, INT J PHARMACEUT, V430, P141, DOI 10.1016/j.ijpharm.2012.04.013	59	17	17	2	34	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 2	2015	10	6							e0126874	10.1371/journal.pone.0126874	http://dx.doi.org/10.1371/journal.pone.0126874			23	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CJ7SJ	26035710	Green Published, Green Submitted, gold			2023-01-03	WOS:000355699100008
J	De Pascalis, V; Varriale, V; Cacace, I				De Pascalis, Vilfredo; Varriale, Vincenzo; Cacace, Immacolata			Pain Modulation in Waking and Hypnosis in Women: Event-Related Potentials and Sources of Cortical Activity	PLOS ONE			English	Article							SOMATOSENSORY-EVOKED-POTENTIALS; POSTTRAUMATIC-STRESS-DISORDER; SELECTIVE SPATIAL ATTENTION; HUMAN ANTERIOR CINGULATE; ELECTROMAGNETIC TOMOGRAPHY; HYPNOTIC ANALGESIA; HUMAN BRAIN; SEX-DIFFERENCES; FOCUSED ANALGESIA; LASER STIMULI	Using a strict subject selection procedure, we tested in High and Low Hypnotizable subjects (HHs and LHs) whether treatments of hypoalgesia and hyperalgesia, as compared to a relaxation-control, differentially affected subjective pain ratings and somatosensory event-related potentials (SERPs) during painful electric stimulation. Treatments were administered in waking and hypnosis conditions. LHs showed little differentiation in pain and distress ratings between hypoalgesia and hyperalgesia treatments, whereas HHs showed a greater spread in the instructed direction. HHs had larger prefrontal N140 and P200 waves of the SERPs during hypnotic hyperalgesia as compared to relaxation-control treatment. Importantly, HHs showed significant smaller frontocentral N140 and frontotemporal P200 waves during hypnotic hypoalgesia. LHs did not show significant differences for these SERP waves among treatments in both waking and hypnosis conditions. Source localization (sLORETA) method revealed significant activations of the bilateral primary somatosensory (BA3), middle frontal gyrus (BA6) and anterior cingulate cortices (BA24). Activity of these contralateral regions significantly correlated with subjective numerical pain scores for control treatment in waking condition. Moreover, multivariate regression analyses distinguished the contralateral BA3 as the only region reflecting a stable pattern of pain coding changes across all treatments in waking and hypnosis conditions. More direct testing showed that hypnosis reduced the strength of the association of pain modulation and brain activity changes at BA3. sLORETA in HHs revealed, for the N140 wave, that during hypnotic hyperalgesia, there was an increased activity within medial, supramarginal and superior frontal gyri, and cingulated gyrus (BA32), while for the P200 wave, activity was increased in the superior (BA22), middle (BA37), inferior temporal (BA19) gyri and superior parietal lobule (BA7). Hypnotic hypoalgesia in HHs, for N140 wave, showed reduced activity within medial and superior frontal gyri (BA9,8), paraippocampal gyrus (BA34), and postcentral gyrus (BA1), while for the P200, activity was reduced within middle and superior frontal gyri (BA9 and BA10), anterior cingulate (BA33), cuneus (BA19) and sub-lobar insula (BA13). These findings demonstrate that hypnotic suggestions can exert a top-down modulatory effect on attention/preconscious brain processes involved in pain perception.	[De Pascalis, Vilfredo; Varriale, Vincenzo; Cacace, Immacolata] Univ Roma La Sapienza, Dept Psychol, I-00185 Rome, Italy	Sapienza University Rome	De Pascalis, V (corresponding author), Univ Roma La Sapienza, Dept Psychol, Piazzale Aldo Moro 5, I-00185 Rome, Italy.	vilfredo.depascalis@uniroma1.it	De Pascalis, Vilfredo/ABC-5534-2021; Varriale, Vincenzo/AAQ-9419-2020	Varriale, Vincenzo/0000-0002-1609-9282; DE PASCALIS, Vilfredo/0000-0003-4594-8877	University of Rome "La Sapienza" [C26A08B8BP]	University of Rome "La Sapienza"	This research was supported by a grant from the University of Rome "La Sapienza" (2008, prot. C26A08B8BP) to V. DePascalis for a research project titled "Suggestioni di analgesia e iperalgesia in veglia e ipnosi: effetto sui potenziali somatosensoriali evento-correlati". The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abrahamsen R, 2010, PAIN, V151, P825, DOI 10.1016/j.pain.2010.09.020; Apkarian AV, 1999, J NEUROPHYSIOL, V81, P2956, DOI 10.1152/jn.1999.81.6.2956; Apkarian AV, 2005, EUR J PAIN, V9, P463, DOI 10.1016/j.ejpain.2004.11.001; BECKER DE, 1993, ELECTROEN CLIN NEURO, V88, P290, DOI 10.1016/0168-5597(93)90053-R; Becker DE, 2000, PAIN, V84, P37, DOI 10.1016/S0304-3959(99)00182-7; Bromm B, 1998, ELECTROEN CLIN NEURO, V107, P227, DOI 10.1016/S0013-4694(98)00075-3; Brown CA, 2008, PAIN, V135, P240, DOI 10.1016/j.pain.2007.05.022; Buchel C, 1999, J NEUROSCI, V19, P10869; Bushnell M, 2006, WALL MELZACKS TXB PA, P107; Bushnell MC, 1999, P NATL ACAD SCI USA, V96, P7705, DOI 10.1073/pnas.96.14.7705; Cardena E., 2007, CONT HYPNOSIS, V24, P154, DOI [10.1002/ch.340, DOI 10.1002/CH.340]; Carlsson K, 2006, NEUROIMAGE, V32, P1804, DOI 10.1016/j.neuroimage.2006.05.027; Caruana F, 2011, CURR BIOL, V21, P195, DOI 10.1016/j.cub.2010.12.042; Casey KL, 1999, P NATL ACAD SCI USA, V96, P7668, DOI 10.1073/pnas.96.14.7668; Chaves JF, 1997, INT J CLIN EXP HYP, V45, P356, DOI 10.1080/00207149708416138; Chen SL, 2006, PSYCHIAT RES-NEUROIM, V146, P65, DOI 10.1016/j.pscychresns.2005.09.006; Clark WC, 2002, PAIN, V98, P241, DOI 10.1016/S0304-3959(01)00474-2; COLLINS DL, 1994, J COMPUT ASSIST TOMO, V18, P192, DOI 10.1097/00004728-199403000-00005; Congedo M, 2009, HDB NEUROFEEDBACK DY, P85; Corbetta M, 2002, NAT REV NEUROSCI, V3, P201, DOI 10.1038/nrn755; Craig AD, 2009, NAT REV NEUROSCI, V10, P59, DOI 10.1038/nrn2555; CRAWFORD HJ, 1994, INT J CLIN EXP HYP, V42, P204, DOI 10.1080/00207149408409352; Crawford HJ., 1992, CONT HYPNOSIS RES, P227; Croft RJ, 2002, INT J PSYCHOPHYSIOL, V46, P101, DOI 10.1016/S0167-8760(02)00118-6; Danziger N, 1998, PAIN, V75, P85, DOI 10.1016/S0304-3959(97)00208-X; De Pascalis V, 1999, PAIN, V83, P499, DOI 10.1016/S0304-3959(99)00157-8; De Pascalis V, 2005, INT J PSYCHOPHYSIOL, V56, P157, DOI 10.1016/j.ijpsycho.2004.11.004; De Pascalis V, 2001, CLIN NEUROPHYSIOL, V112, P1475, DOI 10.1016/S1388-2457(01)00586-7; De Pascalis V, 2000, INT J CLIN EXP HYP, V48, P44, DOI 10.1080/00207140008410360; De Pascalis V, 2002, SUGGESTION SUGGESTIB, P157; De Pascalis V, 2008, PAIN, V134, P197, DOI 10.1016/j.pain.2007.09.005; De Pascalis V, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079605; DEPASCALIS V, 2000, INT J CLIN EXP HYP, V48, P15; Derbyshire SWG, 2009, EUR J PAIN, V13, P542, DOI 10.1016/j.ejpain.2008.06.010; DESMEDT JE, 1989, ELECTROEN CLIN NEURO, V74, P321, DOI 10.1016/0168-5597(89)90001-4; Dum RP, 2009, J NEUROSCI, V29, P14223, DOI 10.1523/JNEUROSCI.3398-09.2009; Duncan Gary H, 2003, Adv Neurol, V93, P69; Egner T, 2005, NEUROIMAGE, V27, P969, DOI 10.1016/j.neuroimage.2005.05.002; Eimer M, 2002, PSYCHOPHYSIOLOGY, V39, P437, DOI 10.1017/S0048577201393162; Eisenberger NI, 2003, SCIENCE, V302, P290, DOI 10.1126/science.1089134; Emdad R, 2006, PSYCHOTHER PSYCHOSOM, V75, P122, DOI 10.1159/000090897; Escera C, 2007, J PSYCHOPHYSIOL, V21, P251, DOI 10.1027/0269-8803.21.34.251; Faymonville ME, 2006, J PHYSIOL-PARIS, V99, P463, DOI 10.1016/j.jphysparis.2006.03.018; Faymonville ME, 2000, ANESTHESIOLOGY, V92, P1257, DOI 10.1097/00000542-200005000-00013; Faymonville ME, 2003, COGNITIVE BRAIN RES, V17, P255, DOI 10.1016/S0926-6410(03)00113-7; Frot M, 1999, CLIN NEUROPHYSIOL, V110, P133, DOI 10.1016/S0168-5597(98)00054-9; Frot M, 2013, HUM BRAIN MAPP, V34, P2655, DOI 10.1002/hbm.22097; Fuchs M, 2002, CLIN NEUROPHYSIOL, V113, P702, DOI 10.1016/S1388-2457(02)00030-5; Garcia-Larrea L, 2003, NEUROPHYSIOL CLIN, V33, P279, DOI 10.1016/j.neucli.2003.10.008; Garcia-Larrea L, 2012, NEUROPHYSIOL CLIN, V42, P299, DOI 10.1016/j.neucli.2012.06.001; Garcia-Larrea L, 2013, PAIN, V154, pS29, DOI 10.1016/j.pain.2013.09.001; Garcia-Larrea L, 2012, NEUROSCI LETT, V520, P188, DOI 10.1016/j.neulet.2012.05.007; GARCIALARREA L, 1995, PSYCHOPHYSIOLOGY, V32, P526, DOI 10.1111/j.1469-8986.1995.tb01229.x; GARCIALARREA L, 1991, ELECTROEN CLIN NEURO, V80, P201, DOI 10.1016/0168-5597(91)90122-E; GarciaLarrea L, 1997, NEUROREPORT, V8, P3785, DOI 10.1097/00001756-199712010-00026; Geuze E, 2007, ARCH GEN PSYCHIAT, V64, P76, DOI 10.1001/archpsyc.64.1.76; GIBSON SJ, 1991, PAIN, V47, P173, DOI 10.1016/0304-3959(91)90202-9; GLASS A, 1984, BIOL PSYCHOL, V19, P169, DOI 10.1016/0301-0511(84)90035-8; GRATTON G, 1983, ELECTROEN CLIN NEURO, V55, P468, DOI 10.1016/0013-4694(83)90135-9; Greenblatt RE, 2005, IEEE T SIGNAL PROCES, V53, P3403, DOI 10.1109/TSP.2005.853201; Gruzelier JH., 2000, CONT HYPNOSIS, V17, P51, DOI DOI 10.1002/CH.193; Hagen MC, 2002, J NEUROPHYSIOL, V88, P1400, DOI 10.1152/jn.2002.88.3.1400; HANDWERKER HO, 1993, PHYSIOL REV, V73, P639, DOI 10.1152/physrev.1993.73.3.639; HARI R, 1983, NEUROSCI LETT, V42, P77, DOI 10.1016/0304-3940(83)90425-1; Hofbauer RK, 2001, J NEUROPHYSIOL, V86, P402, DOI 10.1152/jn.2001.86.1.402; Horton JE, 2004, BRAIN, V127, P1741, DOI 10.1093/brain/awh196; Iannetti GD, 2008, J NEUROPHYSIOL, V100, P815, DOI 10.1152/jn.00097.2008; Iannetti GD, 2010, EXP BRAIN RES, V205, P1, DOI 10.1007/s00221-010-2340-1; Iannetti GD, 2004, CLIN NEUROPHYSIOL, V115, P2629, DOI 10.1016/j.clinph.2004.05.023; Jensen M, 2006, J BEHAV MED, V29, P95, DOI 10.1007/s10865-005-9031-6; JENSEN MP, 1986, PAIN, V27, P117, DOI 10.1016/0304-3959(86)90228-9; Jurcak V, 2007, NEUROIMAGE, V34, P1600, DOI 10.1016/j.neuroimage.2006.09.024; Kirk R.E., 1968, EXPT DESIGN PROCEDUR; KUNDE V, 1993, ELECTROEN CLIN NEURO, V88, P280, DOI 10.1016/0168-5597(93)90052-Q; Lee MC, 2009, J NEUROSCI, V29, P7909, DOI 10.1523/JNEUROSCI.0014-09.2009; Legrain V, 2005, CLIN NEUROPHYSIOL, V116, P2165, DOI 10.1016/j.clinph.2005.05.019; Legrain V, 2012, NEUROPHYSIOL CLIN, V42, P325, DOI 10.1016/j.neucli.2012.06.003; Legrain V, 2003, PAIN, V103, P237, DOI 10.1016/S0304-3959(02)00451-7; Legrain V, 2002, PAIN, V99, P21, DOI 10.1016/S0304-3959(02)00051-9; Legrain V, 2011, PROG NEUROBIOL, V93, P111, DOI 10.1016/j.pneurobio.2010.10.005; Legrain V, 2009, PAIN, V144, P230, DOI 10.1016/j.pain.2009.03.020; Leknes S, 2013, PAIN, V154, P402, DOI 10.1016/j.pain.2012.11.018; Lenz FA, 1998, J NEUROPHYSIOL, V79, P2231, DOI 10.1152/jn.1998.79.4.2231; Lorenz J, 2003, NEUROPHYSIOL CLIN, V33, P293, DOI 10.1016/j.neucli.2003.10.004; MacDonald G, 2005, PSYCHOL BULL, V131, P202, DOI 10.1037/0033-2909.131.2.202; Mancini F, 2012, J NEUROSCI, V32, P17155, DOI 10.1523/JNEUROSCI.3059-12.2012; May A, 1998, PAIN, V74, P61, DOI 10.1016/S0304-3959(97)00144-9; Mazziotta J, 2001, PHILOS T R SOC B, V356, P1293, DOI 10.1098/rstb.2001.0915; MELZACK R, 1968, P423; Mertz H, 2000, GASTROENTEROLOGY, V118, P842, DOI 10.1016/S0016-5085(00)70170-3; Miller EK, 2001, ANNU REV NEUROSCI, V24, P167, DOI 10.1146/annurev.neuro.24.1.167; MIRON D, 1989, PAIN, V39, P345, DOI 10.1016/0304-3959(89)90048-1; Mohr C, 2012, EUR J PAIN, V16, P496, DOI 10.1016/j.ejpain.2011.07.010; MORGAN AH, 1979, AM J CLIN HYPN, V21, P134; Mouraux A, 2007, NEUROSCIENCE, V150, P72, DOI 10.1016/j.neuroscience.2007.08.035; Nichols TE, 2002, HUM BRAIN MAPP, V15, P1, DOI 10.1002/hbm.1058; Nir RR, 2008, J PAIN, V9, P1058, DOI 10.1016/j.jpain.2008.06.008; Omori S, 2013, CLIN NEUROPHYSIOL, V124, P1422, DOI 10.1016/j.clinph.2013.01.006; Page RA, 2007, AM J CLIN HYPN, V49, P283, DOI 10.1080/00029157.2007.10524505; Pascual-Marqui RD, 2002, METHOD FIND EXP CLIN, V24, P91; Pascual-Marqui RD, 2002, METHOD FIND EXP CLIN, V24, P5; PASCUALMARQUI RD, 1994, INT J PSYCHOPHYSIOL, V18, P49, DOI 10.1016/0167-8760(84)90014-X; Petrovic P, 2002, SCIENCE, V295, P1737, DOI 10.1126/science.1067176; Peyron R, 2000, NEUROPHYSIOL CLIN, V30, P263, DOI 10.1016/S0987-7053(00)00227-6; Peyron R, 2000, PAIN, V84, P77, DOI 10.1016/S0304-3959(99)00190-6; Pomares FB, 2013, NEUROIMAGE, V64, P466, DOI 10.1016/j.neuroimage.2012.09.038; Price D.D., 1999, PROGR PAIN RES MANAG; PRICE DD, 1987, PAIN, V28, P297, DOI 10.1016/0304-3959(87)90065-0; Rainville P, 1997, SCIENCE, V277, P968, DOI 10.1126/science.277.5328.968; Rainville P, 1999, J COGNITIVE NEUROSCI, V11, P110, DOI 10.1162/089892999563175; Ray AL, 2002, PRACTICAL PAIN MANAG; RAY WJ, 1976, NEUROPSYCHOLOGIA, V14, P391, DOI 10.1016/0028-3932(76)90035-X; Ray WJ, 2002, BIOL PSYCHOL, V60, P17, DOI 10.1016/S0301-0511(02)00029-7; Raz A., 2004, COGNITIVE NEUROSCIEN, P420; Rudski JM, 2004, INT J CLIN EXP HYP, V52, P39, DOI 10.1076/iceh.52.1.39.23924; SALMASO D, 1985, CORTEX, V21, P533, DOI 10.1016/S0010-9452(58)80003-9; Sawamoto N, 2000, J NEUROSCI, V20, P7438; Sharav Y, 2004, INT J PSYCHOPHYSIOL, V52, P187, DOI 10.1016/j.ijpsycho.2003.10.001; Sharav Y, 2006, PAIN, V124, P280, DOI 10.1016/j.pain.2006.04.016; Shor RE, 1962, HARVASRD GROUP SCALE; Straube T, 2009, HUM BRAIN MAPP, V30, P689, DOI 10.1002/hbm.20536; Talairach J., 1988, CO PLANAR STEREOTAXI; TALBOT JD, 1991, SCIENCE, V251, P1355, DOI 10.1126/science.2003220; Terhune DB, 2010, CONSCIOUS COGN, V19, P1140, DOI 10.1016/j.concog.2010.03.006; TOWLE VL, 1993, ELECTROEN CLIN NEURO, V86, P1, DOI 10.1016/0013-4694(93)90061-Y; Tracey I, 2002, J NEUROSCI, V22, P2748, DOI 10.1523/JNEUROSCI.22-07-02748.2002; Tracey I, 2007, NEURON, V55, P377, DOI 10.1016/j.neuron.2007.07.012; Treede RD, 1999, PAIN, V79, P105, DOI 10.1016/S0304-3959(98)00184-5; Valentini E, 2012, NEUROIMAGE, V59, P1571, DOI 10.1016/j.neuroimage.2011.08.069; Valentini E, 2013, CORTEX, V49, P446, DOI 10.1016/j.cortex.2012.02.005; Valeriani M, 2000, CLIN NEUROPHYSIOL, V111, P1103, DOI 10.1016/S1388-2457(00)00273-X; Valet M, 2009, PSYCHOSOM MED, V71, P49, DOI 10.1097/PSY.0b013e31818d1e02; Vanhaudenhuyse A, 2009, NEUROIMAGE, V47, P1047, DOI 10.1016/j.neuroimage.2009.05.031; VASEY MW, 1987, PSYCHOPHYSIOLOGY, V24, P479, DOI 10.1111/j.1469-8986.1987.tb00324.x; Vogt BA, 2005, NAT REV NEUROSCI, V6, P533, DOI 10.1038/nrn1704; Wager TD, 2004, SCIENCE, V303, P1162, DOI 10.1126/science.1093065; Wager TD, 2013, NEW ENGL J MED, V368, P1388, DOI 10.1056/NEJMoa1204471; Wagner M, 2004, BRAIN TOPOGR, V16, P277; Weitzenhoffer A. M., 1962, STANFORD HYPNOTIC SU; Wicker B, 2003, NEURON, V40, P655, DOI 10.1016/S0896-6273(03)00679-2; Wiech K, 2008, PAIN, V139, P467, DOI 10.1016/j.pain.2008.07.030; Wiech K, 2006, J NEUROSCI, V26, P11501, DOI 10.1523/JNEUROSCI.2568-06.2006; Zachariae R, 1998, EUR J PAIN, V2, P25, DOI 10.1016/S1090-3801(98)90043-X	143	12	12	0	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 1	2015	10	6							e0128474	10.1371/journal.pone.0128474	http://dx.doi.org/10.1371/journal.pone.0128474			38	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CL0KF	26030417	Green Published, Green Submitted, gold			2023-01-03	WOS:000356630900155
J	Schneider, A; Schneider, MP; Krieter, DH; Genser, B; Scharnagl, H; Stojakovic, T; Wanner, C; Drechsler, C				Schneider, Andreas; Schneider, Markus P.; Krieter, Detlef H.; Genser, Bernd; Scharnagl, Hubert; Stojakovic, Tatjana; Wanner, Christoph; Drechsler, Christiane			Effect of High-Flux Dialysis on Circulating FGF-23 Levels in End-Stage Renal Disease Patients: Results from a Randomized Trial	PLOS ONE			English	Article							FIBROBLAST GROWTH FACTOR-23; CARDIOVASCULAR EVENTS; MINERAL METABOLISM; MORTALITY; FIBROBLAST-GROWTH-FACTOR-23; HEMODIAFILTRATION; HEMODIALYSIS; ASSOCIATION; REMOVAL; FGF23	Background In patients undergoing maintenance hemodialysis (HD), increased levels of circulating fibroblast growth factor-23 (FGF-23) are independently associated with cardiovascular events and mortality. Interventional strategies aiming to reduce levels of FGF-23 in HD patients are of particular interest. The purpose of the current study was to compare the impact of high-flux versus low-flux HD on circulating FGF-23 levels. Methods We conducted a post-hoc analysis of the MINOXIS study, including 127 dialysis patients randomized to low-flux (n = 62) and high-flux (n = 65) HD for 52 weeks. Patients with valid measures for FGF-23 investigated baseline and after 52 weeks were included. Results Compared to baseline, a significant increase in FGF-23 levels after one year of low-flux HD was observed (Delta plasma FGF-23: +4026 RU/ml; p < 0.001). In contrast, FGF-23 levels remained stable in the high flux group (Delta plasma FGF-23: +373 RU/ml, p = 0.70). The adjusted difference of the absolute change in FGF-23 levels between the two treatment groups was statistically significant (p < 0.01). Conclusions Over a period of 12 months, high-flux HD was associated with stable FGF-23 levels, whereas the low-flux HD group showed an increase of FGF-23. However, the implications of the different FGF 23 time-trends in patients on high flux dialysis, as compared to the control group, remain to be explored in specifically designed clinical trials.	[Schneider, Andreas; Krieter, Detlef H.; Wanner, Christoph; Drechsler, Christiane] Univ Hosp, Div Nephrol, Dept Med, Wurzburg, Germany; [Schneider, Markus P.] Univ Hosp, Dept Hypertens & Nephrol, Erlangen, Germany; [Genser, Bernd] Mannheim Inst Publ Hlth Social & Prevent Med, Fac Med, Mannheim, Germany; [Genser, Bernd] BGStats Consulting, Vienna, Austria; [Scharnagl, Hubert; Stojakovic, Tatjana] Med Univ Graz, Clin Inst Med & Chem Lab Diagnost, Graz, Austria	University of Wurzburg; University of Erlangen Nuremberg; Ruprecht Karls University Heidelberg; Medical University of Graz	Schneider, A (corresponding author), Univ Hosp, Div Nephrol, Dept Med, Wurzburg, Germany.	schneider_a6@ukw.de		Genser, Bernd/0000-0001-5787-0902; Schneider, Markus/0000-0002-5265-8088	University of Wuerzburg	University of Wuerzburg	B.G. received an unrestricted educational grant from University of Wuerzburg to provide statistical support for the study. Co-author Bernd Genser is employed by BGStats Consulting, which provided support in the form of salary for author BG, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the 'author contributions' section.	Cornelis T, 2014, AM J KIDNEY DIS, V64, P247, DOI 10.1053/j.ajkd.2014.02.016; Covic A, 2009, NEPHROL DIAL TRANSPL, V24, P1506, DOI 10.1093/ndt/gfn613; Diniz H, 2013, NEFROLOGIA, V33, P835, DOI 10.3265/Nefrologia.pre2013.Jul.12091; Drechsler C, 2009, NEPHROL DIAL TRANSPL, V24, P3151, DOI 10.1093/ndt/gfp260; Faul C, 2011, J CLIN INVEST, V121, P4393, DOI 10.1172/JCI46122; Foley RN, 1998, J AM SOC NEPHROL, V9, P267; Gutierrez O, 2005, J AM SOC NEPHROL, V16, P2205, DOI 10.1681/ASN.2005010052; Gutierrez OM, 2008, NEW ENGL J MED, V359, P584, DOI 10.1056/NEJMoa0706130; Gutierrez OM, 2009, CIRCULATION, V119, P2545, DOI 10.1161/CIRCULATIONAHA.108.844506; Kendrick J, 2011, J AM SOC NEPHROL, V22, P1913, DOI 10.1681/ASN.2010121224; Khan AM, 2012, CLIN J AM SOC NEPHRO, V7, P2017, DOI 10.2215/CJN.02160212; Kovesdy CP, 2013, NEPHRON CLIN PRACT, V123, P194, DOI 10.1159/000353593; Makar SH, 2010, IRAN J KIDNEY DIS, V4, P327; McCullough PA, 2010, AM J KIDNEY DIS, V55, pS1, DOI 10.1053/j.ajkd.2009.12.017; Mirza MAI, 2009, ATHEROSCLEROSIS, V205, P385, DOI 10.1016/j.atherosclerosis.2009.01.001; Neirynck N, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044201; Palmer SC, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005016.pub2; Parker BD, 2010, ANN INTERN MED, V152, P640, DOI 10.7326/0003-4819-152-10-201005180-00004; Patrier L, 2013, J NEPHROL, V26, P342, DOI 10.5301/jn.5000150; Prie D, 2009, KIDNEY INT, V75, P882, DOI 10.1038/ki.2008.643; Quarles LD, 2012, EXP CELL RES, V318, P1040, DOI 10.1016/j.yexcr.2012.02.027; Schneider A, 2012, CLIN J AM SOC NEPHRO, V7, P52, DOI 10.2215/CJN.02710311; Stubbs J, 2007, SEMIN DIALYSIS, V20, P302, DOI 10.1111/j.1525-139X.2007.00308.x	23	6	6	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 29	2015	10	5							e0128079	10.1371/journal.pone.0128079	http://dx.doi.org/10.1371/journal.pone.0128079			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CJ2MQ	26024521	Green Submitted, Green Published, gold			2023-01-03	WOS:000355319400069
J	Anota, A; Mouillet, G; Trouilloud, I; Dupont-Gossart, AC; Artru, P; Lecomte, T; Zaanan, A; Gauthier, M; Fein, F; Dubreuil, O; Paget-Bailly, S; Taieb, J; Bonnetain, F				Anota, Amelie; Mouillet, Guillaume; Trouilloud, Isabelle; Dupont-Gossart, Anne-Claire; Artru, Pascal; Lecomte, Thierry; Zaanan, Aziz; Gauthier, Melanie; Fein, Francine; Dubreuil, Olivier; Paget-Bailly, Sophie; Taieb, Julien; Bonnetain, Franck			Sequential FOLFIRI.3+Gemcitabine Improves Health-Related Quality of Life Deterioration-Free Survival of Patients with Metastatic Pancreatic Adenocarcinoma: A Randomized Phase II Trial	PLOS ONE			English	Article							PROPENSITY SCORE METHODS; PATTERN-MIXTURE-MODELS; CLINICAL BENEFIT; CANCER; GEMCITABINE; GUIDELINES; FOLFIRINOX; OUTCOMES	Background A randomized multicenter phase II trial was conducted to assess the sequential treatment strategy using FOLFIRI.3 and gemcitabine alternately ( Arm 2) compared to gemcitabine alone (Arm 1) in patients with metastatic non pre-treated pancreatic adenocarcinoma. The primary endpoint was the progression-free survival (PFS) rate at 6 months. It concludes that the sequential treatment strategy appears to be feasible and effective with a PFS rate of 43.5% in Arm 2 at 6 months (26.1% in Arm 1). This paper reports the results of the longitudinal analysis of the health-related quality of life (HRQoL) as a secondary endpoint of this study. Methods HRQoL was evaluated using the EORTC QLQ-C30 at baseline and every two months until the end of the study or death. HRQoL deterioration-free survival (QFS) was defined as the time from randomization to a first significant deterioration as compared to the baseline score with no further significant improvement, or death. A propensity score was estimated comparing characteristics of partial and complete responders. Analyses were repeated with inverse probability weighting method using the propensity score. Multivariate Cox regression analyses were performed to identify independent factors influencing QFS. Results 98 patients were included between 2007 and 2011. Adjusting on the propensity score, patients of Arm 2 presented a longer QFS of Global Health Status (Hazard Ratio: 0.52 [0.310.85]), emotional functioning (0.35 [0.21-0.59]) and pain (0.50 [0.31 - 0.81]) than those of Arm 1. Conclusion Patients of Arm 2 presented a better HRQoL with a longer QFS than those of Arm 1. Moreover, the propensity score method allows to take into account the missing data depending on patients' characteristics.	[Anota, Amelie; Bonnetain, Franck] Natl Qual Life Oncol Platform, Besancon, France; [Anota, Amelie; Mouillet, Guillaume; Paget-Bailly, Sophie; Bonnetain, Franck] Univ Hosp Besancon, Methodol & Qual Life Oncol Unit EA 3181, Besancon, France; [Trouilloud, Isabelle; Zaanan, Aziz; Dubreuil, Olivier; Taieb, Julien] Univ Paris 05, Georges Pompidou European Hosp, Dept Gastroenterol & Digest Oncol, Paris, France; [Dupont-Gossart, Anne-Claire; Fein, Francine] Univ Hosp Besancon, Dept Gastroenterol, Besancon, France; [Artru, Pascal] Hosp Jean Mermoz, Hepatogastroenterol & Digest Oncol Dept, Lyon, France; [Lecomte, Thierry] Trousseau Hosp, Univ Hosp Tours, Dept Gastroenterol & Digest Oncol, Chambray Les Tours, France; [Gauthier, Melanie] Ctr Georges Francois Leclerc, Biostat & Qual Life Unit, Dijon, France	Universite de Franche-Comte; CHU Besancon; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Europeen Georges-Pompidou - APHP; UDICE-French Research Universities; Universite Paris Cite; Universite de Franche-Comte; CHU Besancon; CHU Tours; UNICANCER; Centre Georges-Francois Leclerc	Anota, A (corresponding author), Natl Qual Life Oncol Platform, Besancon, France.	aanota@chu-besancon.fr		LECOMTE, Thierry/0000-0001-5093-0212; Zaanan, Aziz/0000-0001-8372-5653	Pfizer; AGEO; AROLD (Association pour la Recherche en Oncologie Digestive); French Public Health Research Institute	Pfizer(Pfizer); AGEO; AROLD (Association pour la Recherche en Oncologie Digestive); French Public Health Research Institute	Financial support for this research was provided by Pfizer, AGEO and AROLD (Association pour la Recherche en Oncologie Digestive). This study was also supported by a grant from the French Public Health Research Institute (http://www.iresp.net) under the 2012 call for projects as part of the 2009-2013 Cancer Plan. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	AARONSON NK, 1993, J NATL CANCER I, V85, P365, DOI 10.1093/jnci/85.5.365; [Anonymous], 2006, NCI COMMON TERMINOLO; Anota A, 2015, QUAL LIFE RES, V24, P5, DOI 10.1007/s11136-013-0583-6; Austin PC, 2013, STAT MED, V32, P2837, DOI 10.1002/sim.5705; Bernhard J, 2008, J CLIN ONCOL, V26, P3695, DOI 10.1200/JCO.2007.15.6240; Bonnetain F, 2012, EUR J CANCER, V48, P1781, DOI 10.1016/j.ejca.2012.03.016; Bonnetain F, 2010, EUR J CANCER, V46, P2753, DOI 10.1016/j.ejca.2010.07.023; Burris HA, 2013, CANCER-AM CANCER SOC, V119, P1908, DOI 10.1002/cncr.28010; Conroy T, 2011, NEW ENGL J MED, V364, P1817, DOI 10.1056/NEJMoa1011923; Cortes J, 2013, ANN ONCOL, V24, P2630, DOI 10.1093/annonc/mdt274; Curran D, 1998, STAT MED, V17, P739, DOI 10.1002/(SICI)1097-0258(19980315/15)17:5/7<739::AID-SIM818>3.0.CO;2-M; D'Agostino RB, 1998, STAT MED, V17, P2265, DOI 10.1002/(SICI)1097-0258(19981015)17:19<2265::AID-SIM918>3.0.CO;2-B; Fairclough DL, 2010, DESIGN AND ANALYSIS OF QUALITY OF LIFE STUDIES IN CLINICAL TRIALS, SECOND EDITION, P1, DOI 10.1201/9781420061185; Fairclough DL, 1998, STAT MED, V17, P667, DOI 10.1002/(SICI)1097-0258(19980315/15)17:5/7<667::AID-SIM813>3.0.CO;2-6; Fairclough DL, 1998, STAT MED, V17, P781, DOI 10.1002/(SICI)1097-0258(19980315/15)17:5/7<781::AID-SIM821>3.0.CO;2-O; Fayers P, 2001, EORTC QLQ C30 SCORIN, V3th; Fiteni F, 2014, J VISC SURG, V151, P17, DOI 10.1016/j.jviscsurg.2013.10.001; FLEMING TR, 1982, BIOMETRICS, V38, P143, DOI 10.2307/2530297; Gourgou-Bourgade S, 2013, J CLIN ONCOL, V31, P23, DOI 10.1200/JCO.2012.44.4869; Liao KJ, 2012, STAT MED, V31, P3444, DOI 10.1002/sim.5359; Little R. J. A., 1987, STAT ANAL MISSING DA; Little RJ, 2000, ANNU REV PUBL HEALTH, V21, P121, DOI 10.1146/annurev.publhealth.21.1.121; Little RJA, 1996, BIOMETRICS, V52, P98, DOI 10.2307/2533148; Moinpour CM, 2010, J CLIN ONCOL, V28, P3611, DOI 10.1200/JCO.2009.25.8285; Osoba D, 1998, J CLIN ONCOL, V16, P139, DOI 10.1200/JCO.1998.16.1.139; Pauler DK, 2003, STAT MED, V22, P795, DOI 10.1002/sim.1397; Ross L, 2004, J CLIN EPIDEMIOL, V57, P1131, DOI 10.1016/j.jclinepi.2004.03.010; Seaman SR, 2013, STAT METHODS MED RES, V22, P278, DOI 10.1177/0962280210395740; Seufferlein T, 2012, ANN ONCOL, V23, P33, DOI 10.1093/annonc/mds224; Sherman DW, 2005, APPL NURS RES, V18, P167, DOI 10.1016/j.apnr.2005.04.003; Team RDC, 2010, R LANG ENV STAT COMP; Therasse P, 2000, J NATL CANCER I, V92, P205, DOI 10.1093/jnci/92.3.205; Trojano M, 2009, Int MS J, V16, P90; Trouilloud I, 2014, EUR J CANCER, V50, P3116, DOI 10.1016/j.ejca.2014.09.015; Von Hoff DD, 2013, NEW ENGL J MED, V369, P1691, DOI 10.1056/NEJMoa1304369; Yang JCH, 2013, J CLIN ONCOL, V31, P3342, DOI 10.1200/JCO.2012.46.1764	36	3	3	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 26	2015	10	5							e0125350	10.1371/journal.pone.0125350	http://dx.doi.org/10.1371/journal.pone.0125350			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	CJ0QZ	26010884	Green Published, Green Submitted, gold			2023-01-03	WOS:000355183900012
J	Chang, YC; Yao, G; Hu, SC; Wang, JD				Chang, Yu-Chen; Yao, Grace; Hu, Susan C.; Wang, Jung-Der			Depression Affects the Scores of All Facets of the WHOQOL-BREF and May Mediate the Effects of Physical Disability among Community-Dwelling Older Adults	PLOS ONE			English	Article							QUALITY-OF-LIFE; MINI-MENTAL-STATE; BARTHEL INDEX; STROKE REHABILITATION; ALZHEIMERS-DISEASE; PEOPLE; PREVALENCE; TAIWAN; ADAPTATION; VALIDATION	Background Geriatric depression is associated with the overall quality of life (QOL). However, how depressive symptoms affect the different domains and facets of QOL in older adults, and whether depressive symptoms mediate the relationship between physical disability and QOL in older adults are unclear. Methods A total of 490 ambulatory community-dwelling older adults aged 65 years or above were interviewed using the brief version of the World Health Organisation Quality of Life instrument (WHOQOL-BREF), the Modified Barthel Index (MBI), the 15-item Geriatric Depression Scale (GDS-15), and the Mini-Mental State Examination (MMSE). Sequential models for multiple linear regressions were analysed to determine if the MBI, GDS-15 and MMSE scores predict the WHOQOL-BREF scores. The potential mediation effects of depression (as determined by the GDS-15) on the relationship between MBI and WHOQOL-BREF were also analysed. Results The GDS-15 score was predictive of the scores of the four domains and all 26 facets of the WHOQOL-BREF. The significant predictive effects of the MBI score on 15 of the 26 facets of the WHOQOL-BREF were reduced to three after the adjustment for the GDS-15 score. Depression (as assessed by the GDS-15) is a mediator of the relationship between MBI and the physical, psychological and environmental domains of the WHOQOL-BREF. Conclusions Depression (assessed by the GDS-15) may affect the scores of every domain and all facets of the WHOQOL-BREF in the elderly. Furthermore, it may mediate the relationship between the MBI and on QOL scores. We recommend taking depressive symptoms into consideration when measuring community-dwelling older adults' QOL and providing active ageing programs.	[Chang, Yu-Chen] Chia Yi Christian Hosp, Dept Community Hlth, Chiayi, Taiwan; [Chang, Yu-Chen] Chia Yi Christian Hosp, Div Geriatr, Chiayi, Taiwan; [Yao, Grace] Natl Taiwan Univ, Dept Psychol, Taipei 10764, Taiwan; [Hu, Susan C.; Wang, Jung-Der] Natl Cheng Kung Univ, Coll Med, Dept Publ Hlth, Tainan 70101, Taiwan; [Wang, Jung-Der] Natl Cheng Kung Univ, Dept Internal Med, Tainan 70101, Taiwan; [Wang, Jung-Der] Natl Cheng Kung Univ, Dept Occupt & Environm Med, Tainan 70101, Taiwan	National Taiwan University; National Cheng Kung University; National Cheng Kung University; National Cheng Kung University	Wang, JD (corresponding author), Natl Cheng Kung Univ, Coll Med, Dept Publ Hlth, Tainan 70101, Taiwan.	jdwang121@gmail.com	Hu, Susan C./AFU-5419-2022	Hu, Susan C./0000-0003-2437-5918	National Science Council [NSC 101-3114-Y-006-001]; Chia-Yi Christian Hospital [R102-6]	National Science Council(Ministry of Science and Technology, Taiwan); Chia-Yi Christian Hospital	JDW received the fund from National Science Council (NSC 101-3114-Y-006-001), and YCC received the fund from Chia-Yi Christian Hospital (R102-6). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Arslantas D, 2009, ARCH GERONTOL GERIAT, V48, P127, DOI 10.1016/j.archger.2007.11.005; BARON RM, 1986, J PERS SOC PSYCHOL, V51, P1173, DOI 10.1037/0022-3514.51.6.1173; Beekman ATF, 1999, BRIT J PSYCHIAT, V174, P307, DOI 10.1192/bjp.174.4.307; Berlim MT, 2007, PSYCHIAT RES, V153, P253, DOI 10.1016/j.psychres.2006.07.006; Black SA, 1999, J CLIN EPIDEMIOL, V52, P1095, DOI 10.1016/S0895-4356(99)00100-6; Bowling A, 2007, AGE AGEING, V36, P310, DOI 10.1093/ageing/afm023; Chan ACM, 1996, J AGING HEALTH, V8, P238, DOI 10.1177/089826439600800205; Chan SWC, 2009, INT PSYCHOGERIATR, V21, P1171, DOI 10.1017/S1041610209990950; Chong MY, 2001, BRIT J PSYCHIAT, V178, P29, DOI 10.1192/bjp.178.1.29; Chou KL, 2005, INT J GERIATR PSYCH, V20, P41, DOI 10.1002/gps.1246; Fang CT, 2002, QUAL LIFE RES, V11, P753, DOI 10.1023/A:1020870402019; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Garin N, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0111498; GRANGER CV, 1979, ARCH PHYS MED REHAB, V60, P14; GRANGER CV, 1979, ARCH PHYS MED REHAB, V60, P145; Harper A, 1998, PSYCHOL MED, V28, P551, DOI 10.1017/S0033291798006667; Hwang HF, 2003, AGE AGEING, V32, P593, DOI 10.1093/ageing/afg102; IsHak WW, 2011, HARVARD REV PSYCHIAT, V19, P229, DOI 10.3109/10673229.2011.614099; Jang Y, 2004, ARCH PHYS MED REHAB, V85, P1890, DOI 10.1016/j.apmr.2004.02.032; Kucukdeveci AA, 2000, SCAND J REHABIL MED, V32, P87; Lu IC, 2011, QUAL LIFE RES, V20, P1469, DOI 10.1007/s11136-011-9889-4; MAHONEY F I, 1965, Md State Med J, V14, P61; Marc LG, 2008, AM J GERIAT PSYCHIAT, V16, P914, DOI 10.1097/JGP.0b013e318186bd67; Netuveli G, 2006, J EPIDEMIOL COMMUN H, V60, P357, DOI 10.1136/jech.2005.040071; Preacher KJ, 2004, BEHAV RES METH INS C, V36, P717, DOI 10.3758/BF03206553; Rodda J, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d5219; Ruo B, 2003, JAMA-J AM MED ASSOC, V290, P215, DOI 10.1001/jama.290.2.215; SHAH S, 1989, J CLIN EPIDEMIOL, V42, P703, DOI 10.1016/0895-4356(89)90065-6; Sheikh JI, 1986, GERIATRIC DEPRESSION; Spering CC, 2012, J GERONTOL A-BIOL, V67, P890, DOI 10.1093/gerona/gls006; Strine TW, 2009, J NERV MENT DIS, V197, P61, DOI 10.1097/NMD.0b013e3181924ad8; TOMBAUGH TN, 1992, J AM GERIATR SOC, V40, P922, DOI 10.1111/j.1532-5415.1992.tb01992.x; Ward A, 2002, INT PSYCHOGERIATR, V14, P249, DOI 10.1017/S1041610202008451; Webb E, 2011, J EPIDEMIOL COMMUN H, V65, P542, DOI 10.1136/jech.2009.101758; World Health Organization (WHO), 2014, IMPROVING HLTH WORKP; Yao G, 2007, J FORMOS MED ASSOC, V106, P592, DOI 10.1016/S0929-6646(07)60012-6	36	34	34	1	24	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 26	2015	10	5							e0128356	10.1371/journal.pone.0128356	http://dx.doi.org/10.1371/journal.pone.0128356			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	CJ0QZ	26010571	Green Submitted, Green Published, gold			2023-01-03	WOS:000355183900229
J	Oye, K; Bubela, T; Lawson, JCH				Oye, Kenneth; Bubela, Tania; Lawson, J. Chappell H.			Regulate 'home-brew' opiates	NATURE			English	Editorial Material							SACCHAROMYCES-CEREVISIAE		[Oye, Kenneth; Lawson, J. Chappell H.] MIT, Dept Polit Sci, Cambridge, MA 02139 USA; [Bubela, Tania] Univ Alberta, Sch Publ Hlth, Res, Edmonton, AB, Canada	Massachusetts Institute of Technology (MIT); University of Alberta	Oye, K (corresponding author), MIT, Dept Polit Sci, Cambridge, MA 02139 USA.	oye@mit.edu	Bubela, Tania/F-4860-2014	Bubela, Tania/0000-0002-0807-2899				Baltimore D, 2015, SCIENCE, V348, P36, DOI 10.1126/science.aab1028; Beaudoin GAW., 2015, CHARACTERIZATION OXI, DOI [10.11575/PRISM/25284, DOI 10.11575/PRISM/25284]; Bubela T, 2012, TRENDS BIOTECHNOL, V30, P132, DOI 10.1016/j.tibtech.2011.10.003; DeLoache W. C, 2015, NATURE CHEM BIOL; Fossati E, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0124459; Fossati E, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4283; Hawkins KM, 2008, NAT CHEM BIOL, V4, P564, DOI 10.1038/nchembio.105; International Narcotics Control Board, 2011, REP INT NAR CONTR BO; Oye KA, 2014, SCIENCE, V345, P626, DOI 10.1126/science.1254287; Thodey K, 2014, NAT CHEM BIOL, V10, P837, DOI [10.1038/NCHEMBIO.1613, 10.1038/nchembio.1613]	10	18	19	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 21	2015	521	7552					281	283		10.1038/521281a	http://dx.doi.org/10.1038/521281a			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	CI5RM	25993942	Bronze			2023-01-03	WOS:000354816500029
J	Huang, CY; Hsu, TC; Kuo, WW; Liou, YF; Lee, SD; Ju, DT; Kuo, CH; Tzang, BS				Huang, Chih-Yang; Hsu, Tsai-Ching; Kuo, Wei-Wen; Liou, Yi-Fan; Lee, Shin-Da; Ju, Da-Tong; Kuo, Chia-Hua; Tzang, Bor-Show			The Root Extract of Gentiana macrophylla Pall. Alleviates Cardiac Apoptosis in Lupus Prone Mice	PLOS ONE			English	Article							RISK-FACTORS; CELL-DEATH; ERYTHEMATOSUS; CASPASES; DISEASE; GENTIOPICROSIDE; CARDIOMYOPATHY; SWERTIAMARIN; AUTOIMMUNITY; ARTHRITIS	The roots of the perennial herb Gentiana macrophylla Pall. (GM) are known as Qinjiao, which has been used for centuries to treat systemic lupus erythematosus (SLE). However, little is known about the effects of GM on cholesterol-aggravated cardiac abnormalities in SLE, and the mechanisms thereof. This study investigates whether GM exhibits anti-apoptotic effects, focusing on the left ventricle (LV) of NZB/WF1 mice fed with high-cholesterol diet. The morphology and apoptotic status of ventricular tissues were determined by microscopy and Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assay. Levels of apoptotic biomarkers were determined by immunoblotting. The results thus obtained revealed that GM significantly reduced the cholesterol-aggravated apoptosis of LV in NZB/W F1 mice by suppressing both intrinsic and extrinsic apoptotic pathways. Additionally, GM significantly increased the cardiac insulin-like growth factors (IGF)-1 survival signaling and anti-apoptotic proteins in LV tissues. Accordingly, GM is considered to be beneficial in alleviating cholesterol-aggravated cardiac damage in SLE, and therefore constitute an alternative treatment for SLE patients with cardiac abnormalities.	[Huang, Chih-Yang; Liou, Yi-Fan] China Med Univ, Grad Inst Basic Med Sci, Taichung, Taiwan; [Huang, Chih-Yang] Asia Univ, Dept Hlth & Nutr Biotechnol, Taichung, Taiwan; [Hsu, Tsai-Ching] Chung Shan Med Univ, Inst Microbiol & Immunol, Taichung, Taiwan; [Hsu, Tsai-Ching; Tzang, Bor-Show] Chung Shan Med Univ Hosp, Clin Lab, Taichung 40201, Taiwan; [Kuo, Wei-Wen] China Med Univ, Dept Biol Sci & Technol, Taichung, Taiwan; [Lee, Shin-Da] China Med Univ, Grad Inst Rehabil Sci, Dept Phys Therapy, Taichung, Taiwan; [Ju, Da-Tong] Triserv Gen Hosp, Natl Def Med Ctr, Dept Neurol Surg, Taipei, Taiwan; [Kuo, Chia-Hua] Univ Taipei, Dept Sports Sci, Taipei, Taiwan; [Tzang, Bor-Show] Chung Shan Med Univ, Inst Biochem & Biotechnol, Taichung, Taiwan; [Tzang, Bor-Show] Chung Shan Med Univ, Sch Med, Dept Biochem, Taichung, Taiwan	China Medical University Taiwan; Asia University Taiwan; Chung Shan Medical University; Chung Shan Medical University; Chung Shan Medical University Hospital; China Medical University Taiwan; China Medical University Taiwan; National Defense Medical Center; Tri-Service General Hospital; University of Taipei; Chung Shan Medical University; Chung Shan Medical University	Hsu, TC (corresponding author), Chung Shan Med Univ, Inst Microbiol & Immunol, Taichung, Taiwan.	htc@csmu.edu.tw; bstzang@csmu.edu.tw	Yuang, Chih-Yang/O-5111-2015; Lee, Shin-Da/Q-2798-2015	Lee, Shin-Da/0000-0002-8393-8349; Kuo, Chia-Hua/0000-0002-1731-4984; Bor-Show, Tzang/0000-0003-0140-9943	National Science Council; National Science Council, Taiwan, Republic of China [NSC-99-2632-B-040-001-MY3-(8)]; Chi-Mei Medical Center and Chung-Shan Medical University [CSMU-CMMC-103-01]; Taiwan Ministry of Health and Welfare Clinical Trial and Research Center of Excellence [DOH102-TD-B-111-004]	National Science Council(Ministry of Science and Technology, Taiwan); National Science Council, Taiwan, Republic of China(Ministry of Science and Technology, Taiwan); Chi-Mei Medical Center and Chung-Shan Medical University; Taiwan Ministry of Health and Welfare Clinical Trial and Research Center of Excellence	This work was funded by the National Science Council grants, from the National Science Council, Taiwan, Republic of China (NSC-99-2632-B-040-001-MY3-(8)) and supported in part by cooperated project of Chi-Mei Medical Center and Chung-Shan Medical University (CSMU-CMMC-103-01) and Taiwan Ministry of Health and Welfare Clinical Trial and Research Center of Excellence (DOH102-TD-B-111-004). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Asherson RA, 2002, ANN RHEUM DIS, V61, P859, DOI 10.1136/ard.61.9.859-a; Bjornadal L, 2004, J RHEUMATOL, V31, P713; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Broker LE, 2005, CLIN CANCER RES, V11, P3155, DOI 10.1158/1078-0432.CCR-04-2223; Cao XY, 2010, PHYTOCHEM ANALYSIS, V21, P348, DOI 10.1002/pca.1206; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Esdaile JM, 2001, ARTHRITIS RHEUM, V44, P2331, DOI 10.1002/1529-0131(200110)44:10<2331::AID-ART395>3.0.CO;2-I; Greco CM, 2013, CURR RHEUMATOL REP, V15, DOI 10.1007/s11926-013-0378-3; Hahn BH, 1993, DUBOIS LUPUS ERYTHEM, P69; Hsu TC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068393; Huang CY, 2009, J AGR FOOD CHEM, V57, P8635, DOI 10.1021/jf9020625; Jahns R, 2008, AUTOIMMUNITY, V41, P454, DOI 10.1080/08916930802031603; Jia N, 2012, J ETHNOPHARMACOL, V144, P638, DOI 10.1016/j.jep.2012.10.004; Kelekar A, 1998, TRENDS CELL BIOL, V8, P324, DOI 10.1016/S0962-8924(98)01321-X; KONDO Y, 1994, PLANTA MED, V60, P414, DOI 10.1055/s-2006-959521; Kwak WJ, 2005, BIOL PHARM BULL, V28, P750, DOI 10.1248/bpb.28.750; Li Long-yun, 2001, Zhongguo Zhongyao Zazhi, V26, P808; Lorenz HM, 2000, APOPTOSIS, V5, P443, DOI 10.1023/A:1009692902805; Manzi S, 1997, AM J EPIDEMIOL, V145, P408; Mease PJ, 2000, LANCET, V356, P385, DOI 10.1016/S0140-6736(00)02530-7; PETRI M, 1992, AM J MED, V93, P513, DOI 10.1016/0002-9343(92)90578-Y; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Tincani A, 2006, RHEUMATOLOGY, V45, P8, DOI 10.1093/rheumatology/kel308; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Tsai CC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059724; Tzang BS, 2012, J CELL MOL MED, V16, P2104, DOI 10.1111/j.1582-4934.2011.01511.x; UROWITZ MB, 1976, AM J MED, V60, P221, DOI 10.1016/0002-9343(76)90431-9; WAN ASC, 1971, PLANTA MED, V19, P203, DOI 10.1055/s-0028-1099632; Xu Rui-Sheng, 2009, Zhongguo Gu Shang, V22, P920; YAMAHARA J, 1978, YAKUGAKU ZASSHI, V98, P1446, DOI 10.1248/yakushi1947.98.11_1446; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; Yang S, 1998, DIVINE FARMERS MATER, P341; Yu FR, 2004, J ETHNOPHARMACOL, V95, P77, DOI 10.1016/j.jep.2004.06.025; Yuan Z Z, 1989, Zhong Xi Yi Jie He Za Zhi, V9, P156; Zhao P, 2009, FRONT BIOSCI-LANDMRK, V14, P1708, DOI 10.2741/3334; Zhao SG, 2004, BIOMED CHROMATOGR, V18, P10, DOI 10.1002/bmc.285	36	9	9	1	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 18	2015	10	5							e0127440	10.1371/journal.pone.0127440	http://dx.doi.org/10.1371/journal.pone.0127440			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CI7BG	25985203	Green Published, gold, Green Submitted			2023-01-03	WOS:000354917300125
J	Ussher, M; Lewis, S; Aveyard, P; Manyonda, I; West, R; Lewis, B; Marcus, B; Riaz, M; Taylor, A; Daley, A; Coleman, T				Ussher, Michael; Lewis, Sarah; Aveyard, Paul; Manyonda, Isaac; West, Robert; Lewis, Beth; Marcus, Bess; Riaz, Muhammad; Taylor, Adrian; Daley, Amanda; Coleman, Tim			Physical activity for smoking cessation in pregnancy: randomised controlled trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article							UNITED-STATES; EXERCISE; WOMEN; AID; PREVALENCE; DEPRESSION; EFFICACY; TOBACCO	OBJECTIVE To determine the effectiveness of a physical activity intervention for smoking cessation during pregnancy. DESIGN Parallel group, randomised controlled, multicentre trial. SETTING 13 hospitals in England, April 2009 to January 2014. PARTICIPANTS 789 pregnant smokers, aged 16-50 years and at 10-24 weeks' gestation, who smoked at least one cigarette daily and were prepared to quit smoking one week after enrollment were randomised (1:1); 785 were included in the intention to treat analyses, with 392 assigned to the physical activity group. INTERVENTIONS Interventions began one week before a target quit date. Participants were randomised to six weekly sessions of behavioural support for smoking cessation (control) or to this support plus 14 sessions combining supervised treadmill exercise and physical activity consultations. MAINOUTCOME MEASURES The primary outcome was continuous smoking abstinence from the target quit date until end of pregnancy, validated by exhaled carbon monoxide or salivary cotinine levels. To assess adherence, levels of moderate-vigorous intensity physical activity were self reported and in a 11.5% (n=90) random subsample of participants, physical activity was objectively measured by an accelerometer. RESULTS No significant difference was found in rates of smoking abstinence at end of pregnancy between the physical activity and control groups (8% v 6%; odds ratio 1.21, 95% confidence interval 0.70 to 2.10). For the physical activity group compared with the control group, there was a 40% (95% confidence interval 13% to 73%), 34% (6% to 69%), and 46% (12% to 91%) greater increase in self reported minutes carrying out physical activity per week from baseline to one week, four weeks, and six weeks post-quit day, respectively. According to the accelerometer data there was no significant difference in physical activity levels between the groups. Participants attended a median of four treatment sessions in the intervention group and three in the control group. Adverse events and birth outcomes were similar between the two groups, except for significantly more caesarean births in the control group than in the physical activity group (29% v 21%, P=0.023). CONCLUSION Adding a physical activity intervention to behavioural smoking cessation support for pregnant women did not increase cessation rates at end of pregnancy. During pregnancy, physical activity is not recommended for smoking cessation but remains indicated for general health benefits.	[Ussher, Michael; Riaz, Muhammad] St Georges Univ London, Populat Hlth Res Inst, London SW17 ORE, England; [Lewis, Sarah] Univ Nottingham, Div Epidemiol & Publ Hlth, Nottingham NG7 2RD, England; [Lewis, Sarah; Coleman, Tim] Univ Nottingham, UK Ctr Tobacco & Alcohol Studies, Nottingham NG7 2RD, England; [Aveyard, Paul] Univ Oxford, Nuffield Dept Primary Care Hlth Sci, Oxford, England; [Manyonda, Isaac] St Georges Univ London, Dept Obstet & Gynaecol, London SW17 ORE, England; [Manyonda, Isaac] St Georges NHS Trust, London, England; [West, Robert] UCL, Dept Epidemiol & Publ Hlth, Hlth Behav Res Ctr, London, England; [Lewis, Beth] Univ Minnesota, Sch Kinesiol, Minneapolis, MN USA; [Marcus, Bess] Univ Calif San Diego, Dept Family & Prevent Med, San Diego, CA 92103 USA; [Taylor, Adrian] Univ Plymouth, Peninsula Sch Med & Dent, Plymouth PL4 8AA, Devon, England; [Daley, Amanda] Univ Birmingham, Primary Care Clin Sci, Birmingham, W Midlands, England; [Coleman, Tim] Univ Nottingham, Div Primary Care, Nottingham NG7 2RD, England	St Georges University London; University of Nottingham; University of Nottingham; University of Oxford; St Georges University London; University of London; University College London; University of Minnesota System; University of Minnesota Twin Cities; University of California System; University of California San Diego; University of Plymouth; University of Birmingham; University of Nottingham	Ussher, M (corresponding author), St Georges Univ London, Populat Hlth Res Inst, London SW17 ORE, England.	mussher@sgul.ac.uk	Riaz, Muhammad/AAA-5500-2021; Taylor, Adrian/GME-5077-2022; West, Robert/B-5414-2009	Riaz, Muhammad/0000-0002-5512-1745; Taylor, Adrian/0000-0003-2701-9468; Aveyard, Paul/0000-0002-1802-4217; Coleman, Tim/0000-0002-7303-4805; Ussher, Michael/0000-0002-0995-7955; West, Robert/0000-0001-6398-0921	NIHR health technology assessment programme [07.01.14]; Cancer Research UK [14135] Funding Source: researchfish; Economic and Social Research Council [ES/G007489/1] Funding Source: researchfish; Medical Research Council [MR/K023195/1, MR/K023195/1B] Funding Source: researchfish; National Institute for Health Research [07/01/14] Funding Source: researchfish	NIHR health technology assessment programme(National Institute for Health Research (NIHR)); Cancer Research UK(Cancer Research UK); Economic and Social Research Council(UK Research & Innovation (UKRI)Economic & Social Research Council (ESRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); National Institute for Health Research(National Institute for Health Research (NIHR))	This study was funded by the NIHR health technology assessment programme (grant 07.01.14). The funder had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.	Affonso DD, 2000, J PSYCHOSOM RES, V49, P207, DOI 10.1016/S0022-3999(00)00176-8; Al-Sahab B, 2010, BMC PREGNANCY CHILDB, V10, DOI 10.1186/1471-2393-10-24; Babor T.F., 1992, AUDIT ALCOHOL USE DI; BLAIR SN, 1985, AM J EPIDEMIOL, V122, P794, DOI 10.1093/oxfordjournals.aje.a114163; Chamberlain Catherine, 2013, Cochrane Database Syst Rev, pCD001055, DOI 10.1002/14651858.CD001055.pub4; Coleman T, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010078; Coleman T, 2012, NEW ENGL J MED, V366, P808, DOI 10.1056/NEJMoa1109582; Domenjoz I, 2014, AM J OBSTET GYNECOL, V211, DOI 10.1016/j.ajog.2014.03.030; FERGUSSON D, 2002, BMJ-BRIT MED J, V325, P652, DOI DOI 10.1136/BMJ.325.7365.652; Garber CE, 2011, MED SCI SPORT EXER, V43, P1334, DOI 10.1249/MSS.0b013e318213fefb; Gates S, 2004, BJOG-INT J OBSTET GY, V111, P213, DOI 10.1111/j.1471-0528.2004.00059.x; Gavin NI, 2005, OBSTET GYNECOL, V106, P1071, DOI 10.1097/01.AOG.0000183597.31630.db; Haasova M, 2013, ADDICTION, V108, P26, DOI 10.1111/j.1360-0443.2012.04034.x; Hajek P, 2001, ADDICTION, V96, P485, DOI 10.1046/j.1360-0443.2001.96348511.x; Harrison CL, 2011, INT J BEHAV NUTR PHY, V8, DOI 10.1186/1479-5868-8-19; HEATHERTON TF, 1991, BRIT J ADDICT, V86, P1119; Hedeker D, 2007, ADDICTION, V102, P1564, DOI 10.1111/j.1360-0443.2007.01946.x; Kallen K, 2001, EUR J PUBLIC HEALTH, V11, P329, DOI 10.1093/eurpub/11.3.329; Lumley J, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001055.pub3; Marcus BH, 1999, ARCH INTERN MED, V159, P1229, DOI 10.1001/archinte.159.11.1229; MARCUS BH, 1992, RES Q EXERCISE SPORT, V63, P60, DOI 10.1080/02701367.1992.10607557; Matthey S, 2004, J AFFECT DISORDERS, V78, P269, DOI 10.1016/S0165-0327(02)00313-0; Michie S, 2011, ADDICT BEHAV, V36, P315, DOI 10.1016/j.addbeh.2010.11.016; Murray D., 1990, J REPROD INFANT PSYC, V8, P99, DOI [DOI 10.1080/02646839008403615, 10.1080/02646839008403615]; NHS Information Centre, 2011, INF FEED SURV 2010 E; Richmond R, 2003, ADDICTION, V98, P553, DOI 10.1046/j.1360-0443.2003.00342.x; Rogers JM, 2009, REPROD TOXICOL, V28, P152, DOI 10.1016/j.reprotox.2009.03.012; Salihu HM, 2007, EARLY HUM DEV, V83, P713, DOI 10.1016/j.earlhumdev.2007.08.002; Tong VT, 2013, MMWR SURVEILL SUMM, V62, P1; Troiano RP, 2008, MED SCI SPORT EXER, V40, P181, DOI 10.1249/mss.0b013e31815a51b3; Ussher M, 2013, PSYCHOPHARMACOLOGY, V226, P83, DOI 10.1007/s00213-012-2886-7; Ussher M, 2012, TRIALS, V13, DOI 10.1186/1745-6215-13-186; Ussher M, 2008, BMC PUBLIC HEALTH, V8, DOI 10.1186/1471-2458-8-328; Ussher M, 2007, J SMOK CESS, V2, P12, DOI 10.1375/jsc.2.1.12; Ussher MH, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002295.pub3; West R, 2005, ADDICTION, V100, P299, DOI 10.1111/j.1360-0443.2004.00995.x; West R, 1998, PSYCHOPHARMACOLOGY, V136, P201, DOI 10.1007/s002130050557; WEST RJ, 1985, PSYCHOPHARMACOLOGY, V87, P334, DOI 10.1007/BF00432717	38	37	38	0	19	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 14	2015	350								h2145	10.1136/bmj.h2145	http://dx.doi.org/10.1136/bmj.h2145			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	CI5CI	25976288	hybrid, Green Published, Green Accepted			2023-01-03	WOS:000354770100004
J	McCartney, M				McCartney, Margaret			Margaret McCartney: Daily drug shortages place avoidable pressure on primary care	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material													mccartney, margaret/AAR-4727-2020	McCartney, Margaret/0000-0002-7238-6358				All-Party Pharmacy Group, 2012, REP APPG INQ MED SHO; All-Party Pharmacy Group, 2015, ACT NEW GOV 1 100 DA; [Anonymous], 2015, Drug Ther Bull, V53, P33, DOI 10.1136/dtb.2015.3.0316; Gu A, 2011, INOV PHARM, V2; Koba M, 2015, FORBES MAGAZINE; Torjesen I., 2015, PHARM J	6	3	3	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 11	2015	350								h2514	10.1136/bmj.h2514	http://dx.doi.org/10.1136/bmj.h2514			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CI5BT	25964678	Bronze			2023-01-03	WOS:000354768600013
J	McNabb, M; Chukwu, E; Ojo, O; Shekhar, N; Gill, CJ; Salami, H; Jega, F				McNabb, Marion; Chukwu, Emeka; Ojo, Oluwayemisi; Shekhar, Navendu; Gill, Christopher J.; Salami, Habeeb; Jega, Farouk			Assessment of the Quality of Antenatal Care Services Provided by Health Workers Using a Mobile Phone Decision Support Application in Northern Nigeria: A Pre/Post-Intervention Study	PLOS ONE			English	Article								Background Given the shortage of skilled healthcare providers in Nigeria, frontline community health extension workers (CHEWs) are commonly tasked with providing maternal and child health services at primary health centers. In 2012, we introduced a mobile case management and decision support application in twenty primary health centers in northern Nigeria, and conducted a pre-test/post-test study to assess whether the introduction of the app had an effect on the quality of antenatal care services provided by this lower-level cadre. Methods Using the CommCare mobile platform, the app dynamically guides CHEWs through antenatal care protocols and collects client data in real time. Thirteen health education audio clips are also embedded in the app for improving and standardizing client counseling. To detect changes in quality, we developed an evidence-based quality score consisting of 25 indicators, and conducted a total of 266 client exit interviews. We analyzed baseline and endline data to assess changes in the overall quality score as well as changes in the provision of key elements of antenatal care. Results Overall, the quality score increased from 13.3 at baseline to 17.2 at endline (p<0.0001), out of a total possible score of 25, with the most significant improvements related to health counseling, technical services provided, and quality of health education. Conclusion These study results suggest that the introduction of a low-cost mobile case management and decision support application can spur behavior change and improve the quality of services provided by a lower level cadre of healthcare workers. Future research should employ a more rigorous experimental design to explore potential longer-term effects on client health outcomes.	[McNabb, Marion; Shekhar, Navendu] Pathfinder Int, Watertown, MA 02472 USA; [Chukwu, Emeka; Ojo, Oluwayemisi; Salami, Habeeb; Jega, Farouk] Pathfinder Int Nigeria, Abuja, Nigeria; [Gill, Christopher J.] Boston Univ, Sch Publ Hlth, Boston, MA 02215 USA	Boston University	McNabb, M (corresponding author), Pathfinder Int, Watertown, MA 02472 USA.	mmcnabb@pathfinder.org		gill, christopher/0000-0003-3353-0617; Chukwu, Emeka/0000-0003-3474-8108	Pathfinder International Advisory Board	Pathfinder International Advisory Board	The Pathfinder International Advisory Board funded this project and research study.	Boller C, 2003, B WHO, V81; Chatfield A, 2013, COM MCARE EV BAS; DeRenzi B, 2008, E IMCI IMPROVING PED; DeRenzi B, 2011, MT SINAI J MED, V78, P406, DOI 10.1002/msj.20256; Dimagi Inc, 2014, COMMCARE HQ; Florez-Arango JF, 2011, J AM MED INFORM ASSN, V18, P131, DOI 10.1136/jamia.2010.010025; ICF Macro International; National Population Commission N, 2008, NIG DEM HLTH SURV 20; Lincetto O, ANTENATAL CARE, P51; Medhi I, 2012, P 7 NORD C HUM COMP, V12, P635; Mitchell M, 2012, INT J MED INFORM, V81, P166, DOI 10.1016/j.ijmedinf.2011.11.003; NCC, 2013, TELECOMS SUBSCRIBERS; Pathfinder International, 2011, MAT HLTH CAR IMPR IN; Tetui M, 2012, PAN AFR MED J, V13; WHO, NIG LAUNCH SAV ON MI; WHO, 2010, TRENDS MAT MORT 1990; Zurovac D, 2011, LANCET, V378, P795, DOI 10.1016/S0140-6736(11)60783-6	16	40	40	0	18	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 5	2015	10	5							e0123940	10.1371/journal.pone.0123940	http://dx.doi.org/10.1371/journal.pone.0123940			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CH3PT	25942018	Green Published, gold, Green Submitted			2023-01-03	WOS:000353943400009
J	Misic, VV; Chan, TCY				Misic, Velibor V.; Chan, Timothy C. Y.			The Perils of Adapting to Dose Errors in Radiation Therapy	PLOS ONE			English	Article							IMRT OPTIMIZATION; ORGAN MOTION; RADIOTHERAPY; PATIENT; SETUP; IMPLEMENTATION; COMPENSATION; ALGORITHM; DELIVERY; CANCER	We consider adaptive robust methods for lung cancer that are also dose-reactive, wherein the treatment is modified after each treatment session to account for the dose delivered in prior treatment sessions. Such methods are of interest because they potentially allow for errors in the delivered dose to be corrected as the treatment progresses, thereby ensuring that the tumor receives a sufficient dose at the end of the treatment. We show through a computational study with real lung cancer patient data that while dose reaction is beneficial with respect to the final dose distribution, it may lead to exaggerated daily underdose and overdose relative to non-reactive methods that grows as the treatment progresses. However, by combining dose reaction with a mechanism for updating an estimate of the uncertainty, the magnitude of this growth can be mitigated substantially. The key finding of this paper is that reacting to dose errors - an adaptation strategy that is both simple and intuitively appealing - may backfire and lead to treatments that are clinically unacceptable.	[Misic, Velibor V.] MIT, Ctr Operat Res, Cambridge, MA 02139 USA; [Chan, Timothy C. Y.] Univ Toronto, Dept Mech & Ind Engn, Toronto, ON, Canada	Massachusetts Institute of Technology (MIT); University of Toronto	Misic, VV (corresponding author), MIT, Ctr Operat Res, Cambridge, MA 02139 USA.	vvmisic@mit.edu			NSERC [398106-2011]; CIHR	NSERC(Natural Sciences and Engineering Research Council of Canada (NSERC)); CIHR(Canadian Institutes of Health Research (CIHR))	Collaborative Health Research Projects Grant 398106-2011, sponsored by NSERC (http:// www.nserc-crsng.gc.ca) and CIHR (http://www.cihrirsc.gc.ca), received by TCYC (Principal Investigator) and VVM (advisee of TCYC during time of research). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 2011, IIE T HEALTHC SYST E; Birkner M, 2003, MED PHYS, V30, P2822, DOI 10.1118/1.1610751; BORTFELD T, 1993, MED PHYS, V20, P311, DOI 10.1118/1.597070; Bortfeld T, 2008, OPER RES, V56, P1461, DOI 10.1287/opre.1070.0484; Chan TCY, 2006, PHYS MED BIOL, V51, P2567, DOI 10.1088/0031-9155/51/10/014; Chan TCY, 2013, EUR J OPER RES, V231, P745, DOI 10.1016/j.ejor.2013.06.003; de la Zerda A, 2007, PHYS MED BIOL, V52, P4137, DOI 10.1088/0031-9155/52/14/008; Deng G, 2008, SPRINGER SER OPTIM A, V12, P47; Dink D, 2011, AM J OPER RES, V1, P160, DOI [10.4236/ajor.2011.13018, DOI 10.4236/AJOR.2011.13018]; Ebert MA, 2000, PHYS MED BIOL, V45, P441, DOI 10.1088/0031-9155/45/2/313; Ferris MC, 2004, MATH PROGRAM, V101, P387, DOI 10.1007/s10107-004-0530-y; Lof J, 1998, PHYS MED BIOL, V43, P1605, DOI 10.1088/0031-9155/43/6/018; Lu WG, 2006, PHYS MED BIOL, V51, P4357, DOI 10.1088/0031-9155/51/17/015; Lujan AE, 1999, MED PHYS, V26, P715, DOI 10.1118/1.598577; Mar PA, 2015, PHYS MED BIOL, V60, P3599, DOI 10.1088/0031-9155/60/9/3599; Misic VV, 2012, THESIS U TORONTO; Mohan R, 2005, INT J RADIAT ONCOL, V61, P1258, DOI 10.1016/j.ijrobp.2004.11.033; Rehbinder H, 2004, MED PHYS, V31, P3363, DOI 10.1118/1.1809768; Sir MY, 2012, ANN OPER RES, V196, P767, DOI 10.1007/s10479-010-0779-x; Trofimov A, 2005, PHYS MED BIOL, V50, P2779, DOI 10.1088/0031-9155/50/12/004; Webb S, 2008, PHYS MED BIOL, V53, P1, DOI 10.1088/0031-9155/53/1/001; Wu QW, 2006, PHYS MED BIOL, V51, P1405, DOI 10.1088/0031-9155/51/6/003; Yan D, 1997, PHYS MED BIOL, V42, P123, DOI 10.1088/0031-9155/42/1/008; Yan D, 1997, INT J RADIAT ONCOL, V38, P197, DOI 10.1016/S0360-3016(97)00229-0; Yan D, 1998, INT J RADIAT ONCOL, V41, P715, DOI 10.1016/S0360-3016(97)00567-1	25	6	6	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 5	2015	10	5							e0125335	10.1371/journal.pone.0125335	http://dx.doi.org/10.1371/journal.pone.0125335			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CH3PT	25942407	Green Published, gold, Green Submitted			2023-01-03	WOS:000353943400030
J	Lin, YW; Chen, CC; Lin, LC; Lee, SP				Lin, Yu-Wei; Chen, Chia-Chun; Lin, Li-Ching; Lee, Steve P.			The Impact of Reduced-Volume, Intensity-Modulated Radiation Therapy on Disease Control in Nasopharyngeal Carcinoma	PLOS ONE			English	Article							NECK-CANCER; CLINICAL-OUTCOMES; TARGET VOLUMES; RADIOTHERAPY; HEAD; EXPERIENCE; PATTERNS; FAILURE; IRRADIATION; DELINEATION	Objective To investigate the feasibility of using intensity-modulated radiotherapy (IMRT) with reduced, high-dose target volumes for nasopharyngeal carcinoma (NPC). Methods The first 57 patients (admitted from October 2005 to May 2008) were treated with large-target-volume IMRT (LV-IMRT). For the LV-IMRT group, the CTV at 70 Gy (CTV70) was delineated as the gross target volume (GTV) plus 7mm, with or without the first-echelon lymphnode region. The next 56 patients (admitted from June 2008 to November 2011) were treated with reduced-target-volume IMRT (RV-IMRT). For the RV-IMRT group, the CTV70 was delineated as the GTV alone. Results The 4-year local recurrence-free, regional recurrence-free, distant metastasis-free, progression-free, and overall survival rates were 77.2%, 80.1%, 83.2%, 61.2%, and 74.4% for the LV-IMRT group and 83.5%, 92.6%, 89.1%, 78.5, and 91.0% for the RV-IMRT group, respectively. Late toxicity scoring of xerostomia was lesser in the RV-IMRT group than the LV-IMRT group (P < 0.001). Conclusions The use of RV-IMRT for the treatment of NPC did not negatively affect survival rates but did reduce the late xerostomia events compared to LV-IMRT.	[Lin, Yu-Wei; Lin, Li-Ching] Chi Mei Med Ctr, Dept Radiat Oncol, Tainan, Taiwan; [Lin, Yu-Wei] Natl Sun Yat Sen Univ, Inst Biomed Sci, Kaohsiung 80424, Taiwan; [Lin, Yu-Wei] Kaohsiung Med Univ, Sch Med, Kaohsiung, Taiwan; [Chen, Chia-Chun] Chi Mei Med Ctr, Dept Radiat Oncol, Tainan, Taiwan; [Lin, Li-Ching] Taipei Med Univ, Sch Med, Taipei, Taiwan; [Lee, Steve P.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Radiat Oncol, Los Angeles, CA 90095 USA; [Lee, Steve P.] VA Greater Los Angeles Healthcare Syst, Dept Radiat Oncol, Los Angeles, CA USA	Chi Mei Hospital; National Sun Yat Sen University; Kaohsiung Medical University; Chi Mei Hospital; Taipei Medical University; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Greater Los Angeles Healthcare System	Lin, YW (corresponding author), Chi Mei Med Ctr, Dept Radiat Oncol, Tainan, Taiwan.	marklin1108@gmail.com; splee@mednet.ucla.edu	Lee, Steve Pai-hsun/AAU-8313-2020	Lee, Steve Pai-hsun/0000-0001-7168-1542				Apisarnthanarax S, 2006, INT J RADIAT ONCOL, V64, P678, DOI 10.1016/j.ijrobp.2005.08.020; Cannon DM, 2008, INT J RADIAT ONCOL, V70, P660, DOI 10.1016/j.ijrobp.2007.09.018; Cao CN, 2013, ORAL ONCOL, V49, P175, DOI 10.1016/j.oraloncology.2012.08.013; Caudell JJ, 2010, INT J RADIAT ONCOL, V76, P164, DOI 10.1016/j.ijrobp.2009.01.037; Chao KSC, 2002, INT J RADIAT ONCOL, V53, P1174, DOI 10.1016/S0360-3016(02)02881-X; Chen JZ, 2013, INT J RADIAT ONCOL, V85, P929, DOI 10.1016/j.ijrobp.2012.07.2356; Fang FM, 2008, INT J RADIAT ONCOL, V72, P356, DOI 10.1016/j.ijrobp.2007.12.054; Gregoire Vincent, 2003, Rays, V28, P217; HO JHC, 1978, INT J RADIAT ONCOL, V4, P182; Kam MKM, 2007, J CLIN ONCOL, V25, P4873, DOI 10.1200/JCO.2007.11.5501; Kam MKM, 2004, INT J RADIAT ONCOL, V60, P1440, DOI 10.1016/j.ijrobp.2004.05.022; Kong FF, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091362; Lee AWM, 2013, INT J RADIAT ONCOL, V85, P902, DOI 10.1016/j.ijrobp.2012.09.010; Lee AWM, 2012, RADIOTHER ONCOL, V104, P272, DOI 10.1016/j.radonc.2012.08.001; LEE AWM, 1992, INT J RADIAT ONCOL, V23, P261, DOI 10.1016/0360-3016(92)90740-9; Lee N, 2003, INT J RADIAT ONCOL, V57, P49, DOI 10.1016/S0360-3016(03)00405-X; LEE N, 2002, MACWORLD         FEB, P15; Lee N, 2013, TARGET VOLUME DELINE, P1; Lee N, 2009, J CLIN ONCOL, V27, P3684, DOI 10.1200/JCO.2008.19.9109; Lee NY, 2012, LANCET ONCOL, V13, P172, DOI 10.1016/S1470-2045(11)70303-5; Liao XB, 2008, INT J RADIAT ONCOL, V72, P1368, DOI 10.1016/j.ijrobp.2008.03.017; Lin SJ, 2009, INT J RADIAT ONCOL, V75, P1071, DOI 10.1016/j.ijrobp.2008.12.015; Martinez-Monge R, 1999, RADIOLOGY, V211, P815, DOI 10.1148/radiology.211.3.r99jn40815; Ng WT, 2008, INT J RADIAT ONCOL, V72, P1082, DOI 10.1016/j.ijrobp.2008.02.006; Ng WT, 2011, INT J RADIAT ONCOL, V79, P420, DOI 10.1016/j.ijrobp.2009.11.024; Peng G, 2012, RADIOTHER ONCOL, V104, P286, DOI 10.1016/j.radonc.2012.08.013; Teo P, 1996, INT J RADIAT ONCOL, V36, P291, DOI 10.1016/S0360-3016(96)00323-9; Tham IWK, 2009, INT J RADIAT ONCOL, V75, P1481, DOI 10.1016/j.ijrobp.2009.01.018; Toledano I, 2012, RADIOTHER ONCOL, V103, P57, DOI 10.1016/j.radonc.2011.12.010; Vergeer MR, 2009, INT J RADIAT ONCOL, V74, P1, DOI 10.1016/j.ijrobp.2008.07.059; WITHERS HR, 1995, INT J RADIAT ONCOL, V31, P353, DOI 10.1016/0360-3016(94)00354-N; Wolden SL, 2006, INT J RADIAT ONCOL, V64, P57, DOI 10.1016/j.ijrobp.2005.03.057	32	5	7	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 28	2015	10	4							e0125283	10.1371/journal.pone.0125283	http://dx.doi.org/10.1371/journal.pone.0125283			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CG9SE	25919285	Green Published, gold			2023-01-03	WOS:000353659400079
J	Hadanny, A; Fishlev, G; Bechor, Y; Bergan, J; Friedman, M; Maliar, A; Efrati, S				Hadanny, Amir; Fishlev, Gregori; Bechor, Yair; Bergan, Jacob; Friedman, Mony; Maliar, Amit; Efrati, Shai			Delayed Recompression for Decompression Sickness: Retrospective Analysis	PLoS One			English	Article							HYPERBARIC-OXYGEN; REPERFUSION INJURY; ISCHEMIA; ILLNESS; TIME; MECHANISMS; SEVERITY; EXPOSURE; THERAPY; TISSUES	Introduction Most cases of decompression sickness (DCS) occur soon after surfacing, with 98% within 24 hours. Recompression using hyperbaric chamber should be administrated as soon as feasible in order to decrease bubble size and avoid further tissue injury. Unfortunately, there may be a significant time delay from surfacing to recompression. The time beyond which hyperbaric treatment is non effective is unclear. The aims of the study were first to evaluate the effect of delayed hyperbaric treatment, initiated more than 48h after surfacing for DCS and second, to evaluate the different treatment protocols. Methods From January 2000 to February 2014, 76 divers had delayed hyperbaric treatment (>= 48h) for DCS in the Sagol center for Hyperbaric medicine and Research, Assaf-Harofeh Medical Center, Israel. Data were collected from their medical records and compared to data of 128 patients treated earlier than 48h after surfacing at the same hyperbaric institute. Results There was no significant difference, as to any of the baseline characteristics, between the delayed and early treatment groups. With respect to treatment results, at the delayed treatment divers, complete recovery was achieved in 76% of the divers, partial recovery in 17.1% and no improvement in 6.6%. Similar results were achieved when treatment started early, where 78% of the divers had complete recovery, 15.6% partial recovery and 6.2% no recovery. Delayed hyperbaric treatment using US Navy Table 6 protocol trended toward a better clinical outcome yet not statistically significant (OR=2.786, CI95%[0.896-8.66], p=0.07) compared to standard hyperbaric oxygen therapy of 90 minutes at 2 ATA, irrespective of the symptoms severity at presentation. Conclusions Late recompression for DCS, 48 hours or more after surfacing, has clinical value and when applied can achieve complete recovery in 76% of the divers. It seems that the preferred hyperbaric treatment protocol should be based on US Navy Table 6.	[Hadanny, Amir; Fishlev, Gregori; Bechor, Yair; Bergan, Jacob; Friedman, Mony; Maliar, Amit; Efrati, Shai] Assaf Harofeh Med Ctr, Sagol Ctr Hyperbar Med & Res, IL-70300 Zerifin, Israel; [Hadanny, Amir; Efrati, Shai] Tel Aviv Univ, Sackler Sch Med, IL-69978 Tel Aviv, Israel; [Efrati, Shai] Assaf Harofeh Med Ctr, Res & Dev Unit, IL-70300 Zerifin, Israel; [Efrati, Shai] Tel Aviv Univ, Sagol Sch Neurosci, IL-69978 Tel Aviv, Israel	Shamir Medical Center (Assaf Harofeh); Tel Aviv University; Tel Aviv University; Sackler Faculty of Medicine; Shamir Medical Center (Assaf Harofeh); Tel Aviv University; Tel Aviv University	Hadanny, A (corresponding author), Assaf Harofeh Med Ctr, Sagol Ctr Hyperbar Med & Res, IL-70300 Zerifin, Israel.	amir.had@gmail.com						[Anonymous], 1979, P 16 ANN SCI M EUR U, V28, P1; BALL R, 1993, UNDERSEA HYPERBAR M, V20, P133; Blatteau JE, 2011, DIVING HYPERB MED, V41, P129; Bosco G, 2001, UNDERSEA HYPERBAR M, V28, P207; Boussi-Gross R, 2014, NEUROPSYCHOLOGY; Boussi-Gross R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079995; Boussuges A, 1996, UNDERSEA HYPERBAR M, V23, P151; Buras JA, 2007, NEUROL RES, V29, P127, DOI 10.1179/016164107X174147; Burls A, 2011, EMERG MED J, V28, P917, DOI 10.1136/emj.2010.103564; Desola J, 1997, P 23 ANN SCI M EUR U; Efrati S, 2014, UNDERSEA HYPERBAR M, V41, P71; Efrati S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053716; Freiberger JJ, 2002, AVIAT SPACE ENVIR MD, V73, P980; Gempp E, 2010, J CRIT CARE, V25, P236, DOI 10.1016/j.jcrc.2009.05.011; Gill AL, 2004, QJM-INT J MED, V97, P385, DOI 10.1093/qjmed/hch074; Hugon J, 2009, UNDERSEA HYPERBAR M, V36, P223; Jaeger K, 2002, ANASTH INTENSIV NOTF, V37, P24, DOI 10.1055/s-2001-20003; Jones SR, 2010, PLAST RECONSTR SURG, V126, P403, DOI 10.1097/PRS.0b013e3181df64a5; Kihara K, 2005, LIVER TRANSPLANT, V11, P1574, DOI 10.1002/lt.20533; KIZER KW, 1982, JAMA-J AM MED ASSOC, V247, P2555, DOI 10.1001/jama.247.18.2555; Millar I, 1996, SPUMS J, V26, P135; Nikolaev VP, 2013, AVIAT SPACE ENVIR MD, V84, P938, DOI 10.3357/ASEM.3579.2013; Nossum V, 2002, EUR J APPL PHYSIOL, V86, P209, DOI 10.1007/s00421-001-0531-y; RIVERA JC, 1964, MIL MED, V129, P314, DOI 10.1093/milmed/129.4.314; Ross JAS., 2000, CLIN AUDIT OUTCOME M; Sjoberg F, 2013, J INTERN MED, V274, P505, DOI 10.1111/joim.12139; VANLIEW HD, 1993, AVIAT SPACE ENVIR MD, V64, P859; Vann R D, 1975, Undersea Biomed Res, V2, P185; Vann RD, 2011, LANCET, V377, P153, DOI 10.1016/S0140-6736(10)61085-9; Vann RD, 2009, AVIAT SPACE ENVIR MD, V80, P466, DOI 10.3357/ASEM.2471.2009; Xu WB, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050079	31	28	31	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 23	2015	10	4							e0124919	10.1371/journal.pone.0124919	http://dx.doi.org/10.1371/journal.pone.0124919			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CG5KZ	25906396	gold, Green Published, Green Submitted			2023-01-03	WOS:000353332000093
J	Reetz, K; Abbas, Z; Costa, AS; Gras, V; Tiffin-Richards, F; Mirzazade, S; Holschbach, B; Frank, RD; Vassiliadou, A; Kruger, T; Eitner, F; Gross, T; Schulz, JB; Floege, J; Shah, NJ				Reetz, Kathrin; Abbas, Zaheer; Costa, Ana Sofia; Gras, Vincent; Tiffin-Richards, Frances; Mirzazade, Shahram; Holschbach, Bernhard; Frank, Rolf Dario; Vassiliadou, Athina; Krueger, Thilo; Eitner, Frank; Gross, Theresa; Schulz, Joerg Bernhard; Floege, Juergen; Shah, Nadim Jon			Increased Cerebral Water Content in Hemodialysis Patients	PLOS ONE			English	Article							CHRONIC KIDNEY-DISEASE; MONTREAL COGNITIVE ASSESSMENT; STAGE RENAL-DISEASE; WHITE-MATTER; DEFAULT-MODE; BRAIN; DIALYSIS; IMPAIRMENT; MRI; T-1	Little information is available on the impact of hemodialysis on cerebral water homeostasis and its distribution in chronic kidney disease. We used a neuropsychological test battery, structural magnetic resonance imaging (MRI) and a novel technique for quantitative measurement of localized water content using 3T MRI to investigate ten hemodialysis patients (HD) on a dialysis-free day and after hemodialysis (2.4 +/- 2.2 hours), and a matched healthy control group with the same time interval. Neuropsychological testing revealed mainly attentional and executive cognitive dysfunction in HD. Voxel-based-morphometry showed only marginal alterations in the right inferior medial temporal lobe white matter in HD compared to controls. Marked increases in global brain water content were found in the white matter, specifically in parietal areas, in HD patients compared to controls. Although the global water content in the gray matter did not differ between the two groups, regional increases of brain water content in particular in parieto-temporal gray matter areas were observed in HD patients. No relevant brain hydration changes were revealed before and after hemodialysis. Whereas longer duration of dialysis vintage was associated with increased water content in parieto-temporal-occipital regions, lower intradialytic weight changes were negatively correlated with brain water content in these areas in HD patients. Worse cognitive performance on an attention task correlated with increased hydration in frontal white matter. In conclusion, long-term HD is associated with altered brain tissue water homeostasis mainly in parietal white matter regions, whereas the attentional domain in the cognitive dysfunction profile in HD could be linked to increased frontal white matter water content.	[Reetz, Kathrin; Abbas, Zaheer; Costa, Ana Sofia; Tiffin-Richards, Frances; Mirzazade, Shahram; Schulz, Joerg Bernhard; Shah, Nadim Jon] RWTH Aachen Univ Hosp, Dept Neurol, Aachen, Germany; [Reetz, Kathrin; Abbas, Zaheer; Gras, Vincent; Mirzazade, Shahram; Shah, Nadim Jon] Res Ctr Julich GmbH, Inst Neurosci & Med INM 4, Julich, Germany; [Reetz, Kathrin; Abbas, Zaheer; Costa, Ana Sofia; Tiffin-Richards, Frances; Mirzazade, Shahram; Schulz, Joerg Bernhard; Shah, Nadim Jon] JARA, Translat Brain Med, Julich, Germany; [Reetz, Kathrin; Abbas, Zaheer; Costa, Ana Sofia; Tiffin-Richards, Frances; Mirzazade, Shahram; Schulz, Joerg Bernhard; Shah, Nadim Jon] JARA, Translat Brain Med, Aachen, Germany; [Holschbach, Bernhard] KfH Kuratorium Dialyse & Nierentransplantat eV, Stolberg, Germany; [Frank, Rolf Dario] St Antonius Hosp Eschweiler, Dept Internal Med, Eschweiler, Germany; [Vassiliadou, Athina] Dialysezentrum Aachen, Praxis & Dialyse, Aachen, Germany; [Krueger, Thilo; Eitner, Frank; Gross, Theresa; Floege, Juergen] Rhein Westfal TH Aachen, Div Nephrol & Clin Immunol, Aachen, Germany	RWTH Aachen University; RWTH Aachen University Hospital; Helmholtz Association; Research Center Julich; Saint Antonius Hospital; RWTH Aachen University	Reetz, K (corresponding author), RWTH Aachen Univ Hosp, Dept Neurol, Aachen, Germany.	kreetz@ukaachen.de	Costa, Ana Sofia/O-3913-2017; Shah, N. Jon/H-5849-2013; Schulz, Jörg B/D-9786-2012; Reetz, Kathrin/H-9510-2012	Costa, Ana Sofia/0000-0002-1999-6616; Shah, N. Jon/0000-0002-8151-6169; Schulz, Jörg B/0000-0002-8903-0593; Reetz, Kathrin/0000-0002-9730-9228; Gras, Vincent/0000-0002-4997-2738; Abbas, Zaheer/0000-0002-0650-8388	Excellence Initiative of the German Research Foundation [DFG ZUK32/1]; German Federal Ministry of Education and Research [BMBF 01GQ1402]; Fundacao para a Ciencia e Tecnologia (FCT) -POPH - QREN Program [SFRH/BD/65743 2009]; Helmholtz Alliance ICEMED - Imaging and Curing Environmental Metabolic Diseases through the Initiative and Network Fund of the Helmholtz Association [HA-314]; Bayer Pharma AG	Excellence Initiative of the German Research Foundation(German Research Foundation (DFG)); German Federal Ministry of Education and Research(Federal Ministry of Education & Research (BMBF)); Fundacao para a Ciencia e Tecnologia (FCT) -POPH - QREN Program; Helmholtz Alliance ICEMED - Imaging and Curing Environmental Metabolic Diseases through the Initiative and Network Fund of the Helmholtz Association; Bayer Pharma AG	Sources of support: This work was supported in part by the Excellence Initiative of the German Research Foundation [DFG ZUK32/1] and the German Federal Ministry of Education and Research [BMBF 01GQ1402] to KR; and by a PhD fellowship (SFRH/BD/65743 2009) from the Fundacao para a Ciencia e Tecnologia (FCT), financed by the POPH - QREN Program to ASC. NJS and JBS were in part funded by the Helmholtz Alliance ICEMED - Imaging and Curing Environmental Metabolic Diseases [HA-314], through the Initiative and Network Fund of the Helmholtz Association. The sponsors had no role in the study design, data collection, data analysis, data interpretation, or writing of the report. Bayer Pharma AG provided support for the authors TK and FE, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the 'author contributions' section.	Abbas Z, 2015, NEUROIMAGE, V106, P404, DOI 10.1016/j.neuroimage.2014.11.017; Abbas Z, 2014, MAGN RESON MED, V72, P1735, DOI 10.1002/mrm.25086; Aebi C, 2002, VALIEDIRUNG NEUROPSY; [Anonymous], 2003, EUROPEAN HEART J; [Anonymous], 2000, MINI MENTAL STATUS T; Aschenbrenner S., 2000, REGENSBURG WORD FLUE; Ashburner J, 2000, NEUROIMAGE, V11, P805, DOI 10.1006/nimg.2000.0582; Ashburner J, 2005, NEUROIMAGE, V26, P839, DOI 10.1016/j.neuroimage.2005.02.018; Beddhu S, 2000, AM J MED, V108, P609, DOI 10.1016/S0002-9343(00)00371-5; Biernacki C, 2006, COMPUT STAT DATA AN, V51, P587, DOI 10.1016/j.csda.2005.12.015; Bugnicourt JM, 2013, J AM SOC NEPHROL, V24, P353, DOI 10.1681/ASN.2012050536; Buumler G., 1985, FARBE WORT INTERFERE; Cavanna AE, 2006, BRAIN, V129, P564, DOI 10.1093/brain/awl004; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Cohen J., 2013, STAT POWER ANAL BEHA; Collins DL, 1995, HUM BRAIN MAPP, V3, P190, DOI 10.1002/hbm.460030304; Costa AS, 2014, AM J KIDNEY DIS, V64, P434, DOI 10.1053/j.ajkd.2014.02.012; Costa AS, 2012, DEMENT GERIATR COGN, V33, P379, DOI 10.1159/000340006; Desikan RS, 2006, NEUROIMAGE, V31, P968, DOI 10.1016/j.neuroimage.2006.01.021; Disabato BM, 2012, CURR PSYCHIAT REP, V14, P273, DOI 10.1007/s11920-012-0279-6; Drew DA, 2013, AM J KIDNEY DIS, V61, P271, DOI 10.1053/j.ajkd.2012.08.035; Eldehni MT, 2012, SEMIN DIALYSIS, V25, P253, DOI 10.1111/j.1525-139X.2012.01057.x; Fatouros PP, 1999, J NEUROSURG, V90, P109, DOI 10.3171/jns.1999.90.1.0109; Frazier JA, 2005, AM J PSYCHIAT, V162, P1256, DOI 10.1176/appi.ajp.162.7.1256; Goldstein JM, 2007, BIOL PSYCHIAT, V61, P935, DOI 10.1016/j.biopsych.2006.06.027; Graham JE, 1997, LANCET, V349, P1793, DOI 10.1016/S0140-6736(97)01007-6; Gras V, 2013, CONCEPT MAGN RESON A, V42, P89, DOI 10.1002/cmr.a.21264; Greicius MD, 2004, P NATL ACAD SCI USA, V101, P4637, DOI 10.1073/pnas.0308627101; Griswold MA, 2005, MAGN RESON MED, V54, P1553, DOI 10.1002/mrm.20722; Herrmann LL, 2008, J NEUROL NEUROSUR PS, V79, P619, DOI 10.1136/jnnp.2007.124651; Herrmann-Lingen C., 1995, HOSP ANXIETY DEPRESS; Hsieh TJ, 2009, RADIOLOGY, V252, P518, DOI 10.1148/radiol.2523080484; Ikram MA, 2008, STROKE, V39, P55, DOI 10.1161/STROKEAHA.107.493494; Jahng GH, 2005, MED PHYS, V32, P1524, DOI 10.1118/1.1915014; Jenkinson M, 2001, MED IMAGE ANAL, V5, P143, DOI 10.1016/S1361-8415(01)00036-6; Keil F, 2012, NEUROIMAGE, V63, P1374, DOI 10.1016/j.neuroimage.2012.07.034; Kieseppa T, 2010, J AFFECT DISORDERS, V120, P240, DOI 10.1016/j.jad.2009.04.023; Kobayashi M, 2009, NEPHROL DIAL TRANSPL, V24, P201, DOI 10.1093/ndt/gfn419; Kong X, 2014, MEDICINE, V93, DOI 10.1097/MD.0000000000000313; Kurt A, 2003, RIV NEURORADIOL, V16, P275, DOI 10.1177/197140090301600207; Lux S, 2010, KIDNEY INT, V78, P794, DOI 10.1038/ki.2010.253; Madero M, 2011, SEMIN DIALYSIS, V24, P266, DOI 10.1111/j.1525-139X.2011.00857.x; Makris N, 2006, SCHIZOPHR RES, V83, P155, DOI 10.1016/j.schres.2005.11.020; Mizumasa T, 2004, NEPHRON CLIN PRACT, V97, pC23, DOI 10.1159/000077592; Mogi M, 2011, CARDIOL RES PRACT, V2011, DOI 10.4061/2011/306189; Murray AM, 2006, NEUROLOGY, V67, P216, DOI 10.1212/01.wnl.0000225182.15532.40; Murray AM, 2008, ADV CHRONIC KIDNEY D, V15, P123, DOI 10.1053/j.ackd.2008.01.010; Murray AM, 2007, AM J KIDNEY DIS, V50, P270, DOI 10.1053/j.ajkd.2007.05.010; Nasreddine ZS, 2005, J AM GERIATR SOC, V53, P695, DOI 10.1111/j.1532-5415.2005.53221.x; Neeb H, 2008, NEUROIMAGE, V42, P1094, DOI 10.1016/j.neuroimage.2008.03.060; Neeb H, 2006, MAGN RESON MED, V56, P224, DOI 10.1002/mrm.20929; Neeb H, 2006, NEUROIMAGE, V31, P1156, DOI 10.1016/j.neuroimage.2005.12.063; Neeb H, 2006, NEUROIMAGE, V29, P910, DOI 10.1016/j.neuroimage.2005.08.062; Niemann H., 2008, CALIFORNIA VERBAL LE; OBRIEN JT, 2003, LANCET NEUROL, V2, P89, DOI [10.1016/S1474-4422(03)00305-3, DOI 10.1016/S1474-4422(03)00305-3]; Oros-Peusquens AM KF, 2012, P INT SOC MAGN RESON, P20; Pereira AA, 2005, AM J KIDNEY DIS, V45, P448, DOI 10.1053/j.ajkd.2004.10.024; Pereira Arema A, 2007, Hemodial Int, V11, P309, DOI 10.1111/j.1542-4758.2007.00185.x; Post JB, 2010, NEPHRON CLIN PRACT, V116, pC247, DOI 10.1159/000317206; Radbruch L, 2003, J PAIN SYMPTOM MANAG, V25, P449, DOI 10.1016/S0885-3924(03)00073-3; Raichle ME, 2001, P NATL ACAD SCI USA, V98, P676, DOI 10.1073/pnas.98.2.676; Sanchez-Roman S, 2011, J INT NEUROPSYCH SOC, V17, P80, DOI 10.1017/S1355617710001219; Sarnak MJ, 2013, NEUROLOGY, V80, P471, DOI 10.1212/WNL.0b013e31827f0f7f; Savazzi GM, 2001, NEPHRON, V89, P31, DOI 10.1159/000046040; Shah NJ, 2008, NEUROIMAGE, V41, P706, DOI 10.1016/j.neuroimage.2008.02.057; Shah NJ, 2011, METHODS MOL BIOL, V711, P29, DOI 10.1007/978-1-61737-992-5_3; Shah NJ, 2003, HEPATOLOGY, V38, P1219, DOI 10.1053/jhep.2003.50477; Tofts PS, 2003, QUANTITATIVE MRI OF THE BRAIN: MEASURING CHANGES CAUSED BY DISEASE, P85; von Aste M, 2006, DEUTSCHSPRACHIGE BEA; Wagner S, 2011, ARCH CLIN NEUROPSYCH, V26, P314, DOI 10.1093/arclin/acr024; Warntjes JBM, 2007, MAGN RESON MED, V57, P528, DOI 10.1002/mrm.21165; Warrington E, 1992, TESTBATTERIE VISUELL; Whittall KP, 1997, MAGNET RESON MED, V37, P34, DOI 10.1002/mrm.1910370107; Williams MA, 2004, AM J KIDNEY DIS, V43, P705, DOI 10.1053/j.ajkd.2003.12.031; Yaffe K, 2010, J AM GERIATR SOC, V58, P338, DOI 10.1111/j.1532-5415.2009.02670.x; Yakushiji Y, 2010, HYPERTENS RES, V33, P1232, DOI 10.1038/hr.2010.171; Zimmermann PFB, 2012, TESTBATTERIE AUFMERK	77	16	16	0	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 31	2015	10	3							e0122188	10.1371/journal.pone.0122188	http://dx.doi.org/10.1371/journal.pone.0122188			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CE8IF	25826269	gold, Green Published, Green Submitted			2023-01-03	WOS:000352084800060
J	Ni, WT; Shao, XD; Cai, XJ; Wei, CQ; Cui, JC; Wang, R; Liu, YN				Ni, Wentao; Shao, Xiaodi; Cai, Xuejiu; Wei, Chuanqi; Cui, Junchang; Wang, Rui; Liu, Youning			Prophylactic Use of Macrolide Antibiotics for the Prevention of Chronic Obstructive Pulmonary Disease Exacerbation: A Meta-Analysis	PLOS ONE			English	Article							RESPIRATORY-TRACT INFECTIONS; DOUBLE-BLIND; AZITHROMYCIN; COPD; ERYTHROMYCIN; CLARITHROMYCIN; GUIDELINES; SPUTUM; RISK	Background Acute exacerbations of chronic obstructive pulmonary disease (AECOPDs) can lead to high frequencies and rates of hospitalization and mortality. Macrolides are a class of antibiotics that possess both antimicrobial and anti-inflammatory properties. Since the occurrence of AECOPDs is associated with aggravation of airway inflammation and bacterial infections, prophylactic macrolide treatment may be an effective approach towards the prevention of AECOPDs. Methods We systemically searched the PubMed, Embase and Cochrane Library databases to identify randomized controlled trials (RCTs) that evaluated the effect of prophylactic macrolide therapy on the prevention of AECOPDs. The primary outcomes were the total number of patients with one or more exacerbations as well as the rate of exacerbations per patient per year. Results Nine RCTs comprising 1666 patients met the inclusion criteria. Pooled evidence showed macrolides could reduce the frequency of exacerbations in patients with COPD by both un-weighted (RR = 0.70; 95% CI: 0.56-0.87; P < 0.01) and weighted approaches (RR = 0.58, 95% CI: 0.43-0.78, P < 0.01). Subgroup analysis showed only 6-12 months of erythromycin or azithromycin therapy could be effective. Moreover, among studies with 6-12 months of azithromycin therapy, both the daily dosing regimen and the intermittent regimen significantly reduced exacerbation rates. The overall number of hospitalizations and the all-cause rate of death were not significantly different between the treatment and control groups. A tendency for more adverse events was found in the treatment groups (OR = 1.55, 95% CI: 1.003-2.39, P = 0.049). Conclusions Our results suggest 6-12 months erythromycin or azithromycin therapy could effectively reduce the frequency of exacerbations in patients with COPD. However, Long-term treatment may bring increased adverse events and the emergence of macrolide-resistance. A recommendation for the prophylactic use of macrolide therapy should weigh both the advantages and disadvantages.	[Ni, Wentao; Shao, Xiaodi; Cai, Xuejiu; Wei, Chuanqi; Cui, Junchang; Liu, Youning] Chinese Peoples Liberat Army Gen Hosp, Dept Resp Dis, Beijing, Peoples R China; [Wang, Rui] Chinese Peoples Liberat Army Gen Hosp, Dept Clin Pharmacol, Beijing, Peoples R China	Chinese People's Liberation Army General Hospital; Chinese People's Liberation Army General Hospital	Cui, JC (corresponding author), Chinese Peoples Liberat Army Gen Hosp, Dept Resp Dis, Beijing, Peoples R China.	guoguoyoumeng@163.com	Ni, Wentao/HDN-9973-2022		National Natural Science Foundation of China [81371855]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work was supported by the National Natural Science Foundation of China (No. 81371855, http://www.nsfc.gov.cn/). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Albert RK, 2011, NEW ENGL J MED, V365, P689, DOI 10.1056/NEJMoa1104623; Banerjee D, 2005, RESP MED, V99, P208, DOI 10.1016/j.rmed.2004.06.009; Bearden DT, 1999, INFECT MED, V16, P480; Berkhof FF, 2013, RESP RES, V14, DOI 10.1186/1465-9921-14-125; Blasi F, 2010, PULM PHARMACOL THER, V23, P200, DOI 10.1016/j.pupt.2009.12.002; Cameron EJ, 2012, CLIN EXP ALLERGY, V42, P1302, DOI 10.1111/j.1365-2222.2012.03979.x; Celli BR, 2004, EUR RESPIR J, V23, P932, DOI 10.1183/09031936.04.00014304; Clement A, 2006, THORAX, V61, P895, DOI 10.1136/thx.2005.057950; Donath E, 2013, RESP MED, V107, P1385, DOI 10.1016/j.rmed.2013.05.004; Florescu DF, 2009, PULM PHARMACOL THER, V22, P467, DOI 10.1016/j.pupt.2009.03.002; Global initiative for chronic obstructive lung disease (GOLD), 2016, GLOBAL STRATEGY DIAG; Gomez J, 2000, REV ESP QUIM, V13, P379; Figueiredo BDGE, 2011, PULM MED, V2011, DOI 10.1155/2011/751982; Han MLK, 2014, AM J RESP CRIT CARE, V189, P1503, DOI 10.1164/rccm.201402-0207OC; He ZY, 2010, RESPIRATION, V80, P445, DOI 10.1159/000321374; Herath SC, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009764.pub2; Mannino DM, 2007, LANCET, V370, P765, DOI 10.1016/S0140-6736(07)61380-4; Marchetti N, 2013, CHEST, V143, P1444, DOI 10.1378/chest.12-1801; Marjanovic N, 2011, PHARMACOL RES, V63, P389, DOI 10.1016/j.phrs.2011.02.001; MAZZEI T, 1993, J ANTIMICROB CHEMOTH, V31, P1; Miravitlles M, 2012, ARCH BRONCONEUMOL, V48, P247, DOI 10.1016/j.arbres.2012.04.001; Papi A, 2006, AM J RESP CRIT CARE, V173, P1114, DOI 10.1164/rccm.200506-859OC; Rabe KF, 2013, CHEST, V143, P711, DOI 10.1378/chest.12-1277; Ray WA, 2004, NEW ENGL J MED, V351, P1089, DOI 10.1056/NEJMoa040582; Ray WA, 2012, NEW ENGL J MED, V366, P1881, DOI 10.1056/NEJMc1207269; Rubin BK, 2004, AM J MED, V117, P2, DOI 10.1016/j.amjmed.2004.07.021; Schembri S, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f1235; Seemungal TAR, 2008, AM J RESP CRIT CARE, V178, P1139, DOI 10.1164/rccm.200801-145OC; Sethi S, 2008, NEW ENGL J MED, V359, P2355, DOI 10.1056/NEJMra0800353; Simpson JL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0105609; Spagnolo P, 2013, EUR RESPIR J, V42, P239, DOI 10.1183/09031936.00136712; Suissa S, 2012, THORAX, V67, P957, DOI 10.1136/thoraxjnl-2011-201518; Suzuki T, 2001, CHEST, V120, P730, DOI 10.1378/chest.120.3.730; Uzun S, 2014, LANCET RESP MED, V2, P361, DOI 10.1016/S2213-2600(14)70019-0; Vestbo J, 2011, NEW ENGL J MED, V365, P1184, DOI 10.1056/NEJMoa1105482; Woodhead M, 2011, CLIN MICROBIOL INFEC, V17, pE1, DOI 10.1111/j.1469-0691.2011.03672.x; World Health Organization (WHO), CHRONIC OBSTRUCTIVE; Yamaya M, 2012, EUR RESPIR J, V40, P485, DOI 10.1183/09031936.00208011; Yao GY, 2013, RESPIRATION, V86, P254, DOI 10.1159/000350828	39	60	63	1	18	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 26	2015	10	3							e0121257	10.1371/journal.pone.0121257	http://dx.doi.org/10.1371/journal.pone.0121257			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CK6QW	25812085	Green Published, Green Submitted, gold			2023-01-03	WOS:000356353700089
J	Wang, CH; Chen, BT; Han, BC; Liu, ACY; Hung, PC; Chen, CY; Chao, HJ				Wang, Chi-Hsun; Chen, Bean T.; Han, Bor-Cheng; Liu, Andrew Chi-Yeu; Hung, Po-Chen; Chen, Chih-Yong; Chao, Hsing Jasmine			Field Evaluation of Personal Sampling Methods for Multiple Bioaerosols	PLOS ONE			English	Article							AIRBORNE FUNGI; RESPIRATORY SYMPTOMS; EXPOSURE; WORKERS; SAMPLERS; BACTERIA; DUST; MICROORGANISMS; COLLECTION; PARTICLES	Ambient bioaerosols are ubiquitous in the daily environment and can affect health in various ways. However, few studies have been conducted to comprehensively evaluate personal bioaerosol exposure in occupational and indoor environments because of the complex composition of bioaerosols and the lack of standardized sampling/analysis methods. We conducted a study to determine the most efficient collection/analysis method for the personal exposure assessment of multiple bioaerosols. The sampling efficiencies of three filters and four samplers were compared. According to our results, polycarbonate (PC) filters had the highest relative efficiency, particularly for bacteria. Side-by-side sampling was conducted to evaluate the three filter samplers (with PC filters) and the NIOSH Personal Bioaerosol Cyclone Sampler. According to the results, the Button Aerosol Sampler and the IOM Inhalable Dust Sampler had the highest relative efficiencies for fungi and bacteria, followed by the NIOSH sampler. Personal sampling was performed in a pig farm to assess occupational bioaerosol exposure and to evaluate the sampling/analysis methods. The Button and IOM samplers yielded a similar performance for personal bioaerosol sampling at the pig farm. However, the Button sampler is more likely to be clogged at high airborne dust concentrations because of its higher flow rate (4 L/min). Therefore, the IOM sampler is a more appropriate choice for performing personal sampling in environments with high dust levels. In summary, the Button and IOM samplers with PC filters are efficient sampling/analysis methods for the personal exposure assessment of multiple bioaerosols.	[Wang, Chi-Hsun; Han, Bor-Cheng; Liu, Andrew Chi-Yeu; Chao, Hsing Jasmine] Taipei Med Univ, Sch Publ Hlth, Taipei, Taiwan; [Chen, Bean T.] NIOSH, Hlth Effects Lab Div, Morgantown, WV USA; [Hung, Po-Chen; Chen, Chih-Yong] Minist Labor, Inst Labor Occupat Safety & Hlth, New Taipei City, Taiwan	Taipei Medical University; Centers for Disease Control & Prevention - USA; National Institute for Occupational Safety & Health (NIOSH)	Chao, HJ (corresponding author), Taipei Med Univ, Sch Publ Hlth, Taipei, Taiwan.	hchao@tmu.edu.tw	Chao, Hsing Jasmine/AAR-1390-2021	Han, Bor-Cheng/0000-0002-8493-8199	Institute of Labor, Occupational Safety and Health (ILOSH), Ministry of Labor, Taiwan [IOSH100-H313]	Institute of Labor, Occupational Safety and Health (ILOSH), Ministry of Labor, Taiwan	Funding: This research was supported by the Institute of Labor, Occupational Safety and Health (ILOSH), Ministry of Labor, Taiwan (http://www.ilosh.gov.tw/wSite/mp?mp=12), Grant No. IOSH100-H313. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The opinions, results and conclusions reported in this paper are those of the authors and are independent from the funder.	Adhikari A, 2003, ATMOS ENVIRON, V37, P4723, DOI 10.1016/j.atmosenv.2003.08.021; Agranovski IE, 2002, ATMOS ENVIRON, V36, P889, DOI 10.1016/S1352-2310(01)00488-5; [Anonymous], 2003, J OCCUP ENVIRON MED, V45, P470; Bang B, 2005, J OCCUP ENVIRON MED, V47, P482, DOI 10.1097/01.jom.0000161732.96555.2b; Barnett H., 1998, ILLUSTRATED GENERA O; Burge HA, 1999, CHICAGO 1999 AMERICA; Burton NC, 2005, J ENVIRON MONITOR, V7, P475, DOI 10.1039/b500056d; Chang CW, 2011, INDOOR AIR, V21, P291, DOI 10.1111/j.1600-0668.2010.00701.x; Chang CW, 2001, APPL ENVIRON MICROB, V67, P155, DOI 10.1128/AEM.67.1.155-161.2001; Chen B, 2004, AEROSOL SCI TECH, V38, P926, DOI 10.1080/027868290511218; Burton NC, 2007, ANN OCCUP HYG, V51, P143, DOI 10.1093/annhyg/mel073; Cox-Ganser JM, 2009, INDOOR AIR, V19, P280, DOI 10.1111/j.1600-0668.2009.00586.x; Douwes J, 2003, ANN OCCUP HYG, V47, P187, DOI 10.1093/annhyg/meg032; Durand KTH, 2002, ANN OCCUP HYG, V46, P113, DOI 10.1093/annhyg/mef007; Fischer G, 2003, ARCH MICROBIOL, V179, P75, DOI 10.1007/s00203-002-0495-2; Germain G. S., 1996, IDENTIFYING FILAMENT; Gorner P, 2010, ANN OCCUP HYG, V54, P165, DOI 10.1093/annhyg/mep079; Gorny RL, 1999, ANN AGR ENV MED, V6, P105; Halstensen AS, 2007, ANN OCCUP HYG, V51, P581, DOI [10.1093/annhyg/mem038, 10.1093/annhyg/rnem038]; Hansen VM, 2012, ANN OCCUP HYG, V56, P170, DOI 10.1093/annhyg/mer090; Heederik D, 2007, ENVIRON HEALTH PERSP, V115, P298, DOI 10.1289/ehp.8835; Heldal KK, 2003, OCCUP ENVIRON MED, V60, P444, DOI 10.1136/oem.60.6.444; Hinds WC, 1999, AEROSOL TECHNOLOGY, P394; HOLLANDER A, 1994, OCCUP ENVIRON MED, V51, P73, DOI 10.1136/oem.51.2.73; Hung CC, 2010, THESIS; JENSEN PA, 1992, AM IND HYG ASSOC J, V53, P660, DOI 10.1202/0002-8894(1992)053<0660:EOEBSC>2.0.CO;2; Lee SA, 2014, SCI TOTAL ENVIRON, V466, P725, DOI 10.1016/j.scitotenv.2013.07.104; Lee T, 2011, ANN OCCUP HYG, V55, P180, DOI 10.1093/annhyg/meq075; Li CS, 1997, ARCH ENVIRON HEALTH, V52, P200, DOI 10.1080/00039899709602887; Lin ZZ, 2004, AN ATLAS OF AIRBORNE; Macher J, 1999, BIOAEROSOLS ASSESSME, P5; Macher J.M., 2001, AIR SAMPLING INSTRUM, P661; Macher J, 2008, J OCCUP ENVIRON HYG, V5, P724, DOI 10.1080/15459620802400159; Macher J, 2008, J OCCUP ENVIRON HYG, V5, P702, DOI 10.1080/15459620802380351; Mak C, 2013, JOURNAL OF OCCUPATIO, V21, P481; Mallach D., 1982, MOULDS THEIR ISOLATI; Mamuya SHD, 2007, BMC PUBLIC HEALTH, V7, DOI 10.1186/1471-2458-7-17; Nimmermark S, 2009, ANN AGR ENV MED, V16, P103; Nugent PG, 1997, J AEROSOL SCI, V28, P525, DOI 10.1016/S0021-8502(96)00453-3; Pan CH, 2008, HEALTH HAZARD EVALUA; Schlosser O, 2009, WATER ENVIRON RES, V81, P866, DOI 10.2175/106143009X407258; SKC Inc, 2013, GELATIN FILTERS OPER; SKC Inc, 2013, SKC FILTER SELECTION; Smith EG, 2000, SAMPLING AND IDENTIF; Van Droogenbroeck C, 2009, VET MICROBIOL, V135, P31, DOI 10.1016/j.vetmic.2008.09.042; Wang Z, 2001, J AEROSOL SCI, V32, P661, DOI 10.1016/S0021-8502(00)00108-7; Watanabe T, 2002, PICTORIAL ATLAS OF S; Wouters IM, 2006, ANN OCCUP HYG, V50, P39, DOI 10.1093/annhyg/mei047; Wu HC, 2007, JOURNAL OF OCCUPATIO, V15, P34; Wu Y, 2010, J AEROSOL SCI, V41, P869, DOI 10.1016/j.jaerosci.2010.05.006; Yao MS, 2009, J ENVIRON MONITOR, V11, P1993, DOI 10.1039/b910243d; Zamengo L, 2009, CHEMOSPHERE, V76, P313, DOI 10.1016/j.chemosphere.2009.03.065; Zhen HJ, 2013, APPL ENVIRON MICROB, V79, P7780, DOI 10.1128/AEM.02859-13	53	35	36	8	44	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 23	2015	10	3							e0120308	10.1371/journal.pone.0120308	http://dx.doi.org/10.1371/journal.pone.0120308			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CE6ZS	25799419	Green Published, gold, Green Submitted			2023-01-03	WOS:000351987300129
J	Urbano, J; Gonzalez, R; Lopez, J; Solana, MJ; Bellon, JM; Botran, M; Garcia, A; Fernandez, SN; Lopez-Herce, J				Urbano, Javier; Gonzalez, Rafael; Lopez, Jorge; Solana, Maria J.; Bellon, Jose M.; Botran, Marta; Garcia, Ana; Fernandez, Sarah N.; Lopez-Herce, Jesus			Comparison of Normal Saline, Hypertonic Saline Albumin and Terlipressin plus Hypertonic Saline Albumin in an Infant Animal Model of Hypovolemic Shock	PLOS ONE			English	Article							UNCONTROLLED HEMORRHAGIC-SHOCK; RANDOMIZED CONTROLLED-TRIAL; FLUID RESUSCITATION; HYPERTONIC/HYPERONCOTIC SOLUTION; CEREBRAL OXYGENATION; ARGININE-VASOPRESSIN; SEPTIC SHOCK; BLOOD-VOLUME; MAJOR TRAUMA; SWINE	Introduction In series of cases and animal models suffering hemorrhagic shock, the use of vasopressors has shown potential benefits regarding hemodynamics and tissue perfusion. Terlipressin is an analogue of vasopressin with a longer half-life that can be administered by bolus injection. We have previously observed that hypertonic albumin improves resuscitation following controlled hemorrhage in piglets. The aim of the present study was to analyze whether the treatment with the combination of terlipressin and hypertonic albumin can produce better hemodynamic and tissular perfusion parameters than normal saline or hypertonic albumin alone at early stages of hemorrhagic shock in an infant animal model. Methods Experimental, randomized animal study including 39 2-to-3-month-old piglets. Thirty minutes after controlled 30 ml/kg bleed, pigs were randomized to receive either normal saline (NS) 30 ml/kg (n = 13), 5% albumin plus 3% hypertonic saline (AHS) 15 ml/kg (n = 13) or single bolus of terlipressin 15 mu g/kg i.v. plus 5% albumin plus 3% hypertonic saline 15 ml/kg (TAHS) (n = 13) over 30 minutes. Global hemodynamic and tissular perfusion parameters were compared. Results After controlled bleed a significant decrease of blood pressure, cardiac index, central venous saturation, carotid and peripheral blood flow, brain saturation and an increase of heart rate, gastric PCO2 and lactate was observed. After treatment no significant differences in most hemodynamic (cardiac index, mean arterial pressure) and perfusion parameters (lactate, gastric PCO2, brain saturation, cutaneous blood flow) were observed between the three therapeutic groups. AHS and TAHS produced higher increase in stroke volume index and carotid blood flow than NS. Conclusions In this pediatric animal model of hypovolemic shock, albumin plus hypertonic saline with or without terlipressin achieved similar hemodynamics and perfusion parameters than twice the volume of NS. Addition of terlipressin did not produce better results than AHS.	[Urbano, Javier; Gonzalez, Rafael; Lopez, Jorge; Solana, Maria J.; Botran, Marta; Garcia, Ana; Fernandez, Sarah N.; Lopez-Herce, Jesus] Gregorio Maranon Univ Hosp, Pediat Intens Care Dept, Madrid, Spain; [Urbano, Javier; Gonzalez, Rafael; Lopez, Jorge; Solana, Maria J.; Botran, Marta; Garcia, Ana; Fernandez, Sarah N.; Lopez-Herce, Jesus] Spanish Hlth Inst Carlos III, Res Network Maternal & Child Hlth & Dev RedSAMID, Inst Invest Sanitaria Hosp Gregorio Maranon IiSGM, Madrid, Spain; [Urbano, Javier; Gonzalez, Rafael; Lopez, Jorge; Lopez-Herce, Jesus] Spanish Hlth Inst Carlos III, Hlth Res Fund, Madrid, Spain; [Bellon, Jose M.] Inst Invest Sanitaria Hosp Gregorio Maranon Madri, Prevent & Qual Control Serv, Madrid, Spain	General University Gregorio Maranon Hospital	Urbano, J (corresponding author), Gregorio Maranon Univ Hosp, Pediat Intens Care Dept, Madrid, Spain.	javierurbanovillaescusa@gmail.com	Fernandez Lafever, Sarah Nicole/AAE-4978-2022; López, Jorge Eduardo/HJA-7565-2022; Cortes, Rafael Gonzalez/ABB-4855-2020; Lopez, Jorge/AAD-4109-2022; Lopez-Herce, Jesus/A-1602-2019; Cano, Jose Maria Bellon/G-3061-2012; Bellon-Cano, José María/G-6120-2016	Fernandez Lafever, Sarah Nicole/0000-0003-4859-5966; Cortes, Rafael Gonzalez/0000-0002-3259-7898; Lopez, Jorge/0000-0002-9942-6399; Lopez-Herce, Jesus/0000-0001-6105-9178; Cano, Jose Maria Bellon/0000-0002-8492-1565; Bellon-Cano, José María/0000-0002-8492-1565; SOLANA, MARIA JOSE/0000-0001-6083-2528; Urbano, Javier/0000-0002-3511-2905	Francisco Ruza Research Grant of the Spanish Society of Pediatric Intensive Care Medicine (SECIP); Health Research Fund (FIS) of the Carlos III Health Institute (ISCIII), Madrid Spain [PI14/02046]	Francisco Ruza Research Grant of the Spanish Society of Pediatric Intensive Care Medicine (SECIP); Health Research Fund (FIS) of the Carlos III Health Institute (ISCIII), Madrid Spain	Funding: This study was supported by the Francisco Ruza Research Grant of the Spanish Society of Pediatric Intensive Care Medicine (SECIP), 2012, https://www.secip.com/congresos-secip/congresos-secip/xxvii-congreso-secip. This study was supported by the Research Grant PI14/02046, from the Health Research Fund (FIS), of the Carlos III Health Institute (ISCIII), Madrid Spain. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Anand T, 2012, J SURG RES, V178, P321, DOI 10.1016/j.jss.2012.02.062; Balogh Z, 2003, ARCH SURG-CHICAGO, V138, P637, DOI 10.1001/archsurg.138.6.637; Barbee RW, 2010, SHOCK, V33, P113, DOI 10.1097/SHK.0b013e3181b8569d; Bayram B, 2012, AM J EMERG MED, V30, P1176, DOI 10.1016/j.ajem.2011.09.007; Bein B, 2005, EUR J ANAESTH, V22, P62, DOI 10.1017/S026502150500013X; Borrego R, 2006, PEDIATR CRIT CARE ME, V7, P267, DOI 10.1097/01.PCC.0000216419.84855.D6; Bulger EM, 2011, ANN SURG, V253, P431, DOI 10.1097/SLA.0b013e3181fcdb22; Calvete JO, 2008, REV ASSOC MED BRAS, V54, P116, DOI 10.1590/S0104-42302008000200012; Carcillo JA, 2002, CRIT CARE MED, V30, P1365, DOI 10.1097/00003246-200206000-00040; Choong K, 2009, AM J RESP CRIT CARE, V180, P632, DOI 10.1164/rccm.200902-0221OC; Cossu AP, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/421291; Cotton BA, 2006, SHOCK, V26, P115, DOI 10.1097/01.shk.0000209564.84822.f2; Devlin JJ, 2013, J EMERG MED, V45, P78, DOI 10.1016/j.jemermed.2012.12.023; DYKES EH, 1989, J PEDIATR SURG, V24, P107, DOI 10.1016/S0022-3468(89)80312-4; Horstick G, 2002, CRIT CARE MED, V30, P851, DOI 10.1097/00003246-200204000-00023; Johnson KB, 2006, J CARDIOTHOR VASC AN, V20, P167, DOI 10.1053/j.jvca.2005.11.015; Junger WG, 2012, SHOCK, V38, P341, DOI 10.1097/SHK.0b013e3182635aca; KAWESKI SM, 1990, J TRAUMA, V30, P1215, DOI 10.1097/00005373-199010000-00005; Kentner R, 2005, RESUSCITATION, V65, P87, DOI 10.1016/j.resuscitation.2004.10.012; Krismer AC, 2005, ANAESTHESIST, V54, P220, DOI 10.1007/s00101-004-0793-y; Lee CC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095821; Lopez-Herce J, 2006, RESUSCITATION, V68, P259, DOI 10.1016/j.resuscitation.2005.06.014; Meybohm P, 2007, PEDIATR RES, V62, P440, DOI 10.1203/PDR.0b013e3181425858; Meybohm P, 2007, J TRAUMA, V62, P640, DOI 10.1097/01.ta.0000240962.62319.c8; Meyer S, 2011, WIEN MED WOCHENSCHR, V161, P192, DOI 10.1007/s10354-010-0853-7; Ng KFJ, 2002, BRIT J ANAESTH, V88, P475, DOI 10.1093/bja/88.4.475; Rodriguez-Nunez A, 2010, ANN PHARMACOTHER, V44, P1545, DOI 10.1345/aph.1P254; Schmelzer TM, 2008, AM J EMERG MED, V26, P119, DOI 10.1016/j.ajem.2007.01.024; Skhirtladze K, 2014, BRIT J ANAESTH, V112, P255, DOI 10.1093/bja/aet348; Somasetia DH, 2014, CRIT CARE, V18, DOI 10.1186/s13054-014-0466-4; Sondeen JL, 2007, SHOCK, V28, P426, DOI 10.1097/shk.0b013e31804a5791; Spahn DR, 2013, CRIT CARE, V17, DOI 10.1186/cc12685; Trzeciak S, 2008, INTENS CARE MED, V34, P2210, DOI 10.1007/s00134-008-1193-6; Urbano J, 2012, RESUSCITATION, V83, P1159, DOI 10.1016/j.resuscitation.2012.02.003; Wade CE, 1997, SURGERY, V122, P609, DOI 10.1016/S0039-6060(97)90135-5; Walley KR, 2011, AM J RESP CRIT CARE, V184, P514, DOI 10.1164/rccm.201010-1584CI; Watters JM, 2006, J TRAUMA, V61, P300, DOI 10.1097/01.ta.0000224211.36154.44; Watters JM, 2006, J TRAUMA, V61, P75, DOI 10.1097/01.ta.0000222723.54559.47; Yoo JH, 2007, J VET MED SCI, V69, P459, DOI 10.1292/jvms.69.459; Younes RN, 1997, SHOCK, V7, P79, DOI 10.1097/00024382-199702000-00001	40	6	6	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 20	2015	10	3							e0121678	10.1371/journal.pone.0121678	http://dx.doi.org/10.1371/journal.pone.0121678			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CE8HY	25794276	Green Published, gold, Green Submitted			2023-01-03	WOS:000352083900146
J	Ou, Q; Chen, YC; Zhuo, SQ; Tian, XT; He, CH; Lu, XL; Gao, XL				Ou, Qiong; Chen, Yong-Chi; Zhuo, Sheng-Qing; Tian, Xiang-Ting; He, Chun-Huan; Lu, Xi-Lin; Gao, Xing-Lin			Continuous Positive Airway Pressure Treatment Reduces Mortality in Elderly Patients with Moderate to Severe Obstructive Severe Sleep Apnea: A Cohort Study	PLOS ONE			English	Article							RISK-FACTOR; ASSOCIATION; HYPERTENSION; STROKE	Obstructive sleep apnea (OSA) is much more prevalent in older people than in middle-aged or young populations, and has been associated with cardiovascular disease. Continuous positive airway pressure (CPAP) is the first-line therapy for OSA, but its long-term clinical benefit in the elderly is unclear. Here, we carried out a prospective cohort study to explore the survival rate and incidence of cardiovascular events in elderly patients with moderate to severe OSA who did or did not receive CPAP treatment. The study included 130 patients (104 male, 26 female; mean age: 77.8 +/- 6.2 years) who were followed up for a mean of 5 +/- 2.54 years (range, 1-8 years). Thirty-six patients received CPAP and 88 had no CPAP. The results showed that mortality in the untreated group (21.6%) was significantly higher than in the CPAP group (5.6%). Kaplan-Meier survival analysis showed that the survival rate in the CPAP group was 94.4%, which was markedly higher than the rate of 78.4% in the untreated group. The incidence of cardiovascular events was 13.9% in the CPAP group and 55.7% in the untreated group. The present study provides evidence that CPAP can reduce mortality in older patients with moderate to severe OSA, and lead to a good long-term prognosis. The study also indicates that death in older OSA patients is associated with cardiovascular disease and diabetes.	[Ou, Qiong; Gao, Xing-Lin] Guangdong Acad Med Sci, Guangdong Prov Inst Geriatr, Guangdong Gen Hosp, Sleep Ctr,Dept Resp Med, Guangzhou, Guangdong, Peoples R China; [Chen, Yong-Chi; Zhuo, Sheng-Qing; Tian, Xiang-Ting; He, Chun-Huan] Guangdong Acad Med Sci, Guangdong Prov Inst Geriatr, Dept Cardiol, Guangdong Gen Hosp, Guangzhou, Guangdong, Peoples R China; [Lu, Xi-Lin] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Neurol, Guangzhou 510275, Guangdong, Peoples R China	Guangdong Academy of Medical Sciences & Guangdong General Hospital; Guangdong Academy of Medical Sciences & Guangdong General Hospital; Sun Yat Sen University	Gao, XL (corresponding author), Guangdong Acad Med Sci, Guangdong Prov Inst Geriatr, Guangdong Gen Hosp, Sleep Ctr,Dept Resp Med, Guangzhou, Guangdong, Peoples R China.	xinglingao@hotmail.com			National Key Clinical Department, National Key Discipline [Y3016]; Guangdong Key Laboratory For Diagnosis and Treatment of Major Neurological Diseases [2010A060801005]; Guangdong Technological grant [2008B030301188, 2012B031800107]; Guangdong Department of Science & Technology Translational Medicine Center [2011A080300002]	National Key Clinical Department, National Key Discipline; Guangdong Key Laboratory For Diagnosis and Treatment of Major Neurological Diseases; Guangdong Technological grant; Guangdong Department of Science & Technology Translational Medicine Center	This study was supported by grants from the National Key Clinical Department, National Key Discipline (No. Y3016), Guangdong Key Laboratory For Diagnosis and Treatment of Major Neurological Diseases(No. 2010A060801005), Guangdong Technological grant (No. 2008B030301188, 2012B031800107), and Guangdong Department of Science & Technology Translational Medicine Center grant (No. 2011A080300002).	AncoliIsrael S, 1996, SLEEP, V19, P277, DOI 10.1093/sleep/19.4.277; Arzt M, 2005, AM J RESP CRIT CARE, V172, P1447, DOI 10.1164/rccm.200505-702OC; BLIWISE DL, 1988, AM J PUBLIC HEALTH, V78, P544, DOI 10.2105/AJPH.78.5.544; Campos-Rodriguez F, 2005, CHEST, V128, P624, DOI 10.1378/chest.128.2.624; Caples SM, 2005, ANN INTERN MED, V142, P187, DOI 10.7326/0003-4819-142-3-200502010-00010; Doherty LS, 2005, CHEST, V127, P2076, DOI 10.1378/chest.127.6.2076; Endeshaw Y, 2006, J AM GERIATR SOC, V54, P1740, DOI 10.1111/j.1532-5415.2006.00924.x; Groth M, 2005, CLIN GERIATR MED, V21, P701, DOI 10.1016/j.cger.2005.06.009; Lavie P, 2009, J SLEEP RES, V18, P397, DOI 10.1111/j.1365-2869.2009.00754.x; Li CY, 2002, AM J PHYSIOL-CELL PH, V282, pC227, DOI 10.1152/ajpcell.00112.2001; Lopez-Jimenez F, 2008, CHEST, V133, P793, DOI 10.1378/chest.07-0800; Maekawa M, 2000, Nihon Rinsho, V58, P1702; Martinez-Garcia AA, 2005, CHEST, V128, P2123, DOI 10.1378/chest.128.4.2123; McMahon Joseph P, 2003, WMJ, V102, P36; Mehra R, 2006, AM J RESP CRIT CARE, V173, P910, DOI 10.1164/rccm.200509-1442OC; Munoz R, 2006, STROKE, V37, P2317, DOI 10.1161/01.STR.0000236560.15735.0f; Nieto FJ, 2000, JAMA-J AM MED ASSOC, V283, P1829, DOI 10.1001/jama.283.14.1829; Norman D, 2008, CLIN GERIATR MED, V24, P151, DOI 10.1016/j.cger.2007.08.006; Ohayon MM, 2000, J PSYCHOSOM RES, V48, P593, DOI 10.1016/S0022-3999(00)00142-2; Parish JM, 2004, MAYO CLIN PROC, V79, P1036, DOI 10.4065/79.8.1036; Robinson GV, 2004, THORAX, V59, P777, DOI 10.1136/thx.2003.018739; Sforza E, 2004, EUR RESPIR J, V24, P279, DOI 10.1183/09031936.04.00091903; Silverberg D S, 2001, Curr Hypertens Rep, V3, P209, DOI 10.1007/s11906-001-0040-8; Skinner MA, 2005, CHEST, V127, P66, DOI 10.1378/chest.127.1.66; Thurnheer R, 2007, SWISS MED WKLY, V137, P217; Weaver TE, 2007, SLEEP MED REV, V11, P99, DOI 10.1016/j.smrv.2006.08.001; Yaggi HK, 2005, NEW ENGL J MED, V353, P2034, DOI 10.1056/NEJMoa043104; YOUNG T, 1993, NEW ENGL J MED, V328, P1230, DOI 10.1056/NEJM199304293281704; Young T, 2000, SLEEP, V23, pS122	29	32	34	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 11	2015	10	6							e0127775	10.1371/journal.pone.0127775	http://dx.doi.org/10.1371/journal.pone.0127775			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	CK3FB	26068440	gold, Green Published, Green Submitted			2023-01-03	WOS:000356100900012
J	Hatipoglu, M; Saglam, M; Koseoglu, S; Koksal, E; Keles, A; Esen, HH				Hatipoglu, Mukerrem; Saglam, Mehmet; Koseoglu, Serhat; Koksal, Ekrem; Keles, Ali; Esen, Haci Hasan			The Effectiveness of Crataegus orientalis M Bieber. (Hawthorn) Extract Administration in Preventing Alveolar Bone Loss in Rats with Experimental Periodontitis	PLOS ONE			English	Article							TOTAL ANTIOXIDANT CAPACITY; GINGIVAL CREVICULAR FLUID; REACTIVE OXYGEN; BORIC-ACID; SERUM; CONSTITUENTS; DISEASE; OXIDANT; FRUIT	The purpose of this animal study was to evaluate the effects of hawthorn (Crataeus orientalis M Bieber.) extract on serum oxidative status and alveolar bone loss in experimental periodontitis. Twenty-seven Wistar rats were assigned to one of the following groups: nonligated+placebo (saline) (NL, n = 9), ligature only+placebo (saline) (LO, n = 9), and ligature and treated with hawthorn extract in saline (H, n = 9) (100 mg/kg orogastrically, once a day for 11 days). Periodontitis was induced by submerging a 4/0 silk ligature in the sulcus of the mandibular right first molars of rats, and the animals were sacrificed after 11 days. Micro-CT examinations were performed for linear and volumetric parameter assessment of alveolar bone. Periodontal tissues were histopathologically examined to assess the differences among the study groups. Levels of serum total antioxidant status (TAS)/total oxidant status (TOS), and oxidative stress index (OSI) were also analyzed. Alveolar bone loss was significantly reduced by hawthorn administration compared to LO group (p<0.05). The number of inflammatory cells and osteoclasts in the LO group was significantly higher than that of the NL and H groups (p<0.05). The number of osteoblasts in the LO and H groups was significantly higher than that of the NL group (p<0.05). TOS and OSI levels were significantly reduced in H group compared to LO group (P < 0.05) and TAS levels were similar in H and NL group (p < 0.05). Hawthorn extract showed inhibitory effect on periodontal inflammation and alveolar bone loss by regulating TAS, TOS and OSI levels in periodontal disease in rats when administered systemically.	[Hatipoglu, Mukerrem] Akdeniz Univ, Sch Dent, Dept Periodontol, TR-07058 Antalya, Turkey; [Saglam, Mehmet; Koseoglu, Serhat] Izmir Katip Celebi Univ, Sch Dent, Dept Periodontol, Izmir, Turkey; [Koksal, Ekrem] Ondokuz Mayis Univ, Fac Sci & Arts, Dept Chem, Erzincan, Turkey; [Keles, Ali] Ondokuz Mayis Univ, Sch Dent, Dept Endodont, Samsun, Turkey; [Esen, Haci Hasan] Necmettin Erbakan Univ, Sch Med, Dept Pathol, Konya, Turkey	Akdeniz University; Izmir Katip Celebi University; Ondokuz Mayis University; Ondokuz Mayis University; Necmettin Erbakan University	Saglam, M (corresponding author), Izmir Katip Celebi Univ, Sch Dent, Dept Periodontol, Izmir, Turkey.	dtmehmetsaglam@gmail.com	Keles, Ali/J-5897-2015; Hatipoglu, Mukerrem/C-5431-2016; Hatipoglu, Mükerrem/HII-2944-2022; sağlam, mehmet/HGB-1702-2022	Keles, Ali/0000-0003-2835-767X; 				Baek KH, 2010, CALCIFIED TISSUE INT, V87, P226, DOI 10.1007/s00223-010-9393-9; Bahorun T, 2003, NAHRUNG, V47, P191, DOI 10.1002/food.200390045; Baltacioglu E, 2006, J CLIN PERIODONTOL, V33, P385, DOI 10.1111/j.1600-051X.2006.00923.x; Benli M, 2008, CELL BIOCHEM FUNCT, V26, P844, DOI 10.1002/cbf.1515; Bor Z, 2012, TURK J MED SCI, V42, P315, DOI 10.3906/sag-1011-1304; Bostanci V, 2014, J PERIODONTOL, V85, P706, DOI 10.1902/jop.2013.130230; Buduneli E, 2004, J PERIODONTOL, V75, P1516, DOI 10.1902/jop.2004.75.11.1516; Chapple ILC, 2007, PERIODONTOL 2000, V43, P160, DOI 10.1111/j.1600-0757.2006.00178.x; Chapple ILC, 1997, J CLIN PERIODONTOL, V24, P287, DOI 10.1111/j.1600-051X.1997.tb00760.x; de Lima V, 2000, EUR J ORAL SCI, V108, P123, DOI 10.1034/j.1600-0722.2000.00766.x; Demirer S, 2012, ARCH ORAL BIOL, V57, P60, DOI 10.1016/j.archoralbio.2011.07.012; Erel O, 2004, CLIN BIOCHEM, V37, P277, DOI 10.1016/j.clinbiochem.2003.11.015; Erel O, 2005, CLIN BIOCHEM, V38, P1103, DOI 10.1016/j.clinbiochem.2005.08.008; Flemmig T F, 1999, Ann Periodontol, V4, P32, DOI 10.1902/annals.1999.4.1.32; Greenstein G, 1998, J PERIODONTOL, V69, P507, DOI 10.1902/jop.1998.69.5.507; Hosseinimehr SJ, 2007, J RADIAT RES, V48, P63, DOI 10.1269/jrr.06032; Kao ES, 2005, J AGR FOOD CHEM, V53, P430, DOI 10.1021/jf040231f; Keser S., 2012, CHEM J, V2, P9; Kumar D, 2012, REV BRAS FARMACOGN, V22, P1187, DOI 10.1590/S0102-695X2012005000094; Lima V, 2004, J PERIODONTOL, V75, P162, DOI 10.1902/jop.2004.75.1.162; Ljubuncic P, 2005, J ETHNOPHARMACOL, V101, P153, DOI 10.1016/j.jep.2005.04.024; Luqman S, 2006, PHYTOTHER RES, V20, P303, DOI 10.1002/ptr.1861; Malekinejad H, 2013, J MED FOOD, V16, P593, DOI 10.1089/jmf.2012.2672; Niu Y, 2013, AFR J TRADIT COMPLEM, V10, P567; Oz HS, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/754857; Ozdemir H, 2012, J PERIODONTAL RES, V47, P74, DOI 10.1111/j.1600-0765.2011.01406.x; Popovic-Milenkovic MT, 2014, ACTA POL PHARM, V71, P279; ROBINSON M, 1991, LAB ANIM, V25, P247, DOI 10.1258/002367791780808374; Saglam M, 2014, J PERIODONTAL RES, V49, P472, DOI 10.1111/jre.12126; Saglam M, 2015, J APPL ORAL SCI, V23, P33, DOI 10.1590/1678-775720140288; Sozer U, 2006, SCI PHARM, V74, P189; Struillou X, 2010, OPEN DENT J, V4, P37, DOI 10.2174/1874210601004010037; Tadic VM, 2008, J AGR FOOD CHEM, V56, P7700, DOI 10.1021/jf801668c; Toker H, 2008, J PERIODONTOL, V79, P1089, DOI [10.1902/jop.2008.070462, 10.1902/jop.2008.070462 ]; Toker H, 2009, J PERIODONTOL, V80, P672, DOI 10.1902/jop.2009.080509; Yao M, 2008, J ETHNOPHARMACOL, V118, P127, DOI 10.1016/j.jep.2008.03.020	36	18	21	1	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 1	2015	10	6							e0128134	10.1371/journal.pone.0128134	http://dx.doi.org/10.1371/journal.pone.0128134			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CL0KF	26030160	gold, Green Published, Green Submitted			2023-01-03	WOS:000356630900113
J	Smith, LJ; Kalhan, R; Wise, RA; Sugar, EA; Lima, JJ; Irvin, CG; Dozor, AJ; Holbrook, JT				Smith, Lewis J.; Kalhan, Ravi; Wise, Robert A.; Sugar, Elizabeth A.; Lima, John J.; Irvin, Charles G.; Dozor, Allen J.; Holbrook, Janet T.		Amer Lung Assoc Asthma Clinical	Effect of a Soy Isoflavone Supplement on Lung Function and Clinical Outcomes in Patients With Poorly Controlled Asthma A Randomized Clinical Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							GUINEA-PIG MODEL; DIETARY-INTAKE; VITAMIN-C; GENISTEIN; RELIABILITY; VALIDITY; RESPONSIVENESS; PHYTOESTROGENS; CHALLENGE; MAGNESIUM	IMPORTANCE Soy isoflavone supplements are used to treat several chronic diseases, although the data supporting their use are limited. Some data suggest that supplementation with soy isoflavone may be an effective treatment for patients with poor asthma control. OBJECTIVE To determine whether a soy isoflavone supplement improves asthma control in adolescent and adult patients with poorly controlled disease. DESIGN, SETTING, AND PARTICIPANTS Multicenter, randomized, double-blind, placebo-controlled trial conducted between May 2010 and August 2012 at 19 adult and pediatric pulmonary and allergy centers in the American Lung Association Asthma Clinical Research Centers network. Three hundred eighty-six adults and children aged 12 years or older with symptomatic asthma while taking a controller medicine and low dietary soy intake were randomized, and 345 (89%) completed spirometry at week 24. INTERVENTIONS Participants were randomly assigned to receive soy isoflavone supplement containing 100mg of total isoflavones (n=193) or matching placebo (n=193) in 2 divided doses administered daily for 24 weeks. MAIN OUTCOMES AND MEASURES The primary outcome measure was change in forced expiratory volume in the first second (FEV1) at 24 weeks. Secondary outcome measures were symptoms, episodes of poor asthma control, Asthma Control Test score (range, 5-25; higher scores indicate better control), and systemic and airway biomarkers of inflammation. RESULTS Mean changes in prebronchodilator FEV1 over 24 weeks were 0.03 L (95% CI, -0.01 to 0.08 L) in the placebo group and 0.01 L (95% CI, -0.07 to 0.07 L) in the soy isoflavone group, which were not significantly different (P = .36). Mean changes in symptom scores on the Asthma Control Test (placebo, 1.98 [95% CI, 1.42-2.54] vs soy isoflavones, 2.20 [95% CI, 1.53-2.87]; positive values indicate a reduction in symptoms), number of episodes of poor asthma control (placebo, 3.3 [95% CI, 2.7-4.1] vs soy isoflavones, 3.0 [95% CI, 2.4-3.7]), and changes in exhaled nitric oxide (placebo, -3.48 ppb [95% CI, -5.99 to -0.97 ppb] vs soy isoflavones, 1.39 ppb [95% CI, -1.73 to 4.51 ppb]) did not significantly improve more with the soy isoflavone supplement than with placebo. Mean plasma genistein level increased from 4.87 ng/mL to 37.67 ng/mL (P < .001) in participants receiving the supplement. CONCLUSIONS AND RELEVANCE Among adults and children aged 12 years or older with poorly controlled asthma while taking a controller medication, use of a soy isoflavone supplement, compared with placebo, did not result in improved lung function or clinical outcomes. These findings suggest that this supplement should not be used for patients with poorly controlled asthma.	[Smith, Lewis J.; Kalhan, Ravi] Northwestern Univ, Feinberg Sch Med, Dept Med, Chicago, IL 60611 USA; [Wise, Robert A.; Sugar, Elizabeth A.; Holbrook, Janet T.] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Baltimore, MD USA; [Lima, John J.] Nemours Childrens Clin, Jacksonville, FL USA; [Irvin, Charles G.] Univ Vermont, Dept Med, Burlington, VT 05405 USA; [Dozor, Allen J.] New York Med Coll, Dept Pediat, Valhalla, NY 10595 USA	Northwestern University; Feinberg School of Medicine; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; University of Vermont; New York Medical College	Smith, LJ (corresponding author), Northwestern Univ, Feinberg Sch Med, 750 N Lake Shore Dr,Ste 707, Chicago, IL 60611 USA.	ljsmith@northwestern.edu		Wise, Robert/0000-0002-8353-2349; Vickery, Brian/0000-0002-7243-5543; Calhoun, William/0000-0001-7075-712X; Smith, Lewis J/0000-0002-4728-1562; Bime, Christian/0000-0003-4787-2685; Carr, Tara/0000-0002-6397-5396; Bacharier, Leonard/0000-0003-0432-2704; Kalhan, Ravi/0000-0003-2443-0876; Sumino, Kaharu/0000-0002-6214-2966; Land, Michael/0000-0001-8016-5419; , Rubin/0000-0002-1257-391X; Mougey, Edward/0000-0003-1190-6660	National Institutes of Health [U01 HL087987, U01 HL 0088367, U54TR001018]; American Lung Association; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [U54TR001018] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL087987, U01HL088367] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Lung Association; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	This study was supported by grants from the National Institutes of Health (grants U01 HL087987, U01 HL 0088367, and U54TR001018) and the American Lung Association. Archer Daniels Midland (Decatur, Illinois) provided the soy isoflavone supplement and the matching placebo.	Akinbami Lara J, 2012, NCHS Data Brief, P1; American Thoracic Society, 2005, AM J RESP CRIT CARE, V171, P912, DOI 10.1164/rccm.200406-710ST; Asmussen L, 1999, PEDIATRICS, V104, DOI 10.1542/peds.104.6.e71; Beasley R, 1998, LANCET, V351, P1225, DOI 10.1016/S0140-6736(97)07302-9; Bime C, 2012, PRIM CARE RESP J, V21, P398, DOI 10.4104/pcrj.2012.00073; Bime C, 2012, J ALLERGY CLIN IMMUN, V130, P1078, DOI 10.1016/j.jaci.2012.07.058; Block G, 1990, Epidemiology, V1, P58, DOI 10.1097/00001648-199001000-00013; Cullen KW, 2008, J AM DIET ASSOC, V108, P862, DOI 10.1016/j.jada.2008.02.015; Devereux G, 2005, J ALLERGY CLIN IMMUN, V115, P1109, DOI 10.1016/j.jaci.2004.12.1139; Duan W, 2003, AM J RESP CRIT CARE, V167, P185, DOI 10.1164/rccm.200205-420OC; Dweik RA, 2011, AM J RESP CRIT CARE, V184, P602, DOI 10.1164/rccm.9120-11ST; Fogarty A, 2006, RESP MED, V100, P174, DOI 10.1016/j.rmed.2005.03.038; Fogarty A, 2003, CLIN EXP ALLERGY, V33, P1355, DOI 10.1046/j.1365-2222.2003.01777.x; Ford ES, 2004, J ASTHMA, V41, P179, DOI 10.1081/JAS-120026075; Garcia V, 2005, EUR RESPIR J, V26, P449, DOI 10.1183/09031936.05.00142104; Grievink L, 1998, THORAX, V53, P166, DOI 10.1136/thx.53.3.166; Hanania NA, 2009, NEW ENGL J MED, V360, P1487, DOI 10.1056/NEJMoa0806290; Jackson RL, 2011, NUTR REV, V69, P432, DOI 10.1111/j.1753-4887.2011.00400.x; Janssen LJ, 2001, AM J PHYSIOL-LUNG C, V280, pL930, DOI 10.1152/ajplung.2001.280.5.L930; Kalhan R, 2008, CLIN EXP ALLERGY, V38, P103, DOI 10.1111/j.1365-2222.2007.02862.x; Kishi N, 2001, ANAL SCI, V17, P709, DOI 10.2116/analsci.17.709; Lagakos SW, 2006, NEW ENGL J MED, V354, P1667, DOI 10.1056/NEJMp068070; Lampe JW, 1998, P SOC EXP BIOL MED, V217, P335; MARKS GB, 1992, J CLIN EPIDEMIOL, V45, P461, DOI 10.1016/0895-4356(92)90095-5; McKeever TM, 2004, AM J RESP CRIT CARE, V170, P725, DOI 10.1164/rccm.200405-611PP; MESSINA M, 1995, J NUTR, V125, pS567, DOI 10.1093/jn/125.3_Suppl.567S; Miller MR, 2005, EUR RESPIR J, V26, P319, DOI 10.1183/09031936.05.00034805; Miyake Y, 2005, J ALLERGY CLIN IMMUN, V115, P1176, DOI 10.1016/j.jaci.2005.02.016; National Heart Lung and Blood Institute, ASTHM ACT PLAN; Pearson PJK, 2004, THORAX, V59, P652, DOI 10.1136/thx.2004.022616; Polkowski K, 2000, Acta Pol Pharm, V57, P135; RAM FS, 2004, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD000993.PUB2; Raviv S, 2010, CURR OPIN PULM MED, V16, P71, DOI 10.1097/MCP.0b013e3283323b73; Regal JF, 2000, P SOC EXP BIOL MED, V223, P372, DOI 10.1046/j.1525-1373.2000.22353.x; Revicki DA, 1998, CHEST, V114, P998, DOI 10.1378/chest.114.4.998; Rufer CE, 2006, J AGR FOOD CHEM, V54, P2926, DOI 10.1021/jf053112o; Schabath MB, 2005, JAMA-J AM MED ASSOC, V294, P1493, DOI 10.1001/jama.294.12.1493; Schatz M, 2006, J ALLERGY CLIN IMMUN, V117, P549, DOI 10.1016/j.jaci.2006.01.011; Schatz M, 2009, J ALLERGY CLIN IMMUN, V124, P719, DOI 10.1016/j.jaci.2009.06.053; SEATON A, 1994, THORAX, V49, P171, DOI 10.1136/thx.49.2.171; Smith LJ, 2004, J ASTHMA, V41, P833, DOI 10.1081/JAS-200038447; Stumpf K, 2000, CANCER EPIDEM BIOMAR, V9, P1369; Tepper RS, 2012, J ALLERGY CLIN IMMUN, V129, pS65, DOI 10.1016/j.jaci.2011.12.986; Wakai K, 1999, NUTR CANCER, V33, P139, DOI 10.1207/S15327914NC330204; Wang GJ, 2000, STEROIDS, V65, P339, DOI 10.1016/S0039-128X(00)00089-1; Yang Z, 2012, ANTI-CANCER AGENT ME, V12, P1264, DOI 10.2174/187152012803833107	46	33	34	0	22	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 26	2015	313	20					2033	2043		10.1001/jama.2015.5024	http://dx.doi.org/10.1001/jama.2015.5024			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CJ0DC	26010632	Green Accepted, Bronze			2023-01-03	WOS:000355142400017
J	Means, RT				Means, Robert T., Jr.			Review: IV iron does not increase serious adverse events compared with other forms of iron	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									E Tennessee State Univ, James H Quillen Coll Med, Johnson City, TN 37614 USA	East Tennessee State University	Means, RT (corresponding author), E Tennessee State Univ, James H Quillen Coll Med, Johnson City, TN 37614 USA.		Means, Robert T/A-4454-2008	Means, Robert/0000-0002-0947-2624				Auerbach M, 2008, AM J HEMATOL, V83, P580, DOI 10.1002/ajh.21154	1	0	0	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 19	2015	162	10							JC8	10.7326/ACPJC-2015-162-10-008	http://dx.doi.org/10.7326/ACPJC-2015-162-10-008			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CI8IF	25984881				2023-01-03	WOS:000355015200010
J	Rogers, L; Sergeeva, NN; Paszko, E; Vaz, GMF; Senge, MO				Rogers, Luke; Sergeeva, Natalia N.; Paszko, Edyta; Vaz, Gisela M. F.; Senge, Mathias O.			Lead Structures for Applications in Photodynamic Therapy. 6. Temoporfin Anti-Inflammatory Conjugates to Target the Tumor Microenvironment for In Vitro PDT	PLOS ONE			English	Article							AGENTS; RESPONSIVENESS; ACID; DRUG	Due to the ongoing development of clinical photodynamic therapy (PDT), the search continues for optimized photosensitizers that can overcome some of the side effects associated with this type of treatment modality. The main protagonists being: post-treatment photosensitivity, due to only limited cellular selectivity and post-treatment tumor regrowth, due to the up-regulation of pro-inflammatory agents within the tumor microenvironment. A photosensitizer that could overcome one or both of these drawbacks would be highly attractive to those engaged in clinical PDT. Certain non-steroidal anti-inflammatory drugs (NSAIDs) when used in combination with PDT have shown to increase the cytotoxicity of the treatment modality by targeting the tumor microenvironment. Temoporfin (m-THPC), the gold standard chlorin-based photosensitizer (PS) since its discovery in the 1980's, has successfully been conjugated to non-steroidal anti-inflammatory compounds, in an attempt to address the issue of post-treatment tumor regrowth. Using a modified Steglich esterification reaction, a library of "iPorphyrins" was successfully synthesized and evaluated for their PDT efficacy.	[Rogers, Luke; Senge, Mathias O.] Univ Dublin, Trinity Coll Dublin, Trinity Biomed Sci Inst, Sch Chem,SFI Tetrapyrrole Lab, Dublin 2, Ireland; [Sergeeva, Natalia N.; Paszko, Edyta; Vaz, Gisela M. F.; Senge, Mathias O.] St James Hosp, Trinity Coll Dublin, Trinity Ctr Hlth Sci, Med Chem,Inst Mol Med, Dublin 8, Ireland	Trinity College Dublin; Trinity College Dublin	Senge, MO (corresponding author), Univ Dublin, Trinity Coll Dublin, Trinity Biomed Sci Inst, Sch Chem,SFI Tetrapyrrole Lab, 152-160 Pearse St, Dublin 2, Ireland.	sengem@tcd.ie	Senge, Mathias O./F-1504-2011; Sergeeva, Natalia N/G-7265-2017	Senge, Mathias O./0000-0002-7467-1654; Sergeeva, Natalia N/0000-0003-0008-1560	Science Foundation Ireland (SFI) [12/TIDA/B2381, IvP 13/IA/1894]	Science Foundation Ireland (SFI)(Science Foundation Ireland)	MOS: Science Foundation Ireland (SFI, 12/TIDA/B2381 and IvP 13/IA/1894). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ADAMS S. S., 1967, PROGR MED CHEMPROGRESS IN MEDICINAL CHEMISTRY VOL 5, V5, P59, DOI 10.1016/S0079-6468(08)70442-9; ALTORKI N, 1993, CANCER-AM CANCER SOC, V72, P649, DOI 10.1002/1097-0142(19930801)72:3<649::AID-CNCR2820720305>3.0.CO;2-L; Bajaj S, 2004, BIOORGAN MED CHEM, V12, P3695, DOI 10.1016/j.bmc.2004.04.012; Bakar MB, 2009, TETRAHEDRON, V65, P7064, DOI 10.1016/j.tet.2009.06.037; Bauman DR, 2005, MOL PHARMACOL, V67, P60, DOI 10.1124/mol.104.006569; Bhuvaneswari R, 2009, CELL MOL LIFE SCI, V66, P2275, DOI 10.1007/s00018-009-0016-4; De Rosa A, 2011, CURR CANCER THER REV, V7, P234, DOI 10.2174/157339411796234889; Dolmans DEJGJ, 2003, NAT REV CANCER, V3, P380, DOI 10.1038/nrc1071; Dougherty TJ, 1998, JNCI-J NATL CANCER I, V90, P889, DOI 10.1093/jnci/90.12.889; Dubois RW, 2004, JCR-J CLIN RHEUMATOL, V10, P178, DOI 10.1097/01.rhu.0000128851.12010.46; Ethirajan M, 2011, CHEM SOC REV, V40, P340, DOI 10.1039/b915149b; Ferrario A, 2000, CANCER RES, V60, P4066; Ferrario A, 2005, CANCER RES, V65, P9473, DOI 10.1158/0008-5472.CAN-05-1659; Ferrario A, 2004, CANCER RES, V64, P2328, DOI 10.1158/0008-5472.CAN-04-0071; Ferrario A, 2011, CANCER LETT, V304, P33, DOI 10.1016/j.canlet.2011.01.023; Gomer CJ, 2010, HANDB PORPHYR SCI, V4, P425; Kessel D, 1999, REV CONTEMP PHARMACO, V10, P19; Laville I, 2003, BIOORGAN MED CHEM, V11, P1643, DOI 10.1016/S0968-0896(03)00050-6; Luna M, 2008, PHOTOCHEM PHOTOBIOL, V84, P509, DOI 10.1111/j.1751-1097.2007.00299.x; Montecucco F, 2010, EXPERT REV CARDIOVAS, V8, P1457, DOI 10.1586/ERC.10.116; NEISES B, 1978, ANGEW CHEM INT EDIT, V17, P522, DOI 10.1002/anie.197805221; NEWMAN MS, 1961, J ORG CHEM, V26, P2525, DOI 10.1021/jo01351a093; Nyman ES, 2004, J PHOTOCH PHOTOBIO B, V73, P1, DOI 10.1016/j.jphotobiol.2003.10.002; Peng XJ, 2005, ELECTROPHORESIS, V26, P3861, DOI 10.1002/elps.200500183; Proni G, 2003, J AM CHEM SOC, V125, P12914, DOI 10.1021/ja036294g; Radu A, 2005, PHOTODIAGN PHOTODYN, V2, P35, DOI 10.1016/S1572-1000(05)00035-9; Rancan F, 2005, J PHOTOCH PHOTOBIO B, V78, P17, DOI 10.1016/j.jphotobiol.2004.08.010; Rockett JC, 1997, BRIT J CANCER, V75, P258, DOI 10.1038/bjc.1997.42; Rogers L, 2014, EUR J ORG CHEM, V2014, P4283, DOI 10.1002/ejoc.201402433; Schuster DI, 2006, TETRAHEDRON, V62, P1928, DOI 10.1016/j.tet.2005.07.127; Senge MO, 2012, PHOTODIAGN PHOTODYN, V9, P170, DOI 10.1016/j.pdpdt.2011.10.001; Senge MO, 2011, PHOTOCHEM PHOTOBIOL, V87, P1240, DOI 10.1111/j.1751-1097.2011.00986.x; Smith WL, 2000, ANNU REV BIOCHEM, V69, P145, DOI 10.1146/annurev.biochem.69.1.145; Song J, 2014, J PHOTOCH PHOTOBIO B, V134, P27, DOI 10.1016/j.jphotobiol.2014.03.015; Vaz GMF, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070653; Weiss A, 2014, J CELL MOL MED, V18, P480, DOI 10.1111/jcmm.12199; WILLIAMS A, 1981, CHEM REV, V81, P589, DOI 10.1021/cr00046a004; Wu HY, 2011, TRAC-TREND ANAL CHEM, V30, P133, DOI 10.1016/j.trac.2010.08.009; ZUCKER MB, 1970, J LAB CLIN MED, V76, P66	39	17	19	0	25	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 19	2015	10	5							e0125372	10.1371/journal.pone.0125372	http://dx.doi.org/10.1371/journal.pone.0125372			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CI7BT	25992651	Green Published, gold			2023-01-03	WOS:000354918600014
J	Moler, FW; Silverstein, FS; Holubkov, R; Slomine, BS; Christensen, JR; Nadkarni, VM; Meert, KL; Clark, AE; Browning, B; Pemberton, VL; Page, K; Shankaran, S; Hutchison, JS; Newth, CJL; Bennett, KS; Berger, JT; Topjian, A; Pineda, JA; Koch, JD; Schleien, CL; Dalton, HJ; Ofori-Amanfo, G; Goodman, DM; Fink, EL; McQuillen, P; Zimmerman, JJ; Thomas, NJ; van der Jagt, EW; Porter, MB; Meyer, MT; Harrison, R; Pham, N; Schwarz, AJ; Nowak, JE; Alten, J; Wheeler, DS; Bhalala, US; Lidsky, K; Lloyd, E; Mathur, M; Shah, S; Wu, T; Theodorou, AA; Sanders, RC; Dean, JM				Moler, Frank W.; Silverstein, Faye S.; Holubkov, Richard; Slomine, Beth S.; Christensen, James R.; Nadkarni, Vinay M.; Meert, Kathleen L.; Clark, Amy E.; Browning, Brittan; Pemberton, Victoria L.; Page, Kent; Shankaran, Seetha; Hutchison, Jamie S.; Newth, Christopher J. L.; Bennett, Kimberly S.; Berger, John T.; Topjian, Alexis; Pineda, Jose A.; Koch, Joshua D.; Schleien, Charles L.; Dalton, Heidi J.; Ofori-Amanfo, George; Goodman, Denise M.; Fink, Ericka L.; McQuillen, Patrick; Zimmerman, Jerry J.; Thomas, Neal J.; van der Jagt, Elise W.; Porter, Melissa B.; Meyer, Michael T.; Harrison, Rick; Nga Pham; Schwarz, Adam J.; Nowak, Jeffrey E.; Alten, Jeffrey; Wheeler, Derek S.; Bhalala, Utpal S.; Lidsky, Karen; Lloyd, Eric; Mathur, Mudit; Shah, Samir; Wu, Theodore; Theodorou, Andreas A.; Sanders, Ronald C., Jr.; Dean, J. Michael		THAPCA Trial Investigators	Therapeutic Hypothermia after Out-of-Hospital Cardiac Arrest in Children	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HYPOXIC-ISCHEMIC ENCEPHALOPATHY; AMERICAN-HEART-ASSOCIATION; TRAUMATIC BRAIN-INJURY; WHOLE-BODY HYPOTHERMIA; CARE; CARDIOPULMONARY; RESUSCITATION; TEMPERATURE; EXPERIENCE; EPIDEMIOLOGY	BACKGROUND Therapeutic hypothermia is recommended for comatose adults after witnessed out-of-hospital cardiac arrest, but data about this intervention in children are limited. METHODS We conducted this trial of two targeted temperature interventions at 38 children's hospitals involving children who remained unconscious after out-of-hospital cardiac arrest. Within 6 hours after the return of circulation, comatose patients who were older than 2 days and younger than 18 years of age were randomly assigned to therapeutic hypothermia (target temperature, 33.0 degrees C) or therapeutic normothermia (target temperature, 36.8 degrees C). The primary efficacy outcome, survival at 12 months after cardiac arrest with a Vineland Adaptive Behavior Scales, second edition (VABS-II), score of 70 or higher (on a scale from 20 to 160, with higher scores indicating better function), was evaluated among patients with a VABS-II score of at least 70 before cardiac arrest. RESULTS A total of 295 patients underwent randomization. Among the 260 patients with data that could be evaluated and who had a VABS-II score of at least 70 before cardiac arrest, there was no significant difference in the primary outcome between the hypothermia group and the normothermia group (20% vs. 12%; relative likelihood, 1.54; 95% confidence interval [CI], 0.86 to 2.76; P=0.14). Among all the patients with data that could be evaluated, the change in the VABS-II score from baseline to 12 months was not significantly different (P=0.13) and 1-year survival was similar (38% in the hypothermia group vs. 29% in the normothermia group; relative likelihood, 1.29; 95% CI, 0.93 to 1.79; P=0.13). The groups had similar incidences of infection and serious arrhythmias, as well as similar use of blood products and 28-day mortality. CONCLUSIONS In comatose children who survived out-of-hospital cardiac arrest, therapeutic hypothermia, as compared with therapeutic normothermia, did not confer a significant benefit in survival with a good functional outcome at 1 year.	[Moler, Frank W.; Silverstein, Faye S.] Univ Michigan, Ann Arbor, MI 48109 USA; [Meert, Kathleen L.; Shankaran, Seetha] Wayne State Univ, Detroit, MI USA; [Holubkov, Richard; Clark, Amy E.; Browning, Brittan; Page, Kent; Bennett, Kimberly S.; Dean, J. Michael] Univ Utah, Salt Lake City, UT USA; [Slomine, Beth S.; Christensen, James R.] Kennedy Krieger Inst, Baltimore, MD USA; [Slomine, Beth S.; Christensen, James R.] Johns Hopkins Univ, Baltimore, MD USA; [Bhalala, Utpal S.] Johns Hopkins Childrens Ctr, Baltimore, MD USA; [Pemberton, Victoria L.] NHLBI, Bethesda, MD 20892 USA; [Nadkarni, Vinay M.; Topjian, Alexis] Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA; [Fink, Ericka L.] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA; [Thomas, Neal J.] Penn State Hershey Childrens Hosp, Hershey, PA USA; [Hutchison, Jamie S.] Hosp Sick Children, Toronto, ON M5G 1X8, Canada; [Newth, Christopher J. L.] Childrens Hosp Los Angeles, Los Angeles, CA 90027 USA; [Harrison, Rick] Mattel Childrens Hosp UCLA, Los Angeles, CA USA; [McQuillen, Patrick] Univ Calif San Francisco, Benioff Childrens Hosp, San Francisco, CA 94143 USA; [Schwarz, Adam J.] Childrens Hosp Orange Cty, Orange, CA 92668 USA; [Mathur, Mudit] Loma Linda Univ, Childrens Hosp, Loma Linda, CA 92350 USA; [Berger, John T.] Childrens Natl Med Ctr, Washington, DC 20010 USA; [Pineda, Jose A.] Washington Univ, St Louis, MO 63130 USA; [Koch, Joshua D.] Childrens Med Ctr Dallas, Dallas, TX USA; [Koch, Joshua D.] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA; [Wu, Theodore] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA; [Schleien, Charles L.] Columbia Univ, Med Ctr, New York Presbyterian Morgan Stanley Childrens Ho, New York, NY USA; [van der Jagt, Elise W.] Univ Rochester, Med Ctr, Golisano Childrens Hosp, Rochester, NY 14642 USA; [Dalton, Heidi J.] Phoenix Childrens Hosp, Phoenix, AZ USA; [Theodorou, Andreas A.] Diamond Childrens Med Ctr, Tucson, AZ USA; [Ofori-Amanfo, George] Duke Childrens Hosp & Hlth Ctr, Durham, NC USA; [Goodman, Denise M.] Ann & Robert H Lurie Childrens Hosp Chicago, Chicago, IL 60611 USA; [Zimmerman, Jerry J.] Seattle Childrens Hosp, Seattle, WA USA; [Porter, Melissa B.] Univ Louisville, Kosair Childrens Hosp, Louisville, KY 40292 USA; [Meyer, Michael T.] Med Coll Wisconsin, Milwaukee, WI 53226 USA; [Nga Pham] Childrens Healthcare Atlanta, Atlanta, GA USA; [Nowak, Jeffrey E.] Childrens Hosp & Clin Minnesota, Minneapolis, MN USA; [Alten, Jeffrey] Childrens Alabama, Birmingham, AL USA; [Wheeler, Derek S.] Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH 45229 USA; [Lidsky, Karen] Rainbow Babies & Childrens Hosp, Cleveland, OH 44106 USA; [Lloyd, Eric] Nationwide Childrens Hosp, Columbus, OH USA; [Shah, Samir] Univ Tennessee, Ctr Hlth Sci, Memphis, TN 38163 USA; [Sanders, Ronald C., Jr.] Arkansas Childrens Hosp, Little Rock, AR 72202 USA	University of Michigan System; University of Michigan; Wayne State University; Utah System of Higher Education; University of Utah; Kennedy Krieger Institute; Johns Hopkins University; Johns Hopkins University; Johns Hopkins Medicine; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); Children's Hospital Los Angeles; University of California System; University of California San Francisco; Childrens Hospital of Orange County; Children's Hospital Los Angeles; Loma Linda University; Children's National Health System; Washington University (WUSTL); University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Health San Antonio; Columbia University; NewYork-Presbyterian Hospital; Morgan Stanley Children's Hospital; University of Rochester; Phoenix Children's Hospital; Duke University; Ann & Robert H. Lurie Children's Hospital of Chicago; Seattle Children's Hospital; University of Louisville; Medical College of Wisconsin; Children's Healthcare of Atlanta (CHOA); Children's Hospitals & Clinics of Minnesota; Cincinnati Children's Hospital Medical Center; Case Western Reserve University; Case Western Reserve University Hospital; University Hospitals of Cleveland; Rainbow Babies & Children's Hospital; University System of Ohio; Ohio State University; Nationwide Childrens Hospital; University of Tennessee System; University of Tennessee Health Science Center; Arkansas Children's Hospital	Moler, FW (corresponding author), Univ Michigan Hlth Syst, F-6900 UH South,SPF 5243,1500 E Med Ctr Dr, Ann Arbor, MI 48109 USA.	fmoler@umich.edu	Fink, Ericka/AAU-9792-2021; McQuillen, Patrick/AAF-7119-2020; Hahn, Cecil/J-3372-2016; Pineda, Jose/W-2806-2019	Hahn, Cecil/0000-0002-0887-8761; Holubkov, Richard/0000-0003-0431-3381; Michelson, David/0000-0002-0600-3523; McQuillen, Patrick/0000-0002-8837-364X; Stavinoha, Peter L/0000-0002-3955-9579; Goodman, Denise/0000-0001-9766-9453; Thomas, Neal/0000-0002-7991-7510; Peters, Mark/0000-0003-3653-4808	National Heart, Lung, and Blood Institute; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [U10HD050012, UG1HD050096, U10HD050096, U10HD049983, U01HD049934, U10HD049981] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [U10HD049945, R21HD044955, R34HD050531] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000433] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL094345, U01HL094339] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [K23NS075363] Funding Source: NIH RePORTER	National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	Funded by the National Heart, Lung, and Blood Institute and others; THAPCA-OH ClinicalTrials.gov number, NCT00878644.	Adelson PD, 2013, LANCET NEUROL, V12, P546, DOI 10.1016/S1474-4422(13)70077-2; [Anonymous], 1995, MULL SCAL EARL LEARN; Azzopardi DV, 2009, NEW ENGL J MED, V361, P1349, DOI 10.1056/NEJMoa0900854; Bernard SA, 2002, NEW ENGL J MED, V346, P557, DOI 10.1056/NEJMoa003289; BOHN DJ, 1986, CRIT CARE MED, V14, P529, DOI 10.1097/00003246-198606000-00002; Clifton GL, 2001, NEW ENGL J MED, V344, P556, DOI 10.1056/NEJM200102223440803; Clifton GL, 2001, J NEUROSURG, V95, P751, DOI 10.3171/jns.2001.95.5.0751; Doherty DR, 2009, CIRCULATION, V119, P1492, DOI 10.1161/CIRCULATIONAHA.108.791384; Donoghue AJ, 2005, ANN EMERG MED, V46, P512, DOI 10.1016/j.annemergmed.2005.05.028; Field D, 2013, PEDIATRICS, V132, pE1247, DOI 10.1542/peds.2013-1754; Fink EL, 2010, PEDIATR CRIT CARE ME, V11, P66, DOI 10.1097/PCC.0b013e3181c58237; Fiser DH, 2000, CRIT CARE MED, V28, P2616, DOI 10.1097/00003246-200007000-00072; Hickey RW, 2000, PEDIATRICS, V106, P118, DOI 10.1542/peds.106.1.118; Holubkov R, 2015, PEDIATR CRIT CARE ME, V16, P1, DOI 10.1097/PCC.0000000000000272; Holzer M, 2002, NEW ENGL J MED, V346, P549; Hutchison J, 2006, DEV NEUROSCI-BASEL, V28, P291, DOI 10.1159/000094155; Hutchison JS, 2008, NEW ENGL J MED, V358, P2447, DOI 10.1056/NEJMoa0706930; Jacobs SE, 2011, ARCH PEDIAT ADOL MED, V165, P692, DOI 10.1001/archpediatrics.2011.43; Kochanek PM, 2009, J NEUROTRAUM, V26, P421, DOI 10.1089/neu.2008.0587; Laptook A, 2008, PEDIATRICS, V122, P491, DOI 10.1542/peds.2007-1673; Marshall LF, 2001, J NEUROSURG, V95, P733, DOI 10.3171/jns.2001.95.5.0733; Moler FW, 2013, PEDIATR CRIT CARE ME, V14, pE304, DOI 10.1097/PCC.0b013e31828a863a; Moler FW, 2011, CRIT CARE MED, V39, P141, DOI 10.1097/CCM.0b013e3181fa3c17; Moler FW, 2009, CRIT CARE MED, V37, P2259, DOI 10.1097/CCM.0b013e3181a00a6a; Neumar RW, 2008, CIRCULATION, V118, P2452, DOI 10.1161/CIRCULATIONAHA.108.190652; Nielsen N, 2013, NEW ENGL J MED, V369, P2197, DOI 10.1056/NEJMoa1310519; OBRIEN PC, 1979, BIOMETRICS, V35, P549, DOI 10.2307/2530245; Papile LA, 2014, PEDIATRICS, V133, P1146, DOI 10.1542/peds.2014-0899; Peberdy MA, 2010, CIRCULATION, V122, pS768, DOI 10.1161/CIRCULATIONAHA.110.971002; Pemberton VL, 2013, PEDIATR CRIT CARE ME, V14, P19, DOI 10.1097/PCC.0b013e31825b860b; Psychological Corporation, 1999, WECHSL ABBR SCAL INT; Scholefield B, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009442.pub2; Shankaran S, 2005, NEW ENGL J MED, V353, P1574, DOI 10.1056/NEJMcps050929; Sparrow S. S., 2005, VINELAND ADAPTIVE BE, DOI [10.1037/t15164-000, DOI 10.1037/T15164-000]; VANELTEREN P, 1960, B INT STATIST INST, V37, P351; Young KD, 2004, PEDIATRICS, V114, P157, DOI 10.1542/peds.114.1.157; Zeiner A, 2001, ARCH INTERN MED, V161, P2007, DOI 10.1001/archinte.161.16.2007	37	272	281	1	32	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 14	2015	372	20					1898	1908		10.1056/NEJMoa1411480	http://dx.doi.org/10.1056/NEJMoa1411480			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CI1HB	25913022	Green Accepted, Bronze			2023-01-03	WOS:000354493300005
J	Li, X; Peng, MK; Li, Y; Kang, Z; Hao, YH; Sun, H; Gao, LJ; Jiao, ML; Wu, QH; Quan, HD				Li, Xia; Peng, Mingkai; Li, Yuan; Kang, Zheng; Hao, Yanhua; Sun, Hong; Gao, Lijun; Jiao, Mingli; Wu, Qunhong; Quan, Hude			Chinese Herbal Therapy and Western Drug Use, Belief and Adherence for Hypertension Management in the Rural Areas of Heilongjiang Province, China	PLOS ONE			English	Article							ALTERNATIVE MEDICINE USE; RHEUMATIC-DISEASES; BLOOD-PRESSURE; PREVALENCE; KNOWLEDGE; AWARENESS; VALIDITY; EQ-5D	Background Traditional Chinese medicine (TCM) including Chinese herbal therapy has been widely practiced in China. However, little is known about Chinese herbal therapy use for hypertension management, which is one of the most prevalent chronic conditions in China. Thus we described Chinese herbal therapy and western drug users, beliefs, hypertension knowledge, and Chinese herbal and western drug adherence and determinants of Chinese herbal therapy use among patients with hypertension in rural areas of Heilongjiang Province, China. Methodology and Principal Findings This face-to-face cross sectional survey included 665 hypertensive respondents aged 30 years or older in rural areas of Heilongjiang Province, China. Of 665 respondents, 39.7% were male, 27.4% were aged 65 years or older. At the survey, 14.0% reported using Chinese herbal therapy and 71.3% reported using western drug for hypertension management. A majority of patients had low level of treatment adherence (80.6% for the Chinese herbal therapy users and 81.2% for the western drug users). When respondents felt that their blood pressure was under control, 72.0% of the Chinese herbal therapy users and 69.2% of the western drug users sometimes stopped taking their medicine. Hypertensive patients with high education level or better quality of life are more likely use Chinese herbal therapy. Conclusions and Significance Majority of patients diagnosed with hypertension use western drugs to control blood pressure. Chinese herbal therapy use was associated with education level and quality of life.	[Li, Xia; Li, Yuan; Kang, Zheng; Hao, Yanhua; Sun, Hong; Gao, Lijun; Jiao, Mingli; Wu, Qunhong; Quan, Hude] Harbin Med Univ, Sch Publ Hlth, Dept Social Med, Harbin, Peoples R China; [Peng, Mingkai; Quan, Hude] Univ Calgary, Dept Community Hlth Sci, Calgary, AB, Canada; [Li, Xia] Harbin Med Univ, Coll Pharm, Harbin, Peoples R China	Harbin Medical University; University of Calgary; Harbin Medical University	Wu, QH (corresponding author), Harbin Med Univ, Sch Publ Hlth, Dept Social Med, Harbin, Peoples R China.	wuqunhong@163.com	hao, yan/HGB-0465-2022	Quan, Hude/0000-0002-7848-7256	China Medical Board [08-929]; key program National Natural Science Foundation of China [71333003]; Fund of Heilongjiang Province Education Department [12511316]; Heilongjiang Postdoctoral fund [LBH-Z14175]	China Medical Board; key program National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Fund of Heilongjiang Province Education Department; Heilongjiang Postdoctoral fund	This study was funded by China Medical Board grant (Grant No. 08-929), the key program National Natural Science Foundation of China (Grant No. 71333003), Fund of Heilongjiang Province Education Department (Grant No. 12511316) and Heilongjiang Postdoctoral fund (Grant No. LBH-Z14175). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 2010, CARDIOVASCULAR DIS R; Astin JA, 1998, JAMA-J AM MED ASSOC, V279, P1548, DOI 10.1001/jama.279.19.1548; Burstein HJ, 1999, NEW ENGL J MED, V340, P1733, DOI 10.1056/NEJM199906033402206; CHOBANIAN AV, 2003, HYPERTENSION, V42, P1206, DOI [DOI 10.1161/01.HYP.0000107251.49515.c2, DOI 10.1161/01.HYP.0000107251.49515.C2]; Chou P, 2001, Zhonghua Yi Xue Za Zhi (Taipei), V64, P191; Cunningham CT, 2014, ETHNIC DIS, V24, P276; Eisenberg DM, 1998, JAMA-J AM MED ASSOC, V280, P1569, DOI 10.1001/jama.280.18.1569; Fang YY, 2001, CHINESE J INFORM TRA, V8, P1; Gu DF, 2002, HYPERTENSION, V40, P920, DOI 10.1161/01.HYP.0000040263.94619.D5; Hilsden RJ, 2011, INFLAMM BOWEL DIS, V17, P655, DOI 10.1002/ibd.21360; Hoeymans N, 2005, QUAL LIFE RES, V14, P655, DOI 10.1007/s11136-004-1214-z; Kim MH, 2005, QUAL LIFE RES, V14, P1401, DOI 10.1007/s11136-004-5681-z; King KM, 2011, J ADV NURS, V67, P2267, DOI 10.1111/j.1365-2648.2011.05679.x; Lam TP, 2001, J EPIDEMIOL COMMUN H, V55, P762, DOI 10.1136/jech.55.10.762; Liao CC, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/387164; Luo N, 2003, ANN ACAD MED SINGAP, V32, P685; Ma WJ, 2012, AM J HYPERTENS, V25, P590, DOI 10.1038/ajh.2012.11; Makridakis S, 2014, OPEN HEART, V1, DOI 10.1136/openhrt-2014-000048; Morisky DE, 2008, J CLIN HYPERTENS, V10, P348, DOI 10.1111/j.1751-7176.2008.07572.x; Quan H, 2007, CAN J CARDIOL, V23, P635, DOI 10.1016/S0828-282X(07)70225-8; Quan HD, 2008, CAN FAM PHYSICIAN, V54, P1563; Sanne S, 2008, ETHNIC DIS, V18, P42; Shi NN, 2013, J ALTERN COMPLEM MED, V19, P1, DOI 10.1089/acm.2011.0776; Tan Jie, 2008, Zhongguo Zhong Xi Yi Jie He Za Zhi, V28, P897; Verhoef Marja J, 2005, Integr Cancer Ther, V4, P274, DOI 10.1177/1534735405282361; Wang HX, 2008, CHINESE ARCH TRADITI, V26, P338; Wang LD, 2005, COMPREHENSIVE REPORT; Williams MV, 1998, ARCH INTERN MED, V158, P166, DOI 10.1001/archinte.158.2.166; Yang TY, 2012, PHYTOTHER RES, V26, P291, DOI 10.1002/ptr.3548; Zhang JJ, 2002, SOC SCI MED, V55, P1795, DOI 10.1016/S0277-9536(01)00311-2; Zhao YK, 2005, CHINESE HLTH SERVICE, P504; Zhong GW, 2011, CHIN J INTEGR MED, V17, P414, DOI 10.1007/s11655-011-0761-6	32	3	5	1	18	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 29	2015	10	4							e0123508	10.1371/journal.pone.0123508	http://dx.doi.org/10.1371/journal.pone.0123508			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	CH0LO	25923438	gold, Green Published, Green Submitted			2023-01-03	WOS:000353711600050
J	Nathan, G; Kredo-Russo, S; Geiger, T; Lenz, A; Kaspi, H; Hornstein, E; Efrat, S				Nathan, Gili; Kredo-Russo, Sharon; Geiger, Tamar; Lenz, Ayelet; Kaspi, Haggai; Hornstein, Eran; Efrat, Shimon			MiR-375 Promotes Redifferentiation of Adult Human beta Cells Expanded In Vitro	PLOS ONE			English	Article							GLYCOGEN-SYNTHASE KINASE-3; MESENCHYMAL TRANSITION; MICRORNA EXPRESSION; INSULIN; PROTEIN; PHOSPHORYLATION; GLUCOSE; PROLIFERATION; STABILITY; ABLATION	In-vitro expansion of beta cells from adult human pancreatic islets could provide abundant cells for cell replacement therapy of diabetes. However, proliferation of beta-cell-derived (BCD) cells is associated with dedifferentiation. Here we analyzed changes inmicroRNAs (miRNAs) during BCD cell dedifferentiation and identified miR-375 as one of the miRNAs greatly downregulated. We hypothesized that restoration of miR-375 expression in expanded BCD cells may contribute to their redifferentiation. Our findings demonstrate that overexpression of miR-375 alone leads to activation of beta-cell gene expression, reduced cell proliferation, and a switch from N-cadherin to E-cadherin expression, which characterizes mesenchymal-epithelial transition. These effects, which are reproducible in cells derived from multiple human donors, are likely mediated by repression of PDPK1 transcripts and indirect downregulation of GSK3 activity. These findings support an important role of miR-375 in regulation of human beta-cell phenotype, and suggest that miR-375 upregulation may facilitate the generation of functional insulin-producing cells following ex-vivo expansion of human islet cells.	[Nathan, Gili; Geiger, Tamar; Lenz, Ayelet; Efrat, Shimon] Tel Aviv Univ, Dept Human Mol Genet & Biochem, Sackler Sch Med, IL-69978 Tel Aviv, Israel; [Kredo-Russo, Sharon; Kaspi, Haggai; Hornstein, Eran] Weizmann Inst Sci, Dept Mol Genet, IL-76100 Rehovot, Israel	Tel Aviv University; Sackler Faculty of Medicine; Weizmann Institute of Science	Efrat, S (corresponding author), Tel Aviv Univ, Dept Human Mol Genet & Biochem, Sackler Sch Med, IL-69978 Tel Aviv, Israel.	sefrat@post.tau.ac.il		Efrat, Shimon/0000-0001-5987-232X; Geiger, Tamar/0000-0002-9526-197X	Israel Science Foundation	Israel Science Foundation(Israel Science Foundation)	This work was funded by a grant from the Israel Science Foundation to SE. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Bar-Nur O, 2011, CELL STEM CELL, V9, P17, DOI 10.1016/j.stem.2011.06.007; Baskerville S, 2005, RNA, V11, P241, DOI 10.1261/rna.7240905; Boucher MJ, 2006, J BIOL CHEM, V281, P6395, DOI 10.1074/jbc.M511597200; Bravo-Egana V, 2008, BIOCHEM BIOPH RES CO, V366, P922, DOI 10.1016/j.bbrc.2007.12.052; Correa-Medina M, 2009, GENE EXPR PATTERNS, V9, P193, DOI 10.1016/j.gep.2008.12.003; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Cross DAE, 2001, J NEUROCHEM, V77, P94, DOI 10.1046/j.1471-4159.2001.00251.x; El Ouaamari A, 2008, DIABETES, V57, P2708, DOI 10.2337/db07-1614; Eldar-Finkelman H, 2002, TRENDS MOL MED, V8, P126, DOI 10.1016/S1471-4914(01)02266-3; Elghazi L, 2009, GASTROENTEROLOGY, V136, P1091, DOI 10.1053/j.gastro.2008.11.043; Fabian MR, 2010, ANNU REV BIOCHEM, V79, P351, DOI 10.1146/annurev-biochem-060308-103103; Gregory PA, 2008, NAT CELL BIOL, V10, P593, DOI 10.1038/ncb1722; Han S, 2007, MOL CELL BIOL, V27, P6593, DOI 10.1128/MCB.01573-06; Hashimoto N, 2006, NAT GENET, V38, P589, DOI 10.1038/ng1774; Hong S, 2014, NEOPLASIA, V16, P279, DOI 10.1016/j.neo.2014.03.010; Humphrey RK, 2010, J BIOL CHEM, V285, P3406, DOI 10.1074/jbc.M109.006734; Joglekar MV, 2009, ISLETS, V1, P137, DOI 10.4161/isl.1.2.9578; Joglekar MV, 2009, GENE EXPR PATTERNS, V9, P109, DOI 10.1016/j.gep.2008.10.001; Kameswaran V, 2014, CELL METAB, V19, P135, DOI 10.1016/j.cmet.2013.11.016; Klein D, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055064; Kredo-Russo S, 2012, DEVELOPMENT, V139, P3021, DOI 10.1242/dev.080127; Latreille M, 2014, J CLIN INVEST, V124, P2722, DOI 10.1172/JCI73066; Liu Y, 2010, DIABETOLOGIA, V53, P2600, DOI 10.1007/s00125-010-1882-x; Lynn FC, 2007, DIABETES, V56, P2938, DOI 10.2337/db07-0175; Melkman-Zehavi T, 2011, EMBO J, V30, P835, DOI 10.1038/emboj.2010.361; Ougolkov Andrei V, 2006, Future Oncol, V2, P91, DOI 10.2217/14796694.2.1.91; Ouziel-Yahalom L, 2006, BIOCHEM BIOPH RES CO, V341, P291, DOI 10.1016/j.bbrc.2005.12.187; Patel S, 2008, CANCER CELL, V14, P351, DOI 10.1016/j.ccr.2008.10.013; Poy MN, 2009, P NATL ACAD SCI USA, V106, P5813, DOI 10.1073/pnas.0810550106; Poy MN, 2004, NATURE, V432, P226, DOI 10.1038/nature03076; Rossig L, 2001, MOL CELL BIOL, V21, P5644, DOI 10.1128/MCB.21.16.5644-5657.2001; Russ HA, 2008, DIABETES, V57, P1575, DOI 10.2337/db07-1283; Russ HA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025566; Russ HA, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006417; Silahtaroglu AN, 2007, NAT PROTOC, V2, P2520, DOI 10.1038/nprot.2007.313; Valenta T, 2012, EMBO J, V31, P2714, DOI 10.1038/emboj.2012.150; Wienholds E, 2005, SCIENCE, V309, P310, DOI 10.1126/science.1114519	38	46	50	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 13	2015	10	4							e0122108	10.1371/journal.pone.0122108	http://dx.doi.org/10.1371/journal.pone.0122108			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CF8XK	25875172	gold, Green Submitted, Green Published			2023-01-03	WOS:000352845100058
J	Moghadamtousi, SZ; Rouhollahi, E; Karimian, H; Fadaeinasab, M; Firoozinia, M; Abdulla, MA; Kadir, HA				Moghadamtousi, Soheil Zorofchian; Rouhollahi, Elham; Karimian, Hamed; Fadaeinasab, Mehran; Firoozinia, Mohammad; Abdulla, Mahmood Ameen; Kadir, Habsah Abdul			The Chemopotential Effect of Annona muricata Leaves against Azoxymethane-Induced Colonic Aberrant Crypt Foci in Rats and the Apoptotic Effect of Acetogenin Annomuricin E in HT-29 Cells: A Bioassay-Guided Approach	PLOS ONE			English	Article							NUCLEAR ANTIGEN PCNA; LIPID-PEROXIDATION; OXIDATIVE STRESS; ANTIOXIDANT STATUS; MEDIATED PATHWAY; NATURAL-PRODUCTS; CANCER-CELLS; EXTRACT; EXPRESSION; FAMILY	Annona muricata has been used in folk medicine for the treatment of cancer and tumors. This study evaluated the chemopreventive properties of an ethyl acetate extract of Annona muricata leaves (EEAML) on azoxymethane-induced colonic aberrant crypt foci (ACF) in rats. Moreover, the cytotoxic compound of EEAML (Annomuricin E) was isolated, and its apoptosis-inducing effect was investigated against HT-29 colon cancer cell line using a bioassay-guided approach. This experiment was performed on five groups of rats: negative control, cancer control, EEAML (250 mg/kg), EEAML (500 mg/kg) and positive control (5-fluorouracil). Methylene blue staining of colorectal specimens showed that application of EEAML at both doses significantly reduced the colonic ACF formation compared with the cancer control group. Immunohistochemistry analysis showed the down-regulation of PCNA and Bcl-2 proteins and the up-regulation of Bax protein after administration of EEAML compared with the cancer control group. In addition, an increase in the levels of enzymatic antioxidants and a decrease in the malondialdehyde level of the colon tissue homogenates were observed, suggesting the suppression of lipid peroxidation. Annomuricin E inhibited the growth of HT-29 cells with an IC50 value of 1.62 +/- 0.24 mu g/ml after 48 h. The cytotoxic effect of annomuricin E was further substantiated by G1 cell cycle arrest and early apoptosis induction in HT-29 cells. Annomuricin E triggered mitochondria-initiated events, including the dissipation of the mitochondrial membrane potential and the leakage of cytochrome c from the mitochondria. Prior to these events, annomuricin E activated caspase 3/7 and caspase 9. Upstream, annomuricin E induced a time-dependent upregulation of Bax and downregulation of Bcl-2 at the mRNA and protein levels. In conclusion, these findings substantiate the usage of Annona muricata leaves in ethnomedicine against cancer and highlight annomuricin E as one of the contributing compounds in the anticancer activity of Annona muricata leaves.	[Moghadamtousi, Soheil Zorofchian; Kadir, Habsah Abdul] Univ Malaya, Fac Sci, Inst Biol Sci, Biochem Program,Biomol Res Grp, Kuala Lumpur, Malaysia; [Rouhollahi, Elham; Karimian, Hamed; Abdulla, Mahmood Ameen] Univ Malaya, Fac Sci, Dept Biomed Sci, Kuala Lumpur, Malaysia; [Fadaeinasab, Mehran] Univ Malaya, Fac Sci, Dept Chem, Kuala Lumpur, Malaysia	Universiti Malaya; Universiti Malaya; Universiti Malaya	Kadir, HA (corresponding author), Univ Malaya, Fac Sci, Inst Biol Sci, Biochem Program,Biomol Res Grp, Kuala Lumpur, Malaysia.	habsah@um.edu.my	ABDUL KADIR, HABSAH/B-8561-2010; Fadaeinasab, Mehran/A-8810-2016	Fadaeinasab, Mehran/0000-0002-2501-894X	University of Malaya High Impact Research Chancellery [UM.C/625/1/HIR/175]; University of Malaya Research Grant [RP001-2012C]; Postgraduate Research Fund [PG118-2013A]	University of Malaya High Impact Research Chancellery; University of Malaya Research Grant; Postgraduate Research Fund	This research was supported by the University of Malaya High Impact Research Chancellery (UM.C/625/1/HIR/175), University of Malaya Research Grant (RP001-2012C), and Postgraduate Research Fund (PG118-2013A). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abe K, 2000, NEUROSCI RES, V38, P325, DOI 10.1016/S0168-0102(00)00188-7; Adewole SO, 2006, AFR J BIOMED RES, V9, P173, DOI [10.4314/ajbr.v9i3.48903, DOI 10.4314/AJBR.V9I3.48903]; Adewole SO, 2009, AFR J TRADIT COMPLEM, V6, P30; Alali FQ, 1999, J NAT PROD, V62, P504, DOI 10.1021/np980406d; Almagrami AA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096004; Alrawi SJ, 2006, ANTICANCER RES, V26, P107; Bardi DA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109424; Bardi DA, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/918460; Baskar R, 2007, INDIAN J EXP BIOL, V45, P480; Bermejo A, 2005, NAT PROD REP, V22, P269, DOI 10.1039/b500186m; BIRD RP, 1987, CANCER LETT, V37, P147, DOI 10.1016/0304-3835(87)90157-1; BIRD RP, 1995, CANCER LETT, V93, P55, DOI 10.1016/0304-3835(95)03788-X; Blokhina O, 2003, ANN BOT-LONDON, V91, P179, DOI 10.1093/aob/mcf118; Bouvard V, 2009, LANCET ONCOL, V10, P321, DOI 10.1016/S1470-2045(09)70096-8; Brumatti G, 2008, METHODS, V44, P235, DOI 10.1016/j.ymeth.2007.11.010; Cerea G, 2003, ANTICANCER RES, V23, P1951; Chen WL, 2003, AM J CHINESE MED, V31, P523, DOI 10.1142/S0192415X0300120X; Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883; DELEON MP, 1988, CANCER RES, V48, P4121; Demircan B, 2005, PAIN CLINIC, V17, P383; DESCHNER EE, 1983, J NATL CANCER I, V70, P279; Elmore S, 2007, TOXICOL PATHOL, V35, P495, DOI 10.1080/01926230701320337; Ezirim A., 2013, INDIAN J DRUGS DIS, V2, P241; Fan TJ, 2005, ACTA BIOCH BIOPH SIN, V37, P719, DOI 10.1111/j.1745-7270.2005.00108.x; Fenoglio-Preiser CM, 1999, TOXICOL PATHOL, V27, P632, DOI 10.1177/019262339902700604; Foong CP, 2012, REV BRAS FARMACOGN, V22, P1301, DOI 10.1590/S0102-695X2012005000096; FRAGA CG, 1988, FREE RADICAL BIO MED, V4, P155, DOI 10.1016/0891-5849(88)90023-8; Fulda S, 2010, PLANTA MED, V76, P1075, DOI 10.1055/s-0030-1249961; Fulda S, 2009, INT J CANCER, V124, P511, DOI 10.1002/ijc.24064; Garber JC, 2011, GUIDE CARE USE LAB A; George VC, 2012, ASIAN PAC J CANCER P, V13, P699, DOI 10.7314/APJCP.2012.13.2.699; George VC, 2014, J FOOD SCI TECHNOL, P1; Giovannucci E, 2007, AM J CLIN NUTR, V86, p836S, DOI 10.1093/ajcn/86.3.836S; Gourineni VP, 2011, J NUTR METAB, V2011, DOI 10.1155/2011/983038; Green DR, 2004, SCIENCE, V305, P626, DOI 10.1126/science.1099320; Guo Y.W., 2013, ISRN ONCOL, DOI DOI 10.1155/2013/645817; Gutschner T, 2012, RNA BIOL, V9, P703, DOI 10.4161/rna.20481; Hajrezaie M, 2014, SCI WORLD J, DOI 10.1155/2014/540463; Hajrezaie M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091246; HENDRICKSE CW, 1994, BRIT J SURG, V81, P1219, DOI 10.1002/bjs.1800810849; Ionov Y, 2000, P NATL ACAD SCI USA, V97, P10872, DOI 10.1073/pnas.190210897; ISOZAKI H, 1994, SURG TODAY, V24, P494, DOI 10.1007/BF01884567; Karimian H, 2014, DRUG DES DEV THER, V8, P1481, DOI 10.2147/DDDT.S68818; Karimian H, 2014, MOLECULES, V19, P9478, DOI 10.3390/molecules19079478; Kim G, 1998, J NAT PROD, V61, P432, DOI 10.1021/np970534m; Komiya M, 2013, JPN J CLIN ONCOL, V43, P685, DOI 10.1093/jjco/hyt053; Kumar S, 2009, CANCER METAST REV, V28, P113, DOI 10.1007/s10555-008-9173-4; Lakhani SA, 2006, SCIENCE, V311, P847, DOI 10.1126/science.1115035; LEWIS MA, 1993, PESTIC BIOCHEM PHYS, V45, P15, DOI 10.1006/pest.1993.1003; Liaw CC, 2010, PLANTA MED, V76, P1390, DOI 10.1055/s-0030-1250006; Liew SY, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087286; Liochev SI, 2011, FREE RADIC BIOL MED, V60, P1; LIPKIN M, 1983, CANCER RES, V43, P1899; Lissoni P, 1999, EUR J CANCER, V35, P1688, DOI 10.1016/S0959-8049(99)00159-8; Lovborg H, 2004, MOL CANCER THER, V3, P521; Maga G, 2003, J CELL SCI, V116, P3051, DOI 10.1242/jcs.00653; Martinou JC, 2011, DEV CELL, V21, P92, DOI 10.1016/j.devcel.2011.06.017; MAYER A, 1993, CANCER, V71, P2454, DOI 10.1002/1097-0142(19930415)71:8<2454::AID-CNCR2820710805>3.0.CO;2-2; Meguid NA, 2011, BIOL TRACE ELEM RES, V143, P58, DOI 10.1007/s12011-010-8840-9; Minari J, 2014, EGYPT J MED HUM GENE, V15, P327, DOI DOI 10.1016/J.EJMHG.2014.05.001; Mishra BB, 2011, EUR J MED CHEM, V46, P4769, DOI 10.1016/j.ejmech.2011.07.057; Mishra S, 2013, GLOB J PHARM RES, V2, P1613; Moghadamtousi SZ, 2014, J ETHNOPHARMACOL, V156, P277, DOI 10.1016/j.jep.2014.08.011; Moghadamtousi SZ, 2014, DRUG DES DEV THER, V8, P2099, DOI 10.2147/DDDT.S70096; Moghadamtousi SZ, 2014, BMC COMPLEM ALTERN M, V14, DOI 10.1186/1472-6882-14-299; Moghadamtousi SZ, 2014, SCI WORLD J, DOI 10.1155/2014/768323; MORRE DJ, 1994, LIFE SCI, V56, P343; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Nakanishi Y, 2003, J MED CHEM, V46, P3185, DOI 10.1021/jm020548b; Naryzhny SN, 2007, FEBS LETT, V581, P4917, DOI 10.1016/j.febslet.2007.09.022; Naziroglu M, 2012, J RECEPT SIG TRANSD, V32, P134, DOI 10.3109/10799893.2012.672994; Nirmala P, 2011, EUR J PHARMACOL, V654, P75, DOI 10.1016/j.ejphar.2010.11.034; Oberlies NH, 1997, CANCER LETT, V115, P73, DOI 10.1016/S0304-3835(97)04716-2; Oberlies NH, 1997, J MED CHEM, V40, P2102, DOI 10.1021/jm9700169; Ocker M, 2012, EUR SURG RES, V48, P111, DOI 10.1159/000336875; Pandurangan AK, 2012, ASIAN PAC J CANCER P, V13, P1569, DOI 10.7314/APJCP.2012.13.4.1569; Park MT, 2003, J BIOCHEM MOL BIOL, V36, P60; Raju J, 2008, WORLD J GASTROENTERO, V14, P6632, DOI 10.3748/wjg.14.6632; Ricci-Vitiani L, 2007, NATURE, V445, P111, DOI 10.1038/nature05384; RUPPRECHT JK, 1990, J NAT PROD, V53, P237, DOI 10.1021/np50068a001; Shin HR, 2000, CANCER CAUSE CONTROL, V11, P565, DOI 10.1023/A:1008980200583; Shwter AN, 2014, J ETHNOPHARMACOL, V151, P1194, DOI 10.1016/j.jep.2013.12.044; Skrzydlewska E, 2005, WORLD J GASTROENTERO, V11, P403, DOI 10.3748/wjg.v11.i3.403; Sturm I, 2001, J CLIN ONCOL, V19, P2272, DOI 10.1200/JCO.2001.19.8.2272; Taylor P, 2014, J ETHNOPHARMACOL, V158, P246, DOI 10.1016/j.jep.2014.10.034; Thomson M, 2003, CURR CANCER DRUG TAR, V3, P67, DOI 10.2174/1568009033333736; VACA CE, 1988, MUTAT RES, V195, P137, DOI 10.1016/0165-1110(88)90022-X; Velmurugan B, 2010, MOL CARCINOGEN, V49, P641, DOI 10.1002/mc.20643; Venkateshwarlu Eggadi, 2014, World Applied Sciences Journal, V32, P444; Wang ZY, 2011, J ETHNOPHARMACOL, V133, P751, DOI 10.1016/j.jep.2010.11.004; Wong RSY, 2011, J EXP CLIN CANC RES, V30, DOI 10.1186/1756-9966-30-87; Wu Y, 2006, TRENDS CELL BIOL, V16, P189, DOI 10.1016/j.tcb.2006.02.003; Yuan SSF, 2003, LIFE SCI, V72, P2853, DOI 10.1016/S0024-3205(03)00190-5	93	49	49	0	21	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 10	2015	10	4							e0122288	10.1371/journal.pone.0122288	http://dx.doi.org/10.1371/journal.pone.0122288			28	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CF5II	25860620	Green Published, Green Submitted, gold			2023-01-03	WOS:000352590300039
J	McCormick, D; Hanchate, AD; Lasser, KE; Manze, MG; Lin, MY; Chu, C; Kressin, NR				McCormick, Danny; Hanchate, Amresh D.; Lasser, Karen E.; Manze, Meredith G.; Lin, Mengyun; Chu, Chieh; Kressin, Nancy R.			Effect of Massachusetts healthcare reform on racial and ethnic disparities in admissions to hospital for ambulatory care sensitive conditions: retrospective analysis of hospital episode statistics	BMJ-BRITISH MEDICAL JOURNAL			English	Article							PREVENTABLE HOSPITALIZATIONS; INSURANCE EXPANSION; MEDICAID COVERAGE; ACCESS; IMPACT; IMPLEMENTATION; MORTALITY; REMAINS; ADULTS; RISK	OBJECTIVES To examine the impact of Massachusetts healthcare reform on changes in rates of admission to hospital for ambulatory care sensitive conditions (ACSCs), which are potentially preventable with good access to outpatient medical care, and racial and ethnic disparities in such rates, using complete inpatient discharge data (hospital episode statistics) from Massachusetts and three control states. DESIGN Difference in differences analysis to identify the change, overall and according to race/ethnicity, adjusted for secular changes unrelated to reform. SETTING Hospitals in Massachusetts, New York, New Jersey, and Pennsylvania, United States. PARTICIPANTS Adults aged 18-64 (those most likely to have been affected by the reform) admitted for any of 12 ACSCs in the 21 months before and after the period during which reform was implemented (July 2006 to December 2007). MAIN OUTCOME MEASURES Admission rates for a composite of all 12 ACSCs, and subgroup composites of acute and chronic ACSCs. RESULTS After adjustment for potential confounders, including age, race and ethnicity, sex, and county income, unemployment rate and physician supply, we found no evidence of a change in the admission rate for overall composite ACSC (1.2%, 95% confidence interval -1.6% to 4.1%) or for subgroup composites of acute and chronic ACSCs. Nor did we find a change in disparities in admission rates between black and white people (-1.9%, -8.5% to 5.1%) or white and Hispanic people (2.0%, -7.5% to 12.4%) for overall composite ACSC that existed in Massachusetts before reform. In analyses limited to Massachusetts only, we found no evidence of a change in admission rate for overall composite ACSC between counties with higher and lower rates of uninsurance at baseline (1.4%, -2.3% to 5.3%). CONCLUSIONS Massachusetts reform was not associated with significantly lower overall or racial and ethnic disparities in rates of admission to hospital for ACSCs. In the US, and Massachusetts in particular, additional efforts might be needed to improve access to outpatient care and reduce preventable admissions.	[McCormick, Danny] Harvard Univ, Sch Med, Dept Med, Cambridge Hlth Alliance, Cambridge, MA 02139 USA; [Hanchate, Amresh D.; Kressin, Nancy R.] Vet Affairs Boston Healthcare Syst, Boston, MA 02130 USA; [Hanchate, Amresh D.; Lasser, Karen E.; Manze, Meredith G.; Lin, Mengyun; Chu, Chieh; Kressin, Nancy R.] Boston Univ, Sch Med, Sect Gen Internal Med, Boston, MA 02118 USA	Harvard University; Cambridge Health Alliance; US Department of Veterans Affairs; Veterans Health Administration (VHA); Harvard University; VA Boston Healthcare System; Boston University	McCormick, D (corresponding author), Harvard Univ, Sch Med, Dept Med, Cambridge Hlth Alliance, Cambridge, MA 02139 USA.	mccormick@hms.harvard.edu	Dalla Zuanna, Teresa/G-3133-2015; Lin, Meng-Yun/AAF-5875-2019	Lin, Meng-Yun/0000-0002-8507-031X; Kressin, Nancy/0000-0003-2767-4286; Hanchate, Amresh/0000-0002-7038-4463	US National Institutes of Health [1U01HL105342-01]; Rx foundation; Department of Veterans Affairs, Health Services Research and Development Service [RCS 02-066-1]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL105342] Funding Source: NIH RePORTER; National Institute on Minority Health and Health Disparities [R01MD007705] Funding Source: NIH RePORTER	US National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Rx foundation; Department of Veterans Affairs, Health Services Research and Development Service(US Department of Veterans Affairs); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); National Institute on Minority Health and Health Disparities(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Minority Health & Health Disparities (NIMHD))	This research was funded by US National Institutes of Health grants (1U01HL105342-01, NRK, principal investigator) and a grant from the Rx foundation. NRK is supported in part by a senior research career scientist award from the Department of Veterans Affairs, Health Services Research and Development Service (RCS 02-066-1). The views expressed in this article are those of the authors and do not necessarily represent the views of the National Institutes of Health, the Rx foundation, Boston University, or the Department of Veterans Affairs. The funders had no role in conducting the research or writing of the manuscript.	Agency for Health Care Research and Quality, PREV QUAL IND TECHN; Agency for Health care Research and Quality (AHRQ), 2012, NAT HEALTHC DISP REP; AHRQ Quality Indicator, 2011, NAT QUAL FOR NQF END; Albert MA, 2014, CIRCULATION, V129, P2528, DOI 10.1161/CIRCULATIONAHA.113.005231; [Anonymous], 2010, HISP OR STAT COUNT T; Ansari Z, 2006, MED CARE RES REV, V63, P719, DOI 10.1177/1077558706293637; Baicker K, 2011, NEW ENGL J MED, V365, P683, DOI 10.1056/NEJMp1108222; BINDMAN AB, 1995, JAMA-J AM MED ASSOC, V274, P305, DOI 10.1001/jama.274.4.305; Bindman AB, 2008, MED CARE, V46, P1049, DOI 10.1097/MLR.0b013e318185ce24; Bindman AB, 2008, ANN INTERN MED, V149, P854, DOI 10.7326/0003-4819-149-12-200812160-00004; Buchmueller TC, 2005, MED CARE RES REV, V62, P3, DOI 10.1177/1077558704271718; Cameron A.C, 2005, MICROECONOMETRICS ME; CARTER GM, 1990, J HEALTH ECON, V9, P411, DOI 10.1016/0167-6296(90)90003-L; Chandra A, 2013, BROOKINGS PAP ECO AC, P261, DOI 10.1353/eca.2013.0014; Chang CF, 2008, MED CARE RES REV, V65, P596, DOI 10.1177/1077558708318283; Clark CR, 2011, HEALTH AFFAIR, V30, P247, DOI 10.1377/hlthaff.2010.0319; Craig P, 2012, J EPIDEMIOL COMMUN H, V66, P1182, DOI 10.1136/jech-2011-200375; Davis K, 2014, NEW ENGL J MED, V371, P1567, DOI 10.1056/NEJMp1406707; Finkelstein A, 2012, Q J ECON, V127, P1057, DOI 10.1093/qje/qjs020; Galbraith AA, 2011, HEALTH AFFAIR, V30, P322, DOI 10.1377/hlthaff.2010.0584; Gaskin DJ, 2000, MED CARE RES REV, V57, P85, DOI 10.1177/107755800773743619; Groves RM, 2006, PUBLIC OPIN QUART, V70, P646, DOI 10.1093/poq/nfl033; Hall MA, 2010, COST ADEQUACY SAFETY; Hanchate AD, 2015, BMJ-BRIT MED J, V350, DOI 10.1136/bmj.h440; Health Resources and Services Administration, HLTH PROF SHORT AR D; Health Resources and Services Administration US Department of Health and Human Services, AR RES FIL; HRQ Quality Indicators, PREV QUAL IND OV; Institute of Medicine of the National Academies, 2003, UNEQUAL TREATMENT CO; Joynt KE, 2013, HEALTH AFFAIR, V32, P571, DOI 10.1377/hlthaff.2012.1018; Keating NL, 2011, CANCER, V41, P1; kff.org, STAT MARK PROF; Kolstad JT, 2012, J PUBLIC ECON, V96, P909, DOI 10.1016/j.jpubeco.2012.07.003; Kolstad JT, 2010, 16012 NAT BUR EC RES; Kowalczyk L., BOSTON GLOBE; Kressin NR, 2001, ANN INTERN MED, V135, P352, DOI 10.7326/0003-4819-135-5-200109040-00012; Laditka JN, 2003, SOC SCI MED, V57, P1429, DOI 10.1016/S0277-9536(02)00539-7; Lasser KE, 2014, BMJ-BRIT MED J, V348, DOI 10.1136/bmj.g2329; Levy H, 2008, ANNU REV PUBL HEALTH, V29, P399, DOI 10.1146/annurev.publhealth.28.021406.144042; Link CL, 2010, INT J HEALTH SERV, V40, P507, DOI 10.2190/HS.40.3.g; Long SK, 2008, HEALTH AFFAIR, V27, pW270, DOI 10.1377/hlthaff.27.4.w270; Long SK, 2012, HEALTH AFFAIR, V31, P444, DOI 10.1377/hlthaff.2011.0653; Long SK, 2009, AM ECON REV, V99, P508, DOI 10.1257/aer.99.2.508; Mass.gov, HLTH CAR REF GEN INF; Massachusetts Medical Society, 2009, PHYS WORKF STUD; Maxwell J, 2011, HEALTH AFFAIR, V30, P1451, DOI 10.1377/hlthaff.2011.0347; McCormick D, 2012, J GEN INTERN MED, V27, P1548, DOI 10.1007/s11606-012-2173-7; McDonough JE, 2008, HEALTH AFFAIR, V27, pW285, DOI 10.1377/hlthaff.27.4.w285; McWilliams JM, 2007, JAMA-J AM MED ASSOC, V298, P2886, DOI 10.1001/jama.298.24.2886; Miller S, 2012, INQUIRY-J HEALTH CAR, V49, P317, DOI 10.5034/inquiryjrnl_49.04.05; Miller S, 2012, J PUBLIC ECON, V96, P893, DOI 10.1016/j.jpubeco.2012.07.004; Millett C, 2010, AM J PUBLIC HEALTH, V100, P2235, DOI 10.2105/AJPH.2009.182451; New California Media (NCM), 2003, BRIDG LANG BARR HLTH; O'Neil SS, 2010, AM J PREV MED, V38, P381, DOI 10.1016/j.amepre.2009.12.026; Office of the Asistant Secretary of Planning and Evaluation/US Department of Health and Human Services, 2013, SEC 2013 POV GUID; Pande AH, 2011, AM J PREV MED, V41, P1, DOI 10.1016/j.amepre.2011.03.010; Rosano A, 2013, EUR J PUBLIC HEALTH, V23, P356, DOI 10.1093/eurpub/cks053; Schneider EC, 2002, JAMA-J AM MED ASSOC, V287, P1288, DOI 10.1001/jama.287.10.1288; Smedley BD, 2008, HEALTH AFFAIR, V27, P447, DOI 10.1377/hlthaff.27.2.447; Smulowitz PB, 2011, ANN EMERG MED, V58, P225, DOI 10.1016/j.annemergmed.2011.02.020; Sommers BD, 2014, ANN INTERN MED, V160, P585, DOI 10.7326/M13-2275; Sommers BD, 2012, NEW ENGL J MED, V367, P1025, DOI 10.1056/NEJMsa1202099; Stryjewski TP, 2014, HEALTH SERV RES, V49, P2086, DOI 10.1111/1475-6773.12196; Truffer CJ, 2010, HEALTH AFFAIR, V29, P522, DOI 10.1377/hlthaff.2009.1074; US Census Bureau, 2006, SMALL AR HLTH INS ES; Van der Wees PJ, 2013, MILBANK Q, V91, P663, DOI 10.1111/1468-0009.12029; Wagner AK, 2002, J CLIN PHARM THER, V27, P299, DOI 10.1046/j.1365-2710.2002.00430.x; WEISSMAN JS, 1992, JAMA-J AM MED ASSOC, V268, P2388, DOI 10.1001/jama.268.17.2388; Wennberg JE, 2013, BMJ-BRIT MED J, V346, pf549; Woodword M, 2005, EPIDEMIOLOGY STUDY D; Zhu J, 2010, J GEN INTERN MED, V25, P1356, DOI 10.1007/s11606-010-1482-y	70	29	28	1	12	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	APR 1	2015	350								h1480	10.1136/bmj.h1480	http://dx.doi.org/10.1136/bmj.h1480			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	CF3HO	25833157	Green Published, hybrid			2023-01-03	WOS:000352439300003
J	Brooks, A; Shoup, D; Kustigian, L; Puchalla, J; Carr, CM; Rye, HS				Brooks, Arielle; Shoup, Daniel; Kustigian, Lauren; Puchalla, Jason; Carr, Chavela M.; Rye, Hays S.			Single Particle Fluorescence Burst Analysis of Epsin Induced Membrane Fission	PLOS ONE			English	Article							DOMAIN-CONTAINING PROTEINS; ANALYSIS SPECTROSCOPY; DISTINCT STEPS; VESICLE; DYNAMIN; SCISSION; RECRUITMENT; CURVATURE; FUSION	Vital cellular processes, from cell growth to synaptic transmission, rely on membrane-bounded carriers and vesicles to transport molecular cargo to and from specific intracellular compartments throughout the cell. Compartment-specific proteins are required for the final step, membrane fission, which releases the transport carrier from the intracellular compartment. The role of fission proteins, especially at intracellular locations and in non-neuronal cells, while informed by the dynamin-1 paradigm, remains to be resolved. In this study, we introduce a highly sensitive approach for the identification and analysis of membrane fission machinery, called burst analysis spectroscopy (BAS). BAS is a single particle, free-solution approach, well suited for quantitative measurements of membrane dynamics. Here, we use BAS to analyze membrane fission induced by the potent, fission-active ENTH domain of epsin. Using this method, we obtained temperature-dependent, time-resolved measurements of liposome size and concentration changes, even at sub-micromolar concentration of the epsin ENTH domain. We also uncovered, at 37 degrees C, fission activity for the full-length epsin protein, supporting the argument that the membrane-fission activity observed with the ENTH domain represents a native function of the full-length epsin protein.	[Brooks, Arielle; Shoup, Daniel; Kustigian, Lauren; Carr, Chavela M.; Rye, Hays S.] Texas A&M Univ, Dept Biochem & Biophys, College Stn, TX 77843 USA; [Puchalla, Jason] Princeton Univ, Dept Phys, Princeton, NJ 08544 USA	Texas A&M University System; Texas A&M University College Station; Princeton University	Rye, HS (corresponding author), Texas A&M Univ, Dept Biochem & Biophys, College Stn, TX 77843 USA.	haysrye@tamu.edu		Rye, Hays/0000-0002-9420-3137	NIH [2RO1GM065421]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM065421, R01GM114405] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported by NIH http://www.nigms.nih.gov/Pages/default.aspx 2RO1GM065421. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Beck R, 2011, J CELL BIOL, V194, P765, DOI 10.1083/jcb.201011027; Boucrot E, 2012, CELL, V149, P124, DOI 10.1016/j.cell.2012.01.047; Campelo F, 2012, ANNU REV BIOCHEM, V81, P407, DOI 10.1146/annurev-biochem-051710-094912; Carr CM, 2010, CURR OPIN CELL BIOL, V22, P488, DOI 10.1016/j.ceb.2010.04.006; Chen H, 1998, NATURE, V394, P793, DOI 10.1038/29555; Chen ZM, 2014, J AM CHEM SOC, V136, P4557, DOI 10.1021/ja411607b; Chernomordik LV, 2008, NAT STRUCT MOL BIOL, V15, P675, DOI 10.1038/nsmb.1455; Daumke O, 2014, CELL, V156, P882, DOI 10.1016/j.cell.2014.02.017; Ford MGJ, 2002, NATURE, V419, P361, DOI 10.1038/nature01020; HOPE MJ, 1989, J ELECTRON MICR TECH, V13, P277, DOI 10.1002/jemt.1060130403; Hurley JH, 2010, NAT REV MOL CELL BIO, V11, P556, DOI 10.1038/nrm2937; Krantz KC, 2013, J BIOL CHEM, V288, P26721, DOI 10.1074/jbc.M113.491753; Lee MCS, 2005, CELL, V122, P605, DOI 10.1016/j.cell.2005.07.025; Legendre-Guillemin V, 2004, J CELL SCI, V117, P9, DOI 10.1242/jcs.00928; Loerke D, 2009, PLOS BIOL, V7, P628, DOI 10.1371/journal.pbio.1000057; Massol RH, 2006, P NATL ACAD SCI USA, V103, P10265, DOI 10.1073/pnas.0603369103; Meinecke M, 2013, J BIOL CHEM, V288, P6651, DOI 10.1074/jbc.M112.444869; Merrifield CJ, 2005, CELL, V121, P593, DOI 10.1016/j.cell.2005.03.015; Mills IG, 2003, J CELL BIOL, V160, P213, DOI 10.1083/jcb.200208023; Neumann S, 2013, J BIOL CHEM, V288, P25119, DOI 10.1074/jbc.M113.490474; Pucadyil TJ, 2008, CELL, V135, P1263, DOI 10.1016/j.cell.2008.11.020; Puchalla J, 2008, P NATL ACAD SCI USA, V105, P14400, DOI 10.1073/pnas.0805969105; Rao YJ, 2010, P NATL ACAD SCI USA, V107, P8213, DOI 10.1073/pnas.1003478107; Roux A, 2006, NATURE, V441, P528, DOI 10.1038/nature04718; Shorter J, 2008, EMBO J, V27, P2712, DOI 10.1038/emboj.2008.194; Simpson F, 1999, NAT CELL BIOL, V1, P119, DOI 10.1038/10091; Taylor MJ, 2011, PLOS BIOL, V9, DOI 10.1371/journal.pbio.1000604; WANG LH, 1995, J BIOL CHEM, V270, P10079, DOI 10.1074/jbc.270.17.10079; Wickner W, 2008, NAT STRUCT MOL BIOL, V15, P658, DOI 10.1038/nsmb.1451	29	4	4	0	17	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 23	2015	10	3							e0119563	10.1371/journal.pone.0119563	http://dx.doi.org/10.1371/journal.pone.0119563			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CE6ZS	25799353	gold, Green Submitted, Green Published			2023-01-03	WOS:000351987300059
J	Rothwell, PM				Rothwell, Peter M.			AVERT: a major milestone in stroke research	LANCET			English	Editorial Material							RANDOMIZED CONTROLLED-TRIALS		John Radcliffe Hosp, Nuffield Dept Clin Neurosci, Stroke Prevent Res Unit, Oxford OX2 6HE, England	University of Oxford	Rothwell, PM (corresponding author), John Radcliffe Hosp, Nuffield Dept Clin Neurosci, Stroke Prevent Res Unit, Oxford OX2 6HE, England.	peter.rothwell@clneuro.ox.ac.uk	Rothwell, Peter/ABE-5913-2020	Rothwell, Peter/0000-0001-9739-9211	Department of Health [12/01/16] Funding Source: Medline; National Institute for Health Research [NF-SI-0514-10168, 12/01/16] Funding Source: researchfish; Stroke Association [TSA2009/09] Funding Source: researchfish	Department of Health; National Institute for Health Research(National Institute for Health Research (NIHR)); Stroke Association		AVERT Trial Collaboration group, 2015, LANCET; LANGHORNE P, 1993, LANCET, V342, P395, DOI 10.1016/0140-6736(93)92813-9; Lynch E, 2014, INT J STROKE, V9, P468, DOI 10.1111/ijs.12262; Manning L, 2014, LANCET NEUROL, V13, P364, DOI 10.1016/S1474-4422(14)70018-3; Mishra NK, 2010, STROKE, V41, P2840, DOI 10.1161/STROKEAHA.110.586206; Rothwell PM, 2006, LANCET, V368, P262, DOI 10.1016/S0140-6736(06)69010-7; Rothwell PM, 2005, LANCET, V365, P176, DOI 10.1016/S0140-6736(05)17709-5; Skarin M, 2011, INT J STROKE, V6, P10, DOI 10.1111/j.1747-4949.2010.00534.x	9	7	7	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 4	2015	386	9988					7	9		10.1016/S0140-6736(15)60906-0	http://dx.doi.org/10.1016/S0140-6736(15)60906-0			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CM2OA	25971220	hybrid			2023-01-03	WOS:000357519400006
J	Siew, ML; van Vonderen, JJ; Hooper, SB; te Pas, AB				Siew, Melissa L.; van Vonderen, Jeroen J.; Hooper, Stuart B.; te Pas, Arjan B.			Very Preterm Infants Failing CPAP Show Signs of Fatigue Immediately after Birth	PLOS ONE			English	Article							INITIAL RESPIRATORY MANAGEMENT; AIRWAY PRESSURE FAILURE; STABLE MICROBUBBLE TEST; LUNG LIQUID CLEARANCE; CHEST-WALL; NASAL CPAP; NEWBORN-INFANTS; WEEKS GESTATION; FULL-TERM; SURFACTANT	Objective To investigate the differences in breathing pattern and effort in infants at birth who failed or succeeded on continuous positive airway pressure (CPAP) during the first 48 hours after birth. Methods Respiratory function recordings of 32 preterm infants were reviewed of which 15 infants with a gestational age of 28.6 (0.7) weeks failed CPAP and 17 infants with a GA of 30.1 (0.4) weeks did not fail CPAP. Frequency, duration and tidal volumes (VT) of expiratory holds (EHs), peak inspiratory flows, CPAP-level and FiO(2)-levels were analysed. Results EH incidence increased <6 minutes after birth and remained stable thereafter. EH peak inspiratory flows and VT were similar between CPAP-fail and CPAP-success infants. At 9-12 minutes, CPAP-fail infants more frequently used smaller VTs, 0-9 ml/kg and required higher peak inspiratory flows. However, CPAP-success infants often used large VTs (>9 ml/kg) with higher peak inspiratory flows than CPAP-fail infants (71.8 +/- 15.8 vs. 15.5 +/- 5.2 ml/kg. s, p < 0.05). CPAP-fail infants required higher FiO(2) (0.31 +/- 0.03 vs. 0.21 +/- 0.01), higher CPAP pressures (6.62 +/- 0.3 vs. 5.67 +/- 0.26 cm H2O) and more positive pressure-delivered breaths (45 +/- 12 vs. 19 +/- 9%) (p < 0.05) Conclusion At 9-12 minutes after birth, CPAP-fail infants more commonly used lower VTs and required higher peak inspiratory flow rates while receiving greater respiratory support. VT was less variable and larger VT was infrequently used reflecting early signs of fatigue.	[Siew, Melissa L.; Hooper, Stuart B.] Monash Univ, Ritchie Ctr, MIMR PHI, Clayton, Vic, Australia; [van Vonderen, Jeroen J.; te Pas, Arjan B.] Leiden Univ, Med Ctr, Dept Pediat, Div Neonatol, Leiden, Netherlands	Monash University; Prince Henry's Institute of Medical Research; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Siew, ML (corresponding author), Monash Univ, Ritchie Ctr, MIMR PHI, Clayton, Vic, Australia.	melissa.siew@monash.edu	van Vonderen, Jeroen J./L-4067-2019; pas, arjan te/AAA-9019-2020	van Vonderen, Jeroen J./0000-0002-1258-5224; pas, arjan te/0000-0001-7831-8797; Hooper, Stuart/0000-0003-1676-4825	Veni-grant, the Netherlands Organisation for Health Research and Development (ZonMw), Innovational Research Incentives Scheme Veni-Vidi-Vici [91612027]; Willem-Alexander Children's Foundation scholarship; David Henderson-Smart Travel Scholarship	Veni-grant, the Netherlands Organisation for Health Research and Development (ZonMw), Innovational Research Incentives Scheme Veni-Vidi-Vici; Willem-Alexander Children's Foundation scholarship; David Henderson-Smart Travel Scholarship	A.B. te Pas is recipient of a Veni-grant, the Netherlands Organisation for Health Research and Development (ZonMw), part of the Innovational Research Incentives Scheme Veni-Vidi-Vici, projectnumber 91612027. J.J. van Vonderen is recipient of a Willem-Alexander Children's Foundation scholarship. M.L. Siew was funded by the David Henderson-Smart Travel Scholarship. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ammari A, 2005, J PEDIATR-US, V147, P341, DOI 10.1016/j.jpeds.2005.04.062; Daniel IWBD, 2010, NEONATOLOGY, V98, P150, DOI 10.1159/000279887; Bien MY, 2011, CRIT CARE MED, V39, P2253, DOI 10.1097/CCM.0b013e31822279ed; Bushell T, 2013, J Neonatal Perinatal Med, V6, P53, DOI 10.3233/NPM-1363612; Dargaville PA, 2013, NEONATOLOGY, V104, P8, DOI 10.1159/000346460; De Jaegere AP, 2012, ACTA PAEDIATR, V101, P374, DOI 10.1111/j.1651-2227.2011.02558.x; Dimitriou G, 2011, EUR J PEDIATR, V170, P45, DOI 10.1007/s00431-010-1264-x; Dunn MS, 2011, PEDIATRICS, V128, pE1069, DOI 10.1542/peds.2010-3848; Elgellab A, 2001, INTENS CARE MED, V27, P1782, DOI 10.1007/s00134-001-1117-1; Finer NN, 2010, NEW ENGL J MED, V362, P1970, DOI 10.1056/NEJMoa0911783; Fiori HH, 2006, J PERINAT MED, V34, P66, DOI 10.1515/JPM.2006.008; FISHER JT, 1982, AM REV RESPIR DIS, V125, P650; Frappell PB, 2005, RESP PHYSIOL NEUROBI, V149, P143, DOI 10.1016/j.resp.2005.05.028; Fuchs H, 2011, ARCH DIS CHILD-FETAL, V96, pF343, DOI 10.1136/adc.2010.205898; GAULTIER C, 1995, EUR RESPIR J, V8, P150, DOI 10.1183/09031936.95.08010150; GERHARDT T, 1980, ACTA PAEDIATR SCAND, V69, P359, DOI 10.1111/j.1651-2227.1980.tb07093.x; HARDING R, 1980, SLEEP, V3, P307, DOI 10.1093/sleep/3.3-4.307; HELDT GP, 1987, J APPL PHYSIOL, V62, P164, DOI 10.1152/jappl.1987.62.1.164; Hooper SB, 2007, FASEB J, V21, P3329, DOI 10.1096/fj.07-8208com; Hutchison AA, 2000, BIOL NEONATE, V78, P139, DOI 10.1159/000014262; Kaczmarek J, 2013, ARCH DIS CHILD-FETAL, V98, pF70, DOI 10.1136/fetalneonatal-2011-301340; KELLY E, 1993, PEDIATR PULM, V15, P225, DOI 10.1002/ppul.1950150408; Khan N, 1996, CRIT CARE MED, V24, P1568, DOI 10.1097/00003246-199609000-00023; KOSCH PC, 1984, J APPL PHYSIOL, V57, P1126, DOI 10.1152/jappl.1984.57.4.1126; Morley CJ, 2008, NEW ENGL J MED, V358, P700, DOI 10.1056/NEJMoa072788; MORTOLA JP, 1982, J APPL PHYSIOL, V52, P716, DOI 10.1152/jappl.1982.52.3.716; MORTOLA JP, 1984, AM REV RESPIR DIS, V129, P49; NILSSON R, 1980, ACTA PAEDIATR SCAND, V69, P597, DOI 10.1111/j.1651-2227.1980.tb07328.x; Pas ABT, 2008, PEDIATR RES, V64, P281, DOI 10.1203/PDR.0b013e31817d9c35; Pillai MS, 2011, J TROP PEDIATRICS, V57, P274, DOI 10.1093/tropej/fmq047; Sandri F, 2010, PEDIATRICS, V125, pE1402, DOI 10.1542/peds.2009-2131; Lopez ES, 2011, CLINICS, V66, P823, DOI 10.1590/S1807-59322011000500019; Schilleman K, 2012, RESUSCITATION, V83, P1135, DOI 10.1016/j.resuscitation.2012.01.036; Schmolzer GM, 2010, ARCH DIS CHILD-FETAL, V95, pF295, DOI 10.1136/adc.2009.165878; Siew ML, 2011, PEDIATR RES, V70, P50, DOI 10.1203/PDR.0b013e31821be094; Siew ML, 2009, J APPL PHYSIOL, V106, P1888, DOI 10.1152/japplphysiol.91526.2008; te Pas AB, 2009, PEDIATR RES, V65, P352, DOI 10.1203/PDR.0b013e318193f117; VYAS H, 1986, PEDIATR PULM, V2, P189, DOI 10.1002/ppul.1950020403; Warren RH, 1997, EUR RESPIR J, V10, P2295, DOI 10.1183/09031936.97.10102295; Wong KA, 1998, J APPL PHYSIOL, V85, P849, DOI 10.1152/jappl.1998.85.3.849; Yost CC, 2000, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD001456	41	13	15	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 8	2015	10	6							e0129592	10.1371/journal.pone.0129592	http://dx.doi.org/10.1371/journal.pone.0129592			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CK1GM	26052947	Green Submitted, Green Published, gold			2023-01-03	WOS:000355955300148
J	Vacondio, F; Bassi, M; Silva, C; Castelli, R; Carmi, C; Scalvini, L; Lodola, A; Vivo, V; Flammini, L; Barocelli, E; Mor, M; Rivara, S				Vacondio, Federica; Bassi, Michele; Silva, Claudia; Castelli, Riccardo; Carmi, Caterina; Scalvini, Laura; Lodola, Alessio; Vivo, Valentina; Flammini, Lisa; Barocelli, Elisabetta; Mor, Marco; Rivara, Silvia			Amino Acid Derivatives as Palmitoylethanolamide Prodrugs: Synthesis, In Vitro Metabolism and In Vivo Plasma Profile in Rats	PLOS ONE			English	Article							AMIDE HYDROLASE INHIBITORS; PHARMACOLOGICAL CHARACTERIZATION; ESTER PRODRUGS; STABILITY; HYDROLYSIS; RECEPTOR; PAIN; PEPTIDE; ENZYME; OLEOYLETHANOLAMIDE	Palmitoylethanolamide (PEA) has antinflammatory and antinociceptive properties widely exploited in veterinary and human medicine, despite its poor pharmacokinetics. Looking for prodrugs that could progressively release PEA to maintain effective plasma concentrations, we prepared carbonates, esters and carbamates at the hydroxyl group of PEA. Chemical stability (pH 7.4) and stability in rat plasma and liver homogenate were evaluated by in vitro assays. Carbonates and carbamates resulted too labile and too resistant in plasma, respectively. Ester derivatives, prepared by conjugating PEA with various amino acids, allowed to modulate the kinetics of PEA release in plasma and stability in liver homogenate. L-Val-PEA, with suitable PEA release in plasma, and D-Val-PEA, with high resistance to hepatic degradation, were orally administered to rats and plasma levels of prodrugs and PEA were measured at different time points. Both prodrugs showed significant release of PEA, but provided lower plasma concentrations than those obtained with equimolar doses of PEA. Amino-acid esters of PEA are a promising class to develop prodrugs, even if they need further chemical optimization.	[Vacondio, Federica; Bassi, Michele; Silva, Claudia; Castelli, Riccardo; Carmi, Caterina; Scalvini, Laura; Lodola, Alessio; Vivo, Valentina; Flammini, Lisa; Barocelli, Elisabetta; Mor, Marco; Rivara, Silvia] Univ Parma, Dipartimento Farm, I-43100 Parma, Italy	University of Parma	Rivara, S (corresponding author), Univ Parma, Dipartimento Farm, I-43100 Parma, Italy.	silvia.rivara@unipr.it	Mor, Marco/D-2394-2009; Rivara, Silvia/K-8104-2017; Lodola, Alessio/H-9078-2013; Vacondio, Federica/C-1295-2009	Mor, Marco/0000-0003-0199-1849; Rivara, Silvia/0000-0001-8058-4250; Lodola, Alessio/0000-0002-8675-1002; Vacondio, Federica/0000-0002-0729-4385; Scalvini, Laura/0000-0003-3610-527X; Bassi, Michele/0000-0001-6123-8221				ACEDO M, 1992, TETRAHEDRON LETT, V33, P4989, DOI 10.1016/S0040-4039(00)61253-4; [Anonymous], 2013, MAESTR VERS 9 6; [Anonymous], 2013, GLID VERS 6 1; Astarita G, 2006, J PHARMACOL EXP THER, V318, P563, DOI 10.1124/jpet.106.105221; Balvers MGJ, 2013, CNS NEUROL DISORD-DR, V12, P26; BENNION C, 1992, J MED CHEM, V35, P2939, DOI 10.1021/jm00094a003; Bracey MH, 2002, SCIENCE, V298, P1793, DOI 10.1126/science.1076535; Buchwald P, 1999, J MED CHEM, V42, P5160, DOI 10.1021/jm990145k; Calignano A, 2001, EUR J PHARMACOL, V419, P191, DOI 10.1016/S0014-2999(01)00988-8; Calignano A, 1998, NATURE, V394, P277, DOI 10.1038/28393; Cerrato S, 2012, VET J, V191, P377, DOI 10.1016/j.tvjl.2011.04.002; Clapper JR, 2009, CHEMMEDCHEM, V4, P1505, DOI 10.1002/cmdc.200900210; Cravatt BF, 1996, NATURE, V384, P83, DOI 10.1038/384083a0; Della Valle F, 2013, United States patent, Patent No. [US8470373, 8470373]; Diehl KH, 2001, J APPL TOXICOL, V21, P15, DOI 10.1002/jat.727; Duranti A, 2012, J MED CHEM, V55, P4824, DOI 10.1021/jm300349j; Fleisher D, 1996, ADV DRUG DELIVER REV, V19, P115, DOI 10.1016/0169-409X(95)00103-E; Hong SY, 1999, BIOCHEM PHARMACOL, V58, P1775, DOI 10.1016/S0006-2952(99)00259-2; Ichikawa T, 2001, CHEM PHARM BULL, V49, P1102, DOI 10.1248/cpb.49.1102; Jaggar SI, 1998, PAIN, V76, P189, DOI 10.1016/S0304-3959(98)00041-4; Kaminski GA, 2001, J PHYS CHEM B, V105, P6474, DOI 10.1021/jp003919d; Liederer BM, 2006, J PHARM SCI-US, V95, P1177, DOI 10.1002/jps.20542; Lo Verme J, 2005, CELL MOL LIFE SCI, V62, P708, DOI 10.1007/s00018-004-4494-0; Lo Verme J, 2005, MOL PHARMACOL, V67, P15, DOI 10.1124/mol.104.006353; Luongo E, 2014, EUR J PHARM SCI, V62, P33, DOI 10.1016/j.ejps.2014.05.009; Mazzari S, 1996, EUR J PHARMACOL, V300, P227, DOI 10.1016/0014-2999(96)00015-5; Moreno-Sanz G, 2012, BRIT J PHARMACOL, V167, P1620, DOI 10.1111/j.1476-5381.2012.02098.x; Oh D M, 1999, Pharm Biotechnol, V12, P59; Petrosino S, 2016, BRIT J PHARMACOL, V173, P1154, DOI 10.1111/bph.13084; Piomelli D, 2006, CNS DRUG REV, V12, P21, DOI 10.1111/j.1527-3458.2006.00021.x; Piomelli D, 2014, NAT NEUROSCI, V17, P164, DOI 10.1038/nn.3612; Rivara M, 2008, CHEM BIODIVERS, V5, P140, DOI 10.1002/cbdv.200890004; Russo R, 2007, J PHARMACOL EXP THER, V322, P236, DOI 10.1124/jpet.107.119941; Schrodinger LLC, 2013, MACROMODEL VERS 10 2; Silverman R, 2014, ORGANIC CHEM DRUG DE, V3rd, P423; Solorzano C, 2009, P NATL ACAD SCI USA, V106, P20966, DOI 10.1073/pnas.0907417106; Song XQ, 2005, MOL PHARMACEUT, V2, P157, DOI 10.1021/mp049888e; SOULLAWTON J, 1995, ANTIMICROB AGENTS CH, V39, P2759, DOI 10.1128/AAC.39.12.2759; Sugawara M, 2000, J PHARM SCI-US, V89, P781, DOI 10.1002/(SICI)1520-6017(200006)89:6<781::AID-JPS10>3.0.CO;2-7; Tsume Y, 2014, EUR J PHARM BIOPHARM, V86, P514, DOI 10.1016/j.ejpb.2013.12.009; Ueda N, 2001, J BIOL CHEM, V276, P35552, DOI 10.1074/jbc.M106261200; USANSKY JI, 2001, PK FUNCTIONS MICROSO; Vacondio F, 2011, EUR J MED CHEM, V46, P4466, DOI 10.1016/j.ejmech.2011.07.021; Vacondio F, 2010, DRUG METAB REV, V42, P551, DOI 10.3109/03602531003745960; van der Stelt M, 2004, EUR J BIOCHEM, V271, P1827, DOI 10.1111/j.1432-1033.2004.04081.x; Vig BS, 2003, PHARM RES-DORDR, V20, P1381, DOI 10.1023/A:1025745824632; Wadkins RM, 2001, MOL PHARMACOL, V60, P355, DOI 10.1124/mol.60.2.355; Zhang D, 2007, NEUROPHARMACOLOGY, V52, P1095, DOI 10.1016/j.neuropharm.2006.11.009	48	19	20	0	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 8	2015	10	6							e0128699	10.1371/journal.pone.0128699	http://dx.doi.org/10.1371/journal.pone.0128699			24	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CK1GM	26053855	Green Published, gold, Green Submitted			2023-01-03	WOS:000355955300054
J	Avaldi, VM; Lenzi, J; Castaldini, I; Urbinati, S; Di Pasquale, G; Morini, M; Protonotari, A; Maggioni, AP; Fantini, MP				Avaldi, Vera Maria; Lenzi, Jacopo; Castaldini, Ilaria; Urbinati, Stefano; Di Pasquale, Giuseppe; Morini, Mara; Protonotari, Adalgisa; Maggioni, Aldo Pietro; Fantini, Maria Pia			Hospital Readmissions of Patients with Heart Failure: The Impact of Hospital and Primary Care Organizational Factors in Northern Italy	PLOS ONE			English	Article							DISEASE MANAGEMENT PROGRAM; IMPROVING PRIMARY-CARE; MYOCARDIAL-INFARCTION; RANDOMIZED TRIAL; ELDERLY-PATIENTS; HIGH-RISK; INTERVENTION; METAANALYSIS; ADMISSION; EPIDEMIOLOGY	Background Primary health care is essential for an appropriate management of heart failure (HF), a disease which is a major clinical and public health issue and a leading cause of hospitalization. The aim of this study was to evaluate the impact of different organizational factors on readmissions of patients with HF. Methods The study population included elderly resident in the Local Health Authority of Bologna (Northern Italy) and discharged with a diagnosis of HF from January to December 2010. Unplanned hospital readmissions were measured in four timeframes: 30 (short-term), 90 (medium-term), 180 (mid-long-term), and 365 days (long-term). Using multivariable multilevel Poisson regression analyses, we investigated the association between readmissions and organizational factors (discharge from a cardiology department, general practitioners' monodisciplinary organizational arrangement, and implementation of a specific HF care pathway). Results The 1873 study patients had a median age of 83 years (interquartile range 77-87) and 55.5% were females; 52.0% were readmitted to the hospital for any reason after a year, while 20.1% were readmitted for HF. The presence of a HF care pathway was the only factor significantly associated with a lower risk of readmission for HF in the short-, medium-, mid-long-and long-term period (short-term: IRR [incidence rate ratio] = 0.57, 95% CI [confidence interval] = 0.35-0.92; medium-term: IRR = 0.70, 95% CI = 0.51-0.96; mid-long-term: IRR= 0.79, 95% CI= 0.64-0.98; long-term: IRR = 0.82, 95% CI = 0.67-0.99), and with a lower risk of all-cause readmission in the short-term period (IRR= 0.73, 95% CI = 0.57-0.94). Conclusion Our study shows that the HF care specific pathway implemented at the primary care level was associated with lower readmission rate for HF in each timeframe, and also with lower readmission rate for all causes in the short-term period. Our results suggest that the engagement of primary care professionals starting from the early post-discharge period may be relevant in the management of patients with HF.	[Avaldi, Vera Maria; Lenzi, Jacopo; Fantini, Maria Pia] Univ Bologna, Alma Mater Studiorum, Dept Biomed & Neuromotor Sci, Bologna, Italy; [Castaldini, Ilaria; Protonotari, Adalgisa] Bologna Local Healthcare Author, Dept Programming & Control, Bologna, Italy; [Urbinati, Stefano] Bellaria Hosp, Dept Cardiol, Bologna, Italy; [Di Pasquale, Giuseppe] Maggiore Hosp, Dept Cardiol, Bologna, Italy; [Morini, Mara] Bologna Local Healthcare Author, Dept Primary Care, Bologna, Italy; [Maggioni, Aldo Pietro] ANMCO Res Ctr, Florence, Italy	University of Bologna; AUSL di Bologna; AUSL di Bologna; Associazione Nazionale Medici Cardiologi Ospedalieri (ANMCO)	Fantini, MP (corresponding author), Univ Bologna, Alma Mater Studiorum, Dept Biomed & Neuromotor Sci, Bologna, Italy.	mariapia.fantini@unibo.it	Maggioni, Aldo Pietro/AAL-5334-2020; Lenzi, Jacopo/W-4835-2017	Maggioni, Aldo Pietro/0000-0003-2764-6779; Lenzi, Jacopo/0000-0003-2882-4223; Avaldi, Vera Maria/0000-0003-0609-2439				Armeni P, 2014, MED CARE RES REV, V71, P315, DOI 10.1177/1077558714536618; Barnett K, 2012, LANCET, V380, P37, DOI 10.1016/S0140-6736(12)60240-2; Blue L, 2001, BRIT MED J, V323, P715, DOI 10.1136/bmj.323.7315.715; Bodenheimer T, 2002, JAMA-J AM MED ASSOC, V288, P1775, DOI 10.1001/jama.288.14.1775; Bodenheimer T, 2002, JAMA-J AM MED ASSOC, V288, P1909, DOI 10.1001/jama.288.15.1909; Bottle A, 2014, EUR J HEART FAIL, V16, P846, DOI 10.1002/ejhf.129; Bradley EH, 2013, CIRC-CARDIOVASC QUAL, V6, P444, DOI 10.1161/CIRCOUTCOMES.111.000101; Capomolla S, 2002, J AM COLL CARDIOL, V40, P1259, DOI 10.1016/S0735-1097(02)02140-X; Clark AM, 2008, LANCET, V372, P784, DOI 10.1016/S0140-6736(08)61317-3; Clark RA, 2007, BMJ-BRIT MED J, V334, P942, DOI 10.1136/bmj.39156.536968.55; Coleman K, 2009, HEALTH AFFAIR, V28, P75, DOI 10.1377/hlthaff.28.1.75; Del Sindaco D, 2007, J CARDIOVASC MED, V8, P324, DOI 10.2459/JCM.0b013e32801164cb; Diez-Roux AV, 2000, ANNU REV PUBL HEALTH, V21, P171, DOI 10.1146/annurev.publhealth.21.1.171; Ducharme A, 2005, CAN MED ASSOC J, V173, P40, DOI 10.1503/cmaj.1041137; Fantini MP, 2012, HEALTH CARE MANAGE R, V37, P67, DOI 10.1097/HMR.0b013e31822241cf; Garin N, 2012, EUR J INTERN MED, V23, P760, DOI 10.1016/j.ejim.2012.06.006; Gonseth J, 2004, EUR HEART J, V25, P1570, DOI 10.1016/j.ehj.2004.04.022; Ham C, 2010, HEALTH ECON POLICY L, V5, P71, DOI 10.1017/S1744133109990120; Hansen LO, 2011, ANN INTERN MED, V155, P520, DOI 10.7326/0003-4819-155-8-201110180-00008; Inglis SC, 2011, EUR J HEART FAIL, V13, P1028, DOI 10.1093/eurjhf/hfr039; Jaarsma T, 2013, EUR J CARDIOVASC NUR, V12, P230, DOI [10.1177/1474515113476605, 10.1177/1474515112449539]; Kasper EK, 2002, J AM COLL CARDIOL, V39, P471, DOI 10.1016/S0735-1097(01)01761-2; Kirchmayer U, 2012, J CLIN PHARM THER, V37, P37, DOI 10.1111/j.1365-2710.2010.01242.x; Kirchmayer U, 2013, PHARMACOEPIDEM DR S, V22, P649, DOI 10.1002/pds.3430; Klersy C, 2009, J AM COLL CARDIOL, V54, P1683, DOI 10.1016/j.jacc.2009.08.017; Krumholz HM, 2002, J AM COLL CARDIOL, V39, P83, DOI 10.1016/S0735-1097(01)01699-0; Kul S, 2012, BMC CARDIOVASC DISOR, V12, DOI 10.1186/1471-2261-12-81; Lenzi J, 2015, EUR J CLIN PHARMACOL, V71, P243, DOI 10.1007/s00228-014-1793-8; Linden A, 2014, AM J MANAG CARE, V20; McAlister FA, 2004, J AM COLL CARDIOL, V44, P810, DOI 10.1016/j.jacc.2004.05.055; McAlister FA, 2013, CAN MED ASSOC J, V185, pE681, DOI 10.1503/cmaj.130048; McMurray JJV, 2012, EUR J HEART FAIL, V14, P803, DOI 10.1093/eurjhf/hfs105; Michalsen A, 1998, HEART, V80, P437, DOI 10.1136/hrt.80.5.437; Mosterd A, 2007, HEART, V93, P1137, DOI 10.1136/hrt.2003.025270; Naylor MD, 2004, J AM GERIATR SOC, V52, P675, DOI 10.1111/j.1532-5415.2004.52202.x; Panella M, 2009, QUAL SAF HEALTH CARE, V18, P369, DOI 10.1136/qshc.2008.026559; Profili S., 2009, HLTH SYST TRANSIT, V11, P1; RICH MW, 1995, NEW ENGL J MED, V333, P1190, DOI 10.1056/NEJM199511023331806; Takeda A, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002752.pub3; Tsuyuki RT, 2004, J CARD FAIL, V10, P473, DOI 10.1016/j.cardfail.2004.02.005; Tuppin P, 2014, ARCH CARDIOVASC DIS, V107, P158, DOI 10.1016/j.acvd.2014.01.012; Visca M, 2013, HEALTH POLICY, V113, P188, DOI 10.1016/j.healthpol.2013.05.016; Wagner E H, 1998, Eff Clin Pract, V1, P2; Weinberger M, 1996, NEW ENGL J MED, V334, P1441, DOI 10.1056/NEJM199605303342206	44	20	20	1	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 26	2015	10	5							e0127796	10.1371/journal.pone.0127796	http://dx.doi.org/10.1371/journal.pone.0127796			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	CJ0QZ	26010223	Green Published, Green Submitted, gold			2023-01-03	WOS:000355183900145
J	Conley, AC; Marquez, J; Parsons, MW; Fulham, WR; Heathcote, A; Karayanidis, F				Conley, Alexander C.; Marquez, Jodie; Parsons, Mark W.; Fulham, W. Ross; Heathcote, Andrew; Karayanidis, Frini			Anodal tDCS over the Motor Cortex on Prepared and Unprepared Responses in Young Adults	PLOS ONE			English	Article							DIRECT-CURRENT STIMULATION; NONINVASIVE BRAIN-STIMULATION; EXCITABILITY; TASK; POLARIZATION; INHIBITION; MODULATION; HANDEDNESS	Anodal transcranial direct current stimulation (tDCS) over the primary motor cortex (M1) has been proposed as a possible therapeutic rehabilitation technique for motor impairment. However, despite extensive investigation into the effects of anodal tDCS on motor output, there is little information on how anodal tDCS affects response processes. In this study, we used a cued go/nogo task with both directional and non-directional cues to assess the effects of anodal tDCS over the dominant (left) primary motor cortex on prepared and unprepared motor responses. Three experiments explored whether the effectiveness of tDCS varied with timing between stimulation and test. Healthy, right-handed young adults participated in a double-blind randomised controlled design with crossover of anodal tDCS and sham stimulation. In Experiment 1, twenty-four healthy young adults received anodal tDCS over dominant M1 at least 40 mins before task performance. In Experiment 2, eight participants received anodal tDCS directly before task performance. In Experiment 3, twenty participants received anodal tDCS during task performance. In all three experiments, participants responded faster to directional compared to non-directional cues and with their right hand. However, anodal tDCS had no effect on go/nogo task performance at any stimulation - test interval. Bayesian analysis confirmed that anodal stimulation had no effect on response speed. We conclude that anodal tDCS over M1 does not improve response speed of prepared or unprepared responses of young adults in a go/nogo task.	[Conley, Alexander C.; Fulham, W. Ross; Heathcote, Andrew; Karayanidis, Frini] Univ Newcastle, Sch Psychol, Funct Neuroimaging Lab, Newcastle, NSW 2300, Australia; [Conley, Alexander C.; Marquez, Jodie; Parsons, Mark W.; Fulham, W. Ross; Heathcote, Andrew; Karayanidis, Frini] Univ Newcastle, Prior Res Ctr Translat Neurosci & Mental Hlth, Newcastle, NSW 2300, Australia; [Conley, Alexander C.; Marquez, Jodie; Parsons, Mark W.; Fulham, W. Ross; Heathcote, Andrew; Karayanidis, Frini] Hunter Med Res Inst, Newcastle, NSW, Australia; [Marquez, Jodie] Univ Newcastle, Sch Hlth Sci, Newcastle, NSW 2300, Australia; [Parsons, Mark W.] Univ Newcastle, Sch Med & Publ Hlth, Newcastle, NSW 2300, Australia	University of Newcastle; University of Newcastle; Hunter Medical Research Institute; University of Newcastle; University of Newcastle; University of Newcastle	Karayanidis, F (corresponding author), Univ Newcastle, Sch Psychol, Funct Neuroimaging Lab, Newcastle, NSW 2300, Australia.	Frini.karayanidis@newcastle.edu.au	Karayanidis, Frini/I-9269-2012; Heathcote, Andrew/C-1856-2008; marquez, jodie L/G-8105-2013; Conley, Alexander Christian/O-1700-2019	Karayanidis, Frini/0000-0002-3317-9954; Heathcote, Andrew/0000-0003-4324-5537; marquez, jodie L/0000-0002-9845-5788; Conley, Alexander Christian/0000-0003-1159-5524	University of Newcastle Post-Graduate Research Scholarship [3092298]	University of Newcastle Post-Graduate Research Scholarship	This work was funded by a University of Newcastle Post-Graduate Research Scholarship for ACC (Reference No. 3092298).	Bachmann CG, 2010, CLIN NEUROPHYSIOL, V121, P2083, DOI 10.1016/j.clinph.2010.05.005; Boggio PS, 2006, NEUROSCI LETT, V404, P232, DOI 10.1016/j.neulet.2006.05.051; Bortoletto M, 2015, BRAIN STIMUL, V8, P269, DOI 10.1016/j.brs.2014.11.006; Miranda PC, 2013, NEUROIMAGE, V70, P48, DOI 10.1016/j.neuroimage.2012.12.034; Cogiamanian F, 2007, EUR J NEUROSCI, V26, P242, DOI 10.1111/j.1460-9568.2007.05633.x; Gomes-Osman J, 2013, J MOTOR BEHAV, V45, P361, DOI 10.1080/00222895.2013.808604; Hayduk-Costa G, 2013, BEHAV BRAIN RES, V257, P208, DOI 10.1016/j.bbr.2013.09.030; Hsu TY, 2011, NEUROIMAGE, V56, P2249, DOI 10.1016/j.neuroimage.2011.03.059; JEBSEN R H, 1969, Archives of Physical Medicine and Rehabilitation, V50, P311; Jeffery DT, 2007, EXP BRAIN RES, V182, P281, DOI 10.1007/s00221-007-1093-y; Jeffreys H, 1961, THE THEORY OF PROBAB; KASS RE, 1995, J AM STAT ASSOC, V90, P773, DOI 10.1080/01621459.1995.10476572; Kwon YH, 2013, J PHYS THER SCI, V25, P1083, DOI 10.1589/jpts.25.1083; Leite J., 2011, PLOS ONE, V6; Lindenberg R, 2013, J NEUROSCI, V33, P9176, DOI 10.1523/JNEUROSCI.0055-13.2013; Miniussi C, 2013, NEUROSCI BIOBEHAV R, V37, P1702, DOI 10.1016/j.neubiorev.2013.06.014; Miyaguchi S, 2013, BRAIN RES, V1529, P83, DOI 10.1016/j.brainres.2013.07.026; Morey R. D., 2013, BAYESFACTOR COMPUTAT; Morey RD, 2008, TUTOR QUANT METHODS, V4, P61, DOI 10.20982/tqmp.04.2.p061; Nitsche MA, 2001, NEUROLOGY, V57, P1899, DOI 10.1212/WNL.57.10.1899; Nitsche MA, 2003, J COGNITIVE NEUROSCI, V15, P619, DOI 10.1162/089892903321662994; Nitsche MA, 2000, J PHYSIOL-LONDON, V527, P633, DOI 10.1111/j.1469-7793.2000.t01-1-00633.x; Nitsche MA, 2003, CLIN NEUROPHYSIOL, V114, P600, DOI 10.1016/S1388-2457(02)00412-1; Nitsche MA, 2003, J PHYSIOL-LONDON, V553, P293, DOI 10.1113/jphysiol.2003.049916; Nitsche MA, 2008, BRAIN STIMUL, V1, P206, DOI 10.1016/j.brs.2008.06.004; OLDFIELD RC, 1971, NEUROPSYCHOLOGIA, V9, P97, DOI 10.1016/0028-3932(71)90067-4; Pellicciari MC, 2013, NEUROIMAGE, V83, P569, DOI 10.1016/j.neuroimage.2013.06.076; Rouder JN, 2012, J MATH PSYCHOL, V56, P356, DOI 10.1016/j.jmp.2012.08.001; Schmidt SL, 2000, BRAIN COGNITION, V44, P445, DOI 10.1006/brcg.1999.1204; Tombaugh TN, 2004, ARCH CLIN NEUROPSYCH, V19, P203, DOI 10.1016/S0887-6177(03)00039-8; Utz KS, 2010, NEUROPSYCHOLOGIA, V48, P2789, DOI 10.1016/j.neuropsychologia.2010.06.002; Vines BW, 2008, EUR J NEUROSCI, V28, P1667, DOI 10.1111/j.1460-9568.2008.06459.x; Vines BW, 2008, BMC NEUROSCI, V9, DOI 10.1186/1471-2202-9-103; Wechsler D, 1997, WAIS 3 ADM SCORING M; Zimerman M, 2010, FRONT AGING NEUROSCI, V2, DOI 10.3389/fnagi.2010.00149	35	9	9	3	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 1	2015	10	5							e0124509	10.1371/journal.pone.0124509	http://dx.doi.org/10.1371/journal.pone.0124509			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CH2XA	25933204	Green Published, gold			2023-01-03	WOS:000353887100047
J	Hauck, T; Tanigawa, N; Probst, M; Wohlschlaeger, A; Ille, S; Sollmann, N; Maurer, S; Zimmer, C; Ringel, F; Meyer, B; Krieg, SM				Hauck, Theresa; Tanigawa, Noriko; Probst, Monika; Wohlschlaeger, Afra; Ille, Sebastian; Sollmann, Nico; Maurer, Stefanie; Zimmer, Claus; Ringel, Florian; Meyer, Bernhard; Krieg, Sandro M.			Task Type Affects Location of Language-Positive Cortical Regions by Repetitive Navigated Transcranial Magnetic Stimulation Mapping	PLOS ONE			English	Article							INFERIOR PREFRONTAL CORTEX; BRAIN-STIMULATION; SPOKEN LANGUAGE; VERB GENERATION; WORD PRODUCTION; NEURAL SYSTEMS; NAMING ERRORS; READING ALOUD; SPEECH; NOUNS	Objectives Recent repetitive TMS (rTMS) mapping protocols for language mapping revealed deficits of this method, mainly in posterior brain regions. Therefore this study analyzed the impact of different language tasks on the localization of language-positive brain regions and compared their effectiveness, especially with regard to posterior brain regions. Methods Nineteen healthy, right-handed subjects performed object naming, pseudoword reading, verb generation, and action naming during rTMS language mapping of the left hemisphere. Synchronically, 5 Hz/10 pulses were applied with a 0 ms delay Results The object naming task evoked the highest error rate (14%), followed by verb generation (13%) and action naming (11%). The latter revealed more errors in posterior than in anterior areas. Pseudoword reading barely generated errors, except for phonological paraphasias. Conclusions In general, among the evaluated language tasks, object naming is the most discriminative task to detect language-positive regions via rTMS. However, other tasks might be used for more specific questions.	[Hauck, Theresa; Ille, Sebastian; Sollmann, Nico; Maurer, Stefanie; Ringel, Florian; Meyer, Bernhard; Krieg, Sandro M.] Tech Univ Munich, Klinikum Rechts Isar, Dept Neurosurg, D-80290 Munich, Germany; [Tanigawa, Noriko] Univ Oxford, Fac Linguist Philol & Phonet, Oxford, England; [Probst, Monika; Wohlschlaeger, Afra; Zimmer, Claus] Tech Univ Munich, Klinikum Rechts Isar, Dept Radiol, Neuroradiol Sect, D-80290 Munich, Germany	Technical University of Munich; University of Oxford; Technical University of Munich	Krieg, SM (corresponding author), Tech Univ Munich, Klinikum Rechts Isar, Dept Neurosurg, D-80290 Munich, Germany.	Sandro.Krieg@lrz.tum.de	Krieg, Sandro M./L-8902-2016; Ringel, Florian/E-4933-2014; Meyer, Bernhard/AAH-3329-2019; Meyer, Bernhard/Q-9413-2016	Krieg, Sandro M./0000-0003-4050-1531; Meyer, Bernhard/0000-0001-6486-7955; Probst, Monika/0000-0003-1687-0409; Sollmann, Nico/0000-0002-8120-2223	BrainLab AG	BrainLab AG	BrainLab AG provided support in the form of salaries for authors [SK, FR], but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the 'author contributions' section.	Almairac F., 2014, BRAIN STRUCT FUNCT; Bonner MF, 2013, NEUROIMAGE, V71, P175, DOI 10.1016/j.neuroimage.2013.01.006; Brennan NMP, 2007, NEUROIMAGE, V37, pS100, DOI 10.1016/j.neuroimage.2007.04.052; BUCKNER RL, 1995, J NEUROPHYSIOL, V74, P2163, DOI 10.1152/jn.1995.74.5.2163; Coltheart M, 2001, PSYCHOL REV, V108, P204, DOI 10.1037//0033-295X.108.1.204; Corina DP, 2010, BRAIN LANG, V115, P101, DOI 10.1016/j.bandl.2010.04.001; Corina DP, 2005, HUM BRAIN MAPP, V24, P1, DOI 10.1002/hbm.20063; Corina I, 2005, J INFUS MURS, V28, P12, DOI 10.1097/00000446-200503001-00004; DAMASIO AR, 1993, P NATL ACAD SCI USA, V90, P4957, DOI 10.1073/pnas.90.11.4957; DANIELE A, 1994, NEUROPSYCHOLOGIA, V32, P1325, DOI 10.1016/0028-3932(94)00066-2; DeLeon J, 2007, BRAIN, V130, P1408, DOI 10.1093/brain/awm011; du Boisgueheneuc F, 2006, BRAIN, V129, P3315, DOI 10.1093/brain/awl244; Duffau H, 2013, BRAIN LANG; Epstein CM, 1996, NEUROLOGY, V47, P1590, DOI 10.1212/WNL.47.6.1590; Felty R. A, 2007, CONTEXT EFFECTS SPOK; Frings M, 2006, NEUROSCI LETT, V409, P19, DOI 10.1016/j.neulet.2006.08.058; Gathercole SE, 2006, APPL PSYCHOLINGUIST, V27, P599, DOI 10.1017/S014271640606053X; Gow DW, 2012, BRAIN LANG, V121, P273, DOI 10.1016/j.bandl.2012.03.005; Graves WW, 2008, J COGNITIVE NEUROSCI, V20, P1698, DOI 10.1162/jocn.2008.20113; Graves WW, 2010, CEREB CORTEX, V20, P1799, DOI 10.1093/cercor/bhp245; Henseler I, 2014, J COGNITIVE NEUROSCI, V26, P1403, DOI 10.1162/jocn_a_00572; Hermann BP, 1999, NEUROPSYCHOLOGY, V13, P3, DOI 10.1037/0894-4105.13.1.3; Indefrey P, 2011, FRONT PSYCHOL, V2, DOI 10.3389/fpsyg.2011.00255; Krieg SM, 2014, NEUROIMAGE, V100, P219, DOI 10.1016/j.neuroimage.2014.06.016; Krieg SM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075403; Lioumis P, 2012, J NEUROSCI METH, V204, P349, DOI 10.1016/j.jneumeth.2011.11.003; Melby-Lervag M, 2012, PSYCHOL BULL, V138, P322, DOI 10.1037/a0026744; Moseley RL, 2014, BRAIN LANG, V132, P28, DOI 10.1016/j.bandl.2014.03.001; OLDFIELD RC, 1971, NEUROPSYCHOLOGIA, V9, P97, DOI 10.1016/0028-3932(71)90067-4; Papagno C, 2011, NEUROIMAGE, V55, P1306, DOI 10.1016/j.neuroimage.2011.01.005; Papathanassiou D, 2000, NEUROIMAGE, V11, P347, DOI 10.1006/nimg.2000.0546; PASCUALLEONE A, 1991, NEUROLOGY, V41, P697, DOI 10.1212/WNL.41.5.697; Picht T, 2013, NEUROSURGERY, V72, P808, DOI 10.1227/NEU.0b013e3182889e01; Picht T, 2009, NEUROSURGERY, V65, P93, DOI 10.1227/01.NEU.0000348009.22750.59; Poldrack RA, 1999, NEUROIMAGE, V10, P15, DOI 10.1006/nimg.1999.0441; Price CJ, 2012, NEUROIMAGE, V62, P816, DOI 10.1016/j.neuroimage.2012.04.062; Price CJ, 2005, HUM BRAIN MAPP, V25, P70, DOI 10.1002/hbm.20132; Rossi S, 2009, CLIN NEUROPHYSIOL, V120, P2008, DOI 10.1016/j.clinph.2009.08.016; Roux FE, 2004, BRAIN, V127, P1796, DOI 10.1093/brain/awh204; Salmelin R, 2000, J CLIN NEUROPHYSIOL, V17, P163, DOI 10.1097/00004691-200003000-00005; Scott SK, 2003, NEUROIMAGE, V19, P870, DOI 10.1016/S1053-8119(03)00083-1; Simos PG, 2002, CEREB CORTEX, V12, P297, DOI 10.1093/cercor/12.3.297; Siri S, 2008, CEREB CORTEX, V18, P171, DOI 10.1093/cercor/bhm043; Sollmann N, 2013, BMC NEUROSCI, V14, DOI 10.1186/1471-2202-14-150; Sollmann N, 2013, J NEUROSURG, V118, P175, DOI 10.3171/2012.9.JNS121053; Soros P, 2003, NEUROIMAGE, V19, P1787, DOI 10.1016/S1053-8119(03)00217-9; Tarapore PE, 2013, NEUROIMAGE, V82, P260, DOI 10.1016/j.neuroimage.2013.05.018; Taylor JSH, 2013, PSYCHOL BULL, V139, P766, DOI 10.1037/a0030266; Thompson-Schill SL, 1997, P NATL ACAD SCI USA, V94, P14792, DOI 10.1073/pnas.94.26.14792; Thurling M, 2011, NEUROIMAGE, V57, P1184, DOI 10.1016/j.neuroimage.2011.05.045; Vigliocco G, 2011, NEUROSCI BIOBEHAV R, V35, P407, DOI 10.1016/j.neubiorev.2010.04.007; Wassermann EM, 1999, NEUROPSYCHOLOGIA, V37, P537, DOI 10.1016/S0028-3932(98)00102-X	52	26	26	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 30	2015	10	4							e0125298	10.1371/journal.pone.0125298	http://dx.doi.org/10.1371/journal.pone.0125298			21	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CH0MA	25928744	Green Submitted, Green Published, gold			2023-01-03	WOS:000353713100078
J	Jiang, X; Lim, CZH; Li, ZM; Lee, PL; Yatim, SMJM; Guan, PY; Li, JT; Zhou, JB; Pan, JX; Chng, WJ; Chai, CLL; Yu, Q				Jiang, Xia; Lim, Cheryl Zi Hui; Li, Zhimei; Lee, Puay Leng; Yatim, Siti Maryam J. M.; Guan, Peiyong; Li, Juntao; Zhou, Jianbiao; Pan, Jingxuan; Chng, Wee-Joo; Chai, Christina L. L.; Yu, Qiang			Functional Characterization of D9, a Novel Deazaneplanocin A (DZNep) Analog, in Targeting Acute Myeloid Leukemia (AML)	PLOS ONE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; HISTONE METHYLTRANSFERASE EZH2; MEDIATED DRUG-RESISTANCE; SMALL-MOLECULE INHIBITOR; STEM-CELLS; PHARMACOLOGICAL DISRUPTION; EPIGENETIC THERAPY; TUMOR-CELLS; CANCER; 3-DEAZANEPLANOCIN	Aberrant epigenetic events contribute to tumorigenesis of all human cancers. Significant efforts are underway in developing new generation of epigenetic cancer therapeutics. Although clinical trials for agents targeting DNA hypermethylation and histone deacetylation have yielded promising results, developing agents that target histone methylation remains to be in the early stage. We and others have previously reported that 3-Deazaneplanocin A (DZNep) is a histone methylation inhibitor that has a wide range of anticancer effects in various human cancers. Here, focusing on acute myeloid leukemia (AML) as a model, we reported a less toxic analog of DZNep, named D9, which is shown to be efficacious in AML cell lines and patient-derived samples in vitro, as well as AML tumorigenesis in vivo. Gene expression analysis in a panel of AML cell lines treated with D9 identified a set of genes that is associated with D9 sensitivity and implicated in multiple oncogenic signaling pathways. Moreover, we show that D9 is able to deplete the leukemia stem cells (LSC) and abolish chemotherapy-induced LSC enrichment, leading to dramatic elimination of AML cell survival. Thus, D9 appears to be a robust epigenetic compound that may constitute a potential for AML therapy.	[Jiang, Xia; Lim, Cheryl Zi Hui; Li, Zhimei; Lee, Puay Leng; Yatim, Siti Maryam J. M.; Yu, Qiang] ASTAR, Genome Inst Singapore, Canc Therapeut & Stratified Oncol, Biopolis, Singapore 138672, Singapore; [Guan, Peiyong; Li, Juntao] ASTAR, Genome Inst Singapore, Computat & Syst Biol, Biopolis, Singapore 138672, Singapore; [Zhou, Jianbiao; Chng, Wee-Joo] Natl Univ Singapore, Canc Sci Inst Singapore, Singapore 117599, Singapore; [Pan, Jingxuan] Sun Yat Sen Univ, Sch Med, Dept Pathophysiol, Guangzhou 510089, Guangdong, Peoples R China; [Chng, Wee-Joo] Natl Univ Hlth Syst, Natl Univ Canc Inst Singapore, Dept Haematol Oncol, Singapore, Singapore; [Chng, Wee-Joo] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Med, Singapore 117595, Singapore; [Chai, Christina L. L.] Inst Chem & Engn Sci, Singapore 138665, Singapore; [Chai, Christina L. L.] Natl Univ Singapore, Dept Pharm, Singapore 117543, Singapore; [Yu, Qiang] Jinan Univ, Inst Canc, Guangzhou 510632, Guangdong, Peoples R China; [Yu, Qiang] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Physiol, Singapore 117597, Singapore	Agency for Science Technology & Research (A*STAR); A*STAR - Genome Institute of Singapore (GIS); Agency for Science Technology & Research (A*STAR); A*STAR - Genome Institute of Singapore (GIS); National University of Singapore; Sun Yat Sen University; National University of Singapore; National University of Singapore; Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Sustainability for Chemicals, Energy & Environment (ISCE2); National University of Singapore; Jinan University; National University of Singapore	Yu, Q (corresponding author), ASTAR, Genome Inst Singapore, Canc Therapeut & Stratified Oncol, Biopolis, Singapore 138672, Singapore.	yuq@gis.a-star.edu.sg	Chai, Christina L/A-3133-2014; Guan, Peiyong/A-3715-2015	Guan, Peiyong/0000-0001-9958-0137; Chai, Christina/0000-0002-9199-851X; Yu, Qiang/0000-0003-2132-8278	Joint Council Office and Exploit Technology of Agency for Science, Technology, and Research (A*STAR); Singapore National Research Foundation; Ministry of Education; National Medical Research Council; A*STAR graduate fellowship	Joint Council Office and Exploit Technology of Agency for Science, Technology, and Research (A*STAR); Singapore National Research Foundation(National Research Foundation, Singapore); Ministry of Education; National Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); A*STAR graduate fellowship	This work was supported by the Joint Council Office and Exploit Technology of Agency for Science, Technology, and Research (A*STAR) to Q.Y. and C.C.; by the Singapore National Research Foundation; and by the Ministry of Education under the Research Centre of Excellence Program to W.-J. C.W.-J.C. was supported by the National Medical Research Council Clinician Scientist Investigator Award. X.J. was supported by A*STAR graduate fellowship. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ahmed N, 2010, CURR CANCER DRUG TAR, V10, P268, DOI 10.2174/156800910791190175; Asanuma H, 2005, CANCER RES, V65, P11018, DOI 10.1158/0008-5472.CAN-05-0491; Bernt KM, 2011, CANCER CELL, V20, P66, DOI 10.1016/j.ccr.2011.06.010; Bouillet P, 2001, MAMM GENOME, V12, P163, DOI 10.1007/s003350010242; Crea F, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-40; Daigle SR, 2011, CANCER CELL, V20, P53, DOI 10.1016/j.ccr.2011.06.009; Damiano JS, 2000, LEUKEMIA LYMPHOMA, V38, P71, DOI 10.3109/10428190009060320; Damiano JS, 1999, BLOOD, V93, P1658, DOI 10.1182/blood.V93.5.1658; Fiskus W, 2009, BLOOD, V114, P2733, DOI 10.1182/blood-2009-03-213496; Goardon N, 2011, CANCER CELL, V19, P138, DOI 10.1016/j.ccr.2010.12.012; Hayden A, 2011, BREAST CANCER RES TR, V127, P109, DOI 10.1007/s10549-010-0982-0; Hu XT, 1998, LEUKEMIA RES, V22, P817, DOI 10.1016/S0145-2126(98)00073-3; Hubner A, 2008, MOL CELL, V30, P415, DOI 10.1016/j.molcel.2008.03.025; Ishikawa F, 2007, NAT BIOTECHNOL, V25, P1315, DOI 10.1038/nbt1350; Jiang X, 2008, CANCER CELL, V13, P529, DOI 10.1016/j.ccr.2008.04.019; Kikuchi J, 2012, LUNG CANCER, V78, P138, DOI 10.1016/j.lungcan.2012.08.003; Knutson SK, 2012, NAT CHEM BIOL, V8, P890, DOI [10.1038/NCHEMBIO.1084, 10.1038/nchembio.1084]; Kornblau SM, 2009, BLOOD, V113, P154, DOI 10.1182/blood-2007-10-119438; Krivtsov AV, 2007, NAT REV CANCER, V7, P823, DOI 10.1038/nrc2253; Kubicek S, 2007, MOL CELL, V25, P473, DOI 10.1016/j.molcel.2007.01.017; Liu F, 2010, J MED CHEM, V53, P5844, DOI 10.1021/jm100478y; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; McCabe MT, 2012, NATURE, V492, P108, DOI 10.1038/nature11606; Milella M, 2005, CURR PHARM DESIGN, V11, P2779, DOI 10.2174/1381612054546842; Ninomiya M, 2007, LEUKEMIA, V21, P136, DOI 10.1038/sj.leu.2404432; Piekarz RL, 2009, J CLIN ONCOL, V27, P5410, DOI 10.1200/JCO.2008.21.6150; Puppe J, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2354; Qi W, 2012, P NATL ACAD SCI USA, V109, P21360, DOI 10.1073/pnas.1210371110; Roboz GJ, 2011, HEMATOL-AM SOC HEMAT, P43, DOI 10.1182/asheducation-2011.1.43; Roboz GJ, 2009, EXPERT REV HEMATOL, V2, P663, DOI [10.1586/ehm.09.53, 10.1586/EHM.09.53]; Stone RM, 2007, BEST PRACT RES CL HA, V20, P39, DOI 10.1016/j.beha.2006.11.006; Strasser A, 2005, NAT REV IMMUNOL, V5, P189, DOI 10.1038/nri1568; Stresemann C, 2008, INT J CANCER, V123, P8, DOI 10.1002/ijc.23607; Suva ML, 2013, SCIENCE, V339, P1567, DOI 10.1126/science.1230184; Suva ML, 2009, CANCER RES, V69, P9211, DOI 10.1158/0008-5472.CAN-09-1622; Tallman MS, 2005, BLOOD, V106, P1154, DOI 10.1182/blood-2005-01-0178; Tam EKW, 2015, CHEMMEDCHEM, V10, P173, DOI 10.1002/cmdc.201402315; Tan J, 2007, GENE DEV, V21, P1050, DOI 10.1101/gad.1524107; Tavor S, 2004, CANCER RES, V64, P2817, DOI 10.1158/0008-5472.CAN-03-3693; Trowbridge JJ, 2012, GENE DEV, V26, P344, DOI 10.1101/gad.184341.111; Vedadi M, 2011, NAT CHEM BIOL, V7, P566, DOI [10.1038/NCHEMBIO.599, 10.1038/nchembio.599]; Wang ZW, 2011, NAT REV GASTRO HEPAT, V8, P27, DOI 10.1038/nrgastro.2010.188; Wee ZN, 2014, CELL REP; YATES JW, 1973, CANCER CHEMOTH REP 1, V57, P485; Zhao P, 2010, BIOCHEM BIOPH RES CO, V395, P219, DOI 10.1016/j.bbrc.2010.03.165; Zhou JB, 2011, BLOOD, V118, P2830, DOI 10.1182/blood-2010-07-294827	46	14	14	0	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 30	2015	10	4							e0122983	10.1371/journal.pone.0122983	http://dx.doi.org/10.1371/journal.pone.0122983			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CH0MA	25928216	Green Published, gold, Green Submitted			2023-01-03	WOS:000353713100012
J	Gong, P; Lu, ZD; Xing, J; Wang, N; Zhang, Y				Gong, Ping; Lu, Zhidan; Xing, Jing; Wang, Na; Zhang, Yu			Traditional Chinese Medicine Xuebijing Treatment Is Associated with Decreased Mortality Risk of Patients with Moderate Paraquat Poisoning	PLOS ONE			English	Article							NF-KAPPA-B; HERBICIDE PARAQUAT; IN-VIVO; INJECTION; CELLS; MACROPHAGES; EXPRESSION; IDENTIFICATION; INFLAMMATION; ACTIVATION	Paraquat poisoning causes multiple organ injury and high mortality due to severe toxicity and lack of effective treatment. Xuebijing (XBJ) injection, a traditional Chinese medicine preparation of five Chinese herbs (Radix Salviae Miltiorrhiae, Rhizoma Chuanxiong, Flos Carthami, Angelica Sinensis and Radix Paeoniae Rubra), has an anti-inflammatory effect and is widely used in the treatment of sepsis. This retrospective study was designed to evaluate the effects of XBJ combined with conventional therapy on mortality risk of patients with acute paraquat poisoning. Out of 68 patients, 27 were treated with conventional therapy (control group) and 41 were treated with intravenous administration of XBJ (100 ml, twice a day, up to 7 days) plus conventional therapy (XBJ group). Vital organ function, survival time within 28 days and adverse events during the treatment were reviewed. Results indicated that XBJ treatment significantly increased median survival time among patients ingesting 1030 ml of paraquat (P=0.02) compared with the control group. After adjustment for covariates, XBJ treatment was associated significantly with a lower mortality risk (adjusted HR 0.242, 95% CI 0.113 to 0.516, P=0.001) compared with the control group. Additionally, compared with Day 1, on Day 3 the value of PaO2/FiO(2) was significantly decreased, and the values of serum alanine aminotransferase, creatinine and troponin T were significantly increased in the control group (all P<0.05), but these values were significant improved in the XBJ group (all P<0.05). Only one patient had skin rash with itch within 30 minutes after injection and no severe adverse events were found in the XBJ group. In conclusion, XBJ treatment is associated with decreased mortality risk of patients with moderate paraquat poisoning, which may be attributed to improved function of vital organs with no severe adverse events.	[Gong, Ping; Lu, Zhidan; Xing, Jing; Wang, Na; Zhang, Yu] Dalian Med Univ, Affiliated Hosp 1, Emergency Dept, Dalian 116011, Liaoning Provin, Peoples R China	Dalian Medical University	Zhang, Y (corresponding author), Dalian Med Univ, Affiliated Hosp 1, Emergency Dept, Dalian 116011, Liaoning Provin, Peoples R China.	dljizhen@sina.cn	Gong, Ping/AAV-1936-2021	Gong, Ping/0000-0001-9910-7948	Liaoning Province Nature Science Foundation [2013023020]; Training Programs of Talents in Science and Technology [2013D003]	Liaoning Province Nature Science Foundation; Training Programs of Talents in Science and Technology	This study was supported by the Liaoning Province Nature Science Foundation (2013023020) and the Training Programs of Talents in Science and Technology (2013D003). The funders had no role in study design, data collection/analysis, decision to publish, or preparation of the manuscript.	Aires RD, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073562; Bonneh-Barkay D, 2005, MOL BRAIN RES, V134, P52, DOI 10.1016/j.molbrainres.2004.11.005; Castello PR, 2007, J BIOL CHEM, V282, P14186, DOI 10.1074/jbc.M700827200; Chao WW, 2010, J ETHNOPHARMACOL, V129, P244, DOI 10.1016/j.jep.2010.03.022; Chen Y, 2013, J TRADIT CHIN MED, V33, P243, DOI 10.1016/S0254-6272(13)60133-8; China's State Food and Drug Administration, 2014, QUAL CONTR STAND DRU; Deng J, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010109.pub2; Dinis-Oliveira RJ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007149; Gawarammana IB, 2011, BRIT J CLIN PHARMACO, V72, P745, DOI 10.1111/j.1365-2125.2011.04026.x; Hsieh YW, 2013, PEDIATR EMERG CARE, V29, P487, DOI 10.1097/PEC.0b013e31828a347e; Hsu CW, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048397; Hsu HH, 2003, J TOXICOL-CLIN TOXIC, V41, P89, DOI 10.1081/CLT-120018278; Huang H, 2011, PHYTOCHEM ANALYSIS, V22, P330, DOI 10.1002/pca.1284; Jia P, 2013, TALANTA, V107, P103, DOI 10.1016/j.talanta.2012.12.031; Jiang M, 2013, J ETHNOPHARMACOL, V147, P426, DOI 10.1016/j.jep.2013.03.032; Jiang WY, 2013, INT IMMUNOPHARMACOL, V16, P160, DOI 10.1016/j.intimp.2013.03.028; Jones GM, 2000, J TOXICOL-CLIN TOXIC, V38, P123, DOI 10.1081/CLT-100100926; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; [孔飞飞 Kong Feifei], 2012, [中国新药杂志, Chinese Journal New Drugs], V21, P100; Koo JR, 2002, AM J KIDNEY DIS, V39, P55, DOI 10.1053/ajkd.2002.29880; Kratsovnik E, 2005, J MOL NEUROSCI, V26, P27, DOI 10.1385/JMN:26:1:027; Li M, 2012, PHYTOTHER RES, V26, P1195, DOI 10.1002/ptr.3680; Lin NC, 2003, J TOXICOL-CLIN TOXIC, V41, P877, DOI 10.1081/CLT-120025356; Liu L, 2005, PLANTA MED, V71, P808, DOI 10.1055/s-2005-871231; Qi F, 2011, J TRADIT CHIN MED, V31, P46, DOI 10.1016/S0254-6272(11)60011-3; Ran X, 2011, PHARM BIOL, V49, P1180, DOI 10.3109/13880209.2011.576346; Ren ZH, 2010, PHYTOMEDICINE, V17, P212, DOI 10.1016/j.phymed.2009.08.010; Saw CLL, 2013, BIOPHARM DRUG DISPOS, V34, P303, DOI 10.1002/bdd.1846; Schoonbroodt S, 2000, BIOCHEM PHARMACOL, V60, P1075, DOI 10.1016/S0006-2952(00)00371-3; Shi YY, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040911; Song LJ, 2013, FITOTERAPIA, V84, P107, DOI 10.1016/j.fitote.2012.11.004; Su YW, 2011, INT IMMUNOPHARMACOL, V11, P1166, DOI 10.1016/j.intimp.2011.03.014; Sun JP, 2010, EXP LUNG RES, V36, P211, DOI 10.3109/01902140903312123; Sun ML, 2009, J ALTERN COMPLEM MED, V15, P1375, DOI 10.1089/acm.2009.0049; Tang S, 2011, INFLAMMATION, V34, P111, DOI 10.1007/s10753-010-9214-3; Wang CC, 2011, J SCI FOOD AGR, V91, P218, DOI 10.1002/jsfa.4172; Weng CH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051743; Yang W, 2007, J TOXICOL ENV HEAL A, V70, P1849, DOI 10.1080/15287390701459262; Yin X, 2012, PLOS ONE, V7, DOI [10.1371/journal.pone.0038381, 10.1371/journal.pone.0051853]; Zheng XB, 2012, J TRADIT CHIN MED, V32, P584, DOI 10.1016/S0254-6272(13)60075-8	40	21	24	0	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 29	2015	10	4							e0123504	10.1371/journal.pone.0123504	http://dx.doi.org/10.1371/journal.pone.0123504			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CH0LO	25923333	Green Published, Green Submitted, gold			2023-01-03	WOS:000353711600049
J	Jiang, XQ; Mei, XD; Feng, D; Wang, XJ				Jiang, Xuqin; Mei, Xiaodong; Feng, Di; Wang, Xiaojing			Prophylaxis and Treatment of Pneumocystis jiroveci Pneumonia in Lymphoma Patients Subjected to Rituximab-Contained Therapy: A Systemic Review and Meta-Analysis	PLOS ONE			English	Article							B-CELL LYMPHOMA; CHRONIC LYMPHOCYTIC-LEUKEMIA; NON-HODGKINS-LYMPHOMA; RANDOMIZED CONTROLLED-TRIAL; CHOP-BASED CHEMOTHERAPY; INTERSTITIAL PNEUMONIA; ELDERLY-PATIENTS; PLUS RITUXIMAB; HIGH-RISK; CYCLOPHOSPHAMIDE	Pneumocystis jiroveci pneumonia (PCP) is frequently reported in lymphoma patients treated with rituximab-contained regimens. There is a trend toward a difference in PCP risk between bi- and tri-weekly regimens. The aims of this systemic review and meta-analysis were to estimate the risk for PCP in these patients, compare the impact of different regimens on the risk, and evaluate the efficacy of prophylaxis. The cohort studies with incept up to January 2014 were retrieved from the Cochrane Library, Medline, Embase, and Web of Science databases. Studies that compared the incidence of PCP in patients with and without rituximab treatment were conducted. Studies that reported the results of prophylaxis were concentrated to evaluate the efficacy of prophylaxis. Fixed effect Mantel-Haenszel model was chosen as the main analysis method. Funnel plots were examined to estimate the potential selection bias. Egger's test and Begg's test were used for the determination of possible small study bias. Eleven cohort studies that met the inclusion criteria were finally included. Results indicated that rituximab was associated with a significantly increased risk for PCP (28/942 vs 5/977; risk ratio: 3.65; 95% confidence interval 1.65 to 8.07; P=0.001), and no heterogeneity existed between different studies (I-2=0%). Little significant difference in PCP risk was found between bi-weekly and tri-weekly regimens (risk ratio: 3.11; 95% confidence interval 0.92 to 10.52, P=0.068). PCP risk was inversely associated with prophylaxis in patients treated with rituximab (0/222 vs 26/986; risk ratio: 0.28; 95% confidence interval 0.09 to 0.94; P=0.039). In conclusion, PCP risk was increased significantly in lymphoma patients subjected to rituximab-contained chemotherapies. Difference in PCP risk between biweekly and tri-weekly regimens was not significant. Additionally, prophylaxis was dramatically effective in preventing PCP in rituximab-received lymphoma patients, suggesting that rituximab should be recommended for these patients.	[Jiang, Xuqin; Mei, Xiaodong; Feng, Di; Wang, Xiaojing] Anhui Prov Hosp, Dept Resp Med, Hefei, Peoples R China		Mei, XD (corresponding author), Anhui Prov Hosp, Dept Resp Med, Hefei, Peoples R China.	hfmxd@sina.com						Badoux XC, 2011, BLOOD, V118, P448; Badoux XC, 2011, BLOOD, V118, P2085, DOI 10.1182/blood-2011-03-341032; Beltz K, 2006, KLIN PADIATR, V218, P177, DOI 10.1055/s-2006-933433; Bonilla-Abadia F, 2014, CLIN RHEUMATOL; Boothpur R, 2008, AM J TRANSPLANT, V8, P862, DOI 10.1111/j.1600-6143.2008.02151.x; Bradburn MJ, 2007, STAT MED, V26, P53, DOI 10.1002/sim.2528; Brusamolino E, 2006, HAEMATOLOGICA, V91, P496; Bussone G, 2009, AM J HEMATOL, V84, P153, DOI 10.1002/ajh.21341; Carter SJ, 2011, LEUKEMIA RES, V35, pE223, DOI 10.1016/j.leukres.2011.07.014; Chang H, 2008, J CHIN MED ASSOC, V71, P579, DOI 10.1016/S1726-4901(08)70173-4; Chang H, 2010, ACTA HAEMATOL-BASEL, V123, P30, DOI 10.1159/000261020; Conte GF, 2002, FLUDARABINE THERAPY; Cornely Oliver A, 2004, Wien Med Wochenschr, V154, P209, DOI 10.1007/s10354-004-0067-y; Czarniak P, 2013, PEDIATR NEPHROL, V28, P987, DOI 10.1007/s00467-013-2457-0; DERUNGS A, 2010, SCHWEIZ RUNDSCH MED, V99, P767, DOI DOI 10.1024/1661-8157/a000199; Egle A, 2009, BLOOD, V114, P1341, DOI 10.1182/blood.V114.22.3453.3453; Ennishi D, 2008, INT J HEMATOL, V87, P393, DOI 10.1007/s12185-008-0066-7; FISHER RI, 1993, NEW ENGL J MED, V328, P1002, DOI 10.1056/NEJM199304083281404; Gea-Banacloche JC, 2010, SEMIN HEMATOL, V47, P187, DOI 10.1053/j.seminhematol.2010.01.002; Green H, 2007, MAYO CLIN PROC, V82, P1052, DOI 10.4065/82.9.1052; Habermann TM, 2006, J CLIN ONCOL, V24, P3121, DOI 10.1200/JCO.2005.05.1003; Haeusler GM, 2013, EUR J HAEMATOL, V91, P157, DOI 10.1111/ejh.12135; Hardak E, 2012, ACTA HAEMATOL-BASEL, V127, P110, DOI 10.1159/000334113; Harigai M, 2012, J RHEUMATOL, V39, P486, DOI 10.3899/jrheum.110994; Hashimoto K, 2010, LEUKEMIA LYMPHOMA, V51, P1816, DOI 10.3109/10428194.2010.506569; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; Higgins J, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.ED000049; Huang YC, 2011, ANN HEMATOL, V90, P1145, DOI 10.1007/s00277-011-1268-2; Hugle B, 2010, ARTHRIT CARE RES, V62, P1661, DOI 10.1002/acr.20279; Iguchi Toyotaka, 2005, Rinsho Ketsueki, V46, P1049; Ioannidis JPA, 2007, BRIT MED J, V335, P914, DOI 10.1136/bmj.39343.408449.80; Isidori A, 2011, LEUKEMIA LYMPHOMA, V52, P148, DOI 10.3109/10428194.2010.525726; Jiang XQ, 2013, J THORAC DIS, V5, pE162, DOI 10.3978/j.issn.2072-1439.2013.08.35; Kamel S, 2010, LEUKEMIA LYMPHOMA, V51, P797, DOI 10.3109/10428191003699860; Kato H, 2011, CL LYMPH MYELOM LEUK, V11, P483, DOI 10.1016/j.clml.2011.06.011; Kato H, 2009, CLIN LYMPHOMA MYELOM, V9, P443, DOI 10.3816/CLM.2009.n.087; Katsuya H, 2009, LEUKEMIA LYMPHOMA, V50, P1818, DOI 10.3109/10428190903258780; Kavcic M, 2013, J PEDIATR-US, V162, P1252, DOI 10.1016/j.jpeds.2012.11.038; Kelesidis T, 2011, INT J INFECT DIS, V15, pE2, DOI 10.1016/j.ijid.2010.03.025; Kim MG, 2013, NEPHROLOGY CARLTON; Kim T, 2013, ANN HEMATOL, V92, P231, DOI 10.1007/s00277-012-1592-1; Kolstad A, 2007, HAEMATOL-HEMATOL J, V92, P139, DOI 10.3324/haematol.10564; Kumar D, 2009, TRANSPL INFECT DIS, V11, P167, DOI 10.1111/j.1399-3062.2008.00345.x; Kumar N, 2011, J INFECTION, V62, P484, DOI 10.1016/j.jinf.2011.04.008; Kurokawa T, 2011, HEMATOL ONCOL, V29, P5, DOI 10.1002/hon.947; Kurokawa T, 2010, J CLIN EXP HEMATOP, V50, P159, DOI 10.3960/jslrt.50.159; Lamba M, 2002, CARDIOVASC PATHOL, V11, P346, DOI 10.1016/S1054-8807(02)00126-6; Lim Kyu-Hyoung, 2010, Korean Journal of Internal Medicine, V25, P86, DOI 10.3904/kjim.2010.25.1.86; Lin TS, 2007, CONSOLIDATION THER 1, p232A; Lund FE, 2006, J IMMUNOL, V176, P6147, DOI 10.4049/jimmunol.176.10.6147; Martin-Garrido I, 2013, CHEST, V144, P258, DOI 10.1378/chest.12-0477; Morrison VA, 2007, ALEMTUZUMAB INCREA 1, p233A; Morrison VA, 2010, BEST PRACT RES CL HA, V23, P145, DOI 10.1016/j.beha.2009.12.004; Motto DG, 2002, ISRAEL MED ASSOC J, V4, P1006; Nosori A, 2004, HAEMATOLOGICA, V89, P1415; Otremba MD, 2012, AM J OTOLARYNG, V33, P619, DOI 10.1016/j.amjoto.2012.01.006; Owen RG, 2003, ACTIVITY OF ALEMTUZU, p644a; Perez-Ordono L, 2014, TRANSPL INFECT DIS; Pfreundschuh M, 2004, BLOOD, V104, P634, DOI 10.1182/blood-2003-06-2095; Pfreundschuh M, 2008, LANCET ONCOL, V9, P105, DOI 10.1016/S1470-2045(08)70002-0; Pfreundschuh M, 2006, LANCET ONCOL, V7, P379, DOI 10.1016/S1470-2045(06)70664-7; Ram R, 2009, LEUKEMIA LYMPHOMA, V50, P1083, DOI 10.1080/10428190902934944; Sato M, 2013, PEDIATR NEPHROL, V28, P145, DOI 10.1007/s00467-012-2286-6; Shelton E, 2009, NEPHROLOGY, V14, P696, DOI 10.1111/j.1440-1797.2009.01168.x; Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008; Su Gai-xiu, 2012, Zhonghua Er Ke Za Zhi, V50, P697; Tadmor T, 2010, LEUKEMIA LYMPHOMA, V51, P737, DOI 10.3109/10428191003715377; Takeda K, 2009, TRANSPL P, V41, P3941, DOI 10.1016/j.transproceed.2009.02.094; Tam CS, 2005, HAEMATOLOGICA, V90, P700; Taylor SM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049991; Teichmann LL, 2008, RHEUMATOLOGY, V47, P1256, DOI 10.1093/rheumatology/ken234; Treon SP, 2009, BLOOD, V113, P3673, DOI 10.1182/blood-2008-09-177329; Tsai MJ, 2012, LUPUS, V21, P914, DOI 10.1177/0961203312436855; Venhuizen AC, 2008, EUR J HAEMATOL, V80, P275, DOI 10.1111/j.1600-0609.2007.00994.x; Wells GA, NEWCASTLE OTTAWA SCA; White DA, 2004, CLIN CHEST MED, V25, P179, DOI 10.1016/S0272-5231(03)00134-5; Worth LJ, 2005, BRIT J CANCER, V92, P867, DOI 10.1038/sj.bjc.6602412; Yokoyama H, 2008, INT J HEMATOL, V88, P443, DOI 10.1007/s12185-008-0168-2; Zelenetz Andrew D, 2006, J Natl Compr Canc Netw, V4, P258; Zent CS, 2008, CANCER, V113, P2110, DOI 10.1002/cncr.23824	80	36	38	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 24	2015	10	4							e0122171	10.1371/journal.pone.0122171	http://dx.doi.org/10.1371/journal.pone.0122171			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CG6AH	25909634	Green Published, gold, Green Submitted			2023-01-03	WOS:000353376800018
J	Tessier, L; Bienzle, D; Williams, LB; Koch, TG				Tessier, Laurence; Bienzle, Dorothee; Williams, Lynn B.; Koch, Thomas G.			Phenotypic and Immunomodulatory Properties of Equine Cord Blood-Derived Mesenchymal Stromal Cells	PLOS ONE			English	Article							VERSUS-HOST-DISEASE; TOLL-LIKE RECEPTORS; STEM-CELLS; BONE-MARROW; ADIPOSE-TISSUE; MARKERS; CULTURE; DIFFERENTIATION; IMMUNOPHENOTYPE; THERAPY	Multipotent mesenchymal stromal cells (MSC) have attracted interest for their cytotherapeutic potential, partly due to their immunomodulatory abilities. The aim of this study was to test the robustness of our equine cord blood (CB) MSC isolation protocol, to characterize the CB-MSC before and after cryopreservation, and to evaluate their immunosuppressive phenotype. We hypothesized that MSC can be consistently isolated from equine CB, have unique and reproducible marker expression and in vitro suppress lymphoproliferation. Preliminary investigation of constitutive cytoplasmic Toll-like receptor (TLR) 3 and 4 expression was also preformed due to their possible association with anti-or pro-inflammatory MSC phenotypes, respectively. Surface markers were assessed for antigen and mRNA expression by flow cytometry and quantitative polymerase chain reaction (qPCR). Immunomodulatory properties were evaluated in mixed lymphocyte reaction assays, and TLR3 and TLR4 expression were measured by qPCR and immunocytochemistry (ICC). CB-MSC were isolated from each off nine cord blood samples. CB-MSC highly expressed CD29, CD44, CD90, and lacked or had low expression of major histocompatibility complex (MHC) class I, MHC-II, CD4, CD8, CD11a/18 and CD73 before and after cryopreservation. CB-MSC suppressed in vitro lymphoproliferation and constitutively expressed TLR4. Our findings confirmed CB as a reliable MSC source, provides an association of surface marker phenotype and mRNA expression and suggest anti-inflammatory properties of CB-MSC. The relationship between TLRs and lymphocyte function warrants further investigation.	[Tessier, Laurence; Koch, Thomas G.] Univ Guelph, Ontario Vet Coll, Dept Biomed Sci, Guelph, ON N1G 2W1, Canada; [Bienzle, Dorothee] Univ Guelph, Ontario Vet Coll, Dept Pathobiol, Guelph, ON N1G 2W1, Canada; [Williams, Lynn B.] Univ Guelph, Ontario Vet Coll, Dept Clin Studies, Guelph, ON N1G 2W1, Canada; [Koch, Thomas G.] Aarhus Univ, Orthopaed Res Lab, Aarhus, Denmark	University of Guelph; University of Guelph; University of Guelph; Aarhus University	Koch, TG (corresponding author), Univ Guelph, Ontario Vet Coll, Dept Biomed Sci, Guelph, ON N1G 2W1, Canada.	tkoch@uoguelph.ca	Bienzle, Dorothee/AAY-5009-2020	Bienzle, Dorothee/0000-0002-2301-2931	Danish Agency for Technology, Production and Innovation; Equine Guelph; Department of Biomedical Sciences at the University of Guelph	Danish Agency for Technology, Production and Innovation; Equine Guelph; Department of Biomedical Sciences at the University of Guelph	This project was supported by the Danish Agency for Technology, Production and Innovation, Equine Guelph and the Department of Biomedical Sciences at the University of Guelph. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Arnhold SJ, 2007, AM J VET RES, V68, P1095, DOI 10.2460/ajvr.68.10.1095; Bieback K, 2004, STEM CELLS, V22, P625, DOI 10.1634/stemcells.22-4-625; Braun J, 2010, AM J VET RES, V71, P1228, DOI 10.2460/ajvr.71.10.1228; Bustin SA, 2009, CLIN CHEM, V55, P611, DOI 10.1373/clinchem.2008.112797; Calloni R, 2013, STEM CELLS DEV, V22, P1455, DOI 10.1089/scd.2012.0637; Caplan AI, 2006, J CELL BIOCHEM, V98, P1076, DOI 10.1002/jcb.20886; Carrade DD, 2012, CELL MED, V4, P1, DOI 10.3727/215517912X647217; Carvalho AD, 2009, VET IMMUNOL IMMUNOP, V132, P303, DOI 10.1016/j.vetimm.2009.06.014; Chagastelles PC, 2011, KIDNEY INT SUPPL, V1, P63, DOI 10.1038/kisup.2011.15; Cyranoski D, 2013, NATURE, V496, P148, DOI 10.1038/496148a; De Schauwer C, 2013, EQUINE VET J, V45, P518, DOI 10.1111/evj.12003; De Schauwer C, 2014, STEM CELL RES THER, V5, DOI 10.1186/scrt395; De Schauwer C, 2012, CYTOM PART A, V81A, P312, DOI 10.1002/cyto.a.22026; De Schauwer C, 2011, TISSUE ENG PART C-ME, V17, P1061, DOI 10.1089/ten.tec.2011.0052; Dominici M, 2006, CYTOTHERAPY, V8, P315, DOI 10.1080/14653240600855905; Ferwerda B, 2008, MOL MED, V14, P346, DOI 10.2119/2007-00135.Ferwerda; Figueiredo MD, 2009, VET IMMUNOL IMMUNOP, V131, P65, DOI 10.1016/j.vetimm.2009.03.013; Fortier LA, 2011, STEM CELL RES THER, V2, DOI 10.1186/scrt50; Frisbie DD, 2009, J ORTHOP RES, V27, P1675, DOI 10.1002/jor.20933; Frisbie DD, 2005, VET CLIN N AM-EQUINE, V21, P713, DOI 10.1016/j.cveq.2005.07.001; Galipeau J, 2013, CYTOTHERAPY, V15, P2, DOI 10.1016/j.jcyt.2012.10.002; Geng SM, 2013, ARCH DERMATOL RES, V305, P35, DOI 10.1007/s00403-012-1260-2; Guest DJ, 2008, EQUINE VET J, V40, P178, DOI 10.2746/042516408X276942; Haeryfar SMM, 2004, J IMMUNOL, V173, P3581, DOI 10.4049/jimmunol.173.6.3581; Hass R, 2011, CELL COMMUN SIGNAL, V9, DOI 10.1186/1478-811X-9-12; Iacono E, 2012, REPRODUCTION, V143, P455, DOI 10.1530/REP-10-0408; Kang JG, 2013, J VET SCI, V14, P367, DOI 10.4142/jvs.2013.14.3.367; Kern S, 2006, STEM CELLS, V24, P1294, DOI 10.1634/stemcells.2005-0342; Koch TG, 2008, CAN VET J, V49, P1009; Koch TG, 2007, BMC BIOTECHNOL, V7, DOI 10.1186/1472-6750-7-26; Koch TG, 2009, CAN VET J, V50, P155; Koch TG, 2009, CYTOTHERAPY, V11, P443, DOI 10.1080/14653240902887259; Kogler G, 2006, EXP HEMATOL, V34, P1589, DOI 10.1016/j.exphem.2006.07.011; Lange-Consiglio A, 2013, EQUINE VET J, V45, P737, DOI 10.1111/evj.12052; Le Blanc K, 2004, LANCET, V363, P1439, DOI 10.1016/S0140-6736(04)16104-7; Le Blanc K, 2003, SCAND J IMMUNOL, V57, P11, DOI 10.1046/j.1365-3083.2003.01176.x; Li Q, 2013, J MOL HISTOL, V44, P411, DOI 10.1007/s10735-013-9492-9; Liotta F, 2008, STEM CELLS, V26, P279, DOI 10.1634/stemcells.2007-0454; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lovati AB, 2011, VET RES COMMUN, V35, P103, DOI 10.1007/s11259-010-9457-3; Lundberg AM, 2007, BLOOD, V110, P3245, DOI 10.1182/blood-2007-02-072934; Maia L, 2013, MICROSC RES TECHNIQ, V76, P618, DOI 10.1002/jemt.22208; Mohanty N, 2014, IN VITRO CELL DEV-AN, V50, P538, DOI 10.1007/s11626-013-9729-7; Nailis H, 2006, BMC MOL BIOL, V7, DOI 10.1186/1471-2199-7-25; Paebst F, 2014, CYTOM PART A, V85A, P678, DOI 10.1002/cyto.a.22491; Pascucci L, 2011, VET IMMUNOL IMMUNOP, V144, P499, DOI 10.1016/j.vetimm.2011.07.017; Pevsner-Fischer M, 2007, BLOOD, V109, P1422, DOI 10.1182/blood-2006-06-028704; Pigott JH, 2013, VET IMMUNOL IMMUNOP, V156, P99, DOI 10.1016/j.vetimm.2013.09.003; Raabe O, 2011, VET RES COMMUN, V35, P355, DOI 10.1007/s11259-011-9480-z; Radcliffe CH, 2010, STEM CELLS DEV, V19, P269, DOI 10.1089/scd.2009.0091; Radtke CL, 2013, AM J VET RES, V74, P790, DOI 10.2460/ajvr.74.5.790; Raicevic G, 2011, CELL IMMUNOL, V270, P207, DOI 10.1016/j.cellimm.2011.05.010; Ranera B, 2012, EQUINE VET J, V44, P33, DOI 10.1111/j.2042-3306.2010.00353.x; Ranera B, 2011, VET IMMUNOL IMMUNOP, V144, P147, DOI 10.1016/j.vetimm.2011.06.033; Schnabel LV, 2014, STEM CELL RES THER, V5, DOI 10.1186/scrt402; Schuh EM, 2009, AM J VET RES, V70, P1526, DOI 10.2460/ajvr.70.12.1526; Singh A, 2014, BONE JOINT RES, V3, P32, DOI 10.1302/2046-3758.32.2000187; Tomchuck SL, 2008, STEM CELLS, V26, P99, DOI 10.1634/stemcells.2007-0563; Vandesompele J, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-7-research0034; Verreck FAW, 2006, J LEUKOCYTE BIOL, V79, P285, DOI 10.1189/jlb.0105015; Violini S, 2009, BMC CELL BIOL, V10, DOI 10.1186/1471-2121-10-29; Waterman RS, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010088; Zhang X, 2011, J CELL BIOCHEM, V112, P1206, DOI 10.1002/jcb.23042	63	33	35	0	16	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 22	2015	10	4							e0122954	10.1371/journal.pone.0122954	http://dx.doi.org/10.1371/journal.pone.0122954			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CG5KV	25902064	Green Submitted, Green Published, gold			2023-01-03	WOS:000353331500033
J	Mutimura, E; Hoover, DR; Shi, QH; Dusingize, JC; Sinayobye, JD; Cohen, M; Anastos, K				Mutimura, Eugene; Hoover, Donald R.; Shi, Qiuhu; Dusingize, Jean Claude; Sinayobye, Jean D'Amour; Cohen, Mardge; Anastos, Kathryn			Insulin Resistance Change and Antiretroviral Therapy Exposure in HIV-Infected and Uninfected Rwandan Women: A Longitudinal Analysis	PLOS ONE			English	Article							HOMEOSTASIS MODEL ASSESSMENT; DIABETES-MELLITUS; GLUCOSE-TOLERANCE; DATA-COLLECTION; ADVERSE EVENTS; SENSITIVITY; COHORT; RISK; PREVALENCE; HEART	Background We longitudinally assessed predictors of insulin resistance (IR) change among HIV-uninfected and HIV-infected (ART-initiators and ART-non-initiators) Rwandan women. Methodology HIV-infected (HIV+) and uninfected (HIV-) women provided demographic and clinical measures: age, body mass index (BMI) in Kg/(height in meters)(2), Fat-Mass (FMI) and Fat-FreeMass (FFMI) index, fasting serum glucose and insulin. Homeostasis Model Assessment (HOMA) was calculated to estimate IR change over time in log(10) transformed HOMA measured at study enrollment or prior to ART initiation in 3 groups: HIV-(n = 194), HIV+ART-non- initiators (n= 95) and HIV+ART-initiators (n= 371). ANCOVA linear regression models of change in log(10)-HOMA were fit with all models included the first log10 HOMA as a predictor. Results Mean +/- SD log(10)-HOMA was -0.18 +/- 0.39 at the 1st and -0.21 +/- 0.41 at the 2nd measure, with mean change of 0.03 +/- 0.44. In the final model (all women) BMI at 1st HOMA measure (0.014; 95% CI= 0.006-0.021 per kg/m(2); p<0.001) and change in BMI from 1st to 2nd measure (0.024; 95% CI= 0.013-0.035 per kg/ m(2); p<0.001) predicted HOMA change. When restricted to subjects with FMI measures, FMI at 1st HOMA measure (0.020; 95% CI=0.0100.030 per kg/ m(2); p<0.001) and change in FMI from 1st to 2nd measure (0.032; 95% CI=0.020-0.043 per kg/m2; p<0.0001) predicted change in HOMA. While ART use did not predict change in log(10)-HOMA, untreated HIV+women had a significant decline in IR over time. Use or duration of AZT, d4T and EFV was not associated with HOMA change in HIV+women. Conclusions Baseline BMI and change in BMI, and in particular fat mass and change in fat mass predicted insulin resistance change over similar to 3 years in HIV-infected and uninfected Rwandan women. Exposure to specific ART (d4T, AZT, EFV) did not predict insulin resistance change in ART-treated HIV-infected Rwandan women.	[Mutimura, Eugene; Dusingize, Jean Claude; Sinayobye, Jean D'Amour] Reg Alliance Sustainable Dev RASD Rwanda Kigali, Kigali, Rwanda; [Hoover, Donald R.] SUNY, New Brunswick, NJ USA; [Shi, Qiuhu] New York Med Coll, Sch Hlth Sci & Practice, New York, NY USA; [Cohen, Mardge] Stroger Hosp, Dept Med, Chicago, IL USA; [Anastos, Kathryn] Albert Einstein Coll Med, Bronx, NY 10467 USA; [Anastos, Kathryn] Montefiore Med Ctr, Bronx, NY 10467 USA	New York Medical College; John H Stroger Junior Hospital Cook County; Yeshiva University; Albert Einstein College of Medicine; Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine	Mutimura, E (corresponding author), Reg Alliance Sustainable Dev RASD Rwanda Kigali, Kigali, Rwanda.	eugene.mutimura@gmail.com		Dusingize, Jean Claude/0000-0001-5721-100X	National Institute of Allergy and Infectious [UO1-AI-35004]; Center for AIDS Research of the Albert Einstein College of Medicine and Montefiore Medical Center - National Institutes of Health [NIH AI-51519]; Fogarty International Center of the National Institutes of Health [D71TW009618]; Central Africa International Epidemiological Databases (IeDEA) to evaluate AIDS [5U01-AI-096299]; AIDS International Training and Research Program (Fogarty International Center) [NIH D43-TW001403]; FOGARTY INTERNATIONAL CENTER [D71TW009618, D43TW001403] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR001073] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI096299, U01AI035004] Funding Source: NIH RePORTER	National Institute of Allergy and Infectious(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Center for AIDS Research of the Albert Einstein College of Medicine and Montefiore Medical Center - National Institutes of Health; Fogarty International Center of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); Central Africa International Epidemiological Databases (IeDEA) to evaluate AIDS; AIDS International Training and Research Program (Fogarty International Center)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This study was supported by supplements from the National Institute of Allergy and Infectious Diseases to the Bronx/Manhattan Women's Interagency HIV Study (WIHS), which is funded by the National Institute of Allergy and Infectious (UO1-AI-35004). The study was also supported in part by the Center for AIDS Research of the Albert Einstein College of Medicine and Montefiore Medical Center funded by the National Institutes of Health (NIH AI-51519) and by the Fogarty International Center of the National Institutes of Health under Award Number D71TW009618, and the Central Africa International Epidemiological Databases (IeDEA) to evaluate AIDS (5U01-AI-096299). Additional support was provided by the AIDS International Training and Research Program (Fogarty International Center, NIH D43-TW001403).	Bonora E, 2000, DIABETES CARE, V23, P57, DOI 10.2337/diacare.23.1.57; Boufassa F, 2012, ANTIVIR THER, V17, P91, DOI 10.3851/IMP1916; Brar I, 2007, JAIDS-J ACQ IMM DEF, V45, P66, DOI 10.1097/QAI.0b013e318031d7e3; Brown TT, 2005, ARCH INTERN MED, V165, P1179, DOI 10.1001/archinte.165.10.1179; Butt AA, 2009, AIDS, V23, P1227, DOI 10.1097/QAD.0b013e32832bd7af; Capeau J, 2012, AIDS, V26, P303, DOI 10.1097/QAD.0b013e32834e8776; Danoff A, 2005, JAIDS-J ACQ IMM DEF, V39, P55, DOI 10.1097/01.qai.0000147659.80642.5a; Dave JA, 2011, JAIDS-J ACQ IMM DEF, V57, P284, DOI 10.1097/QAI.0b013e318221863f; De Wit S, 2008, DIABETES CARE, V31, P1224, DOI 10.2337/dc07-2013; Dusingize JC, 2013, BMJ OPEN, V3, DOI 10.1136/bmjopen-2013-003879; Dusingize JC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035079; Hanson RL, 2000, AM J EPIDEMIOL, V151, P190; Henderson M, 2011, DIABETES METAB, V37, P72, DOI 10.1016/j.diabet.2010.06.008; Idiculla J, 2011, INT J GEN MED, V4, P73, DOI 10.2147/IJGM.S15818; Justman JE, 2003, JAIDS-J ACQ IMM DEF, V32, P298, DOI 10.1097/00126334-200303010-00009; Kalra S, 2013, CURR DIABETES REP, V13, P419, DOI 10.1007/s11892-013-0369-9; Kiage JN, 2013, LIPIDS HEALTH DIS, V12, DOI 10.1186/1476-511X-12-50; Kiefer E, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0029625; Kotler Donald P., 1996, American Journal of Clinical Nutrition, V64, p489S, DOI 10.1093/ajcn/64.3.489S; Ledergerber B, 2007, CLIN INFECT DIS, V45, P111, DOI 10.1086/518619; Maruthur NM, 2013, CURR DIABETES REP, V13, P786, DOI 10.1007/s11892-013-0426-4; MATTHEWS DR, 1985, DIABETOLOGIA, V28, P412, DOI 10.1007/BF00280883; Menezes CN, 2014, HIV MED, V15, P3, DOI 10.1111/hiv.12074; Petoumenos K, 2012, J INT AIDS SOC, V15, DOI 10.7448/IAS.15.2.17426; Senn S, 2006, STAT MED, V25, P4334, DOI 10.1002/sim.2682; Shao YM, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a007187; Thienemann F, 2013, EUR HEART J, V34, P3538, DOI 10.1093/eurheartj/eht388; Tien PC, 2008, JAIDS-J ACQ IMM DEF, V49, P369, DOI 10.1097/QAI.0b013e318189a780; UNAIDS, 2010, UNAIDS REP GLOB AIDS; Worm SW, 2009, CIRCULATION, V119, P805, DOI 10.1161/CIRCULATIONAHA.108.790857	30	6	6	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 16	2015	10	4							e0123936	10.1371/journal.pone.0123936	http://dx.doi.org/10.1371/journal.pone.0123936			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CG1ES	25880634	Green Published, gold, Green Submitted			2023-01-03	WOS:000353016500070
J	Kuo, CH; Hsieh, TC; Wang, CH; Chou, CL; Lai, YH; Chen, YY; Lin, YL; Wu, ST; Fang, TC				Kuo, Chiu-Huang; Hsieh, Tsung-Cheng; Wang, Chih-Hsien; Chou, Chu-Lin; Lai, Yu-Hsien; Chen, Yi-Ya; Lin, Yu-Li; Wu, Sheng-Teng; Fang, Te-Chao			Increased Risks of Mortality and Atherosclerotic Complications in Incident Hemodialysis Patients Subsequently with Bone Fractures: A Nationwide Case-Matched Cohort Study	PLOS ONE			English	Article							POPULATION-BASED COHORT; CHRONIC KIDNEY-DISEASE; HIP FRACTURE; DIALYSIS PATIENTS; TEMPORAL TRENDS; OUTCOMES; ASSOCIATION; CHOLESTEROL; IMPACT; RATES	Background Hemodialysis (HD) patients with bone fractures have an increased risk for death. However, the risks for mortality and atherosclerotic complications in incident HD patients subsequently with bone fractures are unknown. Methods Data derived from the Taiwan National Health Institute Research Database between January 1997 and December 2008 was analyzed. The enrolled patients included 3,008 incident HD patients subsequently with a single long bone fracture (LB Fx) and 2,070 incident HD patients subsequently with a single non-long bone fracture (NLB Fx). These patients were matched (1:5 ratio) for age, sex, and same duration of HD with incident HD patients who had no fractures and outcomes were measured over a 3-year follow-up. Results After demographic and co-morbidity adjustment, LB Fx increased the risk for overall mortality (HR = 1.59, p < 0.001) and stroke (HR = 1.09, p = 0.028) in incident HD patients. NLB Fx increased the risk for overall mortality (HR = 1.52, p < 0.001), stroke (HR = 1.19, p < 0.001), coronary artery disease (CAD), (HR = 1.13, p = 0.003), and peripheral arterial occlusive disease (PAOD), (HR = 1.41, p < 0.001) in incident HD patients. Moreover, incident patients subsequently with NLB Fx had significantly higher risks of CAD and PAOD than those subsequently with LB Fx. Conclusions The rates of mortality and stroke were significantly higher in incident HD patients subsequently with bone fractures than in matched patients without bone fractures. Incident HD patients subsequently with NLB Fx had significantly higher risks of CAD and PAOD than those subsequently with LB Fx and without bone fractures. Thus, incident HD patients subsequently with bone fractures should be closely followed for a higher mortality and possible development of atherosclerotic complications.	[Kuo, Chiu-Huang; Wang, Chih-Hsien; Lai, Yu-Hsien; Chen, Yi-Ya; Lin, Yu-Li; Wu, Sheng-Teng] Buddhist Tzu Chi Gen Hosp, Div Nephrol, Dept Internal Med, Hualien, Taiwan; [Hsieh, Tsung-Cheng; Chou, Chu-Lin] Tzu Chi Univ, Inst Med Sci, Hualien, Taiwan; [Fang, Te-Chao] Taipei Med Univ, Wan Fang Hosp, Dept Internal Med, Div Nephrol, Taipei, Taiwan; [Fang, Te-Chao] Taipei Med Univ, Sch Med, Dept Internal Med, Coll Med, Taipei, Taiwan	Buddhist Tzu Chi General Hospital; Hualien Tzu Chi Hospital; Tzu Chi University; Taipei Medical University; Taipei Municipal WanFang Hospital; Taipei Medical University	Fang, TC (corresponding author), Taipei Med Univ, Wan Fang Hosp, Dept Internal Med, Div Nephrol, Taipei, Taiwan.	fangtechao@yahoo.com.tw		Chou, Chu-Lin/0000-0002-9695-1067; Lai, Yu-Hsien/0000-0002-6687-1058; Hsieh, Tsung-Cheng/0000-0003-3024-8675	Tzu Chi General Hospital (Hualien, Taiwan) [TCRD 100-56]	Tzu Chi General Hospital (Hualien, Taiwan)	This study was supported by a grant (TCRD 100-56) from Tzu Chi General Hospital (Hualien, Taiwan). The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alem AM, 2000, KIDNEY INT, V58, P396, DOI 10.1046/j.1523-1755.2000.00178.x; Baigent C, 2011, LANCET, V377, P2181, DOI 10.1016/S0140-6736(11)60739-3; Beaubrun AC, 2013, J AM SOC NEPHROL, V24, P1461, DOI 10.1681/ASN.2012090916; Berry SD, 2007, ARCH INTERN MED, V167, P1971, DOI 10.1001/archinte.167.18.1971; Cauley JA, 2007, JAMA-J AM MED ASSOC, V298, P2761, DOI 10.1001/jama.298.23.2761; Cejka D, 2011, CLIN J AM SOC NEPHRO, V6, P2264, DOI 10.2215/CJN.09711010; Chen LF, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065077; Chou CL, 2014, ARCH MED RES, V45, P188, DOI 10.1016/j.arcmed.2014.01.009; Fellstrom BC, 2009, NEW ENGL J MED, V360, P1395, DOI 10.1056/NEJMoa0810177; Fusaro M, 2014, KIDNEY INT, V85, P20, DOI 10.1038/ki.2013.302; Hung HC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054304; Hung TH, 2014, HEPATOL RES, V44, P863, DOI 10.1111/hepr.12190; Ioannidis G, 2009, CAN MED ASSOC J, V181, P265, DOI 10.1503/cmaj.081720; Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group, 2009, Kidney Int Suppl, pS1, DOI 10.1038/ki.2009.188; Kilpatrick RD, 2007, J AM SOC NEPHROL, V18, P293, DOI 10.1681/ASN.2006070795; Li WH, 2012, NEPHROL DIAL TRANSPL, V27, P833, DOI 10.1093/ndt/gfr277; Lin HF, 2012, NEPHROL DIAL TRANSPL, V27, P1585, DOI 10.1093/ndt/gfr464; Liu YM, 2004, JAMA-J AM MED ASSOC, V291, P451, DOI 10.1001/jama.291.4.451; Mittalhenkle A, 2004, AM J KIDNEY DIS, V44, P672, DOI 10.1053/j.ajkd.2004.07.001; Nair SS, 2013, CLIN J AM SOC NEPHRO, V8, P1336, DOI 10.2215/CJN.10901012; Robbins JA, 2006, J AM GERIATR SOC, V54, P1885, DOI 10.1111/j.1532-5415.2006.00985.x; Rodriguez-Garcia M, 2009, NEPHROL DIAL TRANSPL, V24, P239, DOI 10.1093/ndt/gfn466; Tentori F, 2014, KIDNEY INT, V85, P166, DOI 10.1038/ki.2013.279; Wanner C, 2005, NEW ENGL J MED, V353, P238, DOI 10.1056/NEJMoa043545	24	18	18	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 13	2015	10	4							e0121705	10.1371/journal.pone.0121705	http://dx.doi.org/10.1371/journal.pone.0121705			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CF8XK	25874794	Green Published, gold, Green Submitted			2023-01-03	WOS:000352845100045
J	Young, HML; Hudson, N; Clarke, AL; Dungey, M; Feehally, J; Burton, JO; Smith, AC				Young, Hannah M. L.; Hudson, Nicky; Clarke, Amy L.; Dungey, Maurice; Feehally, John; Burton, James O.; Smith, Alice C.			Patient and Staff Perceptions of Intradialytic Exercise before and after Implementation: A Qualitative Study	PLOS ONE			English	Article							STAGE RENAL-DISEASE; BEHAVIOR-CHANGE; KIDNEY-DISEASE; HEMODIALYSIS-PATIENTS; PHYSICAL FUNCTION; SELF-MANAGEMENT; CARE; PARTICIPATION; FRAMEWORK; INTERVENTIONS	Introduction Despite guidance and evidence for the beneficial effects of intradialytic exercise (IDE), such programmes are rarely adopted within practice and little is known about how they may best be sustained. The Theoretical Domains Framework (TDF) was used to guide the understanding of the barriers and facilitators to initial and ongoing IDE participation and to understand how these are influential at each stage. Materials and Methods Focus groups explored patient (n=24) and staff (n=9) perceptions of IDE prior to the introduction of a programme and, six months later, face to face semi-structured interviews captured exercising patients (n=11) and staffs' (n=8) actual experiences. Data were collected at private and NHS haemodialysis units within the UK. All data were audio-recorded, translated where necessary, transcribed verbatim and subject to framework analysis. Results IDE initiation can be facilitated by addressing the pre-existing beliefs about IDE through the influence of peers (for patients) and training (for staff). Participation was sustained through the observation of positive outcomes and through social influences such as teamwork and collaboration. Despite this, environment and resource limitations remained the greatest barrier perceived by both groups. Conclusions Novel methods of staff training and patient education should enhance engagement. Programmes that clearly highlight the benefits of IDE should be more successful in the longer term. The barrier of staff workload needs to be addressed through specific guidance that includes recommendations on staffing levels, roles, training and skill mix.	[Young, Hannah M. L.; Clarke, Amy L.; Dungey, Maurice; Burton, James O.; Smith, Alice C.] Leicester Gen Hosp, Acad Unit, Leicester Kidney Exercise Team, Leicester LE5 4PW, Leics, England; [Hudson, Nicky] De Montfort Univ, Sch Appl Social Sci, Leicester LE1 9BH, Leics, England; [Clarke, Amy L.; Smith, Alice C.] Univ Leicester, Dept Infect Immun & Inflammat, Leicester, Leics, England; [Dungey, Maurice] Univ Loughborough, Sch Sport Exercise & Hlth Sci, Loughborough, Leics, England; [Feehally, John] Univ Hosp Leicester NHS Trusts, Leicester Gen Hosp, John Walls Renal Unit, Leicester, Leics, England	University Hospitals of Leicester NHS Trust; Leicester General Hospital; De Montfort University; University of Leicester; Loughborough University; University Hospitals of Leicester NHS Trust; Leicester General Hospital	Young, HML (corresponding author), Leicester Gen Hosp, Acad Unit, Leicester Kidney Exercise Team, Gwendolen Rd, Leicester LE5 4PW, Leics, England.	hannah.young@uhl-tr.nhs.uk	Burton, James O/AAQ-7361-2021	Burton, James O/0000-0003-1176-7592; Dungey, Maurice/0000-0003-0762-1726; young, hannah/0000-0002-4249-9060; Hudson, Nicky/0000-0003-4091-1493	National Institute for Health Research (NIHR) Diet, Lifestyle & Physical Activity Biomedical Research Unit based at University Hospital of Leicester; National Institute for Health Research (NIHR) Diet, Lifestyle & Physical Activity Biomedical Research Unit based at University Hospital of Loughborough University; British Renal Society/ British Kidney Patient Association Research Grant; British Renal Society Research Grant; Leicester Kidney Care	National Institute for Health Research (NIHR) Diet, Lifestyle & Physical Activity Biomedical Research Unit based at University Hospital of Leicester; National Institute for Health Research (NIHR) Diet, Lifestyle & Physical Activity Biomedical Research Unit based at University Hospital of Loughborough University; British Renal Society/ British Kidney Patient Association Research Grant; British Renal Society Research Grant; Leicester Kidney Care	This research was supported by the National Institute for Health Research (NIHR) Diet, Lifestyle & Physical Activity Biomedical Research Unit based at University Hospitals of Leicester and Loughborough University. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health. ACS, NH and JOB received grants from British Renal Society/ British Kidney Patient Association Research Grant 2010, the British Renal Society Research Grant 2011 and the Leicester Kidney Care Appeal during the conduct of the study. http://www.britishrenal.org/Home.aspx. http://www.britishkidney-pa.co.uk/. http://www.leicestershospitals.nhs.uk/aboutus/departmentsservices/kidney-services/kidney-care-appeal/ Outside the submitted work Reck United Kingdom (manufacturers of the exercise bike used during the implementation phase) funded HMLY, MD, and JOB to attend the 2012 BMJ Awards. http://www.motomed.com/. The other authors declare that they have no relevant financial interests. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abraham C, 2008, HEALTH PSYCHOL, V27, P379, DOI 10.1037/0278-6133.27.3.379; [Anonymous], 2004, ENGL NAT SERV FRAM 1; [Anonymous], 2014, ENGL CHRON KIDN DIS; Aschner P, 2007, INT J CLIN PRACT, V61, P22, DOI 10.1111/j.1742-1241.2007.01606.x; Bennett PN, 2010, SEMIN DIALYSIS, V23, P62, DOI 10.1111/j.1525-139X.2009.00652.x; Bryman A., 2016, SOCIAL RES METHODS; Cade JE, 2009, DIABETIC MED, V26, P1048, DOI 10.1111/j.1464-5491.2009.02808.x; Cane J, 2012, IMPLEMENT SCI, V7, DOI 10.1186/1748-5908-7-37; Damschroder LJ, 2009, IMPLEMENT SCI, V4, DOI 10.1186/1748-5908-4-50; Delgado C, 2012, NEPHROL DIAL TRANSPL, V27, P1152, DOI 10.1093/ndt/gfr404; Dennis CL, 2003, INT J NURS STUD, V40, P321, DOI 10.1016/S0020-7489(02)00092-5; DOH, 2005, STRUCT PAT ED DIAB R; Doody O, 2013, BR J NURS, V22, P171; Forgeron S, 2001, CANNT J, V11, P19; Francis JJ, 2012, IMPLEMENT SCI, V7, DOI 10.1186/1748-5908-7-35; French SD, 2012, IMPLEMENT SCI, V7, DOI 10.1186/1748-5908-7-38; Funnell MM, 2010, FAM PRACT, V27, pI17, DOI 10.1093/fampra/cmp027; Goodman Eric D, 2004, Nephrol Nurs J, V31, P23; Greenwood SA, 2014, NEPHRON CLIN PRACT, V128, P61, DOI [10.1159/000363297, DOI 10.1159/000363297]; Hancock C, 2011, PRI HLTH CARE, V21, P24; Heiwe S, 2012, IMPLEMENT SCI, V7, DOI 10.1186/1748-5908-7-68; Heiwe S, 2014, AM J KIDNEY DIS, V64, P383, DOI 10.1053/j.ajkd.2014.03.020; Hughes J, 2009, HEALTH EXPECT, V12, P396, DOI 10.1111/j.1369-7625.2009.00568.x; Idier L, 2011, INT J NURS STUD, V48, P1570, DOI 10.1016/j.ijnurstu.2011.08.006; Jain N, 2008, J REN CARE, V34, P173, DOI 10.1111/j.1755-6686.2008.00037.x; Jain Neerja, 2008, Br J Community Nurs, V13, P166; Johansen KL, 2003, AM J KIDNEY DIS, V41, P171, DOI 10.1053/ajkd.2003.50001; Gagliardino JJ, 2013, DIABETES-METAB RES, V29, P152, DOI 10.1002/dmrr.2368; K/DOQI Workgroup, 2005, AM J KIDNEY DIS S, V45, pS16; Karmiel J C, 1999, J Ren Nutr, V9, P214, DOI 10.1016/S1051-2276(99)90037-7; Kitson AL, 2008, IMPLEMENT SCI, V3, DOI 10.1186/1748-5908-3-1; Kolewaski Carrie D, 2005, CANNT J, V15, P22; Konstantinidou E, 2002, J REHABIL MED, V34, P40, DOI 10.1080/165019702317242695; Kontos PC, 2007, INT UROL NEPHROL, V39, P1303, DOI 10.1007/s11255-007-9265-z; Kosmadakis GC, 2010, NEPHRON CLIN PRACT, V115, pE7, DOI 10.1159/000286344; Koufaki P, 2009, ADV CHRONIC KIDNEY D, V16, P410, DOI 10.1053/j.ackd.2009.08.010; Lingerfelt KL, 2011, NEPHROL NURS J, V38, P483; Ma Sunny, 2012, CANNT J, V22, P26; Mason J, 2008, AM J KIDNEY DIS, V51, P933, DOI 10.1053/j.ajkd.2008.01.024; McPherson Sandra L, 2004, Nurs Forum, V39, P5; Michie S, 2005, QUAL SAF HEALTH CARE, V14, P26, DOI 10.1136/qshc.2004.011155; Morse JM, 2002, INT J QUAL METHODS, V1, P13, DOI DOI 10.1177/160940690200100202; Oh-Park M, 2002, AM J PHYS MED REHAB, V81, P814, DOI 10.1097/00002060-200211000-00003; Painter Patricia, 2005, Hemodial Int, V9, P218, DOI 10.1111/j.1492-7535.2005.01136.x; Painter Patricia, 2004, Nephrol Nurs J, V31, P67; Painter P, 2014, AM J KIDNEY DIS, V64, P425, DOI 10.1053/j.ajkd.2014.01.433; Pedersen BK, 2006, SCAND J MED SCI SPOR, V16, P3, DOI 10.1111/j.1600-0838.2006.00520.x; Penn L, 2013, BMJ OPEN, V3, DOI 10.1136/bmjopen-2013-002949; Plummer-D'Amato P, 2008, INT J THER REHABIL, V15, P69, DOI 10.12968/ijtr.2008.15.2.28189; Pope C., 2009, QUALITATIVE RES HLTH, P1; Sheng KX, 2014, AM J NEPHROL, V40, P478, DOI 10.1159/000368722; Sietsema KE, 2004, KIDNEY INT, V65, P719, DOI 10.1111/j.1523-1755.2004.00411.x; Sinclair P, 2011, J REN CARE, V37, P108, DOI 10.1111/j.1755-6686.2011.00217.x; Smart N, 2011, NEPHROLOGY, V16, P626, DOI 10.1111/j.1440-1797.2011.01471.x; Smith AC, 2012, J REN CARE, V38, P52, DOI 10.1111/j.1755-6686.2012.00279.x; Smith Joanna, 2011, Nurse Res, V18, P52; Tavallaii SA, 2009, EUR J INTERN MED, V20, P411, DOI 10.1016/j.ejim.2009.03.007; Tobita I, 2009, J RENAL CARE, V35, P48, DOI 10.1111/j.1755-6686.2009.00079.x; Wilund KR, 2010, NEPHROL DIAL TRANSPL, V25, P2695, DOI 10.1093/ndt/gfq106	59	33	33	2	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 12	2015	10	6							e0128995	10.1371/journal.pone.0128995	http://dx.doi.org/10.1371/journal.pone.0128995			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	CK6GR	26068875	Green Published, gold, Green Submitted			2023-01-03	WOS:000356327000037
J	Kim, HW; Ryu, GW; Park, CH; Kang, EW; Park, JT; Han, SH; Yoo, TH; Shin, SK; Kang, SW; Choi, KH; Han, DS; Chang, TI				Kim, Hyung Woo; Ryu, Geun Woo; Park, Cheol Ho; Kang, Ea Wha; Park, Jung Tak; Han, Seung Hyeok; Yoo, Tae-Hyun; Shin, Sug Kyun; Kang, Shin-Wook; Choi, Kyu Hun; Han, Dae Suk; Chang, Tae Ik			Hyponatremia Predicts New-Onset Cardiovascular Events in Peritoneal Dialysis Patients	PLOS ONE			English	Article							MAINTENANCE HEMODIALYSIS-PATIENTS; SERUM SODIUM CONCENTRATION; HEART-FAILURE; MORTALITY; RISK; INFLAMMATION; OUTCOMES; LEVEL	Background and Aim Cardiovascular (CV) disease is the leading cause of morbidity and mortality in patients on peritoneal dialysis (PD). Hyponatremia was recently shown to be a modifiable factor that is strongly associated with increased mortality in PD patients. However, the clinical impact of hyponatremia on CV outcomes in these patients is unclear. Methods To determine whether a low serum sodium level predicts the development of CV disease, we carried out a prospective observational study of 441 incident patients who started PD between January 2000 and December 2005. Time-averaged serum sodium (TA-Na) levels were determined to investigate the ability of hyponatremia to predict newly developed CV events in these patients. Results During a mean follow-up of 43.2 months, 106 (24.0%) patients developed new CV events. The cumulative incidence of new-onset CV events after the initiation of PD was significantly higher in patients with TA-Na levels <= 138 mEq/L than in those with a TA-Na > 138 mEq/L. After adjustment for multiple potentially confounding covariates, an increase in TA-Na level was found to be associated with a significantly lower risk of CV events (subdistribution hazard ratio per 1 mEq/L increase, 0.90; 95% confidence interval, 0.83-0.96; p = 0.003). Patients with a TA-Na <= 138 mEq/L had a 2.31-fold higher risk of suffering a CV event. Conclusions These results provide evidence of a clear association between low serum sodium and new-onset CV events after dialysis initiation in PD patients. Whether the correction of hyponatremia for this indication provides additional protection for the development of CV disease in these patients remains to be addressed in interventional studies.	[Kim, Hyung Woo; Ryu, Geun Woo; Park, Cheol Ho; Park, Jung Tak; Han, Seung Hyeok; Yoo, Tae-Hyun; Kang, Shin-Wook; Choi, Kyu Hun; Han, Dae Suk] Yonsei Univ, Coll Med, Dept Internal Med, Seoul, South Korea; [Kang, Shin-Wook] Yonsei Univ, Severance Biomed Sci Inst, Brain Korea Med Sci 21, Seoul 120749, South Korea; [Kang, Ea Wha; Shin, Sug Kyun; Chang, Tae Ik] Ilsan Hosp, NHIS Med Ctr, Dept Internal Med, Goyangshi, Gyeonggi Do, South Korea	Yonsei University; Yonsei University Health System; Yonsei University; NHIS Ilsan Hospital	Chang, TI (corresponding author), Ilsan Hosp, NHIS Med Ctr, Dept Internal Med, Goyangshi, Gyeonggi Do, South Korea.	tichang73@hanmail.net	Han, Seung Hyeok/W-8825-2019; Kim, Hyung Woo/AAC-1448-2019; Han, Seung Hyeok/K-4559-2018	Han, Seung Hyeok/0000-0001-7923-5635; Kim, Hyung Woo/0000-0002-6305-452X; Han, Seung Hyeok/0000-0001-7923-5635; Yoo, Tae-Hyun/0000-0002-9183-4507; Kang, Shin-Wook/0000-0002-5677-4756; Park, Cheol Ho/0000-0003-4636-5745; Park, Jung Tak/0000-0002-2325-8982; Choi, Kyu Hun/0000-0003-0095-9011	Brain Korea 21 Project for Medical Science, Yonsei University; National Research Foundation of Korea (NRF) grant - Korean government (MEST) [2011-0030711]; Korea Healthcare Technology R&D Project, Ministry of Health and Welfare, Republic of Korea [A102065]	Brain Korea 21 Project for Medical Science, Yonsei University(Ministry of Education & Human Resources Development (MOEHRD), Republic of Korea); National Research Foundation of Korea (NRF) grant - Korean government (MEST); Korea Healthcare Technology R&D Project, Ministry of Health and Welfare, Republic of Korea	This work was supported by the Brain Korea 21 Project for Medical Science, Yonsei University, by a National Research Foundation of Korea (NRF) grant funded by the Korean government (MEST) (No. 2011-0030711), and by a grant of the Korea Healthcare Technology R&D Project, Ministry of Health and Welfare, Republic of Korea (A102065). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adrogue HJ, 2000, NEW ENGL J MED, V342, P1581, DOI 10.1056/NEJM200005253422107; ARROYO V, 1976, AM J DIG DIS, V21, P249, DOI 10.1007/BF01095898; Bettari L, 2012, J CARD FAIL, V18, P74, DOI 10.1016/j.cardfail.2011.09.005; Bettari L, 2012, HEART FAIL REV, V17, P17, DOI 10.1007/s10741-010-9193-3; Chang TI, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0111373; Combs S, 2014, AM J KIDNEY DIS, V63, P294, DOI 10.1053/j.ajkd.2013.09.017; Fine JP, 1999, J AM STAT ASSOC, V94, P496, DOI 10.2307/2670170; Goldberg A, 2006, ARCH INTERN MED, V166, P781, DOI 10.1001/archinte.166.7.781; GRAY RJ, 1988, ANN STAT, V16, P1141, DOI 10.1214/aos/1176350951; Han SH, 2012, NAT REV NEPHROL, V8, P163, DOI 10.1038/nrneph.2012.12; Hecking M, 2012, AM J KIDNEY DIS, V59, P238, DOI 10.1053/j.ajkd.2011.07.013; Hoorn EJ, 2013, AM J KIDNEY DIS, V62, P139, DOI 10.1053/j.ajkd.2012.09.019; KATZ MA, 1973, NEW ENGL J MED, V289, P843, DOI 10.1056/NEJM197310182891607; Kovesdy CP, 2012, CIRCULATION, V125, P677, DOI 10.1161/CIRCULATIONAHA.111.065391; Krediet RT, 2010, NAT REV NEPHROL, V6, P451, DOI 10.1038/nrneph.2010.68; Kumar S, 1998, LANCET, V352, P220, DOI 10.1016/S0140-6736(97)12169-9; LEE WH, 1986, CIRCULATION, V73, P257, DOI 10.1161/01.CIR.73.2.257; Mandai S, 2013, BMC NEPHROL, V14, DOI 10.1186/1471-2369-14-276; Mc Causland FR, 2012, NEPHROL DIAL TRANSPL, V27, P1613, DOI 10.1093/ndt/gfr497; Nigwekar SU, 2013, AM J KIDNEY DIS, V62, P755, DOI 10.1053/j.ajkd.2013.02.367; Pecoits R, 2002, NEPHROL DIAL TRANSPL, V17, P28, DOI 10.1093/ndt/17.suppl_11.28; SAXON LA, 1993, AM J CARDIOL, V72, P62, DOI 10.1016/0002-9149(93)90220-7; SCHAER GL, 1983, AM J CARDIOL, V51, P1635, DOI 10.1016/0002-9149(83)90200-X; Swart RM, 2011, NEPHRON PHYSIOL, V118, P45, DOI 10.1159/000322238; SZATALOWICZ VL, 1981, NEW ENGL J MED, V305, P263, DOI 10.1056/NEJM198107303050506; Upadhyay A, 2006, AM J MED, V119, pS30, DOI 10.1016/j.amjmed.2006.05.005; Vilar E, 2011, SEMIN DIALYSIS, V24, P487, DOI 10.1111/j.1525-139X.2011.00968.x; Waikar SS, 2011, AM J MED, V124, P77, DOI 10.1016/j.amjmed.2010.07.029; Wang AYM, 2011, SEMIN NEPHROL, V31, P159, DOI 10.1016/j.semnephrol.2011.01.005; WANNAMETHEE G, 1994, J HYPERTENS, V12, P971; Zevallos G, 2001, PERITON DIALYSIS INT, V21, P72	31	12	12	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 8	2015	10	6							e0129480	10.1371/journal.pone.0129480	http://dx.doi.org/10.1371/journal.pone.0129480			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CK1GM	26053619	Green Published, gold, Green Submitted			2023-01-03	WOS:000355955300130
J	Chu, MP; Lieffers, J; Ghosh, S; Belch, AR; Chua, NS; Fontaine, A; Sangha, R; Turner, AR; Baracos, VE; Sawyer, MB				Chu, Michael P.; Lieffers, Jessica; Ghosh, Sunita; Belch, Andrew R.; Chua, Neil S.; Fontaine, Amelie; Sangha, Randeep; Turner, A. Robert; Baracos, Vickie E.; Sawyer, Michael B.			Skeletal Muscle Radio-Density Is an Independent Predictor of Response and Outcomes in Follicular Lymphoma Treated with Chemoimmunotherapy	PLOS ONE			English	Article							INTERNATIONAL PROGNOSTIC INDEX; RANDOMIZED CONTROLLED-TRIAL; COMPUTED-TOMOGRAPHY; 1ST-LINE TREATMENT; ELDERLY-PATIENTS; CELL LYMPHOMAS; PLUS RITUXIMAB; OPEN-LABEL; CHEMOTHERAPY; CHOP	Skeletal muscle radio-density (SMD) measures muscle radiation attenuation (in Hounsfield Units, HU) on computed tomography (CT) scans. Low SMD is prognostic of poor survival in melanoma, however its significance is unknown for hematologic malignancies. We performed a single institution, retrospective review of all follicular lymphoma (FL) patients who received chemoimmunotherapy from 2004-2009. Patient demographics, FL International Prognostic Index 1 (FLIPI-1), progression free (PFS) and overall survival (OS) were collected as primary endpoints. Objective response rates (ORR) were secondary. SMD was calculated using pre-treatment CT scans. In 145 patients reviewed, median values were age 59, FLIPI-1 of 2, stage III, and 8 chemoimmunotherapy cycles received. Median PFS for those with low SMD (<36.6 and <33.1 HU for patients with BMI <= 25 and > 25 kg/m(2), respectively) compared to those with high SMD was profoundly worse, 69.6 vs. 106.7 months (hazard ratio [HR] 1.85; p = 0.01), respectively. Median OS was not reached in patients with high SMD vs. 92.7 months in low SMD patients (HR 4.02; p = 0.0002). Multivariate analysis supported lower SMD's OS detriment (HR = 3.40; p = 0.002) independent of FLIPI-1 (HR 1.46-2.76, p = 0.05) or gender. Low SMD predicted lower ORR, 83 vs. 96% (p = 0.01). SMD predicts survival independent of FLIPI-1 and potentially chemoimmunotherapy response. SMD is an inexpensive and powerful tool that can complement FLIPI-1.	[Chu, Michael P.; Lieffers, Jessica; Ghosh, Sunita; Belch, Andrew R.; Chua, Neil S.; Fontaine, Amelie; Sangha, Randeep; Turner, A. Robert; Baracos, Vickie E.; Sawyer, Michael B.] Univ Alberta, Cross Canc Inst, Dept Med Oncol, Edmonton, AB, Canada	University of Alberta	Sawyer, MB (corresponding author), Univ Alberta, Cross Canc Inst, Dept Med Oncol, Edmonton, AB, Canada.	michael.sawyer@albertahealthservices.ca						Antoun S, 2013, CANCER-AM CANCER SOC, V119, P3377, DOI 10.1002/cncr.28218; Antoun S, 2010, J CLIN ONCOL, V28, P1054, DOI 10.1200/JCO.2009.24.9730; Cheson BD, 2007, J CLIN ONCOL, V25, P579, DOI 10.1200/JCO.2006.09.2403; Federico M, 2000, BLOOD, V95, P783; Federico M, 2009, J CLIN ONCOL, V27, P4555, DOI 10.1200/JCO.2008.21.3991; Goodpaster BH, 2000, J APPL PHYSIOL, V89, P104, DOI 10.1152/jappl.2000.89.1.104; Itchaki G, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008909.pub2; Jager U, 2012, HAEMATOL-HEMATOL J, V97, P1431, DOI 10.3324/haematol.2011.059246; Lanic H, 2014, LEUKEMIA LYMPHOMA, V55, P817, DOI 10.3109/10428194.2013.816421; Marcus R, 2005, BLOOD, V105, P1417, DOI 10.1182/blood-2004-08-3175; Martin L, 2013, J CLIN ONCOL, V31, P1539, DOI 10.1200/JCO.2012.45.2722; Miljkovic I, 2011, METAB SYNDR RELAT D, V9, P319, DOI 10.1089/met.2010.0133; Miljkovic I, 2010, CURR OPIN CLIN NUTR, V13, P260, DOI 10.1097/MCO.0b013e328337d826; Mourtzakis M, 2008, APPL PHYSIOL NUTR ME, V33, P997, DOI 10.1139/H08-075; Muller C, 2012, BLOOD, V119, P3276, DOI 10.1182/blood-2011-09-380949; Pfreundschuh M, 2008, LANCET ONCOL, V9, P105, DOI 10.1016/S1470-2045(08)70002-0; Pfreundschuh M, 2011, LANCET ONCOL, V12, P1013, DOI 10.1016/S1470-2045(11)70235-2; Prado CMM, 2008, LANCET ONCOL, V9, P629, DOI 10.1016/S1470-2045(08)70153-0; Prado CMM, 2009, CLIN CANCER RES, V15, P2920, DOI 10.1158/1078-0432.CCR-08-2242; Riihijarvi S, 2011, EUR J HAEMATOL, V86, P124, DOI 10.1111/j.1600-0609.2010.01541.x; Rummel MJ, 2013, LANCET, V381, P1203, DOI 10.1016/S0140-6736(12)61763-2; Sabel MS, 2011, ANN SURG ONCOL, V18, P3579, DOI 10.1245/s10434-011-1976-9; Salles G, 2011, LANCET, V377, P42, DOI 10.1016/S0140-6736(10)62175-7; Sehn LH, 2007, BLOOD, V109, P1857, DOI 10.1182/blood-2006-08-038257; Shen W, 2004, J APPL PHYSIOL, V97, P2333, DOI 10.1152/japplphysiol.00744.2004; Solal-Celigny P, 2004, BLOOD, V104, P1258, DOI 10.1182/blood-2003-12-4434; Williams BA, 2006, TECHNICAL REPORT SER	27	11	11	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 1	2015	10	6							e0127589	10.1371/journal.pone.0127589	http://dx.doi.org/10.1371/journal.pone.0127589			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CL0KF	26030144	Green Submitted, Green Published, gold			2023-01-03	WOS:000356630900065
J	Ouyang, HL				Ouyang, Helen			The Art of Discharge	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									Columbia Univ, Med Ctr, New York Presbyterian Hosp, New York, NY 10027 USA	Columbia University; NewYork-Presbyterian Hospital	Ouyang, HL (corresponding author), Columbia Univ, Med Ctr, New York Presbyterian Hosp, New York, NY 10027 USA.	ho2216@columbia.edu						Engel KG, 2009, ANN EMERG MED, V53, P454, DOI 10.1016/j.annemergmed.2008.05.016; Horwitz LI, 2013, JAMA INTERN MED, V173, P1715, DOI 10.1001/jamainternmed.2013.9318; Howard T, 2013, J HEALTH COMMUN, V18, P991, DOI 10.1080/10810730.2012.757398; Kellehear, 2014, INNER LIFE DYING PER	4	2	2	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 26	2015	313	20					2027	2028		10.1001/jama.2015.2569	http://dx.doi.org/10.1001/jama.2015.2569			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CJ0DC	26010629				2023-01-03	WOS:000355142400014
J	Szpila, BE; Ozrazgat-Baslanti, T; Zhang, JY; Lanz, J; Davis, R; Rebel, A; Vanzant, E; Gentile, LF; Cuenca, AG; Ang, DN; Liu, HZ; Lottenberg, L; Marker, P; Zumberg, M; Bihorac, A; Moore, FA; Brakenridge, S; Efron, PA				Szpila, Benjamin E.; Ozrazgat-Baslanti, Tezcan; Zhang, Jianyi; Lanz, Jennifer; Davis, Ruth; Rebel, Annette; Vanzant, Erin; Gentile, Lori F.; Cuenca, Alex G.; Ang, Darwin N.; Liu, Huazhi; Lottenberg, Lawrence; Marker, Peggy; Zumberg, Marc; Bihorac, Azra; Moore, Frederick A.; Brakenridge, Scott; Efron, Philip A.			Successful Implementation of a Packed Red Blood Cell and Fresh Frozen Plasma Transfusion Protocol in the Surgical Intensive Care Unit	PLOS ONE			English	Article							PROTHROMBIN TIME; CARDIAC-SURGERY; CRITICALLY-ILL; INCREASED MORTALITY; ELDERLY-PATIENTS; REQUIREMENTS; MORBIDITY; TRAUMA; TRIAL	Background Blood product transfusions are associated with increased morbidity and mortality. The purpose of this study was to determine if implementation of a restrictive protocol for packed red blood cell (PRBC) and fresh frozen plasma (FFP) transfusion safely reduces blood product utilization and costs in a surgical intensive care unit (SICU). Study Design We performed a retrospective, historical control analysis comparing before (PRE) and after (POST) implementation of a restrictive PRBC/FFP transfusion protocol for SICU patients. Univariate analysis was utilized to compare patient demographics and blood product transfusion totals between the PRE and POST cohorts. Multivariate logistic regression models were developed to determine if implementation of the restrictive transfusion protocol is an independent predictor of adverse outcomes after controlling for age, illness severity, and total blood products received. Results 829 total patients were included in the analysis (PRE, n=372; POST, n=457). Despite higher mean age (56 vs. 52 years, p=0.01) and APACHE II scores (12.5 vs. 11.2, p=0.006), mean units transfused per patient were lower for both packed red blood cells (0.7 vs. 1.2, p=0.03) and fresh frozen plasma (0.3 vs. 1.2, p=0.007) in the POST compared to the PRE cohort, respectively. There was no difference in inpatient mortality between the PRE and POST cohorts (7.5% vs. 9.2%, p=0.39). There was a decreased risk of urinary tract infections (OR 0.47, 95% CI 0.28-0.80) in the POST cohort after controlling for age, illness severity and amount of blood products transfused. Conclusions Implementation of a restrictive transfusion protocol can effectively reduce blood product utilization in critically ill surgical patients with no increase in morbidity or mortality.	[Szpila, Benjamin E.; Zhang, Jianyi; Lanz, Jennifer; Davis, Ruth; Vanzant, Erin; Gentile, Lori F.; Cuenca, Alex G.; Lottenberg, Lawrence; Moore, Frederick A.; Brakenridge, Scott; Efron, Philip A.] Univ Florida, Coll Med, Dept Surg, Gainesville, FL 32610 USA; [Ozrazgat-Baslanti, Tezcan; Bihorac, Azra] Univ Florida, Coll Med, Dept Anesthesiol, Gainesville, FL 32610 USA; [Marker, Peggy] Univ Florida, Coll Med, Dept Nursing, Gainesville, FL 32610 USA; [Zumberg, Marc] Univ Florida, Coll Med, Dept Med, Gainesville, FL 32610 USA; [Rebel, Annette] Univ Kentucky, Coll Med, Dept Anesthesia, Lexington, KY 40506 USA; [Ang, Darwin N.; Liu, Huazhi] Univ S Florida, Dept Surg, Tampa, FL 33612 USA	State University System of Florida; University of Florida; State University System of Florida; University of Florida; State University System of Florida; University of Florida; State University System of Florida; University of Florida; University of Kentucky; State University System of Florida; University of South Florida	Efron, PA (corresponding author), Univ Florida, Coll Med, Dept Surg, Gainesville, FL 32610 USA.	philip.efron@surgery.ufl.edu	Brakenridge, Scott/AAD-6691-2019; Bihorac, Azra/Q-6500-2016; Ang, Darwin/AIA-3852-2022	Brakenridge, Scott/0000-0002-7327-3718; Bihorac, Azra/0000-0002-5745-2863; Zhang, Jianyi/0000-0002-1501-4822	NIGMS [T32 GM-008721, R01 GM-40586-24, R01 GM-80576-06]; NIH NIGMS [K23 GM087709]; P50 NIH grant [P50GM111152-01]; NIH; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR001427] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P50GM111152, R01GM040586, T32GM008721, K23GM087709] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P30AG028740] Funding Source: NIH RePORTER	NIGMS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIH NIGMS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); P50 NIH grant; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	BES, AGC, and LFG were supported by a T32 training grant (T32 GM-008721) in burns and trauma from the NIGMS. AB is supported by NIH NIGMS Grant K23 GM087709. Other support was provided by R01 GM-40586-24 and R01 GM-80576-06 awarded by the NIGMS. AB, FM, SB, and PE were supported by a P50 NIH grant P50GM111152-01. NIH funding had a role in the collection, management, analysis, and interpretation of the data; and preparation and review of the manuscript.	Abdel-Wahab OI, 2006, TRANSFUSION, V46, P1279, DOI 10.1111/j.1537-2995.2006.00891.x; Bauer DF, 2011, J TRAUMA, V70, P1112, DOI 10.1097/TA.0b013e3181e7c2ae; Corwin HL, 2007, NEW ENGL J MED, V356, P1667, DOI 10.1056/NEJMe078019; Davis JW, 2004, J TRAUMA, V57, P1173, DOI 10.1097/01.TA.0000151257.79108.FB; Gerber DR, 2008, CRIT CARE MED, V36, P1068, DOI 10.1097/CCM.0b013e318169251f; Hajjar LA, 2010, JAMA-J AM MED ASSOC, V304, P1559, DOI 10.1001/jama.2010.1446; Hebert PC, 1999, NEW ENGL J MED, V340, P409, DOI 10.1056/NEJM199902113400601; Hebert PC, 2004, VOX SANG, V87, P209, DOI 10.1111/j.1741-6892.2004.00497.x; Holst LB, 2014, NEW ENGL J MED, V371, P1381, DOI 10.1056/NEJMoa1406617; Juffermans NP, 2011, SHOCK, V35, P355, DOI 10.1097/SHK.0b013e3182086094; Kiraly LN, 2009, J TRAUMA, V67, P29, DOI 10.1097/TA.0b013e3181af6a8c; Koch CG, 2008, NEW ENGL J MED, V358, P1229, DOI 10.1056/NEJMoa070403; Marik PE, 2008, CRIT CARE MED, V36, P3134; Matevosyan K, 2011, J NEUROSURG, V114, P3, DOI 10.3171/2010.7.JNS091699; Mica Ladislav, 2013, J Trauma Manag Outcomes, V7, P6, DOI 10.1186/1752-2897-7-6; Murad MH, 2010, TRANSFUSION, V50, P1370, DOI 10.1111/j.1537-2995.2010.02630.x; Murphy GJ, 2007, CIRCULATION, V116, P2544, DOI 10.1161/CIRCULATIONAHA.107.698977; Napolitano LM, 2009, J TRAUMA, V67, P1439, DOI 10.1097/TA.0b013e3181ba7074; Pita-Ramirez L, 1999, REV INVEST CLIN, V51, P89; Qiao Q, 2012, J INT MED RES, V40, P1114, DOI 10.1177/147323001204000331; Raghavan M, 2005, CHEST, V127, P295, DOI 10.1378/chest.127.1.295; Robinson WP, 2005, J TRAUMA, V58, P437, DOI 10.1097/01.TA.0000153935.18997.14; Stanworth SJ, 2011, CRIT CARE, V15, DOI 10.1186/cc10129; Stanworth SJ, 2004, BRIT J HAEMATOL, V126, P139, DOI 10.1111/j.1365-2141.2004.04973.x; Tavares M, 2011, TRANSFUSION, V51, P754, DOI 10.1111/j.1537-2995.2010.02900.x; Taylor RW, 2002, CRIT CARE MED, V30, P2249, DOI 10.1097/00003246-200210000-00012; Tinmouth AT, 2011, CRIT CARE, V15, DOI 10.1186/cc10215; Wu WC, 2001, NEW ENGL J MED, V345, P1230, DOI 10.1056/NEJMoa010615; [No title captured]	29	4	4	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 26	2015	10	5							e0126895	10.1371/journal.pone.0126895	http://dx.doi.org/10.1371/journal.pone.0126895			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CJ0QZ	26010247	Green Submitted, Green Published, gold			2023-01-03	WOS:000355183900045
J	O'Brien, MR; Rosenthal, MS; Dharmarajan, K; Krumholz, HM				O'Brien, Michael R.; Rosenthal, Marjorie S.; Dharmarajan, Kumar; Krumholz, Harlan M.			Balloon Animals, Guitars, and Fewer Blood Draws: Applying Strategies From Pediatrics to the Treatment of Hospitalized Adults	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							ELDER LIFE PROGRAM		[O'Brien, Michael R.; Rosenthal, Marjorie S.; Dharmarajan, Kumar; Krumholz, Harlan M.] Yale Univ, New Haven, CT 06520 USA	Yale University	O'Brien, MR (corresponding author), Yale Univ, Sch Med, Robert Wood Johnson Clin Scholars Program, 333 Cedar St,SHM IE-61,POB 208088, New Haven, CT 06520 USA.	michael.robert.obrien@yale.edu	, Harlan/AAI-2875-2020					Bao YJ, 2014, EVID-BASED COMPL ALT, V2014, DOI 10.1155/2014/170396; Brown C, 2014, PEDIATRICS, V133, pE1471, DOI 10.1542/peds.2014-0556; Detsky AS, 2014, JAMA-J AM MED ASSOC, V311, P2169, DOI 10.1001/jama.2014.3695; Duff AJA, 2012, ARCH DIS CHILD, V97, P1, DOI 10.1136/archdischild-2011-300762; Inouye SK, 2000, J AM GERIATR SOC, V48, P1697; Krumholz HM, 2013, NEW ENGL J MED, V368, P100, DOI 10.1056/NEJMp1212324; Mittal V, 2014, PEDIATR CLIN N AM, V61, P663, DOI 10.1016/j.pcl.2014.04.003; Rapoport A, 2014, PEDIATR CLIN N AM, V61, P749, DOI 10.1016/j.pcl.2014.04.010; Rubin FH, 2011, J AM GERIATR SOC, V59, P359, DOI 10.1111/j.1532-5415.2010.03243.x	9	7	7	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 19	2015	162	10					726	+		10.7326/M14-2219	http://dx.doi.org/10.7326/M14-2219			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CI8IF	25984849				2023-01-03	WOS:000355015200023
J	Molina, MA; Diaz, AM; Hesse, C; Ginter, W; Gentilini, MV; Nunez, GG; Canellada, AM; Sparwasser, T; Berod, L; Castro, MS; Manghi, MA				Molina, Matias Alejandro; Diaz, Ailen Magali; Hesse, Christina; Ginter, Wiebke; Gentilini, Maria Virginia; Nunez, Guillermo Gabriel; Canellada, Andrea Mercedes; Sparwasser, Tim; Berod, Luciana; Castro, Marisa Silvia; Manghi, Marcela Alejandra			Immunostimulatory Effects Triggered by Enterococcus faecalis CECT7121 Probiotic Strain Involve Activation of Dendritic Cells and Interferon-Gamma Production	PLOS ONE			English	Article							LIPOTEICHOIC ACID; TRANSGENIC MICE; CUTTING EDGE; T-CELLS; IN-VIVO; INDUCTION; LACTOBACILLI; INFECTION; ANTIGENS; INNATE	Probiotics can modulate the immune system, conferring beneficial effects on the host. Understanding how these microorganisms contribute to improve the health status is still a challenge. Previously, we have demonstrated that Enterococcus faecalis CECT7121 implants itself and persists in the murine gastrointestinal tract, and enhances and skews the profile of cytokines towards the Th1 phenotype in several biological models. Given the importance of dendritic cells (DCs) in the orchestration of immunity, the aim of this work was to elucidate the influence of E. faecalis CECT7121 on DCs and the outcome of the immune responses. In this work we show that E. faecalis CECT7121 induces a strong dose-dependent activation of DCs and secretion of high levels of IL-12, IL-6, TNF alpha, and IL-10. This stimulation is dependent on TLR signaling, and skews the activation of T cells towards the production of IFN gamma. The influence of this activation in the establishment of Th responses in vivo shows the accumulation of specific IFN gamma-producing cells. Our findings indicate that the activation exerted by E. faecalis CECT7121 on DCs and its consequence on the cellular adaptive immune response may have broad therapeutic implications in immunomodulation.	[Molina, Matias Alejandro; Diaz, Ailen Magali; Nunez, Guillermo Gabriel; Castro, Marisa Silvia; Manghi, Marcela Alejandra] Ciudad Autonoma Buenos Aires, IDEHU CONICET UBA, Lab Modulac Respuesta Inmune, Buenos Aires, DF, Argentina; [Hesse, Christina; Ginter, Wiebke; Sparwasser, Tim; Berod, Luciana] Joint Venture Med Sch Hanover MHH, Inst Infect Immunol, TWINCORE, Ctr Expt & Clin Infect Res, Hannover, Germany; [Hesse, Christina; Ginter, Wiebke; Sparwasser, Tim; Berod, Luciana] Helmholtz Ctr Infect Res HZI, Hannover, Germany; [Gentilini, Maria Virginia] Ciudad Autonoma Buenos Aires, Inst Inmunol Genet & Metabol, INIGEM CONICET UBA, Buenos Aires, DF, Argentina; [Canellada, Andrea Mercedes] Ciudad Autonoma Buenos Aires, IDEHU CONICET UBA, Lab Anticuerpos Asimetricos & Inmunol Reprod, Buenos Aires, DF, Argentina	Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); University of Buenos Aires; Helmholtz Association; Helmholtz-Center for Infection Research; Helmholtz Association; Helmholtz-Center for Infection Research; Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); University of Buenos Aires	Manghi, MA (corresponding author), Ciudad Autonoma Buenos Aires, IDEHU CONICET UBA, Lab Modulac Respuesta Inmune, Buenos Aires, DF, Argentina.	manghim@ffyb.uba.ar	Sparwasser, Tim D/AAA-4306-2022; Sparwasser, Tim/AAF-7085-2019; Berod, Luciana/AAG-8095-2019	Sparwasser, Tim/0000-0001-5645-902X; Berod, Luciana/0000-0002-9677-3483; Castro, Marisa/0000-0003-2129-5875	University of Buenos Aires, Argentina [20020100101002]; Institute of Infection Immunology (Twincore, Hannover, Germany); Institute of Infection Immunology (Twincore, Hannover, Germany) [PROALAR DA/10/05]; Laboratorio de Modulacion de la Respuesta Inmune, (IDEHU, CONICET-UBA, Argentina) [PROALAR DA/10/05]; Ministry of Science, Technology and Productive Innovation (MINCyT, Argentina); German Academic Exchange Service (DAAD, Germany)	University of Buenos Aires, Argentina(University of Buenos Aires); Institute of Infection Immunology (Twincore, Hannover, Germany); Institute of Infection Immunology (Twincore, Hannover, Germany); Laboratorio de Modulacion de la Respuesta Inmune, (IDEHU, CONICET-UBA, Argentina); Ministry of Science, Technology and Productive Innovation (MINCyT, Argentina); German Academic Exchange Service (DAAD, Germany)(Deutscher Akademischer Austausch Dienst (DAAD))	Funding: Our work was partly supported by University of Buenos Aires, Argentina (grant number 20020100101002) to MarAM and institutional funding from the Institute of Infection Immunology (Twincore, Hannover, Germany). This work was done in the frame of a scientific collaborative program (PROALAR DA/10/05) between the Institute of Infection Immunology (Twincore, Hannover, Germany) and the Laboratorio de Modulacion de la Respuesta Inmune, (IDEHU, CONICET-UBA, Argentina) granted to TDS and MarAM by the Ministry of Science, Technology and Productive Innovation (MINCyT, Argentina) and the German Academic Exchange Service (DAAD, Germany). The funds granted by this program were exclusively aimed to cover the costs of travel and accommodations for travel between Germany and Argentina for the researchers involved to specific project tasks. The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.	Adachi O, 1998, IMMUNITY, V9, P143, DOI 10.1016/S1074-7613(00)80596-8; Akira S, 2004, NAT REV IMMUNOL, V4, P499, DOI 10.1038/nri1391; ARAKI Y, 1972, J BIOL CHEM, V247, P6312; Atarashi K, 2008, NATURE, V455, P808, DOI 10.1038/nature07240; Baba N, 2009, IMMUNOLOGY, V128, pe523, DOI 10.1111/j.1365-2567.2008.03022.x; Barnden MJ, 1998, IMMUNOL CELL BIOL, V76, P34, DOI 10.1046/j.1440-1711.1998.00709.x; Boirivant M, 2008, MUCOSAL IMMUNOL, V1, pS47, DOI 10.1038/mi.2008.52; Bonifaz LC, 2004, J EXP MED, V199, P815, DOI 10.1084/jem.20032220; Castro M., 2008, INT J PROBIOTICS PRE, V3, P25; Castro M., 2007, INT J PROBIOTICS PRE, V2, P215; Castro MS, 2012, INT ARCH ALLERGY IMM, V157, P11, DOI 10.1159/000324673; Castro MS, 2010, J APPL MICROBIOL, V109, P1234, DOI 10.1111/j.1365-2672.2010.04747.x; Cervi L, 2004, J IMMUNOL, V172, P2016, DOI 10.4049/jimmunol.172.4.2016; Chirdo FG, 2005, EUR J IMMUNOL, V35, P1831, DOI 10.1002/eji.200425882; Coombes JL, 2008, NAT REV IMMUNOL, V8, P435, DOI 10.1038/nri2335; Dudziak D, 2007, SCIENCE, V315, P107, DOI 10.1126/science.1136080; Finkelman FD, 1996, J IMMUNOL, V157, P1406; Food and Agriculture Organization of the United States-World Health Organization, 2001, HLTH NUTR PROP PROB; Ganesh V, 2014, INFECT IMMUN, V82, P1052, DOI 10.1128/IAI.01378-13; Geijtenbeek TBH, 2009, NAT REV IMMUNOL, V9, P465, DOI 10.1038/nri2569; Hawiger D, 2001, J EXP MED, V194, P769, DOI 10.1084/jem.194.6.769; Heeg K, 1998, EUR J CLIN MICROBIOL, V17, P464, DOI 10.1007/BF01691128; Hua MC, 2010, WORLD J GASTROENTERO, V16, P3529, DOI 10.3748/wjg.v16.i28.3529; Ilarregui JM, 2009, NAT IMMUNOL, V10, P981, DOI 10.1038/ni.1772; Iwasaki A, 2007, ANNU REV IMMUNOL, V25, P381, DOI 10.1146/annurev.immunol.25.022106.141634; Kapsenberg ML, 2003, NAT REV IMMUNOL, V3, P984, DOI 10.1038/nri1246; Keler T, 2004, EXPERT OPIN BIOL TH, V4, P1953, DOI 10.1517/14712598.4.12.1953; Kirjavainen PV, 1999, CLIN DIAGN LAB IMMUN, V6, P799, DOI 10.1128/CDLI.6.6.799-802.1999; Kirjavainen PV, 1999, FEMS IMMUNOL MED MIC, V26, P131, DOI 10.1111/j.1574-695X.1999.tb01380.x; Klaenhammer TR, 2012, NAT REV IMMUNOL, V12, P728, DOI 10.1038/nri3312; Kosaka A, 2012, INT IMMUNOPHARMACOL, V14, P729, DOI 10.1016/j.intimp.2012.10.007; Kruisbeek AM, 2001, CURR PROTOC IMMUNOL, V39, P313; Lebeer S, 2010, NAT REV MICROBIOL, V8, P171, DOI 10.1038/nrmicro2297; Lee SJ, 2002, SCIENCE, V295, P1898, DOI 10.1126/science.1069540; MacDonald AS, 2002, J IMMUNOL, V168, P3127, DOI 10.4049/jimmunol.168.7.3127; MacDonald AS, 2001, J IMMUNOL, V167, P1982, DOI 10.4049/jimmunol.167.4.1982; Macpherson AJ, 2004, SCIENCE, V303, P1662, DOI 10.1126/science.1091334; Macpherson AJ, 2012, TRENDS IMMUNOL, V33, P160, DOI 10.1016/j.it.2012.02.002; Mann ER, 2013, IMMUNOL LETT, V150, P30, DOI 10.1016/j.imlet.2013.01.007; Mayer CT, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00183; Morath S, 2001, J EXP MED, V193, P393, DOI 10.1084/jem.193.3.393; Neutra MR, 2006, NAT REV IMMUNOL, V6, P148, DOI 10.1038/nri1777; Pan W, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059746; Plitnick LM, 2001, CLIN DIAGN LAB IMMUN, V8, P972, DOI 10.1128/CDLI.8.5.972-979.2001; Poe SL, 2013, MUCOSAL IMMUNOL, V6, P189, DOI 10.1038/mi.2012.62; Popovic ZV, 2011, J IMMUNOL, V187, P6217, DOI 10.4049/jimmunol.1003478; Schaefer M, 2008, J IMMUNOL, V180, P6836, DOI 10.4049/jimmunol.180.10.6836; Shida K, 2011, GUT MICROBES, V2, P109, DOI 10.4161/gmic.2.2.15661; Smelt MJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047244; Tacke RS, 2012, HEPATOLOGY, V55, P343, DOI 10.1002/hep.24700; Tangye SG, 2013, NAT REV IMMUNOL, V13, P412, DOI 10.1038/nri3447; Toscano MA, 2007, NAT IMMUNOL, V8, P825, DOI 10.1038/ni1482; van Vliet SJ, 2008, IMMUNOL CELL BIOL, V86, P580, DOI 10.1038/icb.2008.55; van Vliet SJ, 2007, CURR OPIN IMMUNOL, V19, P435, DOI 10.1016/j.coi.2007.05.006; Weill FS, 2012, BR J NUTR, P1; Weiss G, 2011, CYTOKINE, V56, P520, DOI 10.1016/j.cyto.2011.07.024	56	38	44	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 15	2015	10	5							e0127262	10.1371/journal.pone.0127262	http://dx.doi.org/10.1371/journal.pone.0127262			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CI7AU	25978357	Green Published, gold			2023-01-03	WOS:000354916100141
J	Du Mont, J; Macdonald, S; Kosa, D; Elliot, S; Spencer, C; Yaffe, M				Du Mont, Janice; Macdonald, Sheila; Kosa, Daisy; Elliot, Shannon; Spencer, Charmaine; Yaffe, Mark			Development of a Comprehensive Hospital-Based Elder Abuse Intervention: An Initial Systematic Scoping Review	PLOS ONE			English	Review							FINANCIAL ABUSE; PREVALENCE; NEGLECT; CARE; INDICATORS; GUIDELINES; MORTALITY; PROGRAMS	Introduction Elder abuse, a universal human rights problem, is associated with many negative consequences. In most jurisdictions, however, there are no comprehensive hospital-based interventions for elder abuse that address the totality of needs of abused older adults: psychological, physical, legal, and social. As the first step towards the development of such an intervention, we undertook a systematic scoping review. Objectives Our primary objective was to systematically extract and synthesize actionable and applicable recommendations for components of a multidisciplinary intersectoral hospital-based elder abuse intervention. A secondary objective was to summarize the characteristics of the responses reviewed, including methods of development and validation. Methods The grey and scholarly literatures were systematically searched, with two independent reviewers conducting the title, abstract and full text screening. Documents were considered eligible for inclusion if they: 1) addressed a response (e.g., an intervention) to elder abuse, 2) contained recommendations for responding to abused older adults with potential relevance to a multidisciplinary and intersectoral hospital-based elder abuse intervention; and 3) were available in English. Analysis The extracted recommendations for care were collated, coded, categorized into themes, and further reviewed for relevancy to a comprehensive hospital-based response. Characteristics of the responses were summarized using descriptive statistics. Results 649 recommendations were extracted from 68 distinct elder abuse responses, 149 of which were deemed relevant and were categorized into 5 themes: Initial contact; Capacity and consent; Interview with older adult, caregiver, collateral contacts, and/or suspected abuser; Assessment: physical/forensic, mental, psychosocial, and environmental/functional; and care plan. Only 6 responses had been evaluated, suggesting a significant gap between development and implementation of recommendations. Discussion To address the lack of evidence to support the recommendations extracted in this review, in a future study, a group of experts will formally evaluate each recommendation for its inclusion in a comprehensive hospital-based response.	[Du Mont, Janice; Kosa, Daisy; Elliot, Shannon] Womens Coll Hosp, Womens Coll Res Inst, Toronto, ON, Canada; [Du Mont, Janice] Univ Toronto, Dalla Lana Sch Publ Hlth Sci, Toronto, ON, Canada; [Macdonald, Sheila; Kosa, Daisy; Elliot, Shannon] Ontario Network Sexual Assault, Domest Violence Treatments Ctr, Toronto, ON, Canada; [Spencer, Charmaine] Simon Fraser Univ, Gerontol Res Ctr, Burnaby, BC V5A 1S6, Canada; [Yaffe, Mark] McGill Univ, Dept Family Med, Montreal, PQ H3A 2T5, Canada; [Yaffe, Mark] St Marys Hosp, Dept Family Med, Montreal, PQ, Canada	University of Toronto; University Toronto Affiliates; Womens College Hospital; University of Toronto; Simon Fraser University; McGill University; McGill University	Du Mont, J (corresponding author), Womens Coll Hosp, Womens Coll Res Inst, Toronto, ON, Canada.	janice.dumont@wchospital.ca			Atkinson Foundation; Canadian Institutes of Health Research [SCI-131864]	Atkinson Foundation; Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR))	Janice Du Mont was supported in part by the Atkinson Foundation. Funding for this review was obtained from the Canadian Institutes of Health Research (Funding Reference Number: SCI-131864, http://www.cihr-irsc.gc.ca/e/193.html). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Acierno R, 2010, AM J PUBLIC HEALTH, V100, P292, DOI 10.2105/AJPH.2009.163089; Anetzberger GJ, 2000, GERONTOLOGIST, V40, P492, DOI 10.1093/geront/40.4.492; [Anonymous], 2007, REACH OUT INT DOM VI; [Anonymous], 2011, GUID DEV ELD AB PROT; [Anonymous], 2011, PROT LAW ENF RESP VI; [Anonymous], 2014, SANE PROGR LIST; [Anonymous], SAF PLANN OLD PERS; [Anonymous], 2011, ELD AB ASS TOOL KIT; [Anonymous], 2014, DEF MEAS ELD AB TOOL; [Anonymous], 2005, ELD AB NETW TRAIN MA; [Anonymous], 2009, RES SERV WORK OLD WO; [Anonymous], 2005, COORD COMM RESP AGR; [Anonymous], 2009, RESP AG VICT GOV PRA; [Anonymous], AB MISTR NEGL AB D 2; [Anonymous], 2005, AD VICT AB PROT; [Anonymous], 2007, ELD AB PROT; [Anonymous], 2013, FIN EXPL; [Anonymous], 2008, ELD AB WHAT YOU NEED; [Anonymous], 2013, COMM OP ELD AB WOM H; [Anonymous], 2010, ELD AB ASS INT REF G; [Anonymous], 2012, COMM RES GUID SERV; [Anonymous], 2010, ELD AB ASS INT REF G; [Anonymous], AB VULN AD; [Anonymous], 2009, ELD AB NEGL FAM VIOL; [Anonymous], 2012, ACT ELD AB PREV PROG; [Anonymous], 2006, AB NEGL OLD VULN PER; [Anonymous], 2011, PROT RESP AB OLD PEO; [Anonymous], 2007, ELD SEX ASS TECHN AS; [Anonymous], 2008, FREE HARM TOOLS; [Anonymous], 2006, PROC GUID HANDL ELD; [Anonymous], 2011, STRAT OCC THER ADDR; Bass DM, 2001, J ELDER ABUSE NEGL, V13, P23, DOI 10.1300/J084v13n02_03; Beaulieu M, 2010, HAND ETHICAL DECISIO; Bomba PA, 2006, J GERONTOL SOC WORK, V46, P103, DOI 10.1300/J083v46n03_06; Boulkedid R, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020476; Brandle Bonnie, 2006, Care Manag J, V7, P64, DOI 10.1891/cmaj.7.2.64; Brown K.M., 2010, QUICK REFERENCE ADUL; Brown Kathleen, 2004, Nurse Pract, V29, P22, DOI 10.1097/00006205-200408000-00004; Burgess AW, 2005, AM J NURS, V105, P66, DOI 10.1097/00000446-200510000-00037; Campbell R, 2005, TRAUMA VIOLENCE ABUS, V6, P313, DOI 10.1177/1524838005280328; Chang ALS, 2013, J AM ACAD DERMATOL, V68, DOI 10.1016/j.jaad.2013.01.001; Colbert M, 2013, ADULT PROTECTIVE SER; Connolly M. T, 2014, ELDER JUSTICE ROADMA; Connors K, 2010, FINANCIAL ABUSE SPEC; Cooper C, 2008, AGE AGEING, V37, P151, DOI 10.1093/ageing/afm194; Daly JM, 2005, J ELDER ABUSE NEGL, V17, P1, DOI 10.1300/J084v17n01_01; Daly JM., 2010, ELDER ABUSE PREVENTI; DeLiema M, 2012, J AM GERIATR SOC, V60, P1333, DOI 10.1111/j.1532-5415.2012.04025.x; Dong XQ, 2011, GERONTOLOGY, V57, P549, DOI 10.1159/000321881; Dong XQ, 2013, JAMA INTERN MED, V173, P911, DOI 10.1001/jamainternmed.2013.238; Dong XQ, 2013, J ELDER ABUSE NEGL, V25, P97, DOI 10.1080/08946566.2013.751811; Dong XQ, 2013, GERONTOLOGY, V59, P132, DOI 10.1159/000341652; Dong XQ, 2012, AM J EMERG MED, V30, P553, DOI 10.1016/j.ajem.2011.02.008; Du Mont J, 2014, MED LAW, V33, P189; Egger M, 1998, BMJ, V316; Erlingsson CL, 2003, J ELDER ABUSE NEGL, V15, P185, DOI 10.1300/J084v15n03_11; Ethier L, 2000, ELDER ABUSE RESOURCE; Fanslow J.L., 2006, FAMILY VIOLENCE INTE; Fisher BS, 2011, J INTERPERS VIOLENCE, V26, P254, DOI 10.1177/0886260510362877; Fulmer Terry, 2003, J Gerontol Nurs, V29, P4; Gargon E, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099111; Gray-Vickrey P, 2000, Nursing, V30, P34; Greenbaum AR, 2006, PLAST RECONSTR SURG, V118, p46E, DOI 10.1097/01.prs.0000227620.31296.2c; GRIMSHAW JM, 1993, LANCET, V342, P1317, DOI 10.1016/0140-6736(93)92244-N; Ha L, 2013, AN EMPIRICAL EXAMINA; Heath H, 2007, VULNERABLE ADULTS PR; Hirsch CH, 1999, WESTERN J MED, V170, P353; Horning SM, 2013, CLIN CASE STUD, V12, P373, DOI 10.1177/1534650113496143; Hussain T, 2009, INT J MED INFORM, V78, P354, DOI 10.1016/j.ijmedinf.2008.11.001; Kartes L, 1997, EDLER ABUSE RESOURCE; Koin D, 2003, J ELDER ABUSE NEGL, V15, P109, DOI 10.1300/J084v15n03_07; Kruger RM, 1999, POSTGRAD MED, V106, P169; Lachs MS, 1998, JAMA-J AM MED ASSOC, V280, P428, DOI 10.1001/jama.280.5.428; Lachs MS, 2004, LANCET, V364, P1263, DOI 10.1016/S0140-6736(04)17144-4; Lafata MJ, 2001, OCCUP THER MENT HLTH, V16, P141; Levac D, 2010, IMPLEMENT SCI, V5, DOI 10.1186/1748-5908-5-69; Lynch SH, 1997, AM J NURS, V97, P27; Malks B, 2003, J ELDER ABUSE NEGL, V15, P55, DOI 10.1300/J084v15n03_04; Manthorpe J, 2012, INT PSYCHOGERIATR, V24, P1454, DOI 10.1017/S1041610212000348; Marshall CE, 2000, GERIATRICS, V55, P42; Missen H, GUIDE ELDER ABUSE PR; Neale AV, 1996, GERONTOLOGIST, V36, P502, DOI 10.1093/geront/36.4.502; Nerenberg L, 2004, IDENTIFYING RESPONDI; Newberry Andrea M, 2008, Psychol Health Med, V13, P438, DOI 10.1080/13548500701694219; OGG J, 1992, BRIT MED J, V305, P998, DOI 10.1136/bmj.305.6860.998; Oh J, 2006, INT J NURS STUD, V43, P203, DOI 10.1016/j.ijnurstu.2005.03.005; Perista H, 2013, MIND GAP IMPROVING I; Pham E, 2009, GERIATR AGING, V12, P323; Phelan A, 2012, EUR GERIATR MED, V3, pS125; Pierce-Weeks J, 2013, SEXUAL VIOLENCE LATE; Ploeg J, 2009, J ELDER ABUSE NEGL, V21, P187, DOI 10.1080/08946560902997181; Podnieks E, 1993, J ELDER ABUSE NEGL, V4; Podnieks E, 2010, J ELDER ABUSE NEGL, V22, P164, DOI 10.1080/08946560903445974; Poole C, 2012, J ELDER ABUSE NEGL, V24, P120, DOI 10.1080/08946566.2011.646503; Quinn M. J., 1997, ELDER ABUSE NEGLECT; Samaan Z, 2013, J MULTIDISCIP HEALTH, V6, P169, DOI 10.2147/JMDH.S43952; Schofield MJ, 2013, J AM GERIATR SOC, V61, P679, DOI 10.1111/jgs.12212; Shaneyfelt T, 1998, JAMA-J AM MED ASSOC, V281, P1900; Siegel S, 2013, LOOK HURT SERVICE GU; Swagerty D, 2003, CLIN FAMILY PRACTICE, V5, P195; Tomita S, 2006, HDB SOCIAL WORK HLTH; Vacarro JV, 1996, VICTIMS VIOLENCE PRA, P293; Welfel ER, 2000, J COUNS DEV, V78, P284, DOI 10.1002/j.1556-6676.2000.tb01909.x; WHO, 2002, WORLD REPORT VIOLENC; Wiseman M, 2008, J CAN DENT ASSOC, V74, P715; Woolf S, 2012, IMPLEMENT SCI, V7; World Health Organization, 2012, ARE YOU READY WHAT Y; World Health Organization, 2011, ELD MALTR FACT SHEET; World Health Organization, 2002, FACTS AB ELD; World Health Organization, 2012, WHO HDB GUID DEV	110	23	23	2	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 4	2015	10	5							e0125105	10.1371/journal.pone.0125105	http://dx.doi.org/10.1371/journal.pone.0125105			21	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	CH3PP	25938414	Green Published, Green Submitted, gold			2023-01-03	WOS:000353943000044
J	Tsai, J; Grant, AM; Beckman, MG; Grosse, SD; Yusuf, HR; Richardson, LC				Tsai, James; Grant, Althea M.; Beckman, Michele G.; Grosse, Scott D.; Yusuf, Hussain R.; Richardson, Lisa C.			Determinants of Venous Thromboembolism among Hospitalizations of US Adults: A Multilevel Analysis	PLOS ONE			English	Article							DEEP-VEIN THROMBOSIS; QUALITY-OF-CARE; RISK-FACTORS; PULMONARY-EMBOLISM; AMERICAN-COLLEGE; MEDICAL PATIENTS; HEALTH; PROPHYLAXIS; THROMBOPROPHYLAXIS; PREVENTION	Background Venous thromboembolism (VTE) is a significant clinical and public health concern. We evaluated a variety of multilevel factors-demographics, clinical and insurance status, preexisting comorbid conditions, and hospital characteristics-for VTE diagnosis among hospitalizations of US adults. Methods We generated adjusted odds ratios with 95% confidence intervals (CIs) and determined sources of outcome variation by conducting multilevel logistic regression analysis of data from the 2011 Nationwide Inpatient Sample that included 6,710,066 hospitalizations of US adults nested within 1,039 hospitals. Results Among hospitalizations of adults, age, sex, race or ethnicity, total days of hospital stay, status of health insurance, and operating room procedure were important determinants of VTE diagnosis; each of the following preexisting comorbid conditions-acquired immune deficiency syndrome, anemia, arthritis, congestive heart failure, coagulopathy, hypertension, lymphoma, metastatic cancer, other neurological disorders, obesity, paralysis, pulmonary circulation disorders, renal failure, solid tumor without metastasis, and weight loss-was associated independently with 1.04 (95% CI: 1.02-1.06) to 2.91 (95% CI: 2.81-3.00) times increased likelihood of VTE diagnosis than among hospitalizations of adults without any of these corresponding conditions. The presence of 2 or more of such conditions was associated a 180%-450% increased likelihood of a VTE diagnosis. Hospitalizations of adults who were treated in urban hospitals were associated with a 14%-15% increased likelihood of having a VTE diagnosis than those treated in rural hospitals. Approximately 7.4% of the total variation in VTE diagnosis occurred between hospitals. Conclusion The presence of certain comorbidities and hospital contextual factors is associated with significantly elevated likelihood of VTE diagnosis among hospitalizations of adults. The findings of this study underscore the importance of clinical risk assessment and adherence to evidence-based clinical practice guidelines in preventing VTE, as well as the need to evaluate potential contextual factors that might modify the risk of VTE among hospitalized patients.	[Tsai, James; Grant, Althea M.; Beckman, Michele G.; Grosse, Scott D.; Yusuf, Hussain R.; Richardson, Lisa C.] Ctr Dis Control & Prevent, Div Blood Disorders, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30333 USA	Centers for Disease Control & Prevention - USA	Tsai, J (corresponding author), Ctr Dis Control & Prevent, Div Blood Disorders, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30333 USA.	jxt9@cdc.gov		Tsai, James/0000-0002-3114-124X; Grosse, Scott/0000-0003-1078-6855; Richardson, Lisa/0000-0002-9555-7674				Ageno W, 2008, CIRCULATION, V117, P93, DOI 10.1161/CIRCULATIONAHA.107.709204; AHRQ, 2013, OV NAT INP SAMPL NIS; AHRQ, 2012, COM SOFTW VERS 3 7; AHRQ, 2012, PROC CLASS 2012; AHRQ, 2012, MAJ OP ROOM PROC IND; Bibas M, 2011, MEDITERR J HEMATOL I, V3, DOI 10.4084/MJHID.2011.030; Carle AC, 2009, BMC MED RES METHODOL, V9, DOI 10.1186/1471-2288-9-49; Chandra D, 2009, ANN INTERN MED, V151, P180, DOI 10.7326/0003-4819-151-3-200908040-00129; Cohen AT, 2005, THROMB HAEMOSTASIS, V94, P750, DOI 10.1160/TH05-06-0385; Dabbagh O, 2010, CHEST, V137, P1145, DOI 10.1378/chest.09-2177; Dean Steven M, 2010, Congest Heart Fail, V16, P164, DOI 10.1111/j.1751-7133.2010.00148.x; DHHS, 2008, SURG GEN CALL ACT PR; Duncan C, 1998, SOC SCI MED, V46, P97, DOI 10.1016/S0277-9536(97)00148-2; Elixhauser A, 1998, MED CARE, V36, P8, DOI 10.1097/00005650-199801000-00004; Folsom AR, 2007, J GERONTOL A-BIOL, V62, P79, DOI 10.1093/gerona/62.1.79; Franchini M, 2008, ANN HEMATOL, V87, P167, DOI 10.1007/s00277-007-0416-1; Guyatt GH, 2012, CHEST, V141, p7S, DOI 10.1378/chest.1412S3; Heit JA, 2000, ARCH INTERN MED, V160, P809, DOI 10.1001/archinte.160.6.809; Heit JA, 2001, MAYO CLIN PROC, V76, P1102, DOI 10.4065/76.11.1102; Houchens R, 2007, HCUP METHODS SERIES, V2007-01; Huseynova K, 2009, J AM COLL SURGEONS, V208, P547, DOI 10.1016/j.jamcollsurg.2009.01.002; Introduction to the HCUP nationwide inpatient sample (NIS), 2011, HEALTHC COST UT PROJ; Kaboli Peter J, 2005, Cleve Clin J Med, V72 Suppl 1, pS7; Keenan CR, 2007, CURR OPIN PULM MED, V13, P377, DOI 10.1097/MCP.0b013e3281eb8ef0; Kim SC, 2013, ARTHRIT CARE RES, V65, P1600, DOI 10.1002/acr.22039; Lopes Antonio Augusto, 2006, Cardiovascular & Hematological Agents in Medicinal Chemistry, V4, P53, DOI 10.2174/187152506775268794; Lyman GH, 2011, CANCER-AM CANCER SOC, V117, P1334, DOI 10.1002/cncr.25714; Maynard GA, 2010, AHRQ PUBLICATION, V08-0075; Papanikolaou PN, 2006, PLOS MED, V3, P1603, DOI 10.1371/journal.pmed.0030341; Piazza G, 2007, CHEST, V132, P554, DOI 10.1378/chest.07-0430; Pickett KE, 2001, J EPIDEMIOL COMMUN H, V55, P111, DOI 10.1136/jech.55.2.111; Qaseem A, 2011, ANN INTERN MED, V155, P625, DOI 10.7326/0003-4819-155-9-201111010-00011; Ruppert Andras, 2011, J Med Econ, V14, P65, DOI 10.3111/13696998.2010.546465; Sarrazin MSV, 2012, JAMA-J AM MED ASSOC, V307, P1433, DOI 10.1001/jama.2012.404; Snijders T. A. B., 2011, MULTILEVEL ANAL INTR; Spencer FA, 2007, ARCH INTERN MED, V167, P1471, DOI 10.1001/archinte.167.14.1471; Streiff MB, 2012, HEMATOL-AM SOC HEMAT, P631, DOI 10.1182/asheducation-2012.1.631; Sundstrom A, 2009, BJOG-INT J OBSTET GY, V116, P91, DOI 10.1111/j.1471-0528.2008.01926.x; Tapson VF, 2007, CHEST, V132, P936, DOI 10.1378/chest.06-2993; Thornlow DK, 2006, MED CARE, V44, P265, DOI 10.1097/01.mlr.0000199668.42261.a3; Tsai J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070061; Tsai J, 2013, INT J MED SCI, V10, P1352, DOI 10.7150/ijms.6714; Tveit DP, 2002, AM J KIDNEY DIS, V39, P1011, DOI 10.1053/ajkd.2002.32774; Valderas JM, 2009, ANN FAM MED, V7, P357, DOI 10.1370/afm.983; Vogeli C, 2009, MED CARE, V47, P591, DOI 10.1097/MLR.0b013e31819432cd; Wattanakit K, 2008, J AM SOC NEPHROL, V19, P135, DOI 10.1681/ASN.2007030308; White RH, 2012, CIRCULATION, V125, P2051, DOI 10.1161/CIRCULATIONAHA.112.102814; Wolberg AS, 2012, ANESTH ANALG, V114, P275, DOI 10.1213/ANE.0b013e31823a088c; Yusuf HR, 2013, CLIN APPL THROM 0627	49	18	18	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 16	2015	10	4							e0123842	10.1371/journal.pone.0123842	http://dx.doi.org/10.1371/journal.pone.0123842			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CG1ES	25879844	gold, Green Published			2023-01-03	WOS:000353016500064
J	Hawkes, N				Hawkes, Nigel			BMJ AWARDS 2015 Palliative care team of the year	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material												nigel.hawkes1@btinternet.com							0	0	0	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	APR 15	2015	350								h1861	10.1136/bmj.h1861	http://dx.doi.org/10.1136/bmj.h1861			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CG5JP	25876989				2023-01-03	WOS:000353328000006
J	Hawkes, N				Hawkes, Nigel			BMJ AWARDS 2015 Innovation team of the year	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material												nigel.hawkes1@btinternet.com							0	0	0	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	APR 8	2015	350								h1749	10.1136/bmj.h1749	http://dx.doi.org/10.1136/bmj.h1749			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CF9SR	25855656				2023-01-03	WOS:000352907500002
J	Fan, ZY; Chen, C; Pang, XY; Yu, Z; Qi, Y; Chen, XY; Liang, HH; Fang, XL; Sha, XY				Fan, Zhuoyang; Chen, Cheng; Pang, Xiaoying; Yu, Zhou; Qi, Yang; Chen, Xinyi; Liang, Huihui; Fang, Xiaoling; Sha, Xianyi			Adding Vitamin E-TPGS to the Formulation of Genexol-PM: Specially Mixed Micelles Improve Drug-Loading Ability and Cytotoxicity against Multidrug-Resistant Tumors Significantly	PLOS ONE			English	Article							CELL LUNG-CANCER; PHASE-II; COPOLYMER MICELLES; CREMOPHOR-FREE; IN-VITRO; PACLITAXEL; DELIVERY; GLYCOPROTEIN; PHARMACOKINETICS; BIODISTRIBUTION	Genexol-PM, produced by Samyang Company (Korea) is an excellent preparation of paclitaxel (PTX) for clinical cancer treatment. However, it cannot resolve the issue of multidrug resistance (MDR)-a significant problem in the administration of PTX to cancer patients. To increase the efficacy of Genexol-PM against MDR tumors, a mixed micelle capable of serving as a vehicle for PTX was developed, and two substances were chosen as carrier materials: 1) Polyethylene glycol-polylactic acid (PEG-PLA), the original vehicle of Genexol-PM. 2) Vitamin E-TPGS, an inhibitor of P-glycoprotein (P-gp). P-gp has been proven to be the main cause of MDR. In vitro evaluation indicated that the mixed micelle was an ideal PTX delivery system for the treatment of MDR tumors; the mixed micelle also showed a significantly better drug-loading coefficient than Genexol-PM.	[Fan, Zhuoyang; Chen, Cheng; Pang, Xiaoying; Yu, Zhou; Qi, Yang; Chen, Xinyi; Liang, Huihui; Fang, Xiaoling; Sha, Xianyi] Fudan Univ, Sch Pharm, Dept Pharmaceut, Minist Educ & PLA,Key Lab Smart Drug Delivery, Shanghai 201203, Peoples R China	Fudan University	Sha, XY (corresponding author), Fudan Univ, Sch Pharm, Dept Pharmaceut, Minist Educ & PLA,Key Lab Smart Drug Delivery, Lane 826,Zhangheng Rd, Shanghai 201203, Peoples R China.	shaxy@fudan.edu.cn			National Natural Science Foundation of China [81273459]; National Basic Research Program of China [2013CB932500]; National Science and Technology Major Project [2012ZX09304004]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Basic Research Program of China(National Basic Research Program of China); National Science and Technology Major Project	This research was supported by the National Natural Science Foundation of China (81273459), National Basic Research Program of China (2013CB932500) and National Science and Technology Major Project (2012ZX09304004). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Berger W, 2005, J CANCER RES CLIN, V131, P355, DOI 10.1007/s00432-004-0653-9; BJORNEBOE A, 1990, J NUTR, V120, P233, DOI 10.1093/jn/120.3.233; Chang G, 2003, FEBS LETT, V555, P102, DOI 10.1016/S0014-5793(03)01085-8; Chen LC, 2013, INT J NANOMED, V8, P73, DOI 10.2147/IJN.S38221; Collnot EM, 2007, MOL PHARM, V4, P465, DOI 10.1021/mp060121r; Collnot EM, 2010, MOL PHARMACEUT, V7, P642, DOI 10.1021/mp900191s; Filipits M, 2004, DRUG DISCOV TODAY, V1, P229, DOI DOI 10.1016/J.DDMEC.2004.10.001; GAISFORD S, 1995, J CHEM SOC CHEM COMM, P1843, DOI 10.1039/c39950001843; Gaisford S, 1997, LANGMUIR, V13, P2606, DOI 10.1021/la962033r; Han LM, 2006, ACTA PHARMACOL SIN, V27, P747, DOI 10.1111/j.1745-7254.2006.00340.x; Hugger ED, 2002, J PHARM SCI-US, V91, P1991, DOI 10.1002/jps.10176; Johnson BM, 2002, AAPS PHARMSCI, V4; Kabanov AV, 2002, ADV DRUG DELIVER REV, V54, P759, DOI 10.1016/S0169-409X(02)00047-9; Kang HK, 2005, MOL CANCER THER, V4, P1358, DOI 10.1158/1535-7163.MCT-05-0139; Kataoka K, 2001, ADV DRUG DELIVER REV, V47, P113, DOI 10.1016/S0169-409X(00)00124-1; Kim SC, 2001, J CONTROL RELEASE, V72, P191, DOI 10.1016/S0168-3659(01)00275-9; Kim SY, 1998, J CONTROL RELEASE, V51, P13, DOI 10.1016/S0168-3659(97)00124-7; Kim TY, 2004, CLIN CANCER RES, V10, P3708, DOI 10.1158/1078-0432.CCR-03-0655; Lee E, 2006, ARCH PHARM RES, V29, P1018, DOI 10.1007/BF02969286; Lee JL, 2012, INVEST NEW DRUG, V30, P1984, DOI 10.1007/s10637-011-9757-7; Letchford K, 2007, EUR J PHARM BIOPHARM, V65, P259, DOI 10.1016/j.ejpb.2006.11.009; Mayer LD, 2001, CANCER METAST REV, V20, P87, DOI 10.1023/A:1013108524062; McLeod AD, 1998, J PHARM SCI, V8, P704; Oerlemans C, 2010, PHARM RES-DORDR, V27, P2569, DOI 10.1007/s11095-010-0233-4; Postma TJ, 2000, ANN ONCOL, V11, P409, DOI 10.1023/A:1008376123066; Prados MD, 1996, J CLIN ONCOL, V14, P2316, DOI 10.1200/JCO.1996.14.8.2316; Qiu LY, 2006, PHARM RES-DORDR, V23, P1, DOI 10.1007/s11095-005-9046-2; ROFSTAD EK, 1986, CELL TISSUE KINET, V19, P205, DOI 10.1111/j.1365-2184.1986.tb00731.x; ROWINSKY EK, 1995, NEW ENGL J MED, V332, P1004, DOI 10.1056/NEJM199504133321507; Santini MT, 1999, PATHOBIOLOGY, V67, P148, DOI 10.1159/000028065; Saxena V, 2012, INT J NANOMED, V7, P713, DOI 10.2147/IJN.S28745; Singla AK, 2002, INT J PHARMACEUT, V235, P179, DOI 10.1016/S0378-5173(01)00986-3; Varma MVS, 2005, EUR J PHARM SCI, V25, P445, DOI 10.1016/j.ejps.2005.04.003; Wang YZ, 2008, ARCH PHARM RES, V31, P530, DOI 10.1007/s12272-001-1189-2; Wang YZ, 2007, INT J PHARM, V337, P63, DOI 10.1016/j.ijpharm.2006.12.033; WEISS RB, 1990, J CLIN ONCOL, V8, P1263, DOI 10.1200/JCO.1990.8.7.1263; Yamazaki T, 2000, CANCER LETT, V149, P153, DOI 10.1016/S0304-3835(99)00355-9; Zhang XC, 1996, INT J PHARM, V132, P195, DOI 10.1016/0378-5173(95)04386-1	38	33	34	1	51	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 1	2015	10	4							e0120129	10.1371/journal.pone.0120129	http://dx.doi.org/10.1371/journal.pone.0120129			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CE9AM	25831130	Green Submitted, Green Published, gold			2023-01-03	WOS:000352135600023
J	Longwe, H; Jambo, KC; Phiri, KS; Mbeye, N; Gondwe, T; Hall, T; Tetteh, KKA; Drakeley, C; Mandala, WL				Longwe, Herbert; Jambo, Kondwani C.; Phiri, Kamija S.; Mbeye, Nyanyiwe; Gondwe, Thandile; Hall, Tom; Tetteh, Kevin K. A.; Drakeley, Chris; Mandala, Wilson L.			The Effect of Daily Co-Trimoxazole Prophylaxis on Natural Development of Antibody-Mediated Immunity against P. falciparum Malaria Infection in HIV-Exposed Uninfected Malawian Children	PLOS ONE			English	Article							MEROZOITE SURFACE PROTEIN-1; PROTECTION; RESPONSES; TRANSMISSION; SALMONELLA; MORTALITY; ANTIGENS; MORBIDITY; EBA-175; BREADTH	Background and Objectives Cotrimoxazole prophylaxis, currently recommended in HIVexposed, uninfected (HEU) children as protection against opportunistic infections, also has some antimalarial efficacy. We determined whether daily cotrimoxazole prophylaxis affects the natural development of antibodymediated immunity to bloodstage Plasmodium falciparum malaria infection. Methods Using an enzymelinked immunosorbent assay, we measured antibodies to 8Plasmodium falciparum antigens (AMA1, MSP1(19), MSP3, PfSE, EBA175RII, GLURP R0, GLURP R2 and CSP) in serum samples from 33 HEU children and 31 HIVunexposed, uninfected (HUU) children, collected at 6, 12 and 18 months of age. Results Compared to HIVuninfected children, HEU children had significantly lower levels of specific IgG against AMA1 at 6 months (p = 0.001), MSP1(19) at 12 months (p = 0.041) and PfSE at 6 months (p = 0.038), 12 months (p = 0.0012) and 18 months (p = 0.0097). No differences in the IgG antibody responses against the rest of the antigens were observed between the two groups at all time points. The breadth of specificity of IgG response was reduced in HEU children compared to HUU children during the follow up period. Conclusions Co-trimoxazole prophylaxis seems to reduce IgG antibody responses to P. falciparum blood stage antigens, which could be as a result of a reduction in exposure of those children under this regime. Although antibody responses were regarded as markers of exposure in this study, further studies are required to establish whether these responses are correlated in any way to clinical immunity to malaria.	[Longwe, Herbert; Mandala, Wilson L.] Univ Malawi, Coll Med, Dept Basic Med Sci, Blantyre, Malawi; [Jambo, Kondwani C.; Mandala, Wilson L.] Malawi Liverpool Wellcome Trust Clin Res Programm, Blantyre, Malawi; [Phiri, Kamija S.] Univ Malawi, Coll Med, Trop Haematol Res Unit, Blantyre, Malawi; [Mbeye, Nyanyiwe; Gondwe, Thandile] Univ Malawi, Coll Med, Dept Publ Hlth, Blantyre, Malawi; [Hall, Tom; Tetteh, Kevin K. A.; Drakeley, Chris] London Sch Hyg & Trop Med, London WC1, England	University of Malawi; University of Malawi; University of Malawi; University of Malawi; University of London; London School of Hygiene & Tropical Medicine	Mandala, WL (corresponding author), Univ Malawi, Coll Med, Dept Basic Med Sci, Blantyre, Malawi.	wmandala2002@gmail.com	Mbeye, Nyanyiwe/ABB-5991-2021; Tetteh, Kevin/GYQ-9704-2022	Tetteh, Kevin/0000-0003-2733-0037; Jambo, Kondwani/0000-0002-3195-2210; Mandala, Wilson/0000-0001-9386-9239; Phiri, Kamija/0000-0003-1753-2727; Hall, Tom/0000-0002-9001-6684	Malawi Health Research Capacity Strengthening Initiative (HRCSI); DFID; Wellcome Trust funded programme; HIV Research Trust UK; Consortium for Advanced Research Training in Africa (CARTA); Southern Africa Consortium for Research Excellence (SACORE); Wellcome Trust (UK) [087547/Z/08/Z]; Department for International Development (DfID) under the Development Partnerships in Higher Education (DelPHE); Carnegie Corporation of New York [B8606]; Ford Foundation [1100-0399]; Sida [54100029]; Bill and Melinda Gates Foundation [51228];  [191994]	Malawi Health Research Capacity Strengthening Initiative (HRCSI); DFID; Wellcome Trust funded programme(Wellcome Trust); HIV Research Trust UK; Consortium for Advanced Research Training in Africa (CARTA); Southern Africa Consortium for Research Excellence (SACORE); Wellcome Trust (UK)(Wellcome Trust); Department for International Development (DfID) under the Development Partnerships in Higher Education (DelPHE); Carnegie Corporation of New York; Ford Foundation; Sida; Bill and Melinda Gates Foundation(Bill & Melinda Gates Foundation); 	The study was funded by the Malawi Health Research Capacity Strengthening Initiative (HRCSI), a DFID and Wellcome Trust funded programme and the HIV Research Trust UK. Partially funded by Fellowship awards provided by the Consortium for Advanced Research Training in Africa (CARTA) and Southern Africa Consortium for Research Excellence (SACORE). CARTA has been funded by the Wellcome Trust (UK) (Grant No: 087547/Z/08/Z), the Department for International Development (DfID) under the Development Partnerships in Higher Education (DelPHE), the Carnegie Corporation of New York (Grant No: B8606), the Ford Foundation (Grant No: 1100-0399), Google.org (Grant No: 191994), Sida (Grant No: 54100029) and the Bill and Melinda Gates Foundation (Grant No: 51228). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ALBRECHT P, 1977, J PEDIATR-US, V91, P715, DOI 10.1016/S0022-3476(77)81021-4; AlYaman F, 1996, AM J TROP MED HYG, V54, P443, DOI 10.4269/ajtmh.1996.54.443; Aponte JJ, 2007, PLOS MED, V4, P1259, DOI 10.1371/journal.pmed.0040242; Artavanis-Tsakonas K, 2003, CLIN EXP IMMUNOL, V133, P145, DOI 10.1046/j.1365-2249.2003.02174.x; Boulanger D, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-363; Bousema T, 2010, J INFECT DIS, V201, P1764, DOI 10.1086/652456; BURGHAUS PA, 1994, MOL BIOCHEM PARASIT, V64, P165, DOI 10.1016/0166-6851(94)90144-9; Bwakura-Dangarembizi M, 2014, NEW ENGL J MED, V370, P41, DOI 10.1056/NEJMoa1214901; COHEN S, 1961, NATURE, V192, P733, DOI 10.1038/192733a0; Collins CR, 2007, J BIOL CHEM, V282, P7431, DOI 10.1074/jbc.M610562200; Dobano C, 2012, CLIN VACCINE IMMUNOL, V19, P157, DOI 10.1128/CVI.05523-11; Dodoo D, 1999, INFECT IMMUN, V67, P2131, DOI 10.1128/IAI.67.5.2131-2137.1999; Dodoo D, 2011, MALARIA J, V10, DOI 10.1186/1475-2875-10-108; Drakeley CJ, 2005, P NATL ACAD SCI USA, V102, P5108, DOI 10.1073/pnas.0408725102; Gordon MA, 2008, CLIN INFECT DIS, V46, P963, DOI 10.1086/529146; Gordon MA, 2008, J INFECT DEV COUNTR, V2, P438, DOI 10.3855/jidc.158; Greenhouse B, 2011, J INFECT DIS, V204, P19, DOI 10.1093/infdis/jir223; GREENWOOD B, 1991, PARASITOL TODAY, V7, P277, DOI 10.1016/0169-4758(91)90096-7; Greenwood BM, 1995, T ROY SOC TROP MED H, V89, P629, DOI 10.1016/0035-9203(95)90419-0; Haeusler GM, 2013, ADV EXP MED BIOL, V764, P13, DOI 10.1007/978-1-4614-4726-9_2; Hamel MJ, 2005, AM J TROP MED HYG, V73, P609, DOI 10.4269/ajtmh.2005.73.609; HOLDER AA, 1982, J EXP MED, V156, P1528, DOI 10.1084/jem.156.5.1528; Ibison F, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052939; Jones CE, 2011, JAMA-J AM MED ASSOC, V305, P576, DOI 10.1001/jama.2011.100; Kastenmuller K, 2013, INFECT IMMUN, V81, P789, DOI 10.1128/IAI.01108-12; Kinyanjui SM, 2007, MALARIA J, V6, DOI 10.1186/1475-2875-6-82; Kusi KA, 2014, MALARIA J, V13, DOI 10.1186/1475-2875-13-103; Langhorne J, 2008, NAT IMMUNOL, V9, P725, DOI 10.1038/ni.f.205; Marsh K, 2006, PARASITE IMMUNOL, V28, P51, DOI 10.1111/j.1365-3024.2006.00808.x; Mbeye NM, 2014, TROP MED INT HEALTH, V19, P1057, DOI 10.1111/tmi.12352; Menendez C, 1997, LANCET, V350, P844, DOI 10.1016/S0140-6736(97)04229-3; Mermin J, 2004, LANCET, V364, P1428, DOI 10.1016/S0140-6736(04)17225-5; Moncunill G, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073624; Mugyenyi CK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068304; Mulenga V, 2007, AIDS, V21, P77, DOI 10.1097/QAD.0b013e3280114ed7; Murray CJL, 2012, LANCET, V379, P413, DOI 10.1016/S0140-6736(12)60034-8; Ndungu FM, 2002, PARASITE IMMUNOL, V24, P77, DOI 10.1046/j.0141-9838.2001.00440.x; Nyirenda TS, 2014, J INFECT DIS, V210, P56, DOI 10.1093/infdis/jiu045; Ogutu BR, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004708; Okenu DMN, 2000, INFECT IMMUN, V68, P5559, DOI 10.1128/IAI.68.10.5559-5566.2000; Osier FHA, 2008, INFECT IMMUN, V76, P2240, DOI 10.1128/IAI.01585-07; Pandey KC, 2002, MOL BIOCHEM PARASIT, V123, P23, DOI 10.1016/S0166-6851(02)00122-6; Persson KEM, 2010, ACTA TROP, V114, P138, DOI 10.1016/j.actatropica.2009.05.017; Proietti C, 2013, PARASITE IMMUNOL, V35, P164, DOI 10.1111/pim.12031; Rantala AM, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-269; Riley EM, 1999, IMMUNOL TODAY, V20, P228, DOI 10.1016/S0167-5699(99)01456-5; Rono J, 2013, CLIN INFECT DIS, V57, P1409, DOI 10.1093/cid/cit556; SABCHAREON A, 1991, AM J TROP MED HYG, V45, P297, DOI 10.4269/ajtmh.1991.45.297; THEISEN M, 1995, CLIN DIAGN LAB IMMUN, V2, P30, DOI 10.1128/CDLI.2.1.30-34.1995; Tsai CW, 2009, MOL BIOCHEM PARASIT, V164, P45, DOI 10.1016/j.molbiopara.2008.11.006; WHO, 2012, WORLD MALARIA REPORT 2012, P1; World Health Organization (WHO), 2006, GUID COTR PROPH HIV; Wright GJ, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1003943	53	7	7	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 25	2015	10	3							e0121643	10.1371/journal.pone.0121643	http://dx.doi.org/10.1371/journal.pone.0121643			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CE5MO	25807475	gold, Green Published, Green Accepted, Green Submitted			2023-01-03	WOS:000351880000169
J	Greineder, CF; Brenza, JB; Carnemolla, R; Zaitsev, S; Hood, ED; Pan, DC; Ding, BS; Esmon, CT; Chacko, AM; Muzykantov, VR				Greineder, Colin F.; Brenza, Jacob B.; Carnemolla, Ronald; Zaitsev, Sergei; Hood, Elizabeth D.; Pan, Daniel C.; Ding, Bi-Sen; Esmon, Charles T.; Chacko, Ann Marie; Muzykantov, Vladimir R.			Dual targeting of therapeutics to endothelial cells: collaborative enhancement of delivery and effect	FASEB JOURNAL			English	Article						drug delivery; PECAM-1; thrombomodulin; EPCR	PROTEIN-C RECEPTOR; SOLUBLE THROMBOMODULIN ART-123; SEVERE SEPSIS; IN-VITRO; ESCHERICHIA-COLI; DRUG-DELIVERY; ACTIVATION; MODEL; COAGULATION; RELEASE	Anchoring pharmacologic agents to the vascular lumen has the potential to modulate critical processes at the blood-tissue interface, avoiding many of the off-target effects of systemically circulating agents. We report a novel strategy for endothelial dual targeting of therapeutics, which both enhances drug delivery and enables targeted agents to partner enzymatically to generate enhanced biologic effect. Based on the recent discovery that paired antibodies directed to adjacent epitopes of platelet endothelial cell adhesion molecule (PECAM)-1 stimulate each other's binding, we fused single-chain fragments (scFv) of paired anti-mouse PECAM-1 antibodies to recombinant murine thrombomodulin (TM) and endothelial protein C receptor (EPCR), endothelial membrane proteins that partner in activation of protein C (PC). scFv/TM and scFv/EPCR bound to mouse endothelial PECAM-1 with high affinity (EC50 1.5 and 3.8 nM, respectively), and codelivery induced a 5-fold increase in PC activation not seen when TM and EPCR are anchored to distinct cell adhesion molecules. In a mouse model of acute lung injury, dual targeting reduces both the expression of lung inflammatory markers and trans-endothelial protein leak by as much as 40%, as compared to either agent alone. These findings provide proof of principle for endothelial dual targeting, an approach with numerous potential biomedical applications.-Greineder, C. F., Brenza, J. B., Carnemolla, R., Zaitsev, S., Hood, E. D., Pan, D. C., Ding, B.-S., Esmon, C. T., Chacko, A. M., Muzykantov, V. R. Dual targeting of therapeutics to endothelial cells: collaborative enhancement of delivery and effect.	[Greineder, Colin F.; Carnemolla, Ronald; Zaitsev, Sergei; Hood, Elizabeth D.; Pan, Daniel C.; Muzykantov, Vladimir R.] Univ Penn, Perelman Sch Med, Dept Pharmacol, Philadelphia, PA 19104 USA; [Greineder, Colin F.; Brenza, Jacob B.; Carnemolla, Ronald; Zaitsev, Sergei; Hood, Elizabeth D.; Pan, Daniel C.; Chacko, Ann Marie; Muzykantov, Vladimir R.] Univ Penn, Inst Translat Med & Therapeut, Ctr Targeted Therapeut & Translat Nanomed, Perelman Sch Med, Philadelphia, PA 19104 USA; [Chacko, Ann Marie] Univ Penn, Perelman Sch Med, Dept Radiol, Philadelphia, PA 19104 USA; [Greineder, Colin F.] Univ Penn, Perelman Sch Med, Dept Emergency Med, Philadelphia, PA 19104 USA; [Ding, Bi-Sen] Weill Cornell Med Coll, Howard Hughes Med Inst, Dept Med Genet, New York, NY USA; [Esmon, Charles T.] Howard Hughes Med Inst, Oklahoma Med Res Fdn, Cardiovasc Biol Res Program, Oklahoma City, OK USA	University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine; Cornell University; Howard Hughes Medical Institute; Howard Hughes Medical Institute; Oklahoma Medical Research Foundation	Muzykantov, VR (corresponding author), Univ Penn, Inst Translat Med & Therapeut, Translat Res Ctr, Perelman Sch Med, TRC 10-125,3400 Civ Ctr Blvd,Bldg 421, Philadelphia, PA 19104 USA.	muzykant@mail.med.upenn.edu		Greineder, Colin/0000-0001-9740-7672	Institute of Translational Medicine and Therapeutics at the University of Pennsylvania; American Heart Association Fellow-to-Faculty Grant [10FTF4150053]; U. S. National Institutes of Health Grant from the National Heart, Lung, and Blood Institute [R01-HL091950]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL110860, T32HL007439, T32HL007915, R01HL091950] Funding Source: NIH RePORTER	Institute of Translational Medicine and Therapeutics at the University of Pennsylvania; American Heart Association Fellow-to-Faculty Grant; U. S. National Institutes of Health Grant from the National Heart, Lung, and Blood Institute; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	The authors thank Dr. Annunciata Vecchi (Mario Negri Institute of Pharmacology Research, Milan, Italy) for her generous gift of Mec13 hybridoma lysate. This work was supported by a Junior Investigator Preliminary/Feasibility Grant Program grant from the Institute of Translational Medicine and Therapeutics at the University of Pennsylvania (to C.F.G.), as well as an American Heart Association Fellow-to-Faculty Grant 10FTF4150053 (to C.F.G.), and a U. S. National Institutes of Health Grant R01-HL091950 from the National Heart, Lung, and Blood Institute (to V.R.M.).	Aird WC, 2003, BLOOD, V101, P3765, DOI 10.1182/blood-2002-06-1887; Bernard GR, 2001, NEW ENGL J MED, V344, P699, DOI 10.1056/NEJM200103083441001; Boehme MWJ, 1996, IMMUNOLOGY, V87, P134; Carnemolla R, 2012, J IMMUNOL METHODS, V384, P21, DOI 10.1016/j.jim.2012.06.012; Carnemolla R, 2010, SEMIN THROMB HEMOST, V36, P332, DOI 10.1055/s-0030-1253455; Chacko AM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034958; Ding BS, 2009, AM J RESP CRIT CARE, V180, P247, DOI 10.1164/rccm.200809-1433OC; DUBEL S, 1994, J IMMUNOL METHODS, V175, P89, DOI 10.1016/0022-1759(94)90334-4; Duncan R, 2003, NAT REV DRUG DISCOV, V2, P347, DOI 10.1038/nrd1088; Esmon CT, 2001, CRIT CARE, V5, pS7, DOI 10.1186/cc1333; ESMON CT, 1995, FASEB J, V9, P946, DOI 10.1096/fasebj.9.10.7615164; ESMON CT, 1989, J BIOL CHEM, V264, P4743; Faust SN, 2001, NEW ENGL J MED, V345, P408, DOI 10.1056/NEJM200108093450603; Feistritzer C, 2006, J BIOL CHEM, V281, P20077, DOI 10.1074/jbc.M600506200; Greineder CF, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080110; Greineder CF, 2013, BLOOD, V122, P1565, DOI 10.1182/blood-2013-03-453498; Gu JM, 2000, BLOOD, V95, P1687, DOI 10.1182/blood.V95.5.1687.005k08_1687_1693; Han HS, 2001, J BIOMAT SCI-POLYM E, V12, P1075, DOI 10.1163/15685620152691869; Kador KE, 2011, ACTA BIOMATER, V7, P2508, DOI 10.1016/j.actbio.2011.03.015; Kearon C, 2005, J THROMB HAEMOST, V3, P962, DOI 10.1111/j.1538-7836.2005.01251.x; Kerschen EJ, 2007, J EXP MED, V204, P2439, DOI 10.1084/jem.20070404; KISHIDA A, 1994, BIOMATERIALS, V15, P848, DOI 10.1016/0142-9612(94)90041-8; Koren E, 2011, IUBMB LIFE, V63, P586, DOI 10.1002/iub.496; Kurosawa S, 1998, BLOOD, V91, P725, DOI 10.1182/blood.V91.2.725; Li W, 2005, J THROMB HAEMOST, V3, P1351, DOI 10.1111/j.1538-7836.2005.01385.x; Maniatis NA, 2008, CURR OPIN CRIT CARE, V14, P22, DOI 10.1097/MCC.0b013e3282f269b9; Muro S, 2005, CURR PHARM DESIGN, V11, P2383, DOI 10.2174/1381612054367274; Muzykantov Vladimir R, 2005, Expert Opin Drug Deliv, V2, P909, DOI 10.1517/17425247.2.5.909; Muzykantov VR, 2013, ISRN VASC MED, V2013, DOI [10.1155/2013/916254, DOI 10.1155/2013/916254]; Newman PJ, 1997, J CLIN INVEST, V99, P3, DOI 10.1172/JCI119129; Opal SM, 2013, AM J RESP CRIT CARE, V187, P1041, DOI 10.1164/rccm.201303-0505ED; REDL H, 1995, J INFECT DIS, V171, P1522, DOI 10.1093/infdis/171.6.1522; Saito H, 2007, J THROMB HAEMOST, V5, P31, DOI 10.1111/j.1538-7836.2006.02267.x; Schouten M, 2014, THROMB HAEMOSTASIS, V111, P970, DOI 10.1160/TH13-10-0859; SOLIS MM, 1991, J VASC SURG, V14, P599; Sperling C, 2004, BIOMATERIALS, V25, P5101, DOI 10.1016/j.biomaterials.2003.12.014; StearnsKurosawa DJ, 1996, P NATL ACAD SCI USA, V93, P10212, DOI 10.1073/pnas.93.19.10212; Su EJ, 2011, J THROMB HAEMOST, V9, P1174, DOI 10.1111/j.1538-7836.2011.04269.x; Sun J, 2000, J CELL SCI, V113, P1459; TAYLOR FB, 1987, J CLIN INVEST, V79, P918, DOI 10.1172/JCI112902; Thorpe PE, 2004, CLIN CANCER RES, V10, P415, DOI 10.1158/1078-0432.CCR-0642-03; Torchilin VP, 2006, ANNU REV BIOMED ENG, V8, P343, DOI 10.1146/annurev.bioeng.8.061505.095735; Tseng PY, 2006, BIOMATERIALS, V27, P2768, DOI 10.1016/j.biomaterials.2005.11.032; Wang J, 2010, AAPS J, V12, P492, DOI 10.1208/s12248-010-9210-4; Xu J, 2000, J BIOL CHEM, V275, P6038, DOI 10.1074/jbc.275.8.6038; Zhang HL, 2013, BIOCONJUGATE CHEM, V24, P550, DOI 10.1021/bc300399f	46	22	22	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2015	29	8					3483	3492		10.1096/fj.15-271213	http://dx.doi.org/10.1096/fj.15-271213			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	CN9VA	25953848	Green Published			2023-01-03	WOS:000358796900034
J	Raja, MAG; Katas, H; Wen, TJ				Raja, Maria Abdul Ghafoor; Katas, Haliza; Wen, Thum Jing			Stability, Intracellular Delivery, and Release of siRNA from Chitosan Nanoparticles Using Different Cross-Linkers	PLOS ONE			English	Article							GENE DELIVERY; MECHANISM; VECTORS	Chitosan (CS) nanoparticles have been extensively studied for siRNA delivery; however, their stability and efficacy are highly dependent on the types of cross-linker used. To address this issue, three common cross-linkers; tripolyphosphate (TPP), dextran sulphate (DS) and poly-D-glutamic acid (PGA) were used to prepare siRNA loaded CS-TPP/DS/PGA nanoparticles by ionic gelation method. The resulting nanoparticles were compared with regard to their physicochemical properties including particle size, zeta potential, morphology, binding and encapsulation efficiencies. Among all the formulations prepared with different cross linkers, CS-TPP-siRNA had the smallest particle size (ranged from 127 +/- 9.7 to 455 +/- 12.9 nm) with zeta potential ranged from +25.1 +/- 1.5 to +39.4 +/- 0.5 mV, and high entrapment (>95%) and binding efficiencies. Similarly, CS-TPP nanoparticles showed better siRNA protection during storage at 4 degrees C and as determined by serum protection assay. TEM micrographs revealed the assorted morphology of CS-TPP-siRNA nanoparticles in contrast to irregular morphology displayed by CS-DS-siRNA and CS-PGA-siRNA nanoparticles. All siRNA loaded CS-TPP/DS/PGA nanoparticles showed initial burst release followed by sustained release of siRNA. Moreover, all the formulations showed low and concentration-dependent cytotoxicity with human colorectal cancer cells (DLD-1), in vitro. The cellular uptake studies with CS-TPP-siRNA nanoparticles showed successful delivery of siRNA within cytoplasm of DLD-1 cells. The results demonstrate that ionically cross-linked CS-TPP nanoparticles are biocompatible non-viral gene delivery system and generate a solid ground for further optimization studies, for example with regard to steric stabilization and targeting.	[Raja, Maria Abdul Ghafoor; Katas, Haliza; Wen, Thum Jing] Univ Kebangsaan Malaysia, Ctr Drug Delivery Res, Fac Pharm, Kuala Lumpur, Malaysia	Universiti Kebangsaan Malaysia	Katas, H (corresponding author), Univ Kebangsaan Malaysia, Ctr Drug Delivery Res, Fac Pharm, Kuala Lumpur, Malaysia.	haliz12@hotmail.com	KATAS, HALIZA/I-6417-2016	KATAS, HALIZA/0000-0001-7249-1628	Ministry of Higher Education Exploratory Research Grant [ERGS/1/2011/SKK/UKM/02/11]	Ministry of Higher Education Exploratory Research Grant	This work was supported by the Ministry of Higher Education Exploratory Research Grant Scheme ERGS/1/2011/SKK/UKM/02/11 to HK. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Akhtar S, 2007, J CLIN INVEST, V117, P3623, DOI 10.1172/JCI33494; Al-Qadi S, 2011, CARBOHYD POLYM, V86, P25, DOI 10.1016/j.carbpol.2011.03.022; Anitha A, 2011, CARBOHYD POLYM, V84, P1158, DOI 10.1016/j.carbpol.2011.01.005; Avadi MR, 2010, NANOMED-NANOTECHNOL, V6, P58, DOI 10.1016/j.nano.2009.04.007; Baldrick P, 2010, REGUL TOXICOL PHARM, V56, P290, DOI 10.1016/j.yrtph.2009.09.015; Calvo P, 1997, J APPL POLYM SCI, V63, P125, DOI 10.1002/(SICI)1097-4628(19970103)63:1<125::AID-APP13>3.0.CO;2-4; Csaba N, 2009, INT J PHARMACEUT, V382, P205, DOI 10.1016/j.ijpharm.2009.07.028; Dash M, 2011, PROG POLYM SCI, V36, P981, DOI 10.1016/j.progpolymsci.2011.02.001; de Fougerolles A, 2007, NAT REV DRUG DISCOV, V6, P443, DOI 10.1038/nrd2310; Dudhani AR, 2010, CARBOHYD POLYM, V81, P243, DOI 10.1016/j.carbpol.2010.02.026; Fan W, 2012, COLLOID SURFACE B, V90, P21, DOI 10.1016/j.colsurfb.2011.09.042; FELGNER JH, 1994, J BIOL CHEM, V269, P2550; Ge CC, 2011, P NATL ACAD SCI USA, V108, P16968, DOI 10.1073/pnas.1105270108; Germershaus O, 2008, J CONTROL RELEASE, V125, P145, DOI 10.1016/j.jconrel.2007.10.013; Hamidi M, 2008, ADV DRUG DELIVER REV, V60, P1638, DOI 10.1016/j.addr.2008.08.002; Hickerson RP, 2008, OLIGONUCLEOTIDES, V18, P345, DOI 10.1089/oli.2008.0149; Hu WB, 2011, ACS NANO, V5, P3693, DOI 10.1021/nn200021j; Illum L, 1998, PHARM RES-DORDR, V15, P1326; Katas H, 2006, J CONTROL RELEASE, V115, P216, DOI 10.1016/j.jconrel.2006.07.021; Kim SH, 2006, BIOCONJUGATE CHEM, V17, P241, DOI 10.1021/bc050289f; Kirchhoff F, 2008, CELL, V134, P566, DOI 10.1016/j.cell.2008.08.004; Kleemann E, 2005, J CONTROL RELEASE, V109, P299, DOI 10.1016/j.jconrel.2005.09.036; Ko JA, 2002, INT J PHARMACEUT, V249, P165, DOI 10.1016/S0378-5173(02)00487-8; Li SD, 2007, J CONTROL RELEASE, V123, P181, DOI 10.1016/j.jconrel.2007.09.004; Lin YH, 2005, BIOMACROMOLECULES, V6, P1104, DOI 10.1021/bm049312a; Liu F, 2002, J CONTROL RELEASE, V78, P259, DOI 10.1016/S0168-3659(01)00494-1; Liu ZH, 2008, ADV DRUG DELIVER REV, V60, P1650, DOI 10.1016/j.addr.2008.09.001; Lundstrom K, 2003, TRENDS BIOTECHNOL, V21, P117, DOI 10.1016/S0167-7799(02)00042-2; Malmo J, 2011, BIOMACROMOLECULES, V12, P721, DOI 10.1021/bm1013525; Papadimitriou SA, 2012, INT J PHARMACEUT, V430, P318, DOI 10.1016/j.ijpharm.2012.04.004; Piao LZ, 2013, NANOMED-NANOTECHNOL, V9, P122, DOI 10.1016/j.nano.2012.03.008; Raja MAG, 2013, J NANOMATER, V2013, DOI 10.1155/2013/653892; Rampino A, 2013, INT J PHARMACEUT, V455, P219, DOI 10.1016/j.ijpharm.2013.07.034; Rodrigues S, 2012, CARBOHYD POLYM, V89, P282, DOI 10.1016/j.carbpol.2012.03.010; Savic R, 2003, SCIENCE, V300, P615, DOI 10.1126/science.1078192; Shim MS, 2010, FEBS J, V277, P4814, DOI 10.1111/j.1742-4658.2010.07904.x; Strand SP, 2008, BIOMACROMOLECULES, V9, P3268, DOI 10.1021/bm800832u; Tsai ML, 2011, CARBOHYD POLYM, V84, P756, DOI 10.1016/j.carbpol.2010.04.040; Tsao CT, 2011, CARBOHYD POLYM, V84, P812, DOI 10.1016/j.carbpol.2010.04.034; Vandenberg GW, 2001, J CONTROL RELEASE, V77, P297, DOI 10.1016/S0168-3659(01)00517-X	40	64	66	0	63	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 11	2015	10	6							e0128963	10.1371/journal.pone.0128963	http://dx.doi.org/10.1371/journal.pone.0128963			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CK3FB	26068222	Green Published, gold, Green Submitted			2023-01-03	WOS:000356100900036
J	Hartmann, JA; Wichers, M; Menne-Lothmann, C; Kramer, I; Viechtbauer, W; Peeters, F; Schruers, KRJ; van Bemmel, AL; Myin-Germeys, I; Delespaul, P; van Os, J; Simons, CJP				Hartmann, Jessica A.; Wichers, Marieke; Menne-Lothmann, Claudia; Kramer, Ingrid; Viechtbauer, Wolfgang; Peeters, Frenk; Schruers, Koen R. J.; van Bemmel, Alex L.; Myin-Germeys, Inez; Delespaul, Philippe; van Os, Jim; Simons, Claudia J. P.			Experience Sampling-Based Personalized Feedback and Positive Affect: A Randomized Controlled Trial in Depressed Patients	PLOS ONE			English	Article							REWARD EXPERIENCE; EMOTIONS; SENSITIVITY; PSYCHOLOGY; VALIDITY; MOOD	Objectives Positive affect (PA) plays a crucial role in the development, course, and recovery of depression. Recently, we showed that a therapeutic application of the experience sampling method (ESM), consisting of feedback focusing on PA in daily life, was associated with a decrease in depressive symptoms. The present study investigated whether the experience of PA increased during the course of this intervention. Design Multicentre parallel randomized controlled trial. An electronic random sequence generator was used to allocate treatments. Settings University, two local mental health care institutions, one local hospital. Participants 102 pharmacologically treated outpatients with a DSM-IV diagnosis of major depressive disorder, randomized over three treatment arms. Intervention Six weeks of ESM self-monitoring combined with weekly PA-focused feedback sessions (experimental group); six weeks of ESM self-monitoring combined with six weekly sessions without feedback (pseudo-experimental group); or treatment as usual (control group). Main outcome The interaction between treatment allocation and time in predicting positive and negative affect (NA) was investigated in multilevel regression models. Results 102 patients were randomized (mean age 48.0, SD 10.2) of which 81 finished the entire study protocol. All 102 patients were included in the analyses. The experimental group did not show a significant larger increase in momentary PA during or shortly after the intervention compared to the pseudo-experimental or control groups (chi(2) (2) = 0.33, p = .846). The pseudo-experimental group showed a larger decrease in NA compared to the control group (chi(2) (1) = 6.29, p = .012). Conclusion PA-focused feedback did not significantly impact daily life PA during or shortly after the intervention. As the previously reported reduction in depressive symptoms associated with the feedback unveiled itself only after weeks, it is conceivable that the effects on daily life PA also evolve slowly and therefore were not captured by the experience sampling procedure immediately after treatment.	[Hartmann, Jessica A.; Wichers, Marieke; Menne-Lothmann, Claudia; Kramer, Ingrid; Viechtbauer, Wolfgang; Peeters, Frenk; Schruers, Koen R. J.; van Bemmel, Alex L.; Myin-Germeys, Inez; Delespaul, Philippe; van Os, Jim; Simons, Claudia J. P.] Maastricht Univ, Med Ctr, European Grad Sch Neurosci, Dept Psychiat & Psychol,SEARCH, NL-6200 MD Maastricht, Netherlands; [Hartmann, Jessica A.; Kramer, Ingrid; van Bemmel, Alex L.; Simons, Claudia J. P.] Inst Mental Hlth Care Eindhoven & Kempen, GGzE, Eindhoven, Netherlands; [Hartmann, Jessica A.] Univ Melbourne, Natl Ctr Excellence Youth Mental Hlth, Orygen, Melbourne, Vic, Australia; [Schruers, Koen R. J.] Leuven Univ, Fac Psychol, Ctr Learning & Expt Psychol, Leuven, Belgium; [Delespaul, Philippe] Mondriaan Mental Hlth Trust, South Limburg, Netherlands; [van Os, Jim] Kings Coll London, Inst Psychiat, Dept Psychosis Studies, London, England	Maastricht University; Orygen, The National Centre of Excellence in Youth Mental Health; University of Melbourne; KU Leuven; University of London; King's College London	Hartmann, JA (corresponding author), Maastricht Univ, Med Ctr, European Grad Sch Neurosci, Dept Psychiat & Psychol,SEARCH, NL-6200 MD Maastricht, Netherlands.	jessica.hartmann@orygen.org.au	van Os, Jim/V-8884-2019; Myin Germeys, Inez/HIR-3364-2022; Vasconcelos, Ana Carolina Souza de/GXW-3453-2022; Delespaul, Philippe/E-8982-2011; van Os, Jim/C-2113-2014; Hartmann, Jessica A/N-7771-2013; Myin-Germeys, Inez/L-5106-2014; Viechtbauer, Wolfgang/M-1549-2013; Schruers, Koen/AAV-2922-2021; Delespaul, Philippe/L-1396-2019; Wichers, Marieke/N-6667-2014	van Os, Jim/0000-0002-7245-1586; Myin Germeys, Inez/0000-0002-3731-4930; Delespaul, Philippe/0000-0001-7420-0898; Hartmann, Jessica A/0000-0001-7662-6155; Viechtbauer, Wolfgang/0000-0003-3463-4063; Schruers, Koen/0000-0003-0134-406X; Delespaul, Philippe/0000-0001-7420-0898; Wichers, Marieke/0000-0001-5024-9064; Peeters, F/0000-0002-6167-8582	Netherlands Organization for Scientific Research; Dutch Health Research Council (ZON-MW) [171001002, 91501003]	Netherlands Organization for Scientific Research(Netherlands Organization for Scientific Research (NWO)); Dutch Health Research Council (ZON-MW)(Netherlands Organization for Health Research and Development)	MW was supported by the Netherlands Organization for Scientific Research (Aspasia Grant). The study was funded by the Dutch Health Research Council (ZON-MW grants nos. 171001002 and 91501003). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. GGzE, Institute of Mental Health Care Eindhoven and the Kempen and Mondriaan Mental Health Trust provided support in the form of salaries for authors JAH, IK, ALvB, PhD, and CJPS, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the 'author contributions' section.	Barge-Schaapveld DQ, 2002, J CLIN PSYCHIAT; Beck A. T., 1979, COGNITIVE THERAPY DE; Ben-Zeev D, 2012, SCHIZOPHRENIA BULL, V38, P384, DOI 10.1093/schbul/sbr179; CLARK LA, 1994, J ABNORM PSYCHOL, V103, P103, DOI 10.1037/0021-843X.103.1.103; Crawford JR, 2004, BRIT J CLIN PSYCHOL, V43, P245, DOI 10.1348/0144665031752934; CSIKSZENTMIHALYI M, 1987, J NERV MENT DIS, V175, P526, DOI 10.1097/00005053-198709000-00004; Delespaul P.A.E.G., 1995, ASSESSING SCHIZOPHRE; Dunn BD, 2012, CLIN PSYCHOL PSYCHOT, V19, P326, DOI 10.1002/cpp.1799; Fredrickson BL, 2001, AM PSYCHOL, V56, P218, DOI 10.1037/0003-066X.56.3.218; Garland EL, 2015, FRONT PSYCHOL, V6, DOI 10.3389/fpsyg.2015.00015; Garland EL, 2010, CLIN PSYCHOL REV, V30, P849, DOI 10.1016/j.cpr.2010.03.002; Geschwind N, 2011, J CONSULT CLIN PSYCH, V79, P618, DOI 10.1037/a0024595; Geschwind N, 2011, EUR NEUROPSYCHOPHARM, V21, P241, DOI 10.1016/j.euroneuro.2010.11.004; HAMILTON M, 1960, J NEUROL NEUROSUR PS, V23, P56, DOI 10.1136/jnnp.23.1.56; Hegerl U, 2010, J PSYCHOPHARMACOL, V24, P445, DOI 10.1177/0269881109106930; Kramer I, 2014, WORLD PSYCHIATRY, V13, P68, DOI 10.1002/wps.20090; Liu RT, 2010, CLIN PSYCHOL REV, V30, P582, DOI 10.1016/j.cpr.2010.04.010; Myin-Germeys I, 2009, PSYCHOL MED, V39, P1533, DOI 10.1017/S0033291708004947; National Institute for Health and Clinical Excellence (NICE), 2018, DEPR AD REC MAN; Palmier-Claus JE, 2011, ACTA PSYCHIAT SCAND, V123, P12, DOI 10.1111/j.1600-0447.2010.01596.x; Peeters F, 2003, J ABNORM PSYCHOL, V112, P203, DOI 10.1037/0021-843X.112.2.203; Snijders TAB, 1999, MULTILEVEL ANALYSIS; StataCorp, 2012, STAT STAT SOFTW REL; Telford C, 2012, PSYCHOL MED, V42, P1119, DOI 10.1017/S0033291711002200; Trull TJ, 2013, ANNU REV CLIN PSYCHO, V9, P151, DOI 10.1146/annurev-clinpsy-050212-185510; Watson D, 1999, J PERS SOC PSYCHOL, V76, P820, DOI 10.1037/0022-3514.76.5.820; Wichers M, 2011, ACTA PSYCHIAT SCAND, V123, P402, DOI 10.1111/j.1600-0447.2011.01684.x; Wichers M, 2011, ACTA PSYCHIAT SCAND, V124, P262, DOI 10.1111/j.1600-0447.2011.01749.x; Wichers MC, 2009, NEUROPSYCHOPHARMACOL, V34, P923, DOI 10.1038/npp.2008.66; Wichers M, 2008, J ABNORM PSYCHOL, V117, P699, DOI 10.1037/a0012909; Wichers MC, 2007, ACTA PSYCHIAT SCAND, V115, P451, DOI 10.1111/j.1600-0447.2006.00924.x; Williams J.B.W., 2002, STRUCTURED CLIN INTE	32	33	33	1	37	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 2	2015	10	6							e0128095	10.1371/journal.pone.0128095	http://dx.doi.org/10.1371/journal.pone.0128095			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	CJ7SJ	26034983	Green Published, gold			2023-01-03	WOS:000355699100027
J	Bhandari, N				Bhandari, Neena			TRADITIONAL MEDICINE Is ayurveda the key to universal healthcare in India?	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							DOUBLE-BLIND					neena@india-voice.com						Central Council of Indian Medicine, 2012, NOT; Central Council of Indian Medicine, 2012, MIN STAND ED IND MED; Chopra A, 2013, RHEUMATOLOGY, V52, P1408, DOI 10.1093/rheumatology/kes414; Furst DE, 2011, JCR-J CLIN RHEUMATOL, V17, P185, DOI 10.1097/RHU.0b013e31821c0310; Johns Hopkins Medicine, AYURV; Ministry of Health and Family Welfare, 2014, NAT HLTH POL DRAFT 2; Narahari SR, 2013, T ROY SOC TROP MED H, V107, P566, DOI 10.1093/trstmh/trt054; University of Maryland Medical Center, AYURVEDA; WHO, 2013, WHO TRADITIONAL MED	9	6	6	0	8	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 28	2015	350								h2879	10.1136/bmj.h2879	http://dx.doi.org/10.1136/bmj.h2879			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CJ5UP	26022091				2023-01-03	WOS:000355557100006
J	Szeto, CC; Kwan, BCH; Chow, KM; Kwok, JSS; Lai, KB; Cheng, PMS; Pang, WF; Ng, JKC; Chan, MHM; Lit, LCW; Leung, CB; Li, PKT				Szeto, Cheuk-Chun; Kwan, Bonnie Ching-Ha; Chow, Kai-Ming; Kwok, Jeffrey Sung-Shing; Lai, Ka-Bik; Cheng, Phyllis Mei-Shan; Pang, Wing-Fai; Ng, Jack Kit-Chung; Chan, Michael Ho-Ming; Lit, Lydia Choi-Wan; Leung, Chi-Bon; Li, Philip Kam-Tao			Circulating Bacterial-Derived DNA Fragment Level Is a Strong Predictor of Cardiovascular Disease in Peritoneal Dialysis Patients	PLOS ONE			English	Article							CHRONIC KIDNEY-DISEASE; SYSTEMIC INFLAMMATION; RENAL-FAILURE; ALL-CAUSE; ENDOTOXEMIA; ATHEROSCLEROSIS; MORTALITY; HEMODIALYSIS; ASSOCIATION; EPIDEMIOLOGY	Background Circulating bacterial DNA fragment is related to systemic inflammatory state in peritoneal dialysis (PD) patients. We hypothesize that plasma bacterial DNA level predicts cardiovascular events in new PD patients. Methods We measured plasma bacterial DNA level in 191 new PD patients, who were then followed for at least a year for the development of cardiovascular event, hospitalization, and patient survival. Results The average age was 59.3 +/- 11.8 years; plasma bacterial DNA level 34.9 +/- 1.5 cycles; average follow up 23.2 +/- 9.7 months. At 24 months, the event-free survival was 86.1%, 69.8%, 55.4% and 30.8% for plasma bacterial DNA level quartiles I, II, III and IV, respectively (p < 0.0001). After adjusting for confounders, plasma bacterial DNA level, baseline residual renal function and malnutrition-inflammation score were independent predictors of composite cardiovascular end-point; each doubling in plasma bacterial DNA level confers a 26.9% (95% confidence interval, 13.0 - 42.5%) excess in risk. Plasma bacterial DNA also correlated with the number of hospital admission (r = -0.379, p < 0.0001) and duration of hospitalization for cardiovascular reasons (r = -0.386, p < 0.0001). Plasma bacterial DNA level did not correlate with baseline arterial pulse wave velocity (PWV), but with the change in carotid-radial PWV in one year (r = -0.238, p = 0.005). Conclusions Circulating bacterial DNA fragment level is a strong predictor of cardiovascular event, need of hospitalization, as well as the progressive change in arterial stiffness in new PD patients.	[Szeto, Cheuk-Chun; Kwan, Bonnie Ching-Ha; Chow, Kai-Ming; Lai, Ka-Bik; Cheng, Phyllis Mei-Shan; Pang, Wing-Fai; Ng, Jack Kit-Chung; Leung, Chi-Bon; Li, Philip Kam-Tao] Chinese Univ Hong Kong, Prince Wales Hosp, Carol & Richard Yu Peritoneal Dialysis Res Ctr, Dept Med & Therapeut, Shatin, Hong Kong, Peoples R China; [Kwok, Jeffrey Sung-Shing; Chan, Michael Ho-Ming; Lit, Lydia Choi-Wan] Chinese Univ Hong Kong, Prince Wales Hosp, Dept Chem Pathol, Shatin, Hong Kong, Peoples R China	Chinese University of Hong Kong; Prince of Wales Hospital; Chinese University of Hong Kong; Prince of Wales Hospital	Szeto, CC (corresponding author), Chinese Univ Hong Kong, Prince Wales Hosp, Carol & Richard Yu Peritoneal Dialysis Res Ctr, Dept Med & Therapeut, Shatin, Hong Kong, Peoples R China.	ccszeto@cuhk.edu.hk	Ming, Chow Kai/Y-5568-2019; Li, Philip K. T./D-4051-2017; Szeto, Cheuk Chun/N-4954-2015; Kwan, Bonnie/N-3463-2015; Ng, Jack KC/L-6473-2019	Ming, Chow Kai/0000-0001-5310-5197; Szeto, Cheuk Chun/0000-0002-8898-8505; Kwan, Bonnie/0000-0001-6742-8480; Ng, Jack KC/0000-0002-9549-9611; Chan, Michael/0000-0003-1949-1666	Baxter Extramural Grant program; Richard Yu Chinese University of Hong Kong (CUHK) PD Research Fund; CUHK research account [6901031]	Baxter Extramural Grant program; Richard Yu Chinese University of Hong Kong (CUHK) PD Research Fund; CUHK research account(Chinese University of Hong Kong)	This study was supported in part by the Baxter Extramural Grant program, the Richard Yu Chinese University of Hong Kong (CUHK) PD Research Fund, and CUHK research account 6901031. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Anders HJ, 2013, KIDNEY INT, V83, P1010, DOI 10.1038/ki.2012.440; Bergstrom J, 1998, PERITON DIALYSIS INT, V18, P467; Bossola M, 2009, CLIN J AM SOC NEPHRO, V4, P379, DOI 10.2215/CJN.03490708; Churchill DN, 1998, J AM SOC NEPHROL, V9, P1285; de Almeida Duarte Joan Bosco, 2004, Urol Res, V32, P266; Dumea R, 2014, INT UROL NEPHROL, V46, P461, DOI 10.1007/s11255-013-0542-8; ENIA G, 1993, NEPHROL DIAL TRANSPL, V8, P1094; Foley RN, 2005, J AM SOC NEPHROL, V16, P489, DOI 10.1681/ASN.2004030203; Harrison LEA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040209; John SG, 2011, CLIN J AM SOC NEPHRO, V6, P2389, DOI 10.2215/CJN.11211210; Kalantar-Zadeh K, 2001, AM J KIDNEY DIS, V38, P1251, DOI 10.1053/ajkd.2001.29222; KREDIET R T, 1986, Blood Purification, V4, P194, DOI 10.1159/000169445; Kwan BCH, 2013, NEPHRON CLIN PRACT, V123, P246, DOI 10.1159/000354714; Kwan BCH, 2013, NEPHROL DIAL TRANSPL, V28, P2139, DOI 10.1093/ndt/gft100; Levin A, 2003, SEMIN DIALYSIS, V16, P101, DOI 10.1046/j.1525-139X.2003.16025.x; McIntyre CW, 2011, CLIN J AM SOC NEPHRO, V6, P133, DOI 10.2215/CJN.04610510; NOE DA, 1991, J PHARM SCI, V80, P501, DOI 10.1002/jps.2600800520; Owen WF, 1998, KIDNEY INT, V54, P627, DOI 10.1046/j.1523-1755.1998.00032.x; Parikh NI, 2006, ARCH INTERN MED, V166, P1884, DOI 10.1001/archinte.166.17.1884; Peritoneal Dialysis Adequacy Work Group, 2001, AM J KIDNEY DIS, V37, pS65; Ramezani A, 2014, J AM SOC NEPHROL, V25, P657, DOI 10.1681/ASN.2013080905; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; Sarnak MJ, 2003, CIRCULATION, V108, P2154, DOI 10.1161/01.CIR.0000095676.90936.80; Selgas R, 1996, Perit Dial Int, V16 Suppl 1, pS215; Stenvinkel P, 1999, KIDNEY INT, V55, P1899, DOI 10.1046/j.1523-1755.1999.00422.x; Stenvinkel P, 2002, NEPHROL DIAL TRANSPL, V17, P33, DOI 10.1093/ndt/17.suppl_8.33; Stoll LL, 2004, ARTERIOSCL THROM VAS, V24, P2227, DOI 10.1161/01.ATV.0000147534.69062.dc; Szeto CC, 2000, KIDNEY INT, V58, P400, DOI 10.1046/j.1523-1755.2000.00179.x; Szeto CC, 2003, J AM SOC NEPHROL, V14, P2119, DOI 10.1097/01.ASN.0000080316.37254.7A; Szeto CC, 2003, NEPHROL DIAL TRANSPL, V18, P977, DOI 10.1093/ndt/gfg027; Szeto CC, 2008, CLIN J AM SOC NEPHRO, V3, P431, DOI 10.2215/CJN.03600807; Szeto CC, 2007, J AM SOC NEPHROL, V18, P1966, DOI 10.1681/ASN.2006101184; Szeto CC, 2007, NEPHROL DIAL TRANSPL, V22, P552, DOI 10.1093/ndt/gfl559; Szeto CC, 2012, AM J NEPHROL, V35, P127, DOI 10.1159/000335580; Szeto CC, 2010, PERITON DIALYSIS INT, V30, P178, DOI 10.3747/pdi.2008.00242; Tripepi G, 2005, J AM SOC NEPHROL, V16, pS83, DOI 10.1681/ASN.2004110972; Wang Angela Y-M, 2005, Curr Opin Investig Drugs, V6, P879; Weiner DE, 2006, AM J KIDNEY DIS, V48, P392, DOI 10.1053/j.ajkd.2006.05.021; Wiedermann CJ, 1999, J AM COLL CARDIOL, V34, P1975, DOI 10.1016/S0735-1097(99)00448-9; Yeun JY, 1997, AM J KIDNEY DIS, V30, P923, DOI 10.1016/S0272-6386(97)90105-0	40	22	22	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 26	2015	10	5							e0125162	10.1371/journal.pone.0125162	http://dx.doi.org/10.1371/journal.pone.0125162			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CJ0QZ	26010741	Green Submitted, Green Published, gold			2023-01-03	WOS:000355183900010
J	Gill, TM; Gahbauer, EA; Han, L; Allore, HG				Gill, Thomas M.; Gahbauer, Evelyne A.; Han, Ling; Allore, Heather G.			The role of intervening hospital admissions on trajectories of disability in the last year of life: prospective cohort study of older people	BMJ-BRITISH MEDICAL JOURNAL			English	Article							RESTRICTED ACTIVITY; SAS PROCEDURE; RISK-FACTORS; CARE; REHABILITATION; PRECIPITANTS; TRANSITIONS; MORTALITY; DISCHARGE; SUBTYPES	OBJECTIVE To evaluate the role of intervening hospital admissions on trajectories of disability in the last year of life. DESIGN Prospective cohort study. SETTING Greater New Haven, Connecticut, United States, from March 1998 to June 2013. PARTICIPANTS 552 decedents from a cohort of 754 community living people, aged 70 years or older, who were initially non-disabled in four essential activities of daily living: bathing, dressing, walking, and transferring. MAIN OUTCOME MEASURE Occurrence of admissions to hospital and severity of disability (range 0-4), ascertained during monthly interviews for more than 15 years. RESULTS In the last year of life, six distinct trajectories of disability were identified, from least disabled to most disabled: 95 participants (17.2%) had no disability, 61 (11.1%) had catastrophic disability, 53 (9.6%) had accelerated disability, 61 (11.1%) had progressively mild disability, 127 (23.0%) had progressively severe disability, and 155 (28.1%) had persistently severe disability. 392 (71.0%) participants had at least one hospital admission and 248 (44.9%) had multiple hospital admissions. For each trajectory the course of disability closely tracked the monthly prevalence of hospital admission. In a set of multivariable models that included several potential confounders, hospital admission in a given month had a strong independent effect on the severity of disability, in both relative and absolute terms. The largest absolute effect was observed for catastrophic disability, with a mean increase in disability score of 1.9 (95% confidence interval 1.5 to 2.4) in the setting of a hospital admission, corresponding to a rate ratio (or relative effect) of 2.0 (95% confidence interval 1.5 to 2.7). CONCLUSIONS In the last year of life, acute hospital admissions play an important role in the disabling process. Knowledge about the course of disability before these intervening events may facilitate clinical decision making at the end of life. For older patients admitted to hospital with progressive or persistent levels of severe disability, representing more than half of the decedents, clinicians might consider a palliative care approach to facilitate discussions about advance care planning and to better deal with personal care needs.	[Gill, Thomas M.; Gahbauer, Evelyne A.; Han, Ling; Allore, Heather G.] Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06510 USA; [Gill, Thomas M.] Adler Geriatr Ctr, New Haven, CT 06510 USA	Yale University	Gill, TM (corresponding author), Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06510 USA.	thomas.gill@yale.edu	Gill, Thomas M./H-7043-2019	Gill, Thomas M./0000-0002-6450-0368; Allore, Heather/0000-0001-7685-8175	National Institute on Aging [R37AG17560, R01AG022993, K07AG043587]; NATIONAL INSTITUTE ON AGING [R37AG017560, R01AG022993, K07AG043587, P30AG021342, P50AG047270] Funding Source: NIH RePORTER	National Institute on Aging(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	This study was supported by grants from the National Institute on Aging (R37AG17560, R01AG022993). The study was conducted at the Yale Claude D Pepper Older Americans Independence Center (P30AG21342). TMG is the recipient of an academic leadership award (K07AG043587) from the National Institute on Aging. The funders had no role in the conduct of the research.	Alpert JS, 2007, AM J MED, V120, P469, DOI 10.1016/j.amjmed.2007.03.006; Carey EC, 2004, J GEN INTERN MED, V19, P1027, DOI 10.1111/j.1525-1497.2004.40016.x; Cohen HJ, 2002, NEW ENGL J MED, V346, P905, DOI 10.1056/NEJMsa010285; Coleman EA, 2006, ARCH INTERN MED, V166, P1822, DOI 10.1001/archinte.166.17.1822; Covinsky KE, 2011, JAMA-J AM MED ASSOC, V306, P1782, DOI 10.1001/jama.2011.1556; CREDITOR MC, 1993, ANN INTERN MED, V118, P219, DOI 10.7326/0003-4819-118-3-199302010-00011; Detsky AS, 2014, JAMA-J AM MED ASSOC, V311, P2169, DOI 10.1001/jama.2014.3695; Diggle PJ, 1994, ANAL LONGITUDINAL DA, V1st; Effron B, 1993, INTRO BOOTSTRAP; Ferrucci L, 1997, JAMA-J AM MED ASSOC, V277, P728; Ferrucci L, 1996, J GERONTOL A-BIOL, V51, pM123, DOI 10.1093/gerona/51A.3.M123; Flood KL, 2013, JAMA INTERN MED, V173, P981, DOI 10.1001/jamainternmed.2013.524; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Gill TM, 2008, J AM GERIATR SOC, V56, P436, DOI 10.1111/j.1532-5415.2007.01603.x; Gill TM, 2014, GERONTOLOGIST, V54, P533, DOI 10.1093/geront/gnu067; Gill TM, 2012, ANN INTERN MED, V156, P131, DOI 10.7326/0003-4819-156-2-201201170-00009; Gill TM, 2010, JAMA-J AM MED ASSOC, V304, P1919, DOI 10.1001/jama.2010.1568; Gill TM, 2010, J AM GERIATR SOC, V58, pS308, DOI 10.1111/j.1532-5415.2010.02914.x; Gill TM, 2010, NEW ENGL J MED, V362, P1173, DOI 10.1056/NEJMoa0909087; Gill TM, 2009, J AM GERIATR SOC, V57, P1850, DOI 10.1111/j.1532-5415.2009.02443.x; Gill TM, 2004, JAMA-J AM MED ASSOC, V292, P2115, DOI 10.1001/jama.292.17.2115; Gill TM, 2004, AM J MED, V117, P484, DOI 10.1016/j.amjmed.2004.05.018; Gill TM, 2006, ARCH INTERN MED, V166, P418, DOI 10.1001/.418; Gill TM, 2002, J AM GERIATR SOC, V50, P1492, DOI 10.1046/j.1532-5415.2002.50403.x; Gill TM, 2001, ANN INTERN MED, V135, P313, DOI 10.7326/0003-4819-135-5-200109040-00007; GURALNIK JM, 1995, NEW ENGL J MED, V332, P556, DOI 10.1056/NEJM199503023320902; Hardy SE, 2005, AM J EPIDEMIOL, V161, P575, DOI 10.1093/aje/kwi083; Hardy SE, 2004, JAMA-J AM MED ASSOC, V291, P1596, DOI 10.1001/jama.291.13.1596; Harrold Joan, 2005, J Palliat Med, V8, P503, DOI 10.1089/jpm.2005.8.503; Hoenig H, 1997, J AM GERIATR SOC, V45, P1371, DOI 10.1111/j.1532-5415.1997.tb02939.x; Inouye SK, 2006, NEW ENGL J MED, V354, P1157, DOI 10.1056/NEJMra052321; Inouye SK, 1998, JAMA-J AM MED ASSOC, V279, P1187, DOI 10.1001/jama.279.15.1187; Jencks SF, 2009, NEW ENGL J MED, V360, P1418, DOI 10.1056/NEJMsa0803563; Jones BL, 2001, SOCIOL METHOD RES, V29, P374, DOI 10.1177/0049124101029003005; Jones BL, 2007, SOCIOL METHOD RES, V35, P542, DOI 10.1177/0049124106292364; Kaplan, 2004, HDB QUANTITATIVE MET, P345, DOI DOI 10.4135/9781412986311.N19; Kellehear, 2014, INNER LIFE DYING PER; LANDEFELD CS, 1995, NEW ENGL J MED, V332, P1338, DOI 10.1056/NEJM199505183322006; Lee AH, 2006, STAT METHODS MED RES, V15, P47, DOI 10.1191/0962280206sm429oa; Nagin D., 2009, GROUP BASED MODELING, DOI [10.4159/9780674041318, DOI 10.4159/9780674041318]; National Hospice and Palliative Care Organization facts and figures, 2013, HOSP CAR AM; Naylor MD, 1999, JAMA-J AM MED ASSOC, V281, P613, DOI 10.1001/jama.281.7.613; Ottenbacher KJ, 2014, JAMA-J AM MED ASSOC, V311, P604, DOI 10.1001/jama.2014.8; Rich MW, 2001, J GERONTOL A-BIOL, V56, pM88, DOI 10.1093/gerona/56.2.M88; Straus SE, 2002, JAMA-J AM MED ASSOC, V288, P1396, DOI 10.1001/jama.288.11.1396; Tinetti ME, 2003, NEW ENGL J MED, V348, P42, DOI 10.1056/NEJMcp020719; Tinetti ME, 2002, JAMA-J AM MED ASSOC, V287, P2098, DOI 10.1001/jama.287.16.2098; US Census Bureau, 2013, AM FACTFINDER	48	74	75	2	14	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 20	2015	350								h2361	10.1136/bmj.h2361	http://dx.doi.org/10.1136/bmj.h2361			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	CI9YZ	25995357	Green Published, hybrid			2023-01-03	WOS:000355128700002
J	Conson, M; Errico, D; Mazzarella, E; Giordano, M; Grossi, D; Trojano, L				Conson, Massimiliano; Errico, Domenico; Mazzarella, Elisabetta; Giordano, Marianna; Grossi, Dario; Trojano, Luigi			Transcranial Electrical Stimulation over Dorsolateral Prefrontal Cortex Modulates Processing of Social Cognitive and Affective Information	PLOS ONE			English	Article							SPATIAL PERSPECTIVE-TAKING; RECOGNITION; BEHAVIOR; FACE; NEUROSCIENCE; ACTIVATION; GENDER; MALES; RISK; SELF	Recent neurofunctional studies suggested that lateral prefrontal cortex is a domain-general cognitive control area modulating computation of social information. Neuropsychological evidence reported dissociations between cognitive and affective components of social cognition. Here, we tested whether performance on social cognitive and affective tasks can be modulated by transcranial direct current stimulation (tDCS) over dorsolateral prefrontal cortex (DLPFC). To this aim, we compared the effects of tDCS on explicit recognition of emotional facial expressions (affective task), and on one cognitive task assessing the ability to adopt another person's visual perspective. In a randomized, cross-over design, male and female healthy participants performed the two experimental tasks after bi-hemispheric tDCS (sham, left anodal/right cathodal, and right anodal/left cathodal) applied over DLPFC. Results showed that only in male participants explicit recognition of fearful facial expressions was significantly faster after anodal right/cathodal left stimulation with respect to anodal left/cathodal right and sham stimulations. In the visual perspective taking task, instead, anodal right/cathodal left stimulation negatively affected both male and female participants' tendency to adopt another's point of view. These findings demonstrated that concurrent facilitation of right and inhibition of left lateral prefrontal cortex can speed-up males' responses to threatening faces whereas it interferes with the ability to adopt another's viewpoint independently from gender. Thus, stimulation of cognitive control areas can lead to different effects on social cognitive skills depending on the affective vs. cognitive nature of the task, and on the gender-related differences in neural organization of emotion processing.	[Conson, Massimiliano; Errico, Domenico; Giordano, Marianna; Grossi, Dario; Trojano, Luigi] Univ Naples 2, Dept Psychol, Neuropsychol Lab, Caserta, Italy; [Mazzarella, Elisabetta] Sci Inst Fdn Santa Lucia, Dept Neuromotor Physiol, Rome, Italy	Universita della Campania Vanvitelli; IRCCS Santa Lucia	Conson, M (corresponding author), Univ Naples 2, Dept Psychol, Neuropsychol Lab, Caserta, Italy.	massimiliano.conson@unina2.it; luigi.trojano@unina2.it	Trojano, Luigi/F-2396-2016; Conson, Massimiliano/AAT-3300-2020	Trojano, Luigi/0000-0002-0328-9642; Conson, Massimiliano/0000-0002-4776-306X				Adolphs R, 1999, TRENDS COGN SCI, V3, P469, DOI 10.1016/S1364-6613(99)01399-6; Adolphs R, 2003, NAT REV NEUROSCI, V4, P165, DOI 10.1038/nrn1056; Boggio PS, 2008, NEUROSCI LETT, V447, P101, DOI 10.1016/j.neulet.2008.10.009; Brass M, 2009, PHILOS T R SOC B, V364, P2359, DOI 10.1098/rstb.2009.0066; Campbell R, 2002, NEUROPSYCHOLOGIA, V40, P575, DOI 10.1016/S0028-3932(01)00164-6; Conson M, 2015, AUTISM RES, V8, P454, DOI 10.1002/aur.1460; Conson M, 2013, FRONT PSYCHOL, V4, DOI 10.3389/fpsyg.2013.00382; David N, 2006, J COGNITIVE NEUROSCI, V18, P898, DOI 10.1162/jocn.2006.18.6.898; DAVIDSON RJ, 1982, SCIENCE, V218, P1235, DOI 10.1126/science.7146906; Decety J, 2006, BRAIN RES, V1079, P4, DOI 10.1016/j.brainres.2005.12.115; Ekman P, 1976, PICTURES FACIAL AFFE; Fecteau S, 2007, J NEUROSCI, V27, P12500, DOI 10.1523/JNEUROSCI.3283-07.2007; Fecteau S, 2007, J NEUROSCI, V27, P6212, DOI 10.1523/JNEUROSCI.0314-07.2007; Feeser M, 2014, BRAIN STIMUL, V7, P105, DOI 10.1016/j.brs.2013.08.006; Frith CD, 2007, CURR BIOL, V17, pR724, DOI 10.1016/j.cub.2007.05.068; Frith CD, 2006, NEURON, V50, P531, DOI 10.1016/j.neuron.2006.05.001; Fumagalli M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008865; Hamann S, 2004, CURR OPIN NEUROBIOL, V14, P233, DOI 10.1016/j.conb.2004.03.010; Hoy KE, 2013, NEUROPSYCHOLOGIA, V51, P1777, DOI 10.1016/j.neuropsychologia.2013.05.018; Kalbe E, 2010, CORTEX, V46, P769, DOI 10.1016/j.cortex.2009.07.010; Kessler K, 2014, P ROY SOC B-BIOL SCI, V281, DOI 10.1098/rspb.2014.0388; Kessler K, 2012, SPAT COGN COMPUT, V12, P133, DOI 10.1080/13875868.2011.634533; Lafontaine MP, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081721; Lapenta OM, 2012, NEUROSCI LETT, V527, P105, DOI 10.1016/j.neulet.2012.08.076; Leslie KR, 2004, NEUROIMAGE, V21, P601, DOI 10.1016/j.neuroimage.2003.09.038; Mathersul D, 2009, J CLIN EXP NEUROPSYC, V31, P278, DOI 10.1080/13803390802043619; Mazzarella E, 2012, Q J EXP PSYCHOL, V65, P2447, DOI 10.1080/17470218.2012.697905; McCleery JP, 2011, J NEUROSCI, V31, P12849, DOI 10.1523/JNEUROSCI.1392-11.2011; Montagne Barbara, 2005, Cogn Process, V6, P136, DOI 10.1007/s10339-005-0050-6; Nakamura A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088628; Nakamura K, 1999, J NEUROPHYSIOL, V82, P1610, DOI 10.1152/jn.1999.82.3.1610; Nitsche M A, 2012, Front Psychiatry, V3, P58, DOI 10.3389/fpsyt.2012.00058; Nitsche MA, 2005, J PHYSIOL-LONDON, V568, P291, DOI 10.1113/jphysiol.2005.092429; Ochsner KN, 2012, ANN NY ACAD SCI, V1251, pE1, DOI 10.1111/j.1749-6632.2012.06751.x; Ochsner KN, 2009, J COGNITIVE NEUROSCI, V21, P1841, DOI 10.1162/jocn.2009.21129; PREMACK D, 1978, BEHAV BRAIN SCI, V1, P515, DOI 10.1017/S0140525X00076512; Ramsey R, 2013, J COGNITIVE NEUROSCI, V25, P670, DOI 10.1162/jocn_a_00345; Rizzolatti G, 2004, ANNU REV NEUROSCI, V27, P169, DOI 10.1146/annurev.neuro.27.070203.144230; Rossion B, 2003, BRAIN, V126, P2381, DOI 10.1093/brain/awg241; Russell M, 2014, FRONT PSYCHIATRY, V5, DOI 10.3389/fpsyt.2014.00104; Samson D, 2005, BRAIN, V128, P1102, DOI 10.1093/brain/awh464; Samson D, 2010, J EXP PSYCHOL HUMAN, V36, P1255, DOI 10.1037/a0018729; Shamay-Tsoory SG, 2007, NEUROPSYCHOLOGIA, V45, P3054, DOI 10.1016/j.neuropsychologia.2007.05.021; Shamay-Tsoory SG, 2007, PSYCHIAT RES, V149, P11, DOI 10.1016/j.psychres.2005.10.018; Shibata H, 2011, NEUROSCI LETT, V491, P187, DOI 10.1016/j.neulet.2011.01.033; Tversky B, 2009, COGNITION, V110, P124, DOI 10.1016/j.cognition.2008.10.008; van Honk J, 2002, BIOL PSYCHIAT, V52, P312, DOI 10.1016/S0006-3223(02)01346-X; Vanderhasselt MA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062219; Vanderhasselt MA, 2013, BIOL PSYCHOL, V92, P433, DOI 10.1016/j.biopsycho.2012.03.005; Weisenbach SL, 2014, SOC COGN AFFECT NEUR, V9, P316, DOI 10.1093/scan/nss137; Weissman DH, 2008, NEUROIMAGE, V40, P955, DOI 10.1016/j.neuroimage.2007.12.021; Zaki J, 2010, J NEUROSCI, V30, P8481, DOI 10.1523/JNEUROSCI.0382-10.2010; Zaki J, 2009, ANN NY ACAD SCI, V1167, P16, DOI 10.1111/j.1749-6632.2009.04601.x; Zar J., 1999, PEARSON, V4th ed.	54	34	34	0	26	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 7	2015	10	5							e0126448	10.1371/journal.pone.0126448	http://dx.doi.org/10.1371/journal.pone.0126448			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CH7KF	25951227	Green Submitted, Green Published, gold			2023-01-03	WOS:000354214400094
J	Robert, S; Peppard, T; Hermann, D				Wallis, Robert S.; Peppard, Thomas; Hermann, David			Month 2 Culture Status and Treatment Duration as Predictors of Recurrence in Pulmonary Tuberculosis: Model Validation and Update	PLOS ONE			English	Article							PHASE-II; MOXIFLOXACIN; ETHAMBUTOL; GATIFLOXACIN; CONVERSION; REGIMENS; ADULTS	Background New regimens capable of shortening tuberculosis treatment without increasing the risk of recurrence are urgently needed. A 2013 meta-regression analysis, using data from trials published from 1973 to 1997 involving 7793 patients, identified 2-month sputum culture status and treatment duration as independent predictors of recurrence. The resulting model predicted that if a new 4-month regimen reduced the proportion of patients positive at month 2 to 1%, it would reduce to 10% the risk of a relapse rate >10% in a trial with 680 subjects per arm. The 1% target was far lower than anticipated. Methods Data from the 8 arms of 3 recent unsuccessful phase 3 treatment-shortening trials of fluoroquinolone-substituted regimens (REMox, OFLOTUB, and RIFAQUIN) were used to assess and refine the accuracy of the 2013 meta-regression model. The updated model was then tested using data from a treatment shortening trial reported in 2009 by Johnson et al. Findings The proportions of patients with recurrence as predicted by the 2013 model were highly correlated with observed proportions as reported in the literature (R2 = 0.86). Using the previously proposed threshold of 10% recurrences as the maximum likely considered acceptable by tuberculosis control programs, the original model correctly identified all 4 six-month regimens as satisfactory, and 3 of 4 four-month regimens as unsatisfactory (sensitivity = 100%, specificity = 75%, PPV = 80%, and NPV = 100%). A revision of the regression model based on the full dataset of 66 regimens and 11181 patients resulted in only minimal changes to its predictions. A test of the revised model using data from the treatment shortening trial of Johnson et al found the reported relapse rates in both arms to be consistent with predictions. Interpretation Meta-regression modeling of recurrence based on month 2 culture status and regimen duration can inform the design of future phase 3 tuberculosis clinical trials.	[Wallis, Robert S.] Aurum Inst, Johannesburg, South Africa; [Peppard, Thomas; Hermann, David] Certara LP, St Louis, MO USA		Robert, S (corresponding author), Aurum Inst, Johannesburg, South Africa.	rwallis@auruminstitute.org	Wallis, Robert S./A-8018-2009	Wallis, Robert S./0000-0001-6152-5183; Peppard, Thomas/0000-0003-2052-4007	Certara, LP	Certara, LP	The authors received no specific funding for this work. Co-authors Thomas Peppard and David Hermann are employed by Certara, LP. Certara, LP provided support in the form of salaries for authors TP and DH, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Agresti A., 1990, CATEGORICAL DATA ANA; Barrett JS, 2008, J CLIN PHARMACOL, V48, P632, DOI 10.1177/0091270008315318; Burman WJ, 2006, AM J RESP CRIT CARE, V174, P331, DOI 10.1164/rccm.200603-360OC; Conde MB, 2009, LANCET, V373, P1183, DOI 10.1016/S0140-6736(09)60333-0; Dorman SE, 2009, AM J RESP CRIT CARE, V180, P273, DOI 10.1164/rccm.200901-0078OC; Gillespie SH, 2014, NEW ENGL J MED, V371, P1577, DOI 10.1056/NEJMoa1407426; Jindani A, 2014, NEW ENGL J MED, V371, P1599, DOI 10.1056/NEJMoa1314210; Johnson JL, 2009, AM J RESP CRIT CARE, V180, P558, DOI 10.1164/rccm.200904-0536OC; JONES BE, 1993, AM REV RESPIR DIS, V148, P1292, DOI 10.1164/ajrccm/148.5.1292; Merle CS, 2014, NEW ENGL J MED, V371, P1588, DOI 10.1056/NEJMoa1315817; MITCHISON DA, 1993, AM REV RESPIR DIS, V147, P1062, DOI 10.1164/ajrccm/147.4.1062; Okwera A, 2006, INT J TUBERC LUNG D, V10, P39; Phillips PPJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063840; Rustomjee R, 2008, INT J TUBERC LUNG D, V12, P128; SAS Institute, 2008, SAS STAT US GUID; Wallis RS, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071116; Wallis RS, 2010, LANCET INFECT DIS, V10, P68, DOI 10.1016/S1473-3099(10)70003-7; Wang JY, 2010, INT J TUBERC LUNG D, V14, P65; WHO, 2014, GLOB TUB REP 2014	19	38	38	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 29	2015	10	4							e0125403	10.1371/journal.pone.0125403	http://dx.doi.org/10.1371/journal.pone.0125403			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CH0LO	25923700	Green Published, Green Submitted, gold			2023-01-03	WOS:000353711600149
J	Kardas-Nelson, M				Kardas-Nelson, Mara			GENERIC DRUGS Can (and should) Africa make its own medicines?	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material												marajenn@gmail.com						African Union-Unido partnership, 2012, PHARM MAN PLAN AFR; de-Graft Aikins Ama, 2010, Global Health, V6, P6, DOI 10.1186/1744-8603-6-6; Lopes C., 2015, MAIL GUARDIAN AFRICA; Marusak Hermann R., 2013, IP WATCH; Medecins Sans Frontieres, 2013, MED SANS FRONT; MSF Access Campaign, 2014, UNT WEB ANT PRIC RED; Ramsurya MV., 2010, EC TIMES; Sidibe M, 2014, B WORLD HEALTH ORGAN, V92, P387, DOI 10.2471/BLT.14.140566; Tomlinson C, 2012, NSP REV; UNAIDS, 2013, ACC ANT THER AFR STA; United Nations Industrial Development Organization, PHARM PROD; Waning B, 2010, J INT AIDS SOC, V13, DOI 10.1186/1758-2652-13-35; World Health Organization, 2011, TRENDS LOC PROD MED	13	1	1	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	APR 28	2015	350								h2178	10.1136/bmj.h2178	http://dx.doi.org/10.1136/bmj.h2178			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CH3UM	25920478				2023-01-03	WOS:000353955900006
J	D'Ambrosio, A; Agricola, E; Russo, L; Gesualdo, F; Pandolfi, E; Bortolus, R; Castellani, C; Lalatta, F; Mastroiacovo, P; Tozzi, AE				D'Ambrosio, Angelo; Agricola, Eleonora; Russo, Luisa; Gesualdo, Francesco; Pandolfi, Elisabetta; Bortolus, Renata; Castellani, Carlo; Lalatta, Faustina; Mastroiacovo, Pierpaolo; Tozzi, Alberto Eugenio			Web-Based Surveillance of Public Information Needs for Informing Preconception Interventions	PLOS ONE			English	Article							HEALTH-PROMOTION; FOLIC-ACID; INTERNET; CARE; RECOMMENDATIONS; MOTHERS; WOMEN	Background The risk of adverse pregnancy outcomes can be minimized through the adoption of healthy lifestyles before pregnancy by women of childbearing age. Initiatives for promotion of preconception health may be difficult to implement. Internet can be used to build tailored health interventions through identification of the public's information needs. To this aim, we developed a semi-automatic web-based system for monitoring Google searches, web pages and activity on social networks, regarding preconception health. Methods Based on the American College of Obstetricians and Gynecologists guidelines and on the actual search behaviors of Italian Internet users, we defined a set of keywords targeting preconception care topics. Using these keywords, we analyzed the usage of Google search engine and identified web pages containing preconception care recommendations. We also monitored how the selected web pages were shared on social networks. We analyzed discrepancies between searched and published information and the sharing pattern of the topics. Results We identified 1,807 Google search queries which generated a total of 1,995,030 searches during the study period. Less than 10% of the reviewed pages contained preconception care information and in 42.8% information was consistent with ACOG guidelines. Facebook was the most used social network for sharing. Nutrition, Chronic Diseases and Infectious Diseases were the most published and searched topics. Regarding Genetic Risk and Folic Acid, a high search volume was not associated to a high web page production, while Medication pages were more frequently published than searched. Vaccinations elicited high sharing although web page production was low; this effect was quite variable in time. Conclusion Our study represent a resource to prioritize communication on specific topics on the web, to address misconceptions, and to tailor interventions to specific populations.	[D'Ambrosio, Angelo; Agricola, Eleonora; Russo, Luisa; Gesualdo, Francesco; Pandolfi, Elisabetta; Tozzi, Alberto Eugenio] Bambino Gesu Pediat Hosp, IRCCS, Multifactorial Dis & Complex Phenotype Res Area, Rome, Italy; [Bortolus, Renata] Verona Univ Hosp, Dept Hosp Management & Pharm, Off Res Promot, Verona, Italy; [Castellani, Carlo] Verona Univ Hosp, Cyst Fibrosis Ctr, Verona, Italy; [Lalatta, Faustina] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Clin Genet Unit, Milan, Italy; [Mastroiacovo, Pierpaolo] Alessandra Lisi Int Ctr Birth Defects & Prematur, Rome, Italy	IRCCS Bambino Gesu; University of Verona; Azienda Ospedaliera Universitaria Integrata Verona; University of Verona; Azienda Ospedaliera Universitaria Integrata Verona; IRCCS Ca Granda Ospedale Maggiore Policlinico	D'Ambrosio, A (corresponding author), Bambino Gesu Pediat Hosp, IRCCS, Multifactorial Dis & Complex Phenotype Res Area, Rome, Italy.	bakaburg1@gmail.com	D'Ambrosio, Angelo/Y-1798-2018; Castellani, Carlo/AAB-3847-2019; Bortolus, Renata/K-6396-2016; Gesualdo, Francesco/H-9221-2012; Tozzi, Alberto Eugenio/F-9494-2012; Pandolfi, Elisabetta/K-5173-2016	D'Ambrosio, Angelo/0000-0002-2045-5155; Bortolus, Renata/0000-0003-3857-4133; Gesualdo, Francesco/0000-0002-9087-4398; Tozzi, Alberto Eugenio/0000-0002-6884-984X; Pandolfi, Elisabetta/0000-0003-2424-2736	Centro nazionale per la prevenzione e il controllo delle malattie (CCM)-Italian Ministry of Health [201301X003129]	Centro nazionale per la prevenzione e il controllo delle malattie (CCM)-Italian Ministry of Health	Centro nazionale per la prevenzione e il controllo delle malattie (CCM)-Italian Ministry of Health. (Grant n. 201301X003129) (http://www.ccmnetwork.it/). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Agricola E, 2013, BMC MED INFORM DECIS, V13, DOI 10.1186/1472-6947-13-14; American College of Obstetricians and Gynecologists, 2005, Obstet Gynecol, V106, P665; Amitai Y, 2004, PREV MED, V39, P731, DOI 10.1016/j.ypmed.2004.02.042; [Anonymous], 2011, Obstet Gynecol, V117, P747, DOI 10.1097/AOG.0b013e318214780e; Atrash H, 2008, AM J OBSTET GYNECOL, V199, pS259, DOI 10.1016/j.ajog.2008.08.059; Ayers JW, 2013, AM J PREV MED, V44, P520, DOI 10.1016/j.amepre.2013.01.012; Bhutta ZA, 2014, LANCET, V384, P347, DOI 10.1016/S0140-6736(14)60792-3; Bock BC, 2008, J MED INTERNET RES, V10, DOI 10.2196/jmir.989; Botto LD, 1999, NEW ENGL J MED, V341, P1509, DOI 10.1056/NEJM199911113412006; Brigo F, 2014, EPILEPSY BEHAV, V31, P67, DOI 10.1016/j.yebeh.2013.11.020; Chunara R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061373; Chung M, 2012, J PEDIATR-US, V161, P1080, DOI 10.1016/j.jpeds.2012.06.004; Committee on Obstetric Practice, 2012, Obstet Gynecol, V120, P416, DOI 10.1097/AOG.0b013e31826804e8; Corchia C, 2013, ITAL J PEDIATR, V39, DOI 10.1186/1824-7288-39-68; Cugelman B, 2011, J MED INTERNET RES, V13, P84, DOI 10.2196/jmir.1367; Dehkordy SF, 2014, ACAD RADIOL, V21, P1172, DOI 10.1016/j.acra.2014.05.005; Delvoye P, 2009, EUR J CONTRACEP REPR, V14, P307, DOI 10.1080/13625180903056123; Gesualdo F, 2010, BMC PUBLIC HEALTH, V10, DOI 10.1186/1471-2458-10-561; Gosselin P, 2008, J MED INTERNET RES, V10, DOI 10.2196/jmir.1127; Helander E, 2014, J MED INTERNET RES, V16, P52, DOI 10.2196/jmir.3084; Jack BW, 2008, AM J OBSTET GYNECOL, V199, pS266, DOI 10.1016/j.ajog.2008.07.067; Larsson M, 2009, MIDWIFERY, V25, P14, DOI 10.1016/j.midw.2007.01.010; Linkov F, 2014, SURG OBES RELAT DIS, V10, P533, DOI 10.1016/j.soard.2013.10.007; Merchant Gina, 2014, J Med Internet Res, V16, pe158, DOI 10.2196/jmir.3267; National Institute of Statistics (ISTAT), 2010, CITT NUOV TECN; Neuhauser L, 2003, J HEALTH PSYCHOL, V8, P7, DOI 10.1177/1359105303008001426; Nicholson L, 2014, BR J OPHTHALMOL, V98; Patton LL, 2014, OR SURG OR MED OR PA, V118, P78, DOI 10.1016/j.oooo.2014.03.019; Plunkett KS, 2002, OBSTET GYN CLIN N AM, V29, P265, DOI 10.1016/S0889-8545(02)00003-7; Shannon GD, 2014, MATERN CHILD HLTH J, V18, P1354, DOI 10.1007/s10995-013-1370-2; Simmering JE, 2014, RES SOC ADMIN PHARM, V10, P896, DOI 10.1016/j.sapharm.2014.01.003; Squiers L, 2013, AM J HEALTH PROMOT, V27, pS10, DOI 10.4278/ajhp.120217-QUAL-95; Stephenson J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103085; Tafuri S, 2014, HUM VACCIN IMMUNOTHE, V10; Tian H, 2009, J MED INTERNET RES, V11, DOI 10.2196/jmir.1278; van der Pal-de Bruin KM, 2000, PAEDIATR PERINAT EP, V14, P111; Vance K, 2009, DERMATOL CLIN, V27, P133, DOI 10.1016/j.det.2008.11.010; Weymann N, 2014, HLTH PROMOT INT	38	3	3	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 16	2015	10	4							e0122551	10.1371/journal.pone.0122551	http://dx.doi.org/10.1371/journal.pone.0122551			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CG1ES	25879682	Green Submitted, gold, Green Published			2023-01-03	WOS:000353016500022
J	Zou, C; Yang, LH; Wu, YC; Su, GB; Chen, SH; Guo, XF; Wu, XQ; Liu, XS; Lin, QZ				Zou, Chuan; Yang, Lihong; Wu, Yuchi; Su, Guobin; Chen, Shuhui; Guo, Xinfeng; Wu, Xiuqing; Liu, Xusheng; Lin, Qizhan			Auricular Acupressure on Specific Points for Hemodialysis Patients with Insomnia: A Pilot Randomized Controlled Trial	PLOS ONE			English	Article							RESTLESS LEGS SYNDROME; SLEEP QUALITY INDEX; DIALYSIS PATIENTS; KIDNEY-DISEASE; OF-LIFE; DISORDERS; RISK	Objectives To assess the feasibility and acceptability of a randomized controlled trial compared auricular acupressure (AA) on specific acupoints with AA on non-specific acupoints for treating maintenance hemodialysis (MHD) patients with insomnia. Methods Sixty three (63) eligible subjects were randomly assigned into either AA group received AA on specific acupoints (n=32), or sham AA (SAA) group received AA on points irrelevant to insomnia treatment (n=31) for eight weeks. All participants were followed up for 12 weeks after treatments. The primary outcome was clinical response at eight weeks after randomization, defined as a reduction of Pittsburgh Sleep Quality Index (PSQI) global score by 3 points and more. Results Fifty-eight (58) participants completed the trial and five dropped out. Twenty participants in AA group (62.5%) and ten in SAA group (32.3%) responded to the eight-week interventions (chi(2) = 5.77, P = 0.02). PSQI global score declined 3.75 +/- 4.36 (95% CI -5.32, -2.18) and 2.26 +/- 3.89 (95% CI -3.68, -0.83) in AA group and SAA group respectively. Three participants died during the follow-up period. No evidence supported their deaths were related to the AA intervention. No other adverse event was observed. Conclusion Feasibility and logistics of patient recruitment, randomization procedure, blinding approach, interventions application and outcome assessment had been tested in this pilot trial. The preliminary data appeared to show a favorable result on AA treatment. A full-scale trial is warranted.	[Zou, Chuan; Wu, Yuchi; Su, Guobin; Wu, Xiuqing; Liu, Xusheng; Lin, Qizhan] Guangdong Prov Hosp Chinese Med, Nephrol Ctr, Guangzhou, Guangdong, Peoples R China; [Yang, Lihong; Chen, Shuhui; Guo, Xinfeng] Guangzhou Univ Chinese Med, Guangdong Prov Acad Chinese Med Sci, Evidence Based Med & Clin Res Serv Grp, Guangdong Prov Hosp Chinese Med,Clin Coll,Affilia, Guangzhou, Guangdong, Peoples R China	Guangzhou University of Chinese Medicine; Guangzhou University of Chinese Medicine	Lin, QZ (corresponding author), Guangdong Prov Hosp Chinese Med, Nephrol Ctr, Guangzhou, Guangdong, Peoples R China.	linqizhan656635@163.com	Su, Guobin/AAD-8807-2020; Guo, Xinfeng/AAG-6818-2019; GUO, Xinfeng/AAM-6850-2021	Su, Guobin/0000-0001-5073-9848; Guo, Xinfeng/0000-0003-2699-9740; Yang, Lihong/0000-0001-6497-1680	Project of Research Studio of Famous Old TCM Practitioners Experience Heritage, State Administration of Traditional Chinese Medicine [2012KT1301]; Research Project for Practice Development of National TCM Clinical Research Bases, P.R. China [201007005]	Project of Research Studio of Famous Old TCM Practitioners Experience Heritage, State Administration of Traditional Chinese Medicine; Research Project for Practice Development of National TCM Clinical Research Bases, P.R. China	This work was supported by the Project of Research Studio of Famous Old TCM Practitioners Experience Heritage, State Administration of Traditional Chinese Medicine (Grant No. 2012KT1301); and Research Project for Practice Development of National TCM Clinical Research Bases, P.R. China (Grant No. 201007005). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abbate S, 2003, CHINESE AURICULAR AC; American Psychiatric Association, DIAGN STAT MAN MENT, V4th; Anand S, 2013, HEMODIAL INT, V17, P50, DOI 10.1111/j.1542-4758.2012.00726.x; [Anonymous], 2011, J MED SCI, DOI DOI 10.3923/JMS.2011.236.240; Bonnet M H, 1997, Sleep Med Rev, V1, P97, DOI 10.1016/S1087-0792(97)90012-5; Bornivelli C, 2008, J NEPHROL, V21, pS78; Buysse DJ, 2011, ARCH INTERN MED, V171, P887, DOI 10.1001/archinternmed.2010.535; BUYSSE DJ, 1989, PSYCHIAT RES, V28, P193, DOI 10.1016/0165-1781(89)90047-4; Cengic B, 2012, INT UROL NEPHROL, V44, P557, DOI 10.1007/s11255-010-9881-x; Chiu YL, 2009, NEPHROL DIAL TRANSPL, V24, P247, DOI 10.1093/ndt/gfn439; Elder SJ, 2008, NEPHROL DIAL TRANSPL, V23, P998, DOI 10.1093/ndt/gfm630; Erden I, 2010, BLOOD PRESS MONIT, V15, P184, DOI 10.1097/MBP.0b013e32833a23a0; Esposito MG, 2008, J NEPHROL, V21, pS92; Hanly PJ, 2001, NEW ENGL J MED, V344, P102, DOI 10.1056/NEJM200101113440204; HAYS RD, 1994, QUAL LIFE RES, V3, P329, DOI 10.1007/BF00451725; He W, 2013, BMC NEUROSCI, V14, DOI 10.1186/1471-2202-14-85; Huang YL, 2011, BLOOD PRESS MONIT, V16, P117, DOI [10.1097/MBP.0b013e328346a8b4, 10.1097/MBP.0b013e32834c672d]; Liu XC, 1996, CHIN J PSYCHIAT, V29, P103; Malaki M, 2012, SAUDI J KIDNEY DIS T, V23, P15; Merlino G, 2008, J NEPHROL, V21, pS66; Molnar MZ, 2005, AM J KIDNEY DIS, V45, P388, DOI 10.1053/j.ajkd.2004.10.007; Morin CM, 2013, SLEEP MED CLIN, V8, P281, DOI 10.1016/j.jsmc.2013.05.002; National Institutes of Health, 2005, Sleep, V28, P1049; Novak M, 2006, SEMIN DIALYSIS, V19, P25, DOI 10.1111/j.1525-139X.2006.00116.x; Ramos RW, 2013, SLEEP MED S1, V14, pe240; Razeghi E, 2012, ACTA NEUROL BELG, V112, P45, DOI 10.1007/s13760-012-0003-7; Roumelioti ME, 2010, NEPHROL DIAL TRANSPL, V25, P3733, DOI 10.1093/ndt/gfq234; Suen LKP, 2003, COMPLEMENT THER MED, V11, P85, DOI 10.1016/S0965-2299(03)00041-4; Tsai PS, 2005, QUAL LIFE RES, V14, P1943, DOI 10.1007/s11136-005-4346-x; Ueno N, 1993, Nihon Jibiinkoka Gakkai Kaiho, V96, P212; Unruh ML, 2006, CLIN J AM SOC NEPHRO, V1, P802, DOI 10.2215/CJN.00710206; Winkelmann J, 2002, MOVEMENT DISORD, V17, P1072, DOI 10.1002/mds.10231; Wu YC, 2014, J ALTERN COMPLEM MED, V20, P356, DOI 10.1089/acm.2013.0319; Yan J., 2006, SKILLS ILLUSTRATIONS; Yeung WF, 2012, SLEEP MED, V13, P971, DOI 10.1016/j.sleep.2012.06.003; Zhang CS, 2014, J ALTERN COMPLEM MED, V20, P147, DOI 10.1089/acm.2013.0238; Zhang Hongwei, 2010, Chin Med, V5, P1, DOI 10.1186/1749-8546-5-1	37	18	20	3	24	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 15	2015	10	4							e0122724	10.1371/journal.pone.0122724	http://dx.doi.org/10.1371/journal.pone.0122724			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CG1EL	25874938	gold, Green Published, Green Submitted			2023-01-03	WOS:000353015800073
J	Gudzune, KA; Doshi, RS; Mehta, AK; Chaudhry, ZW; Jacobs, DK; Vakil, RM; Lee, CJ; Bleich, SN; Clark, JM				Gudzune, Kimberly A.; Doshi, Ruchi S.; Mehta, Ambereen K.; Chaudhry, Zoobia W.; Jacobs, David K.; Vakil, Rachit M.; Lee, Clare J.; Bleich, Sara N.; Clark, Jeanne M.			Efficacy of Commercial Weight-Loss Programs An Updated Systematic Review	ANNALS OF INTERNAL MEDICINE			English	Review							RANDOMIZED CONTROLLED-TRIAL; LOW-CALORIE DIET; LOW-FAT DIET; LOW-CARBOHYDRATE DIET; OLDER OBESE ADULTS; MEAL REPLACEMENTS; GLYCEMIC CONTROL; OVERWEIGHT WOMEN; KETOGENIC DIET; RISK-FACTORS	Background: Commercial and proprietary weight-loss programs are popular obesity treatment options, but their efficacy is unclear. Purpose: To compare weight loss, adherence, and harms of commercial or proprietary weight-loss programs versus control/education (no intervention, printed materials only, health education curriculum, or <3 sessions with a provider) or behavioral counseling among overweight and obese adults. Data Sources: MEDLINE and the Cochrane Database of Systematic Reviews from inception to November 2014; references identified by program staff. Study Selection: Randomized, controlled trials (RCTs) of at least 12 weeks' duration; prospective case series of at least 12 months' duration (harms only). Data Extraction: Two reviewers extracted information on study design, population characteristics, interventions, and mean percentage of weight change and assessed risk of bias. Data Synthesis: We included 45 studies, 39 of which were RCTs. At 12 months, Weight Watchers participants achieved at least 2.6% greater weight loss than those assigned to control/education. Jenny Craig resulted in at least 4.9% greater weight loss at 12 months than control/education and counseling. Nutri-system resulted in at least 3.8% greater weight loss at 3 months than control/education and counseling. Very-low-calorie programs (Health Management Resources, Medifast, and OPTIFAST) resulted in at least 4.0% greater short-term weight loss than counseling, but some attenuation of effect occurred beyond 6 months when reported. Atkins resulted in 0.1% to 2.9% greater weight loss at 12 months than counseling. Results for SlimFast were mixed. We found limited evidence to evaluate adherence or harms for all programs and weight outcomes for other commercial programs. Limitation: Many trials were short (<12 months), had high attrition, and lacked blinding. Conclusion: Clinicians could consider referring overweight or obese patients to Weight Watchers or Jenny Craig. Other popular programs, such as Nutrisystem, show promising weight-loss results; however, additional studies evaluating long-term outcomes are needed.	Johns Hopkins Univ, Sch Med, Baltimore, MD 21287 USA; Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA; Welch Ctr Prevent Epidemiol & Clin Res, Baltimore, MD USA; Johns Hopkins Bayview Med Ctr, Baltimore, MD USA; Univ Maryland, Sch Med, Baltimore, MD 21201 USA; Rutgers Robert Wood Johnson Med Sch, Piscataway, NJ USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Johns Hopkins University; Johns Hopkins Medicine; University System of Maryland; University of Maryland Baltimore; Rutgers State University New Brunswick; Rutgers State University Medical Center	Gudzune, KA (corresponding author), Johns Hopkins Univ, Sch Med, Div Gen Internal Med, 2024 East Monument St,Room 2-621, Baltimore, MD 21287 USA.	gudzune@jhu.edu	Clark, Jeanne/AGG-8199-2022	Clark, Jeanne/0000-0003-1194-0092; Lee, Clare/0000-0002-0824-0207	career development award from the National Heart, Lung, and Blood Institute [K23HL116601, 1K01HL096409]; Johns Hopkins medical student summer research program; medical student research program in diabetes at JHU-UMD Diabetes Research Center (National Institute of Diabetes and Digestive and Kidney Diseases) [P30DK079637]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [TL1TR001078, KL2TR001077] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K01HL096409, K23HL116601] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK079637] Funding Source: NIH RePORTER	career development award from the National Heart, Lung, and Blood Institute; Johns Hopkins medical student summer research program; medical student research program in diabetes at JHU-UMD Diabetes Research Center (National Institute of Diabetes and Digestive and Kidney Diseases); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	Dr. Gudzune was supported by a career development award from the National Heart, Lung, and Blood Institute (K23HL116601). Ms. Doshi was supported by the Johns Hopkins medical student summer research program. Mr. Jacobs was supported by the medical student research program in diabetes at JHU-UMD Diabetes Research Center (National Institute of Diabetes and Digestive and Kidney Diseases grant P30DK079637). Dr. Bleich was supported by a career development award from the National Heart, Lung, and Blood Institute (1K01HL096409).	Ahrens Renee A, 2003, J Am Pharm Assoc (2003), V43, P583; Allen JK, 2013, J OBES, V2013, DOI 10.1155/2013/151597; Anderson JW, 2011, POSTGRAD MED, V123, P205, DOI 10.3810/pgm.2011.09.2476; ANDERSON JW, 1994, DIABETES CARE, V17, P602, DOI 10.2337/diacare.17.6.602; ANDERSON JW, 1991, J AM DIET ASSOC, V91, P1582; Appel LJ, 2003, JAMA-J AM MED ASSOC, V289, P2083, DOI 10.1001/jama.289.16.2083; Ashley JM, 2007, NUTR J, V6, DOI 10.1186/1475-2891-6-12; Bischoff SC, 2012, INT J OBESITY, V36, P614, DOI 10.1038/ijo.2011.107; Bleich SN, 2013, J GEN INTERN MED, V28, P3, DOI 10.1007/s11606-012-2201-7; Bray GA, 2009, LANCET, V374, P1677, DOI 10.1016/S0140-6736(09)61457-4; Clifton PM, 2005, INT J OBESITY, V29, P1445, DOI 10.1038/sj.ijo.0803039; Collins CE, 2012, J MED INTERNET RES, V14, DOI 10.2196/jmir.1980; Collins CE, 2010, BMC PUBLIC HEALTH, V10, DOI 10.1186/1471-2458-10-669; Dansinger ML, 2005, JAMA-J AM MED ASSOC, V293, P43, DOI 10.1001/jama.293.1.43; Davis LM, 2010, NUTR J, V9, DOI 10.1186/1475-2891-9-11; Davis NJ, 2009, DIABETES CARE, V32, P1147, DOI 10.2337/dc08-2108; Ditschuneit HH, 1999, AM J CLIN NUTR, V69, P198; Ditschuneit HH, 2002, EUR J CLIN NUTR, V56, P264, DOI 10.1038/sj.ejcn.1601375; Ditschuneit HH, 2001, OBES RES, V9, p284S, DOI 10.1038/oby.2001.132; DOHERTY JU, 1991, AM J CLIN NUTR, V53, P854, DOI 10.1093/ajcn/53.4.854; Donnelly JE, 2007, INT J OBESITY, V31, P1270, DOI 10.1038/sj.ijo.0803568; Dow CA, 2013, J AM HEART ASSOC, V2, DOI 10.1161/JAHA.113.000152; Figueroa A, 2013, AM J HYPERTENS, V26, P416, DOI 10.1093/ajh/hps050; Finkelstein EA, 2014, OBESITY, V22, P1942, DOI 10.1002/oby.20824; Finley CE, 2007, INT J OBESITY, V31, P292, DOI 10.1038/sj.ijo.0803395; Flechtner-Mors M, 2000, OBES RES, V8, P399, DOI 10.1038/oby.2000.48; Flegal KM, 2007, JAMA-J AM MED ASSOC, V298, P2028, DOI 10.1001/jama.298.17.2028; Foster GD, 2013, NUTR DIABETES, V3, DOI 10.1038/nutd.2013.3; Foster GD, 2010, ANN INTERN MED, V153, P147, DOI 10.7326/0003-4819-153-3-201008030-00005; Foster GD, 2009, POSTGRAD MED, V121, P113, DOI 10.3810/pgm.2009.09.2046; Foster GD, 2003, NEW ENGL J MED, V348, P2082, DOI 10.1056/NEJMoa022207; Friedman AN, 2012, CLIN J AM SOC NEPHRO, V7, P1103, DOI 10.2215/CJN.11741111; Gardner CD, 2007, JAMA-J AM MED ASSOC, V297, P969, DOI 10.1001/jama.297.9.969; Greenberg I, 2009, J AM COLL NUTR, V28, P159, DOI 10.1080/07315724.2009.10719767; Heshka S, 2000, AM J MED, V109, P282, DOI 10.1016/S0002-9343(00)00494-0; Heshka S, 2003, JAMA-J AM MED ASSOC, V289, P1792, DOI 10.1001/jama.289.14.1792; Higgins J, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.ED000049; Hutchesson MJ, 2014, EUR J CLIN NUTR, V68, P64, DOI 10.1038/ejcn.2013.194; IBISWorld, 2014, WEIGHT LOSS SERV US; Jebb SA, 2011, LANCET, V378, P1485, DOI 10.1016/S0140-6736(11)61344-5; Jensen MD, 2014, CIRCULATION, V129, pS102, DOI 10.1161/01.cir.0000437739.71477.ee; Johansson K, 2014, INT J OBESITY, V38, P279, DOI 10.1038/ijo.2013.83; Johnston BC, 2014, JAMA-J AM MED ASSOC, V312, P923, DOI 10.1001/jama.2014.10397; Johnston CA, 2013, AM J MED, V126, DOI 10.1016/j.amjmed.2013.04.025; Jolly K, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d6500; Jolly K, 2010, BMC PUBLIC HEALTH, V10, DOI 10.1186/1471-2458-10-439; Kaiser Commission on Medicaid and the Uninsured, 2012, COV PREV SERV AD MED; Kirschner M A, 1979, J Med Soc N J, V76, P175; Lee JS, 2010, PUBLIC HEALTH REP, V125, P596, DOI 10.1177/003335491012500415; Li Z, 2005, EUR J CLIN NUTR, V59, P411, DOI 10.1038/sj.ejcn.1602089; Madigan CD, 2014, BRIT J GEN PRACT, V64, pE128, DOI 10.3399/bjgp14X677491; McAuley KA, 2005, DIABETOLOGIA, V48, P8, DOI 10.1007/s00125-004-1603-4; Miller GD, 2010, J NUTR HEALTH AGING, V14, P461; Miller GD, 2006, OBESITY, V14, P1219, DOI 10.1038/oby.2006.139; Mitchell NS, 2013, J GEN INTERN MED, V28, P12, DOI 10.1007/s11606-012-2083-8; Moore SD, 2011, EAT BEHAV, V12, P60, DOI 10.1016/j.eatbeh.2010.08.007; Morgan LM, 2009, PUBLIC HEALTH NUTR, V12, P799, DOI 10.1017/S1368980008003236; Noakes M, 2004, J NUTR, V134, P1894, DOI 10.1093/jn/134.8.1894; Ogden CL, 2014, JAMA-J AM MED ASSOC, V311, P806, DOI 10.1001/jama.2014.732; Perna F, 1999, J EXERC PHYSL ONLINE, V2, P2; Pinto AM, 2013, OBESITY, V21, P673, DOI 10.1002/oby.20044; Rippe JM, 1998, OBES RES, V6, P208, DOI 10.1002/j.1550-8528.1998.tb00339.x; Rock CL, 2007, OBESITY, V15, P939, DOI 10.1038/oby.2007.614; Rock CL, 2014, DIABETES CARE, V37, P1573, DOI 10.2337/dc13-2900; Rock CL, 2010, JAMA-J AM MED ASSOC, V304, P1803, DOI 10.1001/jama.2010.1503; Saad L, 2011, GALLUP POLL SOCIAL S; Sebelius K., 2014, REPORT C PREVENTIVE; Shai I, 2008, NEW ENGL J MED, V359, P229, DOI 10.1056/NEJMoa0708681; Smith BC, 2009, ANAL BIOCHEM, V394, P101, DOI 10.1016/j.ab.2009.07.019; Tirosh A, 2013, DIABETES CARE, V36, P2225, DOI 10.2337/dc12-1846; Truby H, 2006, BMJ-BRIT MED J, V332, P1309, DOI 10.1136/bmj.38833.411204.80; Tsai AG, 2005, ANN INTERN MED, V142, P56, DOI 10.7326/0003-4819-142-1-200501040-00012; Tsertsvadze A, 2011, AHRQ PUBLICATION; US Preventive Services Task Force, 2012, OB AD SCREEN MAN; WADDEN TA, 1992, ARCH INTERN MED, V152, P961, DOI 10.1001/archinte.152.5.961; Wadden TA, 1998, J CLIN ENDOCR METAB, V83, P214, DOI 10.1210/jc.83.1.214; Wadden TA, 2004, AM J CLIN NUTR, V80, P560; Walker CG, 2013, OBESITY, V21, P2589, DOI 10.1002/oby.20328; Westman EC, 2006, INT J CARDIOL, V110, P212, DOI 10.1016/j.ijcard.2005.08.034; WING RR, 1994, AM J MED, V97, P354, DOI 10.1016/0002-9343(94)90302-6; Womble LG, 2004, OBES RES, V12, P1011, DOI 10.1038/oby.2004.124; Yancy WS, 2009, QUAL LIFE RES, V18, P281, DOI 10.1007/s11136-009-9444-8; Yancy WS, 2004, ANN INTERN MED, V140, P769, DOI 10.7326/0003-4819-140-10-200405180-00006; Yip I, 2001, OBES RES, V9, p341S, DOI 10.1038/oby.2001.140	84	195	199	0	105	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 7	2015	162	7					501	+		10.7326/M14-2238	http://dx.doi.org/10.7326/M14-2238			14	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CG4UT	25844997	Green Accepted			2023-01-03	WOS:000353283400005
J	Pinheiro, MMG; Miltojevic, AB; Radulovic, NS; Abdul-Wahab, IR; Boylan, F; Fernandes, PD				Gomes Pinheiro, Mariana Martins; Miltojevic, Ana B.; Radulovic, Niko S.; Abdul-Wahab, Ikarastika Rahayu; Boylan, Fabio; Fernandes, Patricia Dias			Anti-Inflammatory Activity of Choisya ternata Kunth Essential Oil, Ternanthranin, and Its Two Synthetic Analogs (Methyl and Propyl N-Methylanthranilates)	PLOS ONE			English	Article							EXCITATORY AMINO-ACIDS; FORMALIN TEST; LEUKOCYTE RECRUITMENT; ACUTE-INFLAMMATION; MODEL; RAT; MECHANISMS; RUTACEAE; RELEASE; CARRAGEENAN	Choisya ternata Kunth (Rutaceae) is native to North America where it is popularly known as "Mexican orange". In this study, the anti-inflammatory effects of the essential oil (EO) obtained from the leaves of C. ternata, one of its minor components (ternanthranin-ISOAN) and its two synthetic analogues (methyl and propyl N-methylanthranilate - MAN and PAN) were evaluated. Mice pretreated with the EO (EO) obtained from C. ternata leaves (3-100 mg/kg, p.o.), ISOAN, MAN or PAN (1-30 mg/kg, p.o.) and the reference drugs, morphine (1 mg/kg, p.o.) and acetylsalicylic acid (ASA, 100 mg/kg, p.o.), were evaluated in inflammation models such as formalin and subcutaneous air pouch models, with measurement of cell migration, exudate volume, protein extravasation, nitric oxide and pro-inflammatory cytokines. The EO from C. ternata significantly inhibited the time that the animals spent licking the formalin-injected paw in the second phase of the model at their higher doses (30 and 100 mg/kg, respectively). An inhibition of the inflammatory reaction induced after subcutaneous carrageenan injection into air pouch was also observed. In this model, the EO significantly reduced cell migration, exudate volume, protein extravased, and the increase in levels of inflammatory mediators (nitric oxide, TNF-alpha and IL-1 beta). ISOAN, MAN and PAN behaved in the same fashion at much smaller doses. Also, these molecules were able to show significant effects in the reduction of paw edema (at all tested doses) when the phlogistic agent was carrageenan, bradykinin, 5-HT, PGE2, C48/80 or 12-O-tetradecanoyl-phorbol-acetate (TPA). None of the tested doses had any effect in reducing histamine-induced edema. Our results indicate that the EO from C. ternata and anthranilate derivatives demonstrates an anti-inflammatory effect.	[Gomes Pinheiro, Mariana Martins; Fernandes, Patricia Dias] Univ Fed Rio de Janeiro, Inst Ciencias Biomed, Lab Farmacol Dor & Inflamacao, Rio De Janeiro, Brazil; [Miltojevic, Ana B.; Radulovic, Niko S.] Univ Nis, Fac Sci & Math, Dept Chem, Nish 18000, Serbia; [Abdul-Wahab, Ikarastika Rahayu; Boylan, Fabio] Trinity Coll Dublin, Sch Pharm & Pharmaceut Sci, Trinity Biomed Sci Inst, Dublin 2, Ireland	Universidade Federal do Rio de Janeiro; University of Nis; Trinity College Dublin	Fernandes, PD (corresponding author), Univ Fed Rio de Janeiro, Inst Ciencias Biomed, Lab Farmacol Dor & Inflamacao, Rio De Janeiro, Brazil.	patricia.dias@icb.ufrj.br	Boylan, Fabio/K-9707-2015; Fernandes, Patricia Dias/C-4489-2013; Fernandes, Patricia Dias/W-1565-2019; Abdul Wahab, Ikarastika Rahayu/D-8571-2013	Boylan, Fabio/0000-0001-5531-1787; Fernandes, Patricia Dias/0000-0001-6870-6745; Fernandes, Patricia Dias/0000-0001-6870-6745; Abdul Wahab, Ikarastika Rahayu/0000-0003-1329-5322; Radulovic, Niko/0000-0003-1342-7567; Miltojevic, Ana/0000-0002-8073-1641	Conselho Nacional de Desenvolvimento Cientifico e Tecnologico [401683/2013-3, 473106/2012-4]; Fundacao Carlos Chagas Filho de Apoio a Pesquisa do Estado do Rio de Janeiro [E-26/010.001643/2014]	Conselho Nacional de Desenvolvimento Cientifico e Tecnologico(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)); Fundacao Carlos Chagas Filho de Apoio a Pesquisa do Estado do Rio de Janeiro	This work was supported by Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (#401683/2013-3 and 473106/2012-4); Fundacao Carlos Chagas Filho de Apoio a Pesquisa do Estado do Rio de Janeiro (E-26/010.001643/2014). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Barreiro EJ, 2009, QUIM NOVA, V32, P679, DOI 10.1590/S0100-40422009000300012; Beninca JP, 2011, FOOD CHEM, V124, P468, DOI 10.1016/j.foodchem.2010.06.056; Butchar JP, 2006, CURR PHARM DESIGN, V12, P4143, DOI 10.2174/138161206778743574; Chavan MJ, 2010, PHYTOMEDICINE, V17, P149, DOI 10.1016/j.phymed.2009.05.016; CRECHE J, 1987, PHYTOCHEMISTRY, V26, P1947, DOI 10.1016/S0031-9422(00)81735-5; Creche J, 1993, BIOTECHNOLOGY AGR FO, P107; Cunha TM, 2005, P NATL ACAD SCI USA, V102, P1755, DOI 10.1073/pnas.0409225102; Dal Secco D, 2003, NITRIC OXIDE-BIOL CH, V9, P153, DOI 10.1016/j.niox.2003.11.001; DENIZOT F, 1986, J IMMUNOL METHODS, V89, P271, DOI 10.1016/0022-1759(86)90368-6; Ding Y, 2010, BIOORG MED CHEM LETT, V20, P1528, DOI 10.1016/j.bmcl.2010.01.096; DIROSA M, 1972, J PHARM PHARMACOL, V24, P89, DOI 10.1111/j.2042-7158.1972.tb08940.x; DREYER DL, 1980, PHYTOCHEMISTRY, V19, P935, DOI 10.1016/0031-9422(80)85141-7; FERREIRA S H, 1979, Journal of Pharmacy and Pharmacology, V31, P648; Ferro VA, 2007, METHODS, V42, P313, DOI 10.1016/j.ymeth.2007.05.005; FIELD L, 1978, J CHEM SOC CHEM COMM, P249, DOI 10.1039/c39780000249; FOSTER SJ, 1986, BIOCHEM PHARMACOL, V35, P1709, DOI 10.1016/0006-2952(86)90328-X; Vigil SV, 2008, TRANSPL IMMUNOL, V19, P25, DOI 10.1016/j.trim.2008.01.003; Pinheiro MMG, 2014, EUR J PHARMACOL, V727, P106, DOI 10.1016/j.ejphar.2013.12.042; GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X; Guerra ASHD, 2011, INT IMMUNOPHARMACOL, V11, P1816, DOI 10.1016/j.intimp.2011.07.010; HUNSKAAR S, 1987, PAIN, V30, P103, DOI 10.1016/0304-3959(87)90088-1; Kelly M, 2007, J ALLERGY CLIN IMMUN, V120, P3, DOI 10.1016/j.jaci.2007.05.017; LEVINE JD, 1984, SCIENCE, V225, P743, DOI 10.1126/science.6087456; Lima DF, 2012, J PHARM PHARMACOL, V64, P283, DOI 10.1111/j.2042-7158.2011.01401.x; MALMBERG AB, 1995, BRIT J PHARMACOL, V114, P1069, DOI 10.1111/j.1476-5381.1995.tb13315.x; Martin MU, 2002, BBA-MOL CELL RES, V1592, P265, DOI 10.1016/S0167-4889(02)00320-8; MARTIN SW, 1994, J PHARMACOL TOX MET, V32, P139, DOI 10.1016/1056-8719(94)90067-1; Martinez V, 1999, PAIN, V81, P179, DOI 10.1016/S0304-3959(99)00008-1; Matheus ME, 2007, EUR J PHARMACOL, V556, P200, DOI 10.1016/j.ejphar.2006.10.057; McRoberts JA, 2011, NEUROSCIENCE, V172, P474, DOI 10.1016/j.neuroscience.2010.10.045; MONCADA S, 1993, NEW ENGL J MED, V329, P2002; Omote K, 1998, BRAIN RES, V787, P161, DOI 10.1016/S0006-8993(97)01568-0; Parada CA, 2001, NEUROSCIENCE, V102, P937, DOI 10.1016/S0306-4522(00)00523-6; Radulovic N.S., 2013, FU PHYS CHEM TECH, V11, P67, DOI [10.2298/FUPCT1301067R, DOI 10.2298/FUPCT1301067R]; Radulovic NS, 2013, LIFE SCI, V93, P840, DOI 10.1016/j.lfs.2013.10.002; Radulovic NS, 2013, PHYTOTHER RES, V27, P1334, DOI 10.1002/ptr.4877; Radulovic NS, 2011, J ETHNOPHARMACOL, V135, P610, DOI 10.1016/j.jep.2011.03.035; RAO VSN, 1990, J PHARM PHARMACOL, V42, P877, DOI 10.1111/j.2042-7158.1990.tb07046.x; Raymundo LJRP, 2011, J ETHNOPHARMACOL, V134, P725, DOI 10.1016/j.jep.2011.01.027; RIDEAU M, 1979, PHYTOCHEMISTRY, V18, P155, DOI 10.1016/S0031-9422(00)90936-1; Romano M, 1997, MEDIAT INFLAMM, V6, P32, DOI 10.1080/09629359791901; ROSLAND JH, 1990, PAIN, V42, P235, DOI 10.1016/0304-3959(90)91167-H; Santos ARS, 1997, NEUROPEPTIDES, V31, P381, DOI 10.1016/S0143-4179(97)90075-5; Schmid-Schonbein GW, 2006, ANNU REV BIOMED ENG, V8, P93, DOI 10.1146/annurev.bioeng.8.061505.095708; Schmidt N, 2010, BIOCHEM PHARMACOL, V79, P722, DOI 10.1016/j.bcp.2009.10.012; SEJOURNE M, 1981, PHYTOCHEMISTRY, V20, P353, DOI 10.1016/0031-9422(81)85129-1; SHIBATA M, 1989, PAIN, V38, P347, DOI 10.1016/0304-3959(89)90222-4; Smiderle FR, 2008, EUR J PHARMACOL, V597, P86, DOI 10.1016/j.ejphar.2008.08.028; TEA K N, 1975, Plantes Medicinales et Phytotherapie, V9, P187; Tjolsen A, 1992, PAIN, V30, P103; Tracey KJ, 2002, NATURE, V420, P853, DOI 10.1038/nature01321; Wahab IRA, 2012, PLANTA MED, V78, P1597, DOI 10.1055/s-0032-1315044; Waterman P. G., 1973, Biochemical Systematics, V1, P153, DOI 10.1016/0305-1978(73)90006-9; Yashpal K, 1998, EUR J PAIN-LONDON, V2, P63, DOI 10.1016/S1090-3801(98)90047-7; Yoshimura A, 2006, CANCER SCI, V97, P439, DOI 10.1111/j.1349-7006.2006.00197.x; Zanardo RCO, 2006, FASEB J, V20, P2118, DOI 10.1096/fj.06-6270fje	56	17	17	0	16	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 25	2015	10	3							e0121063	10.1371/journal.pone.0121063	http://dx.doi.org/10.1371/journal.pone.0121063			21	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CE5MO	25807367	Green Published, Green Submitted, gold			2023-01-03	WOS:000351880000128
J	Basnet, S; Sharma, A; Mathisen, M; Shrestha, PS; Ghimire, RK; Shrestha, DM; Valentiner-Branth, P; Sommerfelt, H; Strand, TA				Basnet, Sudha; Sharma, Arun; Mathisen, Maria; Shrestha, Prakash Sunder; Ghimire, Ram Kumar; Shrestha, Dhiraj Man; Valentiner-Branth, Palle; Sommerfelt, Halvor; Strand, Tor A.			Predictors of Duration and Treatment Failure of Severe Pneumonia in Hospitalized Young Nepalese Children	PLOS ONE			English	Article							RANDOMIZED CONTROLLED-TRIAL; CHILDHOOD PNEUMONIA; PULSE OXIMETRY; RISK-FACTORS; OXYGEN; MORTALITY	Background Pneumonia in young children is still the most frequent cause of death in developing countries. We aimed to identify predictors for recovery and treatment failure in children hospitalized with severe pneumonia. Methods We enrolled 610 Nepalese children, aged 2 - 35 months from February 2006 to June 2008. Study participants were provided with standard treatment for pneumonia and followed up until discharge. Three multiple regression models representing clinical variables, clinical and radiological combined and all variables, including C-reactive protein (CRP) and viral etiology were used to assess the associations. Results The median age of study participants was 6 months with 493 (82%) infants and 367 (61%) males. The median time (IQR) till recovery was 49 (31, 87) hours and treatment failure was experienced by 209 (35%) of the children. Younger age, hypoxia on admission and radiographic pneumonia were independent predictors for both prolonged recovery and risk of treatment failure. While wasting and presence of any danger sign also predicted slower recovery, Parainfluenza type 1 isolated from the nasopharynx was associated with earlier resolution of illness. Gender, being breastfed, stunting, high fever, elevated CRP, presence of other viruses and supplementation with oral zinc did not show any significant association with these outcomes. Conclusion Age, hypoxia and consolidation on chest radiograph were significant predictors for time till recovery and treatment failure in children with severe pneumonia. While chest radiograph is not always needed, detection and treatment of hypoxia is a crucial step to guide the management of hospitalized children with pneumonia.	[Basnet, Sudha; Sharma, Arun; Shrestha, Prakash Sunder] Tribhuvan Univ, Inst Med, Dept Child Hlth, Kathmandu, Nepal; [Basnet, Sudha; Sommerfelt, Halvor; Strand, Tor A.] Univ Bergen, Ctr Int Hlth, Bergen, Norway; [Basnet, Sudha; Sommerfelt, Halvor; Strand, Tor A.] Univ Bergen, Ctr Intervent Sci Maternal & Child Hlth, Bergen, Norway; [Mathisen, Maria] Univ Hosp North Norway, Dept Microbiol & Infect Control, Tromso, Norway; [Ghimire, Ram Kumar] Tribhuvan Univ, Inst Med, Dept Radiol, Kathmandu, Nepal; [Shrestha, Dhiraj Man] Kathmandu Univ, Kathmandu Med Coll, Dept Radiol, Kathmandu, Nepal; [Shrestha, Dhiraj Man] Kathmandu Univ, Teaching Hosp, Kathmandu, Nepal; [Valentiner-Branth, Palle] Statens Serum Inst, Dept Infect Dis Epidemiol, Div Natl Hlth Surveillance & Res, DK-2300 Copenhagen, Denmark; [Sommerfelt, Halvor] Norwegian Inst Publ Hlth, Dept Int Publ Hlth, Oslo, Norway; [Strand, Tor A.] Innlandet Hosp Trust, Div Med Serv, Lillehammer, Norway	Tribhuvan University; Institute of Medicine (IoM) - Nepal; University of Bergen; University of Bergen; UiT The Arctic University of Tromso; University Hospital of North Norway; Tribhuvan University; Institute of Medicine (IoM) - Nepal; Kathmandu University; Kathmandu University; Statens Serum Institut; Norwegian Institute of Public Health (NIPH); Innlandet Hospital Trust	Basnet, S (corresponding author), Tribhuvan Univ, Inst Med, Dept Child Hlth, Kathmandu, Nepal.	sudhacbasnet@gmail.com	Strand, Tor/D-9836-2016; Sommerfelt, Halvor/ABD-3552-2020	Strand, Tor/0000-0002-4038-151X; Sommerfelt, Halvor/0000-0002-5670-9786	European Commission (EU-INCO-DC) [INCO-FP6-003740]; Meltzer Foundation in Bergen, Norway; Danish Council of Developmental Research [91128]; Research Council of Norway (RCN) [151054, 172226]; South-Eastern Norway Regional Health Authority [2012090]	European Commission (EU-INCO-DC)(European CommissionEuropean Commission Joint Research Centre); Meltzer Foundation in Bergen, Norway; Danish Council of Developmental Research; Research Council of Norway (RCN)(Research Council of Norway); South-Eastern Norway Regional Health Authority	This study was funded by grants from the European Commission (EU-INCO-DC contract number INCO-FP6-003740), the Meltzer Foundation in Bergen, Norway, the Danish Council of Developmental Research (project number: 91128), the Research Council of Norway (RCN project numbers: 151054 and 172226) and a grant from the South-Eastern Norway Regional Health Authority (grant number: 2012090) The sponsors of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. The corresponding author had full access to all the data in the study and took the final decision to submit this report for publication.	Asghar R, 2008, BMJ-BRIT MED J, V336, P80, DOI 10.1136/bmj.39421.435949.BE; Basnet S, 2012, PEDIATRICS, V129, P701, DOI 10.1542/peds.2010-3091; Bharti B, 2008, INDIAN PEDIATR, V45, P893; Bradley JS, 2011, CLIN INFECT DIS, V53, pE25, DOI [10.1093/cid/cir531, 10.1093/cid/cir625]; Cherian T, 2005, B WORLD HEALTH ORGAN, V83, P353; Djelantik IGG, 2003, J TROP PEDIATRICS, V49, P327, DOI 10.1093/tropej/49.6.327; Duke T, 2008, LANCET, V372, P1328, DOI 10.1016/S0140-6736(08)61164-2; Fu LY, 2006, PEDIATRICS, V118, pE1822, DOI 10.1542/peds.2005-2673; Ginsburg AS, 2014, TROP MED INT HEALTH, V19, P537, DOI 10.1111/tmi.12291; Ginsburg AS, 2012, J TROP PEDIATRICS, V58, P389, DOI 10.1093/tropej/fmr103; Harris M, 2011, THORAX, V66, pII1, DOI 10.1136/thoraxjnl-2011-200598; Hosmer D.W., 2005, APPL LOGISTIC REGRES; Jackson S, 2013, CROAT MED J, V54, P110, DOI 10.3325/cmj.2013.54.110; Lupisan SP, 2007, TROP MED INT HEALTH, V12, P962, DOI 10.1111/j.1365-3156.2007.01872.x; Mathisen M, 2011, PEDIATR INFECT DIS J, V30, P1032, DOI 10.1097/INF.0b013e31822f845f; Mower WR, 1997, PEDIATRICS, V99, P681, DOI 10.1542/peds.99.5.681; Patel A, 2008, INT J TUBERC LUNG D, V12, P1320; Reed C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0027793; Rudan I, 2013, J GLOB HEALTH, V3, DOI [10.7189/jogh.03.010101, 10.7189/jogh.03.010401]; Rudan I, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1001099; Sigauque B, 2009, J TROP PEDIATRICS, V55, P379, DOI 10.1093/tropej/fmp030; Walker CLF, 2013, LANCET, V381, P1405, DOI 10.1016/S0140-6736(13)60222-6; World Health Organization, 2014, INTEGRATED MANAGEMEN; World Health Organization, 2013, GUIDELINES MANAGEMEN; World Health Organization (WHO), 2005, POCK BOOK HOSP CAR C	25	13	14	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 23	2015	10	3							e0122052	10.1371/journal.pone.0122052	http://dx.doi.org/10.1371/journal.pone.0122052			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CE6ZS	25798907	Green Submitted, Green Published, gold			2023-01-03	WOS:000351987300314
J	Kehoe, S; Hook, J; Nankivell, M; Jayson, GC; Kitchener, H; Lopes, T; Luesley, D; Perren, T; Bannoo, S; Mascarenhas, M; Dobbs, S; Essapen, S; Twigg, J; Herod, J; McCluggage, G; Parmar, M; Swart, AM				Kehoe, Sean; Hook, Jane; Nankivell, Matthew; Jayson, Gordon C.; Kitchener, Henry; Lopes, Tito; Luesley, David; Perren, Timothy; Bannoo, Selina; Mascarenhas, Monica; Dobbs, Stephen; Essapen, Sharadah; Twigg, Jeremy; Herod, Jonathan; McCluggage, Glenn; Parmar, Mahesh; Swart, Ann-Marie			Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial	LANCET			English	Article							PRIMARY CYTOREDUCTIVE SURGERY; NEOADJUVANT CHEMOTHERAPY; SURGICAL CYTOREDUCTION; DEBULKING SURGERY; SURVIVAL; MULTICENTER; GUIDELINES; MORTALITY; CARCINOMA	Background The international standard of care for women with suspected advanced ovarian cancer is surgical debulking followed by platinum-based chemotherapy. We aimed to establish whether use of platinum-based primary chemotherapy followed by delayed surgery was an effective and safe alternative treatment regimen. Methods In this phase 3, non-inferiority, randomised, controlled trial (CHORUS) undertaken in 87 hospitals in the UK and New Zealand, we enrolled women with suspected stage III or IV ovarian cancer. We randomly assigned women (1: 1) either to undergo primary surgery followed by six cycles of chemotherapy, or to three cycles of primary chemotherapy, then surgery, followed by three more cycles of completion chemotherapy. Each 3-week cycle consisted of carboplatin AUC5 or AUC6 plus paclitaxel 175 mg/m(2), or an alternative carboplatin combination regimen, or carboplatin monotherapy. We did the random assignment by use of a minimisation method with a random element, and stratified participants according to the randomising centre, largest radiological tumour size, clinical stage, and prespecified chemotherapy regimen. Patients and investigators were not masked to group assignment. The primary outcome measure was overall survival. Primary analyses were done in the intention-to-treat population. To establish non-inferiority, the upper bound of a one-sided 90% CI for the hazard ratio (HR) had to be less than 1.18. This trial is registered, number ISRCTN74802813, and is closed to new participants. Findings Between March 1, 2004, and Aug 30, 2010, we randomly assigned 552 women to treatment. Of the 550 women who were eligible, 276 were assigned to primary surgery and 274 to primary chemotherapy. All were included in the intention-to-treat analysis; 251 assigned to primary surgery and 253 to primary chemotherapy were included in the per-protocol analysis. As of May 31, 2014, 451 deaths had occurred: 231 in the primary-surgery group versus 220 in the primary-chemotherapy group. Median overall survival was 22.6 months in the primary-surgery group versus 24.1 months in primary chemotherapy. The HR for death was 0.87 in favour of primary chemotherapy, with the upper bound of the one-sided 90% CI 0.98 (95% CI 0.72-1.05). Grade 3 or 4 postoperative adverse events and deaths within 28 days after surgery were more common in the primary-surgery group than in the primary-chemotherapy group (60 [24%] of 252 women vs 30 [14%] of 209, p=0.0007, and 14 women [6%] vs 1 woman [<1%], p=0.001). The most common grade 3 or 4 postoperative adverse event was haemorrhage in both groups (8 women [3%] in the primary-surgery group vs 14 [6%] in the primary-chemotherapy group). 110 (49%) of 225 women receiving primary surgery and 102 (40%) of 253 receiving primary chemotherapy had a grade 3 or 4 chemotherapy related toxic effect (p=0.0654), mostly uncomplicated neutropenia (20% and 16%, respectively). One fatal toxic effect, neutropenic sepsis, occurred in the primary-chemotherapy group. Interpretation In women with stage III or IV ovarian cancer, survival with primary chemotherapy is non-inferior to primary surgery. In this study population, giving primary chemotherapy before surgery is an acceptable standard of care for women with advanced ovarian cancer.	[Kehoe, Sean] Univ Birmingham, Sch Canc Sci, Birmingham, W Midlands, England; [Hook, Jane; Nankivell, Matthew; Bannoo, Selina; Mascarenhas, Monica; Parmar, Mahesh; Swart, Ann-Marie] UCL, MRC, Clin Trials Unit, London WC2B 6NH, England; [Jayson, Gordon C.] Christie Hosp, Dept Med Oncol, Manchester, Lancs, England; [Jayson, Gordon C.] Univ Manchester, Manchester Acad Hlth Sci Ctr, Manchester, Lancs, England; [Kitchener, Henry] Univ Manchester, Inst Canc Sci, Manchester, Lancs, England; [Lopes, Tito] Royal Cornwall NHS Trust, Truro, England; [Luesley, David] City Hosp, Pan Birmingham Gynaecol Canc Ctr, Birmingham, W Midlands, England; [Perren, Timothy] St James Univ Hosp, Inst Oncol, Leeds, W Yorkshire, England; [Dobbs, Stephen] Belfast City Hosp, Dept Gynaecol Oncol, Belfast BT9 7AD, Antrim, North Ireland; [Essapen, Sharadah] Royal Surrey Cty Hosp, St Lukes Canc Ctr, Guildford, Surrey, England; [Twigg, Jeremy] James Cook Univ Hosp, Middlesbrough, Cleveland, England; [Herod, Jonathan] Liverpool Womens Hosp, Dept Gynaecol, Liverpool, Merseyside, England; [McCluggage, Glenn] Belfast Hlth & Social Care Trust, Dept Pathol, Belfast, Antrim, North Ireland; [Swart, Ann-Marie] Univ E Anglia, Dept Med, Norwich NR4 7TJ, Norfolk, England	University of Birmingham; Medical Research Council Clinical Trials Unit; University of London; University College London; Christie NHS Foundation Trust; Christie Hospital; University of Manchester; University of Manchester; Royal Cornwall Hospital; University of Birmingham; Saint James's University Hospital; Belfast City Hospital; Royal Surrey County Hospital; James Cook University Hospital; University of Liverpool; University of East Anglia	Nankivell, M (corresponding author), UCL, MRC Clin Trials Unit, Inst Clin Trials & Methodol, Aviat House, London WC2B 6NH, England.	m.nankivell@ucl.ac.uk	Jayson, Gordon C/O-8224-2015; de Barros Lopes, Alberto/B-2116-2018; Perren, Timothy J/D-5387-2013	Jayson, Gordon C/0000-0002-8515-8944; de Barros Lopes, Alberto/0000-0002-8796-3891; Perren, Timothy J/0000-0001-8472-8856; Mascarenhas, Monica/0000-0002-4623-3147	Cancer Research UK; Royal College of Obstetricians and Gynaecologists; RCOG; core MRC CTU funding; MRC; Medical Research Council [1447122, MC_UU_12023/9, MC_UU_12023/28, MC_U122861379] Funding Source: researchfish; MRC [MC_UU_12023/28, MC_U122861379, MC_UU_12023/9] Funding Source: UKRI	Cancer Research UK(Cancer Research UK); Royal College of Obstetricians and Gynaecologists; RCOG; core MRC CTU funding(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	Cancer Research UK and the Royal College of Obstetricians and Gynaecologists.; Funding was provided by Cancer Research UK. Funding for a pilot phase of the trial was provided by the RCOG and supported by core MRC CTU funding. The trial sponsor was the MRC and the trial was conducted and analysed at the MRC CTU. We thank all the women and their families who agreed to participate in CHORUS, and the investigators and research staff at the trial centres and the MRC CTU.	Ang C, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007697.pub2; Benedet JL, 2000, INT J GYNECOL OBSTET, V70, P209; Bristow RE, 2002, J CLIN ONCOL, V20, P1248, DOI 10.1200/JCO.20.5.1248; Bristow RE, 2006, GYNECOL ONCOL, V103, P1070, DOI 10.1016/j.ygyno.2006.06.025; Cancer Research UK, 2011, CANC STAT REP OV CAN; du Bois A, 2009, CANCER-AM CANCER SOC, V115, P1234, DOI 10.1002/cncr.24149; du Bois A, 2009, GYNECOL ONCOL, V112, P422, DOI 10.1016/j.ygyno.2008.09.036; Fayers P, 2001, EORTC QLQ C30 SCORIN, P86; Fayers PM, 2001, EUR J CANCER, V37, P1331, DOI 10.1016/S0959-8049(01)00127-7; Gerestein CG, 2009, GYNECOL ONCOL, V114, P523, DOI 10.1016/j.ygyno.2009.03.011; GRAMBSCH PM, 1994, BIOMETRIKA, V81, P515; GRIFFITHS CT, 1975, NATL CANCER I MONOGR, P101; Hou JY, 2007, GYNECOL ONCOL, V105, P211, DOI 10.1016/j.ygyno.2006.11.025; Junor EJ, 1999, BRIT J OBSTET GYNAEC, V106, P1130, DOI 10.1111/j.1471-0528.1999.tb08137.x; Kang S, 2009, ANN SURG ONCOL, V16, P2315, DOI 10.1245/s10434-009-0558-6; Kehoe S, 2013, J CLIN ONCOL, V31; National Institute of Clinical Excellence, 2005, GUID US PACL TREATM; Osoba D, 1998, J CLIN ONCOL, V16, P139, DOI 10.1200/JCO.1998.16.1.139; Parmar MKB, 1998, STAT MED, V17, P2815, DOI 10.1002/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8; Perren TJ, 2011, NEW ENGL J MED, V365, P2484, DOI 10.1056/NEJMoa1103799; Pignata S, 2014, LANCET ONCOL, V15, P396, DOI 10.1016/S1470-2045(14)70049-X; Polterauer S, 2012, INT J GYNECOL CANCER, V22, P380, DOI 10.1097/IGC.0b013e31823de6ae; Rose PG, 2004, NEW ENGL J MED, V351, P2489, DOI 10.1056/NEJMoa041125; Thrall MM, 2011, OBSTET GYNECOL, V118, P537, DOI 10.1097/AOG.0b013e31822a6d56; Trope C, 2006, EJSO-EUR J SURG ONC, V32, P844, DOI 10.1016/j.ejso.2006.03.036; VANDERBURG MEL, 1995, NEW ENGL J MED, V332, P629, DOI 10.1056/NEJM199503093321002; Vergote I, 1998, GYNECOL ONCOL, V71, P431, DOI 10.1006/gyno.1998.5213; Vergote I, 2000, J NATL CANCER I, V92, P1534, DOI 10.1093/jnci/92.18.1534; Vergote I, 2010, NEW ENGL J MED, V363, P943, DOI 10.1056/NEJMoa0908806; WHO, 1979, WHO HDB REP RES CANC; Winter WE, 2008, J CLIN ONCOL, V26, P83, DOI 10.1200/JCO.2007.13.1953; Winter WE, 2007, J CLIN ONCOL, V25, P3621, DOI 10.1200/JCO.2006.10.2517; YEDEMA CA, 1992, TUMOR BIOL, V13, P18, DOI 10.1159/000217748	33	765	801	5	65	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 18	2015	386	9990					249	257		10.1016/S0140-6736(14)62223-6	http://dx.doi.org/10.1016/S0140-6736(14)62223-6			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CN1XI	26002111				2023-01-03	WOS:000358213700029
J	Ananthakrishnan, S				Ananthakrishnan, Shubha			Trimethoprim-sulfamethoxazole was linked to sudden death in older patients using spironolactone	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							INDUCED HYPERKALEMIA		Univ Calif Davis, Med Ctr, Sacramento, CA 95817 USA	University of California System; University of California Davis	Ananthakrishnan, S (corresponding author), Univ Calif Davis, Med Ctr, Sacramento, CA 95817 USA.							Antoniou T, 2011, BRIT MED J, V343, DOI 10.1136/bmj.d5228; Hirsch JS, 2014, SEMIN NEPHROL, V34, P307, DOI 10.1016/j.semnephrol.2014.04.006; Juurlink DN, 2004, NEW ENGL J MED, V351, P543, DOI 10.1056/NEJMoa040135; VELAZQUEZ H, 1993, ANN INTERN MED, V119, P296, DOI 10.7326/0003-4819-119-4-199308150-00008	4	0	1	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 16	2015	162	12							JC13	10.7326/ACPJC-2015-162-12-013	http://dx.doi.org/10.7326/ACPJC-2015-162-12-013			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CK8VC	26075778				2023-01-03	WOS:000356516300014
J	Hughes, DA; Pastores, GM				Hughes, Derralynn A.; Pastores, Gregory M.			Eliglustat for Gaucher's disease: trippingly on the tongue	LANCET			English	Editorial Material							GLUCOSYLCERAMIDE SYNTHASE; THERAPY; TYPE-1; INHIBITION; PHASE-2		[Hughes, Derralynn A.] UCL, Royal Free London NHS Fdn Trust, Dept Haematol, Lysosomal Storage Disorders Unit, London NW3 2QG, England; [Pastores, Gregory M.] Mater Misericordiae Univ Hosp, Natl Ctr Inherited Metab Dis, Dept Med, Dublin, Ireland	University of London; University College London; Royal Free London NHS Foundation Trust; Mater Misericordiae University Hospital; University College Dublin	Hughes, DA (corresponding author), UCL, Royal Free London NHS Fdn Trust, Dept Haematol, Lysosomal Storage Disorders Unit, London NW3 2QG, England.	rmgvdah@ucl.ac.uk	Pastores, Gregory M./AAE-8647-2020; hughes, derralynn/J-8012-2013	hughes, derralynn/0000-0003-4531-9173				Arends M, 2013, BRIT J HAEMATOL, V161, P832, DOI 10.1111/bjh.12335; Cerdelga, 2014, HIGHL PRESCR INF; Cox T, 2000, LANCET, V355, P1481, DOI 10.1016/S0140-6736(00)02161-9; Cox TM, 2015, LANCET; Kamath RS, 2014, SKELETAL RADIOL, V43, P1353, DOI 10.1007/s00256-014-1891-9; Kuter DJ, 2013, BLOOD CELL MOL DIS, V51, P116, DOI 10.1016/j.bcmd.2013.04.005; Lukina E, 2014, BLOOD CELL MOL DIS, V53, P274, DOI 10.1016/j.bcmd.2014.04.002; Lukina E, 2010, BLOOD, V116, P893, DOI 10.1182/blood-2010-03-273151; McEachern KA, 2007, MOL GENET METAB, V91, P259, DOI 10.1016/j.ymgme.2007.04.001; Packman S, 2013, 63 AM SOC HUM GEN AN; Pavlova EV, 2013, J PATHOL, V231, P88, DOI 10.1002/path.4227; Pavlova EV, 2015, J PATHOL, V235, P113, DOI 10.1002/path.4452; Thomas AS, 2014, BRIT J HAEMATOL, V165, P427, DOI 10.1111/bjh.12804	13	5	5	0	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 13	2015	385	9985					2328	2330		10.1016/S0140-6736(15)60206-9	http://dx.doi.org/10.1016/S0140-6736(15)60206-9			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CK1XV	25819692				2023-01-03	WOS:000356003700007
J	Huh, WB; Kim, JE; Kang, YG; Park, G; Lim, TG; Kwon, JY; Song, DS; Jeong, EH; Lee, CC; Son, JE; Seo, SG; Lee, E; Kim, JR; Lee, CY; Park, JS; Lee, KW				Huh, Won Bum; Kim, Jong-Eun; Kang, Young-Gyu; Park, Gaeun; Lim, Tae-gyu; Kwon, Jung Yeon; Song, Da Som; Jeong, Eun Hee; Lee, Charles C.; Son, Joe Eun; Seo, Sang Gwon; Lee, Eunjung; Kim, Jong Rhan; Lee, Chang Yong; Park, Jun Seong; Lee, Ki Won			Brown Pine Leaf Extract and Its Active Component Trans-Communic Acid Inhibit UVB-Induced MMP-1 Expression by Targeting PI3K	PLOS ONE			English	Article							ULTRAVIOLET-B IRRADIATION; MATRIX METALLOPROTEINASES; MECHANISMS; ACTIVATION; MODEL; GENE; CONSTITUENTS; DITERPENES; DENSIFLORA; THICKNESS	Japanese red pine (Pinus densiflora) is widely present in China, Japan, and Korea. Its green pine leaves have traditionally been used as a food as well as a coloring agent. After being shed, pine leaves change their color from green to brown within two years, and although the brown pine leaves are abundantly available, their value has not been closely assessed. In this study, we investigated the potential anti-photoaging properties of brown pine leaves for skin. Brown pine leaf extract (BPLE) inhibited UVB-induced matrix metalloproteinase-1 (MMP-1) expression to a greater extent than pine leaf extract (PLE) in human keratinocytes and a human skin equivalent model. HPLC analysis revealed that the quantity of trans-communic acid (TCA) and dehydroabietic acid (DAA) significantly increases when the pine leaf color changes from green to brown. BPLE and TCA elicited reductions in UVB-induced MMP-1 mRNA expression and activator protein-1 (AP-1) transactivation by reducing DNA binding activity of phospho-c-Jun, c-fos and Fra-1. BPLE and TCA also inhibited UVB-induced Akt phosphorylation, but not mitogen activated protein kinase (MAPK), known regulators of AP-1 transactivation. We additionally found that BPLE and TCA inhibited phosphoinositide 3-kinase (PI3K), the upstream kinase of Akt, in vitro. In summary, both BPLE and its active component TCA exhibit protective effects against UVB-induced skin aging. Taken together, these findings underline the potential for BPLE and TCA to be utilized as anti-wrinkling agents and cosmetic ingredients, as they suppress UVB-induced MMP-1 expression.	[Huh, Won Bum; Kim, Jong-Eun; Park, Gaeun; Lim, Tae-gyu; Kwon, Jung Yeon; Song, Da Som; Jeong, Eun Hee; Son, Joe Eun; Seo, Sang Gwon; Lee, Eunjung; Kim, Jong Rhan; Lee, Ki Won] Seoul Natl Univ, Dept Agr Biotechnol, Ctr Food & Bioconvergence, WCU Biomodulat Major, Seoul, South Korea; [Huh, Won Bum; Kim, Jong-Eun; Park, Gaeun; Lim, Tae-gyu; Kwon, Jung Yeon; Song, Da Som; Jeong, Eun Hee; Son, Joe Eun; Seo, Sang Gwon; Lee, Eunjung; Kim, Jong Rhan; Lee, Ki Won] Seoul Natl Univ, Adv Inst Convergence Technol, Suwon, South Korea; [Kang, Young-Gyu; Park, Jun Seong] Amorepacif Corp R&D Ctr, Skin Res Inst, Yongin, South Korea; [Lee, Charles C.; Lee, Chang Yong] Cornell Univ, Dept Food Sci & Technol, Ithaca, NY 14456 USA; [Lee, Eunjung] Korea Food Res Inst, Tradit Alcohol Beverage Res Team, Songnam, South Korea; [Lee, Chang Yong] King Abdulaziz Univ, Dept Biochem, Jeddah 21413, Saudi Arabia	Seoul National University (SNU); Seoul National University (SNU); Cornell University; Korea Food Research Institute (KFRI); King Abdulaziz University	Park, JS (corresponding author), Amorepacif Corp R&D Ctr, Skin Res Inst, Yongin, South Korea.	superbody@amorepacific.com; kiwon@snu.ac.kr	Lee, Ki Won/M-4114-2018; Son, Joe/AAB-7384-2020; Lim, Tae-Gyu/AAO-8475-2020; kim, jong-eun/B-3550-2017	Lim, Tae-Gyu/0000-0001-6930-9565; kim, jong-eun/0000-0002-5030-6126; Son, Joe/0000-0003-3066-2796	R & D program of MOTIE/KIAT (Establishment of Infra Structure for Anti-aging Industry Support) [N0000697]; Leap Research Program Grant through the National Research Foundation - Ministry of Science, ICT and Future Planning of Republic of Korea [2010-0029233]	R & D program of MOTIE/KIAT (Establishment of Infra Structure for Anti-aging Industry Support); Leap Research Program Grant through the National Research Foundation - Ministry of Science, ICT and Future Planning of Republic of Korea	This work was supported by the R & D program (N0000697) of MOTIE/KIAT (Establishment of Infra Structure for Anti-aging Industry Support) and the Leap Research Program Grant (2010-0029233) through the National Research Foundation funded by the Ministry of Science, ICT and Future Planning of Republic of Korea.	ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; Aragane Y, 1997, P NATL ACAD SCI USA, V94, P11490, DOI 10.1073/pnas.94.21.11490; Barrero AF, 2012, MOLECULES, V17, P1448, DOI 10.3390/molecules17021448; Beissert S, 1999, J INVEST DERM SYMP P, V4, P61, DOI 10.1038/sj.jidsp.5640183; BIRKEDALHANSEN H, 1993, CRIT REV ORAL BIOL M, V4, P197, DOI 10.1177/10454411930040020401; Bode A M, 2000, Lancet Oncol, V1, P181, DOI 10.1016/S1470-2045(00)00029-2; Bode Ann M, 2003, Sci STKE, V2003, pRE2, DOI 10.1126/stke.2003.167.re2; Brenneisen P, 2002, ANN NY ACAD SCI, V973, P31, DOI 10.1111/j.1749-6632.2002.tb04602.x; BRULS WAG, 1984, PHOTOCHEM PHOTOBIOL, V40, P485, DOI 10.1111/j.1751-1097.1984.tb04622.x; Chen WX, 1999, ONCOGENE, V18, P7469, DOI 10.1038/sj.onc.1203210; CHEUNG HTA, 1993, TETRAHEDRON, V49, P7903, DOI 10.1016/S0040-4020(01)88015-7; Chiang HM, 2011, FOOD CHEM TOXICOL, V49, P309, DOI 10.1016/j.fct.2010.10.034; Chung JH, 2003, PHOTODERMATOL PHOTO, V19, P109, DOI 10.1034/j.1600-0781.2003.00027.x; Dickinson SE, 2011, MOL CARCINOGEN, V50, P469, DOI 10.1002/mc.20734; Eckl KM, 2011, J INVEST DERMATOL, V131, P1938, DOI 10.1038/jid.2011.126; Evans-Johnson JA, 2013, J PHOTOCH PHOTOBIO B, V126, P17, DOI 10.1016/j.jphotobiol.2013.07.006; Fisher G J, 1998, J Investig Dermatol Symp Proc, V3, P61; Fisher GJ, 2002, ARCH DERMATOL, V138, P1462, DOI 10.1001/archderm.138.11.1462; Fisher GJ, 1996, NATURE, V379, P335, DOI 10.1038/379335a0; Fisher GJ, 1997, NEW ENGL J MED, V337, P1419, DOI 10.1056/NEJM199711133372003; Fisher GJ, 1997, NEW ENGL J MED, V1997, P20; Fumarola C, 2014, BIOCHEM PHARMACOL, V90, P197, DOI 10.1016/j.bcp.2014.05.011; Gilchrest BA, 1996, PHOTOCHEM PHOTOBIOL, V63, P1, DOI 10.1111/j.1751-1097.1996.tb02988.x; Gordien AY, 2009, J ETHNOPHARMACOL, V126, P500, DOI 10.1016/j.jep.2009.09.007; Huang CS, 2000, MOL CARCINOGEN, V27, P65, DOI 10.1002/(SICI)1098-2744(200002)27:2<65::AID-MC2>3.0.CO;2-E; Hwang YP, 2011, J DERMATOL SCI, V61, P23, DOI 10.1016/j.jdermsci.2010.10.016; Jiang Yunyao, 2012, Prev Nutr Food Sci, V17, P116, DOI 10.3746/pnf.2012.17.2.116; Kahari VM, 1997, EXP DERMATOL, V6, P199, DOI 10.1111/j.1600-0625.1997.tb00164.x; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Kim JE, 2010, BIOCHEM PHARMACOL, V79, P1473, DOI 10.1016/j.bcp.2010.01.008; Klotz LO, 1997, FEBS LETT, V408, P289, DOI 10.1016/S0014-5793(97)00440-7; Kwon JH, 2010, ARCH PHARM RES, V33, P2011, DOI 10.1007/s12272-010-1217-y; Li Y, 2010, J DERMATOL SCI, V60, P105, DOI 10.1016/j.jdermsci.2010.08.003; Lim JH, 2008, CHEMOSPHERE, V73, P470, DOI 10.1016/j.chemosphere.2008.06.048; Liu YB, 2011, FOOD CHEM, V124, P527, DOI 10.1016/j.foodchem.2010.06.064; Matsumura Yasuhiro, 2002, Expert Rev Mol Med, V4, P1, DOI 10.1017/S146239940200532X; MAUVIEL A, 1993, J CELL BIOCHEM, V53, P288, DOI 10.1002/jcb.240530404; Muhammad I, 1995, PHYTOTHER RES, V9, P584, DOI 10.1002/ptr.2650090810; Oh JH, 2006, J CELL PHYSIOL, V209, P775, DOI 10.1002/jcp.20754; Perez-Sanchez A, 2014, J PHOTOCH PHOTOBIO B, V136, P12, DOI 10.1016/j.jphotobiol.2014.04.007; Pinus desiflora, PIN DES; Rittie L, 2002, AGEING RES REV, V1, P705, DOI 10.1016/S1568-1637(02)00024-7; Shaulian E, 2010, CELL SIGNAL, V22, P894, DOI 10.1016/j.cellsig.2009.12.008; SHIMIZU M, 1994, BIOL PHARM BULL, V17, P665; Tanaka R, 2000, CANCER LETT, V161, P165, DOI 10.1016/S0304-3835(00)00584-X; van Beek TA, 2007, J NAT PROD, V70, P154, DOI 10.1021/np060325e; van den Bogaard EH, 2014, J INVEST DERMATOL, V134, P719, DOI 10.1038/jid.2013.417; Vincenti MP, 1996, CRIT REV EUKAR GENE, V6, P391, DOI 10.1615/CritRevEukarGeneExpr.v6.i4.40; Vogt P K, 1990, Adv Cancer Res, V55, P1, DOI 10.1016/S0065-230X(08)60466-2; Walker SL., 2003, FITZPATRICKS DERMATO, P1275; Wang S, 2014, EXP DERMATOL, V23, P524, DOI 10.1111/exd.12451; Xu YR, 2006, AM J PATHOL, V169, P823, DOI 10.2353/ajpath.2006.050449; Zhao Y, 1996, J BIOL CHEM, V271, P29773, DOI 10.1074/jbc.271.47.29773	53	18	19	0	22	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 11	2015	10	6							e0128365	10.1371/journal.pone.0128365	http://dx.doi.org/10.1371/journal.pone.0128365			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CK3FB	26066652	gold, Green Published, Green Submitted			2023-01-03	WOS:000356100900019
J	Nagata, T; Yasuda, Y; Ando, M; Abe, T; Katsuno, T; Kato, S; Tsuboi, N; Matsuo, S; Maruyama, S				Nagata, Takanobu; Yasuda, Yoshinari; Ando, Masahiko; Abe, Tomoko; Katsuno, Takayuki; Kato, Sawako; Tsuboi, Naotake; Matsuo, Seiichi; Maruyama, Shoichi			Clinical Impact of Kidney Function on Presepsin Levels	PLOS ONE			English	Article							SOLUBLE CD14 SUBTYPE; SEVERE SEPSIS; EMERGENCY-DEPARTMENT; PROCALCITONIN LEVELS; SEPTIC SHOCK; MULTICENTER; INTERLEUKIN-6; INHIBITION; DIAGNOSIS; MARKER	Objective Presepsin is highlighted as a diagnostic and prognostic marker of sepsis. Little information is available regarding the accurate association between presepsin levels and the degree of kidney function. We analyzed presepsin levels in patients with a glomerular filtration rate (GFR) in the categories G1 to G5, evaluated via inulin renal clearance test, and receiving hemodialysis (HD). Methods Patients who were not receiving HD were included if they had undergone inulin renal clearance measurements for the accurate measurement of GFR (measured GFR), and patients who were receiving hemodialysis (HD) were included if they had anuria. Exclusion criteria were infection, cancer, liver disease, autoimmune disorders, or steroid or immunosuppressant use. GFR category was defined as follows; G1: GFR >= 90 ml/min/1.73m(2), G2: GFR = 60 to 90 ml/min/1.73m(2), G3: GFR = 30 to 60 ml/min/1.73m(2), G4: GFR = 15 to 30 ml/min/1.73m(2), G5: GFR <= 15 ml/min/1.73m(2). Results Seventy-one patients were included. The median (IQR) presepsin values of patients in each GFR category were as follows: G1 + G2: 69.8 (60.8-85.9) pg/ml; G3: 107.0 (68.7-150.0) pg/ml; G4: 171.0 (117.0-200.0) pg/ml; G5: 251.0 (213.0-297.5) pg/ml; and HD: 1160.0 (1070.0-1400.0) pg/ml. The log-transformed presepsin values, excluding patients receiving HD, inversely correlated with the measured GFR (Pearson's correlation coefficient = -0.687, P < 0.001). The multivariate analysis revealed that measured GFR and hemoglobin levels significantly correlated with elevated presepsin levels. Conclusion Presepsin levels were markedly high in patients receiving HD, similar to values seen in patients with severe sepsis or septic shock. In patients who were not receiving HD, presepsin levels increased as GFR decreased. Thus, the evaluation of presepsin levels in patients with chronic kidney disease requires further consideration, and a different cutoff value is needed for diagnosing sepsis in such patients.	[Nagata, Takanobu; Yasuda, Yoshinari; Abe, Tomoko; Katsuno, Takayuki; Kato, Sawako; Tsuboi, Naotake; Matsuo, Seiichi; Maruyama, Shoichi] Nagoya Univ, Grad Sch Med, Dept Nephrol, Nagoya, Aichi 4648601, Japan; [Ando, Masahiko] Nagoya Univ Hosp, Ctr Adv Med & Clin Res, Nagoya, Aichi, Japan	Nagoya University; Nagoya University	Maruyama, S (corresponding author), Nagoya Univ, Grad Sch Med, Dept Nephrol, Nagoya, Aichi 4648601, Japan.	marus@med.nagoya-u.ac.jp	Kato, Sawako/T-2422-2019; Tsuboi, Naotake/L-5960-2019; ANDO, Masahiko/F-7035-2015	Kato, Sawako/0000-0001-7210-1888; Tsuboi, Naotake/0000-0003-0760-845X; 	Kyowa Hakko Kirin Co., Ltd.; Otsuka Pharmaceutical Co., Ltd.; Dainippon Sumitomo Pharma Co., Ltd.; Mochida Pharmaceutical Co., Ltd.; Grants-in-Aid for Scientific Research [15H05291] Funding Source: KAKEN	Kyowa Hakko Kirin Co., Ltd.(Kyowa Kirin Ltd); Otsuka Pharmaceutical Co., Ltd.(Otsuka Pharmaceutical); Dainippon Sumitomo Pharma Co., Ltd.(Dainippon Sumitomo Pharma Co., Ltd.); Mochida Pharmaceutical Co., Ltd.; Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	This work was supported by Kyowa Hakko Kirin Co., Ltd. Otsuka Pharmaceutical Co., Ltd., Dainippon Sumitomo Pharma Co., Ltd., and Mochida Pharmaceutical Co., Ltd. provided support in the form of research grants for authors [TN, YY, MA, TA, TK, SK, NT, SM, SM], but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the 'author contributions' section.	Adhikari NKJ, 2010, LANCET, V376, P1339, DOI 10.1016/S0140-6736(10)60446-1; Angus DC, 2013, NEW ENGL J MED, V369, P840, DOI [10.1056/NEJMra1208623, 10.1056/NEJMc1312359]; Behnes M, 2014, CRIT CARE, V18, DOI 10.1186/s13054-014-0507-z; Chenevier-Gobeaux C, 2014, CLIN CHIM ACTA, V427, P34, DOI 10.1016/j.cca.2013.09.019; COHEN J, 1992, PSYCHOL BULL, V112, P155, DOI 10.1037/0033-2909.112.1.155; Dellinger R. P., 2013, INTENS CARE MED, V41, P580, DOI [DOI 10.1007/s00134-012-2769-8, 10.1007/s00134-012-2769-8]; Endo Shigeatsu, 2008, Journal of Infection and Chemotherapy, V14, P244, DOI 10.1007/s10156-008-0608-1; Endo S, 2014, J INFECT CHEMOTHER, V20, P30, DOI 10.1016/j.jiac.2013.07.005; Endo S, 2012, J INFECT CHEMOTHER, V18, P891, DOI 10.1007/s10156-012-0435-2; Gilbert DN, 2010, J CLIN MICROBIOL, V48, P2325, DOI 10.1128/JCM.00655-10; Henriquez-Camacho C, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/547818; HERBELIN A, 1991, KIDNEY INT, V39, P954, DOI 10.1038/ki.1991.120; HERBELIN A, 1990, KIDNEY INT, V37, P116, DOI 10.1038/ki.1990.16; Horio M, 2010, CLIN EXP NEPHROL, V14, P427, DOI 10.1007/s10157-010-0325-9; Horio M, 2009, CLIN EXP NEPHROL, V13, P50, DOI 10.1007/s10157-008-0084-z; Kanda Y, 2013, BONE MARROW TRANSPL, V48, P452, DOI 10.1038/bmt.2012.244; Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group, 2012, KIDNEY INT SUPP, V2, P1, DOI 10.1038/kisup.2012.1; Kurihara T, 2008, ANAL BIOCHEM, V375, P144, DOI 10.1016/j.ab.2007.12.030; Ledebo I, 1999, ARTIF ORGANS, V23, P37, DOI 10.1046/j.1525-1594.1999.06275.x; Levin A, 2013, KIDNEY INT SUPPL, V3, P5, DOI 10.1038/kisup.2012.77; Liu B, 2013, CRIT CARE, V17, DOI 10.1186/cc13070; Masson S, 2015, INTENS CARE MED, V41, P12, DOI 10.1007/s00134-014-3514-2; Masson S, 2014, CRIT CARE, V18, DOI 10.1186/cc13183; Matsuo S, 2009, AM J KIDNEY DIS, V53, P982, DOI 10.1053/j.ajkd.2008.12.034; McIntyre CW, 2011, CLIN J AM SOC NEPHRO, V6, P133, DOI 10.2215/CJN.04610510; MEANS RT, 1993, J CLIN INVEST, V91, P416, DOI 10.1172/JCI116216; MEANS RT, 1990, J CLIN INVEST, V86, P538, DOI 10.1172/JCI114741; Meisner M, 2002, CLIN CHIM ACTA, V323, P17, DOI 10.1016/S0009-8981(02)00101-8; Nakamura Y, 2014, BMC ANESTHESIOL, V14, DOI 10.1186/1471-2253-14-88; Okamura Y, 2011, CLIN CHIM ACTA, V412, P2157, DOI 10.1016/j.cca.2011.07.024; Pecoits R, 2003, AM J KIDNEY DIS, V41, P1212, DOI 10.1016/S0272-6386(03)00353-6; Raja KB, 2005, BRIT J HAEMATOL, V131, P656, DOI 10.1111/j.1365-2141.2005.05814.x; Shozushima T, 2011, J INFECT CHEMOTHER, V17, P764, DOI 10.1007/s10156-011-0254-x; Ulla M, 2013, CRIT CARE, V17, DOI 10.1186/cc12847; Wacker C, 2013, LANCET INFECT DIS, V13, P426, DOI 10.1016/S1473-3099(12)70323-7; Yaegashi Yasunori, 2005, Journal of Infection and Chemotherapy, V11, P234, DOI 10.1007/s10156-005-0400-4	36	59	61	0	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 1	2015	10	6							e0129159	10.1371/journal.pone.0129159	http://dx.doi.org/10.1371/journal.pone.0129159			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CL0KF	26030716	Green Published, gold, Green Submitted			2023-01-03	WOS:000356630900212
J	Yen, CY; Chiang, WF; Liu, SY; Lin, CC; Liao, KA; Lin, CY; Hsieh, WF; Cheng, YC; Hsu, KC; Lin, PY; Chen, TC; Lee, IL; Lin, MH; Liu, YC				Yen, Ching-Yu; Chiang, Wei-Fan; Liu, Shyun-Yeu; Lin, Chung-Chih; Liao, Kuo-An; Lin, Che-Yi; Hsieh, Wan-Fang; Cheng, Yon-Chi; Hsu, Kai-Cheng; Lin, Pin-Yen; Chen, Tai-Chi; Lee, I-Ling; Lin, Mei-Huei; Liu, Young-Chau			Impacts of Autophagy-Inducing Ingredient of Areca Nut on Tumor Cells	PLOS ONE			English	Article							ACTIVATED PROTEIN-KINASE; BECLIN 1-INDEPENDENT AUTOPHAGY; 30-100 KDA FRACTION; SIGNALING PATHWAY; CROSS-TALK; AMPK; CANCER; INDUCTION; ARECOLINE; APOPTOSIS	Areca nut (AN) is a popular carcinogen used by about 0.6-1.2 billion people worldwide. Although AN contains apoptosis-inducing ingredients, we previously demonstrated that both AN extract (ANE) and its 30-100 kDa fraction (ANE 30-100K) predominantly induce autophagic cell death in both normal and malignant cells. In this study, we further explored the action mechanism of ANE 30-100K-induced autophagy (AIA) in Jurkat T lymphocytes and carcinoma cell lines including OECM-1 (mouth), CE81T/VGH (esophagus), SCC25 (tongue), and SCC-15 (tongue). The results showed that chemical-and small hairpin RNA (shRNA)-mediated inhibition of AMP-activated protein kinase (AMPK) resulted in the attenuation of AIA in Jurkat T but not in OECM-1 cells. Knockdown of Atg5 and Beclin 1 expressions ameliorated AIA in OECM-1/CE81T/VGH/Jurkat T and OECM-1/SCC25/SCC-15, respectively. Furthermore, ANE 30-100K could activate caspase-3 after inhibition of Beclin 1 expression in OECM-1/SCC25/SCC15 cells. Meanwhile, AMPK was demonstrated to be the upstream activator of the extracellular-regulated kinase (ERK) in Jurkat T cells, and inhibition of MEK attenuated AIA in Jurkat T/OECM-1/CE81T/VGH cells. Finally, we also found that multiple myeloma RPMI8226, lymphoma U937, and SCC15 cells survived from long-term non-cytotoxic ANE 30-100K treatment exhibited stronger resistance against serum deprivation through upregulated autophagy. Collectively, our studies indicate that Beclin-1 and Atg5 but not AMPK are commonly required for AIA, and MEK/ERK pathway is involved in AIA. Meanwhile, it is also suggested that long-term AN usage might increase the resistance of survived tumor cells against serum-limited conditions.	[Yen, Ching-Yu; Liu, Shyun-Yeu] Taipei Med Univ, Dept Dent, Taipei, Taiwan; [Yen, Ching-Yu; Liu, Shyun-Yeu] Natl Def Med Ctr, Dept Dent, Taipei, Taiwan; [Yen, Ching-Yu; Liu, Shyun-Yeu] Chi Mei Med Ctr, Oral & Maxillofacial Surg Sect, Tainan, Taiwan; [Chiang, Wei-Fan; Liao, Kuo-An; Lin, Che-Yi; Lee, I-Ling] Chi Mei Hosp, Oral & Maxillofacial Surg Sect, Liouying, Taiwan; [Chiang, Wei-Fan] Natl Yang Ming Univ, Sch Dent, Taipei 112, Taiwan; [Lin, Chung-Chih] Natl Yang Ming Univ, Dept Life Sci, Taipei 112, Taiwan; [Lin, Che-Yi] Natl Yang Ming Univ, Inst Genome Sci, Taipei 112, Taiwan; [Hsieh, Wan-Fang; Cheng, Yon-Chi; Hsu, Kai-Cheng; Lin, Pin-Yen; Lin, Mei-Huei] Chia Nan Univ Pharm, Dept Biotechnol, Tainan, Taiwan; [Hsieh, Wan-Fang; Cheng, Yon-Chi; Hsu, Kai-Cheng; Lin, Pin-Yen; Chen, Tai-Chi; Lin, Mei-Huei; Liu, Young-Chau] Chi Mei Med Ctr, Dept Med Res, Tainan, Taiwan; [Liu, Young-Chau] Shu Te Univ, Coll Liberal Educ, Div Nat Sci, Kaohsiung, Taiwan	Taipei Medical University; National Defense Medical Center; Chi Mei Hospital; National Yang Ming Chiao Tung University; National Yang Ming Chiao Tung University; National Yang Ming Chiao Tung University; Chia Nan University of Pharmacy & Science; Chi Mei Hospital; Shu-Te University	Lin, MH (corresponding author), Chia Nan Univ Pharm, Dept Biotechnol, Tainan, Taiwan.	mhlin3224@mail.cnu.edu.tw; god15539@stu.edu.tw	Yen, Ching Yu/A-2771-2013; Chiang, Wei-Fan/L-6537-2019	Chiang, Wei-Fan/0000-0002-9240-1404	Ministry of Science and Technology [NSC98-2314-B384-002-MY3, NSC98-2314-B041-002, NSC99-2314-B-041-002, NSC101-2320-B-366-001, NSC102-2314-B-041-001-MY3]; Chi Mei Medical Center [CMFHR9903, CMFHR9936, CMFHR9948, CMFHR10051, CMFHR10055, CMFHR10159, CMFHR10203, CMFHR10209, CMFHR10307, CMFHR10301]; Chi Mei Hospital [CLFHR10107, CLFHR10223]	Ministry of Science and Technology(Ministry of Science, ICT & Future Planning, Republic of Korea); Chi Mei Medical Center; Chi Mei Hospital	This study is supported by grants from Ministry of Science and Technology (previously named: National Science Council) (NSC98-2314-B384-002-MY3, NSC98-2314-B041-002, NSC99-2314-B-041-002, NSC101-2320-B-366-001, and NSC102-2314-B-041-001-MY3), Chi Mei Medical Center (CMFHR9903, CMFHR9936, CMFHR9948, CMFHR10051, CMFHR10055, CMFHR10159, CMFHR10203, CMFHR10209, CMFHR10307, and CMFHR10301), and Chi Mei Hospital (CLFHR10107 and CLFHR10223). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alers S, 2012, MOL CELL BIOL, V32, P2, DOI 10.1128/MCB.06159-11; Chen YB, 2012, J SURG ONCOL, V105, P542, DOI 10.1002/jso.22151; Chu CT, 2007, AUTOPHAGY, V3, P663, DOI 10.4161/auto.4625; Damm E, 2012, MOL ENDOCRINOL, V26, P643, DOI 10.1210/me.2011-1218; Gao P, 2010, J BIOL CHEM, V285, P25570, DOI 10.1074/jbc.M110.118125; Gewirtz DA, 2014, CANCER RES, V74, P647, DOI 10.1158/0008-5472.CAN-13-2966; Gillis JM, 2011, TRAFFIC, V12, P1897, DOI 10.1111/j.1600-0854.2011.01270.x; Green DR, 2014, CELL, V157, P65, DOI 10.1016/j.cell.2014.02.049; Honda S, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5004; Hwang SL, 2013, BRIT J PHARMACOL, V169, P69, DOI 10.1111/bph.12124; Juenemann Katrin, 2012, Int J Cell Biol, V2012, P189794, DOI 10.1155/2012/189794; Kayampilly PP, 2012, ENDOCRINOLOGY, V153, P2831, DOI 10.1210/en.2011-1967; Kim MJ, 2010, J BIOL CHEM, V285, P14617, DOI 10.1074/jbc.M109.085456; Klionsky DJ, 2014, AUTOPHAGY, V10, P715, DOI 10.4161/auto.28813; Lee JHW, 2009, J HYDRO-ENVIRON RES, V3, P1, DOI 10.1016/j.jher.2009.05.002; Lee PH, 2006, TOXICOLOGY, V220, P81, DOI 10.1016/j.tox.2005.07.026; Lin HX, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060516; Lin MH, 2008, AUTOPHAGY, V4, P967, DOI 10.4161/auto.6821; Lin MH, 2010, ORAL ONCOL, V46, P822, DOI 10.1016/j.oraloncology.2010.08.002; Liu CY, 2013, BIOMED REP, V1, P855, DOI 10.3892/br.2013.171; Liu SY, 2008, J BIOMED SCI, V15, P823, DOI 10.1007/s11373-008-9273-8; Liu XN, 2014, MOL CANCER THER, V13, P596, DOI 10.1158/1535-7163.MCT-13-0579; Maiuri MC, 2010, EMBO J, V29, P515, DOI 10.1038/emboj.2009.377; Matsui Y, 2007, CIRC RES, V100, P914, DOI 10.1161/01.RES.0000261924.76669.36; Mehrpour M, 2010, CELL RES, V20, P748, DOI 10.1038/cr.2010.82; Mihaylova MM, 2011, NAT CELL BIOL, V13, P1016, DOI 10.1038/ncb2329; Mizushima N, 2008, NATURE, V451, P1069, DOI 10.1038/nature06639; Nishida Y, 2009, NATURE, V461, P654, DOI 10.1038/nature08455; Qu XP, 2003, J CLIN INVEST, V112, P1809, DOI 10.1172/JCI200320039; RHEINWALD JG, 1981, CANCER RES, V41, P1657; Scarlatti F, 2008, CELL DEATH DIFFER, V15, P1318, DOI 10.1038/cdd.2008.51; Seo G, 2011, FREE RADICAL RES, V45, P389, DOI 10.3109/10715762.2010.535530; Shen CH, 2013, MOL CELL, V52, P161, DOI 10.1016/j.molcel.2013.08.044; Sid B, 2014, BIOCHEM PHARMACOL, V91, P168, DOI 10.1016/j.bcp.2014.07.010; Smith DM, 2010, CELL DEATH DIFFER, V17, P1867, DOI 10.1038/cdd.2010.53; Steele S, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003562; Tian SH, 2010, AUTOPHAGY, V6, P1032, DOI 10.4161/auto.6.8.13336; Wang CC, 2009, TOXICOL IN VITRO, V23, P1234, DOI 10.1016/j.tiv.2009.07.033; Wang JR, 2009, J BIOL CHEM, V284, P21412, DOI 10.1074/jbc.M109.026013; White E, 2012, NAT REV CANCER, V12, P401, DOI 10.1038/nrc3262; Williams T, 2009, AUTOPHAGY, V5, P1155, DOI 10.4161/auto.5.8.10090; Wu XY, 2013, TUMOR BIOL, V34, P713, DOI 10.1007/s13277-012-0599-5; Yen CY, 2014, J ORAL PATHOL MED, V43, P91, DOI 10.1111/jop.12102; Yen CY, 2011, ORAL ONCOL, V47, P345, DOI 10.1016/j.oraloncology.2011.02.014; Yeung ED, 2012, PROSTATE, V72, P165, DOI 10.1002/pros.21417; Zhou WH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080338; Zhu BL, 2012, J VIROL, V86, P12003, DOI 10.1128/JVI.01434-12	47	9	10	1	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 27	2015	10	5							e0128011	10.1371/journal.pone.0128011	http://dx.doi.org/10.1371/journal.pone.0128011			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CJ0RO	26017803	gold, Green Published, Green Submitted			2023-01-03	WOS:000355185600107
J	Cerritelli, F; Pizzolorusso, G; Renzetti, C; Cozzolino, V; D'Orazio, M; Lupacchini, M; Marinelli, B; Accorsi, A; Lucci, C; Lancellotti, J; Ballabio, S; Castelli, C; Molteni, D; Besana, R; Tubaldi, L; Perri, FP; Fusilli, P; D'Incecco, C; Barlafante, G				Cerritelli, Francesco; Pizzolorusso, Gianfranco; Renzetti, Cinzia; Cozzolino, Vincenzo; D'Orazio, Marianna; Lupacchini, Mariacristina; Marinelli, Benedetta; Accorsi, Alessandro; Lucci, Chiara; Lancellotti, Jenny; Ballabio, Silvia; Castelli, Carola; Molteni, Daniela; Besana, Roberto; Tubaldi, Lucia; Perri, Francesco Paolo; Fusilli, Paola; D'Incecco, Carmine; Barlafante, Gina			A Multicenter, Randomized, Controlled Trial of Osteopathic Manipulative Treatment on Preterms	PLOS ONE			English	Article							INTENSIVE-CARE-UNIT; HEART-RATE-VARIABILITY; QUALITY-IMPROVEMENT; BIRTH; PREMATURE; COLLABORATION; MATURATION; CULTURE; HEALTH	Background Despite some preliminary evidence, it is still largely unknown whether osteopathic manipulative treatment improves preterm clinical outcomes. Materials and Methods The present multi-center randomized single blind parallel group clinical trial enrolled newborns who met the criteria for gestational age between 29 and 37 weeks, without any congenital complication from 3 different public neonatal intensive care units. Preterm infants were randomly assigned to usual prenatal care (control group) or osteopathic manipulative treatment (study group). The primary outcome was the mean difference in length of hospital stay between groups. Results A total of 695 newborns were randomly assigned to either the study group (n=352) or the control group (n=343). A statistical significant difference was observed between the two groups for the primary outcome (13.8 and 17.5 days for the study and control group respectively, p<0.001, effect size: 0.31). Multivariate analysis showed a reduction of the length of stay of 3.9 days (95% CI -5.5 to -2.3, p<0.001). Furthermore, there were significant reductions with treatment as compared to usual care in cost (difference between study and control group: 1,586.01(sic); 95% CI 1,087.18 to 6,277.28; p<0.001) but not in daily weight gain. There were no complications associated to the intervention. Conclusions Osteopathic treatment reduced significantly the number of days of hospitalization and is cost-effective on a large cohort of preterm infants.	[Cerritelli, Francesco; Accorsi, Alessandro; Lucci, Chiara] COME Collaborat, Ctr Osteopath Med, Clin Based Human Res Dept, Pescara, Italy; [Cerritelli, Francesco; Pizzolorusso, Gianfranco; Renzetti, Cinzia; Cozzolino, Vincenzo; D'Orazio, Marianna; Lupacchini, Mariacristina; Marinelli, Benedetta; Accorsi, Alessandro; Lucci, Chiara; Lancellotti, Jenny; Barlafante, Gina] Accademia Italiana Osteopatia Tradiz, Pescara, Italy; [Ballabio, Silvia; Castelli, Carola; Molteni, Daniela; Besana, Roberto] Desio Publ Hosp, Neonatal Intens Care Unit, Desio, Italy; [Tubaldi, Lucia; Perri, Francesco Paolo] Macerata Publ Hosp, Neonatal Intens Care Unit, Macerata, Italy; [Fusilli, Paola; D'Incecco, Carmine] Pescara Publ Hosp, Neonatal Intens Care Unit, Pescara, Italy		Cerritelli, F (corresponding author), COME Collaborat, Ctr Osteopath Med, Clin Based Human Res Dept, Pescara, Italy.	francesco.cerritelli@gmail.com	Cerritelli, Francesco/AAJ-5003-2020; Cerritelli, Francesco/O-8416-2015	Cerritelli, Francesco/0000-0002-2963-9620				[Anonymous], 2007, PRETERM BIRTH CAUSES; Bakewell-Sachs S, 2009, PEDIATRICS, V123, pE878, DOI 10.1542/peds.2008-2568; Beck S, 2010, B WORLD HEALTH ORGAN, V88, P31, DOI 10.2471/BLT.08.062554; Berghella Vincenzo, 2010, PRETERM BIRTH PREVEN; Bodeker G, 2007, TRADITIONAL, COMPLEMENTARY AND ALTERNATIVE MEDICINE: POLICY AND PUBLIC HEALTH PERSPECTIVES, P1; Brodsky D, 2013, BMJ QUAL SAF, V22, P374, DOI 10.1136/bmjqs-2012-000909; Brown MS, 2003, PEDIATRICS, V111; Cerritelli F, 2014, CHIROPR MAN THER, V22, DOI 10.1186/2045-709X-22-18; Cerritelli F, 2013, BMC PEDIATR, V13, DOI 10.1186/1471-2431-13-65; Davidoff MJ, 2006, SEMIN PERINATOL, V30, P8, DOI 10.1053/j.semperi.2006.01.009; Degenhardt BF, 2007, J AM OSTEOPATH ASSOC, V107, P387; FASDAC, 2012, NOM TAR; Giles PD, 2013, J ALTERN COMPLEM MED, V19, P92, DOI 10.1089/acm.2011.0031; Goldenberg RL, 2010, PRETERM BIRTH, V22; Horbar JD, 2001, PEDIATRICS, V107, P14, DOI 10.1542/peds.107.1.14; Italian Ministry of Health, 2012, RAPP ANN ATT RIC OSP; Jackson DJ, 2003, AM J PUBLIC HEALTH, V93, P999, DOI 10.2105/AJPH.93.6.999; Keller M, 2010, ACTA PAEDIATR, V99, P1624, DOI 10.1111/j.1651-2227.2010.01894.x; Kramer MS, 2000, JAMA-J AM MED ASSOC, V284, P843, DOI 10.1001/jama.284.7.843; LAN KKG, 1983, BIOMETRIKA, V70, P659, DOI 10.2307/2336502; Lemons JA, 1998, PEDIATRICS, V102, P411; Longin E, 2006, J PERINAT MED, V34, P303, DOI 10.1515/JPM.2006.058; Narendran V, 2010, PEDIATR RES, V67, P382, DOI 10.1203/PDR.0b013e3181d00b73; Ohlinger J, 2003, PEDIATRICS, V111; Pizzolorusso G, 2014, EVID-BASED COMPL ALT, V2014, DOI 10.1155/2014/243539; Pizzolorusso G, 2011, CHIROPR MAN THER, V19, DOI 10.1186/2045-709X-19-15; R Development Core Team, 2013, R LANG ENV STAT COMP, DOI [10.3758/s13428-013-0330-5, DOI 10.3758/S13428-013-0330-5]; Rogowski JA, 2001, PEDIATRICS, V107, P23, DOI 10.1542/peds.107.1.23; Silber JH, 2009, HEALTH SERV RES, V44, P444, DOI 10.1111/j.1475-6773.2008.00938.x; Visscher M, 2013, PEDIATRICS, V131, pE1950, DOI 10.1542/peds.2012-1626; WHO March of Dimes PMNCH Save the Children, 2012, BORN SOON GLOB ACT R, DOI [10.1186/1742-4755-10-S1-S1, DOI 10.1186/1742-4755-10-S1-S1]	31	32	32	1	16	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 14	2015	10	5							e0127370	10.1371/journal.pone.0127370	http://dx.doi.org/10.1371/journal.pone.0127370			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CI2AC	25974071	gold, Green Published, Green Submitted			2023-01-03	WOS:000354545600113
J	Ettema, EM; Kuipers, J; Assa, S; Bakker, SJL; Groen, H; Westerhuis, R; Gaillard, CAJM; Gansevoort, RT; Franssen, CFM				Ettema, Esmee M.; Kuipers, Johanna; Assa, Solmaz; Bakker, Stephan J. L.; Groen, Henk; Westerhuis, Ralf; Gaillard, Carlo A. J. M.; Gansevoort, Ron T.; Franssen, Casper F. M.			Changes in Plasma Copeptin Levels during Hemodialysis: Are the Physiological Stimuli Active in Hemodialysis Patients?	PLOS ONE			English	Article							ARGININE-VASOPRESSIN; BLOOD-PRESSURE; FLUID REMOVAL; DIALYSIS; HYPOTENSION; PEPTIDE; PRECURSOR	Objectives Plasma levels of copeptin, a surrogate marker for the vasoconstrictor hormone arginine vasopressin (AVP), are increased in hemodialysis patients. Presently, it is unknown what drives copeptin levels in hemodialysis patients. We investigated whether the established physiological stimuli for copeptin release, i.e. plasma osmolality, blood volume and mean arterial pressure (MAP), are operational in hemodialysis patients. Methods One hundred and eight prevalent, stable hemodialysis patients on a thrice-weekly dialysis schedule were studied during hemodialysis with constant ultrafiltration rate and dialysate conductivity in this observational study. Plasma levels of copeptin, sodium, MAP, and blood volume were measured before, during and after hemodialysis. Multivariate analysis was used to determine the association between copeptin (dependent variable) and the physiological stimuli plasma sodium, MAP, excess weight as well as NT-pro-BNP immediately prior to dialysis and between copeptin and changes of plasma sodium, MAP and blood volume with correction for age, sex and diabetes during dialysis treatment. Results Patients were 63 +/- 15.6 years old and 65% were male. Median dialysis vintage was 1.6 years (IQR 0.7-4.0). Twenty-three percent of the patients had diabetes and 82% had hypertension. Median predialysis copeptin levels were 141.5 pmol/L (IQR 91.0-244.8 pmol/L). Neither predialysis plasma sodium levels, nor NT-proBNP levels, nor MAP were associated with predialysis copeptin levels. During hemodialysis, copeptin levels rose significantly (p<0.01) to 163.0 pmol/L (96.0-296.0 pmol/L). Decreases in blood volume and MAP were associated with increases in copeptin levels during dialysis, whereas there was no significant association between the change in plasma sodium levels and the change in copeptin levels. Conclusions Plasma copeptin levels are elevated predialysis and increase further during hemodialysis. Volume stimuli, i.e. decreases in MAP and blood volume, rather than osmotic stimuli, are associated with change in copeptin levels during hemodialysis.	[Ettema, Esmee M.; Assa, Solmaz; Bakker, Stephan J. L.; Gaillard, Carlo A. J. M.; Gansevoort, Ron T.; Franssen, Casper F. M.] Univ Groningen, Univ Med Ctr Groningen, Div Nephrol, Dept Internal Med, Groningen, Netherlands; [Kuipers, Johanna; Westerhuis, Ralf] Dialysis Ctr Groningen, Groningen, Netherlands; [Groen, Henk] Univ Groningen, Univ Med Ctr Groningen, Dept Epidemiol, Groningen, Netherlands	University of Groningen; University of Groningen	Ettema, EM (corresponding author), Univ Groningen, Univ Med Ctr Groningen, Div Nephrol, Dept Internal Med, Groningen, Netherlands.	e.m.ettema@umcg.nl	Gaillard, Carlo/AAC-6729-2022; Bakker, Stephan J. L./J-4023-2015; Groen, Henk/B-2163-2013	Gaillard, Carlo/0000-0002-8964-0236; Bakker, Stephan J. L./0000-0003-3356-6791; Groen, Henk/0000-0002-6629-318X; Franssen, Casper/0000-0003-1004-9994	Dutch Kidney Foundation (Nierstichting) [C08.2279]	Dutch Kidney Foundation (Nierstichting)	A grant of the Dutch Kidney Foundation (Nierstichting) supported this work. The grant number is C08.2279. The URL of the funder's website is www.nierstichting.nl. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Artunc F, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0086148; Assa S, 2012, CLIN J AM SOC NEPHRO, V7, P1615, DOI 10.2215/CJN.00850112; Balanescu S, 2011, J CLIN ENDOCR METAB, V96, P1046, DOI 10.1210/jc.2010-2499; Barrett LK, 2007, CRIT CARE MED, V35, P33, DOI 10.1097/01.CCM.0000251127.45385.CD; Bhandari SS, 2009, CLIN SCI, V116, P257, DOI 10.1042/CS20080140; Cernaro V, 2012, BLOOD PURIFICAT, V33, P317, DOI 10.1159/000337104; Dabla PK, 2011, CLIN CHIM ACTA, V412, P22, DOI 10.1016/j.cca.2010.09.034; Ettema EM, 2014, AM J NEPHROL, V39, P100, DOI 10.1159/000358203; Fenske W, 2011, J AM SOC NEPHROL, V22, P782, DOI 10.1681/ASN.2010070691; Flythe JE, 2011, KIDNEY INT, V79, P250, DOI 10.1038/ki.2010.383; IITAKE K, 1985, ACTA ENDOCRINOL-COP, V110, P207, DOI 10.1530/acta.0.1100207; Li X, 2013, CHINESE MED J-PEKING, V126, P823, DOI 10.3760/cma.j.issn.0366-6999.20122497; MARTINEZVEA A, 1985, CLIN NEPHROL, V24, P316; Morgenthaler NG, 2006, CLIN CHEM, V52, P112, DOI 10.1373/clinchem.2005.060038; Morgenthaler NG, 2008, TRENDS ENDOCRIN MET, V19, P43, DOI 10.1016/j.tem.2007.11.001; Morgenthaler Nils G, 2010, Congest Heart Fail, V16 Suppl 1, pS37, DOI 10.1111/j.1751-7133.2010.00177.x; Mutlu GM, 2004, INTENS CARE MED, V30, P1276, DOI 10.1007/s00134-004-2283-8; Nakayama M, 1998, NEPHRON, V79, P488, DOI 10.1159/000045104; Nord E, 1979, Proc Eur Dial Transplant Assoc, V16, P238; Park J, 2013, KIDNEY INT, V84, P795, DOI 10.1038/ki.2013.237; Ronco C, 2001, INT J ARTIF ORGANS, V24, P726, DOI 10.1177/039139880102401005; Santoro A, 2007, NAT CLIN PRACT NEPHR, V3, P362, DOI 10.1038/ncpneph0509; Sauerbrei W, 1999, J ROY STAT SOC C-APP, V48, P313, DOI 10.1111/1467-9876.00155; Schneditz D, 2012, ASAIO J, V58, P160, DOI 10.1097/MAT.0b013e318243660f; Sharman A, 2008, BJA EDUC, V8, P134, DOI 10.1093/bjaceaccp/mkn021; Shoji T, 2004, KIDNEY INT, V66, P1212, DOI 10.1111/j.1523-1755.2004.00812.x; Struck J, 2005, PEPTIDES, V26, P2500, DOI 10.1016/j.peptides.2005.04.019; van der Zee S, 2007, KIDNEY INT, V71, P318, DOI 10.1038/sj.ki.5001885; YAMADA K, 1993, REGUL PEPTIDES, V45, P91, DOI 10.1016/0167-0115(93)90188-E; ZOCCALI C, 1991, NEPHROL DIAL TRANSPL, V6, P631, DOI 10.1093/ndt/6.9.631	30	14	16	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 14	2015	10	5							e0127116	10.1371/journal.pone.0127116	http://dx.doi.org/10.1371/journal.pone.0127116			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CI2AC	25973954	Green Published, gold, Green Submitted			2023-01-03	WOS:000354545600100
J	Wang, AP; Ling, ZX; Yang, ZX; Kiela, PR; Wang, T; Wang, C; Cao, L; Geng, F; Shen, MQ; Ran, XZ; Su, YP; Cheng, TM; Wang, JP				Wang, Aiping; Ling, Zongxin; Yang, Zhixiang; Kiela, Pawel R.; Wang, Tao; Wang, Cheng; Cao, Le; Geng, Fang; Shen, Mingqiang; Ran, Xinze; Su, Yongping; Cheng, Tianmin; Wang, Junping			Gut Microbial Dysbiosis May Predict Diarrhea and Fatigue in Patients Undergoing Pelvic Cancer Radiotherapy: A Pilot Study	PLOS ONE			English	Article							PLASMA CITRULLINE CONCENTRATION; BOWEL FUNCTION; RADIATION; DIVERSITY; DISEASE; MARKER; TOOL	Fatigue and diarrhea are the most frequent adverse effects of pelvic radiotherapy, while their etiologies are largely unknown. The aim of this study is to investigate the correlations between fatigue, diarrhea, and alterations in gut microbiota induced by pelvic radiotherapy. During the 5-week treatment of pelvic radiotherapy in 11 cancer patients, the general fatigue score significantly increased and was more prominent in the patients with diarrhea. The fatigue score was closely correlated with the decrease of serum citrulline (an indicator of the functional enterocyte mass) and the increases of systemic inflammatory proteins, including haptoglobin, orosomuoid, alpha(1)-antitrypsin and TNF-alpha. Serum level of lipopolysaccharide (LPS) was also elevated, especially in the patients with diarrhea indicating epithelial barrier breach and endotoxemia. Pyrosequencing analysis of 16S rRNA gene revealed that microbial diversity, richness, and the Firmicutes/Bacteroidetes ratio were significantly altered prior to radiotherapy in patients who later developed diarrhea. Pelvic radiotherapy induced further changes in fecal microbial ecology, some of which were specific to the patients with or without diarrhea. Our results indicate that gut microbial dysbiosis prior to radiation therapy may be exploited to predict development of diarrhea and to guide preventive treatment options. Radiation-induced dysbiosis may contribute to pelvic radiation disease, including mucositis, diarrhea, systemic inflammatory response, and pelvic radiotherapy-associated fatigue in cancer patients.	[Wang, Aiping; Wang, Tao; Wang, Cheng; Cao, Le; Geng, Fang; Shen, Mingqiang; Ran, Xinze; Su, Yongping; Cheng, Tianmin; Wang, Junping] Third Mil Med Univ, Coll Prevent Med, State Key Lab Trauma Burns & Combined Injury, Chongqing Engn Res Ctr Nanomed,Inst Combined Inju, Chongqing, Peoples R China; [Ling, Zongxin] Zhejiang Univ, Sch Med, Affiliated Hosp 1, State Key Lab Diag & Treatment Infect Dis, Hangzhou 310003, Zhejiang, Peoples R China; [Yang, Zhixiang] Chongqing Zhongshan Hosp, Dept Oncol, Chongqing, Peoples R China; [Kiela, Pawel R.] Univ Arizona, Coll Med, Dept Pediat, Tucson, AZ USA; [Kiela, Pawel R.] Univ Arizona, Coll Med, Dept Immunobiol, Tucson, AZ USA	Army Medical University; Zhejiang University; University of Arizona; University of Arizona	Wang, JP (corresponding author), Third Mil Med Univ, Coll Prevent Med, State Key Lab Trauma Burns & Combined Injury, Chongqing Engn Res Ctr Nanomed,Inst Combined Inju, Chongqing, Peoples R China.	wangjunping@tmmu.edu.cn	Wang, Cheng/AAK-7457-2021; Ling, Zongxin/AAM-4059-2021; Kiela, Pawel/AAF-5320-2020; Ling, Zongxin/M-1657-2018	Wang, Cheng/0000-0002-6690-6433; Ling, Zongxin/0000-0001-9662-099X; Wang, Cheng/0000-0001-5850-4533; Kiela, Pawel/0000-0002-0014-3517	National Natural Science Foundation of China grants (NSFC) [81172600, 81272101]; NSFC grant [81000831, 81271898]; National medical science "The Twelfth Five-year Plan" key project of China grant [BWS11J009]; Independent Research Grants of the State Key Laboratory of Trauma, Burn and Combined Injury [SKLZZ201114, SKLZZ201021, SKLZZ201202]; NIH grant [5R01-DK041274]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041274] Funding Source: NIH RePORTER	National Natural Science Foundation of China grants (NSFC)(National Natural Science Foundation of China (NSFC)); NSFC grant(National Natural Science Foundation of China (NSFC)); National medical science "The Twelfth Five-year Plan" key project of China grant; Independent Research Grants of the State Key Laboratory of Trauma, Burn and Combined Injury; NIH grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was supported by National Natural Science Foundation of China grants (NSFC) 81172600, 81272101 to Aiping Wang, NSFC grant 81000831, 81271898 to Junping Wang, National medical science "The Twelfth Five-year Plan" key project of China grant BWS11J009 to Junping Wang, Independent Research Grants of the State Key Laboratory of Trauma, Burn and Combined Injury SKLZZ201114, SKLZZ201021, SKLZZ201202 to Aiping Wang, the NIH grant 5R01-DK041274 to Pawel R. Kiela. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abayomi J, 2005, J HUM NUTR DIET, V18, P353, DOI 10.1111/j.1365-277X.2005.00633.x; Ahlberg K, 2005, INT J NURS STUD, V42, P377, DOI 10.1016/j.ijnurstu.2004.07.008; Andreyev HJN, 2010, LANCET ONCOL, V11, P310, DOI 10.1016/S1470-2045(10)70026-7; Atarashi K, 2013, NATURE, V500, P232, DOI 10.1038/nature12331; Atherton PJ, 2013, SUPPORT CARE CANCER, V21, P1193, DOI 10.1007/s00520-012-1648-8; Crawford PA, 2005, P NATL ACAD SCI USA, V102, P13254, DOI 10.1073/pnas.0504830102; Crenn P, 2000, GASTROENTEROLOGY, V119, P1496, DOI 10.1053/gast.2000.20227; Delia P, 2002, AM J GASTROENTEROL, V97, P2150; Ferreira MR, 2014, LANCET ONCOL, V15, pE139, DOI 10.1016/S1470-2045(13)70504-7; Fierer N, 2008, P NATL ACAD SCI USA, V105, P17994, DOI 10.1073/pnas.0807920105; Fuccio Lorenzo, 2015, World J Gastrointest Pharmacol Ther, V6, P1, DOI 10.4292/wjgpt.v6.i1.1; Haas BJ, 2011, GENOME RES, V21, P494, DOI 10.1101/gr.112730.110; Haddock MG, 2007, J CLIN ONCOL, V25, P1255, DOI 10.1200/JCO.2006.09.0001; Hagelin CL, 2007, ACTA ONCOL, V46, P97, DOI 10.1080/02841860601009430; Hauer-Jensen M, 2014, NAT REV GASTRO HEPAT, V11, P470, DOI 10.1038/nrgastro.2014.46; Hogan NM, 2013, CURR PROB SURG, V50, P395, DOI 10.1067/j.cpsurg.2013.04.004; Jakobsson S, 2010, ONCOLOGIST, V15, P1009, DOI 10.1634/theoncologist.2010-0097; Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI [10.3322/caac.20115, 10.3322/caac.20107]; Kim YS, 2015, ANAEROBE, V33, P1, DOI 10.1016/j.anaerobe.2015.01.004; Ling ZX, 2013, BMC GENOMICS, V14, DOI 10.1186/1471-2164-14-390; Lozupone C, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-371; Lutgens LCHW, 2004, INT J RADIAT ONCOL, V60, P275, DOI 10.1016/j.ijrobp.2004.02.052; Manichanh C, 2008, AM J GASTROENTEROL, V103, P1754, DOI 10.1111/j.1572-0241.2008.01868.x; Mayer EA, 2014, J NEUROSCI, V34, P15490, DOI 10.1523/JNEUROSCI.3299-14.2014; Miquel S, 2013, CURR OPIN MICROBIOL, V16, P255, DOI 10.1016/j.mib.2013.06.003; Pruesse E, 2007, NUCLEIC ACIDS RES, V35, P7188, DOI 10.1093/nar/gkm864; Rosen GL, 2011, BIOINFORMATICS, V27, P127, DOI 10.1093/bioinformatics/btq619; Ryan JL, 2007, ONCOLOGIST, V12, P22, DOI 10.1634/theoncologist.12-S1-22; Schloss PD, 2009, APPL ENVIRON MICROB, V75, P7537, DOI 10.1128/AEM.01541-09; Schubert C, 2007, BRAIN BEHAV IMMUN, V21, P413, DOI 10.1016/j.bbi.2006.11.004; Touchefeu Y, 2014, ALIMENT PHARM THER, V40, P409, DOI 10.1111/apt.12878; Trotti A, 2000, INT J RADIAT ONCOL, V47, P13, DOI 10.1016/S0360-3016(99)00559-3; Urbancsek H, 2001, EUR J GASTROEN HEPAT, V13, P391, DOI 10.1097/00042737-200104000-00015; Wedlake L, 2008, ALIMENT PHARM THER, V27, P980, DOI 10.1111/j.1365-2036.2008.03663.x	34	110	116	3	27	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 8	2015	10	5							e0126312	10.1371/journal.pone.0126312	http://dx.doi.org/10.1371/journal.pone.0126312			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CL2IX	25955845	gold, Green Submitted, Green Published			2023-01-03	WOS:000356768100111
J	Bjorck, L; Capewell, S; O'Flaherty, M; Lappas, G; Bennett, K; Rosengren, A				Bjorck, Lena; Capewell, Simon; O'Flaherty, Martin; Lappas, Georgios; Bennett, Kathleen; Rosengren, Annika			Decline in Coronary Mortality in Sweden between 1986 and 2002: Comparing Contributions from Primary and Secondary Prevention	PLOS ONE			English	Article							HEART-DISEASE MORTALITY; CARDIOVASCULAR-DISEASE; RISK-FACTORS; MYOCARDIAL-INFARCTION; INDIVIDUALS; SENSITIVITY; PREVALENCE; COUNTRIES; DECREASE; DEATHS	Background The relative importance of risk factor reduction in healthy people (primary prevention) versus that in patients with coronary heart disease (secondary prevention) has been debated. We aimed to quantify the contribution of the two. Methodology We used the previously validated IMPACT model to estimate contributions from primary prevention (reducing risk factors in the population, particularly smoking, cholesterol and systolic blood pressure) and from secondary prevention (reducing risk factors in coronary heart disease patients) in the Swedish population. Principal Findings Between 1986 and 2002, about 8,690 fewer deaths were related to changes in the three major risk factors. Population cholesterol fell by 0.64 mmol/L, with approximately 5,210 fewer deaths attributable to diet changes (4,470 in healthy people740 in patients.) plus 810 to statin treatment (200 in healthy people, 610 in patients). Overall smoking prevalence decreased by 10.3%, resulting in 1,195 fewer deaths, attributable to smoking cessation (595 in healthy people, 600 in patients). Mean population systolic blood pressure fell by 2.6 mmHg, resulting in 900 fewer deaths (865 in healthy people, 35 in patients), plus 575 fewer deaths attributable to antihypertensive medication in healthy people. The majority of falls in deaths attributable to risk factors occurred in people without known heart disease: 6,705 fewer deaths compared with 1,985 fewer deaths in patients (secondary prevention), emphasizing the importance of promoting health interventions in the general population. Conclusions The largest effects on mortality came from primary prevention, giving markedly larger mortality reductions than secondary prevention.	[Bjorck, Lena; Lappas, Georgios; Rosengren, Annika] Gothenburg Univ, Sahlgrenska Acad, Dept Mol & Clin Med, Gothenburg, Sweden; [Bjorck, Lena] Gothenburg Univ, Sahlgrenska Acad, Inst Hlth & Care Sci, Gothenburg, Sweden; [Capewell, Simon; O'Flaherty, Martin] Univ Liverpool, Div Publ Hlth, Liverpool L69 3BX, Merseyside, England; [Bennett, Kathleen] St James Hosp, Dept Pharmacol & Therapeut, Trinity Ctr Hlth Sci, Dublin 8, Ireland	University of Gothenburg; University of Gothenburg; University of Liverpool; Trinity College Dublin	Bjorck, L (corresponding author), Gothenburg Univ, Sahlgrenska Acad, Dept Mol & Clin Med, Gothenburg, Sweden.	lena.bjorck@gu.se		Bjorck, Lena/0000-0002-4827-4559; O'Flaherty, Martin/0000-0001-8944-4131; Rosengren, Annika/0000-0002-5409-6605; Bennett, Kathleen/0000-0002-2861-7665	Hjart-Lungfonden [20120463]; Swedish Research Council [2013-5187, 2013-423]; Medical Research Council [G0900847] Funding Source: researchfish; MRC [G0900847] Funding Source: UKRI	Hjart-Lungfonden; Swedish Research Council(Swedish Research CouncilEuropean Commission); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	The study is supported by Hjart-Lungfonden 20120463 (LB) (http://www.hjartlungfonden.se/) and the Swedish Research Council 2013-5187 and 2013-423 (GL) (http://www.vr.se/). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Berg J, 2014, BMC CARDIOVASC DISOR, V14, DOI 10.1186/1471-2261-14-9; Bjorck L, EUR HEART J; Bjorck L, 2009, EUR HEART J, V30, P1046, DOI 10.1093/eurheartj/ehn554; BRIGGS A, 1994, HEALTH ECON, V3, P95, DOI 10.1002/hec.4730030206; Butler J, 2002, J AM COLL CARDIOL, V40, P1589, DOI 10.1016/S0735-1097(02)02379-3; Capewell S, 1999, HEART, V81, P380, DOI 10.1136/hrt.81.4.380; Cooney MT, 2013, EUR J PREV CARDIOL, V20, P686, DOI 10.1177/2047487312445562; Dudas K, 2011, CIRCULATION, V123, P46, DOI 10.1161/CIRCULATIONAHA.110.964999; Ford ES, 2007, NEW ENGL J MED, V356, P2388, DOI 10.1056/NEJMsa053935; Kabir Z, 2007, BMC PUBLIC HEALTH, V7, DOI 10.1186/1471-2458-7-117; Kotseva K, 2001, EUR HEART J, V22, P554, DOI 10.1053/euhj.2001.2610; LAW MR, 1994, BMJ-BRIT MED J, V308, P367, DOI 10.1136/bmj.308.6925.367; Lewington S, 2002, LANCET, V360, P1903, DOI 10.1016/S0140-6736(02)11911-8; Lindblad U, 2012, SCAND J PRIM HEALTH, V30, P88, DOI 10.3109/02813432.2012.684207; MANT J, 1995, BMJ-BRIT MED J, V311, P793, DOI 10.1136/bmj.311.7008.793; Nichol MB, 1999, ANN PHARMACOTHER, V33, P531, DOI 10.1345/aph.18233; Nichols M, 2013, EUR HEART J, V34, P3028, DOI 10.1093/eurheartj/eht356; Rose G, 2001, INT J EPIDEMIOL, V30, P427, DOI 10.1093/ije/30.3.427; Teo K, 2013, JAMA-J AM MED ASSOC, V309, P1613, DOI 10.1001/jama.2013.3519; The Swedish Council of Technology Assessment in Health Care (SBU Statens beredning for medicinsk utvardering), 2004, MODERATELY ELEVATED; Unal B, 2004, CIRCULATION, V109, P1101, DOI 10.1161/01.CIR.0000118498.35499.B2; Unal B, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-1135; Vartiainen E, 2010, INT J EPIDEMIOL, V39, P504, DOI 10.1093/ije/dyp330; Walldius G, 2001, LANCET, V358, P2026, DOI 10.1016/S0140-6736(01)07098-2; Wilhelmsen L, 1997, J INTERN MED, V242, P199, DOI 10.1046/j.1365-2796.1997.00163.x; Young F, 2010, AM J PREV MED, V39, P228, DOI 10.1016/j.amepre.2010.05.009; Yusuf S, 2004, LANCET, V364, P937, DOI 10.1016/S0140-6736(04)17018-9	27	15	16	1	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 5	2015	10	5							e0124769	10.1371/journal.pone.0124769	http://dx.doi.org/10.1371/journal.pone.0124769			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CH3PT	25942424	Green Published, Green Submitted, gold			2023-01-03	WOS:000353943400021
J	Uematsu, H; Kunisawa, S; Yamashita, K; Imanaka, Y				Uematsu, Hironori; Kunisawa, Susumu; Yamashita, Kazuto; Imanaka, Yuichi			The Impact of Patient Profiles and Procedures on Hospitalization Costs through Length of Stay in Community-Acquired Pneumonia Patients Based on a Japanese Administrative Database	PLOS ONE			English	Article							HEALTH-CARE; PREDICTORS; QUALITY; RISK; MORTALITY; ADULTS; AGE	Background Community-acquired pneumonia is a common cause of patient hospitalization, and its burden on health care systems is increasing in aging societies. In this study, we aimed to investigate the factors that affect hospitalization costs in community-acquired pneumonia patients while considering the intermediate influence of patient length of stay. Methods Using a multi-institutional administrative claims database, we analyzed 30,041 patients hospitalized for community-acquired pneumonia who had been discharged between April 1, 2012 and September 30, 2013 from 289 acute care hospitals in Japan. Possible factors associated with hospitalization costs were investigated using structural equation modeling with length of stay as an intermediate variable. We calculated the direct, indirect (through length of stay), and total effects of the candidate factors on hospitalization costs in the model. Lastly, we calculated the ratio of indirect effects to direct effects for each factor. Results The structural equation model showed that higher disease severities (using A-DROP, Barthel Index, and Charlson Comorbidity Index scores), use of mechanical ventilation, and tube feeding were associated with higher hospitalization costs, regardless of the intermediate influence of length of stay. The severity factors were also associated with longer length of stay durations. The ratio of indirect effects to direct effects on total hospitalization costs showed that the former was greater than the latter in the factors, except in the use of mechanical ventilation. Conclusions Our structural equation modeling analysis indicated that patient profiles and procedures impacted on hospitalization costs both directly and indirectly. Furthermore, the profiles were generally shown to have greater indirect effects (through length of stay) on hospitalization costs than direct effects. These findings may be useful in supporting the more appropriate distribution of health care resources.	[Uematsu, Hironori; Kunisawa, Susumu; Yamashita, Kazuto; Imanaka, Yuichi] Kyoto Univ, Dept Healthcare Econ & Qual Management, Grad Sch Med, Kyoto, Kyoto, Japan; [Kunisawa, Susumu] Ritsumeikan Univ, Dept Biomed Sci, Kyoto, Kyoto, Japan	Kyoto University; Ritsumeikan University	Imanaka, Y (corresponding author), Kyoto Univ, Dept Healthcare Econ & Qual Management, Grad Sch Med, Kyoto, Kyoto, Japan.	imanaka-y@umin.net	Yuichi, Imanaka/GYR-2098-2022; KUNISAWA, Susumu/HCH-1094-2022	Yuichi, Imanaka/0000-0003-4613-2159; YAMASHITA, Kazuto/0000-0002-9684-5408	Japan Society for the Promotion of Science [25253033]	Japan Society for the Promotion of Science(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science)	This study was supported in part by a Grant-in-Aid for Scientific Research from the Japan Society for the Promotion of Science ((A) 25253033).	Blough DK., 2000, HLTH SERV OUTCOMES R, V1, P185, DOI [DOI 10.1023/A:1012597123667, 10.1023/A%3A1012597123667, DOI 10.1023/A%3A1012597123667]; Bonafede MM, 2012, AM J MANAG CARE, V18, P380; Cohen-Mansfield J, 2003, J GERONTOL A-BIOL, V58, P271; Collin C, 1988, Int Disabil Stud, V10, P61; Cortoos PJ, 2013, SCAND J INFECT DIS, V45, P219, DOI 10.3109/00365548.2012.726737; DAVIS CK, 1988, HEALTH POLICY, V9, P117, DOI 10.1016/0168-8510(88)90029-2; Fox J., 2002, APPENDIX R S PLUS CO; Garau J, 2008, CLIN MICROBIOL INFEC, V14, P322, DOI 10.1111/j.1469-0691.2007.01915.x; Hamada H, 2012, HEALTH POLICY, V107, P194, DOI 10.1016/j.healthpol.2012.01.002; Kaysar M, 2008, GERIATR GERONTOL INT, V8, P227, DOI 10.1111/j.1447-0594.2008.00480.x; Lim WS, 2003, THORAX, V58, P377, DOI 10.1136/thorax.58.5.377; Marrie TJ, 2000, CLIN INFECT DIS, V31, P1066, DOI 10.1086/318124; Menendez R, 2001, EUR RESPIR J, V18, P151, DOI 10.1183/09031936.01.00090001; Mitchell OS, 2004, AGED CARE SUPPORT JA; Park S, 2013, HEALTH POLICY, V111, P264, DOI 10.1016/j.healthpol.2013.05.015; Rothberg MB, 2014, ANN INTERN MED, V160, P380, DOI 10.7326/M13-1419; Sato R, 2013, APPL HEALTH ECON HEA, V11, P251, DOI 10.1007/s40258-013-0026-0; Sogaard M, 2014, RESP MED; Statistics And Information Department, 2012, PAT SURV 2011 DIS IN, P50; Sundararajan V, 2004, J CLIN EPIDEMIOL, V57, P1288, DOI 10.1016/j.jclinepi.2004.03.012; Suter-Widmer I, 2012, BMC PULM MED, V12, DOI 10.1186/1471-2466-12-21; Thomas CP, 2012, CHEST, V142, P973, DOI 10.1378/chest.11-1160; Torres OH, 2004, J AM GERIATR SOC, V52, P1603, DOI 10.1111/j.1532-5415.2004.52492.x; Uematsu H, 2014, BMC PULM MED, V14, DOI 10.1186/1471-2466-14-203; Uematsu H, 2014, INT J QUAL HEALTH C, V26, P100, DOI 10.1093/intqhc/mzt078; Welte T, 2012, THORAX, V67, P71, DOI 10.1136/thx.2009.129502	26	14	14	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 29	2015	10	4							e0125284	10.1371/journal.pone.0125284	http://dx.doi.org/10.1371/journal.pone.0125284			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	CH0LO	25923785	gold, Green Submitted, Green Published			2023-01-03	WOS:000353711600140
J	Florian, JP; Baisch, FJ; Heer, M; Pawelczyk, JA				Florian, John P.; Baisch, Friedhelm J.; Heer, Martina; Pawelczyk, James A.			Caloric Restriction Decreases Orthostatic Tolerance Independently from 6 degrees Head-Down Bedrest	PLOS ONE			English	Article							SYMPATHETIC NERVOUS-SYSTEM; LEPTIN GENE-EXPRESSION; FREE FATTY-ACIDS; BLOOD-PRESSURE; BED-REST; REFLEX RESPONSES; BODY-FLUID; HUMANS; MUSCLE; SPACEFLIGHT	Astronauts consume fewer calories during spaceflight and return to earth with an increased risk of orthostatic intolerance. Whether a caloric deficiency modifies orthostatic responses is not understood. Thus, we determined the effects of a hypocaloric diet (25% caloric restriction) during 6 degrees head down bedrest (an analog of spaceflight) on autonomic neural control during lower body negative pressure (LBNP). Nine healthy young men completed a randomized crossover bedrest study, consisting of four (2 weeks each) interventions (normocaloric bedrest, normocaloric ambulatory, hypocaloric bedrest, hypocaloric ambulatory), each separated by 5 months. Muscle sympathetic nerve activity (MSNA) was recorded at baseline following normocaloric and hypocaloric interventions. Heart rate (HR) and arterial pressure were recorded before, during, and after 3 consecutive stages (7 min each) of LBNP (-15, -30, -45 mmHg). Caloric and posture effects during LBNP were compared using two-way ANOVA with repeated measures. There was a strong trend toward reduced basal MSNA following caloric restriction alone (normcaloric vs. hypocaloric: 22 +/- 3 vs. 14 +/- 4 burst/min, p = 0.06). Compared to the normocaloric ambulatory, both bedrest and caloric restriction were associated with lower systolic blood pressure during LBNP (p<0.01); however, HR responses were directionally opposite (i.e., increase with bedrest, decrease with caloric restriction). Survival analysis revealed a significant reduction in orthostatic tolerance following caloric restriction (normocaloric finishers: 12/16; hypocaloric finishers: 6/16;chi(2), p = 0.03). Caloric restriction modifies autonomic responses to LBNP, which may decrease orthostatic tolerance after spaceflight.	[Florian, John P.] Navy Expt Div Unit, Panama City, FL 32407 USA; [Pawelczyk, James A.] Penn State Univ, Dept Kinesiol, Noll Lab, University Pk, PA 16802 USA; [Baisch, Friedhelm J.; Heer, Martina] DLR, Inst Aerosp Med, Cologne, Germany	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Helmholtz Association; German Aerospace Centre (DLR)	Florian, JP (corresponding author), Navy Expt Div Unit, Panama City, FL 32407 USA.	john.florian@navy.mil	Heer, Martina/Q-4959-2019	Heer, Martina/0000-0001-5534-911X	National Space Biomedical Research Institute [TD00206]	National Space Biomedical Research Institute	This research was supported by National Space Biomedical Research Institute Contract TD00206. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alvarez GE, 2005, AM J PHYSIOL-ENDOC M, V289, pE665, DOI 10.1152/ajpendo.00487.2004; Bigard AX, 1998, AVIAT SPACE ENVIR MD, V69, P341; Blomqvist C. G., 1994, J GRAVIT PHYSL, V1, P122; BUCKEY JC, 1992, ACTA PHYSIOL SCAND, V144, P53; Buckey JC, 1996, J APPL PHYSIOL, V81, P7, DOI 10.1152/jappl.1996.81.1.7; Capelli C, 2006, EUR J APPL PHYSIOL, V98, P152, DOI 10.1007/s00421-006-0252-3; Coleman RA, 1999, DIABETOLOGIA, V42, P639, DOI 10.1007/s001250051210; DAVDA RK, 1995, HYPERTENSION, V26, P764, DOI 10.1161/01.HYP.26.5.764; Drummer C, 2000, EUR J CLIN INVEST, V30, P1066, DOI 10.1046/j.1365-2362.2000.00766.x; Fabris R, 2001, DIABETES, V50, P601, DOI 10.2337/diabetes.50.3.601; FISCHER CL, 1967, J AMER MED ASSOC, V200, P579, DOI 10.1001/jama.200.7.579; Florian JP, 2010, EXP PHYSIOL, V95, P486, DOI 10.1113/expphysiol.2009.050997; Florian JP, 2010, CLIN SCI, V118, P61, DOI 10.1042/CS20090063; FRITSCH JM, 1992, J APPL PHYSIOL, V73, P664, DOI 10.1152/jappl.1992.73.2.664; Gerzer R, 2005, CURR PHARM BIOTECHNO, V6, P299, DOI 10.2174/1389201054553662; Gohler L, 2000, PREV MED, V30, P95, DOI 10.1006/pmed.1999.0602; Grassi G, 1998, CIRCULATION, V97, P2037, DOI 10.1161/01.CIR.97.20.2037; Heer M, 2000, AM J PHYSIOL-RENAL, V278, pF585, DOI 10.1152/ajprenal.2000.278.4.F585; Heer M, 2000, PFLUG ARCH EUR J PHY, V441, pR8, DOI 10.1007/s004240000334; Heptulla R, 2001, J CLIN ENDOCR METAB, V86, P90, DOI 10.1210/jc.86.1.90; Hesse C, 2005, J APPL PHYSIOL, V99, P2196, DOI 10.1152/japplphysiol.00888.2005; Hunt LM, 2004, AM J PHYSIOL-HEART C, V287, pH1446, DOI 10.1152/ajpheart.00353.2004; KUSHIRO T, 1991, HYPERTENSION, V17, P965, DOI 10.1161/01.HYP.17.6.965; Lam TKT, 2005, NAT NEUROSCI, V8, P579, DOI 10.1038/nn1456; Levine BD, 1997, CIRCULATION, V96, P517; Lin PH, 2003, AM J CLIN NUTR, V77, P639, DOI 10.1093/ajcn/77.3.639; Manzella D, 2001, J CLIN ENDOCR METAB, V86, P2769, DOI 10.1210/jc.86.6.2769; Messaoudi L, 1998, METABOLISM, V47, P592, DOI 10.1016/S0026-0495(98)90245-1; Minuz P, 2002, CIRCULATION, V106, P2800, DOI 10.1161/01.CIR.0000039528.49161.E9; Nisoli E, 1999, DIABETOLOGIA, V42, P495; NIXON JV, 1979, J APPL PHYSIOL, V46, P541, DOI 10.1152/jappl.1979.46.3.541; Paolisso G, 2000, AM J CLIN NUTR, V72, P723; Pawelczyk JA, 2001, AM J PHYSIOL-HEART C, V280, pH2230, DOI 10.1152/ajpheart.2001.280.5.H2230; Roberts SB, 2007, J NUTR, V137, P1076, DOI 10.1093/jn/137.4.1076; Robertson D, 1999, AM J MED SCI, V317, P75, DOI 10.1097/00000441-199902000-00001; Shetty PS, 1999, EUR J CLIN NUTR, V53, pS14, DOI 10.1038/sj.ejcn.1600741; Stein TP, 1999, AM J PHYSIOL-REG I, V276, pR1739; Steinberg HO, 1997, J CLIN INVEST, V100, P1230, DOI 10.1172/JCI119636; Stepniakowski KT, 1996, AM J PHYSIOL-REG I, V270, pR1340, DOI 10.1152/ajpregu.1996.270.6.R1340; STRAZNICKY NE, 1993, J HYPERTENS, V11, P427, DOI 10.1097/00004872-199304000-00014; Straznicky NE, 1999, HYPERTENSION, V34, P580, DOI 10.1161/01.HYP.34.4.580; VOLLENWEIDER L, 1995, DIABETES, V44, P641, DOI 10.2337/diabetes.44.6.641; WALLIN BG, 1982, AM J PHYSIOL, V242, pH185, DOI 10.1152/ajpheart.1982.242.2.H185; Wang JL, 1998, NATURE, V393, P684, DOI 10.1038/31474; Williams TD, 2002, AM J PHYSIOL-REG I, V282, pR1459, DOI 10.1152/ajpregu.00612.2001; Yates AA, 1998, J AM DIET ASSOC, V98, P699, DOI 10.1016/S0002-8223(98)00160-6; YOUNG JB, 1977, SCIENCE, V196, P1473, DOI 10.1126/science.867049; YOUNG JB, 1982, J CHRON DIS, V35, P879, DOI 10.1016/0021-9681(82)90118-7	48	15	15	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 27	2015	10	4							e0118812	10.1371/journal.pone.0118812	http://dx.doi.org/10.1371/journal.pone.0118812			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CG9SB	25915488	gold, Green Published, Green Submitted			2023-01-03	WOS:000353659100002
J	Beissner, F; Brunner, F; Fink, M; Meissner, K; Kaptchuk, TJ; Napadow, V				Beissner, Florian; Bruenner, Franziska; Fink, Maria; Meissner, Karin; Kaptchuk, Ted J.; Napadow, Vitaly			Placebo-Induced Somatic Sensations: A Multi-Modal Study of Three Different Placebo Interventions	PLOS ONE			English	Article							MCGILL PAIN QUESTIONNAIRE; PERSONALITY-TRAIT; NOVELTY SEEKING; MUSCLE PAIN; ACUPUNCTURE; BRAIN; PERCEPTION; MICROSTIMULATION; SYNAESTHESIA; MIGRAINE	Somatic sensations induced by placebos are a frequent phenomenon whose etiology and clinical relevance remains unknown. In this study, we have evaluated the quantitative, qualitative, spatial, and temporal characteristics of placebo-induced somatic sensations in response to three different placebo interventions: (1) placebo irritant solution, (2) placebo laser stimulation, and (3) imagined laser stimulation. The quality and intensity of evoked sensations were assessed using the McGill pain questionnaire and visual analogue scales (VAS), while subjects' sensation drawings processed by a geographic information system (GIS) were used to measure their spatial characteristics. We found that all three interventions are capable of producing robust sensations most frequently described as "tingling" and "warm" that can reach consider-able spatial extent (<= 205mm(2)) and intensity (<= 80/100 VAS). Sensations from placebo stimulation were often referred to areas remote from the stimulation site and exhibit considerable similarity with referred pain. Interestingly, there was considerable similarity of qualitative features as well as spatial patterns across subjects and placebos. However, placebo laser stimulation elicited significantly stronger and more widespread sensations than placebo irritant solution. Finally, novelty seeking, a character trait assessed by the Temperament and Character Inventory and associated with basal dopaminergic activity, was less pronounced in subjects susceptible to report placebo-induced sensations. Our study has shown that placebo-induced sensations are frequent and can reach considerable intensity and extent. As multiple somatosensory subsystems are involved despite the lack of peripheral stimulus, we propose a central etiology for this phenomenon.	[Beissner, Florian] Hannover Med Sch, Somatosensory & Auton Therapy Res, Inst Neuroradiol, D-30625 Hannover, Germany; [Beissner, Florian; Napadow, Vitaly] Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, Dept Radiol, Boston, MA 02129 USA; [Bruenner, Franziska; Fink, Maria] Jena Univ Hosp, Pain & Auton Integrat Res PAIR, Dept Psychiat & Psychotherapy, D-07743 Jena, Germany; [Meissner, Karin] Univ Munich, Inst Med Psychol, D-80336 Munich, Germany; [Kaptchuk, Ted J.] Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Program Placebo Studies, Boston, MA 02215 USA; [Napadow, Vitaly] Kyung Hee Univ, Dept Biomed Engn, Yongin, South Korea	Hannover Medical School; Harvard University; Massachusetts General Hospital; Friedrich Schiller University of Jena; University of Munich; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Kyung Hee University	Beissner, F (corresponding author), Hannover Med Sch, Somatosensory & Auton Therapy Res, Inst Neuroradiol, D-30625 Hannover, Germany.	beissner.florian@mh-hannover.de	MEISSNER, Karin/AAS-2483-2021; Beissner, Florian/I-3474-2019	Beissner, Florian/0000-0003-0513-7551; Napadow, Vitaly/0000-0003-1941-1750	Horst Gortz Foundation; German Research Foundation [BE4677/1-1]; Schweizer-Arau Foundation; Theophrastus Foundation; NIH [K24-AT004095, P01-AT006663, R01-AT007550, R01-AR064367]; National Center for Complementary & Integrative Health [K24AT004095, R01AT007550, P01AT006663] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR064367] Funding Source: NIH RePORTER	Horst Gortz Foundation; German Research Foundation(German Research Foundation (DFG)); Schweizer-Arau Foundation; Theophrastus Foundation; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Center for Complementary & Integrative Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	This study was supported by Horst Gortz Foundation (FBe, FBr), German Research Foundation BE4677/1-1 (FB), Schweizer-Arau Foundation (KM), Theophrastus Foundation (KM) and NIH grants K24-AT004095 (TJK), P01-AT006663 (VN, TJK), R01-AT007550 (VN), and R01-AR064367 (VN). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Banissy MJ, 2009, EXP BRAIN RES, V198, P261, DOI 10.1007/s00221-009-1810-9; Beissner F, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/591304; Benedetti F, 2011, NEUROPSYCHOPHARMACOL, V36, P339, DOI 10.1038/npp.2010.81; Bryant BP, 1999, BRAIN RES, V842, P452, DOI 10.1016/S0006-8993(99)01878-8; CLONINGER CR, 1987, ARCH GEN PSYCHIAT, V44, P573; CLONINGER CR, 1986, PSYCHIAT DEV, V4, P167; Colloca L, 2009, PAIN, V144, P28, DOI 10.1016/j.pain.2009.01.033; Darragh M, 2014, J PSYCHOSOM RES, V76, P414, DOI 10.1016/j.jpsychores.2014.02.011; De Pascalis V, 2002, PAIN, V96, P393, DOI 10.1016/S0304-3959(01)00485-7; Ebstein RP, 1996, NAT GENET, V12, P78, DOI 10.1038/ng0196-78; Enck P, 2013, NAT REV DRUG DISCOV, V12, P191, DOI 10.1038/nrd3923; FEINSTEIN B, 1954, J BONE JOINT SURG AM, V36-A, P981, DOI 10.2106/00004623-195436050-00007; Finniss DG, 2010, LANCET, V375, P686, DOI 10.1016/S0140-6736(09)61706-2; Fiorio M, 2012, NEUROSCIENCE, V217, P96, DOI 10.1016/j.neuroscience.2012.04.066; Gilbert CD, 2007, NEURON, V54, P677, DOI 10.1016/j.neuron.2007.05.019; GravenNielsen T, 1997, BRAIN RES, V744, P121, DOI 10.1016/S0006-8993(96)01077-3; GravenNielsen T, 1997, J MUSCULOSKELET PAIN, V5, P49, DOI 10.1300/J094v05n01_04; Harrison J, 1997, SYNAESTHESIA INTRO, P281; Head H, 1893, BRAIN, V16, P1, DOI DOI 10.1093/BRAIN/16.1-2.1; Hrobjartsson A, 2011, J CLIN EPIDEMIOL, V64, P1223, DOI 10.1016/j.jclinepi.2011.01.008; Hui Kathleen K S, 2007, BMC Complement Altern Med, V7, P33, DOI 10.1186/1472-6882-7-33; Irnich D, 2011, EVID-BASED COMPL ALT, V2011, P1, DOI 10.1093/ecam/neq009; JOHNSON AG, 1994, LANCET, V344, P1140, DOI 10.1016/S0140-6736(94)90637-8; Kaptchuk TJ, 2006, BMJ-BRIT MED J, V332, P391, DOI 10.1136/bmj.38726.603310.55; Kaptchuk TJ, 2000, J CLIN EPIDEMIOL, V53, P786, DOI 10.1016/S0895-4356(00)00206-7; Kerr CE, 2011, CONSCIOUS COGN, V20, P784, DOI 10.1016/j.concog.2010.12.009; Keysers C, 2010, NAT REV NEUROSCI, V11, P417, DOI 10.1038/nrn2833; Kong J, 2007, J ALTERN COMPLEM MED, V13, P1059, DOI 10.1089/acm.2007.0524; Lennertz RC, 2010, J NEUROSCI, V30, P4353, DOI 10.1523/JNEUROSCI.4666-09.2010; LENZ FA, 1993, J NEUROPHYSIOL, V70, P200, DOI 10.1152/jn.1993.70.1.200; Liang ZH, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/620671; Linde K, 2010, FORSCH KOMPLEMENTMED, V17, P259, DOI 10.1159/000320374; Longley P.A., 2005, GEOGRAPHIC INFORM SY, V2nd, P536; Lucas MV, 2015, CEREB CORTEX, V25, P2623, DOI 10.1093/cercor/bhu061; Mackenzie J, 1893, BRAIN, V16, P321; MARCHAND S, 1993, PAIN, V54, P99, DOI 10.1016/0304-3959(93)90104-W; MAUGUIERE F, 1978, BRAIN, V101, P307, DOI 10.1093/brain/101.2.307; Meissner K, 2013, JAMA INTERN MED, V173, P1941, DOI 10.1001/jamainternmed.2013.10391; MELZACK R, 1975, PAIN, V1, P277, DOI 10.1016/0304-3959(75)90044-5; Michael GA, 2011, CONSCIOUS COGN, V20, P603, DOI 10.1016/j.concog.2010.11.013; Napadow V, 2009, NEUROIMAGE, V47, P1055, DOI 10.1016/j.neuroimage.2009.05.079; NORDIN M, 1984, PAIN, V20, P231, DOI 10.1016/0304-3959(84)90013-7; OCHOA J, 1983, J PHYSIOL-LONDON, V342, P633, DOI 10.1113/jphysiol.1983.sp014873; Park H, 2002, AM J CHINESE MED, V30, P45, DOI 10.1142/S0192415X02000053; Penfield W, 1933, ARCH NEURO PSYCHIATR, V30, P709, DOI 10.1001/archneurpsyc.1933.02240160009001; Ramachandran V, 2001, J CONSCIOUSNESS STUD, V8, P3; Ro T, 2007, ANN NEUROL, V62, P433, DOI 10.1002/ana.21219; ROBERTS AH, 1993, CLIN PSYCHOL REV, V13, P375, DOI 10.1016/0272-7358(93)90010-J; Salih N, 2010, BMC COMPLEM ALTERN M, V10, DOI 10.1186/1472-6882-10-81; Schmidt TT, 2014, NEUROIMAGE, V98, P216, DOI 10.1016/j.neuroimage.2014.05.014; Schweinhardt P, 2009, J NEUROSCI, V29, P4882, DOI 10.1523/JNEUROSCI.5634-08.2009; SHAPIRO AK, 1968, PSYCHIAT QUART, V42, P653, DOI 10.1007/BF01564309; Sihvonen R, 2013, NEW ENGL J MED, V369, P2515, DOI 10.1056/NEJMoa1305189; STEIN C, 1988, PAIN, V32, P251, DOI 10.1016/0304-3959(88)90074-7; Streitberger K, 1998, LANCET, V352, P364, DOI 10.1016/S0140-6736(97)10471-8; Suhara T, 2001, NEUROIMAGE, V13, P891, DOI 10.1006/nimg.2001.0761; TANSEY MJB, 1993, J NEUROL SCI, V114, P109, DOI 10.1016/0022-510X(93)90057-6; Tracey I, 2010, NAT MED, V16, P1277, DOI 10.1038/nm.2229; Vecchiet, 1999, Curr Rev Pain, V3, P489; Ward J, 2013, ANNU REV PSYCHOL, V64, P49, DOI 10.1146/annurev-psych-113011-143840; Wartolowska K, 2014, BMJ IN PRESS, P348	61	21	21	15	108	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 22	2015	10	4							e0124808	10.1371/journal.pone.0124808	http://dx.doi.org/10.1371/journal.pone.0124808			21	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	CG5KV	25901350	Green Published, Green Submitted, gold			2023-01-03	WOS:000353331500100
J	Kim, HJ; Kim, WH; Lim, HW; Kim, JA; Kim, DK; Shin, BS; Sim, WS; Hahm, TS; Kim, CS; Lee, SM				Kim, Hyo-Jin; Kim, Won Ho; Lim, Hyung Woo; Kim, Jie Ae; Kim, Duk-Kyung; Shin, Byung Seop; Sim, Woo Seog; Hahm, Tae Soo; Kim, Chung Su; Lee, Sangmin M.			Obesity Is Independently Associated with Spinal Anesthesia Outcomes: A Prospective Observational Study	PLOS ONE			English	Article							BODY-MASS INDEX; ISOBARIC 0.5-PERCENT BUPIVACAINE; CEREBROSPINAL-FLUID VOLUME; SPREAD; INTERSPACE; ANALGESIA; BLOCKADE	The influence of body-mass index (BMI) on spinal anesthesia is still controversial, with discrepant results reported in previous studies. To compare spinal anesthesia in obese and non-obese subjects, the anesthesia profiles in patients who underwent spinal anesthesia using intrathecal hyperbaric bupivacaine were compared. A total of 209 patients undergoing elective total knee replacement arthroplasty (TKRA) surgery under spinal anesthesia were divided into an NO (non-obese) group (BMI < 30 kg/m(2), n = 141) and an O (obese) group (BMI >= 30 kg/m(2), n = 68). Anesthesia was deemed successful if a bilateral T12 sensory block occurred within 15 minutes of intrathecal drug administration, and if the level of sensory block was higher than T12 when the surgery ended. Logistic regression analysis with multiple variables known to influence spinal anesthesia was performed to identify which parameters independently determined the spinal anesthesia outcome. Similar doses of bupivacaine were administered to the NO and O groups. The incidence of anesthesia failure was significantly lower in the O group [n = 43 (30.5%) in the NO group vs. n = 10 (18.9%) in the O group, p = 0.014]. The independent predictors for successful anesthesia in all patients were dose of hyperbaric bupivacaine [odds ratio (OR) 2.12, 95% CI: 1.64-2.73] and obese status (BMI >= 30 kg/m(2), OR 2.86, 95% CI: 1.25-6.52). Time to first report of postoperative pain and time to first self-void were significantly longer in the O group. These results suggest that the duration of block with hyperbaric bupivacaine is prolonged in obese patients and obesity is independently associated with spinal anesthesia outcomes, as is bupivacaine dosage. A further study enrolling patients with morbid obesity and using a fixed bupivacaine dosage is required to confirm the effect of obesity on spinal anesthesia.	[Kim, Hyo-Jin; Kim, Won Ho; Kim, Jie Ae] Sungkyunkwan Univ, Samsung Changwon Hosp, Sch Med, Dept Anesthesiol & Pain Med, Chang Won, South Korea; [Lim, Hyung Woo; Kim, Duk-Kyung; Shin, Byung Seop; Sim, Woo Seog; Hahm, Tae Soo; Kim, Chung Su; Lee, Sangmin M.] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Anesthesiol & Pain Med, Seoul, South Korea	Sungkyunkwan University (SKKU); Samsung Medical Center; Sungkyunkwan University (SKKU); Samsung Medical Center	Kim, WH (corresponding author), Sungkyunkwan Univ, Samsung Changwon Hosp, Sch Med, Dept Anesthesiol & Pain Med, Chang Won, South Korea.	wonhokim.ane@gmail.com	Kim, Won Ho/S-8671-2019; Lim, HW/GRY-3517-2022; Ahn, Hyun Joo/HJA-9552-2022	Kim, Won Ho/0000-0003-1748-1296; 				Barba C, 2004, LANCET, V363, P157, DOI 10.1016/S0140-6736(03)15268-3; BARCLAY DL, 1968, AM J OBSTET GYNECOL, V101, P792, DOI 10.1016/0002-9378(68)90035-5; BLOMBERG R, 1986, ANESTH ANALG, V65, P747; Broadbent CR, 2000, ANAESTHESIA, V55, P1122, DOI 10.1046/j.1365-2044.2000.01547-4.x; BROMAGE PR, 1964, BRIT J ANAESTH, V36, P342, DOI 10.1093/bja/36.6.342; CAPOGNA G, 1995, REGION ANESTH, V20, P369; Carpenter RL, 1998, ANESTHESIOLOGY, V89, P24, DOI 10.1097/00000542-199807000-00007; Carvalho B, 2011, ANESTHESIOLOGY, V114, P529, DOI 10.1097/ALN.0b013e318209a92d; CONCATO J, 1993, ANN INTERN MED, V118, P201, DOI 10.7326/0003-4819-118-3-199302010-00009; Dalton WT, 2014, SOUTH MED J, V107, P348, DOI 10.14423/01.SMJ.0000450708.52011.7c; Demidenko E, 2007, STAT MED, V26, P3385, DOI 10.1002/sim.2771; Ginosar Y, 2004, ANESTHESIOLOGY, V100, P676, DOI 10.1097/00000542-200403000-00031; HARTWELL BL, 1991, REGION ANESTH, V16, P17; Hocking G, 2004, BRIT J ANAESTH, V93, P568, DOI 10.1093/bja/aeh204; Hogan QH, 1996, ANESTHESIOLOGY, V84, P1341, DOI 10.1097/00000542-199606000-00010; JENSEN MP, 1986, PAIN, V27, P117, DOI 10.1016/0304-3959(86)90228-9; Kim WH, 2012, ANAESTH INTENS CARE, V40, P410, DOI 10.1177/0310057X1204000305; Leino KA, 2011, J ANESTH, V25, P213, DOI 10.1007/s00540-010-1082-3; LOGAN MR, 1986, BRIT J ANAESTH, V58, P292, DOI 10.1093/bja/58.3.292; Lundstrom LH, 2009, ANESTHESIOLOGY, V110, P266, DOI 10.1097/ALN.0b013e318194cac8; MCCULLOCH WJD, 1986, BRIT J ANAESTH, V58, P610, DOI 10.1093/bja/58.6.610; Nie JX, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107548; Pan PH, 2004, SOUTH MED J, V97, P359, DOI 10.1097/01.SMJ.0000078681.07409.F7; Patel AV, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109153; PITKANEN M, 1984, BRIT J ANAESTH, V56, P279, DOI 10.1093/bja/56.3.279; PITKANEN MT, 1987, ANESTH ANALG, V66, P127, DOI 10.1213/00000539-198702000-00005; ROBINSON LS, 1949, SURGERY, V25, P329; Schnider TW, 1996, ANESTHESIOLOGY, V85, P502, DOI 10.1097/00000542-199609000-00009; TAIVAINEN T, 1990, BRIT J ANAESTH, V64, P542, DOI 10.1093/bja/64.5.542	29	8	8	1	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 21	2015	10	4							e0124264	10.1371/journal.pone.0124264	http://dx.doi.org/10.1371/journal.pone.0124264			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CG3XJ	25898360	Green Submitted, Green Published, gold			2023-01-03	WOS:000353212600058
J	Zhang, Q; Zhang, Y; Li, K; Wang, HY; Li, HZ; Zheng, JN				Zhang, Qing; Zhang, Yang; Li, Ke; Wang, Haiyu; Li, Huizhong; Zheng, Junnian			A Novel Strategy to Improve the Therapeutic Efficacy of Gemcitabine for Non-Small Cell Lung Cancer by the Tumor-Penetrating Peptide iRGD	PLOS ONE			English	Article							ELDERLY-PATIENTS; SINGLE-AGENT; MODIFIED LIPOSOMES; GROWTH-FACTOR; CHEMOTHERAPY; COMBINATION; PACLITAXEL; NANOPARTICLES; GLYCOPROTEIN; DOXORUBICIN	Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, comprising approximately 75-80% of all lung cancers. Gemcitabine is an approved chemotherapy drug for NSCLC. The objective of this study was to develop a novel strategy to improve the therapeutic efficacy of Gemcitabine for NSCLC by the co-administered iRGD peptide. We showed that the rates of positive expression of alpha v beta 3, alpha v beta 5 and NRP-1 in the A549 cell line were 68.5%, 35.3% and 94.5%, respectively. The amount of Evans Blue accumulated in the tumor of Evans Blue+iRGD group was 2.5 times that of Evans Blue group. The rates of growth inhibition of the tumors of the iRGD group, the Gemcitabine group and the Gemcitabine+iRGD group were 8%, 59.8% and 86.9%, respectively. The results of mechanism studies showed that PCNA expression in the Gemcitabine+iRGD group decreased 71.5% compared with that in Gemcitabine group. The rate of apoptosis in the Gemcitabine+iRGD group was 2.2 time that of the Gemcitabine group. Therefore, the tumor-penetrating Peptide iRGD can enhance the tumor-penetrating ability and therapeutic efficacy of Gemcitabine in the A549 xenograft. The combined application of Gemcitabine with iRGD may be a novel strategy to enhance the clinical therapeutic efficacy of Gemcitabine in patients with NSCLC.	[Zhang, Qing; Zhang, Yang; Li, Ke; Wang, Haiyu; Li, Huizhong; Zheng, Junnian] Xuzhou Med Coll, Inst Canc, Xuzhou 221002, Jiangsu, Peoples R China; [Zheng, Junnian] Xuzhou Med Coll, Inst Canc, Jiangsu Ctr Collaborat & Innovat Canc Biotherapy, Xuzhou 221002, Jiangsu, Peoples R China; [Zhang, Yang] Southeast Univ, Affiliated Hosp, Xuzhou Med Coll, Dept Oncol,Xuzhou Cent Hosp,Xuzhou Clin Sch, Xuzhou 221009, Jiangsu, Peoples R China	Xuzhou Medical University; Xuzhou Medical University; Southeast University - China; Xuzhou Medical University	Zheng, JN (corresponding author), Xuzhou Med Coll, Inst Canc, Xuzhou 221002, Jiangsu, Peoples R China.	jnzheng@xzmc.edu.cn			Natural Science Foundation of Jiangsu Province [BK2012146]; National Natural Science Foundation of China [81301946]; Jiangsu Provincial Office of Education Foundation [JHB2012-34]; China Postdoctoral Science Foundation funded project [2013M540467]; Xuzhou Medical College Foundation [2012KJZ23]	Natural Science Foundation of Jiangsu Province(Natural Science Foundation of Jiangsu Province); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Jiangsu Provincial Office of Education Foundation; China Postdoctoral Science Foundation funded project(China Postdoctoral Science Foundation); Xuzhou Medical College Foundation	This work was supported by Natural Science Foundation of Jiangsu Province (BK2012146, http://www.jstd.gov.cn/), National Natural Science Foundation of China (81301946, http://www.nsfc.gov.cn/), Jiangsu Provincial Office of Education Foundation (JHB2012-34, http://www.ec.js.edu.cn/), China Postdoctoral Science Foundation funded project (2013M540467, http://res.chinapostdoctor.org.cn/BshWeb/index.shtml), and Xuzhou Medical College Foundation (2012KJZ23, http://www.xzmc.edu.cn/). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aizawa K, 2013, LUNG CANCER, V82, P390, DOI 10.1016/j.lungcan.2013.09.012; Akashi Y, 2014, BRIT J CANCER, V110, P1481, DOI 10.1038/bjc.2014.49; Altavilla G, 2000, ANTICANCER RES, V20, P3675; Baker JHE, 2008, CLIN CANCER RES, V14, P2171, DOI 10.1158/1078-0432.CCR-07-4465; Bianco V, 2002, ANTICANCER RES, V22, P3053; Cao K, 2012, CANCER BIOTHER RADIO, V27, P259, DOI 10.1089/cbr.2011.1126; Cerqueira NMFSA, 2007, CHEM-EUR J, V13, P8507, DOI 10.1002/chem.200700260; Cortes-Funes H, 2002, SEMIN ONCOL, V29, P26, DOI 10.1053/sonc.2002.33530; Dai WB, 2015, DRUG DELIV, V22, P10, DOI 10.3109/10717544.2014.903580; Dancey J, 1997, EUR J CANCER, V33, pS2, DOI 10.1016/S0959-8049(96)00325-5; Du R, 2014, INT J NANOMED, V9, P3091, DOI 10.2147/IJN.S65664; Ferrigno D, 2000, LUNG CANCER-J IASLC, V29, P91, DOI 10.1016/S0169-5002(00)00112-4; Gridelli C, 2003, JNCI-J NATL CANCER I, V95, P362, DOI 10.1093/jnci/95.5.362; Gridelli C, 2008, LUNG CANCER, V61, P67, DOI 10.1016/j.lungcan.2007.12.002; Gu GZ, 2013, BIOMATERIALS, V34, P5138, DOI 10.1016/j.biomaterials.2013.03.036; Heldin CH, 2004, NAT REV CANCER, V4, P806, DOI 10.1038/nrc1456; Higgins B, 2004, ANTI-CANCER DRUG, V15, P503, DOI 10.1097/01.cad.0000127664.66472.60; Kim IY, 2009, J CONTROL RELEASE, V140, P55, DOI 10.1016/j.jconrel.2009.07.005; Kim MK, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-98; Kraus-Berthier L, 2000, CLIN CANCER RES, V6, P297; Marx G, 2002, LUNG CANCER-J IASLC, V38, pS51; Mortenson MM, 2004, CANCER CHEMOTH PHARM, V54, P343, DOI 10.1007/s00280-004-0811-4; Pauwels B, 2005, ONCOLOGIST, V10, P34, DOI 10.1634/theoncologist.10-1-34; Pellet-Many C, 2008, BIOCHEM J, V411, P211, DOI 10.1042/BJ20071639; Primeau AJ, 2005, CLIN CANCER RES, V11, P8782, DOI 10.1158/1078-0432.CCR-05-1664; Quoix E, 2005, LUNG CANCER-J IASLC, V47, P405, DOI 10.1016/j.lungcan.2004.08.012; Ren HN, 2009, MOL CANCER THER, V8, P1106, DOI 10.1158/1535-7163.MCT-08-0779; Ricci S, 2000, LUNG CANCER, V27, P75, DOI 10.1016/S0169-5002(99)00098-7; Roth L, 2012, ONCOGENE, V31, P3754, DOI 10.1038/onc.2011.537; Sanchez AJ, 2006, J VIROL, V80, P514, DOI 10.1128/JVI.80.1.514-525.2006; Shelley MD, 2011, BJU INT, V108, P168, DOI 10.1111/j.1464-410X.2011.10341.x; Shen JN, 2014, MOL PHARMACEUT, V11, P2579, DOI 10.1021/mp400576f; Siegel R, 2014, CA-CANCER J CLIN, V64, P9, DOI 10.3322/caac.21208; Song WT, 2012, MACROMOL BIOSCI, V12, P1514, DOI 10.1002/mabi.201200145; Spiro SG, 2002, AM J RESP CRIT CARE, V166, P1166, DOI 10.1164/rccm.200202-070SO; Su SS, 2013, BIOMATERIALS, V34, P3523, DOI 10.1016/j.biomaterials.2013.01.083; Sugahara KN, 2010, SCIENCE, V328, P1031, DOI 10.1126/science.1183057; Sugahara KN, 2009, CANCER CELL, V16, P510, DOI 10.1016/j.ccr.2009.10.013; Takebayashi R, 2013, J EXP CLIN CANC RES, V32, DOI 10.1186/1756-9966-32-34; Teesalu T, 2009, P NATL ACAD SCI USA, V106, P16157, DOI 10.1073/pnas.0908201106; Wang H, 2006, MOL CANCER THER, V5, P1585, DOI 10.1158/1535-7163.MCT-06-0094; Wang K, 2014, BIOMATERIALS, V35, P8735, DOI 10.1016/j.biomaterials.2014.06.042; Wang Lin-Run, 2005, J Zhejiang Univ Sci B, V6, P446, DOI 10.1631/jzus.2005.B0446; Wool-Lewis RJ, 1999, J VIROL, V73, P1419, DOI 10.1128/JVI.73.2.1419-1426.1999; Yang P, 2005, CHEST, V128, P452, DOI 10.1378/chest.128.1.452; Yu KF, 2013, INT J NANOMED, V8, P2473, DOI 10.2147/IJN.S46962; Zhang HT, 2011, ANTI-CANCER DRUG, V22, P409, DOI 10.1097/CAD.0b013e328342050d; Zhang Q, 2012, CANCER BIOTHER RADIO, V27, P384, DOI 10.1089/cbr.2012.1209; Zhang Y, 2013, MOL THER, V21, P1559, DOI 10.1038/mt.2013.120	49	24	25	1	39	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 12	2015	10	6							e0129865	10.1371/journal.pone.0129865	http://dx.doi.org/10.1371/journal.pone.0129865			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CK6GR	26066322	Green Published, gold, Green Submitted			2023-01-03	WOS:000356327000117
J	Braat, S; Kooy, RF				Braat, Sien; Kooy, R. Frank			The GABA(A) Receptor as a Therapeutic Target for Neurodevelopmental Disorders	NEURON			English	Review							FRAGILE-X-SYNDROME; SEVERE MYOCLONIC EPILEPSY; GAMMA-AMINOBUTYRIC-ACID; REDUCED SODIUM CURRENT; MOUSE MODEL; RETT-SYNDROME; AUTISM SPECTRUM; INHIBITORY INTERNEURONS; INTELLECTUAL DISABILITY; INTERNATIONAL UNION	Intellectual disability, autism spectrum disorder, and epilepsy are prime examples of neurodevelopmental disorders that collectively affect a significant percentage of the world population. Recent technological breakthroughs allowed the elucidation of the genetic causes of many of these disorders. As neurodevelopmental disorders are genetically heterogeneous, the development of rational therapy is extremely challenging. Fortunately, many causative genes are interconnected and cluster in specific cellular pathways. Targeting a common node in such a network would allow us to interfere with a series of related neurodevelopmental disorders at once. Here, we argue that the GABAergic system is disturbed in many neurodevelopmental disorders, including fragile X syndrome, Rett syndrome, and Dravet syndrome, and is a key candidate target for therapeutic intervention. Many drugs that modulate the GABAergic system have already been tested in animal models with encouraging outcomes and are readily available for clinical trials.	[Braat, Sien; Kooy, R. Frank] Univ Antwerp, Dept Med Genet, B-2650 Edegem, Belgium	University of Antwerp	Kooy, RF (corresponding author), Univ Antwerp, Dept Med Genet, Prins Boudewijnlaan 43, B-2650 Edegem, Belgium.	frank.kooy@uantwerpen.be	Kooy, Frank/F-5276-2014	Kooy, Frank/0000-0003-2024-0485	FRAXA; Research Foundation Flanders (FWO-Vlaanderen); Fondation Jerome Lejeune; Marguerite-Marie Delacroix; IWT (Agency for Innovation by Science and Technology)	FRAXA; Research Foundation Flanders (FWO-Vlaanderen)(FWO); Fondation Jerome Lejeune; Marguerite-Marie Delacroix; IWT (Agency for Innovation by Science and Technology)	Our research on GABAergic treatment of fragile X syndrome is funded by grants from FRAXA, Research Foundation Flanders (FWO-Vlaanderen), Fondation Jerome Lejeune, and Marguerite-Marie Delacroix to R.F.K. and by a PhD grant from the IWT (Agency for Innovation by Science and Technology) to S.B. R.F.K. successfully applied for funding to cover a clinical trial with ganaxolone for the treatment of behaviors in children with fragile X syndrome. Marinus Pharmaceuticals is the investigational new drug (IND) application holder for ganaxolone and provides global regulatory support for the project. They also manage the study drug supply and have responsibility for the oversight of manufacturing, labeling, shipping, and stability.	Abdala APL, 2010, P NATL ACAD SCI USA, V107, P18208, DOI 10.1073/pnas.1012104107; Allen AS, 2013, NATURE, V501, P217, DOI 10.1038/nature12439; Amir RE, 1999, NAT GENET, V23, P185, DOI 10.1038/13810; Ascano M, 2012, NATURE, V492, P382, DOI 10.1038/nature11737; Atack JR, 2008, CNS NEUROSCI THER, V14, P25, DOI 10.1111/j.1527-3458.2007.00034.x; Baird G, 2006, LANCET, V368, P210, DOI 10.1016/S0140-6736(06)69041-7; Ballard TM, 2009, PSYCHOPHARMACOLOGY, V202, P207, DOI 10.1007/s00213-008-1357-7; Baulac S, 2001, NAT GENET, V28, P46, DOI 10.1038/88254; Bear MF, 2004, TRENDS NEUROSCI, V27, P370, DOI 10.1016/j.tins.2004.04.009; Belelli D, 2009, J NEUROSCI, V29, P12757, DOI 10.1523/JNEUROSCI.3340-09.2009; Ben-Ari Y, 2002, NAT REV NEUROSCI, V3, P728, DOI 10.1038/nrn920; Berry-Kravis EM, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3004214; Blue ME, 1999, EXP NEUROL, V156, P345, DOI 10.1006/exnr.1999.7030; Bowery NG, 2002, PHARMACOL REV, V54, P247, DOI 10.1124/pr.54.2.247; Braat S., 2015, CELL CYCLE; Braat S, 2015, NEUROPHARMACOLOGY, V88, P48, DOI 10.1016/j.neuropharm.2014.06.028; Braat S, 2014, DRUG DISCOV TODAY, V19, P510, DOI 10.1016/j.drudis.2014.01.013; Calfa G, 2011, EXP BIOL MED, V236, P3, DOI 10.1258/ebm.2010.010261; Carter RB, 1997, J PHARMACOL EXP THER, V280, P1284; Carver CM, 2013, PSYCHOPHARMACOLOGY, V230, P151, DOI 10.1007/s00213-013-3276-5; Carvill GL, 2014, NEUROLOGY, V82, P1245, DOI 10.1212/WNL.0000000000000291; Castren E, 2012, J NEUROSCI, V32, P14074, DOI 10.1523/JNEUROSCI.3287-12.2012; Cea-Del Rio CA, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00245; Chahrour M, 2007, NEURON, V56, P422, DOI 10.1016/j.neuron.2007.10.001; Chang S, 2008, NAT CHEM BIOL, V4, P256, DOI 10.1038/nchembio.78; Chao HT, 2010, NATURE, V468, P263, DOI 10.1038/nature09582; Cheah CS, 2012, P NATL ACAD SCI USA, V109, P14646, DOI 10.1073/pnas.1211591109; Chen CH, 2014, MOL AUTISM, V5, DOI 10.1186/2040-2392-5-36; Chen RZ, 2001, NAT GENET, V27, P327, DOI 10.1038/85906; Chiron C, 2000, LANCET, V356, P1638, DOI 10.1016/S0140-6736(00)03157-3; Claes L, 2001, AM J HUM GENET, V68, P1327, DOI 10.1086/320609; Claes LRF, 2009, HUM MUTAT, V30, pE904, DOI 10.1002/humu.21083; Coe BP, 2014, NAT GENET, V46, P1063, DOI 10.1038/ng.3092; Cossette P, 2002, NAT GENET, V31, P184, DOI 10.1038/ng885; Crabbe JC, 1999, SCIENCE, V284, P1670, DOI 10.1126/science.284.5420.1670; D'Hulst C, 2007, TRENDS NEUROSCI, V30, P425, DOI 10.1016/j.tins.2007.06.003; D'Hulst C, 2009, DRUG DISCOV TODAY, V14, P866, DOI 10.1016/j.drudis.2009.06.009; Darnell JC, 2013, NAT NEUROSCI, V16, P1530, DOI 10.1038/nn.3379; Darnell JC, 2011, CELL, V146, P247, DOI 10.1016/j.cell.2011.06.013; Dawson GR, 2006, J PHARMACOL EXP THER, V316, P1335, DOI 10.1124/jpet.105.092320; De Rubeis S, 2014, NATURE, V515, P209, DOI 10.1038/nature13772; Dibbens LM, 2004, HUM MOL GENET, V13, P1315, DOI 10.1093/hmg/ddh146; Dikow N, 2014, AM J MED GENET A, V164, P3061, DOI 10.1002/ajmg.a.36761; Dravet C, 2011, EPILEPSIA, V52, P3, DOI 10.1111/j.1528-1167.2011.02994.x; Dutton SB, 2013, NEUROBIOL DIS, V49, P211, DOI 10.1016/j.nbd.2012.08.012; El-Khoury R, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092169; ERLANDER MG, 1991, NEURON, V7, P91, DOI 10.1016/0896-6273(91)90077-D; Farrant M, 2005, NAT REV NEUROSCI, V6, P215, DOI 10.1038/nrn1625; Fatemi S.H., 2014, SCHIZOPHR RES; Fatemi SH, 2014, J AUTISM DEV DISORD, V44, P1833, DOI 10.1007/s10803-014-2078-x; Fisher JL, 2009, NEUROPHARMACOLOGY, V56, P190, DOI 10.1016/j.neuropharm.2008.06.004; Gassmann M, 2012, NAT REV NEUROSCI, V13, P380, DOI 10.1038/nrn3249; Gilissen C, 2014, NATURE, V511, P344, DOI [10.1038/nature13394, 10.3389/fnhum.2013.00444]; Gilman SR, 2011, NEURON, V70, P898, DOI 10.1016/j.neuron.2011.05.021; Glykys J, 2007, NEURON, V56, P763, DOI 10.1016/j.neuron.2007.11.002; Green ED, 2011, NATURE, V470, P204, DOI 10.1038/nature09764; Grosenbaugh DK, 2013, NEUROPHARMACOLOGY, V67, P136, DOI 10.1016/j.neuropharm.2012.11.002; Guy J, 2001, NAT GENET, V27, P322, DOI 10.1038/85899; Hagerman RJ, 2002, FRAGILE X SYNDROME D, P3; Hallett M., 2015, BRAIN DEV; Hamdan FF, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004772; Han S, 2012, NATURE, V489, P385, DOI 10.1038/nature11356; Harris SW, 2008, AM J MENT RETARD, V113, P427, DOI 10.1352/2008.113:427-438; He Q, 2014, J NEUROSCI, V34, P446, DOI 10.1523/JNEUROSCI.4447-13.2014; Henderson C, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3004218; Heulens I, 2012, BEHAV BRAIN RES, V229, P244, DOI 10.1016/j.bbr.2012.01.031; Hodges LM, 2014, NEUROPSYCHOPHARMACOL, V39, P2423, DOI 10.1038/npp.2014.92; Hu H, 2014, SCIENCE, V345, P529, DOI 10.1126/science.1255263; Iossifov I, 2014, NATURE, V515, P216, DOI 10.1038/nature13908; Jin X, 2013, AM J PHYSIOL-CELL PH, V304, pC844, DOI 10.1152/ajpcell.00399.2012; Kalume F, 2007, J NEUROSCI, V27, P11065, DOI 10.1523/JNEUROSCI.2162-07.2007; Katz DM, 2012, DIS MODEL MECH, V5, P733, DOI 10.1242/dmm.011007; Kaufmann WE, 2004, AM J MED GENET A, V129A, P225, DOI 10.1002/ajmg.a.30229; Kerrigan JF, 2000, EPILEPSY RES, V42, P133, DOI 10.1016/S0920-1211(00)00170-4; Krumm N, 2014, TRENDS NEUROSCI, V37, P95, DOI 10.1016/j.tins.2013.11.005; Laxer K, 2000, EPILEPSIA, V41, P1187, DOI 10.1111/j.1528-1157.2000.tb00324.x; Lemonnier E, 2012, TRANSL PSYCHIAT, V2, DOI 10.1038/tp.2012.124; Lewis P, 2006, J INTELL DISABIL RES, V50, P532, DOI 10.1111/j.1365-2788.2006.00803.x; Li BM, 2011, EPILEPSY BEHAV, V21, P291, DOI 10.1016/j.yebeh.2011.04.060; Li DW, 2014, NEUROPSYCHOPHARMACOL, V39, P907, DOI 10.1038/npp.2013.291; Lossin C, 2009, BRAIN DEV-JPN, V31, P114, DOI 10.1016/j.braindev.2008.07.011; Lucignani G, 2004, NEUROIMAGE, V22, P22, DOI 10.1016/j.neuroimage.2003.10.050; Lynex CN, 2004, BMC NEUROL, V4, DOI 10.1186/1471-2377-4-20; Ma DQ, 2005, AM J HUM GENET, V77, P377, DOI 10.1086/433195; Madsen KK, 2010, PHARMACOL THERAPEUT, V125, P394, DOI 10.1016/j.pharmthera.2009.11.007; Maljevic S, 2006, ANN NEUROL, V59, P983, DOI 10.1002/ana.20874; Marrosu F, 1987, Funct Neurol, V2, P355; McKernan RM, 2000, NAT NEUROSCI, V3, P587, DOI 10.1038/75761; McKernan RM, 1996, TRENDS NEUROSCI, V19, P139, DOI 10.1016/S0166-2236(96)80023-3; Medina-Kauwe LK, 1999, J INHERIT METAB DIS, V22, P414, DOI 10.1023/A:1005500122231; Medrihan L, 2008, J NEUROPHYSIOL, V99, P112, DOI 10.1152/jn.00826.2007; Miyashiro KY, 2003, NEURON, V37, P417, DOI 10.1016/S0896-6273(03)00034-5; Mody I, 2004, TRENDS NEUROSCI, V27, P569, DOI 10.1016/j.tins.2004.07.002; Monaghan EP, 1997, EPILEPSIA, V38, P1026, DOI 10.1111/j.1528-1157.1997.tb01486.x; Musumeci SA, 1999, EPILEPSIA, V40, P1092, DOI 10.1111/j.1528-1157.1999.tb00824.x; Neul JL, 2010, ANN NEUROL, V68, P944, DOI 10.1002/ana.22124; Nohria V, 2007, NEUROTHERAPEUTICS, V4, P102, DOI 10.1016/j.nurt.2006.11.003; Oakley JC, 2013, J PHARMACOL EXP THER, V345, P215, DOI 10.1124/jpet.113.203331; Ogiwara I, 2007, J NEUROSCI, V27, P5903, DOI 10.1523/JNEUROSCI.5270-06.2007; Olmos-Serrano JL, 2011, DEV NEUROSCI-BASEL, V33, P395, DOI 10.1159/000332884; Olsen RW, 2008, PHARMACOL REV, V60, P243, DOI 10.1124/pr.108.00505; Omrani A., 2015, MOL PSYCHIAT; Paluszkiewicz SM, 2011, DEV NEUROSCI-BASEL, V33, P349, DOI 10.1159/000329420; Pearl PL, 2009, NEUROLOGY, V73, P423, DOI 10.1212/WNL.0b013e3181b163a5; Perrin S, 2014, NATURE, V507, P423, DOI 10.1038/507423a; PERRY TL, 1988, J PEDIATR-US, V112, P234, DOI 10.1016/S0022-3476(88)80060-X; Pieribone VA, 2007, EPILEPSIA, V48, P1870, DOI 10.1111/j.1528-1167.2007.01182.x; Prasad DKV, 2014, EPILEPSY RES, V108, P1267, DOI 10.1016/j.eplepsyres.2014.07.001; Puskarjov M, 2014, EMBO REP, V15, P723, DOI 10.1002/embr.201438749; Quilichini PP, 2006, EPILEPSIA, V47, P704, DOI 10.1111/j.1528-1167.2006.00497.x; Ramamoorthi K, 2011, TRENDS MOL MED, V17, P452, DOI 10.1016/j.molmed.2011.03.003; Reis J, 2012, NEUROLOGY, V79, P47, DOI 10.1212/WNL.0b013e31825dcf71; Rowley NM, 2012, NEUROCHEM INT, V61, P546, DOI 10.1016/j.neuint.2012.02.013; Rubenstein JLR, 2003, GENES BRAIN BEHAV, V2, P255, DOI 10.1034/j.1601-183X.2003.00037.x; Rudolph U, 1999, NATURE, V401, P796, DOI 10.1038/44579; Rudolph U, 2014, ANNU REV PHARMACOL, V54, P483, DOI 10.1146/annurev-pharmtox-011613-135947; Rudolph U, 2011, NAT REV DRUG DISCOV, V10, P685, DOI 10.1038/nrd3502; Sieghart W., 2002, Current Topics in Medicinal Chemistry, V2, P795, DOI 10.2174/1568026023393507; Simon DB, 1996, NAT GENET, V13, P183, DOI 10.1038/ng0696-183; Srivastava S, 2014, AM J MED GENET A, V164, P2914, DOI 10.1002/ajmg.a.36714; Suhl JA, 2014, HUM MOL GENET, V23, P5479, DOI 10.1093/hmg/ddu272; Tanaka M, 2008, AM J HUM GENET, V82, P1249, DOI 10.1016/j.ajhg.2008.04.020; Duarte ST, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068851; Tomassy GS, 2014, J NEUROCHEM, V131, P115, DOI 10.1111/jnc.12803; Tsang SY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062322; Tseng WC, 2015, P NATL ACAD SCI USA, V112, P1214, DOI 10.1073/pnas.1417989112; Tyzio R, 2014, SCIENCE, V343, P675, DOI 10.1126/science.1247190; van Bokhoven H, 2011, ANNU REV GENET, V45, P81, DOI 10.1146/annurev-genet-110410-132512; VERKERK AJMH, 1991, CELL, V65, P905, DOI 10.1016/0092-8674(91)90397-H; Violante IR, 2013, BRAIN, V136, P918, DOI 10.1093/brain/aws368; Voineagu I, 2011, NATURE, V474, P380, DOI 10.1038/nature10110; Voituron N, 2011, RESP PHYSIOL NEUROBI, V177, P56, DOI 10.1016/j.resp.2011.02.002; Wafford KA, 2006, CURR OPIN PHARMACOL, V6, P30, DOI 10.1016/j.coph.2005.10.004; Wallace RH, 2001, NAT GENET, V28, P49, DOI 10.1038/88259; Warrier V, 2013, MOL AUTISM, V4, DOI 10.1186/2040-2392-4-48; Yamashita Y, 1998, J NEUROL SCI, V154, P146, DOI 10.1016/S0022-510X(97)00223-2; Yu FH, 2006, NAT NEUROSCI, V9, P1142, DOI 10.1038/nn1754; Zhang L, 2008, HIPPOCAMPUS, V18, P294, DOI 10.1002/hipo.20389; Zhang ZW, 2010, J NEUROPHYSIOL, V103, P2470, DOI 10.1152/jn.00601.2009	139	186	192	1	40	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0896-6273	1097-4199		NEURON	Neuron	JUN 3	2015	86	5					1119	1130		10.1016/j.neuron.2015.03.042	http://dx.doi.org/10.1016/j.neuron.2015.03.042			12	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	CJ7HV	26050032	Bronze			2023-01-03	WOS:000355666400004
J	Peters, CD; Kjaergaard, KD; Jensen, JD; Christensen, KL; Strandhave, C; Tietze, IN; Novosel, MK; Bibby, BM; Jespersen, B				Peters, Christian Daugaard; Kjaergaard, Krista Dybtved; Jensen, Jens Dam; Christensen, Kent Lodberg; Strandhave, Charlotte; Tietze, Ida Noerager; Novosel, Marija Kristina; Bibby, Bo Martin; Jespersen, Bente			Short and Long-Term Effects of the Angiotensin II Receptor Blocker Irbesartan on Intradialytic Central Hemodynamics: A Randomized Double-Blind Placebo-Controlled One-Year Intervention Trial (the SAFIR Study)	PLOS ONE			English	Article							HEMODIALYSIS-ASSOCIATED HYPOTENSION; ULTRASOUND DILUTION METHOD; CALCIUM-ION CONCENTRATION; MEASURE CARDIAC-OUTPUT; LOW-FLUX HEMODIALYSIS; BLOOD-VOLUME; MAINTENANCE HEMODIALYSIS; CARDIOVASCULAR EVENTS; PREDILUTION HEMODIAFILTRATION; ARTERIOVENOUS-FISTULA	Background and Aim Little is known about the tolerability of antihypertensive drugs during hemodialysis treatment. The present study evaluated the use of the angiotensin II receptor blocker (ARB) irbesartan. Design Randomized, double-blind, placebo-controlled, one-year intervention trial. Setting and Participants Eighty-two hemodialysis patients with urine output >300 mL/day and dialysis vintage <1 year. Intervention Irbesartan/placebo 300 mg/day for 12 months administered as add-on to antihypertensive treatment using a predialytic systolic blood pressure target of 140 mmHg in all patients. Outcomes and Measurements Cardiac output, stroke volume, central blood volume, total peripheral resistance, mean arterial blood pressure, and frequency of intradialytic hypotension. Results At baseline, the groups were similar regarding age, comorbidity, blood pressure, antihypertensive medication, ultrafiltration volume, and dialysis parameters. Over the one-year period, predialytic systolic blood pressure decreased significantly, but similarly in both groups. Mean start and mean end cardiac output, stroke volume, total peripheral resistance, heart rate, and mean arterial pressure were stable and similar in the two groups, whereas central blood volume increased slightly but similarly over time. The mean hemodynamic response observed during a dialysis session was a drop in cardiac output, in stroke volume, in mean arterial pressure, and in central blood volume, whereas heart rate increased. Total peripheral resistance did not change significantly. Overall, this pattern remained stable over time in both groups and was uninfluenced by ARB treatment. The total number of intradialytic hypotensive episodes was (placebo/ARB) 50/63 (P = 0.4). Ultrafiltration volume, left ventricular mass index, plasma albumin, and change in intradialytic total peripheral resistance were significantly associated with intradialytic hypotension in a multivariate logistic regression analysis based on baseline parameters. Conclusion Use of the ARB irbesartan as an add-on to other antihypertensive therapy did not significantly affect intradialytic hemodynamics, neither in short nor long-term, and no significant increase in hypotensive episodes was seen.	[Peters, Christian Daugaard; Kjaergaard, Krista Dybtved; Jensen, Jens Dam; Jespersen, Bente] Aarhus Univ Hosp, Dept Renal Med, DK-8000 Aarhus, Denmark; [Peters, Christian Daugaard; Kjaergaard, Krista Dybtved; Jensen, Jens Dam; Jespersen, Bente] Aarhus Univ, Inst Clin Med, Aarhus, Denmark; [Christensen, Kent Lodberg] Aarhus Univ Hosp, Dept Cardiol, DK-8000 Aarhus, Denmark; [Strandhave, Charlotte] Aarhus Univ Hosp, Dept Nephrol, DK-8000 Aarhus, Denmark; [Tietze, Ida Noerager] Viborg Reg Hosp, Dept Med, Viborg, Denmark; [Novosel, Marija Kristina] Fredericia Cty Hosp, Dept Med, Fredericia, Denmark; [Bibby, Bo Martin] Aarhus Univ, Dept Biostat, Aarhus, Denmark	Aarhus University; Aarhus University; Aarhus University; Aarhus University; Aarhus University; Aarhus University	Peters, CD (corresponding author), Aarhus Univ Hosp, Dept Renal Med, DK-8000 Aarhus, Denmark.	cdp@ana.au.dk		Jespersen, Bente/0000-0001-7196-2870; Peters, Christian Daugaard/0000-0002-4917-1535	Danish Council for Independent Research Medical Sciences; Aase og Ejnar Danielsens Fond; Beckett-Fonden; Civilingenior Frode Nygaard og Hustrus Fond; Danish Society of Hypertension; Danish Society of Nephrology; Direktor Kurt Bonnelycke & Hustru Grethe Bonnelyckes Fond; Fabrikant Karl G Andersens Fond; Fausbolls Helsefond; Fonden til udvikling og uddannelse ved Nyremedicinsk Afdeling ved Aarhus Universitetshospital; Fresenius Medical Care Denmark; Frimodt-Heineke Fonden; Helen & Ejnar Bjornows Fond; Institute of Clinical Medicine at Aarhus University; Kirsten Anthonius' Fond; Leo Pharmas Hypertensionslegat; Nyreforeningens Forskningsfond; Overlaege Poul M Christiansen Hustrus Fond; Region Midtjyllands Sundhedsvidenskabelige Forskningsfond; Snedkermester Sophus Jacobsen and Hustru Astrid Jacobsens Fond; Sanofi Denmark	Danish Council for Independent Research Medical Sciences(Det Frie Forskningsrad (DFF)); Aase og Ejnar Danielsens Fond; Beckett-Fonden; Civilingenior Frode Nygaard og Hustrus Fond; Danish Society of Hypertension; Danish Society of Nephrology; Direktor Kurt Bonnelycke & Hustru Grethe Bonnelyckes Fond; Fabrikant Karl G Andersens Fond; Fausbolls Helsefond; Fonden til udvikling og uddannelse ved Nyremedicinsk Afdeling ved Aarhus Universitetshospital; Fresenius Medical Care Denmark; Frimodt-Heineke Fonden; Helen & Ejnar Bjornows Fond; Institute of Clinical Medicine at Aarhus University; Kirsten Anthonius' Fond; Leo Pharmas Hypertensionslegat(LEO Pharma); Nyreforeningens Forskningsfond; Overlaege Poul M Christiansen Hustrus Fond; Region Midtjyllands Sundhedsvidenskabelige Forskningsfond; Snedkermester Sophus Jacobsen and Hustru Astrid Jacobsens Fond; Sanofi Denmark(Sanofi-Aventis)	The SAFIR study was primarily supported by The Danish Council for Independent Research Medical Sciences, but also by (in alphabetical order): Aase og Ejnar Danielsens Fond, Beckett-Fonden, Civilingenior Frode Nygaard og Hustrus Fond, The Danish Society of Hypertension, The Danish Society of Nephrology, Direktor Kurt Bonnelycke & Hustru Grethe Bonnelyckes Fond, Fabrikant Karl G Andersens Fond, Fausbolls Helsefond, Fonden til udvikling og uddannelse ved Nyremedicinsk Afdeling ved Aarhus Universitetshospital, Fresenius Medical Care Denmark, Frimodt-Heineke Fonden, Helen & Ejnar Bjornows Fond, The Institute of Clinical Medicine at Aarhus University, Kirsten Anthonius' Fond, Leo Pharmas Hypertensionslegat, Nyreforeningens Forskningsfond, Overlaege Poul M Christiansen & Hustrus Fond, Region Midtjyllands Sundhedsvidenskabelige Forskningsfond, Snedkermester Sophus Jacobsen and Hustru Astrid Jacobsens Fond. Sanofi Denmark provided original study medication (placebo and active tablets) free of charge and financially supported some meeting activity. NorDiaTech Denmark provided one Transonic Flow-QC Hemodialysis Monitor for three years including yearly calibration. The funders including Sanofi Denmark and NorDiaTech Denmark had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. This does not alter the authors' adherence to PLOS ONE policies on sharing data and materials.	Agarwal R, 2014, NEPHROL DIAL TRANSPL, V29, P672, DOI 10.1093/ndt/gft515; Al-Muhanna FA, 1999, E AFR MED J, V76, P664; BARAKAT MM, 1993, J AM SOC NEPHROL, V3, P1813; Barth C, 2003, NEPHROL DIAL TRANSPL, V18, P1353, DOI 10.1093/ndt/gfg171; Basile C, 2008, NEPHROL DIAL TRANSPL, V23, P282, DOI 10.1093/ndt/gfm549; Beerenhout C, 2004, NEPHROL DIAL TRANSPL, V19, P2354, DOI 10.1093/ndt/gfh315; Brewster UC, 2004, AM J MED, V116, P263, DOI 10.1016/j.amjmed.2003.09.034; Cice G, 2010, J AM COLL CARDIOL, V56, P1701, DOI 10.1016/j.jacc.2010.03.105; CIVATI G, 1991, NEPHROL DIAL TRANSPL, V6, P75; Dahlof B, 2002, LANCET, V359, P995, DOI 10.1016/S0140-6736(02)08089-3; Dasselaar JJ, 2009, NEPHROL DIAL TRANSPL, V24, P604, DOI 10.1093/ndt/gfn501; Daugirdas JT, 2013, AM J KIDNEY DIS, V61, P861, DOI 10.1053/j.ajkd.2013.03.004; DAUGIRDAS JT, 1991, KIDNEY INT, V39, P233, DOI 10.1038/ki.1991.28; Daugirdas JT, 2001, AM J KIDNEY DIS, V38, pS11, DOI 10.1053/ajkd.2001.28090; Davenport A, 2008, KIDNEY INT, V73, P759, DOI 10.1038/sj.ki.5002745; Davenport A, 2008, NEPHRON CLIN PRACT, V109, pC65, DOI 10.1159/000139991; Gabrielli D, 2009, J NEPHROL, V22, P232; Henderson LW, 2012, SEMIN DIALYSIS, V25, P320, DOI 10.1111/j.1525-139X.2012.01068.x; Hung SY, 2004, BLOOD PURIFICAT, V22, P338, DOI 10.1159/000079188; Hur E, 2013, AM J KIDNEY DIS, V61, P957, DOI 10.1053/j.ajkd.2012.12.017; Iseki K, 2013, NEPHROL DIAL TRANSPL, V28, P1579, DOI 10.1093/ndt/gfs590; Karamperis N, 2007, CLIN NEPHROL, V67, P230; Karamperis N, 2005, KIDNEY INT, V67, P1601, DOI 10.1111/j.1523-1755.2005.00242.x; Karamperis N, 2005, AM J KIDNEY DIS, V46, P470, DOI 10.1053/j.ajkd.2005.05.022; Kisloukhine VV, 1996, ASAIO J, V42, pM906, DOI 10.1097/00002480-199609000-00125; Kjaergaard KD, 2014, AM J KIDNEY DIS, V64, P892, DOI 10.1053/j.ajkd.2014.05.011; Knoll GA, 2002, AM J MED, V112, P110, DOI 10.1016/S0002-9343(01)01068-3; Kooman J, 2007, NEPHROL DIAL TRANSPL, V22, P22, DOI 10.1093/ndt/gfm019; Korsheed S, 2011, NEPHROL DIAL TRANSPL, V26, P3296, DOI 10.1093/ndt/gfq851; Krivitski NM, 1999, ADV RENAL REPLACE TH, V6, P225, DOI 10.1016/S1073-4449(99)70018-X; KRIVITSKI NM, 1995, ASAIO J, V41, pM741, DOI 10.1097/00002480-199507000-00111; Leidig M, 2008, CLIN NEPHROL, V69, P425; Man in 't Veld AJ, 1980, BRIT MED J, V280, P288; Marino MR, 1998, J CLIN PHARMACOL, V38, P246, DOI 10.1002/j.1552-4604.1998.tb04422.x; McIntyre CW, 2008, CLIN J AM SOC NEPHRO, V3, P19, DOI 10.2215/CJN.03170707; Mizumasa T, 2004, NEPHRON CLIN PRACT, V97, pC23, DOI 10.1159/000077592; MOSER M, 1988, BASIC RES CARDIOL, V83, P577, DOI 10.1007/BF01906951; Nikiforov YV, 1996, ASAIO J, V42, pM903, DOI 10.1097/00002480-199609000-00124; Peters CD, 2014, KIDNEY INT, V86, P625, DOI 10.1038/ki.2014.69; Peters Christian Daugaard, 2013, Dan Med J, V60, pA4602; Pfeffer MA, 2003, NEW ENGL J MED, V349, P1893, DOI 10.1056/NEJMoa032292; Sands JJ, 2014, HEMODIAL INT, V18, P415, DOI 10.1111/hdi.12138; Santoro Antonio, 2006, Hemodial Int, V10 Suppl 1, pS51, DOI 10.1111/j.1542-4758.2006.01192.x; Sherman R A, 1990, ASAIO Trans, V36, P67, DOI 10.1097/00002480-199004000-00005; Shoji T, 2004, KIDNEY INT, V66, P1212, DOI 10.1111/j.1523-1755.2004.00812.x; Sica DA, 1997, CLIN PHARMACOL THER, V62, P610, DOI 10.1016/S0009-9236(97)90080-1; Suzuki H, 2008, AM J KIDNEY DIS, V52, P501, DOI 10.1053/j.ajkd.2008.04.031; Tai DJ, 2010, CLIN J AM SOC NEPHRO, V5, P623, DOI 10.2215/CJN.07831109; Takahashi A, 2006, NEPHROL DIAL TRANSPL, V21, P2507, DOI 10.1093/ndt/gfl293; TIMMERMANS PBMWM, 1993, PHARMACOL REV, V45, P205; Tisler A, 2002, KIDNEY BLOOD PRESS R, V25, P97, DOI 10.1159/000063515; Toyoda K, 2005, AM J KIDNEY DIS, V45, P1058, DOI 10.1053/j.ajkd.2005.02.028; Tsutsui M, 2009, J CARDIOTHOR VASC AN, V23, P835, DOI 10.1053/j.jvca.2009.03.007; van der Sande FM, 2000, AM J KIDNEY DIS, V35, DOI 10.1016/S0272-6386(00)70284-8; van der Sande FM, 1998, AM J KIDNEY DIS, V32, P125, DOI 10.1053/ajkd.1998.v32.pm9669433; vanKuijk WHM, 1996, NEPHROL DIAL TRANSPL, V11, P323, DOI 10.1093/oxfordjournals.ndt.a027261; Yang LY, 2013, AM J MED SCI, V345, P1, DOI 10.1097/MAJ.0b013e318249d387; Zannad F, 2006, KIDNEY INT, V70, P1318, DOI 10.1038/sj.ki.5001657	58	5	11	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 1	2015	10	6							e0126882	10.1371/journal.pone.0126882	http://dx.doi.org/10.1371/journal.pone.0126882			22	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CL0KF	26030651	gold, Green Published, Green Submitted			2023-01-03	WOS:000356630900036
J	Scoditti, E; Massaro, M; Carluccio, MA; Pellegrino, M; Wabitsch, M; Calabriso, N; Storelli, C; De Caterina, R				Scoditti, Egeria; Massaro, Marika; Carluccio, Maria Annunziata; Pellegrino, Mariangela; Wabitsch, Martin; Calabriso, Nadia; Storelli, Carlo; De Caterina, Raffaele			Additive Regulation of Adiponectin Expression by the Mediterranean Diet Olive Oil Components Oleic Acid and Hydroxytyrosol in Human Adipocytes	PLOS ONE			English	Article							NECROSIS-FACTOR-ALPHA; N-TERMINAL KINASE; FREE FATTY-ACIDS; INSULIN-RESISTANCE; METABOLIC SYNDROME; ADIPOSE-TISSUE; OBESITY; LEPTIN; DIFFERENTIATION; CELLS	Adiponectin, an adipocyte-derived insulin-sensitizing and anti-inflammatory hormone, is suppressed in obesity through mechanisms involving chronic inflammation and oxidative stress. Olive oil consumption is associated with beneficial cardiometabolic actions, with possible contributions from the antioxidant phenol hydroxytyrosol (HT) and the monounsaturated fatty acid oleic acid (OA, 18:1n-9 cis), both possessing anti-inflammatory and vasculo-protective properties. We determined the effects of HT and OA, alone and in combination, on adiponectin expression in human and murine adipocytes under pro-inflammatory conditions induced by the cytokine tumor necrosis factor(TNF)-alpha. We used human Simpson-Golabi-Behmel syndrome (SGBS) adipocytes and murine 3T3-L1 adipocytes as cell model systems, and pretreated them with 1-100 mu mol/L OA, 0.1-20 mu mol/L HT or OA plus HT combination before stimulation with 10 ng/mL TNF-alpha. OA or HT significantly (P<0.05) prevented TNF-alpha-induced suppression of total adiponectin secretion (by 42% compared with TNF-alpha alone) as well as mRNA levels (by 30% compared with TNF-alpha alone). HT and OA also prevented-by 35%-TNF-alpha-induced downregulation of peroxisome proliferator-activated receptor PPAR gamma. Co-treatment with HT and OA restored adiponectin and PPAR gamma expression in an additive manner compared with single treatments. Exploring the activation of JNK, which is crucial for both adiponectin and PPAR gamma suppression by TNF-alpha, we found that HT and OA additively attenuated TNF-alpha-stimulated JNK phosphorylation (up to 55% inhibition). In conclusion, the virgin olive oil components OA and HT, at nutritionally relevant concentrations, have additive effects in preventing adiponectin downregulation in inflamed adipocytes through an attenuation of JNK-mediated PPAR gamma suppression.	[Scoditti, Egeria; Massaro, Marika; Carluccio, Maria Annunziata; Calabriso, Nadia] Natl Res Council CNR, Inst Clin Physiol, Lecce, Italy; [Pellegrino, Mariangela; Storelli, Carlo] Univ Salento, Dept Biol & Environm Sci & Technol DISTEBA, Lecce, Italy; [Wabitsch, Martin] Univ Ulm, Dept Pediat & Adolescent Med, Div Pediat Endocrinol Diabet & Obes, D-89069 Ulm, Germany; [De Caterina, Raffaele] Univ G DAnnunzio, Chieti, Italy; [De Caterina, Raffaele] Ctr Excellence Aging, Chieti, Italy; [De Caterina, Raffaele] G Monasterio Fdn Clin Res, Pisa, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto di Fisiologia Clinica (IFC-CNR); University of Salento; Ulm University; G d'Annunzio University of Chieti-Pescara	De Caterina, R (corresponding author), Univ G DAnnunzio, Chieti, Italy.	rdecater@unich.it	De Caterina, Raffaele/K-3857-2016; massaro, marika/AAQ-1204-2020; Carluccio, Maria Annunziata/AAO-1683-2020; SCODITTI, EGERIA/J-8609-2016	De Caterina, Raffaele/0000-0003-1637-574X; massaro, marika/0000-0001-6124-5077; CARLUCCIO, MARIA ANNUNZIATA/0000-0002-8307-1829; Calabriso, Nadia/0000-0003-0726-2081; SCODITTI, EGERIA/0000-0003-2753-8487	CNR Institute of Clinical Physiology, Pisa, Italy; Apulian Region POR Strategic Projects [CIP PS_101, CIP PS_008]; National Operational Program for Research and Competitiveness [PON01_01958]	CNR Institute of Clinical Physiology, Pisa, Italy; Apulian Region POR Strategic Projects; National Operational Program for Research and Competitiveness	This work was supported by grants from the CNR Institute of Clinical Physiology, Pisa, Italy (Junior Grant 2009 to E. Scoditti), the Apulian Region POR Strategic Projects (CIP PS_101, CIP PS_008), and the National Operational Program for Research and Competitiveness 2007-2013 (PON01_01958, PIVOLIO project). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; Cammisotto PG, 2003, AM J PHYSIOL-ENDOC M, V285, pE521, DOI 10.1152/ajpendo.00052.2003; Camp HS, 1999, ENDOCRINOLOGY, V140, P392, DOI 10.1210/en.140.1.392; Cao K, 2014, FREE RADICAL BIO MED, V67, P396, DOI 10.1016/j.freeradbiomed.2013.11.029; Capurso C, 2012, VASC PHARMACOL, V57, P91, DOI 10.1016/j.vph.2012.05.003; Carluccioll MA, 2007, MOL NUTR FOOD RES, V51, P1225, DOI 10.1002/mnfr.200600305; Chuang CC, 2010, AM J CLIN NUTR, V92, P1511, DOI 10.3945/ajcn.2010.29807; Covas MI, 2006, FREE RADICAL BIO MED, V40, P608, DOI 10.1016/j.freeradbiomed.2005.09.027; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; de Bock M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057622; Drira R, 2011, LIFE SCI, V89, P708, DOI 10.1016/j.lfs.2011.08.012; Esposito K, 2003, JAMA-J AM MED ASSOC, V289, P1799, DOI 10.1001/jama.289.14.1799; Estruch R, 2013, NEW ENGL J MED, V368, P1279, DOI 10.1056/NEJMoa1200303; Fawcett RL, 2000, J CLIN ENDOCR METAB, V85, P530, DOI 10.1210/jc.85.2.530; Fragopoulou E, 2010, J NUTR BIOCHEM, V21, P285, DOI 10.1016/j.jnutbio.2008.12.013; Furukawa S, 2004, J CLIN INVEST, V114, P1752, DOI [10.1172/JCI21625, 10.1172/JCI20042162S]; Giordano E, 2014, NUTR METAB CARDIOVAS, V24, P1144, DOI 10.1016/j.numecd.2014.05.003; Granados N, 2011, BRIT J NUTR, V105, P1226, DOI 10.1017/S0007114510004885; Hao JJ, 2010, J NUTR BIOCHEM, V21, P634, DOI 10.1016/j.jnutbio.2009.03.012; Hirosumi J, 2002, NATURE, V420, P333, DOI 10.1038/nature01137; Houstis N, 2006, NATURE, V440, P944, DOI 10.1038/nature04634; Incani A, 2010, MOL NUTR FOOD RES, V54, P788, DOI 10.1002/mnfr.200900098; Ito M, 2011, J LIPID RES, V52, P1450, DOI 10.1194/jlr.M012427; Iwaki M, 2003, DIABETES, V52, P1655, DOI 10.2337/diabetes.52.7.1655; Kappelle PJWH, 2012, EUR J INTERN MED, V23, P755, DOI 10.1016/j.ejim.2012.06.013; Kawano Jordan, 2009, J Cardiometab Syndr, V4, P44, DOI 10.1111/j.1559-4572.2008.00030.x; Kim K, 2005, BIOCHEM BIOPH RES CO, V327, P460, DOI 10.1016/j.bbrc.2004.12.026; Kliewer SA, 1997, P NATL ACAD SCI USA, V94, P4318, DOI 10.1073/pnas.94.9.4318; Lasa A, 2014, EUR J CLIN NUTR, V68, P767, DOI 10.1038/ejcn.2014.1; Lopez-Jaramillo P, 2014, HORM MOL BIOL CLIN I, V18, P37, DOI 10.1515/hmbci-2013-0053; Lopez-Miranda J, 2010, NUTR METAB CARDIOVAS, V20, P284, DOI 10.1016/j.numecd.2009.12.007; Madonna R, 2011, VASC PHARMACOL, V54, P75, DOI 10.1016/j.vph.2011.03.007; Mantzoros CS, 2006, AM J CLIN NUTR, V84, P328; Massaro M, 2002, THROMB HAEMOSTASIS, V88, P335; Miller TA, 2005, BIOCHEM BIOPH RES CO, V336, P309, DOI 10.1016/j.bbrc.2005.08.088; Norata GD, 2007, STROKE, V38, P2844, DOI 10.1161/STROKEAHA.107.485540; Paniagua JA, 2007, DIABETES CARE, V30, P1717, DOI 10.2337/dc06-2220; Perez-Martinez P, 2011, CURR PHARM DESIGN, V17, P769, DOI 10.2174/138161211795428948; Permana PA, 2006, BIOCHEM BIOPH RES CO, V341, P507, DOI 10.1016/j.bbrc.2006.01.012; Ricci R, 2004, SCIENCE, V306, P1558, DOI 10.1126/science.1101909; Richard N, 2011, PLANTA MED, V77, P1890, DOI 10.1055/s-0031-1280022; Ruan H, 2002, DIABETES, V51, P3176, DOI 10.2337/diabetes.51.11.3176; Ruano J, 2007, AM J CLIN NUTR, V86, P341, DOI 10.1093/ajcn/86.2.341; Ryan M, 2000, QJM-MON J ASSOC PHYS, V93, P85, DOI 10.1093/qjmed/93.2.85; Saadatian-Elahi M, 2009, AM J CLIN NUTR, V89, P331, DOI 10.3945/ajcn.2008.26834; Scoditti E, 2014, VASC PHARMACOL, V63, P127, DOI 10.1016/j.vph.2014.07.001; Scoditti E, 2014, ATHEROSCLEROSIS, V232, P17, DOI 10.1016/j.atherosclerosis.2013.10.017; Scoditti E, 2012, ARCH BIOCHEM BIOPHYS, V527, P81, DOI 10.1016/j.abb.2012.05.003; Shin DW, 2009, BIOCHEM PHARMACOL, V77, P125, DOI 10.1016/j.bcp.2008.09.033; Solinas G, 2010, FASEB J, V24, P2596, DOI 10.1096/fj.09-151340; Tabernero M, 2014, FOOD FUNCT, V5, P1556, DOI 10.1039/c3fo60677e; Tuncman G, 2006, P NATL ACAD SCI USA, V103, P10741, DOI 10.1073/pnas.0603509103; van Dijk SJ, 2009, AM J CLIN NUTR, V90, P1656, DOI 10.3945/ajcn.2009.27792; Wabitsch M, 2001, INT J OBESITY, V25, P8, DOI 10.1038/sj.ijo.0801520; Warodomwichit D, 2009, OBESITY, V17, P510, DOI 10.1038/oby.2008.583; Yeung EH, 2010, OBESITY, V18, P1632, DOI 10.1038/oby.2009.402; Zaletel J, 2010, J ENDOCRINOL INVEST, V33, P514, DOI [10.1007/BF03346639, 10.3275/6811]; Zhang HH, 2000, MOL CELL ENDOCRINOL, V159, P79, DOI 10.1016/S0303-7207(99)00194-X	58	43	45	1	16	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 1	2015	10	6							e0128218	10.1371/journal.pone.0128218	http://dx.doi.org/10.1371/journal.pone.0128218			23	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CL0KF	26030149	Green Published, Green Submitted, gold			2023-01-03	WOS:000356630900129
J	Kamdar, MM; Doyle, KP; Sequist, LV; Rinehart, TJ; Maytal, G; Flores, EJ; Mino-Kenudson, M				Kamdar, Mihir M.; Doyle, Kathleen P.; Sequist, Lecia V.; Rinehart, Todd J.; Maytal, Guy; Flores, Efren J.; Mino-Kenudson, Mari			Case 17-2015: A 44-Year-Old Woman with Intractable Pain Due to Metastatic Lung Cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							OPIOID-INDUCED HYPERALGESIA; PALLIATIVE SEDATION; CLINICAL-TRIAL; GUIDELINES; DELIVERY; MECHANISMS; TOLERANCE; GEFITINIB; ERLOTINIB; THERAPY		[Kamdar, Mihir M.] Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, Boston, MA 02114 USA; [Kamdar, Mihir M.; Doyle, Kathleen P.; Rinehart, Todd J.] Massachusetts Gen Hosp, Dept Palliat Care, Boston, MA 02114 USA; [Sequist, Lecia V.] Massachusetts Gen Hosp, Dept Med Oncol, Boston, MA 02114 USA; [Maytal, Guy] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA; [Flores, Efren J.] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA; [Mino-Kenudson, Mari] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA; [Mino-Kenudson, Mari] Harvard Univ, Sch Med, Dept Anesthesia Crit Care & Pain Med, Boston, MA USA; [Kamdar, Mihir M.; Doyle, Kathleen P.; Rinehart, Todd J.] Harvard Univ, Sch Med, Dept Palliat Care, Boston, MA USA; [Sequist, Lecia V.] Harvard Univ, Sch Med, Dept Med Oncol, Boston, MA USA; [Maytal, Guy] Harvard Univ, Sch Med, Dept Psychiat, Boston, MA 02115 USA; [Flores, Efren J.] Harvard Univ, Sch Med, Dept Radiol, Boston, MA 02115 USA; [Mino-Kenudson, Mari] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	Kamdar, MM (corresponding author), Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, Boston, MA 02114 USA.			Flores, Efren/0000-0003-1398-0426				Allen JP, 1996, JAMA-J AM MED ASSOC, V275, P474; Angst MS, 2006, ANESTHESIOLOGY, V104, P570, DOI 10.1097/00000542-200603000-00025; [Anonymous], ETH PALL SED; Arcidiacono PG, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007519.pub2; Chaft JE, 2011, CLIN CANCER RES, V17, P6298, DOI 10.1158/1078-0432.CCR-11-1468; Chu LF, 2008, CLIN J PAIN, V24, P479, DOI 10.1097/AJP.0b013e31816b2f43; De Graeff A, 2007, J PALLIAT MED, V10, P67, DOI 10.1089/jpm.2006.0139; Deer TR, 2011, PAIN PHYSICIAN, V14, pE283; del Rosario MAB, 2001, J PAIN SYMPTOM MANAG, V21, P439, DOI 10.1016/S0885-3924(01)00254-8; Field MJ, 1997, APPROACHING DEATH IM; Guignard B, 2000, ANESTHESIOLOGY, V93, P409, DOI 10.1097/00000542-200008000-00019; Krakauer EL, 2010, OXFORD TXB PALLIATIV; Lee M, 2011, PAIN PHYSICIAN, V14, P145; MAO JR, 1995, PAIN, V62, P259, DOI 10.1016/0304-3959(95)00073-2; Mercadante S, 2001, J PAIN SYMPTOM MANAG, V21, P338, DOI 10.1016/S0885-3924(01)00250-0; Meuser T, 2001, PAIN, V93, P247, DOI 10.1016/S0304-3959(01)00324-4; Miguel R, 2000, Cancer Control, V7, P149; Mok TS, 2009, NEW ENGL J MED, V361, P947, DOI 10.1056/NEJMoa0810699; Olsen ML, 2010, MAYO CLIN PROC, V85, P949, DOI 10.4065/mcp.2010.0201; Quill TE, 2009, ANN INTERN MED, V151, P421, DOI 10.7326/0003-4819-151-6-200909150-00007; Rosell R, 2012, LANCET ONCOL, V13, P239, DOI 10.1016/S1470-2045(11)70393-X; Sequist LV, 2013, J CLIN ONCOL, V31, P3327, DOI 10.1200/JCO.2012.44.2806; Smith TJ, 2002, J CLIN ONCOL, V20, P4040, DOI 10.1200/JCO.2002.02.118; Swarm R, 2010, J NATL COMPR CANC NE, V8, P1046, DOI 10.6004/jnccn.2010.0076; Vargas-Schaffer G, 2010, CAN FAM PHYSICIAN, V56, P514; Wallace M, 2000, REGION ANESTH PAIN M, V25, P117; Yennurajalingam S, 2010, J PAIN SYMPTOM MANAG, V39, P930, DOI 10.1016/j.jpainsymman.2009.09.015; ZECH DFJ, 1995, PAIN, V63, P65, DOI 10.1016/0304-3959(95)00017-M	28	4	4	1	5	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 28	2015	372	22					2137	2147		10.1056/NEJMcpc1404141	http://dx.doi.org/10.1056/NEJMcpc1404141			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CJ0EI	26017825				2023-01-03	WOS:000355146800012
J	Huberlant, S; Fernandez, H; Vieille, P; Khrouf, M; Ulrich, D; deTayrac, R; Letouzey, V				Huberlant, Stephanie; Fernandez, Herve; Vieille, Pierre; Khrouf, Mohamed; Ulrich, Daniela; deTayrac, Renaud; Letouzey, Vincent			Application of a Hyaluronic Acid Gel after Intrauterine Surgery May Improve Spontaneous Fertility: A Randomized Controlled Trial in New Zealand White Rabbits	PLOS ONE			English	Article							HYSTEROSCOPIC SURGERY; ADHESION FORMATION; PREVENTION; MODEL; EFFICACY; SYNECHIA; AGENTS	Objective Intrauterine adhesions (IUAs) are the most common complication after hysteroscopy in patients of reproductive age. Intra-abdominal anti-adhesion gel reduces the incidence of adhesions, but effects on fertility after uterine surgery are not known. The objective of our work was to evaluate the effect of intrauterine anti-adhesion gel on spontaneous fertility after repeated intrauterine surgery with induced experimental synechiae in the rabbit model. Materials and Methods Twenty New Zealand White rabbits underwent a double uterine curettage 10 days apart and were randomized into two groups. Each rabbit served as its own control: one uterine tube was the treatment group (A), the second uterine tube was the control group (B) to avoid bias through other causes of infertility. Group A received a post curettage intrauterine instillation of anti-adhesion gel whereas group B, the control group, underwent curettage without instillation of the gel. After a recovery period, the rabbits were mated. An abdominal ultrasound performed 21 days after mating allowed us to diagnose pregnancy and quantify the number of viable fetuses. Results There was a significant difference in total fetuses in favor of group A, with an average of 3.7 (range, 0-9) total fetuses per tube against 2.1 (0-7) in group B (p = .04). The number of viable fetuses shows a trend in favor of group A, with an average of 3.4 (0-7) viable fetuses per tube against 1.9 (0-6) viable fetuses per tube in group B (p = .05). Conclusion The use of immediate postoperative anti-adhesion gel improved fertility in an animal model after intrauterine surgery likely to cause uterine synechiae. This experimental model will permit comparison of different anti-adhesion solutions, including assessment of their tolerance and potential mucosal toxicity on embryonic development.	[Huberlant, Stephanie; Vieille, Pierre; Ulrich, Daniela; deTayrac, Renaud; Letouzey, Vincent] Univ Nimes Hosp, Dept Obstet & Gynaecol, F-30006 Nimes, France; [Fernandez, Herve; Khrouf, Mohamed] Hop Bicetre, AP HP, Dept Obstet & Gynaecol, Le Kremlin Bicetre, Paris, France	Universite de Montpellier; CHU de Nimes; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; UDICE-French Research Universities; Universite Paris Saclay	Ulrich, D (corresponding author), Graz Univ Hosp, Dept Obstet & Gynaecol, Graz, Austria.	daniela.ulrich@medunigraz.at	Gold, Daniela/ABE-4818-2020; KHROUF, Mohamed/AGV-7714-2022	Gold, Daniela/0000-0002-7196-454X; FERNANDEZ, Herve/0000-0002-6463-1018				Acunzo G, 2003, HUM REPROD, V18, P1918, DOI 10.1093/humrep/deg368; Binda MM, 2010, BJOG-INT J OBSTET GY, V117, P331, DOI 10.1111/j.1471-0528.2009.02370.x; De Iaco PA, 1998, FERTIL STERIL, V69, P318; Deans R, 2010, J MINIM INVAS GYN, V17, P555, DOI 10.1016/j.jmig.2010.04.016; Fischer B, 2012, REPRODUCTION, V144, P1, DOI 10.1530/REP-12-0091; Guida M, 2004, HUM REPROD, V19, P1461, DOI 10.1093/humrep/deh238; Huberlant S, 2014, J GYNECOL SURG, V30, P347, DOI 10.1089/gyn.2013.0138; Hwang HJ, 2013, INT J COLORECTAL DIS, V28, P1117, DOI 10.1007/s00384-013-1679-8; Kaya C, 2014, EUR J OBSTET GYN R B, V176, P44, DOI 10.1016/j.ejogrb.2014.02.033; Khrouf Mohamed, 2012, J Hum Reprod Sci, V5, P175, DOI 10.4103/0974-1208.101017; Kodaman PH, 2007, CURR OPIN OBSTET GYN, V19, P207, DOI 10.1097/GCO.0b013e32814a6473; Kumar S, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005080.pub2; Kupesic S, 2007, EUR J OBSTET GYN R B, V133, P64, DOI 10.1016/j.ejogrb.2006.10.010; Pellicano M, 2005, FERTIL STERIL, V83, P498, DOI 10.1016/j.fertnstert.2004.09.019; Pucciarelli S, 2003, BRIT J SURG, V90, P66, DOI 10.1002/bjs.4006; Rathat G, 2011, FERTIL STERIL, V95, P405, DOI 10.1016/j.fertnstert.2010.08.055; Revaux A, 2008, GYNECOL OBSTET FERTI, V36, P311, DOI 10.1016/j.gyobfe.2007.11.014; Robinson JK, 2008, FERTIL STERIL, V90, P409, DOI 10.1016/j.fertnstert.2007.06.034; Salzani A, 2007, SAO PAULO MED J, V125, P261, DOI 10.1590/S1516-31802007000500002; Sardo AD, 2011, J MINIM INVAS GYN, V18, P462, DOI 10.1016/j.jmig.2011.04.007; Shamiyeh A, 2007, HEPATO-GASTROENTEROL, V54, P1121; Tao T, 2000, HUM REPROD, V15, P881, DOI 10.1093/humrep/15.4.881; Taskin O, 2000, J AM ASSOC GYN LAP, V7, P351, DOI 10.1016/S1074-3804(05)60478-1; Thomson AJM, 2009, CURR OPIN OBSTET GYN, V21, P335, DOI 10.1097/GCO.0b013e32832e07fc; Touboul C, 2009, FERTIL STERIL, V92, P1690, DOI 10.1016/j.fertnstert.2008.08.108; Yu D, 2008, FERTIL STERIL, V89, P759, DOI 10.1016/j.fertnstert.2008.02.096	26	23	29	0	19	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 11	2015	10	5							e0125610	10.1371/journal.pone.0125610	http://dx.doi.org/10.1371/journal.pone.0125610			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CI1YY	25961307	Green Published, gold, Green Submitted			2023-01-03	WOS:000354542500038
J	Gierczyk, B; Ceglowski, M; Zalas, M				Gierczyk, Blazej; Ceglowski, Michal; Zalas, Maciej			New Gel-Like Polymers As Selective Weak-Base Anion Exchangers	PLOS ONE			English	Article							ADSORPTION-ISOTHERMS; REMOVAL; SORPTION; CHITOSAN; WATER; ARSENIC(V); ARSENATE; RECOVERY	A group of new anion exchangers, based on polyamine podands and of excellent ion-binding capacity, were synthesized. The materials were obtained in reactions between various poly(ethyleneamines) with glycidyl derivatives of cyclotetrasiloxane. The final polymeric, strongly cross-linked materials form gel-like solids. Their structures and interactions with anions adsorbed were studied by spectroscopic methods (CP-MAS NMR, FR-IR, UV-Vis). The sorption isotherms and kinetic parameters were determined for 29 anions. Materials studied show high ion capacity and selectivity towards some important anions, e.g., selenate(VI) or perrhenate.	[Gierczyk, Blazej; Ceglowski, Michal; Zalas, Maciej] Adam Mickiewicz Univ, Fac Chem, PL-60780 Poznan, Poland	Adam Mickiewicz University	Gierczyk, B (corresponding author), Adam Mickiewicz Univ, Fac Chem, Grunwaldzka 6, PL-60780 Poznan, Poland.	hanuman@amu.edu.pl	Gierczyk, Błażej/M-4521-2018; Zalas, Maciej/AAY-3801-2020	Gierczyk, Błażej/0000-0003-3376-5467; Zalas, Maciej/0000-0002-0702-1213; Ceglowski, Michal/0000-0002-8257-642X	Polish National Science Centre (Narodowe Centrum Nauki-NCN) [N N204 155840]	Polish National Science Centre (Narodowe Centrum Nauki-NCN)	Support was provided to BG: grant no. N N204 155840: Polish National Science Centre (Narodowe Centrum Nauki-NCN), (www.ncn.gov.pl).	Awual MR, 2013, ENVIRON SCI POLLUT R, V20, P421, DOI 10.1007/s11356-012-0936-7; Awual MR, 2008, WATER RES, V42, P689, DOI 10.1016/j.watres.2007.08.020; Awual MR, 2014, MICROPOR MESOPOR MAT, V197, P331, DOI 10.1016/j.micromeso.2014.07.005; Awual MR, 2011, DESALINATION, V281, P111, DOI 10.1016/j.desal.2011.07.047; Awual MR, 2011, J HAZARD MATER, V188, P164, DOI 10.1016/j.jhazmat.2011.01.092; Awual MR, 2009, WATER RES, V43, P1229, DOI 10.1016/j.watres.2008.12.018; Barbaro P, 2009, CHEM REV, V109, P515, DOI 10.1021/cr800404j; Boddu VM, 2008, WATER RES, V42, P633, DOI 10.1016/j.watres.2007.08.014; Chassary P, 2004, REACT FUNCT POLYM, V60, P137, DOI 10.1016/j.reactfunctpolym.2004.02.018; CHICZ RM, 1986, J CHROMATOGR, V359, P121, DOI 10.1016/0021-9673(86)80067-X; Dbrowski A, 1996, ADSORPTION NEW MODIF; Deng SB, 2008, LANGMUIR, V24, P10961, DOI 10.1021/la8023138; Depecker G, 2009, REACT FUNCT POLYM, V69, P877, DOI 10.1016/j.reactfunctpolym.2009.09.002; FOGG AG, 1971, ANALYST, V96, P854, DOI 10.1039/an9719600854; Gerente C, 2010, CHEM ENG J, V158, P593, DOI 10.1016/j.cej.2010.02.005; Gierczyk B, 2011, REACT FUNCT POLYM, V71, P463, DOI 10.1016/j.reactfunctpolym.2011.01.007; Guibal E, 1998, IND ENG CHEM RES, V37, P1454, DOI 10.1021/ie9703954; Guibal E, 1999, POLYM INT, V48, P671; Guimaraes D, 2014, J HAZARD MATER, V280, P209, DOI 10.1016/j.jhazmat.2014.07.071; Hibino T, 2014, APPL CLAY SCI, V87, P150, DOI 10.1016/j.clay.2013.10.024; Hickner MA, 2013, J POLYM SCI POL PHYS, V51, P1727, DOI 10.1002/polb.23395; Kailasam V, 2012, HYDROMETALLURGY, V129, P97, DOI 10.1016/j.hydromet.2012.08.010; Kim EM, 2004, J KOREAN MED SCI, V19, P647, DOI 10.3346/jkms.2004.19.5.647; Kumar KV, 2006, J HAZARD MATER, V134, P277, DOI 10.1016/j.jhazmat.2005.11.003; LEYDEN DE, 1976, ANAL CHEM, V48, P67, DOI 10.1021/ac60365a015; Liu Y, 2006, COLLOID SURFACE A, V274, P34, DOI 10.1016/j.colsurfa.2005.08.029; Loganathan P, 2013, J ENVIRON MANAGE, V131, P363, DOI 10.1016/j.jenvman.2013.09.034; MISAK NZ, 1995, COLLOID SURFACE A, V97, P129, DOI 10.1016/0927-7757(94)03073-9; Misak NZ, 2000, REACT FUNCT POLYM, V43, P153, DOI 10.1016/S1381-5148(99)00046-2; Mustafa S, 2010, WATER AIR SOIL POLL, V210, P43, DOI 10.1007/s11270-009-0221-7; Nishimura T, 2007, SEPAR SCI TECHNOL, V42, P3155, DOI 10.1080/01496390701513107; Pande SV, 2011, ION EXCHANGE RESINS; Pillewan P, 2014, ENVIRON PROG SUSTAIN, V33, P1274, DOI 10.1002/ep.11933; Roundhill DM, 2002, CHEM SOC REV, V31, P60, DOI 10.1039/b003141k; Srikanth MV, 2010, ION EXCHANGE RESINS; Walcarius A, 2010, J MATER CHEM, V20, P4478, DOI 10.1039/b924316j; Zhu LL, 2010, J MATER CHEM, V20, P1553, DOI 10.1039/b912345h	37	7	7	2	32	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 6	2015	10	5							e0122891	10.1371/journal.pone.0122891	http://dx.doi.org/10.1371/journal.pone.0122891			23	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CH5BQ	25946220	Green Published, gold, Green Submitted			2023-01-03	WOS:000354049700009
J	Alderliesten, T; de Vries, LS; Khalil, Y; van Haastert, IC; Benders, MJNL; Koopman-Esseboom, C; Groenendaal, F				Alderliesten, Thomas; de Vries, Linda S.; Khalil, Yara; van Haastert, Ingrid C.; Benders, Manon J. N. L.; Koopman-Esseboom, Corine; Groenendaal, Floris			Therapeutic Hypothermia Modifies Perinatal Asphyxia-Induced Changes of the Corpus Callosum and Outcome in Neonates	PLOS ONE			English	Article							HYPOXIC-ISCHEMIC ENCEPHALOPATHY; TERM INFANTS; WALLERIAN DEGENERATION; DIFFUSION; BRAIN; CHILDREN; PATTERN; MRI; LESIONS; INJURY	What Is Known about this Subject? Diffusion-weighted MRI has demonstrated changes in the corpus callosum of term neonates with perinatal asphyxia. The severity of cerebral changes demonstrated using diffusion-weighted MRI is difficult to assess without measuring values of the Apparent Diffusion Coefficient (ADC). What Is New? ADC values of the anterior part of the corpus callosum are slightly higher than of the posterior part in full term infants with perinatal asphyxia. Low ADC values of the corpus callosum were associated with an adverse outcome in infants with perinatal asphyxia. In infants treated with hypothermia lower ADC values than with normothermia were associated with a poor outcome, supporting neuroprotective effects of hypothermia Background Using MRI, changes can be detected in the corpus callosum (CC) following perinatal asphyxia which are associated with later neurodevelopmental outcome. Aim To study the association between the apparent diffusion coefficient of water (ADC) in the CC on MRI in neonates with perinatal asphyxia and neurodevelopmental outcome at 18 months of age. Subjects, Methods Of 121 infants 32 (26%) died and 13 (11%) survived with an adverse neurological outcome. Sixty-five (54%) received therapeutic hypothermia. MRI was performed within 7 days after birth using a 1.5 T or 3.0 T system, and ADC values were measured in the anterior and posterior CC. The association between ADC and composite outcome (death or abnormal neurodevelopment) was analyzed for both normothermia and hypothermia cases using receiver operating characteristics. Results ADC values of the posterior CC were lower than of the anterior part (mean difference 0.050 x 10(-3) mm(2)/s, p<0.001). Field strength did not affect ADC values. ADC values of the posterior part of the CC were significantly lower in infants with basal ganglia/thalamus or near total brain injury (p<0.001). Lower ADC values were associated with an adverse outcome, but cut-off levels were lower after hypothermia (1.024 x 10(-3) mm(2)/s vs 0.969 x 10(-3) mm(2)/s) Conclusion Low ADC values of the posterior part of the corpus callosum are associated with an adverse outcome in term or near term neonates with perinatal asphyxia. Therapeutic hypothermia slightly modifies this association, showing that lower values were needed for an adverse outcome.	[Alderliesten, Thomas; de Vries, Linda S.; Khalil, Yara; van Haastert, Ingrid C.; Benders, Manon J. N. L.; Koopman-Esseboom, Corine; Groenendaal, Floris] Univ Med Ctr Utrecht, Wilhelmina Childrens Hosp, Dept Neonatol, Utrecht, Netherlands	Utrecht University; Utrecht University Medical Center; Wilhelmina Kinderziekenhuis	Groenendaal, F (corresponding author), Univ Med Ctr Utrecht, Wilhelmina Childrens Hosp, Dept Neonatol, Utrecht, Netherlands.	F.groenendaal@umcutrecht.nl	de Vries, Linda S/AAB-6454-2021; Groenendaal, Floris/P-6872-2019	Groenendaal, Floris/0000-0002-9284-1637				Alderliesten T, 2011, RADIOLOGY, V261, P235, DOI 10.1148/radiol.11110213; Ancora G, 2013, NEURORADIOLOGY, V55, P1017, DOI 10.1007/s00234-013-1202-5; Bednarek N, 2012, NEUROLOGY, V78, P1420, DOI 10.1212/WNL.0b013e318253d589; Cowan F, 2003, LANCET, V361, P736, DOI 10.1016/S0140-6736(03)12658-X; de Vries LS, 2010, NEURORADIOLOGY, V52, P555, DOI 10.1007/s00234-010-0674-9; Dudink J, 2008, AM J NEURORADIOL, V29, P1966, DOI 10.3174/ajnr.A1241; EKEN P, 1994, NEUROPEDIATRICS, V25, P301, DOI 10.1055/s-2008-1073044; Epelman M, 2012, PEDIATR RADIOL, V42, P321, DOI 10.1007/s00247-011-2238-5; Griffiths R, 1984, ABILITIES YOUNG CHIL; Groenendaal F, 2006, SEMIN PERINATOL, V30, P146, DOI 10.1053/j.semperi.2006.04.005; Groenendaal F, 2013, NEONATOLOGY, V104, P15, DOI 10.1159/000348823; Harteman JC, 2013, J PEDIATR-US, V163, P968, DOI 10.1016/j.jpeds.2013.06.010; Jacobs SE, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003311.pub3; Kohlhauser C, 2000, LIFE SCI, V67, P2355, DOI 10.1016/S0024-3205(00)00816-X; Maneru C, 2003, BRAIN INJURY, V17, P1003, DOI 10.1080/0269905031000110454; Mazumdar A, 2003, AM J NEURORADIOL, V24, P1057; Nagy Z, 2005, PEDIATR RES, V58, P936, DOI 10.1203/01.pdr.0000186516.85702.61; NJIOKIKTJIEN C, 1994, BEHAV BRAIN RES, V64, P213, DOI 10.1016/0166-4328(94)90133-3; Palisano R, 1997, DEV MED CHILD NEUROL, V39, P214, DOI 10.1111/j.1469-8749.1997.tb07414.x; Porter EJ, 2010, PEDIATR RES, V68, P205, DOI 10.1203/00006450-201011001-00399; RADEMAKERS RP, 1995, J COMPUT ASSIST TOMO, V19, P256, DOI 10.1097/00004728-199503000-00017; Rosenbaum P, 2007, DEV MED CHILD NEUROL, V109, P8, DOI DOI 10.1111/J.1469-8749.2007.TB12610.X; Rutherford M, 2004, PEDIATRICS, V114, P1004, DOI 10.1542/peds.2004-0222; Rutherford M, 2010, LANCET NEUROL, V9, P39, DOI 10.1016/S1474-4422(09)70295-9; Sakai K, 2012, IEEE ENG MED BIO, P2291, DOI 10.1109/EMBC.2012.6346420; Shankaran S, 2012, ARCH DIS CHILD-FETAL, V97, pF398, DOI 10.1136/archdischild-2011-301524; Takenouchi T, 2010, PEDIATR NEUROL, V43, P190, DOI 10.1016/j.pediatrneurol.2010.04.014; Tekgul H, 2004, PEDIATR NEUROL, V31, P35, DOI 10.1016/j.pediatrneurol.2003.11.012; Twomey E, 2010, PEDIATR RADIOL, V40, P1526, DOI 10.1007/s00247-010-1692-9; van der Aa NE, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056784; Van Kooij BJM, 2008, PEDIATR RES, V63, P103, DOI 10.1203/PDR.0b013e31815b4435; van Rooij LGM, 2010, PEDIATRICS, V125, pE358, DOI 10.1542/peds.2009-0136; Vermeulen RJ, 2003, NEUROPEDIATRICS, V34, P72	33	16	16	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 29	2015	10	4							e0123230	10.1371/journal.pone.0123230	http://dx.doi.org/10.1371/journal.pone.0123230			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CH0LO	25923113	Green Published, gold, Green Submitted			2023-01-03	WOS:000353711600035
J	Berman, SI				Berman, Scott I.			Gripers and Whiners	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material												sibshrink225@msn.com						Schiff GD, 2013, JAMA-J AM MED ASSOC, V310, P1233, DOI 10.1001/jama.2013.276133	1	0	0	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 28	2015	313	16					1621	1622		10.1001/jama.2014.13628	http://dx.doi.org/10.1001/jama.2014.13628			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CG8WD	25919523				2023-01-03	WOS:000353595200010
J	Gutierrez, A; Bento, L; Bautista-Gili, AM; Garcia, F; Martinez-Serra, J; Sanchez, B; Martorell, C; Gines, J; Garcia, L; Gimeno, E; Ferraro, M; Del Campo, R; Bargay, J; Perez, A; Vercher, J; Scaff, M; Pacheco, A; Ballester, C; Garcia, F; Ramos, R; Salar, A; Besalduch, J				Gutierrez, Antonio; Bento, Leyre; Maria Bautista-Gili, Antonia; Garcia, Francesc; Martinez-Serra, Jordi; Sanchez, Blanca; Martorell, Clara; Gines, Jordi; Garcia, Lucia; Gimeno, Eva; Ferraro, Mariana; Del Campo, Raquel; Bargay, Joan; Perez, Albert; Vercher, Javier; Scaff, Miguel; Pacheco, Ana; Ballester, Carmen; Garcia, Florencia; Ramos, Rafael; Salar, Antonio; Besalduch, Joan			Differential Impact of Relative Dose-Intensity Reductions in Diffuse Large B-Cell Lymphoma Treated with R-CHOP21 or R-CHOP14	PLOS ONE			English	Article							NON-HODGKINS-LYMPHOMA; ELDERLY-PATIENTS; CHOP CHEMOTHERAPY; PROGNOSTIC-SIGNIFICANCE; PREDICTIVE MODEL; RITUXIMAB-CHOP; DOXORUBICIN; TRIAL; SURVIVAL; DISEASE	DLBCL is an aggressive lymphoma treated with R-CHOP. Recently, attempts have been made to improve the outcome by increasing both dose-density and intensity but there have been no benefits in terms of survival. When treating malignancies RDI is important to consider but there is little published information on DLBCL. The purpose of this study was to analyze the differential prognostic impact of RDI in two cohorts of DLBCL patients treated with R-CHOP21 or R-CHOP14. From January 2001 to August 2013 we included DLBCL patients homogenously treated with R-CHOP21 or R-CHOP14, with or without radiotherapy, at University Hospital Son Espases, Hospital Son Llatzer of Palma and Hospital del Mar of Barcelona (N = 157). In order to avoid selection bias the patients were retrospectively identified from the Pathology Department and Pharmacy registries. Median follow-up was 68 months. There was no difference in the response or survival between the two cohorts. In the R-CHOP21 group, both a reduction higher than 15% in RDI (RR 7.41) and R-IPI (RR 2.99) were independently associated with OS. However, a reduction higher than 15% in RDI (RR 4.41) was only noted for PFS. In the R-CHOP14 group, NCCN-IPI (RR 7.09) and B-symptoms (RR 5.37) for OS; AA stage III-IV (RR 6.26) and bulky disease (RR 4.05) for PFS. There was a trend towards a higher rate of RDI reduction observed in the R-CHOP14 group but it only made an impact in the R-CHOP21 group. We conclude that R-CHOP21 and R-CHOP14 are equivalent regimens in terms of response and survival, but only if RDI reductions are avoided. For patients receiving R-CHOP21 we recommend using clinical and support measures in order to avoid RDI reductions.	[Gutierrez, Antonio; Bento, Leyre; Maria Bautista-Gili, Antonia; Martinez-Serra, Jordi; Garcia, Lucia; Ferraro, Mariana; Perez, Albert; Ballester, Carmen; Besalduch, Joan] Son Espases Univ Hosp, Dept Hematol, Palma De Mallorca, Spain; [Garcia, Francesc; Sanchez, Blanca; Gimeno, Eva; Salar, Antonio] Hosp del Mar, Dept Hematol, Barcelona, Spain; [Martorell, Clara; Gines, Jordi] Son Espases Univ Hosp, Dept Pharm, Palma De Mallorca, Spain; [Del Campo, Raquel; Bargay, Joan] Son Llatzer Hosp, Dept Hematol, Palma De Mallorca, Spain; [Vercher, Javier] Can Misses Hosp, Dept Hematol, Ibiza, Spain; [Scaff, Miguel] Hosp Manacor, Dept Hematol, Manacor, Spain; [Pacheco, Ana] Mateu Orfila Hosp, Dept Hematol, Mahon, Spain; [Garcia, Florencia] Univ Hosp Son Espases, Dept Oncol, Palma De Mallorca, Spain; [Ramos, Rafael] Univ Hosp Son Espases, Dept Pathol, Palma De Mallorca, Spain	Hospital Universitari Son Espases; Institut Hospital del Mar d'Investigacions Mediques (IMIM); Hospital del Mar; Hospital Universitari Son Espases; Hospital Universitari Son Llatzer; Hospital Can Misses; Hospital de Manacor; Hospital Mateu Orfila; Hospital Universitari Son Espases; Hospital Universitari Son Espases	Gutierrez, A (corresponding author), Son Espases Univ Hosp, Dept Hematol, Palma De Mallorca, Spain.	antoniom.gutierrez@ssib.es	Gutiérrez, Antonio/AAL-9381-2021; Llàtzer, Son/ABG-1829-2020; garcia, lucia/GXV-8296-2022	Llàtzer, Son/0000-0002-6739-3916; Salar, Antonio/0000-0002-4652-4825				Aapro MS, 2011, EUR J CANCER, V47, P8, DOI 10.1016/j.ejca.2010.10.013; Bosly A, 2008, ANN HEMATOL, V87, P277, DOI 10.1007/s00277-007-0399-y; Cheson BD, 1999, J CLIN ONCOL, V17, P1244, DOI 10.1200/JCO.1999.17.4.1244; Coiffier B, 2002, NEW ENGL J MED, V346, P235, DOI 10.1056/NEJMoa011795; COX DR, 1972, J R STAT SOC B, V34, P187; Cunningham D, 2013, LANCET, V381, P1817, DOI 10.1016/S0140-6736(13)60313-X; Delarue R, 2013, LANCET ONCOL, V14, P525, DOI 10.1016/S1470-2045(13)70122-0; Doorduijn JK, 2003, J CLIN ONCOL, V21, P3041, DOI 10.1200/JCO.2003.01.076; FISHER RI, 1993, NEW ENGL J MED, V328, P1002, DOI 10.1056/NEJM199304083281404; GREEN JA, 1980, BRIT J CLIN PHARMACO, V9, P511, DOI 10.1111/j.1365-2125.1980.tb05847.x; Habermann TM, 2006, J CLIN ONCOL, V24, P3121, DOI 10.1200/JCO.2005.05.1003; Hershman DL, 2008, J CLIN ONCOL, V26, P3159, DOI 10.1200/JCO.2007.14.1242; HRYNIUK W, 1984, J CLIN ONCOL, V2, P1281, DOI 10.1200/JCO.1984.2.11.1281; Hryniuk W M, 1988, Important Adv Oncol, P121; HRYNIUK WM, 1990, J CLIN ONCOL, V8, P1935, DOI 10.1200/JCO.1990.8.12.1935; Intragumtornchai T, 2000, LEUKEMIA LYMPHOMA, V37, P351, DOI 10.3109/10428190009089435; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KWAK LW, 1990, J CLIN ONCOL, V8, P963, DOI 10.1200/JCO.1990.8.6.963; Landgren O, 2003, HAEMATOLOGICA, V88, P438; LEPAGE E, 1993, ANN ONCOL, V4, P651, DOI 10.1093/oxfordjournals.annonc.a058619; Linch DC, 2010, BRIT J HAEMATOL, V149, P237, DOI 10.1111/j.1365-2141.2010.08081.x; Luminari S, 2010, ANN ONCOL, V21, P1492, DOI 10.1093/annonc/mdp544; Lyman GH, 2004, J CLIN ONCOL, V22, P4302, DOI 10.1200/JCO.2004.03.213; PETO R, 1977, BRIT J CANCER, V35, P1, DOI 10.1038/bjc.1977.1; Pfreundschuh M, 2004, BLOOD, V104, P634, DOI 10.1182/blood-2003-06-2095; ROBERT J, 1983, CANCER RES, V43, P4467; Sehn LH, 2007, BLOOD, V109, P1857, DOI 10.1182/blood-2006-08-038257; SHIPP MA, 1993, NEW ENGL J MED, V329, P987, DOI 10.1056/nejm199309303291402; Smith TJ, 2006, J CLIN ONCOL, V24, P3187, DOI 10.1200/JCO.2006.06.4451; Swerdlow S.H., 2008, WHO CLASSIFICATION T; VANRIJSWIJK REN, 1989, J CLIN ONCOL, V7, P1776, DOI 10.1200/JCO.1989.7.12.1776; Yamaguchi H, 2011, J CLIN EXP HEMATOP, V51, P1, DOI 10.3960/jslrt.51.1; Zelenetz Andrew D, 2003, Oncology (Williston Park), V17, P21; Zhou Z, 2014, BLOOD, V123, P837, DOI 10.1182/blood-2013-09-524108	34	18	18	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 24	2015	10	4							e0123978	10.1371/journal.pone.0123978	http://dx.doi.org/10.1371/journal.pone.0123978			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CG6AH	25909361	Green Submitted, Green Published, gold			2023-01-03	WOS:000353376800053
J	Heeren, A; Baeken, C; Vanderhasselt, MA; Philippot, P; de Raedt, R				Heeren, Alexandre; Baeken, Chris; Vanderhasselt, Marie-Anne; Philippot, Pierre; de Raedt, Rudi			Impact of Anodal and Cathodal Transcranial Direct Current Stimulation over the Left Dorsolateral Prefrontal Cortex during Attention Bias Modification: An Eye-Tracking Study	PLOS ONE			English	Article							SOCIAL ANXIETY; SELECTIVE ATTENTION; FACIAL EXPRESSIONS; CAUSAL ROLE; TIME-COURSE; THREAT; INDIVIDUALS; VALIDATION; GAZE; DISENGAGEMENT	People with anxiety disorders show an attentional bias for threat (AB), and Attention Bias Modification (ABM) procedures have been found to reduce this bias. However, the underlying processes accounting for this effect remain poorly understood. One explanation suggests that ABM requires the modification of attention control, driven by the recruitment of the dorsolateral prefrontal cortex (DLPFC). In the present double-blind study, we examined whether modifying left DLPFC activation influences the effect of ABM on AB. We used transcranial direct current stimulation (tDCS) to directly modulate cortical excitability of the left DLPFC during an ABM procedure designed to reduce AB to threat. Anodal tDCS increases excitability, whereas cathodal tDCS decreases it. We randomly assigned highly trait-anxious individuals to one of three conditions: 1) ABM combined with cathodal tDCS, 2) ABM combined with anodal tDCS, or 3) ABM combined with sham tDCS. We assessed the effects of these manipulations on both reaction times and eye-movements on a task indexing AB. Results indicate that combining ABM and anodal tDCS over the left DLPFC reduces the total duration that participants' gaze remains fixated on threat, as assessed using eye-tracking measurement. However, in contrast to previous studies, there were no changes in AB from baseline to post-training for participants that received ABM without tDCS. As the tendency to maintain attention to threat is known to play an important role in the maintenance of anxiety, the present findings suggest that anodal tDCS over the left DLPFC may be considered as a promising tool to reduce the maintenance of gaze to threat. Implications for future translational research combining ABM and tDCS are discussed.	[Heeren, Alexandre; Philippot, Pierre] Catholic Univ Louvain, Psychol Sci Res Inst, Lab Expt Psychopathol, Louvain La Neuve, Belgium; [Baeken, Chris] Univ Ghent, Dept Psychiat & Med Psychol, B-9000 Ghent, Belgium; [Vanderhasselt, Marie-Anne; de Raedt, Rudi] Univ Ghent, Dept Expt Clin & Hlth Psychol, B-9000 Ghent, Belgium	Universite Catholique Louvain; Ghent University; Ghent University	Heeren, A (corresponding author), Catholic Univ Louvain, Psychol Sci Res Inst, Lab Expt Psychopathol, Louvain La Neuve, Belgium.	Alexandre.Heeren@uclouvain.be	De Raedt, Rudi/AAL-4093-2021; Heeren, Alexandre/U-9748-2019; De Raedt, Rudi/A-3269-2012; Baeken, Chris/D-6790-2013	De Raedt, Rudi/0000-0001-6781-4808; Heeren, Alexandre/0000-0003-0553-6149; De Raedt, Rudi/0000-0001-6781-4808; Vanderhasselt, Marie-Anne/0000-0002-4045-1055	Belgian National Fund for Scientific Research [FC 78142]; Research Foundation Flanders [FWO08/PDO/168]; Concerted Research Action of Ghent University [BOF10/GOA/014]; Ghent University Multidisciplinary Research Partnership "The integrative neuroscience of behavioral control"; Belgian University Foundation [IS179]	Belgian National Fund for Scientific Research(Fonds de la Recherche Scientifique - FNRS); Research Foundation Flanders(FWO); Concerted Research Action of Ghent University; Ghent University Multidisciplinary Research Partnership "The integrative neuroscience of behavioral control"; Belgian University Foundation	This research was supported by a Grant (FC 78142) from the Belgian National Fund for Scientific Research (awarded to Dr. Alexandre Heeren), a Grant (FWO08/PDO/168) from the Research Foundation Flanders (awarded to Dr. Marie- Anne Vanderhasselt), a Grant (BOF10/GOA/014) for a Concerted Research Action of Ghent University (awarded to Prof. Rudi De Raedt). This research was also supported by the Ghent University Multidisciplinary Research Partnership "The integrative neuroscience of behavioral control". The open-access publication of this paper also received the support (IS179) from the Belgian University Foundation (awarded to Dr. Alexandre Heeren). These funders have no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Accornero N, 2007, EXP BRAIN RES, V178, P261, DOI 10.1007/s00221-006-0733-y; Amir N, 2009, J CONSULT CLIN PSYCH, V77, P961, DOI 10.1037/a0016685; [Anonymous], 1980, HANDLEIDING BIJ ZELF; Armstrong T, 2012, CLIN PSYCHOL REV, V32, P704, DOI 10.1016/j.cpr.2012.09.004; Bar-Haim Y, 2007, PSYCHOL BULL, V133, P1, DOI 10.1037/0033-2909.133.1.1; Beck A.T., 1996, BECK DEPRESSION INVE, DOI DOI 10.1037/T00742-000; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Bikson M, 2010, CLIN NEUROPHYSIOL, V121, P1976, DOI 10.1016/j.clinph.2010.05.020; Bishop S, 2004, NAT NEUROSCI, V7, P184, DOI 10.1038/nn1173; Bishop SJ, 2009, NAT NEUROSCI, V12, P92, DOI 10.1038/nn.2242; Browning M, 2010, BIOL PSYCHIAT, V67, P919, DOI 10.1016/j.biopsych.2009.10.031; Brunoni AR, 2014, BRAIN COGNITION, V86, P1, DOI 10.1016/j.bandc.2014.01.008; Calvo MG, 2005, COGNITION EMOTION, V19, P433, DOI 10.1080/02699930441000157; Chen Nigel T. M., 2012, Cognitive Behaviour Therapy, V41, P96, DOI 10.1080/16506073.2012.666562; Cisler JM, 2010, CLIN PSYCHOL REV, V30, P203, DOI 10.1016/j.cpr.2009.11.003; Clarke PJF, 2014, BIOL PSYCHIAT, V76, P946, DOI 10.1016/j.biopsych.2014.03.003; Clarke PJF, 2013, ANXIETY STRESS COPIN, V26, P1, DOI 10.1080/10615806.2011.638054; Cohen J., 2013, STAT POWER ANAL BEHA; DaSilva AF, 2011, JOVE-J VIS EXP, DOI 10.3791/2744; Dear BF, 2011, J PAIN, V12, P1247, DOI 10.1016/j.jpain.2011.07.003; Derryberry D, 2002, J ABNORM PSYCHOL, V111, P225, DOI 10.1037//0021-843X.111.2.225; Eldar S, 2010, PSYCHOL MED, V40, P667, DOI 10.1017/S0033291709990766; Faul F, 2007, BEHAV RES METHODS, V39, P175, DOI 10.3758/BF03193146; Fox E, 2001, J EXP PSYCHOL GEN, V130, P681, DOI 10.1037/0096-3445.130.4.681; Garner M, 2006, J ABNORM PSYCHOL, V115, P760, DOI 10.1037/0021-843X.115.4.760; Goeleven E, 2008, COGNITION EMOTION, V22, P1094, DOI 10.1080/02699930701626582; Hakamata Y, 2010, BIOL PSYCHIAT, V68, P982, DOI 10.1016/j.biopsych.2010.07.021; Heeren A, J BEHAV THE IN PRESS; Heeren A, 2012, BEHAV RES THER, V50, P30, DOI 10.1016/j.brat.2011.10.005; Heeren A, 2015, J ANXIETY DISORD, V29, P35, DOI 10.1016/j.janxdis.2014.10.007; Heeren A, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00119; Heeren A, 2012, COGNITIVE THER RES, V36, P512, DOI 10.1007/s10608-011-9394-7; Heeren A, 2011, J ANXIETY DISORD, V25, P1108, DOI 10.1016/j.janxdis.2011.08.001; Kuckertz JM, 2014, BEHAV RES THER, V53, P30, DOI 10.1016/j.brat.2013.12.003; Langner O, 2010, COGNITION EMOTION, V24, P1377, DOI 10.1080/02699930903485076; Lundqvist D., 1998, KAROLINSKA DIRECTED, DOI 10.1017/S0048577299971664; MacLeod C, 2002, J ABNORM PSYCHOL, V111, P107, DOI 10.1037//0021-843X.111.1.107; MACLEOD C, 1986, J ABNORM PSYCHOL, V95, P15, DOI 10.1037/0021-843X.95.1.15; MacLeod C, 2015, CLIN PSYCHOL SCI, V3, P58, DOI 10.1177/2167702614560749; Maoz K, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00389; Miller EK, 2001, ANNU REV NEUROSCI, V24, P167, DOI 10.1146/annurev.neuro.24.1.167; Mogg K, 2003, ADDICTION, V98, P825, DOI 10.1046/j.1360-0443.2003.00392.x; Mogg K, 2000, J ABNORM PSYCHOL, V109, P695, DOI 10.1037/0021-843X.109.4.695; Mogoase C, 2014, J CLIN PSYCHOL, V70, P1133, DOI 10.1002/jclp.22081; Moliadze V, 2010, CLIN NEUROPHYSIOL, V121, P2165, DOI 10.1016/j.clinph.2010.04.033; Nitsche MA, 2008, BRAIN STIMUL, V1, P206, DOI 10.1016/j.brs.2008.06.004; Nolen-Hoeksema S, 2008, PERSPECT PSYCHOL SCI, V3, P400, DOI 10.1111/j.1745-6924.2008.00088.x; Nummenmaa L, 2006, EMOTION, V6, P257, DOI 10.1037/1528-3542.6.2.257; Raes F, 2007, REVISED VERSION DUTC; RATCLIFF R, 1993, PSYCHOL BULL, V114, P510, DOI 10.1037/0033-2909.114.3.510; Reese HE, 2010, J ANXIETY DISORD, V24, P657, DOI 10.1016/j.janxdis.2010.04.006; Rohner JC, 2002, COGNITION EMOTION, V16, P837, DOI 10.1080/02699930143000572; Roy AK, 2008, J AM ACAD CHILD PSY, V47, P1189, DOI 10.1097/CHI.0b013e3181825ace; Salemink E, 2007, BEHAV RES THER, V45, P607, DOI 10.1016/j.brat.2006.04.004; Schmukle SC, 2005, EUR J PERSONALITY, V19, P595, DOI 10.1002/per.554; Schofield CA, 2012, COGNITION EMOTION, V26, P300, DOI 10.1080/02699931.2011.602050; Sheehan DV, 1998, J CLIN PSYCHIAT, V59, P22, DOI 10.4088/JCP.09m05305whi; Spielberger DC, 1983, MANUAL FOR THE STATE; Staugaard S. R., 2009, PSYCHOL SCI Q, V51, P339, DOI [DOI 10.1080/02699930903205698, DOI 10.4081/MI.2011.E5]; Van Bockstaele B, 2014, PSYCHOL BULL, V140, P682, DOI 10.1037/a0034834; Van Bockstaele B, 2011, J BEHAV THER EXP PSY, V42, P211, DOI 10.1016/j.jbtep.2010.12.004; Van der Does A. J. W., 2002, HANDLEIDING NEDERLAN; Vervoort T, 2013, PAIN, V154, P836, DOI 10.1016/j.pain.2013.02.017	63	56	57	1	43	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 24	2015	10	4							e0124182	10.1371/journal.pone.0124182	http://dx.doi.org/10.1371/journal.pone.0124182			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CG6AH	25909846	gold, Green Published, Green Submitted			2023-01-03	WOS:000353376800062
J	Lepousez, G; Nissant, A; Lledo, PM				Lepousez, Gabriel; Nissant, Antoine; Lledo, Pierre-Marie			Adult Neurogenesis and the Future of the Rejuvenating Brain Circuits	NEURON			English	Review							NEWLY GENERATED NEURONS; NEURAL STEM-CELLS; ENHANCED SYNAPTIC PLASTICITY; BORN HIPPOCAMPAL-NEURONS; LONG-TERM SURVIVAL; OLFACTORY-BULB; DENTATE GYRUS; CRITICAL PERIOD; SUBVENTRICULAR ZONE; GRANULE CELLS	For a long time, the mammalian brain has been perceived to be a static organ. However, the discovery of adult neurogenesis in most mammalian species, including humans, monkeys, and rodents, has disrupted this view. As this continuous regeneration has an effect on established behavioral patterns, it holds promising therapeutic potential. However, before harnessing this potential regenerative power, we must understand what effects new neurons have on existing brain circuits. Ongoing research contributes to several important steps toward bridging the gap between adult-born neurons, circuits, and behavior. The study of adult neurogenesis in different neurogenic regions from a systems neuroscience perspective will pave the way to understanding how it supports adaptive behavior and why its dysfunction correlates with some human brain disorders.	[Lepousez, Gabriel; Nissant, Antoine; Lledo, Pierre-Marie] Inst Pasteur, Lab Percept & Memory, F-75724 Paris, France; [Lepousez, Gabriel; Nissant, Antoine; Lledo, Pierre-Marie] Inst Pasteur, Dept Biotechnol, CNRS, Unite Mixte Rech 3571, F-75724 Paris, France	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Lledo, PM (corresponding author), Inst Pasteur, Lab Percept & Memory, 25 Rue Docteur Roux, F-75724 Paris, France.	pmlledo@pasteur.fr			life insurance company Humanis; Agence Nationale de la Recherche [ANR-BLAN-SVSE4-LS-110624]; Agence Nationale de la Recherche (PLASTMATBEHAV); French state funds	life insurance company Humanis; Agence Nationale de la Recherche(French National Research Agency (ANR)); Agence Nationale de la Recherche (PLASTMATBEHAV)(French National Research Agency (ANR)); French state funds	This work was supported by the life insurance company Humanis and the Agence Nationale de la Recherche (ANR-BLAN-SVSE4-LS-110624 and PLASTMATBEHAV). Our laboratory is also part of the Ecole des Neurosciences de Paris (ENP) Ile-de-France network, and it is supported by French state funds managed by the ANR within the Investissements d'Avenir programme "Biopsy" and "Revive."	Aimone JB, 2011, NEURON, V70, P589, DOI 10.1016/j.neuron.2011.05.010; Aimone JB, 2009, NEURON, V61, P187, DOI 10.1016/j.neuron.2008.11.026; Akers KG, 2014, SCIENCE, V344, P598, DOI 10.1126/science.1248903; Alonso M, 2006, J NEUROSCI, V26, P10508, DOI 10.1523/JNEUROSCI.2633-06.2006; Alonso M, 2012, NAT NEUROSCI, V15, P897, DOI 10.1038/nn.3108; Arenkiel BR, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0029423; Arisi GM, 2012, BEHAV BRAIN RES, V227, P356, DOI 10.1016/j.bbr.2011.03.050; Bannerman DM, 2004, NEUROSCI BIOBEHAV R, V28, P273, DOI 10.1016/j.neubiorev.2004.03.004; Bardy C, 2010, J NEUROSCI, V30, P17023, DOI 10.1523/JNEUROSCI.4543-10.2010; Belluzzi O, 2003, J NEUROSCI, V23, P10411; Belnoue L, 2011, J NEUROSCI, V31, P1010, DOI 10.1523/JNEUROSCI.3941-10.2011; Bergami M, 2015, NEURON, V85, P710, DOI 10.1016/j.neuron.2015.01.001; Bergmann O, 2012, NEURON, V74, P634, DOI 10.1016/j.neuron.2012.03.030; Boldrini M, 2013, NEUROPSYCHOPHARMACOL, V38, P1068, DOI 10.1038/npp.2013.5; Boldrini M, 2012, BIOL PSYCHIAT, V72, P562, DOI 10.1016/j.biopsych.2012.04.024; Bolteus AJ, 2004, J NEUROSCI, V24, P7623, DOI 10.1523/JNEUROSCI.1999-04.2004; Bovetti S, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006359; Boyd AM, 2012, NEURON, V76, P1161, DOI 10.1016/j.neuron.2012.10.020; Bruel-Jungerman E, 2006, J NEUROSCI, V26, P5888, DOI 10.1523/JNEUROSCI.0782-06.2006; Brunner J, 2014, ELIFE, V3, DOI 10.7554/eLife.03104; Burghardt NS, 2012, HIPPOCAMPUS, V22, P1795, DOI 10.1002/hipo.22013; Carleton A, 2003, NAT NEUROSCI, V6, P507, DOI 10.1038/nn1048; Caroni P, 2012, NAT REV NEUROSCI, V13, P478, DOI 10.1038/nrn3258; Cave JW, 2014, FRONT NEUROSCI-SWITZ, V8, DOI 10.3389/fnins.2014.00016; Chancey JH, 2014, J NEUROSCI, V34, P2349, DOI 10.1523/JNEUROSCI.3620-13.2014; Chow SF, 2012, PLOS COMPUT BIOL, V8, DOI 10.1371/journal.pcbi.1002398; Clelland CD, 2009, SCIENCE, V325, P210, DOI 10.1126/science.1173215; Curtis MA, 2007, SCIENCE, V315, P1243, DOI 10.1126/science.1136281; Danzer SC, 2012, EXP NEUROL, V233, P22, DOI 10.1016/j.expneurol.2011.05.023; DeCarolis NA, 2010, NEUROPHARMACOLOGY, V58, P884, DOI 10.1016/j.neuropharm.2009.12.013; Denny CA, 2012, HIPPOCAMPUS, V22, P1188, DOI 10.1002/hipo.20964; Dery N, 2013, FRONT NEUROSCI-SWITZ, V7, DOI 10.3389/fnins.2013.00066; Deshpande A, 2013, P NATL ACAD SCI USA, V110, pE1152, DOI 10.1073/pnas.1218991110; Dieni CV, 2013, J NEUROSCI, V33, P19131, DOI 10.1523/JNEUROSCI.2289-13.2013; Dolorfo CL, 1998, J COMP NEUROL, V398, P25; Dupret D, 2005, EUR J NEUROSCI, V22, P778, DOI 10.1111/j.1460-9568.2005.04262.x; Dupret D, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001959; Eisch AJ, 2012, SCIENCE, V338, P72, DOI 10.1126/science.1222941; Eriksson PS, 1998, NAT MED, V4, P1313, DOI 10.1038/3305; Ernst A, 2014, CELL, V156, P1072, DOI 10.1016/j.cell.2014.01.044; Esposito MS, 2005, J NEUROSCI, V25, P10074, DOI 10.1523/JNEUROSCI.3114-05.2005; Fanselow MS, 2010, NEURON, V65, P7, DOI 10.1016/j.neuron.2009.11.031; Feierstein CE, 2010, FRONT BEHAV NEUROSCI, V4, DOI 10.3389/fnbeh.2010.00176; Feng RB, 2001, NEURON, V32, P911, DOI 10.1016/S0896-6273(01)00523-2; Fotuhi M, 2012, NAT REV NEUROL, V8, P189, DOI 10.1038/nrneurol.2012.27; Frankland PW, 2013, TRENDS NEUROSCI, V36, P497, DOI 10.1016/j.tins.2013.05.002; Fuster-Matanzo A, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/260925; Gage FH, 2013, NEURON, V80, P588, DOI 10.1016/j.neuron.2013.10.037; Ge SY, 2007, NEURON, V54, P559, DOI 10.1016/j.neuron.2007.05.002; Ge SY, 2006, NATURE, V439, P589, DOI 10.1038/nature04404; Gheusi G, 2009, BEHAV BRAIN RES, V200, P315, DOI 10.1016/j.bbr.2009.02.006; GRAY CM, 1988, EXP BRAIN RES, V69, P378; Groves JO, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003718; Gu Y, 2012, NAT NEUROSCI, V15, P1700, DOI 10.1038/nn.3260; Hasselmo ME, 1996, HIPPOCAMPUS, V6, P693, DOI 10.1002/(SICI)1098-1063(1996)6:6<693::AID-HIPO12>3.0.CO;2-W; Haughey NJ, 2002, J NEUROCHEM, V83, P1509, DOI 10.1046/j.1471-4159.2002.01267.x; Hitti FL, 2014, NATURE, V508, P88, DOI 10.1038/nature13028; Huttner HB, 2014, NAT NEUROSCI, V17, P801, DOI 10.1038/nn.3706; Ikrar T, 2013, FRONT NEURAL CIRCUIT, V7, DOI 10.3389/fncir.2013.00204; Imayoshi I, 2008, NAT NEUROSCI, V11, P1153, DOI 10.1038/nn.2185; Isaacson JS, 2011, NEURON, V72, P231, DOI 10.1016/j.neuron.2011.09.027; Jessberger S, 2014, TRENDS CELL BIOL, V24, P558, DOI 10.1016/j.tcb.2014.07.003; Jessberger S, 2009, LEARN MEMORY, V16, P147, DOI 10.1101/lm.1172609; Katagiri Hiroyuki, 2011, Neural Syst Circuits, V1, P6, DOI 10.1186/2042-1001-1-6; Katsimpardi L, 2008, STEM CELLS, V26, P1796, DOI 10.1634/stemcells.2007-0921; Kelsch W, 2008, P NATL ACAD SCI USA, V105, P16803, DOI 10.1073/pnas.0807970105; Kelsch W, 2009, J NEUROSCI, V29, P11852, DOI 10.1523/JNEUROSCI.2406-09.2009; Kempermann G, 1997, NATURE, V386, P493, DOI 10.1038/386493a0; Kheirbek MA, 2013, NEURON, V77, P955, DOI 10.1016/j.neuron.2012.12.038; Kheirbek MA, 2012, NAT NEUROSCI, V15, P1613, DOI 10.1038/nn.3262; Kirby ED, 2013, ELIFE, V2, DOI 10.7554/eLife.00362; Kiselycznyk CL, 2006, LEARN MEMORY, V13, P575, DOI 10.1101/lm.285706; Kitamura T, 2010, MOL BRAIN, V3, DOI 10.1186/1756-6606-3-13; Koehl M, 2011, EUR J NEUROSCI, V33, P1101, DOI 10.1111/j.1460-9568.2011.07609.x; Kohler SJ, 2011, P NATL ACAD SCI USA, V108, P10326, DOI 10.1073/pnas.1017099108; Konefal S, 2013, FRONT NEUROANAT, V7, DOI 10.3389/fnana.2013.00021; Krzisch M., 2014, BRAIN STRUCT FUNCT, V2014, P19; Kumamoto N, 2012, NAT NEUROSCI, V15, P399, DOI 10.1038/nn.3042; Lacefield CO, 2012, HIPPOCAMPUS, V22, P106, DOI 10.1002/hipo.20860; Lagace DC, 2010, P NATL ACAD SCI USA, V107, P4436, DOI 10.1073/pnas.0910072107; Lazarini F, 2011, TRENDS NEUROSCI, V34, P20, DOI 10.1016/j.tins.2010.09.006; Lemaire V, 2012, J NEUROSCI, V32, P3101, DOI 10.1523/JNEUROSCI.4731-11.2012; Lepousez G, 2014, P NATL ACAD SCI USA, V111, P13984, DOI 10.1073/pnas.1404991111; Lepousez G, 2013, ANNU REV PHYSIOL, V75, P339, DOI 10.1146/annurev-physiol-030212-183731; Lepousez G, 2010, J COMP NEUROL, V518, P1976, DOI 10.1002/cne.22317; Leutgeb S, 2007, LEARN MEMORY, V14, P745, DOI 10.1101/lm.703907; Li Y, 2012, P NATL ACAD SCI USA, V109, P4290, DOI 10.1073/pnas.1120754109; Lindvall O, 2011, NEUROTHERAPEUTICS, V8, P539, DOI 10.1007/s13311-011-0069-6; Livneh Y, 2014, NEURON, V81, P1097, DOI 10.1016/j.neuron.2014.01.007; Livneh Y, 2011, J COMP NEUROL, V519, P2212, DOI 10.1002/cne.22625; Livneh Y, 2009, J NEUROSCI, V29, P86, DOI 10.1523/JNEUROSCI.4105-08.2009; Lledo PM, 2006, NAT REV NEUROSCI, V7, P179, DOI 10.1038/nrn1867; Llorens-Martin M, 2015, EXP NEUROL, V263, P285, DOI 10.1016/j.expneurol.2014.10.021; Luzzati F, 2006, J NEUROSCI, V26, P609, DOI 10.1523/JNEUROSCI.4371-05.2006; Magavi SSP, 2005, J NEUROSCI, V25, P10729, DOI 10.1523/JNEUROSCI.2250-05.2005; Magnusson JP, 2014, SCIENCE, V346, P237, DOI 10.1126/science.346.6206.237; Mandairon N, 2006, NEUROSCIENCE, V141, P443, DOI 10.1016/j.neuroscience.2006.03.066; Mandairon N, 2014, FRONT BEHAV NEUROSCI, V8, DOI 10.3389/fnbeh.2014.00138; Maresh A, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002640; Marin-Burgin A, 2012, SCIENCE, V335, P1238, DOI 10.1126/science.1214956; Marin-Burgin A, 2012, BEHAV BRAIN RES, V227, P391, DOI 10.1016/j.bbr.2011.07.001; Markopoulos F, 2012, NEURON, V76, P1175, DOI 10.1016/j.neuron.2012.10.028; Martin C, 2004, J PHYSIOLOGY-PARIS, V98, P467, DOI 10.1016/j.jphysparis.2005.09.003; Maviel T, 2004, SCIENCE, V305, P96, DOI 10.1126/science.1098180; MCCLELLAND JL, 1995, PSYCHOL REV, V102, P419, DOI 10.1037/0033-295X.102.3.419; Mejia-Gervacio S, 2011, NEURAL DEV, V6, DOI 10.1186/1749-8104-6-4; Meltzer LA, 2005, TRENDS NEUROSCI, V28, P653, DOI 10.1016/j.tins.2005.09.007; Merkle FT, 2014, NAT NEUROSCI, V17, P207, DOI 10.1038/nn.3610; Mongiat LA, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005320; Monje ML, 2002, NAT MED, V8, P955, DOI 10.1038/nm749; Moreno MM, 2009, P NATL ACAD SCI USA, V106, P17980, DOI 10.1073/pnas.0907063106; MOSER MB, 1995, P NATL ACAD SCI USA, V92, P9697, DOI 10.1073/pnas.92.21.9697; Mouret A, 2008, J NEUROSCI, V28, P11511, DOI 10.1523/JNEUROSCI.2954-08.2008; Nakashiba T, 2012, CELL, V149, P188, DOI 10.1016/j.cell.2012.01.046; Niibori Y, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms2261; Ninkovic J, 2007, J NEUROSCI, V27, P10906, DOI 10.1523/JNEUROSCI.2572-07.2007; Nissant A, 2009, NAT NEUROSCI, V12, P728, DOI 10.1038/nn.2298; Oboti L, 2014, FRONT NEUROSCI-SWITZ, V8, DOI 10.3389/fnins.2014.00102; Ohara S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078928; Pagano SF, 2000, STEM CELLS, V18, P295, DOI 10.1634/stemcells.18-4-295; Pallotto M, 2012, J NEUROSCI, V32, P9103, DOI 10.1523/JNEUROSCI.0214-12.2012; Panzanelli P, 2009, J NEUROSCI, V29, P15039, DOI 10.1523/JNEUROSCI.3034-09.2009; Petreanu L, 2002, J NEUROSCI, V22, P6106; Ramirez S, 2013, SCIENCE, V341, P387, DOI 10.1126/science.1239073; Rangel LM, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4181; Ray J, 2006, MOL CELL NEUROSCI, V31, P560, DOI 10.1016/j.mcn.2005.11.010; Rochefort C, 2002, J NEUROSCI, V22, P2679, DOI 10.1523/JNEUROSCI.22-07-02679.2002; Rolls ET, 2006, PROG NEUROBIOL, V79, P1, DOI 10.1016/j.pneurobio.2006.04.005; Ruan LH, 2014, PROG NEUROBIOL, V115, P116, DOI 10.1016/j.pneurobio.2013.12.006; Ruediger S, 2012, NAT NEUROSCI, V15, P1563, DOI 10.1038/nn.3224; Sahay A, 2011, NATURE, V472, P466, DOI 10.1038/nature09817; Sanai N, 2004, NATURE, V427, P740, DOI 10.1038/nature02301; Sanai N, 2011, NATURE, V478, P382, DOI 10.1038/nature10487; Santarelli L, 2003, SCIENCE, V301, P805, DOI 10.1126/science.1083328; Schmidt-Hieber C, 2004, NATURE, V429, P184, DOI 10.1038/nature02553; Shors TJ, 2001, NATURE, V410, P372, DOI 10.1038/35066584; Sierra A, 2010, CELL STEM CELL, V7, P483, DOI 10.1016/j.stem.2010.08.014; Small SA, 2011, NAT REV NEUROSCI, V12, P585, DOI 10.1038/nrn3085; Snyder JS, 2009, J NEUROSCI, V29, P14484, DOI 10.1523/JNEUROSCI.1768-09.2009; Snyder JS, 2001, J NEUROPHYSIOL, V85, P2423, DOI 10.1152/jn.2001.85.6.2423; Song J, 2012, NATURE, V489, P150, DOI 10.1038/nature11306; Soria-Gomez E, 2014, NAT NEUROSCI, V17, P407, DOI 10.1038/nn.3647; Spalding KL, 2013, CELL, V153, P1219, DOI 10.1016/j.cell.2013.05.002; Sultan S, 2010, FASEB J, V24, P2355, DOI 10.1096/fj.09-151456; Sultan S, 2011, J NEUROSCI, V31, P14893, DOI 10.1523/JNEUROSCI.3677-11.2011; Sun GJ, 2013, J NEUROSCI, V33, P11400, DOI 10.1523/JNEUROSCI.1374-13.2013; Temprana SG, 2015, NEURON, V85, P116, DOI 10.1016/j.neuron.2014.11.023; Toni N, 2008, NAT NEUROSCI, V11, P901, DOI 10.1038/nn.2156; TREVES A, 1992, HIPPOCAMPUS, V2, P189, DOI 10.1002/hipo.450020209; Valley MT, 2013, J NEUROSCI, V33, P14660, DOI 10.1523/JNEUROSCI.2845-13.2013; van Praag H, 1999, NAT NEUROSCI, V2, P266, DOI 10.1038/6368; Vivar C, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms2101; Wang CM, 2011, CELL RES, V21, P1534, DOI 10.1038/cr.2011.83; Whitman MC, 2007, J NEUROSCI, V27, P9951, DOI 10.1523/JNEUROSCI.1633-07.2007; Wijeyekoon R, 2009, BBA-MOL BASIS DIS, V1792, P688, DOI 10.1016/j.bbadis.2008.10.007; Winner B, 2002, EUR J NEUROSCI, V16, P1681, DOI 10.1046/j.1460-9568.2002.02238.x; Winocur G, 2006, HIPPOCAMPUS, V16, P296, DOI 10.1002/hipo.20163; Wojtowicz JM, 2008, EUR J NEUROSCI, V27, P1494, DOI 10.1111/j.1460-9568.2008.06128.x; Wojtowicz JM, 2012, BEHAV BRAIN RES, V227, P490, DOI 10.1016/j.bbr.2011.08.013; Wu MV, 2014, HIPPOCAMPUS, V24, P751, DOI 10.1002/hipo.22265; Yokoyama TK, 2011, NEURON, V71, P883, DOI 10.1016/j.neuron.2011.05.046; Young SZ, 2011, EUR J NEUROSCI, V33, P1123, DOI 10.1111/j.1460-9568.2011.07611.x; Zhang CL, 2008, NATURE, V451, P1004, DOI 10.1038/nature06562	163	81	84	0	53	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0896-6273	1097-4199		NEURON	Neuron	APR 22	2015	86	2					387	401		10.1016/j.neuron.2015.01.002	http://dx.doi.org/10.1016/j.neuron.2015.01.002			15	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	CG6KS	25905812	Bronze			2023-01-03	WOS:000353410000009
J	Qi, DF; Hu, Y; Li, JH; Peng, T; Su, JL; He, Y; Ji, WD				Qi, Defeng; Hu, Yuan; Li, Jinhui; Peng, Tao; Su, Jialin; He, Yun; Ji, Weidong			Hyperthermia Induces Apoptosis of 786-O Cells through Suppressing Ku80 Expression	PLOS ONE			English	Article							DOUBLE-STRAND BREAK; DEPENDENT PROTEIN-KINASE; IONIZING-RADIATION; CATALYTIC SUBUNIT; ANTICANCER DRUGS; GAMMA-H2AX FOCI; DEFICIENT CELLS; DNA-REPAIR; HEAT-SHOCK; CARCINOMA	Hyperthermia as an anticancer method has been paid increasing attention in recent years. Several studies have shown that hyperthermia can kill tumor cells by inducing apoptosis. However, the underlying molecular mechanisms of hyperthermia-induced apoptosis are largely unknown. To investigate the effects and molecular mechanism of hyperthermia on the apoptosis in renal carcinoma 786-O cells, we firstly examined apoptosis and Ku expression in 786-O cell line treated with heat exposure (42 degrees C for 0-4 h). The results showed that hyperthermia induced apoptosis of 786-O cells, and suppressed significantly Ku80 expression, but not Ku70 expression. Next, we knock-down Ku80 in 786-O cells, generating stable cell line 786-O-shKu80, and detected apoptosis, cell survival and cell cycle distribution. Our data showed higher apoptotic rate and lower surviving fraction in the stable cell line 786-O-shKu80 compared with those in control cells, exposed to the same heat stress (42 degrees C for 0-4 h). Moreover, the results also showed suppression of Ku80 led to G2/M phase arrest in the stable cell line 786-O-shKu80 following heat treatment. Together, these findings indicate that Ku80 may play an important role in hyperthermia-induced apoptosis and heat-sensitivity of renal carcinoma cells through influencing the cell cycle distribution.	[Qi, Defeng; Hu, Yuan; Li, Jinhui; Peng, Tao; Su, Jialin] Guangzhou Med Univ, Affiliated Hosp 1, Minimally Invas Surg Ctr, Dept Urol,Guangdong Prov Key Lab Urol, Guangzhou, Guangdong, Peoples R China; [He, Yun] Sun Yat Sen Univ, Sch Publ Hlth, Guangzhou 510275, Guangdong, Peoples R China; [Ji, Weidong] Sun Yat Sen Univ, Affiliated Hosp 1, Ctr Translat Med, Guangzhou 510275, Guangdong, Peoples R China	Guangzhou Medical University; Sun Yat Sen University; Sun Yat Sen University	Qi, DF (corresponding author), Guangzhou Med Univ, Affiliated Hosp 1, Minimally Invas Surg Ctr, Dept Urol,Guangdong Prov Key Lab Urol, Guangzhou, Guangdong, Peoples R China.	qdf70818@tom.com; heyun_jane@163.com; wdji2008@163.com	ji, weidong/AAX-7397-2020	Peng, Tao/0000-0001-5260-7128	National Natural Science Foundation of China [30872142, 81272350, 81472999]; Natural Science Foundation of Guangdong [S2012010008908, 8151012003000011]; University Talent Program of Guangzhou [12A015G]; Science and Technology Program of Guangdong [2010B060900096]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Guangdong(National Natural Science Foundation of Guangdong Province); University Talent Program of Guangzhou; Science and Technology Program of Guangdong	This work was supported by grants from National Natural Science Foundation of China (No. 30872142, No. 81272350, No. 81472999 to WJ), Natural Science Foundation of Guangdong (No. S2012010008908 to WJ, No. 8151012003000011 to DQ), University Talent Program of Guangzhou (No. 12A015G to WJ) and Science and Technology Program of Guangdong (No. 2010B060900096). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	BARRY MA, 1990, BIOCHEM PHARMACOL, V40, P2353, DOI 10.1016/0006-2952(90)90733-2; Basile A, 2008, J CELL BIOCHEM, V103, P212, DOI 10.1002/jcb.21401; Branzei D, 2008, NAT REV MOL CELL BIO, V9, P297, DOI 10.1038/nrm2351; Campbell SC, 2009, J UROLOGY, V182, P1271, DOI 10.1016/j.juro.2009.07.004; Coffey DS, 2006, JAMA-J AM MED ASSOC, V296, P445, DOI 10.1001/jama.296.4.445; Davis AJ, 2013, J BIOL CHEM, V288, P7037, DOI 10.1074/jbc.M112.434498; DIKOMEY E, 1992, INT J RADIAT BIOL, V61, P221, DOI 10.1080/09553009214550851; DYSON JED, 1986, CELL TISSUE KINET, V19, P311, DOI 10.1111/j.1365-2184.1986.tb00683.x; GABAI VL, 1995, FEBS LETT, V375, P21, DOI 10.1016/0014-5793(95)01152-5; Gabai VL, 1998, FEBS LETT, V438, P1, DOI 10.1016/S0014-5793(98)01242-3; HARMON BV, 1991, INT J RADIAT BIOL, V59, P489, DOI 10.1080/09553009114550441; Hildebrandt B, 2002, CRIT REV ONCOL HEMAT, V43, P33, DOI 10.1016/S1040-8428(01)00179-2; Ihara M, 2014, INT J HYPERTHER, V30, P102, DOI 10.3109/02656736.2014.887793; Iliakis G, 2004, CYTOGENET GENOME RES, V104, P14, DOI 10.1159/000077461; Ismail-Zade RS, 2005, PEDIATR BLOOD CANCER, V44, P679, DOI 10.1002/pbc.20299; Jones EL, 2005, J CLIN ONCOL, V23, P3079, DOI 10.1200/JCO.2005.05.520; Kajihara A, 2008, INT J HYPERTHER, V24, P605, DOI 10.1080/02656730802348339; Khanna KK, 2001, NAT GENET, V27, P247, DOI 10.1038/85798; Kim SH, 1999, CANCER RES, V59, P4012; Kim SH, 2000, LEUKEMIA RES, V24, P917, DOI 10.1016/S0145-2126(00)00061-8; Kuhne M, 2004, CANCER RES, V64, P500, DOI 10.1158/0008-5472.CAN-03-2384; Kurimasa A, 1999, P NATL ACAD SCI USA, V96, P1403, DOI 10.1073/pnas.96.4.1403; Li G, 2002, P NATL ACAD SCI USA, V99, P832, DOI 10.1073/pnas.022649699; Mahaney BL, 2009, BIOCHEM J, V417, P639, DOI 10.1042/BJ20080413; MIKKELSEN RB, 1991, CANCER RES, V51, P359; Moriyama-Gonda N, 2002, BJU INT, V90, P317, DOI 10.1046/j.1464-410X.2002.02810.x; Motzer RJ, 1997, CURR PROB CANCER, V21, P191, DOI 10.1016/S0147-0272(97)80007-4; Munoz P, 1998, MOL CELL BIOL, V18, P5797, DOI 10.1128/MCB.18.10.5797; Nussenzweig A, 1996, NATURE, V382, P551, DOI 10.1038/382551a0; Nussenzweig A, 1997, P NATL ACAD SCI USA, V94, P13588, DOI 10.1073/pnas.94.25.13588; Okamoto N, 2011, INT J HYPERTHER, V27, P297, DOI 10.3109/02656736.2010.545365; Omori S, 2002, DNA REPAIR, V1, P299, DOI 10.1016/S1568-7864(02)00006-X; Ouyang H, 1997, J EXP MED, V186, P921, DOI 10.1084/jem.186.6.921; Ponnala S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026191; RADFORD IR, 1983, INT J RADIAT BIOL, V43, P551, DOI 10.1080/09553008314550641; Riballo E, 2004, MOL CELL, V16, P715, DOI 10.1016/j.molcel.2004.10.029; Takahashi A, 2004, CANCER RES, V64, P8839, DOI 10.1158/0008-5472.CAN-04-1876; Takahashi A, 2008, MUTAT RES-GEN TOX EN, V656, P88, DOI 10.1016/j.mrgentox.2008.07.012; Takahashi A, 2010, J RADIAT RES, V51, P91, DOI [10.1269/jrr.09111, 10.1269/jrr.0911]; VIDAIR CA, 1995, J CELL PHYSIOL, V163, P194, DOI 10.1002/jcp.1041630122; Wang C, 2013, INT J RADIAT ONCOL, V86, P440, DOI 10.1016/j.ijrobp.2013.01.011; Weterings E, 2008, CELL RES, V18, P114, DOI 10.1038/cr.2008.3; Zhuang L, 2011, INT J ONCOL, V39, P443, DOI 10.3892/ijo.2011.1041; Zuo L, 2000, AM J PHYSIOL-CELL PH, V279, pC1058, DOI 10.1152/ajpcell.2000.279.4.C1058	44	16	17	1	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 22	2015	10	4							e0122977	10.1371/journal.pone.0122977	http://dx.doi.org/10.1371/journal.pone.0122977			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CG5KV	25902193	Green Published, Green Submitted, gold			2023-01-03	WOS:000353331500035
J	van Hees, NJM; Giltay, EJ; Tielemans, SMAJ; Geleijnse, JM; Puvill, T; Janssen, N; van der Does, W				van Hees, Nathalie J. M.; Giltay, Erik J.; Tielemans, Susanne M. A. J.; Geleijnse, Johanna M.; Puvill, Thomas; Janssen, Nadine; van der Does, Willem			Essential Amino Acids in the Gluten-Free Diet and Serum in Relation to Depression in Patients with Celiac Disease	PLOS ONE			English	Article							FOOD-FREQUENCY QUESTIONNAIRE; BRANCHED-CHAIN AMINO; TRYPTOPHAN-METABOLISM; FIBER; MOOD; ASSOCIATION; ADOLESCENTS; DISORDERS; DEPLETION; SYMPTOMS	Introduction Celiac disease (CD) is associated with an increased risk of major depressive disorder, possibly due to deficiencies in micronutrients in the gluten-free diet. We aimed to investigate whether essential amino acids (i.e., the precursors of serotonin, dopamine and other neurotransmitters) are depleted in the diet and serum of CD patients with major depressive disorder. Methods In a cross-sectional study we assessed dietary intake of amino acids and serum levels of amino acids, in 77 CD patients on a gluten-free diet and in 33 healthy controls. Major depressive disorder was assessed with structured interviews (using the Mini International Neuropsychiatric Interview Plus). Dietary intake was assessed using a 203-item food frequency questionnaire. Results Participants had a mean age of 55 years and 74% were women. The intake of vegetable protein was significantly lower in CD patients than in healthy controls (mean difference of 7.8 g/d; 95% CI: 4.7-10.8), as were serum concentrations of tyrosine, phenylalanine and tryptophan (all p < 0.005). However, within the CD patient group, the presence of major depressive disorder (n = 42) was not associated with intake or serum levels of essential amino acids. Conclusions Patients with CD on a long-term gluten-free diet, with good adherence, consume significantly less vegetable protein than controls, and their serum levels of several essential amino acids were also lower. Despite its potential adverse effect, intake and serum levels of essential amino acids were not related to major depression.	[van Hees, Nathalie J. M.; Janssen, Nadine; van der Does, Willem] Leiden Univ, Inst Psychol, Leiden, Netherlands; [Giltay, Erik J.; van der Does, Willem] Leiden Univ, Med Ctr, Dept Psychiat, Leiden, Netherlands; [Tielemans, Susanne M. A. J.; Geleijnse, Johanna M.] Wageningen Univ, Div Human Nutr, NL-6700 AP Wageningen, Netherlands; [Puvill, Thomas] Leyden Acad Vital & Ageing, Leiden, Netherlands	Leiden University; Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Wageningen University & Research	van Hees, NJM (corresponding author), Leiden Univ, Inst Psychol, Leiden, Netherlands.	heesnjmvan@fsw.ledenuniv.nl	Geleijnse, Johanna Marianna M/B-5749-2012; Van der Does, Willem/B-1465-2008; Giltay, Erik J./AAL-9948-2021	Geleijnse, Johanna Marianna M/0000-0001-7638-0589; Van der Does, Willem/0000-0002-9753-2454; Giltay, Erik/0000-0001-8874-2292; /0000-0001-6716-0023	Netherlands Science Foundation (N.W.OMaGW Vici grant) [453-06-005]; Leiden University Fund (LUF); Gratama foundation [08.10]	Netherlands Science Foundation (N.W.OMaGW Vici grant); Leiden University Fund (LUF); Gratama foundation	This project was funded by a grant from the Netherlands Science Foundation (N.W.OMaGW Vici grant # 453-06-005 to WVdD), http://www.nwo.nl/en, and grants from the Leiden University Fund (LUF) and Gratama foundation # 08.10, http://www.luf.nl/subsidies/information-in-english. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Addolorato G, 2008, INT J CLIN PRACT, V62, P1063, DOI 10.1111/j.1742-1241.2008.01763.x; Addolorato G, 1996, HEPATO-GASTROENTEROL, V43, P1513; Addolorato G, 2008, DIGEST DIS, V26, P140, DOI 10.1159/000116772; American Psychiatric Association APATFoDSMIV, 2000, DIAGN STAT MAN MENT; [Anonymous], 2006, DUTCH FOOD COMP TABL; Beirao EM, BRAZILIAN J INFECT D; Booij L, 2003, MOL PSYCHIATR, V8, P951, DOI 10.1038/sj.mp.4001423; Carta MG, 2002, J PSYCHOSOM RES, V53, P789, DOI 10.1016/S0022-3999(02)00328-8; [FAO] FaAO, 1993, MAIZ HUM NUTR; FAO/WHO/UNU (Expert Consultation), 2007, WHO TECHN REP SER, V935; Fernstrom JD, 2013, AMINO ACIDS, V45, P419, DOI 10.1007/s00726-012-1330-y; Fernstrom JD, 2012, J NUTR, V142, p2236S, DOI 10.3945/jn.111.157065; FEUNEKES GIJ, 1993, AM J CLIN NUTR, V58, P489, DOI 10.1093/ajcn/58.4.489; Geleijnse JM, 2010, AM HEART J, V159, P539, DOI 10.1016/j.ahj.2009.12.033; HALLERT C, 1983, PSYCHOL MED, V13, P267, DOI 10.1017/S003329170005087X; HALLERT C, 1982, SCAND J GASTROENTERO, V17, P17, DOI 10.3109/00365528209181037; HALLERT C, 1982, SCAND J GASTROENTERO, V17, P87, DOI 10.3109/00365528209181049; HERNANZ A, 1991, GUT, V32, P1478, DOI 10.1136/gut.32.12.1478; HUTSON SM, 1981, AM J CLIN NUTR, V34, P173, DOI 10.1093/ajcn/34.2.173; Kalia M, 2005, METABOLISM, V54, P24, DOI 10.1016/j.metabol.2005.01.009; Le Floc'h N, 2011, AMINO ACIDS, V41, P1195, DOI 10.1007/s00726-010-0752-7; Leffler DA, 2009, CLIN GASTROENTEROL H, V7, P530, DOI 10.1016/j.cgh.2008.12.032; Matthews DE, 2005, J NUTR, V135, p1580S, DOI 10.1093/jn/135.6.1580S; Merens W, 2005, BRIT J NUTR, V94, P415, DOI 10.1079/BJN20051492; Nutt DJ, 2007, J CLIN PSYCHIAT, V68, P42; Ocke MC, 1997, INT J EPIDEMIOL, V26, pS49, DOI 10.1093/ije/26.suppl_1.S49; Pynnonen PA, 2002, PSYCHOSOMATICS, V43, P331, DOI 10.1176/appi.psy.43.4.331; Pynnonen PA, 2005, BMC PSYCHIATRY, V5, DOI 10.1186/1471-244X-5-14; Rostom A, 2006, GASTROENTEROLOGY, V131, P1981, DOI 10.1053/j.gastro.2006.10.004; Rubio-Tapia A, 2010, AM J GASTROENTEROL, V105, P1412, DOI 10.1038/ajg.2010.10; Sainio EL, 1996, AMINO ACIDS, V10, P21, DOI 10.1007/BF00806091; Schulte-van Maaren YWM, 2013, J EVAL CLIN PRACT, V19, P342, DOI 10.1111/j.1365-2753.2012.01830.x; Sheehan DV, 1998, J CLIN PSYCHIAT, V59, P22, DOI 10.4088/JCP.09m05305whi; Solanto MV, 2002, BEHAV BRAIN RES, V130, P65, DOI 10.1016/S0166-4328(01)00431-4; Thompson T, 2000, J AM DIET ASSOC, V100, P1389, DOI 10.1016/S0002-8223(00)00386-2; Thompson T, 2005, J HUM NUTR DIET, V18, P163, DOI 10.1111/j.1365-277X.2005.00607.x; Tommasini A, 2004, ARCH DIS CHILD, V89, P512, DOI 10.1136/adc.2003.029603; Torres MI, 2007, CLIN EXP IMMUNOL, V148, P419, DOI 10.1111/j.1365-2249.2007.03365.x; van Hees NJM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097778; van Hees NJM, 2013, J PSYCHOSOM RES, V74, P155, DOI 10.1016/j.jpsychores.2012.11.007; van Vliet I M, 2007, Tijdschr Psychiatr, V49, P393; WASHBURN RA, 1993, J CLIN EPIDEMIOL, V46, P153, DOI 10.1016/0895-4356(93)90053-4; Wild D, 2010, ALIMENT PHARM THER, V32, P573, DOI 10.1111/j.1365-2036.2010.04386.x; Wood PB, 2007, EUR J NEUROSCI, V25, P3576, DOI 10.1111/j.1460-9568.2007.05623.x; Young SN, 2002, PHARMACOL BIOCHEM BE, V71, P857, DOI 10.1016/S0091-3057(01)00670-0; YOUNG SN, 1985, PSYCHOPHARMACOLOGY, V87, P173, DOI 10.1007/BF00431803	46	15	15	0	24	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 17	2015	10	4							e0122619	10.1371/journal.pone.0122619	http://dx.doi.org/10.1371/journal.pone.0122619			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CG1EX	25884227	Green Published, gold, Green Submitted			2023-01-03	WOS:000353017000036
J	Loxterkamp, D				Loxterkamp, David			LETTER FROM NEW ENGLAND An inconvenient truth: urgent care is not primary care	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material									Seaport Community Hlth Ctr, Belfast, ME 04915 USA		Loxterkamp, D (corresponding author), Seaport Community Hlth Ctr, Belfast, ME 04915 USA.	david.loxterkamp@gmail.com						Japsen B., 2013, FORBES MAGAZINE; PR Newswire, 2014, PR NEWSWIRE     1103; Ziobro P., 2014, WALL STREET J	3	1	1	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 26	2015	350									10.1136/bmj.h1657	http://dx.doi.org/10.1136/bmj.h1657			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CE7OC	25813141				2023-01-03	WOS:000352030200012
J	Salado-Rasmussen, K; Theilgaard, ZP; Chiduo, MG; Bygbjerg, IC; Gerstoft, J; Luneborg-Nielsen, M; Lemnge, M; Katzenstein, TL				Salado-Rasmussen, Kirsten; Theilgaard, Zahra P.; Chiduo, Mercy G.; Bygbjerg, Ib C.; Gerstoft, Jan; Luneborg-Nielsen, Margrethe; Lemnge, Martha; Katzenstein, Terese L.			Nevirapine, Sodium Concentration and HIV-1 RNA in Breast Milk and Plasma among HIV-Infected Women Receiving Short-Course Antiretroviral Prophylaxis	PLOS ONE			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; RANDOMIZED CLINICAL-TRIAL; HUMAN LACTATION; VIRAL LOAD; TRANSMISSION; INFANT; MASTITIS	Introduction Risk factors for breast milk transmission of HIV-1 from mother to child include high plasma and breast milk viral load, low maternal CD4 count and breast pathology such as mastitis. Objective To determine the impact of nevirapine and subclinical mastitis on HIV-1 RNA in maternal plasma and breast milk after intrapartum single-dose nevirapine combined with either 1-week tail of Combivir (zidovudine/lamivudine) or single-dose Truvada (tenofovir/emtricitabine). Methods Maternal plasma and bilateral breast milk samples were collected between April 2008 and April 2011 at 1, 4 and 6 weeks postpartum from HIV-infected Tanzanian women. Moreover, plasma samples were collected at delivery from mother and infant. Results HIV-1 RNA was quantified in 1,212 breast milk samples from 273 women. At delivery, 96% of the women and 99% of the infants had detectable nevirapine in plasma with a median (inter-quartile range, IQR) of 1.5 mu g/mL (0.75-2.20 mu g/mL) and 1.04 mu g/mL (0.39-1.71 mu g/mL), respectively (P < 0.001). At 1 week postpartum, 93% and 98% of the women had detectable nevirapine in plasma and breast milk, with a median (IQR) of 0.13 mu g/mL (0.13-0.39 mu g/mL) and 0.22 mu g/mL (0.13-0.34 mu g/mL), respectively. Maternal plasma and breast milk HIV-1 RNA correlated at all visits (R = 0.48, R = 0.7, R = 0.59; all P = 0.01). Subclinical mastitis was detected in 67% of the women at some time during 6 weeks, and in 38% of the breast milk samples. Breast milk samples with subclinical mastitis had significantly higher HIV-1 RNA at 1, 4 and 6 weeks (all P < 0.05). Conclusion After short-course antiretroviral prophylaxis, nevirapine was detectable in most infant cord blood samples and the concentration in maternal plasma and breast milk was high through week 1 accompanied by suppressed HIV-1 RNA in plasma and breast milk.	[Salado-Rasmussen, Kirsten; Theilgaard, Zahra P.; Gerstoft, Jan; Luneborg-Nielsen, Margrethe; Katzenstein, Terese L.] Rigshosp, Copenhagen Univ Hosp, Dept Infect Dis, DK-2100 Copenhagen, Denmark; [Chiduo, Mercy G.; Lemnge, Martha] Natl Inst Med Res, Tanga, Tanzania; [Bygbjerg, Ib C.] Univ Copenhagen, Fac Hlth Sci, Dept Int Hlth Immunol & Microbiol, Copenhagen, Denmark	Rigshospitalet; University of Copenhagen; University of Copenhagen	Salado-Rasmussen, K (corresponding author), Rigshosp, Copenhagen Univ Hosp, Dept Infect Dis, DK-2100 Copenhagen, Denmark.	ksalado@hotmail.com		Bygbjerg, Ib/0000-0001-9100-2754; Katzenstein, Terese L/0000-0002-2233-500X	European & Developing Countries Clinical Trials Partnership; Laege Agnethe Lovgreens Legat; Bjorn Astrups Foundation	European & Developing Countries Clinical Trials Partnership; Laege Agnethe Lovgreens Legat; Bjorn Astrups Foundation	This research was supported by the European & Developing Countries Clinical Trials Partnership (http://www.edctp.org). KS received research funding for this study from Laege Agnethe Lovgreens Legat and Bjorn Astrups Foundation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aizire J, 2012, JAIDS-J ACQ IMM DEF, V60, P483, DOI 10.1097/QAI.0b013e318246bf9e; Becquet R, 2013, CLIN INFECT DIS, V56, P140, DOI 10.1093/cid/cis813; CONNER AE, 1979, PEDIATRICS, V63, P910; EREMAN RR, 1987, J NUTR, V117, P1154, DOI 10.1093/jn/117.6.1154; Filteau SM, 1999, AM J CLIN NUTR, V69, P953; Filteau SM, 1999, IMMUNOLOGY, V97, P595, DOI 10.1046/j.1365-2567.1999.00834.x; Gantt S, 2007, J INFECT DIS, V196, P570, DOI 10.1086/519843; Holland DT, 2005, ICCAC, pA34; Hudgens MG, 2013, CLIN INFECT DIS, V56, P131, DOI 10.1093/cid/cis808; Lunney KM, 2010, CLIN INFECT DIS, V50, P762, DOI 10.1086/650535; Mirochnick M, 1998, J INFECT DIS, V178, P368, DOI 10.1086/515641; Nduati R, 2000, JAMA-J AM MED ASSOC, V283, P1167, DOI 10.1001/jama.283.9.1167; NEVILLE MC, 1991, AM J CLIN NUTR, V54, P81, DOI 10.1093/ajcn/54.1.81; NEVILLE MC, 1984, AM J CLIN NUTR, V40, P635, DOI 10.1093/ajcn/40.3.635; Phiri W, 2006, AIDS RES HUM RETROV, V22, P607, DOI 10.1089/aid.2006.22.607; Rousseau CM, 2003, J INFECT DIS, V187, P741, DOI 10.1086/374273; Salado-Rasmussen K, 2011, CLIN CHEM LAB MED, V49, P1171, DOI 10.1515/CCLM.2011.184; Salazar-Gonzalez JF, 2011, J VIROL, V85, P2751, DOI 10.1128/JVI.02316-10; Semba R D, 1999, J Hum Lact, V15, P301, DOI 10.1177/089033449901500407; Semba RD, 1999, J INFECT DIS, V180, P93, DOI 10.1086/314854; Semrau K, 2012, J ACQ IMMUN DEF SYND, V62, P346; Semrau K, 2008, JAIDS-J ACQ IMM DEF, V47, P320, DOI 10.1097/QAI.0b013e31815e7436; Shapiro RL, 2009, J INFECT DIS, V199, P414, DOI 10.1086/596034; Slyker JA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029777; Victora CG, 2000, LANCET, V355, P451, DOI 10.1016/S0140-6736(00)82011-5; WHO, 2006, ANT DRUGS TREAT PREG; WHO, 2013, GLOB UPD HIV TREATM; Willumsen JF, 2003, AIDS, V17, P407, DOI 10.1097/00002030-200302140-00015; World Health Organization, 2008, 10 FACTS BREASTF; World Health Organization, 2013, CLIN GUID CONT CAR A; World Health Organization, 2000, MAST CAUS MAN	31	3	4	1	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 26	2015	10	3							e0121111	10.1371/journal.pone.0121111	http://dx.doi.org/10.1371/journal.pone.0121111			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CK6QW	25812161	Green Submitted, Green Published, gold			2023-01-03	WOS:000356353700080
J	Correa, APD; Antunes, CF; Figueira, FR; de Castro, MA; Ribeiro, JP; Schaan, BD				dos Santos Correa, Ana Paula; Antunes, Cristiano Fetter; Figueira, Franciele Ramos; de Castro, Marina Axmann; Ribeiro, Jorge Pinto; Schaan, Beatriz D'Agord			Effect of Acute Inspiratory Muscle Exercise on Blood Flow of Resting and Exercising Limbs and Glucose Levels in Type 2 Diabetes	PLOS ONE			English	Article							FUNCTION-TESTS; RESPONSES; VASODILATION; INTENSITY; CAPACITY; WORK; HYPERGLYCEMIA; VOLUME	To evaluate the effects of inspiratory loading on blood flow of resting and exercising limbs in patients with diabetic autonomic neuropathy. Ten diabetic patients without cardiovascular autonomic neuropathy (DM), 10 patients with cardiovascular autonomic neuropathy (DM-CAN) and 10 healthy controls (C) were randomly assigned to inspiratory muscle load of 60% or 2% of maximal inspiratory pressure (PImax) for approximately 5 min, while resting calf blood flow (CBF) and exercising forearm blood flow (FBF) were measured. Reactive hyperemia was also evaluated. From the 20 diabetic patients initially allocated, 6 wore a continuous glucose monitoring system to evaluate the glucose levels during these two sessions (2%, placebo or 60%, inspiratory muscle metaboreflex). Mean age was 58 +/- 8 years, and mean HbA1c, 7.8% (62 mmol/mol) (DM and DM-CAN). A PImax of 60% caused reduction of CBF in DM-CAN and DM (P<0.001), but not in C, whereas calf vascular resistance (CVR) increased in DM-CAN and DM (P<0.001), but not in C. The increase in FBF during forearm exercise was blunted during 60% of PImax in DM-CAN and DM, and augmented in C (P<0.001). Glucose levels decreased by 40 +/- 18.8% (P<0.001) at 60%, but not at 2%, of PImax. A negative correlation was observed between reactive hyperemia and changes in CVR (Beta coefficient = -0.44, P = 0.034). Inspiratory muscle loading caused an exacerbation of the inspiratory muscle metaboreflex in patients with diabetes, regardless of the presence of neuropathy, but influenced by endothelial dysfunction. High-intensity exercise that recruits the diaphragm can abruptly reduce glucose levels.	[dos Santos Correa, Ana Paula; Antunes, Cristiano Fetter; Figueira, Franciele Ramos; Ribeiro, Jorge Pinto; Schaan, Beatriz D'Agord] Hosp Clin Porto Alegre, Exercise Pathophysiol Res Lab, Porto Alegre, RS, Brazil; [dos Santos Correa, Ana Paula] Univ Sydney, Fac Hlth Sci, Lidcombe, NSW, Australia; [Figueira, Franciele Ramos; Schaan, Beatriz D'Agord] Univ Fed Rio Grande do Sul, Postgrad Program Endocrinol, Porto Alegre, RS, Brazil; [Figueira, Franciele Ramos; Schaan, Beatriz D'Agord] Univ Fed Rio Grande do Sul, Dept Internal Med, Porto Alegre, RS, Brazil; [de Castro, Marina Axmann] Univ Fed Rio Grande do Sul, Postgrad Program Pneumol Sci, Porto Alegre, RS, Brazil; [Ribeiro, Jorge Pinto] Univ Fed Rio Grande do Sul, Postgrad Program Cardiol, Porto Alegre, RS, Brazil	University of Sydney; Universidade Federal do Rio Grande do Sul; Universidade Federal do Rio Grande do Sul; Universidade Federal do Rio Grande do Sul; Universidade Federal do Rio Grande do Sul	Schaan, BD (corresponding author), Hosp Clin Porto Alegre, Exercise Pathophysiol Res Lab, Porto Alegre, RS, Brazil.	beatrizschaan@gmail.com	Schaan, Beatriz D./I-7518-2017	Schaan, Beatriz D./0000-0002-2128-8387	Coordination for the Improvement of Higher Education Personnel (CAPES), Brazil; Fundo de Incentivo a Pesquisa do Hospital de Clinicas de Porto Alegre (FIPE - HCPA)	Coordination for the Improvement of Higher Education Personnel (CAPES), Brazil(Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)); Fundo de Incentivo a Pesquisa do Hospital de Clinicas de Porto Alegre (FIPE - HCPA)	A.P.S. Correa was supported by a grant from the Coordination for the Improvement of Higher Education Personnel (CAPES), Brazil. This study was supported by Fundo de Incentivo a Pesquisa do Hospital de Clinicas de Porto Alegre (FIPE - HCPA). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aldrich TK, 2002, AM J RESP CRIT CARE, V166, P548, DOI 10.1164/rccm.166.4.518; [Anonymous], 1995, AM J RESP CRIT CARE, V152, P1107, DOI 10.1164/ajrccm.152.3.7663792; Bhandari A, 2000, MED SCI SPORT EXER, V32, P1406, DOI 10.1097/00005768-200008000-00008; Borghi-Silva A, 2008, AM J PHYSIOL-HEART C, V294, pH2465, DOI 10.1152/ajpheart.91520.2007; Callegaro CC, 2011, RESP PHYSIOL NEUROBI, V177, P24, DOI 10.1016/j.resp.2011.03.001; Chiappa GR, 2008, J AM COLL CARDIOL, V51, P1663, DOI 10.1016/j.jacc.2007.12.045; Correa APS, 2011, MED SCI SPORT EXER, V43, P1135, DOI 10.1249/MSS.0b013e31820a7c12; Dall'Ago P, 2006, J AM COLL CARDIOL, V47, P757, DOI 10.1016/j.jacc.2005.09.052; Dempsey JA, 2008, MED SCI SPORT EXER, V40, P457, DOI [10.1249/mss.0b013e31815f8957, 10.1249/MSS.0b013e31815f8957]; Dempsey JA, 2006, RESP PHYSIOL NEUROBI, V151, P242, DOI 10.1016/j.resp.2005.12.015; Estacio RO, 1998, DIABETES CARE, V21, P291, DOI 10.2337/diacare.21.2.291; EWING DJ, 1980, ANN INTERN MED, V92, P308, DOI 10.7326/0003-4819-92-2-308; EWING DJ, 1985, DIABETES CARE, V8, P491, DOI 10.2337/diacare.8.5.491; Figueira FR, 2010, PLOS ONE, V8; Guazzi M, 2006, AM J PHYSIOL-HEART C, V291, pH921, DOI 10.1152/ajpheart.00986.2005; HAMILTON AL, 1995, AM J RESP CRIT CARE, V152, P2021, DOI 10.1164/ajrccm.152.6.8520771; Harms CA, 2000, J APPL PHYSIOL, V89, P131, DOI 10.1152/jappl.2000.89.1.131; Ivy JL, 1986, EXERCISE SPORT SCI R, V15, P29; Kabitz HJ, 2008, DIABETOLOGIA, V51, P191, DOI 10.1007/s00125-007-0856-0; KAHN JK, 1986, DIABETES CARE, V9, P389, DOI 10.2337/diacare.9.4.389; Kaijser L, 1991, Clin Auton Res, V1, P239, DOI 10.1007/BF01824993; Kaminski DM, 2011, CLIN AUTON RES, V21, P29, DOI 10.1007/s10286-010-0087-1; Kingwell BA, 2003, DIABETES CARE, V26, P899, DOI 10.2337/diacare.26.3.899; KJAER M, 1990, J APPL PHYSIOL, V68, P2067, DOI 10.1152/jappl.1990.68.5.2067; Little JP, 2011, J APPL PHYSIOL, V111, P1554, DOI 10.1152/japplphysiol.00921.2011; MCVEIGH GE, 1992, DIABETOLOGIA, V35, P771; Neder JA, 1999, BRAZ J MED BIOL RES, V32, P719, DOI 10.1590/S0100-879X1999000600007; Neumann C, 1997, BRAZ J MED BIOL RES, V30, P197, DOI 10.1590/S0100-879X1997000200007; QUANJER PH, 1993, EUR RESPIR J, V6, P5, DOI 10.1183/09041950.005s1693; Roseguini BT, 2008, MED SCI SPORT EXER, V40, P9, DOI 10.1249/mss.0b013e3181590bd9; Sheel AW, 2001, J PHYSIOL-LONDON, V537, P277, DOI 10.1111/j.1469-7793.2001.0277k.x; St Croix CM, 2000, J PHYSIOL-LONDON, V529, P493, DOI 10.1111/j.1469-7793.2000.00493.x; Thaning P, 2011, DIABETES CARE, V34, P1186, DOI 10.2337/dc10-2129; Thaning P, 2010, DIABETES, V59, P182, DOI 10.2337/db09-1068; Umpierre D, 2009, EUR J CARDIOV PREV R, V16, P53, DOI 10.1097/HJR.0b013e32831c8489; da Silva AMV, 2010, CLINICS, V65, P1139, DOI 10.1590/S1807-59322010001100015; Vinik AI, 2003, DIABETES CARE, V26, P1553, DOI 10.2337/diacare.26.5.1553; Wei M, 2000, ANN INTERN MED, V132, P605, DOI 10.7326/0003-4819-132-8-200004180-00002; Williams SB, 1998, CIRCULATION, V97, P1695, DOI 10.1161/01.CIR.97.17.1695	39	7	7	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 24	2015	10	3							e0121384	10.1371/journal.pone.0121384	http://dx.doi.org/10.1371/journal.pone.0121384			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CH2XV	25803283	Green Published, Green Submitted, gold			2023-01-03	WOS:000353889600154
J	Holst, LB; Petersen, MW; Haase, N; Perner, A; Wetterslev, J				Holst, Lars B.; Petersen, Marie W.; Haase, Nicolai; Perner, Anders; Wetterslev, Jorn			Restrictive versus liberal transfusion strategy for red blood cell transfusion: systematic review of randomised trials with meta-analysis and trial sequential analysis	BMJ-BRITISH MEDICAL JOURNAL			English	Article							PEDIATRIC CARDIAC-SURGERY; MYOCARDIAL-INFARCTION; HEMOGLOBIN THRESHOLD; PREMATURE-INFANTS; CLINICAL-PRACTICE; PRETERM INFANTS; MANAGEMENT; CARE; RISK; REQUIREMENTS	OBJECTIVE To compare the benefit and harm of restrictive versus liberal transfusion strategies to guide red blood cell transfusions. DESIGN Systematic review with meta-analyses and trial sequential analyses of randomised clinical trials. DATA SOURCES Cochrane central register of controlled trials, SilverPlatter Medline (1950 to date), SilverPlatter Embase (1980 to date), and Science Citation Index Expanded (1900 to present). Reference lists of identified trials and other systematic reviews were assessed, and authors and experts in transfusion were contacted to identify additional trials. TRIAL SELECTION Published and unpublished randomised clinical trials that evaluated a restrictive compared with a liberal transfusion strategy in adults or children, irrespective of language, blinding procedure, publication status, or sample size. DATA EXTRACTION Two authors independently screened titles and abstracts of trials identified, and relevant trials were evaluated in full text for eligibility. Two reviewers then independently extracted data on methods, interventions, outcomes, and risk of bias from included trials. random effects models were used to estimate risk ratios and mean differences with 95% confidence intervals. RESULTS 31 trials totalling 9813 randomised patients were included. The proportion of patients receiving red blood cells (relative risk 0.54, 95% confidence interval 0.47 to 0.63, 8923 patients, 24 trials) and the number of red blood cell units transfused (mean difference -1.43, 95% confidence interval -2.01 to -0.86) were lower with the restrictive compared with liberal transfusion strategies. Restrictive compared with liberal transfusion strategies were not associated with risk of death (0.86, 0.74 to 1.01, 5707 patients, nine lower risk of bias trials), overall morbidity (0.98, 0.85 to 1.12, 4517 patients, six lower risk of bias trials), or fatal or non-fatal myocardial infarction (1.28, 0.66 to 2.49, 4730 patients, seven lower risk of bias trials). Results were not affected by the inclusion of trials with unclear or high risk of bias. Using trial sequential analyses on mortality and myocardial infarction, the required information size was not reached, but a 15% relative risk reduction or increase in overall morbidity with restrictive transfusion strategies could be excluded. CONCLUSIONS Compared with liberal strategies, restrictive transfusion strategies were associated with a reduction in the number of red blood cell units transfused and number of patients being transfused, but mortality, overall morbidity, and myocardial infarction seemed to be unaltered. Restrictive transfusion strategies are safe in most clinical settings. Liberal transfusion strategies have not been shown to convey any benefit to patients.	[Holst, Lars B.; Petersen, Marie W.; Haase, Nicolai; Perner, Anders] Rigshosp, Copenhagen Univ Hosp, Dept Intens Care 4131, DK-2100 Copenhagen, Denmark; [Wetterslev, Jorn] Rigshosp, Copenhagen Univ Hosp, Copenhagen Trial Unit, Ctr Clin Intervent Res 7812, DK-2100 Copenhagen, Denmark	Rigshospitalet; University of Copenhagen; Rigshospitalet; University of Copenhagen	Holst, LB (corresponding author), Rigshosp, Copenhagen Univ Hosp, Dept Intens Care 4131, Blegdamsvej 9, DK-2100 Copenhagen, Denmark.	lars.broksoe.holst@regionh.dk	Wetterslev, Jørn/ABF-1251-2020	Wetterslev, Jørn/0000-0001-7778-1771; Perner, Anders/0000-0002-4668-0123	Danish Strategic Research Council - Copenhagen University Hospital, Rigshospitalet [09-066938]	Danish Strategic Research Council - Copenhagen University Hospital, Rigshospitalet	This review was funded by the Danish Strategic Research Council (09-066938), supported by Copenhagen University Hospital, Rigshospitalet. The funders had no influence on the protocol, data analyses, or reporting.	Almeida J, 2013, CRIT CARE, V17, ps137, DOI [10.1186/cc11939, DOI 10.1186/CC11939]; Atilla E, 2011, VOX SANG, V101, P121; Bangalore S, 2011, BMJ-BRIT MED J, V342, DOI 10.1136/bmj.d2234; BERGAMIN F, 2014, CRIT CARE, V18, P112; BLAIR SD, 1986, BRIT J SURG, V73, P783, DOI 10.1002/bjs.1800731007; Bracey AW, 1999, TRANSFUSION, V39, P1070, DOI 10.1046/j.1537-2995.1999.39101070.x; Brok J, 2009, INT J EPIDEMIOL, V38, P287, DOI 10.1093/ije/dyn188; Brown CH, 2014, ANESTH ANALG, V119, P242, DOI 10.1213/ANE.0000000000000134; Bush RL, 1997, AM J SURG, V174, P143, DOI 10.1016/S0002-9610(97)00073-1; Carson JL, 2013, AM HEART J, V165, P964, DOI 10.1016/j.ahj.2013.03.001; Carson JL, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002042.pub3; Carson JL, 2011, NEW ENGL J MED, V365, P2453, DOI 10.1056/NEJMoa1012452; Carson JL, 1998, TRANSFUSION, V38, P522, DOI 10.1046/j.1537-2995.1998.38698326331.x; Chatterjee S, 2013, JAMA INTERN MED, V173, P132, DOI 10.1001/2013.jamainternmed.1001; Chen HL, 2009, PEDIATR NEONATOL, V50, P110, DOI 10.1016/S1875-9572(09)60045-0; Cholette JM, 2011, PEDIATR CRIT CARE ME, V12, P39, DOI 10.1097/PCC.0b013e3181e329db; Colomo A, 2008, HEPATOLOGY, V48, p413A; Cooper HA, 2011, AM J CARDIOL, V108, P1108, DOI 10.1016/j.amjcard.2011.06.014; Corwin HL, 2004, CRIT CARE MED, V32, P39, DOI 10.1097/01.CCM.0000104112.34142.79; Dawson N, 2014, EMERG MED J, V31, P207, DOI 10.1136/emermed-2012-202147; de Gast-Bakker DH, 2013, INTENS CARE MED, V39, P2011, DOI 10.1007/s00134-013-3085-7; DEMETS DL, 1987, STAT MED, V6, P341, DOI 10.1002/sim.4780060325; Elterman J, 2013, J TRAUMA ACUTE CARE, V75, P8, DOI 10.1097/TA.0b013e318298492e; FISHER M R, 1956, Br J Clin Pract, V10, P770; FORTUNE JB, 1987, J TRAUMA, V27, P243, DOI 10.1097/00005373-198703000-00003; Foss NB, 2009, TRANSFUSION, V49, P227, DOI 10.1111/j.1537-2995.2008.01967.x; Franz AR, 2012, NEONATOLOGY, V101, P301, DOI 10.1159/000335030; Fredrickson LK, 2011, ARCH DIS CHILD-FETAL, V96, pF249, DOI 10.1136/adc.2010.191023; Gregersen M, 2012, EUR GERIATR MED SUPP, V3, pS74, DOI [10.1016/j.eurger.2012.07.139, DOI 10.1016/J.EURGER.2012.07.139]; Grover M, 2006, VOX SANG, V90, P105, DOI 10.1111/j.1423-0410.2006.00730.x; Guyatt GH, 2008, BMJ-BRIT MED J, V336, P995, DOI 10.1136/bmj.39490.551019.BE; Hajjar LA, 2010, JAMA-J AM MED ASSOC, V304, P1559, DOI 10.1001/jama.2010.1446; Hebert PC, 1999, NEW ENGL J MED, V340, P409, DOI 10.1056/NEJM199902113400601; HEBERT PC, 1995, JAMA-J AM MED ASSOC, V273, P1439, DOI 10.1001/jama.273.18.1439; Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186; Higgins J, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.ED000049; Holst LB, 2014, NEW ENGL J MED, V371, P1381, DOI 10.1056/NEJMoa1406617; JOHNSON RG, 1992, J THORAC CARDIOV SUR, V104, P307; Karam O, 2011, PEDIATR CRIT CARE ME, V12, P512, DOI 10.1097/PCC.0b013e3181fe344b; Karkouti K, 2012, ANESTHESIOLOGY, V116, P613, DOI 10.1097/ALN.0b013e3182475e39; Kirpalani H, 2006, J PEDIATR-US, V149, P301, DOI 10.1016/j.jpeds.2006.05.011; Lacroix J, 2007, NEW ENGL J MED, V356, P1609, DOI 10.1056/NEJMoa066240; LeRoux P, 2013, CURR OPIN CRIT CARE, V19, P83, DOI 10.1097/MCC.0b013e32835eba43; Lotke PA, 1999, J ARTHROPLASTY, V14, P647, DOI 10.1016/S0883-5403(99)90216-4; Mccoy TE, 2011, CHILD NEUROPSYCHOL, V17, P347, DOI 10.1080/09297049.2010.544647; Moher D, 2009, ANN INTERN MED, V151, P399; Nakamura R, 2014, CRIT CARE, V18, pP107; Napolitano LM, 2009, CRIT CARE MED, V37, P3124, DOI 10.1097/CCM.0b013e3181b39f1b; Nopoulos PC, 2011, ARCH PEDIAT ADOL MED, V165, P443, DOI 10.1001/archpediatrics.2010.269; Olgun H, 2009, J PEDIAT HEMATOL ONC, V31, P843, DOI 10.1097/MPH.0b013e3181b27073; Parker MJ, 2013, INJURY, V44, P1916, DOI 10.1016/j.injury.2013.04.033; Pike K, 2011, TRIALS S1, V12, pA121; Prick BW, 2014, BJOG-INT J OBSTET GY, V121, P1005, DOI 10.1111/1471-0528.12531; Robertson CS, 2014, JAMA-J AM MED ASSOC, V312, P36, DOI 10.1001/jama.2014.6490; Rohde JM, 2014, JAMA-J AM MED ASSOC, V311, P1317, DOI 10.1001/jama.2014.2726; Rosland RG, 2014, SCAND J TRAUMA RESUS, V22, DOI 10.1186/1757-7241-22-14; Rouette J, 2010, ANN SURG, V251, P421, DOI 10.1097/SLA.0b013e3181c5dc2e; Salpeter SR, 2014, AM J MED, V127, P124, DOI 10.1016/j.amjmed.2013.09.017; Savovic J, 2012, ANN INTERN MED, V157, P429, DOI 10.7326/0003-4819-157-6-201209180-00537; Shehata N, 2012, TRANSFUSION, V52, P91, DOI 10.1111/j.1537-2995.2011.03236.x; So-Osman C, 2010, VOX SANG, V98, P56, DOI 10.1111/j.1423-0410.2009.01225.x; So-Osman C, 2014, ANESTHESIOLOGY, V120, P839, DOI 10.1097/ALN.0000000000000134; So-Osman C, 2014, ANESTHESIOLOGY, V120, P852, DOI 10.1097/ALN.0000000000000135; Thorlund K, 2009, INT J EPIDEMIOL, V38, P276, DOI 10.1093/ije/dyn179; Turner RM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059202; VICHINSKY EP, 1995, NEW ENGL J MED, V333, P206, DOI 10.1056/NEJM199507273330402; Villanueva C, 2013, NEW ENGL J MED, V368, P11, DOI 10.1056/NEJMoa1211801; Vincent JL, 2006, CRIT CARE MED, V34, P344, DOI 10.1097/01.CCM.0000194725.48928.3A; Walsh TS, 2013, CRIT CARE MED, V41, P2354, DOI 10.1097/CCM.0b013e318291cce4; Webert KE, 2008, TRANSFUSION, V48, P81, DOI 10.1111/j.1537-2995.2007.01485.x; Wetterslev J, 2008, J CLIN EPIDEMIOL, V61, P64, DOI 10.1016/j.jclinepi.2007.03.013; Wetterslev J, 2009, BMC MED RES METHODOL, V9, DOI 10.1186/1471-2288-9-86; Whyte RK, 2009, PEDIATRICS, V123, P207, DOI 10.1542/peds.2008-0338; Willems A, 2010, CRIT CARE MED, V38, P649, DOI 10.1097/CCM.0b013e3181bc816c; Wu JF, 2011, INTENS CARE MED, V37, pS256; Zheng H, 2013, EXP THER MED, V5, P511, DOI 10.3892/etm.2012.834; Zygun DA, 2009, CRIT CARE MED, V37, P1074, DOI 10.1097/CCM.0b013e318194ad22	77	276	280	1	28	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 24	2015	350								h1354	10.1136/bmj.h1354	http://dx.doi.org/10.1136/bmj.h1354			15	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CE7NO	25805204	Green Published, hybrid			2023-01-03	WOS:000352028800006
J	Jung, SW; Thamphiwatana, S; Zhang, LF; Obonyo, M				Jung, Sung Woo; Thamphiwatana, Soracha; Zhang, Liangfang; Obonyo, Marygorret			Mechanism of Antibacterial Activity of Liposomal Linolenic Acid against Helicobacter pylori	PLOS ONE			English	Article							POLYUNSATURATED FATTY-ACIDS; PROPIONIBACTERIUM-ACNES; STAPHYLOCOCCUS-AUREUS; LAURIC ACIDS; INFECTION; MONOGLYCERIDES; MEMBRANE	Helicobacter pylori infects approximately half of the world population and is a major cause of gastritis, peptic ulcer, and gastric cancer. Moreover, this bacterium has quickly developed resistance to all major antibiotics. Recently, we developed a novel liposomal linolenic acid (LipoLLA) formulation, which showed potent bactericidal activity against several clinical isolated antibiotic-resistant strains of H. pylori including both the spiral and coccoid form. In addition, LipoLLA had superior in vivo efficacy compared to the standard triple therapy. Our data showed that LipoLLA associated with H. pylori cell membrane. Therefore, in this study, we investigated the possible antibacterial mechanism of LipoLLA against H. pylori. The antibacterial activity of LipoLLA (C18:3) was compared to that of liposomal stearic acid (LipoSA, C18: 0) and oleic acid (LipoOA, C18: 1). LipoLLA showed the most potent bactericidal effect and completely killed H. pylori within 5 min. The permeability of the outer membrane of H. pylori increased when treated with LipoOA and LipoLLA. Moreover, by detecting released adenosine triphosphate (ATP) from bacteria, we found that bacterial plasma membrane of H. pylori treated with LipoLLA exhibited significantly higher permeability than those treated with LipoOA, resulting in bacteria cell death. Furthermore, LipoLLA caused structural changes in the bacterial membrane within 5 min affecting membrane integrity and leading to leakage of cytoplasmic contents, observed by both transmission electron microscopy (TEM) and scanning electron microscopy (SEM). Our findings showing rapid bactericidal effect of LipoLLA suggest it is a very promising new, effective anti-H. pylori agent.	[Jung, Sung Woo; Obonyo, Marygorret] Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; [Jung, Sung Woo] Korea Univ, Coll Med, Dept Internal Med, Seoul 136705, South Korea; [Thamphiwatana, Soracha; Zhang, Liangfang] Univ Calif San Diego, Dept NanoEngn, La Jolla, CA 92093 USA	University of California System; University of California San Diego; Korea University; Korea University Medicine (KU Medicine); University of California System; University of California San Diego	Zhang, LF (corresponding author), Univ Calif San Diego, Dept NanoEngn, La Jolla, CA 92093 USA.	zhang@ucsd.edu; mobonyo@ucsd.edu	Thamphiwatana, Soracha D./B-5338-2017	Thamphiwatana, Soracha D./0000-0003-3664-9488	National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health [R01DK095168]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK095168] Funding Source: NIH RePORTER	National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work is supported by the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health (http://www.niddk.nih.gov/Pages/default.aspx) under Award Number R01DK095168. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Brown JC, 2013, J APPL MICROBIOL, V114, P982, DOI 10.1111/jam.12129; Chiu HC, 2007, HELICOBACTER, V12, P74; Correia M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035072; Desbois AP, 2010, APPL MICROBIOL BIOT, V85, P1629, DOI 10.1007/s00253-009-2355-3; Duggan AE, 1997, BRIT J NUTR, V78, P515, DOI 10.1079/BJN19970171; GEIS G, 1990, J CLIN MICROBIOL, V28, P930, DOI 10.1128/JCM.28.5.930-932.1990; HAZELL SL, 1990, J CLIN MICROBIOL, V28, P1060, DOI 10.1128/JCM.28.5.1060-1061.1990; Helander IM, 2000, J APPL MICROBIOL, V88, P213, DOI 10.1046/j.1365-2672.2000.00971.x; Huang CM, 2011, BIOMATERIALS, V32, P214, DOI 10.1016/j.biomaterials.2010.08.076; KABARA JJ, 1972, ANTIMICROB AGENTS CH, V2, P23, DOI 10.1128/AAC.2.1.23; KHULUSI S, 1995, J MED MICROBIOL, V42, P276, DOI 10.1099/00222615-42-4-276; Lee A, 1997, GASTROENTEROLOGY, V112, P1386, DOI 10.1016/S0016-5085(97)70155-0; LOH B, 1984, ANTIMICROB AGENTS CH, V26, P546, DOI 10.1128/AAC.26.4.546; Malfertheiner P, 2012, GUT, V61, P646, DOI 10.1136/gutjnl-2012-302084; Megraud F, 2004, GUT, V53, P1374, DOI 10.1136/gut.2003.022111; O'Connor A, 2013, HELICOBACTER, V18, P58, DOI 10.1111/hel.12075; Obonyo M, 2007, INFECT IMMUN, V75, P2408, DOI 10.1128/IAI.01794-06; Obonyo M, 2012, MOL PHARMACEUT, V9, P2677, DOI 10.1021/mp300243w; Parsons JB, 2012, J BACTERIOL, V194, P5294, DOI 10.1128/JB.00743-12; Petschow BW, 1996, ANTIMICROB AGENTS CH, V40, P302, DOI 10.1128/AAC.40.2.302; Pornpattananangkul D, 2013, ADV HEALTHC MATER, V2, P1322, DOI 10.1002/adhm.201300002; SHEU CW, 1973, J BACTERIOL, V115, P869, DOI 10.1128/JB.115.3.869-875.1973; Suerbaum S, 2002, NEW ENGL J MED, V347, P1175, DOI 10.1056/NEJMra020542; Sun CQ, 2003, FEMS IMMUNOL MED MIC, V36, P9, DOI 10.1016/S0928-8244(03)00008-7; Thamphiwatana S, 2014, PNAS IN PRESS; Thamphiwatana S, 2013, LANGMUIR, V29, P12228, DOI 10.1021/la402695c; THOMPSON L, 1994, GUT, V35, P1557, DOI 10.1136/gut.35.11.1557; TRAUBLE H, 1973, BIOCHIM BIOPHYS ACTA, V307, P491, DOI 10.1016/0005-2736(73)90296-4; Yang DR, 2009, BIOMATERIALS, V30, P6035, DOI 10.1016/j.biomaterials.2009.07.033	29	39	40	1	35	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 20	2015	10	3							e0116519	10.1371/journal.pone.0116519	http://dx.doi.org/10.1371/journal.pone.0116519			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CE8IA	25793403	Green Published, gold, Green Submitted			2023-01-03	WOS:000352084200006
J	Lv, Q; Luo, FL; Zhao, XY; Liu, Y; Hu, GB; Sun, CD; Li, X; Chen, KS				Lv, Qiang; Luo, Fenglei; Zhao, Xiaoyong; Liu, Yu; Hu, Guibing; Sun, Chongde; Li, Xian; Chen, Kunsong			Identification of Proanthocyanidins from Litchi (Litchi chinensis Sonn.) Pulp by LC-ESI-Q-TOF-MS and Their Antioxidant Activity	PLOS ONE			English	Article							POLYMERIC PROCYANIDINS; PHENOLIC-COMPOUNDS; OLIGOMERIC PROANTHOCYANIDINS; MASS-SPECTROMETRY; GRAPE; FLAVONOIDS; APPLE; FOODS; COMPONENTS; PRODUCTS	Content of total proanthocyanidins as well as total phenolics, flavonoids, antioxidant activities were evaluated for litchi (Litchi chinensis Sonn.) pulp of 32 cultivars. One cultivar, Hemaoli, showed the highest total proanthocyanidins and total phenolics, and DPPH or ABTS radical scavenging activities. ESI-MS and NMR analysis of the Hemaoli pulp crude extracts (HPCE) showed that procyandins composed of (epi) catechin unites with degree of polymerization (DP) of 2-6 were dominant proanthocyanidins in HPCE. After the HPCE was fractionated by a Sephadex LH-20 column, 32 procyanidins were identified by LC-ESI-Q-TOF-MS in litchi pulp for the first time. Quantification of individual procyanidin in HPCE indicated that epicatechin, procyanidin B2, procyanidin C1 and A-type procyanidin trimer were the main procyanidins. The radical scavenging activities of different fractions of HPCE as well as six procyanidins standards were evaluated by both DPPH and ABTS assays. HPCE fractions showed similar antioxidant activities with those of Vc and six individual procyanidins, the IC50 of which ranged from 1.88 +/- 0.01 to 2.82 +/- 0.10 mu g/ml for DPPH assay, and from 1.52 +/- 0.17 to 2.71 +/- 0.15 mu g/ml for ABTS assay. Such results indicate that litchi cultivars rich in proanthocyanidins are good resources of dietary antioxidants and have the potential to contribute to human health.	[Lv, Qiang; Luo, Fenglei; Zhao, Xiaoyong; Sun, Chongde; Li, Xian; Chen, Kunsong] Zhejiang Univ, Lab Fruit Qual Biol, State Agr Minist, Lab Hort Plant Growth Dev & Qual Improvement, Hangzhou 310003, Zhejiang, Peoples R China; [Liu, Yu] Zhejiang Univ, Coll Life Sci, Hangzhou 310003, Zhejiang, Peoples R China; [Hu, Guibing] South China Agr Univ, Coll Hort, Guangzhou, Guangdong, Peoples R China	Zhejiang University; Zhejiang University; South China Agricultural University	Li, X (corresponding author), Zhejiang Univ, Lab Fruit Qual Biol, State Agr Minist, Lab Hort Plant Growth Dev & Qual Improvement, Zijingang Campus, Hangzhou 310003, Zhejiang, Peoples R China.	xianli@zju.edu.cn		Li, Xian/0000-0002-9526-9031; zhao, xiaoyong/0000-0002-7606-900X	National Project of Scientific and Technical Supporting Programs - Ministry of Science & Technology of China [2012BAD33B08]; Program for New Century Excellent Talents in University of Ministry of Education of China	National Project of Scientific and Technical Supporting Programs - Ministry of Science & Technology of China(Ministry of Science and Technology, China); Program for New Century Excellent Talents in University of Ministry of Education of China(Program for New Century Excellent Talents in University (NCET))	This work was supported by the National Project of Scientific and Technical Supporting Programs Funded by the Ministry of Science & Technology of China (2012BAD33B08) and the Program for New Century Excellent Talents in University of Ministry of Education of China. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Actis-Goretta L, 2008, J NUTR BIOCHEM, V19, P797, DOI 10.1016/j.jnutbio.2007.10.004; Amarowicz R, 2010, FOOD CHEM, V121, P705, DOI 10.1016/j.foodchem.2010.01.009; Bagchi DB, 2003, MUTAT RES-FUND MOL M, V523, P87, DOI 10.1016/S0027-5107(02)00324-X; Bak MJ, 2013, OXID MED CELL LONGEV, V2013, DOI 10.1155/2013/409321; BRAND-WILLIAMS W, 1995, FOOD SCI TECHNOL-LEB, V28, P25; Brat P, 2006, J NUTR, V136, P2368, DOI 10.1093/jn/136.9.2368; Cai YZ, 2004, LIFE SCI, V74, P2157, DOI 10.1016/j.lfs.2003.09.047; Cao GH, 1997, FREE RADICAL BIO MED, V22, P749, DOI 10.1016/S0891-5849(96)00351-6; de Freitas VAP, 1998, PHYTOCHEMISTRY, V49, P1435, DOI 10.1016/S0031-9422(98)00107-1; Deprez S, 2001, ANTIOXID REDOX SIGN, V3, P957, DOI 10.1089/152308601317203503; Es-Safi NE, 2006, J AGR FOOD CHEM, V54, P6969, DOI 10.1021/jf061090f; Flamini R, 2003, MASS SPECTROM REV, V22, P218, DOI 10.1002/mas.10052; Fu C, 2007, J AGR FOOD CHEM, V55, P7689, DOI 10.1021/jf071166n; Gabetta B, 2000, FITOTERAPIA, V71, P162, DOI 10.1016/S0367-326X(99)00161-6; Gu LW, 2004, J NUTR, V134, P613, DOI 10.1093/jn/134.3.613; Gu LW, 2003, J AGR FOOD CHEM, V51, P7513, DOI 10.1021/jf034815d; Gu LW, 2002, J AGR FOOD CHEM, V50, P4852, DOI 10.1021/jf020214v; Guyot S, 1998, J AGR FOOD CHEM, V46, P1698, DOI 10.1021/jf970832p; Hagerman AE, 1998, J AGR FOOD CHEM, V46, P1887, DOI 10.1021/jf970975b; Jerez M, 2009, RAPID COMMUN MASS SP, V23, P4013, DOI 10.1002/rcm.4342; Jia Z, 1999, FOOD CHEM, V64, P555, DOI 10.1016/S0308-8146(98)00102-2; Jiao LH, 2013, FOOD CHEM TOXICOL, V56, P398, DOI 10.1016/j.fct.2013.02.049; Le Roux E, 1998, PHYTOCHEMISTRY, V48, P1251, DOI 10.1016/S0031-9422(97)01070-4; Li SY, 2012, FOOD CHEM, V135, P31, DOI 10.1016/j.foodchem.2012.04.039; Lin LZ, 2014, J AGR FOOD CHEM, V62, P9387, DOI 10.1021/jf501011y; Lv Q, 2014, J FUNCT FOODS, V7, P621, DOI 10.1016/j.jff.2013.12.023; Muchuweti M, 2005, J SCI FOOD AGR, V85, P1647, DOI 10.1002/jsfa.2163; OhnishiKameyama M, 1997, RAPID COMMUN MASS SP, V11, P31, DOI 10.1002/(SICI)1097-0231(19970115)11:1<31::AID-RCM784>3.0.CO;2-T; Ou KQ, 2014, J FUNCT FOODS, V7, P43, DOI 10.1016/j.jff.2013.08.004; Payne MJ, 2010, J AOAC INT, V93, P89; Pesca MS, 2013, J NAT PROD, V76, P29, DOI 10.1021/np300614u; PORTER LJ, 1994, FLAVONOIDS ADV RES 1, P23; Prasad KN, 2009, FOOD CHEM, V116, P1, DOI 10.1016/j.foodchem.2009.01.079; Prior RL, 2005, PHYTOCHEMISTRY, V66, P2264, DOI 10.1016/j.phytochem.2005.03.025; Prior RL, 2001, J AGR FOOD CHEM, V49, P1270, DOI 10.1021/jf001211q; Rasmussen SE, 2005, MOL NUTR FOOD RES, V49, P159, DOI 10.1002/mnfr.200400082; Re R, 1999, FREE RADICAL BIO MED, V26, P1231, DOI 10.1016/S0891-5849(98)00315-3; Gonzalez-Centeno MR, 2012, J AGR FOOD CHEM, V60, P11850, DOI 10.1021/jf303047k; Schieber A, 2001, J CHROMATOGR A, V910, P265, DOI 10.1016/S0021-9673(00)01217-6; Xu XY, 2010, J AGR FOOD CHEM, V58, P11667, DOI 10.1021/jf1033202; Yang DJ, 2012, FOOD CHEM TOXICOL, V50, P3056, DOI 10.1016/j.fct.2012.06.011; Zhao MM, 2006, FOOD CHEM, V98, P539, DOI 10.1016/j.foodchem.2005.06.028; Zhou HC, 2011, FOOD RES INT, V44, P613, DOI 10.1016/j.foodres.2010.12.016	43	62	65	5	82	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 20	2015	10	3							e0120480	10.1371/journal.pone.0120480	http://dx.doi.org/10.1371/journal.pone.0120480			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CE8HY	25793378	Green Published, Green Submitted, gold			2023-01-03	WOS:000352083900040
J	Lin, JG; Hsieh, CL; Lin, YW				Lin, Jaung-Geng; Hsieh, Ching-Liang; Lin, Yi-Wen			Analgesic Effect of Electroacupuncture in a Mouse Fibromyalgia Model: Roles of TRPV1, TRPV4, and pERK	PLOS ONE			English	Article							MEDIATE MECHANICAL HYPERALGESIA; RECEPTOR POTENTIAL VANILLOID-4; CAPSAICIN-RECEPTOR; MUSCLE PAIN; NEUROPATHIC PAIN; ION CHANNELS; ACTIVATION; EXPRESSION; NEURONS; KINASE	Fibromyalgia (FM) is among the most common chronic pain syndromes encountered in clinical practice, but there is limited understanding of FM pathogenesis. We examined the contribution of transient receptor potential vanilloid 1 (TRPV1) and TRPV4 channels to chronic pain in the repeated acid injection mouse model of FM and the potential therapeutic efficacy of electroacupuncture. Electroacupuncture (EA) at the bilateral Zusanli (ST36) acupoint reduced the long-lasting mechanical hyperalgesia induced by repeated acid saline (pH 4) injection in mouse hindpaw. Isolated L5 dorsal root ganglion (DRG) neurons from FM model mice (FM group) were hyperexcitable, an effect reversed by EA pretreatment (FM + EA group). The increase in mechanical hyperalgesia was also accompanied by upregulation of TRPV1 expression and phosphoactivation of extracellular signal regulated kinase (pERK) in the DRG, whereas DRG expression levels of TRPV4, p-p38, and p-JNK were unaltered. Blockade of TRPV1, which was achieved using TRPV1 knockout mice or via antagonist injection, and pERK suppressed development of FM-like pain. Both TRPV1 and TRPV4 protein expression levels were increased in the spinal cord (SC) of model mice, and EA at the ST36 acupoint decreased overexpression. This study strongly suggests that DRG TRPV1 overexpression and pERK signaling, as well as SC TRPV1 and TRPV4 overexpression, mediate hyperalgesia in a mouse FM pain model. The therapeutic efficacy of EA may result from the reversal of these changes in pain transmission pathways.	[Lin, Jaung-Geng] China Med Univ, Sch Chinese Med, Coll Chinese Med, Taichung 40402, Taiwan; [Hsieh, Ching-Liang] China Med Univ, Grad Inst Integrat Med, Coll Chinese Med, Taichung 40402, Taiwan; [Hsieh, Ching-Liang] China Med Univ Hosp, Dept Chinese Med, Taichung 40402, Taiwan; [Hsieh, Ching-Liang; Lin, Yi-Wen] China Med Univ, Res Ctr Chinese Med & Acupuncture, Taichung 40402, Taiwan; [Lin, Yi-Wen] China Med Univ, Grad Inst Acupuncture Sci, Coll Chinese Med, Taichung 40402, Taiwan	China Medical University Taiwan; China Medical University Taiwan; China Medical University Taiwan; China Medical University Hospital - Taiwan; China Medical University Taiwan; China Medical University Taiwan	Lin, YW (corresponding author), China Med Univ, Res Ctr Chinese Med & Acupuncture, Taichung 40402, Taiwan.	yiwenlin@mail.cmu.edu.tw	Lin, Yi-Wen/O-3541-2015	Lin, Yi-Wen/0000-0001-7204-8837	CMU under the Aim for Top University Plan of the Ministry of Education, Taiwan [NSC 101-2320-B-039-014-MY3, CMU103-TC-01]; Taiwan Ministry of Health and Welfare Clinical Trial and Research Center of Excellence [MOHW103-TDU-B-212-113002, DOH102-TD-B-111-004]	CMU under the Aim for Top University Plan of the Ministry of Education, Taiwan; Taiwan Ministry of Health and Welfare Clinical Trial and Research Center of Excellence	This study was supported by CMU under the Aim for Top University Plan of the Ministry of Education, Taiwan, NSC 101-2320-B-039-014-MY3, CMU103-TC-01, and in part by Taiwan Ministry of Health and Welfare Clinical Trial and Research Center of Excellence (MOHW103-TDU-B-212-113002 and DOH102-TD-B-111-004). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abraham TS, 2011, J CHEM NEUROANAT, V41, P129, DOI 10.1016/j.jchemneu.2011.01.001; Alessandri-Haber N, 2005, PAIN, V118, P70, DOI 10.1016/j.pain.2005.07.016; Alessandri-Haber N, 2004, J NEUROSCI, V24, P4444, DOI 10.1523/JNEUROSCI.0242-04.2004; Alessandri-Haber N, 2008, J NEUROSCI, V28, P1046, DOI 10.1523/JNEUROSCI.4497-07.2008; Alessandri-Haber N, 2009, J NEUROSCI, V29, P6217, DOI 10.1523/JNEUROSCI.0893-09.2009; Brierley SM, 2008, GASTROENTEROLOGY, V134, P2059, DOI 10.1053/j.gastro.2008.01.074; Carlton SM, 2009, BRAIN RES, V1248, P86, DOI 10.1016/j.brainres.2008.10.066; Caterina MJ, 1997, NATURE, V389, P816, DOI 10.1038/39807; Caterina MJ, 1999, NATURE, V398, P436, DOI 10.1038/18906; Ceppa E, 2010, AM J PHYSIOL-GASTR L, V299, pG556, DOI 10.1152/ajpgi.00433.2009; Chen WH, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/636848; Chen WH, 2011, J BIOMED SCI, V18, DOI 10.1186/1423-0127-18-82; Chen WN, 2014, MOL PAIN, V10, DOI 10.1186/1744-8069-10-30; Chen WK, 2010, J NEUROSCI, V30, P10360, DOI 10.1523/JNEUROSCI.1041-10.2010; Chen Y, 2011, NEUROSCIENCE, V193, P440, DOI 10.1016/j.neuroscience.2011.06.085; Cheng SJ, 2011, J NEUROSCI, V31, P2258, DOI 10.1523/JNEUROSCI.5564-10.2011; Christoph T, 2008, MOL CELL NEUROSCI, V37, P579, DOI 10.1016/j.mcn.2007.12.006; Chu KL, 2011, BRAIN RES, V1369, P158, DOI 10.1016/j.brainres.2010.10.101; Ding XL, 2010, BEHAV BRAIN RES, V208, P194, DOI 10.1016/j.bbr.2009.11.034; Eid S R, 2009, Handb Exp Pharmacol, P261, DOI 10.1007/978-3-540-79090-7_8; Facer P, 2007, BMC NEUROL, V7, DOI 10.1186/1471-2377-7-11; Fernandes ES, 2011, DISTINCT ROLE TRANSI; Fujii Y, 2008, PAIN, V140, P292, DOI 10.1016/j.pain.2008.08.013; Gibson HE, 2008, NEURON, V57, P746, DOI 10.1016/j.neuron.2007.12.027; Goldman N, 2010, NAT NEUROSCI, V13, P883, DOI 10.1038/nn.2562; Grant AD, 2007, J PHYSIOL-LONDON, V578, P715, DOI 10.1113/jphysiol.2006.121111; Han JS, 2003, TRENDS NEUROSCI, V26, P17, DOI 10.1016/S0166-2236(02)00006-1; Hurt JK, 2012, MOL PAIN, V8, DOI 10.1186/1744-8069-8-28; Immke DC, 2001, NAT NEUROSCI, V4, P869, DOI 10.1038/nn0901-869; Kondo T, 2013, NEUROREPORT, V24, P68, DOI 10.1097/WNR.0b013e32835c7df2; Lin CCJ, 2012, P NATL ACAD SCI USA, V109, pE76, DOI 10.1073/pnas.1108903108; Lin JG, 2002, PAIN, V99, P509, DOI 10.1016/S0304-3959(02)00261-0; Lund JP, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011131; Manjavachi MN, 2010, PAIN, V151, P345, DOI 10.1016/j.pain.2010.07.018; Mense S, 2008, DTSCH ARZTEBL INT, V105, P214, DOI 10.3238/artzebl.2008.0214; Mezey E, 2000, P NATL ACAD SCI USA, V97, P3655, DOI 10.1073/pnas.060496197; Monteith TS, 2011, CURR TREAT OPTION NE, V13, P1, DOI 10.1007/s11940-010-0105-6; Nielsen AN, 2004, EUR J PHARMACOL, V487, P93, DOI 10.1016/j.ejphar.2004.01.017; Ro JY, 2009, PAIN, V144, P270, DOI 10.1016/j.pain.2009.04.021; Sluka KA, 2003, PAIN, V106, P229, DOI 10.1016/S0304-3959(03)00269-0; Sluka KA, 2001, MUSCLE NERVE, V24, P37, DOI 10.1002/1097-4598(200101)24:1<37::AID-MUS4>3.0.CO;2-8; Strotmann R, 2000, NAT CELL BIOL, V2, P695, DOI 10.1038/35036318; Suzuki M, 2003, J BIOL CHEM, V278, P22664, DOI 10.1074/jbc.M302561200; von Banchet GS, 2013, MOL CELL NEUROSCI, V52, P152, DOI 10.1016/j.mcn.2012.11.006; Wei XM, 2011, CEPHALALGIA, V31, P1595, DOI 10.1177/0333102411427600; Yu L, 2008, MOL PAIN, V4, DOI 10.1186/1744-8069-4-61; Zhang ZD, 2012, ANESTH ANALG, V114, P879, DOI 10.1213/ANE.0b013e318246536d; Zhuang ZY, 2006, J NEUROSCI, V26, P3551, DOI 10.1523/JNEUROSCI.5290-05.2006	48	18	24	0	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 4	2015	10	6							e0128037	10.1371/journal.pone.0128037	http://dx.doi.org/10.1371/journal.pone.0128037			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CJ7TC	26043006	Green Published, Green Submitted, gold			2023-01-03	WOS:000355701600030
J	Smolina, K; Hanley, GE; Mintzes, B; Oberlander, TF; Morgan, S				Smolina, Kate; Hanley, Gillian E.; Mintzes, Barbara; Oberlander, Tim F.; Morgan, Steve			Trends and Determinants of Prescription Drug Use during Pregnancy and Postpartum in British Columbia, 2002-2011: A Population-Based Cohort Study	PLOS ONE			English	Article							MEDICATION USE; PRIMARY-CARE; WOMEN; LACTATION; ANTIDEPRESSANTS; TERATOGENICITY; NETHERLANDS; PREVALENCE; DEPRESSION; EXPOSURE	Purpose To describe trends, patterns, and determinants of prescription drug use during pregnancy and postpartum. Methods This is a retrospective, population-based study of all women who gave birth between January 2002 and 31 December 2011 in British Columbia, Canada. Study population consisted of 225,973 women who had 322,219 pregnancies. We examined administrative datasets containing person-specific information on filled prescriptions, hospitalizations, and medical services. Main outcome measures were filled prescriptions during pregnancy and postpartum. We used logistic regressions to examine associations between prescription drug use and maternal characteristics. Results Approximately two thirds of women filled a prescription during pregnancy, increasing from 60% in 2002 to 66% in 2011. The proportion of pregnant women using medicines in all three trimesters of pregnancy increased from 20% in 2002 to 27% in 2011. Use of four or more different types of prescription drug during at least one trimester increased from 8.4% in 2002 to 11.7% in 2011. Higher BMI, smoking during pregnancy, age under 25, carrying multiples, and being diagnosed with a chronic condition all significantly increased the odds of prescription drug use during pregnancy. Conclusions The observed increase in the number of prescriptions and number of different drugs being dispensed suggests a trend in prescribing practices with potentially important implications for mothers, their neonates, and caregivers. Monitoring of prescribing practices and further research into the safety of most commonly prescribed medications is crucial in better understanding risks and benefits to the fetus and the mother.	[Smolina, Kate; Morgan, Steve] Univ British Columbia, Ctr Hlth Serv & Policy Res, Vancouver, BC V5Z 1M9, Canada; [Hanley, Gillian E.] Univ British Columbia, Dept Obstet & Gynaecol, Vancouver, BC V5Z 1M9, Canada; [Mintzes, Barbara] Univ British Columbia, Sch Populat & Publ Hlth, Vancouver, BC V5Z 1M9, Canada; [Oberlander, Tim F.] Univ British Columbia, Child & Family Res Inst, Vancouver, BC V5Z 1M9, Canada	University of British Columbia; University of British Columbia; University of British Columbia; Child & Family Research Institute; University of British Columbia	Smolina, K (corresponding author), Univ British Columbia, Ctr Hlth Serv & Policy Res, Vancouver, BC V5Z 1M9, Canada.	kate.smolina@ubc.ca	Mintzes, Barbara/AFK-6613-2022	Mintzes, Barbara/0000-0002-8671-915X; Morgan, Steven/0000-0002-7529-0028; Oberlander, Tim/0000-0003-4781-6579; Hanley, Gillian/0000-0001-9594-0545	Canadian Institutes of Health Research [CIHR DC0190GP]; Canadian Institutes of Health Research Banting Postdoctoral Fellowship	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Canadian Institutes of Health Research Banting Postdoctoral Fellowship(Canadian Institutes of Health Research (CIHR))	This study was supported by a grant from the Canadian Institutes of Health Research (http://www.cihr-irsc.gc.ca/e/193.html) (CIHR DC0190GP). Dr. Smolina is funded, in part, by a Canadian Institutes of Health Research Banting Postdoctoral Fellowship. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adam MP, 2011, AM J MED GENET C, V157C, P175, DOI 10.1002/ajmg.c.30313; Administration; UFaD, 2007, PUBL HLTH ADV US COD; Alexander GC, 2011, PHARMACOEPIDEM DR S, V20, P177, DOI 10.1002/pds.2082; Andrade SE, 2004, AM J OBSTET GYNECOL, V191, P398, DOI 10.1016/j.ajog.2004.04.025; [Anonymous], 2012, VIT STAT DEATHS; Arsenault Marc-Yvon, 2002, J Obstet Gynaecol Can, V24, P817; Bakker MK, 2006, BJOG-INT J OBSTET GY, V113, P559, DOI 10.1111/j.1471-0528.2006.00927.x; Berard A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093870; Bjorn Anne-Mette Bay, 2011, Clin Epidemiol, V3, P149, DOI 10.2147/CLEP.S17747; British Columbia Ministry of Health, 2013, DISCH ABSTR DAT HOSP; Chan M, 2012, OBSTET GYNAECOL, V14, P87, DOI 10.1111/j.1744-4667.2012.00096.x; Chin JW, 2013, AM J PERINATOL; Cleary BJ, 2010, PHARMACOEPIDEM DR S, V19, P408, DOI 10.1002/pds.1906; Colvin L, 2009, PHARMACOEPIDEM DR S, V18, P211, DOI 10.1002/pds.1705; Daw JR, 2011, PHARMACOEPIDEM DR S, V20, P895, DOI 10.1002/pds.2184; Daw JR, 2011, CLIN THER; Egen-Lappe V, 2004, EUR J CLIN PHARMACOL, V60, P659, DOI 10.1007/s00228-004-0817-1; Engeland A, 2008, BRIT J CLIN PHARMACO, V65, P653, DOI 10.1111/j.1365-2125.2008.03102.x; Food U, 1999, FED REGISTER, V64, P43190; Gagne JJ, 2008, EUR J CLIN PHARMACOL, V64, P1125, DOI 10.1007/s00228-008-0546-y; Hanley GE, 2010, MED CARE, V48, P402, DOI 10.1097/MLR.0b013e3181ca3d5d; Hanley GE, 2008, BMC HEALTH SERV RES, V8, DOI 10.1186/1472-6963-8-79; Health Canada, 2005, IMP SAF INF PAX PAR; Irvine L, 2010, DRUG SAFETY, V33, P593, DOI 10.2165/11532330-000000000-00000; Joseph KS, 2009, J OBSTET GYNAECOL CA, V31, P422, DOI 10.1016/S1701-2163(16)34173-1; Kessler RC, 2006, AM J PSYCHIAT, V163, P716, DOI 10.1176/appi.ajp.163.4.716; Koren G, 2010, AM J OBSTET GYNECOL, V203, DOI 10.1016/j.ajog.2010.07.030; Lacroix I, 2009, EUR J CLIN PHARMACOL, V65, P839, DOI 10.1007/s00228-009-0647-2; Lagoy CT, 2005, J WOMENS HEALTH, V14, P104, DOI 10.1089/jwh.2005.14.104; Lo WY, 2002, OBSTET GYNECOL, V100, P465, DOI 10.1016/S0029-7844(02)02122-1; Lupattelli A, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2013-004365; Malm H, 2003, EUR J CLIN PHARMACOL, V59, P127, DOI 10.1007/s00228-003-0584-4; Mitchell AA, 2011, AM J OBSTET GYNECOL, V205, DOI 10.1016/j.ajog.2011.02.029; Nakhai-Pour HR, 2010, CAN MED ASSOC J, V182, P1031, DOI 10.1503/cmaj.091208; Oberlander TF, 2006, ARCH GEN PSYCHIAT, V63, P898, DOI 10.1001/archpsyc.63.8.898; Olesen C, 1999, EUR J CLIN PHARMACOL, V55, P139, DOI 10.1007/s002280050608; Olesen C, 2006, EUR J CLIN PHARMACOL, V62, P547, DOI 10.1007/s00228-006-0119-x; Parisi MA, 2011, AM J MED GENET C, V157C, P247, DOI 10.1002/ajmg.c.30309; Persaud N, 2014, J OBSTET GYNAECOL CA, V36, P343, DOI 10.1016/S1701-2163(15)30611-3; Riley EH, 2005, J WOMENS HEALTH, V14, P401, DOI 10.1089/jwh.2005.14.401; Schirm E, 2004, EUR J OBSTET GYN R B, V114, P182, DOI 10.1016/j.ejogrb.2003.10.024; Stephansson Olof, 2011, Clin Epidemiol, V3, P43, DOI 10.2147/CLEP.S16305; Swanson LM, 2011, J WOMENS HEALTH, V20, P553, DOI 10.1089/jwh.2010.2371; Tamblyn R, 2014, ANN INTERN MED, V160, P441, DOI 10.7326/M13-1705; World Health Organization, 2011, AN THER CLASS STRUCT; Yang TB, 2008, PHARMACOEPIDEM DR S, V17, P270, DOI 10.1002/pds.1538	46	44	44	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 26	2015	10	5							e0128312	10.1371/journal.pone.0128312	http://dx.doi.org/10.1371/journal.pone.0128312			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CJ0QZ	26011706	Green Submitted, gold, Green Published			2023-01-03	WOS:000355183900221
J	Karimian, H; Fadaeinasab, M; Moghadamtousi, SZ; Hajrezaei, M; Razavi, M; Safi, SZ; Abdulla, MA; Ali, HM; Noordin, MI				Karimian, Hamed; Fadaeinasab, Mehran; Moghadamtousi, Soheil Zorofchian; Hajrezaei, Maryam; Razavi, Mahboubeh; Safi, Sher Zaman; Abdulla, Mahmood Ameen; Ali, Hapipah Mohd; Noordin, Mohamad Ibrahim			Chemopreventive Activity of Ferulago angulate against Breast Tumor in Rats and the Apoptotic Effect of Polycerasoidin in MCF7 Cells: A Bioassay-Guided Approach	PLOS ONE			English	Article							ANNONA MURICATA LEAVES; NUCLEAR ANTIGEN; CYCLE ARREST; IN-VITRO; CANCER; SURVIVAL; FAMILY; BCL-2; GROWTH	Ferulago angulataleaf hexane extract (FALHE) was found to be a potent inducer of MCF7 cell apoptosis. The aims of the present study were to investigate the in vivo chemopreventive effect of FALHE in rats, to identify the contributing anticancer compound in FALHE and to determine its potential mechanism of action against MCF7 cells. Thirty rats harboring LA7-induced breast tumors were divided into five groups: tumor control, low-dose FALHE, high-dose FALHE, treatment control (tamoxifen) and normal control. Breast tissues were then subjected to histopathological and immunohistochemical analyses. A bioassay-guided investigation on FALHE was performed to identify the cytotoxic compound and its mechanism of action through flow cytometry, real-time qPCR and western blotting analyses. An in vivo study showed that FALHE suppressed the expression of the tumor markers PCNA and Ki67. The tumor size was reduced from 2031 +/- 281 mm(3) to 432 +/- 201 mm(3) after FALHE treatment. FALHE administration induced apoptosis in breast tumor cells, and this was confirmed by high expression levels of Bax, p53 and caspase 3. Cell cycle arrest was suggested by the expression of p21 and p27. The in vitro experimental results resulted in the isolation of polycerasoidin as a bioactive ingredient of FALHE with an IC50 value of 3.16 +/- 0.31 mu g/ml against MCF7 cells. Polycerasoidin induced mitochondrial-dependent apoptosis in breast cancer cells via caspase activation and changes in the mRNA and protein expression of Bax and Bcl-2. In addition, flow cytometric analysis demonstrated that the treated MCF7 cells were arrested at the G(1) phase, and this was associated with the up-regulation of p21 and p27 at both the mRNA and protein levels. The results of the present study reinforce further investigations scrutinizing the promising potential of the F. angulata chemical constituents as breast cancer chemopreventive agents.	[Karimian, Hamed; Moghadamtousi, Soheil Zorofchian; Razavi, Mahboubeh; Noordin, Mohamad Ibrahim] Univ Malaya, Fac Med, Dept Pharm, Kuala Lumpur, Malaysia; [Fadaeinasab, Mehran; Ali, Hapipah Mohd] Univ Malaya, Fac Med, Dept Chem, Kuala Lumpur, Malaysia; [Safi, Sher Zaman] Univ Malaya, Fac Med, Dept Med, Kuala Lumpur, Malaysia; [Hajrezaei, Maryam; Abdulla, Mahmood Ameen] Univ Malaya, Fac Med, Dept Biomed Sci, Kuala Lumpur, Malaysia	Universiti Malaya; Universiti Malaya; Universiti Malaya; Universiti Malaya	Karimian, H (corresponding author), Univ Malaya, Fac Med, Dept Pharm, Kuala Lumpur, Malaysia.	hamedkarimian61@gmail.com; ibrahimn@um.edu.my	Safi, Sher Zaman/G-9599-2014; Noordin, Mohamed/AAK-4152-2021; Fadaeinasab, Mehran/A-8810-2016	Fadaeinasab, Mehran/0000-0002-2501-894X	University of Malaya; high impact research research grant (UM-MOHE) [UM.C/625/1/HIR/MOHE/SC/09]; Institute of Research Management and Monitoring research grant [PG053/2012B]	University of Malaya(Universiti Malaya); high impact research research grant (UM-MOHE); Institute of Research Management and Monitoring research grant	Financial support from the University of Malaya, the high impact research research grant (UM-MOHE UM.C/625/1/HIR/MOHE/SC/09), and the Institute of Research Management and Monitoring research grant (PG053/2012B) is greatly appreciated.	Abbasalipourkabir R, 2010, AFR J BIOTECHNOL, V9, P4491; Amirghofran Z, 2006, NEOPLASMA, V53, P428; Andrade FD, 2014, J NUTR BIOCHEM, V25, P613, DOI 10.1016/j.jnutbio.2014.02.002; Bardi DA, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/918460; Bielitzki J., 2011, GUIDE CARE USE LAB A; Breckenridge DG, 2004, CURR OPIN CELL BIOL, V16, P647, DOI 10.1016/j.ceb.2004.09.009; Cheang MC, 2009, J NATL CANC I; Cocola C, 2008, CYTOTECHNOLOGY, V58, P25, DOI 10.1007/s10616-008-9173-9; Coqueret O, 2003, TRENDS CELL BIOL, V13, P65, DOI 10.1016/S0962-8924(02)00043-0; Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883; Elmore S, 2007, TOXICOL PATHOL, V35, P495, DOI 10.1080/01926230701320337; Esposito L, 2013, CURR PHARM DESIGN, V19, P5327, DOI 10.2174/13816128113199990377; Evergetis E, 2014, IND CROP PROD, V54, P70, DOI 10.1016/j.indcrop.2014.01.009; Flores ER, 2002, NATURE, V416, P560, DOI 10.1038/416560a; Frenzel A, 2009, APOPTOSIS, V14, P584, DOI 10.1007/s10495-008-0300-z; GONZALEZ MC, 1995, J NAT PRODUCTS, V58, P1278, DOI 10.1021/np50122a022; Hajrezaie M, 2014, SCI WORLD J, DOI 10.1155/2014/540463; Hajrezaie M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091246; Karimian H, 2014, DRUG DES DEV THER, V8, P1481, DOI 10.2147/DDDT.S68818; Karimian H, 2014, MOLECULES, V19, P9478, DOI 10.3390/molecules19079478; Kelly PN, 2011, CELL DEATH DIFFER, V18, P1414, DOI 10.1038/cdd.2011.17; Kennecke H, 2010, J CLIN ONCOL, V28, P3271, DOI 10.1200/JCO.2009.25.9820; Lakhani SA, 2006, SCIENCE, V311, P847, DOI 10.1126/science.1115035; Lakshmi A, 2014, BIOCHIMIE, V99, P96, DOI 10.1016/j.biochi.2013.11.017; Liew SY, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087286; Lin H, 2008, APOPTOSIS, V13, P247, DOI 10.1007/s10495-007-0170-9; Liu DP, 2010, ONCOGENE, V29, P949, DOI 10.1038/onc.2009.376; Maga G, 2003, J CELL SCI, V116, P3051, DOI 10.1242/jcs.00653; MAYER A, 1993, CANCER, V71, P2454, DOI 10.1002/1097-0142(19930415)71:8<2454::AID-CNCR2820710805>3.0.CO;2-2; Mirzaaghaei S, 2014, ARCH IRAN MED, V17, P278, DOI 014174/AIM.0011; Moghadamtousi SZ, 2014, J ETHNOPHARMACOL, V156, P277, DOI 10.1016/j.jep.2014.08.011; Moghadamtousi SZ, 2014, DRUG DES DEV THER, V8, P2099, DOI 10.2147/DDDT.S70096; Moghadamtousi SZ, 2014, SCI WORLD J, DOI 10.1155/2014/768323; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Ocker M, 2012, EUR SURG RES, V48, P111, DOI 10.1159/000336875; Ola MS, 2011, MOL CELL BIOCHEM, V351, P41, DOI 10.1007/s11010-010-0709-x; Paydar M, 2014, DRUG DES DEV THER, V8, P719, DOI 10.2147/DDDT.S58178; Peto J, 2001, NATURE, V411, P390, DOI 10.1038/35077256; Pietenpol JA, 2002, TOXICOLOGY, V181, P475, DOI 10.1016/S0300-483X(02)00460-2; Randhawa MA, 2011, AM J CHINESE MED, V39, P1075, DOI 10.1142/S0192415X1100941X; Rani M. L., 2014, Indian Journal of Veterinary Pathology, V38, P43; Shahneh F. Z., 2013, Journal of Medicinal Plants Research, V7, P677; Shi YG, 2002, MOL CELL, V9, P459, DOI 10.1016/S1097-2765(02)00482-3; Sodeifian G, 2011, J SUPERCRIT FLUID, V57, P38, DOI 10.1016/j.supflu.2011.02.002; Taran M, 2010, JUNDISHAPUR J MICROB, V3, P10; Teegarden D, 2012, NUTR RES REV, V25, P68, DOI 10.1017/S0954422411000199; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0	47	11	11	0	16	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 21	2015	10	5							e0127434	10.1371/journal.pone.0127434	http://dx.doi.org/10.1371/journal.pone.0127434			21	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CK7VW	25996383	gold, Green Published, Green Submitted			2023-01-03	WOS:000356444000066
J	Vihinen, M				Vihinen, Mauno			No more hidden solutions in bioinformatics	NATURE			English	Editorial Material									Lund Univ, Med Struct Biol, S-22100 Lund, Sweden	Lund University	Vihinen, M (corresponding author), Lund Univ, Med Struct Biol, S-22100 Lund, Sweden.	mauno.vihinen@med.lu.se	Vihinen, Mauno/A-8452-2012	Vihinen, Mauno/0000-0002-9614-7976					0	16	16	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 21	2015	521	7552					261	261		10.1038/521261a	http://dx.doi.org/10.1038/521261a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CI5RM	25993922	Green Submitted, Bronze			2023-01-03	WOS:000354816500020
J	Xu, SX; Wang, ZW; Gao, YQ; Zhang, SM; Wu, K				Xu, Shuxia; Wang, Zhiwei; Gao, Yuqian; Zhang, Shimin; Wu, Kun			Adsorption of Rare Earths(III) Using an Efficient Sodium Alginate Hydrogel Cross-Linked with Poly-gamma-Glutamate	PLOS ONE			English	Article							PHYSICOCHEMICAL PROPERTIES; AQUEOUS-SOLUTIONS; REMOVAL; EQUILIBRIUM; KINETICS; BEADS; WATER; BIOSORPTION; CHROMIUM; ACID	With the exploitation of rare earth ore, more and more REEs came into groundwater. This was a waste of resources and could be harmful to the organisms. This study aimed to find an efficient adsorption material to mitigate the above issue. Through doping sodium alginate (SA) with poly-gamma-glutamate (PGA), an immobilized gel particle material was produced. The composite exhibited excellent capacity for adsorbing rare earth elements (REEs). The amount of La3+ adsorbed on the SA-PGA gel particles reached approximately 163.93 mg/g compared to the 81.97 mg/g adsorbed on SA alone. The factors that potentially affected the adsorption efficiency of the SA-PGA composite, including the initial concentration of REEs, the adsorbent dosage, and the pH of the solution, were investigated. 15 types of REEs in single and mixed aqueous solutions were used to explore the selective adsorption of REEs on gel particles. Scanning electron microscopy (SEM) and Fourier transform infrared (FTIR) spectroscopy analyses of the SA and SA-PGA gel beads suggested that the carboxyl groups in the composite might play a key role in the adsorption process and the morphology of SA-PGA changed from the compact structure of SA to a porous structure after doping PGA. The kinetics and thermodynamics of the adsorption of REEs were well fit with the pseudo-second-order equation and the Langmuir adsorption isotherm model, respectively. It appears that SA-PGA is useful for recycling REEs from wastewater.	[Xu, Shuxia; Wang, Zhiwei; Gao, Yuqian; Zhang, Shimin; Wu, Kun] Henan Agr Univ, Coll Life Sci, Zhengzhou 450002, Peoples R China	Henan Agricultural University	Wu, K (corresponding author), Henan Agr Univ, Coll Life Sci, Zhengzhou 450002, Peoples R China.	wukun63@126.com			Henan Provincial Natural Science Foundation of China [2011180025]; Programs for Science and Technology Development [1224050012]	Henan Provincial Natural Science Foundation of China; Programs for Science and Technology Development	This work was financially supported by Henan Provincial Natural Science Foundation of China (No. 2011180025) and Programs for Science and Technology Development (No. 1224050012). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ashiuchi M, 2002, APPL MICROBIOL BIOT, V59, P9, DOI 10.1007/s00253-002-0984-x; Bao WW, 2013, CHEM RES CHINESE U, V29, P126, DOI 10.1007/s40242-013-2139-2; BREMMER W., 1994, RARE EARTHS SPECIALT, V3, P20; Brioschi L, 2013, PLANT SOIL, V366, P143, DOI 10.1007/s11104-012-1407-0; Chen H, 2011, J HAZARD MATER, V192, P246, DOI 10.1016/j.jhazmat.2011.05.014; Chen H, 2011, J HAZARD MATER, V186, P1320, DOI 10.1016/j.jhazmat.2010.12.006; Chen ZH, 2011, J RARE EARTH, V29, P1, DOI 10.1016/S1002-0721(10)60401-2; Demirbas E, 2004, WATER SA, V30, P533; Diban N, 2008, J FOOD ENG, V84, P82, DOI 10.1016/j.jfoodeng.2007.04.024; Freundlich H, 1906, Z PHYS CHEM-STOCH VE, V57, P385; Gordon B., 2002, RARE EARTH ELEMENTS; Ho YS, 1998, PROCESS SAF ENVIRON, V76, P313, DOI 10.1205/095758298529678; Kilic M, 2009, BIORESOURCE TECHNOL, V100, P2130, DOI 10.1016/j.biortech.2008.11.002; Kwiatkowska-Marks S, 2011, PRZEM CHEM, V90, P1924; Lagergren S., 1898, HANDLINGER, DOI [10.4236/ss.2014.52008, DOI 10.4236/SS.2014.52008]; Langmuir I, 1918, J AM CHEM SOC, V40, P1361, DOI 10.1021/ja02242a004; Mark SS, 2006, BIOTECHNOL PROGR, V22, P523, DOI 10.1021/bp060040s; Moriwaki H, 2013, APPL MICROBIOL BIOT, V97, P3721, DOI 10.1007/s00253-012-4200-3; Ngomsik AF, 2009, J HAZARD MATER, V166, P1043, DOI 10.1016/j.jhazmat.2008.11.109; Sari A, 2008, J HAZARD MATER, V160, P349, DOI 10.1016/j.jhazmat.2008.03.005; Shu T, 2013, BIORESOURCE TECHNOL, V136, P182, DOI 10.1016/j.biortech.2013.02.087; Shukla A, 2002, J HAZARD MATER, V95, P137, DOI 10.1016/S0304-3894(02)00089-4; Studies CfSal, 2010, RAR EARTH EL WRENCH; Taniguchi M, 2005, J BIOSCI BIOENG, V99, P130, DOI 10.1263/jbb.99.130; Wang FC, 2013, IND ENG CHEM RES, V52, P3453, DOI 10.1021/ie302753q; Windhues T, 2003, CARBOHYD POLYM, V52, P47, DOI 10.1016/S0144-8617(02)00265-5; Yu K, 2013, COLLOID SURFACE A, V425, P31, DOI 10.1016/j.colsurfa.2012.12.043; Zhang L, 2011, J CHEM ENG DATA, V56, P2280, DOI 10.1021/je101270j	28	25	27	1	89	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 21	2015	10	5							e0124826	10.1371/journal.pone.0124826	http://dx.doi.org/10.1371/journal.pone.0124826			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CK7VW	25996388	Green Published, gold, Green Submitted			2023-01-03	WOS:000356444000006
J	Tosello, B; Dany, L; Betremieux, P; Le Coz, P; Auquier, P; Gire, C; Einaudi, MA				Tosello, Barthelemy; Dany, Lionel; Betremieux, Pierre; Le Coz, Pierre; Auquier, Pascal; Gire, Catherine; Einaudi, Marie-Ange			Barriers in Referring Neonatal Patients to Perinatal Palliative Care: A French Multicenter Survey	PLOS ONE			English	Article							FETAL ANOMALIES; ETHICAL ASPECTS; MEDICINE; DIAGNOSIS; TERMINATION; MANAGEMENT; PREGNANCY; NEWBORN; LIFE	Background When an incurable fetal condition is detected, some women (or couples) would rather choose to continue with the pregnancy than opt for termination of pregnancy for medical reasons, which, in France, can be performed until full term. Such situations are frequently occurring and sometimes leading to the implementation of neonatal palliative care. The objectives of this study were to evaluate the practices of perinatal care french professionals in this context; to identify the potential obstacles that might interfere with the provision of an appropiate neonatal palliative care; and, from an opposite perspective, to determine the criteria that led, in some cases, to offer this type of care for prenatally diagnosed lethal abnormality. Methods We used an email survey sent to 434 maternal-fetal medicine specialists (MFMs) and fetal care pediatric specialists (FCPs) at 48 multidisciplinary centers for prenatal diagnosis (MCPD). Results Forty-two multidisciplinary centers for prenatal diagnosis (87.5%) took part. In total, 102 MFMs and 112 FCPs completed the survey, yielding response rate of 49.3%. One quarter of professionals (26.2%) estimated that over 20% of fetal pathologies presenting in MCPD could correspond to a diagnosis categorized as lethal (FCPs versus MFMs: 24% vs 17.2%, p = 0.04). The mean proportion of fetal abnormalities eligible for palliative care at birth was estimated at 19.30% (+/- 2.4) (FCPs versus MFMs: 23.4% vs 15.2%, p = 0.029). The degree of diagnostic certainty appears to be the most influencing factor (98.1%, n = 207) in the information provided to the pregnant woman with regard to potential neonatal palliative care. The vast majority of professionals, 92.5%, supported considering the practice of palliative care as a regular option to propose antenatally. Conclusions Our study reveals the clear need for training perinatal professionals in perinatal palliative care and for the standardization of practices in this field.	[Tosello, Barthelemy; Le Coz, Pierre; Einaudi, Marie-Ange] Aix Marseille Univ, EFS, CNRS, UMR 7268,ADES,Espace Eth Mediterraneen, F-13005 Marseille, France; [Tosello, Barthelemy; Gire, Catherine] Hosp Nord, AP HP, Dept Neonatol, F-13015 Marseille, France; [Dany, Lionel] Aix Marseille Univ, LPS EA 849, F-13621 Aix En Provence, France; [Dany, Lionel] Hosp La Timone, AP HP, Dept Oncol, F-13005 Marseille, France; [Betremieux, Pierre] Univ Hosp Ctr, Hosp Sud, Dept Neonatol, Multidisciplinary Ctr Prenatal Diag, F-35000 Rennes, France; [Auquier, Pascal] Aix Marseille Univ, EA 3279, Self Perceived Hlth Assessment Res Unit, F-13005 Marseille, France	Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Ecology & Environment (INEE); Universite Bordeaux-Montaigne; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique Hopitaux Paris (APHP); UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique Hopitaux Paris (APHP); UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; CHU Rennes; UDICE-French Research Universities; Aix-Marseille Universite	Tosello, B (corresponding author), Aix Marseille Univ, EFS, CNRS, UMR 7268,ADES,Espace Eth Mediterraneen, F-13005 Marseille, France.	barthelemy.tosello@ap-hm.fr		Tosello, Barthelemy/0000-0002-1801-9944; Dany, Lionel/0000-0003-2350-4300				[Anonymous], 2012, RAPP MED SCI ASS MED; Aubry R., 2011, ETAT LIEUX DEV SOINS; Aubry R, 2011, PREMIER ETAT LIEUX R; Azria E, 2008, GYNECOL OBSTET FERTI, V36, P476, DOI 10.1016/j.gyobfe.2008.02.014; Balaguer A, 2012, BMC PEDIATR, V12, DOI 10.1186/1471-2431-12-25; Betremieux P, 2010, ARCH PEDIATRIE, V17, P413, DOI 10.1016/j.arcped.2010.01.016; Betremieux P, 2009, ARCH PEDIATRIE, V16, P603, DOI 10.1016/S0929-693X(09)74083-7; Betremieux P, 2010, PRENATAL DIAG, V30, P1112, DOI 10.1002/pd.2621; Bijma HH, 2004, PRENATAL DIAG, V24, P890, DOI 10.1002/pd.883; Breeze ACG, 2013, SEMIN FETAL NEONAT M, V18, P68, DOI 10.1016/j.siny.2012.09.004; Dageville C, 2008, GYNECOL OBSTET FERTI, V36, P571, DOI 10.1016/j.gyobfe.2008.04.003; de Rooy L, 2012, EARLY HUM DEV, V88, P73, DOI 10.1016/j.earlhumdev.2011.12.009; Dommergues M, 2000, J PEDIAT PUERICULT, P67; Dommergues M, 2010, PRENATAL DIAG, V30, P531, DOI 10.1002/pd.2510; Houfflin-Debarge V, 2013, J GYNECOL OBST BIO R, V42, P966, DOI 10.1016/j.jgyn.2013.09.018; International Society of Ultrasound in Obstetrics and Gynecology, 2014, STAND GUID; Leuthner SR, 2004, CLIN PERINATOL, V31, P649, DOI 10.1016/j.clp.2004.04.018; MAYS N, 1995, BRIT MED J, V311, P109, DOI 10.1136/bmj.311.6997.109; McMahon SR, 2003, PEDIATRICS, V111, DOI 10.1542/peds.111.4.e299; McNamara, 2013, PERINATAL PALLIATIVE; Ralston SJ, 2011, PEDIATRICS, V128, pE473, DOI 10.1542/peds.2011-1570; Simeoni U, 2007, ARCH PEDIATRIE, V14, P1171, DOI 10.1016/j.arcped.2007.07.003; Tosello B, 2013, GYNECOL OBSTET FERTI, V41, P251, DOI 10.1016/j.gyobfe.2013.02.013; Tosello B, 2014, J PALLIAT MED, V17, P924, DOI 10.1089/jpm.2014.0023; Whitworth M, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007058.pub2; Wilkinson D, 2014, SEMIN FETAL NEONAT M, V19, P306, DOI 10.1016/j.siny.2014.08.007; Wool C, 2013, JOGNN-J OBST GYN NEO, V42, P372, DOI 10.1111/1552-6909.12034; Wool C, 2013, JOGNN-J OBST GYN NEO, V42, P48, DOI 10.1111/j.1552-6909.2012.01432.x	28	26	27	0	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 15	2015	10	5							e0126861	10.1371/journal.pone.0126861	http://dx.doi.org/10.1371/journal.pone.0126861			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CI7AU	25978417	Green Published, gold, Green Submitted			2023-01-03	WOS:000354916100110
J	van Zanten, ARH				van Zanten, Arthur R. H.			Chlorhexidine Bathing and Infections in Critically Ill Patients RESPONSE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter							TRIAL		[van Zanten, Arthur R. H.] Gelderse Vallei Hosp, Dept Intens Care, NL-6716 RP Ede, Netherlands	Gelderse Vallei Hospital	van Zanten, ARH (corresponding author), Gelderse Vallei Hosp, Dept Intens Care, Care Div, Willy Brandtlaan 10, NL-6716 RP Ede, Netherlands.	zantena@zgv.nl	van Zanten, Arthur R.H./ABB-1169-2021	van Zanten, Arthur R.H./0000-0001-6276-7192				Derde LPG, 2014, LANCET INFECT DIS, V14, P31, DOI 10.1016/S1473-3099(13)70295-0; Noto MJ, 2015, JAMA-J AM MED ASSOC, V313, P369, DOI 10.1001/jama.2014.18400; Pittet D, 2015, JAMA-J AM MED ASSOC, V313, P365, DOI 10.1001/jama.2014.18482	3	1	1	0	5	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 12	2015	313	18					1862	1863		10.1001/jama.2015.3527	http://dx.doi.org/10.1001/jama.2015.3527			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CH9XW	25965238				2023-01-03	WOS:000354391000033
J	Akimoto, M; Iizuka, M; Kanematsu, R; Yoshida, M; Takenaga, K				Akimoto, Miho; Iizuka, Mari; Kanematsu, Rie; Yoshida, Masato; Takenaga, Keizo			Anticancer Effect of Ginger Extract against Pancreatic Cancer Cells Mainly through Reactive Oxygen Species-Mediated Autotic Cell Death	PLOS ONE			English	Article							AUTOPHAGY; APOPTOSIS; HYPOXIA; ROS; ACTIVATION; INDUCTION; MITOCHONDRIA; ANTIOXIDANT; METASTASIS; EXPRESSION	The extract of ginger (Zingiber officinale Roscoe) and its major pungent components, [6]-shogaol and [6]-gingerol, have been shown to have an anti-proliferative effect on several tumor cell lines. However, the anticancer activity of the ginger extract in pancreatic cancer is poorly understood. Here, we demonstrate that the ethanol-extracted materials of ginger suppressed cell cycle progression and consequently induced the death of human pancreatic cancer cell lines, including Panc-1 cells. The underlying mechanism entailed autosis, a recently characterized form of cell death, but not apoptosis or necroptosis. The extract markedly increased the LC3-II/LC3-I ratio, decreased SQSTM1/p62 protein, and enhanced vacuolization of the cytoplasm in Panc-1 cells. It activated AMPK, a positive regulator of autophagy, and inhibited mTOR, a negative autophagic regulator. The autophagy inhibitors 3-methyladenine and chloroquine partially prevented cell death. Morphologically, however, focal membrane rupture, nuclear shrinkage, focal swelling of the perinuclear space and electron dense mitochondria, which are unique morphological features of autosis, were observed. The extract enhanced reactive oxygen species (ROS) generation, and the antioxidant N-acetylcystein attenuated cell death. Our study revealed that daily intraperitoneal administration of the extract significantly prolonged survival (P = 0.0069) in a peritoneal dissemination model and suppressed tumor growth in an orthotopic model of pancreatic cancer (P < 0.01) without serious adverse effects. Although [6]-shogaol but not [6]-gingerol showed similar effects, chromatographic analyses suggested the presence of other constituent(s) as active substances. Together, these results show that ginger extract has potent anticancer activity against pancreatic cancer cells by inducing ROS-mediated autosis and warrants further investigation in order to develop an efficacious candidate drug.	[Akimoto, Miho; Kanematsu, Rie; Takenaga, Keizo] Shimane Univ, Fac Med, Dept Life Sci, Lab Tumor Biol, Izumo, Shimane, Japan; [Iizuka, Mari; Yoshida, Masato] Shimane Univ, Fac Med, Dept Life Sci, Lab Mol Sci, Izumo, Shimane, Japan	Shimane University; Shimane University	Takenaga, K (corresponding author), Shimane Univ, Fac Med, Dept Life Sci, Lab Tumor Biol, Izumo, Shimane, Japan.	biokeizo@med.shimane-u.ac.jp			Shimane University "SUIGANN" Project; Ministry of Education, Culture, Sports, Science, and Technology, Japan [25430110]; Japan Arteriosclerosis Research Foundation; Support for Super Science High Schools from Japan Science and Technology Agency	Shimane University "SUIGANN" Project; Ministry of Education, Culture, Sports, Science, and Technology, Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Japan Arteriosclerosis Research Foundation; Support for Super Science High Schools from Japan Science and Technology Agency	This work was supported in part by Grants-in-Aid from: Shimane University "SUIGANN" Project (http://www.shimane-u.ac.jp) (to KT); Scientific Research from the Ministry of Education, Culture, Sports, Science, and Technology, Japan (http://www.mext.go.jp) (no. 25430110 to KT); and Japan Arteriosclerosis Research Foundation (to KT). This work was also supported by the Support for Super Science High Schools from Japan Science and Technology Agency to Izumo High School (http://rikai.jst.go.jp) (to KT). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Akimoto M., 2013, WORLD J MED GENET, V3, P41, DOI [10.5496/wjmg.v3.i4.41, DOI 10.5496/WJMG.V3.I4.41]; Chen Y, 2009, CELL DEATH DIFFER, V16, P1040, DOI 10.1038/cdd.2009.49; Citronberg J, 2013, CANCER PREV RES, V6, P271, DOI 10.1158/1940-6207.CAPR-12-0327; CORBETT TH, 1984, CANCER RES, V44, P717; Dewaele M, 2010, AUTOPHAGY, V6, P838, DOI 10.4161/auto.6.7.12113; Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210; Ferlay J, 2010, INT J CANCER, V127, P2893, DOI 10.1002/ijc.25516; Filomeni G, 2015, CELL DEATH DIFFER, V22, P377, DOI 10.1038/cdd.2014.150; Filomeni G, 2010, AUTOPHAGY, V6, P999, DOI 10.4161/auto.6.7.12754; Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704; HONMA Y, 1989, CANCER RES, V49, P331; Hu R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039664; HYUGA S, 1994, CANCER RES, V54, P3611; Imanishi H, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023401; Ishikawa K, 2008, SCIENCE, V320, P661, DOI 10.1126/science.1156906; Ito S, 2007, INT J ONCOL, V31, P261; Karna P, 2012, BRIT J NUTR, V107, P473, DOI 10.1017/S0007114511003308; Kim MO, 2014, CARCINOGENESIS, V35, P683, DOI 10.1093/carcin/bgt365; Kirkland RA, 2002, NEUROSCIENCE, V115, P587, DOI 10.1016/S0306-4522(02)00512-2; Koong AC, 2000, INT J RADIAT ONCOL, V48, P919, DOI 10.1016/S0360-3016(00)00803-8; Lee DH, 2014, TOXICOL APPL PHARM, V279, P253, DOI 10.1016/j.taap.2014.06.030; Li F, 2012, FOOD CHEM, V135, P332, DOI 10.1016/j.foodchem.2012.04.145; Liu Q, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-135; Liu Q, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/278652; Liu Y, 2015, CELL DEATH DIFFER, V22, P367, DOI 10.1038/cdd.2014.143; Liu Y, 2013, P NATL ACAD SCI USA, V110, P20364, DOI 10.1073/pnas.1319661110; Loc WS, 2014, WORLD J GASTROENTERO, V20, P14717, DOI 10.3748/wjg.v20.i40.14717; Lu DL, 2014, FOOD CHEM, V165, P191, DOI 10.1016/j.foodchem.2014.05.077; Mizumura K, 2014, J CLIN INVEST, V124, P3987, DOI 10.1172/JCI74985; Monma H, 2013, MOL CANCER THER, V12, P341, DOI 10.1158/1535-7163.MCT-12-0954; Morikane K, 2001, INT IMMUNOL, V13, P233, DOI 10.1093/intimm/13.2.233; NAKATANI H, 1986, JPN J CANCER RES, V77, P849; OGAWA H, 1995, P NATL ACAD SCI USA, V92, P11899, DOI 10.1073/pnas.92.25.11899; Ozaki T, 1999, CANCER RES, V59, P5902; Park EJ, 2002, CANCER METAST REV, V21, P231, DOI 10.1023/A:1021254725842; Partensky C, 2013, PANCREAS, V42, P729, DOI 10.1097/MPA.0b013e318288107a; Radhakrishnan EK, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104401; Rastogi N, 2014, FREE RADICAL BIO MED, V68, P288, DOI 10.1016/j.freeradbiomed.2013.12.016; Sawai H, 2011, BIOCHEM BIOPH RES CO, V411, P569, DOI 10.1016/j.bbrc.2011.06.186; Scherz-Shouval R, 2007, TRENDS CELL BIOL, V17, P422, DOI 10.1016/j.tcb.2007.07.009; Scherz-Shouval R, 2007, AUTOPHAGY, V3, P371, DOI 10.4161/auto.4214; Shimojo Y, 2013, CLIN EXP METASTAS, V30, P143, DOI 10.1007/s10585-012-9519-8; Shukla Y, 2007, FOOD CHEM TOXICOL, V45, P683, DOI 10.1016/j.fct.2006.11.002; SRIVASTAVA KC, 1992, MED HYPOTHESES, V39, P342, DOI 10.1016/0306-9877(92)90059-L; Stoner GD, 2013, CANCER PREV RES, V6, P257, DOI 10.1158/1940-6207.CAPR-13-0055; Takenaga K, 1997, CLIN CANCER RES, V3, P2309; Tan BS, 2013, CANCER LETT, V336, P127, DOI 10.1016/j.canlet.2013.04.014; WILLIAMS CJ, 1990, TUMOR BIOL, V11, P145, DOI 10.1159/000217649; Yokoi K, 2004, CLIN CANCER RES, V10, P2299, DOI 10.1158/1078-0432.CCR-03-0488; Yoshida K, 2008, ONCOGENE, V27, P1183, DOI 10.1038/sj.onc.1210722; Zhang C, 2013, CANCER LETT, V340, P51, DOI 10.1016/j.canlet.2013.06.021; Zhu YD, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054677; Zick SM, 2015, MOL CARCINOGEN, V54, P908, DOI 10.1002/mc.22163; Zick SM, 2009, SUPPORT CARE CANCER, V17, P563, DOI 10.1007/s00520-008-0528-8	54	94	99	1	31	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 11	2015	10	5							e0126605	10.1371/journal.pone.0126605	http://dx.doi.org/10.1371/journal.pone.0126605			22	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CI1YY	25961833	Green Submitted, gold, Green Published			2023-01-03	WOS:000354542500125
J	Gozalo, P; Plotzke, M; Mor, V; Miller, SC; Teno, JM				Gozalo, Pedro; Plotzke, Michael; Mor, Vincent; Miller, Susan C.; Teno, Joan M.			Changes in Medicare Costs with the Growth of Hospice Care in Nursing Homes	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							LIFE; END; EXPENDITURES; RESIDENTS; DEMENTIA; QUALITY; PROGRAM; IMPROVE	BACKGROUND Nursing home residents' use of hospice has substantially increased. Whether this increase in hospice use reduces end-of-life expenditures is unknown. METHODS The expansion of hospice between 2004 and 2009 created a natural experiment, allowing us to conduct a difference-in-differences matched analysis to examine changes in Medicare expenditures in the last year of life that were associated with this expansion. We also assessed intensive care unit (ICU) use in the last 30 days of life and, for patients with advanced dementia, feeding-tube use and hospital transfers within the last 90 days of life. We compared a subset of hospice users from 2009, whose use of hospice was attributed to hospice expansion, with a matched subset of non-hospice users from 2004, who were considered likely to have used hospice had they died in 2009. RESULTS Of 786,328 nursing home decedents, 27.6% in 2004 and 39.8% in 2009 elected to use hospice. The 2004 and 2009 matched hospice and nonhospice cohorts were similar (mean age, 85 years; 35% male; 25% with cancer). The increase in hospice use was associated with significant decreases in the rates of hospital transfers (2.4 percentage-point reduction), feeding-tube use (1.2 percentage-point reduction), and ICU use (7.1 percentage-point reduction). The mean length of stay in hospice increased from 72.1 days in 2004 to 92.6 days in 2009. Between 2004 and 2009, the expansion of hospice was associated with a mean net increase in Medicare expenditures of $6,761 (95% confidence interval, 6,335 to 7,186), reflecting greater additional spending on hospice care ($10,191) than reduced spending on hospital and other care ($3,430). CONCLUSIONS The growth in hospice care for nursing home residents was associated with less aggressive care near death but at an overall increase in Medicare expenditures. (Funded by the Centers for Medicare and Medicaid Services and the National Institute on Aging.)	[Gozalo, Pedro; Mor, Vincent; Miller, Susan C.; Teno, Joan M.] Brown Univ, Sch Publ Hlth, Ctr Gerontol & Hlth Care Res, Providence, RI 02912 USA; [Gozalo, Pedro; Mor, Vincent; Miller, Susan C.; Teno, Joan M.] Brown Univ, Sch Publ Hlth, Dept Hlth Serv Policy & Practice, Providence, RI 02912 USA; [Mor, Vincent] Providence Vet Affairs Med Ctr, Hlth Serv Res, Providence, RI USA; [Plotzke, Michael] Abt Associates Inc, Cambridge, MA USA	Brown University; Brown University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Providence VA Medical Center; ABT Associates	Gozalo, P (corresponding author), Brown Univ, Sch Publ Hlth, Ctr Gerontol & Hlth Care Res, Box G-S121-6, Providence, RI 02912 USA.	pedro_gozalo@brown.edu			Centers for Medicare and Medicaid Services; National Institute on Aging; NATIONAL INSTITUTE ON AGING [P01AG027296] Funding Source: NIH RePORTER	Centers for Medicare and Medicaid Services; National Institute on Aging(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	Funded by the Centers for Medicare and Medicaid Services and the National Institute on Aging.	[Anonymous], 2011, MED HOSP FOC NURS FA; Austin PC, 2009, STAT MED, V28, P3083, DOI 10.1002/sim.3697; Baer WM, 2000, J AM GERIATR SOC, V48, P879, DOI 10.1111/j.1532-5415.2000.tb06883.x; Banaszak-Holl J, 1996, Hosp J, V11, P1, DOI 10.1300/J011v11n03_01; Bureau of Labor Statistics, 2013, CONS PRIC IND MED CA; Campbell DE, 2004, ANN INTERN MED, V140, P269, DOI 10.7326/0003-4819-140-4-200402170-00009; Centers for Medicare Medicaid Services, PROV SERV CURR FIL; Donald SG, 2007, REV ECON STAT, V89, P221, DOI 10.1162/rest.89.2.221; Emanuel EJ, 1996, JAMA-J AM MED ASSOC, V275, P1907, DOI 10.1001/jama.275.24.1907; FRIES JF, 1993, NEW ENGL J MED, V329, P321, DOI 10.1056/NEJM199307293290506; Gozalo P, 2011, NEW ENGL J MED, V365, P1212, DOI 10.1056/NEJMsa1100347; Gozalo PL, 2008, HEALTH SERV RES, V43, P134, DOI 10.1111/j.1475-6773.2007.00746.x; Kelley AS, 2013, HEALTH AFFAIR, V32, P552, DOI 10.1377/hlthaff.2012.0851; Medicare Payment Advisory Commission, 2008, REP C REF DEL SYST; Medicare Payment Advisory Committee, 2014, REP C MED PAYM POL; Miller SC, 2002, J AM GERIATR SOC, V50, P507, DOI 10.1046/j.1532-5415.2002.50118.x; Miller SC, 2010, J AM GERIATR SOC, V58, P1481, DOI 10.1111/j.1532-5415.2010.02968.x; Mitchell SL, 2010, JAMA-J AM MED ASSOC, V304, P1929, DOI 10.1001/jama.2010.1572; Newhouse J P, 1989, Health Care Financ Rev, V10, P41; Normand SLT, 2001, J CLIN EPIDEMIOL, V54, P387, DOI 10.1016/S0895-4356(00)00321-8; Plotzke M, 2014, MEDICARE HOSPICE PAY; Riley GF, 2010, HEALTH SERV RES, V45, P565, DOI 10.1111/j.1475-6773.2010.01082.x; SINGER PA, 1992, ARCH INTERN MED, V152, P478, DOI 10.1001/archinte.152.3.478; Taylor DH, 2007, SOC SCI MED, V65, P1466, DOI 10.1016/j.socscimed.2007.05.028; Teno JM, 2011, J AM GERIATR SOC, V59, P1531, DOI 10.1111/j.1532-5415.2011.03505.x	25	64	64	0	18	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 7	2015	372	19					1823	1831		10.1056/NEJMsa1408705	http://dx.doi.org/10.1056/NEJMsa1408705			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	CH4BB	25946281	Green Accepted, Bronze			2023-01-03	WOS:000353974700007
J	Damiani, E; Adrario, E; Luchetti, MM; Scorcella, C; Carsetti, A; Mininno, N; Pierantozzi, S; Principi, T; Strovegli, D; Bencivenga, R; Gabrielli, A; Romano, R; Pelaia, P; Ince, C; Donati, A				Damiani, Elisa; Adrario, Erica; Luchetti, Michele Maria; Scorcella, Claudia; Carsetti, Andrea; Mininno, Nicoletta; Pierantozzi, Silvia; Principi, Tiziana; Strovegli, Daniele; Bencivenga, Rosella; Gabrielli, Armando; Romano, Rocco; Pelaia, Paolo; Ince, Can; Donati, Abele			Plasma Free Hemoglobin and Microcirculatory Response to Fresh or Old Blood Transfusions in Sepsis	PLOS ONE			English	Article							CELL-FREE HEMOGLOBIN; NITRIC-OXIDE BIOAVAILABILITY; NEAR-INFRARED SPECTROSCOPY; CRITICALLY-ILL; MICROVASCULAR RESPONSE; OXYGEN-SATURATION; SEPTIC PATIENTS; ORGAN FAILURE; STORAGE TIME; RED-CELLS	Background Free hemoglobin (fHb) may induce vasoconstriction by scavenging nitric oxide. It may increase in older blood units due to storage lesions. This study evaluated whether old red blood cell transfusion increases plasma fHb in sepsis and how the microvascular response may be affected. Methods This is a secondary analysis of a randomized study. Twenty adult septic patients received either fresh or old (<10 or >15 days storage, respectively) RBC transfusions. fHb was measured in RBC units and in the plasma before and 1 hour after transfusion. Simultaneously, the sublingual microcirculation was assessed with sidestream-dark field imaging. The perfused boundary region was calculated as an index of glycocalyx damage. Tissue oxygen saturation (StO(2)) and Hb index (THI) were measured with near-infrared spectroscopy and a vascular occlusion test was performed. Results Similar fHb levels were found in the supernatant of fresh and old RBC units. Despite this, plasma fHb increased in the old RBC group after transfusion (from 0.125 [0.098-0.219] mg/mL to 0.238 [0.163-0.369] mg/mL, p = 0.006). The sublingual microcirculation was unaltered in both groups, while THI increased. The change in plasma fHb was inversely correlated with the changes in total vessel density (r = -0.57 [95% confidence interval -0.82, -0.16], p = 0.008), De Backer score (r = -0.63 [95% confidence interval -0.84, -0.25], p = 0.003) and THI (r = -0.72 [95% confidence interval -0.88, -0.39], p = 0.0003). Conclusions Old RBC transfusion was associated with an increase in plasma fHb in septic patients. Increasing plasma fHb levels were associated with decreased microvascular density.	[Damiani, Elisa; Adrario, Erica; Scorcella, Claudia; Carsetti, Andrea; Mininno, Nicoletta; Pierantozzi, Silvia; Romano, Rocco; Pelaia, Paolo; Donati, Abele] Univ Politecn Marche, Dept Biomed Sci & Publ Hlth, Torrette Di Ancona, Italy; [Adrario, Erica; Principi, Tiziana; Strovegli, Daniele; Pelaia, Paolo; Donati, Abele] Azienda Osped Univ Osped Riuniti, Anesthesia & Intens Care Unit, Torrette Di Ancona, Italy; [Luchetti, Michele Maria; Gabrielli, Armando] Univ Politecn Marche, Dept Clin & Mol Sci, Med Clin, Torrette Di Ancona, Italy; [Bencivenga, Rosella] AOU Osped Riuniti, Immunohematol & Transfus Med, Torrette Di Ancona, Italy; [Ince, Can; Donati, Abele] Univ Amsterdam, Acad Med Ctr, Dept Translat Physiol, NL-1105 AZ Amsterdam, Netherlands	Marche Polytechnic University; Marche Polytechnic University; University of Amsterdam; Academic Medical Center Amsterdam	Donati, A (corresponding author), Univ Politecn Marche, Dept Biomed Sci & Publ Hlth, Torrette Di Ancona, Italy.	a.donati@univpm.it	Damiani, Elisa/AAA-8075-2019; Luchetti, Michele Maria/J-6955-2019; Gabrielli, Armando/AAC-3173-2019; Carsetti, Andrea/AAB-9305-2019	Luchetti, Michele Maria/0000-0001-9132-7401; Carsetti, Andrea/0000-0001-6096-6251; Donati, Abele/0000-0001-6792-8741; damiani, elisa/0000-0002-3166-1835				Adamzik M, 2012, CRIT CARE, V16, DOI 10.1186/cc11425; Aubron C, 2013, ANN INTENSIVE CARE, V3, DOI 10.1186/2110-5820-3-2; Ayhan B, 2013, TRANSFUS APHER SCI, V49, P212, DOI 10.1016/j.transci.2013.01.016; Bateman RM, 2003, CRIT CARE, V7, P359, DOI 10.1186/cc2353; Boerma EC, 2005, CRIT CARE, V9, pR601, DOI 10.1186/cc3809; Carter Rickey E, 2004, J Transl Med, V2, P37, DOI 10.1186/1479-5876-2-37; Creteur J, 2009, CRIT CARE, V13, DOI 10.1186/cc8009; De Backer D, 2007, CRIT CARE, V11, DOI 10.1186/cc6118; Dellinger RP, 2008, INTENS CARE MED, V34, P17, DOI 10.1007/s00134-007-0934-2; Donadee C, 2011, CIRCULATION, V124, P465, DOI 10.1161/CIRCULATIONAHA.110.008698; Donati A, 2014, CRIT CARE, V18, DOI 10.1186/cc13730; Donati A, 2013, MICROVASC RES, V90, P86, DOI 10.1016/j.mvr.2013.08.007; Donati A, 2013, BMC ANESTHESIOL, V13, DOI 10.1186/1471-2253-13-25; Donati A, 2013, CRIT CARE, V17, DOI 10.1186/cc11503; Donati A, 2013, CRIT CARE RES PRACT, V2013, DOI 10.1155/2013/892710; Donati A, 2009, CRIT CARE, V13, DOI 10.1186/cc8010; Goedhart PT, 2007, OPT EXPRESS, V15, P15101, DOI 10.1364/OE.15.015101; Gomez H, 2009, CRIT CARE, V13, DOI 10.1186/cc8001; Hebert PC, 1999, NEW ENGL J MED, V340, P409, DOI 10.1056/NEJM199902113400601; Ince C, 2005, CRIT CARE, V9, pS13, DOI 10.1186/cc3753; Janz DR, 2013, CRIT CARE MED, V41, P784, DOI 10.1097/CCM.0b013e3182741a54; Edul VSK, 2012, CRIT CARE MED, V40, P1443, DOI 10.1097/CCM.0b013e31823dae59; Kim-Shapiro DB, 2011, TRANSFUSION, V51, P844, DOI 10.1111/j.1537-2995.2011.03100.x; Levy MM, 2001, INTENS CARE MED, V29, P530, DOI DOI 10.1007/S00134-003-1662-X; Marik PE, 2008, CRIT CARE MED, V36, P2667, DOI 10.1097/CCM.0b013e3181844677; MARIK PE, 1993, JAMA-J AM MED ASSOC, V269, P3024, DOI 10.1001/jama.269.23.3024; Myers DE, 2005, J BIOMED OPT, V10, DOI 10.1117/1.1925250; Myers D, 2009, CRIT CARE, V13, DOI 10.1186/cc8000; Napolitano LM, 2009, CRIT CARE MED, V37, P3124, DOI 10.1097/CCM.0b013e3181b39f1b; Phelan HA, 2012, AM J SURG, V203, P198, DOI 10.1016/j.amjsurg.2011.05.012; Raat NJH, 2007, VOX SANG, V93, P12, DOI 10.1111/j.1423-0410.2007.00909.x; Raat NJ, 2005, CRIT CARE MED, V33, P39, DOI 10.1097/01.CCM.0000150655.75519.02; Reiter CD, 2002, NAT MED, V8, P1383, DOI 10.1038/nm799; Reynolds JD, 2007, P NATL ACAD SCI USA, V104, P17058, DOI 10.1073/pnas.0707958104; Roback JD, 2011, TRANSFUSION, V51, P859, DOI 10.1111/j.1537-2995.2011.03094.x; Sadaka F, 2011, ANN INTENSIVE CARE, V1, DOI 10.1186/2110-5820-1-46; Sakr Y, 2004, CRIT CARE MED, V32, P1825, DOI 10.1097/01.CCM.0000138558.16257.3F; Sakr Y, 2007, CRIT CARE MED, V35, P1639, DOI 10.1097/01.CCM.0000269936.73788.32; Triulzi DJ, 2010, TRANSFUS APHER SCI, V43, P95, DOI 10.1016/j.transci.2010.05.013; van den Berg Bernard M, 2006, Pharmacol Rep, V58 Suppl, P75; Vincent JL, 2002, JAMA-J AM MED ASSOC, V288, P1499, DOI 10.1001/jama.288.12.1499; Vincent JL, 1996, INTENS CARE MED, V22, P707, DOI 10.1007/BF01709751; Vlahu CA, 2012, J AM SOC NEPHROL, V23, P1900, DOI 10.1681/ASN.2011121181; Walsh TS, 2004, CRIT CARE MED, V32, P364, DOI 10.1097/01.CCM.0000108878.23703.E0; Weinberg JA, 2013, J TRAUMA ACUTE CARE, V75, P807, DOI 10.1097/TA.0b013e3182a74a9b; Windsant ICV, 2012, CRIT CARE, V16, DOI 10.1186/cc11359; Yalcin O, 2014, TRANSFUSION, V54, P1015, DOI 10.1111/trf.12361; Yuruk K, 2013, TRANSFUSION, V53, P1346, DOI 10.1111/j.1537-2995.2012.03905.x	48	36	36	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 1	2015	10	5							e0122655	10.1371/journal.pone.0122655	http://dx.doi.org/10.1371/journal.pone.0122655			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CH2XA	25932999	Green Submitted, Green Published, gold			2023-01-03	WOS:000353887100010
J	Wang, TD; Yang, S; Wang, L; Feng, HL				Wang, Tianda; Yang, Sheng; Wang, Lei; Feng, Hailan			Use of Poly (Amidoamine) Dendrimer for Dentinal Tubule Occlusion: A Preliminary Study	PLOS ONE			English	Article							CALCIUM-PHOSPHATE PRECIPITATION; PAMAM DENDRIMERS; AMMONIUM HEXAFLUOROSILICATE; CARBONATED APATITE; IN-VITRO; HYDROXYAPATITE; SURFACE; FLUORIDE; OXALATE; SEM	The occlusion of dentinal tubules is an effective method to alleviate the symptoms caused by dentin hypersensitivity, a significant health problem in dentistry and daily life. The in situ mineralization within dentinal tubules is a promising treatment for dentin hypersensitivity as it induces the formation of mineral on the sensitive regions and occludes the dentinal tubules. This study was carried out to evaluate the in vitro effect of a whole generation poly (amidoamine) (PAMAM) dendrimer (G3.0) on dentinal tubule occlusion by inducing mineralization within dentinal tubules. Dentin discs were treated with PAMAM dendrimers using two methods, followed by the in vitro characterization using Attenuated total reflection Fourier-transform infrared spectroscopy (ATR-FTIR), X-ray diffraction (XRD), Field emission scanning electron microscopy (FE-SEM) and Energy-Dispersive X-ray Spectroscopy (EDS). These results showed that G3.0 PAMAM dendrimers coated on dentin surface and infiltrated in dentinal tubules could induce hydroxyapatite formation and resulted in effective dentinal tubule occlusion. Moreover, crosslinked PAMAM dendrimers could induce the remineralization of demineralized dentin and thus had the potential in dentinal tubule occlusion. In this in vitro study, dentinal tubules occlusion could be achieved by using PAMAM dendrimers. This could lead to the development of a new therapeutic technique for the treatment of dentin hypersensitivity.	[Wang, Tianda; Yang, Sheng; Wang, Lei; Feng, Hailan] Peking Univ, Dept Prosthodont, Sch & Hosp Stomatol, Beijing 100871, Peoples R China; [Yang, Sheng] Chongqing Med Univ, Coll Stomatol, Chongqing Key Lab Oral Dis & Biomed Sci, Chongqing, Peoples R China	Peking University; Chongqing Medical University	Feng, HL (corresponding author), Peking Univ, Dept Prosthodont, Sch & Hosp Stomatol, Beijing 100871, Peoples R China.	Kqfenghl@bjmu.edu.cn	Wang, Tianda/AAV-9811-2020		Specialized Research Fund for the Doctoral Program of Higher Education of China [20100001110092]	Specialized Research Fund for the Doctoral Program of Higher Education of China(Specialized Research Fund for the Doctoral Program of Higher Education (SRFDP))	This study was supported by the Specialized Research Fund for the Doctoral Program of Higher Education of China (No. 20100001110092). [http://www.cutech.edu.cn/cn/kyjj/gdxxbsdkyjj/A010301index_1.htm]. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bedran-Russo AKB, 2007, J BIOMED MATER RES B, V80B, P268, DOI 10.1002/jbm.b.30593; BRANNSTR.M, 1968, J DENT RES, V47, P679, DOI 10.1177/00220345680470050201; BRANNSTROM M, 1966, ORAL SURG ORAL MED O, V21, P517, DOI 10.1016/0030-4220(66)90411-7; Canadian Advisory Board on Dentin Hypersensitivity, 2002, J CAN DENT ASSOC, V69, P221; Chang MC, 2002, BIOMATERIALS, V23, P4811, DOI 10.1016/S0142-9612(02)00232-6; Chiang YC, 2010, J DENT RES, V89, P236, DOI 10.1177/0022034509357148; Damen JJM, 1998, CARIES RES, V32, P435, DOI 10.1159/000016484; Davies M, 2011, EUR J ORAL SCI, V119, P497, DOI 10.1111/j.1600-0722.2011.00872.x; Duncan R, 2005, ADV DRUG DELIVER REV, V57, P2215, DOI 10.1016/j.addr.2005.09.019; Esfand R, 2001, DRUG DISCOV TODAY, V6, P427, DOI 10.1016/S1359-6446(01)01757-3; Gillam DG, 2004, J ORAL REHABIL, V31, P245, DOI 10.1046/j.0305-182X.2003.01230.x; Gillam DG, 2001, J ORAL REHABIL, V28, P1037, DOI 10.1046/j.1365-2842.2001.00775.x; GOLDBERG M, 1993, HISTOCHEM J, V25, P781; Grossman LI, 1922, J AM DENT ASSOC, V22, P592, DOI DOI 10.14219/JADA.ARCHIVE.1935.0110; Habelitz S, 2002, J STRUCT BIOL, V138, P227, DOI 10.1016/S1047-8477(02)00029-1; He G, 2005, J BIOL CHEM, V280, P33109, DOI 10.1074/jbc.M500159200; ISHIKAWA K, 1994, J DENT RES, V73, P1197, DOI 10.1177/00220345940730061101; Kim YK, 2010, J DENT RES, V89, P230, DOI 10.1177/0022034509357172; Kolker Justine L, 2002, J Adhes Dent, V4, P211; Liu Y, 2011, J DENT RES, V90, P953, DOI 10.1177/0022034510391799; Liu Y, 2011, ACTA BIOMATER, V7, P1742, DOI 10.1016/j.actbio.2010.11.028; Lynch E, 2012, DENT MATER, V28, P168, DOI 10.1016/j.dental.2011.11.021; Markowitz K, 2007, J DENT RES, V86, P292, DOI 10.1177/154405910708600401; Mitra T, 2014, J CHEM SCI, V126, P127, DOI 10.1007/s12039-013-0543-2; Morris MF, 1999, AM J DENT, V12, P72; Nancollas GH, 2000, J CRYST GROWTH, V211, P137, DOI 10.1016/S0022-0248(99)00816-7; Niederberger M, 2006, PHYS CHEM CHEM PHYS, V8, P3271, DOI 10.1039/b604589h; Orchardson R, 2006, J AM DENT ASSOC, V137, P990, DOI 10.14219/jada.archive.2006.0321; Pereira JC, 2005, DENT MATER, V21, P129, DOI 10.1016/j.dental.2004.02.007; Pillon FL, 2004, J PERIODONTOL, V75, P1461, DOI 10.1902/jop.2004.75.11.1461; Qia YP, 2012, ACTA BIOMATER, V8, P836, DOI 10.1016/j.actbio.2011.10.033; Rehman I, 1997, J MATER SCI-MATER M, V8, P1, DOI 10.1023/A:1018570213546; Sevenson S, 2012, ADV DRUG DELIVER REV, V64, P102, DOI 10.1016/j.addr.2012.09.030; Shetty S, 2010, J PERIODONTOL, V81, P1781, DOI 10.1902/jop.2010.100172; Suge T, 1995, J DENT RES, V74, P1709, DOI 10.1177/00220345950740101301; SUGE T, 1995, J DENT RES, V74, P1079, DOI 10.1177/00220345950740040801; Suge T, 2008, DENT MATER, V24, P192, DOI 10.1016/j.dental.2007.03.009; Suge T, 2006, AM J DENT, V19, P248; Tanahashi M, 1997, J BIOMED MATER RES, V34, P305; Tay FR, 2008, BIOMATERIALS, V29, P1127, DOI 10.1016/j.biomaterials.2007.11.001; Tian LL, 2014, DENT MATER J, V33, P125, DOI 10.4012/dmj.2013-215; Tirapelli Camila, 2010, Braz. oral res., V24, P381, DOI 10.1590/S1806-83242010000400002; Tomalia DA, 2005, PROG POLYM SCI, V30, P294, DOI 10.1016/j.progpolymsci.2005.01.007; Toworfe GK, 2006, BIOMATERIALS, V27, P631, DOI 10.1016/j.biomaterials.2005.06.017; Wang RZ, 1998, CONNECT TISSUE RES, V39, P269, DOI 10.3109/03008209809021502; Wang TD, 2015, RSC ADV, V5, P11136, DOI 10.1039/c4ra14744h; Wang ZJ, 2010, J DENT, V38, P400, DOI 10.1016/j.jdent.2010.01.007; Wenk HR, 1999, BONE, V24, P361, DOI 10.1016/S8756-3282(98)00192-6; Wong Tak-Sing, 2009, Molecular & Cellular Biomechanics, V6, P1; Xie LB, 2011, POLYM BULL, V66, P119, DOI 10.1007/s00289-010-0350-6; Xu Z, 2011, J BIOMED MATER RES B, V98B, P150, DOI 10.1002/jbm.b.31844; Yan SJ, MAT CHEM, V2; Yang S, 2011, CHEM COMMUN, V47, P10100, DOI 10.1039/c1cc13661e; Zhang Q, 2013, ACS APPL MATER INTER, V5, P1907, DOI 10.1021/am400155b; Zhang SG, 2003, NAT BIOTECHNOL, V21, P1171, DOI 10.1038/nbt874; Zhang X, 2012, J MATER SCI-MATER M, V23, P733, DOI 10.1007/s10856-012-4550-5; Zhou ZH, 2007, MATER RES BULL, V42, P1611, DOI 10.1016/j.materresbull.2006.11.041	57	6	8	0	26	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 17	2015	10	4							e0124735	10.1371/journal.pone.0124735	http://dx.doi.org/10.1371/journal.pone.0124735			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CG1EX	25885090	gold, Green Submitted, Green Published			2023-01-03	WOS:000353017000143
J	Lu, HB; Zheng, C; Wang, ZW; Chen, C; Chen, HB; Hu, JZ				Lu, Hongbin; Zheng, Cheng; Wang, Zhanwen; Chen, Can; Chen, Huabin; Hu, Jianzhong			Effects of Low-Intensity Pulsed Ultrasound on New Trabecular Bone during Bone-Tendon Junction Healing in a Rabbit Model: A Synchrotron Radiation Micro-CT Study	PLOS ONE			English	Article							FEMUR FRACTURE MODEL; PARTIAL PATELLECTOMY; MICROCOMPUTED TOMOGRAPHY; DISTRACTION OSTEOGENESIS; COMPUTED-TOMOGRAPHY; PATELLAR TENDON; RAT MODEL; MU-CT; REPAIR; OSTEOPOROSIS	This study was designed to evaluate the effects of low-intensity pulsed ultrasound on bone regeneration during the bone-tendon junction healing process and to explore the application of synchrotron radiation micro computed tomography in three dimensional visualization of the bone-tendon junction to evaluate the microarchitecture of new trabecular bone. Twenty four mature New Zealand rabbits underwent partial patellectomy to establish a bone-tendon junction injury model at the patella-patellar tendon complex. Animals were then divided into low-intensity pulsed ultrasound treatment (20 min/day, 7 times/week) and placebo control groups, and were euthanized at week 8 and 16 postoperatively (n = 6 for each group and time point). The patella-patellar tendon specimens were harvested for radiographic, histological and synchrotron radiation micro computed tomography detection. The area of the newly formed bone in the ultrasound group was significantly greater than that of control group at postoperative week 8 and 16. The high resolution three dimensional visualization images of the bone-tendon junction were acquired by synchrotron radiation micro computed tomography. Low-intensity pulsed ultrasound treatment promoted dense and irregular woven bone formation at week 8 with greater bone volume fraction, number and thickness of new trabecular bone but with lower separation. At week 16, ultrasound group specimens contained mature lamellar bone with higher bone volume fraction and thicker trabeculae than that of control group; however, there was no significant difference in separation and number of the new trabecular bone. This study confirms that low-intensity pulsed ultrasound treatment is able to promot bone formation and remodeling of new trabecular bone during the bone-tendon junction healing process in a rabbit model, and the synchrotron radiation micro computed tomography could be applied for three dimensional visualization to quantitatively evaluate the microarchitecture of new bone in bone-tendon junction.	[Lu, Hongbin; Zheng, Cheng; Wang, Zhanwen; Chen, Can; Chen, Huabin] Cent S Univ, Xiangya Hosp, Dept Sports Med, Res Ctr Sports Med, Changsha, Hunan, Peoples R China; [Hu, Jianzhong] Cent S Univ, Xiangya Hosp, Dept Spine Surg, Res Ctr Sports Med, Changsha, Hunan, Peoples R China	Central South University; Central South University	Hu, JZ (corresponding author), Cent S Univ, Xiangya Hosp, Dept Spine Surg, Res Ctr Sports Med, Changsha, Hunan, Peoples R China.	jianzhonghu@hotmail.com	Zheng, Cheng/AIA-7877-2022	Zheng, Cheng/0000-0003-1726-0258	National Natural Science Foundation of China [81171699, 84172072]; Specialized Research Fund for the Doctoral Program of Higher Education of China [20110162110068]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Specialized Research Fund for the Doctoral Program of Higher Education of China(Specialized Research Fund for the Doctoral Program of Higher Education (SRFDP))	This work was supported by the National Natural Science Foundation of China (No. 81171699 and No. 84172072) and Specialized Research Fund for the Doctoral Program of Higher Education of China (No. 20110162110068). HL received the funding. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Angle SR, 2011, ULTRASONICS, V51, P281, DOI 10.1016/j.ultras.2010.09.004; Bachl N, 2008, CLIN SPORT MED, V27, P87, DOI 10.1016/j.csm.2007.10.006; Benjamin M, 1998, J ANAT, V193, P481, DOI 10.1046/j.1469-7580.1998.19340481.x; Bonse U, 1996, PROG BIOPHYS MOL BIO, V65, P133, DOI 10.1016/S0079-6107(96)00011-9; Chappard C, 2006, OSTEOARTHR CARTILAGE, V14, P215, DOI 10.1016/j.joca.2005.09.008; Chappard C, 2006, MED PHYS, V33, P3568, DOI 10.1118/1.2256069; Chappard D, 2005, J BONE MINER RES, V20, P1177, DOI 10.1359/JBMR.050205; Chen RC, 2012, J SYNCHROTRON RADIAT, V19, P836, DOI 10.1107/S0909049512029731; Chen SH, 2014, J MED BIOL ENG, V34, P197, DOI 10.5405/jmbe.1346; Cheung EV, 2010, CLIN ORTHOP RELAT R, V468, P1476, DOI 10.1007/s11999-010-1323-7; Fazzalari NL, 2011, OSTEOPOROSIS INT, V22, P2003, DOI 10.1007/s00198-011-1611-4; Gerstenfeld LC, 2003, J CELL BIOCHEM, V88, P873, DOI 10.1002/jcb.10435; Griffin L Y, 2000, J Am Acad Orthop Surg, V8, P141; Hess Gregory William, 2010, Foot Ankle Spec, V3, P29, DOI 10.1177/1938640009355191; Hung L K, 1993, J Orthop Trauma, V7, P252, DOI 10.1097/00005131-199306000-00010; Ito M, 2003, J BONE MINER METAB, V21, P287, DOI 10.1007/s00774-003-0422-x; Kalfas I H, 2001, Neurosurg Focus, V10, pE1; Katano M, 2011, EXP ANIM TOKYO, V60, P385, DOI 10.1538/expanim.60.385; Kinney JH, 2000, J BONE MINER RES, V15, P1981, DOI 10.1359/jbmr.2000.15.10.1981; Kuhn G, 2007, HOMO, V58, P97, DOI 10.1016/j.jchb.2006.11.002; Larrue A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021297; Leung KS, 2002, CLIN BIOMECH, V17, P594, DOI 10.1016/S0268-0033(02)00075-X; Li J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0111939; Lu H, 2008, ULTRASOUND MED BIOL, V34, P1248, DOI 10.1016/j.ultrasmedbio.2008.01.009; Lu H, 2008, CLIN J SPORT MED, V18, P62, DOI 10.1097/JSM.0b013e31815c24ba; Lu HB, 2006, AM J SPORT MED, V34, P1287, DOI 10.1177/0363546506286788; Lu HB, 2011, J ORTHOP RES, V29, P672, DOI 10.1002/jor.21292; Lui PPY, 2010, J ORTHOP SURG RES, V5, DOI 10.1186/1749-799X-5-59; MARDER RA, 1993, J BONE JOINT SURG AM, V75A, P35, DOI 10.2106/00004623-199301000-00006; Nogueira LP, 2010, MICRON, V41, P990, DOI 10.1016/j.micron.2010.06.013; Nolte PA, 2001, J TRAUMA, V51, P693, DOI 10.1097/00005373-200110000-00012; Okazaki N, 2014, BONE, V64, P82, DOI 10.1016/j.bone.2014.03.039; Qin L, 1999, MED SCI SPORT EXER, V31, P502, DOI 10.1097/00005768-199904000-00002; Qin L, 2006, ULTRASOUND MED BIOL, V32, P1905, DOI 10.1016/j.ultrasmedbio.2006.06.028; RODEO SA, 1993, J BONE JOINT SURG AM, V75A, P1795, DOI 10.2106/00004623-199312000-00009; Salem KH, 2014, INT ORTHOP, V38, P1477, DOI 10.1007/s00264-013-2254-1; Salome M, 1999, MED PHYS, V26, P2194, DOI 10.1118/1.598736; SALTZMAN CL, 1990, J BONE JOINT SURG AM, V72A, P1279, DOI 10.2106/00004623-199072090-00001; Schindeler A, 2008, SEMIN CELL DEV BIOL, V19, P459, DOI 10.1016/j.semcdb.2008.07.004; Schofer M. D., 2010, BIOMEDICAL CENTRAL M, V11, P229, DOI DOI 10.1186/1471-2474-11-229; Sone T, 2004, BONE, V35, P432, DOI 10.1016/j.bone.2004.05.011; Thurner PJ, 2006, BONE, V39, P289, DOI 10.1016/j.bone.2006.01.147; Waseem Z, 2010, PM&R, V2, P159, DOI 10.1016/j.pmrj.2009.11.008; Wu SL, 2009, PATHOBIOLOGY, V76, P99, DOI 10.1159/000209387; Xie LK, 2011, INT J ORAL MAX SURG, V40, P730, DOI 10.1016/j.ijom.2011.03.016; Yang KH, 1996, J ORTHOP RES, V14, P802, DOI 10.1002/jor.1100140518; Zehbe R, 2012, MICRON, V43, P1060, DOI 10.1016/j.micron.2012.05.001; Zuluaga MA, 2014, PHYS MED BIOL, V59, P2155, DOI 10.1088/0031-9155/59/9/2155	48	19	20	4	16	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 15	2015	10	4							e0124724	10.1371/journal.pone.0124724	http://dx.doi.org/10.1371/journal.pone.0124724			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CG1EL	25874957	Green Published, gold, Green Submitted			2023-01-03	WOS:000353015800150
J	Wilhelm-Buchstab, T; Buchstab, BM; Leitzen, C; Garbe, S; Mudder, T; Oberste-Beulmann, S; Sprinkart, AM; Simon, B; Nelles, M; Block, W; Schoroth, F; Schild, HH; Schuller, H				Wilhelm-Buchstab, Timo; Buchstab, Barbara Myrthe; Leitzen, Christina; Garbe, Stephan; Muedder, Thomas; Oberste-Beulmann, Susanne; Sprinkart, Alois Martin; Simon, Birgit; Nelles, Michael; Block, Wolfgang; Schoroth, Felix; Schild, Hans Heinz; Schueller, Heinrich			Extraretinal Induced Visual Sensations during IMRT of the Brain	PLOS ONE			English	Article							IONIZING-RADIATION; RAY; ASTRONAUTS; PHOSPHENE; ORBIT	Background We observed visual sensations (VSs) in patients undergoing intensity modulated radiotherapy (IMRT) of the brain without the beam passing through ocular structures. We analyzed this phenomenon especially with regards to reproducibility, and origin. Methods and Findings Analyzed were ten consecutive patients (aged 41-71 years) with glioblastoma multiforme who received pulsed IMRT (total dose 60Gy) with helical tomotherapy (TT). A megavolt-CT (MVCT) was performed daily before treatment. VSs were reported and recorded using a triggered event recorder. The frequency of VSs was calculated and VSs were correlated with beam direction and couch position. Subjective patient perception was plotted on an 8x8 visual field (VF) matrix. Distance to the orbital roof (OR) from the first beam causing a VS was calculated from the Dicom radiation therapy data and MVCT data. During 175 treatment sessions (average 17.5 per patient) 5959 VSs were recorded and analyzed. VSs occurred only during the treatment session not during the MVCTs. Plotting events over time revealed patient-specific patterns. The average cranio-caudad extension of VS-inducing area was 63.4mm (range 43.24-92.1mm). The maximum distance between the first VS and the OR was 56.1mm so that direct interaction with the retina is unlikely. Data on subjective visual perception showed that VSs occurred mainly in the upper right and left quadrants of the VF. Within the visual pathways the highest probability for origin of VSs was seen in the optic chiasm and the optic tract (22%). Conclusions There is clear evidence that interaction of photon irradiation with neuronal structures distant from the eye can lead to VSs.	[Wilhelm-Buchstab, Timo; Buchstab, Barbara Myrthe; Leitzen, Christina; Garbe, Stephan; Muedder, Thomas; Oberste-Beulmann, Susanne; Sprinkart, Alois Martin; Simon, Birgit; Nelles, Michael; Block, Wolfgang; Schoroth, Felix; Schild, Hans Heinz; Schueller, Heinrich] Univ Bonn, Dept Radiol, Radiooncol, D-53105 Bonn, Germany	University of Bonn	Wilhelm-Buchstab, T (corresponding author), Univ Bonn, Dept Radiol, Radiooncol, Sigmund Freud Str 25, D-53105 Bonn, Germany.	Timo.Buchstab@ukb.uni-bonn.de	Wilhelm-Buchstab, Timo/AAE-3112-2020; Sprinkart, Alois Martin/T-5033-2019	Sprinkart, Alois Martin/0000-0002-1435-9562				BACHOFER CS, 1963, RADIAT RES, V18, P246, DOI 10.2307/3571445; Bokkon I, 2008, BIOSYSTEMS, V92, P168, DOI 10.1016/j.biosystems.2008.02.002; Brandes G, 1897, WIEDEMANNS ANN PHYS, V60, P478; Chapman P, 1972, P NAT S NAT MANM RAD, P1102; CHARMAN WN, 1971, NATURE, V232, P574, DOI 10.1038/232574a0; CHARMAN WN, 1971, NATURE, V230, P522, DOI 10.1038/230522a0; Cherenkov P, 1964, NOBEL LECT PHYS 1942, V3, P426; Chiang CS, 1991, BRAIN RES, V566, P256; Clatworthy AL, 1999, NEUROSCI LETT, V268, P45, DOI 10.1016/S0304-3940(99)00069-5; DARCY FJ, 1962, NATURE, V196, P1013, DOI 10.1038/1961013a0; De Vries KD, 2011, REV LETT, V2011; Edison TA, 1896, ELECTRON ENG, V22, P520; Fazzio GG, 1970, NATURE, V228, P260; Fuglesang C, 2006, AVIAT SPACE ENVIR MD, V77, P449; GANGLOFF H., 1965, ADVANCE BIOL MED PHYS, V10, P1; Jenrow KA, 2001, EXP NEUROL, V169, P96, DOI 10.1006/exnr.2000.7616; Jeraj R, 2004, MED PHYS, V31, P396, DOI 10.1118/1.1639148; Kramer M, 2012, GSI BIOPHYS; Lipetz J, 1955, BR J OPHTALMOL, V39, P577; MCNULTY PJ, 1972, SCIENCE, V178, P160, DOI 10.1126/science.178.4057.160; Newman F, 2008, MED PHYS, V35, P77, DOI 10.1118/1.2815358; PINSKY LS, 1974, SCIENCE, V183, P957, DOI 10.1126/science.183.4128.957; Sannita WG, 2006, VISION RES, V46, P2159, DOI 10.1016/j.visres.2005.12.002; Schardt D, 2013, BRAIN STIMUL, V6, P416, DOI 10.1016/j.brs.2012.08.003; SCHOBER H, 1964, VISION RES, V4, P251, DOI 10.1016/0042-6989(64)90007-0; STEIDLEY KD, 1990, VISION RES, V30, P1139, DOI 10.1016/0042-6989(90)90171-G; STEIDLEY KD, 1989, INT J RADIAT ONCOL, V17, P685, DOI 10.1016/0360-3016(89)90125-9; TOBIAS CA, 1971, NATURE, V230, P596, DOI 10.1038/230596a0; Tobias CA, 1970, OBSERVATIONS HUMAN S, P16; Wilhelm-Buchstab T, 2013, 30 JAHR OST GES RAD, V65	30	6	7	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 15	2015	10	4							e0123440	10.1371/journal.pone.0123440	http://dx.doi.org/10.1371/journal.pone.0123440			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CG1EL	25875609	Green Submitted, Green Published, gold			2023-01-03	WOS:000353015800099
J	Ngan, LTM; Jang, MJ; Kwon, MJ; Ahn, YJ				Luong Thi My Ngan; Jang, Myeong Jin; Kwon, Min Jung; Ahn, Young Joon			Antiviral Activity and Possible Mechanism of Action of Constituents Identified in Paeonia lactiflora Root toward Human Rhinoviruses	PLOS ONE			English	Article							RESPIRATORY-INFECTIONS; RECEPTOR; RIBAVIRIN; 1,2,3,4,6-PENTA-O-GALLOYL-BETA-D-GLUCOSE; EXPRESSION; INHIBITORS; DISCOVERY; AGENTS; ICAM-1; ALPHA	Human rhinoviruses (HRVs) are responsible for more than half of all cases of the common cold and cost billions of USD annually in medical visits and missed school and work. An assessment was made of the antiviral activities and mechanisms of action of paeonol (PA) and 1,2,3,4,6-penta-O-galloyl-beta-D-glucopyranose (PGG) from Paeonia lactiflora root toward HRV-2 and HRV-4 in MRC5 cells using a tetrazolium method and real-time quantitative reverse transcription polymerase chain reaction and enzyme-linked immunosorbent assay. Results were compared with those of a reference control ribavirin. Based on 50% inhibitory concentration values, PGG was 13.4 and 18.0 times more active toward HRV-2 (17.89 mu M) and HRV-4 (17.33 mu M) in MRC5 cells, respectively, than ribavirin. The constituents had relatively high selective index values (3.3->8.5). The 100 mu g/mL PA and 20 mu g/mL PGG did not interact with the HRV-4 particles. These constituents inhibited HRV-4 infection only when they were added during the virus inoculation (0 h), the adsorption period of HRVs, but not after 1 h or later. Moreover, the RNA replication levels of HRVs were remarkably reduced in the MRC5 cultures treated with these constituents. These findings suggest that PGG and PA may block or reduce the entry of the viruses into the cells to protect the cells from the virus destruction and abate virus replication, which may play an important role in interfering with expressions of rhinovirus receptors (intercellular adhesion molecule-1 and low-density lipoprotein receptor), inflammatory cytokines (interleukin (IL)-6, IL-8, tumor necrosis factor, interferon beta, and IL-1 beta), and Toll-like receptor, which resulted in diminishing symptoms induced by HRV. Global efforts to reduce the level of synthetic drugs justify further studies on P. lactiflora root-derived materials as potential anti-HRV products or lead molecules for the prevention or treatment of HRV.	[Luong Thi My Ngan] Vietnam Natl Univ, Ho Chi Minh City Univ Sci, Fac Biol, Dept Plant Biotechnol & Biotransformat, Ho Chi Minh, Vietnam; [Jang, Myeong Jin; Kwon, Min Jung; Ahn, Young Joon] Seoul Natl Univ, Dept Agr Biotechnol, Biomodulat Major, Seoul, South Korea	Vietnam National University Hochiminh City; Seoul National University (SNU)	Ahn, YJ (corresponding author), Seoul Natl Univ, Dept Agr Biotechnol, Biomodulat Major, Seoul, South Korea.	yjahn@snu.ac.kr		Luong, Ngan/0000-0003-0500-007X	Brain Korea 21 PLUS through the National Research Foundation of Korea - Ministry of Education of the Korean Government	Brain Korea 21 PLUS through the National Research Foundation of Korea - Ministry of Education of the Korean Government	Funding: This work was carried out with the support by the Brain Korea 21 PLUS through the National Research Foundation of Korea funded by the Ministry of Education of the Korean Government to Y.J. Ahn. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ANDRIES K, 1990, J VIROL, V64, P1117, DOI 10.1128/JVI.64.3.1117-1123.1990; Bochkov YA, 2010, MUCOSAL IMMUNOL, V3, P69, DOI 10.1038/mi.2009.109; Chiang LC, 2003, J ANTIMICROB CHEMOTH, V52, P194, DOI 10.1093/jac/dkg291; Choi HJ, 2010, LETT APPL MICROBIOL, V51, P1, DOI 10.1111/j.1472-765X.2010.02845.x; Choi HJ, 2009, PHYTOMEDICINE, V16, P35, DOI 10.1016/j.phymed.2008.10.012; Choi HJ, 2010, PHYTOTHER RES, V24, P1292, DOI 10.1002/ptr.3101; Choi HJ, 2009, ANTIVIR RES, V81, P77, DOI 10.1016/j.antiviral.2008.10.002; Couch RB, 2006, ELS             0424, DOI [10.1038/npg.els.0004240, DOI 10.1038/NPG.ELS.0004240]; DETOMMASI N, 1992, J NAT PROD, V55, P1067, DOI 10.1021/np50086a006; Garozzo Adriana, 2007, Antiviral Chemistry & Chemotherapy, V18, P277; Gonzales R, 2001, CLIN INFECT DIS, V33, P757, DOI 10.1086/322627; Graci JD, 2006, REV MED VIROL, V16, P37, DOI 10.1002/rmv.483; GREVE JM, 1989, CELL, V56, P839, DOI 10.1016/0092-8674(89)90688-0; Hewson CA, 2005, J VIROL, V79, P12273, DOI 10.1128/JVI.79.19.12273-12279.2005; HOFER F, 1994, P NATL ACAD SCI USA, V91, P1839, DOI 10.1073/pnas.91.5.1839; Ibarra KD, 2009, J VIROL, V83, P4538, DOI 10.1128/JVI.02280-08; ISHITSUKA H, 1982, ANTIMICROB AGENTS CH, V22, P611, DOI 10.1128/AAC.22.4.611; Jacobs SE, 2013, CLIN MICROBIOL REV, V26, P135, DOI 10.1128/CMR.00077-12; Jang YJ, 2009, ANTIVIR RES, V81, P226, DOI 10.1016/j.antiviral.2008.12.001; Jarvis SM, 1998, BRIT J PHARMACOL, V123, P1587, DOI 10.1038/sj.bjp.0701775; Jassim SAA, 2003, J APPL MICROBIOL, V95, P412, DOI 10.1046/j.1365-2672.2003.02026.x; Jiangsu New Medical College, 1977, DICT CHIN TRAD MED, V1; Kitazato K, 2007, DRUG DISCOV THER, V1, P14; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee SJ, 2006, BIOL PHARM BULL, V29, P2131, DOI 10.1248/bpb.29.2131; Liu A.-L., 2012, DIETARY PHYTOCHEMICA, V978, P93, DOI [10.1007/978-94-007-3926-0_3, DOI 10.1007/978-94-007-3926-0_3]; Liu G, 2011, ARCH VIROL, V156, P1359, DOI 10.1007/s00705-011-0989-9; Luong TMN, 2012, J AGR FOOD CHEM, V60, P9062, DOI 10.1021/jf3035034; Morgan D M, 1998, Methods Mol Biol, V79, P179; Newcomb DC, 2007, AM J PHYSIOL-LUNG C, V293, pL1021, DOI 10.1152/ajplung.00060.2007; Nizamutdinova IT, 2007, INT IMMUNOPHARMACOL, V7, P343, DOI 10.1016/j.intimp.2006.11.004; Papi A, 1999, J BIOL CHEM, V274, P9707, DOI 10.1074/jbc.274.14.9707; Pitkaranta A, 1997, J CLIN MICROBIOL, V35, P1791; Pitkaranta A, 1998, PEDIATRICS, V102, P291, DOI 10.1542/peds.102.2.291; Pourianfar HR, 2012, INDIAN J VIROL, V23, P303, DOI 10.1007/s13337-012-0105-0; Raskin I, 2002, TRENDS BIOTECHNOL, V20, P522, DOI 10.1016/S0167-7799(02)02080-2; Roelen CAM, 2011, WORK, V39, P305, DOI 10.3233/WOR-2011-1178; Rollinger JM, 2008, J MED CHEM, V51, P842, DOI 10.1021/jm701494b; Rollinger JM, 2011, MED RES REV, V31, P42, DOI 10.1002/med.20176; Rollinger JM, 2009, PLANTA MED, V75, P195, DOI 10.1055/s-0028-1088397; SAKAR MK, 1993, PHYTOCHEMISTRY, V33, P171, DOI 10.1016/0031-9422(93)85416-O; Savolainen Carita, 2003, Paediatr Respir Rev, V4, P91, DOI 10.1016/S1526-0542(03)00030-7; Spasova M, 2008, BIOORGAN MED CHEM, V16, P7457, DOI 10.1016/j.bmc.2008.06.010; Suzuki T, 2002, AM J RESP CRIT CARE, V165, P1113, DOI 10.1164/ajrccm.165.8.2103094; Tang W., 1992, CHINESE DRUGS PLANT; TSUCHIYA Y, 1985, CHEM PHARM BULL, V33, P3881, DOI 10.1248/cpb.33.3881; Turner RB, 1998, CLIN INFECT DIS, V26, P840, DOI 10.1086/513922; Turner RB, 2001, ANTIVIR RES, V49, P1, DOI 10.1016/S0166-3542(00)00135-2; UNCAPHER CR, 1991, VIROLOGY, V180, P814, DOI 10.1016/0042-6822(91)90098-V; VANHOOF L, 1984, PLANTA MED, V50, P513, DOI 10.1055/s-2007-969786; VLIETINCK AJ, 1991, J ETHNOPHARMACOL, V32, P141, DOI 10.1016/0378-8741(91)90112-Q; Waterer G, 2009, RESPIROLOGY, V14, P651, DOI 10.1111/j.1440-1843.2009.01554.x; Whiteman SC, 2008, J INFLAMM-LOND, V5, DOI 10.1186/1476-9255-5-8; Williams J E, 2001, Altern Med Rev, V6, P567; Yasuda H, 2006, EUR RESPIR J, V28, P51, DOI 10.1183/09031936.06.00058505; Zhao WH, 2007, J CHROMATOGR B, V850, P523, DOI 10.1016/j.jchromb.2006.11.002	56	15	15	0	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 10	2015	10	4							e0121629	10.1371/journal.pone.0121629	http://dx.doi.org/10.1371/journal.pone.0121629			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CF5II	25860871	gold, Green Submitted, Green Published			2023-01-03	WOS:000352590300028
J	Goldberg, MS				Goldberg, Michael S.			Immunoengineering: How Nanotechnology Can Enhance Cancer Immunotherapy	CELL			English	Review							T-CELLS; TARGETING NANOPARTICLES; DENDRITIC CELLS; TUMOR-CELLS; IN-VIVO	Although cancer immunotherapy can lead to durable outcomes, the percentage of patients who respond to this disruptive approach remains modest to date. Encouragingly, nanotechnology can enhance the efficacy of immunostimulatory small molecules and biologics by altering their co-localization, biodistribution, and release kinetics.	Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Boston, MA 02215 USA	Harvard University; Dana-Farber Cancer Institute	Goldberg, MS (corresponding author), Dana Farber Canc Inst, Dept Canc Immunol & AIDS, 450 Brookline Ave, Boston, MA 02215 USA.	michael_goldberg1@dfci.harvard.edu			Cancer Research Institute; Melanoma Research Alliance; Ovarian Cancer Research Fund	Cancer Research Institute; Melanoma Research Alliance; Ovarian Cancer Research Fund	The author thanks the Cancer Research Institute, Melanoma Research Alliance, and Ovarian Cancer Research Fund for their support and apologizes to those investigators whose work could not be referenced because of space limitations.	Ali OA, 2009, SCI TRANSL MED, V1, DOI 10.1126/scitranslmed.3000359; Audran R, 2003, VACCINE, V21, P1250, DOI 10.1016/S0264-410X(02)00521-2; Chow EKH, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005872; Cools-Lartigue J, 2013, J CLIN INVEST, V123, P3446, DOI 10.1172/JCI67484; Cruz LJ, 2012, METHOD ENZYMOL, V509, P143, DOI 10.1016/B978-0-12-391858-1.00008-3; Fridman WH, 2012, NAT REV CANCER, V12, P298, DOI 10.1038/nrc3245; Irvine DJ, 2013, NAT MATER, V12, P978, DOI [10.1038/NMAT3775, 10.1038/nmat3775]; Kanapathipillai M, 2012, NANO LETT, V12, P3213, DOI 10.1021/nl301206p; Kim J, 2015, NAT BIOTECHNOL, V33, P64, DOI 10.1038/nbt.3071; Kwong B, 2013, CANCER RES, V73, P1547, DOI 10.1158/0008-5472.CAN-12-3343; Kwong B, 2011, BIOMATERIALS, V32, P5134, DOI 10.1016/j.biomaterials.2011.03.067; Marabelle A, 2013, J CLIN INVEST, V123, P2447, DOI 10.1172/JCI64859; Maude SL, 2014, NEW ENGL J MED, V371, P1507, DOI 10.1056/NEJMoa1407222; Salmon H, 2012, ONCOIMMUNOLOGY, V1, P992, DOI 10.4161/onci.20239; Stephan MT, 2010, NAT MED, V16, P1035, DOI 10.1038/nm.2198; Stephan SB, 2015, NAT BIOTECHNOL, V33, P97, DOI 10.1038/nbt.3104; Suematsu S, 2004, NAT BIOTECHNOL, V22, P1539, DOI 10.1038/nbt1039; Sunshine JC, 2014, BIOMATERIALS, V35, P269, DOI 10.1016/j.biomaterials.2013.09.050; Swartz MA, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003763; Swartz MA, 2012, NAT REV CANCER, V12, P210, DOI 10.1038/nrc3186; Topalian SL, 2011, J CLIN ONCOL, V29, P4828, DOI 10.1200/JCO.2011.38.0899; Ueno H, 2011, SEMIN IMMUNOL, V23, P21, DOI 10.1016/j.smim.2011.01.004; Zheng Y, 2013, J CONTROL RELEASE, V172, P426, DOI 10.1016/j.jconrel.2013.05.037	23	191	196	5	161	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 9	2015	161	2					201	204		10.1016/j.cell.2015.03.037	http://dx.doi.org/10.1016/j.cell.2015.03.037			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	CF7AL	25860604	Bronze			2023-01-03	WOS:000352708300014
J	Stanifer, JW; Patel, UD; Karia, F; Thielman, N; Maro, V; Shimbi, D; Kilaweh, H; Lazaro, M; Matemu, O; Omolo, J; Boyd, D				Stanifer, John W.; Patel, Uptal D.; Karia, Francis; Thielman, Nathan; Maro, Venance; Shimbi, Dionis; Kilaweh, Humphrey; Lazaro, Matayo; Matemu, Oliver; Omolo, Justin; Boyd, David		Comprehensive Kidney Dis Assessmen	The Determinants of Traditional Medicine Use in Northern Tanzania: A Mixed-Methods Study	PLOS ONE			English	Article							SUB-SAHARAN AFRICA; HEALTH-CARE; HEALERS; COMPLEMENTARY; HIV/AIDS; BEHAVIOR; DISEASE	Introduction Traditional medicines are an important part of healthcare in sub-Saharan Africa, and building successful disease treatment programs that are sensitive to traditional medicine practices will require an understanding of their current use and roles, including from a biomedical perspective. Therefore, we conducted a mixed-method study in Northern Tanzania in order to characterize the extent of and reasons for the use of traditional medicines among the general population so that we can better inform public health efforts in the region. Methods Between December 2013 and June 2014 in Kilimanjaro, Tanzania, we conducted 5 focus group discussions and 27 in-depth interviews of key informants. The data from these sessions were analyzed using an inductive framework method with cultural insider-outsider coding. From these results, we developed a structured survey designed to test different aspects of traditional medicine use and administered it to a random sample of 655 adults from the community. The results were triangulated to explore converging and diverging themes. Results Most structured survey participants (68%) reported knowing someone who frequently used traditional medicines, and the majority (56%) reported using them themselves in the previous year. The most common uses were for symptomatic ailments (42%), chronic diseases (15%), reproductive problems (11%), and malaria/febrile illnesses (11%). We identified five major determinants for traditional medicine use in Northern Tanzania: biomedical healthcare delivery, credibility of traditional practices, strong cultural identities, individual health status, and disease understanding. Conclusions In order to better formulate effective local disease management programs that are sensitive to TM practices, we described the determinants of TM use. Additionally, we found TM use to be high in Northern Tanzania and that its use is not limited to lower-income areas or rural settings. After symptomatic ailments, chronic diseases were reported as the most common reason for TM use which may be particularly important in Northern Tanzania where non-communicable diseases are a rapidly growing burden.	[Stanifer, John W.; Patel, Uptal D.; Thielman, Nathan] Duke Univ, Dept Med, Durham, NC 27708 USA; [Stanifer, John W.; Thielman, Nathan; Boyd, David] Duke Univ, Duke Global Hlth Inst, Durham, NC USA; [Patel, Uptal D.] Duke Univ, Duke Clin Res Inst, Durham, NC USA; [Karia, Francis; Maro, Venance; Shimbi, Dionis; Kilaweh, Humphrey; Lazaro, Matayo; Matemu, Oliver] Kilimanjaro Christian Med Coll, Moshi, Tanzania; [Omolo, Justin] Tanga AIDS Working Grp, Tanga, Tanzania	Duke University; Duke University; Duke University	Stanifer, JW (corresponding author), Duke Univ, Dept Med, Durham, NC 27708 USA.	john.stanifer@duke.edu	Thielman, Nathan/R-5142-2019	Thielman, Nathan/0000-0001-8152-2879	NIH - Fogarty International Center [R25 TW009337]; National Institute of Mental Health; International Society of Nephrology (ISN) Global Outreach Committee; Masters of Science research stipend - Duke Global Health Institute; FOGARTY INTERNATIONAL CENTER [R25TW009337] Funding Source: NIH RePORTER	NIH - Fogarty International Center(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); National Institute of Mental Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); International Society of Nephrology (ISN) Global Outreach Committee; Masters of Science research stipend - Duke Global Health Institute; FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC))	This project was supported by an NIH Research Training Grant (#R25 TW009337) funded by the Fogarty International Center and the National Institute of Mental Health; a Research and Prevention Grant funded by the International Society of Nephrology (ISN) Global Outreach Committee; and a Masters of Science research stipend funded by the Duke Global Health Institute.	Abbo C, 2011, GLOBAL HEALTH ACTION, V4, DOI 10.3402/gha.v4i0.7117; Abdullahi, 2011, AFR J TRADIT COMPLEM, V8, P115, DOI 10.4314/ajtcam.v8i5S.5; Abubakar A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071998; Aderibigbe S A, 2013, J Prev Med Hyg, V54, P35; Aikins AD, 2005, BMJ-BRIT MED J, V331, P737, DOI 10.1136/bmj.331.7519.737; Babb Dale A, 2007, Psychol Health Med, V12, P314, DOI 10.1080/13548500600621511; Bodeker G, 2006, J ALTERN COMPLEM MED, V12, P563, DOI 10.1089/acm.2006.12.563; Cooper M, 2012, ETHNIC HEALTH, V17, P597, DOI 10.1080/13557858.2012.740003; de-Graft Aikins Ama, 2014, BMC Public Health, V14 Suppl 2, pS3, DOI 10.1186/1471-2458-14-S2-S3; Dillip A, 2012, BMC HEALTH SERV RES, V12, DOI 10.1186/1472-6963-12-113; Ensink K., 1999, TRANSCULT PSYCHIATRY, V36, P23, DOI [DOI 10.1177/13634615990, 10.1177/136346159903600102, DOI 10.1177/136346159903600102]; FARRAND D, 1984, S AFR MED J, V66, P779; Gale NK, 2013, BMC MED RES METHODOL, V13, DOI 10.1186/1471-2288-13-117; Gearhart R, 2014, J TRANSCULT NURS, V25, P218, DOI 10.1177/1043659613515713; Gessler MC, 1995, J ETHNOPHARMACOL, V48, P145, DOI 10.1016/0378-8741(95)01295-O; Gyasi RM, 2013, AM INT J CONT RES, V3, P1; Hendriks ME, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032638; Joint United Nations Programme on HIV/ AIDS, 2002, ANC REM NEW DIS INV; Kayombo EJ, 2012, J ETHNOBIOL ETHNOMED, V8, DOI 10.1186/1746-4269-8-5; Krueger RA, 2009, FOCUS GROUPS PRACTIC; Langwick SA, 2008, AM ETHNOL, V35, P428, DOI 10.1111/j.1548-1425.2008.00044.x; Liwa AC, 2014, CURR HYPERTENS REP, V16, DOI 10.1007/s11906-014-0437-9; Malangu N, 2007, AFR J TRADIT COMPLEM, V4, P273; Mbanya JCN, 2010, LANCET, V375, P2254, DOI 10.1016/S0140-6736(10)60550-8; Mhame PP, 2010, WHO CLIN PRACT AFR T; Mushi D, 2011, EPILEPSY BEHAV, V20, P338, DOI 10.1016/j.yebeh.2010.11.016; Nyamongo IK, 2002, SOC SCI MED, V54, P377, DOI 10.1016/S0277-9536(01)00036-3; Peltzer K, 2006, Curationis, V29, P54; Peltzer K, 2008, AFR J TRADIT COMPLEM, V5, P370; Peltzer K, 2008, BMC PUBLIC HEALTH, V8, DOI 10.1186/1471-2458-8-255; Semenya SS, 2014, J ETHNOBIOL ETHNOMED, V10, DOI 10.1186/1746-4269-10-4; Sorsdahl K, 2009, J NERV MENT DIS, V197, P434, DOI 10.1097/NMD.0b013e3181a61dbc; Stangeland T, 2008, J ETHNOPHARMACOL, V117, P290, DOI 10.1016/j.jep.2008.02.008; Stanifer JW, 2014, LANCET GLOB HEALTH, V2, pE174, DOI 10.1016/S2214-109X(14)70002-6; Stekelenburg J, 2005, HEALTH POLICY, V71, P67, DOI 10.1016/j.healthpol.2004.05.008; Tabuti JRS, 2003, J ETHNOPHARMACOL, V85, P119, DOI 10.1016/S0378-8741(02)00378-1; Taylor KD, 2012, ETHNIC HEALTH, V17, P615, DOI 10.1080/13557858.2013.771151; The United Republic of Tanzania, 2013, POPULATION DISTRIBUT; Ulin PR, 2005, QUALITATIVE RES METH; United Republic of Tanzanian Ministry of Health, 2000, NAT BIRTH ATT IMPL P; World Heath Organisation, 2013, TRAD MED STRAT 2014; Wreford J, 2008, SOCIAL DYNAMICS, V31, P55	42	49	49	0	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 7	2015	10	4							e0122638	10.1371/journal.pone.0122638	http://dx.doi.org/10.1371/journal.pone.0122638			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	CF3VU	25848762	gold, Green Published, Green Submitted			2023-01-03	WOS:000352477800154
J	Munoz-Hernandez, R; Vallejo-Vaz, AJ; Armengol, AS; Moreno-Luna, R; Caballero-Eraso, C; Macher, HC; Villar, J; Merino, AM; Castell, J; Capote, F; Stiefel, P				Munoz-Hernandez, Rocio; Vallejo-Vaz, Antonio J.; Sanchez Armengol, Angeles; Moreno-Luna, Rafael; Caballero-Eraso, Candela; Macher, Hada C.; Villar, Jose; Merino, Ana M.; Castell, Javier; Capote, Francisco; Stiefel, Pablo			Obstructive Sleep Apnoea Syndrome, Endothelial Function and Markers of Endothelialization. Changes after CPAP	PLOS ONE			English	Article							POSITIVE AIRWAY PRESSURE; V+ APOPTOTIC MICROPARTICLES; CELL-FREE DNA; CIRCULATING MICROPARTICLES; GROWTH-FACTOR; DYSFUNCTION; HYPOPNEA	Study objectives This study tries to assess the endothelial function in vivo using flow-mediated dilatation (FMD) and several biomarkers of endothelium formation/restoration and damage in patients with obstructive sleep apnoea (OSA) syndrome at baseline and after three months with CPAP therapy. Design Observational study, before and after CPAP therapy. Setting and Patients We studied 30 patients with apnoea/hypopnoea index (AHI) > 15/h that were compared with themselves after three months of CPAP therapy. FMD was assessed non-invasively in vivo using the Laser-Doppler flowmetry. Circulating cell-free DNA (cf-DNA) and microparticles (MPs) were measured as markers of endothelial damage and the vascular endothelial growth factor (VEGF) was determined as a marker of endothelial restoration process. Measurements and results After three month with CPAP, FMD significantly increased (1072.26 +/- 483.21 vs. 1604.38 +/- 915.69 PU, p<0.005) cf-DNA and MPs significantly decreased (187.93 +/- 115.81 vs. 121.28 +/- 78.98 pg/ml, p<0.01, and 69.60 +/- 62.60 vs. 39.82 +/- 22.14 U/mu L, p<0.05, respectively) and VEGF levels increased (585.02 +/- 246.06 vs. 641.11 +/- 212.69 pg/ml, p<0.05). These changes were higher in patients with more severe disease. There was a relationship between markers of damage (r = -0.53, p< 0.005) but not between markers of damage and restoration, thus suggesting that both types of markers should be measured together. Conclusions CPAP therapy improves FMD. This improvement may be related to an increase of endothelial restoration process and a decrease of endothelial damage.	[Munoz-Hernandez, Rocio; Vallejo-Vaz, Antonio J.; Caballero-Eraso, Candela; Villar, Jose; Stiefel, Pablo] Univ Seville, CSIC, Hosp Univ Virgen del Rocio, Inst Biomed Sevilla IBiS,Lab Hipertens Arterial &, Seville, Spain; [Sanchez Armengol, Angeles; Caballero-Eraso, Candela; Capote, Francisco] Hosp Virgen del Rocio, Unidad Sueno, Unidad Med Quirurg Enfermedades Resp, Seville, Spain; [Moreno-Luna, Rafael] Hosp Nacl Paraplej, SESCAM, Dept Fisiopatol Vasc, Toledo, Spain; [Macher, Hada C.] Hosp Virgen del Rocio, Serv Bioquim Clin, Seville, Spain; [Villar, Jose; Stiefel, Pablo] Hosp Virgen del Rocio, Unidad Clin Expt Riesgo Vasc UCAMI, Seville, Spain; [Merino, Ana M.] Inst Invest Biomed Bellvitge IDIBELL, Barcelona, Spain; [Castell, Javier] Hosp Virgen del Rocio, UGC Radiol, Seville, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); University of Sevilla; CSIC-JA-USE - Instituto de Biomedicina de Sevilla (IBIS); Virgen del Rocio University Hospital; Virgen del Rocio University Hospital; Hospital Nacional de Paraplejicos; Virgen del Rocio University Hospital; Virgen del Rocio University Hospital; Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Virgen del Rocio University Hospital	Stiefel, P (corresponding author), Univ Seville, CSIC, Hosp Univ Virgen del Rocio, Inst Biomed Sevilla IBiS,Lab Hipertens Arterial &, Seville, Spain.	stiefel@cica.es	MORENO-LUNA, RAFAEL/AFP-3358-2022; IBIS, NEUROINMUNO/O-9306-2015; SANCHEZ ARMENGOL, ANGELES/C-9430-2015; IBIS, SUEÑO/I-2520-2016; Merino, Ana/L-8347-2017; Bonilla Henao, Victoria/F-1467-2015; Caballero Eraso, Candela/F-1455-2015; Vallejo-Vaz, Antonio J./AAT-9301-2021; Eraso, Candelaria Caballero/J-1059-2018; IBIS, DIGESTIVAS/O-1913-2015; IBIS, NEUROBIOLOGIA/O-9922-2015; IBIS, HIPERCOLESTERO/P-3953-2015; Capote, Francisco/E-9954-2015; Stiefel García-Junco, Pablo/GSI-6577-2022	MORENO-LUNA, RAFAEL/0000-0002-9840-5078; Bonilla Henao, Victoria/0000-0002-5440-5199; Vallejo-Vaz, Antonio J./0000-0001-7954-1253; Macher, Hada/0000-0002-8622-1175; Stiefel Garcia-Junco, Pablo Enrique/0000-0002-6668-5466; Caballero-Eraso, Candela/0000-0002-6428-0027	Instituto de Salud Carlos III [PI/0044/07]; Consejeria de Salud, Junta de Andalucia [P09-CTS-4971]	Instituto de Salud Carlos III(Instituto de Salud Carlos IIIEuropean Commission); Consejeria de Salud, Junta de Andalucia(Junta de Andalucia)	This work was supported by two grants: 1) Instituto de Salud Carlos III, PI/0044/07, to Dr. P. Stiefel. 2) Consejeria de Salud, Junta de Andalucia, P09-CTS-4971, to Dra. M. A Sanchez-Armengol. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bernal-Mizrachi L, 2003, AM HEART J, V145, P962, DOI 10.1016/S0002-8703(03)00103-0; Gottlieb DJ, 2010, CIRCULATION, V122, P352, DOI 10.1161/CIRCULATIONAHA.109.901801; Grebe M, 2006, AM J RESP CRIT CARE, V173, P897, DOI 10.1164/rccm.200508-1223OC; Huang PH, 2010, J HYPERTENS, V28, P1655, DOI 10.1097/HJH.0b013e32833a4d0a; Imagawa S, 2001, BLOOD, V98, P1255, DOI 10.1182/blood.V98.4.1255; Ip MSM, 2004, AM J RESP CRIT CARE, V169, P348, DOI 10.1164/rccm.200306-767OC; Kaczmarek E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070559; Kalka C, 2000, CIRC RES, V86, P1198, DOI 10.1161/01.RES.86.12.1198; Kim J, 2011, CHEST, V140, P408, DOI 10.1378/chest.10-2161; Lattimore JL, 2006, THORAX, V61, P491, DOI 10.1136/thx.2004.039164; Lloberes P, 2011, ARCH BRONCONEUMOL, V47, P143, DOI 10.1016/j.arbres.2011.01.001; Mancia G, 2013, J HYPERTENS, V31, P1281, DOI 10.1097/01.hjh.0000431740.32696.cc; Masa JF, 2004, AM J RESP CRIT CARE, V170, P1218, DOI 10.1164/rccm.200312-1787OC; Miranda ML, 2013, AM J HYPERTENS, V26, P1377, DOI 10.1093/ajh/hpt187; Nieto FJ, 2004, AM J RESP CRIT CARE, V169, P354, DOI 10.1164/rccm.200306-756OC; Phillips CL, 2007, J SLEEP RES, V16, P217, DOI 10.1111/j.1365-2869.2007.00589.x; Priou P, 2010, AM J PATHOL, V177, P974, DOI 10.2353/ajpath.2010.091252; Redline S, 2010, AM J RESP CRIT CARE, V182, P269, DOI 10.1164/rccm.200911-1746OC; Stiefel P, 2013, ARCH MED RES, V44, P409, DOI 10.1016/j.arcmed.2013.08.005; Stiefel P, 2012, CORONARY ARTERY DIS, V23, P57, DOI 10.1097/MCA.0b013e32834e4f34; Trzepizur W, 2011, EUR RESPIR J, V37, P1293, DOI 10.1183/09031936.00150010; Trzepizur W, 2009, SLEEP MED, V10, P746, DOI 10.1016/j.sleep.2008.06.013; Tual-Chalot S, 2012, AM J PATHOL, V181, P1473, DOI 10.1016/j.ajpath.2012.06.020; Valipour A, 2004, RESP MED, V98, P1180, DOI 10.1016/j.rmed.2004.04.009; Werner N, 2006, ARTERIOSCL THROM VAS, V26, P112, DOI 10.1161/01.ATV.0000191634.13057.15; Ye LA, 2010, LUNG, V188, P469, DOI 10.1007/s00408-010-9253-4; Yim-Yeh S, 2011, OBESITY, V19, P17, DOI 10.1038/oby.2010.116; Yim-Yeh S, 2010, SLEEP, V33, P1177, DOI 10.1093/sleep/33.9.1177	28	17	20	0	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 27	2015	10	3							e0122091	10.1371/journal.pone.0122091	http://dx.doi.org/10.1371/journal.pone.0122091			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CE8ZT	25815511	gold, Green Published, Green Submitted			2023-01-03	WOS:000352133600144
J	Tseng, YH; Khan, MA				Tseng, Yu-hwei; Khan, Mujibul Alam			Where Do the Poorest Go to Seek Outpatient Care in Bangladesh: Hospitals Run by Government or Microfinance Institutions?	PLOS ONE			English	Article							MICRO-CREDIT PROGRAM; HEALTH-CARE; RURAL BANGLADESH; SERVICES; EXPERIENCE; BARRIERS; BEHAVIOR; ACCESS; WOMEN; DETERMINANTS	Introduction Health programs implemented by microfinance institutions (MFIs) aim to benefit the poor, but whether these services reach the poorest remains uncertain. This study intended to investigate the socioeconomic distribution of patients in hospitals operated by microfinance institutions (i.e. MFI hospitals) in Bangladesh and compare the differences with public hospitals to determine if the programs were consistent with their pro-poor mandate. Methods In this cross-sectional study, we used the convenience sampling method to conduct an interviewer-assisted questionnaire survey among 347 female outpatients, with 170 in public hospitals and 177 in MFI hospitals. Independent variables were patient characteristics categorized into predisposing factors (age, education, marital status, family size), enabling factors (microcredit membership, household income) and need factors (self-rated health, perceived needs for care). We employed Generalized Estimating Equations (GEE) to evaluate how these factors contributed to MFI hospital use. Results Use of MFI hospitals was associated with microcredit membership over 5 years (OR=2.9, p<.01), moderately poor household (OR=4.09, p<.001), non-poor household (OR=7.34, p<.01) and need for preventive care (OR=3.4, p<.01), compared with public hospitals. Combining membership and income, we found microcredit members had a higher tendency towards utilization but membership effect pertained to the non-and moderately-poor. Compared with the group who were non-members and the poorest, microcredit members who were non-poor had the highest likelihood (OR=7.46, p<.001) to visit MFI hospitals, followed by members with moderate income (OR=6.91, p<.001) and then non-members in non-poor households (OR=4.48, p<.01). Those who were members but the poorest had a negative association (OR=0.42), though not significant. Despite a higher utilization of preventive services in MFI hospitals, expenditure there was significantly higher. Conclusion Inequity was more pronounced in MFI hospitals than public ones. MFI hospitals appeared to miss their target population. We suggest that MFIs reorganize health programs toward primary health care to make care equitable and universally accessible. This study holds practical implications for governments, development agencies and microfinance practitioners working at the grassroots level.	[Tseng, Yu-hwei] Natl Taiwan Univ, Inst Hlth Policy & Management, Taipei 10764, Taiwan; [Khan, Mujibul Alam] RISE, Dhaka, Bangladesh	National Taiwan University	Tseng, YH (corresponding author), Natl Taiwan Univ, Inst Hlth Policy & Management, Taipei 10764, Taiwan.	mayeeshatk@gmail.com			Research Initiative for Social Empowerment (RISE), Dhaka, Bangladesh	Research Initiative for Social Empowerment (RISE), Dhaka, Bangladesh	Research Initiative for Social Empowerment (RISE), Dhaka, Bangladesh was the primary source of funding. The College of Public Health, National Taiwan University provided YHT's Taiwan- Bangladesh airfare. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aday L A, 1974, Health Serv Res, V9, P208; Ahmed NU, 2006, J HEALTH POPUL NUTR, V24, P456; Ahmed SM, 2005, B WORLD HEALTH ORGAN, V83, P109; Ahmed SM, 2006, SOC SCI MED, V63, P2899, DOI 10.1016/j.socscimed.2006.07.024; Ahmed SM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012660; Amin R, 2001, WORLD DEV, V29, P1611, DOI 10.1016/S0305-750X(01)00055-9; Amin R, 2010, INT J EQUITY HEALTH, V9, DOI 10.1186/1475-9276-9-9; Anand S, 2008, J ECON LIT, V46, P57, DOI 10.1257/jel.46.1.57; ANDERSEN RM, 1995, J HEALTH SOC BEHAV, V36, P1, DOI 10.2307/2137284; Andrulis DP, 1996, AM J PUBLIC HEALTH, V86, P162, DOI 10.2105/AJPH.86.2.162; [Anonymous], 2013, ASIA PAC J PUBLIC HL; [Anonymous], REP BANGL LIT SURV; Anwar A., 2004, BANGLADESH INEQUALIT; Anwar I, 2008, B WORLD HEALTH ORGAN, V86, P252, DOI 10.2471/BLT.07.042754; Balabanova D, 2011, GOOD HLTH LOST COST; Begum HA, 2013, ASIA-PAC J PUBLIC HE, V25, P345, DOI 10.1177/1010539511420132; Berhane G, 2011, AM J AGR ECON, V93, P43, DOI 10.1093/ajae/aaq126; Chakraborty N, 2003, HEALTH PROMOT INT, V18, P327, DOI 10.1093/heapro/dag414; Chowdhury ME, 2006, LANCET, V367, P327, DOI 10.1016/S0140-6736(06)68070-7; Cull R, 2007, ECON J, V117, pF107, DOI 10.1111/j.1468-0297.2007.02017.x; El Arifeen S, 2013, LANCET, V382, P2012, DOI 10.1016/S0140-6736(13)62149-2; Ensor T, 2004, HEALTH POLICY PLANN, V19, P69, DOI 10.1093/heapol/czh009; Friel S, 2011, ASIA-PAC J PUBLIC HE, V23, P246, DOI 10.1177/1010539511402053; Galbraith S, 2010, J NEUROSCI, V30, P10601, DOI 10.1523/JNEUROSCI.0362-10.2010; Griffiths P, 2001, J BIOSOC SCI, V33, P339, DOI 10.1017/S002193200100339X; Hadi A, 2002, PUBLIC HEALTH, V116, P238, DOI 10.1038/sj.ph.1900863; Hadi A, 2001, HEALTH PROMOT INT, V16, P219, DOI 10.1093/heapro/16.3.219; Halder Amal Krishna, 2007, World Health Popul, V9, P48; Halder ShantanaR., 2004, J INT DEV, V16, P387, DOI [10.1002/jid.1084, DOI 10.1002/JID.1084]; Hanley JA, 2003, AM J EPIDEMIOL, V157, P364, DOI 10.1093/aje/kwf215; Haque MS, 2004, INT REV ADM SCI, V70, P271, DOI 10.1177/0020852304044255; Hermes N, 2011, WORLD DEV, V39, P875, DOI 10.1016/j.worlddev.2009.10.021; Hossain S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044980; Islam A, 2011, AM J AGR ECON, V93, P843, DOI 10.1093/ajae/aar012; Kamal SMM, 2010, ASIA-PAC J PUBLIC HE, V22, P436, DOI 10.1177/1010539510370780; Kaplan R.S., 1996, BALANCED SCORECARD T; KATZ SJ, 1994, JAMA-J AM MED ASSOC, V272, P530, DOI 10.1001/jama.272.7.530; Killewo J, 2006, J HEALTH POPUL NUTR, V24, P403; Leatherman S, 2010, 12 FREED HUNG; Leatherman S, 2012, HEALTH POLICY PLANN, V27, P85, DOI 10.1093/heapol/czr014; Maes J.P., 2012, STATE MICROCREDIT SU; Mercer A, 2004, HEALTH POLICY PLANN, V19, P187, DOI 10.1093/heapol/czh024; Microcredit Regulatory Authority, NGO MFIS BANGL; Mohammad Sohail, 2005, Bangladesh Development Studies, V31, P63; Mohindra KA., 2005, J HUM DEV, V6, P353, DOI [10.1080/14649880500287662, DOI 10.1080/14649880500287662]; Montgomery R., 1996, Journal of International Development, V8, P289, DOI 10.1002/(SICI)1099-1328(199603)8:2&lt;289::AID-JID368&gt;3.0.CO;2-2; Nanda P, 1999, HEALTH ECON, V8, P415, DOI 10.1002/(SICI)1099-1050(199908)8:5<415::AID-HEC450>3.0.CO;2-L; Nawaz Shah, 2010, J Asian Afr Stud, V45, P670, DOI 10.1177/0021909610383812; Quayyum Z, 2013, INT J EQUITY HEALTH, V12, DOI 10.1186/1475-9276-12-22; Rahman Atiur, 2000, BANGLADESH DEV STUDI, P1; Ravallion M, 2003, INT AFF, V79, P739, DOI 10.1111/1468-2346.00334; Reed L., 2014, STATE MICROCREDIT SU; Rutebemberwa E, 2009, TROP MED INT HEALTH, V14, P472, DOI 10.1111/j.1365-3156.2009.02237.x; Sachs J.D., 2001, MACROECONOMICS HLTH; Saksena P, 2012, TROP MED INT HEALTH, V17, P23, DOI 10.1111/j.1365-3156.2011.02894.x; Sambamoorthi U, 2003, PREV MED, V37, P475, DOI 10.1016/S0091-7435(03)00172-5; Schurmann AT, 2009, J HEALTH POPUL NUTR, V27, P518; Somen Saha, 2011, International Journal of Medicine and Public Health, V1, P1, DOI 10.5530/ijmedph.1.2011.1; STANTON B, 1989, SOC SCI MED, V29, P1199, DOI 10.1016/0277-9536(89)90363-8; Starfield B, 2005, MILBANK Q, V83, P457, DOI 10.1111/j.1468-0009.2005.00409.x; Streefland P., 1990, Health Policy and Planning, V5, P261, DOI 10.1093/heapol/5.3.261; SUBEDI J, 1989, J HEALTH SOC BEHAV, V30, P412, DOI 10.2307/2136989; Szekely M, 1999, WORKING PAPER; Ullah AZ, 2006, HEALTH POLICY PLANN, V21, P143, DOI 10.1093/heapol/czj014; UNICEF, 2011, STAT WORLDS CHILDR 2; United Nations (UN), 2013, MILL DEV GOALS REP 2; World Health Organization, INT C PRIM HLTH CAR INT C PRIM HLTH CAR; Xu K, 2003, LANCET, V362, P111, DOI 10.1016/S0140-6736(03)13861-5; Yunus M., 1998, BANKER TO THE POOR; Zohir S., 2004, ECON POLIT WEEKLY, V39, P4109	70	3	3	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 25	2015	10	3							e0121733	10.1371/journal.pone.0121733	http://dx.doi.org/10.1371/journal.pone.0121733			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	CE5MO	25807500	gold, Green Published, Green Submitted			2023-01-03	WOS:000351880000177
J	Sivasankar, S; Lavanya, R; Brindha, P; Angayarkanni, N				Sivasankar, Shanmuganathan; Lavanya, Ramu; Brindha, Pemaiah; Angayarkanni, Narayanasamy			Aqueous and Alcoholic Extracts of Triphala and Their Active Compounds Chebulagic Acid and Chebulinic Acid Prevented Epithelial to Mesenchymal Transition in Retinal Pigment Epithelial Cells, by Inhibiting SMAD-3 Phosphorylation	PLOS ONE			English	Article							PROLIFERATIVE VITREORETINOPATHY; MATRIX-METALLOPROTEINASE; DIABETIC-RETINOPATHY; RISK-FACTORS; EXPRESSION; GROWTH; RPE; ANTIOXIDANTS; FORMULATION; DETACHMENT	Epithelial to Mesenchymal Transition (EMT) of the retinal pigment epitheliumis involved in the pathogenesis of proliferative vitreoretinopathy (PVR) that often leads to retinal detachment. In this study, Triphala, an ayurvedic formulation and two of its active ingredients, namely chebulagic acid and chebulinic acid were evaluated for anti-EMT properties based on in vitro experiments in human retinal pigment epithelial cell line (ARPE-19) under TGF beta 1 induced conditions. ARPE-19 cells were treated with TGF beta 1 alone or co-treated with various concentrations of aqueous extract (AqE) (30 - 300 mu g/ml); alcoholic extract (AlE) (50 -500 mu g/ml) of triphala and the active principles chebulagic acid (CA) and chebulinic acid (CI) (CA, CI: 50 -200 mu M). The expression of EMT markers namely MMP-2, alpha SMA, vimentin and the tight junction protein ZO-1 were evaluated by qPCR, western blot and immunofluorescence. The functional implications of EMT, namelymigration and proliferation of cells were assessed by proliferation assay, scratch assay and transwell migration assay. AqE, AlE, CA and CI reduced the expression and activity of MMP-2 at an ED50 value of 100 mu g/ml, 50 mu g/ml, 100 mu M and 100 mu M, respectively. At these concentrations, a significant down-regulation of the expression of alpha SMA, vimentin and up-regulation of the expression of ZO-1 altered by TGF beta 1 were observed. These concentrations also inhibited proliferation and migration of ARPE-19 cells induced by TGF beta 1. EMT was found to be induced in ARPE-19 cells, through SMAD-3 phosphorylation and it was inhibited by AqE, AlE, CA and CI. Further studies in experimental animals are required to attribute therapeutic potential of these extracts and their active compounds, as an adjuvant therapy in the disease management of PVR.	[Sivasankar, Shanmuganathan; Angayarkanni, Narayanasamy] Vis Res Fdn, RS Mehta Jain Dept Biochem & Cell Biol, Kamalnayan Bajaj Inst Res Vis & Ophthalmol, Madras, Tamil Nadu, India; [Sivasankar, Shanmuganathan] SASTRA Univ, Sch Chem & Biotechnol, Thanjavur, India; [Lavanya, Ramu; Brindha, Pemaiah] SASTRA Univ, Ctr Adv Res Indian Syst Med, Thanjavur, India	Shanmugha Arts, Science, Technology & Research Academy (SASTRA); Shanmugha Arts, Science, Technology & Research Academy (SASTRA)	Angayarkanni, N (corresponding author), Vis Res Fdn, RS Mehta Jain Dept Biochem & Cell Biol, Kamalnayan Bajaj Inst Res Vis & Ophthalmol, Madras, Tamil Nadu, India.	drak@snmail.org	Narayanasamy, Angayarkanni/ABD-8584-2020		Council of Scientific and Industrial Research [27/0219/09/EMR-II]	Council of Scientific and Industrial Research(Council of Scientific & Industrial Research (CSIR) - India)	Funding provided by a Council of Scientific and Industrial Research grant (27/0219/09/EMR-II). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abraham S, 2005, J PERIODONTOL, V76, P497, DOI 10.1902/jop.2005.76.4.497; Baliga MS, 2012, CHIN J INTEGR MED, V18, P946, DOI 10.1007/s11655-012-1299-x; Bochaton-Piallat ML, 2000, INVEST OPHTH VIS SCI, V41, P2336; Bouayed J, 2010, OXID MED CELL LONGEV, V3, P228, DOI 10.4161/oxim.3.4.12858; Burke JM, 2006, INVEST OPHTH VIS SCI, V47, P3635, DOI 10.1167/iovs.06-0104; Burke JM, 2008, PROG RETIN EYE RES, V27, P579, DOI 10.1016/j.preteyeres.2008.08.002; Campochiaro PA, 1997, ARCH OPHTHALMOL-CHIC, V115, P237, DOI 10.1001/archopht.1997.01100150239014; Casaroli-Marano RP, 1999, INVEST OPHTH VIS SCI, V40, P2062; Chan CM, 2010, MOL VIS, V16, P586; CHARTERIS DG, 1995, BRIT J OPHTHALMOL, V79, P953, DOI 10.1136/bjo.79.10.953; Chen HC, 2012, LAB INVEST, V92, P676, DOI 10.1038/labinvest.2011.201; Coral K, 2008, INVEST OPHTH VIS SCI, V49, P4746, DOI 10.1167/iovs.07-1550; Cui JZ, 2007, EYE, V21, P200, DOI 10.1038/sj.eye.6702169; Duong TD, 2004, DEV DYNAM, V229, P42, DOI 10.1002/dvdy.10465; Eichler W, 2002, INVEST OPHTH VIS SCI, V43, P2767; Ermakova S, 2005, J BIOL CHEM, V280, P16882, DOI 10.1074/jbc.M414185200; Flanders KC, 2004, INT J EXP PATHOL, V85, P47, DOI 10.1111/j.0959-9673.2004.00377.x; Giebel SJ, 2005, LAB INVEST, V85, P597, DOI 10.1038/labinvest.3700251; Hinton DR, 2002, EYE, V16, P422, DOI 10.1038/sj.eye.6700190; Jinnin M, 2006, MOL PHARMACOL, V69, P597, DOI 10.1124/mol.105.017483; Kalluri R, 2003, J CLIN INVEST, V112, P1776, DOI 10.1172/JCI200320530; Kalluri R, 2009, J CLIN INVEST, V119, P1417, DOI 10.1172/JCI39675; KIM J, 2013, NATL GEOGR, V224, P8; Kon CH, 1998, INVEST OPHTH VIS SCI, V39, P1524; Krishnan G, 2012, GLIA, V60, P1629, DOI 10.1002/glia.22380; Kumar MS, 2008, J SURG RES, V144, P94, DOI 10.1016/j.jss.2007.02.049; Lee H, 2007, INVEST OPHTH VIS SCI, V48, P4291, DOI 10.1167/iovs.07-0086; Li H, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023322; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lu K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043934; Moustakas A, 2007, CANCER SCI, V98, P1512, DOI 10.1111/j.1349-7006.2007.00550.x; Nagasaki H, 1998, PROG RETIN EYE RES, V17, P77, DOI 10.1016/S1350-9462(97)00007-4; Nakao A, 1997, EMBO J, V16, P5353, DOI 10.1093/emboj/16.17.5353; Pastor JC, 2002, PROG RETIN EYE RES, V21, P127, DOI 10.1016/S1350-9462(01)00023-4; Pastor JC, 1998, SURV OPHTHALMOL, V43, P3, DOI 10.1016/S0039-6257(98)00023-X; Pawar V, 2009, INDIAN J PHARM SCI, V71, P382, DOI 10.4103/0250-474X.57286; Reddy DB, 2009, BIOCHEM BIOPH RES CO, V381, P112, DOI 10.1016/j.bbrc.2009.02.022; Rothmeier AS, 2009, FASEB J, V23, P1127, DOI 10.1096/fj.08-117127; RYAN SJ, 1993, AM J OPHTHALMOL, V115, P1; Sadaka A, 2012, CLIN OPHTHALMOL, V6, P1325, DOI 10.2147/OPTH.S27896; Saika S, 2004, LAB INVEST, V84, P1245, DOI 10.1038/labinvest.3700156; Saika Shizuya, 2008, Endocrine Metabolic & Immune Disorders-Drug Targets, V8, P69, DOI 10.2174/187153008783928343; Sandhya T, 2006, CANCER LETT, V231, P206, DOI 10.1016/j.canlet.2005.01.035; Shi Y, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-294; Sumantran VN, 2007, J BIOSCIENCES, V32, P755, DOI 10.1007/s12038-007-0075-3; Sun XD, 2013, ONCOL REP, V29, P2401, DOI 10.3892/or.2013.2385; Symeonidis C, 2011, ACTA OPHTHALMOL, V89, P339, DOI 10.1111/j.1755-3768.2009.01701.x; Thornton B, 2011, BIOCHEM MOL BIOL EDU, V39, P145, DOI 10.1002/bmb.20461; Williams RJ, 2004, FREE RADICAL BIO MED, V36, P838, DOI 10.1016/j.freeradbiomed.2004.01.001; Xu J, 2009, CELL RES, V19, P156, DOI 10.1038/cr.2009.5; Zeisberg M, 2009, J CLIN INVEST, V119, P1429, DOI 10.1172/JCI36183	51	26	28	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 20	2015	10	3							e0120512	10.1371/journal.pone.0120512	http://dx.doi.org/10.1371/journal.pone.0120512			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CE8HY	25793924	Green Submitted, Green Published, gold			2023-01-03	WOS:000352083900045
J	Vicario, R; Peg, V; Morancho, B; Zacarias-Fluck, M; Zhang, JJ; Martinez-Barriocanal, A; Jimenez, AN; Aura, C; Burgues, O; Lluch, A; Cortes, J; Nuciforo, P; Rubio, IT; Marangoni, E; Deeds, J; Boehm, M; Schlegel, R; Tabernero, J; Mosher, R; Arribas, J				Vicario, Rocio; Peg, Vicente; Morancho, Beatriz; Zacarias-Fluck, Mariano; Zhang, Junjie; Martinez-Barriocanal, Agueda; Navarro Jimenez, Alexandra; Aura, Claudia; Burgues, Octavio; Lluch, Ana; Cortes, Javier; Nuciforo, Paolo; Rubio, Isabel T.; Marangoni, Elisabetta; Deeds, James; Boehm, Markus; Schlegel, Robert; Tabernero, Josep; Mosher, Rebecca; Arribas, Joaquin			Patterns of HER2 Gene Amplification and Response to Anti-HER2 Therapies	PLOS ONE			English	Article							BREAST-CANCER; GROWTH; NETWORK	A chromosomal region that includes the gene encoding HER2, a receptor tyrosine kinase (RTK), is amplified in 20% of breast cancers. Although these tumors tend to respond to drugs directed against HER2, they frequently become resistant and resume their malignant progression. Gene amplification in double minutes (DMs), which are extrachromosomal entities whose number can be dynamically regulated, has been suggested to facilitate the acquisition of resistance to therapies targeting RTKs. Here we show that similar to 30% of HER2-positive tumors show amplification in DMs. However, these tumors respond to trastuzumab in a similar fashion than those with amplification of the HER2 gene within chromosomes. Furthermore, in different models of resistance to anti-HER2 therapies, the number of DMs containing HER2 is maintained, even when the acquisition of resistance is concomitant with loss of HER2 protein expression. Thus, both clinical and preclinical data show that, despite expectations, loss of HER2 protein expression due to loss of DMs containing HER2 is not a likely mechanism of resistance to anti-HER2 therapies.	[Vicario, Rocio; Morancho, Beatriz; Zacarias-Fluck, Mariano; Zhang, Junjie; Martinez-Barriocanal, Agueda; Arribas, Joaquin] Univ Autonoma Barcelona, Vall dHebron Inst Oncol VHIO, Preclin Oncol Program, Barcelona 08035, Spain; [Cortes, Javier; Rubio, Isabel T.; Tabernero, Josep] Univ Autonoma Barcelona, Vall dHebron Inst Oncol VHIO, Clin Oncol Program, Barcelona 08035, Spain; [Aura, Claudia; Nuciforo, Paolo] Univ Autonoma Barcelona, Vall dHebron Inst Oncol VHIO, Mol Oncol Program, Barcelona 08035, Spain; [Peg, Vicente; Navarro Jimenez, Alexandra] Vall dHebron Univ Hosp, Dept Pathol, Barcelona 08035, Spain; [Burgues, Octavio] INCLIVA Biomed Res Inst, Hosp Clin Univ, Dept Pathol, Valencia 46010, Spain; [Lluch, Ana] INCLIVA Biomed Res Inst, Hosp Clin Univ, Dept Oncol, Valencia 46010, Spain; [Marangoni, Elisabetta] Inst Curie, Translat Res Dept, F-75005 Paris, France; [Deeds, James; Schlegel, Robert; Mosher, Rebecca] Novartis Oncol Translat Res, Cambridge, MA 02139 USA; [Boehm, Markus] Novartis Pharma AG, CH-4002 Basel, Switzerland; [Vicario, Rocio; Arribas, Joaquin] Univ Autonoma Barcelona, Dept Biochem & Mol Biol, Bellaterra 08193, Spain; [Arribas, Joaquin] Inst Catalana Recerca & Estudis Avancats, Barcelona 08010, Spain	Autonomous University of Barcelona; Vall d'Hebron Institut d'Oncologia (VHIO); Autonomous University of Barcelona; Vall d'Hebron Institut d'Oncologia (VHIO); Autonomous University of Barcelona; Vall d'Hebron Institut d'Oncologia (VHIO); Hospital Universitari Vall d'Hebron; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Novartis; Autonomous University of Barcelona; ICREA	Mosher, R (corresponding author), Novartis Oncol Translat Res, Cambridge, MA 02139 USA.	rebecca.mosher@novartis.com; jarribas@vhio.net	rubio, isabel/U-4259-2018; Martinez, Agueda/AAB-7186-2019; Peg., Vicente/AAC-9447-2020; Tabernero, Josep/AAG-5026-2019; Marangoni, Elisabetta/GSO-3945-2022; Zacarias-Fluck, Mariano F./D-9406-2019; Miquel, Josep Maria/AAG-3508-2019; Nuciforo, Paolo/Q-2885-2019; Arribas, Joaquin/M-4482-2014; Morancho, Beatriz/AAD-3540-2021; Burgues, Octavio/ABH-9634-2020; Peg, Vicente/E-9160-2018; Burgues, Octavio/ABC-8699-2021; Lluch, Ana/R-5493-2019	rubio, isabel/0000-0003-0035-0679; Martinez, Agueda/0000-0002-8809-160X; Peg., Vicente/0000-0002-5203-6166; Tabernero, Josep/0000-0002-2495-8139; Marangoni, Elisabetta/0000-0002-3337-6448; Zacarias-Fluck, Mariano F./0000-0002-7171-4268; Arribas, Joaquin/0000-0002-0504-0664; Morancho, Beatriz/0000-0003-3369-8647; Peg, Vicente/0000-0002-5203-6166; Lluch, Ana/0000-0003-2766-407X; Nuciforo, Paolo/0000-0003-1380-0990; Cortes, Javier/0000-0001-7623-1583	Novartis Pharma within the Consorcio de Investigacion Biomedica y Oncologica Translacional Framework Programme; Breast Cancer Research Foundation (BCRF); Spanish Association Against Cancer (Asociacion Espanola Contra el Cancer, AECC); Instituto de Salud Carlos III (Intrasalud) [PI12/02536]; Network of Cooperative Cancer Research [RTICC-RD12/0036/0057/0070/0012]; Ministerio de Economia y Competitividad [JCI-2011-10960]; Novartis; ICREA Funding Source: Custom	Novartis Pharma within the Consorcio de Investigacion Biomedica y Oncologica Translacional Framework Programme; Breast Cancer Research Foundation (BCRF); Spanish Association Against Cancer (Asociacion Espanola Contra el Cancer, AECC); Instituto de Salud Carlos III (Intrasalud); Network of Cooperative Cancer Research; Ministerio de Economia y Competitividad(Spanish Government); Novartis(Novartis); ICREA(ICREA)	This work has been supported by Novartis Pharma within the Consorcio de Investigacion Biomedica y Oncologica Translacional Framework Programme, the Breast Cancer Research Foundation (BCRF), Spanish Association Against Cancer (Asociacion Espanola Contra el Cancer, AECC) and Instituto de Salud Carlos III (Intrasalud PI12/02536) to JA and the Network of Cooperative Cancer Research (RTICC-RD12/0036/0057/0070/0012) to JA, JT, JC and AL. AM-B is supported by a Juan de la Cierva postdoctoral fellow from Ministerio de Economia y Competitividad (JCI-2011-10960). JD, MB, RS, and RM are employed by Novartis and received funding in the form of salaries. The funders participated in study design, decision to publish, and preparation of the manuscript.	Albertson DG, 2006, TRENDS GENET, V22, P447, DOI 10.1016/j.tig.2006.06.007; Arteaga CL, 2014, CANCER CELL, V25, P282, DOI 10.1016/j.ccr.2014.02.025; Bonavia R, 2011, CANCER RES, V71, P4055, DOI 10.1158/0008-5472.CAN-11-0153; Gianni L, 2010, LANCET, V375, P377, DOI 10.1016/S0140-6736(09)61964-4; Gradishar WJ, 2012, NEW ENGL J MED, V366, P176, DOI 10.1056/NEJMe1113641; Hoff Von DD, 1992, P NATL ACAD SCI USA, V89, P8165; KAUFMAN RJ, 1981, MOL CELL BIOL, V1, P1084, DOI 10.1128/MCB.1.12.1084; Parra-Palau JL, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/dju291; Marangoni E, 2007, CLIN CANCER RES, V13, P3989, DOI 10.1158/1078-0432.CCR-07-0078; Mittendorf EA, 2009, CLIN CANCER RES, V15, P7381, DOI 10.1158/1078-0432.CCR-09-1735; Nathanson DA, 2014, SCIENCE, V343, P72, DOI 10.1126/science.1241328; Niikura N, 2012, J CLIN ONCOL, V30, P593, DOI 10.1200/JCO.2010.33.8889; Pedersen K, 2009, MOL CELL BIOL, V29, P3319, DOI 10.1128/MCB.01803-08; Sahlberg KK, 2013, MOL ONCOL, V7, P392, DOI 10.1016/j.molonc.2012.10.012; Wolff AC, 2013, J CLIN ONCOL, V31, P3997, DOI 10.1200/JCO.2013.50.9984; Xuan QJ, 2015, BREAST CANCER RES TR, V150, P581, DOI 10.1007/s10549-015-3334-2; Yarden Y, 2012, NAT REV CANCER, V12, P553, DOI 10.1038/nrc3309; Yu LS, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071988	18	35	36	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 15	2015	10	6							e0129876	10.1371/journal.pone.0129876	http://dx.doi.org/10.1371/journal.pone.0129876			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CK6HU	26075403	gold, Green Published, Green Submitted			2023-01-03	WOS:000356329900108
J	Morscher, RJ; Aminzadeh-Gohari, S; Feichtinger, RG; Mayr, JA; Lang, R; Neureiter, D; Sperl, W; Kofler, B				Morscher, Raphael Johannes; Aminzadeh-Gohari, Sepideh; Feichtinger, Rene Gunther; Mayr, Johannes Adalbert; Lang, Roland; Neureiter, Daniel; Sperl, Wolfgang; Kofler, Barbara			Inhibition of Neuroblastoma Tumor Growth by Ketogenic Diet and/or Calorie Restriction in a CD1-Nu Mouse Model	PLOS ONE			English	Article							TARGETING CANCER METABOLISM; MITOCHONDRIAL-DNA; KETONE-BODIES; TRANSLATION INITIATION; RESPIRATORY-CHAIN; ENERGY-METABOLISM; OXIDATIVE STRESS; H2O2 MEDIATE; COMPLEX-I; GLUCOSE	Introduction Neuroblastoma is a malignant pediatric cancer derived from neural crest cells. It is characterized by a generalized reduction of mitochondrial oxidative phosphorylation. The goal of the present study was to investigate the effects of calorie restriction and ketogenic diet on neuroblastoma tumor growth and monitor potential adaptive mechanisms of the cancer's oxidative phosphorylation system. Methods Xenografts were established in CD-1 nude mice by subcutaneous injection of two neuroblastoma cell lines having distinct genetic characteristics and therapeutic sensitivity [SHSY5Y and SK-N-BE(2)]. Mice were randomized to four treatment groups receiving standard diet, calorie-restricted standard diet, long chain fatty acid based ketogenic diet or calorie-restricted ketogenic diet. Tumor growth, survival, metabolic parameters and weight of the mice were monitored. Cancer tissue was evaluated for diet-induced changes of proliferation indices and multiple oxidative phosphorylation system parameters (respiratory chain enzyme activities, western blot analysis, immunohistochemistry and mitochondrial DNA content). Results Ketogenic diet and/or calorie restriction significantly reduced tumor growth and prolonged survival in the xenograft model. Neuroblastoma growth reduction correlated with decreased blood glucose concentrations and was characterized by a significant decrease in Ki-67 and phospho-histone H3 levels in the diet groups with low tumor growth. As in human tumor tissue, neuroblastoma xenografts showed distinctly low mitochondrial complex II activity in combination with a generalized low level of mitochondrial oxidative phosphorylation, validating the tumor model. Neuroblastoma showed no ability to adapt its mitochondrial oxidative phosphorylation activity to the change in nutrient supply induced by dietary intervention. Conclusions Our data suggest that targeting the metabolic characteristics of neuroblastoma could open a new front in supporting standard therapy regimens. Therefore, we propose that a ketogenic diet and/or calorie restriction should be further evaluated as a possible adjuvant therapy for patients undergoing treatment for neuroblastoma.	[Morscher, Raphael Johannes; Aminzadeh-Gohari, Sepideh; Feichtinger, Rene Gunther; Kofler, Barbara] Paracelsus Med Univ, Res Program Receptor Biochem & Tumor Metab, Salzburg, Austria; [Mayr, Johannes Adalbert; Sperl, Wolfgang] Paracelsus Med Univ, Dept Pediat, Salzburg, Austria; [Lang, Roland] Paracelsus Med Univ, Dept Dermatol, Salzburg, Austria; [Neureiter, Daniel] Paracelsus Med Univ, Dept Pathol, Salzburg, Austria; [Morscher, Raphael Johannes] Med Univ Innsbruck, Div Med Genet, A-6020 Innsbruck, Tirol, Austria	Paracelsus Private Medical University; Paracelsus Private Medical University; Paracelsus Private Medical University; Paracelsus Private Medical University; Medical University of Innsbruck	Morscher, RJ (corresponding author), Paracelsus Med Univ, Res Program Receptor Biochem & Tumor Metab, Salzburg, Austria.	raphael.morscher@pmu.ac.at	Aminzadeh-Gohari, Sepideh/AAS-4529-2021	Kofler, Barbara/0000-0002-1198-4776; Aminzadeh-Gohari, Sepideh/0000-0003-3976-4297; Morscher, Raphael Johannes/0000-0003-3378-9266; Mayr, Johannes/0000-0001-6970-336X	Vereinigung zur Forderung der padiatrischen Forschung und Fortbildung Salzburg; Children's Cancer Foundation Salzburg; Paracelsus Medical University Salzburg [E-10/12/061-KOF]	Vereinigung zur Forderung der padiatrischen Forschung und Fortbildung Salzburg; Children's Cancer Foundation Salzburg(Swedish Cancer Society); Paracelsus Medical University Salzburg	This work was supported by the Vereinigung zur Forderung der padiatrischen Forschung und Fortbildung Salzburg, the Children's Cancer Foundation Salzburg and the Paracelsus Medical University Salzburg, single project grant No.: E-10/12/061-KOF. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Acham-Roschitz B, 2009, MOL GENET METAB, V98, P300, DOI 10.1016/j.ymgme.2009.06.012; Ahmad IM, 2005, J BIOL CHEM, V280, P4254, DOI 10.1074/jbc.M411662200; Allen BG, 2013, CLIN CANCER RES, V19, P3905, DOI 10.1158/1078-0432.CCR-12-0287; Amar L, 2005, J CLIN ONCOL, V23, P8812, DOI 10.1200/JCO.2005.03.1484; Astuti D, 2004, BRIT J CANCER, V91, P1835, DOI 10.1038/sj.bjc.6602202; Aykin-Burns N, 2009, BIOCHEM J, V418, P29, DOI 10.1042/BJ20081258; Barbet NC, 1996, MOL BIOL CELL, V7, P25, DOI 10.1091/mbc.7.1.25; Baysal BE, 2000, SCIENCE, V287, P848, DOI 10.1126/science.287.5454.848; Berger A, 2003, ACTA NEUROPATHOL, V105, P245, DOI 10.1007/s00401-002-0638-1; Bough KJ, 2006, ANN NEUROL, V60, P223, DOI 10.1002/ana.20899; Brodeur GM, 2003, NAT REV CANCER, V3, P203, DOI 10.1038/nrc1014; Butler EB, 2013, CANCER RES, V73, P2709, DOI 10.1158/0008-5472.CAN-12-3009; Chang HT, 2013, NUTR METAB, V10, DOI 10.1186/1743-7075-10-47; Chiang MC, 2014, MITOCHONDRION, V14, P7, DOI 10.1016/j.mito.2013.12.003; Chu-Shore CJ, 2010, BRAIN DEV-JPN, V32, P318, DOI 10.1016/j.braindev.2009.04.009; Dang CV, 2011, J MOL MED, V89, P205, DOI 10.1007/s00109-011-0730-x; De Preter K, 2004, BMC CANCER, V4, DOI 10.1186/1471-2407-4-55; Dey R, 2000, J BIOL CHEM, V275, P7087, DOI 10.1074/jbc.275.10.7087; Dickinson A, 2013, CELL DEATH DIFFER, V20, P1644, DOI 10.1038/cdd.2013.115; Facucho-Oliveira JM, 2009, STEM CELL REV REP, V5, P140, DOI 10.1007/s12015-009-9058-0; Feichtinger Rene G, 2011, Front Biosci (Elite Ed), V3, P194, DOI 10.2741/e233; Feichtinger Rene G, 2011, Front Biosci (Elite Ed), V3, P187, DOI 10.2741/e232; Feichtinger RG, 2014, GLIA, V62, P514, DOI 10.1002/glia.22621; Feichtinger Rene' G, 2011, Front Biosci (Elite Ed), V3, P179, DOI 10.2741/e231; Feichtinger RG, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-149; Fingar DC, 2004, MOL CELL BIOL, V24, P200, DOI 10.1128/MCB.24.1.200-216.2004; Freedland SJ, 2008, PROSTATE, V68, P11, DOI 10.1002/pros.20683; Freeman JM, 2007, PEDIATRICS, V119, P535, DOI 10.1542/peds.2006-2447; Gambhir SS, 2002, NAT REV CANCER, V2, P683, DOI 10.1038/nrc882; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hardie DG, 2011, GENE DEV, V25, P1895, DOI 10.1101/gad.17420111; Hartman AL, 2007, EPILEPSIA, V48, P31, DOI 10.1111/j.1528-1167.2007.00914.x; Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809; HOLLOSZY JO, 1970, BIOCHEM BIOPH RES CO, V40, P1368, DOI 10.1016/0006-291X(70)90017-3; Huffman J, 2006, CURR NEUROL NEUROSCI, V6, P332, DOI 10.1007/s11910-006-0027-6; Hughes SD, 2014, J NEUROCHEM, V129, P426, DOI 10.1111/jnc.12646; Igney FH, 2002, NAT REV CANCER, V2, P277, DOI 10.1038/nrc776; Jones NP, 2012, DRUG DISCOV TODAY, V17, P232, DOI 10.1016/j.drudis.2011.12.017; Kim JW, 2006, CANCER RES, V66, P8927, DOI 10.1158/0008-5472.CAN-06-1501; Kim JY, 2002, ONCOGENE, V21, P3139, DOI 10.1038/sj.onc.1205406; Kimberly MM, 2006, CLIN CHIM ACTA, V364, P292, DOI 10.1016/j.cca.2005.07.027; King A, 2006, ONCOGENE, V25, P4675, DOI 10.1038/sj.onc.1209594; Kollberg G, 2009, NEUROMUSCULAR DISORD, V19, P147, DOI 10.1016/j.nmd.2008.11.014; Kristensen GBB, 2005, CLIN CHEM, V51, P1632, DOI 10.1373/clinchem.2005.049080; Kwong JQ, 2007, J CELL BIOL, V179, P1163, DOI 10.1083/jcb.200704059; Laffel L, 1999, DIABETES-METAB RES, V15, P412, DOI 10.1002/(SICI)1520-7560(199911/12)15:6<412::AID-DMRR72>3.0.CO;2-8; Li ZJ, 2012, CLIN CANCER RES, V18, P3603, DOI 10.1158/1078-0432.CCR-11-3321; Liang JY, 2007, NAT CELL BIOL, V9, P218, DOI 10.1038/ncb1537; Lopez-Rios F, 2007, CANCER RES, V67, P9013, DOI 10.1158/0008-5472.CAN-07-1678; Lv MM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0115147; Maroon J, 2013, J CHILD NEUROL, V28, P1002, DOI 10.1177/0883073813488670; Mayr JA, 2008, CLIN CANCER RES, V14, P2270, DOI 10.1158/1078-0432.CCR-07-4131; Mayr JA, 2011, AM J HUM GENET, V89, P792, DOI 10.1016/j.ajhg.2011.11.011; Meidenbauer JJ, 2015, NUTR METAB, V12, DOI 10.1186/s12986-015-0009-2; Meierhofer D, 2004, CARCINOGENESIS, V25, P1005, DOI 10.1093/carcin/bgh104; Mukherjee P, 2004, CLIN CANCER RES, V10, P5622, DOI 10.1158/1078-0432.CCR-04-0308; Mukherjee P, 2002, BRIT J CANCER, V86, P1615, DOI 10.1038/sj.bjc.6600298; NEBELING LC, 1995, J AM COLL NUTR, V14, P202; Otto C, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-122; Paoli A, 2013, EUR J CLIN NUTR, V67, P789, DOI 10.1038/ejcn.2013.116; Park JR, 2013, PEDIATR BLOOD CANCER, V60, P985, DOI 10.1002/pbc.24433; Payne NE, 2011, EPILEPSIA, V52, P1941, DOI 10.1111/j.1528-1167.2011.03287.x; Pon LA, 2007, MITOCHONDRIA, Vxxiv; Qing GL, 2012, CANCER CELL, V22, P631, DOI 10.1016/j.ccr.2012.09.021; Raez LE, 2013, CANCER CHEMOTH PHARM, V71, P523, DOI 10.1007/s00280-012-2045-1; Rieger J, 2014, INT J ONCOL, V44, P1843, DOI 10.3892/ijo.2014.2382; ROEDER LM, 1982, J NEUROSCI RES, V8, P671, DOI 10.1002/jnr.490080412; RUSTIN P, 1994, CLIN CHIM ACTA, V228, P35, DOI 10.1016/0009-8981(94)90055-8; Schmidt M, 2011, NUTR METAB, V8, DOI 10.1186/1743-7075-8-54; Schneider L, 2011, FREE RADICAL BIO MED, V51, P2007, DOI 10.1016/j.freeradbiomed.2011.08.030; Seyfried Thomas N, 2005, Nutr Metab (Lond), V2, P30, DOI 10.1186/1743-7075-2-30; Seyfried TN, 2011, BBA-BIOENERGETICS, V1807, P577, DOI 10.1016/j.bbabio.2010.08.009; Seyfried TN, 2010, LANCET ONCOL, V11, P811, DOI 10.1016/S1470-2045(10)70166-2; Seyfried TN, 2003, BRIT J CANCER, V89, P1375, DOI 10.1038/sj.bjc.6601269; Shidara Y, 2005, CANCER RES, V65, P1655, DOI 10.1158/0008-5472.CAN-04-2012; Shim H, 1998, P NATL ACAD SCI USA, V95, P1511, DOI 10.1073/pnas.95.4.1511; Skinner R, 2009, J PEDIATR SURG, V44, P212, DOI 10.1016/j.jpedsurg.2008.10.042; Srere P.A., 1969, METHODS ENZYMOLOGY, V13, P3, DOI [10.1016/0076-6879(69)13005-0, DOI 10.1016/0076-6879(69)13005-0]; Tennant DA, 2010, NAT REV CANCER, V10, P267, DOI 10.1038/nrc2817; TISDALE MJ, 1983, BRIT J CANCER, V47, P293, DOI 10.1038/bjc.1983.38; Vander Heiden MG, 2011, NAT REV DRUG DISCOV, V10, P671, DOI 10.1038/nrd3504; Venkateswaran V, 2007, J NATL CANCER I, V99, P1793, DOI 10.1093/jnci/djm231; Warburg O, 1924, NATURWISSENSCHAFTEN, V12, P1131, DOI 10.1007/BF01504608; Xun Z, 2012, MECH AGEING DEV, V133, P176, DOI 10.1016/j.mad.2012.01.008; Zhang DS, 2014, CANCER LETT, V355, P176, DOI 10.1016/j.canlet.2014.09.003; Zimmermann FA, 2009, BRIT J CANCER, V100, P1434, DOI 10.1038/sj.bjc.6605028; Zimmermann Franz A, 2011, Front Biosci (Elite Ed), V3, P315; Zuccoli G, 2010, NUTR METAB, V7, DOI 10.1186/1743-7075-7-33	88	63	66	0	20	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 8	2015	10	6							e0129802	10.1371/journal.pone.0129802	http://dx.doi.org/10.1371/journal.pone.0129802			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CK1GM	26053068	Green Published, gold, Green Accepted, Green Submitted			2023-01-03	WOS:000355955300163
J	Collado, S; Coll, E; Nicolau, C; Pons, M; Cruzado, JM; Pascual, J; Cases, A				Collado, Slvia; Coll, Elisabeth; Nicolau, Carlos; Pons, Mercedes; Cruzado, Josep M.; Pascual, Julio; Cases, Aleix			Carotid Atherosclerotic Disease Predicts Cardiovascular Events in Hemodialysis Patients: A Prospective Study	PLOS ONE			English	Article							INTIMA-MEDIA THICKNESS; CHRONIC KIDNEY-DISEASE; CHRONIC-RENAL-FAILURE; ALL-CAUSE MORTALITY; RISK-FACTORS; DIALYSIS PATIENTS; PROGNOSTIC VALUE; WALL THICKNESS; FOLLOW-UP; PLAQUE	Background To evaluate the predictive value of carotid atherosclerotic disease (CAD) and intima-media thickness (IMT) on incident cardiovascular disease and mortality in hemodialysis patients. Methods Multicenter, observational, prospective study including 110 patients, followed-up to 6 years. Carotid doppler ultrasonographic findings were classified in 4 degrees of severity: 1) IMT < 0.9 mm, 2) IMT > 0.9 mm, 3) carotid plaque with stenosis < 50% and 4) plaque with stenosis > 50%. The associations between IMT and CAD and cardiovascular events, total and cardiovascular mortality were assessed. Results 83% of the patients had atherosclerotic plaques (CAD degrees 3-4). During follow-up, 29.1% of patients experienced cardiovascular events, and 28.2% died, 38.7% of cardiovascular origin. The presence of plaques was associated with cardiovascular events (p = 0.03) while calcified plaques were associated with both cardiovascular events (p = 0.01), cardiovascular mortality (p = 0.03) and non-significantly with overall mortality (p = 0.08) in the survival analysis. Carotid IMT was not associated with outcomes. Cardiovascular events correlated with CAD severity (HR 2.27, 95% CI 1.13-4.54), age (HR 1.04, 1.01-1.06), previous cardiovascular disease (HR 1.75, 1.05-4.42), dyslipidemia (HR 2.25, 1.11-4.53), lipoprotein (a) (HR 1.01, 1.00-1.02), troponin I (HR 3.89, 1.07-14.18), fibrinogen levels (HR 1.38, 0.98-1.94) and antiplatelet therapy (HR 2.14, 1.04-4.4). In an age-adjusted multivariate model, cardiovascular events were independently associated with previous coronary artery disease (HR 3.29, 1.52-7.15) and lipoprotein (a) (HR 1.01, 1.00-1.02). Conclusions The presence of carotid plaques and, especially, calcified plaques, are predictors of new cardiovascular events and cardiovascular mortality in hemodialysis patients, while IMT was not. The prognostic value of calcified plaques should be confirmed in future studies.	[Collado, Slvia; Pascual, Julio] Hosp del Mar, Dept Nephrol, Barcelona, Spain; [Coll, Elisabeth] Fdn Puigvert, Dept Nephrol, Barcelona, Spain; [Nicolau, Carlos] Hosp Clin Barcelona, Dept Radiol, Barcelona, Spain; [Pons, Mercedes] CETIRSA Barcelona, Fresenius Med Care,Barcelona, Barcelona, Spain; [Cruzado, Josep M.] Inst Hemodialisi Barcelona, Barcelona, Spain; [Cases, Aleix] Hosp Clin Barcelona, Dept Nephrol, Barcelona, Spain; [Cases, Aleix] Univ Barcelona, Barcelona, Spain	Institut Hospital del Mar d'Investigacions Mediques (IMIM); Hospital del Mar; Fundacio Puigvert; University of Barcelona; Hospital Clinic de Barcelona; University of Barcelona; Hospital Clinic de Barcelona; University of Barcelona	Collado, S (corresponding author), Hosp del Mar, Dept Nephrol, Barcelona, Spain.	scolladonieto@yahoo.es	Cases, Aleix/N-4736-2018	Cases, Aleix/0000-0002-6962-8184; COLLADO NIETO, SILVIA/0000-0002-1812-1367	Spanish Ministry of Health [03/0791]; Fondo de Investigacion Sanitaria Instituto Carlos III, Ministerio de Sanidad y Consumo [03/0791]	Spanish Ministry of Health(Instituto de Salud Carlos IIISpanish Government); Fondo de Investigacion Sanitaria Instituto Carlos III, Ministerio de Sanidad y Consumo	This study was supported in part by the FISS project 03/0791 (a public grant from the Spanish Ministry of Health) ["Fondo de Investigacion Sanitaria Instituto Carlos III, Ministerio de Sanidad y Consumo. FIS project 03/0791, http://www.isciii.es/ISCIII/es/contenidos/fd-investigacion/fd-financiacion/ convocatorias-ayudas-accion-estrategica-salud.shtml].	Aggarwal HK, 2010, RENAL FAILURE, V32, P647, DOI 10.3109/0886022X.2010.486097; Benedetto FA, 2001, J AM SOC NEPHROL, V12, P2458, DOI 10.1681/ASN.V12112458; Benedetto FA, 2008, J AM SOC NEPHROL, V19, P757, DOI 10.1681/ASN.2007070813; Blacher J, 1999, CIRCULATION, V99, P2434, DOI 10.1161/01.CIR.99.18.2434; Cao JJ, 2007, CIRCULATION, V116, P32, DOI 10.1161/CIRCULATIONAHA.106.645606; Chambless LE, 2000, AM J EPIDEMIOL, V151, P478; Chambless LE, 1997, AM J EPIDEMIOL, V146, P483, DOI 10.1093/oxfordjournals.aje.a009302; Cheung AK, 2000, KIDNEY INT, V58, P353, DOI 10.1046/j.1523-1755.2000.00173.x; Drozdz Maciej, 2011, Przegl Lek, V68, P1162; Falaknazil K, 2012, SAUDI J KIDNEY DIS T, V23, P31; Junyent M, 2010, NEFROLOGIA, V30, P119, DOI 10.3265/Nefrologia.pre2010.Jan.10216; Kato A, 2003, KIDNEY INT, V64, P1472, DOI 10.1046/j.1523-1755.2003.00205.x; Kato K, 2013, CIRC-CARDIOVASC IMAG, V6, P448, DOI 10.1161/CIRCIMAGING.112.000165; Leskinen Y, 2003, ATHEROSCLEROSIS, V171, P295, DOI 10.1016/j.atherosclerosis.2003.08.010; Mancia G, 2007, J HYPERTENS, V25, P1751, DOI 10.1097/HJH.0b013e3282f0580f; Nakano T, 2013, KIDNEY INT, V84, P373, DOI 10.1038/ki.2013.111; Nakashima A, 2003, INTERNAL MED, V42, P1095, DOI 10.2169/internalmedicine.42.1095; Nambi V, 2010, J AM COLL CARDIOL, V55, P1600, DOI 10.1016/j.jacc.2009.11.075; NICHOLS P, 1990, Q J MED, V77, P1175, DOI 10.1093/qjmed/77.2.1175; Ortiz A, 2012, NAT REV NEPHROL, V8, P141, DOI 10.1038/nrneph.2011.170; Ossareh S, 2011, IRAN J KIDNEY DIS, V5, P169; Park SH, 2012, J RENAL NUTR, V22, P120, DOI 10.1053/j.jrn.2011.10.021; Peters SAE, 2011, AM J CARDIOVASC DRUG, V11, P253, DOI 10.2165/11591960-000000000-00000; Rakhit DJ, 2006, HEART, V92, P1402, DOI 10.1136/hrt.2005.074393; Sanchez-Alvarez JE, 2010, NEFROLOGIA, V30, P427, DOI 10.3265/Nefrologia.pre2010.Mar.10277; Savage T, 1998, NEPHROL DIAL TRANSPL, V13, P2004, DOI 10.1093/ndt/13.8.2004; Schwaiger JP, 2006, AM J KIDNEY DIS, V47, P888, DOI 10.1053/j.ajkd.2006.01.011; Schwarz U, 2000, NEPHROL DIAL TRANSPL, V15, P218, DOI 10.1093/ndt/15.2.218; Shah DS, 2008, NEPHROLOGY, V13, P667, DOI 10.1111/j.1440-1797.2008.00982.x; Sharma K, 2009, AM J CARDIOL, V103, P1316, DOI 10.1016/j.amjcard.2009.01.020; Stenvinkel P, 1999, KIDNEY INT, V55, P1899, DOI 10.1046/j.1523-1755.1999.00422.x; Stenvinkel P, 2012, NAT REV NEPHROL, V8, P72, DOI 10.1038/nrneph.2011.212; Touboul PJ, 2012, CEREBROVASC DIS, V34, P290, DOI 10.1159/000343145; van den Oord SCH, 2013, ATHEROSCLEROSIS, V228, P1, DOI 10.1016/j.atherosclerosis.2013.01.025; Wang JG, 2006, STROKE, V37, P1933, DOI 10.1161/01.STR.0000227223.90239.13; Zoccali C, 2000, NEPHROL DIAL TRANSPL, V15, P454, DOI 10.1093/ndt/15.4.454	36	11	11	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 1	2015	10	6							e0127344	10.1371/journal.pone.0127344	http://dx.doi.org/10.1371/journal.pone.0127344			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CL0KF	26029907	Green Published, Green Submitted, gold			2023-01-03	WOS:000356630900048
J	Finlay, K; Stoecker, C; Cunningham, S				Finlay, Keith; Stoecker, Charles; Cunningham, Scott			Willingness-To-Accept Pharmaceutical Retail Inconvenience: Evidence from a Contingent Choice Experiment	PLOS ONE			English	Article							METHAMPHETAMINE USE; PRESCRIPTION; PSEUDOEPHEDRINE; PHENYLEPHRINE; BENEFITS; DRUGS	Objectives Restrictions on retail purchases of pseudoephedrine are one regulatory approach to reduce the social costs of methamphetamine production and use, but may impose costs on legitimate users of nasal decongestants. This is the first study to evaluate the costs of restricting access to medications on consumer welfare. Our objective was to measure the inconvenience cost consumers place on restrictions for cold medication purchases including identification requirements, purchase limits, over-the-counter availability, prescription requirements, and the active ingredient. Methods We conducted a contingent choice experiment with Amazon Mechanical Turk workers that presented participants with randomized, hypothetical product prices and combinations of restrictions that reflect the range of public policies. We used a conditional logit model to calculate willingness-to-accept each restriction. Results Respondents' willingness-to-accept prescription requirements was $14.17 ($9.76-$18.58) and behind-the-counter restrictions was $9.68 ($7.03-$12.33) per box of pseudoephedrine product. Participants were willing to pay $4.09 ($1.66-$6.52) per box to purchase pseudoephedrine- based products over phenylephrine-based products. Conclusions Restricting access to medicines as a means of reducing the social costs of non-medical use can imply large inconvenience costs for legitimate consumers. These results are relevant to discussions of retail access restrictions on other medications.	[Finlay, Keith] Tulane Univ, Dept Econ, New Orleans, LA 70118 USA; [Stoecker, Charles] Tulane Univ, Dept Global Hlth Management & Policy, Sch Publ Hlth & Trop Med, New Orleans, LA 70118 USA; [Cunningham, Scott] Baylor Univ, Dept Econ, Waco, TX 76798 USA	Tulane University; Tulane University; Baylor University	Stoecker, C (corresponding author), Tulane Univ, Dept Global Hlth Management & Policy, Sch Publ Hlth & Trop Med, New Orleans, LA 70118 USA.	cfstoecker@tulane.edu			National Science Foundation award [SMA-1004569]; Robert Wood Johnson Foundation [70509]	National Science Foundation award(National Science Foundation (NSF)); Robert Wood Johnson Foundation(Robert Wood Johnson Foundation (RWJF))	This work was supported by the National Science Foundation award SMA-1004569 (www.nsf. gov, KF SC) and the Robert Wood Johnson Foundation (Public Health Law Research award 70509, http://publichealthlawresearch.org/, KF SC). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Barr AM, 2006, J PSYCHIATR NEUROSCI, V31, P301; Berinsky AJ, 2012, POLIT ANAL, V20, P351, DOI 10.1093/pan/mpr057; Brass EP, 2001, NEW ENGL J MED, V345, P810, DOI 10.1056/NEJMra011080; Buhrmester M, 2011, PERSPECT PSYCHOL SCI, V6, P3, DOI 10.1177/1745691610393980; Cohen JP, 2005, BRIT MED J, V330, P39, DOI 10.1136/bmj.330.7481.39; de Bekker-Grob EW, 2012, HEALTH ECON, V21, P145, DOI 10.1002/hec.1697; DeShazo JR, 2002, J ENVIRON ECON MANAG, V44, P123, DOI 10.1006/jeem.2001.1199; Eccles R, 2007, BRIT J CLIN PHARMACO, V63, P10, DOI 10.1111/j.1365-2125.2006.02833.x; Hanley N, 1998, J AGR ECON, V49, P1, DOI 10.1111/j.1477-9552.1998.tb01248.x; Hatton RC, 2007, ANN PHARMACOTHER, V41, P381, DOI 10.1345/aph.1H679; Hensher D.A., 2005, APPL CHOICE ANAL PRI; Hershey MR, 2009, PS-POLIT SCI POLIT, V42, P87, DOI 10.1017/S1049096509090234; Horton JJ, 2011, EXP ECON, V14, P399, DOI 10.1007/s10683-011-9273-9; Iritani BJ, 2007, ADDICTION, V102, P1102, DOI 10.1111/j.1360-0443.2007.01847.x; Kaye S, 2007, ADDICTION, V102, P1204, DOI 10.1111/j.1360-0443.2007.01874.x; Krieger A. M., 1991, MARKET LETT, V2, P337, DOI DOI 10.1007/BF00664220; Krupnikov Yanna., 2014, J EXP POLIT SCI, V1, P59, DOI DOI 10.1017/XPS.2014.7; Louviere J.J., 2000, STATED CHOICE METHOD; Louviere JJ, 2008, J CONSUM RES, V35, P360, DOI 10.1086/586913; Luchini S, 2014, ECON LETT, V124, P9, DOI 10.1016/j.econlet.2014.04.005; McKetin R, 2014, ADDICTION, V109, P798, DOI 10.1111/add.12474; OEHLERT GW, 1992, AM STAT, V46, P27, DOI 10.2307/2684406; Paolacci G, 2010, JUDGM DECIS MAK, V5, P411; Prasad M, 2002, VALUE HEALTH, V5, P193, DOI [10.1016/S1098-3015(10)60991-6, DOI 10.1016/S1098-3015(10)60991-6]; Reynolds T, 2002, ANN INTERN MED, V136, P177, DOI 10.7326/0003-4819-136-2-200201150-00026; RYAN M, 1990, HEALTH POLICY, V16, P233, DOI 10.1016/0168-8510(90)90424-C; Shoptaw S, 2007, ADDICTION, V102, P130, DOI 10.1111/j.1360-0443.2006.01775.x; Simons DJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051876; Talbert J, 2012, JAMA-J AM MED ASSOC, V308, P1524, DOI 10.1001/jama.2012.12992; [US DEA] United States Drug Enforcement Administration, 2010, FED REGISTER, V75, P79407; [US DEA] United States Drug Enforcement Administration, 2007, 2005 EPH PSEUD LEG M; Wiley JB., 1978, ADV CONSUM RES, V5, P171	32	1	1	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 29	2015	10	5							e0126790	10.1371/journal.pone.0126790	http://dx.doi.org/10.1371/journal.pone.0126790			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	CJ2MQ	26024444	Green Published, Green Submitted, gold			2023-01-03	WOS:000355319400020
J	Zhao, XY; Wang, SM; Wu, JJ; Li, XY; Wang, X; Gao, ZQ; Wu, WT; Wang, HJ; Wang, JC; Qian, J; Ma, K; Li, H; Han, BH; Bai, CX; Li, Q; Liu, WB; Lu, DR				Zhao, Xueying; Wang, Shiming; Wu, Junjie; Li, Xiaoying; Wang, Xun; Gao, Zhiqiang; Wu, Wenting; Wang, Haijian; Wang, Jiucun; Qian, Ji; Ma, Ke; Li, Hui; Han, Baohui; Bai, Chunxue; Li, Qiang; Liu, Wenbin; Lu, Daru			Association of TERT Polymorphisms with Clinical Outcome of Non-Small Cell Lung Cancer Patients	PLOS ONE			English	Article							TELOMERASE REVERSE-TRANSCRIPTASE; PLATINUM-BASED CHEMOTHERAPY; PROGRESSION-FREE SURVIVAL; SURROGATE END-POINT; GENETIC-VARIANTS; SEVERE TOXICITY; NEVER-SMOKERS; EXPRESSION; HTERT; LOCUS	TERT is of great importance in cancer initiation and progression. Many studies have demonstrated the TERT polymorphisms as risk factors for many cancer types, including lung cancer. However, the impacts of TERT variants on cancer progression and treatment efficacy have remained controversial. This study aimed to investigate the association of TERT polymorphisms with clinical outcome of advanced non-small cell lung cancer (NSCLC) patients receiving first-line platinum-based chemotherapy, including response rate, clinical benefit, progression-free survival (PFS), overall survival (OS), and grade 3 or 4 toxicity. Seven polymorphisms of TERT were assessed, and a total of 1004 inoperable advanced NSCLC patients treated with platinum-based chemotherapy were enrolled. It is exhibited that the variant heterozygote of rs4975605 showed significant association with a low rate of clinical benefit, and displayed a much stronger effect in never-smoking female subset, leading to the clinical benefit rate decreased from 82.9% (C/C genotype) to 56.4% (C/A genotype; adjusted OR, 3.58; P=1.40x10(-4)). It is also observed that the polymorphism rs2736109 showed significant correlation with PFS (log-rank P=0.023). In age > 58 subgroup, patients carrying the heterozygous genotype had a longer median PFS than those carrying the wildtype genotypes (P=0.002). The results from the current study, for the first time to our knowledge, provide suggestive evidence of an effect of TERT polymorphisms on disease progression variability among Chinese patients with platinum-treated advanced NSCLC.	[Zhao, Xueying; Wang, Shiming; Wu, Junjie; Li, Xiaoying; Wu, Wenting; Wang, Haijian; Wang, Jiucun; Qian, Ji; Lu, Daru] Fudan Univ, Sch Life Sci, Inst Genet, State Key Lab Genet Engn, Shanghai 200433, Peoples R China; [Zhao, Xueying; Wang, Shiming; Wu, Junjie; Li, Xiaoying; Wu, Wenting; Wang, Haijian; Wang, Jiucun; Qian, Ji; Lu, Daru] Fudan Univ, Sch Life Sci, Inst Genet, MOE Key Lab Contemporary Anthropol, Shanghai 200433, Peoples R China; [Wu, Junjie; Li, Qiang] Second Mil Med Univ, Changhai Hosp Shanghai, Dept Pneumol, Shanghai, Peoples R China; [Wang, Xun; Bai, Chunxue] Fudan Univ, Zhongshan Hosp, Dept Pulm Med, Shanghai 200433, Peoples R China; [Gao, Zhiqiang; Han, Baohui] Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Dept Resp Dis, Shanghai 200030, Peoples R China	Fudan University; Fudan University; Naval Medical University; Fudan University; Shanghai Jiao Tong University	Liu, WB (corresponding author), Shanghai Res Inst Criminal Sci & Technol, Shanghai Key Lab Crime Scene Evidence, Shanghai, Peoples R China.	wbliu1981@163.com; drlu@fudan.edu.cn	wu, wenting/Q-4979-2016	wu, wenting/0000-0003-0982-771X; Bai, Chunxue/0000-0001-5798-3130				Beck S, 2011, MOL CELLS, V31, P9, DOI 10.1007/s10059-011-0008-8; Bertorelle R, 2013, BRIT J CANCER, V108, P278, DOI 10.1038/bjc.2012.602; Cecchin E, 2009, J CLIN ONCOL, V27, P2457, DOI 10.1200/JCO.2008.19.0314; Chen D, 2008, CARCINOGENESIS, V29, P342, DOI 10.1093/carcin/bgm285; Choi JK, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.0040010; Clevers H, 2012, CELL, V149, P1192, DOI 10.1016/j.cell.2012.05.012; Colangelo D, 2005, CURR MED CHEM, V12, P3091, DOI 10.2174/092986705774933416; Ding DQ, 2013, FEBS J, V280, P3205, DOI 10.1111/febs.12258; Gabriel SB, 2002, SCIENCE, V296, P2225, DOI 10.1126/science.1069424; Garon EB, 2012, LUNG CANCER, V77, P475, DOI 10.1016/j.lungcan.2012.06.007; Ghosh A, 2012, NAT CELL BIOL, V14, P1270, DOI 10.1038/ncb2621; Han BH, 2011, LUNG CANCER, V72, P238, DOI 10.1016/j.lungcan.2010.09.001; Han KL, 2014, NEURO-ONCOLOGY, V16, P696, DOI 10.1093/neuonc/not236; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hsiung CA, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1001051; Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI [10.3322/caac.20115, 10.3322/caac.20107]; Lan Q, 2012, NAT GENET, V44, P1330, DOI 10.1038/ng.2456; Lantuejoul S, 2004, BRIT J CANCER, V90, P1222, DOI 10.1038/sj.bjc.6601643; Li YH, 2014, CANCER RES, V74, P1639, DOI 10.1158/0008-5472.CAN-13-3568; McKay JD, 2008, NAT GENET, V40, P1404, DOI 10.1038/ng.254; Mocellin S, 2012, JNCI-J NATL CANCER I, V104, P840, DOI 10.1093/jnci/djs222; Peng Y, 2014, INT J CANCER, V135, P2687, DOI 10.1002/ijc.28892; Rafnar T, 2009, NAT GENET, V41, P221, DOI 10.1038/ng.296; Rudin CM, 2009, CLIN CANCER RES, V15, P5646, DOI 10.1158/1078-0432.CCR-09-0377; Ruzzo A, 2006, J CLIN ONCOL, V24, P1883, DOI 10.1200/JCO.2005.04.8322; Sidhu R, 2013, CLIN CANCER RES, V19, P969, DOI 10.1158/1078-0432.CCR-12-2502; Siegel R, 2014, CA-CANCER J CLIN, V64, P9, DOI 10.3322/caac.21208; Stephens M, 2003, AM J HUM GENET, V73, P1162, DOI 10.1086/379378; Sun YH, 2010, J CLIN ONCOL, V28, P4616, DOI 10.1200/JCO.2010.29.6038; Tchirkov A, 2003, BRIT J CANCER, V88, P516, DOI 10.1038/sj.bjc.6600754; Wang L, 2002, CLIN CANCER RES, V8, P2883; Wang YF, 2010, CARCINOGENESIS, V31, P234, DOI 10.1093/carcin/bgp287; Wang YF, 2008, NAT GENET, V40, P1407, DOI 10.1038/ng.273; Wright WE, 1996, DEV GENET, V18, P173; Wu WT, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033200; Wu WT, 2009, CLIN CANCER RES, V15, P3889, DOI 10.1158/1078-0432.CCR-08-2715	36	10	11	1	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 28	2015	10	5							e0129232	10.1371/journal.pone.0129232	http://dx.doi.org/10.1371/journal.pone.0129232			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CJ0SC	26020272	Green Published, gold, Green Submitted			2023-01-03	WOS:000355187300124
J	Sedgwick, P				Sedgwick, Philip			Measuring the detriment of treatment: number needed to harm	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material									Univ London, Inst Med & Biomed Educ, Med Stat & Med Educ, London, England	University of London	Sedgwick, P (corresponding author), Univ London, Inst Med & Biomed Educ, Med Stat & Med Educ, London, England.	p.sedgwick@sgul.ac.uk	Sedgwick, Philip/C-6997-2019	Sedgwick, Philip/0000-0001-8859-2175				Berlin Ivan, 2014, BMJ, V348, pg1622, DOI 10.1136/bmj.g1622; Sedgwick P, 2015, BMJ-BRIT MED J, V350, DOI 10.1136/bmj.h2206; Sedgwick P, 2013, BMJ-BRIT MED J, V347, DOI 10.1136/bmj.f4869	3	2	2	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 22	2015	350								h2763	10.1136/bmj.h2763	http://dx.doi.org/10.1136/bmj.h2763			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CI9ZO	26002193				2023-01-03	WOS:000355130600003
J	Noguchi-Shinohara, M; Ono, K; Hamaguchi, T; Iwasa, K; Nagai, T; Kobayashi, S; Nakamura, H; Yamada, M				Noguchi-Shinohara, Moeko; Ono, Kenjiro; Hamaguchi, Tsuyoshi; Iwasa, Kazuo; Nagai, Toshitada; Kobayashi, Shoko; Nakamura, Hiroyuki; Yamada, Masahito			Pharmacokinetics, Safety and Tolerability of Melissa officinalisExtract which Contained Rosmarinic Acid in Healthy Individuals: A Randomized Controlled Trial	PLOS ONE			English	Article							PERILLA-FRUTESCENS; ALZHEIMERS-DISEASE; MODULATION; OLIGOMERS; EXTRACT; MEMORY; MOOD; SAGE	The aim of this study was to evaluate the safety, tolerability and pharmacokinetics of single dose of Melissa officinalis extract which contained rosmarinic acid, including food-effects in healthy individuals. A total of eleven healthy individuals were randomly assigned to treatment arms in the two studies [Study 1 (fasted state) and Study 2 (fed state)]. Rosmarinic acid in serum was measured by a coulometric detection method using High-Performance Liquid Chromatography electrochemical detector. The serum concentration of total rosmarinic acid peaked at 1 hour after administration of Melissa officinalisextract containing 500mg rosmarinic acid in fasted state, with a maximum serum concentration 162.20 nmol/L. The area under the curve for intact rosmarinic acid was calculated from the serum concentration-time profile to be 832.13 nmol. hour/L. Food intake increases area under the curve and delayed time at which the maximum serum concentration. Rosmarinic acid supplementation did not affect liver, kidney, or blood cell function parameters. No adverse event was reported by any of the participants due to the study treatment. Single dose of Melissa officinalisextract containing 500 mg rosmarinic acid appears to be safe and tolerable in healthy individuals. Food intake increased the exposure of rosmarinic acid and delayed absorption of rosmarinic acid in healthy individuals.	[Noguchi-Shinohara, Moeko; Ono, Kenjiro; Hamaguchi, Tsuyoshi; Iwasa, Kazuo; Yamada, Masahito] Kanazawa Univ, Grad Sch Med Sci, Dept Neurol & Neurobiol Aging, Kanazawa, Ishikawa, Japan; [Nagai, Toshitada] Takasaki Univ Hlth & Welf, Dept Food & Life Sci, Gunma, Japan; [Kobayashi, Shoko] Univ Tokyo, Grad Sch Agr & Life Sci, Res Ctr Food Safety, Tokyo, Japan; [Nakamura, Hiroyuki] Kanazawa Univ, Grad Sch Med Sci, Dept Environm & Prevent Med, Kanazawa, Ishikawa, Japan	Kanazawa University; University of Tokyo; Kanazawa University	Yamada, M (corresponding author), Kanazawa Univ, Grad Sch Med Sci, Dept Neurol & Neurobiol Aging, Kanazawa, Ishikawa, Japan.	m-yamada@med.kanazawa-u.ac.jp		Nagai, Toshitada/0000-0002-9152-0073	Science of the Ministry of Education, Culture, Sports, Science and Technology of Japan; Ministry of Health, Labour, and Welfare, Japan; Research Project on Development of Agricultural Products and Foods with Health-promoting benefits (NARO)	Science of the Ministry of Education, Culture, Sports, Science and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Ministry of Health, Labour, and Welfare, Japan(Ministry of Health, Labour and Welfare, Japan); Research Project on Development of Agricultural Products and Foods with Health-promoting benefits (NARO)	This work was supported in part by a Grant-in-Aid Scientific Research from the Science of the Ministry of Education, Culture, Sports, Science and Technology of Japan (MY, MN-S), a grant to the Amyloidosis Research Committee from the Ministry of Health, Labour, and Welfare, Japan (MY), and Research Project on Development of Agricultural Products and Foods with Health-promoting benefits (NARO) (SK). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Akhondzadeh S, 2003, J NEUROL NEUROSUR PS, V74, P863, DOI 10.1136/jnnp.74.7.863; Al-Sereiti M. R., 1999, Indian Journal of Experimental Biology, V37, P124; Alkam T, 2007, BEHAV BRAIN RES, V180, P139, DOI 10.1016/j.bbr.2007.03.001; Areias F, 2000, J AGR FOOD CHEM, V48, P6081, DOI 10.1021/jf000440+; Baba S, 2005, EUR J NUTR, V44, P1, DOI 10.1007/s00394-004-0482-2; Ballard C, 2011, LANCET, V377, P1019, DOI 10.1016/S0140-6736(10)61349-9; Carnat A., 1998, PHARM ACTA HELV, V72, P301, DOI DOI 10.1016/S0031-6865(97)00026-5; Center for Drug Evaluation and Research (CDER), 2000, WAIV IN VIV BIOAV BI; Cummings JL, 2004, NEW ENGL J MED, V351, P56, DOI 10.1056/NEJMra040223; Faustmen EM, 1996, CASARETT DOULLS TOXI, P75; Haass C, 2007, NAT REV MOL CELL BIO, V8, P101, DOI 10.1038/nrm2101; Hamaguchi T, 2009, AM J PATHOL, V175, P2557, DOI 10.2353/ajpath.2009.090417; Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994; Iuvone T, 2006, J PHARMACOL EXP THER, V317, P1143, DOI 10.1124/jpet.105.099317; Kennedy DO, 2003, NEUROPSYCHOPHARMACOL, V28, P1871, DOI 10.1038/sj.npp.1300230; Kennedy DO, 2002, PHARMACOL BIOCHEM BE, V72, P953, DOI 10.1016/S0091-3057(02)00777-3; Konishi Y, 2005, J AGR FOOD CHEM, V53, P4740, DOI 10.1021/jf0478307; Konishi Y, 2005, BIOSCI BIOTECH BIOCH, V69, P583, DOI 10.1271/bbb.69.583; Makino T, 1998, PLANTA MED, V64, P541, DOI 10.1055/s-2006-957510; Martin SJ, 2000, ANNU REV NEUROSCI, V23, P649, DOI 10.1146/annurev.neuro.23.1.649; Ono K, 2004, J NEUROSCI RES, V75, P742, DOI 10.1002/jnr.20025; Ono K, 2012, J BIOL CHEM, V287, P14631, DOI 10.1074/jbc.M111.325456; Ono K, 2011, J NEUROCHEM, V117, P19, DOI 10.1111/j.1471-4159.2011.07187.x; Petersen M, 2003, PHYTOCHEMISTRY, V62, P121, DOI 10.1016/S0031-9422(02)00513-7; Stahringer SS, 2012, GENOME RES, V22, P2146, DOI 10.1101/gr.140608.112; Usansky J. I., 2011, PK FUNCTIONS MICROSO	26	45	46	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 15	2015	10	5							e0126422	10.1371/journal.pone.0126422	http://dx.doi.org/10.1371/journal.pone.0126422			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CI7AU	25978046	Green Published, gold, Green Submitted			2023-01-03	WOS:000354916100067
J	Stock, S				Stock, Stephanie			INTERNATIONAL HEALTH CARE SYSTEMS Integrated Ambulatory Specialist Care - Germany's New Health Care Sector	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Inst Hlth Econ & Clin Epidemiol, Cologne, Germany		Stock, S (corresponding author), Inst Hlth Econ & Clin Epidemiol, Cologne, Germany.							[Anonymous], 2012, EARL EV PAT CENT MED; [Anonymous], 2013, HLTH INF TECHN US BE; Nolte E, 2012, HEALTH ECON POLICY L, V7, P125, DOI 10.1017/S1744133111000338; Stock S, 2010, HEALTH AFFAIR, V29, P2197, DOI 10.1377/hlthaff.2009.0799	4	6	6	2	10	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 7	2015	372	19					1781	1785		10.1056/NEJMp1413625	http://dx.doi.org/10.1056/NEJMp1413625			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	CH4BB	25946277				2023-01-03	WOS:000353974700001
J	Chen, YY; Xu, GB; Yang, F				Chen, YangYang; Xu, GuoBin; Yang, Feng			Effect of Neoadjuvant Chemotherapy on the Serum Levels of Bone Turnover Markers in Women with Early-Stage Breast Cancer	PLOS ONE			English	Article							VITAMIN-D; ADJUVANT CHEMOTHERAPY; POSTMENOPAUSAL WOMEN; MINERAL DENSITY; OSTEOPOROSIS; METASTASIS; MECHANISMS	Background To evaluate effects of neoadjuvant chemotherapy on the bone turnover markers of preoperational breast cancer patients. Methods Forty-one breast cancer patients (29 premenopausal and 12 postmenopausal) and 60 healthy women (30 premenopausal and 30 postmenopausal) aged 30-64 years, were evaluated for their bone status. Serum levels of the bone formation markers PINP and BAP, as well as the resorption markers ICTP and beta-Crosslaps in addition to E2, FSH, 25(OH)D and PTH were measured at the initial diagnosis and at 24 hours after each four chemotherapy cycles. BMD T-scores were determined in 12 patients 6 months after the neoadjuvant chemotherapies. Results The baseline levels of both bone formation and resorption markers in premenopausal patients were higher than in premenopausal healthy women (p<0.05), while no statistic difference was observed between postmenopausal patients and postmenopausal healthy women. Regardless of the menopausal status, chemotherapy increased the ICTP and beta-Crosslaps levels (p<0.05), but decreased the BAP and PINP levels (p<0.05), the later one significantly more with Taxane medication (p<0.01, p<0.05). Chemotherapy caused significant decreases of 25(OH) D levels in premenopausal (p<0.01) and postmenopausal (p<0.05) patients, however, did not affect the PTH concentrations. In premenopausal patients the E2 level decreased, while the FSH level increased after chemotherapy (p<0.05). Patients with pronounced ICTP and beta-Crosslaps combined with reduced BAP and PINP serum concentrations after neoadjuvant chemotherapies were prone to develop osteoporosis 6 month later. Conclusions Neoadjuvant chemotherapy appeared to promote bone resorption and inhibit bone formation in both postmenopausal and premenopausal early-stage breast patients.	[Chen, YangYang; Xu, GuoBin] Peking Univ, Canc Hosp & Inst, Dept Clin Lab, Beijing 100871, Peoples R China; [Yang, Feng] Peking Univ, Canc Hosp & Inst, Dept Breast Surg, Beijing 100871, Peoples R China	Peking University; Peking University	Xu, GB (corresponding author), Peking Univ, Canc Hosp & Inst, Dept Clin Lab, Beijing 100871, Peoples R China.	cyyjyk02@163.com						Bendre M, 2003, CLIN ORTHOP RELAT R, pS39, DOI 10.1097/01.blo.0000093844.72468.f4; Bines J, 1996, J CLIN ONCOL, V14, P1718, DOI 10.1200/JCO.1996.14.5.1718; Bischoff-Ferrari HA, 2004, AM J MED, V116, P634, DOI 10.1016/j.amjmed.2003.12.029; Cauley JA, 2010, J BONE MINER RES, V25, P545, DOI 10.1359/jbmr.090826; Coleman RE, 2013, NAT REV RHEUMATOL, V9, P365, DOI 10.1038/nrrheum.2013.36; Delmas PD, 1998, EUR J CANCER, V34, P260, DOI 10.1016/S0959-8049(97)10135-6; Demers Laurence M., 2000, Cancer, V88, P2919, DOI 10.1002/1097-0142(20000615)88:12+<2919::AID-CNCR7>3.0.CO;2-Z; Fohr B, 2003, J CLIN ENDOCR METAB, V88, P5059, DOI 10.1210/jc.2003-030910; Hadji P, 2009, EUR J CANCER, V45, P3205, DOI 10.1016/j.ejca.2009.09.026; Holick MF, 2011, J CLIN ENDOCR METAB, V96, P1911, DOI 10.1210/jc.2011-0385; Kennel KA, 2013, CURR OPIN SUPPORT PA, V7, P272, DOI 10.1097/SPC.0b013e3283640f74; Kleerekoper M, 2005, INT J FERTIL WOMEN M, V50, P61; Marcus R, 1999, J BONE MINER RES, V14, P1583, DOI 10.1359/jbmr.1999.14.9.1583; Miller PD, 1999, J CLIN ENDOCR METAB, V84, P1867, DOI 10.1210/jc.84.6.1867; Pederson L, 1999, CANCER RES, V59, P5849; Pfeilschifter J, 2000, J CLIN ONCOL, V18, P1570, DOI 10.1200/JCO.2000.18.7.1570; Ramaswamy B, 2003, SEMIN ONCOL, V30, P763, DOI 10.1053/j.seminoncol.2003.08.028; Ricos C, 1999, SCAND J CLIN LAB INV, V59, P491; Roodman GD, 2004, NEW ENGL J MED, V350, P1655, DOI 10.1056/NEJMra030831; Rosen CJ, 2011, NEW ENGL J MED, V364, P248, DOI 10.1056/NEJMcp1009570; Saarto T, 1997, J CLIN ONCOL, V15, P1341, DOI 10.1200/JCO.1997.15.4.1341; Seibel Markus J, 2005, Clin Biochem Rev, V26, P97; Seibel MJ, 2005, NAT CLIN PRACT ONCOL, V2, P504, DOI 10.1038/ncponc0320; Shapiro CL, 2001, J CLIN ONCOL, V19, P3306, DOI 10.1200/JCO.2001.19.14.3306; Tan KML, 2013, J CLIN LAB ANAL, V27, P301, DOI 10.1002/jcla.21602; Tang CH, 2013, CLIN CHIM ACTA, V426, P102, DOI 10.1016/j.cca.2013.09.011; Twiss J J, 2001, J Am Acad Nurse Pract, V13, P276; Waltman NL, 2008, CANCER NURS, V31, P182, DOI 10.1097/01.NCC.0000305722.75647.26; Yin JJ, 2005, CELL RES, V15, P57, DOI 10.1038/sj.cr.7290266; Yu B, 2010, CANCER-AM CANCER SOC, V116, P2099, DOI 10.1002/cncr.25037	30	6	6	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 29	2015	10	4							e0126053	10.1371/journal.pone.0126053	http://dx.doi.org/10.1371/journal.pone.0126053			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CH0LO	25923354	Green Published, Green Submitted, gold			2023-01-03	WOS:000353711600169
J	MacGregor, GA; He, FJ; Pombo-Rodrigues, S				MacGregor, Graham A.; He, Feng J.; Pombo-Rodrigues, Sonia			Food and the responsibility deal: how the salt reduction strategy was derailed	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material									[MacGregor, Graham A.] Queen Mary Univ London, Barts & London Sch Med & Dent, Cardiovasc Med, Wolfson Inst Prevent Med, London EC1M 6BQ, England; [He, Feng J.; Pombo-Rodrigues, Sonia] Queen Mary Univ London, Barts & London Sch Med & Dent, Wolfson Inst Prevent Med, London EC1M 6BQ, England	University of London; Queen Mary University London; University of London; Queen Mary University London	MacGregor, GA (corresponding author), Queen Mary Univ London, Barts & London Sch Med & Dent, Cardiovasc Med, Wolfson Inst Prevent Med, London EC1M 6BQ, England.	g.macgregor@qmul.ac.uk	Pombo-Rodrigues, Sonia/ABA-7019-2020; He, Feng/HHS-6457-2022	He, Feng/0000-0002-1996-0744				Brinsden HC, 2013, BMJ OPEN, V3, DOI 10.1136/bmjopen-2013-002936; Department of Health, PUBL HLTH RESP DEAL; Department of Health, 2011, ASS DIET SOD LEV AD; Department of Health, RESP DEAL; Finucane MM, 2011, LANCET, V377, P557, DOI 10.1016/S0140-6736(10)62037-5; Food Standards Agency, 2006, NEW SALT RED TARG PU; Food Standards Agency, UK SALT RED IN; Food Standards Agency, 2009, SALT RED TARG; Food Standards Scotland, 2017, 2017 SALT TARG; He FJ, 2014, J HUM HYPERTENS, V28, P345, DOI 10.1038/jhh.2013.105; He FJ, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2013-004549; Health Education Authority, 1994, NUTR ASP CARD DIS; Institute for Health Metrics and Evaluation, 2010, DIET RISKS AR LEAD C; Ji C, 2013, BMJ OPEN, V3, DOI 10.1136/bmjopen-2012-002246; Lim SS, 2012, LANCET, V380, P2224, DOI 10.1016/S0140-6736(12)61766-8; MacGregor GA, 1996, BRIT MED J, V312, P1287, DOI 10.1136/bmj.312.7041.1287; Mozaffarian D, 2011, BRIT MED J, V343, DOI 10.1136/bmj.d5747; National Institute for Health and Clinical Excellence, 2010, PREV CARD DIS; O'Dowd A, 2011, BRIT MED J, V342, DOI 10.1136/bmj.d1702; Scientific Advisory Committee on Nutrition, 2003, SALT HLTH; Scottish Food and Drink Federation, HIGHL BAK RED SALT C; Stuckler D, 2012, PLOS MED, V9, DOI [10.1371/journal.pmed.1001235, 10.1371/journal.pmed.1001242]; Webster J, 2014, NUTRIENTS, V6, P3274, DOI 10.3390/nu6083274; World Health Organization, WHO FRAM CONV TOB CO	24	28	27	0	9	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	APR 28	2015	350								h1936	10.1136/bmj.h1936	http://dx.doi.org/10.1136/bmj.h1936			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CH3UM	25922339				2023-01-03	WOS:000353955900001
J	March, L				March, Lyn			An exercise program for hands and arms improved hand function in RA controlled with medication	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									[March, Lyn] Univ Sydney, Inst Bone & Joint Res, Sydney, NSW, Australia; [March, Lyn] Univ Sydney, Royal N Shore Hosp, Sydney, NSW, Australia	University of Sydney; Royal North Shore Hospital; University of Sydney	March, L (corresponding author), Univ Sydney, Inst Bone & Joint Res, Sydney, NSW, Australia.								0	0	0	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 21	2015	162	8							JC9	10.7326/ACPJC-2015-162-8-009	http://dx.doi.org/10.7326/ACPJC-2015-162-8-009			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CG4GT	25894054				2023-01-03	WOS:000353244300008
J	Luedtke, K; Rushton, A; Wright, C; Jurgens, T; Polzer, A; Mueller, G; May, A				Luedtke, Kerstin; Rushton, Alison; Wright, Christine; Juergens, Tim; Polzer, Astrid; Mueller, Gerd; May, Arne			Effectiveness of transcranial direct current stimulation preceding cognitive behavioural management for chronic low back pain: sham controlled double blinded randomised controlled trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article							MULTIPLE END-POINTS; INTENTION-TO-TREAT; OF-THE-ART; MOTOR CORTEX; PRIMARY-CARE; CLINICAL-TRIALS; CENTRAL SENSITIZATION; STATISTICS NOTES; BASE-LINE; MODULATION	OBJECTIVE To evaluate the effectiveness of transcranial direct current stimulation alone and in combination with cognitive behavioural management in patients with non-specific chronic low back pain. DESIGN Double blind parallel group randomised controlled trial with six months' follow-up conducted May 2011-March 2013. Participants, physiotherapists, assessors, and analyses were blinded to group allocation. SETTING Interdisciplinary chronic pain centre. PARTICIPANTS 135 participants with non-specific chronic low back pain >12 weeks were recruited from 225 patients assessed for eligibility. INTERVENTION Participants were randomised to receive anodal (20 minutes to motor cortex at 2 mA) or sham transcranial direct current stimulation (identical electrode position, stimulator switched off after 30 seconds) for five consecutive days immediately before cognitive behavioural management (four week multidisciplinary programme of 80 hours). MAIN OUTCOMES MEASURES Two primary outcome measures of pain intensity (0-100 visual analogue scale) and disability (Oswestry disability index) were evaluated at two primary endpoints after stimulation and after cognitive behavioural management. RESULTS Analyses of covariance with baseline values (pain or disability) as covariates showed that transcranial direct current stimulation was ineffective for the reduction of pain (difference between groups on visual analogue scale 1 mm (99% confidence interval -8.69 mm to 6.3 mm; P=0.68)) and disability (difference between groups 1 point (-1.73 to 1.98; P=0.86)) and did not influence the outcome of cognitive behavioural management (difference between group 3 mm (-10.32 mm to 6.73 mm); P=0.58; difference between groups on Oswestry disability index 0 point (-2.45 to 2.62); P=0.92). The stimulation was well tolerated with minimal transitory side effects. CONCLUSIONS This results of this trial on the effectiveness of transcranial direct current stimulation for the reduction of pain and disability do not support its clinical use for managing non-specific chronic low back pain.	[Luedtke, Kerstin; Juergens, Tim; Polzer, Astrid; May, Arne] Univ Med Ctr Hamburg Eppendorf, Dept Syst Neurosci, D-20246 Hamburg, Germany; [Rushton, Alison; Wright, Christine] Univ Birmingham, Coll Life & Environm Sci, Sch Sport Exercise & Rehabil Sci, Birmingham B15 2TT, W Midlands, England; [Mueller, Gerd] Backpain Clin Am Michel, D-20459 Hamburg, Germany	University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Birmingham	May, A (corresponding author), Univ Med Ctr Hamburg Eppendorf, Dept Syst Neurosci, Martinistr 52, D-20246 Hamburg, Germany.	a.may@uke.de	Luedtke, Kerstin/AAM-9722-2020; Rushton, Alison/V-1260-2017	Luedtke, Kerstin/0000-0002-7308-5469; Rushton, Alison/0000-0001-8114-7669	Deutsche Forschungsgemeinschaft DFG [MA 1862/10-1]	Deutsche Forschungsgemeinschaft DFG(German Research Foundation (DFG))	This study was funded by the Deutsche Forschungsgemeinschaft DFG (MA 1862/10-1).	Airaksinen O, 2006, EUR SPINE J, V15, pS192, DOI 10.1007/s00586-006-1072-1; Altman DG, 1999, BRIT MED J, V319, P703, DOI 10.1136/bmj.319.7211.703; Ambrus GG, 2012, BRAIN STIMUL, V5, P499, DOI 10.1016/j.brs.2011.12.001; Antal A, 2008, CLIN J PAIN, V24, P56, DOI 10.1097/AJP.0b013e318157233b; Antal A, 2010, J PAIN SYMPTOM MANAG, V39, P890, DOI 10.1016/j.jpainsymman.2009.09.023; Apkarian AV, 2009, PROG NEUROBIOL, V87, P81, DOI 10.1016/j.pneurobio.2008.09.018; Bachmann CG, 2010, CLIN NEUROPHYSIOL, V121, P2083, DOI 10.1016/j.clinph.2010.05.005; Balague F, 2012, LANCET, V379, P482, DOI 10.1016/S0140-6736(11)60610-7; Beck J.S., 2011, COGNITIVE BEHAV THER, P19; Becker A, 2010, SPINE, V35, P1714, DOI 10.1097/BRS.0b013e3181cd656f; Boggio PS, 2008, EUR J NEUROL, V15, P1124, DOI 10.1111/j.1468-1331.2008.02270.x; Boggio PS, 2009, CLIN J PAIN, V25, P691, DOI 10.1097/AJP.0b013e3181af1414; Chou R, 2010, JAMA-J AM MED ASSOC, V303, P1295, DOI 10.1001/jama.2010.344; Cleophas TJ, 2006, CURR CLIN PHARMACOL, V1, P1, DOI 10.2174/157488406775268228; COHEN J, 1992, PSYCHOL BULL, V112, P155, DOI 10.1037/0033-2909.112.1.155; Cosentino G, 2012, EUR J NEUROSCI, V35, P119, DOI 10.1111/j.1460-9568.2011.07939.x; Csifcsak G, 2009, PAIN MED, V10, P122, DOI 10.1111/j.1526-4637.2008.00508.x; DosSantos Marcos Fabio, 2012, Front Psychiatry, V3, P93, DOI 10.3389/fpsyt.2012.00093; Draper N., 1981, APPL REGRESSION ANAL, V2, DOI DOI 10.1002/9781118625590; Dunn KM, 2005, SPINE, V30, P1887, DOI 10.1097/01.brs.0000173900.46863.02; Fenton BW, 2009, BRAIN STIMUL, V2, P103, DOI 10.1016/j.brs.2008.09.009; Fersum KV, 2013, EUR J PAIN, V17, P916, DOI 10.1002/j.1532-2149.2012.00252.x; Field A., 2018, DISCOVERING STAT USI, V5th; Fregni F, 2006, PAIN, V122, P197, DOI 10.1016/j.pain.2006.02.023; Gandiga PC, 2006, CLIN NEUROPHYSIOL, V117, P845, DOI 10.1016/j.clinph.2005.12.003; Garcia-Larrea L, 2007, NEUROIMAGE, V37, pS71, DOI 10.1016/j.neuroimage.2007.05.062; Grotle M, 2005, SPINE, V30, P976, DOI 10.1097/01.brs.0000158972.34102.6f; Grundmann L, 2011, BRAIN STIMUL, V4, P253, DOI 10.1016/j.brs.2010.12.002; Gurcay E, 2009, DISABIL REHABIL, V31, P840, DOI 10.1080/09638280802355163; Hays R D, 1993, Health Econ, V2, P217, DOI 10.1002/hec.4730020305; Henschke Nicholas, 2008, BMJ, V337, pa171, DOI 10.1136/bmj.a171; Henschke N, 2009, ARTHRITIS RHEUM-US, V60, P3072, DOI 10.1002/art.24853; Herbert RD, 2005, AUST J PHYSIOTHER, V51, P58, DOI 10.1016/S0004-9514(05)70058-1; Hinz A, 2009, PSYCHOTHER PSYCH MED, V59, P394, DOI 10.1055/s-2008-1067578; Holsheimer J, 2007, ACTA NEUROCHIR SUPPL, V97, P57; Ihle K, 2014, PAIN, V155, P2080, DOI 10.1016/j.pain.2014.07.018; Jurgens TP, 2012, EUR J PAIN, V16, P1251, DOI 10.1002/j.1532-2149.2012.00135.x; Kaapa EF, 2008, SPINE, V31, P371; Knotkova H, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00628; Koes BW, 2010, EUR SPINE J, V19, P2075, DOI 10.1007/s00586-010-1502-y; Kohlmann T, 1996, Rehabilitation (Stuttg), V35, pI; Lamb SE, 2010, LANCET, V375, P916, DOI 10.1016/S0140-6736(09)62164-4; Lambert M, 2010, AM FAM PHYSICIAN, V82, P434; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; LANDIS JR, 1977, BIOMETRICS, V33, P363, DOI 10.2307/2529786; Lang Eberhard, 2003, Spine J, V3, P270, DOI 10.1016/S1529-9430(03)00028-7; Lang N, 2004, EXP BRAIN RES, V156, P439, DOI 10.1007/s00221-003-1800-2; Latremoliere A, 2009, J PAIN, V10, P895, DOI 10.1016/j.jpain.2009.06.012; Loo CK, 2010, INT J NEUROPSYCHOPH, V13, P61, DOI 10.1017/S1461145709990411; Luedtke K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048857; Luedtke K, 2012, CLIN J PAIN, V28, P452, DOI 10.1097/AJP.0b013e31823853e3; Maughan EF, 2010, EUR SPINE J, V19, P1484, DOI 10.1007/s00586-010-1353-6; McCracken LM, 2002, SPINE, V27, P2564, DOI 10.1097/00007632-200211150-00033; Medeiros Liciane Fernandes, 2012, Front Psychiatry, V3, P110, DOI 10.3389/fpsyt.2012.00110; Meinert CL., 1986, CLIN TRIALS DESIGN C; Moher D, 2009, J CLIN EPIDEMIOL, V62, P1006, DOI 10.1016/j.jclinepi.2009.06.005; Moher D, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c869; Moseley GL, 2012, NEUROREHAB NEURAL RE, V26, P646, DOI 10.1177/1545968311433209; Neuhauser M, 2006, FUND CLIN PHARMACOL, V20, P515, DOI 10.1111/j.1472-8206.2006.00437.x; Nitsche MA, 2008, BRAIN STIMUL, V1, P206, DOI 10.1016/j.brs.2008.06.004; O'Connell NE, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008208.pub3; O'Connell NE, 2013, CLIN J PAIN, V29, P26, DOI 10.1097/AJP.0b013e318247ec09; O'Connell NE, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047514; Ossipov MH, 2010, J CLIN INVEST, V120, P3779, DOI 10.1172/JCI43766; Ostelo RWJG, 2008, SPINE, V33, P90, DOI 10.1097/BRS.0b013e31815e3a10; Pagano RL, 2011, EUR J PAIN, V15, DOI 10.1016/j.ejpain.2010.08.003; Pfingsten M, 2000, EUR J PAIN-LONDON, V4, P259, DOI 10.1053/eujp.2000.0178; Polania R, 2012, HUM BRAIN MAPP, V33, P2499, DOI 10.1002/hbm.21380; Polit DF, 2010, RES NURS HEALTH, V33, P355, DOI 10.1002/nur.20386; Polit DF, 2009, NURS RES, V58, P391, DOI 10.1097/NNR.0b013e3181bf1505; Priori A, 2009, BRAIN STIMUL, V2, P241, DOI 10.1016/j.brs.2009.02.004; Reidler JS, 2012, J PAIN, V13, P450, DOI 10.1016/j.jpain.2012.01.005; Riberto Marcelo, 2011, Open Rheumatol J, V5, P45, DOI 10.2174/1874312901105010045; Roche N, 2012, CLIN NEUROPHYSIOL, V123, P1027, DOI 10.1016/j.clinph.2011.09.011; Savigny P, 2009, BMJ-BRIT MED J, V338, DOI 10.1136/bmj.b1805; Scascighini L, 2008, RHEUMATOLOGY, V47, P670, DOI 10.1093/rheumatology/ken021; Schulz KF, 2002, LANCET, V359, P515, DOI 10.1016/S0140-6736(02)07683-3; ten Klooster PM, 2006, PAIN, V121, P151, DOI 10.1016/j.pain.2005.12.021; Turk DC, 2002, CLIN J PAIN, V18, P355, DOI 10.1097/00002508-200211000-00003; Turk DC, 2003, PAIN, V106, P337, DOI 10.1016/j.pain.2003.08.001; Turk DC, 2008, PAIN, V139, P485, DOI 10.1016/j.pain.2008.06.025; Twisk J, 2004, J CLIN EPIDEMIOL, V57, P223, DOI 10.1016/j.jclinepi.2003.07.009; Twisk J, 2013, J CLIN EPIDEMIOL, V66, P1022, DOI 10.1016/j.jclinepi.2013.03.017; van Middelkoop M, 2011, EUR SPINE J, V20, P19, DOI 10.1007/s00586-010-1518-3; Vickers AJ, 2001, BMJ-BRIT MED J, V323, P1123, DOI 10.1136/bmj.323.7321.1123; Wand BM, 2008, BMC MUSCULOSKEL DIS, V9, DOI 10.1186/1471-2474-9-11; Wand BM, 2011, MANUAL THER, V16, P15, DOI 10.1016/j.math.2010.06.008; Woolf CJ, 2011, PAIN, V152, pS2, DOI 10.1016/j.pain.2010.09.030; Zelman DC, 2003, PAIN, V106, P35, DOI 10.1016/S0304-3959(03)00274-4; Zhang L, 2005, EUR J NEUROSCI, V22, P1141, DOI 10.1111/j.1460-9568.2005.04302.x	90	46	48	0	8	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	APR 16	2015	350								h1640	10.1136/bmj.h1640	http://dx.doi.org/10.1136/bmj.h1640			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CG5JV	25883244	Green Published, hybrid			2023-01-03	WOS:000353328700002
J	Brewer, C; Irwin, M				Brewer, Colin; Irwin, Michael			END OF LIFE CARE In support of assisted dying	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material												CBrewerbrewerismo@gmail.com	Irwin, Michael/H-4870-2013	Irwin, Michael/0000-0002-1502-8431					0	1	1	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 9	2015	350								h1828	10.1136/bmj.h1828	http://dx.doi.org/10.1136/bmj.h1828			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CF9VG	25857306				2023-01-03	WOS:000352914700012
J	Parikh, PJ; Cole, KJ				Parikh, Pranav J.; Cole, Kelly J.			Effects of Transcranial Direct Current Stimulation on the Control of Finger Force during Dexterous Manipulation in Healthy Older Adults	PLOS ONE			English	Article							DIGIT-OBJECT INTERFACE; HUMAN PRIMARY MOTOR; AGE-RELATED-CHANGES; SKILL ACQUISITION; GRIP; MECHANISMS; FRICTION; YOUNG	The contribution of poor finger force control to age-related decline in manual dexterity is above and beyond ubiquitous behavioral slowing. Altered control of the finger forces can impart unwanted torque on the object affecting its orientation, thus impairing manual performance. Anodal transcranial direct current stimulation (tDCS) over primary motor cortex (M1) has been shown to improve the performance speed on manual tasks in older adults. However, the effects of anodal tDCS over M1 on the finger force control during object manipulation in older adults remain to be fully explored. Here we determined the effects of anodal tDCS over M1 on the control of grip force in older adults while they manipulated an object with an uncertain mechanical property. Eight healthy older adults were instructed to grip and lift an object whose contact surfaces were unexpectedly made more or less slippery across trials using acetate and sandpaper surfaces, respectively. Subjects performed this task before and after receiving anodal or sham tDCS over M1 on two separate sessions using a cross-over design. We found that older adults used significantly lower grip force following anodal tDCS compared to sham tDCS. Friction measured at the finger-object interface remained invariant after anodal and sham tDCS. These findings suggest that anodal tDCS over M1 improved the control of grip force during object manipulation in healthy older adults. Although the cortical networks for representing objects and manipulative actions are complex, the reduction in grip force following anodal tDCS over M1 might be due to a cortical excitation yielding improved processing of object-specific sensory information and its integration with the motor commands for production of manipulative forces. Our findings indicate that tDCS has a potential to improve the control of finger force during dexterous manipulation in older adults.	[Parikh, Pranav J.] Arizona State Univ, Sch Biol & Hlth Syst Engn, Tempe, AZ 85226 USA; [Cole, Kelly J.] Univ Iowa, Dept Hlth & Human Physiol, Motor Control Labs, Iowa City, IA 52242 USA	Arizona State University; Arizona State University-Tempe; University of Iowa	Parikh, PJ (corresponding author), Arizona State Univ, Sch Biol & Hlth Syst Engn, Tempe, AZ 85226 USA.	pranavjp@gmail.com						Aoki T, 2006, EXP BRAIN RES, V172, P425, DOI 10.1007/s00221-006-0350-9; Chouinard PA, 2005, J NEUROSCI, V25, P2277, DOI 10.1523/JNEUROSCI.4649-04.2005; Cole KJ, 2006, EXP BRAIN RES, V175, P285, DOI 10.1007/s00221-006-0553-0; Cole KJ, 2010, EXP BRAIN RES, V201, P239, DOI 10.1007/s00221-009-2030-z; COLE KJ, 1993, EXP BRAIN RES, V95, P523; Cole KJ, 2002, EXP BRAIN RES, V143, P35, DOI 10.1007/s00221-001-0965-9; Cole KJ, 1998, EXP BRAIN RES, V121, P263, DOI 10.1007/s002210050459; Cole KJ, 2001, EXP BRAIN RES, V136, P535, DOI 10.1007/s002210000613; Cole KJ, 1999, J NEUROSCI, V19, P3238; Dayanidhi S., 2014, J GERONTOL A-BIOL, V1, P1, DOI DOI 10.1093/GER0NA/GLU009; Enoka RM, 2003, J ELECTROMYOGR KINES, V13, P1, DOI 10.1016/S1050-6411(02)00084-6; Fritsch B, 2010, NEURON, V66, P198, DOI 10.1016/j.neuron.2010.03.035; Hlustik P, 2001, CEREB CORTEX, V11, P312, DOI 10.1093/cercor/11.4.312; Hummel FC, 2010, NEUROBIOL AGING, V31, P2160, DOI 10.1016/j.neurobiolaging.2008.12.008; JOHANSSON RS, 1984, EXP BRAIN RES, V56, P550; Keel JC, 2001, CLIN NEUROPHYSIOL, V112, P720, DOI 10.1016/S1388-2457(00)00518-6; Kinoshita H, 1996, EUR J APPL PHYSIOL, V74, P450; Kornatz KW, 2005, J APPL PHYSIOL, V98, P2072, DOI 10.1152/japplphysiol.01149.2004; Latash ML, 2012, J APPL PHYSIOL, V112, P1093, DOI 10.1152/japplphysiol.00160.2012; Lauro LJR, 2014, CORTEX, V58, P99, DOI 10.1016/j.cortex.2014.05.003; Lawrence EL, 2014, FRONT NEUROL, V5, DOI 10.3389/fneur.2014.00053; Martina ISJ, 1998, J NEUROL NEUROSUR PS, V65, P743, DOI 10.1136/jnnp.65.5.743; McFadden JL, 2011, BRAIN STIMUL, V4, P38, DOI 10.1016/j.brs.2010.05.002; Muellbacher W, 2002, NATURE, V415, P640, DOI 10.1038/nature712; Niu X, 2008, EXP BRAIN RES, V190, P225, DOI 10.1007/s00221-008-1466-x; Nowak DA, 2001, EUR J NEUROSCI, V14, P756, DOI 10.1046/j.0953-816x.2001.01697.x; Nowak DA, 2009, CORTEX, V45, P473, DOI 10.1016/j.cortex.2007.11.010; Olafsdottir H, 2007, J APPL PHYSIOL, V102, P1490, DOI 10.1152/japplphysiol.00966.2006; Parikh PJ, 2014, PHYSIOL REP, V2, DOI 10.1002/phy2.255; Parikh PJ, 2013, EXP BRAIN RES, V227, P9, DOI 10.1007/s00221-013-3451-2; Parikh PJ, 2012, J APPL PHYSIOL, V112, P1095, DOI 10.1152/japplphysiol.01385.2011; Parikh PJ, 2011, NEUROSCI LETT, V494, P94, DOI 10.1016/j.neulet.2011.02.066; Paulus W, 2011, NEUROPSYCHOL REHABIL, V21, P602, DOI 10.1080/09602011.2011.557292; Reis J, 2009, P NATL ACAD SCI USA, V106, P1590, DOI 10.1073/pnas.0805413106; Schieber MH, 2001, J NEUROPHYSIOL, V86, P2125, DOI 10.1152/jn.2001.86.5.2125; Stagg CJ, 2009, J NEUROSCI, V29, P5202, DOI 10.1523/JNEUROSCI.4432-08.2009; WESTLING G, 1984, EXP BRAIN RES, V53, P277; Zimerman M, 2013, ANN NEUROL, V73, P10, DOI 10.1002/ana.23761	38	9	9	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 9	2015	10	4							e0124137	10.1371/journal.pone.0124137	http://dx.doi.org/10.1371/journal.pone.0124137			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CF5HQ	25855984	Green Published, gold			2023-01-03	WOS:000352588500111
J	Wang, Y; Xie, GQ; Huang, YH; Zhang, H; Yang, B; Mao, ZG				Wang, Yong; Xie, Guoqiang; Huang, Yuanhang; Zhang, Han; Yang, Bo; Mao, Zhiguo			Calcium Acetate or Calcium Carbonate for Hyperphosphatemia of Hemodialysis Patients: A Meta-Analysis	PLOS ONE			English	Article							PHOSPHORUS BINDERS; PHOSPHATE BINDERS; SERUM PHOSPHORUS; MORTALITY RISK; OUTCOMES; FAILURE	Background High levels of serum phosphorus both at baseline and during follow-up are associated with increased mortality in dialysis patients, and administration of phosphate binders was independently associated with improved survival among hemodialysis population. Calcium-based phosphate binders are the most commonly used phosphate binders in developing countries for their relatively low costs. Objectives To compare the efficacy and safety between calcium carbonate and calcium acetate in the treatment of hyperphosphatemia in hemodialysis patients. Methods PubMed, EMBASE, Cochrane Library, Google scholar and Chinese databases (Wanfang, Weipu, National Knowledge Infrastructure of China) were searched for relevant studies published before March 2014. Reference lists of nephrology textbooks and review articles were checked. A meta-analysis of randomized controlled trials (RCTs) and quasi-RCTs that assessed the effects and adverse events of calcium acetate and calcium carbonate in adult patients with MHD was performed using Review Manager 5.0. Results A total of ten studies (625 participants) were included in this meta-analysis. There was insufficient data in all-cause mortality and cardiovascular events for meta-analysis. Compared with calcium carbonate group, the serum phosphorus was significantly lower in calcium acetate group after4 weeks' administration (MD -0.15 mmol/L, 95% CI -0.28 to -0.01) and after 8 weeks' administration (MD -0.25 mmol/L, 95% CI -0.40 to -0.11). There was no difference in serum calcium levels or the incidence of hypercalcemia between two groups at 4 weeks and 8 weeks. No statistical difference was found in parathyroid hormone (PTH) levels or serum calcium by phosphorus (Ca x P) product. There was significantly higher risk of intolerance with calcium acetate treatment (RR 3.46, 95% CI 1.48 to 8.26). Conclusions For hyperphosphatemia treatment, calcium acetate showed better efficacy and with a higher incidence of intolerance compared with calcium carbonate. There are insufficient data to establish the comparative superiority of the two calcium-based phosphate binders on all-cause mortality and cardiovascular end-points in hemodialysis patients.	[Wang, Yong] CPLA 422 Hosp, Div Hemodialysis, Zhanjiang, Guangdong, Peoples R China; [Xie, Guoqiang; Yang, Bo; Mao, Zhiguo] Second Mil Med Univ, Changzheng Hosp, Div Nephrol, Kidney Inst CPLA, Shanghai, Peoples R China; [Huang, Yuanhang] Guangzhou Mil Reg, Div Nephrol, Gen Hosp, Guangzhou, Guangdong, Peoples R China; [Zhang, Han] Second Mil Med Univ, Eastern Hepatobiliary Surg Hosp, Dept Hepat Surg, Shanghai, Peoples R China	Naval Medical University; Naval Medical University	Mao, ZG (corresponding author), Second Mil Med Univ, Changzheng Hosp, Div Nephrol, Kidney Inst CPLA, Shanghai, Peoples R China.	maozhiguo93@126.com	Barretti, Pasqual/K-4156-2012	Barretti, Pasqual/0000-0003-4979-4836	Chinese Society of Nephrology [13030340419]; Major Fundamental Research Program of Shanghai Committee of Science and Technology [12DJ1400300]; Key Projects in the National Science & Technology Pillar Program in the Twelfth Five-year Plan Period [2011BAI10B00]	Chinese Society of Nephrology; Major Fundamental Research Program of Shanghai Committee of Science and Technology; Key Projects in the National Science & Technology Pillar Program in the Twelfth Five-year Plan Period	Zhiguo Mao is an Outstanding Young Scholar of Second Military Medical University. This work was supported by Chinese Society of Nephrology (No. 13030340419), Major Fundamental Research Program of Shanghai Committee of Science and Technology (No. 12DJ1400300) and Key Projects in the National Science & Technology Pillar Program in the Twelfth Five-year Plan Period (No. 2011BAI10B00). The funders of this research had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Afifi A, 2005, INT S HOME HEMODIALY, V9, P409; ALMIRALL J, 1994, AM J NEPHROL, V14, P192, DOI 10.1159/000168713; Block GA, 1998, AM J KIDNEY DIS, V31, P607, DOI 10.1053/ajkd.1998.v31.pm9531176; CARAVACA F, 1992, NEPHRON, V60, P423, DOI 10.1159/000186802; Cubbon RM, 2014, J NEPHROL; d'Almeida Filho  E J, 2000, Sao Paulo Med J, V118, P179; EMMETT M, 1991, AM J KIDNEY DIS, V17, P544, DOI 10.1016/S0272-6386(12)80496-3; Isakova T, 2009, J AM SOC NEPHROL, V20, P388, DOI 10.1681/ASN.2008060609; Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4; Jamal SA, 2013, LANCET, V382, P1268, DOI 10.1016/S0140-6736(13)60897-1; Janssen MJA, 1996, CLIN NEPHROL, V45, P111; Liu Q, 2013, ZHEJIANG MED J, V39, P672, DOI [10.1136/medethics-2013-101815, DOI 10.1136/MEDETHICS-2013-101815]; [陆任华 Lu Renhua], 2013, [中华肾脏病杂志, Chinese Journal of Nephrology], V29, P429; MAI ML, 1989, KIDNEY INT, V36, P690, DOI 10.1038/ki.1989.247; Navaneethan SD, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006023.pub2; PFLANZ S, 1994, NEPHROL DIAL TRANSPL, V9, P1121, DOI 10.1093/ndt/9.8.1121; RING T, 1993, NEPHROL DIAL TRANSPL, V8, P341; Saif Imran, 2007, J Ayub Med Coll Abbottabad, V19, P26; SHEIKH MS, 1989, J CLIN INVEST, V83, P66, DOI 10.1172/JCI113886; Tao YM, 2011, J PRACTICAL MED, V27, P4008; Tentori F, 2008, AM J KIDNEY DIS, V52, P519, DOI 10.1053/j.ajkd.2008.03.020; Tonelli M, 2010, NEW ENGL J MED, V362, P1312, DOI 10.1056/NEJMra0912522; Wang CF, 2012, CHINESE J PRACTICAL, V39, P96; Yusuf AA, 2014, AM J KIDNEY DIS, V64, P95, DOI 10.1053/j.ajkd.2013.11.015; Zhang M, 2013, CLIN MED CHINA, V29, P1285	25	4	4	0	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 23	2015	10	3							e0121376	10.1371/journal.pone.0121376	http://dx.doi.org/10.1371/journal.pone.0121376			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CE6ZS	25799184	Green Published, Green Submitted, gold			2023-01-03	WOS:000351987300247
J	Mannion, CA; Vinturache, AE; McDonald, SW; Tough, SC				Mannion, Cynthia A.; Vinturache, Angela E.; McDonald, Sheila W.; Tough, Suzanne C.			The Influence of Back Pain and Urinary Incontinence on Daily Tasks of Mothers at 12 Months Postpartum	PLOS ONE			English	Article							PELVIC GIRDLE PAIN; QUALITY-OF-LIFE; OBSTETRIC RISK-FACTORS; 1ST 18 MONTHS; CESAREAN-SECTION; VAGINAL DELIVERY; PHYSICAL HEALTH; STRESS-INCONTINENCE; PREGNANCY; PREVALENCE	Objective The present study examined back pain (BP) and/or urinary incontinence (UI) impact on the ability to perform daily tasks at 12 months after childbirth in healthy reproductive women who sought maternity care in community based family practice clinics. Methods This study is a secondary analysis from the All Our Babies Study, a prospective, community-based pregnancy cohort in Calgary, Alberta. Maternal self-reported information on demographics, lifestyle, experiences with pregnancy and childbirth, occurrence of BP, UI and consequent impairment of daily tasks were collected by questionnaires administered before 25 weeks, at 34-36 weeks gestation and at 4 and 12 months postpartum. The occurrence and severity of BP and UI at one year after childbirth was assessed using descriptive and bivariate analyses. Logistic regression models examined the association between demographic and obstetrical variables and the severity of functional impairment due to UI and BP. Results From 1574 women with singleton pregnancies included in the study, 1212 (77%) experienced BP, 773 (49%) UI, and 620 (40%) both BP and UI. From the 821 women reporting impairment of daily tasks due to BP, 199 (24 %) were moderately and 90 (11%) severely affected with the remainder, 532 (64%) being mildly affected. From 267 women with functional impairment due to UI, 52 (19%) reported moderately to severe impairment in their ability to perform daily tasks. Obesity and parity were risk factors for impairment of daily functioning due to BP, whereas obesity and vaginal delivery increased the risk of moderate to severe impairment due to UI. Conclusions BP and UI are common occurrences 1 year after childbirth. Maternal performance of daily tasks and women's health and quality of life are more often impaired due to BP than UI. Our study brings new evidence of the risk factors that predict severity and impact of these conditions on women functioning at 12 months postpartum.	[Mannion, Cynthia A.] Univ Calgary, Fac Nursing, Calgary, AB, Canada; [Vinturache, Angela E.; McDonald, Sheila W.; Tough, Suzanne C.] Univ Calgary, Fac Med, Dept Paediat, Calgary, AB, Canada; [Tough, Suzanne C.] Univ Calgary, Fac Med, Dept Community Hlth Sci, Calgary, AB, Canada	University of Calgary; University of Calgary; University of Calgary	Vinturache, AE (corresponding author), Univ Calgary, Fac Med, Dept Paediat, Calgary, AB, Canada.	aevintur@ucalgary.ca		Vinturache, Angela/0000-0002-2432-2616	Alberta Innovates Health Solutions (AIHS) Interdisciplinary Team Grant [200700595]; Three Cheers for the Early Years, Alberta Health Services; Alberta Children's Hospital Foundation	Alberta Innovates Health Solutions (AIHS) Interdisciplinary Team Grant; Three Cheers for the Early Years, Alberta Health Services; Alberta Children's Hospital Foundation	An Alberta Innovates Health Solutions (AIHS) Interdisciplinary Team Grant (Preterm Birth and Healthy Outcomes #200700595) and Three Cheers for the Early Years, Alberta Health Services, provided funding for the development of the cohort. Additional funding was provided from the Alberta Children's Hospital Foundation.	Altman D, 2007, AM J OBSTET GYNECOL, V197, DOI 10.1016/j.ajog.2007.03.083; Arrue M, 2011, INT J GYNECOL OBSTET, V115, P256, DOI 10.1016/j.ijgo.2011.07.024; BRODIE D J, 1990, Journal of Orthopaedic and Sports Physical Therapy, V11, P519; Brown S, 2000, BRIT J OBSTET GYNAEC, V107, P1194, DOI 10.1111/j.1471-0528.2000.tb11607.x; Brown SJ, 2011, BJOG-INT J OBSTET GY, V118, P991, DOI 10.1111/j.1471-0528.2011.02928.x; Burgio KL, 2003, OBSTET GYNECOL, V102, P1291, DOI 10.1016/j.obstetgynecol.2003.09.013; C Perinatal Health Agency of Canada, 2012, PERINATAL HEALTH IND; Cheng CY, 2008, WOMEN HEALTH ISS, V18, P267, DOI 10.1016/j.whi.2008.02.004; Connolly TJ, 2007, INT UROGYNECOL J, V18, P1033, DOI 10.1007/s00192-006-0286-4; Diez-Itza I, 2010, INT UROGYNECOL J, V21, P439, DOI 10.1007/s00192-009-1055-y; Dolan LM, 2004, INT UROGYNECOL J, V15, P160, DOI 10.1007/s00192-004-1128-x; Ekstrom A, 2008, INT UROGYNECOL J, V19, P459, DOI 10.1007/s00192-007-0461-2; Eliasson K, 2008, MANUAL THER, V13, P206, DOI 10.1016/j.math.2006.12.006; Gartland D, 2012, BJOG-INT J OBSTET GY, V119, P1361, DOI 10.1111/j.1471-0528.2012.03437.x; Pavon AG, 2014, ATEN PRIM, V46, P100, DOI 10.1016/j.aprim.2013.07.004; Gutke A, 2011, EUR SPINE J, V20, P440, DOI 10.1007/s00586-010-1487-6; Gyhagen M, 2013, BJOG-INT J OBSTET GY, V120, P1548, DOI 10.1111/1471-0528.12367; Haddow G, 2005, INT J EVID-BASED HEA, V3, P103, DOI 10.1111/j.1479-6988.2005.00023.x; Hijaz A, 2012, INT UROGYNECOL J, V23, P395, DOI 10.1007/s00192-011-1562-5; Kovacs FM, 2012, SPINE, V37, P1516, DOI 10.1097/BRS.0b013e31824dcb74; MacLennan AH, 2000, BRIT J OBSTET GYNAEC, V107, P1460, DOI 10.1111/j.1471-0528.2000.tb11669.x; Mason L, 2010, J CLIN NURS, V19, P2777, DOI 10.1111/j.1365-2702.2010.03297.x; McDonald SW, 2013, BMC PREGNANCY CHILDB, V13, DOI 10.1186/1471-2393-13-S1-S2; Monz B, 2007, EUR UROL, V51, P1073, DOI 10.1016/j.eururo.2006.09.022; Morkved S, 1999, Int Urogynecol J Pelvic Floor Dysfunct, V10, P394, DOI 10.1007/s001920050067; Noren L, 2002, EUR SPINE J, V11, P267, DOI 10.1007/s00586-001-0357-7; Nygaard I, 2006, SEMIN PERINATOL, V30, P267, DOI 10.1053/j.semperi.2006.07.007; Olsson C, 2004, ACTA OBSTET GYN SCAN, V83, P351, DOI 10.1080/j.0001-6349.2004.00384.x; Ostgaard HC, 1996, SPINE, V21, P2777, DOI 10.1097/00007632-199612010-00013; Robinson Dudley, 2003, J Br Menopause Soc, V9, P75, DOI 10.1258/136218003100322233; Rortveit G, 2001, OBSTET GYNECOL, V98, P1004, DOI 10.1016/S0029-7844(01)01566-6; Rortveit G, 2003, NEW ENGL J MED, V348, P900, DOI 10.1056/NEJMoa021788; Sangsawang B, 2013, INT UROGYNECOL J, V24, P901, DOI 10.1007/s00192-013-2061-7; Saurel-Cubizolles MJ, 2000, BRIT J OBSTET GYNAEC, V107, P1202, DOI 10.1111/j.1471-0528.2000.tb11608.x; Schytt E, 2004, ACTA OBSTET GYN SCAN, V83, P928, DOI 10.1111/j.0001-6349.2004.00431.x; Smith MD, 2008, INT UROGYNECOL J, V19, P205, DOI 10.1007/s00192-007-0421-x; Smith MD, 2014, CLIN J PAIN, V30, P162, DOI 10.1097/AJP.0b013e31828b10fe; Steen Mary, 2013, Nurs Stand, V28, P49, DOI 10.7748/ns2013.09.28.1.49.e7510; Sultan AH, 1996, BRIT J OBSTET GYNAEC, V103, P731, DOI 10.1111/j.1471-0528.1996.tb09864.x; Thompson JF, 2002, BIRTH-ISS PERINAT C, V29, P83, DOI 10.1046/j.1523-536X.2002.00167.x; Thornton MJ, 2006, AUST NZ J OBSTET GYN, V46, P468, DOI 10.1111/j.1479-828X.2006.00644.x; To WWK, 2003, ACTA OBSTET GYN SCAN, V82, P1086, DOI 10.1046/j.1600-0412.2003.00235.x; Torrisi G, 2012, EUR J OBSTET GYN R B, V160, P110, DOI 10.1016/j.ejogrb.2011.10.010; Vermani E, 2010, PAIN PRACT, V10, P60, DOI 10.1111/j.1533-2500.2009.00327.x; Wang SM, 2004, OBSTET GYNECOL, V104, P65, DOI 10.1097/01.AOG.0000129403.54061.0e; Wax JR, 2004, OBSTET GYNECOL SURV, V59, P601, DOI 10.1097/01.OGX.0000133942.76239.57; Wesnes SL, 2009, BJOG-INT J OBSTET GY, V116, P700, DOI 10.1111/j.1471-0528.2008.02107.x; Wohlrab KJ, 2008, CLIN PERINATOL, V35, P583, DOI 10.1016/j.clp.2008.06.001; Woolhouse H, 2012, BIRTH-ISS PERINAT C, V39, P221, DOI 10.1111/j.1523-536X.2012.00551.x; World Health Organization, 2000, WHO TECH REP SER, V894, p[i, 1]; Wu WH, 2004, EUR SPINE J, V13, P575, DOI 10.1007/s00586-003-0615-y	51	16	17	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 17	2015	10	6							e0129615	10.1371/journal.pone.0129615	http://dx.doi.org/10.1371/journal.pone.0129615			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CK9NS	26083252	Green Published, Green Submitted, gold			2023-01-03	WOS:000356567400102
J	Schweizer, ML; Chiang, HY; Septimus, E; Moody, J; Braun, B; Hafner, J; Ward, MA; Hickok, J; Perencevich, EN; Diekema, DJ; Richards, CL; Cavanaugh, JE; Perlin, JB; Herwaldt, LA				Schweizer, Marin L.; Chiang, Hsiu-Yin; Septimus, Edward; Moody, Julia; Braun, Barbara; Hafner, Joanne; Ward, Melissa A.; Hickok, Jason; Perencevich, Eli N.; Diekema, Daniel J.; Richards, Cheryl L.; Cavanaugh, Joseph E.; Perlin, Jonathan B.; Herwaldt, Loreen A.			Association of a Bundled Intervention With Surgical Site Infections Among Patients Undergoing Cardiac, Hip, or Knee Surgery	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RESISTANT STAPHYLOCOCCUS-AUREUS; NASAL CARRIAGE; MUPIROCIN; DECOLONIZATION; PROPHYLAXIS; RISK; CHLORHEXIDINE; ARTHROPLASTY	IMPORTANCE Previous studies suggested that a bundled intervention was associated with lower rates of Staphylococcus aureus surgical site infections (SSIs) among patients having cardiac or orthopedic operations. OBJECTIVE To evaluate whether the implementation of an evidence-based bundle is associated with a lower risk of S aureus SSIs in patients undergoing cardiac operations or hip or knee arthroplasties. DESIGN, SETTING, AND PARTICIPANTS Twenty hospitals in 9 US states participated in this pragmatic study; rates of SSIs were collected for a median of 39 months (range, 39-43) during the preintervention period (March 1, 2009, to intervention) and a median of 21 months (range, 14-22) during the intervention period (from intervention start through March 31, 2014). INTERVENTIONS Patients whose preoperative nares screens were positive for methicillin-resistant S aureus (MRSA) or methicillin-susceptible S aureus (MSSA) were asked to apply mupirocin intranasally twice daily for up to 5 days and to bathe daily with chlorhexidine-gluconate (CHG) for up to 5 days before their operations. MRSA carriers received vancomycin and cefazolin or cefuroxime for perioperative prophylaxis; all others received cefazolin or cefuroxime. Patients who were MRSA-negative and MSSA-negative bathed with CHG the night before and morning of their operations. Patients were treated as MRSA-positive if screening results were unknown. MAIN OUTCOMES AND MEASURES The primary outcomewas complex (deep incisional or organ space) S aureus SSIs. Monthly SSI counts were analyzed using Poisson regression analysis. RESULTS After a 3-month phase-in period, bundle adherence was 83%(39% full adherence; 44% partial adherence). Overall, 101 complex S aureus SSIs occurred after 28 218 operations during the preintervention period and 29 occurred after 14 316 operations during the intervention period (mean rate per 10 000 operations, 36 for preintervention period vs 21 for intervention period, difference, -15 [95% CI, -35 to -2]; rate ratio [RR], 0.58 [95% CI, 0.37 to 0.92]). The rates of complex S aureus SSIs decreased for hip or knee arthroplasties (difference per 10 000 operations, -17 [95% CI, -39 to 0]; RR, 0.48 [95% CI, 0.29 to 0.80]) and for cardiac operations (difference per 10 000 operations, -6 [95% CI, -48 to 8]; RR, 0.86 [95% CI, 0.47 to 1.57]). CONCLUSIONS AND RELEVANCE In this multicenter study, a bundle comprising S aureus screening, decolonization, and targeted prophylaxis was associated with a modest, statistically significant decrease in complex S aureus SSIs.	[Schweizer, Marin L.; Chiang, Hsiu-Yin; Ward, Melissa A.; Perencevich, Eli N.; Diekema, Daniel J.; Herwaldt, Loreen A.] Univ Iowa, Carver Coll Med, Iowa City, IA USA; [Schweizer, Marin L.; Perencevich, Eli N.] Iowa City VA Hlth Care Syst, Iowa City, IA USA; [Schweizer, Marin L.; Cavanaugh, Joseph E.; Herwaldt, Loreen A.] Univ Iowa, Coll Publ Hlth, Iowa City, IA USA; [Septimus, Edward; Moody, Julia; Hickok, Jason; Perlin, Jonathan B.] Hosp Corp America, Nashville, TN USA; [Septimus, Edward] Texas A&M Univ, Coll Med, Texas A&M Hlth Sci Ctr, Houston, TX USA; [Braun, Barbara; Hafner, Joanne; Richards, Cheryl L.] Joint Commiss, Oak Brook Terrace, IL USA; [Herwaldt, Loreen A.] Univ Iowa Hosp & Clin, Iowa City, IA 52242 USA	University of Iowa; US Department of Veterans Affairs; Veterans Health Administration (VHA); Iowa City VA Health Care System; University of Iowa; Hospital Corporation of America; Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; University of Iowa	Herwaldt, LA (corresponding author), Univ Iowa Hosp & Clin, Dept Internal Med, 200 Hawkins Dr, Iowa City, IA 52242 USA.	loreen-herwaldt@uiowa.edu		Perencevich, Eli/0000-0002-3721-3355; Diekema, Daniel/0000-0003-1273-0724; Ward, Melissa/0000-0002-1054-6475; Schweizer, Marin/0000-0002-3604-0093; Herwaldt, Loreen/0000-0002-9530-6859; Chiang, Hsiu-Yin/0000-0002-4205-2787	Agency for Healthcare Research and Quality (AHRQ), US Department of Health and Human Services [HHSA2902006100021I, HS022467-02]; VA Health Services Research and Development [CDA 11-211]; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R18HS022467] Funding Source: NIH RePORTER	Agency for Healthcare Research and Quality (AHRQ), US Department of Health and Human Services; VA Health Services Research and Development(US Department of Veterans Affairs); AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)	This project was funded by the Agency for Healthcare Research and Quality (AHRQ; HHSA2902006100021I and grant HS022467-02), US Department of Health and Human Services. It also received support from the VA Health Services Research and Development (CDA 11-211; Dr Schweizer).	Ammerlaan HSM, 2009, CLIN INFECT DIS, V48, P922, DOI 10.1086/597291; Anderson DJ, 2008, INFECT CONT HOSP EP, V29, P941, DOI 10.1086/591457; Berrios-Torres SI, 2014, INFECT CONT HOSP EP, V35, P231, DOI 10.1086/675289; Bode LGM, 2010, NEW ENGL J MED, V362, P9, DOI 10.1056/NEJMoa0808939; Bratzler Dale W, 2013, Am J Health Syst Pharm, V70, P195, DOI 10.2146/ajhp120568; Braun BI, DEV IMPLEMENTATION C; Centers for Disease Control and Prevention, SURG SIT INF SSI EV; CLSI, METH DIL ANT SUSC TE; Courville XF, 2012, INFECT CONT HOSP EP, V33, P152, DOI 10.1086/663704; DEYO RA, 1992, J CLIN EPIDEMIOL, V45, P613, DOI 10.1016/0895-4356(92)90133-8; Diekema D, 2011, INFECT CONT HOSP EP, V32, P1042, DOI 10.1086/661917; Engelman R, 2007, ANN THORAC SURG, V83, P1569, DOI 10.1016/j.athoracsur.2006.09.046; Finkelstein R, 2002, J THORAC CARDIOV SUR, V123, P326, DOI 10.1067/mtc.2002.119698; Harris AD, 2004, CLIN INFECT DIS, V38, P1586, DOI 10.1086/420936; Haynes AB, 2009, NEW ENGL J MED, V360, P491, DOI 10.1056/NEJMsa0810119; Healthcare Cost and Utilization Project, HEALTHC COST UT PROJ; Hetem DJ, 2013, J HOSP INFECT, V85, P249, DOI 10.1016/j.jhin.2013.09.006; Immerman I, 2012, J ARTHROPLASTY, V27, P870, DOI 10.1016/j.arth.2012.01.010; Kalra L, 2013, AM J INFECT CONTROL, V41, P1253, DOI 10.1016/j.ajic.2013.05.021; Kline S, 2014, INFECT CONT HOSP EP, V35, P880, DOI 10.1086/676866; KLUYTMANS JAJW, 1995, J INFECT DIS, V171, P216, DOI 10.1093/infdis/171.1.216; Lankiewicz JD, 2012, INFECT CONT HOSP EP, V33, P202, DOI 10.1086/663715; McDanel JS, 2013, ANTIMICROB AGENTS CH, V57, P552, DOI 10.1128/AAC.01623-12; Palepou MFI, 1998, J ANTIMICROB CHEMOTH, V42, P577, DOI 10.1093/jac/42.5.577; Perl TM, 2002, NEW ENGL J MED, V346, P1871, DOI 10.1056/NEJMoa003069; Pronovost P, 2006, NEW ENGL J MED, V355, P2725, DOI 10.1056/NEJMoa061115; Roy M., 2003, PREVENTION CONTROL N, V4th, P369; Schweizer M, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f2743; Schweizer ML, 2014, JAMA SURG, V149, P575, DOI 10.1001/jamasurg.2013.4663; Sievert DM, 2013, INFECT CONT HOSP EP, V34, P1, DOI 10.1086/668770; TAYLOR GJ, 1990, AM J CARDIOL, V65, P309, DOI 10.1016/0002-9149(90)90293-A; The Joint Commission, 2010, SPEC MAN JOINT COMM; Thorpe KE, 2009, J CLIN EPIDEMIOL, V62, P464, DOI [10.1503/cmaj.090523, 10.1016/j.jclinepi.2008.12.011]; Tyllianakis ME, 2010, J ARTHROPLASTY, V25, P1078, DOI 10.1016/j.arth.2010.01.105; WENZEL RP, 1995, J HOSP INFECT, V31, P13, DOI 10.1016/0195-6701(95)90079-9; Zwarenstein M, 2008, BMJ-BRIT MED J, V337, DOI 10.1136/bmj.a2390	36	167	171	1	21	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 2	2015	313	21					2162	2171		10.1001/jama.2015.5387	http://dx.doi.org/10.1001/jama.2015.5387			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CJ4CC	26034956				2023-01-03	WOS:000355430900016
J	van Gurp, J; Soyannwo, O; Odebunmi, K; Dania, S; van Selm, M; van Leeuwen, E; Vissers, K; Hasselaar, J				van Gurp, Jelle; Soyannwo, Olaitan; Odebunmi, Kehinde; Dania, Simpa; van Selm, Martine; van Leeuwen, Evert; Vissers, Kris; Hasselaar, Jeroen			Telemedicine's Potential to Support Good Dying in Nigeria: A Qualitative Study	PLOS ONE			English	Article							AFRICAN PALLIATIVE CARE; LIFE CARE; GOOD DEATH; OF-LIFE; CANCER; NEEDS; END; INTERVENTIONS; OPPORTUNITIES; TECHNOLOGIES	Objectives This qualitative study explores Nigerian health care professionals' concepts of good dying/a good death and how telemedicine technologies and services would fit the current Nigerian palliative care practice. Materials and Methods Supported by the Centre for Palliative Care Nigeria (CPCN) and the University College Hospital (UCH) in Ibadan, Nigeria, the authors organized three focus groups with Nigerian health care professionals interested in palliative care, unstructured interviews with key role players for palliative care and representatives of telecom companies, and field visits to primary, secondary and tertiary healthcare clinics that provided palliative care. Data analysis consisted of open coding, constant comparison, diagramming of categorizations and relations, and extensive member checks. Results The focus group participants classified good dying into 2 domains: a feeling of completion of the individual life and dying within the community. Reported barriers to palliative care provision were socio-economic consequences of being seriously ill, taboos on dying and being ill, restricted access to adequate medical-technical care, equation of religion with medicine, and the faulty implementation of palliative care policy by government. The addition of telemedicine to Nigeria's palliative care practice appears problematic, due to irregular bandwidth, poor network coverage, and unstable power supply obstructing interactivity and access to information. However, a tele-education 'lite' scenario seemed viable in Nigeria, wherein low-tech educational networks are central that build on non-synchronous online communication. Discussion Nigerian health care professionals' concepts on good dying/a good death and barriers and opportunities for palliative care provision were, for the greater part, similar to prior findings from other studies in Africa. Information for and education of patient, family, and community are essential to further improve palliative care in Africa. Telemedicine can only help if low-tech solutions are applied that work around network coverage problems by focusing on non-synchronous online communication.	[van Gurp, Jelle; Vissers, Kris; Hasselaar, Jeroen] Radboud Univ Nijmegen, Med Ctr, Dept Anesthesiol Pain & Palliat Med, NL-6525 ED Nijmegen, Netherlands; [Soyannwo, Olaitan] Univ Coll Ibadan Hosp, Ctr Palliat Care Nigeria, Ibadan, Nigeria; [Odebunmi, Kehinde] Univ Coll Ibadan Hosp, Hosp & Palliat Care Unit, Ibadan, Nigeria; [Dania, Simpa] Univ Coll Ibadan Hosp, Dept Telemed, Ibadan, Nigeria; [van Selm, Martine] Univ Amsterdam, Amsterdam Sch Commun Res, Amsterdam, Netherlands; [van Leeuwen, Evert] Radboud Univ Nijmegen, Med Ctr, Eth Sect, Dept IQ Healthcare, NL-6525 ED Nijmegen, Netherlands	Radboud University Nijmegen; University of Amsterdam; Radboud University Nijmegen	van Gurp, J (corresponding author), Radboud Univ Nijmegen, Med Ctr, Dept Anesthesiol Pain & Palliat Med, NL-6525 ED Nijmegen, Netherlands.	Jelle.vanGurp@radboudumc.nl	van Gurp, Jelle/AAW-9371-2021; Vissers, Kris/H-8110-2014; van Gurp, Jelle/P-6169-2015; van Selm, Martine/AAY-3721-2021; Vissers, Kris C.P./D-3569-2009; Hasselaar, Jeroen/C-9446-2011; Leeuwen, E./H-8068-2014	van Gurp, Jelle/0000-0002-9904-2571; Vissers, Kris/0000-0002-2919-6356; van Gurp, Jelle/0000-0002-9904-2571; van Selm, Martine/0000-0001-9188-4021; Vissers, Kris C.P./0000-0002-2919-6356; Leeuwen, E./0000-0001-6356-3917	Netherlands Organisation for Scientific Research (NWO) [313-99-120]	Netherlands Organisation for Scientific Research (NWO)(Netherlands Organization for Scientific Research (NWO))	The Netherlands Organisation for Scientific Research (NWO) funded this research (File number 313-99-120). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 2013, WHO GLOBAL HLTH OBSE; Blaya JA, 2010, HEALTH AFFAIR, V29, P244, DOI 10.1377/hlthaff.2009.0894; Cabieses B, 2013, TELEMED E-HEALTH, V19, P879, DOI 10.1089/tmj.2012.0232; Charmaz Kathy., 2009, CONSTRUCTING GROUNDE; Corbin JM, 2008, BASICS QUALITITIVE R; Donner J, 2008, INFORM SOC, V24, P140, DOI 10.1080/01972240802019970; Downing J, 2014, BMC PALLIAT CARE, V13, DOI 10.1186/1472-684X-13-4; Grant E, 2003, J PALLIATIVE CARE, V19, P159, DOI 10.1177/082585970301900303; Gurman TA, 2012, J HEALTH COMMUN, V17, P82, DOI 10.1080/10810730.2011.649160; Gysels M, 2011, BMC PALLIAT CARE, V10, DOI 10.1186/1472-684X-10-6; Harding R, 2008, J PAIN SYMPTOM MANAG, V36, P304, DOI 10.1016/j.jpainsymman.2008.04.008; Harding R, 2013, LANCET ONCOL, V14, pE183, DOI 10.1016/S1470-2045(12)70396-0; Harding R, 2011, EUR J CANCER, V47, P51, DOI 10.1016/j.ejca.2010.08.003; Hazin R, 2010, LANCET ONCOL, V11, P204, DOI 10.1016/S1470-2045(09)70288-8; Herce ME, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0110457; Higginson IJ, 2013, BMC MED, V11, DOI 10.1186/1741-7015-11-111; International Agency for Research on Cancer, 2012, GLOBOCAN 2012 EST CA; Jemal A, 2012, CANCER-AM CANCER SOC, V118, P4372, DOI 10.1002/cncr.27410; Kallander K, 2013, J MED INTERNET RES, V15, DOI 10.2196/jmir.2130; Kahn JG, 2010, HEALTH AFFAIR, V29, P254, DOI 10.1377/hlthaff.2009.0965; Kikule E, 2003, BRIT MED J, V327, P192, DOI 10.1136/bmj.327.7408.192; Kingham TP, 2013, LANCET ONCOL, V14, pE158, DOI 10.1016/S1470-2045(12)70472-2; Latifi R, 2012, TELEMED E-HEALTH, V18, P388, DOI [10.1089/tmj.2011.0263, 10.1089/tmj.2011.1263]; Lehoux P, 2002, SOC SCI MED, V54, P889, DOI 10.1016/S0277-9536(01)00063-6; Lester RT, 2010, LANCET, V376, P1838, DOI 10.1016/S0140-6736(10)61997-6; Lucas H, 2008, SOC SCI MED, V66, P2122, DOI 10.1016/j.socscimed.2008.01.033; Lynch T, 2013, J PAIN SYMPTOM MANAG, V45, P1094, DOI 10.1016/j.jpainsymman.2012.05.011; Mays N, 2000, BMJ-BRIT MED J, V320, P50, DOI 10.1136/bmj.320.7226.50; Odigie VI, 2012, PSYCHO-ONCOLOGY, V21, P332, DOI 10.1002/pon.1894; Olakunde BO, 2012, ANN NIGERIAN MED, V6, P4, DOI DOI 10.4103/0331-3131.100199; Onyeka TC, 2011, INDIAN J PALLIAT CAR, V17, P131, DOI 10.4103/0973-1075.84534; Patterson V, 2013, GLOBAL HEALTH ACTION, V6, P1, DOI 10.3402/gha.v6i0.21465; Pols Jeannette, 2012, CARE DISTANCE CLOSEN; Powell RA, 2014, J PAIN SYMPTOM MANAG, V47, P620, DOI 10.1016/j.jpainsymman.2013.04.004; Scott RE, 2013, J MED INTERNET RES, V15, P11, DOI 10.2196/jmir.2250; Seale C, 2000, SOC SCI MED, V51, P917, DOI 10.1016/S0277-9536(00)00071-X; Selman L, 2013, BMC PALLIAT CARE, V12, DOI 10.1186/1472-684X-12-35; Selman L, 2013, HEALTH QUAL LIFE OUT, V11, DOI 10.1186/1477-7525-11-94; van der Geest S, 2004, SOC SCI MED, V58, P899, DOI 10.1016/j.socscimed.2003.10.041; van Gurp J, 2013, BMC MED ETHICS, V14, DOI 10.1186/1472-6939-14-12; Van Rensburg JJMJ, 2013, PALLIAT SUPPORT CARE, V11, P21, DOI 10.1017/S1478951512000430; *WHO, 2009, WHO COUNTR COOP STRA; Wootton Richard, 2010, JRSM Short Rep, V1, P37, DOI 10.1258/shorts.2010.010045; World Health Organization, 2014, WHO DEF PALL CAR; World Health Organization, 2011, GLOB HLTH OBS DAT RE; World Health Organization, 2014, AFR PROJ PALL CAR; Worldwide Palliative Care Alliance and World Health Organization, 2014, GLOB ATL PALL CAR EN	47	12	12	0	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 1	2015	10	6							e0126820	10.1371/journal.pone.0126820	http://dx.doi.org/10.1371/journal.pone.0126820			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	CL0KF	26030154	Green Published, gold, Green Submitted			2023-01-03	WOS:000356630900033
J	Uitdehaag, JCM; de Roos, JADM; van Doornmalen, AM; Prinsen, MBW; Spijkers-Hagelstein, JAP; de Vetter, JRF; de Man, J; Buijsman, RC; Zaman, GJR				Uitdehaag, Joost C. M.; de Roos, Jeroen A. D. M.; van Doornmalen, Antoon M.; Prinsen, Martine B. W.; Spijkers-Hagelstein, Jill A. P.; de Vetter, Judith R. F.; de Man, Jos; Buijsman, Rogier C.; Zaman, Guido J. R.			Selective Targeting of CTNBB1-, KRAS-or MYC-Driven Cell Growth by Combinations of Existing Drugs	PLOS ONE			English	Article							SYNTHETIC LETHAL INTERACTION; KINASE INHIBITOR; BETA-CATENIN; COLON-CANCER; TYROSINE KINASE; MEK INHIBITION; BRAF; EGFR; RESISTANCE; MELANOMA	The aim of combination drug treatment in cancer therapy is to improve response rate and to decrease the probability of the development of drug resistance. Preferably, drug combinations are synergistic rather than additive, and, ideally, drug combinations work synergistically only in cancer cells and not in non-malignant cells. We have developed a workflow to identify such targeted synergies, and applied this approach to selectively inhibit the proliferation of cell lines with mutations in genes that are difficult to modulate with small molecules. The approach is based on curve shift analysis, which we demonstrate is a more robust method of determining synergy than combination matrix screening with Bliss-scoring. We show that the MEK inhibitor trametinib is more synergistic in combination with the BRAF inhibitor dabrafenib than with vemurafenib, another BRAF inhibitor. In addition, we show that the combination of MEK and BRAF inhibitors is synergistic in BRAF-mutant melanoma cells, and additive or antagonistic in, respectively, BRAF-wild type melanoma cells and nonmalignant fibroblasts. This combination exemplifies that synergistic action of drugs can depend on cancer genotype. Next, we used curve shift analysis to identify new drug combinations that specifically inhibit cancer cell proliferation driven by difficult-to-drug cancer genes. Combination studies were performed with compounds that as single agents showed preference for inhibition of cancer cells with mutations in either the CTNNB1 gene (coding for beta-catenin), KRAS, or cancer cells expressing increased copy numbers of MYC. We demonstrate that the Wnt-pathway inhibitor ICG-001 and trametinib acted synergistically in Wnt-pathway-mutant cell lines. The ERBB2 inhibitor TAK-165 was synergistic with trametinib in KRAS-mutant cell lines. The EGFR/ERBB2 inhibitor neratinib acted synergistically with the spindle poison docetaxel and with the Aurora kinase inhibitor GSK-1070916 in cell lines with MYC amplification. Our approach can therefore efficiently discover novel drug combinations that selectively target cancer genes.	[Uitdehaag, Joost C. M.; de Roos, Jeroen A. D. M.; van Doornmalen, Antoon M.; Prinsen, Martine B. W.; Spijkers-Hagelstein, Jill A. P.; de Vetter, Judith R. F.; de Man, Jos; Buijsman, Rogier C.; Zaman, Guido J. R.] Netherlands Translat Res Ctr BV, Oss, Netherlands		Zaman, GJR (corresponding author), Netherlands Translat Res Ctr BV, Oss, Netherlands.	guido.zaman@ntrc.nl			Innovation Office of the Ministry of Economic Affairs of the Netherlands [INT 111039]; Netherlands Translational Research Center B. V.	Innovation Office of the Ministry of Economic Affairs of the Netherlands; Netherlands Translational Research Center B. V.	This research was supported by a grant from the Innovation Office of the Ministry of Economic Affairs of the Netherlands (INT 111039). Netherlands Translational Research Center B. V. provided support in the form of salaries for authors JCNU, JADMR, AMVD, MBWP, JAPSH, JDM, RCB and GJRZ, but did not have any additional role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the 'author contributions' section.	Adams ND, 2010, J MED CHEM, V53, P3973, DOI 10.1021/jm901870q; Addepalli MK, 2010, GENE THER, V17, P352, DOI 10.1038/gt.2009.155; Al-Lazikani B, 2012, NAT BIOTECHNOL, V30, P679, DOI 10.1038/nbt.2284; Astsaturov I, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2001083; Babij C, 2011, CANCER RES, V71, P5818, DOI 10.1158/0008-5472.CAN-11-0778; Barbie DA, 2009, NATURE, V462, P108, DOI 10.1038/nature08460; Barretina J, 2012, NATURE, V483, P603, DOI 10.1038/nature11003; Bliss CI, 1939, ANN APPL BIOL, V26, P585, DOI 10.1111/j.1744-7348.1939.tb06990.x; Borisy AA, 2003, P NATL ACAD SCI USA, V100, P7977, DOI 10.1073/pnas.1337088100; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chan DA, 2011, NAT REV DRUG DISCOV, V10, P351, DOI 10.1038/nrd3374; Chapman PB, 2011, NEW ENGL J MED, V364, P2507, DOI 10.1056/NEJMoa1103782; Chou TC, 2010, CANCER RES, V70, P440, DOI 10.1158/0008-5472.CAN-09-1947; Chow LWC, 2013, BRIT J CANCER, V108, P1985, DOI 10.1038/bjc.2013.178; Cokol M, 2011, MOL SYST BIOL, V7, DOI 10.1038/msb.2011.71; Corcoran RB, 2012, CANCER DISCOV, V2, P227, DOI 10.1158/2159-8290.CD-11-0341; Davis MI, 2011, NAT BIOTECHNOL, V29, P1046, DOI 10.1038/nbt.1990; den Hollander J, 2010, BLOOD, V116, P1498, DOI 10.1182/blood-2009-11-251074; Druker BJ, 2001, NEW ENGL J MED, V344, P1031, DOI 10.1056/NEJM200104053441401; Emami KH, 2004, P NATL ACAD SCI USA, V101, P12682, DOI 10.1073/pnas.0404875101; Evan G, 2012, SCIENCE, V335, P293, DOI 10.1126/science.1217819; Flaherty KT, 2012, NEW ENGL J MED, V367, P107, DOI 10.1056/NEJMoa1203421; Garnett MJ, 2012, NATURE, V483, P570, DOI 10.1038/nature11005; Gosens R, 2010, FASEB J, V24, P757, DOI 10.1096/fj.09-136325; Griner LAM, 2014, P NATL ACAD SCI USA, V111, P2349, DOI 10.1073/pnas.1311846111; Haagensen EJ, 2012, BRIT J CANCER, V106, P1386, DOI 10.1038/bjc.2012.70; Hauschild A, 2012, LANCET, V380, P358, DOI 10.1016/S0140-6736(12)60868-X; Hoellein A, 2011, ONCOTARGET, V2, P599; Holohan C, 2013, NAT REV CANCER, V13, P714, DOI 10.1038/nrc3599; Hopkins AL, 2002, NAT REV DRUG DISCOV, V1, P727, DOI 10.1038/nrd892; Hung LY, 2008, NUCLEIC ACIDS RES, V36, P4337, DOI 10.1093/nar/gkn417; Hynes NE, 2001, J MAMMARY GLAND BIOL, V6, P141, DOI 10.1023/A:1009528918064; Kim SY, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008979; King AJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067583; Li FF, 2014, INT J CANCER, V134, P1257, DOI 10.1002/ijc.28261; Liu DX, 2008, THYROID, V18, P853, DOI 10.1089/thy.2007.0357; Loewe S, 1926, N-S ARCH EX PATH PH, V114, P313; McLornan DP, 2014, NEW ENGL J MED, V371, P1725, DOI 10.1056/NEJMra1407390; Mitsui F, 2007, MODERN PATHOL, V20, P622, DOI 10.1038/modpathol.3800777; Nagasawa J, 2006, INT J UROL, V13, P587, DOI 10.1111/j.1442-2042.2006.01342.x; Naik S, 2009, CLIN CANCER RES, V15, P7529, DOI 10.1158/1078-0432.CCR-09-0336; Nair R, 2014, ONCOGENE, V33, P3992, DOI 10.1038/onc.2013.368; Prahallad A, 2012, NATURE, V483, P100, DOI 10.1038/nature10868; Rabindran SK, 2004, CANCER RES, V64, P3958, DOI 10.1158/0008-5472.CAN-03-2868; Scholl C, 2009, CELL, V137, P821, DOI 10.1016/j.cell.2009.03.017; Shimizu T, 2012, CLIN CANCER RES, V18, P2316, DOI 10.1158/1078-0432.CCR-11-2381; Singh A, 2009, CELL CYCLE, V8, P2676, DOI 10.4161/cc.8.17.9336; Solit DB, 2006, NATURE, V439, P358, DOI 10.1038/nature04304; Sos ML, 2009, P NATL ACAD SCI USA, V106, P18351, DOI 10.1073/pnas.0907325106; Straetemans R, 2005, BIOMETRICAL J, V47, P299, DOI 10.1002/bimj.200410124; Sun C, 2014, CELL REP, V7, P86, DOI 10.1016/j.celrep.2014.02.045; Team R.C., 2021, R FOUN DATION STAT C; Toyoshima M, 2012, P NATL ACAD SCI USA, V109, P9545, DOI 10.1073/pnas.1121119109; Uitdehaag JCM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092146; Uitdehaag JCM, 2012, BRIT J PHARMACOL, V166, P858, DOI 10.1111/j.1476-5381.2012.01859.x; Uitdehaag JCM, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-94; Vasan N, 2014, CLIN CANCER RES, V20, P3921, DOI 10.1158/1078-0432.CCR-13-1762; Violette S, 2002, INT J CANCER, V98, P498, DOI 10.1002/ijc.10146; Yang D, 2010, P NATL ACAD SCI USA, V107, P13836, DOI 10.1073/pnas.1008366107; Yap TA, 2013, J CLIN ONCOL, V31, P1592, DOI 10.1200/JCO.2011.37.6418; Zhao L, 2004, CLIN CANCER RES, V10, P7994, DOI 10.1158/1078-0432.CCR-04-1087	61	14	15	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 27	2015	10	5							e0125021	10.1371/journal.pone.0125021	http://dx.doi.org/10.1371/journal.pone.0125021			22	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CJ0RO	26018524	Green Published, gold, Green Submitted			2023-01-03	WOS:000355185600011
J	Saeki, I; Yamasaki, T; Tanabe, N; Iwamoto, T; Matsumoto, T; Urata, Y; Hidaka, I; Ishikawa, T; Takami, T; Yamamoto, N; Uchida, K; Terai, S; Sakaida, I				Saeki, Issei; Yamasaki, Takahiro; Tanabe, Norikazu; Iwamoto, Takuya; Matsumoto, Toshihiko; Urata, Yohei; Hidaka, Isao; Ishikawa, Tsuyoshi; Takami, Taro; Yamamoto, Naoki; Uchida, Koichi; Terai, Shuji; Sakaida, Isao			A New Therapeutic Assessment Score for Advanced Hepatocellular Carcinoma Patients Receiving Hepatic Arterial Infusion Chemotherapy	PLOS ONE			English	Article							GAMMA-CARBOXY PROTHROMBIN; ALPHA-FETOPROTEIN RESPONSE; CLINICAL-OUTCOMES; INTERFERON-ALPHA; STAGING-SYSTEM; TUMOR-MARKERS; 5-FLUOROURACIL; CISPLATIN; JAPAN; CLASSIFICATION	Background & Aims Hepatic arterial infusion chemotherapy (HAIC) is an option for treating advanced hepatocellular carcinoma (HCC). Because of the poor prognosis in HAIC non-responders, it is important to identify patients who may benefit from continuous HAIC treatment; however, there are currently no therapeutic assessment scores for this identification. Therefore, we aimed to establish a new therapeutic assessment score for such patients. Methods We retrospectively analyzed 90 advanced HCC patients with elevated baseline alpha-fetoprotein (AFP) and/or des-gamma-carboxy prothrombin (DCP) levels and analyzed various parameters for their possible use as predictors of response and survival. AFP and DCP responses were assessed after half a course of HAIC (2 weeks); a positive-response was defined as a reduction of >= 20% from baseline. Results Multivariate analysis identified DCP response (odds ratio 16.03, p < 0.001) as an independent predictor of treatment response. In multivariate analysis, Child-Pugh class A (hazard ratio [HR] 1.99, p = 0.018), AFP response (HR 2.17, p = 0.007), and DCP response (HR 1.90, p = 0.030) were independent prognostic predictors. We developed an Assessment for Continuous Treatment with HAIC (ACTH) score, including the above 3 factors, which ranged from 0 to 3. Patients stratified into two groups according to this score showed significantly different prognoses (<= 1 vs. >= 2 points: median survival time, 15.1 vs. 8.7 months; p = 0.003). Conclusions The ACTH score may be useful in the therapeutic assessment of HCC patients receiving HAIC.	[Saeki, Issei; Tanabe, Norikazu; Iwamoto, Takuya; Matsumoto, Toshihiko; Hidaka, Isao; Ishikawa, Tsuyoshi; Takami, Taro; Yamamoto, Naoki; Terai, Shuji; Sakaida, Isao] Yamaguchi Univ, Grad Sch Med, Dept Gastroenterol & Hepatol, Ube, Yamaguchi 755, Japan; [Yamasaki, Takahiro] Yamaguchi Univ, Grad Sch Med, Dept Oncol & Lab Med, Ube, Yamaguchi 755, Japan; [Urata, Yohei] Nagato Gen Hosp, Dept Internal Med, Nagato, Yamaguchi, Japan; [Uchida, Koichi] Yamaguchi Prefectural Univ, Fac Nursing & Human Nutr, Dept Human Nutr, Yamaguchi, Yamaguchi, Japan	Yamaguchi University; Yamaguchi University	Yamasaki, T (corresponding author), Yamaguchi Univ, Grad Sch Med, Dept Oncol & Lab Med, Ube, Yamaguchi 755, Japan.	t.yama@yamaguchi-u.ac.jp						Ando E, 2002, CANCER-AM CANCER SOC, V95, P588, DOI 10.1002/cncr.10694; Aoyagi Y, 1996, CANCER, V77, P1781; Arii S, 2010, HEPATOL RES, V40, P667, DOI 10.1111/j.1872-034X.2010.00673.x; Bruix J, 2005, HEPATOLOGY, V42, P1208, DOI 10.1002/hep.20933; Chan SL, 2009, J CLIN ONCOL, V27, P446, DOI 10.1200/JCO.2008.18.8151; Cheng AL, 2009, LANCET ONCOL, V10, P25, DOI 10.1016/S1470-2045(08)70285-7; Chevret S, 1999, J HEPATOL, V31, P133, DOI 10.1016/S0168-8278(99)80173-1; Ebara M, 2005, J HEPATOL, V43, P458, DOI 10.1016/j.jhep.2005.03.033; Eisenhauer EA, 2009, EUR J CANCER, V45, P228, DOI 10.1016/j.ejca.2008.10.026; El-Serag HB, 2008, GASTROENTEROLOGY, V134, P1752, DOI 10.1053/j.gastro.2008.02.090; Huitzil-Melendez FD, 2010, J CLIN ONCOL, V28, P2889, DOI 10.1200/JCO.2009.25.9895; Japan LCSGo, 2009, GEN RUL CLIN PATH ST; Kim BK, 2011, J CANCER RES CLIN, V137, P659, DOI 10.1007/s00432-010-0917-5; Kim BK, 2011, LIVER INT, V31, P369, DOI 10.1111/j.1478-3231.2010.02368.x; Kishi K, 1992, Radiat Med, V10, P189; Kudo M, 2003, J GASTROENTEROL, V38, P207, DOI 10.1007/s005350300038; Lee MH, 2012, J GASTROEN HEPATOL, V27, P313, DOI 10.1111/j.1440-1746.2011.06867.x; Leung TWT, 2002, CANCER, V94, P1760, DOI 10.1002/cncr.10384; Llovet JM, 1999, SEMIN LIVER DIS, V19, P329, DOI 10.1055/s-2007-1007122; Llovet JM, 2008, NEW ENGL J MED, V359, P378, DOI 10.1056/NEJMoa0708857; Llovet JM, 2008, JNCI-J NATL CANCER I, V100, P698, DOI 10.1093/jnci/djn134; Manghisi G, 1998, HEPATOLOGY, V28, P751; MATSUI O, 1993, RADIOLOGY, V188, P79, DOI 10.1148/radiology.188.1.8390073; Mita Y, 1998, CANCER, V82, P1643, DOI 10.1002/(SICI)1097-0142(19980501)82:9<1643::AID-CNCR8>3.0.CO;2-B; Miyaki D, 2013, J GASTROEN HEPATOL, V28, P1834, DOI 10.1111/jgh.12311; Miyaki D, 2012, J GASTROEN HEPATOL, V27, P1850, DOI 10.1111/j.1440-1746.2012.07276.x; Nagano H, 2011, ONCOLOGY-BASEL, V80, P63, DOI 10.1159/000328281; Nouso K, 2013, BRIT J CANCER, V109, P1904, DOI 10.1038/bjc.2013.542; Obi S, 2006, CANCER-AM CANCER SOC, V106, P1990, DOI 10.1002/cncr.21832; Okita K, 2012, HEPATO-GASTROENTEROL, V59, P533, DOI 10.5754/hge10013; Park H, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/310427; Riaz A, 2009, J CLIN ONCOL, V27, P5734, DOI 10.1200/JCO.2009.23.1282; Shao YY, 2012, BRIT J CANCER, V107, P1672, DOI 10.1038/bjc.2012.466; Takaki-Hamabe S, 2009, HEPATOL RES, V39, P223, DOI 10.1111/j.1872-034X.2008.00458.x; Todo S, 2004, ANN SURG, V240, P451, DOI 10.1097/01.sla.0000137129.98894.42; Toyoda H, 2012, J HEPATOL, V57, P1251, DOI 10.1016/j.jhep.2012.07.018; Urayama N, 2011, KANZO, V52, P449; Vora SR, 2009, ONCOLOGIST, V14, P717, DOI 10.1634/theoncologist.2009-0038; Yamamoto K, 2009, ANN SURG ONCOL, V16, P2795, DOI 10.1245/s10434-009-0618-y; Yamasaki T, 2005, J GASTROENTEROL, V40, P70, DOI 10.1007/s00535-004-1494-7; Yamasaki T, 2003, HEPATOL RES, V27, P36, DOI 10.1016/S1386-6346(03)00195-5; Yamasaki T, 2002, HEPATOL RES, V23, P7, DOI 10.1016/S1386-6346(01)00163-2; Yamasaki T, 2012, HEPATOL RES, V42, P340, DOI 10.1111/j.1872-034X.2011.00938.x; Yamashita T, 2011, ONCOLOGY-BASEL, V81, P281, DOI 10.1159/000334439; Zhou L, 2006, WORLD J GASTROENTERO, V12, P1175, DOI 10.3748/wjg.v12.i8.1175	45	17	21	1	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 20	2015	10	5							e0126649	10.1371/journal.pone.0126649	http://dx.doi.org/10.1371/journal.pone.0126649			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CI7CV	25992784	Green Published, Green Submitted, gold			2023-01-03	WOS:000354921400070
J	Mohni, KN; Thompson, PS; Luzwick, JW; Glick, GG; Pendleton, CS; Lehmann, BD; Pietenpol, JA; Cortez, D				Mohni, Kareem N.; Thompson, Petria S.; Luzwick, Jessica W.; Glick, Gloria G.; Pendleton, Christopher S.; Lehmann, Brian D.; Pietenpol, Jennifer A.; Cortez, David			A Synthetic Lethal Screen Identifies DNA Repair Pathways that Sensitize Cancer Cells to Combined ATR Inhibition and Cisplatin Treatments	PLOS ONE			English	Article							NEGATIVE BREAST-CANCER; POLY(ADP-RIBOSE) POLYMERASE; HOMOLOGOUS RECOMBINATION; REPLICATION FORK; MISMATCH REPAIR; PARP INHIBITOR; PROTEIN-KINASE; TUMOR-CELLS; DEFICIENCY; DAMAGE	The DNA damage response kinase ATR may be a useful cancer therapeutic target. ATR inhibition synergizes with loss of ERCC1, ATM, XRCC1 and DNA damaging chemotherapy agents. Clinical trials have begun using ATR inhibitors in combination with cisplatin. Here we report the first synthetic lethality screen with a combination treatment of an ATR inhibitor (ATRi) and cisplatin. Combination treatment with ATRi/cisplatin is synthetically lethal with loss of the TLS polymerase zeta and 53BP1. Other DNA repair pathways including homologous recombination and mismatch repair do not exhibit synthetic lethal interactions with ATRi/cisplatin, even though loss of some of these repair pathways sensitizes cells to cisplatin as a single-agent. We also report that ATRi strongly synergizes with PARP inhibition, even in homologous recombination-proficient backgrounds. Lastly, ATR inhibitors were able to resensitize cisplatin-resistant cell lines to cisplatin. These data provide a comprehensive analysis of DNA repair pathways that exhibit synthetic lethality with ATR inhibitors when combined with cisplatin chemotherapy, and will help guide patient selection strategies as ATR inhibitors progress into the cancer clinic.	[Mohni, Kareem N.; Thompson, Petria S.; Luzwick, Jessica W.; Glick, Gloria G.; Pendleton, Christopher S.; Lehmann, Brian D.; Pietenpol, Jennifer A.; Cortez, David] Vanderbilt Univ, Sch Med, Dept Biochem, Nashville, TN 37212 USA	Vanderbilt University	Cortez, D (corresponding author), Vanderbilt Univ, Sch Med, Dept Biochem, Nashville, TN 37212 USA.	david.cortez@vanderbilt.edu	Lehmann, Brian D./H-8464-2019	Lehmann, Brian D./0000-0003-0407-5248; Thompson, Petria/0000-0002-3839-4303	National Institutes of Health [CA102792, T32CA093240, CA95131, SAC110030, PDF14302198]; Breast Cancer Research Foundation; NATIONAL CANCER INSTITUTE [T32CA009582, R01CA102729, R01CA102792, T32CA093240] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Breast Cancer Research Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by grants from the National Institutes of Health [CA102792 to D.C., T32CA093240 to K.N.M., CA95131 to J.A.P], Susan G. Komen [SAC110030 to J.A.P., PDF14302198 to K.N.M.] and the Breast Cancer Research Foundation [D.C.]. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aguilera A, 2008, NAT REV GENET, V9, P204, DOI 10.1038/nrg2268; Anders CK, 2010, CLIN CANCER RES, V16, P4702, DOI 10.1158/1078-0432.CCR-10-0939; Bartek J, 2007, ONCOGENE, V26, P7773, DOI 10.1038/sj.onc.1210881; Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; Bhat A, 2013, NUCLEIC ACIDS RES, V41, P2328, DOI 10.1093/nar/gks1442; Bouwman P, 2010, NAT STRUCT MOL BIOL, V17, P688, DOI 10.1038/nsmb.1831; Branzei D, 2010, NAT REV MOL CELL BIO, V11, P208, DOI 10.1038/nrm2852; Bryant HE, 2005, NATURE, V434, P913, DOI 10.1038/nature03443; Bunting SF, 2010, CELL, V141, P243, DOI 10.1016/j.cell.2010.03.012; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Charrier JD, 2011, J MED CHEM, V54, P2320, DOI 10.1021/jm101488z; Cimprich KA, 2008, NAT REV MOL CELL BIO, V9, P616, DOI 10.1038/nrm2450; Couch FB, 2013, GENE DEV, V27, P1610, DOI 10.1101/gad.214080.113; Cufer T, 2013, EUR J CANCER, V49, P1216, DOI 10.1016/j.ejca.2012.11.021; Di Cosimo S, 2010, NAT REV CLIN ONCOL, V7, P139, DOI 10.1038/nrclinonc.2009.234; ELION GB, 1954, J BIOL CHEM, V208, P477; Farmer H, 2005, NATURE, V434, P917, DOI 10.1038/nature03445; Fokas E, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.181; Foote KM, 2013, J MED CHEM, V56, P2125, DOI 10.1021/jm301859s; Gorgoulis VG, 2005, NATURE, V434, P907, DOI 10.1038/nature03485; GRECO WR, 1995, PHARMACOL REV, V47, P331; Guler G, 2011, BREAST CANCER RES TR, V129, P421, DOI 10.1007/s10549-010-1248-6; Hall AB, 2014, ONCOTARGET, V5, P5674, DOI 10.18632/oncotarget.2158; Hammerman PS, 2012, NATURE, V489, P519, DOI 10.1038/nature11404; Harrigan JA, 2011, J CELL BIOL, V193, P97, DOI 10.1083/jcb.201011083; Heacock ML, 2010, DNA REPAIR, V9, P929, DOI 10.1016/j.dnarep.2010.05.007; Horton JK, 2005, J BIOL CHEM, V280, P15773, DOI 10.1074/jbc.M413841200; Hudis CA, 2011, ONCOLOGIST, V16, P1, DOI 10.1634/theoncologist.2011-S1-01; Huntoon CJ, 2013, CANCER RES, V73, P3683, DOI 10.1158/0008-5472.CAN-13-0110; Kedar PS, 2012, MOL CANCER RES, V10, P360, DOI 10.1158/1541-7786.MCR-11-0477; Knobel PA, 2011, CANCER CELL INT, V11, DOI 10.1186/1475-2867-11-39; Knobel PA, 2011, NEOPLASIA, V13, P961, DOI 10.1593/neo.11828; KOI M, 1994, CANCER RES, V54, P4308; Kotov IN, 2014, MOL ONCOL, V8, P1747, DOI 10.1016/j.molonc.2014.07.008; Lukas C, 2011, NAT CELL BIOL, V13, P243, DOI 10.1038/ncb2201; Mohni KN, 2014, CANCER RES, V74, P2835, DOI 10.1158/0008-5472.CAN-13-3229; Morelli C, 2002, ONCOGENE, V21, P7266, DOI 10.1038/sj.onc.1205573; Murai J, 2014, MOL CANCER THER, V13, P433, DOI 10.1158/1535-7163.MCT-13-0803; Murai J, 2012, CANCER RES, V72, P5588, DOI 10.1158/0008-5472.CAN-12-2753; Neboori HJR, 2012, INT J RADIAT ONCOL, V83, pE677, DOI 10.1016/j.ijrobp.2012.01.089; Patel AG, 2011, P NATL ACAD SCI USA, V108, P3406, DOI 10.1073/pnas.1013715108; Postel-Vinay S, 2012, NAT REV CLIN ONCOL, V9, P144, DOI 10.1038/nrclinonc.2012.3; PRICHARD MN, 1990, ANTIVIR RES, V14, P181, DOI 10.1016/0166-3542(90)90001-N; Reaper PM, 2011, NAT CHEM BIOL, V7, P428, DOI [10.1038/NCHEMBIO.573, 10.1038/nchembio.573]; Schlacher K, 2011, CELL, V145, P529, DOI 10.1016/j.cell.2011.03.041; Shen YQ, 2013, CLIN CANCER RES, V19, P5003, DOI 10.1158/1078-0432.CCR-13-1391; Sultana R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057098; Telli ML, 2010, CLIN BREAST CANCER, V10, pE16, DOI 10.3816/CBC.2010.s.003; Toledo LI, 2011, NAT STRUCT MOL BIOL, V18, P721, DOI 10.1038/nsmb.2076; Turner NC, 2008, EMBO J, V27, P1368, DOI 10.1038/emboj.2008.61; Umar A, 1997, CANCER RES, V57, P3949; Wang HY, 2004, CANCER RES, V64, P7139, DOI 10.1158/0008-5472.CAN-04-1289	52	71	75	0	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 12	2015	10	5							e0125482	10.1371/journal.pone.0125482	http://dx.doi.org/10.1371/journal.pone.0125482			22	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CI1ZI	25965342	Green Published, gold, Green Submitted			2023-01-03	WOS:000354543500018
J	Peabody, FW				Peabody, Francis W.			The Care of the Patient	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Reprint																		Peabody FW, 1927, J AMER MED ASSOC, V88, P0877, DOI 10.1001/jama.1927.02680380001001	1	18	18	0	8	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 12	2015	313	18					1868	1868		10.1001/jama.2014.11744	http://dx.doi.org/10.1001/jama.2014.11744			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CH9XW	25965245				2023-01-03	WOS:000354391000039
J	Hillmen, P; Robak, T; Janssens, A; Babu, KG; Kloczko, J; Grosicki, S; Doubek, M; Panagiotidis, P; Kimby, E; Schuh, A; Pettitt, AR; Boyd, T; Montillo, M; Gupta, IV; Wright, O; Dixon, I; Carey, JL; Chang, CN; Lisby, S; McKeown, A; Offner, F				Hillmen, Peter; Robak, Tadeusz; Janssens, Ann; Babu, K. Govind; Kloczko, Janusz; Grosicki, Sebastian; Doubek, Michael; Panagiotidis, Panagiotis; Kimby, Eva; Schuh, Anna; Pettitt, Andrew R.; Boyd, Thomas; Montillo, Marco; Gupta, Ira V.; Wright, Oliver; Dixon, Iestyn; Carey, Jodi L.; Chang, Chai-Ni; Lisby, Steen; McKeown, Astrid; Offner, Fritz		COMPLEMENT 1 Study Investigators	Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trial	LANCET			English	Article							MONOCLONAL-ANTIBODIES; 1ST-LINE TREATMENT; ELDERLY-PATIENTS; HUMAN CD20; RITUXIMAB; FLUDARABINE; CYCLOPHOSPHAMIDE; BENDAMUSTINE; CLL; CHEMOIMMUNOTHERAPY	Background Treatment for patients with chronic lymphocytic leukaemia who are elderly or who have comorbidities is challenging because fludarabine-based chemoimmunotherapies are mostly not suitable. Chlorambucil remains the standard of care in many countries. We aimed to investigate whether the addition of ofatumumab to chlorambucil could lead to better clinical outcomes than does treatment with chlorambucil alone, while also being tolerable for patients who have few treatment options. Methods We carried out a randomised, open-label, phase 3 trial for treatment-naive patients with chronic lymphocytic leukaemia in 109 centres in 16 countries. We included patients who had active disease needing treatment, but in whom fludarabine-based treatment was not possible. We randomly assigned patients (1: 1) to receive oral chlorambucil (10 mg/m(2)) on days 1-7 of a 28 day treatment course or to receive chlorambucil by this schedule plus intravenous ofatumumab (cycle 1: 300 mg on day 1 and 1000 mg on day 8; subsequent cycles: 1000 mg on day 1) for three to 12 cycles. Assignment was done with a randomisation list that was computer generated at GlaxoSmithKline, and was stratified, in a block size of two, by age, disease stage, and performance status. The primary endpoint was progression-free survival in the intention-to-treat population and assessment was done by an independent review committee that was masked to group assignment. The study is registered with ClinicalTrials.gov, number NCT00748189. Findings We enrolled 447 patients, median age 69 years (range 35-92). Between Dec 22, 2008, and May 26, 2011, we randomly assigned 221 patients to chlorambucil plus ofatumumab and 226 patients to chlorambucil alone. Median progression-free survival was 22.4 months (95% CI 19.0-25.2) in the group assigned to chlorambucil plus ofatumumab compared with 13.1 months (10.6-13.8) in the group assigned to chlorambucil only (hazard ratio 0.57, 95% CI 0.45-0.72; p<0.0001). Grade 3 or greater adverse events were more common in the chlorambucil plus ofatumumab group (109 [50%] patients; vs 98 [43%] given chlorambucil alone), with neutropenia being the most common event (56 [26%] vs 32 [14%]). Grade 3 or greater infections had similar frequency in both groups. Grade 3 or greater infusion-related adverse events were reported in 22 (10%) patients given chlorambucil plus ofatumumab. Five (2%) patients died during treatment in each group. Interpretation Addition of ofatumumab to chlorambucil led to clinically important improvements with a manageable side-effect profile in treatment-naive patients with chronic lymphocytic leukaemia who were elderly or had comorbidities. Chlorambucil plus ofatumumab is therefore an important treatment option for these patients who cannot tolerate more intensive therapy.	[Hillmen, Peter] St James Univ Hosp, Dept Haematol, Leeds LS9 7TF, W Yorkshire, England; [Robak, Tadeusz] Med Univ Lodz, Dept Haematol, Lodz, Poland; [Janssens, Ann] Univ Ziekenhuizen Leuven, Leuven, Belgium; [Babu, K. Govind] Kidwai Mem Inst Oncol, Bangalore, Karnataka, India; [Kloczko, Janusz] Med Univ Bialystok, Bialystok, Poland; [Grosicki, Sebastian] Med Univ Silesia, Katowice, Poland; [Doubek, Michael] Univ Hosp Brno, Dept Haematol & Oncol, Brno, Czech Republic; [Panagiotidis, Panagiotis] Univ Athens, Laikon Gen Hosp, Athens, Greece; [Kimby, Eva] Karolinska Univ Hosp, Dept Hematol, Stockholm, Sweden; [Schuh, Anna] Churchill Hosp, Oxford OX3 7LJ, England; [Pettitt, Andrew R.] Univ Liverpool, Royal Liverpool & Broadgreen Hosp NHS Trust, Liverpool L69 3BX, Merseyside, England; [Boyd, Thomas] Yakima Valley Mem Hosp, Yakima, WA USA; [Montillo, Marco] Osped Niguarda Ca Granda, Dept Haematol, Milan, Italy; [Wright, Oliver; Dixon, Iestyn; McKeown, Astrid] GlaxoSmithKline, Uxbridge, Middx, England; [Gupta, Ira V.; Carey, Jodi L.] GlaxoSmithKline, Collegeville, PA USA; [Chang, Chai-Ni] GlaxoSmithKline, Res Triangle Pk, NC USA; [Lisby, Steen] Genmab, Copenhagen, Denmark; [Offner, Fritz] Univ Ziekenhuis Gent, Ghent, Belgium	Saint James's University Hospital; Medical University Lodz; KU Leuven; University Hospital Leuven; Kidwai Memorial Institute of Oncology; Medical University of Bialystok; Medical University Silesia; University Hospital Brno; Laiko General Hospital; National & Kapodistrian University of Athens; Karolinska Institutet; Karolinska University Hospital; University of Oxford; Royal Liverpool & Broadgreen University Hospitals NHS Trust; Royal Liverpool University Hospital; University of Liverpool; IRCCS Ca Granda Ospedale Maggiore Policlinico; Ospedale Niguarda Ca' Granda; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; Genmab; Ghent University; Ghent University Hospital	Hillmen, P (corresponding author), St James Univ Hosp, Dept Haematol, Leeds LS9 7TF, W Yorkshire, England.	peter.hillmen@nhs.net	Grosicki, Sebastian/AAG-2917-2019; Robak, Tadeusz/AAW-7365-2021; Doubek, Michael/J-7011-2018	Robak, Tadeusz/0000-0002-3411-6357; Grosicki, Sebastian/0000-0003-2644-1050; Kimby, Eva/0000-0003-3078-6131; Anna, schuh/0000-0002-3938-8490	GlaxoSmithKline; Genmab A/S	GlaxoSmithKline(GlaxoSmithKline); Genmab A/S(Genmab)	GlaxoSmithKline, Genmab A/S.; GlaxoSmithKline and Genmab A/S cofounded this trial. We thank patients and their families, physicians, and site staff for their participation; Geoffrey Chan of GlaxoSmithKline for valuable insight during the set-up of the trial; and Andrew Rawstron for guidance on flow cytometry. Medicus International New York (NY, USA) provided editorial assistance in the preparation of the manuscript, funded by GlaxoSmithKline. Results were presented in part at the Annual Meeting of the American Society of Hematology; New Orleans, LA, USA; Dec 8-11, 2013.	Beum PV, 2008, J IMMUNOL, V181, P822, DOI 10.4049/jimmunol.181.1.822; Blum KA, 2007, J CLIN ONCOL, V25, P5624, DOI 10.1200/JCO.2007.12.1152; Bottcher S, 2012, J CLIN ONCOL, V30, P980, DOI 10.1200/JCO.2011.36.9348; Byrd JC, 2005, BLOOD, V105, P49, DOI 10.1182/blood-2004-03-0796; Catovsky D, 2007, LANCET, V370, P230, DOI 10.1016/S0140-6736(07)61125-8; Craigen JL, 2009, BLOOD, V114, P687, DOI 10.1182/blood.V114.22.1725.1725; Del Giudice I, 2011, LEUKEMIA LYMPHOMA, V52, P2207, DOI 10.3109/10428194.2011.606386; Eichhorst B, 2009, LEUKEMIA LYMPHOMA, V50, P171, DOI 10.1080/10428190802688517; Eichhorst BF, 2009, BLOOD, V114, P3382, DOI 10.1182/blood-2009-02-206185; Extermann M, 1998, J CLIN ONCOL, V16, P1582, DOI 10.1200/JCO.1998.16.4.1582; Fischer K, 2012, J CLIN ONCOL, V30, P3209, DOI 10.1200/JCO.2011.39.2688; Foa R, 2014, AM J HEMATOL, V89, P480, DOI 10.1002/ajh.23668; Foon KA, 2012, BLOOD, V119, P3184, DOI 10.1182/blood-2012-01-408047; Forconi F, 2008, HEMATOL ONCOL, V26, P247, DOI 10.1002/hon.868; Ghia P, 2007, LEUKEMIA, V21, P1, DOI 10.1038/sj.leu.2404457; Goede V, 2014, NEW ENGL J MED, V370, P1101, DOI 10.1056/NEJMoa1313984; Hallek M, 2010, LANCET, V376, P1164, DOI 10.1016/S0140-6736(10)61381-5; Hallek M, 2008, BLOOD, V111, P5446, DOI 10.1182/blood-2007-06-093906; Hillmen P, 2007, J CLIN ONCOL, V25, P5616, DOI 10.1200/JCO.2007.12.9098; Hillmen P, 2014, J CLIN ONCOL, V32, P1236, DOI 10.1200/JCO.2013.49.6547; Keating MJ, 2005, J CLIN ONCOL, V23, P4079, DOI 10.1200/JCO.2005.12.051; Knauf WU, 2012, BRIT J HAEMATOL, V159, P67, DOI 10.1111/bjh.12000; Knauf WU, 2009, J CLIN ONCOL, V27, P4378, DOI 10.1200/JCO.2008.20.8389; MILLER MD, 1992, PSYCHIAT RES, V41, P237, DOI 10.1016/0165-1781(92)90005-N; Offner F, 2013, 15 INT WORKSH CHRON; Okroj M, 2013, MED ONCOL, V30, DOI 10.1007/s12032-013-0759-5; Rafiq S, 2013, J IMMUNOL, V190, P2702, DOI 10.4049/jimmunol.1202588; Rai KR, 2000, NEW ENGL J MED, V343, P1750, DOI 10.1056/NEJM200012143432402; Rawstron AC, 2007, LEUKEMIA, V21, P956, DOI 10.1038/sj.leu.2404584; Rawstron AC, 2013, LEUKEMIA, V27, P142, DOI 10.1038/leu.2012.216; Salvi F, 2008, J AM GERIATR SOC, V56, P1926, DOI 10.1111/j.1532-5415.2008.01935.x; Teeling JL, 2006, J IMMUNOL, V177, P362, DOI 10.4049/jimmunol.177.1.362; Teeling JL, 2004, BLOOD, V104, P1793, DOI 10.1182/blood-2004-01-0039; Wierda WG, 2011, BLOOD, V118, P5126, DOI 10.1182/blood-2011-04-348656; Wierda WG, 2010, J CLIN ONCOL, V28, P1749, DOI 10.1200/JCO.2009.25.3187; Woyach JA, 2013, J CLIN ONCOL, V31, P440, DOI 10.1200/JCO.2011.41.5646	36	267	273	1	31	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 9	2015	385	9980					1873	1883		10.1016/S0140-6736(15)60027-7	http://dx.doi.org/10.1016/S0140-6736(15)60027-7			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CH6ZE	25882396				2023-01-03	WOS:000354184500031
J	Chatwin, M; Tan, HL; Bush, A; Rosenthal, M; Simonds, AK				Chatwin, Michelle; Tan, Hui-Leng; Bush, Andrew; Rosenthal, Mark; Simonds, Anita Kay			Long Term Non-Invasive Ventilation in Children: Impact on Survival and Transition to Adult Care	PLOS ONE			English	Article							HOME MECHANICAL VENTILATION; SPINAL MUSCULAR-ATROPHY; POSITIVE-PRESSURE VENTILATION; NATURAL-HISTORY; DYSTROPHY; DISABILITY; LIFE	Background The number of children receiving domiciliary ventilatory support has grown over the last few decades driven largely by the introduction and widening applications of non-invasive ventilation. Ventilatory support may be used with the intention of increasing survival, or to facilitate discharge home and/or to palliate symptoms. However, the outcome of this intervention and the number of children transitioning to adult care as a consequence of longer survival is not yet clear. Methods In this retrospective cohort study, we analysed the outcome in children (< 17 years) started on home NIV at Royal Brompton Hospital over an 18 year period 1993-2011. The aim was to establish for different diagnostic groups: survival rate, likelihood of early death depending on diagnosis or discontinuation of ventilation, and the proportion transitioning to adult care. Results 496 children were commenced on home non invasive ventilation; follow-up data were available in 449 (91%). Fifty six per cent (n = 254) had neuromuscular disease. Ventilation was started at a median age (IQR) 10 (3-15) years. Thirteen percent (n = 59) were less than 1 year old. Forty percent (n = 181) have transitioned to adult care. Twenty four percent (n = 109) of patients have died, and nine percent (n = 42) were able to discontinue ventilatory support. Conclusion Long term ventilation is associated with an increase in survival in a range of conditions leading to ventilatory failure in children, resulting in increasing numbers surviving to adulthood. This has significant implications for planning transition and adult care facilities.	[Chatwin, Michelle; Simonds, Anita Kay] Royal Brompton & Harefield NHS Fdn Trust, Acad & Clin Dept Sleep & Breathing, London, England; [Tan, Hui-Leng; Bush, Andrew; Rosenthal, Mark] Royal Brompton & Harefield NHS Fdn Trust, Dept Paediat, London, England; [Chatwin, Michelle; Tan, Hui-Leng; Bush, Andrew; Rosenthal, Mark; Simonds, Anita Kay] Royal Brompton & Harefield NHS Fdn Trust, NIHR Resp Biomed Res Unit, London, England	Royal Brompton & Harefield NHS Foundation Trust; Royal Brompton & Harefield NHS Foundation Trust; Royal Brompton & Harefield NHS Foundation Trust	Chatwin, M (corresponding author), Royal Brompton & Harefield NHS Fdn Trust, Acad & Clin Dept Sleep & Breathing, Sydney St, London, England.	m.chatwin@rbht.nhs.uk			NIHR Respiratory Disease Biomedical Research Unit at the Royal Brompton and Harefield NHS Foundation Trust and Imperial College London; National Institute for Health Research [NF-SI-0510-10192] Funding Source: researchfish	NIHR Respiratory Disease Biomedical Research Unit at the Royal Brompton and Harefield NHS Foundation Trust and Imperial College London; National Institute for Health Research(National Institute for Health Research (NIHR))	The authors were supported by the NIHR Respiratory Disease Biomedical Research Unit at the Royal Brompton and Harefield NHS Foundation Trust and Imperial College London. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Amin R, 2014, PEDIATR PULM, V49, P816, DOI 10.1002/ppul.22868; Bach JR, 2008, PAEDIATR RESPIR REV, V9, P45, DOI 10.1016/j.prrv.2007.11.003; Bach JR, 1997, CHEST, V112, P1024, DOI 10.1378/chest.112.4.1024; Bushby K, 2010, LANCET NEUROL, V9, P177, DOI 10.1016/S1474-4422(09)70272-8; Chatwin M, 2011, ARCH DIS CHILD, V96, P426, DOI 10.1136/adc.2009.177832; Chatwin M, 2010, EUR RESPIR J, V35, P310, DOI 10.1183/09031936.00073409; Chatwin M, 2008, RESP MED, V102, P1528, DOI 10.1016/j.rmed.2008.07.019; DUBOWITZ V, 1995, NEUROMUSCULAR DISORD, V5, P3, DOI 10.1016/0960-8966(94)00075-K; Dubowitz V, 1999, Eur J Paediatr Neurol, V3, P49; Dubowitz V, 1995, MUSCLE DISORDERS CHI, P540; Eagle M, 2002, NEUROMUSCULAR DISORD, V12, P926, DOI 10.1016/S0960-8966(02)00140-2; Fauroux B, 2005, INTENS CARE MED, V31, P965, DOI 10.1007/s00134-005-2669-2; Foley AR, 2013, BRAIN, V136, P3625, DOI 10.1093/brain/awt284; Goodwin S, 2011, EUR J PEDIATR, V170, P1187, DOI 10.1007/s00431-011-1430-9; Hill ME, 2006, NEUROMUSCULAR DISORD, V16, P107, DOI 10.1016/j.nmd.2005.11.011; Hull J, 2012, THORAX, V67, P1, DOI 10.1136/thoraxjnl-2012-201964; Ishikawa Y, 2011, NEUROMUSCULAR DISORD, V21, P47, DOI 10.1016/j.nmd.2010.09.006; Jeppesen J, 2003, NEUROMUSCULAR DISORD, V13, P804, DOI 10.1016/S0960-8966(03)00162-7; Katz S, 2004, ARCH DIS CHILD, V89, P121, DOI 10.1136/adc.2002.018655; Kohler M, 2005, AM J RESP CRIT CARE, V172, P1032, DOI 10.1164/rccm.200503-322OC; Lloyd-Owen SJ, 2005, EUR RESPIR J, V25, P1025, DOI 10.1183/09031936.05.00066704; Matsumura Tsuyoshi, 2011, Rinsho Shinkeigaku, V51, P743; McDougall CM, 2013, ARCH DIS CHILD, V98, P660, DOI 10.1136/archdischild-2012-303062; Oskoui M, 2007, NEUROLOGY, V69, P1931, DOI 10.1212/01.wnl.0000290830.40544.b9; Paulides FM, 2012, INTENS CARE MED, V38, P847, DOI 10.1007/s00134-012-2545-9; Racca F, 2011, MINERVA ANESTESIOL, V77, P892; Rechtschaffen A., 1968, MANUAL STANDARDIZED; Robb Stephanie A, 2010, Neuromuscul Disord, V20, P833, DOI 10.1016/j.nmd.2010.08.002; Shurayatcher Y, 2008, NEUROMUSCULAR DISORD, V18, P561, DOI 10.1016/j.nmd.2008.05.001; Toussaint M, 2006, EUR RESPIR J, V28, P549, DOI 10.1183/09031936.06.00004906; Vianello A, 2004, NEUROMUSCULAR DISORD, V14, P353, DOI 10.1061/j.nmd.2004.03.002; Wallis C, 2011, ARCH DIS CHILD, V96, P998, DOI 10.1136/adc.2010.192864; ZERRES K, 1995, ARCH NEUROL-CHICAGO, V52, P518, DOI 10.1001/archneur.1995.00540290108025	34	67	70	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 1	2015	10	5							e0125839	10.1371/journal.pone.0125839	http://dx.doi.org/10.1371/journal.pone.0125839			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CH2XA	25933065	Green Published, gold, Green Submitted			2023-01-03	WOS:000353887100137
J	Ogoina, D; Finomo, F; Harry, T; Inatimi, O; Ebuenyi, I; Tariladei, WW; Afolayan, AA				Ogoina, Dimie; Finomo, Finomo; Harry, Tubonye; Inatimi, Otonyo; Ebuenyi, Ikenna; Tariladei, Wolo-Wolo; Afolayan, Abimbola Anne			Factors Associated with Timing of Initiation of Antiretroviral Therapy among HIV-1 Infected Adults in the Niger Delta Region of Nigeria	PLOS ONE			English	Article							HIV-INFECTED ADULTS; SUB-SAHARAN AFRICA; PREVENTION	Introduction Based on growing evidence mainly from countries outside Sub-Saharan Africa, the World Health Organisation (WHO) now recommends initiation of antiretroviral therapy (ART) in HIV-infected individuals in developing countries when CD4 cell count (CD4+) is <= 500cells/ul. Nigeria accounts for about 14% of the estimated HIV/AIDS burden in Sub-Saharan Africa. We evaluated the factors associated with timing of initiation of ART among treatment-ineligible HIV-infected adults from Nigeria. Methods We retrospectively reviewed the hospital records of ART ineligible HIV-infected adults who enrolled into HIV care between January 2008 and December 2012 at two major tertiary hospitals in Bayelsa State, South-South Nigeria. Demographic, clinical and laboratories data were obtained at presentation, at each subsequent visit at 6 monthly intervals and at time of initiation of ART. Cox proportional regression and Kaplan-Meier survival analysis were used to evaluate independent predictors of time to initiation of ART. Results Amongst the 280 study participants, 70.6% were females, 62.6% had CD4+ >= 500cells/ul, 48.4% had WHO HIV Stage 1 disease and 34.3% were lost to follow up. In a cohort of 180 participants followed up for >= 3months, participants with CD4+ of 351-500cells/ul and stage 2 disease were more likely to start ART earlier than those with CD4+ >500cells/ul (Hazard ratio [HR]-1.7, 95% confidence interval [CI] of 1.0-2.9) and stage 1 disease (HR-2.3 (95% CI-1.3-4.2) respectively. HIV-infected adults with faster CD4+ decay required earlier ART initiation, especially in the first year of follow up. Conclusion ART-ineligible HIV-infected adults on follow up in South-South Nigeria are more likely to require earlier initiation of ART if they have stage 2 HIV disease or CD4+ <= 500cells/ul at presentation. Our findings suggest faster progression of HIV-disease in these groups of individuals and corroborate the growing evidence in support for earlier initiation of ART.	[Ogoina, Dimie; Harry, Tubonye; Inatimi, Otonyo; Ebuenyi, Ikenna] Niger Delta Univ, Teaching Hosp, Dept Internal Med, Okolobiri, Bayelsa State, Nigeria; [Finomo, Finomo; Tariladei, Wolo-Wolo; Afolayan, Abimbola Anne] Fed Med Ctr, Dept Med, Yenagoa, Bayelsa State, Nigeria		Ogoina, D (corresponding author), Niger Delta Univ, Teaching Hosp, Dept Internal Med, Okolobiri, Bayelsa State, Nigeria.	dimostic@yahoo.co.uk	Ogoina, Dimie/H-4091-2019; Harry, Tubonye/A-2107-2012	Ogoina, Dimie/0000-0002-2098-6300; Harry, Tubonye/0000-0003-3773-5230; Ebuenyi, Ikenna/0000-0002-3329-6296				Agu KA, 2012, WORLD J AIDS, V2, P330, DOI [10.4236/wja.2012.24044, DOI 10.4236/WJA.2012.24044]; Aliyu M H, 2010, Afr J Med Med Sci, V39, P233; Aliyu MH, 2014, JAIDS-J ACQ IMM DEF, V65, pE41, DOI 10.1097/QAI.0b013e31829ceaec; Anglaret X, 2013, ANTIVIR THER, V18, P45, DOI 10.3851/IMP2231; Anglemyer A, 2014, AIDS, V28, pS105, DOI 10.1097/QAD.0000000000000232; Cohen MS, 2011, NEW ENGL J MED, V365, P493, DOI [10.1056/NEJMoa1105243, 10.1056/NEJMoa1600693]; De Cock KM, 2013, NEW ENGL J MED, V368, P886, DOI 10.1056/NEJMp1300458; Easterbrook PJ, 1999, J ANTIMICROB CHEMOTH, V43, P379, DOI 10.1093/jac/43.3.379; Federal Ministry of Health Nigeria, 2010, NATIONAL HIV SEROPRE; Federal Ministry of Health Nigeria, 2010, NATIONAL GUIDELINES; Granich R, 2011, CURR HIV RES, V9, P446, DOI 10.2174/157016211798038597; Kitahata MM, 2009, NEW ENGL J MED, V360, P1815, DOI 10.1056/NEJMoa0807252; Kranzer K, 2012, J INT AIDS SOC, V15, DOI 10.7448/IAS.15.2.17383; Langford Simone E, 2007, AIDS Res Ther, V4, P11, DOI 10.1186/1742-6405-4-11; Le T, 2013, NEW ENGL J MED, V368, P218, DOI 10.1056/NEJMoa1110187; Lepri AC, 1998, EPIDEMIOL INFECT, V121, P369, DOI 10.1017/S095026889800140X; Mugglin C, 2012, TROP MED INT HEALTH, V17, P1509, DOI 10.1111/j.1365-3156.2012.03089.x; National Agency for Control of AIDS (NACA) Nigeria, 2011, FACT SHEET UPDATE ON, P1; Odafe S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051254; Odafe S, 2012, J INT AIDS SOC, V15, DOI 10.7448/IAS.15.2.17424; Opravil M, 2002, AIDS, V16, P1371, DOI 10.1097/00002030-200207050-00009; Salamon R, 2002, J ACQ IMMUN DEF SYND, V29, P149, DOI 10.1097/00042560-200202010-00007; Siegfried N, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008272.pub2; Suthar AB, 2012, PLOS MED, V9, DOI 10.1371/journal.pmed.1001270; World Health Organization, 2013, COMPREHENSIVE CERVIC; Yu JKL, 2007, B WORLD HEALTH ORGAN, V85, P550, DOI 10.2471/BLT.06.037739	26	2	2	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 1	2015	10	5							e0125665	10.1371/journal.pone.0125665	http://dx.doi.org/10.1371/journal.pone.0125665			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CH2XA	25933356	Green Published, Green Submitted, gold			2023-01-03	WOS:000353887100125
J	Wojcik, M; Lewandowski, W; Krol, M; Pawlowski, K; Mieczkowski, J; Lechowski, R; Zabielska, K				Wojcik, Michal; Lewandowski, Wiktor; Krol, Magdalena; Pawlowski, Karol; Mieczkowski, Jozef; Lechowski, Roman; Zabielska, Katarzyna			Enhancing Anti-Tumor Efficacy of Doxorubicin by Non-Covalent Conjugation to Gold Nanoparticles - In Vitro Studies on Feline Fibrosarcoma Cell Lines	PLOS ONE			English	Article							TARGETED DRUG-DELIVERY; MULTIDRUG-RESISTANCE; CANCER-CELLS; TOXICITY; SYSTEMS; CYCLODEXTRINS; CHEMOTHERAPY; COMBINATION; SARCOMAS; RELEASE	Background Feline injection-site sarcomas are malignant skin tumors of mesenchymal origin, the treatment of which is a challenge for veterinary practitioners. Methods of treatment include radical surgery, radiotherapy and chemotherapy. The most commonly used cytostatic drugs are cyclophosphamide, doxorubicin and vincristine. However, the use of cytostatics as adjunctive treatment is limited due to their adverse side-effects, low biodistribution after intravenous administration and multidrug resistance. Colloid gold nanoparticles are promising drug delivery systems to overcome multidrug resistance, which is a main cause of ineffective chemotherapy treatment. The use of colloid gold nanoparticles as building blocks for drug delivery systems is preferred due to ease of surface functionalization with various molecules, chemical stability and their low toxicity. Methods Stability and structure of the glutathione-stabilized gold nanoparticles non-covalently modified with doxorubicin (Au-GSH-Dox) was confirmed using XPS, TEM, FT-IR, SAXRD and SAXS analyses. MTT assay, Annexin V and Propidium Iodide Apoptosis assay and Rhodamine 123 and Verapamil assay were performed on 4 feline fibrosarcoma cell lines (FFS1WAW, FFS1, FFS3, FFS5). Statistical analyses were performed using Graph Pad Prism 5.0 (USA). Results A novel approach, glutathione-stabilized gold nanoparticles (4.3 +/- 1.1 nm in diameter) non-covalently modified with doxorubicin (Au-GSH-Dox) was designed and synthesized. A higher cytotoxic effect (p<0.01) of Au-GSH-Dox than that of free doxorubicin has been observed in 3 (FFS1, FFS3, FFS1WAW) out of 4 feline fibrosarcoma cell lines. The effect has been correlated to the activity of glycoprotein P (main efflux pump responsible for multidrug resistance). Conclusions The results indicate that Au-GSH-Dox may be a potent new therapeutic agent to increase the efficacy of the drug by overcoming the resistance to doxorubicin in feline fibrosarcoma cell lines. Moreover, as doxorubicin is non-covalently attached to glutathione coated nanoparticles the synthesized system is potentially suitable to a wealth of different drug molecules.	[Wojcik, Michal; Lewandowski, Wiktor; Mieczkowski, Jozef] Univ Warsaw, Fac Chem, Warsaw, Poland; [Krol, Magdalena; Pawlowski, Karol; Lechowski, Roman; Zabielska, Katarzyna] Warsaw Univ Life Sci, Fac Vet Med, Warsaw, Poland	University of Warsaw; Warsaw University of Life Sciences	Wojcik, M (corresponding author), Univ Warsaw, Fac Chem, Warsaw, Poland.	mwojcik@chem.uw.edu.pl; katarzyna_zabielska@sggw.pl	Lewandowski, Wiktor/F-5639-2011; Zabielska-Koczywąs, Katarzyna/AFU-6510-2022; Zabielska-Koczywąs, Katarzyna Agnieszka/AAS-8153-2021; Krol, Magdalena/A-5554-2019	Lewandowski, Wiktor/0000-0002-3503-2120; Zabielska-Koczywąs, Katarzyna Agnieszka/0000-0003-1691-3982; Pawlowski, Karol/0000-0003-4565-2873; Krol, Magdalena/0000-0003-0421-5167; Lechowski, Roman/0000-0002-1121-4288	Polish National Science Centre [2013/09/D/ST5/03875, DEC-2012/07/N/NZ4/02413, 2011/01/N/ST5/0329]	Polish National Science Centre	The authors would like to acknowledge support by the Polish National Science Centre (Project 2013/09/D/ST5/03875 [WL], Project No. DEC-2012/07/N/NZ4/02413 [KZ], and Project 2011/01/N/ST5/0329[MW]). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Allen TM, 2013, ADV DRUG DELIVER REV, V65, P36, DOI 10.1016/j.addr.2012.09.037; Aryal S, 2009, J MATER CHEM, V19, P7879, DOI 10.1039/b914071a; Asadishad B, 2010, IND ENG CHEM RES, V49, P1958, DOI 10.1021/ie9011479; Barber LG, 2000, J AM ANIM HOSP ASSOC, V36, P416, DOI 10.5326/15473317-36-5-416; Boisselier E, 2009, CHEM SOC REV, V38, P1759, DOI 10.1039/b806051g; Bregazzi VS, 2001, J AM VET MED ASSOC, V218, P547, DOI 10.2460/javma.2001.218.547; Challa R, 2005, AAPS PHARMSCITECH, V6, DOI 10.1208/pt060243; Chang DK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083239; Chen HY, 2012, BIOMATERIALS, V33, P8461, DOI 10.1016/j.biomaterials.2012.08.034; Chen L, 2014, SENSOR ACTUAT B-CHEM, V193, P857, DOI 10.1016/j.snb.2013.12.053; Cho KJ, 2008, CLIN CANCER RES, V14, P1310, DOI 10.1158/1078-0432.CCR-07-1441; Connor EE, 2005, SMALL, V1, P325, DOI 10.1002/smll.200400093; de Oliveira R, 2013, INT J PHARMACEUT, V454, P703, DOI 10.1016/j.ijpharm.2013.05.031; Ding Y, 2013, BIOMATERIALS, V34, P10217, DOI 10.1016/j.biomaterials.2013.09.008; Doane TL, 2012, CHEM SOC REV, V41, P2885, DOI 10.1039/c2cs15260f; Duncan B, 2010, J CONTROL RELEASE, V148, P122, DOI 10.1016/j.jconrel.2010.06.004; Farokhzad OC, 2009, ACS NANO, V3, P16, DOI 10.1021/nn900002m; Goodman CM, 2004, BIOCONJUGATE CHEM, V15, P897, DOI 10.1021/bc049951i; Gottesman MM, 2002, NAT REV CANCER, V2, P48, DOI 10.1038/nrc706; Gu YJ, 2012, NANOMED-NANOTECHNOL, V8, P204, DOI 10.1016/j.nano.2011.06.005; Gulyaev AE, 1999, PHARM RES-DORDR, V16, P1564, DOI 10.1023/A:1018983904537; Hahn KA, 2007, JAVMA-J AM VET MED A, V231, P742, DOI 10.2460/javma.231.5.742; Janes KA, 2001, J CONTROL RELEASE, V73, P255, DOI 10.1016/S0168-3659(01)00294-2; Joshi P, 2011, J COLLOID INTERF SCI, V355, P402, DOI 10.1016/j.jcis.2010.12.032; Kayal S, 2010, J NANOSCI NANOTECHNO, V10, P5527, DOI 10.1166/jnn.2010.2461; LAMPIDIS TJ, 1985, CANCER RES, V45, P2626; Manju S, 2012, J COLLOID INTERF SCI, V368, P144, DOI 10.1016/j.jcis.2011.11.024; Martano M, 2011, VET J, V188, P136, DOI 10.1016/j.tvjl.2010.04.025; Meng HA, 2010, ACS NANO, V4, P4539, DOI 10.1021/nn100690m; Mimeault M, 2008, CLIN PHARMACOL THER, V83, P673, DOI 10.1038/sj.clpt.6100296; Minati L, 2012, INT J PHARMACEUT, V438, P45, DOI 10.1016/j.ijpharm.2012.08.057; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Murphy CJ, 2008, ACCOUNTS CHEM RES, V41, P1721, DOI 10.1021/ar800035u; Palmeira A, 2012, J PHARM PHARM SCI, V15, P31, DOI 10.18433/J3BG65; Pan Y, 2007, SMALL, V3, P1941, DOI 10.1002/smll.200700378; Pan Y, 2009, SMALL, V5, P2067, DOI 10.1002/smll.200900466; Pawlowski KM, 2013, BMC VET RES, V9, DOI 10.1186/1746-6148-9-119; Peer D, 2007, NAT NANOTECHNOL, V2, P751, DOI 10.1038/nnano.2007.387; Poirier VJ, 2002, J VET INTERN MED, V16, P726, DOI 10.1111/j.1939-1676.2002.tb02415.x; Riss T.L., CELL VIABILITY ASSAY; Samad Abdus, 2007, Current Drug Delivery, V4, P297, DOI 10.2174/156720107782151269; Sapsford KE, 2013, CHEM REV, V113, P1904, DOI 10.1021/cr300143v; Schroeder A, 2012, NAT REV CANCER, V12, P39, DOI 10.1038/nrc3180; Simpson CA, 2013, NANOMED-NANOTECHNOL, V9, P257, DOI 10.1016/j.nano.2012.06.002; Tiwari G, 2010, J PHARM BIOALLIED SC, V2, P72, DOI 10.4103/0975-7406.67003; Tom RT, 2004, LANGMUIR, V20, P1909, DOI 10.1021/la0358567; von Erichsen J, 2012, VET PATHOL, V49, P648, DOI 10.1177/0300985811406887; Wang BY, 2014, BIOMATERIALS, V35, P5897, DOI 10.1016/j.biomaterials.2014.03.068; Wang F, 2011, ACS NANO, V5, P3679, DOI 10.1021/nn200007z; Williams LE, 2001, AM J VET RES, V62, P1354, DOI 10.2460/ajvr.2001.62.1354; Wu ZK, 2011, ADV FUNCT MATER, V21, P177, DOI 10.1002/adfm.201001120; Xie Y, 2014, BIOMATERIALS, V35, P7978, DOI 10.1016/j.biomaterials.2014.05.068; Zabielska K, 2012, VET RES COMMUN, V36, P227, DOI 10.1007/s11259-012-9535-9; Zhang XK, 2009, BIOMATERIALS, V30, P6041, DOI 10.1016/j.biomaterials.2009.07.025; Zhang XA, 2011, BIOCONJUGATE CHEM, V22, P235, DOI 10.1021/bc100374p; Zhou LJ, 2014, BIOMATERIALS, V35, P7666, DOI 10.1016/j.biomaterials.2014.05.051; Zhu D, 2014, RSC ADV, V4, P9372, DOI 10.1039/c3ra45491f	57	28	29	0	52	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 30	2015	10	4							e0124955	10.1371/journal.pone.0124955	http://dx.doi.org/10.1371/journal.pone.0124955			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CH0MA	25928423	Green Published, Green Submitted, gold			2023-01-03	WOS:000353713100055
J	Nansen, C; Ribeiro, LP; Dadour, I; Roberts, JD				Nansen, Christian; Ribeiro, Leandro Prado; Dadour, Ian; Roberts, John Dale			Detection of Temporal Changes in Insect Body Reflectance in Response to Killing Agents	PLOS ONE			English	Article							NEAR-INFRARED SPECTROSCOPY; CUTICULAR HYDROCARBONS; OPTICAL-PROPERTIES; COLEOPTERA; HYMENOPTERA; LARVAE; HOST	Computer vision and reflectance-based analyses are becoming increasingly important methods to quantify and characterize phenotypic responses by whole organisms to environmental factors. Here, we present the first study of how a non-destructive and completely non-invasive method, body reflectance profiling, can be used to detect and time stress responses in adult beetles. Based on high-resolution hyperspectral imaging, we acquired time series of average reflectance profiles (70 spectral bands from 434-876 nm) from adults in two beetle species, maize weevils (Sitophilus zeamais) and larger black flour beetles (Cynaus angustus). For each species, we acquired reflectance data from untreated controls and from individuals exposed continuously to killing agents (an insecticidal plant extract applied to maize kernels or entomopathogenic nematodes applied to soil applied at levels leading to approximate to 100% mortality). In maize weevils (exposed to hexanic plant extract), there was no significant effect of the on reflectance profiles acquired from adult beetles after 0 and 12 hours of exposure, but a significant treatment response in spectral bands from 434 to 550 nm was detected after 36 to 144 hours of exposure. In larger black flour beetles, there was no significant effect of exposure to entomopathogenic nematodes after 0 to 26 hours of exposure, but a significant response in spectral bands from 434-480 nm was detected after 45 and 69 hours of exposure. Spectral bands were used to develop reflectance-based classification models for each species, and independent validation of classification algorithms showed sensitivity (ability to positively detect terminal stress in beetles) and specificity (ability to positively detect healthy beetles) of about 90%. Significant changes in body reflectance occurred at exposure times, which coincided with published exposure times and known physiological responses to each killing agent. The results from this study underscore the potential of hyperspectral imaging as an approach to non-destructively and non-invasively quantify stress detection in insects and other animals.	[Nansen, Christian] Univ Calif Davis, Dept Entomol & Nematol, Davis, CA 95616 USA; [Ribeiro, Leandro Prado] Univ Sao Paulo, Dept Entomol & Acarol, Piracicaba, SP, Brazil; [Dadour, Ian] Univ Western Australia, Ctr Forens Sci, Perth, WA 6009, Australia; [Roberts, John Dale] Univ Western Australia, Sch Anim Biol, Albany, WA, Australia; [Roberts, John Dale] Univ Western Australia, Ctr Evolutionary Biol, Albany, WA, Australia; [Roberts, John Dale] Univ Western Australia, Ctr Excellence Nat Resource Management, Albany, WA, Australia	University of California System; University of California Davis; Universidade de Sao Paulo; University of Western Australia; University of Western Australia; University of Western Australia; University of Western Australia	Nansen, C (corresponding author), Univ Calif Davis, Dept Entomol & Nematol, Davis, CA 95616 USA.	christian.nansen@uwa.edu.au		Dadour, Ian Robert/0000-0001-7527-4936				Aw WC, 2012, G3-GENES GENOM GENET, V2, P1057, DOI 10.1534/g3.112.003103; Berggren A, 2010, INSECT SCI, V17, P400, DOI 10.1111/j.1744-7917.2010.01319.x; Bluhm BA, 2001, MAR BIOL, V138, P247, DOI 10.1007/s002270000458; Burleigh JG, 2013, PLOS CURR-TREE LIFE, DOI 10.1371/currents.tol.085c713acafc8711b2ff7010a4b03733; Butler SM, 2009, MED VET ENTOMOL, V23, P426, DOI 10.1111/j.1365-2915.2009.00831.x; Carter GA, 2001, AM J BOT, V88, P677, DOI 10.2307/2657068; Chapman R.F, 2012, INSECTS STRUCTURE FU; Colom OA, 2008, J PEST SCI, V81, P85, DOI 10.1007/s10340-007-0189-2; Cotter SC, 2008, J EVOLUTION BIOL, V21, P1744, DOI 10.1111/j.1420-9101.2008.01587.x; De Loof A, 2010, J INSECT PHYSIOL, V56, P919, DOI 10.1016/j.jinsphys.2010.02.021; Faber NM, 2007, ANAL CHIM ACTA, V595, P98, DOI 10.1016/j.aca.2007.05.030; Ferreira-Caliman MJ, 2010, J INSECT PHYSIOL, V56, P800, DOI 10.1016/j.jinsphys.2010.02.004; Fisher RA, 1936, ANN EUGENIC, V7, P179, DOI 10.1111/j.1469-1809.1936.tb02137.x; Freitak D, 2005, ENTOMOL EXP APPL, V116, P237, DOI 10.1111/j.1570-7458.2005.00330.x; FUZEAUBR.S, 1972, ANNU REV ENTOMOL, V17, P403, DOI 10.1146/annurev.en.17.010172.002155; GOODWIN TW, 1951, BIOCHEM J, V48, P199, DOI 10.1042/bj0480199; Hawkins DM, 2004, J CHEM INF COMP SCI, V44, P1, DOI 10.1021/ci0342472; Houle D, 2010, NAT REV GENET, V11, P855, DOI 10.1038/nrg2897; Howard RW, 2003, ARCH INSECT BIOCHEM, V53, P1, DOI 10.1002/arch.10078; Howard RW, 2002, ARCH INSECT BIOCHEM, V50, P75, DOI 10.1002/arch.10034; Kastenbaum R, 1989, DEFINITIONS OF DEATH; Koc H, 2008, J CEREAL SCI, V48, P394, DOI 10.1016/j.jcs.2007.09.015; Lacoste C, ENV ENTOMOLOGY; Lammertyn J, 2000, POSTHARVEST BIOL TEC, V18, P121, DOI 10.1016/S0925-5214(99)00071-X; Lapointe SL, 2004, AGR FOREST ENTOMOL, V6, P251, DOI 10.1111/j.1461-9555.2004.00230.x; Mietchen D, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003826; Nansen C, 2013, COMPUT ELECTRON AGR, V97, P21, DOI 10.1016/j.compag.2013.06.007; Nansen C, 2015, J PHOTOCHEMISTRY P B; Nansen C, 2008, J AGR FOOD CHEM, V56, P2933, DOI 10.1021/jf073237o; Nansen C, 2014, J EXP BIOL, V217, P1187, DOI 10.1242/jeb.095661; Nansen C, 2014, J FOOD ENG, V123, P17, DOI 10.1016/j.jfoodeng.2013.09.001; Nansen C, 2013, APPL SPECTROSC, V67, P1332, DOI 10.1366/12-06933; Nansen C, 2013, J ECON ENTOMOL, V106, P648, DOI 10.1603/EC12380; Nunes TM, 2009, GENET MOL RES, V8, P589, DOI 10.4238/vol8-2kerr012; Prabhakar M, 2012, CROP STRESS AND ITS MANAGEMENT: PERSPECTIVES AND STRATEGIES, P517, DOI 10.1007/978-94-007-2220-0_16; Qin JW, 2008, POSTHARVEST BIOL TEC, V49, P355, DOI 10.1016/j.postharvbio.2008.03.010; Ribeiro LD, 2013, J STORED PROD RES, V55, P6, DOI 10.1016/j.jspr.2013.06.001; Ribeiro LP, 2010, BIOPROSPECCAO EXTRAT; Robson SKA, 2009, AUST J ENTOMOL, V48, P102, DOI 10.1111/j.1440-6055.2009.00692.x; Rosa JS, 2002, J INVERTEBR PATHOL, V80, P46, DOI 10.1016/S0022-2011(02)00038-1; Roux O, 2008, MED VET ENTOMOL, V22, P309, DOI 10.1111/j.1365-2915.2008.00752.x; Singh CB, 2009, J STORED PROD RES, V45, P151, DOI 10.1016/j.jspr.2008.12.002; Singh CB, 2010, COMPUT ELECTRON AGR, V73, P118, DOI 10.1016/j.compag.2010.06.001; Wang J, 2011, POSTHARVEST BIOL TEC, V59, P272, DOI 10.1016/j.postharvbio.2010.09.017; Wang J, 2010, J FOOD ENG, V101, P78, DOI 10.1016/j.jfoodeng.2010.06.011; Webster TC, 2009, APIDOLOGIE, V40, P565, DOI 10.1051/apido/2009038; WILSON BC, 1990, IEEE J QUANTUM ELECT, V26, P2186, DOI 10.1109/3.64355; Zhang X, APPL SPECTROSCOPY; Zhu GH, 2006, MED VET ENTOMOL, V20, P438, DOI 10.1111/j.1365-2915.2006.00651.x	49	15	15	0	28	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 29	2015	10	4							e0124866	10.1371/journal.pone.0124866	http://dx.doi.org/10.1371/journal.pone.0124866			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CH0LO	25923362	Green Published, gold			2023-01-03	WOS:000353711600109
J	Branch, WT				Branch, William T., Jr.			The Ethics of Patient Care	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							DOCTOR		Emory Univ, Sch Med, Dept Med, Div Gen Internal Med & Geriatr, Atlanta, GA 30303 USA	Emory University	Branch, WT (corresponding author), Emory Univ, Sch Med, Dept Med, Div Gen Internal Med & Geriatr, Atlanta, GA 30303 USA.	wbranch@emory.edu						[Anonymous], PHILOS MED REBORN PE; [Anonymous], 1983, DIFFERENT VOICE PSYC; [Anonymous], WHAT MATTERS; Barry MJ, 2012, NEW ENGL J MED, V366, P780, DOI 10.1056/NEJMp1109283; Beauchamp T.L., 2012, PRINCIPLES BIOMEDICA, V7th; Branch WT, 2014, HASTINGS CENT REP, V44, P15, DOI 10.1002/hast.250; Branch WT, 2014, MED EDUC, V48, P67, DOI 10.1111/medu.12369; Branch WT, 2000, ACAD MED, V75, P127, DOI 10.1097/00001888-200002000-00006; Noddings N., 1984, CARING FEMININE APPR	9	6	6	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 14	2015	313	14					1421	1422		10.1001/jama.2015.1080	http://dx.doi.org/10.1001/jama.2015.1080			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CF8OK	25871666				2023-01-03	WOS:000352821200014
J	Tang, LQ; Hu, DP; Chen, QY; Zhang, L; Lai, XP; He, Y; Xu, YXX; Wen, SH; Peng, YT; Chen, WH; Guo, SS; Liu, LT; Qian, CN; Guo, X; Zeng, MS; Mai, HQ				Tang, Lin Quan; Hu, Dong Peng; Chen, Qiu Yan; Zhang, Lu; Lai, Xiao Ping; He, Yun; Xu, Yun-Xiu-Xiu; Wen, Shi-Hua; Peng, Yu-Tuan; Chen, Wen-Hui; Guo, Shan-Shan; Liu, Li-Ting; Qian, Chao-Nan; Guo, Xiang; Zeng, Mu-Sheng; Mai, Hai-Qiang			Elevated High-Sensitivity C-Reactive Protein Levels Predict Decreased Survival for Nasopharyngeal Carcinoma Patients in the Intensity-Modulated Radiotherapy Era	PLOS ONE			English	Article							BARR-VIRUS DNA; CONVENTIONAL 2-DIMENSIONAL RADIOTHERAPY; VIRAL-DNA; EBV DNA; PLASMA; DIAGNOSIS; SERUM; CHEMORADIOTHERAPY; QUANTITATION; METASTASIS	Purpose This study aimed to clarify the prognostic utility of high-sensitivity C-reactive protein (hs-CRP) in nasopharyngeal carcinoma (NPC) patients in the Intensity-Modulated Radiotherapy (IMRT) era. Patients and Methods In this observational study, 1,589 non-metastatic NPC patients treated with IMRT were recruited. Blood samples were collected before treatment for examination of hs-CRP levels. We evaluated the association of pretreatment hs-CRP levels with overall survival rate (OS), progression free survival rate (PFS), locoregional relapse free survival rate (LRFS) and distant metastasis free survival rate (DMFS). Results Baseline hs-CRP levels were correlated with sex, clinical stage, body mass index, smoking status, and EBV DNA level. Multivariate analysis showed that hs-CRP had significant association with OS (HR:1.723; 95% CI:1.238-2.398; p = 0.001), PFS (HR:1.621; 95% CI:1.273-2.064; p < 0.001) and DMFS (HR: 1.879; 95% CI: 1.394-2.531; p < 0.001). In subgroups such as advanced-stage group, low EBV DNA group and high EBV DNA group, elevated hs-CRP levels still predicted poor clinical outcomes. Furthermore, in patients with chronic HBV infection, decreased 4-year survival was observed in the cohort of high hs-CRP levels, with 87.4% vs. 94.9% (p = 0.023) for OS, 65.2% vs. 90.8% (p < 0.001) for PFS, and 67.6% vs. 95.0% (p < 0.001) for DMFS. A similar finding was observed for patients with cardiovascular disease, with 79.1% vs. 90.2% (p = 0.020) for PFS, and 71.4% vs. 97.6% (p = 0.002) for DMFS. Conclusion Elevated serum hs-CRP levels were correlated with poor survival for NPC patients in the IMRT era, playing a complementary role to TNM stage and EBV DNA. In addition, elevated hs-CRP level was still an effective indicator for patients with chronic HBV infection and cardiovascular disease.	[Tang, Lin Quan; Chen, Qiu Yan; Chen, Wen-Hui; Guo, Shan-Shan; Liu, Li-Ting; Qian, Chao-Nan; Guo, Xiang; Zeng, Mu-Sheng; Mai, Hai-Qiang] Sun Yat Sen Univ, Ctr Canc, State Key Lab Oncol South China, Guangzhou 510275, Guangdong, Peoples R China; [Tang, Lin Quan; Chen, Qiu Yan; Zhang, Lu; Chen, Wen-Hui; Guo, Shan-Shan; Liu, Li-Ting; Qian, Chao-Nan; Guo, Xiang; Zeng, Mu-Sheng; Mai, Hai-Qiang] Sun Yat Sen Univ, Ctr Canc, Collaborat Innovat Ctr Canc Med, Guangzhou 510275, Guangdong, Peoples R China; [Tang, Lin Quan; Chen, Qiu Yan; Zhang, Lu; Guo, Shan-Shan; Liu, Li-Ting; Qian, Chao-Nan; Guo, Xiang; Zeng, Mu-Sheng; Mai, Hai-Qiang] Sun Yat Sen Univ, Ctr Canc, Dept Nasopharyngeal Carcinoma, Guangzhou 510275, Guangdong, Peoples R China; [Hu, Dong Peng; Lai, Xiao Ping; He, Yun; Xu, Yun-Xiu-Xiu; Wen, Shi-Hua; Peng, Yu-Tuan] Sun Yat Sen Univ, ZhongShan Sch Med, Guangzhou 510275, Guangdong, Peoples R China	State Key Lab Oncology South China; Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University	Zeng, MS (corresponding author), Sun Yat Sen Univ, Ctr Canc, State Key Lab Oncol South China, Guangzhou 510275, Guangdong, Peoples R China.	zengmsh@mail.sysu.edu.cn; maihq@mail.sysu.edu.cn			National Natural Science Foundation of China [81072226]; 863 Project [2012AA02A501]; National Key Basic Research Program of China [2013CB910304]; Sci-Tech Project Foundation of Guangdong Province [2011B080701034, 2011B031800161]; Sci-Tech Project Foundation of Guangzhou City [2011J4300100]; Sun Yatsen University Clinical Research 5010 Program; Fundamental Research Funds for the central universities	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); 863 Project(National High Technology Research and Development Program of China); National Key Basic Research Program of China(National Basic Research Program of China); Sci-Tech Project Foundation of Guangdong Province; Sci-Tech Project Foundation of Guangzhou City; Sun Yatsen University Clinical Research 5010 Program; Fundamental Research Funds for the central universities(Fundamental Research Funds for the Central Universities)	This research was supported by grants from the National Natural Science Foundation of China (No: 81072226, http://www.nsfc.gov.cn), the 863 Project (No: 2012AA02A501, http://www.863.gov.cn/), the National Key Basic Research Program of China (No: 2013CB910304, http://www.973.gov.cn), the Sci-Tech Project Foundation of Guangdong Province (No: 2011B080701034, and 2011B031800161, http://www.gdstc.gov.cn/), the Sci-Tech Project Foundation of Guangzhou City (No: 2011J4300100, http://www.gzsi.gov.cn), the Sun Yatsen University Clinical Research 5010 Program, and the Fundamental Research Funds for the central universities (http://www.sysu.edu.cn). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Allin KH, 2011, CRIT REV CL LAB SCI, V48, P155, DOI 10.3109/10408363.2011.599831; ATONO Y, 1989, Gastroenterologia Japonica, V24, P655; Boncler M, 2009, ACTA BIOCHIM POL, V56, P17; Chan ATC, 2002, JNCI-J NATL CANCER I, V94, P1614, DOI 10.1093/jnci/94.21.1614; Chan KCA, 2003, CANCER RES, V63, P2028; Chen L, 2012, LANCET ONCOL, V13, P163, DOI 10.1016/S1470-2045(11)70320-5; Eliopoulos AG, 1997, ONCOGENE, V14, P2899, DOI 10.1038/sj.onc.1201258; GAULDIE J, 1987, P NATL ACAD SCI USA, V84, P7251, DOI 10.1073/pnas.84.20.7251; Hu QF, 2014, UROL ONCOL-SEMIN ORI, V32, DOI 10.1016/j.urolonc.2013.07.016; Huang PY, 2013, EUR J CANCER, V49, P1923, DOI 10.1016/j.ejca.2013.01.027; Lai SZ, 2011, INT J RADIAT ONCOL, V80, P661, DOI 10.1016/j.ijrobp.2010.03.024; Lee AWM, 2012, RADIOTHER ONCOL, V104, P272, DOI 10.1016/j.radonc.2012.08.001; Lee NY, 2008, J SURG ONCOL, V97, P691, DOI 10.1002/jso.21014; Leung SF, 2014, ANN ONCOL, V25, P1204, DOI 10.1093/annonc/mdu117; Leung SF, 2003, CANCER, V98, P288, DOI 10.1002/cncr.11496; Leung SF, 2006, J CLIN ONCOL, V24, P5414, DOI 10.1200/JCO.2006.07.7982; Liao Q, 2014, ONCOGENE, V33, P2098, DOI 10.1038/onc.2013.161; Lin JC, 2004, NEW ENGL J MED, V350, P2461, DOI 10.1056/NEJMoa032260; Liu X, 2014, CANCER-AM CANCER SOC, V120, P68, DOI 10.1002/cncr.28377; Liu Y, 2012, INT J NONLIN SCI NUM, V13, P1; Liu ZQ, 2014, ASIAN J ANDROL, V16, P467, DOI 10.4103/1008-682X.123686; Lo YMD, 1999, CANCER RES, V59, P1188; Lo YMD, 1999, CANCER RES, V59, P5452; Lo YMD, 2000, ANN NY ACAD SCI, V906, P99; Ma BBY, 2006, INT J RADIAT ONCOL, V66, P714, DOI 10.1016/j.ijrobp.2006.05.064; Mutirangura A, 1998, CLIN CANCER RES, V4, P665; Pearson TA, 2003, CIRCULATION, V107, P499, DOI 10.1161/01.CIR.0000052939.59093.45; Peng G, 2012, RADIOTHER ONCOL, V104, P286, DOI 10.1016/j.radonc.2012.08.013; Quetier I, 2013, J HEPATOL, V59, P285, DOI 10.1016/j.jhep.2013.03.021; Salazar J, 2014, CARDIOL RES PRACT, V2014, DOI 10.1155/2014/605810; Shibutani M, 2015, SURG TODAY, V45, P315, DOI 10.1007/s00595-014-0909-1; Sieghart W, 2013, HEPATOLOGY, V57, P2224, DOI 10.1002/hep.26057; Song CX, 2013, PAK J MED SCI, V29, P885, DOI 10.12669/pjms.293.2907; Strang F, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/757123; Torzewski M, 2000, ARTERIOSCL THROM VAS, V20, P2094, DOI 10.1161/01.ATV.20.9.2094; Wong FCS, 2010, INT J RADIAT ONCOL, V76, P138, DOI 10.1016/j.ijrobp.2009.01.084; Xia WX, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076958; Xia WX, 2013, EUR J CANCER, V49, P2152, DOI 10.1016/j.ejca.2013.03.003; Xiao WW, 2011, CANCER-AM CANCER SOC, V117, P1874, DOI 10.1002/cncr.25754; Yi JH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094632; Zhou GQ, 2012, INT J RADIAT ONCOL, V82, pE359, DOI 10.1016/j.ijrobp.2011.06.1967	41	19	20	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 13	2015	10	4							e0122965	10.1371/journal.pone.0122965	http://dx.doi.org/10.1371/journal.pone.0122965			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CF8XK	25874450	gold, Green Submitted, Green Published			2023-01-03	WOS:000352845100121
J	Uehara, K; Coxon, JP; Byblow, WD				Uehara, Kazumasa; Coxon, James P.; Byblow, Winston D.			Transcranial Direct Current Stimulation Improves Ipsilateral Selective Muscle Activation in a Frequency Dependent Manner	PLOS ONE			English	Article							PRIMARY MOTOR CORTEX; ANTAGONIST MUSCLES; MAGNETIC STIMULATION; EXCITABILITY; INHIBITION; MOVEMENTS; SUPPRESSION; SYNERGIES; FACILITATION; MODULATION	Failure to suppress antagonist muscles can lead to movement dysfunction, such as the abnormal muscle synergies often seen in the upper limb after stroke. A neurophysiological surrogate of upper limb synergies, the selectivity ratio (SR), can be determined from the ratio of biceps brachii (BB) motor evoked potentials to transcranial magnetic stimulation prior to forearm pronation versus elbow flexion. Surprisingly, cathodal transcranial direct current stimulation (c-TDCS) over ipsilateral primary motor cortex (M1) reduces (i.e. improves) the SR in healthy adults, and chronic stroke patients. The ability to suppress antagonist muscles may be exacerbated at high movement rates. The aim of the present study was to investigate whether the selective muscle activation of the biceps brachii (BB) is dependent on altering frequency demands, and whether the c-tDCS improvement of SR is dependent on task frequency. Seventeen healthy participants performed repetitive isometric elbow flexion and forearm pronation at three rates, before and after c-tDCS or sham delivered to ipsilateral left M1. Ipsilateral c-tDCS improved the SR in a frequency dependent manner by selectively suppressing BB antagonist excitability. Our findings confirm that c-tDCS is an effective tool for improving selective muscle activation, and provide novel evidence for its efficacy at rates of movement where it is most likely to benefit task performance.	[Uehara, Kazumasa; Coxon, James P.; Byblow, Winston D.] Univ Auckland, Dept Sport & Exercise Sci, Movement Neurosci Lab, Auckland 1, New Zealand; [Uehara, Kazumasa; Coxon, James P.; Byblow, Winston D.] Univ Auckland, Ctr Brain Res, Auckland 1, New Zealand; [Uehara, Kazumasa] Hiroshima Univ, Grad Sch Integrated Arts & Sci, Div Human Sci, Human Motor Control Lab, Higashihiroshima, Hiroshima 724, Japan	University of Auckland; University of Auckland; Hiroshima University	Byblow, WD (corresponding author), Univ Auckland, Dept Sport & Exercise Sci, Movement Neurosci Lab, Auckland 1, New Zealand.	w.byblow@auckland.ac.nz	Coxon, James/S-1286-2019; Byblow, Winston/D-3579-2009	Coxon, James/0000-0003-2351-8489; Byblow, Winston/0000-0001-8347-6730; Uehara, Kazumasa/0000-0003-2350-8694	Aotearoa Foundation of New Zealand [9133-3627269]; Faculty Research Development Fund (FRDF) grant [3704166]; Japan Society for the Promotion of Science [24-393]	Aotearoa Foundation of New Zealand; Faculty Research Development Fund (FRDF) grant; Japan Society for the Promotion of Science(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science)	KU is supported by a postdoctoral fellow from Japan Society for the Promotion of Science (24-393). JPC is supported by a postdoctoral fellowship from the Aotearoa Foundation of New Zealand (9133-3627269). This study was financially supported by a Faculty Research Development Fund (FRDF) grant awarded to WDB (3704166). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bertolasi L, 1998, J PHYSIOL-LONDON, V511, P947, DOI 10.1111/j.1469-7793.1998.947bg.x; Bradnam LV, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00184; Bradnam LV, 2012, CEREB CORTEX, V22, P2662, DOI 10.1093/cercor/bhr344; Bradnam LV, 2011, J NEUROPHYSIOL, V105, P2582, DOI 10.1152/jn.01084.2010; Bradnam LV, 2010, J NEUROPHYSIOL, V104, P2594, DOI 10.1152/jn.00365.2010; Bradnam LV, 2010, J NEUROPHYSIOL, V103, P2382, DOI 10.1152/jn.01046.2009; Brunnstrom S., 1970, MOVEMENT THERAPY HEM; CHENEY PD, 1985, J NEUROPHYSIOL, V53, P805, DOI 10.1152/jn.1985.53.3.805; d'Avella A, 2008, J NEUROPHYSIOL, V100, P1433, DOI 10.1152/jn.01377.2007; DE LUCA CJ, 1987, J NEUROPHYSIOL, V58, P525, DOI 10.1152/jn.1987.58.3.525; Furuya S, 2012, HUM MOVEMENT SCI, V31, P26, DOI 10.1016/j.humov.2011.01.002; Gerachshenko T, 2008, CLIN NEUROPHYSIOL, V119, P683, DOI 10.1016/j.clinph.2007.11.004; Gerachshenko T, 2007, EXP BRAIN RES, V183, P531, DOI 10.1007/s00221-007-1071-4; Gerard MJ, 2002, HUM FACTORS, V44, P51, DOI 10.1518/0018720024494757; GOWLAND C, 1992, PHYS THER, V72, P624, DOI 10.1093/ptj/72.9.624; Harris-Love ML, 2007, J NEUROPHYSIOL, V97, P2511, DOI 10.1152/jn.01331.2006; Hayashi MJ, 2008, CEREB CORTEX, V18, P2932, DOI 10.1093/cercor/bhn053; Hortobagyi T, 2006, EXP BRAIN RES, V171, P322, DOI 10.1007/s00221-005-0274-9; Kaneko K, 1996, ELECTROMYOGR MOTOR C, V101, P478, DOI 10.1016/S0921-884X(96)96021-X; Kuxhaus L, 2014, J BIOMECH, V47, P1234, DOI 10.1016/j.jbiomech.2013.12.008; Levin MF, 2000, BRAIN RES, V853, P352, DOI 10.1016/S0006-8993(99)02298-2; MARSDEN CD, 1983, J PHYSIOL-LONDON, V335, P1; McCambridge AB, 2011, J NEUROPHYSIOL, V105, P2937, DOI 10.1152/jn.00171.2011; Monte-Silva K, 2010, J NEUROPHYSIOL, V103, P1735, DOI 10.1152/jn.00924.2009; Nakamura H, 1997, J PHYSIOL-LONDON, V498, P817, DOI 10.1113/jphysiol.1997.sp021905; Nitsche MA, 2003, CLIN NEUROPHYSIOL, V114, P2220, DOI 10.1016/S1388-2457(03)00235-9; Nitsche MA, 2000, J PHYSIOL-LONDON, V527, P633, DOI 10.1111/j.1469-7793.2000.t01-1-00633.x; Nitsche MA, 2003, CLIN NEUROPHYSIOL, V114, P600, DOI 10.1016/S1388-2457(02)00412-1; OLDFIELD RC, 1971, NEUROPSYCHOLOGIA, V9, P97, DOI 10.1016/0028-3932(71)90067-4; ROM DM, 1990, BIOMETRIKA, V77, P663, DOI 10.1093/biomet/77.3.663; Schaal S, 2004, NAT NEUROSCI, V7, P1137, DOI 10.1038/nn1322; Simkins M, 2013, EXP BRAIN RES, V229, P517, DOI 10.1007/s00221-013-3613-2; Taylor JL, 1996, J PHYSIOL-LONDON, V490, P519, DOI 10.1113/jphysiol.1996.sp021163; Taylor JL, 2001, MUSCLE NERVE, V24, P18, DOI 10.1002/1097-4598(200101)24:1<18::AID-MUS2>3.3.CO;2-4; Uehara K, 2013, BEHAV BRAIN RES, V240, P33, DOI 10.1016/j.bbr.2012.10.053; Uehara K, 2011, NEUROSCI LETT, V488, P22, DOI 10.1016/j.neulet.2010.10.073; van den Berg FE, 2011, J COGNITIVE NEUROSCI, V23, P3456, DOI 10.1162/jocn_a_00018; Verstynen T, 2005, J NEUROPHYSIOL, V93, P1209, DOI 10.1152/jn.00720.2004; Welmer AK, 2006, AM J PHYS MED REHAB, V85, P112, DOI 10.1097/01.phm.0000197587.78140.17; WIERZBICKA MM, 1986, EXP BRAIN RES, V63, P331	40	14	14	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 27	2015	10	3							e0122434	10.1371/journal.pone.0122434	http://dx.doi.org/10.1371/journal.pone.0122434			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CE8ZT	25816204	Green Published, gold, Green Submitted			2023-01-03	WOS:000352133600180
J	Rajaganapathy, BR; Chancellor, MB; Nirmal, J; Dang, L; Tyagi, P				Rajaganapathy, Bharathi Raja; Chancellor, Michael B.; Nirmal, Jayabalan; Dang, Loan; Tyagi, Pradeep			Bladder Uptake of Liposomes after Intravesical Administration Occurs by Endocytosis	PLOS ONE			English	Article							DIMETHYL-SULFOXIDE; DNA RELEASE; CYSTITIS; CHOLESTEROL; THERAPY; CELLS	Liposomes have been used therapeutically and as a local drug delivery system in the bladder. However, the exact mechanism for the uptake of liposomes by bladder cells is unclear. In the present study, we investigated the role of endocytosis in the uptake of liposomes by cultured human UROtsa cells of urothelium and rat bladder. UROtsa cells were incubated in serum-free media with liposomes containing colloidal gold particles for 2 h either at 37 degrees C or at 4 degrees C. Transmission Electron Microscopy (TEM) images of cells incubated at 37 degrees C found endocytic vesicles containing gold inside the cells. In contrast, only extracellular binding was noticed in cells incubated with liposomes at 4 degrees C. Absence of liposome internalization at 4 degrees C indicates the need of energy dependent endocytosis as the primary mechanism of entry of liposomes into the urothelium. Flow cytometry analysis revealed that the uptake of liposomes at 37 degrees C occurs via clathrin mediated endocytosis. Based on these observations, we propose that clathrin mediated endocytosis is the main route of entry for liposomes into the urothelial layer of the bladder and the findings here support the usefulness of liposomes in intravesical drug delivery.	[Rajaganapathy, Bharathi Raja; Chancellor, Michael B.; Nirmal, Jayabalan] Oakland Univ, William Beaumont Sch Med, William Beaumont Hosp Res Inst, Dept Urol, Royal Oak, MI 48067 USA; [Tyagi, Pradeep] Univ Pittsburgh, Dept Urol, Pittsburgh, PA USA; [Dang, Loan] Oakland Univ, Eye Res Inst, Rochester, MI 48063 USA	Oakland University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Oakland University	Chancellor, MB (corresponding author), Oakland Univ, William Beaumont Sch Med, William Beaumont Hosp Res Inst, Dept Urol, Royal Oak, MI 48067 USA.	chancellormb@gmail.com	J, Nirmal/AAO-5138-2020	J, Nirmal/0000-0001-7864-6053	National Institute of Health [DK083323]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK083323] Funding Source: NIH RePORTER	National Institute of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was supported by the National Institute of Health (Grant number-DK083323). The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Celano M, 2004, BMC CANCER, V4, DOI 10.1186/1471-2407-4-63; Chuang YC, 2009, J UROLOGY, V182, P1393, DOI 10.1016/j.juro.2009.06.024; Chuang YC, 2009, J UROLOGY, V182, P786, DOI 10.1016/j.juro.2009.03.083; Cosco D, 2012, INT J NANOMED, V7, P2535, DOI [10.2147/IJN.S28114, 10.2147/IJN.S34025]; Dellis A, 2014, EXPERT OPIN INV DRUG, V23, P751, DOI 10.1517/13543784.2014.909406; Dowson C, 2012, EUR UROL, V61, P834, DOI 10.1016/j.eururo.2011.12.011; Giannantoni A, 2006, EUR UROL, V50, P1183, DOI 10.1016/j.eururo.2006.08.025; Gregoriadis G, 2005, INT J PHARM, V300, P125, DOI 10.1016/j.ijpharm.2005.06.007; Gregoriadis G, 1995, TRENDS BIOTECHNOL, V13, P527, DOI 10.1016/S0167-7799(00)89017-4; GREGORIADIS G, 1976, BIOCHEM SOC T, V4, P256, DOI 10.1042/bst0040256; Kaufman J, 2010, REV UROL, V12, P181; Koltover I, 1998, SCIENCE, V281, P78, DOI 10.1126/science.281.5373.78; Lai MC, 2013, INT J UROL, V20, P203, DOI 10.1111/j.1442-2042.2012.03135.x; Nirmal J, 2012, UROL SCI, V23, P70, DOI 10.1016/j.urols.2012.07.005; Nirmal J, 2013, J UROLOGY, V189, P1553, DOI 10.1016/j.juro.2012.10.123; Parkin J, 1997, UROLOGY, V49, P105, DOI 10.1016/S0090-4295(97)00181-7; Rodal SK, 1999, MOL BIOL CELL, V10, P961, DOI 10.1091/mbc.10.4.961; Rossi MR, 2001, ENVIRON HEALTH PERSP, V109, P801, DOI 10.1289/ehp.01109801; Sapra Puja, 2005, Current Drug Delivery, V2, P369, DOI 10.2174/156720105774370159; Thomsen P, 2002, MOL BIOL CELL, V13, P238, DOI 10.1091/mbc.01-06-0317; Torchilin VP, 2005, NAT REV DRUG DISCOV, V4, P145, DOI 10.1038/nrd1632; Tyagi P, 2006, MOL PHARMACEUT, V3, P369, DOI 10.1021/mp060001j; Tyagi P, 2009, BJU INT, V104, P1689, DOI 10.1111/j.1464-410X.2009.08673.x; WANG LH, 1993, J CELL BIOL, V123, P1107, DOI 10.1083/jcb.123.5.1107; Xu YH, 1996, BIOCHEMISTRY-US, V35, P5616, DOI 10.1021/bi9602019; Zhou ZX, 2011, INT J TOXICOL, V30, P174, DOI 10.1177/1091581810394548; Zuhorn IS, 2002, J BIOL CHEM, V277, P18021, DOI 10.1074/jbc.M111257200	27	26	27	1	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 26	2015	10	3							e0122766	10.1371/journal.pone.0122766	http://dx.doi.org/10.1371/journal.pone.0122766			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CK6QW	25811468	Green Published, Green Accepted, gold, Green Submitted			2023-01-03	WOS:000356353700200
J	Rockall, TA				Rockall, Timothy A.			Transfusion after acute upper gastrointestinal haemorrhage	LANCET			English	Editorial Material							BLOOD-TRANSFUSION		Royal Surrey Cty Hosp NHS Trust, Guildford GU2 7XX, Surrey, England	Royal Surrey County Hospital	Rockall, TA (corresponding author), Royal Surrey Cty Hosp NHS Trust, Guildford GU2 7XX, Surrey, England.	tim.rockall@btinternet.com						Al-Jaghbeer M, 2013, CRIT CARE, V17, DOI 10.1186/cc13020; [Anonymous], 2015, LANCET; Carson JL, 2011, NEW ENGL J MED, V365, P2453, DOI 10.1056/NEJMoa1012452; Hajjar LA, 2010, JAMA-J AM MED ASSOC, V304, P1559, DOI 10.1001/jama.2010.1446; Hebert PC, 1999, NEW ENGL J MED, V340, P409, DOI 10.1056/NEJM199902113400601; Holst LB, 2014, NEW ENGL J MED, V371, P1381, DOI 10.1056/NEJMoa1406617; Jairath V, 2010, COCHRANE DB SYST REV, V9; Jairath V, 2011, TRANSFUSION, V51, P1940, DOI 10.1111/j.1537-2995.2011.03119.x; Malone DL, 2003, J TRAUMA, V54, P898, DOI 10.1097/01.TA.0000060261.10597.5C; Pape A, 2009, BLOOD TRANSFUS-ITALY, V7, P250, DOI 10.2450/2008.0072-08; Rockall TA, 1996, GUT, V38, P316, DOI 10.1136/gut.38.3.316; Villanueva C, 2013, NEW ENGL J MED, V368, P11, DOI 10.1056/NEJMoa1211801	12	0	0	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 11	2015	386	9989					110	112		10.1016/S0140-6736(14)62351-5	http://dx.doi.org/10.1016/S0140-6736(14)62351-5			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CM5QC	25956717				2023-01-03	WOS:000357742200007
J	Barbadoro, P; Di Tondo, E; Menditto, VG; Pennacchietti, L; Regnicoli, F; Di Stanislao, F; D'Errico, MM; Prospero, E				Barbadoro, Pamela; Di Tondo, Elena; Menditto, Vincenzo Giannicola; Pennacchietti, Lucia; Regnicoli, Februa; Di Stanislao, Francesco; D'Errico, Marcello Mario; Prospero, Emilia			Emergency Department Non-Urgent Visits and Hospital Readmissions Are Associated with Different Socio-Economic Variables in Italy	PLOS ONE			English	Article							ACUTE MYOCARDIAL-INFARCTION; PRIMARY-CARE; 30-DAY READMISSIONS; HEART-FAILURE; HEALTH; NEEDS	Objective The aim of this paper was to evaluate socio-economic factors associated to poor primary care utilization by studying two specific subjects: the hospital readmission rate, and the use of the Emergency Department (ED) for non-urgent visits. Methods The study was carried out by the analysis of administrative database for hospital readmission and with a specific survey for non-urgent ED use. Results Among the 416,698 sampled admissions, 6.39% (95% CI, 6.32-6.47) of re-admissions have been registered; the distribution shows a high frequency of events in the age 65-84 years group, and in the intermediate care hospitals (51.97%; 95% CI 51.37-52.57). The regression model has shown the significant role played by age, type of structure (geriatric acute care), and deprivation index of the area of residence on the readmission, however, after adjusting for the intensity of primary care, the role of deprivation was no more significant. Non-urgent ED visits accounted for the 12.10%, (95% CI 9.38-15.27) of the total number of respondents to the questionnaire (N = 504). The likelihood of performing a non-urgent ED visit was higher among patients aged <65 years (OR 3.2, 95% CI 1.3-7.8 p = 0.008), while it was lower among those perceiving as urgent their health problem (OR 0.50, 95% CI 0.30-0.90). Conclusions In the Italian context repeated readmissions and ED utilization are linked to different trajectories, besides the increasing age and comorbidity of patients are the factors that are related to repeated admissions, the self-perceived trust in diagnostic technologies is an important risk factor in determining ED visits. Better use of public national health care service is mandatory, since its correct utilization is associated to increasing equity and better health care utilization.	[Barbadoro, Pamela; Di Tondo, Elena; Pennacchietti, Lucia; Di Stanislao, Francesco; D'Errico, Marcello Mario; Prospero, Emilia] Univ Politecn Marche, Dept Biomed Sci & Publ Hlth, Ancona, Italy; [Barbadoro, Pamela; D'Errico, Marcello Mario; Prospero, Emilia] AOU Osped Riuniti, Hosp Hyg Serv, Ancona, Italy; [Menditto, Vincenzo Giannicola; Regnicoli, Februa] AOU Osped Riuniti, Dept Emergency Care, Ancona, Italy	Marche Polytechnic University	Barbadoro, P (corresponding author), Univ Politecn Marche, Dept Biomed Sci & Publ Hlth, Ancona, Italy.	p.barbadoro@univpm.it	barbadoro, pamela/AAC-5041-2022; Menditto, Vincenzo G/CAE-9845-2022; menditto, vincenzo g/ABF-1651-2020	Menditto, Vincenzo G/0000-0001-6231-2251; menditto, vincenzo g/0000-0001-6231-2251; Prospero, Emilia/0000-0002-2387-8639	ministry of health	ministry of health	The study was funded by the ministry of health.	Agency for Healthcare Research and Quality (AHRQ), AG HEALTHC RES QUAL; [Anonymous], 2014, INT J HLTH POLICY MA; Ansari Z, 2006, MED CARE RES REV, V63, P719, DOI 10.1177/1077558706293637; Bianco A, 2003, PUBLIC HEALTH, V117, P250, DOI 10.1016/S0033-3506(03)00069-6; Billings J, 2000, Issue Brief (Commonw Fund), P1; Billings J, 2012, BMJ OPEN, V2, DOI 10.1136/bmjopen-2012-001667; Cadum E, 1999, Epidemiol Prev, V23, P175; Chetty VK, 2011, AM FAM PHYSICIAN, V83, P1054; David G, 2015, HEALTH SERV RES, V50, P418, DOI 10.1111/1475-6773.12218; Devaux M., 2013, EUR J HLTH EC; Dharmarajan K, 2013, JAMA-J AM MED ASSOC, V309, P355, DOI 10.1001/jama.2012.216476; Fischer C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0112282; Friedman B, 2004, MED CARE RES REV, V61, P225, DOI 10.1177/1077558704263799; Gerhardt Geoffrey, 2014, Medicare Medicaid Res Rev, V4, DOI 10.5600/mmrr2014-004-01-b03; Grol R, 2006, HEALTH AFFAIR, V25, P1733, DOI 10.1377/hlthaff.25.6.1733; GRUMBACH K, 1993, AM J PUBLIC HEALTH, V83, P372, DOI 10.2105/AJPH.83.3.372; Halfon P, 2002, J CLIN EPIDEMIOL, V55, P573, DOI 10.1016/S0895-4356(01)00521-2; Hasan O, 2010, J GEN INTERN MED, V25, P211, DOI 10.1007/s11606-009-1196-1; Hebert C, 2014, BMC MED INFORM DECIS, V14, DOI 10.1186/1472-6947-14-65; Hoeck S, 2014, INT J ENV RES PUB HE, V11, P355, DOI 10.3390/ijerph110100355; Horwitz LI, 2014, ANN INTERN MED, V161, pS66, DOI 10.7326/M13-3000; Huibers L, 2009, BMC HEALTH SERV RES, V9, DOI 10.1186/1472-6963-9-105; Hurst J, 2001, OECD LABOUR MARKET S, V47; Italian National Institute of Health, NAT OUTC IND SYST; Kelley E., 2006, OECD HLTH WORKING PA, V23; Lang T, 1996, J EPIDEMIOL COMMUN H, V50, P456, DOI 10.1136/jech.50.4.456; Lee Eun Whan, 2012, J Prev Med Public Health, V45, P259, DOI 10.3961/jpmph.2012.45.4.259; Lindenauer PK, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f521; Lowe RA, 2005, MED CARE, V43, P792, DOI 10.1097/01.mlr.0000170413.60054.54; Majeed A, 2012, ANN INTERN MED, V156, P67, DOI 10.7326/0003-4819-156-1-201201030-00019; Mckee M, 2009, LANCET, V373, P349, DOI 10.1016/S0140-6736(09)60098-2; Ministry of Health, 2011, REL SULL STAT SAN PA; Roberts L, 2014, EMERG MED J, V31, P786; Shadmi E, 2015, MED CARE, V53, P283, DOI 10.1097/MLR.0000000000000315; Shaw EK, 2013, J HEALTH CARE POOR U, V24, P1288, DOI 10.1353/hpu.2013.0140; Sibbritt D W, 1995, J Qual Clin Pract, V15, P211; van der Linden MC, 2014, INT J EMERG MED, V7, DOI 10.1186/s12245-014-0028-1; van Walraven C, 2011, CAN MED ASSOC J, V183, pE391, DOI 10.1503/cmaj.101860; Vedovetto A, 2014, HEALTH SERV RES, V49, P1290, DOI 10.1111/1475-6773.12161; Wang M, 2014, J EVAL CLIN PRACT, V20, P20, DOI 10.1111/jep.12074; Zapatero A, 2012, EUR J INTERN MED, V23, P451, DOI 10.1016/j.ejim.2012.01.005	41	9	10	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 15	2015	10	6							e0127823	10.1371/journal.pone.0127823	http://dx.doi.org/10.1371/journal.pone.0127823			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	CK6HU	26076346	Green Submitted, Green Published, gold			2023-01-03	WOS:000356329900015
J	Tookes, H; Chanelle, D; Li, H; Khalid, R; Doblecki-Lewis, S				Tookes, Hansel; Diaz, Chanelle; Li, Hua; Khalid, Rafi; Doblecki-Lewis, Susanne			A Cost Analysis of Hospitalizations for Infections Related to Injection Drug Use at a County Safety-Net Hospital in Miami, Florida	PLOS ONE			English	Article							SOFT-TISSUE INFECTIONS; NECROTIZING FASCIITIS; NEEDLE EXCHANGE; RISK-FACTORS; BACTERIAL-INFECTIONS; SYRINGE PROGRAMS; SAN-FRANCISCO; ENDOCARDITIS; ABSCESSES; CARE	Background Infections related to injection drug use are common. Harm reduction strategies such as syringe exchange programs and skin care clinics aim to prevent these infections in injection drug users (IDUs). Syringe exchange programs are currently prohibited by law in Florida. The goal of this study was to estimate the mortality and cost of injection drug use-related bacterial infections over a 12-month period to the county safety-net hospital in Miami, Florida. Additionally, the prevalence of HIV and hepatitis C virus among this cohort of hospitalized IDUs was estimated. Methods and Findings IDUs discharged from Jackson Memorial Hospital were identified using the International Classification of Diseases, Ninth Revision, codes for illicit drug abuse and endocarditis, bacteremia or sepsis, osteomyelitis and skin and soft tissue infections (SSTIs). 349 IDUs were identified for chart abstraction and 92% were either uninsured or had publicly funded insurance. SSTIs, the most common infection, were reported in 64% of IDUs. HIV seroprevalence was 17%. Seventeen patients (4.9%) died during their hospitalization. The total cost for treatment for injection drug use-related infections to Jackson Memorial Hospital over the 12-month period was $11.4 million. Conclusions Injection drug use-related bacterial infections represent a significant morbidity for IDUs in Miami-Dade County and a substantial financial cost to the county hospital. Strategies aimed at reducing risk of infections associated with injection drug use could decrease morbidity and the cost associated with these common, yet preventable infections.	[Tookes, Hansel] Jackson Mem Hosp, Dept Internal Med, Miami, FL 33136 USA; [Diaz, Chanelle] Univ Miami, Miller Sch Med, Dept Med Educ, Miami, FL 33136 USA; [Li, Hua] Univ Miami, Miller Sch Med, Dept Publ Hlth Sci, Miami, FL 33136 USA; [Khalid, Rafi] Jackson Mem Hosp, Dept Jackson Hlth Syst Res, Miami, FL 33136 USA; [Doblecki-Lewis, Susanne] Univ Miami, Miller Sch Med, Div Infect Dis, Dept Internal Med, Miami, FL 33136 USA	University of Miami; University of Miami; University of Miami	Tookes, H (corresponding author), Jackson Mem Hosp, Dept Internal Med, Miami, FL 33136 USA.	hetookes@med.miami.edu			Infectious Diseases Society of America Medical Scholars Program; Jackson Memorial Hospital Department of Internal Medicine Resident Scholarly Activity Program	Infectious Diseases Society of America Medical Scholars Program; Jackson Memorial Hospital Department of Internal Medicine Resident Scholarly Activity Program	This work was supported by the Infectious Diseases Society of America Medical Scholars Program to HT SD, (http://www.idsociety.org/Medical_Scholars_Program/) and the Jackson Memorial Hospital Department of Internal Medicine Resident Scholarly Activity Program to HT. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	American Hospital Directory, 2015, JACKS MEM HOSP FAC P; Belani HK, 2008, J HIV-AIDS SOC SERV, V7, P229, DOI 10.1080/15381500802307492; Binswanger IA, 2000, CLIN INFECT DIS, V30, P579, DOI 10.1086/313703; Binswanger IA, 2008, J STUD ALCOHOL DRUGS, V69, P924, DOI 10.15288/jsad.2008.69.924; Broz D, 2014, MMWR SURVEILL SUMM, V63, P1; Centers for Disease Control and Prevention, 2012, HIV SURV REP DIAGN H, V24; Centers for Disease Control and Prevention (CDC), 2001, MMWR Morb Mortal Wkly Rep, V50, P381; Chen JL, 2001, CLIN INFECT DIS, V33, P6, DOI 10.1086/320874; Cooper HLF, 2007, CLIN INFECT DIS, V45, P1200, DOI 10.1086/522176; del Giudice P, 2004, BRIT J DERMATOL, V150, P1, DOI 10.1111/j.1365-2133.2004.05607.x; Department of Health, 2013, AG LEG BILL AN HB 73; Ebright JR, 2002, INFECT DIS CLIN N AM, V16, P697, DOI 10.1016/S0891-5520(02)00017-X; Frontera JA, 2000, CLIN INFECT DIS, V30, P374, DOI 10.1086/313664; Gebo KA, 2005, JAIDS-J ACQ IMM DEF, V40, P609, DOI 10.1097/01.qai.0000171727.55553.78; Gold M, 1997, CAN MED ASSOC J, V157, P255; Gordon RJ, 2005, NEW ENGL J MED, V353, P1945, DOI 10.1056/NEJMra042823; Hall JN, 2014, DRUG ABUSE TRENDS MI, P6; Harris HW, 2002, ARCH SURG-CHICAGO, V137, P1217, DOI 10.1001/archsurg.137.11.1217; Heinzerling KG, 2006, J URBAN HEALTH, V83, P176, DOI 10.1007/s11524-005-9021-6; Holtgrave DR, 1998, J ACQ IMMUN DEF SYND, V18, pS133, DOI 10.1097/00042560-199802001-00022; Hyshka E, 2012, INT J DRUG POLICY, V23, P261, DOI 10.1016/j.drugpo.2012.03.006; Jain V, 2008, J INFECTION, V57, P132, DOI 10.1016/j.jinf.2008.05.008; Kak V, 2002, INFECT DIS CLIN N AM, V16, P681, DOI 10.1016/S0891-5520(02)00016-8; Kimura AC, 2004, CLIN INFECT DIS, V38, pE87, DOI 10.1086/383471; Kwon JA, 2012, AIDS, V26, P2201, DOI 10.1097/QAD.0b013e3283578b5d; Lloyd-Smith Elisa, 2005, Harm Reduct J, V2, P24, DOI 10.1186/1477-7517-2-24; Lloyd-Smith E, 2008, BMC PUBLIC HEALTH, V8, DOI 10.1186/1471-2458-8-405; Lonergan S, 2004, J EMERG MED, V26, P47, DOI 10.1016/j.jemermed.2003.06.003; Lurie P, 1998, J ACQ IMMUN DEF SYND, V18, pS126, DOI 10.1097/00042560-199802001-00021; Marks M, 2013, J INFECTION, V66, P95, DOI 10.1016/j.jinf.2012.10.004; Micallef L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101717; Murphy EL, 2001, CLIN INFECT DIS, V33, P35, DOI 10.1086/320879; Palepu A, 2001, CAN MED ASSOC J, V165, P415; Phillips KT, 2010, AM J DRUG ALCOHOL AB, V36, P92, DOI 10.3109/00952991003592311; Saydain G, 2010, J CRIT CARE, V25, P248, DOI 10.1016/j.jcrc.2009.09.007; Simmen HP, 1995, J HAND SURG-BRIT EUR, V20B, P797, DOI 10.1016/S0266-7681(95)80050-6; Spijkerman IJB, 1996, J CLIN EPIDEMIOL, V49, P1149, DOI 10.1016/0895-4356(96)00180-1; Stein MD, 2001, DRUG ALCOHOL DEPEN, V64, P117, DOI 10.1016/S0376-8716(00)00235-0; Sweeney R, 2009, AUST NZ J PUBL HEAL, V33, P352, DOI 10.1111/j.1753-6405.2009.00407.x; Takahashi TA, 2007, J GEN INTERN MED, V22, P382, DOI 10.1007/s11606-006-0079-y; Takahashi TA, 2010, J BEHAV HEALTH SER R, V37, P508, DOI 10.1007/s11414-009-9177-z; Tempalski B, 2009, J URBAN HEALTH, V86, P132, DOI 10.1007/s11524-008-9328-1; Tookes HE, 2012, DRUG ALCOHOL DEPEN, V123, P255, DOI 10.1016/j.drugalcdep.2011.12.001; Tunkel AR, 2002, INFECT DIS CLIN N AM, V16, P589, DOI 10.1016/S0891-5520(02)00015-6; U.S. Census Bureau, 2013, MIAM DAD COUNT QUICK	45	85	86	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 15	2015	10	6							e0129360	10.1371/journal.pone.0129360	http://dx.doi.org/10.1371/journal.pone.0129360			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CK6HU	26075888	Green Submitted, Green Published, gold			2023-01-03	WOS:000356329900066
J	Doi, T; Yamamoto, S; Morinaga, T; Sada, KE; Kurita, N; Onishi, Y				Doi, Toshiki; Yamamoto, Suguru; Morinaga, Takatoshi; Sada, Ken-ei; Kurita, Noriaki; Onishi, Yoshihiro			Risk Score to Predict 1-Year Mortality after Haemodialysis Initiation in Patients with Stage 5 Chronic Kidney Disease under Predialysis Nephrology Care	PLOS ONE			English	Article							DIALYSIS INITIATION; MINERAL METABOLISM; RENAL-DISEASE; SURVIVAL; CALCIUM; MODELS; CALCIFICATION; IMPUTATION; MORBIDITY; OUTCOMES	Background Few risk scores are available for predicting mortality in chronic kidney disease (CKD) patients undergoing predialysis nephrology care. Here, we developed a risk score using predialysis nephrology practice data to predict 1-year mortality following the initiation of haemodialysis (HD) for CKD patients. Methods This was a multicenter cohort study involving CKD patients who started HD between April 2006 and March 2011 at 21 institutions with nephrology care services. Patients who had not received predialysis nephrology care at an estimated glomerular filtration rate (eGFR) of approximately 10 mL/min per 1.73 m(2) were excluded. Twenty-nine candidate predictors were selected, and the final model for 1-year mortality was developed via multivariate logistic regression and was internally validated by a bootstrapping technique. Results A total of 688 patients were enrolled, and 62 (9.0%) patients died within one year of HD initiation. The following variables were retained in the final model: eGFR, serum albumin, calcium, Charlson Comorbidity Index excluding diabetes and renal disease (modified CCI), performance status (PS), and usage of erythropoiesis-stimulating agent (ESA). Their beta-coefficients were transformed into integer scores: three points were assigned to modified CCI >= 3 and PS 3-4; two to calcium>8.5 mg/dL, modified CCI 1-2, and no use of ESA; and one to albumin<3.5 g/dL, eGFR>7 mL/min per 1.73 m(2), and PS 1-2. Predicted 1-year mortality risk was 2.5% (score 0-4), 5.5% (score 5-6), 15.2% (score 7-8), and 28.9% (score 9-12). The area under the receiver operating characteristic curve was 0.83 (95% confidence interval, 0.79-0.89). Conclusions We developed a simple 6-item risk score predicting 1-year mortality after the initiation of HD that might help nephrologists make a shared decision with patients and families regarding the initiation of HD.	[Doi, Toshiki] Hiroshima Univ Hosp, Dept Nephrol, Hiroshima, Japan; [Yamamoto, Suguru] Niigata Univ, Grad Sch Med & Dent Sci, Div Clin Nephrol & Rheumatol, Niigata, Japan; [Morinaga, Takatoshi] Anjo Kosei Hosp, Dept Nephrol, Anjo, Aichi, Japan; [Sada, Ken-ei] Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Med & Clin Sci, Okayama 7008530, Japan; [Kurita, Noriaki] Fukushima Med Univ Hosp, Dept Innovat Res & Educ Clinicians & Trainees DiR, Fukushima, Japan; [Kurita, Noriaki] Kyoto Univ, Sch Publ Hlth, Grad Sch Med, Dept Healthcare Epidemiol, Kyoto, Japan; [Kurita, Noriaki; Onishi, Yoshihiro] iHope Int, Inst Hlth Outcomes & Proc Evaluat Res, Kyoto, Japan	Hiroshima University; Niigata University; Okayama University; Fukushima Medical University; Kyoto University	Sada, KE (corresponding author), Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Med & Clin Sci, Okayama 7008530, Japan.	sadakenn@md.okayama-u.ac.jp	Kurita, Noriaki/I-6023-2019; SADA, KENEI/B-2305-2011	Kurita, Noriaki/0000-0003-4127-7500; Sada, Ken-ei/0000-0003-1020-0818; DOI, TOSHIKI/0000-0001-8870-5790	Institute for Health Outcomes & Process Evaluation research	Institute for Health Outcomes & Process Evaluation research	This work was supported by grants from the Institute for Health Outcomes & Process Evaluation research. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Beddhu S, 2003, J AM SOC NEPHROL, V14, P2305, DOI 10.1097/01.ASN.0000080184.67406.11; Block GA, 2004, J AM SOC NEPHROL, V15, P2208, DOI 10.1097/01.ASN.0000133041.27682.A2; Bradbury BD, 2007, CLIN J AM SOC NEPHRO, V2, P89, DOI 10.2215/CJN.01170905; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Chua HR, 2014, BLOOD PURIFICAT, V37, P85, DOI 10.1159/000357640; Clark WF, 2011, CAN MED ASSOC J, V183, P47, DOI 10.1503/cmaj.100349; Couchoud C, 2009, NEPHROL DIAL TRANSPL, V24, P1553, DOI 10.1093/ndt/gfn698; Fink JC, 2001, AM J KIDNEY DIS, V37, P348, DOI 10.1053/ajkd.2001.21305; Floege J, 2011, NEPHROL DIAL TRANSPL, V26, P1948, DOI 10.1093/ndt/gfq219; Frank H, 2012, CROSS VALIDATED 1220; Goodkin DA, 2004, AM J KIDNEY DIS, V44, pS16, DOI 10.1053/j.akjd.2004.08.006; Harrell FE, 1996, STAT MED, V15, P361, DOI 10.1002/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4; Harrell Frank E., 2001, REGRESSION MODELING; Hasegawa T, 2009, CLIN J AM SOC NEPHRO, V4, P595, DOI 10.2215/CJN.03540708; Hayashi T, 2013, CLIN EXP NEPHROL, V17, P294, DOI 10.1007/s10157-012-0705-4; Kalantar-Zadeh K, 2006, KIDNEY INT, V70, P771, DOI 10.1038/sj.ki.5001514; Kazmi WH, 2005, AM J KIDNEY DIS, V46, P887, DOI 10.1053/j.ajkd.2005.08.005; Matsuo S, 2009, AM J KIDNEY DIS, V53, P982, DOI 10.1053/j.ajkd.2008.12.034; Moons KGM, 2004, J CLIN EPIDEMIOL, V57, P1262, DOI 10.1016/j.jclinepi.2004.01.020; Palmer SC, 2011, JAMA-J AM MED ASSOC, V305, P1119, DOI 10.1001/jama.2011.308; Rubin DB, 1987, MULTIPLE IMPUTATION, DOI [10.1002/sim.6008, DOI 10.1002/SIM.6008]; Russo D, 2007, KIDNEY INT, V72, P1255, DOI 10.1038/sj.ki.5002518; Sauerbrei W, 1999, J ROY STAT SOC C-APP, V48, P313, DOI 10.1111/1467-9876.00155; Susantitaphong P, 2012, AM J KIDNEY DIS, V59, P829, DOI 10.1053/j.ajkd.2012.01.015; Van Buuren S, 1999, STAT MED, V18, P681, DOI 10.1002/(SICI)1097-0258(19990330)18:6<681::AID-SIM71>3.3.CO;2-I; van der Heijden GJMG, 2006, J CLIN EPIDEMIOL, V59, P1102, DOI 10.1016/j.jclinepi.2006.01.015; van Diepen M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089744; Verbeke F, 2011, CLIN J AM SOC NEPHRO, V6, P153, DOI 10.2215/CJN.05120610; Vergouwe Y, 2010, J CLIN EPIDEMIOL, V63, P205, DOI 10.1016/j.jclinepi.2009.03.017; Wright S, 2010, CLIN J AM SOC NEPHRO, V5, P1828, DOI 10.2215/CJN.06230909; Yamagata K, 2012, THER APHER DIAL, V16, P54, DOI 10.1111/j.1744-9987.2011.01005.x; Young EW, 2005, KIDNEY INT, V67, P1179, DOI 10.1111/j.1523-1755.2005.00185.x	32	18	19	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 9	2015	10	6							e0129180	10.1371/journal.pone.0129180	http://dx.doi.org/10.1371/journal.pone.0129180			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CK6PC	26057129	Green Submitted, Green Published, gold			2023-01-03	WOS:000356349000041
J	Zamparo, P; Zorzi, E; Marcantoni, S; Cesari, P				Zamparo, Paola; Zorzi, Elena; Marcantoni, Sara; Cesari, Paola			Is Beauty in the Eyes of the Beholder? Aesthetic Quality versus Technical Skill in Movement Evaluation of Tai Chi	PLOS ONE			English	Article							ACTION ANTICIPATION; BASKETBALL PLAYERS; VISUAL-PERCEPTION; BIOLOGICAL MOTION; DANCE PERCEPTION; RESONANCE; ACCURACY; SOCCER; SPEED	The aim of this study was to compare experts to naive practitioners in rating the beauty and the technical quality of a Tai Chi sequence observed in video-clips (of high and middle level performances). Our hypothesis are: i) movement evaluation will correlate with the level of skill expressed in the kinematics of the observed action but ii) only experts will be able to unravel the technical component from the aesthetic component of the observed action. The judgments delivered indicate that both expert and non-expert observers are able to discern a good from a mediocre performance; however, as expected, only experts discriminate the technical from the aesthetic component of the action evaluated and do this independently of the level of skill shown by the model (high or middle level performances). Furthermore, the judgments delivered were strongly related to the kinematic variables measured in the observed model, indicating that observers rely on specific movement kinematics (e.g. movement amplitude, jerk and duration) for action evaluation. These results provide evidence of the complementary functional role of visual and motor action representation in movement evaluation and underline the role of expertise in judging the aesthetic quality of movements.	[Zamparo, Paola; Zorzi, Elena; Marcantoni, Sara; Cesari, Paola] Univ Verona, Dept Neurol & Movement Sci, I-37100 Verona, Italy	University of Verona	Zamparo, P (corresponding author), Univ Verona, Dept Neurol & Movement Sci, I-37100 Verona, Italy.	paola.zamparo@univr.it	Zamparo, Paola/AAF-7700-2020	Zamparo, Paola/0000-0002-6919-6721; Cesari, Paola/0000-0002-1705-6065				Abreu AM, 2012, EUR J NEUROSCI, V35, P1646, DOI 10.1111/j.1460-9568.2012.08104.x; Aglioti SM, 2008, NAT NEUROSCI, V11, P1109, DOI 10.1038/nn.2182; ALLARD F, 1980, Journal of Sport Psychology, V2, P14; Almasbakk B., 2000, ENERGETICS HUMAN ACT, P228; Basmajian JV, 1977, MUSCLES MOVEMENTS BA; Bertucco M, 2010, NEUROSCIENCE, V171, P205, DOI 10.1016/j.neuroscience.2010.08.023; Best D., 1974, BRIT J AESTHET, V14, P197, DOI DOI 10.1093/BJAESTHETICS/14.3.197; Blasing B, 2012, ACTA PSYCHOL, V139, P300, DOI 10.1016/j.actpsy.2011.12.005; Brown WM, 2005, NATURE, V438, P1148, DOI 10.1038/nature04344; Calvo-Merino B, 2005, CEREB CORTEX, V15, P1243, DOI 10.1093/cercor/bhi007; Chase W.G., 1973, VISUAL INFORM PROCES, P215, DOI [10.1016/b978-0-12-170150-5.50011-1, DOI 10.1016/B978-0-12-170150-5.50011-1]; Cross ES, 2011, FRONT HUM NEUROSCI, V5, DOI 10.3389/fnhum.2011.00102; Didierjean A, 2005, VIS COGN, V12, P265, DOI 10.1080/13506280444000021A; Duarte M, 2007, EXP BRAIN RES, V180, P457, DOI 10.1007/s00221-007-0871-x; ENOKA RM, 1994, NEUROMECHANICAL BASI; Grafton ST, 2009, ANN NY ACAD SCI, V1156, P97, DOI 10.1111/j.1749-6632.2009.04425.x; Humphrey D R, 1983, Adv Neurol, V39, P347; JOHANSSON G, 1973, PERCEPT PSYCHOPHYS, V14, P201, DOI 10.3758/BF03212378; Knoblich G, 2001, PSYCHOL SCI, V12, P467, DOI 10.1111/1467-9280.00387; Makris S, 2015, SOC COGN AFFECT NEUR, V10, P342, DOI 10.1093/scan/nsu052; McPherson SL, 1999, RES Q EXERCISE SPORT, V70, P369, DOI 10.1080/02701367.1999.10608057; Naeve N, 2011, BIOL LETT, V7, P221, DOI [10.1098/rsbl.2010.0619, DOI 10.1098/RSBL.2010.0619]; Newell K.M, 1993, VARIABILITY MOTOR CO; Opacic T, 2009, J EXP PSYCHOL LEARN, V35, P1570, DOI 10.1037/a0017244; Orgs G, 2013, CONSCIOUS COGN, V22, P603, DOI 10.1016/j.concog.2013.03.010; Penrose JMT, 1995, J HUM MOVEMENT STUD, V29, P199; Reber R, 2004, PERS SOC PSYCHOL REV, V8, P364, DOI 10.1207/s15327957pspr0804_3; SCULLY DM, 1986, HUM MOVEMENT SCI, V5, P185, DOI 10.1016/0167-9457(86)90024-2; Tomeo E, 2013, CEREB CORTEX, V23, P2765, DOI 10.1093/cercor/bhs279; Torrents C, 2013, PERCEPTION, V42, P447, DOI 10.1068/p7117; WEWERS ME, 1990, RES NURS HEALTH, V13, P227, DOI 10.1002/nur.4770130405	31	2	2	0	18	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 5	2015	10	6							e0128357	10.1371/journal.pone.0128357	http://dx.doi.org/10.1371/journal.pone.0128357			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	CJ7CR	26047473	Green Published, Green Submitted, gold			2023-01-03	WOS:000355652200061
J	Cope, AB; Powers, KA; Kuruc, JD; Leone, PA; Anderson, JA; Ping, LH; Kincer, LP; Swanstrom, R; Mobley, VL; Foust, E; Gay, CL; Eron, JJ; Cohen, MS; Miller, WC				Cope, Anna B.; Powers, Kimberly A.; Kuruc, Joann D.; Leone, Peter A.; Anderson, Jeffrey A.; Ping, Li-Hua; Kincer, Laura P.; Swanstrom, Ronald; Mobley, Victoria L.; Foust, Evelyn; Gay, Cynthia L.; Eron, Joseph J.; Cohen, Myron S.; Miller, William C.			Ongoing HIV Transmission and the HIV Care Continuum in North Carolina	PLOS ONE			English	Article							SEXUAL TRANSMISSION; VIRAL LOAD; BLACK-MEN; VIRUS; INFECTION; PREVENTION; MULTIPLE; UNAWARE; AWARE	Objective HIV transmission is influenced by status awareness and receipt of care and treatment. We analyzed these attributes of named partners of persons with acute HIV infection (index AHI cases) to characterize the transmission landscape in North Carolina (NC). Design Secondary analysis of programmatic data. Methods We used data from the NC Screening and Tracing of Active Transmission Program (2002-2013) to determine HIV status (uninfected, AHI, or chronic HIV infection [CHI]), diagnosis status (new or previously-diagnosed), and care and treatment status (not in care, in care and not on treatment, in care and on treatment) of index AHI cases' named partners. We developed an algorithm identifying the most likely transmission source among known HIV-infected partners to estimate the proportion of transmissions arising from contact with persons at different HIV continuum stages. We conducted a complementary analysis among a subset of index AHI cases and partners with phylogenetically-linked viruses. Results Overall, 358 index AHI cases named 932 partners, of which 218 were found to be HIV-infected (162 (74.3%) previously-diagnosed, 11 (5.0%) new AHI, 45 (20.6%) new CHI). Most transmission events appeared attributable to previously-diagnosed partners (77.4%, 95% confidence interval 69.4-85.3%). Among these previously-diagnosed partners, 23.2% (14.0-32.3%) were reported as in care and on treatment near the index AHI case diagnosis date. In the subset study of 33 phylogenetically-linked cases and partners, 60.6% of partners were previously diagnosed (43.9-77.3%). Conclusions A substantial proportion of HIV transmission in this setting appears attributable to contact with previously-diagnosed partners, reinforcing the need for improved engagement in care after diagnosis.	[Cope, Anna B.; Powers, Kimberly A.; Cohen, Myron S.; Miller, William C.] Univ N Carolina, Dept Epidemiol, Chapel Hill, NC 27599 USA; [Kuruc, Joann D.; Leone, Peter A.; Anderson, Jeffrey A.; Gay, Cynthia L.; Eron, Joseph J.; Cohen, Myron S.; Miller, William C.] Univ N Carolina, Sch Med, Dept Med, Div Infect Dis, Chapel Hill, NC USA; [Anderson, Jeffrey A.] Bristol Myers Squibb Co, Lawrenceville, NJ USA; [Ping, Li-Hua; Kincer, Laura P.; Swanstrom, Ronald] Univ N Carolina, Sch Med, Lineberger Comprehens Canc Ctr, Chapel Hill, NC USA; [Swanstrom, Ronald] Univ N Carolina, Dept Biochem & Biophys, Chapel Hill, NC USA; [Swanstrom, Ronald; Eron, Joseph J.; Cohen, Myron S.] Univ N Carolina, UNC Ctr AIDS Res, Sch Med, Chapel Hill, NC USA; [Mobley, Victoria L.; Foust, Evelyn] North Carolina Dept Hlth & Human Serv, Div Publ Hlth, Raleigh, NC USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; Bristol-Myers Squibb; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Cope, AB (corresponding author), Univ N Carolina, Dept Epidemiol, Chapel Hill, NC 27599 USA.	acbarry@unc.edu	Laboratory Core, HIV STD/AGD-7085-2022; Miller, William C/H-4800-2014; Gay, Cynthia/AAG-2927-2019	Miller, William C/0000-0002-1934-7827; Gay, Cynthia/0000-0002-3620-3059	National Institutes of Health [KL2-TR001109, R03-MH100987, 1UL1TR00111, UO1-AI067854, R37-AI44667]; Bristol-Myers Squibb;  [P30 AI50410]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [KL2TR001109, UL1TR001111] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI067854, R37AI044667, P30AI050410] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R03MH100987] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Bristol-Myers Squibb(Bristol-Myers Squibb); ; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))	Funding for this study was provided by the National Institutes of Health [www.grants.nih.gov] (grant numbers KL2-TR001109 [KP], R03-MH100987 [KP], 1UL1TR00111, UO1-AI067854, R37-AI44667 [RS]) and an administrative supplement to the University of North Carolina Center for AIDS Research [www.unccfar.org] (P30 AI50410 [KP]). Bristol-Myers Squibb provided support in the form of salaries for JE and CG, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the 'author contributions' section. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abrahams MR, 2009, J VIROL, V83, P3556, DOI 10.1128/JVI.02132-08; Anderson JA, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1001053; [Anonymous], 2013, MMWR-MORBID MORTAL W, V62, P489; Carbon Disclosure Project, 2013, DROP; Cohen MS, 2011, NEW ENGL J MED, V365, P493, DOI [10.1056/NEJMoa1105243, 10.1056/NEJMoa1600693]; Cohen Stacy M., 2011, Morbidity and Mortality Weekly Report, V60, P1618; Crepaz N, 2009, AIDS, V23, P1617, DOI 10.1097/QAD.0b013e32832effae; Dennis AM, 2012, AIDS, V26, P1813, DOI 10.1097/QAD.0b013e3283573244; Drummond AJ, 2007, BMC EVOL BIOL, V7, DOI 10.1186/1471-2148-7-214; Edmonson PF, 1992, NUCL ACIDS RES, V20; Gardner EM, 2011, CLIN INFECT DIS, V52, P793, DOI 10.1093/cid/ciq243; Gulick RM, 2004, NEW ENGL J MED, V350, P1850, DOI 10.1056/NEJMoa031772; Hall HI, 2008, JAMA-J AM MED ASSOC, V300, P520, DOI 10.1001/jama.300.5.520; Hall HI, 2012, AIDS, V26, P893, DOI 10.1097/QAD.0b013e328351f73f; Hurt CB, 2012, JAIDS-J ACQ IMM DEF, V61, P515, DOI 10.1097/QAI.0b013e31827076a4; Kalichman SC, 2008, SEX TRANSM DIS, V35, P55, DOI 10.1097/OLQ.0b013e318141fe9b; Keele BF, 2008, P NATL ACAD SCI USA, V105, P7552, DOI 10.1073/pnas.0802203105; Kuruc J, 2009, 18 INT AIDS C CAP TO; Marks G, 2006, AIDS, V20, P1447, DOI 10.1097/01.aids.0000233579.79714.8d; Mattson CL, 2014, AIDS, V28, P1203, DOI 10.1097/QAD.0000000000000273; Miller WC, 2009, AIDS, V23, P835, DOI 10.1097/QAD.0b013e328326f55e; Millett GA, 2012, LANCET, V380, P341, DOI 10.1016/S0140-6736(12)60899-X; Muessig KE, 2014, CURR HIV AIDS REP; North Carolina Department of Health and Human Services Communicable Disease Branch, 2012, EP PROF HIV STD PREV; Palmer S, 2005, J CLIN MICROBIOL, V43, P406, DOI 10.1128/JCM.43.1.406-413.2005; Paredes R, 2010, J INFECT DIS, V201, P662, DOI 10.1086/650543; Patel P, 2006, JAIDS-J ACQ IMM DEF, V42, P75, DOI 10.1097/01.qai.0000218363.21088.ad; Peters PJ, 2014, MMWR-MORBID MORTAL W, V63, P90; Pilcher CD, 2001, JAMA-J AM MED ASSOC, V286, P1713, DOI 10.1001/jama.286.14.1713; Pilcher CD, 2005, NEW ENGL J MED, V352, P1873, DOI 10.1056/NEJMoa042291; Pilcher CD, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080629; Prejean J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017502; Quinn TC, 2000, NEW ENGL J MED, V342, P921, DOI 10.1056/NEJM200003303421303; Rodger A BT, 2014, TOP ANTIVIR MED, V22, P24; Salazar-Gonzalez JF, 2008, J VIROL, V82, P3952, DOI 10.1128/JVI.02660-07; SIMMONDS P, 1990, J VIROL, V64, P5840, DOI 10.1128/JVI.64.12.5840-5850.1990; Skarbinski J, 2015, JAMA INTERN MED; Stringer JSA, 2005, AIDS, V19, P1309, DOI 10.1097/01.aids.0000180102.88511.7d; Tamura K, 2007, MOL BIOL EVOL, V24, P1596, DOI 10.1093/molbev/msm092; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Volz EM, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001568; William H., SAGE HDB QUANTITATIV; Zetola NM, 2009, BMC PUBLIC HEALTH, V9, DOI 10.1186/1471-2458-9-17	44	22	22	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 4	2015	10	6							e0127950	10.1371/journal.pone.0127950	http://dx.doi.org/10.1371/journal.pone.0127950			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CJ7TC	26042804	gold, Green Published, Green Submitted			2023-01-03	WOS:000355701600028
J	Ferrocino, I; Di Cagno, R; De Angelis, M; Turroni, S; Vannini, L; Bancalari, E; Rantsiou, K; Cardinali, G; Neviani, E; Cocolin, L				Ferrocino, Ilario; Di Cagno, Raffaella; De Angelis, Maria; Turroni, Silvia; Vannini, Lucia; Bancalari, Elena; Rantsiou, Kalliopi; Cardinali, Gianluigi; Neviani, Erasmo; Cocolin, Luca			Fecal Microbiota in Healthy Subjects Following Omnivore, Vegetarian and Vegan Diets: Culturable Populations and rRNA DGGE Profiling	PLOS ONE			English	Article							GUT MICROBIOTA; PCR-DGGE; CONSUMPTION; DIVERSITY; IMPACT; CHILDREN	In this study, the fecal microbiota of 153 healthy volunteers, recruited from four different locations in Italy, has been studied by coupling viable counts, on different microbiological media, with ribosomal RNA Denaturing Gradient Gel Electrophoresis (rRNA-DGGE). The volunteers followed three different diets, namely omnivore, ovo-lacto-vegetarian and vegan. The results obtained from culture-dependent and -independent methods have underlined a high level of similarity of the viable fecal microbiota for the three investigated diets. The rRNA DGGE profiles were very complex and comprised a total number of bands that varied from 67 to 64 for the V3 and V9 regions of the 16S rRNA gene, respectively. Only a few bands were specific in/of all three diets, and the presence of common taxa associated with the dietary habits was found. As far as the viable counts are concerned, the high similarity of the fecal microbiota was once again confirmed, with only a few of the investigated groups showing significant differences. Interestingly, the samples grouped differently, according to the recruitment site, thus highlighting a higher impact of the food consumed by the volunteers in the specific geographical locations than that of the type of diet. Lastly, it should be mentioned that the fecal microbiota DGGE profiles obtained from the DNA were clearly separated from those produced using RNA, thus underlining a difference between the total and viable populations in the fecal samples.	[Ferrocino, Ilario; Rantsiou, Kalliopi; Cocolin, Luca] Univ Turin, Dept Agr Forest & Food Sci, I-10095 Grugliasco, Italy; [Di Cagno, Raffaella; De Angelis, Maria] Univ Bari Aldo Moro, Dept Soil Plant & Food Sci, I-70126 Bari, Italy; [Turroni, Silvia] Alma Mater Studiorum Univ Bologna, Dept Pharm & Biotechnol, I-40126 Bologna, Italy; [Vannini, Lucia] Dept Agr & Food Sci, I-40127 Bologna, Italy; [Bancalari, Elena; Neviani, Erasmo] Univ Parma, Dept Food Sci, I-43124 Parma, Italy; [Cardinali, Gianluigi] Univ Perugia, Dept Pharmaceutr Sci, I-06123 Perugia, Italy	University of Turin; Universita degli Studi di Bari Aldo Moro; University of Bologna; University of Parma; University of Perugia	Cocolin, L (corresponding author), Univ Turin, Dept Agr Forest & Food Sci, Largo P Braccini 2, I-10095 Grugliasco, Italy.	lucasimone.cocolin@unito.it	Ferrocino, Ilario/K-7234-2016; Turroni, Silvia/J-7195-2016; Cocolin, Luca/H-5091-2012; De Angelis, Maria/AAA-9909-2019	Turroni, Silvia/0000-0003-2345-9482; Cocolin, Luca/0000-0003-4799-7074; FERROCINO, ILARIO/0000-0002-1657-0054; De Angelis, Maria/0000-0002-2010-884X; Bancalari, Elena/0000-0002-5975-2923; Vannini, Lucia/0000-0002-9417-8410; Di Cagno, Raffaella/0000-0002-9431-4427	Italian Ministry of University and Research (MIUR)	Italian Ministry of University and Research (MIUR)(Ministry of Education, Universities and Research (MIUR))	This study was supported by the Italian Ministry of University and Research (MIUR) PRIN 2010-2011 program (http://www.diet4microgut.it).	Agans R, 2011, FEMS MICROBIOL ECOL, V77, P404, DOI 10.1111/j.1574-6941.2011.01120.x; Bertrand X, 2007, J APPL MICROBIOL, V102, P1052, DOI 10.1111/j.1365-2672.2006.03148.x; Bianchi F, 2014, FOOD RES INT, V64, P43, DOI 10.1016/j.foodres.2014.05.072; Cecchini DA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072766; Ceuppens S, 2014, COMPR REV FOOD SCI F, V13, P551, DOI 10.1111/1541-4337.12072; Chiba M, 2010, WORLD J GASTROENTERO, V16, P2484, DOI 10.3748/wjg.v16.i20.2484; Claesson MJ, 2012, NATURE, V488, P178, DOI 10.1038/nature11319; David LA, 2014, NATURE, V505, P559, DOI 10.1038/nature12820; De Filippo C, 2010, P NATL ACAD SCI USA, V107, P14691, DOI 10.1073/pnas.1005963107; Eckburg PB, 2005, SCIENCE, V308, P1635, DOI 10.1126/science.1110591; Ferris MJ, 1996, APPL ENVIRON MICROB, V62, P340, DOI 10.1128/AEM.62.2.340-346.1996; Foerster J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109606; Francavilla R, 2012, PEDIAT ALLERG IMM-UK, V23, P420, DOI 10.1111/j.1399-3038.2012.01286.x; Hammer Oyvind, 2001, Palaeontologia Electronica, V4, pUnpaginated; Hayashi H, 2002, MICROBIOL IMMUNOL, V46, P819, DOI 10.1111/j.1348-0421.2002.tb02769.x; Hobbs ME, 2014, BIOCHEMISTRY-US, V53, P4661, DOI 10.1021/bi500656m; Jaquet M, 2009, INT J FOOD MICROBIOL, V130, P117, DOI 10.1016/j.ijfoodmicro.2009.01.011; Kim MS, 2013, ENV MICROBIOL REP, V5, P765, DOI 10.1111/1758-2229.12079; Le Huerou-Luron I, 2010, NUTR RES REV, V23, P23, DOI 10.1017/S0954422410000065; Mai V, 2009, NUTR J, P84; Matijasic BB, 2014, EUR J NUTR, V53, P1051, DOI 10.1007/s00394-013-0607-6; Maukonen J, 2006, FEMS MICROBIOL ECOL, V58, P517, DOI 10.1111/j.1574-6941.2006.00179.x; McEvoy CT, 2012, PUBLIC HEALTH NUTR, V15, P2287, DOI 10.1017/S1368980012000936; MUYZER G, 1993, APPL ENVIRON MICROB, V59, P695, DOI 10.1128/AEM.59.3.695-700.1993; O'Hara AM, 2006, EMBO REP, V7, P688, DOI 10.1038/sj.embor.7400731; Putignani L, 2013, FRONTIERS MEDIA SA, DOI [10.3389/fcimb.2012.00144, DOI 10.3389/FCIMB.2012.00144]; Ruengsomwong S, 2014, J MICROBIOL BIOTECHN, V24, P1026, DOI 10.4014/jmb.1310.10043; Scott KP, 2013, PHARMACOL RES, V69, P52, DOI 10.1016/j.phrs.2012.10.020; Soare A, 2014, NUTR METAB, V11, DOI 10.1186/1743-7075-11-39; Tannock GW, 2004, APPL ENVIRON MICROB, V70, P2129, DOI 10.1128/AEM.70.4.2129-2136.2004; Tap J, 2009, ENVIRON MICROBIOL, V11, P2574, DOI 10.1111/j.1462-2920.2009.01982.x; Tyakht AV, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3469; Vauterin L., 1992, EUR MICROBIOL, V1, P37; Woodmansey EJ, 2007, J APPL MICROBIOL, V102, P1178, DOI 10.1111/j.1365-2672.2007.03400.x; Wu GD, 2013, CLIN GASTROENTEROL H, V11, P774, DOI 10.1016/j.cgh.2013.03.038; Wu GD, 2011, SCIENCE, V334, P105, DOI 10.1126/science.1208344; Wu GD, 2014, GUT, P1, DOI [10.1136/gutjnl-2014-307480, DOI 10.1136/GUTJNL-2014-307480]; Yatsunenko T, 2012, NATURE, V486, P222, DOI 10.1038/nature11053; Zimmer J, 2012, EUR J CLIN NUTR, V66, P53, DOI 10.1038/ejcn.2011.141	40	52	53	0	69	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 2	2015	10	6							e0128669	10.1371/journal.pone.0128669	http://dx.doi.org/10.1371/journal.pone.0128669			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CJ7SJ	26035837	Green Published, gold, Green Submitted			2023-01-03	WOS:000355699100042
J	Hilbe, W; Pall, G; Kocher, F; Pircher, A; Zabernigg, A; Schmid, T; Schumacher, M; Jamnig, H; Fiegl, M; Gachter, A; Freund, M; Kendler, D; Manzl, C; Zelger, B; Popper, H; Woll, E				Hilbe, Wolfgang; Pall, Georg; Kocher, Florian; Pircher, Andreas; Zabernigg, August; Schmid, Thomas; Schumacher, Michael; Jamnig, Herbert; Fiegl, Michael; Gaechter, Anne; Freund, Martin; Kendler, Dorota; Manzl, Claudia; Zelger, Bettina; Popper, Helmut; Woell, Ewald			Multicenter Phase II Study Evaluating Two Cycles of Docetaxel, Cisplatin and Cetuximab as Induction Regimen Prior to Surgery in Chemotherapy-Naive Patients with NSCLC Stage IB-IIIA (INN06-Study)	PLOS ONE			English	Article							CELL LUNG-CANCER; NEOADJUVANT CHEMOTHERAPY; SURVIVAL; TRIAL; TUMORS; FLEX	Background Different strategies for neoadjuvant chemotherapy in patients with early stage NSCLC have already been evaluated. The aim of this study was to evaluate the tolerability and efficacy of a chemoimmunotherapy when limited to two cycles. Methods Between 01/2007 and 03/2010 41 patients with primarily resectable NSCLC stage IB to IIIA were included. Treatment consisted of two cycles cisplatin (40 mg/m(2) d1+2) and docetaxel (75 mg/m(2) d1) q3 weeks, accompanied by the administration of cetuximab (400 mg/m(2) d1, then 250 mg weekly). The primary endpoint was radiological response according to RECIST. Results 40 patients were evaluable for toxicity, 39 for response. The main grade 3/4 toxicities were: neutropenia 25%, leucopenia 11%, febrile neutropenia 6%, nausea 8% and rash 8%. 20 patients achieved a partial response, 17 a stable disease, 2 were not evaluable. 37 patients (95%) underwent surgery and in three of them a complete pathological response was achieved. At a median follow-up of 44.2 months, 41% of the patients had died, median progression- free survival was 22.5 months. Conclusions Two cycles of cisplatin/docetaxel/cetuximab showed promising efficacy in the neoadjuvant treatment of early-stage NSCLC and rapid operation was possible in 95% of patients. Toxicities were manageable and as expected.	[Hilbe, Wolfgang; Pall, Georg; Kocher, Florian; Pircher, Andreas; Fiegl, Michael; Gaechter, Anne] Med Univ Innsbruck, Dept Internal Med Haematol & Oncol 5, Innsbruck, Austria; [Zabernigg, August] Cty Hosp Kufstein, Dept Internal Med, Kufstein, Austria; [Schmid, Thomas] Med Univ Innsbruck, Dept Surg, A-6020 Innsbruck, Austria; [Schumacher, Michael] Gen Hosp Linz, Elisabethinen Linz, Dept Pneumol, Linz, Austria; [Jamnig, Herbert] Cty Hosp Natters, Dept Pneumol, Natters, Austria; [Freund, Martin] Med Univ Innsbruck, Dept Radiol, A-6020 Innsbruck, Austria; [Kendler, Dorota] Med Univ Innsbruck, Nucl Med, A-6020 Innsbruck, Austria; [Manzl, Claudia; Zelger, Bettina; Popper, Helmut] Med Univ Innsbruck, Dept Pathol, A-6020 Innsbruck, Austria; [Popper, Helmut] Med Univ Graz, Dept Pathol, Graz, Austria; [Woell, Ewald] St Vincent Hosp Zams, Dept Internal Med, Zams, Austria; [Kocher, Florian] Tyrolean Canc Res Inst, Innsbruck, Austria	Medical University of Innsbruck; Medical University of Innsbruck; Kepler University Hospital; Ordensklinikum Linz Elisabethinen; Medical University of Innsbruck; Medical University of Innsbruck; Medical University of Innsbruck; Medical University of Graz	Hilbe, W (corresponding author), Med Univ Innsbruck, Dept Internal Med Haematol & Oncol 5, Innsbruck, Austria.	wolfgang.hilbe@i-med.ac.at	Pircher, Andreas/L-2150-2019	Pircher, Andreas/0000-0002-7747-3012	Sanofi-Aventis; Merck; Association of Cancer Research ("Verein fur Tumorforschung")	Sanofi-Aventis(Sanofi-Aventis); Merck(Merck & Company); Association of Cancer Research ("Verein fur Tumorforschung")	This academic study was in part financed by two unrestricted grants offered by the companies Sanofi-Aventis and Merck. Drug supply concerning Cetuximab was donated by Merck. Additional fundings were granted by the Association of Cancer Research ("Verein fur Tumorforschung"). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Fundings do not alter our adherence to PLOS ONE policies on sharing data and materials.	Baik C, 2013, ROLE CHEMOTHERAPY MA; Betticher DC, 2003, J CLIN ONCOL, V21, P1752, DOI 10.1200/JCO.2003.11.040; Burdett S, 2006, J THORAC ONCOL, V1, P611; Depierre A, 2002, J CLIN ONCOL, V20, P247, DOI 10.1200/JCO.20.1.247; Fossella F, 2003, J CLIN ONCOL, V21, P3016, DOI 10.1200/JCO.2003.12.046; Gilligan D, 2007, LANCET, V369, P1929, DOI 10.1016/S0140-6736(07)60714-4; Goldstraw Peter, 2007, J Thorac Oncol, V2, P706, DOI 10.1097/JTO.0b013e31812f3c1a; Greene DL, 2002, AJCC CANC STAGING MA; Pirker R, 2012, LANCET ONCOL, V13, P33, DOI 10.1016/S1470-2045(11)70318-7; Pirker R, 2009, LANCET, V373, P1525, DOI 10.1016/S0140-6736(09)60569-9; Pisters KMW, 2010, J CLIN ONCOL, V28, P1843, DOI 10.1200/JCO.2009.26.1685; Scagliotti GV, 2012, J CLIN ONCOL, V30, P172, DOI 10.1200/JCO.2010.33.7089; Song WA, 2010, J THORAC ONCOL, V5, P510, DOI 10.1097/JTO.0b013e3181cd3345; Steger V, 2013, THORAC CARDIOV SURG, V61, P109, DOI 10.1055/s-0032-1311529; Therasse P, 2000, J NATL CANCER I, V92, P205, DOI 10.1093/jnci/92.3.205; Vansteenkiste J, 2013, ANN ONCOL, V24, P89, DOI 10.1093/annonc/mdt241; Westeel V, 2010, J CLIN ONCOL S15, V28	17	6	7	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 28	2015	10	5							e0125364	10.1371/journal.pone.0125364	http://dx.doi.org/10.1371/journal.pone.0125364			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CJ0SC	26020783	Green Submitted, Green Published, gold			2023-01-03	WOS:000355187300013
J	Kim, A; Im, M; Hwang, YH; Yang, HJ; Ma, JY				Kim, Aeyung; Im, Minju; Hwang, Youn-Hwan; Yang, Hye Jin; Ma, Jin Yeul			Jaeumganghwa-Tang Induces Apoptosis via the Mitochondrial Pathway and Lactobacillus Fermentation Enhances Its Anti-Cancer Activity in HT1080 Human Fibrosarcoma Cells	PLOS ONE			English	Article							TRADITIONAL CHINESE MEDICINE; SIGNALING PATHWAY; HERBAL MEDICINES; CANCER; THERAPY	Jaeumganghwa-tang (JGT, Zi-yin-jiang-huo-tang in Chinese and Jiin-koka-to in Japanese) is an oriental herbal formula that has long been used as a traditional medicine to treat respiratory and kidney diseases. Recent studies revealed that JGT exhibited potent inhibitory effects on allergies, inflammation, pain, convulsions, and prostate hyperplasia. Several constituent herbs in JGT induce apoptotic cancer cell death. However, the anti-cancer activity of JGT has not been examined. In this study, we investigated the anti-cancer effects of JGT using highly tumorigenic HT1080 human fibrosarcoma cells and elucidated the underlying mechanisms. In addition, we examined whether the Lactobacillus fermentation of JGT enhanced its anti-cancer activity using an in vivo xenograft model because fermentation of herbal extracts is thought to strengthen their therapeutic effects. Data revealed that JGT suppressed the growth of cancer cells efficiently by stimulating G1 cell cycle arrest and then inducing apoptotic cell death by causing mitochondrial damage and activating caspases. The phosphorylation of p38 and ERK also played a role in JGT-induced cell death. In vitro experiments demonstrated that JGT fermented with Lactobacillus acidophilus, designated fJGT162, elicited similar patterns of cell death as did non-fermented JGT. Meanwhile, the daily oral administration of 120 mg/kg fJGT162 to HT1080-bearing BALB/c nude mice suppressed tumor growth dramatically (up to 90%) compared with saline treatment, whereas the administration of non-fermented JGT suppressed tumor growth by similar to 70%. Collectively, these results suggest that JGT and fJGT162 are safe and useful complementary and alternative anti-cancer herbal therapies, and that Lactobacillus fermentation improves the in vivo anti-cancer efficacy of JGT significantly.	[Kim, Aeyung; Im, Minju; Hwang, Youn-Hwan; Yang, Hye Jin; Ma, Jin Yeul] KIOM, KM Based Herbal Drug Dev Ctr, Taejon, South Korea	Korea Institute of Oriental Medicine (KIOM)	Ma, JY (corresponding author), KIOM, KM Based Herbal Drug Dev Ctr, Taejon, South Korea.	jyma@kiom.re.kr	Hwang, Youn-Hwan/AAU-9373-2021		Ministry of Science, ICT and Future Planning (MSIP), Republic of Korea [K15280]	Ministry of Science, ICT and Future Planning (MSIP), Republic of Korea	This work has been supported by the Grant K15280 awarded to Korea Institute of Oriental Medicine (KIOM) from Ministry of Science, ICT and Future Planning (MSIP), Republic of Korea.	Bae EA, 2004, ARCH PHARM RES, V27, P61, DOI 10.1007/BF02980048; Efferth T, 2007, TRENDS MOL MED, V13, P353, DOI 10.1016/j.molmed.2007.07.001; Eum HA, 2011, AFR J TRADIT COMPLEM, V8, P312; Hambright HG, 2015, MOL CARCINOGEN, V54, P1227, DOI 10.1002/mc.22192; Hsiao WLW, 2010, PLANTA MED, V76, P1118, DOI 10.1055/s-0030-1250186; Jang DS, 2003, J NAT PROD, V66, P1166, DOI 10.1021/np0302100; Jang YS, 2009, CHINESE SCI BULL, V54, P227, DOI 10.1007/s11434-008-0567-z; Jeong SY, 2008, BMB REP, V41, P11, DOI 10.1146/annurev-genet-102108-134850; Joo SS, 2009, PHYTOTHER RES, V23, P913, DOI 10.1002/ptr.2758; Kang MH, 2009, CLIN CANCER RES, V15, P1126, DOI 10.1158/1078-0432.CCR-08-0144; Kang SH, 2009, ENVIRON TOXICOL PHAR, V28, P430, DOI 10.1016/j.etap.2009.07.007; Kim A, 2014, PHARMACOGN MAG, V10, P463, DOI 10.4103/0973-1296.139774; Kim A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098703; Kim A, 2013, BMC COMPLEM ALTERN M, V13, DOI 10.1186/1472-6882-13-233; Kim EK, 2010, BBA-MOL BASIS DIS, V1802, P396, DOI 10.1016/j.bbadis.2009.12.009; Kim YK, 2004, KOREAN J ORIEN INTER, V25, P174; Konkimalla VB, 2008, J ETHNOPHARMACOL, V116, P207, DOI 10.1016/j.jep.2007.12.009; Kwon KB, 2006, BIOL PHARM BULL, V29, P1082, DOI 10.1248/bpb.29.1082; Lee HJ, 2006, CARCINOGENESIS, V27, P2455, DOI 10.1093/carcin/bgl104; Lee JE, 2011, AM J CHINESE MED, V39, P1235, DOI 10.1142/S0192415X11009524; Lee JH, 2013, KOREAN J ORIEN INTER, V34, P155; Lee JJ, 2014, BMC COMPLEM ALTERN M, V14, DOI 10.1186/1472-6882-14-78; Lee Kwang Jin, 2013, Journal of Applied Biological Chemistry, V56, P131, DOI 10.3839/jabc.2013.021; Li M, 2014, ONCOL REP, V32, P2845, DOI 10.3892/or.2014.3543; Li-Weber M, 2013, CANCER LETT, V332, P304, DOI 10.1016/j.canlet.2010.07.015; Lu W, 2015, MOL MED REP, V11, P3920, DOI 10.3892/mmr.2014.3139; Ly JD, 2003, APOPTOSIS, V8, P115, DOI 10.1023/A:1022945107762; Ng CC, 2011, J BIOSCI BIOENG, V111, P289, DOI 10.1016/j.jbiosc.2010.11.011; Oh YC, 2014, PHARMACOGN MAG, V10, P645, DOI 10.4103/0973-1296.139815; Oh YC, 2012, AM J CHINESE MED, V40, P813, DOI 10.1142/S0192415X12500619; Oh YC, 2012, AM J CHINESE MED, V40, P611, DOI 10.1142/S0192415X12500462; Oh YC, 2012, BMC COMPLEM ALTERN M, V12, DOI 10.1186/1472-6882-12-17; Qi FH, 2010, BIOSCI TRENDS, V4, P297; Santarpia L, 2012, EXPERT OPIN THER TAR, V16, P103, DOI 10.1517/14728222.2011.645805; Seo I, 2011, IMMUNOPHARM IMMUNOT, V33, P682, DOI 10.3109/08923973.2011.560159; Shim KS, 2013, BMC COMPLEM ALTERN M, V13, DOI 10.1186/1472-6882-13-106; Shim KS, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/325791; Shin IS, 2012, J KOREAN SOC APPL BI, V55, P205, DOI 10.1007/s13765-012-1174-x; Sohn Y, 2012, FOOD CHEM TOXICOL, V50, P2987, DOI 10.1016/j.fct.2012.06.001; Thirugnanam S, 2008, ONCOL REP, V20, P1387, DOI 10.3892/or_00000157; Xu W, 2006, EUR J CANCER CARE, V15, P397, DOI 10.1111/j.1365-2354.2006.00685.x; Zheng Hong-mei, 2010, [The Journal of Korean Oriental Internal Medicine, 대한한방내과학회지], V31, P395	42	10	11	1	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 28	2015	10	5							e0127898	10.1371/journal.pone.0127898	http://dx.doi.org/10.1371/journal.pone.0127898			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CJ0SC	26020238	gold, Green Submitted, Green Published			2023-01-03	WOS:000355187300064
J	Dzau, VJ; Ginsburg, GS; Van Nuys, K; Agus, D; Goldman, D				Dzau, Victor J.; Ginsburg, Geoffrey S.; Van Nuys, Karen; Agus, David; Goldman, Dana			Aligning incentives to fulfil the promise of personalised medicine	LANCET			English	Editorial Material									[Dzau, Victor J.] Inst Med, Washington, DC 20001 USA; [Ginsburg, Geoffrey S.] Duke Ctr Appl Genom & Precis Med, Durham, NC USA; [Van Nuys, Karen] Precis Hlth Econ, Los Angeles, CA USA; [Agus, David] Univ So Calif, Keck Sch Med, Beverly Hills, CA USA; [Agus, David] Univ So Calif, Viterbi Sch Engn, Beverly Hills, CA USA; [Goldman, Dana] Univ So Calif, Schaeffer Ctr Hlth Policy & Econ, Los Angeles, CA USA	University of Southern California; University of Southern California; University of Southern California	Dzau, VJ (corresponding author), Inst Med, Washington, DC 20001 USA.	vdzau@nas.edu	Goldman, Dana P/E-7667-2013	Goldman, Dana P/0000-0001-8498-6396; Agus, David B./0000-0002-7499-7822	NIA NIH HHS [P30 AG024968] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [P30AG024968] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Feero WG, 2010, NEW ENGL J MED, V362, P2001, DOI 10.1056/NEJMra0907175; Goldman Dana P, 2013, Forum Health Econ Policy, V16, pS87, DOI 10.1515/fhep-2013-0023; Knowler WC, 2002, NEW ENGL J MED, V346, P393, DOI 10.1056/NEJMoa012512; Michaud PC, 2011, SOC SCI MED, V73, P254, DOI 10.1016/j.socscimed.2011.05.027	4	54	55	0	20	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 23	2015	385	9982					2118	2119		10.1016/S0140-6736(15)60722-X	http://dx.doi.org/10.1016/S0140-6736(15)60722-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	CI7XK	25957453	Green Accepted			2023-01-03	WOS:000354979100031
J	Kallner, HK; Thunell, L; Brynhildsen, J; Lindeberg, M; Danielsson, KG				Kallner, Helena Kopp; Thunell, Louise; Brynhildsen, Jan; Lindeberg, Mia; Danielsson, Kristina Gemzell			Use of Contraception and Attitudes towards Contraceptive Use in Swedish Women - A Nationwide Survey	PLOS ONE			English	Article							UNINTENDED PREGNANCY	Objective To describe contraceptive use and attitudes towards contraceptive use in Sweden which has the highest abortion rate in Western Europe. Secondary objectives were to investigate knowledge of contraceptive methods and outcomes of unplanned and unwanted pregnancies. Design Telephone survey. Setting National survey of women living in Sweden. Population Women between 16 and 49 years. Methods The survey contained 22 questions with free text and multi choice answers on demographics, contraceptive use, knowledge of and attitudes towards contraception, the importance of monthly bleeding and experience of unintended pregnancy. Main Outcome Measures Distribution of use of contraceptive methods and non-use of contraception among Swedish women. Prevalence and outcome of unintended pregnancies. Results A total of 1001 women participated in the survey. Of all women, 721/1001 (72.1%) currently used contraception whereas 268/1001 (26.8%) women did not. Long acting reversible contraception, (LARC; implant and intra uterine contraception) was used by 24.3% of women. The unmet need of contraception in Sweden was estimated at 8.9% (89/1001 women). A total of 781 (78%) women had never experienced an unintended pregnancy whereas 220 (22%) women had had at least one unintended pregnancy. Users and non-users alike stated that one of the most important characteristics of a contraceptive method is its effectiveness. Conclusions Sweden has a large unmet need for contraception. Furthermore, a large proportion of women have experienced at least one unintended pregnancy. Increasing contraceptive use and promotion of LARC is a possible way forward in the effort to reduce the rates of unwanted pregnancies.	[Kallner, Helena Kopp; Danielsson, Kristina Gemzell] Karolinska Inst, Dept Womens & Childrens Hlth, Stockholm, Sweden; [Kallner, Helena Kopp] Karolinska Inst, Danderyd Hosp, Dept Clin Sci, Stockholm, Sweden; [Thunell, Louise] Skane Univ Hosp, Dept Obstet & Gynecol, Malmo, Sweden; [Brynhildsen, Jan] Linkoping Univ, Fac Hlth Sci, Dept Clin & Expt Med, Div Obstet & Gynecol, Linkoping, Sweden; [Lindeberg, Mia] MSD, Stockholm, Sweden	Karolinska Institutet; Danderyds Hospital; Karolinska Institutet; Lund University; Skane University Hospital; Linkoping University	Kallner, HK (corresponding author), Karolinska Inst, Dept Womens & Childrens Hlth, Stockholm, Sweden.	Helena.kopp-kallner@ki.se	Kallner, Helena Kopp/AAD-4423-2020	Kallner, Helena Kopp/0000-0001-7184-9165	MSD Sweden	MSD Sweden	This study was funded by MSD Sweden. MSD Sweden contributed with knowledge on Telephone surveys but has no influence on the questions asked, analysis or interpretation of results.	[Anonymous], 1983, 19831 SOU; [Anonymous], 2002, FORSLAG TILL HANDLIN; [Anonymous], 1990, FORSL TILL AB PROGR; [Anonymous], 1996, HALS FOR UND EFT GRA; [Anonymous], 2014, SWED NAT REC CONTR U; Bajos N, 2003, HUM REPROD, V18, P994, DOI 10.1093/humrep/deg215; Bitzer J, 2012, EUR J CONTRACEP REPR, V17, P65, DOI 10.3109/13625187.2011.637586; Cameron ST, 2012, BJOG-INT J OBSTET GY, V119, P1074, DOI 10.1111/j.1471-0528.2012.03407.x; Falah-Hassani K, 2009, OBSTET GYNECOL, V114, P79, DOI 10.1097/AOG.0b013e3181a99ddd; Lamvu G, 2006, CONTRACEPTION, V73, P399, DOI 10.1016/j.contraception.2005.10.007; Larsson M, 2007, EUR J CONTRACEP REPR, V12, P119, DOI 10.1080/13625180701217026; Milton A, MILTON INVESTIGATION; Moreau C, 2014, CONTRACEPTION, V89, P314, DOI 10.1016/j.contraception.2013.11.004; Rose SB, 2012, AM J OBSTET GYNECOL, V206, DOI 10.1016/j.ajog.2011.06.102; Socialstyrelsen, 2010, SOC STAT; Trussell J, 2008, CONTRACEPTION, V77, P1, DOI 10.1016/j.contraception.2007.09.001; Trussell J, 2011, CONTRACEPTION, V83, P397, DOI 10.1016/j.contraception.2011.01.021; Trussell James, 1999, FAM LIFE MATTERS, P3; Winner B, 2012, NEW ENGL J MED, V366, P1998, DOI 10.1056/NEJMoa1110855	19	47	47	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 20	2015	10	5							e0125990	10.1371/journal.pone.0125990	http://dx.doi.org/10.1371/journal.pone.0125990			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CI7CV	25992901	Green Published, Green Submitted, gold			2023-01-03	WOS:000354921400051
J	Seong, JM; Choi, NK; Shin, JY; Chang, Y; Kim, YJ; Lee, J; Kim, JY; Park, BJ				Seong, Jong-Mi; Choi, Nam-Kyong; Shin, Ju-Young; Chang, Yoosoo; Kim, Ye-Jee; Lee, Joongyub; Kim, Ju-Young; Park, Byung-Joo			Differential Cardiovascular Outcomes after Dipeptidyl Peptidase-4 Inhibitor, Sulfonylurea, and Pioglitazone Therapy, All in Combination with Metformin, for Type 2 Diabetes: A Population-Based Cohort Study	PLOS ONE			English	Article							PATIENTS PRESCRIBED SITAGLIPTIN; ORAL ANTIHYPERGLYCEMIC AGENTS; BLOOD-PRESSURE; MELLITUS; METAANALYSIS; SAFETY; DPP-4	Background/Objectives Data on the comparative effectiveness of oral antidiabetics on cardiovascular outcomes in a clinical practice setting are limited. This study sought to determine whether a differential risk of cardiovascular disease (CVD) exists for the combination of a dipeptidyl peptidase-4 (DPP-4) inhibitor plus metformin versus a sulfonylurea derivative plus metformin or pioglitazone plus metformin. Methods We conducted a cohort study of 349,476 patients who received treatment with a DPP-4 inhibitor, sulfonylurea, or pioglitazone plus metformin for type 2 diabetes using the Korean national health insurance claims database. The incidence of total CVD and individual outcomes of myocardial infarction (MI), heart failure (HF), and ischemic stroke (IS) were assessed using the hazard ratios (HRs) estimated from a Cox proportional-hazards model weighted for a propensity score. Results During follow-up, 3,881 patients developed a CVD, including 428 MIs, 212 HFs, and 1,487 ISs. The adjusted HR with 95% confidence interval (CI) for a sulfonylurea derivative plus metformin compared with a DPP-4 inhibitor plus metformin was 1.20 (1.09-1.32) for total CVD; 1.14 (1.04-1.91) for MI; 1.07 (0.71-1.62) for HF; and 1.51 (1.28-1.79) for IS. The HRs with 95% CI for total CVD, MI, HF, and IS for pioglitazone plus metformin were 0.89 (0.810.99), 1.05 (0.76-1.46), 4.81 (3.53-6.56), and 0.81 (0.67-0.99), respectively. Conclusions Compared with a DPP-4 inhibitor plus metformin, treatment with a sulfonylurea drug plus metformin was associated with increased risks of total CVD, MI, and IS, whereas the use of pioglitazone plus metformin was associated with decreased total CVD and IS risks.	[Seong, Jong-Mi; Park, Byung-Joo] Korea Inst Drug Safety & Risk Management, Off Drug Safety Informat 2, Seoul, South Korea; [Seong, Jong-Mi; Park, Byung-Joo] Seoul Natl Univ, Coll Med, Dept Prevent Med, Seoul, South Korea; [Choi, Nam-Kyong; Lee, Joongyub] Seoul Natl Univ, Coll Med, Seoul Natl Univ Hosp, Div Clin Epidemiol,Med Res Collaborating Ctr, Seoul, South Korea; [Choi, Nam-Kyong] Seoul Natl Univ, Med Res Ctr, Seoul, South Korea; [Shin, Ju-Young; Park, Byung-Joo] Korea Inst Drug Safety & Risk Management, Off Drug Utilizat Review, Seoul, South Korea; [Chang, Yoosoo] Sungkyunkwan Univ, Sch Med, Dept Occupat & Environm Med, Kangbuk Samsung Hosp, Seoul, South Korea; [Kim, Ye-Jee; Park, Byung-Joo] Korea Inst Drug Safety & Risk Management, Off Drug Safety Informat 1, Seoul, South Korea; [Kim, Ju-Young] Seoul Natl Univ, Dept Family Med, Bundang Hosp, Seoul, South Korea	Seoul National University (SNU); Seoul National University (SNU); Seoul National University Hospital; Seoul National University (SNU); Sungkyunkwan University (SKKU); Samsung Medical Center; Seoul National University (SNU); Seoul National University Hospital	Park, BJ (corresponding author), Korea Inst Drug Safety & Risk Management, Off Drug Safety Informat 2, Seoul, South Korea.	bjpark@snu.ac.kr	Kim, Ju Young/AAV-3029-2020	Kim, Ju Young/0000-0001-6018-3337; Choi, Nam-Kyong/0000-0003-1153-9928; Shin, Ju-Young/0000-0003-1010-7525; Chang, Yoosoo/0000-0002-6945-9050				[Anonymous], 2008, ACT PIOGL HYDR PROD; Brookhart MA, 2006, AM J EPIDEMIOL, V163, P1149, DOI 10.1093/aje/kwj149; Cai B, 2010, INT J CLIN PRACT, V64, P1601, DOI 10.1111/j.1742-1241.2010.02516.x; Choi NK, 2007, ANN PHARMACOTHER, V41, P667, DOI 10.1345/aph.1H247; Deacon CF, 2004, DIABETES, V53, P2181, DOI 10.2337/diabetes.53.9.2181; Drucker DJ, 2006, CELL METAB, V3, P153, DOI 10.1016/j.cmet.2006.01.004; Fadini GP, 2011, VASC PHARMACOL, V55, P10, DOI 10.1016/j.vph.2011.05.001; Fadini GP, 2010, DIABETES CARE, V33, P1607, DOI 10.2337/dc10-0187; Fox CS, 2007, CIRCULATION, V115, P1544, DOI 10.1161/CIRCULATIONAHA.106.658948; Fox CS, 2004, JAMA-J AM MED ASSOC, V292, P2495, DOI 10.1001/jama.292.20.2495; Franco OH, 2007, ARCH INTERN MED, V167, P1145, DOI 10.1001/archinte.167.11.1145; Frederich R, 2010, POSTGRAD MED, V122, P16, DOI 10.3810/pgm.2010.05.2138; Graham DJ, 2010, JAMA-J AM MED ASSOC, V304, P411, DOI 10.1001/jama.2010.920; Johansen OE, 2012, CARDIOVASC DIABETOL, V11, DOI 10.1186/1475-2840-11-3; Kimm H, 2012, KOREAN CIRC J, V42, P10, DOI 10.4070/kcj.2012.42.1.10; Korean Diabetes Association Health Insurance Review & Assessment Service, 2007, REP TASK FORC TEAM B; Kurth T, 2006, AM J EPIDEMIOL, V163, P262, DOI 10.1093/aje/kwj047; Mamdani M, 2005, BMJ-BRIT MED J, V330, P960, DOI 10.1136/bmj.330.7497.960; Matikainen N, 2006, DIABETOLOGIA, V49, P2049, DOI 10.1007/s00125-006-0340-2; Mistry GC, 2008, J CLIN PHARMACOL, V48, P592, DOI 10.1177/0091270008316885; Monami M, 2011, CURR MED RES OPIN, V27, P57, DOI 10.1185/03007995.2011.602964; Ogawa S, 2011, TOHOKU J EXP MED, V223, P133, DOI 10.1620/tjem.223.133; Park B., 2003, REPORT EVALUATION VA, P19; Park JK, 2000, KOREAN J PREV MED, V33, P76, DOI DOI 10.1161/01.STR.0000078562.82918.F6; Patrick AR, 2011, PHARMACOEPIDEM DR S, V20, P551, DOI 10.1002/pds.2098; Phung OJ, 2010, JAMA-J AM MED ASSOC, V303, P1410, DOI 10.1001/jama.2010.405; Pratley RE, 2007, CURR MED RES OPIN, V23, P919, DOI 10.1185/030079906X162746; Quan HD, 2005, MED CARE, V43, P1130, DOI 10.1097/01.mlr.0000182534.19832.83; Sato T, 2003, EPIDEMIOLOGY, V14, P680, DOI 10.1097/01.EDE.0000081989.82616.7d; Scirica BM, 2013, NEW ENGL J MED, V369, P1317, DOI 10.1056/NEJMoa1307684; Selva DM, 2009, ENDOCRINOLOGY, V150, P2183, DOI 10.1210/en.2008-1289; Seong JM, 2011, PHARMACOEPIDEM DR S, V20, P344, DOI 10.1002/pds.2112; Shah Z, 2011, CIRCULATION, V124, P2339, DOI 10.1161/CIRCULATIONAHA.111.041418; Sikka R, 2005, AM J MANAG CARE, V11, P453; Starcke S, 2006, GENES NUTR, V1, P177, DOI 10.1007/BF02829967; Tremblay AJ, 2011, DIABETES OBES METAB, V13, P366, DOI 10.1111/j.1463-1326.2011.01362.x; van Poppel PCM, 2011, DIABETES CARE, V34, P2072, DOI 10.2337/dc10-2421; White WB, 2013, NEW ENGL J MED, V369, P1327, DOI 10.1056/NEJMoa1305889; Wright A, 1998, ANN INTERN MED, V128, P165, DOI 10.7326/0003-4819-128-3-199802010-00001; Zhang QY, 2010, CURR MED RES OPIN, V26, P1697, DOI 10.1185/03007995.2010.489029	40	46	48	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 20	2015	10	5							e0124287	10.1371/journal.pone.0124287	http://dx.doi.org/10.1371/journal.pone.0124287			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CI7CV	25992614	Green Submitted, gold, Green Published			2023-01-03	WOS:000354921400016
J	Bos-Touwen, I; Schuurmans, M; Monninkhof, EM; Korpershoek, Y; Spruit-Bentvelzen, L; Ertugrul-van der Graaf, I; de Wit, N; Trappenburg, J				Bos-Touwen, Irene; Schuurmans, Marieke; Monninkhof, Evelyn M.; Korpershoek, Yvonne; Spruit-Bentvelzen, Lotte; Ertugrul-van der Graaf, Inge; de Wit, Niek; Trappenburg, Jaap			Patient and Disease Characteristics Associated with Activation for Self-Management in Patients with Diabetes, Chronic Obstructive Pulmonary Disease, Chronic Heart Failure and Chronic Renal Disease: A Cross-Sectional Survey Study	PLOS ONE			English	Article							PERCEIVED SOCIAL SUPPORT; DUTCH LANGUAGE VERSION; HEALTH SURVEY; MULTIDIMENSIONAL SCALE; DEPRESSION SCALE; HOSPITAL ANXIETY; SHORT-FORM; VALIDATION; POPULATION; IMPUTATION	A substantial proportion of chronic disease patients do not respond to self-management interventions, which suggests that one size interventions do not fit all, demanding more tailored interventions. To compose more individualized strategies, we aim to increase our understanding of characteristics associated with patient activation for self-management and to evaluate whether these are disease-transcending. A cross-sectional survey study was conducted in primary and secondary care in patients with type-2 Diabetes Mellitus (DM-II), Chronic Obstructive Pulmonary Disease (COPD), Chronic Heart Failure (CHF) and Chronic Renal Disease (CRD). Using multiple linear regression analysis, we analyzed associations between self-management activation (13-item Patient Activation Measure; PAM13) and a wide range of socio-demographic, clinical, and psychosocial determinants. Furthermore, we assessed whether the associations between the determinants and the PAM were disease-transcending by testing whether disease was an effect modifier. In addition, we identified determinants associated with low activation for self-management using logistic regression analysis. We included 1154 patients (53% response rate); 422 DM-II patients, 290 COPD patients, 223 HF patients and 219 CRD patients. Mean age was 69.6 +/- 10.9. Multiple linear regression analysis revealed 9 explanatory determinants of activation for self-management: age, BMI, educational level, financial distress, physical health status, depression, illness perception, social support and underlying disease, explaining a variance of 16.3%. All associations, except for social support, were disease transcending. This study explored factors associated with varying levels of activation for self-management. These results are a first step in supporting clinicians and researchers to identify subpopulations of chronic disease patients less likely to be engaged in self-management. Increased scientific efforts are needed to explain the greater part of the factors that contribute to the complex nature of patient activation for self-management.	[Bos-Touwen, Irene; Schuurmans, Marieke; Korpershoek, Yvonne; Spruit-Bentvelzen, Lotte; Ertugrul-van der Graaf, Inge; Trappenburg, Jaap] Univ Med Ctr Utrecht, Dept Rehabil Nursing Sci & Sports, Utrecht, Netherlands; [Monninkhof, Evelyn M.; de Wit, Niek] Univ Med Ctr Utrecht, Julius Ctr Hlth Sci & Primary Care, Utrecht, Netherlands	Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center	Bos-Touwen, I (corresponding author), Univ Med Ctr Utrecht, Dept Rehabil Nursing Sci & Sports, Utrecht, Netherlands.	I.D.Touwen-3@umcutrecht.nl		Trappenburg, Jaap/0000-0003-0489-7401	ZonMw, The Netherlands Organization for Health Research and Development [520001002]	ZonMw, The Netherlands Organization for Health Research and Development(Netherlands Organization for Health Research and DevelopmentNetherlands Government)	This project was funded by ZonMw, The Netherlands Organization for Health Research and Development, Grant 520001002. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aaronson NK, 1998, J CLIN EPIDEMIOL, V51, P1055, DOI 10.1016/S0895-4356(98)00097-3; Ahola AJ, 2013, DIABETIC MED, V30, P413, DOI 10.1111/dme.12105; Alwan A, 2011, GLOBAL STATUS REPORT ON NONCOMMUNICABLE DISEASES 2010, P9; BANDURA A, 1977, PSYCHOL REV, V84, P191, DOI 10.1037/0033-295X.84.2.191; Barlow J, 2002, PATIENT EDUC COUNS, V48, P177, DOI 10.1016/S0738-3991(02)00032-0; Cameron J, 2009, HEART LUNG, V38, P410, DOI 10.1016/j.hrtlng.2008.11.004; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Connelly C E, 1993, Clin Nurse Spec, V7, P247; de Raaij EJ, 2012, MANUAL THER, V17, P330, DOI 10.1016/j.math.2012.03.001; Deakin T, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003417.pub2; Disler RT, 2012, INT J NURS STUD, V49, P230, DOI 10.1016/j.ijnurstu.2011.11.005; Donders ART, 2006, J CLIN EPIDEMIOL, V59, P1087, DOI 10.1016/j.jclinepi.2006.01.014; Effing T, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002990.pub2; Feil DG, 2012, J BEHAV MED, V35, P190, DOI 10.1007/s10865-011-9344-6; Gallant MP, 2003, HEALTH EDUC BEHAV, V30, P170, DOI 10.1177/1090198102251030; Harel O, 2008, THE ESTIMATION OF R2; Hibbard JH, 2005, HEALTH SERV RES, V40, P1918, DOI 10.1111/j.1475-6773.2005.00438.x; Hibbard JH, 2004, HEALTH SERV RES, V39, P1005, DOI 10.1111/j.1475-6773.2004.00269.x; Hibbard JH, 2007, HEALTH SERV RES, V42, P1443, DOI 10.1111/j.1475-6773.2006.00669.x; IBM Corp, 2011, RELEASED 2011 IBM SP; Insignia Health, 2011, PATIENT ACTIVATION M; Jovicic Aleksandra, 2006, BMC Cardiovasc Disord, V6, P43, DOI 10.1186/1471-2261-6-43; Mathers CD, 2006, PLOS MED, V3, DOI 10.1371/journal.pmed.0030442; Mols F, 2009, QUAL LIFE RES, V18, P403, DOI 10.1007/s11136-009-9455-5; Moons KGM, 2006, J CLIN EPIDEMIOL, V59, P1092, DOI 10.1016/j.jclinepi.2006.01.009; Nam S, 2011, DIABETES RES CLIN PR, V93, P1, DOI 10.1016/j.diabres.2011.02.002; Nici Linda, 2014, Ann Am Thorac Soc, V11, P101, DOI 10.1513/AnnalsATS.201306-150FR; Pedersen SS, 2009, PSYCHOSOMATICS, V50, P461, DOI 10.1176/appi.psy.50.5.461; Peduzzi P, 1996, J CLIN EPIDEMIOL, V49, P1373, DOI 10.1016/S0895-4356(96)00236-3; Prochaska JO, 1997, AM J HEALTH PROMOT, V12, P38, DOI 10.4278/0890-1171-12.1.38; Rademakers J, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-577; Rask KJ, 2009, DIABETES EDUCATOR, V35, P622, DOI 10.1177/0145721709335004; Rockwell JM, 2001, HEART LUNG, V30, P18, DOI 10.1067/mhl.2001.112503; Rose M, 2002, DIABETES CARE, V25, P35, DOI 10.2337/diacare.25.1.35; Siabani S, 2013, SPRINGERPLUS, V2, DOI 10.1186/2193-1801-2-320; Spinhoven P, 1997, PSYCHOL MED, V27, P363, DOI 10.1017/S0033291796004382; Sundararajan V, 2004, J CLIN EPIDEMIOL, V57, P1288, DOI 10.1016/j.jclinepi.2004.03.012; Trappenburg J, 2013, PATIENT EDUC COUNS, V92, P134, DOI 10.1016/j.pec.2013.02.009; Valderas JM, 2009, ANN FAM MED, V7, P357, DOI 10.1370/afm.983; Vergouwe Y, 2010, J CLIN EPIDEMIOL, V63, P205, DOI 10.1016/j.jclinepi.2009.03.017; Ware JE, 1996, MED CARE, V34, P220, DOI 10.1097/00005650-199603000-00003; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x; ZIMET GD, 1990, J PERS ASSESS, V55, P610, DOI 10.1207/s15327752jpa5503&4_17	43	124	130	3	42	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 7	2015	10	5							e0126400	10.1371/journal.pone.0126400	http://dx.doi.org/10.1371/journal.pone.0126400			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	CH7KF	25950517	Green Submitted, Green Published, gold			2023-01-03	WOS:000354214400088
J	Bello, ML; Junior, AM; Vieira, BA; Dias, LRS; de Sousa, VP; Castro, HC; Rodrigues, CR; Cabral, LM				Bello, Murilo L.; Junior, Aridio M.; Vieira, Barbara A.; Dias, Luiza R. S.; de Sousa, Valeria P.; Castro, Helena C.; Rodrigues, Carlos R.; Cabral, Lucio M.			Sodium Montmorillonite/Amine-Containing Drugs Complexes: New Insights on Intercalated Drugs Arrangement into Layered Carrier Material	PLOS ONE			English	Article							HEAD GROUP-STRUCTURE; MOLECULAR-DYNAMICS; CLAY-MINERALS; FORCE-FIELD; NANOCOMPOSITES; 5-FLUOROURACIL; DELIVERY; SIMULATION; DENSITY; SURFACE	Layered drug delivery carriers are current targets of nanotechnology studies since they are able to accommodate pharmacologically active substances and are effective at modulating drug release. Sodium montmorillonite (Na-MMT) is a clay that has suitable properties for developing new pharmaceutical materials due to its high degree of surface area and high capacity for cation exchange. Therefore Na-MMT is a versatile material for the preparation of new drug delivery systems, especially for slow release of protonable drugs. Herein, we describe the intercalation of several amine-containing drugs with Na-MMT so we can derive a better understanding of how these drugs molecules interact with and distribute throughout the Na-MMT interlayer space. Therefore, for this purpose nine sodium montmorillonite/amine-containing drugs complexes (Na-MMT/drug) were prepared and characterized. In addition, the physicochemical properties of the drugs molecules in combination with different experimental conditions were assessed to determine how these factors influenced experimental outcomes (e.g. increase of the interlayer spacing versus drugs arrangement and orientation). We also performed a molecular modeling study of these amine-containing drugs associated with different Na-MMT/drug complex models to analyze the orientation and arrangement of the drugs molecules in the complexes studied. Six amine-containing drugs (rivastigmine, doxazosin, 5-fluorouracil, chlorhexidine, dapsone, nystatin) were found to successfully intercalate Na-MMT. These findings provide important insights on the interlayer aspect of the molecular systems formed and may contribute to produce more efficient drug delivery nanosystems.	[Bello, Murilo L.; Vieira, Barbara A.; Rodrigues, Carlos R.] Univ Fed Rio de Janeiro, Fac Farm, Lab Modelagem Mol & QSAR ModMolQSAR, Rio De Janeiro, RJ, Brazil; [Junior, Aridio M.; de Sousa, Valeria P.; Cabral, Lucio M.] Univ Fed Rio de Janeiro, Fac Farm, Lab Tecnol Farmaceut Ind LabTIF, Rio De Janeiro, RJ, Brazil; [Dias, Luiza R. S.] Univ Fed Fluminense, Fac Farm, Lab Quim Med LQMed, Niteroi, RJ, Brazil; [Castro, Helena C.] Univ Fed Fluminense, Inst Biol, LABiEMol, Niteroi, RJ, Brazil	Universidade Federal do Rio de Janeiro; Universidade Federal do Rio de Janeiro; Universidade Federal Fluminense; Universidade Federal Fluminense	Cabral, LM (corresponding author), Univ Fed Rio de Janeiro, Fac Farm, Lab Tecnol Farmaceut Ind LabTIF, Rio De Janeiro, RJ, Brazil.	lmcabral@pharma.ufrj.br	Abrahim-Vieira, Bárbara/ABE-8450-2021; Mattos Junior, Aridio/AAE-4666-2022; Dias, Luiza R S/X-2847-2018; Rodrigues, Carlos Rangel/Q-2316-2019; Cabral, Lucio Mendes/Q-3120-2019; Castro, Helena/V-2137-2019; de sousa, valeria/K-7180-2012	Dias, Luiza R S/0000-0001-5809-5602; Rodrigues, Carlos Rangel/0000-0001-8453-7654; de sousa, valeria/0000-0003-1589-0846; Castro, Helena Carla/0000-0001-5283-1541	Fundacao de Amparo a Pesquisa do Estado do Rio de Janeiro (FAPERJ); Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq); Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)	Fundacao de Amparo a Pesquisa do Estado do Rio de Janeiro (FAPERJ)(Fundacao Carlos Chagas Filho de Amparo a Pesquisa do Estado do Rio De Janeiro (FAPERJ)); Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq)(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)); Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)(Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES))	Financial support and fellowships from Fundacao de Amparo a Pesquisa do Estado do Rio de Janeiro (FAPERJ), Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq), and Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES) were received for this study. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aguzzi C, 2007, APPL CLAY SCI, V36, P22, DOI 10.1016/j.clay.2006.06.015; Arruebo M, 2012, WIRES NANOMED NANOBI, V4, P16, DOI 10.1002/wnan.132; Bar-On P, 2002, BIOCHEMISTRY-US, V41, P3555, DOI 10.1021/bi020016x; Bello ML, 2011, BIOORGAN MED CHEM, V19, P5046, DOI 10.1016/j.bmc.2011.06.023; BERENDSEN HJC, 1984, J CHEM PHYS, V81, P3684, DOI 10.1063/1.448118; Bongur R, 2010, J PHYS CHEM C, V114, P752, DOI 10.1021/jp907051f; Carretero MI, 2002, APPL CLAY SCI, V21, P155, DOI 10.1016/S0169-1317(01)00085-0; Choi YS, 2004, CHEM MATER, V16, P2522, DOI 10.1021/cm0348601; Cygan RT, 2012, J PHYS CHEM C, V116, P13079, DOI 10.1021/jp3007574; Cygan RT, 2009, J MATER CHEM, V19, P2470, DOI 10.1039/b819076c; Ewald PP, 1921, ANN PHYS-BERLIN, V64, P253; Fu YT, 2010, CHEM MATER, V22, P1595, DOI 10.1021/cm902784r; Funk RS, 2012, MOL PHARMACEUT, V9, P1384, DOI 10.1021/mp200641e; Ganguly S, 2011, J THERM ANAL CALORIM, V105, P199, DOI 10.1007/s10973-011-1356-5; Halgren TA, 1996, J COMPUT CHEM, V17, P490, DOI [10.1002/(SICI)1096-987X(199604)17:5/6<490::AID-JCC1>3.0.CO;2-P, 10.1002/(SICI)1096-987X(199604)17:5/6<616::AID-JCC5>3.0.CO;2-X]; Heinz H, 2005, CHEM MATER, V17, P5658, DOI 10.1021/cm0509328; Heinz H, 2012, CLAY MINER, V47, P205, DOI 10.1180/claymin.2012.047.2.05; Heinz H, 2006, J CHEM PHYS, V124, DOI 10.1063/1.2202330; Heinz H, 2007, CHEM MATER, V19, P59, DOI 10.1021/cm062019s; HESTENES MR, 1952, J RES NAT BUR STAND, V49, P409, DOI 10.6028/jres.049.044; Holesova S, 2009, J MOL STRUCT, V923, P85, DOI 10.1016/j.molstruc.2009.02.005; Jha KC, 2013, J PHYS CHEM C, V117, P25969, DOI 10.1021/jp4032404; Joshi GV, 2009, APPL CLAY SCI, V45, P248, DOI 10.1016/j.clay.2009.06.001; Joshi GV, 2009, INT J PHARMACEUT, V374, P53, DOI 10.1016/j.ijpharm.2009.03.004; Kevadiya BD, 2012, EUR J PHARM BIOPHARM, V81, P91, DOI 10.1016/j.ejpb.2012.01.004; Krishnan M, 2013, J PHYS CHEM C, V117, P20592, DOI 10.1021/jp405321t; Lemmer H, 2012, CRYST GROWTH DES, V12, P1683, DOI 10.1021/cg300019f; Lin FH, 2002, BIOMATERIALS, V23, P1981, DOI 10.1016/S0142-9612(01)00325-8; Lopes S, 2002, J PHYS CHEM B, V106, P7278, DOI 10.1021/jp020160s; Markova N, 2010, J PHYS CHEM A, V114, P13154, DOI 10.1021/jp1063879; Meng N, 2009, INT J PHARMACEUT, V382, P45, DOI 10.1016/j.ijpharm.2009.08.004; Murray HH, 2000, APPL CLAY SCI, V17, P207, DOI 10.1016/S0169-1317(00)00016-8; Polizos G, 2013, J PHYS CHEM B, V117, P13667, DOI 10.1021/jp4067845; Pupe CG, 2011, INT J NANOMED, V6, P2581, DOI 10.2147/IJN.S25667; Ranade A, 2002, POLYMER, V43, P3759, DOI 10.1016/S0032-3861(02)00106-4; Rocha GB, 2006, J COMPUT CHEM, V27, P1101, DOI 10.1002/jcc.20425; Scocchi G, 2007, J PHYS CHEM B, V111, P2143, DOI 10.1021/jp067649w; Segad M, 2012, J PHYS CHEM C, V116, P7596, DOI 10.1021/jp300531y; Shaw YJ, 2004, J MED CHEM, V47, P4453, DOI 10.1021/jm049752k; Toth R, 2004, POLYMER, V45, P8075, DOI 10.1016/j.polymer.2004.09.025; TSIPURSKY SI, 1984, CLAY MINER, V19, P177, DOI 10.1180/claymin.1984.019.2.05; Viseras C, 2010, APPL CLAY SCI, V48, P291, DOI 10.1016/j.clay.2010.01.007; Wungu TDK, 2011, J NANOSCI NANOTECHNO, V11, P2793, DOI 10.1166/jnn.2011.3913; Xu Y, 2013, MINER ENG, V53, P101, DOI 10.1016/j.mineng.2013.07.006; Yang D, 2007, J THERM ANAL CALORIM, V89, P847, DOI 10.1007/s10973-006-8318-3; Zheng JP, 2007, J WUHAN UNIV TECHNOL, V22, P250, DOI 10.1007/s11595-005-2250-4	46	29	31	0	31	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 24	2015	10	3							e0121110	10.1371/journal.pone.0121110	http://dx.doi.org/10.1371/journal.pone.0121110			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CH2XV	25803292	gold, Green Published, Green Submitted			2023-01-03	WOS:000353889600126
J	Estill, J; Salazar-Vizcaya, L; Blaser, N; Egger, M; Keiser, O				Estill, Janne; Salazar-Vizcaya, Luisa; Blaser, Nello; Egger, Matthias; Keiser, Olivia			The Cost-Effectiveness of Monitoring Strategies for Antiretroviral Therapy of HIV Infected Patients in Resource-Limited Settings: Software Tool	PLOS ONE			English	Article							CD4 CELL COUNT; VIRAL LOAD; SOUTHERN AFRICA; TRANSMISSION; ADHERENCE; PROGRAMS; OUTCOMES; MALAWI; COHORT; ADULTS	Background The cost-effectiveness of routine viral load (VL) monitoring of HIV-infected patients on anti-retroviral therapy (ART) depends on various factors that differ between settings and across time. Low-cost point-of-care (POC) tests for VL are in development and may make routine VL monitoring affordable in resource-limited settings. We developed a software tool to study the cost-effectiveness of switching to second-line ART with different monitoring strategies, and focused on POC-VL monitoring. Methods We used a mathematical model to simulate cohorts of patients from start of ART until death. We modeled 13 strategies (no 2nd-line, clinical, CD4 (with or without targeted VL), POC-VL, and laboratory-based VL monitoring, with different frequencies). We included a scenario with identical failure rates across strategies, and one in which routine VL monitoring reduces the risk of failure. We compared lifetime costs and averted disability-adjusted life-years (DALYs). We calculated incremental cost-effectiveness ratios (ICER). We developed an Excel tool to update the results of the model for varying unit costs and cohort characteristics, and conducted several sensitivity analyses varying the input costs. Results Introducing 2nd-line ART had an ICER of US$1651-1766/DALY averted. Compared with clinical monitoring, the ICER of CD4 monitoring was US$1896-US$5488/DALY averted and VL monitoring US$951-US$5813/DALY averted. We found no difference between POC- and laboratory-based VL monitoring, except for the highest measurement frequency (every 6 months), where laboratory-based testing was more effective. Targeted VL monitoring was on the cost-effectiveness frontier only if the difference between 1st- and 2nd-line costs remained large, and if we assumed that routine VL monitoring does not prevent failure. Conclusion Compared with the less expensive strategies, the cost-effectiveness of routine VL monitoring essentially depends on the cost of 2nd-line ART. Our Excel tool is useful for determining optimal monitoring strategies for specific settings, with specific sex-and age-distributions and unit costs.	[Estill, Janne; Salazar-Vizcaya, Luisa; Blaser, Nello; Egger, Matthias; Keiser, Olivia] Univ Bern, Inst Social & Prevent Med, Bern, Switzerland; [Egger, Matthias] Univ Cape Town, Ctr Infect Dis Epidemiol & Res, ZA-7925 Cape Town, South Africa	University of Bern; University of Cape Town	Estill, J (corresponding author), Univ Bern, Inst Social & Prevent Med, Bern, Switzerland.	janne.estill@ispm.unibe.ch	Blaser, Nello/V-1028-2019	Blaser, Nello/0000-0001-9489-1657; Egger, Matthias/0000-0001-7462-5132; Keiser, Olivia/0000-0001-8191-2789; Salazar-Vizcaya, Luisa/0000-0003-0527-0141	UNITAID; National Institutes of Health (NIH) [U01AI069924]; Swiss National Science Foundation [32333B_131629, PDFMP3_137106]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI069924] Funding Source: NIH RePORTER	UNITAID; National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	UNITAID, www.unitaid.eu; National Institutes of Health (NIH), grant U01AI069924; Swiss National Science Foundation, grants 32333B_131629 and PDFMP3_137106. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Actuarial Society of South Africa, 2011, ASSA2008 MOD; Bendavid E, 2008, ARCH INTERN MED, V168, P1910, DOI 10.1001/archinternmed.2008.1; Bishai D, 2007, AIDS, V21, P1333, DOI 10.1097/QAD.0b013e328137709e; Blaser N, 2014, J STAT SOFT IN PRESS; Bonner K, 2013, JAIDS-J ACQ IMM DEF, V64, P74, DOI 10.1097/QAI.0b013e31829f05ac; Braithwaite RS, 2011, J INT AIDS SOC, V14, DOI 10.1186/1758-2652-14-38; Brinkhof MWG, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000066; Chimbwandira F, 2013, MMWR-MORBID MORTAL W, V62, P148; Egger M, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1000390; Estill J, 2014, JAIDS-J ACQ IMM DEF, V65, pE179, DOI 10.1097/QAI.0000000000000075; Estill J, 2013, AIDS, V27, P1483, DOI 10.1097/QAD.0b013e328360a4e5; Estill J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057611; Estill J, 2012, AIDS, V26, P1403, DOI 10.1097/QAD.0b013e3283536988; Granich RM, 2009, LANCET, V373, P48, DOI 10.1016/S0140-6736(08)61697-9; Gupta RK, 2014, CLIN INFECT DIS, V58, P1023, DOI 10.1093/cid/cit933; Hamers RL, 2012, AIDS, V26, P1663, DOI 10.1097/QAD.0b013e3283560678; Hoffmann CJ, 2009, CLIN INFECT DIS, V49, P1928, DOI 10.1086/648444; International Diabetes Federation, 2013, IDF DIABETES ATLAS, V6th ed.; International Monetary Fund, 2014, WORLD ECONOMIC AND F; Jani IV, 2011, LANCET, V378, P1572, DOI 10.1016/S0140-6736(11)61052-0; Joint United Nations Programme on HIV/AIDS (UNAIDS) and Medecines Sans Frontieres (MSF), 2012, SPEED SCAL UP STRAT; Kahn JG, 2011, BRIT MED J, V343, DOI 10.1136/bmj.d6884; Keebler D, 2014, LANCET GLOB HEALTH, V2, pE35, DOI 10.1016/S2214-109X(13)70048-2; Kimmel AD, 2010, JAIDS-J ACQ IMM DEF, V54, P258, DOI 10.1097/QAI.0b013e3181d0db97; Maggiolo F, 2007, HIV CLIN TRIALS, V8, P282, DOI 10.1310/hct0805-282; Mermin J, 2011, BRIT MED J, V343, DOI 10.1136/bmj.d6792; Orrell C, 2007, ANTIVIR THER, V12, P83; Phillips AN, 2008, LANCET, V371, P1443, DOI 10.1016/S0140-6736(08)60624-8; Rousseau C, 2012, HIV POINT CARE VIRAL; Salazar Vizcaya L, 2014, GEMS GEN MULTISTATE; Tweya H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075761; UNITAID, 2013, HIV AIDS DIAGN TECHN; Vijayaraghavan A, 2007, JAIDS-J ACQ IMM DEF, V46, P91; Walensky RP, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000382; Walensky RP, 2010, CLIN INFECT DIS, V51, P85, DOI 10.1086/653119; Wandeler G, 2012, JAIDS-J ACQ IMM DEF, V59, pE9, DOI 10.1097/QAI.0b013e31823edb6a; WHO, 2001, MACR HLTH INV HLTH E; World Health Organization, 2004, GLOB BURD DIS 2004 U; Zoufaly A, 2014, J ANTIMICRO IN PRESS	39	7	7	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 20	2015	10	3							e0119299	10.1371/journal.pone.0119299	http://dx.doi.org/10.1371/journal.pone.0119299			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CE8IA	25793531	Green Published			2023-01-03	WOS:000352084200070
J	Lawrence, M; Pringle, J; Kerr, S; Booth, J; Govan, L; Roberts, NJ				Lawrence, Maggie; Pringle, Jan; Kerr, Susan; Booth, Joanne; Govan, Lindsay; Roberts, Nicola J.			Multimodal Secondary Prevention Behavioral Interventions for TIA and Stroke: A Systematic Review and Meta-Analysis	PLOS ONE			English	Article							TRANSIENT ISCHEMIC ATTACK; RISK-FACTOR MODIFICATION; CARDIOVASCULAR-DISEASE; BLOOD-PRESSURE; MINOR STROKE; FOLLOW-UP; MANAGEMENT; PROGRAM; CARE; HEALTH	Background Guidelines recommend implementation of multimodal interventions to help prevent recurrent TIA/stroke. We undertook a systematic review to assess the effectiveness of behavioral secondary prevention interventions. Strategy Searches were conducted in 14 databases, including MEDLINE (1980-January 2014). We included randomized controlled trials (RCTs) testing multimodal interventions against usual care/modified usual care. All review processes were conducted in accordance with Cochrane guidelines. Results Twenty-three papers reporting 20 RCTs (6,373 participants) of a range of multimodal behavioral interventions were included. Methodological quality was generally low. Meta-analyses were possible for physiological, lifestyle, psychosocial and mortality/recurrence outcomes. Note: all reported confidence intervals are 95%. Systolic blood pressure was reduced by 4.21 mmHg (mean) (-6.24 to -2.18, P = 0.01 I-2 = 58%, 1,407 participants); diastolic blood pressure by 2.03 mmHg (mean) (-3.19 to -0.87, P = 0.004, I-2 = 52%, 1,407 participants). No significant changes were found for HDL, LDL, total cholesterol, fasting blood glucose, high sensitivity-CR, BMI, weight or waist: hip ratio, although there was a significant reduction in waist circumference (-6.69 cm, -11.44 to -1.93, P = 0.006, I-2 = 0%, 96 participants). There was no significant difference in smoking continuance, or improved fruit and vegetable consumption. There was a significant difference in compliance with antithrombotic medication (OR 1.45, 1.21 to 1.75, P< 0.0001, I-2 = 0%, 2,792 participants) and with statins (OR 2.53, 2.15 to 2.97, P< 0.00001, I-2 = 0%, 2,636 participants); however, there was no significant difference in compliance with antihypertensives. There was a significant reduction in anxiety (-1.20, -1.77 to -0.63, P< 0.0001, I-2 = 85%, 143 participants). Although there was no significant difference in odds of death or recurrent TIA/stroke, there was a significant reduction in the odds of cardiac events (OR 0.38, 0.16 to 0.88, P = 0.02, I-2 = 0%, 4,053 participants). Conclusions There are benefits to be derived from multimodal secondary prevention interventions. However, the findings are complex and should be interpreted with caution. Further, high quality trials providing comprehensive detail of interventions and outcomes, are required.	[Lawrence, Maggie; Kerr, Susan; Booth, Joanne; Roberts, Nicola J.] Glasgow Caledonian Univ, Inst Appl Hlth Res, Glasgow G4 0BA, Lanark, Scotland; [Pringle, Jan] Univ Dundee, Sch Educ Social Work & Community Educ, Dundee DD1 4HN, Scotland; [Govan, Lindsay] Univ Glasgow, Hlth Econ & Hlth Technol Assessment, Inst Hlth & Wellbeing, Glasgow, Lanark, Scotland	Glasgow Caledonian University; University of Dundee; University of Glasgow	Lawrence, M (corresponding author), Glasgow Caledonian Univ, Inst Appl Hlth Res, Glasgow G4 0BA, Lanark, Scotland.	maggie.lawrence@gcu.ac.uk	Roberts, Nicola/AAJ-5784-2021; Lawrence, Maggie/E-7722-2010	Roberts, Nicola/0000-0002-7589-8113; Lawrence, Maggie/0000-0002-1685-4639; Booth, Joanne/0000-0002-7870-6391	Stroke Association; Stroke Association [TSA SRTF 2011/02]; Medical Research Council [MR/J012459/1] Funding Source: researchfish; Stroke Association [TSASRTF2011/02] Funding Source: researchfish; MRC [MR/J012459/1] Funding Source: UKRI	Stroke Association; Stroke Association; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); Stroke Association; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	This review was undertaken as part of the Stroke Association Senior Research Training Fellowship (2012-2015) held by Dr. Maggie Lawrence. Dr. Pringle's post was funded by the fellowship. Stroke Association: http://www.stroke.org.uk/. Project Ref No: TSA SRTF 2011/02. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adie K, 2010, AGE AGEING, V39, P598, DOI 10.1093/ageing/afq085; Allen K, 2009, J STROKE CEREBROVASC, V18, P443, DOI 10.1016/j.jstrokecerebrovasdis.2009.02.002; [Anonymous], 2008, MAN PAT STROK TIA AS; Bandura A, 2004, HEALTH EDUC BEHAV, V31, P143, DOI 10.1177/1090198104263660; Banet G A, 1997, J Vasc Nurs, V15, P29, DOI 10.1016/S1062-0303(97)90050-9; Campbell SC, 2008, ATHEROSCLEROSIS, V201, P225, DOI 10.1016/j.atherosclerosis.2008.04.046; Chanruengvanich W, 2006, THAI J NURSING RES, V10, P165; Damush TM, 2011, TRANSL BEHAV MED, V1, P561, DOI 10.1007/s13142-011-0070-y; Dixon A., 2008, MOTIVATION CONFIDENC; Eames S, 2013, BMJ OPEN, V3, DOI 10.1136/bmjopen-2012-002538; Ellis G, 2005, AGE AGEING, V34, P389, DOI 10.1093/ageing/afi075; Faulkner J, 2013, NZ MED J, V125, P68; Faulkner J, 2013, J STROKE CEREBROVASC, V22, pE388, DOI 10.1016/j.jstrokecerebrovasdis.2013.04.014; Flemming Kelly D, 2013, Hosp Pract (1995), V41, P70, DOI 10.3810/hp.2013.08.1070; Gillham S, 2010, CLIN REHABIL, V24, P822, DOI 10.1177/0269215510367970; Goldfinger JZ, 2012, CONTEMP CLIN TRIALS, V33, P1065, DOI 10.1016/j.cct.2012.06.003; Goldstein LB, 2006, STROKE, V37, P1583, DOI 10.1161/01.STR.0000223048.70103.F1; HATANO S, 1976, B WORLD HEALTH ORGAN, V54, P541; Hoffmann TC, 2013, BMJ-BRIT MED J, V347, DOI 10.1136/bmj.f3755; Hornnes N, 2011, J STROKE CEREBROVASC, V20, P16, DOI 10.1016/j.jstrokecerebrovasdis.2009.10.002; Horowitz CR, 2013, STROKE, V44; Johnston SC, 2009, LANCET NEUROL, V8, P345, DOI 10.1016/S1474-4422(09)70023-7; Joubert J, 2006, J CLIN NEUROSCI, V13, P84, DOI 10.1016/j.jocn.2005.07.003; Joubert J, 2009, J NEUROL NEUROSUR PS, V80, P279, DOI 10.1136/jnnp.2008.148122; Kernan WN, 2014, STROKE, V45, P2160, DOI 10.1161/STR.0000000000000024; Kirk H, 2014, CLIN REHABIL, V28, P339, DOI 10.1177/0269215513502211; Kono Y, 2013, CEREBROVASC DIS, V36, P88, DOI 10.1159/000352052; Lawrence M, 2014, CEREBROVASC DIS, V37, DOI [10.1159/000362854, DOI 10.1159/000362854]; Lawrence M, 2013, INT J STROKE, V8, P465, DOI 10.1111/ijs.12135; Lawrence M, 2013, DISABIL REHABIL, V35, P586, DOI 10.3109/09638288.2012.711895; Lawrence Maggie, 2011, JBI Libr Syst Rev, V9, P1782; Lawrence M, 2012, INT J STROKE, V7, P243, DOI 10.1111/j.1747-4949.2012.00771.x; Lennon O, 2013, EUR J PREV CARDIOL, P1; Maasland L, 2007, CEREBROVASC DIS, V23, P435, DOI 10.1159/000101468; Macdonald Geraldine, 2012, Cochrane Database Syst Rev, pCD001930, DOI 10.1002/14651858.CD001930.pub3; McManus JA, 2009, CLIN REHABIL, V23, P99, DOI 10.1177/0269215508095874; Mendis S., 2011, GLOB ATL CARD DIS PR; Michie S, 2011, IMPLEMENT SCI, V6, DOI 10.1186/1748-5908-6-42; Mohan KM, 2011, STROKE, V42, P1489, DOI 10.1161/STROKEAHA.110.602615; Moher David, 2009, BMJ, V339, pb2535, DOI [10.1016/j.ijsu.2010.02.007, 10.1136/bmj.b2535]; National Cancer Institute, 2005, THEOR GLANC GUID HLT; National Institute for Health and Clinical Excellence, 2006, BRIEF INT REF SMOK C; National Institute for Health and Clinical Excellence, 2007, BEHAVIOUR CHANGE THE; Negron R., 2014, COMMUNICATION; O'Carroll R, 2011, ANN BEHAV MED, V41, P383, DOI 10.1007/s12160-010-9257-6; O'Donnell MJ, 2010, LANCET, V376, P112, DOI 10.1016/S0140-6736(10)60834-3; Ostlund U, 2014, J FAM NURS, V20, P259, DOI 10.1177/1074840714542962; Peng B, 2014, STROKE, V45, P515, DOI 10.1161/STROKEAHA.113.001424; PROCHASKA JO, 1983, J CONSULT CLIN PSYCH, V51, P390, DOI 10.1037//0022-006X.51.3.390; PROGRESS Collaborat Grp, 2001, LANCET, V358, P1556; Redfern J, 2006, STROKE, V37, P2410, DOI 10.1161/01.STR.0000237097.00342.a9; Richardson WS., 1995, ACP J CLUB, V3, pA12, DOI DOI 10.7326/ACPJC-1995-123-3-A12; Scottish Intercollegiate Guidelines Network (SIGN), SIGN 97 RISK EST PRE; Sharma M, 2008, THEORETICAL FDN HLTH; Sit JWH, 2007, J CLIN NURS, V16, P272, DOI 10.1111/j.1365-2702.2005.01522.x; Strong K, 2007, LANCET NEUROL, V6, P182, DOI 10.1016/S1474-4422(07)70031-5; The Cochrane Collaboration, 2008, REV MAN REVMAN COMP; van Nes M, 2010, J AM ACAD NURSE PRAC, V22, P654, DOI 10.1111/j.1745-7599.2010.00561.x; Visser-Meily A, 2006, DISABIL REHABIL, V28, P1557, DOI 10.1080/09638280600648215; Wolfe CDA, 2010, STROKE, V41, P2470, DOI 10.1161/STROKEAHA.110.588046; Wood DA, 2008, LANCET, V371, P1999, DOI 10.1016/S0140-6736(08)60868-5; Wright LM, 2005, NURSES AND FAMILIES; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	64	50	52	3	24	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 20	2015	10	3							e0120902	10.1371/journal.pone.0120902	http://dx.doi.org/10.1371/journal.pone.0120902			25	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	CE8HY	25793643	Green Accepted, Green Published, gold			2023-01-03	WOS:000352083900087
J	Turner, NC; Ro, J; Andre, F; Loi, S; Verma, S; Iwata, H; Harbeck, N; Loibl, S; Bartlett, CH; Zhang, K; Giorgetti, C; Randolph, S; Koehler, M; Cristofanilli, M				Turner, Nicholas C.; Ro, Jungsil; Andre, Fabrice; Loi, Sherene; Verma, Sunil; Iwata, Hiroji; Harbeck, Nadia; Loibl, Sibylle; Bartlett, Cynthia Huang; Zhang, Ke; Giorgetti, Carla; Randolph, Sophia; Koehler, Maria; Cristofanilli, Massimo			Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							4/6 INHIBITOR PALBOCICLIB; ESTROGEN-RECEPTOR; CYCLIN D; FULVESTRANT; COMBINATION; MUTATIONS; TARGET	BACKGROUND Growth of hormone-receptor-positive breast cancer is dependent on cyclin-dependent kinases 4 and 6 (CDK4 and CDK6), which promote progression from the G1 phase to the S phase of the cell cycle. We assessed the efficacy of palbociclib (an inhibitor of CDK4 and CDK6) and fulvestrant in advanced breast cancer. METHODS This phase 3 study involved 521 patients with advanced hormone-receptor-positive, human epidermal growth factor receptor 2-negative breast cancer that had relapsed or progressed during prior endocrine therapy. We randomly assigned patients in a 2: 1 ratio to receive palbociclib and fulvestrant or placebo and fulvestrant. Premenopausal or perimenopausal women also received goserelin. The primary end point was investigator-assessed progression-free survival. Secondary end points included overall survival, objective response, rate of clinical benefit, patient-reported outcomes, and safety. A preplanned interim analysis was performed by an independent data and safety monitoring committee after 195 events of disease progression or death had occurred. RESULTS The median progression-free survival was 9.2 months (95% confidence interval [CI], 7.5 to not estimable) with palbociclib-fulvestrant and 3.8 months (95% CI, 3.5 to 5.5) with placebo-fulvestrant (hazard ratio for disease progression or death, 0.42; 95% CI, 0.32 to 0.56; P<0.001). The most common grade 3 or 4 adverse events in the palbociclib-fulvestrant group were neutropenia (62.0%, vs. 0.6% in the placebo-fulvestrant group), leukopenia (25.2% vs. 0.6%), anemia (2.6% vs. 1.7%), thrombocytopenia (2.3% vs. 0%), and fatigue (2.0% vs. 1.2%). Febrile neutropenia was reported in 0.6% of palbociclib-treated patients and 0.6% of placebo-treated patients. The rate of discontinuation due to adverse events was 2.6% with palbociclib and 1.7% with placebo. CONCLUSIONS Among patients with hormone-receptor-positive metastatic breast cancer who had progression of disease during prior endocrine therapy, palbociclib combined with fulvestrant resulted in longer progression-free survival than fulvestrant alone.	[Turner, Nicholas C.] Royal Marsden Hosp, London SW3 6JJ, England; [Ro, Jungsil] Natl Canc Ctr, Goyang Si, South Korea; [Andre, Fabrice] Inst Gustave Roussy, Villejuif, France; [Loi, Sherene] Univ Melbourne, Peter MacCallum Canc Ctr, Melbourne, Vic, Australia; [Verma, Sunil] Sunny Brook Odette Canc Ctr, Toronto, ON, Canada; [Iwata, Hiroji] Aichi Canc Ctr Hosp, Nagoya, Aichi 464, Japan; [Harbeck, Nadia] Brustzentrum Univ Munchen, Munich, Germany; [Loibl, Sibylle] German Breast Grp Forschungs, Neu Isenburg, Germany; [Bartlett, Cynthia Huang; Koehler, Maria] Pfizer, New York, NY USA; [Cristofanilli, Massimo] Thomas Jefferson Univ, Philadelphia, PA 19107 USA	Royal Marsden NHS Foundation Trust; National Cancer Center - Korea (NCC); UNICANCER; Gustave Roussy; Peter Maccallum Cancer Center; University of Melbourne; University of Toronto; University Toronto Affiliates; Sunnybrook Health Science Center; Aichi Cancer Center; University of Munich; German Breast Group; Pfizer	Turner, NC (corresponding author), Royal Marsden Hosp, Fulham Rd, London SW3 6JJ, England.	nicholas.turner@icr.ac.uk	ANDRE, Fabrice/AAL-2683-2020; Khasraw, Mustafa/ABH-5962-2020; Loi, Sherene/H-1979-2016	ANDRE, Fabrice/0000-0001-5795-8357; Khasraw, Mustafa/0000-0003-3249-9849; Loi, Sherene/0000-0001-6137-9171; Chalasani, Pavani/0000-0002-7953-2979; Turner, Nicholas/0000-0001-8937-0873; SOTO PARRA, HECTOR/0000-0001-7966-4472; Kroep, Judith/0000-0003-2671-1903	Pfizer	Pfizer(Pfizer)	Supported by Pfizer.	Abe O, 2005, LANCET, V365, P1687, DOI 10.1016/s0140-6736(05)66544-0; Asghar U, 2015, NAT REV DRUG DISCOV, V14, P130, DOI 10.1038/nrd4504; Baselga J, 2012, NEW ENGL J MED, V366, P520, DOI 10.1056/NEJMoa1109653; DeMichele A, 2015, CLIN CANCER RES, V21, P995, DOI 10.1158/1078-0432.CCR-14-2258; Di Leo A, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/djt337; Di Leo A, 2010, J CLIN ONCOL, V28, P4594, DOI 10.1200/JCO.2010.28.8415; Eisenhauer EA, 2009, EUR J CANCER, V45, P228, DOI 10.1016/j.ejca.2008.10.026; Finn RS, 2015, LANCET ONCOL, V16, P25, DOI 10.1016/S1470-2045(14)71159-3; Finn RS, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2419; Francis PA, 2015, NEW ENGL J MED, V372, P436, DOI 10.1056/NEJMoa1412379; HAYBITTLE JL, 1971, BRIT J RADIOL, V44, P793, DOI 10.1259/0007-1285-44-526-793; Klijn JGM, 2000, JNCI-J NATL CANCER I, V92, P903, DOI 10.1093/jnci/92.11.903; Mehta RS, 2012, NEW ENGL J MED, V367, P435, DOI 10.1056/NEJMoa1201622; Miller TW, 2011, CANCER DISCOV, V1, P338, DOI 10.1158/2159-8290.CD-11-0101; Miller TW, 2010, J CLIN INVEST, V120, P2406, DOI 10.1172/JCI41680; Musgrove EA, 2011, NAT REV CANCER, V11, P558, DOI 10.1038/nrc3090; National Comprehensive Cancer Network, 2015, CLIN PRACT GUID ONC; Park IH, 2010, J CLIN ONCOL, V28, P2705, DOI 10.1200/JCO.2009.26.5884; Robinson DR, 2013, NAT GENET, V45, P1446, DOI 10.1038/ng.2823; Schiff R, 2004, CLIN CANCER RES, V10, p331S, DOI 10.1158/1078-0432.CCR-031212; Thangavel C, 2011, ENDOCR-RELAT CANCER, V18, P333, DOI 10.1530/ERC-10-0262; Toogood PL, 2005, J MED CHEM, V48, P2388, DOI 10.1021/jm049354h; Toy W, 2013, NAT GENET, V45, P1439, DOI 10.1038/ng.2822; Yu QY, 2006, CANCER CELL, V9, P23, DOI 10.1016/j.ccr.2005.12.012; Zhang JJ, 2013, CLIN CANCER RES, V19, P2637, DOI 10.1158/1078-0432.CCR-12-3364	25	951	991	0	118	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 16	2015	373	3					209	219		10.1056/NEJMoa1505270	http://dx.doi.org/10.1056/NEJMoa1505270			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CM8MS	26030518	Green Published			2023-01-03	WOS:000357956200004
J	Jameson, JL; Longo, DL				Jameson, J. Larry; Longo, Dan L.			Precision Medicine - Personalized, Problematic, and Promising	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							CLINICAL-PRACTICE; THERAPY; INHIBITION; BIOMARKER; LYMPHOMA; EFFICACY; MUTATION; FUTURE; CANCER; SAFETY		[Jameson, J. Larry] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine	Jameson, JL (corresponding author), Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA.		Longo, Dan L./F-6022-2011	Jameson, James/0000-0001-9538-4059				Asch DA, 2012, NEW ENGL J MED, V367, P1, DOI 10.1056/NEJMp1203869; Blaser MJ, 2014, J CLIN INVEST, V124, P4162, DOI 10.1172/JCI78366; Capell BC, 2006, NAT REV GENET, V7, P940, DOI 10.1038/nrg1906; Caudle KE, 2014, CURR DRUG METAB, V15, P209, DOI 10.2174/1389200215666140130124910; Cohen MS, 2011, NEW ENGL J MED, V364, P1943, DOI 10.1056/NEJMra1011874; Collins FS, 2015, NEW ENGL J MED, V372, P793, DOI 10.1056/NEJMp1500523; Committee on a Framework for Developing a New Taxonomy of Disease; National Research Council, 2011, PREC MED BUILD KNOWL; Dawson SJ, 2013, NEW ENGL J MED, V368, P1199, DOI 10.1056/NEJMoa1213261; Druker BJ, 2006, NEW ENGL J MED, V355, P2408, DOI 10.1056/NEJMoa062867; Evens AM, 2014, BLOOD, V124, P3356, DOI 10.1182/blood-2014-05-577627; Flaherty KT, 2010, NEW ENGL J MED, V363, P809, DOI 10.1056/NEJMoa1002011; Hayden EC, 2014, NATURE, V507, P294, DOI 10.1038/507294a; Hudis CA, 2007, NEW ENGL J MED, V357, P39, DOI 10.1056/NEJMra043186; Jameson JL, 2014, J CLIN INVEST, V124, P2822, DOI 10.1172/JCI77301; Kranzler HR, 2014, AM J PSYCHIAT, V171, P445, DOI 10.1176/appi.ajp.2013.13081014; Kwak EL, 2010, NEW ENGL J MED, V363, P1693, DOI 10.1056/NEJMoa1006448; Lander ES, 2015, NEW ENGL J MED, V372, P1185, DOI 10.1056/NEJMp1501964; Lerman C, 2015, LANCET RESP MED, V3, P131, DOI 10.1016/S2213-2600(14)70294-2; Leypoldt F, 2015, JAMA NEUROL, V72, P180, DOI 10.1001/jamaneurol.2014.2956; Liang TJ, 2014, NEW ENGL J MED, V370, P2043, DOI 10.1056/NEJMe1403619; Maguire AM, 2008, NEW ENGL J MED, V358, P2240, DOI 10.1056/NEJMoa0802315; Mirnezami R, 2012, NEW ENGL J MED, V366, P489, DOI 10.1056/NEJMp1114866; Moore FD, 2005, NEW ENGL J MED, V353, P1162, DOI 10.1056/NEJMe058182; Nathwani AC, 2014, NEW ENGL J MED, V371, P1994, DOI 10.1056/NEJMoa1407309; Paulson EK, 2003, NEW ENGL J MED, V348, P236, DOI 10.1056/NEJMcp013351; Porter DL, 2011, NEW ENGL J MED, V365, P725, DOI 10.1056/NEJMoa1103849; Ramsey BW, 2011, NEW ENGL J MED, V365, P1663, DOI 10.1056/NEJMoa1105185; Ribas A, 2012, NEW ENGL J MED, V366, P2517, DOI 10.1056/NEJMe1205943; Rinne JO, 2010, LANCET NEUROL, V9, P363, DOI 10.1016/S1474-4422(10)70043-0; Rubin R, 2015, JAMA-J AM MED ASSOC, V313, P1089, DOI 10.1001/jama.2015.0957; Siman R, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00190; Simon T, 2009, NEW ENGL J MED, V360, P363, DOI 10.1056/NEJMoa0808227; Stone NJ, 2014, CIRCULATION, V129, pS1, DOI 10.1161/01.cir.0000437738.63853.7a; Suthanthiran M, 2013, NEW ENGL J MED, V369, P20, DOI 10.1056/NEJMoa1215555; VANDENBROUCKE JP, 1994, LANCET, V344, P1453, DOI 10.1016/S0140-6736(94)90286-0	35	599	641	7	254	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 4	2015	372	23					2229	2234		10.1056/NEJMsb1503104	http://dx.doi.org/10.1056/NEJMsb1503104			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	CK1GK	26014593				2023-01-03	WOS:000355955100012
J	Khoury, MJ; Evans, JP				Khoury, Muin J.; Evans, James P.			A Public Health Perspective on a National Precision Medicine Cohort Balancing Long-term Knowledge Generation With Early Health Benefit	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									[Khoury, Muin J.] Ctr Dis Control & Prevent, Off Publ Hlth Genom, Atlanta, GA 30333 USA; [Evans, James P.] Univ N Carolina, Dept Genet, Chapel Hill, NC USA; [Evans, James P.] Univ N Carolina, Dept Med, Chapel Hill, NC USA	Centers for Disease Control & Prevention - USA; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Khoury, MJ (corresponding author), Ctr Dis Control & Prevent, Off Publ Hlth Genom, 1600 Clifton Rd, Atlanta, GA 30333 USA.	muk1@cdc.gov			Intramural CDC HHS [CC999999] Funding Source: Medline	Intramural CDC HHS		Ashley EA., JAMA-J AM MED ASSOC, DOI [10.1001/JAMA.2015.3595, DOI 10.1001/JAMA.2015.3595]; Berg JS, 2011, GENET MED, V13, P499, DOI 10.1097/GIM.0b013e318220aaba; Collins F., 2015, VISION COHORT PRECIS; Dewey FE, 2014, JAMA-J AM MED ASSOC, V311, P1035, DOI 10.1001/jama.2014.1717; Dotson WD, 2014, CLIN PHARMACOL THER, V95, P394, DOI 10.1038/clpt.2013.226; Green RC, 2013, GENET MED, V15, P565, DOI 10.1038/gim.2013.73; Khoury MJ, 2012, CDC BLOG POST; Lerman C, 2015, LANCET RESP MED, V3, P131, DOI 10.1016/S2213-2600(14)70294-2	8	61	66	2	21	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 2	2015	313	21					2117	2118		10.1001/jama.2015.3382	http://dx.doi.org/10.1001/jama.2015.3382			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CJ4CC	26034952	Green Accepted			2023-01-03	WOS:000355430900005
J	Chen, Y; Tang, Y; Zhang, YC; Huang, XH; Xie, YQ; Xiang, Y				Chen, Yu; Tang, Yong; Zhang, Ya-Chen; Huang, Xiao-Hong; Xie, Yu-Quan; Xiang, Yin			A Metabolomic Study of Rats with Doxorubicin-Induced Cardiomyopathy and Shengmai Injection Treatment	PLOS ONE			English	Article							ADRIAMYCIN-INDUCED CARDIOMYOPATHY; OXIDATIVE STRESS; HEART-FAILURE; INDUCED CARDIOTOXICITY; CENTELLA-ASIATICA; SYSTEMS BIOLOGY; DISEASE; AMPK; MOUSE; CARDIOPROTECTION	Doxorubicin-induced cardiomyopathy (DOX-CM) is a severe complication of doxorubicin (DOX) chemotherapy. Characterized by cumulative and irreversible myocardial damage, its pathogenesis has not been fully elucidated. Shengmai Injection (SMI), a Traditional Chinese Medicine, may alleviate myocardial injury and improve heart function in the setting of DOX-CM. As a result of its multi-component and multi-target nature and comprehensive regulation, the pharmacological mechanisms underlying SMI's effects remain obscure. The emerging field of metabolomics provides a potential approach with which to explore the pathogenesis of DOX-CM and the benefits of SMI treatment. DOX-CM was induced in rats via intraperitoneal injections of DOX. Cardiac metabolic profiling was performed via gas chromatography/mass spectrometry and ultra-performance liquid chromatography/tandem mass spectrometry. A bioinformatics analysis was conducted via Ingenuity Pathway Analysis (IPA). Eight weeks following DOX treatment, significant cardiac remodeling, dysfunction and metabolic perturbations were observed in the rats with DOX-CM. The metabolic disturbances primarily involved lipids, amino acids, vitamins and energy metabolism, and may have been indicative of both an energy metabolism disorder and oxidative stress secondary to DOX chemotherapy. However, SMI improved cardiac structure and function, as well as the metabolism of the rats with DOX-CM. The metabolic alterations induced via SMI, including the promotion of glycogenolysis, glycolysis, amino acid utilization and antioxidation, suggested that SMI exerts cardioprotective effects by improving energy metabolism and attenuating oxidative stress. Moreover, the IPA revealed that important signaling molecules and enzymes interacted with the altered metabolites. These findings have provided us with new insights into the pathogenesis of DOX-CM and the effects of SMI, and suggest that the combination of metabolomic analysis and IPA may represent a promising tool with which to explore and better understand both heart disease and TCM therapy.	[Chen, Yu; Tang, Yong; Zhang, Ya-Chen; Huang, Xiao-Hong; Xie, Yu-Quan; Xiang, Yin] Shanghai Jiao Tong Univ, Sch Med, Xin Hua Hosp, Div Cardiol, Shanghai 200092, Peoples R China	Shanghai Jiao Tong University	Zhang, YC (corresponding author), Shanghai Jiao Tong Univ, Sch Med, Xin Hua Hosp, Div Cardiol, Shanghai 200092, Peoples R China.	zhangyachen1965@126.com			National Natural Science Foundation of China [81170125, 81270209]; Shanghai Committee of Science and Technology of China [12JC1406400]; Doctor Innovation Fund of Shanghai Jiao Tong University School of Medicine [BXJ201224]; Shanghai Municipality for further acceleration of the development of Chinese Medicine [ZY3-CCCX-3-3040]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Shanghai Committee of Science and Technology of China; Doctor Innovation Fund of Shanghai Jiao Tong University School of Medicine; Shanghai Municipality for further acceleration of the development of Chinese Medicine	This work was supported by the National Natural Science Foundation of China (No. 81170125, 81270209), the Shanghai Committee of Science and Technology of China (No. 12JC1406400), the Doctor Innovation Fund of Shanghai Jiao Tong University School of Medicine (No. BXJ201224) and the 3-year Action Plan (2014-2016) of Shanghai Municipality for further acceleration of the development of Chinese Medicine (No. ZY3-CCCX-3-3040). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bordoni A, 1999, BBA-MOL CELL BIOL L, V1440, P100, DOI 10.1016/S1388-1981(99)00113-4; Calvert JW, 2008, DIABETES, V57, P696, DOI 10.2337/db07-1098; Cardaci S, 2012, J CELL SCI, V125, P2115, DOI 10.1242/jcs.095216; Carvalho RA, 2010, TOXICOLOGY, V270, P92, DOI 10.1016/j.tox.2010.01.019; Chartoumpekis D, 2010, BIOCHEM BIOPH RES CO, V396, P463, DOI 10.1016/j.bbrc.2010.04.117; Chatterjee K, 2010, CARDIOLOGY, V115, P155, DOI 10.1159/000265166; Chen Lei, 2010, Nan Fang Yi Ke Da Xue Xue Bao, V30, P2036; Cheng PW, 2014, BRIT J PHARMACOL, V171, P2739, DOI 10.1111/bph.12648; Choi YH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081773; Colombo SL, 2009, BIOCHEM J, V421, P163, DOI 10.1042/BJ20090613; Cox MJ, 2002, AM J PHYSIOL-HEART C, V282, pH1197, DOI 10.1152/ajpheart.00483.2001; DeHaven CD, 2010, J CHEMINFORMATICS, V2, DOI 10.1186/1758-2946-2-9; Evans AM, 2009, ANAL CHEM, V81, P6656, DOI 10.1021/ac901536h; Firdous Alikunjhi P, 2012, J Exp Ther Oncol, V10, P101; Ge MK, 2015, LASER MED SCI, V30, P1609, DOI 10.1007/s10103-014-1538-z; Gnanapragasam A, 2007, MOL CELL BIOCHEM, V294, P55, DOI 10.1007/s11010-006-9245-0; Gnanapragasam A, 2004, LIFE SCI, V76, P585, DOI 10.1016/j.lfs.2004.09.009; Grimsrud PA, 2008, J BIOL CHEM, V283, P21837, DOI 10.1074/jbc.R700019200; Hai J., 2006, LISHIZHEN MED MAT ME, V17, P329; Hong YM, 2002, PEDIATR RES, V51, P249, DOI 10.1203/00006450-200202000-00020; Ikeda Y, 2010, MOL ENDOCRINOL, V24, P1338, DOI 10.1210/me.2009-0402; Ingwall JS, 2009, CARDIOVASC RES, V81, P412, DOI 10.1093/cvr/cvn301; Jang YM, 2004, FEBS LETT, V577, P483, DOI 10.1016/j.febslet.2004.10.053; Jones SP, 2004, AM J PHYSIOL-HEART C, V286, pH276, DOI 10.1152/ajpheart.00129.2003; Katare R, 2013, CARDIOVASC RES, V97, P55, DOI 10.1093/cvr/cvs291; Kato T, 2010, CIRC-HEART FAIL, V3, P420, DOI 10.1161/CIRCHEARTFAILURE.109.888479; Kennedy LH, 2013, TOXICOL SCI, V132, P235, DOI 10.1093/toxsci/kfs325; Laplante M, 2012, CELL, V149, P274, DOI 10.1016/j.cell.2012.03.017; Li LH, 2006, MODERN J INTEGRATED, V15, P595; Lovric-Bencic M, 2004, J PHARMACOL SCI, V95, P19, DOI 10.1254/jphs.95.19; MACK CP, 1995, BIOCHEM BIOPH RES CO, V212, P35, DOI 10.1006/bbrc.1995.1932; McNulty PH, 2000, METABOLISM, V49, P1365, DOI 10.1053/meta.2000.9510; Nicholson JK, 2008, NATURE, V455, P1054, DOI 10.1038/4551054a; Octavia Y, 2012, J MOL CELL CARDIOL, V52, P1213, DOI 10.1016/j.yjmcc.2012.03.006; Putri SP, 2013, J BIOSCI BIOENG, V115, P579, DOI 10.1016/j.jbiosc.2012.12.007; Robertson DG, 2011, TOXICOL SCI, V120, pS146, DOI 10.1093/toxsci/kfq358; Rochfort S, 2005, J NAT PROD, V68, P1813, DOI 10.1021/np050255w; Ruiz S, 2013, KIDNEY INT, V83, P1029, DOI 10.1038/ki.2012.439; Shirwany NA, 2010, ACTA PHARMACOL SIN, V31, P1075, DOI 10.1038/aps.2010.139; Simunek T, 2009, PHARMACOL REP, V61, P154; SIVESKIILISKOVIC N, 1994, CIRCULATION, V89, P2829, DOI 10.1161/01.CIR.89.6.2829; Sterba M, 2013, ANTIOXID REDOX SIGN, V18, P899, DOI 10.1089/ars.2012.4795; Subashini R, 2007, PHARMAZIE, V62, P382, DOI 10.1691/ph.2007.5.6678; Surh YJ, 2008, PLANTA MED, V74, P1526, DOI 10.1055/s-0028-1088302; Tan GG, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027683; Thomas Sterling, 2010, Human Genomics, V4, P353; van Bilsen M, 2004, CARDIOVASC RES, V61, P218, DOI 10.1016/j.cardiores.2003.11.014; Vinayavekhin N, 2010, ACS CHEM BIOL, V5, P91, DOI 10.1021/cb900271r; Wang SB, 2012, J BIOL CHEM, V287, P8001, DOI 10.1074/jbc.M111.315812; Wang XJ, 2011, J PHARMACEUT BIOMED, V55, P859, DOI 10.1016/j.jpba.2011.01.042; Wei R, 2011, CURR DRUG METAB, V12, P345, DOI 10.2174/138920011795202947; Xiang P, 2009, CANCER CHEMOTH PHARM, V63, P343, DOI 10.1007/s00280-008-0744-4; Yang X. D., 2008, CENTRAL S PHARM, V6, P162; Yang XL., 2008, GUIDE CHIN MED CHIN, V6, P203, DOI [10.3736/jcim20080220, DOI 10.3736/JCIM20080220]; Yao HT, 2008, J ETHNOPHARMACOL, V116, P49, DOI 10.1016/j.jep.2007.10.043; Yin XH, 1998, BIOCHEM PHARMACOL, V56, P87, DOI 10.1016/S0006-2952(98)00099-9; Zhang AH, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/402159; Zhang AH, 2010, PLANTA MED, V76, P2026, DOI 10.1055/s-0030-1250542; Zhang Ya-chen, 2002, Zhongguo Zhong Xi Yi Jie He Za Zhi, V22, P277; Zhang YK, 2007, J EMERGENCY TRADITIO, V16, P1082; Zhou Q, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005052.pub5	61	24	27	2	40	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 4	2015	10	5							e0125209	10.1371/journal.pone.0125209	http://dx.doi.org/10.1371/journal.pone.0125209			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CH3PP	25938766	gold, Green Published, Green Submitted			2023-01-03	WOS:000353943000051
J	Boyce, WT				Boyce, W. Thomas			Fostering Early Brain Development	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material								IMPORTANCE Severe neglect in early life is associated with compromises in brain development and associated behavioral functioning. Although early intervention has been shown to support more normative trajectories of brain development, specific improvements in the white matter pathways that underlie emotional and cognitive development are unknown. OBJECTIVE To examine associations among neglect in early life, early intervention, and the microstructural integrity of white matter pathways in middle childhood. DESIGN, SETTING, AND PARTICIPANTS The Bucharest Early Intervention Project is a randomized clinical trial of high-quality foster care as an intervention for institutionally reared children in Bucharest, Romania, from 2000 through the present. During infancy, children were randomly selected to remain in an institution or to be placed in foster care. Those who remained in institutions experienced neglect, including social, emotional, linguistic, and cognitive impoverishment. Developmental trajectories of these children were compared with a group of sociodemographically matched children reared in biological families at baseline and several points throughout development. At approximately 8 years of age, 69 of the original 136 children underwent structural magnetic resonance imaging scans. MAIN OUTCOMES AND MEASURES Four estimates of white matter integrity (fractional anisotropy [FA] and mean [MD], radial [RD], and axial [AD] diffusivity) for 48 white matter tracts throughout the brain were obtained through diffusion tensor imaging. RESULTS Significant associations emerged between neglect in early life and microstructural integrity of the body of the corpus callosum (FA, beta = 0.01 [P =.01]; RD, beta = -0.02 [P = .005]; MD, beta = -0.01 [P = .02]) and tracts involved in limbic circuitry (fornix crus [AD, beta = 0.02 (P = .046)] and cingulum [RD, beta = -0.01 (P = .02); MD, beta = -0.01 (P = .049)]), frontostriatal circuitry (anterior [AD, beta = -0.01 (P = .02)] and superior [AD, beta = -0.02 (P = .02); MD, beta = -0.01 (P = .03)] corona radiata and external capsule [right FA, beta = 0.01 (P = .03); left FA, beta = 0.01 (P = .03); RD, beta = -0.01 (P = .01); MD, beta = -0.01 (P = .03)]), and sensory processing (medial lemniscus [AD, beta = -0.02 (P = .045); MD, beta = -0.01 (P = .04)] and retrolenticular internal capsule [FA, beta = -0.01 (P = .002); RD, beta = 0.01 (P = .003); MD, beta = 0.01 (P = .04)]). Follow-up analyses revealed that early intervention promoted more normative white matter development among previously neglected children who entered foster care. CONCLUSIONS AND RELEVANCE Results suggest that removal from conditions of neglect in early life and entry into a high-quality family environment can support more normative trajectories of white matter growth. Our findings have implications for public health and policy efforts designed to promote normative brain development among vulnerable children.	[Boyce, W. Thomas] Univ Calif San Francisco, Sch Med, Dept Pediat, San Francisco, CA 94143 USA; [Boyce, W. Thomas] Univ Calif San Francisco, Sch Med, Dept Psychiat, San Francisco, CA 94143 USA; [Boyce, W. Thomas] Canadian Inst Adv Res, Child & Brain Dev Program, Toronto, ON, Canada	University of California System; University of California San Francisco; University of California System; University of California San Francisco; Canadian Institute for Advanced Research (CIFAR)	Boyce, WT (corresponding author), Dept Pediat, 550 16th St,Fourth Floor, San Francisco, CA 94158 USA.	tom.boyce@ucsf.edu						Bick J, 2015, JAMA PEDIATR, V169, P211, DOI 10.1001/jamapediatrics.2014.3212; Dennis Emily L, 2013, Dialogues Clin Neurosci, V15, P359; Meaney MJ, 2010, CHILD DEV, V81, P41, DOI 10.1111/j.1467-8624.2009.01381.x; Nelson CA, 2007, SCIENCE, V318, P1937, DOI 10.1126/science.1143921; Zeanah, 2014, ROMANIAS ABANDONED C	5	2	2	0	10	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 21	2015	313	15					1564	+		10.1001/jama.2015.34	http://dx.doi.org/10.1001/jama.2015.34			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CG3SA	25898054	Green Published			2023-01-03	WOS:000353198700021
J	Barbaro, D; Di Bari, L; Gandin, V; Evangelisti, C; Vitulli, G; Schiavi, E; Marzano, C; Ferretti, AM; Salvadori, P				Barbaro, Daniele; Di Bari, Lorenzo; Gandin, Valentina; Evangelisti, Claudio; Vitulli, Giovanni; Schiavi, Eleonora; Marzano, Cristina; Ferretti, Anna M.; Salvadori, Piero			Glucose-Coated Superparamagnetic Iron Oxide Nanoparticles Prepared by Metal Vapour Synthesis Are Electively Internalized in a Pancreatic Adenocarcinoma Cell Line Expressing GLUT1 Transporter	PLOS ONE			English	Article							MAGNETIC NANOPARTICLES; THERMOTHERAPY; FEASIBILITY; HYPERTHERMIA; PARTICLES	Iron oxide nanoparticles (IONP) can have a variety of biomedical applications due to their visualization properties through Magnetic Resonance Imaging (MRI) and heating with radio frequency or alternating magnetic fields. In the oncological field, coating IONP with organic compounds to provide specific features and to achieve the ability of binding specific molecular targets appears to be very promising. To take advantage of the high avidity of tumor cells for glucose, we report the development of very small glucose-coated IONP (glc-IONP) by employing an innovative technique, Metal Vapor Synthesis (MVS). Moreover, we tested the internalization of our gl-IONP on a tumor line, BxPC3, over-expressing GLUT 1 transporter. Both glc-IONP and polyvinylpyrrolidone-IONP (PVP-IONP), as control, were prepared with MVS and were tested on BxPC3 at various concentrations. To evaluate the role of GLUT-1 transporter, we also investigated the effect of adding a polyclonal anti-GLUT1 antibody. After proper treatment, the iron value was assessed by atomic absorption spectrometer, reported in mcg/L and expressed in mg of protein. Our IONP prepared with MVS were very small and homogeneously distributed in a narrow range (1.75-3.75 nm) with an average size of 2.7 nm and were super-paramagnetic. Glc-IONP were internalized by BxPC3 cells in a larger amount than PVP-IONP. After 6h of treatment with 50 mcg/mL of IONPs, the content of Fe was 1.5 times higher in glc-IONP-treated cells compared with PVP-IONP-treated cells. After 1h pre-treatment with anti-GLUT1, a reduction of 41% cellular accumulation of glc-IONP was observed. Conversely, the uptake of PVP-IONPs was reduced only by 14% with antibody pretreatment. In conclusion, MVS allowed us to prepare small, homogeneous, super-paramagnetic glc-IONP, which are electively internalized by a tumor line over-expressing GLUT1. Our glc-IONP appear to have many requisites for in vivo use.	[Barbaro, Daniele] Gen Hosp, Endocrinol Sect, I-57100 Livorno, Italy; [Di Bari, Lorenzo] Univ Pisa, Dept Chem & Ind Chem, I-56124 Pisa, Italy; [Gandin, Valentina; Marzano, Cristina] Univ Padua, Dept Pharmaceut & Pharmacol Sci, I-35100 Padua, Italy; [Evangelisti, Claudio; Ferretti, Anna M.] CNR, Inst Mol Sci & Technol, I-20138 Milan, Italy; [Vitulli, Giovanni; Schiavi, Eleonora; Salvadori, Piero] ErreDue SpA, I-57121 Livorno, Italy	University of Pisa; University of Padua; Consiglio Nazionale delle Ricerche (CNR); Istituto di Scienze e Tecnologie Molecolari (ISTM-CNR)	Barbaro, D (corresponding author), Gen Hosp, Endocrinol Sect, Viale Alfieri 36, I-57100 Livorno, Italy.	danielebarbaro@katamail.com; lorenzo.dibari@unipi.it; valentina.gandin@unipd.it	Evangelisti, Claudio/L-4815-2015; Salvadori, Piero A/B-2342-2012; Ferretti, Anna Maria/E-6861-2010; Di Bari, Lorenzo/H-4804-2015	Evangelisti, Claudio/0000-0002-8855-2592; Salvadori, Piero A/0000-0001-6114-1059; Ferretti, Anna Maria/0000-0002-7373-7965; Di Bari, Lorenzo/0000-0003-2347-2150; GANDIN, VALENTINA/0000-0003-0442-0670				Branca RT, 2010, P NATL ACAD SCI USA, V107, P3693, DOI 10.1073/pnas.1000386107; Choi HS, 2007, NAT BIOTECHNOL, V25, P1165, DOI 10.1038/nbt1340; Dudeck O, 2006, INVEST RADIOL, V41, P527, DOI 10.1097/01.rli.0000209601.15533.5a; Gao HJ, 2005, P NATL ACAD SCI USA, V102, P9469, DOI 10.1073/pnas.0503879102; Gromnicova R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081043; Gupta AK, 2007, NANOMEDICINE-UK, V2, P23, DOI 10.2217/17435889.2.1.23; Hassan S, 2014, J NANOSCI NANOTECHNO, V14, P402, DOI 10.1166/jnn.2014.8747; Hayashi K, 2013, THERANOSTICS, V3, P366, DOI 10.7150/thno.5860; Jin RR, 2014, CURR OPIN PHARMACOL, V18, P18, DOI 10.1016/j.coph.2014.08.002; Johannsen M, 2005, INT J HYPERTHER, V21, P637, DOI 10.1080/02656730500158360; Johannsen M, 2007, EUR UROL, V52, P1653, DOI 10.1016/j.eururo.2006.11.023; Jordan A, 2006, J NEURO-ONCOL, V78, P7, DOI 10.1007/s11060-005-9059-z; Jordan A, 1996, INT J HYPERTHER, V12, P705, DOI 10.3109/02656739609027678; Jordan A., 2006, HYPERTHERMIA CANC TR, P1; Kalambur VS, 2007, LANGMUIR, V23, P12329, DOI 10.1021/la701100r; Kim JW, 2006, CANCER RES, V99, P8027; Kirkham M, 2005, J CELL BIOL, V168, P465, DOI 10.1083/jcb.200407078; Klabunde K.J., 1994, FREE ATOMS CLUSTERS; Laurent S, 2008, CHEM REV, V108, P2064, DOI 10.1021/cr068445e; Laurent S, 2014, EXPERT OPIN DRUG DEL, V11, P1449, DOI 10.1517/17425247.2014.924501; Lin GG, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/625095; Maier-Hauff K, 2007, J NEURO-ONCOL, V81, P53, DOI 10.1007/s11060-006-9195-0; Plotkin M, 2006, INT J HYPERTHER, V22, P319, DOI 10.1080/02656730600734128; Schmid G., 1994, CLUSTERS COLLOIDS TH, P459, DOI DOI 10.1002/9783527616077.CH6; Selvi RB, 2012, J NANOBIOTECHNOL, V10, DOI 10.1186/1477-3155-10-35; Shan XH, 2012, EUR J RADIOL, V81, P95, DOI 10.1016/j.ejrad.2011.03.013; Shim H, 1997, P NATL ACAD SCI USA, V94, P6658, DOI 10.1073/pnas.94.13.6658; Szablewski L, 2013, BBA-REV CANCER, V1835, P164, DOI 10.1016/j.bbcan.2012.12.004; Urban C, 2013, TRANSL CANCER RES, V2, P292, DOI 10.3978/j.issn.2218-676X.2013.08.05; Vitulli G, 2008, METAL NANOCLUSTERS IN CATALYSIS AND MATERIALS SCIENCE: THE ISSUE OF SIZE CONTROL, P437, DOI 10.1016/B978-044453057-8.50034-9; Wust P, 2006, INT J HYPERTHER, V22, P673, DOI 10.1080/02656730601106037; Xiong F, 2012, PHARM RES-DORDR, V29, P1087, DOI 10.1007/s11095-011-0653-9	32	22	22	1	30	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 15	2015	10	4							e0123159	10.1371/journal.pone.0123159	http://dx.doi.org/10.1371/journal.pone.0123159			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CG1EL	25874906	Green Published, gold, Green Submitted			2023-01-03	WOS:000353015800087
J	Li, LY; Yoshitomi, H; Wei, Y; Qin, LL; Zhou, JX; Xu, TH; Wu, XL; Zhou, T; Sun, W; Guo, XY; Wu, LL; Wang, HY; Zhang, Y; Li, CN; Liu, T; Gao, M				Li, Linyi; Yoshitomi, Hisae; Wei, Ying; Qin, Lingling; Zhou, Jingxin; Xu, Tunhai; Wu, Xinli; Zhou, Tian; Sun, Wen; Guo, Xiangyu; Wu, Lili; Wang, Haiyan; Zhang, Yan; Li, Chunna; Liu, Tonghua; Gao, Ming			Tang-Nai-Kang Alleviates Pre-diabetes and Metabolic Disorders and Induces a Gene Expression Switch toward Fatty Acid Oxidation in SHR.Cg-Leprcp/NDmcr Rats	PLOS ONE			English	Article							ACTIVATED PROTEIN-KINASE; IMPAIRED GLUCOSE-TOLERANCE; INSULIN-RESISTANCE; CARDIOVASCULAR-DISEASE; MITOCHONDRIAL-FUNCTION; ENERGY HOMEOSTASIS; RECEPTOR-ALPHA; DIABETIC-RATS; LIFE-STYLE; SIRT1	Increased energy intake and reduced physical activity can lead to obesity, diabetes and metabolic syndrome. Transcriptional modulation of metabolic networks has become a focus of current drug discovery research into the prevention and treatment of metabolic disorders associated with energy surplus and obesity. Tang-Nai-Kang (TNK), a mixture of five herbal plant extracts, has been shown to improve abnormal glucose metabolism in patients with prediabetes. Here, we report the metabolic phenotype of SHR.Cg-Leprcp/NDmcr (SHR/cp) rats treated with TNK. Pre-diabetic SHR/cp rats were randomly divided into control, TNK low-dose (1.67 g/kg) and TNK high-dose (3.24 g/kg) groups. After high-dose treatment for 2 weeks, the serum triglycerides and free fatty acids in SHR/cp rats were markedly reduced compared to controls. After 3 weeks of administration, the high dose of TNK significantly reduced the body weight and fat mass of SHR/cp rats without affecting food consumption. Serum fasting glucose and insulin levels in the TNK-treated groups decreased after 6 weeks of treatment. Furthermore, TNK-treated rats exhibited obvious improvements in glucose intolerance and insulin resistance. The improved glucose metabolism may be caused by the substantial reduction in serum lipids and body weight observed in SHR/cp rats starting at 3 weeks of TNK treatment. The mRNA expression of NAD+-dependent deacetylase sirtuin 1 (SIRT1) and genes related to fatty acid oxidation was markedly up-regulated in the muscle, liver and adipose tissue after TNK treatment. Furthermore, TNK promoted the deacetylation of two well-established SIRT1 targets, PPAR. coactivator 1 alpha (PGC1 alpha) and forkhead transcription factor 1 (FOXO1), and induced the phosphorylation of AMP-activated protein kinase (AMPK) and acetyl-CoA carboxylase (ACC) in different tissues. These observations suggested that TNK may be an alternative treatment for pre-diabetes and metabolic syndrome by inducing a gene expression switch toward fat oxidation through the activation of SIRT1 and AMPK signaling.	[Li, Linyi; Wei, Ying; Qin, Lingling; Xu, Tunhai; Wu, Xinli; Sun, Wen; Wu, Lili; Wang, Haiyan; Zhang, Yan; Li, Chunna; Liu, Tonghua] Beijing Univ Chinese Med, Hlth Cultivat Lab, Minist Educ, Beijing, Peoples R China; [Yoshitomi, Hisae; Gao, Ming] Mukogawa Womens Univ, Sch Pharmaceut Sci, Nishinomiya, Hyogo, Japan; [Zhou, Jingxin] Beijing Univ Chinese Med, Dongzhimen Hosp Eastern, Beijing, Peoples R China; [Zhou, Tian; Guo, Xiangyu] Beijing Univ Chinese Med, Dongfang Hosp, Beijing, Peoples R China	Beijing University of Chinese Medicine; Mukogawa Women's University; Beijing University of Chinese Medicine; Beijing University of Chinese Medicine	Liu, T (corresponding author), Beijing Univ Chinese Med, Hlth Cultivat Lab, Minist Educ, Beijing, Peoples R China.	thliu@vip.163.com; gaoming@mukogawa-u.ac.jp		Zhou, Jingxin/0000-0003-0471-1961	International Scientific and Technological Coorperation Program of China [2010DFB33260]; key project of Chinese Ministry of Education [311011]; Cooperation Program of Beijing Municipal Education Commission and the Innovative team of Beijing TCM University [2011-CXTD-19]	International Scientific and Technological Coorperation Program of China; key project of Chinese Ministry of Education(Ministry of Education, China); Cooperation Program of Beijing Municipal Education Commission and the Innovative team of Beijing TCM University	Support was provided by: 1) The International Scientific and Technological Coorperation Program of China (2010DFB33260). Source: Ministry of Science and Technology of the People's Republic of China to author TX [http://www.istcp.org.cn/]; 2) The key project of Chinese Ministry of Education (311011). Source: Ministry of Education of the People's Republic of China to author TL [http://www.moe.gov.cn/]; 3) The Cooperation Program of Beijing Municipal Education Commission and the Innovative team of Beijing TCM University (2011-CXTD-19). Source: Beijing University of Chinese Medicine to author TX [http://kjc.bucm.edu.cn/]. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Atkinson LL, 2002, J BIOL CHEM, V277, P29424, DOI 10.1074/jbc.M203813200; Barroso E, 2011, BIOCHEM PHARMACOL, V81, P534, DOI 10.1016/j.bcp.2010.12.004; Baur JA, 2006, NATURE, V444, P337, DOI 10.1038/nature05354; Bronner M, 2004, BIOCHEM J, V384, P295, DOI 10.1042/BJ20040955; Canto C, 2011, PHYSIOLOGY, V26, P214, DOI 10.1152/physiol.00010.2011; Canto C, 2009, NATURE, V458, P1056, DOI 10.1038/nature07813; Canto C, 2009, CURR OPIN LIPIDOL, V20, P98, DOI 10.1097/MOL.0b013e328328d0a4; Chang HC, 2014, TRENDS ENDOCRIN MET, V25, P138, DOI 10.1016/j.tem.2013.12.001; Chiolero A, 2012, LANCET, V380, P1225, DOI 10.1016/S0140-6736(12)61704-8; Deedwania P, 2012, LANCET, V380, P1225, DOI 10.1016/S0140-6736(12)61705-X; Desvergne B, 2006, PHYSIOL REV, V86, P465, DOI 10.1152/physrev.00025.2005; Diabetes Prevention Progam, 2005, DIABETES, V54, P1150; Feige JN, 2008, CELL METAB, V8, P347, DOI 10.1016/j.cmet.2008.08.017; Feige JN, 2008, CURR OPIN CELL BIOL, V20, P303, DOI 10.1016/j.ceb.2008.03.012; Feige JN, 2007, TRENDS CELL BIOL, V17, P292, DOI 10.1016/j.tcb.2007.04.001; Feige JN, 2006, PROG LIPID RES, V45, P120, DOI 10.1016/j.plipres.2005.12.002; Florez H, 2014, DIABETES OBES METAB, V16, P326, DOI 10.1111/dom.12220; Gao DW, 2009, PHYTOTHER RES, V23, P1257, DOI 10.1002/ptr.2603; Gerhart-Hines Z, 2007, EMBO J, V26, P1913, DOI 10.1038/sj.emboj.7601633; Grant SJ, 2013, BMC COMPLEM ALTERN M, V13, DOI 10.1186/1472-6882-13-104; Gross DN, 2008, ONCOGENE, V27, P2320, DOI 10.1038/onc.2008.25; Grundy SM, 2012, J AM COLL CARDIOL, V59, P635, DOI 10.1016/j.jacc.2011.08.080; Guarente L, 2006, NATURE, V444, P868, DOI 10.1038/nature05486; Guo Xiang-Yu, 2010, Zhong Xi Yi Jie He Xue Bao, V8, P535, DOI 10.3736/jcim20100605; Guo XY, 2013, BMC COMPLEM ALTERN M, V13, DOI 10.1186/1472-6882-13-52; Hardie DG, 2014, PHYSIOLOGY, V29, P99, DOI 10.1152/physiol.00050.2013; Hardie DG, 2012, NAT REV MOL CELL BIO, V13, P251, DOI 10.1038/nrm3311; Hwang SM, 2012, AM J CHINESE MED, V40, P937, DOI 10.1142/S0192415X12500693; Jager S, 2007, P NATL ACAD SCI USA, V104, P12017, DOI 10.1073/pnas.0705070104; Kawai K, 2012, EXP TOXICOL PATHOL, V64, P333, DOI 10.1016/j.etp.2010.09.006; Knowler WC, 2002, NEW ENGL J MED, V346, P393, DOI 10.1056/NEJMoa012512; Lagouge M, 2006, CELL, V127, P1109, DOI 10.1016/j.cell.2006.11.013; Li JB, 2013, J HUAZHONG U SCI-MED, V33, P877, DOI 10.1007/s11596-013-1215-7; Li LY, 2013, BIOL TRACE ELEM RES, V153, P329, DOI 10.1007/s12011-013-9689-5; Liang FX, 2009, NAT REV ENDOCRINOL, V5, P367, DOI 10.1038/nrendo.2009.101; Lin J, 2002, NATURE, V418, P797, DOI 10.1038/nature00904; Liu TH, 2011, CHINA SCI TECHNOLOGY, V12, P79; Liu TH, 2004, PR China Patent, Patent No. [CN02153751.8, 021537518]; Lorenzo C, 2007, DIABETES CARE, V30, P8, DOI 10.2337/dc06-1414; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MATTHEWS DR, 1985, DIABETOLOGIA, V28, P412, DOI 10.1007/BF00280883; Menendez-Gutierrez MP, 2012, CURR TOP MED CHEM, V12, P548; Merrill GF, 1997, AM J PHYSIOL-ENDOC M, V273, pE1107, DOI 10.1152/ajpendo.1997.273.6.E1107; Michan S, 2007, BIOCHEM J, V404, P1, DOI 10.1042/BJ20070140; Moore EM, 2013, DIABETES CARE, V36, P2981, DOI 10.2337/dc13-0229; Nagase M, 2006, J AM SOC NEPHROL, V17, P3438, DOI 10.1681/ASN.2006080944; Rodgers JT, 2005, NATURE, V434, P113, DOI 10.1038/nature03354; Shishtar E, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107391; Smith Dl Jr, 2009, Int J Body Compos Res, V7, P21; Stern MP, 2004, DIABETES CARE, V27, P2676, DOI 10.2337/diacare.27.11.2676; Tabak AG, 2012, LANCET, V379, P2279, DOI 10.1016/S0140-6736(12)60283-9; Vega RB, 2000, MOL CELL BIOL, V20, P1868, DOI 10.1128/MCB.20.5.1868-1876.2000; Wang HJ, 2012, FOOD FUNCT, V3, P1161, DOI 10.1039/c2fo30139c; Wang L, 2013, INT J BIOCHEM CELL B, V45, P1155, DOI 10.1016/j.biocel.2013.03.007; Wang LS, 2009, J ETHNOPHARMACOL, V126, P487, DOI 10.1016/j.jep.2009.09.009; Wang Y, 2012, PHARMACOL THERAPEUT, V136, P305, DOI 10.1016/j.pharmthera.2012.08.009; Wang YX, 2003, CELL, V113, P159, DOI 10.1016/S0092-8674(03)00269-1; Xia JN, 2013, J ETHNOPHARMACOL, V150, P692, DOI 10.1016/j.jep.2013.09.038; Yuan HD, 2012, J GINSENG RES, V36, P27, DOI 10.5142/jgr.2012.36.1.27; Zhang BB, 2009, CELL METAB, V9, P407, DOI 10.1016/j.cmet.2009.03.012	60	14	17	0	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 13	2015	10	4							e0122024	10.1371/journal.pone.0122024	http://dx.doi.org/10.1371/journal.pone.0122024			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CF8XK	25874615	Green Published, gold, Green Submitted			2023-01-03	WOS:000352845100056
J	Zhu, M; Wang, HY; Zhu, A; Niu, KJ; Wang, GL				Zhu, Min; Wang, Haiyun; Zhu, Ai; Niu, Kaijun; Wang, Guolin			Meta-Analysis of Dexmedetomidine on Emergence Agitation and Recovery Profiles in Children after Sevoflurane Anesthesia: Different Administration and Different Dosage	PLOS ONE			English	Article							PEDIATRIC-PATIENTS; POSTOPERATIVE ANALGESIA; REDUCES AGITATION; GREATER INCIDENCE; DELIRIUM; TONSILLECTOMY; HALOTHANE; PAIN; MIDAZOLAM; FENTANYL	The objective of this article is to evaluate the effect of dexmedetomidine on emergence agitation (EA) and recovery profiles in children after sevoflurane anesthesia and its pharmacological mechanisms. Standard bibliographic databases, including MEDLINE, EMBASE, PsycINFP, Springer and ISI Web of Knowledge, were artificially searched to identify all randomized controlled trials (RCTs) comparing the impact of dexmedetomidine with placebo, fentanyl and midazolam on EA and recovery profiles after sevoflurane anesthesia in post-anesthesia care unit (PACU). Two authors assessed the quality of each study independently in accordance with strict inclusion criteria and extracted data. RevMan 5.0 software was applied for performing statistic analysis. The outcomes analyzed included: 1) incidence of EA, 2) emergence time, 3) time to extubation, 4) incidence of post-operation nausea and vomiting, 5) number of patients requiring an analgesic, and 6) time to discharge from PACU. A total of 1364 patients (696 in the dexmedetomidine group and 668 in the placebo, fentanyl and midazolam group) from 20 prospective RCTs were included in the meta-analysis. Compared with placebo, dexmedetomidine decreased the incidence of EA (risk ratio [RR] 0.37; 95% CI 0.30 to 0.46), incidence of nausea and vomiting (RR 0.57; 95% CI 0.38 to 0.85) and number of patients requiring an analgesic (RR 0.43; 95% CI 0.31 to 0.59). However, dexmedetomidine had a significantly delayed effect on the emergence time (weighted mean differences [WMD] 1.16; 95% CI 0.72 to 1.60), time to extubation (WMD 0.61; 95% CI 0.27 to 0.95), and time to discharge from recovery room (WMD 2.67; 95% CI 0.95 to 4.39). Compared with fentanyl (RR 1.39; 95% CI 0.78 to 2.48) and midazolam (RR 1.12; 95% CI 0.54 to 2.35), dexmedetomidine has no significantly difference on the incidence of EA. However, the analgesia effect of dexmedetomidine on postoperation pain has no significantly statistical differences compared with fentanyl (RR 1.12; 95% CI 0.66 to 1.91), which implied that its analgesia effect might play an important role in decreasing the incident of EA. No evidence of publication bias was observed.	[Zhu, Min; Wang, Haiyun; Zhu, Ai; Wang, Guolin] Tianjin Med Univ, Gen Hosp, Tianjin Res Inst Anesthesiol, Dept Anesthesiol, Tianjin 300052, Peoples R China; [Niu, Kaijun] Tianjin Med Univ, Sch Publ Hlth, Dept Epidemiol, Tianjin 300052, Peoples R China	Tianjin Medical University; Tianjin Medical University	Wang, HY (corresponding author), Tianjin Med Univ, Gen Hosp, Tianjin Res Inst Anesthesiol, Dept Anesthesiol, Tianjin 300052, Peoples R China.	wanghy819@hotmail.com		Niu, Kaijun/0000-0002-8772-2481	Natural Science Foundation of China [81071059, 81100984]; Science and Technology Supported Key Project of Tianjin [12ZCZDSY03000]; Scientific Grant from Tianjin Health Bureau [09KZ106]	Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Science and Technology Supported Key Project of Tianjin; Scientific Grant from Tianjin Health Bureau	This work was supported by Natural Science Foundation of China (81071059, 81100984), Science and Technology Supported Key Project of Tianjin (12ZCZDSY03000), Scientific Grant from Tianjin Health Bureau (09KZ106). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Akin A, 2012, PEDIATR ANESTH, V22, P871, DOI 10.1111/j.1460-9592.2012.03802.x; Ali Monaz Abdulrahman, 2013, Saudi J Anaesth, V7, P296, DOI 10.4103/1658-354X.115363; Aono J, 1997, ANESTHESIOLOGY, V87, P1298, DOI 10.1097/00000542-199712000-00006; Arain SR, 2004, ANESTH ANALG, V98, P153, DOI 10.1213/01.ANE.0000093225.39866.75; Asaad OM, 2011, EGYPT J ANAESTH, V27, P233, DOI [10.1016/j.egja.2011.07.006, 10.1016/j.egja.2010.12.005]; Bock M, 2002, BRIT J ANAESTH, V88, P790, DOI 10.1093/bja/88.6.790; Chen JY, 2013, CAN J ANESTH, V60, P385, DOI 10.1007/s12630-013-9886-x; Cohen IT, 2002, ANESTH ANALG, V94, P1178, DOI 10.1097/00000539-200205000-00023; Cohen IT, 2002, PAEDIATR ANAESTH, V12, P604, DOI 10.1046/j.1460-9592.2002.00903.x; Cohen IT, 2003, PAEDIATR ANAESTH, V13, P63, DOI 10.1046/j.1460-9592.2003.00948.x; Coursin D B, 2001, Curr Opin Crit Care, V7, P221, DOI 10.1097/00075198-200108000-00002; Cravero J, 2000, PAEDIATR ANAESTH, V10, P419, DOI 10.1046/j.1460-9592.2000.00560.x; Cravero JP, 2000, J CLIN ANESTH, V12, P397, DOI 10.1016/S0952-8180(00)00180-X; Cravero JP, 2003, ANESTH ANALG, V97, P364, DOI 10.1213/01.ANE.0000070227.78670.43; Dahmani S, 2014, CURR OPIN ANESTHESIO, V27, P309, DOI 10.1097/ACO.0000000000000076; DYCK JB, 1993, ANESTHESIOLOGY, V78, P813, DOI 10.1097/00000542-199305000-00002; El-Rahmawy GF, 2013, EGYPT J ANAESTH, V29, P137, DOI 10.1016/j.egja.2012.10.005; Erdil F, 2009, ANAESTH INTENS CARE, V37, P571, DOI 10.1177/0310057X0903700405; Galinkin JL, 2000, ANESTHESIOLOGY, V93, P1378, DOI 10.1097/00000542-200012000-00006; Gerlach AT, 2007, ANN PHARMACOTHER, V41, P245, DOI 10.1345/aph.1H314; Goa K L, 1999, Paediatr Drugs, V1, P127, DOI 10.2165/00128072-199901020-00005; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; Guler G, 2005, PEDIATR ANESTH, V15, P762, DOI 10.1111/j.1460-9592.2004.01541.x; Gupta N, 2013, J NEUROSURG ANESTH, V25, P271, DOI 10.1097/ANA.0b013e31828cb6c0; Hamunen K, 2005, PAIN, V117, P40, DOI 10.1016/j.pain.2005.05.012; HANNALLAH RS, 1987, ANESTHESIOLOGY, V66, P832, DOI 10.1097/00000542-198706000-00023; Hatch DJ, 1999, BRIT J ANAESTH, V83, P42, DOI 10.1093/bja/83.1.42; He L, 2013, ANAESTH INTENS CARE, V41, P328, DOI 10.1177/0310057X1304100309; Ibacache ME, 2004, ANESTH ANALG, V98, P60, DOI 10.1213/01.ANE.0000094947.20838.8E; Ihmsen H, 2012, ANAESTHESIST, V61, P1059, DOI 10.1007/s00101-012-2114-1; Isik B, 2006, PEDIATR ANESTH, V16, P748, DOI 10.1111/j.1460-9592.2006.01845.x; Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4; Jurgens S, 2003, ANAESTHESIA, V58, P296, DOI 10.1046/j.1365-2044.2003.307226.x; Keaney A, 2004, PEDIATR ANESTH, V14, P866, DOI 10.1111/j.1460-9592.2004.01310.x; Kim NY, 2014, YONSEI MED J, V55, P209, DOI 10.3349/ymj.2014.55.1.209; Koruk S, 2010, J ANESTH, V24, P858, DOI 10.1007/s00540-010-1023-1; Kuratani N, 2008, ANESTHESIOLOGY, V109, P225, DOI 10.1097/ALN.0b013e31817f5c18; Lalicevic S, 2004, CURR THER RES CLIN E, V65, P360, DOI 10.1016/j.curtheres.2004.07.002; Meng QT, 2012, INT J PEDIATR OTORHI, V76, P1036, DOI 10.1016/j.ijporl.2012.03.028; Moir MS, 2000, LARYNGOSCOPE, V110, P1824, DOI 10.1097/00005537-200011000-00011; Mountain Brian W, 2011, AANA J, V79, P219; Ozcengiz D, 2011, J ANESTH, V25, P184, DOI 10.1007/s00540-011-1099-2; Patel A, 2010, ANESTH ANALG, V111, P1004, DOI 10.1213/ANE.0b013e3181ee82fa; Pestieau SR, 2011, PEDIATR ANESTH, V21, P1128, DOI 10.1111/j.1460-9592.2011.03615.x; Phan Hanna, 2008, Paediatr Drugs, V10, P49, DOI 10.2165/00148581-200810010-00006; Saadawy I, 2009, ACTA ANAESTH SCAND, V53, P251, DOI 10.1111/j.1399-6576.2008.01818.x; Sato M, 2010, J ANESTH, V24, P675, DOI 10.1007/s00540-010-0976-4; Shukry M, 2005, PEDIATR ANESTH, V15, P1098, DOI 10.1111/j.1460-9592.2005.01660.x; Sikich N, 2004, ANESTHESIOLOGY, V100, P1138, DOI 10.1097/00000542-200405000-00015; Sun L, 2014, ACTA ANAESTH SCAND, V58, P642, DOI 10.1111/aas.12292; Tobias JD, 2004, SOUTH MED J, V97, P451, DOI 10.1097/00007611-200405000-00007; Tobias JD, 2002, PAEDIATR ANAESTH, V12, P171, DOI 10.1046/j.1460-9592.2002.00805.x; Tobias JD, 2007, PEDIATR CRIT CARE ME, V8, P115, DOI 10.1097/01.PCC.0000257100.31779.41; TWERSKY RS, 1993, J CLIN ANESTH, V5, pS57; Uysal HY, 2011, J CLIN ANESTH, V23, P53, DOI 10.1016/j.jclinane.2010.07.001; Viitanen H, 1999, ANESTH ANALG, V89, P75, DOI 10.1097/00000539-199907000-00014; Vlajkovic GP, 2007, ANESTH ANALG, V104, P84, DOI 10.1213/01.ane.0000250914.91881.a8; Voepel-Lewis T, 2003, ANESTH ANALG, V96, P1625, DOI 10.1213/01.ANE.0000062522.21048.61; Voepel-Lewis Terri, 2005, J Perianesth Nurs, V20, P239, DOI 10.1016/j.jopan.2005.05.006; WATCHA MF, 1992, CAN J ANAESTH, V39, P649, DOI 10.1007/BF03008224; Weldon BC, 2004, ANESTH ANALG, V98, P321, DOI 10.1213/01.ANE.0000096004.96603.08; Xu LL, 2012, J ANESTH, V26, P556, DOI 10.1007/s00540-012-1354-1; Zhang CL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099718	63	63	71	0	16	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 13	2015	10	4							e0123728	10.1371/journal.pone.0123728	http://dx.doi.org/10.1371/journal.pone.0123728			22	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CF8XK	25874562	Green Submitted, Green Published, gold			2023-01-03	WOS:000352845100203
J	An, K; Elkassabany, NM; Liu, JB				An, Ke; Elkassabany, Nabil M.; Liu, Jiabin			Dexamethasone as Adjuvant to Bupivacaine Prolongs the Duration of Thermal Antinociception and Prevents Bupivacaine-Induced Rebound Hyperalgesia via Regional Mechanism in a Mouse Sciatic Nerve Block Model	PLOS ONE			English	Article							BRACHIAL-PLEXUS BLOCKADE; LOCAL-ANESTHETICS; WALLERIAN DEGENERATION; SCHWANN-CELLS; ROPIVACAINE; NEUROTOXICITY; INJURY; RAT; LIDOCAINE; ANALGESIA	Background Dexamethasone has been studied as an effective adjuvant to prolong the analgesia duration of local anesthetics in peripheral nerve block. However, the route of action for dexamethasone and its potential neurotoxicity are still unclear. Methods A mouse sciatic nerve block model was used. The sciatic nerve was injected with 60ul of combinations of various medications, including dexamethasone and/or bupivacaine. Neurobehavioral changes were observed for 2 days prior to injection, and then continuously for up to 7 days after injection. In addition, the sciatic nerves were harvested at either 2 days or 7 days after injection. Toluidine blue dyeing and immunohistochemistry test were performed to study the short-term and long-term histopathological changes of the sciatic nerves. There were six study groups: normal saline control, bupivacaine (10mg/kg) only, dexamethasone (0.5mg/kg) only, bupivacaine (10mg/kg) combined with low-dose (0.14mg/kg) dexamethasone, bupivacaine (10mg/kg) combined with high-dose (0.5mg/kg) dexamethasone, and bupivacaine (10mg/kg) combined with intramuscular dexamethasone (0.5mg/kg). Results High-dose perineural dexamethasone, but not systemic dexamethasone, combined with bupivacaine prolonged the duration of both sensory and motor block of mouse sciatic nerve. There was no significant difference on the onset time of the sciatic nerve block. There was "rebound hyperalgesia" to thermal stimulus after the resolution of plain bupivacaine sciatic nerve block. Interestingly, both low and high dose perineural dexamethasone prevented bupivacaine-induced hyperalgesia. There was an early phase of axon degeneration and Schwann cell response as represented by S-100 expression as well as the percentage of demyelinated axon and nucleus in the plain bupivacaine group compared with the bupivacaine plus dexamethasone groups on post-injection day 2, which resolved on post-injection day 7. Furthermore, we demonstrated that perineural dexamethasone, but not systemic dexamethasone, could prevent axon degeneration and demyelination. There was no significant caspase-dependent apoptosis process in the mouse sciatic nerve among all study groups during our study period. Conclusions Perineural, not systemic, dexamethasone added to a clinical concentration of bupivacaine may not only prolong the duration of sensory and motor blockade of sciatic nerve, but also prevent the bupivacaine-induced reversible neurotoxicity and short-term "rebound hyperalgesia" after the resolution of nerve block.	[An, Ke; Elkassabany, Nabil M.; Liu, Jiabin] Univ Penn, Perelman Sch Med, Dept Anesthesiol & Crit Care, Philadelphia, PA 19104 USA; [An, Ke] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Anesthesiol, Guangzhou 510275, Guangdong, Peoples R China	University of Pennsylvania; Pennsylvania Medicine; Sun Yat Sen University	Liu, JB (corresponding author), Univ Penn, Perelman Sch Med, Dept Anesthesiol & Crit Care, Philadelphia, PA 19104 USA.	Jiabin.Liu@uphs.upenn.edu		LIU, JIABIN/0000-0002-1029-2786				Bailard NS, 2014, AM J HEALTH-SYST PH, V71, P373, DOI 10.2146/ajhp130336; Brummett CM, 2009, ANESTHESIOLOGY, V111, P1111, DOI 10.1097/ALN.0b013e3181bbcc26; Bulka CM, 2014, REGIONAL ANESTHESIA; Chang YC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089563; Clark RD, 2008, CURR TOP MED CHEM, V8, P813, DOI 10.2174/156802608784535011; Conforti L, 2014, NAT REV NEUROSCI, V15, P394, DOI 10.1038/nrn3680; Cummings KC, 2011, BRIT J ANAESTH, V107, P446, DOI 10.1093/bja/aer159; Desmet M, 2013, BRIT J ANAESTHESIA; Drasner K, 2002, REGION ANESTH PAIN M, V27, P576, DOI 10.1053/rapm.2002.37410; Fredrickson MJ, 2013, REGION ANESTH PAIN M, V38, P300, DOI 10.1097/AAP.0b013e318292c121; Gordon SM, 2008, ANESTH ANALG, V106, P321, DOI 10.1213/01.ane.0000296474.79437.23; HARGREAVES KM, 1988, J BIOL CHEM, V263, P19392; Hulata D, 2008, J NEUROSCI METH, V172, P236, DOI 10.1016/j.jneumeth.2008.05.002; Janda A, 2013, REGION ANESTH PAIN M, V38, P151, DOI 10.1097/AAP.0b013e3182813aae; JOHANSSON A, 1990, ACTA ANAESTH SCAND, V34, P335, DOI 10.1111/j.1399-6576.1990.tb03097.x; Kawanishi R, 2014, LOCAL REG ANESTH, V7, P5, DOI 10.2147/LRA.S59158; Kidd GJ, 2013, HAND CLINIC, V115, P55, DOI 10.1016/B978-0-444-52902-2.00005-9; Kim HJ, 2014, KOREAN J PAIN, V27, P112, DOI 10.3344/kjp.2014.27.2.112; Kolarczyk LM, 2011, REGION ANESTH PAIN M, V36, P220, DOI 10.1097/AAP.0b013e3182176f5a; Kroin JS, 2010, REGION ANESTH PAIN M, V35, P343, DOI 10.1097/AAP.0b013e3181e82df0; Long TR, 2002, J CLIN ANESTH, V14, P546, DOI 10.1016/S0952-8180(02)00408-7; Makwana M, 2005, FEBS J, V272, P2628, DOI 10.1111/j.1742-4658.2005.04699.x; Martinez V, 2014, BRIT J ANAESTHESIA; MATA M, 1990, J NEUROCYTOL, V19, P432, DOI 10.1007/BF01188409; Merritt CK, 2014, BEST PRACT RES-CLIN, V28, P41, DOI 10.1016/j.bpa.2014.02.002; Movafegh A, 2006, ANESTH ANALG, V102, P263, DOI 10.1213/01.ane.0000189055.06729.0a; Mueller M, 2001, AM J PATHOL, V159, P2187, DOI 10.1016/S0002-9440(10)63070-2; MYERS RR, 1986, ANESTHESIOLOGY, V64, P29, DOI 10.1097/00000542-198601000-00006; Parrington SJ, 2010, REGION ANESTH PAIN M, V35, P422, DOI 10.1097/AAP.0b013e3181e85eb9; Rahangdale R, 2014, ANESTH ANALG, V118, P1113, DOI 10.1213/ANE.0000000000000137; Cereda CMS, 2012, ANESTH ANALG, V115, P1234, DOI 10.1213/ANE.0b013e318266f3d9; Salzer James L, 2012, J Peripher Nerv Syst, V17 Suppl 3, P14, DOI 10.1111/j.1529-8027.2012.00425.x; SALZER JL, 1980, J CELL BIOL, V84, P739, DOI 10.1083/jcb.84.3.739; SELANDER D, 1993, REGION ANESTH, V18, P461; Shishido H, 2002, SPINE, V27, P581, DOI 10.1097/00007632-200203150-00005; Tandoc MN, 2011, J ANESTH, V25, P704, DOI 10.1007/s00540-011-1180-x; Tang Y, 2014, PLOS ONE, V9, DOI [10.1371/journal.pone.0091571, 10.1371/journal.pone.0073402]; Williams BA, 2007, REGION ANESTH PAIN M, V32, P186, DOI 10.1016/j.rapm.2006.10.011; Williams BA, 2012, INT ANESTHESIOL CLIN, V50, P126, DOI 10.1097/AIA.0b013e31821a00d0; Williams BA, 2011, REGION ANESTH PAIN M, V36, P225, DOI 10.1097/AAP.0b013e3182176f70; Zink W, 2008, CURR OPIN ANESTHESIO, V21, P645, DOI 10.1097/ACO.0b013e32830c214c	41	44	45	0	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 9	2015	10	4							e0123459	10.1371/journal.pone.0123459	http://dx.doi.org/10.1371/journal.pone.0123459			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CF5HQ	25856078	Green Published, gold, Green Submitted			2023-01-03	WOS:000352588500091
J	Joyce, JA; Fearon, DT				Joyce, Johanna A.; Fearon, Douglas T.			T cell exclusion, immune privilege, and the tumor microenvironment	SCIENCE			English	Review							LYMPHOCYTE INFILTRATION; VASCULAR NORMALIZATION; ANTI-PD-L1 ANTIBODY; PROGNOSTIC-FACTOR; TNF-ALPHA; CANCER; IMMUNOTHERAPY; SUPPRESSION; ACTIVATION; EXPRESSION	Effective immunotherapy promotes the killing of cancer cells by cytotoxic T cells. This requires not only that cancer-specific Tcells be generated, but also that these Tcells physically contact cancer cells. The coexistence in some patients of cancer cells and T cells that recognize them indicates that tumors may exhibit the phenomenon of immune privilege, in which immunogenic tissue is protected from immune attack. Here, we review the evidence that stromal cells of the tumor microenvironment mediate this restriction by excluding T cells from the vicinity of cancer cells. Overcoming this T cell checkpoint may thus enable optimal immunotherapy.	[Joyce, Johanna A.] Mem Sloan Kettering Canc Ctr, Canc Biol & Genet Program, New York, NY 10065 USA; [Fearon, Douglas T.] Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA; [Fearon, Douglas T.] Weill Cornell Med Sch, Joan & Sanford I Weill Dept Med, Dept Microbiol & Immunol, New York, NY 10065 USA	Memorial Sloan Kettering Cancer Center; Cold Spring Harbor Laboratory; Cornell University; Qatar Foundation (QF); Weill Cornell Medical College Qatar	Joyce, JA (corresponding author), Mem Sloan Kettering Canc Ctr, Canc Biol & Genet Program, New York, NY 10065 USA.	joycej@mskcc.org; dfearon@cshl.edu			National Cancer Institute; American Cancer Society; Breast Cancer Research Foundation; New York State Health Research Science Board; Cycle for Survival; Center for Metastasis Research at MSKCC; Lustgarten Distinguished Scholar Award; Cancer Research UK [22310] Funding Source: researchfish	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); American Cancer Society(American Cancer Society); Breast Cancer Research Foundation; New York State Health Research Science Board; Cycle for Survival; Center for Metastasis Research at MSKCC; Lustgarten Distinguished Scholar Award; Cancer Research UK(Cancer Research UK)	J.A.J. is supported by grants from the National Cancer Institute, the American Cancer Society, the Breast Cancer Research Foundation, New York State Health Research Science Board, Cycle for Survival, and the Center for Metastasis Research at MSKCC. D.T.F. is the Walter B. Wriston Professor of Pancreatic Cancer Research and is supported by a Lustgarten Distinguished Scholar Award. D.T.F. is a cofounder of Myosotis, which has licensed the potential intellectual property that may be associated with the finding that interfering with the interaction of CXCR4 with CXCL12 promotes the antitumor effects of T cell checkpoint antagonists. The authors thank C. Connell for Fig. 1C. We apologize to all the investigators whose research could not be appropriately cited because of the journal's space limitations.	Affara NI, 2014, CANCER CELL, V25, P809, DOI 10.1016/j.ccr.2014.04.026; Akishima-Fukasawa Y, 2009, AM J CLIN PATHOL, V132, P202, DOI 10.1309/AJCPK35VZJEWCUTL; Bayne LJ, 2012, CANCER CELL, V21, P822, DOI 10.1016/j.ccr.2012.04.025; Beatty GL, 2011, SCIENCE, V331, P1612, DOI 10.1126/science.1198443; Brahmer JR, 2012, NEW ENGL J MED, V366, P2455, DOI 10.1056/NEJMoa1200694; Broz ML, 2014, CANCER CELL, V26, P638, DOI 10.1016/j.ccell.2014.09.007; Buckanovich RJ, 2008, NAT MED, V14, P28, DOI 10.1038/nm1699; Calcinotto A, 2012, J IMMUNOL, V188, P2687, DOI 10.4049/jimmunol.1101877; Cavnar MJ, 2013, J EXP MED, V210, P2873, DOI 10.1084/jem.20130875; Chiba T, 2004, BRIT J CANCER, V91, P1711, DOI 10.1038/sj.bjc.6602201; Colegio OR, 2014, NATURE, V513, P559, DOI 10.1038/nature13490; DeNardo DG, 2011, CANCER DISCOV, V1, P54, DOI 10.1158/2159-8274.CD-10-0028; Eyles J, 2010, J CLIN INVEST, V120, P2030, DOI 10.1172/JCI42002; Feig C, 2013, P NATL ACAD SCI USA, V110, P20212, DOI 10.1073/pnas.1320318110; Gabrilovich DI, 1996, NAT MED, V2, P1096, DOI 10.1038/nm1096-1096; Galon J, 2006, SCIENCE, V313, P1960, DOI 10.1126/science.1129139; Garcia AJ, 2014, MOL CELL BIOL, V34, P2017, DOI 10.1128/MCB.00090-14; Hamzah J, 2008, NATURE, V453, P410, DOI 10.1038/nature06868; Hanahan D, 2012, CANCER CELL, V21, P309, DOI 10.1016/j.ccr.2012.02.022; Herbst RS, 2014, NATURE, V515, P563, DOI 10.1038/nature14011; Hildner K, 2008, SCIENCE, V322, P1097, DOI 10.1126/science.1164206; Hodi FS, 2010, NEW ENGL J MED, V363, P711, DOI 10.1056/NEJMoa1003466; Holmgaard RB, 2013, J EXP MED, V210, P1389, DOI 10.1084/jem.20130066; Huang YH, 2013, CANCER RES, V73, P2943, DOI 10.1158/0008-5472.CAN-12-4354; Huang YH, 2012, P NATL ACAD SCI USA, V109, P17561, DOI 10.1073/pnas.1215397109; Jayson GC, 2012, NAT REV CLIN ONCOL, V9, P297, DOI 10.1038/nrclinonc.2012.8; Johansson A, 2012, P NATL ACAD SCI USA, V109, P7841, DOI 10.1073/pnas.1118296109; Jones FS, 1914, J EXP MED, V20, P404, DOI 10.1084/jem.20.4.404; Josefowicz SZ, 2012, ANNU REV IMMUNOL, V30, P531, DOI 10.1146/annurev.immunol.25.022106.141623; KLEIN G, 1960, CANCER RES, V20, P1561; Kraman M, 2010, SCIENCE, V330, P827, DOI 10.1126/science.1195300; Lesokhin AM, 2012, CANCER RES, V72, P876, DOI 10.1158/0008-5472.CAN-11-1792; Liang JJ, 2010, CANCER EPIDEM BIOMAR, V19, P2598, DOI 10.1158/1055-9965.EPI-10-0405; Ma YT, 2014, CANCER RES, V74, P436, DOI 10.1158/0008-5472.CAN-13-1265; MEDAWAR PB, 1948, BRIT J EXP PATHOL, V29, P58; Molon B, 2011, J EXP MED, V208, P1949, DOI 10.1084/jem.20101956; Motz GT, 2014, NAT MED, V20, P607, DOI 10.1038/nm.3541; Munn DH, 2013, TRENDS IMMUNOL, V34, P137, DOI 10.1016/j.it.2012.10.001; Murata Y, 2014, J BIOCHEM, V155, P335, DOI 10.1093/jb/mvu017; Murray PJ, 2014, IMMUNITY, V41, P14, DOI 10.1016/j.immuni.2014.06.008; Naito Y, 1998, CANCER RES, V58, P3491; Noman MZ, 2014, J EXP MED, V211, P781, DOI 10.1084/jem.20131916; Okazaki T, 2013, NAT IMMUNOL, V14, P1212, DOI 10.1038/ni.2762; PAPADOPOULOS EB, 1994, NEW ENGL J MED, V330, P1185, DOI 10.1056/NEJM199404283301703; Platten M, 2012, CANCER RES, V72, P5435, DOI 10.1158/0008-5472.CAN-12-0569; Pommier A, 2013, P NATL ACAD SCI USA, V110, P13085, DOI 10.1073/pnas.1300314110; Powles T, 2014, NATURE, V515, P558, DOI 10.1038/nature13904; Poznansky MC, 2000, NAT MED, V6, P543, DOI 10.1038/75022; Predina J, 2013, P NATL ACAD SCI USA, V110, pE415, DOI 10.1073/pnas.1211850110; Pylayeva-Gupta Y, 2012, CANCER CELL, V21, P836, DOI 10.1016/j.ccr.2012.04.024; Pyonteck SM, 2013, NAT MED, V19, P1264, DOI 10.1038/nm.3337; Qian BZ, 2010, CELL, V141, P39, DOI 10.1016/j.cell.2010.03.014; Quail DF, 2013, NAT MED, V19, P1423, DOI 10.1038/nm.3394; RIDDELL SR, 1992, SCIENCE, V257, P238; Roberts EW, 2013, J EXP MED, V210, P1137, DOI 10.1084/jem.20122344; Rosenberg SA, 2005, J IMMUNOL, V175, P6169, DOI 10.4049/jimmunol.175.9.6169; Rosenberg SA, 2015, SCIENCE, V348, P62, DOI 10.1126/science.aaa4967; Rosenberg SA, 2011, CLIN CANCER RES, V17, P4550, DOI 10.1158/1078-0432.CCR-11-0116; Royal RE, 2010, J IMMUNOTHER, V33, P828, DOI 10.1097/CJI.0b013e3181eec14c; Ruffell B, 2014, CANCER CELL, V26, P623, DOI 10.1016/j.ccell.2014.09.006; Salmon H, 2012, J CLIN INVEST, V122, P899, DOI 10.1172/JCI45817; Sato E, 2005, P NATL ACAD SCI USA, V102, P18538, DOI 10.1073/pnas.0509182102; Schreiber RD, 2011, SCIENCE, V331, P1565, DOI 10.1126/science.1203486; Scotton CJ, 2002, CANCER RES, V62, P5930; Sharma MD, 2013, IMMUNITY, V38, P998, DOI 10.1016/j.immuni.2013.01.013; Sharma P, 2015, SCIENCE, V348, P56, DOI 10.1126/science.aaa8172; Sherman MH, 2014, CELL, V159, P80, DOI 10.1016/j.cell.2014.08.007; Shrimali RK, 2010, CANCER RES, V70, P6171, DOI 10.1158/0008-5472.CAN-10-0153; Simpson TR, 2013, J EXP MED, V210, P1695, DOI 10.1084/jem.20130579; Smith C, 2012, CANCER DISCOV, V2, P722, DOI 10.1158/2159-8290.CD-12-0014; Strachan DC, 2013, ONCOIMMUNOLOGY, V2, DOI 10.4161/onci.26968; Thompson ED, 2010, J EXP MED, V207, P1791, DOI 10.1084/jem.20092454; Topalian SL, 2012, NEW ENGL J MED, V366, P2443, DOI 10.1056/NEJMoa1200690; Tumeh PC, 2014, NATURE, V515, P568, DOI 10.1038/nature13954; VANDERBRUGGEN P, 1991, SCIENCE, V254, P1643, DOI 10.1126/science.1840703; Wei F, 2013, P NATL ACAD SCI USA, V110, pE2480, DOI 10.1073/pnas.1305394110; Weiskopf K, 2013, SCIENCE, V341, P88, DOI 10.1126/science.1238856; Yang XM, 2014, CANCER CELL, V25, P37, DOI 10.1016/j.ccr.2013.12.004; Zang XX, 2010, MODERN PATHOL, V23, P1104, DOI 10.1038/modpathol.2010.95; Zhang L, 2003, NEW ENGL J MED, V348, P203, DOI 10.1056/NEJMoa020177; Zhou PH, 2014, NATURE, V506, P52, DOI 10.1038/nature12988; Zhu Y, 2014, CANCER RES, V74, P5057, DOI 10.1158/0008-5472.CAN-13-3723	82	1220	1271	30	502	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 3	2015	348	6230					74	80		10.1126/science.aaa6204	http://dx.doi.org/10.1126/science.aaa6204			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CE8GJ	25838376				2023-01-03	WOS:000352079500029
J	Coura, CO; Souza, RB; Rodrigues, JAG; Vanderlei, EDO; de Arajo, IWF; Ribeiro, NA; Frota, AF; Ribeiro, KA; Chaves, HV; Pereira, KMA; da Cunha, RMS; Bezerra, MM; Benevides, NMB				Coura, Chistiane Oliveira; Souza, Ricardo Basto; Gurgel Rodrigues, Jose Arievilo; Oliveira Vanderlei, Edfranck de Sousa; Fernandes de Arajo, Ianna Wivianne; Ribeiro, Natassia Albuquerque; Frota, Annyta Fernandes; Ribeiro, Katia Alves; Chaves, Helliada Vasconcelos; Alves Pereira, Karuza Maria; Silva da Cunha, Rodrigo Maranguape; Bezerra, Mirna Marques; Barros Benevides, Norma Maria			Mechanisms Involved in the Anti-Inflammatory Action of a Polysulfated Fraction from Gracilaria cornea in Rats	PLOS ONE			English	Article							SULFATED-POLYSACCHARIDE FRACTION; MONOXIDE-BILIVERDIN PATHWAY; HO-1 PATHWAY; PAW EDEMA; CARRAGEENAN; MIGRATION; GALACTAN	The anti-inflammatory mechanisms of the sulfated polysaccharidic fraction obtained from red marine alga Gracilaria cornea (Gc-Fl) were investigated using a paw edema model induced in rats by different inflammatory agents (carrageenan, dextran, serotonin, bradykinin, compound 48/80 or L-arginine). Gc-Fl at the doses of 3, 9 or 27 mg/kg, subcutaneously s.c., significantly inhibited rat paw edema induced by carrageenan and dextran, as confirmed by myeloperoxidase and Evans' blue assessments, respectively. Gc-Fl (9 mg/kg, s.c.) inhibited rat paw edema induced by histamine, compound 48/80 and L-arginine. Additionally, Gc-Fl (9 mg/kg, s.c.) inhibited Cg-induced edema in animals with intact mast cells but did not inhibit that with degranulated mast cells by compound 48/80, revealing a protective role on mast cell membranes. Gc-Fl down-regulated the IL-1 beta, TNF-alpha and COX-2 mRNA and protein levels compared with those of the carrageenan group, based on qRT-PCR and immunohistochemistry analyses. After inhibition with ZnPP IX, a specific heme oxygenase-1 (HO-1) inhibitor, the anti-inflammatory effect of Gc-Fl was not observed in Cg-induced paw edema, suggesting that the anti-inflammatory effect of Gc-Fl is, in part, dependent on the integrity of the HO-1 pathway. Gc-Fl can target a combination of multiple points involved in inflammatory phenomena.	[Coura, Chistiane Oliveira; Souza, Ricardo Basto; Gurgel Rodrigues, Jose Arievilo; Oliveira Vanderlei, Edfranck de Sousa; Fernandes de Arajo, Ianna Wivianne; Ribeiro, Natassia Albuquerque; Barros Benevides, Norma Maria] Univ Fed Ceara, Dept Biochem & Mol Biol, Fortaleza, Ceara, Brazil; [Frota, Annyta Fernandes; Ribeiro, Katia Alves; Bezerra, Mirna Marques] Univ Fed Ceara, Fac Med, Sobral, Ceara, Brazil; [Chaves, Helliada Vasconcelos; Alves Pereira, Karuza Maria] Univ Fed Ceara, Fac Dent, Sobral, Ceara, Brazil; [Silva da Cunha, Rodrigo Maranguape] Biotechnol Nucleus Sobral, Sobral, Ceara, Brazil	Universidade Federal do Ceara; Universidade Federal do Ceara; Universidade Federal do Ceara	Benevides, NMB (corresponding author), Univ Fed Ceara, Dept Biochem & Mol Biol, Fortaleza, Ceara, Brazil.	nmbb@ufc.br	da Cunha, Rodrigo M. S./O-9958-2014; Benevides, Norma/K-5647-2015; Souza, Ricardo Basto/G-5292-2015; Frota, Annyta Fernandes/AAH-4082-2019; da Silva Cunha, Rodrigo/GWZ-3902-2022	da Cunha, Rodrigo M. S./0000-0002-4467-3018; Souza, Ricardo Basto/0000-0003-1930-9975; Frota, Annyta Fernandes/0000-0002-4550-0266; Barros Benevides, Norma Maria/0000-0001-5067-2110	Conselho Nacional de Desenvolvimento Cientifico e tecnologico (CNPq); Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)	Conselho Nacional de Desenvolvimento Cientifico e tecnologico (CNPq)(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)); Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)(Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES))	This study was supported by Conselho Nacional de Desenvolvimento Cientifico e tecnologico (CNPq) and Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES). The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abraham NG, 2008, PHARMACOL REV, V60, P179; Bang JS, 2009, ARTHRITIS RES THER, V11, DOI 10.1186/ar2662; BRADLEY PP, 1982, BLOOD, V60, P618; Chaves HV, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/707985; Chaves LD, 2013, IMMUNOPHARM IMMUNOT, V35, P93, DOI 10.3109/08923973.2012.707211; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; Coura CO, 2012, BASIC CLIN PHARMACOL, V110, P335, DOI 10.1111/j.1742-7843.2011.00811.x; de Brito TV, 2013, J PHARM PHARMACOL, V65, P724, DOI 10.1111/jphp.12024; de Sousa AAS, 2013, FUND CLIN PHARMACOL, V27, P173, DOI 10.1111/j.1472-8206.2011.01001.x; DIETRICH CP, 1976, ANAL BIOCHEM, V70, P645, DOI 10.1016/0003-2697(76)90496-6; DIROSA M, 1971, J PATHOL, V104, P15, DOI 10.1002/path.1711040103; Esteves CL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075874; Farias WRL, 2000, J BIOL CHEM, V275, P29299, DOI 10.1074/jbc.M002422200; FARNDALE RW, 1986, BIOCHIM BIOPHYS ACTA, V883, P173, DOI 10.1016/0304-4165(86)90306-5; Feitosa RFG, 2002, MEDIAT INFLAMM, V11, P155, DOI 10.1080/09622935020138000; de Araujo IWF, 2011, CARBOHYD POLYM, V86, P1207, DOI 10.1016/j.carbpol.2011.06.016; Fernandes JC, 2010, MAR DRUGS, V8, P1763, DOI 10.3390/md8061763; Fosslien E, 2005, ANN CLIN LAB SCI, V35, P347; Freitas A, 2006, BRIT J PHARMACOL, V149, P345, DOI 10.1038/sj.bjp.0706882; Gozzelino R, 2010, ANNU REV PHARMACOL, V50, P323, DOI 10.1146/annurev.pharmtox.010909.105600; Grangeiro NMG, 2011, PHARMACOL REP, V63, P112, DOI 10.1016/S1734-1140(11)70405-4; Rodrigues JAG, 2011, CIENC RURAL, V41, P634, DOI 10.1590/S0103-84782011000400014; Haddad JJ, 2002, BIOCHEM BIOPH RES CO, V297, P700, DOI 10.1016/S0006-291X(02)02287-8; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P1349, DOI 10.1177/29.11.6172466; [Кулинский В.И. Kulinsky V.I.], 2007, [Биохимия, BIOCHEMISTRY (MOSCOW), Biokhimiya], V72, P733; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; LO TN, 1982, J PHARMACOL EXP THER, V221, P261; Melo MRS, 2002, CARBOHYD POLYM, V49, P491, DOI 10.1016/S0144-8617(02)00006-1; Ndisang JF., 2010, MED INFLAMM, V2010, P359; Vanderlei EDO, 2011, INFLAMM RES, V60, P1121, DOI 10.1007/s00011-011-0376-8; Pae Hyun-Ock, 2009, Immune Netw, V9, P12, DOI 10.4110/in.2009.9.1.12; Pereira LD, 2012, J ETHNOPHARMACOL, V139, P642, DOI 10.1016/j.jep.2011.12.012; Pomin VH, 2012, BBA-GEN SUBJECTS, V1820, P1971, DOI 10.1016/j.bbagen.2012.08.022; Pomin VH, 2008, GLYCOBIOLOGY, V18, P1016, DOI 10.1093/glycob/cwn085; Posadas I, 2004, BRIT J PHARMACOL, V142, P331, DOI 10.1038/sj.bjp.0705650; Quindere ALG, 2013, PHARMACOL REP, V65, P600, DOI 10.1016/S1734-1140(13)71037-5; Ribeiro NA, 2014, INFLAMM RES, V63, P569, DOI 10.1007/s00011-014-0728-2; Rozen S, 2000, Methods Mol Biol, V132, P365; Silva RO, 2012, MAR DRUGS, V10, P2618, DOI 10.3390/md10122618; Siqueira RCL, 2011, PHARM BIOL, V49, P167, DOI 10.3109/13880209.2010.505605; Souza BWS, 2012, FOOD HYDROCOLLOID, V27, P287, DOI 10.1016/j.foodhyd.2011.10.005; Thorlacius H, 1997, AM J PHYSIOL-HEART C, V272, pH1725, DOI 10.1152/ajpheart.1997.272.4.H1725; VINEGAR R, 1969, J PHARMACOL EXP THER, V166, P96; WILHELM DL, 1962, PHARMACOL REV, V14, P251; WINTER CA, 1962, P SOC EXP BIOL MED, V111, P544	45	57	58	0	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 25	2015	10	3							e0119319	10.1371/journal.pone.0119319	http://dx.doi.org/10.1371/journal.pone.0119319			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CE5MO	25807556	Green Published, gold, Green Submitted			2023-01-03	WOS:000351880000026
J	Rich, JD; McKenzie, M; Larney, S; Wong, JB; Tran, L; Clarke, J; Noska, A; Reddy, M; Zaller, N				Rich, Josiah D.; McKenzie, Michelle; Larney, Sarah; Wong, John B.; Tran, Liem; Clarke, Jennifer; Noska, Amanda; Reddy, Manasa; Zaller, Nickolas			Methadone continuation versus forced withdrawal on incarceration in a combined US prison and jail: a randomised, open-label trial	LANCET			English	Article							OPIOID SUBSTITUTION TREATMENT; COST-EFFECTIVENESS ANALYSIS; DRUG-USERS; MAINTENANCE TREATMENT; CLINICAL-TRIAL; GLOBAL BURDEN; CARE; HEALTH; RISK; DEPENDENCE	Background Methadone is an effective treatment for opioid dependence. When people who are receiving methadone maintenance treatment for opioid dependence are incarcerated in prison or jail, most US correctional facilities discontinue their methadone treatment, either gradually, or more often, abruptly. This discontinuation can cause uncomfortable symptoms of withdrawal and renders prisoners susceptible to relapse and overdose on release. We aimed to study the effect of forced withdrawal from methadone upon incarceration on individuals' risk behaviours and engagement with post-release treatment programmes. Methods In this randomised, open-label trial, we randomly assigned (1: 1) inmates of the Rhode Island Department of Corrections (RI, USA) who were enrolled in a methadone maintenance-treatment programme in the community at the time of arrest and wanted to remain on methadone treatment during incarceration and on release, to either continuation of their methadone treatment or to usual care-forced tapered withdrawal from methadone. Participants could be included in the study only if their incarceration would be more than 1 week but less than 6 months. We did the random assignments with a computer-generated random permutation, and urn randomisation procedures to stratify participants by sex and race. Participants in the continued-methadone group were maintained on their methadone dose at the time of their incarceration (with dose adjustments as clinically indicated). Patients in the forced-withdrawal group followed the institution's standard withdrawal protocol of receiving methadone for 1 week at the dose at the time of their incarceration, then a tapered withdrawal regimen (for those on a starting dose >100 mg, the dose was reduced by 5 mg per day to 100 mg, then reduced by 3 mg per day to 0 mg; for those on a starting dose <= 100 mg, the dose was reduced by 3 mg per day to 0 mg). The main outcomes were engagement with a methadone maintenance-treatment clinic after release from incarceration and time to engagement with methadone maintenance treatment, by intention-to-treat and as-treated analyses, which we established in a follow-up interview with the participants at 1 month after their release from incarceration. Our study paid for 10 weeks of methadone treatment after release if participants needed financial help. This trial is registered with ClinicalTrials.gov, number NCT01874964. Findings Between June 14, 2011, and April 3, 2013, we randomly assigned 283 prisoners to our study, 142 to continued methadone treatment, and 141 to forced withdrawal from methadone. Of these, 60 were excluded because they did not fit the eligibility criteria, leaving 114 in the continued-methadone group and 109 in the forced-withdrawal group (usual care). Participants assigned to continued methadone were more than twice as likely than forced-withdrawal participants to return to a community methadone clinic within 1 month of release (106 [96%] of 110 in the continued-methadone group compared with 68 [78%] of 87 in the forced-withdrawal group; adjusted hazard ratio [HR] 2.04, 95% CI 1.48-2.80). We noted no differences in serious adverse events between groups. For the continued-methadone and forced-withdrawal groups, the number of deaths were one and zero, non-fatal overdoses were one and two, admissions to hospital were one and four; and emergency-room visits were 11 and 16, respectively. Interpretation Although our study had several limitations-eg, it only included participants incarcerated for fewer than 6 months, we showed that forced withdrawal from methadone on incarceration reduced the likelihood of prisoners re-engaging in methadone maintenance after their release. Continuation of methadone maintenance during incarceration could contribute to greater treatment engagement after release, which could in turn reduce the risk of death from overdose and risk behaviours.	[Rich, Josiah D.; McKenzie, Michelle; Larney, Sarah; Clarke, Jennifer; Noska, Amanda; Reddy, Manasa] Brown Univ, Providence, RI 02912 USA; [Zaller, Nickolas] Univ Arkansas Med Sci, Fay W Boozman Coll Publ Hlth, Little Rock, AR 72205 USA; [Rich, Josiah D.; McKenzie, Michelle; Larney, Sarah; Tran, Liem; Clarke, Jennifer; Noska, Amanda; Reddy, Manasa; Zaller, Nickolas] Miriam Hosp, Ctr Prisoner Hlth & Human Rights, Providence, RI 02906 USA; [Larney, Sarah] Univ New S Wales, Natl Drug & Alcohol Res Ctr, Sydney, NSW 2052, Australia; [Wong, John B.] Tufts Univ, Sch Med, Tufts Med Ctr, Boston, MA 02111 USA; [Clarke, Jennifer] Mem Hosp, Pawtucket, RI USA	Brown University; University of Arkansas System; University of Arkansas Medical Sciences; Lifespan Health Rhode Island; Miriam Hospital; University of New South Wales Sydney; Tufts Medical Center; Tufts University	Rich, JD (corresponding author), Miriam Hosp, Ctr Prisoner Hlth & Human Rights, Providence, RI 02906 USA.	jrich@lifespan.org	Larney, Sarah/AAR-1372-2020	Larney, Sarah/0000-0002-5602-4963; Noska, Amanda/0000-0002-9256-0042; Wong, John/0000-0003-4203-9010	National Institute on Drug Abuse [K24DA022112, R01DA027211]; Lifespan/Tufts/Brown Center for AIDS Research, from the National Institutes of Health, Centers for AIDS Research [P30-AI-42853]; National Health and Medical Research Council Early Career Fellowship [APP1035149]; Australian Government under the Substance Misuse Prevention and Service Improvements Grants Fund; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI042853] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA027211, K24DA022112] Funding Source: NIH RePORTER	National Institute on Drug Abuse(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); Lifespan/Tufts/Brown Center for AIDS Research, from the National Institutes of Health, Centers for AIDS Research(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Health and Medical Research Council Early Career Fellowship(National Health and Medical Research Council (NHMRC) of Australia); Australian Government under the Substance Misuse Prevention and Service Improvements Grants Fund(Australian Government); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)	We thank the medical and custodial staff of the Rhode Island Department of Corrections including Ashbel T Wall, Fred Vohr, Gordon Bouchard, Pat Threats, Brenda Abelli, Vincent Jacavone, Eric Lewis, J R Perez, Pauline Marcussen, Jeff Renzi, and Margaret Paquette; our research team Candelaria Barroso, Ricky Lugo, Charlotte Reels, Chandra Cannon, Maria Garcia, Skye Tirado, Christina Anastacio; Sophie Sprecht and the other study nurses; staff in all the methadone clinics in Rhode Island and, in particular, the participants in this study. This research was supported by grants from the National Institute on Drug Abuse (K24DA022112 and R01DA027211) and the Lifespan/Tufts/Brown Center for AIDS Research, from the National Institutes of Health, Centers for AIDS Research (grant P30-AI-42853). Sarah Larney is funded by a National Health and Medical Research Council Early Career Fellowship (APP1035149). The National Drug and Alcohol Research Centre at the University of New South Wales is supported by funding from the Australian Government under the Substance Misuse Prevention and Service Improvements Grants Fund. The content is solely the responsibility of the authors and does not necessarily represent the official views of the funders.	[Anonymous], 2005, MEDICATION ASSISTED; Barnett PG, 1999, ADDICTION, V94, P479, DOI 10.1046/j.1360-0443.1999.9444793.x; Binswanger IA, 2007, NEW ENGL J MED, V356, P157, DOI 10.1056/NEJMsa064115; Boucher R., 2003, V LAW REV, V27, P453; Boutwell Amy E, 2007, J Opioid Manag, V3, P328; Briggs AH, 1997, HEALTH ECON, V6, P327, DOI 10.1002/(SICI)1099-1050(199707)6:4<327::AID-HEC282>3.0.CO;2-W; Connock M, 2007, HEALTH TECHNOL ASSES, V11, P1; Cuellar AE, 2012, HEALTH AFFAIR, V31, P931, DOI 10.1377/hlthaff.2011.0501; Deck D, 2009, J ADDICT DIS, V28, P89, DOI 10.1080/10550880902772373; Degenhardt L, 2014, ADDICTION, V109, P1306, DOI 10.1111/add.12536; Degenhardt L, 2014, ADDICTION, V109, P1320, DOI 10.1111/add.12551; Degenhardt L, 2012, LANCET, V379, P55, DOI 10.1016/S0140-6736(11)61138-0; Degenhardt L, 2011, ADDICTION, V106, P32, DOI 10.1111/j.1360-0443.2010.03140.x; Desgagne A, 1998, PHARMACOECONOMICS, V13, P487, DOI 10.2165/00019053-199813050-00002; Dolan KA, 2003, DRUG ALCOHOL DEPEN, V72, P59, DOI 10.1016/S0376-8716(03)00187-X; DOLE VP, 1969, NEW ENGL J MED, V280, P1372, DOI 10.1056/NEJM196906192802502; Fiscella K, 2004, J URBAN HEALTH, V81, P645, DOI 10.1093/jurban/jth147; Fu JJ, 2013, J SUBST ABUSE TREAT, V44, P502, DOI 10.1016/j.jsat.2012.10.005; Gisev N, 2014, DETERMINING IMPACT O; Gordon MS, 2008, ADDICTION, V103, P1333, DOI 10.1111/j.1360-0443.2008.002238.x; Gruber VA, 2008, DRUG ALCOHOL DEPEN, V94, P199, DOI 10.1016/j.drugalcdep.2007.11.021; GUNNE LM, 1981, DRUG ALCOHOL DEPEN, V7, P249, DOI 10.1016/0376-8716(81)90096-X; Harm Reduction International, GLOB STAT HARM RED 2; Harris A, 2012, SUBST ABUS, V33, P70, DOI 10.1080/08897077.2011.620479; Hedrich D, 2012, ADDICTION, V107, P501, DOI 10.1111/j.1360-0443.2011.03676.x; Hosmer DW, 1999, APPL SURVIVAL ANAL; Humber N, 2013, SOC PSYCH PSYCH EPID, V48, P1177, DOI 10.1007/s00127-012-0632-4; Kerr T, 2007, DRUG ALCOHOL DEPEN, V87, P39, DOI 10.1016/j.drugalcdep.2006.07.009; Kinlock TW, 2007, DRUG ALCOHOL DEPEN, V91, P220, DOI 10.1016/j.drugalcdep.2007.05.022; Larney S, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2013-004666; Larney S, 2012, ADDICTION, V107, P372, DOI 10.1111/j.1360-0443.2011.03618.x; Larney S, 2010, ADDICTION, V105, P216, DOI 10.1111/j.1360-0443.2009.02826.x; Larney S, 2009, EUR ADDICT RES, V15, P107, DOI 10.1159/000199046; MacArthur GJ, 2012, BMJ-BRIT MED J, V345, DOI 10.1136/bmj.e5945; Mattick RP, 2009, COCHRANE DB SYST REV, V3, DOI DOI 10.1002/14651858.CD002209; McKenzie M, 2012, SUBST ABUS, V33, P19, DOI 10.1080/08897077.2011.609446; McKenzie Michelle, 2009, J Opioid Manag, V5, P219; MCLELLAN AT, 1992, J SUBST ABUSE TREAT, V9, P199, DOI 10.1016/0740-5472(92)90062-S; Merrall ELC, 2010, ADDICTION, V105, P1545, DOI 10.1111/j.1360-0443.2010.02990.x; Mitchell SG, 2009, J PSYCHOACTIVE DRUGS, V41, P145, DOI 10.1080/02791072.2009.10399907; NEWMAN RG, 1979, LANCET, V2, P485; Paulozzi Leonard, 2012, Morbidity and Mortality Weekly Report, V61, P10; Ramsey S, 2005, VALUE HEALTH, V8, P521, DOI 10.1111/j.1524-4733.2005.00045.x; Rich JD, 2014, HEALTH AFFAIR, V33, P462, DOI 10.1377/hlthaff.2013.1133; Rivlin A, 2013, CRISIS, V34, P335, DOI 10.1027/0227-5910/a000205; Schwartz RP, 2007, DRUG ALCOHOL DEPEN, V86, P30, DOI 10.1016/j.drugalcdep.2006.04.017; Sees KL, 2000, JAMA-J AM MED ASSOC, V283, P1303, DOI 10.1001/jama.283.10.1303; STRAIN EC, 1993, ANN INTERN MED, V119, P23, DOI 10.7326/0003-4819-119-1-199307010-00004; Thompson MA, 2012, ANN INTERN MED, V156, P817, DOI 10.7326/0003-4819-156-11-201206050-00419; VANICHSENI S, 1991, INT J ADDICT, V26, P1313, DOI 10.3109/10826089109062163; WEI LJ, 1988, CONTROL CLIN TRIALS, V9, P345, DOI 10.1016/0197-2456(88)90048-7; WHO, 2005, 14 MOD LIST ESS MED; Wolfe D, 2010, LANCET, V376, P355, DOI 10.1016/S0140-6736(10)60832-X; World Health Organization, 2009, GUID PSYCH ASS PHARM; World Health Organization (WHO), 2007, HLTH PRIS WHO GUID E; YANCOVITZ SR, 1991, AM J PUBLIC HEALTH, V81, P1185, DOI 10.2105/AJPH.81.9.1185; Zaller ND, 2009, INT J ENV RES PUB HE, V6, P787, DOI 10.3390/ijerph6020787	57	131	131	0	26	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 25	2015	386	9991					350	359		10.1016/S0140-6736(14)62338-2	http://dx.doi.org/10.1016/S0140-6736(14)62338-2			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	CN5CX	26028120	Green Accepted			2023-01-03	WOS:000358448400024
J	Chen, YH; Chiang, MH; Liu, JS; Chang, YK; Kuo, KL; Hung, SC; Tai, HL; Hsu, CC; Tarng, DC				Chen, Yu-Hsin; Chiang, Ming-Han; Liu, Jia-Sin; Chang, Yu-Kang; Kuo, Ko-Lin; Hung, Szu-Chun; Tai, Hsin-Ling; Hsu, Chih-Cheng; Tarng, Der-Cherng			Thiazolidinediones and Risk of Long-Term Dialysis in Diabetic Patients with Advanced Chronic Kidney Disease: A Nationwide Cohort Study	PLOS ONE			English	Article							PIOGLITAZONE CLINICAL-TRIAL; MACROVASCULAR EVENTS; RENAL-FUNCTION; TYPE-2; ROSIGLITAZONE; ASSOCIATION; DECLINE	Thiazolidinediones (TZDs) reduce urinary albumin excretion and proteinuria in diabetic nephropathy. The effect of TZDs on hard renal outcome in diabetic patients with chronic kidney disease (CKD) is unknown. We investigate the association of TZDs and risk of long-term dialysis or death in diabetic patients with advanced CKD. The nationwide population-based cohort study was conducted using Taiwan's National Health Insurance Research Database. From January 2000 to June 2009, 12350 diabetic patients with advanced CKD (serum creatinine levels greater than 6 mg/dL but not yet receiving renal replacement therapy) were selected for the study. We used multivariable Cox regression models and a propensity score-based matching technique to estimate hazard ratios (HRs) for development of long-term dialysis and the composite outcome of long-term dialysis or death for TZD users (n=1224) as compared to nonusers (n=11126). During a median follow-up of 6 months, 8270 (67.0%) patients required long-term dialysis and 2593 (21.0%) patients died before starting long-term dialysis. Using propensity score matched analysis, we found TZD users were associated with a lower risk for long-term dialysis (HR, 0.80; 95% confidence interval [CI], 0.74-0.86) and the composite outcome of long-term dialysis or death (HR, 0.85; 95% CI, 0.80-0.91). The results were consistent across most patient subgroups. Use of TZDs among diabetic patients with advanced CKD was associated with lower risk for progression to end-stage renal disease necessitating long-term dialysis or death. Further randomized controlled studies are required to validate this association.	[Chen, Yu-Hsin] Taipei City Hosp, Dept Internal Med, Div Nephrol, Yang Ming Branch, Taipei, Taiwan; [Chen, Yu-Hsin] Natl Yang Ming Univ, Fac Med, Taipei 112, Taiwan; [Chiang, Ming-Han; Liu, Jia-Sin; Chang, Yu-Kang; Hsu, Chih-Cheng] Natl Hlth Res Inst, Inst Populat Hlth Sci, Zhunan, Taiwan; [Kuo, Ko-Lin; Hung, Szu-Chun] Taipei Tzuchi Hosp, Buddhist Tzuchi Med Fdn, Div Nephrol, Taipei, Taiwan; [Tai, Hsin-Ling] Taipei Vet Gen Hosp, Dept Nursing, Taipei, Taiwan; [Hsu, Chih-Cheng] China Med Univ, Dept Hlth Serv Adm, Taichung, Taiwan; [Tarng, Der-Cherng] Taipei Vet Gen Hosp, Dept Med, Div Nephrol, Taipei, Taiwan; [Tarng, Der-Cherng] Natl Yang Ming Univ, Dept & Inst Physiol, Taipei 112, Taiwan; [Tarng, Der-Cherng] Natl Yang Ming Univ, Inst Clin Med, Taipei 112, Taiwan	Taipei City Hospital; National Yang Ming Chiao Tung University; National Health Research Institutes - Taiwan; Taipei Veterans General Hospital; China Medical University Taiwan; Taipei Veterans General Hospital; National Yang Ming Chiao Tung University; National Yang Ming Chiao Tung University	Hsu, CC (corresponding author), Natl Hlth Res Inst, Inst Populat Hlth Sci, Zhunan, Taiwan.	cch@nhri.org.tw; dctarng@vghtpe.gov.tw		Kuo, Ko-Lin/0000-0002-7477-0388	National Science Council [NSC 102-2314-B-010-004-MY3, NSC 102-2314-B-303-003]; Taipei Veterans General Hospital [V102C129, V103C-024]; Foundation for Poison Control; Ministry of Education Aim for the Top University Plan in Taiwan; National Health Research Institutes [NHRI PH-104-SP08-018]; Ministry of Health and Welfare [04D9-PHBHP01]	National Science Council(Ministry of Science and Technology, Taiwan); Taipei Veterans General Hospital(Taipei Veterans General Hospital); Foundation for Poison Control; Ministry of Education Aim for the Top University Plan in Taiwan; National Health Research Institutes(National Health Research Institutes, Japan); Ministry of Health and Welfare(Ministry of Health, Labour and Welfare, Japan)	This work was supported in part to Dr. DC Tarng by grants from the National Science Council (NSC 102-2314-B-010-004-MY3; NSC 102-2314-B-303-003), Taipei Veterans General Hospital (V102C129; V103C-024), Foundation for Poison Control, and Ministry of Education Aim for the Top University Plan in Taiwan; and to Dr. CC Hsu by grants from the National Health Research Institutes (NHRI PH-104-SP08-018), and Ministry of Health and Welfare (04D9-PHBHP01). The funders had no involvement in the study design, data collection, data analysis, manuscript preparation, and/or publication decisions.	Bolignano D, 2012, NUTR METAB CARDIOVAS, V22, P167, DOI 10.1016/j.numecd.2011.11.005; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Cheng TM, 2003, HEALTH AFFAIR, V22, P61, DOI 10.1377/hlthaff.22.3.61; Dormandy JA, 2005, LANCET, V366, P1279, DOI 10.1016/S0140-6736(05)67528-9; Erdmann E, 2007, J AM COLL CARDIOL, V49, P1772, DOI 10.1016/j.jacc.2006.12.048; Feldman L, 2010, J NEPHROL, V23, P350; Guan YF, 2001, AM J PHYSIOL-RENAL, V281, pF1036, DOI 10.1152/ajprenal.0025.2001; Hsu TW, 2014, JAMA INTERN MED, V174, P347, DOI 10.1001/jamainternmed.2013.12700; Iezzoni LI, 1997, RISK ADJUSTMENT MEAS; Inzucchi SE, 2012, DIABETES CARE, V35, P1364, DOI 10.2337/dc12-0413; Kim Mee Kyoung, 2009, Korean Journal of Internal Medicine, V24, P227, DOI 10.3904/kjim.2009.24.3.227; Sarafidis PA, 2006, KIDNEY INT, V70, P1223, DOI 10.1038/sj.ki.5001620; Sarafidis PA, 2010, AM J KIDNEY DIS, V55, P835, DOI 10.1053/j.ajkd.2009.11.013; Schneider CA, 2008, J AM SOC NEPHROL, V19, P182, DOI 10.1681/ASN.2007060678; United States Renal Data System, 2014 INT COMP; United States Renal Data System, 2013 ANN DAT REP; Whelton A., 1999, AM J MED, V106, p13S, DOI [10.1016/S0002-9343(99)00113-8, DOI 10.1016/S0002-9343(99)00113-8, 10.1016/s0002-9343(99)00113-8]; Wilcox R, 2007, STROKE, V38, P865, DOI 10.1161/01.STR.0000257974.06317.49; Zheng F, 2002, AM J PHYSIOL-RENAL, V282, pF639, DOI 10.1152/ajprenal.00189.2001; Zoccali C, 2009, CLIN J AM SOC NEPHRO, V4, pS18, DOI 10.2215/CJN.05210709	20	8	8	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 17	2015	10	6							e0129922	10.1371/journal.pone.0129922	http://dx.doi.org/10.1371/journal.pone.0129922			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CK9NS	26083376	gold, Green Published, Green Submitted			2023-01-03	WOS:000356567400114
J	Woolf, EC; Curley, KL; Liu, QW; Turner, GH; Charlton, JA; Preul, MC; Scheck, AC				Woolf, Eric C.; Curley, Kara L.; Liu, Qingwei; Turner, Gregory H.; Charlton, Julie A.; Preul, Mark C.; Scheck, Adrienne C.			The Ketogenic Diet Alters the Hypoxic Response and Affects Expression of Proteins Associated with Angiogenesis, Invasive Potential and Vascular Permeability in a Mouse Glioma Model	PLOS ONE			English	Article							ANTIANGIOGENIC THERAPY; ENDOTHELIAL-CELLS; GLIOBLASTOMA; SURVIVAL; CANCER; GROWTH; PROMOTES; EDEMA; ANGIOPOIETIN-1; HYPERGLYCEMIA	Background The successful treatment of malignant gliomas remains a challenge despite the current standard of care, which consists of surgery, radiation and temozolomide. Advances in the survival of brain cancer patients require the design of new therapeutic approaches that take advantage of common phenotypes such as the altered metabolism found in cancer cells. It has therefore been postulated that the high-fat, low-carbohydrate, adequate protein ketogenic diet (KD) may be useful in the treatment of brain tumors. We have demonstrated that the KD enhances survival and potentiates standard therapy in a mouse model of malignant glioma, yet the mechanisms are not fully understood. Methods To explore the effects of the KD on various aspects of tumor growth and progression, we used the immunocompetent, syngeneic GL261-Luc2 mouse model of malignant glioma. Results Tumors from animals maintained on KD showed reduced expression of the hypoxia marker carbonic anhydrase 9, hypoxia inducible factor 1-alpha, and decreased activation of nuclear factor kappa B. Additionally, tumors from animals maintained on KD had reduced tumor microvasculature and decreased expression of vascular endothelial growth factor receptor 2, matrix metalloproteinase-2 and vimentin. Peritumoral edema was significantly reduced in animals fed the KD and protein analyses showed altered expression of zona occludens-1 and aquaporin-4. Conclusions The KD directly or indirectly alters the expression of several proteins involved in malignant progression and may be a useful tool for the treatment of gliomas.	[Woolf, Eric C.; Curley, Kara L.; Charlton, Julie A.; Scheck, Adrienne C.] St Josephs Hosp, Barrow Neurol Inst Dba, Barrow Brain Tumor Res Ctr, Neurooncol Res, Phoenix, AZ 85013 USA; [Woolf, Eric C.; Scheck, Adrienne C.] Arizona State Univ, Sch Life Sci, Tempe, AZ 85281 USA; [Liu, Qingwei; Turner, Gregory H.] St Josephs Hosp, Barrow Neurol Inst Dba, BNI ASU Ctr Preclin Imaging, Phoenix, AZ 85013 USA; [Preul, Mark C.; Scheck, Adrienne C.] St Josephs Hosp, Barrow Neurol Inst Dba, Neurosurg Res, Phoenix, AZ 85013 USA	Barrow Neurological Institute; St. Joseph's Hospital and Medical Center; Arizona State University; Arizona State University-Tempe; Arizona State University; Arizona State University-Downtown Phoenix; Barrow Neurological Institute; St. Joseph's Hospital and Medical Center; Barrow Neurological Institute; St. Joseph's Hospital and Medical Center	Scheck, AC (corresponding author), St Josephs Hosp, Barrow Neurol Inst Dba, Barrow Brain Tumor Res Ctr, Neurooncol Res, Phoenix, AZ 85013 USA.	Adrienne.scheck@dignityhealth.org	Scheck, Adrienne/AAH-5040-2020	Scheck, Adrienne/0000-0003-3497-1895; Curley, Kara/0000-0001-5959-5932	Students Supporting Brain Tumor Research; Nutricia Advanced Medical Nutrition through Nutricia North America; Remi Savioz GLUT1 Foundation; KetoCal	Students Supporting Brain Tumor Research; Nutricia Advanced Medical Nutrition through Nutricia North America(Danone Nutricia); Remi Savioz GLUT1 Foundation; KetoCal	This work was supported by an unrestricted grant from Students Supporting Brain Tumor Research (www.ssbtr.org). The authors also received a grant-in-kind from Nutricia Advanced Medical Nutrition through Nutricia North America (http://nutrition.nutricia.com/), who provided KetoCal and the Remi Savioz GLUT1 Foundation (http://www.rsg1foundation.com/) who provided the blood analysis equipment. The funders had no role in data collection and analysis, decision to publish or preparation of the manuscript, or the study design. No additional external funding was received for this study.	Abdelwahab MG, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036197; Abdelwahab MG, 2011, JOVE-J VIS EXP, DOI 10.3791/3403; Azzi S, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00211; Badiga AV, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020614; Carbonell WS, 2013, CANCER RES, V73, P3145, DOI 10.1158/0008-5472.CAN-13-0011; Chinot OL, 2014, NEW ENGL J MED, V370, P709, DOI 10.1056/NEJMoa1308345; Crocker M, 2011, NEURO-ONCOLOGY, V13, P99, DOI 10.1093/neuonc/noq170; Culver C, 2010, MOL CELL BIOL, V30, P4901, DOI 10.1128/MCB.00409-10; Dai W, 2013, CLIN CANCER RES, V19, P5788, DOI 10.1158/1078-0432.CCR-13-1217; de Groot J., 2013, AM SOC CLIN ONCOL ED, V2013, P71, DOI DOI 10.1200/EDB00K_; Derr RL, 2009, J CLIN ONCOL, V27, P1082, DOI 10.1200/JCO.2008.19.1098; Fischer S, 2002, MICROVASC RES, V63, P70, DOI 10.1006/mvre.2001.2367; Fruehauf JP, 2007, CLIN CANCER RES, V13, P789, DOI 10.1158/1078-0432.CCR-06-2082; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Higashida T, 2011, J NEUROSURG, V114, P92, DOI 10.3171/2010.6.JNS10207; Hu YL, 2012, CANCER RES, V72, P1773, DOI 10.1158/0008-5472.CAN-11-3831; Ishihara H, 2008, J NEUROPATH EXP NEUR, V67, P435, DOI 10.1097/NEN.0b013e31816fd622; Jahangiri A, 2014, CANCER RES, V74, P3, DOI 10.1158/0008-5472.CAN-13-1742; Jain R, 2011, ACAD RADIOL, V18, P955, DOI 10.1016/j.acra.2011.04.003; Jain RK, 2008, NAT REV CANCER, V8, P309, DOI 10.1038/nrc2346; Jiang YS, 2013, J NEURO-ONCOL, V114, P25, DOI 10.1007/s11060-013-1154-y; Kaur B, 2005, NEURO-ONCOLOGY, V7, P134, DOI 10.1215/S1152851704001115; Kossoff Eric H, 2013, Biomed J, V36, P2, DOI 10.4103/2319-4170.107152; Li XR, 2012, TRENDS MOL MED, V18, P119, DOI 10.1016/j.molmed.2011.11.006; Liu D, 2010, ONCOTARGET, V1, P700; Lucio-Eterovic AK, 2009, CLIN CANCER RES, V15, P4589, DOI 10.1158/1078-0432.CCR-09-0575; Ma J, 2014, J CELL PHYSIOL, V229, P916, DOI 10.1002/jcp.24523; Machein MR, 2004, AM J PATHOL, V165, P1557, DOI 10.1016/S0002-9440(10)63413-X; Mayer A, 2014, STRAHLENTHER ONKOL, V190, P933, DOI 10.1007/s00066-014-0696-z; McGirt MJ, 2008, NEUROSURGERY, V63, P286, DOI 10.1227/01.NEU.0000315282.61035.48; Mulrooney TJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018085; Myung JK, 2014, INT J CLIN EXP PATHO, V7, P1977; Navis AC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058262; Nogueira L, 2011, ONCOTARGET, V2, P646, DOI 10.18632/oncotarget.322; Olar A, 2014, J PATHOL, V232, P165, DOI 10.1002/path.4282; Proescholdt MA, 2012, NEURO-ONCOLOGY, V14, P1357, DOI 10.1093/neuonc/nos216; Raghu H, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012458; Raghua H, 2012, MOL ONCOL, V6, P33, DOI 10.1016/j.molonc.2011.11.008; Reardon DA, 2012, J NEURO-ONCOL, V107, P213, DOI 10.1007/s11060-011-0740-0; Ribatti D, 2014, BBA-GEN SUBJECTS, V1840, P1550, DOI 10.1016/j.bbagen.2013.09.025; Rous P, 1914, J EXP MED, V20, P433, DOI 10.1084/jem.20.5.433; Schnell SA, 1999, J HISTOCHEM CYTOCHEM, V47, P719, DOI 10.1177/002215549904700601; Semenza GL, 2009, SEMIN CANCER BIOL, V19, P12, DOI 10.1016/j.semcancer.2008.11.009; Seyfried TN, 2014, CARCINOGENESIS, V35, P515, DOI 10.1093/carcin/bgt480; Stafford P, 2010, NUTR METAB, V7, DOI 10.1186/1743-7075-7-74; Tso CL, 2006, MOL CANCER RES, V4, P607, DOI 10.1158/1541-7786.MCR-06-0005; Urits I, 2012, J ONCOL, V2012, DOI 10.1155/2012/264039; Warburg O, 1927, J GEN PHYSIOL, V8, P519, DOI 10.1085/jgp.8.6.519; Weinberg F, 2009, CELL MOL LIFE SCI, V66, P3663, DOI 10.1007/s00018-009-0099-y; Winkler F, 2004, CANCER CELL, V6, P553, DOI 10.1016/j.ccr.2004.10.011; Woolf EC, 2015, J LIPID RES, V56, P5, DOI 10.1194/jlr.R046797; Woolf Eric C, 2012, CNS Oncol, V1, P7, DOI 10.2217/cns.12.9; Yang LJ, 2012, ONCOL REP, V28, P1633, DOI 10.3892/or.2012.1973; Yang LQ, 2012, EXP CELL RES, V318, P2417, DOI 10.1016/j.yexcr.2012.07.017; Zadeh G, 2005, NEOPLASIA, V7, P1081, DOI 10.1593/neo.05424; Zadeh G, 2004, J NEUROPATH EXP NEUR, V63, P978, DOI 10.1093/jnen/63.9.978; Zhou WH, 2007, NUTR METAB, V4, DOI 10.1186/1743-7075-4-5	57	68	72	0	17	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 17	2015	10	6							e0130357	10.1371/journal.pone.0130357	http://dx.doi.org/10.1371/journal.pone.0130357			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CK9NS	26083629	gold, Green Submitted, Green Published			2023-01-03	WOS:000356567400139
J	Kelley, GA; Kelley, KS				Kelley, George A.; Kelley, Kristi S.			Meditative Movement Therapies and Health-Related Quality-of-Life in Adults: A Systematic Review of Meta-Analyses	PLOS ONE			English	Review							CHRONIC HEART-FAILURE; BREAST-CANCER PATIENTS; METHODOLOGICAL QUALITY; TAI-CHI; MEASUREMENT TOOL; EXERCISE CAPACITY; YOGA; SURVIVORS; BENEFITS; VALIDATION	Poor health-related quality-of-life (HRQOL) is a significant public health issue while the use of meditative movement therapies has been increasing. The purpose of this investigation was to carry out a systematic review of previous meta-analyses that examined the effects of meditative movement therapies (yoga, tai chi and qigong) on HRQOL in adults. Previous meta-analyses of randomized controlled trials published up through February, 2014 were included by searching nine electronic databases and cross-referencing. Dual-selection and data abstraction occurred. The Assessment of Multiple Systematic Reviews Instrument (AMSTAR) was used to assess methodological quality. Standardized mean differences that were pooled using random-effects models were included. In addition, 95% prediction intervals were calculated as well as the number needed-to-treat and percentile improvements. Of the 510 citations screened, 10 meta-analyses representing a median of 3 standardized mean differences in 82 to 528 participants (median = 270) with breast cancer, schizophrenia, low back pain, heart failure and diabetes, were included. Median methodological quality was 70%. Median length, frequency and duration of the meditative movement therapies were 12 weeks, 3 times per week, for 71 minutes per session. The majority of results (78.9%) favored statistically significant improvements (non-overlapping 95% confidence intervals) in HRQOL, with standardized mean differences ranging from 0.18 to 2.28. More than half of the results yielded statistically significant heterogeneity (Q <= 0.10) and large or very large inconsistency (I-2 >= 50%). All 95% prediction intervals included zero. The number-needed-to-treat ranged from 2 to 10 while percentile improvements ranged from 9.9 to 48.9. The results of this study suggest that meditative movement therapies may improve HRQOL in adults with selected conditions. However, a need exists for a large, more inclusive meta-analysis (PROSPERO Registration #CRD42014014576).	[Kelley, George A.; Kelley, Kristi S.] W Virginia Univ, Dept Biostat, Morgantown, WV 26506 USA	West Virginia University	Kelley, GA (corresponding author), W Virginia Univ, Dept Biostat, Morgantown, WV 26506 USA.	gkelley@hsc.wvu.edu	Kelley, Kristi S/B-5151-2008		National Institute of General Medical Sciences (NIGMS) of the National Institutes of Health (NIH) [U54GM104942]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [U54GM104942] Funding Source: NIH RePORTER	National Institute of General Medical Sciences (NIGMS) of the National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	George A. Kelley was funded by the National Institute of General Medical Sciences (NIGMS) of the National Institutes of Health (NIH) under award number U54GM104942. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. URL: http://www.nigms.nih.gov/Pages/default.aspx.	Ades AE, 2013, MED DECIS MAKING, V33, P679, DOI 10.1177/0272989X13485156; [Anonymous], 2009, REF MAN VERS 12 0 3; [Anonymous], 2010, MICR EXC VERS 2007 C; Barnes Patricia M, 2008, Natl Health Stat Report, P1; Barrow DE, 2007, POSTGRAD MED J, V83, P717, DOI 10.1136/pgmj.2007.061267; Biostat, 2006, COMPREHENSIVE METAAN; Borenstein M., 2009, INTRO META ANAL; Buffart LM, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-559; Burnham Judy F, 2006, Biomed Digit Libr, V3, P1; Chandwani Kavita D, 2010, J Soc Integr Oncol, V8, P43; CICCHETTI DV, 1981, AM J MENT DEF, V86, P127; COHEN J, 1968, PSYCHOL BULL, V70, P213, DOI 10.1037/h0026256; COHEN J, 1992, PSYCHOL BULL, V112, P155, DOI 10.1037/0033-2909.112.1.155; Cohen J., 2013, STAT POWER ANAL BEHA; Conn VS, 2009, NURS RES, V58, P175, DOI 10.1097/NNR.0b013e318199b53a; Cooper H, 2009, PSYCHOL METHODS, V14, P165, DOI 10.1037/a0015565; Cramer H, 2013, CLIN J PAIN, V29, P450, DOI 10.1097/AJP.0b013e31825e1492; Cramer H, 2013, BMC PSYCHIATRY, V13, DOI 10.1186/1471-244X-13-32; Cramer H, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-412; Davies EJ, 2010, EUR J HEART FAIL, V12, P706, DOI 10.1093/eurjhf/hfq056; Duijts SFA, 2011, PSYCHO-ONCOLOGY, V20, P115, DOI 10.1002/pon.1728; Durlak JA, 2009, J PEDIATR PSYCHOL, V34, P917, DOI 10.1093/jpepsy/jsp004; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; Gorczynski P, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004412.pub2; Graham PL, 2012, J CLIN EPIDEMIOL, V65, P503, DOI 10.1016/j.jclinepi.2011.09.012; Guyatt GH, 2008, BRIT MED J, V336, P924, DOI 10.1136/bmj.39489.470347.AD; Harzing A.W., 2019, PUBLISH PERISH; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; Higgins JPT, 2009, J R STAT SOC A STAT, V172, P137, DOI 10.1111/j.1467-985X.2008.00552.x; Johnson BT, 2014, J HYPERTENS, V32, P706, DOI 10.1097/HJH.0000000000000097; Kang DY, 2012, EVID-BASED COMPL ALT, V2012, P1; Kelley GA, 2014, BMC MUSCULOSKEL DIS, V15, DOI 10.1186/1471-2474-15-121; Kelley GA, 2009, PREV MED, V49, P473, DOI 10.1016/j.ypmed.2009.09.018; Lee E, 2012, BMC MED RES METHODOL, V12, DOI 10.1186/1471-2288-12-51; Liberati A, 2009, PLOS MED, V6, DOI [10.1371/journal.pmed.1000100, 10.1136/bmj.b2700, 10.7326/0003-4819-151-4-200908180-00136]; Lin KY, 2011, EVID-BASED COMPL ALT, V2011, P1, DOI 10.1155/2011/659876; Macdonald G, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001930.pub3; Mosteller F, 1996, ANNU REV PUBL HEALTH, V17, P1, DOI 10.1146/annurev.pu.17.050196.000245; OXMAN AD, 1991, J CLIN EPIDEMIOL, V44, P1271, DOI 10.1016/0895-4356(91)90160-B; Pan L, 2013, EUR J HEART FAIL, V15, P316, DOI 10.1093/eurjhf/hfs170; Raghavendra RM, 2007, EUR J CANCER CARE, V16, P462, DOI 10.1111/j.1365-2354.2006.00739.x; Riley RD, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c221; SACKS H, 1982, AM J MED, V72, P233, DOI 10.1016/0002-9343(82)90815-4; SACKS HS, 1987, NEW ENGL J MED, V316, P450, DOI 10.1056/NEJM198702193160806; SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V273, P408, DOI 10.1001/jama.273.5.408; Shea BJ, 2007, BMC MED RES METHODOL, V7, DOI 10.1186/1471-2288-7-10; Shea BJ, 2009, J CLIN EPIDEMIOL, V62, P1013, DOI 10.1016/j.jclinepi.2008.10.009; Shea BJ, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001350; Shneerson C, 2013, COMPLEMENT THER MED, V21, P417, DOI 10.1016/j.ctim.2013.05.003; Shorten Allison, 2013, Evid Based Nurs, V16, P3, DOI 10.1136/eb-2012-101118; Smith V, 2011, BMC MED RES METHODOL, V11, DOI 10.1186/1471-2288-11-15; Sterne JAC, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d4002; Thomas DR, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002968.pub2; Wang Fang, 2013, Evid Based Complement Alternat Med, V2013, P152738, DOI 10.1155/2013/152738; Yeh GY, 2011, ARCH INTERN MED, V171, P750, DOI 10.1001/archinternmed.2011.150; Yeh GY, 2004, AM J MED, V117, P541, DOI 10.1016/j.amjmed.2004.04.016; Zack MM, 2013, HLTH RELATED QUALITY, V62, P105; Zeng YC, 2014, COMPLEMENT THER MED, V22, P173, DOI 10.1016/j.ctim.2013.11.010; Zhang J, 2012, J ALTERN COMPLEM MED, V18, P994, DOI 10.1089/acm.2011.0514	59	25	25	1	30	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 8	2015	10	6							e0129181	10.1371/journal.pone.0129181	http://dx.doi.org/10.1371/journal.pone.0129181			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	CK1GM	26053053	Green Published, Green Submitted, gold			2023-01-03	WOS:000355955300098
J	Bourgault, P; Lacasse, A; Marchand, S; Courtemanche-Harel, R; Charest, J; Gaumond, I; de Souza, JB; Choiniere, M				Bourgault, Patricia; Lacasse, Anais; Marchand, Serge; Courtemanche-Harel, Roxanne; Charest, Jacques; Gaumond, Isabelle; de Souza, Juliana Barcellos; Choiniere, Manon			Multicomponent Interdisciplinary Group Intervention for Self-Management of Fibromyalgia: A Mixed-Methods Randomized Controlled Trial	PLOS ONE			English	Article							PAIN CLINICAL-TRIALS; PATIENT GLOBAL IMPRESSION; QUALITY-OF-LIFE; COPING STRATEGIES; PHYSICAL-THERAPY; PROGRAM; METAANALYSIS; INTENSITY; EXERCISE; SCALE	Background This study evaluated the efficacy of the PASSAGE Program, a structured multicomponent interdisciplinary group intervention for the self-management of FMS. Methods A mixed-methods randomized controlled trial (intervention (INT) vs. waitlist (WL)) was conducted with patients suffering from FMS. Data were collected at baseline (T-0), at the end of the intervention (T-1), and 3 months later (T-2). The primary outcome was change in pain intensity (0-10). Secondary outcomes were fibromyalgia severity, pain interference, sleep quality, pain coping strategies, depression, health-related quality of life, patient global impression of change (PGIC), and perceived pain relief. Qualitative group interviews with a subset of patients were also conducted. Complete data from T-0 to T-2 were available for 43 patients. Results The intervention had a statistically significant impact on the three PGIC measures. At the end of the PASSAGE Program, the percentages of patients who perceived overall improvement in their pain levels, functioning and quality of life were significantly higher in the INT Group (73%, 55%, 77% respectively) than in the WL Group (8%, 12%, 20%). The same differences were observed 3 months post-intervention (Intervention group: 62%, 43%, 38% vs Waitlist Group: 13%, 13%, 9%). The proportion of patients who reported >= 50% pain relief was also significantly higher in the INT Group at the end of the intervention (36% vs 12%) and 3 months post-intervention (33% vs 4%). Results of the qualitative analysis were in line with the quantitative findings regarding the efficacy of the intervention. The improvement, however, was not reflected in the primary outcome and other secondary outcome measures. Conclusion The PASSAGE Program was effective in helping FMS patients gain a sense of control over their symptoms. We suggest including PGIC in future clinical trials on FMS as they appear to capture important aspects of the patients' experience.	[Bourgault, Patricia] Univ Sherbrooke, Fac Med & Sci Sante, Ecole Sci Infirmieres, Sherbrooke, PQ J1K 2R1, Canada; [Bourgault, Patricia; Marchand, Serge; Courtemanche-Harel, Roxanne; Gaumond, Isabelle; de Souza, Juliana Barcellos] Univ Sherbrooke, Ctr Hosp, Ctr Rech Clin Etienne Le Bel, Sherbrooke, PQ J1K 2R1, Canada; [Bourgault, Patricia; Lacasse, Anais; Choiniere, Manon] Univ Montreal, Ctr Hosp, Ctr Rech, Montreal, PQ, Canada; [Lacasse, Anais; Charest, Jacques] Univ Quebec Abitibi Temiscamingue, Dept Sci Sante, Rouyn Noranda, PQ, Canada; [Marchand, Serge] Univ Sherbrooke, Fac Med & Sci Sante, Dept Neurochirurg, Sherbrooke, PQ J1K 2R1, Canada; [Choiniere, Manon] Univ Montreal, Fac Med, Dept Anesthesiol, Montreal, PQ H3C 3J7, Canada	University of Sherbrooke; University of Sherbrooke; Universite de Montreal; University of Quebec; University Quebec Abitibi-Temiscamingue; University of Sherbrooke; Universite de Montreal	Choiniere, M (corresponding author), Univ Montreal, Ctr Hosp, Ctr Rech, Montreal, PQ, Canada.	manon.choiniere@umontreal.ca		Barcellos de Souza, Juliana/0000-0003-4657-052X; Marchand, Serge/0000-0002-4234-5977	Canadian Institutes of Health Research [86787]; AstraZeneca Canada Inc [86787]; Pfizer Canada Inc.; Quebec Rehabilitation Research Network - Fonds de la recherche en sante du Quebec; Fonds de la recherche en sante du Quebec	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); AstraZeneca Canada Inc(AstraZeneca); Pfizer Canada Inc.; Quebec Rehabilitation Research Network - Fonds de la recherche en sante du Quebec(Fonds de la Recherche en Sante du Quebec); Fonds de la recherche en sante du Quebec(Fonds de la Recherche en Sante du Quebec)	MC, PB and SM received a team research grant-Community Alliances for Health Research and Knowledge Exchange in Pain-of the Canadian Institutes of Health Research in partnership with AstraZeneca Canada Inc (Grant #86787) (http://www.cihr-irsc.gc.ca) to carry out the study. MC and PB also received an unrestricted research grant from Pfizer Canada Inc. (http://www.pfizer.ca) for the same research project. During the study, PB was the recipient of a postdoctoral research award from the Quebec Rehabilitation Research Network (http://www.repar.ca) which is itself funded by the Fonds de la recherche en sante du Quebec (http:www.frqs.gouv.qc.ca), and AL was the recipient of a postdoctoral research award from the Fonds de la recherche en sante du Quebec (http:www.frqs.gouv.qc.ca). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abeles AM, 2007, ANN INTERN MED, V146, P726, DOI 10.7326/0003-4819-146-10-200705150-00006; Affleck G, 1996, PAIN, V68, P363, DOI 10.1016/S0304-3959(96)03226-5; Amris K, 2014, PAIN; Barcellos de Souza J, 2007, DOULEUR ANALG, V20, P213; Beal CC, 2009, CAN J NURS RES, V41, P16; BECK AT, 1984, J CLIN PSYCHOL, V40, P1365, DOI 10.1002/1097-4679(198411)40:6<1365::AID-JCLP2270400615>3.0.CO;2-D; Bennett R, 2006, NAT CLIN PRACT RHEUM, V2, P416, DOI 10.1038/ncprheum0245; Bieber C, 2008, J PSYCHOSOM RES, V64, P13, DOI 10.1016/j.jpsychores.2007.05.009; Bigatti SM, 2008, ARTHRIT RHEUM-ARTHR, V59, P961, DOI 10.1002/art.23828; Birnie KA, 2012, PAIN, V153, P2311, DOI 10.1016/j.pain.2012.07.033; Bjelland I, 2002, J PSYCHOSOM RES, V52, P69, DOI 10.1016/S0022-3999(01)00296-3; Branco JC, 2010, SEMIN ARTHRITIS RHEU, V39, P448, DOI 10.1016/j.semarthrit.2008.12.003; Brosseau L, 2008, PHYS THER, V88, P857, DOI 10.2522/ptj.20070200; BURCKHARDT CS, 1991, J RHEUMATOL, V18, P728; Busch Angela J., 2008, Physiotherapy Theory and Practice, V24, P151, DOI 10.1080/09593980701686872; Cedraschi C, 2004, ANN RHEUM DIS, V63, P290, DOI 10.1136/ard.2002.004945; Charest J, 1996, LOMBALGIE ECOLE INTE, DOI [10.1016/j.rehab.2014.06.006, DOI 10.1016/J.REHAB.2014.06.006]; Charest J, 1994, RHUMATOLOGIE, V48, P221; Cleeland C. S., 1994, Annals Academy of Medicine Singapore, V23, P129; Dworkin RH, 2005, PAIN, V113, P9, DOI 10.1016/j.pain.2004.09.012; Dworkin RH, 2008, J PAIN, V9, P105, DOI 10.1016/j.jpain.2007.09.005; Dworkin RH, 2009, PAIN, V146, P238, DOI 10.1016/j.pain.2009.08.019; Farrar JT, 2001, PAIN, V94, P149, DOI 10.1016/S0304-3959(01)00349-9; Farrar JT, 2000, PAIN, V88, P287, DOI 10.1016/S0304-3959(00)00339-0; Fitzcharles MA, 2013, J RHEUMATOL, V40, P1388, DOI 10.3899/jrheum.130127; Fitzcharles MA, 2013, PAIN RES MANAG, V18, P119, DOI 10.1155/2013/918216; French DJ, 2005, CAN J BEHAV SCI, V37, P181, DOI 10.1037/h0087255; Gauthier J, 1982, REV QUEBEC PSYCHOL, V3, P1; Geisser ME, 2010, PAIN, V149, P373, DOI 10.1016/j.pain.2010.02.043; Glombiewski JA, 2010, PAIN, V151, P280, DOI 10.1016/j.pain.2010.06.011; Gran JT, 2003, BEST PRACT RES CL RH, V17, P547, DOI 10.1016/S1521-6942(03)00042-1; Hadhazy VA, 2000, J RHEUMATOL, V27, P2911; Hauser W, 2010, ARTHRITIS RES THER, V12, DOI 10.1186/ar3002; Hauser W, 2009, JAMA-J AM MED ASSOC, V301, P198, DOI 10.1001/jama.2008.944; Han C, 2011, DRUG TODAY, V47, P539, DOI 10.1358/dot.2011.47.7.1603503; Hauser W, 2008, GER MED SCI, V9, P6; Havermark AM, 2006, SCAND J CARING SCI, V20, P315, DOI 10.1111/j.1471-6712.2006.00410.x; Haythornthwaite JA, 2001, HDB PAIN ASSESSMENT; Hudson JI, 2009, J RHEUMATOL, V36, P2517, DOI 10.3899/jrheum.090139; Irachabal S, 2008, ENCEPHALE, V34, P47, DOI 10.1016/j.encep.2006.11.002; Jensen MP., 2003, VALIDITY RELIABILITY; Jensen MP., 1992, HDB PAIN ASSESSMENT, P19; JICK TD, 1979, ADMIN SCI QUART, V24, P602, DOI 10.2307/2392366; Kosinski M, 2007, CLIN THER, V29, P2562, DOI 10.1016/j.clinthera.2007.12.001; McGillion MH, 2008, J PAIN SYMPTOM MANAG, V36, P126, DOI 10.1016/j.jpainsymman.2007.09.015; Moore RA, 2010, PAIN, V149, P360, DOI 10.1016/j.pain.2010.02.039; Mucchielli R., 2006, ANAL CONTENU DOCUMEN; Nijs J, 2010, PHYS THER, V90, P1815, DOI 10.2522/ptj.20100046; Oldfield, 2013, WOMENS HLTH URBAN LI, V12, P39; Perrot S, 2003, J RHEUMATOL, V30, P1054; Quartana PJ, 2009, EXPERT REV NEUROTHER, V9, P745, DOI 10.1586/ERN.09.34; Ramel J, 2009, CURR RHEUMATOL REV, V5, P188, DOI 10.2174/157339709790192459; Roland M, 1998, BRIT MED J, V316, P285, DOI 10.1136/bmj.316.7127.285; ROSENSTIEL AK, 1983, PAIN, V17, P33, DOI 10.1016/0304-3959(83)90125-2; Rossy LA, 1999, ANN BEHAV MED, V21, P180, DOI 10.1007/BF02908299; Scascighini L, 2008, RHEUMATOLOGY, V47, P670, DOI 10.1093/rheumatology/ken021; Sim J, 2002, CLIN J PAIN, V18, P324, DOI 10.1097/00002508-200209000-00008; Sullivan MJL, 1995, PSYCHOL ASSESSMENT, V7, P524, DOI 10.1037/1040-3590.7.4.524; Thieme Kati, 2009, Curr Rheumatol Rep, V11, P443; Turk DC, 2003, PAIN, V106, P337, DOI 10.1016/j.pain.2003.08.001; Tyler EJ, 2002, ARCH PHYS MED REHAB, V83, P236, DOI 10.1053/apmr.2002.27466; Ware JE, 1996, MED CARE, V34, P220, DOI 10.1097/00005650-199603000-00003; White KP, 1999, J RHEUMATOL, V26, P1570; WOLFE F, 1990, ARTHRITIS RHEUM-US, V33, P160, DOI 10.1002/art.1780330203; Wolfe F, 2010, ARTHRIT CARE RES, V62, P600, DOI 10.1002/acr.20140	65	47	48	2	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 15	2015	10	5							e0126324	10.1371/journal.pone.0126324	http://dx.doi.org/10.1371/journal.pone.0126324			26	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	CI7AU	25978402	Green Accepted, gold, Green Published, Green Submitted			2023-01-03	WOS:000354916100063
J	Melief, CJM				Melief, Cornelis J. M.			Mutation-Specific T Cells for Immunotherapy of Gliomas	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							MELANOMA; BLOCKADE		[Melief, Cornelis J. M.] Leiden Univ, Med Ctr, Dept Immunohematol & Blood Transfus, Leiden, Netherlands; [Melief, Cornelis J. M.] ISA Pharmaceut, Leiden, Netherlands	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Melief, CJM (corresponding author), Leiden Univ, Med Ctr, Dept Immunohematol & Blood Transfus, Leiden, Netherlands.							Gubin MM, 2014, NATURE, V515, P577, DOI 10.1038/nature13988; KAST WM, 1986, J EXP MED, V164, P723, DOI 10.1084/jem.164.3.723; Quezada SA, 2010, J EXP MED, V207, P637, DOI 10.1084/jem.20091918; Schumacher T, 2014, NATURE, V512, P324, DOI 10.1038/nature13387; Snyder A, 2014, NEW ENGL J MED, V371, P2189, DOI 10.1056/NEJMoa1406498	5	12	12	1	9	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 14	2015	372	20					1956	1958		10.1056/NEJMcibr1501818	http://dx.doi.org/10.1056/NEJMcibr1501818			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CI1HB	25970054				2023-01-03	WOS:000354493300014
J	Procopio, TF; Fernandes, KM; Pontual, EV; Ximenes, RM; de Oliveira, ARC; Souza, CD; Melo, AMMD; Navarro, DMDF; Paiva, PMG; Martins, GF; Napoleao, TH				Procopio, Thamara Figueiredo; Fernandes, Kenner Morais; Pontual, Emmanuel Viana; Ximenes, Rafael Matos; Cardoso de Oliveira, Aline Rafaella; Souza, Carolina de Santana; Mendonca de Albuquerque Melo, Ana Maria; do Amaral Ferraz Navarro, Daniela Maria; Guedes Paiva, Patricia Maria; Martins, Gustavo Ferreira; Napoleao, Thiago Henrique			Schinus terebinthifolius Leaf Extract Causes Midgut Damage, Interfering with Survival and Development of Aedes aegypti Larvae	PLOS ONE			English	Article							MYRACRODRUON-URUNDEUVA; INSECTICIDE RESISTANCE; DIPTERA-CULICIDAE; ESSENTIAL OILS; CELLS; DENGUE; METAMORPHOSIS; ALBOPICTUS; INHIBITOR; APOPTOSIS	In this study, a leaf extract from Schinus terebinthifolius was evaluated for effects on survival, development, and midgut of A. aegypti fourth instar larvae (L4), as well as for toxic effect on Artemia salina. Leaf extract was obtained using 0.15 M NaCl and evaluated for phytochemical composition and lectin activity. Early L4 larvae were incubated with the extract (0.3-1.35%, w/v) for 8 days, in presence or absence of food. Polymeric proanthocyanidins, hydrolysable tannins, heterosid and aglycone flavonoids, cinnamic acid derivatives, traces of steroids, and lectin activity were detected in the extract, which killed the larvae at an LC50 of 0.62% (unfed larvae) and 1.03% (fed larvae). Further, the larvae incubated with the extract reacted by eliminating the gut content. No larvae reached the pupal stage in treatments at concentrations between 0.5% and 1.35%, while in the control (fed larvae), 61.7% of individuals emerged as adults. The extract (1.0%) promoted intense disorganization of larval midgut epithelium, including deformation and hypertrophy of cells, disruption of microvilli, and vacuolization of cytoplasms, affecting digestive, enteroendocrine, regenerative, and proliferating cells. In addition, cells with fragmented DNA were observed. Separation of extract components by solid phase extraction revealed that cinnamic acid derivatives and flavonoids are involved in larvicidal effect of the extract, being the first most efficient in a short time after larvae treatment. The lectin present in the extract was isolated, but did not show deleterious effects on larvae. The extract and cinnamic acid derivatives were toxic to A. salina nauplii, while the flavonoids showed low toxicity. S. terebinthifolius leaf extract caused damage to the midgut of A. aegypti larvae, interfering with survival and development. The larvicidal effect of the extract can be attributed to cinnamic acid derivatives and flavonoids. The data obtained using A. salina indicates that caution should be used when employing this extract as a larvicidal agent.	[Procopio, Thamara Figueiredo; Pontual, Emmanuel Viana; Cardoso de Oliveira, Aline Rafaella; Souza, Carolina de Santana; Guedes Paiva, Patricia Maria; Napoleao, Thiago Henrique] Univ Fed Pernambuco, Ctr Ciencias Biol, Dept Bioquim, BR-50670420 Recife, PE, Brazil; [Fernandes, Kenner Morais; Martins, Gustavo Ferreira] Univ Fed Vicosa, Dept Biol Geral, BR-36570900 Vicosa, MG, Brazil; [Pontual, Emmanuel Viana] Univ Fed Rural Pernambuco, Dept Morfol & Fisiol Anim, BR-52171900 Recife, PE, Brazil; [Ximenes, Rafael Matos] Univ Fed Pernambuco, Dept Antibiot, BR-50670420 Recife, PE, Brazil; [Mendonca de Albuquerque Melo, Ana Maria] Univ Fed Pernambuco, Dept Biofis & Radiobiol CCB, BR-50670420 Recife, PE, Brazil; [do Amaral Ferraz Navarro, Daniela Maria] Univ Fed Pernambuco, Ctr Ciencias Exatas & Nat, Dept Quim Fundamental, BR-50740560 Recife, PE, Brazil	Universidade Federal de Pernambuco; Universidade Federal de Vicosa; Universidade Federal Rural de Pernambuco (UFRPE); Universidade Federal de Pernambuco; Universidade Federal de Pernambuco; Universidade Federal de Pernambuco	Napoleao, TH (corresponding author), Univ Fed Pernambuco, Ctr Ciencias Biol, Dept Bioquim, Cidade Univ, BR-50670420 Recife, PE, Brazil.	thiagohn86@yahoo.com.br	Ximenes, Rafael/AAG-9874-2021; Napoleao, Thiago Henrique/P-2364-2019; Martins, Gustavo Ferreira/AAL-7744-2020; Navarro, Daniela Maria do Amaral Ferraz/GXM-4019-2022; Martins, Gustavo F/L-9107-2015; de Albuquerque Melo, Ana Maria Mendonça/AAG-3879-2021; Pontual, Emmanuel/AAQ-8097-2020; Procópio, Thamara Figueiredo/AAZ-5811-2020; Navarro, Daniela Maria do Amaral Ferraz/C-4975-2013; Ximenes, Rafael M/J-3247-2012; Paiva, Patricia Maria Guedes/S-4038-2019; Morais, Kenner/Z-1667-2019	Ximenes, Rafael/0000-0002-2011-2865; Napoleao, Thiago Henrique/0000-0002-0065-2602; Martins, Gustavo F/0000-0003-0614-8551; de Albuquerque Melo, Ana Maria Mendonça/0000-0002-7223-6472; Pontual, Emmanuel/0000-0002-4399-3650; Navarro, Daniela Maria do Amaral Ferraz/0000-0003-0158-7221; Ximenes, Rafael M/0000-0002-2011-2865; Paiva, Patricia Maria Guedes/0000-0003-3467-708X; Morais, Kenner/0000-0003-0576-8185	Fundacao de Amparo a Ciencia e Tecnologia do Estado de Pernambuco [APQ-0137-2.08/12, BCT-0421-2.08/12, BIC-0312-2.08/13, APQ-0330-2.08/13]; Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (PNPD CAPES-FACEPE) [CAPES/PVE 88881.030429/2013-01]; Conselho Nacional de Desenvolvimento Cientifico e Tecnologico [132375/2013-3, 472546/2012-0, 446902/2014-4]; Brazilian Ministry for Science, Technology and Innovation (MCTI) [01200.003711/2011-11]	Fundacao de Amparo a Ciencia e Tecnologia do Estado de Pernambuco(Fundacao de Amparo a Ciencia e Tecnologia do Estado de Pernambuco (FACEPE)); Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (PNPD CAPES-FACEPE); Conselho Nacional de Desenvolvimento Cientifico e Tecnologico(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)); Brazilian Ministry for Science, Technology and Innovation (MCTI)	This work was supported by the Fundacao de Amparo a Ciencia e Tecnologia do Estado de Pernambuco (APQ-0137-2.08/12 and BCT-0421-2.08/12 to E.V.P.; BIC-0312-2.08/13 for A.R.C.O. and T.H.N.; APQ-0330-2.08/13 for P.M.G.P.; www.facepe.br), Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES/PVE 88881.030429/2013-01 for K.M.F.; PNPD CAPES-FACEPE for E.V.P.; www.capes.gov.br), the Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (132375/2013-3 for T.F.P.; 472546/2012-0 for P.M.G.P.; 446902/2014-4 for T.H.N.), and the Brazilian Ministry for Science, Technology and Innovation (MCTI; 01200.003711/2011-11 for P.M.G.P.; www.mcti.gov.br). P.M.G.P. and G.F.M. are investigators of CNPq. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ABEDI Z. H., 1961, ANN ENT SOC AMER, V54, P539, DOI 10.1093/aesa/54.4.539; Agra-Neto AC, 2014, PARASITOL RES, V113, P175, DOI 10.1007/s00436-013-3640-8; Aiub Claudia Alessandra Fortes, 2002, Genetics and Molecular Research, V1, P159; Al-Mehmadi R. M., 2010, Journal of King Saud University Science, V22, P77, DOI 10.1016/j.jksus.2010.02.004; Amer A, 2006, PARASITOL RES, V99, P466, DOI 10.1007/s00436-006-0182-3; [Anonymous], 1981, World Health Organ Tech Rep Ser, V657, P1; [Anonymous], 2013, LECTINS TRYPSIN INHI; [Anonymous], 1996, PLANT DRUG ANAL; Arruda Walquíria, 2003, Rev. Soc. Bras. Med. Trop., V36, P17, DOI 10.1590/S0037-86822003000100004; ASHIDA M, 1983, BIOCHEM BIOPH RES CO, V113, P562, DOI 10.1016/0006-291X(83)91762-X; Balbachas A, 1959, AS PLANTAS CURAM; Bhatt S, 2013, NATURE, V496, P504, DOI 10.1038/nature12060; BROWN MR, 1985, TISSUE CELL, V17, P709, DOI 10.1016/0040-8166(85)90006-0; BRUSCA GJ, 2003, INVERTEBRATES; Cavalher-Machado SC, 2008, INT IMMUNOPHARMACOL, V8, P1552, DOI 10.1016/j.intimp.2008.06.012; Cheng SS, 2004, J AGR FOOD CHEM, V14, P4935; Coelho AAM, 2009, BIOASSAY, V4, P3; Coelho JS, 2009, CHEMOSPHERE, V77, P934, DOI 10.1016/j.chemosphere.2009.08.022; Costa MS, 2012, NEOTROP ENTOMOL, V41, P311, DOI 10.1007/s13744-012-0050-z; Costa MS, 2014, TOXINS, V6, P1169, DOI 10.3390/toxins6041169; Deletre E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082103; Fernandes KM, 2010, SOCIOBIOLOGY, V56, P489; Fernandes KM, 2014, PARASITOL INT, V63, P506, DOI 10.1016/j.parint.2014.01.004; Fink SL, 2005, INFECT IMMUN, V73, P1907, DOI 10.1128/IAI.73.4.1907-1916.2005; Gomes FS, 2013, J APPL MICROBIOL, V114, P672, DOI 10.1111/jam.12086; Gusmao DS, 2002, MEM I OSWALDO CRUZ, V97, P371, DOI 10.1590/S0074-02762002000300017; Harborne J.B., 1998, BUSINESS MEDIA, V3rd ed., DOI DOI 10.1007/978-94-009-5570-7; JAIN MK, 1995, PHYTOCHEMISTRY, V39, P537, DOI 10.1016/0031-9422(94)00960-2; Kamiabi Fatemeh, 2013, Asian Pacific Journal of Tropical Biomedicine, V3, P767, DOI 10.1016/S2221-1691(13)60153-7; Levi T, 2014, ACTA TROP, V133, P42, DOI 10.1016/j.actatropica.2014.02.001; Lindenmaier D. S., 2008, ETNOBOTANICA COMUNID; LORENZI H., 2008, ARVORES BRASILEIRAS; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Maciel-de-Freitas R, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092424; Matsuo AL, 2011, BIOCHEM BIOPH RES CO, V411, P449, DOI 10.1016/j.bbrc.2011.06.176; Melo-Santos MAV, 2010, ACTA TROP, V113, P180, DOI 10.1016/j.actatropica.2009.10.015; MEYER BN, 1982, PLANTA MED, V45, P31, DOI 10.1055/s-2007-971236; MITCHELL MJ, 1993, INSECT BIOCHEM MOLEC, V23, P65, DOI 10.1016/0965-1748(93)90083-5; Murray T, 2013, NATURAL INSECTICIDES; Napoleao TH, 2012, PARASITOL RES, V110, P609, DOI 10.1007/s00436-011-2529-7; Navarro DMDF, 2013, NAT PROD J, V3, P268, DOI 10.2174/221031550304140328113732; Navarro DMAF, 2003, J APPL ENTOMOL, V127, P46, DOI 10.1046/j.1439-0418.2003.00690.x; Nishiura JT, 2003, J MED ENTOMOL, V40, P498, DOI 10.1603/0022-2585-40.4.498; Ocampo CB, 2011, ACTA TROP, V118, P37, DOI 10.1016/j.actatropica.2011.01.007; Ochieng C.O., 2010, RES J PHARM, V4, P45, DOI [10.3923/rjpharm.2010.45.50, DOI 10.3923/RJPHARM.2010.45.50]; Pawlowski A, 2012, S AFR J BOT, V80, P96, DOI 10.1016/j.sajb.2012.03.003; Perumalsamy H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080226; Polson KA, 2011, ACTA TROP, V117, P31, DOI 10.1016/j.actatropica.2010.09.005; Pontual EV, 2014, PARASITOL RES, V113, P727, DOI 10.1007/s00436-013-3702-y; Pontual EV, 2012, ARCH INSECT BIOCHEM, V79, P135, DOI 10.1002/arch.21012; Pratti DLA, 2015, PARASITE VECTOR, V8, DOI 10.1186/s13071-015-0746-0; Preuss U, 2003, NUCLEIC ACIDS RES, V31, P878, DOI 10.1093/nar/gkg176; Ray K, 2009, J INSECT SCI, V9, DOI 10.1673/031.009.5501; ROBERTS E. A. H., 1956, Journal of the Science of Food and Agriculture, V7, P637, DOI 10.1002/jsfa.2740071003; ROWLEY AF, 1990, J INVERTEBR PATHOL, V56, P31, DOI 10.1016/0022-2011(90)90141-R; Sa RA, 2009, COMP BIOCHEM PHYS C, V149, P300, DOI 10.1016/j.cbpc.2008.08.004; Shaalan EAS, 2005, ENVIRON INT, V31, P1149, DOI 10.1016/j.envint.2005.03.003; Shao QM, 2012, J BIOL CHEM, V287, P14270, DOI 10.1074/jbc.M112.354548; Silva AG, 2010, PARASITE VECTOR, V3, DOI 10.1186/1756-3305-3-79; Silva C. C. A., 2002, BIOTECNOL CIEN DESEN, V2, P68; Vontas J, 2012, PESTIC BIOCHEM PHYS, V104, P126, DOI 10.1016/j.pestbp.2012.05.008; Zhang YE, 2012, J ECON ENTOMOL, V105, P1034, DOI 10.1603/EC11287	62	52	55	1	22	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 14	2015	10	5							e0126612	10.1371/journal.pone.0126612	http://dx.doi.org/10.1371/journal.pone.0126612			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CI2AC	25974067	Green Submitted, Green Published, gold			2023-01-03	WOS:000354545600066
J	Patel, V				Patel, Vikram			Rethinking personalised medicine	LANCET			English	Editorial Material									[Patel, Vikram] London Sch Hyg & Trop Med, Ctr Global Mental Hlth, London WC1, England; [Patel, Vikram] Publ Hlth Fdn India, Inst Area, Ctr Control Chron Condit, Delhi 22002, India; [Patel, Vikram] Sangath, Porvorim, Goa, India	University of London; London School of Hygiene & Tropical Medicine; Public Health Foundation of India	Patel, V (corresponding author), London Sch Hyg & Trop Med, Ctr Global Mental Hlth, London WC1, England.	vikram.patel@lshtm.ac.uk			Wellcome Trust [084674, 091834] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)			0	11	11	0	10	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 9	2015	385	9980					1826	1827		10.1016/S0140-6736(15)60917-5	http://dx.doi.org/10.1016/S0140-6736(15)60917-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	CH6ZE	25987146	Bronze			2023-01-03	WOS:000354184500015
J	Yuksel, A; Olmez, T				Yuksel, Ayhan; Olmez, Tamer			A Neural Network-Based Optimal Spatial Filter Design Method for Motor Imagery Classification	PLOS ONE			English	Article							EEG	In this study, a novel spatial filter design method is introduced. Spatial filtering is an important processing step for feature extraction in motor imagery-based brain-computer interfaces. This paper introduces a new motor imagery signal classification method combined with spatial filter optimization. We simultaneously train the spatial filter and the classifier using a neural network approach. The proposed spatial filter network (SFN) is composed of two layers: a spatial filtering layer and a classifier layer. These two layers are linked to each other with non-linear mapping functions. The proposed method addresses two shortcomings of the common spatial patterns (CSP) algorithm. First, CSP aims to maximize the between-classes variance while ignoring the minimization of within-classes variances. Consequently, the features obtained using the CSP method may have large within-classes variances. Second, the maximizing optimization function of CSP increases the classification accuracy indirectly because an independent classifier is used after the CSP method. With SFN, we aimed to maximize the between-classes variance while minimizing within-classes variances and simultaneously optimizing the spatial filter and the classifier. To classify motor imagery EEG signals, we modified the well-known feed-forward structure and derived forward and backward equations that correspond to the proposed structure. We tested our algorithm on simple toy data. Then, we compared the SFN with conventional CSP and its multi-class version, called one-versus-rest CSP, on two data sets from BCI competition III. The evaluation results demonstrate that SFN is a good alternative for classifying motor imagery EEG signals with increased classification accuracy.	[Yuksel, Ayhan; Olmez, Tamer] Istanbul Tech Univ, Dept Elect & Commun Engn, TR-80626 Istanbul, Turkey	Istanbul Technical University	Yuksel, A (corresponding author), Istanbul Tech Univ, Dept Elect & Commun Engn, TR-80626 Istanbul, Turkey.	yukselay@itu.edu.tr	Olmez, Tamer/ABE-7998-2020	Olmez, Tamer/0000-0001-6124-2394				[Anonymous], 2011, IND ELECT HDB; Barachant A, 2013, NEUROCOMPUTING, V112, P172, DOI 10.1016/j.neucom.2012.12.039; Bertsekas D.P., 2014, CONSTRAINED OPTIMIZA; Blankertz B, 2004, IEEE T BIO-MED ENG, V51, P1044, DOI 10.1109/TBME.2004.826692; Blankertz B., 2007, ADV NEURAL INFORM PR, P113; Blankertz B, 2014, BCI COMPETITION 3 ON; Blankertz B, 2008, IEEE SIGNAL PROC MAG, V25, P41, DOI 10.1109/MSP.2008.4408441; Blankertz B, 2006, IEEE T NEUR SYS REH, V14, P153, DOI 10.1109/TNSRE.2006.875642; CORTES C, 1995, MACH LEARN, V20, P273, DOI 10.1007/BF00994018; Dornhege G, 2004, IEEE T BIO-MED ENG, V51, P993, DOI 10.1109/TBME.2004.827088; Duda R.O., 2000, PATTERN CLASSIFICATI; Falzon O, 2012, J NEURAL ENG, V9, DOI 10.1088/1741-2560/9/4/045009; Fattahi D, 2013, NEUROCOMPUTING, V119, P165, DOI 10.1016/j.neucom.2013.03.044; Fisher RA, 1936, ANN EUGENIC, V7, P179, DOI 10.1111/j.1469-1809.1936.tb02137.x; HAGAN MT, 1994, IEEE T NEURAL NETWOR, V5, P989, DOI 10.1109/72.329697; Levenberg K., 1944, Q APPL MATH, V2, P431; Lotte F, 2011, IEEE T BIO-MED ENG, V58, P355, DOI 10.1109/TBME.2010.2082539; MARQUARDT DW, 1963, J SOC IND APPL MATH, V11, P431, DOI 10.1137/0111030; More J. J., 1978, Proceedings of the Biennial Conference on numerical analysis, P105; Penfield W, 1937, BRAIN, V60, P389, DOI 10.1093/brain/60.4.389; Pfurtscheller G, 1999, CLIN NEUROPHYSIOL, V110, P1842, DOI 10.1016/S1388-2457(99)00141-8; Ramoser H, 2000, IEEE T REHABIL ENG, V8, P441, DOI 10.1109/86.895946; Reuderink B, 2008, TRCTIT0852; RUMELHART DE, 1986, NATURE, V323, P533, DOI 10.1038/323533a0; Samek W, 2012, J NEURAL ENG, V9, DOI 10.1088/1741-2560/9/2/026013; The MathWorks Inc, 2013, MATLAB VERS 8 1 0; Wang HX, 2012, IEEE T BIO-MED ENG, V59, P653, DOI 10.1109/TBME.2011.2177523; Wolpaw JR, 2002, CLIN NEUROPHYSIOL, V113, P767, DOI 10.1016/S1388-2457(02)00057-3; Yamashita N., 2001, TOPICS NUMERICAL ANA, V15, P239	29	25	27	0	28	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 1	2015	10	5							e0125039	10.1371/journal.pone.0125039	http://dx.doi.org/10.1371/journal.pone.0125039			21	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CH2XA	25933101	Green Published, gold			2023-01-03	WOS:000353887100074
J	Davidoff, F				Davidoff, Frank			Improvement Interventions RESPONSE	ANNALS OF INTERNAL MEDICINE			English	Letter									Dartmouth Coll, Geisel Sch Med, Hanover, NH 03755 USA	Dartmouth College	Davidoff, F (corresponding author), Dartmouth Coll, Geisel Sch Med, Hanover, NH 03755 USA.							Campbell D.T, 1963, EXPT QUASIEXPERIMENT, Vfirst; Craig P, 2008, BMJ-BRIT MED J, V337, DOI 10.1136/bmj.a1655; Hurley D, 2014, NY TIMES MAGAZINE, P61; Parry GJ, 2013, ACAD PEDIATR, V13, pS23, DOI 10.1016/j.acap.2013.04.007; Solberg LI, 1997, JOINT COMM J QUAL IM, V23, P135, DOI 10.1016/S1070-3241(16)30305-4	5	0	0	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 21	2015	162	8					597	597		10.7326/L15-5071-3	http://dx.doi.org/10.7326/L15-5071-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CG4GT	25894034				2023-01-03	WOS:000353244300027
J	Lin, MY; Kuo, MC; Hung, CC; Wu, WJ; Chen, LT; Yu, ML; Hsu, CC; Lee, CH; Chen, HC; Hwang, SJ				Lin, Ming Yen; Kuo, Mei Chuan; Hung, Chi Chih; Wu, Wen Jeng; Chen, Li Tzong; Yu, Ming Lung; Hsu, Chih Cheng; Lee, Chien Hung; Chen, Hung Chun; Hwang, Shang Jyh			Association of Dialysis with the Risks of Cancers	PLOS ONE			English	Article							STAGE RENAL-DISEASE; TRANSITIONAL-CELL CARCINOMA; ARISTOLOCHIC ACID; URINARY-TRACT; POPULATION; KIDNEY; NEPHROPATHY; DIAGNOSIS; TAIWAN	Background To increase the survival span after dialysis in patients with end-stage renal disease (ESRD), identifying specific cancer risks is crucial in the cancer screening of these patients. The aim of this study was to investigate the risks of various cancers in an incident dialysis group in comparison with a non-dialysis group. Method We conducted a nationwide cohort study by using data from the Taiwan National Health Insurance Research Database. Patients who initially received long-term dialysis between January 1997 and December 2004, were selected and defined as the dialysis group and were matched with the non-dialysis patients (control group) according to age, sex, and index year. Competing risk analysis was used to estimate cumulative incidence and subdistribution hazard ratios (SHRs) of the first cancer occurrence. Results After consideration for the competing risk of mortality, the dialysis group showed a significantly higher 7-year cancer incidence rate than did the control group (6.4%; 95% confidence interval [CI], 6.0%-6.7% vs 1.7%; 95% CI, 1.4%-2.1%; P <0.001). The modified Cox proportional hazard model revealed that the dialysis group had significantly association with increased risks for all cancers (SHR, 3.43; 95% CI, 3.02-3.88). The risk of cancers was dominated in younger and female patients. Specific cancer risks were significantly higher in the dialysis group particularly in the development of oral, colorectal, liver, blood, breast, renal, upper urinary tract, and bladder cancer than in the control group. Multivariable stratified analyses confirmed the association between long-term dialysis and cancer in all subgroups of patients. Conclusions Dialysis is associated with a higher risk of cancer in patients with ESRD. However, cancer screening in ESRD population should be a selective approach, based on individual patient health condition and life expectancy.	[Lin, Ming Yen; Kuo, Mei Chuan; Hung, Chi Chih; Chen, Hung Chun; Hwang, Shang Jyh] Kaohsiung Med Univ, Kaohsiung Med Univ Hosp, Dept Internal Med, Div Nephrol, Kaohsiung, Taiwan; [Lin, Ming Yen; Kuo, Mei Chuan; Hung, Chi Chih; Chen, Hung Chun; Hwang, Shang Jyh] Kaohsiung Med Univ, Fac Renal Care, Coll Med, Kaohsiung, Taiwan; [Lin, Ming Yen] Natl Appl Res Labs, Instrument Technol Res Ctr, Hsinchu, Taiwan; [Wu, Wen Jeng] Kaohsiung Med Univ, Grad Inst Med, Coll Med, Kaohsiung, Taiwan; [Wu, Wen Jeng; Yu, Ming Lung] Kaohsiung Med Univ, Coll Med, Fac Med, Kaohsiung, Taiwan; [Wu, Wen Jeng] Kaohsiung Med Univ, Kaohsiung Med Univ Hosp, Dept Urol, Kaohsiung, Taiwan; [Wu, Wen Jeng] Kaohsiung Med Univ, Kaohsiung Municipal Hsiao Kang Hosp, Kaohsiung, Taiwan; [Chen, Li Tzong] Kaohsiung Med Univ, Kaohsiung Med Univ Hosp, Div Gastroenterol, Dept Internal Med, Kaohsiung, Taiwan; [Chen, Li Tzong] Natl Hlth Res Inst, Natl Inst Canc Res, Tainan, Taiwan; [Yu, Ming Lung] Kaohsiung Med Univ, Kaohsiung Med Univ Hosp, Div Hepatobiliary, Dept Internal Med, Kaohsiung, Taiwan; [Hsu, Chih Cheng; Hwang, Shang Jyh] Natl Hlth Res Inst, Inst Populat Hlth Sci, Miaoli, Taiwan; [Lee, Chien Hung] Kaohsiung Med Univ, Coll Hlth Sci, Dept Publ Hlth, Kaohsiung, Taiwan	Kaohsiung Medical University; Kaohsiung Medical University Hospital; Kaohsiung Medical University; National Applied Research Laboratories - Taiwan; Kaohsiung Medical University; Kaohsiung Medical University; Kaohsiung Medical University; Kaohsiung Medical University Hospital; Kaohsiung Medical University; Kaohsiung Municipal Siao-Gang Hospital; Kaohsiung Medical University; Kaohsiung Medical University Hospital; National Health Research Institutes - Taiwan; Kaohsiung Medical University; Kaohsiung Medical University Hospital; National Health Research Institutes - Taiwan; Kaohsiung Medical University	Hwang, SJ (corresponding author), Kaohsiung Med Univ, Kaohsiung Med Univ Hosp, Dept Internal Med, Div Nephrol, Kaohsiung, Taiwan.	sjhwang@kmu.edu.tw	Lin, Ming Yen/A-8637-2010; Lee, Chien-Hung/D-4437-2009; Yu, Ming-Lung/AAZ-4306-2020	Lin, Ming Yen/0000-0002-8194-4833; Lee, Chien-Hung/0000-0002-0988-264X; Yu, Ming-Lung/0000-0001-8145-1900; wu, wen jeng/0000-0002-9691-7416	National Science Council, Taiwan [NSC 102-3114-Y-492-076-023]; Ministry of Health and Welfare [MOHW103-TD-B-111-05]; Kaohsiung Medical University [QP094005]	National Science Council, Taiwan(Ministry of Science and Technology, Taiwan); Ministry of Health and Welfare(Ministry of Health, Labour and Welfare, Japan); Kaohsiung Medical University	The authors would like to thank the National Science Council, Taiwan (NSC 102-3114-Y-492-076-023), the Ministry of Health and Welfare (MOHW103-TD-B-111-05), and Kaohsiung Medical University (QP094005) for supporting this study. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Chang CH, 2001, AM J NEPHROL, V21, P441, DOI 10.1159/000046647; Chang CH, 2007, CANCER-AM CANCER SOC, V109, P1487, DOI 10.1002/cncr.22557; Chen CH, 2013, INT J CANCER, V133, P14, DOI 10.1002/ijc.28013; Chen CH, 2012, P NATL ACAD SCI USA, V109, P8241, DOI 10.1073/pnas.1119920109; Cheng CL, 2011, PHARMACOEPIDEM DR S, V20, P236, DOI 10.1002/pds.2087; Chien IC, 2009, SCHIZOPHR RES, V111, P17, DOI 10.1016/j.schres.2009.04.003; Chung CJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044675; Debelle FD, 2008, KIDNEY INT, V74, P158, DOI 10.1038/ki.2008.129; DEYO RA, 1992, J CLIN EPIDEMIOL, V45, P613, DOI 10.1016/0895-4356(92)90133-8; Eggers PW, 2011, CURR OPIN NEPHROL HY, V20, P241, DOI 10.1097/MNH.0b013e3283454319; Fine JP, 1999, J AM STAT ASSOC, V94, P496, DOI 10.2307/2670170; Grandits G, 2018, USING SAS PERFORM IN, V2010; Gray B., CMPRSK SUBDISTRIBUTI; GRAY RJ, 1988, ANN STAT, V16, P1141, DOI 10.1214/aos/1176350951; Hsieh CY, 2013, J FORMOSAN MED ASS; Kato S, 2008, CLIN J AM SOC NEPHRO, V3, P1526, DOI 10.2215/CJN.00950208; Lai MN, 2010, JNCI-J NATL CANCER I, V102, P179, DOI 10.1093/jnci/djp467; Lee JJ, 2010, AM J KIDNEY DIS, V56, P23, DOI 10.1053/j.ajkd.2010.01.015; Liang JA, 2011, JPN J CLIN ONCOL, V41, P752, DOI 10.1093/jjco/hyr051; Lin CC, 2005, J FORMOS MED ASSOC, V104, P157; Lin HF, 2012, NEPHROL DIAL TRANSPL, V27, P1585, DOI 10.1093/ndt/gfr464; Lin MY, 2012, SCI C ANN M 2012 TAI, P308; Maisonneuve P, 1999, LANCET, V354, P93, DOI 10.1016/S0140-6736(99)06154-1; Satoh S, 2005, J UROLOGY, V174, P1749, DOI 10.1097/01.ju.0000177489.98031.54; Shebl FM, 2012, BMC NEPHROL, V13, DOI 10.1186/1471-2369-13-65; Skov Dalgaard L, 2013, BMC NEPHROL, V14, P137, DOI [10.1186/1471-2369-14-137, DOI 10.1186/1471-2369-14-137]; Stefanovic V, 2008, NAT CLIN PRACT UROL, V5, P105, DOI 10.1038/ncpuro1019; Stewart JH, 2003, J AM SOC NEPHROL, V14, P197, DOI 10.1097/01.ASN.0000039608.81046.81; Stewart JH, 2009, NEPHROL DIAL TRANSPL, V24, P3225, DOI 10.1093/ndt/gfp331; Vamvakas S, 1998, AM J NEPHROL, V18, P89, DOI 10.1159/000013314; Wang SM, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/149750; Yang CS, 2000, AM J KIDNEY DIS, V35, P313, DOI 10.1016/S0272-6386(00)70343-X; Yang HY, 2009, J EPIDEMIOL, V19, P17, DOI 10.2188/jea.JE20080035	33	42	42	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 13	2015	10	4							e0122856	10.1371/journal.pone.0122856	http://dx.doi.org/10.1371/journal.pone.0122856			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CF8XK	25874862	gold, Green Published, Green Submitted			2023-01-03	WOS:000352845100110
J	Mbonye, MK; Burnett, SM; Naikoba, S; Colebunders, R; Wouters, K; Weaver, MR; Van Geertruyden, JP				Mbonye, Martin Kayitale; Burnett, Sarah M.; Naikoba, Sarah; Colebunders, Robert; Wouters, Kristien; Weaver, Marcia R.; Van Geertruyden, Jean Pierre			Malaria Care in Infants Aged under Six Months in Uganda: An Area of Unmet Needs!	PLOS ONE			English	Article							MEROZOITE SURFACE PROTEIN-1; PLASMODIUM-FALCIPARUM; AFRICAN INFANTS; CASE-MANAGEMENT; CHILDREN; ANTIMALARIALS; PRESCRIPTION; COMBINATION; CHALLENGES; ANTIBODIES	Background Little information exists on malaria burden, artemisinin-based combination therapy (ACT) use, and malaria care provided to infants under six months of age. The perception that malaria may be rare in this age group has led to lack of clinical trials and evidence-based treatment guidelines. The objective of this study was to identify malaria parasitemia positivity rate (MPPR) among patients under six months, and practices and predictors of malaria diagnosis and treatment in this population. Methods Cross-sectional data collected from October 2010 to September 2011 on 25,997 individual outpatients aged <6 months from 36 health facilities across Uganda were analysed. Findings Malaria was suspected in 18,415 (70.8%) patients, of whom 7,785 (42.3%) were tested for malaria. Of those tested, the MPPR was 36.1%, with 63.9% testing negative, of which 1,545 (31.1%) were prescribed an antimalarial. Among children <5kgs, off-label prescription of ACT was high (104/285, 36.5%). Younger age (1-6 days, aOR=0.47, p=0.01; 7-31 days, aOR=0.43, p<0.001; and 1-2 months, aOR=0.61, p<0.001), pneumonia (aOR=0.78, p=0.01) or cough/cold (aOR=0.65, p<0.001) diagnosis, and fever (aOR=0.56, p=0.01) reduced the odds of receiving a malaria test. Fever (aOR=2.22, p<0.001), anemia diagnosis (aOR=3.51, p=0.01), consulting midwives (aOR=3.58, p=0.04) and other less skilled providers (aOR=4.75, p<0.001) relative to medical officers, consulting at hospitals (aOR=3.31, p=0.03), visiting health facilities in a medium-high malaria transmission area (aOR=2.20, p<0.001), and visiting during antimalarial (aOR=1.82, p=0.04) or antibiotic (aOR=2.23, p=0.04) shortages increased the odds of prescribing an antimalarial despite a negative malaria test result. Conclusions We found high malaria suspicion but low testing rates in outpatient children aged <6 months. Among those tested, MPPR was high. Despite a negative malaria test result, many infants were prescribed antimalarials. Off-label ACT prescription was common in children weighing <5kgs. Evidence-based malaria guidelines for infants weighing <5 kilograms and aged <6 months are urgently needed.	[Mbonye, Martin Kayitale; Naikoba, Sarah] Makerere Univ, Infect Dis Inst, Kampala, Uganda; [Wouters, Kristien] Univ Antwerp Hosp, Dept Sci Coordinat & Biostat, Antwerp, Belgium; [Burnett, Sarah M.] Accordia Global Hlth Fdn, Washington, DC USA; [Mbonye, Martin Kayitale; Burnett, Sarah M.; Naikoba, Sarah; Colebunders, Robert; Van Geertruyden, Jean Pierre] Univ Antwerp, Fac Med & Hlth Sci, Unit Int Hlth, B-2020 Antwerp, Belgium; [Colebunders, Robert] Inst Trop Med, Dept Clin Sci, B-2000 Antwerp, Belgium; [Weaver, Marcia R.] Univ Washington, I TECH, Dept Global Hlth, Seattle, WA 98195 USA	Makerere University; University of Antwerp; University of Antwerp; Institute of Tropical Medicine (ITM); University of Washington; University of Washington Seattle	Mbonye, MK (corresponding author), Makerere Univ, Infect Dis Inst, Kampala, Uganda.	mbonyemarti@yahoo.com	Wouters, Kristien/ADM-4146-2022; Van geertruyden, Jean-Pierre/S-3254-2019; Van geertruyden, Jean-Pierre/K-6425-2014	Van geertruyden, Jean-Pierre/0000-0001-5006-6364; Van geertruyden, Jean-Pierre/0000-0001-5006-6364; Colebunders, Robert/0000-0002-1919-1340	Bill & Melinda Gates Foundation [94298]; VLIR-UOS via the HEFS Platform Harvest Call [ZIUS2013VOA0902]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R24HD042828] Funding Source: NIH RePORTER	Bill & Melinda Gates Foundation(Bill & Melinda Gates Foundation); VLIR-UOS via the HEFS Platform Harvest Call; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))	IDCAP was supported through grant number 94298 to Accordia Global Health Foundation from the Bill & Melinda Gates Foundation. Preparation of this manuscript was supported by VLIR-UOS via the HEFS Platform Harvest Call (ZIUS2013VOA0902). The content expressed within this article is that of the authors and does not necessarily reflect positions or policies of the Bill & Melinda Gates Foundation and VLIR-UOS. Both funders did not influence the study design, data collection, analysis and interpretation, the writing of this manuscript, nor the decision to submit the manuscript for publication.	Afolabi BM, 2001, AM J TROP MED HYG, V65, P822, DOI 10.4269/ajtmh.2001.65.822; [Anonymous], 2014, PLOS ONE, DOI DOI 10.1371/J0URNAL.P0NE.0107965; [Anonymous], 2011, UN ACC MAL DIAGN TES; [Anonymous], 2003, IMPR DAT QUAL GUID D; Billig EMW, 2012, MALARIA J, V11, DOI 10.1186/1475-2875-11-396; Bjorkman A, 2010, CLIN INFECT DIS, V51, P512, DOI 10.1086/655689; Branch OH, 1998, AM J TROP MED HYG, V58, P211, DOI 10.4269/ajtmh.1998.58.211; Clarke SP, 2008, PATIENT SAFETY QUALI, V2, P2; d'Acremont V, 2010, CLIN INFECT DIS, V51, P506, DOI 10.1086/655688; D'Alessandro U, 2012, MALARIA J, V11, DOI 10.1186/1475-2875-11-400; Doolan DL, 2009, CLIN MICROBIOL REV, V22, P13, DOI 10.1128/CMR.00025-08; Godfrey MG, 2011, OBSTET GYNAECOLOGIST, V7, P5; Gove S, 1999, ARCH DIS CHILD, V81, P473, DOI 10.1136/adc.81.6.473; Guinovart C, 2008, MALARIA J, V7, DOI 10.1186/1475-2875-7-36; Gwer S, 2007, AM J TROP MED HYG, V77, P6, DOI 10.4269/ajtmh.2007.77.6; Hamer DH, 2007, JAMA-J AM MED ASSOC, V297, P2227, DOI 10.1001/jama.297.20.2227; IHME, 2013, GBD 2010 AG SPEC MOR; Jensen TP, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-213; Kane R. L., 2007, NURSE STAFFING QUALI; Kassim OO, 2000, J TROP PEDIATRICS, V46, P92, DOI 10.1093/tropej/46.2.92; Kearns GL, 2003, NEW ENGL J MED, V349, P1157, DOI 10.1056/NEJMra035092; KENGEYAKAYONDO JF, 1994, ACTA TROP, V58, P267, DOI 10.1016/0001-706X(94)90020-5; KNBS, 2010, 2010 KEN MAL IND SUR; Larru B, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-310; Macdonald G., 1950, Tropical Diseases Bulletin, V47, P915; Mbonye MK, 2014, BMC FAM PRACT, V15, DOI 10.1186/1471-2296-15-165; Mbonye MK, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0084945; Miceli A, 2012, INT J INFECT DIS, V16, pE708, DOI 10.1016/j.ijid.2012.07.003; Mmbando BP, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-216; Mwaniki MK, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-313; Naikoba S, 2012, INT J CARE PATHWAYS, V16, P152, DOI DOI 10.1177/2040402613479342; Namagembe A, 2012, MALARIA J, V11, DOI 10.1186/1475-2875-11-44; Nankabirwa J, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-66; Needleman J, 2002, NEW ENGL J MED, V346, P1715, DOI 10.1056/NEJMsa012247; Njama-Meya D, 2007, MALARIA J, V6, DOI 10.1186/1475-2875-6-7; Njozi M, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-1097; Nyarango PM, 2006, MALARIA J, V5, DOI 10.1186/1475-2875-5-33; O'Meara WP, 2010, LANCET INFECT DIS, V10, P545, DOI 10.1016/S1473-3099(10)70096-7; Oladosu OO, 2012, OVERDIAGNOSIS OVERTR, V2013; Otten M, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-14; Riley EM, 2000, INFECT IMMUN, V68, P5856, DOI 10.1128/IAI.68.10.5856-5863.2000; Riley EM, 2001, PARASITE IMMUNOL, V23, P51, DOI 10.1046/j.1365-3024.2001.00364.x; Rubin DB, 1987, MULTIPLE IMPUTATION, DOI [10.1002/sim.6008, DOI 10.1002/SIM.6008]; Sears D, 2013, MALARIA J, V12, DOI 10.1186/1475-2875-12-252; Sserwanga A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016316; Stanisic DI, 2003, J IMMUNOL, V171, P5461, DOI 10.4049/jimmunol.171.10.5461; Steinhardt LC, 2014, MALARIA J, V13, DOI 10.1186/1475-2875-13-64; Strom GEA, 2013, MALARIA J, V12, DOI 10.1186/1475-2875-12-228; Thomson J G, 1935, Proc R Soc Med, V28, P391; UBOS, 2009, UG MAL IND SURV CALV; UBOS MI ME, 2007, UG CHILD VERB AUT ST; Uganda Government, 2004, HLTH SECT STRAT PLAN; Uganda Government, 2010, STAT ABSTR 2010; Uganda Government, 2010, HLTH SECT STRAT INV; Uganda Government, 2005, NAT POL MAL TREATM 2; Uganda Government, 2010, HUM RES HLTH AUD REP; vanHensbroek MB, 1996, AM J TROP MED HYG, V54, P237, DOI 10.4269/ajtmh.1996.54.237; Weaver MR, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103017; WHO, 2013, WORLD MALARIA REPORT 2013, P1; WHO, 2010, GUID TREATM MAL, DOI [10.1186/1475-2875-9-212, DOI 10.1186/1475-2875-9-212]; WHO, 2013, MAL IN INF; WHO, 2005, HLTH SYST PROF UG; WHO, 2006, GROWTH REF DAT 5 19; Yeka A, 2012, ACTA TROP, V121, P184, DOI 10.1016/j.actatropica.2011.03.004; Yeka A, 2009, LANCET INFECT DIS, V9, P448, DOI 10.1016/S1473-3099(09)70109-4; Zurovac D, 2008, TROP MED INT HEALTH, V13, P784, DOI 10.1111/j.1365-3156.2008.02072.x; Zurovac D, 2008, TROP MED INT HEALTH, V13, P99, DOI 10.1111/j.1365-3156.2007.01980.x	67	6	6	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 10	2015	10	4							e0123283	10.1371/journal.pone.0123283	http://dx.doi.org/10.1371/journal.pone.0123283			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CF5II	25860016	Green Published, Green Submitted, gold			2023-01-03	WOS:000352590300090
J	Lock, D				Lock, David			BRIEFING Avastin and Lucentis: a guide through the legal maze	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material									Queens Counsel, London, England		Lock, D (corresponding author), Queens Counsel, London, England.	DLock@landmarkchambers.co.uk						NICE, 2008, RAN PEG TREATM AG RE, P155	1	5	5	0	6	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	APR 1	2015	350								h1377	10.1136/bmj.h1377	http://dx.doi.org/10.1136/bmj.h1377			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CF3HO	25834023				2023-01-03	WOS:000352439300002
J	Carvalho, CG; Silveira, RD; Neto, EC; Procianoy, RS				Carvalho, Clarissa Gutierrez; Silveira, Rita de Cassia; Camargo Neto, Eurico; Procianoy, Renato Soibelmann			Plasma Cytokine Levels Fall in Preterm Newborn Infants on Nasal CPAP with Early Respiratory Distress	PLOS ONE			English	Article							IMMEDIATE POSTNATAL-PERIOD; POSITIVE AIRWAY PRESSURE; C-REACTIVE PROTEIN; EXPIRATORY PRESSURE; LUNG INJURY; INFLAMMATION; BIRTH; INTERLEUKIN-6; FLUID; VENTILATION	Introduction Early nCPAP seems to prevent ventilator-induced lung injury in humans, although the pathophysiological mechanisms underlying this beneficial effect have not been clarified yet. Objective To evaluate plasma levels IL-1 beta, IL-6, IL-8, IL-10, and TNF-alpha immediately before the start of nCPAP and 2 hours later in preterm infants. Methods Prospective cohort including preterm infants with 28 to 35 weeks gestational age with moderate respiratory distress requiring nCPAP. Extreme preemies, newborns with malformations, congenital infections, sepsis, surfactant treatment, and receiving ventilatory support in the delivery room were excluded. Blood samples were collected right before and 2 hours after the start of nCPAP. Results 23 preterm infants (birth weight 1851 +/- 403 grams; GA 32.3 +/- 1.7 weeks) were treated with nCPAP. IL-1 beta, IL-10, TNF-alpha levels were similar, IL-8 levels were reduced in 18/23 preterm infants and a significant decrease in IL-6 levels was observed after 2 hours of nCPAP. All newborns whosemothers received antenatal steroids had lower cytokine levels at the onset of nCPAP than those whosemothers didn't receive it; this effect was not sustained after 2 hours of nCPAP. Conclusion Early use nCPAP is not associated with rising of plasma pro-inflammatory cytokines and it seems to be a less harmful respiratory strategy for preterm with moderate respiratory distress.	[Procianoy, Renato Soibelmann] Univ Fed Rio Grande do Sul, Dept Pediat, Porto Alegre, RS, Brazil; Hosp Clin Porto Alegre, Newborn Sect, Porto Alegre, RS, Brazil	Universidade Federal do Rio Grande do Sul	Procianoy, RS (corresponding author), Univ Fed Rio Grande do Sul, Dept Pediat, Porto Alegre, RS, Brazil.	rprocianoy@gmail.com	CG, Carvalho/V-9991-2019; Carvalho, Clarissa Gutierrez/HCG-9064-2022; Procianoy, Renato/I-5133-2014	Procianoy, Renato/0000-0001-8297-4164; SILVEIRA, RITA DE CASSIA/0000-0002-2982-2652	Pro-Reitoria de Pos Graduacao da Universidade Federal do Rio Grande do Sul and Fundo de Pesquisa do Hospital de Clinicas de Porto Alegre	Pro-Reitoria de Pos Graduacao da Universidade Federal do Rio Grande do Sul and Fundo de Pesquisa do Hospital de Clinicas de Porto Alegre	The study was supported by the authors' institutional research grants: Pro-Reitoria de Pos Graduacao da Universidade Federal do Rio Grande do Sul and Fundo de Pesquisa do Hospital de Clinicas de Porto Alegre. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Beresford MW, 2002, PEDIATR RES, V52, P973, DOI 10.1203/01.PDR.0000036626.67304.65; Bohrer B, 2010, J PEDIATR-US, V156, P16, DOI 10.1016/j.jpeds.2009.07.027; Caldas JPS, 2012, J PEDIAT-BRAZIL, V88, P61, DOI 10.2223/JPED.2158; Chiesa C, 2003, CLIN CHEM, V49, P60, DOI 10.1373/49.1.60; Chiesa C, 2001, CLIN CHEM, V47, P1016; Dembinski J, 2003, CYTOKINE, V21, P200, DOI 10.1016/S1043-4666(02)00498-2; DREYFUSS D, 1988, AM REV RESPIR DIS, V137, P1159, DOI 10.1164/ajrccm/137.5.1159; Dudley DJ, 1997, J REPROD IMMUNOL, V33, P147, DOI 10.1016/S0165-0378(97)00020-X; Finer NN, 2010, NEW ENGL J MED, V362, P1970, DOI 10.1056/NEJMoa0911783; Goldenberg RL, 2008, LANCET, V371, P75, DOI 10.1016/S0140-6736(08)60074-4; Hillman NH, 2009, RESP RES, V10, DOI 10.1186/1465-9921-10-124; Hotoura E, 2012, INFLAMMATION, V35, P1094, DOI 10.1007/s10753-011-9416-3; Jobe AH, 2002, PEDIATR RES, V52, P387, DOI 10.1203/01.PDR.0000025341.25481.42; Jonsson B, 2000, ACTA PAEDIATR, V89, P1375, DOI 10.1080/080352500300002606; Lista G, 2006, PEDIATR PULM, V41, P357, DOI 10.1002/ppul.20363; Lista G, 2010, ARCH DIS CHILD-FETAL, V95, pF85, DOI 10.1136/adc.2009.169219; Lusyati Setyadewi, 2013, BMC Res Notes, V6, P547, DOI 10.1186/1756-0500-6-547; Marchini G, 2000, ACTA PAEDIATR, V89, P1082, DOI 10.1080/713794557; MARKOS J, 1993, J APPL PHYSIOL, V74, P2627, DOI 10.1152/jappl.1993.74.6.2627; Morley CJ, 2008, NEW ENGL J MED, V358, P700, DOI 10.1056/NEJMoa072788; Mulrooney N, 2005, AM J RESP CRIT CARE, V171, P488, DOI 10.1164/rccm.200406-774OC; Naik AS, 2001, AM J RESP CRIT CARE, V164, P494, DOI 10.1164/ajrccm.164.3.2010127; Polglase GR, 2009, PEDIATR RES, V65, P67, DOI 10.1203/PDR.0b013e318189487e; Procianoy Renato S., 2004, J. Pediatr. (Rio J.), V80, P407, DOI 10.2223/JPED.1226; Sandri F, 2010, PEDIATRICS, V125, pE1402, DOI 10.1542/peds.2009-2131; Wright CJ, 2011, PEDIATRICS, V128, P111, DOI 10.1542/peds.2010-3875; Yoon BH, 2000, AM J OBSTET GYNECOL, V183, P1124, DOI 10.1067/mob.2000.109035	27	2	2	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 23	2015	10	3							e0120486	10.1371/journal.pone.0120486	http://dx.doi.org/10.1371/journal.pone.0120486			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CE6ZS	25799377	Green Published, Green Submitted, gold			2023-01-03	WOS:000351987300149
J	Maawy, AA; Hiroshima, Y; Zhang, Y; Heim, R; Makings, L; Garcia-Guzman, M; Luiken, GA; Kobayashi, H; Hoffman, RM; Bouvet, M				Maawy, Ali A.; Hiroshima, Yukihiko; Zhang, Yong; Heim, Roger; Makings, Lew; Garcia-Guzman, Miguel; Luiken, George A.; Kobayashi, Hisataka; Hoffman, Robert M.; Bouvet, Michael			Near Infra-Red Photoimmunotherapy with Anti-CEA-IR700 Results in Extensive Tumor Lysis and a Significant Decrease in Tumor Burden in Orthotopic Mouse Models of Pancreatic Cancer	PLOS ONE			English	Article							FLUORESCENCE-GUIDED SURGERY; ANTI-CEA ANTIBODY; HUMAN COLON-CANCER; IMAGING-SYSTEM; NUDE-MICE; PATIENT; RESECTION; SURVIVAL; GROWTH	Photoimmunotherapy (PIT) of cancer utilizes tumor-specific monoclonal antibodies conjugated to a photosensitizer phthalocyanine dye IR700 which becomes cytotoxic upon irradiation with near infrared light. In this study, we aimed to evaluate the efficacy of PIT on human pancreatic cancer cells in vitro and in vivo in an orthotopic nude mouse model. The binding capacity of anti-CEA antibody to BxPC-3 human pancreatic cancer cells was determined by FACS analysis. An in vitro cytotoxicity assay was used to determine cell death following treatment with PIT. For in vivo determination of PIT efficacy, nude mice were orthotopically implanted with BxPC-3 pancreatic tumors expressing green fluorescent protein (GFP). After tumor engraftment, the mice were divided into two groups: (1) treatment with anti-CEA-IR700 + 690 nm laser and (2) treatment with 690 nm laser only. Anti-CEA-IR700 (100 mu g) was administered to group (1) via tail vein injection 24 hours prior to therapy. Tumors were then surgically exposed and treated with phototherapy at an intensity of 150 mW/cm(2) for 30 minutes. Whole body imaging was done subsequently for 5 weeks using an OV-100 small animal imaging system. Anti-CEA-IR700 antibody bound to the BxPC3 cells to a high degree as shown by FACS analysis. Anti-CEA-IR700 caused extensive cancer cell killing after light activation compared to control cells in cytotoxicity assays. In the orthotopic models of pancreatic cancer, the anti-CEA-IR700 group had significantly smaller tumors than the control after 5 weeks (p<0.001). There was no significant difference in the body weights of mice in the anti-CEA-IR700 and control groups indicating that PIT was well tolerated by the mice.	[Maawy, Ali A.; Hiroshima, Yukihiko; Hoffman, Robert M.; Bouvet, Michael] Univ Calif San Diego, Dept Surg, San Diego, CA 92103 USA; [Hiroshima, Yukihiko; Zhang, Yong; Hoffman, Robert M.] AntiCancer Inc, San Diego, CA USA; [Hiroshima, Yukihiko] Yokohama City Univ, Dept Surg, Yokohama, Kanagawa 232, Japan; [Heim, Roger; Makings, Lew; Garcia-Guzman, Miguel] Aspyrian Therapeut, San Diego, CA USA; [Luiken, George A.] OncoFluor Inc, San Diego, CA USA; [Kobayashi, Hisataka] NIH, Bethesda, MD 20892 USA; [Bouvet, Michael] VA Healthcare Syst, Surg Serv, San Diego, CA USA	University of California System; University of California San Diego; Anti Cancer Inc; Yokohama City University; National Institutes of Health (NIH) - USA	Bouvet, M (corresponding author), Univ Calif San Diego, Dept Surg, San Diego, CA 92103 USA.	mbouvet@ucsd.edu			National Cancer Institute [CA142669, CA132971]; AntiCancer, Inc.; Aspyrian Therapeutics; NATIONAL CANCER INSTITUTE [R01CA142669, R01CA132971, ZIABC011513] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); AntiCancer, Inc.(Canadian Institutes of Health Research (CIHR)Cancer Council Victoria); Aspyrian Therapeutics; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by grants from the National Cancer Institute CA142669 and CA132971 (to M.B. and AntiCancer, Inc). AntiCancer, Inc. and Aspyrian Therapeutics provided support in the form of salaries for authors YZ, RH, LM, and MG-G but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bouvet M, 2000, AM J SURG, V180, P13, DOI 10.1016/S0002-9610(00)00405-0; Bouvet M, 2000, CLIN EXP METASTAS, V18, P213, DOI 10.1023/A:1006767405609; Bouvet M, 2002, CANCER RES, V62, P1534; Cao HST, 2012, HEPATO-GASTROENTEROL, V59, P1994, DOI 10.5754/hge11836; FU XY, 1992, P NATL ACAD SCI USA, V89, P5645, DOI 10.1073/pnas.89.12.5645; FURUKAWA T, 1993, CANCER RES, V53, P3070; Hiroshima Y, 2014, J LAPAROENDOSC ADV S, V24, P241, DOI 10.1089/lap.2013.0418; Hiroshima Y, 2014, J SURG RES, V187, P510, DOI 10.1016/j.jss.2013.11.1083; Kaushal S, 2008, J GASTROINTEST SURG, V12, P1938, DOI 10.1007/s11605-008-0581-0; Maawy AA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097965; Maawy AA, 2013, J BIOMED OPT, V18, DOI 10.1117/1.JBO.18.12.126016; Metildi CA, 2014, J AM COLL SURGEONS, V219, P132, DOI 10.1016/j.jamcollsurg.2014.02.021; Metildi CA, 2014, J SURG ONCOL, V109, P451, DOI 10.1002/jso.23507; Metildi CA, 2014, ANN SURG ONCOL, V21, P1405, DOI 10.1245/s10434-014-3495-y; Metildi CA, 2012, J AM COLL SURGEONS, V214, P997, DOI 10.1016/j.jamcollsurg.2012.02.009; Mitsunaga M, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-345; Mitsunaga M, 2012, BIOCONJUGATE CHEM, V23, P604, DOI 10.1021/bc200648m; Mitsunaga M, 2011, NAT MED, V17, P1685, DOI 10.1038/nm.2554; Nakajima T, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-389; Nakajima T, 2013, THERANOSTICS, V3, P357, DOI 10.7150/thno.5908; Ryan DP, 2014, NEW ENGL J MED, V371, P1039, DOI 10.1056/NEJMra1404198; Sato K, 2014, MOL ONCOL, V8, P620, DOI 10.1016/j.molonc.2014.01.006; Yamauchi K, 2006, CANCER RES, V66, P4208, DOI 10.1158/0008-5472.CAN-05-3927	23	44	52	1	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 23	2015	10	3							e0121989	10.1371/journal.pone.0121989	http://dx.doi.org/10.1371/journal.pone.0121989			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CE6ZS	25799218	Green Published, Green Submitted, gold			2023-01-03	WOS:000351987300307
J	Sruamsiri, R; Ross-Degnan, D; Lu, CY; Chaiyakunapruk, N; Wagner, AK				Sruamsiri, Rosarin; Ross-Degnan, Dennis; Lu, Christine Y.; Chaiyakunapruk, Nathorn; Wagner, Anita K.			Policies and Programs to Facilitate Access to Targeted Cancer Therapies in Thailand	PLOS ONE			English	Article							HEALTH TECHNOLOGY-ASSESSMENT; PATIENT ASSISTANCE PROGRAMS; DECISIONS; COVERAGE	Background Increasing access to clinically beneficial targeted cancer medicines is a challenge in every country due to their high cost. We describe the interplay of innovative policies and programs involving multiple stakeholders to facilitate access to these medicines in Thailand, as well as the utilization of selected targeted therapies over time. Methods We selected two medicines on the 2013 Thai national list of essential medicines (NLEM) [letrozole and imatinib] and three unlisted medicines for the same indications [trastuzumab, nilotinib and dasatinib]. We created timelines of access policies and programs for these products based on scientific and grey literature. Using IMS Health sales data, we described the trajectories of sales volumes of the study medicines between January 2001 and December 2012. We compared estimated average numbers of patients treated before and after the implementation of policies and programs for each product. Results Different stakeholders implemented multiple interventions to increase access to the study medicines for different patient populations. During 2007-2009, the Thai Government created a special NLEM category with different coverage requirements for payers and issued compulsory licenses; payers negotiated prices with manufacturers and engaged in pooled procurement; pharmaceutical companies expanded patient assistance programs and lowered prices in different ways. Compared to before the interventions, estimated numbers of patients treated with each medicine increased significantly afterwards: for letrozole from 645 (95% CI 366-923) to 3683 (95% CI 2,748-4,618); for imatinib from 103 (95% CI 72174) to 350 (95% CI 307-398); and for trastuzumab from 68 (95% CI 45-118) to 412 (95% CI 344-563). Conclusions Government, payers, and manufacturers implemented multi-pronged approaches to facilitate access to targeted cancer therapies for the Thai population, which differed by medicine. Routine monitoring is needed to assess clinical and economic impacts of these strategies in the health system.	[Sruamsiri, Rosarin; Chaiyakunapruk, Nathorn] Naresuan Univ, Fac Pharmaceut Sci, Ctr Pharmaceut Outcomes Res, Dept Pharm Practice, Phitsanulok, Thailand; [Sruamsiri, Rosarin; Ross-Degnan, Dennis; Lu, Christine Y.; Wagner, Anita K.] Harvard Univ, Sch Med, Dept Populat Med, Boston, MA USA; [Sruamsiri, Rosarin; Ross-Degnan, Dennis; Lu, Christine Y.; Wagner, Anita K.] Harvard Pilgrim Hlth Care Inst, Boston, MA USA; [Chaiyakunapruk, Nathorn] Monash Univ Malaysia, Sch Pharm, Subang Jaya, Malaysia; [Chaiyakunapruk, Nathorn] Univ Queensland, Sch Populat Hlth, Brisbane, Qld, Australia; [Chaiyakunapruk, Nathorn] Univ Wisconsin, Sch Pharm, Madison, WI 53706 USA	Naresuan University; Harvard University; Harvard Medical School; Harvard Pilgrim Health Care; Monash University; Monash University Sunway; University of Queensland; University of Wisconsin System; University of Wisconsin Madison	Sruamsiri, R (corresponding author), Naresuan Univ, Fac Pharmaceut Sci, Ctr Pharmaceut Outcomes Res, Dept Pharm Practice, Phitsanulok, Thailand.	r.sruamsiri@gmail.com			Thailand Research Fund (TRF) through the Royal Golden Jubilee PhD program [PHD/0127/2552]	Thailand Research Fund (TRF) through the Royal Golden Jubilee PhD program(Thailand Research Fund (TRF))	This study was supported by a grant from the Thailand Research Fund (TRF) through the Royal Golden Jubilee PhD program (Grant No. PHD/0127/2552 to RS). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	American College of Physicians, 2011, CAN OUR NAT CONS DIS; CanTreat Int, 2010, ANN ONCOL, V21, P680, DOI 10.1093/annonc/mdq055; Choudhry NK, 2009, HEALTH AFFAIR, V28, P827, DOI 10.1377/hlthaff.28.3.827; Damrongplasit K, 2009, HEALTH AFFAIR, V28, pW457, DOI 10.1377/hlthaff.28.3.w457; Espin J, 2011, EXP IMP EUR RIUSK SH; Farmer P, 2010, LANCET, V376, P1186, DOI 10.1016/S0140-6736(10)61152-X; Felder TM, 2011, J HEALTH CARE POOR U, V22, P24, DOI 10.1353/hpu.2011.0003; Food Drug and Administration, 2013, PHARM PROD INF; Health Insurance System Research Office, 2012, THAIL U COV SCHE ACH; IMS Health, 2012, ONC SAL CHANN; Internaltional Agency for Research on Cancer, 2008, GLOBOCAN2008 EST CAN; International Agency for Research on Cancer, 2008, WORLD CANC REPORT 20; Kanavos P, 2006, ANN ONCOL, V17, P15, DOI 10.1093/annonc.mdl983; Kanavos P, 2010, OPTIONS FINANCING OP; Keskinaslan A, 2011, ASSESSMENT PRICING R; Lassarat S, 2006, ANN ONCOL, V17, P43, DOI [10.1093/annonc.mdl987, 10.1093/annonc/mdl987]; Lichtenberg FR, 2004, 10328 NAT BUR EC RES; Lopes GD, 2013, NAT REV CLIN ONCOL, V10, P314, DOI 10.1038/nrclinonc.2013.55; Low O, 2012, IDEALS IMPLEMENTATIO; Manager Online, 2012, NHSO SWO ALLOW REIMB; Mohara A, 2012, J COMP EFFECT RES, V1, P137, DOI [10.2217/CER.12.10, 10.2217/cer.12.10]; Mohara A, 2012, VALUE HEALTH, V15, pS95, DOI 10.1016/j.jval.2011.11.016; Murray SA, 2003, BRIT MED J, V326, P368, DOI 10.1136/bmj.326.7385.368; *NAT DRUG COMM, 2004, NAT LIST ESS MED; National Comprehensive Cancer Network, 2013, NCCN CLIN PRACT GUID; National Drug Commitee, 2013, NAT LIST MED 2013; National Drug Committee, 2008, NAT LIS ESS MED 2008; National Health Security Office, 2010, CLIN PRACT GUID BREA; National Health Security Office, 2006, CLIN PRACT AD CHRON; National statistical office Thailand, 2012, Q THAI POP; Rodin J, 2012, LANCET, V380, P861, DOI 10.1016/S0140-6736(12)61340-3; Sakunphanit T, 2006, UNIVERSAL HLTH COVER; Savedoff W.D., 2012, TRANSITIONS HLTH FIN; Savedoff WD, 2012, LANCET, V380, P924, DOI 10.1016/S0140-6736(12)61083-6; Sloan FA, 2007, CANC CONTR OPP LOW M; Tangcharoensathien V, 2011, LANCET, V377, P863, DOI 10.1016/S0140-6736(10)61890-9; Teerawattananon Y, 2009, INT J TECHNOL ASSESS, V25, P241, DOI 10.1017/S0266462309090709; Thai CML Patient Group (THCML), 2010, CLIN PRACT GUID AD C; Thai PR, 2008, 5 ANNIVERSARY GIPAP; Thai working group on National Health Account, 2010, REP 1994 2008 NAT HL; Thailand Health Insurance System Research Office, 2012, THAILANDS UNIVERSAL; The Ministry of Public Health and the National Health Security Office, 2008, 10 BURN QUEST GOV US; The National Health Security Office, 2013, Q ANN REP; The National Health Security Office, 2010, VMI HELPS SAV B4BN D; The World Health Organization, 2014, DEF UN HLTH COV; Towse A, 2004, BRIT MED J, V328, P103, DOI 10.1136/bmj.328.7431.103; Towse A, 2010, PHARMACOECONOMICS, V28, P93, DOI 10.2165/11314080-000000000-00000; Turongkaravee S, 2012, EVALUATION HIGH COST; Turongkarawee S, 2011, EVALUATION HIGH COST; University M, 2010, THAIL HLTH PROF 2009; Vatanasapt V, 2002, JPN J CLIN ONCOL, V32, pS82, DOI 10.1093/jjco/hye134; WHO, 2010, WOR HEALT REP, P1; Wibulpolprasert S, 2011, GLOBALIZATION HEALTH, V7, DOI 10.1186/1744-8603-7-32; World Health Organization, 2009, INT TRAD HLTH REF GU; World Health Organization, PROM RAT US MED COR; World Trade Organization, 2001, AGGR TRAD REL ASP IN; Yamabhai I, 2009, ASSESSING IMPLICATIO; Yamabhai I, 2011, GLOBALIZATION HEALTH, V7, DOI 10.1186/1744-8603-7-28; Yoongthong W, 2012, VALUE HEALTH, V15, pS126, DOI 10.1016/j.jval.2011.11.003	59	19	20	1	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 23	2015	10	3							e0119945	10.1371/journal.pone.0119945	http://dx.doi.org/10.1371/journal.pone.0119945			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	CE6ZS	25798948	Green Published, gold, Green Submitted			2023-01-03	WOS:000351987300095
J	Spencer-Smith, M; Klingberg, T				Spencer-Smith, Megan; Klingberg, Torkel			Benefits of a Working Memory Training Program for Inattention in Daily Life: A Systematic Review and Meta-Analysis	PLOS ONE			English	Review							ATTENTION-DEFICIT/HYPERACTIVITY DISORDER; COGNITIVE DEFICITS; FLUID INTELLIGENCE; CHILDREN; ADOLESCENTS; ADHD; ACHIEVEMENT; MATHEMATICS; PREDICTORS; PLASTICITY	Background Many common disorders across the lifespan feature impaired working memory (WM). Reported benefits of aWM training program include improving inattention in daily life, but this has not been evaluated in a meta-analysis. This study aimed to evaluate whether one WM training method has benefits for inattention in daily life by conducting a systematic review and meta-analysis. Methods We searched Medline and PsycINFO, relevant journals and contacted authors for studies with an intervention and control group reporting post-training estimates of inattention in daily life. To reduce the influence of differentWM training methods on the findings, the review was restricted to trials evaluating the Cogmed method. A meta-analysis calculated the pooled standardised difference in means (SMD) between intervention and control groups. Results A total of 622 studies were identified and 12 studies with 13 group comparisons met inclusion criteria. The meta-analysis showed a significant training effect on inattention in daily life, SMD=-0.47, 95% CI -0.65, -0.29, p<.00001. Subgroup analyses showed this significant effect was observed in groups of children and adults as well as users with and without ADHD, and in studies using control groups that were active and non-adaptive, wait-list and passive as well as studies using specific or general measures. Seven of the studies reported follow-up assessment and a meta-analysis showed persisting training benefits for inattention in daily life, SMD=-0.33, 95% CI -0.57 -0.09, p =.006. Additional meta-analyses confirmed improvements after training on visuospatial WM, SMD=0.66, 95% CI 0.43, 0.89, p<.00001, and verbal WM tasks, SMD=0.40, 95% CI 0.18, 0.62, p = .0004. Conclusions Benefits of aWM training program generalise to improvements in everyday functioning. Initial evidence shows that the Cogmed method has significant benefits for inattention in daily life with a clinically relevant effect size.	[Spencer-Smith, Megan; Klingberg, Torkel] Karolinska Inst, Dept Neurosci, Stockholm, Sweden; [Spencer-Smith, Megan] Monash Univ, Sch Psychol Sci, Melbourne, Vic 3004, Australia	Karolinska Institutet; Monash University	Spencer-Smith, M (corresponding author), Karolinska Inst, Dept Neurosci, Stockholm, Sweden.	megan.spencer-smith@mcri.edu.au		Klingberg, Torkel/0000-0002-3175-2171; Spencer-Smith, Megan/0000-0002-1047-0829				Aarnoudse-Moens CSH, 2009, PEDIATRICS, V124, P717, DOI 10.1542/peds.2008-2816; Alloway T. P., 2012, J INTERACTIVE LEARNI, V23, P1; Beck SJ, 2010, J CLIN CHILD ADOLESC, V39, P825, DOI 10.1080/15374416.2010.517162; Bjorkdahl A, 2013, BRAIN INJURY, V27, P1658, DOI 10.3109/02699052.2013.830196; Brehmer Y, 2012, FRONT HUM NEUROSCI, V6, DOI DOI https://doi.org/10.3389/fnhum.2012.00063; Bull R, 2008, DEV NEUROPSYCHOL, V33, P205, DOI 10.1080/87565640801982312; Castellanos FX, 2002, NAT REV NEUROSCI, V3, P617, DOI 10.1038/nrn896; Chacko A, 2014, J CHILD PSYCHOL PSYC, V55, P247, DOI 10.1111/jcpp.12146; Chacko A, 2013, J CLIN CHILD ADOLESC, V42, P769, DOI 10.1080/15374416.2013.787622; *COGNIFIT LTD, 2008, COGNIFIT PERS COACH; COHEN J, 1992, PSYCHOL BULL, V112, P155, DOI 10.1037/0033-2909.112.1.155; Dahlin KIE, 2011, READ WRIT, V24, P479, DOI 10.1007/s11145-010-9238-y; Egeland J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075660; Forbes NF, 2009, PSYCHOL MED, V39, P889, DOI 10.1017/S0033291708004558; Gathercole S. E., 2003, EDUC CHILD PSYCHOL, V20, P109, DOI DOI 10.1037/A0036633; Gathercole SE, 2004, APPL COGNITIVE PSYCH, V18, P1, DOI 10.1002/acp.934; Gathercole SE, 2008, LEARN INDIVID DIFFER, V18, P214, DOI 10.1016/j.lindif.2007.10.003; Geary DC, 2011, DEV PSYCHOL, V47, P1539, DOI 10.1037/a0025510; Gibson BS, 2011, CHILD NEUROPSYCHOL, V17, P546, DOI 10.1080/09297049.2010.551186; Gray SA, 2012, J CHILD PSYCHOL PSYC, V53, P1277, DOI 10.1111/j.1469-7610.2012.02592.x; Green CT, 2012, NEUROTHERAPEUTICS, V9, P639, DOI 10.1007/s13311-012-0124-y; Gropper R, 2013, THESIS U TORONTO; Grunewaldt KH, 2013, PEDIATRICS, V131, pE747, DOI 10.1542/peds.2012-1965; Hardy KK, 2011, J PEDIATR ONCOL NURS, V28, P27, DOI 10.1177/1043454210377178; Harrison TL, 2013, PSYCHOL SCI, V24, P2409, DOI 10.1177/0956797613492984; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; Higgins J, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.ED000049; Jaeggi SM, 2008, P NATL ACAD SCI USA, V105, P6829, DOI 10.1073/pnas.0801268105; Johansson B, 2012, SCAND J OCCUP THER, V19, P176, DOI 10.3109/11038128.2011.603352; Kirsch I, 2008, PLOS MED, V5, P260, DOI 10.1371/journal.pmed.0050045; Klingberg T, 2005, J AM ACAD CHILD PSY, V44, P177, DOI 10.1097/00004583-200502000-00010; Klingberg T, 2010, TRENDS COGN SCI, V14, P317, DOI 10.1016/j.tics.2010.05.002; Kofler MJ, 2010, J ABNORM CHILD PSYCH, V38, P149, DOI 10.1007/s10802-009-9357-6; Kronenberger WG, 2011, J SPEECH LANG HEAR R, V54, P1182, DOI 10.1044/1092-4388(2010/10-0119); Lohaugen GCC, 2011, J PEDIATR-US, V158, P555, DOI 10.1016/j.jpeds.2010.09.060; Long B, 2011, DEV NEUROPSYCHOL, V36, P971, DOI 10.1080/87565641.2011.581537; Ludqvist A, 2010, BRAIN INJURY, V24, P1173, DOI [10.3109/02699052.2010.498007, DOI 10.3109/02699052.2010.498007]; Martin N, 2002, BRIT J PSYCHIAT, V180, P260, DOI 10.1192/bjp.180.3.260; Martinussen R, 2005, J AM ACAD CHILD PSY, V44, P377, DOI 10.1097/01.chi.0000153228.72591.73; McLoughlin G, 2011, BEHAV GENET, V41, P668, DOI 10.1007/s10519-011-9473-2; Melby-Lervag M, 2013, DEV PSYCHOL, V49, P270, DOI 10.1037/a0028228; Merikangas KR, 2010, PEDIATRICS, V125, P75, DOI 10.1542/peds.2008-2598; Mezzacappa E., 2010, SCH MENTAL HLTH, V2, P202, DOI [DOI 10.1007/S12310-010-9030-9, 10.1007/s12310-010-9030-9]; Morrison AB, 2011, PSYCHON B REV, V18, P46, DOI 10.3758/s13423-010-0034-0; Nutley SB, 2011, DEVELOPMENTAL SCI, V14, P591, DOI 10.1111/j.1467-7687.2010.01022.x; Raghubar KP, 2010, LEARN INDIVID DIFFER, V20, P110, DOI 10.1016/j.lindif.2009.10.005; Rockwood K, 2004, J NEUROL NEUROSUR PS, V75, P677, DOI 10.1136/jnnp.2003.029074; Rogers M, 2011, CHILD NEUROPSYCHOL, V17, P444, DOI 10.1080/09297049.2010.544648; Roughan L, 2011, LEARN INDIVID DIFFER, V21, P759, DOI 10.1016/j.lindif.2011.07.011; Schatz J, 2000, NEUROPSYCHOLOGY, V14, P189, DOI 10.1037//0894-4105.14.2.189; Shipstead Z, 2012, PSYCHOL BULL, V138, P628, DOI 10.1037/a0027473; Shipstead Z, 2010, PSYCHOL BELG, V50, P245, DOI 10.5334/pb-50-3-4-245; Soderqvist S, 2014, J COGNITIVE NEUROSCI, V26, P54, DOI 10.1162/jocn_a_00478; Soderqvist S, 2012, DEV PSYCHOL, V48, P836, DOI 10.1037/a0026179; The Cochrane Collaboration, 2012, REV MAN REVMAN VERS; Thorell LB, 2009, DEVELOPMENTAL SCI, V12, P106, DOI 10.1111/j.1467-7687.2008.00745.x; von Bastian CC, 2014, PSYCHOL RES-PSYCH FO, V78, P803, DOI 10.1007/s00426-013-0524-6; Westerberg H, 2004, CHILD NEUROPSYCHOL, V10, P155, DOI 10.1080/09297040490911014; What Works Clearing House, 2014, WHAT WORKS CLEARINGH	59	99	100	1	97	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 20	2015	10	3							e0119522	10.1371/journal.pone.0119522	http://dx.doi.org/10.1371/journal.pone.0119522			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	CE8IA	25793607	Green Submitted, Green Published, gold			2023-01-03	WOS:000352084200089
J	Naimi, TS; Mosher, JF				Naimi, Timothy S.; Mosher, James F.			Powdered Alcohol Products New Challenge in an Era of Needed Regulation	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							US		[Naimi, Timothy S.] Boston Med Ctr, Gen Internal Med Sect, One Boston Med Ctr Pl, Boston, MA 02118 USA; [Mosher, James F.] Alcohol Policy Consultat, Felton, CA USA	Boston Medical Center	Naimi, TS (corresponding author), Boston Med Ctr, Gen Internal Med Sect, One Boston Med Ctr Pl, Boston, MA 02118 USA.	tim.naimi@bmc.org		Naimi, Timothy/0000-0001-9849-4413				Bouchery EE, 2011, AM J PREV MED, V41, P516, DOI 10.1016/j.amepre.2011.06.045; Centers for Disease Control and Prevention, 2015, ALC REL DIS IMP ARDI; Centers for Disease Control and Prevention (CDC), FACT SHEETS CAFF ALC; Federal Trade Commission, 2014, SELF REG ALC IND REP; Kerr WC, 2013, AM J PREV MED, V44, P459, DOI 10.1016/j.amepre.2013.01.007; Naimi TS, 2011, AM J PREV MED, V41, P546, DOI 10.1016/j.amepre.2011.08.001; National Alcohol Beverage Control Association (NABCA), 2015, POWD ALC ENC; National Conference of State Legislatures (NCSL), 2015, POWD ALC 2015 LEG; US Food and Drug Administration, 2015, FDA CLAR ITS ROL PAL	9	9	9	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 14	2015	314	2					119	120		10.1001/jama.2015.6450	http://dx.doi.org/10.1001/jama.2015.6450			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CM7JI	26075642				2023-01-03	WOS:000357867500006
J	Ligeti, B; Penzvalto, Z; Vera, R; Gyorffy, B; Pongor, S				Ligeti, Balazs; Penzvalto, Zsofia; Vera, Roberto; Gyorffy, Balazs; Pongor, Sandor			A Network-Based Target Overlap Score for Characterizing Drug Combinations: High Correlation with Cancer Clinical Trial Results	PLOS ONE			English	Article							BREAST-CANCER; ADJUVANT CHEMOTHERAPY; ROC ANALYSIS; FOLLOW-UP; PRIORITIZATION; THERAPEUTICS; TRASTUZUMAB; EVALUATE; SEARCH; PLUS	Drug combinations are highly efficient in systemic treatment of complex multigene diseases such as cancer, diabetes, arthritis and hypertension. Most currently used combinations were found in empirical ways, which limits the speed of discovery for new and more effective combinations. Therefore, there is a substantial need for efficient and fast computational methods. Here, we present a principle that is based on the assumption that perturbations generated by multiple pharmaceutical agents propagate through an interaction network and can cause unexpected amplification at targets not immediately affected by the original drugs. In order to capture this phenomenon, we introduce a novel Target Overlap Score (TOS) that is defined for two pharmaceutical agents as the number of jointly perturbed targets divided by the number of all targets potentially affected by the two agents. We show that this measure is correlated with the known effects of beneficial and deleterious drug combinations taken from the DCDB, TTD and Drugs. com databases. We demonstrate the utility of TOS by correlating the score to the outcome of recent clinical trials evaluating trastuzumab, an effective anticancer agent utilized in combination with anthracycline-and taxane- based systemic chemotherapy in HER2-receptor (erb-b2 receptor tyrosine kinase 2) positive breast cancer.	[Ligeti, Balazs; Vera, Roberto; Pongor, Sandor] Pazmany Peter Catholic Univ, Fac Informat Technol, Budapest, Hungary; [Penzvalto, Zsofia; Gyorffy, Balazs] MTA TTK Lendulet Canc Biomarker Res Grp, Budapest, Hungary; [Vera, Roberto; Pongor, Sandor] Int Ctr Genet Engn & Biotechnol, Prot Struct & Bioinformat Grp, I-34012 Trieste, Italy; [Gyorffy, Balazs] Semmelweis Univ, Dept Pediat 2, H-1085 Budapest, Hungary; [Gyorffy, Balazs] MTA SE Pediat & Nephrol Res Grp, Budapest, Hungary	Eotvos Lorand Research Network; Hungarian Academy of Sciences; Hungarian Research Centre for Natural Sciences; International Center for Genetic Engineering & Biotechnology (ICGEB); Semmelweis University; Semmelweis University	Gyorffy, B (corresponding author), MTA TTK Lendulet Canc Biomarker Res Grp, Budapest, Hungary.	zsalab2@yahoo.com; pongor@icgeb.org	Gyorffy, Balazs/AAA-9135-2021	Gyorffy, Balazs/0000-0002-5772-3766; Vera Alvarez, Roberto/0000-0002-4108-5982	Hungarian Scientific Research Fund OTKA [K108655]	Hungarian Scientific Research Fund OTKA(Orszagos Tudomanyos Kutatasi Alapprogramok (OTKA))	LB and RV are graduate students at the Multidisciplinary Doctoral School of Sciences and Technology of Faculty of Information Technology, and Bionics, Pazmany Peter Catholic University, Budapest, Hungary. BG was supported by grant K108655 from the Hungarian Scientific Research Fund OTKA.	Agoston V, 2005, PHYS REV E, V71, DOI 10.1103/PhysRevE.71.051909; [Anonymous], 2008, WALKING INTERACTOME; [Anonymous], 2005, P 11 ACM SIGKDD INT; [Anonymous], 2011, NUCL ACIDS RES DATAB; Barabasi AL, 2011, NAT REV GENET, V12, P56, DOI 10.1038/nrg2918; Bliss CI, 1939, ANN APPL BIOL, V26, P585, DOI 10.1111/j.1744-7348.1939.tb06990.x; Borisy AA, 2003, P NATL ACAD SCI USA, V100, P7977, DOI 10.1073/pnas.1337088100; Busa-Fekete R, 2008, J BIOCHEM BIOPH METH, V70, P1210, DOI 10.1016/j.jbbm.2007.06.003; Calzolari D, 2008, PLOS COMPUT BIOL, V4, DOI 10.1371/journal.pcbi.1000249; Chen J, 2009, BMC BIOINFORMATICS, V10, DOI 10.1186/1471-2105-10-73; Cokol M, 2011, MOL SYST BIOL, V7, DOI 10.1038/msb.2011.71; Csermely P, 2005, TRENDS PHARMACOL SCI, V26, P178, DOI 10.1016/j.tips.2005.02.007; Dawood S, 2010, J CLIN ONCOL, V28, P92, DOI 10.1200/JCO.2008.19.9844; Franceschini A, 2013, NUCLEIC ACIDS RES, V41, pD808, DOI 10.1093/nar/gks1094; Gottlieb A, 2012, MOL SYST BIOL, V8, DOI 10.1038/msb.2012.26; GRECO WR, 1995, PHARMACOL REV, V47, P331; Hopkins AL, 2008, NAT CHEM BIOL, V4, P682, DOI 10.1038/nchembio.118; Hosmer DW, 2013, WILEY SERIES PROBABI; Imming P, 2006, NAT REV DRUG DISCOV, V5, P821, DOI 10.1038/nrd2132; Jin GX, 2011, BIOINFORMATICS, V27, pI310, DOI 10.1093/bioinformatics/btr202; Katzung BGMSBTAJ, 2012, BASIC CLINICAL PHARM; Keith CT, 2005, NAT REV DRUG DISCOV, V4, P71, DOI 10.1038/nrd1609; Kitano H, 2007, NAT REV DRUG DISCOV, V6, P202, DOI 10.1038/nrd2195; Knox C, 2011, NUCLEIC ACIDS RES, V39, pD1035, DOI 10.1093/nar/gkq1126; Kuhn M, 2012, NUCLEIC ACIDS RES, V40, pD876, DOI 10.1093/nar/gkr1011; Lehar J, 2009, NAT BIOTECHNOL, V27, P659, DOI 10.1038/nbt.1549; Li S, 2011, BMC SYST BIOL, V5, DOI 10.1186/1752-0509-5-S1-S10; Ligeti B, 2013, BIOM CIRC SYST C BIO; Liu YB, 2010, BIOINFORMATICS, V26, P587, DOI 10.1093/bioinformatics/btp697; Loewe S, 1926, N-S ARCH EX PATH PH, V114, P313; Nitsch D, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-460; O'Boyle NM, 2008, CHEM CENT J, V2, DOI 10.1186/1752-153X-2-24; Perez EA, 2011, J CLIN ONCOL, V29, P3366, DOI 10.1200/JCO.2011.35.0868; Pesquita C, 2009, PLOS COMPUT BIOL, V5, DOI 10.1371/journal.pcbi.1000443; Resnik P, 1995, INT JOINT CONF ARTIF, P448; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101; Smith I, 2007, LANCET, V369, P29, DOI 10.1016/S0140-6736(07)60028-2; Sonego P, 2008, BRIEF BIOINFORM, V9, P198, DOI 10.1093/bib/bbm064; Therasse P, 2000, J NATL CANCER I, V92, P205, DOI 10.1093/jnci/92.3.205; Vanunu O, 2010, PLOS COMPUT BIOL, V6, DOI 10.1371/journal.pcbi.1000641; Vera R, 2013, DATABASE-OXFORD, DOI 10.1093/database/bat051; Wong PK, 2008, P NATL ACAD SCI USA, V105, P5105, DOI 10.1073/pnas.0800823105; Wu ZK, 2010, BMC SYST BIOL, V4, DOI 10.1186/1752-0509-4-S2-S7; Xiong JH, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013937; Xu KJ, 2012, BMC SYST BIOL, V6, DOI 10.1186/1752-0509-6-S1-S5; Yang K, 2008, MOL SYST BIOL, V4, DOI 10.1038/msb.2008.60; Young SS, 1993, RESAMPLING BASED MUL; Zhao XM, 2011, PLOS COMPUT BIOL, V7, DOI 10.1371/journal.pcbi.1002323; Zhu F, 2012, NUCLEIC ACIDS RES, V40, pD1128, DOI 10.1093/nar/gkr797; Zimmermann GR, 2007, DRUG DISCOV TODAY, V12, P34, DOI 10.1016/j.drudis.2006.11.008	50	6	9	6	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 5	2015	10	6							e0129267	10.1371/journal.pone.0129267	http://dx.doi.org/10.1371/journal.pone.0129267			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CJ7CR	26047322	Green Published, Green Submitted, Green Accepted, gold			2023-01-03	WOS:000355652200140
J	Malani, PN				Malani, Preeti N.			Bundled Approaches for Surgical Site Infection Prevention The Continuing Quest to Get to Zero	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							OLDER-ADULTS; DECOLONIZATION; SURGERY		[Malani, Preeti N.] Univ Michigan Hlth Syst, Dept Internal Med, Div Infect Dis, Ann Arbor, MI USA	University of Michigan System; University of Michigan	Malani, PN (corresponding author), 3119 Taubman Ctr, Ann Arbor, MI 48109 USA.	pmalani@umich.edu						Anderson DJ, 2014, INFECT CONT HOSP EP, V35, P605, DOI [10.1086/676022, 10.1017/S0899823X00193869]; Big C, 2010, J AM GERIATR SOC, V58, P300, DOI 10.1111/j.1532-5415.2009.02666.x; Bode LGM, 2010, NEW ENGL J MED, V362, P9, DOI 10.1056/NEJMoa0808939; Chassin MR, 2015, JAMA-J AM MED ASSOC, V313, P1795, DOI 10.1001/jama.2015.3818; Kline S, 2014, INFECT CONT HOSP EP, V35, P880, DOI 10.1086/676866; Malani PN, 2013, JAMA-J AM MED ASSOC, V309, P1408, DOI 10.1001/jama.2013.3382; Merkow RP, 2015, JAMA-J AM MED ASSOC, V313, P483, DOI 10.1001/jama.2014.18614; Schweizer M, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f2743; Schweizer ML, 2014, JAMA SURG, V149, P575, DOI 10.1001/jamasurg.2013.4663; Schweizer ML, JAMA-J AM MED ASSOC, DOI [10.1001/jama.2015.5387, DOI 10.1001/JAMA.2015]; Sievert DM, 2013, INFECT CONT HOSP EP, V34, P1, DOI 10.1086/668770; Young MH, 2008, DRUG AGING, V25, P399, DOI 10.2165/00002512-200825050-00004	12	4	4	0	6	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 2	2015	313	21					2131	2132		10.1001/jama.2015.6018	http://dx.doi.org/10.1001/jama.2015.6018			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CJ4CC	26034954				2023-01-03	WOS:000355430900012
J	Attaran, A				Attaran, Amir			Unanimity on Death with Dignity - Legalizing Physician-Assisted Dying in Canada	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Attaran, Amir] Univ Ottawa, Fac Law, Ottawa, ON, Canada; [Attaran, Amir] Univ Ottawa, Fac Med, Ottawa, ON, Canada; [Attaran, Amir] Univ Ottawa, Inst Populat Hlth, Ottawa, ON, Canada	University of Ottawa; University of Ottawa; University of Ottawa	Attaran, A (corresponding author), Univ Ottawa, Fac Law, Ottawa, ON, Canada.							Vincent D., 2015, TORONTO STAR	1	24	25	0	26	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 28	2015	372	22					2080	2082		10.1056/NEJMp1502442	http://dx.doi.org/10.1056/NEJMp1502442			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	CJ0EI	26017821				2023-01-03	WOS:000355146800002
J	Chen, LC; Cheng, LJ; Zhang, Y; He, X; Knaggs, RD				Chen, Li-Chia; Cheng, Li-Jen; Zhang, Yan; He, Xin; Knaggs, Roger D.			Acupuncture or Low Frequency Infrared Treatment for Low Back Pain in Chinese Patients: A Discrete Choice Experiment	PLOS ONE			English	Article							WILLINGNESS-TO-PAY; ALTERNATIVE MEDICINE; PREFERENCES; CARE; COMPLEMENTARY; PREVALENCE; PHYSICIANS; BURDEN	Acupuncture is a popular but controversial treatment option for low back pain. In China, it is practised as traditional Chinese medicine; other treatment strategies for low back pain are commonly practised as Western medicine. Research on patient preference for low backpain treatment options has been mainly conducted in Western countries and is limited to a willingness-to-pay approach. A stated-preference, discrete choice experiment was conducted to determine Chinese patient preferences and trade-offs for acupuncture and low frequency infrared treatment in low back pain from September 2011 to August 2012 after approval from the Department of Scientific Research in the study settings. Eight-six adult outpatients who visited the 'traditional medicine department' at a traditional Chinese medicine hospital and the 'rehabilitation department' at a Western medicine hospital in Guangdong Province of China for chronic low back pain during study period participated in an interview survey. A questionnaire containing 10 scenarios (5 attributes in each scenario) was used to ask participants' preference for acupuncture, low frequency infrared treatment or neither option. Validated responses were analysed using a nested-logit model. The decision on whether to receive a therapy was not associated with the expected utility of receiving therapy, female gender and higher out-of-pocket payment significantly decreased chance to receive treatments. Of the utility of receiving either acupuncture or low frequency infrared treatment, the treatment sensation was the most important attribute as an indicator of treatment efficacy, followed by the maximum efficacy, maintenance duration and onset of efficacy, and the out-of-pocket payment. The willingness-to-pay for acupuncture and low frequency infrared treatment were about $618.6 and $592.4 USD per course respectively, demonstrated patients' demand of pain management. The treatment sensation was regarded as an indicator of treatment efficacy and the most important attribute for choosing acupuncture or low frequency infrared treatment. The high willingness-to-pay demonstrated patients' demand of pain management. However, there may be other factors influencing patients' preference to receive treatments.	[Chen, Li-Chia; Knaggs, Roger D.] Univ Nottingham, Sch Pharm, Div Social Res Med & Hlth, Nottingham, England; [Cheng, Li-Jen; Zhang, Yan; He, Xin] Univ Macau, Inst Chinese Med Sci, State Key Lab Qual Res Chinese Med, Macau, Peoples R China; [Zhang, Yan] Univ Iowa, Coll Pharm Pharm Practice & Sci, Iowa City, IA USA; [Knaggs, Roger D.] Nottingham Univ Hosp NHS Trust, Dept Pharm, Nottingham, England	University of Nottingham; University of Macau; University of Iowa; Nottingham University Hospital NHS Trust	Cheng, LJ (corresponding author), Univ Macau, Inst Chinese Med Sci, State Key Lab Qual Res Chinese Med, Macau, Peoples R China.	chenglijen@gmail.com		Zhang, Yan/0000-0002-8526-9599; Chen, Li-Chia/0000-0002-6158-6645	Research Committee of the University of Macau [RG087]	Research Committee of the University of Macau	This research was funded by the Research Committee of the University of Macau (grant reference number RG087)(www.umac.mo)(YZ and XH). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Assendelft W, 2004, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD000447.PUB2; Barnes Patricia M, 2004, Adv Data, P1; Breivik H, 2006, EUR J PAIN, V10, P287, DOI 10.1016/j.ejpain.2005.06.009; Chancellor J, 2012, VALUE HEALTH, V15, P106, DOI 10.1016/j.jval.2011.07.002; Chen W, 2003, J ANHUI TCM COLL, V22, P38; Chenot JF, 2006, BMC HEALTH SERV RES, V6, DOI 10.1186/1472-6963-6-149; Chou R, 2007, ANN INTERN MED, V147, P478, DOI 10.7326/0003-4819-147-7-200710020-00006; Chuck A, 2009, VALUE HEALTH, V12, P498, DOI 10.1111/j.1524-4733.2008.00457.x; Croft P, 1997, LOW BACK PAIN HLTH C; Deyo RA, 2001, NEW ENGL J MED, V344, P363, DOI 10.1056/NEJM200102013440508; Deyo RA, 2006, SPINE, V31, P2724, DOI 10.1097/01.brs.0000244618.06877.cd; Eisenberg DM, 1998, JAMA-J AM MED ASSOC, V280, P1569, DOI 10.1001/jama.280.18.1569; Foltz V, 2005, JOINT BONE SPINE, V72, P571, DOI 10.1016/j.jbspin.2005.03.018; FRYMOYER JW, 1988, NEW ENGL J MED, V318, P291, DOI 10.1056/NEJM198802043180506; FURLAN AD, 2002, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD001929; Gao M, 2006, J PREV MED CHIN PLA, V24, P339; Gaul C, 2011, BMC COMPLEM ALTERN M, V11, DOI 10.1186/1472-6882-11-89; Gureje O, 2001, PAIN, V92, P195, DOI 10.1016/S0304-3959(00)00483-8; Hamelsky SW, 2005, CEPHALALGIA, V25, P87, DOI 10.1111/j.1468-2982.2005.00797.x; Harmsworth K, 2001, SOC SCI MED, V52, P149, DOI 10.1016/S0277-9536(00)00124-6; Hauber AB, 2013, OSTEOARTHR CARTILAGE, V21, P289, DOI 10.1016/j.joca.2012.11.007; Ho KY, 2009, PAIN PHYSICIAN, V12, P685; Hopton AK, 2010, ACUPUNCT MED, V28, P185, DOI 10.1136/aim.2010.002279; Hopton AK, 2011, CHIN J INTEGR MED, V17, P173, DOI 10.1007/s11655-011-0663-9; Klojgaard ME, 2014, VALUE HEALTH, V17, P390, DOI 10.1016/j.jval.2014.01.005; Kroner-Herwig B, 2009, CURR OPIN PSYCHIATR, V22, P200, DOI 10.1097/YCO.0b013e3283252d5a; Lenert LA, 2003, MED CARE, V41, P299, DOI 10.1097/00005650-200302000-00011; Lipton RB., 1999, HEADACHE, V39, pS20, DOI [10.1111/j.1526-4610.1999.00006.x, DOI 10.1111/J.1526-4610.1999.00006.X]; MacPherson Hugh, 2005, Acupunct Med, V23, P112; Manheimer E, 2005, ANN INTERN MED, V142, P651, DOI 10.7326/0003-4819-142-8-200504190-00014; Maniadakis N, 2000, PAIN, V84, P95, DOI 10.1016/S0304-3959(99)00187-6; Paterson C., 2007, J HLTH SERV RES P S1, V12, P39, DOI [10.1258/135581907780318356, DOI 10.1258/135581907780318356]; Pearmain D, 1991, STATED PREFERENCE TE; Phillips Ceri J, 2006, Expert Rev Pharmacoecon Outcomes Res, V6, P591, DOI 10.1586/14737167.6.5.591; Ratcliffe J, 2004, RHEUMATOLOGY, V43, P337, DOI 10.1093/rheumatology/keh038; Ryan M, 2004, HEALTH ECON, V13, P397, DOI 10.1002/hec.821; Sherman Karen J, 2004, BMC Complement Altern Med, V4, P9, DOI 10.1186/1472-6882-4-9; Sherman KJ, 2005, ANN INTERN MED, V143, P849, DOI 10.7326/0003-4819-143-12-200512200-00003; [石学峰 SHI Xuefeng], 2011, [中国全科医学, Chinese General Practice], V14, P1938; Sternbach RA, 1986, CLIN J PAIN, V2, P49, DOI DOI 10.1097/00002508-198602010-00008; Sweeting KR, 2011, PATIENT, V4, P45, DOI 10.2165/11532830-000000000-00000; Trenkwalder C, 2013, LANCET NEUROL, V12, P1141, DOI 10.1016/S1474-4422(13)70239-4; Unruh AM, 1996, PAIN, V65, P123, DOI 10.1016/0304-3959(95)00214-6; van Middelkoop M, 2011, EUR SPINE J, V20, P19, DOI 10.1007/s00586-010-1518-3; van Tulder Maurits, 2003, Clin Evid, P1359; Viney Rosalie, 2002, Expert Rev Pharmacoecon Outcomes Res, V2, P319, DOI 10.1586/14737167.2.4.319; Wolsko PM, 2003, SPINE, V28, P292, DOI 10.1097/00007632-200302010-00018; Wood L, 2012, EUR J ONCOL NURS, V16, P432, DOI 10.1016/j.ejon.2011.10.002; World Health Organisation, 2005, PREP HEALTHC WORKF 2; Yan M, 2011, J SHAANXI COLL TRAD, V34, P87	50	9	10	2	25	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 28	2015	10	5							e0126912	10.1371/journal.pone.0126912	http://dx.doi.org/10.1371/journal.pone.0126912			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CJ0SC	26020251	Green Published, gold, Green Submitted			2023-01-03	WOS:000355187300028
J	Jarvinen, TLN; Michaelsson, K; Jokihaara, J; Collins, GS; Perry, TL; Mintzes, B; Musini, V; Erviti, J; Gorricho, J; Wright, JM; Sievanen, H				Jarvinen, Teppo L. N.; Michaelsson, Karl; Jokihaara, Jarkko; Collins, Gary S.; Perry, Thomas L.; Mintzes, Barbara; Musini, Vijaya; Erviti, Juan; Gorricho, Javier; Wright, James M.; Sievanen, Harri			TOO MUCH MEDICINE Overdiagnosis of bone fragility in the quest to prevent hip fracture	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							POSTMENOPAUSAL WOMEN; VITAMIN-D; ZOLEDRONIC ACID; RISK; OSTEOPOROSIS; COST; BISPHOSPHONATES; THRESHOLDS; MANAGEMENT; DENOSUMAB		[Jarvinen, Teppo L. N.] Univ Helsinki, Dept Orthopaed & Traumatol, Helsinki, Finland; [Jarvinen, Teppo L. N.] Univ Helsinki, Cent Hosp, Helsinki, Finland; [Michaelsson, Karl] Uppsala Univ, Sect Orthopaed, Dept Surg Sci, Uppsala, Sweden; [Jokihaara, Jarkko] Tampere Univ Hosp, Dept Hand Surg, Tampere, Finland; [Collins, Gary S.] Univ Oxford, Botnar Res Ctr, Ctr Stat Med, Oxford, England; [Perry, Thomas L.; Musini, Vijaya; Wright, James M.] Univ British Columbia, Dept Anesthesiol, Vancouver, BC V5Z 1M9, Canada; [Perry, Thomas L.; Musini, Vijaya; Wright, James M.] Univ British Columbia, Dept Pharmacol, Vancouver, BC V5Z 1M9, Canada; [Perry, Thomas L.; Musini, Vijaya; Wright, James M.] Univ British Columbia, Dept Therapeut & Med, Vancouver, BC V5Z 1M9, Canada; [Mintzes, Barbara] Univ Sydney, Fac Pharm, Sydney, NSW 2006, Australia; [Mintzes, Barbara] Univ Sydney, Charles Perkins Ctr, Sydney, NSW 2006, Australia; [Erviti, Juan] Navarre Reg Hlth Serv, Drug Informat Unit, Pamplona, Navarre, Spain; [Gorricho, Javier] Govt Navarre, Dept Hlth, Pamplona, Navarre, Spain; [Sievanen, Harri] UKK Inst Hlth Promot Res, Tampere, Finland	University of Helsinki; University of Helsinki; Helsinki University Central Hospital; Uppsala University; Tampere University; Tampere University Hospital; University of Oxford; University of British Columbia; University of British Columbia; University of British Columbia; University of Sydney; University of Sydney; UKK Institute	Jarvinen, TLN (corresponding author), Univ Helsinki, Dept Orthopaed & Traumatol, Helsinki, Finland.	teppo.jarvinen@helsinki.fi	Gorricho, javier/H-2065-2015; Collins, Gary Stephen/A-2258-2014; Michaelsson, Karl/AAM-9094-2021; Jokihaara, Jarkko/C-5817-2017; Järvinen, Teppo/B-8189-2013; Shah, Syed Imran Ali/D-1324-2012; Mintzes, Barbara/AFK-6613-2022; Erviti, Juan/G-8150-2012	Gorricho, javier/0000-0003-3609-9922; Collins, Gary Stephen/0000-0002-2772-2316; Jokihaara, Jarkko/0000-0001-6153-2180; Järvinen, Teppo/0000-0003-3713-956X; Shah, Syed Imran Ali/0000-0002-0833-0771; Mintzes, Barbara/0000-0002-8671-915X; Musini, Vijaya/0000-0002-8096-6563; Michaelsson, Karl/0000-0003-2815-1217; Erviti, Juan/0000-0003-3396-2102	MRC [G1100513] Funding Source: UKRI; Medical Research Council [G1100513] Funding Source: researchfish	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)		Abrahamsen B, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.b5463; Abrahamsen B, 2010, J CLIN ENDOCR METAB, V95, P5258, DOI 10.1210/jc.2010-1571; Alonso-Coello P, 2008, BMJ-BRIT MED J, V336, P126, DOI 10.1136/bmj.39435.656250.AD; Aspenberg P, 2014, ACTA ORTHOP, V85, P1, DOI 10.3109/17453674.2013.859423; Ballane G, 2014, J BONE MINER RES, V29, P1745, DOI 10.1002/jbmr.2218; Bolland MJ, 2014, LANCET DIABETES ENDO, V2, P307, DOI 10.1016/S2213-8587(13)70212-2; Bolland Mark J, 2011, BMJ, V342, pd2040, DOI 10.1136/bmj.d2040; Boonen S, 2010, J AM GERIATR SOC, V58, P292, DOI 10.1111/j.1532-5415.2009.02673.x; Collins GS, 2012, CURR OSTEOPOROS REP, V10, P199, DOI 10.1007/s11914-012-0108-1; Compston J, 2013, MATURITAS, V75, P392, DOI 10.1016/j.maturitas.2013.05.013; Crilly RG, 2014, OSTEOPOROSIS INT, V25, P205, DOI 10.1007/s00198-013-2453-z; Cummings SR, 2009, NEW ENGL J MED, V361, P756, DOI 10.1056/NEJMoa0809493; Donaldson MG, 2009, J BONE MINER RES, V24, P675, DOI [10.1359/jbmr.081203, 10.1359/JBMR.081203]; El-Khoury F, 2013, BMJ-BRIT MED J, V347, DOI 10.1136/bmj.f6234; European Medicines Agency, EMEAH595210AR; European Medicines Agency, 2010, EMEAHC001120; Feldstein AC, 2009, BONE, V44, P153, DOI 10.1016/j.bone.2008.09.006; Feskanich D, 2002, JAMA-J AM MED ASSOC, V288, P2300, DOI 10.1001/jama.288.18.2300; Food and Drug Administration, 2011, BACKGR DOC M ADV COM; Food and Drug Administration, 2010, STAT REV PROT 200905; Greenspan SL, 2015, JAMA INT MED; Herndon MB, 2007, HEALTH AFFAIR, V26, P1702, DOI 10.1377/hlthaff.26.6.1702; Hernlund E, 2013, ARCH OSTEOPOROS, V8, DOI 10.1007/s11657-013-0136-1; Jarvinen TLN, 2008, BRIT MED J, V336, P124, DOI 10.1136/bmj.39428.470752.AD; Jarvinen TLN, 2014, CAN MED ASSOC J, V186, P165, DOI 10.1503/cmaj.121874; Jarvinen TLN, 2011, BRIT MED J, V342, DOI 10.1136/bmj.d2175; Jarvinen TL, 2011, BMJ-BRIT MED J, V343, pd5040; Johnell O, 2005, J BONE MINER RES, V20, P1185, DOI 10.1359/JBMR.050304; Kanis JA, 2008, OSTEOPOROSIS INT, V19, P385, DOI 10.1007/s00198-007-0543-5; Kanis JA, 2011, OSTEOPOROSIS INT, V22, P2395, DOI 10.1007/s00198-011-1713-z; KANIS JA, 1994, OSTEOPOROSIS INT, V4, P368, DOI 10.1007/BF01622200; Kanis JA, 2005, OSTEOPOROSIS INT, V16, P737, DOI 10.1007/s00198-004-1640-3; Kanis JA, 2000, BONE, V27, P585, DOI 10.1016/S8756-3282(00)00381-1; Kanis JA, 2001, OSTEOPOROSIS INT, V12, P417, DOI 10.1007/s001980170112; Kannus P, 2002, J BONE MINER RES, V17, P1363, DOI 10.1359/jbmr.2002.17.8.1363; Kherad M, 2015, SPINE J, V15, P281, DOI 10.1016/j.spinee.2014.09.016; Korhonen N, 2013, OSTEOPOROSIS INT, V24, P1599, DOI 10.1007/s00198-012-2190-8; LAW MR, 1991, BMJ-BRIT MED J, V303, P453, DOI 10.1136/bmj.303.6800.453; Lyles KW, 2007, NEW ENGL J MED, V357, P1799, DOI 10.1056/NEJMoa074941; Marshall D, 1996, BRIT MED J, V312, P1254, DOI 10.1136/bmj.312.7041.1254; McClung MR, 2001, NEW ENGL J MED, V344, P333, DOI 10.1056/NEJM200102013440503; Michaelsson K, 2007, PLOS MED, V4, P1094, DOI 10.1371/journal.pmed.0040199; Musini VM, 2011, THER LETT, V83, P1; Olofsson H, 2005, J BONE MINER RES, V20, P1208, DOI 10.1359/JBMR.050208; Poole KE, 2012, BRIT MED J, V344, DOI 10.1136/bmj.e3211; Reginster JY, 2005, J CLIN ENDOCR METAB, V90, P2816, DOI 10.1210/jc.2004-1774; Reid IR, 2014, OSTEOPOROSIS INT, V25, P2347, DOI 10.1007/s00198-014-2749-7; Reid Ian R, 2014, J Bone Metab, V21, P21, DOI 10.11005/jbm.2014.21.1.21; Reid IR, 2011, SKELETAL RADIOL, V40, P1191, DOI 10.1007/s00256-011-1164-9; RUBIN SM, 1992, ANN INTERN MED, V116, P990, DOI 10.7326/0003-4819-116-12-990; Sanders KM, 2006, BONE, V38, P694, DOI 10.1016/j.bone.2005.06.004; Schilcher J, 2014, NEW ENGL J MED, V371, P974, DOI 10.1056/NEJMc1403799; Shane E, 2014, J BONE MINER RES, V29, P1, DOI 10.1002/jbmr.1998; Sievanen H, 2007, PLOS MED, V4, P407, DOI 10.1371/journal.pmed.0040027; Stone KL, 2003, J BONE MINER RES, V18, P1947, DOI 10.1359/jbmr.2003.18.11.1947; Tinetti ME, 2003, NEW ENGL J MED, V348, P42, DOI 10.1056/NEJMcp020719; Tinetti ME, 1997, NEW ENGL J MED, V337, P1279, DOI 10.1056/NEJM199710303371806; Tosteson ANA, 2008, OSTEOPOROSIS INT, V19, P437, DOI 10.1007/s00198-007-0550-6; Ulmner M, 2014, J ORAL MAXIL SURG, V72, P76, DOI 10.1016/j.joms.2013.06.221; Wagner H, 2009, AM J EPIDEMIOL, V169, P143, DOI 10.1093/aje/kwn379; Whitaker M, 2012, NEW ENGL J MED, V366, P2048, DOI 10.1056/NEJMp1202619	61	85	85	0	23	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 26	2015	350								h2088	10.1136/bmj.h2088	http://dx.doi.org/10.1136/bmj.h2088			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CJ0AF	26013536				2023-01-03	WOS:000355132600001
J	Snyder, EL; Stramer, SL; Benjamin, RJ				Snyder, Edward L.; Stramer, Susan L.; Benjamin, Richard J.			The Safety of the Blood Supply - Time to Raise the Bar	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							TRANSMISSION; TRANSFUSION; DONORS; VIRUS		[Snyder, Edward L.] Yale Univ, New Haven, CT 06520 USA; [Stramer, Susan L.; Benjamin, Richard J.] Amer Red Cross, Blood Serv, Rockville, MD USA	Yale University; American Red Cross	Snyder, EL (corresponding author), Yale Univ, New Haven, CT 06520 USA.							Bracey AW, 2008, ADVISORY COMMITTEE B; Gallian P, 2014, BLOOD, V123, P3679, DOI 10.1182/blood-2014-03-564880; Kleinman SH, 2009, TRANSFUSION, V49, P2454, DOI 10.1111/j.1537-2995.2009.02322.x; Prowse CV, 2013, VOX SANG, V104, P183, DOI 10.1111/j.1423-0410.2012.01662.x; Stramer SL, 2012, TRANSFUSION, V52, P1657, DOI 10.1111/j.1537-2995.2012.03566.x	5	50	51	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 14	2015	372	20					1882	1885		10.1056/NEJMp1500154	http://dx.doi.org/10.1056/NEJMp1500154			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	CI1HB	25902384				2023-01-03	WOS:000354493300003
J	Hubbard, JM; Grothey, A				Hubbard, Joleen M.; Grothey, Axel			When less is more: maintenance therapy in colorectal cancer	LANCET			English	Editorial Material							PHASE-III; OXALIPLATIN; FLUOROURACIL; LEUCOVORIN; IRINOTECAN; SURVIVAL; TRIAL; BEVACIZUMAB; PROGRESSION; IMPROVES		[Hubbard, Joleen M.; Grothey, Axel] Mayo Clin, Div Med Oncol, Rochester, MN 55905 USA	Mayo Clinic	Hubbard, JM (corresponding author), Mayo Clin, Div Med Oncol, Rochester, MN 55905 USA.	grothey.axel@mayo.edu						Allegra C, 2007, J CLIN ONCOL, V25, P3572, DOI 10.1200/JCO.2007.12.1368; Bennouna J, 2013, LANCET ONCOL, V14, P29, DOI 10.1016/S1470-2045(12)70477-1; Goldberg RM, 2004, J CLIN ONCOL, V22, P23, DOI 10.1200/JCO.2004.09.046; Grothey A, 2004, J CLIN ONCOL, V22, P1209, DOI 10.1200/JCO.2004.11.037; Hegewisch-Becker S, 2014, ANN ONCOL         S4, V25, piv167; Kaplan R, 2013, J CLIN ONCOL, V31, P4562, DOI 10.1200/JCO.2013.50.7905; Saltz LB, 2008, J CLIN ONCOL, V26, P2013, DOI 10.1200/JCO.2007.14.9930; Schmoll H, 2014, ANN ONCOL         S4, V25, piv209; Shi Q, 2015, J CLIN ONCOL, V33, P22, DOI 10.1200/JCO.2014.56.5887; Simkens LHJ, 2015, LANCET; Van Cutsem E, 2012, J CLIN ONCOL, V30, P3499, DOI 10.1200/JCO.2012.42.8201	11	13	13	0	7	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 9	2015	385	9980					1808	1810		10.1016/S0140-6736(14)62350-3	http://dx.doi.org/10.1016/S0140-6736(14)62350-3			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CH6ZE	25862518				2023-01-03	WOS:000354184500006
J	Richardson, SP; Tinaz, S; Chen, R				Richardson, Sarah Pirio; Tinaz, Sule; Chen, Robert			Repetitive Transcranial Magnetic Stimulation in Cervical Dystonia: Effect of Site and Repetition in a Randomized Pilot Trial	PLOS ONE			English	Article							FOCAL HAND DYSTONIA; PREMOTOR CORTEX; WRITERS CRAMP; BOTULINUM TOXIN; RTMS; TMS	Dystonia is characterized by abnormal posturing due to sustained muscle contraction, which leads to pain and significant disability. New therapeutic targets are needed in this disorder. The objective of this randomized, sham-controlled, blinded exploratory study is to identify a specific motor system target for non-invasive neuromodulation and to evaluate this target in terms of safety and tolerability in the cervical dystonia (CD) population. Eight CD subjects were given 15-minute sessions of low-frequency (0.2 Hz) repetitive transcranial magnetic stimulation (rTMS) over the primary motor cortex (MC), dorsal premotor cortex (dPM), supplementary motor area (SMA), anterior cingulate cortex (ACC) and a sham condition with each session separated by at least two days. The Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) score was rated in a blinded fashion immediately pre- and post-intervention. Secondary outcomes included physiology and tolerability ratings. The mean change in TWSTRS severity score by site was 0.25 +/- 1.7 (ACC), -2.9 +/- 3.4 (dPM), -3.0 +/- 4.8 (MC), -0.5 +/- 1.1 (SHAM), and -1.5 +/- 3.2 (SMA) with negative numbers indicating improvement in symptom control. TWSTRS scores decreased from Session 1 (15.1 +/- 5.1) to Session 5 (11.0 +/- 7.6). The treatment was tolerable and safe. Physiology data were acquired on 6 of 8 subjects and showed no change over time. These results suggest rTMS can modulate CD symptoms. Both dPM and MC are areas to be targeted in further rTMS studies. The improvement in TWSTRS scores over time with multiple rTMS sessions deserves further evaluation.	[Richardson, Sarah Pirio] Univ New Mexico, Hlth Sci Ctr, Dept Neurol, Albuquerque, NM 87131 USA; [Tinaz, Sule] NINDS, Human Motor Control Sect, NIH, Bethesda, MD 20892 USA; [Chen, Robert] Univ Toronto, Toronto Western Res Inst, Toronto, ON, Canada	University of New Mexico; University of New Mexico's Health Sciences Center; National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); University of Toronto; University Toronto Affiliates; University Health Network Toronto	Richardson, SP (corresponding author), Univ New Mexico, Hlth Sci Ctr, Dept Neurol, Albuquerque, NM 87131 USA.	spiriorichardson@salud.unm.edu			Dystonia Coalition part of the National Institutes of Health (NIH) Rare Disease Clinical Research Network (RDCRN); National Center for Research Resources and National Center for Advancing Translational Science (NCATS) [KL2TR000089, 8UL1TR000041]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR001449] Funding Source: NIH RePORTER	Dystonia Coalition part of the National Institutes of Health (NIH) Rare Disease Clinical Research Network (RDCRN); National Center for Research Resources and National Center for Advancing Translational Science (NCATS); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS))	The research was supported by the Dystonia Coalition (Grant Number U54NS065701) which is a part of the National Institutes of Health (NIH) Rare Disease Clinical Research Network (RDCRN), supported through a collaboration between the Office of Rare Diseases Research (ORDR), National Center for Advancing Translational Sciences (NCATS), and the National Institute of Neurological Diseases and Stroke (NINDS). This research was also supported (in part or in full) by the National Center for Research Resources and National Center for Advancing Translational Science (NCATS) through Grant Number KL2TR000089 and Grant Number 8UL1TR000041. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Allam N, 2007, ARQ NEURO-PSIQUIAT, V65, P697, DOI 10.1590/S0004-282X2007000400030; Batla A, 2012, CURR TREAT OPTION NE, V14, P213, DOI 10.1007/s11940-012-0169-6; Beck S, 2009, BRAIN STIMUL, V2, P208, DOI 10.1016/j.brs.2009.03.004; Borich M, 2009, RESTOR NEUROL NEUROS, V27, P55, DOI 10.3233/RNN-2009-0461; Breakefield XO, 2008, NAT REV NEUROSCI, V9, P222, DOI 10.1038/nrn2337; Comella CL, 2011, J NEUROL SCI, V308, P103, DOI 10.1016/j.jns.2011.05.041; Kimberley TJ, 2013, RESTOR NEUROL NEUROS, V31, P533, DOI 10.3233/RNN-120259; Lefaucheur JP, 2004, NEUROPHYSIOL CLIN, V34, P141, DOI 10.1016/j.neucli.2004.07.003; Murase N, 2005, BRAIN, V128, P104, DOI 10.1093/brain/awh315; Nijmeijer SWR, 2012, PARKINSONISM RELAT D, V18, P731, DOI 10.1016/j.parkreldis.2012.04.005; Pirio Richardson S, 2014, CLIN NEUROPHYSIOL, DOI [10.1016/jclinph.2014.10.140, DOI 10.1016/JCLINPH.2014.10.140]; Ramos VFML, 2014, J NEUROL NEUROSUR PS, V85, P987, DOI 10.1136/jnnp-2013-306971; Ricci R, 2014, BRAIN STIMUL, V7, P912, DOI 10.1016/j.brs.2014.07.038; Richardson SP, 2014, MOVEMENT DISORD, V29, P797, DOI 10.1002/mds.25878; Siebner HR, 2003, BRAIN, V126, P2710, DOI 10.1093/brain/awg282; Siebner HR, NEUROLOGY, V52, P529; Skogseid IM, 2005, MOVEMENT DISORD, V20, P1604, DOI 10.1002/mds.20670	17	16	16	0	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 29	2015	10	4							e0124937	10.1371/journal.pone.0124937	http://dx.doi.org/10.1371/journal.pone.0124937			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CH0LO	25923718	Green Submitted, gold, Green Published			2023-01-03	WOS:000353711600114
J	Wu, JS; Shi, R; Lu, X; Ma, YM; Cheng, NN				Wu, Jia-Sheng; Shi, Rong; Lu, Xiong; Ma, Yue-Ming; Cheng, Neng-Neng			Combination of Active Components of Xiexin Decoction Ameliorates Renal Fibrosis Through the Inhibition of NF-kappa B and TGF-beta 1/Smad Pathways in db/db Diabetic Mice	PLOS ONE			English	Article							TGF-BETA; NEPHROPATHY; PATHOGENESIS; INFLAMMATION; BLOCKADE; MEDICINE; DISEASE; RATS	Xiexin decoction, a herbal therapeutic agent commonly used in traditional Chinese medicine, is recognized for its beneficial effects on diabetic nephropathy exerted through the combined action of multiple components, including Rhizoma Coptidis alkaloids (A), Radix et Rhizoma Rhei polysaccharides (P), and Radix Scutellaria flavones (F). Our previous studies have shown that a combination of A, P, and F (APF) exhibits renoprotective effects against diabetic nephropathy. This study was aimed at determining the effects of APF on renal fibrosis in diabetic nephropathy and elucidating the underlying molecular mechanisms. To evaluate the effects of APF, in vivo, db/db diabetic mice were orally administered a low or high dose of APF (300 or 600 mg/kg, respectively) once a day for 8 weeks. We evaluated the blood and urine indices of metabolic and renal function, renal tissue histopathology, renal inflammation, and fibrosis. APF treatment significantly ameliorated glucose and lipid metabolism dysfunction, decreased urinary albumin excretion, normalized creatinine clearance, and reduced the morphological changes in renal tissue. Additionally, APF administration in db/db diabetic mice reduced the elevated levels of renal inflammation mediators such as intercellular adhesion molecule-1, monocyte chemotactic protein-1, tumor necrosis factor-alpha, interleukin-1 beta, and active nuclear factor kappa B (NF-kappa B). APF treatment also reduced type I and IV collagen, transforming growth factor-beta 1 (TGF-beta 1), and TGF-beta 1 type II receptor expression levels, and decreased the phosphorylation of Smad2/3 in the kidneys of db/db diabetic mice. These results suggest that APF reduces renal fibrosis in diabetic nephropathy through the NF-kappa B and TGF-beta 1/Smad signaling pathways. In vitro, APF treatment reduced cell proliferation and protein expression of a-smooth muscle actin, collagen I, TGF-beta 1 and NF-kappa B in mesangial cells cultured with high glucose concentrations. Our findings indicate that treatment with multi-component herbal therapeutic formulations may be a useful approach for the treatment of diabetic nephropathy.	[Wu, Jia-Sheng; Shi, Rong; Ma, Yue-Ming] Shanghai Univ Tradit Chinese Med, Dept Pharmacol, Shanghai, Peoples R China; [Lu, Xiong] Shanghai Univ Tradit Chinese Med, Expt Ctr Sci & Technol, Shanghai, Peoples R China; [Cheng, Neng-Neng] Fudan Univ, Sch Pharm, Dept Pharmacol, Shanghai 200433, Peoples R China	Shanghai University of Traditional Chinese Medicine; Shanghai University of Traditional Chinese Medicine; Fudan University	Ma, YM (corresponding author), Shanghai Univ Tradit Chinese Med, Dept Pharmacol, Shanghai, Peoples R China.	mayueming_117@hotmail.com; nncheng@gmail.com	ma, yue/GXE-9897-2022		National Natural Science Foundation of China [30873231]; Budget Project of the Shanghai Municipal Education Commission [2012JW07]; "085" First-Class Discipline Construction of Science and Technology Innovation [085ZY1205]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Budget Project of the Shanghai Municipal Education Commission; "085" First-Class Discipline Construction of Science and Technology Innovation	This work was supported by grants from the National Natural Science Foundation of China (No. 30873231), the Budget Project of the Shanghai Municipal Education Commission (2012JW07), "085" First-Class Discipline Construction of Science and Technology Innovation (085ZY1205). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 2014, PLOS ONE; Chow FY, 2005, J AM SOC NEPHROL, V16, P1711, DOI 10.1681/ASN.2004070612; Deshpande SD, 2013, DIABETES, V62, P3151, DOI 10.2337/db13-0305; Fried LF, 2013, NEW ENGL J MED, V369, P1892, DOI 10.1056/NEJMoa1303154; Heerspink Hiddo J Lambers, 2011, Rev Diabet Stud, V8, P392, DOI 10.1900/RDS.2011.8.392; Huang CL, 2013, DIABETES, V62, P2923, DOI 10.2337/db13-0135; Ka SM, 2012, DIABETOLOGIA, V55, P509, DOI 10.1007/s00125-011-2364-5; Lan HY, 2012, CLIN EXP PHARMACOL P, V39, P731, DOI 10.1111/j.1440-1681.2011.05663.x; Lan HY, 2011, INT J BIOL SCI, V7, P1056, DOI 10.7150/ijbs.7.1056; Liu Y., 2012, CHINESE J CLIN PHARM, V21, P75; Ma LJ, 2004, KIDNEY INT, V65, P106, DOI 10.1111/j.1523-1755.2004.00381.x; Navarro-Gonzalez JF, 2011, NAT REV NEPHROL, V7, P327, DOI 10.1038/nrneph.2011.51; Niu HL, 2014, BMC NEPHROL, V15, DOI 10.1186/1471-2369-15-135; Petersen M, 2008, KIDNEY INT, V73, P705, DOI 10.1038/sj.ki.5002717; Sculy T, 2011, NATURE, V485, pS2; Shi X, 2011, DIABETOLOGIA, V54, P1888, DOI 10.1007/s00125-011-2147-z; Sun SM, 2009, BEI JI QIAN JIN YAO, P33; Tong XL, 2012, AM J CHINESE MED, V40, P877, DOI 10.1142/S0192415X12500656; Van Buren PN, 2013, CURR DIABETES REV, V9, P62, DOI 10.2174/1573399811309010062; Wen XY, 2012, J ETHNOPHARMACOL, V142, P144, DOI 10.1016/j.jep.2012.04.028; [吴家胜 WU Jia-sheng], 2010, [中草药, Chinese Traditional and Herbal Drugs], V41, P73; Wu JS, 2013, EVID-BASED COMPL ALT, V2013, DOI [10.1155/2013/715671, DOI 10.1155/2013/715671]; Xie W., 2011, EVID-BASED COMPL ALT, V2011, DOI DOI 10.1155/2011/726723; Xie Y, 2013, Drug Res (Stuttg), V63, P501, DOI 10.1055/s-0033-1345206; Yamout H, 2014, ADV CHRONIC KIDNEY D, V21, P281, DOI 10.1053/j.ackd.2014.03.005; Yang SM, 2014, DIABETOLOGIA, V57, P424, DOI 10.1007/s00125-013-3115-6; Yi B, 2014, PLOS ONE, V9; Zhao HL, 2012, DIABETES, V61, P933, DOI 10.2337/db11-1164; Zhao TT, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090807; Zhong X, 2013, DIABETOLOGIA, V56, P663, DOI 10.1007/s00125-012-2804-x; Ziyadeh FN, 2004, J AM SOC NEPHROL, V15, pS55, DOI 10.1097/01.ASN.0000093460.24823.5B; Ziyadeh FN, 2008, CURR DIABETES REV, V4, P39, DOI 10.2174/157339908783502370; Zorena K, 2013, MEDIAT INFLAMM, V849457, P9	33	32	36	1	36	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 24	2015	10	3							e0122661	10.1371/journal.pone.0122661	http://dx.doi.org/10.1371/journal.pone.0122661			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CH2XV	25803610	Green Submitted, Green Published, gold			2023-01-03	WOS:000353889600205
J	Liddell, AM; Davey, RT; Mehta, AK; Varkey, JB; Kraft, CS; Tseggay, GK; Badidi, O; Faust, AC; Brown, KV; Suffredini, AF; Barrett, K; Wolcott, MJ; Marconi, VC; Lyon, GM; Weinstein, GL; Weinmeister, K; Sutton, S; Hazbun, M; Albarino, CG; Reed, Z; Cannon, D; Stroher, U; Feldman, M; Ribner, BS; Lane, HC; Fauci, AS; Uyeki, TM				Liddell, Allison M.; Davey, Richard T., Jr.; Mehta, Aneesh K.; Varkey, Jay B.; Kraft, Colleen S.; Tseggay, Gebre K.; Badidi, Oghenetega; Faust, Andrew C.; Brown, Katia V.; Suffredini, Anthony F.; Barrett, Kevin; Wolcott, Mark J.; Marconi, Vincent C.; Lyon, G. Marshall, III; Weinstein, Gary L.; Weinmeister, Kenney; Sutton, Shelby; Hazbun, Munir; Albarino, Cesar G.; Reed, Zachary; Cannon, Debi; Stroeher, Ute; Feldman, Mark; Ribner, Bruce S.; Lane, H. Clifford; Fauci, Anthony S.; Uyeki, Timothy M.			Characteristics and Clinical Management of a Cluster of 3 Patients With Ebola Virus Disease, Including the First Domestically Acquired Cases in the United States	ANNALS OF INTERNAL MEDICINE			English	Article								Background: More than 26 000 cases of Ebola virus disease (EVD) have been reported in western Africa, with high mortality. Several patients have been medically evacuated to hospitals in the United States and Europe. Detailed clinical data are limited on the clinical course and management of patients with EVD outside western Africa. Objective: To describe the clinical characteristics and management of a cluster of patients with EVD, including the first cases of Ebola virus (EBOV) infection acquired in the United States. Design: Retrospective clinical case series. Setting: Three U.S. hospitals in September and October 2014. Patients: First imported EVD case identified in the United States and 2 secondary EVD cases acquired in the United States in critical care nurses who cared for the index case patient. Measurements: Clinical recovery, EBOV RNA level, resolution of Ebola viremia, survival with discharge from hospital, or death. Results: The index patient had high EBOV RNA levels, developed respiratory and renal failure requiring critical care support, and died. Both patients with secondary EBOV infection had nonspecific signs and symptoms and developed moderate illness; EBOV RNA levels were moderate, and both patients recovered. Limitation: Both surviving patients received uncontrolled treatment with multiple investigational agents, including convalescent plasma, which limits generalizability of the results. Conclusion: Early diagnosis, prompt initiation of supportive medical care, and moderate clinical illness likely contributed to successful outcomes in both survivors. The inability to determine the potential benefit of investigational therapies and the effect of patient-specific factors that may have contributed to less severe illness highlight the need for controlled clinical studies of these interventions, especially in the setting of a high level of supportive medical care.	[Liddell, Allison M.] Texas Hlth Presbyterian Hosp Dallas, Dallas, TX 75231 USA; NIH, Ctr Clin, Bethesda, MD 20892 USA; Emory Univ, Sch Med, Atlanta, GA USA; Ctr Dis Control & Prevent, Atlanta, GA USA; US Army, Med Res Inst Infect Dis, Frederick, MD USA	National Institutes of Health (NIH) - USA; NIH Clinical Center (CC); Emory University; Centers for Disease Control & Prevention - USA	Liddell, AM (corresponding author), Texas Hlth Presbyterian Hosp Dallas, 8230 Walnut Hill Lane,Suite 308, Dallas, TX 75231 USA.	allisonliddell@texashealth.org	Kraft, Colleen S/M-2347-2013; Mehta, Aneesh/B-8054-2012; Marconi, Vincent/GRJ-4553-2022; Marconi, Vincent/AFK-5812-2022; Marconi, Vincent/N-3210-2014	Kraft, Colleen S/0000-0003-1757-8477; Mehta, Aneesh/0000-0002-6552-9162; Marconi, Vincent/0000-0001-8409-4689; Marconi, Vincent/0000-0001-8409-4689; HAZBUN, MUNIR/0000-0003-2083-315X	National Center for Advancing Translational Sciences of the National Institutes of Health [Atlanta Clinical and Translational Science Institute] [UL1TR000454]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000454] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI000936, ZIAAI000984] Funding Source: NIH RePORTER	National Center for Advancing Translational Sciences of the National Institutes of Health [Atlanta Clinical and Translational Science Institute]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	The authors thank the entire staff of Texas Health Presbyterian Hospital Dallas, particularly Edward Goodman, MD, Beverly Dickson, MD, Otto Javier Marquez-Kerguelen, MD, Sarah S. Way, MD, Mark Till, MD, Glen Owen, MD, Bruce Wall, MD, Elaine Whitaker, MD, David Gonzales, MD, and Sarita Sharma-Louys, MD; Texas Health Resources for its unwavering support; William Dorman and Samantha Tostenson of the U.S. Army Medical Research Institute of Infectious Diseases for technical work on RT-PCR assays; David Henderson, MD, and Tara Palmore, MD, of the National Institutes of Health Clinical Center for their infection control leadership; the nursing and hospital epidemiology staff at the National Institutes of Health Clinical Center for their outstanding patient care; Anne Winkler, MD, of the Emory University Hospital Serious Communicable Diseases Unit for coordinating the convalescent plasma collection and administration; all of the members of the Emory University Hospital Serious Communicable Diseases Unit team for their outstanding contributions to the patient's excellent care (supported by award UL1TR000454 from the National Center for Advancing Translational Sciences of the National Institutes of Health [Atlanta Clinical and Translational Science Institute]); and Tara Sealy, MS, Aridith Gibbons, and Bobbie Rae Erickson, MPH, of the Centers for Disease Control and Prevention for their technical support on the laboratory assays.	Ansumana R, 2015, NEW ENGL J MED, V372, P587, DOI 10.1056/NEJMc1413685; Aylward B, 2014, NEW ENGL J MED, V371, P1481, DOI 10.1056/NEJMoa1411100; Bah EI, 2015, NEW ENGL J MED, V372, P40, DOI 10.1056/NEJMoa1411249; Baize S, 2014, NEW ENGL J MED, V371, P1418, DOI 10.1056/NEJMoa1404505; Centers for Disease Control and Prevention, 2014, WHAT US HOSP NEED KN; Chertow DS, 2014, NEW ENGL J MED, V371, P2054, DOI 10.1056/NEJMp1413084; Fowler RA, 2014, AM J RESP CRIT CARE, V190, P733, DOI 10.1164/rccm.201408-1514CP; Kreuels B, 2014, NEW ENGL J MED, V371, P2394, DOI 10.1056/NEJMoa1411677; Ksiazek TG, 1999, J INFECT DIS, V179, pS177, DOI 10.1086/514321; Lyon GM, 2014, NEW ENGL J MED, V371, P2402, DOI 10.1056/NEJMoa1409838; Parra JM, 2014, NEW ENGL J MED, V371, P2439, DOI 10.1056/NEJMc1412662; Marty FM, 2013, NEW ENGL J MED, V369, P1227, DOI 10.1056/NEJMoa1303688; Naval Medical Research Center, 2014, EB ZAIR EZ1 RRT PCR; Schieffelin JS, 2014, NEW ENGL J MED, V371, P2092, DOI 10.1056/NEJMoa1411680; Towner JS, 2007, J INFECT DIS, V196, pS205, DOI 10.1086/520601; Trombley AR, 2010, AM J TROP MED HYG, V82, P954, DOI 10.4269/ajtmh.2010.09-0636; WHO, 2015, EB SIT REP; WHO Ebola Response Team, 2015, NEW ENGL J MED, V372, P584, DOI 10.1056/NEJMc1414992; Wolf T, 2015, LANCET, V385, P1428, DOI 10.1016/S0140-6736(14)62384-9	19	90	96	0	16	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 21	2015	163	2					81	+		10.7326/M15-0530	http://dx.doi.org/10.7326/M15-0530			14	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CN4NS	25961438	Green Accepted			2023-01-03	WOS:000358407500015
J	Kuehne, M; Heimrath, K; Heinze, HJ; Zaehle, T				Kuehne, Maria; Heimrath, Kai; Heinze, Hans-Jochen; Zaehle, Tino			Transcranial Direct Current Stimulation of the Left Dorsolateral Prefrontal Cortex Shifts Preference of Moral Judgments	PLOS ONE			English	Article							NONINVASIVE BRAIN-STIMULATION; DECISION-MAKING; AUDITORY-CORTEX; NEURAL BASIS; PSYCHOPATHY; CONSEQUENCES; NEUROBIOLOGY; NEUROSCIENCE; COGNITION; AMYGDALA	Attitude to morality, reflecting cultural norms and values, is considered unique to human social behavior. Resulting moral behavior in a social environment is controlled by a widespread neural network including the dorsolateral prefrontal cortex (DLPFC), which plays an important role in decision making. In the present study we investigate the influence of neurophysiological modulation of DLPFC reactivity by means of transcranial direct current stimulation (tDCS) on moral reasoning. For that purpose we administered anodal, cathodal, and sham stimulation of the left DLPFC while subjects judged the appropriateness of hard moral personal dilemmas. In contrast to sham and cathodal stimulation, anodal stimulation induced a shift in judgment of personal moral dilemmas towards more non-utilitarian actions. Our results demonstrate that alterations of left DLPFC activity can change moral judgments and, in consequence, provide a causal link between left DLPFC activity and moral reasoning. Most important, the observed shift towards non-utilitarian actions suggests that moral decision making is not a permanent individual trait but can be manipulated; consequently individuals with boundless, uncontrollable, and maladaptive moral behavior, such as found in psychopathy, might benefit from neuromodulation-based approaches.	[Kuehne, Maria; Heimrath, Kai; Heinze, Hans-Jochen; Zaehle, Tino] Otto Von Guericke Univ, Dept Neurol, Magdeburg, Germany	Otto von Guericke University	Zaehle, T (corresponding author), Otto Von Guericke Univ, Dept Neurol, Magdeburg, Germany.	tino.zaehle@ovgu.de	Zaehle, Tino/A-5088-2019	Zaehle, Tino/0000-0003-3673-4869	German Research Foundation (DFG) [SFB/TR 31, SFB 779]	German Research Foundation (DFG)(German Research Foundation (DFG))	This work was supported by the German Research Foundation (DFG, SFB/TR 31 and SFB 779).	Adolphs R, 2001, CURR OPIN NEUROBIOL, V11, P231, DOI 10.1016/S0959-4388(00)00202-6; Blair RJR, 2007, TRENDS COGN SCI, V11, P387, DOI 10.1016/j.tics.2007.07.003; Blair RJR, 2003, BRIT J PSYCHIAT, V182, P5, DOI 10.1192/bjp.182.1.5; Borg JS, 2006, J COGNITIVE NEUROSCI, V18, P803, DOI 10.1162/jocn.2006.18.5.803; Chen JC, 2013, CLIN NEUROPHYSIOLOGY; Christensen JF, 2012, NEUROSCI BIOBEHAV R, V36, P1249, DOI 10.1016/j.neubiorev.2012.02.008; Foot P., 1967, OXFORD REV, V5, P5, DOI DOI 10.1093/0199252866.003.0002; Fox D, 2011, NATURE, V472, P156, DOI 10.1038/472156a; Freeman W., 1942, BULL NEW YORK ACAD MED, V18, P794; Glenn AL, 2009, MOL PSYCHIATR, V14, P5, DOI 10.1038/mp.2008.104; Greene JD, 2004, NEURON, V44, P389, DOI 10.1016/j.neuron.2004.09.027; Greene JD, 2001, SCIENCE, V293, P2105, DOI 10.1126/science.1062872; Greene JD, 2007, TRENDS COGN SCI, V11, P322, DOI 10.1016/j.tics.2007.06.004; Heekeren HR, 2005, NEUROIMAGE, V24, P887, DOI 10.1016/j.neuroimage.2004.09.026; Heimrath K, 2014, NEUROSCIENCE, V261, P68, DOI 10.1016/j.neuroscience.2013.12.031; Howard-Snyder Frances, 2011, STANFORD ENCY PHILOS; Jacobson L, 2012, EXP BRAIN RES, V216, P1, DOI 10.1007/s00221-011-2891-9; Jeurissen D, 2014, FRONT NEUROSCI-SWITZ, V8, DOI 10.3389/fnins.2014.00018; Kadosh RC, 2012, CURR BIOL, V22, pR108, DOI 10.1016/j.cub.2012.01.013; Knoch D, 2008, CEREB CORTEX, V18, P1987, DOI 10.1093/cercor/bhm237; Krause B, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00602; Luber B, 2009, BEHAV SCI LAW, V27, P191, DOI 10.1002/bsl.860; Marsh AA, 2011, PSYCHIAT RES-NEUROIM, V194, P279, DOI 10.1016/j.pscychresns.2011.07.008; Moll J, 2005, NAT REV NEUROSCI, V6, P799, DOI 10.1038/nrn1768; Moll J, 2011, NEUROIMAGE, V54, P1735, DOI 10.1016/j.neuroimage.2010.08.026; Monte-Silva K, 2009, J NEUROSCI, V29, P6124, DOI 10.1523/JNEUROSCI.0728-09.2009; Nitsche MA, 2008, BRAIN STIMUL, V1, P206, DOI 10.1016/j.brs.2008.06.004; Passingham RE, 2010, TRENDS COGN SCI, V14, P16, DOI 10.1016/j.tics.2009.11.001; Prehn K, 2008, SOC COGN AFFECT NEUR, V3, P33, DOI 10.1093/scan/nsm037; Sanfey AG, 2003, SCIENCE, V300, P1755, DOI 10.1126/science.1082976; Tassy S, 2012, SOC COGN AFFECT NEUR, V7, P282, DOI 10.1093/scan/nsr008; THOMSON JJ, 1985, YALE LAW J, V94, P1395, DOI 10.2307/796133; Utz KS, 2010, NEUROPSYCHOLOGIA, V48, P2789, DOI 10.1016/j.neuropsychologia.2010.06.002; Woermann FG, 2000, J NEUROL NEUROSUR PS, V68, P162, DOI 10.1136/jnnp.68.2.162; Young L, 2010, P NATL ACAD SCI USA, V107, P6753, DOI 10.1073/pnas.0914826107; Zaehle T, 2011, EXP BRAIN RES, V215, P135, DOI 10.1007/s00221-011-2879-5	36	26	26	2	35	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 18	2015	10	5							e0127061	10.1371/journal.pone.0127061	http://dx.doi.org/10.1371/journal.pone.0127061			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CI7BG	25985442	gold, Green Published, Green Submitted			2023-01-03	WOS:000354917300082
J	Mcgowan, I; Cranston, RD; Duffill, K; Siegel, A; Engstrom, JC; Nikiforov, A; Jacobson, C; Rehman, KK; Elliott, J; Khanukhova, E; Abebe, K; Mauck, C; Spiegel, HML; Dezzutti, CS; Rohan, LC; Marzinke, MA; Hiruy, H; Hendrix, CW; Richardson-Harman, N; Anton, PA				Mcgowan, Ian; Cranston, Ross D.; Duffill, Kathryn; Siegel, Aaron; Engstrom, Jarret C.; Nikiforov, Alexyi; Jacobson, Cindy; Rehman, Khaja K.; Elliott, Julie; Khanukhova, Elena; Abebe, Kaleab; Mauck, Christine; Spiegel, Hans M. L.; Dezzutti, Charlene S.; Rohan, Lisa C.; Marzinke, Mark A.; Hiruy, Hiwot; Hendrix, Craig W.; Richardson-Harman, Nicola; Anton, Peter A.			A Phase 1 Randomized, Open Label, Rectal Safety, Acceptability, Pharmacokinetic, and Pharmacodynamic Study of Three Formulations of Tenofovir 1% Gel (the CHARM-01 Study)	PLOS ONE			English	Article							PREEXPOSURE PROPHYLAXIS; ORAL TENOFOVIR; HIV-INFECTION; TISSUE; INFLAMMATION	Objectives The CHARM-01 study characterized the safety, acceptability, pharmacokinetics (PK), and pharmacodynamics (PD) of three tenofovir (TFV) gels for rectal application. The vaginal formulation (VF) gel was previously used in the CAPRISA 004 and VOICE vaginal microbicide Phase 2B trials and the RMP-02/MTN-006 Phase 1 rectal safety study. The reduced glycerin VF (RGVF) gel was used in the MTN-007 Phase 1 rectal microbicide trial and is currently being evaluated in the MTN-017 Phase 2 rectal microbicide trial. A third rectal specific formulation (RF) gel was also evaluated in the CHARM-01 study. Methods Participants received 4 mL of the three TFV gels in a blinded, crossover design: seven daily doses of RGVF, seven daily doses of RF, and six daily doses of placebo followed by one dose of VF, in a randomized sequence. Safety, acceptability, compartmental PK, and explant PD were monitored throughout the trial. Results All three gels were found to be safe and acceptable. RF and RGVF PK were not significantly different. Median mucosal mononuclear cell (MMC) TFV-DP trended toward higher values for RF compared to RGVF (1136 and 320 fmol/10(6) cells respectively). Use of each gel in vivo was associated with significant inhibition of ex vivo colorectal tissue HIV infection. There was also a significant negative correlation between the tissue levels of TFV, tissue TFV-DP, MMC TFV-DP, rectal fluid TFV, and explant HIV-1 infection. Conclusions All three formulations were found to be safe and acceptable. However, the safety profile of the VF gel was only based on exposure to one dose whereas participants received seven doses of the RGVF and RF gels. There was a trend towards higher tissue MMC levels of TFV-DP associated with use of the RF gel. Use of all gels was associated with significant inhibition of ex vivo tissue HIV infection.	[Mcgowan, Ian; Cranston, Ross D.; Abebe, Kaleab; Dezzutti, Charlene S.; Rohan, Lisa C.] Univ Pittsburgh, Pittsburgh, PA 15260 USA; [Mcgowan, Ian; Duffill, Kathryn; Siegel, Aaron; Engstrom, Jarret C.; Nikiforov, Alexyi; Jacobson, Cindy; Rehman, Khaja K.; Dezzutti, Charlene S.; Rohan, Lisa C.] Magee Womens Res Inst, Pittsburgh, PA USA; [Elliott, Julie; Khanukhova, Elena; Anton, Peter A.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA; [Mauck, Christine] CONRAD, Arlington, VA USA; [Spiegel, Hans M. L.] NIAID, HJF DAIDS, NIH, Dept Hlth & Human Serv, Bethesda, MD 20892 USA; [Marzinke, Mark A.; Hiruy, Hiwot; Hendrix, Craig W.] Johns Hopkins Univ, Dept Med, Baltimore, MD USA; [Richardson-Harman, Nicola] Alpha StatConsult LLC, Damascus, MD USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Magee-Womens Research Institute; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Johns Hopkins University	Mcgowan, I (corresponding author), Univ Pittsburgh, Pittsburgh, PA 15260 USA.	imcgowan@pitt.edu	M, i/HCI-9242-2022; Hendrix, Craig W/G-4182-2014; Spiegel, Hans/AAC-4220-2020; Abebe, Kaleab/K-4400-2019; M, Ian/AAP-1032-2021	Hendrix, Craig W/0000-0002-5696-8665; Abebe, Kaleab/0000-0002-3644-8419; M, Ian/0000-0002-6470-8476; Cranston, Ross/0000-0002-2687-6217; Dezzutti, Charlene/0000-0001-5902-5841	U19 grant under the Integrated Preclinical-Clinical Program for HIV Topical Microbicides (IPCP-HTM), Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIH) [AI082637]; NIH/NIAID/DAIDS [HHSN272201000001C]; Alpha StatConsult, LLC; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000005] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI094189, U19AI082637] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM066691] Funding Source: NIH RePORTER	U19 grant under the Integrated Preclinical-Clinical Program for HIV Topical Microbicides (IPCP-HTM), Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIH); NIH/NIAID/DAIDS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Alpha StatConsult, LLC; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	The study was funded by a U19 grant under the Integrated Preclinical-Clinical Program for HIV Topical Microbicides (IPCP-HTM), Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIH) (AI082637). The CHARM-01 study was registered at http://www.ClinicalTrials.gov (NCT01575405). The PK/PD analysis of CHARM-01 data was supported through a NIH/NIAID/DAIDS contract (HHSN272201000001C) to Advanced BioScience Laboratories, Inc., Rockville, MD. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Co-author Nicola Richardson-Harman is employed by Alpha StatConsult, LLC. Alpha StatConsult, LLC provided support in the form of salary for author NR-H, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The coauthor NR-H, as a statistical consultant, analyzed data and contributed to the statistical sections of the manuscript. The specific role of this author is articulated in the 'author contributions' section.	Anton PA, 2012, AIDS RES HUM RETROV, V28, P1412, DOI [10.1089/aid.2012.0262, 10.1089/AID.2012.0262]; Anton PA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023243; Beyrer C, 2013, CURR OPIN HIV AIDS, V8, P306, DOI 10.1097/COH.0b013e328361f53a; BLAND JM, 1995, BRIT MED J, V310, P446, DOI 10.1136/bmj.310.6977.446; Dezzutti CS, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102585; Dezzutti CS, 2013, CURR HIV-AIDS REP, V10, P12, DOI 10.1007/s11904-012-0148-2; Dezzutti CS, 2012, J ANTIMICROB CHEMOTH, V67, P2139, DOI 10.1093/jac/dks173; Doleans-Jordheim A, 2011, EUR J CLIN MICROBIOL, V30, P1249, DOI 10.1007/s10096-011-1220-3; Faith JJ, 2013, SCIENCE, V341, P44, DOI 10.1126/science.1237439; Geboes K, 2000, GUT, V47, P404, DOI 10.1136/gut.47.3.404; Grant RM, 2010, NEW ENGL J MED, V363, P2587, DOI 10.1056/NEJMoa1011205; Hendrix CW, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055013; Herbst JH, 2008, AIDS BEHAV, V12, P1, DOI 10.1007/s10461-007-9299-3; Hunt PW, 2013, BLOOD, V121, P4635, DOI 10.1182/blood-2012-06-436345; Karim QA, 2010, SCIENCE, V329, P1168, DOI 10.1126/science.1193748; Louissaint NA, 2013, AIDS RES HUM RETROV, V29, P1443, DOI [10.1089/aid.2013.0044, 10.1089/AID.2013.0044]; Marrazzo JM, 2015, NEW ENGL J MED, V372, P509, DOI 10.1056/NEJMoa1402269; McGowan I, 2013, CURR TOP MICROBIOL I; McGowan I, 2007, JAIDS-J ACQ IMM DEF, V46, P417, DOI 10.1097/QAI.0b013e318156ef16; Mcgowan I, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060147; Moher D, 2001, JAMA-J AM MED ASSOC, V285, P1987, DOI 10.1001/jama.285.15.1987; Nuttall J, 2012, ANTIMICROB AGENTS CH, V56, P103, DOI 10.1128/AAC.00597-11; Rabe LK, 2003, J CLIN MICROBIOL, V41, P3260, DOI 10.1128/JCM.41.7.3260-3264.2003; Richardson-Harman N, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0111507; Richardson-Harman N, 2012, AIDS RES HUM RETROV, V28, P1422, DOI [10.1089/aid.2012.0073, 10.1089/AID.2012.0073]; Rohan LC, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009310; Schulz KF, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000251; Schwartz JL, 2007, CONTRACEPTION, V75, P136, DOI 10.1016/j.contraception.2006.09.003; Severy LJ, 2005, J SOC ISSUES, V61, P45, DOI 10.1111/j.0022-4537.2005.00393.x; Stoner KA, 2008, J CLIN MICROBIOL, V46, P2739, DOI 10.1128/JCM.00161-08; Van Damme L, 2012, NEW ENGL J MED, V367, P411, DOI 10.1056/NEJMoa1202614; van der Straten A, 2013, AIDS BEHAV, V17, P640, DOI 10.1007/s10461-012-0330-y	32	50	51	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 5	2015	10	5							e0125363	10.1371/journal.pone.0125363	http://dx.doi.org/10.1371/journal.pone.0125363			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CH3PT	25942472	Green Submitted, Green Accepted, Green Published, gold			2023-01-03	WOS:000353943400032
J	Talactac, MR; Chowdhury, MYE; Park, ME; Weeratunga, P; Kim, TH; Cho, WK; Kim, CJ; Ma, JY; Lee, JS				Talactac, Melbourne R.; Chowdhury, Mohammed Y. E.; Park, Min-Eun; Weeratunga, Prasanna; Kim, Tae-Hwan; Cho, Won-Kyung; Kim, Chul-Joong; Ma, Jin Yeul; Lee, Jong-Soo			Antiviral Effects of Novel Herbal Medicine KIOM-C, on Diverse Viruses	PLOS ONE			English	Article							HETEROLOGOUS STRAINS; IFN-ALPHA/BETA; RIG-I; INTERFERON; INFECTION; MICE; GLYCYRRHIZIN; ACTIVATION; INDUCTION; RECEPTOR	In order to identify new potential antiviral agents, recent studies have advocated thorough testing of herbal medicines or natural substances that are traditionally used to prevent viral infections. Antiviral activities and the mechanism of action of the total aqueous extract preparation of KIOM-C, a novel herbal medicine, against diverse types of viruses were investigated. In vitro antiviral activity against A/Puerto Rico/8/34 (H1N1) (PR8), vesicular stomatitis virus (VSV), and Newcastle disease virus (NDV) through the induction of type-I interferon related protein phosphorylation and up-regulation of pro-inflammatory cytokines in murine macrophage cells (RAW264.7) were determined. In vivo, KIOM-C-treated BALB/c mice showed higher survivability and lower lung viral titers when challenged with A/Aquatic bird/Korea/W81/2005 (H5N2), A/PR/8/34(H1N1), A/Aquatic bird/Korea/W44/2005(H7N3) or A/Chicken/Korea/116/2004(H9N2) influenza subtypes in contrast with the non-treated group. The present study revealed that total aqueous extract preparation of KIOM-C stimulates an antiviral state in murine macrophage cells and in mice leading to inhibition of viral infection and protection against lethal challenges.	[Talactac, Melbourne R.; Chowdhury, Mohammed Y. E.; Park, Min-Eun; Weeratunga, Prasanna; Kim, Tae-Hwan; Kim, Chul-Joong; Lee, Jong-Soo] Chungnam Natl Univ, Coll Vet Med, Taejon, South Korea; [Talactac, Melbourne R.] Cavite State Univ, Coll Vet Med & Biomed Sci, Cavite, Philippines; [Chowdhury, Mohammed Y. E.] Chittagong Vet & Anim Sci Univ, Fac Vet Med, Chittagong, Bangladesh; [Cho, Won-Kyung; Ma, Jin Yeul] Korea Inst Oriental Med, Korean Med KM Based Herbal Drug Dev Grp, Taejon, South Korea	Chungnam National University; Cavite State University; Korea Institute of Oriental Medicine (KIOM)	Lee, JS (corresponding author), Korea Inst Oriental Med, Korean Med KM Based Herbal Drug Dev Grp, Taejon, South Korea.	jyma@kiom.re.kr; jongsool@cnu.ac.kr	Weeratunga, Prasanna/GWZ-5169-2022	Weeratunga, Prasanna/0000-0001-6366-7628; Kim, Chul-Joong/0000-0001-8827-6332; Chowdhury, Mohammed/0000-0003-0935-705X; Lee, Jong-Soo/0000-0001-5119-0711; Weeratunga, Prasanna/0000-0002-4258-6025	Ministry of Education, Science and Technology (MEST), Republic of Korea [K12050]	Ministry of Education, Science and Technology (MEST), Republic of Korea(Ministry of Education, Science & Technology (MEST), Republic of Korea)	This work was supported by the grant K12050 awarded to the Korea Institute of Oriental Medicine (KIOM) from the Ministry of Education, Science and Technology (MEST), Republic of Korea. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Anderson KV, 2000, CURR OPIN IMMUNOL, V12, P13, DOI 10.1016/S0952-7915(99)00045-X; Balasubramanian P., 2010, Journal of Basic and Clinical Pharmacy (JBCP), V1, P37; Calixto JB, 2000, BRAZ J MED BIOL RES, V33, P179, DOI 10.1590/S0100-879X2000000200004; Chiu YH, 2009, CELL, V138, P576, DOI 10.1016/j.cell.2009.06.015; Chung TaeHo, 2012, Journal of Medicinal Plants Research, V6, P4456, DOI 10.5897/JMPR10.691; Coil DA, 2004, J VIROL, V78, P10920, DOI 10.1128/JVI.78.20.10920-10926.2004; Dou J, 2011, ARCH VIROL, V156, P793, DOI 10.1007/s00705-011-0917-z; Ehrhardt C, 2007, ANTIVIR RES, V76, P38, DOI 10.1016/j.antiviral.2007.05.002; Ge H, 2010, NAT PROD REP, V27, P1758, DOI 10.1039/c0np00005a; Goh KC, 1999, EMBO J, V18, P5601, DOI 10.1093/emboj/18.20.5601; Harada S, 2005, BIOCHEM J, V392, P191, DOI 10.1042/BJ20051069; Haruyama T, 2013, J NAT MED-TOKYO, V67, P636, DOI 10.1007/s11418-012-0725-0; He W, 2011, VIROL J, V8, DOI 10.1186/1743-422X-8-538; Hu G, 2012, J INTEGR AGR, V11, P646, DOI 10.1016/S2095-3119(12)60052-5; Huang H, 2010, PLANTA MED, V76, P76, DOI 10.1055/s-0029-1185943; Hwang SY, 2011, NUCL ACIDS, V40, P2724; Javed T, 2011, VIROL J, V8, DOI 10.1186/1743-422X-8-26; Karoline D, 2007, ANTIVIR RES, V76, P1, DOI 10.1016/j.antiviral.2007.04.001; Kim A, 2014, ONCOL REP, V31, P287, DOI 10.3892/or.2013.2822; Kim EH, 2013, ANTIVIR RES, V98, P386, DOI 10.1016/j.antiviral.2013.04.006; Kim MC, 2012, IMMUNOPHARM IMMUNOT, V34, P66, DOI 10.3109/08923973.2011.576254; Konopka JL, 2009, J VIROL, V83, P12432, DOI 10.1128/JVI.00564-09; Kurokawa M, 2010, OPEN ANTIMICROB AGEN, V4, P49, DOI [10.2174/18765181010020200049, DOI 10.2174/18765181010020200049]; Li BQ, 2000, BIOCHEM BIOPH RES CO, V276, P534, DOI 10.1006/bbrc.2000.3485; Li RM, 2014, J IMMUNOL, V193, P4515, DOI 10.4049/jimmunol.1301930; Magadula J. J., 2010, Tanzania Journal of Health Research, V12, punpaginated; Makau JN, 2013, DRUG DISCOV THER, V7, P189, DOI 10.5582/ddt.2013.v7.5.189; Maneewatch S, 2009, ANTIVIR THER, V14, P221; Marie I, 1998, EMBO J, V17, P6660, DOI 10.1093/emboj/17.22.6660; Moon HJ, 2012, ANTIVIR RES, V94, P98, DOI 10.1016/j.antiviral.2012.02.010; Pant M., 2012, INDIAN J SCI TECHNOL, V5, P1, DOI [DOI 10.17485/IJST/2012/V5I5.20, 10.17485/ijst/2012/v5i5.20]; Perrone LA, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000115; Pleschka S, 2009, VIROL J, V6, DOI 10.1186/1743-422X-6-197; Puig-Saus C, 2012, MOL THER, V20, P54, DOI 10.1038/mt.2011.159; Qin Lin, 2002, Zhongguo Zhongyao Zazhi, V27, P541; Quan FS, 2007, J VIROL, V81, P3514, DOI 10.1128/JVI.02052-06; Reed JR, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2246; Sato M, 2000, IMMUNITY, V13, P539, DOI 10.1016/S1074-7613(00)00053-4; Sharma S, 2003, SCIENCE, V300, P1148, DOI 10.1126/science.1081315; Shin Seulmee, 2010, Immune Netw, V10, P55, DOI 10.4110/in.2010.10.2.55; Shirey KA, 2011, J LEUKOCYTE BIOL, V89, P351, DOI 10.1189/jlb.0410216; Strober W., 2001, CURR PROTOC IMMUNOL, V64, p9 2 1, DOI DOI 10.1002/0471142735.IMA03BS21; Takeuchi O, 2007, IMMUNOL REV, V220, P214, DOI 10.1111/j.1600-065X.2007.00562.x; Tenoever BR, 2007, SCIENCE, V315, P1274, DOI 10.1126/science.1136567; Utsunomiya T, 1997, ANTIMICROB AGENTS CH, V41, P551, DOI 10.1128/AAC.41.3.551; Wadsworth TL, 1999, BIOCHEM PHARMACOL, V57, P941, DOI 10.1016/S0006-2952(99)00002-7; Wilden H, 2011, INT J ONCOL, V39, P493, DOI 10.3892/ijo.2011.1033; Wilden H, 2009, INT J ONCOL, V34, P971, DOI 10.3892/ijo_00000223; Xu L, 2014, VIRUSES-BASEL, V6, P2778, DOI 10.3390/v6072778; Xu XJ, 2015, BIOORG MED CHEM LETT, V25, P241, DOI 10.1016/j.bmcl.2014.11.065; Yu CH, 2010, J ETHNOPHARMACOL, V127, P280, DOI 10.1016/j.jep.2009.11.008	51	12	12	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 5	2015	10	5							e0125357	10.1371/journal.pone.0125357	http://dx.doi.org/10.1371/journal.pone.0125357			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CH3PT	25942440	gold, Green Published, Green Submitted			2023-01-03	WOS:000353943400031
J	Piao, J; Lee, JY; Weon, JB; Ma, CJ; Ko, HJ; Kim, DD; Kang, WS; Cho, HJ				Piao, Jingpei; Lee, Jae-Young; Weon, Jin Bae; Ma, Choong Je; Ko, Hyun-Jeong; Kim, Dae-Duk; Kang, Wie-Soo; Cho, Hyun-Jong			Angelica gigas Nakai and Soluplus-Based Solid Formulations Prepared by Hot-Melting Extrusion: Oral Absorption Enhancing and Memory Ameliorating Effects	PLOS ONE			English	Article							DISSOLUTION; DECURSINOL; DISPERSIONS; SCOPOLAMINE; EXTRACT	Oral solid formulations based on Angelica gigas Nakai (AGN) and Soluplus were prepared by the hot-melting extrusion (HME) method. AGN was pulverized into coarse and ultrafine particles, and their particle size and morphology were investigated. Ultrafine AGN particles were used in the HME process with high shear to produce AGN-based formulations. In simulated gastrointestinal fluids (pH 1.2 and pH 6.8) and water, significantly higher amounts of the major active components of AGN, decursin (D) and decursinol angelate (DA), were extracted from the HME-processed AGN/Soluplus (F8) group than the AGN EtOH extract (ext) group (p < 0.05). Based on an in vivo pharmacokinetic study in rats, the relative oral bioavailability of decursinol (DOH), a hepatic metabolite of D and DA, in F8-administered mice was 8.75-fold higher than in AGN EtOH ext-treated group. In scopolamine-induced memory- impaired mice, F8 exhibited a more potent cognitive enhancing effect than AGN EtOH ext in both a Morris water maze test and a passive avoidance test. These findings suggest that HME-processed AGN/Soluplus formulation (F8) could be a promising therapeutic candidate for memory impairment.	[Piao, Jingpei; Kang, Wie-Soo] Kangwon Natl Univ, Sch Biosci & Biotechnol, Chunchon 200701, South Korea; [Lee, Jae-Young; Kang, Wie-Soo] Seoul Natl Univ, Coll Pharm, Seoul 151742, South Korea; [Lee, Jae-Young; Kim, Dae-Duk] Seoul Natl Univ, Pharmaceut Sci Res Inst, Seoul 151742, South Korea; [Weon, Jin Bae; Ma, Choong Je] Kangwon Natl Univ, Coll Biomed Sci, Dept Med Biomat Engn, Chunchon 200701, South Korea; [Ma, Choong Je] Kangwon Natl Univ, Biotechnol Res Inst, Chunchon 200701, South Korea; [Ko, Hyun-Jeong; Cho, Hyun-Jong] Kangwon Natl Univ, Coll Pharm, Chunchon 200701, South Korea	Kangwon National University; Seoul National University (SNU); Seoul National University (SNU); Kangwon National University; Kangwon National University; Kangwon National University	Kang, WS (corresponding author), Kangwon Natl Univ, Sch Biosci & Biotechnol, Chunchon 200701, South Korea.	kangwiso@kangwon.ac.kr; hjcho@kangwon.ac.kr	Kim, Dae Duk/D-8864-2013	Ko, Hyun-Jeong/0000-0002-3844-928X; Lee, Jae-Young/0000-0002-8093-043X; Cho, Hyun-Jong/0000-0002-5070-9371	Kangwon National University; National Research Foundation of Korea (NRF) - Korean government (MSIP) [NRF-2012R1A1A1038944]	Kangwon National University; National Research Foundation of Korea (NRF) - Korean government (MSIP)	This study is supported by Kangwon National University (http://www.kangwon.ac.kr) and the National Research Foundation of Korea (NRF), funded by the Korean government (MSIP) (No. NRF-2012R1A1A1038944, URL http://www.nrf.re.kr/nrf tot cms/index.jsp?pmi-sso-return2=none&pmi-sso-return2=none).	Bae IY, 2011, FOOD SCI BIOTECHNOL, V20, P1113, DOI 10.1007/s10068-011-0151-1; Cho HJ, 2014, INT J NANOMED, V9, P495, DOI 10.2147/IJN.S56648; Choi KO, 2012, J MED FOOD, V15, P863, DOI 10.1089/jmf.2011.2047; Crowley MM, 2007, DRUG DEV IND PHARM, V33, P909, DOI 10.1080/03639040701498759; Djuris J, 2013, EUR J PHARM BIOPHARM, V84, P228, DOI 10.1016/j.ejpb.2012.12.018; Doh HJ, 2013, COLLOID SURFACE B, V101, P475, DOI 10.1016/j.colsurfb.2012.07.019; Godavarti S, 1997, J AGR ENG RES, V67, P277, DOI 10.1006/jaer.1997.0172; Hughey JR, 2013, EUR J PHARM SCI, V48, P758, DOI 10.1016/j.ejps.2013.01.004; Joo SS, 2010, ENVIRON TOXICOL PHAR, V30, P127, DOI 10.1016/j.etap.2010.04.007; Kang SY, 2007, J PHARM PHARMACOL, V59, P863, DOI 10.1211/jpp.59.6.0013; Kang SY, 2003, NEUROBIOL LEARN MEM, V79, P11, DOI 10.1016/S1074-7427(02)00007-2; KITE FRANCIS E., 1957, BAKER S DIGEST, V31, P42; Li L, 2013, PLANTA MED, V79, P275, DOI 10.1055/s-0032-1328202; Linn M, 2012, EUR J PHARM SCI, V45, P336, DOI 10.1016/j.ejps.2011.11.025; Liu X, 2012, PHARM RES-DORDR, V29, P806, DOI 10.1007/s11095-011-0605-4; Mu HL, 2013, INT J PHARMACEUT, V453, P215, DOI 10.1016/j.ijpharm.2013.03.054; Park HS, 2012, PLANTA MED, V78, P909, DOI 10.1055/s-0031-1298517; Park SJ, 2012, J ETHNOPHARMACOL, V143, P611, DOI 10.1016/j.jep.2012.07.019; Pina MF, 2014, J PHARM SCI-US, V103, P1214, DOI 10.1002/jps.23894; Repka MA, 2007, DRUG DEV IND PHARM, V33, P1043, DOI 10.1080/03639040701525627; Repka MA, 2008, EXPERT OPIN DRUG DEL, V5, P1357, DOI [10.1517/17425240802583421, 10.1517/17425240802583421 ]; Sarker SD, 2004, CURR MED CHEM, V11, P1479, DOI 10.2174/0929867043365189; Seo YJ, 2009, ARCH PHARM RES, V32, P937, DOI 10.1007/s12272-009-1617-z; Song JS, 2011, XENOBIOTICA, V41, P895, DOI 10.3109/00498254.2011.587551; Weon JB, 2014, PHARMACOGN MAG, V10, P249, DOI 10.4103/0973-1296.133266; Weon JB, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/464576; Wilson M, 2012, THER DELIV, V3, P787, DOI 10.4155/TDE.12.26; Yan JJ, 2004, PROG NEURO-PSYCHOPH, V28, P25, DOI 10.1016/S0278-5846(03)00168-4; Yun F, 2014, INT J PHARMACEUT, V465, P436, DOI 10.1016/j.ijpharm.2014.02.040; Zhang JH, 2012, ANTI-CANCER AGENT ME, V12, P1239, DOI 10.2174/187152012803833071; Zhang KR, 2013, EUR J PHARM BIOPHARM, V85, P1285, DOI 10.1016/j.ejpb.2013.03.002	31	28	28	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 27	2015	10	4							e0124447	10.1371/journal.pone.0124447	http://dx.doi.org/10.1371/journal.pone.0124447			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CG9SB	25915423	Green Submitted, Green Published, gold			2023-01-03	WOS:000353659100050
J	Soleimanpour, H; Behringer, W; Tabrizi, JS; Sarahrudi, K; Golzari, SEJ; Hajdu, S; Rasouli, M; Nikakhtar, M; Esfanjani, RM				Soleimanpour, Hassan; Behringer, Wilhelm; Tabrizi, Jafar Sadegh; Sarahrudi, Kambiz; Golzari, Samad E. J.; Hajdu, Stefan; Rasouli, Maryam; Nikakhtar, Mehdi; Esfanjani, Robab Mehdizadeh			An Analytical Comparison of the Opinions of Physicians Working in Emergency and Trauma Surgery Departments at Tabriz and Vienna Medical Universities Regarding Family Presence during Resuscitation	PLoS One			English	Article							ATTITUDES	The present study evaluated the opinions of physicians working in the emergency and trauma surgery departments of Vienna Medical University, in Austria, and Tabriz Medical University, in Iran, regarding the presence of patients' relatives during resuscitation. In a descriptive-analytical study, the data obtained from questionnaires that had been distributed randomly to 40 specialists and residents at each of the participating universities were analyzed. The questionnaire consisted of two sections aimed at capturing the participants' demographic data, the participants' opinions regarding their support for the family's presence during resuscitation, and the multiple potential factors affecting the participants' attitudes, including health beliefs, triggers that could facilitate the procedure, self-efficacy, intellectual norms, and perceived behavioral control. The questionnaire also included a direct question (Question 16) on whether the participants approved of family presence. Each question could be answered using a Likert-type scale. The results showed that the mean scores for Question 16 were 4.31 +/- 0.64 and 3.57 +/- 1.31 for participants at Vienna and Tabriz universities, respectively. Moreover, physicians at Vienna University disapproved of the presence of patients' families during resuscitation to a higher extent than did those at Tabriz University (P = 0.018). Of the studied prognostic factors affecting the perspectives of Vienna Medical University's physicians, health beliefs (P = 0.000; B = 1.146), triggers (P = 0.000; B = 1.050), and norms (P = 0.000; B = 0.714) were found to be significant. Moreover, of the studied prognostic factors affecting the perspectives of Tabriz Medical University's physicians, health beliefs (P = 0.000; B = 0.875), triggers (P = 0.000; B = 1.11), self-efficacy (P = 0.001; B = 0.5), and perceived behavioral control (P = 0.03; B = 0.713) were significant. Most physicians at Vienna and Tabriz Medical universities were not open towards family members' presence during resuscitation.	[Soleimanpour, Hassan; Tabrizi, Jafar Sadegh] Tabriz Univ Med Sci, Tabriz Hlth Serv Management Res Ctr, Tabriz 51664, Iran; [Behringer, Wilhelm] Med Univ Vienna, Dept Emergency Med, Vienna Gen Hosp, A-1090 Vienna, Austria; [Sarahrudi, Kambiz; Hajdu, Stefan] Med Univ Vienna, Dept Traumatol, A-1090 Vienna, Austria; [Golzari, Samad E. J.] Tabriz Univ Med Sci, Cardiovasc Res Ctr, Tabriz 51664, Iran; [Rasouli, Maryam] Tabriz Univ Med Sci, Students Res Comm, Tabriz 51664, Iran; [Nikakhtar, Mehdi] Tabriz Univ Med Sci, Dept Emergency Med, Tabriz 51664, Iran; [Esfanjani, Robab Mehdizadeh] Tabriz Univ Med Sci, Neurosci Res Ctr, Tabriz 51664, Iran	Tabriz University of Medical Science; Medical University of Vienna; Medical University of Vienna; Tabriz University of Medical Science; Tabriz University of Medical Science; Tabriz University of Medical Science; Tabriz University of Medical Science	Soleimanpour, H (corresponding author), Tabriz Univ Med Sci, Tabriz Hlth Serv Management Res Ctr, Tabriz 51664, Iran.	soleimanpourh@tbzmed.ac.ir	Soleimanpour, Hassan/AAZ-4667-2020; Golzari, Samad EJ/L-5785-2017; tabrizi, jafarsadegh/L-5036-2017; Soleimanpour, Hassan/GRJ-1741-2022	Soleimanpour, Hassan/0000-0002-1311-4096; Golzari, Samad EJ/0000-0003-3815-8770; tabrizi, jafarsadegh/0000-0002-1458-8672; Behringer, Wilhelm/0000-0003-2261-3193				American Heart Association, 2005, CIRCULATION, V112; Baird G, 2014, EMERG MED J, V31, P889, DOI 10.1136/emermed-2012-201472; Boehm J., 2008, FAMILY PRESENCE RESU, V3; Boyd R, 2000, RESUSCITATION, V43, P171, DOI 10.1016/S0300-9572(99)00147-1; Duran CR, 2007, AM J CRIT CARE, V16, P270; Fishbein M., 1987, HEALTH EDUC RES, V2, P361; Jabre P, 2013, NEW ENGL J MED, V368, P1008, DOI 10.1056/NEJMoa1203366; Lam SN, 2007, HK J PAEDIAT, V12, P253; Meyers T A, 1998, J Emerg Nurs, V24, P400, DOI 10.1016/S0099-1767(98)70005-4; Offord R J, 1998, Intensive Crit Care Nurs, V14, P288, DOI 10.1016/S0964-3397(98)80690-3; Rosenstock I.M., 1990, HLTH BEHAV HLTH ED T, P39; SCHIFTER DE, 1985, J PERS SOC PSYCHOL, V49, P843, DOI 10.1037/0022-3514.49.3.843; Schwarzer R., 1992, SELF EFFICACY THOUGH, P217, DOI 10.4324/9781315800820; SHANER K, 1997, ADVOCATE, V3, P3; Soleimanpour H, 2013, RESUSCITATION, V84, pE149, DOI 10.1016/j.resuscitation.2013.07.031; The American Heart Association in collaboration with the International Liaison Committee on Resuscitation, 2000, CIRCULATION, V102, pI291 ~342; Twibell RS, 2008, AM J CRIT CARE, V17, P101, DOI 10.4037/ajcc2008.17.2.101	17	8	8	0	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 23	2015	10	4							e0123765	10.1371/journal.pone.0123765	http://dx.doi.org/10.1371/journal.pone.0123765			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CG5KZ	25905799	Green Submitted, Green Published, gold			2023-01-03	WOS:000353332000043
J	Periyakoil, VS; Neri, E; Kraemer, H				Periyakoil, Vyjeyanthi S.; Neri, Eric; Kraemer, Helena			No Easy Talk: A Mixed Methods Study of Doctor Reported Barriers to Conducting Effective End-of-Life Conversations with Diverse Patients	PLOS ONE			English	Article							AFRICAN-AMERICAN PHYSICIANS; ETHNIC-DIFFERENCES; ORGANIZED MEDICINE; CARE; PERCEPTIONS; TRUST; RACE	Objective Though most patients wish to discuss end-of-life (EOL) issues, doctors are reluctant to conduct end-of-life conversations. Little is known about the barriers doctors face in conducting effective EOL conversations with diverse patients. This mixed methods study was undertaken to empirically identify barriers faced by doctors (if any) in conducting effective EOL conversations with diverse patients and to determine if the doctors' age, gender, ethnicity and medical sub-specialty influenced the barriers reported. Design Mixed-methods study of multi-specialty doctors caring for diverse, seriously ill patients in two large academic medical centers at the end of the training; data were collected from 2010 to 2012. Outcomes Doctor-reported barriers to EOL conversations with diverse patients. Results 1040 of 1234 potential subjects (84.3%) participated. 29 participants were designated as the development cohort for coding and grounded theory analyses to identify primary barriers. The codes were validated by analyses of responses from 50 randomly drawn subjects from the validation cohort (n=996 doctors). Qualitative responses from the validation cohort were coded and analyzed using quantitative methods. Only 0.01% doctors reported no barriers to conducting EOL conversations with patients. 99.99% doctors reported barriers with 85.7% finding it very challenging to conduct EOL conversations with all patients and especially so with patients whose ethnicity was different than their own. Asian-American doctors reported the most struggles (91.3%), followed by African Americans (85.3%), Caucasians (83.5%) and Hispanic Americans (79.3%) in conducting EOL conversations with their patients. The biggest doctor-reported barriers to effective EOL conversations are (i) language and medical interpretation issues, (ii) patient/family religio-spiritual beliefs about death and dying, (iii) doctors' ignorance of patients' cultural beliefs, values and practices, (iv) patient/family's cultural differences in truth handling and decision making, (v) patients' limited health literacy and (vi) patients' mistrust of doctors and the health care system. The doctors' ethnicity (Chi-Square = 12.77, DF = 4, p = 0.0125) and medical subspecialty (Chi-Square = 19.33, DF = 10, p = 0.036) influenced their reported barriers. Friedman's test used to examine participants relative ranking of the barriers across sub-groups identified significant differences by age group (F statistic = 303.5, DF = 5, p < 0.0001) and medical sub-specialty (F statistic = 163.7, DF = 5, p < 0.0001). Conclusions and Relevance Doctors report struggles with conducting effective EOL conversations with all patients and especially with those whose ethnicity is different from their own. It is vital to identify strategies to mitigate barriers doctors encounter in conducting effective EOL conversations with seriously ill patients and their families.	[Periyakoil, Vyjeyanthi S.; Neri, Eric; Kraemer, Helena] Stanford Univ, Sch Med, Palo Alto, CA 94304 USA; [Periyakoil, Vyjeyanthi S.] VA Palo Alto Hlth Care Syst, Palo Alto, CA 94304 USA	Stanford University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System	Periyakoil, VS (corresponding author), Stanford Univ, Sch Med, Palo Alto, CA 94304 USA.	periyakoil@stanford.edu			NIH [NIHMD/NIH: R25 MD006857]; Department of Veterans Affairs; Stanford University School of Medicine; NATIONAL CANCER INSTITUTE [R25CA115562] Funding Source: NIH RePORTER; National Institute on Minority Health and Health Disparities [R25MD006857] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Department of Veterans Affairs(US Department of Veterans Affairs); Stanford University School of Medicine; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Institute on Minority Health and Health Disparities(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Minority Health & Health Disparities (NIMHD))	Dr. Periyakoil's work is funded by the NIH (NIHMD/NIH: R25 MD006857), the Department of Veterans Affairs and Stanford University School of Medicine. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	American Medical Association website, CURR PROC TERM COD B; ANDERSON JL, 1979, RHEUMATOL REHABIL, V18, P18, DOI 10.1093/rheumatology/18.1.18; Baker RB, 2008, JAMA-J AM MED ASSOC, V300, P306, DOI 10.1001/jama.300.3.306; Barnato AE, 2009, J GEN INTERN MED, V24, P695, DOI 10.1007/s11606-009-0952-6; Boulware LE, 2003, PUBLIC HEALTH REP, V118, P358, DOI 10.1016/S0033-3549(04)50262-5; Buss MK, 2011, CANCER-AM CANCER SOC, V117, P4304, DOI 10.1002/cncr.25952; Buss Mary K, 2007, J Support Oncol, V5, P237; Caracelli V.J, 1997, ADV MIXED METHOD EVA, DOI DOI 10.1002/EV.1069; Centers for Disease Control and Prevention, 2007, STAT AG HLTH AM 2007; Creswell J.W., 2010, BEST PRACTICES MIXED; Creswell JW, 2018, QUAL INQ; Friedman M, 1937, J AM STAT ASSOC, V32, P675, DOI 10.2307/2279372; Friedman M, 1940, ANN MATH STAT, V11, P86, DOI 10.1214/aoms/1177731944; Givens JL, 2010, ARCH INTERN MED, V170, P427, DOI 10.1001/archinternmed.2009.547; Goodman D. C., 2010, QUALITY END OF LIFE; Gordon HS, 2006, J CLIN ONCOL, V24, P904, DOI 10.1200/JCO.2005.03.1955; Greiner KA, 2003, J AM GERIATR SOC, V51, P970, DOI 10.1046/j.1365-2389.2003.51310.x; Hanchate A, 2009, ARCH INTERN MED, V169, P493, DOI 10.1001/archinternmed.2008.616; Hopp FP, 2000, J AM GERIATR SOC, V48, P658, DOI 10.1111/j.1532-5415.2000.tb04724.x; Kessels RPC, 2003, J ROY SOC MED, V96, P219, DOI 10.1258/jrsm.96.5.219; KRUSKAL WH, 1952, J AM STAT ASSOC, V47, P583, DOI 10.1080/01621459.1952.10483441; MANN HB, 1947, ANN MATH STAT, V18, P50, DOI 10.1214/aoms/1177730491; Organization for Economic Cooperation and Development (OECD), COUNTR STAT PROF US; Peek ME, 2009, J GEN INTERN MED, V24, P1135, DOI 10.1007/s11606-009-1047-0; Periyakoil VS, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098246; Periyakoil VS, 2013, J AM GERIATR SOC, V61, P440, DOI 10.1111/jgs.12145; Periyakoil VS, 2010, J PALLIAT MED, V13, P495, DOI 10.1089/jpm.2009.0279; Periyakoil VS, 2009, J PALLIAT MED, V12, P1125, DOI 10.1089/jpm.2009.0123; Schillinger D, 2003, ARCH INTERN MED, V163, P83, DOI 10.1001/archinte.163.1.83; Strauss A, 1990, BASICS QUALITATIVE R, DOI [10.1111/j.1365-2702.2009.02908.x, DOI 10.1111/J.1365-2702.2009.02908.X]; Tong A, INT J QUALITY HLTH C, V19, P349; Washington HA, 2009, J NATL MED ASSOC, V101, P513, DOI 10.1016/S0027-9684(15)30936-6; Welch LC, 2005, J AM GERIATR SOC, V53, P1145, DOI 10.1111/j.1532-5415.2005.53357.x; WILCOXON F, 1946, J ECON ENTOMOL, V39, P269, DOI 10.1093/jee/39.2.269; Yu W, HLTH SERVICES RES DE; Zhang BH, 2009, ARCH INTERN MED, V169, P480, DOI 10.1001/archinternmed.2008.587	36	76	78	0	27	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 22	2015	10	4							e0122321	10.1371/journal.pone.0122321	http://dx.doi.org/10.1371/journal.pone.0122321			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	CG5KV	25902309	Green Submitted, gold, Green Published			2023-01-03	WOS:000353331500019
J	Kirby, T				Kirby, Tony			Ian Anderson: transforming Indigenous medicine and education	LANCET			English	Biographical-Item																			0	0	0	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	APR 4	2015	385	9975					1285	1285		10.1016/S0140-6736(15)60671-7	http://dx.doi.org/10.1016/S0140-6736(15)60671-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CF0ZD	25890903				2023-01-03	WOS:000352272400022
J	Shabbir, M; Syed, DN; Lall, RK; Khan, MR; Mukhtar, H				Shabbir, Maria; Syed, Deeba N.; Lall, Rahul K.; Khan, Muhammad Rashid; Mukhtar, Hasan			Potent Anti-Proliferative, Pro-Apoptotic Activity of the Maytenus Royleanus Extract against Prostate Cancer Cells: Evidence in In-Vitro and In-Vivo Models	PLOS ONE			English	Article							ANDROGEN RECEPTOR GENE; DIETARY; PROGRESSION; THERAPY; RISK; MECHANISMS; RESISTANCE; QUERCETIN; MORTALITY; CYCLINS	Prostate cancer is a leading of cause of cancer related death in men. Despite intensive investment in improving early diagnosis, it often escapes timely detection. Mortality remains high in advanced stage prostate cancer where palliative care remains the only option. Effective strategies are therefore needed to prevent the occurrence and progression of the disease. Plant-derived compounds have been an important source of several clinically useful anti-cancer agents and offer an attractive approach against prostate cancer. We previously showed that the methanol extract of Maytenus royleanus (MEM) leaves and its fractions possess significant antioxidant activity with therapeutic potential against free-radical associated damages. The present study evaluated the anti-proliferative activity of MEM in the prostate cancer model system. Analysis of MEM and its various fractions revealed the presence of triterpenoids, flavonoids and tannins, conjugated to one or more polar groups and carbohydrate moieties. Further studies against known standards established the existence of caffeic acid and quercetin 3-rhamnoside in varying concentration in different MEM fractions. Time course analysis of MEM treated prostate cancer cells indicated significant decrease in cell viability, assessed by MTT and clonogenic survival assays. This was accompanied by G2 phase arrest of cell cycle, downregulation of cyclin/cdk network and increase in cdk inhibitors. MEM treated cells exhibited cleavage of Caspase-3 and PARP, and modulation of apoptotic proteins, establishing apoptosis as the primary mechanism of cell death. Notably MEM suppressed AR/PSA signaling both in prostate cancer cell cultures and in the in vivo model. Intraperitoneal injection of MEM (1.25 and 2.5mg/animal) to athymic nude mice implanted with androgen sensitive CWR22R.1 cells showed significant inhibition in tumor growth and decreased serum PSA levels reciprocating in vitro findings. Taken together, our data suggest that MEM may be explored further for its potential therapeutic effects against prostate cancer progression in humans.	[Shabbir, Maria; Syed, Deeba N.; Lall, Rahul K.; Mukhtar, Hasan] Univ Wisconsin, Dept Dermatol, Madison, WI 53706 USA; [Lall, Rahul K.] Univ Wisconsin, Dept Food Sci, Madison, WI 53706 USA; [Shabbir, Maria; Khan, Muhammad Rashid] Quaid I Azam Univ, Dept Biochem, Islamabad, Pakistan	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; Quaid I Azam University	Mukhtar, H (corresponding author), Univ Wisconsin, Dept Dermatol, Madison, WI 53706 USA.	hmukhtar@wisc.edu	Shabbir, Maria/AAA-5414-2019; Razak, Suhail/ABD-1667-2020	Shabbir, Maria/0000-0002-5685-3059; Lall, Rahulkumar/0000-0002-0042-6103	National Institute of health/National Cancer Institute [RO1CA160867]; NATIONAL CANCER INSTITUTE [R01CA160867] Funding Source: NIH RePORTER	National Institute of health/National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Support was provided by the National Institute of health/National Cancer Institute RO1CA160867. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Baillon L, 2014, SEMIN CELL DEV BIOL, V32, P137, DOI 10.1016/j.semcdb.2014.04.034; Buchanan G, 2001, CANCER METAST REV, V20, P207, DOI 10.1023/A:1015531326689; Cai X, 2013, CURR MED CHEM, V20, P2572, DOI 10.2174/09298673113209990120; Chen CD, 2004, NAT MED, V10, P33, DOI 10.1038/nm972; Chen FZ, 2013, IRAN RED CRESCENT ME, V15, P279, DOI 10.5812/ircmj.6499; Ekstrom AM, 2000, INT J CANCER, V87, P133, DOI 10.1002/1097-0215(20000701)87:1&lt;133::AID-IJC20&gt;3.0.CO;2-E; Farooqi AA, 2014, CANCER CELL INT, V14, DOI 10.1186/1475-2867-14-34; Gottlieb B, 2001, HUM MUTAT, V17, P382, DOI 10.1002/humu.1113; Gregory CW, 1998, CANCER RES, V58, P5718; GUO WD, 1994, INT J EPIDEMIOL, V23, P1127, DOI 10.1093/ije/23.6.1127; Haag P, 2005, J STEROID BIOCHEM, V96, P251, DOI 10.1016/j.jsbmb.2005.04.029; Karantanos T, 2013, ONCOGENE, V32, P5501, DOI 10.1038/onc.2013.206; Kasibhatla S, 2003, MOL CANCER THER, V2, P573; Kellen E, 2006, INT J CANCER, V118, P2572, DOI 10.1002/ijc.21714; Kenfield SA, 2014, EUR UROL, V65, P887, DOI 10.1016/j.eururo.2013.08.009; Khan KH, 2014, CRIT REV ONCOL HEMAT, V90, P200, DOI 10.1016/j.critrevonc.2013.12.012; Kim J, 2008, ASIAN PAC J CANCER P, V9, P543; Lamb DJ, 2001, VITAM HORM, V62, P199, DOI 10.1016/S0083-6729(01)62005-3; Lansky EP, 2005, INVEST NEW DRUG, V23, P11, DOI 10.1023/B:DRUG.0000047101.02178.07; Liu RH, 2013, J FOOD SCI, V78, pA18, DOI 10.1111/1750-3841.12101; Madan RA, 2009, EXPERT OPIN INV DRUG, V18, P1001, DOI 10.1517/13543780902997928; Mahmoud AM, 2014, J STEROID BIOCHEM, V140, P116, DOI 10.1016/j.jsbmb.2013.12.010; Mariani S, 2014, INT J MOL SCI, V15, P1433, DOI 10.3390/ijms15011433; Mellado B, 2009, CLIN TRANSL ONCOL, V11, P5, DOI 10.1007/s12094-009-0304-3; Perestelo NR, 2010, J NAT PROD, V73, P127, DOI 10.1021/np900476a; Russo GL, 2014, CANCER TREAT RES, V159, P185, DOI 10.1007/978-3-642-38007-5_11; Sanchez I, 2005, SEMIN CELL DEV BIOL, V16, P311, DOI 10.1016/j.semcdb.2005.02.007; Santamaria D, 2006, FRONT BIOSCI-LANDMRK, V11, P1164, DOI 10.2741/1871; Schaneberg BT, 2001, J NAT PROD, V64, P624, DOI 10.1021/np010041o; Seeram NP, 2004, J AGR FOOD CHEM, V52, P2512, DOI 10.1021/jf0352778; SHABBIR M, 2013, BMC COMPLEM ALTERN M, V13, DOI DOI 10.1186/1472-6882-13-143; Sharifi N, 2009, ANTI-CANCER AGENT ME, V9, P1046, DOI 10.2174/187152009789735044; Siegel R, 2012, CA-CANCER J CLIN, V62, P10, DOI 10.3322/caac.20138; Sola S, 2013, BBA-GEN SUBJECTS, V1830, P2160, DOI 10.1016/j.bbagen.2012.09.021; Soldani C, 2002, APOPTOSIS, V7, P321, DOI 10.1023/A:1016119328968; Solit DB, 2003, SEMIN ONCOL, V30, P709, DOI 10.1016/S0093-7754(03)00346-4; Syed DN, 2008, CANCER LETT, V265, P167, DOI 10.1016/j.canlet.2008.02.050; Syed DN, 2013, ANTI-CANCER AGENT ME, V13, P1149, DOI 10.2174/1871520611313080003; Touaibia M, 2011, MINI-REV MED CHEM, V11, P695, DOI 10.2174/138955711796268750; Tsao CK, 2014, THER ADV UROL, V6, P97, DOI 10.1177/1756287214528557; Viladomiu M, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/789764; VISAKORPI T, 1995, NAT GENET, V9, P401, DOI 10.1038/ng0495-401	42	24	24	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 23	2015	10	3							e0119859	10.1371/journal.pone.0119859	http://dx.doi.org/10.1371/journal.pone.0119859			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CE6ZS	25798940	Green Submitted, gold, Green Published			2023-01-03	WOS:000351987300085
J	Chen, YF; Bramley, G; Unwin, G; Hanu-Cernat, D; Dretzke, J; Moore, D; Bayliss, S; Cummins, C; Lilford, R				Chen, Yen-Fu; Bramley, George; Unwin, Gemma; Hanu-Cernat, Dalvina; Dretzke, Janine; Moore, David; Bayliss, Sue; Cummins, Carole; Lilford, Richard			Occipital Nerve Stimulation for Chronic Migraine-A Systematic Review and Meta-Analysis	PLOS ONE			English	Review							NEUROSTIMULATION; MULTICENTER; MANAGEMENT; EFFICACY; DISEASE	Background Chronic migraine is a debilitating headache disorder that has significant impact on quality of life. Stimulation of peripheral nerves is increasingly being used to treat chronic refractory pain including headache disorders. This systematic review examines the effectiveness and adverse effects of occipital nerve stimulation (ONS) for chronic migraine. Methods Databases, including the Cochrane Library, MEDLINE, EMBASE, CINAHL and clinical trial registers were searched to September 2014. Randomized controlled trials (RCTs), other controlled and uncontrolled observational studies and case series (n >= 10) were eligible. RCTs were assessed using the Cochrane risk of bias tool. Meta-analysis was carried out using a random-effects model. Findings are presented in summary tables and forest plots. Results Five RCTs (total n=402) and seven case series (total n=115) met the inclusion criteria. Pooled results from three multicenter RCTs show that ONS was associated with a mean reduction of 2.59 days (95% CI 0.91 to 4.27, I2=0%) of prolonged, moderate to severe headache per month at 3 months compared with a sham control. Results for other outcomes generally favour ONS over sham controls but quantitative analysis was hampered by incomplete publication and reporting of trial data. Lead migration and infections are common and often require revision surgery. Open-label follow-up of RCTs and case series suggest long-term effectiveness can be maintained in some patients but evidence is limited. Conclusions While the effectiveness of ONS compared to sham control has been shown in multiple RCTs, the average effect size is modest and may be exaggerated by bias as achieving effective blinding remains a methodological challenge. Further measures to reduce the risk of adverse events and revision surgery are needed. Systematic Review Registration this systematic review is an update and expanded work of part of a broader review registered with PROSPERO. Registration No. CRD42012002633.	[Chen, Yen-Fu; Bramley, George; Unwin, Gemma; Dretzke, Janine; Moore, David; Bayliss, Sue; Cummins, Carole; Lilford, Richard] Univ Birmingham, Sch Hlth & Populat Sci, Birmingham, W Midlands, England; [Unwin, Gemma] Univ Birmingham, Sch Psychol, Birmingham, W Midlands, England; [Hanu-Cernat, Dalvina] Univ Hosp Birmingham NHS Fdn Trust, Birmingham, W Midlands, England; [Chen, Yen-Fu; Lilford, Richard] Univ Warwick, Div Hlth Sci, Coventry CV4 7AL, W Midlands, England	University of Birmingham; University of Birmingham; University of Birmingham; University of Warwick	Bramley, G (corresponding author), Univ Birmingham, Sch Hlth & Populat Sci, Birmingham, W Midlands, England.	g.bramley@bham.ac.uk	Chen, Yen-Fu/AAD-2825-2019	Bayliss, Susan/0000-0003-3025-9323; Cummins, Carole/0000-0001-5464-1944; Unwin, Gemma/0000-0002-5205-3150; Bramley, George/0000-0002-3224-1904; Lilford, Richard/0000-0002-0634-984X; Moore, David/0000-0002-4163-4080; Chen, Yen-Fu/0000-0002-9446-2761	UK National Institute for Health Research (NIHR) Surgical Reconstruction and Microbiology Research Centre (SRMRC); NIHR Collaborations for Leadership in Applied Health Research and Care for Birmingham and Black Country (CLAHRC-BBC); NIHR Health Technology Assessment Programme; UK Engineering and Physical Sciences Research Council Multidisciplinary Assessment of Technology Centre for Healthcare (EPSRC MATCH); National Institute for Health Research [NF-SI-0611-10008] Funding Source: researchfish	UK National Institute for Health Research (NIHR) Surgical Reconstruction and Microbiology Research Centre (SRMRC); NIHR Collaborations for Leadership in Applied Health Research and Care for Birmingham and Black Country (CLAHRC-BBC); NIHR Health Technology Assessment Programme(National Institute for Health Research (NIHR)); UK Engineering and Physical Sciences Research Council Multidisciplinary Assessment of Technology Centre for Healthcare (EPSRC MATCH)(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC)); National Institute for Health Research(National Institute for Health Research (NIHR))	The original systematic review was commissioned by the UK National institute for Health and Care Excellence (NICE) to support the development of Interventional Procedures Guidance. This manuscript presents an update and expansion of part of the original systematic review as an independent academic output (not commissioned by NICE). We acknowledge NICE's input during our preparation of the original review and notify NICE of our submission of this manuscript. The authors have full control over the contents of the manuscript and the decision to publish it. The authors also received funding as salary or project grants not directly related to this review from the UK National Institute for Health Research (NIHR) Surgical Reconstruction and Microbiology Research Centre (SRMRC), NIHR Collaborations for Leadership in Applied Health Research and Care for Birmingham and Black Country (CLAHRC-BBC), NIHR Health Technology Assessment Programme and UK Engineering and Physical Sciences Research Council Multidisciplinary Assessment of Technology Centre for Healthcare (EPSRC MATCH). The views expressed here are those of the authors and not necessarily those of the NICE, NIHR, SRMRC, the CLAHRC-BBC and the EPSRC. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bartsch T, 2011, PROG NEUROL SURG, V24, P16, DOI 10.1159/000323008; Bes A, 2013, CEPHALALGIA, V33, P629, DOI 10.1177/0333102413485658; Bigal ME, 2008, HEADACHE, V48, P1157, DOI 10.1111/j.1526-4610.2008.01217.x; Brewer AC, 2013, NEUROMODULATION, V16, P557, DOI 10.1111/j.1525-1403.2012.00490.x; Chen Y-F, 2012, STIMULATION PERIPHER; Dodick DW, 2014, SAFETY EFFICACY PERI; Goadsby PJ, 2013, CEPHALALGIA, V33, P214, DOI 10.1177/0333102412468680; Goadsby PJ, 2011, STUDY OCCIPITAL NERV; Guyatt GH, 2011, J CLIN EPIDEMIOL, V64, P1311, DOI [10.1016/j.jclinepi.2011.06.004, 10.1016/j.jclinepi.2011.03.017]; Higgins JPT, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d5928; Irimia P, 2011, BMC NEUROL, V11, DOI 10.1186/1471-2377-11-94; Jasper JF, 2008, PAIN PHYSICIAN, V11, P187; Carod-Artal FJ, 2014, J PAIN RES, V7, P185, DOI 10.2147/JPR.S61819; Kinfe TM, 2014, CEPHALALGIA; Kiss ZHT, 2012, CAN J NEUROL SCI, V39, P807, DOI 10.1017/S0317167100015651; Lanteri-Minet M, 2013, FRENCH DATABASE OCCI; Lipton R, 2013, OCCIPITAL NERVE STIM; Lipton RB, 2009, CEPHALALGIA, V29, P30; Lipton RB, 2011, CEPHALALGIA, V31, P18, DOI 10.1177/0333102410372427; Magis D, 2012, LANCET NEUROL, V11, P708, DOI 10.1016/S1474-4422(12)70139-4; Mammis Antonios, 2012, Clin Neurosurg, V59, P114; Martelletti P, 2013, J HEADACHE PAIN, V14, DOI [10.1186/1129-2377-14-86, 10.1186/1129-2377-14-13]; Matharu MS, 2004, BRAIN, V127, P220, DOI 10.1093/brain/awh022; Mercado R, 2006, MOVEMENT DISORD, V21, P1457, DOI 10.1002/mds.20935; Moore A, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f2690; Moore RA, 2013, ANAESTHESIA, V68, P400, DOI 10.1111/anae.12148; Newcombe RG, 1998, STAT MED, V17, P873, DOI 10.1002/(SICI)1097-0258(19980430)17:8<873::AID-SIM779>3.0.CO;2-I; Notaro P, 2014, PAIN PHYSICIAN, V17, pE369; Oh MY, 2004, NEUROMODULATION, V7, P103, DOI 10.1111/j.1094-7159.2004.04014.x; Olesen J, 2006, CEPHALALGIA, V26, P742, DOI 10.1111/j.1468-2982.2006.01172.x; Paemeleire K, 2010, CEPHALALGIA, V30, P662, DOI 10.1111/j.1468-2982.2009.02022.x; Paemeleire K, 2012, J HEADACHE PAIN, V13, P239, DOI 10.1007/s10194-012-0430-0; Palmisani Stefano, 2013, J Headache Pain, V14, P67, DOI 10.1186/1129-2377-14-67; Popeney CA, 2003, HEADACHE, V43, P369, DOI 10.1046/j.1526-4610.2003.03072.x; Royle P, 2011, WARWICK EVIDENCE; Saper JR, 2011, CEPHALALGIA, V31, P271, DOI 10.1177/0333102410381142; Schwedt TJ, 2014, BMJ-BRIT MED J, V348, DOI 10.1136/bmj.g1416; Serra G, 2011, ITALIAN RANDOMIZED O; Serra G, 2012, PAIN PHYSICIAN, V15, P245; Silberstein S, 2008, CEPHALALGIA, V28, P484, DOI 10.1111/j.1468-2982.2008.01555.x; Silberstein S, 2012, HEADACHE, V52, P866; Silberstein SD, 2004, CEPHALALGIA, V24, P2, DOI 10.1111/j.1468-2982.2004.00892.x; SILBERSTEIN SD, 1994, HEADACHE, V34, P1, DOI 10.1111/j.1526-4610.1994.hed3401001.x; Silberstein SD, 2012, CEPHALALGIA, V32, P1165, DOI 10.1177/0333102412462642; Slavin KV, 2011, PROG NEUROL SURG, V24, P1, DOI 10.1159/000323002; Slotty PJ, 2015, CEPHALALGIA, V35, P73, DOI 10.1177/0333102414534082; Trentman TL, 2008, HEADACHE, V48, P319, DOI 10.1111/j.1526-4610.2007.01023.x; Vos T, 2012, LANCET, V380, P2163, DOI 10.1016/S0140-6736(12)61729-2	48	38	41	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 20	2015	10	3							e0116786	10.1371/journal.pone.0116786	http://dx.doi.org/10.1371/journal.pone.0116786			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CE8IA	25793740	Green Published, Green Submitted, gold			2023-01-03	WOS:000352084200009
J	Milloy, MJ; Wood, E				Milloy, M-J; Wood, Evan			Withdrawal from methadone in US prisons: cruel and unusual?	LANCET			English	Editorial Material							DRUG-USERS; INCARCERATION; RISK		[Milloy, M-J; Wood, Evan] St Pauls Hosp, British Columbia Ctr Excellence HIV AIDS, Vancouver, BC V6Z 1Y6, Canada; [Milloy, M-J; Wood, Evan] Univ British Columbia, Dept Med, Div AIDS, Vancouver, BC, Canada	B.C. Centre for Excellence in HIV/AIDS; St. Paul's Hospital; University of Saskatchewan; University of British Columbia	Milloy, MJ (corresponding author), St Pauls Hosp, British Columbia Ctr Excellence HIV AIDS, Vancouver, BC V6Z 1Y6, Canada.	uhri-mjsm@cfenet.ubc.ca	Milloy, M-J/AAY-3618-2020					Binswanger IA, 2007, NEW ENGL J MED, V356, P157, DOI 10.1056/NEJMsa064115; Boucher R., 2003, V LAW REV, V27, P453; Buavirat A, 2003, BRIT MED J, V326, P308, DOI 10.1136/bmj.326.7384.308; Dumont DM, 2013, J HEALTH CARE POOR U, V24, P78, DOI 10.1353/hpu.2013.0000; Fiscella K, 2004, J URBAN HEALTH, V81, P645, DOI 10.1093/jurban/jth147; Fiscella K, 2004, AM J PUBLIC HEALTH, V94, P1522, DOI 10.2105/AJPH.94.9.1522; Milloy MJ, 2014, CURR HIV-AIDS REP, V11, P308, DOI 10.1007/s11904-014-0214-z; Milloy MJ, 2011, J INFECT DIS, V203, P1215, DOI 10.1093/infdis/jir032; Rich J. D., 2015, LANCET	9	13	13	0	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 25	2015	386	9991					316	318		10.1016/S0140-6736(15)60073-3	http://dx.doi.org/10.1016/S0140-6736(15)60073-3			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	CN5CX	26028122				2023-01-03	WOS:000358448400006
J	Alexandrova, EM; Yallowitz, AR; Li, D; Xu, S; Schulz, R; Proia, DA; Lozano, G; Dobbelstein, M; Moll, UM				Alexandrova, E. M.; Yallowitz, A. R.; Li, D.; Xu, S.; Schulz, R.; Proia, D. A.; Lozano, G.; Dobbelstein, M.; Moll, U. M.			Improving survival by exploiting tumour dependence on stabilized mutant p53 for treatment	NATURE			English	Article							MOUSE MODEL; HSP90 COMPLEX; CANCER-CELLS; IN-VITRO; GAIN; GANETESPIB; INHIBITOR; GELDANAMYCIN; METASTASIS; SPECTRUM	Missense mutations in p53 generate aberrant proteins with abrogated tumour suppressor functions that can also acquire oncogenic gain-of-function activities that promote malignant progression, invasion, metastasis and chemoresistance(1-5). Mutant p53 (mutp53) proteins undergo massive constitutive stabilization specifically in tumours, which is the key requisite for the acquisition of gain-of-functions activities(6-8). Although currently 11 million patients worldwide live with tumours expressing highly stabilized mutp53, it is unknown whether mutp53 is a therapeutic target in vivo. Here we use a novel mutp53 mouse model expressing an inactivatable R248Q hotspot mutation (floxQ) to show that tumours depend on sustained mutp53 expression. Upon tamoxifen-induced mutp53 ablation, allotransplanted and autochthonous tumours curb their growth, thus extending animal survival by 37%, and advanced tumours undergo apoptosis and tumour regression or stagnation. The HSP90/HDAC6 chaperone machinery, which is significantly upregulated in cancer compared with normal tissues, is a major determinant of mutp53 stabilization(9-12). We show that long-term HSP90 inhibition significantly extends the survival of mutp53 Q/- (R248Q allele(2)) and H/H (R172H allele(3)) mice by 59% and 48%, respectively, but not their corresponding p53(-/-) (also known as Trp53(-/-)) littermates. This mutp53-dependent drug effect occurs in H/H mice treated with 17DMAG+SAHA and in H/H and Q/- mice treated with the potent Hsp90 inhibitor ganetespib. Notably, drug activity correlates with induction of mutp53 degradation, tumour apoptosis and prevention of T-cell lymphomagenesis. These proof-of-principle data identify mutp53 as an actionable cancer-specific drug target.	[Alexandrova, E. M.; Yallowitz, A. R.; Li, D.; Xu, S.; Moll, U. M.] SUNY Stony Brook, Dept Pathol, Stony Brook, NY 11794 USA; [Schulz, R.; Dobbelstein, M.; Moll, U. M.] Univ Gottingen, Inst Mol Oncol, D-37077 Gottingen, Germany; [Proia, D. A.] Synta Pharmaceut Corp, Lexington, MA 02421 USA; [Lozano, G.] Univ Texas MD Anderson Canc Ctr, Dept Canc Genet, Houston, TX 77030 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; University of Gottingen; University of Texas System; UTMD Anderson Cancer Center	Moll, UM (corresponding author), SUNY Stony Brook, Dept Pathol, Stony Brook, NY 11794 USA.	Ute.Moll@stonybrookmedicine.edu		Dobbelstein, Matthias/0000-0001-5052-3967; Li, Dun/0000-0001-6789-0763	National Cancer Institute [1RO1CA176647]; Deutsche Forschungsgemeinschaft [MO 1998/2-1]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [T32HD007505] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA176647] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We are grateful to S. Schlick, D. Mott and P. Yang for technical assistance. This work was supported by National Cancer Institute award 1RO1CA176647 and Deutsche Forschungsgemeinschaft award MO 1998/2-1.	Barretina J, 2012, NATURE, V483, P603, DOI 10.1038/nature11003; Blagosklonny MV, 1996, P NATL ACAD SCI USA, V93, P8379, DOI 10.1073/pnas.93.16.8379; Bougeard G, 2008, J MED GENET, V45, P535, DOI 10.1136/jmg.2008.057570; Brosh R, 2009, NAT REV CANCER, V9, P701, DOI 10.1038/nrc2693; Dai C, 2007, CELL, V130, P1005, DOI 10.1016/j.cell.2007.07.020; Dobbelstein M, 2014, NAT REV DRUG DISCOV, V13, P179, DOI 10.1038/nrd4201; Doyle B, 2010, J PATHOL, V222, P129, DOI 10.1002/path.2748; Gorska M, 2012, FRONT BIOSCI-LANDMRK, V17, P2269, DOI 10.2741/4050; Hanel W, 2013, CELL DEATH DIFFER, V20, P898, DOI 10.1038/cdd.2013.17; HARVEY M, 1993, FASEB J, V7, P938, DOI 10.1096/fasebj.7.10.8344491; Hoe KK, 2014, NAT REV DRUG DISCOV, V13, P217, DOI 10.1038/nrd4236; Hrzenjak A, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-49; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Landmann H, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.378; Lang GA, 2004, CELL, V119, P861, DOI 10.1016/j.cell.2004.11.006; Li D, 2011, CELL DEATH DIFFER, V18, P1904, DOI 10.1038/cdd.2011.71; Li D, 2011, MOL CANCER RES, V9, P577, DOI 10.1158/1541-7786.MCR-10-0534; Min JN, 2007, ONCOGENE, V26, P5086, DOI 10.1038/sj.onc.1210317; Morton JP, 2010, P NATL ACAD SCI USA, V107, P246, DOI 10.1073/pnas.0908428107; Muller PAJ, 2014, CANCER CELL, V25, P304, DOI 10.1016/j.ccr.2014.01.021; Olive KP, 2004, CELL, V119, P847, DOI 10.1016/j.cell.2004.11.004; Proia DA, 2014, CANCER RES, V74, P1294, DOI 10.1158/0008-5472.CAN-13-3263; Proia DA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018552; Siegel D, 2012, BIOCHEM PHARMACOL, V83, P1033, DOI 10.1016/j.bcp.2011.12.017; Slingerland M, 2014, ANTI-CANCER DRUG, V25, P140, DOI 10.1097/CAD.0000000000000040; Socinski MA, 2013, CLIN CANCER RES, V19, P3068, DOI 10.1158/1078-0432.CCR-12-3381; Suh YA, 2011, CANCER RES, V71, P7168, DOI 10.1158/0008-5472.CAN-11-0459; Terzian T, 2008, GENE DEV, V22, P1337, DOI 10.1101/gad.1662908; Trepel J, 2010, NAT REV CANCER, V10, P537, DOI 10.1038/nrc2887; Ventura A, 2007, NATURE, V445, P661, DOI 10.1038/nature05541; Weissmueller S, 2014, CELL, V157, P382, DOI 10.1016/j.cell.2014.01.066; Whitesell L, 1998, MOL CELL BIOL, V18, P1517, DOI 10.1128/MCB.18.3.1517; Whitesell L, 2005, NAT REV CANCER, V5, P761, DOI 10.1038/nrc1716; Ying WW, 2012, MOL CANCER THER, V11, P475, DOI 10.1158/1535-7163.MCT-11-0755; Zerdoumi Y, 2013, HUM MUTAT, V34, P453, DOI 10.1002/humu.22254; Zou JY, 1998, CELL, V94, P471, DOI 10.1016/S0092-8674(00)81588-3	36	228	232	2	83	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 16	2015	523	7560					352	+		10.1038/nature14430	http://dx.doi.org/10.1038/nature14430			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CM8KY	26009011	Green Accepted			2023-01-03	WOS:000357950900043
J	Zheng, YX; Wu, JM; Feng, XS; Jia, Y; Huang, J; Hao, ZH; Zhao, SY; Wang, JH				Zheng, Yaxin; Wu, Jiming; Feng, Xuesong; Jia, Ying; Huang, Jian; Hao, Zhihui; Zhao, Songyan; Wang, Jinhui			In silico Analysis and Experimental Validation of Lignan Extracts from Kadsura longipedunculata for Potential 5-HT1AR Agonists	PLOS ONE			English	Article							C-18 DIBENZOCYCLOOCTADIENE LIGNANS; MODULATE MEMORY CONSOLIDATION; ANTIDEPRESSANT-LIKE ACTIVITY; CHINENSIS TURCZ. BAILL.; NITRIC-OXIDE SYNTHASE; BLOOD-BRAIN-BARRIER; MASS-SPECTROMETRY; MAJOR DEPRESSION; RAT HIPPOCAMPUS; STRESSED MICE	Objectives Kadsura longipedunculata (KL) has been widely used for the treatment of insomnia in traditional Chinese medicine. The aim of this study was to explore the mechanism of the sedative and hypnotic effects of KL. Materials and Methods The content of KL was evaluated by HPLC-TOF-MS, and a potential target was found and used to construct its 3D structure to screen for potential ligands among the compounds in KL by using bioinformatics analysis, including similarity ensemble approach (SEA) docking, homology modeling, molecular docking and ligand-based pharmacophore. The PCPA-induced insomnia rat model was then applied to confirm the potential targets related to the sedative effects of KL by performing the forced swimming test (FST), the tail suspension test (TST) and the measurement of target-related proteins using western blotting and immunofluorescence. Results Bioinformatics analysis showed that most of lignan compounds in KL were optimal ligands for the 5-HT1A receptor (5-HT1AR), and they were found to be potential targets related to sedative effects; the main lignan content of KL extracts was characterized by HPLC-TOFMS, with 7 proposed lignans detected. Administration of KL could significantly reduce FST and TST immobility time in the PCPA-induced 5HT-depleted insomnia rat model. The expressions of proteins related to the 5-HT1AR pathway were regulated by extracts of KL in a concentration-dependent manner, indicating that extracts of KL had 5-HT1AR agonist-like effects. Conclusion In silico analysis and experimental validation together demonstrated that lignan extracts from KL can target 5-HT1AR in insomniac rats, which could shed light on its use as a potential 5-HT1AR agonist drug.	[Zheng, Yaxin; Wu, Jiming; Huang, Jian; Wang, Jinhui] Shenyang Pharmaceut Univ, Minist Educ, Key Lab Struct Based Drug Design & Discovery, Shenyang 110016, Peoples R China; [Feng, Xuesong] China Med Univ, Sch Pharm, Shenyang 110122, Peoples R China; [Jia, Ying] Shenyang Pharmaceut Univ, Sch Tradit Chinese Mat Med, Shenyang 110016, Peoples R China; [Hao, Zhihui] Shenyang Pharmaceut Univ, Anim Ctr, Shenyang 110016, Peoples R China; [Zhao, Songyan] Shenyang Pharmaceut Univ, Sch Life Sci, Shenyang 110016, Peoples R China	Shenyang Pharmaceutical University; China Medical University; Shenyang Pharmaceutical University; Shenyang Pharmaceutical University; Shenyang Pharmaceutical University	Huang, J (corresponding author), Shenyang Pharmaceut Univ, Minist Educ, Key Lab Struct Based Drug Design & Discovery, Shenyang 110016, Peoples R China.	13504051049@163.com; 15999290001@163.com			Key Projects of the National Science and Technology Pillar Program [2012BAI30B02]; National Natural Science Foundation of China [U1303124, 81260628]; Shengyang Science and Technology Project [F12-157-9-00]; Liaoning Science and Technology Project [2013226027-4]; Natural Science Foundation of Liaoning Province, China [201202252]	Key Projects of the National Science and Technology Pillar Program; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Shengyang Science and Technology Project; Liaoning Science and Technology Project; Natural Science Foundation of Liaoning Province, China(Natural Science Foundation of Liaoning Province)	The authors gratefully acknowledge the financial support of the Key Projects of the National Science and Technology Pillar Program (No. 2012BAI30B02), the National Natural Science Foundation of China (U1303124, 81260628), the Shengyang Science and Technology Project (F12-157-9-00), the Liaoning Science and Technology Project (2013226027-4), and the Natural Science Foundation of Liaoning Province, China (No. 201202252). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Albert PR, 2010, FRONT NEUROSCI-SWITZ, V4, DOI 10.3389/fnins.2010.00035; Alfajaro MM, 2014, RES VET SCI, V96, P567, DOI 10.1016/j.rvsc.2014.03.011; Bevilaqua L, 1997, BEHAV PHARMACOL, V8, P331, DOI 10.1097/00008877-199708000-00006; Bevilaqua L, 1997, BRAZ J MED BIOL RES, V30, P967, DOI 10.1590/S0100-879X1997000800009; Chen WW, 2011, PHYTOMEDICINE, V18, P1144, DOI 10.1016/j.phymed.2011.06.004; Chiavegatto S, 2001, P NATL ACAD SCI USA, V98, P1277, DOI 10.1073/pnas.031487198; Chun JN, 2014, FITOTERAPIA, V97, P224, DOI 10.1016/j.fitote.2014.06.014; Clark DE, 1999, J PHARM SCI, V88, P815, DOI 10.1021/js980402t; Cortes-Canteli M, 2008, J CELL SCI, V121, P1224, DOI 10.1242/jcs.025031; Datla KP, 1996, NEUROPHARMACOLOGY, V35, P315, DOI 10.1016/0028-3908(96)00175-X; Deacon RMJ, 2002, BEHAV NEUROSCI, V116, P494, DOI 10.1037//0735-7044.116.3.494; Dhingra D, 2012, PHARMACOL REP, V64, P796, DOI 10.1016/S1734-1140(12)70875-7; Dong K, 2012, J NAT PROD, V75, P249, DOI 10.1021/np200937h; Einat H, 2001, BEHAV BRAIN RES, V118, P77, DOI 10.1016/S0166-4328(00)00314-4; Gautam BK, 2013, PHARMACOL BIOCHEM BE, V109, P91, DOI 10.1016/j.pbb.2013.05.006; Gross C, 2002, NATURE, V416, P396, DOI 10.1038/416396a; Han Y, 2015, ANAL METHODS-UK, V7, P830, DOI 10.1039/c4ay02340d; Heusler P, 2010, N-S ARCH PHARMACOL, V382, P321, DOI 10.1007/s00210-010-0551-4; Hou CW, 2014, J BIOMED SCI, V21, DOI 10.1186/1423-0127-21-15; Huang X, 2007, J MASS SPECTROM, V42, P1148, DOI 10.1002/jms.1246; Jeong JJ, 2012, INT J ONCOL, V41, P1358, DOI 10.3892/ijo.2012.1582; Jin Z, 2013, PLANTA MED, V79, P1408, DOI 10.1055/s-0033-1350698; Kempermann G, 2002, BIPOLAR DISORD, V4, P17, DOI 10.1034/j.1399-5618.2002.40101.x; Kim Mun Hee, 2014, J Exerc Nutrition Biochem, V18, P97, DOI 10.5717/jenb.2014.18.1.97; Kuo YH, 2005, PLANTA MED, V71, P646, DOI 10.1055/s-2005-871271; Lauder JM, 2000, INT J DEV NEUROSCI, V18, P171, DOI 10.1016/S0736-5748(99)00085-4; Lin JW, 2012, NEURO-ONCOLOGY, V14, P302, DOI 10.1093/neuonc/nor217; Liu HT, 2009, MAGN RESON CHEM, V47, P609, DOI 10.1002/mrc.2430; Liu MM, 2012, EUR J MED CHEM, V52, P33, DOI 10.1016/j.ejmech.2012.03.002; Lu XY, 2008, NEUROPEPTIDES, V42, P387, DOI 10.1016/j.npep.2008.04.009; Ma WH, 2007, CHEM BIODIVERS, V4, P966, DOI 10.1002/cbdv.200790087; Mizrahi C, 2004, INT IMMUNOPHARMACOL, V4, P1125, DOI 10.1016/j.intimp.2004.05.001; Mulyaningsih S, 2010, J PHARM PHARMACOL, V62, P1037, DOI 10.1111/j.2042-7158.2010.01119.x; Pu JX, 2008, CHEM PHARM BULL, V56, P1143, DOI 10.1248/cpb.56.1143; Pu JX, 2008, PHYTOCHEMISTRY, V69, P1266, DOI 10.1016/j.phytochem.2007.11.019; Schwede T, 2003, NUCLEIC ACIDS RES, V31, P3381, DOI 10.1093/nar/gkg520; Shen YC, 2007, CHEM PHARM BULL, V55, P280, DOI 10.1248/cpb.55.280; Sullivan SS, 2009, EXPERT OPIN EMERG DR, V14, P411, DOI 10.1517/14728210903171948; Wang HJ, 2013, CARBOHYD POLYM, V97, P710, DOI 10.1016/j.carbpol.2013.05.042; Wang SY, 2015, CELL PROLIFERAT, V48, P86, DOI 10.1111/cpr.12157; Wang W, 2006, PLANTA MED, V72, P450, DOI 10.1055/s-2005-916263; Wei BB, 2013, J MASS SPECTROM, V48, P448, DOI 10.1002/jms.3176; Wolber G, 2005, J CHEM INF MODEL, V45, P160, DOI 10.1021/ci049885e; Xu LL, 2013, J CHEM INF MODEL, V53, P3202, DOI 10.1021/ci400481p; Yang CP, 2013, TOXICOL APPL PHARM, V273, P561, DOI 10.1016/j.taap.2013.09.030; Zaugg J, 2011, PHYTOCHEMISTRY, V72, P2385, DOI 10.1016/j.phytochem.2011.08.014; Zhang J, 2010, J NEUROSCI, V30, P2433, DOI 10.1523/JNEUROSCI.5880-09.2010; Zhou Y, 2011, J PHARMACEUT BIOMED, V56, P916, DOI 10.1016/j.jpba.2011.07.045; Zisapel N, 2012, EXPERT OPIN EMERG DR, V17, P299, DOI 10.1517/14728214.2012.690735	49	5	6	0	36	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 15	2015	10	6							e0130055	10.1371/journal.pone.0130055	http://dx.doi.org/10.1371/journal.pone.0130055			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CK6HU	26076134	gold, Green Submitted, Green Published			2023-01-03	WOS:000356329900131
J	Terayama, H; Yamazaki, H; Kanazawa, T; Suyama, K; Tanaka, O; Sawada, M; Ito, M; Ito, K; Akamatsu, T; Masuda, R; Suzuki, T; Sakabe, K				Terayama, Hayato; Yamazaki, Hajime; Kanazawa, Teruhisa; Suyama, Kaori; Tanaka, Osamu; Sawada, Makoto; Ito, Miho; Ito, Kenji; Akamatsu, Tadashi; Masuda, Ritsuko; Suzuki, Toshiyasu; Sakabe, Kou			Multi-Acupuncture Point Injections and Their Anatomical Study in Relation to Neck and Shoulder Pain Syndrome (So-Called Katakori) in Japan	PLOS ONE			English	Article							MYOFASCIAL TRIGGER POINTS; SKELETAL-MUSCLE; DOUBLE-BLIND; MANAGEMENT; STIMULATION; THRESHOLDS; HEADACHE; DAMAGE	Katakori is a symptom name that is unique to Japan, and refers to myofascial pain syndrome-like clinical signs in the shoulder girdle. Various methods of pain relief for katakori have been reported, but in the present study, we examined the clinical effects of multi-acupuncture point injections (MAPI) in the acupuncture points with which we empirically achieved an effect, as well as the anatomical sites affected by liquid medicine. The subjects were idiopathic katakori patients (n = 9), and three cadavers for anatomical investigation. BL-10, GB-21, LI-16, SI-14, and BL-38 as the WHO notation were selected as the acupuncture point. Injections of 1 mL of 1% w/v mepivacaine were introduced at the same time into each of these points in the patients. Assessment items were the Pain Relief Score and the therapeutic effect period. Dissections were centered at the puncture sites of cadavers. India ink was similarly injected into each point, and each site that was darkly-stained with India ink was evaluated. Katakori pain in the present study was significantly reduced by MAPI. Regardless of the presence or absence of trigger points, pain was significantly reduced in these cases. Dark staining with India ink at each of the points in the anatomical analysis was as follows: BL-10: over the rectus capitis posterior minor muscle and rectus capitis posterior major muscle fascia; GB-21: over the supraspinatus muscle fascia; LI-16: over the supraspinatus muscle fascia; SI-14: over the rhomboid muscle fascia; and BL-38: over the rhomboid muscle fascia. The anatomical study suggested that the drug effect was exerted on the muscles above and below the muscle fascia, as well as the peripheral nerves because the points of action in acupuncture were darkly-stained in the spaces between the muscle and the muscle fascia.	[Terayama, Hayato; Kanazawa, Teruhisa; Suyama, Kaori; Tanaka, Osamu; Sakabe, Kou] Tokai Univ, Sch Med, Dept Anat, Isehara, Kanagawa 25911, Japan; [Yamazaki, Hajime; Sawada, Makoto; Ito, Miho; Ito, Kenji; Masuda, Ritsuko; Suzuki, Toshiyasu] Tokai Univ, Sch Med, Dept Anesthesiol, Isehara, Kanagawa 25911, Japan; [Akamatsu, Tadashi] Tokai Univ, Sch Med, Dept Plast & Cosmet Surg, Isehara, Kanagawa 25911, Japan	Tokai University; Tokai University; Tokai University	Yamazaki, H (corresponding author), Tokai Univ, Sch Med, Dept Anesthesiol, Isehara, Kanagawa 25911, Japan.	y-hajime@is.icc.u-tokai.ac.jp	Tanaka, Osamu/AAS-9252-2020		Ministry of Education, Culture, Sports, Science and Technology, Japan [C: 25340050, C: 26460809]; Grants-in-Aid for Scientific Research [26460809] Funding Source: KAKEN	Ministry of Education, Culture, Sports, Science and Technology, Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	This work was supported by a Grant-in-Aid for Scientific Research (C: 25340050, C: 26460809) from the Ministry of Education, Culture, Sports, Science and Technology, Japan.	Airaksinen O, 2006, EUR SPINE J, V15, pS192, DOI 10.1007/s00586-006-1072-1; Alvarez DJ, 2002, AM FAM PHYSICIAN, V65, P653; [Anonymous], 2007, COMPR SURV LIV COND; Ashina M, 2000, BRAIN, V123, P1830, DOI 10.1093/brain/123.9.1830; Ashina M, 1999, BRAIN, V122, P1629, DOI 10.1093/brain/122.9.1629; Ashina M, 2003, CEPHALALGIA, V23, P109, DOI 10.1046/j.1468-2982.2003.00520.x; BIRCH S, 1998, CLIN J PAIN, V106, P14; Chen SM, 2000, J MUSCULOSKELET PAIN, V8, P83, DOI 10.1300/J094v08n03_07; Cummings TM, 2001, ARCH PHYS MED REHAB, V82, P986, DOI 10.1053/apmr.2001.24023; Dommerholt J, 2010, BONICAS MANAGEMENT P, P450; Dommerholt J, 2006, J MAN MANIP THER, V14, P203, DOI 10.1179/106698106790819991; Dundar U, 2007, CLIN RHEUMATOL, V26, P930, DOI 10.1007/s10067-006-0438-4; Esenyel M, 2000, AM J PHYS MED REHAB, V79, P48, DOI 10.1097/00002060-200001000-00011; Ezzo J, 2000, PAIN, V86, P217, DOI 10.1016/S0304-3959(99)00304-8; Febbraio MA, 2005, EXERC SPORT SCI REV, V33, P114, DOI 10.1097/00003677-200507000-00003; FINE PG, 1988, PAIN, V32, P15, DOI 10.1016/0304-3959(88)90018-8; FOX EJ, 1976, PAIN, V2, P141, DOI 10.1016/0304-3959(76)90109-3; Gerwin Robert D, 2004, Curr Pain Headache Rep, V8, P468, DOI 10.1007/s11916-004-0069-x; Gissel H, 2000, EUR J APPL PHYSIOL, V83, P175, DOI 10.1007/s004210000276; Graboski CL, 2005, PAIN, V118, P170, DOI 10.1016/j.pain.2005.08.012; Han SC, 1997, REGION ANESTH, V22, P89, DOI 10.1016/S1098-7339(06)80062-3; Heine H, 1988, ACAD TRADITIONAL CHI, V8, P207; Itoh Kazunori, 2004, Acupunct Med, V22, P2; Iwama H, 2000, ANESTH ANALG, V91, P408, DOI 10.1097/00000539-200008000-00033; JENSEN R, 1993, PAIN, V52, P193, DOI 10.1016/0304-3959(93)90131-8; Kendall NAS, 1999, BEST PRACT RES CL RH, V13, P545, DOI 10.1053/berh.1999.0044; Kiralp M. Zeki, 2006, Pain Clinic, V18, P63, DOI 10.1163/156856906775249794; Kumazawa T, 1996, NEUROBIOLOGY NOCICEP, P325; Kuniya H, 2013, J NEUROSURG-SPINE, V19, P76, DOI 10.3171/2013.4.SPINE12683; LEXELL J, 1993, CELL TISSUE RES, V273, P357, DOI 10.1007/BF00312838; Maekawa K, 2002, J PAIN, V3, P251, DOI 10.1054/jpai.2002.125923; MCCLAFLIN RR, 1994, POSTGRAD MED, V96, P56, DOI 10.1080/00325481.1994.11945883; MELZACK R, 1975, PAIN, V1, P357, DOI 10.1016/0304-3959(75)90073-1; MELZACK R, 1977, PAIN, V3, P3, DOI 10.1016/0304-3959(77)90032-X; Okuno H, 2008, J JAPAN SOC ACUPUNCT, V59, P30; Otten E, 1988, Exerc Sport Sci Rev, V16, P89; Ramsay DJ, 1998, JAMA-J AM MED ASSOC, V280, P1518; Sakai F, 1997, CEPHALALGIA, V17, P15, DOI 10.1046/j.1468-2982.1997.1701015.x; Schmidt-Hansen PT, 2007, PAIN, V129, P113, DOI 10.1016/j.pain.2006.09.037; SCHOENEN J, 1987, NEUROLOGY, V37, P1834, DOI 10.1212/WNL.37.12.1834; Shoji S, 2011, ONCOL LETT, V2, P675, DOI 10.3892/ol.2011.314; Simons D.G., 1999, MYOFASCIAL PAIN DYSF, V1; SIMONS DG, 1981, PAIN, V10, P106, DOI 10.1016/0304-3959(81)90053-1; Simons DG., 2002, J BODYW MOV THER, V6, P81, DOI DOI 10.1054/JBMT.2002.0271; SOLA A E, 1955, Northwest Med, V54, P980; SOLA AE, 1956, NEUROLOGY, V6, P91, DOI 10.1212/WNL.6.2.91; Sola AE, 2001, BONICAS MANAGEMENT P, P530; Stecco C, 2007, Morphologie, V91, P38, DOI 10.1016/j.morpho.2007.05.002; Takakuwa T, 2007, CLIN ORTHOPAEDIC SUR, V42, P403; Terayama H, 2008, SURG RADIOL ANAT, V30, P657, DOI 10.1007/s00276-008-0378-6; Terayama H, 2013, ANAT SCI INT, V88, P171, DOI 10.1007/s12565-013-0172-3; Tesarz J, 2011, NEUROSCIENCE, V194, P302, DOI 10.1016/j.neuroscience.2011.07.066; Torelli P, 2004, CEPHALALGIA, V24, P29, DOI 10.1111/j.1468-2982.2004.00633.x; Tough EA, 2009, EUR J PAIN, V13, P3, DOI 10.1016/j.ejpain.2008.02.006; Treaster D, 2006, J ELECTROMYOGR KINES, V16, P115, DOI 10.1016/j.jelekin.2005.06.016; Tsiang T, 1991, PROPOSED STANDARD IN; Wall PD, 1994, TXB PAIN, P79; WHO, 2008, WHO STAND AC POINT L, P64	58	2	3	2	24	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 5	2015	10	6							e0129006	10.1371/journal.pone.0129006	http://dx.doi.org/10.1371/journal.pone.0129006			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CJ7CR	26046784	Green Submitted, gold, Green Published			2023-01-03	WOS:000355652200116
J	Frat, JP; Thille, AW; Mercat, A; Girault, C; Ragot, S; Perbet, S; Prat, G; Boulain, T; Morawiec, E; Cottereau, A; Devaquet, J; Nseir, S; Razazi, K; Mira, JP; Argaud, L; Chakarian, JC; Ricard, JD; Wittebole, X; Chevalier, S; Herbland, A; Fartoukh, M; Constantin, JM; Tonnelier, JM; Pierrot, M; Mathonnet, A; Beduneau, G; Deletage-Metreau, C; Richard, JCM; Brochard, L; Robert, R				Frat, Jean-Pierre; Thille, Arnaud W.; Mercat, Alain; Girault, Christophe; Ragot, Stephanie; Perbet, Sebastien; Prat, Gwenael; Boulain, Thierry; Morawiec, Elise; Cottereau, Alice; Devaquet, Jerome; Nseir, Saad; Razazi, Keyvan; Mira, Jean-Paul; Argaud, Laurent; Chakarian, Jean-Charles; Ricard, Jean-Damien; Wittebole, Xavier; Chevalier, Stephanie; Herbland, Alexandre; Fartoukh, Muriel; Constantin, Jean-Michel; Tonnelier, Jean-Marie; Pierrot, Marc; Mathonnet, Armelle; Beduneau, Gaetan; Deletage-Metreau, Celine; Richard, Jean-Christophe M.; Brochard, Laurent; Robert, Rene		FLORALI Study Grp; REVA Network	High-Flow Oxygen through Nasal Cannula in Acute Hypoxemic Respiratory Failure	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							POSITIVE-PRESSURE VENTILATION; OBSTRUCTIVE PULMONARY-DISEASE; COMMUNITY-ACQUIRED PNEUMONIA; NONINVASIVE VENTILATION; MECHANICAL VENTILATION; BERLIN DEFINITION; DISTRESS-SYNDROME; CLINICAL-TRIALS; THERAPY; ARDS	BACKGROUND Whether noninvasive ventilation should be administered in patients with acute hypoxemic respiratory failure is debated. Therapy with high-flow oxygen through a nasal cannula may offer an alternative in patients with hypoxemia. METHODS We performed a multicenter, open-label trial in which we randomly assigned patients without hypercapnia who had acute hypoxemic respiratory failure and a ratio of the partial pressure of arterial oxygen to the fraction of inspired oxygen of 300 mm Hg or less to high-flow oxygen therapy, standard oxygen therapy delivered through a face mask, or noninvasive positive-pressure ventilation. The primary outcome was the proportion of patients intubated at day 28; secondary outcomes included all-cause mortality in the intensive care unit and at 90 days and the number of ventilator-free days at day 28. RESULTS A total of 310 patients were included in the analyses. The intubation rate (primary outcome) was 38% (40 of 106 patients) in the high-flow-oxygen group, 47% (44 of 94) in the standard group, and 50% (55 of 110) in the noninvasive-ventilation group (P = 0.18 for all comparisons). The number of ventilator-free days at day 28 was significantly higher in the high-flow-oxygen group (24 +/- 8 days, vs. 22 +/- 10 in the standard-oxygen group and 19 +/- 12 in the noninvasive-ventilation group; P = 0.02 for all comparisons). The hazard ratio for death at 90 days was 2.01 (95% confidence interval [CI], 1.01 to 3.99) with standard oxygen versus high-flow oxygen (P = 0.046) and 2.50 (95% CI, 1.31 to 4.78) with noninvasive ventilation versus high-flow oxygen (P = 0.006). CONCLUSIONS In patients with nonhypercapnic acute hypoxemic respiratory failure, treatment with high-flow oxygen, standard oxygen, or noninvasive ventilation did not result in significantly different intubation rates. There was a significant difference in favor of high-flow oxygen in 90-day mortality.	[Frat, Jean-Pierre; Thille, Arnaud W.; Deletage-Metreau, Celine; Robert, Rene] Ctr Hosp Univ Poitiers, Serv Reanimat Med, F-86021 Poitiers, France; [Frat, Jean-Pierre; Thille, Arnaud W.; Ragot, Stephanie; Robert, Rene] Univ Poitiers, INSERM, Ctr Invest Clin 1402, Poitiers, France; [Mercat, Alain; Pierrot, Marc] CHU Angers, Serv Reanimat Med & Med Hyperbare, Angers, France; [Girault, Christophe; Beduneau, Gaetan] CHU Rouen, Hop Charles Nicolle, Serv Reanimat Med, Rouen, France; [Girault, Christophe; Beduneau, Gaetan] Univ Rouen, Inst Biomed Res & Innovat, Rouen, France; [Perbet, Sebastien; Constantin, Jean-Michel] CHU Clermont Ferrand, Pole Med Perioperatoire, Clermont Ferrand, France; [Perbet, Sebastien; Constantin, Jean-Michel] Auvergne Univ, Clermont Ferrand, France; [Prat, Gwenael; Tonnelier, Jean-Marie] CHU Cavale Blanche, Serv Reanimat Med, Brest, France; [Mercat, Alain; Boulain, Thierry] Ctr Hosp Reg Orleans, Reanimat Medicochirurg, Orleans, France; [Morawiec, Elise] Grp Hosp Univ Pitie Salpetriere, Serv Pneumol & Reanimat Med, Paris, France; [Morawiec, Elise] Univ Paris 06, Paris, France; [Mira, Jean-Paul] Hop Cochin, Grp Hosp Univ Paris Ctr, AP HP, Reanimat Med, F-75674 Paris, France; [Mira, Jean-Paul] Univ Paris 05, Paris, France; [Ricard, Jean-Damien] Univ Paris Diderot, Paris, France; [Ricard, Jean-Damien] INSERM, Infect Antimicrobiens Modelisat Evolut 1137, Paris, France; [Fartoukh, Muriel] Hop Tenon, Serv Reanimat, AP HP, F-75970 Paris, France; [Cottereau, Alice] Ctr Hosp Dept La Roche Yon, Serv Reanimat Polyvalente, La Roche Sur Yon, France; [Devaquet, Jerome] Hop Foch, Reanimat Polyvalente, Suresnes, France; [Nseir, Saad] CHU Lille, Ctr Reanimat, F-59037 Lille, France; [Razazi, Keyvan] CHU Henri Mondor, AP HP, Serv Reanimat Med, F-94010 Creteil, France; [Razazi, Keyvan] Univ Paris Est Creteil, Grp Rech Clin, Creteil, France; [Razazi, Keyvan; Richard, Jean-Christophe M.; Brochard, Laurent] Hop Henri Mondor, INSERM, UMR 955, F-94010 Creteil, France; [Argaud, Laurent] Hosp Civils Lyon, Grp Hosp Univ Edouard Herriot, Serv Reanimat Med, Lyon, France; [Chakarian, Jean-Charles] Ctr Hosp Roanne, Reanimat Polyvalente, Roanne, France; [Ricard, Jean-Damien] Hop Louis Mourier, AP HP, Serv Reanimat Medicochirurg, F-92701 Colombes, France; [Chevalier, Stephanie] Ctr Hosp St Malo, Serv Reanimat Polyvalente, St Malo, France; [Herbland, Alexandre] Ctr Hosp La Rochelle, Hop St Louis, Serv Reanimat, La Rochelle, France; [Richard, Jean-Christophe M.] Ctr Hosp Reg Annecy, Serv Urgences, Annecy, France; [Wittebole, Xavier] Clin Univ St Luc, Serv Soins Intensifs, B-1200 Brussels, Belgium; [Brochard, Laurent] Univ Toronto, St Michaels Hosp, Keenan Res Ctr, Toronto, ON, Canada; [Brochard, Laurent] Univ Toronto, St Michaels Hosp, Crit Care Dept, Toronto, ON, Canada; [Brochard, Laurent] Univ Toronto, Interdept Div Crit Care Med, Toronto, ON, Canada	CHU Poitiers; Universite de Poitiers; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Poitiers; Universite d'Angers; Centre Hospitalier Universitaire d'Angers; CHU de Rouen; Universite de Rouen Normandie; CHU Clermont Ferrand; Universite Clermont Auvergne (UCA); CHU Brest; Centre Hospitalier Regional d'Orleans; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Tenon - APHP; UDICE-French Research Universities; Sorbonne Universite; Hospital Foch; Universite de Lille - ISITE; CHU Lille; Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); CHU Lyon; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Louis-Mourier - APHP; UDICE-French Research Universities; Universite Paris Cite; Centre Hospitalier Annecy Genevois; Universite Catholique Louvain; Cliniques Universitaires Saint-Luc; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Toronto	Frat, JP (corresponding author), Ctr Hosp Univ Poitiers, Serv Reanimat Med, 2 Rue Miletrie,CS 90577, F-86021 Poitiers, France.	jean-pierre.frat@chu-poitiers.fr	Boulain, Thierry/M-3309-2019; Asfar, Pierre/K-1402-2015; Mercat, Alain/AFU-4426-2022; Carmen, Team3/Y-7384-2019; Wittebole, Xavier/ABC-2036-2021	Boulain, Thierry/0000-0003-4664-3661; Carmen, Team3/0000-0002-3614-0924; Wittebole, Xavier/0000-0002-0621-8727; Nseir, Saad/0000-0002-7618-0357; Coudroy, Remi/0000-0002-0036-1899; Lab, Carmen/0000-0002-5935-3236; DANIN, Pierre-Eric/0000-0003-4234-7726	Programme Hospitalier de Recherche Clinique Interregional of the French Ministry of Health; FLORALI	Programme Hospitalier de Recherche Clinique Interregional of the French Ministry of Health; FLORALI	Funded by the Programme Hospitalier de Recherche Clinique Interregional 2010 of the French Ministry of Health; FLORALI ClinicalTrials.gov number, NCT01320384.	Antonelli M, 2007, CRIT CARE MED, V35, P18, DOI 10.1097/01.CCM.0000251821.44259.F3; BERNARD GR, 1994, AM J RESP CRIT CARE, V149, P818, DOI 10.1164/ajrccm.149.3.7509706; BROCHARD L, 1995, NEW ENGL J MED, V333, P817, DOI 10.1056/NEJM199509283331301; Carrillo A, 2012, INTENS CARE MED, V38, P458, DOI 10.1007/s00134-012-2475-6; Chanques G, 2013, MINERVA ANESTESIOL, V79, P1344; Confalonieri M, 1999, AM J RESP CRIT CARE, V160, P1585, DOI 10.1164/ajrccm.160.5.9903015; Corley A, 2011, BRIT J ANAESTH, V107, P998, DOI 10.1093/bja/aer265; Cuquemelle E, 2012, RESP CARE, V57, P1571, DOI 10.4187/respcare.01681; de Prost N, 2011, ANN INTENSIVE CARE, V1, DOI 10.1186/2110-5820-1-28; Delclaux C, 2000, JAMA-J AM MED ASSOC, V284, P2352, DOI 10.1001/jama.284.18.2352; Demoule A, 2006, INTENS CARE MED, V32, P1756, DOI 10.1007/s00134-006-0324-1; DREYFUSS D, 1993, AM REV RESPIR DIS, V148, P1194, DOI 10.1164/ajrccm/148.5.1194; Esteban A, 2004, NEW ENGL J MED, V350, P2452, DOI 10.1056/NEJMoa032736; Esteban A, 2013, AM J RESP CRIT CARE, V188, P220, DOI 10.1164/rccm.201212-2169OC; Ferguson ND, 2012, INTENS CARE MED, V38, P1573, DOI 10.1007/s00134-012-2682-1; Ferrer M, 2003, AM J RESP CRIT CARE, V168, P1438, DOI 10.1164/rccm.200301-072OC; Frat JP, 2015, RESP CARE, V60, P170, DOI 10.4187/respcare.03075; Hashemian SM, 2014, NEW ENGL J MED, V370, P979, DOI 10.1056/NEJMc1400293; Keenan SP, 2003, ANN INTERN MED, V138, P861, DOI 10.7326/0003-4819-138-11-200306030-00007; Lightowler JV, 2003, BMJ-BRIT MED J, V326, P185, DOI 10.1136/bmj.326.7382.185; Maggiore SM, 2014, AM J RESP CRIT CARE, V190, P282, DOI 10.1164/rccm.201402-0364OC; Martin TJ, 2000, AM J RESP CRIT CARE, V161, P807, DOI 10.1164/ajrccm.161.3.9808143; Masip J, 2005, JAMA-J AM MED ASSOC, V294, P3124, DOI 10.1001/jama.294.24.3124; Messika J, 2015, RESP CARE, V60, P162, DOI 10.4187/respcare.03423; Pham T. M., 2014, PEDIAT PULMONOL; Ranieri VM, 2012, JAMA-J AM MED ASSOC, V307, P2526, DOI 10.1001/jama.2012.5669; Roca O, 2010, RESP CARE, V55, P408; Schettino G, 2008, CRIT CARE MED, V36, P441, DOI 10.1097/01.CCM.0000300084.67277.90; Sztrymf B, 2012, J CRIT CARE, V27, DOI 10.1016/j.jcrc.2011.07.075; Sztrymf B, 2011, INTENS CARE MED, V37, P1780, DOI 10.1007/s00134-011-2354-6; Thille AW, 2013, CRIT CARE, V17, DOI 10.1186/cc13103; Ugurlu AO, 2014, CHEST, V145, P964, DOI 10.1378/chest.13-1707; Wang R, 2007, NEW ENGL J MED, V357, P2189, DOI 10.1056/NEJMsr077003; WYSOCKI M, 1995, CHEST, V107, P761, DOI 10.1378/chest.107.3.761	34	1145	1258	3	99	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 4	2015	372	23					2185	2196		10.1056/NEJMoa1503326	http://dx.doi.org/10.1056/NEJMoa1503326			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CK1GK	25981908				2023-01-03	WOS:000355955100003
J	Graham, KL; Wilker, EH; Howell, MD; Davis, RB; Marcantonio, ER				Graham, Kelly L.; Wilker, Elissa H.; Howell, Michael D.; Davis, Roger B.; Marcantonio, Edward R.			Differences Between Early and Late Readmissions Among Patients: A Cohort Study	ANNALS OF INTERNAL MEDICINE			English	Article							HOSPITAL READMISSION; HEART-FAILURE; INPATIENT; MORTALITY; RATES; RISK; CARE; PNEUMONIA; QUALITY; PROGRAM	Background: Early and late readmissions may have different causal factors, requiring different prevention strategies. Objective: To determine whether predictors of readmission change within 30 days after discharge. Design: Retrospective cohort study. Setting: Academic medical center. Participants: Patients admitted between 1 January 2009 and 31 December 2010. Measurements: Factors related to the index hospitalization (acute illness burden, inpatient care process factors, and clinical indicators of instability at discharge) and unrelated factors (chronic illness burden and social determinants of health) and how they affect early readmissions (0 to 7 days after discharge) and late readmissions (8 to 30 days after discharge). Results: 13 334 admissions, representing 8078 patients, were included in the analysis. Early readmissions were associated with markers of acute illness burden, including length of hospital stay (odds ratio [OR], 1.02 [95% Cl, 1.00 to 1.03]) and whether a rapid response team was called for assessment (OR, 1.48 [Cl, 1.15 to 1.89]); markers of chronic illness burden, including receiving a medication indicating organ failure (OR, 1.19 [Cl, 1.02 to 1.40]); and social determinants of health, including barriers to learning (OR, 1.18 [Cl, 1.01 to 1.38]). Early readmissions were less likely if a patient was discharged between 8:00 a.m. and 12:59 p.m. (OR, 0.76 [Cl, 0.58 to 0.99]). Late readmissions were associated with markers of chronic illness burden, including receiving a medication indicating organ failure (OR, 1.24 [Cl, 1.08 to 1.41]) or hemodialysis (OR, 1.61 [Cl, 1.12 to 2.17]), and social determinants of health, including barriers to learning (OR, 1.24 [Cl; 1.09 to 1.42]) and having unsupplemented Medicare or Medicaid (OR, 1.16 [Cl, 1.01 to 1.33]). Limitation: Readmissions were ascertained at 1 institution. Conclusion: The time frame of 30 days after hospital discharge may not be homogeneous. Causal factors and readmission prevention strategies may differ for the early versus late periods.	Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA 02215 USA; Univ Chicago, Ctr Qual, Chicago, IL 60637 USA; Univ Chicago, Sect Pulm & Crit Care, Chicago, IL 60637 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; University of Chicago; University of Chicago	Graham, KL (corresponding author), Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Med, 330 Brookline Ave,E Shapiro 607D, Boston, MA 02215 USA.	kgraham@bidmc.harvard.edu	Marcantonio, Edward R/U-3929-2017	Marcantonio, Edward R/0000-0002-2911-4250	Health Resources and Services Administration; National Institute on Aging; National Institutes of Health; Harvard Catalyst; Harvard University; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR001102] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [K99ES022243] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [K24AG035075] Funding Source: NIH RePORTER	Health Resources and Services Administration(United States Department of Health & Human ServicesUnited States Health Resources & Service Administration (HRSA)); National Institute on Aging(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Harvard Catalyst; Harvard University; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	Health Resources and Services Administration, National Institute on Aging, National Institutes of Health, Harvard Catalyst, and Harvard University.	ASHTON CM, 1995, ANN INTERN MED, V122, P415, DOI 10.7326/0003-4819-122-6-199503150-00003; Calvillo-King L, 2013, J GEN INTERN MED, V28, P269, DOI 10.1007/s11606-012-2235-x; Centers for Medicare and Medicaid Services, READM RED PROGR; Escobar GJ, 2008, MED CARE, V46, P232, DOI 10.1097/MLR.0b013e3181589bb6; Fontanarosa PB, 2013, JAMA-J AM MED ASSOC, V309, P398, DOI 10.1001/jama.2013.42; Gorodeski EZ, 2010, NEW ENGL J MED, V363, P297, DOI 10.1056/NEJMc1001882; Halfon P, 2006, MED CARE, V44, P972, DOI 10.1097/01.mlr.0000228002.43688.c2; Jencks SF, 2009, NEW ENGL J MED, V360, P1418, DOI 10.1056/NEJMsa0803563; Joynt KE, 2013, NEW ENGL J MED, V368, P1175, DOI 10.1056/NEJMp1300122; Joynt KE, 2013, JAMA-J AM MED ASSOC, V309, P342, DOI 10.1001/jama.2012.94856; Joynt KE, 2012, NEW ENGL J MED, V366, P1366, DOI 10.1056/NEJMp1201598; Joynt KE, 2011, JAMA-J AM MED ASSOC, V305, P675, DOI 10.1001/jama.2011.123; Kansagara D, 2011, JAMA-J AM MED ASSOC, V306, P1688, DOI 10.1001/jama.2011.1515; Kravet SJ, 2007, HEALTH CARE MANAG, V26, P142, DOI 10.1097/01.HCM.0000268617.33491.60; Krumholz HM, 2013, JAMA-J AM MED ASSOC, V309, P587, DOI 10.1001/jama.2013.333; National Quality Forum, 2014, RISK ADJ SOC STAT OT; Powell ES, 2012, J EMERG MED, V42, P186, DOI 10.1016/j.jemermed.2010.06.028; Quan HD, 2005, MED CARE, V43, P1130, DOI 10.1097/01.mlr.0000182534.19832.83; Stefan MS, 2013, J GEN INTERN MED, V28, P377, DOI 10.1007/s11606-012-2229-8; van Walraven C, 2011, CAN MED ASSOC J, V183, pE1067, DOI 10.1503/cmaj.110400	20	65	67	0	11	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 2	2015	162	11					741	749		10.7326/M14-2159	http://dx.doi.org/10.7326/M14-2159			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CJ5ZH	26030632	Green Accepted			2023-01-03	WOS:000355572300001
J	Werner, MU; Pereira, MP; Andersen, LPH; Dahl, JB				Werner, Mads U.; Pereira, Manuel P.; Andersen, Lars Peter H.; Dahl, Jorgen B.			Endogenous Opioid Antagonism in Physiological Experimental Pain Models: A Systematic Review	PLOS ONE			English	Review							STRESS-INDUCED ANALGESIA; PERIPHERAL CONDITIONING STIMULATION; BUPRENORPHINE-INDUCED ANALGESIA; NOXIOUS INHIBITORY CONTROLS; CENTRAL SENSITIZATION; BRAIN-STIMULATION; CONSORT STATEMENT; BLOOD-PRESSURE; ISCHEMIC PAIN; SAMPLE-SIZE	Opioid antagonists are pharmacological tools applied as an indirect measure to detect activation of the endogenous opioid system (EOS) in experimental pain models. The objective of this systematic review was to examine the effect of mu-opioid-receptor (MOR) antagonists in placebo-controlled, double-blind studies using 'inhibitory' or 'sensitizing', physiological test paradigms in healthy human subjects. The databases PubMed and Embase were searched according to predefined criteria. Out of a total of 2,142 records, 63 studies (1,477 subjects [male/female ratio = 1.5]) were considered relevant. Twenty-five studies utilized 'inhibitory' test paradigms (ITP) and 38 studies utilized 'sensitizing' test paradigms (STP). The ITP-studies were characterized as conditioning modulation models (22 studies) and repetitive transcranial magnetic stimulation models (rTMS; 3 studies), and, the STP-studies as secondary hyperalgesia models (6 studies), 'pain' models (25 studies), summation models (2 studies), nociceptive reflex models (3 studies) and miscellaneous models (2 studies). A consistent reversal of analgesia by a MOR-antagonist was demonstrated in 10 of the 25 ITP-studies, including stress-induced analgesia and rTMS. In the remaining 14 conditioning modulation studies either absence of effects or ambiguous effects by MOR-antagonists, were observed. In the STP-studies, no effect of the opioid-blockade could be demonstrated in 5 out of 6 secondary hyperalgesia studies. The direction of MOR-antagonist dependent effects upon pain ratings, threshold assessments and somatosensory evoked potentials (SSEP), did not appear consistent in 28 out of 32 'pain' model studies. In conclusion, only in 2 experimental human pain models, i.e., stress-induced analgesia and rTMS, administration of MOR-antagonist demonstrated a consistent effect, presumably mediated by an EOS-dependent mechanisms of analgesia and hyperalgesia.	[Werner, Mads U.; Pereira, Manuel P.] Rigshosp, Ctr Neurosci, Ctr Multidisciplinary Pain, DK-2100 Copenhagen, Denmark; [Pereira, Manuel P.; Dahl, Jorgen B.] Rigshosp, Ctr Head & Orthopaed, Dept Anaesthesia, DK-2100 Copenhagen, Denmark; [Andersen, Lars Peter H.] Herlev Hosp, Dept Surg D, Copenhagen, Denmark	Rigshospitalet; University of Copenhagen; Rigshospitalet; University of Copenhagen; University of Copenhagen; Herlev & Gentofte Hospital	Werner, MU (corresponding author), Rigshosp, Ctr Neurosci, Ctr Multidisciplinary Pain, DK-2100 Copenhagen, Denmark.	mads.u.werner@gmail.com	Pereira, Manuel Pedro/AAP-8484-2020	Werner, Mads/0000-0003-1540-8845				ADAMS JE, 1976, PAIN, V2, P161, DOI 10.1016/0304-3959(76)90111-1; Al'Absi M, 2004, PSYCHOSOM MED, V66, P198, DOI 10.1097/01.psy.0000116250.81254.5d; Altman DG, 1996, BRIT MED J, V313, P570; Anderson WS, 2002, PAIN, V99, P207, DOI 10.1016/S0304-3959(02)00103-3; Backonja MM, 2009, CLIN J PAIN, V25, P641, DOI 10.1097/AJP.0b013e3181a68c7e; Benedetti F, 1999, J NEUROSCI, V19, P3639; Bingel U, 2007, PAIN, V131, P21, DOI 10.1016/j.pain.2006.12.005; Bingel U, 2008, PAIN, V140, P393, DOI 10.1016/j.pain.2008.09.030; Borras MC, 2004, J NEUROPHYSIOL, V91, P2723, DOI 10.1152/jn.00249.2003; BOUREAU F, 1978, NEUROPHARMACOLOGY, V17, P565, DOI 10.1016/0028-3908(78)90149-1; Brennum J, 2001, ACTA ANAESTH SCAND, V45, P954, DOI 10.1034/j.1399-6576.2001.450806.x; Brock C, 2012, CLIN NEUROPHYSIOL, V123, P829, DOI 10.1016/j.clinph.2011.07.047; BROMM B, 1983, EUR J PHARMACOL, V87, P431, DOI 10.1016/0014-2999(83)90082-1; Bruehl S, 2012, EUR J PAIN, V16, P370, DOI 10.1002/j.1532-2149.2011.00021.x; Bruehl S, 2013, PAIN, V154, P1856, DOI 10.1016/j.pain.2013.06.002; Bruehl S, 2011, PSYCHOSOM MED, V73, P612, DOI 10.1097/PSY.0b013e318227cb88; BUCHSBAUM MS, 1983, PSYCHOPHARMACOLOGY, V79, P99, DOI 10.1007/BF00427792; BUCHSBAUM MS, 1977, NATURE, V270, P620, DOI 10.1038/270620a0; Butler RK, 2009, PROG NEUROBIOL, V88, P184, DOI 10.1016/j.pneurobio.2009.04.003; Calabrese EJ, 2008, CRIT REV TOXICOL, V38, P579, DOI 10.1080/10408440802026281; CHAMBERLAIN JM, 1994, AM J EMERG MED, V12, P650, DOI 10.1016/0735-6757(94)90033-7; Chan AW, 2013, ANN INTERN MED, V158, P200, DOI 10.7326/0003-4819-158-3-201302050-00583; Chu LF, 2011, J PAIN, V12, P108, DOI 10.1016/j.jpain.2010.05.006; COHEN J, 1992, PSYCHOL BULL, V112, P155, DOI 10.1037/0033-2909.112.1.155; Cook DB, 2000, AM J PHYSIOL-REG I, V279, pR1565, DOI 10.1152/ajpregu.2000.279.5.R1565; Corder G, 2013, SCIENCE, V341, P1394, DOI 10.1126/science.1239403; CRABTREE BL, 1984, CLIN PHARMACY, V3, P273; de Andrade DC, 2011, PAIN, V152, P320, DOI 10.1016/j.pain.2010.10.032; Drummond PD, 2000, ANESTH ANALG, V90, P923, DOI 10.1213/00000539-200004000-00027; Edwards RR, 2004, PERCEPT MOTOR SKILL, V99, P679, DOI 10.2466/pms.99.2.679-687; Eissenberg T, 2000, EXP CLIN PSYCHOPHARM, V8, P47, DOI 10.1037/1064-1297.8.1.47; ELSOBKY A, 1976, NATURE, V263, P783, DOI 10.1038/263783a0; ERNST M, 1986, PAIN, V26, P221, DOI 10.1016/0304-3959(86)90077-1; France CR, 2007, BIOL PSYCHOL, V75, P95, DOI 10.1016/j.biopsycho.2006.12.005; France CR, 2005, BIOL PSYCHOL, V70, P168, DOI 10.1016/j.biopsycho.2005.01.012; Friston KJ, 1999, NEUROIMAGE, V10, P1, DOI 10.1006/nimg.1999.0439; FROST JJ, 1989, J CEREBR BLOOD F MET, V9, P398, DOI 10.1038/jcbfm.1989.59; Geber C, 2011, PAIN, V152, P548, DOI 10.1016/j.pain.2010.11.013; GLASER EM, 1953, J PHYSIOL-LONDON, V122, pP43; GLASS PSA, 1994, ANESTH ANALG, V78, P536; GONZALEZ JP, 1988, DRUGS, V35, P192, DOI 10.2165/00003495-198835030-00002; Gracely RH, 2013, WALL MELZACKS TXB PA, P283; Graven-Nielsen T, 2002, EXP BRAIN RES, V146, P213, DOI 10.1007/s00221-002-1169-7; GREVERT P, 1983, BIOL PSYCHIAT, V18, P1375; GREVERT P, 1977, P NATL ACAD SCI USA, V74, P1291, DOI 10.1073/pnas.74.3.1291; GREVERT P, 1978, SCIENCE, V199, P1093, DOI 10.1126/science.343250; Ioannidis JPA, 2005, PLOS MED, V2, P696, DOI 10.1371/journal.pmed.0020124; Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4; JANAL MN, 1984, PAIN, V19, P13, DOI 10.1016/0304-3959(84)90061-7; Julien N, 2006, NEUROSCI LETT, V401, P256, DOI 10.1016/j.neulet.2006.03.032; JUNGKUNZ G, 1983, PSYCHIAT RES, V8, P13, DOI 10.1016/0165-1781(83)90133-6; Kern D, 2008, PAIN, V135, P291, DOI 10.1016/j.pain.2007.12.001; Kilkenny C, 2011, J CEREBR BLOOD F MET, V31, P991, DOI 10.1038/jcbfm.2010.220; King CD, 2013, J BEHAV MED, V36, P315, DOI 10.1007/s10865-012-9424-2; Koppert W, 2005, J PAIN, V6, P757, DOI 10.1016/j.jpain.2005.07.002; Koppert W, 2005, PAIN, V118, P15, DOI 10.1016/j.pain.2005.06.030; Koppert W, 2003, PAIN, V106, P91, DOI 10.1016/S0304-3959(03)00294-X; Kotlyar M, 2008, BIOL PSYCHOL, V77, P233, DOI 10.1016/j.biopsycho.2007.10.005; Latremoliere A, 2009, J PAIN, V10, P895, DOI 10.1016/j.jpain.2009.06.012; LAUTENBACHER S, 1994, PSYCHOSOM MED, V56, P345, DOI 10.1097/00006842-199407000-00010; LAUTENBACHER S, 1990, PSYCHOSOM MED, V52, P673, DOI 10.1097/00006842-199011000-00008; Le Bars D, 1992, Patol Fiziol Eksp Ter, P55; LEBARS D, 1992, PAIN, V48, P13, DOI 10.1016/0304-3959(92)90126-V; Leonard G, 2010, PAIN, V151, P215, DOI 10.1016/j.pain.2010.07.012; LEVINE JD, 1984, NATURE, V312, P755, DOI 10.1038/312755a0; LEVINE JD, 1979, NATURE, V278, P740, DOI 10.1038/278740a0; LEVINE JD, 1986, BRAIN RES, V365, P377, DOI 10.1016/0006-8993(86)91653-7; Maier C, 2010, PAIN, V150, P439, DOI 10.1016/j.pain.2010.05.002; MCCUBBIN JA, 1994, PAIN, V57, P63, DOI 10.1016/0304-3959(94)90108-2; Mikkelsen S, 1999, ANESTHESIOLOGY, V90, P1539, DOI 10.1097/00000542-199906000-00007; Mobascher A, 2010, INT J PSYCHOPHYSIOL, V75, P16, DOI 10.1016/j.ijpsycho.2009.10.008; Moher D, 2001, BMC Med Res Methodol, V1, P2, DOI 10.1186/1471-2288-1-2; Moher D, 2009, PLOS MED, V6, DOI [10.1371/journal.pmed.1000097, 10.1136/bmj.b4037]; Nickel FT, 2014, EUR J PAIN, V18, P56, DOI 10.1002/j.1532-2149.2013.00339.x; Noordzij M, 2011, NEPHRON CLIN PRACT, V118, pC319, DOI 10.1159/000322830; OLAUSSON B, 1986, ACTA PHYSIOL SCAND, V126, P299, DOI 10.1111/j.1748-1716.1986.tb07818.x; Pereira MP, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064608; PERT A, 1974, BRAIN RES, V80, P135, DOI 10.1016/0006-8993(74)90731-8; PERTOVAARA A, 1982, BRAIN RES, V251, P83, DOI 10.1016/0006-8993(82)91276-8; PERTOVAARA A, 1982, PAIN, V13, P379, DOI 10.1016/0304-3959(82)90006-9; PERTOVAARA A, 1981, BRAIN RES, V215, P426, DOI 10.1016/0006-8993(81)90529-1; Petersen KL, 1999, NEUROREPORT, V10, P1511, DOI 10.1097/00001756-199905140-00022; Pickering G, 2013, FUND CLIN PHARMACOL, V27, P339, DOI 10.1111/j.1472-8206.2011.01010.x; Pielsticker A, 2005, PAIN, V118, P215, DOI 10.1016/j.pain.2005.08.019; POSNER J, 1985, PSYCHOPHARMACOLOGY, V87, P468, DOI 10.1007/BF00432515; Poulsen L, 1996, ANALGESIA, V2, P255; Preacher KJ, 2004, BEHAV RES METH INS C, V36, P717, DOI 10.3758/BF03206553; Price DD, 2002, PAIN, V99, P49, DOI 10.1016/S0304-3959(02)00053-2; Pud D, 2009, PAIN, V144, P16, DOI 10.1016/j.pain.2009.02.015; Rang HP, 2007, RANG DALES PHARM, P588; Ravn P, 2013, J PAIN RES, V6, P23, DOI 10.2147/JPR.S36827; Rennefeld C, 2010, PAIN, V148, P503, DOI 10.1016/j.pain.2009.12.014; RICHARDSON DE, 1976, IEEE T BIO-MED ENG, V23, P304, DOI 10.1109/TBME.1976.324589; Robertson LJ, 2008, J PAIN, V9, P79, DOI 10.1016/j.jpain.2007.08.008; Robertson LJ, 2007, J PAIN, V8, P489, DOI 10.1016/j.jpain.2007.01.007; Rolke R, 2006, PAIN, V123, P231, DOI 10.1016/j.pain.2006.01.041; Schobel HP, 1998, J AUTONOM NERV SYST, V69, P49, DOI 10.1016/S0165-1838(98)00005-8; Schoell ED, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012344; Schulz KF, 2010, LANCET, V376, P1222, DOI 10.1016/S0140-6736(10)61879-X; Schweinhardt P, 2008, NEUROSCIENTIST, V14, P415, DOI 10.1177/1073858407312521; Smith K, 2012, INT J CLIN PHARM TH, V50, P360, DOI 10.5414/CP201646; Sprenger C, 2011, PAIN, V152, P428, DOI 10.1016/j.pain.2010.11.018; STACHER G, 1988, PAIN, V34, P271, DOI 10.1016/0304-3959(88)90122-4; Staud R, 2012, J PAIN, V13, P725, DOI 10.1016/j.jpain.2012.04.006; Taylor JJ, 2013, NEUROPSYCHOPHARMACOL, V38, P1189, DOI 10.1038/npp.2013.13; Taylor JJ, 2012, PAIN, V153, P1219, DOI 10.1016/j.pain.2012.02.030; Taylor R, 2013, EXPERT OPIN INV DRUG, V22, P517, DOI 10.1517/13543784.2013.778973; Troster A, 2012, CLIN J PAIN, V28, P705, DOI 10.1097/AJP.0b013e318241d948; van Wijk G, 2010, J PAIN, V11, P408, DOI 10.1016/j.jpain.2009.10.009; van Wilgen CP, 2012, PAIN MANAG NURS, V13, P60, DOI 10.1016/j.pmn.2010.03.001; Vignoletti F, 2012, J CLIN PERIODONTOL, V39, P6, DOI 10.1111/j.1600-051X.2011.01830.x; Watson M, 2005, OXFORD HDB PALLIATIV, P35; Werner MU, 2013, ACTA ANAESTH SCAND, V57, P957, DOI 10.1111/aas.12150; Werner MU, 2013, SCAND J PAIN, V4, P163, DOI 10.1016/j.sjpain.2013.04.003; WILLER JC, 1980, BRAIN RES, V198, P419, DOI 10.1016/0006-8993(80)90755-6; WILLER JC, 1981, SCIENCE, V212, P689, DOI 10.1126/science.6261330; WILLER JC, 1990, EUR J PHARMACOL, V182, P347, DOI 10.1016/0014-2999(90)90293-F; WILLER JC, 1986, BRAIN RES, V362, P398, DOI 10.1016/0006-8993(86)90472-5; WILLER JC, 1982, BRAIN RES, V239, P322, DOI 10.1016/0006-8993(82)90860-5; WILLER JC, 1986, ANN NY ACAD SCI, V467, P256, DOI 10.1111/j.1749-6632.1986.tb14634.x; Woolf CJ, 2011, PAIN, V152, pS2, DOI 10.1016/j.pain.2010.09.030; Yarnitsky D, 2008, PAIN, V138, P22, DOI 10.1016/j.pain.2007.10.033; Yarnitsky D, 2010, CURR OPIN ANESTHESIO, V23, P611, DOI 10.1097/ACO.0b013e32833c348b; Yarnitsky D, 2010, EUR J PAIN, V14, P339, DOI 10.1016/j.ejpain.2010.02.004; Younger JW, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005180	125	14	13	0	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 1	2015	10	6							e0125887	10.1371/journal.pone.0125887	http://dx.doi.org/10.1371/journal.pone.0125887			37	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CL0KF	26029906	Green Published, gold, Green Submitted			2023-01-03	WOS:000356630900016
J	Vinogradova, Y; Coupland, C; Hippisley-Cox, J				Vinogradova, Yana; Coupland, Carol; Hippisley-Cox, Julia			Use of combined oral contraceptives and risk of venous thromboembolism: nested case-control studies using the QResearch and CPRD databases	BMJ-BRITISH MEDICAL JOURNAL			English	Article							NATIONAL-SURVEY; DROSPIRENONE; WOMEN; LEVONORGESTREL; THROMBOSIS; NORGESTIMATE; CYPROTERONE; COMBINATION; VALIDATION; IMPACT	OBJECTIVE To investigate the association between use of combined oral contraceptives and risk of venous thromboembolism, taking the type of progestogen into account. DESIGN Two nested case-control studies. SETTING General practices in the United Kingdom contributing to the Clinical Practice Research Datalink (CPRD; 618 practices) and QResearch primary care database (722 practices). PARTICIPANTS Women aged 15-49 years with a first diagnosis of venous thromboembolism in 2001-13, each matched with up to five controls by age, practice, and calendar year. MAIN OUTCOME MEASURES Odds ratios for incident venous thromboembolism and use of combined oral contraceptives in the previous year, adjusted for smoking status, alcohol consumption, ethnic group, body mass index, comorbidities, and other contraceptive drugs. RESULTS were combined across the two datasets. Results 5062 cases of venous thromboembolism from CPRD and 5500 from QResearch were analysed. Current exposure to any combined oral contraceptive was associated with an increased risk of venous thromboembolism (adjusted odds ratio 2.97, 95% confidence interval 2.78 to 3.17) compared with no exposure in the previous year. Corresponding risks associated with current exposure to desogestrel (4.28, 3.66 to 5.01), gestodene (3.64, 3.00 to 4.43), drospirenone (4.12, 3.43 to 4.96), and cyproterone (4.27, 3.57 to 5.11) were significantly higher than those for second generation contraceptives levonorgestrel (2.38, 2.18 to 2.59) and norethisterone (2.56, 2.15 to 3.06), and for norgestimate (2.53, 2.17 to 2.96). The number of extra cases of venous thromboembolism per year per 10 000 treated women was lowest for levonorgestrel (6, 95% confidence interval 5 to 7) and norgestimate (6, 5 to 8), and highest for desogestrel (14, 11 to 17) and cyproterone (14, 11 to 17). CONCLUSIONS In these population based, case-control studies using two large primary care databases, risks of venous thromboembolism associated with combined oral contraceptives were, with the exception of norgestimate, higher for newer drug preparations than for second generation drugs.	[Vinogradova, Yana; Coupland, Carol; Hippisley-Cox, Julia] Div Primary Care, Nottingham NG2 7RD, England		Vinogradova, Y (corresponding author), Div Primary Care, Univ Pk, Nottingham NG2 7RD, England.	yana.vinogradova@nottingham.ac.uk	Hippisley-Cox, Julia/AAY-2788-2020	Hippisley-Cox, Julia/0000-0002-2479-7283; Vinogradova, Yana/0000-0002-3030-5257; Coupland, Carol/0000-0002-2327-3306				Bird ST, 2013, CAN MED ASSOC J, V185, pE115, DOI 10.1503/cmaj.120677; Bjerre LM, 2000, BRIT MED J, V320, P503, DOI 10.1136/bmj.320.7233.503; Borenstein M, 2010, RES SYNTH METHODS, V1, P97, DOI 10.1002/jrsm.12; Briggs PE, 2013, J FAM PLAN REPROD H, V39, P190, DOI 10.1136/jfprhc-2012-100376; Department of Economic and Social Affairs, 2013, WORLD CONTR PATT 201; Dinger JC, 2007, CONTRACEPTION, V75, P344, DOI 10.1016/j.contraception.2006.12.019; Dunn N, 2011, BRIT MED J, V342, DOI 10.1136/bmj.d2519; Eastwood BJ, 1996, INT J EPIDEMIOL, V25, P763, DOI 10.1093/ije/25.4.763; Etminan M, 2004, PHARMACOTHERAPY, V24, P1105, DOI 10.1592/phco.24.13.1105.38083; Farmer RDT, 2000, BRIT J CLIN PHARMACO, V49, P580, DOI 10.1046/j.1365-2125.2000.00198.x; Farmer RDT, 1997, LANCET, V349, P83, DOI 10.1016/S0140-6736(96)07496-X; French RS, 2009, J FAM PLAN REPROD H, V35, P9, DOI 10.1783/147118909787072360; Gronich N, 2011, CAN MED ASSOC J, V183, pE1319, DOI 10.1503/cmaj.110463; Heinemann K, 2011, J FAM PLAN REPROD H, V37, P132, DOI 10.1136/jfprhc-2011-14524; Heinemann LAJ, 2002, CONTRACEPTION, V65, P207, DOI 10.1016/S0010-7824(01)00309-2; Heinemann LAJ, 1997, BRIT MED J, V315, P1502, DOI 10.1136/bmj.315.7121.1502; Heinemann LAJ, 2007, CONTRACEPTION, V75, P328, DOI 10.1016/j.contraception.2006.12.018; Heinemann LAJ, 2010, CONTRACEPTION, V81, P401, DOI 10.1016/j.contraception.2009.12.014; Hippisley-Cox J, 2004, HLTH INFORMATICS J, V10, P91, DOI 10.1177/1460458204042230; Hippisley-Cox J., 2013, VALIDITY COMPLETENES; Hippisley-Cox J, 2013, BMJ OPEN, V3, DOI 10.1136/bmjopen-2013-003482; Hippisley-Cox J, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d4656; Jick SS, 2003, PHARMACOTHERAPY, V23, P686, DOI 10.1592/phco.23.5.686.32205; Jick SS, 2006, CONTRACEPTION, V73, P566, DOI 10.1016/j.contraception.2006.02.002; Jick SS, 2011, BMJ-BRIT MED J, V342, DOI 10.1136/bmj.d2151; KUHNZ W, 1994, CONTRACEPTION, V49, P255, DOI 10.1016/0010-7824(94)90043-4; Lader D, 2009, 41 NHS INF CTR HLTH; Lawrenson R, 2000, BRIT J CLIN PHARMACO, V49, P591, DOI 10.1046/j.1365-2125.2000.00199.x; Lawrenson R, 2000, CONTRACEPTION, V62, p21S, DOI 10.1016/S0010-7824(00)00147-5; Lewis MA, 1999, HUM REPROD, V14, P1493, DOI 10.1093/humrep/14.6.1493; Lewis MA, 1996, CONTRACEPTION, V54, P5, DOI 10.1016/0010-7824(96)00112-6; Lidegaard O, 2012, ACTA OBSTET GYN SCAN, V91, P769, DOI 10.1111/j.1600-0412.2012.01444.x; Lidegaard O, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d6423; Lindqvist PG, 2009, BRIT J HAEMATOL, V144, P234, DOI 10.1111/j.1365-2141.2008.07460.x; National Institute for Health and Care Excellence, 2012, NHS EV; Parker C, 2010, BRIT MED J, V341, DOI 10.1136/bmj.c4245; Parkin L, 2011, BMJ-BRIT MED J, V342, DOI 10.1136/bmj.d2139; POULTER NR, 1995, LANCET, V346, P1575; ROTHMAN KJ, 1988, INT J EPIDEMIOL, V17, P955, DOI 10.1093/ije/17.4.955; Royston P, 2004, STATA J, V4, P227, DOI 10.1177/1536867X0400400301; Seaman HE, 2004, PHARMACOEPIDEM DR S, V13, P427, DOI 10.1002/pds.896; Seeger JD, 2007, OBSTET GYNECOL, V110, P587, DOI 10.1097/01.AOG.0000279448.62221.a8; Stegeman BH, 2013, BMJ-BRIT MED J, V347, DOI 10.1136/bmj.f5298; Sultan AA, 2012, BRIT J HAEMATOL, V156, P366, DOI 10.1111/j.1365-2141.2011.08956.x; The Health and Social Care Information Centre, 2005, NHS CONTR SERV ENGL; van Hylckama Vlieg A, 2009, BMJ, V339, pb2921, DOI 10.1136/bmj.b2921; Vasilakis-Scaramozza C, 2001, LANCET, V358, P1427, DOI 10.1016/S0140-6736(01)06522-9; Vaughan B, 2008, CONTRACEPTION, V78, P271, DOI 10.1016/j.contraception.2008.05.007; Vinogradova Y, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2013-004499; White RH, 1998, ANN INTERN MED, V128, P737, DOI 10.7326/0003-4819-128-9-199805010-00006	50	119	129	0	19	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 26	2015	350								h2135	10.1136/bmj.h2135	http://dx.doi.org/10.1136/bmj.h2135			15	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CJ0AF	26013557	hybrid, Green Published, Green Accepted			2023-01-03	WOS:000355132600002
J	Seidman, G; Unnikrishnan, S; Kenny, E; Myslinski, S; Cairns-Smith, S; Mulligan, B; Engmann, C				Seidman, Gabriel; Unnikrishnan, Shalini; Kenny, Emma; Myslinski, Scott; Cairns-Smith, Sarah; Mulligan, Brian; Engmann, Cyril			Barriers and Enablers of Kangaroo Mother Care Practice: A Systematic Review	PLOS ONE			English	Article							SKIN-TO-SKIN; RANDOMIZED CONTROLLED-TRIAL; BIRTH-WEIGHT INFANTS; PRETERM INFANTS; SWEDISH MOTHERS; CONTACT; DETERMINANTS; PERCEPTIONS; EXPERIENCES; MORTALITY	Kangaroo mother care (KMC) is an evidence-based approach to reducing mortality and morbidity in preterm infants. Although KMC is a key intervention package in newborn health initiatives, there is limited systematic information available on the barriers to KMC practice that mothers and other stakeholders face while practicing KMC. This systematic review sought to identify the most frequently reported barriers to KMC practice for mothers, fathers, and health practitioners, as well as the most frequently reported enablers to practice for mothers. We searched nine electronic databases and relevant reference lists for publications reporting barriers or enablers to KMC practice. We identified 1,264 unique publications, of which 103 were included based on pre-specified criteria. Publications were scanned for all barriers / enablers. Each publication was also categorized based on its approach to identification of barriers / enablers, and more weight was assigned to publications which had systematically sought to understand factors influencing KMC practice. Four of the top five ranked barriers to KMC practice for mothers were resource-related: "Issues with the facility environment / resources," "negative impressions of staff attitudes or interactions with staff," "lack of help with KMC practice or other obligations," and "low awareness of KMC / infant health."Considering only publications from low-and middle-income countries, "pain / fatigue" was ranked higher than when considering all publications. Top enablers to practice were included "mother-infant attachment" and "support from family, friends, and other mentors." Our findings suggest that mother can understand and enjoy KMC, and it has benefits for mothers, infants, and families. However, continuous KMC may be physically and emotionally difficult, and often requires support from family members, health practitioners, or other mothers. These findings can serve as a starting point for researchers and program implementers looking to improve KMC programs.	[Seidman, Gabriel] Harvard TH Chan Sch Publ Hlth, Boston, MA 02115 USA; [Unnikrishnan, Shalini; Myslinski, Scott; Cairns-Smith, Sarah] Boston Consulting Grp Inc, Boston, MA USA; [Kenny, Emma] Boston Consulting Grp Inc, New York, NY USA; [Mulligan, Brian; Engmann, Cyril] Bill & Melinda Gates Fdn, Seattle, WA USA	Harvard University; Harvard T.H. Chan School of Public Health; Boston Consulting Group (BCG); Boston Consulting Group (BCG); Bill & Melinda Gates Foundation	Seidman, G (corresponding author), Harvard TH Chan Sch Publ Hlth, Boston, MA 02115 USA.	Gabriel.seidman@gmail.com			Bill & Melinda Gates Foundation	Bill & Melinda Gates Foundation(Bill & Melinda Gates FoundationCGIAR)	The Bill & Melinda Gates Foundation provided funding for this review. Two authors (BM, CE) were employees of the foundation at the time of writing. They were not involved in collection or analysis of data, but did provide input into revisions / edits of the manuscript.	Abul-Fadl AMAM, 2012, BREASTFEED MED, V7, P173, DOI 10.1089/bfm.2011.0028; Bazzano A, 2012, GLOB HEALTH PROMOT, V19, P42, DOI 10.1177/1757975912453185; Beach MC, 2005, MED CARE, V43, P356, DOI 10.1097/01.mlr.0000156861.58905.96; Bergh A-M, 2013, Ghana Med J, V47, P57; Bergh AM, 2012, IMPLEMENT SCI, V7, DOI 10.1186/1748-5908-7-75; Bigelow A, 2012, JOGNN-J OBST GYN NEO, V41, P369, DOI 10.1111/j.1552-6909.2012.01350.x; Blencowe H., 2005, Malawi Medical Journal, V17, P39; Blencowe H, 2009, J TROP PEDIATRICS, V55, P244, DOI 10.1093/tropej/fmn116; Blomqvist YT, 2013, SCAND J CARING SCI, V27, P345, DOI 10.1111/j.1471-6712.2012.01040.x; Blomqvist YT, 2012, J ADV NURS, V68, P1988, DOI 10.1111/j.1365-2648.2011.05886.x; Blomqvist YT, 2011, J CLIN NURS, V20, P1472, DOI 10.1111/j.1365-2702.2010.03369.x; Boo NY, 2007, J PAEDIATR CHILD H, V43, P831, DOI 10.1111/j.1440-1754.2007.01198.x; Bramson L, 2010, JOURNAL OF HUMAN LAC; Brimdyr K, 2012, J PERINAT EDUC, V21, P149, DOI 10.1891/1058-1243.21.3.149; Broughton E, 2013, COST SAVINGS IMPLEME; Cattaneo A, 1998, ACTA PAEDIATR, V87, P976, DOI 10.1080/080352598750031653; Central Intelligence Agency, 2013, WORLD FACTB 2013 201; Charpak N, 1997, PEDIATRICS, V100, P682, DOI 10.1542/peds.100.4.682; Charpak N, 2006, ACTA PAEDIATR, V95, P529, DOI 10.1080/08035250600599735; Conde-Agudelo A, 2014, KANGAROO MOTHER CARE; Department of Reproductive Health and ResearchW, 2003, KANG MOTH CAR PRACT; El-Nagger NSM, 2013, LIFE SCI J, V10, P703; Engmann C, 2013, LANCET, V382, pE26, DOI 10.1016/S0140-6736(13)62293-X; Feldman R, 2003, J FAM PSYCHOL, V17, P94, DOI 10.1037/0893-3200.17.1.94; Fleuren M, 2004, INT J QUAL HEALTH C, V16, P107, DOI 10.1093/intqhc/mzh030; Gathwala G, 2008, INDIAN J PEDIATR, V75, P43, DOI 10.1007/s12098-008-0005-x; Gregson S., 2011, BR J MIDWIFERY, V19, P568, DOI [10.12968/bjom.2011.19.9.568, DOI 10.12968/BJOM.2011.19.9.568, DOI 10.12968/BJ0M.2011.19.9.568]; Heinemann AB, 2013, ACTA PAEDIATR, V102, P695, DOI 10.1111/apa.12267; Kambarami RA, 2002, TROP DOCT, V32, P131, DOI 10.1177/004947550203200303; Kumar V, 2008, LANCET, V372, P1151, DOI 10.1016/S0140-6736(08)61483-X; Kymre IG, 2013, INT J QUALITATIVE ST, V8; Kymre IG, 2013, SCAND J CARING SCI, V27, P669, DOI 10.1111/j.1471-6712.2012.01076.x; Lawn JE, 2010, INT J EPIDEMIOL, V39, P144, DOI 10.1093/ije/dyq031; Lee HC, 2012, BREASTFEED MED, V7, P79, DOI 10.1089/bfm.2011.0004; Lemmen Desiree, 2013, Open Nurs J, V7, P41, DOI 10.2174/1874434601307010041; Leonard A, HLTH SA GESONDHEID, V13, P16; Lessing-Pernak J, 2011, GINEKOLOGIA POLOZNIC, V22, P37; Liberati A, 2009, PLOS MED, V6, DOI [10.1371/journal.pmed.1000100, 10.1136/bmj.b2700, 10.7326/0003-4819-151-4-200908180-00136]; Lima G, 2000, ANN TROP PAEDIATR, V20, P22, DOI 10.1080/02724930092020; Lincetto O, 2000, J TROP PEDIATRICS, V46, P293, DOI 10.1093/tropej/46.5.293; Lipato T, 2012, EVALUATION KANGAROO; March of Dimes PMNCH Save the Children WHO, 2012, BORN TOO SOON GLOB A, DOI [10.1186/1742-4755-10-S1-S1, DOI 10.1186/1742-4755-10-S1-S1]; MCHIP, 2012, MCHIP USAID HOST 1 L; McMaster P, 2000, TROP DOCT, V30, P136, DOI 10.1177/004947550003000307; Muddu GK, 2013, INDIAN J PEDIAT; Nguah SB, 2011, BMC PREGNANCY CHILDB, V11, DOI 10.1186/1471-2393-11-99; Nyqvist K H, 1994, J Hum Lact, V10, P237, DOI 10.1177/089033449401000418; Nyqvist KH, 2008, J HUM LACT, V24, P252, DOI 10.1177/0890334408319156; Parmar VR, 2009, INDIAN J PEDIATR, V76, P25, DOI 10.1007/s12098-009-0024-2; Quasem Iftekhar, 2003, J Perinatol, V23, P646, DOI 10.1038/sj.jp.7210999; Rojas MA, 2003, J DEV BEHAV PEDIATR, V24, P163, DOI 10.1097/00004703-200306000-00006; Roller CG, 2005, JOGNN-J OBST GYN NEO, V34, P210, DOI 10.1177/0884217504273675; Save the Children, 2013, COMMUNICATION    AUG; Sivapriya S, 2007, PERINATOLOGY, V9, P219; Sloan NL, 2008, PEDIATRICS, V121, pE1047, DOI 10.1542/peds.2007-0076; Solomons N, 2012, S AFR J CLIN NUTR, V25, P33; Swider SM, 2002, PUBLIC HEALTH NURS, V19, P11, DOI 10.1046/j.1525-1446.2002.19003.x; Tessier R, 1998, PEDIATRICS, V102, DOI 10.1542/peds.102.2.e17; van der Meijden MJ, 2003, J AM MED INFORM ASSN, V10, P235, DOI 10.1197/jamia.M1094; Vesel L, 2013, TROP MED INT HEALTH, V18, P952, DOI 10.1111/tmi.12134; Victor L, 1994, Crit Care Nurs Clin North Am, V6, P891; Waiswa P, 2010, TROP MED INT HEALTH, V15, P1140, DOI 10.1111/j.1365-3156.2010.02603.x; Worku B, 2005, J TROP PEDIATRICS, V51, P93, DOI 10.1093/tropej/fmh085; World Health Organization, 2014, KANG MOTH CAR RED MO; Yoshida S, 2014, DEFINING NEWBO UNPUB	65	117	120	3	30	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 20	2015	10	5							e0125643	10.1371/journal.pone.0125643	http://dx.doi.org/10.1371/journal.pone.0125643			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	CI7CV	25993306	Green Published, Green Submitted, gold			2023-01-03	WOS:000354921400039
J	Wakatsuki, M; Kato, S; Kiyohara, H; Ohno, T; Karasawa, K; Tamaki, T; Ando, K; Tsujii, H; Nakano, T; Kamada, T; Shozu, M				Wakatsuki, Masaru; Kato, Shingo; Kiyohara, Hiroki; Ohno, Tatsuya; Karasawa, Kumiko; Tamaki, Tomoaki; Ando, Ken; Tsujii, Hirohiko; Nakano, Takashi; Kamada, Tadashi; Shozu, Makio		Working Grp Gynecological Tumor	Clinical Trial of Prophylactic Extended-Field Carbon-Ion Radiotherapy for Locally Advanced Uterine Cervical Cancer (Protocol 0508)	PLOS ONE			English	Article							PARAAORTIC LYMPH-NODES; GYNECOLOGIC-ONCOLOGY-GROUP; RADIATION-THERAPY; CISPLATIN CHEMOTHERAPY; INTRACAVITARY BRACHYTHERAPY; CONCURRENT CHEMOTHERAPY; DOSE-ESCALATION; FOLLOW-UP; IRRADIATION; CARCINOMA	To evaluate the efficacy and the toxicity of prophylactic extended-field carbon-ion radiotherapy (C-ion RT, Protocol 0508) for locally advanced squamous cell carcinoma of the uterine cervix in phase I/II clinical trial. Between May 2006 and January 2012, 26 patients of Protocol 0508 were treated with C-ion RT. The numbers of patients with stage IIB, IIIB, and IVA disease were 13, 11, and 2, respectively. Twenty patients had pelvic lymph node metastases. Median tumor size was 6.1 cm (range, 4.0-10.0 cm). The treatment consisted of extended-field irradiation of 39.0 gray equivalents (GyE) in 13 fractions, and additional 15.0 GyE in 5 fractions was given to the gross tumor volume (GTV) and surrounding tissues. With regard to local boost, 18.0 GyE in 2 fractions was given to GTV only. Total dose to the cervical tumor was 72.0 GyE over 20 fractions. The median follow-up period was 37 months. Twenty-one patients had grade 1 or 2 acute gastrointestinal toxicity, but all patients completed the treatment on schedule. There were no grade 3 or higher late complications, with 8 patients having grade 1 or 2 toxicities, 1 had grade 2 gastrointestinal toxicity and 2 had grade 2 genitourinary toxicity. Four patients (15.4%) developed local recurrence, and 8 patients (30.8%) had distant metastases. The 2-year local control rate, progression-free survival rate and overall survival rate were 83.6%, 61.5% and 73.1%, respectively. There were no severe acute or late complications in this trial. Prophylactic extended-field C-ion RT for locally advanced squamous cell carcinoma of the uterine cervix was a safe treatment. Although the number of patients in this study was small, the results support further investigations to confirm the therapeutic efficacy and to avoid or reduce toxicity.	[Wakatsuki, Masaru; Karasawa, Kumiko; Tsujii, Hirohiko; Kamada, Tadashi] Natl Inst Radiol Sci, Res Ctr Charged Particle Therapy, Chiba 260, Japan; [Kato, Shingo; Tamaki, Tomoaki] Saitama Med Univ, Int Med Ctr, Dept Radiat Oncol, Saitama, Japan; [Kiyohara, Hiroki; Nakano, Takashi] Gunma Univ, Grad Sch Med, Dept Radiat Oncol, Maebashi, Gunma, Japan; [Ohno, Tatsuya] Gunma Univ, Grad Sch Med, Heavy Ion Med Ctr, Maebashi, Gunma, Japan; [Ando, Ken] Gunma Prefectural Canc Ctr, Dept Radiat Oncol, Ota, Gunma, Japan; [Shozu, Makio] Chiba Univ, Grad Sch Med, Dept Reprod Med, Chiba, Japan	National Institutes for Quantum Science & Technology; Saitama Medical University; Gunma University; Gunma University; Chiba University	Wakatsuki, M (corresponding author), Natl Inst Radiol Sci, Res Ctr Charged Particle Therapy, Chiba 260, Japan.	masaru.wakatsuki@nifty.com	Tamaki, Tomoaki/AAU-2699-2020		Research Project with Heavy Ions at the National Institute of Radiological Sciences; Japan Society for the Promotion of Science [26861026]; Grants-in-Aid for Scientific Research [24390288] Funding Source: KAKEN	Research Project with Heavy Ions at the National Institute of Radiological Sciences; Japan Society for the Promotion of Science(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	This work was supported by the Research Project with Heavy Ions at the National Institute of Radiological Sciences and Grant-in-Aid for Young Scientists B for Japan Society for the Promotion of Science Grant Number 26861026.	Ando K, 1998, INT J RADIAT BIOL, V74, P129, DOI 10.1080/095530098141799; Beriwal S, 2007, INT J RADIAT ONCOL, V68, P166, DOI 10.1016/j.ijrobp.2006.12.023; BERMAN ML, 1984, GYNECOL ONCOL, V19, P8, DOI 10.1016/0090-8258(84)90151-3; COX JD, 1995, INT J RADIAT ONCOL, V31, P1341, DOI 10.1016/0360-3016(95)00060-C; Eifel PJ, 2004, J CLIN ONCOL, V22, P872, DOI 10.1200/JCO.2004.07.197; Endo M, 1996, J JASTRO, V8, P231, DOI [10.11182/jastro1989.8.231, DOI 10.11182/JASTRO1989.8.231]; Ferrandina G, 2014, INT J RADIAT ONCOL, V90, P778, DOI 10.1016/j.ijrobp.2014.07.033; Gandhi AK, 2013, INT J RADIAT ONCOL, V87, P542, DOI 10.1016/j.ijrobp.2013.06.2059; Gouy S, 2012, LANCET ONCOL, V13, pE212, DOI 10.1016/S1470-2045(12)70011-6; Grigsby PW, 2001, INT J RADIAT ONCOL, V51, P982, DOI 10.1016/S0360-3016(01)01723-0; HAIE C, 1988, RADIOTHER ONCOL, V11, P101, DOI 10.1016/0167-8140(88)90245-9; Kanai T, 1997, RADIAT RES, V147, P78, DOI 10.2307/3579446; Kanai T, 1999, INT J RADIAT ONCOL, V44, P201, DOI 10.1016/S0360-3016(98)00544-6; Kato S, 2006, INT J RADIAT ONCOL, V65, P388, DOI 10.1016/j.ijrobp.2005.12.050; Nakano T, 1999, CANCER J SCI AM, V5, P362; NELSON JH, 1977, AM J OBSTET GYNECOL, V128, P336, DOI 10.1016/0002-9378(77)90633-0; Parker K, 2009, INT J RADIAT ONCOL, V74, P140, DOI 10.1016/j.ijrobp.2008.06.1920; Pearcey R, 2002, J CLIN ONCOL, V20, P966, DOI 10.1200/JCO.20.4.966; Poorvu PD, 2013, INT J RADIAT ONCOL, V85, P1262, DOI 10.1016/j.ijrobp.2012.10.004; ROTMAN M, 1995, JAMA-J AM MED ASSOC, V274, P387, DOI 10.1001/jama.274.5.387; Small W, 2007, INT J RADIAT ONCOL, V68, P1081, DOI 10.1016/j.ijrobp.2007.01.026; Toita T, 2012, GYNECOL ONCOL, V126, P211, DOI 10.1016/j.ygyno.2012.04.036; Tsujii H, 2012, JPN J CLIN ONCOL, V42, P670, DOI 10.1093/jjco/hys104; Varia MA, 1998, INT J RADIAT ONCOL, V42, P1015, DOI 10.1016/S0360-3016(98)00267-3; Wakatsuki M, 2015, J RADIAT RES, V56, P523, DOI 10.1093/jrr/rru117; Wakatsuki M, 2014, CANCER-AM CANCER SOC, V120, P1663, DOI 10.1002/cncr.28621; Wakatsuki M, 2014, GYNECOL ONCOL, V132, P87, DOI 10.1016/j.ygyno.2013.10.021	27	14	15	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 20	2015	10	5							e0127587	10.1371/journal.pone.0127587	http://dx.doi.org/10.1371/journal.pone.0127587			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CI7CV	25993047	Green Submitted, gold, Green Published			2023-01-03	WOS:000354921400126
J	Kuo, B; Bhasin, M; Jacquart, J; Scult, MA; Slipp, L; Riklin, EIK; Lepoutre, V; Comosa, N; Norton, BA; Dassatti, A; Rosenblum, J; Thurler, AH; Surjanhata, BC; Hasheminejad, NN; Kagan, L; Slawsby, E; Rao, SR; Macklin, EA; Fricchione, GL; Benson, H; Libermann, TA; Korzenik, J; Denninger, JW				Kuo, Braden; Bhasin, Manoj; Jacquart, Jolene; Scult, Matthew A.; Slipp, Lauren; Riklin, Eric Isaac Kagan; Lepoutre, Veronique; Comosa, Nicole; Norton, Beth-Ann; Dassatti, Allison; Rosenblum, Jessica; Thurler, Andrea H.; Surjanhata, Brian C.; Hasheminejad, Nicole N.; Kagan, Leslee; Slawsby, Ellen; Rao, Sowmya R.; Macklin, Eric A.; Fricchione, Gregory L.; Benson, Herbert; Libermann, Towia A.; Korzenik, Joshua; Denninger, John W.			Genomic and Clinical Effects Associated with a Relaxation Response Mind-Body Intervention in Patients with Irritable Bowel Syndrome and Inflammatory Bowel Disease	PLOS ONE			English	Article							QUALITY-OF-LIFE; FOLLOW-UP; CONTROLLED-TRIAL; BEHAVIORAL TREATMENT; STRESS-MANAGEMENT; OXIDATIVE STRESS; CROHNS-DISEASE; T-CELLS; EXPRESSION; THERAPY	Introduction Irritable Bowel Syndrome (IBS) and Inflammatory Bowel Disease (IBD) can profoundly affect quality of life and are influenced by stress and resiliency. The impact of mind-body interventions (MBIs) on IBS and IBD patients has not previously been examined. Methods Nineteen IBS and 29 IBD patients were enrolled in a 9-week relaxation response based mind-body group intervention (RR-MBI), focusing on elicitation of the RR and cognitive skill building. Symptom questionnaires and inflammatory markers were assessed pre- and post-intervention, and at short-term follow-up. Peripheral blood transcriptome analysis was performed to identify genomic correlates of the RR-MBI. Results Pain Catastrophizing Scale scores improved significantly post-intervention for IBD and at short-term follow-up for IBS and IBD. Trait Anxiety scores, IBS Quality of Life, IBS Symptom Severity Index, and IBD Questionnaire scores improved significantly post-intervention and at short-term follow-up for IBS and IBD, respectively. RR-MBI altered expression of more genes in IBD (1059 genes) than in IBS (119 genes). In IBD, reduced expression of RR-MBI response genes was most significantly linked to inflammatory response, cell growth, proliferation, and oxidative stress-related pathways. In IBS, cell cycle regulation and DNA damage related gene sets were significantly upregulated after RR-MBI. Interactive network analysis of RR-affected pathways identified TNF, AKT and NF-kappa B as top focus molecules in IBS, while in IBD kinases (e.g. MAPK, P38 MAPK), inflammation (e.g. VEGF-C, NF-kappa B) and cell cycle and proliferation (e.g. UBC, APP) related genes emerged as top focus molecules. Conclusions In this uncontrolled pilot study, participation in an RR-MBI was associated with improvements in disease-specific measures, trait anxiety, and pain catastrophizing in IBS and IBD patients. Moreover, observed gene expression changes suggest that NF-kappa B is a target focus molecule in both IBS and IBD- and that its regulation may contribute to counteracting the harmful effects of stress in both diseases. Larger, controlled studies are needed to confirm this preliminary finding.	[Kuo, Braden; Comosa, Nicole; Norton, Beth-Ann; Dassatti, Allison; Rosenblum, Jessica; Thurler, Andrea H.; Surjanhata, Brian C.; Korzenik, Joshua] Massachusetts Gen Hosp, Gastrointestinal Unit, Boston, MA 02114 USA; [Bhasin, Manoj; Libermann, Towia A.] Beth Israel Deaconess Med Ctr, Dept Med, Div Interdisciplinary Med & Biotechnol, Boston, MA 02215 USA; [Bhasin, Manoj; Libermann, Towia A.] Beth Israel Deaconess Med Ctr, Dept Med, Genom Prote Bioinformat & Syst Biol Ctr, Boston, MA 02215 USA; [Bhasin, Manoj; Jacquart, Jolene; Scult, Matthew A.; Slipp, Lauren; Riklin, Eric Isaac Kagan; Hasheminejad, Nicole N.; Kagan, Leslee; Slawsby, Ellen; Fricchione, Gregory L.; Benson, Herbert; Libermann, Towia A.; Denninger, John W.] Massachusetts Gen Hosp, Benson Henry Inst Mind Body Med, Boston, MA 02114 USA; [Lepoutre, Veronique; Benson, Herbert; Korzenik, Joshua] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA; [Fricchione, Gregory L.; Denninger, John W.] Massachusetts Gen Hosp, Psychiat, Boston, MA 02114 USA; [Macklin, Eric A.] Harvard Univ, Sch Med, Boston, MA USA; [Rao, Sowmya R.] Univ Massachusetts, Sch Med, Dept Quantitat Hlth Sci, Worcester, MA USA; [Rao, Sowmya R.] Bedford VA Med Ctr, Ctr Healthcare Org & Implementat Res, Bedford, MA USA	Harvard University; Massachusetts General Hospital; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; University of Massachusetts System; University of Massachusetts Worcester	Denninger, JW (corresponding author), Massachusetts Gen Hosp, Benson Henry Inst Mind Body Med, Boston, MA 02114 USA.	jdenninger@mgh.harvard.edu	Macklin, Eric A/E-2955-2013	Macklin, Eric A/0000-0003-1618-3502; Scult, Matthew/0000-0001-5554-8186; Bhasin, Manoj/0000-0001-5172-420X; Libermann, Towia/0000-0002-4006-8179	Center for Disease Control and Prevention [R01DP000339]; International Foundation for Functional Gastrointestinal Diseases (Neuroenteric Research Program Grant); NATIONAL CENTER FOR CHRONIC DISEASE PREV AND HEALTH PROMO [R01DP000339] Funding Source: NIH RePORTER	Center for Disease Control and Prevention; International Foundation for Functional Gastrointestinal Diseases (Neuroenteric Research Program Grant); NATIONAL CENTER FOR CHRONIC DISEASE PREV AND HEALTH PROMO(United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA)	This study was supported by the Center for Disease Control and Prevention (Grant R01DP000339) and the International Foundation for Functional Gastrointestinal Diseases (Neuroenteric Research Program Grant). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Almenier Hazem A, 2012, Front Biosci (Elite Ed), V4, P1335; Ananthakrishnan AN, 2013, CLIN GASTROENTEROL H, V11, P57, DOI 10.1016/j.cgh.2012.08.032; Antoni MH, 2012, BIOL PSYCHIAT, V71, P366, DOI 10.1016/j.biopsych.2011.10.007; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Bhasin MK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062817; BLANCHARD EB, 1988, BEHAV THER, V19, P67, DOI 10.1016/S0005-7894(88)80056-X; Blanchard EB, 2007, BEHAV RES THER, V45, P633, DOI 10.1016/j.brat.2006.07.003; Broom OJ, 2009, CLIN EXP IMMUNOL, V158, P272, DOI 10.1111/j.1365-2249.2009.04033.x; Cannon W. B., 1932, THE WISDOM OF THE BO; Casey A, 2009, J CARDIOPULM REHABIL, V29, P230, DOI 10.1097/HCR.0b013e3181a33352; Cleeland C., 2009, THE BRIEF PAIN INVEN; Creswell JD, 2012, BRAIN BEHAV IMMUN, V26, P1095, DOI 10.1016/j.bbi.2012.07.006; Drossman DA, 2006, GASTROENTEROLOGY, V130, P1377, DOI 10.1053/j.gastro.2006.03.008; Dusek JA, 2008, J ALTERN COMPLEM MED, V14, P129, DOI 10.1089/acm.2007.0623; Dusek Jeffery A, 2009, Minn Med, V92, P47; Dusek JA, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002576; Elsenbruch S, 2005, PSYCHOTHER PSYCHOSOM, V74, P277, DOI 10.1159/000086318; Feng XM, 2010, BLOOD, V115, P510, DOI 10.1182/blood-2009-07-232694; Flik CE, 2013, BMC GASTROENTEROL, V11, DOI 10.1186/1471-230X-11-137; Francis CY, 1997, ALIMENT PHARM THERAP, V11, P395, DOI 10.1046/j.1365-2036.1997.142318000.x; Fukuhara S, 2005, MOL CELL BIOL, V25, P136, DOI 10.1128/MCB.25.1.136-146.2005; GUTHRIE E, 1991, GASTROENTEROLOGY, V100, P450, DOI 10.1016/0016-5085(91)90215-7; GUYATT G, 1989, GASTROENTEROLOGY, V96, P804, DOI 10.1016/0016-5085(89)90905-0; Han XN, 2006, AM J PATHOL, V169, P1999, DOI 10.2353/ajpath.2006.060186; Huang DW, 2007, NUCLEIC ACIDS RES, V35, pW169, DOI 10.1093/nar/gkm415; Husebye H, 2010, IMMUNITY, V33, P583, DOI 10.1016/j.immuni.2010.09.010; Irizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249; Johnson WE, 2007, BIOSTATISTICS, V8, P118, DOI 10.1093/biostatistics/kxj037; Karp SM, 2006, DM-DIS MON, V52, P199, DOI 10.1016/j.disamonth.2006.05.005; Kearney DJ, 2008, NAT CLIN PRACT GASTR, V5, P624, DOI 10.1038/ncpgasthep1257; Keefer L, 2002, BEHAV RES THER, V40, P541, DOI 10.1016/S0005-7967(01)00065-1; Kohane IS, 2012, BIOINFORMATICS, V28, P538, DOI 10.1093/bioinformatics/btr713; Kokkotou E, 2010, NEUROGASTROENT MOTIL, V22, DOI 10.1111/j.1365-2982.2009.01440.x; Kruidenier L, 2003, J PATHOL, V201, P28, DOI 10.1002/path.1409; Labus J, 2013, ALIMENT PHARM THER, V37, P304, DOI 10.1111/apt.12171; Lackner JM, 2007, GASTROENTEROLOGY, V133, P433, DOI 10.1053/j.gastro.2007.05.014; Lackner JM, 2012, CONTEMP CLIN TRIALS, V33, P1293, DOI 10.1016/j.cct.2012.07.013; Litvak V, 2012, NATURE, V490, P421, DOI 10.1038/nature11428; Lowen MBO, 2013, ALIMENT PHARM THER, V37, P1184, DOI 10.1111/apt.12319; Mahvi-Shirazi M, 2012, ARCH MED SCI, V8, P123, DOI 10.5114/aoms.2012.27292; McGuckin MA, 2010, AM J PHYSIOL-GASTR L, V298, pG820, DOI 10.1152/ajpgi.00063.2010; Merico D, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013984; Mittermaier C, 2004, PSYCHOSOM MED, V66, P79, DOI 10.1097/01.PSY.0000106907.24881.F2; Mizrahi MC, 2012, PSYCHOL HEALTH, V27, P1463, DOI 10.1080/08870446.2012.691169; Morgan XC, 2012, GENOME BIOL, V13, DOI 10.1186/gb-2012-13-9-r79; Moser G, 2013, AM J GASTROENTEROL, V108, P602, DOI 10.1038/ajg.2013.19; NEFF DF, 1987, BEHAV THER, V18, P70, DOI 10.1016/S0005-7894(87)80052-7; Patrick DL, 1998, DIGEST DIS SCI, V43, P400, DOI 10.1023/A:1018831127942; Rezaie A, 2007, DIGEST DIS SCI, V52, P2015, DOI 10.1007/s10620-006-9622-2; Rollins B, 2010, AM J MED GENET B, V153B, P919, DOI 10.1002/ajmg.b.31062; Samuelson M, 2010, J ALTERN COMPLEM MED, V16, P187, DOI 10.1089/acm.2009.0142; SCHWARZ SP, 1986, BIOFEEDBACK SELF-REG, V11, P189, DOI 10.1007/BF01003478; SCHWARZ SP, 1990, BEHAV RES THER, V28, P331, DOI 10.1016/0005-7967(90)90085-W; Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303; Song MS, 2013, AM J PATHOL, V182, P1308, DOI 10.1016/j.ajpath.2012.12.022; Spielberger C.D, 1983, PSYCTESTS DATASET, DOI DOI 10.1037/T06496; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Sullivan MJL, 1995, PSYCHOL ASSESSMENT, V7, P524, DOI 10.1037/1040-3590.7.4.524; Timmer A, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006913.pub2; Vogtenhuber C, 2010, BLOOD, V116, P466, DOI 10.1182/blood-2009-11-252825; Woelk CH, 2011, INT REV NEUROBIOL, V101, P41, DOI 10.1016/B978-0-12-387718-5.00003-1; Zijdenbos IL, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006442.pub2	62	49	51	0	18	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 30	2015	10	4							e0123861	10.1371/journal.pone.0123861	http://dx.doi.org/10.1371/journal.pone.0123861			26	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CH0MA	25927528	Green Submitted, Green Published, gold			2023-01-03	WOS:000353713100024
J	Lu, NN; Jin, J; Wang, SL; Wang, WH; Song, YW; Liu, YP; Ren, H; Fang, H; Liu, XF; Yu, ZH; Li, YX				Lu, Ning-Ning; Jin, Jing; Wang, Shu-Lian; Wang, Wei-Hu; Song, Yong-Wen; Liu, Yue-Ping; Ren, Hua; Fang, Hui; Liu, Xin-Fan; Yu, Zi-Hao; Li, Ye-Xiong			Postoperative Capecitabine with Concurrent Intensity-Modulated Radiotherapy or Three-Dimensional Conformal Radiotherapy for Patients with Stage II and III Rectal Cancer	PLOS ONE			English	Article							METASTATIC COLORECTAL-CANCER; TOTAL MESORECTAL EXCISION; FLUOROURACIL PLUS LEUCOVORIN; SURGICAL ADJUVANT BREAST; PREOPERATIVE RADIOTHERAPY; PHASE-III; INTRAVENOUS FLUOROURACIL; RADIATION-THERAPY; ORAL CAPECITABINE; FINAL REPORT	Background The aim of this study was to evaluate the survival outcomes and toxicity of postoperative chemoradiotherapy with capecitabine and concurrent intensity-modulated radiotherapy (IMRT) or three-dimensional conformal radiotherapy (3D-CRT) in patients with stage II and III rectal cancer. Patients We recruited 184 patients with pathologically proven, stage II or III rectal cancer. Following total mesorectal excision (TME), the patients were treated with capecitabine and concurrent IMRT/3D-CRT. The treatment regimen consisted of two cycles of oral capecitabine (1600 mg/m(2)/day), administered twice daily from day 1-14 of radiotherapy, followed by a 7-day rest. The median pelvic dose was 50 Gy in 25 fractions. Oxaliplatin-based adjuvant chemotherapy was administered after the chemoradiotherapy. Results The 5-year overall survival, disease-free survival and locoregional control (LRC) rates were 85.1%, 80% and 95.4%, respectively. Grade 3 and 4 toxicities were observed in 28.3% of patients during treatment. Grade 3 or 4 late toxicity, including neurotoxicity or gastrointestinal toxicity, was only observed in nine patients (4.9%). Conclusions This study demonstrated that capecitabine chemotherapy with concurrent IMRT/3D-CRT following TME is safe, is well tolerated and achieves superior LRC and favorable survival rates, with acceptable toxicity.	[Jin, Jing] CAMS, Canc Hosp, Natl Canc Ctr, Dept Radiat Oncol, Beijing 100021, Peoples R China; PUMC, Beijing 100021, Peoples R China	Chinese Academy of Medical Sciences - Peking Union Medical College; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College	Jin, J (corresponding author), CAMS, Canc Hosp, Natl Canc Ctr, Dept Radiat Oncol, Beijing 100021, Peoples R China.	jingjin1025@163.com; yexiong12@163.com	li, ye/GWN-2672-2022		Ministry of Health of the People's Republic of China [07090010, WKJ2005-3-006(21)]; National Natural Science Foundation of China [81402524]; Beijing Hope Run Special Fund [LC2007A17]	Ministry of Health of the People's Republic of China; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Beijing Hope Run Special Fund	This study was funded from the Ministry of Health of the People's Republic of China Grant [07090010, WKJ2005-3-006(21)], and Dr. YXL received the funding; National Natural Science Foundation of China [81402524] which was received by Dr. NNL; and Beijing Hope Run Special Fund [LC2007A17] which was received by Dr. JJ. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 1985, NEW ENGL J MED, V312, P1465; Arbea L, 2010, RADIAT ONCOL, V5, DOI 10.1186/1748-717X-5-17; Cassidy J, 2002, ANN ONCOL, V13, P566, DOI 10.1093/annonc/mdf089; Cheng L, 2011, AM J CLIN ONCOL-CANC, V34, P573, DOI DOI 10.1097/C0C.0B013E3181FE41ED; Das P, 2006, INT J RADIAT ONCOL, V66, P1378, DOI 10.1016/j.ijrobp.2006.07.1374; [邓垒 DENG Lei], 2008, [中华放射肿瘤学杂志, Chinese Journal of Radiation Oncology], V17, P450; Diaz-Rubio E, 2007, J CLIN ONCOL, V25, P4224, DOI 10.1200/JCO.2006.09.8467; Dunst J, 2002, J CLIN ONCOL, V20, P3983, DOI 10.1200/JCO.2002.02.049; Duthoy W, 2004, INT J RADIAT ONCOL, V60, P794, DOI 10.1016/j.ijrobp.2004.04.016; FISHER B, 1988, JNCI-J NATL CANCER I, V80, P21, DOI 10.1093/jnci/80.1.21; Havenga K, 1999, EUR J SURG ONCOL, V25, P368, DOI 10.1053/ejso.1999.0659; Hoff PM, 2001, J CLIN ONCOL, V19, P2282, DOI 10.1200/JCO.2001.19.8.2282; Hofheinz RD, 2012, LANCET ONCOL, V13, DOI 10.1016/S1470-2045(12)70116-X; Jin J, 2006, INT J RADIAT ONCOL, V64, P725, DOI 10.1016/j.ijrobp.2005.08.017; Kapiteijn E, 2001, NEW ENGL J MED, V345, P638, DOI 10.1056/NEJMoa010580; Kim DY, 2007, INT J RADIAT ONCOL, V67, P378, DOI 10.1016/j.ijrobp.2006.08.063; KROOK JE, 1991, NEW ENGL J MED, V324, P709, DOI 10.1056/NEJM199103143241101; Lembersky BC, 2006, J CLIN ONCOL, V24, P2059, DOI 10.1200/JCO.2005.04.7498; OCONNELL M, 1994, NEW ENGL J MED, V331, P502, DOI 10.1056/NEJM199408253310803; Pacelli F, 2004, DIS COLON RECTUM, V47, P170, DOI 10.1007/s10350-003-0028-3; Parekh Arti, 2013, Gastrointest Cancer Res, V6, P137; Park JH, 2011, CANCER-AM CANCER SOC, V117, P3703, DOI 10.1002/cncr.25943; Porschen R, 2007, J CLIN ONCOL, V25, P4217, DOI 10.1200/JCO.2006.09.2684; Qian LT, 2003, CHIN J RAD ONCOL, V11, P101; Ridgway Paul F, 2003, Cancer Control, V10, P205; Roels S, 2006, INT J RADIAT ONCOL, V65, P1129, DOI 10.1016/j.ijrobp.2006.02.050; Roh MS, 2009, J CLIN ONCOL, V27, P5124, DOI 10.1200/JCO.2009.22.0467; Samuelian JM, 2012, INT J RADIAT ONCOL, V82, P1981, DOI 10.1016/j.ijrobp.2011.01.051; Sauer R, 2004, NEW ENGL J MED, V351, P1731, DOI 10.1056/NEJMoa040694; Sebag-Montefiore D, 2009, LANCET, V373, P811, DOI 10.1016/S0140-6736(09)60484-0; Souglakos J, 2003, INT J RADIAT ONCOL, V56, P1284, DOI 10.1016/S0360-3016(03)00275-X; Tepper JE, 2002, J CLIN ONCOL, V20, P1744, DOI 10.1200/JCO.2002.07.132; Twelves C, 2005, NEW ENGL J MED, V352, P2696, DOI 10.1056/NEJMoa043116; Urbano MTG, 2006, INT J RADIAT ONCOL, V65, P907, DOI 10.1016/j.ijrobp.2005.12.056; Van Cutsem E, 2001, J CLIN ONCOL, V19, P4097, DOI 10.1200/JCO.2001.19.21.4097; van Gijn W, 2011, LANCET ONCOL, V12, P575, DOI 10.1016/S1470-2045(11)70097-3; Wolmark N, 2000, JNCI-J NATL CANCER I, V92, P388, DOI 10.1093/jnci/92.5.388	37	14	14	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 27	2015	10	4							e0124601	10.1371/journal.pone.0124601	http://dx.doi.org/10.1371/journal.pone.0124601			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CG9SB	25915948	gold, Green Published, Green Submitted			2023-01-03	WOS:000353659100055
J	Stolz, E; Burkert, N; Grossschadl, F; Rasky, E; Stronegger, WJ; Freidl, W				Stolz, Erwin; Burkert, Nathalie; Grossschaedl, Franziska; Rasky, Eva; Stronegger, Willibald J.; Freidl, Wolfgang			Determinants of Public Attitudes towards Euthanasia in Adults and Physician-Assisted Death in Neonates in Austria: A National Survey	PLOS ONE			English	Article							EUROPEAN COUNTRIES; SUICIDE; ACCEPTANCE; TRENDS; END; AUTHORITARIANISM; INDIVIDUALISM; NETHERLANDS; CARE	Background Euthanasia remains a controversial topic in both public discourses and legislation. Although some determinants of acceptance of euthanasia and physician-assisted death have been identified in previous studies, there is still a shortage of information whether different forms of euthanasia are supported by the same or different sub-populations and whether authoritarian personality dispositions are linked to attitudes towards euthanasia. Methods A large, representative face-to-face survey was conducted in Austria in 2014 (n = 1,971). Respondents faced three scenarios of euthanasia and one of physician assisted death differing regarding the level of specificity, voluntariness and subject, requiring either approval or rejection: (1) abstract description of euthanasia, (2) abstract description of physician-assisted suicide, (3) the case of euthanasia of a terminally-ill 79-year old cancer patient, and (4) the case of non-voluntary, physician assisted death of a severely disabled or ill neonate. A number of potential determinants for rejection ordered in three categories (socio-demographic, personal experience, orientations) including authoritarianism were tested via multiple logistic regression analyses. Results Rejection was highest in the case of the neonate (69%) and lowest for the case of the older cancer patient (35%). A consistent negative impact of religiosity on the acceptance across all scenarios and differential effects for socio-economic status, area of residence, religious confession, liberalism, and authoritarianism were found. Individuals with a stronger authoritarian personality disposition were more likely to reject physician-assisted suicide for adults but at the same time also more likely to approve of physician-assisted death of a disabled neonate. Conclusion Euthanasia in adults was supported by a partially different sub-population than assisted death of disabled neonates.	[Stolz, Erwin; Burkert, Nathalie; Grossschaedl, Franziska; Rasky, Eva; Stronegger, Willibald J.; Freidl, Wolfgang] Med Univ Graz, Inst Social Med & Epidemiol, Graz, Austria	Medical University of Graz	Freidl, W (corresponding author), Med Univ Graz, Inst Social Med & Epidemiol, Graz, Austria.	wolfgang.freidl@medunigraz.at	Stronegger, Willibald J./C-2425-2018	Stronegger, Willibald J./0000-0003-3496-1208; Stolz, Erwin/0000-0001-7393-1568; Grossschadl, Franziska/0000-0002-6726-0443				Adorno Theodor W., 1995, STUDIEN ZUM AUTORITA; Boehnke K, 2004, ENCY APPL PSYCHOL, V1, P251; Buiting HM, 2012, J MED ETHICS, V38, P267, DOI 10.1136/medethics-2011-100066; Burkhardt S, 2006, MED SCI LAW, V46, P287, DOI 10.1258/rsmmsl.46.4.287; Chambaere K, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-1055; Cohen J, 2006, EUR J PUBLIC HEALTH, V16, P663, DOI 10.1093/eurpub/ckl042; Cohen J, 2006, SOC SCI MED, V63, P743, DOI 10.1016/j.socscimed.2006.01.026; Cohen J, 2013, EUR J PUBLIC HEALTH, V23, P378, DOI 10.1093/eurpub/cks186; Czech Herwig, 2014, HUMAN SUBJECTS RES H, P109; Duncan OD, 2006, J MED ETHICS, V32, P266, DOI 10.1136/jme.2004.011072; Freidl W, 2000, LANCET, V356, P1994, DOI 10.1016/S0140-6736(05)72973-1; Freidl W, 2006, INT J MENT HEALTH, V35, P30, DOI 10.2753/IMH0020-7411350303; Frileux S, 2003, J MED ETHICS, V29, P330, DOI 10.1136/jme.29.6.330; Grassi L, 1999, J PAIN SYMPTOM MANAG, V17, P188, DOI 10.1016/S0885-3924(98)00155-9; Hagelin J, 2004, J MED ETHICS, V30, P521, DOI 10.1136/jme.2002.002543; Hudson L, 2009, J PAEDIATR CHILD H, V8, P508; Inghelbrecht E, 2009, INT J NURS STUD, V46, P1209, DOI 10.1016/j.ijnurstu.2009.02.009; Institut fur empirische Sozialforschung GmbH (IFES), 2014, STUD ZUM THEM LEB; Jaspers E, 2007, INT J PUBLIC OPIN R, V19, P451, DOI 10.1093/ijpor/edm029; Kemmelmeier M, 1999, J APPL SOC PSYCHOL, V29, P2613, DOI 10.1111/j.1559-1816.1999.tb00128.x; Kemmelmeier M, 2002, J APPL SOC PSYCHOL, V32, P60, DOI 10.1111/j.1559-1816.2002.tb01420.x; Lotto L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031735; MacDonald WL, 1998, SOC SCI MED, V46, P73, DOI 10.1016/S0277-9536(97)00146-9; Moulton BW, 2004, J LAW MED ETHICS, V32, P2, DOI 10.1111/j.1748-720X.2004.tb00172.x; O'Neill C, 2003, SOC SCI MED, V57, P721, DOI 10.1016/S0277-9536(02)00421-5; Oesterreich D, 2005, POLIT PSYCHOL, V26, P275, DOI 10.1111/j.1467-9221.2005.00418.x; Peretti-Watel P, 2003, BRIT MED J, V327, P595, DOI 10.1136/bmj.327.7415.595; Rietjens JAC, 2005, SOC SCI MED, V61, P1723, DOI 10.1016/j.socscimed.2005.03.024; Ryynanen OP, 2002, PUBLIC HEALTH, V116, P322, DOI 10.1038/sj.ph.1900875; Seale C, 2009, PALLIATIVE MED, V23, P205, DOI 10.1177/0269216308102041; SINGER PA, 1995, SOC SCI MED, V41, P1517, DOI 10.1016/0277-9536(95)00057-E; Stack S, 1996, OMEGA-J DEATH DYING, V34, P71; Stack S, 2011, J SCI STUD RELIG, V50, P289, DOI 10.1111/j.1468-5906.2011.01568.x; Steck N, 2013, MED CARE, V51, P938, DOI 10.1097/MLR.0b013e3182a0f427; Stronegger WJ, 2013, BMC MED ETHICS, V14, DOI 10.1186/1472-6939-14-26; SuarezAlmazor ME, 1997, J CLIN ONCOL, V15, P418, DOI 10.1200/JCO.1997.15.2.418; Teisseyre N, 2005, SOC SCI MED, V60, P357, DOI 10.1016/j.socscimed.2004.05.016; Teisseyre N, 2010, MONASH BIOETH REV, V14, P1; Televantos A, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-878; Verbakel E, 2010, PUBLIC OPIN QUART, V74, P109, DOI 10.1093/poq/nfp074; Verhagen E, 2005, NEW ENGL J MED, V352, P959, DOI 10.1056/NEJMp058026; Watzka C, 2008, VEREIN SOZIALGESCHIC, P147; 2008, MOSBYS MED DICT	43	13	13	1	20	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 23	2015	10	4							e0124320	10.1371/journal.pone.0124320	http://dx.doi.org/10.1371/journal.pone.0124320			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	CG5KZ	25906265	Green Published, gold, Green Submitted			2023-01-03	WOS:000353332000065
J	van Gurp, J; van Selm, M; Vissers, K; van Leeuwen, E; Hasselaar, J				van Gurp, Jelle; van Selm, Martine; Vissers, Kris; van Leeuwen, Evert; Hasselaar, Jeroen			How Outpatient Palliative Care Teleconsultation Facilitates Empathic Patient-Professional Relationships: A Qualitative Study	PLOS ONE			English	Article							CANCER-PATIENTS; MEDICALISATION; COMMUNICATION	Objective The problems and needs of advanced cancer patients and proxies normally increase as the disease progresses. Home-based advanced cancer patients and their proxies benefit from collaborations between primary care physicians and hospital-based palliative care specialists when confronted with complex problems in the last phase of life. Telemedicine might facilitate direct, patient-centered communication between patients and proxies, primary care physicians, and specialist palliative care teams (SPCTs). This study focuses on the impact of teleconsultation technologies on the relationships between home-based palliative care patients and hospital-based palliative care specialists. Methods This work consists of a qualitative study among patients, family members, and caregivers that utilizes long-term direct observations, semi-structured interviews, and open interviews following the observations. Results The analysis of the empirical data resulted in three key concepts that describe the impact of teleconsultation on the patient-professional relationship in palliative homecare: transcending the institutional walls of home and hospital; transparency of teleconsultation technology; and technologized, intimate patient-professional relationships. Teleconsultation offers (1) condensed encounters between home-based palliative care patients and distant professionals, (2) a unique insight into the patients' daily lives for palliative care specialists, and (3) long-term interaction that results in trustful relationships and experiences of intimacy and relief. Conclusions Teleconsultation fits the practice of home-based palliative care. Teleconsultation can, if well applied, facilitate computer-mediated but empathic patient-palliative care specialist relationships, which enable professional care attuned to the patient's context as well as patient involvement. This article proposes a teleconsultation implementation guide for optimal use of teleconsultation in daily palliative care practice.	[van Gurp, Jelle; Vissers, Kris; Hasselaar, Jeroen] Radboud Univ Nijmegen, Med Ctr, Dept Anesthesiol Pain & Palliat Med, NL-6525 ED Nijmegen, Netherlands; [van Selm, Martine] Univ Amsterdam, Amsterdam Sch Commun Res, Amsterdam, Netherlands; [van Leeuwen, Evert] Radboud Univ Nijmegen, Med Ctr, Dept IQ Healthcare Ethics Sect, NL-6525 ED Nijmegen, Netherlands	Radboud University Nijmegen; University of Amsterdam; Radboud University Nijmegen	van Gurp, J (corresponding author), Radboud Univ Nijmegen, Med Ctr, Dept Anesthesiol Pain & Palliat Med, NL-6525 ED Nijmegen, Netherlands.	Jelle.vanGurp@radboudumc.nl	Leeuwen, E./H-8068-2014; Hasselaar, Jeroen/C-9446-2011; Vissers, Kris C.P./D-3569-2009; van Gurp, Jelle/P-6169-2015; van Selm, Martine/AAY-3721-2021; Vissers, Kris/H-8110-2014; van Gurp, Jelle/AAW-9371-2021	Leeuwen, E./0000-0001-6356-3917; Vissers, Kris C.P./0000-0002-2919-6356; van Gurp, Jelle/0000-0002-9904-2571; van Selm, Martine/0000-0001-9188-4021; Vissers, Kris/0000-0002-2919-6356; van Gurp, Jelle/0000-0002-9904-2571	Netherlands Organisation for Scientific Research (NWO) [313-99-120]	Netherlands Organisation for Scientific Research (NWO)(Netherlands Organization for Scientific Research (NWO))	This work was supported by Netherlands Organisation for Scientific Research (NWO). File number 313-99-120. URL: http://www.nwo.nl/en. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abarshi E, 2011, J PAIN SYMPTOM MANAG, V41, P436, DOI 10.1016/j.jpainsymman.2010.04.016; Bruera E, 2012, ONCOLOGIST, V17, P267, DOI 10.1634/theoncologist.2011-0219; Charmaz Kathy., 2009, CONSTRUCTING GROUNDE; Clark D, 2002, BRIT MED J, V324, P905, DOI 10.1136/bmj.324.7342.905; COLLIS E, 2013, BMJ-BRIT MED J, V347, P23993, DOI DOI 10.1136/BMJ.F4085; Corbin J.M., 2008, BASICS QUALITATIVE R, Vthird, DOI DOI 10.4135/9781452230153.N8; Demiris George, 2006, Nurs Adm Q, V30, P56; Downie, 2006, PHILOS PALLIATIVE CA; Esterle L, 2013, INT J MED INFORM, V82, P684, DOI 10.1016/j.ijmedinf.2013.04.006; Floriani CA, 2012, PALLIAT SUPPORT CARE, V10, P295, DOI 10.1017/S1478951511001039; Frank AW, 2001, QUAL HEALTH RES, V11, P353, DOI 10.1177/104973201129119154; GOLDCOPD.org, GLOB STRAT DIAGN MAN; GUBA EG, 1981, ECTJ-EDUC COMMUN TEC, V29, P75; Gysels Marjolein, 2008, BMC Med Ethics, V9, P7, DOI 10.1186/1472-6939-9-7; Ihde D, 1979, TECHNIQUES PRAXIS PH; Karnofsky DA, 1949, CLIN EVALUATION CHEM, P191; KENDALL M, 2009, BMJ-BRIT MED J, V339, DOI DOI 10.1136/BMJ.B4122; Kendall M, 2006, FAM PRACT, V23, P644, DOI 10.1093/fampra/cml035; Kidd L, 2010, J TELEMED TELECARE, V16, P394, DOI 10.1258/jtt.2010.091108; Kroenke K, 2010, JAMA-J AM MED ASSOC, V304, P163, DOI 10.1001/jama.2010.944; Lopez D, 2009, SOCIOL REV, V56, P181, DOI 10.1111/j.1467-954X.2009.00822.x; Matusitz J, 2007, HEALTH COMMUN, V21, P73, DOI 10.1080/10410230701283439; Mays N, 2000, BMJ-BRIT MED J, V320, P50, DOI 10.1136/bmj.320.7226.50; Murray SA, 2005, BMJ-BRIT MED J, V330, P1007, DOI 10.1136/bmj.330.7498.1007; Murray SA, 2009, BRIT MED J, V339, DOI 10.1136/bmj.b3702; Peterson Mark Allen, 2003, ANTHR MASS COMMUNICA; Pivodic L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0084440; Pols J, 2011, SCI TECHNOL HUM VAL, V36, P451, DOI 10.1177/0162243910366134; Pols Jeannette, 2012, CARE DISTANCE CLOSEN; Quill TE, 2013, NEW ENGL J MED, V368, P1173, DOI 10.1056/NEJMp1215620; Sandman L., 2005, GOOD DEATH VALUE DEA; Seymour JE, 1999, SOC SCI MED, V49, P691, DOI 10.1016/S0277-9536(99)00170-7; Steinhauser AE, 2000, JAMA-J AM MED ASSOC, V284, P2476, DOI 10.1001/jama.284.19.2476; Turkle S., 2012, ALONE TOGETHER WHY W; van Gurp J, 2013, PATIENT EDUC COUNS, V93, P504, DOI 10.1016/j.pec.2013.07.002; van Gurp J, 2013, BMC MED ETHICS, V14, DOI 10.1186/1472-6939-14-12; Watanabe SM, 2013, SUPPORT CARE CANCER, V21, P1201, DOI 10.1007/s00520-012-1649-7; Whitten Pamela, 2004, Am J Hosp Palliat Care, V21, P191, DOI 10.1177/104990910402100307; Worldwide Palliative Care Alliance, GLOB ATL PALL CAR EN	39	38	38	1	22	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 22	2015	10	4							e0124387	10.1371/journal.pone.0124387	http://dx.doi.org/10.1371/journal.pone.0124387			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	CG5KV	25902263	Green Published, Green Submitted, gold			2023-01-03	WOS:000353331500083
J	Hebar, A; Koller, C; Seifert, JM; Chabicovsky, M; Bodenteich, A; Bernkop-Schnurch, A; Grassauer, A; Prieschl-Grassauer, E				Hebar, Alexandra; Koller, Christiane; Seifert, Jan-Marcus; Chabicovsky, Monika; Bodenteich, Angelika; Bernkop-Schnuerch, Andreas; Grassauer, Andreas; Prieschl-Grassauer, Eva			Non-Clinical Safety Evaluation of Intranasal Iota-Carrageenan	PLOS ONE			English	Article							SULFATED POLYSACCHARIDES; ANTIVIRAL ACTIVITY; DENGUE VIRUS; NASAL SPRAY; TNF-ALPHA; COMMON; INDUCTION; EFFICACY; POTENT	Carrageenan has been widely used as food additive for decades and therefore, an extended oral data set is available in the public domain. Less data are available for other routes of administration, especially intranasal administration. The current publication describes the nonclinical safety and toxicity of native (non-degraded) iota-carrageenan when applied intranasally or via inhalation. Intranasally applied iota-carrageenan is a topically applied, locally acting compound with no need of systemic bioavailability for the drug's action. Animal experiments included repeated dose local tolerance and toxicity studies with intranasally applied 0.12% iota-carrageenan for 7 or 28 days in New Zealand White rabbits and nebulized 0.12% iota-carrageenan administered to F344 rats for 7 days. Permeation studies revealed no penetration of iota-carrageenan across nasal mucosa, demonstrating that iota-carrageenan does not reach the blood stream. Consistent with this, no relevant toxic or secondary pharmacological effects due to systemic exposure were observed in the rabbit or rat repeated dose toxicity studies. Data do not provide any evidence for local intolerance or toxicity, when carrageenan is applied intranasally or by inhalation. No signs for immunogenicity or immunotoxicity have been observed in the in vivo studies. This is substantiated by in vitro assays showing no stimulation of a panel of pro-inflammatory cytokines by iota-carrageenan. In conclusion, 0.12% iota-carrageenan is safe for clinical use via intranasal application.	[Hebar, Alexandra; Chabicovsky, Monika] MC Toxicol Consulting GmbH, Vienna, Austria; [Koller, Christiane; Seifert, Jan-Marcus; Bodenteich, Angelika; Grassauer, Andreas; Prieschl-Grassauer, Eva] Marinomed Biotechnol GmbH, Vienna, Austria; [Bernkop-Schnuerch, Andreas] ThioMatriX, Innsbruck, Austria		Chabicovsky, M (corresponding author), MC Toxicol Consulting GmbH, Vienna, Austria.	MC@toxicology.cc	Bernkop-Schnürch, Andreas/HCH-3150-2022	Bernkop-Schnürch, Andreas/0000-0003-4187-8277	Marinomed Biotechnologie GmbH	Marinomed Biotechnologie GmbH	This work was supported by Marinomed Biotechnologie GmbH. Marinomed Biotechnologie GmbH (AG, EPG, AB, CK, JMS) had a role in study design, data collection and analysis, decision to publish, preparation of the manuscript and is financing the processing charge of the manuscript. MC Toxicology Consulting GmbH (MC, AH), as nonclinical consultant to Marinomed Biotechnologie GmbH, had a role in study design, data collection and analysis, decision to publish and preparation of the manuscript. MC Toxicology Consulting's work was financed by Marinomed Biotechnologie GmbH. ThioMatriX (ABS), as contract research organization to Marinomed Biotechnologie GmbH, had a role in study design, data collection and analysis and decision to publish. ThioMatrix's work was financed by Marinomed Biotechnologie GmbH. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	BABA M, 1988, ANTIMICROB AGENTS CH, V32, P1742, DOI 10.1128/AAC.32.11.1742; Batista JA, 2014, CARBOHYD POLYM, V99, P59, DOI 10.1016/j.carbpol.2013.08.071; Buck CB, 2006, PLOS PATHOG, V2, P671, DOI 10.1371/journal.ppat.0020069; Carlucci MJ, 1999, ANTIVIR RES, V43, P93, DOI 10.1016/S0166-3542(99)00038-8; Cohen SM, 2002, CRIT REV TOXICOL, V32, P413, DOI 10.1080/20024091064282; Csonga R, 1998, J IMMUNOL, V160, P273; Eccles R, 2010, RESP RES, V11, DOI 10.1186/1465-9921-11-108; Fazekas T, 2012, BMC COMPLEM ALTERN M, V12, DOI 10.1186/1472-6882-12-147; GONZALEZ ME, 1987, ANTIMICROB AGENTS CH, V31, P1388, DOI 10.1128/AAC.31.9.1388; Grassauer A, 2008, VIROL J, V5, DOI 10.1186/1743-422X-5-107; Harkema JR, 2006, TOXICOL PATHOL, V34, P252, DOI 10.1080/01926230600713475; IUCLID, 2000, IUCLID DAT CARR SUBS; JECFA, 2001, WHO TECHN REP SER, V891; JEFCA, 1974, WHO TECHN REP SER, V539; Li L, 2014, CARBOHYD POLYM, V103, P1, DOI 10.1016/j.carbpol.2013.12.008; Ludwig M, 2013, RESP RES, V14, DOI 10.1186/1465-9921-14-124; Marino DJ, 2012, J TOXICOL ENV HEAL A, V75, P1484, DOI 10.1080/15287394.2012.722520; Mckim JM, 2014, CRIT REV TOXICOL, V44, P211, DOI 10.3109/10408444.2013.861797; Morris Christopher J, 2003, Methods Mol Biol, V225, P115; Necas J, 2013, VET MED-CZECH, V58, P187, DOI 10.17221/6758-VETMED; Paulsen FP, 2002, INVEST OPHTH VIS SCI, V43, P3137; Prieschl EE, 1996, J IMMUNOL, V157, P2645; Rowe R.C., 2009, HDB PHARM EXCIPIENTS, Vsixth; SCF (Scientific Committee for Food), 2003, SCFCSADDEMU199; Talarico LB, 2007, VIROLOGY, V363, P473, DOI 10.1016/j.virol.2007.01.043; Talarico LB, 2005, ANTIVIR RES, V66, P103, DOI 10.1016/j.antiviral.2005.02.001; TARLO SM, 1995, J ALLERGY CLIN IMMUN, V95, P933, DOI 10.1016/S0091-6749(95)70091-9; Tobacman JK, 2001, MED HYPOTHESES, V56, P589, DOI 10.1054/mehy.2000.1208; Tobacman JK, 2001, ENVIRON HEALTH PERSP, V109, P983, DOI 10.2307/3454951; Wang W, 2012, MAR DRUGS, V10, P2795, DOI 10.3390/md10122795; WEINER ML, 1991, AGENTS ACTIONS, V32, P46, DOI 10.1007/BF01983307; Weiner ML, 2014, CRIT REV TOXICOL, V44, P244, DOI 10.3109/10408444.2013.861798	32	23	24	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 13	2015	10	4							e0122911	10.1371/journal.pone.0122911	http://dx.doi.org/10.1371/journal.pone.0122911			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CF8XK	25875737	Green Submitted, Green Published, gold			2023-01-03	WOS:000352845100117
J	Ye, L; Yu, HS; Li, CW; Hirsch, ML; Zhang, LG; Samulski, RJ; Li, WP; Liu, Z				Ye, Lei; Yu, Haisheng; Li, Chengwen; Hirsch, Matthew L.; Zhang, Liguo; Samulski, R. Jude; Li, Wuping; Liu, Zhong			Adeno-Associated Virus Vector Mediated Delivery of the HBV Genome Induces Chronic Hepatitis B Virus Infection and Liver Fibrosis in Mice	PLOS ONE			English	Article							TAUROCHOLATE COTRANSPORTING POLYPEPTIDE; CHRONIC VIRAL-HEPATITIS; TRANSGENIC MICE; SURFACE-ANTIGEN; MOUSE MODEL; TUPAIA HEPATOCYTES; CARRIER STATE; T-LYMPHOCYTE; IN-VITRO; EXPRESSION	Liver cirrhosis and hepatocellular carcinomas are major health problems of chronic hepatitis B virus (HBV) infection. To date, rare model has reproduced liver fibrosis associated with long-term HBV infection which in turn has hindered both the understanding of HBV biology and the development of new treatment options. Here, using adeno-associated virus serotype 8 (AAV8) mediated delivery of a 1.2-kb HBV genome, we successfully generated a chronic HBV infectious mouse model that presents the associated liver fibrosis observed following human infection. After AAV8/HBV1.2 vector administration, mice demonstrated effective HBV replication and transcription which resulted in HBV antigen expression and viremia over 6 months. Although no obvious acute inflammatory response was noted, these mice still developed chronic liver disease and hepatic fibrogenesis as demonstrated by increased ground glass-like hepatocytes, an increasing trend of collagen deposition and upregulated fibrosis markers, including type I collagen, type III collagen, tissue inhibitor of metalloproteinase (TIMP), and transforming growth factor-beta 1(TGF-beta 1). Taken together, AAV-mediated HBV gene delivery to the mouse liver, induced HBV persistent infection accompanied by liver fibrosis which can serve as a model for investigating the precise mechanisms underlying liver fibrosis following chronic HBV infection as well as for the potential development of novel therapeutics.	[Ye, Lei; Li, Wuping; Liu, Zhong] Chinese Acad Med Sci, Inst Blood Transfus, Chengdu, Peoples R China; [Ye, Lei; Li, Wuping; Liu, Zhong] Peking Union Med Coll, Chengdu, Peoples R China; [Yu, Haisheng; Zhang, Liguo] Chinese Acad Sci, Inst Biophys, Key Lab Immun & Infect, Beijing 100080, Peoples R China; [Li, Chengwen; Hirsch, Matthew L.; Samulski, R. Jude] Univ N Carolina, Dept Pharmacol, Gene Therapy Ctr, Chapel Hill, NC USA; [Li, Wuping] Chinese Acad Med Sci, Inst Pathogen Biol, MOH Key Lab Syst Biol Pathogens, Chengdu, Peoples R China	Chinese Academy of Medical Sciences - Peking Union Medical College; Institute of Blood Transfusion - CAMS; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College; Chinese Academy of Sciences; Institute of Biophysics, CAS; University of North Carolina; University of North Carolina Chapel Hill; Chinese Academy of Medical Sciences - Peking Union Medical College	Li, WP (corresponding author), Chinese Acad Med Sci, Inst Blood Transfus, Chengdu, Peoples R China.	lwpzhr@sina.com	Liu, Zhong/ABH-8584-2020	zhang, li guo/0000-0002-9795-0314; liu, zhong/0000-0001-8173-9656	Peking Union Medical College graduated student innovation fund [2011-1001-033]; Institute of Pathogen Biology, Chinese Academy of Medical Sciences [2011IPB106]	Peking Union Medical College graduated student innovation fund; Institute of Pathogen Biology, Chinese Academy of Medical Sciences	Peking Union Medical College graduated student innovation fund, 2011-1001-033, LY. The basic grant of Institute of Pathogen Biology, Chinese Academy of Medical Sciences, 2011IPB106, WPL.	ARAKI K, 1989, P NATL ACAD SCI USA, V86, P207, DOI 10.1073/pnas.86.1.207; ARTHUR MJP, 1995, J HEPATOL, V22, P43; BARKER LF, 1973, J INFECT DIS, V127, P648, DOI 10.1093/infdis/127.6.648; Barrera A, 2005, J VIROL, V79, P9786, DOI 10.1128/JVI.79.15.9786-9798.2005; Baumert TF, 2005, HEPATOLOGY, V41, P247, DOI 10.1002/hep.20553; Bedossa P, 2003, J PATHOL, V200, P504, DOI 10.1002/path.1397; Bertoni R, 1998, J IMMUNOL, V161, P4447; Bility MT, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004032; BRATTIG NW, 1983, HEPATOLOGY, V3, P638; Brunetto MR, 2013, J HEPATOL, V59, P1153, DOI 10.1016/j.jhep.2013.07.017; CHISARI FV, 1985, SCIENCE, V230, P1157, DOI 10.1126/science.3865369; CHISARI FV, 1995, HEPATOLOGY, V22, P1316, DOI 10.1016/0270-9139(95)90645-2; CHISARI FV, 1987, P NATL ACAD SCI USA, V84, P6909, DOI 10.1073/pnas.84.19.6909; Constandinou C, 2005, METH MOLEC MED, V117, P237; Dion S, 2013, J VIROL, V87, P5554, DOI 10.1128/JVI.03134-12; Dong QM, 2009, J VIROL METHODS, V159, P135, DOI 10.1016/j.jviromet.2009.03.012; DUSHEIKO GM, 1983, J CLIN INVEST, V71, P1104, DOI 10.1172/JCI110860; Eng FJ, 2000, AM J PHYSIOL-GASTR L, V279, pG7, DOI 10.1152/ajpgi.2000.279.1.G7; FERNAN A, 1989, CLIN EXP IMMUNOL, V76, P222; GERBER MA, 1974, AM J PATHOL, V75, P489; GERBER MA, 1974, P SOC EXP BIOL MED, V145, P863, DOI 10.3181/00379727-145-37912; GUIDOTTI LG, 1995, J VIROL, V69, P6158, DOI 10.1128/JVI.69.10.6158-6169.1995; Gutierrez-Reyes G, 2007, ARCH MED RES, V38, P644, DOI 10.1016/j.arcmed.2006.10.001; HOOFNAGLE JH, 1987, HEPATOLOGY, V7, P758, DOI 10.1002/hep.1840070424; Hoofnagle JH, 1997, NEW ENGL J MED, V336, P347, DOI 10.1056/NEJM199701303360507; Huang LR, 2006, P NATL ACAD SCI USA, V103, P17862, DOI 10.1073/pnas.0608578103; Iredale JP, 2007, J CLIN INVEST, V117, P539, DOI 10.1172/JCI30542; Iredale JP, 1996, HEPATOLOGY, V24, P176, DOI 10.1002/hep.510240129; Isogawa M, 2005, VIROLOGY, V333, P293, DOI 10.1016/j.virol.2005.01.004; Ke L, 2011, TRANSFUSION, V51, P1909, DOI 10.1111/j.1537-2995.2011.03067.x; KIM CM, 1991, NATURE, V351, P317, DOI 10.1038/351317a0; Kim H, 2008, RADIOLOGY, V247, P696, DOI 10.1148/radiol.2473070605; KNITTEL T, 1992, GASTROENTEROLOGY, V102, P1724, DOI 10.1016/0016-5085(92)91736-N; Lai CL, 1998, NEW ENGL J MED, V339, P61, DOI 10.1056/NEJM199807093390201; Lalazar A, 1997, GENE, V195, P235, DOI 10.1016/S0378-1119(97)00159-5; Lau DTY, 1997, GASTROENTEROLOGY, V113, P1660, DOI 10.1053/gast.1997.v113.pm9352870; Lee WM, 1997, NEW ENGL J MED, V337, P1733, DOI 10.1056/NEJM199712113372406; MABIT H, 1994, J GEN VIROL, V75, P2681, DOI 10.1099/0022-1317-75-10-2681; McMahon BJ, 2001, ANN INTERN MED, V135, P759, DOI 10.7326/0003-4819-135-9-200111060-00006; Nebbia G, 2012, QJM-INT J MED, V105, P109, DOI 10.1093/qjmed/hcr270; NOWICKI MJ, 1986, HEPATOLOGY, V6, P180, DOI 10.1002/hep.1840060205; Perz JF, 2006, J HEPATOL, V45, P529, DOI 10.1016/j.jhep.2006.05.013; PETERS M, 1991, HEPATOLOGY, V13, P977, DOI 10.1016/0270-9139(91)90273-X; Sprinzl MF, 2001, J VIROL, V75, P5108, DOI 10.1128/JVI.75.11.5108-5118.2001; TSUKAMOTO H, 1990, SEMIN LIVER DIS, V10, P56, DOI 10.1055/s-2008-1040457; World health organisation (WHO), 2015, GLOB ACT PLAN ANT RE, V19; Wu EX, 2007, MAGN RESON MED, V58, P687, DOI 10.1002/mrm.21350; Xiao X, 1998, J VIROL, V72, P2224, DOI 10.1128/JVI.72.3.2224-2232.1998; YAMADA G, 1993, INTERNAL MED, V32, P911, DOI 10.2169/internalmedicine.32.911; Yan H, 2013, J VIROL, V87, P7977, DOI 10.1128/JVI.03540-12; Yan H, 2012, ELIFE, V1, DOI 10.7554/eLife.00049; Yang D, 2014, CELL MOL IMMUNOL, V11, P71, DOI 10.1038/cmi.2013.43; Yang PL, 2002, P NATL ACAD SCI USA, V99, P13825, DOI 10.1073/pnas.202398599; Zhang Q, 2014, J VIRAL HEPATITIS, V21, P525, DOI 10.1111/jvh.12177; Zhong GC, 2013, J VIROL, V87, P7176, DOI 10.1128/JVI.03533-12	55	28	35	0	17	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 15	2015	10	6							e0130052	10.1371/journal.pone.0130052	http://dx.doi.org/10.1371/journal.pone.0130052			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CK6HU	26075890	Green Submitted, Green Published, gold			2023-01-03	WOS:000356329900129
J	Roehr, B				Roehr, Bob			Comfortable in their bodies: the rise of transgender care	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material												bobroehr@aol.com						Gates G.J., 2011, MANY PEOPLE ARE LESB; Olson KR, 2015, PSYCHOL SCI, V26, P467, DOI 10.1177/0956797614568156	2	2	2	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 5	2015	350								h3083	10.1136/bmj.h3083	http://dx.doi.org/10.1136/bmj.h3083			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CK0UI	26047624				2023-01-03	WOS:000355920200005
J	Ashley, EA				Ashley, Euan A.			The Precision Medicine Initiative A New National Effort	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									[Ashley, Euan A.] Stanford Univ, Dept Med, Stanford, CA 94305 USA; [Ashley, Euan A.] Stanford Univ, Dept Genet, Stanford, CA 94305 USA	Stanford University; Stanford University	Ashley, EA (corresponding author), Stanford Univ, Falk CVRB, Dept Med, 870 Quarry Rd, Stanford, CA 94305 USA.	euan@stanford.edu						Altman RB, 2007, NAT GENET, V39, P426, DOI 10.1038/ng0407-426; Ashley EA, 2010, LANCET, V375, P1525, DOI 10.1016/S0140-6736(10)60452-7; Basile Jan, 2009, Ther Adv Cardiovasc Dis, V3, P157, DOI 10.1177/1753944708101552; Blair SN, 2009, BRIT J SPORT MED, V43, P1; Committee on a Framework for Developing a New Taxonomy of Disease; National Research Council, 2011, PREC MED BUILD KNOWL; Nherera L, 2011, HEART, V97, P1175, DOI 10.1136/hrt.2010.213975; Ramsey BW, 2011, NEW ENGL J MED, V365, P1663, DOI 10.1056/NEJMoa1105185; Ross JS, 2015, JAMA ONCOL, V1, P40, DOI 10.1001/jamaoncol.2014.216	8	324	346	1	58	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 2	2015	313	21					2119	2120		10.1001/jama.2015.3595	http://dx.doi.org/10.1001/jama.2015.3595			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CJ4CC	25928209				2023-01-03	WOS:000355430900006
J	Tagashira, H; Miyamoto, A; Kitamura, S; Tsubata, M; Yamaguchi, K; Takagaki, K; Imokawa, G				Tagashira, Hideki; Miyamoto, Aki; Kitamura, Sei-ichi; Tsubata, Masahito; Yamaguchi, Kazuya; Takagaki, Kinya; Imokawa, Genji			UVB Stimulates the Expression of Endothelin B Receptor in Human Melanocytes via a Sequential Activation of the p38/MSK1/CREB/MITF Pathway Which Can Be Interrupted by a French Maritime Pine Bark Extract through a Direct Inactivation of MSK1	PLOS ONE			English	Article							NF-KAPPA-B; TRANSCRIPTION FACTOR; HUMAN KERATINOCYTES; HUMAN SKIN; EPIDERMAL-KERATINOCYTES; SIGNALING MECHANISMS; WAARDENBURG-SYNDROME; GENE-EXPRESSION; TYROSINASE GENE; IN-SITU	Melanogenesis is the physiological process by which melanin is synthesized to protect the skin from UV damage. While paracrine interactions between keratinocytes and melanocytes are crucial for regulating epidermal pigmentation, the endothelin (EDN)-endothelin B-receptor (EDNRB) interaction is one of the key linkages. In this study, we found that a single exposure of normal human melanocytes (NHMs) with UVB stimulates the expression of EDNRB and its upstream transcription factor microphthalmia-associated transcription factor (MITF) at the transcriptional and translational levels. That stimulation can be abrogated by post-irradiation treatment with a French maritime pine bark extract (PBE). UVB stimulated the phosphorylation of p38 and c-jun N-terminal kinase (JNK), but not ERK, followed by the increased phosphorylation of MSK1 and CREB. The post-irradiation treatment with PBE did not affect the increased phosphorylation of p38 and JNK, but distinctly abrogated the phosphorylation of MSK1 and CREB. Post-irradiation treatment with the MSK1 inhibitor H89 significantly down-regulated the increased gene expression of MITF and EDNRB in UVB-exposed NHMs. Our findings indicate for the first time that the increased expression of MITF that leads to the up-regulation of melanocyte-specific proteins in UVB-exposed NHMs is mediated via activation of the p38/MSK1/CREB pathway but not the ERK/RSK/CREB pathway. The mode of action by PBE demonstrates that interrupting MSK1 activation is a new target for antioxidants including PBE which can serve as anti-pigmenting agents in a reactive oxygen species-depletion-independent manner.	[Tagashira, Hideki; Miyamoto, Aki; Kitamura, Sei-ichi; Tsubata, Masahito; Yamaguchi, Kazuya; Takagaki, Kinya] Toyo Shinyaku Co Ltd, Div Res & Dev, Tosu, Saga 8410005, Japan; [Imokawa, Genji] Chubu Univ, Res Inst Biol Funct, Kasugai, Aichi 4878501, Japan	Chubu University	Imokawa, G (corresponding author), Chubu Univ, Res Inst Biol Funct, 1200 Matsumoto, Kasugai, Aichi 4878501, Japan.	imokawag@dream.ocn.ne.jp			Toyo Shinyaku Co., Ltd.	Toyo Shinyaku Co., Ltd.	Toyo Shinyaku Co., Ltd., provided support in the form of salaries for authors HT, AM, SK, MT, KY, KT, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the 'author contributions' section.	Abdel-Malek ZA, 2010, PIGM CELL MELANOMA R, V23, P171, DOI 10.1111/j.1755-148X.2010.00679.x; Adhami VM, 2003, NEOPLASIA, V5, P74, DOI 10.1016/S1476-5586(03)80019-2; Afaq F, 2003, ONCOGENE, V22, P1035, DOI 10.1038/sj.onc.1206206; Brenner M, 2009, J INVEST DERMATOL, V129, P1002, DOI 10.1038/jid.2008.325; Carreira S, 2005, NATURE, V433, P764, DOI 10.1038/nature03269; Carreira S, 2000, J BIOL CHEM, V275, P21920, DOI 10.1074/jbc.M000035200; Chida M, 1999, OPHTHALMIC RES, V31, P407, DOI 10.1159/000055565; Choi W, 2010, J INVEST DERMATOL, V130, P1685, DOI 10.1038/jid.2010.5; Chrestensen CA, 2002, J BIOL CHEM, V277, P27733, DOI 10.1074/jbc.M202663200; Deak M, 1998, EMBO J, V17, P4426, DOI 10.1093/emboj/17.15.4426; Du JY, 2004, CANCER CELL, V6, P565, DOI 10.1016/j.ccr.2004.10.014; Furumura M, 2012, CLIN INTERV AGING, V7, P275, DOI 10.2147/CIA.S33165; GANSS R, 1994, J BIOL CHEM, V269, P29808; Hachiya A, 2004, AM J PATHOL, V165, P2099, DOI 10.1016/S0002-9440(10)63260-9; Hachiya A, 2002, J BIOL CHEM, V277, P5395, DOI 10.1074/jbc.M105874200; Hornyak TJ, 2009, PIGM CELL MELANOMA R, V22, P307, DOI 10.1111/j.1755-148X.2009.00551.x; Hou L, 2000, DEVELOPMENT, V127, P5379; Hou L, 2006, P NATL ACAD SCI USA, V103, P9081, DOI 10.1073/pnas.0603114103; Hur S, 2010, J DERMATOL SCI, V59, P163, DOI 10.1016/j.jdermsci.2010.07.001; Hyter S, 2013, PIGM CELL MELANOMA R, V26, DOI 10.1111/pcmr.12063; Imokawa G, 1996, BIOCHEM J, V314, P305, DOI 10.1042/bj3140305; Imokawa G, 1997, PIGM CELL RES, V10, P218, DOI 10.1111/j.1600-0749.1997.tb00488.x; IMOKAWA G, 1995, J INVEST DERMATOL, V105, P32, DOI 10.1111/1523-1747.ep12312500; IMOKAWA G, 1992, J BIOL CHEM, V267, P24675; Kadono S, 2001, J INVEST DERMATOL, V116, P571, DOI 10.1046/j.1523-1747.2001.01296.x; Kim DS, 2003, ARCH PHARM RES, V26, P739, DOI 10.1007/BF02976685; Kim YJ, 2008, FOOD CHEM TOXICOL, V46, P2466, DOI 10.1016/j.fct.2008.04.002; Lee SJ, 2003, MOL CELLS, V16, P97; Li EPH, 2008, ADV CONSUM RES, V35, P444; Liu J, 2006, MOL CELL, V21, P467, DOI 10.1016/j.molcel.2005.12.020; Maimoona A, 2011, J ETHNOPHARMACOL, V133, P261, DOI 10.1016/j.jep.2010.10.041; Matsuzawa A, 2008, BBA-GEN SUBJECTS, V1780, P1325, DOI 10.1016/j.bbagen.2007.12.011; McCoy CE, 2005, BIOCHEM J, V387, P507, DOI 10.1042/BJ20041501; Mccoy CE, 2007, BIOCHEM J, V402, P491, DOI 10.1042/BJ20061183; McGill GG, 2002, CELL, V109, P707, DOI 10.1016/S0092-8674(02)00762-6; Mizutani Y, 2010, ARCH DERMATOL RES, V302, P283, DOI 10.1007/s00403-009-1007-x; Muthusamy V, 2013, INT J MOL SCI, V14, P17029, DOI 10.3390/ijms140817029; Nelson AB, 1998, DRUG DEV IND PHARM, V24, P139, DOI 10.3109/03639049809085598; Ohkita M, 2011, J PHARMACOL SCI, V115, P461, DOI 10.1254/jphs.10R37FM; Packer L, 1999, FREE RADICAL BIO MED, V27, P704, DOI 10.1016/S0891-5849(99)00090-8; Potterf SB, 2000, HUM GENET, V107, P1, DOI 10.1007/s004390050001; Read AP, 1997, J MED GENET, V34, P656, DOI 10.1136/jmg.34.8.656; Redmond RW, 2006, PHOTOCHEM PHOTOBIOL, V82, P1178, DOI 10.1562/2006-04-14-IR-874; Rohdewald P, 2002, INT J CLIN PHARM TH, V40, P158; SAKURAI T, 1990, NATURE, V348, P732, DOI 10.1038/348732a0; Saliou C, 2001, FREE RADICAL BIO MED, V30, P154, DOI 10.1016/S0891-5849(00)00445-7; Sato-Jin K, 2008, FASEB J, V22, P1155, DOI 10.1096/fj.07-9080com; Shimada T, 2012, EUR J PHARMACOL, V677, P147, DOI 10.1016/j.ejphar.2011.12.034; Smit N, 2009, INT J MOL SCI, V10, P5326, DOI 10.3390/ijms10125326; Suzuki Y, 2006, EXP EYE RES, V82, P275, DOI 10.1016/j.exer.2005.06.023; Tada A, 1998, CELL GROWTH DIFFER, V9, P575; Tada A, 2002, J INVEST DERMATOL, V118, P316, DOI 10.1046/j.0022-202x.2001.01694.x; Terazawa S, 2012, EXP DERMATOL, V21, P11, DOI 10.1111/j.1600-0625.2012.01496.x; Vachtenheim J, 2010, EXP DERMATOL, V19, P617, DOI 10.1111/j.1600-0625.2009.01053.x; Vance KW, 2005, CANCER RES, V65, P2260, DOI 10.1158/0008-5472.CAN-04-3045; Vicentini FTMC, 2011, J DERMATOL SCI, V61, P162, DOI 10.1016/j.jdermsci.2011.01.002; Wan P, 2011, MOL CELL BIOCHEM, V354, P241, DOI 10.1007/s11010-011-0823-4; Wiggin GR, 2002, MOL CELL BIOL, V22, P2871, DOI 10.1128/MCB.22.8.2871-2881.2002; YADA Y, 1991, J BIOL CHEM, V266, P18352; YANAGISAWA M, 1988, NATURE, V332, P411, DOI 10.1038/332411a0; Yanase H, 2001, PIGM CELL RES, V14, P103, DOI 10.1034/j.1600-0749.2001.140205.x; Yang RF, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6807; YASUMOTO KI, 1994, MOL CELL BIOL, V14, P8058, DOI 10.1128/MCB.14.12.8058; YOHN JJ, 1993, J INVEST DERMATOL, V100, P23, DOI 10.1111/1523-1747.ep12349932; Yoshida A, 2011, J CLIN BIOCHEM NUTR, V49, P79, DOI 10.3164/jcbn.10-103; Zhu WY, 2008, J INVEST DERM SYMP P, V13, P20, DOI 10.1038/jidsymp.2008.8	66	25	27	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 1	2015	10	6							e0128678	10.1371/journal.pone.0128678	http://dx.doi.org/10.1371/journal.pone.0128678			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CL0KF	26030901	Green Published, gold, Green Submitted			2023-01-03	WOS:000356630900183
J	Benedetto, D; Rao, CM; Cefalu, C; Aguglia, DO; Cattadori, G; D'Ascola, DG; Benedetto, FA; Agostoni, P; Sciomer, S				Benedetto, Daniela; Rao, Carmelo Massimo; Cefalu, Claudia; Aguglia, Demetrio Oreste; Cattadori, Gaia; D'Ascola, Domenico Giuseppe; Benedetto, Frank Antonio; Agostoni, Piergiuseppe; Sciomer, Susanna			Effects of Blood Transfusion on Exercise Capacity in Thalassemia Major Patients	PLOS ONE			English	Article							CHRONIC HEART-FAILURE; MAGNETIC-RESONANCE; ANEMIC PATIENTS; CARDIAC IRON; PERFORMANCE; TOLERANCE	Anemia has an important role in exercise performance. However, the direct link between rapid changes of hemoglobin and exercise performance is still unknown. To find out more on this topic, we studied 18 beta-thalassemia major patients free of relevant cardiac dysfunction (age 33.5 +/- 7.2 years, males = 10). Patients performed a maximal cardiopulmolmonary exercise test (cycloergometer, personalized ramp protocol, breath-by-breath measurements of expired gases) before and the day after blood transfusion (500 cc of red cell concentrates). After blood transfusion, hemoglobin increased from 10.5 +/- 0.8 g/dL to 12.1 +/- 1.2 (p < 0.001), peak VO2 from 1408 to 1546mL/min (p< 0.05), and VO2 at anaerobic threshold from 965 to 1024mL/min (p < 0.05). No major changes were observed as regards heart and respiratory rates either at peak exercise or at anaerobic threshold. Similarly, no relevant changes were observed in ventilation efficiency, as evaluated by the ventilation vs. carbon dioxide production relationship, or in O-2 delivery to the periphery as analyzed by the VO2 vs. workload relationship. The relationship between hemoglobin and VO2 changes showed, for each g/dL of hemoglobin increase, a VO2 increase = 82.5 mL/min and 35 mL/min, at peak exercise and at anaerobic threshold, respectively. In beta-thalassemia major patients, an acute albeit partial anemia correction by blood transfusion determinates a relevant increase of exercise performance, observed both at peak exercise and at anaerobic threshold.	[Benedetto, Daniela; Cefalu, Claudia; Cattadori, Gaia; Agostoni, Piergiuseppe] IRCCS, Ctr Cardiol Monzino, Milan, Italy; [Rao, Carmelo Massimo; Aguglia, Demetrio Oreste; Benedetto, Frank Antonio] Azienda Bianchi Melacrino Morelli, Dept Cardiol, Reggio Di Calabria, Italy; [D'Ascola, Domenico Giuseppe] Azienda Bianchi Melacrino Morelli, Dept Hematol, Reggio Di Calabria, Italy; [Agostoni, Piergiuseppe] Univ Milan, Dipartimento Sci Clin & Comunita, Sez Cardiovasc, Milan, Italy; [Sciomer, Susanna] Univ Roma La Sapienza, Dipartimento Sci Cardiovasc & Respiratorie, I-00185 Rome, Italy	IRCCS Centro Cardiologico Monzino; University of Milan; Sapienza University Rome	Agostoni, P (corresponding author), IRCCS, Ctr Cardiol Monzino, Milan, Italy.	piergiuseppe.agostoni@unimi.it	Corrà, Ugo/AAF-8322-2020; Agostoni, Piergiuseppe/ABG-9556-2020	Corrà, Ugo/0000-0002-9229-3298; Agostoni, Piergiuseppe/0000-0002-8345-6382; Cattadori, Gaia/0000-0002-0954-9871; Sciomer, Susanna/0000-0001-9487-833X; benedetto, daniela/0000-0001-7069-5635				Agostoni P, 1999, AM J CARDIOL, V83, P278, DOI 10.1016/S0002-9149(98)00839-X; Agostoni P, 2010, AM J HEMATOL, V85, P414, DOI 10.1002/ajh.21698; Balady GJ, 2010, CIRCULATION, V122, P191, DOI 10.1161/CIR.0b013e3181e52e69; BISHOP JM, 1955, CLIN SCI, V14, P329; Gargiulo P, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087395; Guazzi M, 2001, AM J CARDIOL, V88, P452, DOI 10.1016/S0002-9149(01)01703-9; HANSEN JE, 1984, AM REV RESPIR DIS, V129, pS49, DOI 10.1164/arrd.1984.129.2P2.S49; KOIKE A, 1990, J APPL PHYSIOL, V68, P2521, DOI 10.1152/jappl.1990.68.6.2521; Mancini DM, 2003, CIRCULATION, V107, P294, DOI 10.1161/01.CIR.0000044914.42696.6A; Marsella M, 2011, HAEMATOL-HEMATOL J, V96, P515, DOI 10.3324/haematol.2010.025510; Nanas S, 2009, SCAND J MED SCI SPOR, V19, P96, DOI 10.1111/j.1600-0838.2008.00778.x; Okonko DO, 2008, J AM COLL CARDIOL, V51, P103, DOI 10.1016/j.jacc.2007.09.036; Palazzuoli A, 2006, AM HEART J, V152, DOI 10.1016/j.ahj.2006.08.005; Pennell DJ, 2011, J CARDIOVASC MAGN R, V13, DOI 10.1186/1532-429X-13-45; Pepe A, 2009, HEART, V95, P1688, DOI 10.1136/hrt.2008.156497; Pepe A, 2013, BRIT J HAEMATOL, V163, P520, DOI 10.1111/bjh.12557; Perego GB, 1996, J APPL PHYSIOL, V80, P623, DOI 10.1152/jappl.1996.80.2.623; Ponikowski P, 2007, J AM COLL CARDIOL, V49, P753, DOI 10.1016/j.jacc.2006.11.024; Positano V, 2009, NMR BIOMED, V22, P707, DOI 10.1002/nbm.1382; Robertson HT, 2004, J APPL PHYSIOL, V97, P697, DOI 10.1152/japplphysiol.00108.2004; Sohn EY, 2013, AM J HEMATOL, V88, P193, DOI 10.1002/ajh.23370; Stringer WW, 2012, PRINCIPLES EXERCISE, V5th, P154; Tanner MA, 2006, HAEMATOLOGICA, V91, P1388; Toblli JE, 2007, J AM COLL CARDIOL, V50, P1657, DOI 10.1016/j.jacc.2007.07.029; Tocco F, 2006, CLIN PHYSIOL FUNCT I, V26, P319, DOI 10.1111/j.1475-097X.2006.00692.x; Vasileiadis I, 2009, ACTA PHYSIOL, V196, P357, DOI 10.1111/j.1748-1716.2008.01937.x	26	10	10	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 26	2015	10	5							e0127553	10.1371/journal.pone.0127553	http://dx.doi.org/10.1371/journal.pone.0127553			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CJ0QZ	26010540	Green Published, gold, Green Submitted			2023-01-03	WOS:000355183900108
J	Lenzer, J				Lenzer, Jeanne			Ending "corrupt" practices in medicine: Harvard conference report	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							RISK					jlenzer@bmj.com						Fain K, 2013, JAMA-J AM MED ASSOC, V310, P202, DOI 10.1001/jama.2013.7900; Graham DJ, 2005, LANCET, V365, P475, DOI 10.1016/S0140-6736(05)17864-7; Olson MK, 2008, J HEALTH ECON, V27, P175, DOI 10.1016/j.jhealeco.2007.10.007	3	0	0	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 15	2015	350								h2618	10.1136/bmj.h2618	http://dx.doi.org/10.1136/bmj.h2618			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CI5CN	25979225				2023-01-03	WOS:000354770600002
J	Li, PP; Qiu, TM; Qin, C				Li, Pingping; Qiu, Tangmeng; Qin, Chao			Efficacy of Acupuncture for Bell's Palsy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials	PLOS ONE			English	Review							POLYMERASE-CHAIN-REACTION; HERPES-SIMPLEX-VIRUS; DNA	Acupuncture has emerged as an alternative therapy for Bell's palsy in both adults and children. However, the use of acupuncture is controversial. We conducted a systematic review and meta-analysis to assess the efficacy of acupuncture for Bell's palsy. We searched PubMed, Embase, and the Cochrane Central Register of Controlled Trials, irrespective of any language restrictions. Randomized controlled trials comparing acupuncture with other therapies for Bell's palsy in adults or children were included. Fourteen randomized controlled trials involving 1541 individuals were included in this meta-analysis. Significant association was observed in acupuncture with a higher effective response rate for Bell's palsy (relative risk, 1.14; 95% confidence interval, 1.04-1.25; P = 0.005) but there was a heterogeneity among the studies (I-2 = 87%). An assessment of the included studies revealed a high risk of bias in methodological quality. An evaluation of the incidence of complications was not available, owing to incomplete data. Acupuncture seems to be an effective therapy for Bell's palsy, but there was insufficient evidence to support the efficacy and safety of acupuncture. However, the results should be interpreted cautiously, because of the poor quality and heterogeneity of the included studies.	[Li, Pingping; Qiu, Tangmeng; Qin, Chao] Guangxi Med Univ, Affiliated Hosp 1, Dept Neurol, Nanning, Guangxi, Peoples R China	Guangxi Medical University	Qin, C (corresponding author), Guangxi Med Univ, Affiliated Hosp 1, Dept Neurol, Nanning, Guangxi, Peoples R China.	qc6699@yeah.net	Li, Ping/GYV-4914-2022					ADOUR KK, 1975, JAMA-J AM MED ASSOC, V233, P527, DOI 10.1001/jama.233.6.527; Ahn CB, 2011, J ACUPUNCT MERIDIAN, V4, P29, DOI 10.1016/S2005-2901(11)60005-8; [Anonymous], 2007, J SICHUAN TRADIT CHI, P109; [Anonymous], 2005, CHINESE J REHABILITA, V11, P1037; [Anonymous], 2004, J CLIN ACUPUNCTURE M, V20, P26; [Anonymous], 2009, ZHEJIANG J TRADIT CH, P444; BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446; BURGESS LPA, 1984, LARYNGOSCOPE, V94, P1472; Chen Ning, 2010, Cochrane Database Syst Rev, pCD002914, DOI 10.1002/14651858.CD002914.pub5; Chen XQ, 2009, CONTEMP CLIN TRIALS, V30, P347, DOI 10.1016/j.cct.2009.02.006; Cumberworth A, 2012, INT J SURG, V10, P310, DOI 10.1016/j.ijsu.2012.04.019; Du LZ, 2013, WORLD J ACUPUNCTURE, P42; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; Fu Xiao-hu, 2007, Zhongguo Zhen Jiu, V27, P494; Furuta Y, 1997, J MED VIROL, V52, P316, DOI 10.1002/(SICI)1096-9071(199707)52:3&lt;316::AID-JMV13&gt;3.0.CO;2-G; Gilden DH, 2004, NEW ENGL J MED, V351, P1323, DOI 10.1056/NEJMcp041120; Grogan PM, 2001, NEUROLOGY, V56, P830, DOI 10.1212/WNL.56.7.830; Harwood-Nuss A, 2009, HARWOOD NUSS CLIN PR; HAUSER WA, 1971, MAYO CLIN PROC, V46, P258; Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186; Holland NJ, 2004, BMJ-BRIT MED J, V329, P553, DOI 10.1136/bmj.329.7465.553; Jiangping L., 2005, CHINESE CLIN MED RES, V11, P1715; Julian Higgins JT, 2022, COCHRANE HDB SYSTEMA; Kim JI, 2012, CHIN J INTEGR MED, V18, P48, DOI 10.1007/s11655-011-0861-5; Kwon HJ, 2011, TRIALS, V12, DOI 10.1186/1745-6215-12-71; Lee Cham Kyul, 2013, Journal of Acupuncture Research, V30, P51, DOI 10.13045/acupunct.2013005; Li J, 2005, CHINESE CLIN MED RES, P1715; Li Y, 2004, CHINESE MED J-PEKING, V117, P1502; Li Y, 2011, ZHONGGUO ZHEN JIU, P289; Li Y, 2011, WOODHEAD PUBL MATER, P1; Liang Fanrong, 2006, J Tradit Chin Med, V26, P3; Liu Li-An, 2012, Zhongguo Zhen Jiu, V32, P587; Liu M., 1996, J CLIN ACUPUNCT MOXI, P56; Ma Z, 2004, SNANGHAI J ACUPUNCTU, P19; Moher David, 2009, BMJ, V339, pb2535, DOI [10.1016/j.ijsu.2010.02.007, 10.1136/bmj.b2535]; Morris AM, 2002, NEUROEPIDEMIOLOGY, V21, P255, DOI 10.1159/000065645; Murakami S, 1996, ANN INTERN MED, V124, P27, DOI 10.7326/0003-4819-124-1_Part_1-199601010-00005; PEITERSEN E, 1982, AM J OTOL, V4, P107; Qi Qi-Hua, 2013, Zhongguo Zhen Jiu, V33, P965; Qu Yong, 2005, Zhongguo Zhen Jiu, V25, P545; Reheman Ainiwan, 2009, Zhongguo Zhen Jiu, V29, P17; Schirm J, 1997, APMIS, V105, P815, DOI 10.1111/j.1699-0463.1997.tb05089.x; Shannon S, 2003, J FAM PRACTICE, V52, P156; Shao SF, 1999, NEW MED, P16; Stjernquist-Desatnik A, 2006, ANN OTO RHINOL LARYN, V115, P306, DOI 10.1177/000348940611500410; Teixeira LJ, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006283.pub3; Theil D, 2001, BRAIN PATHOL, V11, P408, DOI 10.1111/j.1750-3639.2001.tb00408.x; Tong FM, 2009, ACUPUNCT MED, V27, P169, DOI 10.1136/aim.2009.000638; Uchino K, 2013, ANN INTERN MED, V159, DOI 10.7326/0003-4819-159-10-201311190-02008; Wang HW, 2013, ZHONGGUO ZHEN JIU, P306; White A, 2001, BRIT MED J, V323, P485, DOI 10.1136/bmj.323.7311.485; Wong XH ZL, 2004, ZHONGHUA LINCHUANG K, V8, P616; Xia Feng, 2011, Trials, V12, P158, DOI 10.1186/1745-6215-12-158; Xu SB, 2013, CAN MED ASSOC J, V185, P473, DOI 10.1503/cmaj.121108; Xuan LH WL, 2007, CHIN J TRADIT MED SC, P6; Yang C, 2006, SCI TECH INFO GANSU, V35, P240; Yang G, 2001, J ACUPUNCTURE MOXIBU, P28; Yang SB, 2012, ZHONGGUO ZHEN JIU, P21; Yang SB, 2013, WORLD J ACUPUNCTURE, P15; Yu Y., 1999, SHANGHAI J ACUPUNCTU, P26; Zhang CY, 2011, ZHEN CI YAN JIU, P433; Zhao JP, 2010, J TRADIT CHIN MED, V30, P118, DOI 10.1016/S0254-6272(10)60026-X; Zhao Y, 2005, CHINESE J CLIN REHAB, P41; Zhou M, 2009, J ALTERN COMPLEM MED, V15, P759, DOI 10.1089/acm.2008.0179; Zhu HQ, 2004, CHINESE J PAIN MED; Zhu L., 2006, SHANGHAI J ACUPUNCT, V25, P17	66	28	29	0	26	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 14	2015	10	5							e0121880	10.1371/journal.pone.0121880	http://dx.doi.org/10.1371/journal.pone.0121880			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CI2AC	25974022	Green Published, Green Submitted, gold			2023-01-03	WOS:000354545600005
J	Scudellari, M				Scudellari, Megan			DRUG DEVELOPMENT Mix and match	NATURE			English	Editorial Material							COLORECTAL-CANCER											Dienstmann R., 2014, ANN ONCOL         S2, V25, pii115; Johnsson A, 2013, ANN ONCOL, V24, P2335, DOI 10.1093/annonc/mdt236; Morgan RA, 2010, MOL THER, V18, P843, DOI 10.1038/mt.2010.24; Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252; Parkhurst MR, 2011, MOL THER, V19, P620, DOI 10.1038/mt.2010.272; Witek M, 2014, INT J RADIAT ONCOL, V88, P1188, DOI 10.1016/j.ijrobp.2013.12.043	6	8	10	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 14	2015	521	7551					S12	S14		10.1038/521S12a	http://dx.doi.org/10.1038/521S12a			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CH9SY	25970452	Bronze			2023-01-03	WOS:000354377800006
J	Lei, YT; Xiong, YF; Zhang, L; Yan, H; Li, ZY; Cao, L; Huang, JY; Gu, AP; Ni, ZH; Qian, JQ; Fang, W				Lei, Yutian; Xiong, Yifan; Zhang, Lin; Yan, Hao; Li, Zhenyuan; Cao, Liou; Huang, Jiaying; Gu, Aiping; Ni, Zhaohui; Qian, Jiaqi; Fang, Wei			Comparison of Long-Term Outcomes between Peritoneal Dialysis Patients with Diabetes as a Primary Renal Disease or as a Comorbid Condition	PLOS ONE			English	Article							C-REACTIVE PROTEIN; MORBID CONDITION; SURVIVAL; TIME; INFLAMMATION; ASSOCIATION; TRANSPORT; GLUCOSE; FAILURE	Objective To investigate the long-term outcomes of peritoneal dialysis (PD) patients with diabetes as primary renal disease and patients with diabetes as a comorbid condition. Methods All diabetic patients who commenced PD between January 1, 1995 and June 30, 2012 at Ren Ji Hospital, China were included. Patients were divided into diabetic nephropathy group (DN group) and non-diabetic nephropathy group (NDN group) according to their diagnosis of primary renal disease at the initiation of PD. They were followed until death, cessation of PD, transferred to other centers or to the end of study (June 30, 2013). Outcomes were analyzed by Kaplan-Meier method and Cox regression models. Results A total of 163 diabetic patients were enrolled in the study, including 121 (74.2%) in DN group and 42 (25.8%) in NDN group. The 1-, 2-, 3- and 5-year patient survival rates were 89%, 78%, 66% and 51% for DN group, and 85%, 63%, 53% and 25% for NDN group, respectively. Kaplan-Meier analysis showed that patients in NDN group had a worse patient survival compared with DN group (log rank 4.830, P=0.028). Patients in NDN group had a marginally shorter peritonitis-free period (log rank 3.297, P=0.069), however, there was no significant difference in technique survival (log rank 0.040, P=0.841). Multivariate Cox regression analysis showed that older age (HR 1.047, 95% CI 1.022-1.073, p<0.001), cardiovascular disease comorbidity (HR 2.200, 95% CI 0.1.269-3.814, P=0.005) and diabetes as a comorbidity condition (HR 1.806, 95% CI 1.003-3.158, P=0.038) were the independent predictors of increased mortality. Conclusions PD patients with diabetes as a comorbidity had an inferior patient survival compared to those with diabetic nephropathy, and closer monitoring and extra attention in the former subgroup of patients are therefore warranted.	[Lei, Yutian; Xiong, Yifan; Zhang, Lin; Yan, Hao; Li, Zhenyuan; Cao, Liou; Huang, Jiaying; Gu, Aiping; Ni, Zhaohui; Qian, Jiaqi; Fang, Wei] Shanghai Jiao Tong Univ, Ren Ji Hosp, Ctr Peritoneal Dialysis Res, Sch Med,Dept Nephrol, Shanghai 200030, Peoples R China	Shanghai Jiao Tong University	Fang, W (corresponding author), Shanghai Jiao Tong Univ, Ren Ji Hosp, Ctr Peritoneal Dialysis Res, Sch Med,Dept Nephrol, Shanghai 200030, Peoples R China.	fangwei_sh@126.com	Xiong, Yifan/GSD-4318-2022		National Nature Science Foundation Grant of China [81370864]; Science and Technology Commission of Shanghai Municipality [114119a900]	National Nature Science Foundation Grant of China(National Natural Science Foundation of China (NSFC)); Science and Technology Commission of Shanghai Municipality(Science & Technology Commission of Shanghai Municipality (STCSM))	This work was supported by the National Nature Science Foundation Grant of China (81370864), grant from Science and Technology Commission of Shanghai Municipality (114119a900). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ARMSTRONG VW, 1985, NEPHRON, V39, P141, DOI 10.1159/000183358; BODNAR DM, 1993, ADV PERIT D, V9, P114; Catalano C, 1996, NEPHROL DIAL TRANSPL, V11, P1124; Chang YT, 2014, DIABETES CARE, V37, P277, DOI 10.2337/dc13-0781; Chung SH, 2003, NEPHROL DIAL TRANSPL, V18, P590, DOI 10.1093/ndt/18.3.590; Chung SH, 2001, NEPHROL DIAL TRANSPL, V16, P2240, DOI 10.1093/ndt/16.11.2240; Davies SJ, 2001, J AM SOC NEPHROL, V12, P1046, DOI 10.1681/ASN.V1251046; Ducloux D, 2002, KIDNEY INT, V62, P1417, DOI 10.1111/j.1523-1755.2002.kid562.x; Herzig KA, 2001, J AM SOC NEPHROL, V12, P814, DOI 10.1681/ASN.V124814; Liao CT, 2009, NEPHROL DIAL TRANSPL, V24, P2909, DOI 10.1093/ndt/gfp056; Moist LM, 2000, J AM SOC NEPHROL, V11, P556, DOI 10.1681/ASN.V113556; Perl J, 2012, CLIN J AM SOC NEPHRO, V7, P1145, DOI 10.2215/CJN.01480212; Schroijen MA, 2013, DIABETOLOGIA, V56, P1949, DOI 10.1007/s00125-013-2966-1; Schroijen MA, 2011, BMC NEPHROL, V12, DOI 10.1186/1471-2369-12-69; Schwenger V, 2001, DEUT MED WOCHENSCHR, V126, P1322, DOI 10.1055/s-2001-18564; Snaedal S, 2009, AM J KIDNEY DIS, V53, P1024, DOI 10.1053/j.ajkd.2009.02.008; Sorensen VR, 2007, DIABETOLOGIA, V50, P922, DOI 10.1007/s00125-007-0612-5; Su YJ, 2013, BMC NEPHROL, V14, DOI 10.1186/1471-2369-14-185; Van Dijk PCW, 2005, KIDNEY INT, V67, P1489, DOI 10.1111/j.1523-1755.2005.00227.x; Wang AYM, 2003, J AM SOC NEPHROL, V14, P1871, DOI 10.1097/01.ASN.0000070071.57901.B3; Wener MH, 2000, J RHEUMATOL, V27, P2351; Yeun JY, 1997, AM J KIDNEY DIS, V30, P923, DOI 10.1016/S0272-6386(97)90105-0	22	5	6	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 11	2015	10	5							e0126549	10.1371/journal.pone.0126549	http://dx.doi.org/10.1371/journal.pone.0126549			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CI1YY	25961883	Green Published, gold, Green Submitted			2023-01-03	WOS:000354542500111
J	Santini, B; Zanoni, I; Marzi, R; Cigni, C; Bedoni, M; Gramatica, F; Palugan, L; Corsi, F; Granucci, F; Colombo, M				Santini, Benedetta; Zanoni, Ivan; Marzi, Roberta; Cigni, Clara; Bedoni, Marzia; Gramatica, Furio; Palugan, Luca; Corsi, Fabio; Granucci, Francesca; Colombo, Miriam			Cream Formulation Impact on Topical Administration of Engineered Colloidal Nanoparticles	PLOS ONE			English	Article							SKIN; PENETRATION; CELLS	In order to minimize the impact of systemic toxicity of drugs in the treatment of local acute and chronic inflammatory reactions, the achievement of reliable and efficient delivery of therapeutics in/through the skin is highly recommended. While the use of nanoparticles is now an established practice for drug intravenous targeted delivery, their transdermal penetration is still poorly understood and this important administration route remains almost unexplored. In the present study, we have synthesized magnetic (iron oxide) nanoparticles (MNP) coated with an amphiphilic polymer, developed a water-in-oil emulsion formulation for their topical administration and compared the skin penetration routes with the same nanoparticles deposited as a colloidal suspension. Transmission and scanning electron microscopies provided ultrastructural evidence that the amphiphilic nanoparticles (PMNP) cream formulation allowed the efficient penetration through all the skin layers with a controllable kinetics compared to suspension formulation. In addition to the preferential follicular pathway, also the intracellular and intercellular routes were involved. PMNP that crossed all skin layers were quantified by inductively coupled plasma mass spectrometry. The obtained data suggests that combining PMNP amphiphilic character with cream formulation improves the intradermal penetration of nanoparticles. While PMNP administration in living mice via aqueous suspension resulted in preferential nanoparticle capture by phagocytes and migration to draining lymph nodes, cream formulation favored uptake by all the analyzed dermis cell types, including hematopoietic and non-hematopoietic. Unlike aqueous suspension, cream formulation also favored the maintenance of nanoparticles in the dermal architecture avoiding their dispersion and migration to draining lymph nodes via afferent lymphatics.	[Santini, Benedetta; Zanoni, Ivan; Marzi, Roberta; Cigni, Clara; Granucci, Francesca; Colombo, Miriam] Univ Milano Bicocca, Dipartimento Biotecnol & Biosci, NanoBioLab, Milan, Italy; [Zanoni, Ivan] Harvard Univ, Boston Childrens Hosp, Div Gastroenterol, Boston, MA 02115 USA; [Bedoni, Marzia; Gramatica, Furio] Fdn Don Carlo Gnocchi ONLUS, La Nanomed & Biofoton Clin, Milan, Italy; [Palugan, Luca] Univ Milan, Dipartimento Sci Farmaceut, Milan, Italy; [Corsi, Fabio] Univ Milan, Dipartimento Sci Biomed & Clin Luigi Sacco, Milan, Italy; [Zanoni, Ivan; Granucci, Francesca] Humanitas Clin & Res Ctr, Unit Cell Signalling & Innate Immun, Milan, Italy	University of Milano-Bicocca; Harvard University; Boston Children's Hospital; IRCCS Fondazione Don Carlo Gnocchi Onlus; University of Milan; University of Milan; Luigi Sacco Hospital	Colombo, M (corresponding author), Univ Milano Bicocca, Dipartimento Biotecnol & Biosci, NanoBioLab, Milan, Italy.	miriam.colombo@unimib.it	Corsi, Fabio/ABH-9554-2020; Bedoni, Marzia/AAA-7674-2020; GRANUCCI, Francesca/K-6150-2019; Corsi, Fabio/E-9204-2017	Corsi, Fabio/0000-0002-6469-4086; Bedoni, Marzia/0000-0003-2618-3661; Corsi, Fabio/0000-0002-6469-4086; Zanoni, Ivan/0000-0002-3423-7474; Gramatica, Furio/0000-0002-2826-031X; COLOMBO, MIRIAM/0000-0003-3428-5668; granucci, francesca/0000-0002-7046-4914	Fondazione Regionale per la Ricerca Biomedica (FRRB); NanoMeDia Project (A.O. "L. Sacco"); Cariplo Foundation [2011-2096, 2010-0678]; Associazione Italiana per la Ricerca sul Cancro (MFAG) [13235]; NanoMeDia Project (Regione Lombardia); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK034854] Funding Source: NIH RePORTER	Fondazione Regionale per la Ricerca Biomedica (FRRB)(Regione Lombardia); NanoMeDia Project (A.O. "L. Sacco"); Cariplo Foundation(Fondazione Cariplo); Associazione Italiana per la Ricerca sul Cancro (MFAG)(Fondazione AIRC per la ricerca sul cancro); NanoMeDia Project (Regione Lombardia)(Regione Lombardia); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was supported by the following sources: Fondazione Regionale per la Ricerca Biomedica (FRRB), NanoMeDia Project (A.O. "L. Sacco" and Regione Lombardia); the Cariplo Foundation (Grant 2011-2096 and Grant 2010-0678), Associazione Italiana per la Ricerca sul Cancro (MFAG, Rif.13235).	Avvakumova S, 2014, TRENDS BIOTECHNOL, V32, P11, DOI 10.1016/j.tibtech.2013.09.006; Baroli B, 2007, J INVEST DERMATOL, V127, P1701, DOI 10.1038/sj.jid.5700733; Bolzinger MA, 2012, CURR OPIN COLLOID IN, V17, P156, DOI 10.1016/j.cocis.2012.02.001; Colombo M, 2012, CHEM SOC REV, V41, P4306, DOI 10.1039/c2cs15337h; DeLouise LA, 2012, J INVEST DERMATOL, V132, P964, DOI 10.1038/jid.2011.425; Desai P, 2010, MOL MEMBR BIOL, V27, P247, DOI 10.3109/09687688.2010.522203; Dufort S, 2012, ADV DRUG DELIVER REV, V64, P179, DOI 10.1016/j.addr.2011.09.009; Duncan R, 2011, MOL PHARMACEUT, V8, P2101, DOI 10.1021/mp200394t; Elias PM, 2005, EXP DERMATOL, V14, P719, DOI 10.1111/j.1600-0625.2005.00363.x; Gratieri T, 2010, J BIOMED NANOTECHNOL, V6, P586, DOI 10.1166/jbn.2010.1155; Harisinghani MG, 2003, NEW ENGL J MED, V348, P2491, DOI 10.1056/NEJMoa022749; Haun JB, 2010, NAT NANOTECHNOL, V5, P660, DOI [10.1038/NNANO.2010.148, 10.1038/nnano.2010.148]; Jain K, 2014, CURR OPIN PHARMACOL, V15, P97, DOI 10.1016/j.coph.2014.01.006; Klein K., 2003, COSMET TOILETRIES, V118, P24; Labouta HI, 2013, NANOMED-NANOTECHNOL, V9, P39, DOI 10.1016/j.nano.2012.04.004; Labouta HI, 2011, NANOSCALE, V3, P4989, DOI 10.1039/c1nr11109d; Mathias NR, 2010, J PHARM SCI-US, V99, P1, DOI 10.1002/jps.21793; Park J, 2004, NAT MATER, V3, P891, DOI 10.1038/nmat1251; Pellegrino T, 2004, NANO LETT, V4, P703, DOI 10.1021/nl035172j; Prapainop K, 2012, J AM CHEM SOC, V134, P4100, DOI 10.1021/ja300537u; Rosenblum MD, 2011, NATURE, V480, P538, DOI 10.1038/nature10664; Schroeder A, 2012, NAT REV CANCER, V12, P39, DOI 10.1038/nrc3180; Sonavane G, 2008, COLLOID SURFACE B, V65, P1, DOI 10.1016/j.colsurfb.2008.02.013; Verderio P, 2014, ADV HEALTHC MATER, V3, P957, DOI 10.1002/adhm.201300602; Vogt A, 2006, J INVEST DERMATOL, V126, P1316, DOI 10.1038/sj.jid.5700226; Zanoni I, 2012, J CLIN INVEST, V122, P1747, DOI 10.1172/JCI60688	26	20	20	0	17	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 11	2015	10	5							e0126366	10.1371/journal.pone.0126366	http://dx.doi.org/10.1371/journal.pone.0126366			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CI1YY	25962161	Green Published, gold			2023-01-03	WOS:000354542500093
J	Fang, Y; Qin, YF; Zhang, NQ; Wang, J; Wang, HY; Zheng, XQ				Fang, Yun; Qin, Yufang; Zhang, Naiqian; Wang, Jun; Wang, Haiyun; Zheng, Xiaoqi			DISIS: Prediction of Drug Response through an Iterative Sure Independence Screening	PLOS ONE			English	Article							VARIABLE SELECTION; GENE-EXPRESSION; CHEMOSENSITIVITY; METHYLATION; BIOMARKERS; RELEVANCE	Prediction of drug response based on genomic alterations is an important task in the research of personalized medicine. Current elastic net model utilized a sure independence screening to select relevant genomic features with drug response, but it may neglect the combination effect of some marginally weak features. In this work, we applied an iterative sure independence screening scheme to select drug response relevant features from the Cancer Cell Line Encyclopedia (CCLE) dataset. For each drug in CCLE, we selected up to 40 features including gene expressions, mutation and copy number alterations of cancer-related genes, and some of them are significantly strong features but showing weak marginal correlation with drug response vector. Lasso regression based on the selected features showed that our prediction accuracies are higher than those by elastic net regression for most drugs.	[Fang, Yun; Zhang, Naiqian; Wang, Jun; Zheng, Xiaoqi] Shanghai Normal Univ, Dept Math, Shanghai, Peoples R China; [Qin, Yufang] Shanghai Ocean Univ, Dept Math, Shanghai, Peoples R China; [Wang, Haiyun] Tongji Univ, Sch Life Sci & Technol, Dept Bioinformat, Shanghai 200092, Peoples R China	Shanghai Normal University; Shanghai Ocean University; Tongji University	Wang, HY (corresponding author), Tongji Univ, Sch Life Sci & Technol, Dept Bioinformat, Shanghai 200092, Peoples R China.	wanghaiyun@tongji.edu.cn; xqzheng@shnu.edu.cn			National Natural Science Foundation of China [31100953, 31100912, 11201306]; Innovation Program of Shanghai Municipal Education Commission [12YZ088, 13YZ065]; Program of Shanghai Normal University [DZL121, SK201207]; Supporting Program for Young College Teachers of Shanghai	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Innovation Program of Shanghai Municipal Education Commission(Innovation Program of Shanghai Municipal Education Commission); Program of Shanghai Normal University; Supporting Program for Young College Teachers of Shanghai	This work was supported by the National Natural Science Foundation of China (31100953, 31100912 and 11201306), the Innovation Program of Shanghai Municipal Education Commission (12YZ088 and 13YZ065), the Program of Shanghai Normal University (DZL121, SK201207) and the Supporting Program for Young College Teachers of Shanghai. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abudukadeer A, 2012, INT J MOL SCI, V13, P8353, DOI 10.3390/ijms13078353; Barretina J, 2012, NATURE, V483, P603, DOI 10.1038/nature11003; Chernova OB, 1998, ONCOGENE, V17, P2873, DOI 10.1038/sj.onc.1202481; DeRemer DL, 2008, CLIN THER, V30, P1956, DOI 10.1016/j.clinthera.2008.11.014; Ding Chris, 2005, Journal of Bioinformatics and Computational Biology, V3, P185, DOI 10.1142/S0219720005001004; Endoh M, 2005, BRIT J CANCER, V93, P1395, DOI 10.1038/sj.bjc.6602854; Fan JQ, 2008, J R STAT SOC B, V70, P849, DOI 10.1111/j.1467-9868.2008.00674.x; Fan JQ, 2009, J MACH LEARN RES, V10, P2013; Fan JQ, 2001, J AM STAT ASSOC, V96, P1348, DOI 10.1198/016214501753382273; Garnett MJ, 2012, NATURE, V483, P570, DOI 10.1038/nature11005; Hernandez-Caballero E, 2009, BMB REP, V42, P747, DOI 10.5483/BMBRep.2009.42.11.747; Holleman A, 2004, NEW ENGL J MED, V351, P533, DOI 10.1056/NEJMoa033513; Kaczmarek LK, 2006, NEURON, V49, P642, DOI 10.1016/j.neuron.2006.02.011; Kataoka T, 2001, J BIOL CHEM, V276, P19548, DOI 10.1074/jbc.M010520200; Lee JK, 2007, P NATL ACAD SCI USA, V104, P13086, DOI 10.1073/pnas.0610292104; Meinshausen N, 2006, ANN STAT, V34, P1436, DOI 10.1214/009053606000000281; Menden MP, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061318; Niu Yue S, 2011, BMC Proc, V5 Suppl 9, pS108, DOI 10.1186/1753-6561-5-S9-S108; Peng HC, 2005, IEEE T PATTERN ANAL, V27, P1226, DOI 10.1109/TPAMI.2005.159; Ren XW, 2013, NUCLEIC ACIDS RES, V41, DOI 10.1093/nar/gks1288; Riddick G, 2011, BIOINFORMATICS, V27, P220, DOI 10.1093/bioinformatics/btq628; Shen LL, 2007, CANCER RES, V67, P11335, DOI 10.1158/0008-5472.CAN-07-1502; Staunton JE, 2001, P NATL ACAD SCI USA, V98, P10787, DOI 10.1073/pnas.191368598; Stratton MR, 2009, NATURE, V458, P719, DOI 10.1038/nature07943; Tibshirani R, 1996, J ROY STAT SOC B MET, V58, P267, DOI 10.1111/j.2517-6161.1996.tb02080.x; Ueki M, 2012, BMC BIOINFORMATICS, V13, DOI 10.1186/1471-2105-13-72; Vos MD, 2003, J BIOL CHEM, V278, P28045, DOI 10.1074/jbc.M300554200; Wang Y, 2012, BMC SYST BIOL, V6, DOI 10.1186/1752-0509-6-S1-S15	28	11	11	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 20	2015	10	3							e0120408	10.1371/journal.pone.0120408	http://dx.doi.org/10.1371/journal.pone.0120408			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CE8HY	25794193	gold, Green Published, Green Submitted			2023-01-03	WOS:000352083900029
J	Raggi, C; Mousa, HS; Corrent, M; Sica, A; Invernizzi, P				Raggi, C.; Mousa, H. S.; Corrent, M.; Sica, A.; Invernizzi, P.			Cancer stem cells and tumor-associated macrophages: a roadmap for multitargeting strategies	ONCOGENE			English	Review							ACUTE MYELOID-LEUKEMIA; EPIDERMAL-GROWTH-FACTOR; EPITHELIAL-MESENCHYMAL TRANSITION; BONE-MARROW MICROENVIRONMENT; BREAST-CANCER; FACTOR RECEPTOR; SELF-RENEWAL; MYELOGENOUS LEUKEMIA; SIGNALING PATHWAY; CYTOKINE NETWORKS	The idea that tumor initiation and progression are driven by a subset of cells endowed with stem-like properties was first described by Rudolf Virchow in 1855. 'Cancer stem cells', as they were termed more than a century later, represent a subset of tumor cells that are able to generate all tumorigenic and nontumorigenic cell types within the malignancy. Although their existence was hypothesized > 150 years ago, it was only recently that stem-like cells started to be isolated from different neoplastic malignancies. Interestingly, Virchow, in suggesting a correlation between cancer and the inflammatory microenvironment, also paved the way for the 'Seed and Soil' theory proposed by Paget a few years later. Despite the time that has passed since these two important concepts were suggested, the relationships between Virchow's 'stem-like cells' and Paget's 'soil' are far from being fully understood. One emerging topic is the importance of a stem-like niche in modulating the biological properties of stem-like cancer cells and thus in affecting the response of the tumor to drugs. This review aims to summarize the recent molecular data concerning the multilayered relationship between cancer stem cells and tumor-associated macrophages that form a key component of the tumor microenvironment. We also discuss the therapeutic implications of targeting this synergistic interplay.	[Raggi, C.; Mousa, H. S.; Corrent, M.; Invernizzi, P.] Humanitas Clin & Res Ctr, Liver Unit, Via Manzoni 56, I-20089 Milan, Italy; [Raggi, C.; Mousa, H. S.; Corrent, M.; Invernizzi, P.] Humanitas Clin & Res Ctr, Ctr Autoimmune Liver Dis, Via Manzoni 56, I-20089 Milan, Italy; [Sica, A.] Humanitas Clin & Res Ctr, Lab Mol Immunol, Milan, Italy; [Sica, A.] Univ Piemonte Orientale Amedeo Avogadro, Dept Pharmaceut Sci, Novara, Italy	University of Eastern Piedmont Amedeo Avogadro	Raggi, C (corresponding author), Humanitas Clin & Res Ctr, Liver Unit, Via Manzoni 56, I-20089 Milan, Italy.; Raggi, C (corresponding author), Humanitas Clin & Res Ctr, Ctr Autoimmune Liver Dis, Via Manzoni 56, I-20089 Milan, Italy.	Chiara.raggi@humanitasresearch.it	Sica, Antonio/AAB-9546-2020; Invernizzi, Pietro/AAB-8367-2022; RAGGI, Chiara/U-3081-2017	Invernizzi, Pietro/0000-0003-3262-1998; RAGGI, Chiara/0000-0003-2473-3535; Mousa, Hani S./0000-0002-8327-7114	Italian Foundation of Cancer Research (AIRC); Fondazione U Veronesi	Italian Foundation of Cancer Research (AIRC)(Fondazione AIRC per la ricerca sul cancro); Fondazione U Veronesi(Fondazione Umberto Veronesi)	CR, HSM, MC, AS and PI were supported by the Italian Foundation of Cancer Research (AIRC) and Fondazione U Veronesi.	Abbas T, 2009, NAT REV CANCER, V9, P400, DOI 10.1038/nrc2657; Abe Y, 2008, P NATL ACAD SCI USA, V105, P4838, DOI 10.1073/pnas.0712216105; Abel EV, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091983; Ahmed N, 2006, AM J PHYSIOL-CELL PH, V290, pC1532, DOI 10.1152/ajpcell.00478.2005; Allavena P, 2008, CRIT REV ONCOL HEMAT, V66, P1, DOI 10.1016/j.critrevonc.2007.07.004; Arasada RR, 2014, CANCER RES, V74, P5572, DOI 10.1158/0008-5472.CAN-13-3724; Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Asimakopoulos F, 2013, LEUKEMIA LYMPHOMA, V54, P2112, DOI 10.3109/10428194.2013.778409; Baguley BC, 2010, MOL BIOTECHNOL, V46, P308, DOI 10.1007/s12033-010-9321-2; Beachy PA, 2004, NATURE, V432, P324, DOI 10.1038/nature03100; Ben-Porath I, 2008, NAT GENET, V40, P499, DOI 10.1038/ng.127; BHATIA R, 1995, BLOOD, V85, P3636, DOI 10.1182/blood.V85.12.3636.bloodjournal85123636; Biddle A, 2012, CANCER METAST REV, V31, P285, DOI 10.1007/s10555-012-9345-0; Bienz M, 2005, CURR BIOL, V15, pR64, DOI 10.1016/j.cub.2004.12.058; Biswas SK, 2013, SEMIN IMMUNOPATHOL, V35, P585, DOI 10.1007/s00281-013-0367-7; Bonnet D, 1997, NAT MED, V3, P730, DOI 10.1038/nm0797-730; Borovski T, 2011, CANCER RES, V71, P634, DOI 10.1158/0008-5472.CAN-10-3220; BRADSTOCK KF, 1995, LEUKEMIA LYMPHOMA, V18, P1, DOI 10.3109/10428199509064917; Brembeck FH, 2004, GENE DEV, V18, P2225, DOI 10.1101/gad.317604; Brissette MJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036368; Bromberg J, 2002, J CLIN INVEST, V109, P1139, DOI 10.1172/JCI200215617; BUITING AMJ, 1994, J DRUG TARGET, V2, P357, DOI 10.3109/10611869408996810; Carpentino JE, 2009, CANCER RES, V69, P8208, DOI 10.1158/0008-5472.CAN-09-1132; Chaffer CL, 2011, P NATL ACAD SCI USA, V108, P7950, DOI 10.1073/pnas.1102454108; Chaturvedi P, 2014, P NATL ACAD SCI USA, V111, pE2120, DOI 10.1073/pnas.1406655111; Chen J, 2012, NATURE, V488, P522, DOI 10.1038/nature11287; Chow A, 2013, NAT MED, V19, P429, DOI 10.1038/nm.3057; Chow A, 2011, J EXP MED, V208, P261, DOI 10.1084/jem.20101688; Clarke Michael F, 2006, Cancer Res, V66, P9339, DOI 10.1158/0008-5472.CAN-06-3126; Cook AM, 2014, BLOOD, V123, P2826, DOI 10.1182/blood-2013-05-505735; Coussens LM, 2013, SCIENCE, V339, P286, DOI 10.1126/science.1232227; DeNardo DG, 2011, CANCER DISCOV, V1, P54, DOI 10.1158/2159-8274.CD-10-0028; Driessens G, 2012, NATURE, V488, P527, DOI 10.1038/nature11344; Eljaszewicz A, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/831387; Esch JSA, 2005, STEM CELLS, V23, P463, DOI 10.1634/stemcells.2004-0283; Ezekowitz RA, 2002, NAT IMMUNOL, V3, P510, DOI 10.1038/ni0602-510; Fan QM, 2014, CANCER LETT, V352, P160, DOI 10.1016/j.canlet.2014.05.008; Farnie G, 2007, STEM CELL REV, V3, P169, DOI 10.1007/s12015-007-0023-5; Feldmann G, 2007, CANCER RES, V67, P2187, DOI 10.1158/0008-5472.CAN-06-3281; FIDLER IJ, 1982, SCIENCE, V217, P998, DOI 10.1126/science.7112116; Fourcade J, 2010, J EXP MED, V207, P2175, DOI 10.1084/jem.20100637; Galdiero MR, 2013, IMMUNOBIOLOGY, V218, P1402, DOI 10.1016/j.imbio.2013.06.003; Gao L, 2014, CELL BIOCHEM BIOPHYS, V70, P273, DOI 10.1007/s12013-014-9900-0; Gao X, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030676; Germano G, 2010, CANCER RES, V70, P2235, DOI 10.1158/0008-5472.CAN-09-2335; Ginestier C, 2007, CELL STEM CELL, V1, P555, DOI 10.1016/j.stem.2007.08.014; Goswami S, 2005, CANCER RES, V65, P5278, DOI 10.1158/0008-5472.CAN-04-1853; Grivennikov SI, 2010, CELL, V140, P883, DOI 10.1016/j.cell.2010.01.025; Gyorki DE, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2353; Hanayama R, 2002, NATURE, V417, P182, DOI 10.1038/417182a; Hassan KA, 2013, CLIN CANCER RES, V19, P1972, DOI 10.1158/1078-0432.CCR-12-0370; He KF, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/838632; HEPPNER GH, 1983, CANCER METAST REV, V2, P5, DOI 10.1007/BF00046903; Hermann PC, 2007, CELL STEM CELL, V1, P313, DOI 10.1016/j.stem.2007.06.002; Hiramatsu H, 2003, BLOOD, V102, P873, DOI 10.1182/blood-2002-09-2755; Hirsch HA, 2013, P NATL ACAD SCI USA, V110, P972, DOI 10.1073/pnas.1221055110; Hollier BG, 2009, J MAMMARY GLAND BIOL, V14, P29, DOI 10.1007/s10911-009-9110-3; Ishikawa F, 2007, NAT BIOTECHNOL, V25, P1315, DOI 10.1038/nbt1350; Jaiswal S, 2009, CELL, V138, P271, DOI 10.1016/j.cell.2009.05.046; Jan M, 2011, P NATL ACAD SCI USA, V108, P5009, DOI 10.1073/pnas.1100551108; Jeter CR, 2009, STEM CELLS, V27, P993, DOI 10.1002/stem.29; Jin LQ, 2006, NAT MED, V12, P1167, DOI 10.1038/nm1483; Jinushi M, 2011, P NATL ACAD SCI USA, V108, P12425, DOI 10.1073/pnas.1106645108; Jorissen RN, 2003, EXP CELL RES, V284, P31, DOI 10.1016/S0014-4827(02)00098-8; Junttila MR, 2013, NATURE, V501, P346, DOI 10.1038/nature12626; Kaur S, 2013, SCI REP-UK, V3, DOI 10.1038/srep01673; Kikushige Y, 2010, CELL STEM CELL, V7, P708, DOI 10.1016/j.stem.2010.11.014; Kim J, 2009, EXP HEMATOL, V37, P1445, DOI 10.1016/j.exphem.2009.09.004; Kong DJ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012445; Korkaya H, 2011, CLIN CANCER RES, V17, P6125, DOI 10.1158/1078-0432.CCR-10-2743; Korkaya H, 2011, J CLIN INVEST, V121, P3804, DOI 10.1172/JCI57099; Korkaya H, 2011, CELL CYCLE, V10, P2623, DOI 10.4161/cc.10.16.16414; Kreso A, 2014, CELL STEM CELL, V14, P275, DOI 10.1016/j.stem.2014.02.006; Kryczek I, 2006, J EXP MED, V203, P871, DOI 10.1084/jem.20050930; Kusmartsev S, 2005, J IMMUNOL, V175, P4583, DOI 10.4049/jimmunol.175.7.4583; Kusmartsev S, 2005, J IMMUNOL, V174, P4880, DOI 10.4049/jimmunol.174.8.4880; LaBarge MA, 2010, CLIN CANCER RES, V16, P3121, DOI 10.1158/1078-0432.CCR-09-2933; Laoui D, 2014, CANCER RES, V74, P24, DOI 10.1158/0008-5472.CAN-13-1196; LAPIDOT T, 1994, NATURE, V367, P645, DOI 10.1038/367645a0; Lewis CE, 2006, CANCER RES, V66, P605, DOI 10.1158/0008-5472.CAN-05-4005; Li L, 2014, CELL DEATH DIFFER; Li SH, 2013, MOL CELL BIOCHEM, V373, P217, DOI 10.1007/s11010-012-1493-6; Li T, 2010, LAB INVEST, V90, P234, DOI 10.1038/labinvest.2009.127; Li XX, 2008, JNCI-J NATL CANCER I, V100, P672, DOI 10.1093/jnci/djn123; Liao XY, 2009, CARCINOGENESIS, V30, P131, DOI 10.1093/carcin/bgn230; Lim J, 2012, DEVELOPMENT, V139, P3471, DOI 10.1242/dev.071209; Liu DQ, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003291; Liu RY, 2014, INT J ONCOL, V44, P1643, DOI 10.3892/ijo.2014.2310; Liu SL, 2011, CANCER RES, V71, P614, DOI 10.1158/0008-5472.CAN-10-0538; Locati M, 2013, ADV IMMUNOL, V120, P163, DOI 10.1016/B978-0-12-417028-5.00006-5; London A, 2011, J EXP MED, V208, P23, DOI 10.1084/jem.20101202; Lu HH, 2014, NAT CELL BIOL, V16, P1105, DOI 10.1038/ncb3041; Lu HT, 2006, MOL CANCER RES, V4, P221, DOI 10.1158/1541-7786.MCR-05-0261; Lu ZM, 2003, CANCER CELL, V4, P499, DOI 10.1016/S1535-6108(03)00304-0; Ludin A, 2012, NAT IMMUNOL, V13, P1072, DOI 10.1038/ni.2408; Majeti R, 2009, CELL, V138, P286, DOI 10.1016/j.cell.2009.05.045; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Mantovani A, 2004, EUR J CANCER, V40, P1660, DOI 10.1016/j.ejca.2004.03.016; Mantovani A, 2008, NATURE, V454, P436, DOI 10.1038/nature07205; Mantovani A, 2013, J PATHOL, V229, P176, DOI 10.1002/path.4133; Mantovani A, 2009, CANCER CELL, V16, P173, DOI 10.1016/j.ccr.2009.08.014; Margol AS, 2015, CLIN CANCER RES, V21, P1457, DOI 10.1158/1078-0432.CCR-14-1144; Marmor MD, 2004, ONCOGENE, V23, P2057, DOI 10.1038/sj.onc.1207390; Marquardt JU, 2011, HEPATOLOGY, V54, P1031, DOI 10.1002/hep.24454; Medema JP, 2013, NAT CELL BIOL, V15, P338, DOI 10.1038/ncb2717; Mitchem JB, 2013, CANCER RES, V73, P1128, DOI 10.1158/0008-5472.CAN-12-2731; Monney L, 2002, NATURE, V415, P536, DOI 10.1038/415536a; Moore KA, 2006, SCIENCE, V311, P1880, DOI 10.1126/science.1110542; Morel AP, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002888; Morrison SJ, 2006, NATURE, V441, P1068, DOI 10.1038/nature04956; Mosser DM, 2008, NAT REV IMMUNOL, V8, P958, DOI 10.1038/nri2448; Movahedi K, 2010, CANCER RES, V70, P5728, DOI 10.1158/0008-5472.CAN-09-4672; Murray PJ, 2014, IMMUNITY, V41, P14, DOI 10.1016/j.immuni.2014.06.008; Ngiow SF, 2011, CANCER RES, V71, P3540, DOI 10.1158/0008-5472.CAN-11-0096; Nie ZQ, 2012, CELL, V151, P68, DOI 10.1016/j.cell.2012.08.033; Ninov N, 2012, DEVELOPMENT, V139, P1557, DOI 10.1242/dev.076000; Niu GL, 2002, ONCOGENE, V21, P2000, DOI 10.1038/sj.onc.1205260; Normanno N, 2006, GENE, V366, P2, DOI 10.1016/j.gene.2005.10.018; Normanno N, 2001, FRONT BIOSCI-LANDMRK, V6, pD685, DOI 10.2741/Normano; Noy R, 2014, IMMUNITY, V41, P49, DOI 10.1016/j.immuni.2014.06.010; NUSSE R, 1984, NATURE, V307, P131, DOI 10.1038/307131a0; OSULLIVAN C, 1993, LANCET, V342, P148, DOI 10.1016/0140-6736(93)91348-P; Pawlus MR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072358; PEOPLES GE, 1995, P NATL ACAD SCI USA, V92, P6547, DOI 10.1073/pnas.92.14.6547; Pollard JW, 2009, NAT REV IMMUNOL, V9, P259, DOI 10.1038/nri2528; Ponti D, 2005, CANCER RES, V65, P5506, DOI 10.1158/0008-5472.CAN-05-0626; Porta C, 2009, IMMUNOBIOLOGY, V214, P761, DOI 10.1016/j.imbio.2009.06.014; Porta C, 2009, P NATL ACAD SCI USA, V106, P14978, DOI 10.1073/pnas.0809784106; Raggi C, 2015, J HEPATOL, V62, P198, DOI 10.1016/j.jhep.2014.09.007; Raggi C, 2014, HEPATOLOGY, V59, P2251, DOI 10.1002/hep.27026; Rais Y, 2013, NATURE, V502, P65, DOI 10.1038/nature12587; Richards DM, 2013, CANCER MICROENVIRON, V6, P179, DOI 10.1007/s12307-012-0123-x; Ries CH, 2014, CANCER CELL, V25, P846, DOI 10.1016/j.ccr.2014.05.016; Riether C, 2015, CELL DEATH DIFFER, V22, P187, DOI 10.1038/cdd.2014.89; Rokavec M, 2014, J CLIN INVEST, V124, P1853, DOI 10.1172/JCI73531; SALOMON DS, 1995, CRIT REV ONCOL HEMAT, V19, P183, DOI 10.1016/1040-8428(94)00144-I; SALOMON DS, 1990, CANCER CELL-MON REV, V2, P389; Samanani S, 2013, CNS NEUROL DISORD-DR, V12, P741, DOI 10.2174/18715273113126660177; Sapi E, 1999, P SOC EXP BIOL MED, V220, P1, DOI 10.1046/j.1525-1373.1999.d01-1.x; Sarkar S, 2014, NAT NEUROSCI, V17, P46, DOI 10.1038/nn.3597; Schepers AG, 2012, SCIENCE, V337, P730, DOI 10.1126/science.1224676; Schoenhals M, 2009, BIOCHEM BIOPH RES CO, V383, P157, DOI 10.1016/j.bbrc.2009.02.156; Segal E, 2004, NAT GENET, V36, P1090, DOI 10.1038/ng1434; Segall JE, 1996, CLIN EXP METASTAS, V14, P61, DOI 10.1007/BF00157687; Shang YJ, 2013, ONCOL LETT, V6, P490, DOI 10.3892/ol.2013.1410; Sherry MM, 2009, STEM CELLS, V27, P2383, DOI 10.1002/stem.185; Shigdar S, 2012, THER DELIV, V3, P227, DOI 10.4155/TDE.11.148; Sica A, 2012, J CLIN INVEST, V122, P787, DOI 10.1172/JCI59643; Sikora A, 2007, J PHYSIOL PHARMACOL, V58, P43; Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128; Siveen KS, 2009, IMMUNOL LETT, V123, P97, DOI 10.1016/j.imlet.2009.02.011; Smith RE, 2003, BLOOD, V102, P2532, DOI 10.1182/blood-2002-11-3596; Song Z, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017687; Su SC, 2014, CANCER CELL, V25, P605, DOI 10.1016/j.ccr.2014.03.021; Takagi S, 2012, BLOOD, V119, P2768, DOI 10.1182/blood-2011-05-353201; Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024; Tavor S, 2004, CANCER RES, V64, P2817, DOI 10.1158/0008-5472.CAN-03-3693; Thayer SP, 2003, NATURE, V425, P851, DOI 10.1038/nature02009; Theocharides APA, 2012, J EXP MED, V209, P1883, DOI 10.1084/jem.20120502; Tseng D, 2013, P NATL ACAD SCI USA, V110, P11103, DOI 10.1073/pnas.1305569110; van Beek EM, 2005, J IMMUNOL, V175, P7781, DOI 10.4049/jimmunol.175.12.7781; Virchow R, 1881, Br Med J, V2, P198; Wan SS, 2014, GASTROENTEROLOGY, V147, P1393, DOI 10.1053/j.gastro.2014.08.039; Weizman N, 2014, ONCOGENE, V33, P3812, DOI 10.1038/onc.2013.357; Wellner U, 2009, NAT CELL BIOL, V11, P1487, DOI 10.1038/ncb1998; Wilson E, 2014, J CELL SCI, V127, P3039, DOI 10.1242/jcs.140434; Winkler IG, 2010, BLOOD, V116, P4815, DOI 10.1182/blood-2009-11-253534; Wong DJ, 2008, CELL STEM CELL, V2, P333, DOI 10.1016/j.stem.2008.02.009; Wu J, 2013, DNA CELL BIOL, V32, P648, DOI 10.1089/dna.2013.2116; Wynn TA, 2013, NATURE, V496, P445, DOI 10.1038/nature12034; Yamashina T, 2014, CANCER RES, V74, P2698, DOI 10.1158/0008-5472.CAN-13-2169; Yang J, 2013, STEM CELLS, V31, P248, DOI 10.1002/stem.1281; Yang L, 2004, CANCER CELL, V6, P409, DOI 10.1016/j.ccr.2004.08.031; Zhang Y, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019664; Zhang Y, 2013, EUR J CANCER, V49, P3320, DOI 10.1016/j.ejca.2013.06.005; Zhao C, 2009, NATURE, V458, P776, DOI 10.1038/nature07737; Zhao XW, 2011, P NATL ACAD SCI USA, V108, P18342, DOI 10.1073/pnas.1106550108; Zhou B, 2014, J CLIN INVEST, V124, P553, DOI 10.1172/JCI69804; Zhou S, 2001, NAT MED, V7, P1028, DOI 10.1038/nm0901-1028; Zhou WC, 2015, NAT CELL BIOL, V17, P170, DOI 10.1038/ncb3090; Zushi SI, 1998, INT J CANCER, V78, P326, DOI 10.1002/(SICI)1097-0215(19981029)78:3<326::AID-IJC12>3.0.CO;2-4	181	90	95	0	42	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 11	2016	35	6					671	682		10.1038/onc.2015.132	http://dx.doi.org/10.1038/onc.2015.132			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DE0RF	25961921				2023-01-03	WOS:000370331300001
J	Satcher, D; Hook, EW; Coleman, E				Satcher, David; Hook, Edward W., III; Coleman, Eli			Sexual Health in America Improving Patient Care and Public Health	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							INTERVENTIONS		[Satcher, David] Morehouse Sch Med, Satcher Hlth Leadership Inst, Atlanta, GA 30310 USA; [Hook, Edward W., III] Univ Alabama Birmingham, Div Infect Dis, Birmingham, AL USA; [Coleman, Eli] Univ Minnesota, Sch Med, Dept Family Med & Community Hlth, Minneapolis, MN 55454 USA	Morehouse School of Medicine; University of Alabama System; University of Alabama Birmingham; University of Minnesota System; University of Minnesota Twin Cities	Coleman, E (corresponding author), Univ Minnesota, Sch Med, Dept Family Med & Community Hlth, Program Human Sexual, 1300 S Second St,Ste 180, Minneapolis, MN 55454 USA.	colem001@umn.edu						Becasen JS, 2015, J SEX RES, V52, P433, DOI 10.1080/00224499.2014.947399; Frieden TR, 2010, AM J PUBLIC HEALTH, V100, P590, DOI 10.2105/AJPH.2009.185652; Hogben M, 2015, J SEX RES, V52, P444, DOI 10.1080/00224499.2014.973100; Ivankovich MB, 2013, PUBLIC HEALTH REP, V128, P102, DOI 10.1177/00333549131282S112; Mustanski B, 2015, J SEX RES, V52, P220, DOI 10.1080/00224499.2013.867924; Swartzendruber A, 2010, JAMA-J AM MED ASSOC, V304, P1005, DOI 10.1001/jama.2010.1252; U.S. Department of Health and Human Services, 2001, SURG GEN CALL ACT PR	7	46	46	0	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 25	2015	314	8					765	766		10.1001/jama.2015.6831	http://dx.doi.org/10.1001/jama.2015.6831			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	CP6SA	26087251				2023-01-03	WOS:000360017200010
J	Zhang, YL; Lin, CR; Zhang, LL; Cui, YW; Gu, Y; Guo, JK; Wu, D; Li, Q; Song, WS				Zhang, Yulian; Lin, Cuiru; Zhang, Linlin; Cui, Yuanwu; Gu, Yun; Guo, Jiakui; Wu, Di; Li, Qiang; Song, Wanshan			Cognitive Improvement during Treatment for Mild Alzheimer's Disease with a Chinese Herbal Formula: A Randomized Controlled Trial	PLOS ONE			English	Article							DOUBLE-BLIND; TETRAHYDROXYSTILBENE GLUCOSIDE; MEMORY ABILITIES; 23 MG/D; DONEPEZIL; ICARIIN; MODERATE; TETRAMETHYLPYRAZINE; 24-WEEK; DEFICITS	Objectives To explore the efficacy of Chinese herbal formula compared with donepezil 5mg/day in patients with mild Alzheimer's disease (AD). Methods Patients with mild AD meeting the criteria were randomized into Chinese herbal formula Yishen Huazhuo decoction (YHD) group and donepezil hydrochloride (DH) group during the 24-week trial. The outcomes were measured by ADAS-cog, MMSE, ADL, and NPI with linear mixed-effect models. Results 144 patients were randomized. The mean scores of ADAS-cog and MMSE in both YHD group and DH group both improved at the end of the 24-week treatment period. The results also revealed that YHD was better at improving the mean scores of ADAS-cog and MMSE than DH. Linear mixed-effect models with repeated measures showed statistical significance in time x group interaction effect of ADAS-cog and also in time x group interaction effect of MMSE. The data showed YHD was superior to DH in improving the scores and long term efficacy. Conclusions Our study suggests that Chinese herbal formula YHD is beneficial and effective for cognitive improvement in patients with mild AD and the mechanism might be through reducing amyloid-beta (A beta) plaque deposition in the hippocampus.	[Zhang, Yulian; Lin, Cuiru; Cui, Yuanwu; Guo, Jiakui; Song, Wanshan] Tianjin Univ Tradit Chinese Med, Affiliated Hosp 2, Dept Acupuncture & Cerebropathy, Tianjin, Peoples R China; [Zhang, Linlin; Gu, Yun] Shanghai Univ Tradit Chinese Med, Longhua Hosp, Dept Geriatr, Tianjin, Peoples R China; [Wu, Di] Tianjin Huanhu Hosp, Dept Tradit Chinese Med, Tianjin, Peoples R China; [Li, Qiang] Tianjin Univ Tradit Chinese Med, Grad Inst, Tianjin, Peoples R China	Tianjin University of Traditional Chinese Medicine; Shanghai University of Traditional Chinese Medicine; Tianjin University of Traditional Chinese Medicine	Zhang, YL (corresponding author), Tianjin Univ Tradit Chinese Med, Affiliated Hosp 2, Dept Acupuncture & Cerebropathy, Tianjin, Peoples R China.	zhyl220@126.com			973 Program [2010CB530405]	973 Program(National Basic Research Program of China)	This work was supported by the 973 Program: 2010CB530405 (http://www.973.gov.cn/English/Index.aspx). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 1991, GERIATRICS; Bi M, 2011, NEUROSCI LETT, V501, P35, DOI 10.1016/j.neulet.2011.06.036; Brookmeyer R, 2007, ALZHEIMERS DEMENT, V3, P186, DOI 10.1016/j.jalz.2007.04.381; Burns A, 1999, DEMENT GERIATR COGN, V10, P237, DOI 10.1159/000017126; Cheng XR, 2007, CELL BIOL INT, V31, P438, DOI 10.1016/j.cellbi.2006.10.001; CUMMINGS JL, 1994, NEUROLOGY, V44, P2308, DOI 10.1212/WNL.44.12.2308; Cummings JL, 2004, NEW ENGL J MED, V351, P56, DOI 10.1056/NEJMra040223; Cummings JL, 1999, INT J NEUROPSYCHOPH, V2, P59, DOI 10.1017/S1461145799001340; Fan LH, 2006, BMC NEUROSCI, V7, DOI 10.1186/1471-2202-7-48; Farlow MR, 2010, CLIN THER, V32, P1234, DOI 10.1016/j.clinthera.2010.06.019; Feldman H, 2001, NEUROLOGY, V57, P613, DOI 10.1212/WNL.57.4.613; Francis PT, 1999, J NEUROL NEUROSUR PS, V66, P137, DOI 10.1136/jnnp.66.2.137; Gatz M, 2006, ARCH GEN PSYCHIAT, V63, P168, DOI 10.1001/archpsyc.63.2.168; Geng YT, 2010, BIOL PHARM BULL, V33, P836, DOI 10.1248/bpb.33.836; Goedert M, 1991, BRAIN PATHOL, V1, P279, DOI 10.1111/j.1750-3639.1991.tb00671.x; HARDY J, 1991, TRENDS PHARMACOL SCI, V12, P383, DOI 10.1016/0165-6147(91)90609-V; Homma A, 2008, DEMENT GERIATR COGN, V25, P399, DOI 10.1159/000122961; Itzhaki RF, 2008, J ALZHEIMERS DIS, V13, P393; Kim M, 2014, EUR J PHARMACOL, V740, P504, DOI 10.1016/j.ejphar.2014.06.037; Lange S, 2005, BIOMETRICAL J, V47, P12, DOI 10.1002/bimj.200410085; Lei H, 2003, ACTA PHARMACOL SIN, V24, P230; Li F, 2010, PHARMACOL BIOCHEM BE, V96, P301, DOI 10.1016/j.pbb.2010.05.021; Liu JC, 2010, YAKUGAKU ZASSHI, V130, P737, DOI 10.1248/yakushi.130.737; Liu P, 2013, J TRADIT CHIN MED, V33, P449, DOI 10.1016/S0254-6272(13)60147-8; Luo Y, 2007, CLIN EXP PHARMACOL P, V34, P792, DOI 10.1111/j.1440-1681.2007.04647.x; Miao Ying-chun, 2012, Zhong Xi Yi Jie He Xue Bao, V10, P390, DOI 10.3736/jcim20120407; Mohs R C, 1997, ADV ALZ DIS, P407; MUNGAS D, 1991, GERIATRICS, V46, P54; Nadkarni NK, 2006, TRIAL DESIGNS OUTCOM, P85, DOI [10.1080/19552068.2010.9635845, DOI 10.1080/19552068.2010.9635845]; Nie J, 2010, EUR J PHARMACOL, V626, P213, DOI 10.1016/j.ejphar.2009.09.039; Nozawa M, 2009, PSYCHOGERIATRICS, V9, P50, DOI 10.1111/j.1479-8301.2009.00291.x; Rogers SL, 1998, NEUROLOGY, V50, P136, DOI 10.1212/WNL.50.1.136; Rogers SL, 1998, ARCH INTERN MED, V158, P1021, DOI 10.1001/archinte.158.9.1021; Rogers SL, 1998, EUR NEUROPSYCHOPHARM, V8, P67, DOI 10.1016/S0924-977X(97)00079-5; Sabbagh M, 2013, BMC GERIATR, V13, DOI 10.1186/1471-2318-13-56; Sabbagh M, 2011, BMC NEUROL, V11, DOI 10.1186/1471-2377-11-21; Sasaki S, 2014, DEMENT GER COGN D EX, V4, P131, DOI 10.1159/000362871; Shcherbatykh I, 2007, J ALZHEIMERS DIS, V11, P191; Song YH, 2011, J PHARM PHARMACOL, V63, P541, DOI 10.1111/j.2042-7158.2010.01241.x; Tohda C, 2006, BRIT J PHARMACOL, V149, P532, DOI 10.1038/sj.bjp.0706865; Wang R, 2007, NEUROSCIENCE, V149, P739, DOI 10.1016/j.neuroscience.2007.07.065; Wang T, 2009, FREE RADICAL BIO MED, V47, P229, DOI 10.1016/j.freeradbiomed.2009.02.027; Wang Y, 2010, ACTA PHARMACOL SIN, V31, P649, DOI 10.1038/aps.2010.46; Waring SC, 2008, ARCH NEUROL-CHICAGO, V65, P329, DOI 10.1001/archneur.65.3.329; Whitehead A, 2004, INT J GERIATR PSYCH, V19, P624, DOI 10.1002/gps.1133; Wu B, 2012, J ETHNOPHARMACOL, V142, P746, DOI 10.1016/j.jep.2012.05.056; Xu CQ, 2010, EUR J PHARMACOL, V642, P146, DOI 10.1016/j.ejphar.2010.05.012; Yan H, 2007, CLIN INTERV AGING, V2, P201; Yatabe Y, 2013, PSYCHOGERIATRICS, V13, P88, DOI 10.1111/psyg.12004; Zeng KW, 2010, NEUROPHARMACOLOGY, V59, P542, DOI 10.1016/j.neuropharm.2010.07.020; Zhang L, 2006, BEHAV BRAIN RES, V173, P246, DOI 10.1016/j.bbr.2006.06.034; Zhang L, 2014, INT J BIOL SCI, V10, P181, DOI 10.7150/ijbs.6232; Zhang SJ, 2012, ASIAN PAC J TROP MED, V5, P661, DOI 10.1016/S1995-7645(12)60135-7; Zhao Lin, 2008, Zhongguo Yaolixue Tongbao, V24, P1088; Zhou JM, 2011, INT IMMUNOPHARMACOL, V11, P890, DOI 10.1016/j.intimp.2011.01.007; Zhou L, 2012, CAN J PHYSIOL PHARM, V90, P1446, DOI 10.1139/y2012-121	56	30	37	2	28	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 15	2015	10	6							e0130353	10.1371/journal.pone.0130353	http://dx.doi.org/10.1371/journal.pone.0130353			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CK6HU	26076022	Green Published, gold, Green Submitted			2023-01-03	WOS:000356329900166
J	Kling, A; Lukat, P; Almeida, DV; Bauer, A; Fontaine, E; Sordello, S; Zaburannyi, N; Herrmann, J; Wenzel, SC; Konig, C; Ammerman, NC; Barrio, MB; Borchers, K; Bordon-Pallier, F; Bronstrup, M; Courtemanche, G; Gerlitz, M; Geslin, M; Hammann, P; Heinz, DW; Hoffmann, H; Klieber, S; Kohlmann, M; Kurz, M; Lair, C; Matter, H; Nuermberger, E; Tyagi, S; Fraisse, L; Grosset, JH; Lagrange, S; Muller, R				Kling, Angela; Lukat, Peer; Almeida, Deepak V.; Bauer, Armin; Fontaine, Evelyne; Sordello, Sylvie; Zaburannyi, Nestor; Herrmann, Jennifer; Wenzel, Silke C.; Koenig, Claudia; Ammerman, Nicole C.; Barrio, Maria Belen; Borchers, Kai; Bordon-Pallier, Florence; Broenstrup, Mark; Courtemanche, Gilles; Gerlitz, Martin; Geslin, Michel; Hammann, Peter; Heinz, Dirk W.; Hoffmann, Holger; Klieber, Sylvie; Kohlmann, Markus; Kurz, Michael; Lair, Christine; Matter, Hans; Nuermberger, Eric; Tyagi, Sandeep; Fraisse, Laurent; Grosset, Jacques H.; Lagrange, Sophie; Mueller, Rolf			Targeting DnaN for tuberculosis therapy using novel griselimycins	SCIENCE			English	Article							BACTERIAL SLIDING CLAMP; MYCOBACTERIUM-SMEGMATIS; REPLICATION; ORIGIN; MODEL	The discovery of Streptomyces-produced streptomycin founded the age of tuberculosis therapy. Despite the subsequent development of a curative regimen for this disease, tuberculosis remains a worldwide problem, and the emergence of multidrug-resistant Mycobacterium tuberculosis has prioritized the need for new drugs. Here we show that new optimized derivatives from Streptomyces-derived griselimycin are highly active against M. tuberculosis, both in vitro and in vivo, by inhibiting the DNA polymerase sliding clamp DnaN. We discovered that resistance to griselimycins, occurring at very low frequency, is associated with amplification of a chromosomal segment containing dnaN, as well as the ori site. Our results demonstrate that griselimycins have high translational potential for tuberculosis treatment, validate DnaN as an antimicrobial target, and capture the process of antibiotic pressure-induced gene amplification.	[Kling, Angela; Lukat, Peer; Zaburannyi, Nestor; Herrmann, Jennifer; Wenzel, Silke C.; Mueller, Rolf] Univ Saarland, Helmholtz Ctr Infect Res & Pharmaceut Biotechnol, Helmholtz Inst Pharmaceut Res Saarland HIPS, Dept Microbial Nat Prod, D-66123 Saarbrucken, Germany; [Kling, Angela; Lukat, Peer; Zaburannyi, Nestor; Herrmann, Jennifer; Wenzel, Silke C.; Heinz, Dirk W.; Mueller, Rolf] German Ctr Infect Res DZIF, Partner Site Hannover Braunschweig, Hannover, Germany; [Lukat, Peer; Broenstrup, Mark; Heinz, Dirk W.] Helmholtz Ctr Infect Res HZI, D-38124 Braunschweig, Germany; [Almeida, Deepak V.; Ammerman, Nicole C.; Nuermberger, Eric; Tyagi, Sandeep; Grosset, Jacques H.] Johns Hopkins Univ, Ctr TB Res, Sch Med, Baltimore, MD 21231 USA; [Almeida, Deepak V.; Ammerman, Nicole C.; Grosset, Jacques H.] KwaZulu Natal Res Inst TB & HIV K RITH, ZA-4001 Durban, South Africa; [Bauer, Armin; Koenig, Claudia; Borchers, Kai; Broenstrup, Mark; Gerlitz, Martin; Hoffmann, Holger; Kohlmann, Markus; Kurz, Michael; Matter, Hans] Sanofi Aventis R&D, LGCR Chem, D-65926 Frankfurt, Germany; [Fontaine, Evelyne; Sordello, Sylvie; Barrio, Maria Belen; Courtemanche, Gilles; Geslin, Michel; Lair, Christine; Fraisse, Laurent; Lagrange, Sophie] Sanofi Aventis R&D, Infect Dis Therapeut Strateg Unit, F-31036 Toulouse, France; [Bordon-Pallier, Florence] Sanofi Aventis R&D, Strategy Sci Policy & External Innovat S&I, F-75008 Paris, France; [Hammann, Peter] Sanofi Aventis R&D, Infect Dis Therapeut Strateg Unit, D-65926 Frankfurt, Germany; [Klieber, Sylvie] Sanofi Aventis R&D, Disposit Safety & Anim Res, F-34184 Montpellier, France	Helmholtz Association; Saarland University; German Center for Infection Research; Helmholtz Association; Helmholtz-Center for Infection Research; Johns Hopkins University; Sanofi-Aventis; Sanofi-Aventis; Sanofi France; Sanofi-Aventis; Sanofi France; Sanofi-Aventis; Sanofi-Aventis; Sanofi France	Muller, R (corresponding author), Univ Saarland, Helmholtz Ctr Infect Res & Pharmaceut Biotechnol, Helmholtz Inst Pharmaceut Res Saarland HIPS, Dept Microbial Nat Prod, D-66123 Saarbrucken, Germany.	rolf.mueller@helmholtz-hzi.de	Brönstrup, Mark/AAP-7598-2020; Müller, Rolf/B-1559-2008	Brönstrup, Mark/0000-0002-8971-7045; Müller, Rolf/0000-0002-1042-5665; Courtemanche, Gilles/0000-0002-4887-9961; Herrmann, Jennifer/0000-0003-3398-9938; Ammerman, Nicole C./0000-0001-9359-9144	German Ministry for Education and Research (BMBF) [fZ031598]; Sanofi; KwaZulu-Natal Research Institute for Tuberculosis and HIV; Howard Hughes Medical Institute; Sanofi-Aventis [111937, 103671]	German Ministry for Education and Research (BMBF)(Federal Ministry of Education & Research (BMBF)); Sanofi; KwaZulu-Natal Research Institute for Tuberculosis and HIV; Howard Hughes Medical Institute(Howard Hughes Medical Institute); Sanofi-Aventis(Sanofi-Aventis)	We thank the staff at beamlines P11 at PETRA III (DESY, Hamburg, Germany), X06DA at the Swiss Light Source (PSI, Villigen, Switzerland), and BL14.1 at BESSY II (Berlin, Germany) for assistance during data collection. R.M.'s research laboratory was supported by the German Ministry for Education and Research (BMBF) with grant fZ031598. Sanofi funded its contribution. D.V.A., N.C.A., and J.H.G. are supported by the KwaZulu-Natal Research Institute for Tuberculosis and HIV and the Howard Hughes Medical Institute. D.V.A., S.T., E.N., and J.H.G. were supported by two grants from Sanofi-Aventis (Amd. 14, grant 111937, and Amd. 7, grant 103671). We thank C. Wylegalla for technical assistance. We acknowledge the GMAK group at HZI for assistance with genome sequencing of bacterial mutants; S. Franzblau from the University of Illinois at Chicago for performing the in vitro MIC assays both under hypoxic conditions and with different strains of M. tuberculosis (testing agreement) and for the gift of luciferase-expressing M. tuberculosis; and P. Brodin from the Pasteur Institute, Lille, France, for the gift of GFP-expressing M. tuberculosis H37Rv. We thank A. Upton from the TB Alliance for analysis of the manuscript. The sequence of the Streptomyces sp. DSM-40835 GM biosynthetic gene cluster has been deposited in GenBank (accession number KP211414). Atomic coordinates and structure factors for the reported crystal structures have been deposited in the Protein Data Bank (identification numbers listed in table S12). A.B., E.F., S.S., M.B.B., F.B.-P., M.B., G.C., M. G., P.H., S.K., C.L., H.M., C.K., K.B., M.Ger., H.H., M.Ko., M.Ku., L.F., and S.L. are employed by Sanofi-Aventis R&D. Sanofi has filed patent applications on GM derivatives. Author contributions: A.K. performed resistance studies and DnaN expression and physicochemical analysis of the interaction of the protein with GM derivatives. P.L. performed expression of M. smegmatis DnaN and all structural biology experiments. P.L. and D.W.H. were involved in structural analyses and data interpretation. P.H. and F.B.P. identified the GM series from the Rhone-Poulenc archives. G.C., M.Ges., H.H., A. B., and E.F. designed and synthesized all GM derivatives. S.S., M. B. B., E.F., and A. B. managed the drug optimization program. S.L., M. B., and L.F. supervised the overall GM program at Sanofi. C.L. and M. B. B. designed and performed the in vitro experiments with M. tuberculosis H37Rv. S.K. and M. Ko. designed and performed the pharmacokinetic evaluations. M. Ko. and K.B. elucidated the metabolic degradation of GM and its derivatives. M.Ger. and M.Ku. performed analytics and structure confirmation of GM and its derivatives. M.Ku. and H.M. performed conformational analysis and designed models for GM derivatives with improved pharmacokinetic properties. D.V.A., N.C.A., E.N., S.T., and J.H.G. designed and performed all animal infection experiments, including associated assays, and analyzed all resulting data. N.Z. analyzed all genome data. J.H. performed activity assays and identified and analyzed resistant M. smegmatis strains. S.C.W. and C.K. identified and characterized the GM biosynthetic gene cluster. A.K., P.L., A.B., N.C.A., S.L., M.B., and R.M. conceived the studies and wrote the paper. A.K. and P.L. contributed equally to the study. All authors discussed the results and commented on the manuscript.	Aakre CD, 2013, MOL CELL, V52, P617, DOI 10.1016/j.molcel.2013.10.014; ANGEL JH, 1984, BRIT J DIS CHEST, V78, P330; [Anonymous], 1964, G.B. Patent, Patent No. [966,124, 966124]; Benazet F., 1966, ANTIBIOTICS ADVANCES, P262; Bentley SD, 2002, NATURE, V417, P141, DOI 10.1038/417141a; Bouchaudon J., 1981, Fr. Patent, Patent No. [2,469,395, 2469395]; Broenstrup M, 2013, Patent No. [WO2013053857 A2, 2013053857]; Bunting KA, 2003, EMBO J, V22, P5883, DOI 10.1093/emboj/cdg568; Burnouf DY, 2004, J MOL BIOL, V335, P1187, DOI 10.1016/j.jmb.2003.11.049; Dohrmann PR, 2005, J MOL BIOL, V350, P228, DOI 10.1016/j.jmb.2005.04.065; Drlica K, 2008, ANTIMICROB AGENTS CH, V52, P385, DOI 10.1128/AAC.01617-06; Georgescu RE, 2008, P NATL ACAD SCI USA, V105, P11116, DOI 10.1073/pnas.0804754105; Grosset J, 1998, MYCOBACTERIA, VII, P51; Hartkoorn RC, 2012, EMBO MOL MED, V4, P1032, DOI 10.1002/emmm.201201689; Jolles G, 1971, GB Patent, Patent No. [1,252,553, 1252553]; Lee RE, 2014, NAT MED, V20, P152, DOI 10.1038/nm.3458; Movahedzadeh Farahnaz, 2008, V465, P217, DOI 10.1007/978-1-59745-207-6_14; Newman DJ, 2012, J NAT PROD, V75, P311, DOI 10.1021/np200906s; Noufflard-Guy-Loe H, 1965, Rev Tuberc Pneumol (Paris), V29, P301; Nuermberger EL, 2011, PROG RESPIR RES, V40, P145; Qin MH, 1999, GENE, V233, P121, DOI 10.1016/S0378-1119(99)00148-1; SAITO H, 1988, ZBL BAKT-INT J MED M, V268, P448; Salazar L, 2003, MICROBIOL-SGM, V149, P773, DOI 10.1099/mic.0.25832-0; Salazar L, 1996, MOL MICROBIOL, V20, P283, DOI 10.1111/j.1365-2958.1996.tb02617.x; Smith A., 1946, BMJ-BRIT MED J, V1, P278; TERLAIN B, 1969, CR ACAD SCI C CHIM, V269, P1546; TERLAIN B, 1971, B SOC CHIM FR, P2349; TERLAIN B, 1971, B SOC CHIM FR, P2357; TOYOHARA M, 1987, ANN INST PASTEUR MIC, V138, P737, DOI 10.1016/0769-2609(87)90151-7; Wijffels G, 2005, IUBMB LIFE, V57, P413, DOI 10.1080/15216540500138246; Wijffels G, 2011, J MED CHEM, V54, P4831, DOI 10.1021/jm2004333; World Health Organization, 2014, ANTIMICROBIAL RESIST; Yin Z, 2014, J MED CHEM, V57, P2799, DOI 10.1021/jm500122r	33	201	208	2	82	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 5	2015	348	6239					1106	1112		10.1126/science.aaa4690	http://dx.doi.org/10.1126/science.aaa4690			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CJ6FY	26045430				2023-01-03	WOS:000355590500040
J	Padhukasahasram, B; Reddy, CK; Li, Y; Lanfear, DE				Padhukasahasram, Badri; Reddy, Chandan K.; Li, Yan; Lanfear, David E.			Joint Impact of Clinical and Behavioral Variables on the Risk of Unplanned Readmission and Death after a Heart Failure Hospitalization	PLOS ONE			English	Article							PROPORTIONAL HAZARDS MODEL; ADAPTIVE LASSO; SELECTION; REHOSPITALIZATION; REGULARIZATION; REGRESSION	Most current methods for modeling rehospitalization events in heart failure patients make use of only clinical and medications data that is available in the electronic health records. However, information about patient-reported functional limitations, behavioral variables and socio-economic background of patients may also play an important role in predicting the risk of readmission in heart failure patients. We developed methods for predicting the risk of rehospitalization in heart failure patients using models that integrate clinical characteristics with patient-reported functional limitations, behavioral and socio-economic characteristics. Our goal was to estimate the predictive accuracy of the joint model and compare it with models that make use of clinical data alone or behavioral and socio-economic characteristics alone, using real patient data. We collected data about the occurrence of hospital readmissions from a cohort of 789 heart failure patients for whom a range of clinical and behavioral characteristics data is also available. We applied the Cox model, four different variants of the Cox proportional hazards framework as well as an alternative non-parametric approach and determined the predictive accuracy for different categories of variables. The concordance index obtained from the joint prediction model including all types of variables was significantly higher than the accuracy obtained from using only clinical factors or using only behavioral, socioeconomic background and functional limitations in patients as predictors. Collecting information on behavior, patient-reported estimates of physical limitations and frailty and socio-economic data has significant value in the predicting the risk of readmissions with regards to heart failure events and can lead to substantially more accurate events prediction models.	[Padhukasahasram, Badri; Lanfear, David E.] Henry Ford Hlth Syst, Ctr Hlth Policy & Hlth Serv Res, Detroit, MI USA; [Reddy, Chandan K.; Li, Yan] Wayne State Univ, Dept Comp Sci, Detroit, MI 48202 USA	Henry Ford Health System; Henry Ford Hospital; Wayne State University	Padhukasahasram, B (corresponding author), Henry Ford Hlth Syst, Ctr Hlth Policy & Hlth Serv Res, Detroit, MI USA.	bpadhuk1@hfhs.org		Reddy, Chandan/0000-0003-2839-3662	R01 grant [HL103871]; National Cancer Institute of National Institutes of Health [R21CA175974]; US National Science Foundation [IIS-1231742, IIS-1242304]; Div Of Information & Intelligent Systems [1231742, 1242304] Funding Source: National Science Foundation; NATIONAL CANCER INSTITUTE [R21CA175974] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL103871] Funding Source: NIH RePORTER	R01 grant; National Cancer Institute of National Institutes of Health; US National Science Foundation(National Science Foundation (NSF)); Div Of Information & Intelligent Systems(National Science Foundation (NSF)NSF - Directorate for Computer & Information Science & Engineering (CISE)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	This work was supported by R01 grant HL103871 to Dr. David E. Lanfear. This work was also supported in part by the National Cancer Institute of the National Institutes of Health under Award Number R21CA175974 and the US National Science Foundation grants IIS-1231742 and IIS-1242304 to Dr. Chandan K. Reddy. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	AALEN O, 1978, ANN STAT, V6, P701, DOI 10.1214/aos/1176344247; Binder H, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-14; Breiman L., 2001, Machine Learning, V45, P5, DOI 10.1023/A:1010933404324; COX DR, 1972, J R STAT SOC B, V34, P187; Desai AS, 2012, CIRCULATION, V126, P501, DOI 10.1161/CIRCULATIONAHA.112.125435; Dunlay SM, 2010, EUR J HEART FAIL, V12, P367, DOI 10.1093/eurjhf/hfq019; Fan JQ, 2002, ANN STAT, V30, P74; Fonarow GC, 1997, J AM COLL CARDIOL, V30, P725, DOI 10.1016/S0735-1097(97)00208-8; Gheorghiade M, 2013, J AM COLL CARDIOL, V61, P391, DOI 10.1016/j.jacc.2012.09.038; Gonen M, 2005, BIOMETRIKA, V92, P965, DOI 10.1093/biomet/92.4.965; Hans C, 2009, BIOMETRIKA, V96, P835, DOI 10.1093/biomet/asp047; HOERL AE, 1970, TECHNOMETRICS, V12, P55, DOI 10.1080/00401706.1970.10488634; Ishwaran H, 2008, ANN APPL STAT, V2, P841, DOI 10.1214/08-AOAS169; Kansagara D, 2011, JAMA-J AM MED ASSOC, V306, P1688, DOI 10.1001/jama.2011.1515; Kim SM, 2013, JNP-J NURSE PRACT, V9, P224, DOI 10.1016/j.nurpra.2013.01.006; KORNOWSKI R, 1995, AM HEART J, V129, P762, DOI 10.1016/0002-8703(95)90327-5; McCullough PA, 2002, J AM COLL CARDIOL, V39, P60, DOI 10.1016/S0735-1097(01)01700-4; Metra M, 2010, CIRCULATION, V122, P1782, DOI 10.1161/CIRCULATIONAHA.110.982207; NELSON W, 1972, TECHNOMETRICS, V14, P945, DOI 10.2307/1267144; Patnaik D., 2011, P 17 ACM SIGKDD INT; Reddy Chandan K, 2015, HEALTHCARE DATA ANAL; Ross JS, 2008, ARCH INTERN MED, V168, P1371, DOI 10.1001/archinte.168.13.1371; Simon N, 2011, J STAT SOFTW, V39, P1; Sun J., 2012, ACM SIGKDD EXPLOR NE, V14, P16, DOI 10.1145/2408736.2408740; Tibshirani R, 1997, STAT MED, V16, P385, DOI 10.1002/(SICI)1097-0258(19970228)16:4<385::AID-SIM380>3.0.CO;2-3; Tibshirani R, 1996, J ROY STAT SOC B MET, V58, P267, DOI 10.1111/j.2517-6161.1996.tb02080.x; VERWEIJ PJM, 1994, STAT MED, V13, P2427, DOI 10.1002/sim.4780132307; Vinzamuri B, 2013, IEEE DATA MINING, P757, DOI 10.1109/ICDM.2013.89; West JA, 1997, AM J CARDIOL, V79, P58, DOI 10.1016/S0002-9149(96)00676-5; Ye Jieping, 2012, SIGKDD Explor, V14, P4; Zhang HH, 2007, BIOMETRIKA, V94, P691, DOI 10.1093/biomet/asm037; Zou H, 2005, J R STAT SOC B, V67, P301, DOI 10.1111/j.1467-9868.2005.00503.x; Zou H, 2006, J AM STAT ASSOC, V101, P1418, DOI 10.1198/016214506000000735	33	14	14	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 4	2015	10	6							e0129553	10.1371/journal.pone.0129553	http://dx.doi.org/10.1371/journal.pone.0129553			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CJ7TC	26042868	Green Submitted, Green Published, gold			2023-01-03	WOS:000355701600099
J	Soldati, GT; Hanazaki, N; Crivos, M; Albuquerque, UP				Soldati, Gustavo Taboada; Hanazaki, Natalia; Crivos, Marta; Albuquerque, Ulysses Paulino			Does Environmental Instability Favor the Production and Horizontal Transmission of Knowledge regarding Medicinal Plants? A Study in Southeast Brazil	PLOS ONE			English	Article							CULTURAL TRANSMISSION; ETHNOBOTANICAL KNOWLEDGE; ADAPTIVE MEMORY; COMMUNITY; EVOLUTION; ANIMALS; FACE; BIAS	Greater socio-environmental instability favors the individual production of knowledge because innovations are adapted to new circumstances. Furthermore, instability stimulates the horizontal transmission of knowledge because this mechanism disseminates adapted information. This study investigates the following hypothesis: Greater socio-environmental instability favors the production of knowledge (innovation) to adapt to new situations, and socio-environmental instability stimulates the horizontal transmission of knowledge, which is a mechanism that diffuses adapted information. In addition, the present study describes "how", "when", "from whom" and the "stimulus/context", in which knowledge regarding medicinal plants is gained or transferred. Data were collected through semi-structured interviews from three groups that represented different levels of socio-environmental instability. Socio-environmental instability did not favor individual knowledge production or any cultural transmission modes, including vertical to horizontal, despite increasing the frequency of horizontal pathways. Vertical transmission was the most important knowledge transmission strategy in all of the groups in which mothers were the most common models (knowledge sources). Significantly, childhood was the most important learning stage, although learning also occurred throughout life. Direct teaching using language was notable as a knowledge transmission strategy. Illness was the main stimulus that triggered local learning. Learning modes about medicinal plants were influenced by the knowledge itself, particularly the dynamic uses of therapeutic resources.	[Soldati, Gustavo Taboada] Univ Fed Juiz de Fora, Juiz De Fora, MG, Brazil; [Hanazaki, Natalia] Univ Fed Santa Catarina, Lab Ecol Humana & Etnobot, Florianopolis, SC, Brazil; [Crivos, Marta] Univ Nacl La Plata, Lab Etnog Aplicada, RA-1900 La Plata, Buenos Aires, Argentina; [Albuquerque, Ulysses Paulino] Univ Fed Rural Pernambuco, Lab Etnobiol Aplicada & Teor, Recife, PE, Brazil	Universidade Federal de Juiz de Fora; Universidade Federal de Santa Catarina (UFSC); National University of La Plata; Universidade Federal Rural de Pernambuco (UFRPE)	Soldati, GT (corresponding author), Univ Fed Juiz de Fora, Juiz De Fora, MG, Brazil.	gtsoldati@gmail.com; upa@db.ufrpe.br	Hanazaki, Natalia/AAT-3830-2021; Soldati, Gustavo/AAO-2162-2020; Albuquerque, Ulysses P/I-5037-2012	Hanazaki, Natalia/0000-0002-7876-6044; Albuquerque, Ulysses P/0000-0002-8131-8429; Soldati, Gustavo/0000-0002-0173-8440	National Council of Scientific and Technologic Development (Conselho Nacional de Desenvolvimento Cientifico e Tecnologico - CNPq); Foundation for Research of the State of Minas Gerais (Fundacao de Amparo a Pesquisa do Estado de Minas Gerais - FAPEMIG)	National Council of Scientific and Technologic Development (Conselho Nacional de Desenvolvimento Cientifico e Tecnologico - CNPq)(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)); Foundation for Research of the State of Minas Gerais (Fundacao de Amparo a Pesquisa do Estado de Minas Gerais - FAPEMIG)	The authors received specific funding for this work from National Council of Scientific and Technologic Development (Conselho Nacional de Desenvolvimento Cientifico e Tecnologico - CNPq). The authors received specific funding to publish this work from Foundation for Research of the State of Minas Gerais (Fundacao de Amparo a Pesquisa do Estado de Minas Gerais - FAPEMIG).	AbSaber A. N., 2003, DOMINIOS NATUREZA BR; Albuquerque UP, 2013, METHODOS TECHINIQUES, P1; Aunger R, 2000, ETHOS, V28, P445, DOI 10.1525/eth.2000.28.3.445; Boyd R, 2005, ORIGINS EVOLUTION HU; Boyd R, 1996, HUMAN NATURE BIOL SO, P355; Cavalli-Sforza L.L., 1981, CULTURAL TRANSMISSIO; Collard M, 2005, EVOLUTION CULTURAL D, P110; Crivos M, 2001, CAMINOS TERAPEUTICOS, P87; Crivos M, 2004, CONTRIBUCION ESTUDIO; Csibra G, 2006, ATTENTION PERFORM, P249; de Medeiros PM, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/807452; Demps K, 2012, EVOL HUM BEHAV, V33, P460, DOI 10.1016/j.evolhumbehav.2011.12.008; Duque-Brasil R, 2007, REV BRAS BIOCIENCIAS, V5, P864; Durham WH, 1992, ANNU REV ANTHROPOL, V19, P187; Ellen R., 2013, UNDERSTANDING CULTUR, P1; Eyssartier C, 2008, J ETHNOBIOL ETHNOMED, V4, DOI 10.1186/1746-4269-4-25; Frazao-Moreira A, 1997, ED SOC CULTURAS, V7, P75, DOI [10.5056/jnm14040, DOI 10.5056/JNM14040]; Garcia GSC, 2006, J ETHNOBIOL ETHNOMED, V2, DOI 10.1186/1746-4269-2-39; Gurven M, 2006, J HUM EVOL, V51, P454, DOI 10.1016/j.jhevol.2006.05.003; Henrich J, 2011, PHILOS T R SOC B, V366, P1139, DOI 10.1098/rstb.2010.0323; Hewlett BS, 2011, PHILOS T R SOC B, V366, P1168, DOI 10.1098/rstb.2010.0373; HEWLETT BS, 1986, AM ANTHROPOL, V88, P922; HEYES CM, 1994, BIOL REV, V69, P207, DOI 10.1111/j.1469-185X.1994.tb01506.x; Holden C, 2005, EVOLUTION CULTURAL D, P13; Hoppitt W, 2008, ADV STUD BEHAV, V38, P105, DOI 10.1016/S0065-3454(08)00003-X; Ladio AH, 2004, BIODIVERS CONSERV, V13, P1153, DOI 10.1023/B:BIOC.0000018150.79156.50; Laland KN, 2004, LEARN BEHAV, V32, P4; Leonti M, 2013, FRONT PHARMACOL, V4, DOI 10.3389/fphar.2013.00092; Leonti M, 2011, J ETHNOPHARMACOL, V134, P542, DOI 10.1016/j.jep.2011.01.017; Lozada M, 2006, ECON BOT, V60, P374, DOI 10.1663/0013-0001(2006)60[374:CTOEKI]2.0.CO;2; Mathez-Stiefel SL, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/959285; McDade TW, 2007, P NATL ACAD SCI USA, V104, P6134, DOI 10.1073/pnas.0609123104; McElreath R, 2008, CURR ANTHROPOL, V49, P307, DOI 10.1086/524364; Mesoudi A, 2004, EVOLUTION, V58, P1; Mesoudi A., 2011, CULTURAL EVOLUTION D, DOI 10.7208/chicago/9780226520452.001.0001; Mesoudi A, 2008, EVOL HUM BEHAV, V29, P350, DOI 10.1016/j.evolhumbehav.2008.04.005; Mesoudi A, 2006, BEHAV BRAIN SCI, V29, P329, DOI 10.1017/S0140525X06009083; Nairne JS, 2008, J MEM LANG, V59, P377, DOI 10.1016/j.jml.2008.06.001; Nairne JS, 2008, PSYCHOL SCI, V19, P176, DOI 10.1111/j.1467-9280.2008.02064.x; Ndhlala AR, 2011, S AFR J BOT, V77, P830, DOI 10.1016/j.sajb.2011.09.002; Ohmagari K, 1997, HUM ECOL, V25, P197, DOI 10.1023/A:1021922105740; Perez-Ojeda del Arco M., 2011, Bioremediation, Biodiversity and Bioavailability, V5, P92; Pieroni A, 2007, ETHNOBIOLOGY, V7; Reyes-Garcia V, 2008, EVOL HUM BEHAV, V29, P275, DOI 10.1016/j.evolhumbehav.2008.02.002; Reyes-Garcia V, 2009, EVOL HUM BEHAV, V30, P274, DOI 10.1016/j.evolhumbehav.2009.02.001; Richerson P.J, 1988, CULTURE EVOLUTIONARY; Setalaphruk C, 2007, J ETHNOBIOL ETHNOMED, V3, DOI 10.1186/1746-4269-3-33; Srithi K, 2009, J ETHNOPHARMACOL, V123, P335, DOI 10.1016/j.jep.2009.02.035; Takahasi K, 1998, J THEOR BIOL, V190, P147, DOI 10.1006/jtbi.1997.0541; Tehrani J., 2013, UNDERSTANDING CULTUR, P148; Tehrani JJ, 2009, EVOL HUM BEHAV, V30, P286, DOI 10.1016/j.evolhumbehav.2009.03.002; Wyndham FS, 2010, HUM ECOL, V38, P87, DOI 10.1007/s10745-009-9287-5; Zar J.H., 2009, BIOSTATISTICAL ANAL; Zarger RK, 2004, CURR ANTHROPOL, V45, P413, DOI 10.1086/420908; Zarger RK, 2002, ETHNOBIOLOGY AND BIOCULTURAL DIVERSITY, PROCEEDINGS, P593; Zent S., 2001, BIOCULTURAL DIVERSIT, P190	56	25	26	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 20	2015	10	5							e0126389	10.1371/journal.pone.0126389	http://dx.doi.org/10.1371/journal.pone.0126389			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	CI7CV	25992578	Green Published, gold			2023-01-03	WOS:000354921400062
J	Dombrowe, I; Juravle, G; Alavash, M; Giessing, C; Hilgetag, CC				Dombrowe, Isabel; Juravle, Georgiana; Alavash, Mohsen; Giessing, Carsten; Hilgetag, Claus C.			The Effect of 10 Hz Repetitive Transcranial Magnetic Stimulation of Posterior Parietal Cortex on Visual Attention	PLOS ONE			English	Article							VISUOSPATIAL ATTENTION; EXCITABILITY; SYSTEM; TMS; NEGLECT; BRAIN; RTMS	Repetitive transcranial magnetic stimulation (rTMS) of the posterior parietal cortex (PPC) at frequencies lower than 5 Hz transiently inhibits the stimulated area. In healthy participants, such a protocol can induce a transient attentional bias to the visual hemifield ipsilateral to the stimulated hemisphere. This bias might be due to a relatively less active stimulated hemisphere and a relatively more active unstimulated hemisphere. In a previous study, Jin and Hilgetag (2008) tried to switch the attention bias from the hemifield ipsilateral to the hemifield contralateral to the stimulated hemisphere by applying high frequency rTMS. High frequency rTMS has been shown to excite, rather than inhibit, the stimulated brain area. However, the bias to the ipsilateral hemifield was still present. The participants' performance decreased when stimuli were presented in the hemifield contralateral to the stimulation site. In the present study we tested if this unexpected result was related to the fact that participants were passively resting during stimulation rather than performing a task. Using a fully crossed factorial design, we compared the effects of high frequency rTMS applied during a visual detection task and high frequency rTMS during passive rest on the subsequent offline performance in the same detection task. Our results were mixed. After sham stimulation, performance was better after rest than after task. After active 10 Hz rTMS, participants' performance was overall better after task than after rest. However, this effect did not reach statistical significance. The comparison of performance after rTMS with task and performance after sham stimulation with task showed that 10 Hz stimulation significantly improved performance in the whole visual field. Thus, although we found a trend to better performance after rTMS with task than after rTMS during rest, we could not reject the hypothesis that high frequency rTMS with task and high frequency rTMS during rest equally affect performance.	[Dombrowe, Isabel] Otto von Guericke Univ, Dept Expt Psychol, Magdeburg, Germany; [Dombrowe, Isabel; Juravle, Georgiana; Hilgetag, Claus C.] Univ Med Ctr Hamburg Eppendorf, Dept Computat Neurosci, Hamburg, Germany; [Juravle, Georgiana] Univ Med Ctr Hamburg Eppendorf, Dept Syst Neurosci, Hamburg, Germany; [Alavash, Mohsen; Giessing, Carsten] Carl von Ossietzky Univ Oldenburg, European Med Sch, Dept Psychol, Biol Psychol Lab, D-26111 Oldenburg, Germany; [Hilgetag, Claus C.] Boston Univ, Dept Hlth Sci, Boston, MA 02215 USA	Otto von Guericke University; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Hamburg; University Medical Center Hamburg-Eppendorf; Carl von Ossietzky Universitat Oldenburg; Boston University	Dombrowe, I (corresponding author), Otto von Guericke Univ, Dept Expt Psychol, Magdeburg, Germany.	idombrowe@gmail.com	Juravle, Georgiana/N-7762-2016; Hilgetag, Claus C/AAH-1760-2020	Juravle, Georgiana/0000-0001-5810-6973; Hilgetag, Claus C/0000-0003-2129-8910; Alavash, Mohsen/0000-0002-4166-2321	Bundesministerium fur Bildung und Forschung (BMBF) [01EW1002]	Bundesministerium fur Bildung und Forschung (BMBF)(Federal Ministry of Education & Research (BMBF))	This work was supported by grant 01EW1002 Bundesministerium fur Bildung und Forschung (BMBF) to CCH. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bartolomeo P, 2002, NEUROSCI BIOBEHAV R, V26, P217, DOI 10.1016/S0149-7634(01)00065-3; Bartolomeo P, 2007, CURR OPIN NEUROL, V20, P381, DOI 10.1097/WCO.0b013e32816aa3a3; Bestmann S, 2002, NEUROIMAGE, V17, P1512, DOI 10.1006/nimg.2002.1266; Brainard DH, 1997, SPATIAL VISION, V10, P433, DOI 10.1163/156856897X00357; Bressler SL, 2010, TRENDS COGN SCI, V14, P277, DOI 10.1016/j.tics.2010.04.004; Chanes L, 2013, J NEUROSCI, V33, P5000, DOI 10.1523/JNEUROSCI.4401-12.2013; Chen R, 1997, NEUROLOGY, V48, P1398, DOI 10.1212/WNL.48.5.1398; Corbetta M, 2002, NAT REV NEUROSCI, V3, P201, DOI 10.1038/nrn755; Corbetta M, 2008, NEURON, V58, P306, DOI 10.1016/j.neuron.2008.04.017; DIPELLEGRINO G, 1995, NEUROPSYCHOLOGIA, V33, P153, DOI 10.1016/0028-3932(94)00111-2; Fierro B, 2000, NEUROREPORT, V11, P1519, DOI 10.1097/00001756-200005150-00030; Herwig U, 2003, BRAIN TOPOGR, V16, P95, DOI 10.1023/B:BRAT.0000006333.93597.9d; Hilgetag CC, 2001, NAT NEUROSCI, V4, P953, DOI 10.1038/nn0901-953; Jin Y, 2008, EXP BRAIN RES, V189, P121, DOI 10.1007/s00221-008-1449-y; Johnson JS, 2012, J NEUROPHYSIOL, V107, P2383, DOI 10.1152/jn.00707.2011; Karnath HO, 2003, NEUROREPORT, V14, P437, DOI 10.1097/01.wnr.0000059778.23521.88; Kim YH, 2005, NEUROSCI LETT, V382, P280, DOI 10.1016/j.neulet.2005.03.043; Kinsbourne M, 1977, Adv Neurol, V18, P41; Klimesch W, 2007, BRAIN RES REV, V53, P63, DOI 10.1016/j.brainresrev.2006.06.003; Luber B, 2014, NEUROIMAGE, V85, P961, DOI 10.1016/j.neuroimage.2013.06.007; Maeda F, 2000, EXP BRAIN RES, V133, P425, DOI 10.1007/s002210000432; MESULAM MM, 1981, ANN NEUROL, V10, P309, DOI 10.1002/ana.410100402; PASCUALLEONE A, 1994, BRAIN, V117, P847, DOI 10.1093/brain/117.4.847; Peinemann A, 2004, CLIN NEUROPHYSIOL, V115, P1519, DOI 10.1016/j.clinph.2004.02.005; POSNER MI, 1990, ANNU REV NEUROSCI, V13, P25, DOI 10.1146/annurev.ne.13.030190.000325; Romei V, 2010, J NEUROSCI, V30, P8692, DOI 10.1523/JNEUROSCI.0160-10.2010; Rossi S, 2009, CLIN NEUROPHYSIOL, V120, P2008, DOI 10.1016/j.clinph.2009.08.016; Soto D, 2012, J NEUROSCI, V32, P3447, DOI 10.1523/JNEUROSCI.6243-11.2012; Thut G, 2006, J NEUROSCI, V26, P9494, DOI 10.1523/JNEUROSCI.0875-06.2006; Thut G, 2010, BRAIN TOPOGR, V22, P219, DOI 10.1007/s10548-009-0115-4; Wassermann EM, 1998, EVOKED POTENTIAL, V108, P1, DOI 10.1016/S0168-5597(97)00096-8; Worden MS, 2000, J NEUROSCI, V20	32	6	6	0	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 13	2015	10	5							e0126802	10.1371/journal.pone.0126802	http://dx.doi.org/10.1371/journal.pone.0126802			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CI1ZP	25970438	Green Published, gold, Green Submitted			2023-01-03	WOS:000354544200132
J	Goede, V; Hallek, M				Goede, Valentin; Hallek, Michael			Towards improved frontline treatment of CLL in the elderly	LANCET			English	Editorial Material							CHRONIC LYMPHOCYTIC-LEUKEMIA; FLUDARABINE PLUS CYCLOPHOSPHAMIDE; INITIAL THERAPY; OPEN-LABEL; CHLORAMBUCIL; OBINUTUZUMAB; RITUXIMAB		[Goede, Valentin; Hallek, Michael] Univ Cologne, Dept Internal Med 1, Ctr Integrated Oncol Cologne Bonn, German CLL Study Grp, D-50924 Cologne, Germany	University of Cologne	Goede, V (corresponding author), Univ Cologne, Dept Internal Med 1, Ctr Integrated Oncol Cologne Bonn, German CLL Study Grp, D-50924 Cologne, Germany.	valentin.goede@uk-koeln.de	Hallek, Michael/Y-3191-2019	Hallek, Michael/0000-0002-7425-4455				Badoux XC, 2011, BLOOD, V118, P3489, DOI 10.1182/blood-2011-03-339077; Baumann T, 2014, HAEMATOLOGICA, V99, P1599, DOI 10.3324/haematol.2014.107326; Eichhorst BF, 2006, BLOOD, V107, P885, DOI 10.1182/blood-2005-06-2395; Flinn IW, 2007, J CLIN ONCOL, V25, P793, DOI 10.1200/JCO.2006.08.0762; Furman RR, 2014, NEW ENGL J MED, V370, P997, DOI 10.1056/NEJMoa1315226; Goede V, 2015, LEUKEMIA, V29, P1602, DOI 10.1038/leu.2015.14; Goede V, 2014, HAEMATOLOGICA, V99, P1095, DOI 10.3324/haematol.2013.096792; Goede V, 2014, NEW ENGL J MED, V370, P1101, DOI 10.1056/NEJMoa1313984; Hallek M, 2010, LANCET, V376, P1164, DOI 10.1016/S0140-6736(10)61381-5; Hillmen P, 2015, LANCET; Knauf WU, 2009, J CLIN ONCOL, V27, P4378, DOI 10.1200/JCO.2008.20.8389; O'Brien SG, 2014, BLOOD, V124; O'Brien S, 2014, LANCET ONCOL, V15, P48, DOI 10.1016/S1470-2045(13)70513-8; Zelenetz AD, 2014, BLOOD, V124	14	1	1	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 9	2015	385	9980					1814	1815		10.1016/S0140-6736(15)60293-8	http://dx.doi.org/10.1016/S0140-6736(15)60293-8			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CH6ZE	25882395				2023-01-03	WOS:000354184500009
J	Drekonja, D; Reich, J; Gezahegn, S; Greer, N; Shaukat, A; MacDonald, R; Rutks, I; Wilt, TJ				Drekonja, Dimitri; Reich, Jon; Gezahegn, Selome; Greer, Nancy; Shaukat, Aasma; MacDonald, Roderick; Rutks, Indy; Wilt, Timothy J.			Fecal Microbiota Transplantation for Clostridium difficile Infection A Systematic Review	ANNALS OF INTERNAL MEDICINE			English	Review							TERM-FOLLOW-UP; TEMPERED ENTHUSIASM; RECURRENT; DIARRHEA; VANCOMYCIN; THERAPY; COLITIS; DISEASE; BACTERIOTHERAPY; COLONOSCOPY	Background: The role of fecal microbiota transplantation (FMT) for Clostridium difficile infection (CDI) is not well-known. Purpose: To assess the efficacy, comparative effectiveness, and harms of FMT for CDI. Data Sources: MEDLINE (1980 to January 2015), Cochrane Library, and ClinicalTrials.gov, followed by hand-searching references from systematic reviews and identified studies. Study Selection: Any study of FMT to treat adult patients with CDI; case reports were only used to report harms. Data Extraction: Data were extracted by 1 author and verified by another; 2 authors independently assessed risk of bias and strength of evidence. Data Synthesis: Two randomized, controlled trials (RCTs); 28 case-series studies; and 5 case reports were included. Two RCTs and 21 case-series studies (516 patients receiving FMT) reported using FMT for patients with recurrent CDI. A high proportion of treated patients had symptom resolution; however, the role of previous antimicrobials is unclear. One RCT comparing FMT with 2 control groups (n = 43) reported resolution of symptoms in 81%, 31%, and 23% of the FMT, vancomycin, or vancomycin-plus-bowel lavage groups, respectively (P < 0.001 for both control groups vs. FMT). An RCT comparing FMT route (n = 20) reported no difference between groups (60% in the nasogastric tube group and 80% in the colonoscopy group; P = 0.63). Across all studies for recurrent CDI, symptom resolution was seen in 85% of cases. In 7 case-series studies of patients with refractory CDI, symptom resolution ranged from 0% to 100%. Among 7 patients treated with FMT for initial CDI, results were mixed. Limitation: Most studies were uncontrolled case-series studies; only 2 RCTs were available for analysis. Conclusion: Fecal microbiota transplantation may have a substantial effect with few short-term adverse events for recurrent CDI. Evidence is insufficient on FMT for refractory or initial CDI treatment and on whether effects vary by donor, preparation, or delivery method.	Minneapolis Vet Affairs Hlth Care Syst, Chron Dis Outcomes Res, Minneapolis, MN 55417 USA; Univ Minnesota, Sch Med, Minneapolis, MN 55455 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Minneapolis VA Health Care System; University of Minnesota System; University of Minnesota Twin Cities	Drekonja, D (corresponding author), Minneapolis Vet Affairs Hlth Care Syst, 1 Vet Dr,Mail Code 111-F, Minneapolis, MN 55417 USA.	drek0002@umn.edu			U.S. Department of Veterans Affairs	U.S. Department of Veterans Affairs(US Department of Veterans Affairs)	U.S. Department of Veterans Affairs.	Aas J, 2003, CLIN INFECT DIS, V36, P580, DOI 10.1086/367657; Bakken JS, 2011, CLIN GASTROENTEROL H, V9, P1044, DOI 10.1016/j.cgh.2011.08.014; BARTLETT JG, 1978, NEW ENGL J MED, V298, P531, DOI 10.1056/NEJM197803092981003; Bhatt DL, 2014, NEW ENGL J MED, V370, P1393, DOI 10.1056/NEJMoa1402670; BOWDEN TA, 1981, AM SURGEON, V47, P178; Brandt LJ, 2012, AM J GASTROENTEROL, V107, P1079, DOI 10.1038/ajg.2012.60; Cammarota G, 2014, J CLIN GASTROENTEROL, V48, P693, DOI 10.1097/MCG.0000000000000046; Cammarota G, 2014, DIGEST LIVER DIS, V46, P475, DOI 10.1016/j.dld.2013.12.011; CDC, 2013, ANTIBIOTIC RESISTANC; De Leon LM, 2013, CLIN GASTROENTEROL H, V11, P1036, DOI 10.1016/j.cgh.2013.04.045; Debast SB, 2014, CLIN MICROBIOL INFEC, V20, P1, DOI 10.1111/1469-0691.12418; Dutta SK, 2014, CLIN GASTROENTEROL H, V12, P1572, DOI 10.1016/j.cgh.2013.12.032; EISEMAN B, 1958, SURGERY, V44, P854; Emanuelsson F, 2014, SCAND J INFECT DIS, V46, P89, DOI 10.3109/00365548.2013.858181; Garborg K, 2010, SCAND J INFECT DIS, V42, P857, DOI 10.3109/00365548.2010.499541; Gustafsson A, 1999, SCAND J GASTROENTERO, V34, P580, DOI 10.1080/003655299750026038; Hamilton MJ, 2012, AM J GASTROENTEROL, V107, P761, DOI 10.1038/ajg.2011.482; Higgins J, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.ED000049; Johnson S, 2007, CLIN INFECT DIS, V44, P846, DOI 10.1086/511870; Johnson S, 2009, J INFECTION, V58, P403, DOI 10.1016/j.jinf.2009.03.010; Kelly CR, 2014, AM J GASTROENTEROL, V109, P1065, DOI 10.1038/ajg.2014.133; Kelly CR, 2012, J CLIN GASTROENTEROL, V46, P145, DOI 10.1097/MCG.0b013e318234570b; Khan MA, 2014, CAN J GASTROENTEROL, V28, P434, DOI 10.1155/2014/695029; Kleger A, 2013, DTSCH ARZTEBL INT, V110, P108, DOI 10.3238/arztebl.2013.0108; Kuntz JL, 2011, BMC INFECT DIS, V11, DOI 10.1186/1471-2334-11-194; LARSON HE, 1978, LANCET, V1, P1063; Lee CH, 2014, EUR J CLIN MICROBIOL, V33, P1425, DOI 10.1007/s10096-014-2088-9; Louie TJ, 2011, NEW ENGL J MED, V364, P422, DOI 10.1056/NEJMoa0910812; Lund-Tonnesen Stein, 1998, Tidsskrift for den Norske Laegeforening, V118, P1027; Macconnachie AA, 2009, QJM-INT J MED, V102, P781, DOI 10.1093/qjmed/hcp118; Mattila E, 2012, GASTROENTEROLOGY, V142, P490, DOI 10.1053/j.gastro.2011.11.037; McFarland LV, 2002, AM J GASTROENTEROL, V97, P1769, DOI 10.1111/j.1572-0241.2002.05839.x; Mellow Mark H, 2011, J Okla State Med Assoc, V104, P89; Moore TA, 2014, CLIN INFECT DIS, V59, P319, DOI 10.1093/cid/ciu279; Nieuwdorp M, 2008, Ned Tijdschr Geneeskd, V152, P1927; Owens DK, 2010, J CLIN EPIDEMIOL, V63, P513, DOI 10.1016/j.jclinepi.2009.03.009; Patel NC, 2013, MAYO CLIN PROC, V88, P799, DOI 10.1016/j.mayocp.2013.04.022; PATERSON DL, 1994, MED J AUSTRALIA, V160, P232, DOI 10.5694/j.1326-5377.1994.tb126619.x; Pathak R, 2014, CLIN EXP GASTROENTER, V7, P1, DOI 10.2147/CEG.S53410; Polak Pavel, 2011, Klin Mikrobiol Infekc Lek, V17, P214; Quera R, 2014, J CROHNS COLITIS, V8, P252, DOI 10.1016/j.crohns.2013.10.002; Redberg RF, 2014, NEW ENGL J MED, V371, P892, DOI 10.1056/NEJMp1406388; Rohlke F, 2010, J CLIN GASTROENTEROL, V44, P567, DOI 10.1097/MCG.0b013e3181dadb10; Rubin TA, 2013, ANAEROBE, V19, P22, DOI 10.1016/j.anaerobe.2012.11.004; Schwartz M, 2013, AM J GASTROENTEROL, V108, P1367, DOI 10.1038/ajg.2013.164; Sihvonen R, 2013, NEW ENGL J MED, V369, P2515, DOI 10.1056/NEJMoa1305189; Silverman MS, 2010, CLIN GASTROENTEROL H, V8, P471, DOI 10.1016/j.cgh.2010.01.007; Solari PR, 2014, CLIN INFECT DIS, V59, DOI 10.1093/cid/ciu278; Surawicz CM, 2013, AM J GASTROENTEROL, V108, P478, DOI 10.1038/ajg.2013.4; Surawicz CM, 2000, CLIN INFECT DIS, V31, P1012, DOI 10.1086/318130; TEDESCO FJ, 1985, AM J GASTROENTEROL, V80, P867; TVEDE M, 1989, LANCET, V1, P1156; van Nood E, 2013, NEW ENGL J MED, V368, P407, DOI 10.1056/NEJMoa1205037; Weingarden AR, 2013, J CLIN GASTROENTEROL, V47, P735, DOI 10.1097/MCG.0b013e31829004ae; WILSON KH, 1993, CLIN INFECT DIS, V16, pS214, DOI 10.1093/clinids/16.Supplement_4.S214; Yoon SS, 2010, J CLIN GASTROENTEROL, V44, P562, DOI 10.1097/MCG.0b013e3181dac035; Youngster I, 2014, JAMA-J AM MED ASSOC, V312, P1772, DOI 10.1001/jama.2014.13875; Youngster I, 2014, CLIN INFECT DIS, V58, P1515, DOI 10.1093/cid/ciu135; Zainah H, 2015, DIGEST DIS SCI, V60, P181, DOI 10.1007/s10620-014-3296-y	59	240	258	4	49	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 5	2015	162	9					630	U230		10.7326/M14-2693	http://dx.doi.org/10.7326/M14-2693			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CH6AZ	25938992				2023-01-03	WOS:000354119100007
J	Smith, CD; Levinson, WS				Smith, Cynthia D.; Levinson, Wendy S.		Internal Med HVC Advisory Board	A Commitment to High-Value Care Education From the Internal Medicine Community	ANNALS OF INTERNAL MEDICINE			English	Article							PHYSICIANS; COST	The Alliance for Academic Internal Medicine, American Board of Internal Medicine (ABIM), ABIM Foundation, and American College of Physicians are collaborating to enhance the education of physicians in high-value care (HVC) and make its practice an essential competency in undergraduate and postgraduate education by 2017. This article serves as the organizations' formal commitment to providing a foundation of HVC education on which others may build. The 5 key targets for HVC education are experiential learning and curriculum, environment and culture, clinical support, regulatory requirements, and sustainability. The goal is to train future health care professionals for whom HVC is part of normal practice, thus providing patients with improved clinical outcomes at a lower cost.	[Smith, Cynthia D.] Amer Coll Physicians, Philadelphia, PA 19106 USA; Univ Toronto, Toronto, ON, Canada	American College of Physicians; University of Toronto	Smith, CD (corresponding author), Amer Coll Physicians, 190 N Independence Mall West, Philadelphia, PA 19106 USA.			Lang, Valerie J/0000-0003-1119-5029				[Anonymous], 2010, HEALTHC IMP LOW COST; Asch DA, 2014, ACAD MED, V89, P24, DOI 10.1097/ACM.0000000000000067; CUMMINGS KM, 1982, MED CARE, V20, P293, DOI 10.1097/00005650-198203000-00006; Dine C Jessica, 2010, J Grad Med Educ, V2, P175, DOI 10.4300/JGME-D-10-00021.1; Levy AE, 2014, ACAD MED, V89, P1440, DOI 10.1097/ACM.0000000000000496; Ryskina KL, 2014, ANN INTERN MED, V161, P733, DOI 10.7326/M14-0444; Sirovich BE, 2006, ANN INTERN MED, V144, P641, DOI 10.7326/0003-4819-144-9-200605020-00007; Stiefel M, 2012, IHI INNOV SER WHITE; Weinberger SE, 2014, ANN INTERN MED, V161, P73, DOI 10.7326/M13-2993; Weinberger SE, 2011, ANN INTERN MED, V155, P386, DOI 10.7326/0003-4819-155-6-201109200-00007	10	14	16	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 5	2015	162	9					639	U233		10.7326/M14-2610	http://dx.doi.org/10.7326/M14-2610			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CH6AZ	25938993				2023-01-03	WOS:000354119100008
J	Xiao, WW; Liu, S; Tian, YM; Guan, Y; Huang, SM; Lin, CG; Zhao, C; Lu, TX; Han, F				Xiao, WeiWei; Liu, Shuai; Tian, YunMing; Guan, Ying; Huang, ShaoMin; Lin, ChengGuang; Zhao, Chong; Lu, TaiXiang; Han, Fei			Prognostic Significance of Tumor Volume in Locally Recurrent Nasopharyngeal Carcinoma Treated with Salvage Intensity-Modulated Radiotherapy	PLOS ONE			English	Article							T-STAGE; SURVIVAL	Introduction To evaluate the prognostic value of gross tumor volume (TV) in patients with locally recurrent, nonmetastatic nasopharyngeal carcinoma. Methods Between 2001 and 2012, 291 consecutive patients with locally recurrent, nonmetastatic nasopharyngeal carcinoma underwent salvage IMRT were retrospectively reviewed. The correlations between TV and recurrent T classification were analyzed. Survival analyses were performed. Receiver operating characteristic (ROC) curves were calculated to identify cutoff point of TV. The Akaike information criterion and Harrell's concordance index (c-index) were utilized to test the prognostic value. Results The median TV significantly increased with advancing recurrent T classification (P<0.001). The 5-year overall survival rate was 33.2% for the entire cohort. On multivariate analysis, TV was an independent negative prognostic factor for distant metastasis-free survival (hazard ratio = 1.013, P = 0.003), overall survival (hazard ratio = 1.015, P<0.001) and toxicityrelated death (hazard ratio = 1.014, P<0.001). The 5-year overall survival rates were 63.1% and 20.8% for patients with a TV < 22 cm(3) and TV >= 22 cm(3), respectively (P < 0.001). In patient with TV < 22 cm(3), locoregional failure is the leading cause of death. In patients with TV >= 22 cm(3), distant metastasis rate is higher and occurred within short term after local recurrence; meanwhile, radiation-induced injuries became more common and led to half of deaths in this group. The Akaike information criterion and c-index analyses indicated that the predictive ability of recurrent T classification improved when combined with TV. Conclusions Our data suggests TV is a significant prognostic factor for predicting the distant metastasis, overall survival and toxicity-related death of patients with locally recurrent, nonmetastatic nasopharyngeal carcinoma after salvage IMRT. TV should be considered when designing personalized salvage treatments for these patients. For patients with bulky local recurrent tumor, radiation may need to be de-emphasized in favor of systemic treatment or best supportive care.	[Xiao, WeiWei; Liu, Shuai; Guan, Ying; Huang, ShaoMin; Lin, ChengGuang; Zhao, Chong; Lu, TaiXiang; Han, Fei] Sun Yat Sen Univ, Ctr Canc, Collaborat Innovat Ctr Canc Med, Dept Radiotherapy,State Key Lab Oncol South China, Guangzhou 510275, Guangdong, Peoples R China; [Tian, YunMing] Hui Zhou Municipal Cent Hosp, Dept Radiat Oncol, Huizhou, Guangdong, Peoples R China	State Key Lab Oncology South China; Sun Yat Sen University	Han, F (corresponding author), Sun Yat Sen Univ, Ctr Canc, Collaborat Innovat Ctr Canc Med, Dept Radiotherapy,State Key Lab Oncol South China, Guangzhou 510275, Guangdong, Peoples R China.	hanfei@sysucc.org.cn	Han, Fei/AAD-7348-2021	Han, Fei/0000-0002-1598-9048; Xiao, WeiWei/0000-0002-9922-640X	Science and Technology Planning Project of Guangdong Province, China [2012B061700089]; Sun Yat-sen University, China [12ykpy57]	Science and Technology Planning Project of Guangdong Province, China; Sun Yat-sen University, China	This work was supported by Grant: Science and Technology Planning Project of Guangdong Province, China (No. 2012B061700089) and Young scientists fund of Sun Yat-sen University, China (No 12ykpy57). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Akaike H., 1973, INFORM THEORY EXTENS, P267; Chang CC, 2003, J OTOLARYNGOL, V32, P87, DOI 10.2310/7070.2003.37253; Chen CB, 2011, JPN J CLIN ONCOL, V41, P537, DOI 10.1093/jjco/hyq242; Chen HY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073918; Chen MK, 2004, CANCER-AM CANCER SOC, V100, P2160, DOI 10.1002/cncr.20210; Chua DTT, 2006, INT J RADIAT ONCOL, V66, P1415, DOI 10.1016/j.ijrobp.2006.07.1364; De Jaeger K, 1998, INT J RADIAT ONCOL, V42, P717, DOI 10.1016/S0360-3016(98)00323-X; Edge SB, 2009, AJCC CANC STAGING MA, V7; Evans SM, 2003, CANCER LETT, V195, P1, DOI 10.1016/S0304-3835(03)00012-0; Guo R, 2012, RADIOTHER ONCOL, V104, P294, DOI 10.1016/j.radonc.2012.09.001; Han F, 2012, CLIN ONCOL-UK, V24, P569, DOI 10.1016/j.clon.2011.11.010; Harrell FE, 1996, STAT MED, V15, P361, DOI 10.1002/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4; Hua YJ, 2012, EUR J CANCER, V48, P3422, DOI 10.1016/j.ejca.2012.06.016; Lee CC, 2008, ACTA OTO-LARYNGOL, V128, P93, DOI 10.1080/00016480701361921; Sarisahin M, 2011, AURIS NASUS LARYNX, V38, P250, DOI 10.1016/j.anl.2010.09.002; Suarez C, 2010, EUR ARCH OTO-RHINO-L, V267, P1811, DOI 10.1007/s00405-010-1385-x; Sze WM, 2004, INT J RADIAT ONCOL, V59, P21, DOI 10.1016/j.ijrobp.2003.10.027; Tian YM, 2014, BRIT J CANCER, V110, P297, DOI 10.1038/bjc.2013.715; Wei WI, 2005, LANCET, V365, P2041, DOI 10.1016/S0140-6736(05)66698-6; Wu Z, 2013, HEAD NECK-J SCI SPEC, V35, P689, DOI 10.1002/hed.23010; Yu KJ, 2011, CLIN CANCER RES, V17, P1906, DOI 10.1158/1078-0432.CCR-10-1681; ZWEIG MH, 1993, CLIN CHEM, V39, P561	22	23	26	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 30	2015	10	4							e0125351	10.1371/journal.pone.0125351	http://dx.doi.org/10.1371/journal.pone.0125351			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CH0MA	25927527	Green Published, Green Submitted, gold			2023-01-03	WOS:000353713100084
J	Marzola, E; Desedime, N; Giovannone, C; Amianto, F; Fassino, S; Abbate-Daga, G				Marzola, Enrica; Desedime, Nadia; Giovannone, Cristina; Amianto, Federico; Fassino, Secondo; Abbate-Daga, Giovanni			Atypical Antipsychotics as Augmentation Therapy in Anorexia Nervosa	PLOS ONE			English	Article							COMPULSIVE PERSONALITY-TRAITS; PSYCHIATRY WFSBP GUIDELINES; EATING-DISORDERS; DOUBLE-BLIND; OPEN-LABEL; WORLD FEDERATION; ANXIETY; INDIVIDUALS; FLUOXETINE; OLANZAPINE	Anorexia nervosa (AN) is a life-threatening and difficult to treat mental illness with the highest mortality rates of any psychiatric disorder. We aimed to garner preliminary data on the real-world use of olanzapine and aripiprazole as augmentation agents of Selective Serotonin Reuptake Inhibitors (SSRIs) in adult inpatients affected by AN. We retrospectively evaluated the clinical charts of patients who were hospitalized between 2012 and 2014. Patients were evaluated upon admission and discharge. We investigated eating symptomatology, and both general and eating psychopathology using: Hamilton Rating Scale for Anxiety, Hamilton Rating Scale for Depression, and Yale-Brown-Cornell Eating Disorders Scale. The charts of 75 patients were included in this study. The sample resulted equally distributed among those receiving SSRIs and either aripiprazole or olanzapine in addition to SSRIs. Notwithstanding a few baseline clinical differences, upon discharge all groups were significantly improved on all measures. Interestingly, aripiprazole showed the greatest effectiveness in reducing eating-related preoccupations and rituals with a large effect size. The body of evidence on medication management in AN is in dismal condition. Augmentation therapy is a well-established approach to a variety of mental disorders and it is often used in every-day clinical practice with patients affected by AN as well. Nevertheless, to date very little data is available on this topic. Results from our sample yielded promising results on the effectiveness of aripiprazole augmentation in reducing eating-related obsessions and compulsions. Randomized controlled trials are warranted to confirm these encouraging findings.	[Marzola, Enrica; Desedime, Nadia; Giovannone, Cristina; Amianto, Federico; Fassino, Secondo; Abbate-Daga, Giovanni] Univ Turin, Dept Neurosci, Eating Disorders Ctr Treatment & Res, Turin, Italy	University of Turin	Abbate-Daga, G (corresponding author), Univ Turin, Dept Neurosci, Eating Disorders Ctr Treatment & Res, Turin, Italy.	giovanni.abbatedaga@unito.it	Abbate Daga, Giovanni/AAE-3155-2022; Marzola, Enrica/I-5984-2012	Marzola, Enrica/0000-0003-1328-9678; Abbate-Daga, Giovanni/0000-0002-5826-5664				Abbate-Daga G, 2013, BMC PSYCHIATRY, V13, DOI 10.1186/1471-244X-13-294; Abdel-Ahad P, 2013, CURR CLIN PHARMACOL; Aigner M, 2011, WORLD J BIOL PSYCHIA, V12, P400, DOI 10.3109/15622975.2011.602720; American Psychiatric Association, 2000, DIAGNOSTIC AND STATI; Anderluh MB, 2003, AM J PSYCHIAT, V160, P242, DOI 10.1176/appi.ajp.160.2.242; Bailer UF, 2007, BIOL PSYCHIAT, V61, P1090, DOI 10.1016/j.biopsych.2006.07.018; Bailer UF, 2012, INT J EAT DISORDER, V45, P263, DOI 10.1002/eat.20937; Barbarich NC, 2004, J CLIN PSYCHIAT, V65, P1480, DOI 10.4088/JCP.v65n1106; Bauer M, 2013, WORLD J BIOL PSYCHIA, V14, P334, DOI 10.3109/15622975.2013.804195; Bissada H, 2008, AM J PSYCHIAT, V165, P1281, DOI 10.1176/appi.ajp.2008.07121900; Blinder BJ, 2006, PSYCHOSOM MED, V68, P454, DOI 10.1097/01.psy.0000221254.77675.f5; Bosanac P, 2007, HUM PSYCHOPHARM CLIN, V22, P223, DOI 10.1002/hup.845; Brambilla F, 2007, INT CLIN PSYCHOPHARM, V22, P197, DOI 10.1097/YIC.0b013e328080ca31; Cohen J., 1988, STATISTICAL POWER AN, DOI DOI 10.1234/12345678; Court A, 2010, J PSYCHIATR RES, V44, P1027, DOI 10.1016/j.jpsychires.2010.03.011; Crane AM, 2007, INT J EAT DISORDER, V40, P581, DOI 10.1002/eat.20419; Daga GA, 2011, PSYCHOTHER PSYCHOSOM, V80, P319, DOI 10.1159/000324761; Dold M, 2015, PSYCHOTHER PSYCHOSOM, V84, P110, DOI 10.1159/000369978; Fairburn C. G., 2008, COGNITIVE BEHAVIOR T; Fassino S, 2002, EUR NEUROPSYCHOPHARM, V12, P453, DOI 10.1016/S0924-977X(02)00058-5; First M., 1997, STRUCTURED CLIN INTE; Flament MF, 2012, INT J NEUROPSYCHOPH, V15, P189, DOI 10.1017/S1461145711000381; Gable KN, 2005, CURR THER RES CLIN E, V66, P572, DOI 10.1016/j.curtheres.2005.12.011; Halmi KA, 2008, AM J PSYCHIAT, V165, P1227, DOI 10.1176/appi.ajp.2008.08060957; HAMILTON M, 1960, J NEUROL NEUROSUR PS, V23, P56, DOI 10.1136/jnnp.23.1.56; HAMILTON M, 1959, BRIT J MED PSYCHOL, V32, P50, DOI 10.1111/j.2044-8341.1959.tb00467.x; Hoffman ER, 2012, EUR EAT DISORD REV, V20, pe129, DOI 10.1002/erv.2161; Jon DI, 2013, CLIN NEUROPHARMACOL, V36, P157, DOI 10.1097/WNF.0b013e3182a31f3d; Kaye WH, 2013, TRENDS NEUROSCI, V36, P110, DOI 10.1016/j.tins.2013.01.003; Kaye WH, 2001, BIOL PSYCHIAT, V49, P644, DOI 10.1016/S0006-3223(00)01013-1; Kishi Taro, 2012, J Clin Psychiatry, V73, pe757, DOI 10.4088/JCP.12r07691; Klump KL, 2009, INT J EAT DISORDER, V42, P97, DOI 10.1002/eat.20589; Lebow J, 2013, INT J EAT DISORDER, V46, P332, DOI 10.1002/eat.22059; Leucht S, 2014, SCHIZOPHRENIA BULL, V40, P314, DOI 10.1093/schbul/sbu001; MAIER W, 1988, J AFFECT DISORDERS, V14, P61, DOI 10.1016/0165-0327(88)90072-9; MAZURE CM, 1994, J PSYCHIATR RES, V28, P425, DOI 10.1016/0022-3956(94)90002-7; McKnight RF, 2010, EUR EAT DISORD REV, V18, P10, DOI 10.1002/erv.988; Miotto P, 2010, PSYCHIAT RES, V175, P237, DOI 10.1016/j.psychres.2009.03.011; Mischoulon D, 2011, J AFFECT DISORDERS, V130, P470, DOI 10.1016/j.jad.2010.10.043; Mondraty Naresh, 2005, Australas Psychiatry, V13, P72, DOI 10.1111/j.1440-1665.2004.02154.x; National Institute for Clinical Excellence (NICE), 2004, CORE INTERVENTIONS I; Powers PS, 2007, INT J EAT DISORDER, V40, P21, DOI 10.1002/eat.20325; Ruggiero GM, 2001, PROG NEURO-PSYCHOPH, V25, P1049, DOI 10.1016/S0278-5846(01)00174-9; Steinglass Joanna E, 2007, J Psychiatr Pract, V13, P65, DOI 10.1097/01.pra.0000265762.79753.88; Swinbourne J, 2012, AUST NZ J PSYCHIAT, V46, P118, DOI 10.1177/0004867411432071; Trajkovic G, 2011, PSYCHIAT RES, V189, P1, DOI 10.1016/j.psychres.2010.12.007; Trunko ME, 2011, INT J EAT DISORDER, V44, P269, DOI 10.1002/eat.20807; Walsh BT, 2006, JAMA-J AM MED ASSOC, V295, P2605, DOI 10.1001/jama.295.22.2605; Wright BM, 2013, PHARMACOTHERAPY, V33, P344, DOI 10.1002/phar.1204	49	22	23	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 29	2015	10	4							e0125569	10.1371/journal.pone.0125569	http://dx.doi.org/10.1371/journal.pone.0125569			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CH0LO	25922939	Green Submitted, Green Published, gold			2023-01-03	WOS:000353711600154
J	Di Giacomo, C; Vanella, L; Sorrenti, V; Santangelo, R; Barbagallo, I; Calabrese, G; Genovese, C; Mastrojeni, S; Ragusa, S; Acquaviva, R				Di Giacomo, Claudia; Vanella, Luca; Sorrenti, Valeria; Santangelo, Rosa; Barbagallo, Ignazio; Calabrese, Giovanna; Genovese, Carlo; Mastrojeni, Silvana; Ragusa, Salvatore; Acquaviva, Rosaria			Effects of Tithonia diversifolia (Hemsl.) A. Gray Extract on Adipocyte Differentiation of Human Mesenchymal Stem Cells	PLOS ONE			English	Article							ACTIVATED PROTEIN-KINASE; AY DIABETIC MICE; NF-KAPPA-B; HEME OXYGENASE-1; OXIDATIVE STRESS; ENDOTHELIAL-CELLS; SESQUITERPENE LACTONES; LIPID-ACCUMULATION; HYDROGEN-PEROXIDE; ADIPOSE-TISSUE	Tithonia diversifolia (Hemsl.) A. Gray (Asteraceae) is widely used in traditional medicine. There is increasing interest on the in vivo protective effects of natural compounds contained in plants against oxidative damage caused from reactive oxygen species. In the present study the total phenolic and flavonoid contents of aqueous, methanol and dichloromethane extracts of leaves of Tithonia diversifolia (Hemsl.) A. Gray were determined; furthermore, free radical scavenging capacity of each extract and the ability of these extracts to inhibit in vitro plasma lipid peroxidation were also evaluated. Since oxidative stress may be involved in trasformation of pre-adipocytes into adipocytes, to test the hypothesis that Tithonia extract may also affect adipocyte differentiation, human mesenchymal stem cell cultures were treated with Tithonia diversifolia aqueous extract and cell viability, free radical levels, Oil-Red O staining and western bolt analysis for heme oxygenase and 5'-adenosine mono-phoshate-activated protein kinase were carried out. Results obtained in the present study provide evidence that Tithonia diversifolia (Hemsl.) A. Gray exhibits interesting health promoting properties, resulting both from its free radical scavenger capacity and also by induction of protective cellular systems involved in cellular stress defenses and in adipogenesis of mesenchymal cells.	[Di Giacomo, Claudia; Vanella, Luca; Sorrenti, Valeria; Santangelo, Rosa; Barbagallo, Ignazio; Acquaviva, Rosaria] Univ Catania, Dept Drug Sci, Biochem Sect, Catania, Italy; [Calabrese, Giovanna] IOM Ric SRL, Catania, Italy; [Genovese, Carlo; Mastrojeni, Silvana] Univ Catania, Dept Biomed Sci, Microbiol Sect, Catania, Italy; [Ragusa, Salvatore] Magna Graecia Univ Catanzaro, Dept Hlth Sci, Catanzaro, Italy	University of Catania; Consiglio Nazionale delle Ricerche (CNR); Istituto Officina dei Materiali (IOM-CNR); University of Catania; Magna Graecia University of Catanzaro	Acquaviva, R (corresponding author), Univ Catania, Dept Drug Sci, Biochem Sect, Catania, Italy.	racquavi@unict.it	Sorrenti, Valeria/AAC-6099-2022; Acquaviva, Rosaria/A-6750-2018; GENOVESE, Carlo/D-7837-2012; Vanella, Luca/J-7354-2016	Acquaviva, Rosaria/0000-0002-3139-1177; GENOVESE, Carlo/0000-0003-2463-9047; Vanella, Luca/0000-0002-6314-6029; Calabrese, Giovanna/0000-0003-1937-5403; Di Giacomo, Claudia/0000-0002-2665-0007; Barbagallo, Ignazio/0000-0002-7761-0662	IOM Ricerca SRL	IOM Ricerca SRL	IOM Ricerca SRL provided support in the form of salaries for author GC, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abraham NG, 2008, PHARMACOL REV, V60, P79, DOI 10.1124/pr.107.07104; Acquaviva R, 2005, CURR NEUROVASC RES, V2, P141, DOI 10.2174/1567202053586820; Acquaviva R, 2013, MOLECULES, V18, P3241, DOI 10.3390/molecules18033241; Acquaviva R, 2013, NAT PROD RES, V27, P475, DOI 10.1080/14786419.2012.695364; Acquaviva R, 2012, INT J ONCOL, V41, P31, DOI 10.3892/ijo.2012.1428; BALLA J, 1993, P NATL ACAD SCI USA, V90, P9285, DOI 10.1073/pnas.90.20.9285; Ballard TS, 2010, FOOD CHEM, V120, P1185, DOI 10.1016/j.foodchem.2009.11.063; Balogun E, 2003, BIOCHEM J, V371, P887, DOI 10.1042/BJ20021619; Barbagallo I, 2010, J BONE MINER METAB, V28, P276, DOI 10.1007/s00774-009-0134-y; Bray GA, 2000, NUTRITION, V16, P953, DOI 10.1016/S0899-9007(00)00424-X; Caplan AI, 2008, CELL STEM CELL, V3, P229, DOI 10.1016/j.stem.2008.08.008; Chagas-Paula DA, 2012, CHEM BIODIVERS, V9, P210, DOI 10.1002/cbdv.201100019; Cho HS, 2008, NEUROTOXICOLOGY, V29, P656, DOI 10.1016/j.neuro.2008.03.004; Choi AMK, 1996, AM J RESP CELL MOL, V15, P9, DOI 10.1165/ajrcmb.15.1.8679227; Crisan M, 2008, CELL STEM CELL, V3, P301, DOI 10.1016/j.stem.2008.07.003; CRUSE I, 1988, J BIOL CHEM, V263, P3348; Cuadrado A, 2008, CURR PHARM DESIGN, V14, P429, DOI 10.2174/138161208783597407; Daval M, 2006, J PHYSIOL-LONDON, V574, P55, DOI 10.1113/jphysiol.2006.111484; de Madureira MD, 2002, J ETHNOPHARMACOL, V81, P23, DOI 10.1016/S0378-8741(02)00005-3; Ferrandiz ML, 2008, CURR PHARM DESIGN, V14, P473, DOI 10.2174/138161208783597399; Fisslthaler B, 2009, CIRC RES, V105, P114, DOI 10.1161/CIRCRESAHA.109.201590; Foresti R, 1999, FREE RADICAL RES, V31, P459, DOI 10.1080/10715769900301031; Goffin E, 2002, PLANTA MED, V68, P543, DOI 10.1055/s-2002-32552; Grattagliano I, 2008, J NUTR BIOCHEM, V19, P491, DOI 10.1016/j.jnutbio.2007.06.011; Gu JQ, 2002, J NAT PROD, V65, P532, DOI 10.1021/np010545m; Hawley SA, 1996, J BIOL CHEM, V271, P27879, DOI 10.1074/jbc.271.44.27879; Higuchi M, 2013, STEM CELLS DEV, V22, P878, DOI 10.1089/scd.2012.0306; Imhoff BR, 2011, CELL MOL BIOL LETT, V16, P149, DOI 10.2478/s11658-010-0042-0; Jia Z, 1999, FOOD CHEM, V64, P555, DOI 10.1016/S0308-8146(98)00102-2; Kanda Y, 2011, LIFE SCI, V89, P250, DOI 10.1016/j.lfs.2011.06.007; KEYSE SM, 1989, P NATL ACAD SCI USA, V86, P99, DOI 10.1073/pnas.86.1.99; Kim SK, 2010, CHEM-BIOL INTERACT, V186, P24, DOI 10.1016/j.cbi.2010.04.003; Kuroda M, 2007, CHEM PHARM BULL, V55, P1240, DOI 10.1248/cpb.55.1240; LAUTIER D, 1992, CARCINOGENESIS, V13, P227, DOI 10.1093/carcin/13.2.227; LEBEL CP, 1992, CHEM RES TOXICOL, V5, P227, DOI 10.1021/tx00026a012; Lee H, 2009, J BIOL CHEM, V284, P10601, DOI 10.1074/jbc.M808742200; Lee MY, 2011, J AGR FOOD CHEM, V59, P2347, DOI 10.1021/jf105003n; Li C, 2007, ANTIOXID REDOX SIGN, V9, P2227, DOI 10.1089/ars.2007.1783; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAINES MD, 1988, FASEB J, V2, P2557, DOI 10.1096/fasebj.2.10.3290025; McCoubrey WK, 1997, EUR J BIOCHEM, V247, P725, DOI 10.1111/j.1432-1033.1997.00725.x; MCCOUBREY WK, 1994, GENE, V139, P155, DOI 10.1016/0378-1119(94)90749-8; Meirelles LD, 2008, STEM CELLS, V26, P2287, DOI 10.1634/stemcells.2007-1122; Miura T, 2005, BIOL PHARM BULL, V28, P2152, DOI 10.1248/bpb.28.2152; Miura T, 2002, AM J CHINESE MED, V30, P81, DOI 10.1142/S0192415X02000090; Moon HS, 2007, OBESITY, V15, P2571, DOI 10.1038/oby.2007.309; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Motterlini R, 2000, FREE RADICAL BIO MED, V28, P1303, DOI 10.1016/S0891-5849(00)00294-X; NATH KA, 1992, J CLIN INVEST, V90, P267, DOI 10.1172/JCI115847; Novo G, 2011, TRANSL RES, V157, P285, DOI 10.1016/j.trsl.2011.01.003; Owoyele VB, 2004, J ETHNOPHARMACOL, V90, P317, DOI 10.1016/j.jep.2003.10.010; Poss KD, 1997, P NATL ACAD SCI USA, V94, P10925, DOI 10.1073/pnas.94.20.10925; RAJU VS, 1994, BBA-GENE STRUCT EXPR, V1217, P273, DOI 10.1016/0167-4781(94)90286-0; Rungeler P, 1998, PLANTA MED, V64, P588, DOI 10.1055/s-2006-957527; Ryter SW, 2006, PHYSIOL REV, V86, P583, DOI 10.1152/physrev.00011.2005; Sacerdoti D, 2005, CELL MOL BIOL, V51, P363, DOI 10.1170/T639; Scapagnini G, 2004, ANTIOXID REDOX SIGN, V6, P811, DOI 10.1089/ars.2004.6.811; Scapagnini G, 2002, MOL PHARMACOL, V61, P554, DOI 10.1124/mol.61.3.554; SHEPHERD PR, 1993, J BIOL CHEM, V268, P22243; Siedle B, 2004, J MED CHEM, V47, P6042, DOI 10.1021/jm049937r; Sorisky A, 1999, CRIT REV CL LAB SCI, V36, P1, DOI 10.1080/10408369991239169; Tona L, 2000, PHYTOMEDICINE, V7, P31, DOI 10.1016/S0944-7113(00)80019-7; TRAKSHEL GM, 1989, J BIOL CHEM, V264, P1323; Tyrrell R, 1999, FREE RADICAL RES, V31, P335, DOI 10.1080/10715769900300901; Vigilanza P, 2011, J CELL PHYSIOL, V226, P2016, DOI 10.1002/jcp.22542; Viollet B, 2006, J PHYSIOL-LONDON, V574, P41, DOI 10.1113/jphysiol.2006.108506; Volti GL, 2008, WORLD J GASTROENTERO, V14, P6122, DOI 10.3748/wjg.14.6122; WOLFF SP, 1994, METHOD ENZYMOL, V233, P182; Yuan HD, 2010, BIOSCI BIOTECH BIOCH, V74, P322, DOI 10.1271/bbb.90651; Zhao GJ, 2012, FITOTERAPIA, V83, P1590, DOI 10.1016/j.fitote.2012.09.007; Zhou Y, 2009, BIOL PHARM BULL, V32, P993, DOI 10.1248/bpb.32.993; Zhu YZ, 2004, NAT PROD REP, V21, P478, DOI 10.1039/b304821g	72	25	26	2	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 7	2015	10	4							e0122320	10.1371/journal.pone.0122320	http://dx.doi.org/10.1371/journal.pone.0122320			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CF3VU	25848759	Green Submitted, Green Published, gold			2023-01-03	WOS:000352477800118
J	Lu, AT; Yu, YP; Niu, JX; Zhang, JX				Lu, Aitao; Yu, Yanping; Niu, Jiaxin; Zhang, John X.			The Effect of Sign Language Structure on Complex Word Reading in Chinese Deaf Adolescents	PLOS ONE			English	Article							MORPHOLOGICAL AWARENESS; CHILDREN; RECOGNITION; BILINGUALS; KNOWLEDGE; HEARING; CONTEXT	The present study was carried out to investigate whether sign language structure plays a role in the processing of complex words (i.e., derivational and compound words), in particular, the delay of complex word reading in deaf adolescents. Chinese deaf adolescents were found to respond faster to derivational words than to compound words for one-sign-structure words, but showed comparable performance for two-sign-structure words. For both derivational and compound words, response latencies to one-sign-structure words were shorter than to two-sign-structure words. These results provide strong evidence that the structure of sign language affects written word processing in Chinese. Additionally, differences between derivational and compound words in the one-sign-structure condition indicate that Chinese deaf adolescents acquire print morphological awareness. The results also showed that delayed word reading was found in derivational words with two signs (DW-2), compound words with one sign (CW-1), and compound words with two signs (CW-2), but not in derivational words with one sign (DW-1), with the delay being maximum in DW-2, medium in CW-2, and minimum in CW-1, suggesting that the structure of sign language has an impact on the delayed processing of Chinese written words in deaf adolescents. These results provide insight into the mechanisms about how sign language structure affects written word processing and its delayed processing relative to their hearing peers of the same age.	[Lu, Aitao; Yu, Yanping; Niu, Jiaxin] S China Normal Univ, Ctr Studies Psychol Applicat, Guangzhou, Guangdong, Peoples R China; [Lu, Aitao; Yu, Yanping; Niu, Jiaxin] S China Normal Univ, Sch Psychol, Guangzhou, Guangdong, Peoples R China; [Lu, Aitao; Yu, Yanping; Niu, Jiaxin] Guangdong Key Lab Mental Hlth & Cognit Sci, Guangzhou, Guangdong, Peoples R China; [Lu, Aitao; Yu, Yanping; Niu, Jiaxin] Guangdong Ctr Mental Assistance & Contingency Tec, Guangzhou, Guangdong, Peoples R China; [Zhang, John X.] Fudan Univ, Dept Psychol, Shanghai 200433, Peoples R China	South China Normal University; South China Normal University; Fudan University	Lu, AT (corresponding author), S China Normal Univ, Ctr Studies Psychol Applicat, Guangzhou, Guangdong, Peoples R China.	atlupsy@gmail.com	Yu, Yan/GYV-4514-2022		National Natural Science Foundation of China [31200762]; National Training Fund for Basic Research [J1030729, J1210024]; Foundation for Outstanding Young Teachers in Higher Education of Guangdong, China [HS2015001]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Training Fund for Basic Research; Foundation for Outstanding Young Teachers in Higher Education of Guangdong, China	This work was supported by the National Natural Science Foundation of China (No. 31200762), the National Training Fund for Basic Research (J1030729 and J1210024), and the Foundation for Outstanding Young Teachers in Higher Education of Guangdong, China (HS2015001). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alexander KL, 1997, SOCIOL EDUC, V70, P87, DOI 10.2307/2673158; Andrew KN, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089994; Aronoff M., 1994, MORPHOLOGY ITSELF; Beard R., 1995, LEXEME MORPHEME BASE, DOI [10.2307/416107, DOI 10.2307/416107]; Cai Q, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010729; Casey S, 2009, LANG COGNITIVE PROC, V24, P290, DOI 10.1080/01690960801916188; Costa A, 2000, J EXP PSYCHOL LEARN, V26, P1283, DOI 10.1037//0278-7393.26.5.1283; Dijkstra T, 2002, BILING-LANG COGN, V5, P175, DOI 10.1017/S1366728902003012; Dong XF, 2005, CHINESE LANGUAGE LEA, V6, P13; Duyck W, 2007, J EXP PSYCHOL LEARN, V33, P663, DOI 10.1037/0278-7393.33.4.663; Emmorey K, 2008, BILING-LANG COGN, V11, P43, DOI 10.1017/S1366728907003203; Friesen DC, 2012, READ WRIT, V25, P375, DOI 10.1007/s11145-010-9275-6; Gaustad Martha Gonter, 2004, J Deaf Stud Deaf Educ, V9, P269; Gaustad MG, 2002, AM ANN DEAF, V147, P5, DOI 10.1353/aad.2012.0264; Hayes H, 2011, SCI STUD READ, V15, P522, DOI 10.1080/10888438.2010.528480; Hoosain R, 1991, PSYCHOLINGUISTIC IMP; Jin Y, 1988, COMMUNICATION PSYCHO, V1, P16; Kerkhofs R, 2006, BRAIN RES, V1068, P170, DOI 10.1016/j.brainres.2005.10.087; Kuo LJ, 2006, EDUC PSYCHOL-US, V41, P161, DOI 10.1207/s15326985ep4103_3; Liu PP, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055440; Lu J., 2008, P 6 SIGHAN WORKSH CH, P53; Moats LC, 1999, TEACHING IS ROCKET S; Morford JP, 2011, COGNITION, V118, P286, DOI 10.1016/j.cognition.2010.11.006; OLDFIELD RC, 1971, NEUROPSYCHOLOGIA, V9, P97, DOI 10.1016/0028-3932(71)90067-4; Pittman AL, 2005, EAR HEARING, V26, P619, DOI 10.1097/01.aud.0000189921.34322.68; Schwartz AI, 2008, BILING-LANG COGN, V11, P95, DOI 10.1017/S1366728907003239; Shen D, 2008, COGNITIVE CULTURAL I, P255; Shook A, 2012, COGNITION, V124, P314, DOI 10.1016/j.cognition.2012.05.014; Sterne A, 2000, J CHILD PSYCHOL PSYC, V41, P609, DOI 10.1111/1469-7610.00648; Sun FC, 1999, READING CHINESE SCRIPT, P189; Sunderman G, 2006, STUD SECOND LANG ACQ, V28, P387, DOI 10.1017/S0272263106060177; Taft M., 1995, MORPHOLOGICAL ASPECT, P293; Transler C, 1999, J Deaf Stud Deaf Educ, V4, P124, DOI 10.1093/deafed/4.2.124; Traxler C B, 2000, J Deaf Stud Deaf Educ, V5, P337; van Hell JG, 2002, PSYCHON B REV, V9, P780, DOI 10.3758/BF03196335; van Hoogmoed AH, 2013, RES DEV DISABIL, V34, P1083, DOI 10.1016/j.ridd.2012.12.010; Wang M, 2006, J EDUC PSYCHOL, V98, P542, DOI 10.1037/0022-0663.98.3.542; Wauters LN, 2006, READ WRIT, V19, P49, DOI 10.1007/s11145-004-5894-0; Zhou XL, 1995, LANG COGNITIVE PROC, V10, P545, DOI 10.1080/01690969508407114	39	5	5	0	19	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 23	2015	10	3							e0120943	10.1371/journal.pone.0120943	http://dx.doi.org/10.1371/journal.pone.0120943			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	CE6ZS	25799066	gold, Green Published, Green Submitted			2023-01-03	WOS:000351987300196
J	Almeida, TCA; Larentis, AL; Ferraz, HC				Abreu Almeida, Teresa Cristina; Larentis, Ariane Leites; Ferraz, Helen Conceicao			Evaluation of the Stability of Concentrated Emulsions for Lemon Beverages Using Sequential Experimental Designs	PLOS ONE			English	Article							WATER EMULSIONS; RHEOLOGY; GROWTH; GUM	The study of the stability of concentrated oil-in-water emulsions is imperative to provide a scientific approach for an important problem in the beverage industry, contributing to abolish the empiricism still present nowadays. The use of these emulsions would directly imply a reduction of transportation costs between production and the sales points, where dilution takes place. The goal of this research was to evaluate the influence of the main components of a lemon emulsion on its stability, aiming to maximize the concentration of oil in the beverage and to correlate its physicochemical characteristics to product stability, allowing an increase of shelf life of the final product. For this purpose, analyses of surface and interface tension, electrokinetic potential, particle size and rheological properties of the emulsions were conducted. A 24-1 fractional factorial design was performed with the following variables: lemon oil/water ratio (30% to 50%), starch and Arabic gum concentrations (0% to 30%) and dioctyl sodium sulfosuccinate (0 mg/L to 100 mg/L), including an evaluation of the responses at the central conditions of each variable. Sequentially, a full design was prepared to evaluate the two most influential variables obtained in the first plan, in which concentration of starch and gum ranged from 0% to 20%, while concentration of lemon oil/water ratio was fixed at 50%, without dioctyl sodium sulfosuccinate. Concentrated emulsions with stability superior to 15 days were obtained with either starch or Arabic gum and 50% lemon oil. The most stable formulations presented viscosity over 100 cP and ratio between the surface tension of the emulsion and the mucilage of over 1. These two answers were selected, since they better represent the behavior of emulsions in terms of stability and could be used as tools for an initial selection of the most promising formulations.	[Abreu Almeida, Teresa Cristina; Ferraz, Helen Conceicao] Univ Fed Rio de Janeiro, COPPE, Chem Engn Program, BR-21941972 Rio De Janeiro, RJ, Brazil; [Larentis, Ariane Leites] Fiocruz MS, ENSP, CESTEH, BR-21041210 Rio De Janeiro, RJ, Brazil	Universidade Federal do Rio de Janeiro; Fundacao Oswaldo Cruz	Larentis, AL (corresponding author), Fiocruz MS, ENSP, CESTEH, BR-21041210 Rio De Janeiro, RJ, Brazil.	arianelarentis@fiocruz.br; helen@peq.coppe.ufrj.br	Ferraz, Helen/AAF-1060-2019	FERRAZ, HELEN/0000-0002-6058-5296	Capes (Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior/Coordination for the Improvement of Higher Education Personnel); CNPq (Conselho Nacional de Desenvolvimento Cientifico e Tecnologico/National Counsel of Technological and Scientific Development) from Brazil	Capes (Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior/Coordination for the Improvement of Higher Education Personnel); CNPq (Conselho Nacional de Desenvolvimento Cientifico e Tecnologico/National Counsel of Technological and Scientific Development) from Brazil	No specific funding was received for this work. Scholarships and laboratory material was supported by Capes (Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior/Coordination for the Improvement of Higher Education Personnel) and CNPq (Conselho Nacional de Desenvolvimento Cientifico e Tecnologico/National Counsel of Technological and Scientific Development) from Brazil; ENSP/Fiocruz supported language revision. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Acedo-Carrillo JI, 2006, CARBOHYD POLYM, V65, P327, DOI 10.1016/j.carbpol.2006.01.016; Byrd S. J., 2006, SAIB OLDEST NEW INGR; Cottrell T., 2004, Emulsifiers in food technology, P162, DOI 10.1002/9780470995747.ch7; Dickinson E., 1992, INTRO FOOD COLLOIDS; Einsfeldt K, 2011, VACCINE, V29, P7136, DOI 10.1016/j.vaccine.2011.05.073; Friberg SE., 2004, FOOD EMULSIONS; Marini G, 2014, BMC BIOTECHNOL, V14, DOI 10.1186/1472-6750-14-1; McClements D.J., 1999, FOOD EMULSIONS PRINC; McClements DJ, 2007, CRIT REV FOOD SCI, V47, P611, DOI 10.1080/10408390701289292; Mirhosseini H, 2008, COLLOID SURFACE A, V315, P47, DOI 10.1016/j.colsurfa.2007.07.007; Mirhosseini H, 2007, J AGR FOOD CHEM, V55, P7659, DOI 10.1021/jf071061k; Myers D, 1999, SURFACES INTERFACES; Niraula B, 2004, COLLOID SURFACE A, V251, P117, DOI 10.1016/j.colsurfa.2004.08.071; Rodrigues M.I., 2014, EXPT DESIGN PROCESS; Tadros T, 2004, ADV COLLOID INTERFAC, V108, P227, DOI 10.1016/j.cis.2003.10.025; Tadros T.F., 2009, EMULSION SCI TECHNOL; Tesch S, 2002, J FOOD ENG, V54, P167, DOI 10.1016/S0260-8774(01)00206-0; Walstra P., 2003, PHYS CHEM FOODS	18	16	17	1	16	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 20	2015	10	3							e0118690	10.1371/journal.pone.0118690	http://dx.doi.org/10.1371/journal.pone.0118690			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CE8IA	25793301	Green Published, gold, Green Submitted			2023-01-03	WOS:000352084200032
J	Hwang, JC; Jiang, MY; Lu, YH; Wang, CT				Hwang, Jyh-Chang; Jiang, Ming-Yan; Lu, Yi-Hua; Wang, Charn-Ting			Precedent Fluctuation of Serum hs-CRP to Albumin Ratios and Mortality Risk of Clinically Stable Hemodialysis Patients	PLOS ONE			English	Article							C-REACTIVE PROTEIN; CHRONIC KIDNEY-DISEASE; PERITONEAL-DIALYSIS PATIENTS; INFLAMMATION; MALNUTRITION; NUTRITION	Background A high sensitivity C-reactive protein to albumin ratio (hs-CRP/Alb) predicts mortality risk in patients with acute kidney injury. However, it varies dynamically. This study was conducted to evaluate whether a variation of this marker was associated with long-term outcome in clinically stable hemodialysis (HD) patients. Methods hs-CRP/Alb was checked bimonthly in 284 clinically stable HD outpatients throughout all of 2008. Based on the "slope" of trend equation derived from 5-6 hs-CRP/alb ratios for each patient, the total number of patients was divided into quartiles-Group 1: beta <=-0.13, n = 71; group 2: beta>-0.13 <= 0.003; n = 71, group 3: beta>0.003 <= 0.20; and group 4: beta>0.20, n = 71. The observation period was from January 1, 2009 to August 31, 2012. Results Group 1+4 showed a worse long-term survival (p = 0.04) and a longer 5-year hospitalization stay than Group 2+3 (38.7 +/- 44.4 vs. 16.7 +/- 22.4 days, p<0.001). Group 1+4 were associated with older age (OR = 1.03, 95% CI = 1.01-1.05) and a high prevalence of congestive heart failure (OR = 2.02, 95% CI = 1.00-4.11). Standard deviation (SD) of hs-CRP/Alb was associated with male sex (beta = 0.17, p = 0.003), higher Davies co-morbidity score (beta = 0.16, p = 0.03), and baseline hs-CRP (beta = 0.39, p<0.001). Patients with lower baseline and stable trend of hs-CRP/Alb had a better prognosis. By multivariate Cox proportional methods, SD of hs-CRP/alb (HR: 1.05, 95% CI: 1.01-1.08) rather than baseline hs-CRP/Alb was an independent predictive factor for long-term mortality after adjusting for sex and HD vintage. Conclusion Clinically stable HD patients with a fluctuating variation of hs-CRP/Alb are characterized by old age, and more co-morbidity, and they tend to have longer subsequent hospitalization stay and higher mortality risk.	[Hwang, Jyh-Chang; Jiang, Ming-Yan; Lu, Yi-Hua; Wang, Charn-Ting] Chi Mei Med Ctr, Div Nephrol, Tainan, Taiwan; [Hwang, Jyh-Chang] Chia Nan Univ Pharm & Sci, Dept Hosp & Hlth Care Adm, Tainan, Taiwan	Chi Mei Hospital; Chia Nan University of Pharmacy & Science	Hwang, JC (corresponding author), Chi Mei Med Ctr, Div Nephrol, Tainan, Taiwan.	alfonjch@seed.net.tw						Barreto DV, 2010, KIDNEY INT, V77, P550, DOI 10.1038/ki.2009.503; Cooper BA, 2004, AM J KIDNEY DIS, V43, P61, DOI 10.1053/j.ajkd.2003.08.045; DAVIES SJ, 1995, AM J KIDNEY DIS, V26, P353, DOI 10.1016/0272-6386(95)90657-6; DEVILLOTA ED, 1980, INTENS CARE MED, V7, P19, DOI 10.1007/BF01692917; Don BR, 2004, SEMIN DIALYSIS, V17, P432, DOI 10.1111/j.0894-0959.2004.17603.x; Ikizler TA, 2013, KIDNEY INT, V84, P1096, DOI 10.1038/ki.2013.147; Jindal KK, 1988, SEMIN DIALYSIS, V1, P82, DOI DOI 10.1111/J.1525-139X.1988.TB00710.X; Kalantar-Zadeh K, 2003, AM J KIDNEY DIS, V42, P864, DOI 10.1016/j.ajkd.2003.07.016; Kaptoge S, 2010, LANCET, V375, P132, DOI 10.1016/S0140-6736(09)61717-7; Menon V, 2003, AM J KIDNEY DIS, V42, P44, DOI 10.1016/S0272-6386(03)00407-4; Panichi V, 2008, NEPHROL DIAL TRANSPL, V23, P2337, DOI 10.1093/ndt/gfm951; Ranzani OT, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059321; Snaedal S, 2009, AM J KIDNEY DIS, V53, P1024, DOI 10.1053/j.ajkd.2009.02.008; Stenvinkel P, 2004, SEMIN DIALYSIS, V17, P505, DOI 10.1111/j.0894-0959.2004.17611.x; Su YJ, 2013, BMC NEPHROL, V14, DOI 10.1186/1471-2369-14-185; Tsirpanlis G, 2005, NEPHROL DIAL TRANSPL, V20, P658, DOI 10.1093/ndt/gfh663; Yeun JY, 2000, AM J KIDNEY DIS, V35, P469, DOI 10.1016/S0272-6386(00)70200-9	17	19	22	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 20	2015	10	3							e0120266	10.1371/journal.pone.0120266	http://dx.doi.org/10.1371/journal.pone.0120266			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CE8HY	25793462	Green Published, gold, Green Submitted			2023-01-03	WOS:000352083900005
J	Lopez-Sanchez, P; Cersosimo, J; Wang, DJ; Flanagan, B; Stokes, JR; Gidley, MJ				Lopez-Sanchez, Patricia; Cersosimo, Julie; Wang, Dongjie; Flanagan, Bernadine; Stokes, Jason R.; Gidley, Michael J.			Poroelastic Mechanical Effects of Hemicelluloses on Cellulosic Hydrogels under Compression	PLOS ONE			English	Article							PLANT-CELL WALL; XYLOGLUCAN; ARCHITECTURE; COMPOSITES; DEFICIENT; GROWTH	Hemicelluloses exhibit a range of interactions with cellulose, the mechanical consequences of which in plant cell walls are incompletely understood. We report the mechanical properties of cell wall analogues based on cellulose hydrogels to elucidate the contribution of xyloglucan or arabinoxylan as examples of two hemicelluloses displaying different interactions with cellulose. We subjected the hydrogels to mechanical pressures to emulate the compressive stresses experienced by cell walls in planta. Our results revealed that the presence of either hemicellulose increased the resistance to compression at fast strain rates. However, at slow strain rates, only xyloglucan increased composite strength. This behaviour could be explained considering the microstructure and the flow of water through the composites confirming their poroelastic nature. In contrast, small deformation oscillatory rheology showed that only xyloglucan decreased the elastic moduli. These results provide evidence for contrasting roles of different hemicelluloses in plant cell wall mechanics and man-made cellulose-based composite materials.	[Lopez-Sanchez, Patricia; Cersosimo, Julie; Wang, Dongjie; Flanagan, Bernadine; Gidley, Michael J.] Univ Queensland, Australian Res Ctr, Ctr Excellence Plant Cell Walls, Ctr Nutr & Food Sci,Queensland Alliance Agr & Foo, Brisbane, Qld, Australia; [Stokes, Jason R.] Univ Queensland, Australian Res Ctr, Ctr Excellence Plant Cell Walls, Sch Chem Engn, Brisbane, Qld, Australia	University of Queensland; University of Queensland	Lopez-Sanchez, P (corresponding author), Univ Queensland, Australian Res Ctr, Ctr Excellence Plant Cell Walls, Ctr Nutr & Food Sci,Queensland Alliance Agr & Foo, Brisbane, Qld, Australia.	p.lopezsanchez@uq.edu.au	Stokes, Jason R/A-1608-2009; Flanagan, Bernadine/A-7130-2011; Flanagan, Bernadine/AAO-2273-2020; Gidley, Mike/AAT-9543-2021; Flanagan, Bernadine/U-7222-2019; Lopez-Sanchez, Patricia/AAA-8259-2021	Stokes, Jason R/0000-0001-7784-9297; Flanagan, Bernadine/0000-0002-5220-190X; Flanagan, Bernadine/0000-0002-5220-190X; Lopez-Sanchez, Patricia/0000-0002-2461-327X				Astley OM, 2003, INT J BIOL MACROMOL, V32, P28, DOI 10.1016/S0141-8130(03)00022-9; Burton RA, 2010, NAT CHEM BIOL, V6, P724, DOI [10.1038/NCHEMBIO.439, 10.1038/nchembio.439]; Busse-Wicher M, 2014, PLANT J, V79, P492, DOI 10.1111/tpj.12575; Buyanov AL, 2010, J MECH BEHAV BIOMED, V3, P102, DOI 10.1016/j.jmbbm.2009.06.001; CARPITA NC, 1993, PLANT J, V3, P1, DOI 10.1111/j.1365-313X.1993.tb00007.x; Carpita NC, 2001, PLANT PHYSIOL, V127, P551, DOI 10.1104/pp.010146; Cavalier DM, 2008, PLANT CELL, V20, P1519, DOI 10.1105/tpc.108.059873; Chanliaud E, 1999, PLANT J, V20, P25, DOI 10.1046/j.1365-313X.1999.00571.x; Chanliaud E, 2004, PLANT J, V38, P27, DOI 10.1111/j.1365-313X.2004.02018.x; Chanliaud E, 2002, PLANTA, V215, P989, DOI 10.1007/s00425-002-0783-8; CLARK AH, 1985, BRIT POLYM J, V17, P164, DOI 10.1002/pi.4980170214; Cosgrove DJ, 2005, NAT REV MOL CELL BIO, V6, P850, DOI 10.1038/nrm1746; Doblin MS, 2014, CURR OPIN BIOTECH, V26, P108, DOI 10.1016/j.copbio.2013.11.012; Ebringerova A, 2005, ADV POLYM SCI, V186, P1, DOI 10.1007/b136816; FRY SC, 1989, J EXP BOT, V40, P1, DOI 10.1093/jxb/40.1.1; GIDLEY MJ, 1991, CARBOHYD RES, V214, P299, DOI 10.1016/0008-6215(91)80037-N; Hamant O, 2010, CURR OPIN GENET DEV, V20, P454, DOI 10.1016/j.gde.2010.04.009; LOESCHER WH, 1973, PLANT PHYSIOL, V52, P248, DOI 10.1104/pp.52.3.248; Lopez-Sanchez P, 2014, BIOMACROMOLECULES, V15, P2274, DOI 10.1021/bm500405h; Macosko C.W., 1993, RHEOLOGY PRINCIPLES; MCCANN MC, 1990, J CELL SCI, V96, P323; McKenna BA, 2009, CELLULOSE, V16, P1047, DOI 10.1007/s10570-009-9340-y; Mikkelsen D, 2011, J AGR FOOD CHEM, V59, P4025, DOI 10.1021/jf104855e; Mikkelsen D, 2011, METHODS MOL BIOL, V715, P197, DOI 10.1007/978-1-61779-008-9_14; Moeendarbary E, 2013, NAT MATER, V12, P253, DOI [10.1038/NMAT3517, 10.1038/nmat3517]; Park YB, 2012, PLANT PHYSIOL, V158, P1933, DOI 10.1104/pp.111.192880; Park YB, 2012, PLANT PHYSIOL, V158, P465, DOI 10.1104/pp.111.189779; Pauly M, 1999, PLANT J, V20, P629, DOI 10.1046/j.1365-313X.1999.00630.x; Pettolino FA, 2012, NAT PROTOC, V7, P1590, DOI 10.1038/nprot.2012.081; ROSS P, 1991, MICROBIOL REV, V55, P35, DOI 10.1128/MMBR.55.1.35-58.1991; SHEDLETZKY E, 1992, PLANT PHYSIOL, V100, P120, DOI 10.1104/pp.100.1.120; Skotheim JM, 2005, SCIENCE, V308, P1308, DOI 10.1126/science.1107976; Somerville C, 2004, SCIENCE, V306, P2206, DOI 10.1126/science.1102765; Wang T, 2013, P NATL ACAD SCI USA, V110, P16444, DOI 10.1073/pnas.1316290110; Whitney SEC, 2006, AM J BOT, V93, P1402, DOI 10.3732/ajb.93.10.1402; WHITNEY SEC, 1995, PLANT J, V8, P491, DOI 10.1046/j.1365-313X.1995.8040491.x; Whitney SEC, 1999, PLANT PHYSIOL, V121, P657, DOI 10.1104/pp.121.2.657; Whitney SEC, 1998, CARBOHYD RES, V307, P299, DOI 10.1016/S0008-6215(98)00004-4; Zabotina OA, 2012, FRONT PLANT SCI, V3, DOI 10.3389/fpls.2012.00134	39	35	36	2	51	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 20	2015	10	3							e0122132	10.1371/journal.pone.0122132	http://dx.doi.org/10.1371/journal.pone.0122132			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CE8HY	25794048	Green Published, Green Submitted, gold			2023-01-03	WOS:000352083900172
J	Prahallad, A; Bernards, R				Prahallad, A.; Bernards, R.			Opportunities and challenges provided by crosstalk between signalling pathways in cancer	ONCOGENE			English	Review							HISTONE DEACETYLASE INHIBITOR; SYNTHETIC LETHAL INTERACTION; KRAS-MUTANT LUNG; MEK INHIBITION; RAF INHIBITORS; COMBINED BRAF; BRAF(V600E) INHIBITION; TUMOR MICROENVIRONMENT; COLON-CANCER; RESISTANCE	During evolution, connections between the major signalling pathways were established to provide cells with an ability to deal with perturbations of homeostasis. However, these feedback and crosstalk mechanisms can become a liability in the treatment of cancer, as the inhibition of one cancer-relevant signalling pathway can lead to the activation of a secondary survival pathway that interferes with cancer drug efficacy. In this review, we discuss connections between signalling pathways in relation to cancer therapy and we evaluate the use of genetic approaches to identify pathway crosstalk. We also discuss how insight into connections between signalling pathways can be exploited to design powerful synthetic lethal drug combination therapies for the treatment of cancer.	[Prahallad, A.; Bernards, R.] Netherlands Canc Inst, Div Mol Carcinogenesis & Canc Genom Netherlands, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands	Netherlands Cancer Institute	Bernards, R (corresponding author), Netherlands Canc Inst, Div Mol Carcinogenesis & Canc Genom Netherlands, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.	r.bernards@nki.nl		Bernards, Rene/0000-0001-8677-3423	EU FP7 grant 'COLTHERES'; Cancer Genomics Netherlands consortium	EU FP7 grant 'COLTHERES'; Cancer Genomics Netherlands consortium	This work was funded by the EU FP7 grant 'COLTHERES' and by the Cancer Genomics Netherlands consortium.	Adjei AA, 2008, J CLIN ONCOL, V26, P2139, DOI 10.1200/JCO.2007.14.4956; Albini A, 2007, NAT REV CANCER, V7, P139, DOI 10.1038/nrc2067; Alifrangis CC, 2014, MOL ONCOL, V8, P1112, DOI 10.1016/j.molonc.2014.05.014; Ashworth A, 2008, J CLIN ONCOL, V26, P3785, DOI 10.1200/JCO.2008.16.0812; Azad NS, 2008, J CLIN ONCOL, V26, P3709, DOI 10.1200/JCO.2007.10.8332; Barbie DA, 2009, NATURE, V462, P108, DOI 10.1038/nature08460; Bardelli A, 2010, J CLIN ONCOL, V28, P1254, DOI 10.1200/JCO.2009.24.6116; Bertino EM, 2011, EXPERT OPIN INV DRUG, V20, P1151, DOI 10.1517/13543784.2011.594437; Bollag G, 2012, NAT REV DRUG DISCOV, V11, P873, DOI 10.1038/nrd3847; Bonapace L, 2014, NATURE, V515, DOI 10.1038/nature13862; Cai Y, 2014, ONCOGENE, V33, P2157, DOI 10.1038/onc.2013.178; Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047; Chapman PB, 2011, NEW ENGL J MED, V364, P2507, DOI 10.1056/NEJMoa1103782; Chin L, 2008, NATURE, V455, P1061, DOI 10.1038/nature07385; Corcoran RB, 2013, CANCER CELL, V23, P121, DOI 10.1016/j.ccr.2012.11.007; Corcoran RB, 2012, CANCER DISCOV, V2, P227, DOI 10.1158/2159-8290.CD-11-0341; Cunningham D, 2004, NEW ENGL J MED, V351, P337, DOI 10.1056/NEJMoa033025; Dancey JE, 2006, NAT REV DRUG DISCOV, V5, P649, DOI 10.1038/nrd2089; Das Thakur M, 2013, NATURE, V494, P251, DOI 10.1038/nature11814; De Palma M, 2013, CANCER CELL, V23, P277, DOI 10.1016/j.ccr.2013.02.013; Flaherty KT, 2012, NEW ENGL J MED, V367, P107, DOI 10.1056/NEJMoa1203421; Garralda E, 2014, CLIN CANCER RES, V20, P2476, DOI 10.1158/1078-0432.CCR-13-3047; Geel R.V., 2014, J CLIN ONCOL, V32, P5; Geutjes EJ, 2012, ONCOGENE, V31, P3827, DOI 10.1038/onc.2011.552; Girotti MR, 2013, CANCER DISCOV, V3, P158, DOI 10.1158/2159-8290.CD-12-0386; Groenendijk FH, 2014, MOL ONCOL, V8, P1067, DOI 10.1016/j.molonc.2014.05.004; Hata AN, 2014, CANCER RES, V74, P3146, DOI 10.1158/0008-5472.CAN-13-3728; Hatzivassiliou G, 2013, NATURE, V501, P232, DOI 10.1038/nature12441; Hatzivassiliou G, 2010, NATURE, V464, P431, DOI 10.1038/nature08833; Heidorn SJ, 2010, CELL, V140, P209, DOI 10.1016/j.cell.2009.12.040; Helming KC, 2014, NAT MED, V20, P251, DOI 10.1038/nm.3480; Hidalgo M, 2011, MOL CANCER THER, V10, P1311, DOI 10.1158/1535-7163.MCT-11-0233; Hoffman GR, 2014, P NATL ACAD SCI USA, V111, P3128, DOI 10.1073/pnas.1316793111; Janne PA, 2013, LANCET ONCOL, V14, P38, DOI 10.1016/S1470-2045(12)70489-8; Johnson DB, 2014, J CLIN ONCOL, V32, P3697, DOI 10.1200/JCO.2014.57.3535; Julien S, 2012, CLIN CANCER RES, V18, P5314, DOI 10.1158/1078-0432.CCR-12-0372; Kelly TK, 2010, NAT BIOTECHNOL, V28, P1069, DOI 10.1038/nbt.1678; Kopetz S., 2010, J CLIN ONCOL, V28; Kuczynski EA, 2013, NAT REV CLIN ONCOL, V10, P571, DOI 10.1038/nrclinonc.2013.158; Kummar S, 2010, NAT REV DRUG DISCOV, V9, P843, DOI 10.1038/nrd3216; Lamba S, 2014, CELL REP, V8, P1475, DOI 10.1016/j.celrep.2014.07.033; Lee EQ, 2012, NEURO-ONCOLOGY, V14, P1511, DOI 10.1093/neuonc/nos264; Lito P, 2014, CANCER CELL, V25, P697, DOI 10.1016/j.ccr.2014.03.011; Llovet JM, 2008, NEW ENGL J MED, V359, P378, DOI 10.1056/NEJMoa0708857; Long GV, 2014, NEW ENGL J MED, V371, P1877, DOI 10.1056/NEJMoa1406037; Luo J, 2009, CELL, V137, P835, DOI 10.1016/j.cell.2009.05.006; Marks PA, 2007, NAT BIOTECHNOL, V25, P84, DOI 10.1038/nbt1272; Migliardi G, 2012, CLIN CANCER RES, V18, P2515, DOI 10.1158/1078-0432.CCR-11-2683; Misale S, 2012, NATURE, V486, P532, DOI 10.1038/nature11156; Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252; Nebbioso A, 2012, MOL ONCOL, V6, P657, DOI 10.1016/j.molonc.2012.09.004; Packer LM, 2011, CANCER CELL, V20, P715, DOI 10.1016/j.ccr.2011.11.004; Poulikakos PI, 2010, NATURE, V464, P427, DOI 10.1038/nature08902; Prahallad A, 2012, NATURE, V483, P100, DOI 10.1038/nature10868; Rehman FL, 2010, NAT REV CLIN ONCOL, V7, P718, DOI 10.1038/nrclinonc.2010.172; Ribas A, 2013, NEW ENGL J MED, V368, P1365, DOI 10.1056/NEJMc1302338; Rudalska R, 2014, NAT MED, V20, P1138, DOI 10.1038/nm.3679; Saltz LB, 2004, J CLIN ONCOL, V22, P1201, DOI 10.1200/JCO.2004.10.182; Scholl C, 2009, CELL, V137, P821, DOI 10.1016/j.cell.2009.03.017; Sharma SV, 2010, CELL, V141, P69, DOI 10.1016/j.cell.2010.02.027; Singh A, 2012, CELL, V148, P639, DOI 10.1016/j.cell.2011.12.033; Solit DB, 2006, NATURE, V439, P358, DOI 10.1038/nature04304; Sosman JA, 2008, EXPERT REV ANTICANC, V8, P481, DOI 10.1586/14737140.8.3.481; Straussman R, 2012, NATURE, V487, P500, DOI 10.1038/nature11183; Su F, 2012, NEW ENGL J MED, V366, P207, DOI 10.1056/NEJMoa1105358; Sun C, 2014, TRENDS BIOCHEM SCI, V39, P465, DOI 10.1016/j.tibs.2014.08.010; Sun C, 2014, CELL REP, V7, P86, DOI 10.1016/j.celrep.2014.02.045; Sun C, 2014, NATURE, V508, P118, DOI 10.1038/nature13121; Thurn KT, 2011, FUTURE ONCOL, V7, P263, DOI 10.2217/FON.11.2; Tol J, 2009, NEW ENGL J MED, V360, P563, DOI 10.1056/NEJMoa0808268; Valachis A, 2010, BREAST CANCER RES TR, V122, P1, DOI 10.1007/s10549-009-0727-0; Van Cutsem E, 2009, NEW ENGL J MED, V360, P1408, DOI 10.1056/NEJMoa0805019; Wilson TR, 2012, NATURE, V487, P505, DOI 10.1038/nature11249	73	30	32	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 3	2016	35	9					1073	1079		10.1038/onc.2015.151	http://dx.doi.org/10.1038/onc.2015.151			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DF4WH	25982281				2023-01-03	WOS:000371351700001
J	Lean, QY; Eri, RD; Fitton, JH; Patel, RP; Gueven, N				Lean, Qi Ying; Eri, Rajaraman D.; Fitton, J. Helen; Patel, Rahul P.; Gueven, Nuri			Fucoidan Extracts Ameliorate Acute Colitis	PLOS ONE			English	Article							MOLECULAR-WEIGHT FUCOIDAN; SODIUM-INDUCED COLITIS; ULCERATIVE-COLITIS; IN-VITRO; SULFATED POLYSACCHARIDE; BROWN-ALGAE; T-CELLS; INFLAMMATION; INHIBITION; MODEL	Inflammatory bowel diseases (IBD), such as ulcerative colitis and Crohn's disease, are an important cause of morbidity and impact significantly on quality of life. Overall, current treatments do not sustain a long-term clinical remission and are associated with adverse effects, which highlight the need for new treatment options. Fucoidans are complex sulphated, fucose-rich polysaccharides, found in edible brown algae and are described as having multiple bioactivities including potent anti-inflammatory effects. Therefore, the therapeutic potential of two different fucoidan preparations, fucoidan-polyphenol complex (Maritech Synergy) and depyrogenated fucoidan (DPF) was evaluated in the dextran sulphate sodium (DSS) mouse model of acute colitis. Mice were treated once daily over 7 days with fucoidans via oral (Synergy or DPF) or intraperitoneal administration (DPF). Signs and severity of colitis were monitored daily before colons and spleens were collected for macroscopic evaluation, cytokine measurements and histology. Orally administered Synergy and DPF, but not intraperitoneal DPF treatment, significantly ameliorated symptoms of colitis based on retention of body weight, as well as reduced diarrhoea and faecal blood loss, compared to the untreated colitis group. Colon and spleen weight in mice treated with oral fucoidan was also significantly lower, indicating reduced inflammation and oedema. Histological examination of untreated colitis mice confirmed a massive loss of crypt architecture and goblet cells, infiltration of immune cells and oedema, while all aspects of this pathology were alleviated by oral fucoidan. Importantly, in this model, the macroscopic changes induced by oral fucoidan correlated significantly with substantially decreased production of at least 15 proinflammatory cytokines by the colon tissue. Overall, oral fucoidan preparations significantly reduce the inflammatory pathology associated with DSS-induced colitis and could therefore represent a novel nutraceutical option for the management of IBD.	[Lean, Qi Ying; Patel, Rahul P.; Gueven, Nuri] Univ Tasmania, Sch Med, Pharm, Hobart, Tas, Australia; [Lean, Qi Ying] Univ Teknol MARA, Puncak Alam, Selangor, Malaysia; [Eri, Rajaraman D.] Univ Tasmania, Sch Hlth Sci, Launceston, Tas 7250, Australia; [Fitton, J. Helen] Marinova Pty Ltd, Cambridge, Tas, Australia	University of Tasmania; Universiti Teknologi MARA; University of Tasmania	Gueven, N (corresponding author), Univ Tasmania, Sch Med, Pharm, Hobart, Tas, Australia.	nguven@utas.edu.au	Eri, Rajaraman/AAM-3214-2020; Eri, Raj/AAD-1185-2020; Lean, Qi Ying/G-1680-2019	Eri, Raj/0000-0003-1688-8043; Lean, Qi Ying/0000-0003-0331-8607; Guven, Nuri/0000-0003-3782-767X; Patel, Rahul/0000-0001-9344-1013; Fitton, J Helen/0000-0002-1402-0809	Marinova Pty, Ltd.	Marinova Pty, Ltd.	Marinova Pty, Ltd., provided financial support in the form of salaries for co-author J. Helen Fitton and a research grant for consumables, but did not have any input into the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific role of this author is articulated in the 'author contributions' section.	Akobeng AA, 2014, INFLAMM BOWEL DIS, V20, P2132, DOI 10.1097/MIB.0000000000000218; Ale MT, 2011, MAR DRUGS, V9, P2106, DOI 10.3390/md9102106; Alex P, 2009, INFLAMM BOWEL DIS, V15, P341, DOI 10.1002/ibd.20753; Banks C, 2003, J PATHOL, V199, P28, DOI 10.1002/path.1245; Baumgart DC, 2012, LANCET, V380, P1590, DOI 10.1016/S0140-6736(12)60026-9; Ben-Horin S, 2011, ALIMENT PHARM THER, V33, P987, DOI 10.1111/j.1365-2036.2011.04612.x; Cai Jingmei, 2014, Lab Anim Res, V30, P28, DOI 10.5625/lar.2014.30.1.28; Carvalho ACS, 2014, PANCREAS, V43, P82, DOI 10.1097/MPA.0b013e3182a63b9d; Chassaing B., 2014, CURR PROTOC IMMUNOL, V104; Choi JI, 2010, CHEM-BIOL INTERACT, V183, P249, DOI 10.1016/j.cbi.2009.09.015; Chung HJ, 2010, PHYTOTHER RES, V24, P1078, DOI 10.1002/ptr.3138; Cosnes J, 2011, GASTROENTEROLOGY, V140, P1785, DOI 10.1053/j.gastro.2011.01.055; Cui YQ, 2012, CNS NEUROSCI THER, V18, P827, DOI 10.1111/j.1755-5949.2012.00372.x; Cumashi A, 2007, GLYCOBIOLOGY, V17, P541, DOI 10.1093/glycob/cwm014; Eri R, 2012, METHODS MOL BIOL, V844, P261, DOI 10.1007/978-1-61779-527-5_19; Ferrante M, 2008, J CROHNS COLITIS, V2, P219, DOI 10.1016/j.crohns.2008.03.004; Fitton JH, 2011, MAR DRUGS, V9, P1731, DOI 10.3390/md9101731; Heinsbroek SEM, 2009, EXPERT REV MOL MED, V11, DOI 10.1017/S1462399409001069; Heitz FD, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045182; Hlawaty H, 2011, BIOCHEM PHARMACOL, V81, P233, DOI 10.1016/j.bcp.2010.09.021; Ishiguro Y, 1999, J GASTROENTEROL, V34, P66, DOI 10.1007/s005350050218; Jin JO, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099396; Juffrie M., 2011, INDONES J BIOTECH, V11, P908; Kim KJ, 2012, FITOTERAPIA, V83, P1628, DOI 10.1016/j.fitote.2012.09.014; Kim KJ, 2010, TOXICOLOGY, V267, P154, DOI 10.1016/j.tox.2009.11.007; Koetzner L, 2010, DIGEST DIS SCI, V55, P1278, DOI 10.1007/s10620-009-0848-7; Kuznetsova TA, 2014, MAR DRUGS, V12, P886, DOI 10.3390/md12020886; Lee SH, 2013, CARBOHYD POLYM, V92, P84, DOI 10.1016/j.carbpol.2012.09.066; Lee SH, 2012, CARBOHYD POLYM, V89, P599, DOI 10.1016/j.carbpol.2012.03.056; Li CM, 2011, FOOD CHEM TOXICOL, V49, P2090, DOI 10.1016/j.fct.2011.05.022; Low D, 2013, DRUG DES DEV THER, V7, P1341, DOI 10.2147/DDDT.S40107; Lutay N, 2011, APPL BIOCHEM BIOTECH, V164, P1, DOI 10.1007/s12010-010-9109-7; Maillard M. H., 2010, INFLAMM BOWEL DIS, P119; Matsumoto S, 2004, CLIN EXP IMMUNOL, V136, P432, DOI 10.1111/j.1365-2249.2004.02462.x; Melgar S, 2008, INT IMMUNOPHARMACOL, V8, P836, DOI 10.1016/j.intimp.2008.01.036; Mizuno M, 2009, BIOSCI BIOTECH BIOCH, V73, P2324, DOI 10.1271/bbb.90326; Neurath MF, 2014, NAT REV IMMUNOL, V14, P329, DOI 10.1038/nri3661; OKAYASU I, 1990, GASTROENTEROLOGY, V98, P694, DOI 10.1016/0016-5085(90)90290-H; Ordas I, 2012, LANCET, V380, P1606, DOI 10.1016/S0140-6736(12)60150-0; Park KT, 2011, INFLAMM BOWEL DIS, V17, P1603, DOI 10.1002/ibd.21488; Perse M., 2012, BIOMED RES INT, V2012; Peyrin-Biroulet L, 2008, CLIN GASTROENTEROL H, V6, P644, DOI 10.1016/j.cgh.2008.03.014; Rose WA, 2012, BMC IMMUNOL, V13, DOI 10.1186/1471-2172-13-41; Senni K, 2006, ARCH BIOCHEM BIOPHYS, V445, P56, DOI 10.1016/j.abb.2005.11.001; Shintani N, 1997, SCAND J IMMUNOL, V46, P581, DOI 10.1046/j.1365-3083.1997.d01-169.x; Tanoue T, 2008, BIOCHEM BIOPH RES CO, V374, P565, DOI 10.1016/j.bbrc.2008.07.063; Triantafillidis JK, 2011, DRUG DES DEV THER, V5, P185, DOI 10.2147/DDDT.S11290; Wallace KL, 2014, WORLD J GASTROENTERO, V20, P6, DOI 10.3748/wjg.v20.i1.6; Wirtz S, 2007, NAT PROTOC, V2, P541, DOI 10.1038/nprot.2007.41; Wlodarska M, 2014, CELL, V156, P1045, DOI 10.1016/j.cell.2014.01.026; Zhang XW, 2001, SCAND J GASTROENTERO, V36, P270, DOI 10.1080/003655201750074555; Zheng B, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095441; Zhu W, 2014, IMMUNOL INVEST, V43, P638, DOI 10.3109/08820139.2014.909456	53	61	64	1	51	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 17	2015	10	6							e0128453	10.1371/journal.pone.0128453	http://dx.doi.org/10.1371/journal.pone.0128453			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CK9NS	26083103	Green Published, gold			2023-01-03	WOS:000356567400051
J	Lim, LS				Lim, Lionel S.			Review: In patients with dementia who live in care homes, some nondrug interventions reduce agitation	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									Griffin Hosp, Derby, CT 06418 USA		Lim, LS (corresponding author), Griffin Hosp, Derby, CT 06418 USA.			Livingston, Gill/0000-0001-6741-5516; Lim, Lionel/0000-0002-0730-8767				American Geriatrics Society, 10 THINGS PHYS PAT S; [Anonymous], 2015, ALZH DIS FACTS FIG; Van der Mussele S, 2015, AGING MENT HEALTH, V19, P247, DOI 10.1080/13607863.2014.924900	3	0	0	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 16	2015	162	12							JC3	10.7326/ACPJC-2015-162-12-003	http://dx.doi.org/10.7326/ACPJC-2015-162-12-003			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CK8VC	26075780				2023-01-03	WOS:000356516300004
J	Bannantine, JP; Stabel, JR; Laws, E; Cardieri, MCD; Souza, CD				Bannantine, John P.; Stabel, Judith R.; Laws, Elizabeth; Cardieri, Maria Clara D.; Souza, Cleverson D.			Mycobacterium avium Subspecies paratuberculosis Recombinant Proteins Modulate Antimycobacterial Functions of Bovine Macrophages	PLOS ONE			English	Article							GAMMA-INTERFERON; NITRIC-OXIDE; DAIRY-COWS; TUBERCULOSIS; INTERLEUKIN-10; EXPRESSION; MATURATION; INFECTION; CATTLE; LIPOPROTEINS	It has been shown that Mycobacterium avium subspecies paratuberculosis (M. paratuberculosis) activates the Mitogen Activated Protein Kinase (MAPK) p38 pathway, yet it is unclear which components of M. paratuberculosis are involved in the process. Therefore, a set of 42 M. paratuberculosis recombinant proteins expressed from coding sequences annotated as lipoproteins were screened for their ability to induce IL-10 expression, an indicator of MAPKp38 activation, in bovine monocyte-derived macrophages. A recombinant lipoprotein, designated as MAP3837c, was among a group of 6 proteins that strongly induced IL-10 gene transcription in bovine macrophages, averaging a 3.1-fold increase compared to non-stimulated macrophages. However, a parallel increase in expression of IL-12 and TNF-alpha was only observed in macrophages exposed to a subset of these 6 proteins. Selected recombinant proteins were further analyzed for their ability to enhance survival of M. avium within bovine macrophages as measured by recovered viable bacteria and nitrite production. All 6 IL-10 inducing MAP recombinant proteins along with M. paratuberculosis cells significantly enhanced phosphorylation of MAPK-p38 in bovine macrophages. Although these proteins are likely not post translationally lipidated in E. coli and thus is a limitation in this study, these results form the foundation of how the protein component of the lipoprotein interacts with the immune system. Collectively, these data reveal M. paratuberculosis proteins that might play a role in MAPK-p38 pathway activation and hence in survival of this organism within bovine macrophages.	[Bannantine, John P.; Stabel, Judith R.] USDA ARS, Natl Anim Dis Ctr, Ames, IA 50010 USA; [Laws, Elizabeth; Cardieri, Maria Clara D.; Souza, Cleverson D.] Washington State Univ, Dept Vet Clin Sci, Pullman, WA 99164 USA	United States Department of Agriculture (USDA); Washington State University	Souza, CD (corresponding author), Washington State Univ, Dept Vet Clin Sci, Pullman, WA 99164 USA.	souza@vetmed.wsu.edu		Bannantine, John/0000-0002-5692-7898				Ashwell JD, 2006, NAT REV IMMUNOL, V6, P532, DOI 10.1038/nri1865; Bannantine JP, 2002, BMC MICROBIOL, V2, DOI 10.1186/1471-2180-2-2; Bannantine JP, 2010, PROTEIN EXPRES PURIF, V72, P223, DOI 10.1016/j.pep.2010.03.019; Bowdish DME, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000474; Brightbill HD, 1999, SCIENCE, V285, P732, DOI 10.1126/science.285.5428.732; Brulle JK, 2010, BIOCHEM BIOPH RES CO, V391, P679, DOI 10.1016/j.bbrc.2009.11.120; Clark IA, 2007, CYTOKINE GROWTH F R, V18, P335, DOI 10.1016/j.cytogfr.2007.04.002; CLEMENS DL, 1995, J EXP MED, V181, P257, DOI 10.1084/jem.181.1.257; Dennis MM, 2008, VET MICROBIOL, V131, P154, DOI 10.1016/j.vetmic.2008.02.017; Early J, 2011, MICROB PATHOGENESIS, V50, P132, DOI 10.1016/j.micpath.2010.12.004; Harris NB, 2001, CLIN MICROBIOL REV, V14, P489, DOI 10.1128/CMR.14.3.489-512.2001; Hostetter JM, 2002, FEMS IMMUNOL MED MIC, V34, P127, DOI 10.1111/j.1574-695X.2002.tb00613.x; JACOBSEN CN, 1993, VET IMMUNOL IMMUNOP, V39, P461, DOI 10.1016/0165-2427(93)90075-F; Keane J, 2001, NEW ENGL J MED, V345, P1098, DOI 10.1056/NEJMoa011110; Khalifeh MS, 2004, INFECT IMMUN, V72, P1974, DOI 10.1128/IAI.72.4.1974-1982.2004; Kuehnel MP, 2001, CELL MICROBIOL, V3, P551, DOI 10.1046/j.1462-5822.2001.00139.x; Leopold I, 1997, ANAL BIOCHEM, V252, P277, DOI 10.1006/abio.1997.2329; Li LL, 2005, P NATL ACAD SCI USA, V102, P12344, DOI 10.1073/pnas.0505662102; Medzhitov R, 1997, CELL, V91, P295, DOI 10.1016/S0092-8674(00)80412-2; Noss EH, 2001, J IMMUNOL, V167, P910, DOI 10.4049/jimmunol.167.2.910; Raizman EA, 2009, J DAIRY SCI, V92, P4929, DOI 10.3168/jds.2009-2133; Rampini SK, 2008, MICROBIOL-SGM, V154, P2991, DOI 10.1099/mic.0.2008/018895-0; Sakthi S, 2013, MICROBIOL RES, V168, P407, DOI 10.1016/j.micres.2013.02.007; Simutis FJ, 2007, VET IMMUNOL IMMUNOP, V116, P1, DOI 10.1016/j.vetimm.2006.12.005; Souza C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075924; Souza CD, 2006, MICROB PATHOGENESIS, V41, P59, DOI 10.1016/j.micpath.2006.04.002; Stabel JR, 2008, J DAIRY SCI, V91, P3600, DOI 10.3168/jds.2008-1107; Stabel JR, 2014, J DAIRY SCI, V97, P6296, DOI 10.3168/jds.2014-8204; SUTCLIFFE IC, 1995, J BACTERIOL, V177, P1123, DOI 10.1128/jb.177.5.1123-1128.1995; Tschumi A, 2009, J BIOL CHEM, V284, P27146, DOI 10.1074/jbc.M109.022715; Weiss DJ, 2005, AM J VET RES, V66, P1114, DOI 10.2460/ajvr.2005.66.1114; Weiss DJ, 2005, AM J VET RES, V66, P721, DOI 10.2460/ajvr.2005.66.721; Weiss DJ, 2002, INFECT IMMUN, V70, P5556, DOI 10.1128/IAI.70.10.5556-5561.2002; Weiss DJ, 2008, J LEUKOCYTE BIOL, V83, P48, DOI 10.1189/jlb.0707490; Zhao BY, 1997, INFECT IMMUN, V65, P1761, DOI 10.1128/IAI.65.5.1761-1766.1997	35	9	9	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 15	2015	10	6							e0128966	10.1371/journal.pone.0128966	http://dx.doi.org/10.1371/journal.pone.0128966			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CK6HU	26076028	Green Submitted, Green Published, gold			2023-01-03	WOS:000356329900040
J	Chen, LC; Ho, CW; Sun, CH; Lee, JT; Li, TY; Shih, FM; Wu, YT				Chen, Liang-Cheng; Ho, Cheng-Wen; Sun, Chia-Hung; Lee, Jiunn-Tay; Li, Tsung-Ying; Shih, Feng-Mei; Wu, Yung-Tsan			Ultrasound-Guided Pulsed Radiofrequency for Carpal Tunnel Syndrome: A Single-Blinded Randomized Controlled Study	PLOS ONE			English	Article							NERVE-CONDUCTION; SUPRASCAPULAR NERVE; STEROID INJECTIONS; FUNCTIONAL STATUS; SYMPTOMS; PAIN; SEVERITY	Objective We assessed the therapeutic efficiency of ultrasound-guided pulsed radiofrequency (PRF) treatment of the median nerve in patients with carpal tunnel syndrome (CTS). Methods We conducted a prospective, randomized, controlled, single-blinded study. Forty-four patients with CTS were randomized into intervention or control groups. Patients in the intervention group were treated with PRF and night splint, and the control group was prescribed night splint alone. Primary outcome was the onset time of significant pain relief assessed using the visual analog scale (VAS), and secondary outcomes included evaluation of the Boston Carpal Tunnel Syndrome Questionnaire (BCTQ) results, cross-sectional area (CSA) of the median nerve, sensory nerve conduction velocity (SNCV) of the median nerve, and finger pinch strength. All outcome measurements were performed at 1, 4, 8, and 12 weeks after treatment. Results Thirty-six patients completed the study. The onset time of pain relief in the intervention group was significantly shorter (median onset time of 2 days vs. 14 days; hazard ratio = 7.37; 95% CI, 3.04-17.87) compared to the control group (p < 0.001). Significant improvement in VAS and BCTQ scores (p < 0.05) was detected in the intervention group at all follow-up periods compared to the controls (except for the severity subscale of BCTQ at week 1). Ultrasound-guided PRF treatment resulted in a lower VAS score and stronger finger pinch compared to the control group over the entire study. Conclusions Our study shows that ultrasound-guided PRF serves as a better approach for pain relief in patients with CTS.	[Chen, Liang-Cheng; Sun, Chia-Hung; Li, Tsung-Ying; Shih, Feng-Mei; Wu, Yung-Tsan] Natl Def Med Ctr, Triserv Gen Hosp, Sch Med, Dept Phys Med & Rehabil, Taipei, Taiwan; [Chen, Liang-Cheng] Hualien Armed Forces Gen Hosp, Dept Phys Med & Rehabil, Xincheng, Hualien County, Taiwan; [Ho, Cheng-Wen] Natl Def Med Ctr, Sch Med, Grad Inst Aerosp Med, Taipei, Taiwan; [Lee, Jiunn-Tay] Natl Def Med Ctr, Triserv Gen Hosp, Sch Med, Dept Neurol, Taipei, Taiwan	National Defense Medical Center; Tri-Service General Hospital; National Defense Medical Center; National Defense Medical Center; Tri-Service General Hospital	Wu, YT (corresponding author), Natl Def Med Ctr, Triserv Gen Hosp, Sch Med, Dept Phys Med & Rehabil, Taipei, Taiwan.	crwu98@gmail.com	Li, Tsung-Ying/AAJ-2359-2020		Tri-Service General Hospital, Taipei, Taiwan, Republic of China [TSGH-C102-105]	Tri-Service General Hospital, Taipei, Taiwan, Republic of China	The study is (only) supported by the Tri-Service General Hospital (grant no. TSGH-C102-105), Taipei, Taiwan, Republic of China. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Atroshi I, 2000, Lakartidningen, V97, P1668; Chan L, 2007, ARCH PHYS MED REHAB, V88, P19, DOI 10.1016/j.apmr.2006.10.013; Chua NHL, 2011, ACTA NEUROCHIR, V153, P763, DOI 10.1007/s00701-010-0881-5; El Miedany YM, 2004, RHEUMATOLOGY, V43, P887, DOI 10.1093/rheumatology/keh190; Erdine S, 2009, PAIN PRACT, V9, P407, DOI 10.1111/j.1533-2500.2009.00317.x; Farrar JT, 2001, PAIN, V94, P149, DOI 10.1016/S0304-3959(01)00349-9; Gerritsen AAM, 2003, J NEUROL NEUROSUR PS, V74, P1342, DOI 10.1136/jnnp.74.9.1342; Gofeld M, 2013, PAIN PRACT, V13, P96, DOI 10.1111/j.1533-2500.2012.00560.x; Gursoy AE, 2013, NEUROPSYCH DIS TREAT, V9, P65, DOI 10.2147/NDT.S38513; Haider Naeem, 2007, Pain Physician, V10, P765; HUSKISSON EC, 1974, LANCET, V2, P1127, DOI 10.1016/S0140-6736(74)90884-8; JABLECKI CK, 1993, MUSCLE NERVE, V16, P1392; Karadag YS, 2010, RHEUMATOL INT, V30, P761, DOI 10.1007/s00296-009-1061-x; Katz JN, 1998, J HAND SURG-AM, V23A, P697, DOI 10.1016/S0363-5023(98)80058-0; Kaymak B, 2008, ARCH PHYS MED REHAB, V89, P743, DOI 10.1016/j.apmr.2007.09.041; Lakemeier S, 2013, ANESTH ANALG, V117, P228, DOI 10.1213/ANE.0b013e3182910c4d; Lee CH, 2005, ANN PLAS SURG, V54, P20, DOI 10.1097/01.sap.0000141942.27182.55; LEVINE DW, 1993, J BONE JOINT SURG AM, V75A, P1585, DOI 10.2106/00004623-199311000-00002; O'Connor D, 2003, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD003219, DOI 10.1002/14651858.CD003219]; Sites BD, 2006, CURR OPIN ANESTHESIO, V19, P630, DOI 10.1097/ACO.0b013e3280101423; Sluijter ME, 1998, SPINE, V23, P745, DOI 10.1097/00007632-199803150-00022; Soyupek F, 2012, RHEUMATOL INT, V32, P3229, DOI 10.1007/s00296-011-2173-7; Stegink Jansen Caroline W, 2003, J Hand Ther, V16, P326; Taylor-Gjevre RM, 2010, CAN FAM PHYSICIAN, V56, pE250; Ustun N, 2013, AM J PHYS MED REHAB, V92, P999, DOI 10.1097/PHM.0b013e31829b4d72; Van Zundert J, 2005, ANESTHESIOLOGY, V102, P125, DOI 10.1097/00000542-200501000-00021; Werner RA, 2002, CLIN NEUROPHYSIOL, V113, P1373, DOI 10.1016/S1388-2457(02)00169-4; Wong SM, 2002, ARTHRITIS RHEUM, V46, P1914, DOI 10.1002/art.10385; Wu YT, 2014, ANESTH ANALG, V119, P686, DOI 10.1213/ANE.0000000000000354	29	18	18	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 12	2015	10	6							e0129918	10.1371/journal.pone.0129918	http://dx.doi.org/10.1371/journal.pone.0129918			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CK6GR	26067628	Green Published, Green Submitted, gold			2023-01-03	WOS:000356327000124
J	Kill, C; Galbas, M; Neuhaus, C; Hahn, O; Wallot, P; Kesper, K; Wulf, H; Dersch, W				Kill, Clemens; Galbas, Monika; Neuhaus, Christian; Hahn, Oliver; Wallot, Pascal; Kesper, Karl; Wulf, Hinnerk; Dersch, Wolfgang			Chest Compression Synchronized Ventilation versus Intermitted Positive Pressure Ventilation during Cardiopulmonary Resuscitation in a Pig Model	PLOS ONE			English	Article							IMPEDANCE THRESHOLD VALVE; PORCINE MODEL; MECHANICAL VENTILATION; GAS-EXCHANGE; LIFE-SUPPORT; HYPERVENTILATION; SURVIVAL; CPR	Background Guidelines recommend mechanical ventilation with Intermitted Positive Pressure Ventilation (IPPV) during resuscitation. The influence of the novel ventilator mode Chest Compression Synchronized Ventilation (CCSV) on gas exchange and arterial blood pressure compared with IPPV was investigated in a pig model. Methods In 12 pigs (general anaesthesia/intubation) ventricular fibrillation was induced and continuous chest compressions were started after 3min. Pigs were mechanically ventilated in a cross-over setting with 5 ventilation periods of 4min each: Ventilation modes were during the first and last period IPPV (100% O-2, tidalvolumes = 7ml/kgKG, respiratoryrate = 10/min), during the 2nd, 3rd and 4th period CCSV (100% O-2), a pressure-controlled and with each chest compression synchronized breathing pattern with three different presets in randomized order. Presets: CCSVA: P-insp = 60mbar, inspiratorytime = 205ms; CCSVB: P-insp = 60mbar, inspiratorytime = 265ms; CCSVC: P-insp = 45mbar, inspiratorytime = 265ms. Blood gas samples were drawn for each period, mean arterial (MAP) and centralvenous (CVP) blood pressures were continuously recorded. Results asmedian (25%/75% percentiles). Results Ventilation with each CCSV mode resulted in higher PaO2 than IPPV: PaO2: IPPVfirst: 19.6 (13.9/36.2) kPa, IPPVlast: 22.7(5.4/36.9) kPa (p = 0.77 vs IPPVfirst), CCSVA: 48.9(29.0/58.2) kPa (p = 0.028 vs IPPVfirst, p = 0.0001 vs IPPVlast), CCSVB: 54.0 (43.8/64.1) (p = 0.001 vs IPPVfirst, p = 0.0001 vs IPPVlast), CCSVC: 46.0 (20.2/58.4) (p = 0.006 vs IPPVfirst, p = 0.0001 vs IPPVlast). Both the MAP and the difference MAP-CVP did not decrease during twelve minutes CPR with all three presets of CCSV and were higher than the pressures of the last IPPV period. Conclusions All patterns of CCSV lead to a higher PaO2 and avoid an arterial blood pressure drop during resuscitation compared to IPPV in this pig model of cardiac arrest.	[Kill, Clemens; Galbas, Monika; Hahn, Oliver; Wallot, Pascal; Wulf, Hinnerk; Dersch, Wolfgang] Univ Marburg, Dept Anesthesiol & Crit Care, D-35032 Marburg, Germany; [Kill, Clemens; Dersch, Wolfgang] Univ Marburg, Dept Emergency Med, D-35032 Marburg, Germany; [Kesper, Karl] Univ Marburg, Dept Internal Med, Sect Resp Dis, D-35032 Marburg, Germany; [Neuhaus, Christian] Weinmann Emergency Med Technol GmbH Co KG, Hamburg, Germany	Philipps University Marburg; Philipps University Marburg; Philipps University Marburg	Kill, C (corresponding author), Univ Marburg, Dept Anesthesiol & Crit Care, D-35032 Marburg, Germany.	killc@staff.uni-marburg.de			German governmental grant (Bundesministerium fur Wirtschaft und Informationstechnologie) [KF2502403FR0, KF2660001FR0]; Weinmann Emergency Medical Technology GmbH+Co.KG	German governmental grant (Bundesministerium fur Wirtschaft und Informationstechnologie); Weinmann Emergency Medical Technology GmbH+Co.KG	This work as supported by the German governmental grant (Bundesministerium fur Wirtschaft und Informationstechnologie, No KF2502403FR0, KF2660001FR0) as institutional funding to Philipps-University, Marburg URL: www.zim-bmwi.de. Weinmann Emergency Medical Technology GmbH+Co.KG, provided support in the form of a salary for author CN, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of the authors are articulated in the 'author contributions' section.	Aufderheide Tom P, 2004, Crit Care Med, V32, pS345, DOI 10.1097/01.CCM.0000134335.46859.09; Aufderheide TP, 2004, CIRCULATION, V109, P1960, DOI 10.1161/01.CIR.0000126594.79136.61; Bobrow BJ, 2009, ANN EMERG MED, V54, P656, DOI 10.1016/j.annemergmed.2009.06.011; Botran M, 2011, INTENS CARE MED, V37, P1873, DOI 10.1007/s00134-011-2338-6; Brochard L, 1996, AM J RESP CRIT CARE, V154, P1323, DOI 10.1164/ajrccm.154.5.8912743; Chalkias A, 2013, EUR HEART J ACUTE CA; CRILEY JM, 1976, JAMA-J AM MED ASSOC, V236, P1246, DOI 10.1001/jama.236.11.1246; DEAKIN CD, 2010, RESUSCITATION, V81, P1305, DOI DOI 10.1016/J.RESUSCITATI0N.2010.08.017; Dorph E, 2004, RESUSCITATION, V61, P23, DOI 10.1016/j.resuscitation.2003.12.017; Ewy GA, 2005, CIRCULATION, V111, P2134, DOI 10.1161/01.CIR.0000162503.57657.FA; Gazmuri RJ, 2012, RESUSCITATION, V83, P259, DOI 10.1016/j.resuscitation.2011.07.034; HALPERIN HR, 1993, NEW ENGL J MED, V329, P762, DOI 10.1056/NEJM199309093291104; Hupfl M, 2010, LANCET, V376, P1552, DOI 10.1016/S0140-6736(10)61454-7; IDRIS AH, 1994, RESUSCITATION, V28, P143, DOI 10.1016/0300-9572(94)90087-6; Kill C, 2014, CRIT CARE MED, V42, pE89, DOI 10.1097/CCM.0b013e3182a63fa0; Kill C, 2012, CURR OPIN CRIT CARE, V18, P251, DOI 10.1097/MCC.0b013e3283523f69; Kill C, 2009, RESUSCITATION, V80, P1060, DOI 10.1016/j.resuscitation.2009.05.015; Kleinsasser A, 2002, CIRCULATION, V106, P373, DOI 10.1161/01.CIR.0000021428.94652.04; Langhelle A, 2002, RESUSCITATION, V52, P39, DOI 10.1016/S0300-9572(01)00442-7; Lurie KG, 2002, CIRCULATION, V105, P124, DOI 10.1161/hc0102.101391; Lurie KG, 2001, ANESTH ANALG, V93, P649, DOI 10.1097/00000539-200109000-00024; Iglesias JM, 2010, INTENS CARE MED, V36, P712, DOI 10.1007/s00134-010-1777-9; NOC M, 1994, AM J RESP CRIT CARE, V150, P861, DOI 10.1164/ajrccm.150.3.8087362; Richard JCM, 2011, AM J RESP CRIT CARE, V184, P32, DOI 10.1164/rccm.201103-0424UP; Timerman S, 2004, RESUSCITATION, V61, P273, DOI 10.1016/j.resuscitation.2004.01.025; Yannopoulos D, 2005, CIRCULATION, V112, P803, DOI 10.1161/CIRCULATIONAHA.105.541508; Yannopoulos D, 2007, ANESTH ANALG, V104, P157, DOI 10.1213/01.ane.0000249047.80184.5a; Yannopoulos D, 2010, CRIT CARE MED, V38, P254, DOI 10.1097/CCM.0b013e3181b42f6c	28	16	17	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 26	2015	10	5							e0127759	10.1371/journal.pone.0127759	http://dx.doi.org/10.1371/journal.pone.0127759			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CJ0QZ	26011525	Green Submitted, gold, Green Published			2023-01-03	WOS:000355183900140
J	Postow, MA; Chesney, J; Pavlick, AC; Robert, C; Grossmann, K; McDermott, D; Linette, GP; Meyer, N; Giguere, JK; Agarwala, SS; Shaheen, M; Ernstoff, MS; Minor, D; Salama, AK; Taylor, M; Ott, PA; Rollin, LM; Horak, C; Gagnier, P; Wolchok, JD; Hodi, FS				Postow, Michael A.; Chesney, Jason; Pavlick, Anna C.; Robert, Caroline; Grossmann, Kenneth; McDermott, David; Linette, Gerald P.; Meyer, Nicolas; Giguere, Jeffrey K.; Agarwala, Sanjiv S.; Shaheen, Montaser; Ernstoff, Marc S.; Minor, David; Salama, April K.; Taylor, Matthew; Ott, Patrick A.; Rollin, Linda M.; Horak, Christine; Gagnier, Paul; Wolchok, Jedd D.; Hodi, F. Stephen			Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MEK INHIBITION; COMBINED BRAF; VEMURAFENIB; RESPONSES; SAFETY; PD-1; ASSOCIATION; DABRAFENIB; ANTI-PD-1; SURVIVAL	BACKGROUND In a phase 1 dose-escalation study, combined inhibition of T-cell checkpoint pathways by nivolumab and ipilimumab was associated with a high rate of objective response, including complete responses, among patients with advanced melanoma. METHODS In this double-blind study involving 142 patients with metastatic melanoma who had not previously received treatment, we randomly assigned patients in a 2: 1 ratio to receive ipilimumab (3 mg per kilogram of body weight) combined with either nivolumab (1 mg per kilogram) or placebo once every 3 weeks for four doses, followed by nivolumab (3 mg per kilogram) or placebo every 2 weeks until the occurrence of disease progression or unacceptable toxic effects. The primary end point was the rate of investigator-assessed, confirmed objective response among patients with BRAF V600 wild-type tumors. RESULTS Among patients with BRAF wild-type tumors, the rate of confirmed objective response was 61% (44 of 72 patients) in the group that received both ipilimumab and nivolumab (combination group) versus 11% (4 of 37 patients) in the group that received ipilimumab and placebo (ipilimumab-monotherapy group) (P<0.001), with complete responses reported in 16 patients (22%) in the combination group and no patients in the ipilimumab-monotherapy group. The median duration of response was not reached in either group. The median progression-free survival was not reached with the combination therapy and was 4.4 months with ipilimumab monotherapy (hazard ratio associated with combination therapy as compared with ipilimumab monotherapy for disease progression or death, 0.40; 95% confidence interval, 0.23 to 0.68; P<0.001). Similar results for response rate and progression-free survival were observed in 33 patients with BRAF mutation-positive tumors. Drug-related adverse events of grade 3 or 4 were reported in 54% of the patients who received the combination therapy as compared with 24% of the patients who received ipilimumab monotherapy. Select adverse events with potential immunologic causes were consistent with those in a phase 1 study, and most of these events resolved with immune-modulating medication. CONCLUSIONS The objective-response rate and the progression-free survival among patients with advanced melanoma who had not previously received treatment were significantly greater with nivolumab combined with ipilimumab than with ipilimumab monotherapy. Combination therapy had an acceptable safety profile.	[Postow, Michael A.; Wolchok, Jedd D.] NYU, Mem Sloan Kettering Canc Ctr, New York, NY USA; [Postow, Michael A.; Wolchok, Jedd D.] NYU, Weill Cornell Med Coll, New York, NY USA; [Pavlick, Anna C.] NYU, Perlmutter Canc Ctr, New York, NY USA; [Chesney, Jason] Univ Louisville, James Graham Brown Canc Ctr, Louisville, KY 40292 USA; [Robert, Caroline] Inst Gustave Roussy, Villejuif, France; [Robert, Caroline] Univ Paris Sud, Orsay, France; [Meyer, Nicolas] Inst Univ Canc, Toulouse, France; [Grossmann, Kenneth] Huntsman Canc Inst, Salt Lake City, UT USA; [McDermott, David] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA; [Ott, Patrick A.; Hodi, F. Stephen] Dana Farber Canc Inst, Boston, MA 02215 USA; [Linette, Gerald P.] Washington Univ, St Louis, MO USA; [Giguere, Jeffrey K.] Greenville Hlth Syst, Greenville, SC USA; [Agarwala, Sanjiv S.] St Lukes Canc Ctr, Bethlehem, PA USA; [Shaheen, Montaser] Univ New Mexico, Albuquerque, NM 87131 USA; [Ernstoff, Marc S.] Cleveland Clin Fdn, Taussig Canc Inst, Cleveland, OH 44195 USA; [Minor, David] Calif Pacific Ctr Melanoma Res, San Francisco, CA USA; [Salama, April K.] Duke Univ, Durham, NC USA; [Taylor, Matthew] Oregon Hlth & Sci Univ, Portland, OR 97201 USA; [Horak, Christine] Bristol Myers Squibb Co, Lawrenceville, NJ USA; [Rollin, Linda M.; Gagnier, Paul] Bristol Myers Squibb Co, Wallingford, CT 06492 USA	Memorial Sloan Kettering Cancer Center; New York University; Cornell University; New York University; New York University; University of Louisville; UNICANCER; Gustave Roussy; UDICE-French Research Universities; Universite Paris Saclay; Huntsman Cancer Institute; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Dana-Farber Cancer Institute; Washington University (WUSTL); Greenville Health System; University of New Mexico; Cleveland Clinic Foundation; Duke University; Oregon Health & Science University; Bristol-Myers Squibb; Bristol-Myers Squibb	Hodi, FS (corresponding author), Dana Farber Canc Inst, 450 Brookline Ave, Boston, MA 02215 USA.	wolchokj@mskcc.org; stephen_hodi@dfci.harvard.edu	Robert, Caroline/G-6157-2018	Robert, Caroline/0000-0002-9493-0238; Meyer, Nicolas/0000-0003-4519-8666; Salama, April/0000-0002-8105-5374	Bristol-Myers Squibb; NATIONAL CANCER INSTITUTE [P30CA008748] Funding Source: NIH RePORTER	Bristol-Myers Squibb(Bristol-Myers Squibb); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Supported by Bristol-Myers Squibb.	Ascierto PA, 2013, LANCET ONCOL, V14, P249, DOI 10.1016/S1470-2045(13)70024-X; Chapman PB, 2011, NEW ENGL J MED, V364, P2507, DOI 10.1056/NEJMoa1103782; Curran MA, 2010, P NATL ACAD SCI USA, V107, P4275, DOI 10.1073/pnas.0915174107; Eisenhauer EA, 2009, EUR J CANCER, V45, P228, DOI 10.1016/j.ejca.2008.10.026; Flaherty KT, 2012, NEW ENGL J MED, V367, P107, DOI 10.1056/NEJMoa1203421; Hamid O, 2013, NEW ENGL J MED, V369, P134, DOI 10.1056/NEJMoa1305133; Hamid O, 2011, J TRANSL MED, V9, DOI 10.1186/1479-5876-9-204; Hodi FS, 2014, J CLIN ONCOL, V32, DOI 10.1200/jco.2014.32.15_suppl.9002; Hodi FS, 2010, NEW ENGL J MED, V363, P711, DOI 10.1056/NEJMoa1003466; Johnson DB, 2014, J CLIN ONCOL, V32, P3697, DOI 10.1200/JCO.2014.57.3535; Kluger H, 2014, ANN ONCOL, V25, DOI 10.1093/annonc/mdu344.1; Larkin J, 2014, NEW ENGL J MED, V371, P1867, DOI 10.1056/NEJMoa1408868; Long GV, 2014, NEW ENGL J MED, V371, P1877, DOI 10.1056/NEJMoa1406037; McArthur GA, 2014, LANCET ONCOL, V15, P323, DOI 10.1016/S1470-2045(14)70012-9; Okazaki T, 2013, NAT IMMUNOL, V14, P1212, DOI 10.1038/ni.2762; Robert C, 2015, NEW ENGL J MED, V372, P320, DOI 10.1056/NEJMoa1412082; Robert C, 2015, NEW ENGL J MED, V372, P30, DOI 10.1056/NEJMoa1412690; Robert C, 2011, NEW ENGL J MED, V364, P2517, DOI 10.1056/NEJMoa1104621; Selby M, 2013, J CLIN ONCOL, V31; Shahabi V, 2012, CANCER IMMUNOL IMMUN, V61, P733, DOI 10.1007/s00262-012-1227-3; Taube JM, 2014, CLIN CANCER RES, V20, P5064, DOI 10.1158/1078-0432.CCR-13-3271; Topalian SL, 2012, NEW ENGL J MED, V366, P2443, DOI 10.1056/NEJMoa1200690; Tumeh PC, 2014, NATURE, V515, P568, DOI 10.1038/nature13954; Weber JS, 2015, LANCET ONCOL; Wolchok JD, 2013, NEW ENGL J MED, V369, P122, DOI 10.1056/NEJMoa1302369	25	1966	2047	2	126	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 21	2015	372	21					2006	2017		10.1056/NEJMoa1414428	http://dx.doi.org/10.1056/NEJMoa1414428			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CI5PD	25891304	Green Accepted, Bronze			2023-01-03	WOS:000354809300007
J	Antonova, E; Chadwick, P; Kumari, V				Antonova, Elena; Chadwick, Paul; Kumari, Veena			More Meditation, Less Habituation? The Effect of Mindfulness Practice on the Acoustic Startle Reflex	PLOS ONE			English	Article							PHYSIOLOGICAL-RESPONSES; PREPULSE INHIBITION; SCHIZOPHRENIC-PATIENTS; SUSTAINED ATTENTION; LOUD TONES; DEFICITS; PSYCHOSIS	Background Mindfulness as a mode of sustained and receptive attention promotes openness to each incoming stimulus, even if repetitive and/or aversive. Mindful attention has been shown to attenuate sensory habituation in expert meditators; however, others were not able to replicate this effect. The present study used acoustic startle reflex to investigate the effect of mindfulness practice intensity on sensory habituation. Methods Auditory Startle Response (ASR) to 36 startling probes (12 trials x 3 block with 40ms inter-block intervals), was measured using electromyography (EMG) in three groups of participants (N = 12/group): meditation-naive, moderate practice, and intensive practice. Results Intensive practice group showed attenuated startle habituation as evidenced by significantly less habituation over the entire experiment relative to the meditation-naive and moderate practice groups. Furthermore, there was a significant linear effect showing between-block habituation in meditation-naive and moderate practice groups, but not in the intensive practice group. However, the Block x Group interaction between the intensive practice and the meditation-naive groups was not significant. Moderate practice group was not significantly different from the meditation-naive in the overall measure of habituation, but showed significantly stronger habituation than both meditation-naive and intensive practice groups in Block 1. Greater practice intensity was significantly correlated with slower overall habituation and habituation rate in Blocks 2 and 3 in the intensive, but not in the moderate, practice group. Conclusions The study provides tentative evidence that intensive mindfulness practice attenuates acoustic startle habituation as measured by EMG, but the effect is modest. Moderate practice, on the other hand, appears to enhance habituation, suggesting the effect of mindfulness practice on startle habituation might be non-liner. Better understanding of the effect of mindful attention on startle habituation may shed new light on sensory information processing capacity of the human brain and its potential for de-automatisation of hardwired processes.	[Antonova, Elena; Chadwick, Paul; Kumari, Veena] Kings Coll London, Dept Psychol, Inst Psychiat Psychol & Neurosci, London WC2R 2LS, England; [Kumari, Veena] South London & Maudsley Natl Hlth Serv Trust, Natl Inst Hlth Res, Biomed Res Ctr Mental Hlth, London, England	University of London; King's College London; University of London; King's College London	Antonova, E (corresponding author), Kings Coll London, Dept Psychol, Inst Psychiat Psychol & Neurosci, London WC2R 2LS, England.	elena.antonova@kcl.ac.uk	Kumari, Veena/C-6842-2009	Kumari, Veena/0000-0002-9635-5505; Chadwick, Paul/0000-0002-6765-6325; Antonova, Elena/0000-0003-1624-3202	Templeton Positive Neuroscience Award	Templeton Positive Neuroscience Award	This work was supported by the Templeton Positive Neuroscience Award to Dr Elena Antonova (Grant number: PAHWPZA) (http://www.posneuroscience.org/research-awards.html). The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Beck A.T., 1996, MANUAL BDI 2, DOI [10.1037/t00742-000, DOI 10.1037/T00742-000]; Beck A.T., 1993, BECK ANXIETY INVENTO; BECKER DE, 1981, PSYCHOPHYSIOLOGY, V18, P694, DOI 10.1111/j.1469-8986.1981.tb01846.x; BOLINO F, 1992, NEUROSCI LETT, V145, P126, DOI 10.1016/0304-3940(92)90002-O; BRAFF DL, 1992, ARCH GEN PSYCHIAT, V49, P206; Brown KW, 2003, J PERS SOC PSYCHOL, V84, P822, DOI 10.1037/0022-3514.84.4.822; Cahn BR, 2006, PSYCHOL BULL, V132, P180, DOI 10.1037/0033-2909.132.2.180; Chadwick P, 2005, BEHAV COGN PSYCHOTH, V33, P351, DOI 10.1017/S1352465805002158; Chadwick P, 2009, BEHAV COGN PSYCHOTH, V37, P403, DOI 10.1017/S1352465809990166; CORNBLATT BA, 1988, PSYCHIAT RES, V26, P223, DOI 10.1016/0165-1781(88)90076-5; Deatherage G., 1975, J TRANSPERSONAL PSYC, V7, P133; Dunne J, 2011, CONTEMP BUDDHISM, V12, P71, DOI 10.1080/14639947.2011.564820; GEYER MA, 1987, SCHIZOPHRENIA BULL, V13, P643, DOI 10.1093/schbul/13.4.643; GEYER MA, 1982, PSYCHOPHYSIOLOGY, V19, P1, DOI 10.1111/j.1469-8986.1982.tb02589.x; Grossman P, 2011, CONTEMP BUDDHISM, V12, P219, DOI 10.1080/14639947.2011.564841; Hammer TB, 2011, INT J NEUROPSYCHOPH, V14, P913, DOI 10.1017/S1461145711000034; Ivanovski B, 2007, ACTA NEUROPSYCHIATR, V19, P76, DOI 10.1111/j.1601-5215.2007.00175.x; Kabat-Zinn J., 2013, FULL CATASTROPHE LIV; Kabat-Zinn J, 2011, CONTEMP BUDDHISM, V12, P281, DOI 10.1080/14639947.2011.564844; KASAMATSU AKIRA, 1966, FOLIA PSYCHIAT NEUROL JAP, V20, P315, DOI 10.1111/j.1440-1819.1966.tb02646.x; Kumari V, 2005, NEUROIMAGE, V26, P1052, DOI 10.1016/j.neuroimage.2005.03.002; Kumari V, 2008, CORTEX, V44, P1206, DOI 10.1016/j.cortex.2007.11.007; Kumari V, 2008, NEUROPSYCHOPHARMACOL, V33, P2610, DOI 10.1038/sj.npp.1301670; Kumari V, 2007, INT J NEUROPSYCHOPH, V10, P463, DOI 10.1017/S1461145706007139; Kumari V, 2015, PSYCHOPHYSIOLOGY, V52, P714, DOI 10.1111/psyp.12391; Kumari V, 2012, SCHIZOPHR RES, V134, P232, DOI 10.1016/j.schres.2011.11.020; LaRowe SD, 2006, BIOL PSYCHOL, V72, P257, DOI 10.1016/j.biopsycho.2005.11.008; Levenson RW, 2012, EMOTION, V12, P650, DOI 10.1037/a0027472; Ludewig K, 2003, BIOL PSYCHIAT, V54, P121, DOI 10.1016/S0006-3223(02)01925-X; Lutz A, 2007, CAMB HANDB PSYCHOL, P499; MacCoon DG, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097551; MacLean KA, 2010, PSYCHOL SCI, V21, P829, DOI 10.1177/0956797610371339; Martin JR, 1997, J PSYCHOTHER INTEGR, V7, P291, DOI 10.1023/B:JOPI.0000010885.18025.bc; Meincke U, 2004, PSYCHIAT RES, V126, P51, DOI 10.1016/j.psychres.2004.01.003; Moore A, 2009, CONSCIOUS COGN, V18, P176, DOI 10.1016/j.concog.2008.12.008; Orr SP, 1997, BIOL PSYCHIAT, V41, P319, DOI 10.1016/S0006-3223(95)00671-0; SHALEV AY, 1992, ARCH GEN PSYCHIAT, V49, P870; Sharma T, 2003, PSYCHIAT CLIN N AM, V26, P25, DOI 10.1016/S0193-953X(02)00084-9; Tang YY, 2007, P NATL ACAD SCI USA, V104, P17152, DOI 10.1073/pnas.0707678104; van den Hurk PAM, 2010, INT J PSYCHOPHYSIOL, V78, P151, DOI 10.1016/j.ijpsycho.2010.07.002; Walach H, 2006, PERS INDIV DIFFER, V40, P1543, DOI 10.1016/j.paid.2005.11.025; Wechsler D., 1999, WECHSLER ABBREVIATED; Yorston G.A., 2001, MENTAL HLTH RELIG CU, V4, P209, DOI DOI 10.1080/713685624	43	20	20	0	27	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 6	2015	10	5							e0123512	10.1371/journal.pone.0123512	http://dx.doi.org/10.1371/journal.pone.0123512			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	CH5BQ	25946014	gold, Green Submitted, Green Published			2023-01-03	WOS:000354049700014
J	Luna, JLV; Krenn, M; Ramirez, JAC; Mayr, W				Vargas Luna, Jose Luis; Krenn, Matthias; Cortes Ramirez, Jorge Armando; Mayr, Winfried			Dynamic Impedance Model of the Skin-Electrode Interface for Transcutaneous Electrical Stimulation	PLOS ONE			English	Article							NEURAL STIMULATION; STRATUM-CORNEUM; ELECTROPORATION; SYSTEM	Transcutaneous electrical stimulation can depolarize nerve or muscle cells applying impulses through electrodes attached on the skin. For these applications, the electrode-skin impedance is an important factor which influences effectiveness. Various models describe the interface using constant or current-depending resistive-capacitive equivalent circuit. Here, we develop a dynamic impedance model valid for a wide range stimulation intensities. The model considers electroporation and charge-dependent effects to describe the impedance variation, which allows to describe high-charge pulses. The parameters were adjusted based on rectangular, biphasic stimulation pulses generated by a stimulator, providing optionally current or voltage-controlled impulses, and applied through electrodes of different sizes. Both control methods deliver a different electrical field to the tissue, which is constant throughout the impulse duration for current-controlled mode or have a very current peak for voltage-controlled. The results show a predominant dependence in the current intensity in the case of both stimulation techniques that allows to keep a simple model. A verification simulation using the proposed dynamic model shows coefficient of determination of around 0.99 in both stimulation types. The presented method for fitting electrode-skin impedance can be simple extended to other stimulation waveforms and electrode configuration. Therefore, it can be embedded in optimization algorithms for designing electrical stimulation applications even for pulses with high charges and high current spikes.	[Vargas Luna, Jose Luis] Reykjavik Univ, Landspitali, Univ Hosp, Hlth Technol Ctr, Reykjavik, Iceland; [Vargas Luna, Jose Luis; Cortes Ramirez, Jorge Armando] Escuela Ingn & Ciencias Tecnol Monterrey, Monterrey, Nuevo Leon, Mexico; [Krenn, Matthias; Mayr, Winfried] Med Univ Vienna, Ctr Med Phys & Biomed Engn, Vienna, Austria	Landspitali National University Hospital; Reykjavik University; Tecnologico de Monterrey; Medical University of Vienna	Luna, JLV (corresponding author), Reykjavik Univ, Landspitali, Univ Hosp, Hlth Technol Ctr, Reykjavik, Iceland.	joseluis.vargasluna@gmail.com	Luna, José L Vargas/B-4295-2015	Luna, José L Vargas/0000-0002-5125-1999; Krenn, Matthias J./0000-0002-3398-3627	Vienna Science and Technology Fund (WWTF) [LS11-057]; Wings for Life Spinal Cord Research Foundation (WfL) [WFL-AT-007/11]	Vienna Science and Technology Fund (WWTF); Wings for Life Spinal Cord Research Foundation (WfL)	This work was supported by the Vienna Science and Technology Fund (WWTF), Proj. Nr. LS11-057 (www.wwtf.at), and the Wings for Life Spinal Cord Research Foundation (WfL), Proj. Nr. WFL-AT-007/11 (http://www.wingsforlife.com) The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ALMASI JJ, 1970, ANN NY ACAD SCI, V170, P509, DOI 10.1111/j.1749-6632.1970.tb17718.x; Birlea Sinziana I., 2008, IET Irish Signals and Systems Conference. ISSC 2008, P55, DOI 10.1049/cp:20080638; Chen CF, 2012, IEEE T NEUR SYS REH, V20, P574, DOI 10.1109/TNSRE.2012.2188305; CHIZMADZHEV YA, 1995, BIOPHYS J, V68, P749, DOI 10.1016/S0006-3495(95)80250-X; Chizmadzhev YA, 1998, BIOPHYS J, V74, P843, DOI 10.1016/S0006-3495(98)74008-1; Danner SM, 2011, ARTIF ORGANS, V35, P257, DOI 10.1111/j.1525-1594.2011.01213.x; Dorgan S J, 1999, IEEE Trans Rehabil Eng, V7, P341, DOI 10.1109/86.788470; Franks W, 2005, IEEE T BIO-MED ENG, V52, P1295, DOI 10.1109/TBME.2005.847523; Glisson T., 2011, INTRO CIRCUIT ANAL D; Grill WM, 1996, IEEE T BIO-MED ENG, V43, P161, DOI 10.1109/10.481985; GRILL WM, 1995, IEEE ENG MED BIOL, V14, P375, DOI 10.1109/51.395310; GRIMNES S, 1984, ACTA DERM-VENEREOL, V64, P93; GRIMNES S, 1983, MED BIOL ENG COMPUT, V21, P739, DOI 10.1007/BF02464037; Hofer C, 2002, ARTIF ORGANS, V26, P276, DOI 10.1046/j.1525-1594.2002.06951.x; Ivorra A, 2010, SER BIOMED ENG, P23, DOI 10.1007/978-3-642-05420-4_2; Jadoul A, 1999, ADV DRUG DELIVER REV, V35, P89, DOI 10.1016/S0169-409X(98)00065-9; Johnsen GK, 2011, PHYS REV E, V83, DOI 10.1103/PhysRevE.83.031916; KANTOR G, 1994, PROCEEDINGS OF THE 16TH ANNUAL INTERNATIONAL CONFERENCE OF THE IEEE ENGINEERING IN MEDICINE AND BIOLOGY SOCIETY - ENGINEERING ADVANCES: NEW OPPORTUNITIES FOR BIOMEDICAL ENGINEERS, PTS 1&2, P784, DOI 10.1109/IEMBS.1994.415291; Keller T, 2008, J AUTOM CONTROL, V18, P35, DOI [10.2298/JAC0802035K, DOI 10.2298/JAC0802035K]; Krenn M, 2011, ARTIF ORGANS, V35, P253, DOI 10.1111/j.1525-1594.2011.01217.x; Krouchev NI, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090480; Lackermeier A, 1996, P 18 ANN INT C IEEE, V5; Luna JLV, 2014, P IASTED INT C BIOM, P190; LYKKEN DT, 1971, PSYCHOPHYSIOLOGY, V8, P656, DOI 10.1111/j.1469-8986.1971.tb00501.x; LYKKEN DT, 1970, PSYCHOPHYSIOLOGY, V7, P262, DOI 10.1111/j.1469-8986.1970.tb02232.x; PLIQUETT U, 1995, BBA-BIOMEMBRANES, V1239, P111, DOI 10.1016/0005-2736(95)00139-T; Reilly JP, 1992, ELECT SIMULATION ELE; SCHWAN HP, 1968, ANN NY ACAD SCI, V148, P191, DOI 10.1111/j.1749-6632.1968.tb20349.x; Tortora G., 2002, PRINCIPIOS ANATOMIA; VANBOXTEL A, 1977, MED BIOL ENG COMPUT, V15, P679, DOI 10.1007/BF02457927; Vargas Luna JL, 2014, BIOMED TECH BERL, P1045, DOI DOI 10.1515/BMT-2014-5013; Vargas Luna JL, 2013, BIOMED TECH BERL, V58	32	32	34	1	34	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 5	2015	10	5							e0125609	10.1371/journal.pone.0125609	http://dx.doi.org/10.1371/journal.pone.0125609			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CH3PT	25942010	Green Published, Green Submitted, gold			2023-01-03	WOS:000353943400047
J	Burgner, DP; Cooper, MN; Moore, HC; Stanley, FJ; Thompson, PL; de Klerk, NH; Carter, KW				Burgner, David P.; Cooper, Matthew N.; Moore, Hannah C.; Stanley, Fiona J.; Thompson, Peter L.; de Klerk, Nicholas H.; Carter, Kim W.			Childhood Hospitalisation with Infection and Cardiovascular Disease in Early-Mid Adulthood: A Longitudinal Population-Based Study	PLOS ONE			English	Article							MYOCARDIAL-INFARCTION; ATHEROSCLEROSIS; CHILDREN; DYSFUNCTION; BURDEN; RISK	Background Pathogen-specific and overall infection burden may contribute to atherosclerosis and cardiovascular disease (CVD), but the effect of infection severity and timing is unknown. We investigated whether childhood infection-related hospitalisation (IRH, a marker of severity) was associated with subsequent adult CVD hospitalisation. Methods Using longitudinal population-based statutorily-collected administrative health data from Western Australia (1970-2009), we identified adults hospitalised with CVD (ischaemic heart disease, ischaemic stroke, and peripheral vascular disease) and matched them (10:1) to population controls. We used Cox regression to assess relationships between number and type of childhood IRH and adulthood CVD hospitalisation, adjusting for sex, age, Indigenous status, socioeconomic status, and birth weight. Results 631 subjects with CVD-related hospitalisation in adulthood (>= 18 years) were matched with 6310 controls. One or more childhood (< 18 years) IRH was predictive of adult CVD-related hospitalisation (adjusted hazard ratio, 1.3; 95% CI 1.1-1.6; P < 0.001). The association showed a dose-response; >= 3 childhood IRH was associated with a 2.2 times increased risk of CVD-related hospitalisation in adulthood (adjusted hazard ratio, 2.2; 95% CI 1.7-2.9; P < 0.001). The association was observed across all clinical diagnostic groups of infection (upper respiratory tract infection, lower respiratory tract infection, infectious gastroenteritis, urinary tract infection, skin and soft tissue infection, and other viral infection), and individually with CVD diagnostic categories (ischaemic heart disease, ischaemic stroke and peripheral vascular disease). Conclusions Severe childhood infection is associated with CVD hospitalisations in adulthood in a dose-dependent manner, independent of population-level risk factors.	[Burgner, David P.] Royal Childrens Hosp, Murdoch Childrens Res Inst, Parkville, Vic 3052, Australia; [Burgner, David P.; Stanley, Fiona J.] Univ Western Australia, Sch Paediat & Child Hlth, Crawley, WA, Australia; [Burgner, David P.] Univ Melbourne, Dept Paediat, Parkville, Vic 3052, Australia; [Burgner, David P.] Monash Univ, Dept Paediat, Clayton, Vic, Australia; [Cooper, Matthew N.; Moore, Hannah C.; de Klerk, Nicholas H.] Univ Western Australia, Telethon Kids Inst, Div Populat Sci, Subiaco, WA, Australia; [Thompson, Peter L.] Sir Charles Gairdner Hosp, Dept Cardiovasc Med, Nedlands, WA 6009, Australia; [Thompson, Peter L.] Univ Western Australia, Sch Med & Pharmacol & Populat Hlth, Crawley, WA, Australia; [Carter, Kim W.] Univ Western Australia, Telethon Kids Inst, McCusker Charitable Fdn Bioinformat Ctr, Subiaco, WA, Australia	Murdoch Children's Research Institute; Royal Children's Hospital Melbourne; University of Western Australia; University of Melbourne; Monash University; Telethon Kids Institute; University of Western Australia; University of Western Australia; University of Western Australia; Telethon Kids Institute; University of Western Australia	Burgner, DP (corresponding author), Royal Childrens Hosp, Murdoch Childrens Res Inst, Flemington Rd, Parkville, Vic 3052, Australia.	david.burgner@mcri.edu.au	Moore, Hannah C/W-4727-2018; Moore, Hannah/AAA-4107-2019; Cooper, Matthew N/J-4420-2014; de Klerk, Nicholas H/D-8388-2016; Moore, Hannah/AHH-1092-2022	Moore, Hannah C/0000-0001-6434-8290; Moore, Hannah/0000-0001-6434-8290; Cooper, Matthew N/0000-0003-1139-3682; de Klerk, Nicholas H/0000-0001-9223-0767; Moore, Hannah/0000-0001-6434-8290; Burgner, David/0000-0002-8304-4302	Victorian Government's Operational Infrastructure Support Program; University of Western Australia Research Development Award; National Health and Medical Research Council, Australia [APP1064629]; National Heart Foundation, Australia [100026]; National Health and Medical Research Council, Australia; McCusker Charitable Foundation Bioinformatics Centre	Victorian Government's Operational Infrastructure Support Program; University of Western Australia Research Development Award; National Health and Medical Research Council, Australia(National Health and Medical Research Council (NHMRC) of Australia); National Heart Foundation, Australia(National Heart Foundation of Australia); National Health and Medical Research Council, Australia(National Health and Medical Research Council (NHMRC) of Australia); McCusker Charitable Foundation Bioinformatics Centre	The research was supported by the Victorian Government's Operational Infrastructure Support Program and a University of Western Australia Research Development Award. DPB is supported by a Senior Research Fellowship from the National Health and Medical Research Council (APP1064629), Australia and by an honorary Future Leader Fellowship from the National Heart Foundation (100026), Australia. HCM is supported by an Early Career Fellowship from the National Health and Medical Research Council, Australia. KWC is supported by the McCusker Charitable Foundation Bioinformatics Centre. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aiello AE, 2009, BRAIN BEHAV IMMUN, V23, P663, DOI 10.1016/j.bbi.2008.12.006; Anand SS, 2006, INT J EPIDEMIOL, V35, P1239, DOI 10.1093/ije/dyl163; [Anonymous], 2012, NAT BEST PRACT GUID; Australian Bureau of Statistics, 2001, TECHN PAP CENS POP H; Biering-Sorensen S, 2012, PAEDIATR PERINAT EP, V26, P226, DOI 10.1111/j.1365-3016.2011.01255.x; Blair Eve M, 2005, BMC Pediatr, V5, P13, DOI 10.1186/1471-2431-5-13; Brown A, 2010, HEART LUNG CIRC, V19, P299, DOI 10.1016/j.hlc.2010.02.022; Carville KS, 2007, PEDIATR INFECT DIS J, V26, P210, DOI 10.1097/01.inf.0000254148.09831.7f; Charakida M, 2005, CIRCULATION, V111, P1660, DOI 10.1161/01.CIR.0000160365.18879.1C; Elixhauser A, 2006, CLIN CLASSIFICATION; Haas MJ, 2010, DIABETES-METAB RES, V26, P90, DOI 10.1002/dmrr.1057; Holman CDJ, 2008, AUST HEALTH REV, V32, P766, DOI 10.1071/AH080766; JOLLY DL, 1993, J PAEDIATR CHILD H, V29, P438; Kyle RG, 2011, ARCH DIS CHILD, V96, P221, DOI 10.1136/adc.2009.180125; Leffondre K, 2003, STAT MED, V22, P3781, DOI 10.1002/sim.1674; Leffondre K, 2010, STAT MED, V29, P839, DOI 10.1002/sim.3764; Libby P, 2012, ARTERIOSCL THROM VAS, V32, P2045, DOI 10.1161/ATVBAHA.108.179705; Liuba P, 2003, EUR HEART J, V24, P517, DOI 10.1016/S0195-668X(02)00750-9; Mathers CD, 2006, PLOS MED, V3, DOI 10.1371/journal.pmed.0030442; Moore HC, 2012, J PAEDIATR CHILD H, V48, P520, DOI 10.1111/j.1440-1754.2011.02229.x; Moore HC, 2010, BMC PUBLIC HEALTH, V10, DOI 10.1186/1471-2458-10-757; Odermarsky M, 2008, EUR J CLIN INVEST, V38, P381, DOI 10.1111/j.1365-2362.2008.01952.x; Ott SJ, 2006, CIRCULATION, V113, P929, DOI 10.1161/CIRCULATIONAHA.105.579979; Parnaby MG, 2010, J PAEDIATR CHILD H, V46, P527, DOI 10.1111/j.1440-1754.2010.01841.x; Prasad A, 2002, CIRCULATION, V106, P184, DOI 10.1161/01.CIR.0000021125.83697.21; Rosenfeld ME, 2011, THROMB HAEMOSTASIS, V106, P858, DOI 10.1160/TH11-06-0392; Saxena S, 1999, BRIT MED J, V318, P642, DOI 10.1136/bmj.318.7184.642; STANLEY FJ, 1994, PAEDIATR PERINAT EP, V8, P433, DOI 10.1111/j.1365-3016.1994.tb00482.x; Truong QA, 2012, AM HEART J, V163, P972, DOI 10.1016/j.ahj.2012.03.010; Zhu JH, 2001, CIRCULATION, V103, P45	30	23	23	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 4	2015	10	5							e0125342	10.1371/journal.pone.0125342	http://dx.doi.org/10.1371/journal.pone.0125342			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CH3PP	25938548	Green Published, gold			2023-01-03	WOS:000353943000058
J	Origer, A; Le Bihan, E; Baumann, M				Origer, Alain; Le Bihan, Etienne; Baumann, Michele			A Social Gradient in Fatal Opioids and Cocaine Related Overdoses?	PLOS ONE			English	Article							NEW-YORK-CITY; DRUG OVERDOSE; INCOME-DISTRIBUTION; HARM-REDUCTION; MORTALITY; HEALTH; RISK; INEQUALITIES; BARCELONA; POVERTY	Background To determine the existence of a social gradient in fatal overdose cases related to nonprescribed opioids and cocaine use, recorded in Luxembourg between 1994 and 2011. Methods Overdose cases were individually matched with four controls in a nested case-control study design, according to sex, year of birth, drug administration route and duration of drug use. The study sample, composed of 272 cases and 1,056 controls, was stratified according to a Social Inequality Accumulation Score (SIAS), based on educational attainment, employment, income, financial situation of subjects and the professional status of their father or legal guardian. Least squares linear regression analysis on overdose mortality rates and ridit scores were applied to determine the Relative Index of Inequality (RII) of the study sample. Results A negative linear relationship between the overdose mortality rate and the relative socioeconomic position was observed. We found a difference in mortality of 29.22 overdose deaths per 100 drug users in the lowest socioeconomic group compared to the most advantaged group. In terms of the Relative Inequality Index, the overdose mortality rate of opioid and cocaine users with lowest socioeconomic profiles was 9.88 times as high as that of their peers from the highest socioeconomic group (95% CI 6.49-13.26). Conclusions Our findings suggest the existence of a marked social gradient in opioids and cocaine related overdose fatalities. Harm reduction services should integrate socially supportive offers, not only because of their general aim of social (re) integration but crucially in order to meet their most important objective, that is to reduce drug-related mortality.	[Origer, Alain] Minist Hlth, Drug Coordinat Off, Luxembourg, Luxembourg; [Origer, Alain; Le Bihan, Etienne; Baumann, Michele] Univ Luxembourg, Res Unit INSIDE, Inst Hlth & Behav, Walferdange, Luxembourg	University of Luxembourg	Origer, A (corresponding author), Minist Hlth, Drug Coordinat Off, Luxembourg, Luxembourg.	alain.origer@ms.etat.lu						Arias LC, 1998, MED CLIN-BARCELONA, V110, P161; Bergenstrom A, 2008, SUBST USE MISUSE, V43, P73, DOI 10.1080/10826080701205109; Borrell C, 2002, INJURY PREV, V8, P297, DOI 10.1136/ip.8.4.297; BROSS IDJ, 1958, BIOMETRICS, V14, P18, DOI 10.2307/2527727; Cai TX, 2012, BIOSTATISTICS, V13, P89, DOI 10.1093/biostatistics/kxr021; Darke S, 1996, ADDICTION, V91, P1765, DOI 10.1111/j.1360-0443.1996.tb03800.x; DAVOLI M, 1993, INT J EPIDEMIOL, V22, P273, DOI 10.1093/ije/22.2.273; EMCDDA, 2011, MORTALITY RELATED TO; Farrell M, 1996, ADDICTION, V91, P321, DOI 10.1111/j.1360-0443.1996.tb02282.x; Galea S, 2002, PUBLIC HEALTH REP, V117, pS135; Galea S, 2003, DRUG ALCOHOL DEPEN, V70, P139, DOI 10.1016/S0376-8716(02)00342-3; HARLOW KC, 1990, PUBLIC HEALTH REP, V105, P455; ILLSLEY R, 1990, SOC SCI MED, V31, P229, DOI 10.1016/0277-9536(90)90269-X; Jones R, 2002, ADDICTION, V97, P1517, DOI 10.1046/j.1360-0443.2002.00244.x; Langendam MW, 2001, AM J PUBLIC HEALTH, V91, P774, DOI 10.2105/AJPH.91.5.774; Mackenbach JP, 1997, SOC SCI MED, V44, P757, DOI 10.1016/S0277-9536(96)00073-1; MARMOT MG, 1987, ANNU REV PUBL HEALTH, V8, P111, DOI 10.1146/annurev.pu.08.050187.000551; MARMOT MG, 1986, LANCET, V2, P274; Marzuk PM, 1997, AM J DRUG ALCOHOL AB, V23, P221, DOI 10.3109/00952999709040943; O'Driscoll PT, 2001, AM J PUBLIC HEALTH, V91, P984, DOI 10.2105/AJPH.91.6.984; Origer A, 2014, INT J DRUG POLICY; Origer A, 2014, EUR ADDICT RES, V20, P87, DOI 10.1159/000355170; Pasarin M, 1999, Gac Sanit, V13, P431; Pauly B, 2008, INT J DRUG POLICY, V19, P4, DOI 10.1016/j.drugpo.2007.11.005; Rubin DB, 1987, MULTIPLE IMPUTATION, DOI [10.1002/sim.6008, DOI 10.1002/SIM.6008]; Sporer KA, 2003, BMJ-BRIT MED J, V326, P442, DOI 10.1136/bmj.326.7386.442; Torralba L, 1996, ADDICTION, V91, P419, DOI 10.1111/j.1360-0443.1996.tb02291.x; United Nations Office on Drugs and Crime, 2013, WORLD DRUG REPORT 20; URY HK, 1975, BIOMETRICS, V31, P643, DOI 10.2307/2529548; van Buuren S, 2007, STAT METHODS MED RES, V16, P219, DOI 10.1177/0962280206074463; WILKINSON RG, 1989, J SOC POLICY, V18, P307, DOI 10.1017/S0047279400017591; World Health Organization, 2009, GLOBAL HEALTH RISKS	32	7	8	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 4	2015	10	5							e0125568	10.1371/journal.pone.0125568	http://dx.doi.org/10.1371/journal.pone.0125568			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	CH3PP	25938451	Green Published, Green Submitted, gold			2023-01-03	WOS:000353943000076
J	Shafi, T; Meyer, TW; Hostetter, TH; Melamed, ML; Parekh, RS; Hwang, S; Banerjee, T; Coresh, J; Powe, NR				Shafi, Tariq; Meyer, Timothy W.; Hostetter, Thomas H.; Melamed, Michal L.; Parekh, Rulan S.; Hwang, Seungyoung; Banerjee, Tanushree; Coresh, Josef; Powe, Neil R.			Free Levels of Selected Organic Solutes and Cardiovascular Morbidity and Mortality in Hemodialysis Patients: Results from the Retained Organic Solutes and Clinical Outcomes (ROSCO) Investigators	PLOS ONE			English	Article							P-CRESYL SULFATE; INDOXYL SULFATE; UREMIC TOXINS; MICROBIAL FERMENTATION; DIETARY POLYPHENOLS; DIALYSIS PATIENTS; ALL-CAUSE; METABOLISM; ACID; GUT	Background and Objectives Numerous substances accumulate in the body in uremia but those contributing to cardiovascular morbidity and mortality in dialysis patients are still undefined. We examined the association of baseline free levels of four organic solutes that are secreted in the native kidney - p-cresol sulfate, indoxyl sulfate, hippurate and phenylacetylglutamine - with outcomes in hemodialysis patients. Design, Setting, Participants and Measurements We measured these solutes in stored specimens from 394 participants of a US national prospective cohort study of incident dialysis patients. We examined the relation of each solute and a combined solute index to cardiovascular mortality and morbidity (first cardiovascular event) using Cox proportional hazards regression adjusted for demographics, comorbidities, clinical factors and laboratory tests including Kt/V-UREA. Results Mean age of the patients was 57 years, 65% were white and 55% were male. In fully adjusted models, a higher p-cresol sulfate level was associated with a greater risk (HR per SD increase; 95% CI) of cardiovascular mortality (1.62; 1.17-2.25; p=0.004) and first cardiovascular event (1.60; 1.23-2.08; p<0.001). A higher phenylacetylglutamine level was associated with a greater risk of first cardiovascular event (1.37; 1.18-1.58; p<0.001). Patients in the highest quintile of the combined solute index had a 96% greater risk of cardiovascular mortality (1.96; 1.05-3.68; p=0.04) and 62% greater risk of first cardiovascular event (1.62; 1.12-2.35; p=0.01) compared with patients in the lowest quintile. Results were robust in sensitivity analyses. Conclusions Free levels of uremic solutes that are secreted by the native kidney are associated with a higher risk of cardiovascular morbidity and mortality in incident hemodialysis patients.	[Shafi, Tariq; Hwang, Seungyoung; Coresh, Josef] Johns Hopkins Univ, Dept Med, Div Nephrol, Baltimore, MD 21218 USA; [Shafi, Tariq; Coresh, Josef] Johns Hopkins Univ, Welch Ctr Prevent Epidemiol & Clin Res, Baltimore, MD USA; [Meyer, Timothy W.] Vet Adm Palo Alto Hlth Care Syst, Dept Med, Div Nephrol, Palo Alto, CA USA; [Meyer, Timothy W.] Stanford Univ, Palo Alto, CA 94304 USA; [Hostetter, Thomas H.] Case Western Reserve Univ, Sch Med, Dept Med, Cleveland, OH 44106 USA; [Melamed, Michal L.] Montefiore Med Ctr, Albert Einstein Coll Med, Dept Med, Bronx, NY 10467 USA; [Melamed, Michal L.] Albert Einstein Coll Med, Dept Epidemiol & Populat Hlth, Bronx, NY 10467 USA; [Parekh, Rulan S.] Univ Toronto, Dept Med, Toronto, ON, Canada; [Parekh, Rulan S.] Univ Toronto, Dept Pediat, Toronto, ON, Canada; [Banerjee, Tanushree; Powe, Neil R.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA; [Coresh, Josef] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA; [Coresh, Josef] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Stat, Baltimore, MD USA	Johns Hopkins University; Johns Hopkins University; Stanford University; Case Western Reserve University; Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; University of Toronto; University of Toronto; University of California System; University of California San Francisco; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health	Shafi, T (corresponding author), Johns Hopkins Univ, Dept Med, Div Nephrol, Baltimore, MD 21218 USA.	tshafi@jhmi.edu	Parekh, Rulan/AAQ-4411-2020	Shafi, Tariq/0000-0002-7222-4666; Parekh, Rulan/0000-0001-6313-5752	Agency for Healthcare Quality and Research AHRQ [R01-HS008365]; National Heart, Lung, and Blood Institute (NHLBI) [RO1-HL-62985]; National Institute of Diabetes & Digestive & Kidney Diseases NIDDK [R01-DK-059616, R01-DK-080123]; National Kidney Foundation of Maryland Professional Development Award [K23-DK-083514]; American Heart Association [01-4019-7N]; National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health;  [R01-DK-072367];  [K24-DK- 02643]; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R01HS008365] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR001073] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL062985] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK080123, K24DK002643, R01DK059616] Funding Source: NIH RePORTER	Agency for Healthcare Quality and Research AHRQ(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); National Heart, Lung, and Blood Institute (NHLBI)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); National Institute of Diabetes & Digestive & Kidney Diseases NIDDK(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); National Kidney Foundation of Maryland Professional Development Award; American Heart Association(American Heart Association); National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); ; ; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	CHOICE was supported by R01-HS008365 (Agency for Healthcare Quality and Research AHRQ) from 7/1994 to 6/1999, by RO1-HL-62985 (National Heart, Lung, and Blood Institute (NHLBI) from 9/00 to 6/06, R01-DK-059616 (National Institute of Diabetes & Digestive & Kidney Diseases NIDDK) from 9/2000 to 6/2005 and by R01-DK-080123 from 8/2008 to 6/2015 (National Institute of Diabetes & Digestive & Kidney Diseases NIDDK). Dr. Shafi is supported by K23-DK-083514 and National Kidney Foundation of Maryland Professional Development Award. Dr. Parekh was supported by R01-DK-072367. Dr. Coresh is supported in part as an American Heart Association established investigator (01-4019-7N). Dr. Powe is supported in part by K24-DK-02643 and R01-DK-080123. Research reported in this publication was supported by the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. The reagents for low molecular weight solutes beta-Trace Protein, beta 2 microglobulin and cystatin C were provided by Siemens to the University of Minnesota, where the measurements were performed. Siemens had no role in the design, analysis, and interpretation of data or the preparation of this manuscript. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aronov PA, 2011, J AM SOC NEPHROL, V22, P1769, DOI 10.1681/ASN.2010121220; Athienites NV, 2000, SEMIN DIALYSIS, V13, P320, DOI 10.1046/j.1525-139x.2000.00095.x; Bammens B, 2006, KIDNEY INT, V69, P1081, DOI 10.1038/sj.ki.5000115; Barreto FC, 2009, CLIN J AM SOC NEPHRO, V4, P1551, DOI 10.2215/CJN.03980609; Depner TA, 2001, SEMIN DIALYSIS, V14, P9, DOI 10.1046/j.1525-139x.2001.00003-2.x; Depner TA, 2001, SEMIN DIALYSIS, V14, P246, DOI 10.1046/j.1525-139X.2001.00072.x; Dobre M, 2013, CLIN J AM SOC NEPHRO, V8, P322, DOI 10.2215/CJN.04260412; Donders ART, 2006, J CLIN EPIDEMIOL, V59, P1087, DOI 10.1016/j.jclinepi.2006.01.014; Duranton F, 2012, J AM SOC NEPHROL, V23, P1258, DOI 10.1681/ASN.2011121175; Eloot S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076838; Eloot S, 2012, NEPHROL DIAL TRANSPL, V27, P4021, DOI 10.1093/ndt/gfs367; Eloot S, 2012, NEPHROL DIAL TRANSPL, V27, P3975, DOI 10.1093/ndt/gfs435; Eloot S, 2012, SEMIN DIALYSIS, V25, P505, DOI 10.1111/j.1525-139X.2012.01107.x; Evenepoel P, 2009, KIDNEY INT, V76, pS12, DOI 10.1038/ki.2009.402; Foley RN, 1998, J AM SOC NEPHROL, V9, P267; Fujii H, 2011, THER APHER DIAL, V15, P125, DOI 10.1111/j.1744-9987.2010.00883.x; Gonthier MP, 2006, BIOMED PHARMACOTHER, V60, P536, DOI 10.1016/j.biopha.2006.07.084; Liabeuf S, 2010, NEPHROL DIAL TRANSPL, V25, P1183, DOI 10.1093/ndt/gfp592; Lin CJ, 2013, ARCH MED RES, V44, P535, DOI 10.1016/j.arcmed.2013.09.007; Lin CJ, 2013, ARCH MED SCI, V9, P662, DOI 10.5114/aoms.2013.36901; Lin CJ, 2010, NEPHROL DIAL TRANSPL, V25, P3693, DOI 10.1093/ndt/gfq251; Liu YM, 2004, JAMA-J AM MED ASSOC, V291, P451, DOI 10.1001/jama.291.4.451; Longenecker JC, 2005, J AM SOC NEPHROL, V16, P1794, DOI 10.1681/ASN.2004110922; Marquez IO, 2011, CLIN J AM SOC NEPHRO, V6, P290, DOI 10.2215/CJN.06100710; Meijers BKI, 2011, NEPHROL DIAL TRANSPL, V26, P759, DOI 10.1093/ndt/gfq818; Meijers BKI, 2010, CLIN J AM SOC NEPHRO, V5, P1182, DOI 10.2215/CJN.07971109; Meijers BKI, 2009, AM J KIDNEY DIS, V54, P891, DOI 10.1053/j.ajkd.2009.04.022; Melamed ML, 2013, BMC NEPHROL, V14, DOI 10.1186/1471-2369-14-134; Meyer TW, 2007, NEW ENGL J MED, V357, P1316, DOI 10.1056/NEJMra071313; Meyer TW, 2011, SEMIN DIALYSIS, V24, P471, DOI 10.1111/j.1525-139X.2011.00979.x; Miskulin DC, 2002, AM J KIDNEY DIS, V39, P324, DOI 10.1053/ajkd.2002.30552; Mulder TP, 2005, AM J CLIN NUTR, V81, p256S, DOI 10.1093/ajcn/81.1.256S; Niwa T, 2010, J RENAL NUTR, V20, pS2, DOI 10.1053/j.jrn.2010.05.002; OWEN WF, 1993, NEW ENGL J MED, V329, P1001, DOI 10.1056/NEJM199309303291404; Patel KP, 2012, CLIN J AM SOC NEPHRO, V7, P982, DOI 10.2215/CJN.12491211; Pereira-Caro G, 2014, AM J CLIN NUTR, V100, P1378, DOI 10.3945/ajcn.114.090282; Poesen R, 2013, SEMIN DIALYSIS, V26, P323, DOI 10.1111/sdi.12082; Powe NR, 1996, SEMIN DIALYSIS, V9, P9, DOI 10.1111/j.1525-139X.1996.tb00890.x; Rechner AR, 2004, FREE RADICAL BIO MED, V36, P212, DOI 10.1016/j.freeradbiomed.2003.09.022; Rechner AR, 2002, FREE RADICAL RES, V36, P1229, DOI 10.1080/246-1071576021000016472; Rhee EP, 2010, J AM SOC NEPHROL, V21, P1041, DOI 10.1681/ASN.2009111132; Russell WR, 2013, MOL NUTR FOOD RES, V57, P523, DOI 10.1002/mnfr.201200594; Schepers E, 2010, BLOOD PURIFICAT, V29, P130, DOI 10.1159/000245639; SEAKINS JWT, 1971, CLIN CHIM ACTA, V35, P121, DOI 10.1016/0009-8981(71)90302-0; Singer JD., 2003, APPL LONGITUDINAL AN; Sirich TL, 2014, J AM SOC NEPHROL, V25, P615, DOI 10.1681/ASN.2013060597; Sirich TL, 2012, NEPHROL DIAL TRANSPL, V27, P1574, DOI 10.1093/ndt/gfr691; U S Renal Data System, 2015, USRDS 2013 ANN DAT R, V4, P2; Vanholder R, 2012, NAT REV NEPHROL, V8, P579, DOI 10.1038/nrneph.2012.189; Wu IW, 2012, NEPHROL DIAL TRANSPL, V27, P1169, DOI 10.1093/ndt/gfr453; Yu L, 2006, BIOCHEMISTRY-US, V45, P9584, DOI 10.1021/bi060840b	51	63	64	0	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 4	2015	10	5							e0126048	10.1371/journal.pone.0126048	http://dx.doi.org/10.1371/journal.pone.0126048			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CH3PP	25938230	Green Published, Green Submitted, gold			2023-01-03	WOS:000353943000133
J	Kizil, C; Iltzsche, A; Thomas, AK; Bhattarai, P; Zhang, YX; Brand, M				Kizil, Caghan; Iltzsche, Anne; Thomas, Alvin Kuriakose; Bhattarai, Prabesh; Zhang, Yixin; Brand, Michael			Efficient Cargo Delivery into Adult Brain Tissue Using Short Cell-Penetrating Peptides	PLOS ONE			English	Article							END-RULE PEPTIDES; NEUROGENESIS; PROTEIN; MECHANISMS; EXPRESSION; BINDING; SIRNA; RNA	Zebrafish brains can regenerate lost neurons upon neurogenic activity of the radial glial progenitor cells (RGCs) that reside at the ventricular region. Understanding the molecular events underlying this ability is of great interest for translational studies of regenerative medicine. Therefore, functional analyses of gene function in RGCs and neurons are essential. Using cerebroventricular microinjection (CVMI), RGCs can be targeted efficiently but the penetration capacity of the injected molecules reduces dramatically in deeper parts of the brain tissue, such as the parenchymal regions that contain the neurons. In this report, we tested the penetration efficiency of five known cell-penetrating peptides (CPPs) and identified two-polyR and Trans - that efficiently penetrate the brain tissue without overt toxicity in a dose-dependent manner as determined by TUNEL staining and L-Plastin immunohistochemistry. We also found that polyR peptide can help carry plasmid DNA several cell diameters into the brain tissue after a series of coupling reactions using DBCO-PEG4-maleimide-based Michael's addition and azide-mediated copper-free click reaction. Combined with the advantages of CVMI, such as rapidness, reproducibility, and ability to be used in adult animals, CPPs improve the applicability of the CVMI technique to deeper parts of the central nervous system tissues.	[Kizil, Caghan; Bhattarai, Prabesh] German Ctr Neurodegenerat Dis DZNE Dresden Helmho, D-01307 Dresden, Germany; [Kizil, Caghan; Iltzsche, Anne; Brand, Michael] Tech Univ Dresden, DFG Ctr Regenerat Therapies Dresden CRTD Cluster, D-01307 Dresden, Germany; [Thomas, Alvin Kuriakose; Zhang, Yixin] Tech Univ Dresden, Ctr Mol Bioengn, B CUBE, D-01307 Dresden, Germany; [Brand, Michael] Tech Univ Dresden, Ctr Biotechnol, D-01307 Dresden, Germany	Technische Universitat Dresden; Technische Universitat Dresden; Technische Universitat Dresden; Technische Universitat Dresden	Brand, M (corresponding author), Tech Univ Dresden, DFG Ctr Regenerat Therapies Dresden CRTD Cluster, Fetscherstr 105, D-01307 Dresden, Germany.	michael.brand@biotec.tu-dresden.de	Kizil, Caghan/AFG-2073-2022; Kizil, Caghan/J-6923-2015; Brand, Michael/A-5509-2010; Thomas, Alvin Kuriakose/I-7638-2018	Kizil, Caghan/0000-0002-8164-9762; Kizil, Caghan/0000-0002-8164-9762; Brand, Michael/0000-0001-5711-6512; Thomas, Alvin Kuriakose/0000-0002-8544-4983; Bhattarai, Prabesh/0000-0003-2991-5514	Deutsche Forschungsgemeinschaft [SFB-655-A3]; European Union (Zf-Health); Technische Universitat Dresden; German Centre for Neurodegenerative Diseases (DZNE) within Helmholtz Association; Leibniz Association [SAW-2011-IPF-2]; BMBF BioLithoMorphie project [03Z2E511]	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); European Union (Zf-Health); Technische Universitat Dresden; German Centre for Neurodegenerative Diseases (DZNE) within Helmholtz Association; Leibniz Association; BMBF BioLithoMorphie project(Federal Ministry of Education & Research (BMBF))	This work was supported by Deutsche Forschungsgemeinschaft (SFB-655-A3), The European Union (Zf-Health), and Technische Universitat Dresden (AI, CK, MB), German Centre for Neurodegenerative Diseases (DZNE) within Helmholtz Association (CK), and Leibniz Association (SAW-2011-IPF-2 project) and BMBF BioLithoMorphie project 03Z2E511 (AKT, YZ). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adolf B, 2006, DEV BIOL, V295, P278, DOI 10.1016/j.ydbio.2006.03.023; Brand Michael, 2002, P7; Cardozo AK, 2007, BBA-BIOMEMBRANES, V1768, P2222, DOI 10.1016/j.bbamem.2007.06.003; Chapouton P, 2010, METHOD CELL BIOL, V100, P73, DOI 10.1016/B978-0-12-384892-5.00004-9; Dietz GPH, 2004, MOL CELL NEUROSCI, V27, P85, DOI 10.1016/j.mcn.2004.03.005; FIELDS GB, 1990, INT J PEPT PROT RES, V35, P161, DOI 10.1111/j.1399-3011.1990.tb00939.x; FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2; Grandel H, 2006, DEV BIOL, V295, P263, DOI 10.1016/j.ydbio.2006.03.040; GREEN M, 1988, CELL, V55, P1179, DOI 10.1016/0092-8674(88)90262-0; Gros E, 2006, BBA-BIOMEMBRANES, V1758, P384, DOI 10.1016/j.bbamem.2006.02.006; Hans S, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004640; Heitz F, 2009, BRIT J PHARMACOL, V157, P195, DOI 10.1111/j.1476-5381.2009.00057.x; Jarver P, 2013, MOL THER-NUCL ACIDS, V1, pe27; Jewett JC, 2010, CHEM SOC REV, V39, P1272, DOI 10.1039/b901970g; Jones SW, 2005, BRIT J PHARMACOL, V145, P1093, DOI 10.1038/sj.bjp.0706279; Juliano R, 2008, NUCLEIC ACIDS RES, V36, P4158, DOI 10.1093/nar/gkn342; Kizil C, 2013, JOVE-J VIS EXP, DOI 10.3791/50415; Kizil C, 2012, DEV CELL, V23, P1230, DOI 10.1016/j.devcel.2012.10.014; Kizil C, 2012, NEURAL DEV, V7, DOI 10.1186/1749-8104-7-27; Kizil C, 2012, DEV NEUROBIOL, V72, P429, DOI 10.1002/dneu.20918; Kizil C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027395; Knopf F, 2010, P NATL ACAD SCI USA, V107, P19933, DOI 10.1073/pnas.1007799107; Kolb HC, 2001, ANGEW CHEM INT EDIT, V40, P2004, DOI 10.1002/1521-3773(20010601)40:11<2004::AID-ANIE2004>3.3.CO;2-X; Kyritsis N, 2012, SCIENCE, V338, P1353, DOI 10.1126/science.1228773; Lindgren M, 2011, METHODS MOL BIOL, V683, P3, DOI 10.1007/978-1-60761-919-2_1; Malesevic M, 2010, ANGEW CHEM INT EDIT, V49, P213, DOI 10.1002/anie.200904529; Mende F, 2011, ANGEW CHEM INT EDIT, V50, P1232, DOI 10.1002/anie.201005180; Muratovska A, 2004, FEBS LETT, V558, P63, DOI 10.1016/S0014-5793(03)01505-9; Nitin N, 2004, J BIOL INORG CHEM, V9, P706, DOI 10.1007/s00775-004-0560-1; Pantos A, 2008, BBA-BIOMEMBRANES, V1778, P811, DOI 10.1016/j.bbamem.2007.12.003; Rothenaigner I, 2011, DEVELOPMENT, V138, P1459, DOI 10.1242/dev.058156; ROY S, 1990, GENE DEV, V4, P1365, DOI 10.1101/gad.4.8.1365; Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569; Snyder Eric L, 2005, Expert Opin Drug Deliv, V2, P43, DOI 10.1517/17425247.2.1.43; Strassberger V, 2010, PROTEOMICS, V10, P3544, DOI 10.1002/pmic.201000308; Teesalu T, 2009, P NATL ACAD SCI USA, V106, P16157, DOI 10.1073/pnas.0908201106; Torchilin VP, 2008, BIOPOLYMERS, V90, P604, DOI 10.1002/bip.20989; Torchilin VP, 2008, ADV DRUG DELIVER REV, V60, P548, DOI 10.1016/j.addr.2007.10.008; Wender PA, 2000, P NATL ACAD SCI USA, V97, P13003, DOI 10.1073/pnas.97.24.13003; Wieduwild R, 2013, J AM CHEM SOC, V135, P2919, DOI 10.1021/ja312022u; Zanuy D, 2013, J STRUCT BIOL, V182, P78, DOI 10.1016/j.jsb.2013.02.006; Zatsepin TS, 2005, CURR PHARM DESIGN, V11, P3639, DOI 10.2174/138161205774580769; Zhang YX, 2002, BIOCHEMISTRY-US, V41, P11868, DOI 10.1021/bi0262395	43	17	18	1	28	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 20	2015	10	4							e0124073	10.1371/journal.pone.0124073	http://dx.doi.org/10.1371/journal.pone.0124073			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CG3XA	25894337	Green Submitted, Green Published, gold			2023-01-03	WOS:000353211700072
J	Corneli, A; Perry, B; Agot, K; Ahmed, K; Malamatsho, F; Van Damme, L				Corneli, Amy; Perry, Brian; Agot, Kawango; Ahmed, Khatija; Malamatsho, Fulufhelo; Van Damme, Lut			Facilitators of Adherence to the Study Pill in the FEM-PrEP Clinical Trial	PLOS ONE			English	Article							PREEXPOSURE PROPHYLAXIS; HIV PREVENTION; ANTIRETROVIRAL PROPHYLAXIS; TENOFOVIR GEL; ACCEPTABILITY; MICROBICIDE; PARTICIPANTS; INFECTION; MISCONCEPTION; INTERVENTION	Introduction FEM-PrEP did not demonstrate a reduction in HIV acquisition because of low study pill adherence. Yet, plasma and intracellular drug concentrations indicated that some participants had evidence of recent pill use. We conducted a follow-up study to identify, among other topics, participants' reasons for taking the study pill. Methods Qualitative, semi-structured interviews (SSIs) were conducted with 88 FEM-PrEP participants. Participants were purposefully selected based on their adherence drug concentrations collected during FEM-PrEP and placed into three adherence interview groups: "high," "moderate," and "none/scarce." Participants in the high and moderate groups described reasons why they adhered most or some of the time, including factors that facilitated their adherence. Participants in all groups described what they believed made it possible for other FEM-PrEP participants to adhere. In addition, 224 FEM-PrEP participants reported on their reasons for taking the study pills through a quantitative, audio computer-assisted self-interview (ACASI). Thematic analysis and descriptive statistics were used to analyze the qualitative and quantitative data, respectively. Results Five themes were identified from the SSIs as facilitating factors of adherence: 1) participants' support for the research, 2) HIV risk reduction, 3) routine formation and use of tools, 4) adherence counseling, and 5) partner awareness and support. Participants described similar facilitators when they spoke about other participants' adherence. Among the 172 participants who reported in ACASI that they had taken a study pill, wanting to help answer the research question was the most frequently stated reason for taking the pills (94%, n = 161). We also found evidence of preventive misconception. Conclusions Adherence was facilitated by personal motivations, such as risk reduction and interest in the research outcome, and by adherence strategies consisting of external cues, reminders, and support. These findings can inform future HIV prevention clinical trials and the rollout of effective antiretroviral-based HIV prevention technologies for women.	[Corneli, Amy; Perry, Brian; Van Damme, Lut] FHI 360, Durham, NC 27701 USA; [Agot, Kawango] Impact Res & Dev Org, Kisumu, Kenya; [Ahmed, Khatija; Malamatsho, Fulufhelo] Setshaba Res Ctr, Soshanguve, South Africa	FHI 360	Corneli, A (corresponding author), FHI 360, Durham, NC 27701 USA.	acorneli@fhi360.org		Perry, Brian/0000-0002-4648-7673; Corneli, Amy/0000-0002-4629-4329; ahmed, khatija/0000-0003-0309-1641	United States Agency for International Development (USAID); Contraceptive and Reproductive Health Technologies and Research Utilization Program; Preventive Technologies Agreement [GHO A 00 09 00016-00]; Bill & Melinda Gates Foundation; NIH [P30 AI50410]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI050410] Funding Source: NIH RePORTER	United States Agency for International Development (USAID)(United States Agency for International Development (USAID)); Contraceptive and Reproductive Health Technologies and Research Utilization Program; Preventive Technologies Agreement; Bill & Melinda Gates Foundation(Bill & Melinda Gates Foundation); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	FEM-PrEP was conducted under two grants funded by the United States Agency for International Development (USAID): the Contraceptive and Reproductive Health Technologies and Research Utilization Program, and the Preventive Technologies Agreement No. GHO A 00 09 00016-00. Early support was also provided by the Bill & Melinda Gates Foundation. The drug concentration analyses were performed using equipment provided by the University of North Carolina at Chapel Hill Center for AIDS Research (CFAR), an NIH funded program P30 AI50410. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Agot K, 2014, AIDS BEHAV; Amico KR, 2013, AIDS BEHAV, V17, P2143, DOI 10.1007/s10461-013-0429-9; Baeten JM, 2012, NEW ENGL J MED, V367, P399, DOI 10.1056/NEJMoa1108524; Bayer AM, 2010, CULT HEALTH SEX, V12, P771, DOI [10.1080/13691058.2010.488299, 10.1080/13691051003728599]; Carballo-Dieguez A, 2007, AIDS CARE, V19, P1026, DOI 10.1080/09540120701294237; Choopanya K, 2013, LANCET, V381, P2083, DOI 10.1016/S0140-6736(13)61127-7; Corneli A, 2014, CONFERENCE ON RETROV; Corneli A, 2014, JAIDS-J ACQ IMM DEF, V67, P555, DOI 10.1097/QAI.0000000000000362; Corneli AL, 2015, JAIDS-J ACQ IMM DEF, V68, P578, DOI 10.1097/QAI.0000000000000525; Corneli AL, 2014, JAIDS-J ACQ IMM DEF, V66, P324, DOI 10.1097/QAI.0000000000000158; Dellar RC, 2014, AIDS BEHAV, V18, P1746, DOI 10.1007/s10461-014-0771-6; Donnell D, 2014, J ACQUIR IMMUNE DEFI; Grant RM, 2010, NEW ENGL J MED, V363, P2587, DOI 10.1056/NEJMoa1011205; Guest G, 2012, APPLIED THEMATIC ANA; Haberer JE, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001511; Lanham Michele, 2014, J Int AIDS Soc, V17, P19159, DOI 10.7448/IAS.17.3.19159; Mansoor LE, 2014, AIDS BEHAV, V18, P841, DOI 10.1007/s10461-014-0752-9; Marrazzo JM, 2015, NEW ENGL J MED, V372, P509, DOI 10.1056/NEJMoa1402269; McLellan E., 2003, FIELD METHOD, V15, P63, DOI [10.1177/1525822X02239573, DOI 10.1177/1525822X02239573]; Mensch BS, 2008, INT FAM PLAN PERSPEC, V34, P169, DOI 10.1363/ifpp.34.169.08; Mngadi KT, 2014, AIDS BEHAV, V18, P849, DOI 10.1007/s10461-014-0696-0; Montgomery CM, 2008, AIDS CARE, V20, P733, DOI 10.1080/09540120701693974; Psaros C, 2014, JAIDS-J ACQ IMM DEF, V66, P522, DOI 10.1097/QAI.0000000000000212; QSR International Pty Ltd, 2013, NVIVO QUALITATIVE DA; Simon AE, 2007, AM J PREV MED, V32, P370, DOI 10.1016/j.amepre.2007.01.007; Sugarman J, 2015, AM J BIOETH EMP RESE; Thigpen MC, 2012, NEW ENGL J MED, V367, P423, DOI 10.1056/NEJMoa1110711; Van Damme L, 2012, NEW ENGL J MED, V367, P411, DOI 10.1056/NEJMoa1202614; van der Straten A, 2012, AIDS BEHAV, V16, P1775, DOI 10.1007/s10461-012-0215-0; van der Straten A, 2014, AIDS BEHAV; van der Straten A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089118; Woodsong C, 2004, INT FAM PLAN PERSPEC, V30, P94, DOI 10.1363/3009404; Woodsong C, 2012, AIDS BEHAV, V16, P785, DOI 10.1007/s10461-011-0027-7	33	49	49	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 13	2015	10	4							e0125458	10.1371/journal.pone.0125458	http://dx.doi.org/10.1371/journal.pone.0125458			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CF8XK	25867624	Green Published, gold, Green Submitted			2023-01-03	WOS:000352845100293
J	Jodal, A; Pape, F; Becker-Pauly, C; Maas, O; Schibli, R; Behe, M				Jodal, Andreas; Pape, Fabienne; Becker-Pauly, Christoph; Maas, Ole; Schibli, Roger; Behe, Martin			Evaluation of In-111-Labelled Exendin-4 Derivatives Containing Different Meprin beta-Specific Cleavable Linkers	PLOS ONE			English	Article							GLP-1 RECEPTOR; ALPHA-SUBUNIT; SUBSTRATE; LINKAGES	Background Cleavable linkers, which are specifically cleaved by defined conditions or enzymes, are powerful tools that can be used for various purposes. Amongst other things, they have been successfully used to deliver toxic payloads as prodrugs into target tissues. In this work novel linker sequences targeting meprin beta, a metalloprotease expressed in the kidney brush-border membrane, were designed and included in the sequence of three radiolabelled exendin-4 derivatives. As radiolabelled exendin-4 derivatives strongly accumulate in the kidneys, we hypothesised that specific cleavage of the radiolabelled moiety at the kidney brush-border membrane would allow easier excretion of the activity into the urine and therefore improve the pharmacological properties of the peptide. Results The insertion of a cleavable linker did not negatively influence the in vitro properties of the peptides. They showed a good affinity to the GLP-1 receptor expressed in CHL cells, a high internalisation and sufficiently high stability in fresh human blood plasma. In vitro digestion with recombinant meprin beta rapidly metabolised the corresponding linker sequences. After 60 min the majority of the corresponding peptides were digested and at the same time the anticipated fragments were formed. The peptides were also quickly metabolised in CD1 nu/nu mouse kidney homogenates. Immunofluorescence staining of meprin beta in kidney sections confirmed the expression of the protease in the kidney brush-border membrane. Biodistribution in GLP-1 receptor positive tumour-xenograft bearing mice revealed high specific uptake of the In-111-labelled tracers in receptor positive tissue. Accumulation in the kidneys, however, was still high and comparable to the lead compound In-111-Ex4NOD40. Conclusion In conclusion, we show that the concept of cleavable linkers specific for meprin beta is feasible, as the peptides are rapidly cleaved by the enzyme while retaining their biological properties.	[Jodal, Andreas; Pape, Fabienne; Schibli, Roger; Behe, Martin] Paul Scherrer Inst, Ctr Radiopharmaceut Sci ETH PSI USZ, Villigen, Switzerland; [Pape, Fabienne; Schibli, Roger] ETH, Dept Chem & Appl Biosci, Zurich, Switzerland; [Becker-Pauly, Christoph] Univ Kiel, Inst Biochem, Kiel, Germany; [Maas, Ole] Univ Basel Hosp, Div Nucl Med, Dept Radiol & Nucl Med, CH-4031 Basel, Switzerland	Swiss Federal Institutes of Technology Domain; Paul Scherrer Institute; Swiss Federal Institutes of Technology Domain; ETH Zurich; University of Kiel; University of Basel	Behe, M (corresponding author), Paul Scherrer Inst, Ctr Radiopharmaceut Sci ETH PSI USZ, Villigen, Switzerland.	martin.behe@psi.ch	Becker-Pauly, Christoph/B-7569-2011	Schibli, Roger/0000-0002-1537-3833	Seventh Framework Programme [222980, 602812]; Juvenile Diabetes Research Foundation International [37-2012-4]; Deutsche Forschungsgemeinschaft [SFB 877/2];  [A9]	Seventh Framework Programme(European Commission); Juvenile Diabetes Research Foundation International(Juvenile Diabetes Research Foundation); Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); 	This work was supported by the following sources of funding: Seventh Framework Programme (http://ec.europa.eu/research/fp7/index_en.cfm) grant numbers 222980 and 602812; Juvenile Diabetes Research Foundation International (http://jdrf.org/) grant number 37-2012-4; and Deutsche Forschungsgemeinschaft (http://www.dfg.de/en/index.jsp) grant number SFB 877/2 2014; Projekt A9. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Akizawa H, 2013, BIOCONJUGATE CHEM, V24, P291, DOI 10.1021/bc300428b; Baggio LL, 2007, GASTROENTEROLOGY, V132, P2131, DOI 10.1053/j.gastro.2007.03.054; Becker C, 2003, BIOL CHEM, V384, P825, DOI 10.1515/BC.2003.092; Becker-Pauly C, 2007, J INVEST DERMATOL, V127, P1115, DOI 10.1038/sj.jid.5700675; Becker-Pauly C, 2011, MOL CELL PROTEOMICS, V10, DOI 10.1074/mcp.M111.009233; Bertenshaw GP, 2001, J BIOL CHEM, V276, P13248, DOI 10.1074/jbc.M011414200; Biasin V, 2014, J PATHOL, V233, P7, DOI 10.1002/path.4303; Bodei L, 2008, EUR J NUCL MED MOL I, V35, P1847, DOI 10.1007/s00259-008-0778-1; Broder C, 2013, P NATL ACAD SCI USA, V110, P14219, DOI 10.1073/pnas.1305464110; Broder C, 2013, BIOCHEM J, V450, P253, DOI 10.1042/BJ20121751; Brom M, 2014, DIABETOLOGIA, V57, P950, DOI 10.1007/s00125-014-3166-3; Brom M, 2012, CONTRAST MEDIA MOL I, V7, P160, DOI 10.1002/cmmi.475; Chen YJ, 2014, BIOMATERIALS, V35, P304, DOI 10.1016/j.biomaterials.2013.09.100; Christ E, 2013, LANCET DIABETES ENDO, V1, P115, DOI 10.1016/S2213-8587(13)70049-4; Fujioka Y, 2005, BIOCONJUGATE CHEM, V16, P1610, DOI 10.1021/bc050211z; Gotthardt M, 2007, J NUCL MED, V48, P596, DOI 10.2967/jnumed.106.036020; Herzog C, 2005, CYTOKINE, V31, P394, DOI 10.1016/j.cyto.2005.06.012; Jefferson T, 2013, CELL MOL LIFE SCI, V70, P309, DOI 10.1007/s00018-012-1106-2; Jodal A, 2014, EJNMMI RES, V4, DOI 10.1186/s13550-014-0031-9; Leriche G, 2012, BIOORGAN MED CHEM, V20, P571, DOI 10.1016/j.bmc.2011.07.048; Lottaz D, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026450; Pattou F, 2010, NEW ENGL J MED, V363, P1289, DOI 10.1056/NEJMc1004547; Sloniec J, 2013, J PHYS CHEM B, V117, P14336, DOI 10.1021/jp409388b; Sterchi EE, 2008, MOL ASPECTS MED, V29, P309, DOI 10.1016/j.mam.2008.08.002; Trejtnar F, 2002, Q J NUCL MED, V46, P181; Uehara T, 2014, BIOCONJUGATE CHEM, V25, P2038, DOI 10.1021/bc5004058; VANEYLL B, 1994, FEBS LETT, V348, P7, DOI 10.1016/0014-5793(94)00553-2; Vegt E, 2011, EUR J NUCL MED MOL I, V38, P623, DOI 10.1007/s00259-010-1685-9; Wessels BW, 2008, J NUCL MED, V49, P1884, DOI 10.2967/jnumed.108.053173; Wild D, 2006, J NUCL MED, V47, P2025; Yim CB, 2013, NUCL MED BIOL, V40, P1006, DOI 10.1016/j.nucmedbio.2013.06.012; Zhang W, 2011, BIOORG MED CHEM LETT, V21, P1452, DOI 10.1016/j.bmcl.2011.01.013	32	16	17	1	34	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 9	2015	10	4							e0123443	10.1371/journal.pone.0123443	http://dx.doi.org/10.1371/journal.pone.0123443			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CF5HQ	25855967	Green Published, Green Submitted, gold			2023-01-03	WOS:000352588500090
J	Farrell, B; Tsang, C; Raman-Wilms, L; Irving, H; Conklin, J; Pottie, K				Farrell, Barbara; Tsang, Corey; Raman-Wilms, Lalitha; Irving, Hannah; Conklin, James; Pottie, Kevin			What Are Priorities for Deprescribing for Elderly Patients? Capturing the Voice of Practitioners: A Modified Delphi Process	PLOS ONE			English	Article							BENZODIAZEPINE USE; OLDER-ADULTS; POLYPHARMACY; MEDICATIONS; APPROPRIATENESS; OVERDIAGNOSIS; THERAPY; HEALTH; IMPACT; TRIALS	Polypharmacy and inappropriate medication use among older adults contribute to adverse drug reactions, falls, cognitive impairment, noncompliance, hospitalization and mortality. While deprescribing - tapering, reducing or stopping a medication - is feasible and relatively safe, clinicians find it difficult to carry out. Deprescribing guidelines would facilitate this process. The aim of this paper is to identify and prioritize medication classes where evidence-based deprescribing guidelines would be of benefit to clinicians. A modified Delphi approach included a literature review to identify potentially inappropriate medications for the elderly, an expert panel to develop survey content and three survey rounds to seek consensus on priorities. Panel participants included three pharmacists, two family physicians and one social scientist. Sixty-five Canadian geriatrics experts (36 pharmacists, 19 physicians and 10 nurse practitioners) participated in the survey. Twenty-nine drugs/drug classes were included in the first survey with 14 reaching the required (>= 70%) level of consensus, and 2 new drug classes added from qualitative comments. Fifty-three participants completed round two, and 47 participants completed round three. The final five priorities were benzodiazepines, atypical antipsychotics, statins, tricyclic antidepressants, and proton pump inhibitors; nine other drug classes were also identified as being in need of evidence-based deprescribing guidelines. The Delphi consensus process identified five priority drug classes for which expert clinicians felt guidance is needed for deprescribing. The classes of drugs that emerged strongly from the rankings dealt with mental health, cardiovascular, gastroenterological, and neurological conditions. The results suggest that deprescribing and overtreatment occurs through the full spectrum of primary care, and that evidence-based deprescribing guidelines are a priority in the care of the elderly.	[Farrell, Barbara; Tsang, Corey; Irving, Hannah; Conklin, James; Pottie, Kevin] Bruyere Res Inst, Ottawa, ON, Canada; [Farrell, Barbara; Pottie, Kevin] Univ Ottawa, Dept Family Med, Ottawa, ON, Canada; [Farrell, Barbara; Tsang, Corey] Univ Waterloo, Sch Pharm, Waterloo, ON N2L 3G1, Canada; [Raman-Wilms, Lalitha] Univ Toronto, Leslie Dan Fac Pharm, Toronto, ON, Canada; [Conklin, James] Concordia Univ, Dept Appl Human Sci, Montreal, PQ, Canada	University of Ottawa; University of Ottawa; University of Waterloo; University of Toronto; Concordia University - Canada	Farrell, B (corresponding author), Bruyere Res Inst, Ottawa, ON, Canada.	bfarrell@bruyere.org	Pottie, Kevin/ABC-4385-2020	Tsang, Corey/0000-0002-2087-1888	Ontario Ministry of Health and Long-Term Care	Ontario Ministry of Health and Long-Term Care(Ministry of Health and Long-Term Care, Ontario)	This study was funded by the Ontario Ministry of Health and Long-Term Care (http://www.health.gov.on.ca/en/). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. BF is the principal investigator; JC is the co-principal investigator.	American Geriatrics Society, 2012, AGS UPD BEERS CRIT P; [Anonymous], 2010, DELPHI TECHNIQUE NUR; [Anonymous], 2007, PRACTICAL ASSESSMENT, DOI [DOI 10.1576/T0AG.7.2.120.27071, DOI 10.7275/PDZ9-TH90]; Anthierens S, 2010, BMC FAM PRACT, V11, DOI 10.1186/1471-2296-11-65; Bain KT, 2008, J AM GERIATR SOC, V56, P1946, DOI 10.1111/j.1532-5415.2008.01916.x; Bierman Arlene S, 2007, Am J Geriatr Pharmacother, V5, P147, DOI 10.1016/j.amjopharm.2007.06.005; Borghesani PR, 2011, J AM GERIATR SOC, V59, P376, DOI 10.1111/j.1532-5415.2011.03252.x; bpacnz, 2010, BEST PRACTICE J, V27; Brouwers MC, 2010, CAN MED ASSOC J, V182, pE839, DOI 10.1503/cmaj.090449; Daniel SB, 2011, NEW ENGL J MED, V365, P2002, DOI 10.1056/NEJMsa1103053; Byatt Kit, 2014, Evid Based Med, V19, P121, DOI 10.1136/eb-2013-101646; Canadian Institute for Health Information, 2007, DRUG CLAIMS SEN AN F; Canadian Institute for Health Information, 2012, US SEL PSYCH DRUGS S; Canadian Institute for Health Information (CIHI), 2013, ADVERSE DRUG REACT T; Chokshi NP, 2012, AM J CARDIOL, V110, P1477, DOI 10.1016/j.amjcard.2012.06.058; Declercq T, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007726.pub2; Fick D, 2012, J AM GERIATR SOC, V60, P616, DOI 10.1111/j.1532-5415.2012.03923.x; Field A., 2009, DISCOVERING STAT USI, P539, DOI DOI 10.1111/J.1365-2648.2007.04270_1.X; Garfinkel D, 2007, ISR MED ASSOC J, V9, P430; Garfinkel D, 2010, ARCH INTERN MED, V170, P1648, DOI 10.1001/archinternmed.2010.355; Gnjidic D, 2012, CLIN GERIATR MED, V28, P237, DOI 10.1016/j.cger.2012.01.006; Godlee F., 2012, BMJ-BRIT MED J, V344, pe3783, DOI [10.1136/bmj.e3783, DOI 10.1136/BMJ.E3783]; Gokula M, 2012, CLIN GERIATR MED, V28, P323, DOI 10.1016/j.cger.2012.01.011; Gould RL, 2014, BRIT J PSYCHIAT, V204, P98, DOI 10.1192/bjp.bp.113.126003; Guyatt GH, 2011, J CLIN EPIDEMIOL, V64, P1294, DOI 10.1016/j.jclinepi.2011.03.017; Hajjar Emily R, 2007, Am J Geriatr Pharmacother, V5, P345, DOI 10.1016/j.amjopharm.2007.12.002; Hamilton Hilary J, 2009, BMC Geriatr, V9, P5, DOI 10.1186/1471-2318-9-5; Hardy James E., 2011, Journal of Pharmacy Practice and Research, V41, P146; Hasson F, 2000, J ADV NURS, V32, P1008, DOI 10.1046/j.1365-2648.2000.01567.x; Heath I, 2013, BMJ-BRIT MED J, V347, DOI 10.1136/bmj.f6361; Heidelbaugh JJ, 2010, AM J MANAG CARE, V16, pE228; Heidelbaugh JJ, 2009, AM J GASTROENTEROL, V104, pS27, DOI 10.1038/ajg.2009.49; Holey EA, 2007, BMC MED RES METHODOL, V7, DOI 10.1186/1471-2288-7-52; Holmes HM, 2006, ARCH INTERN MED, V166, P605, DOI 10.1001/archinte.166.6.605; Hsieh HF, 2005, QUAL HEALTH RES, V15, P1277, DOI 10.1177/1049732305276687; Huang AR, 2012, DRUG AGING, V29, P359, DOI 10.2165/11599460-000000000-00000; Iyer S, 2008, DRUG AGING, V25, P1021, DOI 10.2165/0002512-200825120-00004; Jyrkka J, 2009, DRUG AGING, V26, P1039, DOI 10.2165/11319530-000000000-00000; Lane CJ, 2004, J AM GERIATR SOC, V52, P861, DOI 10.1111/j.1532-5415.2004.52250.x; Le Couteur D, 2011, AUST PRESCR, V34, P182; Mottram P, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003491.pub2; Moynihan R, 2012, BMJ-BRIT MED J, V344, DOI 10.1136/bmj.e3502; O'Mahony D, 2010, EUR GERIATR MED, V1, P45, DOI 10.1016/j.eurger.2010.01.007; Ontario Drug Benefit Program, 2012, 2010 11 REP CARD ONT; Ott SM, 2011, CLEV CLIN J MED, V78, P619, DOI 10.3949/ccjm.78a.11022; Pare G, 2013, INFORM MANAGE-AMSTER, V50, P207, DOI 10.1016/j.im.2013.03.003; Patton MQ, 2002, QUALITATIVE ANAL INT, V3rd, P431; Reason B, 2012, FAM PRACT, V29, P427, DOI 10.1093/fampra/cmr124; Reeve E, 2013, DRUG AGING, V30, P793, DOI 10.1007/s40266-013-0106-8; Schmidt RC, 1997, DECISION SCI, V28, P763, DOI 10.1111/j.1540-5915.1997.tb01330.x; Schunemann HJ, 2014, CAN MED ASSOC J, V186, pE123, DOI 10.1503/cmaj.131237; Sergi G, 2011, DRUG AGING, V28, P509, DOI 10.2165/11592010-000000000-00000; Sithamparanathan K., 2012, ASIAN J GERONTOL GER, V7, P107; Spijker-Huiges Antje, 2006, Eur J Gen Pract, V12, P10, DOI 10.1080/13814780600757120; Steinman MA, 2010, JAMA-J AM MED ASSOC, V304, P1592, DOI 10.1001/jama.2010.1482; Swinkels H, 2011, CAN MED ASSOC J, V183, pE928, DOI 10.1503/cmaj.090290; Sykes L, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005398.pub3; Voshaar RCO, 2006, BRIT J PSYCHIAT, V189, P213, DOI 10.1192/bjp.189.3.213; Welch GH, 2011, OVER DIAGNOSED MAKIN; Woodward MC., 2003, J PHARM PRACT RES, V33, P323, DOI DOI 10.1002/jppr2003334323; Wu C, 2012, DRUG SAFETY, V35, P769, DOI 10.2165/11599540-000000000-00000; Ziere G, 2006, BRIT J CLIN PHARMACO, V61, P218, DOI 10.1111/j.1365-2125.2005.02543.x; Zulman DM, 2011, J GEN INTERN MED, V26, P783, DOI 10.1007/s11606-010-1629-x	63	108	112	0	29	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 7	2015	10	4							e0122246	10.1371/journal.pone.0122246	http://dx.doi.org/10.1371/journal.pone.0122246			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	CF3VU	25849568	gold, Green Submitted, Green Published			2023-01-03	WOS:000352477800112
J	Maruyama, T; Akutsu, Y; Suganami, A; Tamura, Y; Fujito, H; Ouchi, T; Akanuma, N; Isozaki, Y; Takeshita, N; Hoshino, I; Uesato, M; Toyota, T; Hayashi, H; Matsubara, H				Maruyama, Tetsuro; Akutsu, Yasunori; Suganami, Akiko; Tamura, Yutaka; Fujito, Hiromichi; Ouchi, Tomoki; Akanuma, Naoki; Isozaki, Yuka; Takeshita, Nobuyoshi; Hoshino, Isamu; Uesato, Masaya; Toyota, Taro; Hayashi, Hideki; Matsubara, Hisahiro			Treatment of Near-Infrared Photodynamic Therapy Using a Liposomally Formulated Indocyanine Green Derivative for Squamous Cell Carcinoma	PLOS ONE			English	Article							CANCER-CELLS; NANOPARTICLES; MECHANISMS; DRUG	Introduction Photodynamic therapy (PDT) is a less invasive option for cancer treatment that has evolved through recent developments in nanotechnology. We have designed and synthesized a novel liposome system that includes an indocyanine green (ICG) derivative, ICG-C18, in its bilayer. In addition to its use as an optical imager to visualize blood, lymphatic, and bile flow, ICG has also been used as an optical sensitizer. In the present report, we evaluate the use of our novel liposome system, LP-ICG-C18, in PDT for squamous cell carcinoma in an autologous murine model. Materials and Methods An excitation pulse beam (300 mu J/pulse) of a single band (800 nm) was used for sensitization. The cytotoxicity of the photodynamic therapy was evaluated in terms of cellular morphology changes, methyl thiazolyl tetrazolium (MTT) assay results, and terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate-biotin nick end labeling (TUNEL) staining. We tested the enhanced permeability and retention effect of LP-ICG-C18 in tumor-bearing C3H/He mice using a near-infrared fluorescence imaging system and fluorescence microscopy. We also examined the antitumor effect of PDT by measuring tumor volume in tumor-bearing mice. Results Cell death and apoptosis were only observed in the PDT group receiving LP-ICG-C18. LPICG-C18 itself had no cytotoxic activity and showed good biocompatibility. LP-ICG-C18 accumulated on the tumor 24 hours after injection and was retained for approximately 3 weeks. Tumor cell apoptosis following PDT with LP-ICG-C18 was also observed under optical microscopy, MTT assay, and TUNEL staining. Conclusion These findings suggest that LP-ICG-C18 may be an effective intervening material in PDT for malignant disease.	[Maruyama, Tetsuro; Akutsu, Yasunori; Akanuma, Naoki; Isozaki, Yuka; Takeshita, Nobuyoshi; Hoshino, Isamu; Uesato, Masaya; Matsubara, Hisahiro] Chiba Univ, Grad Sch Med, Dept Frontier Surg, Chiba, Japan; [Suganami, Akiko; Tamura, Yutaka] Chiba Univ, Grad Sch Med, Dept Bioinformat, Chiba, Japan; [Fujito, Hiromichi] Chiba Univ, Fac Engn, Dept Med Syst Engn, Chiba 260, Japan; [Ouchi, Tomoki] Chiba Univ, Grad Sch Adv Integrat Sci, Div Neurosci, Chiba, Japan; [Toyota, Taro] Univ Tokyo, Grad Sch Arts & Sci, Dept Basic Sci, Tokyo, Japan; [Hayashi, Hideki] Chiba Univ, Ctr Frontier Med Engn, Chiba, Japan	Chiba University; Chiba University; Chiba University; Chiba University; University of Tokyo; Chiba University	Akutsu, Y (corresponding author), Chiba Univ, Grad Sch Med, Dept Frontier Surg, Chiba, Japan.	yakutsu@faculty.chiba-u.jp			Nakayama Cancer Research Institute Gastrointestinal Project grant	Nakayama Cancer Research Institute Gastrointestinal Project grant	Nakayama Cancer Research Institute Gastrointestinal Project grant (http://ncri.or.jp/prize/prize.html) TM. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bareford LA, 2007, ADV DRUG DELIVER REV, V59, P748, DOI 10.1016/j.addr.2007.06.008; Barth BM, 2011, ACS NANO, V5, P5325, DOI 10.1021/nn2005766; Baumler W, 1999, BRIT J CANCER, V80, P360, DOI 10.1038/sj.bjc.6690363; Cheng Y, 2011, J AM CHEM SOC, V133, P2583, DOI 10.1021/ja108846h; Cui SS, 2013, ACS NANO, V7, P676, DOI 10.1021/nn304872n; Douillard S, 2013, PHOTODIAGN PHOTODYN, V10, P62, DOI 10.1016/j.pdpdt.2012.05.004; Fang J, 2011, ADV DRUG DELIVER REV, V63, P136, DOI 10.1016/j.addr.2010.04.009; Fickweiler S, 1997, J PHOTOCH PHOTOBIO B, V38, P178, DOI 10.1016/S1011-1344(96)07453-2; Hirano T, 2007, J JPN SOC LASER SURG, V28, P122, DOI DOI 10.2530/jslsm.28.122; Hocine O, 2010, INT J PHARMACEUT, V402, P221, DOI 10.1016/j.ijpharm.2010.10.004; HOPEROSS M, 1994, OPHTHALMOLOGY, V101, P529; Huang CJ, 2013, NANO LETT, V13, P1611, DOI 10.1021/nl400033h; Hulchanskyy TY, 2007, NANO LETT, V7, P2835, DOI 10.1021/nl0714637; Karakullukcu B, 2013, EUR ARCH OTO-RHINO-L, V270, P1093, DOI 10.1007/s00405-012-2104-6; Lee SJ, 2011, J CONTROL RELEASE, V152, P21, DOI 10.1016/j.jconrel.2011.03.027; Lee YEK, 2011, METHODS MOL BIOL, V726, P151, DOI 10.1007/978-1-61779-052-2_11; MAC E., 2003, PHOTODYNAMIC THERAPY; Panyam J, 2002, FASEB J, V16, DOI 10.1096/fj.02-0088com; Paszko E, 2013, EUR J PHARM SCI, V48, P202, DOI 10.1016/j.ejps.2012.10.018; Proulx ST, 2010, CANCER RES, V70, P7053, DOI 10.1158/0008-5472.CAN-10-0271; Qin M, 2011, PHOTOCH PHOTOBIO SCI, V10, P832, DOI 10.1039/c1pp05022b; Qumseya BJ, 2013, CLIN ENDOSC, V46, P30, DOI 10.5946/ce.2013.46.1.30; Radzi R, 2012, J VET MED SCI, V74, P545, DOI 10.1292/jvms.11-0464; Reddy GR, 2006, CLIN CANCER RES, V12, P6677, DOI 10.1158/1078-0432.CCR-06-0946; Rungta P, 2011, MACROMOL BIOSCI, V11, P927, DOI 10.1002/mabi.201100043; Sahay G, 2010, J CONTROL RELEASE, V145, P182, DOI 10.1016/j.jconrel.2010.01.036; Sakagami H, 2006, IN VIVO, V20, P499; SHIBAMOTO Y, 1991, CANCER RES, V51, P5134; Suganami A, 2012, BIOORG MED CHEM LETT, V22, P7481, DOI 10.1016/j.bmcl.2012.10.044; Toyota T, 2013, BIOORGANIC MEDICINAL, V22, P721; Urbanska K, 2002, ACTA BIOCHIM POL, V49, P387; Vranic S, 2013, PART FIBRE TOXICOL, V10, DOI 10.1186/1743-8977-10-2; Yano T, 2012, RADIAT ONCOL, V7, DOI 10.1186/1748-717X-7-113; Yoon HY, 2012, KOREAN J INTERN MED, V27, P278, DOI 10.3904/kjim.2012.27.3.278; Zhao BZ, 2010, EXPERT REV ANTICANC, V10, P1797, DOI [10.1586/era.10.154, 10.1586/ERA.10.154]	35	11	11	1	37	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 7	2015	10	4							e0122849	10.1371/journal.pone.0122849	http://dx.doi.org/10.1371/journal.pone.0122849			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CF3VU	25850029	Green Submitted, gold, Green Published			2023-01-03	WOS:000352477800165
J	Zunino, B; Rubio-Patino, C; Villa, E; Meynet, O; Proics, E; Cornille, A; Pommier, S; Mondragon, L; Chiche, J; Bereder, JM; Carles, M; Ricci, JE				Zunino, B.; Rubio-Patino, C.; Villa, E.; Meynet, O.; Proics, E.; Cornille, A.; Pommier, S.; Mondragon, L.; Chiche, J.; Bereder, J-M; Carles, M.; Ricci, J-E			Hyperthermic intraperitoneal chemotherapy leads to an anticancer immune response via exposure of cell surface heat shock protein 90	ONCOGENE			English	Article							PERITONEAL CARCINOMATOSIS; CYTOREDUCTIVE SURGERY; DENDRITIC CELL; CANCER; TUMOR; HEAT-SHOCK-PROTEIN-90; IMMUNOSURVEILLANCE; INHIBITION; APOPTOSIS	The occurrence of peritoneal carcinomatosis is a major cause of treatment failure in colorectal cancer and is considered incurable. However, new therapeutic approaches have been proposed, including cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy (HIPEC). Although HIPEC has been effective in selected patients, it is not known how HIPEC prolongs a patient's lifespan. Here, we have demonstrated that HIPEC-treated tumor cells induce the activation of tumor-specific T cells and lead to vaccination against tumor cells in mice. We have established that this effect results from the HIPEC-mediated exposure of heat shock protein (HSP) 90 at the plasma membrane. Inhibition or blocking of HSP90, but not HSP70, prevented the HIPECmediated antitumoral vaccination. Our work raises the possibility that the HIPEC procedure not only kills tumor cells but also induces an efficient anticancer immune response, therefore opening new opportunities for cancer treatment.	[Zunino, B.; Rubio-Patino, C.; Villa, E.; Meynet, O.; Proics, E.; Cornille, A.; Pommier, S.; Mondragon, L.; Chiche, J.; Carles, M.; Ricci, J-E] Ctr Mediterraneen Med Mol C3M, INSERM, U1065, Equipe Controle Metab Morts Cellulaires, F-06204 Nice 03, France; [Zunino, B.; Rubio-Patino, C.; Villa, E.; Meynet, O.; Proics, E.; Cornille, A.; Pommier, S.; Mondragon, L.; Chiche, J.; Carles, M.; Ricci, J-E] Univ Nice Sophia Antipolis, Fac Med, F-06189 Nice, France; [Zunino, B.; Pommier, S.; Carles, M.; Ricci, J-E] CHU Nice, Dept Anesthesie Reanimat, F-06202 Nice, France; [Bereder, J-M] CHU Nice, Serv Chirurg Gen & Cancerol Digest, F-06202 Nice, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; UDICE-French Research Universities; Universite Cote d'Azur; CHU Nice; CHU Nice	Ricci, JE (corresponding author), Ctr Mediterraneen Med Mol C3M, INSERM, U1065, Equipe Controle Metab Morts Cellulaires, 151 Route St Antoine de Ginestiere,BP 23194, F-06204 Nice 03, France.	ricci@unice.fr	Martinez, Laura Mondragon/P-1670-2018; Martinez, Laura Mondragon/X-1577-2019; Ricci, Jean Ehrland/I-7117-2016; Chiche, Johanna/P-6382-2016; Carles, Michel/CAH-0065-2022; RICCI, Jean Ehrland/AAS-4379-2020	Martinez, Laura Mondragon/0000-0002-3257-045X; Martinez, Laura Mondragon/0000-0002-3257-045X; Ricci, Jean Ehrland/0000-0003-1585-8117; Chiche, Johanna/0000-0001-5276-1125; RICCI, Jean Ehrland/0000-0003-1585-8117; CARLES, MICHEL/0000-0001-5485-1511; Rubio-Patino, Camila/0000-0002-0489-2419	Fondation ARC (Association pour la Recherche sur le Cancer); Agence Nationale de la Recherche (LABEX SIGNALIFE) [ANR-11-LABX-0028-01]; Fondation ARC; la Ville de Nice; Fondation pour la Recherche Medicale (FRM); la Fondation de France	Fondation ARC (Association pour la Recherche sur le Cancer)(Fondation ARC pour la Recherche sur le Cancer); Agence Nationale de la Recherche (LABEX SIGNALIFE)(French National Research Agency (ANR)); Fondation ARC; la Ville de Nice; Fondation pour la Recherche Medicale (FRM)(Fondation pour la Recherche Medicale); la Fondation de France(Fondation de France)	We gratefully acknowledge the Centre Mediterraneen de Medecine Moleculaire animal room and imaging facilities. We thank Jozef Bossowski, Drs Raucoules and Benchimol, Benjamin Lefebvre and all of the operating room and surgical digestive service nurses for their help. This work was supported by the Fondation ARC (Association pour la Recherche sur le Cancer), the Agence Nationale de la Recherche (LABEX SIGNALIFE ANR-11-LABX-0028-01). CRP is supported by the Fondation ARC, LM is supported by la Ville de Nice and by Fondation pour la Recherche Medicale (FRM) and JC is supported by la Fondation de France.	Bae J, 2007, J IMMUNOL, V178, P7730, DOI 10.4049/jimmunol.178.12.7730; Beneteau M, 2012, P NATL ACAD SCI USA, V109, P20071, DOI 10.1073/pnas.1206360109; Botzler C, 1998, CELL STRESS CHAPERON, V3, P6, DOI 10.1379/1466-1268(1998)003<0006:DOELEO>2.3.CO;2; Castellino F, 2000, J EXP MED, V191, P1957, DOI 10.1084/jem.191.11.1957; Elias D, 2009, J CLIN ONCOL, V27, P681, DOI 10.1200/JCO.2008.19.7160; Garg AD, 2010, BBA-REV CANCER, V1805, P53, DOI 10.1016/j.bbcan.2009.08.003; John K, 2002, BIOPHYS J, V83, P3315, DOI 10.1016/S0006-3495(02)75332-0; Kepp O, 2014, ONCOIMMUNOLOGY, V3, DOI 10.4161/21624011.2014.955691; Kim YS, 2009, CURR TOP MED CHEM, V9, P1479, DOI 10.2174/156802609789895728; Klaver YLB, 2010, BRIT J SURG, V97, P1874, DOI 10.1002/bjs.7249; Kroemer G, 2013, ANNU REV IMMUNOL, V31, P51, DOI 10.1146/annurev-immunol-032712-100008; Lanneau D, 2008, J CELL MOL MED, V12, P743, DOI 10.1111/j.1582-4934.2008.00273.x; Massey AJ, 2010, CANCER CHEMOTH PHARM, V66, P535, DOI 10.1007/s00280-009-1194-3; Murshid A, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00063; Pelz JOW, 2013, ANN SURG ONCOL, V20, P1105, DOI 10.1245/s10434-012-2784-6; Pockley AG, 2003, LANCET, V362, P469, DOI 10.1016/S0140-6736(03)14075-5; Schmitt E, 2006, CANCER RES, V66, P4191, DOI 10.1158/0008-5472.CAN-05-3778; Senovilla L, 2012, SCIENCE, V337, P1678, DOI 10.1126/science.1224922; Spiliotis JD, 2010, HEPATO-GASTROENTEROL, V57, P1173; Spisek R, 2007, BLOOD, V109, P4839, DOI 10.1182/blood-2006-10-054221; Sugarbaker PH, 2012, GASTROENT RES PRACT, V2012, DOI 10.1155/2012/623417; Tsutsumi S, 2008, ONCOGENE, V27, P2478, DOI 10.1038/sj.onc.1210897; Tsvetkova NM, 2002, P NATL ACAD SCI USA, V99, P13504, DOI 10.1073/pnas.192468399; Wilke CM, 2010, INT J CANCER, V127, P748, DOI 10.1002/ijc.25464; Yang XJ, 2009, ANN SURG ONCOL, V16, P345, DOI 10.1245/s10434-008-0226-2; Zitvogel L, 2006, NAT REV IMMUNOL, V6, P715, DOI 10.1038/nri1936	26	34	45	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 14	2016	35	2					261	268		10.1038/onc.2015.82	http://dx.doi.org/10.1038/onc.2015.82			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DB0JH	25867070				2023-01-03	WOS:000368193900012
J	Schott, M; Klein, B; Vilcinskas, A				Schott, Matthias; Klein, Birgit; Vilcinskas, Andreas			Detection of Illicit Drugs by Trained Honeybees (Apis mellifera)	PLOS ONE			English	Article							BIOSENSORS; VOLATILES; SYSTEM	Illegal drugs exacerbate global social challenges such as substance addiction, mental health issues and violent crime. Police and customs officials often rely on specially-trained sniffer dogs, which act as sensitive biological detectors to find concealed illegal drugs. However, the dog "alert" is no longer sufficient evidence to allow a search without a warrant or additional probable cause because cannabis has been legalized in two US states and is decriminalized in many others. Retraining dogs to recognize a narrower spectrum of drugs is difficult and training new dogs is time consuming, yet there are no analytical devices with the portability and sensitivity necessary to detect substance-specific chemical signatures. This means there is currently no substitute for sniffer dogs. Here we describe an insect screening procedure showing that the western honeybee (Apis mellifera) can sense volatiles associated with pure samples of heroin and cocaine. We developed a portable electroantennographic device for the on-site measurement of volatile perception by these insects, and found a positive correlation between honeybee antennal responses and the concentration of specific drugs in test samples. Furthermore, we tested the ability of honeybees to learn the scent of heroin and trained them to show a reliable behavioral response in the presence of a highly-diluted scent of pure heroin. Trained honeybees could therefore be used to complement or replace the role of sniffer dogs as part of an automated drug detection system. Insects are highly sensitive to volatile compounds and provide an untapped resource for the development of biosensors. Automated conditioning as presented in this study could be developed as a platform for the practical detection of illicit drugs using insect-based sensors.	[Schott, Matthias; Vilcinskas, Andreas] Univ Giessen, Inst Phytopathol & Appl Zool, D-35390 Giessen, Germany; [Schott, Matthias; Vilcinskas, Andreas] Fraunhofer Inst Mol Biol & Appl Ecol IME, Dept Bioresources, Giessen, Germany; [Klein, Birgit] Forens Inst, Sect Narcot Chem, State Off Criminal Investigat Hessen, Wiesbaden, Germany	Justus Liebig University Giessen; Fraunhofer Gesellschaft	Vilcinskas, A (corresponding author), Univ Giessen, Inst Phytopathol & Appl Zool, D-35390 Giessen, Germany.	andreas.vilcinskas@agrar.uni-giessen.de		Schott, Matthias/0000-0002-3034-9305	Hessen State Ministry of Higher Education, Research and the Arts (HMWK) via LOEWE research focus "AmbiProbe"; LOEWE center for Insect Biotechnology and Bioressources	Hessen State Ministry of Higher Education, Research and the Arts (HMWK) via LOEWE research focus "AmbiProbe"; LOEWE center for Insect Biotechnology and Bioressources	This research was funded by the Hessen State Ministry of Higher Education, Research and the Arts (HMWK) via the LOEWE research focus "AmbiProbe" to AV and the LOEWE center for Insect Biotechnology and Bioressources to AV. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	AKERS RP, 1992, CHEM SENSES, V17, P191, DOI 10.1093/chemse/17.2.191; [Anonymous], WORLD DRUG REP 2014; Behrends A, 2010, FRONT BEHAV NEUROSCI, V4, DOI 10.3389/fnbeh.2010.00015; Coffman K, 2012, WASHINGTON 1 STATES; Davis PJ, 2007, Great Britain patent, Patent No. 237504; Frederickx C, 2011, BIOTECHNOL AGRON SOC, V15, P449; HANSSON BS, 1990, J CHEM ECOL, V16, P1887, DOI 10.1007/BF01020502; HOLM S, 1979, SCAND J STAT, V6, P65; Kirkerud NH, 2013, FRONT BEHAV NEUROSCI, V7, DOI 10.3389/fnbeh.2013.00029; LAWRENCE AH, 1984, CAN J CHEM, V62, P1886, DOI 10.1139/v84-323; Leal WS, 2013, ANNU REV ENTOMOL, V58, P373, DOI 10.1146/annurev-ento-120811-153635; Leitch O, 2013, FORENSIC SCI INT, V232, P92, DOI 10.1016/j.forsciint.2013.07.004; Lent DD, 2004, J EXP BIOL, V207, P369, DOI 10.1242/jeb.00736; Matsumoto Y, 2012, J NEUROSCI METH, V211, P159, DOI 10.1016/j.jneumeth.2012.08.018; Michel R, 2014, PHEROMONES GEN ODOR, P23; Missbach C, 2014, ELIFE, V3, DOI 10.7554/eLife.02115; Oldham J, 2013, DRUG SNIFFING DOGS P; Park KC, 2002, J INSECT PHYSIOL, V48, P1139, DOI 10.1016/S0022-1910(02)00207-X; Rains GC, 2008, TRENDS BIOTECHNOL, V26, P288, DOI 10.1016/j.tibtech.2008.02.007; Room R, 2014, ADDICTION, V109, P345, DOI 10.1111/add.12355; Schott M, 2013, ADV BIOCHEM ENG BIOT, V136, P101, DOI 10.1007/10_2013_210; Schott M, 2013, ANAL BIOANAL CHEM, V405, P7457, DOI 10.1007/s00216-013-7196-3; United Nations Office on Drugs and Crime, 2012, WORLD DRUG REP 2012	23	15	15	0	61	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 17	2015	10	6							e0128528	10.1371/journal.pone.0128528	http://dx.doi.org/10.1371/journal.pone.0128528			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CK9NS	26083377	Green Published, Green Submitted, gold			2023-01-03	WOS:000356567400054
J	Vin-Raviv, N; Akinyemiju, TF; Galea, S; Bovbjerg, DH				Vin-Raviv, Neomi; Akinyemiju, Tomi F.; Galea, Sandro; Bovbjerg, Dana H.			Depression and Anxiety Disorders among Hospitalized Women with Breast Cancer	PLOS ONE			English	Article							POSTTRAUMATIC-STRESS-DISORDER; QUALITY-OF-LIFE; PSYCHOSOCIAL SUPPORT; MAJOR DEPRESSION; SURVIVAL; PREVALENCE; SYMPTOMS; INTERVENTION; COMORBIDITY; MORTALITY	Purpose To document the prevalence of depression and anxiety disorders, and their associations with mortality among hospitalized breast cancer patients. Methods We examined the associations between breast cancer diagnosis and the diagnoses of anxiety or depression among 4,164 hospitalized breast cancer cases matched with 4,164 non-breast cancer controls using 2006-2009 inpatient data obtained from the Nationwide Inpatient Sample database. Conditional logistic regression models were used to compute odds ratios (ORs) and 95% confidence intervals (CI) for the associations between breast cancer diagnosis and diagnoses of anxiety or depression. We also used binary logistic regression models to examine the association between diagnoses of depression or anxiety, and in-hospital mortality among breast cancer patients. Results We observed that breast cancer cases were less likely to have a diagnosis of depression (OR=0.63, 95% CI: 0.52-0.77), and less likely to have a diagnosis of anxiety (OR=0.68, 95% CI: 0.52-0.90) compared with controls. This association remained after controlling for race/ethnicity, residential income, insurance and residential region. Breast cancer patients with a depression diagnosis also had lower mortality (OR=0.69, 95% CI: 0.52-0.89) compared with those without a depression diagnosis, but there was no significant difference in mortality among those with and without anxiety diagnoses. Conclusion Diagnoses of depression and anxiety in breast cancer patients were less prevalent than expected based on our analysis of hospitalized breast cancer patients and matched non-breast cancer controls identified in the NIS dataset using ICD-9 diagnostic codes. Results suggest that under-diagnosis of mental health problems may be common among hospitalized women with a primary diagnosis of breast cancer. Future work may fruitfully explore reasons for, and consequences of, inappropriate identification of the mental health needs of breast cancer patients.	[Vin-Raviv, Neomi] Univ Colorado, Rocky Mt Canc Rehabil Inst, Sch Sport & Exercise Sci, Greeley, CO USA; [Akinyemiju, Tomi F.] Univ Alabama Birmingham, Sch Publ Hlth, Dept Epidemiol, Birmingham, AL 35294 USA; [Galea, Sandro] Boston Univ, Sch Publ Hlth, Boston, MA USA; [Bovbjerg, Dana H.] Univ Pittsburgh, Inst Canc, Biobehav Oncol Program, Dept Psychiat, Pittsburgh, PA USA; [Bovbjerg, Dana H.] Univ Pittsburgh, Inst Canc, Biobehav Oncol Program, Dept Psychol, Pittsburgh, PA USA; [Bovbjerg, Dana H.] Univ Pittsburgh, Inst Canc, Biobehav Oncol Program, Dept Behav & Community Hlth Sci, Pittsburgh, PA USA	University of Colorado System; University of Alabama System; University of Alabama Birmingham; Boston University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Akinyemiju, TF (corresponding author), Univ Alabama Birmingham, Sch Publ Hlth, Dept Epidemiol, Birmingham, AL 35294 USA.	tomiakin@uab.edu	Galea, Sandro/GLR-6066-2022; Vin-Raviv, Neomi/AAL-6384-2021	Vin-Raviv, Neomi/0000-0003-1726-6596; Galea, Sandro/0000-0002-7534-0945	National Cancer Institute's R25 Cancer Training Grant [2-R25-CA-09529]; University of Pittsburgh Cancer Institute; Mailman School of Public Health; National Cancer Institute [P30 CA047904]; NATIONAL CANCER INSTITUTE [P30CA047904, T32CA009529] Funding Source: NIH RePORTER	National Cancer Institute's R25 Cancer Training Grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); University of Pittsburgh Cancer Institute; Mailman School of Public Health; National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	The study was financially supported by the National Cancer Institute's R25 Cancer Training Grant 2-R25-CA-09529 (TA); Neomi Vin-Raviv was supported by postdoctoral fellowship funding from the University of Pittsburgh Cancer Institute and the Mailman School of Public Health. Support for Dr. Dana H. Bovbjerg was provided in part by institutional funds from the University of Pittsburgh Cancer Institute and a grant from the National Cancer Institute (P30 CA047904). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Andersen BL, 2010, CLIN CANCER RES, V16, P3270, DOI 10.1158/1078-0432.CCR-10-0278; Andersen BL, 2008, CANCER-AM CANCER SOC, V113, P3450, DOI 10.1002/cncr.23969; Andrykowski Michael A, 2008, Semin Oncol Nurs, V24, P193, DOI 10.1016/j.soncn.2008.05.007; Barefoot JC, 2000, PSYCHOSOM MED, V62, P790, DOI 10.1097/00006842-200011000-00008; Burgess C, 2005, BRIT MED J, V330, P702, DOI 10.1136/bmj.38343.670868.D3; Clark PG, 2011, PSYCHO-ONCOLOGY, V20, P664, DOI 10.1002/pon.1908; Dehal A, 2013, BREAST CANCER RES TR, V139, P469, DOI 10.1007/s10549-013-2543-9; Earle Craig C, 2007, J Cancer Surviv, V1, P156, DOI 10.1007/s11764-007-0013-2; Einsle F, 2012, J PSYCHOSOM RES, V72, P434, DOI 10.1016/j.jpsychores.2012.02.008; Ell K, 2005, J CLIN ONCOL, V23, P3052, DOI 10.1200/JCO.2005.08.041; ENDICOTT J, 1984, CANCER, V53, P2243; Fann JR, 2008, GEN HOSP PSYCHIAT, V30, P112, DOI 10.1016/j.genhosppsych.2007.10.008; Fann JR, 2012, J CLIN ONCOL, V30, P1178, DOI 10.1200/JCO.2011.39.7398; FAWZY FI, 1993, ARCH GEN PSYCHIAT, V50, P681; Ganz PA, 2005, AM J MED, V118, P1410, DOI 10.1016/j.amjmed.2005.10.024; Goodwin JS, 2004, J AM GERIATR SOC, V52, P106, DOI 10.1111/j.1532-5415.2004.52018.x; Goodwin PJ, 2001, NEW ENGL J MED, V345, P1719, DOI 10.1056/NEJMoa011871; Goodwin PJ, 2004, J CLIN ONCOL, V22, P4184, DOI 10.1200/jco.2004.12.091; Guan NC, 2013, INT J PSYCHIAT MED, V45, P73, DOI 10.2190/PM.45.1.f; Himelhoch S, 2004, MED CARE, V42, P512, DOI 10.1097/01.mlr.0000127998.89246.ef; Hjerl K, 2003, PSYCHOSOMATICS, V44, P24, DOI 10.1176/appi.psy.44.1.24; Holland JC, 2002, PSYCHOSOM MED, V64, P206, DOI 10.1097/00006842-200203000-00004; Howden LM, 2011, AGE AND SEX COMPOSIT; Ickovics JR, 2001, JAMA-J AM MED ASSOC, V285, P1466, DOI 10.1001/jama.285.11.1466; IEZZONI LI, 1995, ANN INTERN MED, V123, P763, DOI 10.7326/0003-4819-123-10-199511150-00004; Iezzoni LI, 1997, ADMINISTRATIVE DATAB; Kangas Maria, 2013, Front Psychiatry, V4, P122, DOI 10.3389/fpsyt.2013.00122; Knobf M Tish, 2007, Semin Oncol Nurs, V23, P71, DOI 10.1016/j.soncn.2006.11.009; Low CA, 2014, PSYCHOSOM MED, V76, P248, DOI 10.1097/PSY.0000000000000067; Mandreker JN, 2012, AN INTRODUCTION TO M, P208; Massie Mary Jane, 2004, J Natl Cancer Inst Monogr, P57; Mehnert A, 2008, J PSYCHOSOM RES, V64, P383, DOI 10.1016/j.jpsychores.2007.12.005; Mehnert A, 2007, PSYCHO-ONCOLOGY, V16, P181, DOI 10.1002/pon.1057; Mitchell A, 2008, PSYCHO-ONCOL, V17, P226, DOI 10.1002/pon.1228; Mitchell AJ, 2011, LANCET ONCOL, V12, P160, DOI 10.1016/S1470-2045(11)70002-X; Osborne RH, 2003, EUR J CANCER, V39, P755, DOI 10.1016/S0959-8049(02)00814-6; Palesh O, 2007, J PSYCHOSOM RES, V63, P233, DOI 10.1016/j.jpsychores.2007.05.012; PHILLIPS KE, 2008, AUDUBON, V110, P26, DOI DOI 10.1016/j.jpsychores.2007.05.012; Pinquart M, 2010, PSYCHOL MED, V40, P1797, DOI 10.1017/S0033291709992285; Ravi P, 2014, UROL ONCOL-SEMIN ORI, V32, P1333, DOI 10.1016/j.urolonc.2014.05.005; Reiche EMV, 2004, LANCET ONCOL, V5, P617, DOI 10.1016/S1470-2045(04)01597-9; ROBINS LN, 1988, ARCH GEN PSYCHIAT, V45, P1069; Saquib N, 2011, PSYCHO-ONCOLOGY, V20, P252, DOI 10.1002/pon.1742; Satin JR, 2009, CANCER-AM CANCER SOC, V115, P5349, DOI 10.1002/cncr.24561; Siegel R, 2013, CA-CANCER J CLIN, V63, P11, DOI 10.3322/caac.21166; Sollner W, 2001, BRIT J CANCER, V84, P179, DOI 10.1054/bjoc.2000.1545; Spiegel D, 2007, CANCER-AM CANCER SOC, V110, P1130, DOI 10.1002/cncr.22890; Stark DPH, 2000, BRIT J CANCER, V83, P1261, DOI 10.1054/bjoc.2000.1405; Tross S, 1996, J NATL CANCER I, V88, P661, DOI 10.1093/jnci/88.10.661; Walker J, 2013, ANN ONCOL, V24, P895, DOI 10.1093/annonc/mds575; Walker J, 2014, LANCET PSYCHIAT, V1, P343, DOI 10.1016/S2215-0366(14)70313-X; Watson M, 2005, EUR J CANCER, V41, P1710, DOI 10.1016/j.ejca.2005.01.012; Zabora J, 2001, PSYCHO-ONCOL, V10, P19, DOI 10.1002/1099-1611(200101/02)10:1<19::AID-PON501>3.0.CO;2-6; Zhang AY, 2010, NURS RES PRACT, V2010, DOI 10.1155/2010/693961; Zhang SF, 2010, HEALTH CARE MANAG SC, V13, P137, DOI 10.1007/s10729-009-9119-6	55	35	38	2	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 2	2015	10	6							e0129169	10.1371/journal.pone.0129169	http://dx.doi.org/10.1371/journal.pone.0129169			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	CJ7SJ	26035180	Green Published, gold, Green Accepted, Green Submitted			2023-01-03	WOS:000355699100068
J	Ceschi, A; Heistermann, E; Gros, S; Reichert, C; Kupferschmidt, H; Banner, NR; Krahenbuhl, S; Taegtmeyer, AB				Ceschi, Alessandro; Heistermann, Elja; Gros, Sonja; Reichert, Cornelia; Kupferschmidt, Hugo; Banner, Nicholas R.; Kraehenbuehl, Stephan; Taegtmeyer, Anne B.			Acute Sirolimus Overdose: A Multicenter Case Series	PLOS ONE			English	Article							PRELIMINARY PHARMACOKINETICS; POISON CENTER; DOUBLE-BLIND; TRANSPLANT; RAPAMYCIN; TOLERANCE; SAFETY	Background There are few data relating to sirolimus overdose in the medical literature. Our objectives were to describe all cases of overdose with sirolimus reported to Swiss, German and Austrian Poisons Centres between 2002-2013. Methods An observational case-series analysis was performed to determine circumstances, magnitude, management and outcome of sirolimus overdose. Results Five cases of acute sirolimus overdose were reported - three in young children and two in adults. Four were accidental and one was with suicidal intent. Two patients developed symptoms probably related to sirolimus overdose: mild elevation of alkaline phosphatase, fever and gastroenteritis in a 2.5-year-old male who ingested 3 mg, and mild changes in total cholesterol in an 18-year-old female after ingestion of 103 mg. None of these events were life-threatening. Serial blood concentration measurements were performed starting 24 h after ingestion of 103 mg in a single case, and these followed a similar pharmacokinetic time-course to measurements taken after dosing in the therapeutic range. Conclusions Acute sirolimus overdose occurred accidentally in the majority of cases. Even large overdoses appeared to be well-tolerated, however children might be at greater risk of developing complications. Further study of sirolimus overdose is needed.	[Ceschi, Alessandro; Reichert, Cornelia; Kupferschmidt, Hugo] Univ Zurich, Swiss Toxicol Informat Ctr, Associated Inst, Zurich, Switzerland; [Ceschi, Alessandro] Univ Zurich Hosp, Dept Clin Pharmacol & Toxicol, CH-8091 Zurich, Switzerland; [Heistermann, Elja] Berlin Poison Informat Ctr, Berlin, Germany; [Gros, Sonja] Mainz Poison Control Ctr, Mainz, Germany; [Banner, Nicholas R.] Harefield Hosp, Royal Brompton & Harefield NHS Fdn Trust, Harefield UB9 6JH, Middx, England; [Banner, Nicholas R.] Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, London, England; [Banner, Nicholas R.] Univ London Imperial Coll Sci Technol & Med, Inst Cardiovasc Med & Res, London, England; [Kraehenbuehl, Stephan; Taegtmeyer, Anne B.] Univ Basel, Dept Clin Pharmacol & Toxicol, Basel, Switzerland	University of Zurich; University of Zurich; University Zurich Hospital; Royal Brompton & Harefield NHS Foundation Trust; Harefield Hospital; Imperial College London; Imperial College London; University of Basel	Taegtmeyer, AB (corresponding author), Univ Basel, Dept Clin Pharmacol & Toxicol, Basel, Switzerland.	anne.taegtmeyer@usb.ch	Krähenbühl, Stephan/Z-4744-2019	Ceschi, Alessandro/0000-0002-4308-0405	University and University Hospital Basel; Swiss Toxicological Information Centre; Society of Clinical Toxicology (GfKT); Swiss National Science Foundation [SNF31003A-132992]	University and University Hospital Basel; Swiss Toxicological Information Centre; Society of Clinical Toxicology (GfKT); Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission)	Funding was through internal funds of the University and University Hospital Basel, the Swiss Toxicological Information Centre, and the Society of Clinical Toxicology (GfKT). SK is supported by grants from the Swiss National Science Foundation (SNF31003A-132992). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Brattstrom C, 1997, THER DRUG MONIT, V19, P397, DOI 10.1097/00007691-199708000-00007; Brattstrom C, 1996, TRANSPLANT P, V28, P985; Ceschi A, 2013, AM J TRANSPLANT, V13, P786, DOI 10.1111/j.1600-6143.2012.04347.x; Ceschi A, 2014, EXPERT OPIN DRUG SAF, V13, P525, DOI 10.1517/14740338.2014.903032; Ferron GM, 1997, CLIN PHARMACOL THER, V61, P416, DOI 10.1016/S0009-9236(97)90192-2; Gregoriano C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0086390; Hoffinan RS, 2007, CLIN TOXICOL, V45, P943, DOI 10.1080/15563650701233370; Howland MA, 2010, GOLDFRANKS TOXICOLOG, P108; Johnson EM, 1996, TRANSPLANT P, V28, P987; Kasiske BL, 2008, AM J TRANSPLANT, V8, P1384, DOI 10.1111/j.1600-6143.2008.02272.x; Kelly PA, 1997, PHARMACOTHERAPY, V17, P1148; Klasco RK, 2014, POISINDEX TOMES SYST; Mahalati K, 2001, CLIN PHARMACOKINET, V40, P573, DOI 10.2165/00003088-200140080-00002; Persson HE, 1998, J TOXICOL-CLIN TOXIC, V36, P205, DOI 10.3109/15563659809028940; Pfizer AG, 2012, SWITZERLAND PRODUCT; Sturer A, 2013, CODEX ZUSAMMENARBEIT; WHO-UMC, 2014, US WHO UMC SYST STAN; Wu K, 2012, CPT-PHARMACOMET SYST, V1, DOI 10.1038/psp.2012.18; Zhang Y, 2010, COMPUT METH PROG BIO, V99, P306, DOI 10.1016/j.cmpb.2010.01.007; Zimmerman JJ, 1997, J CLIN PHARMACOL, V37, P405, DOI 10.1002/j.1552-4604.1997.tb04318.x	20	7	7	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 28	2015	10	5							e0128033	10.1371/journal.pone.0128033	http://dx.doi.org/10.1371/journal.pone.0128033			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CJ0SC	26020944	Green Published, gold, Green Accepted			2023-01-03	WOS:000355187300074
J	Cao, XY; Chen, L; Diao, YS; Tian, L; Liu, WJ; Jiang, XL				Cao, Xiaoyi; Chen, Lin; Diao, Yongshu; Tian, Lang; Liu, Wenjie; Jiang, Xiaolian			Validity and Reliability of the Chinese Version of the Care Transition Measure	PLOS ONE			English	Article							OLDER PATIENTS; VALIDATION; QUALITY; PREVALENCE	Background The 15-item care transition measure (CTM-15) is a reliable and valid instrument assessing the quality of care transition from patients' perspectives. The aim of this study was to evaluate the psychometric properties of the CTM-15 and the CTM-3 (a 3-item short version of the CTM-15) in Mainland China. Methodology/Findings This was a cross-sectional study with a convenience sample of 646 patients in a general tertiary-level hospital in Chengdu, China. The results indicated that the Cronbach's a values of the Chinese version of the two measures were 0.90 and 0.56, and the test-retest reliability values were 0.91 and 0.87, respectively. Three factors were extracted for the CTM-15 in Chinese populations. The CTM-15 and the CTM-3 scores discriminated well between patients with and without re-hospitalization for their index condition. The CTM-15 and the CTM-3 had significant positive relationships with self-rated health status. The CTM-3 score was significantly related to the CTM-15 score, and the CTM-3 score accounted for 64.23% of the variance of the CTM-15 score. Conclusions/Significance This study has demonstrated the psychometric properties of the CTM-15 and the CTM-3 in Mainland China. Although the Cronbach's a value of the CTM-3 is suboptimal, it has exhibited high test-retest reliability, convergent validity and criterion validity. Therefore, the CTM3 can substitute the CTM-15 as a performance measurement tool when the sample size is large enough to compensate its suboptimal reliability or the reduced response burden is a concern.	[Cao, Xiaoyi; Chen, Lin] Sichuan Univ, West China Hosp, Dept Nephrol, Hemodialysis Ctr, Chengdu 610064, Sichuan Provinc, Peoples R China; [Diao, Yongshu] Sichuan Univ, West China Hosp, Dept Nephrol, Chengdu 610064, Sichuan Provinc, Peoples R China; [Tian, Lang] Sichuan Canc Hosp, Dept Hepatobiliary Surg, Chengdu 610064, Sichuan Provinc, Peoples R China; [Liu, Wenjie; Jiang, Xiaolian] Sichuan Univ, West China Hosp, Dept Nursing, Chengdu 610064, Sichuan Provinc, Peoples R China	Sichuan University; Sichuan University; Sichuan University	Jiang, XL (corresponding author), Sichuan Univ, West China Hosp, Dept Nursing, Chengdu 610064, Sichuan Provinc, Peoples R China.	xiaolian_jiang@126.com	Cao, XiaoYi/H-1548-2017		Science and Technology department of Sichuan Province [2014FZ0109]	Science and Technology department of Sichuan Province	The project was supported by the Science and Technology department of Sichuan Province (number: 2014FZ0109). The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Anatchkova MD, 2014, J AM HEART ASSOC, V3, DOI 10.1161/JAHA.114.001053; Bakshi AB, 2012, BMC HEALTH SERV RES, V12, DOI 10.1186/1472-6963-12-256; Baumgartner H., 1996, INT J RES MARK, V13, P139, DOI [10.1016/0167-8116(95)00038-0, DOI 10.1016/0167-8116(95)00038-0]; Blendon RJ, 2003, HEALTH AFFAIR, V22, P106, DOI 10.1377/hlthaff.22.3.106; Centers for Medicare and Medicaid Services (CMS), 2008, FACT SHEET CMS AW CO; Chang XX, 2007, J CHIN PLA NURS, V24, P1; Coleman EA, 2003, J AM GERIATR SOC, V51, P556, DOI 10.1046/j.1532-5415.2003.51186.x; Coleman EA, 2005, MED CARE, V43, P246, DOI 10.1097/00005650-200503000-00007; Coleman Eric A, 2002, Int J Integr Care, V2, pe02; Davis LL, 1992, APPL NURS RES, V5, P194, DOI [DOI 10.1016/S0897-1897(05)80008-4, 10.1016/S0897-1897(05)80008-4]; Flacker J, 2007, J HOSP MED, V2, P291, DOI 10.1002/jhm.166; Greenwald JL., 2007, J PATIENT SAF, V3, P97, DOI 10.1097/01.jps.0000236916.94696.12; Hu LT, 1999, STRUCT EQU MODELING, V6, P1, DOI 10.1080/10705519909540118; Institute of Medicine, 2006, PERF MEAS ACC IMPR; Institute of Medicine (IOM), 2001, CROSS QUAL CHASM NEW; Lee WL, 2013, EUR J CARDIOVASC NUR, V12, P512, DOI 10.1177/1474515112470056; LYNN MR, 1986, NURS RES, V35, P382; Marcum ZA, 2013, RES SOC ADMIN PHARM, V9, P817, DOI 10.1016/j.sapharm.2012.12.002; MCDONALD RP, 1981, BRIT J MATH STAT PSY, V34, P100, DOI 10.1111/j.2044-8317.1981.tb00621.x; McLeod J, 2014, MUSCULOSKELET CARE, V12, P13, DOI 10.1002/msc.1043; Muthen L. K., 2010, MPLUS USERS GUIDE, V6th; National Quality Forum, 2006, PREV REV SAF PRACT B; National Quality Forum, 2010, NAT VOL CONS STAND N; Paiva CE, 2014, BMC MED RES METHODOL, V14, DOI 10.1186/1471-2288-14-8; Polit DF, 2007, RES NURS HEALTH, V30, P459, DOI 10.1002/nur.20199; POLIT DF, 1999, NURSING RES PRINCIPL; Scott IA, 2004, MED J AUSTRALIA, V180, pS83; Shadmi E, 2009, INT J QUAL HEALTH C, V21, P97, DOI 10.1093/intqhc/mzp004; Waltz CF, 2005, MEASUREMENT NURSING, V4th, DOI DOI 10.1891/9780826170620; Ware J, 2002, USERS MANUAL SF 12V2, DOI DOI 10.1038/nrendo.2016.14; Wu SFV, 2008, INT J NURS STUD, V45, P534, DOI 10.1016/j.ijnurstu.2006.08.020; Xie BQ, 2011, J CHIN PLA NURS, V28, P3; Zhang FX, 2009, NURS, V16, P15	33	8	10	3	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 22	2015	10	5							e0127403	10.1371/journal.pone.0127403	http://dx.doi.org/10.1371/journal.pone.0127403			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	CI7GR	26000708	Green Published, Green Submitted, gold			2023-01-03	WOS:000354931700057
J	Wilunda, C; Putoto, G; Dalla Riva, D; Manenti, F; Atzori, A; Calia, F; Assefa, T; Turri, B; Emmanuel, O; Straneo, M; Kisika, F; Tarmbulini, G				Wilunda, Calistus; Putoto, Giovanni; Dalla Riva, Donata; Manenti, Fabio; Atzori, Andrea; Calia, Federico; Assefa, Tigist; Turri, Bruno; Emmanuel, Onapa; Straneo, Manuela; Kisika, Firma; Tarmbulini, Giorgio			Assessing Coverage, Equity and Quality Gaps in Maternal and Neonatal Care in Sub-Saharan Africa: An Integrated Approach	PLOS ONE			English	Article							EMERGENCY OBSTETRIC CARE; NEWBORN HEALTH; CHILD HEALTH; INTERVENTIONS; AVAILABILITY; MORTALITY	Background Gaps in coverage, equity and quality of health services hinder the achievement of the Millennium Development Goals 4 and 5 in most countries of sub-Saharan Africa as well as in other high-burden countries, yet few studies attempt to assess all these dimensions as part of the situation analysis. We present the base-line data of a project aimed at simultaneously addressing coverage, equity and quality issues in maternal and neonatal health care in five districts belonging to three African countries. Methods Data were collected in cross-sectional studies with three types of tools. Coverage was assessed in three hospitals and 19 health centres (HCs) utilising emergency obstetric and newborn care needs assessment tools developed by the Averting Maternal Death and Disability program. Emergency obstetrics care (EmOC) indicators were calculated. Equity was assessed in three hospitals and 13 HCs by means of proxy wealth indices and women delivering in health facilities were compared with those in the general population to identify inequities. Quality was assessed in three hospitals using the World Health Organization's maternal and neonatal quality of hospital care assessment tool which evaluates the whole range of aspects of obstetric and neonatal care and produces an average score for each main area of care. Results All the three hospitals qualified as comprehensive EmOC facilities but none of the HCs qualified for basic EmOC. None of the districts met the minimum requisites for EmOC indicators. In two out of three hospitals, there were major quality gaps which were generally greater in neonatal care, management of emergency and complicated cases and monitoring. Higher access to care was coupled by low quality and good quality by very low access. Stark inequities in utilisation of institutional delivery care were present in all districts and across all health facilities, especially at hospital level. Conclusion Our findings confirm the existence of serious issues regarding coverage, equity and quality of health care for mothers and newborns in all study districts. Gaps in one dimension hinder the potential gains in health outcomes deriving from good performances in other dimensions, thus confirm the need for a three-dimensional profiling of health care provision as a basis for data-driven planning.	[Wilunda, Calistus; Putoto, Giovanni; Dalla Riva, Donata; Manenti, Fabio; Atzori, Andrea] Doctors Africa CUAMM, Projects Dept, Padua, Italy; [Wilunda, Calistus] Kyoto Univ, Grad Sch Med & Publ Hlth, Dept Pharmacoepidemiol, Kyoto, Japan; [Calia, Federico] Doctors Africa CUAMM, Wolisso, Ethiopia; [Assefa, Tigist] WolissoHospital, Wolisso, Ethiopia; [Turri, Bruno] Doctors Africa CUAMM, Aber, Uganda; [Emmanuel, Onapa] Aber Hosp, Aber, Uganda; [Straneo, Manuela] Doctors Africa CUAMM, Iringa, Tanzania; [Kisika, Firma] Minist Hlth & Social Welf, Iringa, Tanzania; [Tarmbulini, Giorgio] European Sch Maternal Newborn Child & Adolescent, Trieste, Italy; [Tarmbulini, Giorgio] Ctr Salute Bambino, Trieste, Italy	Kyoto University	Wilunda, C (corresponding author), Doctors Africa CUAMM, Projects Dept, Padua, Italy.	calistuswilunda@yahoo.co.uk	Putoto, Giovanni/ABG-2069-2020	Wilunda, Calistus/0000-0002-6606-6534	Italian Banks Foundation; Cordaid	Italian Banks Foundation; Cordaid(CGIAR)	The project "mothers and children first" is funded by Italian Banks Foundation. The assessments were funded by Cordaid (https://www.cordaid.org/en/). The funding sources played no role in the study design, data collection and analysis, and preparation of the manuscript.	Averting Maternal Deaths and Disability, 2009, AMDD NEEDS ASSESSMEN; Bailey P, 2006, INT J GYNECOL OBSTET, V93, P285, DOI 10.1016/j.ijgo.2006.01.028; Barros AJD, 2012, LANCET, V379, P1225, DOI 10.1016/S0140-6736(12)60113-5; Central Statistical Agency [Ethiopia], 2012, ICF INTERNATIONAL ET; Commission on Social Determinants of Health, 2008, CLOSING THE GAP IN A; Countdown to 2015, MATERNAL NEWBORN AND; Dettrick Z, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083070; Dickson KE, 2014, LANCET, V384, P438, DOI 10.1016/S0140-6736(14)60582-1; Doctors with Africa CUAMM, 2008, STRENGTHENING AFRICA; Freedman LP, 2007, LANCET, V370, P1383, DOI 10.1016/S0140-6736(07)61581-5; Holmer H, 2015, BJOG-INT J OBSTET GY, V122, P183, DOI 10.1111/1471-0528.13230; Kerber KJ, 2007, LANCET, V370, P1358, DOI 10.1016/S0140-6736(07)61578-5; Lawn Joy, 2006, OPPORTUNITIES FOR AF; Lim SS, 2010, LANCET, V375, P2009, DOI 10.1016/S0140-6736(10)60744-1; Lozano R, 2011, LANCET, V378, P1139, DOI 10.1016/S0140-6736(11)61337-8; Ministry of Health and Social Welfare United Republic of Tanzania, 2008, THE NATIONAL ROAD MA; Ministry of Health Federal Democratic Republic of Ethiopia, 2006, NATIONAL REPRODUCTIV, DOI [10.1016/j.fertnstert.2014.09.002, DOI 10.1016/J.FERTNSTERT.2014.09.002]; Ministry of Health Republic of Uganda, 2007, ROADMAP FOR ACCELERA; Mphatswe W, 2012, B WORLD HEALTH ORGAN, V90, P176, DOI 10.2471/BLT.11.092759; Partnership for Maternal Newborn & Child Health, 2014, WHO A POLICY GUIDE F; Paxton A, 2006, INT J GYNECOL OBSTET, V93, P300, DOI 10.1016/j.ijgo.2006.01.030; Pitchforth E, 2007, HEALTH POLICY PLANN, V22, P311, DOI 10.1093/heapol/czm022; Ronsmans C, 2006, LANCET, V368, P1189, DOI 10.1016/S0140-6736(06)69380-X; Souza JP, 2013, LANCET, V381, P1747, DOI 10.1016/S0140-6736(13)60686-8; StataCorp, 2009, STATA SURVEY DATA RE; Tamburlini G, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078282; Tamburlini G, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028763; United Nations, 2010, GLOBAL STRATEGY FOR; van den Broek NR, 2009, BJOG-INT J OBSTET GY, V116, P18, DOI 10.1111/j.1471-0528.2009.02333.x; Victora CG, 2012, LANCET, V380, P1149, DOI 10.1016/S0140-6736(12)61427-5; Wang HD, 2014, LANCET, V384, P957, DOI 10.1016/S0140-6736(14)60497-9; WHO, 2009, MONITORING EMERGENCY; WHO Regional Office for Europe, 2009, MAKING PREGNANCY SAF; Wilunda C, 2013, INT J EQUITY HEALTH, V12, DOI 10.1186/1475-9276-12-27; World Health Organisation, 2007, STRENGTHENING HEALTH, DOI [10.1186/s12916-015-0309-4, DOI 10.1186/S12916-015-0309-4]	35	20	20	0	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 22	2015	10	5							e0127827	10.1371/journal.pone.0127827	http://dx.doi.org/10.1371/journal.pone.0127827			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CI7GR	26000964	Green Published, Green Submitted, gold			2023-01-03	WOS:000354931700088
J	Shaikh, H; Boudes, E; Khoja, Z; Shevell, M; Wintermark, P				Shaikh, Henna; Boudes, Elodie; Khoja, Zehra; Shevell, Michael; Wintermark, Pia			Angiogenesis Dysregulation in Term Asphyxiated Newborns Treated with Hypothermia	PLOS ONE			English	Article							ENDOTHELIAL GROWTH-FACTOR; FOCAL CEREBRAL-ISCHEMIA; HYPOXIA-INDUCIBLE FACTOR-1-ALPHA; DEVELOPING RAT-BRAIN; LARGE GENE LISTS; PERINATAL ASPHYXIA; NEONATAL ENCEPHALOPATHY; ENHANCES NEUROGENESIS; CEREBROSPINAL-FLUID; IGF-I	Background Neonatal encephalopathy following birth asphyxia is a major predictor of long-term neurological impairment. Therapeutic hypothermia is currently the standard of care to prevent brain injury in asphyxiated newborns but is not protective in all cases. More robust and versatile treatment options are needed. Angiogenesis is a demonstrated therapeutic target in adult stroke. However, no systematic study examines the expression of angiogenesis-related markers following birth asphyxia in human newborns. Objective This study aimed to evaluate the expression of angiogenesis-related protein markers in asphyxiated newborns developing and not developing brain injury compared to healthy control newborns. Design/Methods Twelve asphyxiated newborns treated with hypothermia were prospectively enrolled; six developed eventual brain injury and six did not. Four healthy control newborns were also included. We used Rules-Based Medicine multi-analyte profiling and protein array technologies to study the plasma concentration of 49 angiogenesis-related proteins. Mean protein concentrations were compared between each group of newborns. Results Compared to healthy newborns, asphyxiated newborns not developing brain injury showed up-regulation of pro-angiogenic proteins, including fatty acid binding protein-4, glucose-6-phosphate isomerase, neuropilin-1, and receptor tyrosine-protein kinase erbB-3; this up-regulation was not evident in asphyxiated newborns eventually developing brain injury. Also, asphyxiated newborns developing brain injury showed a decreased expression of anti-angiogenic proteins, including insulin-growth factor binding proteins -1, -4, and -6, compared to healthy newborns. Conclusions These findings suggest that angiogenesis pathways are dysregulated following birth asphyxia and are putatively involved in brain injury pathology and recovery.	[Shaikh, Henna; Boudes, Elodie; Khoja, Zehra; Wintermark, Pia] McGill Univ, Dept Pediat, Div Newborn Med, Montreal, PQ H3A 2T5, Canada; [Shevell, Michael] McGill Univ, Dept Neurol & Neurosurg, Montreal, PQ H3A 2T5, Canada	McGill University; McGill University	Wintermark, P (corresponding author), McGill Univ, Dept Pediat, Div Newborn Med, Montreal, PQ H3A 2T5, Canada.	pia.wintermark@bluemail.ch			Fonds de la Recherche en Sante Quebec (FRQS) Clinical Research Scholar Career Award Junior 1; NeuroDevNet Networks of Centres of Excellence (NCE) Cerebral Palsy Demonstration Project; Canadian Institutes of Health Research (CIHR) Operating Grant; New Investigator Research Grant from the SickKids Foundation; CIHR Institute of Human Development, Child and Youth Health (IHDCYH)	Fonds de la Recherche en Sante Quebec (FRQS) Clinical Research Scholar Career Award Junior 1; NeuroDevNet Networks of Centres of Excellence (NCE) Cerebral Palsy Demonstration Project; Canadian Institutes of Health Research (CIHR) Operating Grant(Canadian Institutes of Health Research (CIHR)); New Investigator Research Grant from the SickKids Foundation; CIHR Institute of Human Development, Child and Youth Health (IHDCYH)(Canadian Institutes of Health Research (CIHR))	Pia Wintermark received research grant funding from the Fonds de la Recherche en Sante Quebec (FRQS) Clinical Research Scholar Career Award Junior 1, NeuroDevNet Networks of Centres of Excellence (NCE) Cerebral Palsy Demonstration Project, Canadian Institutes of Health Research (CIHR) Operating Grant, and New Investigator Research Grant from the SickKids Foundation and the CIHR Institute of Human Development, Child and Youth Health (IHDCYH).	Abumiya T, 2005, BRAIN RES, V1049, P95, DOI 10.1016/j.brainres.2005.05.011; Aimes RT, 2003, THROMB HAEMOSTASIS, V89, P561, DOI 10.1055/s-0037-1613388; Aly H, 2009, BRAIN DEV-JPN, V31, P600, DOI 10.1016/j.braindev.2008.09.004; [Anonymous], 2014, Obstet Gynecol, V123, P896, DOI 10.1097/01.AOG.0000445580.65983.d2; Ara J, 2013, J NEUROCHEM, V124, P735, DOI 10.1111/jnc.12110; Azzopardi DV, 2009, NEW ENGL J MED, V361, P1349, DOI 10.1056/NEJMoa0900854; Bader M, 2009, ARTERIOSCL THROM VAS, V29, P617, DOI 10.1161/ATVBAHA.109.184549; Barkovich AJ, 1998, AM J NEURORADIOL, V19, P143; Beck H, 2002, J NEUROPATH EXP NEUR, V61, P339, DOI 10.1093/jnen/61.4.339; Bednarek N, 2012, PEDIATR RES, V71, P63, DOI 10.1038/pr.2011.3; Beresewicz M, 2010, INT J DEV NEUROSCI, V28, P91, DOI 10.1016/j.ijdevneu.2009.09.002; Boudes E, 2015, ARCH DIS CHILD FETAL; Carmeliet P, 2003, NAT MED, V9, P653, DOI 10.1038/nm0603-653; Clawson TF, 1999, BIOL SIGNAL RECEPT, V8, P281; Contois LW, 2012, J BIOL CHEM, V287, P1779, DOI 10.1074/jbc.M111.267732; Council on Children With Disabilities and Medical Home Implementation-Project Advisory Committee, 2014, PEDIATRICS, V133, pe1451, DOI DOI 10.1542/PEDS.2014-0724; Cunningham LA, 2005, GLIA, V50, P329, DOI 10.1002/glia.20169; Delafontaine P, 2004, ARTERIOSCL THROM VAS, V24, P435, DOI 10.1161/01.ATV.0000105902.89459.09; Dilenge ME, 2001, J CHILD NEUROL, V16, P781, DOI 10.1177/08830738010160110201; Doverhag C, 2010, NEUROBIOL DIS, V38, P36, DOI 10.1016/j.nbd.2009.12.024; Dragun P, 2008, J PHYSIOL PHARMACOL, V59, P441; Dzietko M, 2013, TRANSL STROKE RES, V4, P189, DOI 10.1007/s12975-012-0221-6; Ergenekon E, 2004, BRAIN DEV-JPN, V26, P283, DOI 10.1016/S0387-7604(03)00166-9; Feng YZ, 2008, PEDIATR RES, V64, P370, DOI 10.1203/PDR.0b013e318180ebe6; Gluckman PD, 2005, LANCET, V365, P663, DOI 10.1016/S0140-6736(05)17946-X; Graham EM, 2004, NEUROBIOL DIS, V17, P89, DOI 10.1016/j.nbd.2004.05.007; Gustafson K, 1999, PEDIATR RES, V45, P318, DOI 10.1203/00006450-199903000-00005; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Huang DW, 2009, NUCLEIC ACIDS RES, V37, P1, DOI 10.1093/nar/gkn923; Imam S S, 2009, Pak J Biol Sci, V12, P1498, DOI 10.3923/pjbs.2009.1498.1504; Jacobs SE, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003311.pub3; Jin KL, 2004, J CEREBR BLOOD F MET, V24, P399, DOI 10.1097/00004647-200404000-00005; Kimura R, 2005, STROKE, V36, P1259, DOI 10.1161/01.STR.0000165925.20413.14; Korhonen L, 1998, NEUROSCI LETT, V240, P151, DOI 10.1016/S0304-3940(97)00937-3; KRUPINSKI J, 1994, STROKE, V25, P1794, DOI 10.1161/01.STR.25.9.1794; Lee WH, 1996, J CEREBR BLOOD F MET, V16, P227, DOI 10.1097/00004647-199603000-00007; Li LH, 2008, BRAIN RES, V1197, P152, DOI 10.1016/j.brainres.2007.12.059; Li LH, 2008, ACTA NEUROPATHOL, V115, P297, DOI 10.1007/s00401-008-0339-5; Li L, 2007, BRAIN RES, V1180, P133, DOI 10.1016/j.brainres.2007.08.059; Liu F, 2013, CELL BIOCHEM BIOPHYS, V66, P389, DOI 10.1007/s12013-012-9478-3; Mu DZ, 2003, NEUROBIOL DIS, V14, P524, DOI 10.1016/j.nbd.2003.08.020; Muramatsu K, 1997, STROKE, V28, P2281, DOI 10.1161/01.STR.28.11.2281; Okazaki K, 2012, CYTOKINE, V60, P812, DOI 10.1016/j.cyto.2012.08.001; Oyagi A, 2011, NEUROSCIENCE, V185, P116, DOI 10.1016/j.neuroscience.2011.04.034; Rho SB, 2008, CARCINOGENESIS, V29, P2106, DOI 10.1093/carcin/bgn206; Rosenkranz K, 2012, CELL TISSUE RES, V348, P429, DOI 10.1007/s00441-012-1401-0; Satar M, 2004, BIOL NEONATE, V85, P15, DOI 10.1159/000074952; Savman K, 2013, TRANSL STROKE RES, V4, P228, DOI 10.1007/s12975-012-0216-3; Shankaran S, 2005, NEW ENGL J MED, V353, P1574, DOI 10.1056/NEJMcps050929; Sugiura S, 2005, STROKE, V36, P859, DOI 10.1161/01.STR.0000158905.22871.95; Sun YJ, 2003, J CLIN INVEST, V111, P1843, DOI 10.1172/JCI200317977; Sunagawa S, 2009, BRAIN DEV-JPN, V31, P588, DOI 10.1016/j.braindev.2008.09.001; Svedin P, 2007, J NEUROSCI, V27, P1511, DOI 10.1523/JNEUROSCI.4391-06.2007; Tagin MA, 2012, ARCH PEDIAT ADOL MED, V166, P558, DOI 10.1001/archpediatrics.2011.1772; Taguchi A, 2004, J CLIN INVEST, V114, P330, DOI 10.1172/jci200420622; Vasiljevic B, 2011, PEDIATR INT, V53, P454, DOI 10.1111/j.1442-200X.2010.03290.x; Wang L, 2004, STROKE, V35, P1732, DOI 10.1161/01.STR.0000132196.49028.a4; Wang Y, 2013, INT J NEUROSCI, V123, P191, DOI 10.3109/00207454.2012.744755; Wei Ling, 2005, Pathophysiology, V12, P47, DOI 10.1016/j.pathophys.2004.11.002; Xiong Y, 2010, CURR OPIN INVEST DR, V11, P298; Yenari MA, 2012, NAT REV NEUROSCI, V13, P267, DOI 10.1038/nrn3174; Zhang ZG, 2000, J CLIN INVEST, V106, P829, DOI 10.1172/JCI9369	62	6	6	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 21	2015	10	5							e0128028	10.1371/journal.pone.0128028	http://dx.doi.org/10.1371/journal.pone.0128028			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CK7VW	25996847	Green Published, Green Submitted, gold			2023-01-03	WOS:000356444000100
J	Yirdaw, KD; Hattingh, S				Yirdaw, Kesetebirhan Delele; Hattingh, Susan			Prevalence and Predictors of Immunological Failure among HIV Patients on HAART in Southern Ethiopia	PLOS ONE			English	Article							ANTIRETROVIRAL THERAPY; ADHERENCE; TUBERCULOSIS; CARE; SETTINGS; HIV/AIDS; CRITERIA	Immunological monitoring is part of the standard of care for patients on antiretroviral treatment. Yet, little is known about the routine implementation of immunological laboratory monitoring and utilization in clinical care in Ethiopia. This study assessed the pattern of immunological monitoring, immunological response, level of immunological treatment failure and factors related to it among patients on antiretroviral therapy in selected hospitals in southern Ethiopia. A retrospective longitudinal analytic study was conducted using documents of patients started on antiretroviral therapy. Adequacy of timely immunological monitoring was assessed every six months the first year and every one year thereafter. Immunological response was assessed every six months at cohort level. Immunological failure was based on the criteria: fall of follow-up CD4 cell count to baseline (or below), or CD4 levels persisting below 100 cells/mm(3), or 50% fall from on-treatment peak value. A total of 1,321 documents of patients reviewed revealed timely immunological monitoring were inadequate. There was adequate immunological response, with pediatric patients, females, those with less advanced illness (baseline WHO Stage I or II) and those with higher base-line CD4 cell count found to have better immunological recovery. Thirty-nine patients (3%) were not evaluated for immunological failure because they had frequent treatment interruption. Despite overall adequate immunological response at group level, the prevalence of those who ever experienced immunological failure was 17.6% (n=226), while after subsequent re-evaluation it dropped to 11.5%(n=147). Having WHO Stage III/IV of the disease or a higher CD4 cell count at baseline was identified as a risk for immunological failure. Few patients with confirmed failure were switched to second line therapy. These findings highlight the magnitude of the problem of immunological failure and the gap in management. Prioritizing care for high risk patients may help in effective utilization of meager resources.	[Yirdaw, Kesetebirhan Delele] Univ S Africa, Dept Hlth Studies, Addis Ababa, Ethiopia; [Hattingh, Susan] King Saud bin Abdulaziz Univ Hlth Sci, Coll Nursing Al Ahsa, Natl Guard Hlth Affairs, Dean Off, Riyadh, Eastern Region, Saudi Arabia	King Saud Bin Abdulaziz University for Health Sciences; King Abdulaziz Medical City - Riyadh; Ministry of National Guard - Health Affairs; National Guard Health Affairs - Saudi Arabia	Yirdaw, KD (corresponding author), Univ S Africa, Dept Hlth Studies, Addis Ababa, Ethiopia.	kcgp2005@yahoo.com						ALEMU A, 2010, DETERMINANTS OF SURV, V29, P3; Anude CJ, 2013, BMC INFECT DIS, V13, DOI 10.1186/1471-2334-13-113; Assefa A, 2014, BMC INFECT DIS, V14, DOI 10.1186/1471-2334-14-468; Assefa Y, 2011, BMC HEALTH SERV RES, V11, DOI 10.1186/1472-6963-11-81; Azmeraw Daniel, 2012, Ethiop Med J, V50, P115; Azzoni L, 2012, PLOS MED, V9, DOI 10.1371/journal.pmed.1001207; Bacha T, 2012, BMC INFECT DIS, V12, DOI 10.1186/1471-2334-12-197; Barnighausen T, 2011, LANCET INFECT DIS, V11, P942, DOI 10.1016/S1473-3099(11)70181-5; Belec L, 2011, FUTURE MICROBIOL, V6, P1251, DOI [10.2217/fmb.11.121, 10.2217/FMB.11.121]; Berhan Yifru, 2011, Ethiop Med J, V49, P199; Beyene KA, 2009, PHARMACOEPIDEM DR S, V18, P1007, DOI 10.1002/pds.1814; Central Statistical Agency, 2013, POPULATION PROJECTIO, P2007; Chalker JC, 2010, BMC HEALTH SERV RES, V10, DOI 10.1186/1472-6963-10-43; Chernick M, 2011, THE ESSENTIALS OF BI; Collet D., 2003, MODELLING SURVIVAL D; Crawford KW, 2015, HIV MED, V16, P95, DOI 10.1111/hiv.12177; Dagnew YW, 2009, FACTORS INFLUENCING; Department of Health and Human Services [USA], 2013, GUIDELINES FOR THE U; El-Khatib Z, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017518; Ethiopian Health and Nutrition Research Institute, 2012, HIV RELATED ESTIMATE; Federal HIV/AIDS Prevention and Control Office, 2014, COUNTRY PROGRESS REP; Federal HIV/AIDS Prevention and Control Office & Federal Ministry of Health, 2008, GUIDELINE FOR ANTIRE; Federal Ministry of Health, 2010, HEALTH MANAGEMENT IN; Federal Ministry of Health, 2013, TECHNICAL UPDATES ON; Giday Araya, 2010, Ethiop Med J, V48, P187; Hosmer D., 2008, APPLIED SURVIVAL ANA; Jaka H, 2009, TANZANIA MEDICAL JOU, V24; Joint United Nations Programme on HIV/AIDS (UNAIDS), 2013, GLOBAL REPORT UNAIDS; Kassa D, 2013, AIDS RES THER, V10, DOI 10.1186/1742-6405-10-18; Kebede A, 2012, N AM J MED SCI, V4, P67, DOI 10.4103/1947-2714.93376; Keiser O, 2010, TROP MED INT HEALTH, V15, P251, DOI 10.1111/j.1365-3156.2009.02445.x; Keiser O, 2009, TROP MED INT HEALTH, V14, P1220, DOI 10.1111/j.1365-3156.2009.02338.x; Machin D., 2006, SURVIVAL ANALYSIS A; Mulu A, 2014, BMC INFECT DIS, V14, DOI 10.1186/1471-2334-14-28; Palchaudhuri S, 2014, MALAWI MED J, V26, P42; Palladino C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082718; Rawizza HE, 2011, CLIN INFECT DIS, V53, P1283, DOI 10.1093/cid/cir729; Reda AA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058595; Reynolds SJ, 2009, AIDS, V23, P697, DOI 10.1097/QAD.0b013e3283262a78; Tiyou A, 2010, AIDS RES THER, V7, DOI 10.1186/1742-6405-7-39; Tsegaye E, 2011, ETHIOP J HEALTH DEV, V25, P102; Turner BJ, 2002, J INFECT DIS, V185, pS143, DOI 10.1086/340197; Were MC, 2011, J AM MED INFORM ASSN, V18, P150, DOI 10.1136/jamia.2010.005520; WHO, 2013, CONSOLIDATED GUIDELI; Workneh N., 2009, ETHIOP J HEALTH SCI, V19, DOI DOI 10.4314/EJHS.V19I2.69419; World Health Organisation, 2003, ADHERENCE TO LONG TE; World Health Organisation, 2010, ANTIRETROVIRAL THERA; Zachariah R, 2011, TROP MED INT HEALTH, V16, P37, DOI 10.1111/j.1365-3156.2010.02669.x	48	28	28	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 11	2015	10	5							e0125826	10.1371/journal.pone.0125826	http://dx.doi.org/10.1371/journal.pone.0125826			21	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CI1YY	25961732	gold, Green Submitted, Green Published			2023-01-03	WOS:000354542500047
J	Chen, HG; Zhou, X; Zhao, Y; Gong, XJ; He, Y; Ma, FW; Zhou, M; Zhao, C; Niu, Y; Deng, J				Chen, Huaguo; Zhou, Xin; Zhao, Yang; Gong, Xiao-Jian; He, Yan; Ma, Feng-Wei; Zhou, Mei; Zhao, Chao; Niu, Yi; Deng, Jie			HPLC-DAD-ELSD Combined Pharmacodynamics and Serum Medicinal Chemistry for Quality Assessment of Huangqi Granule	PLOS ONE			English	Article							PERFORMANCE LIQUID-CHROMATOGRAPHY; RADIX-ASTRAGALI; PHOTODIODE-ARRAY; IN-VIVO; IV; ISOFLAVONOIDS; RATS; SAPONINS; EXTRACTION; EXPRESSION	Objective To more scientifically and reasonably control the quality of Huangqi Granules, preliminary studies on the pharmacodynamics and serum pharmacochemistry of this medicine were performed. DPPH and MTT experiments showed that water extracts of Huangqi Granules had good antioxidant activity and increased immunity. Timed blood samples collected 5 min, 15 min, and 30 min after oral administration of a set amount of Huangqi Granules were collected and tested using UPLC-ESI-MS/MS. As a result, calycosin-7-O-beta-D-glucoside, ononin, calycosin, astragaloside IV, and formononetin were found to exist in rat blood after dosing, indicating that the five chemical compounds might have pharmacological activity, and based on this result, they were designated biomarkers for quality control of Huangqi Granules. Consequently, a simple, rapid and efficient method was developed in the present study for the simultaneous determination of the five characteristic compounds in Huangqi Granules using HPLC-DAD-ELSD. Materials and Methods The separation was performed using an Agilent Hypersil ODS column (4.6 x 250 mm, 5 mu m) at 30 degrees C. The mobile phase was composed of water (solvent A) and acetonitrile (solvent B) with a flow rate of 1 mL/min. The drift tube temperature of the ELSD system was set to 85 degrees C, and the nitrogen pressure was 3.5 bar. Results All five characteristic compounds had good linear behavior with r2 values greater than 0.9972. The recoveries varied from 96.31% to 101.22%. Subsequently, the developed method was applied to evaluate the quality of Huangqi Granules from different batches, and hierarchical clustering analysis (HCA) was used to analyze the classification of the samples based on the values of the five compounds. Conclusion The established HPLC method combined with HCA proved to be effective to evaluate the quality of Huangqi Granules.	[Chen, Huaguo; Zhou, Xin; Zhao, Yang; Gong, Xiao-Jian; He, Yan; Ma, Feng-Wei; Zhou, Mei; Zhao, Chao] Guizhou Engn Lab Qual Control & Evaluat Technol M, Guiyang, Guizhou, Peoples R China; [Chen, Huaguo; Zhou, Xin; Zhao, Yang; Gong, Xiao-Jian; He, Yan; Ma, Feng-Wei; Zhou, Mei; Zhao, Chao] Guizhou Normal Univ, Res Ctr Qual Control Nat Med, Guiyang, Guizhou, Peoples R China; [Chen, Huaguo; Zhou, Xin; Zhao, Yang; Gong, Xiao-Jian; He, Yan; Ma, Feng-Wei; Zhou, Mei; Zhao, Chao] Guizhou Normal Univ, Key Lab Informat Syst Mountainous Areas & Protect, Guiyang, Guizhou, Peoples R China; [Niu, Yi; Deng, Jie] Han Fang Pharmaceut Co Ltd Guizhou Prov, Guiyang, Guizhou, Peoples R China	Guizhou Normal University; Guizhou Normal University	Zhou, X (corresponding author), Guizhou Engn Lab Qual Control & Evaluat Technol M, Guiyang, Guizhou, Peoples R China.	642452984@qq.com			Natural Science Research Project from the Department of Education of the Guizhou Province [2011 026]; Science and Technology Plan Projects of Guiyang [2011 204-24]; Guizhou Provincial Special Program on Research and Development of Science and Technology Industry on Modernization of TCMs [ZY 2011 3013, KY 2012 005, 2011040]	Natural Science Research Project from the Department of Education of the Guizhou Province; Science and Technology Plan Projects of Guiyang; Guizhou Provincial Special Program on Research and Development of Science and Technology Industry on Modernization of TCMs	Natural Science Research Project from the Department of Education of the Guizhou Province (No. 2011 026), Science and Technology Plan Projects of Guiyang (No. 2011 204-24), Guizhou Provincial Special Program on Research and Development of Science and Technology Industry on Modernization of TCMs (No. ZY 2011 3013) were used to fund study design and manuscript preparation, project (No. KY 2012 005) was used for data collection and project (No. 2011040) provided funds for sample analysis.	Bahorun T, 2004, J SCI FOOD AGR, V84, P1553, DOI 10.1002/jsfa.1820; Committee NP, 2010, PHARMACOPOEIA PEOPLE; Deschamps FS, 2002, ANALYST, V127, P35, DOI 10.1039/b108810f; Gui SY, 2006, J ETHNOPHARMACOL, V103, P154, DOI 10.1016/j.jep.2005.07.025; GUIOCHON G, 1988, J LIQ CHROMATOGR, V11, P2547, DOI 10.1080/01483918808076746; Huang XL, 2009, TALANTA, V78, P1129, DOI 10.1016/j.talanta.2009.01.029; Juan YC, 2011, EVID-BASED COMPL ALT, V2011, DOI DOI 10.1155/2011/349807; Li ZP, 2002, ACTA PHARMACOL SIN, V23, P898; Liang XR, 2013, PHARMACOGN MAG, V9, P238, DOI 10.4103/0973-1296.113277; Lin YW, 2008, PROCESS BIOCHEM, V43, P244, DOI 10.1016/j.procbio.2007.11.020; Liu RR, 2006, PLANT CELL REP, V25, P705, DOI 10.1007/s00299-005-0072-7; Luo YM, 2004, NEUROSCI LETT, V363, P218, DOI 10.1016/j.neulet.2004.03.036; Ouyang Z, 2012, PHARMACOGN MAG, V8, P256, DOI 10.4103/0973-1296.103648; Qi LW, 2006, J CHROMATOGR A, V1134, P162, DOI 10.1016/j.chroma.2006.08.085; Sinclair S, 1998, Altern Med Rev, V3, P338; Song JZ, 2008, J PHARMACEUT BIOMED, V47, P399, DOI 10.1016/j.jpba.2007.12.036; Song JZ, 2007, J SEP SCI, V30, P819, DOI 10.1002/jssc.200600340; Wang D, 2006, J SEP SCI, V29, P2012, DOI 10.1002/jssc.200500486; Wang SG, 2009, BIOL PHARM BULL, V32, P132, DOI 10.1248/bpb.32.132; Wu T, 2005, FITOTERAPIA, V76, P157, DOI 10.1016/j.fitote.2004.11.006; Xiao HB, 2004, J CHROMATOGR A, V1032, P117, DOI 10.1016/j.chroma.2003.09.032; Yong-Chun J., 2012, PHARMACOGN MAG, V8, P42; Yu JX, 2006, CAN J PHYSIOL PHARM, V84, P579, DOI 10.1139/Y06-015; Yu QT, 2007, J SEP SCI, V30, P1292, DOI 10.1002/jssc.200600422; Zhang WD, 2006, PLANTA MED, V72, P4, DOI 10.1055/s-2005-873126; Zhang WJ, 2003, THROMB HAEMOSTASIS, V90, P904, DOI 10.1160/TH03-03-0136	26	41	46	1	57	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 27	2015	10	4							e0123176	10.1371/journal.pone.0123176	http://dx.doi.org/10.1371/journal.pone.0123176			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CG9SB	25915040	Green Published, gold, Green Submitted			2023-01-03	WOS:000353659100014
J	Mougin, B; Tian, RBD; Drancourt, M				Mougin, Benjamin; Tian, Roger B. D.; Drancourt, Michel			Tropical Plant Extracts Modulating the Growth of Mycobacterium ulcerans	PLOS ONE			English	Article							BURULI ULCER; ENVIRONMENT; DISEASE; FLUORESCENCE; TUBERCULOSIS; MYCOLACTONE; INFECTION; EVOLUTION; CAMEROON; CULTURE	Mycobacterium ulcerans, the etiologic agent of Buruli ulcer, has been detected on aquatic plants in endemic tropical regions. Here, we tested the effect of several tropical plant extracts on the growth of M. ulcerans and the closely related Mycobacterium marinum. M. ulcerans and M. marinum were inoculated on Middlebrook 7H11 medium with and without extracts from tropical aquatic plants, including Ammannia gracilis, Crinum calamistratum, Echinodorus africanus, Vallisneria nana and Vallisneria torta. Delay of detection of the first colony and the number of colonies at day 7 (M. marinum) or day 16 (M. ulcerans) were used as endpoints. The first M. ulcerans colonies were detected at 8 +/- 0 days on control Middlebrook 7H11 medium, 6.34 +/- 0.75 days on A. gracilis-enriched medium (p<0.01), 6 +/- 1 days on E. africanus- and V. torta-enriched media (p<0.01), 6 +/- 0 days on V. nana-enriched medium (p<0.01) and 5.67 +/- 0.47 days on C. calamistratum-enriched medium (p<0.01). Furthermore, the number of detected colonies was significantly increased in C. calamistratum-and E. africanus-enriched media at each time point compared to Middlebrook 7H11 (p<0.05). V. nana- and V. torta-enriched media significantly increased the number of detected colonies starting from day 6 and day 10, respectively (p<0.001). At the opposite, A. gracilis-enriched medium significantly decreased the number of detected colonies starting from day 8 PI (p<0.05). In conclusion, some aquatic plant extracts, could be added as adjuvants to the Middlebrook 7H11 medium for the culturing of M. marinum and M. ulcerans.	[Mougin, Benjamin; Tian, Roger B. D.; Drancourt, Michel] Aix Marseille Univ, Inserm 1095, IRD 198, URMITE,UMR CNRS 7278, Marseille, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Aix-Marseille Universite; Institut National de la Sante et de la Recherche Medicale (Inserm); Institut de Recherche pour le Developpement (IRD)	Drancourt, M (corresponding author), Aix Marseille Univ, Inserm 1095, IRD 198, URMITE,UMR CNRS 7278, Marseille, France.	michel.drancourt@univ-amu.fr						Adekambi T, 2003, J CLIN MICROBIOL, V41, P5699, DOI 10.1128/JCM.41.12.5699-5708.2003; [Anonymous], 2008, Wkly Epidemiol Rec, V83, P145; Bouricha M, 2014, INT J INFECT DIS, V21, P17, DOI 10.1016/j.ijid.2013.11.020; Bratschi MW, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0002756; CLARK HF, 1963, J BACTERIOL, V86, P1057, DOI 10.1128/JB.86.5.1057-1069.1963; Dailloux M, 1999, WATER RES, V33, P2219, DOI 10.1016/S0043-1354(98)00466-7; El Khechine A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024720; FRICKER MD, 1992, J MICROSC-OXFORD, V166, P29, DOI 10.1111/j.1365-2818.1992.tb01505.x; Fyfe JAM, 2007, APPL ENVIRON MICROB, V73, P4733, DOI 10.1128/AEM.02971-06; George KM, 1999, SCIENCE, V283, P854, DOI 10.1126/science.283.5403.854; Ghodbane R, 2014, SCI REP-UK, V4, DOI 10.1038/srep04236; Kaser M, 2007, BMC EVOL BIOL, V7, DOI 10.1186/1471-2148-7-177; Kenu E, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0003279; LANG M, 1991, RADIAT ENVIRON BIOPH, V30, P333, DOI 10.1007/BF01210517; Marion E, 2011, EMERG INFECT DIS, V17, P551, DOI 10.3201/eid1703.091859; Marsollier L, 2004, APPL ENVIRON MICROB, V70, P1097, DOI 10.1128/AEM.70.2.1097-1103.2004; Merritt RW, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000911; Nakanaga K, 2011, J CLIN MICROBIOL, V49, P3829, DOI 10.1128/JCM.00783-11; Noeske J, 2004, AM J TROP MED HYG, V70, P520, DOI 10.4269/ajtmh.2004.70.520; Patino S, 2008, J CLIN MICROBIOL, V46, P3296, DOI [10.1128/JCM.02183-08, 10.1128/JCM.02183-07]; Petrini B, 2006, Eur J Clin Microbiol Infect Dis, V25, P609, DOI 10.1007/s10096-006-0201-4; Portaels F, 2008, PLOS NEGLECT TROP D, V2, DOI 10.1371/journal.pntd.0000178; Qi WH, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000580; Williamson HR, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001506; World Health Organization, 2013, BUR ULC; YENTSCH CS, 1963, DEEP-SEA RES, V10, P221, DOI 10.1016/0011-7471(63)90358-9; Yip MJ, 2007, J BACTERIOL, V189, P2021, DOI 10.1128/JB.01442-06	27	4	4	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 23	2015	10	4							e0124626	10.1371/journal.pone.0124626	http://dx.doi.org/10.1371/journal.pone.0124626			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CG5KZ	25905816	Green Published, gold, Green Submitted			2023-01-03	WOS:000353332000080
J	Cesano, A; Willman, CL; Kopecky, KJ; Gayko, U; Putta, S; Louie, B; Wesdall, M; Purvis, N; Spellmeyer, DC; Marimpietri, C; Cohen, AC; Hackett, J; Shi, J; Walker, MG; Sun, ZX; Paietta, E; Tallman, MS; Cripe, LD; Atwater, S; Appelbaum, FR; Radich, JP				Cesano, Alessandra; Willman, Cheryl L.; Kopecky, Kenneth J.; Gayko, Urte; Putta, Santosh; Louie, Brent; Wesdall, Matt; Purvis, Norman; Spellmeyer, David C.; Marimpietri, Carol; Cohen, Aileen C.; Hackett, James; Shi, Jing; Walker, Michael G.; Sun, Zhuoxin; Paietta, Elisabeth; Tallman, Martin S.; Cripe, Larry D.; Atwater, Susan; Appelbaum, Frederick R.; Radich, Jerald P.			Cell Signaling-Based Classifier Predicts Response to Induction Therapy in Elderly Patients with Acute Myeloid Leukemia	PLOS ONE			English	Article							OLDER PATIENTS; EARLY DEATH; DAUNORUBICIN; TRIAL; CHEMOTHERAPY; MITOXANTRONE; CYTARABINE; ADULTS; AML	Single-cell network profiling (SCNP) data generated from multi-parametric flow cytometry analysis of bone marrow (BM) and peripheral blood (PB) samples collected from patients >55 years old with non-M3 AML were used to train and validate a diagnostic classifier (DXSCNP) for predicting response to standard induction chemotherapy (complete response [CR] or CR with incomplete hematologic recovery [CRi] versus resistant disease [RD]). SCNP-evaluable patients from four SWOG AML trials were randomized between Training (N = 74 patients with CR, CRi or RD; BM set = 43; PB set = 57) and Validation Analysis Sets (N = 71; BM set = 42, PB set = 53). Cell survival, differentiation, and apoptosis pathway signaling were used as potential inputs for DXSCNP. Five DXSCNP classifiers were developed on the SWOG Training set and tested for prediction accuracy in an independent BM verification sample set (N = 24) from ECOG AML trials to select the final classifier, which was a significant predictor of CR/CRi (area under the receiver operating characteristic curve AUROC = 0.76, p = 0.01). The selected classifier was then validated in the SWOG BM Validation Set (AUROC = 0.72, p = 0.02). Importantly, a classifier developed using only clinical and molecular inputs from the same sample set (DXCLINICAL2) lacked prediction accuracy: AUROC = 0.61 (p = 0.18) in the BM Verification Set and 0.53 (p = 0.38) in the BM Validation Set. Notably, the DXSCNP classifier was still significant in predicting response in the BM Validation Analysis Set after controlling for DXCLINICAL2 (p = 0.03), showing that DXSCNP provides information that is independent from that provided by currently used prognostic markers. Taken together, these data show that the proteomic classifier may provide prognostic information relevant to treatment planning beyond genetic mutations and traditional prognostic factors in elderly AML.	[Cesano, Alessandra; Gayko, Urte; Putta, Santosh; Louie, Brent; Wesdall, Matt; Purvis, Norman; Spellmeyer, David C.; Marimpietri, Carol; Cohen, Aileen C.; Hackett, James; Shi, Jing; Walker, Michael G.] Nodality Inc, San Francisco, CA 94080 USA; [Willman, Cheryl L.] Univ New Mexico, Ctr Canc, Albuquerque, NM 87131 USA; [Kopecky, Kenneth J.] Fred Hutchinson Canc Res Ctr, SWOG Stat Ctr, Seattle, WA 98104 USA; [Sun, Zhuoxin] Frontier Sci, ECOG Coordinating Ctr, Boston, MA USA; [Paietta, Elisabeth] Montefiore Med Ctr, North Div, Bronx, NY 10467 USA; [Tallman, Martin S.] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA; [Cripe, Larry D.] Indiana Univ, Simon Canc Ctr, Indianapolis, IN 46204 USA; [Atwater, Susan] Stanford Univ, Palo Alto, CA 94304 USA; [Appelbaum, Frederick R.; Radich, Jerald P.] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA	University of New Mexico; Fred Hutchinson Cancer Center; Southwest Oncology Group; Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine; Memorial Sloan Kettering Cancer Center; Indiana University System; Indiana University-Purdue University Indianapolis; Stanford University; Fred Hutchinson Cancer Center	Putta, S (corresponding author), Nodality Inc, San Francisco, CA 94080 USA.	sputta@nodality.com			Nodality; NIH grants: National Cancer Institute, DHHS [CA32102, CA38926, CA12213, CA20319, CA14958, CA49883, CA17145, CA21115]; NATIONAL CANCER INSTITUTE [U10CA180820, U10CA180828, U10CA021115, U10CA012213, U10CA032102, U10CA038926, U10CA049883, U10CA180888, U10CA017145, P01CA018029, U10CA020319, U10CA014958, U24CA114737, U24CA196172, U10CA180791, U10CA180794] Funding Source: NIH RePORTER	Nodality; NIH grants: National Cancer Institute, DHHS; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This study was funded by Nodality. and employees of Nodality played a role in design, data collection and analysis, decision to publish, or preparation of the manuscript. Authors SP, DS, BL are employees and shareholders of Nodality Inc. AC, UG, CW were employees of Nodality at the time of conduct of the this study. The specific roles of these authors are articulated in the 'author contributions' section. The authors acknowledge the following NIH grants: PHS Cooperative Agreement grant numbers awarded by the National Cancer Institute, DHHS: CA32102, CA38926, CA12213, CA20319, CA14958, CA49883, CA17145 and CA21115.	Anderson JE, 2002, BLOOD, V100, P3869, DOI 10.1182/blood-2001-12-0354; Breiman L., 2001, Machine Learning, V45, P5, DOI 10.1023/A:1010933404324; Buchner T, 1999, BLOOD, V93, P4116; Buchner T, 2009, J CLIN ONCOL, V27, P61, DOI 10.1200/JCO.2007.15.4245; Cesano A, 2011, BLOOD, V118; Cesano A, 2010, ASH ANN M, V116, P4843; Cesano A, 2013, HAEMATOLOGICA, V98, P626, DOI 10.3324/haematol.2012.071910; Cesano A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056714; Cesano A, 2012, CYTOM PART B-CLIN CY, V82B, P158, DOI 10.1002/cyto.b.21007; Chauncey TR, 2010, BRIT J HAEMATOL, V148, P48, DOI 10.1111/j.1365-2141.2009.07919.x; Cheson BD, 2003, J CLIN ONCOL, V21, P4642, DOI 10.1200/JCO.2003.04.036; Cripe LD, 2010, BLOOD, V116, P4077, DOI 10.1182/blood-2010-04-277269; Estey E, 2006, LANCET, V368, P1894, DOI 10.1016/S0140-6736(06)69780-8; FIRTH D, 1993, BIOMETRIKA, V80, P27, DOI 10.2307/2336755; Godwin JE, 1998, BLOOD, V91, P3607, DOI 10.1182/blood.V91.10.3607.3607_3607_3615; Goeman JJ, 2010, BIOMETRICAL J, V52, P70, DOI 10.1002/bimj.200900028; Grimwade D, 2001, BLOOD, V98, P1312, DOI 10.1182/blood.V98.5.1312; Harrell Frank E., 2001, REGRESSION MODELING; Hollander MaW, 1999, NONPARAMETRIC STAT M; Kornblau SM, 2010, CLIN CANCER RES, V16, P3721, DOI 10.1158/1078-0432.CCR-10-0093; Krug U, 2010, LANCET, V376, P2000, DOI 10.1016/S0140-6736(10)62105-8; Lacayo NJ, 2013, BRIT J HAEMATOL, V162, P250, DOI 10.1111/bjh.12370; Lacayo NJ, 2011, BLOOD, V118, P1512, DOI 10.1182/blood.V118.21.3544.3544; Law A, 2002, R NEWS; Lee JA, 2008, CYTOM PART A, V73A, P926, DOI 10.1002/cyto.a.20623; Lowenberg B, 2009, NEW ENGL J MED, V361, P1235, DOI 10.1056/NEJMoa0901409; MASON SJ, 2002, Q J ROY METEOR SOC, V128, P21; Obuchowski NA, 1998, ACAD RADIOL, V5, P561, DOI 10.1016/S1076-6332(98)80208-0; Pepe M.S., 2003, OXFORD STAT SCI SERI; POCOCK SJ, 1975, BIOMETRICS, V31, P103, DOI 10.2307/2529712; Rosen DB, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013543; Rowe JM, 2004, BLOOD, V103, P479, DOI 10.1182/blood-2003-05-1686; Vo TT, 2012, CELL, V151, P344, DOI 10.1016/j.cell.2012.08.038; Walter RB, 2011, J CLIN ONCOL, V29, P4417, DOI 10.1200/JCO.2011.35.7525; Walter RB, 2010, BLOOD, V116, P2420, DOI 10.1182/blood-2010-05-285387	35	5	6	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 17	2015	10	4							e0118485	10.1371/journal.pone.0118485	http://dx.doi.org/10.1371/journal.pone.0118485			23	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CG1EX	25884949	Green Submitted, gold, Green Published			2023-01-03	WOS:000353017000002
J	Kessel, L; Larsen, M				Kessel, Line; Larsen, Michael			Action Spectrum for Photobleaching of Human Lenses by Short Wavelength Visible Irradiation	PLOS ONE			English	Article							CATARACT-SURGERY; OCULAR MEDIA; PROTEINS; AGE; GLYCATION; UV; PHOTOOXIDATION; ARGPYRIMIDINE; TRANSMISSION; CHROMOPHORES	Purpose Cataract is the world-leading cause of blindness. In search for a new treatment of cataract we have found that the yellow discolouration of aged human lenses can be photobleached using a non-invasive, infra-red, femtosecond laser treatment. These results were presented in an earlier PlosOne publication. The objective of the study was to characterize the single-photon photobleaching action spectrum of the aged human lens in vitro. Methods Ninety-one human donor lenses were irradiated with continuous wave laser light at 375, 405, 420, 445, 457 or 473 nm. Photobleaching was monitored by photography and transmission measurements. Results The action spectrum peaked at 420 nm followed by, in order of decreasing effect, 445, 457, 473, 405 and 375 nm. Younger and less absorbent lenses showed smaller changes than older and more absorbent lenses. There was a dose-dependent increase in lens transmission with increasing laser irradiation. Conclusions For a 75 year old lens an effect corresponding to elimination of 15 years or more of optical ageing was obtained. This study of the spectral characteristics and intensity needed to bleach the human lens with single-photon laser effects found an action-spectrum peak at 420 nm tailing gradually off toward longer wavelengths and more steeply toward shorter wavelengths. The results may be used to guide experiments with two-photon bleaching.	[Kessel, Line; Larsen, Michael] Glostrup Cty Hosp, Dept Ophthalmol, Glostrup, Denmark; [Larsen, Michael] Univ Copenhagen, Dept Clin Med, Fac Hlth Sci, Copenhagen, Denmark	University of Copenhagen; University of Copenhagen	Kessel, L (corresponding author), Glostrup Cty Hosp, Dept Ophthalmol, Glostrup, Denmark.	line.kessel@dadlnet.dk	Larsen, Michael/E-9620-2010	Larsen, Michael/0000-0002-5172-5891; Kessel, Line/0000-0002-9375-1510	Danish Medical Research Council (Det Frie Forskningsrad); National Danish Advanced Science Foundation; CIP (Competitiveness and Innovation framework programme) [621088]; Foundation of June 15 (15. Juni Fonden)	Danish Medical Research Council (Det Frie Forskningsrad); National Danish Advanced Science Foundation; CIP (Competitiveness and Innovation framework programme); Foundation of June 15 (15. Juni Fonden)	The study received financial support from the Danish Medical Research Council (Det Frie Forskningsrad), the National Danish Advanced Science Foundation, CIP (Competitiveness and Innovation framework programme 2007-2013) grant number 621088 and the Foundation of June 15 (15. Juni Fonden). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Algvere PV, 2006, ACTA OPHTHALMOL SCAN, V84, P4, DOI 10.1111/j.1600-0420.2005.00627.x; ANDLEY UP, 1994, INVEST OPHTH VIS SCI, V35, P367; Balasubramanian D, 2005, PHOTOCHEM PHOTOBIOL, V81, P498, DOI 10.1562/2004-11-01-RA-354.1; Barbazetto IA, 2004, EXP EYE RES, V78, P917, DOI 10.1016/j.exer.2004.01.003; Bloemendal H, 2004, PROG BIOPHYS MOL BIO, V86, P407, DOI 10.1016/j.pbiomolbio.2003.11.012; Bockelbrink A, 2008, SURV OPHTHALMOL, V53, P359, DOI 10.1016/j.survophthal.2008.04.001; BOETTNER EA, 1962, INVEST OPHTH VISUAL, V1, P776; Davies MJ, 2001, J PHOTOCH PHOTOBIO B, V63, P114, DOI 10.1016/S1011-1344(01)00208-1; FOSTER A, 1991, LANCET, V337, P1267, DOI 10.1016/0140-6736(91)92929-V; GORGELS TGMF, 1995, INVEST OPHTH VIS SCI, V36, P851; He L, 2010, CURR OPIN OPHTHALMOL; Holm Thomas, 2015, BMC Res Notes, V8, P5, DOI 10.1186/s13104-015-0977-3; JACQUES SL, 1992, SURG CLIN N AM, V72, P531; Kessel L, 2005, ACTA OPHTHALMOL SCAN, V83, P221, DOI 10.1111/j.1600-0420.2005.00388.x; Kessel L, 2011, ACTA OPHTHALMOL, V89, pe289, DOI 10.1111/j.1755-3768.2009.01839.x; Kessel L, 2010, J CATARACT REFR SURG, V36, P308, DOI 10.1016/j.jcrs.2009.08.035; Kessel L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009711; McNulty R, 2004, J PHYSIOL-LONDON, V559, P883, DOI 10.1113/jphysiol.2004.068619; MONNIER VM, 1981, SCIENCE, V211, P491, DOI 10.1126/science.6779377; Oriowo OM, 2001, INVEST OPHTH VIS SCI, V42, P2596; Ortwerth BJ, 1997, PHOTOCHEM PHOTOBIOL, V65, P666, DOI 10.1111/j.1751-1097.1997.tb01909.x; Ortwerth BJ, 2002, EXP EYE RES, V74, P217, DOI 10.1006/exer.2001.1114; Padayatti PS, 2001, INVEST OPHTH VIS SCI, V42, P1299; PIRIE A, 1971, BIOCHEM J, V125, P203, DOI 10.1042/bj1250203; Ponce A, 2006, MOL VIS, V12, P879; Regini JW, 2004, J MOL BIOL, V336, P1185, DOI 10.1016/S0022-2836(03)00814-3; Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844; Roberts JE, 2001, PHOTOCHEM PHOTOBIOL, V74, P740, DOI 10.1562/0031-8655(2001)074<0740:POLPWX>2.0.CO;2; Tuulonen A, 2009, ACTA OPHTHALMOL; Ulrich P, 2001, RECENT PROG HORM RES, V56, P1, DOI 10.1210/rp.56.1.1; van de Kraats J, 2007, J OPT SOC AM A, V24, P1842, DOI 10.1364/JOSAA.24.001842; Vogel A, 2005, APPL PHYS B-LASERS O, V81, P1015, DOI 10.1007/s00340-005-2036-6; WEALE RA, 1988, J PHYSIOL-LONDON, V395, P577, DOI 10.1113/jphysiol.1988.sp016935	33	0	0	0	18	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 17	2015	10	4							e0123732	10.1371/journal.pone.0123732	http://dx.doi.org/10.1371/journal.pone.0123732			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CG1EX	25884924	gold, Green Published, Green Submitted			2023-01-03	WOS:000353017000081
J	Martinez-Ramirez, D; Giugni, JC; Little, CS; Chapman, JP; Ahmed, B; Monari, E; Shukla, AW; Hess, CW; Okun, MS				Martinez-Ramirez, Daniel; Giugni, Juan C.; Little, Christopher S.; Chapman, John P.; Ahmed, Bilal; Monari, Erin; Shukla, Aparna Wagle; Hess, Christopher W.; Okun, Michael S.			Missing Dosages and Neuroleptic Usage May Prolong Length of Stay in Hospitalized Parkinson's Disease Patients	PLOS ONE			English	Article							MEDICATION; ADMISSIONS; OUTCOMES; MULTICENTER; ADHERENCE; PEOPLE; RISK	Background Parkinson's disease patients are more likely to be hospitalized, have higher rates of hospital complications, and have an increased risk of deterioration during hospitalization. Length of stay is an important underlying factor for these increased risks. We aimed to investigate potential medication errors that may occur during hospitalization and its impact on length of hospital stay. Methods A cross-sectional chart review of 339 consecutive hospital encounters from 212 PD subjects was performed. Medication errors were defined as wrong timing or omission of administration for dopaminergic drugs and administration of contraindicated dopamine blockers. An analysis of covariance was applied to examine whether these medication errors were related to increased length of hospital stays. Results A significant effect for dopaminergic administration (p<0.01) on length of hospital stay was observed. Subjects who had delayed administration or missed at least one dose stayed longer (M=8.2 days, SD=8.9 vs. M=3.6 days SD=3.4). Contraindicated dopamine blocking agents were administered in 23% (71/339) of cases, and this was also significantly related to an increased length of stay (M=8.2 days, SD=8.9 vs. M=3.6 days SD=3.4), p<0.05. Participants who received a contraindicated dopamine blocker stayed in the hospital longer (M=7.5 days, SD=9.1) compared to those who did not (M=5.9 days, SD=6.8). Neurologists were consulted in 24.5% of encounters. Specialty consultation had no effect on the medication related errors. Conclusions Missing dopaminergic dosages and administration of dopamine blockers occur frequently in hospitalized Parkinson's disease patients and this may impact length of stay. These potentially modifiable factors may reduce the risk of a longer stay related to hospitalization.	[Martinez-Ramirez, Daniel; Giugni, Juan C.; Little, Christopher S.; Chapman, John P.; Ahmed, Bilal; Monari, Erin; Shukla, Aparna Wagle; Hess, Christopher W.; Okun, Michael S.] Univ Florida, Coll Med, Dept Neurol, Ctr Movement Disorders & Neurorestorat, Gainesville, FL USA; [Okun, Michael S.] Univ Florida, Coll Med, Dept Neurosurg, Ctr Movement Disorders & Neurorestorat, Gainesville, FL 32611 USA	State University System of Florida; University of Florida; State University System of Florida; University of Florida	Okun, MS (corresponding author), Univ Florida, Coll Med, Dept Neurosurg, Ctr Movement Disorders & Neurorestorat, Gainesville, FL 32611 USA.	okun@neurology.ufl.edu	Ramirez, Daniel Martinez/O-6719-2018; Martinez-Ramirez, Daniel/H-2546-2016; Ahmed, Bilal/A-6926-2016; Shukla, Aparna Wagle/AAN-1344-2020	Ramirez, Daniel Martinez/0000-0001-8003-0610; Martinez-Ramirez, Daniel/0000-0001-8003-0610; Ahmed, Bilal/0000-0001-9110-4136; Hess, Christopher/0000-0002-7317-8999; Hastings Monari, Erin/0000-0002-4075-3360; Okun, Michael/0000-0002-6247-9358; WAGLE SHUKLA, APARNA/0000-0002-9757-9973	National Parkinson Foundation; Tyler's Hope; Bachmann-Strauss Foundation	National Parkinson Foundation; Tyler's Hope; Bachmann-Strauss Foundation	We would like to acknowledge the support of the National Parkinson Foundation, Tyler's Hope and the Bachmann-Strauss Foundation to the Center. Also we would like to acknowledge the UF Foundation and the UF INFORM database, as well as Dr. Masa-aki Higuchi and Caroline Mignacca for helping obtaining data.	Aminoff MJ, 2011, PARKINSONISM RELAT D, V17, P139, DOI 10.1016/j.parkreldis.2010.11.009; Barker KN, 2002, ARCH INTERN MED, V162, P1897, DOI 10.1001/archinte.162.16.1897; Braga M, 2014, PARKINSONISM RELAT D, V20, P488, DOI 10.1016/j.parkreldis.2014.01.022; Buetow S, 2010, PARKINSONS DIS-US, V2010, DOI 10.4061/2010/432983; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Chou KL, 2011, PARKINSONISM RELAT D, V17, P440, DOI 10.1016/j.parkreldis.2011.03.002; Cilia R, 2014, J NEUROL NEUROSURG P; Dent E, 2014, AGE AGEING, V43, P477, DOI 10.1093/ageing/aft181; Derry CP, 2010, POSTGRAD MED J, V86, P334, DOI 10.1136/pgmj.2009.080432; Driver JA, 2008, NEUROLOGY, V70, P1423, DOI 10.1212/01.wnl.0000310414.85144.ee; Gerlach OHH, 2012, BMC NEUROL, V12, DOI 10.1186/1471-2377-12-13; Gerlach OHH, 2011, PARKINSONISM RELAT D, V17, P498, DOI 10.1016/j.parkreldis.2011.04.004; Gerlach OHH, 2011, MOVEMENT DISORD, V26, P197, DOI 10.1002/mds.23449; Gilboy N, 2020, EMERGENCY SEVERITY I, V2020; Goldman JG, 2014, CURR TREAT OPTION NE, V16, DOI 10.1007/s11940-013-0281-2; Grosset D, 2009, MOVEMENT DISORD, V24, P826, DOI 10.1002/mds.22112; Hassan A, 2013, PARKINSONISM RELAT D, V19, P949, DOI 10.1016/j.parkreldis.2013.06.006; Hassan Anhar, 2012, Parkinsonism Relat Disord, V18 Suppl 3, pS10, DOI 10.1016/j.parkreldis.2012.06.014; Hely MA, 2005, MOVEMENT DISORD, V20, P190, DOI 10.1002/mds.20324; Hou JG, 2012, PARKINSONISM RELAT D, V18, P377, DOI 10.1016/j.parkreldis.2011.12.007; Kulkarni AS, 2008, MOVEMENT DISORD, V23, P359, DOI 10.1002/mds.21831; Lubomski M, 2014, J NEUROL NEUROSURG P; Magdalinou KN, 2007, PARKINSONISM RELAT D, V13, P539, DOI 10.1016/j.parkreldis.2006.11.006; Martignoni E, 2004, NEUROL SCI, V25, P66, DOI 10.1007/s10072-004-0232-5; Skelly R, 2014, PARKINSONISM RELAT D, V20, P1242, DOI 10.1016/j.parkreldis.2014.09.015; Vossius C, 2010, ACTA NEUROL SCAND, V121, P38, DOI 10.1111/j.1600-0404.2009.01239.x; Woodford H, 2005, MOVEMENT DISORD, V20, P1104, DOI 10.1002/mds.20485; Zhan CL, 2003, JAMA-J AM MED ASSOC, V290, P1868, DOI 10.1001/jama.290.14.1868	28	24	25	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 17	2015	10	4							e0124356	10.1371/journal.pone.0124356	http://dx.doi.org/10.1371/journal.pone.0124356			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CG1EX	25884484	Green Submitted, gold, Green Published			2023-01-03	WOS:000353017000118
J	Pereira, L; Choquet, C; Perozziello, A; Wargon, M; Juillien, G; Colosi, L; Hellmann, R; Ranaivoson, M; Casalino, E				Pereira, Laurent; Choquet, Christophe; Perozziello, Anne; Wargon, Mathias; Juillien, Gaelle; Colosi, Luisa; Hellmann, Romain; Ranaivoson, Michel; Casalino, Enrique			Unscheduled-Return-Visits after an Emergency Department (ED) Attendance and Clinical Link between Both Visits in Patients Aged 75 Years and Over: A Prospective Observational Study	PLOS ONE			English	Article							HOSPITAL READMISSIONS; HIGH-RISK; ADMISSIONS; CARE; QUALITY	Background Predictors of unscheduled return visits (URV), best time-frame to evaluate URV rate and clinical relationship between both visits have not yet been determined for the elderly following an ED visit. Methods We conducted a prospective-observational study including 11,521 patients aged >= 75-years and discharged from ED (5,368 patients (53.5%)) or hospitalized after ED visit (6,153 patients). Logistic Regression and time-to-failure analyses including Cox proportional model were performed. Results Mean time to URV was 17 days; 72-hour, 30-day and 90-day URV rates were 1.8%, 6.1% and 10% respectively. Multivariate analysis indicates that care-pathway and final disposition decisions were significantly associated with a 30-day URV. Thus, we evaluated predictors of 30-day URV rates among non-admitted and hospitalized patient groups. By using the Cox model we found that, for non-admitted patients, triage acuity and diagnostic category and, for hospitalized patients, that visit time (day, night) and diagnostic categories were significant predictors (p< 0.001). For URV, we found that 25% were due to closely related-clinical conditions. Time lapses between both visits constituted the strongest predictor of closely related-clinical conditions. Conclusion Our study shows that a decision of non-admission in emergency departments is linked with an accrued risk of URV, and that some diagnostic categories are also related for non- admitted and hospitalized subjects alike. Our study also demonstrates that the best time frame to evaluate the URV rate after an ED visit is 30 days, because this is the time period during which most URVs and cases with close clinical relationships between two visits are concentrated. Our results suggest that URV can be used as an indicator or quality.	[Pereira, Laurent; Choquet, Christophe; Juillien, Gaelle; Colosi, Luisa; Hellmann, Romain; Ranaivoson, Michel; Casalino, Enrique] Univ Hosp Bichat Claude Bernard, AP HP, Emergency Dept, Paris, France; [Pereira, Laurent; Choquet, Christophe; Perozziello, Anne; Wargon, Mathias; Juillien, Gaelle; Colosi, Luisa; Hellmann, Romain; Ranaivoson, Michel; Casalino, Enrique] Study Grp Efficiency & Qual, Emergency Dept, Paris, France; [Pereira, Laurent; Choquet, Christophe; Perozziello, Anne; Wargon, Mathias; Juillien, Gaelle; Colosi, Luisa; Hellmann, Romain; Ranaivoson, Michel; Casalino, Enrique] Nonscheduled Act Dept, Paris, France; [Perozziello, Anne] Univ Hosp Bichat Claude Bernard, Med Informat Syst Program PMSI, Paris, France; [Wargon, Mathias] Hop St Camille, Bry Sur Marne, France; [Casalino, Enrique] Univ Paris Diderot, Sorbonne Paris Cite, REMES, EA 7334, Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite	Casalino, E (corresponding author), Univ Hosp Bichat Claude Bernard, AP HP, Emergency Dept, Paris, France.	enrique.casalino@bch.aphp.fr	Casalino, Enrique/GYU-1974-2022	Casalino, Enrique/0000-0002-4352-6729				[Anonymous], 2008, EMERGENCY READMISSIO; Benbassat J, 2000, ARCH INTERN MED, V160, P1074, DOI 10.1001/archinte.160.8.1074; Bianco A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048263; Billings J, 2006, BRIT MED J, V333, P327, DOI 10.1136/bmj.38870.657917.AE; Bottle A, 2006, J ROY SOC MED, V99, P406, DOI 10.1258/jrsm.99.8.406; Carret ML, 2007, BMC HEALTH SERV RES, V7, DOI 10.1186/1472-6963-7-131; de Stampa M, 2010, INT J INTEGR CARE, V10; Department of Health, 2010, A E CLIN QUAL IND IM; Epstein AM, 2009, NEW ENGL J MED, V360, P1457, DOI 10.1056/NEJMe0901006; Fan LJ, 2015, EMERG MED J, V32, P738, DOI 10.1136/emermed-2014-203770; Foo CL, 2012, AUSTRALAS J AGEING, V31, P40, DOI 10.1111/j.1741-6612.2010.00499.x; Friedman B, 2004, MED CARE RES REV, V61, P225, DOI 10.1177/1077558704263799; George G, 2006, EMERG MED J, V23, P379, DOI 10.1136/emj.2005.029793; Gruneir Andrea, 2011, Open Med, V5, pe104; Guttmann A, 2011, BMJ-BRIT MED J, V342, DOI 10.1136/bmj.d2983; Hampton T, 2008, JAMA-J AM MED ASSOC, V299, P2613, DOI 10.1001/jama.299.22.2613; Hastings SN, 2011, AM J MANAG CARE, V17, pE215; Huang AR, 2011, CAN GERIATR J, V14, P100, DOI [10.5770/cgj.v14i4.8, 10.57700/cgj.v14i4.8]; Kansagara D, 2011, JAMA-J AM MED ASSOC, V306, P1688, DOI 10.1001/jama.2011.1515; KEITH KD, 1989, ANN EMERG MED, V18, P964, DOI 10.1016/S0196-0644(89)80461-5; Laniece I, 2008, AGE AGEING, V37, P416, DOI 10.1093/ageing/afn093; Lowthian J, 2013, INTERN MED J, V43, P554, DOI 10.1111/imj.12061; McBride S, 2008, PARAMETERS FOR THE A, P4; McCusker J, 2006, J GERONTOL A-BIOL, V61, P53, DOI 10.1093/gerona/61.1.53; McCusker J, 2007, ACAD EMERG MED, V14, P426, DOI 10.1197/j.aem.2006.11.020; McCusker J, 2012, J AM GERIATR SOC, V60, P1534, DOI 10.1111/j.1532-5415.2012.04058.x; Newnham HH, 2012, MED J AUSTRALIA, V196, P101, DOI 10.5694/mja11.10619; ODWYER F, 1991, ARCH EMERG MED, V8, P196; Roberts C, 2005, STAT METHODS MED RES, V14, P493, DOI 10.1191/0962280205sm413oa; Roland M, 2012, BRIT MED J, V345, DOI 10.1136/bmj.e6017; Silow-Carroll S, REDUCING HOSPITAL RE; Tang N, 2010, JAMA-J AM MED ASSOC, V304, P664, DOI 10.1001/jama.2010.1112; Trivedy CR, 2015, EMERG MED J, V32, P324, DOI 10.1136/emermed-2013-202719; Uno H, 2011, STAT MED, V30, P1105, DOI 10.1002/sim.4154; van Walraven C, 2010, CAN MED ASSOC J, V182, P551, DOI 10.1503/cmaj.091117; Zapatero A, 2012, EUR J INTERN MED, V23, P451, DOI 10.1016/j.ejim.2012.01.005	36	21	21	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 8	2015	10	4							e0123803	10.1371/journal.pone.0123803	http://dx.doi.org/10.1371/journal.pone.0123803			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	CF3WA	25853822	Green Published, gold, Green Submitted			2023-01-03	WOS:000352478400118
J	Infurna, FJ; Rivers, CT; Reich, J; Zautra, AJ				Infurna, Frank J.; Rivers, Crystal T.; Reich, John; Zautra, Alex J.			Childhood Trauma and Personal Mastery: Their Influence on Emotional Reactivity to Everyday Events in a Community Sample of Middle-Aged Adults	PLOS ONE			English	Article							DAILY STRESSORS; PHYSICAL HEALTH; LIFE STRESS; PERCEIVED CONTROL; POSITIVE AFFECT; RISK; EXPERIENCES; RESILIENCE; ORIGINS; ABUSE	Childhood trauma is associated with premature declines in health in midlife and old age. Pathways that have been implicated, but less studied include social-emotional regulation, biological programming, and habitual patterns of thought and action. In this study we focused on childhood trauma's influence via alterations in social-emotional regulation to everyday life events, a pathway that has been linked to subsequent health effects. Data from a 30-day daily diary of community residents who participated in a study of resilience in Midlife (n = 191, M-age = 54, SD = 7.50, 54% women) was used to examine whether self-reports of childhood trauma were associated with daily well-being, as well as reported and emotional reactivity to daily negative and positive events. Childhood trauma reports were associated with reporting lower overall levels of and greater variability in daily well-being. Childhood trauma was linked to greater reports of daily negative events, but not to positive events. Focusing on emotional reactivity to daily events, residents who reported higher levels of childhood trauma showed stronger decreases in well-being when experiencing negative events and also stronger increases in well-being with positive events. For those reporting childhood trauma, higher levels of mastery were associated with stronger decreases in well-being with negative events and stronger increases in well-being with positive events, suggesting that mastery increases sensitivity to daily negative and positive events. Our results suggest that childhood trauma may lead to poorer health in midlife through disturbances in the patterns of everyday life events and responses to those events. Further, our findings indicate that mastery may have a different meaning for those who experienced childhood trauma. We discuss social-emotional regulation as one pathway linking childhood trauma to health, and psychosocial resources to consider when building resilience-promoting interventions for mitigating the detrimental health effects of childhood trauma.	[Infurna, Frank J.; Rivers, Crystal T.; Reich, John; Zautra, Alex J.] Arizona State Univ, Dept Psychol, Tempe, AZ 85287 USA	Arizona State University; Arizona State University-Tempe	Infurna, FJ (corresponding author), Arizona State Univ, Dept Psychol, Tempe, AZ 85287 USA.	Frank.Infurna@asu.edu			National Institute on Aging [R01 AG26006]; NATIONAL INSTITUTE ON AGING [R01AG026006] Funding Source: NIH RePORTER	National Institute on Aging(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	This work was funded by the National Institute on Aging R01 AG26006. The funders had no role in study design, data collection, and analysis, decision to publish, or preparation of the manuscript.	Almeida DM, 2010, HDB PSYCHOL AGING, P191; BALTES PB, 1987, DEV PSYCHOL, V23, P611, DOI 10.1037/0012-1649.23.5.611; BANDURA A, 1989, AM PSYCHOL, V44, P1175, DOI 10.1037/0003-066X.44.9.1175; Bandura A, 1997, SELF EFFICACY THE EX; Bernstein DP, 2003, CHILD ABUSE NEGLECT, V27, P169, DOI 10.1016/S0145-2134(02)00541-0; Blackertz L, 1998, AMERICAN JOURNAL OF, V19, P307; Bolger N, 2003, ANNU REV PSYCHOL, V54, P579, DOI 10.1146/annurev.psych.54.101601.145030; Boyce WT, 2005, DEV PSYCHOPATHOL, V17, P271, DOI 10.1017/S0954579405050145; Bradbum N. M., 1969, THE STRUCTURE OF PSY; Carstensen LL, 2011, PSYCHOL AGING, V26, P21, DOI 10.1037/a0021285; Caspi A, 2003, SCIENCE, V301, P386, DOI 10.1126/science.1083968; Caspi A, 2002, SCIENCE, V297, P851, DOI 10.1126/science.1072290; Cassidy J., 2008, HANDBOOK OF ATTACHME; Charles ST, 2013, PSYCHOL SCI, V24, P733, DOI 10.1177/0956797612462222; Cloitre M, 2005, BEHAV THER, V36, P119, DOI 10.1016/S0005-7894(05)80060-7; Cook T. D., 1979, QUASIEXPERIMENTATION, P19; Davis MC, 2000, PSYCHOSOM MED, V62, P17, DOI 10.1097/00006842-200001000-00003; Dickerson SS, 2004, PSYCHOL BULL, V130, P355, DOI 10.1037/0033-2909.130.3.355; Diehl M, 2010, DEV PSYCHOL, V46, P1132, DOI 10.1037/a0019937; Division of Behavioral and Social Research National Institute on Aging, 2013, NETWORK ON REVERSIBI; Fagundes CP, 2013, BRAIN BEHAV IMMUN, V27, P8, DOI 10.1016/j.bbi.2012.06.014; Felitti VJ, 1998, AM J PREV MED, V14, P245, DOI 10.1016/S0749-3797(98)00017-8; Ferraro KF, 2009, GERONTOLOGIST, V49, P333, DOI 10.1093/geront/gnp034; Glaser JP, 2006, J PSYCHOSOM RES, V61, P229, DOI 10.1016/j.jpsychores.2006.04.014; Goleman D., 2006, WORKING EMOTIONAL IN; Gross J.J., 1998, REV GEN PSYCHOL, V2, P271, DOI 10.1037/1089-2680.2.3.271; Hay EL, 2010, PSYCHOL AGING, V25, P118, DOI 10.1037/a0018747; Hostinar CE, 2013, CURR DIR PSYCHOL SCI, V22, P400, DOI 10.1177/0963721413488889; Infurna FJ, 2013, DEV PSYCHOL, V49, P1833, DOI 10.1037/a0031041; JAMES SA, 1983, J BEHAV MED, V6, P259, DOI 10.1007/BF01315113; Kahn RL, 1978, CLIN PSYCHOL AGING, P43; Kok BE, 2013, PSYCHOL SCI, V24, P1123, DOI 10.1177/0956797612470827; Lachman ME, 2006, CURR DIR PSYCHOL SCI, V15, P282, DOI 10.1111/j.1467-8721.2006.00453.x; Lieberman MD, 2013, SOCIAL WHY ARE BRAIN; Littell R.C., 2006, SAS SYSTEM MIXED MOD, V2nd; Little R. J. A., 1987, STATISTICAL ANALYSIS; Luecken LJ, 2004, CLIN PSYCHOL REV, V24, P171, DOI 10.1016/j.cpr.2004.01.003; Luthar SS, 2000, CHILD DEV, V71, P543, DOI 10.1111/1467-8624.00164; Mallers MH, 2010, DEV PSYCHOL, V46, P1651, DOI 10.1037/a0021020; Masi CM, 2011, PERS SOC PSYCHOL REV, V15, P219, DOI 10.1177/1088868310377394; Masten AS, 2001, AM PSYCHOL, V56, P227, DOI 10.1037/0003-066X.56.3.227; Miller GE, 2007, PSYCHOL BULL, V133, P25, DOI 10.1037/0033-2909.133.1.25; Miller GE, 2011, PSYCHOL BULL, V137, P959, DOI 10.1037/a0024768; Miller GE, 2009, P NATL ACAD SCI USA, V106, P14716, DOI 10.1073/pnas.0902971106; Mroczek DK, JOURNALS OF GERONTOL; Neupert SD, 2007, J GERONTOL B-PSYCHOL, V62, pP216, DOI 10.1093/geronb/62.4.P216; O'Rand AM, 2005, J GERONTOL B-PSYCHOL, V60, P117, DOI 10.1093/geronb/60.Special_Issue_2.S117; Ong AD, 2013, ANN BEHAV MED, V46, P52, DOI 10.1007/s12160-013-9484-8; Pearlin LI, 2007, J HEALTH SOC BEHAV, V48, P164, DOI 10.1177/002214650704800205; PEARLIN LI, 1978, J HEALTH SOC BEHAV, V19, P2, DOI 10.2307/2136319; Piazza JR, 2013, ANN BEHAV MED, V45, P110, DOI 10.1007/s12160-012-9423-0; Piazza JR, 2010, J GERONTOL B-PSYCHOL, V65, P513, DOI 10.1093/geronb/gbq049; Pluess M, 2013, PSYCHOL BULL, V139, P901, DOI 10.1037/a0030196; Porter CA, 1999, J CHILD SEX ABUS, V8, P3, DOI DOI 10.1300/J070V08N01_02; Power C, 2005, INT J EPIDEMIOL, V34, P335, DOI 10.1093/ije/dyh394; Power C, 2013, ANNU REV PUBL HEALTH, V34, P7, DOI 10.1146/annurev-publhealth-031912-114423; Pressman SD, 2005, PSYCHOL BULL, V131, P925, DOI 10.1037/0033-2909.131.6.925; Raposa EB, PSYCHOLOGICAL SCIENC; REICH JW, 1984, J COMMUNITY PSYCHOL, V12, P312, DOI 10.1002/1520-6629(198410)12:4<312::AID-JCOP2290120404>3.0.CO;2-B; Reich JW, 1981, J PERS SOC PSYCHOL, V41, P1082; Repetti RL, 2002, PSYCHOL BULL, V128, P330, DOI 10.1037/0033-2909.128.2.330; Rivers C, THE ENCYCLO PEDIA OF; RODIN J, 1986, SCIENCE, V233, P1271, DOI 10.1126/science.3749877; RYFF CD, 1989, J PERS SOC PSYCHOL, V57, P1069, DOI 10.1037/0022-3514.57.6.1069; Schafer MH, 2012, GERONTOLOGIST, V52, P111, DOI 10.1093/geront/gnr071; Schafer MH, CHILD ABUSE NEGLECT; Shields A, 1998, J CLIN CHILD PSYCHOL, V27, P381, DOI 10.1207/s15374424jccp2704_2; Singer JD., 2003, APPL LONGITUDINAL AN; Skinner E. A., 1995, PERCEIVED CONTROL MO, V8; Steptoe A, 2012, PSYCHOSOM MED, V74, P501, DOI 10.1097/PSY.0b013e31824f82c8; Strand EB, 2007, COGNITIVE THER RES, V31, P503, DOI 10.1007/s10608-006-9028-7; TAYLOR SE, 1983, AM PSYCHOL, V38, P1161, DOI 10.1037/0003-066X.38.11.1161; Thombs BD, 2006, ARCH INTERN MED, V166, P2020, DOI 10.1001/archinte.166.18.2020; Thorndike E.L., 1920, HARPERS MAGAZINE, V140, P227, DOI DOI 10.1234/12345678; van IJzendoorn MH, 2012, TRANSL PSYCHIAT, V2, DOI 10.1038/tp.2012.73; WATSON D, 1988, J PERS SOC PSYCHOL, V54, P1063, DOI 10.1037/0022-3514.54.6.1063; Wegman HL, 2009, PSYCHOSOM MED, V71, P805, DOI 10.1097/PSY.0b013e3181bb2b46; Whitelock CF, 2013, CLIN PSYCHOL SCI, V1, P351, DOI 10.1177/2167702613480136; Zautra A., 2013, RESILIENCE HDB APPRO, P185; Zautra AJ, 2005, J PERS, V73, P1511, DOI 10.1111/j.0022-3506.2005.00357.x; Zautra AJ, NEW DEV EMOTIONAL AG; Zautra AJ, 2012, J PSYCHOTHER INTEGR, V22, P206, DOI 10.1037/a0029573	82	42	42	3	23	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 7	2015	10	4							e0121840	10.1371/journal.pone.0121840	http://dx.doi.org/10.1371/journal.pone.0121840			21	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	CF3VU	25849572	Green Submitted, Green Published, gold			2023-01-03	WOS:000352477800078
J	Boittin, FX; Denis, J; Mayol, JF; Martigne, P; Raffin, F; Coulon, D; Grenier, N; Drouet, M; Herodin, F				Boittin, Francois-Xavier; Denis, Josiane; Mayol, Jean-Francois; Martigne, Patrick; Raffin, Florent; Coulon, David; Grenier, Nancy; Drouet, Michel; Herodin, Francis			The Extent of Irradiation-Induced Long-Term Visceral Organ Damage Depends on Cranial/Brain Exposure	PLOS ONE			English	Article							TOTAL-BODY IRRADIATION; PITUITARY-ADRENAL AXIS; NECROSIS-FACTOR-ALPHA; IONIZING-RADIATION; BRAIN IRRADIATION; DRUG PHARMACOKINETICS; DYSFUNCTION SYNDROME; RAT-BRAIN; ADULT-RAT; MICE	In case of high-dose radiation exposure, mechanisms controlling late visceral organ damage are still not completely understood and may involve the central nervous system. To investigate the influence of cranial/brain irradiation on late visceral organ damage in case of high-dose exposure, Wistar rats were irradiated at 12 Gy, with either the head and fore limbs or the two hind limbs protected behind a lead wall (head-and hind limbs-protected respectively), which allows long-term survival thanks to bone marrow protection. Although hind limbs- and head-protected irradiated rats exhibited similar hematopoietic and spleen reconstitution, a late body weight loss was observed in hind limbs-protected rats only. Histological analysis performed at this time revealed that late damages to liver, kidney and ileum were attenuated in rats with head exposed when compared to animals whose head was protected. Plasma measurements of inflammation biomarkers (haptoglobin and the chemokine CXCL1) suggest that the attenuated organ damage in hind limbs-protected rats may be in part related to reduced acute and chronic inflammation. Altogether our results demonstrate the influence of cranial/brain exposure in the onset of organ damage.	[Boittin, Francois-Xavier; Denis, Josiane; Mayol, Jean-Francois; Martigne, Patrick; Raffin, Florent; Coulon, David; Grenier, Nancy; Drouet, Michel; Herodin, Francis] Inst Rech Biomed Armees, Dept Radiobiol, Bretigny Sur Orge, France		Boittin, FX (corresponding author), Inst Rech Biomed Armees, Dept Radiobiol, Bretigny Sur Orge, France.	francois-xavier.boittin@irba.fr			DGA (Direction Generale de l'Armement) [PDH2-NRBC4-NR404]	DGA (Direction Generale de l'Armement)	This work was supported by a grant from DGA (Direction Generale de l'Armement): Grant PDH2-NRBC4-NR404.	Booth C, 2012, HEALTH PHYS, V103, P400, DOI 10.1097/HP.0b013e31826530e2; Chiang CS, 1997, INT J RADIAT BIOL, V72, P45, DOI 10.1080/095530097143527; De la Cal C, 2012, OPEN DENT J, V6, P8, DOI 10.2174/1874210601206010008; Eckersall PD, 2010, VET J, V185, P23, DOI 10.1016/j.tvjl.2010.04.009; Fares RP, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053888; Fernandez R, 2014, FRONT PHYSIOL, V5, DOI 10.3389/fphys.2014.00489; Franko AJ, 1997, RADIAT RES, V147, P245, DOI 10.2307/3579426; Gaugler M-H, 2005, BRIT J RADIOL, V78, P100, DOI [10.1259/bjr/24511652, DOI 10.1259/BJR/24511652]; GERACI JP, 1995, RADIAT RES, V143, P58, DOI 10.2307/3578926; GIRINSKY TA, 1994, RADIAT RES, V139, P360, DOI 10.2307/3578835; Gourmelon P., 2005, BR J RADIOL S, V78, P62; Groza P, 1975, Physiologie, V12, P53; Hellstraom NAK, 2009, STEM CELLS, V27, P634, DOI 10.1634/stemcells.2008-0732; HONG JH, 1995, INT J RADIAT ONCOL, V33, P619, DOI 10.1016/0360-3016(95)00279-8; Johnston CJ, 2010, RADIAT RES, V173, P522, DOI 10.1667/RR1882.1; Lebaron-Jacobs L, 2004, RADIAT RES, V161, P712, DOI 10.1667/RR3180; Linard C, 2005, J NEUROIMMUNOL, V168, P83, DOI 10.1016/j.jneuroim.2005.07.007; Ma SH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056607; Magana E, 2003, SOUTH MED J, V96, P521, DOI 10.1097/01.SMJ.0000054502.81803.A3; MAGIC Z, 1995, RADIAT RES, V143, P187, DOI 10.2307/3579156; Marquette C, 2003, INT J RADIAT BIOL, V79, P777, DOI 10.1080/09553000310001610998; Merino-Sanjuan M, 2011, NUTR HOSP, V26, P1296, DOI [10.1590/S0212-16112011000600016, 10.3305/nh.2011.26.6.5403]; MICHALOWSKI AS, 1994, ACTA ONCOL, V33, P139, DOI 10.3109/02841869409098397; MINKOVA M I, 1988, Acta Physiologica et Pharmacologica Bulgarica, V14, P63; Mizock BA, 2009, DM-DIS MON, V55, P476, DOI 10.1016/j.disamonth.2009.04.002; Monje ML, 2003, SCIENCE, V302, P1760, DOI 10.1126/science.1088417; MOULDER JE, 1990, INT J RADIAT ONCOL, V19, P1389, DOI 10.1016/0360-3016(90)90349-O; Olson TS, 2002, AM J PHYSIOL-REG I, V283, pR7, DOI 10.1152/ajpregu.00738.2001; Paris F, 2001, SCIENCE, V293, P293, DOI 10.1126/science.1060191; Rabbani ZN, 2007, INT J RADIAT ONCOL, V67, P573, DOI 10.1016/j.ijrobp.2006.09.053; Randall K, 1996, INT J RADIAT BIOL, V70, P351, DOI 10.1080/095530096145085; RAO KR, 1988, BRIT J RADIOL, V61, P839, DOI 10.1259/0007-1285-61-729-839; Robinson ICAF, 2001, J ENDOCRINOL, V169, P519, DOI 10.1677/joe.0.1690519; RUBIN P, 1995, INT J RADIAT ONCOL, V33, P99, DOI 10.1016/0360-3016(95)00095-G; Slamberova Romana, 2014, Prague Med Rep, V115, P43; Spitz DR, 2014, ANTIOXID REDOX SIGN, V20, P1407, DOI 10.1089/ars.2013.5769; Sternberg EM, 2006, NAT REV IMMUNOL, V6, P318, DOI 10.1038/nri1810; Tonomura Y, 2009, HUM EXP TOXICOL, V28, P293, DOI 10.1177/0960327109105404; VANDYKE D, 1964, BLOOD, V24, P356, DOI 10.1182/blood.V24.4.356.356; Velickovic N, 2012, CELL MOL NEUROBIOL, V32, P1175, DOI 10.1007/s10571-012-9843-1; Weidenfeld J, 2013, NEUROIMMUNOMODULAT, V20, P57, DOI 10.1159/000342522; Williams JP, 2011, INT J RADIAT BIOL, V87, P851, DOI 10.3109/09553002.2011.560996; Yoshie O, 2001, ADV IMMUNOL, V78, P57, DOI 10.1016/S0065-2776(01)78002-9; Zeilstra LJW, 2000, INT J RADIAT BIOL, V76, P419, DOI 10.1080/095530000138763	44	6	7	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 2	2015	10	4							e0122900	10.1371/journal.pone.0122900	http://dx.doi.org/10.1371/journal.pone.0122900			21	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CE9BS	25836679	Green Submitted, gold, Green Published			2023-01-03	WOS:000352139000118
J	Guo, TC; Gamil, AAA; Koenig, M; Evensen, O				Guo, Tz Chun; Gamil, Amr Ahmed Abdelrahim; Koenig, Melanie; Evensen, Oystein			Sequence Analysis and Identification of New Isoform of EP4 Receptors in Different Atlantic Salmon Tissues (Salmo salar L.) and Its Role in PGE2 Induced Immunomodulation In Vitro	PLOS ONE			English	Article							AGONIST-INDUCED DESENSITIZATION; PROSTANOID RECEPTORS; MESSENGER-RNA; PROSTAGLANDIN E-2; PHARMACOLOGICAL CHARACTERIZATION; TERMINAL DOMAINS; SUBTYPE; INFLAMMATION; MACROPHAGES; PROTEIN	PGE2 plays an important role in a broad spectrum of physiological and pathological processes mediated through a membrane-bound G protein-coupled receptor (GPCR) called EP receptor. In mammals, four subtypes of EP receptor (EP 1-4) are identified and each of them functions through different signal transduction pathways. Orthologous EP receptors have also been identified in other non-mammalian species, such as chicken and zebrafish. EP4 is the only identified PGE2 receptor to date in Atlantic salmon but its tissue distribution and function have not been studied in any detail. In this study, we first sequenced EP4 receptor in different tissues and found that the presence of the 3nt deletion in the 5' untranslated region was accompanied by silent mutation at nt 668. While attempting to amplify the same sequence in TO cells (an Atlantic salmon macrophage-like cell line), we failed to obtain the full-length product. Further investigation revealed different isoform of EP4 receptor in TO cells and we subsequently documented its presence in different Atlantic salmon tissues. These two isoforms of EP4 receptor share high homology in their first half of sequence but differ in the second half part with several deletion segments though the final length of coding sequence is the same for two isoforms. We further studied the immunomodulation effect of PGE2 in TO cells and found that PGE2 inhibited the induction of CXCL-10, CCL-4, IL-8 and IL-1 beta genes expression in a time dependent manner and without cAMP upregulation.	[Guo, Tz Chun; Gamil, Amr Ahmed Abdelrahim; Evensen, Oystein] Norwegian Univ Life Sci, Fac Vet Med & Biosci, Sea Lice Res Ctr, N-0033 Oslo, Norway; [Koenig, Melanie] Synapt Vesicle Dynam, European Neurosci Inst, D-37077 Gottingen, Germany	Norwegian University of Life Sciences	Evensen, O (corresponding author), Norwegian Univ Life Sci, Fac Vet Med & Biosci, Sea Lice Res Ctr, POB 8146 Dep, N-0033 Oslo, Norway.	oystein.evensen@nmbu.no	Evensen, Øystein/O-3011-2015	Evensen, Øystein/0000-0002-4856-3043; Gamil, Amr/0000-0001-9920-6487	Research Council of Norway, SFI-Sea Lice Research Centre [203513]	Research Council of Norway, SFI-Sea Lice Research Centre(Research Council of Norway)	The work was supported by Research Council of Norway, SFI-Sea Lice Research Centre, grant number 203513. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Akaogi J, 2004, J LEUKOCYTE BIOL, V76, P227, DOI 10.1189/jlb.1203627; Bastepe M, 1997, MOL PHARMACOL, V51, P343, DOI 10.1124/mol.51.2.343; Birchler JA, 2007, PLANT CELL, V19, P395, DOI 10.1105/tpc.106.049338; Breyer RM, 2001, ANNU REV PHARMACOL, V41, P661, DOI 10.1146/annurev.pharmtox.41.1.661; Caughey GE, 2001, J IMMUNOL, V167, P2831, DOI 10.4049/jimmunol.167.5.2831; Dereeper A, 2010, BMC EVOL BIOL, V10, DOI 10.1186/1471-2148-10-8; Fabre JE, 2001, J CLIN INVEST, V107, P603, DOI 10.1172/JCI10881; Frolov A, 2013, PROSTAG LEUKOTR ESS, V89, P351, DOI 10.1016/j.plefa.2013.08.003; Froystad MK, 1998, DEV COMP IMMUNOL, V22, P533, DOI 10.1016/S0145-305X(98)00032-9; Fujino H, 2006, MOL PHARMACOL, V69, P13, DOI 10.1124/mol.105.017749; Fujino H, 2005, MOL PHARMACOL, V68, P251, DOI 10.1124/mol.105.011833; GEROZISSIS K, 1991, PROSTAG OTH LIPID M, V41, P345, DOI 10.1016/0090-6980(91)90004-Y; Goodson ML, 2005, J BIOL CHEM, V280, P7493, DOI 10.1074/jbc.M411514200; Hansson MC, 2004, AQUAT TOXICOL, V68, P219, DOI 10.1016/j.aquatox.2004.02.006; Harizi H, 2003, J LEUKOCYTE BIOL, V73, P756, DOI 10.1189/jlb.1002483; Hata AN, 2004, PHARMACOL THERAPEUT, V103, P147, DOI 10.1016/j.pharmthera.2004.06.003; Horseman ND, 2002, TRENDS ENDOCRIN MET, V13, P47, DOI 10.1016/S1043-2760(01)00558-6; Hubbard NE, 2001, PROSTAG LEUKOTR ESS, V65, P287, DOI 10.1054/plef.2001.0327; Iwasaki R, 2013, BIOCHEM BIOPH RES CO, V438, P353, DOI 10.1016/j.bbrc.2013.07.075; KATOH H, 1995, BBA-GEN SUBJECTS, V1244, P41, DOI 10.1016/0304-4165(94)00182-W; KOTANI M, 1995, MOL PHARMACOL, V48, P869; Kwok AHY, 2012, GEN COMP ENDOCR, V179, P88, DOI 10.1016/j.ygcen.2012.07.019; LANNAN CN, 1984, IN VITRO CELL DEV B, V20, P671, DOI 10.1007/BF02618871; Leong JS, 2010, BMC GENOMICS, V11, DOI 10.1186/1471-2164-11-279; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Luschnig-Schratl P, 2011, CELL MOL LIFE SCI, V68, P3573, DOI 10.1007/s00018-011-0642-5; NAMBA T, 1993, NATURE, V365, P166, DOI 10.1038/365166a0; Narumiya S, 1999, PHYSIOL REV, V79, P1193, DOI 10.1152/physrev.1999.79.4.1193; NEGISHI M, 1993, J BIOL CHEM, V268, P9517; NOMURA T, 1976, BIOCHIM BIOPHYS ACTA, V431, P127; Plata G, 2014, NUCLEIC ACIDS RES, V42, P2405, DOI 10.1093/nar/gkt1200; RENZ H, 1988, J IMMUNOL, V141, P2388; Ricciotti E, 2011, ARTERIOSCL THROM VAS, V31, P986, DOI 10.1161/ATVBAHA.110.207449; SCHNEIDER WP, 1972, J AM CHEM SOC, V94, P2122, DOI 10.1021/ja00761a060; SUGIMOTO Y, 1993, J BIOL CHEM, V268, P2712; Sugimoto Y, 2007, J BIOL CHEM, V282, P11613, DOI 10.1074/jbc.R600038200; Sun L, 2012, ACTA PHARMACOL SIN, V33, P342, DOI 10.1038/aps.2011.200; Takayama K, 2002, J BIOL CHEM, V277, P44147, DOI 10.1074/jbc.M204810200; Tsuge K, 2013, BIOCHEM BIOPH RES CO, V436, P685, DOI 10.1016/j.bbrc.2013.06.017; van der Velden AW, 1999, INT J BIOCHEM CELL B, V31, P87, DOI 10.1016/S1357-2725(98)00134-4; Warren IA, 2014, GENOME BIOL EVOL, V6, P1790, DOI 10.1093/gbe/evu131; Wergeland HI, 2001, DIS AQUAT ORGAN, V44, P183, DOI 10.3354/dao044183; WOLF K, 1962, SCIENCE, V135, P1065, DOI 10.1126/science.135.3508.1065; Yao CC, 2009, NAT MED, V15, P633, DOI 10.1038/nm.1968; Yokoyama U, 2013, PHARMACOL REV, V65, P1010, DOI 10.1124/pr.112.007195	45	6	6	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 2	2015	10	4							e0120483	10.1371/journal.pone.0120483	http://dx.doi.org/10.1371/journal.pone.0120483			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CE9BS	25837516	Green Published, Green Accepted, gold			2023-01-03	WOS:000352139000022
J	Cohen, D				Cohen, Deborah			BANNER Why have UK doctors been deterred from prescribing Avastin?	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material												dcohen@bmj.com						Hawkes N, 2014, BMJ-BRIT MED J, V349, DOI 10.1136/bmj.g6867; Lock D, 2015, BMJ-BRIT MED J, V350, DOI 10.1136/bmj.h1377; Martin DF, 2010, NEW ENGL J MED, V363, P105, DOI 10.1056/NEJMp1001201; Moja L, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011230.pub2	4	25	25	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	APR 1	2015	350								h1654	10.1136/bmj.h1654	http://dx.doi.org/10.1136/bmj.h1654			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CF3HO	25834024				2023-01-03	WOS:000352439300008
J	Scaioli, G; Gualano, MR; Gili, R; Masucci, S; Bert, F; Siliquini, R				Scaioli, Giacomo; Gualano, Maria R.; Gili, Renata; Masucci, Simona; Bert, Fabrizio; Siliquini, Roberta			Antibiotic Use: A Cross-Sectional Survey Assessing the Knowledge, Attitudes and Practices amongst Students of a School of Medicine in Italy	PLOS ONE			English	Article							ANTIMICROBIAL STEWARDSHIP; GENERAL-PRACTITIONERS; PUBLIC KNOWLEDGE; CARE; PERCEPTIONS; RESISTANCE; QUESTIONNAIRE; MEDICATION; AWARENESS; BEHAVIOR	Background Since antibiotic resistance has become a worldwide public health concern and is in part related to physicians' lack of knowledge, it is essential to focus our attention on healthcare profession students. The present study aims at evaluating the knowledge and attitudes of the School of Medicine's students towards antibiotic usage and antibiotic resistance. Methods In December 2013, a cross sectional study was conducted amongst medical, dental, nursing and other health care profession students of the School of Medicine at the University of Torino. Students of all the academic years took part in this study. Questionnaires were submitted during regular lectures (only students who attended courses on one specific day were surveyed) and the data collected was analyzed using StataMP11 statistical software. Results Overall, 1,050 students were interviewed. The response rate was 100%. Around 20% of the sample stated that antibiotics are appropriate for viral infections and 15% of the students that they stop taking those drugs when symptoms decrease. Results of the multivariate analyses showed that females were more likely than males to take antibiotics only when prescribed (OR 1.43, 95% CI 1.04-1.98). Interestingly, students with a relative working in a health-related field, as well as those who took at least one course of antibiotics in the last year, had a lower probability of taking those drugs only under prescription (OR = 0.69 95% CI: 0.49-0.97 and OR = 0.38 95% CI: 0.27-0.53, respectively). Conclusion The present paper shows how healthcare profession students do not practice what they know. Since those students will be a behavioral model for citizens and patients, it is important to generate more awareness around this issue throughout their studies. It would be advisable to introduce a specific course and training on antibiotics in the core curriculum of the School of Medicine.	[Scaioli, Giacomo; Gualano, Maria R.; Gili, Renata; Masucci, Simona; Bert, Fabrizio; Siliquini, Roberta] Univ Turin, Dept Publ Hlth, Turin, Italy	University of Turin	Gili, R (corresponding author), Univ Turin, Dept Publ Hlth, Turin, Italy.	renata.gili@unito.it	Gualano, Maria Rosaria/AAJ-2525-2020	Scaioli, Giacomo/0000-0001-5189-1294; Bert, Fabrizio/0000-0002-4329-9028; Gualano, Maria Rosaria/0000-0001-7357-2892	Department of Public Health Sciences University of Torino	Department of Public Health Sciences University of Torino	Department of Public Health Sciences University of Torino. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abbo LM, 2013, CLIN INFECT DIS, V57, P631, DOI 10.1093/cid/cit370; Andre M, 2010, J ANTIMICROB CHEMOTH, V65, P1292, DOI 10.1093/jac/dkq104; Butler CC, 1998, BMJ-BRIT MED J, V317, P637, DOI 10.1136/bmj.317.7159.637; Cars O, 2001, LANCET, V357, P1851, DOI 10.1016/S0140-6736(00)04972-2; Centers for Disease Control and Prevention (CDC), 2013, ANT AR ALW ANSW; Chambers H.F., 2006, GOODMAN GILMANS PHAR, P1095; Corbett KK, 2005, PREV MED, V40, P162, DOI 10.1016/j.ypmed.2004.05.016; de Leeuw E. D., 2008, INT HDB SURVEY METHO; Dyar OJ, 2013, MED MALADIES INFECT, V43, P423, DOI 10.1016/j.medmal.2013.07.010; Dyar OJ, 2014, J ANTIMICROB CHEMOTH, V69, P842, DOI 10.1093/jac/dkt440; El Ezz N F A, 2011, J Prev Med Hyg, V52, P196; European Center for Disease Prevention and Control (ECDC), 2013, ANT CONS INT DAT ESA; European Center for Disease Prevention and Control (ECDC), 2013, EUR ANT RES SURV NET; European commission, 2013, SPEC EUR 407 ANT RES; Faber MS, 2010, EURO SURVEILL B EUR, V15; Ficarra MG, 2011, EUR J PUBLIC HEALTH, V21, P29, DOI 10.1093/eurpub/ckq017; Gendel MH, 2012, J MED ETHICS, V38, P294, DOI 10.1136/medethics-2011-100167; Grigoryan L, 2007, J ANTIMICROB CHEMOTH, V59, P152, DOI 10.1093/jac/dkl457; Groves Robert M., 2011, SURV METHODOL, V2nd; Gualano MR, 2015, PHARMACOEPIDEM DR S, V24, P2, DOI 10.1002/pds.3716; Gualano MR, 2011, EPIDEMIOL BIOSTAT PU, V8, P392; Hosmer Jr D. W, 2004, APPL LOGISTIC REGRES; Huang Y, 2013, BMC MED EDUC, V13, DOI 10.1186/1472-6920-13-163; Kardas P, 2007, INT J ANTIMICROB AG, V30, P530, DOI 10.1016/j.ijantimicag.2007.08.005; Khan AKA, 2013, J CLIN DIAGN RES, V7, P1613, DOI 10.7860/JCDR/2013/6290.3230; Kim SS, 2011, J KOREAN ACAD NURS, V41, P742, DOI 10.4040/jkan.2011.41.6.742; Kumar S, 2003, BMJ-BRIT MED J, V326, P138, DOI 10.1136/bmj.326.7381.138; LAPUMA J, 1991, NEW ENGL J MED, V325, P1290, DOI 10.1056/NEJM199110313251806; Lim Ka Keat, 2012, South Med Rev, V5, P26; Manteuffel M, 2014, J WOMENS HEALTH, V23, P112, DOI 10.1089/jwh.2012.3972; McNulty CAM, 2007, J ANTIMICROB CHEMOTH, V59, P727, DOI 10.1093/jac/dkl558; McNulty CAM, 2011, J ANTIMICROB CHEMOTH, V66, pV3, DOI 10.1093/jac/dkr119; Minen MT, 2010, MICROB DRUG RESIST, V16, P285, DOI 10.1089/mdr.2010.0009; Napolitano F, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0084177; Ohl CA, 2014, INFECT DIS CLIN N AM, V28, P177, DOI 10.1016/j.idc.2014.02.001; Osservasalute, 2011, RAPP OSS 2011; Pulcini C, 2013, VIRULENCE, V4, P192, DOI 10.4161/viru.23706; Rodrigues AT, 2013, INT J ANTIMICROB AG, V41, P203, DOI 10.1016/j.ijantimicag.2012.09.003; Suaifan GARY, 2012, AFR J PHARM PHARMACO, V6, P763, DOI 10.5897/AJPP12.080; Thriemer K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055495; Tonkin-Crine S, 2011, J ANTIMICROB CHEMOTH, V66, P2215, DOI 10.1093/jac/dkr279; WHO, 2012, EVOLVING THREAT OF ANTIMICROBIAL RESISTANCE: OPTIONS FOR ACTION, P1; World Health Organization, 2014, ANTIMICROBIAL RESIST; Wright EP, 2004, J ANTIMICROB CHEMOTH, V53, P550, DOI 10.1093/jac/dkh096	44	81	84	0	21	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 1	2015	10	4							e0122476	10.1371/journal.pone.0122476	http://dx.doi.org/10.1371/journal.pone.0122476			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	CE9AM	25831072	gold, Green Published, Green Submitted			2023-01-03	WOS:000352135600113
J	Kasteridis, P; Mason, AR; Goddard, MK; Jacobs, R; Santos, R; McGonigal, G				Kasteridis, Panagiotis; Mason, Anne R.; Goddard, Maria K.; Jacobs, Rowena; Santos, Rita; McGonigal, Gerard			The Influence of Primary Care Quality on Hospital Admissions for People with Dementia in England: A Regression Analysis	PLOS ONE			English	Article							PERFORMANCE; PAY; UK; ASSOCIATION; MANAGEMENT; DISEASE	Objectives To test the impact of a UK pay-for-performance indicator, the Quality and Outcomes Framework (QOF) dementia review, on three types of hospital admission for people with dementia: emergency admissions where dementia was the primary diagnosis; emergency admissions for ambulatory care sensitive conditions (ACSCs); and elective admissions for cataract, hip replacement, hernia, prostate disease, or hearing loss. Methods Count data regression analyses of hospital admissions from 8,304 English general practices from 2006/7 to 2010/11. We identified relevant admissions from national Hospital Episode Statistics and aggregated them to practice level. We merged these with practice-level data on the QOF dementia review. In the base case, the exposure measure was the reported QOF register. As dementia is commonly under-diagnosed, we tested a predicted practice register based on consensus estimates. We adjusted for practice characteristics including measures of deprivation and uptake of a social benefit to purchase care services (Attendance Allowance). Results In the base case analysis, higher QOF achievement had no significant effect on any type of hospital admission. However, when the predicted register was used to account for underdiagnosis, a one-percentage point improvement in QOF achievement was associated with a small reduction in emergency admissions for both dementia (-0.1%; P=0.011) and ACSCs (-0.1%; P=0.001). In areas of greater deprivation, uptake of Attendance Allowance was consistently associated with significantly lower emergency admissions. In all analyses, practices with a higher proportion of nursing home patients had significantly lower admission rates for elective and emergency care. Conclusion In one of three analyses at practice level, the QOF review for dementia was associated with a small but significant reduction in unplanned hospital admissions. Given the rising prevalence of dementia, increasing pressures on acute hospital beds and poor outcomes associated with hospital stays for this patient group, this small change may be clinically and economically relevant.	[Kasteridis, Panagiotis; Mason, Anne R.; Goddard, Maria K.; Jacobs, Rowena; Santos, Rita] Univ York, Ctr Hlth Econ, York YO10 5DD, N Yorkshire, England; [McGonigal, Gerard] York Teaching Hosp NHS Fdn Trust, Dept Med Elderly, York, N Yorkshire, England	University of York - UK	Kasteridis, P (corresponding author), Univ York, Ctr Hlth Econ, York YO10 5DD, N Yorkshire, England.	panos.kasteridis@york.ac.uk		Santos, Rita/0000-0001-7953-1960; Jacobs, Rowena/0000-0001-5225-6321; Goddard, Maria Karen/0000-0002-1517-7461; Mason, Anne/0000-0002-5823-3064	Department of Health (England, UK) [103/0001]; National Institute for Health Research [PDA/02/06/038] Funding Source: researchfish	Department of Health (England, UK); National Institute for Health Research(National Institute for Health Research (NIHR))	The work was funded by the Department of Health (England, UK) to the Policy Research Unit in the Economics of Social and Health Care [103/0001]. The funders have approved the manuscript for submission but had no role in the design or conduct of the study. The views expressed are those of the authors and not necessarily those of the funders.	Audit Commission, 2000, FORG ME NOT MENT HLT; Banerjee S, 2003, J NEUROL NEUROSUR PS, V74, P1315, DOI 10.1136/jnnp.74.9.1315; Bardsley M, 2013, BMJ OPEN, V3, DOI 10.1136/bmjopen-2012-002007; Bliss RL, 2012, MED CARE, V50, P99, DOI 10.1097/MLR.0b013e31822944d1; Bottle A, 2008, J GEN INTERN MED, V23, P135, DOI 10.1007/s11606-007-0390-2; Bottle A, 2008, J AMBUL CARE MANAG, V31, P226, DOI 10.1097/01.JAC.0000324668.83530.6d; Bynum JPW, 2004, J AM GERIATR SOC, V52, P187, DOI 10.1111/j.1532-5415.2004.52054.x; Calderon-Larranaga A, 2011, THORAX, V66, P191, DOI 10.1136/thx.2010.147058; Cameron A., 1998, ECONOMETRIC SOC MONO; Care Quality Commission, 2013, STAT HLTH CAR AD SOC; Care Services Improvement Partnership, 2005, EV BUS INT MENT HLTH; Department of Health, 2013, DEM STAT NAT REP DEM; Department of Health, 2012, PRIM MIN CHALL DEM D; Department of Health, 2009, LIVING WELL DEMENTIA; Department of Health, 2011, OP FRAM NHS 2012 13; Doran T, 2012, BMJ-BRIT MED J, V344, DOI 10.1136/bmj.e2405; Downing A, 2007, BMC HEALTH SERV RES, V7, DOI 10.1186/1472-6963-7-166; Dusheiko M, 2009, GISRUK 2009 P GIS RE, P1; Dusheiko M, 2011, HEALTH SERV RES, V46, P27, DOI 10.1111/j.1475-6773.2010.01184.x; Forder J, 2009, HEALTH ECON, V18, P1322, DOI 10.1002/hec.1438; Gillam SJ, 2012, ANN FAM MED, V10, P461, DOI 10.1370/afm.1377; Gravelle H, 2010, ECON J, V120, pF129, DOI 10.1111/j.1468-0297.2009.02340.x; HAUSMAN J, 1984, ECONOMETRICA, V52, P909, DOI 10.2307/1911191; HSCIC Clinical Indicators Team, 2014, NHS OUTC FRAM 2014 1; Knapp M, 2013, INT J GERIATR PSYCH, V28, P551, DOI 10.1002/gps.3864; Knapp Martin, 2007, DEMENTIA UK; Lakey L., 2009, COUNTING COST CARING; Lin PJ, 2013, ALZHEIMERS DEMENT, V9, P30, DOI 10.1016/j.jalz.2012.11.002; Natalwala A, 2008, DEMENT GERIATR COGN, V26, P499, DOI 10.1159/000171044; National Institute for Health and Care Excellence, 2013, Q30 QUAL STAND SUPP; NHS England Urgent and Emergency Care Review Team, 2014, TRANSF URG EM CAR SE; Nicholl J, 2007, EMERG MED J, V24, P665, DOI 10.1136/emj.2007.047654; Purdy S, 2011, PUBLIC HEALTH, V125, P46, DOI 10.1016/j.puhe.2010.07.006; Purdy S, 2009, PUBLIC HEALTH, V123, P169, DOI 10.1016/j.puhe.2008.11.001; Purdy S, 2010, AVOIDING HOSPITAL AD; Royal College of Psychiatrists, 2013, REP NAT AUD DEM CAR; Sampson EL, 2009, BRIT J PSYCHIAT, V195, P61, DOI 10.1192/bjp.bp.108.055335; Shohet C, 2007, SEIZURE-EUR J EPILEP, V16, P351, DOI 10.1016/j.seizure.2007.02.005; Soljak M, 2011, BRIT J GEN PRACT, V61, DOI 10.3399/bjgp11X613142; Toot S, 2013, J AM MED DIR ASSOC, V14, P463, DOI 10.1016/j.jamda.2013.01.011; Vroomen JM, 2013, BMC GERIATR, V13, DOI 10.1186/1471-2318-13-10; World Health Organization Alzheimer's Disease International, 2012, ALZH DIS INT DEM PUB, DOI [10.1186/alzrt143, DOI 10.1186/ALZRT143]	42	11	11	0	28	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 27	2015	10	3							e0121506	10.1371/journal.pone.0121506	http://dx.doi.org/10.1371/journal.pone.0121506			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	CE8ZT	25816231	Green Submitted, gold, Green Published			2023-01-03	WOS:000352133600101
J	Numico, G; Cristofano, A; Mozzicafreddo, A; Cursio, OE; Franco, P; Courthod, G; Trogu, A; Malossi, A; Cucchi, M; Sirotova, Z; Alvaro, MR; Stella, A; Grasso, F; Spinazze, S; Silvestris, N				Numico, Gianmauro; Cristofano, Antonella; Mozzicafreddo, Alessandro; Cursio, Olga Elisabetta; Franco, Pierfrancesco; Courthod, Giulia; Trogu, Antonio; Malossi, Alessandra; Cucchi, Mariella; Sirotova, Zuzana; Alvaro, Maria Rosa; Stella, Anna; Grasso, Fulvia; Spinazze, Silvia; Silvestris, Nicola			Hospital Admission of Cancer Patients: Avoidable Practice or Necessary Care?	PLOS ONE			English	Article							HEALTH-CARE; LIFE; END; OUTPATIENTS; QUALITY	Background Cancer patients are frequently admitted to hospital due to acute conditions or refractory symptoms. This occurs through the emergency departments and requires medical oncologists to take an active role. The use of acute-care hospital increases in the last months of life. Patients and methods We aimed to describe the admissions to a medical oncology inpatient service within a 16-month period with respect to patients and tumor characteristics, and the outcome of the hospital stay. Results 672 admissions of 454 patients were analysed. The majority of admissions were urgent (74.1%), and were due to uncontrolled symptoms (79.6%). Among the chief complaints, dyspnoea occurred in 15.7%, pain in 15.2%, and neurological symptoms in 14.5%. The majority of the hospitalizations resulted in discharge to home (60.6%); in 26.5% the patient died and in 11.0% was transferred to a hospice. Admissions due to symptoms correlated with a longer hospital stay and a higher incidence of in-hospital death. Conclusion We suggest that hospital use is not necessarily a sign of inappropriately aggressive care: inpatient care is probably an unavoidable step in the cancer trajectory. Optimization of inpatient supportive procedures should be a specific task of modern medical oncology.	[Numico, Gianmauro; Cristofano, Antonella; Mozzicafreddo, Alessandro; Cursio, Olga Elisabetta; Courthod, Giulia; Trogu, Antonio; Malossi, Alessandra; Cucchi, Mariella; Sirotova, Zuzana; Alvaro, Maria Rosa; Stella, Anna; Grasso, Fulvia; Spinazze, Silvia] Azienda USL Aosta, Med Oncol & Hematol, I-11100 Aosta, Italy; [Franco, Pierfrancesco] Univ Turin, Dept Oncol, Radiat Oncol Unit, I-10126 Turin, Italy; [Silvestris, Nicola] Natl Canc Res Ctr, Ist Tumori Giovanni Paolo II, Med Oncol Unit, I-70124 Bari, Italy	University of Turin; IRCCS Istituto Tumori Bari Giovanni Paolo II	Numico, G (corresponding author), Azienda USL Aosta, Med Oncol & Hematol, Viale Ginevra 3, I-11100 Aosta, Italy.	gnumico@ausl.vda.it	Silvestris, Nicola/K-5889-2012; Numico, Gianmauro/AAE-4489-2020	Silvestris, Nicola/0000-0001-7814-7318; Numico, Gianmauro/0000-0003-3253-2960; Franco, Pierfrancesco/0000-0003-2276-0687				Alonso-Babarro A, 2011, J CLIN ONCOL, V29, P1159, DOI 10.1200/JCO.2010.31.6752; Aprile G, 2013, SUPPORT CARE CANCER, V21, P397, DOI 10.1007/s00520-012-1524-6; Bakitas M, 2009, JAMA-J AM MED ASSOC, V302, P741, DOI 10.1001/jama.2009.1198; Barbera L, 2010, CAN MED ASSOC J, V182, P563, DOI 10.1503/cmaj.091187; Barnett K, 2012, LANCET, V380, P37, DOI 10.1016/S0140-6736(12)60240-2; Beccaro M, 2006, J EPIDEMIOL COMMUN H, V60, P412, DOI 10.1136/jech.2005.043646; Brooks GA, 2014, J CLIN ONCOL, V32, P496, DOI 10.1200/JCO.2013.52.4330; Chastek B, 2013, J ONCOL PRACTICE, V8, P75; Cohen J, 2010, J CLIN ONCOL, V28, P2267, DOI 10.1200/JCO.2009.23.2850; De Korte-Verhoef MC, 2014, SUPPORT CARE CANCER, V22, P645, DOI 10.1007/s00520-013-2019-9; Delgado-Guay MO, 2015, J PAIN SYMPTOM MANAG, V49, P497, DOI 10.1016/j.jpainsymman.2014.07.007; DiMartino LD, 2014, J PALLIAT MED, V17, P1384, DOI 10.1089/jpm.2014.0092; Earle CC, 2003, J CLIN ONCOL, V21, P1133, DOI 10.1200/JCO.2003.03.059; Earle CC, 2008, J CLIN ONCOL, V26, P3860, DOI 10.1200/JCO.2007.15.8253; Espinosa E, 2010, SUPPORT CARE CANCER, V18, P1231, DOI 10.1007/s00520-010-0903-0; Foltran L, 2014, SUPPORT CARE CANCER, V22, P2527, DOI 10.1007/s00520-014-2234-z; Gomes B, 2013, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD007760.pub2, 10.1590/1516-3180.20161341T2]; Hjermstad MJ, 2013, BMJ OPEN, V3, DOI 10.1136/bmjopen-2012-002515; Huang J, 2002, J CLIN ONCOL, V20, P1584, DOI 10.1200/JCO.20.6.1584; Jordhoy MS, 2000, LANCET, V356, P888, DOI 10.1016/S0140-6736(00)02678-7; Mansour D, 2011, CLIN ONCOL-UK, V23, P168, DOI 10.1016/j.clon.2010.12.005; Manzano JGM, 2014, J CLIN ONCOL, V32, P3527, DOI 10.1200/JCO.2014.55.3131; Mayer DK, 2011, J CLIN ONCOL, V29, P2683, DOI 10.1200/JCO.2010.34.2816; Numico G, 2011, SUPPORT CARE CANCER, V19, P1823, DOI 10.1007/s00520-010-1024-5; Popescu RA, 2014, ANN ONCOL, V25, P9, DOI 10.1093/annonc/mdt522; Reuben DB, 2014, NEW ENGL J MED, V370, P694, DOI 10.1056/NEJMp1315568; Rocque GB, 2013, J ONCOL PRACT, V9, P51, DOI 10.1200/JOP.2012.000698; Teno JM, 2013, JAMA-J AM MED ASSOC, V309, P470, DOI 10.1001/jama.2012.207624; Van den Block L, 2007, BMC HEALTH SERV RES, V7, DOI 10.1186/1472-6963-7-69; Wright AA, 2014, J CLIN ONCOL, V32, P3534, DOI 10.1200/JCO.2014.55.5383; Yates M, 2009, CLIN ONCOL-UK, V21, P226, DOI 10.1016/j.clon.2008.12.006	31	78	79	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 26	2015	10	3							e0120827	10.1371/journal.pone.0120827	http://dx.doi.org/10.1371/journal.pone.0120827			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CK6QW	25812117	Green Published, gold, Green Submitted			2023-01-03	WOS:000356353700062
J	Charmsaz, S; Beckett, K; Smith, FM; Bruedigam, C; Moore, AS; Al-Ejeh, F; Lane, SW; Boyd, AW				Charmsaz, Sara; Beckett, Kirrilee; Smith, Fiona M.; Bruedigam, Claudia; Moore, Andrew S.; Al-Ejeh, Fares; Lane, Steven W.; Boyd, Andrew W.			EphA2 Is a Therapy Target in EphA2-Positive Leukemias but Is Not Essential for Normal Hematopoiesis or Leukemia	PLOS ONE			English	Article							GENE-EXPRESSION; STEM-CELLS; EPHRIN; RECEPTORS; KINASE; FAMILY; HEK; ACTIVATION; LIGANDS; CLONING	Members of the Eph family of receptor tyrosine kinases and their membrane bound ephrin ligands have been shown to play critical roles in many developmental processes and more recently have been implicated in both normal and pathological processes in post-embryonic tissues. In particular, expression studies of Eph receptors and limited functional studies have demonstrated a role for the Eph/ephrin system in hematopoiesis and leukemogenesis. In particular, EphA2 was reported on hematopoietic stem cells and stromal cells. There are also reports of EphA2 expression in many different types of malignancies including leukemia, however there is a lack of knowledge in understanding the role of EphA2 in hematopoiesis and leukemogenesis. We explored the role of EphA2 in hematopoiesis by analyzing wild type and EphA2 knockout mice. Mature, differentiated cells, progenitors and hematopoietic stem cells derived from knockout and control mice were analyzed and no significant abnormality was detected. These studies showed that EphA2 does not have an obligatory role in normal hematopoiesis. Comparative studies using EphA2-negative MLL-AF9 leukemias derived from EphA2-knockout animals showed that there was no detectable functional role for EphA2 in the initiation or progression of the leukemic process. However, expression of EphA2 in leukemias initiated by MLL-AF9 suggested that this protein might be a possible therapy target in this type of leukemia. We showed that treatment with EphA2 monoclonal antibody IF7 alone had no effect on tumorigenicity and latency of the MLL-AF9 leukemias, while targeting of EphA2 using EphA2 monoclonal antibody with a radioactive payload significantly impaired the leukemic process. Altogether, these results identify EphA2 as a potential radio-therapeutic target in leukemias with MLL translocation.	[Charmsaz, Sara; Beckett, Kirrilee; Smith, Fiona M.; Bruedigam, Claudia; Al-Ejeh, Fares; Lane, Steven W.; Boyd, Andrew W.] QIMR Berghofer Med Res Inst, Brisbane, Qld, Australia; [Moore, Andrew S.; Lane, Steven W.; Boyd, Andrew W.] Univ Queensland, Brisbane, Qld, Australia; [Moore, Andrew S.] Childrens Hlth Queensland Hosp & Hlth Serv, Brisbane, Qld, Australia	QIMR Berghofer Medical Research Institute; University of Queensland	Charmsaz, S (corresponding author), QIMR Berghofer Med Res Inst, Brisbane, Qld, Australia.	Sara.Charmsaz@qimrberghofer.edu.au	Bruedigam, Claudia/P-6326-2018; Al-Ejeh, Fares/M-7032-2016; Bruedigam, Claudia/ABC-8681-2020; Moore, Andrew S/I-6275-2012	Bruedigam, Claudia/0000-0002-9580-1446; Al-Ejeh, Fares/0000-0002-1553-0077; Bruedigam, Claudia/0000-0002-9580-1446; Moore, Andrew S/0000-0001-8062-1779	Ph.D scholarship Leukaemia Foundation Australia; Leukaemia Foundation Australia; Conquer Cancer	Ph.D scholarship Leukaemia Foundation Australia; Leukaemia Foundation Australia; Conquer Cancer	This work was funded by Ph.D scholarship Leukaemia Foundation Australia to SC, Leukaemia Foundation Australia to AWB, Ride to Conquer Cancer to AWB and SC.	Al-Ejeh F, 2014, GROWTH FACTORS, V32, P254, DOI 10.3109/08977194.2014.984807; Al-Ejeh F, 2009, NUCL MED BIOL, V36, P395, DOI 10.1016/j.nucmedbio.2009.01.001; Annunziata CM, 2013, INVEST NEW DRUG, V31, P77, DOI 10.1007/s10637-012-9801-2; Bagger FO, 2013, NUCLEIC ACIDS RES, V41, pD1034, DOI 10.1093/nar/gks1021; Binda E, 2012, CANCER CELL, V22, P765, DOI 10.1016/j.ccr.2012.11.005; Boyd AW, 2014, NAT REV DRUG DISCOV, V13, P39, DOI 10.1038/nrd4175; BOYD AW, 1992, J BIOL CHEM, V267, P3262; Bruedigam C, 2014, CELL STEM CELL, V15, P775, DOI 10.1016/j.stem.2014.11.010; Charmsaz S, 2013, J LEUKEMIA; Dottori M, 1999, BLOOD, V94, P2477, DOI 10.1182/blood.V94.7.2477.419k13_2477_2486; Easty DJ, 2011, PIGM CELL MELANOMA R, V24, P446, DOI 10.1111/j.1755-148X.2011.00836.x; EASTY DJ, 1995, INT J CANCER, V60, P129, DOI 10.1002/ijc.2910600119; Gale NW, 1996, NEURON, V17, P9, DOI 10.1016/S0896-6273(00)80276-7; Herath NI, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-144; Herath NI, 2012, EUR J CANCER, V48, P753, DOI 10.1016/j.ejca.2011.07.003; Herath NI, 2010, INT J CANCER, V126, P2003, DOI 10.1002/ijc.25147; Kullander K, 2002, NAT REV MOL CELL BIO, V3, P475, DOI 10.1038/nrm856; Lane SW, 2010, BLOOD, V115, P3489, DOI 10.1182/blood-2009-11-251728; Lazarova P, 2006, INT J IMMUNOPATH PH, V19, P49; Nakanishi H, 2007, P NATL ACAD SCI USA, V104, P14442, DOI 10.1073/pnas.0703211104; Naruse-Nakajima C, 2001, MECH DEVELOP, V102, P95, DOI 10.1016/S0925-4773(01)00290-8; Noberini R, 2009, CANCER CELL, V16, P452, DOI 10.1016/j.ccr.2009.11.008; Oricchio E, 2011, CELL, V147, P554, DOI 10.1016/j.cell.2011.09.035; Pasquale EB, 1997, CURR OPIN CELL BIOL, V9, P608, DOI 10.1016/S0955-0674(97)80113-5; Pasquale EB, 2008, CELL, V133, P38, DOI 10.1016/j.cell.2008.03.011; Rao AV, 2005, CLIN MED RES, V3, P157, DOI 10.3121/cmr.3.3.157; Steube KG, 1999, LEUKEMIA LYMPHOMA, V33, P371, DOI 10.3109/10428199909058438; Ting MJ, 2010, EXP HEMATOL, V38, P1087, DOI 10.1016/j.exphem.2010.07.007; Ting MJ, 2008, OEPN HEMATOLOGY J, V2, P7; WICKS IP, 1992, P NATL ACAD SCI USA, V89, P1611, DOI 10.1073/pnas.89.5.1611	30	17	18	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 17	2015	10	6							e0130692	10.1371/journal.pone.0130692	http://dx.doi.org/10.1371/journal.pone.0130692			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CK9NS	26083390	Green Submitted, gold, Green Published			2023-01-03	WOS:000356567400155
J	Yang, SH; Kao, TI; Chiang, BL; Chen, HY; Chen, KH; Chen, JL				Yang, Sien-Hung; Kao, Ting-I; Chiang, Bor-Luen; Chen, Hsing-Yu; Chen, Kuang-Hua; Chen, Jiun-Liang			Immune-Modulatory Effects of Bu-Zhong-Yi-Qi-Tang in Ovalbumin-Induced Murine Model of Allergic Asthma	PLOS ONE			English	Article							HOCHU-EKKI-TO; ATTENUATES AIRWAY INFLAMMATION; TRADITIONAL CHINESE MEDICINE; IGE PRODUCTION; HYPERRESPONSIVENESS; HYPERREACTIVITY; EOSINOPHILS; MEPOLIZUMAB; MECHANISMS; PATHOLOGY	Background Bu-zhong-yi-qi-tang (BZYQT), an herbal formula of traditional Chinese medicine, has been an effective regimen of allergic diseases for nearly 800 years. Our previous report has demonstrated its anti-inflammatory effects in patients with perennial allergic rhinitis, and the aim of this study is to investigate the anti-asthmatic effect of BZYQT. Methods Female BALB/cByJNarl mice were sensitized with normal saline (control group) or OVA. Mice sensitized by OVA were fed with distilled water (OVA group), oral 0.5 g/Kg (low-dose group) or 1 g/Kg (high-dose group) of BZYQT solution once daily on days 36-40 besides their routine diet. Airway hyper-responsiveness (AHR), eosinophil infiltration, levels of cytokines and total immunoglobulin E (IgE) in broncho-alveolar lavage fluid (BALF) were determined. The lungs and tracheas were removed, and histopathologic examination was subsequently performed. Results AHR was significantly reduced in both low-and high-dose BZYQT groups compared with the OVA group after inhalation of the highest dose of methacholine (50 mg/ml). The levels of eotaxin, Th2-related cytokines (IL-4, IL-5, IL-13), IgE, and eosinophil infiltration in BALF were significantly decreased in both BZYQT groups compared with the OVA group. Histopathologic examination revealed that eosinophil infiltration of the lung and trachea tissues was remarkably attenuated in both BZYQT groups. Conclusions Oral administration of BZYQT solution may exert anti-asthmatic effect by relieving AHR in OVA-sensitized mice, which is compatible with our clinical experience. Although detailed mechanism is to be determined, we surmise that it may be correlated with the immune-modulatory effects of inhibiting Th2 responses on the basis of our limited results.	[Yang, Sien-Hung; Kao, Ting-I; Chen, Hsing-Yu; Chen, Jiun-Liang] Chang Gung Mem Hosp, Dept Tradit Chinese Med, Div Chinese Internal Med, Taoyuan, Taiwan; [Yang, Sien-Hung; Chen, Jiun-Liang] Chang Gung Univ, Sch Chinese Med, Taoyuan, Taiwan; [Kao, Ting-I] Chang Gung Univ, Grad Inst Biomed Sci, Div Nat Prod, Taoyuan, Taiwan; [Chiang, Bor-Luen] Natl Taiwan Univ, Grad Inst Immunol, Taipei 10764, Taiwan; [Chiang, Bor-Luen] Natl Taiwan Univ, Dept Pediat, Taipei 10764, Taiwan; [Chen, Hsing-Yu] Chang Gung Univ, Coll Med, Grad Inst Clin Med Sci, Taoyuan, Taiwan; [Chen, Kuang-Hua] Chang Gung Mem Hosp, Dept Pathol, Taoyuan, Taiwan	Chang Gung Memorial Hospital; Chang Gung University; Chang Gung University; National Taiwan University; National Taiwan University; Chang Gung University; Chang Gung Memorial Hospital	Yang, SH (corresponding author), Chang Gung Mem Hosp, Dept Tradit Chinese Med, Div Chinese Internal Med, Taoyuan, Taiwan.	dryang@cgmh.org.tw		CHIANG, BOR-LUEN/0000-0002-6705-0286	New Century Health Care Promotion Foundation	New Century Health Care Promotion Foundation	This study was supported by a grant from the New Century Health Care Promotion Foundation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	AZZAWI M, 1990, AM REV RESPIR DIS, V142, P1407, DOI 10.1164/ajrccm/142.6_Pt_1.1407; Barrios RJ, 2006, ARCH PATHOL LAB MED, V130, P447; Beal DR, 2013, AM J PHYSIOL-LUNG C, V305, pL866, DOI 10.1152/ajplung.00120.2013; Berend N, 2008, RESPIROLOGY, V13, P624, DOI 10.1111/j.1440-1843.2008.01330.x; Bousquet J, 2000, AM J RESP CRIT CARE, V161, P1720, DOI 10.1164/ajrccm.161.5.9903102; BOUSQUET J, 1990, NEW ENGL J MED, V323, P1033, DOI 10.1056/NEJM199010113231505; BRUSSELLE GG, 1994, CLIN EXP ALLERGY, V24, P73, DOI 10.1111/j.1365-2222.1994.tb00920.x; Chang HC, 2013, BMC COMPLEM ALTERN M, V13, DOI 10.1186/1472-6882-13-174; Cho JY, 2004, J CLIN INVEST, V113, P551, DOI 10.1172/JCI200419133; Cohn L, 2004, ANNU REV IMMUNOL, V22, P789, DOI 10.1146/annurev.immunol.22.012703.104716; Dai Han-yuan, 2011, Zhong Yao Cai, V34, P250; Deckers J, 2013, TRENDS IMMUNOL, V34, P540, DOI 10.1016/j.it.2013.08.004; Foster PS, 1996, J EXP MED, V183, P195, DOI 10.1084/jem.183.1.195; Georas SN, 2005, EUR RESPIR J, V26, P1119, DOI 10.1183/09031936.05.00006005; GLEICH GJ, 1979, J IMMUNOL, V123, P2925; Gluck J, 2012, INFLAMM RES, V61, P547, DOI 10.1007/s00011-012-0443-9; Haldar P, 2009, NEW ENGL J MED, V360, P973, DOI 10.1056/NEJMoa0808991; Huang WC, 2008, AM J CHINESE MED, V36, P579, DOI 10.1142/S0192415X08005990; Ishimitsu R, 2001, INT IMMUNOPHARMACOL, V1, P857, DOI 10.1016/S1567-5769(01)00022-4; Kaneko M, 1997, IMMUNOPHARMACOLOGY, V36, P79, DOI 10.1016/S0162-3109(96)00162-2; Kao ST, 2000, IMMUNOPHARM IMMUNOT, V22, P711, DOI 10.3109/08923970009016434; Kao ST, 2001, LIFE SCI, V69, P1485, DOI 10.1016/S0024-3205(01)01226-7; Kariyawasam HH, 2007, CURR OPIN IMMUNOL, V19, P681, DOI 10.1016/j.coi.2007.07.021; KAY AB, 1991, J ALLERGY CLIN IMMUN, V87, P893, DOI 10.1016/0091-6749(91)90408-G; Kobayashi H, 2003, DRUG EXP CLIN RES, V29, P81; Kudo M, 2013, FRONT MICROBIOL, V4, DOI 10.3389/fmicb.2013.00263; Lee MY, 2012, BMC COMPLEM ALTERN M, V12, DOI 10.1186/1472-6882-12-257; Liou CJ, 2010, FOOD CHEM TOXICOL, V48, P2592, DOI 10.1016/j.fct.2010.06.020; Nair P, 2009, NEW ENGL J MED, V360, P985, DOI 10.1056/NEJMoa0805435; Nakada T, 2002, INT IMMUNOPHARMACOL, V2, P901, DOI 10.1016/S1567-5769(02)00027-9; Park SJ, 2007, FOOD CHEM TOXICOL, V45, P1459, DOI 10.1016/j.fct.2007.02.013; Rothenberg ME, 2006, ANNU REV IMMUNOL, V24, P147, DOI 10.1146/annurev.immunol.24.021605.090720; SANTING RE, 1994, J ALLERGY CLIN IMMUN, V93, P1021, DOI 10.1016/S0091-6749(94)70051-6; Scichilone N, 2005, EUR RESPIR J, V25, P364, DOI 10.1183/09031936.05.00080204; Shin IS, 2013, INT IMMUNOPHARMACOL, V17, P867, DOI 10.1016/j.intimp.2013.09.017; Suzuki T, 1999, BIOL PHARM BULL, V22, P1180, DOI 10.1248/bpb.22.1180; Sy LB, 2006, INT IMMUNOPHARMACOL, V6, P1053, DOI 10.1016/j.intimp.2006.01.015; Tanaka H, 2000, CLIN EXP ALLERGY, V30, P874; Venkayya R, 2002, AM J RESP CELL MOL, V26, P202, DOI 10.1165/ajrcmb.26.2.4600; Wu CJ, 2006, CLIN EXP IMMUNOL, V145, P116, DOI 10.1111/j.1365-2249.2006.03099.x; Yang SH, 2008, J ETHNOPHARMACOL, V115, P104, DOI 10.1016/j.jep.2007.09.011	41	22	22	0	24	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 2	2015	10	6							e0127636	10.1371/journal.pone.0127636	http://dx.doi.org/10.1371/journal.pone.0127636			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CJ7SJ	26035827	Green Published, Green Submitted, gold			2023-01-03	WOS:000355699100017
J	Baek, SH; Ahn, SY; Lee, SW; Park, YS; Kim, S; Na, KY; Chae, DW; Kim, S; Chin, HJ				Baek, Seon Ha; Ahn, Shin Young; Lee, Sung Woo; Park, Youn Su; Kim, Sejoong; Na, Ki Young; Chae, Dong-Wan; Kim, Suhnggwon; Chin, Ho Jun			Outcomes of Predialysis Nephrology Care in Elderly Patients Beginning to Undergo Dialysis	PLOS ONE			English	Article							CHRONIC KIDNEY-DISEASE; STAGE RENAL-DISEASE; EARLY MORTALITY; HEMODIALYSIS-PATIENTS; PRACTICE PATTERNS; 1ST YEAR; PREDICTORS; SURVIVAL; IMPACT; CONSEQUENCES	Background The proportion of elderly patients beginning to undergo dialysis is increasing globally. Whether early referral (ER) of elderly patients is associated with favorable outcomes remains under debate. We investigated the influence of referral timing on the mortality of elderly patients. Methods We retrospectively assessed mortality in 820 patients aged >= 70 years with end-stage renal disease (ESRD) who initiated hemodialysis at a tertiary university hospital between 2000 and 2010. Mortality data was obtained from the time of dialysis initiation until December 2010. We assigned patients to one of two groups according to the time of their first encounters with nephrologists: ER (>= 3 months) and late referral (LR; < 3 months). Results During a mean follow-up period of 25.1 months, the ER group showed a 24% reduced risk of long-term mortality relative to the LR group (HR = 0.760, P = 0.009). Rate of reduction in 90-day mortality for ER patients was 58% (HR = 0.422, P=0.012). However, the statistical significance of the difference in mortality rates between ER and LR group was not observed across age groups after 90 days. Old age, LR, central venous catheter, high white blood cell count and corrected Ca level, and lower levels of albumin, creatinine, hemoglobin, and sodium were significantly associated with increased risk of mortality. Conclusions Timely referral was also associated with reduced mortality in elderly ESRD patients who initiated hemodialysis. In particular, the initial 90-day mortality reduction in ER patients contributed to mortality differences during the follow-up period.	[Baek, Seon Ha; Ahn, Shin Young; Lee, Sung Woo; Park, Youn Su; Kim, Sejoong; Na, Ki Young; Chae, Dong-Wan; Chin, Ho Jun] Seoul Natl Univ, Bundang Hosp, Dept Internal Med, Songnam, Gyeonggi Do, South Korea; [Kim, Sejoong; Na, Ki Young; Chae, Dong-Wan; Kim, Suhnggwon; Chin, Ho Jun] Seoul Natl Univ, Coll Med, Dept Internal Med, Seoul 151, South Korea	Seoul National University (SNU); Seoul National University (SNU)	Chin, HJ (corresponding author), Seoul Natl Univ, Bundang Hosp, Dept Internal Med, Songnam, Gyeonggi Do, South Korea.	mednep@hanmail.net	Kim, Sejoong/J-5356-2015	Kim, Sejoong/0000-0002-7238-9962				Arora P, 1999, J AM SOC NEPHROL, V10, P1281; Astor BC, 2001, AM J KIDNEY DIS, V38, P494, DOI 10.1053/ajkd.2001.26833; Bradbury BD, 2007, CLIN J AM SOC NEPHRO, V2, P89, DOI 10.2215/CJN.01170905; Carson RC, 2009, CLIN J AM SOC NEPHRO, V4, P1611, DOI 10.2215/CJN.00510109; Cass A, 2002, MED J AUSTRALIA, V177, P135, DOI 10.5694/j.1326-5377.2002.tb04698.x; Chan KE, 2011, CLIN J AM SOC NEPHRO, V6, P2642, DOI 10.2215/CJN.03680411; Collins AJ, 2009, CLIN J AM SOC NEPHRO, V4, pS5, DOI 10.2215/CJN.05980809; de Jager DJ, 2011, NEPHROL DIAL TRANSPL, V26, P652, DOI 10.1093/ndt/gfq438; Dogan E, 2005, NEPHROLOGY, V10, P516, DOI 10.1111/j.1440-1797.2005.00433.x; Ellis PA, 1998, QJM-MON J ASSOC PHYS, V91, P727, DOI 10.1093/qjmed/91.11.727; Foley RN, 2007, J AM SOC NEPHROL, V18, P2644, DOI 10.1681/ASN.2007020220; Foote C, 2014, AM J KIDNEY DIS, V64, P359, DOI 10.1053/j.ajkd.2014.02.023; Foote C, 2012, NEPHROL DIAL TRANSPL, V27, P3581, DOI 10.1093/ndt/gfs096; Gallego E, 2003, NEFROLOGIA, V23, P234; Hoffmann Maxime, 2006, Nephrol Ther, V2, P15, DOI 10.1016/j.nephro.2005.08.004; Jungers P, 2006, PRESSE MED, V35, P17, DOI 10.1016/S0755-4982(06)74514-6; JUNGERS P, 1993, KIDNEY INT, V43, pS170; Kazmi WH, 2004, NEPHROL DIAL TRANSPL, V19, P1808, DOI 10.1093/ndt/gfg573; Kim do H, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0055323, DOI 10.1371/J0URNAL.P0NE.0055323]; Krishnan M, 2002, SEMIN DIALYSIS, V15, P79, DOI 10.1046/j.1525-139X.2002.00028.x; Kurella M, 2007, ANN INTERN MED, V146, P177, DOI 10.7326/0003-4819-146-3-200702060-00006; Levey AS, 2006, ANN INTERN MED, V145, P247, DOI 10.7326/0003-4819-145-4-200608150-00004; Lukowsky LR, 2012, AM J NEPHROL, V35, P548, DOI 10.1159/000338673; McQuillan R, 2012, INT J NEPHROL, V2012, DOI 10.1155/2012/435736; Perl J, 2011, J AM SOC NEPHROL, V22, P1113, DOI 10.1681/ASN.2010111155; Quaglia M, 2011, ARCH INTERN MED, V171, P2065, DOI 10.1001/archinternmed.2011.585; Roubicek C, 2000, AM J KIDNEY DIS, V36, P35, DOI 10.1053/ajkd.2000.8241; Schmidt RJ, 1998, AM J KIDNEY DIS, V32, P278, DOI 10.1053/ajkd.1998.v32.pm9708613; Schwenger V, 2006, NEPHROL DIAL TRANSPL, V21, P962, DOI 10.1093/ndt/gfk030; Smart NA, 2011, AM J MED, V124, P1073, DOI 10.1016/j.amjmed.2011.04.026; Stack AG, 2003, AM J KIDNEY DIS, V41, P310, DOI 10.1053/ajkd.2003.50038; Stoves J, 2001, POSTGRAD MED J, V77, P586, DOI 10.1136/pmj.77.911.586; Winkelmayer WC, 2003, J AM SOC NEPHROL, V14, P486, DOI 10.1097/01.ASN.0000046047.66958.C3; Winkelmayer WC, 2001, AM J KIDNEY DIS, V38, P1178, DOI 10.1053/ajkd.2001.29207; Winkelmayer WC, 2011, ARCH INTERN MED, V171, P1371, DOI 10.1001/archinternmed.2011.360	35	18	19	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 1	2015	10	6							e0128715	10.1371/journal.pone.0128715	http://dx.doi.org/10.1371/journal.pone.0128715			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CL0KF	26030256	Green Published, gold, Green Submitted			2023-01-03	WOS:000356630900186
J	Koh, CL; Pan, SL; Jeng, JS; Chen, BB; Wang, YH; Hsueh, IP; Hsieh, CL				Koh, Chia-Lin; Pan, Shin-Liang; Jeng, Jiann-Shing; Chen, Bang-Bin; Wang, Yen-Ho; Hsueh, I-Ping; Hsieh, Ching-Lin			Predicting Recovery of Voluntary Upper Extremity Movement in Subacute Stroke Patients with Severe Upper Extremity Paresis	PLOS ONE			English	Article							MOTOR RECOVERY; REHABILITATION ASSESSMENT; UPPER-LIMB; INTERRATER RELIABILITY; FUNCTIONAL RECOVERY; IMPAIRMENT; STREAM; IMPACT; DEXTERITY; SCALE	Background and Objective Prediction of voluntary upper extremity (UE) movement recovery is largely unknown in patients with little voluntary UE movement at admission. The present study aimed to investigate (1) the extent and variation of voluntary UE movement recovery, and (2) the best predictive model of the recovery of voluntary UE movement by clinical variables in patients with severe UE paresis. Design Prospective cohort study. Methods 140 (out of 590) stroke patients with severe UE paresis completed all assessments. Voluntary UE movement was assessed using the UE subscale of the Stroke Rehabilitation Assessment of Movement (STREAM-UE). Two outcome measures, STREAM-UE scores at discharge (DCSTREAM-UE) and changes between admission and discharge (Delta(STREAM-UE))(,) were investigated to represent the final states and improvement of the recovery of voluntary UE movement. Stepwise regression analyses were used to investigate 19 clinical variables and to find the best predictive models of the two outcome measures. Results The participants showed wide variation in both DCSTREAM-UE and Delta(STREAM-UE). 3.6% of the participants almost fully recovered at discharge (DCSTREAM-UE > 15). A large improvement (Delta(STREAM-UE) >= 10) occurred in 16.4% of the participants, while 32.9% of the participants did not have any improvement. The four predictors for the DCSTREAM-UE (R-2 = 35.0%) were 'baseline STREAM-UE score', 'hemorrhagic stroke', 'baseline National Institutes of Health Stroke Scale (NIHSS) score', and 'cortical lesion excluding primary motor cortex'. The three predictors for the Delta(STREAM-UE) (R-2 = 22.0%) were 'hemorrhagic stroke', 'baseline NIHSS score', and 'cortical lesion excluding primary motor cortex'. Conclusions Recovery of voluntary UE movement varied widely in patients with severe UE paresis after stroke. The predictive power of clinical variables was poor. Both results indicate the complex nature of voluntary UE movement recovery in patients with severe UE paresis after stroke.	[Koh, Chia-Lin; Hsueh, I-Ping; Hsieh, Ching-Lin] Natl Taiwan Univ, Coll Med, Sch Occupat Therapy, Taipei, Taiwan; [Pan, Shin-Liang; Wang, Yen-Ho; Hsueh, I-Ping; Hsieh, Ching-Lin] Natl Taiwan Univ Hosp, Dept Phys Med & Rehabil, Taipei, Taiwan; [Jeng, Jiann-Shing] Natl Taiwan Univ Hosp, Dept Neurol, Taipei, Taiwan; [Chen, Bang-Bin] Natl Taiwan Univ Hosp, Dept Med Imaging & Radiol, Taipei, Taiwan	National Taiwan University; National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University Hospital	Hsueh, IP (corresponding author), Natl Taiwan Univ, Coll Med, Sch Occupat Therapy, Taipei, Taiwan.	iping@ntu.edu.tw	Hsieh, Ching-Lin/G-6057-2011; Koh, Chia-Lin/G-2127-2010	Hsieh, Ching-Lin/0000-0001-9468-9969; Koh, Chia-Lin/0000-0002-9927-2553; JENG, JIANN-SHING/0000-0002-1456-3686; PAN, SHIN-LIANG/0000-0001-6451-4666; CHEN, BANG-BIN/0000-0001-7058-1427; HSUEH, I-PING/0000-0002-8852-8242	National Taiwan University Hospital [UN102-069]	National Taiwan University Hospital(National Taiwan University)	This study was supported by the National Taiwan University Hospital (UN102-069).	Ahmed S, 2003, PHYS THER, V83, P617, DOI 10.1093/ptj/83.7.617; Baker K, 2011, STROKE, V42, P1787, DOI 10.1161/STROKEAHA.110.608505; Binkofski F, 2001, CEREBROVASC DIS, V11, P273, DOI 10.1159/000047650; BONITA R, 1988, STROKE, V19, P1497, DOI 10.1161/01.STR.19.12.1497; Daley K, 1999, PHYS THER, V79, P8, DOI 10.1093/ptj/79.1.8; Daley K, 1997, PHYSIOTHER CAN, V49, P269; DEHAAN RJ, 1995, STROKE, V26, P402, DOI 10.1161/01.STR.26.3.402; DUNCAN PW, 1992, STROKE, V23, P1084, DOI 10.1161/01.STR.23.8.1084; Feys H, 2000, Physiother Res Int, V5, P1, DOI 10.1002/pri.180; GOLDSTEIN LB, 1989, ARCH NEUROL-CHICAGO, V46, P660, DOI 10.1001/archneur.1989.00520420080026; Hendricks HT, 2002, ARCH PHYS MED REHAB, V83, P1629, DOI 10.1053/apmr.2002.35473; Hsueh IP, 2008, NEUROREHAB NEURAL RE, V22, P737, DOI 10.1177/1545968308315999; Kelly PJ, 2003, ARCH PHYS MED REHAB, V84, P968, DOI 10.1016/S0003-9993(03)00040-6; Kong KH, 2013, NEUROREHABILITATION, V32, P345, DOI 10.3233/NRE-130854; Kothari U, 1996, STROKE, V27, P1304, DOI 10.1161/01.STR.27.8.1304; Kwakkel G, 2003, STROKE, V34, P2181, DOI 10.1161/01.STR.0000087172.16305.CD; Lang CE, 2013, J HAND THER, V26, P104, DOI 10.1016/j.jht.2012.06.005; Lee YC, 2010, OCCUP THER INT, V17, P152, DOI 10.1002/oti.301; Lindenberg R, 2012, HUM BRAIN MAPP, V33, P1040, DOI 10.1002/hbm.21266; Lu WS, 2008, J REHABIL MED, V40, P615, DOI 10.2340/16501977-0230; Maddala GS, 2000, APPL ECON, V32, P635, DOI 10.1080/000368400322534; NAKAYAMA H, 1994, ARCH PHYS MED REHAB, V75, P852, DOI 10.1016/0003-9993(94)90108-2; Nijland RHM, 2010, STROKE, V41, P745, DOI 10.1161/STROKEAHA.109.572065; Pedraza S, 2012, J NEUROIMAGING, V22, P155, DOI 10.1111/j.1552-6569.2011.00588.x; Prabhakaran S, 2008, NEUROREHAB NEURAL RE, V22, P64, DOI 10.1177/1545968307305302; Riachy M, 2008, BMC NEUROL, V8, DOI 10.1186/1471-2377-8-24; Riley JD, 2011, STROKE, V42, P421, DOI 10.1161/STROKEAHA.110.599340; Shelton FDAP, 2001, NEUROREHAB NEURAL RE, V15, P229, DOI 10.1177/154596830101500311; Shi ZS, 2012, STROKE, V43, P1806, DOI 10.1161/STROKEAHA.111.649152; Sims JR, 2009, NEUROLOGY, V72, P2104, DOI 10.1212/WNL.0b013e3181aa5329; Stinear CM, 2007, BRAIN, V130, P170, DOI 10.1093/brain/awl333; Stinear CM, 2012, BRAIN, V135, P2527, DOI 10.1093/brain/aws146; TRFfS Computing, 2011, R LANG ENV STAT COMP, DOI [10.1016/j.neuroimage.2011.01.013, DOI 10.1016/J.NEUROIMAGE.2011.01.013]; Tsair TJ, 2010, RADIOGRAPHY, V16, P209, DOI 10.1016/j.radi.2010.04.004; van Kuijk AA, 2009, NEUROREHAB NEURAL RE, V23, P45, DOI 10.1177/1545968308317578; Wang CH, 2002, J REHABIL MED, V34, P20, DOI 10.1080/165019702317242668; Zarahn E, 2011, CEREB CORTEX, V21, P2712, DOI 10.1093/cercor/bhr047	38	21	22	1	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 14	2015	10	5							e0126857	10.1371/journal.pone.0126857	http://dx.doi.org/10.1371/journal.pone.0126857			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CI2AC	25973919	Green Published, gold, Green Submitted			2023-01-03	WOS:000354545600087
J	Chen, X; Li, XL; Zheng, J; Zhao, JS; He, JM; Zhang, GQ; Tang, XM				Chen, Xi; Li, Xingli; Zheng, Jun; Zhao, Junshi; He, Jianmei; Zhang, Guoqiang; Tang, Xuemin			Club Drugs and HIV/STD Infection: An Exploratory Analysis among Men Who Have Sex with Men in Changsha, China	PLOS ONE			English	Article							METHAMPHETAMINE USE; HIV-INFECTION; RISK BEHAVIOR; SUBSTANCE USE; PREVALENCE; SYPHILIS; GAY; PREDICTORS; SHANGHAI; PATTERNS	Objective To evaluate current club drug use and its potential association with the transmission of HIV/STD among Changsha men who have sex with men (MSM). Method A cross-sectional survey was conducted by using self-administered questionnaires including information regarding socio-demographics, club drug use, high-risk behaviors, and HIV/STD infections. Multiple methods including venue-based, peer referral using "snowball" techniques, and internet advertisements were used to recruit study participants. Results Of the 826 participants, 177 (21.4%) reported that they had used club drugs at some time before or during sex in the past six months. MSM with young age, low education level, and seeking partners through the internet or bars were the main population who used drugs. Poppers were the most common drug used among Changsha MSM. The prevalence of HIV, syphilis, and herpes simplex virus-2 were higher among drug users. There were no significant differences in unprotected sexual intercourse and condom use between drug users and non-users. Compared with non-users, risk behaviors such as group sex, multiple sex partners, and sex with foreigners were more frequent among drug users. Conclusion Club drug use is common among Changsha MSM, and is related to unsafe sex activities and HIV/STD infection. It is necessary to build novel targeted HIV prevention strategies to monitor and reduce club drug use among MSM.	[Chen, Xi; Zheng, Jun; Zhao, Junshi; He, Jianmei; Zhang, Guoqiang] Hunan Prov Ctr Dis Prevent & Control, Dept AIDS STI Control & Prevent, Changsha, Hunan, Peoples R China; [Li, Xingli; Tang, Xuemin] Cent S Univ, Sch Publ Hlth, Changsha, Hunan, Peoples R China	Central South University	Li, XL (corresponding author), Cent S Univ, Sch Publ Hlth, Changsha, Hunan, Peoples R China.	lixingli@csu.edu.cn			Natural Science Foundation of China [81202257]; National Science and Technology Major Project of China [2012ZX10001-001]; Foundation of Central South University for Outstanding Young Teachers [2013JSJJ032]	Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Science and Technology Major Project of China; Foundation of Central South University for Outstanding Young Teachers	This work funded by the Natural Science Foundation of China(NO.81202257) and National Science and Technology Major Project of China (NO:2012ZX10001-001) and Foundation of Central South University for Outstanding Young Teachers (No. 2013JSJJ032). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bai HL, 2011, J BIOMED RES, V25, P17, DOI 10.1016/S1674-8301(11)60002-X; Barrett SP, 2006, HUM PSYCHOPHARM CLIN, V21, P255, DOI 10.1002/hup.766; Bolding G, 2006, ADDICTION, V101, P1622, DOI 10.1111/j.1360-0443.2006.01571.x; Carey JW, 2009, AIDS BEHAV, V13, P1084, DOI 10.1007/s10461-008-9403-3; Ding Ying-ying, 2012, Fudan Xuebao (Yixueban), V39, P551, DOI 10.3969/j.issn.1672-8467.2012.06.001; Ding YY, 2013, DRUG ALCOHOL DEPEN, V131, P278, DOI 10.1016/j.drugalcdep.2012.12.019; Drumright LN, 2006, JAIDS-J ACQ IMM DEF, V43, P344, DOI 10.1097/01.qai.0000230530.02212.86; Halkitis PN, 2007, DRUG ALCOHOL DEPEN, V89, P153, DOI 10.1016/j.drugalcdep.2006.12.028; He N, 2007, AIDS, V21, pS73, DOI 10.1097/01.aids.0000304700.85379.f3; Kerr T, 2007, DRUG ALCOHOL DEPEN, V87, P39, DOI 10.1016/j.drugalcdep.2006.07.009; Li HM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023431; Li XF, 2010, CHINESE J AIDS STD, V16, P449; Li XH, 2009, AIDS PATIENT CARE ST, V23, P877, DOI 10.1089/apc.2009.0015; Li Y, 2012, AIDS BEHAV, V16, P491, DOI 10.1007/s10461-012-0157-6; Liu SS, 2012, SEX TRANSM DIS, V39, P251, DOI 10.1097/OLQ.0b013e31824a0903; Ma XY, 2007, JAIDS-J ACQ IMM DEF, V45, P581, DOI 10.1097/QAI.0b013e31811eadbc; McCambridge J, 2005, ADDICTION, V100, P1140, DOI 10.1111/j.1360-0443.2005.001127.x; Ministry of Health, 2009, PEOPL REP CHIN 2009; Operario D, 2006, PREV SCI, V7, P19, DOI 10.1007/s11121-005-0018-x; Plankey MW, 2007, JAIDS-J ACQ IMM DEF, V45, P85, DOI 10.1097/QAI.0b013e3180417c99; Ruan YH, 2007, SEX TRANSM DIS, V34, P592, DOI 10.1097/01.olq.0000253336.64324.ef; Rudy ET, 2009, SEX TRANSM DIS, V36, P693, DOI 10.1097/OLQ.0b013e3181ad54a3; Schwarcz S, 2007, AM J PUBLIC HEALTH, V97, P1067, DOI 10.2105/AJPH.2005.072249; Semple SJ, 2009, ARCH SEX BEHAV, V38, P583, DOI 10.1007/s10508-007-9292-y; Spindler HH, 2007, SEX TRANSM DIS, V34, P586, DOI 10.1097/01.olq.0000258339.17325.93; State Council AIDS Working Committee Office and UN Theme Group on AIDS in China, 2007, JOINT ASS HIV AIDS P; Xu JJ, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/725361; Xu JJ, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-287; Xu JJ, 2013, BMC INFECT DIS, V13, DOI 10.1186/1471-2334-13-3	29	29	41	0	21	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 7	2015	10	5							e0126320	10.1371/journal.pone.0126320	http://dx.doi.org/10.1371/journal.pone.0126320			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CH7KF	25950912	gold, Green Published, Green Submitted			2023-01-03	WOS:000354214400079
J	Benzon, HT; Huntoon, MA; Rathmell, JP				Benzon, Honorio T.; Huntoon, Marc A.; Rathmell, James P.			Improving the Safety of Epidural Steroid Injections	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									[Benzon, Honorio T.] Northwestern Univ, Dept Anesthesiol, Feinberg Sch Med, Chicago, IL 60611 USA; [Huntoon, Marc A.] Vanderbilt Univ, Sch Med, Dept Anesthesiol, Nashville, TN 37212 USA; [Rathmell, James P.] Massachusetts Gen Hosp, Dept Anesthesiol, Boston, MA 02114 USA; [Rathmell, James P.] Harvard Univ, Sch Med, Boston, MA USA	Northwestern University; Feinberg School of Medicine; Vanderbilt University; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Benzon, HT (corresponding author), Northwestern Univ, Dept Anesthesiol, Feinberg Sch Med, 251 E Huron St,Feinberg Pavil,Ste 5-704, Chicago, IL 60611 USA.	h-benzon@northwestern.edu	Rathmell, James/GQZ-1503-2022					[Anonymous], SUMM MIN AN AN DRUG; Benzon HT, 2007, ANESTHESIOLOGY, V106, P331, DOI 10.1097/00000542-200702000-00022; Dawley JD, 2009, SPINE, V34, P1638, DOI 10.1097/BRS.0b013e3181ac0018; Huntoon MA, 2005, PAIN, V117, P104, DOI 10.1016/j.pain.2005.05.030; Karasek M, 2004, PAIN MED, V5, P202, DOI 10.1111/j.1526-4637.2004.04028.x; Kennedy DJ, 2014, PAIN MED, V15, P548, DOI 10.1111/pme.12325; Malani AN, 2013, JAMA-J AM MED ASSOC, V309, P2465, DOI 10.1001/jama.2013.6293; Manchikanti L, 2013, PAIN PHYSICIAN, V16, pE349; Rathmell JP, 2015, ANESTHESIOLOGY, V122, P974, DOI 10.1097/ALN.0000000000000614	9	20	21	1	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 5	2015	313	17					1713	1714		10.1001/jama.2015.2912	http://dx.doi.org/10.1001/jama.2015.2912			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CH3HQ	25822848	Bronze			2023-01-03	WOS:000353921000014
J	Bogaert, P; Bochenek, T; Prokop, A; Pilc, A				Bogaert, Petronille; Bochenek, Tomasz; Prokop, Anna; Pilc, Andrzej			A Qualitative Approach to a Better Understanding of the Problems Underlying Drug Shortages, as Viewed from Belgian, French and the European Union's Perspectives	PLOS ONE			English	Article							IMPACT	The problem of drug shortages has been reported worldwide, gaining prominence in multiple domains and several countries in recent years. The aim of the study was to analyze, characterise and assess this problem in Belgium and France, while also adopting a wider perspective from the European Union. A qualitative methodological approach was employed, including semi-structured interviews with the representatives of respective national health authorities, pharmaceutical companies and wholesalers, as well as hospital and community pharmacists. The research was conducted in early 2014. Four themes, which were identified through the interviews, were addressed in the paper, i.e. a) defining drug shortages, b) their dynamics and perception, c) their determinants, d) the role of the European and national institutions in coping with the problem. Three groups of determinants of drug shortages were identified throughout this study: manufacturing problems, distribution and supply problems, and problems related to economic aspects. Currently, the Member States of the European Union are striving to resolve the problem very much on their own, although a far more focused and dedicated collaboration may well prove instrumental in coping with drug shortages throughout Europe more effectively. To the best of the authors' knowledge, this is the first qualitative study to investigate the characteristics, key determinants, and the problem drivers of drug shortages, focusing on this particular group of countries, while also adopting the European Union's perspective.	[Bogaert, Petronille; Bochenek, Tomasz] Jagiellonian Univ, Coll Med, Fac Hlth Sci, Dept Drug Management, Krakow, Poland; [Prokop, Anna] Jagiellonian Univ, Coll Med, Fac Med, Chair Epidemiol & Prevent Med, Krakow, Poland; [Pilc, Andrzej] Polish Acad Sci, Inst Pharmacol, Dept Neurobiol, Krakow, Poland	Jagiellonian University; Collegium Medicum Jagiellonian University; Jagiellonian University; Collegium Medicum Jagiellonian University; Polish Academy of Sciences	Bochenek, T (corresponding author), Jagiellonian Univ, Coll Med, Fac Hlth Sci, Dept Drug Management, Krakow, Poland.	mxbochen@cyf-kr.edu.pl	Pilc, Andrzej/A-3948-2008	Pilc, Andrzej/0000-0002-4045-0597				Agence nationale de securite du medicament et des produits de sante, 2014, INF SEC RUPT STOCK A; All-Party Pharmacy Group, 2012, REP APPG INQ MED SHO, P30; American Hospital Association, 2011, AHA SURV DRUG SHORT, P14; [Anonymous], 2011, LANCET ONCOL, V12, P313, DOI 10.1016/S1470-2045(11)70087-0; [Anonymous], 2010, LANCET, V376, P1712, DOI 10.1016/S0140-6736(10)62116-2; ASHP Drug Shortage Resource Center, 2014, DRUG SHORT CURR SHOR; ASHP Expert Panel on Drug Product Shortages, 2009, Am J Health Syst Pharm, V66, P1399, DOI 10.2146/ajhp090026; Autorite de la concurrence, 2012, AV 12 A 18 20 JUILL, P34; Bible JR, 2014, JPEN-PARENTER ENTER, V38, p65S, DOI 10.1177/0148607114550317; Birgli AG, 2013, EV MED SHORT EUR MOR; Canadian Agency for Drugs and Technologies in Health, 2011, ENV SCAN; Canadian Pharmacists Association, 2010, CAN DRUG SHORT SURV; Center for Drug Evaluation and Research, 2012, MAN POL PROC MAPP, P21; Chave J, 2013, MED SHORTAGES, P18; Costelloe E.M., 2014, IR J MED SCI; Dal Moro F, 2013, PREV MED, V57, P146, DOI 10.1016/j.ypmed.2013.04.019; De Weerdt E, 2015, REGUL TOXICOL PHARM, V71, P251, DOI 10.1016/j.yrtph.2015.01.005; European Association of Hospital Pharmacists, 2013, MED SHORT EUR HOSP; European Association of Pharmaceutical Full-line Wholesalers, 2013, MED SHORT EUR THEIR; European Federation of Pharmaceutical Industries and Associations, EFPIA GOOD PRACT RED, P6; European Medicines Agency, 2013, MED SHORT SHORT CAT; European Medicines Agency, 2012, EMA5907452012, P6; Federal Agency for Medicines and Health Products, 2014, FAGG ONB GEN; Food and Drug Administration, 2013, PERM DISC INT MAN CE; Fox E, 2014, DRUG STATUS UPDATE C, P4; Generics and Biosimilarrs Initiative, 2012, UK DRUG SHORT AR FAR; Gesundheit Osterreich GmbH, 2014, WHO COLL CTR PHARM P; Gibbs G.R., 2007, ANAL QUALITATIVE DAT; Gray A, 2012, B WORLD HEALTH ORGAN, V90, P157; Huys Isabelle, 2013, Int J Pharm Pract, V21, P1, DOI 10.1111/ijpp.12012; IMS Institute for Healthcare Informatics, 2011, DRUG SHORT CLOS LOOK; Institute for Safe Medication Practices, 2010, DRUG SHORT NAT SURV; ISPE, 2013, REP ISPE DRUG SHORT; Jensen V, 2002, AM J HEALTH-SYST PH, V59, P1423, DOI 10.1093/ajhp/59.15.1423; Johnson Thomas J, 2011, S D Med, V64, P14; Kaakeh R, 2011, AM J HEALTH-SYST PH, V68, pe13; Kaakeh R, 2011, AM J HEALTH-SYST PH, V68, P1811, DOI 10.2146/ajhp110210; Kosarek L, 2011, OCHSNER J, V11, P143; Kweder SL, 2013, CLIN PHARMACOL THER, V93, P245, DOI 10.1038/clpt.2012.235; Linthorst GE, 2013, JIMD REP, V8, P51, DOI 10.1007/8904_2012_160; Mayring P., 2000, FORUM QUALITATIVE SO, V1, P20, DOI [10.17169/fqs-1.2.1089, DOI 10.17169/FQS-1.2.1089, DOI 10.17169/FQS-22.2.3826]; Mazzoleni G, 1999, POLIT COMMUN, V16, P247, DOI 10.1080/105846099198613; McBride A, 2013, AM J HEALTH-SYST PH, V70, P609, DOI 10.2146/ajhp120563; Milmo S, 2013, PHARM TECHNOL, V2013, P32; Morrissey John, 2012, Trustee, V65, P10; Pauwels K, 2014, BMC HEALTH SERV RES, V14, DOI 10.1186/1472-6963-14-438; Pharmaceutical Group of European Union, MED SHORT EUR COMM P, P4; Pope C, 2000, BMJ-BRIT MED J, V320, P114, DOI 10.1136/bmj.320.7227.114; Schulman R, 2011, IMPACT DRUG SHORTAGE; Transcriber Lite, TRANSCR ONL TRANSCR; U.S. Food and Drug Administration, DRUG SHORT; US Food and Drug Administration, 2011, REV FDAS APPR MED PR; Ventola C Lee, 2011, P T, V36, P740; VERBI GmbH, MAXQDA QUAL DAT AN S; Woodcock J, 2013, CLIN PHARMACOL THER, V93, P170, DOI 10.1038/clpt.2012.220	55	38	38	0	16	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 5	2015	10	5							e0125691	10.1371/journal.pone.0125691	http://dx.doi.org/10.1371/journal.pone.0125691			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CH3PT	25942432	Green Published, Green Submitted			2023-01-03	WOS:000353943400050
J	Kader, R; Govender, R; Seedat, S; Koch, JR; Parry, C				Kader, Rehana; Govender, Rajen; Seedat, Soraya; Koch, John Randy; Parry, Charles			Understanding the Impact of Hazardous and Harmful Use of Alcohol and/or Other Drugs on ARV Adherence and Disease Progression	PLOS ONE			English	Article							HIV-INFECTED ADULTS; ANTIRETROVIRAL THERAPY; MEDICATION ADHERENCE; MENTAL-DISORDERS; PROBLEM DRINKING; SOUTH-AFRICA; PREDICTORS; NONADHERENCE; PREVALENCE; HIV/AIDS	The objective of this study was to understand the impact of hazardous and harmful use of alcohol and/or other drugs on ARV adherence and disease progression among HIV patients. A cross-sectional study design was used. A total of 1503 patients attending HIV clinics in Cape Town, South Africa were screened for problematic substance use. A sub-sample of 607 patients (303 patients who screened positive for problematic substance use and 304 who did not) participated in this study. Hazardous or harmful alcohol use and problematic drug use predicted missing and stopping ARVs which, in turn, was associated with a decrease in CD4 counts and more rapid HIV-disease progression and poorer health outcomes in people living with HIV/AIDS (PLWHA). The findings of this study underscore the need for an integrated approach to managing substance-use disorders in PLWHA.	[Kader, Rehana; Parry, Charles] MRC, Alcohol Tobacco & Other Drug Res Unit, Cape Town, South Africa; [Govender, Rajen] Univ Cape Town, Ctr Social Sci Res, ZA-7925 Cape Town, South Africa; [Govender, Rajen] Univ Cape Town, Dept Sociol, ZA-7925 Cape Town, South Africa; [Seedat, Soraya; Parry, Charles] Univ Stellenbosch, Dept Psychiat, ZA-7600 Stellenbosch, South Africa; [Koch, John Randy] Virginia Commonwealth Univ, Inst Drug & Alcohol Studies, Richmond, VA USA	University of Cape Town; University of Cape Town; Stellenbosch University; Virginia Commonwealth University	Kader, R (corresponding author), MRC, Alcohol Tobacco & Other Drug Res Unit, Cape Town, South Africa.	kaderrehana@gmail.com	Govender, Rajen/Y-4477-2019; Parry, Charles/A-2906-2009	Govender, Rajen/0000-0003-2720-7653; Parry, Charles/0000-0001-9787-2785; Seedat, Soraya/0000-0002-5118-786X	US President's Emergency Fund for AIDS Relief (PEPFAR) through the US Centers for Disease Control and Prevention (CDC) [5U2GPS001137]	US President's Emergency Fund for AIDS Relief (PEPFAR) through the US Centers for Disease Control and Prevention (CDC)	This research has been supported by the US President's Emergency Fund for AIDS Relief (PEPFAR) through the US Centers for Disease Control and Prevention (CDC), under the terms of Co-operative agreement grant number 5U2GPS001137. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the CDC or PEPFAR. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Berman A., 2005, DUDIT MANUAL DRUG US; Chander G, 2006, JAIDS-J ACQ IMM DEF, V43, P411, DOI 10.1097/01.qai.0000243121.44659.a4; Cook RL, 2001, J GEN INTERN MED, V16, P83, DOI 10.1046/j.1525-1497.2001.00122.x; Dada S, 2013, MONITORING ALCOHOL T, V34; Do NT, 2010, AIDS RES HUM RETROV, V26, P685, DOI 10.1089/aid.2009.0222; Farley John, 2010, J Int Assoc Physicians AIDS Care (Chic), V9, P218, DOI 10.1177/1545109710371133; Freeman M, 2007, AIDS CARE, V19, P1201, DOI 10.1080/09540120701426482; Hendershot CS, 2009, JAIDS-J ACQ IMM DEF, V52, P180, DOI 10.1097/QAI.0b013e3181b18b6e; Higgins-Biddle J., 2010, ALCOHOL USE DISORDER; Kader R, 2012, AFR J PSYCHIATRY, V15, P346, DOI [10.4314/ajpsy.v15i5.43, http://dx.doi.org/10.4314/ajpsy.v15i5.43]; Lucas GM, 2001, J ACQ IMMUN DEF SYND, V27, P251, DOI 10.1097/00126334-200107010-00006; Mellins CA, 2003, AIDS PATIENT CARE ST, V17, P407, DOI 10.1089/108729103322277420; Mellins CA, 2009, AIDS CARE, V21, P168, DOI 10.1080/09540120802001705; Mohammed H, 2004, AIDS PATIENT CARE ST, V18, P289, DOI 10.1089/108729104323076025; MORISKY DE, 1986, MED CARE, V24, P67, DOI 10.1097/00005650-198601000-00007; Myer L, 2008, AIDS PATIENT CARE ST, V22, P147, DOI 10.1089/apc.2007.0102; Nachega JB, 2004, AIDS RES HUM RETROV, V20, P1053, DOI 10.1089/aid.2004.20.1053; Olley BO, 2003, SAMJ S AFR MED J, V93, P928; Palepu A, 2008, J CRIT CARE, V23, P275, DOI 10.1016/j.jcrc.2007.04.001; Parry C.D., 2010, AFRICAN J DRUG ALCOH, V9, P81; Parry C. D. H., 2006, AFRICAN J DRUG ALCOH, V5, P140; Parry CD, 2007, CURR OPIN PSYCHIATR, V20, P235; Parsons JT, 2008, HEALTH PSYCHOL, V27, P628, DOI 10.1037/a0012664; Peltzer K, 2011, AFR J PSYCHIATRY, V14, P30; Peretti-Watel P, 2003, SUBST ALCOHOL DEP S1, V82, pS71; Schlebusch L, 2010, AFR J PSYCHIATRY, V13, P280; Schneider M., 2012, J AIDS CLIN RES, VS1:005, DOI [10.4712/2155-6113.S1-005, DOI 10.4172/2155-6113.S1-005]; Sebit M B, 2003, East Afr Med J, V80, P503; Sullivan LE, 2008, ADDICTION, V103, P1461, DOI 10.1111/j.1360-0443.2008.02245.x; Turner BJ, 2001, J GEN INTERN MED, V16, P625, DOI 10.1046/j.1525-1497.2001.016009625.x; Van Dyk AC, 2010, AJAR-AFR J AIDS RES, V9, P235, DOI 10.2989/16085906.2010.530177; Venkatesh KK, 2010, AIDS PATIENT CARE ST, V24, P795, DOI 10.1089/apc.2010.0153; Wagner GJ, 2000, AIDS CARE, V12, P405, DOI 10.1080/09540120050123800; WHO, 2014, GLOBAL STATUS REPORT ON VIOLENCE PREVENTION 2014, P1; Yunusa MA, 2011, AFR J DRUG ALCOHOL S, V10, P11	35	35	35	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 1	2015	10	5							e0125088	10.1371/journal.pone.0125088	http://dx.doi.org/10.1371/journal.pone.0125088			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CH2XA	25933422	Green Published, gold			2023-01-03	WOS:000353887100077
J	Louis, J; Schaal, K; Bieuzen, F; Le Meur, Y; Filliard, JR; Volondat, M; Brisswalter, J; Hausswirth, C				Louis, Julien; Schaal, Karine; Bieuzen, Francois; Le Meur, Yann; Filliard, Jean-Robert; Volondat, Marielle; Brisswalter, Jeanick; Hausswirth, Christophe			Head Exposure to Cold during Whole-Body Cryostimulation: Influence on Thermal Response and Autonomic Modulation	PLOS ONE			English	Article							WATER FACE IMMERSION; RATE-VARIABILITY; DORSAL HEAD; EXERCISE; PERFORMANCE; REFLEX; STIMULATION; PREDICTOR; PRESSURE; DESIGN	Recent research on whole-body cryotherapy has hypothesized a major responsibility of head cooling in the physiological changes classically reported after a cryostimulation session. The aim of this experiment was to verify this hypothesis by studying the influence of exposing the head to cold during whole-body cryostimulation sessions, on the thermal response and the autonomic nervous system (ANS). Over five consecutive days, two groups of 10 participants performed one whole-body cryostimulation session daily, in one of two different systems; one exposing the whole-body to cold (whole-body cryostimulation, WBC), and the other exposing the whole-body except the head (partial-body cryostimulation, PBC). 10 participants constituted a control group (CON) not receiving any cryostimulation. In order to isolate the head-cooling effect on recorded variables, it was ensured that the WBC and PBC systems induced the same decrease in skin temperature for all body regions (mean decrease over the 5 exposures: -8.6 degrees C +/- 1.3 degrees C and -8.3 +/- 0.7 degrees C for WBC and PBC, respectively), which persisted up to 20-min after the sessions (P20). The WBC sessions caused an almost certain decrease in tympanic temperature from Pre to P20 (-0.28 +/- 0.11 degrees C), while it only decreased at P20 (-0.14 +/- 0.05 degrees C) after PBC sessions. Heart rate almost certainly decreased after PBC (-8.6%) and WBC (-12.3%) sessions. Resting vagal-related heart rate variability indices (the root-mean square difference of successive normal RR intervals, RMSSD, and high frequency band, HF) were very likely to almost certainly increased after PBC (RMSSD:+49.1%, HF:+123.3%) and WBC (RMSSD:+38.8%, HF:+70.3%). Plasma norepinephrine concentration was likely increased in similar proportions after PBC and WBC, but only after the first session. Both cryostimulation techniques stimulated the ANS with a predominance of parasympathetic tone activation from the first to the fifth session and in slightly greater proportion with WBC than PBC. The main result of this study indicates that the head exposure to cold during whole-body cryostimulation may not be the main factor responsible for the effects of cryostimulation on the ANS.	[Louis, Julien; Schaal, Karine; Bieuzen, Francois; Le Meur, Yann; Hausswirth, Christophe] French Natl Inst Sport Expertise & Performance IN, Res Dept, Sport Expertise & Performance SEP Lab, Paris, France; [Schaal, Karine] Univ Calif Davis, Sports Med Program, Sports Performance Lab, Sacramento, CA 95817 USA; [Filliard, Jean-Robert; Volondat, Marielle] French Natl Inst Sport Expertise & Performance IN, Dept Med, Paris, France; [Brisswalter, Jeanick] Univ Nice Sophia Antipolis, Lab Human Motr Educ Sport & Hlth, F-06189 Nice, France	University of California System; University of California Davis; Sanofi-Aventis; Sanofi France; UDICE-French Research Universities; Universite Cote d'Azur	Louis, J (corresponding author), French Natl Inst Sport Expertise & Performance IN, Res Dept, Sport Expertise & Performance SEP Lab, Paris, France.	julien.louis@insep.fr	Louis, Julien/AAI-4392-2021; Bieuzen, Francois/F-8162-2013	Louis, Julien/0000-0002-9109-0958; Schaal, Karine/0000-0001-9215-9665; Bieuzen, Francois/0000-0002-9690-9168				Al Haddad H, 2011, INT J SPORTS MED, V32, P598, DOI 10.1055/s-0031-1275356; Al Haddad H, 2010, EUR J APPL PHYSIOL, V108, P599, DOI 10.1007/s00421-009-1253-9; Anderson LJ, 2012, NUTR RES, V32, P479, DOI 10.1016/j.nutres.2012.05.009; Buch AN, 2002, EXP PHYSIOL, V87, P423, DOI 10.1111/j.1469-445X.2002.tb00055.x; Buchheit M, 2009, AM J PHYSIOL-HEART C, V296, pH421, DOI 10.1152/ajpheart.01017.2008; Camm AJ, 1996, CIRCULATION, V93, P1043; Cholewka A, 2012, SKIN RES TECHNOL, V18, P180, DOI 10.1111/j.1600-0846.2011.00550.x; Chudecka M, 2014, AVIAT SPACE ENVIR MD, V85, P1170, DOI 10.3357/ASEM.3678.2014; Cohen J., 2013, STAT POWER ANAL BEHA; Cole CR, 1999, NEW ENGL J MED, V341, P1351, DOI 10.1056/NEJM199910283411804; Communal C, 1999, CIRCULATION, V100, P2210, DOI 10.1161/01.CIR.100.22.2210; Costello JT, 2012, SCAND J MED SCI SPOR, V22, P190, DOI 10.1111/j.1600-0838.2011.01292.x; Costello JT, 2013, COCHRANE LIB; ECKBERG DL, 1984, J PHYSIOL-LONDON, V347, P75, DOI 10.1113/jphysiol.1984.sp015054; Giesbrecht GG, 2005, J APPL PHYSIOL, V99, P1958, DOI 10.1152/japplphysiol.00052.2005; Hausswirth C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072658; Hausswirth C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027749; HAYWARD JS, 1984, RESUSCITATION, V11, P21, DOI 10.1016/0300-9572(84)90031-5; HEISTAD DD, 1968, J APPL PHYSIOL, V25, P542, DOI 10.1152/jappl.1968.25.5.542; Hopkins W.G., 2006, SPORTSCIENCE, V10, P46; Hopkins WG, 1999, MED SCI SPORT EXER, V31, P472, DOI 10.1097/00005768-199903000-00018; Hopkins WG, 2009, MED SCI SPORT EXER, V41, P3, DOI 10.1249/MSS.0b013e31818cb278; HURWITZ BE, 1986, PHYSIOL BEHAV, V36, P287, DOI 10.1016/0031-9384(86)90018-1; Jouven X, 2005, NEW ENGL J MED, V352, P1951, DOI 10.1056/NEJMoa043012; KAWAKAMI Y, 1967, J APPL PHYSIOL, V23, P964, DOI 10.1152/jappl.1967.23.6.964; Khurana RK, 2006, CLIN AUTON RES, V16, P202, DOI 10.1007/s10286-006-0332-9; Khurana RK, 1997, HEADACHE, V37, P522, DOI 10.1046/j.1526-4610.1997.3708522.x; Kinoshita T, 2006, CIRC J, V70, P773, DOI 10.1253/circj.70.773; Larsen PD, 2010, RESP PHYSIOL NEUROBI, V174, P111, DOI 10.1016/j.resp.2010.04.021; Lockhart TL, 2005, AVIAT SPACE ENVIR MD, V76, P954; Lubkowska A, 2010, INT J OCCUP MED ENV, V23, P367, DOI 10.2478/v10001-010-0037-0; MANN DL, 1992, CIRCULATION, V85, P790, DOI 10.1161/01.CIR.85.2.790; Paton JFR, 2005, BRAIN RES REV, V49, P555, DOI 10.1016/j.brainresrev.2005.02.005; Pournot H, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022748; Pretorius T, 2006, J APPL PHYSIOL, V101, P669, DOI 10.1152/japplphysiol.01241.2005; Pump B, 2001, AM J PHYSIOL-HEART C, V280, pH2607, DOI 10.1152/ajpheart.2001.280.6.H2607; Ring EFJ, 2015, INFRARED IMAGING: A CASEBOOK IN CLINICAL MEDICINE, DOI 10.1088/978-0-7503-1143-4ch1; Schaal K, 2013, APPL PHYSIOL NUTR ME, V38, P126, DOI 10.1139/apnm-2012-0155; SCHUITEMA K, 1988, ACTA PHYSIOL SCAND, V132, P119, DOI 10.1111/j.1748-1716.1988.tb08306.x; Shibahara N, 1996, J AUTONOM NERV SYST, V61, P109, DOI 10.1016/S0165-1838(96)00065-3; Stanley J, 2013, EUR J APPL PHYSIOL, V113, P371, DOI 10.1007/s00421-012-2445-2; Stanley J, 2012, EUR J APPL PHYSIOL, V112, P951, DOI 10.1007/s00421-011-2052-7; Udo T, 2013, J STUD ALCOHOL DRUGS, V74, P787, DOI 10.15288/jsad.2013.74.787; Utter AC, 2010, MED SCI SPORT EXER, V42, P361, DOI 10.1249/MSS.0b013e3181b2e8b4; Vaile J, 2011, BRIT J SPORT MED, V45, P825, DOI 10.1136/bjsm.2009.067272; Westerlund T, 2006, J THERM BIOL, V31, P342, DOI 10.1016/j.jtherbio.2006.01.004	46	10	11	0	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 27	2015	10	4							e0124776	10.1371/journal.pone.0124776	http://dx.doi.org/10.1371/journal.pone.0124776			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CG9SB	25915642	Green Submitted, gold, Green Published			2023-01-03	WOS:000353659100066
J	Dalgaard, LS; Norgaard, M; Jespersen, B; Jensen-Fangel, S; Ostergaard, LJ; Schonheyder, HC; Sogaard, OS				Dalgaard, Lars Skov; Norgaard, Mette; Jespersen, Bente; Jensen-Fangel, Soren; Ostergaard, Lars Jorgen; Schonheyder, Henrik Carl; Sogaard, Ole Schmeltz			Risk and Prognosis of Bloodstream Infections among Patients on Chronic Hemodialysis: A Population-Based Cohort Study	PLOS ONE			English	Article							AUREUS NASAL CARRIAGE; DIALYSIS PATIENTS; CLINICAL-SIGNIFICANCE; BACTEREMIA; SEPTICEMIA; CULTURES; QUALITY; SURVEILLANCE; PROPHYLAXIS; FUNGEMIA	Background and Objectives Infections are common complications among patients on chronic hemodialysis. This population-based cohort study aims to estimate risk and case fatality of bloodstream infection among chronic hemodialysis patients. Methods In this population-based cohort study we identified residents with end-stage renal disease in Central and North Jutland, Denmark who had hemodialysis as first renal replacement therapy (hemodialysis patients) during 1995-2010. For each hemodialysis patient, we sampled 19 persons from the general population matched on age, gender, and municipality. Information on positive blood cultures was obtained from regional microbiology databases. All persons were observed from cohort entry until first episode of bloodstream infection, emigration, death, or end of hemodialysis treatment, whichever came first. Incidence-rates and incidence-rate ratios were computed and risk factors for bloodstream infection assessed by Poisson regression. Case fatality was compared by Cox regression. Results Among 1792 hemodialysis patients and 33 618 matched population controls, we identified 461 and 1126 first episodes of bloodstream infection, respectively. Incidence rates of first episode of bloodstream infection were 13.7 (95% confidence interval (CI), 12.5-15.0) per 100 person-years among hemodialysis patients and 0.53 (95% CI, 0.50-0.56) per 100 person-years among population controls. In hemodialysis patients, the most common causative microorganisms were Staphylococcus aureus (43.8%) and Escherichia coli (12.6%). The 30-day case fatality was similar among hemodialysis patients and population controls 16% (95% CI, 13%-20%) vs. 18% (95% CI, 15%-20%). Conclusions Hemodialysis patients have extraordinary high risk of bloodstream infection while short-term case fatality following is similar to that of population controls.	[Dalgaard, Lars Skov; Jensen-Fangel, Soren; Ostergaard, Lars Jorgen; Sogaard, Ole Schmeltz] Aarhus Univ Hosp, Dept Infect Dis, DK-8000 Aarhus, Denmark; [Norgaard, Mette] Aarhus Univ Hosp, Dept Clin Epidemiol, DK-8000 Aarhus, Denmark; [Jespersen, Bente] Aarhus Univ Hosp, Dept Nephrol, DK-8000 Aarhus, Denmark; [Schonheyder, Henrik Carl] Aalborg Univ Hosp, Dept Clin Microbiol, Aalborg, Denmark; [Schonheyder, Henrik Carl] Aalborg Univ, Dept Clin Med, Aalborg, Denmark	Aarhus University; Aarhus University; Aarhus University; Aalborg University; Aalborg University Hospital; Aalborg University	Dalgaard, LS (corresponding author), Aarhus Univ Hosp, Dept Infect Dis, DK-8000 Aarhus, Denmark.	lars.dalgaard@clin.au.dk	Søgaard, Ole Schmeltz/AEP-7968-2022; Søgaard, Ole S/P-6058-2016; Ostergaard, Lars/AAA-3020-2020	Søgaard, Ole Schmeltz/0000-0001-9107-2023; Ostergaard, Lars/0000-0003-2459-0511; Ostergaard, Lars/0000-0002-7619-605X; Jespersen, Bente/0000-0001-7196-2870; Skov Dalgaard, Lars/0000-0002-4398-6821	Faculty of Health Science, University of Aarhus, Denmark	Faculty of Health Science, University of Aarhus, Denmark	LD is supported by a PhD grant from the Faculty of Health Science, University of Aarhus, Denmark. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abbott KC, 2001, CLIN NEPHROL, V56, P124; Allon M, 2003, J AM SOC NEPHROL, V14, P1863, DOI 10.1097/01.ASN.0000074237.78764.D1; BOELAERT JR, 1993, NEPHROL DIAL TRANSPL, V8, P235; CHOW JW, 1989, ARCH INTERN MED, V149, P1258, DOI 10.1001/archinte.149.6.1258; CHURCHILL DN, 1992, AM J KIDNEY DIS, V19, P214, DOI 10.1016/S0272-6386(13)80002-9; Foley RN, 2004, J AM SOC NEPHROL, V15, P1038, DOI 10.1097/01.ASN.0000119144.95922.C4; Foley RN, 2007, INFECT DIS CLIN N AM, V21, P659, DOI 10.1016/j.idc.2007.06.005; Gradel KO, 2012, BMC MED RES METHODOL, V12, DOI 10.1186/1471-2288-12-139; Hoen B, 1998, J AM SOC NEPHROL, V9, P869; Hommel K, 2010, NEPHROL DIAL TRANSPL, V25, P947, DOI 10.1093/ndt/gfp571; Ishani A, 2005, KIDNEY INT, V68, P311, DOI 10.1111/j.1523-1755.2005.00414.x; Johnson DW, 2002, NEPHROL DIAL TRANSPL, V17, P1802, DOI 10.1093/ndt/17.10.1802; Lynge E, 2011, SCAND J PUBLIC HEALT, V39, P30, DOI 10.1177/1403494811401482; Madsen KM, 1998, INFECT CONT HOSP EP, V19, P175; Nephrology DSo, 2010, DAN NEPHR REG ANN RE; Nephrology DSo, 2012, DAN NEPHR REG ANN RE; Ollendorf DA, 2002, VALUE HEALTH, V5, P79, DOI 10.1046/j.1524-4733.2002.52013.x; Powe NR, 1999, KIDNEY INT, V55, P1081, DOI 10.1046/j.1523-1755.1999.0550031081.x; Prevention CfDCa, BLOODSTR INF EV CENT; Rosenblum A, 2014, AM J KIDNEY DIS, V63, P259, DOI 10.1053/j.ajkd.2013.08.019; Sesso R, 1998, J AM SOC NEPHROL, V9, P1085; Tacconelli E, 2003, CLIN INFECT DIS, V37, P1629, DOI 10.1086/379715; Taylor G, 2004, AM J INFECT CONTROL, V32, P155, DOI 10.1016/j.ajic.2003.05.007; Thomson PC, 2007, QJM-INT J MED, V100, P415, DOI 10.1093/qjmed/hcm040; Tokars JI, 2004, CLIN INFECT DIS, V39, P333, DOI 10.1086/421941; U.S. Renal Data System, 2013, USRDS 2013 ANN DAT R; Vaziri ND, 2012, J RENAL NUTR, V22, P149, DOI 10.1053/j.jrn.2011.10.020; Weinstein MP, 1997, CLIN INFECT DIS, V24, P584, DOI 10.1093/clind/24.4.584; WEINSTEIN MP, 1983, REV INFECT DIS, V5, P35, DOI 10.1093/clinids/5.1.35; YU VL, 1986, NEW ENGL J MED, V315, P91, DOI 10.1056/NEJM198607103150204	30	31	33	1	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 24	2015	10	4							e0124547	10.1371/journal.pone.0124547	http://dx.doi.org/10.1371/journal.pone.0124547			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CG6AH	25910221	Green Published, Green Submitted, gold			2023-01-03	WOS:000353376800088
J	Hoppe, AL; Raghavan, ML; Hasan, DM				Hoppe, Anna L.; Raghavan, Madhavan L.; Hasan, David M.			Comparison of the Association of Sac Growth and Coil Compaction with Recurrence in Coil Embolized Cerebral Aneurysms	PLOS ONE			English	Article							RUPTURED INTRACRANIAL ANEURYSMS; GUGLIELMI DETACHABLE COILS; ENDOVASCULAR TREATMENT; RECANALIZATION; EXPERIENCE	Background and Purpose In recurrent cerebral aneurysms treated by coil embolization, coil compaction is regarded as the presumptive mechanism. We test the hypothesis that aneurysm growth is the primary recurrence mechanism. We also test the hypothesis that the coil mass will translate a measurable extent when recurrence occurs. Methods An objective, quantitative image analysis protocol was developed to determine the volumes of aneurysms and coil masses during initial and follow-up visits from 3D rotational angiograms. The population consisted of 15 recurrence and 12 non-recurrence control aneurysms initially completely coiled at a single center. An investigator sensitivity study was performed to assess the objectivity of the methods. Paired Wilcoxon tests (p<0.05, one-tailed) were performed to assess for aneurysm and coil growth. The translation of the coil mass center at follow-up was computed. A Mann Whitney U-Test (p<0.05, one-tailed) was used to compare translation of coil mass centers between recurrence and control subjects. Results Image analysis protocol was found to be insensitive to the investigator. Aneurysm growth was evident in the recurrence cohort (p=0.003) but not the control (p=0.136). There was no evidence of coil compaction in either the recurrence or control cohorts (recurrence: p=0.339; control: p=0.429). The translation of the coil mass centers was found to be significantly larger in the recurrence cohort than the control cohort (p=0.047). Conclusion Aneurysm sac growth, not coil compaction, was the primary mechanism of recurrence following successful coil embolization. The coil mass likely translates to a measurable extent when recurrence occurs and has the potential to serve as a non-angiographic recurrence marker.	[Hoppe, Anna L.; Raghavan, Madhavan L.] Univ Iowa, Dept Biomed Engn, Iowa City, IA 52242 USA; [Hasan, David M.] Univ Iowa, Carver Coll Med, Dept Neurosurg, Iowa City, IA 52242 USA	University of Iowa; University of Iowa	Hasan, DM (corresponding author), Univ Iowa, Carver Coll Med, Dept Neurosurg, Iowa City, IA 52242 USA.	david-hasan@uiowa.edu		hasan, david/0000-0002-8335-5442	NIH/NINDS [R03NS079227-01A1]; NIH/NHLBI [R01HL083475];  [K08NS082363-01A1]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL083475] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R03NS079227, K08NS082363] Funding Source: NIH RePORTER	NIH/NINDS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIH/NHLBI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); ; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	This study was supported by grants from NIH/NINDS R03NS079227-01A1 (DH), NIH/NHLBI R01HL083475 (MLR) and K08NS082363-01A1 (DH).	Abdihalim M, 2014, J NEUROIMAGING, V24, P171, DOI 10.1111/j.1552-6569.2012.00786.x; Bavinzski G, 1999, J NEUROSURG, V91, P284, DOI 10.3171/jns.1999.91.2.0284; Byrne JV, 1999, J NEUROSURG, V90, P656, DOI 10.3171/jns.1999.90.4.0656; De Craene M, 2008, SPIE MED IMAGING 200; Ford MD, 2009, BRIT J RADIOL, V82, pS55, DOI 10.1259/bjr/67593727; Gallas S, 2005, AM J NEURORADIOL, V26, P1723; Hasan DM, 2012, STROKE, V43, P866, DOI 10.1161/STROKEAHA.111.637827; Hwang GJ, 2000, INTERV NEURORADIOL, V6, P195, DOI 10.1177/159101990000600304; Kang HS, 2006, NEUROSURGERY, V58, P60, DOI 10.1227/01.NEU.0000194188.51731.13; Lorensen W, 1987, 14 ANN C COMP GRAPH; Mericle RA, 1998, J NEUROSURG, V89, P142, DOI 10.3171/jns.1998.89.1.0142; Murayama Y, 2003, J NEUROSURG, V98, P959, DOI 10.3171/jns.2003.98.5.0959; OSHER S, 1988, J COMPUT PHYS, V79, P12, DOI 10.1016/0021-9991(88)90002-2; Otsu N., 1975, AUTOMATICA, V11, P62; Raymond J, 2003, STROKE, V34, P1398, DOI 10.1161/01.STR.0000073841.88563.E9; Sluzewski M, 2004, RADIOLOGY, V231, P653, DOI 10.1148/radiol.2313030460	16	8	8	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 20	2015	10	4							e0123017	10.1371/journal.pone.0123017	http://dx.doi.org/10.1371/journal.pone.0123017			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CG3XA	25894532	Green Submitted, gold, Green Published			2023-01-03	WOS:000353211700021
J	Bernatz, JT; Tueting, JL; Anderson, PA				Bernatz, James T.; Tueting, Jonathan L.; Anderson, Paul A.			Thirty-Day Readmission Rates in Orthopedics: A Systematic Review and Meta-Analysis	PLOS ONE			English	Review							HOSPITAL READMISSION; RISK-FACTORS; TOTAL HIP; UNPLANNED READMISSION; KNEE ARTHROPLASTY; PREDICTORS; SURGERY	Background Hospital readmission rates are being used to evaluate performance. A survey of the present rates is needed before policies can be developed to decrease incidence of readmission. We address three questions: What is the present rate of 30-day readmission in orthopedics? How do factors such as orthopedic specialty, data source, patient insurance, and time of data collection affect the 30-day readmission rate? What are the causes and risk factors for 30-day readmissions? Methods/Findings A review was first registered with Prospero (CRD42014010293, 6/17/2014) and a meta-analysis was performed to assess the current 30-day readmission rate in orthopedics. Studies published after 2006 were retrieved, and 24 studies met the inclusion criteria. The 30-day readmission rate was extrapolated from each study along with the orthopedic subspecialty, data source, patient insurance, time of collection, patient demographics, and cause of readmission. A sensitivity analysis was completed on the stratified groups. The overall 30-day readmission rate across all orthopedics was 5.4 percent (95% confidence interval: 4.8,6.0). There was no significant difference between subspecialties. Studies that retrieved data from a multicenter registry had a lower 30-day readmission rate than those reporting data from a single hospital or a large national database. Patient populations that only included Medicare patients had a higher 30-day readmission rate than populations of all insurance. The 30-day readmission rate has decreased in the past ten years. Age, length of stay, discharge to skilled nursing facility, increased BMI, ASA score greater than 3, and Medicare/Medicaid insurance showed statistically positive correlation with increased 30-day readmissions in greater than 75 percent of studies. Surgical site complications accounted for 46 percent of 30-day readmissions. Conclusions This meta-analysis shows the present rate of 30-day readmissions in orthopedics. Demonstrable heterogeneity between studies underlines the importance of uniform collection and reporting of readmission rates for hospital evaluation and reimbursement.	[Bernatz, James T.; Tueting, Jonathan L.; Anderson, Paul A.] Univ Wisconsin, Dept Orthoped & Rehabil Med, Sch Med & Publ Hlth, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Bernatz, JT (corresponding author), Univ Wisconsin, Dept Orthoped & Rehabil Med, Sch Med & Publ Hlth, Madison, WI 53706 USA.	jbernatz@wisc.edu			Shapiro Summer Research Program at the University of Wisconsin School of Medicine and Public Health	Shapiro Summer Research Program at the University of Wisconsin School of Medicine and Public Health	James Bernatz received support from the Shapiro Summer Research Program at the University of Wisconsin School of Medicine and Public Health. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. No other outside funding was involved.	Amin BY, 2012, J NEUROSURG-SPINE, V16, P105, DOI 10.3171/2011.9.SPINE11644; Au AG, 2014, ACAD MED, V89, P517, DOI 10.1097/ACM.0000000000000154; Basques BA, 2014, SPINE, V39, P833, DOI 10.1097/BRS.0000000000000276; Bosco JA, 2014, J ARTHROPLASTY, V29, P903, DOI 10.1016/j.arth.2013.11.006; Centers for Medicare & Medicaid Services, 2014, READM RED PROGR; Chen AF, 2013, J ARTHROPLASTY, V28, P18, DOI 10.1016/j.arth.2013.03.036; Clement RC, 2013, J ARTHROPLASTY, V28, P7, DOI 10.1016/j.arth.2013.04.055; Cram P, 2012, MAYO CLIN PROC, V87, P341, DOI 10.1016/j.mayocp.2011.11.017; Cullen C, 2006, ANN ROY COLL SURG, V88, P475, DOI 10.1308/003588406X116909; Dailey EA, 2013, J BONE JOINT SURG AM, V95A, P1012, DOI 10.2106/JBJS.K.01569; Hageman MG, 2014, J ORTHOP TRAUMA, P5; Hayden JA, 2013, ANN INTERN MED, V158, P280, DOI 10.7326/0003-4819-158-4-201302190-00009; Hoyer EH, 2014, J HOSP MED, V9, P277, DOI 10.1002/jhm.2152; Huguet A, 2013, SYST REV-LONDON, V2, DOI 10.1186/2046-4053-2-71; Issa K, 2014, J KNEE SURG, P5; Jencks SF, 2009, NEW ENGL J MED, V360, P1418, DOI 10.1056/NEJMsa0803563; Joynt KE, 2011, JAMA-J AM MED ASSOC, V305, P675, DOI 10.1001/jama.2011.123; Kassin MT, 2012, J AM COLL SURGEONS, V215, P322, DOI 10.1016/j.jamcollsurg.2012.05.024; Kim BD, 2014, J NEUROSURG-SPINE, V20, P606, DOI 10.3171/2014.3.SPINE13699; Kocher RP, 2011, JAMA-J AM MED ASSOC, V306, P1794, DOI 10.1001/jama.2011.1561; Kurtz S, 2007, J BONE JOINT SURG AM, V89A, P780, DOI 10.2106/JBJS.F.00222; Leaper DJ, 2014, INT WOUND J, P2; Lovecchio F, 2014, SPINE, V39, P127, DOI 10.1097/BRS.0000000000000051; McCormack R, 2013, J HEALTHC MANAG, V58, P64, DOI 10.1097/00115514-201301000-00011; McCormack RA, 2012, SPINE, V37, P1260, DOI 10.1097/BRS.0b013e318245f561; Medicare Payment Advisory Commission, 2008, REP C REF DEL SYST; Mednick RE, 2014, J BONE JOINT SURG AM, V96A, P1201, DOI 10.2106/JBJS.M.00556; Mesko NW, 2014, J ARTHROPLASTY, P5, DOI [10.1093/jscr/rju043, DOI 10.1093/JSCR/RJU043]; Morris MS, 2014, JAMA SURG, V149, P348, DOI 10.1001/jamasurg.2013.4064; Pugely AJ, 2014, SPINE, P4; Pugely AJ, 2014, SPINE, V39, P761, DOI 10.1097/BRS.0000000000000270; Richmond JC, 2013, CLIN ORTHOP RELAT R, V471, P2372, DOI 10.1007/s11999-013-2909-7; Sacks GD, 2014, JAMA SURG, P6; Schairer WW, 2014, CLIN ORTHOP RELAT R, V472, P464, DOI 10.1007/s11999-013-3121-5; Schairer WW, 2013, SPINE, V38, P1681, DOI 10.1097/BRS.0b013e31829c08c9; Schairer WW, 2014, CLIN ORTHOP RELAT R, V472, P181, DOI 10.1007/s11999-013-3030-7; Spagnolo A M, 2013, J Prev Med Hyg, V54, P131; Vorhies JS, 2012, CLIN ORTHOP RELAT R, V470, P166, DOI 10.1007/s11999-011-1957-0; Vorhies JS, 2011, J ARTHROPLASTY, V26, P119, DOI 10.1016/j.arth.2011.04.036; Wang MC, 2012, SPINE J, V12, P902, DOI 10.1016/j.spinee.2012.09.051; Wright JG, 2003, J BONE JOINT SURG AM, V85A, P1, DOI 10.2106/00004623-200301000-00001; Zmistowski B, 2013, J BONE JOINT SURG AM, V95A, P1869, DOI 10.2106/JBJS.L.00679	42	80	80	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 17	2015	10	4							e0123593	10.1371/journal.pone.0123593	http://dx.doi.org/10.1371/journal.pone.0123593			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CG1EX	25884444	Green Published, Green Submitted, gold			2023-01-03	WOS:000353017000077
J	Falcone, PH; Tai, CY; Carson, LR; Joy, JM; Mosman, MM; Vogel, RM; McCann, TR; Crona, KP; Griffin, JD; Kim, MP; Moon, JR				Falcone, Paul H.; Tai, Chih Yin; Carson, Laura R.; Joy, Jordan M.; Mosman, Matt M.; Vogel, Roxanne M.; McCann, Tyler R.; Crona, Kevin P.; Griffin, J. Daniel; Kim, Michael P.; Moon, Jordan R.			Subcutaneous and Segmental Fat Loss with and without Supportive Supplements in Conjunction with a Low-Calorie High Protein Diet in Healthy Women	PLOS ONE			English	Article							CONJUGATED LINOLEIC-ACID; BODY-COMPOSITION CHANGES; X-RAY ABSORPTIOMETRY; WEIGHT-LOSS; ENERGY-EXPENDITURE; RANDOMIZED-TRIAL; GREEN TEA; BEHAVIOR-THERAPY; METABOLIC-RATE; ABDOMINAL FAT	Background Weight loss benefits of multi-ingredient supplements in conjunction with a low-calorie, high-protein diet in young women are unknown. Therefore, the purpose of this study was to investigate the effects of a three-week low-calorie diet with and without supplementation on body composition. Methods Thirty-seven recreationally-trained women (n = 37; age = 27.1 +/- 4.2; height = 165.1 +/- 6.4; weight = 68.5 +/- 10.1; BMI = 25.1 +/- 3.4) completed one of the following three-week interventions: no change in diet (CON); a high-protein, low-calorie diet supplemented with a thermogenic, conjugated linoleic acid (CLA), a protein gel, and a multi-vitamin (SUP); or the high-protein diet with isocaloric placebo supplements (PLA). Before and after the three-week intervention, body weight, % Fat via dual X-ray absorptiometry (DXA), segmental fat mass via DXA, % Fat via skinfolds, and skinfold thicknesses at seven sites were measured. Results SUP and PLA significantly decreased body weight (SUP: PRE, 70.47 +/- 8.01 kg to POST, 67.51 +/- 8.10 kg; PLA: PRE, 67.88 +/- 12.28 kg vs. POST, 66.38 +/- 11.94 kg; p +/- 0.05) with a greater (p +/- 0.05) decrease in SUP than PLA or CON. SUP and PLA significantly decreased % Fat according to DXA (SUP: PRE, 34.98 +/- 7.05% to POST, 32.99 +/- 6.89%; PLA: PRE, 34.22 +/- 6.36% vs. POST, 32.69 +/- 5.84%; p <= 0.05), whereas only SUP significantly decreased % Fat according to skinfolds (SUP: PRE, 27.40 +/- 4.09% to POST, 24.08 +/- 4.31%; p <= 0.05). SUP significantly (p <= 0.05) decreased thicknesses at five skinfolds (chest, waist, hip, subscapular, and tricep) compared to PLA, but not at two skinfolds (axilla and thigh). Conclusions The addition of a thermogenic, CLA, protein, and a multi-vitamin to a three-week low-calorie diet improved weight loss, total fat loss and subcutaneous fat loss, compared to diet alone.	[Falcone, Paul H.; Tai, Chih Yin; Carson, Laura R.; Joy, Jordan M.; Mosman, Matt M.; Kim, Michael P.; Moon, Jordan R.] MusclePharm Sports Sci Inst, Denver, CO USA; [Vogel, Roxanne M.] Metropolitan State Univ Denver, Denver, CO USA; [McCann, Tyler R.] Univ Colorado, Boulder, CO 80309 USA; [Crona, Kevin P.] Univ Colorado, Denver, CO 80202 USA; [Griffin, J. Daniel] Widener Univ, Chester, PA 19013 USA; [Moon, Jordan R.] US Sports Acad, Dept Sports Exercise Sci, Daphne, AL USA	Metropolitan State University of Denver; University of Colorado System; University of Colorado Boulder; University of Colorado System; University of Colorado Denver; Widener University	Moon, JR (corresponding author), MusclePharm Sports Sci Inst, Denver, CO USA.	jordan@musclepharm.com	Biguzzi, Felipe A/E-4724-2015		MusclePharm Corporation	MusclePharm Corporation	MusclePharm Corporation funded this study. The funder provided support in the form of salaries for authors PHF, CYT, LRC, JMJ, MMM, MPK, TRM and JRM, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the 'author contributions' section.	Acheson KJ, 2013, EUR J CLIN NUTR, V67, P462, DOI 10.1038/ejcn.2012.194; Alvarez VP, 2007, OBES SURG, V17, P211, DOI 10.1007/s11695-007-9032-3; ANDERSEN T, 1984, NEW ENGL J MED, V310, P352, DOI 10.1056/NEJM198402093100604; Baba NH, 1999, INT J OBESITY, V23, P1202, DOI 10.1038/sj.ijo.0801064; Ball S, 2004, RES Q EXERCISE SPORT, V75, P248, DOI 10.1080/02701367.2004.10609158; Berube-Parent S, 2005, BRIT J NUTR, V94, P432, DOI 10.1079/BJN20051502; Blankson H, 2000, J NUTR, V130, P2943, DOI 10.1093/jn/130.12.2943; BRACCO D, 1995, AM J PHYSIOL-ENDOC M, V269, pE671, DOI 10.1152/ajpendo.1995.269.4.E671; Cha YS, 2012, NUTR RES PRACT, V6, P520, DOI 10.4162/nrp.2012.6.6.520; Chen SC, 2012, NUTRITION, V28, P559, DOI 10.1016/j.nut.2011.09.008; Claessens M, 2009, INT J OBESITY, V33, P296, DOI 10.1038/ijo.2008.278; Delbridge EA, 2009, AM J CLIN NUTR, V90, P1203, DOI 10.3945/ajcn.2008.27209; Di Pierro F, 2009, ALTERN MED REV, V14, P154; DULLOO AG, 1989, AM J CLIN NUTR, V49, P44, DOI 10.1093/ajcn/49.1.44; Dulloo AG, 1999, AM J CLIN NUTR, V70, P1040; Foster GD, 2003, NEW ENGL J MED, V348, P2082, DOI 10.1056/NEJMoa022207; Gaullier JM, 2004, AM J CLIN NUTR, V79, P1118; Glickman SG, 2004, J APPL PHYSIOL, V97, P509, DOI 10.1152/japplphysiol.01234.2003; Hursel R, 2009, AM J CLIN NUTR, V89, P822, DOI 10.3945/ajcn.2008.27043; JACKSON AS, 1985, PHYSICIAN SPORTSMED, V13, P76, DOI 10.1080/00913847.1985.11708790; Janssen I, 2002, DIABETES CARE, V25, P431, DOI 10.2337/diacare.25.3.431; Jebb SA, 2000, BRIT J NUTR, V83, P115, DOI 10.1017/S0007114500000155; Kadooka Y, 2010, EUR J CLIN NUTR, V64, P636, DOI 10.1038/ejcn.2010.19; Kamphuis MMJW, 2003, INT J OBESITY, V27, P840, DOI 10.1038/sj.ijo.0802304; Lee SY, 2008, CURR OPIN CLIN NUTR, V11, P566, DOI 10.1097/MCO.0b013e32830b5f23; Lejeune MPGM, 2005, BRIT J NUTR, V93, P281, DOI 10.1079/BJN20041305; Leung FW, 2014, PROG DRUG RES, V68, P171, DOI 10.1007/978-3-0348-0828-6_7; Lopez HL, 2013, J INT SOC SPORT NUTR, V10, DOI 10.1186/1550-2783-10-22; Maki KC, 2009, J NUTR, V139, P264, DOI 10.3945/jn.108.098293; Minderico CS, 2008, BRIT J NUTR, V99, P432, DOI 10.1017/S0007114507815789; Moon JR, 2009, EUR J APPL PHYSIOL, V105, P119, DOI 10.1007/s00421-008-0881-9; Najafpanah MJ, 2014, GENE, V543, P253, DOI 10.1016/j.gene.2014.04.006; Norris LE, 2009, AM J CLIN NUTR, V90, P468, DOI 10.3945/ajcn.2008.27371; Outlaw J, 2013, J INT SOC SPORT NUTR, V10, DOI 10.1186/1550-2783-10-25; Pfeuffer M, 2011, J AM COLL NUTR, V30, P19, DOI 10.1080/07315724.2011.10719940; Riserus U, 2001, INT J OBESITY, V25, P1129, DOI 10.1038/sj.ijo.0801659; Rosenblum JL, 2012, AM J CLIN NUTR, V95, P101, DOI 10.3945/ajcn.111.019489; Rudelle S, 2007, OBESITY, V15, P349, DOI 10.1038/oby.2007.529; Rumpler W, 2001, J NUTR, V131, P2848, DOI 10.1093/jn/131.11.2848; Sillanpaa E, 2013, EUR J APPL PHYSIOL, V113, P2331, DOI 10.1007/s00421-013-2669-9; Sites CK, 2007, FERTIL STERIL, V88, P1609, DOI 10.1016/j.fertnstert.2007.01.061; Skov AR, 1999, INT J OBESITY, V23, P528, DOI 10.1038/sj.ijo.0800867; Smedman A, 2001, LIPIDS, V36, P773, DOI 10.1007/s11745-001-0784-7; Vasudev Sudha, 2004, J Assoc Physicians India, V52, P877; WADDEN TA, 1990, JAMA-J AM MED ASSOC, V263, P83, DOI 10.1001/jama.263.1.83; WADDEN TA, 1986, J CONSULT CLIN PSYCH, V54, P482, DOI 10.1037/0022-006X.54.4.482; WADDEN TA, 1988, J CONSULT CLIN PSYCH, V56, P925, DOI 10.1037/0022-006X.56.6.925; Wadden TA, 2011, OBESITY, V19, P1987, DOI 10.1038/oby.2011.230; Wang J, 2002, OBES RES, V10, P885, DOI 10.1038/oby.2002.121; Wang J, 2000, ANN NY ACAD SCI, V904, P317; Wycherley TP, 2012, AM J CLIN NUTR, V96, P1281, DOI 10.3945/ajcn.112.044321	52	4	5	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 15	2015	10	4							e0123854	10.1371/journal.pone.0123854	http://dx.doi.org/10.1371/journal.pone.0123854			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CG1EL	25875200	Green Submitted, Green Published, gold			2023-01-03	WOS:000353015800121
J	Chen, YM; Li, WY; Wu, VC; Wang, YC; Hwang, SJ; Lin, SH; Wu, KD				Chen, Yung-Ming; Li, Wen-Yi; Wu, Vin-Cent; Wang, Yi-Cheng; Hwang, Shang-Jyh; Lin, Shih-Hwa; Wu, Kwan-Dun			Impact of Weaning from Acute Dialytic Therapy on Outcomes of Chronic Kidney Disease following Urgent-Start Dialysis	PLOS ONE			English	Article							STAGE RENAL-DISEASE; LONG-TERM PROGNOSIS; REPLACEMENT THERAPY; UNITED-STATES; MORTALITY; INJURY; INITIATION; DEATH; WITHDRAWAL; RATES	Discontinuation of acute, unplanned dialysis is always an important therapeutic goal in dialysis- requiring patients with existing chronic kidney disease. Only a limited proportion of patients could be weaned off dialysis and remained dialysis-free. Here we performed a multicenter, observational study to investigate factors associated with successful weaning from acute dialysis, and to explore the potential impact of weaning itself on outcomes of patients with chronic kidney disease following urgent-start dialysis. We recruited 440 chronic kidney disease patients with a baseline estimated glomerular filtration rate < 45 ml/min per 1/73 m2, and used propensity score-adjusted Cox regression analysis to measure the effect of weaning from acute dialysis on death during the index hospitalization and death or readmission after discharge. Over 2 years, 64 of 421 (15.2%) patients who survived > 1 month died, and 36 (8.6%) were removed from dialysis, with 26 (6.2%) remaining alive and dialysis- free. Logistic regression analysis found that age. 65 years, ischemic acute tubular necrosis, nephrotoxic exposure, urinary obstruction, and higher predialysis estimated glomerular filtration rate and serum hemoglobin were predictors of weaning off dialysis. After adjustment for propensity scores for dialysis weaning, Cox proportional hazards models showed successful weaning from dialysis (adjusted hazard ratio 0.06; 95% confidence interval 0.01 to 0.35), along with a history of hypertension and serum albumin, were independent protectors for early death. Conversely, a history of stroke, peripheral arterial disease and cancer predicted the occurrence of early mortality. In conclusion, this prospective cohort study shows that compared to patients with chronic kidney disease who became end-stage renal disease after acute dialysis, patients who could be weaned off acute dialytic therapy were associated with reduced risk of premature death over a 2-year observation period.	[Chen, Yung-Ming; Li, Wen-Yi] Natl Taiwan Univ Hosp, Dept Internal Med, Div Renal, Yun Lin Branch, Yunlin, Taiwan; [Chen, Yung-Ming; Wu, Vin-Cent; Wang, Yi-Cheng; Wu, Kwan-Dun] Natl Taiwan Univ, Natl Taiwan Univ Hosp, Coll Med, Renal Div,Dept Internal Med, Taipei 10764, Taiwan; [Hwang, Shang-Jyh] Kaohsiung Med Univ Hosp, Dept Internal Med, Div Nephrol, Kaohsiung, Taiwan; [Hwang, Shang-Jyh] Kaohsiung Med Univ, Coll Med, Fac Renal Care, Kaohsiung, Taiwan; [Hwang, Shang-Jyh] Natl Hlth Res Inst, Inst Populat Hlth Sci, Div Geriatr & Gerontol, Taipei, Taiwan; [Lin, Shih-Hwa] Natl Def Med Ctr, Triserv Gen Hosp, Dept Internal Med, Div Nephrol, Taipei, Taiwan	National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University Hospital; Kaohsiung Medical University; Kaohsiung Medical University Hospital; Kaohsiung Medical University; National Health Research Institutes - Taiwan; National Defense Medical Center; Tri-Service General Hospital	Chen, YM (corresponding author), Natl Taiwan Univ Hosp, Dept Internal Med, Div Renal, Yun Lin Branch, Yunlin, Taiwan.	chenym@ntuh.gov.tw	Li, Wen-Yi/AAM-9668-2021	WU, VIN-CENT/0000-0001-7935-0991; WU, KWAN-DUN/0000-0002-3339-1509; CHEN, YUNG-MING/0000-0002-9241-1258	Department of Health (now the Ministry of Health and Welfare) [DOH97-HP-1102]; Ta-Tung Kidney Foundation; Mrs Hsiu-Chin Lee Kidney Research Fund, Taipei, Taiwan	Department of Health (now the Ministry of Health and Welfare); Ta-Tung Kidney Foundation; Mrs Hsiu-Chin Lee Kidney Research Fund, Taipei, Taiwan	This study was supported by grants from the Department of Health (now the Ministry of Health and Welfare), DOH97-HP-1102, the Ta-Tung Kidney Foundation, and the Mrs Hsiu-Chin Lee Kidney Research Fund, Taipei, Taiwan. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Barbour SJ, 2010, NEPHROL DIAL TRANSPL, V25, P3663, DOI 10.1093/ndt/gfq189; Cerda J, 2007, NEPHROL DIAL TRANSPL, V22, P2781, DOI 10.1093/ndt/gfm395; Claure-Del Granado R, 2011, SEMIN DIALYSIS, V24, P208, DOI 10.1111/j.1525-139X.2011.00832.x; Coca SG, 2012, KIDNEY INT, V81, P442, DOI 10.1038/ki.2011.379; Conneen S, 1998, DIALYSIS TRANSPLANT, V27, P200; Derose SF, 2013, AM J KIDNEY DIS, V62, P236, DOI 10.1053/j.ajkd.2013.01.019; Eckardt KU, 2012, KIDNEY INT SUPPL, V2, P7, DOI 10.1038/kisup.2012.8; Ellwood AD, 2013, CLIN J AM SOC NEPHRO, V8, P265, DOI 10.2215/CJN.01000112; Foley RN, 2009, J AM SOC NEPHROL, V20, P1432, DOI 10.1681/ASN.2009030282; Gibney N, 2008, CLIN J AM SOC NEPHRO, V3, P876, DOI 10.2215/CJN.04871107; Goodkin DA, 2003, J AM SOC NEPHROL, V14, P3270, DOI 10.1097/01.ASN.0000100127.54107.57; Hall YN, 2005, J AM SOC NEPHROL, V16, P3711, DOI 10.1681/ASN.2005060580; Hsu CY, 2009, CLIN J AM SOC NEPHRO, V4, P891, DOI 10.2215/CJN.05571008; Iseki K, 2000, AM J KIDNEY DIS, V36, P820, DOI 10.1053/ajkd.2000.17676; Iseki K, 2000, NEPHROL DIAL TRANSPL, V15, P1808, DOI 10.1093/ndt/15.11.1808; Ishani A, 2009, J AM SOC NEPHROL, V20, P223, DOI 10.1681/ASN.2007080837; Khosla N, 2009, CLIN J AM SOC NEPHRO, V4, P1914, DOI 10.2215/CJN.01690309; Koch M, 2012, NEPHROL DIAL TRANSPL, V27, P375, DOI 10.1093/ndt/gfr262; Kovesdy CP, 2009, SEMIN NEPHROL, V29, P3, DOI 10.1016/j.semnephrol.2008.10.002; Lee PH, 2011, AM J NEPHROL, V34, P95, DOI 10.1159/000329082; Levey AS, 2009, ANN INTERN MED, V150, P604, DOI 10.7326/0003-4819-150-9-200905050-00006; Levey AS, 2003, ANN INTERN MED, V139, P137, DOI 10.7326/0003-4819-139-2-200307150-00013; Mehta RL, 2007, CRIT CARE, V11, DOI 10.1186/cc5713; Mehta RL, 2004, KIDNEY INT, V66, P1613, DOI 10.1111/j.1523-1755.2004.00927.x; Mendelssohn DC, 2009, BMC NEPHROL, V10, DOI 10.1186/1471-2369-10-22; Metcalfe W, 2000, KIDNEY INT, V57, P2539, DOI 10.1046/j.1523-1755.2000.00113.x; O'Hare A, 2001, J AM SOC NEPHROL, V12, P2838, DOI 10.1681/ASN.V12122838; Steenkamp R, 2013, NEPHRON CLIN PRACT, V123, P93, DOI 10.1159/000353324; Tennankore KK, 2012, BMC NEPHROL, V13, DOI 10.1186/1471-2369-13-72; Teo BW, 2010, ANN ACAD MED SINGAP, V39, P79; Vanholder R, 2012, J AM SOC NEPHROL, V23, P1291, DOI 10.1681/ASN.2011111094; Wei SY, 2010, NEPHROLOGY, V15, P108, DOI 10.1111/j.1440-1797.2009.01154.x; Wen CP, 2008, LANCET, V371, P2173, DOI 10.1016/S0140-6736(08)60952-6; Weng PH, 2011, CLIN J AM SOC NEPHRO, V6, P1121, DOI 10.2215/CJN.09011010; Wu VC, 2008, INTENS CARE MED, V34, P101, DOI 10.1007/s00134-007-0813-x; Wu VC, 2011, KIDNEY INT, V80, P1222, DOI 10.1038/ki.2011.259; Yang WC, 2008, NEPHROL DIAL TRANSPL, V23, P3977, DOI 10.1093/ndt/gfn406; Yoshino M, 2006, J AM SOC NEPHROL, V17, P3510, DOI 10.1681/ASN.2006020156	38	2	2	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 9	2015	10	4							e0123386	10.1371/journal.pone.0123386	http://dx.doi.org/10.1371/journal.pone.0123386			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CF5HQ	25856435	Green Published, Green Submitted, gold			2023-01-03	WOS:000352588500089
J	Yang, Y; Qiu, WQ; Hao, YL; Lv, ZY; Jiao, SJ; Teng, JF				Yang, Yan; Qiu, Wei Qing; Hao, Yan Lei; Lv, Zhan Yun; Jiao, Shu Ji; Teng, Jun Feng			The Efficacy of Traditional Chinese Medical Exercise for Parkinson's Disease: A Systematic Review and Meta-analysis	PLOS ONE			English	Review							TAI CHI EXERCISE; BEHAVIORAL RECOVERY; QIGONG; MOTOR; NEUROPLASTICITY; INDIVIDUALS; PERFORMANCE; QUALITY; BALANCE	Background and Objective Several studies assessed the efficacy of traditional Chinese medical exercise in the management of Parkinson's disease (PD), but its role remained controversial. Therefore, the purpose of this systematic review is to evaluate the evidence on the effect of traditional Chinese medical exercise for PD. Methods Seven English and Chinese electronic databases, up to October 2014, were searched to identify relevant studies. The PEDro scale was employed to assess the methodological quality of eligible studies. Meta-analysis was performed by RevMan 5.1 software. Results Fifteen trials were included in the review. Tai Chi and Qigong were used as assisting pharmacological treatments of PD in the previous studies. Tai Chi plus medication showed greater improvements in motor function (standardized mean difference, SMD, -0.57; 95% confidence intervals, CI, -1.11 to -0.04), Berg balance scale (BBS, SMD, -1.22; 95% CI -1.65 to -0.80), and time up and go test (SMD, -1.06; 95% CI -1.44 to -0.68). Compared with other therapy plus medication, Tai Chi plus medication also showed greater gains in motor function (SMD, -0.78; 95% CI -1.46 to -0.10), BBS (SMD, -0.99; 95% CI -1.44 to -0.54), and functional reach test (SMD, -0.77; 95% CI -1.51 to -0.03). However, Tai Chi plus medication did not showed better improvements in gait or quality of life. There was not sufficient evidence to support or refute the effect of Qigong plus medication for PD. Conclusions In the previous studies, Tai Chi and Qigong were used as assisting pharmacological treatments of PD. The current systematic review showed positive evidence of Tai Chi plus medication for PD of mild-to-moderate severity. So Tai Chi plus medication should be recommended for PD management, especially in improving motor function and balance. Qigong plus medication also showed potential gains in the management of PD. However, more high quality studies with long follow-up are warrant to confirm the current findings.	[Yang, Yan; Hao, Yan Lei; Lv, Zhan Yun] Jining Med Univ, Dept Neurol, Affiliated Hosp, Jining, Shandong, Peoples R China; [Qiu, Wei Qing] Laizhou Peoples Hosp Shangdong, Dept Neurol, Laizhou, Shandong, Peoples R China; [Qiu, Wei Qing] Binzhou Med Univ Hosp, Binzhou, Shandong, Peoples R China; [Jiao, Shu Ji; Teng, Jun Feng] First Peoples Hosp Hebi, Dept Neurol, Hebi, Henan, Peoples R China	Jining Medical University; Binzhou Medical University	Yang, Y (corresponding author), Jining Med Univ, Dept Neurol, Affiliated Hosp, Jining, Shandong, Peoples R China.	yanyangdr@126.com; qingweiqiudr@163.com	hao, yan/HGB-0465-2022; Northcote, Matthew/B-8209-2019; Northcote, Matthew/L-1135-2019		National Natural Science Fund Projects of China [81271398]	National Natural Science Fund Projects of China(National Natural Science Foundation of China (NSFC))	This study is supported by the National Natural Science Fund Projects of China (81271398). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Allen NE, 2011, MOVEMENT DISORD, V26, P1605, DOI 10.1002/mds.23790; Amano S, 2013, PARKINSONISM RELAT D, V19, P955, DOI 10.1016/j.parkreldis.2013.06.007; An BC, 2008, J ALTERN COMPLEM MED, V14, P167, DOI 10.1089/acm.2007.0600; Burini D, 2006, Eura Medicophys, V42, P231; Canning CG, 2012, CLIN REHABIL, V26, P817, DOI 10.1177/0269215511432652; Cheng L., 2014, THESIS YUNNAN COLL T; Cheon SM, 2013, J CLIN NEUROL, V9, P237, DOI 10.3988/jcn.2013.9.4.237; Cheon SM, 2006, P 1 INT C TAI CHI HL, P68; Choi Hye-Jung, 2013, ISRN Neurol, V2013, P548240, DOI 10.1155/2013/548240; Ding M, 2014, J ALTERN COMPLEM MED, V20, P79, DOI 10.1089/acm.2013.0087; Fisher BE, 2004, J NEUROSCI RES, V77, P378, DOI 10.1002/jnr.20162; Frazzitta G, 2013, AM J PHYS MED REHAB, V92, P523, DOI 10.1097/PHM.0b013e31828cd254; Gao Q, 2014, CLIN REHABI IN PRESS; Gladfelter BA., 2011, THESIS VALPARAISO U; Gu AM, 2002, HENAN J PRACTICAL NE, V5, P3; Hackney ME, 2008, GAIT POSTURE, V28, P456, DOI 10.1016/j.gaitpost.2008.02.005; Hackney ME, 2009, PARKINSONISM RELAT D, V15, P644, DOI 10.1016/j.parkreldis.2009.03.003; Hackney ME, 2009, J REHABIL MED, V41, P475, DOI 10.2340/16501977-0362; Hass CJ, 2006, ANN M AM SOC BIOM; Hausdorff JM, 2009, CHAOS, V19, DOI 10.1063/1.3147408; HEYES MP, 1988, LIFE SCI, V42, P1537, DOI 10.1016/0024-3205(88)90011-2; Jankovic J, 2008, J NEUROL NEUROSUR PS, V79, P368, DOI 10.1136/jnnp.2007.131045; King LA, 2009, PHYS THER, V89, P384, DOI 10.2522/ptj.20080214; Lan C., 2013, EVID-BASED COMPL ALT, V2013, DOI DOI 10.1155/2013/502131; Lauche R, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/635182; Lee MS, 2009, MOVEMENT DISORD, V24, P301, DOI 10.1002/mds.22275; Lee MS, 2008, PARKINSONISM RELAT D, V14, P589, DOI 10.1016/j.parkreldis.2008.02.003; Li F, 2001, Prev Sci, V2, P229, DOI 10.1023/A:1013614200329; Li FZ, 2007, J AGING PHYS ACTIV, V15, P139, DOI 10.1123/japa.15.2.139; Li FZ, 2012, NEW ENGL J MED, V366, P511, DOI 10.1056/NEJMoa1107911; Li JX., 2011, THESIS NANJING U CHI; Li R, 2014, EVID-BASED COMPL ALT, V2014, DOI 10.1155/2014/784059; Macedo LG, 2010, J CLIN EPIDEMIOL, V63, P920, DOI 10.1016/j.jclinepi.2009.10.005; MacLaggan L, 2000, THESIS DALHOUSIE U H; Maher CG, 2003, PHYS THER, V83, P713, DOI 10.1093/ptj/83.8.713; Marjama-Lyons J, 2002, MOVEMENT DISORD, V17, pS70; Ni XJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099377; Nocera Joe R, 2013, J Yoga Phys Ther, V3, DOI 10.4172/2157-7595.1000137; Ospina Maria B, 2007, Evid Rep Technol Assess (Full Rep), P1; Petzinger GM, 2013, LANCET NEUROL, V12, P716, DOI 10.1016/S1474-4422(13)70123-6; Purchas MA, 2007, MOVEMENT DISORD, V22, pS80; Sung Hyeryun, 2006, [Korean Journal of Sport Studies, 한국체육학회지], V45, P583; Temlett JA, 2006, INTERN MED J, V36, P524, DOI 10.1111/j.1445-5994.2006.01123.x; Tian BW, 2012, THESIS BEIJING SPORT; Tillerson JL, 2003, NEUROSCIENCE, V119, P899, DOI 10.1016/S0306-4522(03)00096-4; Toh SFM, 2013, HONG KONG J OCCUP TH, V23, P69, DOI 10.1016/j.hkjot.2013.11.001; Van Den Eeden SK, 2003, AM J EPIDEMIOL, V157, P1015, DOI 10.1093/aje/kwg068; van Praag H, 1999, NAT NEUROSCI, V2, P266, DOI 10.1038/6368; Welsh M, 1997, MOV DISORD, V12, P137; Yang Y, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102942; Yu XH, 1998, CHINESE JOURNAL OF B, V7, P303; Zeng YC, 2014, COMPLEMENT THER MED, V22, P173, DOI 10.1016/j.ctim.2013.11.010; Zhang F, 2014, J PHYS THER SCI, V26, P881, DOI 10.1589/jpts.26.881; Zhang ZX, 2005, LANCET, V365, P595, DOI 10.1016/S0140-6736(05)70801-1; [朱毅 Zhu Yi], 2011, [中国康复理论与实践, Chinese Journal of Rehabilitation Theory and Practice], V17, P355	55	26	26	0	49	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 1	2015	10	4							e0122469	10.1371/journal.pone.0122469	http://dx.doi.org/10.1371/journal.pone.0122469			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CE9AM	25830664	gold, Green Published, Green Submitted			2023-01-03	WOS:000352135600110
J	Zhang, WZ; Zhai, TT; Lu, JY; Chen, JZ; Chen, ZJ; Li, DR; Chen, CZ				Zhang, Wu-Zhe; Zhai, Tian-Tian; Lu, Jia-Yang; Chen, Jian-Zhou; Chen, Zhi-Jian; Li, De-Rui; Chen, Chuang-Zhen			Volumetric Modulated Arc Therapy vs. c-IMRT for the Treatment of Upper Thoracic Esophageal Cancer	PLOS ONE			English	Article							CELL LUNG-CANCER; PHASE-II TRIAL; RADIOTHERAPY; OXALIPLATIN; CARCINOMA	Objective To compare plans using volumetric-modulated arc therapy (VMAT) with conventional sliding window intensity-modulated radiation therapy (c-IMRT) to treat upper thoracic esophageal cancer (EC). Methods CT datasets of 11 patients with upper thoracic EC were identified. Four plans were generated for each patient: c-IMRT with 5 fields (5F) and VMAT with a single arc (1A), two arcs (2A), or three arcs (3A). The prescribed doses were 64 Gy/32 F for the primary tumor (PTV64). The dose-volume histogram data, the number of monitoring units (MUs) and the treatment time (TT) for the different plans were compared. Results All of the plans generated similar dose distributions for PTVs and organs at risk (OARs), except that the 2A- and 3A-VMAT plans yielded a significantly higher conformity index (CI) than the c-IMRT plan. The CI of the PTV64 was improved by increasing the number of arcs in the VMAT plans. The maximum spinal cord dose and the planning risk volume of the spinal cord dose for the two techniques were similar. The 2A- and 3A-VMAT plans yielded lower mean lung doses and heart V-50 values than the c-IMRT. The V-20 and V-30 for the lungs in all of the VMAT plans were lower than those in the c-IMRT plan, at the expense of increasing V-5, V-10 and V-13. The VMAT plan resulted in significant reductions in MUs and TT. Conclusion The 2A-VMAT plan appeared to spare the lungs from moderate-dose irradiation most effectively of all plans, at the expense of increasing the low-dose irradiation volume, and also significantly reduced the number of required MUs and the TT. The CI of the PTVs and the OARs was improved by increasing the arc-number from 1 to 2; however, no significant improvement was observed using the 3A-VMAT, except for an increase in the TT.	[Zhang, Wu-Zhe; Zhai, Tian-Tian; Lu, Jia-Yang; Chen, Jian-Zhou; Li, De-Rui; Chen, Chuang-Zhen] Shantou Univ, Coll Med, Canc Hosp, Dept Radiat Oncol, Shantou, Guangdong, Peoples R China; [Chen, Zhi-Jian] Univ Hongkong, Shenzhen Hosp 1, Ctr Clin Oncol, Shenzhen, Peoples R China	Shantou University	Chen, CZ (corresponding author), Shantou Univ, Coll Med, Canc Hosp, Dept Radiat Oncol, Shantou, Guangdong, Peoples R China.	stccz@139.com	Chen, Jianzhou/AAW-1443-2021		Science and Technology Planning Project of Shantou [2012-165-131]; Shantou University Medical College Clinical Research Enhancement Initivitate [201424]	Science and Technology Planning Project of Shantou; Shantou University Medical College Clinical Research Enhancement Initivitate	Support was provided by the Science and Technology Planning Project of Shantou: 2012-165-131, for CZC; Shantou University Medical College Clinical Research Enhancement Initivitate: 201424, for CZC. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Amendola BE, 2013, REP PRACT ONCOL RADI, V18, P383, DOI 10.1016/j.rpor.2013.07.005; Bertelsen A, 2010, RADIOTHER ONCOL, V95, P142, DOI 10.1016/j.radonc.2010.01.011; BRAHME A, 1988, RADIOTHER ONCOL, V12, P129, DOI 10.1016/0167-8140(88)90167-3; Burmeister BH, 2009, INVEST NEW DRUG, V27, P275, DOI 10.1007/s10637-008-9178-4; Chandra A, 2005, RADIOTHER ONCOL, V77, P247, DOI 10.1016/j.radonc.2005.10.017; Cozzi L, 2008, RADIOTHER ONCOL, V89, P180, DOI 10.1016/j.radonc.2008.06.013; Fu WH, 2004, WORLD J GASTROENTERO, V10, P1098; Graham MV, 1999, INT J RADIAT ONCOL, V45, P323, DOI 10.1016/S0360-3016(99)00183-2; Guckenberger M, 2009, RADIOTHER ONCOL, V93, P259, DOI 10.1016/j.radonc.2009.08.015; Hall EJ, 2003, INT J RADIAT ONCOL, V56, P83, DOI 10.1016/S0360-3016(03)00073-7; Jiang ZQ, 2012, INT J RADIAT ONCOL, V83, P332, DOI 10.1016/j.ijrobp.2011.06.1963; Lee TF, 2012, CLIN ONCOL-UK, V24, P196, DOI 10.1016/j.clon.2011.06.006; Ma P, 2014, J APPL CLIN MED PHYS, V15, P221, DOI 10.1120/jacmp.v15i3.4732; Mayo CS, 2010, INT J RADIAT ONCOL, V78, P1457, DOI 10.1016/j.ijrobp.2009.10.005; Pera M, 2012, ANN ONCOL, V23, P664, DOI 10.1093/annonc/mdr291; Van Benthuysen L, 2011, MED DOSIM, V36, P404, DOI 10.1016/j.meddos.2010.09.009; Wagner D, 2009, RADIOTHER ONCOL, V93, P593, DOI 10.1016/j.radonc.2009.10.002; Wang J, 2008, INT J RADIAT ONCOL, V17, P275; Wang SL, 2006, INT J RADIAT ONCOL, V66, P1399, DOI 10.1016/j.ijrobp.2006.07.1337; Wolff D, 2009, RADIOTHER ONCOL, V93, P226, DOI 10.1016/j.radonc.2009.08.011; Wu QW, 2000, INT J RADIAT ONCOL, V46, P195, DOI 10.1016/S0360-3016(99)00304-1; Wu VWC, 2004, RADIOTHER ONCOL, V71, P201, DOI 10.1016/j.radonc.2004.03.004; Yin L, 2012, WORLD J GASTROENTERO, V18, P5266, DOI 10.3748/wjg.v18.i37.5266; [张丹丹 Zhang Dandan], 2012, [中华放射肿瘤学杂志, Chinese Journal of Radiation Oncology], V21, P364	24	16	20	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 27	2015	10	3							e0121385	10.1371/journal.pone.0121385	http://dx.doi.org/10.1371/journal.pone.0121385			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CE8ZT	25815477	Green Submitted, gold, Green Published			2023-01-03	WOS:000352133600088
J	Gonsalves, G; Zuckerman, D				Gonsalves, Gregg; Zuckerman, Diana			Commentary: Will 20th century patient safeguards be reversed in the 21st century?	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material									[Gonsalves, Gregg] Yale Univ, Law, New Haven, CT USA; [Zuckerman, Diana] Natl Ctr Hlth Res, Washington, DC 20230 USA	Yale University	Zuckerman, D (corresponding author), Natl Ctr Hlth Res, Washington, DC 20230 USA.	info@center4research.org		Gonsalves, Gregg/0000-0002-5789-9841				Darrow JJ, 2014, NEW ENGL J MED, V370, P1252, DOI 10.1056/NEJMhle1311493; Energy and Commerce Committee of the US House of Representatives, 2015, 21 CENT CUR DISC DRA; Epstein S, 1996, Med Soc (Berkeley), P1; Food and Drug Administration, 2013, APPL ORPH DRUG DES; Food and Drug Administration, 2014, FDA PROP NEW EXP ACC; Food and Drug Administration, 2011, AN PREM REV TIM 510; Food and Drug Administration, 2014, EXP ACC PREM APPR ME; Hilts P, 2003, PROTECTING AM HLTH F; Kaplan JE, 2000, CLIN INFECT DIS, V30, pS5, DOI 10.1086/313843; Moore TJ, 2014, JAMA INTERN MED, V174, P90, DOI 10.1001/jamainternmed.2013.11813; Perrone M, 2014, AIDS ACTIVIST TAKES; US Food and Drug Administration, 2014, GUID IND EXP PROGR S; US Government Accountability Office, 2009, MED DEV FDA SHOULD T; Washburn J, 2001, AM PROSPECT	14	9	9	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 25	2015	350								h1500	10.1136/bmj.h1500	http://dx.doi.org/10.1136/bmj.h1500			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CE7NV	25814537				2023-01-03	WOS:000352029500002
J	Mao, WH; Vu, HY; Xie, ZN; Chen, W; Tang, SL				Mao, Wenhui; Vu, Huyen; Xie, Zening; Chen, Wen; Tang, Shenglan			Systematic Review on Irrational Use of Medicines in China and Vietnam	PLOS ONE			English	Review							VILLAGE HEALTH CLINICS; ADVERSE DRUG-REACTIONS; PRIVATE PHARMACIES; 10 PROVINCES; ANTIBIOTICS; CHILDREN; INJECTIONS; MEDICATION; BEHAVIOR; ILLNESS	Background Irrational use of medicines has been an issue concerned all over the world and the outlooks in developing countries are more severe. This study aimed to assess the different patterns of irrational use of medicines and its influential factors in China and Vietnam. Methods A systematic review was performed on both published and grey literatures in English, Chinese and Vietnamese languages between 1993 and 2013 based on the WHO framework. Quality assessment was conducted on the basis of the Critical Appraisal Skills Programme. Key indicators were analyzed to compare the irrational use of medicines in two countries. Results A total of 67 published works about China and 29 about Vietnam were included, the majority of which were cross-sectional prescription studies in both China and Vietnam. Irrational use of medicines was found in both the countries but issues with polypharmacy as well as overuse of antibiotics were more severe in Vietnam while overuse of injections was unique to China. Various patterns of irrational use were also indicated between urban and rural areas, and among different levels of hospitals. Rarely does literature focus on the analysis of influential factors of irrational use of medicines. While lack of proper knowledge from both providers and patients were the most recognized influential factors in both countries, economic incentives from pharmaceutical companies in China, and weak control and regulation over prescriptions in Vietnam were the main factors attributed to this issue. Conclusion Severe irrational use of medicines has been abundantly evidenced in both China and Vietnam, highlighting the importance of policy interventions on the issue. However, limited evidence on the appropriateness or its compliance (conformity) to guidelines of prescription has been found. In addition, convincing evidence on the underlying explanation of this issue is lacking, although economic incentives, health insurance coverage, and knowledge of service providers and users have been implied to be factors influencing irrational drug use.	[Mao, Wenhui; Xie, Zening; Chen, Wen] Fudan Univ, Sch Publ Hlth, Shanghai 200032, Peoples R China; [Chen, Wen] Duke Univ, Collaborat Innovat Ctr Social Risks Governance Hl, Durham, NC 27708 USA; [Vu, Huyen; Tang, Shenglan] Duke Univ, Duke Global Hlth Inst, Durham, NC 27708 USA; [Tang, Shenglan] Duke Kunshan Univ, Kunshan 215316, Jiangsu, Peoples R China	Fudan University; Duke University; Duke University; Duke Kunshan University	Chen, W (corresponding author), Fudan Univ, Sch Publ Hlth, POB 187,138 Yi Xue Yuan Rd, Shanghai 200032, Peoples R China.	wenchen@fudan.edu.cn; shenglan.tang@duke.edu	Tang, Shenglan/AAO-7403-2020; Mao, Wenhui/T-3573-2019; MAO, Wenhui/L-1734-2019	Mao, Wenhui/0000-0001-9214-7787; 				Center for Health Statistics and Information Ministry of Health, 2013, CHIN HLTH FAM PLANN; Chen MS, 2014, PHARMACOECONOMICS, V32, P245, DOI 10.1007/s40273-013-0068-z; China National Health Economics Institute, 2012, CHIN NAT HLTH ACC RE; Chuc NTK, 1999, EUR J CLIN PHARMACOL, V55, P325, DOI 10.1007/s002280050636; Chuc NTK, 2001, ANN PHARMACOTHER, V35, P1283, DOI 10.1345/aph.10313; Critical Appraisal Skills Programme, 2013, MAK SENS EV; Dong HJ, 1999, INT J TECHNOL ASSESS, V15, P686, DOI 10.1017/S0266462399015482; Dong LF, 2008, J ANTIMICROB CHEMOTH, V62, P410, DOI 10.1093/jac/dkn153; GREENHALGH T, 1987, SOC SCI MED, V25, P307, DOI 10.1016/0277-9536(87)90233-4; Gumodoka B, 1996, TROP MED INT HEALTH, V1, P874; Han S, 2013, INT J HEALTH SERV, V43, P91, DOI 10.2190/HS.43.1.g; Hitchen L, 2006, BRIT MED J, V332, P1109, DOI 10.1136/bmj.332.7550.1109; Hoa NQ, 2007, HEALTH POLICY, V82, P320, DOI 10.1016/j.healthpol.2006.10.005; Hoan LT, 2009, PHARMACOEPIDEM DR S, V18, P448, DOI 10.1002/pds.1730; HOGERZEIL HV, 1995, BRIT J CLIN PHARMACO, V39, P1; Huong DB, 2007, INT J HEALTH SERV, V37, P555, DOI 10.2190/H0L2-8004-6182-6826; Kaljee LM, 2011, J BEHAV MED, V34, P254, DOI 10.1007/s10865-010-9305-5; Larsson M, 2000, TROP MED INT HEALTH, V5, P711, DOI 10.1046/j.1365-3156.2000.00630.x; Larsson M, 1999, THESIS KAROLINSKA I; Lazarou J, 1998, JAMA-J AM MED ASSOC, V279, P1200, DOI 10.1001/jama.279.15.1200; Li YB, 2012, HEALTH AFFAIR, V31, P1075, DOI 10.1377/hlthaff.2010.0965; Lieu DH, 2005, HLTH FINANCING HOUSE; Lonnroth K, 1998, HEALTH POLICY, V45, P81, DOI 10.1016/S0168-8510(98)00035-9; Luo J, 2009, THESIS CENTRAL S U; Mao WH, 2013, EXPERT REV PHARM OUT, V13, P693, DOI 10.1586/14737167.2013.856266; Michanek E, 1992, DOI MOI AND HLTH; Ministry of Health, 1996, STRAT OR PEOPL HLTH; Moher D, 2009, PLOS MED, V6, DOI [10.1371/journal.pmed.1000097, 10.1136/bmj.b4037]; National Health and Family Planning Commission of People's Republic of China, 2012, CHIN HLTH STAT YB 20; Nguyen QH, 2010, BMC INFECT DIS, V10, DOI 10.1186/1471-2334-10-85; Nguyen TKC, 2002, THESIS KAROLINSKA I; Pirmohamed M, 2004, BMJ-BRIT MED J, V329, P15, DOI 10.1136/bmj.329.7456.15; Reeler AV, 1994, WHODAP948; Reynolds L, 2011, INT J HEALTH PLAN M, V26, P449, DOI 10.1002/hpm.1112; State Planning Commission, 1996, INT MEAS DRUG PRIC; State Planning Commission, 1998, STAT PLANN COMM NOT; Sun Q, 2008, HEALTH AFFAIR, V27, P1042, DOI 10.1377/hlthaff.27.4.1042; Tang S, 2007, PHARM POLICIES CHINA; van Staa A, 1996, WHODAP964; Vietnam's Ministry of Health, 2011, NAT STRAT H IN PRESS; Vietnam's Ministry of Health, 2004, NAT HLTH ACC PROC IM; Vietnam's Ministry of Health and WHO, 2010, NAT HLTH ACC IMPL VI; White TJ, 1999, PHARMACOECONOMICS, V15, P445, DOI 10.2165/00019053-199915050-00003; WHO, 2002, WHO POLICY PERSPECTI; World Health Organization, 1993, INV DRUG US HLTH FAC, V007; World Health Organization, 2004, EQ ACC ESS MED FRAM; World Health Organization, 2012, PURS RESP US MED SHA; World Health Organization, 2011, WORLD MED SIT 2011 R, DOI [10.1186/1475-2875-10-326, DOI 10.1186/1475-2875-10-326]; World Health Organization, 2009, MED US PRIM CAR DEV; World Health Organization, 2001, INV DRUG US HLTH FAC; Yip W, 2009, CHINA ECON REV, V20, P613, DOI 10.1016/j.chieco.2009.08.003	51	93	96	1	36	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 20	2015	10	3							e0117710	10.1371/journal.pone.0117710	http://dx.doi.org/10.1371/journal.pone.0117710			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	CE8IA	25793497	Green Published, Green Submitted, gold			2023-01-03	WOS:000352084200016
J	Arabi, YM; Aldawood, AS; Haddad, SH; Al-Dorzi, HM; Tamim, HM; Jones, G; Mehta, S; McIntyre, L; Solaiman, O; Sakkijha, MH; Sadat, M; Afesh, L				Arabi, Yaseen M.; Aldawood, Abdulaziz S.; Haddad, Samir H.; Al-Dorzi, Hasan M.; Tamim, Hani M.; Jones, Gwynne; Mehta, Sangeeta; McIntyre, Lauralyn; Solaiman, Othman; Sakkijha, Maram H.; Sadat, Musharaf; Afesh, Lara		PermiT Trial Grp	Permissive Underfeeding or Standard Enteral Feeding in Critically Ill Adults	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CALORIE RESTRICTION; PARENTERAL-NUTRITION; SURGICAL-PATIENTS; CARE; INJURY; MULTICENTER; GUIDELINES; THERAPY; SUPPORT; TRIAL	BACKGROUND The appropriate caloric goal for critically ill adults is unclear. We evaluated the effect of restriction of nonprotein calories (permissive underfeeding), as compared with standard enteral feeding, on 90-day mortality among critically ill adults, with maintenance of the full recommended amount of protein in both groups. METHODS At seven centers, we randomly assigned 894 critically ill adults with a medical, surgical, or trauma admission category to permissive underfeeding (40 to 60% of calculated caloric requirements) or standard enteral feeding (70 to 100%) for up to 14 days while maintaining a similar protein intake in the two groups. The primary outcome was 90-day mortality. RESULTS Baseline characteristics were similar in the two groups; 96.8% of the patients were receiving mechanical ventilation. During the intervention period, the permissive-underfeeding group received fewer mean (+/- SD) calories than did the standard-feeding group (835 +/- 297 kcal per day vs. 1299 +/- 467 kcal per day, P< 0.001; 46 +/- 14% vs. 71 +/- 22% of caloric requirements, P< 0.001). Protein intake was similar in the two groups (57 +/- 24 g per day and 59 +/- 25 g per day, respectively; P = 0.29). The 90-day mortality was similar: 121 of 445 patients (27.2%) in the permissive-underfeeding group and 127 of 440 patients (28.9%) in the standard-feeding group died (relative risk with permissive underfeeding, 0.94; 95% confidence interval [CI], 0.76 to 1.16; P = 0.58). No serious adverse events were reported; there were no significant between-group differences with respect to feeding intolerance, diarrhea, infections acquired in the intensive care unit (ICU), or ICU or hospital length of stay. CONCLUSIONS Enteral feeding to deliver a moderate amount of nonprotein calories to critically ill adults was not associated with lower mortality than that associated with planned delivery of a full amount of nonprotein calories.	[Arabi, Yaseen M.; Aldawood, Abdulaziz S.; Haddad, Samir H.; Al-Dorzi, Hasan M.; Tamim, Hani M.; Sakkijha, Maram H.; Sadat, Musharaf; Afesh, Lara] King Saud bin Abdulaziz Univ Hlth Sci, Riyadh 11426, Saudi Arabia; [Arabi, Yaseen M.; Aldawood, Abdulaziz S.; Haddad, Samir H.; Al-Dorzi, Hasan M.; Tamim, Hani M.; Sakkijha, Maram H.; Sadat, Musharaf; Afesh, Lara] King Abdullah Int Med Res Ctr, Riyadh, Saudi Arabia; [Solaiman, Othman] King Faisal Specialist Hosp & Res Ctr, Riyadh 11211, Saudi Arabia; [Tamim, Hani M.] Amer Univ Beirut, Beirut Med Ctr, Dept Internal Med, Beirut, Lebanon; [Jones, Gwynne; McIntyre, Lauralyn] Univ Ottawa, Dept Med, Div Crit Care Med, Ottawa Hosp Res Inst, Ottawa, ON, Canada; [Mehta, Sangeeta] Univ Toronto, Interdept Div Crit Care Med, Dept Med, Div Respirol, Toronto, ON, Canada; [Mehta, Sangeeta] Mt Sinai Hosp, Toronto, ON M5G 1X5, Canada	King Saud Bin Abdulaziz University for Health Sciences; King Saud Bin Abdulaziz University for Health Sciences; King Abdullah International Medical Research Center (KAIMRC); King Faisal Specialist Hospital & Research Center; American University of Beirut; Beirut Medical Center; University of Ottawa; Ottawa Hospital Research Institute; University of Toronto; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto	Arabi, YM (corresponding author), King Saud bin Abdulaziz Univ Hlth Sci, Dept Intens Care, King Abdullah Int Med Res Ctr, ICU 1425,POB 22490, Riyadh 11426, Saudi Arabia.	arabi@ngha.med.sa	McIntyre, Lauralyn/AAR-7710-2021; Mehta, Sangeeta/C-4623-2015; Arabi, Yaseen/ABF-3316-2020	McIntyre, Lauralyn/0000-0001-7421-1407; Arabi, Yaseen/0000-0001-5735-6241; Deeb, Ahmad/0000-0002-3680-7338; Al-Dorzi, Hasan M/0000-0002-3772-8949	King Abdullah International Medical Research Center	King Abdullah International Medical Research Center	Funded by the King Abdullah International Medical Research Center; PermiT Current Controlled Trials number, ISRCTN68144998.	Ahrens CL, 2005, CRIT CARE MED, V33, P2507, DOI 10.1097/01.CCM.0000186746.64572.8A; [Anonymous], 2015, CDC NHSN SURV DEF HE; Arabi YM, 2012, TRIALS, V13, DOI 10.1186/1745-6215-13-191; Arabi YM, 2011, AM J CLIN NUTR, V93, P569, DOI 10.3945/ajcn.110.005074; Arabi YM, 2010, JPEN-PARENTER ENTER, V34, P280, DOI 10.1177/0148607109353439; Boitano Megan, 2006, Nutr Clin Pract, V21, P617, DOI 10.1177/0115426506021006617; Briet F, 2001, AM J CLIN NUTR, V73, P975; Casaer MP, 2011, NEW ENGL J MED, V365, P506, DOI 10.1056/NEJMoa1102662; Charles EJ, 2014, AM J CLIN NUTR, V100, P1337, DOI 10.3945/ajcn.114.088609; Cohen HY, 2004, SCIENCE, V305, P390, DOI 10.1126/science.1099196; Colman RJ, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4557; Dickerson RN, 2002, NUTRITION, V18, P241, DOI 10.1016/S0899-9007(01)00793-6; Doig GS, 2013, JAMA-J AM MED ASSOC, V309, P2130, DOI 10.1001/jama.2013.5124; Doig GS, 2008, JAMA-J AM MED ASSOC, V300, P2731, DOI 10.1001/jama.2008.826; Frankenfield D, 2004, JPEN-PARENTER ENTER, V28, P259, DOI 10.1177/0148607104028004259; Heilbronn LK, 2006, JAMA-J AM MED ASSOC, V295, P1539, DOI 10.1001/jama.295.13.1539; Heilbronn LK, 2003, AM J CLIN NUTR, V78, P361, DOI 10.1093/ajcn/78.3.361; Heyland DK, 2011, CRIT CARE MED, V39, P2619, DOI 10.1097/CCM.0b013e318226641d; IRETON-JONES C S, 1992, Journal of Burn Care and Rehabilitation, V13, P330, DOI 10.1097/00004630-199205000-00005; Klein J A, 1996, Nutr Clin Pract, V11, P206, DOI 10.1177/0115426596011005206; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; Krishnan JA, 2003, CHEST, V124, P297, DOI 10.1378/chest.124.1.297; Lempiainen J, 2013, ACTA PHYSIOL, V208, P410, DOI 10.1111/apha.12120; Lin SJ, 2002, NATURE, V418, P344, DOI 10.1038/nature00829; Martin CM, 2004, CAN MED ASSOC J, V170, P197, DOI 10.1503/cmaj.1040621; Martindale RG, 2009, CRIT CARE MED, V37, P1757, DOI 10.1097/CCM.0b013e3181a40116; McCowen KC, 2000, CRIT CARE MED, V28, P3606, DOI 10.1097/00003246-200011000-00007; Mitchell JR, 2010, AGING CELL, V9, P40, DOI 10.1111/j.1474-9726.2009.00532.x; Ning YC, 2013, NEPHRON EXP NEPHROL, V124, P19, DOI 10.1159/000357380; Norman K, 2008, CLIN NUTR, V27, P5, DOI 10.1016/j.clnu.2007.10.007; Rice TW, 2012, JAMA-J AM MED ASSOC, V307, P795, DOI 10.1001/jama.2012.137; Rice TW, 2011, CRIT CARE MED, V39, P967, DOI 10.1097/CCM.0b013e31820a905a; Rubinson L, 2004, CRIT CARE MED, V32, P350, DOI 10.1097/01.CCM.0000089641.06306.68; Singer P, 2014, CLIN NUTR, V33, P246, DOI 10.1016/j.clnu.2013.12.004; Singer P, 2011, INTENS CARE MED, V37, P601, DOI 10.1007/s00134-011-2146-z; Taylor SJ, 1999, CRIT CARE MED, V27, P2525, DOI 10.1097/00003246-199911000-00033; Van den Berghe G, 2001, NEW ENGL J MED, V345, P1359, DOI 10.1056/NEJMoa011300; Vincent JL, 1998, CRIT CARE MED, V26, P1793, DOI 10.1097/00003246-199811000-00016; Walker RN, 2009, RESP CARE, V54, P509; Weijs PJM, 2014, CRIT CARE, V18, DOI 10.1186/s13054-014-0591-0	40	346	377	1	40	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 18	2015	372	25					2398	2408		10.1056/NEJMoa1502826	http://dx.doi.org/10.1056/NEJMoa1502826			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CK6RF	25992505				2023-01-03	WOS:000356354600006
J	Bella, R; Lanza, G; Cantone, M; Giuffrida, S; Puglisi, V; Vinciguerra, L; Pennisi, M; Ricceri, R; D'Agate, CC; Malaguarnera, G; Ferri, R; Pennisi, G				Bella, Rita; Lanza, Giuseppe; Cantone, Mariagiovanna; Giuffrida, Salvatore; Puglisi, Valentina; Vinciguerra, Luisa; Pennisi, Manuela; Ricceri, Riccardo; D'Agate, Carmela Cinzia; Malaguarnera, Giulia; Ferri, Raffaele; Pennisi, Giovanni			Effect of a Gluten-Free Diet on Cortical Excitability in Adults with Celiac Disease	PLOS ONE			English	Article							SUBCLINICAL NEUROLOGICAL ABNORMALITIES; ISCHEMIC VASCULAR DEMENTIA; MOTOR-EVOKED-POTENTIALS; AGE-RELATED-CHANGES; CORTICOMOTOR EXCITABILITY; INTRACORTICAL INHIBITION; ANTINEURONAL ANTIBODIES; MAGNETIC STIMULATION; CHILDREN; RELIABILITY	Introduction An imbalance between excitatory and inhibitory synaptic excitability was observed in de novo patients with celiac disease (CD) in a previous study with Transcranial Magnetic Stimulation (TMS), suggesting a subclinical involvement of GABAergic and glutamatergic neurotransmission in asymptomatic patients. The aim of this investigation was to monitor the eventual changes in the same cohort of patients, evaluated after a period of gluten-free diet. Methods Patients were re-evaluated after a median period of 16 months during which an adequate gluten-free diet was maintained. Clinical, cognitive and neuropsychiatric assessment was repeated, as well as cortical excitability by means of single-and paired-pulse TMS from the first dorsal interosseous muscle of the dominant hand. Results Compared to baseline, patients showed a significant decrease of the median resting motor threshold (from 35% to 33%, p<0.01). The other single-pulse (cortical silent period, motor evoked potentials latency and amplitude, central motor conduction time) and paired-pulse TMS measures (intracortical inhibition and intracortical facilitation) did not change significantly after the follow-up period. Antibodies were still present in 7 subjects. Discussion In patients under a gluten-free diet, a global increase of cortical excitability was observed, suggesting a glutamate-mediated functional reorganization compensating for disease progression. We hypothesize that glutamate receptor activation, probably triggered by CD-related immune system dysregulation, might result in a long-lasting motor cortex hyperexcitability with increased excitatory post-synaptic potentials, probably related to phenomena of long-term plasticity. The impact of the gluten-free diet on subclinical neurological abnormalities needs to be further explored.	[Bella, Rita; Giuffrida, Salvatore; Puglisi, Valentina; Vinciguerra, Luisa; Ricceri, Riccardo] Univ Catania, Sect Neurosci, Dept GF Ingrassia, Catania, Italy; [Lanza, Giuseppe; Cantone, Mariagiovanna; Ferri, Raffaele] Oasi Inst Res Mental Retardat & Brain Aging, IRCCS, Dept Neurol IC, Troina, EN, Italy; [Pennisi, Manuela] Emergency Hosp Cannizzaro, Spinal Unit, Catania, Italy; [D'Agate, Carmela Cinzia] Univ Catania, Gastroenterol & Endoscopy Unit, Catania, Italy; [Malaguarnera, Giulia] Univ Catania, Dept Biomed Sci, Catania, Italy; [Pennisi, Giovanni] Univ Catania, Dept Specialita Medicochirurg, Catania, Italy	University of Catania; IRCCS Oasi Maria SS; University of Catania; University of Catania; University of Catania	Pennisi, G (corresponding author), Univ Catania, Dept Specialita Medicochirurg, Catania, Italy.	pennigi@unict.it	Cantone, Mariagiovanna/C-9392-2017; Malaguarnera, Giulia/ABD-4968-2020; Pennisi, Manuela/AAC-2362-2019; Ferri, Raffaele/B-5439-2013; Lanza, Giuseppe/R-3065-2017	Cantone, Mariagiovanna/0000-0002-9072-4971; Malaguarnera, Giulia/0000-0003-3655-4307; Pennisi, Manuela/0000-0003-0776-1411; Ferri, Raffaele/0000-0001-6937-3065; Lanza, Giuseppe/0000-0002-5659-662X				Abenavoli L, 2008, J AM DIET ASSOC, V108, P1995, DOI 10.1016/j.jada.2008.10.027; Addolorato G, 2004, ALIMENT PHARM THER, V20, P777, DOI 10.1111/j.1365-2036.2004.02193.x; Addolorato G, 2001, SCAND J GASTROENTERO, V36, P502, DOI 10.1080/00365520119754; Biagi F, 2012, BRIT J NUTR, V108, P1884, DOI 10.1017/S0007114511007367; Briani C, 2004, ALIMENT PHARM THER, V20, P231, DOI 10.1111/j.1365-2036.2004.02016.x; Burk K, 2009, MOVEMENT DISORD, V24, P2358, DOI 10.1002/mds.22821; Cacchio A, 2011, J NEUROL SCI, V303, P90, DOI 10.1016/j.jns.2011.01.004; Cacchio A, 2009, CLIN NEUROPHYSIOL, V120, P414, DOI 10.1016/j.clinph.2008.11.019; Cakir D, 2007, J PEDIATR GASTR NUTR, V45, P366, DOI 10.1097/MPG.0b013e31806907e8; Chin RL, 2003, NEUROLOGY, V60, P1581, DOI 10.1212/01.WNL.0000063307.84039.C7; Christie A, 2007, J NEUROSCI METH, V164, P320, DOI 10.1016/j.jneumeth.2007.05.011; Cohen J., 2016, CURR DIR PSYCHOL SCI, V1, P98, DOI [10.1111%2F1467-8721.ep10768783, 10.1111/1467-8721.ep10768783]; CONGDON P, 1981, AM J DIS CHILD, V135, P118, DOI 10.1001/archpedi.1981.02130260010004; Coppi E, 2014, FRONT AGING NEUROSCI, V6, DOI 10.3389/fnagi.2014.00209; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Fujiyama H, 2012, J COGNITIVE NEUROSCI, V24, P1253, DOI 10.1162/jocn_a_00201; Ganor Y, 2005, EXP NEUROL, V195, P92, DOI 10.1016/j.expneurol.2005.04.002; Giordano D, 2012, COMPUT METH PROG BIO, V107, P4, DOI 10.1016/j.cmpb.2011.10.008; GREFTE JMM, 1988, J CLIN PATHOL, V41, P886, DOI 10.1136/jcp.41.8.886; Groppa S, 2012, CLIN NEUROPHYSIOL, V123, P858, DOI 10.1016/j.clinph.2012.01.010; Guerra A, 2015, CLIN NEUROPHYSIOL, V126, P906, DOI 10.1016/j.clinph.2014.07.036; Hadjivassiliou M, 2006, MUSCLE NERVE, V34, P762, DOI 10.1002/mus.20642; Hadjivassiliou M, 2010, LANCET NEUROL, V9, P318, DOI 10.1016/S1474-4422(09)70290-X; HALLERT C, 1983, PSYCHOL MED, V13, P267, DOI 10.1017/S003329170005087X; HAMILTON M, 1960, J NEUROL NEUROSUR PS, V23, P56, DOI 10.1136/jnnp.23.1.56; Hu WT, 2006, ARCH NEUROL-CHICAGO, V63, P1440, DOI 10.1001/archneur.63.10.1440; Husby S, 2012, J PEDIATR GASTR NUTR, V54, P136, DOI 10.1097/MPG.0b013e31821a23d0; Jackson JR, 2012, PSYCHIAT QUART, V83, P91, DOI 10.1007/s11126-011-9186-y; Koski L, 2007, NEUROSCI RES, V58, P19, DOI 10.1016/j.neures.2007.01.007; KUJIRAI T, 1993, J PHYSIOL-LONDON, V471, P501, DOI 10.1113/jphysiol.1993.sp019912; Levite M, 2014, J NEURAL TRANSM, V121, P1029, DOI 10.1007/s00702-014-1193-3; Liu H, 2014, J NEUROL SCI, V341, P105, DOI 10.1016/j.jns.2014.04.012; Luostarinen L, 2003, J NEUROL NEUROSUR PS, V74, P490, DOI 10.1136/jnnp.74.4.490; Mavroudi A, 2005, PEDIATR NEUROL, V33, P292, DOI 10.1016/j.pediatrneurol.2005.05.010; OLDFIELD RC, 1971, NEUROPSYCHOLOGIA, V9, P97, DOI 10.1016/0028-3932(71)90067-4; Oliviero A, 2006, NEUROSCI RES, V55, P74, DOI 10.1016/j.neures.2006.02.002; Parisi P, 2015, SEIZURE-EUR J EPILEP, V25, P181, DOI 10.1016/j.seizure.2014.09.016; Paulus W, 2008, BRAIN STIMUL, V1, P151, DOI 10.1016/j.brs.2008.06.002; Peinemann A, 2001, NEUROSCI LETT, V313, P33, DOI 10.1016/S0304-3940(01)02239-X; Pellecchia MT, 1999, NEUROLOGY, V53, P1606, DOI 10.1212/WNL.53.7.1606-a; Pennisi G, 2015, CLIN NEUROPHYSIOL, V126, P851, DOI 10.1016/j.clinph.2014.09.001; Pennisi G, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102790; Petitjean M, 2013, CLIN NEUROPHYSIOL, V124, P346, DOI 10.1016/j.clinph.2012.07.006; Pynnonen PA, 2004, PSYCHOSOMATICS, V45, P325, DOI 10.1176/appi.psy.45.4.325; ROSSINI PM, 1994, ELECTROEN CLIN NEURO, V91, P79, DOI 10.1016/0013-4694(94)90029-9; ROSSINI PM, 1992, BRAIN RES, V593, P14, DOI 10.1016/0006-8993(92)91256-E; Rothwell J.C., 1999, INT FED CLIN NEUROPH, V52, P97; Rubio-Tapia A, 2013, AM J GASTROENTEROL, V108, P656, DOI 10.1038/ajg.2013.79; Selby WS, 1999, SCAND J GASTROENTERO, V34, P909, DOI 10.1080/003655299750025390; Shmerling DH, 1986, J PEDIAT GASTROENTER, V5, P560; Tursi A, 2006, DIGEST DIS SCI, V51, P1869, DOI 10.1007/s10620-005-9054-4; Volta U, 2002, SCAND J GASTROENTERO, V37, P1276, DOI 10.1080/003655202761020542; Wahab PJ, 2002, AM J CLIN PATHOL, V118, P459; Ziemann U, 1996, J PHYSIOL-LONDON, V496, P873, DOI 10.1113/jphysiol.1996.sp021734	54	41	41	1	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 8	2015	10	6							e0129218	10.1371/journal.pone.0129218	http://dx.doi.org/10.1371/journal.pone.0129218			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CK1GM	26053324	Green Published, gold, Green Submitted			2023-01-03	WOS:000355955300101
J	Ogata, S; Hayashi, C; Sugiura, K; Hayakawa, K				Ogata, Soshiro; Hayashi, Chisato; Sugiura, Keiko; Hayakawa, Kazuo			Associations between Depressive State and Impaired Higher-Level Functional Capacity in the Elderly with Long-Term Care Requirements	PLOS ONE			English	Article							PROPENSITY SCORE METHODS; DAILY LIVING DISABILITY; HIPPOCAMPAL VOLUME LOSS; LATE-LIFE DEPRESSION; INSTRUMENTAL ACTIVITIES; OLDER-ADULTS; LOGISTIC-REGRESSION; CONTROLLED-TRIAL; COMMUNITY; LIMITATIONS	Depressive state has been reported to be significantly associated with higher-level functional capacity among community-dwelling elderly. However, few studies have investigated the associations among people with long-term care requirements. We aimed to investigate the associations between depressive state and higher-level functional capacity and obtain marginal odds ratios using propensity score analyses in people with long-term care requirements. We conducted a cross-sectional study based on participants aged >= 65 years (n = 545) who were community dwelling and used outpatient care services for long-term preventive care. We measured higher-level functional capacity, depressive state, and possible confounders. Then, we estimated the marginal odds ratios (i.e., the change in odds of impaired higher-level functional capacity if all versus no participants were exposed to depressive state) by logistic models using generalized linear models with the inverse probability of treatment weighting (IPTW) for propensity score and design-based standard errors. Depressive state was used as the exposure variable and higher-level functional capacity as the outcome variable. The all absolute standardized differences after the IPTW using the propensity scores were <10% which indicated negligible differences in the mean or prevalence of the covariates between non-depressive state and depressive state. The marginal odds ratios were estimated by the logistic models with IPTW using the propensity scores. The marginal odds ratios were 2.17 (95% CI: 1.13-4.19) for men and 2.57 (95% CI: 1.26-5.26) for women. Prevention of depressive state may contribute to not only depressive state but also higher-level functional capacity.	[Ogata, Soshiro] Osaka City Univ, Support Off Female Researchers, Osaka 558, Japan; [Hayashi, Chisato] Osaka City Univ, Grad Sch Nursing, Dept Publ Hlth Nursing, Osaka 558, Japan; [Sugiura, Keiko] Senri Kinran Univ, Fac Nursing, Osaka, Japan; [Hayakawa, Kazuo] Mie Prefectural Coll Nursing, Tsu, Mie, Japan	Osaka Metropolitan University; Osaka Metropolitan University	Ogata, S (corresponding author), Osaka Univ, Grad Sch Med, Dept Hlth Promot Sci, Osaka, Japan.	sob0405@sahs.med.osaka-u.ac.jp			Osaka City University; Ministry of Education, Culture, Sports, Sciences and Technology	Osaka City University; Ministry of Education, Culture, Sports, Sciences and Technology(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT))	This work was supported by Osaka City University subsidized by the Program to Support Female Researchers realized by the Ministry of Education, Culture, Sports, Sciences and Technology. http://www.jst.go.jp/shincho/en/program/woman_ken.html. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 2004, J STAT SOFTW, DOI DOI 10.18637/JSS.V009.I05; Austin PC, 2011, MULTIVAR BEHAV RES, V46, P399, DOI 10.1080/00273171.2011.568786; Brookhart MA, 2006, AM J EPIDEMIOL, V163, P1149, DOI 10.1093/aje/kwj149; Cahn-Weiner DA, 2007, J INT NEUROPSYCH SOC, V13, P747, DOI 10.1017/S1355617707070853; Callahan CM, 2005, J AM GERIATR SOC, V53, P367, DOI 10.1111/j.1532-5415.2005.53151.x; Carriere I, 2011, J AFFECT DISORDERS, V133, P42, DOI 10.1016/j.jad.2011.03.020; Cepeda MS, 2003, AM J EPIDEMIOL, V158, P280, DOI 10.1093/aje/kwg115; Covinsky KE, 2010, J AM GERIATR SOC, V58, P551, DOI 10.1111/j.1532-5415.2010.02723.x; Drageset J, 2011, J CLIN NURS, V20, P3111, DOI 10.1111/j.1365-2702.2010.03663.x; DRAKE C, 1993, BIOMETRICS, V49, P1231, DOI 10.2307/2532266; Fujiwara Y, 2003, ARCH GERONTOL GERIAT, V36, P141, DOI 10.1016/S0167-4943(02)00081-X; Fujiwara Y., 2002, GERIATR GERONTOL INT, V2, P57; Graham JW, 2007, PREV SCI, V8, P206, DOI 10.1007/s11121-007-0070-9; Hybels CF, 2009, PSYCHOL MED, V39, P1677, DOI 10.1017/S0033291709005650; Iwasa H, 2009, INT J GERIATR PSYCH, V24, P1192, DOI 10.1002/gps.2245; Joffe MM, 2004, AM STAT, V58, P272, DOI 10.1198/000313004X5824; Kazama Mari, 2011, Environmental Health and Preventive Medicine, V16, P196, DOI 10.1007/s12199-010-0186-6; KOYANO W, 1991, ARCH GERONTOL GERIAT, V13, P103, DOI 10.1016/0167-4943(91)90053-S; Marshall A, 2010, BMC MED RES METHODOL, V10, DOI 10.1186/1471-2288-10-7; Marshall A, 2009, BMC MED RES METHODOL, V9, DOI 10.1186/1471-2288-9-57; Nickel MK, 2006, ARCH GERONTOL GERIAT, V42, P247, DOI 10.1016/j.archger.2005.07.004; Nickel MK, 2005, AGING CLIN EXP RES, V17, P293; Oakley F, 2002, ACTA PSYCHIAT SCAND, V105, P231, DOI 10.1034/j.1600-0447.2002.1sc021.x; Ogata S, 2015, ARCH GERONTOL GERIAT, V60, P201, DOI 10.1016/j.archger.2014.10.015; Okamoto N, 2006, ARCH GERONTOL GERIAT, V42, P175, DOI 10.1016/j.archger.2005.06.012; Patrick JH, 2004, QUAL LIFE RES, V13, P959, DOI 10.1023/B:QURE.0000025585.92340.7a; Pirracchio R, 2012, BMC MED RES METHODOL, V12, DOI 10.1186/1471-2288-12-70; R.C. Team Vienna Austria R.F. f.S. Computing, 2021, R LANG ENV STAT COMP; Schreiner AS, 2003, INT J GERIATR PSYCH, V18, P498, DOI 10.1002/gps.880; Sheline YI, 2003, AM J PSYCHIAT, V160, P1516, DOI 10.1176/appi.ajp.160.8.1516; Sheline YI, 1999, J NEUROSCI, V19, P5034; Stampf S, 2010, STAT MED, V29, P760, DOI 10.1002/sim.3811; van Buuren S, 2011, J STAT SOFTW, V45, P1; Videbech P, 2004, AM J PSYCHIAT, V161, P1957, DOI 10.1176/appi.ajp.161.11.1957; Vu NQ, 2013, CURR OPIN NEUROL, V26, P656, DOI 10.1097/WCO.0000000000000028; Wada T, 2004, ARCH GERONTOL GERIAT, V39, P15, DOI 10.1016/j.archger.2003.12.003; Yamazaki S, 2012, GERIATR GERONTOL INT, V12, P680, DOI 10.1111/j.1447-0594.2012.00841.x; Yochim BP, 2008, J CLIN EXP NEUROPSYC, V30, P236, DOI 10.1080/13803390701370006	38	4	4	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 2	2015	10	6							e0127410	10.1371/journal.pone.0127410	http://dx.doi.org/10.1371/journal.pone.0127410			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	CJ7SJ	26035183	Green Published, gold, Green Submitted			2023-01-03	WOS:000355699100012
J	Ramasamy, S; Chin, SP; Sukumaran, SD; James, M; Buckle, C; Kiew, LV; Chung, LY				Ramasamy, Seetha; Chin, Sek Peng; Sukumaran, Sri Devi; James, Michael; Buckle, Christopher; Kiew, Lik Voon; Chung, Lip Yong			In Silico and In Vitro Analysis of Bacoside A Aglycones and Its Derivatives as the Constituents Responsible for the Cognitive Effects of Bacopa monnieri	PLOS ONE			English	Article							MUSCARINIC ACETYLCHOLINE-RECEPTOR; TRANSMEMBRANE DOMAIN; 5-HYDROXYTRYPTAMINE(2A) RECEPTOR; ALLOSTERIC MODULATION; SCANNING MUTAGENESIS; NEURITE OUTGROWTH; LIGAND-BINDING; GINKGO-BILOBA; SEROTONIN; AGONIST	Bacopa monnieri has been used in Ayurvedic medicine to improve memory and cognition. The active constituent responsible for its pharmacological effects is bacoside A, a mixture of dammarane-type triterpenoid saponins containing sugar chains linked to a steroid aglycone skeleton. Triterpenoid saponins have been reported to be transformed in vivo to metabolites that give better biological activity and pharmacokinetic characteristics. Thus, the activities of the parent compounds (bacosides), aglycones (jujubogenin and pseudojujubogenin) and their derivatives (ebelin lactone and bacogenin A(1)) were compared using a combination of in silico and in vitro screening methods. The compounds were docked into 5-HT1A, 5-HT2A, D-1, D-2, M-1 receptors and acetylcholinesterase (AChE) using AutoDock and their central nervous system (CNS) drug-like properties were determined using Discovery Studio molecular properties and ADMET descriptors. The compounds were screened in vitro using radioligand receptor binding and AChE inhibition assays. In silico studies showed that the parent bacosides were not able to dock into the chosen CNS targets and had poor molecular properties as a CNS drug. In contrast, the aglycones and their derivatives showed better binding affinity and good CNS drug-like properties, were well absorbed through the intestines and had good blood brain barrier (BBB) penetration. Among the compounds tested in vitro, ebelin lactone showed binding affinity towards M-1 (K-i = 0.45 mu M) and 5-HT2A (4.21 mu M) receptors. Bacoside A and bacopaside X (9.06 mu M) showed binding affinity towards the D-1 receptor. None of the compounds showed any inhibitory activity against AChE. Since the stimulation of M-1 and 5-HT2A receptors has been implicated in memory and cognition and ebelin lactone was shown to have the strongest binding energy, highest BBB penetration and binding affinity towards M-1 and 5-HT2A receptors, we suggest that B. monnieri constituents may be transformed in vivo to the active form before exerting their pharmacological activity.	[Ramasamy, Seetha; Chin, Sek Peng; Sukumaran, Sri Devi; James, Michael; Buckle, Christopher; Chung, Lip Yong] Univ Malaya, Fac Med, Dept Pharm, Kuala Lumpur 50603, Malaysia; [Kiew, Lik Voon] Univ Malaya, Fac Med, Dept Pharmacol, Kuala Lumpur 50603, Malaysia; [Chung, Lip Yong] Univ Malaya, Ctr Nat Prod & Drug Res CENAR, Kuala Lumpur 50603, Malaysia	Universiti Malaya; Universiti Malaya; Universiti Malaya	Chung, LY (corresponding author), Univ Malaya, Fac Med, Dept Pharm, Kuala Lumpur 50603, Malaysia.	chungly@um.edu.my	CHUNG, LIP YONG/B-7764-2010; Chin, Sek Peng/AHE-3964-2022; Chin, Sek Peng/O-1186-2016; Buckle, Michael/B-5233-2010; devi, sri/GWQ-8417-2022; DEVI, SRI/AAL-2122-2020; KIEW, LIK VOON/B-8789-2010	CHUNG, LIP YONG/0000-0002-3596-768X; Chin, Sek Peng/0000-0001-5555-0729; Buckle, Michael/0000-0003-2438-2376; KIEW, LIK VOON/0000-0002-6855-9631; Devi, Sri/0000-0002-1561-3331	University of Malaya [RG032/10BIO]; High Impact Research Grants HIR-MOHE - Ministry of Higher Education, Malaysia [UM.C/625/1/HIR/MOHE/MED/17, UM.C/625/1/HIR/MOHE/MED/33]	University of Malaya(Universiti Malaya); High Impact Research Grants HIR-MOHE - Ministry of Higher Education, Malaysia	The authors wish to acknowledge the grants RG032/10BIO provided by the University of Malaya, and High Impact Research Grants HIR-MOHE (UM.C/625/1/HIR/MOHE/MED/17 and UM.C/625/1/HIR/MOHE/MED/33) provided by the Ministry of Higher Education, Malaysia, for this study. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aghajanian GK, 2000, BRAIN RES REV, V31, P302, DOI 10.1016/S0165-0173(99)00046-6; Aguiar S, 2013, REJUV RES, V16, P313, DOI 10.1089/rej.2013.1431; Ahirwar S., 2012, Asian Journal of Experimental Sciences, V26, P65; Allman K, 2000, MOL PHARMACOL, V58, P175, DOI 10.1124/mol.58.1.175; Almaula N, 1996, J BIOL CHEM, V271, P14672, DOI 10.1074/jbc.271.25.14672; Anelli T, 2007, BIOCHEM BIOPH RES CO, V362, P269, DOI 10.1016/j.bbrc.2007.07.093; Barbhaiya H. C., 2008, Journal of Pharmacology and Toxicology, V3, P425; Bhattacharya SK, 1999, RES COMMUN PHARM TOX, V4, P1; BLUML K, 1994, J BIOL CHEM, V269, P18870; Braden MR, 2007, MOL PHARMACOL, V72, P1200, DOI 10.1124/mol.107.039255; Charles PD, 2011, J ETHNOPHARMACOL, V134, P55, DOI 10.1016/j.jep.2010.11.045; Chen CYC, 2009, J TAIWAN INST CHEM E, V40, P36, DOI 10.1016/j.jtice.2008.07.011; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; Chin SP, 2014, J MOL GRAPH MODEL, V49, P91, DOI 10.1016/j.jmgm.2014.02.002; Chung LY, 2009, PHYTOTHER RES, V23, P330, DOI 10.1002/ptr.2627; Chung LY, 2005, PHARM BIOL, V43, P280, DOI 10.1080/13880200590928889; Clader JW, 2005, CURR PHARM DESIGN, V11, P3353, DOI 10.2174/138161205774370762; Conn PJ, 2009, NAT REV DRUG DISCOV, V8, P41, DOI 10.1038/nrd2760; Das A, 2002, PHARMACOL BIOCHEM BE, V73, P893, DOI 10.1016/S0091-3057(02)00940-1; Day AJ, 2000, FEBS LETT, V468, P166, DOI 10.1016/S0014-5793(00)01211-4; De Jaco A, 2002, NEUROSCIENCE, V113, P331, DOI 10.1016/S0306-4522(02)00179-3; Deepak M, 2005, PHYTOCHEM ANALYSIS, V16, P24, DOI 10.1002/pca.805; Dhawan BN, 1996, EUR NEUROPSYCHOPHARM, V3, P144; Egan WJ, 2000, J MED CHEM, V43, P3867, DOI 10.1021/jm000292e; Egan WJ, 2002, ADV DRUG DELIVER REV, V54, P273, DOI 10.1016/S0169-409X(02)00004-2; ELLMAN GL, 1961, BIOCHEM PHARMACOL, V7, P88, DOI 10.1016/0006-2952(61)90145-9; Fisher A, 2008, NEUROTHERAPEUTICS, V5, P433, DOI 10.1016/j.nurt.2008.05.002; HANSCH C, 1987, J PHARM SCI, V76, P663, DOI 10.1002/jps.2600760902; Harvey JA, 2003, LEARN MEMORY, V10, P355, DOI 10.1101/lm.60803; Hollman PCH, 2004, PHARM BIOL, V42, P74, DOI 10.3109/13880200490893492; Huang XP, 1999, BRIT J PHARMACOL, V126, P735, DOI 10.1038/sj.bjp.0702301; Indian Drug Manufacturers Association (IDMA), 2002, IND HERB PHARM; Jager AK, 2011, MOLECULES, V16, P1471, DOI 10.3390/molecules16021471; Jakab RL, 1998, P NATL ACAD SCI USA, V95, P735, DOI 10.1073/pnas.95.2.735; Keov P, 2011, NEUROPHARMACOLOGY, V60, P24, DOI 10.1016/j.neuropharm.2010.07.010; Kongkeaw C, 2014, J ETHNOPHARMACOL, V151, P528, DOI 10.1016/j.jep.2013.11.008; Kren V, 2001, CURR MED CHEM, V8, P1303, DOI 10.2174/0929867013372193; Kristiansen K, 2000, J PHARMACOL EXP THER, V293, P735; Kruse AC, 2014, NAT REV DRUG DISCOV, V13, P549, DOI 10.1038/nrd4295; Kruse AC, 2013, NATURE, V504, P101, DOI 10.1038/nature12735; KULSHRESHTHA DK, 1973, PHYTOCHEMISTRY, V12, P2074, DOI 10.1016/S0031-9422(00)91552-8; Lefkowitz R. J., 1990, PHARMACOL BASIS THER, P84; Leung Kar Wah, 2010, Chin Med, V5, P20, DOI 10.1186/1749-8546-5-20; LEVEY AI, 1995, J NEUROSCI, V15, P4077; Lu ZL, 2001, J BIOL CHEM, V276, P34098, DOI 10.1074/jbc.M104217200; Lu ZL, 1999, J BIOL CHEM, V274, P7309, DOI 10.1074/jbc.274.11.7309; Manach C, 2004, AM J CLIN NUTR, V79, P727, DOI 10.1093/ajcn/79.5.727; Megias M, 2001, NEUROSCIENCE, V102, P527, DOI 10.1016/S0306-4522(00)00496-6; Mercado E, 2008, PSYCHOL BULL, V134, P109, DOI 10.1037/0033-2909.134.1.109; Morris GM, 2009, J COMPUT CHEM, V30, P2785, DOI 10.1002/jcc.21256; Morris GM, 1998, J COMPUT CHEM, V19, P1639, DOI 10.1002/(SICI)1096-987X(19981115)19:14<1639::AID-JCC10>3.0.CO;2-B; Nemeth K, 2003, EUR J NUTR, V42, P29, DOI 10.1007/s00394-003-0397-3; Pajouhesh Hassan, 2005, NeuroRx, V2, P541, DOI 10.1602/neurorx.2.4.541; Pravina K, 2007, PHYTOMEDICINE, V14, P301, DOI 10.1016/j.phymed.2007.03.010; QUIRION R, 1985, BRAIN RES, V333, P345, DOI 10.1016/0006-8993(85)91590-2; Rajani M., 2008, P175, DOI 10.1007/978-3-540-74603-4_9; Ramasamy S, 2014, MOLECULES, V19, P2588, DOI 10.3390/molecules19022588; Rangel-Ordonez L, 2010, PLANTA MED, V76, P1683, DOI 10.1055/s-0030-1249962; Rastogi M, 2012, BIOGERONTOLOGY, V13, P183, DOI 10.1007/s10522-011-9367-y; Roth BL, 1997, MOL PHARMACOL, V52, P259, DOI 10.1124/mol.52.2.259; Ruan JQ, 2010, J AGR FOOD CHEM, V58, P5770, DOI 10.1021/jf1005885; Russo A, 2005, PHYTOMEDICINE, V12, P305, DOI 10.1016/j.phymed.2003.12.008; Saraf MK, 2011, EVID-BASED COMPL ALT, V2011, P1, DOI 10.1093/ecam/neq038; SHAPIRO G, 1992, J MED CHEM, V35, P15, DOI 10.1021/jm00079a002; Sharma RJ, 2012, NEUROSCI RES LETT, V3, P35; Sheikh N, 2007, J ETHNOPHARMACOL, V111, P671, DOI 10.1016/j.jep.2007.01.025; Shen H, 2013, CHIN MED-UK, V8, DOI 10.1186/1749-8546-8-22; Singh H., 1988, PHYTOTHER RES, V2, P70, DOI DOI 10.1002/PTR.2650020205; Singh H. K., 1997, Indian Journal of Pharmacology, V29, pS359; Singh RR, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0068036, 10.1371/journal.pone.0072517]; Sivaramakrishna C, 2005, PHYTOCHEMISTRY, V66, P2719, DOI 10.1016/j.phytochem.2005.09.016; Spruston N, 2008, NAT REV NEUROSCI, V9, P206, DOI 10.1038/nrn2286; Srivastava A, 2014, NATURE, V513, P124, DOI 10.1038/nature13494; Swaminathan M, 2014, MOLECULES, V19, P8933, DOI 10.3390/molecules19078933; Tabuchi M, 2012, CELL MOL NEUROBIOL, V32, P1139, DOI 10.1007/s10571-012-9839-x; Tawab MA, 2003, DRUG METAB DISPOS, V31, P1065, DOI 10.1124/dmd.31.8.1065; VanderZee EA, 1997, HIPPOCAMPUS, V7, P271, DOI 10.1002/(SICI)1098-1063(1997)7:3<271::AID-HIPO3>3.0.CO;2-O; Vollala VR, 2011, CLINICS, V66, P663, DOI 10.1590/S1807-59322011000400023; WANG CD, 1993, MOL PHARMACOL, V43, P931; Ward SDC, 1999, MOL PHARMACOL, V56, P1031, DOI 10.1124/mol.56.5.1031; Weiss C, 2000, J NEUROSCI, V20, P783, DOI 10.1523/JNEUROSCI.20-02-00783.2000; Le XT, 2013, NEUROCHEM RES, V38, P2201, DOI 10.1007/s11064-013-1129-6; Yamasaki M, 2010, J NEUROSCI, V30, P4408, DOI 10.1523/JNEUROSCI.5719-09.2010; Yap BK, 2012, J MOL MODEL, V18, P3639, DOI 10.1007/s00894-012-1368-5; Zhang Y, 2014, INT J FOOD PROP, V17, P1841, DOI 10.1080/10942912.2012.749410	85	42	43	0	21	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 12	2015	10	5							e0126565	10.1371/journal.pone.0126565	http://dx.doi.org/10.1371/journal.pone.0126565			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CI1ZI	25965066	gold, Green Published, Green Submitted			2023-01-03	WOS:000354543500064
J	Sanzey, M; Rahim, SAA; Oudin, A; Dirkse, A; Kaoma, T; Vallar, L; Herold-Mende, C; Bjerkvig, R; Golebiewska, A; Niclou, SP				Sanzey, Morgane; Rahim, Siti Aminah Abdul; Oudin, Anais; Dirkse, Anne; Kaoma, Tony; Vallar, Laurent; Herold-Mende, Christel; Bjerkvig, Rolf; Golebiewska, Anna; Niclou, Simone P.			Comprehensive Analysis of Glycolytic Enzymes as Therapeutic Targets in the Treatment of Glioblastoma	PLOS ONE			English	Article							LARGE GENE LISTS; STEM-LIKE CELLS; PYRUVATE-KINASE; TUMOR-GROWTH; CANCER; BRAIN; HEXOKINASE; HYPOXIA; NORMALIZATION; MITOCHONDRIA	Major efforts have been put in anti-angiogenic treatment for glioblastoma (GBM), an aggressive and highly vascularized brain tumor with dismal prognosis. However clinical outcome with anti-angiogenic agents has been disappointing and tumors quickly develop escape mechanisms. In preclinical GBM models we have recently shown that bevacizumab, a blocking antibody against vascular endothelial growth factor, induces hypoxia in treated tumors, which is accompanied by increased glycolytic activity and tumor invasiveness. Genomewide transcriptomic analysis of patient derived GBM cells including stem cell lines revealed a strong up-regulation of glycolysis-related genes in response to severe hypoxia. We therefore investigated the importance of glycolytic enzymes in GBM adaptation and survival under hypoxia, both in vitro and in vivo. We found that shRNA-mediated attenuation of glycolytic enzyme expression interfered with GBM growth under normoxic and hypoxic conditions in all cellular models. Using intracranial GBM xenografts we identified seven glycolytic genes whose knockdown led to a dramatic survival benefit in mice. The most drastic effect was observed for PFKP ( PFK1, +21.8%) and PDK1 (+20.9%), followed by PGAM1 and ENO1 (+14.5% each), HK2 (+11.8%), ALDOA (+10.9%) and ENO2 (+7.2%). The increase in mouse survival after genetic interference was confirmed using chemical inhibition of PFK1 with clotrimazole. We thus provide a comprehensive analysis on the importance of the glycolytic pathway for GBM growth in vivo and propose PFK1 and PDK1 as the most promising therapeutic targets to address the metabolic escape mechanisms of GBM.	[Sanzey, Morgane; Rahim, Siti Aminah Abdul; Oudin, Anais; Dirkse, Anne; Bjerkvig, Rolf; Golebiewska, Anna; Niclou, Simone P.] Luxembourg Inst Hlth, Dept Oncol, NorLux Neurooncol Lab, Luxembourg, Luxembourg; [Kaoma, Tony; Vallar, Laurent] Luxembourg Inst Hlth, Genom Res Unit, Luxembourg, Luxembourg; [Herold-Mende, Christel] Heidelberg Univ, Dept Neurosurg, Expt Neurosurg, Heidelberg, Germany; [Bjerkvig, Rolf] Univ Bergen, Dept Biomed, NorLux Neurooncol Lab, Bergen, Norway; [Bjerkvig, Rolf; Niclou, Simone P.] Univ Bergen, Dept Biomed, KG Jebsen Brain Tumour Res Ctr, Bergen, Norway	Luxembourg Institute of Health; Luxembourg Institute of Health; Ruprecht Karls University Heidelberg; University of Bergen; University of Bergen	Niclou, SP (corresponding author), Luxembourg Inst Hlth, Dept Oncol, NorLux Neurooncol Lab, Luxembourg, Luxembourg.	simone.niclou@lih.lu	Golebiewska, Anna/E-1332-2015; Niclou, Simone/P-2304-2018	Golebiewska, Anna/0000-0002-4160-2521; Niclou, Simone/0000-0002-3417-9534; Dirkse, Anne/0000-0003-0778-6651; Vallar, Laurent/0000-0002-4404-1010; Oudin, Anais/0000-0001-5552-9823	Fonds National de la Recherche (FNR) of Luxembourg [ESCAPE 784322 BM]; AFR; Centre de Recherche Public de la Sante (CRP-Sante)	Fonds National de la Recherche (FNR) of Luxembourg(Luxembourg National Research Fund); AFR(Luxembourg National Research Fund); Centre de Recherche Public de la Sante (CRP-Sante)	This work was supported by the Fonds National de la Recherche (FNR) of Luxembourg (ESCAPE 784322 BM to SPN and AFR grant to SAAR) and the Centre de Recherche Public de la Sante (CRP-Sante). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ahmed BY, 2004, BMC NEUROSCI, V5, DOI 10.1186/1471-2202-5-4; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Bonnet S, 2007, CANCER CELL, V11, P37, DOI 10.1016/j.ccr.2006.10.020; Campos B, 2010, CLIN CANCER RES, V16, P2715, DOI 10.1158/1078-0432.CCR-09-1800; Carmeliet P, 2011, NAT REV DRUG DISCOV, V10, P417, DOI 10.1038/nrd3455; Chen W, 2007, J NUCL MED, V48, P1468, DOI 10.2967/jnumed.106.037689; Chi JT, 2006, PLOS MED, V3, P395, DOI 10.1371/journal.pmed.0030047; Chinot OL, 2014, NEW ENGL J MED, V370, P2049, DOI 10.1056/NEJMc1403303; Christofk HR, 2008, NATURE, V452, P230, DOI 10.1038/nature06734; Dennis G, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-9-r60; Du JL, 2014, MOL BIOSYST, V10, P2441, DOI 10.1039/c4mb00287c; Fack F, 2014, ACTA NEUROPATHOLOGIC; Ganapathy-Kanniappan S, 2010, CURR PHARM BIOTECHNO, V11, P510, DOI 10.2174/138920110791591427; Gao HS, 2013, J NEUROSURG, V118, P846, DOI 10.3171/2012.9.JNS112134; Gilbert MR, 2014, NEW ENGL J MED, V370, P699, DOI 10.1056/NEJMoa1308573; Goidts V, 2012, ONCOGENE, V31, P3235, DOI 10.1038/onc.2011.490; Golebiewska A, 2013, BRAIN, V136, P1462, DOI 10.1093/brain/awt025; Hamer PCDW, 2008, ONCOGENE, V27, P2091, DOI 10.1038/sj.onc.1210850; Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809; Hirschhaeuser F, 2010, J BIOTECHNOL, V148, P3, DOI 10.1016/j.jbiotec.2010.01.012; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Huang DW, 2009, NUCLEIC ACIDS RES, V37, P1, DOI 10.1093/nar/gkn923; Kathagen A, 2013, ACTA NEUROPATHOL, V126, P763, DOI 10.1007/s00401-013-1173-y; Keunen O, 2011, P NATL ACAD SCI USA, V108, P3749, DOI 10.1073/pnas.1014480108; Kumar K, 2013, J MOL MED, V91, P749, DOI 10.1007/s00109-013-0996-2; Lal A, 2001, JNCI-J NATL CANCER I, V93, P1337, DOI 10.1093/jnci/93.17.1337; Marcondes MC, 2010, ARCH BIOCHEM BIOPHYS, V497, P62, DOI 10.1016/j.abb.2010.03.013; Mazurek S, 2005, SEMIN CANCER BIOL, V15, P300, DOI 10.1016/j.semcancer.2005.04.009; Michelakis ED, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000677; Muller FL, 2012, NATURE, V488, P337, DOI 10.1038/nature11331; Niclou SP, 2008, FASEB J, V22, P3120, DOI 10.1096/fj.08-109611; Pastorino JG, 2002, J BIOL CHEM, V277, P7610, DOI 10.1074/jbc.M109950200; Penso J, 1998, EUR J PHARMACOL, V342, P113, DOI 10.1016/S0014-2999(97)01507-0; Plate KH, 2012, ACTA NEUROPATHOL, V124, P763, DOI 10.1007/s00401-012-1066-5; Ren FL, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-81; Stieber D, 2011, EXPERT OPIN THER TAR, V15, P1227, DOI 10.1517/14728222.2011.588211; Supek F, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021800; Sutendra G, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00038; Torsvik A, 2014, CANCER MED-US, V3, P812, DOI 10.1002/cam4.219; Velpula KK, 2013, CANCER RES, V73, P7277, DOI 10.1158/0008-5472.CAN-13-1868; Weller M, 2013, NEURO-ONCOLOGY, V15, P4, DOI 10.1093/neuonc/nos273; Wolf A, 2011, NEUROBIOL DIS, V44, P84, DOI 10.1016/j.nbd.2011.06.007; Wolf A, 2011, J EXP MED, V208, P313, DOI 10.1084/jem.20101470; Yan T, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-524; Zhang XD, 2009, ANTICANCER RES, V29, P1249	45	70	71	1	23	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 1	2015	10	5							e0123544	10.1371/journal.pone.0123544	http://dx.doi.org/10.1371/journal.pone.0123544			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CH2XA	25932951	gold, Green Submitted, Green Published			2023-01-03	WOS:000353887100023
J	Sen, A				Sen, Ayan			Review: In acute respiratory failure, prehospital CPAP reduces mortality and intubation rates	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							VENTILATION; DISTRESS		Mayo Clin, Dept Crit Care Med, Phoenix, AZ 85054 USA	Mayo Clinic; Mayo Clinic Phoenix	Sen, A (corresponding author), Mayo Clin, Dept Crit Care Med, Phoenix, AZ 85054 USA.							Brower RG, 2000, NEW ENGL J MED, V342, P1301, DOI 10.1056/nejm200005043421801; Carrillo A, 2012, INTENS CARE MED, V38, P458, DOI 10.1007/s00134-012-2475-6; Diez A, 2011, DEFENDING LUNG INJUR; Mal S, 2014, ANN EMERG MED, V63, P600, DOI 10.1016/j.annemergmed.2013.11.013; Shahin J, 2015, J CRIT CARE, V30, P649, DOI [10.1016/j.jcrc.2015.03.003, 10.1016/j.jcrc.2014.09.021]	5	0	0	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 21	2015	162	8							JC5	10.7326/ACPJC-2015-162-8-005	http://dx.doi.org/10.7326/ACPJC-2015-162-8-005			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CG4GT	25894050				2023-01-03	WOS:000353244300004
J	Sharma, P; Allison, JP				Sharma, Padmanee; Allison, James P.			Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential	CELL			English	Review							COLONY-STIMULATING FACTOR; CTLA-4 BLOCKADE SYNERGIZES; RESISTANT PROSTATE-CANCER; T-CELLS; IMMUNOTHERAPY; MELANOMA; PD-1; ACTIVATION; IPILIMUMAB; SURVIVAL	Research in two fronts has enabled the development of therapies that provide significant benefit to cancer patients. One area stems from a detailed knowledge of mutations that activate or inactivate signaling pathways that drive cancer development. This work triggered the development of targeted therapies that lead to clinical responses in the majority of patients bearing the targeted mutation, although responses are often of limited duration. In the second front are the advances in molecular immunology that unveiled the complexity of the mechanisms regulating cellular immune responses. These developments led to the successful targeting of immune checkpoints to unleash anti-tumor T cell responses, resulting in durable long-lasting responses but only in a fraction of patients. In this Review, we discuss the evolution of research in these two areas and propose that intercrossing them and increasing funding to guide research of combination of agents represent a path forward for the development of curative therapies for the majority of cancer patients.	[Sharma, Padmanee; Allison, James P.] Univ Texas Houston, MD Anderson Canc Ctr, Dept Immunol, Houston, TX 77030 USA; [Sharma, Padmanee] Univ Texas Houston, MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, Houston, TX 77030 USA	University of Texas System; University of Texas Health Science Center Houston; UTMD Anderson Cancer Center; University of Texas System; University of Texas Health Science Center Houston; UTMD Anderson Cancer Center	Sharma, P (corresponding author), Univ Texas Houston, MD Anderson Canc Ctr, Dept Immunol, Houston, TX 77030 USA.	padsharma@mdanderson.org; jallison@mdanderson.org		Allison, James/0000-0001-8980-5697	PCF Challenge Grant in Immunology; NCI/NIH [1-R01 CA1633793-01]; Cancer Prevention Research in Texas grants; Stand Up To Cancer-Cancer Research Institute Cancer Immunology Dream Team Translational Cancer Research Grant; NATIONAL CANCER INSTITUTE [P30CA016672, R01CA163793] Funding Source: NIH RePORTER	PCF Challenge Grant in Immunology; NCI/NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Cancer Prevention Research in Texas grants; Stand Up To Cancer-Cancer Research Institute Cancer Immunology Dream Team Translational Cancer Research Grant; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	P.S. and J.P.A. are founders and advisors for Jounce Therapeutics. P.S. also serves as a consultant for Bristol-Myers Squibb, Amgen, and Glaxo SmithKline. J.P.A. is an inventor of intellectual property owned by the University of California, Berkeley, and licensed to Bristol-Myers Squibb and has received royalties from Bristol-Myers Squibb. Our research is supported by a PCF Challenge Grant in Immunology (J.P.A. and P.S.), NCI/NIH 1-R01 CA1633793-01 (P.S.), Cancer Prevention Research in Texas grants (J.P.A. and P.S.), and a Stand Up To Cancer-Cancer Research Institute Cancer Immunology Dream Team Translational Cancer Research Grant (P.S. and J.P.A.). Stand Up To Cancer is a program of the Entertainment Industry Foundation administered by the American Association for Cancer Research.	Alexandrov LB, 2013, NATURE, V500, P415, DOI 10.1038/nature12477; Ansell SM, 2015, NEW ENGL J MED, V372, P311, DOI 10.1056/NEJMoa1411087; Atefi M, 2014, CLIN CANCER RES, V20, P3446, DOI 10.1158/1078-0432.CCR-13-2797; Bass AJ, 2014, NATURE, V513, P202, DOI 10.1038/nature13480; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; Brahmer JR, 2012, NEW ENGL J MED, V366, P2455, DOI 10.1056/NEJMoa1200694; Brignone C, 2010, J TRANSL MED, V8, DOI 10.1186/1479-5876-8-71; Brignone C, 2009, CLIN CANCER RES, V15, P6225, DOI 10.1158/1078-0432.CCR-09-0068; Carthon BC, 2010, CLIN CANCER RES, V16, P2861, DOI 10.1158/1078-0432.CCR-10-0569; Chambers CA, 1997, IMMUNITY, V7, P885, DOI 10.1016/S1074-7613(00)80406-9; Chapman PB, 2011, NEW ENGL J MED, V364, P2507, DOI 10.1056/NEJMoa1103782; Chen YB, 2014, INTELL SYST SER, P1, DOI 10.1016/B978-0-12-397199-9.00001-X; Curti BD, 2013, CANCER RES, V73, P7189, DOI 10.1158/0008-5472.CAN-12-4174; Curtin JA, 2005, NEW ENGL J MED, V353, P2135, DOI 10.1056/NEJMoa050092; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; DAVIS MM, 1988, NATURE, V334, P395, DOI 10.1038/334395a0; Dong HD, 2002, NAT MED, V8, P793, DOI 10.1038/nm730; Fan XZ, 2014, J EXP MED, V211, P715, DOI 10.1084/jem.20130590; Frederick DT, 2013, CLIN CANCER RES, V19, P1225, DOI 10.1158/1078-0432.CCR-12-1630; Freeman GJ, 2000, J EXP MED, V192, P1027, DOI 10.1084/jem.192.7.1027; Gao J., 2015, ONCOGENE; Greenwald RJ, 2005, ANNU REV IMMUNOL, V23, P515, DOI 10.1146/annurev.immunol.23.021704.115611; Gros A, 2014, J CLIN INVEST, V124, P2246, DOI [10.1172/JC173639, 10.1172/JCI73639]; Gubin MM, 2014, NATURE, V515, P577, DOI 10.1038/nature13988; Hamid O, 2013, NEW ENGL J MED, V369, P134, DOI 10.1056/NEJMoa1305133; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hanna N, 2004, J CLIN ONCOL, V22, P1589, DOI 10.1200/JCO.2004.08.163; Hodi FS, 2008, P NATL ACAD SCI USA, V105, P3005, DOI 10.1073/pnas.0712237105; Hodi FS, 2010, NEW ENGL J MED, V363, P711, DOI 10.1056/NEJMoa1003466; Hurwitz AA, 1998, P NATL ACAD SCI USA, V95, P10067, DOI 10.1073/pnas.95.17.10067; ISHIDA Y, 1992, EMBO J, V11, P3887, DOI 10.1002/j.1460-2075.1992.tb05481.x; JENKINS MK, 1987, J EXP MED, V165, P302, DOI 10.1084/jem.165.2.302; Keir ME, 2008, ANNU REV IMMUNOL, V26, P677, DOI 10.1146/annurev.immunol.26.021607.090331; Knudson AG, 2001, NAT REV CANCER, V1, P157, DOI 10.1038/35101031; KRUMMEL MF, 1995, J EXP MED, V182, P459, DOI 10.1084/jem.182.2.459; Kwon ED, 2014, LANCET ONCOL, V15, P700, DOI 10.1016/S1470-2045(14)70189-5; Larkin J, 2014, NEW ENGL J MED, V371, P1867, DOI 10.1056/NEJMoa1408868; Le Mercier I, 2014, CANCER RES, V74, P1933, DOI 10.1158/0008-5472.CAN-13-1506; Leach DR, 1996, SCIENCE, V271, P1734, DOI 10.1126/science.271.5256.1734; Liakou CI, 2008, P NATL ACAD SCI USA, V105, P14987, DOI 10.1073/pnas.0806075105; Linnemann C, 2015, NAT MED, V21, P81, DOI 10.1038/nm.3773; Martz CA, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.aaa1877; Melero I, 1997, NAT MED, V3, P682, DOI 10.1038/nm0697-682; Melero I, 2014, NAT REV CLIN ONCOL, V11, P509, DOI 10.1038/nrclinonc.2014.111; MUELLER DL, 1989, J IMMUNOL, V142, P2617; Pardoll DM, 2012, NAT REV CANCER, V12, P252, DOI 10.1038/nrc3239; Peggs KS, 2009, J EXP MED, V206, P1717, DOI 10.1084/jem.20082492; Powles T, 2014, NATURE, V515, P558, DOI 10.1038/nature13904; Quezada SA, 2006, J CLIN INVEST, V116, P1935, DOI 10.1172/JCI27745; Ramanujam S, 2015, CHIN CLIN ONCOL, V4, DOI 10.3978/j.issn.2304-3865.2015.06.06; Ribas A, 2013, NEW ENGL J MED, V368, P1365, DOI 10.1056/NEJMc1302338; Robert C, 2015, NEW ENGL J MED, V372, P320, DOI 10.1056/NEJMoa1412082; Robert C, 2015, NEW ENGL J MED, V372, P30, DOI 10.1056/NEJMoa1412690; Robert C, 2011, NEW ENGL J MED, V364, P2517, DOI 10.1056/NEJMoa1104621; Rosenberg SA, 2004, NAT MED, V10, P909, DOI 10.1038/nm1100; Sakuishi K, 2010, J EXP MED, V207, P2187, DOI 10.1084/jem.20100643; Segal NH, 2008, CANCER RES, V68, P889, DOI 10.1158/0008-5472.CAN-07-3095; Sharma P, 2011, NAT REV CANCER, V11, P805, DOI 10.1038/nrc3153; Shaw AT, 2013, NEW ENGL J MED, V368, P2385, DOI 10.1056/NEJMoa1214886; Shoushtari AN, 2015, J CLIN ONCOL, V33; Sjoblom T, 2006, SCIENCE, V314, P268, DOI 10.1126/science.1133427; Snyder A, 2014, NEW ENGL J MED, V371, P2189, DOI 10.1056/NEJMoa1406498; Soda M, 2007, NATURE, V448, P561, DOI 10.1038/nature05945; SOLOMON E, 1991, SCIENCE, V254, P1153, DOI 10.1126/science.1957167; Sosman JA, 2012, NEW ENGL J MED, V366, P707, DOI 10.1056/NEJMoa1112302; Tang C, 2014, CANCER IMMUNOL RES, V2, P831, DOI 10.1158/2326-6066.CIR-14-0069; Tang DN, 2013, CANCER IMMUNOL RES, V1, P229, DOI 10.1158/2326-6066.CIR-13-0020; TIVOL EA, 1995, IMMUNITY, V3, P541, DOI 10.1016/1074-7613(95)90125-6; Topalian SL, 2012, NEW ENGL J MED, V366, P2443, DOI 10.1056/NEJMoa1200690; TOWNSEND SE, 1993, SCIENCE, V259, P368, DOI 10.1126/science.7678351; Tran E, 2014, SCIENCE, V344, P641, DOI 10.1126/science.1251102; TRIEBEL F, 1990, J EXP MED, V171, P1393, DOI 10.1084/jem.171.5.1393; van den Eertwegh AJM, 2012, LANCET ONCOL, V13, P509, DOI 10.1016/S1470-2045(12)70007-4; van Elsas A, 1999, J EXP MED, V190, P355, DOI 10.1084/jem.190.3.355; Waitz R, 2012, ONCOIMMUNOLOGY, V1, DOI 10.4161/onci.19442; WALUNAS TL, 1994, IMMUNITY, V1, P405, DOI 10.1016/1074-7613(94)90071-X; Wang L, 2011, J EXP MED, V208, P577, DOI 10.1084/jem.20100619; WATERHOUSE P, 1995, SCIENCE, V270, P985, DOI 10.1126/science.270.5238.985; Wolchok JD, 2013, NEW ENGL J MED, V369, P122, DOI 10.1056/NEJMoa1302369; Zamarin D, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3008095	80	1427	1504	15	426	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 9	2015	161	2					205	214		10.1016/j.cell.2015.03.030	http://dx.doi.org/10.1016/j.cell.2015.03.030			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	CF7AL	25860605	Green Accepted, Bronze			2023-01-03	WOS:000352708300015
J	Xue, J; Chi, Y; Chen, Y; Huang, S; Ye, X; Niu, J; Wang, W; Pfeffer, LM; Shao, ZM; Wu, ZH; Wu, J				Xue, J.; Chi, Y.; Chen, Y.; Huang, S.; Ye, X.; Niu, J.; Wang, W.; Pfeffer, L. M.; Shao, Z-m; Wu, Z-H; Wu, J.			MiRNA-621 sensitizes breast cancer to chemotherapy by suppressing FBXO11 and enhancing p53 activity	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; PATHOLOGICAL COMPLETE RESPONSE; NEOADJUVANT CHEMOTHERAPY; GENE-EXPRESSION; PACLITAXEL; MICRORNAS; CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDICTOR; PROMOTES	MicroRNAs (miRNAs) have been demonstrated to have critical roles in regulating cancer cell proliferation, survival and sensitivity to chemotherapy. The potential application of using miRNAs to predict therapeutic response to cancer treatment holds high promise, but miRNAs with predictive value remain to be identified and underlying mechanisms have not been completely understood. Here, we show a strong correlation between miR-621 expression and chemosensitivity to paclitaxel plus carboplatin (PTX/CBP) regimen, an effective neoadjuvant chemotherapy for breast cancer patients. High level of miR-621 predicts better response to PTX/CBP regimen neoadjuvant chemotherapy in breast cancer patients, who also tend to achieve pathological complete response. Ectopic overexpression of miR-621 promoted apoptosis and increased chemosensitivity to PTX and CBP both in cultured breast cancer cells and in xenograft tumor model. We further show that FBXO11 is a direct functional target of miR-621 and miR-621 level is negatively correlated with FBXO11 expression in breast cancer patients. Ectopic expression of FBXO11 attenuated increased apoptosis in breast cancer cells overexpressing miR-621 upon PTX or CBP treatment. Consistently, high FBXO11 expression significantly correlated with poor survival in breast cancer patients. Mechanistically, we found in breast cancer cells FBXO11 interacts with p53 and promotes its neddylation, which suppressed the p53 transactivity. Accordingly, miR-621-dependent FBXO11 suppression enhanced p53 activity and increased apoptosis in breast cancer cells exposed to chemotherapeutics. Taken together, our data suggest that miR-621 enhances chemosensitivity of breast cancer cells to PTX/CBP chemotherapy by suppressing FBXO11depedent inhibition of p53. miR-621 may serve as a predictive biomarker and a potential therapeutic target in breast cancer treatment.	[Xue, J.; Chi, Y.; Chen, Y.; Huang, S.; Shao, Z-m; Wu, J.] Fudan Univ, Shanghai Canc Ctr, Dept Breast Surg, 270 Dong An Rd, Shanghai 200032, Peoples R China; [Xue, J.; Chi, Y.; Chen, Y.; Huang, S.; Shao, Z-m; Wu, J.] Fudan Univ, Dept Oncol, Shanghai Med Coll, Shanghai 200433, Peoples R China; [Xue, J.; Niu, J.; Wang, W.; Pfeffer, L. M.; Wu, Z-H] Univ Tennessee, Ctr Hlth Sci, Ctr Canc Res, 19 S Manassas St, Memphis, TN 38163 USA; [Chen, Y.] Wenzhou Med Coll, Dept Surg Oncol, Affiliated Hosp 1, Wenzhou, Zhejiang, Peoples R China; [Ye, X.] Fudan Univ, Inst Merieux Lab, Shanghai Canc Ctr, Shanghai 200433, Peoples R China; [Niu, J.; Wang, W.; Pfeffer, L. M.; Wu, Z-H] Univ Tennessee, Ctr Hlth Sci, Dept Pathol & Lab Med, Memphis, TN 38163 USA	Fudan University; Fudan University; University of Tennessee System; University of Tennessee Health Science Center; Wenzhou Medical University; Fudan University; University of Tennessee System; University of Tennessee Health Science Center	Wu, J (corresponding author), Fudan Univ, Shanghai Canc Ctr, Dept Breast Surg, 270 Dong An Rd, Shanghai 200032, Peoples R China.; Wu, ZH (corresponding author), Univ Tennessee, Ctr Hlth Sci, Ctr Canc Res, 19 S Manassas St, Memphis, TN 38163 USA.	zwu6@uthsc.edu; wujiong1122@vip.sina.com		Pfeffer, Lawrence/0000-0003-2809-1234	National Natural Science Foundation of China (NSFC) [81272924]; National Cancer Institute [R01 CA149251]; American Cancer Society [RSG-13-186-01-CSM]; NATIONAL CANCER INSTITUTE [R01CA149251] Funding Source: NIH RePORTER	National Natural Science Foundation of China (NSFC)(National Natural Science Foundation of China (NSFC)); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); American Cancer Society(American Cancer Society); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Bert Vogelstein (Johns Hopkins University) for wild-type, DICER<SUP>-/-</SUP> and p53<SUP>-/-</SUP> HCT116 cells. This work was supported in part by the National Natural Science Foundation of China (NSFC) (81272924 to JW), National Cancer Institute (R01 CA149251 to ZW), and American Cancer Society (RSG-13-186-01-CSM to ZW).	Abbas T, 2013, MOL CELL, V49, P1147, DOI 10.1016/j.molcel.2013.02.003; Abida WM, 2007, J BIOL CHEM, V282, P1797, DOI 10.1074/jbc.M609001200; Balko JM, 2014, CANCER DISCOV, V4, P232, DOI 10.1158/2159-8290.CD-13-0286; Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002; Berry DA, 2005, NEW ENGL J MED, V353, P1784, DOI 10.1056/NEJMoa050518; Blower PE, 2008, MOL CANCER THER, V7, P1, DOI 10.1158/1535-7163.MCT-07-0573; Bonnefoi H, 2014, ANN ONCOL, V25, P1128, DOI 10.1093/annonc/mdu118; Borst P, 2010, CELL CYCLE, V9, P4836, DOI 10.4161/cc.9.24.14326; Chang XZ, 2008, BREAST CANCER RES TR, V111, P65, DOI 10.1007/s10549-007-9761-y; Chen XS, 2010, ANN ONCOL, V21, P961, DOI 10.1093/annonc/mdq041; Chen YZ, 2011, CANCER LETT, V302, P63, DOI 10.1016/j.canlet.2010.12.014; Cummins JM, 2006, P NATL ACAD SCI USA, V103, P3687, DOI 10.1073/pnas.0511155103; Dhami GK, 2013, MOL CELL, V50, P565, DOI 10.1016/j.molcel.2013.04.028; Dieras V, 2004, J CLIN ONCOL, V22, P4958, DOI 10.1200/JCO.2004.02.122; Duan S, 2012, NATURE, V481, P90, DOI 10.1038/nature10688; Ebert MS, 2007, NAT METHODS, V4, P721, DOI 10.1038/NMETH1079; Green DR, 2009, NATURE, V458, P1127, DOI 10.1038/nature07986; Gregory RI, 2005, CELL, V123, P631, DOI 10.1016/j.cell.2005.10.022; Harris L, 2007, J CLIN ONCOL, V25, P5287, DOI 10.1200/JCO.2007.14.2364; Hatzis C, 2011, JAMA-J AM MED ASSOC, V305, P1873, DOI 10.1001/jama.2011.593; Hess KR, 2006, J CLIN ONCOL, V24, P4236, DOI 10.1200/JCO.2006.05.6861; Iwata H, 2011, JPN J CLIN ONCOL, V41, P867, DOI 10.1093/jjco/hyr081; Lagos-Quintana M, 2001, SCIENCE, V294, P853, DOI 10.1126/science.1064921; Lawrence G, 2002, J CLIN ONCOL, V20, P2905, DOI 10.1200/JCO.2002.20.12.2905; Lee JK, 2010, CLIN CANCER RES, V16, P711, DOI 10.1158/1078-0432.CCR-09-2247; Li JY, 2012, BREAST CANCER RES TR, V131, P837, DOI 10.1007/s10549-011-1502-6; Li LH, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/dju083; Ling H, 2013, NAT REV DRUG DISCOV, V12, P847, DOI 10.1038/nrd4140; Mamounas EP, 2012, J CLIN ONCOL, V30, P3960, DOI 10.1200/JCO.2011.40.8369; Mulrane L, 2013, CANCER RES, V73, P6554, DOI 10.1158/0008-5472.CAN-13-1841; Nowak AK, 2004, LANCET ONCOL, V5, P372, DOI 10.1016/S1470-2045(04)01494-9; Pan YZ, 2009, MOL PHARMACOL, V75, P1374, DOI 10.1124/mol.108.054163; Petitjean A, 2007, ONCOGENE, V26, P2157, DOI 10.1038/sj.onc.1210302; Powell E, 2014, CANCER DISCOV, V4, P405, DOI 10.1158/2159-8290.CD-13-0136; Shivdasani RA, 2006, BLOOD, V108, P3646, DOI 10.1182/blood-2006-01-030015; Skaar JR, 2013, NAT REV MOL CELL BIO, V14, P369, DOI 10.1038/nrm3582; Skawran B, 2008, MODERN PATHOL, V21, P1479, DOI 10.1038/modpathol.2008.147; Smith IC, 2002, J CLIN ONCOL, V20, P1456, DOI 10.1200/JCO.20.6.1456; Tabchy A, 2010, CLIN CANCER RES, V16, P5351, DOI 10.1158/1078-0432.CCR-10-1265; Thuerigen O, 2006, J CLIN ONCOL, V24, P1839, DOI 10.1200/JCO.2005.04.7019; Walerych D, 2012, CARCINOGENESIS, V33, P2007, DOI 10.1093/carcin/bgs232; Wang H, 2012, PLOS ONE, V7, P34210, DOI DOI 10.1371/J0URNAL.P0NE.0034210; Weigelt B, 2012, NAT REV CLIN ONCOL, V9, P58, DOI 10.1038/nrclinonc.2011.125; Wu X, 2009, BIOINFORMATICS, V25, P832, DOI 10.1093/bioinformatics/btp059; Xirodimas DP, 2004, CELL, V118, P83, DOI 10.1016/j.cell.2004.06.016; Yang CH, 2015, J BIOL CHEM, V290, P6037, DOI 10.1074/jbc.M114.632125; Yang F, 2012, EMBO J, V31, P110, DOI 10.1038/emboj.2011.364; Yerushalmi R, 2010, LANCET ONCOL, V11, P174, DOI 10.1016/S1470-2045(09)70262-1; Zheng HQ, 2014, CANCER CELL, V26, P358, DOI 10.1016/j.ccr.2014.07.022; Zhou M, 2010, J BIOL CHEM, V285, P21496, DOI 10.1074/jbc.M109.083337	50	84	86	0	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 28	2016	35	4					448	458		10.1038/onc.2015.96	http://dx.doi.org/10.1038/onc.2015.96			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DC2OT	25867061	Green Accepted, hybrid, Green Published			2023-01-03	WOS:000369056700005
J	Lyon, RP; Bovee, TD; Doronina, SO; Burke, PJ; Hunter, JH; Neff-LaFord, HD; Jonas, M; Anderson, ME; Setter, JR; Senter, PD				Lyon, Robert P.; Bovee, Tim D.; Doronina, Svetlana O.; Burke, Patrick J.; Hunter, Joshua H.; Neff-LaFord, Haley D.; Jonas, Mechthild; Anderson, Martha E.; Setter, Jocelyn R.; Senter, Peter D.			Reducing hydrophobicity of homogeneous antibody-drug conjugates improves pharmacokinetics and therapeutic index	NATURE BIOTECHNOLOGY			English	Article							SITE-SPECIFIC CONJUGATION; LINKERS	The in vitro potency of antibody-drug conjugates (ADCs) increases with the drug-to-antibody ratio (DAR); however, ADC plasma clearance also increases with DAR, reducing exposure and in vivo efficacy. Here we show that accelerated clearance arises from ADC hydrophobicity, which can be modulated through drug-linker design. We exemplify this using hydrophilic auristatin drug linkers and PEGylated ADCs that yield uniform, high-DAR ADCs with superior in vivo performance.	[Lyon, Robert P.; Bovee, Tim D.; Doronina, Svetlana O.; Burke, Patrick J.; Hunter, Joshua H.; Setter, Jocelyn R.; Senter, Peter D.] Seattle Genet, Dept Chem, Bothell, WA 98021 USA; [Neff-LaFord, Haley D.] Seattle Genet, Dept Pharmacol & Toxicol, Bothell, WA USA; [Jonas, Mechthild] Seattle Genet, Dept Translat Res, Bothell, WA USA; [Anderson, Martha E.] Seattle Genet, Dept Preclin Res, Bothell, WA USA	Seattle Genetics; Seattle Genetics; Seattle Genetics; Seattle Genetics	Lyon, RP (corresponding author), Seattle Genet, Dept Chem, Bothell, WA 98021 USA.	rlyon@seagen.com						Hamblett KJ, 2004, CLIN CANCER RES, V10, P7063, DOI 10.1158/1078-0432.CCR-04-0789; Herbertson RA, 2009, CLIN CANCER RES, V15, P6709, DOI 10.1158/1078-0432.CCR-09-0536; Jeffrey SC, 2006, BIOCONJUGATE CHEM, V17, P831, DOI 10.1021/bc0600214; Jeffrey SC, 2013, BIOCONJUGATE CHEM, V24, P1256, DOI 10.1021/bc400217g; Junutula JR, 2008, NAT BIOTECHNOL, V26, P925, DOI 10.1038/nbt.1480; King HD, 2002, J MED CHEM, V45, P4336, DOI 10.1021/jm020149g; Lyori R.P., 2012, METHOD ENZYMOL, V502, P123; McDonagh CF, 2006, PROTEIN ENG DES SEL, V19, P299, DOI 10.1093/protein/gzl013; Miller ML, 2004, J MED CHEM, V47, P4802, DOI 10.1021/jm049705s; Moon SJ, 2008, J MED CHEM, V51, P6916, DOI 10.1021/jm800719t; Sievers EL, 2013, ANNU REV MED, V64, P15, DOI 10.1146/annurev-med-050311-201823; Strop P, 2013, CHEM BIOL, V20, P161, DOI 10.1016/j.chembiol.2013.01.010; Wang LT, 2005, PROTEIN SCI, V14, P2436, DOI 10.1110/ps.051478705; Zhao RY, 2011, J MED CHEM, V54, P3606, DOI 10.1021/jm2002958	14	279	296	12	129	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	JUL	2015	33	7					733	735		10.1038/nbt.3212	http://dx.doi.org/10.1038/nbt.3212			3	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	CN4JJ	26076429				2023-01-03	WOS:000358396100028
J	Zhu, LL; Yuan, L; Wang, H; Ye, L; Yao, GY; Liu, C; Sun, NN; Li, XJ; Zhai, SC; Niu, LJ; Zhang, JB; Ji, HL; Li, XM				Zhu, Li-Li; Yuan, Ling; Wang, Hui; Ye, Lin; Yao, Gui-Ying; Liu, Cui; Sun, Niu-Niu; Li, Xiao-Jing; Zhai, Shi-Cong; Niu, Ling-Juan; Zhang, Jun-Bo; Ji, Hong-Long; Li, Xiu-Min			A Meta-Analysis of Concurrent Chemoradiotherapy for Advanced Esophageal Cancer	PLOS ONE			English	Article							SQUAMOUS-CELL CARCINOMA; HIGH-DOSE RADIATION; PHASE-II; NEOADJUVANT CHEMOTHERAPY; RANDOMIZED-TRIAL; CONFORMAL RADIOTHERAPY; CISPLATIN; 5-FLUOROURACIL; THERAPY; CONCOMITANT	Background Concurrent chemoradiotherapy is a standard treatment for local advanced esophageal cancer, but the outcomes are controversial. Our goals were to compare the therapeutic effects of concurrent chemoradiotherapy and radiotherapy alone in local advanced esophageal cancer using meta-analysis. Methods MEDLINE, EMBASE and the Cochrane library were searched for studies comparing chemoradiotherapy with radiotherapy alone for advanced esophageal cancer. Only randomized controlled trials were included, and extracted data were analyzed with Review Manager Version 5.2. The pooled relative risks (RR) and their 95% confidence intervals (CI) were calculated for statistical analysis. Results Nine studies were included. Of 1,135 cases, 612 received concurrent chemoradiotherapy and 523 were treated with radiotherapy alone. The overall response rate (complete remission and partial remission) was 93.4% for concurrent chemoradiotherapy and 83.7% for radiotherapy alone (P = 0.05). The RR values of 1-year, 3-year, and 5-year survival rates were 1.14 (95% CI: 1.04 - 1.24, P = 0.006), 1.66 (95% CI: 1.34 - 2.06, P < 0.001), and 2.43 (95% CI: 1.63 - 3.63, P < 0.001), respectively. The RR value of the merged occurrence rate of acute toxic effects was 2.34 (95% CI: 1.90 - 2.90, P < 0.001). There was no difference in the incidence of late toxic effects, which had an RR value of 1.21 (95% CI: 0.96 - 1.54, P = 0.11). The RR level of persistence and recurrence was 0.71 (95% CI: 0.62 - 0.81, P < 0.001), and for the distant metastasis rate, the RR value was 0.79 ( 95% CI: 0.61 - 1.02, P = 0.07). Conclusions Concurrent chemoradiotherapy significantly improved overall survival rate, reduced the risk of persistence and recurrence, but had little effect on the primary tumor response, and increased the occurrence of acute toxic effects.	[Zhu, Li-Li; Ye, Lin; Yao, Gui-Ying; Liu, Cui; Sun, Niu-Niu; Li, Xiao-Jing; Niu, Ling-Juan; Zhang, Jun-Bo] Xinxiang Med Univ, Sch Nursing, Xinxiang, Henan, Peoples R China; [Yuan, Ling] Henan Canc Hosp, Radiat Dept, Zhengzhou, Henan, Peoples R China; [Yuan, Ling] Zhengzhou Univ, Canc Hosp, Zhengzhou, Henan, Peoples R China; [Wang, Hui] Univ Toronto, Ontario Canc Inst, Toronto, ON M5S 1A1, Canada; [Zhai, Shi-Cong] Xinxiang Med Univ, Affiliated Hosp 3, Dept Oncol, Xinxiang, Henan, Peoples R China; [Ji, Hong-Long] Univ Texas Tyler, Sci Ctr Tyler, Dept Mol & Cellular Biol, Tyler, TX 75799 USA; [Li, Xiu-Min] Xinxiang Med Univ, Ctr Canc Res, Xinxiang, Henan, Peoples R China	Xinxiang Medical University; Zhengzhou University; Zhengzhou University; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Xinxiang Medical University; University of Texas System; University of Texas at Tyler; Xinxiang Medical University	Ji, HL (corresponding author), Univ Texas Tyler, Sci Ctr Tyler, Dept Mol & Cellular Biol, Tyler, TX 75799 USA.	honglong.ji@uthct.edu; lxm3029981@126.com	li, xiu/GXV-1745-2022		American Heart Association [14GRNT20130034]; National High Technology Research and Development Program of China [2012AA02A201-1]; Science and Technology Development Plan [112102310283, 122102310198]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL087017] Funding Source: NIH RePORTER	American Heart Association(American Heart Association); National High Technology Research and Development Program of China(National High Technology Research and Development Program of China); Science and Technology Development Plan; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	This work was supported by the American Heart Association (14GRNT20130034 to HLJ), National High Technology Research and Development Program of China (2012AA02A201-1, http://program.most.gov.cn/) to LXM, who conceived and designed the experiments for this manuscript. The study was also supported by the Science and Technology Development Plan (112102310283; 122102310198, http://www.hnkjt.gov.cn/).	Abitbol AA, 1997, CANCER-AM CANCER SOC, V80, P266, DOI 10.1002/(SICI)1097-0142(19970715)80:2<266::AID-CNCR15>3.0.CO;2-S; ARAUJO CMM, 1991, CANCER, V67, P2258, DOI 10.1002/1097-0142(19910501)67:9<2258::AID-CNCR2820670908>3.0.CO;2-G; Bedford JL, 2000, RADIOTHER ONCOL, V57, P183, DOI 10.1016/S0167-8140(00)00258-9; Button MR, 2009, INT J RADIAT ONCOL, V73, P818, DOI 10.1016/j.ijrobp.2008.04.062; Cho SH, 2008, DIS ESOPHAGUS, V21, P697, DOI 10.1111/j.1442-2050.2008.00837.x; Constantinou M, 2003, CANCER INVEST, V21, P887, DOI 10.1081/CNV-120025092; Cooper JS, 1999, JAMA-J AM MED ASSOC, V281, P1623, DOI 10.1001/jama.281.17.1623; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; Enzinger PC, 2003, NEW ENGL J MED, V349, P2241, DOI 10.1056/NEJMra035010; Fan YJ, 2008, WORLD J SURG, V32, P1980, DOI 10.1007/s00268-008-9674-x; Fenkell L, 2008, RADIOTHER ONCOL, V89, P287, DOI 10.1016/j.radonc.2008.08.008; Gao XS, 2002, ONCOL REP, V9, P767; Greer SE, 2005, SURGERY, V137, P172, DOI 10.1016/j.surg.2004.06.033; Han JH, 2012, TUMORI J, V98, P60, DOI 10.1700/1053.11501; Han QX SX, 1994, MODERN ONCOLOGY; HERSKOVIC A, 1988, INT J RADIAT ONCOL, V15, P655, DOI 10.1016/0360-3016(88)90308-2; HERSKOVIC A, 1992, NEW ENGL J MED, V326, P1593, DOI 10.1056/NEJM199206113262403; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; Ishida K, 2004, JPN J CLIN ONCOL, V34, P615, DOI 10.1093/jjco/hyh107; Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI [10.3322/caac.20115, 10.3322/caac.20107]; Jemal A, 2010, CA-CANCER J CLIN, V60, P277, DOI [10.3322/caac.20073, 10.3322/caac.20105]; Jin HL, 2009, WORLD J GASTROENTERO, V15, P5983, DOI 10.3748/wjg.15.5983; Kumar S, 2007, RADIOTHER ONCOL, V83, P139, DOI 10.1016/j.radonc.2007.03.013; Lin JY, 2012, ASIAN PAC J CANCER P, V13, P5415, DOI 10.7314/APJCP.2012.13.11.5415; Liu Q, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097225; Macdonald G, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001930.pub3; Minsky BD, 1996, J CLIN ONCOL, V14, P149, DOI 10.1200/JCO.1996.14.1.149; Minsky BD, 1999, INT J RADIAT ONCOL, V43, P517, DOI 10.1016/S0360-3016(98)00463-5; Mirinezhad SK, 2013, ASIAN PAC J CANCER P, V14, P1677, DOI 10.7314/APJCP.2013.14.3.1677; Poltinnikov IM, 2005, INT J RADIAT ONCOL, V62, P652, DOI 10.1016/j.ijrobp.2004.10.030; Seung SK, 2004, SEMIN ONCOL, V31, P13, DOI 10.1053/j.seminoncol.2004.12.006; Sharma D, 1997, AM J CLIN ONCOL-CANC, V20, P151, DOI 10.1097/00000421-199704000-00009; Sheng W FX, 2011, CHINESE J ONCOL, P9; Shim HJ, 2012, CANCER CHEMOTH PHARM, V70, P683, DOI 10.1007/s00280-012-1962-3; Sjoquist KM, 2011, LANCET ONCOL, V12, P681, DOI 10.1016/S1470-2045(11)70142-5; Slabber CF, 1998, AM J CLIN ONCOL-CANC, V21, P462, DOI 10.1097/00000421-199810000-00008; Suntharalingam M, 2003, INT J RADIAT ONCOL, V56, P981, DOI 10.1016/S0360-3016(03)00256-6; TF CJSJP, 1995, INT J RADIALONCOL BI, V31, P6; Therasse P, 2000, J NATL CANCER I, V92, P205, DOI 10.1093/jnci/92.3.205; Vosmik M, 2010, WORLD J GASTROENTERO, V16, P5555, DOI 10.3748/wjg.v16.i44.5555; Welsh J, 2011, CURR ONCOL REP, V13, P157, DOI 10.1007/s11912-011-0158-z; Wong RKS, 2003, INT J RADIAT ONCOL, V55, P930, DOI 10.1016/S0360-3016(02)04278-5; Yin YB YZ, 2008, RADIOTION ONCOLOGY; Zhao KL, 2005, INT J RADIAT ONCOL, V62, P1014, DOI 10.1016/j.ijrobp.2004.12.022; Zheng B, 2013, CHINESE MED J-PEKING, V126, P1178, DOI 10.3760/cma.j.issn.0366-6999.20121798	45	25	29	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 5	2015	10	6							e0128616	10.1371/journal.pone.0128616	http://dx.doi.org/10.1371/journal.pone.0128616			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CJ7CR	26046353	Green Published, gold, Green Submitted			2023-01-03	WOS:000355652200083
J	Donnelly, NA; Hickey, A; Burns, A; Murphy, P; Doyle, F				Donnelly, Nora-Ann; Hickey, Anne; Burns, Annette; Murphy, Paul; Doyle, Frank			Systematic Review and Meta-Analysis of the Impact of Carer Stress on Subsequent Institutionalisation of Community-Dwelling Older People	PLOS ONE			English	Review							NURSING-HOME PLACEMENT; CRITICAL-APPRAISAL TOOL; CAREGIVERS; PREDICTORS; DEMENTIA; HEALTH; HOSPITALIZATION; INTERVENTIONS; DISEASE; BURDEN	Background In the caregiving literature there is a common assertion that a higher level of carer stress is a critical determinant of premature ending of homecare. However, this contention has not been systematically assessed. We therefore systematically reviewed and meta-analysed the prospective association between various forms of carer stress and subsequent institutionalisation of community-dwelling older people. Methods Systematic literature search of prospective studies measuring carer stress at baseline and institutionalisation at follow-up. Given substantial interchangeability in the measurement of carer stress, we included a wide number of exposure measures, namely: carer stress, burden, depression, distress, anxiety, burnout, and strain. Institutionalisation included both acute and long-term care utilisation. The standardised mean difference between stressed and non-stressed carers was the primary measure of effect. We assessed study quality with the Crowe Critical Appraisal Tool (CCAT). Pre-planned sensitivity analysis included examination of estimates according to study size; decade published; study quality according to quartiles of CCAT scores; population; follow-up period; study design and impact of adjusted or unadjusted estimates. Results The search yielded 6,963 articles. After exclusions, we analysed data from 54 datasets. The meta-analysis found that while carer stress has a significant effect on subsequent institutionalisation of care recipients, the overall effect size was negligible (SMD=0.05, 95% CI=0.04-0.07). Sensitivity analyses found that, the effect size was higher for measurements of stress than for other measures, though still relatively small (SMD=0.23, 95% CI=0.09-0.38). Thus, whether analysing the association between carer stress, burden, distress, or depression with either acute or long-term care, the effect size remains small to negligible. Concurrently, we found estimates reduce over time and were smaller with larger studies and those of higher quality, according to the CCAT scores. Conclusion Despite strong statements to the contrary, it appears that the effect of carer stress on subsequent care recipient institutionalisation is small to negligible. The current findings point to a biased literature, with significant small study effects. The results suggest a need to reevaluate the degree to which carer stress predicts premature ending of home care. Concurrently, other factors may be more crucial in institutional placement than carer stress and should be investigated.	[Donnelly, Nora-Ann; Hickey, Anne; Burns, Annette; Doyle, Frank] Royal Coll Surgeons Ireland, Dept Psychol, Dublin 2, Ireland; [Murphy, Paul] Royal Coll Surgeons Ireland, Mercer Lib, Dublin 2, Ireland	Royal College of Surgeons - Ireland; University College Dublin; Royal College of Surgeons - Ireland	Donnelly, NA (corresponding author), Royal Coll Surgeons Ireland, Dept Psychol, Dublin 2, Ireland.	noraadonnelly@rcsi.ie	Murphy, Paul/E-2305-2011; Doyle, Frank/C-2750-2012; Burns, Annette/ABF-7763-2020	Murphy, Paul/0000-0001-5056-1971; Doyle, Frank/0000-0002-3785-7433; Burns, Annette/0000-0002-4924-7640; Donnelly, Nora-Ann/0000-0002-8468-8695	Health Research Board (HRB) in Ireland [PHD/2007/16]	Health Research Board (HRB) in Ireland	This work was funded by the Health Research Board (HRB) in Ireland under Grant No. PHD/2007/16. The funder had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.	Andrieu S, 2002, INT J GERIATR PSYCH, V17, P422, DOI 10.1002/gps.624; Bastawrous M, 2013, INT J NURS STUD, V50, P431, DOI 10.1016/j.ijnurstu.2012.10.005; Bauer ME, 2000, J NEUROIMMUNOL, V103, P84, DOI 10.1016/S0165-5728(99)00228-3; Borsboom D, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027407; Bradburn M, 2009, META ANALYSIS IN STA; Brodaty H, 2003, J AM GERIATR SOC, V51, P657, DOI 10.1034/j.1600-0579.2003.00210.x; BRODATY H, 1989, BMJ-BRIT MED J, V299, P1375, DOI 10.1136/bmj.299.6712.1375; Campbell SE, 2004, AGE AGEING, V33, P110, DOI 10.1093/ageing/afh036; Chou K R, 2000, J Pediatr Nurs, V15, P398, DOI 10.1053/jpdn.2000.16709; Cohen J., 2013, STAT POWER ANAL BEHA; Cramer AOJ, 2010, BEHAV BRAIN SCI, V33, P137, DOI 10.1017/S0140525X09991567; Crowe M, 2012, J CLIN EPIDEMIOL, V65, P375, DOI 10.1016/j.jclinepi.2011.08.006; Crowe M, 2011, INT J NURS STUD, V48, P1505, DOI 10.1016/j.ijnurstu.2011.06.004; Crowe M, 2011, INT J EVID-BASED HEA, V9, P444, DOI 10.1111/j.1744-1609.2011.00237.x; Deeken JF, 2003, J PAIN SYMPTOM MANAG, V26, P922, DOI 10.1016/S0885-3924(03)00327-0; Doyle F, 2014, PSYCHOSOM MED, V76, P44, DOI 10.1097/PSY.0000000000000020; Ferguson CJ, 2012, PERSPECT PSYCHOL SCI, V7, P555, DOI 10.1177/1745691612459059; Fisher L, 1999, GERONTOLOGIST, V39, P677, DOI 10.1093/geront/39.6.677; Garcia-Perez L, 2011, QJM-INT J MED, V104, P639, DOI 10.1093/qjmed/hcr070; Gaugler JE, 2005, J AM GERIATR SOC, V53, P2098, DOI 10.1111/j.1532-5415.2005.00495.x; Gaugler JE, 2003, GERONTOLOGIST, V43, P219, DOI 10.1093/geront/43.2.219; Gaugler JE, 2006, J CROSS-CULT GERONTO, V21, P139, DOI 10.1007/s10823-006-9029-8; Gaugler Joseph E, 2007, BMC Geriatr, V7, P13, DOI 10.1186/1471-2318-7-13; Gaugler JE, 2009, MED CARE, V47, P191, DOI 10.1097/MLR.0b013e31818457ce; Goldberg D., 1988, INTERNOISE NOISECON; Harbord R, 2009, METAANALYSIS STATA U; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; Higgins Julian P T, 2011, BMJ, V343, pd5928, DOI 10.1136/bmj.d5928; Ioannidis JPA, 2005, PLOS MED, V2, P696, DOI 10.1371/journal.pmed.0020124; JETTE AM, 1995, J GERONTOL B-PSYCHOL, V50, pS4, DOI 10.1093/geronb/50B.1.S4; KIECOLTGLASER JK, 1995, LANCET, V346, P1194, DOI 10.1016/S0140-6736(95)92899-5; Kontopantelis E, 2011, METAEFF STATA MODULE; Kuhberger A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0105825; Kuzuya M, 2011, AM J GERIAT PSYCHIAT, V19, P382, DOI 10.1097/JGP.0b013e3181e9b98d; Lazarus R. S., 1984, STRESS APPRAISAL AND; Li XH, 2013, J NANOPART RES, V15, DOI 10.1007/s11051-013-1472-1; Livingston G, 2014, HEALTH TECHNOL ASSES, V18, P1, DOI 10.3310/hta18390; Luppa M, 2010, AGE AGEING, V39, P31, DOI 10.1093/ageing/afp202; Miller EA, 2000, MED CARE RES REV, V57, P259, DOI 10.1177/107755870005700301; Moher D, 2009, BMJ-BRIT MED J, V339, DOI [10.1136/bmj.i4086, 10.1186/2046-4053-4-1, 10.1136/bmj.b2535]; Nobili A, 2004, ALZ DIS ASSOC DIS, V18, P75, DOI 10.1097/01.wad.0000126618.98867.fc; NOLAN MR, 1990, J ADV NURS, V15, P544, DOI 10.1111/j.1365-2648.1990.tb01853.x; PEARLIN LI, 1990, GERONTOLOGIST, V30, P583, DOI 10.1093/geront/30.5.583; Pinquart M, 2003, PSYCHOL AGING, V18, P250, DOI 10.1037/0882-7974.18.2.250; Schubert CC, 2008, J GEN INTERN MED, V23, P1736, DOI 10.1007/s11606-008-0711-0; Schulz R, 2008, AM J NURS, V108, P23, DOI 10.1097/01.NAJ.0000336406.45248.4c; Selwood A, 2007, J AFFECT DISORDERS, V101, P75, DOI 10.1016/j.jad.2006.10.025; Sharp S, 2009, METAANALYSIS STATA U; Spillman BC, 2009, INQUIRY-J HEALTH CAR, V46, P140, DOI 10.5034/inquiryjrnl_46.02.140; Steichen T, 2009, METAANALYSIS STATA U; Tak LM, 2010, PSYCHOSOM MED, V72, P253, DOI 10.1097/PSY.0b013e3181d714e1; Thompson SG, 2002, STAT MED, V21, P1559, DOI 10.1002/sim.1187; Yaffe K, 2002, JAMA-J AM MED ASSOC, V287, P2090, DOI 10.1001/jama.287.16.2090; Yates ME, 1999, J GERONTOL B-PSYCHOL, V54, pP12, DOI 10.1093/geronb/54B.1.P12; Zarit S., 2006, CAREGIVER ASSESSMENT, P12; Zarit Steven H, 2008, Handb Clin Neurol, V89, P101, DOI 10.1016/S0072-9752(07)01209-2	56	19	19	0	24	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 2	2015	10	6							e0128213	10.1371/journal.pone.0128213	http://dx.doi.org/10.1371/journal.pone.0128213			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	CJ7SJ	26035433	Green Published, gold, Green Submitted			2023-01-03	WOS:000355699100030
J	Eshima, S; Yokoyama, S; Abe, T; Hayakawa, Y; Saiki, I				Eshima, Shizuka; Yokoyama, Satoru; Abe, Takashi; Hayakawa, Yoshihiro; Saiki, Ikuo			Multi-Pathway Cellular Analysis on Crude Natural Drugs/Herbs from Japanese Kampo Formulations	PLOS ONE			English	Article								Kampo formulations comprise a number of crude natural drugs/herbs as constituents. The crude drugs/herbs have been traditionally classified by their traditional classifications or efficacies in Kampo medicines; however, it has been difficult to establish the scientific link between experimental evidence and traditional classifications in Kampo medicine. To clarify such traditional conceptions, we tested 112 crude drugs/herbs that are major components of Kampo formulations, in the multi-pathway analysis of 10 well-studied transcriptional activities including CREB, ERSF, HIF-1 alpha, IRFs, MYC, NF-kappa B, p53, SMAD, SOX2, and TCF/LEF in A549 human lung cancer cells. By clustering the results of multi-pathway analysis with the Spearman rank-correlation coefficient and Ward linkage, three distinct traditional categories were significantly enriched in the major groupings, which are heat-clearing and dampness-drying herbs, acrid and warm exterior-resolving herbs, and acrid and cool exterior-resolving herbs. These results indicate that these crude drugs/herbs have similar effects on intracellular signaling and further imply that the traditional classifications of those enriched crude drugs/herbs can be supported by such experimental evidence. Collectively, our new in vitro multi-pathway analysis may be useful to clarify the mechanism of action of crude drugs/herbs and Kampo formulations.	[Eshima, Shizuka; Yokoyama, Satoru; Hayakawa, Yoshihiro; Saiki, Ikuo] Toyama Univ, Inst Nat Med, Div Pathogen Biochem, Toyama 930, Japan; [Abe, Takashi] Niigata Univ, Grad Sch Sci & Technol, Niigata 9518510, Japan	University of Toyama; Niigata University	Yokoyama, S (corresponding author), Toyama Univ, Inst Nat Med, Div Pathogen Biochem, Toyama 930, Japan.	yokoyama@inm.u-toyama.ac.jp	Yokoyama, Satoru/AAT-3254-2021	Yokoyama, Satoru/0000-0001-8336-486X	Ministry of Education, Culture, Sports, Science, and Technology, Japan [24700971, 24659348, 15K08902]; Uehara Memorial Foundation; Joint Usage/Research Center (Joint Usage/Research Center for Science-Based Natural Medicine), Institute of Natural Medicine, University of Toyama	Ministry of Education, Culture, Sports, Science, and Technology, Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Uehara Memorial Foundation(Uehara Memorial Foundation); Joint Usage/Research Center (Joint Usage/Research Center for Science-Based Natural Medicine), Institute of Natural Medicine, University of Toyama	This work was supported in part by a Grant-in-Aid for Young Scientists (B) 24700971 (SY), by a Grant-in-Aid for Challenging Exploratory Research 24659348 (IS), by a Grant-in-Aid for Scientific Research (B) 15K08902 (IS) from the Ministry of Education, Culture, Sports, Science, and Technology, Japan, by The Uehara Memorial Foundation (SY), and by a Grant-in-Aid for the Cooperative Research Project (TA, IS, and SY) from the Joint Usage/Research Center (Joint Usage/Research Center for Science-Based Natural Medicine), Institute of Natural Medicine, University of Toyama, in 2014. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	BRASIER AR, 1992, METHOD ENZYMOL, V216, P386; Fallahi M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0115517; Hetz C, 2012, NAT REV MOL CELL BIO, V13, P89, DOI 10.1038/nrm3270; Hijikata Y, 2006, EXPERT REV NEUROTHER, V6, P795, DOI 10.1586/14737175.6.5.795; Yz S, 2005, INTRO KAMPO JAPANESE, Vxvi	5	1	1	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 2	2015	10	6							e0128872	10.1371/journal.pone.0128872	http://dx.doi.org/10.1371/journal.pone.0128872			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CJ7SJ	26035432	Green Submitted, Green Published, gold			2023-01-03	WOS:000355699100054
J	Kanda, E; Bieber, BA; Pisoni, RL; Robinson, BM; Fuller, DS				Kanda, Eiichiro; Bieber, Brian A.; Pisoni, Ronald L.; Robinson, Bruce M.; Fuller, Douglas S.			Importance of Simultaneous Evaluation of Multiple Risk Factors for Hemodialysis Patients' Mortality and Development of a Novel Index: Dialysis Outcomes and Practice Patterns Study	PLOS ONE			English	Article							BODY-MASS INDEX; CARDIOVASCULAR-DISEASE; NUTRITIONAL-STATUS; SERUM-ALBUMIN; PROTEIN; PHOSPHORUS; PREDICTOR; CALCIUM	Background For hemodialysis (HD) patients, many risk factors for death are associated with each other intricately. However, they are often considered separately in clinical settings. We evaluated the maintenance HD patients' risk of death within one year from multiple risk factors simultaneously considering their interrelationships using a novel index (survival index, SI) for HD patients in the United States developed using data from the Dialysis Outcomes and Practice Patterns Study (DOPPS). Methods We analyzed data from 3899 and 3765 patients to develop and validate SI, respectively. To predict death within one year, candidate models were developed using logistic regression models. The final model was determined by comparing the accuracy among the models for the prediction of deaths. Results The model included age; body mass index; serum creatinine, albumin, total cholesterol and phosphorus levels; history of cardiovascular diseases; and arteriovenous fistula use. SI showed a higher accuracy in predicting death (c-statistic, 0.739) than geriatric nutritional risk index (0.647) and serum albumin level (0.637). The probability of death predicted on the basis of SI matched the observed number of deaths. Cox proportional hazard models for time-dependent SI showed that patients with low SI had a higher risk of death than patients with high SI [reference, Group 4 (26.1 <= SI)]; Group 1 (SI<12.7), adjusted hazard ratio, 7.97 (95% CI, 5.02, 12.65); Group 2 (12.7 <= SI<19.0), 3.18 (95% CI, 1.96, 5.16); Group 3 (19.0 <= SI<26.1), 2.20 (95% CI, 1.33, 3.66). Conclusion Results of this study suggest that the simultaneous evaluation of multiple risk factors can more accurately assess patients' prognosis and identify patients at an increased risk of death than single factors.	[Kanda, Eiichiro] Tokyo Kyosai Hosp, Dept Nephrol, Meguro Ku, Tokyo, Japan; [Kanda, Eiichiro] Tokyo Med & Dent Univ, Life Sci & Bioeth Ctr, Bunkyo Ku, Tokyo, Japan; [Bieber, Brian A.; Pisoni, Ronald L.; Robinson, Bruce M.; Fuller, Douglas S.] Arbor Res Collaborat Hlth, Ann Arbor, MI USA; [Robinson, Bruce M.] Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA	Tokyo Medical & Dental University (TMDU); Arbor Research Collaborative for Health; University of Michigan System; University of Michigan	Kanda, E (corresponding author), Tokyo Kyosai Hosp, Dept Nephrol, Meguro Ku, Tokyo, Japan.	tokyo.kyosai.kanda@gmail.com		Bieber, Brian/0000-0001-8505-0979; Robinson, Bruce/0000-0003-0749-1714	Amgen; Kyowa Hakko Kirin (Japan); Sanofi Renal; AbbVie; Baxter; Vifor Fresenius Renal Pharma	Amgen(Amgen); Kyowa Hakko Kirin (Japan); Sanofi Renal; AbbVie(AbbVie); Baxter; Vifor Fresenius Renal Pharma	The DOPPS is administered by Arbor Research Collaborative for Health. The DOPPS Program has been supported by scientific research grants from Amgen (since 1996), Kyowa Hakko Kirin (since 1999, in Japan), Sanofi Renal (since 2009), AbbVie (since 2009), Baxter (since 2011), and Vifor Fresenius Renal Pharma (since 2011), with the shared mission of providing a strong scientific basis for the identification of dialysis and CKD practices that are most associated with improved patient survival and quality of life. The funders had no role in the study design, data collection and analysis, decision to publish, or manuscript preparation. All support has been provided without restrictions on publications.	Athienites NV, 2000, SEMIN DIALYSIS, V13, P320, DOI 10.1046/j.1525-139x.2000.00095.x; Beddhu S, 2004, J AM SOC NEPHROL, V15, P733, DOI 10.1097/01.ASN.0000113319.57131.28; Beddhu S, 2003, J AM SOC NEPHROL, V14, P2366, DOI 10.1097/01.ASN.0000083905.72794.E6; Bouillanne O, 2005, AM J CLIN NUTR, V82, P777, DOI 10.1093/ajcn/82.4.777; Bradbury BD, 2007, CLIN J AM SOC NEPHRO, V2, P89, DOI 10.2215/CJN.01170905; CANAUD B, 1995, NEPHROL DIAL TRANSPL, V10, P1405; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Chua HR, 2014, BLOOD PURIFICAT, V37, P85, DOI 10.1159/000357640; de Gonzalez AB, 2010, NEW ENGL J MED, V363, P2211, DOI 10.1056/NEJMoa1000367; de Mutsert R, 2008, NEPHROL DIAL TRANSPL, V23, P2957, DOI 10.1093/ndt/gfn167; Depner TA, 1996, J AM SOC NEPHROL, V7, P780; Foley RN, 2005, J AM SOC NEPHROL, V16, P489, DOI 10.1681/ASN.2004030203; Fouque D, 2008, KIDNEY INT, V73, P391, DOI 10.1038/sj.ki.5002585; Fouque D, 2013, NEPHROL DIAL TRANSPL, V28, P360, DOI 10.1093/ndt/gfs404; Gama-Axelsson T, 2012, CLIN J AM SOC NEPHRO, V7, P1446, DOI 10.2215/CJN.10251011; Goodkin DA, 2003, J AM SOC NEPHROL, V14, P3270, DOI 10.1097/01.ASN.0000100127.54107.57; Herselman M, 2010, J RENAL NUTR, V20, P281, DOI 10.1053/j.jrn.2010.03.010; Hoogeveen EK, 2012, CLIN J AM SOC NEPHRO, V7, P280, DOI 10.2215/CJN.05700611; Kalantar-Zadeh K, 2003, KIDNEY INT, V63, P793, DOI 10.1046/j.1523-1755.2003.00803.x; Kalantar-Zadeh K, 2010, CLIN J AM SOC NEPHRO, V5, P519, DOI 10.2215/CJN.06080809; KESHAVIAH PR, 1994, J AM SOC NEPHROL, V4, P1475; Kobayashi I, 2010, NEPHROL DIAL TRANSPL, V25, P3361, DOI 10.1093/ndt/gfq211; Leavey SF, 2001, NEPHROL DIAL TRANSPL, V16, P2386, DOI 10.1093/ndt/16.12.2386; Liu JN, 2010, KIDNEY INT, V77, P141, DOI 10.1038/ki.2009.413; Longenecker JC, 2002, J AM SOC NEPHROL, V13, P1918, DOI 10.1097/01.ASN.0000019641.41496.1E; Lopes AA, 2010, J RENAL NUTR, V20, P224, DOI 10.1053/j.jrn.2009.10.002; Lynch KE, 2011, CLIN J AM SOC NEPHRO, V6, P620, DOI 10.2215/CJN.04620510; Miskulin D, 2009, CLIN J AM SOC NEPHRO, V4, P1818, DOI 10.2215/CJN.00640109; Moss AH, 2008, CLIN J AM SOC NEPHRO, V3, P1379, DOI 10.2215/CJN.00940208; Palmer SC, 2011, JAMA-J AM MED ASSOC, V305, P1119, DOI 10.1001/jama.2011.308; Pisoni RL, 2004, AM J KIDNEY DIS, V44, P94, DOI 10.1053/j.ajkd.2004.03.023; Plantinga LC, 2007, BMC HEALTH SERV RES, V7, DOI 10.1186/1472-6963-7-5; Rocco MV, 2006, ANN INTERN MED, V145, P512, DOI 10.7326/0003-4819-145-7-200610030-00009; ROSENBAUM PR, 1983, BIOMETRIKA, V70, P41, DOI 10.1093/biomet/70.1.41; Shoji T, 2011, CLIN J AM SOC NEPHRO, V6, P1112, DOI 10.2215/CJN.09961110; Takahashi R, 2012, AM J NEPHROL, V36, P136, DOI 10.1159/000339940; Tentori F, 2008, AM J KIDNEY DIS, V52, P519, DOI 10.1053/j.ajkd.2008.03.020; WILLIFORD WO, 1991, NEW ENGL J MED, V325, P525; Young EW, 2000, KIDNEY INT, V57, pS74, DOI 10.1046/j.1523-1755.2000.07413.x	39	12	12	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 1	2015	10	6							e0128652	10.1371/journal.pone.0128652	http://dx.doi.org/10.1371/journal.pone.0128652			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CL0KF	26030526	Green Published, Green Submitted, gold			2023-01-03	WOS:000356630900180
J	Etheridge, Z; Gatland, E				Etheridge, Zac; Gatland, Emma			When and how to discuss "do not resuscitate" decisions with patients	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material									[Etheridge, Zac] Stoke Mandeville Hosp, Med Older People, Aylesbury HP21 8AL, Bucks, England; [Gatland, Emma] Harcourt Chambers, London, England		Etheridge, Z (corresponding author), Stoke Mandeville Hosp, Med Older People, Aylesbury HP21 8AL, Bucks, England.	zac.etheridge@yahoo.co.uk						[Anonymous], 2014, DEC REL CARD RES GUI; General Medical Council, 2010, TREATM CAR END LIF G	2	25	25	0	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 20	2015	350								h2640	10.1136/bmj.h2640	http://dx.doi.org/10.1136/bmj.h2640			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CI9YZ	25994629				2023-01-03	WOS:000355128700008
J	Vaseghi, B; Zoghi, M; Jaberzadeh, S				Vaseghi, Bita; Zoghi, Maryam; Jaberzadeh, Shapour			A Meta-Analysis of Site-Specific Effects of Cathodal Transcranial Direct Current Stimulation on Sensory Perception and Pain	PLOS ONE			English	Article							MOTOR CORTEX EXCITABILITY; SOMATOSENSORY CORTEX; DC-STIMULATION; METHODOLOGICAL QUALITY; MAGNETIC STIMULATION; PEDRO SCALE; MODULATION; MECHANISMS; RESPONSES; INSULA	The primary aim of our meta-analysis was to evaluate the effects of cathodal transcranial direct current stimulation (c-tDCS) on sensory and pain thresholds (STh and PTh) in healthy individuals and pain level (PL) in patients with chronic pain. Electronic databases were searched for c-tDCS studies. Methodological quality was evaluated using the PEDro and Downs and Black (D&B) assessment tools. C-tDCS of the primary motor cortex (S1) increases both STh (P<0.001, effect size of 26.84%) and PTh (P<0.001, effect size of 11.62%). In addition, c-tDCS over M1 led to STh increase (P<0.005, effect size of 30.44%). Likewise, PL decreased significantly in the patient group following application of c-tDCS. The small number of studies precluded subgroup analysis. Nevertheless, meta-analysis showed that in all groups (except c-tDCS of S1) active c-tDCS and sham stimulation produced significant differences in STh/PTh in healthy and PL in patient group. This review provides evidence for the site-specific effectiveness of c-tDCS in increasing STh/PTh in healthy individuals and decreasing PL in patients with chronic pain. However, due to small sample sizes in the included studies, our results should be interpreted with caution. Given that the level of blinding was not considered in the inclusion criteria, the results of the current study should be interpreted with caution.	[Vaseghi, Bita; Jaberzadeh, Shapour] Monash Univ, Dept Physiotherapy, Sch Primary Hlth Care, Fac Med Nursing & Hlth Sci, Melbourne, Vic 3004, Australia; [Zoghi, Maryam] Univ Melbourne, Dept Med, Royal Melbourne Hosp, Melbourne, Australia	Monash University; Royal Melbourne Hospital; University of Melbourne	Vaseghi, B (corresponding author), Monash Univ, Dept Physiotherapy, Sch Primary Hlth Care, Fac Med Nursing & Hlth Sci, Melbourne, Vic 3004, Australia.	bita.vaseghi@monash.edu.au	, Zoghi/AAF-9536-2019	, Zoghi/0000-0002-1819-6895; jaberzadeh, shapour/0000-0003-2957-4510				Amer Assoc Electrodiagnost Med, 2004, MUSCLE NERVE, V29, P734, DOI 10.1002/mus.20053; Antal A, 2008, PERCEPTION, V37, P367, DOI 10.1068/p5872; Antal A, 2008, CLIN J PAIN, V24, P56, DOI 10.1097/AJP.0b013e318157233b; Antal A, 2011, CEPHALALGIA, V31, P820, DOI 10.1177/0333102411399349; Apkarian AV, 2005, EUR J PAIN, V9, P463, DOI 10.1016/j.ejpain.2004.11.001; Ardolino G, 2005, J PHYSIOL-LONDON, V568, P653, DOI 10.1113/jphysiol.2005.088310; Bachmann CG, 2010, CLIN NEUROPHYSIOL, V121, P2083, DOI 10.1016/j.clinph.2010.05.005; Bantick SJ, 2002, BRAIN, V125, P310, DOI 10.1093/brain/awf022; Batsikadze G, 2013, J PHYSIOL-LONDON, V591, P1987, DOI 10.1113/jphysiol.2012.249730; Bax L, 2007, BMC MED RES METHODOL, V7, DOI 10.1186/1471-2288-7-40; Bingel U, 2004, NEUROIMAGE, V23, P224, DOI 10.1016/j.neuroimage.2004.05.021; Bolton JE, 1998, J MANIP PHYSIOL THER, V21, P1; Bornhovd K, 2002, BRAIN, V125, P1326, DOI 10.1093/brain/awf137; Csifcsak G, 2009, PAIN MED, V10, P122, DOI 10.1111/j.1526-4637.2008.00508.x; de Morton NA, 2009, AUST J PHYSIOTHER, V55, P129, DOI 10.1016/S0004-9514(09)70043-1; Debanne D, 2003, J PHYSIOLOGY-PARIS, V97, P403, DOI 10.1016/j.jphysparis.2004.01.004; Soler MD, 2010, BRAIN, V133, P2565, DOI 10.1093/brain/awq184; Downs SH, 1998, J EPIDEMIOL COMMUN H, V52, P377, DOI 10.1136/jech.52.6.377; Fernandez-de-las-Penas C, 2010, ARTHRIT CARE RES, V62, P1055, DOI 10.1002/acr.20189; Fregni F, 2007, LANCET NEUROL, V6, P188, DOI 10.1016/S1474-4422(07)70032-7; Fregni F, 2006, PAIN, V122, P197, DOI 10.1016/j.pain.2006.02.023; FULLER GN, 1989, J NEUROL NEUROSUR PS, V52, P810, DOI 10.1136/jnnp.52.6.810-a; Furubayashi T, 2008, EXP BRAIN RES, V185, P279, DOI 10.1007/s00221-007-1149-z; Garcia-Larrea L, 1999, PAIN, V83, P259, DOI 10.1016/S0304-3959(99)00114-1; Giesecke T, 2005, ARTHRITIS RHEUM-US, V52, P1577, DOI 10.1002/art.21008; Grundmann L, 2011, BRAIN STIMUL, V4, P253, DOI 10.1016/j.brs.2010.12.002; Hansen N, 2011, CEPHALALGIA, V31, P661, DOI 10.1177/0333102410390394; Higgins J., 2011, COCHRANE HDB SYST RE; Hoshi E, 2006, NEUROSCI RES, V54, P73, DOI 10.1016/j.neures.2005.10.013; Iannetti GD, 2010, EXP BRAIN RES, V205, P1, DOI 10.1007/s00221-010-2340-1; ISLAM N, 1995, BRAIN RES, V684, P206, DOI 10.1016/0006-8993(95)00434-R; Joseph A., 2011, PLOT DIGITIZER 2 5 1; Kanda M, 2000, BRAIN RES, V853, P282, DOI 10.1016/S0006-8993(99)02274-X; Khedr EM, 2005, J NEUROL NEUROSUR PS, V76, P833, DOI 10.1136/jnnp.2004.055806; Kinkelin I, 2000, NEUROSCI LETT, V283, P149, DOI 10.1016/S0304-3940(00)00944-7; Kulkarni B, 2005, EUR J NEUROSCI, V21, P3133, DOI 10.1111/j.1460-9568.2005.04098.x; Latremoliere A, 2009, J PAIN, V10, P895, DOI 10.1016/j.jpain.2009.06.012; Laurent B, 2000, REV NEUROL-FRANCE, V156, P341; Liebetanz D, 2002, BRAIN, V125, P2238, DOI 10.1093/brain/awf238; Loeb GE, 1986, ELECTROMYOGRAPHY FOR; Luedtke K, 2012, CLIN J PAIN, V28, P452, DOI 10.1097/AJP.0b013e31823853e3; Maher CG, 2003, PHYS THER, V83, P713, DOI 10.1093/ptj/83.8.713; McCarthy G, 1997, J NEUROPHYSIOL, V77, P1630, DOI 10.1152/jn.1997.77.3.1630; Mendonca ME, 2011, J PAIN, V12, P610, DOI 10.1016/j.jpain.2010.12.015; Moseley AM, 2002, AUST J PHYSIOTHER, V48, P43, DOI 10.1016/S0004-9514(14)60281-6; Mouraux A, 2011, NEUROIMAGE, V54, P2237, DOI 10.1016/j.neuroimage.2010.09.084; NETZER R, 1993, EUR J PHARMACOL, V238, P209, DOI 10.1016/0014-2999(93)90849-D; Nitsche MA, 2004, NEUROPSYCHOPHARMACOL, V29, P1573, DOI 10.1038/sj.npp.1300517; Nitsche MA, 2004, EUR J NEUROSCI, V19, P2720, DOI 10.1111/j.0953-816X.2004.03398.x; Nitsche MA, 2000, J PHYSIOL-LONDON, V527, P633, DOI 10.1111/j.1469-7793.2000.t01-1-00633.x; Nitsche MA, 2005, J PHYSIOL-LONDON, V568, P291, DOI 10.1113/jphysiol.2005.092429; O'Connell NE, 2011, EUR J PHYS REHAB MED, V47, P309; Oliviero A, 2005, CLIN NEUROPHYSIOL, V116, P1072, DOI 10.1016/j.clinph.2004.12.003; Ostrowsky K, 2002, CEREB CORTEX, V12, P376, DOI 10.1093/cercor/12.4.376; Palm U, 2013, BRAIN STIMUL, V6, P690, DOI 10.1016/j.brs.2013.01.005; Peyron R, 2000, NEUROPHYSIOL CLIN, V30, P263, DOI 10.1016/S0987-7053(00)00227-6; Ploghaus A, 1999, SCIENCE, V284, P1979, DOI 10.1126/science.284.5422.1979; Reidler JS, 2012, J PAIN, V13, P450, DOI 10.1016/j.jpain.2012.01.005; Rogalewski A, 2004, EUR J NEUROSCI, V20, P313, DOI 10.1111/j.0953-816X.2004.03450.x; Roizenblatt Suely, 2007, Pain Pract, V7, P297, DOI 10.1111/j.1533-2500.2007.00152.x; Russo R, 2013, BRAIN STIMUL, V6, P946, DOI 10.1016/j.brs.2013.05.009; Sawamoto N, 2000, J NEUROSCI, V20, P7438; Smith BH, 2001, FAM PRACT, V18, P292, DOI 10.1093/fampra/18.3.292; STOLLBERG J, 1988, J CELL BIOL, V107, P1397, DOI 10.1083/jcb.107.4.1397; Summers J, 2004, NEUROSCI LETT, V368, P197, DOI 10.1016/j.neulet.2004.07.008; TANG CM, 1990, P NATL ACAD SCI USA, V87, P6445, DOI 10.1073/pnas.87.16.6445; Terney D, 2008, J PAIN SYMPTOM MANAG, V36, P79, DOI 10.1016/j.jpainsymman.2007.08.014; Vaseghi B, 2014, CLIN NEUROPHYSIOL; Wood L, 2008, BMJ-BRIT MED J, V336, P601, DOI 10.1136/bmj.39465.451748.AD	70	30	32	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 15	2015	10	5							e0123873	10.1371/journal.pone.0123873	http://dx.doi.org/10.1371/journal.pone.0123873			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CI7AU	25978673	Green Submitted, Green Published, gold			2023-01-03	WOS:000354916100009
J	Ishikawa, S; Okamoto, S; Isogai, K; Akiyama, Y; Yanagihara, N; Yamada, Y				Ishikawa, Shun; Okamoto, Shogo; Isogai, Kaoru; Akiyama, Yasuhiro; Yanagihara, Naomi; Yamada, Yoji			Assessment of Robotic Patient Simulators for Training in Manual Physical Therapy Examination Techniques	PLOS ONE			English	Article							STRETCH REFLEX THRESHOLD; MODIFIED ASHWORTH SCALES; HAPTIC ELBOW SPASTICITY; LEG-ROBOT; RELIABILITY; ACCURACY; CHILDREN; HESS	Robots that simulate patients suffering from joint resistance caused by biomechanical and neural impairments are used to aid the training of physical therapists in manual examination techniques. However, there are few methods for assessing such robots. This article proposes two types of assessment measures based on typical judgments of clinicians. One of the measures involves the evaluation of how well the simulator presents different severities of a specified disease. Experienced clinicians were requested to rate the simulated symptoms in terms of severity, and the consistency of their ratings was used as a performance measure. The other measure involves the evaluation of how well the simulator presents different types of symptoms. In this case, the clinicians were requested to classify the simulated resistances in terms of symptom type, and the average ratios of their answers were used as performance measures. For both types of assessment measures, a higher index implied higher agreement among the experienced clinicians that subjectively assessed the symptoms based on typical symptom features. We applied these two assessment methods to a patient knee robot and achieved positive appraisals. The assessment measures have potential for use in comparing several patient simulators for training physical therapists, rather than as absolute indices for developing a standard.	[Ishikawa, Shun; Okamoto, Shogo; Akiyama, Yasuhiro; Yamada, Yoji] Nagoya Univ, Grad Sch Engn, Dept Mech Sci & Engn, Nagoya, Aichi 4648601, Japan; [Isogai, Kaoru] Tokoha Univ, Fac Hlth & Med Sci, Dept Phys Therapy, Hamamatsu, Shizuoka, Japan; [Yanagihara, Naomi] Nagoya Univ, Grad Sch Med, Dept Phys & Occupat Therapy, Nagoya, Aichi 4648601, Japan	Nagoya University; Nagoya University	Okamoto, S (corresponding author), Nagoya Univ, Grad Sch Engn, Dept Mech Sci & Engn, Nagoya, Aichi 4648601, Japan.	okamoto-shogo@nagoya-u.jp	Akiyama, Yasuhiro/AAV-6248-2021	Akiyama, Yasuhiro/0000-0002-4169-3734	Naito Science & Engineering Foundation	Naito Science & Engineering Foundation	This work was supported by Naito Science & Engineering Foundation (no grant number), http://www.naitozaidan.or.jp/. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bohannon R. W., 1987, PHYS THER, V67, P206; Calota A, 2008, CLIN NEUROPHYSIOL, V119, P2329, DOI 10.1016/j.clinph.2008.07.215; Dietz V, 2007, LANCET NEUROL, V6, P725, DOI 10.1016/S1474-4422(07)70193-X; Fleuren JF, 2009, JOURNAL OF NEUROLOGY, V81, P1; Fujisawa T, 2007, INT C REHAB ROBOT, P48, DOI 10.1109/ICORR.2007.4428405; Grow DI, 2008, SYMPOSIUM ON HAPTICS INTERFACES FOR VIRTUAL ENVIRONMENT AND TELEOPERATOR SYSTEMS 2008, PROCEEDINGS, P475; Ishikawa S., 2012, Proceedings of the 2012 IEEE International Conference on Robotics and Biomimetics (ROBIO), P1409, DOI 10.1109/ROBIO.2012.6491166; Ishikawa S, 2013, 2013 IEEE/SICE INTERNATIONAL SYMPOSIUM ON SYSTEM INTEGRATION (SII), P300, DOI 10.1109/SII.2013.6776731; Jobin A, 2000, DEV MED CHILD NEUROL, V42, P531, DOI 10.1017/S0012162200001018; Kaya T, 2011, INT J REHABIL RES, V34, P59, DOI 10.1097/MRR.0b013e32833d6cdf; Kikuchi T, 2010, J INTEL MAT SYST STR, V21, P1523, DOI 10.1177/1045389X10367838; Kikuchi T, 2010, ADV ROBOTICS, V24, P671, DOI 10.1163/016918610X493534; Kim J, 2011, IEEE ENG MED BIO, P8527, DOI 10.1109/IEMBS.2011.6092104; McCrea PH, 2003, J NEUROSCI METH, V128, P121, DOI 10.1016/S0165-0270(03)00169-9; Mehrholz J, 2005, CLIN REHABIL, V19, P751, DOI 10.1191/0269215505cr889oa; Mehrholz J, 2005, CLIN REHABIL, V19, P63, DOI 10.1191/0269215505cr824oa; Morita Y, 2011, P INT WORKSH ROB MOT, P393; Mouri T, 2008, J ROBOT MECHATRON, V20, P280, DOI 10.20965/jrm.2008.p0280; Mutlu A, 2008, BMC MUSCULOSKEL DIS, V9, DOI 10.1186/1471-2474-9-44; Okumura H, 2013, PROC SICE ANN CONF, P2272; Pandyan AD, 1999, CLIN REHABIL, V13, P373, DOI 10.1191/026921599677595404; Park HS, 2012, IEEE T NEUR SYS REH, V20, P361, DOI 10.1109/TNSRE.2012.2195330; POWERS RK, 1988, ANN NEUROL, V23, P115, DOI 10.1002/ana.410230203; Stebbins GT, 1998, MOVEMENT DISORD, V13, P633, DOI 10.1002/mds.870130404; Takhashi Y., 2011, P IEEE INT C REH ROB, P1; Urban PP, 2010, STROKE, V41, P2016, DOI 10.1161/STROKEAHA.110.581991; Wakura S, 2006, Patient simulating robot for rehabilitation education and rehabilitation education method, Patent No. [JP2006204832 (A), 2006204832]; Wissel J, 2013, NEUROLOGY, V80, pS13, DOI 10.1212/WNL.0b013e3182762448	28	7	7	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 29	2015	10	4							e0126392	10.1371/journal.pone.0126392	http://dx.doi.org/10.1371/journal.pone.0126392			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CH0LO	25923719	Green Published, gold, Green Submitted			2023-01-03	WOS:000353711600174
J	Brenner, S; De Allegri, M; Gabrysch, S; Chinkhumba, J; Sarker, M; Muula, AS				Brenner, Stephan; De Allegri, Manuela; Gabrysch, Sabine; Chinkhumba, Jobiba; Sarker, Malabika; Muula, Adamson S.			The Quality of Clinical Maternal and Neonatal Healthcare - A Strategy for Identifying 'Routine Care Signal Functions'	PLOS ONE			English	Article							EMERGENCY OBSTETRIC CARE; LOW-RESOURCE SETTINGS; OVERCOME CHALLENGES; MEDICAL-CARE; 3 DISTRICTS; SURVIVAL 1; INDICATORS; ATTENDANTS; COUNTRIES; SERVICES	Background A variety of clinical process indicators exists to measure the quality of care provided by maternal and neonatal health (MNH) programs. To allow comparison across MNH programs in low-and middle-income countries (LMICs), a core set of essential process indicators is needed. Although such a core set is available for emergency obstetric care (EmOC), the 'EmOC signal functions', a similar approach is currently missing for MNH routine care evaluation. We describe a strategy for identifying core process indicators for routine care and illustrate their usefulness in a field example. Methods We first developed an indicator selection strategy by combining epidemiological and programmatic aspects relevant to MNH in LMICs. We then identified routine care process indicators meeting our selection criteria by reviewing existing quality of care assessment protocols. We grouped these indicators into three categories based on their main function in addressing risk factors of maternal or neonatal complications. We then tested this indicator set in a study assessing MNH quality of clinical care in 33 health facilities in Malawi. Results Our strategy identified 51 routine care processes: 23 related to initial patient risk assessment, 17 to risk monitoring, 11 to risk prevention. During the clinical performance assessment a total of 82 cases were observed. Birth attendants' adherence to clinical standards was lowest in relation to risk monitoring processes. In relation to major complications, routine care processes addressing fetal and newborn distress were performed relatively consistently, but there were major gaps in the performance of routine care processes addressing bleeding, infection, and pre-eclampsia risks. Conclusion The identified set of process indicators could identify major gaps in the quality of obstetric and neonatal care provided during the intra-and immediate postpartum period. We hope our suggested indicators for essential routine care processes will contribute to streamlining MNH program evaluations in LMICs.	[Brenner, Stephan; De Allegri, Manuela; Gabrysch, Sabine; Sarker, Malabika] Heidelberg Univ, Inst Publ Hlth, Heidelberg, Germany; [Chinkhumba, Jobiba; Muula, Adamson S.] Univ Malawi, Coll Med, Dept Community Hlth, Blantyre, Malawi	Ruprecht Karls University Heidelberg; University of Malawi	Brenner, S (corresponding author), Heidelberg Univ, Inst Publ Hlth, Heidelberg, Germany.	stephan.brenner@uni-heidelberg.de	Muula, Adamson/AAF-1153-2020; Gabrysch, Sabine/A-3503-2013	Gabrysch, Sabine/0000-0002-7081-0506; Sarker, Malabika/0000-0001-7293-8805	United States Agency for International Development (USAID) [GHS-A-00-09-00015-00]; Norwegian Ministry of Foreign Affairs [MWI 12/0010]; Malawi College of Medicine	United States Agency for International Development (USAID)(United States Agency for International Development (USAID)); Norwegian Ministry of Foreign Affairs; Malawi College of Medicine	This research project is made possible through Translating Research into Action, TRAction, and is funded by United States Agency for International Development (USAID) under cooperative agreement number GHS-A-00-09-00015-00. The project team includes prime recipient, University Research Co., LLC (URC), Harvard University School of Public Health (HSPH), and sub-recipient research organization, University of Heidelberg. This research project is co-funded through a grant by the Norwegian Ministry of Foreign Affairs to the Government of Malawi under Programme Title MWI 12/0010 Effect Evaluation of Performance Based Financing in Health Sector. The Malawi College of Medicine as implementing institution is recipient of this grant. No funding bodies had any role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 2009, MAL STAND TREATM GUI; [Anonymous], 2005, MAL NAT ROAD MAP ACC; [Anonymous], 2009, INT MAN PREGN CHILDB, DOI [10.1186/1471-2393-9-20, DOI 10.1186/1471-2393-9-20]; [Anonymous], 2006, MAL NAT REPR HLTH SE; [Anonymous], 2010, COUNTD 2015 DEC REP, DOI [10.1016/S0140-6736(10)60678-2, DOI 10.1016/S0140-6736(10)60678-2]; [Anonymous], 2010, CLIN MAN HIV CHILDR; [Anonymous], 2010, NAT INT INF PREV REP; Ashebir Getachew, 2011, QUALITY CARE PREVENT; Bates I, 2008, BJOG-INT J OBSTET GY, V115, P1331, DOI 10.1111/j.1471-0528.2008.01866.x; Bayley O, 2013, MALAWI MED J, V25, P105; Betran Ana P., 2006, MONITORING EVALUATIO; Brenner S, 2014, BMC HEALTH SERV RES, V14, DOI 10.1186/1472-6963-14-180; Chin MH, 2003, PERSPECT BIOL MED, V46, P5, DOI 10.1353/pbm.2003.0002; de Bernis L, 2003, BRIT MED BULL, V67, P39, DOI 10.1093/bmb/ldg017; Diana B, 2010, EXPLORING EVIDENCE D; Edmond K., 2006, OPTIMAL FEEDING LOW; Fidele Ngabo, 2012, QUALITY CARE PREVENT; Gabrysch S, 2012, PLOS MED, V9, DOI 10.1371/journal.pmed.1001340; Hermida J, 1999, INT J QUAL HEALTH C, V11, P429, DOI 10.1093/intqhc/11.5.429; Hirshon JM, 2013, B WORLD HEALTH ORGAN, V91, P386, DOI 10.2471/BLT.12.112664; Hofmeyr GJ, 2009, INT J GYNECOL OBSTET, V107, pS21, DOI 10.1016/j.ijgo.2009.07.017; Hussein J, 2005, HEALTH POLICY, V73, P294, DOI 10.1016/j.healthpol.2004.11.021; Ith P, 2013, MIDWIFERY, V29, P300, DOI 10.1016/j.midw.2012.01.010; Kagema F, 2011, QUALITY CARE PREVENT; Khan KS, 2006, LANCET, V367, P1066, DOI 10.1016/S0140-6736(06)68397-9; Kobusingye OC, 2005, B WORLD HEALTH ORGAN, V83, P626; Kongnyuy E J, 2008, Women Birth, V21, P149, DOI 10.1016/j.wombi.2008.08.002; Kongnyuy EJ, 2009, WOMEN HEALTH ISS, V19, P14, DOI 10.1016/j.whi.2008.09.008; Lawn JE, 2005, LANCET, V365, P891, DOI 10.1016/S0140-6736(05)71048-5; Lawn JE, 2012, HEALTH POLICY PLANN, V27, P6, DOI 10.1093/heapol/czs053; Lawn JE, 2009, INT J GYNECOL OBSTET, V107, pS123, DOI 10.1016/j.ijgo.2009.07.021; Lawn JE, 2009, INT J GYNECOL OBSTET, V107, pS5, DOI 10.1016/j.ijgo.2009.07.016; Lidia Chongo, 2013, QUALITY HUMANIZATION; Liu L, 2012, LANCET, V379, P2151, DOI 10.1016/S0140-6736(12)60560-1; Mainz J, 2003, INT J QUAL HEALTH C, V15, P523, DOI 10.1093/intqhc/mzg081; Makaula P, 2012, BMC HEALTH SERV RES, V12, DOI 10.1186/1472-6963-12-328; Marya Plotkin, 2011, QUALITY CARE PREVENT; Marya Plotkin, 2012, QUALITY MATERNAL NEW; Ministry of Health Malawi, 2011, MAL HLTH SECT STRAT; Nesbitt RC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081089; Nour Nawal M, 2008, Rev Obstet Gynecol, V1, P77; Paxton A, 2006, INT J GYNECOL OBSTET, V95, P192, DOI 10.1016/j.ijgo.2006.08.009; Ranjalahy Justin, 2011, QUALITY CARE PREVENT; Razzak JA, 2002, B WORLD HEALTH ORGAN, V80, P900; Ronsmans C, 2006, LANCET, V368, P1189, DOI 10.1016/S0140-6736(06)69380-X; Samuel Rigbe, 2005, Afr Health Sci, V5, P4; Tawfik Y, 2010, FINDING COMMON GROUN; The Partnership for Maternal Newborn and Child Health, 2011, MAT NEWB CHILD HLTH; United Nations Children's Fund (UNICEF), STAT WORLDS CHILDR R; Wall SN, 2009, INT J GYNECOL OBSTET, V107, pS47, DOI 10.1016/j.ijgo.2009.07.013; Wang HD, 2014, LANCET, V384, P957, DOI 10.1016/S0140-6736(14)60497-9; WHO, 2011, IMCI INS TRAIN; WHO UNICEF UNFPA The World Bank United Nations Population Division., 2014, WHO TRENDS MAT MORT; World Health Organization, 2005, WORLD HLTH REPORT 20; World Health Organization, 2010, PACK INT FAM PLANN S; World Health Organization, 2012, WHO REC PREV TREATM; World Health Organization, 2021, ANT DRUGS TREAT PREG; World Health Organization, 2011, WHO REC PREV TREATM; World Health Organization (WHO), 2004, MAK PREGN SAF CRIT R; World Health Organization (WHO), 2003, KANGAROO MOTHER CARE; World Health Organization (WHO); UNFPA; UNICEF; Columbia University. Mailman School of Public Health, 2009, MON EM OBST CAR HDB; Yakoob MY, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-S3-S7	62	16	16	0	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 15	2015	10	4							e0123968	10.1371/journal.pone.0123968	http://dx.doi.org/10.1371/journal.pone.0123968			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	CG1EL	25875252	Green Published, Green Accepted, Green Submitted, gold			2023-01-03	WOS:000353015800126
J	Jeong, BH; Ko, MG; Nam, J; Yoo, H; Chung, CR; Suh, GY; Jeon, K				Jeong, Byeong Ho; Ko, Myeong Gyun; Nam, Jimyoung; Yoo, Hongseok; Chung, Chi Ryang; Suh, Gee Young; Jeon, Kyeongman			Differences in Clinical Outcomes According to Weaning Classifications in Medical Intensive Care Units	PLOS ONE			English	Article							MECHANICAL VENTILATION; FAILURE	Background Although the weaning classification based on the difficulty and duration of the weaning process has been evaluated in the different type of intensive care units (ICUs), little is known about clinical outcomes and validity among the three groups in medical ICU. The objectives of this study were to evaluate the clinical relevance of weaning classification and its association with hospital mortality in a medical ICU with a protocol-based weaning program. Methods All consecutive patients admitted to the medical ICU and requiring mechanical ventilation (MV) for more than 24 hours were prospectively registered and screened for weaning readiness by a standardized weaning program between July 2010 and June 2013. Baseline characteristics and outcomes were compared across weaning classifications. Results During the study period, a total of 680 patients were weaned according to the standardized weaning protocol. Of these, 457 (67%) were classified as simple weaning, 136 (20%) as difficult weaning, and 87 (13%) as prolonged weaning. Ventilator-free days within 28 days decreased significantly from simple to difficult to prolonged weaning groups (P < 0.001, test for trends). In addition, reintubation within 48 hours after extubation (P < 0.001) and need for tracheostomy during the weaning process (P < 0.001) increased significantly across weaning groups. Finally, ICU (P < 0.001), post-ICU (P = 0.001), and hospital (P < 0.001) mortalities significantly increased across weaning groups. In a multiple logistic regression model, prolonged weaning but not difficult weaning was still independently associated with ICU (adjusted OR 8.265, 95% CI 3.484-19.605, P < 0.001), and post-ICU (adjusted OR 3.180, 95% CI 1.349-7.497, P = 0.005), and hospital (adjusted OR 5.528, 95% CI 2.801-10.910, P < 0.001) mortalities. Conclusions Weaning classification based on the difficulty and duration of the weaning process may provide prognostic information for mechanically ventilated patients who undergo the weaning process.	[Jeong, Byeong Ho; Yoo, Hongseok; Suh, Gee Young; Jeon, Kyeongman] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Med,Div Pulm & Crit Care Med, Seoul, South Korea; [Ko, Myeong Gyun; Nam, Jimyoung] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Intens Care Unit,Nursing Dept, Seoul, South Korea; [Chung, Chi Ryang; Suh, Gee Young; Jeon, Kyeongman] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Crit Care Med, Seoul, South Korea	Sungkyunkwan University (SKKU); Samsung Medical Center; Sungkyunkwan University (SKKU); Samsung Medical Center; Sungkyunkwan University (SKKU); Samsung Medical Center	Jeon, K (corresponding author), Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Med,Div Pulm & Crit Care Med, Seoul, South Korea.	kjeon@skku.edu	Yoo, Hongseok/AAZ-8139-2020; Suh, Gee Young/O-3676-2019; Jeon, Kyeongman/F-5963-2019	Suh, Gee Young/0000-0001-5473-1712; Jeon, Kyeongman/0000-0002-4822-1772; Yoo, Hongseok/0000-0002-2227-6441; Jeong, Byeong-Ho/0000-0002-3124-1718	Samsung Medical Center grant [CRO1121611]	Samsung Medical Center grant(Samsung)	This work was supported by Samsung Medical Center grant (CRO1121611). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bewick V, 2004, CRIT CARE, V8, P46, DOI 10.1186/cc2428; Bewick Viv, 2004, Crit Care, V8, P196, DOI 10.1186/cc2857; Blackwood B, 2011, BMJ-BRIT MED J, V342, DOI 10.1136/bmj.c7237; Boles JM, 2007, EUR RESPIR J, V29, P1033, DOI 10.1183/09031936.00010206; Cheng KC, 2006, CRIT CARE MED, V34, P1345, DOI 10.1097/01.CCM.0000214678.92134.BD; Cox CE, 2004, CRIT CARE MED, V32, P2219, DOI 10.1097/01.CCM.0000145232.46143.40; Epstein SK, 2009, CURR OPIN CRIT CARE, V15, P36, DOI 10.1097/MCC.0b013e3283220e07; Esteban A, 2002, JAMA-J AM MED ASSOC, V287, P345, DOI 10.1001/jama.287.3.345; Esteban A, 2008, AM J RESP CRIT CARE, V177, P170, DOI 10.1164/rccm.200706-893OC; Frutos-Vivar F, 2006, CHEST, V130, P1664, DOI 10.1378/chest.130.6.1664; Funk GC, 2010, EUR RESPIR J, V35, P88, DOI 10.1183/09031936.00056909; Kriner Eric J, 2005, Respir Care, V50, P1632; McConville JF, 2012, NEW ENGL J MED, V367, P2233, DOI 10.1056/NEJMra1203367; Moreno RP, 2005, INTENS CARE MED, V31, P1345, DOI 10.1007/s00134-005-2763-5; Patel KN, 2009, RESP CARE, V54, P1462; Penuelas O, 2011, AM J RESP CRIT CARE, V184, P430, DOI 10.1164/rccm.201011-1887OC; Sellares J, 2011, INTENS CARE MED, V37, P775, DOI 10.1007/s00134-011-2179-3; Tonnelier A, 2011, RESP CARE, V56, P583, DOI 10.4187/respcare.00842; Vallverdu I, 1998, AM J RESP CRIT CARE, V158, P1855, DOI 10.1164/ajrccm.158.6.9712135; Vincent JL, 1996, INTENS CARE MED, V22, P707, DOI 10.1007/BF01709751	20	35	39	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 15	2015	10	4							e0122810	10.1371/journal.pone.0122810	http://dx.doi.org/10.1371/journal.pone.0122810			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CG1EL	25876004	gold, Green Published, Green Submitted			2023-01-03	WOS:000353015800077
J	Aoun, SM; Grande, G; Howting, D; Deas, K; Toye, C; Troeung, L; Stajduhar, K; Ewing, G				Aoun, Samar M.; Grande, Gunn; Howting, Denise; Deas, Kathleen; Toye, Chris; Troeung, Lakkhina; Stajduhar, Kelli; Ewing, Gail			The Impact of the Carer Support Needs Assessment Tool (CSNAT) in Community Palliative Care Using a Stepped Wedge Cluster Trial	PLOS ONE			English	Article							OF-LIFE CARE; FAMILY CAREGIVERS; HOME; END; CANCER; VALIDATION; INTERVENTIONS; MORTALITY; OUTCOMES; BASE	Family caregiving towards the end-of-life entails considerable emotional, social, financial and physical costs for caregivers. Evidence suggests that good support can improve caregiver psychological outcomes. The primary aimof this study was to investigate the impact of using the carer support needs assessment tool (CSNAT), as an intervention to identify and address support needs in end of life home care, on family caregiver outcomes. A stepped wedge design was used to trial the CSNAT intervention in three bases of Silver Chain Hospice Care in Western Australia, 2012-14. The intervention consisted of at least two visits from nurses (2-3 weeks apart) to identify, review and address caregivers' needs. The outcome measures for the intervention and control groups were caregiver strain and distress as measured by the Family Appraisal of Caregiving Questionnaire (FACQ-PC), caregiver mental and physical health as measured by SF-12v2, and caregiver workload as measured by extent of caregiver assistance with activities of daily living, at baseline and follow up. Total recruitment was 620. There was 45% attrition for each group between baseline and follow-up mainly due to patient deaths resulting in 322 caregivers completing the study (233 in the intervention group and 89 in the control group). At follow-up, the intervention group showed significant reduction in caregiver strain relative to controls, p=0.018, d=0.348 (95% CI 0.25 to 0.41). Priority support needs identified by caregivers included knowing what to expect in the future, having time for yourself in the day and dealing with your feelings and worries. Despite the challenges at the clinician, organisational and trial levels, the CSNAT intervention led to an improvement in caregiver strain. Effective implementation of an evidence-informed and caregiver-led tool represents a necessary step towards helping palliative care providers better assess and address caregiver needs, ensuring adequate family caregiver support and reduction in caregiver strain.	[Aoun, Samar M.; Howting, Denise; Deas, Kathleen; Toye, Chris] Curtin Univ, Sch Nursing & Midwifery, Perth, WA 6845, Australia; [Grande, Gunn] Univ Manchester, Sch Nursing Midwifery & Social Work, Manchester, Lancs, England; [Troeung, Lakkhina] Univ Western Australia, Sch Populat Hlth, Crawley, WA, Australia; [Troeung, Lakkhina] Univ Notre Dame Australia, Sch Med, Fremantle, WA, Australia; [Stajduhar, Kelli] Univ Victoria, Sch Nursing, Victoria, BC, Canada; [Stajduhar, Kelli] Univ Victoria, Ctr Aging, Victoria, BC, Canada; [Ewing, Gail] Univ Cambridge, Ctr Family Res, Cambridge, England	Curtin University; University of Manchester; University of Western Australia; University of Notre Dame Australia; University of Victoria; University of Victoria; University of Cambridge	Aoun, SM (corresponding author), Curtin Univ, Sch Nursing & Midwifery, Perth, WA 6845, Australia.	s.aoun@curtin.edu.au	Howting, Denise Ann/GWU-5045-2022; Toye, Christine M/I-4288-2012; Grande, Gunn/A-6163-2011; Stajduhar, Kelli/AAJ-5914-2021	Howting, Denise Ann/0000-0001-8753-5849; Toye, Christine M/0000-0003-4932-0016; Grande, Gunn/0000-0003-2200-1680; Stajduhar, Kelli/0000-0003-2381-4712; Aoun, Samar/0000-0002-4073-4805	Australian Research Council linkage grant and Silver Chain [LP110100622]	Australian Research Council linkage grant and Silver Chain(Australian Research Council)	This research was financially supported by an Australian Research Council linkage grant and Silver Chain (LP110100622).	Aoun S, 2015, PALLIAT MED; Aoun S., 2004, 0975229508 PALL CAR; Aoun SM, 2014, J PAIN SYMPTOM MANAG, V48, P1222, DOI 10.1016/j.jpainsymman.2014.01.007; Bedini LA, 2002, FAMILY CAREGIVERS LE, P25; Briggs H, 2000, WARNING CARING HLTH; Candy B, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007617.pub2; Carers Association of Australia, 1997, CAR EN BE POOR SURV; Carers UK, 2003, MISS OPPRT IMP NEW R; Christakis NA, 2003, SOC SCI MED, V57, P465, DOI 10.1016/S0277-9536(02)00370-2; Cooper B, 2006, PSYCHO-ONCOLOGY, V15, P613, DOI 10.1002/pon.1001; Currow DC, 2012, J PAIN SYMPTOM MANAG, V44, P595, DOI 10.1016/j.jpainsymman.2011.10.028; Ewing G, 2013, J PAIN SYMPTOM MANAG, V46, P395, DOI 10.1016/j.jpainsymman.2012.09.008; Ewing G, 2013, PALLIATIVE MED, V27, P244, DOI 10.1177/0269216312440607; Gomes B, 2006, BMJ-BRIT MED J, V332, P515, DOI 10.1136/bmj.38740.614954.55; Grande G, 2009, PALLIATIVE MED, V23, P339, DOI 10.1177/0269216309104875; Grande G, 2014, PALLIATIVE MED, V28, P609; Grande GE, 2009, PALLIATIVE MED, V23, P248, DOI 10.1177/0269216309102620; Harding R, 2003, PALLIATIVE MED, V17, P63, DOI 10.1191/0269216303pm667oa; Harrop E, 2014, BMC PALLIAT CARE, V13, DOI 10.1186/1472-684X-13-22; Hawkins NG, 2007, AM J PREV MED, V33, P162, DOI 10.1016/j.amepre.2007.03.020; Henwood M, 1998, IGNORED INVISIBLE CA; Holden JE, 2008, AM J NEPHROL, V28, P792, DOI 10.1159/000131102; Hudson P., 2005, EUR J PALLAIT CARE, V12, P165; Hudson P, 2009, J PAIN SYMPTOM MANAG, V38, P299, DOI 10.1016/j.jpainsymman.2008.08.010; Hudson PL, 2011, J PALLIAT MED, V14, P397, DOI 10.1089/jpm.2010.0345; Hudson PL, 2010, PALLIATIVE MED, V24, P656, DOI 10.1177/0269216310373167; Kristjanson LJ, 2004, CAN J PSYCHIAT, V49, P359, DOI 10.1177/070674370404900604; Lee LA, 2010, ENCY RES DESIGN; McGough James J, 2009, Psychiatry (Edgmont), V6, P21; Nijboer C, 2001, CANCER, V91, P1029, DOI 10.1002/1097-0142(20010301)91:5<1029::AID-CNCR1094>3.3.CO;2-T; Northouse LL, 2010, CA-CANCER J CLIN, V60, P317, DOI 10.3322/caac.20081; Payne S, 2013, NURS STAND, V28, P57, DOI [10.7748/ns2013.09.28.3.57.s50, DOI 10.7748/NS2013.09.28.3.57.S50]; Peat J, 2002, HEALTH SCIENCE RESEA; Sanderson K, 2002, AUST NZ J PUBL HEAL, V26, P343, DOI 10.1111/j.1467-842X.2002.tb00182.x; Schulz R, 1999, JAMA-J AM MED ASSOC, V282, P2215, DOI 10.1001/jama.282.23.2215; Stajduhar KI, 2010, PALLIATIVE MED, V24, P573, DOI 10.1177/0269216310371412; Tan H, 2010, EXPLORE-NY, V6, P159, DOI 10.1016/j.explore.2010.03.008; Wagenaar AC, 2000, J STUD ALCOHOL, V61, P85, DOI 10.15288/jsa.2000.61.85	38	59	60	1	26	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 7	2015	10	4							e0123012	10.1371/journal.pone.0123012	http://dx.doi.org/10.1371/journal.pone.0123012			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	CF3VU	25849348	gold, Green Submitted, Green Published			2023-01-03	WOS:000352477800194
J	Schumacher, TN; Schreiber, RD				Schumacher, Ton N.; Schreiber, Robert D.			Neoantigens in cancer immunotherapy	SCIENCE			English	Review							EXOME ANALYSIS REVEALS; MHC CLASS-I; T-CELLS; PD-1 BLOCKADE; NEO-ANTIGENS; CD4+T CELLS; LYMPHOCYTES; THERAPY; IDENTIFICATION; NEOEPITOPES	The clinical relevance of T cells in the control of a diverse set of human cancers is now beyond doubt. However, the nature of the antigens that allow the immune system to distinguish cancer cells from noncancer cells has long remained obscure. Recent technological innovations have made it possible to dissect the immune response to patient-specific neoantigens that arise as a consequence of tumor-specific mutations, and emerging data suggest that recognition of such neoantigens is a major factor in the activity of clinical immunotherapies. These observations indicate that neoantigen load may form a biomarker in cancer immunotherapy and provide an incentive for the development of novel therapeutic approaches that selectively enhance T cell reactivity against this class of antigens.	[Schumacher, Ton N.] Netherlands Canc Inst, Div Immunol, NL-1066 CX Amsterdam, Netherlands; [Schreiber, Robert D.] Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO 63110 USA	Netherlands Cancer Institute; Washington University (WUSTL)	Schumacher, TN (corresponding author), Netherlands Canc Inst, Div Immunol, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.	t.schumacher@nki.nl; schreiber@immunology.wustl.edu	Schreiber, Robert/Q-7550-2019; Schumacher, Ton/Y-2432-2019	Schumacher, Ton/0000-0003-0517-8804; Schreiber, Robert/0000-0003-1590-2341	Worldwide Cancer Research grant [14-0321]; Dutch Cancer Society grant [NKI 2012-5463]; Dutch Cancer Society Queen Wilhelmina Award; Stand Up To Cancer-Cancer Research Institute Cancer Immunology Translational Cancer Research Grant; National Cancer Institute [RO1CA04305926]; Cancer Research Institute; WWWW Foundation; Cancer Frontier Fund from The Siteman Cancer Center/Barnes-Jewish Hospital; Third Rock Ventures; Kite Pharma; Jounce Therapeutics; Worldwide Cancer Research [14-0321] Funding Source: researchfish	Worldwide Cancer Research grant; Dutch Cancer Society grant(KWF Kankerbestrijding); Dutch Cancer Society Queen Wilhelmina Award; Stand Up To Cancer-Cancer Research Institute Cancer Immunology Translational Cancer Research Grant; National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Cancer Research Institute; WWWW Foundation; Cancer Frontier Fund from The Siteman Cancer Center/Barnes-Jewish Hospital; Third Rock Ventures; Kite Pharma; Jounce Therapeutics; Worldwide Cancer Research	This work is supported by Worldwide Cancer Research grant 14-0321, Dutch Cancer Society grant NKI 2012-5463, the Dutch Cancer Society Queen Wilhelmina Award, the Stand Up To Cancer-Cancer Research Institute Cancer Immunology Translational Cancer Research Grant (to T.N.S.), the National Cancer Institute (RO1CA04305926), the Cancer Research Institute, the WWWW Foundation, and the Cancer Frontier Fund from The Siteman Cancer Center/Barnes-Jewish Hospital (to R.D.S.). SU2C is a program of the Entertainment Industry Foundation administered by the American Association for Cancer Research. We thank J. Haanen, M. van Buuren, and P. Kvistborg for valuable discussions. T.N.S. has an paid advisory relationship with Third Rock Ventures and Kite Pharma. R.D.S. has a paid advisory relationship with Third Rock Ventures and Jounce Therapeutics.	Alexandrov LB, 2013, NATURE, V500, P415, DOI 10.1038/nature12477; Boisguerin V, 2014, BRIT J CANCER, V111, P1469, DOI 10.1038/bjc.2013.820; Brown SD, 2014, GENOME RES, V24, P743, DOI 10.1101/gr.165985.113; Cabrera CM, 2003, TISSUE ANTIGENS, V61, P211, DOI 10.1034/j.1399-0039.2003.00020.x; Calis JJA, 2013, PLOS COMPUT BIOL, V9, DOI 10.1371/journal.pcbi.1003266; Castle JC, 2012, CANCER RES, V72, P1081, DOI 10.1158/0008-5472.CAN-11-3722; Chen DS, 2013, IMMUNITY, V39, P1, DOI 10.1016/j.immuni.2013.07.012; Duan F, 2014, J EXP MED, V211, P2231, DOI 10.1084/jem.20141308; Dudley ME, 2013, J CLIN ONCOL, V31, P2152, DOI 10.1200/JCO.2012.46.6441; Dudley ME, 1996, J EXP MED, V184, P441, DOI 10.1084/jem.184.2.441; DuPage M, 2012, NATURE, V482, P405, DOI 10.1038/nature10803; Forbes SA, 2015, NUCLEIC ACIDS RES, V43, pD805, DOI 10.1093/nar/gku1075; Fortier MH, 2008, J EXP MED, V205, P595, DOI 10.1084/jem.20071985; Fritsch EF, 2014, ONCOIMMUNOLOGY, V3, DOI 10.4161/onci.29311; Fritsch EF, 2014, CANCER IMMUNOL RES, V2, P522, DOI 10.1158/2326-6066.CIR-13-0227; Futreal PA, 2004, NAT REV CANCER, V4, P177, DOI 10.1038/nrc1299; Gerlinger M, 2012, NEW ENGL J MED, V366, P883, DOI 10.1056/NEJMoa1113205; Gilboa E, 1999, IMMUNITY, V11, P263, DOI 10.1016/S1074-7613(00)80101-6; Gubin MM, 2014, NATURE, V515, P577, DOI 10.1038/nature13988; Heemskerk B, 2013, EMBO J, V32, P194, DOI 10.1038/emboj.2012.333; Hinrichs CS, 2014, IMMUNOL REV, V257, P56, DOI 10.1111/imr.12132; Hodi FS, 2010, NEW ENGL J MED, V363, P711, DOI 10.1056/NEJMoa1003466; Hunder NN, 2008, NEW ENGL J MED, V358, P2698, DOI 10.1056/NEJMoa0800251; Johnson LA, 2009, BLOOD, V114, P535, DOI 10.1182/blood-2009-03-211714; Joseph CG, 2014, SCIENCE, V343, P152, DOI 10.1126/science.1246886; Koebel CM, 2007, NATURE, V450, P903, DOI 10.1038/nature06309; Kvistborg P, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3008918; Kvistborg P, 2012, ONCOIMMUNOLOGY, V1, DOI 10.4161/onci.18851; Linnemann C, 2015, NAT MED, V21, P81, DOI 10.1038/nm.3773; Lu YC, 2014, CLIN CANCER RES, V20, P3401, DOI 10.1158/1078-0432.CCR-14-0433; Matsushita H, 2012, NATURE, V482, P400, DOI 10.1038/nature10755; Rajasagi M, 2014, BLOOD, V124, P453, DOI 10.1182/blood-2014-04-567933; Rizvi NA, 2015, SCIENCE, V348, P124, DOI 10.1126/science.aaa1348; Robbins PF, 2015, CLIN CANCER RES, V21, P1019, DOI 10.1158/1078-0432.CCR-14-2708; Robbins PF, 2013, NAT MED, V19, P747, DOI 10.1038/nm.3161; Rooney MS, 2015, CELL, V160, P48, DOI 10.1016/j.cell.2014.12.033; Schreiber RD, 2011, SCIENCE, V331, P1565, DOI 10.1126/science.1203486; Schumacher T, 2014, NATURE, V512, P324, DOI 10.1038/nature13387; Schumacher TN, 2015, CANCER CELL, V27, P12, DOI 10.1016/j.ccell.2014.12.004; Segal NH, 2008, CANCER RES, V68, P889, DOI 10.1158/0008-5472.CAN-07-3095; Shankaran V, 2001, NATURE, V410, P1107, DOI 10.1038/35074122; Sharma P, 2015, SCIENCE, V348, P56, DOI 10.1126/science.aaa8172; Snyder A, 2014, NEW ENGL J MED, V371, P2189, DOI 10.1056/NEJMoa1406498; Tran E, 2014, SCIENCE, V344, P641, DOI 10.1126/science.1251102; Tumeh PC, 2014, NATURE, V515, P568, DOI 10.1038/nature13954; Van Bergen CAM, 2010, CANCER RES, V70, P9073, DOI 10.1158/0008-5472.CAN-10-1832; van Buuren MM, 2014, ONCOIMMUNOLOGY, V3, DOI 10.4161/onci.28836; van Rooij N, 2013, J CLIN ONCOL, V31, pE439, DOI 10.1200/JCO.2012.47.7521; Vonderheide RH, 2013, NAT MED, V19, P1098, DOI 10.1038/nm.3317; Wick DA, 2014, CLIN CANCER RES, V20, P1125, DOI 10.1158/1078-0432.CCR-13-2147; WOLFEL T, 1995, SCIENCE, V269, P1281, DOI 10.1126/science.7652577; Yadav M, 2014, NATURE, V515, P572, DOI 10.1038/nature14001	52	2855	2981	44	878	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 3	2015	348	6230					69	74		10.1126/science.aaa4971	http://dx.doi.org/10.1126/science.aaa4971			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CE8GJ	25838375				2023-01-03	WOS:000352079500028
J	Laflamme, L; Monarrez-Espino, J; Johnell, K; Elling, B; Moller, J				Laflamme, Lucie; Monarrez-Espino, Joel; Johnell, Kristina; Elling, Berty; Moller, Jette			Type, Number or Both? A Population-Based Matched Case-Control Study on the Risk of Fall Injuries among Older People and Number of Medications beyond Fall-Inducing Drugs	PLOS ONE			English	Article							HOSPITALIZED-PATIENTS; HIP FRACTURE; POLYPHARMACY; REGISTER; MODEL; METAANALYSIS; ASSOCIATION; VALIDATION; MORTALITY; MEDICINES	Objectives Drug use is a modifiable risk factor for fall-related injuries in older people. Whereas the injurious effect of polypharmacy is established, that of low numbers of medications has not been fully ascertained. Neither do we know whether it is the number per se or the type of medications that actually matters. We assessed this question for fall injuries leading to hospitalization. Design National register-based, population-based, matched case-control study. Setting Community dwellers aged 65+ years living in Sweden between March 2006 and December 2009. Methods Cases (n = 64,399) were identified in the national inpatient register and four controls per case were randomly matched by gender, date of birth and residential area. The association between number of prescribed medications, assessed through linkage with the Swedish prescribed drug register, and the risk of injurious falls was estimated with odds ratios with 95% confidence intervals using conditional logistic regression, adjusted for demographic and health status. Results The number of medications was associated with an increased risk of fall injury in a dose-response fashion, even after adjustment for marital status, comorbidity and number of fall-risk-inducing drugs (FRIDs). Using ten or more medications was associated with an almost two-fold higher risk (adjusted OR: 1.76, 95% CI: 1.66 to 1.88). When stratified by use (or not) of at least one FRID, the association weakened slightly among both non-users (adjusted OR: 1.50, 95% CI: 1.34 to 1.67) and users (adjusted OR: 1.67, 95% CI: 1.58 to 1.77). Conclusion In older people, not only large but also small numbers of medications may affect the risk for them to sustain injurious falls. Although the mechanisms lying behind this are complex, the finding challenges the prevention strategies targeting either specific types of medications (FRIDs) or high numbers of them.	[Laflamme, Lucie; Monarrez-Espino, Joel; Elling, Berty; Moller, Jette] Karolinska Inst, Dept Publ Hlth Sci, Stockholm, Sweden; [Johnell, Kristina] Karolinska Inst, Aging Res Ctr, Stockholm, Sweden; [Johnell, Kristina] Stockholm Univ, S-10691 Stockholm, Sweden	Karolinska Institutet; Karolinska Institutet; Stockholm University	Laflamme, L (corresponding author), Karolinska Inst, Dept Publ Hlth Sci, Stockholm, Sweden.	Lucie.Laflamme@ki.se	Laflamme, Lucie/T-2953-2019	Laflamme, Lucie/0000-0002-6443-1307; Moller, Jette/0000-0001-9513-5896	Swedish Civil Contingencies Agency [2010-2808-13]	Swedish Civil Contingencies Agency	This work was supported by the Swedish Civil Contingencies Agency (Grant number: 2010-2808-13). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aranda-Gallardo M, 2013, BMC HEALTH SERV RES, V13, DOI 10.1186/1472-6963-13-122; Baranzini F, 2009, BMC HEALTH SERV RES, V9, DOI 10.1186/1472-6963-9-228; Beer C, 2011, BRIT J CLIN PHARMACO, V71, P592, DOI 10.1111/j.1365-2125.2010.03875.x; Bennett A, 2014, DRUG AGING, V31, P225, DOI 10.1007/s40266-013-0151-3; Boyle N, 2010, CLIN GERIATR MED, V26, P583, DOI 10.1016/j.cger.2010.06.007; Caldevilla MN, 2013, SCAND J CARING SCI, V27, P468, DOI 10.1111/j.1471-6712.2012.01031.x; Cashin Richard P, 2011, Can J Hosp Pharm, V64, P321; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Chien WC, 2013, INT J INJ CONTROL SA, V20, P50, DOI 10.1080/17457300.2012.674042; CUMMING RG, 1991, AGE AGEING, V20, P455, DOI 10.1093/ageing/20.6.455; Evans DC, 2012, J AM GERIATR SOC, V60, P1465, DOI 10.1111/j.1532-5415.2012.04075.x; Evans David C, 2011, Int J Crit Illn Inj Sci, V1, P104, DOI 10.4103/2229-5151.84793; Frankenthal D, 2013, INT J CLIN PHARM-NET, V35, P677, DOI 10.1007/s11096-013-9790-z; Freeland KN, 2012, ANN PHARMACOTHER, V46, P1188, DOI 10.1345/aph.1Q689; Gnjidic D, 2012, J CLIN EPIDEMIOL, V65, P989, DOI 10.1016/j.jclinepi.2012.02.018; Haasum Y, 2012, ANN PHARMACOTHER, V46, P339, DOI 10.1345/aph.1Q597; Hartikainen S, 2007, J GERONTOL A-BIOL, V62, P1172, DOI 10.1093/gerona/62.10.1172; Helgadottir B, 2014, BMC GERIATR, V14, DOI 10.1186/1471-2318-14-92; Hendrich AL, 2003, APPL NURS RES, V16, P9, DOI 10.1053/apnr.2003.YAPNR2; Hovstadius Bo, 2009, BMC Clin Pharmacol, V9, P11, DOI 10.1186/1472-6904-9-11; Huang AR, 2012, DRUG AGING, V29, P359, DOI 10.2165/11599460-000000000-00000; Ivziku D, 2011, INT J NURS STUD, V48, P468, DOI 10.1016/j.ijnurstu.2010.09.002; Johnell K, 2007, ANN PHARMACOTHER, V41, P1243, DOI 10.1345/aph.1K154; Johnell K, 2012, DRUG AGING, V29, P751, DOI 10.1007/s40266-012-0002-7; Kanis JA, 2002, J BONE MINER RES, V17, P1237, DOI 10.1359/jbmr.2002.17.7.1237; Kojima T, 2011, GERIATR GERONTOL INT, V11, P438, DOI 10.1111/j.1447-0594.2011.00703.x; Kolla BP, 2013, J HOSP MED, V8, P1, DOI 10.1002/jhm.1985; Kool B, 2012, INJURY PREV, V18, P200, DOI 10.1136/injuryprev-2011-040202; Kraynov E, 2011, DRUG METAB DISPOS, V39, P1779, DOI 10.1124/dmd.111.040808; Lai SW, 2010, MEDICINE, V89, P295, DOI 10.1097/MD.0b013e3181f15efc; Leikola S, 2011, DRUG AGING, V28, P227, DOI 10.2165/11586890-000000000-00000; Monarrez-Espino J, 2014, INJURY PREV, V20, P81, DOI 10.1136/injuryprev-2013-040762; Murray CJL, 2012, LANCET, V380, P2197, DOI 10.1016/S0140-6736(12)61689-4; National Board of Health and Welfare, 2010, IND PHARM ELD; Petridou ET, 2008, J AGING HEALTH, V20, P159, DOI 10.1177/0898264307310467; Quan HD, 2005, MED CARE, V43, P1130, DOI 10.1097/01.mlr.0000182534.19832.83; Schneeweiss S, 2001, AM J EPIDEMIOL, V154, P854, DOI 10.1093/aje/154.9.854; Swedish Association of Local Authorities and Regions. Fall injuries among eldery, 2009, FALL INJ ELD SUMM SY; Swedish Civil Contingencies Agency, 2009, INJ ELD SWED; Voermans N C, 2007, Pract Neurol, V7, P158, DOI 10.1136/jnnp.2007.120980; Vollmer WM, 2012, BMC HEALTH SERV RES, V12, DOI 10.1186/1472-6963-12-155; Wettermark B, 2007, PHARMACOEPIDEM DR S, V16, P726, DOI 10.1002/pds.1294; WHO, 2007, WHO GLOB REP FALLP; Woolcott JC, 2009, ARCH INTERN MED, V169, P1952, DOI 10.1001/archinternmed.2009.357; World Health Organization Regional Office for Europe, COP RISK FACT ILL HL	45	45	45	0	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 27	2015	10	3							e0123390	10.1371/journal.pone.0123390	http://dx.doi.org/10.1371/journal.pone.0123390			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	CE8ZT	25815483	Green Published, gold			2023-01-03	WOS:000352133600208
J	Frias, M; Rivero-Juarez, A; Gordon, A; Camacho, A; Cantisan, S; Cuenca-Lopez, F; Torre-Cisneros, J; Pena, J; Rivero, A				Frias, Mario; Rivero-Juarez, Antonio; Gordon, Ana; Camacho, Angela; Cantisan, Sara; Cuenca-Lopez, Francisca; Torre-Cisneros, Julian; Pena, Jose; Rivero, Antonio			Persistence of Pathological Distribution of NK Cells in HIV-Infected Patients with Prolonged Use of HAART and a Sustained Immune Response	PLOS ONE			English	Article							NATURAL-KILLER-CELL; RECEPTORS NKP46; RECONSTITUTION; INDIVIDUALS; EXPRESSION; DISEASE; NKP30	Objective A prospective analysis of the distribution of NK subsets and natural cytotoxicity receptors (NKp30/NKp46) in HIV patients with long-term HAART use and sustained virological and immunological response. Methods The main inclusion criteria were: at least 3 years' receipt of HAART; current CD4(+) count >= 500 cells/mm(3); undetectable viral load for at least 24 months; no hepatotropic virus co-infection. Percentages of CD56(dim), CD56(bright) NK cells and CD56(neg) CD16(+) cells were obtained. Expression of the NCRs, NKp30 and NKp46 was analysed in CD56(+) cells. Thirty-nine infected patients and sixteen healthy donors were included in the study. Results The percentages of total CD56(+) and CD56(dim) NK cells were significantly lower in HIV-infected patients than in healthy donors (70.4 vs. 50.3 and 80.9 vs. 66.1 respectively). The percentage of total CD56(+) NK cells expressing NCR receptors was lower in HIV patients than in healthy donors (NKp30: 25.20 vs. 58.63; NKp46: 24.8 vs. 50.59). This was also observed for CD56(dim) and CD56(bright) NK cells. Length of time with undetectable HIV viral load was identified as an independent factor associated with higher expression of NKp30 and NKp46. Conclusion Despite the prolonged and effective use of HAART, HIV-infected patients do not fully reconstitute the distribution of NK cells. Length of time with an undetectable viral load was related to greater recovery of NKp30/NKp46 receptors.	[Frias, Mario; Rivero-Juarez, Antonio; Gordon, Ana; Camacho, Angela; Cantisan, Sara; Cuenca-Lopez, Francisca; Torre-Cisneros, Julian; Rivero, Antonio] Hosp Univ Reina Sofia Cordoba, Inst Maimonides Invest Biomed Cordoba IMIBIC, Infect Dis Unit, Cordoba, Spain; [Pena, Jose] Hosp Univ Reina Sofia Cordoba, Inst Maimonides Invest Biomed Cordoba IMIBIC, Immunol Unit, Cordoba, Spain	Hospital Universitario Reina Sofia - Cordoba; Hospital Universitario Reina Sofia - Cordoba	Rivero, A (corresponding author), Hosp Univ Reina Sofia Cordoba, Inst Maimonides Invest Biomed Cordoba IMIBIC, Infect Dis Unit, Cordoba, Spain.	ariveror@gmail.com	Cantisán, Sara/AAS-3490-2021; DE LA TORRE CISNEROS, JULIAN/AAL-5723-2021; Gordon, Ana/Q-5853-2018; Rivero-Juarez, Antonio/E-4528-2019; Espejo, Angela Camacho/AAM-9991-2021; Rivero, Antonio/ABE-5294-2020; Frias, Mario/AAL-6494-2021	Gordon, Ana/0000-0002-4911-1436; Rivero-Juarez, Antonio/0000-0002-5813-6889; Rivero, Antonio/0000-0001-5005-8268; Rivero Roman, Antonio/0000-0002-8643-4250	Fundacion Progreso y Salud, Consejeria de Salud de la Junta de Andalucia [PI-0430/2012, PI-0247/2010, PI-0208/2008, PI-0124/2008, PI-0305/2009]; Consejeria de Salud, Innovacion y Ciencia de la Junta de Andalucia; Consejeria de Igualdad, Salud y Politicas Sociales [RH-0024-2013]	Fundacion Progreso y Salud, Consejeria de Salud de la Junta de Andalucia(Junta de Andalucia); Consejeria de Salud, Innovacion y Ciencia de la Junta de Andalucia; Consejeria de Igualdad, Salud y Politicas Sociales	The study was funded by Fundacion Progreso y Salud, Consejeria de Salud de la Junta de Andalucia (grants for health research projects: refs. PI-0430/2012; PI-0247/2010; PI-0208/2008; PI-0124/2008; PI-0305/2009). AR has received a Research Extension Grant from the Consejeria de Salud, Innovacion y Ciencia de la Junta de Andalucia. ARJ is the recipient of a post-doctoral perfection grant, in the recently-qualified doctors category, from the Consejeria de Igualdad, Salud y Politicas Sociales (RH-0024-2013). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alter G, 2005, BLOOD, V106, P3366, DOI 10.1182/blood-2005-03-1100; Biassoni R, 2001, IMMUNOL REV, V181, P203, DOI 10.1034/j.1600-065X.2001.1810117.x; Bisio F, 2013, IMMUNOL LETT, V152, P16, DOI 10.1016/j.imlet.2013.03.003; Bjorkstrom NK, 2010, TRENDS IMMUNOL, V31, P401, DOI 10.1016/j.it.2010.08.003; Brunetta E, 2010, J LEUKOCYTE BIOL, V88, P1119, DOI 10.1189/jlb.0410225; Chehimi J, 2007, J IMMUNOL, V179, P2642, DOI 10.4049/jimmunol.179.4.2642; De Maria A, 2003, EUR J IMMUNOL, V33, P2410, DOI 10.1002/eji.200324141; De Maria A, 2008, CURR HIV RES, V6, P433, DOI 10.2174/157016208785861221; Fauci AS, 2005, NAT REV IMMUNOL, V5, P835, DOI 10.1038/nri1711; HU PF, 1995, J ACQ IMMUN DEF SYND, V10, P331; Jost S, 2013, ANNU REV IMMUNOL, V31, P163, DOI 10.1146/annurev-immunol-032712-100001; Mavilio D, 2005, P NATL ACAD SCI USA, V102, P2886, DOI 10.1073/pnas.0409872102; Mavilio D, 2003, P NATL ACAD SCI USA, V100, P15011, DOI 10.1073/pnas.2336091100; Michaelsson J, 2008, J INFECT DIS, V197, P117, DOI 10.1086/524141; Milush JM, 2013, RETROVIROLOGY, V10, DOI 10.1186/1742-4690-10-158; Milush JM, 2009, BLOOD, V114, P4823, DOI 10.1182/blood-2009-04-216374; Moretta A, 2002, NAT IMMUNOL, V3, P6, DOI 10.1038/ni0102-6; Scott-Algara Daniel, 2002, Current Molecular Medicine (Hilversum), V2, P757, DOI 10.2174/1566524023361781	18	9	9	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 26	2015	10	3							e0121019	10.1371/journal.pone.0121019	http://dx.doi.org/10.1371/journal.pone.0121019			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CK6QW	25811634	gold, Green Published, Green Submitted			2023-01-03	WOS:000356353700075
J	Traverso, G; Langer, R				Traverso, Giovanni; Langer, Robert			PERSPECTIVE Special delivery for the gut	NATURE			English	Editorial Material									[Traverso, Giovanni] Massachusetts Gen Hosp, Boston, MA 02114 USA; [Traverso, Giovanni] Harvard Univ, Sch Med, Boston, MA USA; [Langer, Robert] MIT, Koch Inst Integrat Canc Res, Cambridge, MA 02139 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts Institute of Technology (MIT)	Traverso, G (corresponding author), Massachusetts Gen Hosp, Boston, MA 02114 USA.	ctraverso@partners.org; rlanger@mit.edu	Traverso, Carlo Giovanni/ABC-9065-2020	Traverso, Carlo Giovanni/0000-0001-7851-4077				CARGILL R, 1988, PHARM RES-DORDR, V5, P533, DOI 10.1023/A:1015981627525; Ereqat S, 2011, LANCET INFECT DIS, V11, P662, DOI 10.1016/S1473-3099(11)70227-4; Fallon SC, 2013, J PEDIATR SURG, V48, P830, DOI 10.1016/j.jpedsurg.2012.07.046; Gordi T, 2008, CLIN THER, V30, P909, DOI 10.1016/j.clinthera.2008.05.008; Kethu SR, 2012, GASTROINTEST ENDOSC, V76, P1, DOI 10.1016/j.gie.2012.02.020; Lam PL, 2014, J CONTROL RELEASE, V178, P25, DOI 10.1016/j.jconrel.2013.12.028; Sabate E, 2003, ADHERENCE LONG TERM	7	48	53	0	52	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 26	2015	519	7544					S19	S19		10.1038/519S19a	http://dx.doi.org/10.1038/519S19a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CE1WF	25806494	Bronze			2023-01-03	WOS:000351602800007
J	Fukasawa, H; Kaneko, M; Niwa, H; Matsuyama, T; Yasuda, H; Kumagai, H; Furuya, R				Fukasawa, Hirotaka; Kaneko, Mai; Niwa, Hiroki; Matsuyama, Takashi; Yasuda, Hideo; Kumagai, Hiromichi; Furuya, Ryuichi			Circulating 20S Proteasome Is Independently Associated with Abdominal Muscle Mass in Hemodialysis Patients	PLOS ONE			English	Article							UBIQUITIN; MORTALITY; LEVEL; INDEX; INFLAMMATION; PROTEOLYSIS; MECHANISMS; GENERATION; DISEASE	Protein-energy wasting is highly prevalent in hemodialysis patients, and it contributes to patient morbidity and mortality. The ubiquitin-proteasome system is the major pathway for intracellular protein degradation and it is involved in the regulation of basic cellular processes. However, the role of this system in the determination of nutritional status is largely unknown. To examine a relationship between protein-energy wasting and the ubiquitin-proteasome system, a cross-sectional study of 76 hemodialysis patients was performed. Plasma concentrations of 20S proteasome were studied to evaluate its association with muscle and fat mass, which were investigated by abdominal muscle and fat areas measured using computed tomography and by creatinine production estimated using the creatinine kinetic model. Plasma 20S proteasome concentrations significantly and negatively correlated with abdominal muscle areas and creatinine production (rho = -0.263, P < 0.05 and rho = -0.241, P < 0.05, respectively), but not abdominal subcutaneous and visceral fat areas. Multiple regression analyses showed that 20S proteasome was a significant independent predictor of abdominal muscle area (P < 0.05). In conclusion, plasma 20S proteasome concentrations were independently associated with abdominal muscle mass in hemodialysis patients. Our findings indicate a relationship between circulating 20S proteasomes and muscle metabolism in these patients.	[Fukasawa, Hirotaka; Kaneko, Mai; Niwa, Hiroki; Matsuyama, Takashi; Furuya, Ryuichi] Iwata City Hosp, Div Renal, Dept Internal Med, Iwata, Shizuoka, Japan; [Yasuda, Hideo] Hamamatsu Univ Sch Med, Dept Med 1, Hamamatsu, Shizuoka 4313192, Japan; [Kumagai, Hiromichi] Univ Shizuoka, Dept Clin Nutr, Sch Food & Nutr Sci, Shizuoka, Shizuoka 4228526, Japan	Hamamatsu University School of Medicine; University of Shizuoka	Fukasawa, H (corresponding author), Iwata City Hosp, Div Renal, Dept Internal Med, Iwata, Shizuoka, Japan.	hfukasawaucsd@gmail.com			Japanese Association of Dialysis Physicians (JADP) [2011-08]	Japanese Association of Dialysis Physicians (JADP)	Support was provided by the Japanese Association of Dialysis Physicians (JADP Grant 2011-08, to HF) [http://touseki-ikai.or.jp/]. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bellavista E, 2014, AUTOIMMUN DIS, V2014, DOI 10.1155/2014/739705; BERGSTROM J, 1995, J AM SOC NEPHROL, V6, P1329; Bochmann I, 2014, J CELL MOL MED, V18, P59, DOI 10.1111/jcmm.12160; Bouillanne O, 2005, AM J CLIN NUTR, V82, P777, DOI 10.1093/ajcn/82.4.777; Cabezas-Rodriguez I, 2013, CLIN J AM SOC NEPHRO, V8, P1725, DOI 10.2215/CJN.10951012; Carrero JJ, 2011, KIDNEY INT, V79, P749, DOI 10.1038/ki.2010.487; Carrero JJ, 2008, CLIN NUTR, V27, P557, DOI 10.1016/j.clnu.2008.04.007; Du J, 2004, J CLIN INVEST, V113, P115, DOI 10.1172/JCI200418330; Egerer K, 2002, J RHEUMATOL, V29, P2045; Fischer D, 2000, BIOCHEM BIOPH RES CO, V270, P215, DOI 10.1006/bbrc.2000.2398; Fouque D, 2008, KIDNEY INT, V73, P391, DOI 10.1038/sj.ki.5002585; Fukasawa H, 2012, CLIN EXP NEPHROL, V16, P507, DOI 10.1007/s10157-012-0643-1; Glickman MH, 2002, PHYSIOL REV, V82, P373, DOI 10.1152/physrev.00027.2001; Henry L, 2010, EXP DERMATOL, V19, P1054, DOI 10.1111/j.1600-0625.2010.01151.x; Heubner M, 2011, GYNECOL ONCOL, V120, P233, DOI 10.1016/j.ygyno.2010.10.014; Jakob C, 2007, BLOOD, V109, P2100, DOI 10.1182/blood-2006-04-016360; Kaizu Y, 2002, NEPHROL DIAL TRANSPL, V17, P442, DOI 10.1093/ndt/17.3.442; Kopple JD, 1999, KIDNEY INT, V56, P1136, DOI 10.1046/j.1523-1755.1999.00615.x; Lai Ruenn Chai, 2012, Int J Proteomics, V2012, P971907, DOI 10.1155/2012/971907; Lavabre-Bertrand T, 2001, CANCER, V92, P2493, DOI 10.1002/1097-0142(20011115)92:10<2493::AID-CNCR1599>3.0.CO;2-F; Levin A, 2007, AM J KIDNEY DIS, V49, pS10, DOI 10.1053/j.ajkd.2006.12.004; Mak RH, 2006, NAT CLIN PRACT NEPHR, V2, P527, DOI 10.1038/ncpneph0273; Mitch WE, 1996, NEW ENGL J MED, V335, P1897, DOI 10.1056/NEJM199612193352507; Park J, 2013, NEPHROL DIAL TRANSPL, V28, P2146, DOI 10.1093/ndt/gft213; PRICE SR, 1994, AM J PHYSIOL-CELL PH, V267, pC955, DOI 10.1152/ajpcell.1994.267.4.C955; Roth GA, 2005, EUR J CLIN INVEST, V35, P399, DOI 10.1111/j.1365-2362.2005.01508.x; Shinzato T, 1997, ARTIF ORGANS, V21, P864; Sixt SU, 2008, BBA-MOL BASIS DIS, V1782, P817, DOI 10.1016/j.bbadis.2008.06.005; Stenvinkel P, 1999, KIDNEY INT, V55, P1899, DOI 10.1046/j.1523-1755.1999.00422.x; Tanaka K, 2009, P JPN ACAD B-PHYS, V85, P12, DOI [10.2183/pjab.85.12, 10.2183/pjab/85.12]; WADA M, 1993, J LAB CLIN MED, V121, P215; Yoshida T, 2012, NEPHROL DIAL TRANSPL, V27, P2190, DOI 10.1093/ndt/gfr618; Zoeger A, 2006, CLIN CHEM, V52, P2079, DOI 10.1373/clinchem.2006.072496	33	11	12	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 24	2015	10	3							e0121352	10.1371/journal.pone.0121352	http://dx.doi.org/10.1371/journal.pone.0121352			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CH2XV	25803510	Green Submitted, Green Published, gold			2023-01-03	WOS:000353889600148
J	Lonial, S; Dimopoulos, M; Palumbo, A; White, D; Grosicki, S; Spicka, I; Walter-Croneck, A; Moreau, P; Mateos, MV; Magen, H; Belch, A; Reece, D; Beksac, M; Spencer, A; Oakervee, H; Orlowski, RZ; Taniwaki, M; Rollig, C; Einsele, H; Wu, KL; Singhal, A; San-Miguel, J; Matsumoto, M; Katz, J; Bleickardt, E; Poulart, V; Anderson, KC; Richardson, P				Lonial, Sagar; Dimopoulos, Meletios; Palumbo, Antonio; White, Darrell; Grosicki, Sebastian; Spicka, Ivan; Walter-Croneck, Adam; Moreau, Philippe; Mateos, Maria-Victoria; Magen, Hila; Belch, Andrew; Reece, Donna; Beksac, Meral; Spencer, Andrew; Oakervee, Heather; Orlowski, Robert Z.; Taniwaki, Masafumi; Roellig, Christoph; Einsele, Hermann; Wu, Ka Lung; Singhal, Anil; San-Miguel, Jesus; Matsumoto, Morio; Katz, Jessica; Bleickardt, Eric; Poulart, Valerie; Anderson, Kenneth C.; Richardson, Paul		ELOQUENT-2 Investigators	Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MONOCLONAL-ANTIBODY; SERUM-PROTEIN; DEXAMETHASONE; LENALIDOMIDE; INTERFERENCE; CYTOTOXICITY; CS1	BACKGROUND Elotuzumab, an immunostimulatory monoclonal antibody targeting signaling lymphocytic activation molecule F7 (SLAMF7), showed activity in combination with lenalidomide and dexamethasone in a phase 1b-2 study in patients with relapsed or refractory multiple myeloma. METHODS In this phase 3 study, we randomly assigned patients to receive either elotuzumab plus lenalidomide and dexamethasone (elotuzumab group) or lenalidomide and dexamethasone alone (control group). Coprimary end points were progression-free survival and the overall response rate. Final results for the coprimary end points are reported on the basis of a planned interim analysis of progression-free survival. RESULTS Overall, 321 patients were assigned to the elotuzumab group and 325 to the control group. After a median follow-up of 24.5 months, the rate of progression-free survival at 1 year in the elotuzumab group was 68%, as compared with 57% in the control group; at 2 years, the rates were 41% and 27%, respectively. Median progression-free survival in the elotuzumab group was 19.4 months, versus 14.9 months in the control group (hazard ratio for progression or death in the elotuzumab group, 0.70; 95% confidence interval, 0.57 to 0.85; P<0.001). The overall response rate in the elotuzumab group was 79%, versus 66% in the control group (P<0.001). Common grade 3 or 4 adverse events in the two groups were lymphocytopenia, neutropenia, fatigue, and pneumonia. Infusion reactions occurred in 33 patients (10%) in the elotuzumab group and were grade 1 or 2 in 29 patients. CONCLUSIONS Patients with relapsed or refractory multiple myeloma who received a combination of elotuzumab, lenalidomide, and dexamethasone had a significant relative reduction of 30% in the risk of disease progression or death. (Funded by Bristol-Myers Squibb and AbbVie Biotherapeutics; ELOQUENT-2 ClinicalTrials.gov number, NCT01239797.)	[Lonial, Sagar] Emory Univ, Sch Med, Winship Canc Inst, Atlanta, GA 30322 USA; [Dimopoulos, Meletios] Natl & Kapodistrian Univ Athens, Athens, Greece; [Palumbo, Antonio] AOU San Giovanni Battista Torino Osped Molinette, Turin, Italy; [White, Darrell] QEII Hlth Sci Ctr, Halifax, NS, Canada; [White, Darrell] Dalhousie Univ, Halifax, NS, Canada; [Belch, Andrew] Cross Canc Inst, Edmonton, AB T6G 1Z2, Canada; [Belch, Andrew] Univ Alberta, Edmonton, AB, Canada; [Reece, Donna] Princess Margaret Canc Ctr, Toronto, ON, Canada; [Grosicki, Sebastian] Silesian Med Univ, Katowice, Poland; [Walter-Croneck, Adam] Med Univ Lublin, Lublin, Poland; [Spicka, Ivan] Charles Univ Hosp, Prague, Czech Republic; [Moreau, Philippe] Univ Hosp, Nantes, France; [Mateos, Maria-Victoria] Complejo Asistencial Univ Salamanca, Inst Invest Biomed Salamanca, Salamanca, Spain; [San-Miguel, Jesus] Univ Navarra Clin, Ctr Invest Med Aplicada, Inst Invest Sanitaria Navarra, Pamplona, Spain; [Magen, Hila] Rabin Med Ctr, Davidoff Canc Ctr, Petah Tiqwa, Israel; [Magen, Hila] Tel Aviv Univ, Ramat Aviv, Israel; [Beksac, Meral] Ankara Univ, TR-06100 Ankara, Turkey; [Spencer, Andrew] Monash Univ, Alfred Health, Melbourne, Vic 3004, Australia; [Oakervee, Heather] Barts & London NHS Trust, London, England; [Orlowski, Robert Z.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA; [Taniwaki, Masafumi] Kyoto Prefectural Univ Med, Kyoto, Japan; [Matsumoto, Morio] Nishigunma Natl Hosp, Shibukawa, Japan; [Roellig, Christoph] Tech Univ Dresden, Univ Klinikum, D-01062 Dresden, Germany; [Einsele, Hermann] Univ Klinikum Wurzburg, Wurzburg, Germany; [Wu, Ka Lung] Zeikenhuis Netwerk Antwerpen, Antwerp, Belgium; [Singhal, Anil] AbbVie Biotherapeut, Redwood City, CA USA; [Katz, Jessica] Bristol Myers Squibb Co, Princeton, NJ USA; [Anderson, Kenneth C.; Richardson, Paul] Dana Farber Canc Inst, Boston, MA 02115 USA	Emory University; National & Kapodistrian University of Athens; A.O.U. Citta della Salute e della Scienza di Torino; AOU San Giovanni Battista-Molinette; Queen Elizabeth II Health Sciences Centre; Dalhousie University; University of Alberta; University of Alberta; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; Medical University Silesia; Medical University of Lublin; Charles University Prague; General University Hospital Prague; Nantes Universite; CHU de Nantes; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC-USAL - Instituto de Biologia Molecular y Celular del Cancer de Salamanca (IBMCC); University of Navarra; Rabin Medical Center; Tel Aviv University; Ankara University; Monash University; Barts Health NHS Trust; University of Texas System; UTMD Anderson Cancer Center; Kyoto Prefectural University of Medicine; Technische Universitat Dresden; University of Wurzburg; AbbVie; Bristol-Myers Squibb; Harvard University; Dana-Farber Cancer Institute	Lonial, S (corresponding author), Emory Univ, Sch Med, Dept Hematol & Med Oncol, Winship Canc Inst, Atlanta, GA 30322 USA.	sloni01@emory.edu	San-Miguel, Jesús F./V-8977-2018; Grosicki, Sebastian/AAG-2917-2019; Dimopoulos, Meletios Athanasios/AAD-4130-2019	San-Miguel, Jesús F./0000-0002-9183-4857; Walter-Croneck, Adam/0000-0003-0908-0396; moreau, philippe/0000-0003-1780-8746; Dimopoulos, Meletios/0000-0001-8990-3254; Spicka, Ivan/0000-0002-5451-5283; Orlowski, Robert/0000-0002-5723-4129; Grosicki, Sebastian/0000-0003-2644-1050	Bristol-Myers Squibb; AbbVie Biotherapeutics; NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER	Bristol-Myers Squibb(Bristol-Myers Squibb); AbbVie Biotherapeutics(AbbVie); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Funded by Bristol-Myers Squibb and AbbVie Biotherapeutics; ELOQUENT-2 ClinicalTrials.gov number, NCT01239797.	[Anonymous], 2013, PLOS ONE, V8; Axel AE, 2014, CANCER RES, V74, DOI 10.1158/1538-7445.AM2014-2563; Cannons JL, 2011, ANNU REV IMMUNOL, V29, P665, DOI 10.1146/annurev-immunol-030409-101302; Collins SM, 2013, CANCER IMMUNOL IMMUN, V62, P1841, DOI 10.1007/s00262-013-1493-8; Dimopoulos MA, 2009, LEUKEMIA, V23, P2147, DOI 10.1038/leu.2009.147; Genzen JR, 2011, BRIT J HAEMATOL, V155, P123, DOI 10.1111/j.1365-2141.2011.08644.x; Guo HJ, 2015, MOL CELL BIOL, V35, P41, DOI 10.1128/MCB.01107-14; Hsi ED, 2008, CLIN CANCER RES, V14, P2775, DOI 10.1158/1078-0432.CCR-07-4246; McCudden CR, 2010, CLIN CHEM, V56, P1897, DOI 10.1373/clinchem.2010.152116; National Comprehensive Cancer Network (NCCN), 2015, NCCN CLIN PRACT GUID; Perez-Quintero LA, 2014, J EXP MED, V211, P727, DOI 10.1084/jem.20132038; Richardson P, 2014, BLOOD, V124, P302; Siegel RL, 2015, CA-CANCER J CLIN, V65, P5, DOI 10.3322/caac.21254; Stewart AK, 2015, NEW ENGL J MED, V372, P142, DOI 10.1056/NEJMoa1411321; Tai YT, 2008, BLOOD, V112, P1329, DOI 10.1182/blood-2007-08-107292	15	930	953	3	70	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 13	2015	373	7					621	631		10.1056/NEJMoa1505654	http://dx.doi.org/10.1056/NEJMoa1505654			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CP2LE	26035255	Green Published			2023-01-03	WOS:000359707700007
J	Kang, S				Kang, Sokbom			Neoadjuvant chemotherapy for ovarian cancer: do we have enough evidence?	LANCET			English	Editorial Material									Natl Canc Ctr, Goyang 411769, South Korea	National Cancer Center - Korea (NCC)	Kang, S (corresponding author), Natl Canc Ctr, Goyang 411769, South Korea.	sokbom@gmail.com		Kang, Sokbom/0000-0002-8428-9555				Chi DS, 2011, J CLIN ONCOL, V29, P4073, DOI 10.1200/JCO.2011.35.9935; Kang S, 2011, ANN SURG ONCOL, V18, P3824, DOI 10.1245/s10434-011-1830-0; Kehoe S, 2015, LANCET; ONDA T, 2014, J CLIN ONCOL S, V32; Vergote I, 2010, NEW ENGL J MED, V363, P943, DOI 10.1056/NEJMoa0908806	5	21	21	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 18	2015	386	9990					223	224		10.1016/S0140-6736(14)62259-5	http://dx.doi.org/10.1016/S0140-6736(14)62259-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CN1XI	26002110				2023-01-03	WOS:000358213700006
J	Burke, A; Nahin, RL; Stussman, BJ				Burke, Adam; Nahin, Richard L.; Stussman, Barbara J.			Limited Health Knowledge as a Reason for Non-Use of Four Common Complementary Health Practices	PLOS ONE			English	Article							LOW-BACK-PAIN; UNITED-STATES; ALTERNATIVE MEDICINE; CHRONIC DISEASE; LITERACY; ASSOCIATION; INCOME; ADULTS; INTERVENTIONS; EPIDEMIOLOGY	Background Complementary health practices are an important element of health/healthcare seeking behavior among adults in the United States. Reasons for use include medical need, prevention and wellness promotion, and cultural relevance. Survey studies published over the past several decades have provided important information on the use of complementary health practices, such as acupuncture and yoga. A review of the literature, however, reveals an absence of studies looking specifically at who does not use these approaches, and why not. Methods To explore this issue two samples were created using data from the 2007 National Health Interview Survey Complementary and Alternative Medicine supplement. Of particular interest was the relationship between lack of health knowledge, as a reason for non-use, and key independent variables. The first sample was comprised of individuals who had never used any of four common complementary health practices - acupuncture, chiropractic, natural products, and yoga. The second was a subset of those same non-users who had also reported low back pain, the most frequently cited health concern related to use of complementary therapies. Results A hypothesized association between lack of health knowledge, lower educational attainment, and other key socioeconomic indicators was supported in the findings. Although it was hypothesized that low back pain would be associated with greater information seeking, regardless of level of education, that hypothesis was not supported. Conclusion Lack of knowledge was found to affect utilization of common complementary health practices, regardless of the potentially motivating presence of back pain. Disparities in the utilization of complementary medicine, related to educational attainment and other socioeconomic factors, may negatively affect quality of care for many Americans. Creative approaches are needed to help reduce inequities in understanding and improve access to care for underserved populations.	[Burke, Adam] San Francisco State Univ, Inst Holist Hlth Studies, Dept Hlth Educ, San Francisco, CA 94132 USA; [Nahin, Richard L.; Stussman, Barbara J.] NIH, Natl Ctr Complementary & Integrat Hlth, Bethesda, MD USA	California State University System; San Francisco State University; National Institutes of Health (NIH) - USA	Burke, A (corresponding author), San Francisco State Univ, Inst Holist Hlth Studies, Dept Hlth Educ, San Francisco, CA 94132 USA.	aburke@sfsu.edu						ANDERSEN R, 1973, MILBANK FUND Q, V51, P95, DOI 10.2307/3349613; [Anonymous], 2014, CHIR SERV; Bains SS, 2011, BMC COMPLEM ALTERN M, V11, DOI 10.1186/1472-6882-11-138; Baker DW, 2006, J GEN INTERN MED, V21, P878, DOI 10.1111/j.1525-1497.2006.00540.x; Barnes Patricia M, 2004, Adv Data, P1; Barnes Patricia M, 2008, Natl Health Stat Report, P1; Benjamin-Garner Ruby, 2002, Ethnicity and Disease, V12, P124; Berkman ND, 2011, ANN INTERN MED, V155, P97, DOI 10.7326/0003-4819-155-2-201107190-00005; Burke A, 2012, ENCY LIFESTYLE MED H, P706; Chou R, 2007, ANN INTERN MED, V147, P478, DOI 10.7326/0003-4819-147-7-200710020-00006; Cui Y, 2012, J ALTERN COMPLEM MED, V18, P844, DOI 10.1089/acm.2011.0363; Daley A, 2006, CLIMACTERIC, V9, P336, DOI 10.1080/13697130600864074; Deyo RA, 2015, PHYS THER, V95, P159, DOI 10.2522/ptj.2015.95.2.e1; Druss BG, 1999, JAMA-J AM MED ASSOC, V282, P651, DOI 10.1001/jama.282.7.651; Dunn K M, 2004, Eura Medicophys, V40, P9; Garcia Tamyra Carroll, 2010, NCHS Data Brief, P1; Gardiner P, 2013, J HEALTH COMMUN, V18, P290, DOI 10.1080/10810730.2013.830663; Gazmararian JA, 2003, PATIENT EDUC COUNS, V51, P267, DOI 10.1016/S0738-3991(02)00239-2; Goff DC, 1998, ARCH INTERN MED, V158, P2329, DOI 10.1001/archinte.158.21.2329; Gray Carolyn M, 2002, Eff Clin Pract, V5, P17; Homayoon B, 2013, AM J CLIN ONCOL-CANC, V36, P167, DOI 10.1097/COC.0b013e3182439068; Hoy D, 2010, BEST PRACT RES CL RH, V24, P769, DOI 10.1016/j.berh.2010.10.002; Kutner M, 2006, 2006483 NCES; Long SK, 2009, EMERGENCY DEP VISITS; Macabasco-O'Connell A, 2011, J GEN INTERN MED, V26, P979, DOI 10.1007/s11606-011-1668-y; Manchikanti L, 2009, PAIN PHYSICIAN, V12, P35; Marmot M, 2002, HEALTH AFFAIR, V21, P31, DOI 10.1377/hlthaff.21.2.31; Martin LT, 2009, J GEN INTERN MED, V24, P1211, DOI 10.1007/s11606-009-1105-7; McIntosh Aileen, 2003, Health Expect, V6, P19, DOI 10.1046/j.1369-6513.2003.00197.x; Mosher HJ, 2012, J HEALTH COMMUN, V17, P241, DOI 10.1080/10810730.2012.712611; Muir KW, 2012, PATIENT EDUC COUNS, V87, P160, DOI 10.1016/j.pec.2011.09.009; Muller A, 2002, BRIT MED J, V324, P23, DOI 10.1136/bmj.324.7328.23; Nahin RL, 2007, BMC PUBLIC HEALTH, V7, DOI 10.1186/1471-2458-7-217; Nahin RL, 2010, BMC HEALTH SERV RES, V10, DOI 10.1186/1472-6963-10-220; National Center for Health Statistics, 2012, HLTH US 2011 SPEC FE; Ni HY, 2002, MED CARE, V40, P353, DOI 10.1097/00005650-200204000-00011; Nielsen-Bohlman L., 2004, HLTH LITERACY PRESCR; Rahman M, 2012, J AM COLL NUTR, V31, P397, DOI 10.1080/07315724.2012.10720465; Research Triangle Institute, 2009, SUDAAN REL 10 0 1; Robinson AR, 2002, PREV MED, V34, P51, DOI 10.1006/pmed.2001.0950; Rogers RG, 2013, POPUL RES POLICY REV, V32, P325, DOI 10.1007/s11113-013-9268-7; Saper RB, 2004, ALTERN THER HEALTH M, V10, P44; SAS Institute, 2008, SAS REL 10 0 1; Savoia E, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-328; Saydah SH, 2006, J ALTERN COMPLEM MED, V12, P805, DOI 10.1089/acm.2006.12.805; Schillinger D, 2002, JAMA-J AM MED ASSOC, V288, P475, DOI 10.1001/jama.288.4.475; Schoenborn Charlotte A, 2010, Vital Health Stat 10, P1; Sheridan SL, 2011, J HEALTH COMMUN, V16, P30, DOI 10.1080/10810730.2011.604391; Tindle HA, 2005, ALTERN THER HEALTH M, V11, P42; Viswanath K, 2006, EXAMINING HLTH DISPA, P215; Weiss B, 2007, HLTH LIT PATIENT SAF; Williams MV, 1998, ARCH INTERN MED, V158, P166, DOI 10.1001/archinte.158.2.166; Wolf MS, 2005, ARCH INTERN MED, V165, P1946, DOI 10.1001/archinte.165.17.1946; Zhang Y, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/710750	54	17	17	0	21	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 17	2015	10	6							e0129336	10.1371/journal.pone.0129336	http://dx.doi.org/10.1371/journal.pone.0129336			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	CK9NS	26083564	Green Submitted, Green Published, gold			2023-01-03	WOS:000356567400088
J	Briesacher, BA; Madden, JM; Zhang, F; Fouayzi, H; Ross-Degnan, D; Gurwitz, JH; Soumerai, SB				Briesacher, Becky A.; Madden, Jeanne M.; Zhang, Fang; Fouayzi, Hassan; Ross-Degnan, Dennis; Gurwitz, Jerry H.; Soumerai, Stephen B.			Did Medicare Part D Affect National Trends in Health Outcomes or Hospitalizations? A Time-Series Analysis	ANNALS OF INTERNAL MEDICINE			English	Article							DRUG-USE; IMPLEMENTATION; NONADHERENCE	Background: Medicare Part D increased economic access to medications, but its effect on population-level health outcomes and use of other medical services remains unclear. Objective: To examine changes in health outcomes and medical services in the Medicare population after implementation of Part D. Design: Population-level longitudinal time-series analysis with generalized linear models. Setting: Community. Patients: Nationally representative sample of Medicare beneficiaries (n = 56 293 [unweighted and unique]) from 2000 to 2010. Measurements: Changes in self-reported health status, limitations in activities of daily living (ADLs) (ADLs and instrumental ADLs), emergency department visits and hospital admissions (prevalence, counts, and spending), and mortality. Medicare claims data were used for confirmatory analyses. Results: Five years after Part D implementation, no clinically or statistically significant reductions in the prevalence of fair or poor health status or limitations in ADLs or instrumental ADLs, relative to historical trends, were detected. Compared with trends before Part D, no changes in emergency department visits, hospital admissions or days, inpatient costs, or mortality after Part D were seen. Confirmatory analyses were consistent. Limitations: Only total population-level outcomes were studied. Self-reported measures may lack sensitivity. Conclusion: Five years after implementation, and contrary to previous reports, no evidence was found of Part D's effect on a range of population-level health indicators among Medicare enrollees. Further, there was no clear evidence of gains in medical care efficiencies.	[Briesacher, Becky A.] Northeastern Univ, Sch Pharm, Boston, MA 02115 USA; [Madden, Jeanne M.; Zhang, Fang; Ross-Degnan, Dennis; Soumerai, Stephen B.] Harvard Univ, Sch Med, Dept Populat Med, Boston, MA 02215 USA; [Madden, Jeanne M.; Zhang, Fang; Ross-Degnan, Dennis; Soumerai, Stephen B.] Harvard Pilgrim Hlth Care Inst, Boston, MA 02215 USA; [Fouayzi, Hassan; Gurwitz, Jerry H.] Univ Massachusetts, Sch Med, Dept Med, Div Geriatr Med, Worcester, MA 01605 USA	Northeastern University; Harvard University; Harvard Medical School; Harvard Pilgrim Health Care; University of Massachusetts System; University of Massachusetts Worcester	Briesacher, BA (corresponding author), Northeastern Univ, Sch Pharm, 360 Huntington Ave,R218 TF, Boston, MA 02115 USA.	b.briesacher@neu.edu	Zhang, Fang/HHN-2153-2022; Fouayzi, Hassan/AHD-0143-2022		National Institute on Aging (NIA) [R01AG028745, R01AG022362]; NIA [K01AG031836]; Agency for Healthcare Research and Quality [R01AG032249, R01HS018577]; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R01HS018577] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG028745, R01AG022362, R01AG032249, K01AG031836] Funding Source: NIH RePORTER	National Institute on Aging (NIA)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); Agency for Healthcare Research and Quality(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	By the National Institute on Aging (NIA) (grants R01AG028745 and R01AG022362; Dr. Soumerai [principal investigator]), a Research Scientist Award from the NIA (K01AG031836; Dr. Briesacher), and related support from the NIA and Agency for Healthcare Research and Quality (grants R01AG032249 and R01HS018577, respectively; Drs. Madden, Zhang, Ross-Degnan, and Soumerai).	Adler G S, 1994, Health Care Financ Rev, V15, P153; Afendulis CC, 2011, HEALTH SERV RES, V46, P1022, DOI 10.1111/j.1475-6773.2011.01244.x; [Anonymous], 2014, HLTH CAR SPEND MED P; [Anonymous], 2010, 2010 COST US COD; Briesacher BA, 2011, MED CARE, V49, P834, DOI 10.1097/MLR.0b013e3182162afb; DeSalvo KB, 2005, HEALTH SERV RES, V40, P1234, DOI 10.1111/j.1475-6773.2005.00404.x; Ingber MJ, 2011, MEDICARE D; KATZ S, 1983, J AM GERIATR SOC, V31, P721, DOI 10.1111/j.1532-5415.1983.tb03391.x; Madden JM, 2008, JAMA-J AM MED ASSOC, V299, P1922, DOI 10.1001/jama.299.16.1922; Madden JM, 2009, JAMA-J AM MED ASSOC, V302, P1755, DOI 10.1001/jama.2009.1516; Majumdar SR, 2009, HEALTH AFFAIR, V28, pW900, DOI 10.1377/hlthaff.28.5.w900; McWilliams JM, 2011, JAMA-J AM MED ASSOC, V306, P402, DOI 10.1001/jama.2011.1026; Polinski JM, 2010, J AM GERIATR SOC, V58, P1764, DOI 10.1111/j.1532-5415.2010.03025.x; Sarndal C. E., 2003, MODEL ASSISTED SURVE; Shadish C., 2002, EXPT QUASIEXPERIMENT; *US BUR LAB STAT, 2007, CONS EXP 2005; US Congressional Budget Office, 2012, OFFS EFF PRESCR DRUG; Zhang Y, 2009, NEW ENGL J MED, V361, P52, DOI 10.1056/NEJMsa0807998	18	6	6	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 16	2015	162	12					825	+		10.7326/M14-0726	http://dx.doi.org/10.7326/M14-0726			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	CK8VC	26075753	Green Accepted			2023-01-03	WOS:000356516300017
J	Ringh, M; Rosenqvist, M; Hollenberg, J; Jonsson, M; Fredman, D; Nordberg, P; Jarnbert-Pettersson, H; Hasselqvist-Ax, I; Riva, G; Svensson, L				Ringh, Mattias; Rosenqvist, Marten; Hollenberg, Jacob; Jonsson, Martin; Fredman, David; Nordberg, Per; Jarnbert-Pettersson, Hans; Hasselqvist-Ax, Ingela; Riva, Gabriel; Svensson, Leif			Mobile-Phone Dispatch of Laypersons for CPR in Out-of-Hospital Cardiac Arrest	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CARDIOPULMONARY-RESUSCITATION; SURVIVAL; DEFIBRILLATION; SYSTEM; SCALE	BACKGROUND Cardiopulmonary resuscitation (CPR) performed by bystanders is associated with increased survival rates among persons with out-of-hospital cardiac arrest. We investigated whether rates of bystander-initiated CPR could be increased with the use of a mobile-phone positioning system that could instantly locate mobile-phone users and dispatch lay volunteers who were trained in CPR to a patient nearby with out-of-hospital cardiac arrest. METHODS We conducted a blinded, randomized, controlled trial in Stockholm from April 2012 through December 2013. A mobile-phone positioning system that was activated when ambulance, fire, and police services were dispatched was used to locate trained volunteers who were within 500 m of patients with out-of-hospital cardiac arrest; volunteers were then dispatched to the patients (the intervention group) or not dispatched to them (the control group). The primary outcome was bystander-initiated CPR before the arrival of ambulance, fire, and police services. RESULTS A total of 5989 lay volunteers who were trained in CPR were recruited initially, and overall 9828 were recruited during the study. The mobile-phone positioning system was activated in 667 out-of-hospital cardiac arrests: 46% (306 patients) in the intervention group and 54% (361 patients) in the control group. The rate of bystander-initiated CPR was 62% (188 of 305 patients) in the intervention group and 48% (172 of 360 patients) in the control group (absolute difference for intervention vs. control, 14 percentage points; 95% confidence interval, 6 to 21; P< 0.001). CONCLUSIONS A mobile-phone positioning system to dispatch lay volunteers who were trained in CPR was associated with significantly increased rates of bystander-initiated CPR among persons with out-of-hospital cardiac arrest.	[Ringh, Mattias; Hollenberg, Jacob; Jonsson, Martin; Fredman, David; Nordberg, Per; Hasselqvist-Ax, Ingela; Riva, Gabriel; Svensson, Leif] Karolinska Inst, Ctr Resuscitat Sci, Dept Med, Solna, Sweden; [Rosenqvist, Marten] Karolinska Inst, Danderyd Univ Hosp, Dept Clin Sci, Danderyd, Sweden; [Jarnbert-Pettersson, Hans] Soder Sjukhuset, Karolinska Inst, Dept Clin Sci & Educ, S-10064 Stockholm, Sweden	Karolinska Institutet; Danderyds Hospital; Karolinska Institutet; Karolinska Institutet; Sodersjukhuset Hospital	Svensson, L (corresponding author), Soder Sjukhuset, Ctr Resuscitat Sci, Sjukhusbacken 10, S-11883 Stockholm, Sweden.	leif.svensson@ki.se	Jonsson, Martin/AEF-9167-2022; Fredman, David/C-6139-2015	Riva, Gabriel/0000-0003-3038-0027; Jonsson, Martin/0000-0002-3539-8317; Fredman, David/0000-0002-4138-6515	Swedish Heart-Lung Foundation; Stockholm County	Swedish Heart-Lung Foundation(Swedish Heart-Lung Foundation); Stockholm County(Stockholm County Council)	Funded by the Swedish Heart-Lung Foundation and Stockholm County; ClinicalTrials.gov number, NCT01789554.	[Anonymous], BEF BEF; Bradley SM, 2011, CURR OPIN CRIT CARE, V17, P219, DOI 10.1097/MCC.0b013e32834697d8; Chen MY, 2006, LECT NOTES COMPUT SC, V4206, P225; Dorph E, 2003, RESUSCITATION, V56, P265, DOI 10.1016/S0300-9572(02)00374-X; Drane C, 1998, IEEE COMMUN MAG, V36, P46, DOI 10.1109/35.667413; Folke F, 2010, CIRCULATION, V122, P623, DOI 10.1161/CIRCULATIONAHA.109.924423; Groeneveld PW, 2005, AM J MED, V118, P58, DOI 10.1016/j.amjmed.2004.08.014; Hasselqvist-Ax I, 2015, NEW ENGL J MED, V372, P2307, DOI 10.1056/NEJMoa1405796; Holmberg M, 1998, RESUSCITATION, V36, P29, DOI 10.1016/S0300-9572(97)00089-0; Isbye DL, 2007, CIRCULATION, V116, P1380, DOI 10.1161/CIRCULATIONAHA.107.710616; Iwami T, 2006, RESUSCITATION, V69, P221, DOI 10.1016/j.resuscitation.2005.08.018; Kuth DE, 1981, ART COMPUTER PROGRAM, V2; Merchant RM, 2013, CIRC-CARDIOVASC QUAL, V6, P229, DOI 10.1161/CIRCOUTCOMES.113.000140; Newcombe RG, 1998, STAT MED, V17, P2635, DOI 10.1002/(SICI)1097-0258(19981130)17:22<2635::AID-SIM954>3.0.CO;2-C; Nordberg P, 2014, EUR HEART J-ACUTE CA, V3, P293, DOI 10.1177/2048872614532415; Rea TD, 2003, CIRCULATION, V107, P2780, DOI 10.1161/01.CIR.0000070950.17208.2A; Ringh M, 2011, RESUSCITATION, V82, P1514, DOI 10.1016/j.resuscitation.2011.07.033; Sasson C, 2010, CIRC-CARDIOVASC QUAL, V3, P63, DOI 10.1161/CIRCOUTCOMES.109.889576; Valenzuela TD, 1997, CIRCULATION, V96, P3308; Waalewijn RA, 2001, RESUSCITATION, V50, P273, DOI 10.1016/S0300-9572(01)00354-9; Wissenberg M, 2013, JAMA-J AM MED ASSOC, V310, P1377, DOI 10.1001/jama.2013.278483; Yonekawa C, 2014, J TELEMED TELECARE, V20, P75, DOI 10.1177/1357633X14524152; Zijlstra JA, 2014, RESUSCITATION, V85, P1444, DOI 10.1016/j.resuscitation.2014.07.020	23	301	316	2	29	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 11	2015	372	24					2316	2325		10.1056/NEJMoa1406038	http://dx.doi.org/10.1056/NEJMoa1406038			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CK2DB	26061836				2023-01-03	WOS:000356019200007
J	Gussgard, AM; Jokstad, A; Wood, R; Hope, AJ; Tenenbaum, H				Gussgard, Anne Margrete; Jokstad, Asbjorn; Wood, Robert; Hope, Andrew J.; Tenenbaum, Howard			Symptoms Reported by Head and Neck Cancer Patients during Radiotherapy and Association with Mucosal Ulceration Site and Size: An Observational Study	PLOS ONE			English	Article							ORAL MUCOSITIS; OROFACIAL PAIN; MODULATED RADIOTHERAPY; SCORING SYSTEM; PREVALENCE; CHEMOTHERAPY; VALIDATION; MANAGEMENT; RADIATION; SEVERITY	Background Self-reported pain and impairment of oral functions varies markedly and often in spite of extensive oral mucositis (OM). The aim of the current study was to appraise how patient-reported debilitation caused by OM is influenced by the extent and possibly location of the OM lesions. Methods Patients with head and neck cancer undergoing radiotherapy were examined before treatment, twice weekly during 6-7 weeks of therapy, and 3-4 weeks after therapy completion. OM signs of 33 participants were evaluated using the Oral Mucositis Assessment Scale (OMAS), while OM symptoms were recorded using Patient-Reported Oral Mucositis Symptom ( PROMS)-questionnaires. Changes in OM experience as a function of OM signs was undertaken by comparing the aggregated and individual PROMS scale values at the point of transition of OMAS ulceration scores between 0 to 1, 1 to 2 and 2 to 3, respectively in the nine intra-oral locations designated in the OMAS. ANOVA with pairwise contrasts using the LSD procedure was applied for comparisons of mean changes of PROMS scale values for the participants who experienced an OMAS score of 2 or more during therapy (n=24). Results Impairment of eating hard foods was more when the OMAS score for ulceration anywhere in the mouth or in the soft palate changed from 1 to 2, compared to between score 0 and 1 (p=.002 and p=.05) or between score 2 and 3 (p=.001 and p=.02). Mouth pain increased more upon transition of OMAS score anywhere in the mouth from 1 to 2 compared to 0 to 1 (p=.05). Conclusion The relationship between patient-reported impairment of oral function and pain caused by OM ulceration is not linear, but rather curvilinear. Our findings should prompt investigators of future interventional trials to consider using a less severe outcome than maximum OM scores as the primary study outcome.	[Gussgard, Anne Margrete; Wood, Robert; Hope, Andrew J.; Tenenbaum, Howard] Princess Margaret Canc Ctr, Toronto, ON, Canada; [Jokstad, Asbjorn; Tenenbaum, Howard] Univ Toronto, Fac Dent, Toronto, ON, Canada; [Tenenbaum, Howard] Mt Sinai Hosp, Dept Dent, Toronto, ON M5G 1X5, Canada; [Tenenbaum, Howard] Tel Aviv Univ, Div Periodontol, IL-69978 Tel Aviv, Israel	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; University of Toronto; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Tel Aviv University	Gussgard, AM (corresponding author), UiT Arctic Univ Norway, Fac Hlth Sci, Tromso, Norway.	anne.m.gussgard@uit.no	Jokstad, Asbjørn/C-8743-2012	Jokstad, Asbjørn/0000-0002-5902-4520; Gussgard, Anne Margrete/0000-0003-0395-1242				Bender JL, 2008, J PAIN SYMPTOM MANAG, V35, P177, DOI 10.1016/j.jpainsymman.2007.03.011; Bennett MI, 2012, PAIN, V153, P359, DOI 10.1016/j.pain.2011.10.028; Benoliel R, 2007, J DENT RES, V86, P491, DOI 10.1177/154405910708600604; Bentzen SA, 2001, RADIOTHER ONCOL, V60, P123, DOI 10.1016/S0167-8140(01)00358-9; Connelly ST, 2004, J PAIN, V5, P505, DOI 10.1016/j.jpain.2004.09.002; Dios PD, 2010, ORAL ONCOL, V46, P448, DOI 10.1016/j.oraloncology.2010.02.017; Elting LS, 2008, CANCER-AM CANCER SOC, V113, P2704, DOI 10.1002/cncr.23898; Elting LS, 2007, INT J RADIAT ONCOL, V68, P1110, DOI 10.1016/j.ijrobp.2007.01.053; Epstein JB, 2007, J DENT RES, V86, P506, DOI 10.1177/154405910708600605; Epstein JB, 2010, SUPPORT CARE CANCER, V18, P1023, DOI 10.1007/s00520-010-0897-7; Frampton CL, 2011, CLIN ONCOL-UK, V23, P381, DOI 10.1016/j.clon.2011.04.008; Gussgard AM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091733; Hebuterne X, 2014, JPEN-PARENTER ENTER, V38, P196, DOI 10.1177/0148607113502674; Jehn CF, 2012, BREAST CANCER RES TR, V136, P789, DOI 10.1007/s10549-012-2311-2; Kawakami-Wong H, 2007, J BIOMED OPT, V12, DOI 10.1117/1.2779025; Knudsen AK, 2011, EUR J PAIN, V15, P320, DOI 10.1016/j.ejpain.2010.08.001; Kushner JA, 2008, J CAN DENT ASSOC, V74, P59; List MA, 2000, J CLIN ONCOL, V18, P877, DOI 10.1200/JCO.2000.18.4.877; Macfarlane TV, 2012, J ORAL MAXILLOFAC RE, V3, pe1, DOI [DOI 10.5037/JOMR.2012.3301, DOI 10.5037/J0MR.2012.3101]; Miaskowski C, 2001, J Natl Cancer Inst Monogr, P37; Moore RA, 2013, ANAESTHESIA, V68, P400, DOI 10.1111/anae.12148; Murphy BA, 2009, J PAIN SYMPTOM MANAG, V38, P522, DOI 10.1016/j.jpainsymman.2008.12.004; Nutting CM, 2011, LANCET ONCOL, V12, P127, DOI 10.1016/S1470-2045(10)70290-4; Palazzi M, 2008, INT J RADIAT ONCOL, V70, P330, DOI 10.1016/j.ijrobp.2007.06.022; Rayment C, 2013, PALLIATIVE MED, V27, P714, DOI 10.1177/0269216312464408; Reich M, 2014, ANN ONCOL, V25, P2115, DOI 10.1093/annonc/mdu105; Reich M, 2014, ANN ONCOL; Sonis ST, 1999, CANCER-AM CANCER SOC, V85, P2103, DOI 10.1002/(SICI)1097-0142(19990515)85:10<2103::AID-CNCR2>3.0.CO;2-0; Urbano TG, 2007, RADIOTHER ONCOL, V85, P36, DOI 10.1016/j.radonc.2007.07.011; Wells NL, 2012, CURR PAIN HEADACHE R, V16, P292, DOI 10.1007/s11916-012-0272-0; Wendt TG, 2006, RADIAT ONCOL, V1, DOI 10.1186/1748-717X-1-18	31	5	6	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 10	2015	10	6							e0129001	10.1371/journal.pone.0129001	http://dx.doi.org/10.1371/journal.pone.0129001			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CK1PO	26060992	gold, Green Published, Green Submitted			2023-01-03	WOS:000355979500114
J	Arora, A; Shafiq, N; Jain, S; Khuller, GK; Sharma, S; Malhotra, S				Arora, Anjuman; Shafiq, Nusrat; Jain, Sanjay; Khuller, G. K.; Sharma, Sadhana; Malhotra, Samir			Development of Sustained Release "NanoFDC (Fixed Dose Combination)" for Hypertension - An Experimental Study	PLOS ONE			English	Article							DRUG-DELIVERY; ARTERIAL-HYPERTENSION; MANAGEMENT; NANOPARTICLES; OPTIMIZATION; THERAPY	Objectives The present study was planned to formulate, characterize and evaluate the pharmacokinetics of a novel "NanoFDC" comprising three commonly prescribed anti-hypertensive drugs, hydrochlorothiazide (a diuretic), candesartan (ARB) and amlodipine (a calcium channel blocker). Basic Methods The candidate drugs were loaded in Poly (DL-lactide-co-gycolide) (PLGA) by emulsion-diffusion-evaporation method. The formulations were evaluated for their size, morphology, drug loading and in vitro release individually. Single dose pharmacokinetic profiles of the nanoformulations alone and in combination, as a NanoFDC, were evaluated in Wistar rats. Results The candidate drugs encapsulated inside PLGA showed entrapment efficiencies ranging from 30%, 33.5% and 32% for hydrochlorothiazide, candesartan and amlodipine respectively. The nanoparticles ranged in size from 110 to 180 nm. In vitro release profile of the nanoformulation showed 100% release by day 6 in the physiological pH 7.4 set up with PBS (phosphate buffer saline) and by day 4-5 in the intestinal pH 1.2 and 8.0 set up SGF (simulated gastric fluid) and SIF (simulated intestinal fluid) respectively. In pharmacokinetic analysis a sustained-release for 6 days and significant increase in the mean residence time (MRT), as compared to the respective free drugs was noted [MRT of amlodipine, hydrochlorothiazide and candesartan changed from 8.9 to 80.59 hours, 11 to 69.20 hours and 9 to 101.49 hours respectively]. Conclusion We have shown for the first time that encapsulating amlodipine, hydrochlorothiazide and candesartan into a single nanoformulation, to get the "NanoFDC (Fixed Dose Combination)" is a feasible strategy which aims to decrease pill burden.	[Arora, Anjuman; Shafiq, Nusrat; Malhotra, Samir] Postgrad Inst Med Educ & Res, Dept Pharmacol, Chandigarh 160012, India; [Jain, Sanjay] Postgrad Inst Med Educ & Res, Dept Internal Med, Chandigarh 160012, India; [Khuller, G. K.; Sharma, Sadhana] Postgrad Inst Med Educ & Res, Dept Biochem, Chandigarh 160012, India	Post Graduate Institute of Medical Education & Research (PGIMER), Chandigarh; Post Graduate Institute of Medical Education & Research (PGIMER), Chandigarh; Post Graduate Institute of Medical Education & Research (PGIMER), Chandigarh	Malhotra, S (corresponding author), Postgrad Inst Med Educ & Res, Dept Pharmacol, Chandigarh 160012, India.	Samirmalhotra345@yahoo.com		Jain, Sanjay K/0000-0002-9241-3114	Department of Science and Technology, new Delhi [SR/FT/LS-047/2008]	Department of Science and Technology, new Delhi(Department of Science & Technology (India))	Funding provided by Department of Science and Technology, new Delhi: SR/FT/LS-047/2008. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 2005, PHARM TOXICOLOGY JUL; Arora A, 2014, CURR NANOSCI, V10, P816, DOI 10.2174/1573413710666140512221814; Baggarly SA, 2014, RES SOC ADMIN PHARM, P1, DOI [10.1016/j.sapharm.2014.04.002, DOI 10.1016/J.SAPHARM.2014.04.002]; Barrios V, 2010, EXPERT REV CARDIOVAS, V8, P1609, DOI [10.1586/erc.10.115, 10.1586/ERC.10.115]; Cao Y, 2011, FUTURE ONCOL, V7, P1347, DOI [10.2217/FON.11.109, 10.2217/fon.11.109]; Chobanian AV, 2003, HYPERTENSION, V42, P1206, DOI 10.1161/01.HYP.0000107251.49515.c2; Dickson M, 2008, AM J CARDIOVASC DRUG, V8, P45, DOI 10.2165/00129784-200808010-00006; Hackam DG, 2010, CAN J CARDIOL, V26, P249, DOI 10.1016/S0828-282X(10)70379-2; He WL, 2007, INT J PHARMACEUT, V334, P173, DOI 10.1016/j.ijpharm.2006.10.025; Heng D, 2008, PHARM RES-DORDR, V25, P1696, DOI 10.1007/s11095-008-9560-0; Italia JL, 2007, J CONTROL RELEASE, V119, P197, DOI 10.1016/j.jconrel.2007.02.004; Jain R, 1998, DRUG DEV IND PHARM, V24, P703, DOI 10.3109/03639049809082719; Jain RA, 2000, BIOMATERIALS, V21, P2475, DOI 10.1016/S0142-9612(00)00115-0; JAMES PA, 2014, JAMA-J AM MED ASSOC, V311, P507, DOI DOI 10.1001/JAMA.2013.284427; Khan MU, 2014, J PHARM BIOALLIED SC, V6, P104, DOI 10.4103/0975-7406.129175; Kumar G, 2012, J PHARM SCI-US, V101, P2165, DOI 10.1002/jps.23087; Kumar G, 2011, DRUG DELIV, V18, P65, DOI 10.3109/10717544.2010.509367; Mancia G, 2007, J HYPERTENS, V25, P1751, DOI 10.1097/HJH.0b013e3282f0580f; Martin J., 2008, JLGH, V3, P91; Okuda T., 2012, J BIOMATER NANOBIOTE, V3, P50; Pandey Rajesh, 2006, Indian Journal of Experimental Biology, V44, P459; Rojas J, 1999, INT J PHARM, V183, P67, DOI 10.1016/S0378-5173(99)00046-0; Sanz G, 2009, NAT CLIN PRACT CARD, V6, P101, DOI 10.1038/ncpcardio1419; Stevanovic M, 2009, CURR NANOSCI, V5, P1, DOI 10.2174/157341309787314566; Thrall G, 2004, J HUM HYPERTENS, V18, P595, DOI 10.1038/sj.jhh.1001722; Tocci G, 2011, HIGH BLOOD PRESS CAR, V18, P3, DOI 10.2165/1159615-s0-000000000-00000; Ullavapally KR, 2011, J PHARM RES, V4, P894; van Galen KA, 2014, AIDS RES TREAT, V2014, DOI 10.1155/2014/967073; Wald NJ, 2003, BMJ-BRIT MED J, V326, P1419, DOI 10.1136/bmj.326.7404.1419; Wald NJ, 2004, UK patent GB, Patent No. 2361186; Xinhuan W, 2014, ASIAN J PHARM SCI, V9, P1, DOI 10.1016/j.ajps.2013.12.005	31	15	15	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 5	2015	10	6							e0128208	10.1371/journal.pone.0128208	http://dx.doi.org/10.1371/journal.pone.0128208			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CJ7CR	26047011	gold, Green Published, Green Submitted			2023-01-03	WOS:000355652200048
J	Hao, J; Zhang, YY; Wang, XR; Yan, H; Liu, EW; Gao, XM				Hao, Jia; Zhang, Yingyue; Wang, Xingrui; Yan, Huo; Liu, Erwei; Gao, Xiumei			Interaction between the Natural Components in Danhong Injection (DHI) with Serum Albumin (SA) and the Influence of the Coexisting Multi-Components on the SaB-BSA Binding System: Fluorescence and Molecular Docking Studies	PLOS ONE			English	Article							SPECTROSCOPIC ANALYSIS; BOVINE; CONSTITUENTS; PROTEINS; HEMOGLOBIN; SIMULATION; QUALITY; DRUGS; ACID	Danhong injection (DHI) is a widely used Chinese Materia Medica standardized product for the clinical treatment of ischemic encephalopathy and coronary heart disease. The bindings of eight natural components in DHI between bovine serum albumin (BSA) were studied by fluorescence spectroscopy technology and molecular docking. According to the results, the quenching process of salvianolic acid B and hydroxysafflor yellow A was a static quenching procedure through the analysis of quenching data by the Stern-Volmer equation, the modified Stern-Volmer equation, and the modified Scatchard equation. Meanwhile, syringin (Syr) enhanced the fluorescence of BSA, and the data were analyzed using the Lineweaver-Burk equation. Molecular docking suggested that all of these natural components bind to serum albumin at the site I location. Further competitive experiments of SaB confirmed the result of molecular docking studies duo to the displacement of warfarin by SaB. Base on these studies, we selected SaB as a research target because it presented the strongest binding ability to BSA and investigated the influence of the multi-components coexisting in DHI on the interaction between the components of the SaB-BSA binding system. The participation of these natural components in DHI affected the interaction between the components of the SaB-BSA system. Therefore, when DHI is used in mammals, SaB is released from serum albumin more quickly than it is used alone. This work would provide a new experiment basis for revealing the scientific principle of compatibility for Traditional Chinese Medicine.	[Hao, Jia; Zhang, Yingyue; Gao, Xiumei] Tianjin Univ Tradit Chinese Med, Tianjin State Key Lab Modern Chinese Med, Tianjin 300193, Peoples R China; [Hao, Jia; Wang, Xingrui; Yan, Huo; Liu, Erwei] Tianjin Univ Tradit Chinese Med, Tianjin Key Lab Phytochem & Pharmaceut Anal, Tianjin 300193, Peoples R China	Tianjin University of Traditional Chinese Medicine; Tianjin University of Traditional Chinese Medicine	Liu, EW (corresponding author), Tianjin Univ Tradit Chinese Med, Tianjin Key Lab Phytochem & Pharmaceut Anal, Tianjin 300193, Peoples R China.	hastjtcm@126.com			National Key Basic Research Program of China (973 Program); Important Drug Development of MOST, China [2012ZX09304007]; Natural Science Foundation of China [NSFC81125024]; National program for Innovative Research Team in Universities of Tianjin	National Key Basic Research Program of China (973 Program)(National Basic Research Program of China); Important Drug Development of MOST, China; Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National program for Innovative Research Team in Universities of Tianjin	The authors acknowledge the support of National Key Basic Research Program of China (973 Program), the Important Drug Development of MOST, China (2012ZX09304007), the Natural Science Foundation of China (NSFC81125024), and the National program for Innovative Research Team in Universities of Tianjin.	Agudelo D, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043814; Bardhan M, 2012, J PHOTOCH PHOTOBIO B, V106, P113, DOI 10.1016/j.jphotobiol.2011.10.014; BHATTACHARYYA J, 1994, BIOCHEM PHARMACOL, V47, P2049, DOI 10.1016/0006-2952(94)90080-9; Chang YX, 2008, J CHROMATOGR A, V1208, P76, DOI 10.1016/j.chroma.2008.08.054; Chang YX, 2009, CHROMATOGRAPHIA, V69, P319, DOI 10.1365/s10337-008-0876-z; Charbonneau DM, 2010, J PHYS CHEM B, V114, P1148, DOI 10.1021/jp910077h; Chatterjee T, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037468; Chen TT, 2011, SPECTROCHIM ACTA A, V81, P645, DOI 10.1016/j.saa.2011.06.068; Duman O, 2013, J FLUORESC, V23, P659, DOI 10.1007/s10895-013-1177-y; Fan L, 2009, J CHROMATOGR A, V1216, P2063, DOI 10.1016/j.chroma.2008.03.046; Fani N, 2013, SPECTROCHIM ACTA A, V103, P11, DOI 10.1016/j.saa.2012.11.003; Gao WH, 2010, J MOL STRUCT, V983, P133, DOI 10.1016/j.molstruc.2010.08.042; Ge YS, 2014, SPECTROCHIM ACTA A, V124, P265, DOI 10.1016/j.saa.2014.01.009; Ghuman J, 2005, J MOL BIOL, V353, P38, DOI 10.1016/j.jmb.2005.07.075; Gupta BS, 2013, PROCESS BIOCHEM, V48, P1686, DOI 10.1016/j.procbio.2013.08.018; HE XM, 1992, NATURE, V358, P209, DOI 10.1038/358209a0; He Y, 2008, J FLUORESC, V18, P433, DOI 10.1007/s10895-007-0283-0; He Y, 2012, J ETHNOPHARMACOL, V144, P387, DOI 10.1016/j.jep.2012.09.025; Hetenyi C, 2006, FEBS LETT, V580, P1447, DOI 10.1016/j.febslet.2006.01.074; Hossain M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018333; Huang JC, 2009, BIOSENS BIOELECTRON, V25, P320, DOI 10.1016/j.bios.2009.07.012; Kong WJ, 2011, J CHROMATOGR B, V879, P3565, DOI 10.1016/j.jchromb.2011.09.045; Lakowicz J. R, 2006, PRINCIPLES FLUORESCE, P1, DOI [10.1007/978-0-387-46312-4, DOI 10.1007/978-0-387-46312-4]; LAKOWICZ JR, 1980, BIOPHYS J, V32, P591, DOI 10.1016/S0006-3495(80)84992-7; Li YS, 2013, J PHOTOCH PHOTOBIO B, V128, P12, DOI 10.1016/j.jphotobiol.2013.07.027; Liao ZX, 2014, SPECTROCHIM ACTA A, V129, P314, DOI 10.1016/j.saa.2014.03.057; Liu HT, 2013, BIOMED CHROMATOGR, V27, P655, DOI 10.1002/bmc.2842; Mahesha HG, 2006, FEBS J, V273, P451, DOI 10.1111/j.1742-4658.2005.05071.x; Mehranfar F, 2013, J PHOTOCH PHOTOBIO B, V127, P100, DOI 10.1016/j.jphotobiol.2013.07.019; Morris GM, 2009, J COMPUT CHEM, V30, P2785, DOI 10.1002/jcc.21256; MULLER WE, 1979, PHARMACOLOGY, V19, P59, DOI 10.1159/000137289; Naik KM, 2013, J LUMIN, V143, P484, DOI 10.1016/j.jlumin.2013.05.013; Petitpas I, 2001, J BIOL CHEM, V276, P22804, DOI 10.1074/jbc.M100575200; Seeliger D, 2010, J COMPUT AID MOL DES, V24, P417, DOI 10.1007/s10822-010-9352-6; Sekula B, 2013, INT J BIOL MACROMOL, V60, P316, DOI 10.1016/j.ijbiomac.2013.06.004; Singh RB, 2009, PHOTOCH PHOTOBIO SCI, V8, P101, DOI 10.1039/b814050b; Skrt M, 2012, FOOD CHEM, V135, P2418, DOI 10.1016/j.foodchem.2012.06.114; SUDLOW G, 1976, MOL PHARMACOL, V12, P1052; Sun M, 2009, PHYTOMEDICINE, V16, P683, DOI 10.1016/j.phymed.2009.03.020; Tian FF, 2010, J PHYS CHEM B, V114, P14842, DOI 10.1021/jp105766n; Tian J, 2011, SPECTROSC-BIOMED APP, V26, P195, DOI 10.1155/2011/932060; Uto T, 2012, BIOCHEM BIOPH RES CO, V417, P473, DOI 10.1016/j.bbrc.2011.11.143; Vlasova IM, 2012, RUSS J PHYS CHEM A+, V86, P509, DOI 10.1134/S0036024412030338; Vuignier K, 2010, ANAL BIOANAL CHEM, V398, P53, DOI 10.1007/s00216-010-3737-1; WAGGONER AS, 1971, BIOCHEMISTRY-US, V10, P3250; Yu XY, 2014, SPECTROCHIM ACTA A, V133, P372, DOI 10.1016/j.saa.2014.05.085	46	6	7	3	47	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 2	2015	10	6							e0128919	10.1371/journal.pone.0128919	http://dx.doi.org/10.1371/journal.pone.0128919			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CJ7SJ	26035712	Green Submitted, gold, Green Published			2023-01-03	WOS:000355699100056
J	Tsai, MH; Liou, HH; Leu, JG; Yen, MF; Chen, HH				Tsai, Ming-Hsien; Liou, Hung-Hsiang; Leu, Jyh-Gang; Yen, Ming-Fang; Chen, Hsiu-Hsi			Sites of Peripheral Artery Occlusive Disease as a Predictor for All-Cause and Cardiovascular Mortality in Chronic Hemodialysis	PLOS ONE			English	Article							CHRONIC KIDNEY-DISEASE; BLOOD-PRESSURE INDEX; ANKLE BRACHIAL INDEX; DIALYSIS; ASSOCIATION; PREVALENCE; RISK; CALCIFICATION; DIFFERENCE	Background The ankle-brachial blood pressure (BP) index (ABI) not only indicates the presence of peripheral artery occlusive disease (PAOD) but predicts mortality in patients undergoing hemodialysis (HD). However, whether the site of PAOD can provide additional contribution to predicting mortality have not been investigated yet. Our primary objective was to determine the associations between the site of PAOD and all-cause and cardiovascular mortality in chronic HD (CHD) patients. Methods A retrospective cohort study was conducted to evaluate 444 Taiwanese CHD patients between December 2006 and June 2013. The site of PAOD together with other explanatory variables such as demographic data, body mass index, a history of cardiovascular diseases, HD vintage, biochemical data, and cardiothoracic ratio (CTR) were assessed by the Cox proportional hazards regression model. Results The frequency of PAOD was 14.6% in both legs, 4.9% in the right side only, and 5.1% in the left side only. During the study period, 127 all-cause and 93 cardiovascular deaths occurred. PAOD site was found to have significant predictive power for all-cause mortality with the order of 3.04 (95% CI: 1.56-5.90) hazard ratio on the right side, 2.48 (95% CI: 1.27-4.82) on the left side, and 4.11 (95% CI: 2.76-6.13) on both sides. The corresponding figures for cardiovascular mortality were 3.81 (95% CI: 1.87-7.76) on the right side, 2.76 (95% CI: 1.30-5.82) on the left side, and 3.95 (95% CI: 2.45-6.36) on both sides. After adjustment for other explanatory variables, only right-sided PAOD still remained to have significant predictive power for all-cause and cardiovascular mortality and bilateral PAOD kept the significant association with all-cause mortality. Conclusions The site of PAOD revealed various predictive powers for all-cause and cardiovascular mortality in CHD patients and only right-sided PAOD remained an independent predictor for both types of mortality making allowance for relevant confounding factors.	[Tsai, Ming-Hsien; Leu, Jyh-Gang] Shin Kong Wu Ho Su Mem Hosp, Dept Internal Med, Div Nephrol, Taipei, Taiwan; [Liou, Hung-Hsiang] Hsin Jen Hosp, Dept Med, Div Nephrol, New Taipei City, Taiwan; [Yen, Ming-Fang] Taipei Med Univ, Coll Oral Med, Sch Oral Hyg, Taipei, Taiwan; [Tsai, Ming-Hsien; Chen, Hsiu-Hsi] Natl Taiwan Univ, Inst Epidemiol, Coll Publ Hlth, Div Biostat, Taipei 10764, Taiwan; [Tsai, Ming-Hsien; Chen, Hsiu-Hsi] Natl Taiwan Univ, Inst Prevent Med, Coll Publ Hlth, Taipei 10764, Taiwan	Shin Kong Wu Ho Su Memorial Hospital; Taipei Medical University; National Taiwan University; National Taiwan University	Chen, HH (corresponding author), Natl Taiwan Univ, Inst Epidemiol, Coll Publ Hlth, Div Biostat, Taipei 10764, Taiwan.	Chenlin@ntu.edu.tw		Tsai, Ming Hsien/0000-0003-3561-4689; Chen, Hsiu-Hsi/0000-0002-5799-6705	Shin Kong Wu Ho-Su Memorial Hospital [SKH-8302-104-DR-08]	Shin Kong Wu Ho-Su Memorial Hospital	This study was sponsored by the Shin Kong Wu Ho-Su Memorial Hospital (SKH-8302-104-DR-08). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bohn E, 2013, BMC NEPHROL, V14, DOI 10.1186/1471-2369-14-263; Jimenez ZNC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042290; Chen KH, 2011, THER APHER DIAL, V15, P81, DOI 10.1111/j.1744-9987.2010.00860.x; Chen SC, 2012, CLIN J AM SOC NEPHRO, V7, P1646, DOI 10.2215/CJN.04570512; Chen SC, 2010, NEPHROLOGY, V15, P294, DOI 10.1111/j.1440-1797.2010.01187.x; Cheung AK, 2000, KIDNEY INT, V58, P353, DOI 10.1046/j.1523-1755.2000.00173.x; Clark CE, 2002, FAM PRACT, V19, P439, DOI 10.1093/fampra/19.5.439; de Vinuesa SG, 2005, KIDNEY INT, V67, pS44, DOI 10.1111/j.1523-1755.2005.09310.x; Disthabanchong Sinee, 2012, World J Nephrol, V1, P43, DOI 10.5527/wjn.v1.i2.43; FISHBANE S, 1995, AM J KIDNEY DIS, V25, P34, DOI 10.1016/0272-6386(95)90622-3; Guerrero A, 2006, NEPHROL DIAL TRANSPL, V21, P3525, DOI 10.1093/ndt/gfl470; Kitahara T, 2005, AM J KIDNEY DIS, V46, P688, DOI 10.1053/j.ajkd.2005.06.016; LAING S, 1983, BRIT J SURG, V70, P628, DOI 10.1002/bjs.1800701017; Leng GC, 1996, INT J EPIDEMIOL, V25, P1172, DOI 10.1093/ije/25.6.1172; Leskinen Y, 2002, AM J KIDNEY DIS, V40, P472, DOI 10.1053/ajkd.2002.34885; Lin CY, 2015, RENAL FAILURE, V37, P88, DOI 10.3109/0886022X.2014.976104; MALLICK NP, 1995, AM J KIDNEY DIS, V25, P176, DOI 10.1016/0272-6386(95)90642-8; Mehrotra R, 2006, KIDNEY INT, V69, P195, DOI 10.1038/sj.ki.5000039; Merkus MP, 2000, AM J KIDNEY DIS, V35, P69, DOI 10.1016/S0272-6386(00)70304-0; Newman AB, 1997, J AM GERIATR SOC, V45, P1472, DOI 10.1111/j.1532-5415.1997.tb03198.x; NEWMAN AB, 1993, JAMA-J AM MED ASSOC, V270, P487, DOI 10.1001/jama.270.4.487; Newman AB, 1999, ARTERIOSCL THROM VAS, V19, P538, DOI 10.1161/01.ATV.19.3.538; O'Hare AM, 2002, J AM SOC NEPHROL, V13, P497, DOI 10.1681/ASN.V132497; Ono K, 2003, J AM SOC NEPHROL, V14, P1591, DOI 10.1097/01.ASN.0000065547.98258.3D; Ortiz A, 2014, LANCET, V383, P1831, DOI 10.1016/S0140-6736(14)60384-6; Shinzato T, 1999, KIDNEY INT, V55, P700, DOI 10.1046/j.1523-1755.1999.00297.x; SHINZATO T, 1994, NEPHRON, V67, P280, DOI 10.1159/000187980; Yen TH, 2009, AM J MED SCI, V337, P421, DOI 10.1097/MAJ.0b013e31819bbec1; Zhang ZH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070777	29	9	11	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 2	2015	10	6							e0128968	10.1371/journal.pone.0128968	http://dx.doi.org/10.1371/journal.pone.0128968			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CJ7SJ	26035831	Green Submitted, Green Published, gold			2023-01-03	WOS:000355699100058
J	Kim, J; Shin, JY; Lee, J; Song, HJ; Choi, NK; Park, BJ				Kim, Jungmee; Shin, Ju-Young; Lee, Joongyub; Song, Hong-Ji; Choi, Nam-Kyong; Park, Byung-Joo			Comparison of the Prescribing Pattern of Bisphosphonate and Raloxifene in Korean Women with Osteoporosis: From a National Health Insurance Claims Database	PLOS ONE			English	Article							HIP FRACTURE INCIDENCE; POSTMENOPAUSAL WOMEN; BREAST-CANCER; BONE TURNOVER; ALENDRONATE; RISEDRONATE; PREVALENCE; PATIENT; ADULTS; RISK	This study aimed to evaluate the differences of prescribing pattern between bisphosphonate and raloxifene users among Korean women with osteoporosis, focusing on the underlying conditions, concurrent medications, nature of healthcare utilization, and regional disparity. We used the Health Insurance Review and Assessment Service National Patients Sample database of the year 2010. Study subjects were defined as female osteoporosis patients aged over 50 years with both the diagnosis of osteoporosis and prescriptions of bisphosphonate or raloxifene. The frequency and the proportion of bisphosphonate and raloxifene were compared using chi-square test and the trend of the proportion using the Cochran-Armitage test. Medications were quantified as defined daily doses per 1,000 patients per day. The prescription pattern was visualized by using the Quantum Geographic Information Systems program. Of the 1,367,367 people who utilized medical services in 2010, the final number of study subjects was 26,881-26,032 (96.8%) bisphosphonate and 849 (3.2%) raloxifene recipients. Raloxifene users were younger than bisphosphonate users and were more frequently patients with a lipid disorder (16.0% vs. 22.1%, p-value < 0.0001), rheumatic disease (4.0% vs. 6.1%, p-value = 0.0024), hot flash (1.8% vs. 6.1%, p < 0.0001), and coronary artery disease (1.2% vs. 2.8%, p < 0.0001). The proportion of raloxifene users was higher in tertiary care institutions (21.6% vs. 44.7%, p-value < 0.0001). A regional distribution showed that raloxifene use was higher in the Seoul metropolitan area. These differences in demographic and clinical profiles of each recipient may influence prescription decisions.	[Kim, Jungmee; Park, Byung-Joo] Seoul Natl Univ, Coll Med, Dept Prevent Med, Seoul, South Korea; [Shin, Ju-Young; Park, Byung-Joo] Korea Inst Drug Safety & Risk Management, Seoul, South Korea; [Lee, Joongyub; Choi, Nam-Kyong] Seoul Natl Univ Hosp, Med Res Collaborating Ctr, Seoul 110744, South Korea; [Lee, Joongyub] Seoul Natl Univ, Coll Med, Seoul, South Korea; [Song, Hong-Ji] Hallym Univ, Coll Med, Dept Family Med, Chunchon, South Korea	Seoul National University (SNU); Seoul National University (SNU); Seoul National University Hospital; Seoul National University (SNU); Hallym University	Park, BJ (corresponding author), Korea Inst Drug Safety & Risk Management, Boryung Bldg, Seoul, South Korea.	bjpark@snu.ac.kr		Shin, Ju-Young/0000-0003-1010-7525; Choi, Nam-Kyong/0000-0003-1153-9928				Bachmann G, 2011, MENOPAUSE, V18, P851, DOI 10.1097/gme.0b013e31820b80f1; Barrett-Connor E, 2006, NEW ENGL J MED, V355, P125, DOI 10.1056/NEJMoa062462; Brookhart MA, 2006, J CLIN EPIDEMIOL, V59, P18, DOI 10.1016/j.jclinepi.2005.07.005; Choi HJ, 2012, J BONE MINER METAB, V30, P54, DOI 10.1007/s00774-011-0280-x; Choi YJ, 2012, J BONE MINER RES, V27, P1879, DOI 10.1002/jbmr.1635; CHREN MM, 1994, JAMA-J AM MED ASSOC, V271, P684, DOI 10.1001/jama.271.9.684; Curtis JR, 2009, OSTEOPOROSIS INT, V20, P973, DOI 10.1007/s00198-008-0772-2; Ferrari S, 2011, J BONE MINER METAB, V29, P561, DOI 10.1007/s00774-010-0249-1; Foster SA, 2013, BMC WOMENS HEALTH, V13, DOI 10.1186/1472-6874-13-15; Foster SA, 2010, CURR MED RES OPIN, V26, P2521, DOI 10.1185/03007995.2010.515456; Foster Shonda A, 2008, BMC Womens Health, V8, P24, DOI 10.1186/1472-6874-8-24; Gadam RK, 2013, ENDOCR PRACT, V19, P780, DOI 10.4158/EP12416.OR; Gehlbach S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082840; Gong HS, 2009, J BONE JOINT SURG AM, V91A, P2376, DOI 10.2106/JBJS.H.01871; Harmankaya N, 2013, ACTA BIOMATER, V9, P7064, DOI 10.1016/j.actbio.2013.02.040; Kanis JA, 2012, OSTEOPOROSIS INT, V23, P2239, DOI 10.1007/s00198-012-1964-3; Kim HA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098043; Kim KH, 2012, BONE, V50, P1039, DOI 10.1016/j.bone.2012.02.007; Kim Logyoung, 2013, [Health Policy and Mangemnet, 보건행정학회지], V23, P152; Kwon S, 2009, HEALTH POLICY PLANN, V24, P63, DOI 10.1093/heapol/czn037; Lin TC, 2013, J CLIN ENDOCRINOL ME; Park C, 2011, J BONE MINER METAB, V29, P744, DOI 10.1007/s00774-011-0279-3; Pasion EG, 2007, J BONE MINER METAB, V25, P105, DOI 10.1007/s00774-006-0735-7; Recker RR, 2007, BONE, V40, P843, DOI 10.1016/j.bone.2006.11.001; Ro C, 2013, CURR OSTEOPOROS REP, V11, P45, DOI 10.1007/s11914-012-0129-9; Sambrook PN, 2004, J INTERN MED, V255, P503, DOI 10.1111/j.1365-2796.2004.01317.x; Sanad Z, 2011, CLIMACTERIC, V14, P369, DOI 10.3109/13697137.2010.537408; Schneeweiss S, 2005, J CLIN EPIDEMIOL, V58, P323, DOI 10.1016/j.jclinepi.2004.10.012; Shin CS, 2012, J BONE MINER METAB, V30, P183, DOI 10.1007/s00774-011-0300-x	29	7	7	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 1	2015	10	6							e0127970	10.1371/journal.pone.0127970	http://dx.doi.org/10.1371/journal.pone.0127970			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CL0KF	26030300	Green Published, Green Submitted, gold			2023-01-03	WOS:000356630900098
J	Reilly, S; McKean, C; Morgan, A; Wake, M				Reilly, Sheena; McKean, Cristina; Morgan, Angela; Wake, Melissa			Identifying and managing common childhood language and speech impairments	BMJ-BRITISH MEDICAL JOURNAL			English	Review							PREDICTING TREATMENT TIME; QUALITY-OF-LIFE; FOLLOW-UP; PRESCHOOL-CHILDREN; LIDCOMBE PROGRAM; YOUNG-CHILDREN; AGE; PREVALENCE; DISORDERS; OUTCOMES		[Reilly, Sheena; McKean, Cristina; Morgan, Angela; Wake, Melissa] Murdoch Childrens Res Inst, Parkville, Vic 3052, Australia; [Reilly, Sheena; McKean, Cristina; Morgan, Angela; Wake, Melissa] Univ Melbourne, Dept Paediat, Parkville, Vic 3052, Australia; [McKean, Cristina] Newcastle Univ, Speech & Language Sci, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England; [Wake, Melissa] Royal Childrens Hosp, Ctr Community Child Hlth, Parkville, Vic 3052, Australia	Murdoch Children's Research Institute; University of Melbourne; Newcastle University - UK; Royal Children's Hospital Melbourne	Reilly, S (corresponding author), Murdoch Childrens Res Inst, Parkville, Vic 3052, Australia.	sheena.reilly@mcri.edu.au	Reilly, Sheena/A-7035-2016; Wake, Melissa/J-1396-2012; Morgan, Angela/J-5235-2017	Reilly, Sheena/0000-0001-6506-4767; Wake, Melissa/0000-0001-7501-9257; McKean, Cristina/0000-0001-9058-9813; Morgan, Angela/0000-0003-1147-7405				Andrews G, 1964, CLIN DEV MED, V17; Baird G, 2008, UNDERSTANDING DEV LA, P1; Baker E, 2011, LANG SPEECH HEAR SER, V42, P140, DOI 10.1044/0161-1461(2010/10-0023); BEITCHMAN JH, 1986, J SPEECH HEAR DISORD, V51, P98, DOI 10.1044/jshd.5102.98; Bernthal JE, 1998, ARTICULATION PHONOLO; Blood GW, 2010, J FLUENCY DISORD, V35, P92, DOI 10.1016/j.jfludis.2010.03.003; Bricker-Katz G, 2009, DISABIL REHABIL, V31, P1742, DOI 10.1080/09638280902738672; Cirrin FM, 2010, LANG SPEECH HEAR SER, V41, P233, DOI 10.1044/0161-1461(2009/08-0128); Craig A, 2009, J FLUENCY DISORD, V34, P61, DOI 10.1016/j.jfludis.2009.05.002; Dodd B., 2005, DIFFERENTIAL DIAGNOS, V2nd; Eadie P, 2014, DEV MED CHILD NEUROL; Ebbels SH, 2014, INT J LANG COMM DIS, V49, P30, DOI 10.1111/1460-6984.12047; Fenson L, 1993, MACARTHUR COMMUNICAT; Foy JG, 2012, READ WRIT, V25, P799, DOI 10.1007/s11145-011-9300-4; Gunther T, 2010, INT J LANG COMM DIS, V45, P345, DOI [10.3109/13682820903026762, 10.1080/13682820903026762]; Johnson CJ, 2010, AM J SPEECH-LANG PAT, V19, P51, DOI 10.1044/1058-0360(2009/08-0083); Jones M, 2005, BMJ-BRIT MED J, V331, P659, DOI 10.1136/bmj.38520.451840.E0; Jones M, 2000, J SPEECH LANG HEAR R, V43, P1440, DOI 10.1044/jslhr.4306.1440; Kefalianos E, 2014, J SPEECH LANG HEAR R, V57, P1314, DOI 10.1044/2014_JSLHR-S-13-0069; Kingston M, 2003, INT J LANG COMM DIS, V38, P165, DOI 10.1080/1368282031000062882; Law J, 2003, Cochrane Database Syst Rev, pCD004110, DOI 10.1002/14651858.CD004110; Levickis P, 2014, LATE TALKING DOES PA, V4; Lewis BA, 2011, J SPEECH LANG HEAR R, V54, P1628, DOI 10.1044/1092-4388(2011/10-0124); Liegeois Frederique, 2014, Curr Dev Disord Rep, V1, P215; Mansson H, 2000, J FLUENCY DISORD, V25, P47, DOI 10.1016/S0094-730X(99)00023-6; Mayes AK, 2015, DEV MED CHILD NEUROL; McAllister J, 2012, J FLUENCY DISORD, V37, P106, DOI 10.1016/j.jfludis.2012.01.002; McCartney E, INT J LANG COMMUN DI, V46, P74; McCormack J, 2011, J SPEECH LANG HEAR R, V54, P1328, DOI 10.1044/1092-4388(2011/10-0155); McCormick DP, 2006, AMBUL PEDIATR, V6, P280, DOI 10.1016/j.ambp.2006.04.010; Messenger M, 2004, J FLUENCY DISORD, V29, P201, DOI 10.1016/j.jfludis.2004.06.002; Morgan AT, 2008, COCHRANE DB SYST REV, V3; Morgan AT, 2008, COCHRANE DB SYST REV, V3, DOI DOI 10.1002/14651858.CD006279.PUB2; Nelson HD, 2006, PEDIATRICS, V117, pE298, DOI 10.1542/peds.2005-1467; Nye C, 2013, J SPEECH LANG HEAR R, V56, P921, DOI 10.1044/1092-4388(2012/12-0036); Pennington BF, 2009, ANNU REV PSYCHOL, V60, P283, DOI 10.1146/annurev.psych.60.110707.163548; Pennington L, 2009, COCHRANE DB SYST REV, V4; Proctor A, 2008, J SPEECH LANG HEAR R, V51, P1465, DOI 10.1044/1092-4388(2008/07-0057); Reilly S, 2007, PEDIATRICS, V120, pE1441, DOI 10.1542/peds.2007-0045; Reilly S, 2014, INT J LANG COMM DIS, V49, P416, DOI 10.1111/1460-6984.12102; Reilly S, 2013, PEDIATRICS, V132, P460, DOI 10.1542/peds.2012-3067; Reilly S, 2010, PEDIATRICS, V126, pE1530, DOI 10.1542/peds.2010-0254; Reilly S, 2009, PEDIATRICS, V123, P270, DOI 10.1542/peds.2007-3219; Roberts JE, 2004, PEDIATRICS, V113, pE238, DOI 10.1542/peds.113.3.e238; Sandler AD, 2001, PEDIATRICS, V107; Schoon I, 2010, PEDIATRICS, V126, pE73, DOI 10.1542/peds.2009-3282; Schoon I, 2010, PEDIATRICS, V125, pE459, DOI 10.1542/peds.2008-2111; Shriberg LD, 1999, J SPEECH LANG HEAR R, V42, P1461, DOI 10.1044/jslhr.4206.1461; SHRIBERG LD, 1994, J SPEECH HEAR RES, V37, P1100, DOI 10.1044/jshr.3705.1100; Stothard SE, 1998, J SPEECH LANG HEAR R, V41, P407, DOI 10.1044/jslhr.4102.407; The Royal Children's Hospital Melbourne Centre for Community Child Health, 2014, PRACTICE BRIEF   MAR; Tomblin JB, 1997, J SPEECH LANG HEAR R, V40, P1245, DOI 10.1044/jslhr.4006.1245; Ukoumunne OC, 2012, CHILD CARE HLTH DEV, V38, P341, DOI 10.1111/j.1365-2214.2011.01234.x; Wake M, 2013, PEDIATRICS, V132, pE895, DOI 10.1542/peds.2012-3878; Wake M, 2012, BMC PEDIATR, V12, DOI 10.1186/1471-2431-12-96; YAIRI E, 1993, J SPEECH HEAR RES, V36, P521, DOI 10.1044/jshr.3603.521	56	27	27	2	13	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 14	2015	350								h2318	10.1136/bmj.h2318	http://dx.doi.org/10.1136/bmj.h2318			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	CI5CI	25976972	Green Published			2023-01-03	WOS:000354770100006
J	Aguero, J; Ishikawa, K; Fish, KM; Hammoudi, N; Hadri, L; Garcia-Alvarez, A; Ibanez, B; Fuster, V; Hajjar, RJ; Leopold, JA				Aguero, Jaume; Ishikawa, Kiyotake; Fish, Kenneth M.; Hammoudi, Nadjib; Hadri, Lahouaria; Garcia-Alvarez, Ana; Ibanez, Borja; Fuster, Valentin; Hajjar, Roger J.; Leopold, Jane A.			Combination Proximal Pulmonary Artery Coiling and Distal Embolization Induces Chronic Elevations in Pulmonary Artery Pressure in Swine	PLOS ONE			English	Article							HYPERTENSION; MODEL; MORTALITY	Pulmonary hypertension (PH) is associated with aberrant vascular remodeling and right ventricular (RV) dysfunction that contribute to early mortality. Large animal models that recapitulate human PH are essential for mechanistic studies and evaluating novel therapies; however, these models are not readily accessible to the field owing to the need for advanced surgical techniques or hypoxia. In this study, we present a novel swine model that develops cardiopulmonary hemodynamics and structural changes characteristic of chronic PH. This percutaneous model was created in swine (n= 6) by combining distal embolization of dextran beads with selective coiling of the lobar pulmonary arteries (2 procedures per lung over 4 weeks). As controls, findings from this model were compared with those from a standard weekly distal embolization model (n= 6) and sham animals (n= 4). Survival with the combined embolization model was 100%. At 8 weeks after the index procedure, combined embolization procedure animals had increased mean pulmonary artery pressure (mPA) and pulmonary vascular resistance (PVR) compared to the controls with no effect on left heart or systemic pressures. RV remodeling and RV dysfunction were also present with a decrease in the RV ejection fraction, increase in the myocardial performance index, impaired longitudinal function, as well as cardiomyocyte hypertrophy, and interstitial fibrosis, which were not present in the controls. Pulmonary vascular remodeling occurred in both embolization models, although only the combination embolization model had a decrease in pulmonary capacitance. Taken together, these cardiopulmonary hemodynamic and structural findings identify the novel combination embolization swine model as a valuable tool for future studies of chronic PH.	[Aguero, Jaume; Ishikawa, Kiyotake; Fish, Kenneth M.; Hammoudi, Nadjib; Hadri, Lahouaria; Hajjar, Roger J.] Icahn Sch Med Mt Sinai, Cardiovasc Res Ctr, New York, NY 10029 USA; [Aguero, Jaume; Garcia-Alvarez, Ana; Ibanez, Borja; Fuster, Valentin] Ctr Nacl Invest Cardiovasc Carlos III CNIC Epidem, Atherothrombosis & Imaging Dept, Madrid, Spain; [Fuster, Valentin] Icahn Sch Med Mt Sinai, Zena & Michael A Wiener Cardiovasc Inst, New York, NY 10029 USA; [Leopold, Jane A.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Cardiovasc Med, Boston, MA 02115 USA	Icahn School of Medicine at Mount Sinai; Centro Nacional de Investigaciones Cardiovasculares (CNIC); Icahn School of Medicine at Mount Sinai; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Aguero, J (corresponding author), Icahn Sch Med Mt Sinai, Cardiovasc Res Ctr, New York, NY 10029 USA.	jaimeaguero30@hotmail.com	Ishikawa, Kiyotake/I-6013-2015; Ibáñez, Borja/J-6993-2014; Hadri, Lahouaria/AAP-6415-2020; Aguero, Jaume/I-8582-2016; Alvarez, Ana García/AAB-4999-2021; Fuster, Valentin/H-4319-2015	Ibáñez, Borja/0000-0002-5036-254X; Hadri, Lahouaria/0000-0001-8108-7993; Aguero, Jaume/0000-0001-7416-871X; Alvarez, Ana García/0000-0002-1718-2424; Fuster, Valentin/0000-0002-9043-9986; ishikawa, kiyotake/0000-0002-8287-3483; Hammoudi, Nadjib/0000-0003-2085-8525; FISH, KENNETH/0000-0002-7781-0314	National Institutes of Health [RO1 HL083156, HL093183, HL119046, P20HL100396]; NHLBI Program of Excellence in Nanotechnology Award [HHSN268201000045C]; NIH [R01 105301]; Leducq Foundation; Fundacion Alfonso Martin-Escudero; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL125215, R01HL093183, R01HL083156, R01HL119046, P20HL100396] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NHLBI Program of Excellence in Nanotechnology Award; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Leducq Foundation(Leducq Foundation); Fundacion Alfonso Martin-Escudero; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	This work is supported by National Institutes of Health RO1 HL083156, HL093183, HL119046, P20HL100396 and a NHLBI Program of Excellence in Nanotechnology Award, Contract # HHSN268201000045C (RJH) and NIH R01 105301 (JAL). Part of the work was funded by a Leducq Foundation grant (RJH). JA was supported by the Fundacion Alfonso Martin-Escudero.	Bauer NR, 2007, AM J PHYSIOL-LUNG C, V293, pL580, DOI 10.1152/ajplung.00281.2007; Burrowes K S, 2011, Pulm Circ, V1, P365, DOI 10.4103/2045-8932.87302; Champion HC, 2009, CIRCULATION, V120, P992, DOI 10.1161/CIRCULATIONAHA.106.674028; Garcia-Alvarez A, 2013, J AM COLL CARDIOL, V62, P1621, DOI 10.1016/j.jacc.2013.07.037; Gomez-Arroyo JG, 2012, AM J PHYSIOL-LUNG C, V302, pL363, DOI 10.1152/ajplung.00212.2011; Guihaire J, 2013, EUR HEART J-CARD IMG, V14, P1140, DOI 10.1093/ehjci/jet092; KELLEY KW, 1973, J ANIM SCI, V36, P927; Kim H, 2000, EUR RESPIR J, V15, P640, DOI 10.1034/j.1399-3003.2000.15d04.x; Mahapatra S, 2006, J AM COLL CARDIOL, V47, P799, DOI 10.1016/j.jacc.2005.09.054; Mercier O, 2013, PULM CIRC, V3, P908, DOI 10.1086/674757; Pereda D, 2014, J CARDIOVASC TRANSL, V7, P494, DOI 10.1007/s12265-014-9564-6; PERKETT EA, 1991, AM J PATHOL, V139, P1319; Pietra GG, 2004, J AM COLL CARDIOL, V43, p25S, DOI 10.1016/j.jacc.2004.02.033; Pohlmann JR, 2012, J SURG RES, V175, P44, DOI 10.1016/j.jss.2011.02.049; Rondelet B, 2003, CIRCULATION, V107, P1329, DOI 10.1161/01.CIR.0000053443.27512.33; Sato H, 2008, ASAIO J, V54, P396, DOI 10.1097/MAT.0b013e31817efa85; SHELUB I, 1984, J APPL PHYSIOL, V56, P810, DOI 10.1152/jappl.1984.56.3.810; SILOVE ED, 1972, CARDIOVASC RES, V6, P36, DOI 10.1093/cvr/6.1.36; Song JK, 2000, J NEUROSURG, V92, P955, DOI 10.3171/jns.2000.92.6.0955; Stenmark KR, 2005, CIRC RES, V97, P95, DOI 10.1161/01.RES.00000175934.68087.29; Stenmark KR, 2009, AM J PHYSIOL-LUNG C, V297, pL1013, DOI 10.1152/ajplung.00217.2009; Stevens GR, 2012, JACC-CARDIOVASC IMAG, V5, P378, DOI 10.1016/j.jcmg.2011.11.020; Weimann J, 1999, J CRIT CARE, V14, P133, DOI 10.1016/S0883-9441(99)90026-6; Zeng GQ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078965; Zhou XQ, 2011, J SURG RES, V170, pE11, DOI 10.1016/j.jss.2011.04.030	25	11	11	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 29	2015	10	4							e0124526	10.1371/journal.pone.0124526	http://dx.doi.org/10.1371/journal.pone.0124526			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CH0LO	25923775	Green Submitted, Green Published, gold			2023-01-03	WOS:000353711600090
J	Husain, I; Spence, D				Husain, Iltifat; Spence, Des			HEAD TO HEAD Can healthy people benefit from health apps?	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							WEIGHT-LOSS; TECHNOLOGY		[Husain, Iltifat] Wake Forest Sch Med, Emergency Med, Winston Salem, NC 27157 USA	Wake Forest University	Husain, I (corresponding author), Wake Forest Sch Med, Emergency Med, Winston Salem, NC 27157 USA.	ihusain@wakehealth.edu; destwo@yahoo.co.uk						[Anonymous], 2010, SEV ANX OV BLOOD PRE; Brookings Institution, 2013, MOD HLTH CAR MOB TEC; Burke LE, 2012, AM J PREV MED, V43, P20, DOI 10.1016/j.amepre.2012.03.016; Carter MC, 2013, J MED INTERNET RES, V15, DOI 10.2196/jmir.2283; DiFilippo KN, 2015, J TELEMED TELECARE, V21, P243, DOI 10.1177/1357633X15572203; Dolan B, 2014, MOBI HLTH NEWS  0107; Gates A, 2014, PROFILES MED OUTREAC; Kessels RPC, 2003, J ROY SOC MED, V96, P219, DOI 10.1258/jrsm.96.5.219; Medicines and Healthcare Products Regulatory Agency, 2014, MED DEV SOFTW APPL A; Moynihan R, 2012, BMJ-BRIT MED J, V344, DOI 10.1136/bmj.e3502; NHS Choices, HLTH APPS LIB; Nielsen, 2014, HACKING HLTH CONSUME; Odosoft, FET DOPPL UNB IT PRE; RAVEN R J, 1988, American Museum Novitates, P1; Spring B, 2013, JAMA INTERN MED, V173, P105, DOI 10.1001/jamainternmed.2013.1221; US Food and Drug Administration, MOB MED APPL	16	38	39	0	11	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	APR 14	2015	350								h1887	10.1136/bmj.h1887	http://dx.doi.org/10.1136/bmj.h1887			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CG5JL	25873345				2023-01-03	WOS:000353327500006
J	Brehler, ACE; Hartmann, W; Wiebe, S; Kerkhoff, A; Schliemann, C; Palmes, D; Senninger, N; Lenze, F; Ullerich, H; Berdel, WE; Kessler, T				Brehler, Ann-Christin E.; Hartmann, Wolfgang; Wiebe, Stefanie; Kerkhoff, Andrea; Schliemann, Christoph; Palmes, Daniel; Senninger, Norbert; Lenze, Frank; Ullerich, Hansjoerg; Berdel, Wolfgang E.; Kessler, Torsten			Perioperative Chemotherapy in Gastroesophageal Cancer. A Retrospective Monocenter Evaluation of 42 Cases	PLOS ONE			English	Article							ESMO CLINICAL RECOMMENDATIONS; GASTRIC-CANCER; ESOPHAGEAL; CAPECITABINE; OXALIPLATIN; CHEMORADIOTHERAPY; 5-FLUOROURACIL; MULTICENTER; PANITUMUMAB; EPIRUBICIN	Background Perioperative chemotherapy increases the overall and progression-free survival of patients suffering from resectable adenocarcinomas of the lower esophagus, gastroesophageal junction and stomach (GEC). Comparing different chemotherapy regimens platin-based protocols with 5-fluorouracil (5-FU)/calcium folinate (CF) or oral fluoropyrimidines were favorable in terms of efficacy and side-effects. However, there is no consensus which regimen is the most efficacious. Methods 42 consecutive patients with resectable GEC (UICC II and III) were treated with 3 pre- and postoperative chemotherapy cycles each consisting of epirubicin, oxaliplatin and capecitabine (EOX). We analyzed the overall survival, progression-free survival and toxicity retrospectively in comparison to published data. Results The median overall survival in our cohort was 29 months and the progression-free survival was 17 months. The most frequent grade 3 and 4 toxicities during preoperative chemotherapy were diarrhea (16.7%), leukocytopenia (9.5%) and nausea (9.5%); overall 38.1% of our patients suffered from grade 3 or 4 toxicity. Surgery was carried out in 83% of our patients, 69% of those achieved R0 resection. Conclusion Comparing our data with the results of previously published randomized trials EOX is at least non-inferior with regard to overall survival, progression-free survival and toxicity. In conclusion, EOX is an appropriate perioperative therapy for patients with resectable GEC.	[Brehler, Ann-Christin E.; Wiebe, Stefanie; Kerkhoff, Andrea; Schliemann, Christoph; Berdel, Wolfgang E.; Kessler, Torsten] Univ Munster, Dept Med Hematol & Oncol, D-48149 Munster, Germany; [Hartmann, Wolfgang] Univ Munster, Gerhard Domagk Inst Pathol, D-48149 Munster, Germany; [Palmes, Daniel; Senninger, Norbert] Univ Munster, Dept Gen & Visceral Surg, D-48149 Munster, Germany; [Lenze, Frank; Ullerich, Hansjoerg] Univ Munster, Dept Med, Gastroenterol, D-48149 Munster, Germany	University of Munster; University of Munster; University of Munster; University of Munster	Kessler, T (corresponding author), Univ Munster, Dept Med Hematol & Oncol, D-48149 Munster, Germany.	torstenkessler@uni-muenster.de	Hartmann, Wolfgang/G-1893-2017; Kessler, Torsten/S-3319-2016	Hartmann, Wolfgang/0000-0002-7609-5021; Kessler, Torsten/0000-0001-7679-5362				Baldus SE, 2004, PATHOLOGE, V25, P421, DOI 10.1007/s00292-004-0697-2; Cunningham D, 2008, ANN ONCOL, V19, P23, DOI 10.1093/annonc/mdn075; Cunningham D, 2008, NEW ENGL J MED, V358, P36, DOI 10.1056/NEJMoa073149; Cunningham D, 2006, NEW ENGL J MED, V355, P11, DOI 10.1056/NEJMoa055531; Devesa SS, 1998, CANCER, V83, P2049, DOI 10.1002/(SICI)1097-0142(19981115)83:10<2049::AID-CNCR1>3.0.CO;2-2; Eisenhauer EA, 2009, EUR J CANCER, V45, P228, DOI 10.1016/j.ejca.2008.10.026; Faivre J, 1998, EUR J CANCER, V34, P2167, DOI 10.1016/S0959-8049(98)00329-3; Ferlay J, 2010, INT J CANCER, V127, P2893, DOI 10.1002/ijc.25516; Ferri LE, 2012, ANN ONCOL, V23, P1512, DOI 10.1093/annonc/mdr465; Gebski V, 2007, LANCET ONCOL, V8, P226, DOI 10.1016/S1470-2045(07)70039-6; Gomez-Martin C, 2012, CLIN TRANSL ONCOL, V14, P689, DOI 10.1007/s12094-012-0858-3; HERMANS J, 1993, J CLIN ONCOL, V11, P1441, DOI 10.1200/JCO.1993.11.8.1441; Homann N, 2012, INT J CANCER, V130, P1706, DOI 10.1002/ijc.26180; Lorenzen S, 2013, BRIT J CANCER, V108, P519, DOI 10.1038/bjc.2012.588; Mariette C, 2011, LANCET ONCOL, V12, P296, DOI 10.1016/S1470-2045(10)70125-X; Norman G, 2010, HEALTH TECHNOL ASSES, V14, P11, DOI 10.3310/hta14suppl2/02; Okines AFC, 2010, J CLIN ONCOL, V28, P3945, DOI 10.1200/JCO.2010.29.2847; Parkin DM, 2001, EUR J CANCER, V37, pS4, DOI 10.1016/S0959-8049(01)00267-2; Sehdev A, 2013, J HEMATOL ONCOL, V6, DOI 10.1186/1756-8722-6-66; Stahl M, 2008, ANN ONCOL, V19, P21, DOI 10.1093/annonc/mdn074; van Hagen P, 2012, NEW ENGL J MED, V366, P2074, DOI 10.1056/NEJMoa1112088; Waddell T, 2013, LANCET ONCOL, V14, P481, DOI 10.1016/S1470-2045(13)70096-2; Ychou M, 2011, J CLIN ONCOL, V29, P1715, DOI 10.1200/JCO.2010.33.0597	23	0	0	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 9	2015	10	4							e0122974	10.1371/journal.pone.0122974	http://dx.doi.org/10.1371/journal.pone.0122974			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CF5HQ	25855972	Green Published, gold			2023-01-03	WOS:000352588500069
J	Rupp, R; Schliessmann, D; Plewa, H; Schuld, C; Gerner, HJ; Weidner, N; Hofer, EP; Knestel, M				Rupp, Ruediger; Schliessmann, Daniel; Plewa, Harry; Schuld, Christian; Gerner, Hans Juergen; Weidner, Norbert; Hofer, Eberhard P.; Knestel, Markus			Safety and Efficacy of At-Home Robotic Locomotion Therapy in Individuals with Chronic Incomplete Spinal Cord Injury: A Prospective, Pre-Post Intervention, Proof-of-Concept Study	PLOS ONE			English	Article							WEIGHT-SUPPORTED TREADMILL; MODIFIED ASHWORTH SCALE; RHYTHMIC LEG MOVEMENTS; NEUROLOGICAL CLASSIFICATION; INTERNATIONAL STANDARDS; PARAPLEGIC PATIENTS; WALKING ABILITY; HUMAN INFANTS; WISCI-II; GAIT	Background The compact Motorized orthosis for home rehabilitation of Gait (MoreGait) was developed for continuation of locomotion training at home. MoreGait generates afferent stimuli of walking with the user in a semi-supine position and provides feedback about deviations from the reference walking pattern. Objective Prospective, pre-post intervention, proof-of-concept study to test the feasibility of an unsupervised home-based application of five MoreGait prototypes in subjects with incomplete spinal cord injury (iSCI). Methods Twenty-five (5 tetraplegia, 20 paraplegia) participants with chronic (mean time since injury: 5.8 +/- 5.4 (standard deviation, SD) years) sensorimotor iSCI (7 ASIA Impairment Scale (AIS) C, 18 AIS D; Walking Index for Spinal Cord Injury (WISCI II): Interquartile range 9 to 16) completed the training (45 minutes / day, at least 4 days / week, 8 weeks). Baseline status was documented 4 and 2 weeks before and at training onset. Training effects were assessed after 4 and 8 weeks of therapy. Results After therapy, 9 of 25 study participants improved with respect to the dependency on walking aids assessed by the WISCI II. For all individuals, the short-distance walking velocity measured by the 10-Meter Walk Test showed significant improvements compared to baseline (100%) for both self-selected (Mean 139.4% +/- 35.5% (SD)) and maximum (Mean 143.1% +/- 40.6% (SD)) speed conditions as well as the endurance estimated with the six-minute walk test (Mean 166.6% +/- 72.1% (SD)). One device-related adverse event (pressure sore on the big toe) occurred in over 800 training sessions. Conclusions Home-based robotic locomotion training with MoreGait is feasible and safe. The magnitude of functional improvements achieved by MoreGait in individuals with iSCI is well within the range of complex locomotion robots used in hospitals. Thus, unsupervised MoreGait training potentially represents an option to prolong effective training aiming at recovery of locomotor function beyond in-patient rehabilitation.	[Rupp, Ruediger; Schliessmann, Daniel; Plewa, Harry; Schuld, Christian; Gerner, Hans Juergen; Weidner, Norbert] Univ Heidelberg Hosp, Spinal Cord Injury Ctr, Heidelberg, Germany; [Hofer, Eberhard P.; Knestel, Markus] Univ Ulm, Inst Measurement Control & Microtechnol, D-89069 Ulm, Germany	Ruprecht Karls University Heidelberg; Ulm University	Rupp, R (corresponding author), Univ Heidelberg Hosp, Spinal Cord Injury Ctr, Heidelberg, Germany.	Ruediger.Rupp@med.uni-heidelberg.de			German Federal Ministry of Education and Research (BMBF) [01EZ601, 01EZ0602]; German Federal Ministry of Economic affairs and Energy (BMWi); German Bundestag [KF2906701]; Deutsche Forschungsgemeinschaft; Ruprecht-Karls-University Heidelberg	German Federal Ministry of Education and Research (BMBF)(Federal Ministry of Education & Research (BMBF)); German Federal Ministry of Economic affairs and Energy (BMWi); German Bundestag; Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Ruprecht-Karls-University Heidelberg	This project was supported by the German Federal Ministry of Education and Research (BMBF, www.bmbf.de) under grant no. 01EZ601 and 01EZ0602 from 2006-2010 and from 2011-2014 by the German Federal Ministry of Economic affairs and Energy (BMWi, www.bmwi.de) on the basis of a decision by the German Bundestag under grant no. KF2906701. Additionally, financial support was received by the Deutsche Forschungsgemeinschaft and Ruprecht-Karls-University Heidelberg within the funding program "Open Access Publishing". The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Behmran AL, 2000, PHYS THER, V80, P688, DOI 10.1093/ptj/80.7.688; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Borggraefe I, 2010, DEV NEUROREHABIL, V13, P114, DOI 10.3109/17518420903321767; Burns AS, 2011, NEUROREHAB NEURAL RE, V25, P149, DOI 10.1177/1545968310376756; Colombo G, 2001, SPINAL CORD, V39, P252, DOI 10.1038/sj.sc.3101154; Craven BC, 2010, SPINAL CORD, V48, P207, DOI 10.1038/sc.2009.107; Demers L, 2000, ASSIST TECHNOL, V12, P96, DOI 10.1080/10400435.2000.10132015; DIETZ V, 1995, ANN NEUROL, V37, P574, DOI 10.1002/ana.410370506; Dietz V, 1995, ANN NEUROL, V38, P965, DOI 10.1002/ana.410380621; Dietz V, 2002, BRAIN, V125, P2626, DOI 10.1093/brain/awf273; Dimitrijevic MR, 1998, ANN NY ACAD SCI, V860, P360, DOI 10.1111/j.1749-6632.1998.tb09062.x; Ditunno PL, 2001, SPINAL CORD, V39, P654, DOI 10.1038/sj.sc.3101223; Dobkin B, 2006, NEUROLOGY, V66, P484, DOI 10.1212/01.wnl.0000202600.72018.39; Dobkin BH, 1995, J NEUROL REHABIL, V9, P183; Dobkin BH, 2012, NEUROREHAB NEURAL RE, V26, P308, DOI 10.1177/1545968312439687; Edgerton VR, 2008, BRAIN RES REV, V57, P241, DOI 10.1016/j.brainresrev.2007.09.002; Field-Fote EC, 2001, ARCH PHYS MED REHAB, V82, P818, DOI 10.1053/apmr.2001.23752; Graham JE, 2012, ARCH PHYS MED REHAB, V93, pS111, DOI 10.1016/j.apmr.2011.12.017; GRILLNER S, 1975, BRAIN RES, V88, P367, DOI 10.1016/0006-8993(75)90401-1; Harkema S, 2011, LANCET, V377, P1938, DOI 10.1016/S0140-6736(11)60547-3; Harkema SJ, 2012, ARCH PHYS MED REHAB, V93, P1588, DOI 10.1016/j.apmr.2012.04.032; Harkema SJ, 2012, ARCH PHYS MED REHAB, V93, P1508, DOI 10.1016/j.apmr.2011.01.024; Hesse S, 2001, NEUROREHAB NEURAL RE, V15, P39, DOI 10.1177/154596830101500106; Hicks AL, 2005, SPINAL CORD, V43, P291, DOI 10.1038/sj.sc.3101710; Hofer EP, 2008, European Patent, Patent No. [EP000001959909A1, 000001959909]; Hultborn H, 2007, ACTA PHYSIOL, V189, P111, DOI 10.1111/j.1748-1716.2006.01651.x; Kirshblum SC, 2011, J SPINAL CORD MED, V34, P547, DOI 10.1179/107902611X13186000420242; Knestel M., 2008, IFAC PROC VOL, V41, P773, DOI [DOI 10.3182/20080706-5-KR-1001.00133, 10.3182/20080706-5-KR-1001.00133]; Knestel M, 2008, 2 INT CONV REH ENG A, P175; Krakauer JW, 2006, CURR OPIN NEUROL, V19, P84, DOI 10.1097/01.wco.0000200544.29915.cc; Layne CS, 2002, NEUROSCI LETT, V334, P75, DOI 10.1016/S0304-3940(02)01104-7; Marino RJ, 2010, AM J PHYS MED REHAB, V89, P7, DOI 10.1097/PHM.0b013e3181c560eb; Mehrholz J, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006676.pub3; Morawietz C, 2013, ARCH PHYS MED REHABI; Musselman KE, 2008, J NEUROPHYSIOL, V100, P2225, DOI 10.1152/jn.90532.2008; Musselman KE, 2007, J NEUROPHYSIOL, V97, P1247, DOI 10.1152/jn.00891.2006; NSCISC, 2006, 2006 ANN STAT REP MO; Olmos LE, 2008, SPINAL CORD, V46, P331, DOI 10.1038/sj.sc.3102132; Pearson KG, 2000, ANNU REV PHYSIOL, V62, P723, DOI 10.1146/annurev.physiol.62.1.723; R Core Team, 2012, LANG ENV STAT COMP; Rossignol S, 2011, ANNU REV NEUROSCI, V34, P413, DOI 10.1146/annurev-neuro-061010-113746; Rupp Rudiger, 2009, 2009 IEEE International Conference on Rehabilitation Robotics: Reaching Users & the Community (ICORR), P395, DOI 10.1109/ICORR.2009.5209497; Rupp R., 2009, PARAPLEGIKER, V27, P52; Rupp R, 2011, BIOMED TECH, V56, P11, DOI 10.1515/BMT.2010.051; Schmidt R. A., 2005, MOTOR CONTROL LEARNI; Schuld C, 2013, SPINAL CORD, V51, P282, DOI 10.1038/sc.2012.149; Schuld C, 2012, J NEUROTRAUM, V29, P453, DOI 10.1089/neu.2011.2085; SHEA JD, 1975, CLIN ORTHOP RELAT R, P89; Sigrist R, 2013, PSYCHON B REV, V20, P21, DOI 10.3758/s13423-012-0333-8; Singh A, 2011, J NEUROTRAUM, V28, P2405, DOI 10.1089/neu.2010.1660; Smith AW, 2002, AM J PHYS MED REHAB, V81, P202, DOI 10.1097/00002060-200203000-00008; Spiess MR, 2009, J NEUROTRAUM, V26, P2027, DOI 10.1089/neu.2008-0760; van Hedel H, 2006, SPINAL CORD, V44, P352, DOI 10.1038/sj.sc.3101853; van Hedel HJ, 2005, ARCH PHYS MED REHAB, V86, P190, DOI 10.1016/j.apmr.2004.02.010; WERNIG A, 1992, PARAPLEGIA, V30, P229, DOI 10.1038/sc.1992.61; Wirz M, 2005, ARCH PHYS MED REHAB, V86, P672, DOI 10.1016/j.apmr.2004.08.004; Wolpaw JR, 2006, PROG BRAIN RES, V157, P261, DOI 10.1016/S0079-6123(06)57017-7; Yang JF, 2012, J SPINAL CORD MED, V35, P293, DOI 10.1179/2045772312Y.0000000036	58	6	6	2	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 24	2015	10	3							e0119167	10.1371/journal.pone.0119167	http://dx.doi.org/10.1371/journal.pone.0119167			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CH2XV	25803577	Green Submitted, Green Published, gold			2023-01-03	WOS:000353889600016
J	Tsang, P; Bailey, AZ; Nelson, AJ				Tsang, Philemon; Bailey, Aaron Z.; Nelson, Aimee J.			Rapid-Rate Paired Associative Stimulation over the Primary Somatosensory Cortex	PLOS ONE			English	Article							TRANSCRANIAL MAGNETIC STIMULATION; THETA-BURST-STIMULATION; MEDIAN NERVE-STIMULATION; HUMAN MOTOR CORTEX; CORTICAL PLASTICITY; EVOKED-POTENTIALS; SUSTAINED INCREASE; RECEPTIVE-FIELDS; HUMAN HAND; HUMANS	Rapid-rate paired associative stimulation (rPAS) involves repeat pairing of peripheral nerve stimulation and Transcranial magnetic stimulation (TMS) pulses at a 5 Hz frequency. RPAS over primary motor cortex (M1) operates with spike-timing dependent plasticity such that increases in corticospinal excitability occur when the nerve and TMS pulse temporally coincide in cortex. The present study investigates the effects of rPAS over primary somatosensory cortex (SI) which has not been performed to date. In a series of experiments, rPAS was delivered over SI and M1 at varying timing intervals between the nerve and TMS pulse based on the latency of the N20 somatosensory evoked potential (SEP) component within each participant (intervals for SI-rPAS: N20, N20-2.5 ms, N20+2.5 ms, intervals for M1-rPAS: N20, N20+5 ms). Changes in SI physiology were measured via SEPs (N20, P25, N20-P25) and SEP paired-pulse inhibition, and changes in M1 physiology were measured with motor evoked potentials and short-latency afferent inhibition. Measures were obtained before rPAS and at 5, 25 and 45 minutes following stimulation. Results indicate that paired-pulse inhibition and short-latency afferent inhibition were reduced only when the SI-rPAS nerve-TMS timing interval was set to N20-2.5 ms. SI-rPAS over SI also led to remote effects on motor physiology over a wider range of nerve-TMS intervals (N20-2.5 ms -N20+2.5 ms) during which motor evoked potentials were increased. M1-rPAS increased motor evoked potentials and reduced short-latency afferent inhibition as previously reported. These data provide evidence that, similar to M1, rPAS over SI is spike-timing dependent and is capable of exerting changes in SI and M1 physiology.	[Tsang, Philemon; Bailey, Aaron Z.; Nelson, Aimee J.] McMaster Univ, Dept Kinesiol, Hamilton, ON, Canada	McMaster University	Nelson, AJ (corresponding author), McMaster Univ, Dept Kinesiol, Hamilton, ON, Canada.	nelsonaj@mcmaster.ca			Natural Sciences and Engineering Research Council of Canada	Natural Sciences and Engineering Research Council of Canada(Natural Sciences and Engineering Research Council of Canada (NSERC)CGIAR)	The research was funded by the Natural Sciences and Engineering Research Council of Canada to AJN. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ALLISON T, 1991, BRAIN, V114, P2465, DOI 10.1093/brain/114.6.2465; Asmussen MJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060496; Balzamo E, 2004, CLIN NEUROPHYSIOL, V115, P1616, DOI 10.1016/j.clinph.2004.02.012; Bliem B, 2008, J COGNITIVE NEUROSCI, V20, P1517, DOI 10.1162/jocn.2008.20106; BRINKMAN J, 1985, J PHYSIOL-LONDON, V368, P611, DOI 10.1113/jphysiol.1985.sp015879; Carmen T, 2013, BRAIN STIMUL, V6, P62, DOI 10.1016/j.brs.2012.01.010; Chen LM, 2003, SCIENCE, V302, P881, DOI 10.1126/science.1087846; Di Lazzaro V, 2004, CLIN NEUROPHYSIOL, V115, P255, DOI 10.1016/j.clinph.2003.10.009; Fathi D, 2010, CLIN NEUROPHYSIOL, V121, P90, DOI 10.1016/j.clinph.2009.07.048; Friedman RM, 2008, J NEUROPHYSIOL, V100, P3185, DOI 10.1152/jn.90278.2008; GARDNER EP, 1980, J NEUROPHYSIOL, V43, P444, DOI 10.1152/jn.1980.43.2.444; GOLDRING S, 1970, ELECTROEN CLIN NEURO, V29, P537, DOI 10.1016/0013-4694(70)90096-9; Hoffken O, 2007, J PHYSIOL-LONDON, V584, P463, DOI 10.1113/jphysiol.2007.140079; Ishikawa S, 2007, CLIN NEUROPHYSIOL, V118, P1033, DOI 10.1016/j.clinph.2007.02.003; Jacobs MF, 2014, BRAIN STIMUL, V7, P269, DOI 10.1016/j.brs.2013.12.009; Jacobs MF, 2012, NEUROREPORT, V23, P927, DOI 10.1097/WNR.0b013e328358b0f3; Kozyrev V, 2014, P NATL ACAD SCI USA, V111, P13553, DOI 10.1073/pnas.1405508111; Krivanekova L, 2011, EUR J NEUROSCI, V34, P1292, DOI 10.1111/j.1460-9568.2011.07849.x; Lee KGH, 2013, BMC NEUROSCI, V14, DOI 10.1186/1471-2202-14-89; Litvak V, 2007, EUR J NEUROSCI, V25, P2862, DOI 10.1111/j.1460-9568.2007.05531.x; Mao TY, 2011, NEURON, V72, P111, DOI 10.1016/j.neuron.2011.07.029; Muller-Dahlhaus F, 2010, FRONT SYNAPTIC NEURO, V2, P34, DOI DOI 10.3389/FNSYN.2010.00034; NUWER MR, 1994, ELECTROEN CLIN NEURO, V91, P1, DOI 10.1016/0013-4694(94)90011-6; Okamoto M, 2004, NEUROIMAGE, V21, P99, DOI 10.1016/j.neuroimage.2003.08.026; OLDFIELD RC, 1971, NEUROPSYCHOLOGIA, V9, P97, DOI 10.1016/0028-3932(71)90067-4; PAVLIDES C, 1993, J NEUROPHYSIOL, V70, P733, DOI 10.1152/jn.1993.70.2.733; Quartarone A, 2006, J PHYSIOL-LONDON, V575, P657, DOI 10.1113/jphysiol.2006.114025; Ragert P, 2004, NEUROSCI LETT, V356, P91, DOI 10.1016/j.neulet.2003.11.034; Ragert P, 2003, NEUROSCI LETT, V348, P105, DOI 10.1016/S0304-3940(03)00745-6; Rai N, 2012, CLIN NEUROPHYSIOL, V123, P1226, DOI 10.1016/j.clinph.2011.09.026; Ridding MC, 2010, J PHYSIOL-LONDON, V588, P2291, DOI 10.1113/jphysiol.2010.190314; Rossi S, 2009, CLIN NEUROPHYSIOL, V120, P2008, DOI 10.1016/j.clinph.2009.08.016; Sale MV, 2010, REV NEUROSCIENCE, V21, P55; Sale MV, 2008, J NEUROSCI, V28, P8285, DOI 10.1523/JNEUROSCI.1963-08.2008; Sattler V, 2012, EXP BRAIN RES, V221, P449, DOI 10.1007/s00221-012-3187-4; Sattler V, 2014, MOVEMENT DISORD, V29, P787, DOI 10.1002/mds.25768; Siebner HR, 2003, EXP BRAIN RES, V148, P1, DOI 10.1007/s00221-002-1234-2; Sripati AP, 2006, J NEUROSCI, V26, P2101, DOI 10.1523/JNEUROSCI.3720-05.2006; Stefan K, 2004, J NEUROPHYSIOL, V92, P66, DOI 10.1152/jn.00383.2003; Tamburin S, 2001, EXP BRAIN RES, V141, P232, DOI 10.1007/s002210100859; Tokimura H, 2000, J PHYSIOL-LONDON, V523, P503, DOI 10.1111/j.1469-7793.2000.t01-1-00503.x; TOKUNO H, 1993, J COMP NEUROL, V333, P199, DOI 10.1002/cne.903330206; Tossi MAG, 2013, NEUROREPORT, V24, P451, DOI 10.1097/WNR.0b013e3283616378; Tsang P., 2014, CLIN NEUROPHYSIOL; Wolters A, 2005, J PHYSIOL-LONDON, V565, P1039, DOI 10.1113/jphysiol.2005.084954; Wolters A, 2003, J NEUROPHYSIOL, V89, P2339, DOI 10.1152/jn.00900.2002	46	14	15	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 23	2015	10	3							e0120731	10.1371/journal.pone.0120731	http://dx.doi.org/10.1371/journal.pone.0120731			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CE6ZS	25799422	Green Submitted, Green Published, gold			2023-01-03	WOS:000351987300169
J	Laut, J; Cappa, F; Nov, O; Porfiri, M				Laut, Jeffrey; Cappa, Francesco; Nov, Oded; Porfiri, Maurizio			Increasing Patient Engagement in Rehabilitation Exercises Using Computer-Based Citizen Science	PLOS ONE			English	Article							UPPER-LIMB; FUNCTIONAL RECOVERY; MOTOR IMPAIRMENT; STROKE; IMPROVES; THERAPY; CHILDREN; MOTIVATION; ADHERENCE; ENHANCE	Patient motivation is an important factor to consider when developing rehabilitation programs. Here, we explore the effectiveness of active participation in web-based citizen science activities as a means of increasing participant engagement in rehabilitation exercises, through the use of a low-cost haptic joystick interfaced with a laptop computer. Using the joystick, patients navigate a virtual environment representing the site of a citizen science project situated in a polluted canal. Participants are tasked with following a path on a laptop screen representing the canal. The experiment consists of two conditions: in one condition, a citizen science component where participants classify images from the canal is included; and in the other, the citizen science component is absent. Both conditions are tested on a group of young patients undergoing rehabilitation treatments and a group of healthy subjects. A survey administered at the end of both tasks reveals that participants prefer performing the scientific task, and are more likely to choose to repeat it, even at the cost of increasing the time of their rehabilitation exercise. Furthermore, performance indices based on data collected from the joystick indicate significant differences in the trajectories created by patients and healthy subjects, suggesting that the low-cost device can be used in a rehabilitation setting for gauging patient recovery.	[Laut, Jeffrey; Porfiri, Maurizio] NYU, Dept Mech & Aerosp Engn, Polytech Sch Engn, MetroTech Ctr 6, Brooklyn, NY 11201 USA; [Laut, Jeffrey; Porfiri, Maurizio] Univ Roma La Sapienza, Dept Mech & Aerosp Engn, I-00185 Rome, Italy; [Cappa, Francesco] LUISS Guido Carli Univ, Dept Business & Management, I-00198 Rome, Italy; [Nov, Oded] NYU, Dept Technol Management & Innovat, Polytech Sch Engn, MetroTech Ctr 5, Brooklyn, NY USA	New York University; New York University Tandon School of Engineering; Sapienza University Rome; Luiss Guido Carli University; New York University; New York University Tandon School of Engineering	Porfiri, M (corresponding author), NYU, Dept Mech & Aerosp Engn, Polytech Sch Engn, MetroTech Ctr 6, Brooklyn, NY 11201 USA.	mporfiri@nyu.edu	Cappa, Francesco/D-5055-2016	Cappa, Francesco/0000-0001-5628-731X; Porfiri, Maurizio/0000-0002-1480-3539	National Science Foundation [BCS-1124795]; COOPERLINK	National Science Foundation(National Science Foundation (NSF)); COOPERLINK	This research was supported by the National Science Foundation under Grant #BCS-1124795 and through a scholarship to J. Laut from COOPERLINK. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 2008, CONCISE ENCY STAT, P344; Betker AL, 2006, ARCH PHYS MED REHAB, V87, P1141, DOI 10.1016/j.apmr.2006.04.010; Burke JW, 2009, PROCEEDINGS OF THE IEEE VIRTUAL WORLDS FOR SERIOUS APPLICATIONS, P103, DOI 10.1109/VS-GAMES.2009.17; Burke JW, 2009, VISUAL COMPUT, V25, P1085, DOI 10.1007/s00371-009-0387-4; BUTEFISCH C, 1995, J NEUROL SCI, V130, P59, DOI 10.1016/0022-510X(95)00003-K; Campbell R, 2001, J EPIDEMIOL COMMUN H, V55, P132, DOI 10.1136/jech.55.2.132; Cappa P, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083945; Carpinella I, 2009, J REHABIL MED, V41, P966, DOI 10.2340/16501977-0401; Casella G., 1990, STAT INFERENCE; Charles SK, 2005, INT C REHAB ROBOT, P13; Colombo R, 2005, IEEE T NEUR SYS REH, V13, P311, DOI 10.1109/TNSRE.2005.848352; Colombo R, 2007, J NEUROENG REHABIL, V4, DOI 10.1186/1743-0003-4-3; Cooper S, 2010, NATURE, V466, P756, DOI 10.1038/nature09304; Cordova DI, 1996, J EDUC PSYCHOL, V88, P715, DOI 10.1037/0022-0663.88.4.715; De Weyer Tom, 2012, Entertainment Computing, 11th International Conference (ICEC - 2012). Proceedings, P476, DOI 10.1007/978-3-642-33542-6_57; Deutsch JE, 2008, PHYS THER, V88, P1196, DOI 10.2522/ptj.20080062; DISHMAN R K, 1981, Journal of Behavioral Medicine, V4, P421, DOI 10.1007/BF00846151; DISHMAN RK, 1980, J APPL SOC PSYCHOL, V10, P115, DOI 10.1111/j.1559-1816.1980.tb00697.x; Duncan PW, 2002, STROKE, V33, P167, DOI 10.1161/hs0102.101014; Ellul C, 2011, ENGAGING LOCAL COMMU; Fasoli SE, 2003, ARCH PHYS MED REHAB, V84, P477, DOI 10.1053/apmr.2003.50110; Forster J, 2003, ORGAN BEHAV HUM DEC, V90, P148, DOI 10.1016/S0749-5978(02)00509-5; Frascarelli F, 2009, J REHABIL MED, V41, P988, DOI 10.2340/16501977-0412; Gentile D, 2009, PSYCHOL SCI, V20, P594, DOI 10.1111/j.1467-9280.2009.02340.x; GLOBERSON S, 1989, IIE TRANS, V21, P376, DOI 10.1080/07408178908966244; Greenberg BS, 2010, SIMULAT GAMING, V41, P238, DOI 10.1177/1046878108319930; GUNASEKERA WSL, 2005, SPR SP SURG SER, P407; Haklay M., 2013, CROWDSOURCING GEOGRA, P105, DOI [10.1007/978-94-007-4587-2_7, DOI 10.1007/978-94-007-4587-2_7]; Harris JE, 2009, STROKE, V40, P2123, DOI 10.1161/STROKEAHA.108.544585; Hidler Joseph, 2005, Top Stroke Rehabil, V12, P22, DOI 10.1310/RYT5-62N4-CTVX-8JTE; Hill AM, 2011, ARCH PHYS MED REHAB, V92, P1395, DOI 10.1016/j.apmr.2011.04.009; ICE R, 1985, PHYS THER, V65, P1832, DOI 10.1093/ptj/65.12.1832; Jaramillo P, 2012, PROCEEDINGS OF THE ASME 5TH ANNUAL DYNAMIC SYSTEMS AND CONTROL DIVISION CONFERENCE AND JSME 11TH MOTION AND VIBRATION CONFERENCE, DSCC 2012, VOL 2, P483; JAY S, 1984, J ADOLESCENT HEALTH, V5, P124, DOI 10.1016/S0197-0070(84)80012-1; Kafai YB, 1998, FROM BARBIE TO MORTAL KOMBAT, P90; Kwakkel G, 2004, STROKE, V35, P2529, DOI 10.1161/01.STR.0000143153.76460.7d; Lange B, 2009, PHYS THER REV, V14, P355, DOI 10.1179/108331909X12488667117258; Laut J, 2014, IEEE-ASME T MECH, V19, P1541, DOI 10.1109/TMECH.2013.2287705; Lee H, 2014, IEEE T NEUR SYS REH, V22, P44, DOI 10.1109/TNSRE.2013.2262689; Leversen JSR, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038830; Liepert J, 2000, STROKE, V31, P1210, DOI 10.1161/01.STR.31.6.1210; Lintott CJ, 2008, MON NOT R ASTRON SOC, V389, P1179, DOI 10.1111/j.1365-2966.2008.13689.x; Luft AR, 2004, JAMA-J AM MED ASSOC, V292, P1853, DOI 10.1001/jama.292.15.1853; Masiero S, 2007, ARCH PHYS MED REHAB, V88, P142, DOI 10.1016/j.apmr.2006.10.032; Mazzoleni S, 2014, IEEE T HAPTICS, V7, P175, DOI 10.1109/TOH.2013.73; Nov O., 2010, PROC 19 INT C WORLD, P741, DOI [10.1145/1772690.1772766, DOI 10.1145/1772690.1772766]; Nov O, 2011, P 2011 ICONFERENCE, P68, DOI [DOI 10.1145/1940761.1940771, 10.1145/1940761.1940771]; Nov O, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090375; Patton JL, 2006, EXP BRAIN RES, V168, P368, DOI 10.1007/s00221-005-0097-8; Prestopnik N. R., 2011, Proceedings of the 2011 IEEE Seventh International Conference on e-Science Workshops (eScienceW 2011), P28, DOI 10.1109/eScienceW.2011.14; Raddick M. Jordan, 2010, Astronomy Education Review, V9, DOI 10.3847/AER2009036; Rand Debbie, 2008, J Neurol Phys Ther, V32, P155, DOI 10.1097/NPT.0b013e31818ee779; Ravichandran R, 2010, J R SOC INTERFACE, V7, pS559, DOI 10.1098/rsif.2010.0120.focus; Reinkensmeyer DJ, 2002, IEEE T NEUR SYS REH, V10, P102, DOI 10.1109/TNSRE.2002.1031978; Reker DM, 2002, ARCH PHYS MED REHAB, V83, P750, DOI 10.1053/apmr.2002.99736; Riener R, 2005, MED BIOL ENG COMPUT, V43, P2, DOI 10.1007/BF02345116; Rohrer B, 2002, J NEUROSCI, V22, P8297; Sandlund M, 2011, DEV NEUROREHABIL, V14, P15, DOI 10.3109/17518423.2010.533329; Sandlund M, 2009, DEV MED CHILD NEUROL, V51, P173, DOI 10.1111/j.1469-8749.2008.03184.x; Shelton FDAP, 2001, NEUROREHAB NEURAL RE, V15, P229, DOI 10.1177/154596830101500311; Silvertown J, 2009, TRENDS ECOL EVOL, V24, P467, DOI 10.1016/j.tree.2009.03.017; SLUIJS EM, 1993, PHYS THER, V73, P786, DOI 10.1093/ptj/73.11.786; THOMAS KW, 1990, ACAD MANAGE REV, V15, P666, DOI 10.2307/258687; Timmermans AAA, 2010, IEEE T NEUR SYS REH, V18, P284, DOI 10.1109/TNSRE.2010.2047608; Trewin S, 1999, INT J HUM-COMPUT ST, V50, P109, DOI 10.1006/ijhc.1998.0238; Vischer P, 1998, ROBOTICA, V16, P207, DOI 10.1017/S0263574798000538; Von Ahn Luis, 2004, P SIGCHI C HUM FACT, P319, DOI DOI 10.1145/985692.985733; Vong SK, 2011, ARCH PHYS MED REHAB, V92, P176, DOI 10.1016/j.apmr.2010.10.016; Whitall J, 2000, STROKE, V31, P2390, DOI 10.1161/01.STR.31.10.2390; Wong WY, 2007, PROSTHET ORTHOT INT, V31, P62, DOI 10.1080/03093640600983949; Zollo L, 2011, MED BIOL ENG COMPUT, V49, P1131, DOI 10.1007/s11517-011-0808-1; Zyda M, 2005, COMPUTER, V38, P25, DOI 10.1109/MC.2005.297	73	31	32	0	30	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 20	2015	10	3							e0117013	10.1371/journal.pone.0117013	http://dx.doi.org/10.1371/journal.pone.0117013			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	CE8IA	25793867	Green Published, gold, Green Submitted			2023-01-03	WOS:000352084200010
J	Schmitt, A; Rodel, P; Anamur, C; Seeliger, C; Imhoff, AB; Herbst, E; Vogt, S; van Griensven, M; Winter, G; Engert, J				Schmitt, Andreas; Roedel, Philipp; Anamur, Cihad; Seeliger, Claudine; Imhoff, Andreas B.; Herbst, Elmar; Vogt, Stephan; van Griensven, Martijn; Winter, Gerhard; Engert, Julia			Calcium Alginate Gels as Stem Cell Matrix - Making Paracrine Stem Cell Activity Available for Enhanced Healing after Surgery	PLOS ONE			English	Article							HYDROGELS	Regeneration after surgery can be improved by the administration of anabolic growth factors. However, to locally maintain these factors at the site of regeneration is problematic. The aim of this study was to develop a matrix system containing human mesenchymal stem cells (MSCs) which can be applied to the surgical site and allows the secretion of endogenous healing factors from the cells. Calcium alginate gels were prepared by a combination of internal and external gelation. The gelling behaviour, mechanical stability, surface adhesive properties and injectability of the gels were investigated. The permeability of the gels for growth factors was analysed using bovine serum albumin and lysozyme as model proteins. Human MSCs were isolated, cultivated and seeded into the alginate gels. Cell viability was determined by AlamarBlue assay and fluorescence microscopy. The release of human VEGF and bFGF from the cells was determined using an enzyme-linked immunoassay. Gels with sufficient mechanical properties were prepared which remained injectable through a syringe and solidified in a sufficient time frame after application. Surface adhesion was improved by the addition of polyethylene glycol 300,000 and hyaluronic acid. Humans MSCs remained viable for the duration of 6 weeks within the gels. Human VEGF and bFGF was found in quantifiable concentrations in cell culture supernatants of gels loaded with MSCs and incubated for a period of 6 weeks. This work shows that calcium alginate gels can function as immobilization matrices for human MSCs.	[Roedel, Philipp; Anamur, Cihad; Winter, Gerhard; Engert, Julia] Univ Munich, Dept Pharm Pharmaceut Technol & Biopharmaceut, D-81377 Munich, Germany; [Schmitt, Andreas; Imhoff, Andreas B.; Herbst, Elmar; Vogt, Stephan] Tech Univ Munich, Dept Sports Orthoped, D-81675 Munich, Germany; [Seeliger, Claudine; van Griensven, Martijn] Tech Univ Munich, Dept Trauma Surg, D-81675 Munich, Germany; [Herbst, Elmar] Med Univ Innsbruck, Dept Trauma Surg, A-6020 Innsbruck, Austria	University of Munich; Technical University of Munich; Technical University of Munich; Medical University of Innsbruck	Schmitt, A (corresponding author), Tech Univ Munich, Dept Sports Orthoped, Ismaninger Str 22, D-81675 Munich, Germany.	dr.schmitt@tum.de	Vogt, Stephan/AAQ-7456-2021; van Griensven, Martijn/F-5808-2012	van Griensven, Martijn/0000-0001-5104-9881; Seeliger, Claudine/0000-0002-7631-444X	German Research Foundation (DFG); Technische Universitat Munchen	German Research Foundation (DFG)(German Research Foundation (DFG)); Technische Universitat Munchen	This work was supported by the German Research Foundation (DFG) and the Technische Universitat Munchen within the funding programme Open Access Publishing. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Allodi I, 2014, GLIA, V62, P1736, DOI 10.1002/glia.22712; ANDERSEN T, 2012, SPR CARB CH, V37, P227, DOI DOI 10.1039/9781849732765-00227; Asane GS, 2008, DRUG DEV IND PHARM, V34, P1246, DOI [10.1080/03639040802026012, 10.1080/03639040802026012 ]; Baksh D, 2004, J CELL MOL MED, V8, P301, DOI 10.1111/j.1582-4934.2004.tb00320.x; Buchmann S, 2013, J ORTHOP RES, V31, P300, DOI 10.1002/jor.22211; Caplan AI, 2011, CELL STEM CELL, V9, P11, DOI 10.1016/j.stem.2011.06.008; Carreau A, 2011, J CELL MOL MED, V15, P1239, DOI 10.1111/j.1582-4934.2011.01258.x; Chang CP, 2013, CLIN SCI, V124, P165, DOI 10.1042/CS20120226; de Groot M, 2004, J SURG RES, V121, P141, DOI 10.1016/j.jss.2004.02.018; DeVolder R, 2012, WIRES SYST BIOL MED, V4, P351, DOI 10.1002/wsbm.1174; DRAGET KI, 1990, CARBOHYD POLYM, V14, P159; Ehnert S, 2009, LANGENBECKS ARCH SUR; Ehnert S, 2009, LANGENBECK ARCH SURG, V394, P985, DOI 10.1007/s00423-009-0546-0; Elliott RB, 2005, TRANSPL P, V37, P3505, DOI 10.1016/j.transproceed.2005.09.038; Fannon M, 1996, J BIOL CHEM, V271, P17949, DOI 10.1074/jbc.271.30.17949; Hatef DA, 2008, ANN PLAS SURG, V61, P468, DOI 10.1097/SAP.0b013e3181641c17; Hou Y, 2009, MATRIX BIOL, V28, P324, DOI 10.1016/j.matbio.2009.04.007; Jeon O, 2014, ACTA BIOMATER, V10, P47, DOI 10.1016/j.actbio.2013.09.004; Kretlow JD, 2009, ADV MATER, V21, P3368, DOI 10.1002/adma.200802009; Kuo CK, 2001, BIOMATERIALS, V22, P511, DOI 10.1016/S0142-9612(00)00201-5; Lee KY, 2012, PROG POLYM SCI, V37, P106, DOI 10.1016/j.progpolymsci.2011.06.003; Liu C, 2014, BIOTECHNOL APPL BIOC; Lyras DN, 2010, ACTA ORTHOP BELG, V76, P380; Mandal K, 2011, ANGEW CHEM INT EDIT, V50, P8029, DOI 10.1002/anie.201103237; Oryan A, 2014, J TISSUE ENG REGEN M, V8, P421, DOI 10.1002/term.1534; Porada CD, 2010, ADV DRUG DELIVER REV, V62, P1156, DOI 10.1016/j.addr.2010.08.010; Rijcken E, 2014, J SURG RES, V187, P202, DOI 10.1016/j.jss.2013.10.013; Schmitt A, 2012, STEM CELLS INT, V2012, DOI 10.1155/2012/394962; Schnabel LV, 2009, J ORTHOP RES, V27, P1392, DOI 10.1002/jor.20887; Vaithilingam Vijayaganapathy, 2011, Rev Diabet Stud, V8, P51, DOI 10.1900/RDS.2011.8.51	30	34	37	1	18	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 20	2015	10	3							e0118937	10.1371/journal.pone.0118937	http://dx.doi.org/10.1371/journal.pone.0118937			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CE8IA	25793885	Green Submitted, gold, Green Published			2023-01-03	WOS:000352084200047
J	Doshi, P				Doshi, Peter			PATIENT INFORMATION FDA drug summaries: a simplification too far?	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material												pdoshi@bmj.com						Center for Drug Evaluation and Research, 2015, DRUG EV RES MED REV, P90; Center for Drug Evaluation and Research, 2015, STAT REV CEFT AV; FDA, MOR INF DALV DALB; FDA, 2015, DRUG TRAILS SNAPSH S; FDA, CDER CONV DRUG TRAIL; FDA, 2015, HIGHL PRESCR INF CEF; FDA, 2010, GUID IND NON CLIN TR; Whyte J., DRUG TRIAL SNAPSH MA; Woloshin S, 2011, N Y TIMES, pA21	9	0	0	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 12	2015	350								h3135	10.1136/bmj.h3135	http://dx.doi.org/10.1136/bmj.h3135			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CK7DN	26070648				2023-01-03	WOS:000356391300008
J	Kelly, CR; Higgins, AR; Chandra, S				Kelly, Christopher R.; Higgins, Andrew R.; Chandra, Subani			Noninvasive Positive-Pressure Ventilation	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							RESPIRATORY-FAILURE		[Kelly, Christopher R.; Higgins, Andrew R.; Chandra, Subani] Columbia Univ, Med Ctr, New York Presbyterian Hosp, New York, NY 10032 USA	Columbia University; NewYork-Presbyterian Hospital	Kelly, CR (corresponding author), Columbia Univ, Med Ctr, New York Presbyterian Hosp, Dept Med, 622 W 168th St,PH-342, New York, NY 10032 USA.	crk2002@columbia.edu						Barach AL, 1938, ANN INTERN MED, V12, P754, DOI 10.7326/0003-4819-12-6-754; BROCHARD L, 1995, NEW ENGL J MED, V333, P817, DOI 10.1056/NEJM199509283331301; Esteban A, 2004, NEW ENGL J MED, V350, P2452, DOI 10.1056/NEJMoa032736; Ferrer M, 2009, LANCET, V374, P1082, DOI 10.1016/S0140-6736(09)61038-2; Girault C, 2009, CRIT CARE MED, V37, P124, DOI 10.1097/CCM.0b013e3181928706; Gray A, 2008, NEW ENGL J MED, V359, P142, DOI 10.1056/NEJMoa0707992; Hilbert G, 2001, NEW ENGL J MED, V344, P481, DOI 10.1056/NEJM200102153440703; Lim WJ, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004360.pub4; Mehta S, 2001, AM J RESP CRIT CARE, V163, P540, DOI 10.1164/ajrccm.163.2.9906116; Nava S, 2013, LANCET ONCOL, V14, P219, DOI 10.1016/S1470-2045(13)70009-3; Navalesi P, 2000, CRIT CARE MED, V28, P1785, DOI 10.1097/00003246-200006000-00015; Schettino G, 2005, CRIT CARE MED, V33, P1976, DOI 10.1097/01.CCM.0000178176.51024.82; Zarbock A, 2009, CHEST, V135, P1252, DOI 10.1378/chest.08-1602	13	12	15	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 4	2015	372	23								10.1056/NEJMvcm1313336	http://dx.doi.org/10.1056/NEJMvcm1313336			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CK1GK	26039621				2023-01-03	WOS:000355955100006
J	Bellmunt, J; Werner, L; Leow, JJ; Mullane, SA; Fay, AP; Riester, M; Van Hummelen, P; Taplin, ME; Choueiri, TK; Van Allen, E; Rosenberg, J				Bellmunt, Joaquim; Werner, Lillian; Leow, Jeffrey J.; Mullane, Stephanie A.; Fay, Andre P.; Riester, Markus; Van Hummelen, Paul; Taplin, Mary-Ellen; Choueiri, Toni K.; Van Allen, Eliezer; Rosenberg, Jonathan			Somatic Copy Number Abnormalities and Mutations in PI3K/AKT/mTOR Pathway Have Prognostic Significance for Overall Survival in Platinum Treated Locally Advanced or Metastatic Urothelial Tumors	PLOS ONE			English	Article							BLADDER-CANCER; PIK3CA MUTATION; FGFR3; CARCINOMA; FREQUENT; TARGETS; AMPLIFICATION; THERAPY; RAS	Background An integrative analysis was conducted to identify genomic alterations at a pathway level that could predict overall survival (OS) in patients with advanced urothelial carcinoma (UC) treated with platinum-based chemotherapy. Patients and Methods DNA and RNA were extracted from 103 formalin-fixed paraffin embedded (FFPE) invasive high-grade UC samples and were screened for mutations, copy number variation (CNV) and gene expression analysis. Clinical data were available from 85 cases. Mutations were analyzed by mass-spectrometry based on genotyping platform (Oncomap 3) and genomic imbalances were detected by comparative genomic hybridization (CGH) analysis. Regions with threshold of log2 ratio >= 0.4, or <= 0.6 were defined as either having copy number gain or loss and significantly recurrent CNV across the set of samples were determined using a GISTIC analysis. Expression analysis on selected relevant UC genes was conducted using Nanostring. To define the co-occurrence pattern of mutations and CNV, we grouped genomic events into 5 core signal transduction pathways: 1) TP53 pathway, 2) RTK/RAS/RAF pathway, 3) PI3K/AKT/mTOR pathway, 4) WNT/CTNNB1, 5) RB1 pathway. Cox regression was used to assess pathways abnormalities with survival outcomes. Results 35 samples (41%) harbored mutations on at least one gene: TP53 (16%), PIK3CA (9%), FGFR3 (2%), HRAS/KRAS (5%), and CTNNB1 (1%). 66% of patients had some sort of CNV. PIK3CA/AKT/mTOR pathway alteration (mutations+CNV) had the greatest impact on OS (p=0.055). At a gene level, overexpression of CTNNB1 (p=0.0008) and PIK3CA (p=0.02) were associated with shorter OS. Mutational status on PIK3CA was not associated with survival. Among other individually found genomic alterations, TP53 mutations (p=0.07), mTOR gain (p=0.07) and PTEN overexpression (p=0.08) have a marginally significant negative impact on OS. Conclusions Our study suggests that targeted therapies focusing on the PIK3CA/AKT/mTOR pathway genomic alterations can generate the greatest impact in the overall patient population of high-grade advanced UC.	[Bellmunt, Joaquim; Leow, Jeffrey J.; Mullane, Stephanie A.; Fay, Andre P.; Taplin, Mary-Ellen; Choueiri, Toni K.; Van Allen, Eliezer] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dana Farber Canc Inst,Lank Ctr Genitourinary Onco, Boston, MA 02115 USA; [Werner, Lillian; Riester, Markus] Harvard Univ, Sch Med, Dana Farber Canc Inst, Biostat & Computat Biol, Boston, MA 02115 USA; [Van Hummelen, Paul] Dana Farber Canc Inst, Ctr Canc Genome Discovery, Boston, MA 02115 USA; [Rosenberg, Jonathan] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA	Harvard University; Brigham & Women's Hospital; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Memorial Sloan Kettering Cancer Center	Bellmunt, J (corresponding author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Dana Farber Canc Inst,Lank Ctr Genitourinary Onco, Boston, MA 02115 USA.	joaquim_bellmunt@dfci.harvard.edu	Leow, Jeffrey/AAL-8931-2020; Bellmunt, Joaquim/B-8151-2019; Choueiri, Toni/K-5238-2019	Leow, Jeffrey/0000-0002-6216-1913; Bellmunt, Joaquim/0000-0003-2328-3421; Choueiri, Toni/0000-0002-9201-3217; Rosenberg, Jonathan/0000-0003-2637-4249; van hummelen, paul/0000-0002-4801-8600	Spanish Health Ministry Grant "Fondo de Investigacion Sanitaria" [PI061513]; RTICC grants [06/0020/19]; Pla Director d'Oncologia de Catalunya (XBTC); Friends of Dana-Farber; Retired Professional Fire Fighters Cancer Fund; Whole Foods Golf Classic; NATIONAL CANCER INSTITUTE [P30CA008748] Funding Source: NIH RePORTER	Spanish Health Ministry Grant "Fondo de Investigacion Sanitaria"; RTICC grants; Pla Director d'Oncologia de Catalunya (XBTC); Friends of Dana-Farber; Retired Professional Fire Fighters Cancer Fund; Whole Foods Golf Classic; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work has been supported by PI061513 (Spanish Health Ministry Grant "Fondo de Investigacion Sanitaria") and RTICC 06/0020/19 grants. Fundacio Cellex (Barcelona) provided a generous donation to the Group of Molecular Therapeutics and Biomarkers, Hospital del Mar. The Tumor Bank of the Department of Pathology of Hospital del Mar (RD09/0076/0036) and the Xarxa de Bancs de Tumors sponsored by Pla Director d'Oncologia de Catalunya (XBTC) provided tissue samples. This study was also possible thanks to a Grant from Friends of Dana-Farber, the Retired Professional Fire Fighters Cancer Fund, and the generous support of Whole Foods Golf Classic for bladder cancer research in memoriam of Christopher Snell. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abol-Enein H, 2005, EUR UROL, V48, P202, DOI 10.1016/j.eururo.2005.04.006; Ahmad I, 2011, DIS MODEL MECH, V4, P548, DOI 10.1242/dmm.006874; Bambury RM, 2013, CURR OPIN UROL, V23, P472, DOI 10.1097/MOU.0b013e328363a3cd; Burger M, 2013, EUR UROL, V63, P36, DOI 10.1016/j.eururo.2012.08.061; CAIRNS P, 1991, ONCOGENE, V6, P2305; Cancer Genome Atlas Research Network, 2014, NATURE; Ching CB, 2010, LAB INVEST, V90, P1406, DOI 10.1038/labinvest.2010.133; Fleischmann A, 2011, EUR UROL, V60, P350, DOI 10.1016/j.eururo.2011.05.035; Galsky MD, 2012, INVEST NEW DRUG, V30, P695, DOI 10.1007/s10637-010-9541-0; Gui YT, 2011, NAT GENET, V43, P875, DOI 10.1038/ng.907; Houede N, 2014, PHARM THERAPEUTICS; Iyer G, 2013, J CLIN ONCOL, V31, P3133, DOI 10.1200/JCO.2012.46.5740; Juanpere N, 2012, HUM PATHOL, V43, P1573, DOI 10.1016/j.humpath.2011.10.026; Kalinsky K, 2009, CLIN CANCER RES, V15, P5049, DOI 10.1158/1078-0432.CCR-09-0632; Kim PH, 2014, EUROPEAN UROLOGY; Kompier LC, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013821; Korkolopoulou P, 2012, BJU INT, V110, pE1237, DOI 10.1111/j.1464-410X.2012.11569.x; Lae M, 2010, ANN ONCOL, V21, P815, DOI 10.1093/annonc/mdp488; Lamont FR, 2011, BRIT J CANCER, V104, P75, DOI 10.1038/sj.bjc.6606016; MacConaill LE, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007887; Matulonis UA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024433; Memon AA, 2006, BRIT J CANCER, V94, P1703, DOI 10.1038/sj.bjc.6603154; Mermel CH, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-4-r41; Millis SZ, 2014, CLIN GENITOURINARY C; Milowsky MI, 2013, J CLIN ONCOL, V31, DOI 10.1200/jco.2013.31.6_suppl.255; Neshat MS, 2001, P NATL ACAD SCI USA, V98, P10314, DOI 10.1073/pnas.171076798; Platt FM, 2009, CLIN CANCER RES, V15, P6008, DOI 10.1158/1078-0432.CCR-09-0898; Polivka J, 2014, PHARMACOL THERAPEUT, V142, P164, DOI 10.1016/j.pharmthera.2013.12.004; Rastislav B, 2014, J CLIN ONCOL S, V32, p5s; Ross JS, 2014, MODERN PATHOL, V27, P271, DOI 10.1038/modpathol.2013.135; Sequist LV, 2014, 2014 AACR ANN M APR; Shigaki H, 2013, CLIN CANCER RES, V19, P2451, DOI 10.1158/1078-0432.CCR-12-3559; Siegel R, 2014, CA-CANCER J CLIN, V64, P9, DOI 10.3322/caac.21208; van Rhijn BWG, 2012, J UROLOGY, V187, P310, DOI 10.1016/j.juro.2011.09.008; Williams SV, 2013, HUM MOL GENET, V22, P795, DOI 10.1093/hmg/dds486	35	16	16	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 3	2015	10	6							e0124711	10.1371/journal.pone.0124711	http://dx.doi.org/10.1371/journal.pone.0124711			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CJ7ST	26039708	gold, Green Published			2023-01-03	WOS:000355700700004
J	Kaija, H; Pakanen, L; Kortelainen, ML; Porvari, K				Kaija, Helena; Pakanen, Lasse; Kortelainen, Marja-Leena; Porvari, Katja			Hypothermia and Rewarming Induce Gene Expression and Multiplication of Cells in Healthy Rat Prostate Tissue	PLOS ONE			English	Article							RECEPTOR LIGANDS; CANCER CELLS; EGF RECEPTOR; COLD STRESS; AMPHIREGULIN; P21; THROMBOMODULIN; FIBROBLASTS; ACTIVATION; MECHANISMS	Prostate cancer has been extensively studied, but cellular stress responses in healthy prostate tissue are rarely investigated. Hypothermia is known to cause alterations in mRNA and protein expressions and stability. The aim of this study was to use normal rat prostate as a model in order to find out consequences of cold exposure and rewarming on the expressions of genes which are either members or functionally/structurally related to erythroblastic leukemia viral oncogene B (ErbB) signaling pathway. Relative mRNA expressions of amphiregulin (AMR), cyclin D1 (CyD1), cyclin-dependent kinase inhibitor 1A (p21), transmembrane form of the prostatic acid phosphatase (PAcP), thrombomodulin (TM) and heat shock transcription factor 1 (HSF1) in rat ventral prostate were quantified in mild (2 or 4.5 h at room temperature) and severe (2 or 4.5 h at + 10 degrees C) hypothermia and in rewarming after cold exposure (2 h at + 10 degrees C followed by 2 h at room temperature or 3 h at + 28 degrees C). AMR protein level, apoptotic Bcl-2 associated X protein to B-cell CLL/lymphoma 2(Bax/Bcl-2) mRNA ratio and proliferative index Ki-67 were determined. 4.5-h mild hypothermia, 2-h severe hypothermia and rewarming increased expression of all these genes. Elevated proliferation index Ki-67 could be seen in 2-h severe hypothermia, and the proliferation index had its highest value in longer rewarming with totally recovered normal body temperature. Proapoptotic tendency could be seen in 2-h mild hypothermia while anti-apoptosis was predominant in 4.5-h mild hypothermia and in shorter rewarming with only partly recovered body temperature. Hypothermia and following rewarming promote the proliferation of cells in healthy rat prostate tissue possibly via ErbB signaling pathway.	[Kaija, Helena; Pakanen, Lasse; Kortelainen, Marja-Leena; Porvari, Katja] Univ Oulu, Fac Med, Dept Forens Med, Oulu, Finland; [Kaija, Helena; Pakanen, Lasse; Porvari, Katja] Oulu Univ Hosp, Med Res Ctr Oulu, Oulu, Finland; [Kaija, Helena; Pakanen, Lasse; Porvari, Katja] Univ Oulu, Oulu, Finland	University of Oulu; University of Oulu; University of Oulu	Porvari, K (corresponding author), Univ Oulu, Fac Med, Dept Forens Med, Oulu, Finland.	katja.porvari@oulu.fi						Alam HB, 2010, J TRAUMA, V68, P1084, DOI 10.1097/TA.0b013e3181d76bd1; Baust JG, 2004, CRYOBIOLOGY, V48, P190, DOI 10.1016/j.cryobiol.2004.01.005; Bostwick DG, 2004, PROSTATE, V58, P164, DOI 10.1002/pros.10322; Busser B, 2011, BBA-REV CANCER, V1816, P119, DOI 10.1016/j.bbcan.2011.05.003; De Witte JL, 2010, ANESTH ANALG, V110, P829, DOI 10.1213/ANE.0b013e3181cb3ebf; ESMON CT, 1981, P NATL ACAD SCI-BIOL, V78, P2249, DOI 10.1073/pnas.78.4.2249; Gan Y, 2010, ONCOGENE, V29, P4947, DOI 10.1038/onc.2010.240; Harris RC, 2003, EXP CELL RES, V284, P2, DOI 10.1016/S0014-4827(02)00105-2; Hedelin H, 2007, SCAND J UROL NEPHROL, V41, P430, DOI 10.1080/00365590701365123; Hynson J M, 1992, J Clin Anesth, V4, P194, DOI 10.1016/0952-8180(92)90064-8; Iacopino F, 2006, ANTICANCER RES, V26, P1849; Janicke RU, 2007, CELL CYCLE, V6, P407; Jiang JY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0085179; Kaija H, 2014, STRESS, V17, P504, DOI 10.3109/10253890.2014.953477; Kang KH, 1999, EXP CELL RES, V253, P403, DOI 10.1006/excr.1999.4644; Kasina S, 2009, CELL PROLIFERAT, V42, P799, DOI 10.1111/j.1365-2184.2009.00645.x; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; Matijasevic Z, 1998, ONCOL RES, V10, P605; Meng TC, 1998, J BIOL CHEM, V273, P22096, DOI 10.1074/jbc.273.34.22096; Roobol A, 2011, BIOCHEM J, V435, P499, DOI 10.1042/BJ20101303; Roobol A, 2009, FEBS J, V276, P286, DOI 10.1111/j.1742-4658.2008.06781.x; Schneider MR, 2009, J CELL PHYSIOL, V218, P460, DOI 10.1002/jcp.21635; Sessler DI, 2009, CRIT CARE MED, V37, pS203, DOI 10.1097/CCM.0b013e3181aa5568; SHOYAB M, 1989, SCIENCE, V243, P1074, DOI 10.1126/science.2466334; Sonna LA, 2002, J APPL PHYSIOL, V92, P1725, DOI 10.1152/japplphysiol.01143.2001; Stacey DW, 2003, CURR OPIN CELL BIOL, V15, P158, DOI 10.1016/S0955-0674(03)00008-5; Swindle CS, 2001, J CELL BIOL, V154, P459, DOI 10.1083/jcb.200103103; Tikhomirov O, 2005, J CELL SCI, V118, P5681, DOI 10.1242/jcs.02676; Torring N, 1998, PROSTATE CANCER P D, V1, P262, DOI 10.1038/sj.pcan.4500250; Tveita AA, 2012, CRYOBIOLOGY, V64, P201, DOI 10.1016/j.cryobiol.2012.01.009; Van de Wouwer M, 2004, CRIT CARE MED, V32, pS254, DOI 10.1097/01.CCM.0000128036.64448.9e; Vihervaara A, 2014, J CELL SCI, V127, P261, DOI 10.1242/jcs.132605	32	8	9	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 21	2015	10	5							e0127854	10.1371/journal.pone.0127854	http://dx.doi.org/10.1371/journal.pone.0127854			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CK7VW	25996932	gold, Green Submitted, Green Published			2023-01-03	WOS:000356444000092
J	Yu, QY; Zhu, ZL; Liu, Y; Zhang, J; Li, K				Yu, Qiuyan; Zhu, Zhenli; Liu, Yan; Zhang, Jun; Li, Ke			Efficacy and Safety of HER2-Targeted Agents for Breast Cancer with HER2-Overexpression: A Network Meta-Analysis	PLOS ONE			English	Article							LAPATINIB PLUS CAPECITABINE; PHASE-III TRIAL; TRASTUZUMAB EMTANSINE; 1ST-LINE TREATMENT; NEOADJUVANT THERAPY; CLINICAL-TRIALS; ERBB RECEPTORS; DOUBLE-BLIND; OPEN-LABEL; CHEMOTHERAPY	Background Clinical trials of human epidermal growth factor receptor 2 (HER2)-targeted agents added to standard treatment have been efficacious for HER2-positive (HER2+) advanced breast cancer. To our knowledge, no meta-analysis has evaluated HER2-targeted therapy including trastuzumab emtansine (T-DM1) and pertuzumab for HER2-positive breast caner and ranked the targeted treatments. We performed a network meta-analysis of both direct and indirect comparisons to evaluate the effect of adding HER2-targeted agents to standard treatment and examined side effects. Methods We performed a Bayesian-framework network meta-analysis of randomized controlled trials to compare 6 HER2-targeted treatment regimens and 1 naive standard treatment (NST, without any-targeted drugs) in targeted treatment of HER2+ breast cancer in adults. These treatment regimens were T-DM1, LC (lapatinib), HC (trastuzumab), PEC (pertuzumab), LHC (lapatinib and trastuzumab), and PEHC (pertuzumab and trastuzumab). The main outcomes were overall survival and response rates. We also examined side effects of rash, LVEF (left ventricular ejection fraction), fatigue, and gastrointestinal disorders, and performed subgroup analysis for the different treatment regimens in metastatic or advanced breast cancer. Results We identified 25 articles of 21 trials, with data for 11,276 participants. T-DM1 and PEHC were more efficient drug regimens with regard to overall survival as compared with LHC, LC, HC and PEC. The incidence of treatment-related rash occurs more frequently in the patients who received LC treatment regimen than PEHC and T-DM1 and HC. In subgroup analysis, T-DM1 was associated with increased overall survival as compared with LC and HC. PEHC was associated with increased overall response as compared with LC, HC, and NST. Conclusions Overall, the regimen of T-DM1 as well as pertuzumab in combination with trastuzumab and docetaxel is efficacious with fewer side effects as compared with other regimens, especially for advanced HER2+ breast cancer. Impact This study suggests that both T-DM1 and PEHC therapy are potentially and equally useful treatments for HER2+ breast cancer.	[Yu, Qiuyan; Zhu, Zhenli; Liu, Yan; Zhang, Jun; Li, Ke] Shantou Univ, Coll Med, Dept Publ Hlth, Shantou 515041, Guangdong, Peoples R China	Shantou University	Li, K (corresponding author), Shantou Univ, Coll Med, Dept Publ Hlth, 22 Xinling Rd, Shantou 515041, Guangdong, Peoples R China.	kli@stu.edu.cn	xiaoxiao, zhang/HHN-4916-2022					Ades AE, 2006, PHARMACOECONOMICS, V24, P1, DOI 10.2165/00019053-200624010-00001; Andersson M, 2011, J CLIN ONCOL, V29, P264, DOI 10.1200/JCO.2010.30.8213; Botrel TEA, 2013, CORE EVID, V8, P69, DOI 10.2147/CE.S50474; Azim HA, 2013, J CLIN ONCOL, V31, P4504, DOI 10.1200/JCO.2013.50.9448; Bangalore S, 2011, LANCET ONCOL, V12, P65, DOI 10.1016/S1470-2045(10)70260-6; Baselga J, 2014, ANN ONCOL, V25, P592, DOI 10.1093/annonc/mdt543; Baselga J, 2012, NEW ENGL J MED, V366, P109, DOI 10.1056/NEJMoa1113216; Borenstein M., 2009, INTRO META ANAL; Bucher HC, 1997, J CLIN EPIDEMIOL, V50, P683, DOI 10.1016/S0895-4356(97)00049-8; Burstein HJ, 2007, CANCER-AM CANCER SOC, V110, P965, DOI 10.1002/cncr.22885; Caldwell DM, 2010, J CLIN EPIDEMIOL, V63, P875, DOI 10.1016/j.jclinepi.2009.08.025; Cameron D, 2010, ONCOLOGIST, V15, P924, DOI 10.1634/theoncologist.2009-0181; Chen T, 2011, CANCER TREAT REV, V37, P312, DOI 10.1016/j.ctrv.2010.09.001; Chu D, 2008, J HEMATOL ONCOL, V1, DOI 10.1186/1756-8722-1-16; Cipriani Andrea, 2009, Lancet, V373, P746, DOI 10.1016/S0140-6736(09)60046-5; Cortes J, 2013, ANN ONCOL, V24, P2630, DOI 10.1093/annonc/mdt274; DerSimonian R, 2007, CONTEMP CLIN TRIALS, V28, P105, DOI 10.1016/j.cct.2006.04.004; Di Leo A, 2008, J CLIN ONCOL, V26, P5544, DOI 10.1200/JCO.2008.16.2578; Drucker AM, 2012, BREAST CANCER RES TR, V135, P347, DOI 10.1007/s10549-012-2157-7; Eiermann W, 2001, ANN ONCOL, V12, P57, DOI 10.1023/A:1011172125897; Elliott WJ, 2007, LANCET, V369, P201, DOI 10.1016/S0140-6736(07)60108-1; Gasparini G, 2007, BREAST CANCER RES TR, V101, P355, DOI 10.1007/s10549-006-9306-9; Geyer CE, 2006, NEW ENGL J MED, V355, P2733, DOI 10.1056/NEJMoa064320; Gianni L, 2013, J CLIN ONCOL, V31, P1719, DOI 10.1200/JCO.2012.44.7912; Gianni L, 2012, LANCET ONCOL, V13, P25, DOI 10.1016/S1470-2045(11)70336-9; Guan ZZ, 2013, J CLIN ONCOL, V31, P1947, DOI 10.1200/JCO.2011.40.5241; Harris CA, 2011, ANN ONCOL, V22, P1308, DOI 10.1093/annonc/mdq593; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; Higgins Julian P T, 2011, BMJ, V343, pd5928, DOI 10.1136/bmj.d5928; Huober J, 2012, BREAST, V21, P27, DOI 10.1016/j.breast.2011.07.006; Hurvitz SA, 2013, J CLIN ONCOL, V31, P1157, DOI 10.1200/JCO.2012.44.9694; Jemal A, 2007, CA-CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43; Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI [10.3322/caac.20115, 10.3322/caac.20107]; Joensuu H, 2006, NEW ENGL J MED, V354, P809, DOI 10.1056/NEJMoa053028; Johnston S, 2009, J CLIN ONCOL, V27, P5538, DOI 10.1200/JCO.2009.23.3734; Kaufman B, 2009, J CLIN ONCOL, V27, P5529, DOI 10.1200/JCO.2008.20.6847; Lam SKH, 2007, BMJ-BRIT MED J, V335, P925, DOI 10.1136/bmj.39343.511389.BE; Lu G, 2004, STAT MED, V23, P3105, DOI 10.1002/sim.1875; Marty M, 2005, J CLIN ONCOL, V23, P4265, DOI 10.1200/JCO.2005.04.173; Mauri D, 2008, JNCI-J NATL CANCER I, V100, P1780, DOI 10.1093/jnci/djn414; McCormack PL, 2013, DRUGS, V73, P1491, DOI 10.1007/s40265-013-0109-0; Miller KD, 2014, J CLIN ONCOL, V32, P1437, DOI 10.1200/JCO.2013.52.6590; Niculescu-Duvaz I, 2010, CURR OPIN MOL THER, V12, P350; Owen A, 2010, INT J CARDIOL, V142, P218, DOI 10.1016/j.ijcard.2009.11.045; Perez EA, 2011, J CLIN ONCOL, V29, P4491, DOI 10.1200/JCO.2011.36.7045; Psaty BN, 2003, JAMA-J AM MED ASSOC, V289, P2534, DOI 10.1001/jama.289.19.2534; Robidoux A, 2013, LANCET ONCOL, V14, P1183, DOI 10.1016/S1470-2045(13)70411-X; Salanti G, 2011, J CLIN EPIDEMIOL, V64, P163, DOI 10.1016/j.jclinepi.2010.03.016; Salanti G, 2009, J CLIN EPIDEMIOL, V62, P857, DOI 10.1016/j.jclinepi.2008.10.001; Schwarzberg LS, 2010, ONCOLOGIST, V15, P122, DOI 10.1634/theoncologist.2009-0240; Slamon D, 2011, NEW ENGL J MED, V365, P1273, DOI 10.1056/NEJMoa0910383; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Spiegelhalter DJ, 2002, J R STAT SOC B, V64, P583, DOI 10.1111/1467-9868.00353; Stettler C, 2007, LANCET, V370, P937, DOI 10.1016/S0140-6736(07)61444-5; Stettler C, 2008, BMJ-BRIT MED J, V337, DOI 10.1136/bmj.a1331; Strassmann R, 2009, EUR RESPIR J, V34, P634, DOI 10.1183/09031936.00167708; Swain SM, 2013, LANCET ONCOL, V14, P461, DOI 10.1016/S1470-2045(13)70130-X; Theriault RL, 2013, J NATL COMPR CANC NE, V11, P753, DOI 10.6004/jnccn.2013.0098; Thijs V, 2008, EUR HEART J, V29, P1086, DOI 10.1093/eurheartj/ehn106; Trikalinos TA, 2001, J CLIN EPIDEMIOL, V54, P245, DOI 10.1016/S0895-4356(00)00311-5; Trikalinos TA, 2009, LANCET, V373, P911, DOI 10.1016/S0140-6736(09)60319-6; Untch M, 2012, LANCET ONCOL, V13, P135, DOI 10.1016/S1470-2045(11)70397-7; van der Valk R, 2009, J CLIN EPIDEMIOL, V62, P1279, DOI 10.1016/j.jclinepi.2008.04.012; Verma S, 2012, NEW ENGL J MED, V367, P1783, DOI 10.1056/NEJMoa1209124; Vogel UF, 2010, DIAGN PATHOL, V5, DOI 10.1186/1746-1596-5-50; von Minckwitz G, 2009, J CLIN ONCOL, V27, P1999, DOI 10.1200/JCO.2008.19.6618; Wandel S, 2010, BMJ-BRIT MED J, V341, DOI 10.1136/bmj.c4675; Zahnow Cynthia A., 2006, Expert Reviews in Molecular Medicine, V8, P1, DOI 10.1017/S146239940600010X; Zhang HT, 2007, J CLIN INVEST, V117, P2051, DOI 10.1172/JCI32278; Zhu Z, 2014, BRIT J CANCER, V110, P2396, DOI 10.1038/bjc.2014.197	71	15	16	0	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 20	2015	10	5							e0127404	10.1371/journal.pone.0127404	http://dx.doi.org/10.1371/journal.pone.0127404			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CI7CV	25993646	Green Published, gold, Green Submitted			2023-01-03	WOS:000354921400114
J	Paul, M; Bishara, J; Yahav, D; Goldberg, E; Neuberger, A; Ghanem-Zoubi, N; Dickstein, Y; Nseir, W; Dan, M; Leibovici, L				Paul, Mical; Bishara, Jihad; Yahav, Dafna; Goldberg, Elad; Neuberger, Ami; Ghanem-Zoubi, Nesrin; Dickstein, Yaakov; Nseir, William; Dan, Michael; Leibovici, Leonard			Trimethoprim-sulfamethoxazole versus vancomycin for severe infections caused by meticillin resistant Staphylococcus aureus: randomised controlled trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article							SOFT-TISSUE INFECTIONS; ANTIMICROBIAL SUSCEPTIBILITY; BACTEREMIA; THERAPY; COTRIMOXAZOLE; SKIN; TRIMETHOPRIM/SULFAMETHOXAZOLE; ENDOCARDITIS; COMBINATION; DAPTOMYCIN	OBJECTIVE To show non-inferiority of trimethoprim-sulfamethoxazole compared with vancomycin for the treatment of severe infections due to meticillin resistant Staphylococcus aureus (MRSA). DESIGN Parallel, open label, randomised controlled trial. SETTING Four acute care hospitals in Israel. PARTICIPANTS Adults with severe infections caused by MRSA susceptible to trimethoprim-sulfamethoxazole and vancomycin. Patients with left sided endocarditis, meningitis, chronic haemodialysis, and prolonged neutropenia were excluded. INTERVENTIONS Trimethoprim-sulfamethoxazole 320 mg/1600 mg twice daily versus vancomycin 1 g twice daily for a minimum of seven days and then by indication. MAINOUTCOME MEASURES The primary efficacy outcome was treatment failure assessed at day 7, consisting of death, persistence of haemodynamic instability or fever, stable or worsening Sequential Organ Failure Assessment score, and persistence of bacteraemia. The primary safety outcome was all cause mortality at day 30. Non-inferiority was defined by a difference of less than 15% for treatment failure. RESULTS 252 patients were included in the trial, of whom 91 (36%) had bacteraemia. No significant difference in treatment failure was seen for trimethoprimsulfamethoxazole (51/135, 38%) versus vancomycin (32/117, 27%)-risk ratio 1.38 (95% confidence interval 0.96 to 1.99). However, trimethoprim-sulfamethoxazole did not meet the non-inferiority criterion-absolute difference 10.4% (95% confidence interval -1.2% to 21.5%). For patients with bacteraemia, the risk ratio was 1.40 (0.91 to 2.16). In a multivariable logistic regression analysis, trimethoprim-sulfamethoxazole was significantly associated with treatment failure (adjusted odds ratio 2.00, 1.09 to 3.65). The 30 day mortality rate was 32/252 (13%), with no significant difference between arms. Among patients with bacteraemia, 14/41 (34%) treated with trimethoprimsulfamethoxazole and 9/50 (18%) with vancomycin died (risk ratio 1.90, 0.92 to 3.93). CONCLUSIONS High dose trimethoprim-sulfamethoxazole did not achieve non-inferiority to vancomycin in the treatment of severe MRSA infections. The difference was particularly marked for patients with bacteraemia.	[Paul, Mical; Bishara, Jihad] Beilinson Med Ctr, Rabin Med Ctr, Unit Infect Dis, Petah Tiqwa, Israel; [Paul, Mical; Bishara, Jihad; Yahav, Dafna; Goldberg, Elad; Dan, Michael; Leibovici, Leonard] Tel Aviv Univ, Sackler Fac Med, Ramat Aviv, Israel; [Yahav, Dafna; Leibovici, Leonard] Beilinson Med Ctr, Rabin Med Ctr, Unit Infect Dis, Med E, Petah Tiqwa, Israel; [Goldberg, Elad] Beilinson Med Ctr, Rabin Med Ctr, Unit Infect Dis, Med F, Petah Tiqwa, Israel; [Neuberger, Ami] Rambam Hlth Care Campus, Div Infect Dis, Med B, IL-31096 Haifa, Israel; [Neuberger, Ami; Dickstein, Yaakov] Technion Israel Inst Technol, Haifa, Israel; [Neuberger, Ami; Dickstein, Yaakov] Ruth & Bruce Rappaport Fac Med, Haifa, Israel; [Paul, Mical; Ghanem-Zoubi, Nesrin] Rambam Hlth Care Campus, Div Infect Dis, IL-31096 Haifa, Israel; [Dickstein, Yaakov] Rambam Hlth Care Campus, Div Infect Dis, Med A, IL-31096 Haifa, Israel; [Nseir, William] Holy Family Hosp, Internal Med Dept, Nazareth, Israel; [Nseir, William] Bar Ilan Univ, Fac Med Galilee, Safed, Israel; [Dan, Michael] E Wolfson Hosp, Infect Dis Unit, Holon, Israel	Rabin Medical Center; Tel Aviv University; Sackler Faculty of Medicine; Rabin Medical Center; Rabin Medical Center; Rambam Health Care Campus; Technion Israel Institute of Technology; Technion Israel Institute of Technology; Rappaport Faculty of Medicine; Rambam Health Care Campus; Rambam Health Care Campus; Bar Ilan University	Paul, M (corresponding author), Rambam Hlth Care Campus, Div Infect Dis, IL-31096 Haifa, Israel.	paulm@post.tau.ac.il	Yahav, Dafna/AAX-9961-2020; Bishara, Jihad/AAV-1519-2021	Yahav, Dafna/0000-0003-3181-9791; Dickstein, Yaakov/0000-0002-1063-5478	Sima Lior scholarship; Rabin Medical Center Young Investigator scholarship	Sima Lior scholarship; Rabin Medical Center Young Investigator scholarship	The study was partially funded by the Sima Lior scholarship 2008 (MP) and Rabin Medical Center Young Investigator scholarship 2009 (DY). The funders had no role in trial design; data collection, analysis, or interpretation; or manuscript preparation.	Australian Group on Antimicrobial Resistance (AGAR), SAP 2012 ANT SUSC RE; Australian Group on Antimicrobial Resistance (AGAR), SAP 2011 ANT SUSC RE; Bellomo R, 2007, INTENS CARE MED, V33, P409, DOI 10.1007/s00134-006-0478-x; BONE RC, 1989, CRIT CARE MED, V17, P389, DOI 10.1097/00003246-198905000-00002; Bonett DG, 2002, PSYCHOL METHODS, V7, P370, DOI 10.1037//1082-989X.7.3.370; Campbell ML, 2012, ANN PHARMACOTHER, V46, P1587, DOI 10.1345/aph.1R211; Carnicer-Pont D, 2006, EPIDEMIOL INFECT, V134, P1167, DOI 10.1017/S0950268806006327; Cenizal MJ, 2007, ANTIMICROB AGENTS CH, V51, P2628, DOI 10.1128/AAC.00206-07; DEGORGOLAS M, 1995, ANTIMICROB AGENTS CH, V39, P953, DOI 10.1128/AAC.39.4.953; ELWELL LP, 1986, ANTIMICROB AGENTS CH, V29, P1092, DOI 10.1128/AAC.29.6.1092; Euba G, 2009, ANTIMICROB AGENTS CH, V53, P2672, DOI 10.1128/AAC.01504-08; Farrell DJ, 2014, ANTIMICROB AGENTS CH, V58, P3882, DOI 10.1128/AAC.02465-14; Florescu I, 2008, J ANTIMICROB CHEMOTH, V62, pI17, DOI 10.1093/jac/dkn250; Fowler VG, 2006, NEW ENGL J MED, V355, P653, DOI 10.1056/NEJMoa053783; Goldberg E, 2010, J ANTIMICROB CHEMOTH, V65, P1779, DOI 10.1093/jac/dkq179; Hanaki H, 2014, J INFECT CHEMOTHER, V20, P527, DOI 10.1016/j.jiac.2014.06.012; Harbarth S, 2015, J ANTIMICROB CHEMOTH, V70, P264, DOI 10.1093/jac/dku352; Holland TL, 2014, JAMA-J AM MED ASSOC, V312, P1330, DOI 10.1001/jama.2014.9743; Horan TC, 2008, AM J INFECT CONTROL, V36, P309, DOI 10.1016/j.ajic.2008.03.002; Kali A, 2013, J CLIN DIAGN RES, V7, P1979, DOI 10.7860/JCDR/2013/6142.3377; Kalil AC, 2013, BMJ OPEN, V3, DOI 10.1136/bmjopen-2013-003912; Kim SH, 2008, ANTIMICROB AGENTS CH, V52, P192, DOI 10.1128/AAC.00700-07; Levesque S, 2015, EPIDEMIOL INFECT, V143, P1511, DOI 10.1017/S095026881400209X; LEVITZ RE, 1984, ANN INTERN MED, V100, P881, DOI 10.7326/0003-4819-100-6-881; Liu C, 2011, CLIN INFECT DIS, V53, P319, DOI [10.1093/cid/ciq146, 10.1093/cid/cir353]; MARKOWITZ N, 1992, ANN INTERN MED, V117, P390, DOI 10.7326/0003-4819-117-5-390; Muileboom J, 2013, CAN J INFECT DIS MED, V24, pE42, DOI 10.1155/2013/169409; Nathwani D, 2010, BMJ CLIN EVID, V2010; Nurjadi D, 2014, J ANTIMICROB CHEMOTH, V69, P2361, DOI 10.1093/jac/dku174; Pappas G, 2009, J CHEMOTHERAPY, V21, P115, DOI 10.1179/joc.2009.21.2.115; Richter SS, 2011, ANTIMICROB AGENTS CH, V55, P4154, DOI 10.1128/AAC.00315-11; Rodvold KA, 2014, CLIN INFECT DIS, V58, pS20, DOI 10.1093/cid/cit614; Rubinstein E, 2011, CLIN INFECT DIS, V52, P31, DOI 10.1093/cid/ciq031; Schaumburg F, 2014, CLIN MICROBIOL INFEC, V20, pO554, DOI 10.1111/1469-0691.12519; SCHELD WM, 1987, J ANTIMICROB CHEMOTH, V19, P647, DOI 10.1093/jac/19.5.647; Sharma NK, 2013, J CLIN DIAGN RES, V7, P2178, DOI 10.7860/JCDR/2013/6750.3463; SPICEHANDLER J, 1982, REV INFECT DIS, V4, P562; Stryjewski ME, 2008, CLIN INFECT DIS, V46, pS368, DOI 10.1086/533593; Wackett A, 2012, J EMERG MED, V43, P754, DOI 10.1016/j.jemermed.2011.08.018; Wood JB, 2012, ANTIMICROB AGENTS CH, V56, P5655, DOI 10.1128/AAC.01011-12; Zhanel GG, 2013, J ANTIMICROB CHEMOTH, V68, pi7, DOI 10.1093/jac/dkt022	41	83	84	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 14	2015	350								h2219	10.1136/bmj.h2219	http://dx.doi.org/10.1136/bmj.h2219			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CI5CI	25977146	Green Published, hybrid			2023-01-03	WOS:000354770100005
J	Ponce, D; Buffarah, MB; Goes, C; Balbi, A				Ponce, Daniela; Buffarah, Marina Berbel; Goes, Cassiana; Balbi, Andre			Peritoneal Dialysis in Acute Kidney Injury: Trends in the Outcome across Time Periods	PLOS ONE			English	Article							ACUTE-RENAL-FAILURE; CRITICALLY-ILL PATIENTS; AKI; MORTALITY; SURVIVAL; ADEQUATE	Peritoneal dialysis (PD) should be considered a suitable method of renal replacement therapy in acute kidney injury (AKI) patients. This study is the largest cohort providing patient characteristics, clinical practice, patterns and their relationship to outcomes in a developing country. Its objective was to describe the main determinants of patient and technique survival, including trends over time of PD treatment in AKI patients. This was a Brazilian prospective cohort study in which all adult AKI patients on PD were studied from January/2004 to January/2014. For comparison purposes, patients were divided into 2 groups according to the year of treatment: 2004-2008 and 2009-2014. Patient survival and technique failure (TF) were analyzed using the competing risk model of Fine and Gray. A total of 301 patients were included, 51 were transferred to hemodialysis (16.9%) during the study period. The main cause of TF was mechanical complication (47%) followed by peritonitis (41.2%). There was change in TF during the study period: compared to 2004-2008, patients treated at 2009-2014 had relative risk (RR) reduction of 0.86 (95% CI 0.77-0.96) and three independent risk factors were identified: period of treatment at 2009 and 2014, sepsis and age>65 years. There were 180 deaths (59.8%) during the study. Death was the leading cause of dropout (77.9% of all cases) mainly by sepsis (58.3%), followed cardiovascular disease (36.1%). The overall patient survival was 41% at 30 days. Patient survival improved along study periods: compared to 2004-2008, patients treated at 2009-2014 had a RR reduction of 0.87 (95% CI 0.79-0.98). The independent risk factors for mortality were sepsis, age>70 years, ATN-ISS > 0.65 and positive fluid balance. As conclusion, we observed an improvement in patient survival and TF along the years even after correction for several confounders and using a competing risk approach.	[Ponce, Daniela; Buffarah, Marina Berbel; Goes, Cassiana; Balbi, Andre] Univ Sao Paulo State UNESP, Botucatu, SP, Brazil	Universidade Estadual Paulista	Ponce, D (corresponding author), Univ Sao Paulo State UNESP, Botucatu, SP, Brazil.	dponce@fmb.unesp.br	Goes, Cassiana/AFQ-6502-2022; Ponce, Daniela/Q-4221-2019; Balbi, André Luis/O-9278-2016; Balbi, Andre/AAD-9859-2019; Ponce, Daniela/M-8271-2015	Ponce, Daniela/0000-0002-6178-6938; Balbi, André Luis/0000-0001-8366-5064; Balbi, Andre/0000-0001-8366-5064; Ponce, Daniela/0000-0002-6178-6938; Goes, Cassiana/0000-0003-1166-637X				Brown EA, 2003, J AM SOC NEPHROL, V14, P2948, DOI 10.1097/01.ASN.0000092146.67909.E2; Chionh CY, 2013, CLIN J AM SOC NEPHRO, V8, P1649, DOI 10.2215/CJN.01540213; Chionh CY, 2010, NEPHROL DIAL TRANSPL, V25, P3155, DOI 10.1093/ndt/gfq178; Chitalia VC, 2002, KIDNEY INT, V61, P747, DOI 10.1046/j.1523-1755.2002.00177.x; CHUMLEA WC, 1985, J AM GERIATR SOC, V33, P116, DOI 10.1111/j.1532-5415.1985.tb02276.x; Cullis B, 2014, PERITON DIALYSIS INT, V34, P494, DOI 10.3747/pdi.2013.00222; Druml W., 1998, Handbook of nutrition and the kidney., P213; DuBois D, 1915, ARCH INTERN MED, V15, P868; Fine JP, 1999, J AM STAT ASSOC, V94, P496, DOI 10.2307/2670170; Gabriel DP, 2008, KIDNEY INT, V73, pS87, DOI 10.1038/sj.ki.5002608; Gabriel DP, 2007, PERITON DIALYSIS INT, V27, P277; Gabriel DP, 2006, RENAL FAILURE, V28, P451, DOI 10.1080/0886022060081245; George J, 2011, PERITON DIALYSIS INT, V31, P422, DOI 10.3747/pdi.2009.00231; Honore PM, 2011, ANN INTENSIVE CARE, V1, DOI 10.1186/2110-5820-1-32; KATIRTZOGLOU A, 1983, PERITON DIALYSIS B, V3, P178; Kilonzo KG, 2012, PERITON DIALYSIS INT, V32, P261, DOI 10.3747/pdi.2012.00083; Korbet MS, 2001, HDB DIALYSIS, P333; Levy MM, 2005, CRIT CARE MED, V33, P2194, DOI 10.1097/01.CCM.0000182798.39709.84; LIANO F, 1993, NEPHRON, V63, P21, DOI 10.1159/000187139; Liborio AB, 2015, CLIN J AM SOC NEPHRO, V10, P21, DOI 10.2215/CJN.04750514; Mehta RL, 2007, CRIT CARE, V11, DOI 10.1186/cc5713; Nolph KD, 1988, ACUTE RENAL FAILURE, P809; Passadakis Ploumis S, 2007, Adv Perit Dial, V23, P7; Phu NH, 2002, NEW ENGL J MED, V347, P895, DOI 10.1056/NEJMoa020074; Ponce D, 2012, BLOOD PURIFICAT, V34, P107, DOI 10.1159/000341648; Ponce D, 2012, CLIN J AM SOC NEPHRO, V7, P887, DOI 10.2215/CJN.11131111; Ponce Daniela, 2011, Adv Perit Dial, V27, P118; Ponce D, 2011, PERITON DIALYSIS INT, V31, P387, DOI 10.3747/pdi.2011.00312; Rao P, 2003, PERITON DIALYSIS INT, V23, P320; Ricci Z, 2006, NEPHROL DIAL TRANSPL, V21, P690, DOI 10.1093/ndt/gfi296; Ronco C, 2007, PERITON DIALYSIS INT, V27, P251; Ronco C, 2006, CONTRIB NEPHROL, V150, P1, DOI 10.1159/000093441; SCHRIER RW, 1979, KIDNEY INT, V15, P205, DOI 10.1038/ki.1979.26; Silversides JA, 2014, CRIT CARE, V18, DOI 10.1186/s13054-014-0624-8; STEINER RW, 1989, PERITON DIALYSIS INT, V9, P5; Uchino S, 2005, JAMA-J AM MED ASSOC, V294, P813, DOI 10.1001/jama.294.7.813; Waikar SS, 2006, J AM SOC NEPHROL, V17, P1143, DOI 10.1681/ASN.2005091017; WATSON PE, 1980, AM J CLIN NUTR, V33, P27, DOI 10.1093/ajcn/33.1.27	38	30	32	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 12	2015	10	5							e0126436	10.1371/journal.pone.0126436	http://dx.doi.org/10.1371/journal.pone.0126436			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CI1ZI	25965868	gold, Green Published, Green Submitted			2023-01-03	WOS:000354543500059
J	Nguyen, TV; Melville, A; Nath, S; Story, C; Howell, S; Sutton, R; Zannettino, A; Revesz, T				Nguyen, Tuong-Vi; Melville, Anna; Nath, Shriram; Story, Colin; Howell, Stuart; Sutton, Rosemary; Zannettino, Andrew; Revesz, Tamas			Bone Marrow Recovery by Morphometry during Induction Chemotherapy for Acute Lymphoblastic Leukemia in Children	PLOS ONE			English	Article							MINIMAL RESIDUAL DISEASE; FIBROSIS; NICHE; PAIN	Bone marrow architecture is grossly distorted at the diagnosis of ALL and details of the morphological changes that accompany response to Induction chemotherapy have not been reported before. While marrow aspirates are widely used to assess initial response to ALL therapy and provide some indications, we have enumerated marrow components using morphometric analysis of trephine samples with the aim of achieving a greater understanding of changes in bone marrow niches. Morphometric analyses were carried out in the bone marrow trephine samples of 44 children with ALL, using a NanoZoomer HT digital scanner. Diagnostic samples were compared to those of 32 control patients with solid tumors but without marrow involvement. Samples from patients with ALL had significantly increased fibrosis and the area occupied by bony trabeculae was lower than in controls. Cellularity was higher in ALL samples due to leukemic infiltration while the percentage of normal elements such as megakaryocytes, adipocytes, osteoblasts and osteoclasts were all significantly lower. During the course of Induction therapy, there was a decrease in the cellularity of ALL samples at day 15 of therapy with a further decrease at the end of Induction and an increase in the area occupied by adipocytes and the width of sinusoids. Reticulin fibrosis decreased throughout Induction. Megakaryocytes increased, osteoblasts and osteoclasts remained unchanged. No correlation was found between clinical presentation, early response to treatment and morphological changes. Our results provide a morphological background to further studies of bone marrow stroma in ALL.	[Nguyen, Tuong-Vi] Erasmus Univ, Rotterdam, Netherlands; [Nguyen, Tuong-Vi; Story, Colin; Revesz, Tamas] SA Pathol Womens & Childrens Hosp, Adelaide, SA, Australia; [Melville, Anna] Womens & Childrens Res Inst, Adelaide, SA, Australia; [Nath, Shriram] SA Pathol, Adelaide, SA, Australia; [Howell, Stuart] Univ Adelaide, Discipline Publ Hlth, Data Management & Anal Ctr, Adelaide, SA, Australia; [Sutton, Rosemary] UNSW, Lowy Canc Res Ctr, Childrens Canc Inst Australia, Randwick, NSW, Australia; [Zannettino, Andrew; Revesz, Tamas] Univ Adelaide, Fac Hlth Sci, Adelaide, SA, Australia; [Zannettino, Andrew] SA Pathol, Ctr Canc Biol, Adelaide, SA, Australia	Erasmus University Rotterdam; SA Pathology; SA Pathology; University of Adelaide; Children's Cancer Institute; University of New South Wales Sydney; University of Adelaide; Centre for Cancer Biology; SA Pathology	Revesz, T (corresponding author), SA Pathol Womens & Childrens Hosp, Adelaide, SA, Australia.	tom.revesz@health.sa.gov.au	nath, shriram/ABI-3571-2020; Sutton, Rosemary/J-3784-2014	Sutton, Rosemary/0000-0002-0188-6005; Zannettino, Andrew/0000-0002-6646-6167; Howell, Stuart/0000-0002-8158-3273; Nath, Shriram/0000-0002-9622-939X	Joan Norris Fellowship Fund; National Health and Medical Research Council Australia	Joan Norris Fellowship Fund; National Health and Medical Research Council Australia(National Health and Medical Research Council (NHMRC) of Australia)	The work was supported by a grant from the benevolent Joan Norris Fellowship Fund and the National Health and Medical Research Council Australia. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bharos A, 2010, LEUKEMIA, V24, P1537, DOI 10.1038/leu.2010.134; Caers J, 2007, LEUKEMIA, V21, P1580, DOI 10.1038/sj.leu.2404658; Jayanthan A, 2010, PEDIATR HEMAT ONCOL, V27, P212, DOI 10.3109/08880011003663382; JONSSON OG, 1990, J PEDIATR-US, V117, P233, DOI 10.1016/S0022-3476(05)80535-9; Kopp HG, 2009, ANN NY ACAD SCI, V1176, P47, DOI 10.1111/j.1749-6632.2009.04964.x; Krevvata M, 2014, BLOOD, V124, P2834, DOI 10.1182/blood-2013-07-517219; Leeuw JA, 2003, PEDIATR RES, V54, P814, DOI 10.1203/01.PDR.0000090929.16450.DE; Levental KR, 2009, CELL, V139, P891, DOI 10.1016/j.cell.2009.10.027; Levesque JP, 2010, LEUKEMIA, V24, P1979, DOI 10.1038/leu.2010.214; Lu PF, 2012, J CELL BIOL, V196, P395, DOI 10.1083/jcb.201102147; Nakamura Y, 2010, BLOOD, V116, P1422, DOI 10.1182/blood-2009-08-239194; Nath SV, 2011, MED HYPOTHESES, V77, P333, DOI 10.1016/j.mehy.2011.05.007; Noren-Nystrom U, 2008, LEUKEMIA, V22, P504, DOI 10.1038/sj.leu.2405072; Schultz KR, 2007, BLOOD, V109, P926, DOI 10.1182/blood-2006-01-024729; Sison EAR, 2014, ONCOTARGET, V5, P8947, DOI 10.18632/oncotarget.2407; Sutton R, 2009, BRIT J HAEMATOL, V146, P292, DOI 10.1111/j.1365-2141.2009.07744.x; Szaloki N, 2013, CYTOM PART A, V83, P818, DOI 10.1002/cyto.a.22315; Tabe Y, 2014, BRIT J HAEMATOL, V164, P767, DOI 10.1111/bjh.12725; van der Have N, 2012, LEUKEMIA RES, V36, P521, DOI 10.1016/j.leukres.2012.01.001; van der Velden VHJ, 2007, LEUKEMIA, V21, P706, DOI 10.1038/sj.leu.2404535; Yu HM, 2011, TRENDS CELL BIOL, V21, P47, DOI 10.1016/j.tcb.2010.08.015	21	12	13	1	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 11	2015	10	5							e0126233	10.1371/journal.pone.0126233	http://dx.doi.org/10.1371/journal.pone.0126233			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CI1YY	25962143	Green Published, gold			2023-01-03	WOS:000354542500078
J	Loganathan, T; Lee, WS; Lee, KF; Jit, M; Ng, CW				Loganathan, Tharani; Lee, Way-Seah; Lee, Kok-Foo; Jit, Mark; Ng, Chiu-Wan			Household Catastrophic Healthcare Expenditure and Impoverishment Due to Rotavirus Gastroenteritis Requiring Hospitalization in Malaysia	PLOS ONE			English	Article							COST-EFFECTIVENESS; VACCINATION; IMPACT; COUNTRIES; DISEASE; BURDEN; ASIA	Background While healthcare costs for rotavirus gastroenteritis requiring hospitalization may be burdensome on households in Malaysia, exploration on the distribution and catastrophic impact of these expenses on households are lacking. Objectives We assessed the economic burden, levels and distribution of catastrophic healthcare expenditure, the poverty impact on households and inequities related to healthcare payments for acute gastroenteritis requiring hospitalization in Malaysia. Methods A two-year prospective, hospital-based study was conducted from 2008 to 2010 in an urban (Kuala Lumpur) and rural (Kuala Terengganu) setting in Malaysia. All children under the age of 5 years admitted for acute gastroenteritis were included. Patients were screened for rotavirus and information on healthcare expenditure was obtained. Results Of the 658 stool samples collected at both centers, 248 (38%) were positive for rotavirus. Direct and indirect costs incurred were significantly higher in Kuala Lumpur compared with Kuala Terengganu (US$222 Vs. US$45; p<0.001). The mean direct and indirect costs for rotavirus gastroenteritis consisted 20% of monthly household income in Kuala Lumpur, as compared with only 5% in Kuala Terengganu. Direct medical costs paid out-of-pocket caused 141 (33%) households in Kuala Lumpur to experience catastrophic expenditure and 11 (3%) households to incur poverty. However in Kuala Terengganu, only one household (0.5%) experienced catastrophic healthcare expenditure and none were impoverished. The lowest income quintile in Kuala Lumpur was more likely to experience catastrophic payments compared to the highest quintile (87% vs 8%). The concentration index for out-of-pocket healthcare payments was closer to zero at Kuala Lumpur (0.03) than at Kuala Terengganu (0.24). Conclusions While urban households were wealthier, healthcare expenditure due to gastroenteritis had more catastrophic and poverty impact on the urban poor. Universal rotavirus vaccination would reduce both disease burden and health inequities in Malaysia.	[Loganathan, Tharani; Ng, Chiu-Wan] Univ Malaya, Dept Social & Prevent Med, Kuala Lumpur 50603, Malaysia; [Lee, Way-Seah] Univ Malaya, Dept Paediat, Kuala Lumpur 50603, Malaysia; [Lee, Way-Seah] Univ Malaya, Paediat & Child Hlth Res Grp, Kuala Lumpur 50603, Malaysia; [Lee, Kok-Foo] Hosp Sultanah Nur Zahirah, Dept Paediat, Kuala Terengganu, Malaysia; [Jit, Mark] Publ Hlth England, Modeling & Econ Unit, London, England; [Jit, Mark] London Sch Hyg & Trop Med, Dept Infect Dis Epidemiol, London WC1, England	Universiti Malaya; Universiti Malaya; Universiti Malaya; Public Health England; University of London; London School of Hygiene & Tropical Medicine	Loganathan, T (corresponding author), Univ Malaya, Fac Med, Dept Social & Prevent Med, Julius Ctr Clin Epidemiol & Evidence Based Med, Kuala Lumpur 50603, Malaysia.	drtharani@gmail.com	Loganathan, Tharani/L-8836-2018; NG, CHIU WAN/B-9222-2010; LEE, WAY SEAH/B-8844-2010; Jit, Mark/HDM-7797-2022; NG, CHIU WAN/B-5218-2010	Loganathan, Tharani/0000-0001-6690-000X; LEE, WAY SEAH/0000-0001-9163-2828; NG, CHIU WAN/0000-0002-7687-2310; Jit, Mark/0000-0001-6658-8255	University of Malaya/Ministry of Higher Education (UM/MOHE) High Impact Research Grant [E000010-20001]; Merck Sharp and Dohme Co. Ltd	University of Malaya/Ministry of Higher Education (UM/MOHE) High Impact Research Grant; Merck Sharp and Dohme Co. Ltd	The economic evaluation is part of the STeMM Programme supported by the University of Malaya/Ministry of Higher Education (UM/MOHE) High Impact Research Grant (Grant number E000010-20001). The data collection, specimen testing and genotyping was funded by Merck Sharp and Dohme Co. Ltd. to Way-Seah Lee. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 3 NAT HLTH MORB SURV; [Anonymous], EPU MEAN MONTHL GROS; [Anonymous], WORLD DEV IND DAT CO; [Anonymous], 2010, WORLD HLTH REP; [Anonymous], 2002, GEN PROT 1 HOSP BAS; [Anonymous], WORLD HLTH REP 2013, DOI [10.1186/1478-4505-11-47, DOI 10.1186/1478-4505-11-47]; [Anonymous], GDP GNI CURR CONST P; [Anonymous], 1996, NAT HLTH MORB SURV; [Anonymous], 2008, ANAL HLTH EQUITY USI; Chai PF, 2009, VACCINE, V27, pF112, DOI 10.1016/j.vaccine.2009.08.069; Chee Heng Leng, 2007, HLTH CARE MALAYSIA D; Deogaonkar R, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-878; Department of Statistics, 2009, HOUS INC BAS AM SURV; Department of Statistics Malaysia, 2010, POP DISTR BAS DEM CH; Hsu VP, 2005, J INFECT DIS, V192, pS80, DOI 10.1086/431494; Jaafar S, 2013, HLTH SYSTEMS TRANSIT; Kananatu K, 2002, Asia Pac J Public Health, V14, P23; Lee WS, 2007, J PAEDIATR CHILD H, V43, P818, DOI 10.1111/j.1440-1754.2007.01160.x; Lee WS, 2012, HUM VACC IMMUNOTHER, V8, P1401, DOI 10.4161/hv.21577; Mirzayeva R, 2009, VACCINE, V27, pF120, DOI 10.1016/j.vaccine.2009.09.039; O'Donnell OA, 2008, CATASTROPHIC PAYMENT, P203; Parashar UD, 2009, J INFECT DIS, V200, pS9, DOI 10.1086/605025; Phua KB, 2009, VACCINE, V27, P5936, DOI 10.1016/j.vaccine.2009.07.098; Rheingans R, 2012, VACCINE, V30, pA15, DOI 10.1016/j.vaccine.2012.01.018; Savedoff WD, 2011, ACHIEVING UNIVERSAL; Van Doorslaer E, 2007, HEALTH ECON, V16, P1159, DOI 10.1002/hec.1209; Verguet S, 2013, VACCINE, V31, P4902, DOI 10.1016/j.vaccine.2013.07.014; WAGSTAFF A, 1991, SOC SCI MED, V33, P545, DOI 10.1016/0277-9536(91)90212-U; World Health Organization, 2013, ROT VACC; Xu K, 2006, SOC SCI MED, V62, P866, DOI 10.1016/j.socscimed.2005.07.004; Zaman K, 2010, LANCET, V376, P615, DOI 10.1016/S0140-6736(10)60755-6	31	18	18	0	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 5	2015	10	5							e0125878	10.1371/journal.pone.0125878	http://dx.doi.org/10.1371/journal.pone.0125878			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	CH3PT	25941805	Green Published, Green Accepted, gold			2023-01-03	WOS:000353943400055
J	Chang, SS; Hu, HY				Chang, Shen-Shong; Hu, Hsiao-Yun			Long-Term Use of Steroids Protects from the Development of Symptomatic Diverticulitis Requiring Hospitalization in the Asian Population	PLOS ONE			English	Article							COMPLICATED DIVERTICULITIS; DISEASE; COLON; EPIDEMIOLOGY; HEALTH; IMPACT	Objective The pathophysiology of diverticulitis is poorly understood. Factors such as physical inactivity, constipation, obesity, smoking, and the use of nonsteroidal antiinflammatory drugs (NSAIDs) have been associated with an increased risk of diverticular disease. To evaluate whether patients exhibiting long-term steroid use are at increased risk of colonic diverticulitis. Method We conducted a population-based, nested case-control study. Data were retrospectively collected from the National Health Insurance Research Database. The study cohort comprised patients diagnosed with diverticulitis, identified using inpatient discharge records using International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) codes (562.11 and 562.13), and those who were administered one or more prescriptions for corticosteroids for systemic use. Control patients were matched to cases by age, sex, NSAID use, laxative drug use, and index date. We enrolled 690 patients with colonic diverticulitis and 2760 in the control group. The adjusted odds ratios (ORs) and 95% confidence intervals (CIs) were estimated using conditional logistic regression. Results Compared with steroid nonusers, the adjusted ORs were 0.60 (95% CI = 0.35-1.06) and 0.80 (95% CI = 0.64-1.008) in current steroid users and previous steroid users, respectively. In addition, the adjusted ORs were 0.55 (95% CI = 0.31-0.98), 0.57 (95% CI = 0.31-0.98), and 0.44 (95% CI = 0.22-0.86) for steroid use duration more than half time by an exposure period of 90 days, 180 days, and 365 days before the claim date of colonic diverticulitis, respectively. Conclusions The results indicated that long-term steroid use within one year is associated with lower risk of colonic diverticulitis.	[Chang, Shen-Shong] Taipei City Hosp, Yang Ming Branch, Div Gastroenterol, Taipei, Taiwan; [Chang, Shen-Shong] Taipei City Hosp, Yang Ming Branch, Dept Internal Med, Taipei, Taiwan; [Chang, Shen-Shong] Natl Yang Ming Univ, Sch Med, Taipei 112, Taiwan; [Hu, Hsiao-Yun] Natl Yang Ming Univ, Inst Publ Hlth, Taipei 112, Taiwan; [Hu, Hsiao-Yun] Natl Yang Ming Univ, Dept Publ Hlth, Taipei 112, Taiwan; [Hu, Hsiao-Yun] Taipei City Hosp, Dept Educ & Res, Taipei, Taiwan	Taipei City Hospital; Taipei City Hospital; National Yang Ming Chiao Tung University; National Yang Ming Chiao Tung University; National Yang Ming Chiao Tung University; Taipei City Hospital	Hu, HY (corresponding author), Natl Yang Ming Univ, Inst Publ Hlth, Taipei 112, Taiwan.	hyhu@ym.edu.tw						ALMY TP, 1980, NEW ENGL J MED, V302, P324, DOI 10.1056/NEJM198002073020605; [Anonymous], [No title captured]; Bose KP, 2013, J CLIN GASTROENTEROL, V47, P160, DOI 10.1097/MCG.0b013e318259e71c; Chapman J, 2005, ANN SURG, V242, P576, DOI 10.1097/01.sla.0000184843.89836.35; Cheng SH, 1997, JAMA-J AM MED ASSOC, V278, P89, DOI 10.1001/jama.278.2.89; Delvaux M, 2003, ALIMENT PHARM THERAP, V18, P71, DOI 10.1046/j.0953-0673.2003.01720.x; Humes DJ, 2011, GUT, V60, P219, DOI 10.1136/gut.2010.217281; Jacobs DO, 2007, NEW ENGL J MED, V357, P2057, DOI 10.1056/NEJMcp073228; Laine L, 2008, GASTROENTEROLOGY, V135, P1517, DOI 10.1053/j.gastro.2008.07.067; Lanas A, 2006, DIGESTION, V73, P136, DOI 10.1159/000089789; Lanas A, 2009, GASTROENTEROL CLIN N, V38, P333, DOI 10.1016/j.gtc.2009.03.007; Morris CR, 2002, POSTGRAD MED J, V78, P654, DOI 10.1136/pmj.78.925.654; PARKS TG, 1968, POSTGRAD MED J, V44, P680, DOI 10.1136/pgmj.44.515.680; SLACK WW, 1962, BRIT J SURG, V50, P185, DOI 10.1002/bjs.18005022012; Stollman NH, 1999, J CLIN GASTROENTEROL, V29, P241, DOI 10.1097/00004836-199910000-00004; Strate LL, 2012, AM J GASTROENTEROL, V107, P1486, DOI 10.1038/ajg.2012.194; Strate LL, 2011, GASTROENTEROLOGY, V140, P1427, DOI 10.1053/j.gastro.2011.02.004; von Rahden BHA, 2012, COLORECTAL DIS, V14, P1276, DOI 10.1111/j.1463-1318.2012.02967.x	18	2	2	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 28	2015	10	4							e0124598	10.1371/journal.pone.0124598	http://dx.doi.org/10.1371/journal.pone.0124598			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CG9SE	25919040	Green Published, Green Submitted, gold			2023-01-03	WOS:000353659400056
J	Ogasawara, S; Chiba, T; Ooka, Y; Kanogawa, N; Motoyama, T; Suzuki, E; Tawada, A; Azemoto, R; Shinozaki, M; Yoshikawa, M; Yokosuka, O				Ogasawara, Sadahisa; Chiba, Tetsuhiro; Ooka, Yoshihiko; Kanogawa, Naoya; Motoyama, Tenyu; Suzuki, Eiichiro; Tawada, Akinobu; Azemoto, Ryosaku; Shinozaki, Masami; Yoshikawa, Masaharu; Yokosuka, Osamu			A Prognostic Score for Patients with Intermediate-Stage Hepatocellular Carcinoma Treated with Transarterial Chemoembolization	PLOS ONE			English	Article							SUBCLASSIFICATION; MANAGEMENT; SURVIVAL	Background Intermediate-stage hepatocellular carcinoma (HCC), defined according to the Barcelona Clinic Liver Cancer (BCLC) staging system, is a heterogeneous condition with variable clinical benefits from transarterial chemoembolization (TACE). This study aimed to develop a simple validated prognostic score based on the predictive factors for survival in patients with intermediate-stage HCC treated with TACE. Methods Three-hundred and fifty patients with intermediate-stage HCC undergoing initial TACE at Chiba University Hospital (training cohort; n = 187) and two affiliated hospitals (validation cohort; n = 163) were included. Following variables were entered into univariate and multivariate Cox regression models to develop a points-based clinical scoring system: gender, age, etiology, pretreatment, Child-Pugh score, aspartate aminotransferase, creatinine, Creactive protein, alfa-fetoprotein, size of the largest lesion, and number and location of lesions. Results The number of lesions and the Child-Pugh score were identified as independent prognostic factors in the training cohort. The development of a 0-7-point prognostic score, named the Chiba HCC in intermediate-stage prognostic (CHIP) score, was based on the sum of three subscale scores (Child-Pugh score = 0, 1, 2, or 3, respectively, number of lesions = 0, 2, or 3, respectively, HCV-RNA positivity = 0 or 1, respectively). The generated scores were then differentiated into five groups (0-2 points, 3 points, 4 points, 5 points, and 6-7 points) by the median survival time (65.2, 29.2, 24.3, 13.1, and 8.4 months, respectively; p < 0.0001). These results were confirmed in the external validation cohort (p < 0.0001). Conclusions The CHIP score is easy-to-use and may assist in finding an appropriate treatment strategy for intermediate-stage HCC.	[Ogasawara, Sadahisa; Chiba, Tetsuhiro; Ooka, Yoshihiko; Kanogawa, Naoya; Motoyama, Tenyu; Suzuki, Eiichiro; Tawada, Akinobu; Yoshikawa, Masaharu; Yokosuka, Osamu] Chiba Univ, Grad Sch Med, Dept Gastroenterol & Nephrol, Chiba, Japan; [Azemoto, Ryosaku] Kimitsu Chuo Hosp, Dept Gastroenterol, Chiba, Japan; [Shinozaki, Masami] Numazu City Hosp, Dept Gastroenterol, Shizuoka, Japan	Chiba University	Chiba, T (corresponding author), Chiba Univ, Grad Sch Med, Dept Gastroenterol & Nephrol, Chiba, Japan.	techiba@faculty.chiba-u.jp	Ogasawara, Sadahisa/GRF-7061-2022	Ogasawara, Sadahisa/0000-0002-6540-9064	Dainippon Sumitomo Pharma Co, Ltd (Osaka, Japan); Nippon Kayaku Co, Ltd (Tokyo, Japan)	Dainippon Sumitomo Pharma Co, Ltd (Osaka, Japan); Nippon Kayaku Co, Ltd (Tokyo, Japan)	Prof. Osamu Yokosuka received grant support (scholarship contribution) from Dainippon Sumitomo Pharma Co, Ltd (Osaka, Japan) and Nippon Kayaku Co, Ltd (Tokyo, Japan). The remaining authors disclose no conflicts. This does not alter the authors' adherence to PLOS ONE policies on sharing data and materials.	Bolondi L, 2012, SEMIN LIVER DIS, V32, P348, DOI 10.1055/s-0032-1329906; Bruix J, 2005, HEPATOLOGY, V42, P1208, DOI 10.1002/hep.20933; Bruix J, 2011, HEPATOLOGY, V53, P1020, DOI 10.1002/hep.24199; Dumortier J, 2006, DIGEST LIVER DIS, V38, P125, DOI 10.1016/j.did.2005.10.025; Ferlay J, 2010, INT J CANCER, V127, P2893, DOI 10.1002/ijc.25516; Gao HJ, 2014, LIVER INT, V34, P612, DOI 10.1111/liv.12307; Golfieri R, 2011, HEPATOLOGY, V53, P1580, DOI 10.1002/hep.24246; Ha Y, 2014, J GASTROEN HEPATOL, V29, P787, DOI 10.1111/jgh.12452; Kadalayil L, 2013, ANN ONCOL, V24, P2565, DOI 10.1093/annonc/mdt247; Kudo M, 2011, DIGEST DIS, V29, P339, DOI 10.1159/000327577; Llovet JM, 2012, J HEPATOL, V56, P908, DOI 10.1016/j.jhep.2011.12.001; Marelli L, 2007, CARDIOVASC INTER RAD, V30, P6, DOI 10.1007/s00270-006-0062-3; Mazzaferro V, 2009, LANCET ONCOL, V10, P35, DOI 10.1016/S1470-2045(08)70284-5; Omata M, 2010, HEPATOL INT, V4, P439, DOI 10.1007/s12072-010-9165-7; Poon RTP, 2003, ANN SURG, V237, P376, DOI 10.1097/00000658-200303000-00012; Sieghart W, 2013, HEPATOLOGY, V57, P2261, DOI 10.1002/hep.26256; Takayasu K, 2012, J HEPATOL, V56, P886, DOI 10.1016/j.jhep.2011.10.021; Uno H, 2011, STAT MED, V30, P1105, DOI 10.1002/sim.4154; Wang JH, 2015, J GASTROEN HEPATOL, V30, P358, DOI 10.1111/jgh.12686; Xiao J, 2014, INT J CLIN EXP PATHO, V7, P1114; Yamakado K, 2014, JPN J RADIOL, V32, P260, DOI 10.1007/s11604-014-0298-9	21	27	28	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 28	2015	10	4							e0125244	10.1371/journal.pone.0125244	http://dx.doi.org/10.1371/journal.pone.0125244			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CG9SE	25919025	Green Published, gold, Green Submitted			2023-01-03	WOS:000353659400077
J	Liu, Y; Li, M; Yang, D; Zhang, XN; Wu, AS; Yao, SL; Xue, ZG; Yue, Y				Liu, Yu; Li, Min; Yang, Dong; Zhang, Xuena; Wu, Anshi; Yao, Shanglong; Xue, Zhanggang; Yue, Yun			Closed-Loop Control Better than Open-Loop Control of Profofol TCI Guided by BIS: A Randomized, Controlled, Multicenter Clinical Trial to Evaluate the CONCERT-CL Closed-Loop System	PLOS ONE			English	Article							BISPECTRAL INDEX; DELIVERY-SYSTEM; PROPOFOL; REMIFENTANIL; ANESTHESIA; TITRATION; CONSCIOUSNESS; PERFORMANCE; INFUSION; SURGERY	Background The CONCERT-CL closed-loop infusion system designed by VERYARK Technology Co., Ltd. (Guangxi, China) is an innovation using TCI combined with closed-loop controlled intravenous anesthesia under the guide of BIS. In this study we performed a randomized, controlled, multicenter study to compare closed-loop control and open-loop control of propofol by using the CONCERT-CL closed-loop infusion system. Methods 180 surgical patients from three medical centers undergone TCI intravenous anesthesia with propofol and remifentanil were randomly assigned to propofol closed-loop group and propofol opened-loop groups. Primary outcome was global score (GS, GS = (MDAPE + Wobble)/% of time of bispectral index (BIS) 40-60). Secondary outcomes were doses of the anesthetics and emergence time from anesthesia, such as, time to tracheal extubation. Results There were 89 and 86 patients in the closed-loop and opened-loop groups, respectively. GS in the closed-loop groups (22.21 +/- 8.50) were lower than that in the opened-loop group (27.19 +/- 15.26) (p= 0.009). The higher proportion of time of BIS between 40 and 60 was also observed in the closed-loop group (84.11 +/- 9.50%), while that was 79.92 +/- 13.17% in the opened-loop group, (p= 0.016). No significant differences in propofol dose and time of tracheal extubation were observed. The frequency of propofol regulation in the closed-loop group (31.55 +/- 9.46 times/hr) was obverse higher than that in the opened-loop group (6.84 +/- 6.21 times/hr) (p= 0.000). Conclusion The CONCERT-CL closed-loop infusion system can automatically regulate the TCI of propofol, maintain the BIS value in an adequate range and reduce the workload of anesthesiologists better than open-loop system.	[Liu, Yu; Zhang, Xuena; Wu, Anshi; Yue, Yun] Capital Med Univ, Beijing Chaoyang Hosp, Dept Anesthesiol, Beijing, Peoples R China; [Li, Min; Xue, Zhanggang] Fudan Univ, Zhongshan Hosp, Dept Anesthesiol, Shanghai 200433, Peoples R China; [Yang, Dong; Yao, Shanglong] Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Dept Anesthesiol, Wuhan 430074, Peoples R China	Capital Medical University; Fudan University; Huazhong University of Science & Technology	Yue, Y (corresponding author), Capital Med Univ, Beijing Chaoyang Hosp, Dept Anesthesiol, Beijing, Peoples R China.	yueyun@hotmail.com	Yang, Dong/GSD-6859-2022	Wu, Anshi/0000-0003-2353-2184				Agarwal J, 2009, ACTA ANAESTH SCAND, V53, P390, DOI 10.1111/j.1399-6576.2008.01884.x; Biswas I, 2013, PEDIATR ANESTH, V23, P1145, DOI 10.1111/pan.12265; Dussaussoy C, 2014, J CLIN MONIT COMPUT, V28, P35, DOI 10.1007/s10877-013-9453-6; Guignard B, 2000, ANESTH ANALG, V90, P161, DOI 10.1097/00000539-200001000-00034; Hemmerling TM, 2013, BRIT J ANAESTH, V110, P1031, DOI 10.1093/bja/aet001; Hemmerling TM, 2010, CAN J ANESTH, V57, P725, DOI 10.1007/s12630-010-9335-z; Iselin-Chaves IA, 1998, ANESTH ANALG, V87, P949; Kenny GN, 1999, BR J ANAESTH; Liu N, 2006, ANESTHESIOLOGY, V104, P686, DOI 10.1097/00000542-200604000-00012; Liu N, 2008, J CARDIOTHOR VASC AN, V22, P611, DOI 10.1053/j.jvca.2008.04.022; Liu N, 2012, ANESTHESIOLOGY, V116, P286, DOI 10.1097/ALN.0b013e318242ad4f; Liu N, 2011, ANESTH ANALG, V112, P546, DOI 10.1213/ANE.0b013e318205680b; MARSH B, 1991, BRIT J ANAESTH, V67, P41, DOI 10.1093/bja/67.1.41; Minto CF, 1997, ANESTHESIOLOGY, V86, P10, DOI 10.1097/00000542-199701000-00004; Puri GD, 2007, ANAESTH INTENS CARE, V35, P357, DOI 10.1177/0310057X0703500306; SCHWILDEN H, 1989, BRIT J ANAESTH, V62, P290, DOI 10.1093/bja/62.3.290; VARVEL JR, 1992, J PHARMACOKINET BIOP, V20, P63, DOI 10.1007/BF01143186; Westenskow DR, 1987, J CLIN MONIT COMPUT, V2, P69	18	9	22	0	16	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 17	2015	10	4							e0123862	10.1371/journal.pone.0123862	http://dx.doi.org/10.1371/journal.pone.0123862			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CG1EX	25886041	Green Published, gold, Green Submitted			2023-01-03	WOS:000353017000089
J	Smeulers, M; Verweij, L; Maaskant, JM; de Boer, M; Krediet, CTP; van Dijkum, EJMN; Vermeulen, H				Smeulers, Marian; Verweij, Lotte; Maaskant, Jolanda M.; de Boer, Monica; Krediet, C. T. Paul; van Dijkum, Els J. M. Nieveen; Vermeulen, Hester			Quality Indicators for Safe Medication Preparation and Administration: A Systematic Review	PLOS ONE			English	Review							EVIDENCE-BASED MEDICINE; HEALTH-CARE; IMPROVEMENT	Background One-third of all medication errors causing harm to hospitalized patients occur in the medication preparation and administration phase, which is predominantly a nursing activity. To monitor, evaluate and improve the quality and safety of this process, evidence-based quality indicators can be used. Objectives The aim of study was to identify evidence-based quality indicators (structure, process and outcome) for safe in-hospital medication preparation and administration. Methods MEDLINE, EMBASE and CINAHL were searched for relevant studies published up to January 2015. Additionally, nine databases were searched to identify relevant grey literature. Two reviewers independently selected studies if (1) the method for quality indicator development combined a literature search with expert panel opinion, (2) the study contained quality indicators on medication safety, and (3) any of the quality indicators were applicable to hospital medication preparation and administration. A multidisciplinary team appraised the studies independently using the AIRE instrument, which contains four domains and 20 items. Quality indicators applicable to in-hospital medication preparation and administration were extracted using a structured form. Results The search identified 1683 studies, of which 64 were reviewed in detail and five met the inclusion criteria. Overall, according to the AIRE domains, all studies were clear on purpose; most of them applied stakeholder involvement and used evidence reasonably; usage of the indicator in practice was scarcely described. A total of 21 quality indicators were identified: 5 structure indicators (e.g. safety management and high alert medication), 11 process indicators (e.g. verification and protocols) and 5 outcome indicators (e.g. harm and death). These quality indicators partially cover the 7 rights. Conclusion Despite the relatively small number of included studies, the identified quality indicators can serve as an excellent starting point for further development of nursing specific quality indicators for medication safety. Especially on the right patient, right route, right time and right documentation there is room future development of quality indicators.	[Smeulers, Marian; Verweij, Lotte; Vermeulen, Hester] Univ Amsterdam, Acad Med Ctr, Dept Qual Assurance & Proc Innovat, NL-1105 AZ Amsterdam, Netherlands; [Maaskant, Jolanda M.] Univ Amsterdam, Acad Med Ctr, Emma Childrens Hosp, NL-1105 AZ Amsterdam, Netherlands; [Maaskant, Jolanda M.] Univ Amsterdam, Acad Med Ctr, Fac Med, Dept Clin Epidemiol Biostat & Bioinformat, NL-1105 AZ Amsterdam, Netherlands; [de Boer, Monica] Univ Amsterdam, Acad Med Ctr, Dept Hosp Pharm, NL-1105 AZ Amsterdam, Netherlands; [Krediet, C. T. Paul] Univ Amsterdam, Acad Med Ctr, Dept Internal Med, NL-1105 AZ Amsterdam, Netherlands; [van Dijkum, Els J. M. Nieveen; Vermeulen, Hester] Univ Amsterdam, Acad Med Ctr, Dept Surg, NL-1105 AZ Amsterdam, Netherlands; [Vermeulen, Hester] Amsterdam Sch Hlth Profess, Dept Nursing, Amsterdam, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam; Emma Children's Hospital; University of Amsterdam; Academic Medical Center Amsterdam; Vrije Universiteit Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam	Smeulers, M (corresponding author), Univ Amsterdam, Acad Med Ctr, Dept Qual Assurance & Proc Innovat, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands.	m.smeuters@amc.uva.nl	Vermeulen, Hester/P-5739-2016; van dijkum, elisabeth nieveen/M-2243-2019	Vermeulen, Hester/0000-0002-0743-2979; Krediet, C T Paul/0000-0002-3433-6907; Verweij, Lotte/0000-0002-4727-0126	internal hospital fund for quality improvement	internal hospital fund for quality improvement	This work was supported by internal hospital fund for quality improvement: "What if your mother was in the hospital". There are no other sources of support. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 1995, QRC ADVISOR, V11, P1; Aspden P, 2007, PREVENTING MEDICATIO; Barker KN, 2002, ARCH INTERN MED, V162, P1897, DOI 10.1001/archinte.162.16.1897; Brook RH, 2000, INT J QUAL HEALTH C, V12, P281, DOI 10.1093/intqhc/12.4.281; Campbell SM, 2003, BRIT MED J, V326, P816, DOI 10.1136/bmj.326.7393.816; Cheng R, 2010, HEALTHCARE Q, V13; Classen DC, 1997, JAMA-J AM MED ASSOC, V277, P301, DOI 10.1001/jama.277.4.301; de Koning J, 2006, APPRAISAL INDICATORS, DOI [10.1111/acem.12591, DOI 10.1111/ACEM.12591]; Donabedian A., 1980, EXPLORATION QUALITY; Glasziou P, 2011, BMJ QUAL SAF, V20, pI13, DOI 10.1136/bmjqs.2010.046524; Hughes RG, 2008, PATIENT SAFETY QUALI, P397; Institute for Safe Medication Practices ISMP, 2011, AC CAR GUID TIM ADM; ISMP, 2007, 5 RIGHTS DEST MAP; Krahenbuhl-Melcher A, 2007, DRUG SAFETY, V30, P379; LEAPE LL, 1995, JAMA-J AM MED ASSOC, V274, P35, DOI 10.1001/jama.1995.03530010049034; Levin RF, 2010, J NURS CARE QUAL, V25, P117, DOI 10.1097/NCQ.0b013e3181b5f19f; Lisby M, 2010, INT J QUAL HEALTH C, V22, P507, DOI 10.1093/intqhc/mzq059; Mainz J, 2003, INT J QUAL HEALTH C, V15, P523, DOI 10.1093/intqhc/mzg081; McDonnell J., 2001, RANDUCLA APPROPRIATE; McLoughlin V, 2006, INT J QUAL HEALTH C, V18, P14, DOI 10.1093/intqhc/mzl030; Moher David, 2009, BMJ, V339, pb2535, DOI [10.1016/j.ijsu.2010.02.007, 10.1136/bmj.b2535]; National Institution for Health and Care Excellence NICE, 2014, NICE GUID SAF STAFF; Nigam Rita, 2008, Healthc Q, V11, P47; NSW Therapeutic Advisory Group, 2007, IND QUAL US MED AUST; Pape Theresa M, 2003, Medsurg Nurs, V12, P77; Sackett DL, 2007, CLIN ORTHOP RELAT R, P3, DOI 10.1097/BLO.06013e31802fba1e; Shojania KG, 2005, HEALTH AFFAIR, V24, P138, DOI 10.1377/hlthaff.24.1.138; The National Coordinating Council for Medication Error Reporting and Prevention (NCCMERP), WHAT IS MED ERR; Wakefield DS, 1999, AM J MED QUAL, V14, P73, DOI 10.1177/106286069901400202	29	35	40	0	22	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 17	2015	10	4							e0122695	10.1371/journal.pone.0122695	http://dx.doi.org/10.1371/journal.pone.0122695			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	CG1EX	25884623	Green Published, Green Submitted, gold			2023-01-03	WOS:000353017000039
J	Wang, YF; Lv, JP; Cheng, Y; Du, JP; Chen, DG; Li, CT; Zhang, J				Wang, Yufang; Lv, Junping; Cheng, Yao; Du, Jipei; Chen, Degao; Li, Chengtao; Zhang, Ji			Apoptosis Induced by Ginkgo biloba (EGb761) in Melanoma Cells Is Mcl-1-Dependent	PLOS ONE			English	Article							BCL-2 FAMILY PROTEINS; CANCER-CELLS; OVERCOMING RESISTANCE; CARCINOMA-CELLS; EXTRACT; INHIBITION; BAX; MITOCHONDRIA; MCL-1; ACTIVATION	Melanoma is an aggressive skin cancer. Unfortunately, there is currently no chemotherapeutic agent available to significantly prolong the survival of the most patients with metastatic melanomas. Here we report that the Ginkgo biloba extract (EGb761), one of the most widely sold herbal supplements in the world, potently induces apoptosis in human melanoma cells by disturbing the balance between pro-and anti-apoptosis Bcl-2 family proteins. Treatment with EGb761 induced varying degrees of apoptosis in melanoma cell lines but not in melanocytes. Induction of apoptosis was caspase-dependent and appeared to be mediated by the mitochondrial pathway, in that it was associated with reduction in mitochondrial membrane potential and activation of Bax and Bak. Although EGb761 did not cause significant change in the expression levels of the BH3-only Bcl-2 family proteins Bim, Puma, Noxa, and Bad, it significantly downregulated Mcl-1 in sensitive but not resistant melanoma cells, suggesting a major role of Mcl-1 in regulating apoptosis of melanoma cells induced by EGb761. Indeed, siRNA knockdown of Mcl-1 enhanced EGb761-induced apoptosis, which was associated with increased activation of Bax and Bak. Taken together, these results demonstrate that EGb761 kills melanoma cells through the mitochondrial apoptotic pathway, and that Mcl-1 is a major regulator of sensitivity of melanoma cells to apoptosis induced by EGb761. Therefore, EGb761 with or without in combination with targeting Mcl-1 may be a useful strategy in the treatment of melanoma.	[Wang, Yufang; Cheng, Yao; Du, Jipei; Chen, Degao] Sichuan Univ, Sch Preclin & Forens Med, Dept Pathophysiol, Chengdu 610064, Peoples R China; [Lv, Junping] Beijing Inst Biomed, Dept Pharmacol, Beijing, Peoples R China; [Li, Chengtao] Inst Forens Sci, Shanghai Key Lab Forens Med, Minist Justice, Shanghai, Peoples R China; [Zhang, Ji] Sichuan Univ, Sch Preclin & Forens Med, Dept Forens Genet, Chengdu 610064, Peoples R China	Sichuan University; Institute of Forensic Science Ministry of Justice PRC; Sichuan University	Zhang, J (corresponding author), Sichuan Univ, Sch Preclin & Forens Med, Dept Forens Genet, Chengdu 610064, Peoples R China.	zhangj@scu.edu.cn		Li, Chengtao/0000-0001-6852-9144	National Nature Science Foundation [81201560, 81471551]; priming scientific research foundation for the junior teachers of medicine in Sichuan University [2012SCU11020]	National Nature Science Foundation(National Natural Science Foundation of China (NSFC)); priming scientific research foundation for the junior teachers of medicine in Sichuan University	This work was supported by research grants from the National Nature Science Foundation (81201560 and 81471551); the priming scientific research foundation for the junior teachers of medicine in Sichuan University (2012SCU11020).	Adams JM, 2007, ONCOGENE, V26, P1324, DOI 10.1038/sj.onc.1210220; Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Breckenridge DG, 2004, CURR OPIN CELL BIOL, V16, P647, DOI 10.1016/j.ceb.2004.09.009; Chaabane W, 2013, ARCH IMMUNOL THER EX, V61, P43, DOI 10.1007/s00005-012-0205-y; Chao JCJ, 2004, WORLD J GASTROENTERO, V10, P37; Chipuk JE, 2008, P NATL ACAD SCI USA, V105, P20327, DOI 10.1073/pnas.0808036105; Czabotar PE, 2014, NAT REV MOL CELL BIO, V15, P49, DOI 10.1038/nrm3722; DeFeudis FV, 2003, FUND CLIN PHARMACOL, V17, P405, DOI 10.1046/j.1472-8206.2003.00156.x; DEFEUDIS FV, 1991, LIFE SCI, V49, P689, DOI 10.1016/0024-3205(91)90101-G; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Fabrega A, 2012, THERIOGENOLOGY, V78, P867, DOI 10.1016/j.theriogenology.2012.03.039; Ghobrial IM, 2005, CA-CANCER J CLIN, V55, P178, DOI 10.3322/canjclin.55.3.178; Gohil K, 2002, CELL MOL BIOL, V48, P625; Hersey P, 2003, J CELL PHYSIOL, V196, P9, DOI 10.1002/jcp.10256; Hersey P, 2001, NAT REV CANCER, V1, P142, DOI 10.1038/35101078; Hersey P, 2008, ADV EXP MED BIOL, V615, P105, DOI 10.1007/978-1-4020-6554-5_6; Hersey P, 2006, INT REV CYTOL, V251, P131, DOI 10.1016/S0074-7696(06)51004-6; Jacobs BP, 2000, AM J MED, V108, P341, DOI 10.1016/S0002-9343(00)00290-4; Jiang CC, 2007, CANCER RES, V67, P9750, DOI 10.1158/0008-5472.CAN-07-2047; Jiang CC, 2011, CLIN CANCER RES, V17, P721, DOI 10.1158/1078-0432.CCR-10-2225; Jung IH, 2012, EXP MOL MED, V44, P311, DOI 10.3858/emm.2012.44.5.035; Kim KS, 2005, ORAL ONCOL, V41, P383, DOI 10.1016/j.oraloncology.2004.09.013; Limberg, 1976, TECHNIQUES CLIN APPL; Liu XP, 2007, LIFE SCI, V80, P1586, DOI 10.1016/j.lfs.2007.01.034; Lu G, 2006, BRAIN RES, V1090, P23, DOI 10.1016/j.brainres.2006.02.138; Martinou JC, 2001, NAT REV MOL CELL BIO, V2, P63, DOI 10.1038/35048069; Mattson MP, 2008, NEURON, V60, P748, DOI 10.1016/j.neuron.2008.10.010; Mikhailov V, 2003, J BIOL CHEM, V278, P5367, DOI 10.1074/jbc.M203392200; Mutoh M, 2000, CARCINOGENESIS, V21, P959, DOI 10.1093/carcin/21.5.959; Nijhawan D, 2003, GENE DEV, V17, P1475, DOI 10.1101/gad.1093903; Raso GM, 2001, LIFE SCI, V68, P921, DOI 10.1016/S0024-3205(00)00999-1; Shamas-Din A, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a008714; Soengas MS, 2003, ONCOGENE, V22, P3138, DOI 10.1038/sj.onc.1206454; Sosman JA, 2012, NEW ENGL J MED, V366, P707, DOI 10.1056/NEJMoa1112302; Trotter Shannon C, 2013, J Clin Aesthet Dermatol, V6, P18; Uzdensky AB, 2013, CURR CANCER DRUG TAR, V13, P843; Vilar JB, 2009, GENET MOL RES, V8, P328, DOI 10.4238/vol8-1gmr519; von Haefen C, 2002, ONCOGENE, V21, P4009, DOI 10.1038/sj.onc.1205497; Wang YF, 2007, CLIN CANCER RES, V13, P4934, DOI 10.1158/1078-0432.CCR-07-0665; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; Wouters J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076550; Xiaodong Liu GY, 1992, J PRACTICAL ONCOLOGY, V3, P2; Youle RJ, 2005, NAT REV MOL CELL BIO, V6, P657, DOI 10.1038/nrm1697; Zekanowski C, 2001, J MED SCREEN, V8, P132, DOI 10.1136/jms.8.3.132; Zhai DY, 2008, J BIOL CHEM, V283, P9580, DOI 10.1074/jbc.M708426200; Zhang XD, 2006, CLIN CANCER RES, V12, P1355, DOI 10.1158/1078-0432.CCR-05-2084; Zhang XD, 2001, CANCER RES, V61, P7339; Zhuang LQ, 2007, MODERN PATHOL, V20, P416, DOI 10.1038/modpathol.3800750; Zixin Li LW, 1988, CHINESE OBSTETRICS G, V23, P3	50	47	47	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 10	2015	10	4							e0124812	10.1371/journal.pone.0124812	http://dx.doi.org/10.1371/journal.pone.0124812			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CF5II	25860257	Green Submitted, Green Published, gold			2023-01-03	WOS:000352590300148
J	El-Sayed, YS; Lebda, MA; Hassinin, M; Neoman, SA				El-Sayed, Yasser S.; Lebda, Mohamed A.; Hassinin, Mohammed; Neoman, Saad A.			RETRACTED: Chicory (Cichorium intybus L.) Root Extract Regulates the Oxidative Status and Antioxidant Gene Transcripts in CCl4-Induced Hepatotoxicity (Retracted article. See vol. 12, e0173587, 2017)	PLOS ONE			English	Article; Retracted Publication							INDUCED LIVER-INJURY; PARAOXONASE; EXPRESSION; STRESS; ARYLESTERASE; GLUTATHIONE; SERUM; RAT; GENOMICS; ENZYMES	The ability of Cichorium intybus root extract (chicory extract) to protect against carbon tetrachloride (CCl4)-induced oxidative stress and hepatotoxicity was evaluated in male rats. The rats were divided into four groups according to treatment: saline (control); chicory extract (100 mg/kg body weight daily, given orally for 2 weeks); CCl4 (1 ml/kg body weight by intraperitoneal injection for 2 consecutive days only); or chicory extract (100 mg/kg body weight daily for 2 weeks) + CCl4 injection on days 16 and 17. The levels of hepatic lipid peroxidation, antioxidants, and molecular biomarkers were estimated twenty-four hours after the last CCl4 injection. Pretreatment with chicory extract significantly reduced CCl4-induced elevation of malondialdehyde levels and nearly normalized levels of glutathione and activity of glutathione S-transferase, glutathione peroxidase (GPx), glutathione reductase, catalase (CAT), paraoxonase-1 (PON1), and arylesterase in the liver. Chicory extract also attenuated CCl4-induced downregulation of hepatic mRNA expression levels of GPx1, CAT and PON1 genes. Results of DNA fragmentation support the ability of chicory extract to ameliorate CCl4-induced liver toxicity. Taken together, our results demonstrate that chicory extract is rich in natural antioxidants and able to attenuate CCl4-induced hepatocellular injury, likely by scavenging reactive free radicals, boosting the endogenous antioxidant defense system, and overexpressing genes encoding antioxidant enzymes.	[El-Sayed, Yasser S.] Damanhour Univ, Fac Vet Med, Dept Vet Forens Med & Toxicol, Damanhour, Egypt; [Lebda, Mohamed A.] Univ Alexandria, Fac Vet Med, Dept Biochem, Edfina, Egypt; [Hassinin, Mohammed] King Abdulaziz Univ, Coll Med, Dept Clin Biochem, Jeddah 21413, Saudi Arabia; [Hassinin, Mohammed; Neoman, Saad A.] Tanta Univ, Fac Med, Dept Med Biochem, Tanta, Egypt	Egyptian Knowledge Bank (EKB); Damanhour University; Egyptian Knowledge Bank (EKB); Alexandria University; King Abdulaziz University; Egyptian Knowledge Bank (EKB); Tanta University	El-Sayed, YS (corresponding author), Damanhour Univ, Fac Vet Med, Dept Vet Forens Med & Toxicol, Damanhour, Egypt.	yasser_tf@yahoo.com	Hassanien, Mohammed/B-7061-2012; El-Sayed, Yasser S./E-6400-2010; Lebda, Mohamed A./S-9126-2018	Hassanien, Mohammed/0000-0001-6559-9710; El-Sayed, Yasser S./0000-0003-3915-4640; Lebda, Mohamed A./0000-0003-2548-5465				AEBI H, 1984, METHOD ENZYMOL, V105, P121; Al-Akhras MAH, 2012, ELECTROMAGN BIOL MED, V31, P299, DOI 10.3109/15368378.2012.662193; Al-Harbi NO, 2014, INT IMMUNOPHARMACOL, V21, P383, DOI 10.1016/j.intimp.2014.05.014; Ali EMM, 2009, CLIN BIOCHEM, V42, P1394, DOI 10.1016/j.clinbiochem.2009.06.007; Alloush GA, 2003, J AGRON CROP SCI, V189, P96, DOI 10.1046/j.1439-037X.2003.00014.x; Amirghofran Z, 2000, J ETHNOPHARMACOL, V72, P167, DOI 10.1016/S0378-8741(00)00234-8; [Anonymous], 1993, MED PLANTS TRADITION; Aquilano K, 2014, FRONT PHARMACOL, V5, DOI 10.3389/fphar.2014.00196; Ashry KM, 2010, FOOD CHEM TOXICOL, V48, P236, DOI 10.1016/j.fct.2009.10.006; Azay-Milhau J, 2013, J ETHNOPHARMACOL, V150, P755, DOI 10.1016/j.jep.2013.09.046; Beltowski J, 2002, ACTA BIOCHIM POL, V49, P927; BEUTLER E, 1963, J LAB CLIN MED, V61, P882; Bulera SJ, 2001, HEPATOLOGY, V33, P1239, DOI 10.1053/jhep.2001.23560; Cavin C, 2005, BIOCHEM BIOPH RES CO, V327, P742, DOI 10.1016/j.bbrc.2004.12.061; Cemek M, 2010, FOOD CHEM TOXICOL, V48, P2827, DOI 10.1016/j.fct.2010.07.013; CHANCE B, 1952, ARCH BIOCHEM BIOPHYS, V37, P301, DOI 10.1016/0003-9861(52)90194-X; Costa LG, 2003, ANNU REV MED, V54, P371, DOI 10.1146/annurev.med.54.101601.152421; Dalar A, 2014, IND CROP PROD, V60, P79, DOI 10.1016/j.indcrop.2014.05.043; Djeridane A, 2006, J ENZYM INHIB MED CH, V21, P719, DOI 10.1080/14756360600810399; Djordjevic VB, 2004, INT REV CYTOL, V237, P57, DOI 10.1016/S0074-7696(04)37002-6; Evans WC., 1989, PHARMACOGNOSY; Goldberg DM., 1983, METHODS ENZYM ANAL, V3, P258, DOI DOI 10.1016/B978-0-12-091302-2.X5001-4; HABIG WH, 1974, J BIOL CHEM, V249, P7130; Harries HM, 2001, TOXICOL IN VITRO, V15, P399, DOI 10.1016/S0887-2333(01)00043-1; Hassan HA, 2010, FOOD CHEM TOXICOL, V48, P2163, DOI 10.1016/j.fct.2010.05.023; Hazra B, 2002, FITOTERAPIA, V73, P730, DOI 10.1016/S0367-326X(02)00232-0; Ichi I, 2009, TOXICOLOGY, V261, P33, DOI 10.1016/j.tox.2009.04.040; Ilaiyaraja N., 2010, International Journal of Integrative Biology, V10, P101; Jaeschke H, 2002, TOXICOL SCI, V65, P166, DOI 10.1093/toxsci/65.2.166; Jarvik GP, 2002, ARTERIOSCL THROM VAS, V22, P1329, DOI 10.1161/01.ATV.0000027101.40323.3A; Jia XD, 2002, CANCER EPIDEM BIOMAR, V11, P1663; Kanter M, 2005, WORLD J GASTROENTERO, V11, P6684, DOI 10.3748/wjg.v11.i42.6684; Khan RA, 2012, BMC COMPLEM ALTERN M, V12, DOI 10.1186/1472-6882-12-90; Kilic SS, 2005, WORLD J GASTROENTERO, V11, P7351, DOI 10.3748/wjg.v11.i46.7351; Kilkenny C, 2010, BRIT J PHARMACOL, V160, P1577, DOI [10.1111/j.1476-5381.2010.00872.x, 10.1113/expphysiol.2010.053793, 10.1113/jphysiol.2010.192278]; Kim JH, 2002, INT IMMUNOPHARMACOL, V2, P733, DOI 10.1016/S1567-5769(02)00008-5; Kim MY, 1996, J NUTR, V126, P2236, DOI 10.1093/jn/126.9.2236; Kim TW, 2001, ARCH PHARM RES, V24, P431, DOI 10.1007/BF02975190; Kiyici A, 2010, J MED FOOD, V13, P725, DOI 10.1089/jmf.2009.0232; Krylova S. G., 2006, Eksperimental'naya i Klinicheskaya Farmakologiya, V69, P34; Kuo JHS, 2005, J CONTROL RELEASE, V108, P442, DOI 10.1016/j.jconrel.2005.08.026; Lee KT, 2000, BIOL PHARM BULL, V23, P1005, DOI 10.1248/bpb.23.1005; Liu HT, 2013, J FOOD SCI, V78, pM258, DOI 10.1111/1750-3841.12040; Manubolu M, 2014, J ETHNOPHARMACOL, V153, P744, DOI 10.1016/j.jep.2014.03.040; Mares D, 2005, MYCOPATHOLOGIA, V160, P85, DOI 10.1007/s11046-004-6635-2; Marsillach J, 2009, BMC GASTROENTEROL, V9, DOI 10.1186/1471-230X-9-3; MORON MS, 1979, BIOCHIM BIOPHYS ACTA, V582, P67, DOI 10.1016/0304-4165(79)90289-7; Mulabagal V, 2009, EUR FOOD RES TECHNOL, V230, P47, DOI 10.1007/s00217-009-1144-7; Nallamilli BR, 2013, DRUG INVENT TODAY, V5, P311, DOI [10.1016/j.dit.2013.08.005, DOI 10.1016/J.DIT.2013.08.005]; Ng TB, 2005, BIOCHEM CELL BIOL, V83, P78, DOI [10.1139/o04-100, 10.1139/O04-100]; Nguyen SD, 2003, FREE RADICAL RES, V37, P1319, DOI 10.1080/1071-5760310001621351; Noll C, 2009, J NUTR BIOCHEM, V20, P586, DOI 10.1016/j.jnutbio.2008.06.002; PAGLIA DE, 1967, J LAB CLIN MED, V70, P158; Petrovic J, 2004, FITOTERAPIA, V75, P737, DOI 10.1016/j.fitote.2004.05.001; PLACER ZA, 1966, ANAL BIOCHEM, V16, P359, DOI 10.1016/0003-2697(66)90167-9; Preethi KC, 2009, INDIAN J EXP BIOL, V47, P163; Pushparaj PN, 2007, J ETHNOPHARMACOL, V111, P430, DOI 10.1016/j.jep.2006.11.028; Rosenblat M, 2006, ATHEROSCLEROSIS, V187, P363, DOI 10.1016/j.atherosclerosis.2005.09.006; Saggu S, 2014, FOOD CHEM TOXICOL, V72, P138, DOI 10.1016/j.fct.2014.06.029; Samarghandian Saeed, 2013, Cardiovascular & Hematological Disorders - Drug Targets, V13, P231; Siegel R, 2014, CA-CANCER J CLIN, V64, P9, DOI 10.3322/caac.21208; Singh N, 2008, ENVIRON TOXICOL PHAR, V26, P241, DOI 10.1016/j.etap.2008.05.006; Street RA, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/579319; Szymonik-Lesiuk Stanislawa, 2003, J Hepatobiliary Pancreat Surg, V10, P309, DOI 10.1007/s00534-002-0824-5; Takaeidi MR, 2014, JUNDISHAPUR J NAT PH, V9, P30, DOI 10.17795/jjnpp-10368; Ustundag B, 2007, DIGEST DIS SCI, V52, P2006, DOI 10.1007/s10620-006-9251-9; Zafar R, 1998, J ETHNOPHARMACOL, V63, P227, DOI 10.1016/S0378-8741(98)00087-7; Zhang C, 2008, J GENE MED, V10, P94, DOI 10.1002/jgm.1128	68	57	57	0	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 25	2015	10	3							e0121549	10.1371/journal.pone.0121549	http://dx.doi.org/10.1371/journal.pone.0121549			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CE5MO	25807561	Green Published, gold			2023-01-03	WOS:000351880000162
J	Comblain, F; Sanchez, C; Lesponne, I; Balligand, M; Serisier, S; Henrotin, Y				Comblain, Fanny; Sanchez, Christelle; Lesponne, Isabelle; Balligand, Marc; Serisier, Samuel; Henrotin, Yves			Curcuminoids Extract, Hydrolyzed Collagen and Green Tea Extract Synergically Inhibit Inflammatory and Catabolic Mediator's Synthesis by Normal Bovine and Osteoarthritic Human Chondrocytes in Monolayer	PLOS ONE			English	Article							FACTOR-KAPPA-B; ARTICULAR CHONDROCYTES; KNEE OSTEOARTHRITIS; EXPRESSION; INTERLEUKIN-1-BETA; CARTILAGE	The main objective of this study was to assess the in vitro effects of curcuminoids extract, hydrolyzed collagen and green tea extract in normal bovine chondrocytes and osteoarthritic human chondrocytes cultured in monolayer. This study also investigated the synergic or additive effects of these compounds. Enzymatically isolated primary bovine or human chondrocytes were cultured in monolayer until confluence and then incubated for 24 hours or 48 hours in the absence or in the presence of interleukin-1 beta and with or without curcuminoids extract, hydrolyzed collagen or green tea extract, added alone or in combination, at different concentrations. Cell viability was neither affected by these compounds, nor by interleukin 1 beta. In the absence of interleukin-1 beta, compounds did not significantly affect bovine chondrocytes metabolism. In human chondrocytes and in the absence of interleukin 1 beta, curcuminoids extract alone or in combination with hydrolyzed collagen and green tea extract significantly inhibited matrix metalloproteinase-3 production. In interleukin-1 beta-stimulated bovine chondrocytes, interleukin-6, inducible nitric oxide synthase, cyclooxygenase2, matrix metalloproteinase 3, a disintegrin and metalloproteinase with thrombospondin type I motifs 4 and a disintegrin and metalloproteinase with thrombospondin type I motifs 5 expressions were decreased by curcuminoids extract alone or in combination with hydrolyzed collagen and green tea extract. The combination of the three compounds was significantly more efficient to inhibit interleukin-1 beta stimulated matrix metalloproteinase-3 expression than curcuminoids extract alone. In interleukin-1 beta-stimulated human chondrocytes, nitric oxide, interleukin-6 and matrix metalloproteinase 3 productions were significantly reduced by curcuminoids extract alone or in combination with hydrolyzed collagen and green tea extract. These findings indicate that a mixture of curcuminoids extract, hydrolyzed collagen and green tea extract has beneficial effects on chondrocytes culture in inflammatory conditions and provide a preclinical basis for the in vivo testing of this mixture.	[Comblain, Fanny; Sanchez, Christelle; Henrotin, Yves] Univ Liege, CHU Sart Tilman, Bone & Cartilage Res Unit, Arthropole Liege, Liege, Belgium; [Lesponne, Isabelle; Serisier, Samuel] Royal Canin Res Ctr, Aimargues, France; [Balligand, Marc] Univ Liege, Dept Clin Sci, Fac Vet Med, Liege, Belgium; [Henrotin, Yves] Princess Paola Hosp, Phys Therapy & Rehabil Dept, Marche En Famenne, Belgium	University of Liege; University of Liege	Henrotin, Y (corresponding author), Univ Liege, CHU Sart Tilman, Bone & Cartilage Res Unit, Arthropole Liege, Liege, Belgium.	yhenrotin@ulg.ac.be	Serisier, Samuel/AAI-4608-2020	sanchez, christelle/0000-0002-1005-8172; Henrotin, Yves/0000-0003-1073-449X; Serisier, Samuel/0000-0002-5702-1350	Royal Canin SAS	Royal Canin SAS	The research leading to these results was supported by a grant of Royal Canin SAS. FC receives her PhD fellow from Royal Canin SAS. Royal Canin conceived and designed the work, analyzed the data, contributed compounds, revised the article, gave their final approval of the version to be published and agreed to be accountable for all aspects of the work.	Aggarwal BB, 2007, EXPERT OPIN THER TAR, V11, P109, DOI 10.1517/14728222.11.2.109; Ahmed S, 2004, J PHARMACOL EXP THER, V308, P767, DOI 10.1124/jpet.103.059220; Ahmed S, 2010, ARTHRITIS RES THER, V12, DOI 10.1186/ar2982; Akhtar N, 2011, ARTHRITIS RES THER, V13, DOI 10.1186/ar3368; Ameye LG, 2006, ARTHRITIS RES THER, V8, DOI 10.1186/ar2016; Belcaro G, 2010, PANMINERVA MED, V52, P269; Belcaro G, 2010, ALTERN MED REV, V15, P337; Carter GT, 2014, PHYS MED REH CLIN N, V25, P457, DOI 10.1016/j.pmr.2014.01.007; Cheng AL, 2001, ANTICANCER RES, V21, P2895; Csaki C, 2009, ARTHRITIS RES THER, V11, DOI 10.1186/ar2850; Daheshia M, 2008, J RHEUMATOL, V35, P2306, DOI 10.3899/jrheum.080346; EFSA, 2005, EUROPEAN FOOD SAFETY, V174, P1; Heinecke LF, 2010, OSTEOARTHR CARTILAGE, V18, P220, DOI 10.1016/j.joca.2009.08.015; Henrotin Y, 2011, OSTEOARTHR CARTILAGE, V19, P1, DOI 10.1016/j.joca.2010.10.017; Henrotin Y, 2010, OSTEOARTHR CARTILAGE, V18, P141, DOI 10.1016/j.joca.2009.10.002; Henrotin Y, 2013, SPRINGERPLUS, V2, DOI 10.1186/2193-1801-2-56; Hochberg MC, 2012, OSTEOARTHR CARTILAGE, V20, P1465, DOI 10.1016/j.joca.2012.07.022; Kapoor M, 2011, NAT REV RHEUMATOL, V7, P33, DOI 10.1038/nrrheum.2010.196; Kobayashi M, 2005, ARTHRITIS RHEUM-US, V52, P128, DOI 10.1002/art.20776; Kumar A, 2004, J MOL MED, V82, P434, DOI 10.1007/s00109-004-0555-y; LABARCA C, 1980, ANAL BIOCHEM, V102, P344, DOI 10.1016/0003-2697(80)90165-7; Lee AS, 2013, GENE, V527, P440, DOI 10.1016/j.gene.2013.05.069; Malemud CJ, 2010, DRUG AGING, V27, P95, DOI 10.2165/11319950-000000000-00000; Mathy M, 2007, OSTEOARTHR CARTILAGE, V15, pC115; Mathy-Hartert M, 2008, OSTEOARTHR CARTILAGE, V16, P756, DOI 10.1016/j.joca.2007.10.009; Mathy-Hartert M, 2009, INFLAMM RES, V58, P899, DOI 10.1007/s00011-009-0063-1; McAlindon TE, 2014, OSTEOARTHR CARTILAGE, V22, P363, DOI 10.1016/j.joca.2014.01.003; Nakagawa Y, 2014, J ORTHOP SCI, V19, P933, DOI 10.1007/s00776-014-0633-0; Nakatani S, 2009, OSTEOARTHR CARTILAGE, V17, P1620, DOI 10.1016/j.joca.2009.07.001; Nelson AE, 2014, SEMIN ARTHRITIS RHEU, V43, P701, DOI 10.1016/j.semarthrit.2013.11.012; Oesser S, 2003, CELL TISSUE RES, V311, P393, DOI 10.1007/s00441-003-0702-8; Ohara H, 2010, BIOSCI BIOTECH BIOCH, V74, P2096, DOI 10.1271/bbb.100193; Pesesse L, 2013, OSTEOARTHR CARTILAGE, V21, P1913, DOI 10.1016/j.joca.2013.08.018; Rasheed Z, 2009, ARTHRITIS RES THER, V11, DOI 10.1186/ar2700; Sanchez C, 2012, ARTHRITIS RHEUM-US, V64, P1193, DOI 10.1002/art.33445; Schadow S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053955; Schulze-Tanzil G, 2004, ANN NY ACAD SCI, V1030, P578, DOI 10.1196/annals.1329.067; Schunck M, 2006, OSTEOARTHR CARTILAGE, V14, pS114; Shakibaei M, 2007, BIOCHEM PHARMACOL, V73, P1434, DOI 10.1016/j.bcp.2007.01.005; Shoba G, 1998, PLANTA MED, V64, P353, DOI 10.1055/s-2006-957450; Walrand S, 2008, J AGR FOOD CHEM, V56, P7790, DOI 10.1021/jf800691f; Xu J, 2014, IN VITRO CELL DEV BI	42	21	23	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 23	2015	10	3							e0121654	10.1371/journal.pone.0121654	http://dx.doi.org/10.1371/journal.pone.0121654			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CE6ZS	25799427	Green Published, Green Submitted, gold			2023-01-03	WOS:000351987300280
J	Yang, SP; Lin, SM; Fu, Q; Cai, BZ; Kong, F; Huang, G; Li, FF; Wang, H				Yang, Shiping; Lin, Shaomin; Fu, Qiang; Cai, Baizhen; Kong, Fei; Huang, Guang; Li, Fafen; Wang, Han			The Effect of Adjuvant Chemotherapy on Survival in Patients with Residual Nasopharyngeal Carcinoma after Undergoing Concurrent Chemoradiotherapy	PLOS ONE			English	Article							THERAPEUTIC GAIN; PHASE-III; RADIOTHERAPY; CANCER; TRIAL; BRACHYTHERAPY	Background Guidelines from the U.S. National Comprehensive Cancer Network have recommended use of concurrent chemoradiotherapy (CCRT), followed by a 3-cycles combination of platinum and 5-fluorouracil chemotherapy as standard treatment for nasopharyngeal carcinoma (NPC). The benefits of CCRT for treatment of locally advanced NPC have been established. Whether platinum and 5-fluorouracil chemotherapy should be routinely added to locally advanced NPC after CCRT is still open to debate. Whether adjuvant chemotherapy provides an additional survival benefit for the subgroup of patients with residual nasopharyngeal carcinoma who have undergone CCRT is also unclear. This retrospective study was initiated to determine the survival benefit of adjuvant chemotherapy (AC) in residual NPC patients who have undergone concurrent chemoradiotherapy. Methods The retrospective study included 155 nasopharyngeal carcinoma patients who had local residual lesions after the platinum-based CCRT without or with AC. Kaplan-Meier analysis and the log-rank test were used to estimate overall survival (OS), failure-free survival (FFS), local relapse-free survival (LRFS) and distant metastasis-free survival (DMFS). Results Median follow-up was 47 months. Adjuvant cisplatin or nedaplatin plus 5-fluorouracil chemotherapy did not significantly improve 3-year OS, LRFS, FFS, and DMFS for patients with residual nasopharyngeal carcinoma after undergoing CCRT. The 3-year OS rates for the no-AC group and AC group were 71.6% and 73.7%, respectively (P= 0.44). The 3-year FFS rates for no-AC group and AC group were 57.5% and 66.9%, respectively ((P= 0.19). The 3-year LRFS rates for no-AC group and AC group were 84.7% and 87.9%, respectively ((P= 0.51). The 3-year DMFS rates for no-AC group and AC group were 71.4% and 77.4%, respectively ((P= 0.23). Conclusions Since we did not find sufficient data to support significant survival in 3-year OS, LRFS, FFS, and DMFS, whether Adjuvant cisplatin or nedaplatin and 5-fluorouracil chemotherapy should be routinely added to residual nasopharyngeal carcinoma patients after undergoing CCRT remain uncertain.	[Yang, Shiping; Lin, Shaomin; Fu, Qiang; Cai, Baizhen; Kong, Fei; Huang, Guang; Li, Fafen] Hainan Prov Peoples Hosp, Dept Radiat Oncol, Haikou, Hainan, Peoples R China; [Wang, Han] Hainan Med Coll, Dept Physiol, Haikou, Hainan, Peoples R China	Hainan Medical University	Yang, SP (corresponding author), Hainan Prov Peoples Hosp, Dept Radiat Oncol, Haikou, Hainan, Peoples R China.	shipingyang1982@sina.com; wanghan2801@sohu.com						Al-Sarraf M, 1998, J CLIN ONCOL, V16, P1310, DOI 10.1200/JCO.1998.16.4.1310; Al-Sarraf M, 2001, P AN M AM SOC CLIN, V20, p227a; Chen L, 2012, LANCET ONCOL, V13, P163, DOI 10.1016/S1470-2045(11)70320-5; Chi KH, 2002, INT J RADIAT ONCOL, V52, P1238, DOI 10.1016/S0360-3016(01)02781-X; Chua DTT, 2001, CANCER-AM CANCER SOC, V92, P2845, DOI 10.1002/1097-0142(20011201)92:11<2845::AID-CNCR10133>3.0.CO;2-7; Edge SB, 2010, ANN SURG ONCOL, V17, P1471, DOI 10.1245/s10434-010-0985-4; Kwong DLW, 2004, J CLIN ONCOL, V22, P2643, DOI 10.1200/JCO.2004.05.173; Kwong DLW, 1999, CANCER, V85, P1446, DOI 10.1002/(SICI)1097-0142(19990401)85:7<1446::AID-CNCR4>3.0.CO;2-3; Lai SZ, 2011, INT J RADIAT ONCOL, V80, P661, DOI 10.1016/j.ijrobp.2010.03.024; Lee AWM, 2006, INT J RADIAT ONCOL, V66, P142, DOI 10.1016/j.ijrobp.2006.03.054; Lee AWM, 2005, J CLIN ONCOL, V23, P6966, DOI 10.1200/JCO.2004.00.7542; Leung TW, 2000, INT J RADIAT ONCOL, V47, P405, DOI 10.1016/S0360-3016(00)00463-6; Leung TW, 2005, HEAD NECK-J SCI SPEC, V27, P555, DOI 10.1002/hed.20189; ROSSI A, 1988, J CLIN ONCOL, V6, P1401, DOI 10.1200/JCO.1988.6.9.1401; Stoker SD, 2013, CURR TREAT OPTION ON, V14, P475, DOI 10.1007/s11864-013-0261-5; TEO P, 1994, BRIT J RADIOL, V67, P181, DOI 10.1259/0007-1285-67-794-181; Teo P M, 1996, Clin Oncol (R Coll Radiol), V8, P160, DOI 10.1016/S0936-6555(96)80040-9; Vikram B, 2003, RADIOTHER ONCOL, V67, P1, DOI 10.1016/S0167-8140(03)00058-6; Wee J, 2005, J CLIN ONCOL, V23, P6730, DOI 10.1200/JCO.2005.16.790; Zheng XK, 2004, INT J RADIAT ONCOL, V60, P165, DOI 10.1016/j.ijrobp.2004.02.059	20	8	8	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 23	2015	10	3							e0120019	10.1371/journal.pone.0120019	http://dx.doi.org/10.1371/journal.pone.0120019			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CE6ZS	25799566	Green Submitted, gold, Green Published			2023-01-03	WOS:000351987300102
J	Jairath, V; Kahan, BC; Gray, A; Dore, CJ; Mora, A; James, MW; Stanley, AJ; Everett, SM; Bailey, AA; Dallal, H; Greenaway, J; Le Jeune, I; Darwent, M; Church, N; Reckless, I; Hodge, R; Dyer, C; Meredith, S; Llewelyn, C; Palmer, KR; Logan, RF; Travis, SP; Walsh, TS; Murphy, MF				Jairath, Vipul; Kahan, Brennan C.; Gray, Alasdair; Dore, Caroline J.; Mora, Ana; James, Martin W.; Stanley, Adrian J.; Everett, Simon M.; Bailey, Adam A.; Dallal, Helen; Greenaway, John; Le Jeune, Ivan; Darwent, Melanie; Church, Nicholas; Reckless, Ian; Hodge, Renate; Dyer, Claire; Meredith, Sarah; Llewelyn, Charlotte; Palmer, Kelvin R.; Logan, Richard F.; Travis, Simon P.; Walsh, Timothy S.; Murphy, Michael F.			Restrictive versus liberal blood transfusion for acute upper gastrointestinal bleeding (TRIGGER): a pragmatic, open-label, cluster randomised feasibility trial	LANCET			English	Article							CELL TRANSFUSION; RISK; REQUIREMENTS; MULTICENTER; STRATEGIES; CONSENSUS; OUTCOMES	Background Transfusion thresholds for acute upper gastrointestinal bleeding are controversial. So far, only three small, underpowered studies and one single-centre trial have been done. Findings from the single-centre trial showed reduced mortality with restrictive red blood cell (RBC) transfusion. We aimed to assess whether a multicentre, cluster randomised trial is a feasible method to substantiate or refute this finding. Methods In this pragmatic, open-label, cluster randomised feasibility trial, done in six university hospitals in the UK, we enrolled all patients aged 18 years or older with new presentations of acute upper gastrointestinal bleeding, irrespective of comorbidity, except for exsanguinating haemorrhage. We randomly assigned hospitals (1: 1) with a computer-generated randomisation sequence (random permuted block size of 6, without stratification or matching) to either a restrictive (transfusion when haemoglobin concentration fell below 80 g/L) or liberal (transfusion when haemoglobin concentration fell below 100 g/L) RBC transfusion policy. Neither patients nor investigators were masked to treatment allocation. Feasibility outcomes were recruitment rate, protocol adherence, haemoglobin concentration, RBC exposure, selection bias, and information to guide design and economic evaluation of the phase 3 trial. Main exploratory clinical outcomes were further bleeding and mortality at day 28. We did analyses on all enrolled patients for whom an outcome was available. This trial is registered, ISRCTN85757829 and NCT02105532. Findings Between Sept 3, 2012, and March 1, 2013, we enrolled 936 patients across six hospitals (403 patients in three hospitals with a restrictive policy and 533 patients in three hospitals with a liberal policy). Recruitment rate was significantly higher for the liberal than for the restrictive policy (62% vs 55%; p=0.04). Despite some baseline imbalances, Rockall and Blatchford risk scores were identical between policies. Protocol adherence was 96% (SD 10) in the restrictive policy vs 83% (25) in the liberal policy (difference 14%; 95% CI 7-21; p=0.005). Mean last recorded haemoglobin concentration was 116 (SD 24) g/L for patients on the restrictive policy and 118 (20) g/L for those on the liberal policy (diff erence -2.0 [95% CI -12.0 to 7.0]; p=0.50). Fewer patients received RBCs on the restrictive policy than on the liberal policy (restrictive policy 133 [33%] vs liberal policy 247 [46%]; diff erence -12% [95% CI -35 to 11]; p=0.23), with fewer RBC units transfused (mean 1.2 [SD 2.1] vs 1.9 [2.8]; diff erence -0.7 [-1.6 to 0.3]; p=0.12), although these differences were not significant. We noted no significant diff erence in clinical outcomes. Interpretation A cluster randomised design led to rapid recruitment, high protocol adherence, separation in degree of anaemia between groups, and non-significant reduction in RBC transfusion in the restrictive policy. A large cluster randomised trial to assess the effectiveness of transfusion strategies for acute upper gastrointestinal bleeding is both feasible and essential before clinical practice guidelines change to recommend restrictive transfusion for all patients with acute upper gastrointestinal bleeding.	[Jairath, Vipul; Murphy, Michael F.] NHS Blood & Transplant, Oxford, England; [Jairath, Vipul; Bailey, Adam A.; Travis, Simon P.] Univ Oxford, Nuffield Dept Med, Translat Gastroenterol Unit, Oxford, England; [Kahan, Brennan C.; Dore, Caroline J.; Meredith, Sarah] UCL, MRC, Clin Trials Unit, London, England; [Gray, Alasdair] Royal Edinburgh Infirm, Dept Emergency Med, Edinburgh, Midlothian, Scotland; [Church, Nicholas] Royal Edinburgh Infirm, Dept Gastroenterol, Edinburgh, Midlothian, Scotland; [Mora, Ana; Hodge, Renate; Dyer, Claire; Llewelyn, Charlotte] NHS Blood & Transplant Clin Trials Unit, Cambridge, England; [James, Martin W.; Logan, Richard F.] Nottingham Univ Hosp NHS Trust, Natl Inst Hlth Res, Nottingham Digest Dis Biomed Res Unit, Nottingham, England; [Le Jeune, Ivan] Nottingham Univ Hosp NHS Trust, Dept Res & Educ Emergency Med Acute Med & Trauma, Nottingham, England; [Stanley, Adrian J.] Glasgow Royal Infirm, Gastroenterol Unit, Glasgow G4 0SF, Lanark, Scotland; [Everett, Simon M.] St James Univ Hosp, Dept Gastroenterol, Leeds, W Yorkshire, England; [Dallal, Helen; Greenaway, John] James Cook Univ Hosp, Dept Gastroenterol, Middlesbrough, Cleveland, England; [Reckless, Ian] Oxford Univ Hosp NHS Trust, Dept Acute Gen Med, Dept Emergency Med, Oxford, England; [Palmer, Kelvin R.] Western Gen Hosp, Edinburgh EH4 2XU, Midlothian, Scotland; [Walsh, Timothy S.] Univ Edinburgh, Queens Med Res Inst, Ctr Inflammat Res, Edinburgh, Midlothian, Scotland; [Murphy, Michael F.] Oxford Univ Hosp, Oxford Biomed Res Ctr, Natl Inst Hlth Res, Oxford, England	University of Oxford; Medical Research Council Clinical Trials Unit; University of London; University College London; Royal Infirmary of Edinburgh; Royal Infirmary of Edinburgh; Nottingham University Hospital NHS Trust; University of Nottingham; Nottingham University Hospital NHS Trust; University of Glasgow; Saint James's University Hospital; James Cook University Hospital; Oxford University Hospitals NHS Foundation Trust; University of Edinburgh; University of Edinburgh; University of Oxford	Jairath, V (corresponding author), Univ Oxford, Nuffield Dept Med, Translat Gastroenterol Unit, Oxford OX3 9DU, England.	vipul.jairath@nhsbt.nhs.uk	Jairath, Vipul/GLS-6449-2022; Dore, Caroline J/J-4716-2012	Dore, Caroline J/0000-0001-9796-4970; Stanley, Adrian/0000-0002-9761-9795; Travis, Simon/0000-0002-2690-4361; Bailey, Adam/0000-0002-8371-2147	NHS Blood and Transplant Research and Development; NHS Blood and Transplant Research and Development [10-09-CSU]; National Institute for Health Research Clinical Research Networks; Medical Research Council [MC_U122870183] Funding Source: researchfish; MRC [MC_U122870183] Funding Source: UKRI	NHS Blood and Transplant Research and Development; NHS Blood and Transplant Research and Development; National Institute for Health Research Clinical Research Networks; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	NHS Blood and Transplant Research and Development.; This study was funded by NHS Blood and Transplant Research and Development (grant number 10-09-CSU) and run by the NHS Blood and Transplant Clinical Trials Unit (formerly NHS Blood and Transplant/Medical Research Council Clinical Trials Unit). The views and opinions expressed herein are those of the authors and do not necessarily represent those of NHS Blood and Transplant. The trial was supported by the National Institute for Health Research Clinical Research Networks. We thank the independent members of the Trial Steering Committee and independent data monitoring committee, members of the lay focus group and patient panel who contributed to trial design, and Age UK Abingdon for allowing us to run a focus group with members of the public. We thank all clinical teams in participating centres for their support and following the transfusion policies.	Barkun AN, 2010, ANN INTERN MED, V152, P101, DOI 10.7326/0003-4819-152-2-201001190-00009; Bellomo R, 2009, CRIT CARE MED, V37, P3114, DOI 10.1097/CCM.0b013e3181bc7bd5; BLAIR SD, 1986, BRIT J SURG, V73, P783, DOI 10.1002/bjs.1800731007; British Society of Gastroenterology, 2007, UK COMP AUD UPP GAST; Carless PA, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002042.pub2; Carson JL, 2013, AM HEART J, V165, P964, DOI 10.1016/j.ahj.2013.03.001; Carson JL, 2011, NEW ENGL J MED, V365, P2453, DOI 10.1056/NEJMoa1012452; Crooks C, 2011, GASTROENTEROLOGY, V141, P62, DOI 10.1053/j.gastro.2011.03.048; Crooks CJ, 2013, GASTROENTEROLOGY, V144, P1384, DOI 10.1053/j.gastro.2013.02.040; de Franchis R, 2010, J HEPATOL, V53, P762, DOI 10.1016/j.jhep.2010.06.004; Dechartres A, 2011, ANN INTERN MED, V155, P39, DOI 10.7326/0003-4819-155-1-201107050-00006; Elizalde JI, 1998, J HEPATOL, V29, P789, DOI 10.1016/S0168-8278(98)80260-2; Hajjar LA, 2010, JAMA-J AM MED ASSOC, V304, P1559, DOI 10.1001/jama.2010.1446; Hayes RJ, 2009, INTERD STAT, P3; Hearnshaw SA, 2010, ALIMENT PHARM THER, V32, P215, DOI 10.1111/j.1365-2036.2010.04348.x; Hebert PC, 1999, NEW ENGL J MED, V340, P409, DOI 10.1056/NEJM199902113400601; Jairath V, 2013, TRANSFUSION MED, V23, P139, DOI 10.1111/tme.12048; Jairath V, 2010, COCHRANE DB SYST REV, V9; Jairath V, 2013, TRANSFUS MED REV, V27, P146, DOI 10.1016/j.tmrv.2013.04.001; Jairath V, 2011, TRANSFUSION, V51, P1940, DOI 10.1111/j.1537-2995.2011.03119.x; Kahan BC, 2014, TRIALS, V15, DOI 10.1186/1745-6215-15-139; Kahan BC, 2013, TRIALS, V14, DOI 10.1186/1745-6215-14-206; Klar N, 2000, DESIGN ANAL CLUSTER, DOI [10.17843/rpmesp.2016.333.2293, DOI 10.17843/RPMESP.2016.333.2293]; Napolitano LM, 2009, CRIT CARE MED, V37, P3124, DOI 10.1097/CCM.0b013e3181b39f1b; Restellini S, 2013, ALIMENT PHARM THER, V37, P316, DOI 10.1111/apt.12170; Rockall TA, 1996, GUT, V38, P316, DOI 10.1136/gut.38.3.316; Tinegate H, 2013, TRANSFUSION, V53, P483, DOI 10.1111/j.1537-2995.2012.03782.x; Villanueva C, 2013, NEW ENGL J MED, V368, P11, DOI 10.1056/NEJMoa1211801; Villarejo F., 1999, Acta Gastroenterologica Latinoamericana, V29, P261; Walsh TS, 2013, CRIT CARE MED, V41, P2354, DOI 10.1097/CCM.0b013e318291cce4; Walsh TS, 2010, BMJ-BRIT MED J, V341, DOI 10.1136/bmj.c4408	31	143	152	0	31	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 11	2015	386	9989					137	144		10.1016/S0140-6736(14)61999-1	http://dx.doi.org/10.1016/S0140-6736(14)61999-1			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CM5QC	25956718	Green Submitted			2023-01-03	WOS:000357742200030
J	Fousteri, G; Jofra, T; Di Fonte, R; Battaglia, M				Fousteri, Georgia; Jofra, Tatiana; Di Fonte, Roberta; Battaglia, Manuela			Combination of an Antigen-Specific Therapy and an Immunomodulatory Treatment to Simultaneous Block Recurrent Autoimmunity and Alloreactivity in Non-Obese Diabetic Mice	PLOS ONE			English	Article							TRANSPLANTATION TOLERANCE INDUCTION; ALLOGENEIC ISLET TRANSPLANTATION; T-CELL COSTIMULATION; PANCREAS TRANSPLANTATION; NOD MICE; GRAFT-SURVIVAL; PRONE MICE; TYPE-1; IMMUNOSUPPRESSION; RESPONSES	Restoration of endogenous insulin production by islet transplantation is considered a curative option for patients with type 1 diabetes. However, recurrent autoimmunity and alloreactivity cause graft rejection hindering successful transplantation. Here we tested whether transplant tolerance to allogeneic islets could be achieved in non-obese diabetic (NOD) mice by simultaneously tackling autoimmunity via antigen-specific immunization, and alloreactivity via granulocyte colony stimulating factor (G-CSF) and rapamycin (RAPA) treatment. Immunization with insB(9-23) peptide alone or in combination with two islet peptides (IGRP(206-214) and GAD(524-543)) in incomplete Freund's adjuvant (IFA) were tested for promoting syngeneic pancreatic islet engraftment in spontaneously diabetic NOD mice. Treatment with G-CSF/RAPA alone or in combination with insB(9-23)/IFA was examined for promoting allogeneic islet engraftment in the same mouse model. InsB(9-23)/IFA immunization significantly prolonged syngeneic pancreatic islet survival in NOD mice by a mechanism that necessitated the presence of CD4(+)CD25(+)T regulatory (Treg) cells, while combination of three islet epitopes was less efficacious in controlling recurrent autoimmunity. G-CSF/RAPA treatment was unable to reverse T1D or control recurrent autoimmunity but significantly prolonged islet allograft survival in NOD mice. Blockade of interleukin-10 (IL-10) during G-CSF/RAPA treatment resulted in allograft rejection suggesting that IL-10-producing cells were fundamental to achieve transplant tolerance. G-CSF/RAPA treatment combined with insB(9-23)/IFA did not further increase the survival of allogeneic islets. Thus, insB(9-23)/IFA immunization controls recurrent autoimmunity and G-CSF/RAPA treatment limits alloreactivity, however their combination does not further promote allogeneic pancreatic islet engraftment in NOD mice.	[Fousteri, Georgia; Jofra, Tatiana; Di Fonte, Roberta; Battaglia, Manuela] Ist Sci San Raffaele, IRCCS, DRI, I-20132 Milan, Italy	Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele	Fousteri, G (corresponding author), Ist Sci San Raffaele, IRCCS, DRI, Via Olgettina 58, I-20132 Milan, Italy.	fousteri.georgia@hsr.it; battaglia.manuela@hsr.it	Di Fonte, Roberta/AAC-5886-2020; Jofra, Tatiana/AAN-4727-2020; Fousteri, Georgia/B-1226-2012	Di Fonte, Roberta/0000-0002-8541-686X; Jofra, Tatiana/0000-0003-2825-155X; Battaglia, Manuela/0000-0003-4535-3152; Fousteri, Georgia/0000-0001-7745-7517	Juvenile Diabetes Research Foundation (JDRF) [10-2012-204]; Telethon-JDRF [JT-01]	Juvenile Diabetes Research Foundation (JDRF)(Juvenile Diabetes Research Foundation); Telethon-JDRF(Juvenile Diabetes Research Foundation)	This work was supported by grants: Juvenile Diabetes Research Foundation (JDRF) advanced postdoctoral fellowship (10-2012-204) to G. Fousteri and Telethon-JDRF (JT-01) career development award to M. Battaglia. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abreu JRF, 2013, CURR DIABETES REP, V13, P704, DOI 10.1007/s11892-013-0399-3; Bluestone JA, 2010, NATURE, V464, P1293, DOI 10.1038/nature08933; Bresson D, 2009, DIABETES CARE, V32, P1753, DOI 10.2337/dc09-0373; Burke GW, 2011, CURR DIABETES REP, V11, P413, DOI 10.1007/s11892-011-0206-y; Chujo D, 2012, CELL TRANSPLANT, V21, P2783, DOI 10.3727/096368912X654993; Coppieters KT, 2013, CLIN IMMUNOL, V149, P345, DOI 10.1016/j.clim.2013.02.002; Fousteri G, 2010, DIABETOLOGIA, V53, P1958, DOI 10.1007/s00125-010-1777-x; Fousteri G, 2007, ADV EXP MED BIOL, V601, P313; Fousteri G, 2010, DIABETES, V59, P3148, DOI 10.2337/db10-0561; Fousteri G, 2009, J AUTOIMMUN, V32, P70, DOI 10.1016/j.jaut.2008.12.001; Gagliani N, 2013, AM J TRANSPLANT, V13, P1963, DOI 10.1111/ajt.12333; Gagliani N, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028434; Gruessner RWG, 2013, NAT REV ENDOCRINOL, V9, P555, DOI 10.1038/nrendo.2013.138; Han BY, 2005, NAT MED, V11, P645, DOI 10.1038/nm1250; Kimelman M, 2013, CURR OPIN ORGAN TRAN, V18, P76, DOI 10.1097/MOT.0b013e32835c6eda; Kirk AD, 2006, TRANSPLANTATION, V82, P593, DOI 10.1097/01.tp.0000234905.56926.7f; Krishnamurthy B, 2006, J CLIN INVEST, V116, P3258, DOI 10.1172/JCI29602; Larsen CP, 2006, AM J TRANSPLANT, V6, P876, DOI 10.1111/j.1600-6143.2006.01259.x; Laughlin E, 2008, CLIN IMMUNOL, V128, P23, DOI 10.1016/j.clim.2008.03.459; Lutterotti A, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3006168; Makhlouf L, 2002, DIABETES, V51, P3202, DOI 10.2337/diabetes.51.11.3202; Markees TG, 1999, DIABETES, V48, P967, DOI 10.2337/diabetes.48.5.967; Molano RD, 2001, DIABETES, V50, P270, DOI 10.2337/diabetes.50.2.270; Monti P, 2008, J CLIN INVEST, V118, P1806, DOI 10.1172/JCI35197; Olcott AP, 2005, J IMMUNOL, V175, P1991, DOI 10.4049/jimmunol.175.3.1991; Orlando G, 2014, DIABETES, V63, P1433, DOI 10.2337/db13-1742; Peakman M, 2010, DIABETES, V59, P2087, DOI 10.2337/db10-0630; Pearson T, 2003, ANN NY ACAD SCI, V1005, P148, DOI 10.1196/annals.1288.016; Pearson T, 2003, DIABETES, V52, P321, DOI 10.2337/diabetes.52.2.321; Ramesh A, 2013, CURR DIABETES REV, V9, P294, DOI 10.2174/15733998113099990063; Ravanan R, 2007, CLIN EXP IMMUNOL, V148, P368, DOI 10.1111/j.1365-2249.2007.03358.x; Rayat GR, 2000, TRANSPLANTATION, V70, P976, DOI 10.1097/00007890-200009270-00016; Roep BO, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a007781; Rossini AA, 2001, TRANSPLANTATION, V72, pS43; Ryden AKE, 2014, HUM VACC IMMUNOTHER, V10, P838, DOI 10.4161/hv.26890; Setiady YY, 2010, EUR J IMMUNOL, V40, P780, DOI 10.1002/eji.200939613; Shapiro A M James, 2012, Rev Diabet Stud, V9, P385, DOI 10.1900/RDS.2012.9.385; Shoda LKM, 2005, IMMUNITY, V23, P115, DOI 10.1016/j.immuni.2005.08.002; Stegall MD, 1996, TRANSPLANTATION, V61, P1272, DOI 10.1097/00007890-199604270-00027; Stratta RJ, 2014, EXPERT REV CLIN IMMU, V10, P117, DOI 10.1586/1744666X.2014.853616; Tian J, 2002, J IMMUNOL, V169, P6564, DOI 10.4049/jimmunol.169.11.6564; Tian JD, 1996, J EXP MED, V183, P1561, DOI 10.1084/jem.183.4.1561; Tian JD, 1996, NAT MED, V2, P1348, DOI 10.1038/nm1296-1348; Van Belle TL, 2011, PHYSIOL REV, V91, P79, DOI 10.1152/physrev.00003.2010; van de Linde Pieter, 2005, Am J Ther, V12, P573, DOI 10.1097/01.mjt.0000178768.44987.cb; Vendrame F, 2010, DIABETES, V59, P947, DOI 10.2337/db09-0498; Yoon JW, 1999, SCIENCE, V284, P1183, DOI 10.1126/science.284.5417.1183	47	6	6	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 16	2015	10	6							e0127631	10.1371/journal.pone.0127631	http://dx.doi.org/10.1371/journal.pone.0127631			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CK9EB	26080071	Green Published, gold, Green Submitted			2023-01-03	WOS:000356542300005
J	Wang, JP; Chiu, CC; Yang, TH; Liu, TH; Wu, CY; Chou, P				Wang, Jen-Pang; Chiu, Chih-Chiang; Yang, Tsu-Hui; Liu, Tzong-Hsien; Wu, Chia-Yi; Chou, Pesus			The Low Proportion and Associated Factors of Involuntary Admission in the Psychiatric Emergency Service in Taiwan	PLOS ONE			English	Article							INFLUENCING COMPULSORY ADMISSION; HEALTH ACT 1983; MENTALLY-ILL; CHANGING PATTERNS; BIPOLAR DISORDER; ACUTE MANIA; AMSTERDAM; RISK; ETHNICITY; CARE	Background The involuntary admission regulated under the Mental Health Act has become an increasingly important issue in the developed countries in recent years. Most studies about the distribution and associated factors of involuntary admission were carried out in the western countries; however, the results may vary in different areas with different legal and sociocultural backgrounds. Aims The aim of this study was to investigate the proportion and associated factors of involuntary admission in a psychiatric emergency service in Taiwan. Methods The study cohort included patients admitted from a psychiatric emergency service over a two-year period. Demographic, psychiatric emergency service utilization, and clinical variables were compared between those who were voluntarily and involuntarily admitted to explore the associated factors of involuntary admission. Results Among 2,777 admitted patients, 110 (4.0%) were involuntarily admitted. Police referrals and presenting problems as violence assessed by psychiatric nurses were found to be associated with involuntary admission. These patients were more likely to be involuntarily admitted during the night shift and stayed longer in the psychiatric emergency service. Conclusions The proportion of involuntary admissions in Taiwan was in the lower range when compared to Western countries. Dangerous conditions evaluated by the psychiatric nurses and police rather than diagnosis made by the psychiatrists were related factors of involuntary admission. As it spent more time to admit involuntary patients, it was suggested that multidisciplinary professionals should be included in and educated for during the process of involuntary admission.	[Wang, Jen-Pang; Chou, Pesus] Natl Yang Ming Univ, Inst Publ Hlth, Taipei 112, Taiwan; [Wang, Jen-Pang; Chou, Pesus] Natl Yang Ming Univ, Community Med Res Ctr, Taipei 112, Taiwan; [Wang, Jen-Pang; Chiu, Chih-Chiang; Yang, Tsu-Hui; Liu, Tzong-Hsien] Taipei City Hosp, Taipei City Psychiat Ctr, Dept Psychiat, Taipei, Taiwan; [Wang, Jen-Pang] Natl Taipei Univ Nursing & Hlth Sci, Dept Healthcare Management, Taipei, Taiwan; [Chiu, Chih-Chiang] Taipei Med Univ, Sch Med, Dept Psychiat, Taipei, Taiwan; [Yang, Tsu-Hui] Taipei City Govt, Dept Hlth, Med Affairs Div, Taipei, Taiwan; [Wu, Chia-Yi] Natl Taiwan Univ, Coll Med, Dept Nursing, Taipei 10764, Taiwan	National Yang Ming Chiao Tung University; National Yang Ming Chiao Tung University; Taipei City Hospital; National Taipei University of Nursing & Health Science (NTUNHS); Taipei Medical University; National Taiwan University	Chou, P (corresponding author), Natl Yang Ming Univ, Inst Publ Hlth, Taipei 112, Taiwan.	pschou@ym.edu.tw	WU, CHIA-YI/E-4992-2010	WU, CHIA-YI/0000-0003-1756-557X	Taipei City Hospital, Taiwan [10201-62-051]	Taipei City Hospital, Taiwan	This study was funded by Taipei City Hospital, Taiwan in 2013 (grant number: 10201-62-051). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	BEBBINGTON PE, 1994, BRIT J PSYCHIAT, V165, P743, DOI 10.1192/bjp.165.6.743; Beveridge R., 1999, CAN J EMERG MED, V1, pS1; Bola JR, 2011, COMMUNITY MENT HLT J, V47, P603, DOI 10.1007/s10597-011-9396-7; Chen YY, 2008, LANCET, V372, P1629, DOI 10.1016/S0140-6736(08)61679-7; Chen YY, 2012, EPIDEMIOL REV, V34, P129, DOI 10.1093/epirev/mxr025; Cougnard A, 2004, SOC PSYCH PSYCH EPID, V39, P804, DOI 10.1007/s00127-004-0826-5; Davies S, 1996, BRIT MED J, V312, P533, DOI 10.1136/bmj.312.7030.533; Douzenis A, 2012, INT J SOC PSYCHIATR, V58, P172, DOI 10.1177/0020764010387477; Dressing H, 2004, SOC PSYCH PSYCH EPID, V39, P797, DOI 10.1007/s00127-004-0814-9; Fennig S, 1999, PSYCHIAT SERV, V50, P1049, DOI 10.1176/ps.50.8.1049; Hansson L, 1999, SOC PSYCH PSYCH EPID, V34, P99, DOI 10.1007/s001270050118; Hotopf M, 2000, BRIT J PSYCHIAT, V176, P479, DOI 10.1192/bjp.176.5.479; Keown P, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d3736; Keown P, 2008, BRIT MED J, V337, DOI 10.1136/bmj.a1837; Kessell ER, 2006, PSYCHIAT SERV, V57, P1435, DOI 10.1176/appi.ps.57.10.1435; Lelliott P, 2003, BRIT J PSYCHIAT, V182, P68, DOI 10.1192/bjp.182.1.68; Lindsey MA, 2010, GEN HOSP PSYCHIAT, V32, P300, DOI 10.1016/j.genhosppsych.2010.01.007; Morgan C, 2005, BRIT J PSYCHIAT, V186, P281, DOI 10.1192/bjp.186.4.281; Mulder CL, 2008, INT J LAW PSYCHIAT, V31, P331, DOI 10.1016/j.ijlp.2008.06.007; Mulder CL, 2006, BRIT J PSYCHIAT, V188, P386, DOI 10.1192/bjp.188.4.386; Myklebust LH, 2012, NORD J PSYCHIAT, V66, P178, DOI 10.3109/08039488.2011.611252; Oluwatayo O, 2004, SOC PSYCH PSYCH EPID, V39, P739, DOI 10.1007/s00127-004-0794-9; RIECHER A, 1991, PSYCHOL MED, V21, P197, DOI 10.1017/S0033291700014781; RIECHERROSSLER A, 1993, ACTA PSYCHIAT SCAND, V87, P231, DOI 10.1111/j.1600-0447.1993.tb03363.x; Salize HJ, 2004, BRIT J PSYCHIAT, V184, P163, DOI 10.1192/bjp.184.2.163; Schuepbach D, 2008, PHARMACOPSYCHIATRY, V41, P29, DOI 10.1055/s-2007-993213; Schuepbach D, 2006, J AFFECT DISORDERS, V90, P57, DOI 10.1016/j.jad.2005.09.012; Singh SP, 1998, SOC PSYCH PSYCH EPID, V33, P39; THOMAS CS, 1993, BRIT J PSYCHIAT, V163, P91, DOI 10.1192/bjp.163.1.91; van der Post L, 2012, INT J SOC PSYCHIATR, V58, P374, DOI 10.1177/0020764011399970; van der Post L, 2009, PSYCHIAT SERV, V60, P1543, DOI 10.1176/appi.ps.60.11.1543; van der Post LFM, 2014, INT J SOC PSYCHIATR, V60, P125, DOI 10.1177/0020764012470234; van der Post LFM, 2014, SOC PSYCH PSYCH EPID, V49, P283, DOI 10.1007/s00127-013-0742-7; van der Post LFM, 2012, PSYCHIAT SERV, V63, P577, DOI 10.1176/appi.ps.201100080; Wierdsma AI, 2007, J EPIDEMIOL COMMUN H, V61, P613, DOI 10.1136/jech.2005.044974; Wierdsma Andre I, 2009, Int J Integr Care, V9, pe90; Zinkler M, 2002, ACTA PSYCHIAT SCAND, V106, P3, DOI 10.1034/j.1600-0447.2002.02268.x	37	14	14	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 5	2015	10	6							e0129204	10.1371/journal.pone.0129204	http://dx.doi.org/10.1371/journal.pone.0129204			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	CJ7CR	26046529	gold, Green Published			2023-01-03	WOS:000355652200134
J	Yan, M; Wen, J; Liang, M; Lu, YF; Kamata, M; Chen, ISY				Yan, Ming; Wen, Jing; Liang, Min; Lu, Yunfeng; Kamata, Masakazu; Chen, Irvin S. Y.			Modulation of Gene Expression by Polymer Nanocapsule Delivery of DNA Cassettes Encoding Small RNAs	PLOS ONE			English	Article							VECTORS; SYSTEM; CCR5; CURE	Small RNAs, including siRNAs, gRNAs and miRNAs, modulate gene expression and serve as potential therapies for human diseases. Delivery to target cells remains the fundamental limitation for use of these RNAs in humans. To address this challenge, we have developed a nanocapsule delivery technology that encapsulates small DNA molecules encoding RNAs into a small (30nm) polymer nanocapsule. For proof of concept, we transduced DNA expression cassettes for three small RNAs. In one application, the DNA cassette encodes an shRNA transcriptional unit that downregulates CCR5 and protects from HIV-1 infection. The DNA cassette nanocapsules were further engineered for timed release of the DNA cargo for prolonged knockdown of CCR5. Secondly, the nanocapsules provide an efficient means for delivery of gRNAs in the CRISPR/Cas9 system to mutate integrated HIV-1. Finally, delivery of microRNA-125b to mobilized human CD34+ cells enhances survival and expansion of the CD34+ cells in culture.	[Yan, Ming; Wen, Jing; Liang, Min; Chen, Irvin S. Y.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Microbiol Immunol & Mol Genet, Los Angeles, CA 90095 USA; [Lu, Yunfeng] Univ Calif Los Angeles, Dept Biomol & Chem Engn, Los Angeles, CA 90095 USA; [Yan, Ming; Lu, Yunfeng] Univ Calif Los Angeles, Calif NanoSyst Inst CNSI, Los Angeles, CA 90095 USA; [Kamata, Masakazu] Univ Calif Los Angeles, David Geffen Sch Med, Dept Hematol Oncol, Los Angeles, CA 90095 USA; [Yan, Ming; Wen, Jing; Kamata, Masakazu; Chen, Irvin S. Y.] Univ Calif Los Angeles, AIDS Inst, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles	Chen, ISY (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Microbiol Immunol & Mol Genet, Los Angeles, CA 90095 USA.	syuchen@mednet.ucla.edu	KAMATA, MASAKAZU/E-7550-2017; Wen, Jing/F-1949-2019	Wen, Jing/0000-0002-6127-6276; Kamata, Masakazu/0000-0003-0323-3742	UCLA AIDS Institute; UCLA Center for AIDS Research [AI28697]; UCLA California NanoSystems Institute; NIH [R21 AI114433]; NATIONAL CANCER INSTITUTE [P30CA016042] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI114433] Funding Source: NIH RePORTER	UCLA AIDS Institute; UCLA Center for AIDS Research; UCLA California NanoSystems Institute; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This work was supported by the UCLA AIDS Institute, the UCLA Center for AIDS Research (AI28697), the UCLA California NanoSystems Institute, and NIH R21 AI114433. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Al-Dosari MS, 2009, AAPS J, V11, P671, DOI 10.1208/s12248-009-9143-y; An DS, 2007, P NATL ACAD SCI USA, V104, P13110, DOI 10.1073/pnas.0705474104; Bousquet M, 2010, P NATL ACAD SCI USA, V107, P21558, DOI 10.1073/pnas.1016611107; Castanotto D, 2002, RNA, V8, P1454, DOI 10.1017/S1355838202021362; Cho SW, 2014, GENOME RES, V24, P132, DOI 10.1101/gr.162339.113; Cong L, 2013, SCIENCE, V339, P819, DOI 10.1126/science.1231143; Davidson BL, 2011, NAT REV GENET, V12, P329, DOI 10.1038/nrg2968; Ding QR, 2013, CELL STEM CELL, V12, P393, DOI 10.1016/j.stem.2013.03.006; Ebina H, 2013, SCI REP-UK, V3, DOI 10.1038/srep02510; Holkers M, 2014, NAT METHODS, V11, P1051, DOI [10.1038/NMETH.3075, 10.1038/nmeth.3075]; Jinek M, 2013, ELIFE, V2, DOI 10.7554/eLife.00471; Johnston SH, 2009, J VIROL, V83, P11016, DOI 10.1128/JVI.01242-09; Jones CH, 2013, MOL PHARMACEUT, V10, P4082, DOI 10.1021/mp400467x; Kim DH, 2007, NAT REV GENET, V8, P173, DOI 10.1038/nrg2006; Klinman DM, 1997, J IMMUNOL, V158, P3635; Li MJ, 2003, MOL THER, V8, P196, DOI 10.1016/S1525-0016(03)00165-5; Mali P, 2013, SCIENCE, V339, P823, DOI 10.1126/science.1232033; Miyagishi M, 2002, NAT BIOTECHNOL, V20, P497, DOI 10.1038/nbt0502-497; O'Connell RM, 2008, J EXP MED, V205, P585, DOI 10.1084/jem.20072108; O'Connell RM, 2010, P NATL ACAD SCI USA, V107, P14235, DOI 10.1073/pnas.1009798107; Pang S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096445; Ran FA, 2013, CELL, V154, P1380, DOI 10.1016/j.cell.2013.08.021; Rao DD, 2009, ADV DRUG DELIVER REV, V61, P746, DOI 10.1016/j.addr.2009.04.004; Sampson TR, 2013, NATURE, V497, P254, DOI 10.1038/nature12048; Sander JD, 2014, NAT BIOTECHNOL, V32, P347, DOI 10.1038/nbt.2842; Schiffer JT, 2012, J VIROL, V86, P8920, DOI 10.1128/JVI.00052-12; Shimizu S, 2010, BLOOD, V115, P1534, DOI 10.1182/blood-2009-04-215855; Shimizu Saki, 2009, Genet Vaccines Ther, V7, P8, DOI 10.1186/1479-0556-7-8; So AYL, 2014, BLOOD, V124, P1502, DOI 10.1182/blood-2014-02-553842; Wang JB, 2014, P NATL ACAD SCI USA, V111, P13157, DOI 10.1073/pnas.1410785111; Wang WW, 2013, CURR PHARM BIOTECHNO, V14, P46; Yan M, 2012, J AM CHEM SOC, V134, P13542, DOI 10.1021/ja304649a; Yan M, 2010, NAT NANOTECHNOL, V5, P48, DOI [10.1038/nnano.2009.341, 10.1038/NNANO.2009.341]; Yin H, 2014, NAT REV GENET, V15, P541, DOI 10.1038/nrg3763	34	19	22	2	49	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 2	2015	10	6							e0127986	10.1371/journal.pone.0127986	http://dx.doi.org/10.1371/journal.pone.0127986			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CJ7SJ	26035832	Green Published, gold			2023-01-03	WOS:000355699100026
J	Kohan, HG; Kaur, K; Jamali, F				Kohan, Hamed Gilzad; Kaur, Kamaljit; Jamali, Fakhreddin			Synthesis and Characterization of a New Peptide Prodrug of Glucosamine with Enhanced Gut Permeability	PLOS ONE			English	Article							INTESTINAL-ABSORPTION; KNEE OSTEOARTHRITIS; DOUBLE-BLIND; SULFATE; PHARMACOKINETICS; PROGRESSION; ACYCLOVIR	The aim of this study was to synthesize a peptide prodrug of glucosamine (GlcN) with increased gut permeability through the gut peptide transporter 1 (PepT1). Glycine-Valine ester derivative of GlcN (GVG) was synthesised using solid phase synthesis followed by characterization and evaluation of its physicochemical and intestinal stability. In addition, GVG was evaluated for its ability to be biotransformed to GlcN in the liver homogenate. In vitro absorption of the new prodrug through everted rat gut was also assessed. GVG demonstrated significant and meaningful increased gut permeability as compared with GlcN. It showed favorable stability in the gut and a quick cleavage to GlcN after exposure to the liver homogenate. In conclusion, a novel prodrug of glucosamine with superior gut permeability compared to GlcN was developed and successfully tested in vitro.	[Kohan, Hamed Gilzad; Kaur, Kamaljit; Jamali, Fakhreddin] Univ Alberta, Fac Pharm & Pharmaceut Sci, Edmonton, AB T6G 2N8, Canada; [Kohan, Hamed Gilzad] Albany Coll Pharm & Hlth Sci, Dept Pharmaceut Sci, Albany, NY USA; [Kaur, Kamaljit] Chapman Univ, CUSP, Harry & Diane Rinker Hlth Sci Campus, Irvine, CA USA	University of Alberta; Albany College of Pharmacy & Health Sciences; Chapman University System; Chapman University	Kohan, HG (corresponding author), Univ Alberta, Fac Pharm & Pharmaceut Sci, Edmonton, AB T6G 2N8, Canada.	Hamed.Kohan@acphs.edu		Gilzad Kohan, Mojtaba/0000-0002-3956-444X; Gilzad Kohan, Mohammadhossein/0000-0002-8028-0481	Natural Sciences and Engineering Research Council of Canada (NSERC)	Natural Sciences and Engineering Research Council of Canada (NSERC)(Natural Sciences and Engineering Research Council of Canada (NSERC))	This work was supported by Natural Sciences and Engineering Research Council of Canada (NSERC) (FJ), http://www.nserc-crsng.gc.ca/index_eng.asp. Canada Foundation for Innovation (CFI) is also acknowledged (FJ), http://www.innovation.ca/. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Agahzadeh-Habashi A, J PHARM SCI, V103, P760, DOI [10.1002/jps.23819, DOI 10.1002/JPS.23819]; Aghazadeh-Habashi A, J PHARM PHARM SCI, V14, P264; Amblard M, MOL BIOTECHNOL, V33, P239; Anand BS, J PHARM EXP THER, V311, P659; Bailey PD, CHEM COMMUN CAMB, V21, P323; Barthe L, 1999, FUND CLIN PHARMACOL, V13, P154, DOI 10.1111/j.1472-8206.1999.tb00334.x; Gilzad-Kohan MH, EUR J PHARM SCI, V47, P387; Gouze JN, 2002, FEBS LETT, V510, P166, DOI 10.1016/S0014-5793(01)03255-0; Han HK, AAPS PHARMSCI, V2, pE6; Herrero-Beaumont G, ARTHRITIS RHEUM, V56, P555; Hoekstra WJ, CURR MED CHEM, V8, P715; Hua J, INFLAMM RES, V54, P127; Ibrahim A, 2012, J PHARM SCI-US, V101, P2574, DOI 10.1002/jps.23145; Jackson CG, 2010, OSTEOARTHR CARTILAGE, V18, P297, DOI 10.1016/j.joca.2009.10.013; Jamali F, J PHARM PHARM SCI, V13, P128; Jamali F, Glucosamine Prodrugs, Patent No. [US 20130196897 A1, 20130196897]; Korda A, AMINO ACIDS, V30, P95; Noack W, OSTEOARTHRITIS CARTI, V2, P51; Oke S, EQUINE VET J, V38, P93; Pang KS, DRUG METAB DISPOS, V31, P1507; Pavelka K, 2002, ARCH INTERN MED, V162, P2113, DOI 10.1001/archinte.162.18.2113; Persiani S, OSTEOARTHRITIS CARTI, V15, P764; Purifoy DJ, J MED VIROL S, V1, P139; Reginster JY, 2001, LANCET, V357, P251, DOI 10.1016/S0140-6736(00)03610-2; Rovati LC, ADV MUSCULOSKELET DI, V4, P167, DOI [10.1177/1759720X12437753, DOI 10.1177/1759720X12437753]; Russell AS, J RHEUMATOL, V29, P2407; Sherman AL, 2012, PM&R, V4, pS110, DOI 10.1016/j.pmrj.2012.02.021; Soliman W, J MED CHEM, V54, P2399; Szczech GM, CLIN INFECT DIS, V22, P355; Talluri RS, INT J PHARM, V1, P118; Thieriet N, ORG LETT, V2, P1815; Wang SX, ARTHRITIS RHEUM, V56, P1537; Weller S, CLIN PHARM THER, V54, P595; Wen ZH, 2010, OSTEOARTHR CARTILAGE, V18, P1192, DOI 10.1016/j.joca.2010.05.012; Yu LX, ADV DRUG DELIV REV, V19, P359	35	11	13	1	24	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 15	2015	10	5							e0126786	10.1371/journal.pone.0126786	http://dx.doi.org/10.1371/journal.pone.0126786			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CI7AU	25978315	Green Published, gold, Green Submitted			2023-01-03	WOS:000354916100100
J	Simkens, LHJ; van Tinteren, H; May, A; ten Tije, AJ; Creemers, GJM; Loosveld, OJL; de Jongh, FE; Erdkamp, FLG; Erjavec, Z; van der Torren, AME; Tol, J; Braun, HJJ; Nieboer, P; van der Hoeven, JJM; Haasjes, JG; Jansen, RLH; Wals, J; Cats, A; Derleyn, VA; Honkoop, AEH; Mol, L; Punt, CJA; Koopman, M				Simkens, Lieke H. J.; van Tinteren, Harm; May, Anne; ten Tije, Albert J.; Creemers, Geert-Jan M.; Loosveld, Olaf J. L.; de Jongh, Felix E.; Erdkamp, Frans L. G.; Erjavec, Zoran; van der Torren, Adelheid M. E.; Tol, Jolien; Braun, Hans J. J.; Nieboer, Peter; van der Hoeven, Jacobus J. M.; Haasjes, Janny G.; Jansen, Rob L. H.; Wals, Jaap; Cats, Annemieke; Derleyn, Veerle A.; Honkoop, Aafk E. H.; Mol, Linda; Punt, Cornelis J. A.; Koopman, Miriam			Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group	LANCET			English	Article							COMBINATION CHEMOTHERAPY; 1ST-LINE TREATMENT; HEPATIC RESECTION; PLUS BEVACIZUMAB; III TRIAL; OXALIPLATIN; SURVIVAL; FLUOROURACIL; INTERMITTENT; IRINOTECAN	Background The optimum duration of first-line treatment with chemotherapy in combination with bevacizumab in patients with metastatic colorectal cancer is unknown. The CAIRO3 study was designed to determine the efficacy of maintenance treatment with capecitabine plus bevacizumab versus observation. Methods In this open-label, phase 3, randomised controlled trial, we recruited patients in 64 hospitals in the Netherlands. We included patients older than 18 years with previously untreated metastatic colorectal cancer, with stable disease or better after induction treatment with six 3-weekly cycles of capecitabine, oxaliplatin, and bevacizumab (CAPOX-B), WHO performance status of 0 or 1, and adequate bone marrow, liver, and renal function. Patients were randomly assigned (1: 1) to either maintenance treatment with capecitabine and bevacizumab (maintenance group) or observation (observation group). Randomisation was done centrally by minimisation, with stratification according to previous adjuvant chemotherapy, response to induction treatment, WHO performance status, serum lactate dehydrogenase concentration, and treatment centre. Both patients and investigators were aware of treatment assignment. We assessed disease status every 9 weeks. On first progression (defined as PFS1), patients in both groups were to receive the induction regimen of CAPOX-B until second progression (PFS2), which was the study's primary endpoint. All endpoints were calculated from the time of randomisation. Analyses were done by intention to treat. This trial is registered with ClinicalTrials.gov,number NCT00442637. Findings Between May 30, 2007, and Oct 15, 2012, we randomly assigned 558 patients to either the maintenance group (n=279) or the observation group (n=279). Median follow-up was 48 months (IQR 36-57). The primary endpoint of median PFS2 was significantly improved in patients on maintenance treatment, and was 8.5 months in the observation group and 11.7 months in the maintenance group (HR 0.67, 95% CI 0.56-0.81, p<0.0001). This difference remained signifi cant when any treatment after PFS1 was considered. Maintenance treatment was well tolerated, although the incidence of hand-foot syndrome was increased (64 [23%] patients with hand-foot skin reaction during maintenance). The global quality of life did not deteriorate during maintenance treatment and was clinically not different between treatment groups. Interpretation Maintenance treatment with capecitabine plus bevacizumab after six cycles of CAPOX-B in patients with metastatic colorectal cancer is effective and does not compromise quality of life.	[Simkens, Lieke H. J.; Punt, Cornelis J. A.] Univ Amsterdam, Acad Med Ctr, Dept Med Oncol, NL-1105 AZ Amsterdam, Netherlands; [van Tinteren, Harm] Netherlands Canc Inst, Dept Biostat, Amsterdam, Netherlands; [May, Anne] Univ Med Ctr Utrecht, Julius Ctr Hlth Sci & Primary Care, NL-3508 GA Utrecht, Netherlands; [ten Tije, Albert J.] Amphia Hosp, Dept Med Oncol, Breda, Netherlands; [ten Tije, Albert J.; Loosveld, Olaf J. L.] Tergooi Hosp, Dept Med Oncol, Blaricum, Netherlands; [Creemers, Geert-Jan M.] Catharina Hosp, Dept Med Oncol, Eindhoven, Netherlands; [de Jongh, Felix E.] Ikazia Hosp, Dept Med Oncol, Rotterdam, Netherlands; [Erdkamp, Frans L. G.] Orbis Med Ctr, Dept Med Oncol, Sittard, Netherlands; [Erjavec, Zoran] Ommelander Hosp Grp, Dept Med Oncol, Delfzijl, Netherlands; [van der Torren, Adelheid M. E.] Groene Hart Hosp, Dept Med Oncol, Gouda, Netherlands; [Tol, Jolien] Radboud Univ Nijmegen, Dept Med Oncol, Med Ctr, NL-6525 ED Nijmegen, Netherlands; [Braun, Hans J. J.] Vlietland Hosp, Dept Med Oncol, Schiedam, Netherlands; [Nieboer, Peter] Wilhemina Hosp, Dept Med Oncol, Assen, Netherlands; [van der Hoeven, Jacobus J. M.] Med Ctr Alkmaar, Dept Med Oncol, Alkmaar, Netherlands; [Haasjes, Janny G.] Bethesda Hosp, Dept Med Oncol, Hoogeveen, Netherlands; [Jansen, Rob L. H.] Maastricht Univ, Dept Med Oncol, Med Ctr, NL-6200 MD Maastricht, Netherlands; [Wals, Jaap] Atrium Med Ctr, Dept Med Oncol, Heerlen, Netherlands; [Cats, Annemieke] Antoni van Leeuwenhoek Hosp, Dept Gastroenterol & Hepatol, Amsterdam, Netherlands; [Derleyn, Veerle A.] Elkerliek Hosp, Dept Med Oncol, Helmond, Netherlands; [Honkoop, Aafk E. H.] Isala Klin, Dept Med Oncol, Zwolle, Netherlands; [Mol, Linda] Netherlands Comprehens Canc Org, Nijmegen, Netherlands; [Koopman, Miriam] Univ Med Ctr Utrecht, Dept Med Oncol, NL-3508 GA Utrecht, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam; Netherlands Cancer Institute; Utrecht University; Utrecht University Medical Center; Amphia Hospital; Tergooi Blaricum; Catharina Hospital; Ikazia Hospital; Orbis Medical Center; Radboud University Nijmegen; Medical Center Of Alkmaar; Maastricht University; Atrium Medical Center; Isala Clinics; Utrecht University; Utrecht University Medical Center	Koopman, M (corresponding author), Univ Med Ctr Utrecht, Dept Med Oncol, POB 85500, NL-3508 GA Utrecht, Netherlands.	m.koopman-6@umcutrecht.nl	May, Anne M/G-9183-2011; Tol, J./L-4695-2015; van der Hoeven, Koos JM/S-3281-2017	van Tinteren, Harm/0000-0002-4626-8702	Dutch Colorectal Cancer Group (DCCG); Commissie Klinische Studies (CKS) of the Dutch Cancer Foundation (KWF); Roche; Sanofi-Aventis; Commissie Klinische Studies of the Dutch Cancer Foundation	Dutch Colorectal Cancer Group (DCCG); Commissie Klinische Studies (CKS) of the Dutch Cancer Foundation (KWF); Roche(Roche Holding); Sanofi-Aventis(Sanofi-Aventis); Commissie Klinische Studies of the Dutch Cancer Foundation	Dutch Colorectal Cancer Group (DCCG). The DCCG received financial support for the study from the Commissie Klinische Studies (CKS) of the Dutch Cancer Foundation (KWF), Roche, and Sanofi-Aventis.; We thank the participating patients and staff at each of the study centres, and Frans A Timmer for performing the independent radiology review. We highly appreciated the valuable input of the members of the independent data monitoring committee, Elizabeth G E de Vries, Kit C Roes, Marc Buyse, Johan W Nortier, and Elsken E van der Wall. The study was supported by the Dutch Colorectal Cancer Group (DCCG). The DCCG received grants for data management and statistical analysis from the Commissie Klinische Studies of the Dutch Cancer Foundation, and unrestricted scientific grants from Roche and Sanofi-Aventis.	AARONSON NK, 1993, J NATL CANCER I, V85, P365, DOI 10.1093/jnci/85.5.365; Adams RA, 2011, LANCET ONCOL, V12, P642, DOI 10.1016/S1470-2045(11)70102-4; Arnold D, 2014, J CLIN ONCOL, V32, DOI 10.1200/jco.2014.32.15_suppl.3503; Bennouna J, 2013, LANCET ONCOL, V14, P29, DOI 10.1016/S1470-2045(12)70477-1; Budman DR, 1998, J CLIN ONCOL, V16, P1795, DOI 10.1200/JCO.1998.16.5.1795; Chibaudel B, 2014, ANN ONCOL          S, V25, P4; Chibaudel B, 2009, J CLIN ONCOL, V27, P5727, DOI 10.1200/JCO.2009.23.4344; Cummings LC, 2007, CANCER, V109, P718, DOI 10.1002/cncr.22448; Cunningham D, 2008, NEW ENGL J MED, V358, P36, DOI 10.1056/NEJMoa073149; Cunningham D, 2013, LANCET ONCOL, V14, P1077, DOI 10.1016/S1470-2045(13)70154-2; Cunningham D, 2010, LANCET, V375, P1030, DOI 10.1016/S0140-6736(10)60353-4; Diaz-Rubio E, 2012, ONCOLOGIST, V17, P15, DOI 10.1634/theoncologist.2011-0249; Giantonio BJ, 2007, J CLIN ONCOL, V25, P1539, DOI 10.1200/JCO.2006.09.6305; Grothey A, 2005, J CLIN ONCOL, V23, P9441, DOI 10.1200/JCO.2005.04.4792; Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691; Johnsson A, 2013, ANN ONCOL, V24, P2335, DOI 10.1093/annonc/mdt236; Kabbinavar FF, 2005, J CLIN ONCOL, V23, P3706, DOI 10.1200/JCO.2005.00.232; Kerbel RS, 2004, NAT REV CANCER, V4, P423, DOI 10.1038/nrc1369; Koopman M, 2007, LANCET, V370, P135, DOI 10.1016/S0140-6736(07)61086-1; Kopetz S, 2009, J CLIN ONCOL, V27, P3677, DOI 10.1200/JCO.2008.20.5278; Labianca R, 2011, ANN ONCOL, V22, P1236, DOI 10.1093/annonc/mdq580; LAN KKG, 1983, BIOMETRIKA, V70, P659, DOI 10.2307/2336502; Maughan TS, 2003, LANCET, V361, P457, DOI 10.1016/S0140-6736(03)12461-0; Mekenkamp LJM, 2010, BRIT J CANCER, V103, P159, DOI 10.1038/sj.bjc.6605737; Mol L, 2010, ANN ONCOL, V21, P415, DOI 10.1093/annonc/mdp330; OBRIEN PC, 1979, BIOMETRICS, V35, P549, DOI 10.2307/2530245; Osoba D, 1998, J CLIN ONCOL, V16, P139, DOI 10.1200/JCO.1998.16.1.139; Saltz LB, 2008, J CLIN ONCOL, V26, P2013, DOI 10.1200/JCO.2007.14.9930; Seymour MT, 2007, LANCET, V370, P143, DOI 10.1016/S0140-6736(07)61087-3; Tebbutt NC, 2010, J CLIN ONCOL, V28, P3191, DOI 10.1200/JCO.2009.27.7723; Tournigand C, 2006, J CLIN ONCOL, V24, P394, DOI 10.1200/JCO.2005.03.0106; Venderbosch S, 2011, ANN SURG ONCOL, V18, P3252, DOI 10.1245/s10434-011-1951-5	32	335	346	1	39	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 9	2015	385	9980					1843	1852		10.1016/S0140-6736(14)62004-3	http://dx.doi.org/10.1016/S0140-6736(14)62004-3			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CH6ZE	25862517				2023-01-03	WOS:000354184500028
J	Mansouri, A; Sarayani, A; Ashouri, A; Sherafatmand, M; Hadjibabaie, M; Gholami, K				Mansouri, Ava; Sarayani, Amir; Ashouri, Asieh; Sherafatmand, Mona; Hadjibabaie, Molouk; Gholami, Kheirollah			Is 'Self-Medication' a Useful Term to Retrieve Related Publications in the Literature? A Systematic Exploration of Related Terms	PLOS ONE			English	Article							THE-COUNTER DRUGS; COMMUNITY PHARMACIES; CLARIFICATION; TERMINOLOGY; MEDICINES; ILLNESSES; SAFETY; ADULTS; PAPER; CARE	Background Self-Medication (SM), i.e. using medications to treat oneself, is a major concern for health researchers and policy makers. The terms "self medication" or "self-medication" (SM terms) have been used to explain various concepts while several terms have also been employed to define this practice. Hence, retrieving relevant publications would require exhaustive literature screening. So, we assessed the current situation of SM terms in the literature to improve the relevancy of search outcomes. Methods In this Systematic exploration, SM terms were searched in the 6 following databases and publisher's portals till April 2012: Web of Science, Scopus, PubMed, Google scholar, ScienceDirect, and Wiley. A simple search query was used to include only publications with SM terms. We used Relative-Risk (RR) to estimate the probability of SM terms use in related compared to unrelated publications. Sensitivity and specificity of SM terms as keywords in search query were also calculated. Relevant terms to SM practice were extracted and their Likelihood Ratio positive and negative (LR+/-) were calculated to assess their effect on the probability of search outcomes relevancy in addition to previous search queries. We also evaluated the content of unrelated publications. All mentioned steps were performed in title (TI) and title or abstract (TIAB) of publications. Results 1999 related and 1917 unrelated publications were found. SM terms RR was 4.5 in TI and 2.1 in TIAB. SM terms sensitivity and specificity respectively were 55.4% and 87.7% in TI and 84.0% and 59.5% in TIAB. "OTC" and "Over-The-Counter Medication", with LR+ 16.78 and 16.30 respectively, provided the most conclusive increase in the probability of the relevancy of publications. The most common unrelated SM themes were self-medication hypothesis, drug abuse and Zoopharmacognosy. Conclusions Due to relatively low specificity or sensitivity of SM terms, relevant terms should be employed in search queries and clear definitions of SM applications should be applied to improve the relevancy of publications.	[Mansouri, Ava; Sarayani, Amir; Ashouri, Asieh; Hadjibabaie, Molouk; Gholami, Kheirollah] Univ Tehran Med Sci, Res Ctr Rat Use Drugs, Tehran, Iran; [Ashouri, Asieh] Univ Tehran Med Sci, Sch Publ Hlth, Dept Epidemiol & Biostat, Tehran, Iran; [Sherafatmand, Mona; Hadjibabaie, Molouk; Gholami, Kheirollah] Univ Tehran Med Sci, Fac Pharm, Tehran, Iran	Tehran University of Medical Sciences; Tehran University of Medical Sciences; Tehran University of Medical Sciences	Hadjibabaie, M (corresponding author), Univ Tehran Med Sci, Res Ctr Rat Use Drugs, Tehran, Iran.	hajibaba@tums.ac.ir	Ashouri, Asieh/H-3630-2018	Ashouri, Asieh/0000-0002-3791-8451; Sarayani, Amir/0000-0003-2790-9938	Tehran University of Medical Sciences (TUMS) [18373-156-02-91]	Tehran University of Medical Sciences (TUMS)(Tehran University of Medical Sciences)	This work was supported by Tehran University of Medical Sciences (TUMS) (Grant number: 18373-156-02-91). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Almasdy D, 2011, ARCH PHARM PRACT, V2, P95; Aronson JK, 2005, DRUG SAFETY, V28, P851, DOI 10.2165/00002018-200528100-00003; Blenkinsopp A, 1996, BRIT MED J, V312, P629; Brata C, 2013, RES SOC ADMIN PHARM, V9, P370, DOI 10.1016/j.sapharm.2012.08.001; Cavaco AM, 2012, RES SOC ADMIN PHARM, V8, P87, DOI 10.1016/j.sapharm.2011.07.004; Du Y, 2009, BRIT J CLIN PHARMACO, V68, P599, DOI 10.1111/j.1365-2125.2009.03477.x; Elliott Rohan A, 2009, BMC Geriatr, V9, P27, DOI 10.1186/1471-2318-9-27; Ferner RE, 2006, DRUG SAFETY, V29, P1011, DOI 10.2165/00002018-200629110-00001; Fried PW, 2001, J THORAC CARDIOV SUR, V121, pS3, DOI 10.1067/mtc.2001.114493; Gambescia Stephen F, 2013, Educ Health (Abingdon), V26, P122, DOI 10.4103/1357-6283.120706; Geissler PW, 2000, SOC SCI MED, V50, P1771, DOI 10.1016/S0277-9536(99)00428-1; Godfrey CM, 2011, JBI DATABASE SYSTEMA, V8, P1351; Goh LY, 2009, BMC COMPLEM ALTERN M, V9, DOI 10.1186/1472-6882-9-42; Grigoryan L, 2006, EMERG INFECT DIS, V12, P452, DOI 10.3201/eid1203.050992; Hall DH, 2007, J PSYCHOACTIVE DRUGS, V39, P151, DOI 10.1080/02791072.2007.10399873; Huffman MA, 2003, P NUTR SOC, V62, P371, DOI 10.1079/PNS2003257; Hughes CM, 2001, DRUG SAFETY, V24, P1027, DOI 10.2165/00002018-200124140-00002; Hughes GF, 1999, PHARM WORLD SCI, V21, P251, DOI 10.1023/A:1008788726842; Jamali HR, 2011, SCIENTOMETRICS, V88, P653, DOI 10.1007/s11192-011-0412-z; Jenkins Michelle, 2004, Health Info Libr J, V21, P148, DOI 10.1111/j.1471-1842.2004.00511.x; Kaizer F, 2010, J REHABIL MED, V42, P239, DOI 10.2340/16501977-0523; Landers TF, 2010, J AM ACAD NURSE PRAC, V22, P488, DOI 10.1111/j.1745-7599.2010.00539.x; Lawrence S, 1999, INT TECHN SERV 1999; Lefebvre C, 2011, COCHRANE COLLABORATI; Masic Izet, 2011, Acta Inform Med, V19, P68, DOI 10.5455/aim.2011.19.68-79; McKenna L, 2006, J ADV NURS, V56, P636, DOI 10.1111/j.1365-2648.2006.04037.x; Montgomery AJ, 2011, OCCUP MED-OXFORD, V61, P490, DOI 10.1093/occmed/kqr098; Morgan DJ, 2011, LANCET INFECT DIS, V11, P692, DOI 10.1016/S1473-3099(11)70054-8; Ryan A, 2009, BMC PUBLIC HEALTH, V9, DOI 10.1186/1471-2458-9-96; Sallam S. A., 2009, Eastern Mediterranean Health Journal, V15, P683; Sanz F, 2000, AM J HEALTH-SYST PH, V57, P1601, DOI 10.1093/ajhp/57.17.1601; Schroeder K, 2009, EVID BASED CHILD HLT, V4, P65; Segarra R, 2011, EUR ARCH PSY CLIN N, V261, P241, DOI 10.1007/s00406-010-0146-6; Setiati Siti, 2007, Acta Med Indones, V39, P50; Vrijens B, 2012, BRIT J CLIN PHARMACO, V73, P691, DOI 10.1111/j.1365-2125.2012.04167.x; Wertheimer AI, 2008, PHARM WORLD SCI, V30, P309, DOI 10.1007/s11096-007-9187-y; Wimpenny P., 2010, JBI LIB SYST REV, V8, P405, DOI [10.11124/jbisrir-2010-123, DOI 10.11124/JBISRIR-2010-123]	37	5	5	0	16	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 1	2015	10	5							e0125093	10.1371/journal.pone.0125093	http://dx.doi.org/10.1371/journal.pone.0125093			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	CH2XA	25932634	Green Published, Green Submitted, gold			2023-01-03	WOS:000353887100078
J	Lopez-Campos, JL; Hartl, S; Pozo-Rodriguez, F; Roberts, M				Luis Lopez-Campos, Jose; Hartl, Sylvia; Pozo-Rodriguez, Francisco; Roberts, Michael		European COPD Audit Team	Antibiotic Prescription for COPD Exacerbations Admitted to Hospital: European COPD Audit	PLOS ONE			English	Article							OBSTRUCTIVE PULMONARY-DISEASE; C-REACTIVE PROTEIN; PROCALCITONIN; MOXIFLOXACIN; MANAGEMENT; OUTCOMES; SPUTUM; SEX	Objective Appropriate use of antibiotics in the management of hospitalised patients with COPD exacerbations is defined within the GOLD strategy. This paper analyses the factors associated with antibiotic prescribing in patients to better understand how prescribing may be improved. Methods The European COPD audit was a study of clinical care in 384 hospitals from 13 European countries between 2010 and 2011 enrolling 16018 patients. Those admitted to hospital due to a clinician-made diagnosis of exacerbation of COPD at the time of discharge were audited. We defined antibiotic prescribing compliance as consistent with the GOLD 2010 recommendations. Two different multivariate models were used to evaluate factors associated with the prescription of antibiotics and the guideline-compliant prescriptions. Results Overall 86% of admissions were given antibiotics but only 61.4% cases met the GOLD recommendations. Antibiotics were more likely to be given in hospital and at discharge if received prior to admission. Antibiotic prescription was more likely in patients who met the GOLD recommendations and in those with radiological consolidation but there was also a significant use of antibiotics in patients who did not meet either criterion. Patients cared for on a Respiratory Ward were more likely to receive GOLD compliant antibiotic management. Conclusions The present study describes the audited in-hospital antibiotic prescription for COPD exacerbation across different European countries. In general, there is an apparent overuse of antibiotics likely to be associated with both patient and practice-related variables.	[Luis Lopez-Campos, Jose] Hosp Univ Virgen del Rocio, Inst Biomed Sevilla IBiS, Seville, Spain; [Luis Lopez-Campos, Jose; Pozo-Rodriguez, Francisco] Inst Salud Carlos III, CIBER Enfermedades Resp CIBERES, Madrid, Spain; [Hartl, Sylvia] Ludwig Boltzmann Inst COPD & Resp Epidemiol, Vienna, Austria; [Pozo-Rodriguez, Francisco] Hosp 12 Octubre, Inst Invest I 12, E-28041 Madrid, Spain; [Roberts, Michael] Univ London, Barts & London Sch Med & Dent, London WC1E 7HU, England	Consejo Superior de Investigaciones Cientificas (CSIC); University of Sevilla; CSIC-JA-USE - Instituto de Biomedicina de Sevilla (IBIS); Virgen del Rocio University Hospital; CIBER - Centro de Investigacion Biomedica en Red; CIBERES; Instituto de Salud Carlos III; Ludwig Boltzmann Institute; Hospital Universitario 12 de Octubre; University of London; Queen Mary University London	Lopez-Campos, JL (corresponding author), Hosp Univ Virgen del Rocio, Inst Biomed Sevilla IBiS, Seville, Spain.	lcampos@separ.es	López-Quílez, Antonio/H-5945-2011; Özgür, Eylem Sercan/I-1921-2015; Bodineau, José Luis López-Campos/AAG-5203-2019; Arghir, Oana C/F-8515-2015; Guardia, Sergi Pascual/L-7652-2014	López-Quílez, Antonio/0000-0002-7022-9260; Özgür, Eylem Sercan/0000-0003-4459-232X; Bodineau, José Luis López-Campos/0000-0003-1703-1367; Arghir, Oana C/0000-0001-9844-8521; Guardia, Sergi Pascual/0000-0002-6567-0916; CORBACHO, DOLORES/0000-0003-1239-5276; roberts, christopher/0000-0001-8212-1460	Almirall; Takeda; Bohringer; Novartis; GlaxoSmithKline; Torrex Chiesi; AstraZeneca; MeckSharpDome	Almirall(Almirall); Takeda(Takeda Pharmaceutical Company Ltd); Bohringer; Novartis(Novartis); GlaxoSmithKline(GlaxoSmithKline); Torrex Chiesi(Chiesi Pharmaceuticals Inc); AstraZeneca(AstraZeneca); MeckSharpDome	Almirall, Takeda, Bohringer, Novartis, GlaxoSmithKline, Torrex Chiesi, AstraZeneca, and MeckSharpDome provided support in the form of salaries for authors SH and CMR, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the 'author contributions' section.	Aryal S, 2014, INT J CHRONIC OBSTR, V9, P1145, DOI 10.2147/COPD.S54476; Brusse-Keizer M, 2013, BMJ OPEN RESPIR RES, V1, DOI 10.1136/bmjresp-2014-000052; Christ-Crain M, 2004, LANCET, V363, P600, DOI 10.1016/S0140-6736(04)15591-8; Daniels JMA, 2010, CHEST, V138, P1108, DOI 10.1378/chest.09-2927; DiSantostefano RL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097149; Huerta A, 2013, CHEST, V144, P1134, DOI 10.1378/chest.13-0488; Liu KX, 2014, J THORAC DIS, V6, P221, DOI 10.3978/j.issn.2072-1439.2013.11.12; Llor C, 2013, THER ADV RESPIR DIS, V7, P131, DOI 10.1177/1753465812472387; Lopez-Campos JL, 2013, EUR RESPIR J, V41, P270, DOI 10.1183/09031936.00021812; Myint PK, 2011, RESPIRATION, V82, P320, DOI 10.1159/000327203; Papaioannou AI, 2014, INT J CHRONIC OBSTR, V9, P203, DOI 10.2147/COPD.S52500; Pozo-Rodriguez F, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042156; Rabe KF, 2007, AM J RESP CRIT CARE, V176, P532, DOI 10.1164/rccm.200703-456SO; Roberts CM, 2013, THORAX, V68, P1169, DOI 10.1136/thoraxjnl-2013-203465; Roche N, 2007, RESPIRATION, V74, P19, DOI 10.1159/000093158; Roche N, 2014, RESP RES, V15, DOI 10.1186/1465-9921-15-20; Schwarzmann S W, 2000, Postgrad Med, V108, P25, DOI 10.3810/pgm.12.2000.suppl10.53; Stefan MS, 2013, CHEST, V143, P82, DOI 10.1378/chest.12-0649; Stockley RA, 2000, CHEST, V117, P1638, DOI 10.1378/chest.117.6.1638; Stolz D, 2009, CURR OPIN PULM MED, V15, P126, DOI 10.1097/MCP.0b013e328324e6d7; Vollenweider Daniela J, 2012, Cochrane Database Syst Rev, V12, pCD010257, DOI 10.1002/14651858.CD010257; Weis N, 2006, EUR J INTERN MED, V17, P88, DOI 10.1016/j.ejim.2005.09.020; Wilson R, 2012, EUR RESPIR J, V40, P17, DOI 10.1183/09031936.00090311; Woodhead M, 2005, EUR RESPIR J, V26, P1138, DOI 10.1183/09031936.05.00055705	24	32	32	2	17	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 23	2015	10	4							e0124374	10.1371/journal.pone.0124374	http://dx.doi.org/10.1371/journal.pone.0124374			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CG5KZ	25905726	Green Published, gold, Green Submitted			2023-01-03	WOS:000353332000069
J	Szanton, SL; Leff, B; Gitlin, LN				Szanton, Sarah L.; Leff, Bruce; Gitlin, Laura N.			Improvement Interventions	ANNALS OF INTERNAL MEDICINE			English	Letter									[Szanton, Sarah L.; Leff, Bruce; Gitlin, Laura N.] Johns Hopkins Univ, Baltimore, MD 21218 USA	Johns Hopkins University	Szanton, SL (corresponding author), Johns Hopkins Univ, Baltimore, MD 21218 USA.							Davidoff F, 2014, ANN INTERN MED, V161, P526, DOI 10.7326/M14-1789; Szanton SL, 2011, J AM GERIATR SOC, V59, P2314, DOI 10.1111/j.1532-5415.2011.03698.x	2	0	0	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 21	2015	162	8					596	597		10.7326/L15-5071-2	http://dx.doi.org/10.7326/L15-5071-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CG4GT	25894033				2023-01-03	WOS:000353244300026
J	Rong, Y; Evans, J; Xu-Welliver, M; Pickett, C; Jia, G; Chen, Q; Zuo, L				Rong, Yi; Evans, Josh; Xu-Welliver, Meng; Pickett, Cadron; Jia, Guang; Chen, Quan; Zuo, Li			Dosimetric Evaluation of Intensity-Modulated Radiotherapy, Volumetric Modulated Arc Therapy, and Helical Tomotherapy for Hippocampal-Avoidance Whole Brain Radiotherapy	PLOS ONE			English	Article							ADULT NEUROGENESIS; RADIATION-THERAPY; IRRADIATION; METASTASES; IMRT; PROLIFERATION	Background Whole brain radiotherapy (WBRT) is a vital tool in radiation oncology and beyond, but it can result in adverse health effects such as neurocognitive decline. Hippocampal Avoidance WBRT (HA-WBRT) is a strategy that aims to mitigate the neuro-cognitive side effects of whole brain radiotherapy treatment by sparing the hippocampi while delivering the prescribed dose to the rest of the brain. Several competing modalities capable of delivering HA-WBRT, include: Philips Pinnacle step-and-shoot intensity modulated radiotherapy (IMRT), Varian RapidArc volumetric modulated arc therapy (RapidArc), and helical TomoTherapy (TomoTherapy). Methods In this study we compared these methods using 10 patient datasets. Anonymized planning CT (computerized tomography) scans and contour data based on fused MRI images were collected. Three independent planners generated treatment plans for the patients using three modalities, respectively. All treatment plans met the RTOG 0933 criteria for HA-WBRT treatment. Results In dosimetric comparisons between the three modalities, TomoTherapy has a significantly superior homogeneity index of 0.15 +/- 0.03 compared to the other two modalities (0.28 +/- .04, p < .005 for IMRT and 0.22 +/- 0.03, p < .005 for RapidArc). RapidArc has the fastest average delivery time of 2.5 min compared to the other modalities (15 min for IMRT and 18 min for TomoTherapy). Conclusion TomoTherapy is considered to be the preferred modality for HA-WBRT due to its superior dose distribution. When TomoTherapy is not available or treatment time is a concern, RapidArc can provide sufficient dose distribution meeting RTOG criteria and efficient treatment delivery.	[Rong, Yi; Xu-Welliver, Meng] Ohio State Univ, James Canc Hosp, Wexner Med Ctr, Dept Radiat Oncol, Columbus, OH 43210 USA; [Zuo, Li] Ohio State Univ, Wexner Med Ctr, Coll Med,Biophys Grad Program, Sch Hlth & Rehabil Sci,Radiol Sci & Resp Therapy, Columbus, OH 43210 USA; [Evans, Josh; Chen, Quan] Univ Virginia Hlth Syst, Dept Radiat Oncol, Charlottesville, VA 22903 USA; [Pickett, Cadron; Jia, Guang] Louisiana State Univ, Dept Phys & Astron, Baton Rouge, LA 70803 USA	James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University of Virginia; Louisiana State University System; Louisiana State University	Chen, Q (corresponding author), Univ Virginia Hlth Syst, Dept Radiat Oncol, Charlottesville, VA 22903 USA.	QC3K@hscmail.mcc.virginia.edu; zuo.4@osu.edu	Jia, Guang/A-1275-2016; Chen, Quan/E-5943-2012; Jia, Guang/E-3312-2011	Chen, Quan/0000-0001-5570-2462; Jia, Guang/0000-0001-5306-5607				Abayomi OK, 1996, ACTA ONCOL, V35, P659, DOI 10.3109/02841869609083995; Awad R, 2013, RADIAT ONCOL, V8, DOI 10.1186/1748-717X-8-62; CAMERON HA, 1994, NEUROSCIENCE, V61, P203, DOI 10.1016/0306-4522(94)90224-0; Chang EL, 2009, LANCET ONCOL, V10, P1037, DOI 10.1016/S1470-2045(09)70263-3; Chen Q, 2012, MED PHYS, V39, P1877, DOI 10.1118/1.3693057; Chen QA, 2011, MED PHYS, V38, P1150, DOI 10.1118/1.3551996; DEANGELIS LM, 1989, NEUROLOGY, V39, P789, DOI 10.1212/WNL.39.6.789; Eriksson PS, 1998, NAT MED, V4, P1313, DOI 10.1038/3305; FERRER I, 1993, J NEUROPATH EXP NEUR, V52, P370, DOI 10.1097/00005072-199307000-00004; Gondi V, 2010, RADIOTHER ONCOL, V97, P370, DOI 10.1016/j.radonc.2010.09.013; Gondi V, 2010, INT J RADIAT ONCOL, V78, P1244, DOI 10.1016/j.ijrobp.2010.01.039; Gondi V, 2010, RADIOTHER ONCOL, V95, P327, DOI 10.1016/j.radonc.2010.02.030; Lemaire V, 2000, P NATL ACAD SCI USA, V97, P11032, DOI 10.1073/pnas.97.20.11032; Li J, 2007, J CLIN ONCOL, V25, P1260, DOI 10.1200/JCO.2006.09.2536; Lu WG, 2010, PHYS MED BIOL, V55, P7175, DOI 10.1088/0031-9155/55/23/002; Lu WG, 2010, PHYS MED BIOL, V55, P7211, DOI 10.1088/0031-9155/55/23/003; Madsen TM, 2003, NEUROSCIENCE, V119, P635, DOI 10.1016/S0306-4522(03)00199-4; Marsh JC, 2013, J MED IMAG RADIAT ON, V57, P378, DOI 10.1111/1754-9485.12048; Meyers CA, 2006, J CLIN ONCOL, V24, P1305, DOI 10.1200/JCO.2005.04.6086; Meyers CA, 2004, J CLIN ONCOL, V22, P157, DOI 10.1200/JCO.2004.05.128; Mizumatsu S, 2003, CANCER RES, V63, P4021; Monje ML, 2002, NAT MED, V8, P955, DOI 10.1038/nm749; Nagai R, 2000, SURG NEUROL, V53, P503, DOI 10.1016/S0090-3019(00)00214-7; Nussbaum ES, 1996, CANCER-AM CANCER SOC, V78, P1781, DOI 10.1002/(SICI)1097-0142(19961015)78:8<1781::AID-CNCR19>3.3.CO;2-Z; Raber J, 2004, RADIAT RES, V162, P39, DOI 10.1667/RR3206; Regine WF, 2004, INT J RADIAT ONCOL, V58, P1346, DOI 10.1016/j.ijrobp.2003.09.023; ROMAN DD, 1995, INT J RADIAT ONCOL, V31, P983, DOI 10.1016/0360-3016(94)00550-8; Rong Y, 2014, MED PHYS, V41, DOI 10.1118/1.4870987; Siglin J, 2014, PRACT RADIAT ONCOL, V4, P378, DOI 10.1016/j.prro.2013.11.008; Tada E, 2000, NEUROSCIENCE, V99, P33, DOI 10.1016/S0306-4522(00)00151-2; Van Vulpen M, 2005, INT J RADIAT ONCOL, V62, P1535, DOI 10.1016/j.ijrobp.2005.04.011; Welzel G, 2008, INT J RADIAT ONCOL, V72, P1311, DOI 10.1016/j.ijrobp.2008.03.009	32	31	36	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 20	2015	10	4							e0126222	10.1371/journal.pone.0126222	http://dx.doi.org/10.1371/journal.pone.0126222			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CG3XA	25894615	Green Published, Green Submitted, gold			2023-01-03	WOS:000353211700141
J	Wang, SX; Zhai, X; Li, SY; McCabe, MF; Wang, X; Rong, PJ				Wang, Shuxing; Zhai, Xu; Li, Shaoyuan; McCabe, Michael F.; Wang, Xing; Rong, Peijing			Transcutaneous Vagus Nerve Stimulation Induces Tidal Melatonin Secretion and Has an Antidiabetic Effect in Zucker Fatty Rats	PLOS ONE			English	Article							FAR-FIELD POTENTIALS; BRAIN-STEM; HALF-LIFE; CELLS; RECEPTORS; INSULIN; MOUSE; OBESITY; PLASMA	Melatonin plays a protective role in type 2 diabetes (T2D) through regulation of glucose metabolism. Whether transcutaneous vagus nerve stimulation (taVNS) is antidiabetic and whether a modulated melatonin production is involved in the antidiabetic mechanism of taVNS is unknown. In this study, once daily 30min noninvasive taVNS was administered in Zucker diabetic fatty (ZDF, fa/fa) and Zucker lean (ZL, +/fa) littermates under anesthesia for 5 consecutive weeks. The acute and chronic influences of taVNS on the secretion of melatonin were studied as well as the effects of taVNS on blood glucose metabolism. We found that naive ZDF rats develop hyperglycemia naturally with age. Each taVNS session would trigger a tidal secretion of melatonin both during and after the taVNS procedure and induce an acute two-phase glycemic change, a steep increase followed by a gradual decrease. Once daily taVNS sessions eventually reduced the glucose concentration to a normal level in seven days and effectively maintained the normal glycemic and plasma glycosylated hemoglobin (HbA(lc)) levels when applied for five consecutive weeks. These beneficial effects of taVNS also exist in pinealectomized rats, which otherwise would show overt and continuous hyperglycemia, hyperinsulinemia, and high HbA(lc) levels. We concluded that multiple taVNS sessions are antidiabetic in T2D through triggering of tidal secretion of melatonin. This finding may have potential importance in developing new approaches to the treatment of T2D, which is highly prevalent, incurable with any current approaches, and very costly to the world.	[Wang, Shuxing; Wang, Xing] Xinxiang Med Univ, Dept Anat, Xinxiang, Henan Province, Peoples R China; [Wang, Shuxing; Zhai, Xu; Li, Shaoyuan; Rong, Peijing] China Acad Chinese Med Sci, Inst Acupuncture & Moxibust, Dept Physiol, Beijing, Peoples R China; [Wang, Shuxing; McCabe, Michael F.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, MGH Ctr Translat Pain Res,Dept Anesthesia Crit Ca, Boston, MA USA; [Wang, Shuxing] Guangdong Landau Biotechnol Inc Ltd, Guangzhou, Guangdong, Peoples R China	Xinxiang Medical University; China Academy of Chinese Medical Sciences; Institute of Acupuncture & Moxibustion, CACMS; Harvard University; Harvard Medical School; Massachusetts General Hospital	Wang, SX (corresponding author), Guangdong Entomol Inst, Guangzhou, Guangdong, Peoples R China.	shuxingw@yahoo.com; rongpj@hotmail.com			National Natural Science Foundation of China [81271243, 81473780]; Natural Science Foundation of Beijing [7111007]; National Basic Research Program of China (973 Program) [2012CB518503];  [2012BAF14B10]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Beijing(Beijing Natural Science Foundation); National Basic Research Program of China (973 Program)(National Basic Research Program of China); 	This work was supported by National Natural Science Foundation of China-81271243, 81473780; Natural Science Foundation of Beijing, 7111007; National Basic Research Program of China (973 Program) -2012CB518503; and Project Supported National Science and Technology Ministry-2012BAF14B10. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bahr I, 2011, J PINEAL RES, V50, P336, DOI 10.1111/j.1600-079X.2010.00848.x; Belivani M, 2013, ACUPUNCT MED, V31, P88, DOI 10.1136/acupmed-2012-010247; Bubenik GA, 2002, DIGEST DIS SCI, V47, P2336, DOI 10.1023/A:1020107915919; Conti A, 2000, J PINEAL RES, V28, P193, DOI 10.1034/j.1600-079X.2000.280401.x; Contreras-Alcantara S, 2010, OBESITY, V18, P1861, DOI 10.1038/oby.2010.24; Dantzer R, 2000, AUTON NEUROSCI-BASIC, V85, P60, DOI 10.1016/S1566-0702(00)00220-4; Dubocovich ML, 2010, PHARMACOL REV, V62, P343, DOI 10.1124/pr.110.002832; Fallgatter AJ, 2005, INT J PSYCHOPHYSIOL, V56, P37, DOI 10.1016/j.ijpsycho.2004.09.007; Fallgatter AJ, 2003, J NEURAL TRANSM, V110, P1437, DOI 10.1007/s00702-003-0087-6; Frese T, 2009, LIFE SCI, V85, P526, DOI 10.1016/j.lfs.2009.08.004; Fu Z, 2013, CURR DIABETES REV, V9, P25, DOI 10.2174/157339913804143225; Gerdin MJ, 2004, BIOCHEM PHARMACOL, V67, P2023, DOI 10.1016/j.bcp.2004.01.027; GIBBS FP, 1981, ENDOCRINOLOGY, V109, P1796, DOI 10.1210/endo-109-5-1796; Kniaz'kin I V, 2008, Adv Gerontol, V21, P80; La Marca R, 2010, CLIN SCI, V118, P537, DOI 10.1042/CS20090264; Langenberg C, 2009, DIABETOLOGIA, V52, P1537, DOI 10.1007/s00125-009-1392-x; Li SY, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0111100; Liu RP, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/789674; Maganhin CC, 2009, ACTA CIR BRAS, V24, P321, DOI 10.1590/S0102-86502009000400013; MATTHEWS DR, 1985, CLIN ENDOCRINOL, V23, P71, DOI 10.1111/j.1365-2265.1985.tb00185.x; McMullan CJ, 2013, JAMA-J AM MED ASSOC, V309, P1388, DOI 10.1001/jama.2013.2710; Muhlbauer E, 2012, J PINEAL RES, V52, P446, DOI 10.1111/j.1600-079X.2012.00959.x; Nagorny CLF, 2011, J PINEAL RES, V50, P412, DOI 10.1111/j.1600-079X.2011.00859.x; Nogueira TC, 2011, ENDOCRINOLOGY, V152, P1253, DOI 10.1210/en.2010-1088; Oleson T, 2002, NEUROREHABILITATION, V17, P49; OZAKI Y, 1976, ENDOCRINOLOGY, V99, P641, DOI 10.1210/endo-99-2-641; Peplow PV, 2012, J ACUPUNCT MERIDIAN, V5, P1, DOI 10.1016/j.jams.2011.11.018; Peschke E, 2007, J PINEAL RES, V42, P350, DOI 10.1111/j.1600-079X.2007.00426.x; Rong PJ, 2012, BMC COMPLEM ALTERN M, V12, DOI 10.1186/1472-6882-12-255; Round R., 2013, EVID-BASED COMPL ALT, V2013, P984763, DOI DOI 10.1155/2013/984763; Smyth S, 2006, NAT MED, V12, P75, DOI 10.1038/nm0106-75; Stumpf I, 2009, J PINEAL RES, V46, P140, DOI 10.1111/j.1600-079X.2008.00638.x; Vinik AI, 2011, DIABETIC MED, V28, P643, DOI 10.1111/j.1464-5491.2010.03184.x; WURTMAN RJ, 1978, J NEURAL TRANSM, P59	34	22	26	2	16	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 16	2015	10	4							e0124195	10.1371/journal.pone.0124195	http://dx.doi.org/10.1371/journal.pone.0124195			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CG1ES	25880500	Green Published, Green Submitted, gold			2023-01-03	WOS:000353016500089
J	Nicoli, E; Syga, MI; Bosetti, M; Shastri, VP				Nicoli, Elena; Syga, Marie Isabel; Bosetti, Michela; Shastri, V. Prasad			Enhanced Gene Silencing through Human Serum Albumin-Mediated Delivery of Polyethylenimine-siRNA Polyplexes	PLOS ONE			English	Article							ENDOTHELIAL-CELLS; IN-VIVO; NANOPARTICLES; MECHANISM; EXPRESSION; CAVEOLAE; CANCER; SIZE; ENDOCYTOSIS; STRATEGIES	Small interfering RNA (siRNA) targeted therapeutics (STT) offers a compelling alternative to tradition medications for treatment of genetic diseases by providing a means to silence the expression of specific aberrant proteins, through interference at the expression level. The perceived advantage of siRNA therapy is its ability to target, through synthetic antisense oligonucleotides, any part of the genome. Although STT provides a high level of specificity, it is also hindered by poor intracellular uptake, limited blood stability, high degradability and nonspecific immune stimulation. Since serum proteins has been considered as useful vehicles for targeting tumors, in this study we investigated the effect of incorporation of human serum albumin (HSA) in branched polyethylenimine (bPEI)-siRNA polyplexes in their internalization in epithelial and endothelial cells. We observed that introduction of HSA preserves the capacity of bPEI to complex with siRNA and protect it against extracellular endonucleases, while affording significantly improved internalization and silencing efficiency, compared to bPEI-siRNA polyplexes in endothelial and metastatic breast cancer epithelial cells. Furthermore, the uptake of the HSA-bPEI-siRNA ternary polyplexes occurred primarily through a caveolae-mediated endocytosis, thus providing evidence for a clear role for HSA in polyplex internalization. These results provide further impetus to explore the role of serum proteins in delivery of siRNA.	[Nicoli, Elena; Bosetti, Michela] Univ Piemonte Orientale, Dipartimento Sci Farmaco, Novara, Italy; [Nicoli, Elena; Syga, Marie Isabel; Shastri, V. Prasad] Univ Freiburg, Inst Macromol Chem, Freiburg, Germany; [Syga, Marie Isabel] Univ Freiburg, BIOSS, Ctr Biol Signalling Studies, Freiburg, Germany	University of Eastern Piedmont Amedeo Avogadro; University of Freiburg; University of Freiburg	Shastri, VP (corresponding author), Univ Freiburg, Inst Macromol Chem, Freiburg, Germany.	prasad.shastri@gmail.com	Bosetti, Michela/AAR-9556-2021	Bosetti, Michela/0000-0002-3682-8702	5th INTERREG Upper Rhine Program (Project A21: NANO@MATRIX); German Federal Government; State Government (Centre for Biological Signalling Studies, BIOSS); State Government [EXC 294]	5th INTERREG Upper Rhine Program (Project A21: NANO@MATRIX); German Federal Government; State Government (Centre for Biological Signalling Studies, BIOSS); State Government	This work was funded by the 5th INTERREG Upper Rhine Program (Project A21: NANO@MATRIX), the excellence initiative of the German Federal and State Governments (grant EXC 294; Centre for Biological Signalling Studies, BIOSS). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abbasi S, 2011, CELL BIOCHEM BIOPHYS, V61, P277, DOI 10.1007/s12013-011-9201-9; Aigner A, 2006, J BIOTECHNOL, V124, P12, DOI 10.1016/j.jbiotec.2005.12.003; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Carrabino S, 2005, J GENE MED, V7, P1555, DOI 10.1002/jgm.799; Desai N, 2009, TRANSL ONCOL, V2, P59, DOI 10.1593/tlo.09109; Folkman J, 2007, NAT REV DRUG DISCOV, V6, P273, DOI 10.1038/nrd2115; Galbiati F, 2001, MOL BIOL CELL, V12, P2229, DOI 10.1091/mbc.12.8.2229; GATTER KC, 1983, J CLIN PATHOL, V36, P539, DOI 10.1136/jcp.36.5.539; Han JF, 2014, SMALL, V10, P524, DOI 10.1002/smll.201301992; Kanasty R, 2013, NAT MATER, V12, P967, DOI [10.1038/NMAT3765, 10.1038/nmat3765]; Kanasty RL, 2012, MOL THER, V20, P513, DOI 10.1038/mt.2011.294; Kang JH, 2012, J CONTROL RELEASE, V163, P119, DOI 10.1016/j.jconrel.2012.08.030; Kim JA, 2012, NAT NANOTECHNOL, V7, P62, DOI [10.1038/nnano.2011.191, 10.1038/NNANO.2011.191]; Kim SI, 2009, J HEPATOL, V50, P479, DOI 10.1016/j.jhep.2008.10.029; Kratz F, 1998, DRUG DELIV, V5, P281, DOI 10.3109/10717549809065759; Kratz F, 2008, J CONTROL RELEASE, V132, P171, DOI 10.1016/j.jconrel.2008.05.010; Kwok A, 2011, NANOMED-NANOTECHNOL, V7, P210, DOI 10.1016/j.nano.2010.07.005; Lavie Y, 2001, ADV DRUG DELIVER REV, V49, P317, DOI 10.1016/S0169-409X(01)00144-2; Lundqvist M, 2008, P NATL ACAD SCI USA, V105, P14265, DOI 10.1073/pnas.0805135105; Malek A, 2009, TOXICOL APPL PHARM, V236, P97, DOI 10.1016/j.taap.2009.01.014; Malik AB, 2009, J MED SCI, V2, P13; McDaneld TG, 2009, J ANIM SCI, V87, pE21, DOI 10.2527/jas.2008-1303; Nguyen DX, 2009, NAT REV CANCER, V9, P274, DOI 10.1038/nrc2622; O'Connor TP, 2006, NAT REV GENET, V7, P261, DOI 10.1038/nrg1829; Ogris M, 2001, AAPS PHARMSCI, V3, part. no.; Pan T, 2009, J LUMIN, V129, P741, DOI 10.1016/j.jlumin.2009.02.006; Rejman J, 2005, MOL THER, V12, P468, DOI 10.1016/j.ymthe.2005.03.038; Rejman J, 2004, BIOCHEM J, V377, P159, DOI 10.1042/BJ20031253; Rhaese S, 2003, J CONTROL RELEASE, V92, P199, DOI 10.1016/S0168-3659(03)00302-X; SCHNITZER JE, 1992, AM J PHYSIOL, V263, pH1872, DOI 10.1152/ajpheart.1992.263.6.H1872; Singh HD, 2010, ACTA BIOMATER, V6, P4277, DOI 10.1016/j.actbio.2010.06.017; Son S, 2013, BIOMATERIALS, V34, P9475, DOI 10.1016/j.biomaterials.2013.08.085; Tiruppathi C, 1997, J BIOL CHEM, V272, P25968, DOI 10.1074/jbc.272.41.25968; Voigt J, 2014, P NATL ACAD SCI USA, V111, P2942, DOI 10.1073/pnas.1322356111; Whitehead KA, 2009, NAT REV DRUG DISCOV, V8, P129, DOI 10.1038/nrd2742; Zuckerman JE, 2014, P NATL ACAD SCI USA, V111, P11449, DOI 10.1073/pnas.1411393111	36	31	32	5	36	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 9	2015	10	4							e0122581	10.1371/journal.pone.0122581	http://dx.doi.org/10.1371/journal.pone.0122581			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CF5HQ	25856158	Green Published, Green Submitted, gold			2023-01-03	WOS:000352588500043
J	Zhang, Y; Wang, H; Cui, LJ; Zhang, YY; Liu, Y; Chu, X; Liu, ZY; Zhang, JP; Chu, L				Zhang, Ying; Wang, Hao; Cui, Lijing; Zhang, Yuanyuan; Liu, Yang; Chu, Xi; Liu, Zhenyi; Zhang, Jianping; Chu, Li			Continuing Treatment with Salvia miltiorrhiza Injection Attenuates Myocardial Fibrosis in Chronic Iron-Overloaded Mice	PLOS ONE			English	Article							CALCIUM-CHANNEL BLOCKER; THALASSEMIA MAJOR; OXIDATIVE STRESS; COMPOUND ASTRAGALUS; COLLAGEN-SYNTHESIS; DANSHEN INJECTION; HEPATIC-FIBROSIS; CARDIAC FIBROSIS; CA2+ CHANNELS; EXTRACT	Iron overload cardiomyopathy results from iron accumulation in the myocardium that is closely linked to iron-mediated myocardial fibrosis. Salvia miltiorrhiza (SM, also known as Danshen), a traditional Chinese medicinal herb, has been widely used for hundreds of years to treat cardiovascular diseases. Here, we investigated the effect and potential mechanism of SM on myocardial fibrosis induced by chronic iron overload (CIO) in mice. Kunming male mice (8 weeks old) were randomized to six groups of 10 animals each: control (CONT), CIO, low-dose SM (L-SM), high-dose SM (H-SM), verapamil (VRP) and deferoxamine (DFO) groups. Normal saline was injected in the CONT group. Mice in the other five groups were treated with iron dextran at 50 mg/kg per day intraperitoneally for 7 weeks, and those in the latter four groups also received corresponding daily treatments, including 3 g/kg or 6 g/kg of SM, 100 mg/kg of VRP, or 100 mg/kg of DFO. The iron deposition was estimated histologically using Prussian blue staining. Myocardial fibrosis was determined by Masson's trichrome staining and hydroxyproline (Hyp) quantitative assay. Superoxide dismutase (SOD) activity, malondialdehyde (MDA) content and protein expression levels of type I collagen (COL I), type I collagen (COL III), transforming growth factor-beta(1) (TGF-beta(1)) and matrix metalloproteinase-9 (MMP-9) were analyzed to investigate the mechanisms underlying the effects of SM against iron-overloaded fibrosis. Treatment of chronic iron-overloaded mice with SM dose-dependently reduced iron deposition levels, fibrotic area percentage, Hyp content, expression levels of COL I and COL III, as well as upregulated the expression of TGF-beta(1) and MMP-9 proteins in the heart. Moreover, SM treatment decreased MDA content and increased SOD activity. In conclusion, SM exerted activities against cardiac fibrosis induced by CIO, which may be attributed to its inhibition of iron deposition, as well as collagen metabolism and oxidative stress.	[Zhang, Ying; Cui, Lijing; Liu, Yang; Zhang, Jianping; Chu, Li] Hebei Med Univ, Dept Pharmacol, Shijiazhuang, Peoples R China; [Wang, Hao] Hebei Med Univ, Dept Chinese Mat Med, Shijiazhuang, Peoples R China; [Zhang, Yuanyuan; Liu, Zhenyi] Hebei Univ Chinese Med, Dept Pharmaceut, Shijiazhuang, Peoples R China; [Chu, Xi] Hebei Med Univ, Hosp 4, Shijiazhuang, Peoples R China	Hebei Medical University; Hebei Medical University; Hebei University of Chinese Medicine; Hebei Medical University	Chu, L (corresponding author), Hebei Med Univ, Dept Pharmacol, Shijiazhuang, Peoples R China.	chuli0614@126.com	zhang, yuanyuan/GYA-4428-2022		Nature Fund of Hebei Province, China [C2011206025, H2014206244]; Fund of Hebei Science and Technology Bureau [10276105D-2]	Nature Fund of Hebei Province, China; Fund of Hebei Science and Technology Bureau	This study was supported by the Nature Fund of Hebei Province, China http://hensf.hebstd.gov.cn/(No. C2011206025 and H2014206244) and the Fund of Hebei Science and Technology Bureau http://www.hebstd.gov.cn/(No. 10276105D-2). In this study, the funder conceived and designed the experiments, and wrote the paper.	Andrews NC, 1999, NEW ENGL J MED, V341, P1986, DOI 10.1056/NEJM199912233412607; Arezzini B, 2003, INT J BIOCHEM CELL B, V35, P486, DOI 10.1016/S1357-2725(02)00298-4; Barton JC, 1996, NAT MED, V2, P394, DOI 10.1038/nm0496-394; Berdoukas V, 2012, J BLOOD MED, V3, P119, DOI 10.2147/JBM.S27400; Boin F, 2014, ORPHANET J RARE DIS, V9, DOI 10.1186/s13023-014-0123-7; Borgna-Pignatti C, 2005, ANN NY ACAD SCI, V1054, P40, DOI 10.1196/annals.1345.006; Borgna-Pignatti C, 2006, BLOOD, V107, P3733, DOI 10.1182/blood-2005-07-2933; Borgna-Pignatti C, 2004, HAEMATOLOGICA, V89, P1187; Cao CM, 2003, LIFE SCI, V72, P2451, DOI 10.1016/S0024-3205(03)00142-5; Cappellini Maria D, 2009, Hemoglobin, V33 Suppl 1, pS58, DOI 10.3109/03630260903346924; Chang WT, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097455; Chen L, 2009, PLANTA MED, V75, P1573, DOI 10.1055/s-0029-1185905; Chern JPS, 2007, PEDIATR BLOOD CANCER, V48, P550, DOI 10.1002/pbc.21028; Ding M, 2006, J ALTERN COMPLEM MED, V12, P5, DOI 10.1089/acm.2006.12.5; Fernandes JL, 2013, AM J MED, V126, P834, DOI 10.1016/j.amjmed.2013.05.002; Fraga CG, 2002, TOXICOLOGY, V180, P23, DOI 10.1016/S0300-483X(02)00379-7; Franchini M, 2004, HEMATOL J, V5, P287, DOI 10.1038/sj.thj.6200407; FRIDOVICH I, 1989, FREE RADICAL BIO MED, V7, P557, DOI 10.1016/0891-5849(89)90032-4; Galey JB, 2000, J MED CHEM, V43, P1418, DOI 10.1021/jm9911635; Gao YG, 2014, J ETHNOPHARMACOL, V158, P397, DOI 10.1016/j.jep.2014.10.049; Gao YG, 2013, J ETHNOPHARMACOL, V145, P254, DOI 10.1016/j.jep.2012.10.060; Ge GH, 2014, GENE, V546, P97, DOI 10.1016/j.gene.2014.05.021; Guan SJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074318; Gujja P, 2010, J AM COLL CARDIOL, V56, P1001, DOI 10.1016/j.jacc.2010.03.083; GUTTERIDGE JMC, 1995, CLIN CHEM, V41, P1819; He S, 2012, BRIT J DERMATOL, V166, P564, DOI 10.1111/j.1365-2133.2011.10674.x; Hentze MW, 2010, CELL, V142, P24, DOI 10.1016/j.cell.2010.06.028; HOU J, 1999, CHINESE J TUBERCULOS, V22, P43; Hsu YC, 2005, J BIOMED SCI, V12, P185, DOI 10.1007/s11373-004-8167-7; IKEDA H, 1992, HEPATOLOGY, V15, P282, DOI 10.1002/hep.1840150218; Jesmin S, 2002, DIABETOLOGIA, V45, P402, DOI 10.1007/s00125-001-0765-6; Karwinski W, 1996, J SURG RES, V64, P150, DOI 10.1006/jsre.1996.0321; Kudo H, 2008, TOXICOLOGY, V246, P143, DOI 10.1016/j.tox.2008.01.004; Kumfu S, 2011, EUR J HAEMATOL, V86, P156, DOI 10.1111/j.1600-0609.2010.01549.x; Lam FFY, 2006, EUR J PHARMACOL, V553, P240, DOI 10.1016/j.ejphar.2006.09.030; Lee SH, 2011, J ETHNOPHARMACOL, V137, P1409, DOI 10.1016/j.jep.2011.08.007; Lee TY, 2006, J PHARM PHARMACOL, V58, P659, DOI 10.1211/jpp.58.5.0011; Lian WS, 2011, J BIOMED SCI, V18, DOI 10.1186/1423-0127-18-26; Lin H, 2013, MOL PHARMACOL, V84, P275, DOI 10.1124/mol.112.083964; Liu L, 2012, MOL MED REP, V6, P1231, DOI 10.3892/mmr.2012.1076; Lu HY, 2014, BIOL PHARM BULL, V37, P961, DOI 10.1248/bpb.b13-00921; Matsui T, 2010, BIOCHEM BIOPH RES CO, V396, P566, DOI 10.1016/j.bbrc.2010.04.149; Murphy CJ, 2010, J CARD FAIL, V16, P888, DOI 10.1016/j.cardfail.2010.05.009; Nan JX, 2001, J PHARM PHARMACOL, V53, P197, DOI 10.1211/0022357011775406; Oudit GY, 2006, J MOL MED, V84, P349, DOI 10.1007/s00109-005-0029-x; Oudit GY, 2003, NAT MED, V9, P1187, DOI 10.1038/nm920; Patel R, 2006, J VASC SURG, V43, P364, DOI 10.1016/j.jvs.2005.10.032; Pepe A, 2009, HEART, V95, P1688, DOI 10.1136/hrt.2008.156497; Poggiali E, 2012, BLOOD TRANSFUS-ITALY, V10, P411, DOI 10.2450/2012.0008-12; Psaltis PJ, 2011, INT J CARDIOVAS IMAG, V27, P25, DOI 10.1007/s10554-010-9657-5; Reagan-Shaw S, 2008, FASEB J, V22, P659, DOI 10.1096/fj.07-9574LSF; Reed AL, 2011, AM J PHYSIOL-HEART C, V301, pH824, DOI 10.1152/ajpheart.00407.2010; Reeder BJ, 2008, FREE RADICAL BIO MED, V44, P264, DOI 10.1016/j.freeradbiomed.2007.08.006; Rui WJ, 2014, J ETHNOPHARMACOL, V151, P198, DOI 10.1016/j.jep.2013.10.022; Saewong T, 2010, MED CHEM, V6, P57, DOI 10.2174/157340610791321479; Santos MM, 2000, AM J PATHOL, V157, P1883, DOI 10.1016/S0002-9440(10)64827-4; Selim M, 2010, TRANSL STROKE RES, V1, P35, DOI 10.1007/s12975-009-0001-0; Sugishita K, 2009, INT HEART J, V50, P829, DOI 10.1536/ihj.50.829; Tian Xiao-hui, 2005, Zhongguo Zhong Xi Yi Jie He Za Zhi, V25, P404; Usunier B, 2014, STEM CELLS INT, V2014, DOI 10.1155/2014/340257; Verrecchia F, 2001, J BIOL CHEM, V276, P17058, DOI 10.1074/jbc.M100754200; Wang M, 2012, J ETHNOPHARMACOL, V141, P96, DOI 10.1016/j.jep.2012.02.005; Wang XH, 2007, MED RES REV, V27, P133, DOI 10.1002/med.20077; Wasser S, 1998, J HEPATOL, V29, P760, DOI 10.1016/S0168-8278(98)80257-2; Weatherall DJ, 1996, NAT MED, V2, P847, DOI 10.1038/nm0896-847; Wu WY, 2012, ACTA PHARMACOL SIN, V33, P1119, DOI 10.1038/aps.2012.126; Yang Y, 2008, J ETHNOPHARMACOL, V118, P264, DOI 10.1016/j.jep.2008.04.012; Yu QL, 2014, MYCOPATHOLOGIA, V177, P167, DOI 10.1007/s11046-014-9735-7; Zeisberg EM, 2007, NAT MED, V13, P952, DOI 10.1038/nm1613; Zhang JP, 2013, PLANTA MED, V79, P744, DOI 10.1055/s-0032-1328588; Zhang Y, 2012, EUR J PHARMACOL, V680, P95, DOI 10.1016/j.ejphar.2012.01.010; Zhang Y, 2013, J ETHNOPHARMACOL, V148, P671, DOI 10.1016/j.jep.2013.05.028; Zhou XL, 2012, PHYTOMEDICINE, V19, P1263, DOI 10.1016/j.phymed.2012.08.011; Zou CB, 2013, ENDOCRINE, V44, P666, DOI 10.1007/s12020-013-9907-0	74	29	31	0	18	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 7	2015	10	4							e0124061	10.1371/journal.pone.0124061	http://dx.doi.org/10.1371/journal.pone.0124061			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CF3VU	25850001	Green Submitted, Green Published, gold			2023-01-03	WOS:000352477800261
J	Sharma, P; Allison, JP				Sharma, Padmanee; Allison, James P.			The future of immune checkpoint therapy	SCIENCE			English	Review							COLONY-STIMULATING FACTOR; CTLA-4 BLOCKADE SYNERGIZES; CD8(+) T-CELLS; PD-1 BLOCKADE; TUMOR MICROENVIRONMENT; CANCER-IMMUNOTHERAPY; ANTI-PD-L1 ANTIBODY; UP-REGULATION; REGULATORY T; IPILIMUMAB	Immune checkpoint therapy, which targets regulatory pathways in T cells to enhance antitumor immune responses, has led to important clinical advances and provided a new weapon against cancer. This therapy has elicited durable clinical responses and, in a fraction of patients, long-term remissions where patients exhibit no clinical signs of cancer for many years. The way forward for this class of novel agents lies in our ability to understand human immune responses in the tumor microenvironment. This will provide valuable information regarding the dynamic nature of the immune response and regulation of additional pathways that will need to be targeted through combination therapies to provide survival benefit for greater numbers of patients.	[Sharma, Padmanee; Allison, James P.] Univ Texas MD Anderson Canc Ctr, Dept Immunol, Houston, TX 77030 USA; [Sharma, Padmanee] Univ Texas MD Anderson Canc Ctr, Genitourinary Med Oncol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Sharma, P (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Immunol, Houston, TX 77030 USA.	padsharma@mdanderson.org; jallison@mdanderson.org		Allison, James/0000-0001-8980-5697	PCF Challenge Grant in Immunology; NCI/NIH [1-R01 CA1633793-01]; Cancer Prevention Research in Texas grants; Stand Up To Cancer-Cancer Research Institute Cancer Immunology Dream Team Translational Cancer Research Grant; NATIONAL CANCER INSTITUTE [R01CA163793] Funding Source: NIH RePORTER	PCF Challenge Grant in Immunology; NCI/NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Cancer Prevention Research in Texas grants; Stand Up To Cancer-Cancer Research Institute Cancer Immunology Dream Team Translational Cancer Research Grant; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	P.S. and J.P.A. are founders and advisors for Jounce Therapeutics. P.S. also serves as a consultant for Bristol-Myers Squibb, Amgen, and GlaxoSmithKline. J.P.A. is an inventor of intellectual property owned by the University of California, Berkeley, and licensed to Bristol-Myers Squibb and has received royalties from Bristol-Myers Squibb. Our research is supported by a PCF Challenge Grant in Immunology (J.P.A. and P.S.), NCI/NIH 1-R01 CA1633793-01 (P.S.), Cancer Prevention Research in Texas grants (J.P.A. and P.S.), and a Stand Up To Cancer-Cancer Research Institute Cancer Immunology Dream Team Translational Cancer Research Grant (P.S. and J.P.A.). Stand Up To Cancer is a program of the Entertainment Industry Foundation administered by the American Association for Cancer Research.	Alexandrov LB, 2013, NATURE, V500, P415, DOI 10.1038/nature12477; Amin A., 2014, J CLIN ONCOL S, V32, P4010; Ansell SM, 2015, NEW ENGL J MED, V372, P311, DOI 10.1056/NEJMoa1411087; Brahmer JR, 2012, NEW ENGL J MED, V366, P2455, DOI 10.1056/NEJMoa1200694; Carthon BC, 2010, CLIN CANCER RES, V16, P2861, DOI 10.1158/1078-0432.CCR-10-0569; Crittenden M, 2015, SEMIN RADIAT ONCOL, V25, P54, DOI 10.1016/j.semradonc.2014.07.003; Curran MA, 2010, P NATL ACAD SCI USA, V107, P4275, DOI 10.1073/pnas.0915174107; Curtin JA, 2005, NEW ENGL J MED, V353, P2135, DOI 10.1056/NEJMoa050092; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Derre L, 2010, J CLIN INVEST, V120, P157, DOI 10.1172/JCI40070; Dong HD, 2002, NAT MED, V8, P793, DOI 10.1038/nm730; Engeland CE, 2014, MOL THER, V22, P1949, DOI 10.1038/mt.2014.160; Fan XZ, 2014, J EXP MED, V211, P715, DOI 10.1084/jem.20130590; Fourcade J, 2012, CANCER RES, V72, P887, DOI 10.1158/0008-5472.CAN-11-2637; Fourcade J, 2010, J EXP MED, V207, P2175, DOI 10.1084/jem.20100637; Frederick DT, 2013, CLIN CANCER RES, V19, P1225, DOI 10.1158/1078-0432.CCR-12-1630; Freeman GJ, 2000, J EXP MED, V192, P1027, DOI 10.1084/jem.192.7.1027; Fu TH, 2011, CANCER RES, V71, P5445, DOI 10.1158/0008-5472.CAN-11-1138; Goldberg MV, 2011, CURR TOP MICROBIOL, V344, P269, DOI 10.1007/82_2010_114; Greenwald RJ, 2005, ANNU REV IMMUNOL, V23, P515, DOI 10.1146/annurev.immunol.23.021704.115611; Grosso J, 2013, J CLIN ONCOL, V31; Hamid O, 2013, NEW ENGL J MED, V369, P134, DOI 10.1056/NEJMoa1305133; Hammers J. H., 2014, J CLIN ONCOL S, V32, P4504; Herbst RS, 2014, NATURE, V515, P563, DOI 10.1038/nature14011; Hodi F. S., 2014, J AM MED ASS, V312, P1744; Hodi FS, 2008, P NATL ACAD SCI USA, V105, P3005, DOI 10.1073/pnas.0712237105; Hodi FS, 2010, NEW ENGL J MED, V363, P711, DOI 10.1056/NEJMoa1003466; Hurwitz AA, 1998, P NATL ACAD SCI USA, V95, P10067, DOI 10.1073/pnas.95.17.10067; Kohrt HE, 2014, J CLIN INVEST, V124, P2668, DOI 10.1172/JCI73014; KRUMMEL MF, 1995, J EXP MED, V182, P459, DOI 10.1084/jem.182.2.459; Kuchroo VK, 2003, NAT REV IMMUNOL, V3, P454, DOI 10.1038/nri1111; Le DT, 2013, J IMMUNOTHER, V36, P382, DOI 10.1097/CJI.0b013e31829fb7a2; Le Mercier I, 2014, CANCER RES, V74, P1933, DOI 10.1158/0008-5472.CAN-13-1506; Leach DR, 1996, SCIENCE, V271, P1734, DOI 10.1126/science.271.5256.1734; Liakou CI, 2008, P NATL ACAD SCI USA, V105, P14987, DOI 10.1073/pnas.0806075105; LINSLEY PS, 1992, J EXP MED, V176, P1595, DOI 10.1084/jem.176.6.1595; Llosa NJ, 2015, CANCER DISCOV, V5, P43, DOI 10.1158/2159-8290.CD-14-0863; Madore J, 2015, PIGM CELL MELANOMA R, V28, DOI 10.1111/pcmr.12340; Pardoll DM, 2012, NAT REV CANCER, V12, P252, DOI 10.1038/nrc3239; Powles T, 2014, NATURE, V515, P558, DOI 10.1038/nature13904; Redmond WL, 2014, CANCER IMMUNOL RES, V2, P142, DOI 10.1158/2326-6066.CIR-13-0031-T; Rizvi NA, 2015, SCIENCE, V348, P124, DOI 10.1126/science.aaa1348; Robert C, 2015, NEW ENGL J MED, V372, P320, DOI 10.1056/NEJMoa1412082; Robert C, 2014, LANCET, V384, P1109, DOI 10.1016/S0140-6736(14)60958-2; Robert C, 2011, NEW ENGL J MED, V364, P2517, DOI 10.1056/NEJMoa1104621; Rosenberg SA, 2004, NAT MED, V10, P909, DOI 10.1038/nm1100; Sakuishi K, 2010, J EXP MED, V207, P2187, DOI 10.1084/jem.20100643; Schadendorf D, 2015, J CLIN ONCOL, V33, P1889, DOI 10.1200/JCO.2014.56.2736; Schumacher TN, 2015, SCIENCE, V348, P69, DOI 10.1126/science.aaa4971; Sharma P, 2011, NAT REV CANCER, V11, P805, DOI 10.1038/nrc3153; Snyder A, 2014, NEW ENGL J MED, V371, P2189, DOI 10.1056/NEJMoa1406498; Tang C, 2014, CANCER IMMUNOL RES, V2, P831, DOI 10.1158/2326-6066.CIR-14-0069; Tang DN, 2013, CANCER IMMUNOL RES, V1, P229, DOI 10.1158/2326-6066.CIR-13-0020; Topalian SL, 2012, NEW ENGL J MED, V366, P2443, DOI 10.1056/NEJMoa1200690; TOWNSEND SE, 1993, SCIENCE, V259, P368, DOI 10.1126/science.7678351; TRIEBEL F, 1990, J EXP MED, V171, P1393, DOI 10.1084/jem.171.5.1393; Tumeh PC, 2014, NATURE, V515, P568, DOI 10.1038/nature13954; van den Eertwegh AJM, 2012, LANCET ONCOL, V13, P509, DOI 10.1016/S1470-2045(12)70007-4; van Elsas A, 1999, J EXP MED, V190, P355, DOI 10.1084/jem.190.3.355; VANDERBRUGGEN P, 1991, SCIENCE, V254, P1643, DOI 10.1126/science.1840703; Waitz R, 2012, ONCOIMMUNOLOGY, V1, DOI 10.4161/onci.19442; WALUNAS TL, 1994, IMMUNITY, V1, P405, DOI 10.1016/1074-7613(94)90071-X; Wang L, 2011, J EXP MED, V208, P577, DOI 10.1084/jem.20100619; Weber JS, 2008, J CLIN ONCOL, V26, P5950, DOI 10.1200/JCO.2008.16.1927; Wolchok JD, 2013, NEW ENGL J MED, V369, P122, DOI 10.1056/NEJMoa1302369; Woo SR, 2012, CANCER RES, V72, P917, DOI 10.1158/0008-5472.CAN-11-1620; Yang JC, 2007, J IMMUNOTHER, V30, P825, DOI 10.1097/CJI.0b013e318156e47e; Zamarin D, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3008095	68	2850	2986	84	1740	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 3	2015	348	6230					56	61		10.1126/science.aaa8172	http://dx.doi.org/10.1126/science.aaa8172			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CE8GJ	25838373				2023-01-03	WOS:000352079500026
J	Liu, JL; Sun, K; Zheng, CL; Chen, XT; Zhang, WJ; Wang, ZZ; Shar, PA; Xiao, W; Wang, YH				Liu, Jianling; Sun, Ke; Zheng, Chunli; Chen, Xuetong; Zhang, Wenjuan; Wang, Zhengzhong; Shar, Piar Ali; Xiao, Wei; Wang, Yonghua			Pathway as a Pharmacological Target for Herbal Medicines: An Investigation from Reduning Injection	PLOS ONE			English	Article							NF-KAPPA-B; NETWORK PHARMACOLOGY; SYSTEMS PHARMACOLOGY; MOLECULAR-MECHANISMS; SIGNALING PATHWAYS; DRUG DISCOVERY; INFLAMMATION; COMBINATION; ALPHA	As a rich natural resource for drug discovery, Traditional Chinese Medicine (TCM) plays an important role in complementary and alternative medical systems. TCM shows a daunting complexity of compounds featuring multi-components and multi-targets to cure diseases, which thus always makes it extremely difficult to systematically explain the molecular mechanisms adequately using routine methods. In the present work, to reveal the systematic mechanism of herbal formulae, we developed a pathway-based strategy by combining the pathways integrating, target selection, reverse drug targeting and network analysis together, and then exemplified it by Reduning injection (RDN), a clinically widely used herbal medicine injection, in combating inflammation. The anti-inflammatory effects exerted by the major ingredients of RDN at signaling pathways level were systematically investigated. More importantly, our predicted results were also experimentally validated. Our strategy provides a deep understanding of the pharmacological functions of herbal formulae from molecular to systematic level, which may lead to more successful applications of systems pharmacology for drug discovery and development.	[Liu, Jianling; Sun, Ke] NW Univ Xian, Coll Life Sci, Xian 710069, Shaanxi, Peoples R China; [Sun, Ke; Zheng, Chunli; Chen, Xuetong; Zhang, Wenjuan; Shar, Piar Ali; Wang, Yonghua] Northwest A&F Univ, Coll Life Sci, Yangling 712100, Shaanxi, Peoples R China; [Sun, Ke; Zheng, Chunli; Chen, Xuetong; Zhang, Wenjuan; Shar, Piar Ali; Wang, Yonghua] Northwest A&F Univ, Ctr Bioinformat, Yangling 712100, Shaanxi, Peoples R China; [Wang, Zhengzhong; Xiao, Wei] State Key Lab New Tech Chinese Med Pharmaceut Pro, Lianyungang 222001, Jiangsu, Peoples R China	Northwest University Xi'an; Northwest A&F University - China; Northwest A&F University - China	Xiao, W (corresponding author), State Key Lab New Tech Chinese Med Pharmaceut Pro, Lianyungang 222001, Jiangsu, Peoples R China.	kanionlunwen@163.com; yh_wang@nwsuaf.edu.cn		Jiang, Meng/0000-0002-2488-1389	Fund of Northwest A F University; National Natural Science Foundation of China [31170796, 81373892]; Jiangsu Kanion Pharmaceutical Co. Ltd.	Fund of Northwest A F University; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Jiangsu Kanion Pharmaceutical Co. Ltd.	The research is supported by the Fund of Northwest A & F University (http://www.nwsuaf.edu.cn/) and is financially supported by the National Natural Science Foundation of China (http://www.nsfc.gov.cn/) (Grant No. 31170796 and 81373892). Jiangsu Kanion Pharmaceutical Co. Ltd. provided support in the form of salaries for authors ZW and WX and provided experimental devices and laboratory for this study, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the 'author contributions' section.	Akhurst RJ, 2012, NAT REV DRUG DISCOV, V11, P790, DOI 10.1038/nrd3810; [Anonymous], 2013, STUDIES PHARMACODYNA; Bhalla US, 1999, SCIENCE, V283, P381, DOI 10.1126/science.283.5400.381; Castoreno AB, 2010, NAT CHEM BIOL, V6, P457, DOI 10.1038/nchembio.363; Chen ZJ, 1996, CELL, V84, P853, DOI 10.1016/S0092-8674(00)81064-8; Cheng JQ, 2005, ONCOGENE, V24, P7482, DOI 10.1038/sj.onc.1209088; Christman JW, 1998, INTENS CARE MED, V24, P1131, DOI 10.1007/s001340050735; Dong C, 2002, ANNU REV IMMUNOL, V20, P55, DOI 10.1146/annurev.immunol.20.091301.131133; Guha M, 2001, CELL SIGNAL, V13, P85, DOI 10.1016/S0898-6568(00)00149-2; Hopkins AL, 2008, NAT CHEM BIOL, V4, P682, DOI 10.1038/nchembio.118; Huang C, 2014, BRIEF BIOINFORM, V15, P710, DOI 10.1093/bib/bbt035; Johnson GL, 2002, SCIENCE, V298, P1911, DOI 10.1126/science.1072682; Kaminska B, 2005, BBA-PROTEINS PROTEOM, V1754, P253, DOI 10.1016/j.bbapap.2005.08.017; Kim TH, 2012, MOL MED, V18, P455, DOI 10.2119/molmed.2011.00308; Kroncke KD, 1997, NITRIC OXIDE-BIOL CH, V1, P107, DOI 10.1006/niox.1997.0118; Li BH, 2012, INT J MOL SCI, V13, P13501, DOI 10.3390/ijms131013501; Li P, 2015, BIOINFORMATICS; Li P, 2014, J ETHNOPHARMACOL, V151, P93, DOI 10.1016/j.jep.2013.07.001; Liang XJ, 2014, MOL BIOSYST, V10, P1014, DOI 10.1039/c3mb70507b; Normile D, 2003, SCIENCE, V299, P188, DOI 10.1126/science.299.5604.188; Otterbein LE, 2000, NAT MED, V6, P422, DOI 10.1038/74680; Popa C, 2007, J LIPID RES, V48, P751, DOI 10.1194/jlr.R600021-JLR200; Rao KMK, 2001, J LEUKOCYTE BIOL, V69, P3; Shan JH, 2009, INT IMMUNOPHARMACOL, V9, P1042, DOI 10.1016/j.intimp.2009.04.011; Smalley KSM, 2006, MOL CANCER THER, V5, P1136, DOI 10.1158/1535-7163.MCT-06-0084; Smoot ME, 2011, BIOINFORMATICS, V27, P431, DOI 10.1093/bioinformatics/btq675; Surh YJ, 2001, MUTAT RES-FUND MOL M, V480, P243, DOI 10.1016/S0027-5107(01)00183-X; Tak PP, 2001, J CLIN INVEST, V107, P7, DOI 10.1172/JCI11830; Tao WY, 2013, J ETHNOPHARMACOL, V145, P1, DOI 10.1016/j.jep.2012.09.051; Thalhamer T, 2008, RHEUMATOLOGY, V47, P409, DOI 10.1093/rheumatology/kem297; Tung YT, 2008, BIORESOURCE TECHNOL, V99, P3908, DOI 10.1016/j.biortech.2007.07.050; Wang X, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/519031; Xu HM, 2009, PHARM WORLD SCI, V31, P458, DOI 10.1007/s11096-009-9297-9; Yao XJ, 2012, INT IMMUNOPHARMACOL, V14, P454, DOI 10.1016/j.intimp.2012.07.024; Yao Y, 2013, J ETHNOPHARMACOL, V150, P619, DOI 10.1016/j.jep.2013.09.018; Yu H, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037608	36	26	28	0	36	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 1	2015	10	4							e0123109	10.1371/journal.pone.0123109	http://dx.doi.org/10.1371/journal.pone.0123109			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CE9AM	25830385	Green Submitted, gold, Green Published			2023-01-03	WOS:000352135600139
J	Tzivian, L; Friger, M; Kushnir, T				Tzivian, Lilian; Friger, Michael; Kushnir, Talma			Associations between Stress and Quality of Life: Differences between Owners Keeping a Living Dog or Losing a Dog by Euthanasia	PLOS ONE			English	Article							COMPANION ANIMAL DEATH; PET OWNERSHIP; HUMAN HEALTH; ATTACHMENT; BEREAVEMENT; CLIENTS; GRIEF	Objectives The loss of a pet may be stressful to the owner. The main objectives of this study were to compare the levels of stress and to explore the correlates of QOL of healthy adults who currently own or who have just lost their dog. Methods The study sample contained 110 current, and 103 bereaved dog owners, all females, who lost their dogs due to euthanasia. QOL was assessed with the WHOQOL-BREF questionnaire and divided into four major domains-Physical, Psychological, Relationship, and Environmental. Demographic variables, stress, health behaviors, and social support from family, friends, and significant other were included in multivariate analysis. Results Stress levels were significantly higher in bereaved owners. QOL in three of the four domains (Physical, Psychological, and Relationship) of current owners were significantly better than among bereaved owners. Stress was significantly associated with these three domains of QOL. Quality of life was found to be positively associated with social support. Age was related directly only to current owners' QOL. Conclusions The results suggest that a loss of a dog is associated with stress for the bereaved owner and reduced physical, psychological, and relationship QOL. Lack of social support in the case of death of a companion animal has a strong effect on owners' grief reactions.	[Tzivian, Lilian; Friger, Michael; Kushnir, Talma] Ben Gurion Univ Negev, Fac Hlth Sci, Dept Publ Hlth, Beer Sheva, Israel	Ben Gurion University	Tzivian, L (corresponding author), Ben Gurion Univ Negev, Fac Hlth Sci, Dept Publ Hlth, Beer Sheva, Israel.	lili66@smile.net.il	Tzivian, Lilian/AAM-5799-2020	Tzivian, Lilian/0000-0001-6253-9130; Kushnir, Talma/0000-0002-7494-6777				Adams CL, 1999, CAN VET J, V40, P33; Adams CL, 2000, J AM VET MED ASSOC, V217, P1303, DOI 10.2460/javma.2000.217.1303; Adrian JAL, 2009, B MENNINGER CLIN, V73, P176, DOI 10.1521/bumc.2009.73.3.176; ARCHER J, 1994, BRIT J PSYCHOL, V85, P259, DOI 10.1111/j.2044-8295.1994.tb02522.x; BARKER SB, 1989, COMPANION ANIM PRACT, V19, P3; COHEN S, 1983, J HEALTH SOC BEHAV, V24, P385, DOI 10.2307/2136404; Dunn KL, 2005, SOC WORK HEALTH CARE, V41, P59, DOI 10.1300/J010v41n02_04; DUPONT WD, 1990, CONTROL CLIN TRIALS, V11, P116, DOI 10.1016/0197-2456(90)90005-M; Edenburg N, 1992, TIJDSCHR DIERGENEESK, V117, P56; Feldmann BM, 2000, J AM VET MED ASSOC, V217, P1473, DOI 10.2460/javma.2000.217.1473; Field NP, 2009, DEATH STUD, V33, P334, DOI 10.1080/07481180802705783; Fogle B., 1992, Anthrozoos, V3, P143, DOI 10.2752/089279390787057568; Frid MH, 2007, J VET BEHAV, V2, P35, DOI 10.1016/j.jveb.2007.02.001; Garrity TF., 1989, ANTHROZOOS, V3, P35, DOI DOI 10.2752/089279390787057829; Graf S, 1996, PSYCHOL REP, V78, P467; HANCOCK G, 1989, VET CLIN N AM-SMALL, V19, P187, DOI 10.1016/S0195-5616(89)50013-5; HART LA, 1990, J AM VET MED ASSOC, V197, P1292; Hawley DR, 1996, FAM PROCESS, V35, P283, DOI 10.1111/j.1545-5300.1996.00283.x; Hawthorne G, 2006, SOC INDIC RES, V77, P37, DOI 10.1007/s11205-005-5552-1; Headey B, 2003, MED J AUSTRALIA, V179, P460, DOI 10.5694/j.1326-5377.2003.tb05646.x; Kaufman KR, 2009, DEATH STUD, V30, P61; KEDDIE KMG, 1977, BRIT J PSYCHIAT, V131, P21, DOI 10.1192/bjp.131.1.21; Kellehear A, 1996, OMEGA-J DEATH DYING, V34, P191, DOI 10.2190/3Q32-2FH7-JMG6-M1DN; Kim HS, 2008, AM PSYCHOL, V63, P518, DOI 10.1037/0003-066X; Knight S, 2008, J AGING HEALTH, V20, P437, DOI 10.1177/0898264308315875; Kolodny S W, 1991, Probl Vet Med, V3, P1; Kurdek LA, 2008, J SOC PERS RELAT, V25, P247, DOI 10.1177/0265407507087958; Kurdek LA, 2009, ANTHROZOOS, V22, P359, DOI 10.2752/089279309X12538695316149; Kushnir T, 2009, ASS PRIMARY PHYS BUR; KUYKEN W, 1994, INT J MENT HEALTH, V23, P24, DOI 10.1080/00207411.1994.11449286; Lewis A., 2009, ELECT J APPL PSYCHOL, V5, P96, DOI [DOI 10.7790/ejap.v5i1.138, 10.7790/ejap.v5i1.138, DOI 10.7790/EJAP.V5I1.138]; McNicholas J, 2005, BMJ-BRIT MED J, V331, P1252, DOI 10.1136/bmj.331.7527.1252; Nieburg HA, 1982, PET LOSS THOUGHTFUL; NUCKOLLS KB, 1972, AM J EPIDEMIOL, V95, P431, DOI 10.1093/oxfordjournals.aje.a121410; Parslow RA, 2003, MED J AUSTRALIA, V179, P466, DOI 10.5694/j.1326-5377.2003.tb05649.x; Planchon LA, 1996, ANTHROZOOS, V9, P107, DOI 10.2752/089279396787001491; RAJARAM SS, 1993, ANTHROZOOS, V6, P8, DOI 10.2752/089279393787002349; ROSENBERG MA, 1981, CANINE PRACT, V8, P6; Schmaltz HN, 2007, J GEN INTERN MED, V22, P572, DOI 10.1007/s11606-007-0106-7; SERPELL J, 1991, J ROY SOC MED, V84, P717, DOI 10.1177/014107689108401208; SHIRLEY VA, 1983, GERONTOLOGIST, V23, P276; STEWART CS, 1985, DEATH STUD, V9, P383, DOI 10.1080/07481188508252532; Stroebe W, 1987, BEREAVEMENT HLTH; Tzivian L, 2014, DEATH STUD, V38, P109, DOI 10.1080/07481187.2012.738764; Walsh F, 2009, FAM PROCESS, V48, P481, DOI 10.1111/j.1545-5300.2009.01297.x; WATSON D, 1989, PSYCHOL REV, V96, P234, DOI 10.1037/0033-295X.96.2.234; Wilson C. C, 1998, COMPANION ANIMALS HU; Winius EED, 1996, TIJDSCHR DIERGENEESK, V121, P250; Wrobel TA, 2003, OMEGA-J DEATH DYING, V47, P385, DOI 10.2190/QYV5-LLJ1-T043-U0F9; ZIMET GD, 1988, J PERS ASSESS, V52, P30, DOI 10.1207/s15327752jpa5201_2	50	10	10	1	54	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 31	2015	10	3							e0121081	10.1371/journal.pone.0121081	http://dx.doi.org/10.1371/journal.pone.0121081			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	CE8IF	25826295	Green Published, Green Submitted, gold			2023-01-03	WOS:000352084800034
J	Han, P; Liu, SB; Zhang, MT; Zhao, J; Wang, YQ; Wu, GC; Mi, WL				Han, Ping; Liu, Shenbin; Zhang, Mengting; Zhao, Jing; Wang, Yanqing; Wu, Gencheng; Mi, Wenli			Inhibition of Spinal Interlukin-33/ST2 Signaling and Downstream ERK and JNK Pathways in Electroacupuncture Analgesia in Formalin Mice	PLOS ONE			English	Article							INDUCED INFLAMMATORY PAIN; ADJUNCTIVE THERAPY; ANTI-HYPERALGESIA; CONTROLLED-TRIAL; ACUPUNCTURE; RATS; INTERLEUKIN-33; MODEL; IL-33; INVOLVEMENT	Although acupuncture is widely used to manage pain, it remains highly controversial, largely due to the lack of a clear mechanism for its benefits. Here, we investigated the role of IL-33, a novel interleukin (IL)-1 family member, and its receptor ST2 in the analgesic effects of electroacupuncture (EA) on formalin-induced inflammatory pain. The results showed that 1) EA stimulation of ipsilateral Zusanli (ST 36) and Yanglingquan (GB 34) acupoints for 30 min remarkably suppressed the two phases of formalin-induced spontaneous pain; 2) subcutaneous or intrathecal administration of recombinant IL-33 (rIL-33) significantly inhibited the analgesic effect of EA, whereas the ST2 antibody potentiated EA analgesia in formalin mice; 3) EA treatment decreased the up-regulation of IL-33 and ST2 protein following formalin injection; and 4) the suppression of the formalin-induced expression of spinal phosphorylated ERK and JNK induced by EA treatment was significantly attenuated following subcutaneous rIL-33 delivery, and was further decreased by the ST2 antibody. These data suggest that EA alleviates formalin-induced inflammatory pain, at least partially, by inhibiting of spinal IL-33/ST2 signaling and the downstream ERK and JNK pathways.	[Han, Ping; Liu, Shenbin; Zhang, Mengting; Zhao, Jing; Wang, Yanqing; Wu, Gencheng; Mi, Wenli] Fudan Univ, Dept Integrat Med & Neurobiol, Collaborat Innovat Ctr Brain Sci, Sch Basic Med Sci,State Key Lab Med Neurobiol,Ins, Shanghai 200433, Peoples R China; [Han, Ping] Shanghai Jiao Tong Univ, Med X Res Inst, Neurosci & Neuroengn Ctr, Shanghai 200030, Peoples R China	Fudan University; Shanghai Jiao Tong University	Mi, WL (corresponding author), Fudan Univ, Dept Integrat Med & Neurobiol, Collaborat Innovat Ctr Brain Sci, Sch Basic Med Sci,State Key Lab Med Neurobiol,Ins, Shanghai 200433, Peoples R China.	wenlimi@fudan.edu.cn	Mi, Wenli/P-5541-2019; Han, Ping/GYD-5588-2022	Han, Ping/0000-0001-7945-2613	National Key Basic Research Program of China [2013CB531906]; National Natural Science Foundation of China [31000495, 81171045, 81371247, 81473749]; National Natural Science Foundation of Shanghai [15ZR1402800]	National Key Basic Research Program of China(National Basic Research Program of China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Natural Science Foundation of Shanghai	This work was supported by the National Key Basic Research Program of China (2013CB531906), the National Natural Science Foundation of China (31000495, 81171045, 81371247, and 81473749) and the National Natural Science Foundation of Shanghai (15ZR1402800).	Andre R, 2005, J NEUROCHEM, V95, P324, DOI 10.1111/j.1471-4159.2005.03364.x; Berman BM, 2004, ANN INTERN MED, V141, P901, DOI 10.7326/0003-4819-141-12-200412210-00006; Chang KH, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/324039; Chen XY, 2013, J PAIN, V14, P1310, DOI 10.1016/j.jpain.2013.05.011; Choi SS, 2006, BRAIN RES, V1108, P28, DOI 10.1016/j.brainres.2006.06.048; Crown ED, 2012, EXP NEUROL, V234, P330, DOI 10.1016/j.expneurol.2011.10.019; Du Jing, 2008, Zhen Ci Yan Jiu, V33, P37; DUBUISSON D, 1977, PAIN, V4, P161, DOI 10.1016/0304-3959(77)90130-0; Fang JQ, 2013, MOL PAIN, V9, DOI 10.1186/1744-8069-9-13; Funakoshi-Tago M, 2011, CELL SIGNAL, V23, P363, DOI 10.1016/j.cellsig.2010.10.006; Goldman N, 2010, NAT NEUROSCI, V13, P883, DOI 10.1038/nn.2562; Han JS, 2003, TRENDS NEUROSCI, V26, P17, DOI 10.1016/S0166-2236(02)00006-1; Han P, 2013, NEUROSCIENCE, V241, P59, DOI 10.1016/j.neuroscience.2013.03.019; Han P, 2011, NEUROSCI BULL, V27, P351, DOI 10.1007/s12264-011-1025-5; Ji RR, 2009, BRAIN RES REV, V60, P135, DOI 10.1016/j.brainresrev.2008.12.011; Jiang HR, 2012, EUR J IMMUNOL, V42, P1804, DOI 10.1002/eji.201141947; Kakkar R, 2008, NAT REV DRUG DISCOV, V7, P827, DOI 10.1038/nrd2660; Lee JY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073948; Leung L, 2012, J ACUPUNCT MERIDIAN, V5, P261, DOI 10.1016/j.jams.2012.07.017; Magro DAC, 2013, BRAZ J MED BIOL RES, V46, P601, DOI 10.1590/1414-431X20132894; Mao-Ying QL, 2006, EUR J PAIN, V10, P689, DOI 10.1016/j.ejpain.2005.11.001; Martin MU, 2013, SEMIN IMMUNOL, V25, P449, DOI 10.1016/j.smim.2013.10.006; Mavrommatis CI, 2012, PAIN, V153, P1720, DOI 10.1016/j.pain.2012.05.005; Mi WL, 2008, BRAIN RES BULL, V77, P98, DOI 10.1016/j.brainresbull.2008.04.008; Mi WL, 2011, J PAIN, V12, P974, DOI 10.1016/j.jpain.2011.03.002; Miller AM, 2011, PHARMACOL THERAPEUT, V131, P179, DOI 10.1016/j.pharmthera.2011.02.005; Park JY, 2014, J PAIN; Schmitz J, 2005, IMMUNITY, V23, P479, DOI 10.1016/j.immuni.2005.09.015; Song MJ, 2009, BRAIN RES BULL, V78, P335, DOI 10.1016/j.brainresbull.2008.10.009; Su TF, 2012, EUR J PAIN, V16, P624, DOI 10.1002/j.1532-2149.2011.00055.x; TJOLSEN A, 1992, PAIN, V51, P5, DOI 10.1016/0304-3959(92)90003-T; Vas J, 2012, PAIN, V153, P1883, DOI 10.1016/j.pain.2012.05.033; Verri WA, 2008, P NATL ACAD SCI USA, V105, P2723, DOI 10.1073/pnas.0712116105; Vickers AJ, 2012, ARCH INTERN MED, V172, P1444, DOI 10.1001/archinternmed.2012.3654; Villarreal DO, 2014, CURR OPIN IMMUNOL, V28, P102, DOI 10.1016/j.coi.2014.03.004; Yasuoka S, 2011, BRAIN RES, V1385, P8, DOI 10.1016/j.brainres.2011.02.045; Yi M, 2011, MOL PAIN, V7, DOI 10.1186/1744-8069-7-61; Zarpelon AC, 2013, BRIT J PHARMACOL, V169, P90, DOI 10.1111/bph.12110; Zhang RX, 2014, ANESTHESIOLOGY, V120, P482, DOI 10.1097/ALN.0000000000000101; Zhao J, 2013, NEUROSCIENCE, V253, P172, DOI 10.1016/j.neuroscience.2013.08.026; Zhao ZQ, 2008, PROG NEUROBIOL, V85, P355, DOI 10.1016/j.pneurobio.2008.05.004; ZIMMERMANN M, 1983, PAIN, V16, P109, DOI 10.1016/0304-3959(83)90201-4	42	24	31	0	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 12	2015	10	6							e0129576	10.1371/journal.pone.0129576	http://dx.doi.org/10.1371/journal.pone.0129576			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CK6GR	26067287	Green Published, gold, Green Submitted			2023-01-03	WOS:000356327000092
J	Park, TW; Saitz, R; Ganoczy, D; Ilgen, MA; Bohnert, ASB				Park, Tae Woo; Saitz, Richard; Ganoczy, Dara; Ilgen, Mark A.; Bohnert, Amy S. B.			Benzodiazepine prescribing patterns and deaths from drug overdose among US veterans receiving opioid analgesics: case-cohort study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							RISK; MORTALITY; PRESCRIPTIONS; PREVENTION; SUICIDE	OBJECTIVE To study the association between benzodiazepine prescribing patterns including dose, type, and dosing schedule and the risk of death from drug overdose among US veterans receiving opioid analgesics. DESIGN Case-cohort study. Setting Veterans Health Administration (VHA), 2004-09. Participants US veterans, primarily male, who received opioid analgesics in 2004-09. All veterans who died from a drug overdose (n=2400) while receiving opioid analgesics and a random sample of veterans (n=420 386) who received VHA medical services and opioid analgesics. MAIN OUTCOME MEASURE Death from drug overdose, defined as any intentional, unintentional, or indeterminate death from poisoning caused by any drug, determined by information on cause of death from the National Death Index. RESULTS During the study period 27% (n=112 069) of veterans who received opioid analgesics also received benzodiazepines. About half of the deaths from drug overdose (n=1185) occurred when veterans were concurrently prescribed benzodiazepines and opioids. Risk of death from drug overdose increased with history of benzodiazepine prescription: adjusted hazard ratios were 2.33 (95% confidence interval 2.05 to 2.64) for former prescriptions versus no prescription and 3.86 (3.49 to 4.26) for current prescriptions versus no prescription. Risk of death from drug overdose increased as daily benzodiazepine dose increased. Compared with clonazepam, temazepam was associated with a decreased risk of death from drug overdose (0.63, 0.48 to 0.82). Benzodiazepine dosing schedule was not associated with risk of death from drug overdose. CONCLUSIONS Among veterans receiving opioid analgesics, receipt of benzodiazepines was associated with an increased risk of death from drug overdose in a dose-response fashion.	[Park, Tae Woo] Brown Univ, Warren Alpert Med Sch, Dept Med, Providence, RI 02903 USA; [Park, Tae Woo] Brown Univ, Warren Alpert Med Sch, Dept Psychiat, Providence, RI 02903 USA; [Park, Tae Woo] Brown Univ, Warren Alpert Med Sch, Dept Human Behav, Providence, RI 02903 USA; [Saitz, Richard] Boston Univ, Sch Publ Hlth, Dept Community Hlth Sci, Boston, MA 02118 USA; [Ganoczy, Dara; Ilgen, Mark A.; Bohnert, Amy S. B.] HSR&D, Dept Vet Affairs, Ann Arbor, MI 48105 USA; [Bohnert, Amy S. B.] Univ Michigan, Sch Med, Dept Psychiat, Ann Arbor, MI 48109 USA	Brown University; Brown University; Brown University; Boston University; University of Michigan System; University of Michigan	Park, TW (corresponding author), Brown Univ, Warren Alpert Med Sch, Dept Med, 111 Plain St, Providence, RI 02903 USA.	tpark1@lifespan.org		/0000-0002-2535-1427	Veteran Affairs Health Services Research and Development Service Career Development Award [CDA-09-204]; National Institutes of Health [R03 AG042899]; NATIONAL INSTITUTE ON AGING [R03AG042899] Funding Source: NIH RePORTER	Veteran Affairs Health Services Research and Development Service Career Development Award; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	This work was supported by funding from a Veteran Affairs Health Services Research and Development Service Career Development Award (CDA-09-204; ASBB.) and by the National Institutes of Health (R03 AG042899). The sponsors had no role in the design and conduct of the study; in the collection, analysis, and interpretation of the data; or in the preparation, review, or approval of the manuscript of the decision to submit.	Arbogast PG, 2009, STAT METHODS MED RES, V18, P67, DOI 10.1177/0962280208092347; Beletsky L, 2012, JAMA-J AM MED ASSOC, V308, P1863, DOI 10.1001/jama.2012.14205; Bohnert ASB, 2012, AM J PSYCHIAT, V169, P64, DOI 10.1176/appi.ajp.2011.10101476; Bohnert ASB, 2011, JAMA-J AM MED ASSOC, V305, P1315, DOI 10.1001/jama.2011.370; Bohnert ASB, 2011, MED CARE, V49, P393, DOI 10.1097/MLR.0b013e318202aa27; Buckley NA, 1995, BMJ-BRIT MED J, V310, P21; Center for Substance Abuse Treatment, 2005, DHHS PUBL NO SMA, V(SMA) 05-4048; Centers for Disease Control and Prevention, NAT VIT STAT; Centers for Disease Control and Prevention, NAT DEATH IND; Cone EJ, 2004, J ANAL TOXICOL, V28, P616, DOI 10.1093/jat/28.7.616; Dunn KM, 2010, ANN INTERN MED, V152, P85, DOI 10.7326/0003-4819-152-2-201001190-00006; Ekstrom MP, 2014, BMJ-BRIT MED J, V348, pg445, DOI DOI 10.1136/BMJ.G445; Galanter M, 2008, TXB SUBSTANCE ABUSE; Gammaitoni AR, 2003, CLIN J PAIN, V19, P286, DOI 10.1097/00002508-200309000-00002; Gomes T, 2011, ARCH INTERN MED, V171, P686, DOI 10.1001/archinternmed.2011.117; Hawkins EJ, 2013, J ADDICT MED, V7, P354, DOI 10.1097/ADM.0b013e31829e3957; Hermos JA, 2004, ARCH INTERN MED, V164, P2361, DOI 10.1001/archinte.164.21.2361; Isbister GK, 2004, BRIT J CLIN PHARMACO, V58, P88, DOI 10.1111/j.1365-2125.2004.02089.x; Jones CM, 2013, JAMA-J AM MED ASSOC, V309, P657, DOI 10.1001/jama.2013.272; Krieger N, GEOCODING MONITORING; Langholz B, 2007, COMPUT STAT DATA AN, V51, P3737, DOI 10.1016/j.csda.2006.12.028; Lindqvist P, 2002, FORENSIC SCI INT, V128, P136, DOI 10.1016/S0379-0738(02)00188-3; Morasco BJ, 2010, PAIN, V151, P625, DOI 10.1016/j.pain.2010.08.002; Okie S, 2010, NEW ENGL J MED, V363, P1981, DOI 10.1056/NEJMp1011512; Paulozzi LJ, 2006, PHARMACOEPIDEM DR S, V15, P618, DOI 10.1002/pds.1276; Paulozzi LJ, 2012, J SAFETY RES, V43, P283, DOI 10.1016/j.jsr.2012.08.009; Pfeiffer PN, 2009, DEPRESS ANXIETY, V26, P752, DOI 10.1002/da.20583; PRENTICE RL, 1986, BIOMETRIKA, V73, P1; Prommer E, 2006, SUPPORT CARE CANCER, V14, P109, DOI 10.1007/s00520-005-0917-1; Quan HD, 2005, MED CARE, V43, P1130, DOI 10.1097/01.mlr.0000182534.19832.83; Salas M, 1999, AM J EPIDEMIOL, V149, P981; SALZMAN C, 1991, AM J PSYCHIAT, V148, P151; Saunders KW, 2012, J PAIN, V13, P266, DOI 10.1016/j.jpain.2011.11.004; Sgadari A, 2000, J CLIN PSYCHOPHARM, V20, P234, DOI 10.1097/00004714-200004000-00017; Suissa S, 2008, AM J EPIDEMIOL, V167, P492, DOI 10.1093/aje/kwm324; Valenstein M, 2004, AM J PSYCHIAT, V161, P654, DOI 10.1176/appi.ajp.161.4.654; Wysowski DK, 2007, DRUG SAFETY, V30, P533, DOI 10.2165/00002018-200730060-00007	37	353	355	2	32	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 10	2015	350								h2698	10.1136/bmj.h2698	http://dx.doi.org/10.1136/bmj.h2698			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CK7CZ	26063215	hybrid, Green Published			2023-01-03	WOS:000356389600003
J	Sandak, B; Huss, E; Sarid, O; Harel, D				Sandak, Billie; Huss, Ephrat; Sarid, Orly; Harel, David			Computational Paradigm to Elucidate the Effects of Arts-Based Approaches and Interventions: Individual and Collective Emerging Behaviors in Artwork Construction	PLOS ONE			English	Article							MUSIC-THERAPY; CANCER; DANCE; STATECHARTS; SYMPTOMS; DISEASE; QUALITY; PEOPLE; HEALTH; PAIN	Art therapy, as well as other arts-based therapies and interventions, is used to reduce pain, stress, depression, breathlessness and other symptoms in a wide variety of serious and chronic diseases, such as cancer, Alzheimer and schizophrenia. Arts-based approaches are also known to contribute to one's well-being and quality of life. However, much research is required, since the mechanisms by which these non-pharmacological treatments exert their therapeutic and psychosocial effects are not adequately understood. A typical clinical setting utilizing the arts consists of the creation work itself, such as the artwork, as well as the therapist and the patient, all of which constitute a rich and dynamic environment of occurrences. The underlying complex, simultaneous and interwoven processes of this setting are often considered intractable to human observers, and as a consequence are usually interpreted subjectively and described verbally, which affect their subsequent analyses and understanding. We introduce a computational research method for elucidating and analyzing emergent expressive and social behaviors, aiming to understand how arts-based approaches operate. Our methodology, which centers on the visual language of Statecharts and tools for its execution, enables rigorous qualitative and quantitative tracking, analysis and documentation of the underlying creation and interaction processes. Also, it enables one to carry out exploratory, hypotheses-generating and knowledge discovery investigations, which are empirical-based. Furthermore, we illustrate our method's use in a proof-of-principle study, applying it to a real-world artwork investigation with human participants. We explore individual and collective emergent behaviors impacted by diverse drawing tasks, yielding significant gender and age hypotheses, which may account for variation factors in response to art use. We also discuss how to gear our research method to systematic and mechanistic investigations, as we wish to provide a broad empirical evidence for the uptake of arts-based approaches, also aiming to ameliorate their use in clinical settings.	[Sandak, Billie; Harel, David] Weizmann Inst Sci, Fac Math & Comp Sci, Dept Comp Sci & Appl Math, IL-76100 Rehovot, Israel; [Huss, Ephrat; Sarid, Orly] Ben Gurion Univ Negev, Fac Humanities & Social Sci, Spitzer Dept Social Work, IL-84105 Beer Sheva, Israel	Weizmann Institute of Science; Ben Gurion University	Sandak, B (corresponding author), Weizmann Inst Sci, Fac Math & Comp Sci, Dept Comp Sci & Appl Math, IL-76100 Rehovot, Israel.	billie.sandak@alumni.weizmann.ac.il		Sarid, Orly/0000-0002-6967-8755; Huss, Ephrat/0000-0003-3121-977X	Braginsky Center for the Interface between Science and the Humanities, at the Weizmann Institute of Science	Braginsky Center for the Interface between Science and the Humanities, at the Weizmann Institute of Science	The authors thank the Braginsky Center for the Interface between Science and the Humanities, at the Weizmann Institute of Science (http://www.weizmann.ac.il/pages/research-institutes-institute-wide), for support. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Allen P. B., 1995, ART IS WAY KNOWING G; Ball B, 2002, ART PSYCHOTHER, V29, P79, DOI 10.1016/S0197-4556(02)00138-7; Bar-Sela G, 2007, PSYCHO-ONCOLOGY, V16, P980, DOI 10.1002/pon.1175; Batson G, 2014, PHYS OCCUP THER GERI, V32, P188, DOI 10.3109/02703181.2014.927946; Belkofer CM, 2014, ART THER, V31, P61, DOI 10.1080/07421656.2014.903821; Benesh Rudolf, 1983, READING DANCE BIRTH; Bergstrom-Nielsen C., 2009, MUSIC THERAPY SPECIA, V1, P72, DOI [10.3389/fpsyg.2014.00706, DOI 10.3389/FPSYG.2014.00706]; Bittman BB, 2001, ALTERN THER HEALTH M, V7, P38; Bolwerk A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101035; Burns SJI, 2001, ALTERN THER HEALTH M, V7, P48; Chanda ML, 2013, TRENDS COGN SCI, V17, P179, DOI 10.1016/j.tics.2013.02.007; Chapman L., 2001, ART THER, V18, P100, DOI [10.1080/07421656.2001.10129750, DOI 10.1080/07421656.2001.10129750]; COHEN BM, 1988, ART PSYCHOTHER, V15, P11, DOI 10.1016/0197-4556(88)90048-2; Cruz RF, 2013, ART SCI EVALUATION A; Czamanski-Cohen J, 2014, ART PSYCHOTHER, V41, P320, DOI 10.1016/j.aip.2014.05.002; Dalley T, 2009, ART THERAPY INTRO US; Dassa A, 2014, J MUSIC THER, V51, P131, DOI 10.1093/jmt/thu007; Devlin B, 2006, INT J PALLIAT NURS, V12, P16, DOI 10.12968/ijpn.2006.12.1.20391; Dileo Cheryl, 2006, J Soc Integr Oncol, V4, P67, DOI 10.2310/7200.2006.002; Douglass B. P., 1998, Lectures on Embedded Systems. European Educational Forum School on Embedded Systems, P368; Drusinsky D, 1987, P IEEE CAD C SANT CL; Ekman P., 1999, HDB COGNITION EMOTIO, P301, DOI [DOI 10.1002/0470013494.CH16, 10.1002/0470013494.ch16]; Eshkol N, 1958, MOVEMENT NOTATION; Everingham M, 2014, INT J COMPUT VISION, P1; Fridin M., 2009, P S MENT STAT EM THE; Gantt LM, 2001, ART THER, V18, P51, DOI DOI 10.1080/07421656.2001.10129453; Gilboa A, 2007, MUSIC THER PERSPECT, V25, P32, DOI 10.1093/mtp/25.1.32; Gold C, 2009, CLIN PSYCHOL REV, V29, P193, DOI 10.1016/j.cpr.2009.01.001; Graham JE, 2008, J BEHAV MED, V31, P201, DOI 10.1007/s10865-008-9149-4; Greenberg LS, 1994, REASSESSING PSYCHOTH, P114; GUZZETTA CE, 1989, HEART LUNG, V18, P609; HAREL D, 1988, COMMUN ACM, V31, P514, DOI 10.1145/42411.42414; HAREL D, 1987, SCI COMPUT PROGRAM, V8, P231, DOI 10.1016/0167-6423(87)90035-9; Harel D, 2004, LECT NOTES COMPUT SC, V3147, P325; Harel D., 1985, LOGICS MODELS CONCUR, P477, DOI [10.1007/978-3-642-82453-1_17, DOI 10.1007/978-3-642-82453-1_17]; Hilliard RE, 2003, J MUSIC THER, V40, P113, DOI 10.1093/jmt/40.2.113; Huss E, 2014, ART PSYCHOTHER, V41, P409, DOI 10.1016/j.aip.2014.07.004; Huss E, 2009, ART PSYCHOTHER, V36, P154, DOI 10.1016/j.aip.2009.01.003; Hutchinson A, 1987, LABANOTATION SYSTEM, P528; Italia S, 2008, PSYCHO-ONCOLOGY, V17, P676, DOI 10.1002/pon.1293; Jones P., 2005, ARTS THERAPIES REVOL; Junge MB, 1994, HIST THERAPY US; Kam N, 2001, P VIS LANG FORM METH; Kiepe MS, 2012, ART PSYCHOTHER, V39, P404, DOI 10.1016/j.aip.2012.06.001; Kim SI, 2010, ART PSYCHOTHER, V37, P378, DOI 10.1016/j.aip.2010.09.002; Koch S, 2014, ART PSYCHOTHER, V41, P46, DOI 10.1016/j.aip.2013.10.004; Kruk KA, 2014, ART THER, V31, P52, DOI 10.1080/07421656.2014.903826; Kumar AM, 1999, ALTERN THER HEALTH M, V5, P49; Lindblad F, 2007, STRESS HEALTH, V23, P9, DOI 10.1002/smi.1109; Malchiodi C., 2012, ART THERAPY HEALTHCA; Marsella S, 2014, COMMUN ACM, V57, P56, DOI 10.1145/2631912; Mason J., 2018, QUALITATIVE RES, V3rd; McLean C. L., 2014, CREATIVE ARTS HUMANE; McNiff S., 1992, ART MED; Monti DA, 2006, PSYCHO-ONCOL, V15, P363, DOI 10.1002/pon.988; Nainis N, 2006, J PAIN SYMPTOM MANAG, V31, P162, DOI 10.1016/j.jpainsymman.2005.07.006; Orr P, 2012, ART PSYCHOTHER, V39, P234, DOI 10.1016/j.aip.2012.03.010; Pacchetti C, 2000, PSYCHOSOM MED, V62, P386, DOI 10.1097/00006842-200005000-00012; Park H., 2011, SCI SOCIAL VISION, P75, DOI 10.1093/acprof:oso/9780195333176.003.0004; Perruzza N, 2010, BRIT J OCCUP THER, V73, P261, DOI 10.4276/030802210X12759925468943; Reuderink B, 2008, LECT NOTES COMPUT SC, V5237, P137, DOI 10.1007/978-3-540-85853-9_13; Richardson P., 2007, J MENT HEALTH, V16, P483, DOI [DOI 10.1080/09638230701483111, https://doi.org/10.1080/09638230701483111]; Sandak B, 1998, PROTEINS, V32, P159, DOI 10.1002/(SICI)1097-0134(19980801)32:2<159::AID-PROT3>3.3.CO;2-U; Sandak B, 1998, J COMPUT BIOL, V5, P631, DOI 10.1089/cmb.1998.5.631; Sandel SL, 2005, CANCER NURS, V28, P301; Sarid O, 2011, ART PSYCHOTHER, V38, P252, DOI 10.1016/j.aip.2011.07.001; Silver R. A., 2005, AGGRESSION DEPRESSIO; Smolen D, 2002, APPL NURS RES, V15, P126, DOI 10.1053/apnr.2002.34140; Sobolev B, 2008, HEALTH CARE MANAG SC, V11, P79, DOI 10.1007/s10729-007-9026-7; Stuckey HL, 2010, AM J PUBLIC HEALTH, V100, P254, DOI 10.2105/AJPH.2008.156497; Swerdlin N, 2008, P IEEE COMP SYST BIO; Thyme Karin Egberg, 2009, Palliat Support Care, V7, P87, DOI 10.1017/S147895150900011X; Tusek D L, 1999, J Cardiovasc Manag, V10, P22; Ullman S., 1996, HIGH LEVEL VISION OB	74	4	4	1	42	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 10	2015	10	6							e0126467	10.1371/journal.pone.0126467	http://dx.doi.org/10.1371/journal.pone.0126467			32	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI); Arts &amp; Humanities Citation Index (A&amp;HCI)	Science & Technology - Other Topics	CK1PO	26061736	gold, Green Published, Green Submitted			2023-01-03	WOS:000355979500015
J	Barroso, SPC; Nico, D; Nascimento, D; Santos, ACV; Couceiro, JNSS; Bozza, FA; Ferreira, AMA; Ferreira, DF; Palatnik-de-Sousa, CB; Souza, TML; Gomes, AMO; Silva, JL; Oliveira, AC				Barroso, Shana P. C.; Nico, Dirlei; Nascimento, Danielle; Santos, Ana Clara V.; Couceiro, Jose Nelson S. S.; Bozza, Fernando A.; Ferreira, Ana M. A.; Ferreira, Davis F.; Palatnik-de-Sousa, Clarisa B.; Souza, Thiago Moreno L.; Gomes, Andre M. O.; Silva, Jerson L.; Oliveira, Andrea C.			Intranasal Immunization with Pressure Inactivated Avian Influenza Elicits Cellular and Humoral Responses in Mice	PLOS ONE			English	Article							FC-ALPHA-RI; HYDROSTATIC-PRESSURE; A-VIRUS; HIGH IMMUNOGENICITY; IMMUNE-RESPONSES; VACCINE; PROTECTION; CHALLENGE; INFECTION; H5N1	Influenza viruses pose a serious global health threat, particularly in light of newly emerging strains, such as the avian influenza H5N1 and H7N9 viruses. Vaccination remains the primary method for preventing acquiring influenza or for avoiding developing serious complications related to the disease. Vaccinations based on inactivated split virus vaccines or on chemically inactivated whole virus have some important drawbacks, including changes in the immunogenic properties of the virus. To induce a greater mucosal immune response, intranasally administered vaccines are highly desired as they not only prevent disease but can also block the infection at its primary site. To avoid these drawbacks, hydrostatic pressure has been used as a potential method for viral inactivation and vaccine production. In this study, we show that hydrostatic pressure inactivates the avian influenza A H3N8 virus, while still maintaining hemagglutinin and neuraminidase functionalities. Challenged vaccinated animals showed no disease signs (ruffled fur, lethargy, weight loss, and huddling). Similarly, these animals showed less Evans Blue dye leakage and lower cell counts in their bronchoalveolar lavage fluid compared with the challenged non-vaccinated group. We found that the whole inactivated particles were capable of generating a neutralizing antibody response in serum, and IgA was also found in nasal mucosa and feces. After the vaccination and challenge we observed Th1/Th2 cytokine secretion with a prevalence of IFN-gamma Our data indicate that the animals present a satisfactory immune response after vaccination and are protected against infection. Our results may pave the way for the development of a novel pressure-based vaccine against influenza virus.	[Barroso, Shana P. C.; Santos, Ana Clara V.; Gomes, Andre M. O.; Silva, Jerson L.; Oliveira, Andrea C.] Univ Fed Rio de Janeiro, Inst Bioquim Med Leopoldo de Meis, BR-21941902 Rio De Janeiro, RJ, Brazil; [Barroso, Shana P. C.; Santos, Ana Clara V.; Bozza, Fernando A.; Gomes, Andre M. O.; Silva, Jerson L.; Oliveira, Andrea C.] Inst Nacl Ciencia & Tecnol Biol Estrutural & Bioi, Rio De Janeiro, Brazil; [Nico, Dirlei; Couceiro, Jose Nelson S. S.; Ferreira, Ana M. A.; Ferreira, Davis F.; Palatnik-de-Sousa, Clarisa B.] Univ Fed Rio de Janeiro, Inst Microbiol Paulo Goes, BR-21941590 Rio De Janeiro, RJ, Brazil; [Nascimento, Danielle; Bozza, Fernando A.] Fundacao Oswaldo Cruz FIOCRUZ, Fundacao Pesquisa Clin Evandro Chagas, Rio De Janeiro, RJ, Brazil; [Barroso, Shana P. C.; Souza, Thiago Moreno L.] Fiocruz MS, Inst Oswaldo Cruz, WHO NIC, Lab Virus Resp, BR-21045900 Rio De Janeiro, RJ, Brazil	Universidade Federal do Rio de Janeiro; Universidade Federal do Rio de Janeiro; Fundacao Oswaldo Cruz; Fundacao Oswaldo Cruz	Oliveira, AC (corresponding author), Univ Fed Rio de Janeiro, Inst Bioquim Med Leopoldo de Meis, BR-21941902 Rio De Janeiro, RJ, Brazil.	cheble@bioqmed.ufrj.br	NASCIMENTO, DANIELLE/ABE-1057-2020; Ferreira, Davis/D-9356-2014; Gomes, Andre M.O./C-4009-2014; Bozza, Fernando A/A-2618-2013; Souza, Thiago Moreno L./G-2900-2012; SILVA, JERSON Lima/GRF-1442-2022; Silva, Jerson/J-8984-2014; Barroso, Shana/ABH-9716-2020; Nico, Dirlei/GZA-3726-2022; Couceiro, José Nelson SS/J-3933-2016; Oliveira, Andrea C/O-6695-2018	NASCIMENTO, DANIELLE/0000-0001-8946-6998; Gomes, Andre M.O./0000-0003-1052-8004; Bozza, Fernando A/0000-0003-4878-0256; Souza, Thiago Moreno L./0000-0003-2212-3899; SILVA, JERSON Lima/0000-0001-9523-9441; Silva, Jerson/0000-0001-9523-9441; Couceiro, José Nelson SS/0000-0001-8712-4847; Barroso, Shana/0000-0001-7890-9255; de Amorim Ferreira, Ana Maria/0000-0003-2507-0171; Palatnik-de-Sousa, Clarisa B./0000-0002-6231-0608	Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq); Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES); Fundacao Carlos Chagas Filho de Amparo a Pesquisa do Estado do Rio de Janeiro (FAPERJ); Instituto Milenio de Biologia Estrutural em Biomedicina e Biotecnologia (IMBEBB); Instituto Nacional de Ciencia e Tecnologia de Biologia Estrutural e Bioimagem (INBEB); Programa de Apoio a Nucleos de Excelencia (PRONEX)	Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq)(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)); Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)(Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)); Fundacao Carlos Chagas Filho de Amparo a Pesquisa do Estado do Rio de Janeiro (FAPERJ)(Fundacao Carlos Chagas Filho de Amparo a Pesquisa do Estado do Rio De Janeiro (FAPERJ)); Instituto Milenio de Biologia Estrutural em Biomedicina e Biotecnologia (IMBEBB); Instituto Nacional de Ciencia e Tecnologia de Biologia Estrutural e Bioimagem (INBEB); Programa de Apoio a Nucleos de Excelencia (PRONEX)	This work was supported by grants from Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq), Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES), Fundacao Carlos Chagas Filho de Amparo a Pesquisa do Estado do Rio de Janeiro (FAPERJ), Instituto Milenio de Biologia Estrutural em Biomedicina e Biotecnologia (IMBEBB), Instituto Nacional de Ciencia e Tecnologia de Biologia Estrutural e Bioimagem (INBEB), and Programa de Apoio a Nucleos de Excelencia (PRONEX) to J.L.S., A.M.O.G., and A.C.O. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adams S, 2010, MED PRIN PRACT, V19, P421, DOI 10.1159/000320299; Amorij JP, 2008, PHARM RES-DORDR, V25, P1256, DOI 10.1007/s11095-008-9559-6; [Anonymous], 2003, INFL OV; Asanuma H, 2007, VACCINE, V25, P6975, DOI 10.1016/j.vaccine.2007.06.060; Aucouturier J, 2001, VACCINE, V19, P2666, DOI 10.1016/S0264-410X(00)00498-9; Belser JA, 2010, J VIROL, V84, P4194, DOI 10.1128/JVI.02742-09; Boonyaratanakornkit BB, 2002, BBA-PROTEIN STRUCT M, V1595, P235, DOI 10.1016/S0167-4838(01)00347-8; Calci KR, 2005, APPL ENVIRON MICROB, V71, P339, DOI 10.1128/AEM.71.1.339-343.2005; Capua I, 2004, AVIAN PATHOL, V33, P393, DOI 10.1080/03079450410001724085; Carrat F, 2007, VACCINE, V25, P6852, DOI 10.1016/j.vaccine.2007.07.027; Castleman WL, 2010, VET PATHOL, V47, P507, DOI 10.1177/0300985810363718; Ceylan C, 2012, VET MICROBIOL, V154, P266, DOI 10.1016/j.vetmic.2011.07.026; Chawla R, 2011, J FOOD SCI TECH MYS, V48, P260, DOI 10.1007/s13197-010-0180-4; Committee for Proprietary Medicinal Products, 1997, NOT GUID HARM REQ IN; Cox RJ, 2009, INFLUENZA OTHER RESP, V3, P107, DOI 10.1111/j.1750-2659.2009.00082.x; Cox RJ, 2004, SCAND J IMMUNOL, V59, P1, DOI 10.1111/j.0300-9475.2004.01382.x; Crawford PC, 2005, SCIENCE, V310, P482, DOI 10.1126/science.1117950; Dumard CH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080785; Epstein SL, 2002, EMERG INFECT DIS, V8, P796; Freitas TRP, 2003, J VIROL METHODS, V108, P205, DOI 10.1016/S0166-0934(02)00289-6; Fukushi M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021207; Gaspar LP, 2008, J VIROL METHODS, V150, P57, DOI 10.1016/j.jviromet.2008.03.002; Geeraedts F, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000138; Geeraedts F, 2008, INFLUENZA OTHER RESP, V2, P41, DOI 10.1111/j.1750-2659.2008.00038.x; Gehlen Marcelo Luiz, 2004, Arq. Bras. Oftalmol., V67, P219, DOI 10.1590/S0004-27492004000200007; Gomes AMO, 2003, BIOCHEMISTRY-US, V42, P5540, DOI 10.1021/bi027207k; Hannoun C, 2004, VIRUS RES, V103, P133, DOI 10.1016/j.virusres.2004.02.025; Hehme N, 2002, MED MICROBIOL IMMUN, V191, P203, DOI 10.1007/s00430-002-0147-9; Heremans K, 1998, BBA-PROTEIN STRUCT M, V1386, P353, DOI 10.1016/S0167-4838(98)00102-2; Hierholzer JC, 1995, VIROLOGY METHODS MAN, P25; Hoffman AM, 1997, VET CLIN N AM-EQUINE, V13, P463, DOI 10.1016/S0749-0739(17)30224-9; INGRAM DK, 1982, MECH AGEING DEV, V20, P253, DOI 10.1016/0047-6374(82)90092-6; JAKAB GJ, 1983, AM REV RESPIR DIS, V128, P730; JURKIEWICZ E, 1995, P NATL ACAD SCI USA, V92, P6935, DOI 10.1073/pnas.92.15.6935; KIDA H, 1987, VIROLOGY, V159, P109, DOI 10.1016/0042-6822(87)90353-9; Kingsley DH, 2007, APPL ENVIRON MICROB, V73, P581, DOI 10.1128/AEM.02117-06; Koyama S, 2007, J IMMUNOL, V179, P4711, DOI 10.4049/jimmunol.179.7.4711; Kreijtz JHCM, 2008, J VIROL, V82, P5161, DOI 10.1128/JVI.02694-07; LaMere MW, 2011, J VIROL, V85, P5027, DOI 10.1128/JVI.00150-11; Lamm ME, 2002, J EXP MED, V195, pF5, DOI 10.1084/jem.20011910; Le Goffic R, 2007, J IMMUNOL, V178, P3368, DOI 10.4049/jimmunol.178.6.3368; Li JE, 2013, SCI CHINA LIFE SCI, V56, P619, DOI 10.1007/s11427-013-4504-2; Liu H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069649; Longhi MP, 2008, PLOS PATHOG, V4, DOI [10.1371/ journal. ppat. 1000006, DOI 10.1371/J0URNAL.PPAT.1000006]; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LU BL, 1982, INFECT IMMUN, V38, P530, DOI 10.1128/IAI.38.2.530-535.1982; Marchal S, 2005, BRAZ J MED BIOL RES, V38, P1175, DOI 10.1590/S0100-879X2005000800004; Masson Patrick, 2001, Journal of Biomedicine and Biotechnology, V1, P85, DOI 10.1155/S1110724301000158; Meeusen ENT, 2007, CLIN MICROBIOL REV, V20, P489, DOI 10.1128/CMR.00005-07; Mei L, 2013, BIOSCI TRENDS, V7, P64, DOI 10.5582/bst.2013.v7.2.64; Mesquita M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101056; Moran TM, 1999, J INFECT DIS, V180, P579, DOI 10.1086/314952; Otten MA, 2004, IMMUNOL LETT, V92, P23, DOI 10.1016/j.imlet.2003.11.018; PALADINI AA, 1981, BIOCHEMISTRY-US, V20, P2587, DOI 10.1021/bi00512a034; Proietti E, 2002, J IMMUNOL, V169, P375, DOI 10.4049/jimmunol.169.1.375; REED L. J., 1938, AMER JOUR HYG, V27, P493; Riberdy JM, 1999, J VIROL, V73, P1453, DOI 10.1128/JVI.73.2.1453-1459.1999; Rovozzo GC, 1973, MANUAL VIROLOGICAL B; Schwarcz WD, 2004, CELL MOL BIOL, V50, P419; Silva JL, 2014, CHEM REV, V114, P7239, DOI 10.1021/cr400204z; SILVA JL, 1992, J VIROL, V66, P2111, DOI 10.1128/JVI.66.4.2111-2117.1992; Silva JL, 1996, CURR OPIN STRUC BIOL, V6, P166, DOI 10.1016/S0959-440X(96)80071-6; Silva JL, 2001, TRENDS BIOCHEM SCI, V26, P612, DOI 10.1016/S0968-0004(01)01949-1; Song JM, 2005, ANTIVIR RES, V68, P66, DOI 10.1016/j.antiviral.2005.06.010; Steel J, 2010, MBIO, V1, DOI 10.1128/mBio.00018-10; Sundararajan A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034377; Balish Amanda L, 2013, Curr Protoc Microbiol, VChapter 15, DOI [10.1002/0471729256.mc15g01s3, 10.1002/9780471729259.mc15g01s29]; Thomas PG, 2006, EMERG INFECT DIS, V12, P48, DOI 10.3201/eid1201.051237; Tian SM, 2000, EUR J BIOCHEM, V267, P4486, DOI 10.1046/j.1432-1327.2000.01496.x; Tian SM, 1999, ACTA BIOCH BIOPH SIN, V31, P334; van Egmond M, 2000, NAT MED, V6, P680, DOI 10.1038/76261; Van Reeth K, 2000, VET MICROBIOL, V74, P109, DOI 10.1016/S0378-1135(00)00171-1; van Schaik SM, 2000, J MED VIROL, V62, P257, DOI 10.1002/1096-9071(200010)62:2<257::AID-JMV19>3.0.CO;2-M; Vandegrift KJ, 2010, ANN NY ACAD SCI, V1195, P113, DOI 10.1111/j.1749-6632.2010.05451.x; WHO, MAN AN INFL DIAGN SU; Wilschut JC, 2006, INFLUENZA, P150; WOOD JM, 1998, TXB INFLUENZA, P333; Yondon M, 2014, EMERG INFECT DIS, V20, P2144, DOI 10.3201/eid2012.140435; Zosky GR, 2009, J APPL PHYSIOL, V107, P1472, DOI 10.1152/japplphysiol.00393.2009	79	7	7	1	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 9	2015	10	6							e0128785	10.1371/journal.pone.0128785	http://dx.doi.org/10.1371/journal.pone.0128785			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CK6PC	26056825	Green Submitted, Green Published, gold			2023-01-03	WOS:000356349000030
J	Calcaterra, V; Veggiotti, P; Palestrini, C; De Giorgis, V; Raschetti, R; Tumminelli, M; Mencherini, S; Papotti, F; Klersy, C; Albertini, R; Ostuni, S; Pelizzo, G				Calcaterra, Valeria; Veggiotti, Pierangelo; Palestrini, Clara; De Giorgis, Valentina; Raschetti, Roberto; Tumminelli, Massimiliano; Mencherini, Simonetta; Papotti, Francesca; Klersy, Catherine; Albertini, Riccardo; Ostuni, Selene; Pelizzo, Gloria			Post-Operative Benefits of Animal-Assisted Therapy in Pediatric Surgery: A Randomised Study	PLOS ONE			English	Article							CHILDREN; LONELINESS; ANXIETY; STRESS; THETA; DOGS	Background Interest in animal-assisted therapy has been fuelled by studies supporting the many health benefits. The purpose of this study was to better understand the impact of an animal-assisted therapy program on children response to stress and pain in the immediate postsurgical period. Patients and Methods Forty children (3-17 years) were enrolled in the randomised open-label, controlled, pilot study. Patients were randomly assigned to the animal-assisted therapy-group (n = 20, who underwent a 20 min session with an animal-assisted therapy dog, after surgery) or the standard- group (n = 20, standard postoperative care). The study variables were determined in each patient, independently of the assigned group, by a researcher unblinded to the patient's group. The outcomes of the study were to define the neurological, cardiovascular and endocrinological impact of animal-assisted therapy in response to stress and pain. Electroencephalogram activity, heart rate, blood pressure, oxygen saturation, cerebral prefrontal oxygenation, salivary cortisol levels and the faces pain scale were considered as outcome measures. Results After entrance of the dog faster electroencephalogram diffuse beta-activity (> 14 Hz) was reported in all children of the animal-assisted therapy group; in the standard-group no beta-activity was recorded (100% vs 0%, p<0.001). During observation, some differences in the time profile between groups were observed for heart rate (test for interaction p = 0.018), oxygen saturation (test for interaction p = 0.06) and cerebral oxygenation (test for interaction p = 0.09). Systolic and diastolic blood pressure were influenced by animal-assisted therapy, though a higher variability in diastolic pressure was observed. Salivary cortisol levels did not show different behaviours over time between groups (p=0.70). Lower pain perception was noted in the animal-assisted group in comparison with the standard-group (p = 0.01). Conclusion Animal-assisted therapy facilitated rapid recovery in vigilance and activity after anaesthesia, modified pain perception and induced emotional prefrontal responses. An adaptative cardiovascular response was also present.	[Calcaterra, Valeria; Raschetti, Roberto] Fdn IRCCS Policlin San Matteo, Dept Mother & Child Hlth, Pediat Unit, Pavia, Italy; [Calcaterra, Valeria] Univ Pavia, Dept Internal Med, I-27100 Pavia, Italy; [Veggiotti, Pierangelo; Tumminelli, Massimiliano] C Mondino Natl Neurol Inst, Dept Child Neurol & Psychiat, Pavia, Italy; [Veggiotti, Pierangelo; De Giorgis, Valentina] Univ Pavia, Brain & Behav Dept, I-27100 Pavia, Italy; [Palestrini, Clara; Papotti, Francesca] Univ Milan, Dipartimento Sci Vet & Sanita Pubbl, Milan, Italy; [Mencherini, Simonetta] Fdn IRCCS Policlin San Matteo, Dept Anaesthesiol & Intens Care, Pavia, Italy; [Klersy, Catherine] Fdn IRCCS Policlin San Matteo, Biometry & Clin Epidemiol, Sci Direct, Pavia, Italy; [Albertini, Riccardo] Fdn IRCCS Policlin San Matteo, Clin Chem Lab, Pavia, Italy; [Ostuni, Selene; Pelizzo, Gloria] Fdn IRCCS Policlin San Matteo, Dept Mother & Child Hlth, Pediat Surg Unit, Pavia, Italy; [Pelizzo, Gloria] Univ Pavia, Dept Clin Surg Diagnost & Pediat Sci, I-27100 Pavia, Italy	IRCCS Fondazione San Matteo; University of Pavia; IRCCS Fondazione Casimiro Mondino; University of Pavia; University of Milan; IRCCS Fondazione San Matteo; IRCCS Fondazione San Matteo; IRCCS Fondazione San Matteo; IRCCS Fondazione San Matteo; University of Pavia	Pelizzo, G (corresponding author), Fdn IRCCS Policlin San Matteo, Dept Mother & Child Hlth, Pediat Surg Unit, Pavia, Italy.	g.pelizzo@smatteo.pv.it	De Giorgis, Valentina/AAB-7643-2019; De Giorgis, Valentina/K-4730-2018; albertini, riccardo/AAB-7779-2019; Raschetti, Roberto/AAH-5397-2019; palestrini, clara/K-6721-2017; klersy, catherine/AAA-3003-2019; Calcaterra, Valeria/AAB-7563-2022	De Giorgis, Valentina/0000-0002-5828-7070; De Giorgis, Valentina/0000-0002-5828-7070; palestrini, clara/0000-0002-5178-906X; klersy, catherine/0000-0003-0314-8548; Calcaterra, Valeria/0000-0002-2137-5974; ALBERTINI, REGIANE/0000-0002-4143-0387; Pelizzo, Gloria/0000-0002-5253-8828; Calcaterra, Valeria/0000-0003-3862-7872				[Anonymous], 2012, FRONT PSYCHOL, DOI DOI 10.3389/FPSYG.2012.00234; Banks MR, 2008, J AM MED DIR ASSOC, V9, P173, DOI 10.1016/j.jamda.2007.11.007; Banks MR, 2002, J GERONTOL A-BIOL, V57, pM428, DOI 10.1093/gerona/57.7.M428; Barba B E, 1995, Clin Nurse Spec, V9, P199, DOI 10.1097/00002800-199507000-00005; Bardill N, 1997, J Child Adolesc Psychiatr Nurs, V10, P17, DOI 10.1111/j.1744-6171.1997.tb00208.x; Barker SB, 2008, J VET MED EDUC, V35, P487, DOI 10.3138/jvme.35.4.487; Barker SB, 2005, PSYCHOL REP, V96, P713; Barker SB, 2003, J ECT, V19, P38, DOI 10.1097/00124509-200303000-00008; Barker SB, 1998, PSYCHIATR SERV, V49, P797, DOI 10.1176/ps.49.6.797; Beetz A, 2012, FRONT PSYCHOL, V3, DOI 10.3389/fpsyg.2012.00352; Bekkedal MYV, 2011, NEUROSCI BIOBEHAV R, V35, P1959, DOI 10.1016/j.neubiorev.2011.05.001; Berry A, 2013, J ALTERN COMPLEM MED, V19, P73, DOI 10.1089/acm.2011.0835; Braun Carie, 2009, Complement Ther Clin Pract, V15, P105, DOI 10.1016/j.ctcp.2009.02.008; Cole K M, 2000, AACN Clin Issues, V11, P139, DOI 10.1097/00044067-200002000-00015; Corazza I, 2014, COMPUT METH PROG BIO, V117, P267, DOI 10.1016/j.cmpb.2014.08.002; Ernst Lorraine S, 2013, Nurs Manage, V44, P16, DOI 10.1097/01.NUMA.0000427181.19436.19; Ernst Lorraine S, 2012, Nursing, V42, P54; Fisher A, 2014, LAB ANIMAL, V43, P122, DOI 10.1038/laban.499; Harmon-Jones E., 2007, SOCIAL NEUROSCIENCE, P137; Herrmann MJ, 2003, BIOL PSYCHOL, V64, P255, DOI 10.1016/S0301-0511(03)00095-4; Hooker Shirley D, 2002, Holist Nurs Pract, V16, P17; Jausovec N, 2001, NEUROSCI LETT, V311, P93, DOI 10.1016/S0304-3940(01)02141-3; Kaldy Joanne, 2013, Consult Pharm, V28, P84, DOI 10.4140/TCP.n.2013.84; Kamioka H, 2014, COMPLEMENT THER MED, V22, P371, DOI 10.1016/j.ctim.2013.12.016; Kim MK, 2013, COMPUT MATH METHOD M, V2013, DOI 10.1155/2013/573734; Kinner VL, 2014, FRONT BEHAV NEUROSCI, V8, DOI 10.3389/fnbeh.2014.00397; Makovac E, 2015, NEUROPSYCHOPHARMACOL, V40, P1649, DOI 10.1038/npp.2015.10; Marcus DA, 2013, CURR PAIN HEADACHE R, V17, DOI 10.1007/s11916-013-0322-2; Martin F, 2002, WESTERN J NURS RES, V24, P657, DOI 10.1177/019394502320555403; Mhuircheartaigh RN, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3006007; Miller J, 2003, NURSING, V30, P65; Moghimi S, 2012, NEUROSCI LETT, V525, P7, DOI 10.1016/j.neulet.2012.07.009; Murphy M, 2011, SLEEP, V34, P283, DOI 10.1093/sleep/34.3.283; O'Haire ME, 2013, J AUTISM DEV DISORD, V43, P1606, DOI 10.1007/s10803-012-1707-5; Richeson Nancy E, 2003, Am J Alzheimers Dis Other Demen, V18, P353, DOI 10.1177/153331750301800610; Spiga F, 2014, COMPR PHYSIOL, V4, P1273, DOI 10.1002/cphy.c140003; Viau R, 2010, PSYCHONEUROENDOCRINO, V35, P1187, DOI 10.1016/j.psyneuen.2010.02.004; Wohlfarth R, 2013, FRONT PSYCHOL, V4, DOI 10.3389/fpsyg.2013.00796; WOODSIDE DB, 1991, CAN J PSYCHIAT, V36, P746, DOI 10.1177/070674379103601011	39	56	57	3	99	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 3	2015	10	6							e0125813	10.1371/journal.pone.0125813	http://dx.doi.org/10.1371/journal.pone.0125813			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	CJ7ST	26039494	Green Submitted, Green Published, gold			2023-01-03	WOS:000355700700013
J	Debevc, M; Milosevic, D; Kozuh, I				Debevc, Matjaz; Milosevic, Danijela; Kozuh, Ines			A Comparison of Comprehension Processes in Sign Language Interpreter Videos with or without Captions	PLOS ONE			English	Article							HARD-OF-HEARING; DEAF; ADULTS	One important theme in captioning is whether the implementation of captions in individual sign language interpreter videos can positively affect viewers' comprehension when compared with sign language interpreter videos without captions. In our study, an experiment was conducted using four video clips with information about everyday events. Fifty-one deaf and hard of hearing sign language users alternately watched the sign language interpreter videos with, and without, captions. Afterwards, they answered ten questions. The results showed that the presence of captions positively affected their rates of comprehension, which increased by 24% among deaf viewers and 42% among hard of hearing viewers. The most obvious differences in comprehension between watching sign language interpreter videos with and without captions were found for the subjects of hiking and culture, where comprehension was higher when captions were used. The results led to suggestions for the consistent use of captions in sign language interpreter videos in various media.	[Debevc, Matjaz; Kozuh, Ines] Univ Maribor, Fac Elect Engn & Comp Sci, Inst Media Commun, SLO-2000 Maribor, Slovenia; [Milosevic, Danijela] Univ Kragujevac, Fac Tech Sci Cacak, Dept Informat Technol, Cacak, Serbia	University of Maribor; University of Kragujevac	Debevc, M (corresponding author), Univ Maribor, Fac Elect Engn & Comp Sci, Inst Media Commun, SLO-2000 Maribor, Slovenia.	matjaz.debevc@um.si	Debevc, Matjaž/AAY-3715-2021; Kozuh, Ines/AAL-3680-2020	Debevc, Matjaž/0000-0003-4638-7864; Kozuh, Ines/0000-0001-7875-5583	Swiss National Science Foundation [IZKOZ3_136107/1]	Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission)	Swiss National Science Foundation, Project Number: IZKOZ3_136107/1. The "International Short Visits" of the Swiss National Science Foundation (SNSF) allow for researchers working in Switzerland to go abroad or for researchers from elsewhere to come to Switzerland. Dr. Matjaz Debevc visited ETH Zurich and performed the research at this institution.	Allen C, 2009, WORLD FEDERATION DEA; Andrew KN, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089994; Brickman B, 1995, J SCI PERSONS DISABI, V3, P40; Burnham D, 2008, J DEAF STUD DEAF EDU, V13, P391, DOI 10.1093/deafed/enn003; Cambra C, 2008, AM ANN DEAF, V153, P425; Cambra C, 2010, DEAF EDUC INT, V12, P34, DOI 10.1179/146431510X12626982043606; Cavender A, 2008, HUM-COMPUT INT-SPRIN, P25, DOI 10.1007/978-1-84800-050-6_3; Cohen J., 2013, STAT POWER ANAL BEHA; d'Ydewalle G, 2007, EUR PSYCHOL, V12, P196, DOI 10.1027/1016-9040.12.3.196; De Linde Zoe., 1999, SEMIOTICS SUBTITLING; Deaf News Network (DNN), 2014, FCC REQ CAPT VID CLI; Debevc M, 2011, MULTIMED TOOLS APPL, V54, P181, DOI 10.1007/s11042-010-0529-8; Debevc M, 2010, LECT NOTES COMPUT SC, V6389, P203; dYdewalle G, 1987, EYE MOVEMENTS PHYSL, DOI DOI 10.1016/B978-0-444-70113-8.50047-3; European Broadcasting Union (EBU), 2004, ACC SERV INCL REC RE; European Commission, 2010, EUR DIS STRAT 2010 2; European Federation of Hard of Hearing People, 2011, STAT SUBT ACC EU 201; European Union of the Deaf, 2012, SLOV; Fajardo I, 2003, HCI INT, P950; Gulliver S.R., 2003, INF SOC J, V2, P374, DOI [10.1007/s10209-003-0067-5, DOI 10.1007/S10209-003-0067-5]; Gulliver SR, 2003, P IEEE INT C MULT EX, V1, P753; Hanson VL, 2013, ACM T WEB, V7, DOI 10.1145/2435215.2435217; Hanson VL, 2008, HUM-COMPUT INT-SPRIN, P215, DOI 10.1007/978-1-84800-050-6_13; Holzinger A, 2005, COMMUN ACM, V48, P71, DOI 10.1145/1039539.1039541; Hong R., 2011, P ACM INT C MULT MM, V7, P35, DOI DOI 10.1145/2043612.2043613; Howell D.C., 2002, STAT METHODS PSYCHOL; Jacobs I, 2001, INTERACTIONS, V8, P35, DOI [10.1145/379537.379550, DOI 10.1145/379537.379550]; Jelinek Lewis M S, 2001, J Deaf Stud Deaf Educ, V6, P43; Kim Y, 2006, J SPECIAL ED THEORY, V7, P489; Kirkland CE, 1995, ANN M AM ED RES ASS; KOSKINEN PS, 1993, READ TEACH, V47, P36; Kozuh I, 2014, ENHANCING UNIVERSAL, P1; Margaret SJ, 2001, J DEAF STUDIES DEAL, V6, P43; Marschark M, 1996, READING COMPREHENSION DIFFICULTIES, P279; Marschark M., 2004, SIGN LANGUAGE STUDIE, V4, P345, DOI DOI 10.1353/SLS.2004.0018; NUGENT GC, 1983, J SPEC EDUC, V17, P227, DOI 10.1177/002246698301700214; Paivio A., 1986, MENTAL REPRESENTATIO; Perego E, 2010, MEDIA PSYCHOL, V13, P243, DOI 10.1080/15213269.2010.502873; Sadler KL, 2009, THESIS U PITTSBURGH; Schirmer BR, 2001, DIMENSIONS DEAFNESS; Steinfeld A, 1998, VOLTA REV, V100, P29; Strassman BK, 2012, AM ANN DEAF, V157, P340; Szarkowska A, 2011, AM ANN DEAF, V156, P363, DOI 10.1353/aad.2011.0039; Wehrmeyer J, 2014, J EYE MOVEMENT RES, V7; Yoon JO, 2011, AM ANN DEAF, V156, P283, DOI 10.1353/aad.2011.0026	45	9	9	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 26	2015	10	5							e0127577	10.1371/journal.pone.0127577	http://dx.doi.org/10.1371/journal.pone.0127577			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	CJ0QZ	26010899	Green Published, gold, Green Submitted			2023-01-03	WOS:000355183900113
J	Zhao, YL; Li, HL; Wu, RQ; Li, SH; Wang, P; Wang, HT; Wang, J; Zhou, JG				Zhao, Yali; Li, Hailiang; Wu, Ruiqin; Li, Shanhu; Wang, Peng; Wang, Hongtao; Wang, Jian; Zhou, Jianguang			Antitumor Effects of Oncolytic Adenovirus-Carrying siRNA Targeting Potential Oncogene EphA3	PLOS ONE			English	Article							AUTOPHAGIC CELL-DEATH; TUMOR-CELLS; RECEPTORS; EPHRINS	Conditionally replicating adenoviruses (CRAds) armed with antitumor transgenes hold promise for cancer treatment. In previous studies, we showed that the 1504-siRNA targeting potential oncogene EphA3 was an efficient therapeutic transgene and that the telomerase reverse transcriptase promoter (TERTp) driving the CRAd was a more advanced generation of CRAd. Therefore, we combined Ad-TERTp-E1A-1504 by inserting 1504-siRNA into the CRAd to study its antitumor effects and mechanism of action, using Ad-TERTp-E1A-NC and nonreplicating adenovirus carrying 1504-siRNA as controls. Cell viability assays and ED50 studies of growth inhibition confirmed that Ad-TERTp-E1A-1504 has 3.5- and 1,400-fold greater ability to kill EphA3- and TERT-expressing tumor cells compared to Ad-TERTp-E1A-NC and Ad-Delta E1A-1504, respectively. Also, Ad-TERTp-E1A-1504 had little effect on cells that modestly expressed EphA3 and TERT such as 2BS. The antitumor efficacy of Ad-TERTp-E1A-1504 was also validated in vivo. Furthermore, the virus yield of Ad-TERTp-E1A-1504 in C4-2B was similar to 1,000 times greater than that in 2BS. No obvious differences were observed between Ad-TERTp-E1A-1504 and Ad-TERTp-E1A-NC. Both acridine orange staining and Beclin1 protein measurements indicated that autophagy with Ad-TERTp-E1A-1504 at 5 and 10 MOI was higher than that of Ad-TERTp-E1A-NC. Finally, the classical negatively regulated autophagy signaling pathway, PI3K/AKT/mTOR, was suppressed (reduced phosphorylated form) in contrast to NC, and that this was mediated by 1504-siRNA. Thus, Ad-TERTp-E1A-1504 does not harm normal cells but has dual inhibiting and killing effects on TERT-and EphA3-positive tumor cells, and this effect is mediated by the AKT/mTOR signaling pathway via induction of autophagy. These data may offer a foundation for novel antitumor therapies targeting this mechanism.	[Li, Hailiang; Wu, Ruiqin; Li, Shanhu; Wang, Peng; Wang, Hongtao; Wang, Jian; Zhou, Jianguang] Beijing Inst Biotechnol, Dept Med Mol Biol, Beijing, Peoples R China; [Zhao, Yali] Astronaut Res & Training Ctr China, Beijing, Peoples R China; [Li, Hailiang] Southern Med Univ, Guangzhou, Guangdong, Peoples R China	Southern Medical University - China	Wang, J (corresponding author), Beijing Inst Biotechnol, Dept Med Mol Biol, Beijing, Peoples R China.	zhou.jianguang@aliyun.com; newgeno2003@aliyun.com			National Natural Science Foundation of China [81172445, 81372740, 81372770]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	The source of funding for this study was the National Natural Science Foundation of China, grant numbers are 81172445, 81372740 (JW) and 81372770 (JZ), the website is http://www.nsfc.gov.cn/. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ding L, 2008, NATURE, V455, P1069, DOI 10.1038/nature07423; Hafner C, 2004, CLIN CHEM, V50, P490, DOI 10.1373/clinchem.2003.026849; Hu ZB, 2008, CANCER GENE THER, V15, P173, DOI 10.1038/sj.cgt.7701105; Ito H, 2006, JNCI-J NATL CANCER I, V98, P625, DOI 10.1093/jnci/djj161; Liang C, 2006, NAT CELL BIOL, V8, P688, DOI 10.1038/ncb1426; Liu HY, 2009, J VIROL METHODS, V162, P8, DOI 10.1016/j.jviromet.2009.07.011; Logue SE, 2008, BIOCHEM SOC T, V36, P1, DOI 10.1042/BST0360001; Meerani S, 2010, EUROPEAN J SCI RES, V40, P156; Nihira K, 2014, CANCER SCI, V105, P568, DOI 10.1111/cas.12396; NybergHoffman C, 1997, NAT MED, V3, P808, DOI 10.1038/nm0797-808; Pasquale EB, 2010, NAT REV CANCER, V10, P165, DOI 10.1038/nrc2806; Qu XP, 2003, J CLIN INVEST, V112, P1809, DOI 10.1172/JCI200320039; Smith LM, 2004, EXP CELL RES, V292, P295, DOI 10.1016/j.yexcr.2003.08.021; Vearing C, 2005, CANCER RES, V65, P6745, DOI 10.1158/0008-5472.CAN-05-0758; Wimmer-Kleikamp SH, 2005, IUBMB LIFE, V57, P421, DOI 10.1080/15216540500138337; Wu RQ, 2014, ONCOL REP, V32, P2657, DOI 10.3892/or.2014.3482; Yokoyama T, 2008, GENE THER, V15, P1233, DOI 10.1038/gt.2008.98; Yu ST, 2009, INT J ONCOL, V35, P329, DOI 10.3892/ijo_00000344; [赵亚丽 Zhao Yali], 2012, [军事医学, Military Medical Sciences], V36, P272; Zhao YL, 2012, LETT BIOTECH, V23, P503; Zhuang GL, 2012, JNCI-J NATL CANCER I, V104, P1182, DOI 10.1093/jnci/djs297; Zou WG, 2004, ONCOGENE, V23, P457, DOI 10.1038/sj.onc.1207033	22	9	11	2	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 15	2015	10	5							e0126726	10.1371/journal.pone.0126726	http://dx.doi.org/10.1371/journal.pone.0126726			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CI7AU	25978371	Green Published, gold, Green Submitted			2023-01-03	WOS:000354916100094
J	Abud, MJ; Hall, B; Helmers, C				Abud, Maria Jose; Hall, Bronwyn; Helmers, Christian			An Empirical Analysis of Primary and Secondary Pharmaceutical Patents in Chile	PLOS ONE			English	Article							PROTECTION	We analyze the patent filing strategies of foreign pharmaceutical companies in Chile distinguishing between "primary" (active ingredient) and "secondary" patents (patents on modified compounds, formulations, dosages, particular medical uses, etc.). There is prior evidence that secondary patents are used by pharmaceutical originator companies in the U.S. and Europe to extend patent protection on drugs in length and breadth. Using a novel dataset that comprises all drugs registered in Chile between 1991 and 2010 as well as the corresponding patents and trademarks, we find evidence that foreign originator companies pursue similar strategies in Chile. We find a primary to secondary patents ratio of 1:4 at the drug-level, which is comparable to the available evidence for Europe; most secondary patents are filed over several years following the original primary patent and after the protected active ingredient has obtained market approval in Chile. This points toward effective patent term extensions through secondary patents. Secondary patents dominate "older" therapeutic classes like anti-ulcer and anti-depressants. In contrast, newer areas like anti-virals and anti-neoplastics (anti-cancer) have a much larger share of primary patents.	[Abud, Maria Jose] Columbia Univ, Sch Int & Publ Affairs, New York, NY USA; [Hall, Bronwyn] Univ Calif Berkeley, Dept Econ, Berkeley, CA 94720 USA; [Hall, Bronwyn] Maastricht Univ, UNU MERIT, NL-6200 MD Maastricht, Netherlands; [Helmers, Christian] Santa Clara Univ, Dept Econ, Santa Clara, CA 95053 USA	Columbia University; University of California System; University of California Berkeley; Maastricht University; Santa Clara University	Helmers, C (corresponding author), Santa Clara Univ, Dept Econ, Santa Clara, CA 95053 USA.	chelmers@scu.edu		Hall, Bronwyn/0000-0002-3802-5567	World Intellectual Property Organization; United Nations University-MERIT; Santa Clara University	World Intellectual Property Organization; United Nations University-MERIT; Santa Clara University	This study was supported by the World Intellectual Property Organization to MA, BH, and CH (WIPO, http://www.wipo.int); United Nations University-MERIT to BH; and Santa Clara University to CH. WIPO's chief economist, Carsten Fink, provided advice in the study design and data collection, and manuscript.	Abud M.J., 2013, 11 WIPO; Amin T, 2012, HEALTH AFFAIR, V31, P2286, DOI 10.1377/hlthaff.2012.0107; Arora A, 2011, LOCATION BIOPHARMACE; Burdon M, 2003, INT J MED MARKETING, V3; Chaudhuri S, 2006, AM ECON REV, V96, P1477, DOI 10.1257/aer.96.5.1477; European Commission, 2009, PHARM SECT INQ FIN R; Goldberg PK, 2010, J EUR ECON ASSOC, V8, P326, DOI 10.1111/j.1542-4774.2010.tb00506.x; Hemphill CS, 2012, J HEALTH ECON, V31, P327, DOI 10.1016/j.jhealeco.2012.01.004; Hutchins M, 2003, J GENERIC MED, V1, P57, DOI DOI 10.1057/PALGRAVE.JGM.4940018; Hutchins M, 2003, J MED MARKETING DEVI, V3, P212; Kapczynski A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049470; Sternitzke C, 2013, RES POLICY, V42, P542, DOI 10.1016/j.respol.2012.11.003	12	14	14	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 27	2015	10	4							e0124257	10.1371/journal.pone.0124257	http://dx.doi.org/10.1371/journal.pone.0124257			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	CG9SB	25915050	Green Published, gold			2023-01-03	WOS:000353659100042
J	Sandoval, C; Ortega, A; Sanchez, SA; Morales, J; Gunther, G				Sandoval, Catalina; Ortega, Anakenna; Sanchez, Susana A.; Morales, Javier; Gunther, German			Structuration in the Interface of Direct and Reversed Micelles of Sucrose Esters, Studied by Fluorescent Techniques	PLOS ONE			English	Article							BETA-D-THIOGLUCOSIDE; MIXED MICELLES; EXCITED-STATE; SOLVATION DYNAMICS; SURFACTANT; SOLVENT; PYRANINE; SOLUBILIZATION; PROBE; DEACTIVATION	Background Reactors found in nature can be described as micro-heterogeneous systems, where media involved in each micro-environment can behave in a markedly different way compared with the properties of the bulk solution. The presence of water molecules in micro-organized assemblies is of paramount importance for many chemical processes, ranging from biology to environmental science. Self-organized molecular assembled systems are frequently used to study dynamics of water molecules because are the simplest models mimicking biological membranes. The hydrogen bonds between sucrose and water molecules are described to be stronger (or more extensive) than the ones between water molecules themselves. In this work, we studied the capability of sucrose moiety, attached to alkyl chains of different length, as a surface blocking agent at the water-interface and we compared its properties with those of polyethylenglycol, a well-known agent used for this purposes. Published studies in this topic mainly refer to the micellization process and the stability of mixed surfactant systems using glycosides. We are interested in the effect induced by the presence of sucrose monoesters at the interface (direct and reverse micelles) and at the palisade (mixtures with Triton X-100). We believe that the different functional group (ester), the position of alkyl chain (6-O) and the huge capability of sucrose to interact with water will dramatically change the water structuration at the interface and at the palisade, generating new possibilities for technological applications of these systems. Results Our time resolved and steady state fluorescence experiments in pure SEs micelles show that sucrose moieties are able to interact with a high number of water molecules promoting water structuration and increased viscosity. These results also indicate that the barrier formed by sucrose moieties on the surface of pure micelles is more effective than the polyoxyethylene palisade of Triton X-100. The fluorescence quenching experiments of SEs at the palisade of Triton X-100 micelles indicate a blocking effect dependent on the number of methylene units present in the hydrophobic tail of the surfactant. A remarkable blocking effect is observed when there is a match in size between the hydrophobic regions forming the apolar core (lauryl SE/Triton X-100). This blocking effect disappears when a mismatch in size between hydrophobic tails, exists due to the disturbing effect on the micelle core.	[Sandoval, Catalina; Ortega, Anakenna; Gunther, German] Univ Chile, Fac Ciencias Quim & Farmaceut, Dept Quim Organ & Fisicoquim, Santiago, Chile; [Sanchez, Susana A.] Univ Concepcion, Fac Quim, Dept Polimeros, Concepcion, Chile; [Morales, Javier] Univ Chile, Fac Ciencias Quim & Farmaceut, Dept Ciencias Tecnol & Farmaceut, Santiago, Chile	Universidad de Chile; Universidad de Concepcion; Universidad de Chile	Gunther, G (corresponding author), Univ Chile, Fac Ciencias Quim & Farmaceut, Dept Quim Organ & Fisicoquim, Santiago, Chile.	ggunther@ciq.uchile.cl	Sánchez, Susana/HII-3113-2022; Gunther, German/I-1028-2013	Gunther, German/0000-0002-4733-8426; Morales Valenzuela, Javier Eduardo/0000-0002-9880-2567; Sandoval-Altamirano, Catalina/0000-0002-8550-3218	Fondo Nacional de Desarrollo Cientifico y Tecnologico (FONDECYT) [1120196, 1140454]	Fondo Nacional de Desarrollo Cientifico y Tecnologico (FONDECYT)(Comision Nacional de Investigacion Cientifica y Tecnologica (CONICYT)CONICYT FONDECYT)	Funding was received from the Fondo Nacional de Desarrollo Cientifico y Tecnologico (FONDECYT) 1120196, http://www.conicyt.cl/fondecyt/, GG; and the Fondo Nacional de Desarrollo Cientifico y Tecnologico (FONDECYT) 1140454, http://www.conicyt.cl/fondecyt/, SAS. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ALMGREN M, 1992, ADV COLLOID INTERFAC, V41, P9, DOI 10.1016/0001-8686(92)80004-H; Avnir Y, 2005, ANAL BIOCHEM, V347, P34, DOI 10.1016/j.ab.2005.09.026; Bales BL, 2000, J PHYS CHEM B, V104, P264, DOI 10.1021/jp993290i; Barnadas-Rodriguez R, 2008, J PHOTOCH PHOTOBIO A, V198, P262, DOI 10.1016/j.jphotochem.2008.04.003; Becerra N, 2008, COLLOID SURFACE A, V327, P134, DOI 10.1016/j.colsurfa.2008.06.012; Becerra N, 2006, COLLOID SURFACE A, V272, P2, DOI 10.1016/j.colsurfa.2005.04.024; Berrios E, 2008, J CHIL CHEM SOC, V53, P1728, DOI 10.4067/S0717-97072008000400021; Borsarelli CD, 1997, J PHYS CHEM B, V101, P6036, DOI 10.1021/jp971184f; Ruiz CC, 2012, PHOTOCH PHOTOBIO SCI, V11, P1331, DOI 10.1039/c2pp25049g; Ruiz CC, 2011, J COLLOID INTERF SCI, V361, P178, DOI 10.1016/j.jcis.2011.05.019; Chaudhuri A, 2009, BIOCHEM BIOPH RES CO, V390, P728, DOI 10.1016/j.bbrc.2009.10.037; DONG DC, 1984, CAN J CHEM, V62, P2560, DOI 10.1139/v84-437; DRUMMOND CJ, 1985, J PHYS CHEM-US, V89, P2103, DOI 10.1021/j100256a060; Garcia MT, 1997, CHEMOSPHERE, V35, P545; Garofalakis G, 2000, J COLLOID INTERF SCI, V229, P391, DOI 10.1006/jcis.2000.7035; GEHLEN MH, 1993, CHEM REV, V93, P199, DOI 10.1021/cr00017a010; Granizo N, 2004, J COLLOID INTERF SCI, V273, P638, DOI 10.1016/j.jcis.2004.02.004; Grasjo J, 2009, J PHYS CHEM B, V113, P8201, DOI 10.1021/jp902058w; Hara K, 2001, J PHYS CHEM A, V105, P7174, DOI 10.1021/jp0109776; Hierrezuelo JM, 2006, J COLLOID INTERF SCI, V294, P449, DOI 10.1016/j.jcis.2005.07.024; JENNY TA, 1982, TETRAHEDRON LETT, V23, P2923, DOI 10.1016/S0040-4039(00)87495-X; Jimenez-Banzo A, 2008, PHOTOCH PHOTOBIO SCI, V7, P1003, DOI 10.1039/b804333g; KONDO H, 1982, J PHYS CHEM-US, V86, P4826, DOI 10.1021/j100221a035; Kumbhakar M, 2004, J CHEM PHYS, V121, P6026, DOI 10.1063/1.1784774; Mondal SK, 2005, CHEM PHYS LETT, V412, P228, DOI 10.1016/j.cplett.2005.07.001; Montenegro MA, 2002, PHOTOCHEM PHOTOBIOL, V75, P353, DOI 10.1562/0031-8655(2002)075<0353:SMOQAO>2.0.CO;2; Nonell S, 2000, METHOD ENZYMOL, V319, P37; Noritomi H, 2006, COLLOID POLYM SCI, V284, P677, DOI 10.1007/s00396-005-1419-x; Parasassi T, 1998, J FLUORESC, V8, P365, DOI 10.1023/A:1020528716621; PARASASSI T, 1994, BIOPHYS J, V66, P120, DOI 10.1016/S0006-3495(94)80763-5; Rameez S, 2011, LANGMUIR, V27, P8829, DOI 10.1021/la201246m; Regev O, 1999, J COLLOID INTERF SCI, V210, P8, DOI 10.1006/jcis.1998.5776; Rodriguez HB, 2012, PHOTOCHEM PHOTOBIOL, V88, P831, DOI 10.1111/j.1751-1097.2012.01152.x; Ruiz CC, 2003, COLLOID POLYM SCI, V281, P531, DOI 10.1007/s00396-002-0801-1; Ruiz CC, 2000, LANGMUIR, V16, P7946, DOI 10.1021/la000154s; Salokhiddinov K. I., 1981, Journal of Applied Spectroscopy, V34, P561, DOI 10.1007/BF00613067; Sanchez SA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0029278; SCHMIDT R, 1987, J AM CHEM SOC, V109, P6976, DOI 10.1021/ja00257a012; Sierra ML, 1999, LANGMUIR, V15, P2301, DOI 10.1021/la9804177; Szuts A, 2012, INT J PHARMACEUT, V433, P1, DOI 10.1016/j.ijpharm.2012.04.076; Thevenet S, 1999, CARBOHYD RES, V318, P52, DOI 10.1016/S0008-6215(99)00079-8; Tong S, 2011, NANO LETT, V11, P3720, DOI 10.1021/nl201978c; Toro C, 2009, CHEM PHYS LIPIDS, V157, P104, DOI 10.1016/j.chemphyslip.2008.11.004; Ullrich S, 2008, EUR J PHARM BIOPHARM, V70, P550, DOI 10.1016/j.ejpb.2008.05.014; Valdes K, 2014, COLLOID SURFACE B, V117, P1, DOI 10.1016/j.colsurfb.2014.01.029; Verma PK, 2009, PHYS CHEM CHEM PHYS, V11, P8467, DOI 10.1039/b905573h; Vlahov IR, 1997, J CARBOHYD CHEM, V16, P1, DOI 10.1080/07328309708006506; WEBER G, 1979, BIOCHEMISTRY-US, V18, P3075, DOI 10.1021/bi00581a025; Wolszczak M, 2002, J PHOTOCH PHOTOBIO A, V147, P45, DOI 10.1016/S1010-6030(01)00611-6; Youan BBC, 2003, AAPS PHARMSCI, V5; Zhao SN, 2014, LANGMUIR, V30, P6920, DOI 10.1021/la501141m; ZULAUF M, 1979, J PHYS CHEM-US, V83, P480, DOI 10.1021/j100467a011	52	5	5	1	17	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 23	2015	10	4							e0123669	10.1371/journal.pone.0123669	http://dx.doi.org/10.1371/journal.pone.0123669			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CG5KZ	25905632	Green Published, gold, Green Submitted			2023-01-03	WOS:000353332000041
J	Psaty, BM; Platt, R; Altman, RB				Psaty, Bruce M.; Platt, Richard; Altman, Russ B.			Neurotoxicity of Generic Anesthesia Agents in Infants and Children An Orphan Research Question in Search of a Sponsor	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							NEURODEGENERATION; EXPOSURE		[Psaty, Bruce M.] Univ Washington, Dept Med, Cardiovasc Hlth Res Unit, Seattle, WA USA; [Psaty, Bruce M.] Univ Washington, Dept Epidemiol, Cardiovasc Hlth Res Unit, Seattle, WA 98195 USA; [Psaty, Bruce M.] Grp Hlth Cooperat Puget Sound, Grp Hlth Res Inst, Seattle, WA USA; [Platt, Richard] Harvard Univ, Sch Med, Boston, MA USA; [Platt, Richard] Harvard Pilgrim Hlth Care Inst, Dept Populat Med, Boston, MA USA; [Altman, Russ B.] Stanford Univ, Dept Bioengn, Stanford, CA 94305 USA; [Altman, Russ B.] Stanford Univ, Dept Genet & Med, Stanford, CA 94305 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Group Health Cooperative; Harvard University; Harvard Medical School; Harvard Pilgrim Health Care; Stanford University; Stanford University	Psaty, BM (corresponding author), Cardiovasc Hlth Res Unit, 1730 Minor Ave,Ste 1360, Seattle, WA 98101 USA.	psaty@u.washington.edu		Altman, Russ/0000-0003-3859-2905	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL078888, R01HL103612, R01HL105756] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL078888, HL103612, R01 HL103612, HL105756] Funding Source: Medline; NIGMS NIH HHS [GM61374] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Andropoulos DB, FDA PUBLIC SESSION R; Brambrink AM, 2012, ANN NEUROL, V72, P525, DOI 10.1002/ana.23652; Hays SR, 2013, J UROLOGY, V189, P1222, DOI 10.1016/j.juro.2012.11.090; Ikonomidou C, 1999, SCIENCE, V283, P70, DOI 10.1126/science.283.5398.70; Ing C, 2012, PEDIATRICS, V130, pE476, DOI 10.1542/peds.2011-3822; Jevtovic-Todorovic V, 2003, J NEUROSCI, V23, P876, DOI 10.1523/jneurosci.23-03-00876.2003; Seok J, 2013, P NATL ACAD SCI USA, V110, P3507, DOI 10.1073/pnas.1222878110; US Food and Drug Administration, SIGN EX NONCL CLIN D; US Food and Drug Administration, CLIN INV POT EFF AN; Yu CK, 2013, F1000RESEARCH, V2, P166, DOI [DOI 10.12688/F1000RESEARCH.2-166.V1, 10.12688/f1000research.2-166.v2]	10	39	39	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 21	2015	313	15					1515	1516		10.1001/jama.2015.1149	http://dx.doi.org/10.1001/jama.2015.1149			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CG3SA	25898045				2023-01-03	WOS:000353198700012
J	Tran, MP; Phuong, NT; Scippo, ML; Dalsgaard, A				Tran Minh Phu; Phuong, Nguyen Thanh; Scippo, Marie-Louise; Dalsgaard, Anders			Quality of Antimicrobial Products Used in Striped Catfish (Pangasianodon hypophthalmus) Aquaculture in Vietnam	PLOS ONE			English	Article							EDWARDSIELLA-ICTALURI; ANTIBIOTICS; FEED	Antimicrobial usage is common in Asian aquaculture. This study aimed to determine the quality of antimicrobial products used by Vietnamese striped catfish (Pangasianodon hypophthalmus) farmers. Twenty one antimicrobial products (11 products contained a single antimicrobial and 10 products contained a mixture of two different antimicrobials) commonly used by catfish farmers were obtained from so-called chemical shops located in the Mekong Delta, Vietnam. Ultra High Performance Liquid Chromatography Mass Spectrometry was used to analyze concentration of sulfonamides, trimethoprim, amoxicillin, cefalexin and ciprofloxacin whereas concentrations of florfenicol and doxycycline were analyzed by High Performance Liquid Chromatography with UV detection. Results revealed that only 4/11 products with a single antimicrobial and 2/10 products with a mixture of antimicrobials contained active substances within +/- 10% of the concentration declared on the product label. Two products with antimicrobial mixtures did not contain any of the declared antimicrobials. Comparing two batches, analysis of 11 products revealed that only one product contained a concentration of active compound that varied with less than 10% in both batches. Several product labels provided inadequate information on how to calculate therapeutic dosage and further stated withdrawal time despite lack of pharmacokinetic data on the antimicrobials in catfish. There is an urgent need to strengthen approval procedures and in particular regularly to monitor the quality of antimicrobials used in Vietnamese aquaculture.	[Tran Minh Phu; Phuong, Nguyen Thanh] Can Tho Univ, Coll Aquaculture & Fisheries, Dept Aquat Nutr & Prod Proc, Can Tho, Vietnam; [Tran Minh Phu; Dalsgaard, Anders] Univ Copenhagen, Fac Hlth & Med Sci, Dept Vet Dis Microbiol, Copenhagen, Denmark; [Scippo, Marie-Louise] Univ Liege, Fac Vet Med, Dept Food Sci, Liege, Belgium	Can Tho University; University of Copenhagen; University of Liege	Tran, MP (corresponding author), Can Tho Univ, Coll Aquaculture & Fisheries, Dept Aquat Nutr & Prod Proc, Can Tho, Vietnam.	tmphu@ctu.edu.vn		Tran, Minh Phu/0000-0002-2521-0667	EU-funded FP7 project "Sustaining Ethical Aquaculture Trade" (SEAT) [222889]	EU-funded FP7 project "Sustaining Ethical Aquaculture Trade" (SEAT)	The work presented received financial and other support from the EU-funded FP7 project "Sustaining Ethical Aquaculture Trade" (SEAT project number 222889; www.seatglobal.eu). The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abdulah R., 2012, PHARM REGUL AFF, V1, P2, DOI [10.4172/2167-7689.1000e106, DOI 10.4172/2167-7689.1000E106]; [Anonymous], 2017, 17025 ISOIEC; Bekoe SO, 2014, ANAL METHODS-UK, V6, P5847, DOI 10.1039/c4ay00748d; Cabello FC, 2006, ENVIRON MICROBIOL, V8, P1137, DOI 10.1111/j.1462-2920.2006.01054.x; Depaola Angelo, 1995, Journal of Aquatic Animal Health, V7, P155, DOI 10.1577/1548-8667(1995)007&lt;0155:TRBBIR&gt;2.3.CO;2; Dung TT, 2008, MICROB DRUG RESIST, V14, P311, DOI 10.1089/mdr.2008.0848; Gaunt PS, 2004, J WORLD AQUACULT SOC, V35, P257, DOI 10.1111/j.1749-7345.2004.tb01083.x; KAMAKURA K, 1994, J FOOD HYG SOC JPN, V35, P310; Mai Van Tai, 2012, FAO Fisheries and Aquaculture Technical Paper, V547, P91; Pearce JN, 2009, FOOD ADDIT CONTAM A, V26, P39, DOI 10.1080/02652030802189757; Phan LT, 2009, AQUACULTURE, V296, P227, DOI 10.1016/j.aquaculture.2009.08.017; Phuc NT, 2012, INT FISH S SHAR KNOW, P98; Prazuck T, 2002, SEX TRANSM DIS, V29, P624, DOI 10.1097/00007435-200211000-00002; Rico A, 2013, AQUACULTURE, V412, P231, DOI 10.1016/j.aquaculture.2013.07.028; Phu TM, 2015, AQUACULTURE, V438, P1, DOI 10.1016/j.aquaculture.2014.12.032; United States Department of Agriculture, 2010, CLG FLOR, V1. 04, P1; US Food and Drug Administration, 2011, US FISH WILDL SERV A; USDA, 2021, OILS WORLD MARK TRAD; Vietnamese Ministry of Agriculture and Rural Development, 2003, GUID 788 TY QLT REG; Zhao L, 2012, 201259905086EN AG, P5990	20	24	24	0	18	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 21	2015	10	4							e0124267	10.1371/journal.pone.0124267	http://dx.doi.org/10.1371/journal.pone.0124267			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CG3XJ	25897517	Green Published, Green Submitted, gold			2023-01-03	WOS:000353212600059
J	Sugyo, A; Tsuji, AB; Sudo, H; Okada, M; Koizumi, M; Satoh, H; Kurosawa, G; Kurosawa, Y; Saga, T				Sugyo, Aya; Tsuji, Atsushi B.; Sudo, Hitomi; Okada, Maki; Koizumi, Mitsuru; Satoh, Hirokazu; Kurosawa, Gene; Kurosawa, Yoshikazu; Saga, Tsuneo			Evaluation of Efficacy of Radioimmunotherapy with Y-90- Labeled Fully Human Anti-Transferrin Receptor Monoclonal Antibody in Pancreatic Cancer Mouse Models	PLOS ONE			English	Article							EXTERNAL-BEAM RADIOTHERAPY; TRANSFERRIN RECEPTOR; THERAPEUTIC AGENTS; TARGETED DELIVERY; CELL-GROWTH; GEMCITABINE; INHIBITION; CHEMOTHERAPY; METASTASES; BIOLOGY	Objective Pancreatic cancer is an aggressive tumor and the prognosis remains poor. Therefore, development of more effective therapy is needed. We previously reported that Zr-89-labeled TSP-A01, an antibody against transferrin receptor (TfR), is highly accumulated in a pancreatic cancer xenograft, but not in major normal organs. In the present study, we evaluated the efficacy of radioimmunotherapy (RIT) with Y-90-TSP-A01 in pancreatic cancer mouse models. Methods TfR expression in pancreatic cancer cell lines (AsPC-1, BxPC-3, MIAPaCa-2) was evaluated by immunofluorescence staining. In-111-labeled anti-TfR antibodies (TSP-A01, TSP-A02) were evaluated in vitro by cell binding assay with the three cell lines and by competitive inhibition assay with MIAPaCa-2. In vivo biodistribution was evaluated in mice bearing BxPC-3 and MIAPaCa-2 xenografts. Tumor volumes of BxPC-3 and MIAPaCa-2 were sequentially measured after Y-90-TSP-A01 injection and histological analysis of tumors was conducted. Results MIAPaCa-2 cells showed the highest TfR expression, followed by AsPC-1 and BxPC-3 cells. In-111-TSP-A01 and In-111-TSP-A02 bound specifically to the three cell lines according to TfR expression. The dissociation constants for TSP-A01, DOTA-TSP-A01, TSP-A02, and DOTA-TSP-A02 were 0.22, 0.28, 0.17, and 0.22 nM, respectively. In-111-TSP-A01 was highly accumulated in tumors, especially in MIAPaCa-2, but this was not true of In-111-TSP-A02. The absorbed dose for Y-90- TSP-A01 was estimated to be 8.3 Gy/MBq to BxPC-3 and 12.4 Gy/MBq to MIAPaCa-2. MIAPaCa-2 tumors treated with 3.7 MBq of Y-90-TSP-A01 had almost completely disappeared around 3 weeks after injection and regrowth was not observed. Growth of BxPC-3 tumors was inhibited by 3.7 MBq of Y-90-TSP-A01, but the tumor size was not reduced. Conclusion Y-90-TSP-A01 treatment achieved an almost complete response in MIAPaCa-2 tumors, whereas it merely inhibited the growth of BxPC-3 tumors. Y-90-TSP-A01 is a promising RIT agent for pancreatic cancer, although further investigation is necessary to improve the efficacy for the radioresistant types like BxPC-3.	[Sugyo, Aya; Tsuji, Atsushi B.; Sudo, Hitomi; Saga, Tsuneo] Natl Inst Radiol Sci, Mol Imaging Ctr, Diagnost Imaging Program, Inage Ku, Chiba 260, Japan; [Okada, Maki] Natl Inst Radiol Sci, Mol Imaging Ctr, Mol Probe Program, Inage Ku, Chiba 260, Japan; [Koizumi, Mitsuru] Canc Inst Hosp, Dept Nucl Med, Koto Ku, Tokyo, Japan; [Satoh, Hirokazu] Perseus Prote Inc, Reserch & Dev Div, Meguro Ku, Tokyo, Japan; [Kurosawa, Gene; Kurosawa, Yoshikazu] Fujita Hlth Univ, Sch Med, Innovat Ctr Adv Med, Toyoake, Aichi 47011, Japan	National Institutes for Quantum Science & Technology; National Institutes for Quantum Science & Technology; Fujita Health University	Tsuji, AB (corresponding author), Natl Inst Radiol Sci, Mol Imaging Ctr, Diagnost Imaging Program, Inage Ku, Chiba 260, Japan.	a_tsuji@nirs.go.jp	TSUJI, Atsushi B/I-9922-2019; Kurosawa, Gene/R-6508-2018	TSUJI, Atsushi B/0000-0003-2726-288X; Kurosawa, Gene/0000-0001-9477-7467; Satoh, Hirokazu/0000-0001-7629-3346	Ministry of Education, Culture, Sports, Science and Technology of Japan [KAKENHI 25861140]; National Institute of Radiological Sciences	Ministry of Education, Culture, Sports, Science and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); National Institute of Radiological Sciences	This study was supported by the grants from the Ministry of Education, Culture, Sports, Science and Technology of Japan (KAKENHI 25861140 to AS) and the National Institute of Radiological Sciences (to TS). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Barendswaard EC, 1999, J NUCL MED, V40, P1764; Boyle P, 2008, WORLD CANC REPORT; BURAS RR, 1993, INT J RADIAT ONCOL, V25, P473, DOI 10.1016/0360-3016(93)90069-8; Cheson BD, 2003, BLOOD, V101, P391, DOI 10.1182/blood-2002-06-1793; Daniels TR, 2006, CLIN IMMUNOL, V121, P144, DOI 10.1016/j.clim.2006.06.010; Daniels TR, 2006, CLIN IMMUNOL, V121, P159, DOI 10.1016/j.clim.2006.06.006; Daniels TR, 2012, BBA-GEN SUBJECTS, V1820, P291, DOI 10.1016/j.bbagen.2011.07.016; Donohue E, 2013, J CANCER, V4, P585, DOI 10.7150/jca.7030; Eckerman K. F., 2008, MIRD RADIONUCLIDE DA; Evans J, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2013-004215; GATTER KC, 1983, J CLIN PATHOL, V36, P539, DOI 10.1136/jcp.36.5.539; Graf F, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088239; Halperin E C, 2008, PEREZ BRADYS PRINCIP; Hidalgo M, 2010, NEW ENGL J MED, V362, P1605, DOI 10.1056/NEJMra0901557; Illidge TM, 2014, J CLIN ONCOL, V32, P212, DOI 10.1200/JCO.2013.50.3110; Kano MR, 2007, P NATL ACAD SCI USA, V104, P3460, DOI 10.1073/pnas.0611660104; Kassis AI, 2008, SEMIN NUCL MED, V38, P358, DOI 10.1053/j.semnuclmed.2008.05.002; Klee GG, 2000, ARCH PATHOL LAB MED, V124, P921; Knoop RF, 2014, NEOPLASIA, V16, P463, DOI 10.1016/j.neo.2014.05.010; Koppe MJ, 2006, CANCER BIOTHER RADIO, V21, P506, DOI 10.1089/cbr.2006.21.506; LESLEY JF, 1985, MOL CELL BIOL, V5, P1814, DOI 10.1128/MCB.5.8.1814; LINDMO T, 1984, J IMMUNOL METHODS, V72, P77, DOI 10.1016/0022-1759(84)90435-6; Matsumura Y, 2012, ADV DRUG DELIVER REV, V64, P710, DOI 10.1016/j.addr.2011.12.010; MEARES CF, 1990, BRIT J CANCER, V62, P21; Minchinton AI, 2006, NAT REV CANCER, V6, P583, DOI 10.1038/nrc1893; NECKERS LM, 1986, CANCER INVEST, V4, P461, DOI 10.3109/07357908609017524; NIITSU Y, 1987, TOHOKU J EXP MED, V153, P239, DOI 10.1620/tjem.153.239; Olive KP, 2009, SCIENCE, V324, P1457, DOI 10.1126/science.1171362; PANACCIO M, 1987, IMMUNOL CELL BIOL, V65, P461, DOI 10.1038/icb.1987.55; Rahib L, 2014, CANCER RES, V74, P2913, DOI 10.1158/0008-5472.CAN-14-0155; Rucki AA, 2014, WORLD J GASTROENTERO, V20, P2237, DOI 10.3748/wjg.v20.i9.2237; Ryschich E, 2004, EUR J CANCER, V40, P1418, DOI 10.1016/j.ejca.2004.01.036; Siegel R, 2014, CA-CANCER J CLIN, V64, P9, DOI 10.3322/caac.21208; Sogawa C, 2010, NUCL MED BIOL, V37, P179, DOI 10.1016/j.nucmedbio.2009.10.008; Sudo H, 2012, CANCER SCI, V103, P203, DOI 10.1111/j.1349-7006.2011.02126.x; Sugyo A, 2015, NUCL MED COMMUN, V36, P286, DOI 10.1097/MNM.0000000000000245; TROWBRIDGE IS, 1982, P NATL ACAD SCI-BIOL, V79, P1175, DOI 10.1073/pnas.79.4.1175; van Bree C, 2008, BRIT J CANCER, V98, P1226, DOI 10.1038/sj.bjc.6604287; Vogel CA, 1997, CANCER RES, V57, P447; Yoshida C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059248	40	19	20	1	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 20	2015	10	4							e0123761	10.1371/journal.pone.0123761	http://dx.doi.org/10.1371/journal.pone.0123761			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CG3XA	25893775	Green Submitted, Green Published, gold			2023-01-03	WOS:000353211700055
J	Xiao, Y; Liu, YY; Huang, SH; Sun, XM; Tang, Y; Cheng, JR; Wang, T; Li, F; Kuang, YX; Luo, R; Zhao, XS				Xiao, Ya; Liu, Yanyan; Huang, Shaohui; Sun, Xiaomin; Tang, Yang; Cheng, Jingru; Wang, Tian; Li, Fei; Kuang, Yuxiang; Luo, Ren; Zhao, Xiaoshan			The Efficacy of Shugan Jianpi Zhixie Therapy for Diarrhea-Predominant Irritable Bowel Syndrome: A Meta-Analysis of Randomized, Double-Blind, Placebo-Controlled Trials	PLOS ONE			English	Article							CHINESE HERBAL MEDICINE; QUALITY-OF-LIFE; ALTERNATIVE MEDICINE; RESPONSE RATE; RISK-FACTORS; COMPLEMENTARY	Background Shugan Jianpi Zhixie therapy (SJZT) has been widely used to treat diarrhea-predominant irritable bowel syndrome (IBS-D), but the results are still controversial. A meta-analysis of randomized, double-blind, placebo-controlled trials was performed to assess the efficacy and tolerability of SJZT for IBS-D. Methods The MEDLINE, EMBASE, Cochrane Library, the China National Knowledge Infrastructure database, the Chinese Biomedical Literature database and the Wanfang database were searched up to June 2014 with no language restrictions. Summary estimates, including 95% confidence intervals (CI), were calculated for global symptom improvement, abdominal pain improvement, and Symptom Severity Scale (BSS) score. Results Seven trials (N=954) were included. The overall risk of bias assessment was low. SJZT showed significant improvement for global symptom compared to placebo (RR 1.61; 95% CI 1.24, 2.10; P = 0.0004; therapeutic gain = 33.0%; number needed to treat (NNT) = 3.0). SJZT was significantly more likely to reduce overall BSS score (SMD-0.67; 95% CI 0.94, -0.40; P < 0.00001) and improve abdominal pain (RR 4.34; 95% CI 2.64, 7.14; P < 0.00001) than placebo. The adverse events of SJZT were no different from those of placebo. Conclusions This meta-analysis suggests that SJZT is an effective and safe therapy option for patients with IBS-D. However, due to the high clinical heterogeneity and small sample size of the included trials, further standardized preparation, large-scale and rigorously designed trials are needed.	[Xiao, Ya; Tang, Yang; Cheng, Jingru; Wang, Tian; Li, Fei; Luo, Ren] Southern Med Univ, Nanfang Hosp, Dept Tradit Chinese Med, Guangzhou 510515, Guangdong, Peoples R China; [Xiao, Ya; Huang, Shaohui; Sun, Xiaomin; Tang, Yang; Cheng, Jingru; Wang, Tian; Li, Fei; Luo, Ren; Zhao, Xiaoshan] Southern Med Univ, Sch Tradit Chinese Med, Guangzhou 510515, Guangdong, Peoples R China; [Liu, Yanyan] Guangzhou Univ Chinese Med, Affiliated Hosp 1, Dept Rheumat Dis, Guangzhou 510405, Guangdong, Peoples R China; [Kuang, Yuxiang] Guangdong Prov Hosp TCM, Digest Dept, Guangzhou 510120, Guangdong, Peoples R China	Southern Medical University - China; Southern Medical University - China; Guangzhou University of Chinese Medicine; Guangzhou University of Chinese Medicine	Zhao, XS (corresponding author), Southern Med Univ, Sch Tradit Chinese Med, Guangzhou 510515, Guangdong, Peoples R China.	zhaoxs0609@163.com	liu, yan/HCI-5542-2022; liu, yan/HGV-1365-2022; Zhao, Xiaoshan/GPF-7929-2022		NSFC-Guangdong joint fund [U1132001]; National Science Foundation of China [81173146, 81373707, 81403447]; State Administration of Traditional Chinese Medicine [JDZX2012013]; Major State Basic Research Development Program of China (973 Program) [2013CB531700]; Guangdong Provincial Department of Science and Technology and Guangdong Provincial Academy of Traditional Chinese Medicine joint fund [2011B032200004, 2012A032500004]; Guangdong Provincial Department of Science and Technology fund [2011B031700018]; China Postdoctoral Science Foundation [2014M552187]; Administration of Traditional Chinese Medicine of Guangdong Province, China [2012KT1145]	NSFC-Guangdong joint fund; National Science Foundation of China(National Natural Science Foundation of China (NSFC)); State Administration of Traditional Chinese Medicine; Major State Basic Research Development Program of China (973 Program)(National Basic Research Program of China); Guangdong Provincial Department of Science and Technology and Guangdong Provincial Academy of Traditional Chinese Medicine joint fund; Guangdong Provincial Department of Science and Technology fund; China Postdoctoral Science Foundation(China Postdoctoral Science Foundation); Administration of Traditional Chinese Medicine of Guangdong Province, China	This work was supported by the NSFC-Guangdong joint fund (Nos. U1132001), the National Science Foundation of China (Nos. 81173146, 81373707 and 81403447), the State Administration of Traditional Chinese Medicine (Nos. JDZX2012013), the Major State Basic Research Development Program of China (973 Program Nos. 2013CB531700), the Guangdong Provincial Department of Science and Technology and Guangdong Provincial Academy of Traditional Chinese Medicine joint fund (Nos. 2011B032200004 and 2012A032500004), the Guangdong Provincial Department of Science and Technology fund (Nos. 2011B031700018), China Postdoctoral Science Foundation (Nos. 2014M552187), and Administration of Traditional Chinese Medicine of Guangdong Province, China (Nos. 2012KT1145). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alonso-Coello P, 2006, BRIT J SURG, V93, P909, DOI 10.1002/bjs.5378; [Anonymous], 2010, CHINA J TRAD CHIN ME, V25, P1062; BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446; Bensoussan A, 1998, JAMA-J AM MED ASSOC, V280, P1585, DOI 10.1001/jama.280.18.1585; Bian ZX, 2006, J ALTERN COMPLEM MED, V12, P401, DOI 10.1089/acm.2006.12.401; Brandt LJ, 2009, AM J GASTROENTEROL, V104, pS1, DOI 10.1038/ajg.2008.122; Cai LJ, 2013, CHIN ARCH TRAD CHIN, V5, P1097; Chang JY, 2010, TRENDS PHARMACOL SCI, V31, P326, DOI 10.1016/j.tips.2010.04.008; Chen DF, 2010, CHIN J DIG, V30, P327; Chitkara DK, 2008, AM J GASTROENTEROL, V103, P765, DOI 10.1111/j.1572-0241.2007.01722.x; Cong J, 2013, WORLD CHIN J DIGEST, V21, P1234; Dean BB, 2005, AM J MANAG CARE, V11, pS17; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; Dorn SD, 2007, NEUROGASTROENT MOTIL, V19, P630, DOI 10.1111/j.1365-2982.2007.00937.x; El-Serag HB, 2002, ALIMENT PHARM THER, V16, P1171, DOI 10.1046/j.1365-2036.2002.01290.x; Ford AC, 2010, ALIMENT PHARM THER, V32, P144, DOI 10.1111/j.1365-2036.2010.04328.x; Ford AC, 2009, AM J GASTROENTEROL, V104, P1831, DOI 10.1038/ajg.2009.223; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; Hussain Z, 2006, ALIMENT PHARM THER, V23, P465, DOI 10.1111/j.1365-2036.2006.02776.x; Karantanos T, 2010, GUT PATHOG, V2, DOI 10.1186/1757-4749-2-3; Leung WK, 2006, AM J GASTROENTEROL, V101, P1574, DOI 10.1111/j.1572-0241.2006.00576.x; Li YM, 2014, CHIN J INTEGR TRAD W, V22, P1; Li YM, 2010, SHANGHAI J TRAD CHIN, V44, P33; Lin JZ, 2010, CHINESE J CHEM ENG, V18, P1, DOI 10.1016/S1004-9541(08)60315-8; Lin M, 2012, SHANGHAI J TCM, V46, P82; Liu JP, 2006, COCHRANE DB SYST REV, VJ 25; Lovell RM, 2012, CLIN GASTROENTEROL H, V10, P712, DOI 10.1016/j.cgh.2012.02.029; Pogue JM, 1997, CONTROL CLIN TRIALS, V18, P580, DOI 10.1016/S0197-2456(97)00051-2; Rapps N, 2008, J PSYCHOSOM RES, V64, P599, DOI 10.1016/j.jpsychores.2008.02.018; Ringel Y, 2013, AM J PHYSIOL-GASTR L, V305, pG529, DOI 10.1152/ajpgi.00207.2012; Saito YA, 2002, AM J GASTROENTEROL, V97, P1910; Sands BE, 2009, DIGEST DIS, V27, P68, DOI 10.1159/000268123; Shi J, 2008, WORLD J GASTROENTERO, V14, P454, DOI 10.3748/wjg.14.454; Sung JJY, 2004, ALIMENT PHARM THER, V20, P1205, DOI 10.1111/j.1365-2036.2004.02242.x; TALLEY NJ, 1995, GASTROENTEROLOGY, V109, P1736, DOI 10.1016/0016-5085(95)90738-6; Tang X. D., 2011, P OFC, P1; Tornblom H, 2002, GASTROENTEROLOGY, V123, P1972, DOI 10.1053/gast.2002.37059; Xiao HT, 2015, AM J CHINESE MED, V43, P1, DOI 10.1142/S0192415X15500019	38	15	16	4	24	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 8	2015	10	4							e0122397	10.1371/journal.pone.0122397	http://dx.doi.org/10.1371/journal.pone.0122397			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CF3WA	25853241	Green Submitted, Green Published, gold			2023-01-03	WOS:000352478400067
J	Guan, M; Ma, LJ; Li, L; Yan, B; Zhao, L; Tong, L; Dou, SW; Xia, LJ; Wang, MY; Shi, DP				Guan, Min; Ma, Lijia; Li, Li; Yan, Bin; Zhao, Lu; Tong, Li; Dou, Shewei; Xia, Linjie; Wang, Meiyun; Shi, Dapeng			Self-Regulation of Brain Activity in Patients with Postherpetic Neuralgia: A Double-Blind Randomized Study Using Real-Time fMRI Neurofeedback	PLOS ONE			English	Article							ANTERIOR CINGULATE; VISUAL FEEDBACK; CORTEX ACTIVITY; INSULAR CORTEX; CHRONIC PAIN; MODULATION; ACTIVATION; BIOFEEDBACK; GYRUS	Background A pilot study has shown that real-time fMRI (rtfMRI) neurofeedback could be an alternative approach for chronic pain treatment. Considering the relative small sample of patients recruited and not strictly controlled condition, it is desirable to perform a replication as well as a double-blinded randomized study with a different control condition in chronic pain patients. Here we conducted a rtfMRI neurofeedback study in a subgroup of pain patients - patients with postherpetic neuralgia (PHN) and used a different sham neurofeedback control. We explored the feasibility of self-regulation of the rostral anterior cingulate cortex (rACC) activation in patients with PHN through rtfMRI neurofeedback and regulation of pain perception. Methods Sixteen patients (46-71 years) with PHN were randomly allocated to a experimental group (n = 8) or a control group (n = 8). 2 patients in the control group were excluded for large head motion. The experimental group was given true feedback information from their rACC whereas the control group was given sham feedback information from their posterior cingulate cortex (PCC). All subjects were instructed to perform an imagery task to increase and decrease activation within the target region using rtfMRI neurofeedback. Results Online analysis showed 6/8 patients in the experimental group were able to increase and decrease the blood oxygen level dependent (BOLD) fMRI signal magnitude during intermittent feedback training. However, this modulation effect was not observed in the control group. Offline analysis showed that the percentage of BOLD signal change of the target region between the last and first training in the experimental group was significantly different from the control group's and was also significantly different than 0. The changes of pain perception reflected by numerical rating scale (NRS) in the experimental group were significantly different from the control group. However, there existed no significant correlations between BOLD signal change and NRS change. Conclusion Patients with PHN could learn to voluntarily control over activation in rACC through rtfMRI neurofeedback and alter their pain perception level. The present study may provide new evidence that rtfMRI neurofeedback training may be a supplemental approach for chronic clinical pain management.	[Guan, Min; Ma, Lijia; Dou, Shewei; Wang, Meiyun; Shi, Dapeng] Zhengzhou Univ, Peoples Hosp, Dept Radiol, Zhengzhou 450052, Henan, Peoples R China; [Li, Li] Zhengzhou Univ, Peoples Hosp 2, Dept Dermatol, Zhengzhou 450052, Henan, Peoples R China; [Yan, Bin; Tong, Li] China Natl Digital Switching Syst Engn & Technol, Zhengzhou, Henan, Peoples R China; [Zhao, Lu] McGill Univ, Montreal Neurol Inst, McConnell Brain Imaging Ctr, Quebec City, PQ, Canada; [Xia, Linjie] Zhengzhou Univ, Peoples Hosp, Dept Pain Management, Zhengzhou 450052, Henan, Peoples R China	Zhengzhou University; Zhengzhou University; PLA Information Engineering University; McGill University; Zhengzhou University	Wang, MY (corresponding author), Zhengzhou Univ, Peoples Hosp, Dept Radiol, Zhengzhou 450052, Henan, Peoples R China.	meiyun9999@gmail.com; cjr.shidapeng@vip.163.com	li, li/AAT-2097-2020; LI, LI QING/GRR-8855-2022; Li, Li/AEM-3636-2022; li, li/GPX-3938-2022; LI, LI/GVS-5344-2022; li, li/HII-4157-2022		National High Technology Research and Development Program of China [2012AA011603]; National Natural Science Foundation of China [81271534]	National High Technology Research and Development Program of China(National High Technology Research and Development Program of China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This study was supported by 1. The National High Technology Research and Development Program of China (no. 2012AA011603). (http://www.863.gov.cn/). BY, LT, MYW, DPS received the funding. 2. The National Natural Science Foundation of China (no. 81271534). (http://www.nsfc.gov.cn/). MG, LJM, DPS received the funding. Both funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 1994, IASP TASK FORCE TAXO; Bray S, 2007, J NEUROSCI, V27, P7498, DOI 10.1523/JNEUROSCI.2118-07.2007; Caria A, 2012, NEUROSCIENTIST, V18, P487, DOI 10.1177/1073858411407205; Caria A, 2010, BIOL PSYCHIAT, V68, P425, DOI 10.1016/j.biopsych.2010.04.020; Caro XJ, 2011, APPL PSYCHOPHYS BIOF, V36, P193, DOI 10.1007/s10484-011-9159-9; Cauda F, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041929; Chapin H, 2012, NEUROSCI LETT, V520, P174, DOI 10.1016/j.neulet.2012.02.076; Decharms RC, 2008, NAT REV NEUROSCI, V9, P720, DOI 10.1038/nrn2414; deCharms RC, 2005, P NATL ACAD SCI USA, V102, P18626, DOI 10.1073/pnas.0505210102; DeCharms RC, 2004, NEUROIMAGE, V21, P436, DOI 10.1016/j.neuroimage.2003.08.041; Decharms RC, 2012, 1ST SWISS RTFMRI NEU; Denkinger MD, 2014, AGE AGEING, V43, P510, DOI 10.1093/ageing/afu013; Emmert K, 2014, FRONT BEHAV NEUROSCI, V8, DOI 10.3389/fnbeh.2014.00350; Ferreira-Valente MA, 2011, PAIN, V152, P2399, DOI 10.1016/j.pain.2011.07.005; Geha PY, 2007, PAIN, V128, P88, DOI 10.1016/j.pain.2006.09.014; Glick RM, 2010, PRIMARY CARE, V37, P91, DOI 10.1016/j.pop.2009.09.005; Goebel R, 2012, NEUROIMAGE, V62, P748, DOI 10.1016/j.neuroimage.2012.01.083; Grech R, 2008, J NEUROENG REHABIL, V5, DOI 10.1186/1743-0003-5-25; Haller S, 2010, EUR RADIOL, V20, P696, DOI 10.1007/s00330-009-1595-z; Hamilton JP, 2011, HUM BRAIN MAPP, V32, P22, DOI 10.1002/hbm.20997; Iannetti GD, 2010, EXP BRAIN RES, V205, P1, DOI 10.1007/s00221-010-2340-1; Johnson RW, 2010, BMC MED, V8, DOI 10.1186/1741-7015-8-37; Mansour AR, 2013, PAIN, V154, P2160, DOI 10.1016/j.pain.2013.06.044; Martin SJ, 2002, HIPPOCAMPUS, V12, P609, DOI 10.1002/hipo.10107; Melzack R, 1999, PAIN, pS121, DOI 10.1016/S0304-3959(99)00145-1; Mercier C, 2009, NEUROREHAB NEURAL RE, V23, P587, DOI 10.1177/1545968308328717; Oaklander AL, 2001, PAIN, V92, P139, DOI 10.1016/S0304-3959(00)00481-4; Posner MI, 2007, COGN AFFECT BEHAV NE, V7, P391, DOI 10.3758/CABN.7.4.391; Posse S, 2003, NEUROIMAGE, V18, P760, DOI 10.1016/S1053-8119(03)00004-1; Rance M, 2014, HUM BRAIN MAPP, V35, P5784, DOI 10.1002/hbm.22585; Rota G, 2009, HUM BRAIN MAPP, V30, P1605, DOI 10.1002/hbm.20621; Sato K, 2010, PAIN MED, V11, P622, DOI 10.1111/j.1526-4637.2010.00819.x; Schmidt-Wilcke T, 2005, NEUROLOGY, V65, P1483, DOI 10.1212/01.wnl.0000183067.94400.80; Schmidt-Wilcke T, 2010, HEADACHE, V50, P1278, DOI 10.1111/j.1526-4610.2010.01637.x; Shackman AJ, 2011, NAT REV NEUROSCI, V12, P154, DOI 10.1038/nrn2994; Sitaram R, 2012, NEUROREHAB NEURAL RE, V26, P256, DOI 10.1177/1545968311418345; Subramanian L, 2011, J NEUROSCI, V31, P16309, DOI 10.1523/JNEUROSCI.3498-11.2011; Sulzer J, 2013, NEUROIMAGE, V76, P386, DOI 10.1016/j.neuroimage.2013.03.033; Tracey I, 2007, NEURON, V55, P377, DOI 10.1016/j.neuron.2007.07.012; Tracey I, 2009, J PAIN, V10, P1113, DOI 10.1016/j.jpain.2009.09.001; TURNER JA, 1982, PAIN, V12, P1, DOI 10.1016/0304-3959(82)90167-1; Weiskopf N, 2003, NEUROIMAGE, V19, P577, DOI 10.1016/S1053-8119(03)00145-9; World Medical Association General Assembly, 2004, J Int Bioethique, V15, P124; Young KD, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088785	44	34	35	1	21	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 7	2015	10	4							e0123675	10.1371/journal.pone.0123675	http://dx.doi.org/10.1371/journal.pone.0123675			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CF3VU	25848773	Green Published, gold, Green Submitted			2023-01-03	WOS:000352477800250
J	Asfaw, A; Ali, D; Eticha, T; Alemayehu, A; Alemayehu, M; Kindeya, F				Asfaw, Addisu; Ali, Dagim; Eticha, Tadele; Alemayehu, Adissu; Alemayehu, Mussie; Kindeya, Filmon			CD4 Cell Count Trends after Commencement of Antiretroviral Therapy among HIV-Infected Patients in Tigray, Northern Ethiopia: A Retrospective Cross-Sectional Study	PLOS ONE			English	Article							HIV-1-INFECTED PATIENTS; INITIATION; AFRICA; MORTALITY; CD4+COUNT; RECOVERY; OUTCOMES	Background The rate and extent of CD4 cell recovery varies widely among HIV-infected patients with different baseline CD4 cell count strata. The objective of the study was to assess trends in CD4 cell counts in HIV-infected patients after initiation of antiretroviral therapy in Tigray, Northern Ethiopia. Methods A retrospective cross-sectional study was conducted by reviewing medical records of HIV patients who received antiretroviral treatment at twenty health centers in Tigray region during 2008-2012. Multi-stage cluster sampling technique was employed to collect data, and the data were analyzed using SPSS version 20.0 software. Results The median change from baseline to the most recent CD4 cell count was +292 cells/mu l. By 5 years, the overall median (inter-quartile range, IQR) CD4 cell count was 444(263-557) cells/mu l while the median (IQR) CD4 cell count was 342(246-580) cells/mu l among patients with baseline CD4 cell counts <= 200 cells/mu l, 500(241-557) cells/mu l among those with baseline CD4 cell counts of 201-350 cells/mu l, and 652(537-767) cells/mu l among those with baseline CD4 cell counts >350 cells/mu l. Higher baseline CD4 cell counts and being male were independently associated with the risk of immunological non-response at 12 months. Furthermore, it was also investigated that these factors were significant predictors of subsequent CD4 cell recovery. Conclusions Patients with higher baseline CD4 cell stratum returned to normal CD4 Cell counts though they had an increased risk of immunological non-response at 12 months compared to those with the least baseline CD4 cell stratum. The findings suggest that consideration be given to initiation of HAART at a CD4 cell count >350 cells/mu l to achieve better immune recovery, and to HIV-infected male patients to improve their health seeking behavior.	[Asfaw, Addisu; Ali, Dagim; Eticha, Tadele; Alemayehu, Adissu] Mekelle Univ, Coll Hlth Sci, Dept Pharm, Mekelle, Ethiopia; [Alemayehu, Mussie] Mekelle Univ, Coll Hlth Sci, Dept Publ Hlth, Mekelle, Ethiopia; [Kindeya, Filmon] Tigray Reg Hlth Bur, Social Mobilizat, Advocacy & Commun HIV Div, Mekelle, Ethiopia	Mekelle University; Mekelle University	Eticha, T (corresponding author), Mekelle Univ, Coll Hlth Sci, Dept Pharm, Mekelle, Ethiopia.	td.eticha@gmail.com	Alemayehu, Mussie/AAH-3016-2019	Alemayehu, Mussie/0000-0002-0035-631X	MSH/USAID under Ethiopian Network for HIV/AIDS Treatment, Care and Support programme	MSH/USAID under Ethiopian Network for HIV/AIDS Treatment, Care and Support programme(United States Agency for International Development (USAID))	This study was funded by MSH/USAID under Ethiopian Network for HIV/AIDS Treatment, Care and Support programme. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Anude CJ, 2013, BMC INFECT DIS, V13, DOI 10.1186/1471-2334-13-113; Baker JV, 2008, AIDS, V22, P841, DOI 10.1097/QAD.0b013e3282f7cb76; Florence E, 2003, HIV Med, V4, P255, DOI 10.1046/j.1468-1293.2003.00156.x; Fox M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069300; Galdas PM, 2005, J ADV NURS, V49, P616, DOI 10.1111/j.1365-2648.2004.03331.x; Gottlieb GS, 2002, J INFECT DIS, V185, P905, DOI 10.1086/339295; Kelley CF, 2009, CLIN INFECT DIS, V48, P787, DOI 10.1086/597093; Kilaru KR, 2006, HIV MED, V7, P99, DOI 10.1111/j.1468-1293.2006.00347.x; Kyaw NL, 2013, SE ASIAN J TROP MED, V44, P232; Lawn SD, 2006, BMC INFECT DIS, V6, DOI 10.1186/1471-2334-6-59; Lawn SD, 2005, AIDS, V19, P2141, DOI 10.1097/01.aids.0000194802.89540.e1; Lepri AC, 2001, AIDS, V15, P983, DOI 10.1097/00002030-200105250-00006; Malaza A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070126; Michael CG, 2002, SCAND J INFECT DIS, V34, P45, DOI 10.1080/00365540110076930; Moore RD, 2007, CLIN INFECT DIS, V44, P441, DOI 10.1086/510746; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301; Panel on Antiretroviral Guidelines for Adults and Adolescents, GUID US ANT AG HIV 1; Rajasekaran S, 2009, J POSTGRAD MED, V55, P261, DOI 10.4103/0022-3859.58929; Reda AA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058595; Shastri S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072188; Smith CJ, 2004, J INFECT DIS, V190, P1860, DOI 10.1086/425075; Sterne JAC, 2009, LANCET, V373, P1352, DOI 10.1016/S0140-6736(09)60612-7; WHO, 2010, ANT THER HIV INF AD	23	25	26	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 27	2015	10	3							e0122583	10.1371/journal.pone.0122583	http://dx.doi.org/10.1371/journal.pone.0122583			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CE8ZT	25816222	Green Submitted, Green Published, gold			2023-01-03	WOS:000352133600188
J	Hung, TH; Hsieh, TT; Liu, HP				Hung, Tai-Ho; Hsieh, T'sang-T'ang; Liu, Hung-Pin			Differential Effects of Epidural Analgesia on Modes of Delivery and Perinatal Outcomes between Nulliparous and Multiparous Women: A Retrospective Cohort Study	PLOS ONE			English	Article							INSTRUMENTAL DELIVERY; LABOR; POPULATION; RISK; LENGTH; AGE	Background Epidural analgesia is considered one of the most effective methods for pain relief during labor. However, it is not clear whether similar effects of epidural analgesia on the progression of labor, modes of delivery, and perinatal outcomes exist between nulliparous and multiparous women. Methodology/Principal Findings A retrospective cohort study was conducted to analyze all deliveries after 37 weeks of gestation, with the exclusion of pregnancies complicated by multiple gestations and fetal anomalies and deliveries without trials of labor; these criteria produced a study population of n = 16,852. A multivariable logistic regression model was constructed to control for confounders. In total, 7260 of 10,175 (71.4%) nulliparous and 2987 of 6677 (44.7%) multiparous parturients were administered epidural analgesia. The independent factors for intrapartum epidural analgesia included a low prepregnancy body mass index, genetic amniocentesis, group B streptococcal colonization of the genito-rectal tract, and augmentation and induction of labor. In the nulliparous women, epidural analgesia was a significant risk factor for operative vaginal delivery (adjusted odds ratio [OR] 2.14, 95% confidence interval [CI] 1.80-2.54); however, it was a protective factor against Caesarean delivery (adjusted OR 0.62, 95% CI 0.55-0.69). Epidural analgesia remained a significant risk factor for operative vaginal delivery (adjusted OR 2.17, 95% CI 1.58-2.97) but not for Caesarean delivery (adjusted OR 1.09, 95% CI 0.77-1.55) in the multiparous women. Furthermore, the women who were administered epidural analgesia during the trials of labor had similar rates of adverse perinatal outcomes compared with the women who were not administered epidural analgesia, except that a higher rate of 1-minute Apgar scores less than 7 was noted in the nulliparous women who were administered epidural analgesia. Conclusions/Significance Intrapartum epidural analgesia has differential effects on the modes of delivery between nulliparous and multiparous women, and it is not associated with adverse perinatal outcomes.	[Hung, Tai-Ho; Hsieh, T'sang-T'ang] Chang Gung Mem Hosp, Dept Obstet & Gynecol, Taipei 10591, Taiwan; [Hung, Tai-Ho] Chang Gung Univ, Dept Chinese Med, Coll Med, Taoyuan, Taiwan; [Liu, Hung-Pin] Chang Gung Mem Hosp, Dept Anesthesiol, Taipei 10591, Taiwan	Chang Gung Memorial Hospital; Chang Gung University; Chang Gung Memorial Hospital	Hung, TH (corresponding author), Chang Gung Mem Hosp, Dept Obstet & Gynecol, 199 Tung Hwa N Rd, Taipei 10591, Taiwan.	thh20@cgmh.org.tw	Hung, Tai-Ho/ABD-1800-2020; Hung, Tai-Ho/C-7584-2011	Hung, Tai-Ho/0000-0003-2354-7060				Anim-Somuah M, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000331.pub3; Boyle A, 2013, OBSTET GYNECOL, V122, P33, DOI 10.1097/AOG.0b013e3182952242; Decca L, 2004, J Matern Fetal Neonatal Med, V16, P115; Ekeus C, 2009, ACTA OBSTET GYN SCAN, V88, P397, DOI 10.1080/00016340902763236; Eriksen LM, 2011, BIRTH-ISS PERINAT C, V38, P317, DOI 10.1111/j.1523-536X.2011.00486.x; Eriksson SL, 2006, EUR J OBSTET GYN R B, V128, P270, DOI 10.1016/j.ejogrb.2005.10.030; Halpern SH, 2010, CURR OPIN ANESTHESIO, V23, P317, DOI 10.1097/ACO.0b013e3283385492; Hasegawa J, 2013, J ANESTH, V27, P43, DOI 10.1007/s00540-012-1480-9; Hsieh TT, 2010, EUR J OBSTET GYN R B, V148, P21, DOI 10.1016/j.ejogrb.2009.08.022; HUESTON WJ, 1994, OBSTET GYNECOL, V84, P579; Hung TH, 2013, INT J GYNECOL OBSTET, V122, P212, DOI 10.1016/j.ijgo.2013.03.033; Indraccolo U, 2012, CLIN EXP OBSTET GYN, V39, P310; Jones L, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009234.pub2; Koteles J, 2012, INT J OBSTET ANESTH, V21, P317, DOI 10.1016/j.ijoa.2012.06.006; Lee Hui-Ling, 2008, Chang Gung Med J, V31, P395; Liu EHC, 2004, BMJ-BRIT MED J, V328, P1410, DOI 10.1136/bmj.38097.590810.7C; NERI A, 1986, EUR J OBSTET GYN R B, V22, P1, DOI 10.1016/0028-2243(86)90083-3; Nguyen USDT, 2010, MATERN CHILD HLTH J, V14, P705, DOI 10.1007/s10995-009-0515-9; O'Hana HP, 2008, J MATERN-FETAL NEO M, V21, P517, DOI 10.1080/14767050802040864; Sheiner E, 2000, ANESTH ANALG, V90, P109, DOI 10.1097/00000539-200001000-00024; Wassen MMLH, 2011, BJOG-INT J OBSTET GY, V118, P655, DOI 10.1111/j.1471-0528.2011.02906.x; Worstell T, 2014, OBSTET GYNECOL, V123, p84S, DOI 10.1097/01.AOG.0000447412.62293.82; WUITCHIK M, 1989, OBSTET GYNECOL, V73, P35	23	18	19	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 25	2015	10	3							e0120907	10.1371/journal.pone.0120907	http://dx.doi.org/10.1371/journal.pone.0120907			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CE5MO	25807240	Green Published, gold, Green Submitted			2023-01-03	WOS:000351880000111
J	Valsecchi, ME				Valsecchi, Matias E.			Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma	NEW ENGLAND JOURNAL OF MEDICINE			English	Letter									Huntington Internal Med Grp, Huntington, WV 25705 USA		Valsecchi, ME (corresponding author), Huntington Internal Med Grp, Huntington, WV 25705 USA.	meval78@yahoo.com	Haanen, John/AAD-8578-2022; Haanen, John/AAD-8534-2022; Long, Georgina V/C-1771-2013; gonzález, rene/W-2081-2019; Carlino, Matteo/GRS-7198-2022; Schadendorf, Dirk/AAE-8206-2019; sileni, vanna chiarion/B-9042-2018; Ascierto, Paolo A/J-9106-2016; Ferrucci, Pier Francesco/AAQ-9002-2020; Marquez-Rodas, Ivan/ABD-5532-2021; Rutkowski, Piotr/B-3907-2013	Haanen, John/0000-0001-5884-7704; Long, Georgina V/0000-0001-8894-3545; sileni, vanna chiarion/0000-0001-9191-9124; Ascierto, Paolo A/0000-0002-8322-475X; Marquez-Rodas, Ivan/0000-0002-2476-668X; Rutkowski, Piotr/0000-0002-8920-5429; McArthur, Grant/0000-0001-8908-6071; Sznol, Mario/0000-0002-4359-8749; Larkin, James/0000-0001-5569-9523; Ferrucci, Pier Francesco/0000-0001-6255-5851; Bastholt, Lars/0000-0001-5478-9826; coral, sandra/0000-0002-1308-3082; Melucci, Maria Teresa/0000-0002-1677-3345; Wagstaff, John/0000-0002-1140-5981; Grob, Jean-Jacques/0000-0002-0667-153X; Carlino, Matteo/0000-0002-7861-4104; Maio, Michele/0000-0002-0323-6321	NATIONAL CANCER INSTITUTE [P30CA008748] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Atkins MB, 1999, J CLIN ONCOL, V17, P2105, DOI 10.1200/JCO.1999.17.7.2105; Hodi FS, 2015, ASCO ANN M CHIC MAY; Valsecchi ME, 2015, NEW ENGL J MED, V373, P1270, DOI [10.1056/NEJMc1509660, 10.1056/NEJMoa1504030]	3	5391	5595	15	535	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 24	2015	373	13					1270	1270		10.1056/NEJMc1509660	http://dx.doi.org/10.1056/NEJMc1509660			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CR8WP	26398076	Green Published, Green Submitted, Green Accepted			2023-01-03	WOS:000361635200016
J	Larkin, J; Hodi, FS; Wolchok, JD				Larkin, James; Hodi, F. Stephen; Wolchok, Jedd D.			Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma REPLY	NEW ENGLAND JOURNAL OF MEDICINE			English	Letter									[Larkin, James] Royal Marsden Hosp, London SW3 6JJ, England; [Hodi, F. Stephen] Dana Farber Canc Inst, Boston, MA 02115 USA; [Wolchok, Jedd D.] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA	Royal Marsden NHS Foundation Trust; Harvard University; Dana-Farber Cancer Institute; Memorial Sloan Kettering Cancer Center	Larkin, J (corresponding author), Royal Marsden Hosp, London SW3 6JJ, England.	wolchokj@mskcc.org	Haanen, John/AAD-8578-2022; Haanen, John/AAD-8534-2022; Long, Georgina V/C-1771-2013; gonzález, rene/W-2081-2019; Carlino, Matteo/GRS-7198-2022; Schadendorf, Dirk/AAE-8206-2019; sileni, vanna chiarion/B-9042-2018; Ascierto, Paolo A/J-9106-2016; Ferrucci, Pier Francesco/AAQ-9002-2020; Marquez-Rodas, Ivan/ABD-5532-2021; Rutkowski, Piotr/B-3907-2013	Haanen, John/0000-0001-5884-7704; Long, Georgina V/0000-0001-8894-3545; sileni, vanna chiarion/0000-0001-9191-9124; Ascierto, Paolo A/0000-0002-8322-475X; Marquez-Rodas, Ivan/0000-0002-2476-668X; Rutkowski, Piotr/0000-0002-8920-5429; McArthur, Grant/0000-0001-8908-6071; Sznol, Mario/0000-0002-4359-8749; Larkin, James/0000-0001-5569-9523; Ferrucci, Pier Francesco/0000-0001-6255-5851; Bastholt, Lars/0000-0001-5478-9826; coral, sandra/0000-0002-1308-3082; Melucci, Maria Teresa/0000-0002-1677-3345; Wagstaff, John/0000-0002-1140-5981; Grob, Jean-Jacques/0000-0002-0667-153X; Carlino, Matteo/0000-0002-7861-4104; Maio, Michele/0000-0002-0323-6321	NATIONAL CANCER INSTITUTE [P30CA008748] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Postow MA, 2015, NEW ENGL J MED, V372, P2006, DOI 10.1056/NEJMoa1414428	1	5391	5595	15	535	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 24	2015	373	13					1270	1271						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CR8WP	26398076				2023-01-03	WOS:000361635200017
J	Larkin, J; Chiarion-Sileni, V; Gonzalez, R; Grob, JJ; Cowey, CL; Lao, CD; Schadendorf, D; Dummer, R; Smylie, M; Rutkowski, P; Ferrucci, PF; Hill, A; Wagstaff, J; Carlino, MS; Haanen, JB; Maio, M; Marquez-Rodas, I; McArthur, GA; Ascierto, PA; Long, GV; Callahan, MK; Postow, MA; Grossmann, K; Sznol, M; Dreno, B; Bastholt, L; Yang, A; Rollin, LM; Horak, C; Hodi, FS; Wolchok, JD				Larkin, J.; Chiarion-Sileni, V.; Gonzalez, R.; Grob, J. J.; Cowey, C. L.; Lao, C. D.; Schadendorf, D.; Dummer, R.; Smylie, M.; Rutkowski, P.; Ferrucci, P. F.; Hill, A.; Wagstaff, J.; Carlino, M. S.; Haanen, J. B.; Maio, M.; Marquez-Rodas, I.; McArthur, G. A.; Ascierto, P. A.; Long, G. V.; Callahan, M. K.; Postow, M. A.; Grossmann, K.; Sznol, M.; Dreno, B.; Bastholt, L.; Yang, A.; Rollin, L. M.; Horak, C.; Hodi, F. S.; Wolchok, J. D.			Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PLUS DACARBAZINE; BRAF; SURVIVAL; VEMURAFENIB	BACKGROUND Nivolumab (a programmed death 1 [PD-1] checkpoint inhibitor) and ipilimumab (a cytotoxic T-lymphocyte-associated antigen 4 [CTLA-4] checkpoint inhibitor) have been shown to have complementary activity in metastatic melanoma. In this randomized, double-blind, phase 3 study, nivolumab alone or nivolumab plus ipilimumab was compared with ipilimumab alone in patients with metastatic melanoma. METHODS We assigned, in a 1:1:1 ratio, 945 previously untreated patients with unresectable stage III or IV melanoma to nivolumab alone, nivolumab plus ipilimumab, or ipilimumab alone. Progression-free survival and overall survival were coprimary end points. Results regarding progression-free survival are presented here. RESULTS The median progression-free survival was 11.5 months (95% confidence interval [CI], 8.9 to 16.7) with nivolumab plus ipilimumab, as compared with 2.9 months (95% CI, 2.8 to 3.4) with ipilimumab (hazard ratio for death or disease progression, 0.42; 99.5% CI, 0.31 to 0.57; P<0.001), and 6.9 months (95% CI, 4.3 to 9.5) with nivolumab (hazard ratio for the comparison with ipilimumab, 0.57; 99.5% CI, 0.43 to 0.76; P<0.001). In patients with tumors positive for the PD-1 ligand (PD-L1), the median progression-free survival was 14.0 months in the nivolumab-plus-ipilimumab group and in the nivolumab group, but in patients with PD-L1-negative tumors, progression-free survival was longer with the combination therapy than with nivolumab alone (11.2 months [95% CI, 8.0 to not reached] vs. 5.3 months [95% CI, 2.8 to 7.1]). Treatment-related adverse events of grade 3 or 4 occurred in 16.3% of the patients in the nivolumab group, 55.0% of those in the nivolumab-plus-ipilimumab group, and 27.3% of those in the ipilimumab group. CONCLUSIONS Among previously untreated patients with metastatic melanoma, nivolumab alone or combined with ipilimumab resulted in significantly longer progression-free survival than ipilimumab alone. In patients with PD-L1-negative tumors, the combination of PD-1 and CTLA-4 blockade was more effective than either agent alone. (Funded by Bristol-Myers Squibb; CheckMate 067 ClinicalTrials.gov number, NCT01844505.)	[Larkin, J.] Royal Marsden Hosp, Dept Med Oncol, London SW3 6JJ, England; [Wagstaff, J.] Singleton Hosp, South West Wales Canc Inst, Swansea SA2 8QA, W Glam, Wales; [Chiarion-Sileni, V.] Veneto Reg Oncol Res Inst, Melanoma Oncol Unit, Padua, Italy; [Ferrucci, P. F.] European Inst Oncol, Oncol Melanoma Unit, Milan, Italy; [Maio, M.] Univ Hosp Siena, Siena, Italy; [Ascierto, P. A.] Ist Nazl Tumori, Fdn Pascale, Naples, Italy; [Gonzalez, R.] Univ Colorado, Div Med Oncol, Denver, CO 80202 USA; [Grob, J. J.] Aix Marseille Univ, Hop La Timone, AP HM, Marseille, France; [Dreno, B.] Hop Hotel Dieu, Nantes, France; [Cowey, C. L.] Baylor Charles A Sammons Canc Ctr, Dallas, TX USA; [Lao, C. D.] Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA; [Lao, C. D.] Univ Michigan, Dept Dermatol, Ann Arbor, MI 48109 USA; [Schadendorf, D.] Univ Essen Gesamthsch, Dept Dermatol, Essen, Germany; [Dummer, R.] Univ Zurich Hosp, CH-8091 Zurich, Switzerland; [Smylie, M.] Cross Canc Inst, Edmonton, AB T6G 1Z2, Canada; [Rutkowski, P.] Maria Sklodowska Curie Mem Canc Ctr & Inst Oncol, Warsaw, Poland; [Hill, A.] Tasman Oncol Res, Southport Gold Coast, Qld, Australia; [Carlino, M. S.] Univ Sydney, Westmead Hosp, Sydney, NSW 2006, Australia; [Carlino, M. S.] Univ Sydney, Blacktown Hosp, Sydney, NSW 2006, Australia; [Carlino, M. S.; Long, G. V.] Univ Sydney, Melanoma Inst Australia, Sydney, NSW 2006, Australia; [Long, G. V.] Mater Hosp, Sydney, NSW, Australia; [McArthur, G. A.] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia; [McArthur, G. A.] Univ Melbourne, Melbourne, Vic, Australia; [Haanen, J. B.] Netherlands Canc Inst, Div Med Oncol, Amsterdam, Netherlands; [Marquez-Rodas, I.] Hosp Gen Univ Gregorio Maranon, Med Oncol Serv, Madrid, Spain; [Callahan, M. K.; Postow, M. A.; Wolchok, J. D.] Mem Sloan Kettering Canc Ctr, Ludwig Ctr, New York, NY 10021 USA; [Callahan, M. K.; Postow, M. A.; Wolchok, J. D.] Weill Cornell Med Coll, New York, NY USA; [Grossmann, K.] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA; [Sznol, M.] Yale Univ, Sch Med, Yale New Haven Hosp, Yale Canc Ctr,Smilow Canc Hosp, New Haven, CT USA; [Bastholt, L.] Odense Univ Hosp, Dept Oncol, DK-5000 Odense, Denmark; [Yang, A.; Rollin, L. M.] Bristol Myers Squibb Co, Wallingford, CT 06492 USA; [Horak, C.] Bristol Myers Squibb Co, Lawrenceville, NJ USA; [Hodi, F. S.] Dana Farber Canc Inst, Boston, MA 02115 USA	Royal Marsden NHS Foundation Trust; Singleton Hospital; IRCCS Istituto Oncologico Veneto (IOV); IRCCS European Institute of Oncology (IEO); University of Siena; University Hospital of Siena; IRCCS Fondazione Pascale; University of Colorado System; University of Colorado Denver; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Nantes Universite; CHU de Nantes; Baylor University Medical Center; Texas Oncology-Baylor Charles A Sammons Cancer Center; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Duisburg Essen; University of Zurich; University Zurich Hospital; University of Alberta; Maria Sklodowska-Curie National Research Institute of Oncology; University of Sydney; Blacktown & Mount Druitt Hospital; University of Sydney; Melanoma Institute Australia; University of Sydney; Peter Maccallum Cancer Center; University of Melbourne; Netherlands Cancer Institute; General University Gregorio Maranon Hospital; Memorial Sloan Kettering Cancer Center; Cornell University; Huntsman Cancer Institute; Utah System of Higher Education; University of Utah; Yale University; University of Southern Denmark; Odense University Hospital; Bristol-Myers Squibb; Bristol-Myers Squibb; Harvard University; Dana-Farber Cancer Institute	Hodi, FS (corresponding author), Royal Marsden Hosp, Dept Med Oncol, London SW3 6JJ, England.	stephen_hodi@dfci.harvard.edu; wolchokj@mskcc.org	Haanen, John/AAD-8578-2022; Haanen, John/AAD-8534-2022; Long, Georgina V/C-1771-2013; gonzález, rene/W-2081-2019; Carlino, Matteo/GRS-7198-2022; Schadendorf, Dirk/AAE-8206-2019; sileni, vanna chiarion/B-9042-2018; Ascierto, Paolo A/J-9106-2016; Ferrucci, Pier Francesco/AAQ-9002-2020; Marquez-Rodas, Ivan/ABD-5532-2021; Rutkowski, Piotr/B-3907-2013	Haanen, John/0000-0001-5884-7704; Long, Georgina V/0000-0001-8894-3545; sileni, vanna chiarion/0000-0001-9191-9124; Ascierto, Paolo A/0000-0002-8322-475X; Marquez-Rodas, Ivan/0000-0002-2476-668X; Rutkowski, Piotr/0000-0002-8920-5429; McArthur, Grant/0000-0001-8908-6071; Sznol, Mario/0000-0002-4359-8749; Larkin, James/0000-0001-5569-9523; Ferrucci, Pier Francesco/0000-0001-6255-5851; Bastholt, Lars/0000-0001-5478-9826; coral, sandra/0000-0002-1308-3082; Melucci, Maria Teresa/0000-0002-1677-3345; Wagstaff, John/0000-0002-1140-5981; Grob, Jean-Jacques/0000-0002-0667-153X; Carlino, Matteo/0000-0002-7861-4104; Maio, Michele/0000-0002-0323-6321	Bristol-Myers Squibb; NATIONAL CANCER INSTITUTE [P30CA008748] Funding Source: NIH RePORTER	Bristol-Myers Squibb(Bristol-Myers Squibb); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Funded by Bristol-Myers Squibb; CheckMate 067 ClinicalTrials.gov number, NCT01844505.	Chapman PB, 2011, NEW ENGL J MED, V364, P2507, DOI 10.1056/NEJMoa1103782; Dummer R, 2015, J TRANSL MED, V13, P2062, DOI [10.1016/ S0140-6736(14) 60958-2, DOI 10.1016/S0140-6736(14)60958-2]; Eisenhauer EA, 2009, EUR J CANCER, V45, P228, DOI 10.1016/j.ejca.2008.10.026; Hodi FS, 2010, NEW ENGL J MED, V363, P711, DOI 10.1056/NEJMoa1003466; Larkin J, 2014, NEW ENGL J MED, V371, P1867, DOI 10.1056/NEJMoa1408868; Long GV, 2014, NEW ENGL J MED, V371, P1877, DOI 10.1056/NEJMoa1406037; Maio M, 2015, J CLIN ONCOL, V33, P1191, DOI 10.1200/JCO.2014.56.6018; Postow MA, 2015, NEW ENGL J MED, V372, P2006, DOI 10.1056/NEJMoa1414428; Ramanujam S, 2015, CHIN CLIN ONCOL, V4, DOI 10.3978/j.issn.2304-3865.2015.06.06; Robert C, 2015, NEW ENGL J MED, V372, P2521, DOI 10.1056/NEJMoa1503093; Robert C, 2015, NEW ENGL J MED, V372, P320, DOI 10.1056/NEJMoa1412082; Robert C, 2015, NEW ENGL J MED, V372, P30, DOI 10.1056/NEJMoa1412690; Robert C, 2011, NEW ENGL J MED, V364, P2517, DOI 10.1056/NEJMoa1104621; Shtivelman E, 2014, ONCOTARGET, V5, P1701, DOI 10.18632/oncotarget.1892; Sznol M, 2014, J CLIN ONCOL S, V52; Weber JS, 2015, LANCET ONCOL, V16, P375, DOI 10.1016/S1470-2045(15)70076-8; Wolchok JD, 2013, NEW ENGL J MED, V369, P122, DOI 10.1056/NEJMoa1302369	17	5391	5595	15	535	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 2	2015	373	1					23	34		10.1056/NEJMoa1504030	http://dx.doi.org/10.1056/NEJMoa1504030			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CL8IS	26398076	Green Published, Green Accepted, Green Submitted			2023-01-03	WOS:000357218700005
